<SEC-DOCUMENT>0001193125-23-224097.txt : 20230830
<SEC-HEADER>0001193125-23-224097.hdr.sgml : 20230830
<ACCEPTANCE-DATETIME>20230829204843
ACCESSION NUMBER:		0001193125-23-224097
CONFORMED SUBMISSION TYPE:	S-4/A
PUBLIC DOCUMENT COUNT:		66
FILED AS OF DATE:		20230830
DATE AS OF CHANGE:		20230829

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			enGene Holdings Inc.
		CENTRAL INDEX KEY:			0001980845
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			Z4
		FISCAL YEAR END:			1031

	FILING VALUES:
		FORM TYPE:		S-4/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-273851
		FILM NUMBER:		231223543

	BUSINESS ADDRESS:	
		STREET 1:		7171 RUE FREDERICK BANTING
		CITY:			SAINT-LAURENT
		STATE:			A8
		ZIP:			H4S 1Z9
		BUSINESS PHONE:		(514) 332-4888

	MAIL ADDRESS:	
		STREET 1:		7171 RUE FREDERICK BANTING
		CITY:			SAINT-LAURENT
		STATE:			A8
		ZIP:			H4S 1Z9
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-4/A
<SEQUENCE>1
<FILENAME>d459793ds4a.htm
<DESCRIPTION>S-4/A
<TEXT>
<HTML><HEAD>
<TITLE>S-4/A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>As filed with the Securities and Exchange Commission on August&nbsp;29, 2023. </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>Registration No.&nbsp;333-273851 </B></P>  <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES
AND EXCHANGE COMMISSION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Amendment
No.&nbsp;1 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>to </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT STYLE="white-space:nowrap">S-4</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>THE
SECURITIES ACT OF 1933 </I></B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:22pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE HOLDINGS INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name of Registrant as Specified in Its Charter) </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>Canada</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>6770</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Not Applicable</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(Primary Standard Industrial</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Classification Code Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>7171 Rue Frederick Banting </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Saint-Laurent, QC H4S 1Z9, Canada </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(514) <FONT STYLE="white-space:nowrap">332-4888</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(Address, including Zip Code, and Telephone Number, Including Area Code, of Registrant&#146;s Principal Executive Offices) </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>C T Corporation System </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>155
Federal Street </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Suite 700 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Boston, Massachusetts 02110 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(Name, Address, including Zip Code, and Telephone Number, including Area Code, of Agent for Service) </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>With a copy to: </I></B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="27%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="21%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Howard A. Kenny</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Todd A. Hentges</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Morgan,
Lewis&nbsp;&amp; Bockius LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>101 Park Avenue</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>New York, New York 10178</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Tel: (212) <FONT STYLE="white-space:nowrap">309-6000</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Joseph Garcia</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Kyle Misewich</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Blake,
Cassels&nbsp;&amp; Graydon LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>1133 Melville Street, Suite 3500 Vancouver BC V6E 4E5</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Tel: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(604)-631-3307</FONT></FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Leo Borchardt</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Davis Polk&nbsp;&amp; Wardwell London LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>5 Aldermanbury Square <BR>London EC2V 7HR<BR>United Kingdom</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Tel: +44 20 7418 1300</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Daniel Borlack</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Stikeman Elliott LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>5300
Commerce Court West</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>199 Bay Street</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Toronto, ON, M5L 1B9</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Canada</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Tel: <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(416)-869-5283</FONT></FONT></B></P></TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman"><B>Approximate date of commencement of proposed sale of the securities to the public: </B>As soon as practicable after this registration
statement is declared effective. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If the securities being registered on this form are being offered in connection with the formation of a
holding company and there is compliance with General Instruction G, please check the following box.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If this form is
filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), check the following box and list the Securities Act registration statement number of the
earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If this form is a post-effective amendment filed
pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
<FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, a smaller reporting company or emerging growth company. See the definitions of&nbsp; &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting
company&#148; and &#147;emerging growth company&#148; in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 (&#147;Exchange Act&#148;). </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Non-accelerated</FONT> filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging&nbsp;growth&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
</TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If applicable, place an X in the box to designate the appropriate rule provision relied upon in conducting this transaction: </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">Exchange Act Rule <FONT STYLE="white-space:nowrap">13e-4(i)</FONT> (Cross-Border Issuer Tender Offer)&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">Exchange Act Rule <FONT STYLE="white-space:nowrap">14d-1(d)</FONT> (Cross-Border Third-Party Tender Offer)&nbsp;&nbsp;&#9744; </P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman"><B>The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the
registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933, as amended or until the registration statement
shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Arial Narrow"><FONT COLOR="#ff4338"><B>The information in this preliminary proxy statement/prospectus is not complete and may
be changed. These securities may not be issued until the registration statement filed with the U.S. Securities and Exchange Commission is effective. The preliminary proxy statement/prospectus is not an offer to sell these securities and does not
constitute the solicitation of offers to buy these securities in any jurisdiction where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ff4338"><B>SUBJECT TO COMPLETION, DATED AUGUST&nbsp;29, 2023 </B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ff4338"><B>PRELIMINARY&nbsp;PROSPECTUS </B></FONT></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE HOLDINGS INC. </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>PROXY STATEMENT OF </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>FORBION
EUROPEAN ACQUISITION CORP. </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS FOR 27,090,013 COMMON SHARES, 6,896,099 WARRANTS AND 6,896,099 COMMON SHARES UNDERLYING
WARRANTS OF ENGENE HOLDINGS INC. </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:7pt; font-family:Times New Roman">The board of directors of Forbion European Acquisition Corp., a Cayman Islands exempted company (&#147;FEAC&#148;), has approved FEAC entering
into a Business Combination Agreement, dated as of May&nbsp;16, 2023 (as it may be amended and/or restated from time to time, the &#147;Business Combination Agreement&#148;) with enGene Inc., a corporation incorporated under the laws of Canada
(&#147;enGene&#148;), and enGene Holdings Inc., a corporation incorporated under the laws of Canada (&#147;New enGene&#148;). A copy of the Business Combination Agreement is attached to this proxy statement/prospectus as <B><U>Annex A</U></B>. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:7pt; font-family:Times New Roman">The Business Combination Agreement contemplates that the proposed business combination among FEAC, enGene and New enGene (the &#147;Business
Combination&#148;) will be completed through, among other things, the following series of transactions: </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:7pt">FEAC will incorporate or cause to be incorporated Can Merger Sub as a corporation under the laws of Canada and a
direct wholly owned subsidiary of FEAC (&#147;Can Merger Sub&#148;) and New enGene will incorporate or cause to be incorporated Cayman Merger Sub as a Cayman Islands exempted company and a direct wholly owned subsidiary of New enGene (&#147;Cayman
Merger Sub&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:7pt">pursuant to a Sponsor and Insiders Letter Agreement entered into concurrently with the execution and delivery of
the Business Combination Agreement (the &#147;Sponsor and Insiders Letter Agreement&#148;), Forbion Growth Sponsor FEAC I B.V., a private limited liability company incorporated in The Netherlands (the &#147;Sponsor&#148;), has agreed to surrender,
after giving effect to the conversion of all or part of the principal amount outstanding under loans made by the Sponsor to FEAC into private placement warrants of FEAC (&#147;FEAC Private Placement Warrants&#148;), 1,789,004 FEAC Class&nbsp;B
Shares and 5,463,381 FEAC Private Placement Warrants, as a contribution to the capital of FEAC and for no consideration (the &#147;Surrender&#148;), effective immediately prior to the Class&nbsp;B Conversion (as defined below) on the day which is
two business days prior to the Closing Date (as defined below); </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:7pt">on the day which is two business days prior to the Closing Date, each FEAC Class&nbsp;B Share that remains
outstanding following the Surrender shall be exchanged for one FEAC Class&nbsp;A Share (the &#147;Class&nbsp;B Conversion&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:7pt">on the day which is one business day prior to the Closing Date, Cayman Merger Sub will merge with and into FEAC
with FEAC as the surviving entity pursuant to a plan of merger under the laws of the Cayman Islands (the &#147;Cayman Merger&#148;) as follows: (i)&nbsp;New enGene will issue to the holders of FEAC Shares (including the Sponsor but excluding the
holders of any dissenting FEAC Shares) New enGene Shares in exchange for such holders&#146; FEAC Shares and such FEAC Shares will not be cancelled but will be transferred to New enGene, (ii)&nbsp;FEAC will thereby become a wholly owned subsidiary of
New enGene, and (iii)&nbsp;each issued share of Cayman Merger Sub will be exchanged for a FEAC Class&nbsp;A Share as the surviving entity and Cayman Merger Sub (having merged into FEAC) will cease to exist as a separate entity by virtue of the
Cayman Merger; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:7pt">concurrently with the Cayman Merger, and effective at the same time the Cayman Merger becomes effective under
Cayman Islands law, (i)&nbsp;New enGene will assume the warrants of FEAC to purchase one FEAC Class&nbsp;A Share at an exercise price of $11.50 per share, subject to adjustment (as so assumed, &#147;New enGene Warrants&#148;) pursuant to a warrant
assignment, assumption and amendment agreement to be entered into on or around the Closing Date, (ii)&nbsp;FEAC as the entity surviving the Cayman Merger will issue to New enGene a <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing demand
promissory note payable denominated in Canadian dollars (&#147;C$&#148;) having a principal amount equal to the fair market value of the FEAC Warrants assumed by New enGene (&#147;Note 3&#148;) in consideration of the assumption by New enGene of
obligations under the FEAC Warrants (as so assumed, New enGene Warrants), and (iii)&nbsp;New enGene will redeem the initial Class&nbsp;B common shares of New enGene held by the sole shareholder of New enGene for an amount equal to the amount of
capital that the sole shareholder of New enGene contributed for purposes of the incorporation of New enGene (such transactions, together with the Cayman Merger, the &#147;Cayman Reorganization&#148;); </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:7pt">following the Cayman Reorganization, FEAC will file an election to change its classification for U.S. federal
income tax purposes from a corporation to an entity disregarded as separate from its owner New enGene, to be effective as of the beginning of the Closing Date (the &#147;U.S. Entity Classification Election&#148; and, together with the Cayman
Reorganization, the &#147;FEAC Reorganization&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:7pt">on the Closing Date and pursuant to the Plan of Arrangement, subsequent to the FEAC Reorganization becoming
effective and prior to the consummation of the PIPE Financing, FEAC will loan to New enGene an amount equal to the total funds held in its Trust Account (subject to certain deductions described in the Business Combination Agreement), less the
principal amount of Note 3 (together, the &#147;Loan Amount&#148;) in consideration for which New enGene will issue a C$ denominated <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing demand promissory note to FEAC having a principal
amount equal to the Loan Amount converted into its Canadian dollar equivalent based on the C$:U.S.$ Bank of Canada daily exchange rate on the business day immediately prior to the Closing Date, following which FEAC will sell to New enGene, and New
enGene will purchase, all of the outstanding common shares of Can Merger Sub for a purchase price of C$10 (the &#147;Can Merger Sub Share Sale&#148;) and, following the Can Merger Sub Share Sale but prior to the Amalgamation, the PIPE Financing
shall be consummated; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:7pt">subsequent to the Can Merger Sub Share Sale and PIPE Financing, Can Merger Sub and enGene will amalgamate pursuant
to the Plan of Arrangement (the &#147;Amalgamation&#148;; the date of the Amalgamation being the &#147;Closing Date&#148;), and pursuant to the Amalgamation, (i)&nbsp;each enGene Share outstanding immediately prior to the Amalgamation shall be
exchanged for New enGene Shares at the enGene Exchange Ratio and each enGene Warrant outstanding immediately prior to the Amalgamation shall be exchanged for New enGene Warrants per the enGene Exchange Ratio; (ii)&nbsp;each Can Merger Sub share
outstanding immediately prior to the Amalgamation shall be exchanged for one common share in the authorized share capital of the amalgamated entity; and (iii)&nbsp;in consideration for the issuance of New enGene Shares, the amalgamated entity shall
issue its common shares to New enGene; and </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:7pt">following the Amalgamation, New enGene will continue from being a corporation incorporated under and governed by
the Canada Business Corporations Act to a company continued to and governed by the Business Corporations Act (British Columbia). </P></TD></TR></TABLE>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:7pt; font-family:Times New Roman">The transactions described above, together with the other transactions contemplated by the Business Combination Agreement, are hereinafter
referred to as the &#147;Transactions.&#148; </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:7pt; font-family:Times New Roman">The implied enterprise value of enGene at the time of signing the Business Combination
Agreement was equal to $111 million. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:7pt; font-family:Times New Roman">As described in this proxy statement/prospectus, FEAC Shareholders are being asked to consider and
vote upon the Business Combination<B><I> </I></B>and the other proposals set forth herein. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:7pt; font-family:Times New Roman">This proxy statement/prospectus covers the
following securities of New enGene to be issued in connection with the Business Combination: 27,090,013 common shares, 6,896,099 warrants and 6,896,099 common shares underlying the warrants. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:7pt; font-family:Times New Roman">FEAC Units (each comprising one FEAC Class&nbsp;A Share and one third of a FEAC Warrant), FEAC Class&nbsp;A Shares and FEAC Warrants are
currently each listed on The Nasdaq Stock Market (&#147;Nasdaq&#148;) under the symbols &#147;FRBNU,&#148; &#147;FRBN&#148; and &#147;FRBNW,&#148; respectively. FEAC Class&nbsp;A Shares and FEAC Warrants began separate trading on February&nbsp;1,
2022. FEAC and enGene intend to apply to Nasdaq for listing New enGene Shares and New enGene Warrants effective upon the consummation of the Business Combination under the proposed symbols &#147;ENGN&#148; and &#147;ENGNW,&#148; respectively. </P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman"><B>This proxy statement/prospectus provides you with detailed information about the Business Combination and other matters to be considered at
the extraordinary general meeting of shareholders of FEAC (the &#147;Special Meeting&#148;). You are urged to carefully read this entire document and the documents incorporated herein by reference. You should also carefully consider the risk factors
described in &#147;</B><B><I><A HREF="#rom459793_14">Risk Factors</A></I></B><B>&#148; beginning on page 73 of this proxy statement/prospectus. </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of the transactions described
in this proxy statement/prospectus, passed upon the fairness of the Business Combination Agreement or the transactions contemplated thereby, or passed upon the adequacy or accuracy of this proxy statement/prospectus. Any representation to the
contrary is a criminal offense. </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:3%; font-size:7pt; font-family:Times New Roman">This proxy statement/prospectus is dated
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023, and is first being mailed to FEAC Shareholders on or about &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORBION EUROPEAN ACQUISITION CORP. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>4001 Kennett Pike, Suite 302 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Wilmington, Delaware 19807 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO BE HELD ON &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TO THE SHAREHOLDERS OF FORBION EUROPEAN ACQUISITION CORP.: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOTICE IS HEREBY GIVEN that an extraordinary general meeting (the &#147;Special Meeting&#148;) of the shareholders of Forbion European
Acquisition Corp., a Cayman Islands exempted company (&#147;FEAC,&#148; &#147;we,&#148; &#147;us&#148; or &#147;our&#148;), will be convened at 10:00 a.m., New York City time,
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023, or at such other date, time and place to which such meeting may be adjourned or postponed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To facilitate shareholders&#146; attendance and participation, Forbion European Acquisition Corp. encourages its shareholders to attend the
meeting virtually through live webcast. For the purposes of Cayman Islands law and our current amended and restated memorandum and articles of association (the &#147;Current Articles&#148;), the physical location of the meeting shall be at
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. You or your proxyholder will be able to attend and vote at the meeting online by visiting and using a control number assigned
to you. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Special Meeting will be held in order to consider and vote on the following proposals: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>a)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Proposal No.</B><B></B><B>&nbsp;1</B><B>&nbsp;</B><B>-</B><B>&nbsp;</B><B>The Business Combination Proposal
</B>&#151;<B> </B>to consider and vote upon a proposal to approve and adopt by special resolution the Business Combination Agreement (the &#147;Business Combination Agreement&#148;), dated as of May&nbsp;16, 2023, by and among FEAC, enGene Inc. a
corporation incorporated under the laws of Canada (&#147;enGene&#148;), and enGene Holdings Inc., a corporation incorporated under the laws of Canada (&#147;New enGene&#148;), a copy of which is attached to the accompanying proxy
statement/prospectus as <B><U>Annex A</U></B>, and the transactions contemplated therein (the &#147;Transactions&#148;), whereby, among other things, FEAC, enGene and New enGene will complete a business combination (the &#147;Business
Combination&#148;) (we refer to this proposal as the &#147;Business Combination Proposal&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>b)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Proposal No.</B><B></B><B>&nbsp;2</B><B>&nbsp;</B><B>-</B><B>&nbsp;</B><B>The Governing Documents Proposal
</B>&#151; to consider and vote upon a proposal to approve the following material differences between the articles of New enGene to be in effect following the Business Combination (the &#147;Proposed Articles&#148;) and FEAC&#146;s Current Articles:
(i)&nbsp;the name of the new public entity will be &#147;enGene Holdings Inc.&#148; as opposed to &#147;Forbion European Acquisition Corp.&#148;; (ii) New enGene will have an unlimited number of authorized common shares and an unlimited number of
authorized blank cheque preferred shares, as opposed to FEAC having 500,000,000 Class&nbsp;A ordinary shares authorized, 50,000,000 Class&nbsp;B ordinary shares authorized and 5,000,000 preference shares authorized; (iii) New enGene&#146;s Proposed
Articles would reduce the requisite quorum for a meeting of shareholders from a majority of votes as required under the Current Articles to 33 1/3% of the shares entitled to vote at such meeting; (iv)&nbsp;New enGene&#146;s Proposed Articles would
include an advance notice provision that requires a nominating shareholder to provide notice to New enGene in advance of a meeting of shareholders should such nominating shareholder wish to nominate a person for election to the board of directors;
(v) New enGene&#146;s corporate existence will be perpetual as opposed to FEAC&#146;s corporate existence terminating if the initial business combination (as defined below) is not consummated by FEAC within a specified period of time; and (vi) New
enGene&#146;s constitutional documents will not include the various provisions applicable only to special purpose acquisition corporations that FEAC&#146;s Current Articles contain (we refer to this proposal as the &#147;Governing Documents
Proposal&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>c)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Proposal No.</B><B></B><B>&nbsp;3</B><B>&nbsp;</B><B>-</B><B>&nbsp;</B><B>The Nasdaq Proposal </B>&#151;<B>
</B>to consider and vote upon a proposal to approve, for purposes of complying with Nasdaq Listing Rule 5635(a), (b) and (d), the issuance of more than 20% of the issued and outstanding FEAC Class&nbsp;A Shares and the resulting change in control in
connection with the Business Combination (we refer to this proposal as the &#147;Nasdaq Proposal&#148;). </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>d)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Proposal No.</B><B></B><B>&nbsp;4</B><B>&nbsp;</B><B>-</B><B>&nbsp;</B><B>The Incentive Equity Plan Proposal
</B>&#151;<B> </B>to consider and vote upon a proposal to approve the enGene Holdings Inc. 2023 Incentive Equity Plan (we refer to this proposal as the &#147;Incentive Equity Plan Proposal&#148;). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>e)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Proposal No.</B><B></B><B>&nbsp;5</B><B>&nbsp;</B><B>-</B><B>&nbsp;</B><B>The Adjournment Proposal
</B>&#151;&nbsp;to consider and vote upon a proposal to approve the adjournment of the Special Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies if, based upon the tabulated vote at the time of the
Special Meeting, any of the condition precedent proposals would not be duly approved and adopted by FEAC Shareholders or we determine that one or more of the closing conditions under the Business Combination Agreement is not satisfied or waived (we
refer to this proposal as the &#147;Adjournment Proposal&#148;). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If FEAC Shareholders do not approve each of the
Business Combination Proposal, the Governing Documents Proposal, the Nasdaq Proposal, the Incentive Equity Plan Proposal and the Adjournment Proposal, and we and enGene do not waive the applicable closing condition under the Business Combination
Agreement, then the Business Combination may not be consummated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Special Meeting will be convened
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023 at 10:00 a.m., New York City time, at &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and in a
virtual format. Shareholders may attend, vote and examine the list of FEAC Shareholders entitled to vote at the Special Meeting by visiting <B><U>https://www.cstproxy.com/feac/2023</U></B> and entering the control number found on their proxy card,
voting instruction form or notice included in their proxy materials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The board of directors of FEAC (the &#147;FEAC Board&#148;) has
established&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023 as the record date for the Special Meeting. Only holders of record of FEAC Shares at the close of business
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023 are entitled to notice of and to vote and have their votes counted at the Special Meeting and any further adjournments or postponements of the Special Meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will provide you with the proxy statement/prospectus and a proxy card in connection with the solicitation of proxies to be voted at the
Special Meeting and at any adjournment of the Special Meeting. <B>Whether or not you plan to attend the Special Meeting, you are urged to read the proxy statement/prospectus (and any documents incorporated into the proxy statement/prospectus by
reference) carefully. Please pay particular attention to the section entitled &#147;</B><B><I>Risk Factors</I></B><B>.&#148;</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>After
careful consideration, the FEAC Board has determined that each of the Business Combination Proposal, the Governing Documents Proposal, the Nasdaq Proposal, the Incentive Equity Plan Proposal and the Adjournment Proposal are in the best interests of
and advisable to FEAC and the FEAC Shareholders and recommends that you vote, or give instruction to vote, &#147;FOR&#148; each of those proposals. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>The existence of financial and personal interests of FEAC&#146;s sponsor (the &#147;Sponsor&#148;) and FEAC&#146;s directors and officers
may result in a conflict of interest on the part of one or more of the directors between what they may believe is in the best interests of FEAC and its shareholders and what they may believe is best for themselves or the Sponsor in determining to
recommend that shareholders vote for the proposals. See the section entitled &#147;</B><B><I>Proposal No.</I></B><B></B><B><I></I></B><B></B><B><I>&nbsp;1 &#151; The Business Combination Proposal &#151; Interests of FEAC&#146;s Sponsor, Directors
and Executive Officers in the Business Combination</I></B><B>&#148; in the proxy statement/prospectus for a further discussion. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
connection with FEAC&#146;s IPO, the Sponsor and FEAC&#146;s directors at the time of its IPO entered into a letter agreement to vote their shares in favor of the initial business combination. As of the date hereof, the Sponsor owns approximately
20% and FGOF, together with the Sponsor, owns approximately 32.7%, of the total outstanding FEAC Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, concurrently with
the execution and delivery of the Business Combination Agreement: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FEAC, the Sponsor, FGOF and the other holders of FEAC Class B Shares, enGene, New enGene and the other parties
named therein (collectively, other than enGene and New enGene, the &#147;Sponsor Parties&#148;) entered into the Sponsor and Insiders Letter Agreement, pursuant to which the Sponsor has
</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
agreed to surrender, after giving effect to the conversion of all or part of the principal amount outstanding under loans made by the Sponsor to FEAC into FEAC Private Placement Warrants,
1,789,004 FEAC Class B Shares and 5,463,381 FEAC Private Placement Warrants, as a contribution to the capital of FEAC and for no consideration, effective immediately prior to the Class B Conversion on the day which is two business days prior to the
Closing Date (the &#147;Surrender&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FEAC, New enGene, enGene, the directors of enGene and certain shareholders of enGene (collectively, other than
FEAC, the &#147;enGene Parties&#148;) entered into voting agreements (the &#147;enGene Voting Agreements&#148;) and <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements (the &#147;enGene <FONT STYLE="white-space:nowrap">Lock-Up</FONT>
Agreements&#148;) pursuant to which the enGene Parties agreed to, among other things, (i)&nbsp;vote or cause to be voted all of their enGene Shares in favor of the enGene Arrangement Resolution and the Transactions; (ii)&nbsp;be bound by certain
other covenants and agreements related to the Business Combination and (iii)&nbsp;be bound by certain transfer restrictions with respect to the enGene Shares and New enGene Shares, as applicable, in each case, on the terms and subject to the
conditions set forth in the enGene Voting Agreements and the enGene <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enGene, New enGene, and the Sponsor Parties entered into a voting agreement (the &#147;FEAC Voting
Agreement&#148;) pursuant to which the Sponsor Parties agreed to, among other things, (i)&nbsp;vote or cause to be voted all of their FEAC Shares in favor of the Transaction Proposals; (ii)&nbsp;be bound by certain other covenants and agreements
related to the Business Combination and (iii)&nbsp;be bound by certain transfer restrictions with respect to the FEAC Shares, in each case, on the terms and subject to the conditions set forth in the FEAC Voting Agreement; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FEAC and a FEAC Shareholder entered into a <FONT STYLE="white-space:nowrap">non-redemption</FONT> agreement (the <FONT
STYLE="white-space:nowrap">&#147;Non-Redemption</FONT> Agreement&#148;), pursuant to which, among other things, FEAC will issue an additional 26,575 FEAC Class&nbsp;A Shares and 81,158 FEAC Warrants (or after the Assumption, New enGene will issue
additional New enGene Shares and New enGene Warrants) to such FEAC Shareholder in consideration of such FEAC Shareholder&#146;s commitment (i)&nbsp;to vote or cause to be voted all of its 166,665 FEAC Class&nbsp;A Shares in favor of the Transaction
Proposals and (ii)&nbsp;not to redeem its 166,665 FEAC Class&nbsp;A Shares in connection with the approval of the Business Combination by the FEAC Shareholders. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to FEAC&#146;s Current Articles, a holder of FEAC Class&nbsp;A Shares may request that FEAC redeem all or a portion of such
holder&#146;s FEAC Class&nbsp;A Shares (which would become New enGene Shares in the Business Combination) upon the completion of the Business Combination. <B><U>Holders of FEAC Class</U></B><B><U></U></B><B><U>&nbsp;A Shares may elect to redeem all
or a portion of their FEAC Class</U></B><B><U></U></B><B><U>&nbsp;A Shares regardless of whether such holders vote on the Business Combination, and if they do vote, regardless of whether they vote for or against the Business Combination</U></B>. If
the Business Combination is not consummated, the FEAC Class&nbsp;A Shares will not be redeemed for cash. If the Business Combination is consummated and a holder of FEAC Class&nbsp;A Shares properly exercises its right to redeem its FEAC Class&nbsp;A
Shares and timely delivers its FEAC Class&nbsp;A Shares to the transfer agent, we will redeem each FEAC Class&nbsp;A Share at a per share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account calculated as of two
business days prior to the consummation of the Business Combination, including interest (which interest will be net of taxes payable) earned on the funds held in the Trust Account and not previously released to FEAC to pay FEAC&#146;s income taxes,
if any, divided by the number of then-outstanding FEAC Class&nbsp;A Shares, subject to the limitations described herein. Furthermore, as it is expected that we are and will be considered a Dutch tax resident, any redemption proceeds (including
interest income on the Trust Account) distributed to FEAC Shareholders in excess of the <FONT STYLE="white-space:nowrap">paid-up</FONT> capital for Dutch tax purposes may be subject to 15% Dutch dividend withholding tax. The amount in the Trust
Account is anticipated to be $10.35 per FEAC Class&nbsp;A Share, excluding interest earned on amounts in the Trust Account. The per share amount we will distribute to investors who properly redeem their shares will not be reduced by the deferred
underwriting commissions we will pay to the underwriters. A beneficial holder of FEAC Class&nbsp;A Shares must identify itself in order to validly redeem its shares. There will be no redemption rights with respect to FEAC Warrants. Further, we will
not proceed with redeeming our FEAC Class&nbsp;A Shares, even if a holder thereof has properly elected to redeem its FEAC Class&nbsp;A Shares, if the Business Combination does not close. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a holder of FEAC Class&nbsp;A Shares, you will be entitled to receive cash for any FEAC
Class&nbsp;A Shares to be redeemed only if you: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">(a) hold FEAC Class A Shares or (b) hold FEAC Class A Shares through FEAC Units and you elect to separate your
FEAC Units into the underlying FEAC Class&nbsp;A Shares and FEAC Warrants prior to exercising your redemption rights with respect to the FEAC Class A Shares; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">prior to 5:00 p.m., New York City time,
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023 (two business days before the Special Meeting), (a) submit a written request to Continental Stock Transfer&nbsp;&amp; Trust Company, FEAC&#146;s transfer agent (the
&#147;transfer agent&#148;), that FEAC redeem all or a portion of your FEAC Class&nbsp;A Shares for cash and (b)&nbsp;identify yourself as a beneficial holder of the FEAC Class&nbsp;A Shares and provide your legal name, phone number, and address;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">deliver your FEAC Class&nbsp;A Shares to the transfer agent, physically or electronically through The
Depository Trust Company (&#147;DTC&#148;). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of FEAC Units must elect to separate the underlying FEAC
Class&nbsp;A Shares and FEAC Warrants prior to exercising redemption rights with respect to the FEAC Class&nbsp;A Shares. If holders hold their FEAC Units in an account at a brokerage firm or bank, holders must notify their broker or bank that they
elect to separate the FEAC Units into the underlying FEAC Class&nbsp;A Shares and FEAC Warrants, or if a holder holds units registered in its own name, the holder must contact the transfer agent, directly and instruct it to do so. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a holder of FEAC Class&nbsp;A Shares exercises its redemption rights, then it will be exchanging its redeemed FEAC Class&nbsp;A Shares for
cash and will no longer own such shares. Any request to redeem FEAC Class&nbsp;A Shares, once made, may be withdrawn at any time until the deadline for submitting redemption requests and thereafter, with the consent of FEAC&#146;s directors (acting
in their sole discretion). If a holder of FEAC Class&nbsp;A Shares delivers its shares in connection with an election to redeem and subsequently decides prior to the deadline for submitting redemption requests not to elect to exercise such rights,
it may simply request that FEAC instruct its transfer agent to return the shares (physically or electronically). The holder can make such request by contacting the transfer agent, at the address or email address listed in this proxy
statement/prospectus. See &#147;<I>Information About the Special Meeting</I><I>&nbsp;</I> <I>&#151; Redemption Rights</I>&#148; in the proxy statement/prospectus for a detailed description of the procedures to be followed if you wish to redeem your
FEAC Class&nbsp;A Shares for cash. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, a holder of FEAC Class&nbsp;A Shares, together with any affiliate of
such shareholder or any other person with whom such shareholder is acting in concert or as a &#147;group&#148; (as defined in Section&nbsp;13 of the Exchange Act), will be restricted from redeeming its shares with respect to more than an aggregate
of 15% of the shares sold in our IPO, without our prior consent. Accordingly, if a holder of FEAC Class&nbsp;A Shares, alone or acting in concert or as a group, seeks to redeem more than 15% of the FEAC Class&nbsp;A Shares, then any such FEAC
Class&nbsp;A Shares in excess of that 15% limit would not be redeemed for cash. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>All FEAC Shareholders are cordially invited to attend
the Special Meeting which will be held at &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and in a virtual format. To ensure your representation at the Special Meeting, you are urged to complete,
sign, date and return the proxy card accompanying the proxy statement/prospectus as soon as possible. If you are a shareholder of record holding FEAC Shares, you may also cast your vote at the Special Meeting in person or electronically by visiting
<U>https://www.cstproxy.com/feac/2023</U>. If your shares are held in an account at a brokerage firm or bank, you must instruct your broker or bank on how to vote your shares or, if you wish to attend the Special Meeting and vote in person or
electronically, obtain a proxy from your broker or bank. If you do not vote or do not instruct your broker or bank how to vote, it will have no effect on certain proposals because such action would not count as a vote cast at the Special Meeting.
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Your vote is important regardless of the number of shares you own. Whether you plan to attend the Special Meeting or not, please
sign, date and return the proxy card accompanying the proxy statement/prospectus as soon as possible in the envelope provided. If your shares are held in &#147;street name&#148; or are in a margin or similar account, you should contact your broker
to ensure that votes related to the shares you beneficially own are properly counted. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you have any questions or need assistance voting your FEAC Shares, please contact Morrow
Sodali LLC, the proxy solicitation agent for FEAC, by calling <FONT STYLE="white-space:nowrap">(800)&nbsp;662-5200&nbsp;(toll-free),</FONT> or banks and brokers can call <FONT STYLE="white-space:nowrap">(203)&nbsp;658-9400,&nbsp;or</FONT> by
emailing <U>FEAC.info@investor.morrowsodali.com</U>. This notice of Special Meeting is and the proxy statement/prospectus relating to the Business Combination will be available at <B><U>https://www.cstproxy.com/feac/2023</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Thank you for your participation. We look forward to your continued support. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By Order of the Board of Directors,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Sander Slootweg</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><I>Chairman of the Board</I></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IF YOU RETURN YOUR PROXY CARD WITHOUT AN INDICATION OF HOW YOU WISH TO VOTE, YOUR SHARES WILL BE
VOTED IN FAVOR OF EACH OF THE PROPOSALS. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Redemption Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>TO EXERCISE YOUR REDEMPTION RIGHTS, YOU MUST (I)&nbsp;IF YOU HOLD FEAC CLASS A SHARES THROUGH FEAC UNITS, ELECT TO SEPARATE YOUR FEAC UNITS
INTO THE UNDERLYING FEAC CLASS A SHARES AND FEAC WARRANTS PRIOR TO EXERCISING YOUR REDEMPTION RIGHTS WITH RESPECT TO THE FEAC CLASS A SHARES, (II)&nbsp;SUBMIT A WRITTEN REQUEST TO THE TRANSFER AGENT THAT YOUR FEAC CLASS A SHARES BE REDEEMED FOR
CASH, AND IDENTIFY YOURSELF AS A BENEFICIAL HOLDER OF THE FEAC CLASS A SHARES AND PROVIDE YOUR LEGAL NAME, PHONE NUMBER, AND ADDRESS, AND (III)&nbsp;DELIVER YOUR FEAC CLASS A SHARES TO THE TRANSFER AGENT, PHYSICALLY OR ELECTRONICALLY USING THE
DEPOSITORY TRUST COMPANY&#146;S DWAC (DEPOSIT WITHDRAWAL AT CUSTODIAN) SYSTEM, IN EACH CASE, IN ACCORDANCE WITH THE PROCEDURES AND DEADLINES DESCRIBED IN THE PROXY STATEMENT/PROSPECTUS. IF THE BUSINESS COMBINATION IS NOT CONSUMMATED, THEN THE FEAC
CLASS A SHARES WILL NOT BE REDEEMED FOR CASH. IF YOU HOLD THE FEAC CLASS A SHARES IN &#147;STREET NAME,&#148; YOU WILL NEED TO INSTRUCT THE ACCOUNT EXECUTIVE AT YOUR BANK OR BROKER TO WITHDRAW THE FEAC CLASS A SHARES FROM YOUR ACCOUNT IN ORDER TO
EXERCISE YOUR REDEMPTION RIGHTS. SEE &#147;</B><B><I>INFORMATION ABOUT </I></B><B></B><B><I>THE SPECIAL MEETING</I></B><B></B><B><I>&nbsp;</I></B><B></B><B><I>&#151;</I></B><B></B><B><I>&nbsp;</I></B><B></B><B><I>REDEMPTION RIGHTS</I></B><B>&#148;
IN THE PROXY STATEMENT/PROSPECTUS FOR MORE SPECIFIC INSTRUCTIONS. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom459793_1">ABOUT THIS PROXY STATEMENT/PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom459793_2">ADDITIONAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom459793_3">TRADEMARKS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom459793_3a">PRESENTATION OF ESTIMATED PER SHARE REDEMPTION PRICE </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom459793_4">SELECTED DEFINITIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom459793_5">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom459793_6">QUESTIONS AND ANSWERS ABOUT THE BUSINESS COMBINATION AND THE SPECIAL MEETING
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom459793_7">SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom459793_8">SUMMARY HISTORICAL CONSOLIDATED FINANCIAL INFORMATION OF FEAC</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom459793_9">SUMMARY HISTORICAL CONSOLIDATED FINANCIAL INFORMATION OF
ENGENE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom459793_10">SELECTED UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL
INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom459793_11">COMPARATIVE HISTORICAL AND UNAUDITED PRO FORMA PER SHARE FINANCIAL INFORMATION
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom459793_12">MARKET PRICE, TICKER SYMBOL AND DIVIDEND INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom459793_13">SUMMARY RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom459793_14">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom459793_15">INFORMATION ABOUT THE PARTIES TO THE BUSINESS COMBINATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom459793_16">INFORMATION ABOUT THE SPECIAL MEETING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom459793_17">PROPOSAL NO. 1 &#151; THE BUSINESS COMBINATION PROPOSAL</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom459793_18">THE BUSINESS COMBINATION AGREEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom459793_19">ANCILLARY AGREEMENTS RELATED TO THE BUSINESS COMBINATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom459793_20">PROPOSAL NO. 2 &#151; THE GOVERNING DOCUMENTS PROPOSAL</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom459793_21">COMPARISON OF CORPORATE GOVERNANCE AND SHAREHOLDER RIGHTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">229</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom459793_22">PROPOSAL NO. 3 &#151; THE NASDAQ PROPOSAL</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom459793_23">PROPOSAL NO. 4 &#151; THE INCENTIVE EQUITY PLAN PROPOSAL</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom459793_24">PROPOSAL NO. 5 &#151; THE ADJOURNMENT PROPOSAL</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom459793_25">UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom459793_26">SELECTED HISTORICAL FINANCIAL INFORMATION OF FEAC</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom459793_27">SELECTED HISTORICAL FINANCIAL DATA OF ENGENE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom459793_28">INFORMATION ABOUT FEAC</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom459793_29">FEAC&#146;S MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
 AND RESULTS OF OPERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">294</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom459793_30">FEAC&#146;S EXECUTIVE AND DIRECTOR COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom459793_31">BUSINESS OF ENGENE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom459793_32">ENGENE&#146;S MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
 AND RESULTS OF OPERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom459793_33">DIRECTORS AND EXECUTIVE OFFICERS OF ENGENE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">364</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom459793_34">ENGENE&#146;S EXECUTIVE AND DIRECTOR COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom459793_34a">DESCRIPTION OF ENGENE&#146;S MATERIAL INDEBTEDNESS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom459793_34b">CURRENT DIRECTORS AND EXECUTIVE OFFICERS OF NEW ENGENE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom459793_35">DIRECTORS AND EXECUTIVE OFFICERS OF NEW ENGENE AFTER THE BUSINESS COMBINATION
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">376</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom459793_36">DESCRIPTION OF NEW ENGENE SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom459793_37">SECURITIES ACT RESTRICTIONS ON RESALE OF COMMON SHARES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">391</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom459793_38">CANADIAN SECURITIES LAW MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom459793_39">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT OF
ENGENE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom459793_40">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT OF
FEAC</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">398</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom459793_41">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT OF NEW ENGENE
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom459793_42">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom459793_43">MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom459793_44">MATERIAL DUTCH TAX CONSEQUENCES OF THE BUSINESS COMBINATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">422</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom459793_45">CERTAIN CANADIAN FEDERAL INCOME TAX CONSIDERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom459793_46">CAYMAN ISLAND APPRAISAL RIGHTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom459793_47">SHAREHOLDER COMMUNICATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom459793_48">VALIDITY OF COMMON SHARES AND WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom459793_49">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom459793_50">HOUSEHOLDING; DELIVERY OF DOCUMENTS TO SHAREHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">432</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom459793_51">ENFORCEABILITY OF CIVIL LIABILITY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">432</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom459793_52">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">433</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom459793_53">INDEX TO FINANCIAL STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Annexes </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A HREF="#ii459793_1">Annex A: Business Combination Agreement </A> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="96%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">-</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Exhibit A: Company Arrangement Resolution</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">-</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Exhibit B: Plan of Arrangement</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">-</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Exhibit <FONT STYLE="white-space:nowrap">C-1:</FONT> Form of Subscription Agreement</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">-</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Exhibit <FONT STYLE="white-space:nowrap">C-2:</FONT> Form of Subscription Agreement Side Letter Agreement</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">-</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Exhibit <FONT STYLE="white-space:nowrap">C-3:</FONT> Form of <FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreement</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">-</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Exhibit D: Form of Registration Rights Agreement</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">-</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Exhibit <FONT STYLE="white-space:nowrap">E-1:</FONT> Form of enGene Voting Agreement</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">-</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Exhibit <FONT STYLE="white-space:nowrap">E-2:</FONT> Form of enGene <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">-</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Exhibit <FONT STYLE="white-space:nowrap">E-3:</FONT> Form of FEAC Voting Agreement</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">-</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Exhibit F: Form of Proposed Articles of New enGene</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">-</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Exhibit G: Form of New enGene 2023 Incentive Equity Plan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">-</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Exhibit H: Capitalization Table</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A HREF="#rom459793_101">Annex B: Fairness Opinion of Lincoln International LLC </A> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A HREF="#ii459793_2">Annex C: Sponsor and Insiders Letter Agreement </A> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A HREF="#ii459793_5">Annex D: Form of Warrant Assignment, Assumption and Amendment Agreement </A> </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="96%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">-</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Exhibit A - Restrictive Legend for New enGene Warrant</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">-</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Exhibit B - Form of New enGene Warrant</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A HREF="#rom459793_102">Annex E: Form of Proxy for the Special Meeting of FEAC Shareholders </A> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom459793_1"></A>ABOUT THIS PROXY STATEMENT/PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This document, which forms part of a registration statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> filed with the U.S. Securities
and Exchange Commission (the &#147;SEC&#148;) by enGene Holdings Inc. (&#147;New enGene&#148;) (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-273851),</FONT> constitutes a prospectus of New enGene under Section&nbsp;5 of the Securities Act,
with respect to the New enGene Shares, New enGene Warrants and New enGene Shares underlying such warrants to be issued if the Business Combination described below is consummated. This document also constitutes a notice of meeting and a proxy
statement under Section&nbsp;14(a) of the U.S. Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;) with respect to the Special Meeting of Forbion European Acquisition Corp. (&#147;FEAC&#148;) shareholders at which FEAC
Shareholders will be asked to consider and vote upon a proposal to approve the Business Combination by the approval and adoption of the Business Combination Agreement, among other matters. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom459793_2"></A>ADDITIONAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you have questions about the Business Combination or the Special Meeting, or if you need to obtain copies of the enclosed proxy
statement/prospectus, proxy card or other documents incorporated by reference in the proxy statement/prospectus, you may contact FEAC&#146;s proxy solicitor listed below. You will not be charged for any of the documents you request. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Morrow Sodali LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">333 Ludlow
Street, 5<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Floor, South Tower </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Stamford, CT 06902 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Individuals call toll-free <FONT STYLE="white-space:nowrap">(800)&nbsp;662-5200</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Banks and brokers call <FONT STYLE="white-space:nowrap">(203)&nbsp;658-9400</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Email: <U>FEAC.info@investor.morrowsodali.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order for you to receive timely delivery of the documents in advance of the Special Meeting to be <B>held on
</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>, 2023, you must request the information no later than </B><B>four</B><B> business days prior to the date of the Special Meeting, by
</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>, 2023. </B> </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>For a more detailed description of the
information incorporated by reference in the enclosed proxy statement/prospectus and how you may obtain it, see the section captioned &#147;</B><B><I>Where You Can Find More Information</I></B><B>&#148; beginning on page&nbsp;433 of the enclosed
proxy statement/prospectus. </B></P>  <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom459793_3"></A>TRADEMARKS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This document contains references to trademarks and service marks belonging to other entities. Solely for convenience, trademarks and trade
names referred to in this proxy statement/prospectus may appear without the <SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> or <SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> symbols, but such references are not intended to
indicate, in any way, that the applicable licensor will not assert, to the fullest extent under applicable law, its rights to these trademarks and trade names. We do not intend our use or display of other companies&#146; trade names, trademarks or
service marks to imply a relationship with, or endorsement or sponsorship of us by, any other companies. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom459793_3a"></A>PRESENTATION OF ESTIMATED PER SHARE REDEMPTION PRICE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this proxy statement/prospectus, the per share redemption price for FEAC Class A Shares is presented excluding interest earned in the Trust
Account. As of June&nbsp;30, 2023, the amount held in the Trust Account was $135,786,170 ($10.35&nbsp;per share (excluding interest earned in the Trust Account)), which includes the deposit by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Sponsor of an additional $1,265,000, or $0.10 per unit, into the Trust Account, on June 6, 2023 in connection with the extension by FEAC of the time available to consummate its initial
business combination from June 14, 2023 to September 14, 2023. FEAC currently intends, in accordance with its obligations under the Business Combination Agreement, to extend the time available to it to consummate its initial business combination
from September 14, 2023, to December 14, 2023, by depositing an additional $1,265,000 (or $0.10 per FEAC Class A Share) into the Trust Account on or before September 14, 2023, and the Sponsor is expected to fund such amount in the form of an
additional extension note on the same terms. For illustrative purposes, based on the fair value of interest earned and marketable securities held in the Trust Account as of June&nbsp;30, 2023 of $135,786,170, the actual estimated per share
redemption price would have been approximately&nbsp;$10.73 as of June&nbsp;30, 2023. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom459793_4"></A>SELECTED DEFINITIONS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;Aggregate Closing PIPE Proceeds&#148; means the sum of the cash proceeds to be received by New enGene in
respect of the PIPE Financing on the Closing Date and the cash proceeds actually received by enGene in respect of the Convertible Bridge Financing prior to the Closing Date.</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;Aggregate Exercise Price&#148; means the aggregate exercise price of the enGene Options that will be
exchanged for Rollover Equity Awards, converted to its U.S. dollar equivalent based on the C$:US$ Bank of Canada daily exchange rate on the business day immediately prior to the Closing Date, and rounding the resulting exercise price up to the
nearest whole cent.</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;Aggregate Transaction Proceeds&#148; means an amount equal to (a)</I><I></I><I>&nbsp;the sum (without
duplication) of (i)</I><I></I><I>&nbsp;the aggregate cash proceeds available for release to FEAC from the Trust Account in connection with the Transactions (after, for the avoidance of doubt, giving effect to all of the FEAC Shareholder
Redemptions), (ii) the unrestricted cash on the balance sheet of FEAC as of the Closing Date, and (iii)</I><I></I><I>&nbsp;the Aggregate Closing PIPE Proceeds, minus (b)</I><I></I><I>&nbsp;the sum (without duplication) of the Unpaid FEAC Expenses
(as defined in the BCA) and the Unpaid FEAC Liabilities (as defined in the BCA).</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;Amalgamation&#148; refers to the amalgamation of Can Merger Sub and enGene pursuant to the Plan of
Arrangement. Pursuant to the Amalgamation, (i)</I><I></I><I>&nbsp;each enGene Share outstanding immediately prior to the Amalgamation will be exchanged for New enGene Shares per the enGene Exchange Ratio and each enGene Warrant outstanding
immediately prior to the Amalgamation will be exchanged for New enGene Warrants per the enGene Exchange Ratio; (ii)</I><I></I><I>&nbsp;each Can Merger Sub share outstanding immediately prior to the Amalgamation will be exchanged for one common share
in the authorized share capital of the amalgamated entity; and (iii)</I><I></I><I>&nbsp;in consideration for the issuance of New enGene Shares, the amalgamated entity will issue its common shares to New enGene, in each case upon and subject to the
other terms and conditions set forth in the Business Combination Agreement.</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;Ancillary Agreements&#148; means the Plan of Arrangement, the Registration Rights Agreement (as defined
in the Registration Rights Agreement), the Sponsor and Insiders Letter Agreement, the Subscription Agreements, the Side Letter Agreements, the Non-Redemption Agreement (as defined in the BCA), the Convertible Bridge Financing Documents (as defined
in the BCA), the Letter of Transmittal (as defined in the BCA), the Transaction Support Agreements (as defined in the BCA), the Joinder Agreements (as defined in the BCA), the Warrant Assignment, Assumption and Amendment Agreement, the New enGene
Warrant Agreement (as defined in the BCA), the Working Capital Loan Note, any Extension Loan Note and each other agreement, document, instrument and/or certificate contemplated by the BCA executed or to be executed by the parties thereto in
connection with the Transactions.</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;Arrangement&#148; means the arrangement under Section</I><I></I><I>&nbsp;192 of the CBCA on the terms
and subject to the conditions set out in the Plan of Arrangement, subject to any amendments or variations to the Plan of Arrangement made in accordance with the terms of the Business Combination Agreement and the Plan of Arrangement or made at the
direction of the Court in the Final Order with the prior written consent of FEAC and enGene, such consent not to be unreasonably withheld, conditioned or delayed.</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;Assumption&#148; has the meaning ascribed thereto in the definition of PIPE Investors.</I>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;BCBCA&#148; means the Business Corporations Act (British Columbia).</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;BCG-unresponsive NMIBC with Cis&#148; refers to non-muscle invasive bladder cancer, or
&#147;NMIBC,&#148; with carcinoma in situ, or &#147;Cis,&#148; that has been unresponsive to the typical treatment with the bacterium Bacillus Calmette-Gurin, or BCG. enGene is developing its product EG-70 as a monotherapy for treatment of
BCG-unresponsive NMIBC with Cis. </I></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;Bridge Consideration&#148; means (A)</I><I></I><I>&nbsp;with respect to the New enGene Shares, the
number of New enGene Shares equal to (i)</I><I></I><I>&nbsp;the number of enGene Common Shares issued upon the conversion of the enGene</I> <I>Convertible Notes in accordance with their terms, multiplied by (ii)</I><I></I><I>&nbsp;the enGene
Exchange Ratio, and</I> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
<I>(B)</I><I></I><I>&nbsp;with respect to the New enGene Warrants, the number of New enGene Warrants equal to (i)</I><I></I><I>&nbsp;the number of enGene Warrants multiplied by
(ii)</I><I></I><I>&nbsp;the enGene Exchange Ratio.</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;Business Combination Agreement&#148; or the &#147;BCA&#148;, refers to the Business Combination
Agreement, dated as of May</I><I></I><I>&nbsp;16, 2023, (and as it may be further amended or modified) by and among Forbion European Acquisition Corp., a Cayman Islands exempted company, enGene Inc., a corporation existing under the laws of Canada,
and enGene Holdings Inc., a corporation existing under the laws of Canada.</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;business day&#148; means a day, other than a Saturday or Sunday, on which commercial banks in New York,
New York and Vancouver, British Columbia are open for the general transaction of business.</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;Can Merger Sub&#148; refers to a to be incorporated wholly owned subsidiary of Forbion European
Acquisition Corp. </I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;Cayman Act&#148; means the Cayman Islands Companies Act (As Revised).</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;Cayman Exchange Ratio&#148; means one for one (1:1).</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;Cayman Merger Sub&#148; refers to a to be incorporated Cayman Islands exempted company and a direct
wholly owned subsidiary of enGene Holdings Inc. </I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;CBCA&#148; means the Canada Business Corporations Act.</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;Closing&#148; refers to the closing of the Business Combination.</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;Closing Date&#148; refers to the date on which the Closing actually occurs.</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;Code&#148; means the United States Internal Revenue Code of 1986, as amended.</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;Combined Company&#148; refers to FEAC, New enGene and enGene, collectively, following the Transactions
(as defined below).</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;Continental&#148; refers to Continental Stock Transfer&nbsp;&amp; Trust Company, the trustee, transfer
agent, warrant agent and escrow agent of FEAC. Following the Business Combination, Continental will serve as the transfer agent and warrant agent for New enGene. </I></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;Court&#148; means the Supreme Court of British Columbia or other competent court, as applicable.</I>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;DDX&#148; means dually derivatized chitosan, enGene&#146;s proprietary carrier for genetic medicines to
mucosal tissues and is the foundation for our nanoparticle formulations.</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I><FONT STYLE="white-space:nowrap">&#147;EG-70&#148;</FONT> refers to enGene&#146;s lead product candidate,
detalimogene voraplasmid.</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;enGene&#148; means, prior to the Amalgamation, enGene Inc., a corporation existing under the laws of
Canada, and following the Amalgamation, the corporation resulting from the amalgamation of enGene Inc. and Can Merger Sub pursuant to the Plan of Arrangement. </I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;enGene Arrangement Resolution&#148; means the special resolutions of the enGene Shareholders approving
the Plan of Arrangement, which is to be considered at the enGene Shareholder Meeting.</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;enGene&#146;s Board of Directors&#148; or the &#147;enGene Board&#148; refers to enGene&#146;s board of
directors.</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;enGene Class</I><I></I><I>&nbsp;A Preferred Shares&#148; means Class</I><I></I><I>&nbsp;A Preferred
shares in the capital of enGene Inc.</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;enGene Class</I><I></I><I>&nbsp;B Preferred Shares&#148; means Class</I><I></I><I>&nbsp;B Preferred
shares in the capital of enGene Inc.</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;enGene Class</I><I></I><I>&nbsp;C Preferred Shares&#148; means Class</I><I></I><I>&nbsp;C Preferred
shares in the capital of enGene Inc. issuable in series, one series being designated Series 1 Class</I><I></I><I>&nbsp;C Preferred Shares, one series being designated Series</I> <I>2 Class</I><I></I><I>&nbsp;C Preferred Shares, one series designated
Series 3 Class</I><I></I><I>&nbsp;C Preferred Shares and one series being designated Series 4 Class</I><I></I><I>&nbsp;C Preferred Shares</I>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;enGene Change of Control Payment&#148; means (a) any success, change of control, retention, transaction
bonus or other similar payment or amount to any Person as a result of or in connection with the BCA or the</I> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
<I>Transactions or any other Change of Control Transaction (as defined in the BCA) (including any such payments or similar amounts that may become due and payable based upon the occurrence of one
or more additional circumstances, matters or events) or (b) any payments made or required to be made pursuant to or in connection with or upon termination of, and any fees, expenses or other payments owing or that will become owing in respect of,
any Company Related Party Transaction (as defined in the BCA) (in the case of each of clause (a) and (b), regardless of whether paid or payable prior to, at or after the Closing or in connection with or otherwise related to the BCA or any Ancillary
Agreement)</I><I>.</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;enGene Common Shareholder Agreements&#148; means the common shareholder agreements of enGene in the form
attached to the enGene Majority Shareholder Agreement, as amended, modified, restated, replaced or supplemented by the enGene Board from time to time.</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;enGene Common Shares&#148; means common shares of enGene Inc.</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;enGene Convertible Notes&#148; means the Amended 2022 Convertible Notes (as defined herein) and the 2023
Convertible Notes (as defined below)</I>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;enGene Disclosure Schedules</I><B></B><I>&#148;</I><B> </B><I>means the disclosure schedules to the BCA
delivered to FEAC by the Group Companies on the date of the BCA.</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;enGene Equity Award&#148; means, as of any determination time, each enGene Option, restricted stock
unit, stock appreciation, phantom equity, and each other award to any current or former director, manager, officer, employee, individual independent contractor or other individual service provider of any Group Company of rights of any kind to
receive any Equity Security (as defined in the BCA) of any Group Company or benefits measured in whole or in part by reference to any Equity Security of any Group Company, in each case, under any enGene Equity Plan or otherwise that is outstanding.
For the avoidance of doubt, the enGene Warrants shall not be considered an enGene Equity Award.</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;enGene Equity Plan&#148; means, collectively, (a)</I><I></I><I>&nbsp;the amended and restated equity
incentive plan of enGene dated June</I><I></I><I>&nbsp;30, 2021 and as may be further amended and/or restated from time to time, and (b)</I><I></I><I>&nbsp;each other plan that provides for the award to any current or former director, manager,
officer, employee, individual independent contractor or other individual service provider of any Group Company of rights of any kind to receive Equity Securities of any Group Company or benefits measured in whole or in part by reference to equity
securities of any Group Company.</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;enGene Exchange Ratio&#148; means the quotient obtained by dividing (a)</I><I></I><I>&nbsp;the enGene
Per Share Value, by (b)</I><I></I><I>&nbsp;the Reference Price.</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;enGene Fully Diluted Shares&#148; means the sum of (without duplication)</I><I></I><I>&nbsp;(a) the
aggregate number of enGene Shares issued and outstanding immediately prior to the Closing (not including, for the avoidance of doubt, the number of enGene Common Shares issuable upon conversion of the Convertible Bridge Financing), and
(b)</I><I></I><I>&nbsp;the aggregate number of enGene Shares issued or issuable upon exercise of all issued and outstanding enGene Equity Awards (whether vested or unvested), including enGene Equity Awards exercised prior to or in connection with
the Closing.</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;enGene Majority Shareholder Agreement&#148; means the fourth amended and restated majority shareholders
agreement dated May</I><I></I><I>&nbsp;16, 2023 between enGene, the holders of enGene Class</I><I></I><I>&nbsp;A Preferred Shares, the holders of enGene Class</I><I></I><I>&nbsp;B Preferred Shares, the holders of enGene Class</I><I></I><I>&nbsp;C
Preferred Shares, IQ and the Sponsor.</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;enGene <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Shares&#148; means the <FONT
STYLE="white-space:nowrap">non-voting</FONT> common shares in the capital of enGene.</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;enGene Options&#148; means, as of any determination time, each option to purchase enGene Shares that are
outstanding and unexercised (whether vested or unvested), whether granted under an enGene Equity Plan or otherwise.</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;enGene Per Share Value&#148; means the quotient obtained by dividing (a)</I><I></I><I>&nbsp;the
Reference Value, by (b)</I><I></I><I>&nbsp;the enGene Fully Diluted Shares.</I> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;enGene Preferred Shares&#148; refers to the Class</I><I></I><I>&nbsp;A Preferred Shares, the
Class</I><I></I><I>&nbsp;B Preferred Shares and the Class</I><I></I><I>&nbsp;C Preferred Shares of enGene.</I> </P></TD></TR></TABLE>   <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;enGene Required Approval&#148; means the approval by the affirmative vote of holders present in person
or represented by proxy at the enGene Shareholders Meeting of not less than (i) two-thirds of the votes cast by such holders of the enGene Shares, voting together as a single class, and (ii) two-thirds of the votes cast by such holders of each class
of enGene Shares.</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;enGene Shareholders&#148; means, collectively, the holders of enGene Shares as of any determination time
prior to the Closing.</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;enGene Shareholders Agreements&#148; means the enGene Majority Shareholder Agreement and the enGene
Common Shareholder Agreements.</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;enGene Shareholders Meeting&#148; means the special meeting of the enGene Shareholders, including any
adjournment or postponement thereof in accordance with the terms of this Agreement, that is to be convened as provided by the Interim Order (as defined below) to consider, and if deemed advisable approve, the enGene Arrangement Resolution and, with
the prior written consent of FEAC, for any other purpose as may be set out in the Company Information Circular (as defined in the BCA).</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;enGene Shares&#148; means the enGene Common Shares, enGene
<FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Shares, enGene Class</I><I></I><I>&nbsp;A Preferred Shares, enGene Class</I><I></I><I>&nbsp;B Preferred Shares, and enGene Class</I><I></I><I>&nbsp;C Preferred Shares.</I>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;enGene Warrants&#148; means the 2022 Warrants and the 2023 Warrants (each as defined in the BCA).</I>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;Exchange Act&#148; refers to the U.S. Securities Exchange Act of 1934, as amended.</I>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;Extension Loan Note&#148; means any unsecured promissory note to be issued by FEAC to the Sponsor (or
any of the Sponsor&#146;s Affiliates (as defined in the BCA) or designees, as applicable), in connection with the deposit of funds in the Trust Account (as defined below) for purposes of the extension of the time available to FEAC to consummate an
initial business combination in accordance with FEAC&#146;s Governing Documents and the Trust Agreement (as defined in the BCA), in an amount not to exceed $1,265,000 per note for each applicable three-month period.</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;FEAC Board&#148; refers to FEAC&#146;s board of directors.</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>FEAC Change of Control Payment&#148; means (a) any success, change of control, retention, transaction
bonus or other similar payment or amount to any Person as a result of or in connection with the BCA or the Transactions or any other Change of Control Transaction (as defined in the BCA) (including any such payments or similar amounts that may
become due and payable based upon the occurrence of one or more additional circumstances, matters or events), or (b) any payments made or required to be made pursuant to or in connection with or upon termination of, and any fees, expenses or other
payments owing or that will become owing in respect of, any FEAC Related Party Transaction (as defined in the BCA) (in the case of each of clause (a) and (b), regardless of whether paid or payable prior to, at or after the Closing or in connection
with or otherwise related to the BCA or any Ancillary Agreement), in each case, for the avoidance of doubt, other than the payment of fees of legal and other advisors in connection with the Transactions.</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;FEAC Class</I><I></I><I>&nbsp;A Shares&#148; means FEAC&#146;s Class</I><I></I><I>&nbsp;A ordinary
shares, $0.0001 par value.</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;FEAC Class</I><I></I><I>&nbsp;B Shares&#148; means FEAC&#146;s Class</I><I></I><I>&nbsp;B ordinary
shares, $0.0001 par value.</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;FEAC Disclosure Schedules</I><B>&#148; </B><I>means the disclosure schedules to the BCA delivered to
enGene by FEAC on the date of the BCA.</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;FEAC Private Placement Warrants&#148; means the warrants (each entitling the holder thereof to purchase
one FEAC Class</I><I></I><I>&nbsp;A Share) issued by FEAC to the Sponsor in a private placement simultaneously with the</I> <I>closing of its IPO and to be issued by FEAC to the Sponsor (or the Sponsor&#146;s Affiliates or designees, as applicable),
upon the conversion of up to $1,500,000 of the principal outstanding amount of the Working</I> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
<I>Capital Loan Note (as defined below) and any Extension Loan Note in connection with the consummation of the Business Combination.</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;FEAC Public Warrants&#148; means the FEAC Warrants issued as part of the FEAC Units in connection with
FEAC&#146;s IPO (as defined below).</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;FEAC Registration Rights Agreement&#148; means the Registration and Shareholder Rights Agreement dated
December</I><I></I><I>&nbsp;9, 2021, between FEAC and the Sponsor.</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;FEAC Shareholder&#148; means any holder of any FEAC Shares.</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;FEAC Shareholder Redemptions&#148; means the redemption by the holders of FEAC
Class</I><I></I><I>&nbsp;A Shares of all or a portion of their FEAC Class</I><I></I><I>&nbsp;A Shares (in connection with the Transactions or otherwise), as set forth in Governing Documents of FEAC.</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;FEAC Shares&#148; means (a)</I><I></I><I>&nbsp;prior to the Class</I><I></I><I>&nbsp;B Conversion,
collectively, the FEAC Class</I><I></I><I>&nbsp;A Shares and the FEAC Class</I><I></I><I>&nbsp;B Shares, and (b)</I><I></I><I>&nbsp;from and after the Class</I><I></I><I>&nbsp;B Conversion, the FEAC Class</I><I></I><I>&nbsp;A Shares after giving
effect to the Class</I><I></I><I>&nbsp;B Conversion. Any reference to the FEAC Shares in this proxy statement/prospectus will be deemed to refer to clause (a)</I><I></I><I>&nbsp;and/or clause (b)</I><I></I><I>&nbsp;of this definition as the context
so requires.</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;FEAC Unit&#148; means each outstanding unit consisting of one FEAC Class</I><I></I><I>&nbsp;A Share and <FONT
STYLE="white-space:nowrap">one-third</FONT> of one FEAC Warrant.</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;FEAC Warrant&#148; means each warrant to purchase one FEAC Class</I><I></I><I>&nbsp;A Share at an
exercise price of $11.50 per share, subject to adjustment, upon the terms and conditions in the FEAC Warrant Agreement.</I> </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;FEAC Warrant Agreement&#148; means the warrant agreement, dated as of December</I><I></I><I>&nbsp;9,
2021, by and between FEAC and Continental, as warrant agent.</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;FGOF&#148; means Forbion Growth Opportunities Fund I Cooperatief U.A.</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;Final Order&#148; means the final order of the Court pursuant to Section</I><I></I><I>&nbsp;192 of the
CBCA, in the form and substance satisfactory to FEAC and enGene (each acting reasonably), approving the Arrangement, as such order may be amended, modified, supplemented or varied by the Court at any time prior to the Closing or, if appealed, then,
unless such appeal is withdrawn, abandoned or dismissed, at such time which the Arrangement is affirmed or as amended, on appeal, provided that any such amendment is acceptable to each of FEAC and enGene, each acting reasonably.</I>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;Forbion&#148; means Forbion Group Holding B.V., a life sciences specialist venture fund manager with
headquarters in Naarden, the Netherlands, and offices in Munich, Germany, and Singapore.</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;Forbion Capital Fund III&#148; means Forbion Capital Fund III Cooperatief U.A.</I>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;Forbion Management&#148; means Forbion Growth Management B.V.</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;Governing Documents&#148; means the legal document(s) by which any Person (other than an individual)
establishes its legal existence or which govern its internal affairs.</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;Group Company&#148; and &#147;Group Companies&#148; means, collectively enGene and its subsidiary and
New enGene and its subsidiaries.</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;Interim Order&#148; means the interim order of the Court contemplated by the Business Combination
Agreement and made pursuant to Section&nbsp;192(4) of the CBCA, in a form acceptable to each of enGene and FEAC (each acting reasonably), providing for, among other things, the calling and holding of the enGene Shareholders Meeting, as the same may
be amended, modified, supplemented or varied by the Court with the consent of FEAC and enGene, such consent not to be unreasonably withheld, conditioned or delayed, provided that any such amendment is acceptable to each of the Company and FEAC, each
acting reasonably. </I></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;IPO&#148; means FEAC&#146;s initial public offering.</I> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;Leerink Partners&#148; refers to Leerink Partners LLC (formerly SVB Securities LLC).</I>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;Lumira/Merck Investors&#148; means, collectively, Lumira Ventures III, L.P., Lumira Ventures III
(International), L.P., Lumira Ventures IV, L.P., Lumira Ventures IV (International), L.P., Merck Lumira Biosciences Fund, L.P. and Merck Lumira Biosciences Fund (Qu&eacute;bec), L.P.</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;Nasdaq&#148; refers to The Nasdaq Stock Market LLC.</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;New enGene&#148; means enGene Holdings Inc., a corporation incorporated under the laws of Canada, which
will be the parent company of the combined operating business following the consummation of the Business Combination.</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;New enGene&#146;s Board of Directors&#148; or the &#147;New enGene Board&#148; refers to New
enGene&#146;s board of directors.</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;New enGene Shares&#148; means the Class</I><I></I><I>&nbsp;A common shares of New enGene.</I>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;New enGene Shareholders&#148; means, collectively, the holders of New enGene Shares following Closing of
the Business Combination.</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;New enGene Warrant Agreement&#148; means the FEAC Warrant Agreement as amended and assumed by New enGene
pursuant to the Warrant Assignment, Assumption and Amendment Agreement setting forth the terms and conditions of the New enGene Warrants.</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;New enGene Warrants&#148; means each warrant of New enGene to purchase one New enGene Share at an
exercise price of $11.50 per share, subject to adjustment, upon the terms and conditions in the New enGene Warrant Agreement.</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;NMIBC&#148; means <FONT STYLE="white-space:nowrap">non-muscle</FONT> invasive bladder cancer.</I>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;Non-Redemption Agreement&#148; means the non-redemption agreement among New enGene, FEAC and a FEAC
Shareholder pursuant to which, among other things, FEAC will issue an additional 26,575 FEAC Class A Shares and 81,158 FEAC Warrants (or after the Assumption, New enGene will issue additional New enGene Shares and New enGene Warrants) to such FEAC
Shareholder in consideration of such FEAC Shareholder&#146;s commitment (i) to vote or cause to be voted all of its 166,665 FEAC Class A Shares in favor of the Transaction Proposals and (ii) not to redeem its 166,665 FEAC Class A Shares in
connection with the approval of the Business Combination by the shareholders of FEAC.</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;Person&#148; means an individual, partnership, corporation, limited liability company, joint stock
company, unincorporated organization or association, trust, joint venture or other similar entity, whether or not a legal entity.</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;PIPE Financing&#148; has the meaning set forth in the definition of PIPE Investors.</I>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;PIPE Financing Amount&#148; has the meaning set forth in the definition of PIPE Investors.</I>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;PIPE Investors&#148; refers to certain institutional investors who are parties with FEAC and New enGene
to the Subscription Agreements, pursuant to which, among other things, the PIPE Investors have agreed, subject to the completion of each element of the Transactions (other than those Transactions that are scheduled to be completed following the
Closing), to subscribe for and purchase, and FEAC has agreed that it will issue and sell to the PIPE Investors (which obligation will be assumed (the &#147;Assumption&#148;) by New enGene after the completion of the FEAC Reorganization and prior to
the consummation of the PIPE Financing (as defined below)) the number of FEAC Class</I><I></I><I>&nbsp;A Shares (or after the Assumption, New enGene Shares) provided for in the applicable Subscription Agreement (as amended by the applicable Side
Letter Agreement) (as defined below) in exchange for the purchase price set forth therein (the aggregate purchase price under the Subscription Agreements and the Side Letter Agreements, the &#147;PIPE Financing Amount,&#148; and the equity financing
under the Subscription Agreements and the Side Letter Agreements is hereinafter referred to as the &#147;PIPE Financing&#148;).</I> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;Plan of Arrangement&#148; means the Plan of Arrangement in substantially the form attached to the
Business Combination as Exhibit B, subject to any amendments or variations to such plan made in accordance with the Business Combination Agreement and the Plan of Arrangement or made at the direction of the Court in</I> <I>the Final Order with the
prior written consent of enGene and FEAC, each acting reasonably.</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;Reference Price&#148; means $10.25.</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;</I><I>Reference Value</I><I>&#148;</I><I> means the sum of: (i) $90,000,000, plus
(ii)</I><I></I><I>&nbsp;the Aggregate Exercise Price.</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;Rollover Equity Award&#148; means an equity award with respect to New enGene Shares that is outstanding
on the day following the Closing Date and that is received in exchange for an enGene Equity Award upon disposition and cancellation of such enGene Equity Award.</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;SEC&#148; refers to the U.S. Securities and Exchange Commission.</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;Securities Act&#148; refers to the U.S. Securities Act of 1933, as amended.</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;Side Letter Agreements&#148; collectively refers to the Side Letter Agreements, dated May 16, 2023, by
and among FEAC and New enGene and each PIPE Investor, pursuant to which the relevant Subscription Agreements are amended.</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;Sponsor&#148; refers to Forbion Growth Sponsor FEAC I B.V., a private limited liability company
incorporated in the Netherlands.</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;Sponsor and Insiders Letter Agreement&#148; refers to the agreement entered into on
May</I><I></I><I>&nbsp;16, 2023 by and among Sponsor, FEAC and the other parties thereto, pursuant to which, the Sponsor has agreed to surrender, after giving effect to the Sponsor Loans Conversion, 1,789,004 FEAC Class</I><I></I><I>&nbsp;B Shares
and 5,463,381 FEAC Private Placement Warrants, as a contribution to the capital of FEAC and for no consideration, effective immediately prior to the Class</I><I></I><I>&nbsp;B Conversion on the day which is two </I><I></I><I>business days prior to
the Closing Date, in each case, on the terms and conditions set forth in the Business Combination Agreement and the Sponsor and Insiders Letter Agreement.</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;Subscription Agreements&#148; refers to the subscription agreements, dated May</I><I></I><I>&nbsp;16,
2023, by and among FEAC, New enGene and the PIPE Investors, as amended by the Side Letter Agreements, pursuant to which the PIPE Investors will collectively subscribe for 6,435,441 FEAC Class</I><I></I><I>&nbsp;A Shares (or after the Assumption, New
enGene Shares) and 2,702,791 FEAC Warrants (or after the Assumption, New enGene Warrants) for an aggregate purchase price equal to $56,891,682.</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;Transaction Proposals&#148; refers to the Business Combination Proposal, the Governing Documents
Proposal and the Nasdaq Proposal.</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;Transactions&#148; refers to the transactions described in &#147;Proposal No.</I><I></I><I>&nbsp;1
&#151; The Business Combination Proposal &#151; Description of the Business Combination &#151;Transaction Structure.&#148;</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;Trust Account&#148; refers to the trust account established by FEAC in accordance with, that certain
Investment Management Trust Agreement, dated as of December</I><I></I><I>&nbsp;9, 2021, between FEAC and Continental, as trustee.</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;Trustee&#148; refers to Continental.</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;Warrant Assignment, Assumption and Amendment Agreement&#148; means the warrant assignment, assumption
and amendment agreement to be entered into on or around the Closing Date among FEAC, New enGene and the Trustee to amend the FEAC Warrant Agreement.</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>&#147;Working Capital Loan Note&#148; or &#147;First Loan Note&#148; means collectively, the unsecured
promissory note issued by FEAC to the Sponsor on March 24, 2023 in a total principal amount of up to $900,000</I> and the unsecured promissory note issued by FEAC to Sponsor on June 6, 2023 in a total principal amount of up to $300,000. As of June
30, 2023 there was $1,200,000 outstanding under the Working Capital Loan Note <I>.</I> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom459793_5"></A>CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Certain statements in this proxy statement/prospectus may constitute &#147;forward-looking statements&#148; within the meaning of
U.S. securities laws and &#147;forward-looking information&#148; within the meaning of Canadian securities laws (collectively, &#147;forward-looking statements&#148;). New enGene&#146;s and FEAC&#146;s forward-looking statements include, but are not
limited to, statements regarding New enGene&#146;s, FEAC&#146;s or their management teams&#146; expectations, hopes, beliefs, intentions, goals or strategies regarding the future. In addition, any statements that refer to projections, forecasts or
other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words &#147;anticipate,&#148; &#147;appear,&#148; &#147;approximate,&#148; &#147;believe,&#148;
&#147;continue,&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;foresee,&#148; &#147;intends,&#148; &#147;may,&#148; &#147;might,&#148; &#147;plan,&#148; &#147;possible,&#148; &#147;potential,&#148; &#147;predict,&#148;
&#147;project,&#148; &#147;seek,&#148; &#147;should,&#148; &#147;would&#148; and similar expressions (or the negative version of such words or expressions) may identify forward-looking statements, but the absence of these words does not mean that a
statement is not forward-looking. Forward-looking statements in this proxy statement/prospectus may include, for example, statements about: </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability of FEAC, enGene, New enGene and other parties to consummate the Business Combination and related
transactions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the expected benefits of the Business Combination; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">New enGene&#146;s financial performance following the Business Combination, including financial projections and
business metrics and any underlying assumptions thereunder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to obtain or maintain the listing of New enGene securities on a national securities exchange
following the Business Combination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">New enGene&#146;s success in recruiting and retaining, or changes required in, officers, key personnel or
directors following the completion of the Business Combination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">New enGene&#146;s plans and ability to execute product development, manufacturing process development,
preclinical and clinical development efforts successfully and on anticipated timelines; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">New enGene&#146;s ability to design, initiate and successfully complete clinical trials and other studies for its
product candidates and its plans and expectations regarding its ongoing or planned clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">New enGene&#146;s plans and ability to obtain and maintain marketing approval from the U.S. Food and Drug
Administration and other regulatory authorities, including the European Medicines Agency, for its product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">New enGene&#146;s plans and ability to commercialize its product candidates, if approved by applicable regulatory
authorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the degree of market acceptance of New enGene&#146;s product candidates, if approved, and the availability of
third-party coverage and reimbursement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability of New enGene&#146;s external contract manufacturers to support the manufacturing, release testing,
stability analysis, clinical labeling and packaging of New enGene&#146;s products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">following the Business Combination, New enGene&#146;s future financial performance and the sufficiency of New
enGene&#146;s cash and cash equivalents to fund its operations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the outcome of any known and unknown litigation and regulatory proceedings; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">New enGene&#146;s ability to implement and maintain effective internal controls. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All forward looking-statements, including, without limitation, our examination of historical operating trends, are based upon our current
expectations and various assumptions. Certain assumptions made in preparing the forward-looking statements include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FEAC, enGene, New enGene and other parties successfully consummate the Business Combination;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">New enGene is able to recruit and retain qualified scientific and management personnel, establish clinical trial
sites and patient registration for clinical trials and acquire technologies complementary to, or necessary for, its programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">New enGene is able to enroll a cohort of patients in the Phase 2 LEGEND trial to assess <FONT
STYLE="white-space:nowrap">EG-70&#146;s</FONT> efficacy and safety in the <FONT STYLE="white-space:nowrap">BCG-na&iuml;ve</FONT> patient population to evaluate its ultimate potential as a monotherapy in first line patients and expanding <FONT
STYLE="white-space:nowrap">EG-70&#146;s</FONT> opportunity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">New enGene is able to file a Biologics License Application in 2025 with the FDA for approval to market <FONT
STYLE="white-space:nowrap">EG-70</FONT> in the United States as a monotherapy to treat BCG-unresponsive NMIBC; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">EG-70&#146;s</FONT> product profile can be integrated seamlessly into community
urology clinics where the vast majority of NMIBC patients are treated; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">New enGene is able to retain commercial rights to <FONT STYLE="white-space:nowrap">EG-70</FONT> in the United
States and commercialize <FONT STYLE="white-space:nowrap">EG-70</FONT> independently, while selectively partnering outside of the United States; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">New enGene is able to execute the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">&#147;pipeline-in-a-product&#148;</FONT></FONT></FONT> development strategy for <FONT STYLE="white-space:nowrap">EG-70;</FONT> and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">New enGene is able to utilize the DDX gene delivery platform to develop effective, new agents for the delivery of
genetic medicines to mucosal tissues. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should not place undue reliance on these forward-looking statements in
deciding how to vote your proxy or instruct how your vote should be cast on the proposals set forth in this proxy statement/prospectus. The forward-looking statements contained in this proxy statement/prospectus are based primarily on current
expectations and projections about future events and trends that may affect our business, financial condition and operating results. The following uncertainties and factors, among other things (including those described in &#147;<I>Risk
Factors</I>&#148;), could affect future performance and actual results to differ materially and adversely from those expressed in, anticipated or implied by forward-looking statements: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the occurrence of any event, change or other circumstances that could give rise to the termination of the
definitive agreements with respect to the Business Combination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the outcome of any legal proceedings that may be instituted against FEAC, enGene, New enGene or others following
the announcement of the Business Combination and the definitive agreements with respect thereto; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability to complete the Business Combination due to the failure to obtain approval of the shareholders of
FEAC or enGene, or to satisfy other conditions to Closing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes to the proposed structure of the Business Combination that may be required or appropriate as a result of
applicable laws or regulations or as a condition to obtaining regulatory approval of the Business Combination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability of New enGene to meet stock exchange listing standards following the consummation of the Business
Combination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk that the Business Combination disrupts current plans and operations of enGene as a result of
consummation of the Business Combination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to recognize the anticipated benefits of the Business Combination, which may be affected by, among
other things, the net cash proceeds to New enGene following redemptions and transaction expenses; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks applicable to enGene&#146;s business, including the extensive regulation of all aspects of enGene&#146;s
business, competition from other existing or newly developed products and treatments; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks associated with the protection of intellectual property, New enGene&#146;s ability to raise additional
capital to fund its produce development activity, and its ability to maintain key relationships and to attract and retain talented personnel; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs related to the Business Combination; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possibility that enGene or New enGene may be adversely affected by changes in domestic and foreign business,
market, financial, political, legal conditions and laws and regulations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability of the parties to successfully or timely consummate the Business Combination, including the risk
that any regulatory approvals are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect New enGene or the expected benefits of the Business Combination; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enGene and New enGene&#146;s estimates of expenses; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other risks and uncertainties set forth in the section entitled &#147;<I>Risk Factors</I>&#148; in this
proxy&nbsp;statement/prospectus. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, statements that &#147;we believe&#148; and similar statements reflect
beliefs and opinions on the relevant subject. These statements are based on information available to us as of the date of this proxy statement/prospectus. While we believe that information provides a reasonable basis for these statements, that
information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all relevant information. These statements are inherently uncertain, and investors are cautioned
not to unduly rely on these statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The forward-looking statements made in this proxy statement/prospectus relate only to events as
of the date on which the statements are made. We undertake no obligation to update any forward-looking statements made in this proxy statement/prospectus to reflect events or circumstances after the date of this proxy statement/prospectus or to
reflect new information or the occurrence of unanticipated events, except as required by law. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on
our forward-looking statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom459793_6"></A>QUESTIONS AND ANSWERS ABOUT THE BUSINESS COMBINATION AND THE
SPECIAL MEETING </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following are answers to certain questions that you may have regarding the Special Meeting. FEAC urges you to
read carefully the remainder of this proxy statement/prospectus because the information in this section may not provide all the information that might be important to you in determining how to vote. Additional important information is also contained
in the appendices to, and the documents incorporated by reference in, this proxy statement/prospectus. </I></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Why am I receiving this proxy statement/prospectus? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">FEAC Shareholders are being asked to consider and vote upon, among other things, a proposal to approve the
Business Combination Agreement. The Business Combination Agreement provides, subject to the terms and conditions contained therein, that FEAC, enGene and New enGene will complete the Business Combination. Shareholder approval of the Business
Combination Agreement and the Transactions contemplated thereby is required pursuant to the Business Combination Agreement and FEAC&#146;s Current Articles, as well as to comply with Nasdaq Listing Rule 5635. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">A copy of the Business Combination Agreement is attached to this proxy statement/prospectus as <B><U>Annex A</U></B>. This proxy
statement/prospectus and its annexes contain important information about the Business Combination and the other matters to be acted upon at the Special Meeting. You should read this proxy statement/prospectus, including the attached annexes,
carefully and in their entirety. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">YOUR VOTE IS IMPORTANT. YOU ARE ENCOURAGED TO SUBMIT YOUR PROXY AS SOON AS POSSIBLE AFTER CAREFULLY
REVIEWING THIS PROXY STATEMENT/PROSPECTUS, INCLUDING THE ATTACHED ANNEXES. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Why is FEAC proposing the Business Combination? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">FEAC is a blank check company incorporated for the purpose of effecting a merger, share exchange, asset
acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">enGene is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. enGene is developing <FONT
STYLE="white-space:nowrap">non-viral</FONT> gene therapies based on its novel and proprietary dually derived chitosan, or &#147;DDX&#148;, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues
and other organs. enGene has established integrated capabilities with this platform to support the clinical development and potential commercialization of its gene therapies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In determining to approve entry into the Business Combination Agreement and ancillary agreements and the Transactions contemplated thereby,
the FEAC Board considered, among other things, the following factors (although not weighted or in any order of significance): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Experienced management team with leading industry experience and track record. </I></B>The FEAC Board
believed that enGene&#146;s management team has extensive experience in the biopharma industry in general and the gene therapies market in particular. The FEAC Board is confident in the management team&#146;s deep industry knowledge and strategic
vision and believes that both the FEAC and the enGene teams (together with the new incoming directors of New enGene) have extensive executive experience working in the biopharma industry, which will position enGene to create and enhance a
collaborative and effective long-term partnership that is positioned to create and enhance shareholder value going forward. For additional information regarding enGene&#146;s executive officers, please see the section entitled &#147;<I>Directors and
Executive Officers of New enGene After the Business Combination</I>.&#148; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Next-generation non-viral gene delivery platform supporting substantial timeline and new programs.
</I></B>The FEAC Board considered that the current product pipeline of enGene provides multiple product </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
candidates that may be developed in several indications where the existing unmet medical need could provide significant market opportunities and long-term shareholder value. For additional
information regarding enGene&#146;s pipeline, please see the section entitled &#147;<I>Business of enGene</I>.&#148; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Upcoming milestones and potential value inflection point. </I></B>The FEAC Board considered that with the
funds that enGene is expected to receive as a result of the Business Combination, it may be able to reach significant clinical milestones for EG-70, including the Phase 2 interim efficacy studies. These milestones could provide opportunity for
potential uplifts in valuation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Established regulatory registrational pathway, market and pricing dynamics for lead program. </I></B>The
FEAC Board considered that NMIBC is an indication which is well-defined, with high unmet medical need and for which prior regulatory guidance provides a clear regulatory pathway. The FEAC Board believes that
<FONT STYLE="white-space:nowrap">EG-70</FONT> has a profile which, if proven in later clinical studies, is commercially viable. Given the high unmet medical need of NMIBC patients, and availability of independent third parties&#146; reports
confirming favorable pricing dynamics for a similar product, the FEAC Board believes that the overall market dynamics of <FONT STYLE="white-space:nowrap">EG-70</FONT> might be favorable. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Benefit for enGene of being U.S. listed</I></B>. As a result of the proposed transaction, it is expected
that enGene will become a public company listed on the Nasdaq Capital Market (via New enGene). The FEAC Board considered that by having access to the world&#146;s largest biotech capital market, enGene will be better positioned to have the capacity
to raise additional funds in the future if and when needed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Investment by Third Parties</I></B><B>. </B>The FEAC Board considered that certain third-party investors
(other than the Sponsor, FGOF and existing enGene investors) (i)&nbsp;subscribed for the PIPE Financing in the aggregate amount of approximately $55.7&nbsp;million and (ii)&nbsp;entered into the Convertible Bridge Financing in the aggregate amount
of approximately $10.0&nbsp;million. The FEAC Board noted that the Sponsor (i)&nbsp;will invest an amount of approximately $1.2 million in the PIPE Financing and (ii)&nbsp;participated in the Convertible Bridge Financing in an amount equal to $20.0
million. Furthermore, the FEAC Board noted with respect to the price per share of FEAC Shares, that (i) in its IPO, FEAC issued FEAC Units at an offering price of $10.00 per FEAC Unit, each of which consisted of one FEAC Class A Share and one-third
of one FEAC Public Warrant; (ii) in connection with the PIPE Financing, FEAC entered into Subscription Agreements pursuant to which it agreed that it (or after the Assumption, New enGene) will issue and sell to the PIPE Investors the number of FEAC
Class A Shares (or after the Assumption, New enGene Shares) provided for in the applicable Subscription Agreement in exchange for the purchase price of $10.25 per FEAC Class A Share (or after the Assumption, New enGene Share), which purchase price
was set on the basis of the initial amount available per FEAC Class A Share in FEAC&#146;s Trust Account immediately upon the consummation of its IPO and the exercise in full of the underwriters&#146; over-allotment option (which resulted in
$129,662,500, or $10.25 per FEAC Unit, being held in the Trust Account). Immediately following the execution and delivery of the Subscription Agreements, FEAC and New enGene entered into a Side Letter Agreement with each PIPE Investor, amending such
PIPE Investor&#146;s Subscription Agreement, pursuant to which each PIPE Investor will receive a specified number of additional FEAC Class A Shares (or after the Assumption, New enGene Shares) and a specified number of FEAC Public Warrants (of after
the Assumption, New enGene Warrants), in each case in consideration of the aggregate purchase price set forth in the relevant PIPE Investor&#146;s original Subscription Agreement; (iii) pursuant to the Non-Redemption Agreement, FEAC will, in
consideration of a specific FEAC shareholder&#146;s commitment not to redeem its FEAC Class A Shares in connection with the approval of the Business Combination by the FEAC Shareholders, issue additional FEAC Class A Shares and FEAC Public Warrants
(or after the Assumption, New enGene will issue additional New enGene Shares and New enGene Warrants) to such FEAC shareholder, such that, in the aggregate, such FEAC shareholder will hold the same amount of FEAC Class A Shares and FEAC Public
Warrants (or after the Assumption, New enGene Shares and New enGene Warrants) as it would have received if it had subscribed, in an amount equal to its existing IPO investment in FEAC Class A Shares, for FEAC Class A Shares in the PIPE Financing (or
after the Assumption, New enGene Shares) on the same </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
terms and at the same purchase price per FEAC Class A Share as the PIPE Financing, taking into account the additional FEAC Class A Shares and FEAC Public Warrants (or after the Assumption, New
enGene Shares and New enGene Warrants) allocated to the PIPE Investors pursuant to the Side Letter Agreements; and (iv) the Convertible Bridge Financing indebtedness will be converted in the Transactions into that number of New enGene Shares and New
enGene Warrants that, when exchanged at the Company Exchange Ratio, shall equal that number of FEAC Class A Shares and FEAC Public Warrants (or after the Assumption, New enGene Shares and New enGene Warrants) that the holders of such indebtedness
would have received if they had subscribed, in an amount equal to their existing investment in the Convertible Bridge Financing, for FEAC Class A Shares in the PIPE Financing (or after the Assumption, New enGene Shares) on the same terms and at the
same purchase price per FEAC Class A Share as the PIPE Financing, taking into account the additional FEAC Class A Shares and FEAC Public Warrants (or after the Assumption, New enGene Shares and New enGene Warrants) allocated to the PIPE Investors
pursuant to the Side Letter Agreements. </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Terms of the Business Combination Agreement and the Ancillary Agreements</I></B><B>. </B>The FEAC Board
considered the terms and conditions of the Business Combination Agreement and the Ancillary Agreements, including the transactions contemplated thereby, each party&#146;s representations, warranties and covenants, the conditions to each party&#146;s
obligation to close and the termination provisions, as well as FEAC&#146;s and enGene&#146;s strong commitment to complete the Business Combination. The FEAC Board determined that such terms and conditions are reasonable and were the product of
extensive arm&#146;s-length negotiations between FEAC and enGene. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Continued Ownership of enGene Shareholders</I></B><B>. </B>The FEAC Board considered that the enGene
Shareholders would be receiving a significant amount of shares of New enGene in the proposed Business Combination. Certain enGene Shareholders have demonstrated confidence in the long-term prospects of New enGene by agreeing not to transfer their
shares in New enGene for 180&nbsp;days following the Closing. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>The Role of the Independent Directors</I></B><B>. </B>In connection with the Business Combination,
FEAC&#146;s independent directors evaluated the proposed terms of the Business Combination, including the Business Combination Agreement and the related agreements, and unanimously approved, as members of the FEAC Board, the Business Combination
Agreement, the Ancillary Agreements, and the Transactions contemplated thereby. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Other Alternatives</I></B><B>. </B>The FEAC Board believed, after a thorough review of other business
combination opportunities reasonably available to or explored by FEAC, that the proposed Business Combination represented the optimal potential business combination for FEAC and its shareholders based upon the process utilized to evaluate and assess
other potential acquisition targets and the FEAC Board&#146;s belief that such processes had not presented a better alternative. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Negotiated Transaction</I></B>. The FEAC Board believed that the financial and other terms of the Business
Combination Agreement, including the consideration to be paid by FEAC to enGene Shareholders, are reasonable and were the product of arm&#146;s length negotiations between FEAC and enGene. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FEAC Board also identified and considered a variety of uncertainties and risks and other potentially negative factors concerning the
Business Combination, including, but not limited to, the following (although not weighted or in any order of significance): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>New enGene&#146;s competition risks: </I></B>The FEAC Board considered that New enGene will face
significant competition from other biotechnology and pharmaceutical companies, which may result in its competitors discovering, developing or commercializing products before New enGene or more successfully than New enGene will do.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>New enGene&#146;s highly regulated business.</I></B> The FEAC Board considered that New enGene&#146;s
activity, products and services are subject to extensive regulation by various U.S. federal and state agencies, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
regulatory bodies in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions, and compliance with existing or future regulations could result in unanticipated expenses or limit New
enGene&#146;s ability to offer its products and services. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Ability of New enGene to commercialize its products and generate revenues. </I></B>The FEAC Board
considered that if New enGene is not able to obtain or if there are delays in obtaining required regulatory approvals for its product candidates, New enGene will not be able to commercialize or will be delayed in commercializing its product
candidates and its ability to generate revenue will be adversely affected. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Ongoing regulatory compliance. </I></B>The FEAC Board considered that New enGene may not obtain or maintain
regulatory approval in all jurisdictions in which such approval may be required. Obtaining and maintaining regulatory approval of New enGene&#146;s product candidates in one jurisdiction does not mean that New enGene will obtain and/or maintain
regulatory approval of its product candidates in other jurisdictions, while a failure or delay in obtaining or maintaining regulatory approval of its product candidates in one jurisdiction may have a material adverse effect on the regulatory
approval or maintenance process in other jurisdictions. Even if New enGene receives regulatory approval of any product candidates or therapies, it will be subject to ongoing regulatory obligations, reporting requirements and continued regulatory
review, which may result in significant additional expenses. If New enGene fails to comply with regulatory requirements or experiences unanticipated problems with its product candidates, it may be subject to substantial penalties, fines, delays,
suspensions, refusals and withdrawals of approvals. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Third party risks. </I></B>The FEAC Board considered that New enGene&#146;s contract manufacturers are
subject to significant regulation with respect to the manufacturing of New enGene&#146;s current and future product candidates. The manufacturing facilities on which New enGene will rely may not meet or continue to meet regulatory requirements
and/or may have limited capacity. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Drug marketing, price controls and reimbursement regulations. </I></B>The FEAC Board assessed that
regulations concerning drug marketing, control of prices and reimbursement may materially affect New enGene&#146;s ability to market and receive coverage for New enGene&#146;s product candidates, if approved, in the European Union, the United
Kingdom, Japan and other <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">For additional information, see
&#147;<I>Proposal No.</I><I></I><I>&nbsp;1&nbsp;&#151; The Business Combination Proposal&nbsp;&#151; The FEAC Board&#146;s Reasons for the Business Combination.</I>&#148; </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>When and where will the Special Meeting take place? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Special Meeting will be convened on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;, 2023, at 10:00 a.m., New York City time, at &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and in a virtual format. Shareholders may attend,
vote and examine the list of FEAC Shareholders entitled to vote at the Special Meeting by visiting <B><U>https://www.cstproxy.com/feac/2023</U></B> and entering the control number found on their proxy card, voting instruction form or notice included
in their proxy materials. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Who is entitled to vote at the Special Meeting? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As a shareholder of FEAC, you have a right to vote on certain matters affecting FEAC. The proposals that will
be presented at the Special Meeting and upon which you are being asked to vote are summarized below (see &#147;&#151;<I>What is being voted on at the Special Meeting?</I>&#148;) and fully set forth in this proxy statement/&nbsp;prospectus. FEAC
Shareholders will be entitled to vote or direct votes to be cast at the Special Meeting if they owned FEAC Shares at the close of business on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; , 2023, which is the record date
for the Special Meeting. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Attendance at the Special Meeting is not required to vote. See &#147;&#151; <I>How can I vote
my shares without attending the Special Meeting</I>?&#148; for instructions on how to vote your FEAC Shares without attending the Special Meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What is the record date for the Special Meeting? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The FEAC Board has established &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;, 2023
as the record date for the Special Meeting. Only holders of record of FEAC Shares at the close of business on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;, 2023 are entitled to notice of and to vote and have their votes
counted at the Special Meeting and any further adjournments or postponements of the Special Meeting. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What is being voted on at the Special Meeting? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">FEAC Shareholders will vote on the following proposals at the Special Meeting: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Business Combination Proposal &#151; to consider and vote upon a proposal to approve and adopt the Business
Combination Agreement, a copy of which is attached as <B><U>Annex A</U></B> to this proxy statement/prospectus, and the Transactions contemplated therein, whereby, among other things, FEAC, enGene and New enGene will complete a business combination;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Governing Documents Proposal &#151; to consider and vote upon a proposal to approve material differences
between New enGene&#146;s Proposed Articles to be in effect following the Business Combination and FEAC&#146;s Current Articles; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Nasdaq Proposal &#151; to consider and vote upon a proposal to approve, for purposes of complying with
Nasdaq Listing Rule 5635(a), (b) and (d), the issuance of more than 20% of the issued and outstanding FEAC Class&nbsp;A Shares and the resulting change in control in connection with the Business Combination; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Incentive Equity Plan Proposal &#151; to consider and vote upon a proposal to approve the enGene Holdings
Inc. 2023 Incentive Equity Plan; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Adjournment Proposal &#151; to consider and vote upon a proposal to approve the adjournment of the Special
Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies if, based upon the tabulated vote at the time of the Special Meeting, any of the condition precedent proposals would not be duly approved and adopted
by FEAC Shareholders or we determine that one or more of the closing conditions under the Business Combination Agreement is not satisfied or waived. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>After careful consideration, the FEAC Board has determined that each of the Business Combination Proposal, the Governing Documents Proposal,
the Nasdaq Proposal, the Incentive Equity Plan Proposal and the Adjournment Proposal are in the best interests of and advisable to FEAC and the FEAC Shareholders and recommends that you vote, or give instruction to vote, &#147;FOR&#148; each of
those proposals. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>The existence of financial and personal interests of the Sponsor and FEAC&#146;s directors and officers may result
in a conflict of interest on the part of one or more of the directors between what they may believe is in the best interests of FEAC and its shareholders and what they may believe is best for themselves or the Sponsor in determining to recommend
that shareholders vote for the proposals. See the section entitled &#147;</B><B><I>Proposal No.</I></B><B></B><B><I></I></B><B></B><B><I>&nbsp;1 &#151; The Business Combination Proposal &#151; Interests of FEAC&#146;s Sponsor, Directors and
Executive Officers in the Business Combination</I></B><B>&#148; in the proxy&nbsp;statement/prospectus for a further discussion. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>THE VOTE OF SHAREHOLDERS IS IMPORTANT. SHAREHOLDERS ARE URGED TO SUBMIT THEIR PROXIES AS SOON AS POSSIBLE AFTER CAREFULLY REVIEWING THIS
PROXY STATEMENT/PROSPECTUS, INCLUDING THE ATTACHED ANNEXES. </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Do New enGene&#146;s Proposed Articles differ materially from FEAC&#146;s Current Articles?
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Following the consummation of the Business Combination, the rights of FEAC Shareholders who become New enGene
Shareholders in the Business Combination will no longer be governed by FEAC&#146;s Current Articles and instead will be governed by New enGene&#146;s Proposed Articles, which differ in some material respects. See &#147;<I>Comparison of Corporate
Governance and Shareholder Rights</I>&#148; for further information. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Why is FEAC providing shareholders with the opportunity to vote on the Business Combination Proposal?
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Under FEAC&#146;s Current Articles, FEAC must provide FEAC Shareholders with the opportunity to have their FEAC
Shares redeemed upon the consummation of the Business Combination in conjunction with a tender offer or submit the Business Combination to a shareholder vote. For business and other reasons, we have elected to provide FEAC Shareholders with the
opportunity to vote on the approval of the Business Combination Agreement rather than holding a tender offer. Therefore, FEAC is seeking to obtain FEAC Shareholders&#146; approval of the Business Combination Proposal in order to allow FEAC to
proceed with the Transactions. The approval of FEAC Shareholders of the Business Combination Proposal and the other proposals is also a condition to the closing of the Business Combination in the Business Combination Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What interests do FEAC&#146;s current officers and directors have in the Business Combination?
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In considering the recommendation of the FEAC Board to vote in favor of the Business Combination, FEAC
Shareholders should be aware that, aside from their interests as FEAC Shareholders, the Sponsor and certain of FEAC&#146;s directors and officers have interests in the Business Combination that are different from, or in addition to, those of other
FEAC Shareholders generally. FEAC&#146;s directors were aware of and considered these interests, among other matters, in evaluating the Business Combination and in recommending to FEAC Shareholders that they approve the Business Combination. FEAC
Shareholders should take these interests into account in deciding whether to approve the Business Combination. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">These
interests include, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that after giving effect to the Sponsor Loans Conversion and the Surrender, the Sponsor will retain
1,373,496 FEAC Class&nbsp;B Shares which it purchased at a price of approximately $0.009 per share and 731,619 FEAC Private Placement Warrants which it purchased at a price of $1.50 per warrant, and such securities will have a significantly higher
value at the time of the Business Combination as described further below: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;FEAC<BR>Class&nbsp;B&nbsp;Shares</B><br><B>beneficially&nbsp;owned&nbsp;as</B><br><B>of the date hereof</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;FEAC</B><br><B>Private&nbsp;Placement</B><br><B>Warrants&nbsp;owned&nbsp;as&nbsp;of<BR>the date hereof</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate&nbsp;value<BR>of&nbsp;FEAC&nbsp;Class&nbsp;B</B><br><B>Shares&nbsp;and&nbsp;FEAC</B><br><B>Private&nbsp;Placement</B><br><B>Warrants&nbsp;
implied&nbsp;by</B><br><B>the&nbsp;Business</B><br><B>Combination<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate&nbsp;value</B><br><B>of&nbsp;FEAC&nbsp;Class&nbsp;B</B><br><B>Shares&nbsp;and&nbsp;FEAC</B><br><B>Private&nbsp;Placement</B><br><B>Warrants&nbsp;
based&nbsp;on</B><br><B>&nbsp;&nbsp;recent&nbsp;trading&nbsp;price<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sponsor<SUP STYLE="font-size:75%; vertical-align:top">(3)(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,373,496</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">731,619</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,215,684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Assumes a value of $10.35 per share, the deemed value of the FEAC Class B Shares on the basis of the
anticipated amount in the Trust Account of $10.35 per FEAC Class A Shares (excluding interest earned on amounts in the Trust Account), and $0.00 per warrant, which reflects that the exercise price of the warrants ($11.50 per warrant) exceeds the
value of the underlying ordinary shares in the Business Combination. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Assumes a value of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the closing price of the FEAC
Class&nbsp;B Shares on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;, 2023, and $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per warrant, the closing price of the FEAC Private Placement Warrants on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;, 2023. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Sponsor is the record holder of the FEAC Class&nbsp;B Shares reported herein. Jasper Bos, Cyril Lesser,
Sander Slootweg and Wouter Joustra, who are directors of the Sponsor, have voting and investment discretion with respect to the FEAC Shares owned by the Sponsor and may be deemed to have indirect shared beneficial ownership of the FEAC Shares held
by the Sponsor. Jasper Bos, Cyril Lesser, Sander Slootweg and Wouter Joustra each disclaim beneficial ownership over the FEAC Class&nbsp;B Shares except to the extent of their pecuniary interest therein. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">FGOF wholly owns the Sponsor and therefore the Sponsor and FGOF have shared voting and investment power over
the FEAC Class&nbsp;B Shares held by the Sponsor. FGOF also holds 2,000,000 FEAC Class&nbsp;A Shares underlying the 2,000,000 FEAC Units held by it. Therefore, FGOF has shared voting and investment power over 5,162,500 FEAC Shares in the aggregate,
representing approximately 32.7% of FEAC&#146;s issued </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
and outstanding ordinary shares as of the date hereof. Forbion Management is the sole director of FGOF and therefore shares voting and investment power (i)&nbsp;with FGOF over the 2,000,000 FEAC
Class&nbsp;A Shares underlying the FEAC Units held by FGOF and (ii)&nbsp;with FGOF and, indirectly, the Sponsor, over the 3,162,500 FEAC Class&nbsp;B Shares held by the Sponsor. Forbion Management exercises voting and investment power through its
investment committee (the &#147;Investment Committee&#148;) consisting of Sander Slootweg, Martien van Osch, <FONT STYLE="white-space:nowrap">Geert-Jan</FONT> Mulder, Vincent van Houten, Dirk Kersten, Nanna L&uuml;neborg, Wouter Joustra and Jasper
Bos. None of the members of the Investment Committee has individual voting and investment power with respect to the ordinary shares, and each such member disclaims beneficial ownership of the ordinary shares except to the extent of their
proportionate pecuniary interest therein. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Prior to the Surrender and the Sponsor Loan Conversions (see &#147;<I>Certain Relationships and Related Party
Transactions</I> &#151;<I> Sponsor and Insiders Letter; Surrender; Sponsor Loans Conversion</I>&#148;), the Sponsor owns 3,162,500 FEAC Class&nbsp;B Shares and 5,195,000 FEAC Private Placement Warrants. Pursuant to the Sponsor Loans Conversions
agreed in the Sponsor and Insiders Letter Agreement, the Sponsor agreed to convert an amount equal to $1,500,000 of the aggregate principal amount outstanding under the Sponsor Loans, taken together, into additional FEAC Private Placement Warrants
immediately prior to the Surrender (following which the Sponsor will own 6,195,000 FEAC Private Placement Warrants). Pursuant to the Surrender agreed in the Sponsor and Insiders Letter Agreement, the Sponsor will forfeit 1,789,004 of its FEAC
Class&nbsp;B Shares and 5,463,381 of its FEAC Private Placement Warrants as a contribution to the capital of FEAC, for no consideration. After the Surrender, such 1,789,004 of its FEAC Class&nbsp;B Shares and 5,463,381 of its FEAC Private Placement
Warrants will be cancelled and no longer outstanding and the Sponsor will own 1,373,496 FEAC Class&nbsp;B Shares and 731,619 FEAC Private Placement Warrants. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that if FEAC does not complete its initial business combination within 18 months from the closing of
FEAC&#146;s IPO (or up to 24 months from the closing of our IPO if FEAC extends the period of time to consummate a business combination, subject to the Sponsor depositing additional funds in the Trust Account), the FEAC Class&nbsp;B Shares and the
FEAC Private Placement Warrants will expire worthless; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that given the differential in the purchase price that the Sponsor paid for the FEAC Class&nbsp;B Shares
as compared to the price of the FEAC Class&nbsp;A Shares sold in FEAC&#146;s IPO, the Sponsor and its affiliates may earn a positive rate of return on their investment even if the FEAC Class&nbsp;A Shares trade below the price initially paid for the
FEAC Class&nbsp;A Shares in FEAC&#146;s IPO and the holders of FEAC Class&nbsp;A Shares experience a negative rate of return following the completion of the Business Combination. It is not practicable to quantify the Sponsor&#146;s rate of return
because, among other things, the timing (including as a result of the <FONT STYLE="white-space:nowrap">lock-up</FONT> applicable to the FEAC Class&nbsp;B Shares) and the price at which the Sponsor may ultimately sell New enGene Shares (into which
the FEAC Class&nbsp;B Shares will be converted in connection with the Business Combination), New enGene Warrants (into which the FEAC Private Placement Warrants will be converted in connection with the Business Combination) and other equity
securities of New enGene are uncertain, both of which would have a material impact on the applicable rate of return; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that pursuant to the Sponsor&#146;s subscription agreement entered into on May&nbsp;16, 2023 with FEAC
and New enGene (as amended by the Sponsor&#146;s subscription agreement side letter entered into on May&nbsp;16, 2023 by the Sponsor, FEAC and New enGene), the Sponsor will receive, upon consummation of the Business Combination, in consideration of
the purchase price to be paid by the Sponsor set forth in such agreement, 130,085 FEAC Class&nbsp;A Shares (or following the Assumption, New enGene Shares) and 54,634 FEAC Private Placement Warrants (or following the Assumption, New enGene
Warrants); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the Sponsor purchased or will purchase from enGene pursuant to a purchase agreement entered into
with enGene on May&nbsp;16, 2023 for an aggregate amount of $20,000,000 (i) warrants of enGene and (ii)&nbsp;convertible notes of enGene which will get converted upon the consummation of the Business Combination into common shares of enGene, and
which, in each case, when exchanged at the enGene Exchange Ratio pursuant to the Transactions, shall equal that number of FEAC Warrants and FEAC Class&nbsp;A Shares (or after the Assumption, New enGene Warrants and New enGene Shares,
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
respectively), that the Sponsor would have received if it had participated in that amount on the same terms as the PIPE Financing; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that if a business combination is not consummated within the required period, the Sponsor will lose its
entire investment in FEAC, which investment included a capital contribution of $25,000 for the Sponsor&#146;s FEAC Class&nbsp;B Shares, $7,792,500 for the Sponsor&#146;s FEAC Private Placement Warrants, $1,200,000 in Working Capital Loans and
$1,265,000 in Extension Loans (as defined below); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the Sponsor and FEAC&#146;s current officers and directors have entered into a letter agreement
with FEAC dated December&nbsp;9, 2021 in which they agreed to waive their rights to liquidating distributions from the Trust Account with respect to any FEAC Class&nbsp;B Shares held by them if FEAC fails to complete an initial business combination
within the required period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that pursuant to the FEAC Voting Agreement, the Sponsor, FGOF and FEAC&#146;s directors and executive
officers agreed, among other things, (a)&nbsp;to vote any FEAC Class&nbsp;B Shares and FEAC Class&nbsp;A Shares held by it in favor of any proposed business combination and (b)&nbsp;not to redeem any FEAC Class&nbsp;B Shares or FEAC Class&nbsp;A
Shares held by it in connection with a shareholder vote to approve a proposed Business Combination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the Sponsor and FGOF, collectively, after giving effect to the Transactions and the transfer of
20,000 New enGene Shares to each of three of FEAC&#146;s independent directors as described below, are expected to own 5,705,932 New enGene Shares, which collectively will represent approximately 24% of outstanding New enGene Shares (assuming
maximum FEAC Shareholder Redemptions) and have a value of approximately $59,056,396.20 based on an implied value of $10.35 per New enGene Share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the Sponsor agreed to transfer 20,000 of the New enGene Shares it expects to receive in connection
with the Business Combination to each of three of FEAC&#146;s independent directors following the consummation of the Business Combination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the anticipated designation by FEAC of Jasper Bos, its current Chief Executive Officer and director, as director
of New enGene upon the consummation of the Business Combination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the continued indemnification of FEAC&#146;s directors and officers and the continuation of FEAC&#146;s
directors&#146; and officers&#146; liability insurance after the Business Combination (i.e., a &#147;tail policy&#148;); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the Sponsor has agreed that in the event of the liquidation of the Trust Account upon the failure
of FEAC to consummate the Business Combination it will be liable to FEAC if and to the extent any claims by a third-party for services rendered or products sold to FEAC, or a prospective target business with which we have discussed entering into a
transaction agreement, reduce the amounts in the Trust Account to below the lesser of (i) $10.25 per FEAC Class&nbsp;A Share and (ii)&nbsp;the actual amount per FEAC Class&nbsp;A Share held in the Trust Account as of the date of the liquidation of
the Trust Account if less than $10.25 per FEAC Class&nbsp;A Share due to reductions in the value of the trust assets, in each case net of the interest that may be withdrawn to pay our tax obligations (less up to $100,000 of interest to pay
dissolution expenses), provided that such liability will not apply to any claims by a third-party or prospective target business that executed a waiver of any and all rights to seek access to the Trust Account nor will it apply to any claims under
FEAC&#146;s indemnity of the underwriters of FEAC&#146;s IPO against certain liabilities, including liabilities under the Securities Act. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Commencing on the date that FEAC&#146;s securities were first listed on the Nasdaq through the earlier of consummation of the initial business
combination and the liquidation of FEAC, FEAC agreed to pay the Sponsor a total of $10,000 per month for office space, utilities, secretarial and administrative support and to reimburse the Sponsor for any out-of-pocket expenses related to
identifying, investigating and completing an initial business combination. As of the date of this proxy statement/prospectus, no such fees or expenses are outstanding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>If my shares are held in &#147;street name,&#148; will my broker, bank or nominee automatically vote my
shares for me? </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No. If your FEAC Shares are held in an account through a broker, bank or other nominee or intermediary, you
must instruct the broker, bank or other nominee how to vote your shares by following the instructions that the broker, bank or other nominee provides you along with this proxy statement/prospectus. Your broker, bank or other nominee may have an
earlier deadline by which you must provide instructions to it as to how to vote your FEAC Shares, so you should read carefully the materials provided to you by your broker, bank or other nominee or intermediary. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If you do not provide voting instructions to your bank, broker or other nominee or intermediary, your shares will not be voted on any proposal
on which your bank, broker or other nominee does not have discretionary authority to vote. In these cases, the bank, broker or other nominee or intermediary will not be able to vote your shares on those matters for which specific authorization is
required. Brokers do not generally have discretionary authority to vote on any of the proposals. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Under Nasdaq rules, if a shareholder
holds their shares in &#147;street name&#148; through a bank, broker or other nominee and the shareholder does not instruct their broker, bank or other nominee how to vote their shares on a proposal, the broker, bank or other nominee has the
authority to vote the shares in its discretion on certain &#147;routine&#148; matters. However, banks, brokers and other nominees are not authorized to exercise their voting discretion on any
<FONT STYLE="white-space:nowrap">&#147;non-routine&#148;</FONT> matters. This can result in a &#147;broker <FONT STYLE="white-space:nowrap">non-vote,&#148;</FONT> which occurs on a proposal when (i)&nbsp;a bank, broker or other nominee has
discretionary authority to vote on one or more &#147;routine&#148; proposals to be voted on at a meeting, (ii)&nbsp;there are one or more <FONT STYLE="white-space:nowrap">&#147;non-routine&#148;</FONT> proposals to be voted on at the meeting for
which the bank, broker or other nominee does not have authority to vote without instructions from the beneficial owner of the shares and (iii)&nbsp;the beneficial owner fails to provide the bank, broker or other nominee with voting instructions on a
<FONT STYLE="white-space:nowrap">&#147;non-routine&#148;</FONT> matter. We believe that all of the proposals to be voted on at the Special Meeting will be considered <FONT STYLE="white-space:nowrap">non-routine</FONT> matters. As a result, if you
hold your shares in &#147;street name,&#148; your bank, brokerage firm or other nominee cannot vote your shares on any of the proposals to be voted on at the Special Meeting without your instruction. Because all of the proposals to be voted on at
the Special Meeting are <FONT STYLE="white-space:nowrap">&#147;non-routine&#148;</FONT> matters, banks, brokers and other nominees will not have authority to vote on any proposals unless instructed, so FEAC does not expect there to be any broker <FONT
STYLE="white-space:nowrap">non-votes</FONT> at the Special Meeting. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What vote is required to approve the proposals presented at the Special Meeting? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The adoption and approval of the Business Combination Agreement and the Transactions including the Plan of
Arrangement requires the affirmative vote of the holders of at least a majority of the FEAC Shares present in person or represented by proxy and entitled to vote at the Special Meeting; the approval of (i)&nbsp;the Cayman Merger and (ii)&nbsp;the
Cayman Reorganization, which is part of the Business Combination Proposal, requires the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the FEAC Shares present in person or represented by proxy and
entitled to vote at the Special Meeting. Therefore, the approval of the Business Combination Proposal requires the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the FEAC Shares present in person or
represented by proxy and entitled to vote at the Special Meeting. Abstentions will have no effect on the outcome of the proposal. The Business Combination cannot be completed unless the Business Combination Proposal is adopted by affirmative vote of
the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the votes cast by FEAC Shareholders present or represented by proxy at the Special Meeting and entitled to vote thereon. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The adoption and approval of each of the Governing Documents Proposal, the Nasdaq Proposal, the Incentive Equity Plan Proposal and the
Adjournment Proposal requires the affirmative vote of the holders of at least a majority of the FEAC Shares present in person or represented by proxy and entitled to vote at the Special Meeting. Abstentions will have no effect on the outcome of the
proposal. The Business Combination cannot be completed unless each of the Governing Documents Proposal, the Nasdaq Proposal, the Incentive Equity Plan Proposal and the Adjournment Proposal is adopted by affirmative vote of the holders of at least a
majority of the votes cast by FEAC Shareholders present or represented by proxy at the Special Meeting and entitled to vote thereon. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Who will be the management and directors of New enGene following the Business Combination?
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Following completion of the Business Combination, the existing management of enGene will initially continue to
serve in their current positions as executive officers of New enGene. </P></TD></TR></TABLE>  <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Business Combination
Agreement, New enGene anticipates that its board of directors will initially consist of seven (7)&nbsp;directors, including (i)&nbsp;one (1) independent director and one (1)&nbsp;other director (whether or not independent), each to be identified by
FEAC, (ii)&nbsp;Jason D. Hanson, the Chief Executive Officer of enGene, and (iii)&nbsp;three (3) independent directors and one (1)&nbsp;other director to be identified by enGene. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">See &#147;<I>Directors and Executive Officers of New enGene after the Business Combination</I>&#148; for more information. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What is the form of consideration that the FEAC Shareholders will receive as a result of and in connection
with the Business Combination between enGene and FEAC? </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As a result of the Cayman Merger, New enGene will (i)&nbsp;issue to the holders of FEAC Shares (including the
Sponsor but excluding the holders of any Dissenting FEAC Shares (as defined below)) New enGene Shares in exchange for such holders&#146; FEAC Shares on a one for one (1:1) basis, and (ii)&nbsp;New enGene will assume the FEAC Warrants (as so assumed,
New enGene Warrants) pursuant to the Warrant Assignment, Assumption and Amendment Agreement. See <I>&#147;The Business Combination Agreement</I> <I>&#151; Consideration &#151; To current holders of FEAC Shares</I>&#148; for more information.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What is the form of consideration that the current holders of enGene Shares and enGene Options will receive
as a result of and in connection with the Business Combination between enGene and FEAC? </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">After the consummation of the PIPE Financing and the conversion of the enGene Convertible Notes, Can Merger Sub
and enGene will amalgamate in accordance with the terms of the Plan of Arrangement, pursuant to which (i)&nbsp;each enGene Share outstanding immediately prior to the Amalgamation shall be exchanged for New enGene Shares per the enGene Exchange
Ratio, (ii)&nbsp;each enGene Warrant outstanding immediately prior to the Amalgamation shall be exchanged for New enGene Warrants per the enGene Exchange Ratio and (iii)&nbsp;each enGene Equity Award outstanding immediately prior to the Amalgamation
shall be deemed vested and exercisable and exchanged for Rollover Equity Awards and the number of New enGene Shares that will be subject to each Rollover Equity Award shall be determined by multiplying the number of enGene Shares subject to the
corresponding Rollover Equity Award immediately prior to the Closing by the enGene Exchange Ratio. See &#147;<I>The Business Combination Agreement &#150; Consideration &#150; To current holders of enGene Shares and enGene Options</I>&#148; for more
information. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What will the respective percentage ownership interests of New enGene be following the consummation of the
Business Combination? </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The following table describes the pro forma expected percentage ownership of New enGene following the
consummation of the Business Combination, based on all shares that may be issued in the Business Combination on a fully diluted basis, assuming (i)&nbsp;that no FEAC public shareholders exercise redemption rights to have their FEAC Class&nbsp;A
Shares converted into their pro rata share of the Trust Account (the &#147;no redemption scenario&#148;), (ii) that FEAC public shareholders holding fifty percent of the FEAC Class A Shares exercise redemption rights to have such percentage of the
FEAC Class&nbsp;A Shares converted into the pro rata share of the Trust Account (the &#147;50% redemption scenario&#148;), and (iii)&nbsp;that all FEAC public shareholders, other than those subject to contractual restrictions on redemption, exercise
redemption rights to have their FEAC Class&nbsp;A Shares converted into their pro rata share of the Trust Account (the &#147;maximum redemption scenario&#148;). </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Type of Holder</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>No<BR>Redemption&nbsp;Scenario</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>50%<BR>Redemption&nbsp;Scenario</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Maximum<BR>Redemption&nbsp;Scenario</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">#&nbsp;of&nbsp;shares</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">%*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">#&nbsp;of&nbsp;shares</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">#&nbsp;of&nbsp;shares</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">%</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FEAC public shareholders<SUP STYLE="font-size:75%; vertical-align:top">(1)(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,676,575</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,351,575</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">193,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FEAC Public Warrant holders<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,631,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="FONT-FAMILY:'WINGDINGS 3'">&#103;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="FONT-FAMILY:'WINGDINGS 3'">&#103;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sponsor (including FGOF)<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,771,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="FONT-FAMILY:'WINGDINGS 3'">&#103;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="FONT-FAMILY:'WINGDINGS 3'">&#103;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">enGene Shareholders<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,686,695</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="FONT-FAMILY:'WINGDINGS 3'">&#103;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="FONT-FAMILY:'WINGDINGS 3'">&#103;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">enGene Options holders<SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,736,735</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="FONT-FAMILY:'WINGDINGS 3'">&#103;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="FONT-FAMILY:'WINGDINGS 3'">&#103;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">enGene Convertible Notes holders<SUP STYLE="font-size:75%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,059,254</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="FONT-FAMILY:'WINGDINGS 3'">&#103;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="FONT-FAMILY:'WINGDINGS 3'">&#103;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PIPE Investors<SUP STYLE="font-size:75%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,138,232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="FONT-FAMILY:'WINGDINGS 3'">&#103;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="FONT-FAMILY:'WINGDINGS 3'">&#103;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New enGene option pool<SUP STYLE="font-size:75%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,353,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,971,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,600,799</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Totals</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I></I>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I></I>50,054,051</TD>
<TD NOWRAP VALIGN="bottom"><I></I>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44,346,656</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,817,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">percentages presented in the table above may not add up to 100% due to rounding. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:'WINGDINGS 3'">&#103;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">no change (same as in the No Redemption Scenario). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes in all scenarios presented an additional 26,575 New enGene Shares to be issued to a FEAC public
shareholder pursuant to the Non-Redemption Agreement. The 50% redemption scenario is calculated as the result of (i)&nbsp;fifty percent of the 10,650,000 New enGene Shares to be issued to FEAC public stockholders in the no redemption scenario plus
(ii)&nbsp;the 26,575 New enGene Shares to be issued to a FEAC public shareholder pursuant to the Non-Redemption Agreement. Excludes in all scenarios presented 2,000,000 New enGene Shares to be issued to FGOF (which 2,000,000 FEAC Class A Shares are
presented together with the Sponsor elsewhere in the table above). The maximum redemption scenario assumes that 10,483,335 FEAC Class&nbsp;A Shares are redeemed by FEAC public shareholders, which share number is calculated by reducing the total of
FEAC Class&nbsp;A Shares outstanding (exclusive of the 2,000,000 FEAC Class A Shares held by FGOF) by 166,665 FEAC Class&nbsp;A Shares held by a FEAC public shareholder that is subject to the Non-Redemption Agreement, resulting in an aggregate cash
payment of approximately $112.5&nbsp;million out of the Trust Account (based on an assumed redemption price of $10.73 per share that is calculated using the $135.8&nbsp;million cash in the Trust Account as at June 30, 2023, divided by 12,650,000
FEAC Class A Shares subject to redemption). After a redemption of approximately $112.5&nbsp;million out of the $135.8&nbsp;million Trust Account (based on an assumed redemption price of $10.73 per share that is calculated using the $135.8 million
cash in the Trust Account as at June 30, 2023, divided by 12,650,000 FEAC Class A Shares subject to redemption), the available cash at Closing from the Trust Account would be approximately $23.3&nbsp;million. See also <I>&#147;Proposal No.&nbsp;1
&#151; The Business Combination Proposal &#151; Sources and Uses for the Business Combination.&#148;</I> included elsewhere in this proxy statement/prospectus. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In connection with its IPO, FEAC entered into an underwriting agreement pursuant to which it agreed to pay the
underwriters thereunder underwriting commissions in the aggregate amount of 2.0% of the gross proceeds of the FEAC Units sold to the FEAC public shareholders upon the consummation of the IPO (including gross proceeds of FEAC Units sold upon the
exercise of the underwriters&#146; overallotment option, but exclusive of the 2,000,000 FEAC Units sold to FGOF). Following the exercise by the underwriters of their overallotment option, these earned underwriting commissions
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
totaled $2.1&nbsp;million, which amount was paid to the underwriters at the time of the consummation of the IPO. In addition, FEAC agreed in the underwriting agreement to pay to the underwriters
upon the consummation of its initial business combination a deferred underwriting commission of 3.5% of the gross proceeds of the FEAC Units sold to the FEAC public shareholders in the IPO (including FEAC Units sold upon exercise of the
underwriters&#146; overallotment option, but exclusive of FEAC Units sold to FGOF). These deferred underwriting commissions total $3.7&nbsp;million. Neither the earned underwriting commission nor the deferred underwriting commission are contingent
upon, or adjusted as a result of, the exercise of redemption rights by the FEAC public shareholders in connection with the consummation of the Business Combination. This means that, in each redemption scenario presented, the FEAC IPO underwriters
will be paid the entire $3.7&nbsp;million in deferred underwriting commissions from amounts released from the Trust Account upon consummation of the Business Combination. These aggregate underwriting commissions in the amount of $5.9&nbsp;million
represent 5.5%, 11.0% and 352.5%, respectively, of the gross proceeds of the FEAC Units sold in FEAC&#146;s IPO (including the proceeds of FEAC Units sold upon the exercise of the underwriters&#146; over-allotment option, but exclusive of the
2,000,000 FEAC Units sold to FGOF) after giving effect to assumed redemptions by FEAC public shareholders in the no redemption, 50% redemption and maximum redemption scenarios presented in the table above. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes in all scenarios presented (i) 3,550,000 New enGene Shares issuable upon exercise of FEAC Public
Warrants to be assumed and reissued by New enGene in the Business Combination, which warrants have an exercise price of $11.50 per share and are first exercisable 30 days following the Closing, and (ii) 81,158 New enGene Shares issuable upon
exercise of 81,158 additional New enGene Warrants to be issued to a FEAC public shareholder pursuant to the Non-Redemption Agreement. Excludes in all scenarios presented New enGene Shares issuable upon exercise of FEAC Public Warrants held by FGOF
to be assumed and reissued by New enGene in the Business Combination (which shares are presented together with the Sponsor elsewhere in the table above). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes in all scenarios presented (i) 2,000,000 New enGene Shares to be issued to FGOF in exchange for
2,000,000 FEAC Class&nbsp;A Shares acquired by FGOF in the FEAC IPO, (ii) 666,666 shares issuable upon exercise of 666,666 FEAC Public Warrants acquired by FGOF in the FEAC IPO that will be assumed and reissued by New enGene in the Business
Combination, which warrants have an exercise price of $11.50 per share and are first exercisable 30 days following the Closing, (iii) 1,373,496 New enGene Shares to be issued to the Sponsor in exchange for the Sponsor&#146;s FEAC Class&nbsp;B Shares
after giving effect to the surrender by the Sponsor of 1,789,004 FEAC Class&nbsp;B Shares pursuant to the Sponsor and Insiders Letter Agreement and (iv) 731,619 shares issuable upon exercise of FEAC Private Placement Warrants to be assumed and
reissued by New enGene in the Business Combination, which warrants have an exercise price of $11.50 per share and are first exercisable 30 days following the Closing. Such number of shares issuance upon exercise of the Sponsor&#146;s FEAC Private
Placement Warrants to be assumed and reissued by New enGene in the Business Combination is calculated by adding (x)&nbsp;the 5,195,000 FEAC Private Placement Warrants acquired by the Sponsor for $1.50 per warrant at the time of the FEAC IPO and
(y)&nbsp;the 1,000,000 FEAC Private Placement Warrants to be issued to the Sponsor immediately prior to the Closing upon conversion of $1,500,000 of the principal outstanding amount of the Working Capital Loan Note and any Extension Loan Note in
connection with the consummation of the Business Combination, and reducing such result by (z)&nbsp;the 5,463,381 FEAC Private Placement Warrants to be surrendered by the Sponsor immediately prior to the Closing pursuant to the Sponsor and Insiders
Letter Agreement. Excludes (A)(i) 2,262,351 New enGene Shares and (ii) 950,153 New enGene Shares issuable upon exercise of New enGene Warrants, in each case to be issued to the Sponsor in connection with its investment in the enGene Convertible
Notes (which shares are presented together with other investors in the enGene Convertible Notes elsewhere in the table above) and (B)(i) 130,085 New enGene Shares and (ii) 54,634 New enGene Shares issuable upon exercise of 54,634 New enGene
Warrants, in each case to be issued to the Sponsor in connection with its investment in the PIPE Financing (which shares are presented together with other investors in the PIPE Financing elsewhere in the table above). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Excludes in all scenarios New enGene Shares to be issued upon conversion of the enGene Convertible Notes, and
New enGene Shares issuable upon exercise of enGene Warrants issued to holders of Convertible Notes that will be assumed and reissued to enGene note holders by New enGene in the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Business Combination. The presentation of the number of New enGene Shares issuable in connection with the Amalgamation is based on an estimated enGene Exchange Ratio of approximately 0.1805.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents the number of New enGene Shares that New enGene will be authorized to issue or transfer under its
Incentive Equity Plan (as defined below) in respect of options to acquire enGene Common Shares that were granted under the Prior Plans (as defined below) and that are being assumed by New enGene in connection with the Amalgamation and converted into
options to acquire New enGene Shares. Such number of New enGene Shares presented assumes that no such options granted under the Prior Plans will be exercised or forfeited prior to the Closing, and that all shares available for grant under the Prior
Plans will have been granted as options prior to the Closing. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 6,379,822 New enGene Shares to be issued upon conversion of the enGene Convertible Notes, and
2,679,432 New enGene Shares issuable upon exercise of enGene Warrants to be assumed and reissued to enGene note holders by New enGene in the Business Combination, which warrants have an exercise price of $11.50 per share and are first exercisable 30
days following the Closing. The enGene Convertible Notes holders acquired the enGene Convertible Notes for an aggregate purchase price of $56.4&nbsp;million. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 6,435,441 New enGene Shares and 2,702,791 New enGene Shares issuable upon exercise of New enGene
Warrants, which warrants have an exercise price of $11.50 per share and are first exercisable 30 days following the Closing, to be issued pursuant to the Subscription Agreements in exchange for an aggregate purchase price of $56.9&nbsp;million.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents the number of New enGene Shares that New enGene will be authorized to issue or transfer pursuant to
new awards granted after the Closing under its Incentive Equity Plan, which is calculated as 6.7% of the fully diluted capitalization of New enGene after giving effect to the Business Combination. The Incentive Equity Plan contains an evergreen
provision, pursuant to which, commencing with the first business day of each calendar year beginning in 2024, the aggregate number of New enGene Shares that may be issued or transferred under the Incentive Equity Plan will be increased by a number
of New enGene Shares equal to the lesser of (x) 5% of the fully diluted capitalization of New enGene after giving effect to the Business Combination, or (y)&nbsp;such lesser number of shares as may be determined by New enGene Board, or the committee
of the New enGene Board delegated the authority to administer the Incentive Equity Plan. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">See also &#147;<I>Unaudited
Pro Forma Condensed Combined Financial Information</I>,&#148; &#147;<I>Security Ownership of Certain Beneficial Owners and Management of enGene</I>,&#148; &#147;<I>Security Ownership of Certain Beneficial Owners and </I><I>Management of
FEAC</I>&#148; and &#147;<I>Security Ownership of Certain Beneficial Owners and Management of New enGene</I>&#148; included elsewhere in this proxy statement/prospectus. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What happens to the funds deposited in the Trust Account after consummation of the Business Combination?
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Business Combination Proposal is approved, FEAC intends to use a portion of the funds held in the Trust
Account, together with the funds of the PIPE Financing, (i)&nbsp;to pay for any redemptions of FEAC Class&nbsp;A Shares, (ii)&nbsp;to pay the transaction expenses in connection with the Business Combination, and (iii)&nbsp;to fund New enGene&#146;s
cash on balance sheet. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">See &#147;<I>Proposal No.</I><I></I><I>&nbsp;1 &#151; The Business Combination Proposal &#151;
Sources and Uses for the Business Combination.</I>&#148; </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What happens if a substantial number of the holders of FEAC Class&nbsp;A Shares vote in favor of the
proposals and exercise their redemption rights? </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">FEAC Shareholders who vote in favor of the Business Combination may also nevertheless exercise their redemption
rights. Accordingly, the Business Combination may be consummated even though the funds available from the Trust Account and the number of holders of FEAC Class&nbsp;A Shares is reduced as a result of redemptions by holders of FEAC Class&nbsp;A
Shares. However, with fewer FEAC Class&nbsp;A Shares and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
holders thereof, the trading market for New enGene Shares may be less liquid than the market for FEAC&#146;s Class&nbsp;A Shares was prior to consummation of the Business Combination and New
enGene may not be able to meet the Nasdaq listing standards. In addition, with less funds available from the Trust Account, the cash infusion from the Trust Account into New enGene&#146;s business will be reduced. As a result, the proceeds will be
greater in the event that no holders of FEAC Class&nbsp;A Shares exercise redemption rights with respect to their FEAC Class&nbsp;A Shares for a pro rata portion of the Trust Account as opposed to the scenario in which the maximum number of holders
of FEAC Class&nbsp;A Shares exercise their redemption rights. </TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Do I have redemption rights? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Yes, if you are a holder of FEAC Class&nbsp;A Shares you may seek to redeem the FEAC Class&nbsp;A Shares you
hold, regardless of whether you vote for or against the Business Combination or do not vote at the Special Meeting. Any holder of FEAC Class&nbsp;A Shares may request redemption of their FEAC Class&nbsp;A Shares for a per share price, payable in
cash, equal to the aggregate amount then on deposit in the Trust Account, calculated as of two business days prior to the consummation of the Business Combination, including interest (which interest will be net of taxes payable) earned on the funds
held in the trust account and not previously released to FEAC to pay FEAC&#146;s income taxes, if any, divided by the number of then-outstanding FEAC Class&nbsp;A Shares, subject to the limitations described herein. Furthermore, as it is expected
that we are and will be considered a Dutch tax resident, any redemption proceeds (including interest income on the Trust Account) distributed to FEAC Shareholders in excess of the <FONT STYLE="white-space:nowrap">paid-up</FONT> capital for Dutch tax
purposes may be subject to 15% Dutch dividend withholding tax. If a holder of FEAC Class&nbsp;A Shares properly seeks redemption and the Business Combination is consummated, such holder will no longer own these FEAC Class&nbsp;A Shares following the
Business Combination. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, a holder of FEAC Class&nbsp;A Shares, together with any affiliate
of such shareholder or any other person with whom such shareholder is acting in concert or as a &#147;group&#148; (as defined in Section&nbsp;13 of the Exchange Act), will be restricted from redeeming its shares with respect to more than an
aggregate of 15% of the shares sold in our IPO, without our prior consent. Accordingly, if a holder of FEAC Class&nbsp;A Shares, alone or acting in concert or as a group, seeks to redeem more than 15% of the FEAC Class&nbsp;A Shares, then any such
FEAC Class&nbsp;A Shares in excess of that 15% limit would not be redeemed for cash. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">See &#147;<I>Information about the Special Meeting
&#151;</I> <I>Redemption Rights</I>&#148; for further information. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Is there a limit on the total number of FEAC Class&nbsp;A Shares that may be redeemed?
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Yes. A holder of FEAC Class&nbsp;A Shares, together with any affiliate of such shareholder or any other person
with whom such shareholder is acting in concert or as a &#147;group&#148; (as defined in Section&nbsp;13 of the Exchange Act), will be restricted from redeeming its shares with respect to more than an aggregate of 15% of the shares sold in our IPO,
without our prior consent. Accordingly, if a holder of FEAC Class&nbsp;A Shares, alone or acting in concert or as a group, seeks to redeem more than 15% of the FEAC Class&nbsp;A Shares, then any such FEAC Class&nbsp;A Shares in excess of that 15%
limit would not be redeemed for cash. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In addition, FEAC&#146;s Current Articles provide that in no event will FEAC
redeem FEAC Class&nbsp;A Shares in an amount that would cause our net tangible assets to be less than $5,000,001 (so that we do not then become subject to the SEC&#146;s &#147;penny stock&#148; rules). </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Will how I vote affect my ability to exercise redemption rights? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No. Holders of FEAC Class&nbsp;A Shares may elect to redeem all or a portion of their FEAC Class&nbsp;A Shares
regardless of whether such holders vote on the Business Combination, and if they do vote, regardless of whether they vote for or against the Business Combination. As a result, the Business Combination can be approved by holders of FEAC Class&nbsp;A
Shares who will redeem their FEAC Class&nbsp;A Shares and no longer remain shareholders. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>How do I exercise my redemption rights? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As a holder of FEAC Class&nbsp;A Shares, you will be entitled to receive cash for any FEAC Class&nbsp;A Shares
to be redeemed only if you: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">(a) hold FEAC Class A Shares or (b) hold FEAC Class A Shares through FEAC Units and you elect to separate your
FEAC Units into the underlying FEAC Class&nbsp;A Shares and FEAC Warrants prior to exercising your redemption rights with respect to the FEAC Class&nbsp;A Shares; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">prior to 5:00 p.m., New York City time, on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;, 2023 (two business days before the Special Meeting), (a) submit a written request to Continental Stock Transfer&nbsp;&amp; Trust Company, FEAC&#146;s transfer agent (the &#147;transfer agent&#148;), that FEAC redeem all or
a portion of your FEAC Class&nbsp;A Shares for cash and (b)&nbsp;identify yourself as a beneficial holder of the FEAC Class&nbsp;A Shares and provide your legal name, phone number, and address; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">deliver your FEAC Class&nbsp;A Shares to the transfer agent, physically or electronically through DTC.
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If you hold the FEAC Class&nbsp;A Shares in &#147;street name,&#148; you will need to instruct the account executive at
your bank or broker to withdraw the FEAC Class&nbsp;A Shares from your account in order to exercise your redemption rights. There is a nominal cost associated with this process and the act of certificating the FEAC Class&nbsp;A Shares or delivering
them through the DWAC system. The transfer agent will typically charge the tendering broker $80 and it would be up to the broker whether or not to pass this cost on to the redeeming holder of FEAC Class&nbsp;A Shares. In the event the Business
Combination is not consummated, this may result in an additional cost to holders of FEAC Class&nbsp;A Shares for the return of their shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Holders of FEAC Units must elect to separate the underlying FEAC Class&nbsp;A Shares and FEAC Warrants prior to exercising redemption rights
with respect to the FEAC Class&nbsp;A Shares. If holders hold their FEAC Units in an account at a brokerage firm or bank, holders must notify their broker or bank that they elect to separate the FEAC Units into the underlying FEAC Class&nbsp;A
Shares and FEAC Warrants, or if a holder holds units registered in its own name, the holder must contact the transfer agent, directly and instruct it to do so. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">See &#147;<I>Information about the Special Meeting &#151; Redemption Rights</I>&#148; for further information. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What are the U.S. federal income tax consequences of exercising my redemption rights?
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The U.S. federal income tax consequences of the Business Combination are discussed in more detail under
&#147;<I>Material U.S. Federal Income Tax Considerations</I>.&#148; The discussion of the material U.S. federal income tax consequences contained in this proxy statement/prospectus is intended to provide only a general discussion and is not a
complete analysis or description of all potential U.S. federal income tax consequences that are applicable to you in respect of the Business Combination, nor does it address any tax considerations arising under U.S. state or local or <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> tax laws. You are urged to consult your tax advisors regarding the tax consequences of the Business Combination. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>If I am a holder of FEAC Warrants, can I exercise redemption rights with respect to my FEAC Warrants?
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No. The holders of FEAC Warrants have no redemption rights with respect to FEAC Warrants. Assuming maximum FEAC
Shareholder Redemptions of 10,483,335 FEAC Class&nbsp;A Shares and based on the closing price of such FEAC Warrants of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; on Nasdaq as of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023, the aggregate value that can be retained by FEAC Shareholders who have properly exercised their FEAC Shareholders Redemptions is
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. The actual market price of the FEAC Warrants may be higher or lower on the date that a holder of FEAC Warrants seeks to sell or exercise such FEAC Warrants. Additionally,
FEAC cannot assure the holders of FEAC Warrants that they will be able to sell their FEAC Warrants in the open market as there may not be sufficient liquidity in such FEAC Warrants when a holder thereof desires to sell. Further, while the level of
redemptions of FEAC Class&nbsp;A Shares will not directly change the value of the FEAC Warrants, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
as the FEAC Warrants will remain outstanding regardless of the level of redemptions, as redemptions of FEAC Class&nbsp;A Shares increase, a holder of FEAC Warrants will ultimately own a greater
interest in FEAC (or, after completion of the Business Combination, New enGene) because there would be fewer FEAC Class&nbsp;A Shares (or, after completion of the Business Combination, New enGene Shares) outstanding overall. Further, the potential
for the issuance of a substantial number of FEAC Class&nbsp;A Shares (or, after completion of the Business Combination, New enGene Shares) upon exercise of the FEAC Warrants (or, after completion of the Business Combination, New enGene Warrants)
could make New enGene less attractive to investors. Any such issuance will increase the number of issued and outstanding FEAC Class&nbsp;A Shares (or, after completion of the Business Combination, New enGene Shares) and reduce the value of the
outstanding FEAC Class&nbsp;A Shares (or, after completion of the Business Combination, New enGene Shares). Therefore, the outstanding FEAC Warrants (or, after completion of the Business Combination, New enGene Warrants) could have the effect of
depressing the market price of FEAC Class&nbsp;A Shares (or, after completion of the Business Combination, New enGene Shares). For additional information see &#147;<I>&#151; What will the respective percentage ownership interests of New enGene be
following the consummation of the Business Combination?</I>&#148; </TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>How do FEAC Public Warrants differ from FEAC Private Placement Warrants? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">FEAC Warrants are warrants to purchase one FEAC Class&nbsp;A Share at an exercise price of $11.50 per share,
subject to adjustment, upon the terms and conditions in the FEAC Warrant Agreement. FEAC Warrants include both FEAC Public Warrants and FEAC Private Placement Warrants. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">FEAC Private Placement Warrants are warrants (each entitling the holder thereof to purchase one FEAC Class&nbsp;A Share) issued by FEAC to the
Sponsor in a private placement simultaneously with the closing of FEAC&#146;s IPO and to be issued by FEAC to the Sponsor (or the Sponsor&#146;s Affiliates or designees, as applicable), upon the conversion of up to $1,500,000 of the principal
outstanding amount of the outstanding Working Capital Loan Note and any Extension Loan Notes in connection with the consummation of the Business Combination. The FEAC Private Placement Warrants are not transferable, assignable or salable (and the
FEAC Class&nbsp;A Shares issuable upon exercise of the FEAC Private Placement Warrants will not be transferable, assignable or salable until 30 days after the completion of the Business Combination), except pursuant to limited exceptions, and they
are not redeemable by FEAC. The Sponsor, or its permitted transferees, have the option to exercise the FEAC Private Placement Warrants on a cashless basis. Otherwise, the FEAC Private Placement Warrants have terms and provisions that are identical
to those of the FEAC Public Warrants, including as to exercise price, exercisability and exercise period. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>How does the FEAC Board recommend that I vote? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">After careful consideration, the FEAC Board has determined that each of the Business Combination Proposal, the
Governing Documents Proposal, the Nasdaq Proposal, the Incentive Equity Plan Proposal and the Adjournment Proposal are in the best interests of and advisable to FEAC and the FEAC Shareholders and recommends that you vote, or give instruction to
vote, &#147;<B>FOR</B>&#148; each of those proposals. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">For additional information, see &#147;<I>Proposal
No.</I><I></I><I>&nbsp;1 &#151; The Business Combination Proposal &#151; The FEAC Board&#146;s Reasons for the Business Combination.</I>&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The existence of financial and personal interests of the Sponsor and FEAC&#146;s directors and officers may result in a conflict of interest on
the part of one or more of the directors between what they may believe is in the best interests of FEAC and its shareholders and what they may believe is best for themselves or the Sponsor in determining to recommend that shareholders vote for the
proposals. See the section entitled &#147;<I>Proposal No.</I><I></I><I>&nbsp;1 &#151; The Business Combination Proposal &#151; Interests of FEAC&#146;s Sponsor, Directors and Executive Officers in the Business Combination</I>&#148; in the proxy
statement/prospectus for a further discussion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>How will FEAC&#146;s Sponsor, directors and officers vote? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">FEAC&#146;s Sponsor and FEAC&#146;s directors at the time of its IPO have entered into a letter agreement with
us pursuant to which they will vote in favor of FEAC&#146;s initial business combination, pursuant to which they will vote &#147;<B>FOR</B>&#148; the approval of the Business Combination Proposal, &#147;<B>FOR</B>&#148; the approval of the Governing
Documents Proposal, &#147;<B>FOR</B>&#148; the approval of the Nasdaq Proposal, &#147;<B>FOR</B>&#148; the approval of the Incentive Equity Plan Proposal, and &#147;<B>FOR</B>&#148; the approval of the Adjournment Proposal. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In addition, concurrently with the execution and delivery of the Business Combination Agreement, enGene, New enGene and the Sponsor Parties
entered into the FEAC Voting Agreement pursuant to which the Sponsor Parties agreed to, among other things, (i) vote or cause to be voted all of their FEAC Shares in favor of the Transaction Proposals; (ii) be bound by certain other covenants and
agreements related to the Business Combination; and (iii) be bound by certain transfer restrictions with respect to the FEAC Shares, in each case, on the terms and subject to the conditions set forth in the FEAC Voting Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">See &#147;<I>Ancillary Agreements Related to the Business Combination</I> &#151; <I>Transaction Support Agreements</I>.&#148; </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>How many votes do I have at the Special Meeting? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each FEAC Class&nbsp;A Share and each FEAC Class&nbsp;B Share outstanding is entitled to one vote per share at
the Special Meeting. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What constitutes a quorum at the Special Meeting? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A quorum of FEAC Shareholders is necessary to hold a valid meeting. A quorum will exist at the Special Meeting
with respect to each matter to be considered at the Special Meeting if the holders of a majority of FEAC Shares are present in person or represented by proxy at the Special Meeting. All shares represented by proxy are counted as present for purposes
of establishing a quorum. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Your FEAC Shares will be counted for purposes of determining a quorum if you vote: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in person; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">via the Internet; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by telephone; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by submitting a properly executed proxy card or voting instruction form by mail; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">electronically at the Special Meeting. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Abstentions will be counted for determining whether a quorum is present for the Special Meeting. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What is enGene? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">enGene is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of
patients. enGene is developing <FONT STYLE="white-space:nowrap">non-viral</FONT> gene therapies based on its novel and proprietary dually derived chitosan, or &#147;DDX&#148;, gene delivery platform, which allows localized delivery of multiple gene
cargos directly to mucosal tissues and other organs. enGene has established integrated capabilities with this platform to support the clinical development and potential commercialization of its gene therapies. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">See &#147;<I>Business of enGene</I>&#148; for further information. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What will happen to FEAC as a result of the Business Combination? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In connection with the Business Combination, FEAC will become a wholly owned subsidiary of New enGene as
pursuant to the Cayman Merger. FEAC will be liquidated following the Closing of the Business Combination. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What is the Cayman Merger? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the Cayman Merger, which will occur on the day which is one business day prior to the Closing Date, Cayman
Merger Sub will merge with and into FEAC with FEAC as the surviving entity pursuant to a plan of merger under the laws of the Cayman Islands as follows: (i)&nbsp;New enGene will issue to the holders of FEAC Shares (including the Sponsor but
excluding the holders of any dissenting FEAC Shares) New enGene Shares in exchange for such holders&#146; FEAC Shares and such FEAC Shares will not be cancelled but will be transferred to New enGene, (ii)&nbsp;FEAC will thereby become a wholly owned
subsidiary of New enGene, and (iii)&nbsp;each issued share of Cayman Merger Sub will be exchanged for a FEAC Class&nbsp;A Share as the surviving entity and Cayman Merger Sub (having merged into FEAC) will cease to exist as a separate entity by
virtue of the Cayman Merger. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What is the Cayman Reorganization? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Cayman Reorganization comprises the Cayman Merger as well as the following steps to become effective at the
same time the Cayman Merger becomes effective under Cayman Islands law: (i)&nbsp;New enGene will assume the warrants of FEAC to purchase one FEAC Class&nbsp;A Share at an exercise price of $11.50 per share, subject to adjustment (as so assumed, New
enGene Warrants) pursuant to a warrant assignment, assumption and amendment agreement to be entered into on or around the Closing Date, (ii)&nbsp;FEAC as the entity surviving the Cayman Merger will issue to New enGene a <FONT
STYLE="white-space:nowrap">non-interest</FONT> bearing demand promissory note payable denominated in Canadian dollars having a principal amount equal to the fair market value of the FEAC Warrants assumed by New enGene in consideration of the
assumption by New enGene of obligations under the FEAC Warrants (as so assumed, New enGene Warrants), and (iii)&nbsp;New enGene will redeem the initial Class&nbsp;B common shares of New enGene held by the sole shareholder of New enGene for an amount
equal to the amount of capital that the sole shareholder of New enGene contributed for purposes of the incorporation of New enGene. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What is the FEAC Reorganization? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The FEAC Reorganization comprises the Cayman Reorganization as well as the following step, which will occur
after the Cayman Reorganization: FEAC will file an election to change its classification for U.S. federal income tax purposes from a corporation to an entity disregarded as separate from its owner New enGene, to be effective as of the beginning of
the Closing Date.<B> </B> </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What is the Amalgamation? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the Amalgamation, which will occur on the Closing Date, Can Merger Sub and enGene will amalgamate pursuant
to the Plan of Arrangement, and pursuant to the Amalgamation, (i)&nbsp;each enGene Share outstanding immediately prior to the Amalgamation shall be exchanged for New enGene Shares per the enGene Exchange Ratio and each enGene Warrant outstanding
immediately prior to the Amalgamation shall be exchanged for New enGene Warrants per the enGene Exchange Ratio; (ii)&nbsp;each Can Merger Sub share outstanding immediately prior to the Amalgamation shall be exchanged for one common share in the
authorized share capital of the amalgamated entity; and (iii)&nbsp;in consideration for the issuance of New enGene Shares, the amalgamated entity shall issue its common shares to New enGene. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What is the PIPE Financing? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On May&nbsp;16, 2023, concurrently with the execution of the Business Combination Agreement, FEAC, New enGene
and certain PIPE Investors entered into Subscription Agreements pursuant to which Subscription Agreements as amended by the Side Letter Agreements, among other things, the PIPE Investors have agreed, subject to the completion of each element of the
Transactions (other than those Transactions that are scheduled to be completed following the Closing Date), to subscribe for and purchase, and FEAC has </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
agreed that it will issue and sell to the PIPE Investors (which obligation will be assumed by New enGene after the completion of the FEAC Reorganization and prior to the consummation of the PIPE
Financing) an aggregate of 6,435,441 FEAC Class&nbsp;A Shares (or after the Assumption, New enGene Shares) and an aggregate of 2,702,791 FEAC Warrants (or after the Assumption, New enGene Warrants) for an aggregate purchase price equal to
$56,891,682. New enGene intends to use the net proceeds from the PIPE Financing to repay all or a portion of the BDC Notes (as defined herein) and for general corporate purposes. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">See &#147;<I>Ancillary Agreements Related to the Business Combination &#151; Subscription Agreements and Side Letter Agreements</I>&#148; for
further information. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What is the Convertible Bridge Financing? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Prior to the execution and delivery of the Business Combination Agreement, enGene agreed to certain
modifications of existing convertible indebtedness in an aggregate principal amount of $18.4&nbsp;million as consideration for the issuance of enGene Warrants. Concurrently with the execution and delivery of the Business Combination Agreement,
enGene entered into agreements pursuant to which it will issue new convertible indebtedness and enGene warrants (i)&nbsp;for cash in an aggregate principal amount of $30.0&nbsp;million and (ii)&nbsp;in repayment of certain outstanding indebtedness
in an aggregate principal amount of $8.0&nbsp;million. The Convertible Bridge Financing (as defined below) indebtedness will be converted in the Transactions into that number of common shares of enGene that, when exchanged at the enGene Exchange
Ratio, shall equal that number of FEAC Class&nbsp;A Shares (or after the Assumption, New enGene Shares) that the holders of such indebtedness would have received if they had subscribed for FEAC Class&nbsp;A Shares (or after the Assumption, New
enGene Shares) on the same terms as the PIPE Financing. enGene used a portion of the net proceeds of the Convertible Bridge Financing to repay certain indebtedness and for general corporate purposes. The remaining net proceeds of the Convertible
Bridge Financing are expected to be used by New enGene for general corporate purposes. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">See &#147;<I>Ancillary Agreements
Related to the Business Combination &#151; Convertible Bridge Financing</I>&#148; for further information. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What happens if the Business Combination is not consummated or is terminated? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">There are certain circumstances under which the Business Combination Agreement may be terminated. See
&#147;<I>The Business Combination Agreement &#151; Termination</I>&#148; for additional information regarding the parties&#146; specific termination rights. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In accordance with FEAC&#146;s Current Articles, if an initial business combination is not consummated within 18 months after the closing of
FEAC&#146;s IPO (or up to 24 months from the closing of our IPO if FEAC extends the period of time to consummate a business combination), FEAC will (i)&nbsp;cease all operations except for the purpose of winding up; (ii)&nbsp;as promptly as
reasonably possible but not more than ten business days thereafter, redeem the FEAC Class&nbsp;A Shares, at a per share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (which interest
will be net of taxes payable) earned on the funds held in the Trust Account and not previously released to us to pay our income taxes, if any (less up to $100,000 of interest to pay dissolution expenses and any withholding tax), divided by the
number of the then-outstanding FEAC Class&nbsp;A Shares, which redemption will completely extinguish such FEAC Shareholders&#146; rights as shareholders (including the right to receive further liquidation distributions, if any); and (iii)&nbsp;as
promptly as reasonably possible following such redemption, subject to the approval of our remaining shareholders and our board of directors, liquidate and dissolve, subject in the case of clauses (ii)&nbsp;and (iii), to our obligations under Cayman
Islands law to provide for claims of creditors and the requirements of other applicable law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">On June 6, 2023, FEAC extended the time
available to consummate its initial business combination from June 14, 2023 to September 14, 2023 by having the Sponsor deposit an additional $1,265,000, or $0.10 per unit, into the Trust Account, in accordance with FEAC&#146;s Current Articles and
the Investment Management </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Trust Agreement by and between the Company and Continental Stock Transfer &amp; Trust Company, dated as of December 9, 2021. In connection with the Extension Funding, on June 6, 2023, FEAC issued
an unsecured promissory note in the total principal amount of $1,265,000 to the Sponsor. The Sponsor funded the principal amount of $1,265,000 by depositing such amount into the Trust Account on June 6, 2023. The Extension Note bears no interest and
shall be due and payable on the Loan Note Maturity Date. In the event that FEAC does not consummate an initial business combination, the Extension Note will be repaid only from amounts remaining outside of the Trust Account, if any. FEAC currently
intends, in accordance with its obligations under the Business Combination Agreement, to extend the time available to it to consummate its initial business combination from September 14, 2023, to December 14,2023, by depositing an additional
$1,265,000 (or $0.10 per FEAC Class A Share) into the Trust Account on or before September 14, 2023, and the Sponsor is expected to fund such amount in the form of an additional extension note on the same terms. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">FEAC&#146;s Current Articles provide that, if we wind up for any other reason prior to the consummation of our initial business combination, we
will follow the foregoing procedures with respect to the liquidation of the Trust Account as promptly as reasonably possible but not more than ten business days thereafter, subject to applicable Cayman Islands law. In either such case, FEAC
Shareholders may receive only $10.35 per FEAC Class&nbsp;A Share, or less than $10.35 per FEAC Class&nbsp;A Share (assuming we do not extend the period of time to consummate a business combination beyond 21 months), on the redemption of their
shares, in each case, excluding interest earned in the Trust Account, and FEAC Warrants will expire worthless. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>How do I vote? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If you were a holder of record of FEAC Shares at the close of business on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;, 2023, the record date for the Special Meeting of FEAC Shareholders, you may vote with respect to the proposals in person at the Special Meeting, electronically at the Special
Meeting by visiting <B><U>https://www.cstproxy.com/feac/2023</U></B> or by proxy. FEAC recommends that you submit your proxy even if you plan to attend the Special Meeting. If you vote by proxy, you may change your vote by submitting a later dated
proxy before the deadline or by voting electronically at the Special Meeting. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If your FEAC Shares are owned directly in
your name with our transfer agent, Continental, you are considered, with respect to those shares, the &#147;shareholder of record.&#148; If your shares are held in a stock brokerage account or by a bank or other nominee or intermediary, you are
considered the beneficial owner of shares held in &#147;street name&#148; and are considered a <FONT STYLE="white-space:nowrap">&#147;non-record</FONT> (beneficial) shareholder.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If you are a FEAC Shareholder of record you may use the enclosed proxy card to tell the persons named as proxies how to vote your shares. If
you properly complete, sign and date your proxy card, your shares will be voted in accordance with your instructions. The named proxies will vote all FEAC Shares at the meeting for which proxies have been properly submitted and not revoked. If you
sign and return your proxy card but do not mark your card to tell the proxies how to vote, your FEAC Shares will be voted &#147;<B>FOR</B>&#148; the proposals to adopt the Business Combination Agreement and the other proposals presented at the
Special Meeting. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If your FEAC Shares are held in an account through a broker, bank or other nominee or intermediary, you must instruct the
broker, bank or other nominee how to vote your shares by following the instructions that the broker, bank or other nominee provides you along with this proxy statement/prospectus. Your broker, bank or other nominee may have an earlier deadline by
which you must provide instructions to it as to how to vote your FEAC Shares, so you should read carefully the materials provided to you by your broker, bank or other nominee or intermediary. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If you do not provide voting instructions to your bank, broker or other nominee or intermediary, your shares will not be voted on any proposal
on which your bank, broker or other nominee does not have discretionary authority to vote. In these cases, the bank, broker or other nominee or intermediary will not be able to vote your shares on those matters for which specific authorization is
required. Brokers do not generally have discretionary authority to vote on any of the proposals. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What will happen if I abstain from voting or fail to vote at the Special Meeting? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">At the Special Meeting, abstentions will be counted for determining whether a quorum is present for the Special
Meeting. For purposes of approval, abstentions, while considered present for the purposes of establishing a quorum, will not count as votes cast and will have no effect on the outcome of the vote on any of the proposals. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>How can I vote my shares without attending the Special Meeting? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">FEAC Shareholders may vote in person at the Special Meeting, electronically at the Special Meeting by visiting
<B><U>https://www.cstproxy.com/feac/2023</U></B> or by proxy. FEAC recommends that you submit your proxy even if you plan to attend the Special Meeting. If you vote by proxy, you may change your vote by submitting a later dated proxy before the
deadline or by voting in person or electronically at the Special Meeting. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If your FEAC Shares are owned directly in your
name with our transfer agent, Continental, you are considered, with respect to those shares, the &#147;shareholder of record.&#148; If your shares are held in a stock brokerage account or by a bank or other nominee or intermediary, you are
considered the beneficial owner of shares held in &#147;street name&#148; and are considered a <FONT STYLE="white-space:nowrap">&#147;non-record</FONT> (beneficial) shareholder.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If you are a FEAC Shareholder of record you may use the enclosed proxy card to tell the persons named as proxies how to vote your shares. If
you properly complete, sign and date your proxy card, your shares will be voted in accordance with your instructions. The named proxies will vote all FEAC Shares at the meeting for which proxies have been properly submitted and not revoked. If you
sign and return your proxy card but do not mark your card to tell the proxies how to vote, your FEAC Shares will be voted &#147;<B>FOR</B>&#148; the proposals to adopt the Business Combination Agreement and the other proposals presented at the
Special Meeting. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>How will my FEAC Shares be voted if I return a blank proxy? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If you sign and return your proxy card but do not mark your card to tell the proxies how to vote, your FEAC
Shares will be voted &#147;<B>FOR</B>&#148; each of the Business Combination Proposal, the Governing Documents Proposal, the Nasdaq Proposal, the Incentive Equity Plan Proposal and the Adjournment Proposal. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>If I am not going to attend the Special Meeting in person, should I submit my proxy card instead?
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Yes. Whether you plan to attend the Special Meeting or not, please sign, date and return the proxy card
accompanying the proxy statement/prospectus as soon as possible in the envelope provided. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>May I revoke my proxy or change my vote after I have submitted my executed proxy card?
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Yes. If you are a FEAC Shareholder of record, you may revoke your proxy at any time before it is voted at the
Special Meeting by: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">timely delivering a written revocation letter to the Corporate Secretary of FEAC; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">timely submitting your voting instructions again by telephone or over the Internet; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">signing and returning by mail a proxy card with a later date so that it is received prior to the Special Meeting;
or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">attending the Special Meeting and voting in person or electronically by visiting
<B><U>https://www.cstproxy.com/feac/2023</U></B> and entering the control number found on your proxy card, voting instruction form or notice you previously received. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Attendance at the Special Meeting will not, in and of itself, revoke a proxy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Do I have appraisal rights if I object to the Business Combination? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">FEAC Shareholders that dissent from the Business Combination in accordance with the Cayman Act are entitled to
be paid the fair market value of their shares, which if necessary may ultimately be determined by the court. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">However,
regardless of whether or not such rights are available, FEAC Shareholders are still entitled to exercise the rights of redemption, see &#147;&#151; <I>Do I have redemption rights?</I>&#148; </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What happens if I sell or otherwise transfer my FEAC Shares before the Special Meeting?
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The record date for the Special Meeting is earlier than the date that the Business Combination is expected to
be completed. If you transfer your FEAC Shares after the record date, but before the Special Meeting, unless the transferee obtains from you a proxy to vote those shares, you will retain your right to vote at the Special Meeting. However, you will
not be able to seek redemption of your FEAC Class&nbsp;A Shares because you will no longer be able to deliver them for cancellation upon consummation of the Business Combination in accordance with the provisions described herein. If you transfer
your FEAC Shares prior to the record date, you will have no right to vote those shares at the Special Meeting or have your FEAC Shares redeemed for a pro rata portion of the proceeds held in the Trust Account. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>When is the Business Combination expected to be consummated? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">It is currently anticipated that the Business Combination will be consummated as promptly as possible following
the Special Meeting of FEAC Shareholders to be held on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;, 2023, provided that all the requisite shareholder approvals are obtained and other conditions to the consummation of
the Business Combination have been satisfied or waived. The Closing is subject to certain approvals and requirements. For a description of the conditions for the completion of the Business Combination, see &#147;<I>The Business Combination Agreement
&#151; Conditions to Consummation of the Transactions</I>.&#148; </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What happens if I vote against any of the proposals contemplated by this proxy statement/prospectus?
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A.<B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Properly exercising your redemption rights as a FEAC Shareholder does not result in either a vote
&#147;FOR&#148; or &#147;AGAINST&#148; the Business Combination Proposal or any of the other proposals described in this proxy statement/prospectus. If the Business Combination is not completed, you will continue to hold your FEAC Shares, and if
FEAC does not otherwise consummate an initial business combination within 18 months after the closing of FEAC&#146;s IPO (or up to 24 months from the closing of our IPO if FEAC extends the period of time to consummate a business combination) or
amend FEAC&#146;s Governing Documents to extend the date by which FEAC must consummate an initial business combination, FEAC will be required to dissolve and liquidate. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Who will solicit and pay for the cost of soliciting proxies? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">FEAC will solicit proxies by mail. In addition, the directors, officers and employees of FEAC may solicit
proxies from FEAC Shareholders by telephone, electronic communication, or in person, but will not receive any additional compensation for their services. FEAC will make arrangements with brokerage houses and other custodians, nominees, and
fiduciaries for forwarding proxy solicitation material to the beneficial owners of FEAC Shares held of record by those persons and will reimburse them for their reasonable
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in forwarding such proxy solicitation materials. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">FEAC will bear the cost of soliciting proxies from FEAC Shareholders. FEAC has engaged a professional proxy solicitation firm, Morrow Sodali
LLC, to assist in soliciting proxies for the Special Meeting. FEAC has agreed to pay Morrow a fee of $27,500, plus disbursements. FEAC will reimburse Morrow for reasonable
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses and will indemnify Morrow and its affiliates against certain claims, liabilities, losses, damages and expenses. FEAC will also reimburse banks,
brokers and other custodians, nominees and fiduciaries representing beneficial owners of FEAC Shares for their expenses in forwarding soliciting materials to beneficial owners of FEAC Shares and in obtaining voting instructions from those owners.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What conditions must be satisfied to complete the Business Combination? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The obligation of the parties to the Business Combination Agreement to consummate the Business Combination is
subject to certain closing conditions, including, but not limited to, (i) the approval of FEAC Shareholders, (ii) the approval of enGene&#146;s shareholders, (iii) the Interim Order and the Final Order having been granted and not set aside or
modified in a manner unacceptable to the parties, (iv) this proxy statement/prospectus becoming effective, (v) the listing of the New enGene Shares and New enGene Warrants on Nasdaq or any other national securities exchange having been approved, and
(vi) the dissenting rights with respect to the Plan of Arrangement not having been validly exercised or withdrawn with respect to more than 10% of the issued and outstanding enGene Shares. However, such conditions may be waived, in whole or in part,
if permitted by law, either unilaterally or by agreement of FEAC and enGene. In the event of a waiver of a condition, each of the FEAC Board and the enGene Board will evaluate the materiality of any such waiver to determine whether amendment of this
proxy statement/prospectus and resolicitation of stockholder approval is necessary (see &#147;<I>Risk Factors &#151; Risks Related to the Business Combination &#151; FEAC or enGene may waive one or more of the conditions to the completion of the
Business Combination without</I> <I>recirculation of this proxy statement/prospectus or resoliciting stockholder approval</I>&#148; for more information). For a summary of the conditions that must be satisfied or waived prior to completion of the
Business Combination, see &#147;<I>The Business Combination Agreement &#151; Conditions to Consummation of the Transactions</I>.&#148; </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What do I need to do now? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">You are urged to read carefully and consider the information contained in this proxy statement/prospectus,
including the information set forth under &#147;<I>Risk Factors,</I>&#148; more detailed information concerning the Business Combination Agreement, a copy of which is attached as <B><U>Annex A</U></B>, as well as the other annexes attached hereto,
and to consider how the Business Combination will affect you as a shareholder. You should then vote as soon as possible in accordance with the instructions provided in this proxy statement/prospectus and on the enclosed proxy card or, if you hold
your shares through a brokerage firm, bank or other nominee, on the voting instruction form provided by the broker, bank or nominee. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What should I do if I receive more than one set of voting materials? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">You may receive more than one set of voting materials, including multiple copies of this proxy
statement/prospectus and multiple proxy cards or voting instruction cards. For example, if you hold your FEAC Shares in more than one brokerage account, you will receive a separate voting instruction card for each brokerage account in which you hold
FEAC Shares. If you are a holder of record and your FEAC Shares are registered in more than one name, you will receive more than one proxy card. Please complete, sign, date and return each proxy card and voting instruction card that you receive in
order to cast your vote with respect to all of your shares. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Q:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Who can help answer my questions? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If you have questions about the proposals or if you need additional copies of the proxy statement/prospectus or
the enclosed proxy card you should contact: </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Forbion European Acquisition Corp. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4001 Kennett Pike, Suite 302 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Wilmington, Delaware 19807 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attention: Jasper Bos / Cyril Lesser </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Email: jasper.bos@forbion.com / cyril.lesser@forbion.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">You may also contact our proxy solicitor at: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Morrow Sodali LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">333 Ludlow
Street, 5th Floor, South Tower </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Stamford, CT 06902 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Individuals call toll-free <FONT STYLE="white-space:nowrap">(800)&nbsp;662-5200</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Banks and brokers call <FONT STYLE="white-space:nowrap">(203)&nbsp;658-9400</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Email: FEAC.info@investor.morrowsodali.com </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">To obtain timely delivery, FEAC Shareholders must request the materials no later than five business days prior to the Special Meeting. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">You may also obtain additional information about FEAC from documents filed with the SEC by following the instructions under &#147;<I>Where You
Can Find More Information.</I>&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If you intend to seek redemption of your FEAC Class&nbsp;A Shares, you will need to send a letter
demanding redemption and deliver your shares electronically to our transfer agent, Continental prior to 5:00 p.m., New York City time, on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023 (two
business days before the Special Meeting) in accordance with the procedures detailed under the question &#147;&#151; <I>How do I exercise my redemption rights?</I>&#148; If you have questions regarding the certification of your position or delivery
of your shares, please contact: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Continental Stock Transfer&nbsp;&amp; Trust Company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 State Street, 30<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>&nbsp;Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">New York, New York 10004 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attention: SPAC Redemption Team </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Email: spacredemptions@continentalstock.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom459793_7"></A>SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights selected information included in this document and does not contain all of the information that may be important to
you. You should read this entire document and its appendices and the other documents to which FEAC and enGene refer before you decide how to vote with respect to the proposals to be considered and voted on at the Special Meeting. Each item in this
summary includes a page reference directing you to a more complete description of that item. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Capitalized terms used in this
section &#147;Summary&#148; but not otherwise defined in this proxy statement/prospectus shall have the meanings assigned to them in the Business Combination Agreement. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information About the Parties to the Business Combination (page&nbsp;164) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B><I>Forbion European Acquisition Corp.</I></B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">4001 Kennett Pike, Suite 302 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Wilmington, Delaware 19807 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(302)
<FONT STYLE="white-space:nowrap">273-0765</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FEAC is a blank check company incorporated on August&nbsp;9, 2021 as a Cayman Islands
exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. Prior to executing the Business Combination Agreement,
FEAC&#146;s efforts were limited to organizational activities, completion of its IPO and the evaluation of possible business combinations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B><I>enGene Inc.</I></B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">7171
Rue Frederick Banting </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Saint-Laurent, QC H4S 1Z9, Canada </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(514) <FONT STYLE="white-space:nowrap">332-4888</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">enGene is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. enGene is developing <FONT
STYLE="white-space:nowrap">non-viral</FONT> gene therapies based on its novel and proprietary dually derived chitosan, or &#147;DDX&#148;, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues
and other organs. enGene has established integrated capabilities with this platform to support the clinical development and potential commercialization of its gene therapies, if approved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B><I>enGene Holdings Inc.</I></B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">7171 Rue Frederick Banting </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Saint-Laurent, QC H4S 1Z9, Canada </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(514) <FONT STYLE="white-space:nowrap">332-4888</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">enGene Holdings Inc., a corporation incorporated under the laws of Canada, was formed for the purpose of consummating the Business Combination
and will be the parent company of the combined operating business following the consummation of the Business Combination. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B><I>Cayman
Merger Sub</I></B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cayman Merger Sub refers to a to be incorporated Cayman Islands exempted company and a direct wholly owned subsidiary
of enGene Holdings Inc. (&#147;Cayman Merger Sub&#148;). On the date that is one business day prior to the Closing Date, Cayman Merger Sub will merge with and into FEAC with FEAC as the surviving entity pursuant to a plan of merger under the laws of
the Cayman Islands. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B><I>Can Merger Sub</I></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Can Merger Sub refers to a to be incorporated wholly owned subsidiary of Forbion European Acquisition Corp. (&#147;Can Merger Sub&#148;). Can
Merger Sub and enGene Inc. will amalgamate pursuant to the Plan of Arrangement. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Business Combination Agreement (page&nbsp;208) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms and conditions of the Business Combination are contained in the Business Combination Agreement, which is attached to this proxy
statement/prospectus as <B><U>Annex A</U></B>, and is incorporated by reference herein in its entirety. FEAC encourages you to read the Business Combination Agreement carefully, as it is the legal document that governs the Business Combination. For
more information on the Business Combination Agreement, see the section entitled &#147;<I>The Business Combination Agreement</I>.&#148; </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Ancillary
Agreements Related to the Business Combination (page&nbsp;223) </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Business Combination Agreement, the
transaction parties and other certain investors have entered into or agreed to enter into a number of ancillary agreements, including, the Sponsor and Insiders Letter Agreement, Transaction Support Agreements, Subscription Agreements and Side Letter
Agreements, <FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreement, Registration Rights Agreement and Warrant Assignment, Assumption and Amendment Agreement. For more information on the ancillary agreements to the Business Combination
Agreement, see the section entitled &#147;<I>Ancillary Agreements Related to the Business Combination</I>.&#148; </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transaction Structure
(page&nbsp;173) </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination Agreement contemplates that the Business Combination will be completed through, among
other things, the following series of transactions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FEAC will incorporate or cause to be incorporated Can Merger Sub as a corporation under the laws of Canada and a
direct wholly owned subsidiary of FEAC (&#147;Can Merger Sub&#148;) and New enGene will incorporate or cause to be incorporated Cayman Merger Sub as a Cayman Islands exempted company and a direct wholly owned subsidiary of New enGene (&#147;Cayman
Merger Sub&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pursuant to the Sponsor and Insiders Letter Agreement, Forbion Growth Sponsor FEAC I B.V., a private limited
liability company incorporated in The Netherlands (the &#147;Sponsor&#148;), has agreed to surrender, after giving effect to the conversion of all or part of the principal amount outstanding under loans made by the Sponsor to FEAC into private
placement warrants of FEAC (&#147;FEAC Private Placement Warrants&#148;), 1,789,004 FEAC Class&nbsp;B Shares and 5,463,381 FEAC Private Placement Warrants, as a contribution to the capital of FEAC and for no consideration (the
&#147;Surrender&#148;), effective immediately prior to the Class&nbsp;B Conversion (as defined below) on the day which is two business days prior to the Closing Date (as defined below); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on the day which is two business days prior to the Closing Date, each FEAC Class&nbsp;B Share that remains
outstanding following the Surrender shall be exchanged for one FEAC Class&nbsp;A Share (the &#147;Class&nbsp;B Conversion&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on the day which is one business day prior to the Closing Date, Cayman Merger Sub will merge with and into FEAC
with FEAC as the surviving entity pursuant to a plan of merger under the laws of the Cayman Islands (the &#147;Cayman Merger&#148;) as follows: (i)&nbsp;New enGene will issue to the holders of FEAC Shares (including the Sponsor but excluding the
holders of any dissenting FEAC Shares) New enGene Shares in exchange for such holders&#146; FEAC Shares and such FEAC Shares will not be cancelled but will be transferred to New enGene, (ii)&nbsp;FEAC will thereby become a wholly owned subsidiary of
New </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
enGene, and (iii)&nbsp;each issued share of Cayman Merger Sub will be exchanged for a FEAC Class&nbsp;A Share as the surviving entity and Cayman Merger Sub (having merged into FEAC) will cease to
exist as a separate entity by virtue of the Cayman Merger; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">concurrently with the Cayman Merger, and effective at the same time the Cayman Merger becomes effective under
Cayman Islands law, (i)&nbsp;New enGene will assume the warrants of FEAC to purchase one FEAC Class&nbsp;A Share at an exercise price of $11.50 per share, subject to adjustment (as so assumed, &#147;New enGene Warrants&#148;) pursuant to a warrant
assignment, assumption and amendment agreement to be entered into on or around the Closing Date, (ii)&nbsp;FEAC as the entity surviving the Cayman Merger will issue to New enGene a <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing demand
promissory note payable denominated in Canadian dollars (&#147;C$&#148;) having a principal amount equal to the fair market value of the FEAC Warrants assumed by New enGene (&#147;Note 3&#148;) in consideration of the assumption by New enGene of
obligations under the FEAC Warrants (as so assumed, New enGene Warrants), and (iii)&nbsp;New enGene will redeem the initial Class&nbsp;B common shares of New enGene held by the sole shareholder of New enGene for an amount equal to the amount of
capital that the sole shareholder of New enGene contributed for purposes of the incorporation of New enGene (such transactions, together with the Cayman Merger, the &#147;Cayman Reorganization&#148;); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">following the Cayman Reorganization, FEAC will file an election to change its classification for U.S. federal
income tax purposes from a corporation to an entity disregarded as separate from its owner New enGene, to be effective as of the beginning of the Closing Date (the &#147;U.S. Entity Classification Election&#148; and, together with the Cayman
Reorganization, the &#147;FEAC Reorganization&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on the Closing Date and pursuant to the Plan of Arrangement, subsequent to the FEAC Reorganization becoming
effective and prior to the consummation of the PIPE Financing, FEAC will loan to New enGene an amount equal to the total funds held in its Trust Account (subject to certain deductions described in the Business Combination Agreement), less the
principal amount of Note 3 (together, the &#147;Loan Amount&#148;) in consideration for which New enGene will issue a C$ denominated <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing demand promissory note to FEAC having a principal
amount equal to the Loan Amount converted into its Canadian dollar equivalent based on the C$:U.S.$ Bank of Canada daily exchange rate on the business day immediately prior to the Closing Date, following which FEAC will sell to New enGene, and New
enGene will purchase, all of the outstanding common shares of Can Merger Sub for a purchase price of C$10 (the &#147;Can Merger Sub Share Sale&#148;) and, following the Can Merger Sub Share Sale but prior to the Amalgamation, the PIPE Financing
shall be consummated; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subsequent to the Can Merger Sub Share Sale and PIPE Financing, Can Merger Sub and enGene will amalgamate
pursuant to the Plan of Arrangement, and pursuant to the Amalgamation, (i)&nbsp;each enGene Share outstanding immediately prior to the Amalgamation shall be exchanged for New enGene Shares at the enGene Exchange Ratio and each enGene Warrant
outstanding immediately prior to the Amalgamation shall be exchanged for New enGene Warrants per the enGene Exchange Ratio; (ii)&nbsp;each Can Merger Sub share outstanding immediately prior to the Amalgamation shall be exchanged for one common share
in the authorized share capital of the amalgamated entity; and (iii)&nbsp;in consideration for the issuance of New enGene Shares, the amalgamated entity shall issue its common shares to New enGene; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">following the Amalgamation, New enGene will continue from being a corporation incorporated under and governed by
the Canada Business Corporations Act to a company continued to and governed by the Business Corporations Act (British Columbia). </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transactions described above, together with the other transactions contemplated by the Business Combination Agreement, are hereinafter
referred to as the &#147;Transactions.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination is expected to close in the second half of 2023, subject to the
satisfaction of customary closing conditions. The Business Combination Agreement and the Transactions were approved by the board of directors of each of FEAC and enGene. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following diagrams illustrate in simplified terms the current structure of FEAC and
enGene and the expected structure of New enGene and its operating subsidiaries upon the Closing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Current Organizational Charts of
FEAC and enGene </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">


<IMG SRC="g459793g70s01.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">


<IMG SRC="g459793g70s02.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Organizational Chart of New enGene Post-Business Combination (including cash positions) </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g459793g70s03.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>The PIPE Financing </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;16, 2023, concurrently with the execution of the Business Combination Agreement, FEAC, New enGene and certain investors (the
&#147;PIPE Investors&#148;) entered into subscription agreements (the &#147;Subscription Agreements&#148; and each a &#147;Subscription Agreement&#148;) pursuant to which Subscription Agreements as amended by the Side Letter Agreements (as defined
below), among other things, the PIPE Investors have agreed, subject to the completion of each element of the Transactions (other than those Transactions that are scheduled to be completed following the Closing Date), to subscribe for and purchase,
and FEAC has agreed that it will issue and sell to the PIPE Investors (which obligation will be assumed (the &#147;Assumption&#148;) by New enGene after the completion of the FEAC Reorganization and prior to the consummation of the PIPE Financing
(as defined below)) an aggregate of 6,435,441 FEAC Class&nbsp;A Shares (or after the Assumption, New enGene Shares) and an aggregate of 2,702,791 FEAC Warrants (or after the Assumption, New enGene Warrants) for an aggregate purchase price equal to
$56,891,682 (the &#147;PIPE Financing&#148;). The Subscription Agreements for the PIPE Investors provide for certain registration rights. New enGene intends to use the net proceeds from the PIPE Financing to repay all or a portion of the BDC Notes
and for general corporate purposes. For more information regarding the PIPE Financing, see the section entitled <I>&#147;Ancillary Agreements Related to the Business Combination &#151; Subscription Agreements and Side Letter Agreements</I>.&#148;
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>The <FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;16, 2023, New enGene, FEAC and a FEAC Shareholder entered into a <FONT STYLE="white-space:nowrap">non-redemption</FONT> agreement
(the <FONT STYLE="white-space:nowrap">&#147;Non-Redemption</FONT> Agreement&#148;), pursuant to which, among other things, FEAC will issue an additional 26,575 FEAC Class&nbsp;A Shares and 81,158 FEAC Warrants (or after the Assumption, New enGene
will issue additional New enGene Shares and New enGene Warrants) to such FEAC Shareholder in consideration of such FEAC Shareholder&#146;s commitment (i)&nbsp;vote or cause to be voted all of its 166,665 FEAC Class A Shares in favor of the
Transaction Proposals and (ii)&nbsp;not to redeem its 166,665 FEAC Class&nbsp;A Shares in connection with the approval of the Business Combination by the shareholders of FEAC. For more information regarding the
<FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreement, see the section entitled &#147;<I>Ancillary Agreements Related to the Business Combination &#151; <FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreement</I>.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Convertible Bridge Financing </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the execution and delivery of the Business Combination Agreement, enGene agreed to certain modifications of existing convertible
indebtedness in an aggregate principal amount of $18.4&nbsp;million (the &#147;Amended 2022 Convertible Notes&#148; and, together with the enGene warrants to be issued by enGene as consideration for such modifications, the &#147;Amended 2022
Financing&#148;). Concurrently with the execution and delivery of the Business Combination Agreement, enGene entered into agreements pursuant to which it will issue new convertible indebtedness and enGene warrants (i)&nbsp;for cash in an aggregate
principal amount of $30.0&nbsp;million and (ii)&nbsp;in repayment of certain outstanding indebtedness in an aggregate principal amount of $8.0&nbsp;million (collectively, the &#147;2023 Convertible Notes&#148; and, together with the enGene warrants
purchased concurrently, the &#147;2023 Financing&#148;; the 2023 Financing together with the Amended 2022 Financing, the &#147;Convertible Bridge Financing&#148;). The Convertible Bridge Financing indebtedness will be converted in the Transactions
into that number of common shares of enGene that, when exchanged at the enGene Exchange Ratio, shall equal that number of FEAC Class&nbsp;A Shares (or after the Assumption, New enGene Shares) that the holders of such indebtedness would have received
if they had subscribed for FEAC Class&nbsp;A Shares (or after the Assumption, New enGene Shares) on the same terms as the PIPE Financing. enGene used a portion of the net proceeds of the Convertible Bridge Financing to repay certain indebtedness and
for general corporate purposes. The remaining net proceeds of the Convertible Bridge Financing are expected to be used by New enGene for general corporate purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For more information regarding the Convertible Bridge Financing, see &#147;<I>Ancillary Agreements Related to the Business Combination &#151;
Convertible Bridge Financing</I>.&#148; </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consideration (page&nbsp;211) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>To current holders of FEAC Shares </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of the Cayman Merger, New enGene will (i)&nbsp;issue to the holders of FEAC Shares (including the Sponsor but excluding the holders
of any Dissenting FEAC Shares) New enGene Shares in exchange for such holders&#146; FEAC Shares on a one for one (1:1) basis, and (ii)&nbsp;New enGene will assume the FEAC Warrants (as so assumed, New enGene Warrants) pursuant to the Warrant
Assignment, Assumption and Amendment Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>To current holders of enGene Shares and enGene Options </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the consummation of the PIPE Financing and the conversion of the enGene Convertible Notes, Can Merger Sub and enGene will amalgamate in
accordance with the terms of the Plan of Arrangement, pursuant to which (i)&nbsp;each enGene Share outstanding immediately prior to the Amalgamation shall be exchanged for New enGene Shares per the enGene Exchange Ratio, (ii)&nbsp;each enGene
Warrant outstanding immediately prior to the Amalgamation shall be exchanged for New enGene Warrants per the enGene Exchange Ratio and (iii)&nbsp;each enGene Equity Award outstanding immediately prior to the Amalgamation shall be deemed vested and
exercisable and exchanged for Rollover Equity Awards and the number of New enGene Shares that will be subject to each Rollover Equity Award shall be determined by multiplying the number of enGene Shares subject to the corresponding enGene Equity
Award immediately prior to the Closing by the enGene Exchange Ratio. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate number of New enGene Shares to be allocated in respect of enGene Shares, the
aggregate number of Rollover Equity Awards to be allocated in respect of the aggregate number of enGene Equity Awards, and the New enGene Warrants to be allocated in respect of the aggregate number of enGene Warrants, shall in the aggregate equal
the portion of the Exchange Consideration issuable in respect of such enGene Shares, enGene Equity Awards and enGene Warrants pursuant to the Plan of Arrangement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Special Meeting of the FEAC Shareholders and the Proposals (page&nbsp;165) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Special Meeting will be convened on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023 at 10:00 a.m., New York
City time, at &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and in a virtual format. Shareholders may attend, vote and examine the list of FEAC Shareholders entitled to vote at the Special Meeting
by visiting <B><U>https://www.cstproxy.com/feac/2023</U></B> and entering the control number found on their proxy card, voting instruction form or notice included in their proxy materials. The purpose of the Special Meeting is to consider and vote
on the proposals described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If FEAC Shareholders do not approve each of the Business Combination Proposal, the Governing Documents
Proposal, the Nasdaq Proposal, the Incentive Equity Plan Proposal and the Adjournment Proposal, and we and enGene do not waive the applicable closing condition under the Business Combination Agreement, then the Business Combination may not be
consummated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only holders of record of FEAC Shares at the close of business
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023 are entitled to notice of and to vote and have their votes counted at the Special Meeting and any further adjournments or postponements of the Special Meeting. As of
the close of business on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023, there were &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; FEAC Class&nbsp;A Shares
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; FEAC Class&nbsp;B Shares outstanding and entitled
to vote. Each FEAC Share is entitled to one vote per share at the Special Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A quorum of FEAC Shareholders is necessary to hold a
valid meeting. A quorum will exist at the Special Meeting with respect to each matter to be considered at the Special Meeting if the holders of a majority of FEAC Shares are present in person or represented by proxy at the Special Meeting. All
shares represented by proxy are counted as present for purposes of establishing a quorum. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Approval of the Business Combination Proposal
requires the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the FEAC Shares present in person or represented by proxy and entitled to vote at the Special Meeting. Abstentions will have no effect on
the outcome of the proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Approval of the Governing Documents Proposal requires the affirmative vote of the holders of at least a
majority of the FEAC Shares present in person or represented by proxy and entitled to vote at the Special Meeting. Abstentions will have no effect on the outcome of the proposal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Approval of the Nasdaq Proposal requires the affirmative vote of the holders of at least a majority of the FEAC Shares present in person or
represented by proxy and entitled to vote at the Special Meeting. Abstentions will have no effect on the outcome of the proposal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Approval of the Incentive Equity Plan Proposal requires the affirmative vote of the holders of at least a majority of the FEAC Shares present
in person or represented by proxy and entitled to vote at the Special Meeting. Abstentions will have no effect on the outcome of the proposal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The approval of the Adjournment Proposal will require affirmative vote of a majority of the FEAC Shares present in person or by proxy and
entitled to vote at the Special Meeting. Abstentions will count as votes &#147;against&#148; the proposal. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recommendation of FEAC&#146;s Board of
Directors (page&nbsp;166) </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After careful consideration, the FEAC Board has determined that each of the Business Combination
Proposal, the Governing Documents Proposal, the Nasdaq Proposal, the Incentive Equity Plan Proposal and the </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Adjournment Proposal are in the best interests of and advisable to FEAC and the FEAC Shareholders and recommends that you vote, or give instruction to vote, &#147;<B>FOR</B>&#148; each of those
proposals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FEAC Board recommends that you vote &#147;<B>FOR</B>&#148; the approval of the Business Combination Proposal,
&#147;<B>FOR</B>&#148; the approval of the Governing Documents Proposal, &#147;<B>FOR</B>&#148; the approval of the Nasdaq Proposal, &#147;<B>FOR</B>&#148; the approval of the Incentive Equity Plan Proposal and &#147;<B>FOR</B>&#148; the approval of
the Adjournment Proposal. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For more information about the FEAC Board&#146;s recommendation and the proposals, see the sections
entitled &#147;<I>Information About the Special Meeting</I> &#151; <I>Vote Required and FEAC Board Recommendation</I>&#148; beginning on page&nbsp;166 and &#147;<I>Proposal No.</I><I></I><I>&nbsp;1</I> &#151; <I>The Business Combination
Proposal</I>&#148; beginning on page&nbsp;173. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FEAC&#146;s Board of Directors&#146; Reasons for Approval of the Business Combination (page&nbsp;190)
</B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;14, 2023, the FEAC Board, after consultation with its legal, financial, accounting and other advisors,
(i)&nbsp;determined that it is desirable, advisable and in the best commercial interests of FEAC to approve and enter into the Business Combination Agreement and the Ancillary Agreements, (ii)&nbsp;approved the execution and delivery of the Business
Combination Agreement and the Ancillary Agreements and (iii)&nbsp;recommended the adoption and approval of the Business Combination Agreement and the Ancillary Agreements, and each of the proposals presented in this proxy statement/prospectus, by
the FEAC Shareholders. In evaluating the Business Combination and making these determinations and this recommendation, the FEAC Board consulted with FEAC senior management and considered a wide variety of factors, including the reasons for the
Business Combination and the risks related thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a more complete description of the FEAC Board&#146;s reasons for the Business
Combination, see &#147;<I>Proposal No.</I><I></I><I>&nbsp;1 &#150; The Business Combination Proposal </I>&#151; <I>The FEAC Board&#146;s Reasons for the Business Combination.</I>&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conditions to Closing (page&nbsp;218) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The obligations of each party to consummate the Transactions are subject to the satisfaction of the following mutual conditions (in each case,
unless waived in writing by FEAC and enGene): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company Arrangement Resolution shall have been approved by the requisite number of shareholders of enGene in
accordance with applicable law and enGene&#146;s governing documents in accordance with the Interim Order and applicable law; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Interim Order and the Final Order shall have been granted and shall not have been set aside or modified in a
manner unacceptable to FEAC and enGene, each acting reasonably, on appeal or otherwise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the absence of any order or law or other legal restraints or prohibition preventing the consummation of the
Transactions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">this proxy statement/prospectus becoming effective in accordance with the provisions of the Securities Act, no
stop order being issued by the SEC and remaining in effect with respect to this proxy statement/prospectus, and no proceeding seeking such a stop order being threatened or initiated by the SEC and remaining pending; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the approval of the Business Combination Agreement, the Ancillary Agreements to the Business Combination
Agreement to which FEAC is or will be a party and the Transactions contemplated by each of the foregoing agreements being obtained by the requisite number of shareholders of FEAC in accordance with applicable law and FEAC&#146;s governing documents;
</P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">after giving effect to the Transactions (including the PIPE Financing), New enGene having at least $5,000,001 of
net tangible assets (as determined in accordance with Rule <FONT STYLE="white-space:nowrap">3a51-1(g)(1)</FONT> of the Exchange Act) immediately after the Closing Date; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">New enGene&#146;s initial listing application with the Nasdaq or other exchange in connection with the
Transactions shall have been approved and, immediately following the Closing, New enGene shall satisfy any applicable initial and continuing listing requirements of the Nasdaq or other relevant Exchange, as applicable, and no party shall have
received any notice of <FONT STYLE="white-space:nowrap">non-compliance</FONT> therewith that has not been cured or would not be cured at or immediately following the Closing, and the New enGene Shares and New enGene Warrants shall have been approved
for listing on the Nasdaq or other relevant Exchange, as applicable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Articles of Arrangement to be filed with the Director under the CBCA in accordance with the Arrangement shall
be in a form and content satisfactory to enGene and FEAC, each acting reasonably; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Arrangement Dissent Rights shall have not been validly exercised, and not withdrawn or deemed to have been
withdrawn, with respect to more than 10% of the issued and outstanding enGene Shares; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Transaction Support Agreements shall continue to be in full force and effect. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Other Conditions to the Obligations of FEAC </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The obligations of FEAC to consummate the Transactions are also subject to the satisfaction of the following further conditions (in each case,
unless waived in writing by FEAC): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(i) the Company Fundamental Representations shall be true and correct in all material respects as of the date of
the Business Combination Agreement and as of the Closing Date, as though made on and as of the Closing Date (except to the extent that any such representation and warranty is made as of an earlier date, in which case such representation and warranty
shall be true and correct in all material respects as of such earlier date, other than failures to be true and correct that result from actions that are expressly required by the terms of the Business Combination Agreement or approved in writing by
FEAC), (ii) the representations and warranties set forth in Section&nbsp;3.2(a) of the Business Combination Agreement shall be true and correct in all respects (except for <I>de minimis </I>inaccuracies) as of the date of the Business Combination
Agreement and as of the Closing Date, as though made on and as of the Closing Date (except to the extent that any such representation and warranty is made as of an earlier date, in which case such representation and warranty shall be true and
correct in all respects (except for <I>de minimis </I>inaccuracies) as of such earlier date), and (iii)&nbsp;the representations and warranties of enGene set forth in Article 3 of the Business Combination Agreement (other than the Company
Fundamental Representations and the representations and warranties of enGene set forth in Section&nbsp;3.2(a) of the Business Combination Agreement) shall be true and correct (without giving effect to any limitation as to &#147;materiality&#148; or
&#147;Company Material Adverse Effect&#148; or any similar limitation set forth therein) in all respects as of the date of the Business Combination Agreement and as of the Closing Date, as though made on and as of the Closing Date (except to the
extent that any such representation and warranty is made as of an earlier date, in which case such representation and warranty shall be true and correct in all respects as of such earlier date), except where the failure of such representations and
warranties to be true and correct, taken as a whole, does not cause a Company Material Adverse Effect; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enGene having performed and complied in all material respects with the covenants and agreements required to be
performed or complied with by enGene under the Business Combination Agreement at or prior to the Closing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that since the date of the Business Combination Agreement, no Company Material Adverse Effect has occurred that
is continuing; and </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that enGene deliver, or cause to be delivered, to FEAC (i)&nbsp;at or prior to the Closing, a certificate
executed by an authorized officer of enGene (without personal liability), dated as of the Closing Date, confirming that the conditions set forth in the first three bullet points in this section have been satisfied, in a form and substance reasonably
satisfactory to FEAC and (ii)&nbsp;the Registration Rights Agreement duly executed by the applicable enGene Shareholders. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Other Conditions to the Obligations of enGene </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The obligations of enGene to consummate the Transactions are also subject to the satisfaction of the following further conditions (in each
case, unless waived in writing by enGene): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(i) the FEAC Fundamental Representations and the representations and warranties of FEAC set forth in
Section&nbsp;4.19(q) of the Business Combination Agreement shall be true and correct in all respects as of the date of the Business Combination Agreement and as of the Closing Date, as though made on and as of the Closing Date (except to the extent
that any such representation and warranty is made as of an earlier date, in which case such representation and warranty shall be true and correct in all material respects as of such earlier date), (ii) the representations and warranties set forth in
Section&nbsp;4.2(a) of the Business Combination Agreement shall be true and correct in all respects (except for <I>de</I> <I>minimis </I>inaccuracies) as of the date of the Business Combination Agreement and as of the Closing Date, as though made on
and as of the Closing Date (except to the extent that any such representation and warranty is made as of an earlier date, in which case such representation and warranty shall be true and correct in all respects (except for <I>de minimis
</I>inaccuracies) as of such earlier date), (iii) the representations and warranties of FEAC contained in Article 4 of the Business Combination Agreement (other than the FEAC Fundamental Representations and the representations and warranties of FEAC
set forth in Section&nbsp;4.2(a) and Section&nbsp;4.19(q) of the Business Combination Agreement) shall be true and correct (without giving effect to any limitation as to &#147;materiality&#148; or &#147;FEAC Material Adverse Effect&#148; or any
similar limitation set forth therein) in all respects as of the date of the Business Combination Agreement and the Closing Date, as though made on and as of the Closing Date (except to the extent that any such representation and warranty is made as
of an earlier date, in which case such representation and warranty shall be true and correct as of such earlier date), except where the failure of such representations and warranties to be true and correct, taken as a whole, does not cause a FEAC
Material Adverse Effect; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FEAC having performed and complied in all material respects with the covenants and agreements required to be
performed or complied with by FEAC under the Business Combination Agreement at or prior to the Closing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that since the date of the Business Combination Agreement, no FEAC Material Adverse Effect has occurred that is
continuing; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that FEAC deliver, or cause to be delivered, to enGene (i)&nbsp;at or prior to the Closing, a certificate
executed by an authorized officer of FEAC (without personal liability), dated as of the Closing Date, confirming that the conditions set forth in the first three bullet points in this section have been satisfied, in a form and substance reasonably
satisfactory to enGene and (ii)&nbsp;the Registration Rights Agreement duly executed by FEAC and the Sponsor. </P></TD></TR></TABLE>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Termination
(page&nbsp;220) </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination may be terminated under certain customary and limited circumstances prior to the Closing
(i)&nbsp;by mutual written consent of FEAC and enGene; (ii)&nbsp;by FEAC if the representations and warranties of enGene are not true and correct or if enGene fails to perform any covenant or agreement set forth in the Business Combination Agreement
such that certain conditions to Closing cannot be satisfied and the breach </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or breaches of such representations or warranties or the failure to perform such covenant or agreement, as applicable, are not cured or cannot be cured within certain specified time periods,
provided however that FEAC is not then in breach of the Business Combination Agreement so as to prevent such condition to Closing from being satisfied; (iii)&nbsp;by enGene if (a)&nbsp;the representations and warranties of FEAC are not true and
correct or if FEAC fails to perform any covenant or agreement set forth in the Business Combination Agreement such that certain conditions to Closing cannot be satisfied and the breach or breaches of such representations or warranties or the failure
to perform such covenant or agreement, as applicable, are not cured or cannot be cured within certain specified time periods, provided however that enGene is not then in breach of the Business Combination Agreement so as to prevent such condition to
Closing from being satisfied or (b)&nbsp;prior to the receipt of approval by the FEAC Shareholders, if FEAC&#146;s board of directors changes its recommendation with respect to the Business Combination; or (iv)&nbsp;by either FEAC or enGene, if
(a)&nbsp;the Transactions have not been consummated by December&nbsp;14, 2023; (b) the FEAC Shareholders&#146; meeting has been held and has concluded and the approval by FEAC Shareholders of the Business Combination has not been obtained;
(c)&nbsp;the enGene Required Approval in respect of the Company Arrangement Resolution shall not have been obtained at the enGene&#146;s shareholders meeting in accordance with the Interim Order and applicable law; or (d)&nbsp;if any Governmental
Entity shall have issued an Order permanently enjoining, restraining or otherwise prohibiting the Transactions and such Order shall have become final and nonappealable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Business Combination Agreement is validly terminated, and except in the case of any willful or material breach of any covenant or
agreement or fraud (involving scienter), none of the parties to the Business Combination Agreement will have any liability or any further obligation under the Business Combination Agreement other than customary confidentiality obligations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Redemption Rights (page&nbsp;169) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to FEAC&#146;s Current Articles, a holder of FEAC Class&nbsp;A Shares may request that FEAC redeem all or a portion of their FEAC
Class&nbsp;A Shares (which would become New enGene Shares as a result of the Business Combination) for cash if the Business Combination is consummated. As a holder of FEAC Class&nbsp;A Shares, you will be entitled to receive cash for any FEAC
Class&nbsp;A Shares to be redeemed only if you: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(a) hold FEAC Class&nbsp;A Shares or (b)&nbsp;hold FEAC Class&nbsp;A Shares through FEAC Units and you elect to
separate your FEAC Units into the underlying FEAC Class&nbsp;A Shares and FEAC Warrants prior to exercising your redemption rights with respect to the FEAC Class&nbsp;A Shares; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prior to 5:00 p.m., New York City time, on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023 (two business days before the Special Meeting), (a) submit a written request to Continental Stock Transfer&nbsp;&amp; Trust Company, FEAC&#146;s transfer agent (the
&#147;transfer agent&#148;), that FEAC redeem all or a portion of your FEAC Class&nbsp;A Shares for cash and (b)&nbsp;identify yourself as a beneficial holder of the FEAC Class&nbsp;A Shares and provide your legal name, phone number, and address;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">deliver your FEAC Class&nbsp;A Shares to the transfer agent, physically or electronically through DTC.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As noted above, holders of FEAC Units must elect to separate the underlying FEAC Class&nbsp;A Shares and FEAC Warrants
prior to exercising redemption rights with respect to the FEAC Class&nbsp;A Shares. If holders hold their FEAC Units in an account at a brokerage firm or bank, holders must notify their broker or bank that they elect to separate the FEAC Units into
the underlying FEAC Class&nbsp;A Shares and FEAC Warrants, or if a holder holds units registered in its own name, the holder must contact the transfer agent, directly and instruct it to do so. Holders of FEAC Class&nbsp;A Shares may seek to redeem
the FEAC Class&nbsp;A Shares they hold, regardless of whether they vote for or against the Business Combination or do not vote at the Special Meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Business Combination is not consummated, the FEAC Class&nbsp;A Shares will not be redeemed for cash. If a holder of FEAC Class&nbsp;A
Shares properly exercises its right to redeem its FEAC Class&nbsp;A Shares and timely </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
delivers its FEAC Class&nbsp;A Shares to the transfer agent, FEAC will redeem such FEAC Class&nbsp;A Shares upon the Closing for a per share price, payable in cash, equal to the aggregate amount
then on deposit in the Trust Account, calculated as of two business days prior to the consummation of the Business Combination, including interest (which interest will be net of taxes payable) earned on the funds held in the Trust Account and not
previously released to FEAC to pay FEAC&#146;s income taxes, if any, divided by the number of then-outstanding FEAC Class&nbsp;A Shares, subject to the limitations described herein. If a holder of FEAC Class&nbsp;A Shares exercises its redemption
rights, then it will be exchanging its redeemed FEAC Class&nbsp;A Shares for cash and will no longer own such FEAC Class&nbsp;A Shares. See the section entitled &#147;<I>Information About the Special Meeting</I><I></I><I>&nbsp;&#151; Redemption
Rights</I>&#148; for a detailed description of the procedures to be followed if you wish to redeem your FEAC Class&nbsp;A Shares for cash. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, a holder of FEAC Class&nbsp;A Shares, together with any affiliate of such shareholder or any other person with
whom such shareholder is acting in concert or as a &#147;group&#148; (as defined in Section&nbsp;13 of the Exchange Act), will be restricted from redeeming its shares with respect to more than an aggregate of 15% of the shares sold in our IPO,
without our prior consent. Accordingly, if a holder of FEAC Class&nbsp;A Shares, alone or acting in concert or as a group, seeks to redeem more than 15% of the FEAC Class&nbsp;A Shares, then any such FEAC Class&nbsp;A Shares in excess of that 15%
limit would not be redeemed for cash. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Proxy Solicitation (page&nbsp;172) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FEAC will solicit proxies by mail. In addition, the directors, officers and employees of FEAC may solicit proxies from FEAC Shareholders by
telephone, electronic communication, or in person, but will not receive any additional compensation for their services. FEAC will make arrangements with brokerage houses and other custodians, nominees, and fiduciaries for forwarding proxy
solicitation material to the beneficial owners of FEAC Shares held of record by those persons and will reimburse them for their reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses
incurred in forwarding such proxy solicitation materials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FEAC will bear the cost of soliciting proxies from FEAC Shareholders. FEAC has
engaged a professional proxy solicitation firm, Morrow Sodali LLC, to assist in soliciting proxies for the Special Meeting. FEAC has agreed to pay Morrow a fee of $27,500, plus disbursements. FEAC will reimburse Morrow for reasonable <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses and will indemnify Morrow and its affiliates against certain claims, liabilities, losses, damages and expenses. FEAC will also reimburse banks, brokers
and other custodians, nominees and fiduciaries representing beneficial owners of FEAC Shares for their expenses in forwarding soliciting materials to beneficial owners of FEAC Shares and in obtaining voting instructions from those owners. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A shareholder also may change its vote by submitting a later-dated&nbsp;proxy as described in the section entitled &#147;<I>Information About
the Special Meeting</I> &#151; <I>Revoking Your Proxy</I>.&#148; </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Interests of FEAC&#146;s Sponsor, Directors and Executive Officers in the Business Combination
(page&nbsp;195) </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When you consider the recommendation of the FEAC Board in favor of approval of the Business Combination Proposal,
you should keep in mind that the Sponsor and FEAC&#146;s directors and executive officers have interests in such proposal that are different from, or in addition to, those of FEAC Shareholders and FEAC Warrant holders generally. These interests
include, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that after giving effect to the Sponsor Loans Conversion and the Surrender, the Sponsor will retain
1,373,496 FEAC Class&nbsp;B Shares which it purchased at a price of approximately $0.009 per share and 731,619 FEAC Private Placement Warrants which it purchased at a price of $1.50 per warrant, and such securities will have a significantly higher
value at the time of the Business Combination as described further below: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;FEAC<BR>Class&nbsp;B&nbsp;Shares</B><br><B>beneficially&nbsp;owned&nbsp;as</B><br><B>of the date hereof</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;FEAC</B><br><B>Private&nbsp;Placement</B><br><B>Warrants&nbsp;owned&nbsp;as&nbsp;of<BR>the date hereof</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate&nbsp;value<BR>of&nbsp;FEAC&nbsp;Class&nbsp;B</B><br><B>Shares&nbsp;and&nbsp;FEAC</B><br><B>Private&nbsp;Placement</B><br><B>Warrants&nbsp;
implied&nbsp;by</B><br><B>the&nbsp;Business</B><br><B>Combination<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate&nbsp;value</B><br><B>of&nbsp;FEAC&nbsp;Class&nbsp;B</B><br><B>Shares&nbsp;and&nbsp;FEAC</B><br><B>Private&nbsp;Placement</B><br><B>Warrants&nbsp;
based&nbsp;on</B><br><B>&nbsp;&nbsp;recent&nbsp;trading&nbsp;price<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sponsor<SUP STYLE="font-size:75%; vertical-align:top">(3)(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,373,496</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">731,619</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,215,684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Assumes a value of $10.35 per share, the deemed value of the FEAC Class B Shares on the basis of the
anticipated amount in the Trust Account of $10.35 per FEAC Class A Shares (excluding interest earned on amounts in the Trust Account), and $0.00 per warrant, which reflects that the exercise price of the warrants ($11.50 per warrant) exceeds the
value of the underlying ordinary shares in the Business Combination. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Assumes a value of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the closing price of the FEAC
Class&nbsp;B Shares on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;, 2023, and $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per warrant, the closing price of the FEAC Private Placement Warrants on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;, 2023. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Sponsor is the record holder of the FEAC Class&nbsp;B Shares reported herein. Jasper Bos, Cyril Lesser,
Sander Slootweg and Wouter Joustra, who are directors of the Sponsor, have voting and investment discretion with respect to the FEAC Shares owned by the Sponsor and may be deemed to have indirect shared beneficial ownership of the FEAC Shares held
by the Sponsor. Jasper Bos, Cyril Lesser, Sander Slootweg and Wouter Joustra each disclaim beneficial ownership over the FEAC Class&nbsp;B Shares except to the extent of their pecuniary interest therein. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">FGOF wholly owns the Sponsor and therefore the Sponsor and FGOF have shared voting and investment power over
the FEAC Class&nbsp;B Shares held by the Sponsor. FGOF also holds 2,000,000 FEAC Class&nbsp;A Shares underlying the 2,000,000 FEAC Units held by it. Therefore, FGOF has shared voting and investment power over 5,162,500 FEAC Shares in the aggregate,
representing approximately 32.7% of FEAC&#146;s issued and outstanding ordinary shares as of the date hereof. Forbion Management is the sole director of FGOF and therefore shares voting and investment power (i)&nbsp;with FGOF over the 2,000,000 FEAC
Class&nbsp;A Shares underlying the FEAC Units held by FGOF and (ii)&nbsp;with FGOF and, indirectly, the Sponsor, over the 3,162,500 FEAC Class&nbsp;B Shares held by the Sponsor. Forbion Management exercises voting and investment power through its
investment committee (the &#147;Investment Committee&#148;) consisting of Sander Slootweg, Martien van Osch, <FONT STYLE="white-space:nowrap">Geert-Jan</FONT> Mulder, Vincent van Houten, Dirk Kersten, Nanna L&uuml;neborg, Wouter Joustra and Jasper
Bos. None of the members of the Investment Committee has individual voting and investment power with respect to the ordinary shares, and each such member disclaims beneficial ownership of the ordinary shares except to the extent of their
proportionate pecuniary interest therein. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Prior to the Surrender and the Sponsor Loan Conversions (see &#147;<I>Certain Relationships and Related Party
Transactions</I> &#151;<I> Sponsor and Insiders Letter Agreement; Surrender; Sponsor Loans Conversion</I>&#148;), the Sponsor owns 3,162,500 FEAC Class&nbsp;B Shares and 5,195,000 FEAC Private Placement Warrants. Pursuant to the Sponsor Loans
Conversions agreed in the Sponsor and Insiders Letter Agreement, the Sponsor agreed to convert an amount equal to $1,500,000 of the aggregate principal amount outstanding under the Sponsor Loans, taken together, into additional FEAC Private
Placement Warrants immediately prior to the Surrender </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
(following which the Sponsor will own 6,195,000 FEAC Private Placement Warrants). Pursuant to the Surrender agreed in the Sponsor and Insiders Letter Agreement, the Sponsor will forfeit 1,789,004
of its FEAC Class&nbsp;B Shares and 5,463,381 of its FEAC Private Placement Warrants as a contribution to the capital of FEAC, for no consideration. After the Surrender, such 1,789,004 of its FEAC Class&nbsp;B Shares and 5,463,381 of its FEAC
Private Placement Warrants will be cancelled and no longer outstanding and the Sponsor will own 1,373,496 FEAC Class&nbsp;B Shares and 731,619 FEAC Private Placement Warrants. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that if FEAC does not complete its initial business combination within 18 months from the closing of
FEAC&#146;s IPO (or up to 24 months from the closing of our IPO if FEAC extends the period of time to consummate a business combination, subject to the Sponsor depositing additional funds in the Trust Account), the FEAC Class&nbsp;B Shares and the
FEAC Private Placement Warrants will expire worthless; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that given the differential in the purchase price that the Sponsor paid for the FEAC Class&nbsp;B Shares
as compared to the price of the FEAC Class&nbsp;A Shares sold in FEAC&#146;s IPO, the Sponsor and its affiliates may earn a positive rate of return on their investment even if the FEAC Class&nbsp;A Shares trade below the price initially paid for the
FEAC Class&nbsp;A Shares in FEAC&#146;s IPO and the holders of FEAC Class&nbsp;A Shares experience a negative rate of return following the completion of the Business Combination. It is not practicable to quantify the Sponsor&#146;s rate of return
because, among other things, the timing (including as a result of the <FONT STYLE="white-space:nowrap">lock-up</FONT> applicable to the FEAC Class&nbsp;B Shares) and the price at which the Sponsor may ultimately sell New enGene Shares (into which
the FEAC Class&nbsp;B Shares will be converted in connection with the Business Combination), New enGene Warrants (into which the FEAC Private Placement Warrants will be converted in connection with the Business Combination) and other equity
securities of New enGene are uncertain, both of which would have a material impact on the applicable rate of return; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that pursuant to the Sponsor&#146;s subscription agreement entered into on May&nbsp;16, 2023 with FEAC
and New enGene (as amended by the Sponsor&#146;s subscription agreement side letter entered into on May&nbsp;16, 2023 by the Sponsor, FEAC and New enGene), the Sponsor will receive, upon consummation of the Business Combination, in consideration of
the purchase price to be paid by the Sponsor set forth in such agreement, 130,085 FEAC Class&nbsp;A Shares (or following the Assumption, New enGene Shares) and 54,634 FEAC Private Placement Warrants (or following the Assumption, New enGene
Warrants); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the Sponsor purchased or will purchase from enGene pursuant to a purchase agreement entered into
with enGene on May&nbsp;16, 2023 for an aggregate amount of $20,000,000 (i) warrants of enGene and (ii)&nbsp;convertible notes of enGene which will get converted upon the consummation of the Business Combination into common shares of enGene, and
which, in each case, when exchanged at the enGene Exchange Ratio pursuant to the Transactions, shall equal that number of FEAC Warrants and FEAC Class&nbsp;A Shares (or after the Assumption, New enGene Warrants and New enGene Common Shares,
respectively), that the Sponsor would have received if it had participated in that amount on the same terms as the PIPE Financing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that if a business combination is not consummated within the required period, the Sponsor will lose its
entire investment in FEAC, which investment included a capital contribution of $25,000 for the Sponsor&#146;s FEAC Class&nbsp;B Shares, $7,792,500 for the Sponsor&#146;s FEAC Private Placement Warrants, $1,200,000 in Working Capital Loans and
$1,265,000 in Extension Loans (as defined below); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the Sponsor and FEAC&#146;s current officers and directors have entered into a letter agreement
with FEAC dated December&nbsp;9, 2021 in which they agreed to waive their rights to liquidating distributions from the Trust Account with respect to any FEAC Class&nbsp;B Shares held by them if FEAC fails to complete an initial business combination
within the required period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that pursuant to the FEAC Voting Agreement, the Sponsor, FGOF and FEAC&#146;s directors and executive
officers agreed, among other things, (a)&nbsp;to vote any FEAC Class&nbsp;B Shares and FEAC Class&nbsp;A </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
Shares held by it in favor of any proposed business combination and (b)&nbsp;not to redeem any FEAC Class&nbsp;B Shares or FEAC Class&nbsp;A Shares held by it in connection with a shareholder
vote to approve a proposed Business Combination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the Sponsor and FGOF, collectively, after giving effect to the Transactions and the transfer of
20,000 New enGene Shares to each of three of FEAC&#146;s independent directors as described below, are expected to own 5,705,932 New enGene Shares, which collectively will represent approximately 24% of outstanding New enGene Shares (assuming
maximum FEAC Shareholder Redemptions) and have a value of approximately $59,056,396.20 based on an implied value of $10.35 per New enGene Share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the Sponsor agreed to transfer 20,000 of the New enGene Shares it expects to receive in connection
with the Business Combination to each of three of FEAC&#146;s independent directors following the consummation of the Business Combination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the anticipated designation by FEAC of Jasper Bos, its current Chief Executive Officer and director, as director
of New enGene upon the consummation of the Business Combination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the continued indemnification of FEAC&#146;s directors and officers and the continuation of FEAC&#146;s
directors&#146; and officers&#146; liability insurance after the Business Combination (i.e., a &#147;tail policy&#148;); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the Sponsor has agreed that in the event of the liquidation of the Trust Account upon the failure
of FEAC to consummate the Business Combination it will be liable to FEAC if and to the extent any claims by a third-party for services rendered or products sold to FEAC, or a prospective target business with which we have discussed entering into a
transaction agreement, reduce the amounts in the Trust Account to below the lesser of (i) $10.25 per FEAC Class&nbsp;A Share and (ii)&nbsp;the actual amount per FEAC Class&nbsp;A Share held in the Trust Account as of the date of the liquidation of
the Trust Account if less than $10.25 per FEAC Class&nbsp;A Share due to reductions in the value of the trust assets, in each case net of the interest that may be withdrawn to pay our tax obligations (less up to $100,000 of interest to pay
dissolution expenses), provided that such liability will not apply to any claims by a third-party or prospective target business that executed a waiver of any and all rights to seek access to the Trust Account nor will it apply to any claims under
FEAC&#146;s indemnity of the underwriters of FEAC&#146;s IPO against certain liabilities, including liabilities under the Securities Act. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Interests of enGene&#146;s Significant Shareholders, Directors and Executive Officers in the Business Combination (page&nbsp;204) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When you consider the recommendation of the FEAC Board in favor of approval of the Business Combination Proposal, you should keep in mind that
enGene&#146;s significant shareholders, directors and officers have interests in the Business Combination that are different from, or in addition to, those of FEAC Shareholders and FEAC Warrant holders generally. These interests include, among other
things, the interests listed below: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Forbion Capital Fund III, an affiliate of Forbion, the Sponsor and FGOF, is a significant shareholder of enGene,
currently holding an equity interest in enGene of approximately 26% of the share capital. Based on enGene&#146;s implied enterprise valuation of $111 million at the time of signing the Business Combination Agreement, such equity interests have an
implied value equal to $28,860,000 (26% of $111 million). The consideration originally paid by Forbion Capital Fund III for the 26% equity interest in enGene was equal to $17,027,974. Also, Forbion Capital Fund III is an investor in both of
enGene&#146;s Amended 2022 Convertible Notes and the 2023 Convertible Notes. While the Sponsor and Forbion Capital Fund III are part of the Forbion group, Forbion Capital Fund III is part of a different fund structure with a different investment
mandate and with independent discretion in its investment decision-making process. None of the independent members of the FEAC Board has any interest in Forbion Capital Fund III. Therefore, Forbion Capital Fund III&#146;s status as current
shareholder of enGene and as investor in both of enGene&#146;s Amended </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
2022 Convertible Notes and the 2023 Convertible Notes has not been taken into consideration by the FEAC Board in approving, and did not influence the decision to discuss, negotiate or execute,
the Business Combination. For additional information regarding enGene&#146;s significant shareholders, see <I>&#147;Security Ownership of Certain Beneficial Owners and Management of enGene.&#148;</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Marco Boorsma, a member of the enGene Board is affiliated with Forbion and was designated for enGene&#146;s Board
by Forbion Capital Fund&nbsp;III. For additional information regarding enGene&#146;s significant shareholders, see <I>&#147;Security Ownership of Certain Beneficial Owners and Management of enGene.&#148;</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Gerry Brunk, a member of the enGene Board is affiliated with the Lumira/Merck Investors, a significant
shareholder of enGene and an investor in both the Amended 2022 Convertible Notes and the 2023 Convertible Notes. Mr.&nbsp;Brunk was designated for enGene&#146;s Board by the Lumira/Merck Investors. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Members of enGene&#146;s current management will initially continue in the same roles as management of New
enGene, and Jason D. Hanson, enGene&#146;s Chief Executive Officer and certain other members of enGene management will enter into employment agreements with New enGene or a subsidiary thereof in connection with the Business Combination.
</P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Unvested stock options held by executive officers and other employees of enGene will vest upon the consummation
of the Business Combination and become stock options to acquire New enGene Shares on the same terms. </P></TD></TR></TABLE>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock Exchange Listing
(page&nbsp;206) </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect the New enGene Shares and the New enGene Warrants to trade on Nasdaq under the symbols &#147;ENGN&#148;
and &#147;ENGNW&#148;, respectively, following the Closing. Under the Business Combination Agreement, the obligations of the parties to consummate the Transactions are subject to the satisfaction or waiver by FEAC and enGene prior to the Closing, of
various conditions, including that New enGene&#146;s initial listing application with Nasdaq for the listing of New enGene Shares and Warrants has been approved. The terms of the Business Combination Agreement permit that this condition may be
waived by agreement between FEAC and enGene without requiring recirculation or resolicitation of this proxy statement/prospectus. See &#147;<I>Risk Factors &#151; Risks Related to the Business Combination &#151; FEAC or enGene may waive one or more
of the conditions to the completion of the Business Combination without recirculation of this proxy statement/prospectus or resoliciting stockholder approval</I>&#148; for more information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sources and Uses of Funds (page&nbsp;205) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables summarize the sources and uses for funding the Business Combination. All of the sources and uses below are for
illustrative purposes only. Where actual amounts are not known or knowable, the figures below represent FEAC&#146;s good faith estimate of such amounts. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>No redemption scenario </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Sources</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Uses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="10" NOWRAP ALIGN="center"><B></B><I>(in millions of U.S. dollars)</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing cash held in Trust
Account<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rollover equity<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transaction financing<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash to balance sheet</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rollover equity<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated transaction
expenses<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total* sources:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>346</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total* uses:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>346</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(*)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Totals might be affected by rounding. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">$135,786,170 held in the Trust Account as of June&nbsp;30, 2023. Assumes that none of the FEAC Class&nbsp;A
Shares are redeemed in connection with the Business Combination. Excludes interest earned in the Trust Account; the actual amount of cash in the Trust Account is subject to change depending on actual interest earned. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Excludes the $1.7&nbsp;million non-redemption commitment from a FEAC Shareholder that is the beneficial owner
of 166,665 FEAC Class A Shares as part of the $115&nbsp;million transaction financing that is comprised of (i)&nbsp;the PIPE Financing ($56.9&nbsp;million), (ii)&nbsp;the Convertible Bridge Financing ($56.4&nbsp;million) and (iii)&nbsp;the
non-redemption commitment ($1.7&nbsp;million). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Rollover equity refers to equity of enGene Shareholders and includes the aggregate exercise price of its stock
options outstanding as of July 31, 2023. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents an estimate of transaction expenses. Actual amounts may vary and may include expenses unknown at
this time. </P></TD></TR></TABLE> <P STYLE="margin-top:14pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Maximum redemption scenario </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Sources</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Uses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="10" NOWRAP ALIGN="center"><B></B><I>(in millions of U.S. dollars)</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing cash held in Trust
Account<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rollover equity<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transaction financing<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash to balance sheet</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rollover equity<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated transaction
expenses<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total* sources:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>233</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total* uses:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>233</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(*)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Totals might be affected by rounding. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">$135,786,170 held in the Trust Account as of June&nbsp;30, 2023. Assumes that all holders of FEAC Class&nbsp;A
Shares redeem their shares in connection with the Business Combination at an assumed redemption price of $10.73 per share (calculated using the $135.8 million cash in the Trust Account as at June 30, 2023, divided by 12,650,000 outstanding FEAC
Class A Shares), except for 2,166,665&nbsp;million <FONT STYLE="white-space:nowrap">non-redeemable</FONT> FEAC Class&nbsp;A Shares held by FGOF and a FEAC Shareholder that is the beneficial owner of 166,665 FEAC Class&nbsp;A Shares, who have each
undertaken not to redeem their shares in connection with the Business Combination. The actual amount of cash in the Trust Account is subject to change depending on actual interest earned. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Excludes the $1.7&nbsp;million non-redemption commitment from a FEAC Shareholder that is the beneficial owner
of 166,665 FEAC Class A Shares as part of the $115&nbsp;million transaction financing that is comprised of (i) the PIPE Financing ($56.9&nbsp;million), (ii)&nbsp;the Convertible Bridge Financing ($56.4&nbsp;million) and (iii)&nbsp;the non-redemption
commitment ($1.7&nbsp;million). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Rollover equity refers to equity of enGene Shareholders and includes the aggregate exercise price of its stock
options outstanding as of July&nbsp;31, 2023. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents an estimate of transaction expenses. Actual amounts may vary and may include expenses unknown at
this time. </P></TD></TR></TABLE>  <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Accounting Treatment of the Business Combination (page 206) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the legal form, the Business Combination will be accounted for as a reverse recapitalization in accordance with U.S. generally
accepted accounting principles (&#147;US GAAP&#148;). Under this method of accounting, FEAC will be treated as the acquired company for financial reporting purposes, whereas enGene will be treated as the accounting acquirer. In accordance with this
accounting method, New enGene is considered to be a continuation of enGene, with the net identifiable assets of FEAC deemed to have been acquired by enGene in exchange for common shares of enGene accompanied by a recapitalization. The net assets of
FEAC will be stated at historical cost, with no goodwill or other intangible assets recorded, and operations prior to the Business Combination will be those of enGene. enGene has been determined to be the accounting acquirer based on an evaluation
of the following facts and circumstances, and accordingly the Business Combination is treated as an equivalent to an acquisition of FEAC accompanied by a recapitalization. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Senior management of enGene will continue as senior management of the post-Business Combination combined company
(the &#147;Combined Company&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Directors of enGene will form a majority on the board of directors of the Combined Company;
</P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The name of the Combined Company will be &#147;enGene Holdings Inc.&#148; and it will utilize enGene&#146;s
current headquarters; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enGene&#146;s operations will comprise the ongoing operations of the Combined Company. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Material U.S. Federal Income Tax Considerations (page&nbsp;411) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a discussion summarizing the U.S. federal income tax consequences of (i)&nbsp;the Business Combination generally applicable to U.S. Holders
(as defined herein) of FEAC Class&nbsp;A Shares and FEAC Warrants, (ii)&nbsp;the exercise of redemption rights by U.S. Holders of FEAC Class&nbsp;A Shares and (iii)&nbsp;the ownership and disposition of New enGene Shares and New enGene Warrants
received by U.S. Holders of FEAC Class&nbsp;A Shares and FEAC Warrants, respectively, in the Business Combination, please see &#147;<I>Material U.S. Federal Income Tax Considerations.</I>&#148; The tax consequences of the foregoing to any particular
shareholder will depend on that shareholder&#146;s particular facts and circumstances. Accordingly, please consult your tax advisor to determine the tax consequences to you of the Business Combination and related Transactions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Material Dutch Tax Consequences of the Business Combination (page&nbsp;422) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a discussion summarizing the principal Dutch tax consequences, for a holder of FEAC Class&nbsp;A Shares or FEAC Warrants (other than the
Sponsor), of the ownership and/or disposal of such FEAC Class&nbsp;A Shares and/or FEAC Warrants following the Transactions, please see &#147;<I>Material Dutch Tax Consequences of the Business Combination</I>.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain Canadian Federal Income Tax Considerations (page&nbsp;426) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a discussion summarizing the principal Canadian federal income tax considerations under the Income Tax Act (Canada) and the regulations
thereunder generally applicable to a beneficial owner (other than the Sponsor) of New enGene Shares or New enGene Warrants following the Transactions, please see &#147;<I>Certain Canadian Federal Income Tax Considerations</I>.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Comparison of Corporate Governance and Shareholder Rights (page&nbsp;229) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the consummation of the Business Combination, the rights of FEAC Shareholders who become New enGene Shareholders in the Business
Combination will no longer be governed by FEAC&#146;s Current Articles and instead will be governed by New enGene&#146;s &#147;Proposed Articles.&#148; See &#147;<I>Comparison of Corporate Governance and Shareholder Rights</I>.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Emerging Growth Company and Smaller Reporting Company (page&nbsp;361) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;102(b)(1) of the Jumpstart Our Business Startups Act of 2012 (the &#147;JOBS Act&#148;) exempts emerging growth companies from
being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a registration statement under the Securities Act declared effective or do not have a class of securities
registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply
to <FONT STYLE="white-space:nowrap">non-emerging</FONT> growth companies but any such an election to opt out is irrevocable. We have elected not to opt out of such extended transition period which means that when a standard is issued or revised and
it has different application dates for public or private companies, we, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. We expect that New enGene will be an
emerging growth company after the completion of the Business Combination and will continue not to opt out of the extended transition period. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This may make comparison of FEAC&#146;s and New enGene&#146;s consolidated financial
statements with those of another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in
accounting standards used. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will remain an emerging growth company until the earlier of: (1)&nbsp;the last day of the fiscal year
(a)&nbsp;following the fifth anniversary of the closing of FEAC&#146;s IPO, (b)&nbsp;in which we have total annual revenue of at least $1.23&nbsp;billion, or (c)&nbsp;in which we are deemed to be a large accelerated filer, which means the market
value of our common equity that is held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700&nbsp;million as of the end of the prior fiscal year&#146;s second fiscal quarter; and (2)&nbsp;the date on which we have issued more than
$1.00&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities during the prior three-year period. References herein to &#147;emerging growth company&#148; have the meaning associated with it in the JOBS Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we are a &#147;smaller reporting company&#148; as defined in Item 10(f)(1) of Regulation
<FONT STYLE="white-space:nowrap">S-K.</FONT> Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We will remain a smaller
reporting company until the last day of the fiscal year in which (1)&nbsp;the market value of our common shares held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $250&nbsp;million as of the prior April&nbsp;30, or (2)&nbsp;our
annual revenues exceed $100&nbsp;million during such completed fiscal year and the market value of our common shares held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700&nbsp;million as of the prior April 30. To the extent we
take advantage of such reduced disclosure obligations, it may also make comparison of our financial statements with those of other public companies difficult or impossible. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom459793_8"></A>SUMMARY HISTORICAL CONSOLIDATED FINANCIAL INFORMATION OF FEAC
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FEAC is providing the following summary historical financial information to assist the analysis of the financial aspects of the
Business Combination Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summary historical statements of operations and cash flows data of FEAC for the year ended
December&nbsp;31, 2022 and the period from August&nbsp;9, 2021 (inception) through December&nbsp;31, 2021, and the historical balance sheet data of FEAC as of December&nbsp;31, 2022 and 2021 are derived from FEAC&#146;s audited financial statements
included elsewhere in this proxy statement/prospectus. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summary historical statements of operations and cash flows data
of FEAC for the six months ended June&nbsp;30, 2023 and June&nbsp;30, 2022, and the historical balance sheet data of FEAC as of June&nbsp;30, 2023 are derived from the FEAC&#146;s unaudited interim consolidated financial statements included
elsewhere in this proxy statement/prospectus. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information below is only a summary and should be read in conjunction with the
sections entitled &#147;<I>FEAC&#146;s</I> <I>Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</I>&#148; and the financial statements, and the notes and schedules related thereto, which are included
elsewhere in this proxy statement/prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The historical results included below and elsewhere in this proxy statement/prospectus are
not indicative of the future performance of FEAC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Statement of Operations </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the six</B><br><B>months&nbsp;ended</B><br><B>June&nbsp;30,&nbsp;2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the six</B><br><B>months&nbsp;ended</B><br><B>June&nbsp;30,&nbsp;2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the year</B><br><B>ended&nbsp;December&nbsp;31,</B><br><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;period</B><br><B>from</B><br><B>August&nbsp;9,&nbsp;2021</B><br><B>(inception)</B><br><B>through</B><br><B>December&nbsp;
31,</B><br><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Operating costs <SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,050,505</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">816,351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,831,421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">232,346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Loss from operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(6,050,505</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(816,351</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(1,831,421</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(232,346</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Other Income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Interest earned from Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,989,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">154,482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,861,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Bank interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Total other income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,989,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">154,538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,862,147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Net (loss)/income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(3,060,575</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(661,813</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>30,726</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(225,437</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Basic and diluted weighted average shares outstanding, Class&nbsp;A ordinary shares subject to
possible redemption</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,650,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,650,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,650,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,558,966</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Basic and diluted net (loss)/income per share, Class&nbsp;A ordinary shares subject to possible
redemption</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(0.19</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(0.04</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>0.00</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(0.05</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Basic and diluted, weighted average shares outstanding &#151; Class&nbsp;B ordinary shares</P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,162,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,162,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,162,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,162,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Basic and diluted net (loss)/income per share, Class&nbsp;B ordinary shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(0.19</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(0.04</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>0.00</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(0.05</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the period from August&nbsp;9, 2021 through December&nbsp;31, 2021 and the year ended December&nbsp;31,
2022, the description of this line item was &#147;Formation and Operating Costs.&#148; </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Statements of Cash Flows Data </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the six</B><br><B>months&nbsp;ended</B><br><B>June&nbsp;30,&nbsp;2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the six</B><br><B>months&nbsp;ended</B><br><B>June&nbsp;30,&nbsp;2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the year</B><br><B>ended&nbsp;December&nbsp;31,</B><br><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the period</B><br><B>from</B><br><B>August&nbsp;9, 2021</B><br><B>(inception)</B><br><B>through</B><br><B>December&nbsp;31,</B><br><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,245,013</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>294,385</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(755,147</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(796,248</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,265,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(129,662,500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2,465,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>131,528,046</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net change in cash</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(45,013</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>294,385</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(755,147</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,069,298</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, beginning of the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">314,151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,069,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,069,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash, end of the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>269,138</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>774,913</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>314,151</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,069,298</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Balance Sheets </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30, 2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">269,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">314,151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,069,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,668</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">197,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">498,591</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>309,806</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>511,804</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,567,889</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses <FONT STYLE="white-space:nowrap">&#151;&nbsp;non-current</FONT> portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">209,052</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and securities held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">135,786,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">131,531,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">129,669,409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>136,095,976</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>132,043,138</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>131,446,350</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities, Shares Subject to Redemption and Shareholders&#146; Deficit:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current liabilities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued offering costs and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,493,223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">844,605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">316,651</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Due to related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48,699</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48,904</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Promissory note &#151; related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">965,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible Note &#151; Related Party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>8,006,922</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>893,509</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>327,447</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred underwriting commissions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,727,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,727,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,727,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>11,734,422</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>4,621,009</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>4,054,947</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Commitments and Contingencies</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;A ordinary shares subject to possible redemption, 12,650,000 shares at redemption value
of approximately $10.73, $10.40 and $10.25 at June&nbsp;30, 2023 and December&nbsp;31, 2022 and 2021, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">135,786,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">131,531,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">129,669,409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June 30, 2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Shareholders&#146; Deficit:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preference shares, $0.0001&nbsp;par value; 5,000,000&nbsp;shares authorized; none issued and
outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;A ordinary shares, $0.0001&nbsp;par value;&nbsp;500,000,000&nbsp;shares authorized;
none outstanding (excluding&nbsp;12,650,000&nbsp;shares subject to possible redemption issued) at June&nbsp;30, 2023, December&nbsp;31, 2022 and 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;B ordinary shares, $0.0001&nbsp;par value;&nbsp;50,000,000&nbsp;shares
authorized;&nbsp;3,162,500&nbsp;shares issued and outstanding at June&nbsp;30, 2023, December&nbsp;31, 2022 and December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Additional&nbsp;paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,424,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,109,521</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,278,322</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total shareholders&#146; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>11,424,616</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(4,109,205</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(2,278,006</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Liabilities, Shares Subject to Redemption and Shareholders&#146; Deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>136,095,976</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>132,043,138</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>131,446,350</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom459793_9"></A>SUMMARY HISTORICAL CONSOLIDATED FINANCIAL INFORMATION OF ENGENE
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The summary statement of consolidated operations and comprehensive loss and cash flows data of enGene for the years ended
October&nbsp;31, 2022, 2021, and 2020 and the balance sheet data as of October&nbsp;31, 2022 and 2021, were derived from the audited historical consolidated financial statements of enGene included elsewhere in this proxy statement/prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The summary statement of consolidated operations and comprehensive loss and cash flows data of enGene for the three and six months ended
April&nbsp;30, 2023, and 2022 and the balance sheet data as of April&nbsp;30, 2023, were derived from the unaudited interim historical consolidated financial statements of enGene included elsewhere in this proxy statement/prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information below is only a summary and should be read in conjunction with the sections entitled &#147;<I>enGene&#146;s Management&#146;s
Discussion and Analysis of Financial Condition and Results of Operations</I>&#148; and in enGene&#146;s consolidated financial statements, and the notes related thereto, which are included elsewhere in this proxy statement/prospectus. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Statements of Operations and Comprehensive Loss Data </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Three Months Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Six Months Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>Year Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>April&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>April&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>October&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(dollar amounts in<BR>thousands,&nbsp;except&nbsp;share<BR>and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(dollar amounts in<BR>thousands,&nbsp;except&nbsp;share<BR>and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(dollar amounts in</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>thousands, except share and</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>per share data)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,853</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Total other (income) expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,767</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss per share of common shares, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Weighted average number of common shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,849,767</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,622,186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,768,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,616,193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,640,030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,562,638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,763,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Balance Sheet Data </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>April&nbsp;30,</B><br><B>2023</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>October&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(dollar&nbsp;amounts&nbsp;in<BR>thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(dollar&nbsp;amounts in<BR>thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,641</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,517</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-current</FONT> liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42,301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shareholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">89,238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">76,614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53,442</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Statements of Cash Flows Data </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Six Months Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>Year Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>April&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>October&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(dollar amounts in</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(dollar amounts in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10,667</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,186</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(17,592</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15,984</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(13,061</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(23</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(115</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(153</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(247</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(192</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of exchange rate changes on cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(342</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(805</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(51</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase (decrease) in cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,936</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,039</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(456</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The historical results included below and elsewhere in this proxy statement/prospectus are not indicative of
the future performance of enGene. As explained elsewhere in this proxy statement/prospectus, the financial information contained in this section relates to enGene, prior to and without giving pro forma effect to the impact of the Business
Combination and, as a result, the results reflected in this section may not be indicative of the results of New enGene going forward. For additional information, see &#147;<I>Unaudited Pro Forma Condensed Combined Financial Information</I>.&#148;
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom459793_10"></A>SELECTED UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL
INFORMATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following selected unaudited pro forma condensed combined financial data is derived from the unaudited pro forma
condensed combined balance sheet and unaudited pro forma condensed combined statement of operations included elsewhere in this proxy statement/prospectus and is provided to aid you in your analysis of the financial aspects of the Business
Combination. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial statements are based on FEAC&#146;s historical financial
statements, New enGene&#146;s historical financial statements, and enGene&#146;s historical consolidated financial statements as adjusted to give effect to the Transactions, including the Business Combination, PIPE Financing, the <FONT
STYLE="white-space:nowrap">Non-Redemption</FONT> Agreement, the Convertible Bridge Financing, the Working Capital Loans, the Sponsor and Insiders Letter Agreement, the Extension Loan and related transactions. The unaudited pro forma condensed
combined balance sheet gives pro forma effect to the Transactions as if they had been consummated on April&nbsp;30, 2023. The unaudited pro forma condensed combined statement of operations for the six months ended April&nbsp;30, 2023 and the year
ended October&nbsp;31, 2022, gives effect to the Transactions as if they had occurred on November&nbsp;1, 2021, which is the beginning of the earliest period presented. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FEAC is a blank check company incorporated on August&nbsp;9, 2021, as a Cayman Islands exempted company for the purpose of effecting a merger,
share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. Prior to executing the Business Combination Agreement, FEAC&#146;s efforts were limited to organizational
activities, completion of its IPO and the evaluation of possible business combinations. As of March&nbsp;31, 2023, there was $132.9&nbsp;million in investments and cash held in the Trust Account and $474,437 of cash held outside the Trust Account
available for general corporate purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">enGene is a clinical-stage biotechnology company developing
<FONT STYLE="white-space:nowrap">non-viral</FONT> gene therapies based on localized delivery of nucleic acid payloads to mucosal tissues. enGene&#146;s proprietary DDX platform has a high degree of payload flexibility, including DNA and various
forms of RNA with broad tissue and disease application. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial statements were prepared in
accordance with Article 11 of SEC Regulation <FONT STYLE="white-space:nowrap">S-X.</FONT> The adjustments presented in the unaudited pro forma condensed combined financial statements have been identified and presented to provide relevant information
necessary for an understanding of the combined company reflecting the Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial
statements have been derived from and should be read in conjunction with: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the accompanying notes to the unaudited pro forma condensed combined financial statements included elsewhere in
this proxy statement/prospectus, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the historical unaudited condensed financial statements of FEAC as of and for the three months ended
March&nbsp;31, 2023, and the related notes not included in this proxy statement/prospectus, </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the historical audited financial statements of FEAC as of and for the year ended December&nbsp;31, 2022, and the
related notes included elsewhere in this proxy statement/prospectus, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the historical unaudited condensed financial statements of FEAC as of and for the nine months ended
September&nbsp;30, 2022 (used to determine the results of operations of FEAC for the six months ended March&nbsp;31, 2023) not included in this proxy statement/prospectus, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the historical unaudited consolidated financial statements of enGene as of and for the six months ended
April&nbsp;30, 2023, and the related notes included elsewhere in this proxy statement/prospectus, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the historical audited consolidated financial statements of enGene as of and for the year ended October&nbsp;31,
2022, and the related notes included elsewhere in this proxy statement/prospectus. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the historical audited financial statements of New enGene as of July&nbsp;31, 2023 and for the period from April
24, 2023 (inception) to July 31, 2023, and the related notes included elsewhere in this proxy statement/prospectus, and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the sections entitled &#147;<I>FEAC&#146;s Management&#146;s Discussion and Analysis of Financial Condition and
Results of Operations,&#148;</I> &#147;<I>enGene&#146;s Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</I>,&#148; and other financial information relating to FEAC and enGene included elsewhere in this
proxy statement/prospectus. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial statements present two redemption
scenarios as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">No Redemption Scenario: This presentation assumes that no FEAC public shareholders exercise redemption rights to
have their FEAC Class&nbsp;A Shares converted into their pro rata share of the Trust Account and thus the full amount held in the Trust Account as of the Closing is available for the Business Combination; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Maximum Redemption Scenario: This presentation assumes that 10,483,335 FEAC Class&nbsp;A Shares are redeemed,
resulting in an aggregate cash payment of approximately $111.2&nbsp;million out of the Trust Account based on an assumed redemption price of $10.61 per share that is calculated using the sum of approximately $132.9&nbsp;million cash in the Trust
Account at March&nbsp;31, 2023 and the $1.3&nbsp;million Extension Loan Note deposited into the Trust Account on June&nbsp;6, 2023, divided by 12,650,000 FEAC Class&nbsp;A Shares subject to redemption assuming the pro forma maximum redemptions
scenario pursuant to the Business Combination Agreement. The number of FEAC Class&nbsp;A Shares that are redeemed is derived by reducing the total of 12,650,000 FEAC Class&nbsp;A Shares outstanding by 2,000,000 FEAC Class&nbsp;A Shares held by the
Sponsor that are subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements and 166,665 FEAC Class&nbsp;A Shares held by public shareholders that are subject to a <FONT STYLE="white-space:nowrap">non-redemption</FONT> agreement. After a
redemption of approximately $111.2&nbsp;million out of the $134.2&nbsp;million Trust Account, including the $1.3&nbsp;million Extension Loan Note, the available cash at Closing from the Trust Account would be approximately $23.0&nbsp;million.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination will result in the combination of enGene and New enGene, with a fiscal year end of
October&nbsp;31, with FEAC, with a fiscal year end of December 31. The pro forma statement of operations for the six months ended April&nbsp;30, 2023 and the year ended October&nbsp;31, 2022, presents the combination of financial information of New
enGene, FEAC and enGene, after giving effect to the Transactions described in the accompanying notes. The unaudited pro forma statement of operations for the six months ended April&nbsp;30, 2023 includes enGene&#146;s statement of operations for the
six months ended April&nbsp;30, 2023, FEAC&#146;s results of operations for the six months ended March&nbsp;31, 2023, and New enGene&#146;s results of operations for the period from April&nbsp;24, 2023 (inception) to July&nbsp;31, 2023. The
unaudited pro forma statement of operations for the year ended October&nbsp;31, 2022 includes enGene&#146;s statement of operations for the year ended October&nbsp;31, 2022, and FEAC&#146;s statement of operations for the year ended
December&nbsp;31, 2022. The unaudited pro forma balance sheet as of April&nbsp;30, 2023 is based on a historical New enGene balance sheet as of July&nbsp;31, 2023, historical enGene balance sheet as of April&nbsp;30, 2023, and a historical FEAC
balance sheet as of March&nbsp;31, 2023. FEAC&#146;s results of operations for the three months ended December&nbsp;31, 2022 are included in the unaudited pro forma statement of operations for both the six months ended April&nbsp;30, 2023 and the
year ended October&nbsp;31, 2022. FEAC&#146;s loss from operations and other income for the three months ended December&nbsp;31, 2022 were $491,000 and $1.1&nbsp;million, respectively, resulting in net income for the three months ended
December&nbsp;31, 2022 of $621,000. The operations of New enGene are nominal in the unaudited pro forma condensed combined statement of operations for the period from April&nbsp;24, 2023 (inception) to July&nbsp;31, 2023 and had not commenced in the
unaudited pro forma condensed combined statements of operations for the fiscal year ended October&nbsp;31, 2022. Subsequent to the Transactions, FEAC, New enGene and enGene are collectively referred to herein as the &#147;Combined Company.&#148;
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selected unaudited pro forma condensed combined financial data have been presented for
illustrative purposes only and do not necessarily reflect what the Combined Company&#146;s financial condition or results of operations would have been had the Transactions occurred on the dates indicated, nor are they indicative of the future
consolidated results of operations or financial position of the Combined Company. The actual financial position and results of operations may differ significantly from the pro forma amounts reflected herein due to a variety of factors. The unaudited
pro forma adjustments represent management&#146;s estimates based on information available as of the date of these unaudited pro forma condensed combined financial statements and are subject to change as additional information becomes available and
analyses are performed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Selected Unaudited Pro Forma Condensed Combined Balance Sheet Data As of April&nbsp;30, 2023 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unaudited Pro Forma</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of April&nbsp;30, 2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Scenario 1<BR>(Assuming<BR>No&nbsp;Redemptions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Scenario 2<BR>(Assuming<BR>Maximum<BR>Redemptions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">211,477</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">215,947</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">104,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,801</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,801</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total shareholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">201,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">89,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Selected Unaudited Pro Forma Condensed Combined Statement of Operations Data for the Six Months Ended April&nbsp;30, 2023
and the Year Ended October&nbsp;31, 2022 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Combined Pro Forma</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended</B><br><B>April&nbsp;30, 2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended</B><br><B>October&nbsp;31, 2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Scenario 1<BR>(Assuming No<BR>Redemptions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Scenario 2<BR>(Assuming<BR>Maximum<BR>Redemptions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Scenario 1<BR>(Assuming No<BR>Redemptions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Scenario 2<BR>(Assuming<BR>Maximum<BR>Redemptions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except share and per share amounts)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11,628</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11,628</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(33,835</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(33,835</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,288</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,288</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(36,070</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(36,070</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss per common share&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.37</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.53</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1.08</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1.56</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,552,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,068,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,552,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,068,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom459793_11"></A>COMPARATIVE HISTORICAL AND UNAUDITED </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PRO FORMA PER SHARE FINANCIAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth summary historical comparative share information for FEAC, enGene and New enGene and unaudited pro forma
Combined Company per share information after giving effect to the Transactions, including the Business Combination, PIPE Financing and Convertible Bridge Financing, assuming two redemption scenarios as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">No Redemption Scenario: This presentation assumes that no FEAC public shareholders exercise redemption rights to
have their FEAC Class&nbsp;A Shares converted into their pro rata share of the Trust Account and thus the full amount held in the Trust Account as of the Closing is available for the Business Combination; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Maximum Redemption Scenario: This presentation assumes that 10,483,335 FEAC Class&nbsp;A Shares are redeemed,
resulting in an aggregate cash payment of approximately $111.2&nbsp;million out of the Trust Account based on an assumed redemption price of $10.61 per share that is calculated using the sum of approximately $132.9&nbsp;million cash in the Trust
Account and the $1.3&nbsp;million Extension Loan Note deposited into the Trust Account on June&nbsp;6, 2023, divided by 12,650,000 FEAC Class&nbsp;A Shares subject to redemption assuming the pro forma maximum redemptions scenario pursuant to the
Business Combination Agreement. The number of FEAC Class&nbsp;Shares that are redeemed is derived by reducing the total of 12,650,000 FEAC Class&nbsp;A Shares outstanding by 2,000,000 FEAC Class&nbsp;A Shares held by the Sponsor that are subject to <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements and 166,665 FEAC Class&nbsp;A shares held by public shareholders that are subject to <FONT STYLE="white-space:nowrap">non-redemption</FONT> agreements. After a redemption of approximately
$111.2&nbsp;million out of the $134.2&nbsp;million Trust Account, including the $1.3&nbsp;million Extension Loan Note, the available cash at Closing from the Trust Account would be approximately $23.0&nbsp;million. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination will result in the combination of enGene and New enGene, with a fiscal year end of October&nbsp;31, with FEAC, with a
fiscal year end of December 31. The unaudited pro forma book value information and ending shares reflect the Transactions, including the Business Combination, PIPE Financing and Convertible Bridge Financing, as if they had occurred on April&nbsp;30,
2023. The weighted average shares outstanding and net loss per share information reflect the Transactions as if they had occurred on November&nbsp;1, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This information is only a summary and should be read together with the summary historical financial information included elsewhere in this
proxy statement/prospectus, and the historical financial statements of FEAC, enGene and New enGene and related notes that are included elsewhere in this proxy statement/prospectus. The unaudited pro forma Combined Company per share information of
FEAC and enGene is derived from, and should be read in conjunction with, the unaudited pro forma condensed combined financial statements and related notes included elsewhere in this proxy statement/prospectus. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma Combined Company earnings per share information below does not
purport to represent the earnings per share which would have occurred had the companies been combined during the periods presented, nor earnings per share for any future date or period. The unaudited pro forma Combined Company book value per share
information below does not purport to represent what the value of FEAC, enGene and New enGene would have been had the companies been combined during the periods presented. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>July&nbsp;31,&nbsp;2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,&nbsp;2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>April&nbsp;30, 2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>enGene<BR>Holdings&nbsp;Inc.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FEAC</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>enGene</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma</B><br><B>Combined&nbsp;(No<BR>Redemptions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma</B><br><B>Combined</B><br><B>(Full&nbsp;Redemptions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) (1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(72</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,700</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,288</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,288</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shareholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(72</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,876</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(89,238</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">201,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">89,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FEAC Shares subject to redemption</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp; </TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,483,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp; </TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending common shares at period end</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,162,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,885,897</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,552,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,068,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending common shares at period end (including shares subject to redemption)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,645,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,885,897</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,552,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,068,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average common shares outstanding&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,162,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,768,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,552,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,068,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Book value per share (2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,200</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.43</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(22.96</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted income (loss) per common share (3)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,200</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4.00</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.37</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.53</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash dividends per share</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">NA</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">NA</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">NA</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">NA</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">NA</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Net income (loss) is derived from: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">New enGene&#146;s audited statement of operations for the period from April&nbsp;24, 2023 (inception) to
July&nbsp;31, 2023, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FEAC&#146;s results of operations for the six months ended March&nbsp;31, 2023 which are derived from its
unaudited condensed statement of operations for the three months ended March&nbsp;31, 2023 and the results of operations for the three months ended December&nbsp;31, 2022, calculated using its statement of operations for the year ended
December&nbsp;31, 2022 and unaudited condensed statement of operations for the nine months ended September&nbsp;30, 2022. FEAC&#146;s results of operations for the three months ended December&nbsp;31, 2022 are included in the unaudited pro forma
statement of operations for both the six months ended April&nbsp;30, 2023 and the year ended October&nbsp;31, 2022. FEAC&#146;s loss from operations and other income for the three months ended December&nbsp;31, 2022 were $491,000 and
$1.1&nbsp;million, respectively, resulting in net income for the three months ended December&nbsp;31, 2022 of $621,000, and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enGene&#146;s unaudited condensed consolidated statement of operations for the six months ended April&nbsp;30,
2023. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Book value per share is determined as the ending period balance of total shareholders&#146; equity (deficit)
divided by: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">New enGene Class&nbsp;B common shares outstanding at July&nbsp;31, 2023, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FEAC Class&nbsp;A Shares outstanding at March&nbsp;31, 2023, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enGene Common Shares outstanding at April&nbsp;30, 2023, and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of common shares based on each redemption scenario for the Combined Company at April&nbsp;30, 2023.
</P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Loss per common shares is based on: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Weighted average number of New enGene Class&nbsp;B common shares outstanding for the period from April&nbsp;24,
2023 (inception) to July&nbsp;31, 2023, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Weighted average number of FEAC Class&nbsp;A shares outstanding for the six months ended March&nbsp;31, 2023,
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Weighted average number of enGene Common Shares outstanding for the six months ended April&nbsp;30, 2023, and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The number of common shares based on each redemption scenario for the Combined Company for the six months ended
April&nbsp;30, 2023. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom459793_12"></A>MARKET PRICE, TICKER SYMBOL AND DIVIDEND INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FEAC </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Market Price and Ticker
Symbol </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FEAC&#146;s units, Class&nbsp;A ordinary shares and public warrants are currently listed on the Nasdaq Global Market
under the symbols &#147;FRBNU,&#148; &#147;FRBN,&#148; and &#147;FRBNW,&#148; respectively. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The closing prices of FEAC Units, FEAC
Class&nbsp;A Shares and FEAC Public Warrants on May&nbsp;16, 2023, the last trading day before announcement of the execution of the Business Combination Agreement, were $10.58, $10.55 and $0.14, respectively. As of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;, 2023, the record date for the Special Meeting, the closing price for each unit, Class&nbsp;A ordinary share and public warrant was
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Holders </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of
June&nbsp;30, 2023, there was one holder of record of FEAC Units, one holder of record of FEAC Class&nbsp;A Shares, one holder of record of FEAC Class&nbsp;B Shares and two holders of record of FEAC Public Warrants. The number of holders of record
does not include a substantially greater number of &#147;street name&#148; holders or beneficial holders whose FEAC Units, FEAC Class&nbsp;A Shares and FEAC Public Warrants are held of record by banks, brokers and other financial institutions. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Dividend Policy </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FEAC has not paid any cash dividends on FEAC Shares to date and does not intend to pay any cash dividends prior to the completion of the
Business Combination. The payment of cash dividends in the future will be dependent upon New enGene revenues and earnings, if any, capital requirements and general financial condition subsequent to completion of the Business Combination. The payment
of any cash dividends subsequent to the Business Combination will be within the discretion of New enGene&#146;s Board of Directors at such time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>enGene </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is no public market for
common shares of enGene. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom459793_13"></A>SUMMARY RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of select risks and uncertainties that could materially adversely affect the Business Combination, enGene and its
business, financial condition and results of operations. You should read this summary together with the full and complete discussion of risk factors contained below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to enGene and New enGene&#146;s Business Following the Business Combination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Unless otherwise indicated or the context otherwise requires, references in this section to &#147;we,&#148; &#147;us,&#148; &#147;our,&#148;
and other similar terms refer to enGene and its subsidiary prior to the consummation of the Business Combination and to New enGene and its consolidated subsidiaries following the consummation of the Business Combination. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Risks Relating to Our Business </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The sizes of the markets and forecasts of market growth for the demand of our novel gene therapy platform,
product candidates and other key potential success factors are based on a number of complex assumptions and estimates, and may be inaccurate. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We expect to make significant investments in our continued research and development of <FONT
STYLE="white-space:nowrap">EG-70,</FONT> a novel <FONT STYLE="white-space:nowrap">non-viral</FONT> gene therapy for the purpose of stimulating the adaptive immune system, <FONT STYLE="white-space:nowrap">EG-i08,</FONT> a pulmonary program, and other
new product candidates and gene therapies and services, which may not be successful, and if they are not successful, we may not be able to achieve or sustain profitability in the future. As an organization, we do not have any experience in any such
new lines of business, and failure to identify other product candidates and/or execute on the expansion of our business would adversely affect our business and results of operations. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have incurred net losses in every year since our inception and anticipate that we will continue to incur net
losses in the foreseeable future. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our recurring losses from operations and negative cash flows from operating activities raise substantial doubt
about our ability to continue as a going concern. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We identified material weaknesses in our internal control over financial reporting. If we are unable to remedy
these material weaknesses, or if we fail to establish and maintain effective internal controls, we may be unable to produce timely and accurate financial statements, and we may determine that our internal control over financial reporting is not
effective, which could adversely impact our investors&#146; confidence and the price of our common shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">To date, we have not generated any product revenue, have a history of losses and will need to raise additional
capital to fund our operations. If we fail to obtain necessary financing, we will not be able to complete the development and commercialization of our product candidates. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We face significant competition from other biotechnology and pharmaceutical companies, which may result in our
competitors discovering, developing or commercializing products before us or more successfully than we do. Our business and results of operations could be adversely affected if we fail to compete effectively. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The genetic medicine field is relatively new and evolving rapidly. Because of our limited technical, financial
and human resources, we are focusing our research and development efforts on our gene therapy platform and our therapeutic product candidates among many potential options. As a result, we may forego or delay pursuit of other gene therapy
technologies or other therapeutic product candidates that provide significant advantages over our platform, which could materially harm our business and results of operations. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our gene therapy platform is based on novel technologies that are unproven, which makes it difficult to predict
the time and cost of development and of subsequently obtaining regulatory approval, if at all. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Development of new therapeutics involves a lengthy and expensive process, with an uncertain outcome. We may incur
additional costs, fail to replicate the positive results from our earlier preclinical or clinical studies of our product candidates in later preclinical studies and any clinical trials or experience delays in completing or ultimately be unable to
complete, the development and commercialization of any product candidates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our use of third parties to manufacture, develop and test our therapeutic product candidates for preclinical
studies and clinical trials increases the risk that we will not have sufficient quantities of our product candidates or products, or necessary quantities of such materials on time or at an acceptable cost. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our most advanced product candidates are complex to manufacture and we may encounter difficulties in production,
particularly with respect to scaling our manufacturing capabilities. If we or any of our third-party manufacturers with whom we contract encounter these types of difficulties, our ability to provide supply of our product candidates for clinical
trials or our products for patients, if approved, could be delayed or stopped, or we may be unable to maintain a commercially viable cost structure. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The market opportunities for our product candidates may be limited to a small group of patients who are
ineligible for or have failed prior treatments and our estimates of the prevalence of our target patient populations may be inaccurate. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We rely on our senior management team and key personnel, and our business could be harmed if we are unable to
attract and retain personnel necessary for our success. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our research and development initiatives, manufacturing processes and business depend on our ability to attract
and retain highly skilled scientists and other specialized individuals. We may not be able to attract or retain such qualified scientists and other specialized individuals in the future due to the competition for qualified personnel among life
science and technology businesses. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Nearly all aspects of our activity and our products and services are subject to extensive regulation by various
U.S. federal and state agencies and regulatory bodies in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions, and compliance with existing or future regulations could result in unanticipated expenses or limit our ability to offer our
products and services. Once developed, our gene therapy platform and therapeutic product candidates will require regulatory approval, which is a lengthy, expensive, and inherently unpredictable process with uncertain outcomes and cost and the
potential for substantial delays. We cannot give any assurance whether or when our product candidates will receive regulatory approval, which is necessary before they can be commercialized. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We cannot predict whether or when we will obtain regulatory approval to commercialize a product candidate we may
develop in the United States or any other jurisdiction and any such approval may be for a narrower indication than we seek. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we are not able to obtain or if there are delays in obtaining required regulatory approvals for our product
candidates, we will not be able to commercialize or will be delayed in commercializing our product candidates and our ability to generate revenue will be adversely affected. Even if we eventually gain approval for any of our product candidates, we
may be unable to commercialize them. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may not obtain or maintain regulatory approval in all jurisdictions in which such approval may be required.
Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will obtain and/or maintain regulatory approval of our product candidates in other jurisdictions, while a failure or delay in obtaining
or maintaining regulatory approval of our product candidates in one jurisdiction may have a material adverse effect on the regulatory approval or maintenance process in other jurisdictions. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Even if we receive regulatory approval of any product candidates or therapies, we will be subject to ongoing
regulatory obligations, reporting requirements and continued regulatory review, which may result in significant additional expenses. If we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates,
we may be subject to substantial penalties, fines, delays, suspensions, refusals and withdrawals of approvals. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Changes in regulatory requirements could result in delays or discontinuation of development of our product
candidates or therapies, or unexpected costs in obtaining or maintaining regulatory approval, and thereby adversely affect our business and results of operations. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our contract manufacturers are subject to significant regulation with respect to the manufacturing of our current
and future product candidates. The manufacturing facilities on which we rely may not meet or continue to meet regulatory requirements and/or may have limited capacity. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Any product candidates we develop may become subject to unfavorable or unprofitable third-party coverage and
reimbursement practices, as well as pricing regulations. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Drug marketing, price controls and reimbursement regulations may materially affect our ability to market and
receive coverage for our product candidates, if approved, in the European Union, the United Kingdom, Japan and other <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are an international organization and we plan to expand operations internationally where we have limited
operating experience and where we may be subject to increased regulatory risks and local competition. If we are unsuccessful in any efforts to expand internationally, our business and results of operations may be adversely affected.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Global economic uncertainty, changes in geopolitical conditions and weakening product demand caused by political
instability, changes in trade agreements and disputes, such as the conflict between Russia and Ukraine and other macroeconomic factors, could adversely affect our business and results of operations. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we are unable to obtain and maintain, enforce and defend patent protection for any product candidates we
develop or for our novel gene therapy platform, or if the scope of the patent protection obtained is not sufficiently broad, our competitors or other third parties could develop and commercialize products or technology similar or identical to ours
and our ability to successfully commercialize any product candidates we may develop and our technology may be adversely affected. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Issued patents covering our product candidates or gene therapy platform could be found invalid or unenforceable
if challenged in court or before administrative bodies in the United States or other jurisdictions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may be involved in legal proceedings in relation to intellectual property rights and to protect or enforce our
patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We will need to grow the size of our organization, both organically and through acquisitions, and we may
experience difficulties identifying and hiring the right employees and successfully managing this growth </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Acquisitions, collaborations or other strategic partnerships may increase our capital requirements, dilute our
shareholders, cause us to incur debt or assume contingent liabilities and subject us to other risks. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Because New enGene is a Canadian company, shareholder protections differ from shareholder protections in the
United States and elsewhere, and New enGene is subject to a variety of additional risks that may negatively impact New enGene&#146;s operations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Proposed Articles to be in effect following the consummation of the Business Combination and certain Canadian
legislation contain provisions that may have the effect of delaying, preventing or making undesirable an acquisition of all or a significant portion of New enGene&#146;s shares or assets or preventing a change in control. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to the Business Combination and FEAC </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Unless the context otherwise requires, all references in this section to &#147;FEAC,&#148; &#147;we,&#148; &#147;us&#148; and
&#147;ours&#148; refer to FEAC prior to the consummation of the Business Combination, which will be the business of New enGene and its subsidiaries following the consummation of the Business Combination. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Risks Related to the Business Combination </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FEAC may not have sufficient funds outside the Trust Account to fund its working capital requirements pending the
consummation of the Business Combination. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Since the Sponsor, its parent FGOF and FEAC&#146;s directors and executive officers have interests that are
different from, or in addition to (and which may conflict with), the interests of FEAC&#146;s other shareholders, a conflict of interest may exist in determining whether the Business Combination is appropriate as FEAC&#146;s initial business
combination. Such interests include that the Sponsor may lose its entire investment if a Business Combination is not completed, and that the Sponsor, FGOF and certain of FEAC&#146;s directors will benefit from the completion of a Business
Combination and may be incentivized to complete the Business Combination, even if it is with a less favorable target company or on less favorable terms to FEAC Shareholders, rather than liquidate FEAC. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Forbion Capital Fund III, an affiliate of Forbion, the Sponsor and FGOF is a significant shareholder of enGene
and an investor in both of enGene&#146;s Amended 2022 Convertible Notes and the 2023 Convertible Notes, and as a result, a conflict of interest may exist in determining whether the Business Combination is appropriate as FEAC&#146;s initial business
combination. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Business Combination may be completed even though material adverse effects may result from the public
announcement or completion of the proposed Business Combination, general business or economic conditions, industry-wide changes, and other causes. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The ability to successfully effect the Business Combination and to be successful thereafter will be dependent
upon the efforts of key personnel, some of whom may be from FEAC and enGene, and some of whom may join New enGene following the Business Combination. The loss of key personnel or the hiring of ineffective personnel after the Business Combination
could negatively impact operations and profitability of New enGene. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FEAC and enGene could be a target of securities class action and derivative lawsuits, which could result in
substantial costs and may delay or prevent the Business Combination from being completed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Sponsor, FGOF and FEAC&#146;s executive officers and directors have agreed to vote in favor the Business
Combination, regardless of how FEAC Shareholders vote. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are attempting to complete the Business Combination with a private company about which little information is
available, which may result in a business combination that does not deliver the expected benefits or is not as profitable as we suspected, if at all. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">There is no assurance that the due diligence undertaken in relation to the Business Combination has uncovered all
material issues in relation to the business or financial condition of enGene. Accordingly, subsequent to the completion of the Business Combination, New enGene may be required to take write-downs or write-offs, restructuring and impairment or other
charges that could have a significant negative effect on New enGene&#146;s financial condition, results of operations and share price, which could cause you to lose some or all of your investment. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FEAC will have limited rights after the Closing to make claims for damages against enGene or enGene&#146;s
stockholders for the breach of representations, warranties, agreements or covenants made by enGene in the Business Combination Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The FEAC Reorganization may be a taxable event for U.S. Holders of FEAC Class&nbsp;A Shares or FEAC Warrants.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We believe that FEAC (the predecessor to New enGene for this purpose) was a passive foreign investment company (a
&#147;PFIC&#148;) PFIC for its 2021 and 2022 taxable years, and there is significant risk that New enGene may be or become a PFIC, which could result in adverse U.S. federal income tax consequences to U.S. Holders of New enGene Shares or New enGene
Warrants. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FEAC may not be able to complete the Business Combination if the Business Combination is subject to U.S. foreign
investment regulations or review by a U.S. government entity, such as the Committee on Foreign Investment in the United States (&#147;CFIUS&#148;). </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">You do not have any rights or interests in funds from the Trust Account, except under certain limited
circumstances. If FEAC does not complete the Business Combination, you may therefore be forced to sell your FEAC Class&nbsp;A Shares or FEAC Warrants to liquidate your investment, potentially at a loss. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The exercise of FEAC&#146;s directors&#146; and executive officers&#146; discretion in agreeing to changes or
waivers with respect to the terms of the Business Combination may result in a conflict of interest when determining whether such changes to the terms of the Business Combination or waivers of conditions are appropriate and in FEAC Shareholders&#146;
best interest. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FEAC has identified a material weakness in its internal control over financial reporting. If FEAC and, following
the Business Combination, New enGene, is unable to develop and maintain an effective system of internal control over financial reporting, FEAC and, following the Business Combination, New enGene, may not be able to accurately report its financial
results in a timely manner, meet reporting obligations, prevent fraud and/or file periodic reports in a timely manner, which may adversely affect investor confidence in FEAC or New enGene, as applicable, and materially and adversely affect
FEAC&#146;s or New enGene&#146;s, as applicable, business and operating results. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Risks Related to Being a Public
Company </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">New enGene&#146;s management team has limited experience managing a public company, and the additional
requirements for public companies may strain resources and divert management&#146;s attention. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">There are risks to FEAC Shareholders related to becoming shareholders of enGene through the Business Combination
rather than through an underwritten public offering, including no independent due diligence review by an underwriter. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Nasdaq may not list New enGene&#146;s securities on its exchange, in which event, if not waived by the parties to
the Business Combination Agreement as one of the closing conditions thereof, FEAC would not be able to consummate the Business Combination with enGene. If New enGene&#146;s securities are listed, New enGene may be unable to satisfy listing
requirements in the future, which could limit investors&#146; ability to effect transactions in New enGene&#146;s securities and subject it to additional trading restrictions. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Risks Regarding Redemption </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Holders of FEAC Class&nbsp;A Shares who wish to redeem their FEAC Class&nbsp;A Shares for a pro rata portion of
the Trust Account must comply with specific requirements for redemption that may make it more difficult for them to exercise their redemption rights prior to the deadline. If such FEAC Shareholders fail to comply with the redemption requirements
specified in this proxy statement/prospectus, they will not be entitled to redeem their FEAC Class&nbsp;A Shares for the right to receive a pro rata portion of the funds held in the Trust Account. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If you or a &#147;group&#148; of holders of FEAC Class&nbsp;A Shares are deemed to hold in excess of 15% of FEAC
Class&nbsp;A Shares, you may lose the ability to redeem all such shares in excess of 15% of FEAC&#146;s Class&nbsp;A Shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Holders of FEAC Class&nbsp;A Shares may in limited circumstances be required to repay unlawful distributions
knowingly received by them upon redemption of their shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If third parties bring claims against FEAC, the proceeds held in the Trust Account could be reduced and the per
share redemption amount received by holders of FEAC Class&nbsp;A Shares may be less than $10.35 per FEAC Class&nbsp;A Share. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Risks Related to FEAC </I></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FEAC may not be able to consummate an initial business combination within 18 months after the closing of
FEAC&#146;s IPO (or up to 24 months from the closing of our IPO if FEAC extends the period of time to consummate a business combination), in which case we would cease all operations except for the purpose of winding up and we would redeem our FEAC
Class&nbsp;A Shares and liquidate, in which case FEAC Shareholders may receive only $10.35 per share, or less than such amount in certain circumstances, and our warrants will expire worthless. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FEAC&#146;s directors may decide not to enforce the indemnification obligations of the Sponsor, resulting in a
reduction in the amount of funds in the Trust Account available for distribution to FEAC Shareholders. If, after FEAC distributes the proceeds in the Trust Account to FEAC Shareholders, we file a bankruptcy or
<FONT STYLE="white-space:nowrap">winding-up</FONT> petition or an involuntary bankruptcy or <FONT STYLE="white-space:nowrap">winding-up</FONT> petition is filed against us that is not dismissed, a bankruptcy or insolvency court may seek to recover
such proceeds, and the members of FEAC&#146;s board of directors may be viewed as having breached their fiduciary duties to FEAC&#146;s creditors, thereby exposing the members of our board of directors and us to claims of punitive damages.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If, before distributing the proceeds in the Trust Account to FEAC Shareholders, FEAC files a bankruptcy or <FONT
STYLE="white-space:nowrap">winding-up</FONT> petition or an involuntary bankruptcy or <FONT STYLE="white-space:nowrap">winding-up</FONT> petition is filed against us that is not dismissed, the claims of creditors in such proceeding may have priority
over the claims of our shareholders and the per share amount that would otherwise be received by our shareholders in connection with our liquidation may be reduced. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom459793_14"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>You should carefully review and consider the following risk factors and the other information contained in this proxy statement/prospectus,
including the Annexes, in evaluating the Business Combination and the proposals to be voted on at the Special Meeting. You should carefully consider the following risk factors in addition to the other information included in this proxy
statement/prospectus, including matters addressed in the section entitled &#147;Cautionary Statement Regarding Forward-Looking Statements.&#148; enGene, FEAC or New enGene may face additional risks and uncertainties that are not presently known to
enGene, FEAC or New enGene, or that enGene, FEAC or New enGene currently deems immaterial, which may also impair enGene&#146;s, FEAC&#146;s or New enGene&#146;s respective business, financial condition, results of operations and prospects. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to enGene and New enGene&#146;s Business Following the Business Combination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Unless otherwise indicated or the context otherwise requires, references in this section to &#147;we,&#148; &#147;us,&#148; &#147;our,&#148; and other
similar terms refer to enGene and its subsidiary prior to the consummation of the Business Combination and to New enGene and its consolidated subsidiaries following the consummation of the Business Combination. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Risks Relating to Our Business </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The sizes of the markets and forecasts of market growth for the demand of our novel gene therapy platform, product candidates and other key potential
success factors are based on a number of complex assumptions and estimates, and may be inaccurate. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate total addressable
markets and forecasts of market growth for our novel gene therapy platform and differentiated product candidates. Our forecasts and key performance indicators are based on a number of complex assumptions, internal and third-party estimates in
published literature, and other business data, including assumptions and estimates relating to our ability to manage operating expenses of, invest in, develop and generate revenue from our gene therapy platform, product candidates and related
services in the future. While we believe our assumptions and the data underlying our estimates and key performance indicators are reasonable, there are inherent challenges in measuring or forecasting such information. As a result, these assumptions
and estimates may not be correct and the conditions supporting our assumptions or estimates may change at any time, thereby reducing the predictive accuracy of these underlying factors and metrics. Consequently, our estimates of the total
addressable markets and our forecasts of market growth for our novel gene therapy platform and differentiated product candidates may prove to be incorrect. For example, if the annual total addressable markets or the potential market growth for our
gene therapies is smaller than we have estimated or if the key business metrics we utilize to forecast commercial opportunities are inaccurate, it may have an adverse effect on our business, financial condition, results of operations and prospects.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We expect to make significant investments in our continued research and development of <FONT STYLE="white-space:nowrap">EG-70,</FONT> a novel <FONT
STYLE="white-space:nowrap">non-viral</FONT> gene therapy for the purpose of stimulating the adaptive immune system, <FONT STYLE="white-space:nowrap">EG-i08,</FONT> a pulmonary program, and other new product candidates and gene therapies and
services, which may not be successful, and if they are not successful, we may not be able to achieve or sustain profitability in the future. As an organization, we do not have any experience in any such new lines of business, and failure to identify
other product candidates and/or execute on the expansion of our business would adversely affect our business and results of operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Biotechnology product development is expensive, takes years to complete, and has uncertain outcomes. Failure can occur at any stage of product
development. In addition, if we determine that any of our current or future products or services are unlikely to succeed, we may abandon them without any return on our investment. We expect to incur significant expenses to advance our gene therapy
development efforts, which may be unsuccessful. Developing new product candidates is a speculative, risky and highly competitive endeavor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Product candidates that initially show promise may fail to achieve the desired results in development and clinical studies and may ultimately not prove to be safe and effective or meet
expectations for clinical utility. We may be unable to establish clinical endpoints that applicable regulatory authorities would consider clinically meaningful, and a clinical trial can fail at any stage of testing. We may need to alter our
offerings in development and repeat clinical studies before we develop a potentially successful product. If, after development, a product appears successful, we will still need to obtain U.S. Food and Drug Administration (&#147;FDA&#148;) and other
regulatory approvals before we can market it. The FDA&#146;s approval pathways are likely to involve significant time, as well as additional research, development and clinical study expenditures. The FDA may not clear, authorize or approve any
product we develop. Even if we develop a product that receives regulatory clearance, authorization or approval, we would need to commit substantial resources to commercialize, sell and market it before it could be profitable, and the product may
never be commercially successful. Additionally, development of any product or service may be disrupted or made less viable by the development of competing products or services. Because of the numerous risks and uncertainties associated with
developing product candidates, we are unable to predict whether or when our therapeutics business may successfully commercialize a product candidate. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have incurred net losses in every year since our inception and anticipate that we will continue to incur net losses in the foreseeable future.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biotechnology company and have incurred net losses in each reporting period since our inception, have not
generated any revenue from product sales to date and have financed our operations principally through third-party investments in our debt and share instruments. Our net losses were $24.5&nbsp;million and $23.4&nbsp;million for the fiscal years ended
October&nbsp;31, 2022 and October&nbsp;31, 2021, respectively, and $12.7&nbsp;million and $9.3&nbsp;million for the six months ended April&nbsp;30, 2023 and April&nbsp;30, 2022, respectively. As of April&nbsp;30, 2023, we had an accumulated deficit
of $112.4&nbsp;million. Our lead product candidate, <FONT STYLE="white-space:nowrap">EG-70,</FONT> is in clinical trials. Our other programs are in preclinical research and we plan on filing an investigational new drug application (&#147;IND&#148;)
with the FDA for a pulmonary program during the first-half of 2025, subject to a multifactor <FONT STYLE="white-space:nowrap">go/no-go</FONT> assessment involving technical review and assessment of grant support availability. As a result, we expect
that it will be several years, if ever, before we have a commercialized product and generate revenue from product sales. Even if we succeed in receiving marketing approval for and commercializing one or more of our product candidates, we expect that
we will continue to incur substantial research and development and other expenses in order to discover, develop and market additional potential products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. The net losses we incur may
fluctuate significantly from quarter to quarter such that a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">period-to-period</FONT></FONT> comparison of our results of operations may not be a good indication of our future
performance. The size of our future net losses will depend, in part, on the pace of our development activities and the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had
and will continue to have an adverse effect on our working capital, our ability to fund the development of our product candidates and our ability to achieve and maintain profitability and the performance of our common shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our recurring losses from operations and negative cash flows from operating activities raise substantial doubt about our ability to continue as a going
concern. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Without giving pro forma effect to the anticipated net proceeds from the Business Combination and the PIPE Financing, we
do not believe our existing cash and cash equivalents will be sufficient to fund our obligations, anticipated operating expenses and capital expenditure requirements for 12 months from the date of issuance of the financial statements. In our audited
consolidated financial statements as of and for the year ended October&nbsp;31, 2022, and in our unaudited condensed consolidated financial statements as of and for the six months ended April 30, 2023, neither of which give pro forma effect to the
Business Combination and the PIPE Financing, we concluded that our net loss, negative cash flows from operating activities and accumulated deficit raised substantial doubt about our ability to continue as a going concern. Similarly, in its report on
such financial statements, our independent registered public accounting firm included an explanatory paragraph stating that as we incurred a net loss and negative cash flows from operating activities for the year ended October&nbsp;31, 2022, have
accumulated deficit at October&nbsp;31, 2022, and will need additional financing in order to meet our obligations </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and fund our future expected negative cash flows, there is substantial doubt about our ability to continue as a going concern. Additionally, if we do not receive all or a material portion of the
anticipated proceeds of the PIPE Financing for any reason, our financial condition will be adversely affected and we may be unable to fund our operations or fail to achieve our product development and commercialization objectives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the consummation of the Business Combination, in our own required quarterly assessments, we may continue to conclude that there is
substantial doubt about our ability to continue as a going concern, and future reports from our independent registered public accounting firm may also contain statements expressing substantial doubt about our ability to continue as a going concern.
If we seek additional financing to fund our business activities in the future and there remains substantial doubt about our ability to continue as a going concern, investors or other financing sources may be unwilling to provide additional funding
on commercially reasonable terms or at all. If we cannot continue as a going concern, we may not be able to continue operations, which may result in us winding down, selling or <FONT STYLE="white-space:nowrap">out-licensing</FONT> our technology or
pursuing an alternative strategy. If we fund our operations through debt financings, including senior secured debt, any liquidation of our assets could result in us receiving less than the value at which those assets are carried on our financial
statements, and it is likely that our shareholders may lose some or all of their investment in us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We identified material weaknesses in our
internal control over financial reporting. If we are unable to remedy these material weaknesses, or if we fail to establish and maintain effective internal controls, we may be unable to produce timely and accurate financial statements, and we may
determine that our internal control over financial reporting is not effective, which could adversely impact our investors&#146; confidence and the price of our common shares. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the consummation of the Business Combination, we have been a private company with limited accounting personnel and other resources
with which to address internal control over financial reporting. In connection with the preparation and the audit of the consolidated financial statements as of and for the year ended October&nbsp;31, 2022, we and our independent registered public
accounting firm identified material weaknesses, as defined under the Exchange Act and by the Public Company Accounting Oversight Board (United States), in the internal control over financial reporting, and such material weaknesses remain
unremediated. A material weakness is defined as a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our financial statements will
not be prevented or detected on a timely basis. The material weaknesses related to: lack of formal policies, procedures and controls related to the design of internal controls over financial reporting including risk assessment process and control
activities for certain key financial reporting processes;&nbsp;lack of sufficient accounting and financial reporting personnel with requisite knowledge and experience in the application of complex areas of US GAAP; general information technology
controls that were not designed appropriately (access and system changes); and lack of appropriate segregation of duties in the preparation and review of account reconciliations and journal entries. As disclosed in our audited financial statements,
we recently corrected previously presented financial results due to immaterial errors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to implement in the near term measures
designed to improve our internal control over financial reporting to remediate these material weaknesses, including formalizing our processes and internal control documentation and strengthening supervisory reviews by our financial management;
hiring additional qualified accounting and finance personnel with requisite knowledge and experience in the application of complex areas of US GAAP, managing and collaborating with our financial consultants to enable the implementation of internal
control over financial reporting and improve the segregation of duties amongst accounting and finance personnel in the preparation and review of account reconciliations and journal entries. We will also review and improve the design of our general
information technology controls including managing user access and privileged access, managing changes in the information system and segregation of duties. The process of designing and implementing effective internal controls is a continuous effort
that requires us to anticipate and react to changes in our business and the economic and regulatory environments and to expend significant resources to maintain a system of internal controls that is adequate to satisfy our reporting obligations as a
public company. For example, to maintain and improve the effectiveness of our financial reporting, we will need to commit significant resources, implement and strengthen existing reporting processes, train personnel and provide additional
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
management oversight. We will incur additional costs to remediate these weaknesses, primarily personnel costs and external consulting fees. We cannot assure you that any measures we may take in
the future will be sufficient to remediate the control deficiencies that led to our material weaknesses in our internal control over financial reporting or to avoid potential future material weaknesses. In addition, neither our management nor an
independent registered public accounting firm has ever performed an evaluation of our internal control over financial reporting in accordance with the provisions of the Sarbanes-Oxley Act because no such evaluation has been required. Had we or our
independent registered public accounting firm performed an evaluation of our internal control over financial reporting in accordance with the provisions of the Sarbanes-Oxley Act, additional material weaknesses may have been identified. If we are
unable to successfully remediate our existing or any future material weaknesses in our internal control over financial reporting, or if we identify any additional material weaknesses, the accuracy and timing of our financial reporting may be
adversely affected, we may be unable to maintain compliance with securities law requirements regarding timely filing of periodic reports in addition to applicable stock exchange listing requirements, investors may lose confidence in our financial
reporting, and our share price may decline as a result. We also could become subject to investigations by the applicable stock exchange upon which our securities are traded, the SEC or other regulatory authorities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>To date, we have not generated any product revenue, have a history of losses and will need to raise additional capital to fund our operations. If we
fail to obtain necessary financing, we will not be able to complete the development and commercialization of our product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operations have consumed substantial amounts of cash since our inception. We expect to continue to spend substantial amounts to conduct
further research and development and preclinical or nonclinical testing and studies and clinical trials of our current and future programs, to seek regulatory approvals for our product candidates and to launch and commercialize any products for
which we receive regulatory approval. As of April&nbsp;30, 2023, we had $17.5&nbsp;million in cash and cash equivalents. Although we have a detailed current operating plan, it is nonetheless challenging or impossible to give full pro forma effect to
the Business Combination as the amount of total proceeds remains uncertain due to the potential for FEAC Shareholder Redemptions. Even if we were able to accurately give full pro forma treatment of the Business Combination, our future capital
requirements and the period for which our existing resources will support our operations may vary significantly from what we expect. We will in any event require additional capital in order to complete clinical development of any of our current
programs. Our monthly spending levels will vary based on new and ongoing development and corporate activities. Because the length of time and activities associated with development of our product candidates is highly uncertain, we are unable to
estimate the actual funds we will require for product development and any approved marketing and commercialization activities. Our funding requirements, both near- and long-term, as well as the timing and amount of our operating expenditures, will
depend largely on: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the initiation, progress, scope, timing, costs and results of preclinical or nonclinical testing and studies and
clinical trials for our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the clinical development plans we establish for these product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number and characteristics of product candidates that we develop or may
<FONT STYLE="white-space:nowrap">in-license;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of any collaboration agreements we may choose to execute; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the outcome, timing and cost of meeting regulatory requirements established by the FDA and other comparable
regulatory authorities outside of the United States; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property
rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of defending intellectual property disputes, including any patent infringement actions that may be
brought by third parties in the future against us or our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of competing technological and market developments; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost and timing of formulation development and manufacturing of our product candidates, including the
completion of commercial-scale outsourced manufacturing activities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of establishing sales, marketing and distribution capabilities for any product candidates for which we
may receive regulatory approval in regions where we choose to commercialize our products on our own or with a partner; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs related to any domestic and/or international expansion. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not have any committed external source of funds or other support for our development efforts and we cannot be certain that additional
funding will be available on acceptable terms, or at all. Until we can generate sufficient revenue to finance our cash requirements, which we may never do, we expect to finance our future cash needs through a combination of public or private equity
offerings, debt financings, collaborations, strategic alliances, licensing arrangements, royalty revenues, sales or monetization of future revenue streams, marketing or distribution arrangements or other strategic transactions. If we raise
additional funds through public or private equity offerings, the terms of these securities may include liquidation or other preferences that adversely affect our shareholders&#146; rights. Further, to the extent that we raise additional capital
through the sale of our common shares or securities convertible or exchangeable into our common shares, your ownership interest will be diluted. If we raise additional capital through debt financing, we would be subject to fixed payment obligations
and may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional capital through marketing and distribution
arrangements or other collaborations, strategic alliances, licensing arrangements, royalty revenues, sales or monetization of future revenue streams, or strategic transactions with third parties, we may have to relinquish certain valuable rights to
our product candidates, technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable to us. We also could be required to seek collaborators for one or more of our current or future product candidates
at an earlier stage than otherwise would be desirable or relinquish our rights to product candidates or technologies that we otherwise would seek to develop or commercialize ourselves. If we are unable to raise additional capital in sufficient
amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of one or more of our products or product candidates or one or more of our other research or development
initiatives. Any of the above events could significantly harm our business, financial condition, results of operations and prospects and cause the price of our common shares to decline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We face significant competition from other biotechnology and pharmaceutical companies, which may result in our competitors discovering, developing or
commercializing products before us or more successfully than we do. Our business and results of operations could be adversely affected if we fail to compete effectively. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The biotechnology and pharmaceutical industries, including the development of <FONT STYLE="white-space:nowrap">non-viral</FONT> gene therapies
for administration into mucosal tissues, are characterized by rapid growth, a dynamic landscape of competitive product candidates and a strong reliance on intellectual property. We face competition from a variety of organizations, including larger
pharmaceutical companies, specialty biotechnology companies, specialty medical device companies, academic research institutions, governmental agencies, as well as public and private institutions. There are several companies that are currently
developing gene-based therapeutics for use in a variety of indications, from cancer to rare disease, to regenerative medicine. There are also companies and institutions developing <FONT STYLE="white-space:nowrap">non-gene</FONT> based therapies such
as, but not limited to, drug/device combinations that may be effective in the clinical indications we choose to pursue and oncology drugs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">DDX is our proprietary carrier for genetic medicines to mucosal tissues and is the foundation for our nanoparticle formulations. We developed
DDX and our patented <FONT STYLE="white-space:nowrap">non-viral</FONT> gene therapies to penetrate mucus barriers and to deliver genes to mucosal epithelial cells in a way that is <FONT STYLE="white-space:nowrap">re-dosable,</FONT> scalable, and
designed to integrate into existing clinical practice. Our gene therapy platform&#146;s leading program is in the area of immuno-oncology and we are developing additional programs focused on diseases of the respiratory, urogenital and
gastrointestinal mucosal tissues. Our lead product candidate, <FONT STYLE="white-space:nowrap">EG-70,</FONT> for the treatment of <FONT STYLE="white-space:nowrap">BCG-unresponsive</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap">non-muscle</FONT> invasive bladder cancer, or &#147;NMIBC&#148;, faces competition from numerous companies and specialty biotechnology companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We understand that our competitors use their gene therapy candidates in numerous therapeutic applications, some of which may directly compete
with our product candidates and early-stage programs. Competing therapeutic applications include cancer, respiratory disease, metabolic diseases, various rare diseases, central nervous system disorders, neuromuscular disorders, diseases of the
immune system and infectious diseases. Competitors using genetic medicines for mucosal tissues include CG Oncology, Inc. and Ferring Pharmaceuticals Inc. We also face competition outside of the gene therapeutics field, in particular for our lead
indication of <FONT STYLE="white-space:nowrap">BCG-unresponsive</FONT> NMIBC with Cis, including from some of the largest pharmaceutical companies and other specialty biotechnology companies, such as Merck&nbsp;&amp; Co., Inc., AstraZeneca, Pfizer,
Roche, Bristol Myers Squibb, Johnson &amp; Johnson and Janssen. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, many of our current or potential competitors, either alone
or with their collaboration partners, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials and marketing approved products than we do. Mergers and
acquisitions in the biotechnology and pharmaceutical industry may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly
through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration
for and participation in clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunities could be reduced or eliminated if our competitors develop and commercialize products that
are safer, more effective, have fewer or less severe side effects, are more convenient, are more shelf-stable or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their
products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market, if we successfully enter it at all. The key competitive factors affecting
the success of all of our programs are likely to be their efficacy, safety, convenience and availability of reimbursement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our current
programs are approved for the indications for which we are currently planning clinical trials, they may compete with other products currently under development. We may not be aware of all competitive or potentially competitive products under
development by other market participants, and information relating to such products may not be publicly accessible. Competition with other related products currently under development may include competition for clinical trial sites, patient
recruitment and product sales. For additional information regarding our competition, see &#147;<I>Business of enGene &#151; Competition</I>.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The genetic medicine field is relatively new and evolving rapidly. Because of our limited technical, financial and human resources, we are focusing our
research and development efforts on our gene therapy platform and our therapeutic product candidates among many potential options. As a result, we may forego or delay pursuit of other gene therapy technologies or other therapeutic product candidates
that provide significant advantages over our platform, which could materially harm our business and results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Genetic
medicine is an emerging field of product development with only a small number of genetic medicines having received FDA or European Medicines Agency (&#147;EMA&#148;) approval to date. Our genetic medicine research programs are still at an early
stage, and there remain several areas of product development risk, which pose particular uncertainty for our programs given the relatively limited development history of, and our limited prior experience with, genetic medicines. Translational
science, manufacturing materials and processes, safety concerns, regulatory pathway and clinical trial design and execution all pose particular risk to our product development activities. Furthermore, the medical community&#146;s understanding of
the causes of many diseases continues to evolve and further research may change the medical community&#146;s views on what therapies and approaches are most effective for addressing certain diseases. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As an organization, we have not previously conducted any
<FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies or clinical trials, including any later stage or pivotal clinical trials. In pursuing our new technologies, we have begun to establish our own genetic medicine technical capabilities, but
we will need to continue to expand those capabilities by either hiring internally or seeking assistance from outside service providers. Genetic medicine is an area of significant investment by biotechnology and pharmaceutical companies and there may
be a scarcity of talent available to us in these areas. If we are not able to expand our genetic medicine capabilities, we may not be able to develop in the way we intend or desire any promising product candidates that emerge from our program, which
would limit our prospects for future growth. We may require more time and incur greater costs than our competitors and may not succeed in obtaining regulatory approvals of product candidates that we may develop. We may also rely on third-party
vendors or service providers, including contract research organizations (&#147;CROs&#148;), among others who may fail to meet their commitments to us or deliver their products to us. We may also be forced to rely on a single such provider with no
redundancy or alternative. Failure to commence or complete, or delays in our clinical trials, could prevent us from or delay us in commercializing our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because we have limited financial and managerial resources, we focus on research programs and on gene therapy technologies and product
candidates that we identify for specific indications among many potential options. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial
potential, or we may choose to focus our efforts and resources on a potential product candidate that ultimately proves to be unsuccessful. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or
profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial
potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other arrangements in cases in which it would have been more advantageous for us to retain
sole development and commercialization rights to such product candidate. Failure to pursue opportunities with greater commercial potential or relinquishing valuable rights to product candidates may have a material adverse effect on our business,
financial condition, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our gene therapy platform is based on novel technologies that are unproven, which makes
it difficult to predict the time and cost of development and of subsequently obtaining regulatory approval, if at all. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have
concentrated our research and development efforts on our gene therapy platform, and our future success depends on the successful development and maintenance of our platform. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, the technologies that comprise our platform are new and largely unproven. These technologies have not been clinically tested and the
scientific and clinical evidence to support the feasibility of developing product candidates based on those technologies in pursuit of regulatory approval and potential commercial viability and success, may be considered preliminary and limited.
Successful development of product candidates by us will require solving a number of issues, including proving the safety and efficacy of our treatments for <FONT STYLE="white-space:nowrap">BCG-unresponsive</FONT> NMIBC and expanding our mucosal
tissue delivery system to treat patient tissues beyond the bladder, such as respiratory, urogenital and gastrointestinal mucosal tissues. There can be no assurance we will be successful in solving any or all of these issues. We have concentrated our
research efforts to date on developing the components of our gene therapy platform, and our future success is highly dependent on the successful development of our proprietary carrier for genetic medicines to mucosal tissues, therapeutic
applications of such technology and the advancement of additional programs focused on diseases of the respiratory, urogenital and gastrointestinal mucosal tissues. We may decide to alter or abandon our initial programs as new data become available
and we gain experience in developing our therapeutics. We cannot be sure that our technologies will yield satisfactory products that are safe and effective, scalable or profitable in any indication we pursue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can be no assurance that any development problems we experience in the future related to our gene therapy platform will not cause
significant delays or unanticipated costs, or that such development problems can </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
be solved. We may also experience delays in developing sustainable, reproducible and scalable manufacturing processes or transferring such processes to any commercial partners, which may prevent
us from initiating or conducting clinical trials or commercializing our products on a timely or profitable basis, if at all. We may also fail to build redundancy in these manufacturing processes, such that we will be vulnerable to third-party
provider failures that may impair the supply of or manufacture of critical materials, products, or reagents. In addition, the clinical trial requirements of the FDA, the EMA and other regulatory agencies and the criteria these regulators use to
determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of the potential products. The regulatory approval process for novel product candidates can be more
expensive and take longer than for other, better known or extensively studied pharmaceutical or other product candidates. FDA&#146;s regulatory guidance documents, including those that may be applicable to enGene&#146;s programs, may change, be
cancelled or evolve. Only a small number of gene therapies have successfully reached the clinical trial phase of development or beyond, limiting insight into the regulatory review process for this field of genetic medicine. As a result, it is
difficult to determine how long it will take or how much it will cost to obtain regulatory approvals in either the United States or the European Union for any product candidates we may develop or how long it will take to commercialize any product
candidate that receives marketing approval. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Development of new therapeutics involves a lengthy and expensive process, with an uncertain outcome. We
may incur additional costs, fail to replicate the positive results from our earlier preclinical or clinical studies of our product candidates in later preclinical studies and any clinical trials or experience delays in completing or ultimately be
unable to complete, the development and commercialization of any product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To obtain the requisite regulatory approvals
to commercialize any product candidates, we must demonstrate through extensive preclinical studies and clinical trials that our products are safe and effective. Many of our product candidates are in early stages of development and thus their risk of
failure is high. Before we can commence clinical trials for a product candidate, we must complete extensive preclinical studies that support our filed and planned INDs in the United States, or similar applications in other jurisdictions. We cannot
be certain of the timely completion or outcome of our preclinical studies and cannot predict if the FDA or other regulatory authorities will accept our proposed clinical programs or if the outcome of our preclinical studies will ultimately support
the further development of our product candidates. As a result, we cannot be sure that we will be able to submit INDs or similar applications for our preclinical programs on the timelines we expect, if at all, and we cannot be sure that submission
of INDs or similar applications will result in the FDA or other regulatory authorities allowing clinical trials to begin. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials
are expensive, difficult to design and implement, can take many years to complete, and their outcome is inherently uncertain. Failure can occur at any time during, or even after, the clinical trial process and our ongoing and future clinical results
may not be successful. We may be unable to establish clinical endpoints that applicable regulatory authorities would consider clinically meaningful and a clinical trial can fail at any stage of testing. Similarly, if regulatory authorities agree,
implicitly or explicitly, that a certain set of clinical endpoints is clinically meaningful or adequate to demonstrate safety and efficacy, they may change their determination at a later date. The outcome of preclinical studies and early clinical
trials may not be predictive of the success of later clinical trials and interim results of a clinical trial do not necessarily predict final results. Differences in trial design between early-stage clinical trials and later-stage clinical trials
make it difficult to extrapolate the results of earlier clinical trials to later clinical trials. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses and many companies that have believed their
product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Successful completion of clinical trials is a prerequisite to submitting a BLA to the FDA and similar marketing applications to other
regulatory authorities, for each product candidate and, consequently, the ultimate approval and commercial marketing of any product candidates. We do not know whether any of our clinical trials will be completed on schedule, if at all. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may experience delays in initiating or completing clinical trials and preclinical
studies. We also may experience numerous unforeseen events during, or as a result of, any ongoing and future clinical trials that we conduct that could delay or prevent our ability to receive marketing approval or commercialize our product
candidates, including that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be unable to generate sufficient preclinical, toxicology, <I>in vivo</I>, <I>in vitro</I>, or other data
to support the initiation of clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may experience delays in our discussions with the FDA and other regulatory authorities regarding trial design;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulators or Institutional Review Boards (&#147;IRBs&#148;), or ethics committees may not authorize us or our
investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may experience delays in reaching, or fail to reach, agreement on acceptable terms with prospective trial
sites and prospective CROs, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">positive results from our preclinical studies of our product candidates may not necessarily be predictive of the
results from required later preclinical studies and clinical trials and positive results from such preclinical studies and clinical trials of our product candidates may not be replicated in subsequent preclinical studies or clinical trial results;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical trials of any product candidates may fail to show safety, purity or potency or produce negative or
inconclusive results and we may decide, or regulators may require us, to conduct additional preclinical studies or clinical trials or we may decide to abandon product development programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of patients required for clinical trials of any product candidates may be larger than we anticipate,
enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials or fail to return for post-treatment <FONT STYLE="white-space:nowrap">follow-up</FONT> at a higher rate than we anticipate;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may need to add new or additional clinical trial sites; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations
to us in a timely manner, or at all, or may deviate from the clinical trial. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We could also encounter delays if a
clinical trial is suspended, placed on clinical hold or terminated by us, the IRBs of the institutions in which such trials are being conducted, or the FDA or other regulatory authorities or recommended for suspension or termination by the Data
Safety Monitoring Board, for such trial. A suspension or termination may be imposed due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the
clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product or treatment,
failure to establish or achieve clinically meaningful trial endpoints, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. Many of the factors that cause, or lead to, a delay in
the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. Further, the FDA or other regulatory authorities may disagree with our clinical trial design and our
interpretation of data from clinical trials, or may change the requirements for approval even after they have reviewed and commented on the design for our clinical trials. Moreover, preclinical and clinical data are often susceptible to varying
interpretations and analyses and many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials nonetheless failed to obtain FDA approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product development costs will increase if we experience delays in clinical testing or marketing approvals. Our preclinical studies or
clinical trials may not begin as planned, may need to be restructured or may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
not be completed on schedule, or at all. Significant preclinical studies or clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our
product candidates and may allow our competitors to bring products to market before we do, potentially impairing our ability to successfully commercialize our product candidates and harming our business and results of operations. Any delays in our
preclinical or clinical development programs may harm our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interim <FONT
STYLE="white-space:nowrap">top-line</FONT> and preliminary data from our clinical trials that we announce or publish from time to time will change as more patient data become available and are subject to audit and verification procedures that could
result in material changes in the final data. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we may publish interim
<FONT STYLE="white-space:nowrap">top-line</FONT> or preliminary results from our clinical trials. Interim results from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as
participant enrollment continues and more participant data become available. We also make assumptions, estimations, calculations, and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully evaluate
all data. Preliminary or <FONT STYLE="white-space:nowrap">top-line</FONT> results also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we have previously
published. As a result, interim and preliminary data should be expected to change as additional patient data become available and as such new data and/or existing data is audited and verified; all data should viewed with caution until the final data
is available. Adverse differences between preliminary or interim data and final data could be material and could significantly harm our reputation and business prospects and may cause the trading price of our common shares to fluctuate
significantly. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we encounter difficulties enrolling patients in clinical trials, our clinical development activities could be delayed or
otherwise adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The timely completion of clinical trials in accordance with their protocols depends, among other
things, on our ability to enroll a sufficient number of patients who remain in the trial until its conclusion. We have from time to time experienced and may in the future experience difficulties in patient enrollment in our clinical trials for a
variety of reasons, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of a sizeable population of eligible patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the proximity of patients to study sites; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the design of the trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to recruit clinical trial investigators with the appropriate competencies and experience;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">competing clinical trials for similar therapies or other new therapeutics; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinicians&#146; and patients&#146; perceptions as to the potential advantages and side effects of our product
candidate being studied in relation to other available therapies or surgical procedures; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain and maintain patient consents; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the failure of patients to complete a clinical trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of approved therapies that are similar in mechanism to our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost to, or lack of adequate compensation for, prospective patients; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk that patients enrolled in clinical trials will not complete such trials for any reason, including due to
health crises, including pandemics, geopolitical conflicts, acts of terrorism, and/or &#147;acts of God&#148; that affect our contract development and manufacturing organizations (CDMOs), suppliers, clinical investigator sites and governing
regulatory bodies. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our clinical trials will compete with other clinical trials for product
candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us because some patients who might have opted to enroll in our trials may instead opt to
enroll in a trial being conducted by one of our competitors. Because the number of qualified clinical investigators is limited, we may conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which would
reduce the number of patients who are available for our clinical trials at such clinical trial sites. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we are able to enroll a
sufficient number of patients in our clinical trials, delays in patient enrollment may result in increased costs or may affect the timing or outcome of the planned clinical trials, which could prevent completion of these trials and adversely affect
our ability to advance the development of our product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of our novel gene therapy platform and therapeutic product candidates could
result in or be associated with harmful side effects, adverse events or other safety risks, which could cause us to delay, suspend or discontinue their clinical trials and/or development or abandon them, delay or prevent their regulatory approval,
limit their commercial potential, if approved, or result in other significant negative consequences (including voluntary corrective actions or agency enforcement actions) that could severely harm our business and results of operations. In addition,
these harmful side effects, adverse events or other safety risks may not be appropriately recognized or managed by our treating staff, which could result in litigation and reputational damage. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product candidates may be associated with harmful side effects, adverse events or other safety risks. Results of clinical trials could
reveal severe or recurring side effects, toxicities or unexpected events, including death. There may also be delayed adverse events that may not be appropriately recognized or managed by our treating staff, which could result in litigation and
reputational damage. We expect to have to train medical personnel using any product candidates we may develop to understand the side effect profiles for our clinical trials and upon any commercialization of such product candidates. Inadequate
training in recognizing or managing the potential side effects of such product candidates could result in patient injury or death. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any
such events occur, clinical trials or commercial distribution of any product candidates or products we develop could be suspended or terminated, and our business and reputation may be substantially harmed. Treatment-related side effects could affect
patient recruitment and the ability of enrolled patients to complete the trial or result in potential liability claims. Regulatory authorities could order us to cease further development of, deny approval of or require us to cease selling any
product candidates or products for any or all targeted indications. If we elect, or are required, to delay, suspend or terminate any clinical trial or commercialization efforts, the commercial prospects of such product candidates or products may be
harmed, and our ability to generate product revenues from them or other product candidates that we develop may be delayed or eliminated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, if we successfully develop a product candidate and it receives marketing approval, the FDA could require us to adopt a Risk
Evaluation and Mitigation Strategy (&#147;REMS&#148;) to ensure that the benefits of treatment with such product candidate outweigh the risks for each potential patient, which may include, among other things, a communication plan to health care
practitioners, patient education, extensive patient monitoring or distribution systems and processes that are highly controlled, restrictive and more costly than what is typical for the industry. We may also be required to adopt a REMS or engage in
similar actions, such as patient education, certification of health care professionals or specific monitoring, if we and others later identify undesirable side effects caused by any product that we develop. Such identification could also have
several additional significant negative consequences, such as: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may suspend, withdraw or limit approvals of such product, or seek an injunction against
its manufacture or distribution; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may require additional warnings on the label, including &#147;boxed&#148; warnings, or
issue safety alerts, &#147;Dear Healthcare Provider&#148; letters, press releases or other communications containing warnings or other safety information about the product; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to create a medication guide outlining the risks of such side effects for distribution to
patients; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to change the way a product is administered or conduct additional trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the product may become less competitive; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may decide to remove the product from the marketplace; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be subject to fines, injunctions or the imposition of civil or criminal penalties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we could be sued and be held liable for harm caused to patients; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reputation could be harmed. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these events could prevent us from achieving or maintaining market acceptance of any potential product. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if any of our current or future therapeutic product candidates receives regulatory approval, they may fail to achieve the degree of market
acceptance by physicians, patients, third-party payors (including government health administration authorities and private health insurers) and others in the medical community necessary for commercial success, in which case we may not generate
significant revenues and become profitable, which could adversely affect our ability to conduct our business and our results of operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The commercial success of any of our product candidates will depend upon its degree of market acceptance by physicians, patients, third-party
payors, and others in the medical community. Even if any product candidates developed by us receives regulatory approval, they may nonetheless fail to gain sufficient market acceptance by physicians, patients, healthcare payors, and others in the
medical community. The degree of market acceptance of any product candidates we may develop, if approved for commercial sale, will depend on a number of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the wider acceptance by patients of products derived from or involving RNA or DNA manufacturing processes;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the efficacy and safety of such product candidates as demonstrated in pivotal clinical trials published in
peer-reviewed journals or otherwise made available to the public (e.g., through FDA advisory committee meetings); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential and perceived advantages compared to alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to offer our products for sale at competitive prices and to obtain coverage by third-party payors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to offer appropriate patient access programs, such as <FONT STYLE="white-space:nowrap">co-pay</FONT>
assistance; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which physicians recommend our products to their patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">convenience and ease of handling, dosing and administration compared to alternative treatments;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the clinical indications for which the product candidate is approved by the FDA, EMA or other comparable <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> regulatory agencies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product labeling or product insert requirements of the FDA, EMA or other comparable <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities, including any limitations, contraindications or warnings contained in a product&#146;s approved labeling; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on how the product is distributed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of market introduction of competitive products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">publicity concerning our products or competing products and treatments; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effectiveness of marketing and distribution efforts by us and other licenses and distributors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">shortages or lack thereof of competitive or potentially competitive products, or products utilized in the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> for our patients, such as BCG; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sufficient governmental third-party coverage or reimbursement; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prevalence and severity of any side effects. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any product candidate developed by us does not achieve an adequate level of acceptance by physicians, healthcare payors, patients and the
medical community, we will not be able to generate significant revenue, and may not become or remain profitable. The failure of any product candidates to find market acceptance could harm our business, financial condition, results of operations and
prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Negative developments in the field of gene therapy, intravesical or NMIBC therapeutic development could damage public
perception of any product candidates that we develop, which could adversely affect our ability to conduct our business and our results of operations, or to obtain regulatory approvals for such product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our novel gene therapy platform is comprised of new and largely unproven technologies, with no gene therapeutic product candidates approved to
date. Gene therapeutics may not gain the acceptance of the public or the medical community and/or they may not gain the acceptance of the public or medical community within our indications of interest or development areas. To date, several other
efforts to leverage gene therapy technologies have generally demonstrated an inability to generate predictable results or to manufacture products at suitable scale to treat more than a small number of patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success will depend on our ability to demonstrate that our gene therapy platform, product candidates and related services can overcome
these challenges. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If one of our current or future product candidates is unable to successfully treat the intended organ or lesion and
establish proof of concept in a certain disease, it may indicate that we will not be able to apply our gene therapy platform to other diseases affecting the intended tissue area or other areas. This may also indicate a decrease in the probability of
our success for other targets using the same modality in the same or different cell types, as well as our engineered approach and delivery approach, more generally. Such failures could negatively affect the public or medical community&#146;s
perception of our gene therapy platform and gene therapeutics in general. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, our success will depend upon physicians who
specialize in the treatment of diseases targeted by our product candidates, if approved, prescribing treatments that involve the use of our product candidates, if approved, in lieu of, or in addition to, existing treatments with which they are more
familiar and for which greater clinical data may be available. Adverse events in clinical trials of our product candidates or in clinical trials of others developing similar products and the resulting publicity, as well as any other adverse events
in the field of gene therapeutics, could result in a decrease in demand for any product that we may develop. These events could also result in the suspension, discontinuation, or clinical hold of, or modification to, our clinical trials. Any future
negative developments in the field of gene therapy could also result in greater governmental regulation, stricter labeling requirements and potential regulatory delays in the testing or approvals of our product candidates. Any increased scrutiny
could delay or increase the costs of obtaining marketing approval for any of our product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be successful in our efforts to utilize our novel gene therapy platform to identify and
develop additional product candidates. Due to our limited technical, financial and human resources and access to capital, we may choose to prioritize development of certain product candidates, such as our initial focus on developing <FONT
STYLE="white-space:nowrap">EG-70,</FONT> which may prove to be the wrong choice and may adversely affect our business and results of operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A key element of our strategy is utilizing our gene therapy platform to generate multiple product candidates. Although we intend to develop
numerous product candidates targeting various cell types and indications and carrying different biologically active drug molecules, in addition to the product candidates we are currently developing, we may fail to identify viable new product
candidates for clinical development for a number of reasons. For example, while we believe our genetic therapy platform is capable of transfecting many different tissue types with varied genetic cargos, such as nucleic acid therapeutics (e.g., DNA),
antisense oligonucleotides, siRNA, miRNA, mRNA, gene therapy and gene editing mechanisms, we have not yet successfully advanced any proprietary enGene developed drug candidate incorporating these cargoes into clinical trials beyond <FONT
STYLE="white-space:nowrap">EG-70,</FONT> and we may not be successful in developing products to effectively employ these types of cargoes or molecules. If we fail to identify additional potential product candidates, our business could be materially
harmed. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research programs to pursue the development of our product candidates and using our gene therapy platform to design and
identify new product candidates and disease targets require substantial technical, financial and human resources whether or not they are ultimately successful. Our gene therapy platform and research programs may initially show promise in identifying
potential indications and/or product candidates, yet fail to yield results for clinical development for a number of reasons, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the research methodology used may not be successful in identifying potential indications and/or product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential product candidates may, after further study, be shown to have harmful adverse effects or other
characteristics that indicate they are unlikely to be effective drugs, or that make the product candidates impracticable to manufacture, unmarketable or unlikely to receive marketing approval; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it may take greater human and financial resources than we will possess to identify additional
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">therapeutic opportunities for our product candidates or to develop suitable potential product candidates through
internal research programs, thereby limiting our ability to develop, diversify and expand our product portfolio. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any
of these events occur, we may be forced to abandon our research or development efforts for a program or programs, which would have a material adverse effect on our business, financial condition, results of operations and prospects. Accordingly,
there can be no assurance that we will ever be able to identify additional therapeutic opportunities for our product candidates or to develop suitable potential product candidates through internal research programs, which could materially adversely
affect our future growth and prospects. We may focus our efforts and resources on potential product candidates or other potential programs that ultimately prove to be unsuccessful, which would be costly and time-consuming. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our use of third parties to manufacture, develop and test our therapeutic product candidates for preclinical studies and clinical trials increases the
risk that we will not have sufficient quantities of our product candidates or products, or necessary quantities of such materials on time or at an acceptable cost. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not currently have, nor do we plan to acquire, the infrastructure or capability internally to manufacture drug supplies for our ongoing
clinical trials or any future clinical trials that we may conduct, and we lack the resources to internally manufacture any product candidates on a commercial scale. We rely, and expect to continue to rely, on third-party manufacturers to produce our
product candidates or other product candidates that we may identify for clinical trials, as well as for commercial manufacture if any product candidates receive marketing authorization and approval. We rely entirely on numerous third-party suppliers
to provide us with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
various product components. We may not have alternative suppliers for certain of these product components. Any significant delay or discontinuity in the supply of a product candidate, or the raw
material components thereof, for an ongoing clinical trial due to the need to replace a third-party manufacturer or testing laboratory could considerably delay the clinical development and potential regulatory authorization of our product
candidates, which could harm our business, financial condition, results of operations and prospects. We currently do not have relationships with alternate third-party contract manufacturers and testing laboratories for our critical raw materials and
product candidates that could sustain our operations in the event we experience a disruption of service from our existing third-party contract manufacturers and testing laboratories. As a result, we are materially reliant on our existing contract
manufacturers and testing laboratories and susceptible to material operational disruptions due to factors that may be unknown to us and unforeseeable. Our providers may also materially change the terms of our commercial arrangements for any reason
or no reason, which could adversely affect our materials costs, ability to manufacture the drug at a sustainable cost, and profit margin on any sales. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may be unable to identify and appropriately qualify third-party manufacturers and testing laboratories or establish agreements with
third-party manufacturers and testing laboratories or do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers and testing laboratories, reliance on third-party manufacturers entails additional risks,
including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reliance on the third-party for sourcing of raw materials, components, testing and such other goods as may be
required for execution party of its suppliers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risk of single sourced critical raw materials, drug substance and drug product, where secondary <FONT
STYLE="white-space:nowrap">back-up</FONT> vendors are not available; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risk of increased and/or extended lead times for critical raw materials, reagents and equipment, thus requiring
significant investment in building adequate inventory to avoid significant disruptions to manufacturing processes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reliance on third-party to ensure availability of adequate manufacturing capacity to meet product demand based on
the needs of their other clients; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reliance on the third-party for regulatory compliance and quality assurance for the manufacturing and/or testing
activities each performs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reliance on third-party to adequately validate processes for timely approval of the BLA required for
commercialization of product; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possible breach of the manufacturing and/or testing agreement by the third-party; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possible misappropriation of proprietary information, including trade secrets and <FONT
STYLE="white-space:nowrap">know-how;</FONT> and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possible termination or <FONT STYLE="white-space:nowrap">non-renewal</FONT> of the agreement by the
third-party at a time that is costly or inconvenient for us. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, our contract manufacturing organizations
(&#147;CMOs&#148;) and testing laboratories are engaged with other companies to supply and/or manufacture and/or test materials or products, which exposes our manufacturers and testing laboratories to regulatory risks for the production and testing
of such materials and products. The facilities used by our CMOs to manufacture and/or test our product candidates are subject to review by the FDA and other <FONT STYLE="white-space:nowrap">non-U.S.</FONT> authorities pursuant to inspections that
will be conducted after we submit an NDA, or other marketing application to the FDA and other <FONT STYLE="white-space:nowrap">non-U.S.</FONT> authorities. We do not directly control or conduct the manufacturing and testing of any material or
products. Therefore, we are materially dependent on our CMO partners and contract testing laboratories to operate in compliance with the regulatory requirements, known as current good manufacturing practice (&#147;cGMP&#148;) requirements for
manufacture of drug and device products or similar requirements outside the United States. If our CMOs and contract testing laboratories cannot successfully manufacture and/or test material that conforms to our specifications and the strict
regulatory requirements of the FDA or others, we will not be able to secure or maintain regulatory authorization for our product candidates </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
manufactured at these manufacturing facilities, resulting in delay or failure in the clinical development and commercialization of our products, which would have a material adverse effect on us.
In addition, we have no control over the ability of our CMOs to maintain adequate quality control, quality assurance and qualified personnel. If the FDA, or another <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory agency does not approve
these facilities for the manufacture and/or testing of our product candidates or if any agency withdraws its approval in the future, we may need to find alternative manufacturing facilities, which would negatively impact our ability to develop and
deliver our products to markets around the world. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product candidates may compete with other product candidates and marketed products
for access to manufacturing and/or testing facilities. Any performance failure on the part of our existing or future CMOs could delay clinical development, marketing approval or commercialization. Our current and anticipated future dependence upon
others for the manufacturing of our product candidates may adversely affect our future profit margins and our ability to commercialize any product candidates that receive marketing approval on a timely and competitive basis. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our most advanced product candidates are complex to manufacture and we may encounter difficulties in production, particularly with respect to scaling
our manufacturing capabilities. If we or any of our third-party manufacturers with whom we contract encounter these types of difficulties, our ability to provide supply of our product candidates for clinical trials or our products for patients, if
approved, could be delayed or stopped, or we may be unable to maintain a commercially viable cost structure. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The manufacturing
processes used to produce our product candidates are complex and novel and have not been validated for clinical or commercial production. As a result of these complexities, the cost to manufacture our product candidates is generally higher than
traditional biopharmaceutical compounds and the manufacturing processes may prove to be less reliable and may be more difficult to reproduce. For example, for <FONT STYLE="white-space:nowrap">EG-70</FONT> we must separately manufacture a novel
plasmid DNA drug substance (DS), a novel copolymer excipient (DDX) and a novel block copolymer excipient <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(PEG-b-PLE).</FONT></FONT> We then combine those ingredients in the drug
product manufacturing process. There are many points throughout this process, and the manufacturing processes of our other product candidates, that can lead to failure. Failure in the production of any of our product candidates could have a material
adverse effect on our business, financial condition, results of operations and prospects. Some examples of manufacturing challenges and potential failure we may encounter follow: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">As part of the manufacturing process of DS, bacterial cells are inoculated to a fermenter and expanded. These
bacteria produce the plasmid DNA DS, which is purified from the cells by an extensive purification process. At any stage, any or all of these processes can fail, including the biological or purification processes, which would result in batch
failure. These processes can fail due to contamination, inadequate purification or other reasons. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The manufacture of DDX and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PEG-b-PLE</FONT></FONT> involves multiple complex chemical synthesis and purification steps to produce final products with target specifications and yield. At any stage, any or all of
these processes can fail, including the chemical or purification processes. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The manufacture of <FONT STYLE="white-space:nowrap">EG-70</FONT> requires careful and complex combination of DS
with DDX and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PEG-b-PLE</FONT></FONT> to yield the intermediate drug product. At any stage, any or all of the processes involved can fail, including the mixing, sterilization, filling,
lyophilization or storage processes. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our manufacturing processes are also susceptible to product loss or failure due to
logistical issues associated with multiple outsourced activities across the range of manufacturing, shipping of materials to analytical laboratories, cold chain distribution to where products will be administered to patients, interruptions in the
manufacturing processes, contamination, equipment or reagent failure, improper installation or operation of equipment, vendor or operator error, and variability of product characteristics. Even minor deviations from normal manufacturing processes
could result in reduced production yields, lot failures, product defects, product recalls, product liability claims and other supply disruptions. If microbial, viral or other contaminations are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
discovered in our product candidates or in the manufacturing facilities in which our product candidates are made, the manufacturing facilities may need to be closed for an extended period of time
to investigate and remedy the contamination, which could result in our inability to produce or ship product. Further, as product candidates are developed through preclinical to later-stage clinical trials toward approval and commercialization, it is
common that various aspects of the development program, such as manufacturing methods, are altered in an effort to optimize processes and results. If we make these types of changes, we may not achieve our intended objectives, and any of these
changes could cause our product candidates to perform differently than we expect, potentially affecting the results of clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we continue to optimize our manufacturing processes, doing so is difficult and uncertain. There are risks associated with scaling to
the level required for advanced clinical trials or commercialization, including, among other things, cost overruns, potential problems with process <FONT STYLE="white-space:nowrap">scale-out,</FONT> process reproducibility, stability issues, lot
consistency and timely availability of reagents or raw materials. If we are unable to adequately validate or <FONT STYLE="white-space:nowrap">scale-up</FONT> our manufacturing processes with our current manufacturing partners, we will need to
transfer such processes to another manufacturing partner and complete the manufacturing validation process, which can be a lengthy process. We ultimately may not be successful completing the transfer of our manufacturing processes to one or more of
the manufacturers on whom we rely. The manufacturers who become responsible for our processes may not have the necessary capabilities to complete the implementation and development processes to our specifications or standards. If we are able to
adequately validate and <FONT STYLE="white-space:nowrap">scale-up</FONT> a particular manufacturing process for our product candidates with a contract manufacturer, we will still need to negotiate an agreement for commercial supply with that
contract manufacturer and it is not certain we will be able to come to agreement on commercially reasonable terms, or at all. As a result, we may ultimately be unable to reduce the cost of goods for our product candidates to levels that will allow
for an attractive return on investment if and when those product candidates are approved and commercialized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The manufacturing processes
for any products that we may develop are subject to the FDA and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authority approval processes, and we will need to contract with manufacturers who we believe can meet applicable FDA and <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authority requirements on an ongoing basis. If we or our CMOs are unable to reliably produce products to specifications acceptable to the FDA or other regulatory authorities, we may not obtain or
maintain the approvals we need to commercialize our products. Even if we obtain regulatory approval for any of our product candidates, there is no assurance that either we or our CMOs will be able to manufacture the approved product to
specifications and under required good manufacturing practices acceptable to the FDA or other regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of the product, or to meet potential
future demand. Any of these challenges could delay completion of clinical trials, require bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates, impair
commercialization efforts, increase our cost of goods and have an adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our future success depends on our ability to manufacture our products on a timely basis with acceptable manufacturing costs, while at the same
time maintaining good quality control and complying with applicable regulatory requirements, and an inability to do so could have a material adverse effect on our business, financial condition, results of operations and prospects. In addition, we
could incur higher manufacturing costs if manufacturing processes or standards change, and we could need to replace, modify, design or build and install equipment, all of which would require additional capital expenditures. Specifically, because our
product candidates may have a higher cost of goods than conventional therapies, and may require long-term follow up evaluations, the risk that coverage and reimbursement rates may be inadequate for us to achieve profitability may be greater. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the FDA, the EMA and other <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities may require us to submit
samples of any lot of any approved product, together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA, the EMA or other <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities
may require that we </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
not distribute a lot until the relevant agency authorizes its release. Slight deviations in our manufacturing processes, including those affecting quality attributes and stability, may result in
unacceptable changes in the product that could result in lot failures or product recalls. Lot failures or product recalls could cause us to delay product launches or clinical trials, which could be costly to us and otherwise harm our business,
financial condition, results of operations and prospects. Problems in our manufacturing processes could restrict our ability to meet market demand for our products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any problems in our manufacturing processes or facilities at our CMOs could make us a less attractive collaborator for potential partners,
including larger pharmaceutical companies and academic research institutions, which could limit our access to additional attractive development programs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have no experience in developing a manufacturing facility for our biologic products and may never be successful in developing our own manufacturing
facility or capability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to evaluate the possibility of establishing our own capabilities and infrastructure, including a
manufacturing facility. If we choose to build our own manufacturing facility, we will need significant funding and will need to select an adequate location. We expect that development of our own manufacturing facility would provide us with enhanced
control of material supply for both clinical trials and the commercial market, enable the more rapid implementation of process changes, and allow for better long-term margins. However, we have no experience in developing a manufacturing facility and
may never be successful in developing our own manufacturing facility or capability. If we determine to establish our own manufacturing capabilities and infrastructure, we will also need to hire additional personnel to manage our operations and
facilities and develop the necessary infrastructure to continue the research and development, and eventual commercialization, if approved, of our product candidates. If we fail to select the correct location, complete the construction in an
efficient manner, recruit the required personnel and generally manage our growth effectively, the development and production of our product candidates could be curtailed or delayed. We may establish multiple manufacturing facilities as we expand our
commercial footprint to multiple geographies, which may lead to regulatory delays or could prove costly. Even if we are successful, any manufacturing capabilities we develop could be affected by cost-overruns, unexpected delays, equipment failures,
labor shortages, natural disasters, power failures and numerous other factors that could prevent us from realizing the intended benefits of our manufacturing strategy and have a material adverse effect on our business, financial condition, results
of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in product candidate manufacturing or formulation may result in additional costs or delay, which could
adversely affect our business and results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As product candidates are developed through preclinical studies to
later-stage clinical trials toward approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods or formulation, are altered along the way in an effort to optimize processes and results.
Any of these changes could cause our product candidates to perform differently and affect the results of ongoing or planned clinical trials or other future clinical trials conducted with the altered materials. In addition, such changes and any other
similar changes in the future may also require additional testing or notification to or approval by the FDA or other regulatory authorities. This could delay completion of clinical trials, require the conduct of bridging clinical trials or studies,
require the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and/or jeopardize our ability to commence product sales and generate revenue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our most advanced product candidates are complex to analyze and we may encounter difficulties in
product release testing, particularly with respect to bioassay potency testing. If we or any of our contract testing laboratories encounter difficulties, our ability to provide supply of our product candidates for clinical trials or our products for
patients, if approved, could be delayed or stopped, or we may be unable to maintain a commercially viable cost structure. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
analytical methods used to test our product candidates are complex and many are novel and have not&nbsp;been validated for clinical or commercial production. For example, in addition to several complex
<FONT STYLE="white-space:nowrap">physico-chemical</FONT> tests for <FONT STYLE="white-space:nowrap">EG-70,</FONT> DS and novel excipients, we must also test <FONT STYLE="white-space:nowrap">EG-70</FONT> and the DS for biological potency using
multiple unique cell-based assays. We rely on third-party laboratories to develop and conduct these assays. These assays may be subject to inherent variability and limitations such as, but not limited to, variations in assay conditions, reagents,
equipment, or interpretation of results that could lead to inconsistent or inaccurate measurements of potency. Inaccurate potency assessments may affect our ability to demonstrate the efficacy and safety of our drug product to regulatory
authorities, potentially resulting in regulatory delays, additional testing requirements, or even rejection of our product. Furthermore, changes in regulatory guidelines or evolving scientific understanding may necessitate modifications to the
biological potency assays, requiring additional validation studies and potential delays in the development or commercialization of our product candidates. It is important to note that despite our efforts to ensure the accuracy and reliability of
these assays, there may be factors beyond our control that could impact their effectiveness, thereby affecting the overall success of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we continue to optimize our testing methods, doing so is a difficult and uncertain task, and there are risks associated with
developing these methods to the level required for advanced clinical trials and commercialization, including, among other things, cost overruns, potential problems with reproducibility, stability issues, consistency and timely availability of
reagents or raw materials needed to execute the testing. If we are unable to adequately validate testing methods with our current testing laboratories, we will need to transfer to another laboratory and complete the analytical validation process,
which can be a lengthy process. We ultimately may not be successful in transferring the analytical methods to contract testing laboratories and the selected contract laboratories may not have the necessary capabilities to complete the implementation
and validation process for the assays. If we are able to adequately transfer and validate testing methods for our product candidates with a contract laboratory, we will still need to negotiate a service agreement with that contract laboratory and it
is not certain we will be able to come to agreement on terms acceptable to us. As a result, we may ultimately be unable to reduce the cost of goods for our product candidates to levels that will allow for an attractive return on investment if and
when those product candidates are approved and commercialized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The analytical testing methods for any products that we may develop are
subject to the FDA and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authority approval processes, and we will need to contract with laboratories we believe can meet applicable FDA and <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
regulatory authority requirements on an ongoing basis. If we or our CMOs are unable to reliably test products in a manner acceptable to the FDA or other regulatory authorities, we may not obtain or maintain the approvals we need to commercialize our
products. Even if we obtain regulatory approval for any of our product candidates, there is no assurance that either we or our CMOs will be able to test the approved product in a manner required by good manufacturing practices acceptable to the FDA
or other regulatory authorities, to test products with sufficient throughput to meet the requirements for the potential launch of the product, or to meet potential future demand. Any of these challenges could delay completion of clinical trials,
require bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates, impair commercialization efforts, increase our cost of goods and have an adverse effect on
our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our future success depends on our ability to test our products on
a timely basis with acceptable costs, while at the same time maintaining good quality control and complying with applicable regulatory requirements, and an inability to do so could have a material adverse effect on our business, financial condition,
results of operations </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and prospects. In addition, we could incur higher testing costs if testing methods or standards change, and we could need to replace, modify, design or build and install equipment, all of which
would require additional capital expenditure. Specifically, because our product candidates may have a higher testing requirement than conventional therapies, the risk that coverage and reimbursement rates may be inadequate for us to achieve
profitability may be greater. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The market opportunities for our product candidates may be limited to a small group of patients who are ineligible
for or have failed prior treatments and our estimates of the prevalence of our target patient populations may be inaccurate. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cancer and other disease therapies are sometimes characterized as first-line, second-line or third-line and the FDA often approves new
therapies initially only for third-line use. When cancers are detected they are treated with first line of therapy with the intention of curing the cancer. This treatment generally consists of chemotherapy, radiation, antibody drugs, tumor targeted
small molecules, or a combination of these. If the patient&#146;s cancer relapses, then the patient is given a second line or third line therapy, which can consist of more chemotherapy, radiation, antibody drugs, tumor targeted small molecules, or a
combination of these. Generally, the higher the line of therapy, the lower the chance of a cure. With third or higher line, the goal of the therapy is to control the growth of the tumor and extend the life of the patient, as a cure is unlikely to
happen. Patients are generally referred to clinical trials in these situations. Initial approvals for new cancer and other disease therapies are often restricted to later lines of therapy for patients with advanced or metastatic disease, limiting
the number of patients who may be eligible for such new therapies, which may include our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead product candidate, <FONT
STYLE="white-space:nowrap">EG-70,</FONT> is being developed to treat patients with <FONT STYLE="white-space:nowrap">BCG-unresponsive</FONT> NMIBC. Our projections of both the number of people who have the disease we are targeting, as well as the
subset of people with these diseases in a position to receive our therapies, if approved, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including scientific literature, input from key opinion
leaders, patient foundations or secondary market research databases and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these diseases. The number of patients may turn out to be lower than
expected. Additionally, the potentially addressable patient population for our product candidates may be limited or may not be amenable to treatment with our product candidates. Even if we obtain significant market share for our product candidates,
because certain of the potential target populations may be small, we may never achieve profitability without obtaining regulatory approval for additional indications. For example, we believe there are approximately 60,000 new patients globally each
year with <FONT STYLE="white-space:nowrap">BCG-unresponsive</FONT> NMIBC with limited available therapies. The prevalence of patients experiencing this condition implies high unmet medical need. If the market opportunities for any product candidates
we may develop are smaller than we believe they are, our potential revenues may be adversely affected and our business may be harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely on
our senior management team and key personnel, and our business could be harmed if we are unable to attract and retain personnel necessary for our success. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success depends on the skills, experience and performance of members of our senior management team and key personnel. The individual and
collective efforts of these and other members of our senior management team and key personnel will be important as we continue to develop product candidates, establish strategic partnerships and build out our operations. The loss or incapacity of
existing members of our executive management team and key personnel could adversely affect our operations if we experience difficulties in hiring qualified successors. In connection with the Business Combination, it is anticipated that we will
significantly expand our senior management team in a manner commensurate with our needs as a clinical-stage biotechnology company that will soon be public If we are not successful in attracting and retaining highly qualified personnel, our business,
financial condition, results of operations and prospects may be harmed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our research and development initiatives, manufacturing processes and business depend on our ability
to attract and retain highly skilled scientists and other specialized individuals. We may not be able to attract or retain such qualified scientists and other specialized individuals in the future due to the competition for qualified personnel among
life science and technology businesses. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our research and development initiatives, laboratory operations and manufacturing
processes depend on our ability to attract and retain highly skilled and experienced scientists, clinical personnel, technicians, engineers, quality-control and manufacturing personnel. We may not be able to attract or retain qualified scientists,
clinical personnel, technicians or engineers in the future due to the competition for qualified personnel among life science and technology businesses. We also face competition from universities and public and private research institutions in
recruiting and retaining highly qualified scientific personnel. Additionally, we may be unable to identify, hire and retain the experienced scientific, quality-control and manufacturing personnel needed to transfer our manufacturing processes and
test methods to CMOs and external testing laboratories. Further, if we endeavor to conduct manufacturing processes internally, we may be unable to identify, hire or retain the personnel needed to conduct our manufacturing processes, which could
result in delays in production or difficulties in maintaining compliance with applicable regulatory requirements. We may have difficulties locating, recruiting or retaining qualified personnel across functions that we deem critical to our success.
Recruiting, training and retention difficulties can limit our ability to support our research and development and commercialization efforts. All of our employees are <FONT STYLE="white-space:nowrap">at-will,</FONT> which means that either we or the
employee may terminate their employment at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we rely on consultants and advisors, including scientific and clinical
advisors, to assist us in formulating our research and development, regulatory and commercialization strategy. Our consultants and advisors may provide services to other organizations and may have commitments under consulting or advisory contracts
with other entities that may limit their availability to us. The loss of the services of one or more of our current consultants or advisors might impede the achievement of our research, development, regulatory and commercialization objectives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot assure you that we will be able to adequately address these additional risks. If we are unable to do so, our operations might
suffer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We face risks related to epidemics and other outbreaks of communicable diseases, such as the coronavirus
<FONT STYLE="white-space:nowrap">(COVID-19)</FONT> pandemic, which could significantly disrupt our operations, including our clinical trials and preclinical studies, and adversely affect our business and results of operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Public health crises, such as the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic or similar outbreaks, could have an adverse effect
our business. Quarantines, travel restrictions and other public health and safety measures implemented in response to a pandemic, including a resurgence of <FONT STYLE="white-space:nowrap">COVID-19,</FONT> could adversely impact our operations, and
the ultimate impact is highly uncertain and cannot be predicted with confidence. Effects of a pandemic, including a resurgence of <FONT STYLE="white-space:nowrap">COVID-19,</FONT> that may delay or otherwise adversely affect our ongoing and planned
preclinical activities, our planned clinical trials as well as our business generally, include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays related to disruptions at CROs and contract manufacturers, or in the supply chain; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in receiving approval from regulatory authorities to initiate our planned clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site
investigators and clinical site staff who, as healthcare providers, may have heightened exposure; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays or difficulties in enrolling and retaining patients in clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in clinical sites receiving the supplies and materials needed to conduct our planned clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulties interpreting data from clinical trials; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals
serving as clinical trial sites and hospital staff supporting the conduct of clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on
travel imposed or recommended by federal or state governments, employers and others; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interruption or delays in the operations of the FDA or other regulatory authorities, which may impact review and
approval timelines; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interruptions, difficulties or delays arising in our existing operations and company culture as a result of many
of our employees working remotely, including those hired during the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these effects, and other effects of a pandemic, including a resurgence of <FONT STYLE="white-space:nowrap">COVID-19,</FONT> could have
a material adverse effect on our business, financial condition, results of operations and prospects. Further, uncertainty around these and related issues could lead to adverse effects on the economy of the United States, Canada, and other economies,
which could impact our ability to raise the necessary capital needed to develop and commercialize our programs and product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We or the
third parties upon whom we depend may be adversely affected by risks beyond our control, such as natural disasters, political crises, acts of terrorism, epidemics and other outbreaks of communicable diseases, war or other catastrophic events and our
business continuity and disaster recovery plans may not adequately protect us from the adverse effects of such events. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, our
suppliers and third-party service providers are vulnerable to damage from natural disasters, including but not limited to earthquakes, fires or floods, power loss, communications failures, public health crises, such as pandemics and epidemics,
political crises, such as terrorism, war, political instability or other conflict and similar events. If any such disaster were to occur, our ability to operate our business at any of our facilities could be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters or
other facilities, that damaged critical infrastructure, such as our enterprise financial systems or manufacturing resource planning and enterprise quality systems, or that otherwise disrupted operations, it may be difficult or, in certain cases,
impossible, for us to continue our business for a substantial period of time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, in late February 2022, Russian military forces
launched its significant military invasion of Ukraine. The impact to Ukraine, as well as actions taken by other countries, including new and stricter sanctions by the United States, Canada, the United Kingdom, the European Union and other countries
and organizations against certain officials, individuals, regions, and industries in Russia, Belarus and occupied areas of Ukraine, and each country&#146;s potential response to such sanctions, tensions, and military actions could continue to have a
material adverse effect on the global economy and political situation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date of this proxy statement/prospectus, we (i)&nbsp;are
not conducting clinical or <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies in Ukraine, Belarus or Russia, (ii)&nbsp;are not relying upon service providers or vendors from any of these regions to advance our product development programs,
(iii)&nbsp;do not source biomanufacturing critical raw materials, equipment, or other supplies directly from Ukraine, Belarus or Russia, and (iv)&nbsp;are not aware nor have we received notification from our supply vendors that the sourcing of any
general laboratory or manufacturing materials may be negatively impacted due to such conflict and related sanctions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The disaster
recovery and business continuity plans we have in place currently are limited and are unlikely to prove adequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster
recovery and business continuity plans, which, particularly when taken together with our lack of earthquake insurance, could have a material adverse effect on our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, integral parties in our supply chain are similarly vulnerable to natural
disasters or other sudden, unforeseen and severe adverse events. If such an event were to affect our supply chain, it could have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Regulatory Risks </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Nearly all aspects of our
activity and our products and services are subject to extensive regulation by various U.S. federal and state agencies and regulatory bodies in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions, and compliance with existing or future
regulations could result in unanticipated expenses or limit our ability to offer our products and services. Once developed, our gene therapy platform and therapeutic product candidates will require regulatory approval, which is a lengthy, expensive,
and inherently unpredictable process with uncertain outcomes and cost and the potential for substantial delays. We cannot give any assurance whether or when our product candidates will receive regulatory approval, which is necessary before they can
be commercialized. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regulatory requirements governing gene and cell therapy products, and in particular any novel gene therapy
products we may develop, have changed frequently and may continue to change in the future. We are aware of a limited number of gene therapy products that have received marketing authorization from the FDA and EMA. Even with respect to more
established products in the gene therapy field, the regulatory landscape is still developing. In 2016, the FDA established the Office of Tissues and Advanced Therapies (&#147;OTAT&#148;) within its Center for Biologics Evaluation and Research to
consolidate the review of gene therapy and related products, and has established the Cellular, Tissue and Gene Therapies Advisory Committee, among others, to advise this review. In September 2022, the FDA announced retitling of OTAT to the Office of
Therapeutic Products (&#147;OTP&#148;) and elevation of OTP to a &#147;Super Office&#148; to meet its growing cell and gene therapy workload. Gene therapy clinical trials conducted at institutions that receive funding for recombinant DNA research
from the U.S. National Institutes of Health (&#147;NIH&#148;), also are potentially subject to review by the Office of Biotechnology Activities&#146; Recombinant DNA Advisory Committee (&#147;RAC&#148;); however, the NIH announced that the RAC will
only publicly review clinical trials if the trials cannot be evaluated by standard oversight bodies and pose unusual risks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The same
applies in the European Union. The EMA&#146;s Committee for Advanced Therapies (&#147;CAT&#148;), is responsible for assessing the quality, safety and efficacy of advanced-therapy medicinal products. The role of CAT is to prepare a draft opinion on
an application for marketing authorization for a gene therapy medicinal candidate that is submitted to the Committee for Medicinal Products for Human Use (&#147;CHMP&#148;), before CHMP adopts its final opinion. In the European Union, the
development and evaluation of a gene therapy medicinal product must be considered in the context of the relevant European Union guidelines. The EMA may issue new guidelines concerning the development and marketing authorization for gene therapy
medicinal products and require that we comply with these new guidelines. As a result, the procedures and standards applied to gene therapy products and cell therapy products may be applied to any product candidates we may develop, but that remains
uncertain at this point. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These regulatory review committees and advisory groups and the new guidelines they promulgate may lengthen the
regulatory review process, require us to perform additional studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of any product candidates we may
develop or lead to significant post-approval limitations or restrictions. As we advance any product candidates we may develop, we will be required to consult with these regulatory and advisory groups and comply with applicable guidelines. If we fail
to do so, we may be required to delay or discontinue development of these product candidates. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product to market could decrease our
ability to generate sufficient product revenue to maintain our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although the FDA decides whether individual genetic medicine
protocols may proceed, the RAC public review process, if undertaken, can delay the initiation of a clinical trial, even if the FDA has reviewed the trial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
design and details and approved its initiation. Conversely, the FDA can put an IND on a clinical hold even if the RAC has provided a favorable review or an exemption from <FONT
STYLE="white-space:nowrap">in-depth,</FONT> public review. If we were to engage an <FONT STYLE="white-space:nowrap">NIH-funded</FONT> institution to conduct a clinical trial, now or in the future, that institution&#146;s institutional biosafety
committee, as well as its IRB would need to review the proposed clinical trial to assess the safety of the trial. In addition, adverse developments in clinical trials of genetic medicine products conducted by others may cause the FDA or other
oversight bodies to change the requirements for approval of any product candidates we may develop. Similarly, the EMA may issue new guidelines concerning the development and marketing authorization for genetic medicine products and require that we
comply with these new guidelines. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As we are initially seeking to identify and develop product candidates to treat diseases using
novel technologies, there is heightened risk that the FDA, the EMA or other regulatory authority may not consider the clinical trial endpoints that we propose to provide clinically meaningful results. Even if the endpoints are deemed clinically
meaningful, we may not achieve these endpoints to a degree of statistical significance, particularly because many of the diseases we are targeting with our platform have small patient populations, making development of large and rigorous clinical
trials more difficult. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Adverse developments in post-marketing experience or in clinical trials conducted by others of gene therapy
products or cell therapy products may cause the FDA, the EMA, and other regulatory bodies to revise the requirements for development or approval of any product candidates we may develop or limit the use of products utilizing <FONT
STYLE="white-space:nowrap">non-viral</FONT> gene therapy technologies, either of which could materially harm our business. In addition, the clinical trial requirements of the FDA, the EMA, and other regulatory authorities and the criteria these
regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of the potential products. The regulatory approval process for novel product
candidates such as the product candidates we may develop can be more expensive and take longer than for other, better known or more extensively studied pharmaceutical or other product candidates. Regulatory agencies administering existing or future
regulations or legislation may not allow production and marketing of products utilizing <FONT STYLE="white-space:nowrap">non-viral</FONT> gene therapy technology in a timely manner or under technically or commercially feasible conditions. In
addition, regulatory action or private litigation could result in expenses, delays or other impediments to our research programs or the commercialization of resulting products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, ethical, social and legal concerns about genetic medicine, genetic testing and genetic research could result in additional
regulations or prohibiting the processes we may use. Federal and state agencies, congressional committees and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> governments have expressed their intentions to further regulate biotechnology. More
restrictive regulations or claims that any product candidates we may develop are unsafe or pose a hazard could prevent us from commercializing any products. New government requirements may be established that could delay or prevent regulatory
approval of any product candidates we may develop under development. It is impossible to predict whether legislative changes will be enacted, regulations, policies or guidance changed, or interpretations by agencies or courts changed, or what the
impact of such changes, if any, may be. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As we advance any product candidates we may develop through clinical development, we will be
required to consult with these regulatory and advisory groups and comply with applicable guidelines. These regulatory review committees and advisory groups and any new guidelines they promulgate may lengthen the regulatory review process, require us
to perform additional studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of any product candidates we may develop or lead to significant post-approval
limitations or restrictions. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product to market could decrease our ability to generate sufficient product revenue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have designed and are currently conducting the clinical trials for <FONT STYLE="white-space:nowrap">EG-70,</FONT> our most advanced product
candidate in accordance with the FDA&#146;s 2018 Guidance Document entitled &#147;Bacillus <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Calmette-Gu&eacute;rin-Unresponsive</FONT></FONT> Nonmuscle Invasive Bladder Cancer:
Developing Drugs and Biologics for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Treatment Guidance for Industry.&#148; This document sets forth guidance for patient selection and describes a potentially abbreviated regulatory path for approval provided certain recruitment,
efficacy, and safety data are met. The FDA may review, revoke, or otherwise modify these guidelines at any time, for any reason, which would have a material adverse effect on our approval timelines or process. Furthermore, approval of other
competitive products treating the same indication may reduce the agency&#146;s propensity to support abbreviated approval pathways, which could cause our programs to be delayed in achieving regulatory approval or contribute to our failure to achieve
approval at all. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We cannot predict whether or when we will obtain regulatory approval to commercialize a product candidate we may develop in the
United States or any other jurisdiction and any such approval may be for a narrower indication than we seek. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot
commercialize a product candidate until the appropriate regulatory authorities have reviewed and approved the product candidate and our application to commercialize it. Even if any product candidates we may develop meet their safety and efficacy
endpoints in clinical trials, regulatory authorities may not complete their review processes in a timely manner or we may not be able to obtain regulatory approval. Additional delays may result if an FDA panel of experts (&#147;Advisory
Committee&#148;) or other regulatory authority recommends <FONT STYLE="white-space:nowrap">non-approval</FONT> or restrictions on approval. In addition, we may experience delays or rejections based upon additional government regulation from future
legislation or administrative action or changes in regulatory authority policy during the period of product development, clinical trials and the review process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regulatory authorities also may approve a product candidate for more limited indications than requested or they may impose significant
limitations in the form of narrow indications, warnings or a REMS. These regulatory authorities may require labeling that includes precautions, boxed warnings or contra-indications with respect to conditions of use, or they may grant approval
subject to the performance of costly post-marketing clinical trials. In addition, regulatory authorities may not approve the labeling claims that are necessary or desirable for the successful commercialization of any product candidates we may
develop. Any of the foregoing scenarios could materially harm the commercial prospects for any product candidates we may develop and materially adversely affect our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are not able to obtain or if there are delays in obtaining required regulatory approvals for our product candidates, we will not be able to
commercialize or will be delayed in commercializing our product candidates and our ability to generate revenue will be adversely affected. Even if we eventually gain approval for any of our product candidates, we may be unable to commercialize them.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product candidates and the activities associated with their development and commercialization, including their design,
testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, distribution, import and export are subject to comprehensive regulation by the FDA and other regulatory agencies in the United States
and by comparable authorities in other countries. Before we can commercialize any of our product candidates, we must obtain marketing approval. All of the product candidates that we are developing, or may develop in the future, require research and
development, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies, nonclinical testing, and clinical trials prior to seeking regulatory approval, and commencing commercial sales. We have not received approval to market any of our product
candidates from regulatory authorities in any jurisdiction and it is possible that none of our product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval. In certain instances, we may need
to rely on third-party CROs and/or regulatory consultants to assist us in this process, and we may have limited control over those third parties and their conduct with respect to our development programs and product candidates. To date, we have
focused substantially all of our efforts and financial resources on identifying and developing our product candidates, including conducting lead optimization, nonclinical studies, preclinical studies and clinical trials, and providing general and
administrative support for these operations. Securing regulatory approval requires the submission of extensive preclinical and clinical data and supporting information to the various regulatory authorities for each therapeutic indication to
establish the biologic product candidate&#146;s safety, purity, efficacy and potency. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Securing regulatory approval also requires the submission of information about the
manufacturing processes for the biologic product candidate to, and inspection of manufacturing facilities by, the relevant regulatory authority. Manufacturing facilities must comply with cGMP regulations, which include requirements relating to
organization of personnel, buildings and facilities, equipment, control of components and drug product containers and closures, production and process controls, packaging and labeling controls, holding and distribution, laboratory controls, records
and reports. In addition, given the novelty of our therapeutics approach and technologies, our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other
characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use of such products if approved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The process of obtaining regulatory approvals, both in the United States and abroad, is expensive, may take many years if additional clinical
trials are required, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. FDA and other regulatory bodies may continually change
the requirements for Chemistry, Manufacturing and Controls (CMC) and other aspects of product manufacturing such that the approval to continue a clinical trial and/or commercially sell a product may never occur. Changes in marketing approval
policies during the development period, changes in or the enactment of additional statutes or regulations or changes in regulatory review for each submitted IND, BLA or equivalent application types, may cause delays in the approval or rejection of
an application. The FDA and comparable authorities in other countries have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional
preclinical, clinical or other studies. Our product candidates could be delayed in receiving or fail to receive regulatory approval for many reasons, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or other regulatory authorities may disagree with the design or implementation of our clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be unable to demonstrate to the satisfaction of the FDA or other regulatory authorities that a product
candidate is safe and effective for its proposed indication or that a potential related companion diagnostic, should we develop one, is suitable to identify appropriate patient populations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the results of clinical trials may not meet the level of statistical significance or clinical significance
required by the FDA or other regulatory authorities for biologic product approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be unable to demonstrate that a product candidate&#146;s clinical and other benefits outweigh its safety
risks; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or other regulatory authorities may disagree with our interpretation of data from preclinical studies or
clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the data collected from clinical trials of our product candidates may not be sufficient to support the submission
of a BLA or other submission or to obtain regulatory approval in the United States or elsewhere; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or other authorities may fail to approve the manufacturing processes or facilities of third-party
manufacturers with which we contract for clinical and commercial supplies; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the approval policies or regulations of the FDA or other regulatory authorities may significantly change in a
manner rendering our clinical data insufficient for approval. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Of the large number of drugs and biologics in
development, only a small percentage successfully complete the FDA or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory approval processes and are commercialized. The lengthy approval process as well as the unpredictability of clinical
trial results may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm our business, financial condition, results of operations and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect the novel nature of our product candidates to create further challenges in
obtaining regulatory approval. As a result, our ability to develop product candidates and obtain regulatory approval may be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, the general approach for FDA approval of a new biologic or drug is for sponsors to seek licensure or approval based on
dispositive data from well-controlled, Phase 3 clinical trials of the relevant product candidate in the relevant patient population. Phase 3 clinical trials typically involve hundreds of patients, have significant costs and take years to complete.
We believe that we may be able to utilize the requirements defined in the FDA&#146;s guidance for industry on developing therapeutics for <FONT STYLE="white-space:nowrap">BCG-unresponsive</FONT> high-risk NMIBC given the limited alternatives for
treatments for cancer and other serious diseases, but the FDA may not agree with our plans or permit us to proceed under such alternative guidance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may also require an Advisory Committee to deliberate on the adequacy of the safety and efficacy data to support BLA approval. The
opinion of the Advisory Committee, although not binding, may have a significant impact on our ability to obtain approval of any product candidates that we develop based on the completed clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, approval of genetic or biomarker diagnostic tests may be necessary in order to advance some of our product candidates to clinical
trials or potential commercialization. In the future, regulatory agencies may require the development and approval of such tests. Accordingly, the regulatory approval pathway for such product candidates may be uncertain, complex, expensive and
lengthy and approval may not be obtained. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, even if we were to obtain approval, regulatory authorities may approve any of our
product candidates for fewer or more limited indications than we request, may not approve the price we intend to charge for our products (where such regulatory approvals are required), may grant approval contingent on the performance of costly
post-marketing clinical trials or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could
materially harm the commercial prospects for our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we experience delays in obtaining approval or if we fail to
obtain approval of our product candidates, the commercial prospects for our product candidates may be harmed and our ability to generate revenues will be materially harmed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not obtain or maintain regulatory approval in all jurisdictions in which such approval may be required. Obtaining and maintaining regulatory
approval of our product candidates in one jurisdiction does not mean that we will obtain and/or maintain regulatory approval of our product candidates in other jurisdictions, while a failure or delay in obtaining or maintaining regulatory approval
of our product candidates in one jurisdiction may have a material adverse effect on the regulatory approval or maintenance process in other jurisdictions. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain
or maintain regulatory approval in any other jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA grants
marketing approval of a product candidate, comparable regulatory authorities in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions must also approve the manufacturing, marketing and promotion of the product candidate in those countries.
Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States, including additional preclinical studies or clinical trials, as clinical trials
conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions, a product candidate must be approved for reimbursement before it can be
approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also submit marketing applications in other countries. Regulatory authorities in
jurisdictions outside of the United States have requirements for approval of product candidates with which we must comply prior to marketing in those jurisdictions and such regulatory requirements can vary widely from country to country. Obtaining
other regulatory approvals and compliance with other regulatory requirements could result in significant delays, difficulties and costs for us and could require additional preclinical studies or clinical trials, which could be costly and
time-consuming and could delay or prevent the introduction of our products in certain countries. The <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory approval process involves all of the risks associated with FDA approval. We do not have
any product candidates approved for sale in any jurisdiction, including international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with the regulatory requirements in
international markets and/or obtain and maintain applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may seek priority review designation for one or more of our product candidates, but we might not receive such designation, and even if we do, such
designation may not lead to a faster regulatory review or approval process. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the FDA determines that a product candidate offers
a treatment for a serious condition and, if approved, the product would provide a significant improvement in safety or effectiveness of the treatment, the FDA may designate the marketing application for that product candidate for priority review. A
priority review designation is intended to direct overall attention and resources to the evaluation of such applications and to shorten the goal for the FDA to review an application to six months, rather than the standard review period of ten
months. We may request priority review for one or more original BLAs for our product candidates in the future. The FDA has broad discretion with respect to whether or not to grant priority review status to a marketing application, so even if we
believe an application for a particular product candidate is eligible for such designation or status, the FDA may decide not to grant it. Moreover, a priority review designation does not necessarily result in expedited regulatory review or approval
process or necessarily confer any advantage with respect to approval compared to conventional FDA procedures. Receiving priority review from the FDA does not guarantee approval within the <FONT STYLE="white-space:nowrap">six-month</FONT> review
cycle, or at all. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we receive regulatory approval of any product candidates or therapies, we will be subject to ongoing regulatory
obligations, reporting requirements and continued regulatory review, which may result in significant additional expenses. If we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates, we may be
subject to substantial penalties, fines, delays, suspensions, refusals and withdrawals of approvals. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of our product
candidates are approved, they will be subject to ongoing regulatory requirements and reporting requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, recordkeeping, conduct of post-marketing studies and
submission of safety, efficacy and other post-market information, including both federal and state requirements in the United States and requirements of comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities. In addition,
we will be subject to continued compliance with cGMP and Good Clinical Practice (&#147;GCP&#148;) requirements for any clinical trials that we conduct post-approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Facilities of CMOs and testing laboratories are required to comply with extensive FDA, and <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to cGMP, and in certain cases, current Good Tissue Practices (&#147;cGTP&#148;), regulations. As a result, we and our contract
manufacturers will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any BLA, other marketing application, and previous responses to inspection observations. Accordingly, we and others
with whom we work with must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any regulatory approvals that we receive for our product candidates may be subject to limitations on the approved indicated uses for which the
product may be marketed or to the conditions of approval or contain </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
requirements for potentially costly post-marketing testing, including Phase 4 clinical trials and surveillance to monitor the safety and efficacy of the product candidate. The FDA may also
require that we implement a REMS program as a condition of approval of our product candidates, which could entail requirements for long-term patient <FONT STYLE="white-space:nowrap">follow-up,</FONT> a medication guide, physician communication plans
or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or a comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authority
approves our product candidates, we will have to comply with requirements including submissions of safety and other post-marketing information and reports and establishment registration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may seek consent decrees or withdraw approval if compliance with regulatory requirements and standards is not maintained or if
problems occur after the product reaches the market. Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers, manufacturing
processes or testing laboratories, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or
imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the marketing or manufacturing of our products, withdrawal of the product from the market or
voluntary or mandatory product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, warning or untitled letters or holds on clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or
suspension or revocation of license approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product seizure or detention or refusal to permit the import or export of our product candidates; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Products may be promoted
only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses
and a company that is found to have improperly promoted <FONT STYLE="white-space:nowrap">off-label</FONT> uses may be subject to significant liability. The policies of the FDA and of other regulatory authorities may change and additional government
regulations maybe enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action,
either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval
that we may have obtained and we may not achieve or sustain profitability. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in regulatory requirements could result in delays or
discontinuation of development of our product candidates or therapies, or unexpected costs in obtaining or maintaining regulatory approval, and thereby adversely affect our business and results of operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Government authorities in the United States at the federal, state and local level and in other countries regulate, among other things, the
research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, recordkeeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of drug and biological
products. Generally, before a new drug or biologic can be marketed, considerable data demonstrating its quality, safety and efficacy and durability of effect must be obtained, organized into a format specific for each regulatory authority, submitted
for review and approved by the regulatory authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because we are developing novel gene therapy product candidates, the regulatory
requirements that we will be subject to are continually evolving and may not be clear. Even with respect to more established products that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
fit into the category of gene therapies, the regulatory landscape is still developing. For example, regulatory requirements governing gene therapy products have changed frequently and may
continue to change in the future. Moreover, there is substantial, and sometimes uncoordinated, overlap in those responsible for regulation of existing cell therapy products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Complex regulatory environments exist in other jurisdictions in which we might consider seeking regulatory approvals for our product
candidates, further complicating the regulatory landscape. For example, in the European Union a special committee called the CAT was established within the EMA in accordance with Regulation (&#147;EC&#148;) No 1394/2007 on advanced-therapy medicinal
products (&#147;ATMPs&#148;) to assess the quality, safety and efficacy of ATMPs, and to follow scientific developments in the field. ATMPs include gene therapy products. These various regulatory review committees and advisory groups and new or
revised guidelines that they promulgate from time to time may lengthen the regulatory review process, require us to perform additional studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay or
prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions. Because the regulatory landscape for our gene therapies and product candidates is new, we may face even more
cumbersome and complex regulations than those emerging for cell therapy products. Furthermore, even if our product candidates obtain required regulatory approvals, such approvals may later be withdrawn as a result of changes in regulations or the
interpretation of regulations by applicable regulatory agencies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Delay or failure to obtain, or unexpected costs in obtaining, the
regulatory approval necessary to bring a potential product to market could decrease our ability to generate sufficient product revenue to maintain our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our contract manufacturers are subject to significant regulation with respect to the manufacturing of our current and future product candidates. The
manufacturing facilities on which we rely may not meet or continue to meet regulatory requirements and/or may have limited capacity. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Contract manufacturers and their facilities are required to comply with extensive regulatory requirements, including ensuring that quality
control and manufacturing procedures conform to cGMP requirements. These regulations cover all aspects of manufacturing relating to our product candidates and components used in clinical studies and commercial production. These regulations govern
manufacturing processes and procedures (including record keeping) and the implementation and operation of quality systems to control and assure the quality of investigational product candidates and products approved for sale. Poor control of
production processes can lead to the introduction of contaminants or to inadvertent changes in the properties or stability of our product candidates that may not be detectable in final product testing. We and our contract manufacturers must supply
all necessary documentation in support of a BLA or Market Authorization Application (&#147;MAA&#148;) on a timely basis and must adhere to Good Laboratory Practices (&#147;GLP&#148;) and cGMP regulations enforced by the FDA and other regulatory
authorities through their facilities inspection program. The facilities and quality systems of our third-party contractors must pass a <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection for compliance with the applicable regulations as
a condition of regulatory approval of our product candidates or any of our other potential product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the
regulatory authorities may, at any time, audit or inspect a manufacturing facility involved with the preparation of our product candidates or our other potential product candidates or the associated quality systems for compliance with the
regulations applicable to the activities being conducted. We do not control the manufacturing process of, and are completely dependent on, our contract manufacturing partners for compliance with the regulatory requirements. If these facilities do
not pass a <FONT STYLE="white-space:nowrap">pre-approval</FONT> plant inspection, regulatory approval of the product candidates may not be granted or may be substantially delayed until any violations are corrected to the satisfaction of the
regulatory authority, if ever. Moreover, if our contract manufacturers fail to achieve and maintain high manufacturing standards, in accordance with applicable regulatory requirements, or there are substantial manufacturing errors, this could result
in patient injury or death, product shortages, product recalls or withdrawals, delays or failures in product testing or delivery, cost overruns, revocation of regulatory approvals, or other problems that could seriously harm our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ongoing healthcare legislative and regulatory reform measures, including the U.S. federal
government&#146;s determination that any of our product candidates is an &#147;essential&#148; biologic medicine, may have a material adverse effect on our business and results of operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The United States and many <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions have enacted or proposed legislative and regulatory
changes affecting the healthcare system, including implementing cost-containment programs to limit the growth of government-paid healthcare costs, including price controls, restrictions on reimbursement and requirements for substitution of generic
products for branded prescription products. In recent years, Congress has considered reductions in Medicare reimbursement levels for products administered by physicians. The Centers for Medicare&nbsp;&amp; Medicaid Services (&#147;CMS&#148;), the
agency that administers the Medicare and Medicaid programs, also has authority to revise reimbursement rates and to implement coverage restrictions for some products. Cost reduction initiatives and changes in coverage implemented through legislation
or regulation could decrease utilization of and reimbursement for any approved products. While Medicare regulations apply only to drug benefits for Medicare beneficiaries, private payers often follow Medicare coverage policy and payment limitations
in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from federal legislation or regulation may result in a similar reduction in payments from private payers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act (as amended, the
&#147;Affordable Care Act&#148;) substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacts the pharmaceutical industry. The Affordable Care Act is intended to broaden access to health
insurance, reduce or constrain the growth of healthcare spending, enhance remedies against healthcare fraud and abuse, add new transparency requirements for healthcare and health insurance industries, impose new taxes and fees on pharmaceutical and
medical device manufacturers, and impose additional health policy reforms. Among other things, the Affordable Care Act expanded manufacturers&#146; rebate liability under the Medicaid Drug Rebate Program by increasing the minimum Medicaid rebate for
both branded and generic products, expanded the 340B program, and revised the definition of average manufacturer price, which could increase the amount of Medicaid rebates manufacturers are required to pay to states. The legislation also extended
Medicaid rebates, previously due only on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fee-for-service</FONT></FONT> Medicaid utilization, to include the utilization of Medicaid managed care organizations as well and created an
alternative rebate formula for certain new formulations of certain existing products that is intended to increase the amount of rebates due on those products. On February&nbsp;1, 2016, CMS issued final regulations to implement the changes to the
Medicaid Drug Rebate Program under the Affordable Care Act. These regulations became effective on April&nbsp;1, 2016. Since that time, there have been significant ongoing efforts to modify or eliminate the Affordable Care Act. The Tax Act, enacted
on December&nbsp;22, 2017, repealed the shared responsibility payment for individuals who fail to maintain minimum essential coverage under section 5000A of the United States Internal Revenue Code of 1986, as amended (the &#147;Code&#148;) or the
individual mandate. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other legislative changes have been proposed and adopted since the passage of the Affordable Care Act. The
Budget Control Act of 2011, among other things, created the Joint Select Committee on Deficit Reduction (the &#147;Joint Select Committee&#148;), to provide recommendations and legislative language that would significantly improve the short-term and
long-term fiscal imbalance of the U.S. federal government. The Joint Select Committee did not achieve its targeted deficit reduction of an amount greater than $1.2 trillion for the fiscal years 2012 through 2021, triggering the legislation&#146;s
automatic reductions to several government programs. These reductions included aggregate reductions to Medicare payments to healthcare providers of up to 2% per fiscal year, which went into effect in April 2013 and will remain in effect through
2031, with the exception of a temporary suspension implemented under various <FONT STYLE="white-space:nowrap">COVID-19</FONT> relief legislation from May&nbsp;1, 2020 through March&nbsp;31, 2022. Under the Consolidated Appropriations Act, 2023, the
2% Medicare sequester is extended for the first six months of fiscal year 2032 and revises the sequester percentage up to 2% for fiscal years 2030 and 2031. These
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">across-the-board</FONT></FONT> spending cuts could adversely affect our future revenues, earnings, and cash flows. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2022, President Biden signed the Inflation Reduction Act of 2022 (the &#147;IRA&#148;). The IRA contains substantial drug pricing
reforms, including the establishment of a drug price negotiation program within the U.S. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Department of Health and Human Services that would require manufacturers to charge a negotiated &#147;maximum fair price&#148; for certain selected drugs or pay an excise tax for noncompliance,
the establishment of rebate payment requirements on manufacturers of certain drugs payable under Medicare Parts B and D to penalize price increases that outpace inflation, and requires manufacturers to provide discounts on Part D drugs. Substantial
penalties can be assessed for noncompliance with the drug pricing provisions in the IRA. The IRA could have the effect of reducing the prices we can charge and reimbursement we receive for our products, if approved, thereby reducing our
profitability, and could have a material adverse effect on our financial condition, results of operations and growth prospects. The effect of the IRA on our business and the pharmaceutical industry in general is not yet known. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Affordable Care Act, has also been subject to challenges in the courts. On December&nbsp;14, 2018, a Texas U.S. District Court Judge ruled
that the Affordable Care Act is unconstitutional in its entirety because the &#147;individual mandate&#148; was repealed by Congress. On December&nbsp;18, 2019, the Fifth Circuit U.S. Court of Appeals held that the individual mandate is
unconstitutional and remanded the case to the Texas District Court to reconsider its earlier invalidation of the entire Affordable Care Act. An appeal was taken to the U.S. Supreme Court. On June&nbsp;17, 2021, the Supreme Court ruled that the
plaintiffs lacked standing to challenge the law as they had not alleged personal injury traceable to the allegedly unlawful conduct. As a result, the Supreme Court did not rule on the constitutionality of the Affordable Care Act or any of its
provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further changes to and under the Affordable Care Act remain possible but it is unknown what form any such changes or any law
proposed to replace or revise the Affordable Care Act would take, and how or whether it may affect our business in the future. We expect that changes to the Affordable Care Act, the Medicare and Medicaid programs and changes stemming from other
healthcare reform measures, especially with regard to healthcare access, financing or other legislation in individual states, could have a material adverse effect on the healthcare industry. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product
pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and
bulk purchasing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that additional federal, state and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> healthcare reform measures
will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in limited coverage and reimbursement and reduced demand for our products, once
approved, or additional pricing pressures. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Any product candidates we develop may become subject to unfavorable or unprofitable third-party coverage
and reimbursement practices, as well as pricing regulations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patients rely on insurance coverage by third-party payors
(third-party payors include Medicare and Medicaid (government payors) and commercial insurance companies such as Blue Cross Blue Shield, Humana, Cigna, etc.), to pay for products. The availability and extent of coverage and adequate reimbursement by
third-party payors, including government health administration authorities, private health coverage insurers, managed care organizations and other third-party payors is essential for most patients to be able to afford expensive treatments. Sales of
any of our product candidates that receive marketing approval will depend substantially, both in the United States and internationally, on the extent to which the costs of such product candidates will be covered and reimbursed by third-party payors.
</P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Private insurance companies, commercial payors and various other healthcare intermediaries such as pharmacy benefit managers may take
steps to thwart physician and/or patient access to our products including not covering the product, blocking access to our products or adding step edits or prior approval requirements before reimbursing patients or health care providers for using
our products. This could result in reduced or failure </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to achieve revenues and/or margins. In addition, third-party organizations that purport to study and issue reports regarding the pricing of certain therapeutic medicines may issue reports
regarding our products that negatively effect pricing and our product use and uptake by physicians and patients. Additionally, private insurance companies are increasingly imposing utilization management tools, such as requiring prior authorization
for a proprietary product if a generic product or less expensive product is available or requiring the patient to first fail on one or more generic or less expensive products before permitting access to a proprietary medicine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is significant uncertainty related to third-party payor coverage and reimbursement of newly approved products. Factors payors consider
in determining reimbursement are based on whether the product is: (i)&nbsp;a covered benefit under its health plan; (ii)&nbsp;safe, effective and medically necessary; (iii)&nbsp;appropriate for the specific patient; (iv)&nbsp;cost-effective; and
(v)&nbsp;neither experimental nor investigational. This process will require us to provide scientific and clinical support for the use of our products to each third-party payor separately, with no assurance that coverage and adequate reimbursement
will be applied consistently or obtained in the first instance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No uniform policy exists for coverage and reimbursement in the United
States. If reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to
allow us to establish or maintain pricing sufficient to realize an adequate return on our investment. Coverage and reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. If coverage
and reimbursement are not available or reimbursement is available only to limited levels, we may not successfully commercialize any product candidate for which we obtain marketing approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As U.S. federal and state governments implement additional health care cost containment measures, including measures to lower prescription
drug pricing, we cannot be sure that our products, if approved, will be covered by private or public payors, and if covered, whether the reimbursement will be adequate or competitive with other marketed products. Such other actions by federal and
state governments and health plans may put additional downward pressure on pharmaceutical pricing and health care costs, which could negatively impact coverage and reimbursement for our products if approved, our revenue, and our ability to compete
with other marketed products and to recoup the costs of our research and development. Outside the United States, the commercialization of therapeutics is generally subject to extensive governmental price controls and other market regulations, and we
believe the increasing emphasis on cost containment initiatives in the European Union, the United Kingdom, Japan and other countries has and will continue to put pressure on the pricing and usage of therapeutics such as our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to establish or sustain coverage and adequate reimbursement for any product candidates from third-party payors, the adoption
of those products and sales revenue will be adversely affected, which, in turn, could adversely affect the ability to market or sell those product candidates, if approved. Coverage policies and third-party payor reimbursement rates may change at any
time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future or subject to
recoupment or overpayment challenges. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Drug marketing, price controls and reimbursement regulations may materially affect our ability to market and
receive coverage for our product candidates, if approved, in the European Union, the United Kingdom, Japan and other <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to seek approval to market our product candidates in both the United States and in selected
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions. If we obtain approval in one or more <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions for our product candidates, we will be subject to rules and regulations in those
jurisdictions. In some countries outside of the United States, particularly those in the European Union, the pricing of pharmaceutical products is subject to governmental control and other market regulations, which could put pressure on the pricing
and usage of our product candidates. In these countries, pricing negotiations with governmental authorities can take considerable time after </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
obtaining marketing approval of a product candidate. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the
cost-effectiveness of our product candidate to other available therapies. If required to execute such a trial, we cannot be sure of a favorable outcome. In general, product prices under such systems are substantially lower than in the United States.
Price controls in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions or changes in pricing regulations in such jurisdictions could reduce the amount we are able to charge for our product candidates. In addition, market acceptance and
sales of our product candidates will depend significantly on the availability of adequate coverage and reimbursement from third-party payors for our product candidates and may be affected by existing and future healthcare reform measures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Much like the federal Anti-Kickback Statute (&#147;AKS&#148;) prohibition in the United States, the provision of benefits or advantages to
physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products are also prohibited in the European Union. The provision of benefits or advantages to physicians is governed by the
national anti-bribery laws of EU member states, such as the UK Bribery Act 2010. Infringement of these laws could result in substantial fines and imprisonment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payments made to physicians in certain EU member states must be publicly disclosed. Moreover, agreements with physicians often must be the
subject of prior notification and approval by the physician&#146;s employer, their competent professional organization and/or the regulatory authorities of the individual EU member states. These requirements are provided in the national laws,
industry codes or professional codes of conduct, applicable in the EU member states. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in most countries outside of the United States, including the European Economic Area (&#147;EEA&#148;), the proposed pricing for
a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing and reimbursement vary widely from country to country. For example, the European Union provides options for its member states to restrict the range
of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. Reference pricing used by various EU member states and parallel distribution, or arbitrage
between <FONT STYLE="white-space:nowrap">low-priced</FONT> and high-priced member states, can further reduce prices. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect
controls on the profitability of the company placing the medicinal product on the market. In some countries, we may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of any of our product candidates to
other available therapies in order to obtain or maintain reimbursement or pricing approval. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable
reimbursement and pricing arrangements for any of our products. Historically, products launched in the European Union do not follow price structures of the United States and generally, prices tend to be significantly lower. Publication of discounts
by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If pricing is set at unsatisfactory levels or if reimbursement of our products is
unavailable or limited in scope or amount, our revenues from sales by us and the potential profitability of any of our product candidates in those countries would be negatively affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Guidelines and recommendations published by various organizations may impact the use or reimbursement of <FONT STYLE="white-space:nowrap">EG-70,</FONT>
if approved, as well as other future products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Government authorities promulgate regulations and guidelines that may be directly
applicable to us and any approved products. However, professional societies, practice management groups, insurance carriers, physicians&#146; groups, private health and science foundations and organizations involved in various diseases also publish
guidelines and recommendations to healthcare providers, administrators and payors, as well as patient communities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recommendations by
government authorities or other groups and organizations may relate to such matters as usage, dosage, route of administration and use of related therapies, and a growing number of organizations are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
providing assessments of the value and pricing of pharmaceutical products. These assessments may come from private organizations, such as the Institute for Clinical and Economic Review
(&#147;ICER&#148;), which publish their findings and offer recommendations relating to the products&#146; reimbursement by government and private payors. On December&nbsp;17, 2020,&nbsp;ICER&nbsp;published its final report assessing the
effectiveness and value of nadofaragene firadenovec and oportuzumab monatox for <FONT STYLE="white-space:nowrap">BCG-unresponsive</FONT> NMIBC, both of which are potential competitors to <FONT STYLE="white-space:nowrap">EG-70.</FONT> The guidance
was updated on January&nbsp;15, 2021. Nadofargene firadenovec, sold under the brand name Adstiladrin, is a <FONT STYLE="white-space:nowrap">FDA-approved</FONT> gene therapy approved in 2022 for the treatment of adult patients with high-risk <FONT
STYLE="white-space:nowrap">BCG-unresponsive</FONT> NMIBC with Cis with or without papillary tumors; oportuzumab monatox, also known as Vicineum, is an experimental therapy that has been studied in a highly similar patient group. The findings of this
or any future&nbsp;ICER&nbsp;report or similar recommendations or guidelines from ICER or similar third parties may affect our reputation as well as the perception of our value, and any recommendations or guidelines that result in decreased use or
reimbursement of <FONT STYLE="white-space:nowrap">EG-70,</FONT> if approved or adopted into commercial or clinical practice, could have a material adverse effect on our business, financial condition, results of operations and prospects. In addition,
the occurrence of any of the foregoing, or the perception by the investment community or shareholders that such recommendations or guidelines will result in decreased use or reimbursement of <FONT STYLE="white-space:nowrap">EG-70,</FONT> if
approved, could adversely affect the market price of our securities. The effect, if any, of any ICER report, recommendations or guidelines on our any of our products relating to usage, dosage, administration, pricing, reimbursement or other matters
is not foreseeable and we make no assurance regarding the effect of any current or future ICER report, recommendations or guidelines on our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to stringent privacy laws, information security laws, regulations, policies and contractual obligations related to data privacy and
security and changes in such laws, regulations, policies and contractual obligations could adversely affect our business and results of operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to data privacy and protection laws, rules and regulations, as well as contractual obligations, that apply to the collection,
transmission, storage, use and other processing of personally-identifying information, which among other things, impose certain requirements relating to the privacy, security and transmission of personal information, including comprehensive
regulatory systems in the United States, European Union and United Kingdom. The legislative and regulatory landscape for privacy and data protection continues to evolve in jurisdictions worldwide, and there has been an increasing focus on privacy
and data protection issues with the potential to affect our business. Failure to comply with any of these laws and regulations could result in enforcement action against us, including fines, imprisonment of company officials and public censure,
claims for damages by affected individuals, damage to our reputation and loss of goodwill, any of which could have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are numerous U.S. federal and state laws, rules and regulations governing the collection, sharing, use, retention, disclosure, security,
transfer, storage and other processing of personal information, including federal and state data privacy and security laws, data breach notification laws, and data disposal laws. In particular, at the federal level, regulations promulgated pursuant
to the Health Insurance Portability and Accountability Act (&#147;HIPAA&#148;) establish privacy and security standards that limit the use and disclosure of individually identifiable health information, or protected health information, and require
the implementation of administrative, physical and technological safeguards to protect the privacy of protected health information and ensure the confidentiality, integrity and availability of electronic protected health information. Determining
whether protected health information has been handled in compliance with applicable privacy standards and our contractual obligations can be complex and may be subject to changing interpretation. These obligations may be applicable to some or all of
our business activities now or in the future. At the federal level, we are also subject to, among other laws and regulations, the rules and regulations promulgated under the authority of the Federal Trade Commission (&#147;FTC&#148;) (which has the
authority to regulate and enforce against unfair or deceptive acts or practices in or affecting commerce, including acts and practices with respect to data privacy and security), as well as the Electronic Communication Privacy Act. The United States
Congress also has considered, is currently considering, and may in the future consider, various proposals for comprehensive federal data privacy and security legislation, to which we may become subject if passed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to properly protect the privacy and security of protected health
information, we could be found to have breached certain contracts or obligations. Further, if we fail to comply with applicable privacy laws, including applicable HIPAA privacy and security standards, we could face civil and criminal penalties. HHS
enforcement activity can result in financial liability and reputational harm, and responses to such enforcement activity can consume significant internal resources. In addition, state attorneys general are authorized to bring civil actions seeking
either injunctions or damages in response to violations that threaten the privacy of state residents. We cannot be sure how these regulations will be interpreted, enforced or applied to our operations. In addition to the risks associated with
enforcement activities and potential contractual liabilities, our ongoing efforts to comply with evolving laws and regulations at the federal and state level may be costly and require ongoing modifications to our policies, procedures and systems.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the state level, we are subject to similar and sometimes more onerous data protection and privacy laws and regulations such as the
California Consumer Privacy Act of 2018, as amended by the California Privacy Rights Act (the &#147;CPRA&#148;) (collectively, the &#147;CCPA&#148;). The CCPA imposes many requirements on certain businesses that process the personal information of
California residents, including requirements similar to those found in the General Data Protection Regulation (&#147;GDPR&#148;). For example, the CCPA requires covered businesses to provide notice to California residents regarding the information
collected about them and how such information is used and shared, provides California residents the right to request access to such personal information and, in certain cases, request the erasure of such personal information. The CCPA also affords
California residents the right to <FONT STYLE="white-space:nowrap">opt-out</FONT> of certain &#147;sales&#148; of their personal information. The CCPA provides for significant civil penalties and statutory damages for companies that violate its
requirements, and also provides for a private right of action for certain data breaches that result in the loss of unencrypted personal information. This private right of action is expected to increase the likelihood of, and risks associated with,
data breach litigation. The CPRA significantly expands the CCPA to incorporate additional GDPR-like provisions including requiring that the use, retention, and sharing of personal information of California residents be reasonably necessary and
proportionate to the purposes of collection or processing, granting additional protections for sensitive personal information, and requiring greater disclosures related to notice to residents regarding retention of information. These provisions may
apply to some of our business activities. In addition, other states, including Virginia and Colorado, already have passed comprehensive state-level data privacy and security laws, rules and regulations that share similarities with the CCPA. Other
states are in the process of enacting or will be considering these laws in the future. Moreover, laws in all 50 U.S. states require businesses to provide notice under certain circumstances to consumers whose personal information has been disclosed
as a result of a data breach. These laws, and other similar laws that may be enacted in the future, may impact our business activities, including our identification of research subjects and ultimately the marketing and distribution of our products.
</P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similar to the laws in the United States, there are significant privacy and data security laws that apply in Europe and other
countries. The collection, use, disclosure, transfer, or other processing of personal data, including personal health data, regarding individuals who are located in the EEA, and the processing of personal data that takes place in the EEA is
regulated by the GDPR, which went into effect in May 2018 and imposes obligations on companies that operate in our industry with respect to the processing of personal data and the cross-border transfer of such data. The GDPR imposes onerous
accountability obligations, including requiring data controllers and processors to maintain a record of their data processing and policies. Following the withdrawal of the United Kingdom from the European Union, the United Kingdom&#146;s Data
Protection Act 2018 (the &#147;U.K. GDPR&#148;), which &#147;implements&#148; and complements the GDPR and achieved formal approval by United Kingdom&#146;s monarchy on May&nbsp;23, 2018, applies to the processing of personal data that takes place
in the United Kingdom and includes parallel obligations to those set forth by GDPR. While the GDPR and U.K. GDPR remain substantially similar for the time being, the U.K. government has announced that it would seek to chart its own path on data
protection and reform its relevant laws, including in ways that may differ from the GDPR. While these developments increase uncertainty with regard to data protection regulation in the United Kingdom, even in their current, substantially similar
form, the GDPR and U.K. GDPR can expose businesses to divergent parallel regimes that may be subject to potentially different interpretations and enforcement actions for certain violations and related uncertainty. If our or our service
providers&#146; privacy or data security measures fail to comply with the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
GDPR and U.K. GDPR requirements, we may be subject to litigation, regulatory investigations, enforcement notices requiring us to change the way we use personal data and/or fines of up to
20&nbsp;million Euros (or GBP 17.5&nbsp;million under the U.K. GDPR) or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, as well as compensation claims by affected individuals, negative publicity,
reputational harm and a potential loss of business and goodwill. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The GDPR places restrictions on the cross-border transfer of personal
data from the EEA to countries that have not been found by the European Commission to offer adequate data protection legislation, such as the United States. There are ongoing concerns about the ability of companies to transfer personal data from the
EEA to other countries. Similar complexities and uncertainties also apply to transfers from the U.K. to third countries. In July 2020, the Court of Justice of the European Union (&#147;CJEU&#148;), invalidated the
<FONT STYLE="white-space:nowrap">EU-U.S.</FONT> Privacy Shield, one of the mechanisms used to legitimize the transfer of personal data from the EEA to the United States. The CJEU&#146;s decision also drew into question the long-term viability of an
alternative means of data transfer, the standard contractual clauses (&#147;SCCs&#148;), for transfers of personal data from the EEA to the United States. While we were not self-certified under the <FONT STYLE="white-space:nowrap">EU-U.S.</FONT>
Privacy Shield, this CJEU decision may lead to increased scrutiny on data transfers from the EEA to the United States generally and increase our costs of compliance with data privacy legislation as well as our costs of negotiating appropriate
privacy and security agreements with our vendors. While we may take steps to mitigate the impact on us, such as implementing SCCs, the efficacy and longevity of these mechanisms remains uncertain. Moreover, in 2021, the European Commission adopted
new SCCs, which impose on companies additional obligations relating to personal data transfers out of the EEA, including the obligation to update internal privacy practices, conduct transfer impact assessments and, as required, implement additional
security measures. The new SCCs may increase the legal risks and liabilities under European Union laws associated with cross-border data transfers, and result in material increased compliance and operational costs. While the European Commission
announced in March 2022 that an agreement in principle had been reached between European Union and U.S. authorities regarding a new transatlantic data privacy framework, no formal agreement has been finalized, and any such agreement, if formalized,
is likely to face challenge at the CJEU. Moreover, while the U.K. GDPR is now effective in the United Kingdom, it is still unclear whether transfer of data from the EEA to the United Kingdom will remain lawful under the GDPR. The United Kingdom has
already determined that it considers all European Union and EEA member states to be adequate for the purposes of data protection, ensuring that data flows from the United Kingdom to the European Union and EEA remain unaffected. In addition, a
decision from the European Commission appears to deem the United Kingdom as being &#147;essentially adequate&#148; for purposes of data transfer from the EEA to the United Kingdom, such that SCCs are not required for the transfer of personal data
from the EEA to the United Kingdom, although such decision will sunset in June 2025 unless extended and it may be revoked in the future by the European Commission if the United Kingdom data protection regime is reformed in ways that deviate
substantially from the GDPR. Adding further complexity for international data flows, in March 2022, the United Kingdom adopted its own International Data Transfer Agreement for transfers of personal data out of the United Kingdom to <FONT
STYLE="white-space:nowrap">so-called</FONT> third countries, as well as an international data transfer addendum that can be used with the SCCs for the same purpose. The European Union has also proposed legislation that would regulate <FONT
STYLE="white-space:nowrap">non-personal</FONT> data and establish new cybersecurity standards, and other countries, including the United Kingdom, may similarly do so in the future. If we are otherwise unable to transfer data, including personal
data, between and among countries and regions in which we operate, it could affect the manner in which we provide our services, the geographical location or segregation of our relevant systems and operations, and could adversely affect our financial
results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beyond the GDPR and U.K. GDPR, there are privacy and data security laws in a growing number of countries around the world. While
many loosely follow the GDPR as a model, other laws contain different or conflicting provisions. These laws will impact our ability to conduct our business activities, including both our clinical trials and any eventual sale and distribution of
commercial products, through increased compliance costs, costs associated with contracting and potential enforcement actions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While we
continue to address the implications of the recent changes to data privacy regulations, data privacy remains an evolving landscape at both the domestic and international level, with new regulations coming
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
into effect and continued legal challenges, and our efforts to comply with the evolving data protection rules may be unsuccessful. It is possible that these laws may be interpreted and applied in
a manner that is inconsistent with our practices. We must devote significant resources to understanding and complying with this changing landscape. Any failure, actual or perceived, to comply with laws regarding data protection would expose us to
risk of enforcement actions taken by data protection authorities in the EEA and elsewhere and carries with it the potential for significant penalties if we are found to be <FONT STYLE="white-space:nowrap">non-compliant.</FONT> Similarly, any
failure, actual or perceived, to comply with federal and state laws in the United States regarding privacy and security of personal information could expose us to penalties under such laws. Any such failure to comply with data protection and privacy
laws could result in government- imposed fines or orders requiring that we change our practices, claims for damages or other liabilities, regulatory investigations and enforcement action, litigation and significant costs for remediation, any of
which could adversely affect our business. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could
harm our reputation and our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cyber-attacks or other failures in our or our
third-party vendors&#146;, contractors&#146; or consultants&#146; telecommunications or information technology systems could result in information theft, data corruption and significant disruption of our business operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, our programs, our CROs, third-party logistics providers, distributors and other contractors and consultants utilize information technology
(&#147;IT&#148;), systems and networks to process, transmit and store electronic information, including but not limited to intellectual property, proprietary business information and personal information, in connection with our business activities.
Our internal IT systems and those of current and future third parties on which we rely may fail and are vulnerable to breakdown, breach, interruption or damage from cyber incidents, employee error or malfeasance, theft or misuse, sophisticated
nation-state and nation-state-supported actors, unauthorized access, natural disasters, terrorism, war, telecommunication and electrical failures or other compromises. As use of digital technologies has increased, cyber incidents, including third
parties gaining access to employee accounts using stolen or inferred credentials, computer malware (e.g., ransomware), viruses, spamming, phishing attacks,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">denial-of-service</FONT></FONT> attacks or other means, and deliberate attacks and attempts to gain unauthorized access to computer systems and networks, have increased in frequency,
intensity, and sophistication. These threats pose a risk to the security of our, our programs&#146;, our CROs&#146;, third-party logistics providers&#146;, distributors&#146; and other contractors&#146; and consultants&#146; systems and networks,
and the confidentiality, availability and integrity of our intellectual property, confidential information, preclinical and clinical trial data, proprietary business information, personal data, and health-related information. There can be no
assurance that we or any of our third-party partners will be successful in preventing cyberattacks or successfully mitigating their effects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Advances in computer and software capabilities, encryption technology, and other discoveries increase the complexity of our technological
environment, including how each interacts with our various software platforms. Such advances could delay or hinder our ability to conduct business or could compromise the integrity of our data, resulting in a material adverse impact on our financial
condition and results of operations. The risk of system disruption is increased when significant system changes are undertaken. If we fail to timely integrate and update our information technology systems and processes, we may fail to realize the
cost savings or operational benefits anticipated to be derived from these initiatives. We also may experience occasional system interruptions and delays that make our information technology systems unavailable or slow to respond, including the
interaction of our information technology systems with those of third parties. A lack of sophistication or reliability of our information technology systems could adversely impact our operations and consumer service and could require major repairs,
replacements or remodelings, resulting in significant costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The risk of a security breach or disruption, particularly through
cyberattacks or cyber intrusion, including by computer hackers, <FONT STYLE="white-space:nowrap">non-U.S.</FONT> governments, and cyber terrorists, has generally increased as the number, intensity, and sophistication of attempted attacks and
intrusions from around the world have increased. In addition, in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
response to the changes in workforce habits driven by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, varying parts of our workforce are currently working remotely on a part or
full time basis. This could increase our cyber security risk, create data accessibility concerns, and make us more susceptible to communication disruptions. We may not be able to anticipate all types of security threats, and we may not be able to
implement preventive measures effective against all such security threats. The techniques used by cyber criminals change frequently, may not be recognized until launched, and can originate from a wide variety of sources, including outside groups
such as external service providers, organized crime affiliates, terrorist organizations or hostile <FONT STYLE="white-space:nowrap">non-U.S.</FONT> governments or agencies. We may also experience security incidents that may remain undetected for an
extended period. Even if identified, we may be unable to adequately investigate or remediate incidents or breaches due to attackers increasingly using tools and techniques that are designed to circumvent controls, to avoid detection, and to remove
or obfuscate forensic evidence. Similarly, there can be no assurance that our CROs, third-party logistics providers, distributors and other contractors, consultants and third parties will be successful in protecting our clinical and other data that
is stored on their systems. Any loss of clinical trial data from our completed or ongoing clinical trials for any of our product candidates could result in delays in our development and regulatory approval efforts and significantly increase our
costs to recover or reproduce the data. We and certain of our service providers are from time to time subject to cyberattacks and security incidents. We have experienced and expect to continue to experience actual and attempted cyberattacks of our
IT networks, such as through phishing scams and ransomware. Although we do not believe that we have experienced any significant system failure, accident or security incidents to date, we cannot guarantee that we will not experience such incidents in
the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any cyberattack that leads to unauthorized access, use, or disclosure of personal information, including personal information
regarding clinical trial participants or employees, data breach or destruction or loss of data could result in a violation of applicable U.S. and international privacy, data protection and other laws and regulations, require us to notify affected
individuals or supervisory authorities, subject us to litigation and governmental investigations, proceedings and regulatory actions by federal, state and local regulatory entities in the United States and by international regulatory entities, cause
our exposure to material civil and/or criminal liability and cause us to breach our contractual obligations, which could result in significant legal and financial exposure and reputational damages. Further, we could be forced to expend significant
financial and operational resources in response to a security breach, including repairing system damage, increasing security protection costs by deploying additional personnel and modifying or enhancing our protection technologies, investigating and
remediating any information security vulnerabilities and defending against and resolving legal and regulatory claims, all of which could divert resources and the attention of our management and key personnel away from our business operations and
adversely affect our business, financial condition and results of operations. As cyber threats continue to evolve, we may be required to incur significant additional expenses in order to implement further data protection measures or to remediate any
information security vulnerability. Further, we do not maintain separate cyber liability insurance and our general liability insurance and corporate risk program may not cover all potential claims to which we are exposed and may not be adequate to
indemnify us for all liability. There can be no assurance that the limitations of liability in our contracts would be enforceable or adequate or would otherwise protect us from liabilities or damages as a result of the events referenced above. We
also cannot be certain that our existing insurance coverage will continue to be available on acceptable terms or in amounts sufficient to cover the potentially significant losses that may result from a security incident or breach or that the insurer
will not deny coverage of any future claim. Accordingly, if our cybersecurity measures, and those of our service providers, fail to protect against unauthorized access, attacks and the mishandling of data by our employees and third-party service
providers, then our business, financial condition, results of operations and prospects could be adversely affected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our employees, independent contractors and contract manufacturers, consultants, commercial partners
and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to the risk of fraud or other illegal activity by our employees, independent contractors, consultants, commercial partners and
vendors. Misconduct by these parties could include intentional, reckless and/or negligent conduct that fails to comply with the laws enforced by the FDA and other regulatory bodies in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions,
provide true, complete and accurate information to the FDA and other similar regulatory bodies in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions, comply with manufacturing standards we have established, comply with healthcare fraud
and abuse laws in the United States and similar <FONT STYLE="white-space:nowrap">non-U.S.</FONT> laws, or report financial information or data accurately or to disclose unauthorized activities to us. If we obtain FDA approval of any of our product
candidates and begin commercializing those products in the United States, our potential exposure under these laws will increase significantly and our costs associated with compliance with these laws are also likely to increase. These laws may
impact, among other things, our current activities with principal investigators and research patients, as well as proposed and future sales, marketing and education programs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our relationships with healthcare providers and physicians and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other
healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and result in diminished profits and future earnings and thereby adversely affect our business and results of
operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to applicable fraud and abuse and other healthcare laws and regulations, including, without limitation,
the AKS and the False Claims Act (&#147;FCA&#148;), which may constrain our business or financial arrangements and relationships through which we sell, market and distribute our products. In particular, the promotion, sales and marketing of
healthcare items and services, as well as certain business arrangements in the healthcare industry (e.g., healthcare providers, physicians and third-party payors), are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and
other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, structuring and commission(s), certain customer incentive programs and other business arrangements generally.
We also may be subject to patient information and privacy and security regulation by both the federal government and the states and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions in which we conduct our business. The applicable
federal, state and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> healthcare laws and regulations that may affect our ability to operate include, but are not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The AKS, which prohibits the knowing and willful offer, receipt, or payment of remuneration in exchange for or to
induce the referral of patients or the use of products or services that would be paid for in whole or part by Medicare, Medicaid or other federal health care programs. Remuneration has been broadly defined to include anything of value, including but
not limited to cash, improper discounts, and free or reduced price items and services. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Further, courts
have found that if &#147;one purpose&#148; of remuneration is to induce referrals, the AKS is violated. The AKS has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers, and
formulary managers on the other. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution; but the exceptions and safe harbors are drawn narrowly and require strict compliance in order
to offer protection. A claim including items or services resulting from a violation of the AKS constitutes a false or fraudulent claim for purposes of the FCA. Many states have similar laws that apply to their state health care programs as well as
private payors. Violations of anti-kickback and other applicable laws can result in exclusion from federal health care programs and substantial civil and criminal penalties. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The federal civil and criminal false claims laws and civil monetary penalty laws, including the FCA, which
prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, false or fraudulent claims for payment to, or approval by Medicare, Medicaid, or other federal healthcare programs, knowingly making, using
or causing to be made or used a false record or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
statement material to a false or fraudulent claim or an obligation to pay or transmit money to the federal government, or knowingly concealing or knowingly and improperly avoiding or decreasing
or concealing an obligation to pay money to the federal government. The FCA has been used to prosecute persons submitting claims for payment that are inaccurate or fraudulent, that are for services not provided as claimed, or for services that are
not medically necessary. The FCA includes a whistleblower provision that allows individuals to bring actions on behalf of the federal government and share a portion of the recovery of successful claims. Some state law equivalents of the above
federal laws, such as the AKS and FCA, apply to items or services regardless of whether the good or service was reimbursed by a government program, so called <FONT STYLE="white-space:nowrap">all-payor</FONT> laws. These <FONT
STYLE="white-space:nowrap">all-payor</FONT> laws could apply to our sales and marketing activities even if the AKS and FCA laws are inapplicable. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA, which created new federal criminal statutes that prohibit knowingly and willfully executing, or attempting
to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit
program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or
payment for, healthcare benefits, items or services relating to healthcare matters. Similar to the AKS, a person or entity can be found guilty of violating HIPAA without actual knowledge of the statute or specific intent to violate it.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009
(&#147;HITECH&#148;), and their implementing regulations, and as amended again by the Final HIPAA Omnibus Rule, published in January 2013, which imposes certain obligations, including mandatory contractual terms, with respect to safeguarding the
privacy, security and transmission of individually identifiable health information without appropriate authorization by covered entities subject to the rule, such as health plans, healthcare clearinghouses and certain healthcare providers, as well
as their business associates that perform certain services involving the use or disclosure of individually identifiable health information also implicate our business. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make
civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#146;
fees and costs associated with pursuing federal civil actions. In addition to other federal laws, state laws and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> laws, such as the General Data Protection Regulation in the European Union, create the
potential for substantial penalties in the event of any <FONT STYLE="white-space:nowrap">non-compliance</FONT> with the applicable data privacy and data protection laws. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The federal Physician Payment Sunshine Act, created under the ACA, and its implementing regulations, which
requires manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program (with certain exceptions) to report annually to HHS, information
related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by physicians and their
immediate family members. For the data submitted on or after January&nbsp;1, 2022, these reporting obligations will extend to include transfers of value made to certain <FONT STYLE="white-space:nowrap">non-physician</FONT> providers such as
physician assistants and nurse practitioners. States may also have similar reporting requirements related to payments made to clinical providers, and failure to comply with such requirements can adversely impact the business. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform,
especially in light of the lack of applicable precedent and regulatory guidance. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies, healthcare providers and other third parties,
including charitable foundations, which has led to a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
number of investigations, prosecutions, convictions and settlements in the healthcare industry. Responding to investigations can be <FONT STYLE="white-space:nowrap">time-and</FONT>
resource-consuming and can divert management&#146;s attention from our business. Any such investigation or settlement could increase our costs or otherwise have an adverse effect on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our marketing or other arrangements were determined to violate anti-kickback or related laws, including the FCA or an <FONT
STYLE="white-space:nowrap">all-payor</FONT> law, then we could be subject to penalties, including administrative, civil and criminal penalties, damages, fines, disgorgement, the exclusion from participation in federal and state healthcare programs,
individual imprisonment, reputational harm and the curtailment or restructuring of our operations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve
allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws. Any action for violation of these laws, even if successfully defended, could cause us to incur significant legal expenses and divert management&#146;s attention
from the operation of our business. Prohibitions or restrictions on sales or withdrawal of future marketed products could materially affect our business in an adverse way. Efforts to ensure that our business arrangements will comply with applicable
healthcare laws may involve substantial costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">State and federal authorities have aggressively targeted pharmaceutical companies for
alleged violations of these anti-fraud statutes, based on improper research or consulting contracts with doctors, certain marketing arrangements with pharmacies and other healthcare providers that rely on volume-based pricing, <FONT
STYLE="white-space:nowrap">off-label</FONT> marketing schemes, and other improper promotional practices. Companies targeted in such prosecutions have paid substantial fines, have been ordered to implement extensive corrective action plans, and have
in many cases become subject to consent decrees severely restricting the manner in which they conduct their business, among other consequences. Additionally, federal and state regulators have brought criminal actions against individual employees
responsible for alleged violations. If we become the target of such an investigation or prosecution based on our contractual relationships with providers or institutions, or our marketing and promotional practices, we could face similar sanctions,
which would materially harm our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also, the U.S. Foreign Corrupt Practices Act (&#147;FCPA&#148;) and similar worldwide
anti-bribery laws, including the Canadian Corruption of Foreign Public Officials Act, generally prohibit companies and their intermediaries from making improper payments to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> officials for the purpose
of obtaining or retaining business. Our internal control policies and procedures may not protect us from reckless or negligent acts committed by our employees, future distributors, partners or agents. Violations of these laws, or allegations of such
violations, could result in fines, penalties or prosecution and have a negative impact on our business, results of operations and reputation. For additional information regarding the compliance of our operations with the FCPA and <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> laws and regulations, see the Risk Factor entitled &#147;<I>Additional laws and regulations governing international operations may preclude or delay us from developing, manufacturing or selling certain
products and product candidates outside the United States, which could limit our growth potential and increase our development costs</I>.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We
are subject to certain U.S. and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations. We can face serious consequences for violations thereof.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Among other matters, U.S. and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> anti-corruption, anti-money laundering, export
control, sanctions, and other trade laws and regulations (collectively, the &#147;Trade Laws&#148;) prohibit companies and their employees, agents, clinical research organizations, legal counsel, accountants, consultants, contractors, and other
partners from authorizing, promising, offering, providing, soliciting, or receiving directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of the Trade Laws
can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences. We have direct or indirect
interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. We also expect our <FONT STYLE="white-space:nowrap">non-U.S.</FONT> activities to increase intime, including
when and if we conduct clinical trials outside the United States. We plan to engage </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
third parties for clinical trials and/or to obtain necessary permits, licenses, patent registrations and other regulatory approvals and we can be held liable for the corrupt or other illegal
activities of our personnel, agents, even if we do not explicitly authorize or have prior knowledge of such activities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks Related to
International Operations </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are an international organization and we plan to expand operations internationally where we have limited
operating experience and where we may be subject to increased regulatory risks and local competition. If we are unsuccessful in any efforts to expand internationally, our business and results of operations may be adversely affected. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are already an international organization and we plan to further expand our operations internationally. We currently source drug product
excipients and other product components that are critical to our manufacturing processes from CMOs located in the European Union. In the future, we expect to opportunistically engage with CMOs located in other
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions to facilitate the manufacture of our products on a basis that is cost effective and responsive to customer demand. As part of our business strategy, we plan to commercialize <FONT
STYLE="white-space:nowrap">EG-70</FONT> and other current and future products under development for sale in the United States and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions. Our business strategy incorporates potential
international operational expansion, independently and through third parties as we seek to obtain regulatory approval for, and commercialize, our product candidates in patient populations outside the United States. If approved, we may hire sales
representatives and conduct physician and patient association outreach activities outside of the United States. Doing business internationally involves a number of risks, including, but not limited to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">multiple, conflicting and changing laws and regulations such as privacy regulations, tax laws, export and import
restrictions, employment laws, regulatory requirements and other governmental approvals, permits and licenses; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure by us to obtain and maintain regulatory approvals for the use of our products in various countries;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">rejection or qualification of <FONT STYLE="white-space:nowrap">non-U.S.</FONT> clinical trial data by the
competent authorities of other countries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays or interruptions in the supply of clinical trial materials resulting from any events affecting raw
material supply or manufacturing capabilities abroad; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additional potentially relevant third-party patent and other intellectual property rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">complexities and difficulties in obtaining, maintaining, protecting and enforcing our intellectual property;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulties in staffing and managing <FONT STYLE="white-space:nowrap">non-U.S.</FONT> operations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">complexities associated with managing multiple payor reimbursement regimes, government payors or patient <FONT
STYLE="white-space:nowrap">self-pay</FONT> systems; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limits in our ability to penetrate international markets; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local
and regional financial crises on demand and payment for our product candidates and exposure to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> currency exchange rate fluctuations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">trade protection measures, import or export licensing requirements or other restrictive actions by U.S. or <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> governments; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">workforce uncertainty in countries where labor unrest is more common than in the United States;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">natural disasters, political and economic instability, including wars, terrorism and political unrest, outbreak
of disease, including a <FONT STYLE="white-space:nowrap">COVID-19</FONT> resurgence, and related <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">shelter-in-place</FONT></FONT> orders, travel, social distancing and quarantine
policies, boycotts, curtailment of trade and other business restrictions; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain expenses including, among other things, expenses for travel, translation and insurance; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory and compliance risks that relate to anti-corruption compliance and recordkeeping that may fall within
the purview of the FCPA, its accounting provisions or its anti-bribery provisions or provisions of anti-corruption or anti-bribery laws in other countries. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these factors could harm our future international expansion and operations and, consequently, our results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Global economic uncertainty, changes in geopolitical conditions and weakening product demand caused by political instability, changes in trade
agreements and disputes, such as the conflict between Russia and Ukraine and other macroeconomic factors, could adversely affect our business and results of operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operations and performance depend on global, regional and U.S. economic and geopolitical conditions. General worldwide economic conditions
have experienced significant instability in recent years, including due to recent global economic uncertainty and turbulent financial market conditions. Russia&#146;s ongoing military invasion of Ukraine has triggered significant sanctions from U.S.
and European leaders and disruptions to financial markets around the world. Resulting changes in U.S. trade policy could trigger retaliatory actions by Russia, its allies and other affected countries, including China, resulting in a &#147;trade
war.&#148; In addition, changes in political conditions in China and changes in the state of <FONT STYLE="white-space:nowrap">China-U.S.</FONT> relations, including any tensions relating to potential military conflict between China and Taiwan, are
difficult to predict and could adversely affect our business. Furthermore, if other countries, including the United States, become further involved in the conflict, we could face significant adverse effects to our business and financial condition.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The uncertain financial markets, disruptions in supply chains, mobility restraints, and changing priorities as well as volatile asset
values could impact our business in the future. For example, increasing inflation has raised operating costs for us and many businesses, and, in the future, could impact demand, pricing or the cost we incur to manufacture our product candidates,
foreign exchange rates (including in particular U.S. dollar and Canadian dollar exchange rates) or employee wages. Inflation rates have increased recently to levels not seen in years. Among other potential effects, increased inflation may result in
reduced liquidity and limits on our ability to access credit or otherwise raise capital. The Federal Reserve has raised, and may again raise, interest rates in response to concerns about inflation, which coupled with reduced government spending and
volatility in financial markets may have the effect of further increasing economic uncertainty and heightening these risks and creating new, unforeseen risks to our operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Actual events involving reduced or limited liquidity, defaults, <FONT STYLE="white-space:nowrap">non-performance</FONT> or other adverse
developments that affect financial institutions or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds, have in the past and may in the future lead to
market-wide liquidity problems. For example, on March&nbsp;10, 2023, Silicon Valley Bank, was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation as receiver. Although
we did not lose any cash or cash equivalent balances in connection with the collapse of Silicon Valley Bank, uncertainty and liquidity concerns in the broader financial services industry remain and the failure of Silicon Valley Bank and its
potential near- and long-term effects on the biotechnology industry and its participants, such as certain of our vendors, suppliers, and investors, may also adversely affect our operations and stock price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These conditions make it extremely difficult for us to accurately forecast and plan future business activities. The above factors, including a
number of other known and unknown economic and geopolitical factors in the United States and abroad, could ultimately have material adverse effects on our business, financial condition, results of operations and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We expect certain of our research and development and manufacturing activities may take place in <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions, such as China, through third-party CROs, collaborators or manufacturers. A significant disruption in the operation of those CROs, collaborators or manufacturers could materially adversely
affect our business and results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may contract many of our research, manufacturing and preclinical activities to
third parties outside the United States, including without limitation, in China. Any disruption in the operations of such third parties or in their ability to meet our needs, whether as a result of a natural disaster, war or other causes, could
impair our ability to operate our business on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> basis and to continue development of our programs. Furthermore, since many of these third parties are located
outside the United States, we are exposed to the possibility of disruption and increased costs in the event of changes in the policies of the United States or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> governments, war, political unrest or
unstable economic conditions in any of the countries where we conduct such activities. For example, a war or trade war could lead to tariffs, embargoes, sanctions or other limitations on trade, including without limitation those placed on Russia as
a result of its ongoing military invasion of Ukraine, that may affect our ability to source from affected third parties the reagents and raw materials used in our product candidates. Additionally, a natural disaster, war, civil or political unrest
or similar circumstances could hinder our ability to maintain or initiate clinical studies at our preferred sites, causing trial initiation or implementation delays. Any of these matters could materially and adversely affect our product development
timelines, business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Additional laws and regulations governing international operations
may preclude or delay us from developing, manufacturing or selling certain products and product candidates outside the United States, which could limit our growth potential and increase our development costs. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As an international company with operations outside of the United States, we must dedicate additional resources to comply with numerous laws
and regulations in each jurisdiction in which we operate. The FCPA prohibits any U.S. individual or business from paying, offering, authorizing payment or offering of anything of value, directly or indirectly, to any
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> official, political party or candidate for the purpose of influencing any act or decision of the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> entity in order to assist the individual or business
in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring the company to maintain books and records that accurately and fairly
reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the
FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government and doctors and other hospital employees are considered <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Various laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with
certain <FONT STYLE="white-space:nowrap">non-U.S.</FONT> nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. As we continue to expand our presence outside of
the United States, we will need to dedicate additional resources to complying with these laws, and these laws may preclude us from developing, manufacturing or selling certain products and product candidates outside of the United States, which could
limit our growth potential and increase our development costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The failure to comply with laws governing international business practices
may result in substantial civil and criminal penalties and suspension or debarment from government contracting. The SEC also may suspend or bar issuers from trading securities on U.S. securities exchanges for violations of the FCPA&#146;s accounting
provisions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks Related to Our Intellectual Property </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to obtain and maintain, enforce and defend patent protection for any product candidates we develop or for our novel gene therapy
platform, or if the scope of the patent protection obtained is not sufficiently broad, our competitors or other third parties could develop and commercialize products or technology similar or identical to ours and our ability to successfully
commercialize any product candidates we may develop and our technology may be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success depends in large
part on our and our licensors&#146; ability to seek, obtain and maintain patent and other intellectual property protection in the United States, Canada and other jurisdictions with respect to any product candidates we may develop and our technology,
including our gene therapy platform, manufacturing processes and their respective components, formulations, combination therapies, methods of treatment, processes and development that are important to our business, as well as successfully defending
these patents and other intellectual property against third-party challenges. The risks associated with patent rights generally apply to patent rights that we <FONT STYLE="white-space:nowrap">in-license</FONT> now or in the future, as well as patent
rights that we may own now or in the future. We have sought, and will seek, to protect our proprietary position by filing patent applications in the United States and abroad related to certain technologies and our gene therapy platform that are
important to our business. However, elements of our patent portfolio are at an early stage and there can be no assurance as to whether or when such patent applications will issue as granted patents. Our ability to stop third parties from making,
using, selling, marketing, offering to sell, importing and commercializing any product candidates we may develop and our technology is dependent upon the extent to which we and our licensors have rights under valid and enforceable patents and other
intellectual property that cover our gene therapy platform and proprietary technology. If we are or our licensors are unable to secure, maintain, defend and enforce patents and other intellectual property with respect to any product candidates or
technology that we may develop, it would have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We own certain granted patents and pending patent applications which cover our gene therapy platform, use and/or function, product candidates
and their use, and manufacturing processes, as applicable. Our pending Patent Cooperation Treaty (&#147;PCT&#148;) patent application, and any PCT application we may file in the future, is not eligible to become issued patents until, among other
things, we file one or more national stage patent applications within 30 to 32 months, depending on the jurisdiction, from such application&#146;s priority date in the jurisdictions in which we are seeking patent protection. Similarly, should we in
the future file a pending provisional patent application such application would not be eligible to become an issued patent until, among other things, we file a <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application within 12
months of such provisional patent application&#146;s filing date. If we do not timely file such national stage patent applications or <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent applications, we may lose our priority date with
respect to such PCT or provisional patent applications, respectively, and any patent protection on the inventions disclosed in such PCT or provisional patent applications, respectively. While we and our licensors intend to timely file national stage
and <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent applications relating to our PCT and provisional patent applications, respectively, we cannot predict whether any such patent applications will result in the issuance of patents. If
we or our licensors do not successfully obtain issued patents, or, if the scope of any patent protection we or our licensors obtain is not sufficiently broad, we will be unable to prevent others from using any product candidates we may develop or
our technology or from developing or commercializing technology and products similar or identical to ours or other competing products and technologies. Any failure to obtain or maintain patent protection with respect to gene therapy platform,
manufacturing processes or our product candidates and technology would have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent prosecution process is expensive, time-consuming and complex, and we and our licensors may not be able to file, prosecute,
maintain, defend, enforce or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. We and our licensors may not be able to obtain, maintain or defend patents and patent applications due to the subject
matter claimed in such patents and patent applications being in the public domain. For example, in some cases, the work of certain academic researchers in the genetic medicine field has entered or will enter the public domain, which may compromise
our and our licensors&#146; ability to obtain </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
patent protection for certain inventions related to or building upon such prior work. It is also possible that we will fail to identify patentable aspects of our research and development output
before it is too late to obtain patent protection. Although we enter into <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and
development output, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach these agreements and disclose such output
before a patent application is filed, thereby jeopardizing our ability to seek patent protection. Consequently, we would not be able to prevent any third-party from using any of our technology that is in the public domain to compete with our product
candidates and technology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves
complex legal and factual questions and has, in recent years, been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of patent rights are highly uncertain. Our pending and future owned
and licensed patent applications may not result in patents being issued which protect our technology or product candidates, effectively prevent others from commercializing competitive technologies and products or otherwise provide any competitive
advantage. In fact, patent applications may not issue as patents at all, and even if such patent applications do issue as patents, they may not issue in a form, or with a scope of claims, that will provide us with any meaningful protection, prevent
others from competing with us or otherwise provide us with any competitive advantage. In addition, the scope of claims in a patent application can be significantly reduced before the patent is issued, and such scope of an issued patent can be
reinterpreted after issuance, and changes in either the patent laws or interpretation of the patent laws in the United States and other jurisdictions may diminish the value of our patent rights or narrow the scope of our patent protection.
Furthermore, our competitors or other third parties may be able to circumvent our patents by developing similar or alternative technologies or products in a <FONT STYLE="white-space:nowrap">non-infringing</FONT> manner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third parties have developed technologies that may be related or competitive to our own technologies and product candidates and may have filed
or may file patent applications, or may have obtained or may obtain issued patents, claiming inventions that may overlap or conflict with those claimed in our owned or licensed patent applications or issued patents. We may not be aware of all
third-party intellectual property rights potentially relating to our current and future product candidates and technology. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in
the United States and other jurisdictions are typically not published until 18 months after filing or, in some cases, not at all. Therefore, we cannot know for certain whether the inventors of our owned or licensed patents and patent applications
were the first to make the inventions claimed in any owned or licensed patents or pending patent applications, or that we were the first to file for patent protection of such inventions. If a third-party can establish that we or our licensors were
not the first to make or the first to file for patent protection of such inventions, our owned or licensed patent applications may not issue as patents and even if issued, may be challenged and invalidated or ruled unenforceable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may in the future be subject to claims that former employees, collaborators, or other third parties have an interest in our patents or
other intellectual property as an inventor or <FONT STYLE="white-space:nowrap">co-inventor.</FONT> For example, inventorship disputes may arise from conflicting obligations of consultants or others who are involved in developing our product
candidates. Litigation may be necessary to defend against these and other claims challenging inventorship. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as
exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business, financial condition, results of operations and prospects. Even if we are successful in defending against
such claims, litigation could result in substantial costs and be a distraction to management and other employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The issuance of a
patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States and other jurisdictions. For example, we may be subject to
a third-party submission of prior art to the U.S. Patent and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Trademark Office (&#147;USPTO&#148;) challenging the validity of one or more claims of our owned or licensed patents. Such submissions may also be made prior to a patent&#146;s issuance,
precluding the granting of a patent based on one of our owned or licensed pending patent applications. We may become involved in opposition, derivation, <FONT STYLE="white-space:nowrap">re-examination,</FONT> inter partes review, post-grant review
or interference proceedings and similar proceedings in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions (for example, opposition proceedings) challenging the validity, priority or other features of patentability of our owned or
licensed patent rights. In addition, a third-party may claim that our owned or licensed patent rights are invalid or unenforceable in a litigation. The outcome following legal assertions of invalidity and unenforceability is unpredictable. An
adverse result in any litigation or patent office proceeding could put one or more of our owned or licensed patents at risk of being invalidated, ruled unenforceable or interpreted narrowly and could allow third parties to commercialize products
identical or similar to any product candidates we may develop and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. Moreover, we, or one
of our licensors, may have to participate in interference proceedings declared by the USPTO to determine priority of invention or in post-grant challenge proceedings, such as oppositions in a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> patent
office, that challenge priority of invention or other features of patentability. Such challenges and proceedings may result in loss of patent rights, exclusivity, freedom to operate or in patent claims being narrowed, invalidated or held
unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the scope and duration of the patent protection of our technology and any product
candidates we may develop. Such challenges and proceedings may also result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us. Moreover, there could be public
announcements of the results of hearings, motions or other interim proceedings or developments related to such challenges and proceedings and if securities analysts or investors perceive these results to be negative, it could have a substantial
adverse effect on the price of our common shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may in the future <FONT STYLE="white-space:nowrap">co-own</FONT> intellectual
property rights relating to our gene therapy platform and our future product candidates with third parties. In addition, our licensors may <FONT STYLE="white-space:nowrap">co-own</FONT> the patent rights we
<FONT STYLE="white-space:nowrap">in-license</FONT> with other third parties with whom we do not have a direct relationship. If we or our licensors do not have exclusive control of the grant of licenses under any such third-party <FONT
STYLE="white-space:nowrap">co-owners&#146;</FONT> interest in such patent rights or we or our licensors are otherwise unable to secure such exclusive rights, such <FONT STYLE="white-space:nowrap">co-owners</FONT> may be able to license their rights
to other third parties, including our competitors, and our competitors could market competing products and technology. In addition, we may need the cooperation of any such <FONT STYLE="white-space:nowrap">co-owners</FONT> of our patent rights in
order to enforce such patent rights against third parties and such cooperation may not be provided to us. Further, any such <FONT STYLE="white-space:nowrap">co-owner</FONT> may be able to license a <FONT STYLE="white-space:nowrap">co-owned</FONT>
patent to a third-party we believe infringes such patent, preventing us from obtaining compensation or other remedies from such third-party through litigation or settlement arrangements. We may also become engaged in disputes with our <FONT
STYLE="white-space:nowrap">co-owners</FONT> related to patent prosecution strategy or the apportionment of costs associated with the prosecution, maintenance or enforcement of <FONT STYLE="white-space:nowrap">co-owned</FONT> patents or patent
applications. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Issued patents covering our product candidates or gene therapy platform could be found invalid or unenforceable if challenged in court or before
administrative bodies in the United States or other jurisdictions. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we initiated legal proceedings against a third-party to
enforce a patent covering our gene therapy platform, product candidates or other technologies, the defendant could counterclaim that such patent is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging
invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, written description,
<FONT STYLE="white-space:nowrap">non-enablement</FONT> or failure to claim patent-eligible subject matter. Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent withheld
information material to patentability from the USPTO, or made a misleading statement, during prosecution. Third parties may raise claims </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
challenging the validity or enforceability of our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents before administrative bodies in the United States or abroad, even outside
the context of litigation. Such mechanisms include <FONT STYLE="white-space:nowrap">re-examination,</FONT> post-grant review, inter partes review, interference proceedings, derivation proceedings and equivalent proceedings in <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions (e.g., opposition proceedings). Such proceedings could result in the revocation of, cancellation of, or amendment to our patents in such a way that they no longer cover our product candidates
or other technologies or prevent third parties from competing with us. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is
no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a third-party were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent
protection on the gene therapy platform, our product candidates or other technologies. Such a loss of patent protection would have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements
imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these requirements. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents and patent applications will be due to be
paid to the USPTO and various <FONT STYLE="white-space:nowrap">non-U.S.</FONT> government patent agencies over the lifetime of our owned or licensed patents and patent applications. In certain circumstances, we may rely on our licensing partners to
pay these fees due to the USPTO and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> patent agencies. The USPTO and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> patent agencies require compliance with several procedural, documentary, fee payment
and other similar provisions during the patent application process. We may also be dependent on our licensors to take the necessary action to comply with these requirements with respect to our licensed intellectual property. In some cases, an
inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which <FONT STYLE="white-space:nowrap">non-compliance</FONT> can result in abandonment or lapse of
the patent or patent application, resulting in a partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market with similar or identical products or technologies,
which could have a material adverse effect on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in either patent laws
or interpretation of the patent laws in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our product candidates and gene therapy platform. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs
surrounding the prosecution of patent applications and the enforcement or defense of issued patents. Prior to March 2013, in the United States, the first to invent an invention was entitled to a patent claiming the invention, while outside the
United States, the first to file a patent application was entitled to the patent, assuming that other requirements for patentability were met. After March 2013, under the Leahy-Smith America Invents Act (the &#147;America Invents Act&#148;) enacted
in September 2011, the United States transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application is entitled to the patent on an invention,
regardless of whether a third-party was the first to invent the claimed invention. A third-party that files a patent application in the USPTO after the date of invention but before the filing date of our owned or
<FONT STYLE="white-space:nowrap">in-licensed</FONT> patent application could therefore be awarded a patent covering an invention of ours, even if we had made the invention before it was made by the third-party. This will require us and our licensors
to be aware going forward of the time from invention to filing of a patent application. Furthermore, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our technologies and the prior art allow
our technologies to be patentable over the prior art. Since patent applications in the United States and most other countries are confidential for a period of time after filing, we cannot be certain that we were the first to either (1)&nbsp;file any
patent application related to our technologies or product candidates or (2)&nbsp;invent any of the inventions claimed in our patents or patent applications. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The America Invents Act also includes a number of significant changes that affect the way
patent applications are prosecuted and may also affect patent litigation. These include allowing third-party submissions of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by
USPTO-administered post-grant proceedings, including post-grant review, inter partes review, and derivation proceedings. Because the evidentiary standard in USPTO proceedings is lower than the evidentiary standard in U.S. federal court necessary to
invalidate a patent claim, a third-party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid, even though the same evidence would be insufficient to invalidate the claim if first presented in a
district court action. Accordingly, a third-party may attempt to use USPTO proceedings to invalidate our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent claims that would not have been invalidated if first challenged by the
third-party as a defendant in a district court action. Accordingly, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our owned and
<FONT STYLE="white-space:nowrap">in-licensed</FONT> patent applications and the enforcement or defense of our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> issued patents, all of which could have a material adverse effect on our
business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the patent positions of companies in the development and
commercialization of pharmaceuticals are particularly uncertain. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination
of events has created uncertainty with respect to the validity and enforceability of patents. We cannot predict how decisions by the courts, the U.S. Congress or the USPTO may impact the value of our owned or
<FONT STYLE="white-space:nowrap">in-licensed</FONT> patents. Any similar adverse changes in the patent laws of other jurisdictions could also have a material adverse effect on our business, financial condition, results of operations and prospects.
Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our existing patent portfolio and our
ability to protect and enforce our intellectual property in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent terms may be inadequate to protect our competitive position, product
candidates or gene therapy platform for an adequate amount of time, and we may need to obtain patent term extension and equivalent extensions outside of the United States for our product candidates or gene therapy platform. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally
20 years from its earliest filing date of the first U.S. <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application to which the patent claims priority. Various adjustments and extensions may be available, but the life of a patent
and the protection it affords is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including biosimilars. Given the amount of time
required for the development, testing and regulatory review of new product candidates, patents protecting our product candidates might expire before or shortly after we commercialize those candidates. As a result, our owned and licensed patent
portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending upon the timing, duration and specifics of any FDA marketing approval of our product candidates or gene therapy platform, one or
more U.S. patents that we own or license may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984 (&#147;the Hatch-Waxman Amendments&#148;). The Hatch-Waxman Amendments permit a
patent extension term of up to five years as compensation for patent term lost during the FDA regulatory review process based on the first regulatory approval for a particular drug or biologic. A patent term extension cannot extend the remaining
term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it or a method for manufacturing it may be extended. In Europe,
supplementary protection certificates are available to extend a patent term up to five years to compensate for patent term lost during regulatory review, and can be extended for an additional six months if data from clinical trials is obtained in
accordance with an agreed-upon pediatric investigation plan. Although all countries in Europe must provide supplementary protection certificates, there is no unified legislation among European </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
countries and so supplementary protection certificates must be applied for and granted on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT>
basis. This can lead to a substantial cost to apply for and receive these certificates, which may vary among countries or not be provided at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be granted any extensions for which we apply in the United States or any other jurisdiction because of, for example, failing to
exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover,
the applicable time period or the scope of patent protection afforded could be less than we request. In addition, to the extent we wish to pursue patent term extension based on a patent that we <FONT STYLE="white-space:nowrap">in-license</FONT> from
a third-party, we would need the cooperation of that third-party. If we are unable to obtain patent term extension, or the foreign equivalent, or if the term of any such extension is less than we request, our competitors may be able to enter the
market sooner, and our revenue could be reduced. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our rights to develop and commercialize our product candidates and gene therapy platform may be subject, in part, to the terms and conditions of
licenses. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are reliant upon licenses to certain intellectual property and proprietary technologies from third parties that are
important or necessary to the development of our technologies and product candidates. We have entered into license agreements with third parties and may need to obtain additional licenses from others to advance our research or allow
commercialization of product candidates we may develop. It is possible that we may be unable to obtain or maintain additional licenses at a reasonable cost or on reasonable terms, if at all. In that event, we may be required to expend significant
time and resources to redesign our technologies, product candidates, or the methods for manufacturing them or to develop or license replacement technologies, all of which may not be feasible on a technical or commercial basis. If we are unable to do
so, we may be unable to develop or commercialize the affected product candidates, which could significantly harm our competitive position, business, financial condition, results of operations and prospects. We cannot provide any assurances that
third-party patents do not exist which might be enforced against our technologies and product candidates resulting in either an injunction prohibiting our manufacture or sales, or, with respect to our sales, an obligation on our part to pay
royalties and/or other forms of compensation to third parties, which could be significant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our current and future licenses may not
provide exclusive rights to use such intellectual property and proprietary technologies in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technologies and products in the future. As a result,
we may not be able to prevent competitors from developing and commercializing competitive products in territories included in all of our licenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, subject to the terms of any such license agreements, we may not have the right to control the preparation, filing, prosecution,
maintenance, enforcement, and defense of patents and patent applications covering the technologies that we license from third parties. In such an event, we cannot be certain that these patents and patent applications will be prepared, filed,
prosecuted, maintained, enforced, and defended in a manner consistent with the best interests of our business or in compliance with applicable laws and regulations, or will result in valid and enforceable patents and other intellectual property
rights. It is possible that our licensors&#146; infringement proceedings or defense activities may be less vigorous than had we conducted them ourselves or may not be conducted in accordance with our best interests. If our licensors fail to
prosecute, maintain, enforce, and defend such patents, or lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated, and our right to develop and commercialize any of our products that are subject
of such licensed rights could be adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our licensors may have relied on third-party consultants or collaborators or on
funds from third parties such that our licensors are not the sole and exclusive owners of the patents we <FONT STYLE="white-space:nowrap">in-licensed.</FONT> If other third parties have </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
ownership rights to our <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents, they may be able to license such patents to our competitors, and our competitors could market competing
products and technologies. This could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In spite of our best efforts, our licensors might conclude that we have materially breached our license agreements and might therefore
terminate our license agreements, thereby removing our ability to develop and commercialize products and technologies covered by these license agreements. If these license agreements are terminated, or if the underlying patents fail to provide the
intended exclusivity, competitors would have the freedom to seek regulatory approval of, and to market, products identical to ours. This could have a material adverse effect on our competitive position, business, financial condition, results of
operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be unable to acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> any relevant third-party intellectual
property rights that we identify as necessary or important to our business and results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may be unable to acquire
or <FONT STYLE="white-space:nowrap">in-license</FONT> intellectual property rights from third parties relating to, or necessary for, the development of our product candidates on commercially reasonable terms, or at all. In that event, we may be
unable to develop or commercialize such product candidates. Because our programs may involve additional product candidates that may require the use of proprietary rights held by third parties, the growth of our business will likely depend in part on
our ability to acquire, <FONT STYLE="white-space:nowrap">in-license</FONT> or use these proprietary rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product candidates may
also require specific formulations to work effectively and efficiently and these rights may be held by others. We may develop products containing our compounds and <FONT STYLE="white-space:nowrap">pre-existing</FONT> pharmaceutical compounds. We may
be required by the FDA or comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities to provide a companion diagnostic test or tests with our product candidates, which test or tests may be covered by intellectual property
rights held by others. We may be unable to acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary
or important to our business operations. In addition, we may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all, which would harm our business. Were that to happen, we may need to cease use of the
compositions or methods covered by those third-party intellectual property rights and seek to develop alternative approaches that do not infringe on those intellectual property rights, which may entail additional costs and development delays, even
if we were able to develop such alternatives, which may not be feasible. Even if we are able to obtain a license, it may be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> which means that our competitors may also receive access to the same
technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The licensing and acquisition of third-party intellectual property rights is a competitive area and companies that may be more established or
have greater resources than we do may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our product candidates. More established
companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. Furthermore, companies that perceive us to be a competitor may be unwilling to assign or
license rights to us. In addition, we expect that competition for the <FONT STYLE="white-space:nowrap">in-licensing</FONT> or acquisition of third-party intellectual property rights for product candidates that are attractive to us may increase in
the future, which may mean fewer suitable opportunities for us as well as higher acquisition or licensing costs. We may be unable to <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire the third-party intellectual property rights for
product candidates on terms that would allow us to make an appropriate return on our investment. If we are unable to successfully obtain rights to suitable product candidates, our business, financial condition, results of operations and prospects
for growth may be harmed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply with our obligations under the agreements pursuant to which we license
intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose the rights to intellectual property that are important to our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license under certain patents and/or
<FONT STYLE="white-space:nowrap">know-how</FONT> to develop and commercialize certain elements or components of our potential product candidates which may not be available elsewhere. Our existing license agreements impose, and we expect that any
future license agreements will impose on us, various obligations. If we fail to comply with our obligations under these agreements, the licensor may have the right to terminate the license. If any of our licenses are terminated and we are not able
to negotiate other agreements for use of the intellectual property protections underlying these product candidates, we would not be able to manufacture and market these potential products, which would have a material adverse effect on our business,
financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, disputes may arise regarding intellectual property subject to a
licensing agreement, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of rights granted under the license agreement and other interpretation-related issues;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial or other obligations under the license agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which our product candidates, technology and processes infringe on intellectual property of the
licensor that is not subject to the licensing agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the sublicensing of patent and other rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inventorship and ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from
the joint creation or use of intellectual property by any licensors or partners&#146; licensors; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the priority of invention of patented technology. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, certain provisions in our license agreements may be susceptible to multiple interpretations. The resolution of any contract
interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the agreement,
either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our
current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on our competitive position, business, financial
condition, results of operations and prospects. In addition, certain of these license agreements, may not be assignable by us without the consent of the respective licensor, which may have an adverse effect on our ability to engage in certain
transactions. Moreover, we may seek to obtain additional licenses from our licensors and, in connection with obtaining such licenses, we may agree to amend our existing licenses in a manner that may be more favorable to the licensors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to protect our intellectual property and proprietary rights throughout the world. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Filing, prosecuting and defending patents on our product candidates and other technologies in all countries throughout the world would be
prohibitively expensive, and our intellectual property rights in some countries outside of the United States and Canada are less extensive than those in the United States and Canada. In addition, the laws of countries outside the United States and
Canada may not protect our or our licensors&#146; rights to the same extent as the laws of the United States and Canada, even in jurisdictions where we or our licensors do pursue patent protection. Consequently, we may not be able to prevent third
parties from practicing our or our licensors&#146; inventions in all countries outside the United States and Canada, even in jurisdictions where we or our licensors do pursue patent protection, or from selling or importing products made using our
inventions in and into </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the United States, Canada or other jurisdictions. Competitors may use our technologies in jurisdictions where we and our licensors have not obtained patent protection to develop their own
products and, further, may export otherwise infringing products to territories where we have patent protection but enforcement is not as strong as that in the United States and Canada. These products may compete with our products and our or our
licensors&#146; patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many
companies have encountered significant problems in protecting and defending intellectual property rights in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions. The legal systems of certain countries, particularly certain developing
countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents, if
pursued and obtained, or marketing of competing products in violation of our intellectual property and proprietary rights generally. Proceedings to enforce our or our licensors&#146; intellectual property and proprietary rights in <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our or our licensors&#146; patents at risk of being invalidated or
interpreted narrowly, could put our or our licensors&#146; patent applications at risk of not issuing and could provoke third parties to assert claims against us. We or our licensors may not prevail in any lawsuits that we or our licensors initiate,
and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial
advantage from the intellectual property that we develop or license. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many countries have compulsory licensing laws under which a patent
owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which
could materially diminish the value of such patent. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be harmed and our business, financial
condition, results of operations and prospects may be adversely affected. Patent protection must ultimately be sought on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, which is an
expensive and time-consuming process with uncertain outcomes. Accordingly, we may choose not to seek patent protection in certain countries and we will not have the benefit of patent protection in such countries. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be involved in legal proceedings in relation to intellectual property rights and to protect or enforce our patents or the patents of our
licensors, which could be expensive, time-consuming and unsuccessful. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competitors may infringe our patents or the patents of our
licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming, and we may not have the financial resources to do so. In addition, in an infringement proceeding, a
court may decide that one or more of our patents is not valid or is unenforceable or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in
any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, held unenforceable or interpreted narrowly and could put our patent applications at risk of not issuing. Defense of these types of claims,
regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may choose to challenge the patentability of claims in a third-party&#146;s U.S. patent by requesting that the USPTO review the patent
claims in an <FONT STYLE="white-space:nowrap">ex-parte</FONT> <FONT STYLE="white-space:nowrap">re-examination,</FONT> inter partes review or post-grant review proceedings. These proceedings are expensive and may consume our time or other resources.
We may choose to challenge a third-party&#146;s patent in patent opposition proceedings in the European Patent Office (&#147;EPO&#148;), or another <FONT STYLE="white-space:nowrap">non-U.S.</FONT> patent office. The costs of these opposition
proceedings could be substantial, and may consume our time or other resources. If we fail to obtain a favorable result at the USPTO, EPO or other patent office then we may be exposed to litigation by a third-party alleging that the patent may be
infringed by our product candidates or proprietary technologies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, because some patent applications in the United States may be maintained in
secrecy until the patents are issued, patent applications are typically not published in the United States until 18 months after their respective filing dates. Further, publications in the scientific literature often lag behind actual discoveries.
Consequently, we cannot be certain that others have not filed patent applications for technology covered by our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> issued patents or our pending applications, or that we or, if applicable, a
licensor were the first to invent the technology. It is possible that our competitors may have filed, and may in the future file, patent applications covering our products or technology similar to ours and that those patent applications may have
priority over our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent applications or patents, which could require us to obtain rights to issued patents covering such technologies. If another party has filed a U.S. patent
application on inventions similar to those owned by or <FONT STYLE="white-space:nowrap">in-licensed</FONT> to us, we or, in the case of <FONT STYLE="white-space:nowrap">in-licensed</FONT> technology, the licensor may have to participate in an
interference proceeding declared by the USPTO to determine priority of invention in the United States. If we or one of our licensors is a party to an interference proceeding involving a U.S. patent application on inventions owned by or <FONT
STYLE="white-space:nowrap">in-licensed</FONT> to us, we may incur substantial costs, divert management&#146;s time and expend other resources, even if we are successful. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interference proceedings provoked by third parties or brought by the USPTO may be necessary to determine the priority of inventions with
respect to our patents or patent applications or those of our licensors. An unfavorable outcome in an interference proceeding could result in a loss of our current patent rights and could require us to cease using the related technology or to
attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms, or at all. Litigation or interference proceedings may result in a decision
adverse to our interests and, even if we are successful, may result in substantial costs and distract our management and other employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that
some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities
analysts or investors perceive these results to be negative, that perception could have a substantial adverse effect on the price of our common shares. Such litigation or proceedings could substantially increase our operating losses and reduce the
resources available for development activities or any future sales, marketing or distribution activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not have sufficient
financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors or other third parties may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their
greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our business,
financial condition, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to protect the confidentiality of our trade secrets, our business and
competitive position would be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the protection afforded by patents, we rely on trade secret
protection, confidentiality agreements, and license and other agreements to protect proprietary <FONT STYLE="white-space:nowrap">know-how</FONT> that is not patentable or that we elect not to patent, processes for which patents are difficult to
enforce and any other elements of our product discovery and development processes that involve proprietary <FONT STYLE="white-space:nowrap">know-how,</FONT> information, or technology that is not covered by patents. We cannot be certain that our
trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Furthermore, the
laws of some countries outside of the United States do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our
intellectual property both in the United States and abroad. If we are unable to prevent unauthorized material disclosure of our intellectual property to third parties, we will not be able to establish or maintain a competitive advantage in our
market, which could materially adversely affect our business, operating results and financial condition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some courts both within and outside the United States and Canada are sometimes less willing
or unwilling to protect trade secrets. If we choose to go to court to stop a third-party from using any of our trade secrets, we may incur substantial costs. These lawsuits may consume our time and other resources even if we are successful. For
example, significant elements of our gene therapy platform and product candidates, including aspects of sample preparation, methods of manufacturing, cell culturing conditions, computational-biological algorithms and related processes are based on
unpatented trade secrets that are not publicly disclosed. Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may independently
develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Thus, we may not be able to meaningfully protect our trade secrets. It is our policy to require our employees, consultants, outside scientific
collaborators, sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide that certain information and data concerning our business
made known to the individual or entity during the course of the party&#146;s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. However, we may not be able to prevent the unauthorized
disclosure or use of our technical <FONT STYLE="white-space:nowrap">know-how</FONT> or other trade secrets by the parties to these agreements. Monitoring unauthorized uses and disclosures is difficult and we do not know whether the steps we have
taken to protect our proprietary technologies will be effective. Moreover, we cannot guarantee that we have entered into such agreements with each party that may have or has had access to our trade secrets or proprietary technology and processes. In
addition, we take other appropriate precautions, such as physical and technological security measures, to guard against misappropriation of our proprietary technology by third parties. We have also adopted policies and conduct training that provides
guidance on our expectations, and our advice for best practices, in protecting our trade secrets. However, we cannot provide assurance that these agreements and policies will not be breached by our employees, consultants, outside scientific
collaborators, sponsored researchers and other advisors and that our trade secrets and other proprietary and confidential information will not be disclosed to publicly or to competitors. If any of the employees, consultants, outside scientific
collaborators, sponsored researchers and other advisors who are parties to these agreements breach or violate the terms of any of these agreements, we may not have adequate remedies for any such breach or violation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our trade secrets may otherwise become known or be independently discovered by competitors or other third parties. Competitors or
third parties could attempt to replicate some or all of the competitive advantages we derive from our development efforts, willfully infringe our intellectual property rights, design around our protected technology or develop their own competitive
technologies that fall outside the scope of our intellectual property rights. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third-party, we would have no right to prevent them, or those
to whom they communicate such trade secrets, from using that technology or information to compete with us. If our trade secrets are not adequately protected so as to protect our market against competitors&#146; products, our business, financial
condition, results of operations and prospects could be materially and adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Third-party claims of intellectual property
infringement, misappropriation or other violation against us, our licensors or our collaborators may prevent or delay the development and commercialization of our novel gene therapy platform, our product candidates and other technologies.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The field of biotherapeutics, including the development of gene therapies, is competitive and dynamic. Due to the focused research
and development that is taking place by several companies, including us and our competitors, in this field, the intellectual property landscape is in flux and it may remain uncertain in the future. As such, there may be significant intellectual
property related litigation and proceedings relating to our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> and other third-party intellectual property and proprietary rights in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success depends in part on our and our licensors&#146; ability to avoid infringing, misappropriating and otherwise violating
the patents and other intellectual property rights of third parties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
However, our research, development and commercialization activities may be subject to claims that we infringe, misappropriate or otherwise violate patents or other intellectual property rights
owned or controlled by third parties. There is a substantial amount of complex litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries, as well as administrative proceedings for
challenging patents, including interference, derivation and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in jurisdictions outside of the United States. As discussed above, recently, due to changes in
U.S. law referred to as patent reform, new procedures including inter partes review and post-grant review have been implemented. As stated above, this reform adds uncertainty to the possibility of challenge to our patents in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Numerous U.S., Canadian and other foreign issued patents and pending patent applications owned by third parties exist relating to gene therapy
technologies and products and in the fields in which we are developing our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our gene therapy platform, product
candidates and other technologies may give rise to claims of infringement of the patent rights of others. We cannot be sure that our gene therapy platform, product candidates and other technologies that we have developed, are developing or may
develop in the future do not infringe existing patents or will not infringe future patents owned by third parties. Many companies and institutions have filed, and continue to file, patent applications related to gene therapy and related
manufacturing methods. Some of these patent applications have already been allowed or issued and others may issue in the future. It is difficult for industry participants, including us, to identify all third-party patent rights that may be relevant
to our gene therapy platform, product candidates and other technologies because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. We may
not be aware of patents that have already been issued and that a third-party, for example, a competitor in the fields in which we are developing our gene therapy platform, product candidates and other technologies might assert are infringed by our
current or future product candidates, gene therapy platform or other technologies, including claims to compositions, formulations, methods of manufacture or methods of use or treatment that cover our gene therapy platform, product candidates and
other technologies. It is also possible that patents owned by third parties of which we are aware, but which we do not believe are relevant to our gene therapy platform, product candidates and other technologies, could be found to be infringed by
our gene therapy platform, product candidates and other technologies. In addition, because patent applications can take many years to issue, may be confidential for 18 months or more after filing and can be revised before issuance, there may be
currently pending patent applications that may later result in issued patents that our gene therapy platform, product candidates and other technologies may infringe. Furthermore, applications filed before November&nbsp;29, 2000 and certain
applications filed after that date that will not be filed outside the United States may remain confidential until a patent issues. Additionally, pending patent applications that have been published can, subject to certain limitations, be later
amended in a manner that could cover our product candidates or technologies. We cannot provide any assurances that third-party patents do not exist which might be enforced against our current technology, including our gene therapy platform,
manufacturing methods, product candidates, or future methods or products resulting in either an injunction prohibiting our manufacture or future sales, or, with respect to our future sales, an obligation on our part to pay royalties and/or other
forms of compensation to third parties, which could be significant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third parties have patents and may obtain patents in the future and
may claim that the manufacture, use or sale of our gene therapy platform, product candidates or other technologies infringes upon these patents. Patent and other types of intellectual property litigation can involve complex factual and legal
questions, and their outcome is uncertain. In the event that any third-party claims that we infringe their patents or that we are otherwise employing their proprietary technology without authorization and initiates litigation against us, even if we
believe such claims are without merit, a court of competent jurisdiction could hold that such patents are valid, enforceable and infringed by our gene therapy platform, product candidates or other technologies. In order to successfully challenge the
validity of any such U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is
no assurance that a court of competent jurisdiction would </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
invalidate the claims of any such U.S. patent or find that our product candidates or technology did not infringe any such claims. Further, even if we were successful in defending against any such
claims, such claims could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business. If we are found to infringe, misappropriate or otherwise violate a third-party&#146;s valid and
enforceable patent rights, the holders of such patents may be able to block our ability to commercialize the applicable product candidate or technology unless we obtain a license under the applicable patents, or until such patents expire or are
finally determined to be held invalid or unenforceable. Such a license may not be available on commercially reasonable terms or at all. Even if we are able to obtain a license, the license would likely obligate us to pay substantial license fees or
royalties or both and the rights granted to us might be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> which could result in our competitors and other third parties gaining access to the same intellectual property. If we are unable to obtain
a necessary license to a third-party patent on commercially reasonable terms, we may be unable to commercialize our gene therapy platform, product candidates or other technologies, or such commercialization efforts may be significantly delayed,
which could in turn significantly harm our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Defense of infringement claims, regardless of their merit, would involve substantial
litigation expense and would be a substantial diversion of management and other employee resources from our business and may impact our reputation. In the event of a successful claim of infringement against us, we may be enjoined from further
developing, manufacturing or commercializing our infringing gene therapy platform, product candidates or other technologies. In addition, we may have to pay substantial damages, including treble damages and attorneys&#146; fees for willful
infringement, obtain one or more licenses from third parties, pay royalties and/or redesign our infringing product candidates or technologies, which may be impossible or require substantial time and monetary expenditure. In that event, we would be
unable to further develop and commercialize the gene therapy platform, our product candidates or other technologies, which could harm our business significantly. Moreover, we may face patent infringement claims from nonpracticing entities that have
no relevant product revenue and against whom our owned or licensed patent portfolio may therefore have no deterrent effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Engaging in
litigation to defend against third parties alleging that we have infringed, misappropriated or otherwise violated their patents or other intellectual property rights is very expensive, particularly for a company of our size and time-consuming. Some
of our competitors may be able to sustain the costs of litigation or administrative proceedings more effectively than we can because of greater financial resources. Patent litigation and other proceedings may also absorb significant management time.
Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings against us could have an adverse effect on our ability to raise additional funds and attract collaborators and could impair our ability to compete
in the marketplace. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be
compromised by disclosure. The occurrence of any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims asserting that our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of their
current or former employers or claims asserting ownership of what we regard as our own intellectual property. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of our
employees, consultants or advisors are currently, or were previously, employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees,
consultants and advisors do not use the proprietary information or <FONT STYLE="white-space:nowrap">know-how</FONT> of others in their work for us, we may be subject to claims that these individuals or we have used or disclosed intellectual
property, including trade secrets or other proprietary information, of any such individual&#146;s current or former employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying
monetary damages, we may lose valuable intellectual property rights or be required to obtain licenses to such intellectual property rights, which may not be available on commercially reasonable terms or at all. An inability to incorporate such
intellectual property rights would harm our business and may prevent us from successfully commercializing any product candidates we may develop or at all. In </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
addition, we may lose personnel as a result of such claims and any such litigation or the threat thereof may adversely affect our ability to hire employees or contract with independent
contractors. A loss of key personnel or their work product could hamper or prevent our ability to commercialize any product candidates we may develop and our technology, which would have a material adverse effect on our business, results of
operations, financial condition and prospects. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to our scientific and management personnel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of
intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own.
Moreover, even when we obtain agreements assigning intellectual property to us, the assignment of intellectual property rights may not be self-executing or the assignment agreements may be breached, and we may be forced to bring claims against third
parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Furthermore, individuals executing agreements with us may have <FONT STYLE="white-space:nowrap">pre-existing</FONT>
or competing obligations to a third-party, such as an academic institution, and thus an agreement with us may be ineffective in perfecting ownership of inventions developed by that individual. Disputes about the ownership of intellectual property
that we own may have a material adverse effect on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we
or our licensors may in the future be subject to claims by former employees, consultants or other third parties asserting an ownership right in our owned or licensed patent rights. An adverse determination in any such submission or proceeding may
result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar technology and
therapeutics, without payment to us, or could limit the duration of the patent protection covering our technology and any product candidates we may develop. Such challenges may also result in our inability to develop, manufacture or commercialize
our technology and product candidates without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our owned or licensed patent rights are threatened, it could dissuade companies from collaborating
with us to license, develop or commercialize current or future technology and product candidates. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual property rights do not necessarily address all potential threats to our competitive advantage. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations
and may not adequately protect our business or permit us to maintain our competitive advantage. For example: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may be able to make next generation cancer and infectious disease immunotherapies that are similar to ours
but that are not covered by the claims of the patents that we own or have licensed; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we or our licensors or future collaborators might not have been the first to make the inventions covered by the
issued patents or pending patent applications that we own or have licensed; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we or our licensors or future collaborators might not have been the first to file patent applications covering
certain of our inventions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without
infringing our intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is possible that our pending patent applications or those that we license will not lead to issued patents;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issued patents that we own or have licensed may be held invalid or unenforceable, including as a result of legal
challenges by our competitors; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may have access to the same intellectual property rights licensed to us in the future on a nonexclusive
basis; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitors might conduct research and development activities in countries where we do not have patent rights
and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may choose not to file a patent for certain trade secrets or <FONT STYLE="white-space:nowrap">know-how,</FONT>
and a third-party may subsequently file a patent covering such intellectual property; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not develop additional proprietary technologies that are patentable; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the patents of others may have an adverse effect on our business. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should any of these events occur, they could significantly harm our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to protect and enforce our trademarks and trade names, or build name recognition in our markets of interest thereby harming our
competitive position. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our current and future trademark applications in the United States and in foreign jurisdictions may not be
allowed or may subsequently be opposed. Once filed and registered, our registered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect
our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our
ability to build brand identity and possibly leading to market confusion. As a means to enforce our trademark rights and prevent infringement, we may be required to file trademark claims against third parties or initiate trademark opposition
proceedings. This can be expensive and time-consuming, particularly for a company of our size. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that
incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our
business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and
diversion of resources and could adversely affect our competitive position, business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks Related to Acquisitions and Collaborations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will need to grow the size of our organization, both organically and through acquisitions, and we may experience difficulties identifying and hiring
the right employees and successfully managing this growth. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of July&nbsp;31, 2023, we had 33 employees, three of whom worked
less than full-time and we are engaged with eight consultants (contractors) on a regular basis. As our development and commercialization plans and strategies develop, we may experience significant growth in the number of our employees and the scope
of our operations, particularly in the areas of technology research, product development and manufacturing, regulatory affairs and, if any product candidates are submitted for or receive marketing approval, sales, marketing and distribution. Our
management, personnel and systems currently in place may not be adequate to support this future growth. Future growth would impose significant added responsibilities on members of management, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">managing our preclinical studies and clinical trials effectively; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identifying, recruiting, integrating, maintaining and motivating additional employees; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">managing our internal development efforts effectively, including the clinical and FDA review process for our
product candidates, while complying with our contractual obligations to contractors, licensors and other third parties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">improving our operational, financial and management controls, reporting systems and procedures; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expanding our facilities. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our future financial performance and our ability to commercialize our product candidates may depend, in part, on our ability to effectively
manage any future growth and our management may also have to divert a disproportionate amount of its attention away from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities in order to devote a
substantial amount of time to managing these growth activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently rely, and for the foreseeable future will continue to rely,
in substantial part on certain independent organizations, advisors, contractors and consultants to provide certain services, including substantially all aspects of regulatory approval, clinical management and manufacturing. There can be no assurance
that the services of independent organizations, advisors, contractors and consultants will continue to be available to us on a timely basis when needed or that we will be able to find qualified replacements. In addition, if we are unable to
effectively manage our outsourced activities or if the quality or accuracy of the services provided by independent organizations, advisors, contractors or consultants is compromised for any reason, our clinical trials may be extended, delayed or
terminated and we may not be able to obtain regulatory approval of our product candidates or otherwise advance our business. There can be no assurance that we will be able to manage our existing independent organizations, advisors, contractors or
consultants or find other competent resources on economically reasonable terms, or at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are not able to effectively expand our
organization by hiring new employees and expanding the roster of independent organizations, advisors and consultants on whom we rely on an outsourced basis, we may not be able to successfully implement the tasks necessary to further develop and
commercialize our product candidates and, accordingly, may not achieve our research, development and commercialization goals. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Acquisitions,
collaborations or other strategic partnerships may increase our capital requirements, dilute our shareholders, cause us to incur debt or assume contingent liabilities and subject us to other risks. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may from time to time evaluate collaborations and strategic partnerships or potential acquisitions, including licensing or acquiring
molecules for use in our gene therapy platform, intellectual property rights, technologies or businesses. For example, we may seek collaboration arrangements for the commercialization, or potentially for the development, of certain of our product
candidates depending on the merits of retaining commercialization rights for ourselves as compared to entering into collaboration arrangements. Collaboration, strategic partnerships or acquisitions entail numerous risks, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">increased operating expenses and cash requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced control over the development of certain of aspects of our gene therapy platform or product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the assumption of indebtedness or contingent liabilities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the issuance of our equity securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assimilation of operations, intellectual property and products of an acquired company, including difficulties
associated with integrating new personnel; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the diversion of our management&#146;s attention from our internal product development efforts and initiatives in
pursuing such a strategic merger or acquisition; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">retention of key employees, the loss of key personnel and uncertainties in our ability to maintain key business
relationships; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks and uncertainties associated with the other party to such a transaction, including the prospects of that
party, their regulatory compliance status and their existing products or product candidates and marketing approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to recognize the synergies or other benefits intended for the acquisition, partnership or collaboration;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential inability to generate revenue from acquired technology and/or products sufficient to meet our
objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition, if we undertake acquisitions, we may issue dilutive securities, assume or incur debt obligations, incur large <FONT STYLE="white-space:nowrap">one-time</FONT> expenses and acquire intangible assets that could result in significant future
amortization expense. Moreover, we may not be able to locate suitable acquisition opportunities and this inability could impair our ability to grow or obtain access to technology or products that may be important to the development of our business.
Any of the foregoing may materially harm our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may make acquisitions to expand
our business and as a result, our results of operations may be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may choose to expand our current business
through the acquisition of other businesses, products or technologies, or through strategic alliances. Acquisitions involve numerous risks, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possibility that we will pay more than the value derived from the acquisition which could result in future <FONT
STYLE="white-space:nowrap">non-cash</FONT> impairment charges, and incremental operating losses; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulties in integration of the operations, technologies and products of the acquired companies, which may
require significant attention of our management that otherwise would be available for the ongoing development of our business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the assumption of certain known and unknown liabilities of the acquired companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulties in retaining key relationships with employees, customers, collaborators, vendors and suppliers of
the acquired company; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of acquisitions outside of the jurisdictions we currently operate in, the need to address the
particular economic, currency, political, and regulatory risks associated with specific countries, particularly those related to our collection of sensitive data, regulatory approvals, and tax management, which may result in significant additional
costs or management overhead for our business. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these factors could have a negative impact on our business,
financial condition, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Risks Relating to Investment in New enGene&#146;s Securities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Because New enGene is a Canadian company, shareholder protections differ from shareholder protections in the United States and elsewhere, and New enGene
is subject to a variety of additional risks that may negatively impact New enGene&#146;s operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the continuation of
New enGene into British Columbia, we will be organized and exist under the laws of British Columbia, Canada and, accordingly, will be governed by the BCBCA and other relevant laws, which may affect the rights of shareholders differently than those
of a company governed by the laws of a U.S. jurisdiction or Cayman Islands law. For a summary chart outlining certain similarities and differences in the corporate governance and stockholder/shareholder rights associated with each of FEAC and New
enGene according to applicable law and/or the organizational documents of FEAC and New enGene, see &#147;<I>Comparison of Corporate Governance and Shareholder Rights.</I>&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to special considerations or risks associated with companies operating in
Canada that may, at any time differ from the considerations and risks of companies operating in the United States, including any of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">political regimes, rules and regulations or currency conversion or corporate withholding taxes on individuals;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">tariffs and trade barriers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulations related to customs and import/export matters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">longer payment cycles; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">tax issues, such as tax law changes and variations in tax laws as compared to the United States;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">requirements to maintain a company nexus with Canada or a particular province of Canada; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">currency fluctuations and exchange controls; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">challenges in collecting accounts receivable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cultural and language differences; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">employment regulations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">crime, strikes, riots, civil disturbances, terrorist attacks and wars; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">deterioration of political relations with the United States, which could result in uncertainty and/or changes in
or to existing trade treaties. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In particular, we are subject to the&nbsp;risk&nbsp;of changes in economic conditions,
social conditions and political conditions inherent in&nbsp;Canada, including changes in laws and policies that govern international investment, as well as changes in&nbsp;U.S.&nbsp;laws and regulations relating to international trade and
investment, including the new trilateral trade agreement among the United States, Mexico and Canada called the United States-Mexico-Canada&nbsp;Agreement (the &#147;USMCA&#148;), which has been ratified by all three countries. The USMCA entered into
force on July&nbsp;1, 2020 and superseded the North American Free Trade Agreement. Although we believe that there have been no immediate effects on New enGene&#146;s operations with respect to the USMCA, we cannot predict future developments in the
political climate involving the United States, Mexico and Canada and such developments may have a material adverse effect on New enGene&#146;s business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Proposed Articles to be in effect following the consummation of the Business Combination and certain Canadian legislation contain provisions that
may have the effect of delaying, preventing or making undesirable an acquisition of all or a significant portion of New enGene&#146;s shares or assets or preventing a change in control. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain provisions of the Proposed Articles and certain provisions under the BCBCA, together or separately, could discourage, delay or prevent
a merger, acquisition or other change in control of us that shareholders may consider favorable, including transactions in which they might otherwise receive a premium for their common shares. These provisions include the establishment of a
staggered board of directors, which divides the board into three groups, with directors in each group serving a three-year term. The existence of a staggered board can make it more difficult for shareholders to replace or remove incumbent members of
New enGene&#146;s Board of Directors. As such, these provisions could also limit the price that investors might be willing to pay in the future for New enGene&#146;s common shares, thereby depressing the market price of New enGene&#146;s common
shares. In addition, because New enGene&#146;s Board of Directors is responsible for appointing the members of New enGene&#146;s management team, these provisions may frustrate or prevent any attempts by New enGene&#146;s shareholders to replace or
remove New enGene&#146;s current management by making it more difficult for shareholders to replace members of New enGene&#146;s Board of Directors. Among other things, these provisions include the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">shareholders cannot amend New enGene&#146;s articles unless such amendment is approved by shareholders holding at
least 66 2/3% of the shares entitled to vote on such approval; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">New enGene&#146;s Board of Directors may, without shareholder approval, issue preferred shares in one or more
series having any terms, conditions, rights, preferences and privileges as the board of directors may determine; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">shareholders must give advance notice to nominate directors or to submit proposals for consideration at
shareholders&#146; meetings. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">A&nbsp;non-Canadian&nbsp;must</FONT> file an application
for review with the Minister responsible for the Investment Canada Act and obtain approval of the Minister prior to acquiring control of a &#147;Canadian business&#148; within the meaning of the Investment Canada Act, where prescribed financial
thresholds are exceeded. A reviewable acquisition may not proceed unless the Minister is satisfied that the investment is likely to be of net benefit to Canada. If the applicable financial thresholds were exceeded such that a net benefit to Canada
review would be required, this could prevent or delay a change of control and may eliminate or limit strategic opportunities for shareholders to sell their common shares. Furthermore, limitations on the ability to acquire and hold New enGene&#146;s
common shares may be imposed under the Competition Act (Canada). This legislation has <FONT STYLE="white-space:nowrap">a&nbsp;pre-merger&nbsp;notification</FONT> regime and mandatory waiting period that applies to certain types of transactions that
meet specified financial thresholds, and permits the Commissioner of Competition to review any acquisition, directly or indirectly, including through the acquisition of shares, of control over or of a significant interest in us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Proposed Articles to be in effect following the consummation of the Business Combination designate specific courts in Canada and the United States
as the exclusive forum for certain litigation that may be initiated by New enGene&#146;s shareholders without New enGene&#146;s prior written consent, which could limit New enGene&#146;s shareholders&#146; ability to obtain a favourable judicial
forum for disputes with us. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Proposed Articles, unless we consent in writing to the selection of an alternative
forum, the courts of the Province of British Columbia and the appellate courts therefrom shall, to the fullest extent permitted by law, be the sole and exclusive forum for: (a)&nbsp;any derivative action or proceeding brought on New enGene&#146;s
behalf; (b)&nbsp;any action or proceeding asserting a claim of breach of fiduciary duty owed by any director, officer or other employee of New enGene&#146;s to New enGene; (c)&nbsp;any action or proceeding asserting a claim arising out of any
provision of the BCBCA or the Proposed Articles (as either may be amended from time to time); or (d)&nbsp;any action or proceeding asserting a claim or otherwise related to New enGene&#146;s affairs (the &#147;Canadian Forum Provision&#148;). In
addition, pursuant to the Proposed Articles further provide that unless we consent in writing to the selection of an alternative forum, the United States District Court for the District of Delaware shall be the sole and exclusive forum for resolving
any complaint filed in the United States asserting a cause of action arising under the Securities Act or the Exchange Act (the &#147;U.S. Forum Provision&#148;). In addition, the Proposed Articles provide that any person or entity purchasing or
otherwise acquiring any interest in New enGene&#146;s common shares is deemed to have notice of and consented to the Canadian Forum Provision and the U.S. Forum Provision; provided, however, that shareholders cannot and will not be deemed to have
waived New enGene&#146;s compliance with the U.S. federal securities laws and the rules and regulations thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Canadian Forum
Provision and the U.S. Forum Provision in the Proposed Articles may impose additional litigation costs on shareholders in pursuing any such claims. Additionally, the forum selection clauses in the Proposed Articles may limit New enGene&#146;s
shareholders&#146; ability to bring a claim in a judicial forum that they find favorable for disputes with New enGene or New enGene&#146;s directors, officers or employees, which may discourage the filing of lawsuits against New enGene and New
enGene&#146;s directors, officers and employees, even though an action, if successful, might benefit New enGene&#146;s shareholders. In addition, while the Delaware Supreme Court ruled in March 2020 that federal forum selection provisions purporting
to require claims under the Securities Act be brought in federal court are &#147;facially valid&#148; under Delaware law, there is uncertainty as to whether other courts, including courts in Canada and other courts within the U.S., will enforce New
enGene&#146;s U.S. Forum Provision. If the U.S. Forum Provision is found to be unenforceable, we may incur additional costs associated with resolving such matters. The U.S. Forum Provision may also impose additional litigation costs on shareholders
who assert that the provision is not enforceable or invalid. The courts of the Province of British </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Columbia and the United States District Court for the District of Delaware may also reach different judgments or results than would other courts, including courts where a shareholder considering
an action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than New enGene&#146;s shareholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Because we are a Canadian company, it may be difficult to serve legal process or enforce judgments against us. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will be incorporated and maintain operations in Canada. In addition, certain directors of New enGene are expected to reside in the United
States, while others are expected to reside outside of the United States. Accordingly, service of process upon us may be difficult to obtain within the United States. Furthermore, because substantially all of our assets are located outside the
United States, any judgment obtained in the United States against us, including one predicated on the civil liability provisions of the U.S. federal securities laws, may not be collectible within the United States. Therefore, it may not be possible
to enforce those actions against us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, it may be difficult to assert U.S. securities law claims in original actions instituted
in Canada. Canadian courts may refuse to hear a claim based on an alleged violation of U.S. securities laws against us or these persons on the grounds that Canada is not the most appropriate forum in which to bring such a claim. Even if a Canadian
court agrees to hear a claim, it may determine that Canadian law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must be proved as a fact, which can be a time-consuming and
costly process. Certain matters of procedure will also be governed by Canadian law. Furthermore, it may not be possible to subject foreign persons or entities to the jurisdiction of the courts in Canada. Similarly, to the extent that New
enGene&#146;s assets are located in Canada, investors may have difficulty collecting from us any judgments obtained in the U.S. courts and predicated on the civil liability provisions of U.S. securities provisions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>enGene&#146;s ability to use net operating loss carry-forwards and certain other tax attributes are limited </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For Canadian tax purposes, enGene currently has a substantial pool of net operating losses (known as noncapital losses) and other tax
attributes. In general terms, where control of a corporation is acquired or deemed to be acquired, as is expected to apply to enGene as a result of the Transactions, the corporation is subject to a &#147;loss restriction event&#148;, and the
corporation&#146;s non-capital loss carryforwards, other losses and certain other tax attributes will be subject to limitation and possibly expiry after the Transactions. Similar rules are expected to apply for Canadian provincial purposes.
Consequently, enGene may not be able to utilize a material portion of its non-capital loss carryforwards and certain other tax attributes in certain circumstances. Further, enGene may realize capital gains or foreign exchange gains as a result of
the Transactions. Non-capital losses and other tax attributes arising prior to the Amalgamation will generally not be available to offset such gains. As a result, enGene may have tax payable after the Amalgamation, unless it generates non-capital
losses (or other tax attributes) after the Amalgamation in an amount sufficient to offset such gains. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For U.S. tax purposes, net
operating loss carryforwards allow companies to use past year net operating losses to offset against future years&#146; profits, if any, to reduce future tax liabilities. Sections 382 and 383 of the Code limit a corporation&#146;s ability to utilize
its net operating loss carryforwards and certain other tax attributes (including research credits) to offset any future taxable income or tax if the corporation experiences a cumulative ownership change of more than 50% over any rolling three-year
period. State net operating loss carryforwards (and certain other tax attributes) may be similarly limited. An ownership change can therefore result in significantly greater tax liabilities than a corporation would incur in the absence of such a
change and any increased liabilities could adversely affect the corporation&#146;s business, results of operations, financial condition and cash flow. Even if another ownership change has not occurred and does not occur as a result of this offering,
additional ownership changes may occur in the future as a result of additional equity offerings or events over enGene will have little or no control, including purchases and sales of its equity by its five percent security holders, the emergence of
new five percent security holders, redemptions of its securities or certain changes in the ownership of any of its five percent security holders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>New enGene&#146;s Proposed Articles will include provisions that may discourage takeover attempts,
including a classified or &#147;staggered&#148; board. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain provisions in the Proposed Articles may have the effect of
deterring coercive takeover practices and inadequate takeover bids by making such practices or bids unacceptably expensive to the bidder and by encouraging prospective acquirers to negotiate with the New enGene Board rather than to attempt a hostile
takeover. These provisions include, among others: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the existence of a classified or &#147;staggered&#148; board; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the right of the New enGene Board to issue preferred stock and to determine the voting, dividend, and other
rights of preferred stock without shareholder approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability of New enGene&#146;s directors, and not shareholders, to fill vacancies on the New enGene Board in
most circumstances and to determine the size of the New enGene Board; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the requirement for <FONT STYLE="white-space:nowrap">two-thirds&nbsp;of</FONT> the votes cast by shareholders on
a special resolution in order to remove directors or amend certain provisions of the Proposed Articles; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the absence of cumulative rights in the election of directors. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While these provisions are not intended to make New enGene immune from takeovers, they will apply even if the offer may be considered
beneficial by some shareholders and may delay or prevent an acquisition that the New enGene Board determines is not in the best interests of New enGene and its shareholders. These provisions may also prevent or discourage attempts to remove and
replace incumbent directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Certain of New enGene&#146;s financing agreements place operating restrictions on its business, which may limit its
flexibility to respond to opportunities and may have a material adverse effect on its business, financial condition and results of operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;16, 2023, New enGene entered into a letter agreement with Investissement Quebec (&#147;IQ&#148;), FEAC and enGene (the &#147;IQ
Letter Agreement&#148;), in connection with IQ&#146;s investment in the 2023 Convertible Notes. Among the terms of the IQ Letter Agreement, New enGene agreed to comply with certain covenants that may restrict its ability to expand its operations or
engage and pursue certain business opportunities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From the time that IQ first holds New enGene Shares until the earlier of (1)&nbsp;the
date IQ ceases to hold at least 2% of New enGene&#146;s outstanding shares on a fully-diluted basis, and (2)&nbsp;the date that is five years after the date of the IQ Letter Agreement, unless New enGene receives prior written consent from IQ:
(i)&nbsp;New enGene must maintain its head office in the Province of Qu&eacute;bec, and (ii)&nbsp;New enGene shall cause enGene to (A)&nbsp;maintain operations in the Province of Qu&eacute;bec, (B)&nbsp;maintain a research and development center in
the Province of Qu&eacute;bec, and (C)&nbsp;engage at least 20 employees who are residents and work in the Province of Qu&eacute;bec (the &#147;Employment Threshold&#148;), provided that, if in good faith, the New enGene Board determines that
maintaining the Employment Threshold puts enGene at risk of bankruptcy, insolvency or determines that it is in the best interests of enGene to effect a general reduction in workforce, IQ shall not unreasonably withhold consent to reduce the
Employment Threshold. Additionally, after the consummation of the Transactions, IQ will, for so long as IQ holds shares representing, in the aggregate, ownership of greater than 2% of New enGene on a fully diluted basis, be permitted to have an
observer attend any meeting of the New enGene Board subject to the terms and conditions of a board observer agreement to be negotiated in good faith between New enGene and IQ. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">New enGene&#146;s compliance with these provisions may affect its ability to react to changes in industry conditions, take advantage of
business opportunities it believes to be desirable, hire and retain critical personnel, execute or product development and commercialization initiatives, among other potential effects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The terms of the New enGene Warrants could cause the downward&nbsp;adjustment&nbsp;of the exercise
price and the redemption trigger price for the warrants in connection with the PIPE Financing, which could lead to further dilution for holders of New enGene Shares. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms of the New enGene Warrants will provide that if (i)&nbsp;New enGene issues additional New enGene Shares or equity-linked securities
for capital raising purposes in connection with the closing of the Business Combination at a newly issued price of less than $9.20 per New enGene Share (with such issue price or effective issue price to be determined in good faith by New
enGene&#146;s Board of Directors and, in the case of any such issuance to FEAC&#146;s Sponsor or its affiliates, without taking into account any founder shares held by FEAC&#146;s Sponsor or such affiliates, as applicable, prior to such issuance)
(the &#147;Newly Issued Price&#148;), (ii) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the Business Combination on the date of the
completion of the Business Combination (net of redemptions), and (iii)&nbsp;the volume weighted average trading price of the New enGene Shares during the 20 trading day period starting on the trading day prior to the day on which the Business
Combination is consummated is below $9.20 per share (such price, the &#147;Market Value&#148;), then the exercise price of the New enGene Warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the
Newly Issued Price, and the $18.00 per share redemption trigger price will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price, respectively. This provision of the New enGene Warrants
makes it possible that the exercise price and redemption price trigger of the New enGene Warrants would be adjusted downward as a result of the PIPE Financing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the PIPE Financing, the New enGene Board of Directors will evaluate the terms of the PIPE Financing and determine whether the
foregoing conditions have been satisfied that would result in adjustments to the exercise price and redemption trigger price of the New enGene Warrants. If the exercise price of the New enGene Warrants is adjusted downward, it may be more likely
that the New enGene Warrants will be exercised by holders of such warrants. Any exercise of the New enGene Warrants would result in dilution to holders of New enGene Shares. Additionally, any downward adjustment to the redemption trigger price of
the New enGene Shares may result in increased redemptions of the New enGene Warrants by New enGene. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to the Business Combination and FEAC
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Unless the context otherwise requires, all references in this section to &#147;FEAC,&#148; &#147;we,&#148; &#147;us&#148; and
&#147;ours&#148; refer to FEAC prior to the consummation of the Business Combination, which will be the business of New enGene and its subsidiaries following the consummation of the Business Combination. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Risks Related to the Business Combination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>FEAC may not have sufficient funds outside the Trust Account to fund its working capital requirements pending the consummation of the Business
Combination. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2023, FEAC had $269,138 available to it outside the Trust Account to fund its working capital
requirements. If FEAC is required to seek additional capital to fund its working capital requirements pending the consummation of the Business Combination, it would need to borrow additional funds from the Sponsor or its affiliates under the working
capital loans discussed elsewhere in this proxy statement/prospectus. As of the date hereof, FEAC has $2.47&nbsp;million outstanding under working capital loans and extension loans and under the terms of the Business Combination Agreement, FEAC
cannot incur indebtedness under the working capital loans (excluding the extension loans discussed elsewhere in this proxy statement/prospectus) in an amount in excess of $1,500,000. The Sponsor is not under any obligation to advance funds to FEAC
in such circumstances. Any such advances would be (i)&nbsp;repaid only from funds held outside the Trust Account or from funds released to FEAC or (ii)&nbsp;converted pursuant to the Business Combination Agreement into FEAC Private Placement
Warrants to be issued by FEAC up to an aggregate amount of $1,500,000, in each case upon completion of the Business Combination. If FEAC is unable to consummate the Business Combination because it does not have sufficient funds available to fund its
working capital requirements, FEAC may be forced to cease </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
operations and liquidate the Trust Account. Consequently, FEAC Shareholders may receive less than $10.35 per share, excluding interest earned in the Trust Account, and their warrants may expire
worthless. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Since the Sponsor, its parent FGOF and FEAC&#146;s directors and executive officers have interests that are different from, or in
addition to (and which may conflict with), the interests of FEAC&#146;s other shareholders, a conflict of interest may exist in determining whether the Business Combination is appropriate as FEAC&#146;s initial business combination. Such interests
include that the Sponsor may lose its entire investment if a Business Combination is not completed, and that the Sponsor, FGOF and certain of FEAC&#146;s directors will benefit from the completion of a Business Combination and may be incentivized to
complete the Business Combination, even if it is with a less favorable target company or on less favorable terms to FEAC Shareholders, rather than liquidate FEAC. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When you consider the recommendation of the FEAC Board in favor of approval of the Business Combination Proposal and the other proposals, you
should keep in mind that the Sponsor, FGOF and certain of FEAC&#146;s directors and executive officers have interests in such proposals that are different from, or in addition to (and which may conflict with), those of FEAC Shareholders and holders
of FEAC Warrants generally. These interests include, among other things, the interests listed below: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that after giving effect to the Sponsor Loans Conversion and the Surrender, the Sponsor will retain
1,373,496 FEAC Class&nbsp;B Shares which it purchased at a price of approximately $0.009 per share and 731,619 FEAC Private Placement Warrants which it purchased at a price of $1.50 per warrant, and such securities will have a significantly higher
value at the time of the Business Combination as described further below: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;FEAC<BR>Class&nbsp;B&nbsp;Shares</B><br><B>beneficially&nbsp;owned&nbsp;as</B><br><B>of the date hereof</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;FEAC</B><br><B>Private&nbsp;Placement</B><br><B>Warrants&nbsp;owned&nbsp;as&nbsp;of<BR>the date hereof</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate&nbsp;value<BR>of&nbsp;FEAC&nbsp;Class&nbsp;B</B><br><B>Shares&nbsp;and&nbsp;FEAC</B><br><B>Private&nbsp;Placement</B><br><B>Warrants&nbsp;
implied&nbsp;by</B><br><B>the&nbsp;Business</B><br><B>Combination<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate&nbsp;value</B><br><B>of&nbsp;FEAC&nbsp;Class&nbsp;B</B><br><B>Shares&nbsp;and&nbsp;FEAC</B><br><B>Private&nbsp;Placement</B><br><B>Warrants&nbsp;
based&nbsp;on</B><br><B>&nbsp;&nbsp;recent&nbsp;trading&nbsp;price<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sponsor<SUP STYLE="font-size:75%; vertical-align:top">(3)(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,373,496</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">731,619</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,215,684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Assumes a value of $10.35 per share, the deemed value of the FEAC Class B Shares on the basis of the
anticipated amount in the Trust Account of $10.35 per FEAC Class A Shares (excluding interest earned on amounts in the Trust Account), and $0.00 per warrant, which reflects that the exercise price of the warrants ($11.50 per warrant) exceeds the
value of the underlying ordinary shares in the Business Combination. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Assumes a value of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the closing price of the FEAC
Class&nbsp;B Shares on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;, 2023, and $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per warrant, the closing price of the FEAC Private Placement Warrants on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;, 2023. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Sponsor is the record holder of the FEAC Class&nbsp;B Shares reported herein. Jasper Bos, Cyril Lesser,
Sander Slootweg and Wouter Joustra, who are directors of the Sponsor, have voting and investment discretion with respect to the FEAC Shares owned by the Sponsor and may be deemed to have indirect shared beneficial ownership of the FEAC Shares held
by the Sponsor. Jasper Bos, Cyril Lesser, Sander Slootweg and Wouter Joustra each disclaim beneficial ownership over the FEAC Class&nbsp;B Shares except to the extent of their pecuniary interest therein. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">FGOF wholly owns the Sponsor and therefore the Sponsor and FGOF have shared voting and investment power over
the FEAC Class&nbsp;B Shares held by the Sponsor. FGOF also holds 2,000,000 FEAC Class&nbsp;A Shares underlying the 2,000,000 FEAC Units held by it. Therefore, FGOF has shared voting and investment power over 5,162,500 FEAC Shares in the aggregate,
representing approximately 32.7% of FEAC&#146;s issued and outstanding ordinary shares as of the date hereof. Forbion Management is the sole director of FGOF and therefore shares voting and investment power (i)&nbsp;with FGOF over the 2,000,000 FEAC
Class&nbsp;A Shares underlying the FEAC Units held by FGOF and (ii)&nbsp;with FGOF and, indirectly, the Sponsor, over the 3,162,500 FEAC Class&nbsp;B Shares held by the Sponsor. Forbion Management exercises voting and investment power through its
investment committee (the &#147;Investment Committee&#148;) consisting of Sander Slootweg, Martien van Osch, <FONT STYLE="white-space:nowrap">Geert-Jan</FONT> Mulder, Vincent van Houten, Dirk Kersten, Nanna L&uuml;neborg, Wouter Joustra
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
and Jasper Bos. None of the members of the Investment Committee has individual voting and investment power with respect to the ordinary shares, and each such member disclaims beneficial ownership
of the ordinary shares except to the extent of their proportionate pecuniary interest therein. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Prior to the Surrender and the Sponsor Loan Conversions (see &#147;<I>Certain Relationships and Related Party
Transactions</I> &#151;<I> Sponsor and Insiders Letter Agreement; Surrender; Sponsor Loans Conversion</I>&#148;), the Sponsor owns 3,162,500 FEAC Class&nbsp;B Shares and 5,195,000 FEAC Private Placement Warrants. Pursuant to the Sponsor Loans
Conversions agreed in the Sponsor and Insiders Letter Agreement, the Sponsor agreed to convert an amount equal to $1,500,000 of the aggregate principal amount outstanding under the Sponsor Loans, taken together, into additional FEAC Private
Placement Warrants immediately prior to the Surrender (following which the Sponsor will own 6,195,000 FEAC Private Placement Warrants). Pursuant to the Surrender agreed in the Sponsor and Insiders Letter Agreement, the Sponsor will forfeit 1,789,004
of its FEAC Class&nbsp;B Shares and 5,463,381 of its FEAC Private Placement Warrants as a contribution to the capital of FEAC, for no consideration. After the Surrender, such 1,789,004 of its FEAC Class&nbsp;B Shares and 5,463,381 of its FEAC
Private Placement Warrants will be cancelled and no longer outstanding and the Sponsor will own 1,373,496 FEAC Class&nbsp;B Shares and 731,619 FEAC Private Placement Warrants. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that if FEAC does not complete its initial business combination within 18 months from the closing of
FEAC&#146;s IPO (or up to 24 months from the closing of our IPO if FEAC extends the period of time to consummate a business combination, subject to the Sponsor depositing additional funds in the Trust Account), the FEAC Class&nbsp;B Shares and the
FEAC Private Placement Warrants will expire worthless; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that given the differential in the purchase price that the Sponsor paid for the FEAC Class&nbsp;B Shares
as compared to the price of the FEAC Class&nbsp;A Shares sold in FEAC&#146;s IPO, the Sponsor and its affiliates may earn a positive rate of return on their investment even if the FEAC Class&nbsp;A Shares trade below the price initially paid for the
FEAC Class&nbsp;A Shares in FEAC&#146;s IPO and the holders of FEAC Class&nbsp;A Shares experience a negative rate of return following the completion of the Business Combination. It is not practicable to quantify the Sponsor&#146;s rate of return
because, among other things, the timing (including as a result of the <FONT STYLE="white-space:nowrap">lock-up</FONT> applicable to the FEAC Class&nbsp;B Shares) and the price at which the Sponsor may ultimately sell New enGene Shares (into which
the FEAC Class&nbsp;B Shares will be converted in connection with the Business Combination), New enGene Warrants (into which the FEAC Private Placement Warrants will be converted in connection with the Business Combination) and other equity
securities of New enGene are uncertain, both of which would have a material impact on the applicable rate of return; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that pursuant to the Sponsor&#146;s subscription agreement entered into on May&nbsp;16, 2023 with FEAC
and New enGene (as amended by the Sponsor&#146;s subscription agreement side letter entered into on May&nbsp;16, 2023 by the Sponsor, FEAC and New enGene), the Sponsor will receive, upon consummation of the Business Combination, in consideration of
the purchase price to be paid by the Sponsor set forth in such agreement, 130,085 FEAC Class&nbsp;A Shares (or following the Assumption, New enGene Shares) and 54,634 FEAC Private Placement Warrants (or following the Assumption, New enGene
Warrants); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the Sponsor purchased or will purchase from enGene pursuant to a purchase agreement entered into
with enGene on May&nbsp;16, 2023 for an aggregate amount of $20,000,000 (i) warrants of enGene and (ii)&nbsp;convertible notes of enGene which will get converted upon the consummation of the Business Combination into common shares of enGene, and
which, in each case, when exchanged at the enGene Exchange Ratio pursuant to the Transactions, shall equal that number of FEAC Warrants and FEAC Class&nbsp;A Shares (or after the Assumption, New enGene Warrants and New enGene Common Shares,
respectively), that the Sponsor would have received if it had participated in that amount on the same terms as the PIPE Financing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that if a business combination is not consummated within the required period, the Sponsor will lose its
entire investment in FEAC, which investment included a capital contribution of $25,000 for the Sponsor&#146;s FEAC Class&nbsp;B Shares, $7,792,500 for the Sponsor&#146;s FEAC Private Placement Warrants, $1,200,000 in Working Capital Loans and
$1,265,000 in Extension Loans (as defined below); </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the Sponsor and FEAC&#146;s current officers and directors have entered into a letter agreement
with FEAC dated December&nbsp;9, 2021 in which they agreed to waive their rights to liquidating distributions from the Trust Account with respect to any FEAC Class&nbsp;B Shares held by them if FEAC fails to complete an initial business combination
within the required period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that pursuant to the FEAC Voting Agreement, the Sponsor, FGOF and FEAC&#146;s directors and executive
officers agreed, among other things, (a)&nbsp;to vote any FEAC Class&nbsp;B Shares and FEAC Class&nbsp;A Shares held by it in favor of any proposed business combination and (b)&nbsp;not to redeem any FEAC Class&nbsp;B Shares or FEAC Class&nbsp;A
Shares held by it in connection with a shareholder vote to approve a proposed Business Combination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the Sponsor and FGOF, collectively, after giving effect to the Transactions and the transfer of
20,000 New enGene Shares to each of three of FEAC&#146;s independent directors as described below, are expected to own 5,705,932 New enGene Shares, which collectively will represent approximately 24% of outstanding New enGene Shares (assuming
maximum FEAC Shareholder Redemptions) and have a value of approximately $59,056,396.20 based on an implied value of $10.35 per New enGene Share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the Sponsor agreed to transfer 20,000 of the New enGene Shares it expects to receive in connection
with the Business Combination to each of three of FEAC&#146;s independent directors following the consummation of the Business Combination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the anticipated designation by FEAC of Jasper Bos, its current Chief Executive Officer and director, as director
of New enGene upon the consummation of the Business Combination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the continued indemnification of FEAC&#146;s directors and officers and the continuation of FEAC&#146;s
directors&#146; and officers&#146; liability insurance after the Business Combination (i.e., a &#147;tail policy&#148;); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the Sponsor has agreed that in the event of the liquidation of the Trust Account upon the failure
of FEAC to consummate the Business Combination it will be liable to FEAC if and to the extent any claims by a third-party for services rendered or products sold to FEAC, or a prospective target business with which we have discussed entering into a
transaction agreement, reduce the amounts in the Trust Account to below the lesser of (i) $10.25 per FEAC Class&nbsp;A Share and (ii)&nbsp;the actual amount per FEAC Class&nbsp;A Share held in the Trust Account as of the date of the liquidation of
the Trust Account if less than $10.25 per FEAC Class&nbsp;A Share due to reductions in the value of the trust assets, in each case net of the interest that may be withdrawn to pay our tax obligations (less up to $100,000 of interest to pay
dissolution expenses), provided that such liability will not apply to any claims by a third-party or prospective target business that executed a waiver of any and all rights to seek access to the Trust Account nor will it apply to any claims under
FEAC&#146;s indemnity of the underwriters of FEAC&#146;s IPO against certain liabilities, including liabilities under the Securities Act. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the foregoing, the existence of financial and personal interests of the Sponsor, FGOF and certain of FEAC&#146;s directors and
executive officers may result in a conflict of interest between what they may believe is best for FEAC and FEAC Shareholders and what they may believe is best for themselves or the Sponsor in determining whether the Business Combination is
appropriate as FEAC&#146;s initial business combination, and accordingly the interests of the Sponsor, FGOF and certain of FEAC&#146;s directors and executive officers may not be aligned with the interests of FEAC Shareholders generally. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, there can be no assurance that the personal and financial interests of certain directors and executive officers of FEAC have not
influenced their motivation in identifying enGene as a target business, despite having taken several measures to avoid such a potential conflict of interest, such as obtaining a fairness opinion in connection with the Business Combination from the
independent investment bank Lincoln International LLC, stating that as of the date of the opinion, the Company Consideration (as defined in the Business Combination Agreement) to be issued by FEAC in connection with the Business Combination is
deemed fair from a financial point of view to the holders of FEAC Class&nbsp;A Shares. There is no guarantee, however, that there has not been a conflict of interest when determining whether the terms, conditions and timing of the Business
Combination are appropriate and in the best interests of FEAC Shareholders generally. See &#147;<I>Proposal No.</I><I></I><I>&nbsp;1 </I><B><I>&#151;</I></B><I> The Business Combination Proposal &#151;</I> <I>Lincoln&#146;s Fairness
Opinion</I>.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please see the section entitled &#147;<I>Proposal No.</I><I></I><I>&nbsp;1 </I><B><I>&#151;
</I></B><I>The Business Combination Proposal &#151; Interests of FEAC&#146;s Sponsor, Directors and Executive Officers in the Business Combination</I>&#148; for additional information on interests of the Sponsor, FGOF and FEAC&#146;s directors and
executive officers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Forbion Capital Fund III (an affiliate of Forbion, the Sponsor and FGOF) is a significant shareholder of enGene and an investor
in both of enGene&#146;s Amended 2022 Convertible Notes and the 2023 Convertible Notes, and as a result, a conflict of interest may exist in determining whether the Business Combination is appropriate as FEAC&#146;s initial business combination.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When you consider the recommendation of the FEAC Board in favor of approval of the Business Combination Proposal, you should keep
in mind that as a result of Forbion Capital Fund III&#146;s significant investment in enGene, a minority of FEAC&#146;s directors and executive officers could have interests in such proposal that are different from, or in addition to (and which may
conflict with), those of FEAC Shareholders and holders of FEAC Warrants generally. In addition, there can be no assurance that the interest of Forbion in assisting enGene obtain financing has not influenced the motivation of FEAC and the Sponsor in
identifying enGene as a target business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please see the section entitled &#147;<I>Proposal No.</I><I></I><I>&nbsp;1
</I><B><I>&#151;</I></B><I> The Business Combination Proposal &#151; Interests of FEAC&#146;s Sponsor, Directors and Executive Officers in the Business Combination</I>&#148; for additional information on interests of the Sponsor, FGOF and
FEAC&#146;s directors and executive officers.<I></I> For additional information regarding enGene&#146;s significant shareholders, see &#147;<I>Security Ownership of Certain Beneficial Owners and Management of enGene</I>.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Business Combination may be completed even though material adverse effects may result from the public announcement or completion of the proposed
Business Combination, general business or economic conditions, industry-wide changes, and other causes. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, either FEAC or
enGene can refuse to complete the Business Combination if there is a material adverse effect, event, change or occurrence affecting the other party between the signing date of the Business Combination Agreement and the planned closing of the
Business Combination. However, certain types of changes, events, effects or occurrences do not permit either party to refuse to complete the Business Combination under the terms of the Business Combination Agreement, even if such change could be
said to have a material adverse effect on the relevant party, including, but not limited to, changes, events, effects or occurrences resulting from the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any change, development, condition or event generally affecting the industries or markets in which enGene
operates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general business or economic conditions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any outbreak or escalation of war or hostilities, any military or terrorist attack, sabotage, civil unrest,
cyberterrorism, riots, prolonged demonstrations or public disorders, or changes in global, national, regional, provincial, state or local political conditions, or any escalation or worsening thereof; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the financial, banking, capital or securities markets generally; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes or proposed changes in, or changes or proposed changes in the interpretation of, applicable laws,
regulatory framework, IFRS or GAAP; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the negotiation, execution or delivery of the Business Combination Agreement, public announcement of the Business
Combination Agreement or the pendency or consummation of the Transactions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to meet any internal or published budgets, projections, forecasts, estimates or predictions;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any hurricane, tornado, flood, earthquake, tsunami, natural disaster, mudslides, wild fires, acts of God or other
natural disasters or comparable events; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any epidemics, pandemics, disease outbreaks or quarantines, including
<FONT STYLE="white-space:nowrap">COVID-19.</FONT> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, FEAC or enGene may waive the occurrence of any material adverse effect
affecting the other party. If a material adverse effect occurs and the parties still complete the Business Combination, New enGene&#146;s financial condition and results of operations may be adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The ability to successfully effect the Business Combination and to be successful thereafter will be dependent upon the efforts of key personnel, some of
whom will be from enGene, and some of whom may join New enGene following the Business Combination. The loss of key personnel or the hiring of ineffective personnel after the Business Combination could negatively impact the operations and
profitability of New enGene. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FEAC and enGene&#146;s ability to recognize certain benefits of the Business Combination and
successfully operate New enGene&#146;s business following the Business Combination will depend upon the efforts of certain key personnel of enGene. Although FEAC and enGene expect the current key personnel of enGene to remain with New enGene
following the Business Combination, the unexpected loss of key personnel may adversely affect the operations and profitability of New enGene. In addition, New enGene&#146;s future success depends in part on its ability to execute on its growth plan,
identify and retain key personnel to succeed senior management, to successfully integrate and retain such key personnel, and to identify and recruit additional key individuals New enGene determines may be necessary following the Business
Combination, including, but not limited to, a Chief Financial Officer, a Chief Medical Officer, and a Vice President of Finance. Competition for highly skilled personnel is frequently intense and, as with any company with limited resources, there
can be no guarantee that New enGene will be able to attract such individuals or that the presence of such individuals will necessarily translate into New enGene&#146;s profitability. In addition, because New enGene will operate in a newly emerging
industry, there may also be limited personnel available with relevant business experience, and such personnel may be subject to non-competition and other agreements with third parties that restrict their ability to work for New enGene. Furthermore,
while FEAC has closely scrutinized the skills, abilities and qualifications of the key enGene personnel that will be employed by New enGene, FEAC&#146;s assessment may not prove to be correct. If such personnel do not possess the skills,
qualifications or abilities FEAC expects or those necessary to manage a public company, the operations and profitability of New enGene&#146;s business may be negatively impacted. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The consummation of the Business Combination is subject to a number of conditions, and if those conditions are not satisfied or waived, the Business
Combination Agreement may be terminated in accordance with its terms and the Business Combination may not be completed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Business Combination is subject to a number of conditions, including the condition that FEAC have at least $5,000,001 of net tangible assets (as determined in accordance with Rule <FONT STYLE="white-space:nowrap">3a51-5(g)(1)</FONT> of the Exchange
Act) after giving effect to the transactions contemplated by the Business Combination Agreement and the PIPE Financing. In addition, the obligation of the parties to consummate the Business Combination is subject to certain closing conditions,
including, but not limited to, (i)&nbsp;the requisite approval of FEAC Shareholders, (ii)&nbsp;the requisite approval of enGene Shareholders, (iii)&nbsp;the Interim Order and the Final Order having been granted and not set aside or modified in a
manner unacceptable to the parties (and enGene&#146;s relatively widespread shareholder base may increase the chances of that an enGene Shareholder may successfully oppose the Interim Order or the Final Order), (iv)&nbsp;the effectiveness of the
registration statement of which this proxy statement/prospectus forms part, (v)&nbsp;the dissenting rights with respect to the Arrangement not having been validly exercised or withdrawn with respect to more than 10% of the issued and outstanding
enGene Shares, and (vi)&nbsp;the <FONT STYLE="white-space:nowrap">non-occurrence&nbsp;of</FONT> any material adverse effect with respect to the other party from the date of the Business Combination Agreement that exists as of the closing. Therefore,
unless these conditions are satisfied or waived (to the extent waivable) by the applicable parties to the Business Combination Agreement, the Business Combination Agreement could terminate and the Business Combination may not be consummated. In
addition, if the Business Combination is not completed by December 14, 2023, either enGene or FEAC may terminate the Business Combination Agreement. See also &#147;<I>The Business Combination Agreement &#151;Termination</I>.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Delays in completing the Business Combination may substantially reduce the expected benefits of the Business Combination. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Satisfying the conditions to, and completion of, the Business Combination may take longer, and could cost more, than FEAC and enGene expect.
Any delay in completing or any additional conditions imposed in order to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
complete the Business Combination may materially adversely affect the benefits that FEAC and enGene expect to achieve from the Business Combination. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>FEAC and enGene could be a target of securities class action and derivative lawsuits, which could result in substantial costs and may delay or prevent
the Business Combination from being completed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, lawsuits are brought against companies that have entered into
business combination agreements. Even if the lawsuits are without merit, defending against these claims can result in substantial costs and divert management time and resources. Additionally, if a plaintiff is successful in obtaining an injunction
prohibiting completion of a business combination, then that injunction may delay or prevent the Business Combination from being completed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The
Sponsor, FGOF and FEAC&#146;s executive officers and directors have agreed to vote in favor the Business Combination, regardless of how FEAC Shareholders vote. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unlike other blank check companies in which the initial shareholders agree to vote their FEAC Class&nbsp;B Shares in accordance with the
majority of the votes cast by FEAC Shareholders in connection with an initial business combination, FEAC, the Sponsor, FGOF and FEAC&#146;s executive officers and directors entered into the FEAC Voting Agreement concurrently with the execution of
the Business Combination Agreement pursuant to which the Sponsor, FGOF and FEAC&#146;s executive officers and directors agreed to vote in favor of the Business Combination and the Transactions to which FEAC is a party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Sponsor owns approximately 20% and FGOF, together with the Sponsor, owns approximately 32.7%, of the outstanding FEAC Shares (excluding,
for the avoidance of doubt, the FEAC Class&nbsp;A Shares underlying the FEAC Private Placement Warrants) as of the date of this proxy statement/prospectus. As a result, FEAC would need only &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, or
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;%, of the &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; FEAC Shares outstanding as of the record date to be voted in favor of the Business Combination Proposal (assuming all outstanding shares are
voted) in order to have the Business Combination approved. Accordingly, it is more likely that the necessary shareholder approval will be received than would be the case if such persons agreed to vote their FEAC Class&nbsp;A Shares in accordance
with the majority of the votes cast by FEAC Shareholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>FGOF, the Sponsor, enGene and FEAC&#146;s directors, officers or their respective
affiliates may elect to purchase shares or warrants from FEAC Shareholders in connection with the Business Combination, which may influence the vote on the Business Combination and reduce the public &#147;float&#148; of FEAC Class A Shares.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FGOF, the Sponsor, enGene and FEAC&#146;s directors, officers, or their respective affiliates may purchase FEAC Class A Shares or
FEAC Warrants in privately negotiated transactions or in the open market either prior to or following the completion of the Business Combination, although they are under no obligation to do so. Such a purchase may include a contractual
acknowledgement that the selling FEAC Shareholder, although still the record holder of FEAC Shares, is no longer the beneficial owner thereof and therefore agrees not to exercise its redemption rights. In the event that FGOF, the Sponsor, enGene or
FEAC&#146;s directors, officers or their respective affiliates purchase shares in privately negotiated transactions from FEAC Shareholders who have already elected to exercise their redemption rights, such selling shareholders would be required to
revoke their prior elections to redeem their shares. In such transactions, the purchase price for the FEAC Class A Shares will not exceed the per-share redemption amount available to redeeming FEAC Shareholders. In addition, the purchasers described
above will waive redemption rights, if any, with respect to the FEAC Class A Shares they acquire in such transactions. The purpose of such purchases would be to increase the likelihood that the proposals presented to FEAC Shareholders for approval
at the Special Meeting are approved, however, such purchased shares would not be voted in favor of approving the Business Combination. Any such share purchases and other transactions may thereby increase the likelihood of obtaining shareholder
approval of the Business Combination. This may result in the completion of the Business Combination in a way that may not otherwise have been possible. Further, in the event the Sponsor, enGene, FEAC&#146;s directors, officers, or any of their
respective affiliates were to purchase </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
FEAC Class A Shares in privately negotiated transactions from public shareholders, such purchases would be structured in compliance with the requirements of Rule 14e-5 under the Exchange Act,
including, in relevant part, through adherence to the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">this proxy statement/prospectus discloses the possibility that FGOF, the Sponsor, enGene, FEAC&#146;s directors,
officers or any of their respective affiliates may purchase FEAC Class A Shares from FEAC Shareholders outside the redemption process, along with the purpose of such purchases; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If FGOF, the Sponsor, enGene, FEAC&#146;s directors, officers or any of their respective affiliates were to
purchase FEAC Class A Shares from FEAC Shareholders: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FGOF, the Sponsor, enGene, FEAC&#146;s directors, officers or any of their respective affiliates would do so at a
price no higher than the price offered through the redemption process; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such purchased shares would not be voted in favor of approving the Business Combination transaction;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FGOF, the Sponsor, enGene, FEAC&#146;s directors, officers or their respective affiliates would not possess any
redemption rights with respect to such purchased shares or, if they do acquire and possess redemption rights, they would waive such rights; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FEAC would disclose in a Current Report on Form 8-K, before the Special Meeting, the following:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount of FEAC securities purchased outside of the redemption offer by FGOF, the Sponsor, FEAC&#146;s
directors, officers or any of their respective affiliates, along with the purchase price; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the purpose of such purchases; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact, if any, of such purchases on the likelihood that the Business Combination will be approved;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the identities of FEAC&#146;s selling shareholders for such purchases (if not purchased on the open market) or
the nature of FEAC&#146;s shareholders (e.g., 5% shareholders) who sold to FGOF, the Sponsor, enGene, FEAC&#146;s directors, officers or any of their respective affiliates; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of FEAC Class A Shares for which FEAC has received redemption requests pursuant to the redemption
offer. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are attempting to complete the Business Combination with a private company about which little information is available,
which may result in a business combination that does not deliver the expected benefits or is not as profitable as we suspected, if at all. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are seeking to effectuate the Business Combination with a privately held company. Very little public information generally exists about
private companies, including enGene. FEAC&#146;s board of directors was required, and FEAC Shareholders will be required, to evaluate the Business Combination on the basis of limited information, which may result in the Business Combination not
delivering the expected benefits or being less profitable than we suspected, if at all. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>There is no assurance that the due diligence undertaken in relation to the Business Combination has
uncovered all material issues in relation to the business or financial condition of enGene. Accordingly, subsequent to the completion of the Business Combination, New enGene may be required to take write-downs or write-offs, restructuring and
impairment or other charges that could have a significant negative effect on New enGene&#146;s financial condition, results of operations and share price, which could cause you to lose some or all of your investment. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FEAC cannot assure you that the extensive due diligence it has conducted on enGene would have surfaced all material issues that may be present
inside enGene, that it would be possible to uncover all material issues through a customary amount of due diligence, or that factors outside of enGene&#146;s business and outside of FEAC&#146;s control will not arise at a later stage. As a result of
these factors, New enGene may be forced to later write-down or <FONT STYLE="white-space:nowrap">write-off</FONT> assets, restructure its operations, or incur impairment or other charges that could result in New enGene reporting losses. Even if
FEAC&#146;s due diligence successfully identified certain risks, further unexpected risks may arise and previously known risks may materialize in a manner not consistent with FEAC&#146;s preliminary risk analysis. Even though these charges may be <FONT
STYLE="white-space:nowrap">non-cash</FONT> items and not have an immediate impact on New enGene&#146;s liquidity, the fact that charges of this nature are reported could contribute to negative market perceptions about New enGene or New enGene&#146;s
securities. In addition, charges of this nature may cause New enGene to violate covenants to which it may be subject as a result of assuming <FONT STYLE="white-space:nowrap">pre-existing</FONT> debt held by enGene or by virtue of post-combination
debt financing. Accordingly, any shareholders who choose to remain shareholders following the Business Combination could suffer a reduction in the value of their shares. Such shareholders are unlikely to have a remedy for such reduction in value.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>FEAC or enGene may waive one or more of the conditions to the completion of the Business Combination without recirculation of this proxy
statement/prospectus or resoliciting stockholder approval. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Business Combination Agreement, FEAC&#146;s and
enGene&#146;s obligations to consummate the Transactions are subject to certain conditions. Such conditions may be waived, in whole or in part, if permitted by law, either unilaterally or by agreement of FEAC and enGene. In the event of a waiver of
a condition, each of the FEAC Board and the enGene Board will evaluate the materiality of any such waiver to determine whether amendment of this proxy statement/prospectus and resolicitation of stockholder approval is necessary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that the FEAC Board and/or the enGene Board, in their own reasonable discretion, determine any such waiver is not significant
enough to require recirculation of this proxy statement/prospectus and resolicitation of stockholder approval, they will have the discretion to complete the Transactions without seeking further stockholder approval, which decision may have a
material adverse effect on the FEAC Shareholders. For example, FEAC and enGene could agree to waive the requirement that the New enGene Shares and New enGene Warrants be listed on Nasdaq or any other national securities exchange prior to the
Amalgamation, and their respective boards of directors could elect to proceed with the consummation of the Transactions despite such listing not having occurred. New enGene may try again in the future to have the New enGene Shares and New enGene
Warrants listed on Nasdaq or any other national securities exchange, but if New enGene does not apply for a listing or if such listing application is not successful, New enGene Shares and New enGene Warrants will not be listed. See &#147;<I>Risks
Related to Being a Public Company &#151; Nasdaq may not list New enGene&#146;s securities on its exchange, in which event, if not waived by the parties to the Business Combination Agreement as one of the closing conditions thereof, FEAC would not be
able to consummate the Business Combination with enGene. If New enGene&#146;s securities are listed, New enGene may be unable to satisfy listing requirements in the future, which could limit investors&#146; ability to effect transactions in New
enGene&#146;s securities and subject it to additional trading restrictions</I>&#148; for further information on this risk. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For more
information about the conditions to the completion of the Business Combination, see the section titled &#147;<I>The Business Combination Agreement &#151; Conditions to Consummation of the Transactions</I>.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>FEAC will have limited rights after the Closing to make claims for damages against enGene or enGene
Shareholders for the breach of representations, warranties, agreements or covenants made by enGene in the Business Combination Agreement. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination Agreement provides that the representations, warranties, agreements and covenants in the Business Combination
Agreement or in any certificate, statement or instrument delivered thereunder shall terminate at the Closing, except for those covenants and agreements that by their terms contemplate performance in whole or in part after the Closing. Accordingly,
except in the aforementioned limited circumstances, FEAC will have no rights to make damage claims against enGene after the Closing with respect to covenants or agreements contained in the Business Combination Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The FEAC Reorganization may be a taxable event for U.S. Holders of FEAC Class&nbsp;A Shares or FEAC Warrants. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the limitations and qualifications described in the section entitled &#147;<I>Material U.S. Federal Income Tax Considerations
</I><I>&#151; </I><I>Consequences of the Business Combination to U.S. Holders of FEAC Securities</I>.&#148; Although the treatment of the FEAC Reorganization for U.S. federal income tax purposes is not free from doubt, the FEAC Reorganization should
be treated as a &#147;reorganization&#148; described in Section&nbsp;368(a)(1)(F) of the Code. If this treatment applies, a U.S. Holder (as defined in &#147;<I>Material U.S. Federal Income Tax Considerations</I>&#148;) will not recognize gain or
loss on the exchange of the FEAC Class&nbsp;A Shares for New enGene Shares or the exchange of FEAC Warrants for New enGene Warrants pursuant to the Business Combination. However, there can be no assurance that the U.S. Internal Revenue Service will
not assert that the FEAC Reorganization does not qualify as a reorganization within the meaning of Section&nbsp;368 of the Code, or otherwise as a <FONT STYLE="white-space:nowrap">tax-free</FONT> transaction. In that case, a U.S. Holder that
exchanges its FEAC Class&nbsp;A Shares or FEAC Warrants for New enGene Shares or New enGene Warrants, as applicable, pursuant to the Business Combination will be required to recognize gain or loss equal to the difference between (i)&nbsp;the sum of
the fair market value of the New enGene Shares or New enGene Warrants received and (ii)&nbsp;the U.S. Holder&#146;s adjusted tax basis in the FEAC Class&nbsp;A Shares or FEAC Warrants exchanged. In addition, unless the FEAC Reorganization qualifies
as a reorganization described in Section&nbsp;368(a)(1)(F) of the Code, it is possible that the PFIC rules, further described below, could apply to the exchange of the FEAC Class&nbsp;A Shares or FEAC Warrants pursuant to the FEAC Reorganization,
depending on New enGene&#146;s PFIC status. U.S. Holders of FEAC Class&nbsp;A Shares or FEAC Warrants should consult their tax advisers regarding the U.S. federal income tax consequences of the FEAC Reorganization, including in the event that the
FEAC Reorganization does not qualify for a <FONT STYLE="white-space:nowrap">tax-free</FONT> treatment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We believe that FEAC (the predecessor to New
enGene for this purpose) was a passive foreign investment company (a &#147;PFIC&#148;) for its 2021 and 2022 taxable years, and there is a significant risk that New enGene may be or become a PFIC, which could result in adverse U.S. federal income
tax consequences to U.S. Holders of New enGene Shares or New enGene Warrants. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general and as relevant here, a non-U.S.
corporation is a PFIC for U.S. federal income tax purposes for any taxable year in which (i) 50% or more of the value of its assets (generally determined on the basis of a quarterly average) consists of assets, including its pro rata share of the
assets of any corporation in which it is considered to own at least 25% of the shares by value, that produce, or are held for the production of, passive income, or (ii) 75% or more of its gross income, including its pro rata share of the gross
income of any corporation in which it is considered to own at least 25% of the shares by value, consists of passive income. Passive income generally includes dividends, interest, rents and royalties (other than rents or royalties derived from the
active conduct of a trade or business) and gains from the disposition of passive assets. Cash and cash equivalents are generally passive assets. The value of goodwill will generally be treated as an active or passive asset based on the nature of the
income produced in the activity to which the goodwill is attributable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FEAC believes that it did not qualify for the PFIC &#147;start-up
exception&#148; (as described in <I>&#147;Material U.S. Federal Income Tax Considerations &#151; </I><I>Consequences to U.S. Holders of New enGene Securities of the Ownership and Disposition of New enGene Shares or New enGene Warrants &#151; Passive
Foreign Investment</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<I>Company</I> <I>Rules&#148;</I>) for its taxable year ended December 31, 2021. Therefore, because FEAC is a blank check company with no current active business, based on the composition of
FEAC&#146;s income and assets, FEAC believes that it was a PFIC for its taxable years ended December 31, 2021 and December 31, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
remainder of the discussion in this risk factor assumes that FEAC&#146;s intended treatment of the FEAC Reorganization as a reorganization described in Section 368(a)(1)(F) of the Code will be respected. If so treated, subject to the U.S.
Holder&#146;s making one or more (as appropriate) of the PFIC elections discussed under <I>&#147;Material U.S. Federal Income Tax Considerations &#151; Consequences to U.S. Holders of New enGene Securities of the Ownership and Disposition of New
enGene Shares or New enGene Warrants &#151; Passive Foreign Investment Company Rules,&#148;</I> New enGene will be treated as the same corporation as FEAC for purposes of the corporation&#146;s qualification as a PFIC and consequently FEAC&#146;s
income and assets may affect the PFIC status of New enGene for New enGene&#146;s taxable year in which the Business Combination occurs. New enGene&#146;s PFIC status for any taxable year is a factual annual determination that can be made only after
the end of that year and will depend on the composition of New enGene&#146;s income and assets and the value of its assets from time to time and, for the taxable year in which the Business Combination occurs, the income and assets of FEAC, its
predecessor for this purpose. The value of New enGene&#146;s assets includes the value of its goodwill and other intangible assets not shown on its financial statements, which may be determined, in large part, by reference to the market price of the
New enGene Shares from time to time, which is subject to change and may be particularly volatile while the business is at the pre-commercialization stage. In addition, prior to the commercialization of any of New enGene&#146;s drug candidates its
income may be primarily passive. Accordingly, there is a significant risk that New enGene will be a PFIC for its current or any future taxable year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if New enGene is not a PFIC for its current or any subsequent taxable year, if FEAC is or was a PFIC (as FEAC believes to be the case for
its 2021 and 2022 taxable years) for any taxable year during the holding period of a U.S. Holder (as defined in <I>&#147;Material U.S. Federal Income Tax</I> <I>Considerations</I>&#148;) in its FEAC Class A Shares, and such U.S. Holder did not make
one or more (as appropriate) of the PFIC Elections discussed under <I>&#147;Material U.S. Federal Income Tax </I><I>Considerations </I><I>&#151; </I><I>Consequences to U.S. Holders of New enGene Securities of the Ownership and Disposition of New
enGene Shares or New enGene Warrants &#151; Passive Foreign Investment Company Rules</I><I>,</I>&#148; then, although not free from<I> </I>doubt, New enGene would also be treated as a PFIC as to such U.S. Holder with respect to the<I> </I>New enGene
Shares received in the FEAC Reorganization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if FEAC is or was a PFIC for any taxable year during which a U.S. Holder owned
FEAC Warrants, the U.S. Holder may be subject to the general PFIC rules with respect to the shares underlying the FEAC Warrants unless the U.S. Holder makes a &#147;qualified electing fund&#148; election and a purging election under the PFIC rules
in respect of such underlying shares received upon an exercise of the warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If New enGene is a PFIC (or is treated as a PFIC with
respect to a U.S. Holder, <I>e.g. </I>due to prior ownership of FEAC Class A Shares without an applicable PFIC election or elections in effect) for any taxable year during which a U.S. Holder owns New enGene Shares, the U.S. Holder generally will be
subject to adverse U.S. federal income tax consequences, including increased tax liability on disposition gains and certain &#147;excess distributions&#148; and additional reporting requirements, unless the U.S. Holder makes one or more (as
appropriate) PFIC Elections (as defined below). Under proposed Treasury regulations relating to PFICs which have a retroactive effective date, the PFIC rules may apply to rights to acquire shares of a PFIC as if they were shares, and thus could
apply to dispositions (other than exercises) of the FEAC Warrants or New enGene Warrants. U.S. Holders of FEAC Class A Shares or FEAC Warrants, and prospective U.S. Holders of New enGene Shares or New enGene Warrants, should consult their tax
advisors regarding the application of the PFIC rules to FEAC and New enGene and the risks of owning equity securities, including warrants, in a company that may be a PFIC. See &#147;<I>Material U.S. Federal Income Tax</I> <I>Considerations
</I><I>&#151; </I><I>Consequences to U.S. Holders of New enGene Securities of the Ownership and Disposition of New enGene Shares or New enGene Warrants &#151; Passive Foreign Investment Company Rules</I>.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>FEAC may not be able to complete the Business Combination if the Business Combination is subject to
U.S. foreign investment regulations or review by a U.S. government entity, such as CFIUS. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Sponsor is controlled by, and has
substantial ties with, <FONT STYLE="white-space:nowrap">non-U.S.</FONT> persons domiciled principally in The Netherlands. Acquisitions and investments by <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Persons in certain U.S. businesses may be
subject to rules or regulations that limit foreign ownership. In addition, CFIUS is an interagency committee authorized to review certain transactions involving investments by foreign persons in U.S. businesses that have a nexus to, amongst other
things, critical technologies, critical infrastructure and/or sensitive personal data in order to determine the effect of such transactions on the national security of the United States. For so long as the Sponsor retains a material ownership
interest in FEAC, FEAC may be deemed a &#147;foreign person&#148; under such rules and regulations, any proposed business combination between FEAC and a U.S. business engaged in a regulated industry or which may affect national security (including
the Business Combination) could be subject to such foreign ownership restrictions, CFIUS review and/or mandatory filings. FEAC has concluded that the Business Combination will not fall within the scope of foreign ownership restrictions or within
CFIUS&#146;s jurisdiction. However, if the Business Combination falls within the scope of foreign ownership restrictions, we may be unable to consummate the Business Combination. In addition, if the Business Combination falls within CFIUS&#146;s
jurisdiction, FEAC may be required to make a mandatory filing or determine to submit a voluntary notice to CFIUS, or to proceed with the Business Combination without notifying CFIUS and risk CFIUS intervention, before or after closing the Business
Combination. CFIUS may decide to block or delay the Business Combination, impose conditions to mitigate national security concerns with respect to such Business Combination or order us to divest all or a portion of any U.S. business of New enGene if
FEAC proceeds without first obtaining CFIUS clearance. Moreover, the process of government review, whether by CFIUS or otherwise, could be lengthy. Because FEAC has only a limited time to complete its initial business combination, FEAC&#146;s
failure to obtain any required approvals within the requisite time-period may require FEAC to liquidate. If FEAC liquidates, the holders of FEAC Class&nbsp;A Shares may only receive their pro rata share of amounts held in the Trust Account, and the
FEAC Warrants will expire worthless. This will also cause the FEAC Shareholders to lose any potential investment opportunity in New enGene and the chance of realizing future gains on their investment through any price appreciation in New enGene.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If New enGene&#146;s performance following the Business Combination does not meet market expectations, the price of its securities may decline.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If New enGene&#146;s performance following the Business Combination does not meet market expectations, the price of New enGene
Shares may decline and be lower than the price of FEAC Class&nbsp;A Shares prior to the closing of the Business Combination. The market value of FEAC Class&nbsp;A Shares at the time of the Business Combination may vary significantly from the price
on the date the Business Combination Agreement was executed, the date of this proxy statement/prospectus, or the date on which FEAC Shareholders vote on the Business Combination. Because the number of New enGene Shares issued in connection with the
Business Combination will not be adjusted to reflect any changes in the market price of FEAC Class&nbsp;A Shares, the value of the New enGene Shares issued in connection with the Business Combination may be higher or lower than the value of the same
number of FEAC Class&nbsp;A Shares on earlier dates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, following the Business Combination, fluctuations in the price of FEAC
Class&nbsp;A Shares could contribute to the loss of all or part of your investment. Prior to the Business Combination, there has not been a public market for New enGene Shares, and trading in FEAC Class&nbsp;A Shares has not been active.
Accordingly, the valuation ascribed to New enGene Shares and FEAC Class&nbsp;A Shares in the Business Combination may not be indicative of the price that will prevail in the trading market following the Business Combination. If an active market for
FEAC Class&nbsp;A Shares develops and continues, the trading price of New enGene Shares following the Business Combination could be volatile and subject to wide fluctuations in response to various factors, some of which are beyond FEAC&#146;s,
enGene&#146;s and New enGene&#146;s control. Any of the factors listed below could have a material adverse effect on your investment in FEAC Class&nbsp;A Shares and New enGene Shares and, following the Business Combination, New enGene Shares may
trade at prices significantly below the price you paid for them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Factors affecting the trading price of New enGene Shares following the
Business Combination may include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">New enGene&#146;s operating results failing to meet market expectations in a particular period;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the market&#146;s expectations about New enGene&#146;s operating results; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in financial estimates and recommendations by securities analysts concerning New enGene or the biotech
industry and market in general; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">operating and share price performance of other companies that investors deem comparable to New enGene;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in laws and regulations affecting New enGene&#146;s business; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">commencement of, or involvement in, litigation involving New enGene; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in New enGene&#146;s capital structure, such as future issuances of securities or the incurrence of debt;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actual or anticipated fluctuations in New enGene&#146;s quarterly financial results or the quarterly financial
results of companies perceived to be similar to it; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the volume of New enGene Shares available for public sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any significant change in New enGene&#146;s Board or management; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales of substantial amounts of New enGene Shares by New enGene&#146;s directors, executive officers or
significant shareholders or the perception that such sales could occur; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general economic and political conditions such as recessions, inflation, interest rates, fuel prices,
international currency fluctuations and acts of war or terrorism. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Broad market and industry factors may depress the
market price of New enGene Shares irrespective of its operating performance. The stock market in general has experienced price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of the particular
companies affected. The trading prices and valuations of these stocks, and of New enGene&#146;s securities, may not be predictable. A loss of investor confidence in the market for biotech companies or the stocks of other companies which investors
perceive to be similar to New enGene could depress its stock price regardless of its business, prospects, financial conditions or results of operations. A decline in the market price of New enGene Shares also could adversely affect its ability to
issue additional securities and its ability to obtain additional financing in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">New enGene&#146;s stock price may be exposed to
additional risks because New enGene will become a public company through a &#147;de-SPAC&#148; transaction. There has been increased focus by government agencies on such transactions, and such increased focus is expected to continue, and New enGene
may be subject to increased scrutiny by the SEC and other government agencies on holders of New enGene&#146;s securities as a result, which could adversely affect the price of New enGene Shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Beginning in January 2022, there has been a precipitous drop in the market values of growth-oriented companies. Accordingly, securities of growth
companies such as New enGene may be more volatile than other securities and may involve special risks. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beginning in January 2022,
there has been a precipitous drop in the market values of growth-oriented companies like New enGene. In recent months, inflationary pressures, increases in interest rates and other adverse economic and market forces have contributed to these drops
in market value. As a result, New enGene&#146;s securities are subject to potential downward pressures. In addition, if there are substantial redemptions of FEAC Shares, there will be a lower float of New enGene Shares outstanding following the
Business Combination, which may cause further volatility in the price of New enGene securities and adversely impact New enGene&#146;s ability to secure financing following the closing of the Business Combination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Securities of companies formed through special purpose acquisition company mergers, such as New
enGene, may experience a material decline in price relative to the share price of the special purpose acquisition company prior to the merger. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As with most special purpose acquisition company initial public offerings in recent years, FEAC issued securities for $10.00 per unit upon the
closing of its IPO. As with other special purpose acquisition companies, the $10.00 per unit price of FEAC reflected each FEAC Unit being comprised of a FEAC Class A Share having a one-time right to redeem such share for a pro rata portion of the
proceeds held in the Trust Account equal to approximately $10.35 per share prior to the Closing of the Business Combination. Following Closing, the New enGene Shares will no longer have any such redemption right and will be solely dependent upon the
fundamental value of the combined company, which, like the securities of other companies formed through special purpose acquisition company mergers in recent years, may be significantly less than $10.35 per share. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>FEAC and enGene will incur significant transaction costs in connection with the Business Combination and related transactions. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FEAC and enGene have both incurred and expect to incur significant transaction costs in connection with consummating the Business Combination
and related transactions and New enGene expects to incur significant costs in connection with operating as a public company following the consummation of the Business Combination. New enGene may also incur additional costs to retain key employees.
All expenses incurred in connection with the Business Combination, including all legal, accounting, consulting, investment banking and other fees, expenses and costs, will be for the account of the party incurring such fees, expenses and costs or
paid by New enGene following the closing of the Business Combination. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>You do not have any rights or interests in funds from the Trust Account,
except under certain limited circumstances. If FEAC does not complete the Business Combination, you may therefore be forced to sell your FEAC Class&nbsp;A Shares or FEAC Warrants to liquidate your investment, potentially at a loss. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FEAC Shareholders will be entitled to receive funds from the Trust Account only upon the earlier to occur of: (i)&nbsp;FEAC&#146;s completion
of an initial business combination, and then only in connection with those FEAC Class&nbsp;A Shares that such shareholder properly elected to redeem, subject to the limitations described herein, (ii)&nbsp;the redemption of any FEAC Class&nbsp;A
Shares properly tendered in connection with a shareholder vote to amend FEAC&#146;s Current Articles (A)&nbsp;to modify the substance or timing of FEAC&#146;s obligation to provide holders of FEAC Class&nbsp;A Shares the right to have their shares
redeemed in connection with FEAC&#146;s initial business combination or to redeem 100% of FEAC&#146;s Class&nbsp;A Shares if FEAC does not complete its initial business combination within 18 months from the closing of our IPO (or up to 24 months
from the closing of our IPO if we extend the period of time to consummate a business combination, subject to our sponsor depositing additional funds in the Trust Account), or (B)&nbsp;with respect to any other provision relating to the rights of
holders of our FEAC Class&nbsp;A Shares, and (iii)&nbsp;the redemption of FEAC Class&nbsp;A Shares if we have not consummated an initial business combination within 18 months from the closing of our IPO (or up to 24 months from the closing of our
IPO if we extend the period of time to consummate a business combination, subject to our sponsor depositing additional funds in the Trust Account), subject to applicable law and as further described herein. FEAC Shareholders who redeem their FEAC
Class&nbsp;A Shares in connection with a shareholder vote described in clause (ii)&nbsp;in the preceding sentence shall not be entitled to funds from the Trust Account upon the subsequent completion of an initial business combination or liquidation
if we have not consummated an initial business combination within 18 months from the closing of our IPO (or up to 24 months from the closing of our IPO if we extend the period of time to consummate a business combination, subject to our sponsor
depositing additional funds in the Trust Account), with respect to such FEAC Class&nbsp;A Shares so redeemed. In no other circumstances will a holder of FEAC Class&nbsp;A Shares have any right or interest of any kind in the Trust Account.
Accordingly, to liquidate your investment, you may be forced to sell your FEAC Class&nbsp;A Shares or FEAC Warrants, potentially at a loss. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The exercise of FEAC&#146;s directors&#146; and executive officers&#146; discretion in agreeing to
changes or waivers with respect to the terms of the Business Combination may result in a conflict of interest when determining whether such changes to the terms of the Business Combination or waivers of conditions are appropriate and in FEAC
Shareholders&#146; best interest. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the period leading up to the closing of the Business Combination, events may occur that,
pursuant to the Business Combination Agreement, would require to agree to amend the Business Combination Agreement, to consent to certain actions to be taken by enGene, or to waive rights that FEAC is entitled to under the Business Combination
Agreement. Such events could arise because of changes in the course of enGene&#146;s business, a request by enGene to undertake actions that would otherwise be prohibited by the terms of the Business Combination Agreement, or the occurrence of other
events that would have a material adverse effect on enGene&#146;s business and would entitle FEAC to terminate the Business Combination Agreement. In any of such circumstances, it would be at FEAC&#146;s discretion, acting through the FEAC Board, to
grant its consent or waive those rights. The existence of financial and personal interests of one or more of the directors described under &#147;<I>&#151; Since the Sponsor, its parent FGOF and FEAC&#146;s directors and executive officers have
interests that are different from, or in addition to (and which may conflict with), the interests of FEAC&#146;s other shareholders, a conflict of interest may exist in determining whether the Business Combination is appropriate as FEAC&#146;s
initial business combination. Such interests include that the Sponsor may lose its entire investment if a Business Combination is not completed, and that the Sponsor, FGOF and certain of FEAC&#146;s directors will benefit from the completion of a
Business Combination and may be incentivized to complete the Business Combination, even if it is with a less favorable target company or on less favorable terms to FEAC Shareholders, rather than liquidate FEAC</I>&#148; may result in a conflict of
interest on the part of such director(s) between what such director(s) may believe is best for FEAC and FEAC Shareholders and what such director(s) may believe is best for himself or herself or themselves in determining whether or not to take the
requested action. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>FEAC has identified a material weakness in its internal control over financial reporting. If FEAC and, following the Business
Combination, New enGene, is unable to develop and maintain an effective system of internal control over financial reporting, FEAC and, following the Business Combination, New enGene, may not be able to accurately report its financial results in a
timely manner, meet reporting obligations, prevent fraud and/or file periodic reports in a timely manner, which may adversely affect investor confidence in FEAC or New enGene, as applicable, and materially and adversely affect FEAC&#146;s or New
enGene&#146;s, as applicable, business and operating results. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In conjunction with the audit of FEAC&#146;s consolidated financial
statements for the year ended December&nbsp;31, 2022, FEAC identified a material weakness in its internal control over financial reporting as of December&nbsp;31, 2022. A material weakness is a deficiency, or combination of control deficiencies, in
internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the annual or interim condensed consolidated financial statements will not be prevented or detected on a timely basis. The
material weakness identified principally relates to (i)&nbsp;an inadvertent discrepancy between the description of the FEAC Private Placement Warrants in the notes to our financial statements in our Form <FONT STYLE="white-space:nowrap">10-K</FONT>
for the year ended December&nbsp;31, 2021 and our Forms <FONT STYLE="white-space:nowrap">10-Q</FONT> for the three-month periods ended September&nbsp;30, 2021, March&nbsp;31, 2022, June&nbsp;30, 2022 and September&nbsp;30, 2022 (the &#147;Forms <FONT
STYLE="white-space:nowrap">10-Q&#148;)</FONT> and in the underlying warrant agreement, and (ii)&nbsp;the inadvertent omission of the signatures of our principal financial officer and principal accounting officer in our Forms <FONT
STYLE="white-space:nowrap">10-Q.</FONT> This material weakness did not result in a material misstatement to our consolidated financial statements included herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective internal controls are necessary for us to provide reliable financial reports and prevent fraud. We continue to evaluate steps to
remediate the material weakness. These remediation measures may be time consuming and costly and there is no assurance that these initiatives will ultimately have the intended effects. While we already have processes in place to ensure that our
periodic reports satisfy the applicable reporting and compliance requirements, we will continue to enhance and invest in accounting resources and processes necessary to comply with the reporting and compliance requirements of a public company and
include a greater level of supervision needed in relation to our disclosure controls and procedures. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If FEAC or New enGene, as applicable, identify any new material weaknesses in the future,
any such newly identified material weakness could limit FEAC&#146;s or New enGene&#146;s, as applicable, ability to prevent or detect a misstatement of its accounts or disclosures that could result in a material misstatement of its annual or interim
financial statements. In such case, FEAC or New enGene, as applicable, may be unable to maintain compliance with securities law requirements regarding timely filing of periodic reports in addition to applicable stock exchange listing requirements,
investors may lose confidence in its financial reporting and FEAC&#146;s or New enGene&#146;s share price, as applicable, may decline as a result. Neither FEAC nor, following Business Combination, New enGene can assure you that any measures it may
take in the future will be sufficient to avoid potential future material weaknesses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>FEAC is, and New enGene will be following the Business
Combination, subject to changing law and regulations regarding regulatory matters, corporate governance, and public disclosure that have increased both FEAC&#146;s costs and the risk of <FONT STYLE="white-space:nowrap">non-compliance</FONT> and will
increase both New enGene&#146;s costs and the risk of <FONT STYLE="white-space:nowrap">non-compliance.</FONT> </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FEAC is, and New
enGene will be following the Business Combination, subject to rules and regulations by various governing bodies, including, for example, the SEC (including with respect to FEAC the SEC&#146;s proposed rules and amendments to enhance disclosure and
investor protection in business combination transactions involving special purpose acquisition companies), which are charged with the protection of investors and the oversight of companies whose securities are publicly traded, and to new and
evolving regulatory measures under applicable law. FEAC&#146;s efforts to comply with new and changing laws and regulations have resulted in, and New enGene&#146;s efforts to comply likely will result in, increased general and administrative
expenses and a diversion of management time and attention. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, because these laws, regulations, and standards are subject to
varying interpretations, their application in practice may evolve over time as new guidance becomes available. This evolution may result in continuing uncertainty regarding compliance matters and additional costs necessitated by ongoing revisions to
New enGene&#146;s disclosure and governance practices. If either FEAC or New enGene fails to address and comply with these regulations and any subsequent changes, FEAC or New enGene may be subject to penalty and FEAC&#146;s or New enGene&#146;s
business may be harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If the Adjournment Proposal is not approved, and an insufficient number of votes have been obtained to authorize the
consummation of the Business Combination, the FEAC Board will not have the ability to adjourn the Special Meeting to a later date in order to, among other things, solicit further votes. As a result, the Business Combination will not be approved,
and, therefore, the Business Combination may not be consummated. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FEAC Board is seeking approval, as an ordinary resolution, to
adjourn the Special Meeting to a later date or dates to the extent reasonable (i)&nbsp;to ensure that any supplement or amendment to this proxy statement/prospectus is provided to FEAC Shareholders, or (ii)&nbsp;in order to solicit additional
proxies from FEAC Shareholders in favor of, among other things, the Business Combination Proposal or for any other reason in connection with the transactions contemplated by the Business Combination Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Adjournment Proposal is not approved, the FEAC Board will not have the ability to adjourn the Special Meeting to a later date and,
therefore, will not have more time to take actions in furtherance of consummating the transactions contemplated by the Business Combination Agreement, including solicit votes. In such events, the Business Combination may not be completed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>During the <FONT STYLE="white-space:nowrap">pre-closing</FONT> period, (i)&nbsp;FEAC and enGene are prohibited from entering into certain transactions
that might otherwise be beneficial to FEAC, enGene or their respective shareholders and (ii)&nbsp;uncertainties about whether the Business Combination will be consummated may cause third parties to delay or defer decisions concerning enGene or seek
to change existing arrangements. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until the earlier of the consummation of the Business Combination or termination of the Business
Combination Agreement, FEAC and enGene are subject to certain limitations on the operations of their </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
businesses. Please see the section entitled &#147;<I>The Business Combination Agreement &#151; Covenants</I>&#148; for additional information. The limitations on FEAC&#146;s and enGene&#146;s
conduct of their businesses during this period could have the effect of delaying or preventing other strategic transactions and may, in some cases, make it impossible to pursue business opportunities that are available only for a limited time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There may also be uncertainty regarding whether the Business Combination will occur. This uncertainty may cause third parties to delay or
defer decisions concerning enGene, which could negatively affect enGene&#146;s business. Third parties may seek to change existing agreements with enGene as a result of the proposed Business Combination for these or other reasons. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Being a Public Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>New
enGene&#146;s management team has limited experience managing a public company, and the additional requirements for public companies may strain resources and divert management&#146;s attention. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The individuals who will constitute New enGene&#146;s management have not previously managed enGene&#146;s business, or in some cases any
business, as a publicly traded company. Compliance with public company requirements will place significant additional demands on management and will require them to enhance investor relations, legal, financial reporting and corporate communications
functions. New enGene&#146;s management will be required to devote substantial time to maintaining and improving its internal controls over financial reporting and the requirements of being a public company. These additional efforts may strain
resources and divert management&#146;s attention from other business concerns and affect its ability to accurately report its financial results and prevent fraud, which could adversely affect New enGene&#146;s business and profitability. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>There are risks to FEAC Shareholders related to becoming shareholders of enGene through the Business Combination rather than through an underwritten
public offering, including no independent due diligence review by an underwriter. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;11 of the Securities Act
(&#147;Section&nbsp;11&#148;) imposes liability on parties, including underwriters, involved in a securities offering if the registration statement contains a materially false statement or material omission. To effectively establish a due diligence
defense against a cause of action brought pursuant to Section&nbsp;11, a defendant, including an underwriter, carries the burden of proof to demonstrate that such defendant, after reasonable investigation, believed that the statements in the
registration statement were true and free of material omissions. In order to meet this burden of proof, underwriters in a registered offering typically conduct extensive due diligence of the registrant and vet the registrant&#146;s disclosure. Such
due diligence may include calls with the issuer&#146;s management, review of material agreements, and background checks on key personnel, among other investigations. Because enGene intends to become publicly traded through a business combination
with a special purpose acquisition company rather than through an underwritten offering of enGene Shares, no underwriter is involved in the Business Combination. As a result, no underwriter has conducted independent due diligence on enGene in order
to establish a due diligence defense with respect to the disclosure presented in this proxy statement/prospectus. If such investigation had occurred, certain information in this proxy statement/prospectus may have been presented in a different
manner or additional information may have been presented at the request of such underwriter. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Nasdaq may not list New enGene&#146;s securities on
its exchange, in which event, if not waived by the parties to the Business Combination Agreement as one of the closing conditions thereof, FEAC would not be able to consummate the Business Combination with enGene. If New enGene&#146;s securities are
listed, New enGene may be unable to satisfy listing requirements in the future, which could limit investors&#146; ability to effect transactions in New enGene&#146;s securities and subject it to additional trading restrictions. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of the Business Combination, Nasdaq rules require that New enGene applies for the listing of the New enGene Shares and New enGene
Warrants. FEAC, enGene and New enGene have undertaken in the Business </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Combination Agreement to apply to have the New enGene Shares and New enGene Warrants listed on Nasdaq or any other national securities exchange prior to the Amalgamation, and the approval of such
application is a condition of the consummation of the Business Combination. There can be no assurance that such listing condition will be met. If such listing condition is not met, the Business Combination will not be consummated unless the
satisfaction of such condition is waived by FEAC and enGene by mutual agreement as provided in the Business Combination Agreement. See also <I>&#147;&#151; Risks Related to the Business Combination &#151; FEAC or enGene may waive one or more of the
conditions to the completion of the Business Combination without recirculation of this proxy statement/prospectus or resoliciting stockholder approval.&#148;</I> As a result, the FEAC Shareholders will not have certainty at the time they vote or
make their redemption decision with respect to their FEAC Class A Shares regarding whether the New enGene Shares and the New enGene Warrants will be listed on Nasdaq or any other national securities exchange following the Business Combination. If
the parties to the Business Combination Agreement do not waive such closing condition, FEAC might not be able to consummate the Business Combination with New enGene and will need to seek for an alternative business combination to complete its
initial business combination within the prescribed time period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">New enGene will be required to meet Nasdaq&#146;s initial listing
requirements and may be unable to meet those requirements. Even if New enGene&#146;s securities are listed on the Nasdaq immediately prior to the Amalgamation, New enGene may be unable to maintain the listing of its securities in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If New enGene fails to meet the initial listing requirements and the Nasdaq does not list New enGene&#146;s securities on its exchange, or if
New enGene is delisted, there could be significant material adverse consequences, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a limited availability of market quotations for our securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced liquidity for New enGene&#146;s securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a determination that New enGene Shares are a &#147;penny stock&#148; which will require brokers trading in New
enGene Shares to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for New enGene&#146;s securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a limited amount of news and analyst coverage for New enGene; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a decreased ability to obtain capital or pursue acquisitions by issuing additional equity or convertible
securities. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>New enGene will incur increased costs as a result of operating as a public company, and its management will devote
substantial time to new compliance initiatives. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a privately held company, enGene has not been required to comply with many
corporate governance and financial reporting practices and policies required of a publicly traded company. As a publicly traded company, New enGene will incur significant legal, accounting and other expenses that enGene was not required to incur in
the past. In addition, new and changing laws, regulations and standards relating to corporate governance and public disclosure for public companies, including the Dodd-Frank Act, the Sarbanes-Oxley Act, regulations related thereto and the rules and
regulations of the SEC and Nasdaq, have increased the costs and the time that must be devoted to compliance matters. We expect these rules and regulations will increase New enGene&#146;s legal and financial costs and lead to a diversion of
management time and attention from revenue-generating activities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A market for New enGene&#146;s securities may not develop, which would adversely
affect the liquidity and price of its securities. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the Business Combination, the price of New enGene&#146;s securities
may fluctuate significantly due to the market&#146;s reaction to the Business Combination as well as general market and economic conditions. An active trading market for New enGene&#146;s securities following the Business Combination may never
develop or, if it develops, it may not be sustained, which could have a material adverse effect on the liquidity and price of New enGene&#146;s securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">156 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>New enGene could be a target of securities class action and derivative lawsuits, which could result in
substantial costs. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the Business Combination, New enGene&#146;s share price may be volatile and, in the past, companies
that have experienced volatility in the market price of their shares have from time to time been subject to securities class action litigation. New enGene may be the target of this type of litigation in the future. Litigation of this type could
result in substantial costs and diversion of management&#146;s attention and resources, which could have a material adverse effect on New enGene business, financial condition, results of operations and prospects. Any adverse determination in
litigation could also subject New enGene to significant liabilities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If securities or industry analysts do not publish research about New enGene at
all or publish inaccurate or unfavorable research about New enGene or its business, the market price and/or the trading volume of the New enGene Shares could decline </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading market for the New enGene Shares will depend in part on the research and reports that securities or industry analysts publish about
New enGene or its business. If no or few securities or industry analysts cover New enGene, then the market price for the New enGene Shares could be adversely affected. If one or more of the analysts who cover New enGene downgrade a recommendation
with regard to the New enGene Shares, publish inaccurate or unfavorable research about New enGene or its business, cease to cover New enGene or fail to publish reports on it regularly, the market price and/or the trading volume of the New enGene
Shares could decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Regarding Redemption </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Holders of FEAC Class&nbsp;A Shares who wish to redeem their FEAC Class&nbsp;A Shares for a pro rata portion of the Trust Account must comply with
specific requirements for redemption that may make it more difficult for them to exercise their redemption rights prior to the deadline. If such FEAC Shareholders fail to comply with the redemption requirements specified in this proxy
statement/prospectus, they will not be entitled to redeem their FEAC Class&nbsp;A Shares for the right to receive a pro rata portion of the funds held in the Trust Account. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A holder of FEAC Class&nbsp;A Shares will be entitled to receive the right for an amount in cash for any FEAC Class&nbsp;A Shares to be
redeemed only if such holder: (i)(a) holds FEAC Class&nbsp;A Shares, or (b)&nbsp;holds FEAC Class&nbsp;A Shares through FEAC Units and elects to separate its FEAC Units into the underlying FEAC Class&nbsp;A Shares and FEAC Warrants prior to
exercising its redemption rights with respect to the FEAC Class&nbsp;A Shares; (ii)&nbsp;submits a written request to Continental, FEAC&#146;s transfer agent, in which it (a)&nbsp;requests that FEAC redeem all or a portion of its FEAC Class&nbsp;A
Shares for the right to receive an amount in cash, and (b)&nbsp;identifies itself as a beneficial holder of the FEAC Class&nbsp;A Shares and provides its legal name, phone number, and address; and (iii)&nbsp;delivers its share certificates (if any)
and other redemption forms (as applicable) to Continental physically or electronically through DTC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of FEAC Class&nbsp;A Shares
must complete the procedures for electing to redeem their FEAC Class&nbsp;A Shares in the manner described above prior to 5:00 p.m., New York City time,
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023 (two business days before the Special Meeting) in order for their FEAC Class&nbsp;A Shares to be redeemed. In order to obtain a physical share
certificate, such FEAC Shareholder&#146;s broker and/or clearing broker, DTC and Continental, will need to act to facilitate this request. It is FEAC&#146;s understanding that holders of FEAC Class&nbsp;A Shares should generally allot at least two
weeks to obtain physical certificates from the transfer agent. However, because FEAC does not have any control over this process or over DTC, it may take significantly longer than two weeks to obtain a physical stock certificate. If it takes longer
than anticipated to obtain a physical certificate, such FEAC Shareholders who wish to redeem their FEAC Class&nbsp;A Shares may be unable to obtain physical certificates by the deadline for exercising their redemption rights and thus will be unable
to redeem their shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Business Combination is consummated, and if a holder of FEAC Class&nbsp;A Shares has properly exercised
its right to redeem all or a portion of the FEAC Class&nbsp;A Shares that it holds and timely delivers its share certificates (if any) and other redemption forms (as applicable) to Continental, FEAC will redeem such
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">157 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
FEAC Class&nbsp;A Shares for the right to receive a per share price, payable in cash by FEAC, equal to the pro rata portion of the Trust Account established at the consummation of the IPO,
calculated as of two business days prior to the consummation of the Business Combination. Please see the section entitled &#147;<I>Information About the Special Meeting &#151; Redemption Rights</I>&#148; for additional information on how to exercise
your redemption rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If you or a &#147;group&#148; of holders of FEAC Class&nbsp;A Shares are deemed to hold in excess of 15% of FEAC
Class&nbsp;A Shares, you may lose the ability to redeem all such shares in excess of 15% of FEAC&#146;s Class&nbsp;A Shares. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A
holder of FEAC Class&nbsp;A Shares, together with any of his, her or its affiliates or any other person with whom it is acting in concert or as a &#147;group&#148; (as defined under Section&nbsp;13 of the Exchange Act), will be restricted from
redeeming in the aggregate his, her or its shares or, if part of such a group, the group&#146;s shares, in excess of 15% of the shares sold in our IPO. In order to determine whether a shareholder is acting in concert or as a group with another
shareholder, FEAC will require each holder of FEAC Class&nbsp;A Shares seeking to exercise redemption rights to certify to FEAC whether such shareholder is acting in concert or as a group with any other shareholder. Such certifications, together
with other public information relating to share ownership available to FEAC at that time, such as Section&nbsp;13D, Section&nbsp;13G, and Section&nbsp;16 filings under the Exchange Act, will be the sole basis on which FEAC makes the above-referenced
determination. Your inability to redeem any such excess shares will reduce your influence over FEAC&#146;s ability to consummate the Business Combination and you could suffer a material loss on your investment in FEAC if you sell such excess shares
in open market transactions. Additionally, you will not receive redemption distributions with respect to such excess shares if FEAC consummates the Business Combination. As a result, you will continue to hold that number of shares aggregating to
more than 15% of the FEAC Class&nbsp;A Shares and, in order to dispose of such excess shares, would be required to sell your shares in open market transactions, potentially at a loss. FEAC cannot assure you that the value of such excess shares will
appreciate over time following the Business Combination or that the market price of a FEAC Class&nbsp;A Share will exceed the per share redemption price. Notwithstanding the foregoing, shareholders may challenge FEAC&#146;s determination as to
whether a shareholder is acting in concert or as a group with another shareholder in a court of competent jurisdiction. However, FEAC Shareholders&#146; ability to vote all of their shares (including such excess shares) for or against the Business
Combination is not restricted by this limitation on redemption. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Holders of FEAC Class&nbsp;A Shares may in limited circumstances be required to
repay unlawful distributions knowingly received by them upon redemption of their shares. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If FEAC is forced to enter into an
insolvent liquidation, any distributions received by shareholders could be viewed as an unlawful payment if it was proved that immediately following the date on which the distribution was made, we were unable to pay FEAC&#146;s debts as they fall
due in the ordinary course of business. As a result, a liquidator could in certain circumstances seek to recover all unlawful distributions knowingly received by holders of FEAC Class&nbsp;A Shares. Furthermore, FEAC&#146;s directors may be viewed
as having breached their fiduciary duties to us or FEAC&#146;s creditors and/or may have acted in bad faith, thereby exposing themselves and FEAC to claims, by paying holders of FEAC Class&nbsp;A Shares from the Trust Account prior to addressing the
claims of creditors. We cannot assure you that claims will not be brought against us for these reasons. We and FEAC&#146;s directors and officers who knowingly and willfully authorized or permitted any distribution to be paid out of FEAC&#146;s
share premium account while we were unable to pay FEAC&#146;s debts as they fall due in the ordinary course of business would be guilty of an offence and may be liable to a fine of $18,292.68 and imprisonment for five years in the Cayman Islands.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If a shareholder fails to receive notice of FEAC&#146;s offer to redeem FEAC Class&nbsp;A Shares in connection with the Business Combination, or
fails to comply with the procedures for tendering its shares, such shares may not be redeemed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FEAC intends to comply with the
proxy rules when conducting redemptions in connection with the<B><I> </I></B>Business Combination. Despite FEAC&#146;s compliance with these rules, if a shareholder fails to receive FEAC&#146;s proxy materials,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">158 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such shareholder may not become aware of the opportunity to redeem its shares. In addition, this proxy statement/prospectus describes the various procedures that must be complied with in order to
validly redeem FEAC Class&nbsp;A Shares. In the event that a shareholder fails to comply with these procedures, its shares may not be redeemed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Termination of the Business Combination Agreement could negatively impact FEAC. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Business Combination is not completed for any reason, the ongoing business of FEAC may be adversely impacted and, without realizing any
of the anticipated benefits of completing the Business Combination, FEAC would be subject to a number of risks, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FEAC may experience negative reactions from the financial markets, including negative impacts on its share price
(including to the extent that the current market price reflects a market assumption that the Business Combination will be completed); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FEAC will have incurred substantial expenses and will be required to pay certain costs relating to the Business
Combination, whether or not it is completed. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Business Combination Agreement is terminated and the FEAC Board
seeks another merger or business combination, FEAC Shareholders cannot be certain that FEAC will be able to find another acquisition target that would constitute a business combination or that such other merger or business combination will be
completed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If third parties bring claims against FEAC, the proceeds held in the Trust Account could be reduced and the per share redemption amount
received by holders of FEAC Class&nbsp;A Shares may be less than $ 10.35 per FEAC Class&nbsp;A Share. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our placing of funds in the
Trust Account may not protect those funds from third-party claims against us. Although we will seek to have all vendors, service providers, prospective target businesses and other entities with which we do business execute agreements with us waiving
any right, title, interest or claim of any kind in or to any monies held in the Trust Account for the benefit of holders of FEAC Class&nbsp;A Shares, such parties may not execute such agreements, or even if they execute such agreements, they may not
be prevented from bringing claims against the Trust Account, including, but not limited to, fraudulent inducement, breach of fiduciary responsibility or other similar claims, as well as claims challenging the enforceability of the waiver, in each
case in order to gain advantage with respect to a claim against our assets, including the funds held in the Trust Account. If any third-party refuses to execute an agreement waiving such claims to the monies held in the Trust Account, our management
will perform an analysis of the alternatives available to it and will only enter into an agreement with a third-party that has not executed a waiver if management believes that such third- party&#146;s engagement would be significantly more
beneficial to us than any alternative. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Examples of possible instances where we may engage a third-party that refuses to execute a
waiver include the engagement of a third-party consultant whose particular expertise or skills are believed by management to be significantly superior to those of other consultants that would agree to execute a waiver or in cases where management is
unable to find a service provider willing to execute a waiver. In addition, there is no guarantee that such entities will agree to waive any claims they may have in the future as a result of, or arising out of, any negotiations, contracts or
agreements with us and will not seek recourse against the Trust Account for any reason. Upon the exercise of a redemption right in connection with the Business Combination, we will be required to provide for payment of claims of creditors that were
not waived that may be brought against us within the ten years following redemption. Accordingly, the per share redemption amount received by holders of FEAC Class&nbsp;A Shares could be less than the $10.35 per FEAC Class&nbsp;A Share currently
held in the Trust Account, due to claims of such creditors. Pursuant to the letter agreement we entered into concurrently with our IPO, the Sponsor has agreed that it will be liable to us if and to the extent any claims by a third party (other than
our independent registered public accounting firm) for services rendered or products sold to us, or a prospective target business with which we have discussed entering into a transaction agreement, reduce the amounts in the Trust Account to below
the lesser of (i) $10.25 per FEAC Class&nbsp;A Share and (ii)&nbsp;the actual amount per FEAC Class&nbsp;A Share held </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">159 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in the Trust Account as of the date of the liquidation of the Trust Account if less than $10.25 per FEAC Class&nbsp;A Share due to reductions in the value of the trust assets, in each case net of
the interest that may be withdrawn to pay our tax obligations, provided that such liability will not apply to any claims by a third-party or prospective target business that executed a waiver of any and all rights to seek access to the Trust Account
nor will it apply to any claims under our indemnity of the underwriters of our IPO against certain liabilities, including liabilities under the Securities Act. Moreover, in the event that an executed waiver is deemed to be unenforceable against a
third-party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, we have not asked
the Sponsor to reserve for such indemnification obligations, nor have we independently verified whether the Sponsor has sufficient funds to satisfy its indemnity obligations and we believe that the Sponsor&#146;s only assets are securities of FEAC.
Therefore, we cannot assure you that the Sponsor would be able to satisfy those obligations. As a result, if any such claims were successfully made against the Trust Account, the funds available for the Business Combination and redemptions could be
reduced to less than $10.35 per FEAC Class&nbsp;A Share. In such event, we may not be able to complete the Business Combination, and you would receive such lesser amount per share in connection with any redemption of your FEAC Class&nbsp;A Shares.
None of our officers or directors will indemnify us for claims by third parties including, without limitation, claims by vendors and prospective target businesses. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>FEAC may redeem your unexpired warrants prior to their exercise at a time that is disadvantageous to you, thereby making your warrants worthless.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FEAC has the ability to redeem the outstanding public warrants at any time after they become exercisable and prior to their
expiration, at a price of $0.01 per warrant, provided that the closing price of FEAC Class&nbsp;A Shares equals or exceeds $18.00 per share (as adjusted for certain adjustments to the number of shares issuable upon exercise or the exercise price of
a warrant) for any 20 trading days within a 30 <FONT STYLE="white-space:nowrap">trading-day</FONT> period ending on the third trading day prior to proper notice of such redemption and provided that certain other conditions are met. If and when the
warrants become redeemable by us, we may exercise our redemption right even if we are unable to register or qualify the underlying securities for sale under all applicable state securities laws. As a result, we may redeem the warrants as set forth
above even if the holders are otherwise unable to exercise the warrants. Redemption of the outstanding warrants could force you to (i)&nbsp;exercise your warrants and pay the exercise price therefor at a time when it may be disadvantageous for you
to do so, (ii)&nbsp;sell your warrants at the then-current market price when you might otherwise wish to hold your warrants or (iii)&nbsp;accept the nominal redemption price which, at the time the outstanding warrants are called for redemption, we
expect would be substantially less than the market value of your warrants. None of the private placement warrants will be redeemable by us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks
Related to FEAC </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>FEAC may not be able to consummate an initial business combination within 18 months after the closing of FEAC&#146;s IPO (or up
to 24 months from the closing of our IPO if we extend the period of time to consummate a business combination), in which case we would cease all operations except for the purpose of winding up and we would redeem our FEAC Class&nbsp;A Shares and
liquidate, in which case FEAC Shareholders may receive only $10.35 per share, or less than such amount in certain circumstances, and our warrants will expire worthless. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FEAC&#146;s Current Articles provide that we have only 18 months from the closing of our IPO on December&nbsp;14, 2021 to consummate an initial
business combination. If we anticipate that we may not be able to consummate our initial business combination within 18 months, and subject to our sponsor depositing additional funds into the Trust Account as set out below, our time to consummate a
business combination shall be extended two times for an additional three months each time, for a total of up to 24 months to complete a business combination. This will occur as long as the Sponsor or its affiliates or designees, on or prior to the
date of the applicable deadline, deposits into the Trust Account, for each three-month extension, $1,265,000 ($0.10 per unit). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If
the<B><I> </I></B>Business Combination does not occur, FEAC may not be able to find a suitable target business and complete FEAC&#146;s initial business combination within such time period. If FEAC has not consummated an initial
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">160 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
business combination within such applicable time period, we will: (i)&nbsp;cease all operations except for the purpose of winding up; (ii)&nbsp;as promptly as reasonably possible but not more
than ten business days thereafter, redeem the FEAC Class&nbsp;A Shares, at a per share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (which interest will be net of taxes payable)
earned on the funds held in the Trust Account and not previously released to us to pay our income taxes, if any (less up to $100,000 of interest to pay dissolution expenses and any withholding tax), divided by the number of the then-outstanding FEAC
Class&nbsp;A Shares, which redemption will completely extinguish such FEAC Shareholders&#146; rights as shareholders (including the right to receive further liquidation distributions, if any); and (iii)&nbsp;as promptly as reasonably possible
following such redemption, subject to the approval of our remaining shareholders and our board of directors, liquidate and dissolve, subject in the case of clauses (ii)&nbsp;and (iii), to our obligations under Cayman Islands law to provide for
claims of creditors and the requirements of other applicable law. Our Current Articles provide that, if we wind up for any other reason prior to the consummation of our initial business combination, we will follow the foregoing procedures with
respect to the liquidation of the Trust Account as promptly as reasonably possible but not more than ten business days thereafter, subject to applicable Cayman Islands law. In either such case, FEAC Shareholders may receive only $10.35 per FEAC
Class&nbsp;A Share, or less than $10.35 per FEAC Class&nbsp;A Share (assuming we do not extend the period of time to consummate a business combination beyond 21 months), on the redemption of their shares, and FEAC Warrants will expire worthless. See
&#147;&#151; <I>If third parties bring claims</I> <I>against FEAC, the proceeds</I> <I>held in the Trust Account could be reduced and the per share redemption amount received by holders of FEAC Class</I><I></I><I>&nbsp;A Shares may be less than
$10.35 per FEAC Class</I><I></I><I>&nbsp;A Share</I>&#148; and other risk factors herein. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>FEAC&#146;s directors may decide not to enforce the
indemnification obligations of the Sponsor, resulting in a reduction in the amount of funds in the Trust Account available for distribution to FEAC Shareholders. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that the proceeds in the Trust Account are reduced below the lesser of (i) $10.25 per FEAC Class&nbsp;A Share and (ii)&nbsp;the
actual amount per FEAC Class&nbsp;A Share held in the Trust Account as of the date of the liquidation of the Trust Account if less than $10.25 per FEAC Class&nbsp;A Share due to reductions in the value of the trust assets, in each case net of the
interest that may be withdrawn to pay our tax obligations, and the Sponsor asserts that it is unable to satisfy its obligations or that it has no indemnification obligations related to a particular claim, our independent directors would determine
whether to take legal action against the Sponsor to enforce its indemnification obligations. While we currently expect that our independent directors would take legal action on our behalf against the Sponsor to enforce its indemnification
obligations to us, it is possible that our independent directors in exercising their business judgment and subject to their fiduciary duties may choose not to do so in any particular instance. If our independent directors choose not to enforce these
indemnification obligations, the amount of funds in the Trust Account available for distribution to FEAC Shareholders may be reduced below $10.35 per FEAC Class&nbsp;A Share. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If, after FEAC distributes the proceeds in the Trust Account to FEAC Shareholders, we file a bankruptcy or
<FONT STYLE="white-space:nowrap">winding-up</FONT> petition or an involuntary bankruptcy or <FONT STYLE="white-space:nowrap">winding-up</FONT> petition is filed against us that is not dismissed, a bankruptcy or insolvency court may seek to recover
such proceeds, and the members of FEAC&#146;s board of directors may be viewed as having breached their fiduciary duties to FEAC&#146;s creditors, thereby exposing the members of our board of directors and us to claims of punitive damages.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If, after FEAC distributes the proceeds in the Trust Account to FEAC Shareholders, we file a bankruptcy or <FONT
STYLE="white-space:nowrap">winding-up</FONT> petition or an involuntary bankruptcy or <FONT STYLE="white-space:nowrap">winding-up</FONT> petition is filed against us that is not dismissed, any distributions received by shareholders could be viewed
under applicable debtor/creditor and/or bankruptcy or insolvency laws as either a &#147;preferential transfer&#148; or a &#147;fraudulent conveyance.&#148; As a result, a bankruptcy or insolvency court could seek to recover some or all amounts
received by our shareholders. In addition, our board of directors may be viewed as having breached its fiduciary duty to our creditors and/or having acted in bad faith, thereby exposing itself and us to claims of punitive damages, by paying FEAC
Shareholders from the Trust Account prior to addressing the claims of creditors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">161 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If, before distributing the proceeds in the Trust Account to FEAC Shareholders, FEAC files a
bankruptcy or <FONT STYLE="white-space:nowrap">winding-up</FONT> petition or an involuntary bankruptcy or <FONT STYLE="white-space:nowrap">winding-up</FONT> petition is filed against us that is not dismissed, the claims of creditors in such
proceeding may have priority over the claims of our shareholders and the per share amount that would otherwise be received by our shareholders in connection with our liquidation may be reduced. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If, before distributing the proceeds in the Trust Account to FEAC Shareholders, FEAC files a bankruptcy or
<FONT STYLE="white-space:nowrap">winding-up</FONT> petition or an involuntary bankruptcy or <FONT STYLE="white-space:nowrap">winding-up</FONT> petition is filed against us that is not dismissed, the proceeds held in the Trust Account could be
subject to applicable bankruptcy or insolvency law, and may be included in our bankruptcy estate and subject to the claims of third parties with priority over the claims of our shareholders. To the extent any bankruptcy claims deplete the Trust
Account, the per share amount that would otherwise be received by our shareholders in connection with our liquidation may be reduced. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If FEAC is
unable to consummate its initial business combination within 18 months from the closing of FEAC&#146;s IPO (or up to 24 months from the closing of our IPO if we extend the period of time to consummate a business combination, subject to the Sponsor
depositing additional funds in the Trust Account), FEAC Shareholders may be forced to wait beyond such periods before redemption from FEAC&#146;s Trust Account. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If FEAC is unable to consummate the Business Combination or another initial business combination prior to December&nbsp;14, 2023, we will
distribute the aggregate amount then on deposit in the Trust Account (less up to $100,000 of the net interest earned thereon to pay dissolution expenses), pro rata to FEAC Shareholders by way of redemption and cease all operations except for the
purposes of winding up of FEAC&#146;s affairs, as further described herein. Any redemption of FEAC Shareholders from the Trust Account shall be effected automatically by function of FEAC&#146;s Current Articles prior to any voluntary winding up. If
FEAC is required to windup, liquidate the Trust Account and distribute such amount therein, pro rata, to FEAC Shareholders, as part of any liquidation process, such winding up, liquidation and distribution must comply with the applicable provisions
of the Companies Act. In that case, investors may be forced to wait beyond December&nbsp;14, 2023 before the redemption proceeds of FEAC&#146;s Trust Account become available to them and they receive the return of their pro rata portion of the
proceeds from FEAC&#146;s Trust Account. We have no obligation to return funds to investors prior to the date of FEAC&#146;s redemption or liquidation unless we consummate FEAC&#146;s initial business combination prior thereto and only then in cases
where investors have sought to redeem their FEAC Class&nbsp;A Shares. Only upon FEAC&#146;s redemption or any liquidation will FEAC Shareholders be entitled to distributions if FEAC is unable to complete FEAC&#146;s initial business combination.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If FEAC has not consummated an initial business combination within 18 months from the closing of its IPO (or up to 24 months from the
closing of our IPO if we extend the period of time to consummate a business combination, subject to our sponsor depositing additional funds in the Trust Account), the proceeds then on deposit in the Trust Account, including interest earned on the
funds held in the Trust Account and not previously released to us to pay our income taxes, if any (less up to $100,000 of interest to pay dissolution expenses and subject to any withholding tax), will be used to fund the redemption of our FEAC
Class&nbsp;A Shares, as further described herein. Any redemption of FEAC Shareholders from the Trust Account will be effected automatically by function of our Current Articles prior to any voluntary winding up. If we are required to wind up,
liquidate the Trust Account and distribute such amount therein, pro rata, to FEAC Shareholders, as part of any liquidation process, such winding up, liquidation and distribution must comply with the applicable provisions of the Companies Act. In
that case, investors may be forced to wait beyond 18 months from the closing of our IPO (or up to 24 months from the closing of our IPO if we extend the period of time to consummate a business combination, subject to our sponsor depositing
additional funds in the Trust Account) before the redemption proceeds of our Trust Account become available to them, and they receive the return of their pro rata portion of the proceeds from our Trust Account. We have no obligation to return funds
to investors prior to the date of our redemption or liquidation unless, prior thereto, we consummate our initial business combination or amend certain provisions of our Current Articles, and only then in cases where investors have sought to redeem
their FEAC Class&nbsp;A Shares. Only upon our redemption or any liquidation will FEAC Shareholders be entitled to distributions if we do not complete our initial business </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">162 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
combination and do not amend certain provisions of our Current Articles. Our Current Articles provide that, if we wind up for any other reason prior to the consummation of our initial business
combination, we will follow the foregoing procedures with respect to the liquidation of the Trust Account as promptly as reasonably possible but not more than ten business days thereafter, subject to applicable Cayman Islands law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Past performance by FEAC&#146;s management team or their respective affiliates may not be indicative of future performance of an investment in
FEAC&#146;s securities. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information regarding performance is presented for informational purposes only. Any past experience or
performance of FEAC&#146;s management team and their respective affiliates is not a guarantee of either (i)&nbsp;our ability to successfully identify and execute a transaction or (ii)&nbsp;success with respect to any business combination that we may
consummate. You should not rely on the historical record of our management team or their respective affiliates as indicative of the future performance of an investment in our securities or the returns we will, or are likely to, generate going
forward. Our management has no experience in operating special purpose acquisition companies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>FEAC is dependent upon FEAC&#146;s officers and
directors and their departure could adversely affect FEAC&#146;s ability to operate. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operations are dependent upon a
relatively small group of individuals. We believe that FEAC&#146;s success depends on the continued service of FEAC&#146;s officers and directors, at least until we have completed the Business Combination or another initial business combination. In
addition, FEAC&#146;s officers and directors are not required to commit any specified amount of time to FEAC&#146;s affairs and, accordingly, will have conflicts of interest in allocating management time among various business activities, including
completion of the Business Combination or identifying an alternative business combinations and monitoring the related due diligence. We do not have an employment agreement with, or <FONT STYLE="white-space:nowrap">key-man</FONT> insurance on the
life of, any of FEAC&#146;s directors or officers. The unexpected loss of the services of one or more of FEAC&#146;s directors or officers could have a detrimental effect on us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">163 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom459793_15"></A>INFORMATION ABOUT THE PARTIES TO THE BUSINESS COMBINATION
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forbion European Acquisition Corp. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FEAC is a blank check company incorporated on August&nbsp;9, 2021 as a Cayman Islands exempted company for the purpose of effecting a merger,
share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. Prior to executing the Business Combination Agreement, FEAC&#146;s efforts were limited to organizational
activities, completion of its IPO and the evaluation of possible business combinations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>enGene Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">enGene is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. enGene is developing <FONT
STYLE="white-space:nowrap">non-viral</FONT> gene therapies based on its novel and proprietary dually derived chitosan, or &#147;DDX&#148;, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues
and other organs. enGene has established integrated capabilities with this platform to support the clinical development and potential commercialization of its gene therapies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>enGene Holdings Inc. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">enGene Holdings
Inc., a corporation incorporated under the laws of Canada, was formed for the purpose of consummating the Business Combination and will be the parent company of the combined operating business following the consummation of the Business
Combination.<B><I> </I></B> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cayman Merger Sub </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cayman Merger Sub refers to a to be incorporated Cayman Islands exempted company and a direct wholly owned subsidiary of enGene Holdings Inc.
(&#147;Cayman Merger Sub&#148;). On the date that is one business day prior to the Closing Date, Cayman Merger Sub will merge with and into FEAC with FEAC as the surviving entity pursuant to a plan of merger under the laws of the Cayman Islands.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Can Merger Sub </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Can Merger Sub
refers to a to be incorporated wholly owned subsidiary of Forbion European Acquisition Corp. (&#147;Can Merger Sub&#148;). Can Merger Sub and enGene Inc. will amalgamate pursuant the Plan of Arrangement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">164 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom459793_16"></A>INFORMATION ABOUT THE SPECIAL MEETING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This proxy statement/prospectus
is being provided to FEAC Shareholders as part of a solicitation of proxies by the FEAC Board for use at the Special Meeting to be convened on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023 and at any adjournments or
postponements of such meeting. This proxy statement/prospectus is being furnished to FEAC Shareholders on or about&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023. In addition, this proxy statement/prospectus
constitutes a prospectus for New enGene in connection with the issuance by New enGene of 27,090,013 common shares, 6,896,099 warrants and 6,896,099 common shares underlying the warrants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Date, Time and Place of the Special Meeting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FEAC has called the Special Meeting for&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023 at 10:00 a.m., New York
City time at &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. FEAC Shareholders may attend, vote and examine the list of FEAC Shareholders entitled to vote at the Special Meeting by visiting
<B><U>https://www.cstproxy.com/feac/2023</U></B> and entering the control number found on their proxy card, voting instruction form or notice they previously received. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Proposals </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the Special Meeting, FEAC
Shareholders will vote upon: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Business Combination Proposal, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Governing Documents Proposal, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Nasdaq Proposal, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Incentive Equity Plan Proposal, and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Adjournment Proposal. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>AFTER CAREFUL CONSIDERATION, THE FEAC BOARD HAS DETERMINED THAT EACH OF THE BUSINESS COMBINATION PROPOSAL, THE GOVERNING DOCUMENTS PROPOSAL, THE NASDAQ
PROPOSAL, THE INCENTIVE EQUITY PLAN PROPOSAL AND THE ADJOURNMENT PROPOSAL ARE IN THE BEST INTERESTS OF AND ADVISABLE TO FEAC AND THE FEAC SHAREHOLDERS AND RECOMMENDS THAT YOU VOTE, OR GIVE INSTRUCTION TO VOTE, &#147;FOR&#148; EACH OF THOSE
PROPOSALS. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Record Date; Outstanding Shares; Shares Entitled to Vote </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FEAC has established the close of business on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023 as the &#147;record
date&#148; for determining FEAC Shareholders entitled to notice of and to attend and vote at the Special Meeting. As of the close of business on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023, there were
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;FEAC Class&nbsp;A Shares and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;FEAC
Class&nbsp;B Shares outstanding and entitled to vote. Each FEAC Share is entitled to one vote per share at the Special Meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quorum </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A quorum of FEAC Shareholders is necessary to hold a valid meeting. A quorum will exist at the Special Meeting with respect to each matter to
be considered at the Special Meeting if the holders of a majority of FEAC Shares are present in person or represented by proxy at the Special Meeting. All shares represented by proxy are counted as present for purposes of establishing a quorum. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">165 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vote Required and FEAC Board Recommendation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>The Business Combination Proposal </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FEAC Shareholders are being asked to consider and vote on a proposal to adopt the Business Combination Agreement and thereby approve the
Business Combination. You should carefully read this proxy statement/prospectus in its entirety for more detailed information concerning the Business Combination. In particular, your attention is directed to the full text of the Business Combination
Agreement, which is attached as <B><U>Annex A</U></B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The adoption and approval of the Business Combination Agreement and the
Transactions including the Plan of Arrangement requires the affirmative vote of the holders of at least a majority of the FEAC Shares present in person or represented by proxy and entitled to vote at the Special Meeting; the approval of (i)&nbsp;the
Cayman Merger and (ii)&nbsp;the Cayman Reorganization requires the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the FEAC Shares present in person or represented by proxy and entitled to vote at
the Special Meeting. Therefore, the approval of the Business Combination Proposal also requires the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the FEAC Shares present in person or represented by
proxy and entitled to vote at the Special Meeting. Abstentions will have no effect on the outcome of the proposal. The Business Combination cannot be completed unless the Business Combination Proposal is adopted by affirmative vote of the holders of
at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the votes cast by FEAC Shareholders present or represented by proxy at the Special Meeting and entitled to vote thereon. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>The Governing Documents Proposal </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FEAC Shareholders are being asked to consider and vote on a proposal to adopt the Governing Documents Proposal. You should carefully read this
proxy statement/prospectus in its entirety for more detailed information concerning the Governing Documents Proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The adoption and
approval of the Governing Documents Proposal requires the affirmative vote of the holders of at least a majority of the FEAC Shares present in person or represented by proxy and entitled to vote at the Special Meeting. Abstentions will have no
effect on the outcome of the proposal. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>The Nasdaq Proposal </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FEAC Shareholders are being asked to consider and vote on a proposal to adopt the Nasdaq Proposal. You should carefully read this proxy
statement/prospectus in its entirety for more detailed information concerning the Nasdaq Proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The adoption and approval of the
Nasdaq Proposal requires the affirmative vote of the holders of at least a majority of the FEAC Shares present in person or represented by proxy and entitled to vote at the Special Meeting. Abstentions will have no effect on the outcome of the
proposal. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>The Incentive Equity Plan Proposal </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FEAC Shareholders are being asked to consider and vote on a proposal to adopt the Incentive Equity Plan Proposal. You should carefully read
this proxy statement/prospectus in its entirety for more detailed information concerning the Incentive Equity Plan Proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The adoption
and approval of the Incentive Equity Plan Proposal requires the affirmative vote of the holders of at least a majority of the FEAC Shares present in person or represented by proxy and entitled to vote at the Special Meeting. Abstentions will have no
effect on the outcome of the proposal. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>The Adjournment Proposal </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FEAC Shareholders may be asked to vote on a proposal to adjourn the Special Meeting, or any postponement thereof, to a later date or dates, if
necessary. In no event will FEAC solicit proxies to adjourn the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">166 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Special Meeting or consummate the Business Combination beyond the date by which it may properly do so under its Current Articles and Cayman Islands law. The purpose of the Adjournment Proposal is
to provide more time for the FEAC officers, directors, initial stockholders, enGene, and the enGene Shareholders to make purchases of public shares or other arrangements that would increase the likelihood of obtaining a favorable vote on the
Business Combination proposal and to meet the requirements that are necessary to consummate the Business Combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The approval of the
Adjournment Proposal will require affirmative vote of a majority of the shares present in person or by proxy and entitled to vote at the Special Meeting. Abstentions will count as votes &#147;against&#148; the proposal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THE BOARD OF DIRECTORS RECOMMENDS THAT YOU VOTE &#147;FOR&#148; EACH OF THESE PROPOSALS. </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Voting Your Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FEAC
Shareholders may vote in person at the Special Meeting, electronically at the Special Meeting by visiting <B><U>https://www.cstproxy.com/feac/2023</U></B> or by proxy. FEAC recommends that you submit your proxy even if you plan to attend the Special
Meeting. If you vote by proxy, you may change your vote by submitting a later dated proxy before the deadline or by voting in person or electronically at the Special Meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If your FEAC Shares are owned directly in your name with our transfer agent, Continental, you are considered, with respect to those shares,
the &#147;shareholder of record.&#148; If your shares are held in a stock brokerage account or by a bank or other nominee or intermediary, you are considered the beneficial owner of shares held in &#147;street name&#148; and are considered a <FONT
STYLE="white-space:nowrap">&#147;non-record</FONT> (beneficial) shareholder.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you are a FEAC Shareholder of record you may use
the enclosed proxy card to tell the persons named as proxies how to vote your shares. If you properly complete, sign and date your proxy card, your shares will be voted in accordance with your instructions. The named proxies will vote all FEAC
Shares at the meeting for which proxies have been properly submitted and not revoked. If you sign and return your proxy card but do not mark your card to tell the proxies how to vote, your FEAC Shares will be voted &#147;<B>FOR</B>&#148; the
proposals to adopt the Business Combination Agreement and the other proposals presented at the Special Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Your FEAC Shares will be
counted for purposes of determining a quorum if you vote: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in person; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">via the Internet; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by telephone; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by submitting a properly executed proxy card or voting instruction form by mail; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">electronically at the Special Meeting. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Abstentions will be counted for determining whether a quorum is present for the Special Meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting Shares Held in Street Name </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If
your FEAC Shares are held in an account through a broker, bank or other nominee or intermediary, you must instruct the broker, bank or other nominee how to vote your shares by following the instructions that the broker, bank or other nominee
provides you along with this proxy statement/prospectus. Your broker, bank or other nominee may have an earlier deadline by which you must provide instructions to it as to how to vote your FEAC Shares, so you should read carefully the materials
provided to you by your broker, bank or other nominee or intermediary. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">167 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you do not provide voting instructions to your bank, broker or other nominee or
intermediary, your shares will not be voted on any proposal on which your bank, broker or other nominee does not have discretionary authority to vote. In these cases, the bank, broker or other nominee or intermediary will not be able to vote your
shares on those matters for which specific authorization is required. Brokers do not generally have discretionary authority to vote on any of the proposals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Nasdaq rules, if a shareholder holds their shares in &#147;street name&#148; through a bank, broker or other nominee and the shareholder
does not instruct their broker, bank or other nominee how to vote their shares on a proposal, the broker, bank or other nominee has the authority to vote the shares in its discretion on certain &#147;routine&#148; matters. However, banks, brokers
and other nominees are not authorized to exercise their voting discretion on any <FONT STYLE="white-space:nowrap">&#147;non-routine&#148;</FONT> matters. This can result in a &#147;broker <FONT STYLE="white-space:nowrap">non-vote,&#148;</FONT> which
occurs on a proposal when (i)&nbsp;a bank, broker or other nominee has discretionary authority to vote on one or more &#147;routine&#148; proposals to be voted on at a meeting, (ii)&nbsp;there are one or more
<FONT STYLE="white-space:nowrap">&#147;non-routine&#148;</FONT> proposals to be voted on at the meeting for which the bank, broker or other nominee does not have authority to vote without instructions from the beneficial owner of the shares and
(iii)&nbsp;the beneficial owner fails to provide the bank, broker or other nominee with voting instructions on a <FONT STYLE="white-space:nowrap">&#147;non-routine&#148;</FONT> matter. We believe that all of the proposals to be voted on at the
Special Meeting will be considered <FONT STYLE="white-space:nowrap">non-routine</FONT> matters. As a result, if you hold your shares in &#147;street name,&#148; your bank, brokerage firm or other nominee cannot vote your shares on any of the
proposals to be voted on at the Special Meeting without your instruction. Because all of the proposals to be voted on at the Special Meeting are <FONT STYLE="white-space:nowrap">&#147;non-routine&#148;</FONT> matters, banks, brokers and other
nominees will not have authority to vote on any proposals unless instructed, so FEAC does not expect there to be any broker <FONT STYLE="white-space:nowrap">non-votes</FONT> at the Special Meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Revoking Your Proxy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you are a FEAC
Shareholder of record, you may revoke your proxy at any time before it is voted at the Special Meeting by: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">timely delivering a written revocation letter to the Corporate Secretary of FEAC; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">timely submitting your voting instructions again by telephone or over the Internet; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">signing and returning by mail a proxy card with a later date so that it is received prior to the Special Meeting;
or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">attending the Special Meeting and voting in person or electronically by visiting
<B><U>https://www.cstproxy.com/feac/2023</U></B> and entering the control number found on your proxy card, voting instruction form or notice you previously received. Attendance at the Special Meeting, whether in person or electronically, will not,
in and of itself, revoke a proxy. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you are a <FONT STYLE="white-space:nowrap">non-record</FONT> (beneficial) FEAC
Shareholder, you should follow the instructions of your bank, broker or other nominee regarding the revocation of proxies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Share Ownership and Voting
by FEAC&#146;s Officers and Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the record date, the FEAC directors and officers and their affiliates had the right to
vote approximately &nbsp;&nbsp;&nbsp;&nbsp; FEAC Class&nbsp;A Shares and &nbsp;&nbsp;&nbsp;&nbsp; FEAC Class&nbsp;B Shares, representing approximately &nbsp;&nbsp;&nbsp;&nbsp;% and &nbsp;&nbsp;&nbsp;&nbsp;%, respectively, of the FEAC Class&nbsp;A
Shares and FEAC Class&nbsp;B Shares then outstanding and entitled to vote at the meeting. FEAC&#146;s initial shareholder (consisting of the Sponsor) and its directors at the time of its IPO have entered into a letter agreement with us pursuant to
which they will vote &#147;<B>FOR</B>&#148; the approval of the Business Combination Proposal, &#147;<B>FOR</B>&#148; the approval of the Governing Documents Proposal, &#147;<B>FOR</B>&#148; the approval of the Nasdaq Proposal,
&#147;<B>FOR</B>&#148; the approval of the Incentive Equity Plan Proposal, and &#147;<B>FOR</B>&#148; the approval of the Adjournment Proposal. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">168 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Redemption Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of FEAC Class&nbsp;A Shares may seek to redeem the FEAC Class&nbsp;A Shares they hold, regardless of whether they vote for or against
the Business Combination or do not vote at the Special Meeting. Any holder of FEAC Class&nbsp;A Shares may request redemption of their FEAC Class&nbsp;A Shares for a per share price, payable in cash, equal to the aggregate amount then on deposit in
the Trust Account, calculated as of two business days prior to the consummation of the Business Combination, including interest (which interest will be net of taxes payable) earned on the funds held in the trust account and not previously released
to FEAC to pay FEAC&#146;s income taxes, if any, divided by the number of then-outstanding FEAC Class&nbsp;A Shares, subject to the limitations described herein. Furthermore, as it is expected that we are and will be considered a Dutch tax resident,
any redemption proceeds (including interest income on the Trust Account) distributed to FEAC Shareholders in excess of the <FONT STYLE="white-space:nowrap">paid-up</FONT> capital for Dutch tax purposes may be subject to 15% Dutch dividend
withholding tax. If a holder of FEAC Class&nbsp;A Shares properly seeks redemption as described in this section and the Business Combination is consummated, such holder will no longer own these FEAC Class&nbsp;A Shares following the Business
Combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, a holder of FEAC Class&nbsp;A Shares, together with any affiliate of such shareholder or any
other person with whom such shareholder is acting in concert or as a &#147;group&#148; (as defined in Section&nbsp;13 of the Exchange Act), will be restricted from redeeming its shares with respect to more than an aggregate of 15% of the shares sold
in our IPO, without our prior consent. Accordingly, if a holder of FEAC Class&nbsp;A Shares, alone or acting in concert or as a group, seeks to redeem more than 15% of the FEAC Class&nbsp;A Shares, then any such FEAC Class&nbsp;A Shares in excess of
that 15% limit would not be redeemed for cash. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a holder of FEAC Class&nbsp;A Shares, you will be entitled to receive cash for any FEAC
Class&nbsp;A Shares to be redeemed only if you: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">(a) hold FEAC Class&nbsp;A Shares or (b)&nbsp;hold FEAC Class&nbsp;A Shares through FEAC Units and you elect to
separate your FEAC Units into the underlying FEAC Class&nbsp;A Shares and FEAC Warrants prior to exercising your redemption rights with respect to the FEAC Class&nbsp;A Shares; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">5:00 p.m., New York City time, on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023
(two business days before the Special Meeting), (a) submit a written request to Continental Stock Transfer&nbsp;&amp; Trust Company, FEAC&#146;s transfer agent (the &#147;transfer agent&#148;), that FEAC redeem all or a portion of your FEAC
Class&nbsp;A Shares for cash and (b)&nbsp;identify yourself as a beneficial holder of the FEAC Class&nbsp;A Shares and provide your legal name, phone number, and address; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">deliver your FEAC Class&nbsp;A Shares to the transfer agent, physically or electronically through DTC.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you hold the FEAC Class&nbsp;A Shares in &#147;street name,&#148; you will need to instruct the account executive at
your bank or broker to withdraw the FEAC Class&nbsp;A Shares from your account in order to exercise your redemption rights. There is a nominal cost associated with this process and the act of certificating the FEAC Class&nbsp;A Shares or delivering
them through the DWAC system. The transfer agent will typically charge the tendering broker $80 and it would be up to the broker whether or not to pass this cost on to the redeeming holder of FEAC Class&nbsp;A Shares. In the event the Business
Combination is not consummated, this may result in an additional cost to holders of FEAC Class&nbsp;A Shares for the return of their shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of FEAC Units must elect to separate the underlying FEAC Class&nbsp;A Shares and FEAC Warrants prior to exercising redemption rights
with respect to the FEAC Class&nbsp;A Shares. If holders hold their FEAC Units in an account at a brokerage firm or bank, holders must notify their broker or bank that they elect to separate the FEAC Units into the underlying FEAC Class&nbsp;A
Shares and FEAC Warrants, or if a holder holds units registered in its own name, the holder must contact the transfer agent, directly and instruct it to do so. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">169 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any request to redeem FEAC Class&nbsp;A Shares, once made, may be withdrawn at any time
until the deadline for submitting redemption requests and thereafter, with the consent of FEAC&#146;s directors (acting in their sole discretion). If a holder of FEAC Class&nbsp;A Shares delivers its shares in connection with an election to redeem
and subsequently decides prior to the deadline for submitting redemption requests not to elect to exercise such rights, it may simply request that FEAC instruct its transfer agent to return the shares (physically or electronically). The holder can
make such request by contacting the transfer agent, at the address or email address listed in this proxy statement/prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the
Business Combination is not approved or completed for any reason, then holders of FEAC Class&nbsp;A Shares who elected to exercise their redemption rights will not be entitled to redeem their FEAC Class&nbsp;A Shares. In such case, FEAC will
promptly return any FEAC Class&nbsp;A Shares previously delivered by such holders. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For illustrative purposes, the cash held in the
Trust Account on June&nbsp;30, 2023 was $135,786,170. Prior to exercising redemption rights, holders of FEAC Class&nbsp;A Shares should verify the market price of FEAC Class&nbsp;A Shares as they may receive higher proceeds from the sale of their
FEAC Class&nbsp;A Shares in the public market than from exercising their redemption rights if the market price per share is higher than the redemption price. FEAC cannot assure you that you will be able to sell you FEAC Class&nbsp;A Shares in the
open market, even if the market price per share is higher than the redemption price stated above, as there may not be sufficient liquidity in its securities when FEAC Shareholders wish to sell their shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a holder of FEAC Class&nbsp;A Shares exercises its redemption rights, then it will be exchanging its redeemed FEAC Class&nbsp;A Shares for
cash and will no longer own such shares. You will be entitled to receive cash for your FEAC Class&nbsp;A Shares only if you properly exercise your right to redeem your FEAC Class&nbsp;A Shares and deliver them (either physically or electronically)
to the transfer agent, in each case prior to 5:00 p.m., New York City time, on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023 (two business days before the Special Meeting), the deadline for submitting redemption
requests, and the Business Combination is consummated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with Closing, FEAC will pay holders of FEAC Class&nbsp;A Shares who
properly exercised their redemption rights in respect of their FEAC Class&nbsp;A Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Assuming maximum FEAC Shareholder Redemptions of
10,483,335 FEAC Class A Shares and based on the closing price of such FEAC Warrants of $&nbsp;&nbsp;&nbsp;&nbsp; on Nasdaq as of &nbsp;&nbsp;&nbsp;&nbsp;, 2023, the aggregate value that can be retained by FEAC Shareholders who have properly
exercised their FEAC Shareholders Redemptions is $&nbsp;&nbsp;&nbsp;&nbsp;. The actual market price of the FEAC Warrants may be higher or lower on the date that a holder of FEAC Warrants seeks to sell or exercise such FEAC Warrants. Additionally,
FEAC cannot assure the holders of FEAC Warrants that they will be able to sell their FEAC Warrants in the open market as there may not be sufficient liquidity in such FEAC Warrants when a holder thereof desires to sell. Further, while the level of
redemptions of FEAC Class A Shares will not directly change the value of the FEAC Warrants, as the FEAC Warrants will remain outstanding regardless of the level of redemptions, as redemptions of FEAC Class A Shares increase, a holder of FEAC
Warrants will ultimately own a greater interest in FEAC (or, after completion of the Business Combination, New enGene) because there would be fewer FEAC Class A Shares (or, after completion of the Business Combination, New enGene Shares) outstanding
overall. Further, the potential for the issuance of a substantial number of FEAC Class A Shares (or, after completion of the Business Combination, New enGene Shares) upon exercise of the FEAC Warrants (or, after completion of the Business
Combination, New enGene Warrants) could make New enGene less attractive to investors. Any such issuance will increase the number of issued and outstanding FEAC Class A Shares (or, after completion of the Business Combination, New enGene Shares) and
reduce the value of the outstanding FEAC Class A Shares (or, after completion of the Business Combination, New enGene Shares). Therefore, the outstanding FEAC Warrants (or, after completion of the Business Combination, New enGene Warrants) could
have the effect of depressing the market price of FEAC Class A Shares (or, after completion of the Business Combination, New enGene Shares). For additional information see &#147;<I>Questions and Answers Abou</I><I>t the Business Combination and the
Special Meeting &#151; What will the respective percentage ownership interests of New enGene be following the consummation of the Business Combination?</I>&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">170 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Underwriting Fees as a Percentage of Amount in Trust Account </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding the hypothetical effective underwriting fee payable to the underwriters of FEAC&#146;s IPO
upon completion of the Business Combination as a percentage of the amount in the Trust Account under the following scenarios: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">No Redemption Scenario: assumes that no holder of FEAC Class A Shares exercises redemption rights to have its
FEAC Class A Shares converted into their pro rata share of the Trust Account and thus the full amount held in the Trust Account as of the Closing is available for the Business Combination; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Maximum Redemption Scenario: assumes that 10,483,335 FEAC Class A Shares are redeemed, resulting in an aggregate
cash payment of approximately $112.5 million out of the Trust Account based on an assumed redemption price of $10.73 per share that is calculated using the $135.8 million cash in the Trust Account divided by 12,650,000 FEAC Class A Shares subject to
redemption assuming the pro forma maximum redemptions scenario pursuant to the Business Combination Agreement. The number of FEAC Class A Shares that are redeemed in this scenario is derived by reducing the total of 12,650,000 FEAC Class A Shares
outstanding by 2,000,000, FEAC Class A Shares held by the FGOF that are subject to lock-up agreements and 166,665 FEAC Class A Shares held by a FEAC Shareholder that are subject to the Non-Redemption Agreement; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In connection with its IPO, FEAC entered into an underwriting agreement pursuant to which it agreed to pay the
underwriters thereunder underwriting commissions in the aggregate amount of 2.0% of the gross proceeds of the FEAC Units sold to the FEAC public shareholders upon the consummation of the IPO (including gross proceeds of FEAC Units sold upon the
exercise of the underwriters&#146; overallotment option, but exclusive of the 2,000,000 FEAC Units sold to FGOF). Following the exercise by the underwriters of their overallotment option, these earned underwriting commissions totaled
$2.1&nbsp;million, which amount was paid to the underwriters at the time of the consummation of the IPO. In addition, FEAC agreed in the underwriting agreement to pay to the underwriters upon the consummation of its initial business combination a
deferred underwriting commission of 3.5% of the gross proceeds of the FEAC Units sold to the FEAC public shareholders in the IPO (including FEAC Units sold upon exercise of the underwriters&#146; overallotment option, but exclusive of FEAC Units
sold to FGOF). These deferred underwriting commissions total $3.7&nbsp;million. Neither the earned underwriting commission nor the deferred underwriting commission are contingent upon, or adjusted as a result of, the exercise of redemption rights by
the FEAC public shareholders in connection with the consummation of the Business Combination. This means that, in each redemption scenario presented, the FEAC IPO underwriters will be paid the entire $3.7&nbsp;million in deferred underwriting
commissions from amounts released from the Trust Account upon consummation of the Business Combination. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>No Redemption<BR>scenario</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Maximum<BR>Redemption<BR>scenario</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IPO underwriting fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,727,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,727,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amount in Trust Account net of redemptions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">135,786,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,299,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting fees as a % of Amount in Trust Account net of&nbsp;redemptions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.75</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Appraisal Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FEAC Shareholders that dissent from the Business Combination in accordance with the Cayman Act are entitled to be paid the fair market value of
their shares, which if necessary may ultimately be determined by the court. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Potential Purchases of Shares and/or Public Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At any time prior to the Special Meeting, during a period when they are not then aware of any material nonpublic information regarding FEAC or
its securities, the Sponsor, enGene and FEAC&#146;s directors, officers or their respective affiliates may purchase FEAC Class A Shares and/or FEAC Warrants from investors, or they may enter into transactions with such investors and others to
provide them with incentives to acquire FEAC </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">171 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Class&nbsp;A Shares or vote their shares in favor of the Business Combination. In such transactions, the purchase price for each FEAC Class A Share will not exceed the per-share redemption amount
available to redeeming FEAC Shareholders. In addition, the purchasers described above will waive redemption rights, if any, with respect to the FEAC Class A Shares they acquire in such transactions. The purpose of such share purchases and other
transactions would be to increase the likelihood that the proposals presented to shareholders for approval at the Special Meeting are approved. Any such share purchases and other transactions may thereby increase the likelihood of obtaining
shareholder approval of the Business Combination, however, such purchased shares would not be voted in favor of approving the Business Combination. This may result in the completion of the Business Combination in a way that may not otherwise have
been possible. While the exact nature of any such incentives has not been determined as of the date of this proxy statement/prospectus, they might include, without limitation, arrangements to protect such investors or holders against potential loss
in value of their shares, including the granting of put options and the transfer to such investors or holders of shares or rights owned by the Sponsor for nominal value. The details of such purchases would be disclosed by FEAC in a Form 8-K Current
Report prior to the Special Meeting, and would be made in compliance with Rule 14e-5 under the Exchange Act, relying on Tender Offer Compliance and Disclosure Interpretation 166.01 (March 22, 2022). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Costs of Solicitation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FEAC will bear the
cost of soliciting proxies from FEAC Shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FEAC will solicit proxies by mail. In addition, the directors, officers and employees
of FEAC may solicit proxies from FEAC Shareholders by telephone, electronic communication, or in person, but will not receive any additional compensation for their services. FEAC will make arrangements with brokerage houses and other custodians,
nominees, and fiduciaries for forwarding proxy solicitation material to the beneficial owners of FEAC Shares held of record by those persons and will reimburse them for their reasonable
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in forwarding such proxy solicitation materials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FEAC has engaged a professional proxy solicitation firm, Morrow Sodali LLC (&#147;Morrow&#148;), to assist in soliciting proxies for the
Special Meeting. FEAC has agreed to pay Morrow a fee of $27,500, plus disbursements. FEAC will reimburse Morrow for reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses and will indemnify
Morrow and its affiliates against certain claims, liabilities, losses, damages and expenses. FEAC will also reimburse banks, brokers and other custodians, nominees and fiduciaries representing beneficial owners of FEAC Shares for their expenses in
forwarding soliciting materials to beneficial owners of FEAC Shares and in obtaining voting instructions from those owners. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Business </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FEAC is not aware of any other business to be acted upon at the Special Meeting. If, however, other matters are properly brought before the
Special Meeting, the proxies will have discretion to vote or act on those matters according to their best judgment and they intend to vote the shares as the FEAC Board may recommend. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Attendance </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only FEAC Shareholders on the
record date or persons holding a written proxy for any shareholder or account of FEAC as of the record date may attend the Special Meeting. If you hold your FEAC Shares in your name as a shareholder of record and you wish to attend the Special
Meeting virtually, please visit <B><U>https://www.cstproxy.com/feac/2023</U></B> and enter the control number found on your proxy card. If your FEAC Shares are held in &#147;street name&#148; in a stock brokerage account or by a bank, broker or
other holder of record and you wish to attend the Special Meeting, you must obtain a legal proxy from the bank, broker or other holder of record in order to vote your shares in person or electronically at the Special Meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Assistance </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you need assistance in
completing your proxy card or have questions regarding the Special Meeting, please contact Morrow, the proxy solicitation agent for FEAC, by calling <FONT STYLE="white-space:nowrap">(800)&nbsp;662-5200&nbsp;(toll-free),</FONT> or banks and brokers
can call <FONT STYLE="white-space:nowrap">(203)&nbsp;658-9400,&nbsp;or</FONT> by emailing FEAC.info@investor.morrowsodali.com. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">172 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom459793_17"></A>PROPOSAL NO. 1 &#151; THE BUSINESS COMBINATION PROPOSAL
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Description of the Business Combination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>General </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
shareholders are being asked to approve and adopt the Business Combination Agreement and the Transactions contemplated thereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
shareholders should read carefully this proxy statement/prospectus in its entirety for more detailed information concerning the Business Combination Agreement, a copy of which is attached as <B><U>Annex A</U></B> to this proxy statement/prospectus.
You are urged to read carefully the Business Combination Agreement in its entirety before voting on this Business Combination Proposal. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Transaction Structure </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination Agreement contemplates that the proposed business combination among FEAC, enGene and New enGene (the &#147;Business
Combination&#148;) will be completed through, among other things, the following series of transactions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FEAC will incorporate or cause to be incorporated Can Merger Sub as a corporation under the laws of Canada and a
direct wholly owned subsidiary of FEAC (&#147;Can Merger Sub&#148;) and New enGene will incorporate or cause to be incorporated Cayman Merger Sub as a Cayman Islands exempted company and a direct wholly owned subsidiary of New enGene (&#147;Cayman
Merger Sub&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pursuant to the Sponsor and Insiders Letter Agreement, Forbion Growth Sponsor FEAC I B.V., a private limited
liability company incorporated in The Netherlands (the &#147;Sponsor&#148;), has agreed to surrender, after giving effect to the conversion of all or part of the principal amount outstanding under loans made by the Sponsor to FEAC into private
placement warrants of FEAC (&#147;FEAC Private Placement Warrants&#148;), 1,789,004 FEAC Class&nbsp;B Shares and 5,463,381 FEAC Private Placement Warrants, as a contribution to the capital of FEAC and for no consideration (the
&#147;Surrender&#148;), effective immediately prior to the Class&nbsp;B Conversion (as defined below) on the day which is two business days prior to the Closing Date (as defined below); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on the day which is two business days prior to the Closing Date, each FEAC Class&nbsp;B Share that remains
outstanding following the Surrender shall be exchanged for one FEAC Class&nbsp;A Share (the &#147;Class&nbsp;B Conversion&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on the day which is one business day prior to the Closing Date, Cayman Merger Sub will merge with and into FEAC
with FEAC as the surviving entity pursuant to a plan of merger under the laws of the Cayman Islands (the &#147;Cayman Merger&#148;) as follows: (i)&nbsp;New enGene will issue to the holders of FEAC Shares (including the Sponsor but excluding the
holders of any dissenting FEAC Shares) New enGene Shares in exchange for such holders&#146; FEAC Shares and such FEAC Shares will not be cancelled but will be transferred to New enGene, (ii)&nbsp;FEAC will thereby become a wholly owned subsidiary of
New enGene, and (iii)&nbsp;each issued share of Cayman Merger Sub will be exchanged for a FEAC Class&nbsp;A Share as the surviving entity and Cayman Merger Sub (having merged into FEAC) will cease to exist as a separate entity by virtue of the
Cayman Merger; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">concurrently with the Cayman Merger, and effective at the same time the Cayman Merger becomes effective under
Cayman Islands law, (i)&nbsp;New enGene will assume the warrants of FEAC to purchase one FEAC Class&nbsp;A Share at an exercise price of $11.50 per share, subject to adjustment (as so assumed, &#147;New enGene Warrants&#148;) pursuant to a warrant
assignment, assumption and amendment agreement to be entered into on or around the Closing Date, (ii)&nbsp;FEAC as the entity surviving the Cayman Merger will issue to New enGene a <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing demand
promissory note payable denominated in Canadian dollars (&#147;C$&#148;) </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">173 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
having a principal amount equal to the fair market value of the FEAC Warrants assumed by New enGene (&#147;Note 3&#148;) in consideration of the assumption by New enGene of obligations under the
FEAC Warrants (as so assumed, New enGene Warrants), and (iii)&nbsp;New enGene will redeem the initial Class&nbsp;B common shares of New enGene held by the sole shareholder of New enGene for an amount equal to the amount of capital that the sole
shareholder of New enGene contributed for purposes of the incorporation of New enGene (such transactions, together with the Cayman Merger, the &#147;Cayman Reorganization&#148;); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">following the Cayman Reorganization, FEAC will file an election to change its classification for U.S. federal
income tax purposes from a corporation to an entity disregarded as separate from its owner New enGene, to be effective as of the beginning of the Closing Date (the &#147;U.S. Entity Classification Election&#148; and, together with the Cayman
Reorganization, the &#147;FEAC Reorganization&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on the Closing Date and pursuant to the Plan of Arrangement, subsequent to the FEAC Reorganization becoming
effective and prior to the consummation of the PIPE Financing, FEAC will loan to New enGene an amount equal to the total funds held in its Trust Account (subject to certain deductions described in the Business Combination Agreement), less the
principal amount of Note 3 (together, the &#147;Loan Amount&#148;) in consideration for which New enGene will issue a C$ denominated <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing demand promissory note to FEAC having a principal
amount equal to the Loan Amount converted into its Canadian dollar equivalent based on the C$:U.S.$ Bank of Canada daily exchange rate on the business day immediately prior to the Closing Date, following which FEAC will sell to New enGene, and New
enGene will purchase, all of the outstanding common shares of Can Merger Sub for a purchase price of C$10 (the &#147;Can Merger Sub Share Sale&#148;) and, following the Can Merger Sub Share Sale but prior to the Amalgamation, the PIPE Financing
shall be consummated; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subsequent to the Can Merger Sub Share Sale and PIPE Financing, Can Merger Sub and enGene will amalgamate
pursuant to the Plan of Arrangement, and pursuant to the Amalgamation, (i)&nbsp;each enGene Share outstanding immediately prior to the Amalgamation shall be exchanged for New enGene Shares at the enGene Exchange Ratio and each enGene Warrant
outstanding immediately prior to the Amalgamation shall be exchanged for New enGene Warrants per the enGene Exchange Ratio; (ii)&nbsp;each Can Merger Sub share outstanding immediately prior to the Amalgamation shall be exchanged for one common share
in the authorized share capital of the amalgamated entity; and (iii)&nbsp;in consideration for the issuance of New enGene Shares, the amalgamated entity shall issue its common shares to New enGene; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">following the Amalgamation, New enGene will continue from being a corporation incorporated under and governed by
the Canada Business Corporations Act to a company continued to and governed by the Business Corporations Act (British Columbia). </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transactions described above, together with the other transactions contemplated by the Business Combination Agreement, are hereinafter
referred to as the &#147;Transactions.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">174 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Current Organizational Charts of FEAC and enGene </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:0pt; margin-left:2.00em">


<IMG SRC="g459793g19s02.jpg" ALT="LOGO">
</P> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g459793g19s00.jpg" ALT="LOGO">
</P> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Organizational Charts of FEAC and enGene immediately prior to the Cayman Merger </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g459793g19s01.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">175 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Organizational Charts of FEAC and enGene following the Cayman Merger and immediately prior to the
Amalgamation </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g459793g71r05.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Organizational Chart of New enGene Immediately
Post-Business Combination </I></B></P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g459793g01a54.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">176 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Organizational Chart of New enGene Post-Business Combination and Post-Liquidation
(including cash positions) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g459793g93z51.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Description of the Business Combination Agreement
and Ancillary Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See &#147;<I>The Business Combination Agreement</I>&#148; for a description of the Business Combination
Agreement and &#147;<I>Ancillary Agreements Related to the Business Combination</I>&#148; for a description of certain other agreements entered into in connection with the Business Combination. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Background of the Business Combination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FEAC is a blank check company incorporated on August&nbsp;9, 2021 as a Cayman Islands exempted company for the purpose of effecting a merger,
share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. In conducting a targeted search for a business combination target, as described in greater detail below, FEAC
drew upon the broad experience, network, and team-based, multidisciplinary investment process of the Forbion group, of which the Sponsor is part, FEAC&#146;s management and the FEAC Board. The terms of the Business Combination Agreement and the
related Ancillary Agreements are the result of extensive negotiations among representatives of FEAC and enGene with advice from their respective representatives and advisors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&nbsp;12, 2021, Forbion European Sponsor LLP paid $25,000, or approximately $0.009 per share, in consideration for 2,875,000 FEAC
Class&nbsp;B Shares. On November&nbsp;23, 2021, Forbion European Sponsor LLP transferred 2,875,000 FEAC Class&nbsp;B Shares to the Sponsor in exchange for $25,000, or approximately $0.009 per share. The registration statement for FEAC&#146;s IPO was
declared effective on December&nbsp;9, 2021. On December&nbsp;9, 2021, FEAC issued an additional 287,500 FEAC Class&nbsp;B Shares to the Sponsor resulting from a 1.1 for 1 share dividend. The FEAC Class&nbsp;B Shares will be exchanged for FEAC
Class&nbsp;A Shares, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis, on the day that is two business days prior to the Closing of the Business Combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;14, 2021, FEAC completed its IPO of 11,000,000 FEAC Units at a price of $10.00 per unit, generating gross proceeds of
$110,000,000. On December&nbsp;15, 2021, the underwriters of FEAC&#146;s IPO exercised their full over-allotment option and purchased the additional FEAC Units available to them. The aggregate amount of FEAC Units sold in FEAC&#146;s IPO and
subsequent exercise of the over-allotment option was 12,650,000 and generated gross proceeds of $126,500,000. Each FEAC Unit consisted of one FEAC Class&nbsp;A Share and <FONT STYLE="white-space:nowrap">one-third</FONT> of one FEAC Warrant. Each
whole FEAC Warrant entitles the holder thereof to purchase one FEAC Class&nbsp;A Share at an exercise price of $11.50 per share, subject to certain adjustments. After the over-allotment exercise, there were 4,216,666 FEAC Warrants and 5,195,000 FEAC
Private Placement Warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">177 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There will be no redemption rights or liquidating distributions with respect to the FEAC
Class&nbsp;B Shares or FEAC Private Placement Warrants. Also, the FEAC Private Placement Warrants will expire worthless if FEAC fails to consummate a business combination within the Combination Period (as defined below). Holders of FEAC Class&nbsp;B
Shares have waived their redemption rights in return for no consideration pursuant to a letter agreement, dated December&nbsp;9, 2021, between FEAC and each of the directors and officers of FEAC which was agreed prior to FEAC&#146;s IPO. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the consummation of its IPO, neither FEAC, nor anyone on its behalf, contacted any prospective target business or had any substantive
discussions, formal or otherwise, with respect to any business combination transaction with FEAC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the process that led to identifying
enGene as an attractive investment opportunity, FEAC&#146;s management identified 85 potential business combination targets (some of which it met with), entered into <FONT STYLE="white-space:nowrap">non-disclosure</FONT> agreements with 31 potential
business combination targets (other than enGene), and submitted <FONT STYLE="white-space:nowrap">non-binding</FONT> indications of interest with respect to three potential business combination targets one of which was enGene.<I> </I>The two other
potential targets to which FEAC submitted a non-binding indication of interest are companies at a similar stage of development as enGene but that focused on different indications for drug compounds. One company focused on immune-oncology indications
and discussions between FEAC and that company were aborted on May&nbsp;6, 2022, principally because the amount of funds required to make meaningful progress in the clinical study results, the proposed valuation, as well as the status of the
available clinical data, were not satisfactory to FEAC. The other company focused on neurological disorders and discussions were aborted on June&nbsp;3, 2022, principally because the proposed terms for a potential business combination transaction
and the results of FEAC&#146;s preliminary due diligence were not sufficiently attractive to FEAC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 85 potential business combination
targets were identified by FEAC with a view to source investment opportunities in late-stage biotech companies and mainly through FEAC&#146;s proprietary network, such as existing relationships with European and U.S. companies, investors, chief
executive officers, entrepreneurs, members of boards of directors and advisors. FEAC&#146;s screening and due diligence process included interactions with potential targets&#146; management teams and focused on, amongst others, the following
criteria for such potential targets: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Compelling risk/reward proposition, with the potential to generate a financial return; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Therapeutics-focused, with a key product candidate in later stages of clinical development;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Experienced management team with proven track record of success; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Product candidate that addresses a high unmet medical need and improves patients&#146; lives, serves a
significant patient population and can deliver a pharmacoeconomic benefit; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">High likelihood of reimbursement based on health-economic analysis; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Sustainable competitive edge, usually involving patent protection and regulatory status; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Sustainable future financing plan, including multiple exit strategies within a reasonable time frame.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On the basis of, amongst others, the above criteria, targets that had later stage clinical programs in areas of high
unmet medical need, a favorable risk-return reward and ability to reach further clinical validation in the form of (interim) clinical study endpoints within the financing plan, were identified as potential targets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to the potential business combination targets other than enGene, FEAC engaged in preliminary discussions with respect to a
potential business combination involving each such target and, in the case of three potential business combinations, one of which was with enGene, FEAC engaged in further business, operational and financial due diligence with respect to such target,
which included, among other things, operational due diligence, review of financial data and discussions with management. FEAC&#146;s consideration of each of the other potential business combination targets was on a sequential basis, and at any
given time FEAC was engaged in discussions </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">178 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with only one such potential target at a time. Following these preliminary discussions, and based on its due diligence, evaluation and analysis of each such potential target, FEAC submitted <FONT
STYLE="white-space:nowrap">non-binding</FONT> indications of interest or letters of intent with respect to each (including enGene), and further discussed and explored a potential business combination on terms that it believed could satisfy one or
more of its key criteria for a business combination as set forth in its IPO prospectus. With respect to the two potential business combination targets other than enGene, FEAC ultimately ceased exploration of, and discussions with, such targets
because of, among other things, the results of FEAC&#146;s directors&#146; and management&#146;s preliminary due diligence, evaluation and analysis of such potential targets, as well as the terms and valuation of the respective <FONT
STYLE="white-space:nowrap">non-binding</FONT> indications of interest or letters of intent. Compared to the other two potential business combination targets, FEAC&#146;s directors and management believed, based on its preliminary due diligence,
evaluation and analysis of its business, as well as the terms of the <FONT STYLE="white-space:nowrap">non-binding</FONT> letter of intent with enGene, that enGene was a more attractive potential business combination target that was better aligned
with FEAC&#146;s key criteria for a business combination target. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;29, 2022, Marco Boorsma, an employee of an affiliate of
the Sponsor and a director of enGene introduced Jason Hanson, Chief Executive Officer of enGene, and Lazar Bojic, then Vice President Corporate Development of enGene to Jasper Bos, Chief Executive Officer of FEAC. The introduction was made at the
request of the enGene management to begin a preliminary discussion on a potential business combination transaction involving FEAC and enGene. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;7, 2022, Jasper Bos and Mathias Vinther, an employee of an affiliate of the Sponsor, met with Jason Hanson and Lazar Bojic to
discuss enGene&#146;s operations, business, assets and a potential transaction with FEAC. On the same date, the enGene management gave a detailed presentation of detalimogene voraplasmid (or <FONT STYLE="white-space:nowrap">EG-70),</FONT>
enGene&#146;s intravesical candidate for <FONT STYLE="white-space:nowrap">BCG-unresponsive,</FONT> <FONT STYLE="white-space:nowrap">non-muscle</FONT> invasive bladder cancer (&#147;NMIBC&#148;) with <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">carcinoma-in-situ</FONT></FONT> (&#147;Cis&#148;), one of enGene&#146; product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;14,
2022, the parties executed a confidentiality agreement. On the same date, enGene granted FEAC access to an electronic data room and provided FEAC with detailed information on enGene&#146;s technical, HR, business, legal and financial items for the
purpose of facilitating a preliminary due diligence exercise by FEAC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2022, and on July&nbsp;1, 2022, enGene engaged,
respectively, Morgan, Lewis&nbsp;&amp; Bockius LLP (&#147;Morgan Lewis&#148;) as its U.S. legal counsel and Blake, Cassels&nbsp;&amp; Graydon LLP (&#147;Blakes&#148;), as its Canadian legal counsel each in connection with a potential business
combination transaction between enGene and FEAC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;19, 2022, FEAC sent to enGene a written due diligence questionnaire. On
the same date, the enGene management introduced FEAC to several key opinion leaders in the field of <FONT STYLE="white-space:nowrap">non-invasive</FONT> bladder cancer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Between April&nbsp;14, 2022 and April&nbsp;17, 2023, FEAC and its advisors conducted a preliminary business, technical, intellectual property,
regulatory and manufacturing due diligence with respect to enGene and researched enGene&#146; industry, product candidates and outlook. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;5, 2022, FEAC sent to enGene, via <FONT STYLE="white-space:nowrap">e-mail,</FONT> an initial
<FONT STYLE="white-space:nowrap">non-binding</FONT> business combination proposal detailing the proposed structure, financing requirements and deal terms related to such proposed business combination. In particular, the proposal included, among
other things, (i)&nbsp;a proposed <FONT STYLE="white-space:nowrap">pre-money</FONT> valuation of enGene of $200&nbsp;million, (ii)&nbsp;a proposed target of <FONT STYLE="white-space:nowrap">$60-75&nbsp;million</FONT> in PIPE financing (of which <FONT
STYLE="white-space:nowrap">$10-20&nbsp;million</FONT> was to be committed by the Sponsor and $20&nbsp;million was to be committed by enGene&#146;s then existing debtholders), (iii) a post-closing <FONT STYLE="white-space:nowrap">lock-up</FONT> of
one year for enGene&#146;s equity holders and for the Sponsor, (iv)&nbsp;mutual exclusivity and <FONT STYLE="white-space:nowrap">no-shop</FONT> arrangements, (v)&nbsp;a governance arrangement of the combined entity so that the post-closing board of
directors would consist of (a)&nbsp;two directors designated by FEAC, (b)&nbsp;two directors designated by enGene and (c)&nbsp;three independent directors and (vi)&nbsp;certain other customary closing conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;12, 2022, representatives of FEAC met with the enGene management to discuss the clinical study design and planning as part of
FEAC&#146;s due diligence on enGene. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">179 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;13, 2022, representatives of FEAC, including Wouter Joustra, a director of
FEAC, met with representatives of enGene to discuss the terms of the <FONT STYLE="white-space:nowrap">non-binding</FONT> business combination proposal, including enGene&#146;s valuation and the potential size of a PIPE financing. On May&nbsp;22,
2022, a further meeting was held between representatives of FEAC, including Jasper Bos, Sander Slootweg and Wouter Joustra and representatives of enGene, including Jason Hanson and Lazar Boijc, to discuss further business terms, including the
pro-forma capitalization table of the combined entity. On May 30, 2022, a further meeting was held with the same representatives attending the May 22, 2022 meeting as well as with Gerry Brunk, member of the enGene Board, to further discuss budget
and size of the PIPE financing. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;31, 2022, the FEAC Board convened to discuss and approve a draft <FONT
STYLE="white-space:nowrap">non-binding</FONT> letter of interest (the &#147;Preliminary LoI&#148;) detailing the terms of the proposed business combination between enGene and FEAC. The draft LoI included, among other provisions (i) a proposed
pre-money valuation of enGene of $200 million, (ii) a proposed target of $80 million in PIPE financing (of which $15 million was to be committed by the Sponsor and $15 million was to be committed by enGene&#146;s then existing debtholders), (iii) a
$110 million minimum cash condition, (iv) a governance arrangement of the combined entity so that the post-Closing board of directors would consist of (a) two directors designated by enGene, (b) two directors designated by FEAC, and (c) three
independent directors designated by enGene, (vi) a post-Closing lock-up of 12 months for enGene&#146;s equity holders and 12 months for the Sponsor, (vii) certain customary demand, piggy-back and shelf registration rights after the expiration of the
lock-up period, (viii) mutual exclusivity and no-shop arrangements and (ix) certain other customary closing conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;6,
2022, the enGene management shared with FEAC further information on the budget and financing needs of enGene. On June&nbsp;7, 2022, a virtual meeting was held between the enGene management and FEAC to discuss the update on clinical trial results of
enGene&#146;s lead product candidate, including the determination of a recommended &#147;phase 2 dose&#148; for the clinical study. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
June&nbsp;9, 2022, the investment committee of the Sponsor also considered and approved terms of the potential business combination with enGene. Such terms included the participation of an affiliate of the Sponsor in a PIPE financing for an amount
equal to $20&nbsp;million to be consummated at closing of the proposed business combination with enGene. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;11, 2022, FEAC sent
to enGene the Preliminary LoI. On June&nbsp;17, 2022 enGene and FEAC discussed the Preliminary LoI and enGene sent a <FONT STYLE="white-space:nowrap">follow-up</FONT> email to FEAC with a list of key issues of FEAC&#146;s Preliminary LoI, including
(i)&nbsp;the size of the Sponsor&#146;s commitment to the PIPE transaction, (ii)&nbsp;clarification requests related to valuation assumptions, (iii)&nbsp;the length of the exclusivity period and the <FONT STYLE="white-space:nowrap">carve-out</FONT>
for continuation of certain <FONT STYLE="white-space:nowrap">pre-existing</FONT> private financing discussions, (iv)&nbsp;the size of the combined entity&#146;s employee incentive option pool, (v)&nbsp;the domicile of the combined entity and
(vi)&nbsp;the possibility of a <FONT STYLE="white-space:nowrap">non-redemption</FONT> agreement by the Sponsor. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;23,
2022, representatives of FEAC including Sander Slootweg and Wouter Joustra presented the terms of the proposed business combination, the background of FEAC and terms of the Preliminary LoI to the enGene Board. On June&nbsp;29, 2022, the presentation
materials discussed at the meeting were provided by email to the enGene Board of Directors. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Between June&nbsp;11, 2022 and
July&nbsp;3, 2022, the parties exchanged several drafts of the Preliminary LoI. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;24, 2022, a telephonic meeting was held
between Jason Hanson and Jasper Bos to address feedback from the enGene Board of Directors on the proposed business combination between FEAC and enGene. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;28, 2022, Morgan Stanley entered into an engagement letter with enGene to act as exclusive financial advisor to enGene in
connection with a potential business combination transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;29, 2022, enGene sent to FEAC an email including certain
comments to the Preliminary LoI, in particular on certain Canadian tax structuring considerations, registration rights and the PIPE commitment from then existing shareholders of enGene. The parties held a call on the same date to address any
outstanding issues. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">180 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;3, 2022, the parties signed a final letter of intent (the &#147;LoI&#148;). The
signed version of the LoI included, among other provisions (i)&nbsp;a proposed <FONT STYLE="white-space:nowrap">pre-money</FONT> valuation of enGene of $200&nbsp;million, (ii)&nbsp;a proposed target of $80&nbsp;million in PIPE financing (of which
$20&nbsp;million was to be committed by the Sponsor and $20&nbsp;million was to be committed by enGene&#146;s then existing debtholders), (iii) a $110&nbsp;million minimum cash condition, (iv)&nbsp;an equity incentive plan of the combined entity of
at least 10% of the combined entity&#146;s fully diluted equity, (v)&nbsp;a governance arrangement of the combined entity so that the post-Closing board of directors would consist of (a)&nbsp;enGene&#146;s Chief Executive Officer, (b)&nbsp;two
directors designated by FEAC and (c)&nbsp;four independent directors designated by enGene, (vi)&nbsp;a post-Closing <FONT STYLE="white-space:nowrap">lock-up</FONT> of six months for enGene&#146;s equity holders and one year for the Sponsor,
(vii)&nbsp;certain customary demand, piggy-back and shelf registration rights after the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period, (viii)&nbsp;mutual exclusivity and <FONT STYLE="white-space:nowrap">no-shop</FONT>
arrangements and (ix)&nbsp;certain other customary closing conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Between April 2022 and August 2022, FEAC held regular telephonic
meetings with UBS Securities LLC (&#147;UBS Securities&#148;), in its capacity as an underwriter to the FEAC IPO, to discuss progress on the business combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;22, 2022, Philip Astley Spark, a director of FEAC, introduced Jasper Bos to Leerink Partners, who was later engaged by FEAC on
September&nbsp;29, 2022, as FEAC&#146;s lead placement agent for the PIPE financing. On October&nbsp;23, 2022, UBS Securities, one of the underwriters of FEAC&#146;s IPO, was also engaged by FEAC (with effect from September&nbsp;29, 2022) as
FEAC&#146;s <FONT STYLE="white-space:nowrap">co-placement</FONT> agent for the PIPE financing. On November&nbsp;9, 2022, Leerink Partners and UBS Securities were also engaged by FEAC as FEAC&#146;s lead capital markets advisor and lead financial and
capital markets advisor to FEAC, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Between July 2022 and August 2022, the representatives of FEAC and enGene held regular
telephonic meetings to discuss progress on FEAC&#146;s due diligence and the preparation of an investor presentation to be used in connection with the marketing of the PIPE financing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&nbsp;29, 2022, FEAC, enGene, representatives of Leerink Partners, in its capacity as a lead placement agent for the PIPE financing
and lead capital markets advisor to FEAC, and UBS Securities, in its capacity as <FONT STYLE="white-space:nowrap">co-placement</FONT> agent for the PIPE financing and lead financial and capital markets advisor to FEAC, held a telephonic call to
prepare an investor presentation to be used in connection with the marketing of the PIPE financing in upcoming investor meetings. The same parties held regular telephonic meetings with the same purpose until October&nbsp;6, 2022, when a PIPE
financing investor presentation including a proposed target of $90&nbsp;million in PIPE financing was posted to the virtual data room for potential PIPE investors. The <FONT STYLE="white-space:nowrap">co-placement</FONT> agents conducted formal
outreaches to certain potential PIPE investors, with PIPE investor meetings occurring between September&nbsp;30, 2022 and November&nbsp;10, 2022 as well as between December&nbsp;20 and April&nbsp;3, 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;1, 2022, Jasper Bos proposed to the enGene management that the exclusivity provision of the LoI, initially set to expire on
September&nbsp;3, 2022, be extended until November&nbsp;15, 2022. On September&nbsp;22, 2022, the parties executed an amendment agreement to the LoI extending the exclusivity period of the LoI until November&nbsp;15, 2022. On December&nbsp;23, 2022,
and March&nbsp;7, 2023, the parties executed further amendment agreements to the LoI extending the exclusivity period to January&nbsp;31 and April&nbsp;6, 2023, respectively. Additionally, on March&nbsp;7, 2023, the parties agreed that Forbion
Growth Opportunities Fund I Cooperatief U.A., an affiliate of the Sponsor, would acquire prior to March&nbsp;20, 2023, convertible promissory notes issued by enGene for a minimum of $10,000,000 USD, on terms substantially similar to those of the
Convertible Bridge Financing term sheet between enGene and Forbion Growth Opportunities Fund I Cooperatief U.A. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;8,
2022, Jasper Bos introduced representatives from Dechert LLP (&#147;Dechert&#148;), intellectual property legal counsel to FEAC, to Jason Hanson and Lazar Bojic for the purposes of facilitating a preliminary intellectual property (&#147;IP&#148;)
due diligence exercise by FEAC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;12, 2022, representatives of Dechert, Jason Hanson and Anthony Cheung (Chief Technology
Officer and an executive of enGene) held a call for the purposes of the due diligence regarding certain IP technology and filings. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">181 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Between September&nbsp;12, 2022 and November&nbsp;21, 2022, regular interactions took place
between enGene, FEAC and Dechert on the IP due diligence. On November&nbsp;21, 2022, Dechert provided a report to FEAC including certain preliminary findings of the IP due diligence carried out by Dechert. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beginning on August&nbsp;29, 2022, Kirkland&nbsp;&amp; Ellis LLP (&#147;Kirkland&nbsp;&amp; Ellis&#148;), as legal counsel to Leerink Partners
and UBS Securities, requested Morgan Lewis to provide certain information and documents in the context of the due diligence exercise related to the PIPE financing. Morgan Lewis responded to these due diligence requests on a rolling basis and granted
virtual data room access to Kirkland&nbsp;&amp; Ellis and Davis Polk&nbsp;&amp; Wardwell London LLP (&#147;Davis Polk&#148;), as legal counsel to FEAC. Between September&nbsp;9, 2022 and September&nbsp;29, 2022, the parties held due diligence calls
with enGene and FEAC in the context of the due diligence exercise related to the PIPE financing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Between August&nbsp;29, 2022 and
September&nbsp;29, 2022, the parties and their advisors discussed updated versions of the PIPE financing investor presentation as well as the wall-cross scripts and procedures (including the &#147;cleansing&#148; dates) for the outreach to the
potential PIPE investors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;19, 2022, Jason Hanson and Lazar Bojic presented enGene to the FEAC Board, focusing in
particular on enGene&#146;s products, business, technology, clinical trial design and operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October 25, 2022, Ernst &amp; Young
LLP, the UK member firm of the EY network (&#147;Ernst &amp; Young LLP&#148;) was engaged as advisor to FEAC for the purposes of providing tax advisory services in relation to the proposed transaction. On October&nbsp;31, 2022, KPMG LLP
(&#147;KPMG&#148;) was appointed as tax advisor to enGene for the primary purpose of assisting the enGene management in the analysis of tax structuring alternatives and related tax implications in relation to the transaction. Also on
September&nbsp;29, 2022, Venn Life Sciences ED B.V. (&#147;Venn Life Sciences&#148;) was appointed as advisor to FEAC for the purpose of conducting certain chemistry, manufacturing and controls (&#147;CMC&#148;) as well as regulatory due diligence
of enGene. On October&nbsp;7, 2022, Venn Life Sciences was provided with access to a virtual data room set up by enGene. Between October 2022 and April 2023, interactions took place between Venn Life Sciences, enGene and FEAC on the due diligence
regarding CMC and regulatory aspects. On November&nbsp;11, 2022 and April&nbsp;17, 2023, Venn Life Sciences provided reports to FEAC including certain findings of the CMC and regulatory due diligence carried out by Venn Life Sciences. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;18, 2022, Leerink Partners and FEAC had a telephonic meeting to discuss terms and conditions of the PIPE financing proposed
by a potential PIPE investor. Such proposal included a <FONT STYLE="white-space:nowrap">pre-money</FONT> valuation of enGene of $90&nbsp;million, a redistribution of certain FEAC Private Placement Warrants from the Sponsor to the potential PIPE
investors, and a reduction in size of the combined entity equity incentive plan to 8% of the combined entity&#146;s equity on a fully diluted basis. On December&nbsp;7, 2022, Leerink Partners and FEAC presented the revised terms and conditions of
the PIPE financing to enGene&#146;s Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;8, 2022 a telephonic meeting was held between Jason Hanson and
Jasper Bos to discuss comments on the new terms and conditions of the PIPE financing. On December&nbsp;15, 2022, the enGene Board of Directors agreed to the new terms and conditions of the PIPE financing. Formal outreaches by Leerink Partners to the
other potential PIPE investors continued from December&nbsp;19, 2022 to May&nbsp;15, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;8, 2022, Granzer Regulatory
Consulting&nbsp;&amp; Services GmbH (&#147;Granzer&#148;) was appointed as advisor to FEAC for the purpose of conducting certain regulatory due diligence of enGene. Subsequently, Granzer was provided with access to a virtual data room set up by
enGene, and on December&nbsp;13, 2022, Granzer provided a report to FEAC including certain findings of the regulatory due diligence carried out by Granzer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;23, 2022, a telephonic meeting was held between enGene, FEAC, KPMG, Ernst &amp; Young LLP, Davis Polk, Morgan Lewis, Blakes
and Stikeman Elliott LLP, as Canadian legal counsel to FEAC (&#147;Stikeman&#148;). The purpose of the meeting was to discuss preliminary key aspects for transaction structuring and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">182 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the preparation of a memorandum describing the transaction structure in detail. In advance of the meeting, on December&nbsp;22, 2022, Ernst &amp; Young LLP shared with the parties a draft
presentation via email. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Between December&nbsp;23, 2022, and April&nbsp;14, 2023, the parties, with their respective counsels and
advisors, held several conference calls and exchanged emails to discuss the potential structure of the transactions, in particular with respect to the jurisdiction of incorporation of the combined entity, the PIPE financing, the then-existing
convertible debt of enGene in the context of the transaction and the relevant corporate, tax and securities law analysis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
February&nbsp;3, 2023, Jasper Bos presented an update on the status of the transaction and, in particular, the outreach to potential PIPE investors to the enGene Board of Directors. On February&nbsp;14, 2023, Davis Polk and Kirkland&nbsp;&amp; Ellis
discussed the potential FEAC extension process over a telephone call and on February&nbsp;28, 2023 and March&nbsp;7, 2023, Davis Polk, Stikeman, Morgan Lewis and Blakes discussed the proposed drafting process with respect to the Business Combination
Agreement and the Ancillary Agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;8, 2023, FEAC entered into an engagement letter with Lincoln International LLC for
the purpose of providing a fairness opinion to the FEAC Board of Directors with respect to the valuation of enGene. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;11,
2023, Blakes circulated to Morgan Lewis, Davis Polk, Stikeman and enGene initial drafts of the amended and restated note purchase agreement and the form of the 2023 Convertible Notes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;12, 2023, Davis Polk circulated to FEAC, enGene, Morgan Lewis, Blakes, Stikeman, Ernst &amp; Young LLP, and KPMG initial drafts
of the form Subscription Agreements and Side Letter Agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;14, 2023, Blakes circulated a draft closing agenda for the
Convertible Bridge Financing and relevant ancillary agreements. On the same date, Davis Polk circulated the first draft of a short form PIPE term sheet to the working group. On the same day, Leerink Partners circulated an updated <FONT
STYLE="white-space:nowrap">pre-closing</FONT> and <FONT STYLE="white-space:nowrap">pro-forma</FONT> post-closing capitalization table of enGene to the working group. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;14, 2023, a telephonic meeting was held between Jasper Bos and Maxime Daigle from Investissement Quebec (&#147;IQ&#148;) to
discuss a potential participation in the Convertible Bridge Financing together with the Sponsor. On March&nbsp;16, 2023, FEAC provided an initial draft of the term sheet of the Convertible Bridge Financing to IQ.
<FONT STYLE="white-space:nowrap">Follow-up</FONT> calls among FEAC, enGene, IQ and their respective advisors were held and emails exchanged through March&nbsp;30, 2023. In particular, the draft term sheet of the Convertible Bridge Financing
included, among other things, (i)&nbsp;an upsize from $20&nbsp;million to $30&nbsp;million, to be funded immediately after signing of the Subscription Agreements, (ii)&nbsp;a right for IQ to appoint an observer to the enGene Board and (iii)&nbsp;a
conversion of the Convertible Bridge Financing into securities of enGene to be subsequently exchanged for securities of New enGene in connection with the Business Combination on terms not less favorable from an economic perspective than the terms of
the PIPE Financing. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Between March&nbsp;14, 2023 and March&nbsp;24, 2023, Kirkland&nbsp;&amp; Ellis, Morgan Lewis and Blakes provided
comments to the short form PIPE term sheet as well as the draft form Subscription Agreement and Side Letter Agreements, including with respect to the representations, warranties and covenants of FEAC and the combined entity included therein. On
March&nbsp;24, 2023, Leerink Partners sent a draft PIPE term sheet to potential PIPE investors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March 23, 2023, Davis Polk had a
telephonic meeting with Morgan Lewis to discuss the presentation of certain preliminary updated clinical study data to potential PIPE investors. Throughout the PIPE marketing process, enGene endeavored to provide all material information respecting
clinical trial data to potential PIPE investors. See &#147;<I>Business of enGene</I>&#148; below for a description of enGene&#146;s clinical data as shared with potential PIPE investors, updated to the nearest practicable date prior to the date
hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">183 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;31, 2023, Blakes provided initial drafts of the proposed form of Subscription
Agreement for the Convertible Bridge Financing and the proposed form of warrant certificate for the Convertible Bridge Financing based off the public warrant certificate, with the terms of the warrant agreement with the participants in the
Convertible Bridge Financing to be appended once received. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;1, 2023, Davis Polk circulated updated drafts of the form
Subscription Agreement and Side Letter Agreements. On April&nbsp;5, 2023, Morgan Lewis, Blakes and Kirkland&nbsp;&amp; Ellis provided their comments, including to reflect the status of discussion of the transaction steps as well as with respect to
the representations, warranties and covenants of FEAC and the combined entity included therein. The legal advisors of the parties exchanged several drafts, reflecting comments from FEAC, enGene, and other parties. Leerink Partners circulated such
drafts as well as the draft transaction structure to the potential PIPE investors on April&nbsp;6, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;3, 2023, Davis
Polk and Stikeman sent to Morgan Lewis and Blakes a legal due diligence request list of documents and information with respect to enGene. On April&nbsp;5, 2023, Ernst &amp; Young LLP sent to enGene a draft tax due diligence request list of documents
and information with respect to enGene in advance of being formally engaged. On April&nbsp;6, 2023, Ernst &amp; Young LLP sent to enGene a draft financial due diligence request list of documents and information with respect to enGene in advance of
being formally engaged. On April&nbsp;12, 2023, Morgan Lewis returned enGene&#146;s answers to the legal due diligence request list to Davis Polk and Stikeman. Davis Polk and Morgan Lewis discussed the legal due diligence request list over a
telephone conversation on April&nbsp;13, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Between April&nbsp;3, 2023 and May&nbsp;12, 2023, Davis Polk and Stikeman conducted a due
diligence exercise of enGene based on the information and documents provided in a virtual data room set up by enGene. During the same period, the parties held multiple calls in which enGene&#146;s representatives provided further feedback to the
legal due diligence requests sent by Davis Polk and Stikeman, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;4, 2023, enGene informed FEAC that it and
certain then existing investors had executed a note purchase agreement pursuant to which such investors purchased interest-bearing promissory notes from enGene in an aggregate amount of US$8,000,000 (the &#147;2023 Subordinated Notes&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;5, 2023, Davis Polk shared an updated draft of the Convertible Bridge Financing term sheet with Morgan Lewis and Blakes. Davis
Polk, Stikeman and Blakes discussed such draft over a telephone call on the same day. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;7, 2023, Kirkland&nbsp;&amp; Ellis
circulated the updated transaction terms summary of the PIPE financing, which included an updated capitalization table. Morgan Lewis returned comments on April&nbsp;12, 2023. The parties exchanged several drafts, reflecting comments from FEAC,
enGene, and their respective counsel and advisors. On April&nbsp;7, 2023, Leerink Partners provided the potential PIPE investors with an updated term sheet, an updated <FONT STYLE="white-space:nowrap">pro-forma</FONT> capitalization table and a
summary of the proposed PIPE financing and the transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;7, 2023, Davis Polk provided an initial draft of the Business
Combination Agreement to enGene, Morgan Lewis, KPMG, Ernst &amp; Young LLP and Blakes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;8, 2023, Morgan Lewis provided Davis
Polk, Stikeman and FEAC initial drafts of the Registration Rights Agreement, the form of enGene Voting Agreement and the form of enGene <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement, the Sponsor and Insiders Letter Agreement as well as
the form of Incentive Equity Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;12, 2023, Jasper Bos informed the FEAC Board of Directors of the Transaction status,
timeline and process. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April 12, 2023, Ernst &amp; Young LLP was engaged by FEAC to perform certain tax and financial due diligence
activities in relation to the transaction. The financial diligence activities were undertaken between April&nbsp;12, 2023 and April 27, 2023 and the tax due diligence activities were undertaken between April 12, 2023 and May 10, 2023, respectively.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">184 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;12, 2023, a telephonic meeting was held between Jasper Bos, Jason Hanson and
Dr. Alex Nichols, to discuss timelines and deliverables for completion of various due diligence items as well as comments to the transaction documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;13, 2023, Ernst &amp; Young LLP shared an updated structure deck of the transaction. Leerink Partners shared such document with
the potential PIPE investors on April&nbsp;14, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;14, 2023, Blakes sent a
<FONT STYLE="white-space:nowrap">mark-up</FONT> to the draft Business Combination Agreement providing for, among other things, (i)&nbsp;revisions in the calculations of the consideration to be paid to enGene&#146;s shareholders in the Transaction,
(ii)&nbsp;the allocation of costs and expenses in case of changes to the transaction structures and <FONT STYLE="white-space:nowrap">non-occurrence</FONT> of the transaction, and (iii)&nbsp;changes to certain representations and warranties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;14, a telephonic meeting was held between Jasper Bos, Mathias Vinther, Jason Hanson and Dr. Alex Nichols, Chief Operating
Officer and President of enGene to discuss timelines of the potential transaction, update on progress on the PIPE financing, outstanding issues and next steps. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;15, 2023, Davis Polk shared an updated due diligence request list with Morgan Lewis and Blakes. FEAC, enGene and their
respective counsels and advisors had a telephone call on the same day to discuss outstanding legal due diligence issues. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
April&nbsp;15, 2023, a telephonic meeting was held among Blakes, Morgan Lewis, Davis Polk, Jasper Bos and Jason Hanson to discuss outstanding commercial terms of the Business Combination Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;17, 2023, Davis Polk circulated a revised draft Business Combination Agreement as well as revised drafts of the FEAC Voting
Agreement, the form enGene Voting Agreement and enGene <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement, the Sponsor and Insiders Letter Agreement as well as the form of Incentive Equity Plan. Over the next several days, Morgan Lewis,
Blakes, Davis Polk, Stikeman, Maples, and Loyens reviewed the Business Combination Agreement and provided comments to the document consistent with the contemplated transaction structure of the business combination. The parties exchanged several
drafts, reflecting comments from FEAC, enGene, and their advisors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;18, 2023, FEAC, enGene and their respective counsels
held a telephonic meeting to discuss comments to the Business Combination Agreement. On April&nbsp;21, 2023, a draft of the Business Combination Agreement was shared with the potential PIPE investors. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April 18, 2023 and April 26, 2023, Ernst &amp; Young LLP held calls with enGene&#146;s representatives in relation to the financial and tax
due diligence requests and information and documents provided in the virtual dataroom. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Between April&nbsp;18, 2023 and early May
2023, Davis Polk, Morgan Lewis and Blakes collected comments from Leerink Partners, UBS Securities, Kirkland&nbsp;&amp; Ellis and certain potential PIPE investors to the draft forms Subscription Agreement and Side Letter Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;20, 2023, Leerink Partners shared an updated capitalization table with FEAC, enGene and their respective counsels and advisors.
On the same day, FEAC and its counsels held a telephonic meeting with enGene, Leerink Partners and their respective counsels discussing the capitalization table. Over the following days multiple drafts of the capitalization table were exchanged.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;21, 2023, FEAC, enGene and Leerink Partners held a conference call to discuss the capitalization table. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;21, 2023, Blakes sent comments to the Business Combination Agreement to Davis Polk. The comments included, among other things,
(i)&nbsp;revisions in the calculation of the consideration to be paid to enGene&#146;s shareholders in the Business Combination, (ii)&nbsp;changes to certain representations and warranties, and (iii)&nbsp;alignment of certain transaction steps and
mechanics with tax advisor plan. FEAC&#146;s and enGene&#146; counsels had a telephone call </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">185 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
on the same date regarding certain key open issues relating to the Business Combination Agreement. Davis Polk returned an updated draft of the Business Combination Agreement to Blakes on the same
day. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;22, 2023, Blakes shared with Stikeman a draft of the IQ Letter Agreement providing for certain rights in favor of IQ
to be executed in connection with the Convertible Bridge Financing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;22, 2023, Davis Polk provided an updated draft of the
forms of Subscription Agreement and Side Letter Agreement. Over the next several days, Morgan Lewis, Blakes, Davis Polk, Stikeman and Kirkland&nbsp;&amp; Ellis reviewed the updated drafts and provided comments to the documents. On April&nbsp;24,
2023, Davis Polk delivered updated drafts, which were shared by Leerink Partners with the potential PIPE investors on the same day. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
April&nbsp;23, 2023, Davis Polk shared a first draft of the <FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreement. Morgan Lewis and Blakes returned comments on April&nbsp;24, 2023. Davis Polk returned a revised draft to the working group
on April&nbsp;25, 2023, and on the same date Leerink Partners shared the draft with the <FONT STYLE="white-space:nowrap">non-redeeming</FONT> investor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Between April&nbsp;23, 2023, and May&nbsp;11, 2023, the parties exchanged drafts of certain ancillary agreements, including among other things
New enGene&#146;s Proposed Articles and the Plan of Arrangement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;24, 2023, Morgan Lewis, Blakes, Davis Polk, Stikeman,
Walkers, Maples, KPMG and Ernst &amp; Young LLP discussed the proposed Cayman Merger mechanics over a telephone call. Over the following days, the parties exchanged several revised drafts of the transaction structure deck. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;25, 2023, representatives of enGene held a bringdown due diligence call for the purposes of the due diligence regarding the PIPE
financing and with the virtual attendance of Morgan Lewis, Blakes, Leerink Partners, UBS Securities, Kirkland&nbsp;&amp; Ellis, Davis Polk and Stikeman. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;26, 2023, Davis Polk circulated a draft deal announcement press release to all parties. In the following days, Davis Polk
collected comments from the various parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;26, 2023, certain potential PIPE investors returned comments to the drafts of
the form of Subscription Agreement and form of Side Letter Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;27, 2023, Davis Polk and a potential PIPE investor
discussed the draft <FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreement over a telephone call. On the same date, Blakes provided updated drafts of the Convertible Bridge Financing documents including the amended and restated note
purchase agreement, the form of the 2023 Convertible Notes, the enGene Majority Shareholder Agreement, the IQ Letter Agreement, the form of warrant certificate, and the Board Observer Term Sheet. Over the following days, comments were exchanged
among Blakes, Stikeman, Davis Polk, IQ&#146;s counsel and counsel to then existing investors in enGene. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;28, 2023, Davis
Polk provided an initial draft of the FEAC Disclosures Schedules. On April&nbsp;28, 2023, Morgan Lewis provided an initial draft of the enGene Disclosure Schedules. On May&nbsp;1, 2023, Morgan Lewis provided comments to Davis Polk and Stikeman on
the FEAC Disclosure Schedules. On May&nbsp;8, 2023, May&nbsp;10, 2023 and May&nbsp;12, 2023, Davis Polk provided comments to Blakes and Morgan Lewis on the enGene Disclosure Schedules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;29, 2023, Davis Polk provided an updated draft of the Business Combination Agreement to the working group. Morgan Lewis and
Blakes returned comments on May&nbsp;1, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;29, 2023, Davis Polk provided an updated draft of the forms of Subscription
Agreement, Side Letter Agreement and Non-Redemption Agreement. Morgan Lewis and Blakes returned comments on April&nbsp;30, 2023. The parties exchanged several drafts in the following days. On May&nbsp;10, 2023, Leerink Partners circulated revised
drafts to the potential PIPE investors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;1, 2023, Jason Hanson sent an email to Jasper Bos and Wouter Joustra, discussing
certain clinical study efficacy and safety data recently released by a potential competitor of enGene alongside that of <FONT STYLE="white-space:nowrap">EG-70.</FONT> On </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">186 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
May&nbsp;2, 2023, a virtual meeting between Leerink Partners and FEAC took place to discuss such recently released data. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Between May&nbsp;2, 2023 and May&nbsp;5, 2023, FEAC discussed such recently released data with several key opinion leaders in the field of
NMIBC to confirm the profile of <FONT STYLE="white-space:nowrap">EG-70.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Between May&nbsp;2, 2023 and May&nbsp;7, 2023, FEAC
discussed with potential PIPE investors the profile of <FONT STYLE="white-space:nowrap">EG-70,</FONT> as well as the clinical study efficacy and safety data recently released by a potential competitor of enGene. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;9, 2023, Davis Polk shared an updated draft of the Business Combination Agreement with the working group. Morgan Lewis and Blakes
returned comments on the same day. The parties exchanged several drafts in the following days with minor changes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;9, 2023,
Blakes shared the updated Convertible Bridge Financing transaction documents, which reflected the repayment of the 2023 Subordinated Notes by way of issuing the holders of the 2023 Subordinated Notes the 2023 Convertible Notes and the accompanying
warrants. Morgan Lewis and Blakes collected comments from the relevant parties in the following days. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;10, 2023, Leerink
Partners circulated the drafts Business Combination Agreement, forms of Subscription Agreement, Side Letter Agreement and Non-Redemption Agreement to the potential PIPE investors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;11, 2023, Morgan Lewis and Davis Polk held a telephone call to discuss the enGene Disclosure Schedules. On the same day, Blakes
shared updated drafts of certain ancillary agreements related to the Convertible Bridge Financing with Stikeman, IQ&#146;s counsel and counsel to the 2022 Noteholders (as defined below). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;12, 2023, Blakes circulated the proposed final transaction documents for the Convertible Bridge Financing to Davis Polk, Stikeman,
IQ&#146;s counsel and the 2022 Noteholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;12, 2023, two parties indicated interest in joining the transaction as potential
PIPE investors. Leerink Partners shared the transaction documentation with all prospective PIPE investors, as well as an updated capitalization table, on the same day. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Between May&nbsp;10, 2023 and May&nbsp;16, 2023, Davis Polk and Leerink Partners shared with the prospective PIPE investors final drafts of
the Transaction documents as well as the relevant signature packets and collected signatures to be held in escrow pending release. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">enGene
advised FEAC that on the morning of May&nbsp;13, 2023, the enGene Board held a telephonic meeting attended by all members of the enGene Board. Representatives from Blakes and Morgan Lewis were also in attendance. During the meeting, Blakes provided
the enGene Board with a summary of the terms and structure of the proposed Business Combination, the Business Combination Agreement and the related Ancillary Agreements, including, among other things, the material terms and conditions of the
proposed Business Combination Agreement and the post-Business Combination Closing structure of New enGene. Blakes also provided a summary of the Convertible Bridge Financing. The enGene Board then engaged in discussions and deliberations with the
other directors and advisors. Following these discussions and deliberations, the enGene Board, having determined that entry into the Business Combination Agreement and Ancillary Agreements and the Transactions contemplated thereby were in the best
interest of enGene and its shareholders, unanimously approved the entry into the Business Combination Agreement and Ancillary Agreements and the transactions contemplated thereby by way of written resolution. Over the following days, the enGene
Board was given updates reflecting the addition of new investors into the PIPE Financing, and provided consent to those modifications to the Transactions and the respective changes to the written resolutions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">187 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;13, 2023, enGene informed FEAC that the enGene Board of Directors had held a
telephonic meeting attended by all members of the enGene Board of Directors and representatives from Blakes and Morgan Lewis. enGene reported to FEAC that during the meeting Blakes provided the enGene Board of Directors with a summary of the terms
and structure of the proposed Business Combination, the Business Combination Agreement and the related Ancillary Agreements, including, among other things, the material terms and conditions of the proposed Business Combination Agreement and the
post-Business Combination Closing structure of New enGene. According to enGene, Blakes also provided a summary of the Convertible Bridge Financing. The enGene Board of Directors then engaged in discussions and deliberations with the other directors
and advisors. Following these discussions and deliberations, the enGene Board, having determined that entry into the Business Combination Agreement and Ancillary Agreements and the Transactions contemplated thereby were in the best interest of
enGene and its shareholders, unanimously approved the entry into the Business Combination Agreement and Ancillary Agreements and the transactions contemplated thereby by way of written resolution. Over the following days, the enGene Board received
updates reflecting the addition of new potential investors into the PIPE Financing, and consented to those modifications to the Transactions and the respective changes to the written resolutions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;13, 2023, FEAC, enGene, Leerink Partners and their respective counsels and advisors held telephone calls to discuss outstanding
issues in the transaction documents, the potential interest of new investors and the signing mechanics. On the same date, the parties held a telephone call to discuss the draft press release, and Davis Polk shared an updated draft of the press
release. The parties exchanged multiple rounds of drafts of the press release over the coming days and circulated the final draft of the press release on May&nbsp;16, 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;13, 2023, Davis Polk shared with Morgan Lewis and Blakes updated drafts of the Business Combination Agreement and Ancillary
Agreements. On the same day, Davis Polk shared with Kirkland&nbsp;&amp; Ellis the final draft of the Sponsor and Insiders Letter Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On the morning of May&nbsp;14, 2023, the FEAC Board held a telephonic meeting attended by all members of the FEAC Board. Representatives from
Davis Polk and Lincoln were also in attendance. During the meeting, Jasper Bos provided an update on general market conditions for special purpose acquisition companies and reviewed the general deal framework. Jasper Bos also provided the FEAC Board
with a summary of the terms and structure of the proposed Business Combination, the Business Combination Agreement and the related Ancillary Agreements. The summary included, among other things, the main factors considered by FEAC for the purposes
of the valuation attributed to enGene. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In particular, Jasper Bos noted that the pre-money valuation of enGene of $200 million, which was
first discussed between FEAC management and enGene management in an email exchange on May&nbsp;5, 2022, and later agreed in the LoI, was subsequently revised to $90 million. Jasper Bos explained that this downward adjustment was the result of a
significant deterioration in the macro economic environment, capital markets activity and financing conditions (for example, in 2021 approximately 152 biotech companies completed an initial public offering, raising over $25 billion in total,
compared to only approximately 47 biotech companies in 2022, raising approximately $4 billion in total) following the execution of the LoI, and the adverse impact thereof on valuations of biotech companies generally. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FEAC management first discussed a potential downward adjustment of the pre-money valuation of enGene with Leerink Partners on
November&nbsp;18, 2022, when Leerink Partners and FEAC held a teleconference to discuss the PIPE financing terms that were proposed by a potential PIPE financing investor. The proposed terms included, among others, a pre-money equity valuation of
enGene of $90 million, a redistribution of certain amount of FEAC Private Placement Warrants from the Sponsor to the potential PIPE investors, and a reduction in size of enGene&#146;s equity incentive plan to 8% of enGene&#146;s equity (following
the initial business combination) on a fully diluted basis. On December&nbsp;7, 2022, Leerink Partners and FEAC presented these terms to the enGene Board and explained that the revised terms were a prerequisite to obtain financing for the proposed
initial business combination in light of the deteriorated macro-economic environment and the impact thereof on valuations of biotech companies. On December&nbsp;8, 2022, a telephonic meeting was held between Jason Hanson
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">188 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
from enGene and Jasper Bos from FEAC to further discuss the new proposed terms and conditions of the PIPE financing. On December&nbsp;15, 2022, the enGene Board agreed to the new terms and
conditions of the PIPE financing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;14, 2023, Lincoln provided a Fairness Opinion to the FEAC Board with respect to the
valuation of enGene in connection with the proposed Business Combination and derived an implied enterprise value of $111 million, comprised of a pre-money equity value of $90 million, plus the aggregate exercise value of the existing enGene warrants
in an amount of $2 million, plus existing enGene indebtedness amounting to $33 million and minus an amount of $14 million in cash and cash equivalents. The FEAC Board approved the proposed Business Combination on the basis of the implied enterprise
value of $111 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other material terms of the Business Combination were discussed, including (i) the material terms and conditions
of the proposed Business Combination Agreement and (ii) the post-Business Combination Closing structure of New enGene. Lincoln provided the FEAC Board of Directors with an overview of its draft fairness opinion and the analysis underlying the
opinion. The FEAC Board then engaged in discussions and deliberations with the other directors and advisors. Following these discussions and deliberations, FEAC&#146;s independent directors held an executive session to further discuss the merits of
the proposed transaction. Following discussions, the FEAC Board, having determined that entry into the Business Combination Agreement and Ancillary Agreements and the Transactions contemplated thereby were in the best interest of FEAC and its
shareholders, unanimously approved the entry into the Business Combination Agreement and Ancillary Agreements and the transactions contemplated thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;14, 2023, Lincoln delivered to the FEAC&#146;s Board of Directors the fairness opinion. See also &#147;<I>Proposal
No.</I><I></I><I>&nbsp;1 &#151; The Business Combination Proposal &#151; Summary of Lincoln&#146;s Financial Analysis</I>.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
May&nbsp;14, 2023, Davis Polk shared with Kirkland&nbsp;&amp; Ellis the final draft of the Sponsor and Insiders Letter Agreement. Kirkland&nbsp;&amp; Ellis provided comments on the same day and Davis Polk provided a final draft on May&nbsp;15, 2023.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Between May&nbsp;14, 2023 and May&nbsp;16, 2023, the parties exchanged final drafts of the transaction documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;15, 2023, a new party confirmed its interest in joining the proposed PIPE Financing. On the same day, Leerink Partners shared the
transaction documents with such new potential investor. On May&nbsp;16, 2023, Davis Polk, Leerink Partners, the potential new PIPE investor and its counsel held telephone calls to discuss drafts of the Subscription Agreement and Side Letter
Agreement as well as the structure of the Transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;15, 2023, following final discussions with the syndicate of
prospective PIPE investors, the amount of the PIPE Financing (including the Convertible Bridge Financing), and the <FONT STYLE="white-space:nowrap">non-redemption</FONT> commitment of an existing FEAC Shareholder, was set at, in the aggregate,
$115&nbsp;million. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;16, 2023, after the close of public markets in the United States, FEAC, New enGene and enGene executed
the Business Combination Agreement. Concurrently with the execution of the Business Combination Agreement, among others, (i)&nbsp;FEAC and New enGene entered into the Subscription Agreements and the Side Letter Agreements with the PIPE Investors,
(ii)&nbsp;FEAC and New enGene entered into the <FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreement, (iii)&nbsp;enGene, FEAC and the enGene Shareholders party thereto entered into the Transaction Support Agreements and (iv)&nbsp;FEAC,
enGene the Sponsor and the directors and officers of FEAC entered into the Sponsor and Insiders Letter Agreement and the FEAC Voting Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently with the execution of the Business Combination Agreement, enGene and the lenders under the Convertible Bridge Financing entered
into an amended and restated note purchase agreement providing for financing in an aggregate amount of $30&nbsp;million, together with other related documents including the enGene Majority Shareholder Agreement and the IQ Letter Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">189 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;17, 2023, and prior to the open of public markets in the United States, the
parties issued a joint press release announcing the Business Combination and, shortly thereafter, FEAC filed a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (the &#147;First Current Report&#148;) attaching the press release and
the final investor presentation previously provided to certain potential PIPE financing investors and enGene Shareholders. On May&nbsp;17, 2023, enGene issued notes and warrants to the 2023 Noteholders (as defined below) in accordance with the terms
of the amended and restated note purchase agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;22, 2023, FEAC filed a Current Report on Form <FONT
STYLE="white-space:nowrap">8-K/A</FONT> amending Item 1.01 and supplementing Item 9.01 (solely to add additional exhibits) of the First Current Report solely to file the Business Combination Agreement (including the exhibits thereto), the Sponsor
and Insiders Letter Agreement, the form of enGene Voting Agreement, the form of enGene <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement, the FEAC Voting Agreement, the forms of Subscription Agreement and Side Letter Agreement, the <FONT
STYLE="white-space:nowrap">Non-Redemption</FONT> Agreement and the form of Registration Rights Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>The FEAC Board&#146;s
Reasons for the Business Combination </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FEAC was formed for the purpose of effecting a merger, share exchange, asset acquisition, share
purchase, reorganization or similar business combination with one or more businesses or entities and the intent to capitalize on the ability of FEAC&#146;s management team to identify a potential target within the life sciences industry. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;14, 2023, the FEAC Board, after consultation with its legal, financial, accounting and other advisors, (i)&nbsp;determined that it
is desirable, advisable and in the best commercial interests of FEAC to approve and enter into the Business Combination Agreement and the Ancillary Agreements, (ii)&nbsp;approved the execution and delivery of the Business Combination Agreement and
the Ancillary Agreements and (iii)&nbsp;recommended the adoption and approval of the Business Combination Agreement and the Ancillary Agreements, and each of the proposals presented in this proxy statement/prospectus, by the FEAC Shareholders. In
evaluating the Business Combination and making these determinations and this recommendation, the FEAC Board consulted with FEAC senior management and considered a wide variety of factors, including the reasons for the Business Combination and the
risks related thereto, in each case, as described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In light of the complexity of those factors, the FEAC Board did not consider it
practicable to, nor did it attempt to, quantify or otherwise assign relative weights to the specific factors it considered in reaching the directors&#146; respective decisions. See also &#147;<I>Proposal No.</I><I></I><I>&nbsp;1 &#151; The Business
Combination Proposal &#151; Interests of FEAC&#146;s Sponsor, Directors and Executive Officers in the Business Combination.</I>&#148; Individual members of the FEAC Board may have given different weight to different factors. This explanation of the
reasons for the FEAC Board&#146;s approval of the Business Combination, and all other information presented in this section, is not intended to be exhaustive but includes material factors considered by the FEAC Board and is forward-looking in nature
and, therefore, should be read in light of the factors discussed under the section entitled &#147;<I>Cautionary Statement Regarding Forward-Looking Statements</I>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FEAC Board and management of FEAC considered the general criteria and guidelines that FEAC believed would be important in evaluating
prospective target businesses as described in the prospectus for FEAC&#146;s IPO. The FEAC Board also considered that FEAC could enter into a business combination with a target business that does not meet those criteria and guidelines. In the
prospectus for its IPO, FEAC stated that it intended to focus primarily on acquiring a company or companies exhibiting some of the following criteria and guidelines: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Compelling risk/reward proposition, with the potential to generate a financial return; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Therapeutics-focused, with a key product candidate in later stages of clinical development;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Experienced management team with proven track record of success; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Product candidate that addresses a high unmet medical need and improves patients&#146; lives;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">190 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Product candidate that serves a sizeable patient population and can deliver a pharmaco-economic benefit;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">High likelihood of reimbursement based on health-economic analysis; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Sustainable competitive edge, usually involving patent protection and regulatory status; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Sustainable future financing plan, including multiple exit strategies within a reasonable time frame; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Europe-based or significant footprint in Europe. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In considering the Business Combination, the FEAC Board determined that the Business Combination was an attractive business opportunity and
sufficiently met the majority of the criteria and guidelines above (although not weighted or in any order of significance). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
particular, the FEAC Board considered the following factors (although not weighted or in any order of significance) in deciding to approve the proposed Business Combination: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>Experienced management team with leading industry experience and track record. </I></B>The FEAC Board
believed that enGene&#146; management team has extensive experience in the biopharma industry in general and the gene therapies market in particular. The FEAC Board is confident in the management team&#146;s deep industry knowledge and strategic
vision and believes that both the FEAC and the enGene teams (together with the new incoming directors of New enGene) have extensive executive experience working in the biopharma industry, which will position enGene to create and enhance a
collaborative and effective long-term partnership that is positioned to create and enhance shareholder value going forward. For additional information regarding enGene&#146; executive officers, please see the section entitled &#147;<I>Directors and
Executive Officers of New enGene After the Business Combination</I>.&#148; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>Next-generation <FONT STYLE="white-space:nowrap">non-viral</FONT> gene delivery platform supporting
substantial timeline and new programs. </I></B>The FEAC Board considered that the current pipeline of enGene provides multiple product candidates that may be developed in several indications where the existing unmet medical need could provide
significant market opportunities and long-term shareholder value. For additional information regarding enGene&#146; pipeline, please see the section entitled<B><I> </I></B>&#147;<I>Business of enGene</I>.&#148; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>Upcoming milestones and potential value inflection point. </I></B>The FEAC Board considered that with the
funds that enGene is expected to receive as a result of the Business Combination, it may be able to reach significant clinical milestones for <FONT STYLE="white-space:nowrap">EG-70,</FONT> including the Phase 2 interim efficacy studies. These
milestones could provide opportunity for potential uplifts in valuation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>Established regulatory registrational pathway, market and pricing dynamics for lead program. </I></B>The
FEAC Board considered that NMIBC is an indication which is well-defined, with high unmet medical need and for which prior regulatory guidance provides a clear regulatory pathway. The FEAC Board believes that
<FONT STYLE="white-space:nowrap">EG-70</FONT> has a profile which, if proven in later clinical studies, is commercially viable. Given the high unmet medical need of NMIBC patients, and availability of independent third parties&#146; reports
confirming favorable pricing dynamics for a similar product, the FEAC Board believes that the overall market dynamics of <FONT STYLE="white-space:nowrap">EG-70</FONT> might be favorable. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>Benefit for enGene of being U.S. listed</I></B>. As a result of the proposed transaction, it is expected
that enGene will become a public company listed on the Nasdaq Capital Market (via New enGene). The FEAC Board considered that by having access to the world&#146;s largest biotech capital market, enGene will be better positioned to have the capacity
to raise additional funds in the future if and when needed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>Investment by Third Parties</I></B><B>. </B>The FEAC Board considered that certain third-party investors
(other than the Sponsor, FGOF and existing enGene investors)&nbsp;(i) subscribed for the PIPE Financing in the aggregate amount of approximately $55.7&nbsp;million and (ii)&nbsp;entered into the Convertible Bridge Financing in the aggregate amount
of approximately $10.0&nbsp;million. The FEAC Board noted that the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">191 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Sponsor (i) will invest an amount of approximately $1.2 million in the PIPE Financing and (ii)&nbsp;participated in the Convertible Bridge Financing in an amount equal to $20.0 million.
Furthermore, the FEAC Board noted with respect to the price per share of FEAC Shares, that (i) in its IPO, FEAC issued FEAC Units at an offering price of $10.00 per FEAC Unit, each of which consisted of one FEAC Class A Share and one-third of one
FEAC Public Warrant; (ii) in connection with the PIPE Financing, FEAC entered into Subscription Agreements pursuant to which it agreed that it (or after the Assumption, New enGene) will issue and sell to the PIPE Investors the number of FEAC Class A
Shares (or after the Assumption, New enGene Shares) provided for in the applicable Subscription Agreement in exchange for the purchase price of $10.25 per FEAC Class A Share (or after the Assumption, New enGene Share), which purchase price was set
on the basis of the initial amount available per FEAC Class A Share in FEAC&#146;s Trust Account immediately upon the consummation of its IPO and the exercise in full of the underwriters&#146; over-allotment option (which resulted in $129,662,500,
or $10.25 per FEAC Unit, being held in the Trust Account). Immediately following the execution and delivery of the Subscription Agreements, FEAC and New enGene entered into a Side Letter Agreement with each PIPE Investor, amending such PIPE
Investor&#146;s Subscription Agreement, pursuant to which each PIPE Investor will receive a specified number of additional FEAC Class A Shares (or after the Assumption, New enGene Shares) and a specified number of FEAC Public Warrants (of after the
Assumption, New enGene Warrants), in each case in consideration of the aggregate purchase price set forth in the relevant PIPE Investor&#146;s original Subscription Agreement; (iii) pursuant to the Non-Redemption Agreement, FEAC will, in
consideration of a specific FEAC shareholder&#146;s commitment not to redeem its FEAC Class A Shares in connection with the approval of the Business Combination by the FEAC Shareholders, issue additional FEAC Class A Shares and FEAC Public Warrants
(or after the Assumption, New enGene will issue additional New enGene Shares and New enGene Warrants) to such FEAC shareholder, such that, in the aggregate, such FEAC shareholder will hold the same amount of FEAC Class A Shares and FEAC Public
Warrants (or after the Assumption, New enGene Shares and New enGene Warrants) as it would have received if it had subscribed, in an amount equal to its existing IPO investment in FEAC Class A Shares, for FEAC Class A Shares in the PIPE Financing (or
after the Assumption, New enGene Shares) on the same terms and at the same purchase price per FEAC Class A Share as the PIPE Financing, taking into account the additional FEAC Class A Shares and FEAC Public Warrants (or after the Assumption, New
enGene Shares and New enGene Warrants) allocated to the PIPE Investors pursuant to the Side Letter Agreements; and (iv) the Convertible Bridge Financing indebtedness will be converted in the Transactions into that number of New enGene Shares and New
enGene Warrants that, when exchanged at the Company Exchange Ratio, shall equal that number of FEAC Class A Shares and FEAC Public Warrants (or after the Assumption, New enGene Shares and New enGene Warrants) that the holders of such indebtedness
would have received if they had subscribed, in an amount equal to their existing investment in the Convertible Bridge Financing, for FEAC Class A Shares in the PIPE Financing (or after the Assumption, New enGene Shares) on the same terms and at the
same purchase price per FEAC Class A Share as the PIPE Financing, taking into account the additional FEAC Class A Shares and FEAC Public Warrants (or after the Assumption, New enGene Shares and New enGene Warrants) allocated to the PIPE Investors
pursuant to the Side Letter Agreements. </TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>Terms of the Business Combination Agreement and the Ancillary Agreements</I></B><B>. </B>The FEAC Board
considered the terms and conditions of the Business Combination Agreement and the Ancillary Agreements, including the transactions contemplated thereby, each party&#146;s representations, warranties and covenants, the conditions to each party&#146;s
obligation to close and the termination provisions, as well as FEAC&#146;s and enGene&#146; strong commitment to complete the Business Combination. The FEAC Board determined that such terms and conditions are reasonable and were the product of
extensive <FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> negotiations between FEAC and enGene. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>Continued Ownership of enGene Shareholders</I></B><B>.</B> The FEAC Board considered that the enGene
Shareholders would be receiving a significant amount of shares of New enGene in the proposed Business Combination. Certain enGene Shareholders have demonstrated confidence in the long-term
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">192 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
prospects of New enGene by agreeing not to transfer their shares in New enGene for 180 days following the Closing. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>The Role of the Independent Directors</I></B><B>.</B> In connection with the Business Combination,
FEAC&#146;s independent directors evaluated the proposed terms of the Business Combination, including the Business Combination Agreement and the related agreements, and unanimously approved, as members of the FEAC Board, the Business Combination
Agreement, the Ancillary Agreements, and the transactions contemplated thereby. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>Other Alternatives</I></B><B>. </B>The FEAC Board believed, after a thorough review of other business
combination opportunities reasonably available to or explored by FEAC, that the proposed Business Combination represented the optimal potential business combination for FEAC and its shareholders based upon the process utilized to evaluate and assess
other potential acquisition targets and the FEAC Board&#146;s belief that such processes had not presented a better alternative. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>Negotiated Transaction.</I></B> The FEAC Board believed that the financial and other terms of the
Business Combination Agreement, including the consideration to be paid by FEAC to enGene Shareholders, are reasonable and were the product of arm&#146;s length negotiations between FEAC and enGene. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The FEAC Board also identified and considered a variety of uncertainties and risks and other potentially negative factors concerning the
Business Combination, including, but not limited to, the following (although not weighted or in any order of significance): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>Macroeconomic Risk</I></B>: macroeconomic uncertainty and the effects it could have on New enGene in the
future; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>Uncertainty of Benefits</I></B>: the risk that the potential benefits of the Business Combination may not
be fully achieved, or may not be achieved within the expected timeframe; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>Redemption Risk</I></B>: the risk that some or all of the FEAC Shareholders (other than those FEAC
Shareholders who have undertaken not to redeem their FEAC Shares) decide to exercise their redemption rights, thereby depleting the amount of cash available in the Trust Account and adequately support New enGene&#146;s development plans following
completion of the Business Combination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>Liquidation of FEAC</I></B>: the risks and costs to FEAC if the Business Combination is not completed,
including the risk of diverting management focus and resources from other business combination opportunities, which could result in FEAC being unable to effectuate a business combination within the Combination Period, and force FEAC to liquidate in
accordance with its Current Articles; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>Exclusivity</I></B>: that the Business Combination Agreement includes an exclusivity provision that
prohibits FEAC from, among other things, initiating discussions in connection with other business combination proposals, restricting FEAC&#146;s ability, as long as the Business Combination Agreement is in effect, to consider other potential
business combinations prior to the termination of the Business Combination Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>Diversion of Management; Risk of Management Departures</I></B>: the potential for diversion of management
and employee attention during the period prior to the completion of the Business Combination, and the potential negative effects on enGene&#146; business as a result thereof, and the risk that key employees of enGene may not remain with enGene
following the closing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>Shareholder Vote</I></B>: the risk that FEAC Shareholders may fail to provide the respective votes
necessary to effectuate the Business Combination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>Closing Conditions</I></B><I>: </I>that completion of the Business Combination is conditioned on the
satisfaction of certain closing conditions that are not within FEAC&#146;s control, including (i)&nbsp;approval by FEAC Shareholders and (ii)&nbsp;approval by the Nasdaq of the initial listing application made for the shares and warrants of New
enGene to be issued in connection with the Business Combination<I>.</I><B><I> </I></B> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">193 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I><FONT STYLE="white-space:nowrap">Non-Survival</FONT></I></B>: that the remedies for breach of
representations, warranties or covenants will not survive the Closing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>Public Company Readiness</I></B>: the challenges associated with preparing New enGene and its future
subsidiary enGene, both foreign, private entities, for the applicable disclosure and listing requirements and other rules, as well as market and other expectations, that New enGene will be subject to as a publicly traded company on the Nasdaq Stock
Market, including the time and attention of management and employees that will be diverted from operating matters to achieve and meet such requirements and expectations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>FEAC Shareholders Receiving a Minority Position in New enGene</I></B>: the risks associated with FEAC
Shareholders holding a minority position in New enGene following the Closing and the transactions contemplated thereby; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>Litigation</I></B>: the possibility of litigation challenging the Business Combination or that an adverse
judgment granting permanent injunctive relief could indefinitely enjoin consummation of the Business Combination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>Fees and Expenses</I></B>: the significant fees and expenses associated with completing the Business
Combination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>Conflicts of Interest</I></B>; the potential conflicts of interest described in the section entitled
&#147;<I>Certain Relationships and Related Party Transactions &#151; FEAC</I>&#148;; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">15.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I>Other Risks</I></B>: various other risks associated with the Business Combination, the business of FEAC
and the business of enGene, as described further under the section entitled &#147;<I>Risk Factors</I>.&#148; </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition to considering the factors described above, the FEAC Board also considered that certain of the officers and directors of FEAC may have interests in the Business Combination as individuals that are in addition to, and that may be different
from, the interests of FEAC Shareholders, including as a result of the corporate opportunities waiver included in FEAC&#146;s Current Articles. The potential conflict of interest relating to the waiver of the corporate opportunities doctrine in
FEAC&#146;s Current Articles did not impact FEAC&#146;s search for an acquisition target and FEAC was not prevented from reviewing any opportunities as a result of such waiver. The executive officers and directors of FEAC have established
reputations in the life sciences industry and might have had many opportunities available to them, which would not have needed to be disclosed to the FEAC Board in connection with its consideration of the potential Business Combination. These
potential conflicts are more thoroughly described in more detail under the section entitled &#147;<I>Certain Relationships and Related Party Transactions</I>.&#148; FEAC&#146;s independent directors reviewed and considered these interests during the
negotiation of the Business Combination and in evaluating and approving, as members of the FEAC Board, the Business Combination Agreement and the transactions contemplated therein, including the Business Combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FEAC Board concluded, based on its review of the foregoing considerations as a whole, that the potential benefits that it expected FEAC
and its shareholders to achieve as a result of the Business Combination outweighed the potentially negative factors associated with the Business Combination. Accordingly, the FEAC Board unanimously determined that the Business Combination Agreement
and the Business Combination were desirable, advisable and in the best commercial interests of FEAC. The FEAC Board realized that there can be no assurance about future results, including results considered or expected, as disclosed in the foregoing
reasons. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Satisfaction of 80% Test </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After consideration of the factors identified and discussed in the section entitled &#147;<I>The FEAC Board&#146;s Reasons for the Business
Combination,&#148; </I>the FEAC Board concluded that the Business Combination met all of the requirements disclosed in the prospectus for its IPO with respect to FEAC&#146;s initial business combination, including that the transaction had an
aggregate fair market value of at least 80% of the net assets held in the Trust Account (excluding the deferred underwriting commissions and taxes payable on the interest earned on the Trust Account) at the time of signing the Business Combination
Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">194 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Interests of FEAC&#146;s Sponsor, Directors and Executive Officers in the Business Combination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When you consider the recommendation of the FEAC Board in favor of approval of the Business Combination Proposal, you should keep in mind that
the Sponsor and FEAC&#146;s directors and executive officers have interests in such proposal that are different from, or in addition to, those of FEAC Shareholders and FEAC Warrant holders generally. These interests include, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that after giving effect to the Sponsor Loans Conversion and the Surrender, the Sponsor will retain
1,373,496 FEAC Class&nbsp;B Shares which it purchased at a price of approximately $0.009 per share and 731,619 FEAC Private Placement Warrants which it purchased at a price of $1.50 per warrant, and such securities will have a significantly higher
value at the time of the Business Combination as described further below: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;FEAC<BR>Class&nbsp;B&nbsp;Shares</B><br><B>beneficially&nbsp;owned&nbsp;as</B><br><B>of the date hereof</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;FEAC</B><br><B>Private&nbsp;Placement</B><br><B>Warrants&nbsp;owned&nbsp;as&nbsp;of<BR>the date hereof</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate&nbsp;value<BR>of&nbsp;FEAC&nbsp;Class&nbsp;B</B><br><B>Shares&nbsp;and&nbsp;FEAC</B><br><B>Private&nbsp;Placement</B><br><B>Warrants&nbsp;
implied&nbsp;by</B><br><B>the&nbsp;Business</B><br><B>Combination<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate&nbsp;value</B><br><B>of&nbsp;FEAC&nbsp;Class&nbsp;B</B><br><B>Shares&nbsp;and&nbsp;FEAC</B><br><B>Private&nbsp;Placement</B><br><B>Warrants&nbsp;
based&nbsp;on</B><br><B>&nbsp;&nbsp;recent&nbsp;trading&nbsp;price<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sponsor<SUP STYLE="font-size:75%; vertical-align:top">(3)(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,373,496</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">731,619</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,215,684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Assumes a value of $10.35 per share, the deemed value of the FEAC Class B Shares on the basis of the
anticipated amount in the Trust Account of $10.35 per FEAC Class A Shares (excluding interest earned on amounts in the Trust Account), and $0.00 per warrant, which reflects that the exercise price of the warrants ($11.50 per warrant) exceeds the
value of the underlying ordinary shares in the Business Combination. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Assumes a value of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the closing price of the FEAC
Class&nbsp;B Shares on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;, 2023, and $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per warrant, the closing price of the FEAC Private Placement Warrants on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;, 2023. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Sponsor is the record holder of the FEAC Class&nbsp;B Shares reported herein. Jasper Bos, Cyril Lesser,
Sander Slootweg and Wouter Joustra, who are directors of the Sponsor, have voting and investment discretion with respect to the FEAC Shares owned by the Sponsor and may be deemed to have indirect shared beneficial ownership of the FEAC Shares held
by the Sponsor. Jasper Bos, Cyril Lesser, Sander Slootweg and Wouter Joustra each disclaim beneficial ownership over the FEAC Class&nbsp;B Shares except to the extent of their pecuniary interest therein. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">FGOF wholly owns the Sponsor and therefore the Sponsor and FGOF have shared voting and investment power over
the FEAC Class&nbsp;B Shares held by the Sponsor. FGOF also holds 2,000,000 FEAC Class&nbsp;A Shares underlying the 2,000,000 FEAC Units held by it. Therefore, FGOF has shared voting and investment power over 5,162,500 FEAC Shares in the aggregate,
representing approximately 32.7% of FEAC&#146;s issued and outstanding ordinary shares as of the date hereof. Forbion Management is the sole director of FGOF and therefore shares voting and investment power (i)&nbsp;with FGOF over the 2,000,000 FEAC
Class&nbsp;A Shares underlying the FEAC Units held by FGOF and (ii)&nbsp;with FGOF and, indirectly, the Sponsor, over the 3,162,500 FEAC Class&nbsp;B Shares held by the Sponsor. Forbion Management exercises voting and investment power through its
investment committee (the &#147;Investment Committee&#148;) consisting of Sander Slootweg, Martien van Osch, <FONT STYLE="white-space:nowrap">Geert-Jan</FONT> Mulder, Vincent van Houten, Dirk Kersten, Nanna L&uuml;neborg, Wouter Joustra and Jasper
Bos. None of the members of the Investment Committee has individual voting and investment power with respect to the ordinary shares, and each such member disclaims beneficial ownership of the ordinary shares except to the extent of their
proportionate pecuniary interest therein. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Prior to the Surrender and the Sponsor Loan Conversions (see &#147;<I>Certain Relationships and Related Party
Transactions</I> &#151;<I> Sponsor and Insiders Letter Agreement; Surrender; Sponsor Loans Conversion</I>&#148;), the Sponsor owns 3,162,500 FEAC Class&nbsp;B Shares and 5,195,000 FEAC Private Placement Warrants. Pursuant to the Sponsor Loans
Conversions agreed in the Sponsor and Insiders Letter Agreement, the Sponsor agreed to convert an amount equal to $1,500,000 of the aggregate principal amount outstanding under the Sponsor Loans, taken together, into additional FEAC Private
Placement Warrants immediately prior to the Surrender (following which the Sponsor will own 6,195,000 FEAC Private Placement Warrants). Pursuant to the Surrender agreed in the Sponsor and Insiders Letter Agreement, the Sponsor will forfeit 1,789,004
of its </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">195 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
FEAC Class&nbsp;B Shares and 5,463,381 of its FEAC Private Placement Warrants as a contribution to the capital of FEAC, for no consideration. After the Surrender, such 1,789,004 of its FEAC
Class&nbsp;B Shares and 5,463,381 of its FEAC Private Placement Warrants will be cancelled and no longer outstanding and the Sponsor will own 1,373,496 FEAC Class&nbsp;B Shares and 731,619 FEAC Private Placement Warrants. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that if FEAC does not complete its initial business combination within 18 months from the closing of
FEAC&#146;s IPO (or up to 24 months from the closing of our IPO if FEAC extends the period of time to consummate a business combination, subject to the Sponsor depositing additional funds in the Trust Account), the FEAC Class&nbsp;B Shares and the
FEAC Private Placement Warrants will expire worthless; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that given the differential in the purchase price that the Sponsor paid for the FEAC Class&nbsp;B Shares
as compared to the price of the FEAC Class&nbsp;A Shares sold in FEAC&#146;s IPO, the Sponsor and its affiliates may earn a positive rate of return on their investment even if the FEAC Class&nbsp;A Shares trade below the price initially paid for the
FEAC Class&nbsp;A Shares in FEAC&#146;s IPO and the holders of FEAC Class&nbsp;A Shares experience a negative rate of return following the completion of the Business Combination. It is not practicable to quantify the Sponsor&#146;s rate of return
because, among other things, the timing (including as a result of the <FONT STYLE="white-space:nowrap">lock-up</FONT> applicable to the FEAC Class&nbsp;B Shares) and the price at which the Sponsor may ultimately sell New enGene Shares (into which
the FEAC Class&nbsp;B Shares will be converted in connection with the Business Combination), New enGene Warrants (into which the FEAC Private Placement Warrants will be converted in connection with the Business Combination) and other equity
securities of New enGene are uncertain, both of which would have a material impact on the applicable rate of return; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that pursuant to the Sponsor&#146;s subscription agreement entered into on May&nbsp;16, 2023 with FEAC
and New enGene (as amended by the Sponsor&#146;s subscription agreement side letter entered into on May&nbsp;16, 2023 by the Sponsor, FEAC and New enGene), the Sponsor will receive, upon consummation of the Business Combination, in consideration of
the purchase price to be paid by the Sponsor set forth in such agreement, 130,085 FEAC Class&nbsp;A Shares (or following the Assumption, New enGene Shares) and 54,634 FEAC Private Placement Warrants (or following the Assumption, New enGene
Warrants); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the Sponsor purchased or will purchase from enGene pursuant to a purchase agreement entered into
with enGene on May&nbsp;16, 2023 for an aggregate amount of $20,000,000 (i) warrants of enGene and (ii)&nbsp;convertible notes of enGene which will get converted upon the consummation of the Business Combination into common shares of enGene, and
which, in each case, when exchanged at the enGene Exchange Ratio pursuant to the Transactions, shall equal that number of FEAC Warrants and FEAC Class&nbsp;A Shares (or after the Assumption, New enGene Warrants and New enGene Shares, respectively),
that the Sponsor would have received if it had participated in that amount on the same terms as the PIPE Financing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that if a business combination is not consummated within the required period, the Sponsor will lose its
entire investment in FEAC, which investment included a capital contribution of $25,000 for the Sponsor&#146;s FEAC Class&nbsp;B Shares, $7,792,500 for the Sponsor&#146;s FEAC Private Placement Warrants, $1,200,000 in Working Capital Loans and
$1,265,000 in Extension Loans (as defined below); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the Sponsor and FEAC&#146;s current officers and directors have entered into a letter agreement
with FEAC dated December&nbsp;9, 2021 in which they agreed to waive their rights to liquidating distributions from the Trust Account with respect to any FEAC Class&nbsp;B Shares held by them if FEAC fails to complete an initial business combination
within the required period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that pursuant to the FEAC Voting Agreement, the Sponsor, FGOF and FEAC&#146;s directors and executive
officers agreed, among other things, (a)&nbsp;to vote any FEAC Class&nbsp;B Shares and FEAC Class&nbsp;A Shares held by it in favor of any proposed business combination and (b)&nbsp;not to redeem any FEAC Class&nbsp;B Shares or FEAC Class&nbsp;A
Shares held by it in connection with a shareholder vote to approve a proposed Business Combination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the Sponsor and FGOF, collectively, after giving effect to the Transactions and the transfer of
20,000 New enGene Shares to each of three of FEAC&#146;s independent directors as described below, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">196 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
are expected to own 5,705,932 New enGene Shares, which collectively will represent approximately 24% of outstanding New enGene Shares (assuming maximum FEAC Shareholder Redemptions) and have a
value of approximately $59,056,396.20 based on an implied value of $10.35 per New enGene Share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the Sponsor agreed to transfer 20,000 of the New enGene Shares it expects to receive in connection
with the Business Combination to each of three of FEAC&#146;s independent directors following the consummation of the Business Combination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the anticipated designation by FEAC of Jasper Bos, its current Chief Executive Officer and director, as director
of New enGene upon the consummation of the Business Combination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the continued indemnification of FEAC&#146;s directors and officers and the continuation of FEAC&#146;s
directors&#146; and officers&#146; liability insurance after the Business Combination (i.e., a &#147;tail policy&#148;); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fact that the Sponsor has agreed that in the event of the liquidation of the Trust Account upon the failure
of FEAC to consummate the Business Combination it will be liable to FEAC if and to the extent any claims by a third-party for services rendered or products sold to FEAC, or a prospective target business with which we have discussed entering into a
transaction agreement, reduce the amounts in the Trust Account to below the lesser of (i) $10.25 per FEAC Class&nbsp;A Share and (ii)&nbsp;the actual amount per FEAC Class&nbsp;A Share held in the Trust Account as of the date of the liquidation of
the Trust Account if less than $10.25 per FEAC Class&nbsp;A Share due to reductions in the value of the trust assets, in each case net of the interest that may be withdrawn to pay our tax obligations (less up to $100,000 of interest to pay
dissolution expenses), provided that such liability will not apply to any claims by a third-party or prospective target business that executed a waiver of any and all rights to seek access to the Trust Account nor will it apply to any claims under
FEAC&#146;s indemnity of the underwriters of FEAC&#146;s IPO against certain liabilities, including liabilities under the Securities Act. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Lincoln&#146;s Fairness Opinion </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FEAC
retained Lincoln International LLC (&#147;Lincoln&#148;) to provide a fairness opinion (the &#147;Opinion&#148;) to the FEAC Board as to whether the Company Consideration (as defined in the Business Combination Agreement) to be issued in connection
with the Transaction (as defined in the Opinion) is fair from a financial point of view to the holders of FEAC Class&nbsp;A Shares (&#147;FEAC Unaffiliated Shareholders&#148;) prior to the consummation of the Transaction, other than (i)&nbsp;holders
of FEAC Class&nbsp;A Shares who elect to redeem their FEAC Class&nbsp;A Shares prior to or in connection with the Transaction, (ii)&nbsp;officers, directors, or affiliates of FEAC, or (iii)&nbsp;the Sponsor or any affiliates of the Sponsor. Lincoln
is a reputable investment banking firm with substantial experience advising companies. Lincoln, as part of its investment banking business, is regularly engaged in the valuation of businesses and their securities in connection with mergers and
acquisitions, negotiated underwritings, secondary distributions of listed and unlisted securities, private placements and valuations for corporate and other purposes. Capitalized terms used but not defined in this description of the Opinion will
have the meaning ascribed to them in the Business Combination Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;14, 2023, Lincoln delivered the Opinion to the FEAC
Board to the effect that, as of the date of such Opinion, and subject to and based on the assumptions, limitations, qualifications, conditions and other matters set forth therein, the Company Consideration to be issued in connection with the
Transaction is fair from a financial point of view to the FEAC Unaffiliated Shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>The Opinion was directed to the FEAC Board
(in its capacity as such) and only addressed the fairness, from a financial point of view, of the Company Consideration to be issued in connection with the Transaction to the FEAC Unaffiliated Shareholders and did not address any other terms,
aspects or implications of the Transaction, or any agreements, arrangements or understandings entered into in connection with the Transaction. The summary of the Opinion in this proxy statement/prospectus is qualified in its entirety by reference to
the full text of the Opinion, which is attached as <U>Annex B</U> to this </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">197 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>
proxy statement/prospectus and which describes the assumptions, limitations, qualifications, conditions and other matters considered by Lincoln in connection with the preparation of the Opinion.
The Opinion and the summary of the Opinion and the related analyses set forth in this proxy statement/prospectus are not intended to be, and do not constitute, advice or a recommendation to the FEAC Board or any security holder as to how they should
act or vote with respect to any matter relating to the Transaction (including as to whether they should redeem any FEAC Shares in the FEAC Shareholder Redemptions). FEAC Unaffiliated Shareholders are urged to read the entire Opinion carefully in
connection with their consideration of the Transaction. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with rendering the Opinion, Lincoln has, among other things:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reviewed the following documents: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Cash and debt balances for enGene as of January&nbsp;31, 2023; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The pro forma equity ownership table of FEAC and an estimated Transaction sources and uses schedule provided to
us by FEAC; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A draft of the Business Combination Agreement dated May&nbsp;14, 2023; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">enGene&#146;s Corporate Presentation dated May&nbsp;14, 2023; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">e.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Other documents relating to the history, past and current operations, financial condition, and probable future
outlook of enGene provided to Lincoln by the management of each of enGene and FEAC; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Discussed the business, financial outlook and prospects of enGene and its addressable market, as well as the
terms and circumstances surrounding the Transaction, with management of enGene and FEAC; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reviewed certain financial and other information for enGene, and compared that data and information with
certain stock trading and corresponding data and information for companies with publicly traded securities that Lincoln deemed relevant, none of which is directly comparable to enGene; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reviewed certain financial and other information for enGene and the Transaction, and compared that data and
information with certain financial and corresponding data and information for companies that have been subject to change of control M&amp;A transactions and capital raise transactions that Lincoln deemed relevant, none of which is directly
comparable to enGene and the Transaction; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Considered such other information and financial, economic and market criteria and analyses that Lincoln deemed
relevant. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In performing its analyses and rendering its Opinion with respect to the Company Consideration, Lincoln, with
FEAC&#146;s management&#146;s consent, relied upon and assumed the accuracy and completeness of all of the financial, accounting, legal, tax and other information Lincoln reviewed, and Lincoln did not assume any responsibility for the independent
verification of, nor did Lincoln independently verify, any of such information. Lincoln relied upon the assurances of the management of FEAC that the information provided was complete and correct in all material respects and did not contain any
untrue statement of a material fact or omit to state a material fact necessary that would have made such information materially incomplete or misleading. Lincoln assumed that the Transaction will be consummated in a timely manner that complies in
all respects with all applicable federal and state statutes, rules and regulations. Lincoln further assumed that in the course of obtaining any necessary regulatory and third-party consents, approvals and agreements for the Transaction, no
modification, delay, limitation, restriction, or condition will be imposed that will have an adverse effect on FEAC, enGene or the Transaction. Lincoln also assumed that the Transaction will be consummated in accordance with the terms outlined by
FEAC and other documents made available to Lincoln, without waiver, modification or amendment of any term, condition or agreement therein that is material to Lincoln&#146;s analysis. Lincoln assumed that there was no material change in the assets,
liabilities, business, condition (financial or otherwise), results of operations, or prospects of enGene since the date of the most recent information was made </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">198 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
available to Lincoln. Lincoln further assumed that the final terms of the Transaction will not vary materially from those set forth in the copies or drafts, as applicable, reviewed by Lincoln and
that the final versions of all documents conform in all material respects to the drafts reviewed by Lincoln. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Opinion was necessarily
based on financial, economic, market and other conditions as they existed on and the information made available to Lincoln as of May&nbsp;14, 2023. Although subsequent developments may affect the Opinion, Lincoln did not have any obligation to
update, revise or reaffirm its Opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lincoln did not evaluate FEAC&#146;s or enGene&#146;s solvency and was not requested to make, and
did not make, an independent evaluation or appraisal of the assets or liabilities (contingent, derivative, <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet or otherwise) of FEAC or enGene or any of their respective subsidiaries, nor was
Lincoln furnished with any such evaluations or appraisals. Lincoln did not perform any financial analyses to evaluate the value of FEAC or to derive valuation reference ranges for shares of FEAC for purposes of comparison with the Company
Consideration or otherwise. Lincoln was not requested to, nor did Lincoln participate in the negotiation or structuring of the Transaction. Lincoln was not requested to, nor did Lincoln seek, alternative candidates for the Transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Opinion (i)&nbsp;did not address the underlying business decision of the FEAC Board or FEAC to proceed with or effect the Transaction or
the relative merits of the Transaction as compared to other transaction structures, transactions or business strategies that may have been available to FEAC or the effect of any other transaction in which FEAC might engage, and did not address
whether the Company Consideration to be issued by FEAC pursuant to the Business Combination Agreement is the best possibly attainable under the circumstances, (ii)&nbsp;did not address the capital structure of FEAC, whether FEAC should be issuing
debt or equity securities or a combination of both in connection with the Transaction, including, without limitation, the Amended 2022 Financing, the PIPE Financing and the 2023 Financing, the <FONT STYLE="white-space:nowrap">Non-Redemption</FONT>
Transaction or the Sponsor Loans Conversion, or the form, structure or any aspect or terms of any debt or equity financing for the Transaction, including, without limitation, the Amended 2022 Financing, the PIPE Financing and the 2023 Financing, the
<FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Transaction or the Sponsor Loans Conversion or the likelihood of closing such financings, (iii)&nbsp;does not constitute advice or a recommendation to the FEAC Board, FEAC or any security holder
as to how they should act, elect to redeem or vote with respect to any matter relating to the Transaction, (iv)&nbsp;does not constitute advice or a recommendation to the FEAC Board, FEAC or any security holder as to how they should act, elect to
redeem or vote with respect to any matter relating to the Transaction, (v)&nbsp;only addressed the fairness from a financial point of view to the FEAC Unaffiliated Shareholders of the Company Consideration to be issued pursuant to the Business
Combination Agreement in the Transaction and did not address any other terms, aspects or implications of the Transaction, or any agreements, arrangements or understandings entered into in connection with the Transaction or otherwise, (vi)&nbsp;did
not address the individual circumstances of specific shareholders of FEAC with respect to rights or aspects which may distinguish such holders or equity securities held by such holders, and (vii)&nbsp;did not address, take into consideration or give
effect to any existing or future rights, preferences, restrictions or limitations or other attributes of any such securities or holders (including the Sponsor). Lincoln expressed no opinion as to the fairness of any portion or aspect of the
Transaction to (i)&nbsp;the holders of any class of securities, creditors or other constituencies of FEAC, enGene or any other party, except as expressly set forth in the Opinion, or (ii)&nbsp;any one class or group of FEAC&#146;s or enGene&#146;s
security holders, creditors or other constituencies <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">vis-&agrave;-vis</FONT></FONT> any other class or group of FEAC&#146;s or enGene&#146;s security holders, creditors or other
constituents (including, without limitation, the allocation of any Company Consideration among or within such classes or groups of security holders, creditors or other constituents). The decision as to whether to proceed with the Transaction or any
related transaction depends on an assessment of various factors, many of which are unrelated to the financial analyses on which the Opinion is based. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lincoln expressed no opinion as to what the market price or value of the stock of FEAC would be after the announcement or consummation of the
Transaction (including as compared to the amount which holders of FEAC Class&nbsp;A Shares may receive on redemption of their FEAC Class&nbsp;A Shares in connection with the FEAC Shareholder Redemptions). The Opinion should not be construed as a
valuation opinion, credit rating, solvency </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">199 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
opinion, an analysis of FEAC&#146;s credit worthiness, as tax advice, or as accounting advice. Lincoln also expressed no opinion about the amount or nature of any compensation or equity
arrangement to be given to FEAC&#146;s officers, directors or employees, or class of such persons, in connection with the Transaction relative to the Company Consideration in the Transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Set forth below is a summary of the material financial analyses reviewed by Lincoln with the FEAC Board on May&nbsp;14, 2023 in connection
with rendering its Opinion. The following summary, however, does not purport to be a complete description of the analysis performed by Lincoln. The order of the individual analyses described, and the results of these analyses, do not represent
relative importance or weight given to these analyses by Lincoln. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Summary of Lincoln&#146;s Financial Analysis </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>The following is a summary of the material financial analyses prepared and reviewed with the FEAC Board in connection with the Opinion,
dated May&nbsp;14, 2022.<B> The summary set forth below does not purport to be a complete description of the financial analyses performed or factors considered by, and underlying the Opinion, nor does the order of the financial analyses described
represent the relative importance or weight given to those financial analyses by Lincoln. Lincoln may have deemed various assumptions more or less probable than other assumptions, so the ranges resulting from any particular portion of the analyses
summarized below should not be taken to be Lincoln&#146;s view of the actual value of enGene. Some of the summaries of the financial analyses set forth below include information presented in tabular format. In order to fully understand the financial
analyses, the tables must be read together with the full text of each summary, as the tables are not intended to stand alone and do not constitute a complete description of the financial analyses performed by Lincoln. Considering the data in the
tables below without considering all financial analyses or factors or the full narrative description of such analyses or factors, including the methodologies and assumptions underlying such analyses or factors, could create a misleading or
incomplete view of the processes underlying Lincoln&#146;s financial analyses and its Opinion. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>In performing its analyses, Lincoln
made numerous assumptions with respect to industry performance, general business and economic conditions and other matters, many of which are beyond the control of FEAC, enGene, or any other parties to the Transaction. None of FEAC, enGene or
Lincoln or any other person assumes responsibility if future results are materially different from those discussed. Any estimates contained in these analyses are not necessarily indicative of actual values or predictive of future results or values,
which may be significantly more or less favorable than as set forth below. In addition, analyses relating to the value of enGene do not purport to be appraisals or reflect the prices at which enGene may actually be sold. Accordingly, the assumptions
and estimates used in, and the results derived from, the financial analyses are inherently subject to substantial uncertainty. Except as otherwise noted, the following quantitative information, to the extent that it is based on market data, is based
on market data as it existed on or before May&nbsp;11, 2023 and is not necessarily indicative of current market conditions. </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Implied Transaction Enterprise Value </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Using information obtained from management of enGene, for purposes of the financial analysis described below, Lincoln derived an implied
enterprise value of enGene from the Transaction (the &#147;Transaction Enterprise Value&#148;) of $111&nbsp;million. Lincoln first calculated the Company Consideration by summing (i) $90&nbsp;million and (ii)&nbsp;the Aggregate Exercise Price of
$2&nbsp;million resulting in a Reference Value of $92&nbsp;million. Lincoln then divided the Reference Value by the Reference Price of $10.25 to derive the Company Consideration of 8,958,168 New enGene Shares. Lincoln then multiplied Company
Consideration by the Reference Price to calculate the implied equity value of enGene of $92&nbsp;million. Lincoln then calculated a Transaction Enterprise Value of $111&nbsp;million assuming (i)&nbsp;the implied equity value of $92&nbsp;million,
(ii)&nbsp;the debt balance of enGene as of January&nbsp;31, 2023 of $32&nbsp;million, and (iii)&nbsp;the cash balance of enGene as of January&nbsp;31, 2023 of $14&nbsp;million. Lincoln did not include a discounted cash flow based income approach due
to the lack of a FEAC Board reviewed and approved forecast for enGene. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">200 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Selected Public Companies Analysis </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lincoln performed a selected public companies analysis for enGene. Lincoln selected publicly traded drug development companies focused on
bladder cancer drug development of gene therapy cancer drug development. The set is comprised of clinical stage companies that are <FONT STYLE="white-space:nowrap">pre-revenue</FONT> with two companies that recently achieved FDA approval and
commercialization of their primary compound and one company that is in the process of seeking FDA approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, because none of the
selected public companies is identical to enGene and Lincoln did not have access to <FONT STYLE="white-space:nowrap">non-public</FONT> information regarding those companies, Lincoln believed that it was inappropriate to, and therefore did not, rely
solely on the quantitative results of the selected public company analysis. Accordingly, Lincoln also made qualitative judgments, based on its experience and professional judgment, concerning differences between the operational, business and/or
financial characteristics of enGene and the selected public companies that could affect their public trading values in order to provide a context in which to consider the results of the quantitative analysis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Using publicly available information obtained from SEC filings and other publicly available data sources as of May&nbsp;11, 2023, Lincoln
calculated, for each selected public company, such selected public company&#146;s enterprise value (calculated as the equity value (determined using the treasury stock method and taking into account outstanding <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">in-the-money</FONT></FONT> options, warrants, restricted share units and other convertible securities) plus the book value of debt and certain liabilities less cash, cash equivalents and certain <FONT
STYLE="white-space:nowrap">non-operating</FONT> assets), which is referred to, with respect to the selected public companies, as the &#147;Enterprise Value.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selected public companies and their respective Enterprise Values are listed below (dollars in millions): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><I>Selected Public Company</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><I>Enterprise&nbsp;Value</I><br><I>($&nbsp;in&nbsp;millions)</I></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>Commercialized</U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>UroGen Pharma Ltd.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>$</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>358</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>G1 Therapeutics, Inc.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>$</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>109</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>ImmunityBio, Inc.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>$</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>1,856</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>Clinical Stage</U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Gritstone bio, Inc.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>$</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>127</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Genenta Science S.p.A.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>$</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>86</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Tyra Biosciences, Inc.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>$</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>308</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Fusion Pharmaceuticals Inc.</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>$</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>111</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Median</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B><I>$</I></B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B><I>127</I></B></TD>
<TD NOWRAP VALIGN="bottom"><B><I>&nbsp;</I></B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Mean</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B><I>$</I></B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B><I>422</I></B></TD>
<TD NOWRAP VALIGN="bottom"><B><I>&nbsp;</I></B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lincoln compared certain quantitative and qualitative factors of the selected public companies to enGene
including, but not limited to, (i)&nbsp;total number and efficacy of compounds in development or currently commercialized, (ii)&nbsp;development stage of compounds (e.g., Phase 1, Phase 2, etc.), (iii) commercialization year, (iv)&nbsp;patent
protection term, (v)&nbsp;patient population, and (vi)&nbsp;consensus peak revenue, based on consensus equity research analyst estimates, public filings and Lincoln&#146;s experience and professional judgment. Taking into account such qualitative
and quantitative factors, Lincoln observed the illustrative enterprise value range of the selected public companies of $86&nbsp;million to $1,856&nbsp;million and the mean and median enterprise value of the selected companies of $422&nbsp;million
and $127&nbsp;million, respectively. Lincoln then analyzed and compared the Transaction Enterprise Value of $111&nbsp;million to the Enterprise Values of the selected public companies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Selected Precedent Transaction Analysis </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lincoln reviewed and compared certain information relating to the following selected transactions involving companies focused on bladder cancer
drug development or gene therapy cancer drug development (which </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">201 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
transactions are referred to as the &#147;selected M&amp;A transactions&#148; in this summary of the Opinion) that Lincoln, based on its experience and professional judgement, deemed relevant to
consider in relation to enGene and the Transaction. Although none of the selected M&amp;A transactions is directly comparable to the Transaction, the transactions listed below were chosen by Lincoln because, among other reasons, their total number
of compounds, the development stage of such compounds and the comparability of such compounds to <FONT STYLE="white-space:nowrap">EG-70</FONT> or other factors, for purposes of Lincoln&#146;s analysis, may be considered similar to the Transaction.
Lincoln used its experience, expertise and knowledge of these industries to select transactions that involved companies with certain operational, business and/or financial characteristics that, for purposes of this analysis, may be considered
similar to those of enGene. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, because none of the target companies in the selected M&amp;A transactions used in this analysis is
identical to enGene, Lincoln believed that it was inappropriate to rely solely on the quantitative results of the selected transactions analysis. Accordingly, Lincoln also made qualitative judgments, based on its experience and professional
judgment, concerning differences between the operational, business and/or financial characteristics of enGene and each target company as well as the Transaction and the selected M&amp;A transactions that could affect the transaction values of each
in order to provide a context in which to consider the results of the quantitative analysis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Using publicly available information
obtained from SEC filings and other data sources as of the time of the announcement of the relevant transactions, Lincoln calculated, for each selected M&amp;A transaction, the transaction value (calculated as the offer value (determined using the
treasury stock method and taking into account outstanding <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">in-the-money</FONT></FONT> options, warrants, restricted stock units, performance stock units and other convertible
securities), plus the book value of debt and certain liabilities less cash and cash equivalents) implied for each target company based on the consideration payable in the applicable selected M&amp;A transaction, in each case excluding any contingent
payments, which amount is referred to, with respect to the selected M&amp;A transactions, as &#147;Enterprise Value.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selected
M&amp;A transactions considered in this analysis are summarized below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><I>Date&nbsp;Announced</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><I>Target</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><I>Acquirer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><I>Enterprise&nbsp;Value</I><br><I>($&nbsp;in millions)</I></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Jan-20</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Neon Therapeutics, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>BioNTech SE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Nov-19</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>FerGene, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Ferring / BlackRock</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Nov-19</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Elevar Therapeutics, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>HLB Life Science Co., Ltd.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Sep-16</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Viventia Bio Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Eleven Biotherapeutics, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Jun-14</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Precision Genome Engineering, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>bluebird bio, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Jun-14</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>EGWU, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Celsion Corporation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP><B><I>Median</I></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP><B><I>Mean</I></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Taking into account various quantitative and qualitative factors and other considerations that Lincoln deemed
relevant in its professional judgment and experience, including differences between the business, financial and operating characteristics of enGene and the target companies included in the selected transactions set forth above, Lincoln observed the
illustrative enterprise value range of the selected transactions of $43&nbsp;million to $570&nbsp;million, the mean enterprise value of the selected transactions of $100&nbsp;million and the median enterprise value of the selected transactions of
$52&nbsp;million, and compared such Enterprise Value to the Transaction Enterprise Value of $111&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Selected Capital Raise
Transaction Analysis </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lincoln reviewed and compared certain information relating to the following selected transactions involving
companies focused on bladder cancer drug development of gene therapy cancer drug development (which transactions are referred to as the &#147;selected capital raise transactions&#148; in this summary of the Opinion) that
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">202 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Lincoln, based on its experience and professional judgement, deemed relevant to consider in relation to enGene and the Transaction. The selected capital raise transactions involved clinical stage
companies that were <FONT STYLE="white-space:nowrap">pre-revenue.</FONT> Although none of the selected capital raise transactions is directly comparable to the Transaction, the transactions listed below were chosen by Lincoln because, among other
reasons, their total number of compounds, the development stage of such compounds and the comparability of such compounds to <FONT STYLE="white-space:nowrap">EG-70</FONT> or other factors, for purposes of Lincoln&#146;s analysis, may be considered
similar to the Transaction. Lincoln used its experience, expertise and knowledge of these industries to select capital raise transactions that involved companies with certain operational, business and/or financial characteristics that, for purposes
of this analysis, may be considered similar to those of enGene. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, because none of the target companies in the selected capital
raise transactions used in this analysis is identical to enGene, Lincoln believed that it was inappropriate to rely solely on the quantitative results of the selected transaction analysis. Accordingly, Lincoln also made qualitative judgments, based
on its experience and professional judgment, concerning differences between the operational, business and/or financial characteristics of enGene and each target company as well as the Transaction and the selected capital raise transactions that
could affect the transaction values of each in order to provide a context in which to consider the results of the quantitative analysis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Using publicly available information obtained from data sources as of the time of the announcement of the relevant transactions, Lincoln
calculated, for each selected capital raise transaction, the transaction value implied for each target company based on the amount raised in the applicable selected capital raise transaction and the amount of ownership in the targets that was sold,
which transaction value is referred to, with respect to the selected capital raise transactions, as the <FONT STYLE="white-space:nowrap">&#147;Pre-Money</FONT> Valuation.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selected capital raise transactions considered in this analysis are summarized below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><I>Date&nbsp;Announced</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><I>Target</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><I>Lead Investors</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><I><FONT STYLE="white-space:nowrap">Pre-Money</FONT></I><br><I>Valuation</I><br><I>($&nbsp;in&nbsp;millions)</I></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Sep-22</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>CG Oncology, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>ORI Capital, Decheng Capital, and Longitude Capital</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">$</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">280</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Mar-21</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tyra Biosciences, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Nextech Invest</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Jan-21</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Ikena Oncology, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Omega Funds</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Sep-19</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Genenta Science S.r.l.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Fidim and Qianzhan Investment Management</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">$</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Aug-19</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Oncorus, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Cowen Healthcare</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Jun-18</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Gritstone Oncology, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>PFM Health Sciences and Aberdare Venture</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">$</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">267</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Dec-16</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Neon Therapeutics</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Partner Fund Management</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Apr-16</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>G1 Therapeutics, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Cormorant Asset Management</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Sep-15</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Corvus Pharmaceuticals, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Rock Springs Capital</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Median</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Mean</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Taking into account various quantitative and qualitative factors and other considerations that Lincoln deemed
relevant in its professional judgment and experience, including differences between the business, financial and operating characteristics of enGene and the target companies included in the selected transactions set forth above, Lincoln observed the
illustrative enterprise value range of the selected transactions of $91&nbsp;million to $280&nbsp;million, the mean enterprise value of the selected transactions of $189&nbsp;million and the median enterprise value of the selected transactions of
$200&nbsp;million, and compared such <FONT STYLE="white-space:nowrap">Pre-Money</FONT> Valuations to the Transaction Enterprise Value of $111&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">203 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Miscellaneous </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the past two years, Lincoln has not been engaged by either FEAC or enGene or received fees from either of FEAC or enGene, other than in
connection with the Opinion. Lincoln earned customary fees from FEAC for its services, in the amount of $450,000, a portion of which was paid upon Lincoln&#146;s retention, and the balance of which is payable upon the earlier of termination of the
Transaction in accordance with the Business Combination Agreement or the consummation of the Transaction. No portion of Lincoln&#146;s fee was contingent upon the conclusion reached in its Opinion. In addition, FEAC has agreed to indemnify Lincoln
and certain related parties against certain liabilities, and to reimburse Lincoln for certain expenses, arising in connection with or as a result of its engagement. Lincoln and its affiliates provide a range of investment banking and financial
services and, in that regard, Lincoln and its affiliates may in the future provide investment banking and other financial services to FEAC, enGene and each of their respective affiliates, for which Lincoln and its affiliates would expect to receive
compensation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Interests of enGene&#146;s Significant Shareholders, Directors and Executive Officers in the Business Combination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When you consider the recommendation of the FEAC Board in favor of approval of the Business Combination Proposal, you should keep in mind that
enGene&#146;s significant shareholders, directors and officers have interests in the Business Combination that are different from, or in addition to, those of FEAC Shareholders and FEAC Warrant holders generally. These interests include, among other
things, the interests listed below: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Forbion Capital Fund III, an affiliate of Forbion, the Sponsor and FGOF, is a significant shareholder of enGene,
currently holding an equity interest in enGene of approximately 26% of the share capital. Based on enGene&#146;s implied enterprise valuation of $111 million at the time of signing the Business Combination Agreement, such equity interests have an
implied value equal to $28,860,000 (26% of $111 million). The consideration originally paid by Forbion Capital Fund III for the 26% equity interest in enGene was equal to $17,027,974. Also, Forbion Capital Fund III is an investor in both of
enGene&#146;s Amended 2022 Convertible Notes and the 2023 Convertible Notes. While the Sponsor and Forbion Capital Fund III are part of the Forbion group, Forbion Capital Fund III is part of a different fund structure with a different investment
mandate and with independent discretion in its investment decision-making process. None of the independent members of the FEAC Board has any interest in Forbion Capital Fund III. Therefore, Forbion Capital Fund III&#146;s status as current
shareholder of enGene and as investor in both of enGene&#146;s Amended 2022 Convertible Notes and the 2023 Convertible Notes has not been taken into consideration by the FEAC Board in approving, and did not influence the decision to discuss,
negotiate or execute, the Business Combination. See &#147;<I>Description of enGene&#146;s Material Indebtedness</I>,&#148;<I> </I>&#147;<I>Security Ownership of Certain Beneficial Holders and Management of enGene</I>,&#148; and &#147;<I>Certain
Relationships and Related Party Transactions</I>.&#148; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Marco Boorsma, a member of the enGene Board is affiliated with Forbion and was designated for enGene&#146;s Board
by Forbion Capital Fund III. See &#147;<I>Directors and Executive Officers of enGene</I>.&#148; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Gerry Brunk, a member of the enGene Board is affiliated with the Lumira/Merck Investors, a significant
shareholder of enGene and an investor in both the Amended 2022 Convertible Notes and the 2023 Convertible Notes. Mr.&nbsp;Brunk was designated for enGene&#146;s Board by the Lumira/Merck Investors. See &#147;<I>Directors and Executive Officers of
enGene</I>,&#148; &#147;<I>Description of enGene&#146;s Material Indebtedness</I>,&#148; &#147;<I>Security</I> <I>Ownership of Certain Beneficial Holders and Management of enGene</I>,&#148; and &#147;<I>Certain Relationships and Related Party
Transactions</I>.&#148; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Members of enGene&#146;s current management will initially continue in the same roles as management of New
enGene, and Jason D. Hanson, enGene&#146;s Chief Executive Officer and certain other members of enGene management will enter into employment agreements with New enGene or a subsidiary thereof in connection with the Business Combination. See
&#147;<I>Directors and Executive Officers of enGene</I>,&#148; and &#147;<I>Directors and Officers of New enGene after the Business Combination</I>.&#148; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">204 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Unvested stock options held by executive officers and other employees of enGene will vest upon the consummation
of the Business Combination and become stock options to acquire New enGene Shares on the same terms. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sources and Uses for the
Business Combination </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables summarize the sources and uses for funding the Business Combination. All of the sources and
uses below are for illustrative purposes only. Where actual amounts are not known or knowable, the figures below represent FEAC&#146;s good faith estimate of such amounts. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>No redemption scenario </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Sources</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Uses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B></B><I>(in millions of U.S. dollars)</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing cash held in Trust
Account<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Rollover equity<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transaction financing<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Cash to balance sheet</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rollover equity<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated transaction
expenses<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total* sources:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>346</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Total* uses:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>346</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(*)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Totals might be affected by rounding. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">$135,786,170 held in the Trust Account as of June&nbsp;30, 2023. Assumes that none of the FEAC Class&nbsp;A
Shares are redeemed in connection with the Business Combination. Excludes interest earned in the Trust Account; the actual amount of cash in the Trust Account is subject to change depending on actual interest earned. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Excludes the $1.7&nbsp;million non-redemption commitment from a FEAC Shareholder that is the beneficial owner
of 166,665 FEAC Class&nbsp;A Shares as part of the $115&nbsp;million transaction financing that is comprised of (i) the PIPE Financing ($56.9&nbsp;million), (ii) the Convertible Bridge Financing ($56.4&nbsp;million) and (iii) the non-redemption
commitment ($1.7&nbsp;million). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Rollover equity refers to equity of enGene Shareholders and includes the aggregate exercise price of its stock
options outstanding as of July 31, 2023. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents an estimate of transaction expenses. Actual amounts may vary and may include expenses unknown at
this time. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Maximum redemption scenario </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Sources</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Uses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B></B><I>(in millions of U.S. dollars)</I><B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing cash held in Trust
Account<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Rollover equity<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transaction financing<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Cash to balance sheet</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rollover equity<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Estimated transaction expenses<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total* sources:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>233</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>Total* uses:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>233</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(*)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Totals might be affected by rounding. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">$135,786,170 held in the Trust Account as of June&nbsp;30, 2023. Assumes that all holders of FEAC Class&nbsp;A
Shares redeem their shares in connection with the Business Combination at an assumed redemption price of $10.73 per share (calculated using the $135.8 million cash in the Trust Account as at June 30, 2023, divided by 12,650,000 outstanding FEAC
Class A Shares), except for 2,166,665&nbsp;million <FONT STYLE="white-space:nowrap">non-redeemable</FONT> FEAC Class&nbsp;A Shares held by FGOF and a FEAC Shareholder that is the beneficial owner of 166,665 FEAC Class&nbsp;A Shares, who have each
undertaken not to redeem their shares in connection with the Business Combination. The actual amount of cash in the Trust Account is subject to change depending on actual interest earned. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Excludes the $1.7 million non-redemption commitment from a FEAC Shareholder that is the beneficial owner of
166,665 FEAC Class&nbsp;A Shares as part of the $115&nbsp;million transaction financing that is comprised </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">205 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
of (i) the PIPE Financing ($56.9&nbsp;million), (ii) the Convertible Bridge Financing ($56.4&nbsp;million) and (iii) the non-redemption commitment ($1.7&nbsp;million). </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Rollover equity refers to equity of enGene Shareholders and includes the aggregate exercise price of its stock
options outstanding as of July&nbsp;31, 2023. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents an estimate of transaction expenses. Actual amounts may vary and may include expenses unknown at
this time. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Name; Headquarters of New enGene </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the Amalgamation, New enGene will continue from being a corporation incorporated under and governed by the Canada Business
Corporations Act to a company continued to and governed by the Business Corporations Act (British Columbia). New enGene will maintain its headquarters at 7171 Rue Frederick Banting, Saint-Laurent, QC H4S 1Z9, Canada. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board of New enGene following the Business Combination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Business Combination Agreement, New enGene anticipates that its board of directors will initially consist of seven
(7)&nbsp;directors, including (i)&nbsp;one (1) independent director and one (1)&nbsp;other director (whether or not independent), each to be identified by FEAC, (ii)&nbsp;Jason D. Hanson, the Chief Executive Officer of enGene, and (iii)&nbsp;three
(3) independent directors and one (1)&nbsp;other director to be identified by enGene. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing of New enGene Shares and Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the Closing, FEAC and enGene will use reasonable best efforts to cause the New enGene Shares and New enGene Warrants to be issued in
connection with the Business Combination to be approved for listing on The Nasdaq Stock Market LLC, or another national securities exchange registered under the Exchange Act as agreed by FEAC and New enGene, under the ticker symbols &#147;ENGN&#148;
and &#147;ENGNW&#148;, respectively (or if any such ticker symbol becomes unavailable, such other ticker symbol as may be agreed upon in writing by the parties). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Business Combination Agreement, the obligations of the parties to consummate the transactions are subject to the satisfaction or
waiver by FEAC and enGene prior to the Closing, of various conditions, including that the New enGene&#146;s initial listing application with Nasdaq for the listing of New enGene Shares and Warrants has been approved. The terms of the Business
Combination Agreement permit that this condition may be waived by agreement between FEAC and enGene without requiring recirculation or resolicitation of this proxy statement/prospectus. See <I>&#147;Risk Factors &#151; Risks Related to the Business
Combination &#151; FEAC or enGene may waive one or more of the conditions to the completion of the Business Combination without recirculation of this proxy statement/prospectus or resoliciting stockholder approval&#148;</I> for more information.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cancellation of Certain Warrants of enGene; Assumption of enGene Options </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately prior to the commencement of the Plan of Arrangement, warrants issued to certain warrant holders of enGene to purchase enGene
Class&nbsp;C Preferred Shares will be cancelled and no longer outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the Closing of the Business Combination, all outstanding
enGene options will be assumed by New enGene and will accelerate and become vested and exercisable (if not previously vested and exercisable). For additional information, see footnote 5 to the &#147;<I>Outstanding Equity Awards at 2022 Fiscal <FONT
STYLE="white-space:nowrap">Year-End</FONT></I>&#148; table included in &#147;<I>Executive Compensation</I>.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Accounting Treatment of the Business
Combination </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the legal form, the Business Combination will be accounted for as a reverse recapitalization in accordance
with US GAAP. Under this method of accounting, FEAC will be treated as the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">206 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
acquired company for financial reporting purposes, whereas enGene will be treated as the accounting acquirer. In accordance with this accounting method, New enGene is considered to be a
continuation of enGene, with the net identifiable assets of FEAC deemed to have been acquired by enGene in exchange for common shares of enGene accompanied by a recapitalization. The net assets of FEAC will be stated at historical cost, with no
goodwill or other intangible assets recorded, and operations prior to the Business Combination will be those of enGene. enGene has been determined to be the accounting acquirer based on an evaluation of the following facts and circumstances, and
accordingly the Business Combination is treated as an equivalent to an acquisition of FEAC accompanied by a recapitalization. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Senior management of enGene will continue as senior management of the post-Business Combination combined company
(the &#147;Combined Company&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Directors of enGene will form a majority on the board of directors of the Combined Company;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The name of the Combined Company will be &#147;enGene Holdings Inc.&#148; and it will utilize enGene&#146;s
current headquarters; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enGene&#146;s operations will comprise the ongoing operations of the Combined Company. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vote Required for the Business Combination Proposal Approval </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The adoption and approval of the Business Combination Agreement and the Transactions including the Plan of Arrangement requires the affirmative
vote of the holders of at least a majority of the FEAC Shares present in person or represented by proxy and entitled to vote at the Special Meeting; the approval of (i)&nbsp;the Cayman Merger and (ii)&nbsp;the Cayman Reorganization, which is part of
the Business Combination Proposal, requires the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the FEAC Shares present in person or represented by proxy and entitled to vote at the Special Meeting.
Therefore, the approval of the Business Combination Proposal requires the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the FEAC Shares present in person or represented by proxy and entitled to
vote at the Special Meeting. Abstentions will have no effect on the outcome of the proposal. The Business Combination cannot be completed unless the Business Combination Proposal is adopted by affirmative vote of the holders of at least <FONT
STYLE="white-space:nowrap">two-thirds</FONT> of the votes cast by FEAC Shareholders present or represented by proxy at the Special Meeting and entitled to vote thereon. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Resolutions to be Voted Upon </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The full
text of the resolutions to be proposed is as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;RESOLVED, as a special resolution, that (i)&nbsp;the Business Combination
Agreement, the Business Combination and the Transactions including the Plan of Arrangement be and are hereby authorized, approved and confirmed in all respects; (ii)&nbsp;FEAC be and is hereby authorized to consummate the Cayman Merger, pursuant to
which Cayman Merger Sub will merge with and into FEAC so that FEAC be the surviving entity and all the undertaking, property and liabilities of Cayman Merger Sub vest in FEAC by virtue of such merger pursuant to the Companies Act (As Revised) of the
Cayman Islands; (iii)&nbsp;the plan of merger in the form attached as <B><U>Annex E</U> </B>to this proxy statement/prospectus (the &#147;Plan of Merger&#148;) be and is hereby authorized, approved and confirmed in all respects; and (iv)&nbsp;FEAC
be and is hereby authorized to enter into the Business Combination Agreement and the Plan of Merger.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">207 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom459793_18"></A>THE BUSINESS COMBINATION AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The discussion in this proxy statement/prospectus of the Business Combination and the principal terms of the Business Combination Agreement is
subject to, and is qualified in its entirety by reference to, the Business Combination Agreement. A copy of the Business Combination Agreement is attached as <B><U>Annex A</U></B><I> </I>to this proxy statement/prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Capitalized terms used in this section &#147;<I>The Business Combination Agreement</I>&#148; but not otherwise defined in this proxy
statement/prospectus shall have the meanings assigned to them in the Business Combination Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The subsections that follow this
subsection describe the material provisions of the Business Combination Agreement, but do not purport to describe all of the terms of the Business Combination Agreement. The following summary is qualified in its entirety by reference to the complete
text of the Business Combination Agreement, a copy of which is attached as <B><U>Annex A</U></B> hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our shareholders are urged to
read the Business Combination Agreement carefully and in its entirety (and, if appropriate, with the advice of financial and legal counsel) because it is the primary legal document that governs the Business Combination. The legal rights and
obligations of the parties to the Business Combination Agreement are governed by the specific language of the Business Combination Agreement, and not this summary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The representations, warranties and covenants in the Business Combination Agreement were made solely for the benefit of the parties to the
Business Combination Agreement, may be subject to limitations agreed upon by the contracting parties, including being qualified by confidential disclosures made for the purposes of allocating contractual risk between the parties to the Business
Combination Agreement instead of establishing these matters as facts, and may be subject to standards of materiality applicable to the contracting parties that differ from those generally applicable to investors. Investors are not third-party
beneficiaries under the Business Combination Agreement, and in reviewing the representations, warranties and covenants contained in the Business Combination Agreement or any descriptions thereof in this summary, it is important to bear in mind that
such representations, warranties and covenants or any descriptions thereof were not intended by the parties to the Business Combination Agreement to be characterizations of the actual state of facts or condition of FEAC, enGene or any of their
respective subsidiaries or affiliates. Moreover, information concerning the subject matter of the representations, warranties and covenants may change after the date of the Business Combination Agreement, which subsequent information may or may not
be fully reflected in public disclosures. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General Structure of the Business Combination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination Agreement contemplates that the Business Combination will be completed through, among other things, the following
series of transactions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FEAC will incorporate or cause to be incorporated Can Merger Sub as a corporation under the laws of Canada and a
direct wholly owned subsidiary of FEAC (&#147;Can Merger Sub&#148;) and New enGene will incorporate or cause to be incorporated Cayman Merger Sub as a Cayman Islands exempted company and a direct wholly owned subsidiary of New enGene (&#147;Cayman
Merger Sub&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pursuant to the Sponsor and Insiders Letter Agreement, Forbion Growth Sponsor FEAC I B.V., a private limited
liability company incorporated in The Netherlands (the &#147;Sponsor&#148;), has agreed to surrender, after giving effect to the conversion of all or part of the principal amount outstanding under loans made by the Sponsor to FEAC into private
placement warrants of FEAC (&#147;FEAC Private Placement Warrants&#148;), 1,789,004 FEAC Class&nbsp;B Shares and 5,463,381 FEAC Private Placement Warrants, as a contribution to the capital of FEAC and for no consideration (the
&#147;Surrender&#148;), effective immediately prior to the Class&nbsp;B Conversion (as defined below) on the day which is two business days prior to the Closing Date (as defined below); </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">208 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on the day which is two business days prior to the Closing Date, each FEAC Class&nbsp;B Share that remains
outstanding following the Surrender shall be exchanged for one FEAC Class&nbsp;A Share (the &#147;Class&nbsp;B Conversion&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on the day which is one business day prior to the Closing Date, Cayman Merger Sub will merge with and into FEAC
with FEAC as the surviving entity pursuant to a plan of merger under the laws of the Cayman Islands (the &#147;Cayman Merger&#148;) as follows: (i)&nbsp;New enGene will issue to the holders of FEAC Shares (including the Sponsor but excluding the
holders of any dissenting FEAC Shares) New enGene Shares in exchange for such holders&#146; FEAC Shares and such FEAC Shares will not be cancelled but will be transferred to New enGene, (ii)&nbsp;FEAC will thereby become a wholly owned subsidiary of
New enGene, and (iii)&nbsp;each issued share of Cayman Merger Sub will be exchanged for a FEAC Class&nbsp;A Share as the surviving entity and Cayman Merger Sub (having merged into FEAC) will cease to exist as a separate entity by virtue of the
Cayman Merger; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">concurrently with the Cayman Merger, and effective at the same time the Cayman Merger becomes effective under
Cayman Islands law, (i)&nbsp;New enGene will assume the warrants of FEAC to purchase one FEAC Class&nbsp;A Share at an exercise price of $11.50 per share, subject to adjustment (as so assumed, &#147;New enGene Warrants&#148;) pursuant to a warrant
assignment, assumption and amendment agreement to be entered into on or around the Closing Date, (ii)&nbsp;FEAC as the entity surviving the Cayman Merger will issue to New enGene a <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing demand
promissory note payable denominated in Canadian dollars (&#147;C$&#148;) having a principal amount equal to the fair market value of the FEAC Warrants assumed by New enGene (&#147;Note 3&#148;) in consideration of the assumption by New enGene of
obligations under the FEAC Warrants (as so assumed, New enGene Warrants), and (iii)&nbsp;New enGene will redeem the initial Class&nbsp;B common shares of New enGene held by the sole shareholder of New enGene for an amount equal to the amount of
capital that the sole shareholder of New enGene contributed for purposes of the incorporation of New enGene (such transactions, together with the Cayman Merger, the &#147;Cayman Reorganization&#148;); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">following the Cayman Reorganization, FEAC will file an election to change its classification for U.S. federal
income tax purposes from a corporation to an entity disregarded as separate from its owner New enGene, to be effective as of the beginning of the Closing Date (the &#147;U.S. Entity Classification Election&#148; and, together with the Cayman
Reorganization, the &#147;FEAC Reorganization&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on the Closing Date and pursuant to the Plan of Arrangement, subsequent to the FEAC Reorganization becoming
effective and prior to the consummation of the PIPE Financing, FEAC will loan to New enGene an amount equal to the total funds held in its Trust Account (subject to certain deductions described in the Business Combination Agreement), less the
principal amount of Note 3 (together, the &#147;Loan Amount&#148;) in consideration for which New enGene will issue a C$ denominated <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing demand promissory note to FEAC having a principal
amount equal to the Loan Amount converted into its Canadian dollar equivalent based on the C$:U.S.$ Bank of Canada daily exchange rate on the business day immediately prior to the Closing Date, following which FEAC will sell to New enGene, and New
enGene will purchase, all of the outstanding common shares of Can Merger Sub for a purchase price of C$10 (the &#147;Can Merger Sub Share Sale&#148;) and, following the Can Merger Sub Share Sale but prior to the Amalgamation, the PIPE Financing
shall be consummated; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subsequent to the Can Merger Sub Share Sale and PIPE Financing, Can Merger Sub and enGene will amalgamate
pursuant to the Plan of Arrangement, and pursuant to the Amalgamation, (i)&nbsp;each enGene Share outstanding immediately prior to the Amalgamation shall be exchanged for New enGene Shares at the enGene Exchange Ratio and each enGene Warrant
outstanding immediately prior to the Amalgamation shall be exchanged for New enGene Warrants per the enGene Exchange Ratio; (ii)&nbsp;each Can Merger Sub share outstanding immediately prior to the Amalgamation shall be exchanged for one common share
in the authorized share capital of the amalgamated entity; and (iii)&nbsp;in consideration for the issuance of New enGene Shares, the amalgamated entity shall issue its common shares to New enGene; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">209 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">following the Amalgamation, New enGene will continue from being a corporation incorporated under and governed by
the Canada Business Corporations Act to a company continued to and governed by the Business Corporations Act (British Columbia). </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transactions described above, together with the other transactions contemplated by the Business Combination Agreement, are hereinafter
referred to as the &#147;Transactions.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination is expected to close in the second half of 2023, subject to the
satisfaction of customary closing conditions. The Business Combination Agreement and the Transactions were approved by the board of directors of each of FEAC and enGene. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently with the execution of the Business Combination Agreement, FEAC, New enGene and the PIPE Investors also entered into the
Subscription Agreements, pursuant to which, among other things, the PIPE Investors have agreed, subject to the completion of each element of the Transactions (other than those Transactions that are scheduled to be completed following the Closing
Date), to subscribe for and purchase, and FEAC has agreed that it will issue and sell to the PIPE Investors (which obligation will be assumed (the &#147;Assumption&#148;) by New enGene after the completion of the FEAC Reorganization and prior to the
consummation of the PIPE Financing (as defined below)) the number of FEAC Class&nbsp;A Shares (or after the Assumption, New enGene Shares) provided for in the applicable Subscription Agreement. Immediately following the execution and delivery of the
Subscription Agreements, FEAC and New enGene also entered into a side letter with each PIPE Investor (collectively, the &#147;Side Letter Agreements&#148; and each a &#147;Side Letter Agreement&#148;) to amend the relevant Subscription Agreement and
which, together with the relevant Subscription Agreement, reflects the total number of FEAC Class&nbsp;A Shares and FEAC Warrants to be issued by FEAC (or after the Assumption, the total number of New enGene Shares and New enGene Warrants to be
issued by New enGene) pursuant to the PIPE Financing in consideration of the purchase price set forth in the relevant Subscription Agreement. Pursuant to the Subscription Agreements, as amended by the Side Letter Agreements, the PIPE Investors will
collectively subscribe for 6,435,441 FEAC Class&nbsp;A Shares (or after the Assumption, New enGene Shares) and an aggregate of 2,702,791 FEAC Warrants (or after the Assumption, New enGene Warrants) for an aggregate purchase price equal to
$56,891,682 (the &#147;PIPE Financing&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, concurrently with the execution of the Business Combination Agreement, New
enGene, FEAC and a FEAC shareholder entered into a <FONT STYLE="white-space:nowrap">non-redemption</FONT> agreement (the <FONT STYLE="white-space:nowrap">&#147;Non-Redemption</FONT> Agreement&#148;), pursuant to which, among other things, FEAC will
issue an additional 26,575 FEAC Class&nbsp;A Shares and 81,158 FEAC Warrants (or after the Assumption, New enGene will issue additional New enGene Shares and New enGene Warrants) to such FEAC shareholder in consideration of such FEAC
shareholder&#146;s commitment (i)&nbsp;to vote or cause to be voted all of its 166,665 FEAC Class&nbsp;A Shares in favor of the Transaction Proposals and (ii)&nbsp;not to redeem its 166,665 FEAC Class&nbsp;A Shares in connection with the approval of
the Business Combination by the shareholders of FEAC (the <FONT STYLE="white-space:nowrap">&#147;Non-Redemption</FONT> Transaction&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the execution and delivery of the Business Combination Agreement, enGene agreed to certain modifications of existing convertible
indebtedness in an aggregate principal amount of $18.4&nbsp;million (the &#147;Amended 2022 Convertible Notes&#148; and, together with the enGene warrants to be issued by enGene as consideration for such modifications, the &#147;Amended 2022
Financing&#148;). Concurrently with the execution and delivery of the Business Combination Agreement, enGene entered into agreements pursuant to which it will issue new convertible indebtedness and enGene warrants (i)&nbsp;for cash in an aggregate
principal amount of $30.0&nbsp;million and (ii)&nbsp;in repayment of certain outstanding indebtedness in an aggregate principal amount of $8.0&nbsp;million. The Convertible Bridge Financing indebtedness will be converted in the Transactions into
that number of common shares of enGene that, when exchanged at the enGene Exchange Ratio, shall equal that number of FEAC Class&nbsp;A Shares (or after the Assumption, New enGene Shares) that the holders of such indebtedness would have received if
they had subscribed for FEAC Class&nbsp;A Shares (or after the Assumption, New enGene Shares) on the same terms as the PIPE Financing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">210 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consideration </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>To current holders of FEAC Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of the Cayman Merger, New enGene will (i)&nbsp;issue to the holders of FEAC Shares (including the Sponsor but excluding the holders
of any Dissenting FEAC Shares) New enGene Shares in exchange for such holders&#146; FEAC Shares on a one for one (1:1) basis, and (ii)&nbsp;New enGene will assume the FEAC Warrants (as so assumed, New enGene Warrants) pursuant to the Warrant
Assignment, Assumption and Amendment Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>To current holders of enGene Shares and enGene Options </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the consummation of the PIPE Financing and the conversion of the enGene Convertible Notes, Can Merger Sub and enGene will amalgamate in
accordance with the terms of the Plan of Arrangement, pursuant to which (i)&nbsp;each enGene Share outstanding immediately prior to the Amalgamation shall be exchanged for New enGene Shares per the enGene Exchange Ratio, (ii)&nbsp;each enGene
Warrant outstanding immediately prior to the Amalgamation shall be exchanged for New enGene Warrants per the enGene Exchange Ratio and (iii)&nbsp;each enGene Equity Award outstanding immediately prior to the Amalgamation shall be deemed vested and
exercisable and exchanged for Rollover Equity Awards and the number of New enGene Shares that will be subject to each Rollover Equity Award shall be determined by multiplying the number of enGene Shares subject to the corresponding enGene Equity
Award immediately prior to the Closing by the enGene Exchange Ratio. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate number of New enGene Shares to be allocated in respect
of enGene Shares, the aggregate number of Rollover Equity Awards to be allocated in respect of the aggregate number of enGene Equity Awards, and the New enGene Warrants to be allocated in respect of the aggregate number of enGene Warrants, shall in
the aggregate equal the portion of the Exchange Consideration issuable in respect of such enGene Shares, enGene Equity Awards and enGene Warrants pursuant to the Plan of Arrangement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Exchange Consideration is comprised of the Company Consideration and the Bridge Consideration: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Company Consideration equals (A)&nbsp;with respect to the New enGene Shares, the number of New enGene Shares
equal to the portion of the Reference Value divided by $10.25 (the &#147;Reference Price&#148;) that is attributable to the aggregate number of enGene Shares issued and outstanding immediately prior to the Closing (not including, for the avoidance
of doubt, the number of enGene Common Shares issuable upon conversion of the Convertible Bridge Financing) including any enGene Equity Awards exercised prior to or in connection with Closing, and (B)&nbsp;with respect to the Rollover Equity Awards,
the number of Rollover Equity Awards equal to the portion of the Reference Value divided by the Reference Price that is attributable to the aggregate number of enGene Equity Awards (whether vested or unvested), and in each case without duplication
of the enGene Shares taken into account for calculating the Company Consideration in respect of the New enGene Shares and Rollover Equity Awards. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Bridge Consideration equals (A)&nbsp;with respect to the New enGene Shares, the number of New enGene Shares
equal to (i)&nbsp;the number of enGene Common Shares issued upon the conversion of the enGene Convertible Notes in accordance with their terms, multiplied by (ii)&nbsp;the enGene Exchange Ratio, and (B)&nbsp;with respect to the New enGene Warrants,
the number of New enGene Warrants equal to (i)&nbsp;the number of enGene Warrants multiplied by (ii)&nbsp;the enGene Exchange Ratio. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Reference Value used to determine the enGene Exchange Ratio, the Company Consideration and the Bridge Consideration equals the sum of: (i)
$90,000,000, plus (ii)&nbsp;the aggregate exercise price of the enGene Options that will be exchanged for Rollover Equity Awards, converted to its U.S. dollar equivalent. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Representations and Warranties </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Business Combination Agreement contains representations and warranties of the parties customary for transactions of this type and that the respective parties made to each other as of the date of such agreement or other specific dates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">211 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Amongst others, enGene made customary representations and warranties to FEAC relating to,
among other things: organization and qualification; capitalization; authorization; financial statements; consents and approvals; permits; material contracts; absence of undisclosed liabilities or certain changes; brokers; litigation; compliance with
law; employee plans; environmental matters; intellectual property; labor matters; insurance; tax matters; real and personal property; transactions with affiliates; suppliers; data privacy and security; compliance with international trade and
anti-corruption laws; information supplied; and regulatory compliance and investigation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Amongst other, FEAC made customary
representations and warranties to enGene relating to, among other things: organization and qualification; authorization; consent and approvals; brokers; capitalization; SEC filings; listing on Nasdaq; the Trust Account; employees; investment company
status; transactions with affiliates; litigation; compliance with law; contracts; business activities; internal controls and financial statements; absence of undisclosed liabilities or certain changes; tax matters; investigation; compliance with
international trade and anti-corruption laws; information supplied; and regulatory compliance and investigation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assertions embodied
in those representations and warranties were made for purposes of the contract among the respective parties and are subject to important qualifications and limitations agreed to by the parties in connection with negotiating such agreement. The
representations and warranties in the Business Combination Agreement were made only as of the date of the Business Combination Agreement or, with respect to certain representations, in the event the Closing occurs, as of the date of the Closing, or
such other date as is specified in the Business Combination Agreement and are also modified in part by the underlying disclosure schedules which are not filed publicly and which are subject to a contractual standard of materiality different from
that generally applicable to stockholders and were used for the purpose of allocating risk among the parties rather than establishing matters as facts. We do not believe that the disclosure schedules contain information that is material to an
investment decision. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Material Adverse Effect </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to enGene, a &#147;Company Material Adverse Effect&#148; as used in the Business Combination Agreement means any change, event,
effect or occurrence that, individually or in the aggregate with any other change, event, effect or occurrence, has had or would reasonably be expected to have a material adverse effect on (i)&nbsp;the business, results of operations or financial
condition of the Group Companies, taken as a whole or (ii)&nbsp;the ability of enGene to consummate the Transactions, provided, however, that in the case of clause (i)&nbsp;none of the following, either alone or in combination, shall constitute or
be taken into account in determining whether a Company Material Adverse Effect has occurred or is reasonably expected to occur: any adverse change, event, effect or occurrence resulting from or related to (a)&nbsp;any change, development, condition
or event generally affecting the industries or markets in which the Group Companies operate, (b)&nbsp;general business or economic conditions in or affecting the United States, Canada or elsewhere, or changes therein, (c)&nbsp;any outbreak or
escalation of war or hostilities, whether or not pursuant to the declaration of a national emergency or war, or the occurrence in any place of any military or terrorist attack, sabotage, civil unrest, cyberterrorism, riots, prolonged demonstrations
or public disorders, or changes in global, national, regional, provincial, state or local political conditions, or any escalation or worsening thereof, (d)&nbsp;changes in the financial, banking, capital or securities markets generally in the United
States, Canada or any other country or region in the world, or changes therein, including changes in interest rates in the United States, Canada or any other country and changes in exchange rates for the currencies of any countries, (e)&nbsp;changes
or proposed changes in, or changes or proposed changes in the interpretation of, any applicable laws, regulatory framework, IFRS or GAAP, (f)&nbsp;the negotiation, execution or delivery of the Business Combination Agreement, public announcement of
the Business Combination Agreement or the pendency or consummation of the Transactions (<I>provided</I> that the exception in this clause (f)&nbsp;shall not apply to the representations and warranties set forth in Section&nbsp;3.5(b) of the Business
Combination Agreement to the extent that its purpose is to address the consequences resulting from the public announcement or pendency or consummation of the Transactions or the condition set forth in Section&nbsp;6.2(a) thereof, to the extent it
relates to such representations and warranties), (g) any failure by any Group Company to meet, or changes to, any internal or published budgets, projections, forecasts, estimates or predictions, including, but not limited to any predictions
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">212 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or results (expressly excluding any treatment-related severe adverse events, grade 4 or higher, as that such terms are used by the FDA) related to any clinical studies or trials (although the
underlying facts and circumstances resulting in such failure may be taken into account to the extent not otherwise excluded from this definition pursuant to clauses (a)&nbsp;through (f), (h) or (i)), (h) any hurricane, tornado, flood, earthquake,
tsunami, natural disaster, mudslides, wild fires, acts of God or other natural disasters or comparable events in the United States, Canada or any other country or region in the world, or any escalation of the foregoing, (i)&nbsp;any epidemics,
pandemics, disease outbreaks or quarantines, including <FONT STYLE="white-space:nowrap">COVID-19</FONT> or any <FONT STYLE="white-space:nowrap">COVID-19</FONT> Measures or any change in such <FONT STYLE="white-space:nowrap">COVID-19</FONT> Measures
or interpretations thereof following the date of the Business Combination Agreement, (j)&nbsp;the taking of any action required by the terms of the Business Combination Agreement or any Ancillary Agreement, (k)&nbsp;any actions taken or omitted to
be taken by a Group Company at the written request or with the prior written consent of FEAC, (l)&nbsp;ordinary course deterioration of enGene&#146;s cash position (although the underlying facts and circumstances resulting in such failure may be
taken into account to the extent not otherwise excluded from this definition pursuant to clauses (a)&nbsp;through (f), (h) or (i)), (m) any material breach of the Business Combination Agreement or any Ancillary Agreement by FEAC or (n)&nbsp;any
matter set forth on Section&nbsp;1.1 of the enGene Disclosure Schedules; provided, however, that if any change, event, effect or occurrence resulting from a matter described in any of the foregoing clauses (a)&nbsp;through (f), (h) or
(i)&nbsp;materially and disproportionately adversely effects the Group Companies, taken as a whole, relative to other comparable companies and entities operating in the industries or markets in which the Group Companies operate, such change, event,
effect or occurrence may be taken into account in determining whether a Company Material Adverse Effect has occurred but only to the extent of the disproportionate effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to FEAC, a &#147;FEAC Material Adverse Effect&#148; as used in the Business Combination Agreement means any change, event, effect
or occurrence that, individually or in the aggregate with any other change, event, effect or occurrence, has had or would reasonably be expected to have a material adverse effect on the business, results of operations or financial condition of FEAC;
provided, however, that none of the following, either alone or in combination, shall constitute or be taken into account in determining whether a FEAC Material Adverse Effect has occurred or is reasonably expected to occur: any adverse change,
event, effect or occurrence resulting from or related to (a)&nbsp;general business or economic conditions in or affecting the United States, Canada or elsewhere, or changes therein, or the global economy generally, (b)&nbsp;any outbreak or
escalation of war or hostilities, whether or not pursuant to the declaration of a national emergency or war, or the occurrence in any place of any military or terrorist attack, sabotage, civil unrest, cyberterrorism, riots, prolonged demonstrations
or public disorders, or changes in global, national, regional, provincial, state or local political conditions, or any escalation or worsening thereof, (c)&nbsp;changes in the financial, banking, capital or securities markets generally in the United
States, Canada or any other country or region in the world, or changes therein, including changes in interest rates in the United States, Canada or any other country and changes in exchange rates for the currencies of any countries,
(d)&nbsp;changes, or proposed changes in or changes or proposed changes in interpretation of any applicable Laws, regulatory framework, IFRS or GAAP, (e)&nbsp;any change, event, effect or occurrence that is generally applicable to the industries or
markets in which FEAC operates, (f)&nbsp;the negotiation, execution or delivery of the Business Combination Agreement, public announcement of the Business Combination Agreement or the pendency or consummation of the Transactions (<I>provided</I>
that the exception in this clause (f)&nbsp;shall not apply to the representations and warranties set forth in Section&nbsp;4.5(b) of the Business Combination Agreement to the extent that its purpose is to address the consequences resulting from the
public announcement or pendency or consummation of the Transactions or the condition set forth in Section&nbsp;6.3(a) thereof to the extent it relates to such representations and warranties), (g) any failure by FEAC to meet, or changes to, any
internal or published budgets, projections, forecasts, estimates or predictions (although the underlying facts and circumstances resulting in such failure may be taken into account to the extent not otherwise excluded from this definition pursuant
to clauses (a)&nbsp;through (f) or (h)), (h) any hurricane, tornado, flood, earthquake, tsunami, natural disaster, mudslides, wild fires, acts of God or other natural disasters or comparable events in the United States, Canada or any other country
or region in the world, or any escalation of the foregoing, (i)&nbsp;any epidemics, pandemics, disease outbreaks or quarantines, including <FONT STYLE="white-space:nowrap">COVID-19</FONT> or any <FONT STYLE="white-space:nowrap">COVID-19</FONT>
Measures or any change in such <FONT STYLE="white-space:nowrap">COVID-19</FONT> Measures or interpretations thereof following the date of the Business Combination Agreement, (j)&nbsp;the taking of any action required by the terms of the Business
Combination Agreement or any Ancillary </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">213 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Agreement, (k)&nbsp;any actions taken or omitted to be taken by FEAC at the written request or with the prior written consent of enGene (l)&nbsp;any material breach of the Business Combination
Agreement or any Ancillary Agreement by enGene or (m)&nbsp;any matter set forth on Section&nbsp;1.1 of the FEAC Disclosure Schedules; provided, however, that if any change, event, effect or occurrence resulting from a matter described in any of the
foregoing clauses (a)&nbsp;through (f), (h) or (i)&nbsp;materially and disproportionately adversely effects FEAC relative to other &#147;SPACs&#148; comparable to FEAC on the basis of its listing, share conditions, obligations and assets, such
change, event, effect or occurrence may be taken into account in determining whether a FEAC Material Adverse Effect has occurred but only to the extent of the disproportionate effect. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governance </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Business
Combination Agreement, the parties have agreed to take all action within their power as may be necessary or appropriate such that, effective immediately after the Closing, the members of the board of directors of New enGene will initially be seven
(7)&nbsp;directors, including (i)&nbsp;one (1) independent director and one (1)&nbsp;other director (whether or not independent), each to be identified by FEAC, (ii)&nbsp;the Chief Executive Officer of enGene, and (iii)&nbsp;three (3) independent
directors and one (1)&nbsp;other director to be identified by enGene. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">New enGene has agreed to adopt an equity incentive plan
effective upon the Closing, as described in the Business Combination Agreement and a form of which is attached as Exhibit G thereto. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Covenants
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Conduct of Business </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of enGene, New enGene and FEAC have agreed to comply with, and to cause their respective Subsidiaries to comply with, certain covenants
under the Business Combination Agreement from and after the date of the Business Combination Agreement until the earlier of the Closing and the termination of the Business Combination Agreement in accordance with its terms, including, among other
things, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Except (w)&nbsp;as expressly contemplated by the Business Combination Agreement or any Ancillary Agreement,
(x)&nbsp;as required by applicable Law or any Governmental Entity, (y)&nbsp;in the case of enGene and its Subsidiaries only, as set forth on Section&nbsp;5.1(a) of the enGene Disclosure Schedules, or (z)&nbsp;as consented to in writing by, in the
case of the Group Companies, FEAC and in the case of FEAC, enGene (such consent not to be unreasonably withheld, conditioned or delayed), (i) operate their respective business (including, in the case of enGene and New enGene, that of the Group
Companies) in the ordinary course and consistent with past practice and (ii)&nbsp;use commercially reasonable efforts to maintain and preserve intact their respective business organization, assets, properties and material business relations
(including, in the case of enGene and New enGene, those of the Group Companies), taken as a whole; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Without limiting the generality of the foregoing, except (i)&nbsp;as expressly contemplated by the Business
Combination Agreement or any Ancillary Agreement and required in connection with the consummation of the Transactions, (w)&nbsp;as required by applicable Law or any Governmental Entity, (x)&nbsp;in the case of enGene and its Subsidiaries only, as
set forth on Section&nbsp;5.1(b) of the Company Disclosure Schedules or (y)&nbsp;as consented to in writing by, in the case of the Group Companies, FEAC and in the case of FEAC, enGene (such consent not to be unreasonably withheld, conditioned or
delayed) not to do any of the following: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">declare, set aside, make or pay a dividend on, or make any other distribution or payment in respect of, any
Equity Securities of any Group Company or repurchase any outstanding Equity Securities of any Subsidiary, other than, in the case of enGene only, (A)&nbsp;dividends or distributions, declared, set aside or paid by any of enGene&#146;s Subsidiaries
to enGene or any Subsidiary that is, directly or indirectly, wholly owned by enGene, and (B)&nbsp;the withholding of shares of the applicable class of capital stock of enGene in connection with the payment of taxes or the exercise price upon the
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">214 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
exercise or conversion of any enGene Equity Awards outstanding on the date of the Business Combination Agreement in accordance with the terms of the applicable enGene Equity Plan and the
underlying grant, award or similar agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(A) merge, consolidate, combine or amalgamate with any Person or (B)&nbsp;purchase or otherwise acquire (whether
by merging or consolidating with, purchasing any Equity Security in or a substantial portion of the assets of, or by any other manner) any corporation, partnership, association or other business entity or organization or division thereof;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adopt any amendments, supplements, restatements or modifications to any (A)&nbsp;Governing Documents, (B)&nbsp;in
the case of enGene, enGene Shareholders Agreements (other than as agreed with IQ, the Sponsor and enGene Shareholders in connection with the 2023 Financing) or, any enGene Equity Plan, other than (x)&nbsp;amendments of solely an administrative
nature which will not impact the terms of any Rollover Equity Award or (y)&nbsp;in accordance with enGene growth plan described on Section&nbsp;5.1(b)(viii) of the enGene Disclosure Schedules, or (C)&nbsp;in the case of FEAC, the Trust Agreement or
the FEAC Warrant Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(A) sell, assign, abandon, let lapse, lease, license, transfer or otherwise dispose of any material assets or
properties, other than (x)&nbsp;inventory or obsolete equipment in the ordinary course of business or <FONT STYLE="white-space:nowrap">(y)&nbsp;non-exclusive</FONT> licenses to Intellectual Property Rights granted in the ordinary course of business
consistent with past practice, (B)&nbsp;create, subject to or incur any Lien on any material assets or properties (other than Permitted Liens) or (C)&nbsp;disclose any Trade Secrets of the Group Companies (other than pursuant to a written
confidentiality agreement entered into in the ordinary course of business with reasonable protections of such Trade Secrets); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(A) other than in accordance with enGene growth plan described on Section&nbsp;5.1(b)(viii) of the enGene
Disclosure Schedules, issue, sell or grant (1)&nbsp;any Equity Securities of itself or any Subsidiary or (2)&nbsp;any options, warrants, rights of conversion or other rights, agreements, arrangements or commitments obligating itself or any
Subsidiary to issue, deliver or sell any Equity Securities of itself or any Subsidiary, other than, in the case of enGene only, the issuance of shares of the applicable class of capital stock of enGene upon the exercise, vesting or conversion of any
enGene Equity Awards outstanding on the date of the Business Combination Agreement in accordance with the terms of the applicable enGene Equity Plan and the underlying grant, award or similar agreement, (B)&nbsp;in the case of enGene only, consent
to the transfer of any enGene Shares, or (C)&nbsp;transfer or otherwise directly or indirectly dispose of, agree or consent to the transfer of, or subject to a Lien (other than a Permitted Lien), (1) any Equity Securities of any Subsidiary or
(2)&nbsp;any options, warrants, rights of conversion or other rights, agreements, arrangements or commitments obligating itself or any Subsidiary to issue, deliver or sell any Equity Securities of any of its Subsidiaries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">incur, create or assume any Indebtedness, other than, (x)&nbsp;in the case of enGene and its Subsidiaries only,
in connection with the 2023 Financing or ordinary course trade payables and, (y)&nbsp;in the case of FEAC only, Indebtedness under (A)&nbsp;the Working Capital Loan Note, (B)&nbsp;any Extension Loan Note or (C)&nbsp;any other indebtedness owed to
the Sponsor, its Affiliates or designees in an aggregate outstanding amount not to exceed $600,000; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make any loans, advances or capital contributions to, or guarantees for the benefit of, or any investments in,
any Person, other than, (A)&nbsp;in the case of enGene only, intercompany loans or capital contributions between enGene and any of its wholly owned Subsidiaries and (B)&nbsp;the reimbursement of expenses of employees in the ordinary course of
business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of the Group Companies only, except as required under the terms of any Employee Benefit Plan of any
Group Company that is set forth on Section&nbsp;3.11(a) of the enGene Disclosure Schedules or in accordance with enGene growth plan described on Section&nbsp;5.1(b)(viii) of the enGene Disclosure Schedules, (A)&nbsp;establish, amend, modify, adopt,
enter into or terminate any </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">215 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
Employee Benefit Plan or any other benefit or compensation plan, policy, program, agreement, arrangement or Contract that would be an Employee Benefit Plan if in effect as of the date of the
Business Combination Agreement, other than amendments of health or welfare benefit plans in connection with the annual renewal and reenrollment of such plans in the ordinary course of business and consistent with past practice that would not
increase the aggregate cost to the Group Companies of maintaining all Employee Benefit Plans that are health or welfare plans by more than 5% in the aggregate for all such amendments, (B)&nbsp;make, promise or grant any salary, bonus, benefit,
incentive or any other compensation increase or decrease payable to any current or former director, manager, officer, employee, individual independent contractor or other individual service provider receiving annual compensation equal to or greater
than $180,000, other than (i)&nbsp;salary increases in the ordinary course of business to such individuals that, in the aggregate, represent an increase of less than $180,000 on an annual basis, or (ii)&nbsp;Contracts with independent contractors
where such Contract is for a fixed term and the compensation paid during that term does not exceed $180,000, or (C)&nbsp;take any action other than as agreed herein to accelerate any payment, right to payment, or benefit, or the funding of any
payment, right to payment or benefit, payable or to become payable to any current or former director, manager, officer, employee, individual independent contractor or other individual service provider; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">waive or release any noncompetition, <FONT STYLE="white-space:nowrap">non-solicitation,</FONT> <FONT
STYLE="white-space:nowrap">no-hire,</FONT> nondisclosure, noninterference, <FONT STYLE="white-space:nowrap">non-disparagement</FONT> or other restrictive covenant obligation of any current or former director, manager, officer, employee, individual
independent contractor or other individual service provider other than in connection with Section&nbsp;5.22 of the Business Combination Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of enGene only, modify, extend, or enter into any CBA, or recognize or certify any labor union, labor
organization, works council, or group of employees of any Group Company as the bargaining representative for any employees of any Group Company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of enGene only, implement any employee layoffs, plant closings, reductions in force, furloughs,
temporary layoffs, salary or wage reductions, work schedule changes or other such actions to the extent that such actions that could implicate WARN; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of enGene only, enter into or terminate any executive employment agreements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of FEAC and New enGene only, hire any employees or retain any contractors or establish, amend,
modify, adopt, enter into or terminate any employee benefit plan, program, agreement, policy or arrangement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make, change or revoke any material election concerning Taxes, change any method of Tax accounting or Tax
accounting period, amend any Tax Return, enter into any material Tax closing agreement, seek any ruling from any Tax Authority with respect to material taxes, settle or compromise any material Tax Contest, or consent to any extension or waiver of
the limitation period applicable to or relating to any material Tax Contest, other than any such extension or waiver that is an extension of time to file a Tax Return obtained in the ordinary course of business; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into any settlement, conciliation or similar Contract outside of the ordinary course of business other
than, in the case of enGene only, any settlement, conciliation or similar Contract the performance of which would involve the payment by the Group Companies of less than $150,000 in the aggregate, or that imposes, or by its terms will impose at any
point in the future, any material, <FONT STYLE="white-space:nowrap">non-monetary</FONT> obligations on any Group Company (or FEAC or any of its Affiliates after the Closing), in the case of enGene, or on FEAC, in the case of FEAC;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">waive, release or assign, compromise or settle any Proceeding, outside of the ordinary course of business, other
than, in the case of enGene only, the settlement of any proceeding involving only the payment of money (not covered by insurance) by any Group Company of any amount not exceeding $100,000 in the aggregate; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">216 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authorize or incur any capital expenditures or commitments, outside of the ordinary course of business, other
than, in the case of enGene only, capital expenditures or commitments not exceeding $180,000 individually; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authorize, recommend, propose or announce an intention to adopt, or otherwise effect, a plan of complete or
partial liquidation, dissolution, restructuring, recapitalization, reorganization or similar transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">change any method of accounting in any material respect, other than changes that are made in accordance with GAAP
or IFRS, as the case may be; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into any Contract with any broker, finder, investment banker or other Person under which such Person is or
will be entitled to any brokerage fee, finders&#146; fee or other commission in connection with the Transactions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make or promise any enGene Change of Control Payment or FEAC Change of Control Payment, other than (A)&nbsp;in
the case of enGene only, those set forth in the employment agreements, offer letters or similar Contracts made available to FEAC and (B)&nbsp;in the case of FEAC only, those in connection with the Working Capital Loan or any Extension Loan;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(A) in the case of enGene only, other than in the ordinary course of business, (1)&nbsp;amend, modify or
terminate any Material Contract (excluding, for the avoidance of doubt, any expiration or automatic extension or renewal of any such Material Contract pursuant to its terms), (2) waive any material benefit or right under any Material Contract or
(3)&nbsp;enter into any Contract that would constitute a Material Contract, and (B)&nbsp;in the case of FEAC only, (1)&nbsp;amend, modify or terminate any material Contract (excluding, for the avoidance of doubt, any expiration or automatic
extension or renewal of any such material Contract pursuant to its terms), (2) waive any material benefit or right under any material Contract or (3)&nbsp;other than in the ordinary course of business, enter into any Contract; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of enGene only, fail to maintain in full force and effect in all material respects, or fail to
replace or renew, the material insurance policies of enGene and its Subsidiaries to the extent commercially reasonable in enGene&#146;s business judgment in light of prevailing conditions in the insurance market; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">agree to take any of the actions set forth above. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Other Covenants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination Agreement also contains additional other customary covenants and agreements among enGene, New enGene and FEAC,
including, among other things, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">use commercially reasonable best efforts to consummate the Transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">confidentiality and public announcements and other communications covenants regarding the Business Combination
Agreement and the transactions and other documents contemplated thereby and related matters, as well as access to information, properties and personnel; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">tax matters; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exclusivity with respect to the transactions contemplated by the Business Combination Agreement and matters
relating to alternative transactions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the preparation, filing and distribution of this Form <FONT STYLE="white-space:nowrap">S-4</FONT> and the proxy
statement/ prospectus included herein (and any amendments and supplements); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that FEAC convene a meeting of FEAC Shareholders for purposes of obtaining the adoption and approval of the
Business Combination Agreement and other related shareholders proposals; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">217 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that the board of directors of FEAC do not, except as set forth in the Business Combination Agreement, change,
withdraw, withhold, qualify or modify, or publicly propose to change, withdraw, withhold, qualify or modify, the FEAC Board Recommendation to adopt and approve the Business Combination Agreement and other related shareholders proposal;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">listing on Nasdaq or another national securities exchange in the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">director and officer indemnification and resignations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">post-Closing governance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">financial statements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">equity incentive plan of New enGene from the Closing Date; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain organizational matters related to New enGene, Can Merger Sub and Cayman Merger Sub;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">amendment of and compliance with the terms of the Subscription Agreements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">termination of certain related party agreements of FEAC; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disclosure of certain matters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain arrangements related to the Working Capital Loan Note and any Extension Loan Note between FEAC and the
Sponsor (see &#147;&#151; <I>Repayment of the Working Capital Loan Note and Extension Loan Notes&#148; </I>for more information); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">transaction costs; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">filing and similar fees payable to governmental authorities. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conditions to Consummation of the Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Conditions to the Obligations of the Parties </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The obligations of each party to consummate the Transactions are subject to the satisfaction of the following mutual conditions (in each case,
unless waived in writing by FEAC and enGene): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company Arrangement Resolution shall have been approved by the requisite number of shareholders of enGene in
accordance with applicable law and enGene&#146;s governing documents in accordance with the Interim Order and applicable law; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Interim Order and the Final Order shall have been granted and shall not have been set aside or modified in a
manner unacceptable to FEAC and enGene, each acting reasonably, on appeal or otherwise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the absence of any order or law or other legal restraints or prohibition preventing the consummation of the
Transactions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">this proxy statement/prospectus becoming effective in accordance with the provisions of the Securities Act, no
stop order being issued by the SEC and remaining in effect with respect to this proxy statement/prospectus, and no proceeding seeking such a stop order being threatened or initiated by the SEC and remaining pending; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the approval of the Business Combination Agreement, the Ancillary Agreements to the Business Combination
Agreement to which FEAC is or will be a party and the Transactions contemplated by each of the foregoing agreements being obtained by the requisite number of shareholders of FEAC in accordance with applicable law and FEAC&#146;s governing documents;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">after giving effect to the Transactions (including the PIPE Financing), New enGene having at least $5,000,001 of
net tangible assets (as determined in accordance with Rule <FONT STYLE="white-space:nowrap">3a51-1(g)(1)</FONT> of the Exchange Act) immediately after the Closing Date; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">218 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">New enGene&#146;s initial listing application with the Nasdaq or other exchange in connection with the
Transactions shall have been approved and, immediately following the Closing, New enGene shall satisfy any applicable initial and continuing listing requirements of the Nasdaq or other relevant Exchange, as applicable, and no party shall have
received any notice of <FONT STYLE="white-space:nowrap">non-compliance</FONT> therewith that has not been cured or would not be cured at or immediately following the Closing, and the New enGene Shares and New enGene Warrants shall have been approved
for listing on the Nasdaq or other relevant Exchange, as applicable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Articles of Arrangement to be filed with the Director under the CBCA in accordance with the Arrangement shall
be in a form and content satisfactory to enGene and FEAC, each acting reasonably; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Arrangement Dissent Rights shall have not been validly exercised, and not withdrawn or deemed to have been
withdrawn, with respect to more than 10% of the issued and outstanding enGene Shares; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Transaction Support Agreements shall continue to be in full force and effect. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Other Conditions to the Obligations of FEAC </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The obligations of FEAC to consummate the Transactions are also subject to the satisfaction of the following further conditions (in each case,
unless waived in writing by FEAC): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(i) the Company Fundamental Representations shall be true and correct in all material respects as of the date of
the Business Combination Agreement and as of the Closing Date, as though made on and as of the Closing Date (except to the extent that any such representation and warranty is made as of an earlier date, in which case such representation and warranty
shall be true and correct in all material respects as of such earlier date, other than failures to be true and correct that result from actions that are expressly required by the terms of the Business Combination Agreement or approved in writing by
FEAC), (ii) the representations and warranties set forth in Section&nbsp;3.2(a) of the Business Combination Agreement shall be true and correct in all respects (except for <I>de minimis </I>inaccuracies) as of the date of the Business Combination
Agreement and as of the Closing Date, as though made on and as of the Closing Date (except to the extent that any such representation and warranty is made as of an earlier date, in which case such representation and warranty shall be true and
correct in all respects (except for <I>de minimis </I>inaccuracies) as of such earlier date), and (iii)&nbsp;the representations and warranties of enGene set forth in Article 3 of the Business Combination Agreement (other than the Company
Fundamental Representations and the representations and warranties of enGene set forth in Section&nbsp;3.2(a) of the Business Combination Agreement) shall be true and correct (without giving effect to any limitation as to &#147;materiality&#148; or
&#147;Company Material Adverse Effect&#148; or any similar limitation set forth therein) in all respects as of the date of the Business Combination Agreement and as of the Closing Date, as though made on and as of the Closing Date (except to the
extent that any such representation and warranty is made as of an earlier date, in which case such representation and warranty shall be true and correct in all respects as of such earlier date), except where the failure of such representations and
warranties to be true and correct, taken as a whole, does not cause a Company Material Adverse Effect; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enGene having performed and complied in all material respects with the covenants and agreements required to be
performed or complied with by enGene under the Business Combination Agreement at or prior to the Closing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that since the date of the Business Combination Agreement, no Company Material Adverse Effect has occurred that
is continuing; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that enGene deliver, or cause to be delivered, to FEAC (i)&nbsp;at or prior to the Closing, a certificate
executed by an authorized officer of enGene (without personal liability), dated as of the Closing </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">219 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
Date, confirming that the conditions set forth in the first three bullet points in this section have been satisfied, in a form and substance reasonably satisfactory to FEAC and (ii)&nbsp;the
Registration Rights Agreement duly executed by the applicable enGene Shareholders. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Other Conditions to the
Obligations of enGene </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The obligations of enGene to consummate the Transactions are also subject to the satisfaction of the
following further conditions (in each case, unless waived in writing by enGene): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(i) the FEAC Fundamental Representations and the representations and warranties of FEAC set forth in
Section&nbsp;4.19(q) of the Business Combination Agreement shall be true and correct in all respects as of the date of the Business Combination Agreement and as of the Closing Date, as though made on and as of the Closing Date (except to the extent
that any such representation and warranty is made as of an earlier date, in which case such representation and warranty shall be true and correct in all material respects as of such earlier date), (ii) the representations and warranties set forth in
Section&nbsp;4.2(a) of the Business Combination Agreement shall be true and correct in all respects (except for <I>de</I> <I>minimis </I>inaccuracies) as of the date of the Business Combination Agreement and as of the Closing Date, as though made on
and as of the Closing Date (except to the extent that any such representation and warranty is made as of an earlier date, in which case such representation and warranty shall be true and correct in all respects (except for <I>de minimis
</I>inaccuracies) as of such earlier date), (iii) the representations and warranties of FEAC contained in Article 4 of the Business Combination Agreement (other than the FEAC Fundamental Representations and the representations and warranties of FEAC
set forth in Section&nbsp;4.2(a) and Section&nbsp;4.19(q) of the Business Combination Agreement) shall be true and correct (without giving effect to any limitation as to &#147;materiality&#148; or &#147;FEAC Material Adverse Effect&#148; or any
similar limitation set forth therein) in all respects as of the date of the Business Combination Agreement and the Closing Date, as though made on and as of the Closing Date (except to the extent that any such representation and warranty is made as
of an earlier date, in which case such representation and warranty shall be true and correct as of such earlier date), except where the failure of such representations and warranties to be true and correct, taken as a whole, does not cause a FEAC
Material Adverse Effect; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FEAC having performed and complied in all material respects with the covenants and agreements required to be
performed or complied with by FEAC under the Business Combination Agreement at or prior to the Closing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that since the date of the Business Combination Agreement, no FEAC Material Adverse Effect has occurred that is
continuing; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that FEAC deliver, or cause to be delivered, to enGene (i)&nbsp;at or prior to the Closing, a certificate
executed by an authorized officer of FEAC (without personal liability), dated as of the Closing Date, confirming that the conditions set forth in the first three bullet points in this section have been satisfied, in a form and substance reasonably
satisfactory to enGene and (ii)&nbsp;the Registration Rights Agreement duly executed by FEAC and the Sponsor. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Termination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination may be terminated under certain customary and limited circumstances prior to the Closing (i)&nbsp;by mutual written
consent of FEAC and enGene; (ii)&nbsp;by FEAC if the representations and warranties of enGene are not true and correct or if enGene fails to perform any covenant or agreement set forth in the Business Combination Agreement such that certain
conditions to Closing cannot be satisfied and the breach or breaches of such representations or warranties or the failure to perform such covenant or agreement, as applicable, are not cured or cannot be cured within certain specified time periods,
provided however that FEAC is not then in breach of the Business Combination Agreement so as to prevent such condition to Closing from being satisfied; (iii)&nbsp;by enGene if </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">220 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(a)&nbsp;the representations and warranties of FEAC are not true and correct or if FEAC fails to perform any covenant or agreement set forth in the Business Combination Agreement such that
certain conditions to Closing cannot be satisfied and the breach or breaches of such representations or warranties or the failure to perform such covenant or agreement, as applicable, are not cured or cannot be cured within certain specified time
periods, provided however that enGene is not then in breach of the Business Combination Agreement so as to prevent such condition to Closing from being satisfied or (b)&nbsp;prior to the receipt of approval by the FEAC Shareholders, if FEAC&#146;s
board of directors changes its recommendation with respect to the Business Combination; or (iv)&nbsp;by either FEAC or enGene, if (a)&nbsp;the Transactions have not been consummated by December&nbsp;14, 2023; (b) the FEAC Shareholders&#146; meeting
has been held and has concluded and the approval by FEAC Shareholders of the Business Combination has not been obtained; (c)&nbsp;the enGene Required Approval in respect of the Company Arrangement Resolution shall not have been obtained at the
enGene&#146;s shareholders meeting in accordance with the Interim Order and applicable law; or (d)&nbsp;if any Governmental Entity shall have issued an Order permanently enjoining, restraining or otherwise prohibiting the Transactions and such Order
shall have become final and nonappealable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Business Combination Agreement is validly terminated, and except in the case of any
willful or material breach of any covenant or agreement or fraud (involving scienter), none of the parties to the Business Combination Agreement will have any liability or any further obligation under the Business Combination Agreement other than
customary confidentiality obligations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Redemption Offer </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of FEAC Class&nbsp;A Shares will have the right to redeem all or a portion of their FEAC Class&nbsp;A Shares (in connection with
the Business Combination), as set forth in the governing documents of FEAC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FEAC Shareholder Dissent Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent available under the Cayman Act, FEAC Shares that are issued and outstanding immediately prior to the Initial Merger Effective
Time and that are held by FEAC Shareholders who shall have validly exercised their dissenters&#146; rights for such FEAC Shares in accordance with Section&nbsp;238 of the Cayman Act and otherwise complied with all of the provisions of the Cayman Act
relevant to the exercise and perfection of dissenters&#146; rights (the &#147;Dissenting FEAC Shares&#148;, and the holders of such Dissenting FEAC Shares being the &#147;Dissenting FEAC Shareholders&#148;) shall not be converted into, and no
Dissenting FEAC Shareholder shall be entitled to receive, the applicable consideration or any New enGene Warrants unless and until such Dissenting FEAC Shareholder fails to perfect or withdraws or otherwise loses his, her or its right to
dissenters&#146; rights under the Cayman Act. The FEAC Shares owned by any FEAC Shareholder who fails to perfect or who effectively withdraws or otherwise loses his, her or its dissenters&#146; rights pursuant to the Cayman Act shall cease to be
Dissenting FEAC Shares and shall thereupon automatically be cancelled and cease to exist in exchange for the right to receive the applicable number of New enGene Shares on the basis of the Cayman Exchange Ratio, without any interest thereon. The
FEAC Warrants owned by any FEAC Shareholder who fails to perfect or who effectively withdraws or otherwise loses his, her or its dissenters&#146; rights pursuant to the Cayman Act shall thereupon automatically be cancelled and cease to exist in
exchange for the right to receive the applicable number of New enGene Warrants on the basis of the Cayman Exchange Ratio, without any interest thereon. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Survival of Representations, Warranties and Covenants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The representations, warranties, agreements and covenants in the Business Combination Agreement, or in any related certificate, statement or
instrument delivered pursuant to the Business Combination Agreement, will terminate at the Closing except for, among other things, any covenants and agreements contained therein that by their terms expressly contemplate performance either in whole
or in part after the Closing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Specific Performance </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each party is entitled under the Business Combination Agreement to an injunction or injunctions, specific performance and other equitable
relief to prevent breaches of the Business Combination Agreement and to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">221 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
enforce specifically the terms and provisions of the Business Combination Agreement, in each case, without posting a bond or undertaking and without proof of damages and this being in addition to
any other remedy to which they are entitled at law or in equity. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Trust Account Waiver </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each party other than FEAC agreed to waive any right, title, interest or claim of any kind in or to any monies in the Trust Account or
distributions therefrom, or the ability to make any claim against the Trust Account (including any distributions therefrom), regardless of whether such claim arises as a result of, in connection with or relating in any way to, the Business
Combination Agreement or any proposed or actual business relationship between FEAC, on the one hand, and, such other party, on the other hand, or any other matter, and regardless of whether such claim arises based on contract, tort, equity or any
other theory of legal liability. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Repayment of the Working Capital Loan Note and Extension Loan Notes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything to the contrary in the promissory notes governing the Working Capital Loan Note and any Extension Loan Notes, FEAC
shall cause the Sponsor (or its Affiliate or designee, as applicable), as payee of the Working Capital Loan Note and any Extension Loan Notes, to elect to convert an amount equal to $1,500,000 of the aggregate principal amount outstanding under the
Working Capital Loan Note and any Extension Loan Notes, taken together, into additional FEAC Private Placement Warrants which upon such election will be issued by FEAC to the Sponsor (or its Affiliate or designee, as applicable) immediately prior to
the Surrender on the day which is two business days prior to the Closing Date, in each case in accordance with the FEAC Warrant Agreement and the relevant promissory note governing the Working Capital Loan Note and/or any Extension Loan Notes, as
applicable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law and Jurisdiction; Waiver of Jury Trial </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination Agreement is governed by Delaware law except to the extent mandatorily governed by the federal laws of Canada,
including the provisions relating to the Arrangement and the Plan of Arrangement. Except as it relates to the Arrangement and the Plan of Arrangement, any proceeding arising under the Business Combination Agreement, any Ancillary Agreement or in any
way connected with or related or incidental to the dealings of the parties in respect of the Business Combination Agreement or any Ancillary Agreement or any of the Transactions shall be brought in the Court of Chancery of the State of Delaware or,
solely if such court declines to accept jurisdiction, any other state or federal court located in the State of Delaware. Each party has waived its rights to trial by jury in any action based upon, arising out of or related to the Business
Combination Agreement or the Transactions contemplated thereby. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amendments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination Agreement may be amended or modified only by a written agreement executed and delivered by FEAC and enGene. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Recourse </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination
Agreement may only be enforced against, and any action for breach of the Business Combination Agreement may only be made against, the entities expressly named as parties to the Business Combination Agreement, and none of the Representatives of FEAC
(including the Sponsor) or enGene (including directors, officers, employees and shareholders) will have any liability arising out of or relating to the Business Combination Agreement or the Transactions, including with respect to any claim (whether
in tort, contract or otherwise) for breach of the Business Combination Agreement or in respect of any written or oral representations made or alleged to be made in connection therewith, as expressly provided therein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing description of the Business Combination Agreement is not complete and is qualified in its entirety by reference to the Business
Combination Agreement, which is attached as <B><U>Annex A</U></B> hereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">222 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom459793_19"></A>ANCILLARY AGREEMENTS RELATED TO THE BUSINESS COMBINATION
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sponsor and Insiders Letter Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;16, 2023, concurrently with the execution of the Business Combination Agreement, FEAC, the Sponsor, FGOF and the other holders of
FEAC Class&nbsp;B Shares, enGene, New enGene and the other parties named therein (collectively, other than enGene and New enGene, the &#147;Sponsor Parties&#148;) entered into the Sponsor and Insiders Letter Agreement, pursuant to which the Sponsor
has agreed to surrender, after giving effect to the conversion of all or part of the principal amount outstanding under loans made by the Sponsor to FEAC into FEAC Private Placement Warrants, 1,789,004 FEAC Class&nbsp;B Shares and 5,463,381 FEAC
Private Placement Warrants, as a contribution to the capital of FEAC and for no consideration, effective immediately prior to the Class&nbsp;B Conversion on the day which is two business days prior to the Closing Date (the &#147;Surrender&#148;).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Sponsor Parties agreed to (i)&nbsp;be bound by certain other covenants and agreements related to the Business
Combination, (ii)&nbsp;waive the anti-dilution protection with respect to the FEAC Class&nbsp;B Shares (whether resulting from the PIPE Financing or otherwise) and (iii)&nbsp;be bound by certain transfer restrictions with respect to the FEAC Shares
and the FEAC Private Placement Warrants held by them (including the New enGene Shares and New enGene Warrants received in exchange therefore in connection with the Business Combination and the Transactions), in each case, on the terms and subject to
the conditions set forth in the Sponsor and Insiders Letter Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing description of the Sponsor and Insiders Letter
Agreement is subject to and qualified in its entirety by reference to the full text of the Sponsor and Insiders Letter Agreement, a copy of which is attached as <B><U>Annex C</U></B> hereto, and the terms of which are incorporated herein by
reference. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transaction Support Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently with the execution and delivery of the Business Combination Agreement, FEAC, New enGene, enGene, the directors of enGene and
certain shareholders of enGene (collectively, other than FEAC, the &#147;enGene Parties&#148;) entered into voting agreements (the &#147;enGene Voting Agreements&#148;) and <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements (the &#147;enGene
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements&#148;) pursuant to which the enGene Parties agreed to, among other things, (i)&nbsp;vote or cause to be voted all of its enGene Shares in favor of the enGene Arrangement Resolution and the
Transactions; (ii)&nbsp;be bound by certain other covenants and agreements related to the Business Combination and (iii)&nbsp;be bound by certain transfer restrictions with respect to the enGene Shares and New enGene Shares, as applicable, in each
case, on the terms and subject to the conditions set forth in the enGene Voting Agreements and the enGene <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, concurrently with the execution and delivery of the Business Combination Agreement, enGene, New enGene and the Sponsor Parties
entered into a voting agreement (the &#147;FEAC Voting Agreement&#148;) pursuant to which the Sponsor Parties agreed to, among other things, (i)&nbsp;vote or cause to be voted all of their FEAC Shares in favor of the Transaction Proposals;
(ii)&nbsp;be bound by certain other covenants and agreements related to the Business Combination and (iii)&nbsp;be bound by certain transfer restrictions with respect to the FEAC Shares, in each case, on the terms and subject to the conditions set
forth in the FEAC Voting Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing description of the enGene Voting Agreements and the enGene <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Agreements is subject to and qualified in its entirety by reference to the full text of the enGene Voting Agreements and the enGene <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements, forms of which
are attached as Exhibit <FONT STYLE="white-space:nowrap">E-1</FONT> and Exhibit <FONT STYLE="white-space:nowrap">E-2,</FONT> respectively, to <B><U>Annex A</U></B> hereto, respectively, and the terms of which are incorporated herein by reference.
The foregoing description of the FEAC Voting Agreement is subject to and qualified in its entirety by reference to the full text of the FEAC Voting Agreement, a copy of which is attached as Exhibit <FONT STYLE="white-space:nowrap">E-3</FONT> to
<B><U>Annex A</U></B> hereto, and the terms of which are incorporated herein by reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">223 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Subscription Agreements and Side Letter Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;16, 2023, concurrently with the execution of the Business Combination Agreement, FEAC, New enGene and certain investors (the
&#147;PIPE Investors&#148;) entered into subscription agreements (the &#147;Subscription Agreements&#148; and each a &#147;Subscription Agreement&#148;) pursuant to which, among other things, the PIPE Investors have agreed, subject to the completion
of each element of the Transactions (other than those Transactions that are scheduled to be completed following the Closing Date), to subscribe for and purchase, and FEAC has agreed that it will issue and sell to the PIPE Investors (which obligation
will be assumed (the &#147;Assumption&#148;) by New enGene after the completion of the FEAC Reorganization and prior to the consummation of the PIPE Financing (as defined below) the number of FEAC Class&nbsp;A Shares (or after the Assumption, New
enGene Shares) provided for in the applicable Subscription Agreement. Pursuant to the Subscription Agreements, as amended by the Side Letter Agreements (as defined below), the PIPE Investors will collectively subscribe for 6,435,441 FEAC
Class&nbsp;A Shares (or after the Assumption, New enGene Shares) and an aggregate of 2,702,791 FEAC Warrants (or after the Assumption, New enGene Warrants) for an aggregate purchase price equal to $56,891,682 (the &#147;PIPE Financing&#148;). New
enGene intends to use the net proceeds from the PIPE Financing to repay all or a portion of the BDC Notes and for general corporate purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Subscription Agreements for the PIPE Investors provide for certain registration rights. In particular, FEAC (or subject to and in
accordance with the Assumption, New enGene) agreed that, as soon as practicable, but in no event later than 15 business days after the Closing Date, it shall use its commercially reasonable efforts to file with the SEC a registration statement (the
&#147;Registration Statement&#148;) registering the resale of the Subscribed Shares (as defined in the Subscription Agreements) and/or any other equity security (of FEAC, any successor entity or otherwise) issued or issuable with respect to the
Subscribed Shares by way of share split, dividend, distribution, recapitalization, merger, exchange, replacement or similar event or otherwise, and FEAC shall use its commercially reasonable efforts to have the Registration Statement declared
effective as soon as practicable after the filing thereof, but no later than the 60<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> calendar day (or 90<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> calendar day if the Staff of the
SEC notifies FEAC that it will &#147;review&#148; the Registration Statement) following the Closing Date. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The relevant Subscription
Agreement shall terminate and be void and of no further force and effect, and all rights and obligations of the parties thereunder shall terminate without any further liability on the part of any party in respect thereof, upon the earliest to occur
of (i)&nbsp;such date and time as the Business Combination Agreement is validly terminated in accordance with its terms without being consummated, (ii)&nbsp;upon the mutual written agreement of each of the parties thereto to terminate the relevant
Subscription Agreement, (iii)&nbsp;the Termination Date (as defined in the Business Combination Agreement), (iv) if the conditions to Closing set forth in Section&nbsp;3.3 of the relevant Subscription Agreement are not satisfied or (to the extent
permitted by applicable law) waived in writing, or are not capable of being satisfied or (to the extent permitted by applicable law) waived in writing, on or prior to the Closing Date and, as a result thereof, the transactions contemplated by the
relevant Subscription Agreement will not be or are not consummated on the Closing Date and (v)&nbsp;FEAC&#146;s notification to the Subscriber (as defined in the Subscription Agreements) in writing that it has, with the prior written consent of New
enGene and enGene, abandoned its plans to move forward with the Transactions and/or terminated the Subscriber&#146;s obligations with respect to the subscription without the issuance of the Subscribed Shares having occurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately following the execution and delivery of the Subscription Agreements, FEAC and New enGene also entered into a side letter with each
PIPE Investor (the &#147;Side Letter Agreement&#148; and collectively, the &#147;Side Letter Agreements&#148;) to amend the relevant Subscription Agreement and which, together with the relevant Subscription Agreement, reflects the total number of
FEAC Class&nbsp;A Shares and FEAC Warrants to be issued by FEAC (or after the Assumption, the total number of New enGene Shares and New enGene Warrants to be issued by New enGene) pursuant to the PIPE Financing in consideration of the purchase price
set forth in the relevant Subscription Agreement.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">224 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing description of the Subscription Agreements and the Side Letter Agreements is
subject to and qualified in its entirety by reference to the full text of the Subscription Agreements and the Side Letter Agreements, forms of which are attached as Exhibit <FONT STYLE="white-space:nowrap">C-1</FONT> and Exhibit <FONT
STYLE="white-space:nowrap">C-2,</FONT> respectively, to <B><U>Annex A</U></B> hereto, and the terms of which are incorporated herein by reference. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT
STYLE="white-space:nowrap">Non-Redemption</FONT> Agreement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;16, 2023, concurrently with the execution of the Business
Combination Agreement, FEAC and a FEAC shareholder entered into a <FONT STYLE="white-space:nowrap">non-redemption</FONT> agreement (the <FONT STYLE="white-space:nowrap">&#147;Non-Redemption</FONT> Agreement&#148;), pursuant to which, among other
things, FEAC will issue an additional 26,575 FEAC Class&nbsp;A Shares and 81,158 FEAC Warrants (or after the Assumption, New enGene will issue additional New enGene Shares and New enGene Warrants) to such FEAC shareholder in consideration of such
FEAC shareholder&#146;s commitment (i)&nbsp;to vote or cause to be voted all of its 166,665 FEAC Class A Shares in favor of the Transaction Proposals and (ii)&nbsp;not to redeem its 166,665 FEAC Class&nbsp;A Shares in connection with the approval of
the Business Combination by the shareholders of FEAC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing description of the
<FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreement is subject to and qualified in its entirety by reference to the full text of the <FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreement, a form of which is attached as
Exhibit <FONT STYLE="white-space:nowrap">C-3</FONT> to <B><U>Annex A</U></B> hereto, and the terms of which are incorporated herein by reference. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights Agreement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On or
around the Closing Date, New enGene, FEAC, the Sponsor Holders (as defined in the Registration Rights Agreement) and the enGene Holders (as defined in the Registration Rights Agreement) will enter into a registration rights agreement (the
&#147;Registration Rights Agreement&#148;), pursuant to which, among other things, the Sponsor Holders and the enGene Holders will be granted certain customary registration rights with respect to their respective Equity Securities of New enGene, in
each case, on the terms and subject to the conditions therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing description of the Registration Rights Agreement is subject
to and qualified in its entirety by reference to the full text of the Registration Rights Agreement, a form of which is attached as Exhibit D to <B><U>Annex A</U></B> hereto, and the terms of which are incorporated herein by reference. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Convertible Bridge Financing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to
the execution and delivery of the Business Combination Agreement, enGene agreed to certain modifications of existing convertible indebtedness in an aggregate principal amount of $18.4&nbsp;million (the &#147;Amended 2022 Convertible Notes&#148; and,
together with the enGene warrants to be issued by enGene as consideration for such modifications, the &#147;Amended 2022 Financing&#148;). Concurrently with the execution and delivery of the Business Combination Agreement, enGene entered into
agreements pursuant to which it will issue new convertible indebtedness and enGene warrants (i)&nbsp;for cash in an aggregate principal amount of $30.0&nbsp;million and (ii)&nbsp;in repayment of certain outstanding indebtedness in an aggregate
principal amount of $8.0&nbsp;million. The Convertible Bridge Financing indebtedness will be converted in the Transactions into that number of common shares of enGene that, when exchanged at the enGene Exchange Ratio, shall equal that number of FEAC
Class&nbsp;A Shares (or after the Assumption, New enGene Shares) that the holders of such indebtedness would have received if they had subscribed for FEAC Class&nbsp;A Shares (or after the Assumption, New enGene Shares) on the same terms as the PIPE
Financing. enGene used a portion of the net proceeds of the Convertible Bridge Financing to repay certain indebtedness and for general corporate purposes. The remaining net proceeds of the Convertible Bridge Financing are expected to be used by New
enGene for general corporate purposes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Working Capital Loans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;24, 2023, the Sponsor and FEAC entered into an unsecured promissory note (the &#147;First Loan Note&#148;) under which the
Sponsor agreed to extend to FEAC a Working Capital Loan of up to $900,000, to be used </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">225 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
for FEAC&#146;s general corporate purposes. The Sponsor funded the initial principal amount of $450,000 under the Note on March&nbsp;24, 2023. The First Loan Note bears no interest and will be
due and payable on the earlier of (i)&nbsp;the date of consummation of a business combination and (ii)&nbsp;December&nbsp;14, 2023. If FEAC completes the Business Combination, FEAC may repay the First Loan Note out of the proceeds of the Trust
Account released to FEAC. Otherwise, no proceeds from the Trust Account can be used to repay the Note. See also &#147;<I>Certain Relationships and Related Party Transactions &#151; FEAC &#151; Working Capital Loans</I>&#148; for further information.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;6, 2023, FEAC issued an additional unsecured promissory note (the &#147;Second Loan Note&#148;) under which the Sponsor
agreed to extend to FEAC a Working Capital Loan in the total principal amount of $300,000 to the Sponsor. The proceeds of the Second Loan Note will be used by FEAC for general corporate purposes. The Sponsor funded the principal amount of $300,000
on June&nbsp;6, 2023. The Second Loan Note bears no interest and shall be due and payable on the Loan Note Maturity Date. If FEAC completes an initial business combination, FEAC may repay the Second Loan Note out of the proceeds of the Trust Account
released to FEAC. In the event that FEAC does not consummate an initial business combination, the Second Loan Note will be repaid only from amounts remaining outside of the Trust Account, if any. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Extension Loans </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;6, 2023,
FEAC extended the time available to consummate its initial business combination from June&nbsp;14, 2023 to September&nbsp;14, 2023 by having the Sponsor deposit an additional $1,265,000, or $0.10 per unit, into the Trust Account (the &#147;Extension
Funding&#148;), in accordance with FEAC&#146;s Current Articles and the Investment Management Trust Agreement by and between the Company and Continental Stock Transfer&nbsp;&amp; Trust Company, dated as of December&nbsp;9, 2021. In connection with
the Extension Funding, on June&nbsp;6, 2023, FEAC issued an unsecured promissory note (the &#147;Extension Note&#148;) in the total principal amount of $1,265,000 to the Sponsor. The Sponsor funded the principal amount of $1,265,000 by depositing
such amount into the Trust Account on June&nbsp;6, 2023. The Extension Note bears no interest and shall be due and payable on the Loan Note Maturity Date. In the event that FEAC does not consummate an initial business combination, the Extension Note
will be repaid only from amounts remaining outside of the Trust Account, if any. See also &#147;<I>Certain Relationships and Related Party Transactions&nbsp;&#151; FEAC&nbsp;&#151; Extension Loans; Business Combination Deadline Extension</I>&#148;
for further information. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FEAC currently intends, in accordance with its obligations under the Business Combination Agreement, to
extend the time available to it to consummate its initial business combination from September 14, 2023, to December 14, 2023, by depositing an additional $1,265,000 (or $0.10 per FEAC Class A Share) into the Trust Account on or before September 14,
2023, and the Sponsor is expected to fund such amount in the form of an additional extension note on the same terms. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Warrant Assignment,
Assumption and Amendment Agreement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Business Combination Agreement, on or around the Closing Date, FEAC, New enGene and
the Trustee will enter into a warrant assignment, assumption and amendment agreement to amend the FEAC Warrant Agreement in order to give effect to the Transactions contemplated pursuant to the Business Combination Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">226 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom459793_20"></A>PROPOSAL NO. 2 &#151; THE GOVERNING DOCUMENTS PROPOSAL </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Governing Documents Proposal, if approved, will approve the following material differences between New enGene&#146;s Proposed Articles to
be in effect following the Business Combination and FEAC&#146;s Current Articles: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the name of the new public entity will be &#147;enGene Holdings Inc.&#148; as opposed to &#147;Forbion European
Acquisition Corp.&#148;; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">New enGene will have an unlimited number of authorized common shares and an unlimited number of authorized blank
cheque preferred shares, as opposed to FEAC having 500,000,000 Class&nbsp;A ordinary shares authorized, 50,000,000 Class&nbsp;B ordinary shares authorized and 5,000,000 preference shares authorized; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">New enGene&#146;s Proposed Articles would reduce the requisite quorum for a meeting of shareholders from a
majority of votes as required under the Current Articles to 33 1/3% of the shares entitled to vote at such meeting. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">New enGene&#146;s Proposed Articles would include an advance notice provision that requires a nominating
shareholder to provide notice to New enGene in advance of a meeting of shareholders should such nominating shareholder wish to nominate a person for election to the board of directors. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">New enGene&#146;s corporate existence will be perpetual as opposed to FEAC&#146;s corporate existence terminating
if the initial business combination is not consummated by FEAC within a specified period of time; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">New enGene&#146;s constitutional documents will not include the various provisions applicable only to special
purpose acquisition corporations that FEAC&#146;s Current Articles contain. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the judgment of the FEAC Board, the
Governing Documents Proposal is desirable for the following reasons: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The name of the new public entity is desirable to reflect the Business Combination with enGene and the business
going forward. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The unlimited number of authorized common shares and unlimited number of authorized blank cheque preferred shares
are desirable for New enGene to have sufficient shares to issue to the holders of FEAC Class&nbsp;A Shares and FEAC Warrants, to issue as consideration to the FEAC Shareholders in the Business Combination, to reserve shares for issuance under the
Incentive Equity Plan and have additional authorized shares for financing its business, for acquiring other businesses, for forming strategic partnerships and alliances and for stock dividends and stock splits (neither of which are currently
contemplated). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The provisions that relate to the operation of FEAC as a blank check company prior to the consummation of its
initial business combination would not be applicable after the Business Combination (such as the obligation to dissolve and liquidate if the initial business combination is not consummated in a specified period of time). </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, an unlimited number of authorized but unissued common shares may enable New enGene&#146;s Board of Directors to
render it more difficult or to discourage an attempt to obtain control of New enGene and thereby protect continuity of or entrench its management, which may adversely affect the market price of New enGene&#146;s securities. If, in the due exercise
of its fiduciary obligations, for example, New enGene&#146;s Board of Directors were to determine that a takeover proposal were not in the best interests of New enGene, such shares could be issued by the board of directors without shareholder
approval in one or more private placements or other transactions that might prevent or render more difficult or make more costly the completion of any attempted takeover transaction by diluting voting or other rights of the proposed acquirer or
insurgent stockholder group, by creating a substantial voting block in institutional or other hands that might support the position of the incumbent board of directors, by effecting an acquisition that might complicate or preclude the takeover, or
otherwise. The authorization of additional shares will, however, enable New enGene to have the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">227 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
flexibility to authorize the issuance of shares in the future for financing its business, for acquiring other businesses, for forming strategic partnerships and alliances and for stock dividends
and stock splits. New enGene currently has no such plans, proposals, or arrangements, written or otherwise, to issue any of the additional authorized shares for such purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A copy of New enGene&#146;s Proposed Articles, as will be in effect assuming approval of all of the Governing Documents Proposal and upon
consummation of the Business Combination, is attached to this proxy statement/prospectus as <B><U>Annex A</U></B><B>.</B> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vote Required for Approval
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The adoption and approval of the Governing Documents Proposal requires the affirmative vote of the holders of at least a majority of
the FEAC Shares present in person or represented by proxy and entitled to vote at the Special Meeting. Abstentions will have no effect on the outcome of the proposal. The Business Combination cannot be completed unless the Governing Documents
Proposal is adopted by affirmative vote of the holders of at least a majority of the votes cast by FEAC Shareholders present or represented by proxy at the Special Meeting and entitled to vote thereon. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recommendation of FEAC Board </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THE FEAC
BOARD RECOMMENDS THAT THE FEAC SHAREHOLDERS VOTE &#147;FOR&#148; THE GOVERNING DOCUMENTS PROPOSAL. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The existence of financial and
personal interests of FEAC&#146;s directors may result in a conflict of interest on the part of one or more of the directors between what they may believe is in the best interests of FEAC and its shareholders and what they may believe is best for
themselves in determining to recommend that shareholders vote for the proposals. See the section entitled &#147;<I>Proposal No.</I><I></I><I>&nbsp;1 </I><B><I>&#151;</I></B><I> The Business Combination Proposal &#151; Interests of FEAC&#146;s
Sponsor, Directors and Executive Officers in the Business Combination</I>&#148; for a further discussion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">228 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom459793_21"></A>COMPARISON OF CORPORATE GOVERNANCE AND SHAREHOLDER RIGHTS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FEAC is an exempted company incorporated under the Cayman Act. The Cayman Act differs in some material respects from laws generally
applicable to United States corporations and their shareholders. New enGene is a corporation incorporated under the laws of Canada that will be continued into British Columbia upon consummation of the Business Combination. Cayman Islands law and
FEAC&#146;s Current Articles govern the rights of FEAC&#146; Shareholders. In addition, FEAC&#146;s Current Articles differ in certain material respects from the Proposed Articles of New enGene. As a result, when you become a shareholder of New
enGene, your rights will differ in some regards as compared to when you were a shareholder of FEAC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Below is a summary outlining
important similarities and differences in the corporate governance and stockholder/shareholder rights associated with each of FEAC and New enGene according to applicable law and/or the constitutional or organizational documents of FEAC and New
enGene. You should also review the Proposed Articles of New enGene (as the same will be in effect assuming approval of the Business Combination Proposal and upon consummation of the Business Combination) attached as Exhibit F to <B><U>Annex
A</U></B><I> </I>to this proxy statement/prospectus, and the corporate laws of the Cayman Islands, including the Cayman Act, to understand how these laws apply to New enGene and FEAC. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Corporate Law </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain Corporate
Differences Between the BCBCA and the Cayman Act </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following should be read together with the information and statements contained
elsewhere in this proxy statement/prospectus. Upon being continued under the BCBCA, New enGene will be subject to the notice of articles of New enGene (the &#147;New enGene Notice of Articles&#148;) and the Proposed Articles. Although the rights and
privileges of FEAC Shareholders under the Cayman Act are in many instances comparable to the rights and privileges of the New enGene Shareholders under the BCBCA, there are several differences. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary and overview of New enGene Shareholder&#146;s rights under the BCBCA and certain differences between the Cayman Act
and the BCBCA, but it is not intended to be a comprehensive review of the New enGene Notice of Articles, the Proposed Articles, FEAC&#146;s Current Articles, the Cayman Act, or the BCBCA. Reference should be made to the full text of the Cayman Act
and the BCBCA and the regulations thereunder for particulars of any differences between them, FEAC&#146;s Current Articles and the Proposed Articles attached to the Business Combination Agreement as Exhibit F. FEAC Shareholders should consult their
own legal or other professional advisors with regard to all of the implications of the Business Combination which may be of importance to them. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Charter Documents </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under
the BCBCA, the charter documents of New enGene will consist of a &#147;Notice of Articles&#148; which sets forth, among other things, the name of New enGene and the amount and type of authorized capital and indicates if there are any rights and
restrictions attached to the shares, and &#147;Articles&#148; which govern the management of New enGene (collectively, the &#147;Charter Documents&#148;). The New enGene Notice of Articles are filed with the British Columbia Business Registry and
the Proposed Articles are filed only with New enGene&#146;s registered and records office. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Cayman Act, FEAC has (a)&nbsp;a
&#147;Memorandum of Association&#148;, which sets forth, among other things, the name of FEAC, that the objects for which FEAC was established are unrestricted and FEAC shall have the full power and authority to carry out any object not prohibited
by the laws of the Cayman Islands, and the amount and classes of authorized share capital, and (b) &#147;Articles of Association&#148; which, among other things, govern the management of FEAC. FEAC&#146;s Current Articles are filed with the
Registrar of Companies of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">229 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Cayman Islands under the Cayman Act. If shareholders approve the Business Combination, the New enGene Notice of Articles and the Proposed Articles under the BCBCA will provide for authorized
capital consisting of an unlimited number of New enGene Shares without par value and an unlimited number preferred shares of New enGene without par value, whereas FEAC&#146;s authorized share capital is US$55,500 divided into 500,000,000
Class&nbsp;A ordinary shares of a par value of US$0.0001 each, 50,000,000 Class&nbsp;B ordinary shares of a par value of US$0.0001 each and 5,000,000 preference shares of a par value of US$0.0001 each. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Amendments to Corporate Charter </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any substantive change to the notice of articles or articles of a company under the BCBCA, such as an alteration of the restrictions, if any,
of the business carried on by the company, a change in the name of the company or an increase or reduction of the authorized capital of the company requires a Special Resolution, unless another type of approval is specified in its articles. A
special resolution is a resolution (i)&nbsp;passed at a meeting by not less than <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the votes cast by the shareholders who voted in respect of the resolution, or (ii)&nbsp;approved in writing by all
shareholders entitled to vote on the matter (a &#147;Special Resolution&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other fundamental changes such as an alteration of the
special rights and restrictions attached to issued shares, also require a Special Resolution of the holders of shares of each class entitled to vote at a general meeting of the company, unless another type of approval is specified in its articles.
The holders of all classes of shares adversely affected by an alteration of special rights and restrictions must vote by separate special resolution to the alteration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">New enGene will adopt the Proposed Articles which alter the requirements for Special Resolutions in certain instances, as more particularly
described below. The Proposed Articles to be adopted by New enGene provide in Article 9.1 that the following matters may be approved by a Special Resolution: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the creation of one or more classes or series of shares or, if none of the shares of a class or series of
shares are allotted or issued, the elimination that class or series of shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any increase, reduction or elimination of the maximum number of shares that New enGene is authorized to issue
out of any class or series of shares or establishing a maximum number of shares that New enGene is authorized to issue out of any class or series of shares for which no maximum is established; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if New enGene is authorized to issue shares of a class of shares with par value: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a decrease to the par value of those shares; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if none of the shares of that class of shares are allotted or issued, an increase to the par value of those
shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a change of all or any of its unissued, or fully paid issued, shares with par value into shares without par
value or any of its unissued shares without par value into shares with par value; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">otherwise alter its shares or authorized share structure when required or permitted to do so by the BCBCA.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, Article 9.2 and Article 28.3 of the Proposed Articles to be adopted by New enGene permits the following
matters to be approved by the directors of New enGene: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the subdivision or consolidation all or any of its unissued, or fully paid issued, shares;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the alteration of the identifying name of any of its shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if none of the preferred shares of a particular series are issued: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">determining the maximum number of shares of any of those series of preferred shares that New enGene is
authorized to issue, determine that there is no such maximum number, or alter any determination of the foregoing or otherwise in relation to a maximum number of those shares; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">230 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the creation of an identifying name by which the shares of any of those series of preferred shares that may be
identified, or alter any identifying name created for those shares; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">attach special rights or restrictions to the shares of any of those series of preferred shares or alter any
special rights or restrictions attached to those shares, including, but without limiting or restricting the generality of the foregoing, special rights or restrictions with respect to: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(I)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the rate, amount, method of calculation and payment of any dividends, whether cumulative, partly cumulative or <FONT
STYLE="white-space:nowrap">non-cumulative,</FONT> and whether such rate, amount, method of calculation or payment is subject to change or adjustment in the future; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(II)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any rights upon a dissolution, liquidation or <FONT STYLE="white-space:nowrap">winding-up</FONT> of New enGene
or upon any other return of capital or distribution of the assets of New enGene among its shareholders for the purpose of winding up its affairs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(III)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any rights of redemption, retraction or purchase for cancellation and the prices and terms and conditions of
any such rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(IV)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any rights of conversion, exchange or reclassification and the terms and conditions of any such rights;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(V)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any voting rights and restrictions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(VI)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the terms and conditions of any share purchase plan or sinking fund; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(VII)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any other special rights or restrictions, not inconsistent with these share provisions, attaching to such
series of preferred shares. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Article 9.5 of the Proposed Articles to be adopted by New enGene permits that the directors
may authorize and cause New enGene to alter its New enGene Notice of Articles in order to change its name. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Article 18.1 of
FEAC&#146;s Current Articles, FEAC may by ordinary resolution, which requires the approval of a simple majority of members being entitled to vote at a meeting or approval in writing by all members entitled to vote on the matter (&#147;FEAC Ordinary
Resolution&#148;): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">increase its share capital by such sum as the FEAC Ordinary Resolution shall prescribe and with such rights,
priorities and privileges annexed thereto, as FEAC in general meeting may determine; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">divide all or any of its share capital into shares of larger amount than its existing shares;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">convert all or any of its <FONT STYLE="white-space:nowrap">paid-up</FONT> shares into stock, and reconvert that
stock into <FONT STYLE="white-space:nowrap">paid-up</FONT> shares of any denomination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by subdivision of its existing shares or any of them divide the whole or any part of its share capital into
shares of smaller amount than is fixed by the memorandum of FEAC or into shares without par value; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">cancel any shares that at the date of the passing of the FEAC Ordinary Resolution have not been taken or agreed
to be taken by any person and diminish the amount of its share capital by the amount of the shares so cancelled. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Article&nbsp;18.3 of FEAC&#146;s Current Articles, and subject to the provisions of the Cayman Act and the provisions of
FEAC&#146;s Current Articles as regards the matters to be dealt with by ordinary resolution, FEAC may by special resolution, which requires the approval of not less than <FONT STYLE="white-space:nowrap">two-thirds</FONT> of members being entitled to
vote at a meeting or approval in writing by all members entitled to vote on the matter (&#147;FEAC Special Resolution&#148;): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">change FEAC&#146;s name; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">alter or add to the articles of association of FEAC; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">231 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">alter or add to the memorandum of FEAC with respect to any objects, powers or other matters specified therein;
and </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">reduce FEAC&#146;s share capital or any capital redemption reserve fund. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Certain Voting Requirements for Extraordinary Fundamental Changes </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the BCBCA, certain extraordinary corporate actions, such as certain amalgamations, continuations and sales, leases or other dispositions
of all or substantially all a company&#146;s undertaking other than in the ordinary course of business, and other extraordinary corporate actions such as liquidations, and (if ordered by a court) arrangements, are required to be approved by Special
Resolution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In certain cases, a Special Resolution to approve an extraordinary corporate action is also required to be approved
separately by the holders of a class or series of shares, including in certain cases a class or series of shares not otherwise carrying voting rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mergers and consolidations are governed by Part XVI of the Cayman Act. The directors of FEAC must, on behalf of FEAC, approve a written plan
of merger or consolidation including the particulars set out in section&nbsp;233(4) of the Cayman Act (the &#147;Plan of Merger&#148;) and the Plan of Merger must be authorized by a FEAC Special Resolution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mergers, amalgamations and reconstructions may also be achieved by way of a scheme of arrangement under section&nbsp;86 or 87 of the Cayman
Act. A scheme of arrangement is a court-supervised arrangement between a company and its members or its creditors (or classes thereof). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By such procedure, a creditor of FEAC or a member of FEAC may apply to the court to order a meeting of the creditors of FEAC or of any class
of creditors affected by the scheme, and/or a meeting of all members of FEAC or of any class of members affected by the scheme. In the case of a creditors&#146; scheme of arrangement, if a majority in number of the creditors, present at the meeting
held to consider the arrangement, representing at least 75% in value of the creditors or class of creditors, as the case may be, agree to the scheme, the scheme, if sanctioned by the court, shall bind FEAC and all relevant creditors. In the case of
a members&#146; scheme of arrangement, if a majority present at the meeting held to consider the arrangement, representing at least 75% in value of the members or class of members, as the case may be, agree to the scheme, the scheme, if sanctioned
by the court, shall bind FEAC and all relevant members. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Cayman companies may be acquired by other companies by the direct
acquisition of the shares of the target company. Section 88 of the Cayman Act provides that when an offer is made for the shares or any class of shares of a Cayman Islands company and, within four months of the offer, the holders of not less than
90% of those shares accept, the offeror may, at any time within two months after the expiration of that four-month period, require the remaining shareholders to transfer their shares to the acquiror on the same terms as the original offer, subject
in each instance to an order of the court to the contrary upon application of any dissenting shareholder. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Dividend Rights </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to any rights and restrictions of any other class or series of shares outstanding (of which there are currently none), the New enGene
Board may, from time to time, declare dividends on the issued shares and authorize payment of the dividends out of New enGene&#146;s lawfully available funds (and otherwise subject to the provisions of the BCBCA including with respect to solvency).
The New enGene Board may declare that any dividend be paid wholly or partly by the distribution of shares and/or specific assets of New enGene. This is consistent with the rules applicable to dividends under the Cayman Act and under Article 39 of
the Current Articles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If at any time New enGene issues preferred shares, the dividend rights attributable to those shares would be
prescribed by the New enGene Board prior to their issuance. As a result, those shares may have a dividend right that ranks senior to the New enGene Shares and may affect the amount of lawful funds of New enGene that is available for distribution to
the holders of New enGene Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">232 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Rights upon Liquidation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of the liquidation of New enGene, after the full amounts that holders of any issued shares ranking senior to the New enGene Shares
(there are currently no such shares issued and outstanding) plus creditors as to distribution on liquidation or winding up are entitled to receive have been paid or set aside for payment, the holders of New enGene Shares would be entitled to
receive, pro rata, any remaining assets of New enGene available for distribution to the holders of New enGene Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If at any time New
enGene issues preferred shares, the liquidation rights attributable to those shares would be prescribed by the New enGene Board prior to their issuance. As a result, those shares may have a liquidation right that ranks senior to the New enGene
Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Cayman Islands law, in the event of the liquidation of FEAC, a liquidator shall be appointed whose function would be to (i)
realize FEAC&#146;s unsecured assets, (ii) identify FEAC&#146;s unsecured creditors and the amounts of their claims and (iii) distribute the proceeds of realisation of FEAC&#146;s unsecured assets (net of expenses and claims of preferred creditors)
to FEAC&#146;s unsecured creditors pro rata, and after the creditors have been paid in full to FEAC&#146;s shareholders in accordance with FEAC&#146;s Current Articles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Cayman Islands law, a liquidator&#146;s duties are owed principally to those with the economic interest in the winding up of the
company&#146;s affairs and the distribution of its assets. In circumstances where a company is solvent i.e. has sufficient assets to pay its unsecured creditors in full, then the liquidator&#146;s principal duty will be owed to the company&#146;s
shareholders. If there is a risk that the company will have insufficient assets to meet in full the claims of its creditors, then the liquidator must act in the best interests of the general body of the company&#146;s unsecured creditors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Inspection of Books and Records </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the BCBCA, any shareholder of a company may for any proper purpose inspect or make copies of the company&#146;s central securities
register, list of shareholders and certain other books and records. Pursuant to Article&nbsp;41.2 of FEAC&#146;s Current Articles, the directors of FEAC shall determine whether and to what extent and at what times and places and under what
conditions or regulations the accounts and books of FEAC shall be open to the inspection of shareholders not being directors and no shareholder (not being a director) shall have any right of inspecting any account or book or document of FEAC except
as conferred by the Cayman Act or authorized by the directors or by FEAC in general meeting. Pursuant to Section&nbsp;64 of the Cayman Act the court may order one or more competent inspectors to examine into the affairs of any company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Dissent Rights </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The BCBCA
provides that shareholders who dissent to certain actions being taken by New enGene may exercise a right of dissent and require New enGene to purchase the New enGene Shares held by such shareholder at the fair value of such New enGene Shares. The
dissent right is applicable where any court order permits the dissent or where New enGene proposes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by resolution to alter the Proposed Articles to alter restrictions on the powers of New enGene or on the
business it is permitted to carry on; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by resolution to adopt an amalgamation agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by resolution to approve an amalgamation into a foreign jurisdiction; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by resolution to approve an arrangement, the terms of which arrangement permit dissent; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by resolution to authorize or ratify the sale, lease or other disposition of all or substantially all of New
enGene&#146;s undertaking; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">233 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by resolution to authorize the continuation of New enGene into a jurisdiction other than British Columbia; or
</P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to ask shareholders to approve any other resolution, if dissent is authorized by the resolution.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the BCBCA, shareholders are also entitled to dissent under any court order that permits dissent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as provided in Sections 88 and 238 of the Cayman Act, there are no rights of dissent for shareholders under the Cayman Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A dissenting shareholder has the right to be paid a payment of the fair value of its share(s) in FEAC upon its dissenting to the merger or
consolidation. To do so, such dissenting shareholder must follow the procedure set out in section 238 of the Cayman Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At first
instance, FEAC may determine the fair value of the relevant share(s) which the dissenting shareholder may agree to. If FEAC and the dissenting shareholder fail to agree a price, the court ultimately has the power to determine the fair value of the
share(s) together with a fair rate of interest, if any, to be paid by FEAC upon the amount determined to be the fair value. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Oppression
Remedies </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the BCBCA, a shareholder, or any other person whom the court considers to be an appropriate person to make an
application, has the right to apply to court on the grounds that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the affairs of New enGene are being or have been conducted, or that the powers of the directors are being or
have been exercised, in a manner oppressive to one or more of the shareholders, including the applicant, or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">some act of New enGene has been done or is threatened, or that some resolution of the shareholders or of the
shareholders holding shares of a class or series of shares has been passed or is proposed, that is unfairly prejudicial to one or more of the shareholders, including the applicant. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On such an application, the court may make such order as it sees fit including an order to prohibit any act proposed by New enGene. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The laws of the Cayman Islands do not provide for a similar remedy. There is, however, a right under the Cayman Act for a shareholder to apply
to court to have, among other things, a Cayman Islands company wound up by the court on the grounds that it would be just and equitable to do so. Also, please see the section entitled &#147;Derivative Action&#148;, where certain other minority
rights are discussed. There are a number of different reasons why such a winding up order may be sought &#150; for example if there is a fundamental dispute between the shareholders that will not otherwise be resolved. When a winding up order is
made, an automatic moratorium on proceedings is imposed. Dispositions of property, transfers of shares and alterations in the status of shareholders are void. When the liquidation process is complete, and the company&#146;s assets have been
distributed to those entitled to them, the court will order the dissolution of the company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Derivative Action </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the BCBCA, a complainant, who is either a shareholder (including a beneficial owner or any other person who the court considers to be an
appropriate person to make an application) or director of a company, may, with leave of the court, bring an action in the name of a company to enforce a right, duty or obligation owed to the company, obtain damages for any breach of such a right,
duty or obligation, or intervene to defend a legal proceeding brought against the company, when the company cannot or does not take up or defend the action. No action may be brought and no intervention in an action may be made unless the court is
satisfied that: (i)&nbsp;the complainant has first applied for leave to the court, (ii)&nbsp;the complainant has given notice to the company or to any other person that the court orders of the application for leave, (iii)&nbsp;the complainant is
acting in good faith, and (iv)&nbsp;bringing the action is in the interests of the company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">234 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the BCBCA, the court may make any order it thinks appropriate including but not
limited to: (i)&nbsp;an order authorizing the complainant or any other person to control the conduct of the action; (ii)&nbsp;an order giving directions for the conduct of the action; (iii)&nbsp;an order that the company pay the person controlling
the conduct of the action interim costs including legal fees; and (iv)&nbsp;an order requiring the company to pay reasonable legal fees incurred in connection with the action by the complainant or person controlling the legal proceeding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Cayman Islands law, a distinction needs to be made between actions brought by shareholders in the name of a company where they believe
that harm will result to such company (known as derivative actions) and those brought by shareholders relating to an infringement of a personal right. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With regards actions brought in the name of a company, the general rule is that the proper plaintiff is, prima facie, the company itself (by
its board of directors, or liquidators, or possibly the company in general meeting), not an individual shareholder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With regards
shareholders&#146; personal rights of action, it is established under English law (which would be persuasive although not technically binding in the courts of the Cayman Islands) that certain rights of the individual shareholder may be acted upon by
him on his own behalf. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Requisition of Meetings </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The BCBCA provides that shareholders of a company holding at least <FONT STYLE="white-space:nowrap">one-twentieth</FONT> (5%) of the issued
voting shares of a company may give notice to the directors requiring them to call and hold a general meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Article 20.3 of
FEAC&#146;s Current Articles provides that the directors, the chief executive officer, the secretary or the chairman of the board of directors may call general meetings, and they shall on a members&#146; requisition forthwith proceed to convene an
extraordinary general meeting of FEAC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Shareholder Proposals </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The BCBCA provides that qualified shareholders of a company have the right to put any proposal before the annual general meeting of
shareholders to which the proposal relates, provided the proposal complies with the requirements of the BCBCA. A qualified shareholder means a person who is the registered or beneficial owner of one or more voting shares of the company and has been
a registered or beneficial owner of at least one voting share for an uninterrupted period of at least two years before the date the proposal is signed. The proposal must be signed by qualified shareholders who collectively are registered or
beneficial owners of shares that constitute at least 1% of the issued voting shares or have a fair market value in excess of C$2,000. A qualified shareholder means a person who is the registered or beneficial owner of one or more voting shares of
the company and has been a registered or beneficial owner of at least one voting share for an uninterrupted period of at least two years before the date the proposal is signed. The proposal must be signed by the issued voting shares or have a fair
market value in excess of C$2,000. The Cayman Act does not provide shareholders with any right to put any proposal before a general meeting. However, this right may be provided in a company&#146;s articles of association. FEAC&#146;s Current
Articles provide that FEAC Shareholders may bring business before an annual general meeting provided they deliver notice to the principal executive offices of FEAC within the relevant timeframe set in FEAC&#146;s Current Articles. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Place of Shareholders&#146; Meetings </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the BCBCA, general meetings of shareholders are to be held in British Columbia or may be held at a location outside of British Columbia
if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the location is provided for in the articles; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">235 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the articles do not restrict a company from approving a location outside of British Columbia, the location is
approved by the resolution required by the articles for that purpose, or if no resolution is specified then the location approved by ordinary resolution; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the location is approved in writing by the B.C. Registrar before the meeting is held. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the general meeting is a partially electronic meeting, the location of the meeting described above applies to the location where persons
attend the meeting in person. If the general meeting is a fully electronic meeting, the requirements for the location of the meeting described above does not apply to the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Proposed Articles permit the directors to determine that a meeting of the New enGene Shareholders be held entirely by means of telephonic,
electronic or other communication facilities that permit all participants to participate in the meeting, whether by telephone, electronic or other communications medium. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Article 21.1 of FEAC&#146;s Current Articles provide that at least five clear days&#146; notice shall be given of any general meeting. Every
notice shall specify the place, the day and the hour of the meeting. A general meeting may be partially electronic but may not be fully electronic. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Voting at Shareholder Meetings </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">So long as the only class of shares outstanding are the New enGene Shares, then pursuant to the Proposed Articles, each holder of New enGene
Shares, present in person, by proxy or otherwise at a shareholders&#146; meeting, would be entitled to one vote on a show of hands or one vote per share on the taking of a poll on all matters to be voted upon. There are no limitations imposed by
under the BCBCA on the rights of nonresident shareholders to hold or vote their New enGene Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the BCBCA, most regular
decisions or actions requiring approval by the New enGene Shareholders would require approval by an ordinary resolution, meaning approval by a simple majority of votes cast by the holders of the New enGene Shares present in person, by proxy or
otherwise at a shareholders&#146; meeting, or approval, after being submitted to all holders of the New enGene Shares, by consent in writing of holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the New enGene Shares (such
approval by shareholders at a meeting or in writing being an &#147;Ordinary Resolution&#148;). However, some matters require a Special Resolution as described above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If at any time New enGene issues preferred shares, the voting rights attributable to those shares would be prescribed by the New enGene Board
prior to their issuance. As a result, thereafter depending upon the voting rights prescribed for those other classes of shares, an Ordinary Resolution and a Special Resolution of the New enGene Shareholders could include or exclude the votes of the
holders of those other outstanding classes of shares. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to FEAC&#146;s Current Articles, matters requiring approval by
ordinary resolution may be passed by approval of a simple majority members being entitled to vote at a meeting or approval in writing by all members entitled to vote on the matter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to Article 29.4 of the Articles, matters requiring approval by special resolution (whether pursuant to the Cayman Act or FEAC&#146;s
Current Articles) may be passed by approval of not less than two-thirds of members being entitled to vote at a meeting or approval in writing by all members entitled to vote on the matter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If at any time FEAC were to issue another class of shares (for example preferred shares), the voting rights attributable to such shares would
be set out in FEAC&#146;s Current Articles or prescribed by the directors prior to their issuance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Quorum for New enGene Shareholder
Meetings </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FEAC&#146;s Current Articles provide that the presence, in person or by proxy, of the holders of a majority of the
outstanding FEAC Shares will constitute a quorum for the transaction of business at any general meeting of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">236 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
FEAC Shareholders. The Proposed Articles will provide that the quorum for any New enGene Shareholders&#146; meeting will be two persons who are, or who represent by proxy, shareholders who, in
the aggregate, hold at least 33<SUP STYLE="vertical-align:top">1</SUP>&#8260;<SUB STYLE="vertical-align:bottom">3</SUB> of the issued shares entitled to be voted at the meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Directors </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The BCBCA
provides that a public company must have a minimum of three directors but does not impose any residency requirements on the directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Proposed Articles set out the procedure to nominate eligible persons to be elected to the New enGene Board at any annual meeting of
shareholders, or at any special meeting of shareholders if the election of directors is a matter specified in the notice of meeting. The Proposed Articles, will among other things, fix a deadline by which shareholders must notify New enGene of their
intention to nominate directors and set out the information that shareholders must provide in the notice for it to be valid. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Proposed
Articles provide that 1/3rd of the initial directors of New enGene will hold office for a three year term, 1/3rd of the initial directors of New enGene will hold office for a two year term, and 1/3rd of the initial directors of New enGene will hold
office for a one year term. Upon the expiration of the directors&#146; initial term, each director elected at an annual general meeting shall hold office for a three-year term expiring on the third annual general meeting following their election.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Proposed Articles permit the directors of New enGene may appoint one or more additional directors provided that the number of
additional directors does not exceed <FONT STYLE="white-space:nowrap">one-third</FONT> of the number of the current directors who were elected or appointed as directors by the shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FEAC&#146;s Current Articles provide that the minimum number of directors is one (1). The Cayman Act, like the BCBCA, does not impose any
residency requirements on directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FEAC&#146;s Current Articles provide that, prior to the closing of a Business Combination, FEAC may
by ordinary resolution of the holders of the Class&nbsp;B Shares appoint or remove directors. In addition, the directors of FEAC may appoint any person to be a director, either to fill a vacancy or as an additional director provided that the
appointment does not cause the number of directors to exceed any number fixed by or in accordance with FEAC&#146;s Current Articles as the maximum number of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FEAC&#146;s Current Articles provide that, after the closing of a Business Combination, FEAC may by a FEAC Ordinary Resolution appoint any
person to be a director or may by a FEAC Ordinary Resolution remove any director. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similar to the Proposed Articles, FEAC&#146;s Current
Articles provide for the division of the directors into three classes. Following the adoption of FEAC&#146;s Current Articles, the Class&nbsp;I directors were appointed for a term expiring after FEAC&#146;s first annual general meeting, the
Class&nbsp;II directors were appointed for a term expiring after FEAC&#146;s second annual general meeting and the Class&nbsp;III directors were appointed for a term expiring after FEAC&#146;s third annual general meeting. Upon the expiration of the
directors&#146; initial terms, each director elected to succeed those directors whose terms have expired at an annual general meeting shall hold office for three-year terms expiring on the third annual general meeting following their election. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Duties of Directors and Officers </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the BCBCA, in exercising their powers and discharging their duties, directors and officers must act honestly and in good faith, with a
view to the best interests of the company and exercise the care, diligence and skill that a reasonably prudent person would exercise in comparable circumstances. No provision in the company&#146;s notice of articles, articles, resolutions or
contracts can relieve a director or officer of these duties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">237 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Cayman Islands law each director of FEAC owes fiduciary duties to FEAC which may
broadly be characterised as duties of loyalty, honesty and good faith. Such duties are generally owed to FEAC itself but can, very occasionally, be owed directly to creditors or shareholders if there are special factual circumstances. In addition to
the fiduciary duties, each director owes a duty of care, diligence and skill to FEAC. Directors (even where appointed by individual shareholders) are obliged to act in a manner which the director believes to be in the best interests of FEAC as a
whole (even though it may not be in the best interests of the appointing shareholder). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Indemnification of Officers and Directors
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The BCBCA allows a company to indemnify, reimburse and/or advance expenses to a director or former director or officer or former
officer of a company or its affiliates against all liability and expenses reasonably incurred by him in a proceeding to which he is made party by reason of being or having been a director or officer unless he did not act honestly and in good faith
with a view to the best interests of the company or in the case of a proceeding other than a civil proceeding, he did not have reasonable grounds for believing that his conduct was lawful. In addition, the BCBCA requires a company to pay the
expenses actually and reasonably incurred by a director, former director, officer or former officer in respect of a proceeding in which the person is joined as a party or is liable for a judgment, penalty or expenses by reason of being or having
been a director or officer of the company, if the director or officer has not already been reimbursed for such expenses and is wholly successful or substantially successful on the merits in the outcome of the proceeding. Additional details with
respect to the indemnification of directors and officers under the BCBCA and the Proposed Articles are set out in &#147;<I>Part II &#151; Information Not Required in Prospectus.</I>&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Cayman Islands law a company&#146;s articles of association may provide for the indemnification of its directors, officers, employees
and agents except to the extent that such provision may be held by the Cayman Islands courts to be contrary to public policy. For instance, a provision purporting to provide indemnification against the consequences of committing a crime may be
deemed contrary to public policy. In addition, an officer or director may not be indemnified for his or her own fraud, willful neglect or willful default. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to FEAC&#146;s Current Articles, every director and officer (each an &#147;Indemnified Person&#148;) shall be indemnified out of the
assets of FEAC against any liability, action, proceeding, claim, demand, costs, damages or expenses, including legal expenses, whatsoever which they or any of them may incur as a result of any act or failure to act in carrying out their functions
other than such liability (if any) that they may incur by reason of their own actual fraud, wilful neglect or wilful default. No Indemnified Person shall be liable to FEAC for any loss or damage incurred by FEAC as a result (whether direct or
indirect) of the carrying out of their functions unless that liability arises through the actual fraud, wilful neglect or wilful default of such Indemnified Person. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Giving Financial Assistance </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the BCBCA, subject to certain exceptions, a company must disclose in its corporate records and make available to its shareholders, upon
request, a brief description of any material financial assistance, including the nature and extent of the financial assistance given, the terms on which the financial assistance was given and the amount of the financial assistance given, to:
(i)&nbsp;a person known to the company to be a shareholder of, a beneficial owner of a share of, a director of, an officer of or an employee of the company or an Affiliate of the company, (ii)&nbsp;a person known to the company to be an Affiliate of
any such persons, or (iii)&nbsp;any person for the purpose of a purchase by that person of a share issued or to be issued by the company or an Affiliate of the company. The Cayman Act does not provide similar protections or rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">238 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom459793_22"></A>PROPOSAL NO. 3 &#151; THE NASDAQ PROPOSAL </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are proposing the Nasdaq
Proposal in order to comply with Nasdaq Listing Rules 5635(a), (b) and (d). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Nasdaq Listing Rule 5635(a), shareholder approval is
required prior to the issuance of securities in connection with the acquisition of another company (a)&nbsp;where, due to the present or potential issuance of common shares, including shares issued pursuant to
<FONT STYLE="white-space:nowrap">an&nbsp;earn-out&nbsp;provision</FONT> or similar type of provision, or securities convertible into or exercisable for common shares, other than a public offering for cash: (i)&nbsp;the common shares have or will
have upon issuance voting power equal to or in excess of 20% of the voting power outstanding before the issuance of stock or securities convertible into or exercisable for common shares; or (ii)&nbsp;the number of common shares to be issued is or
will be equal to or in excess of 20% of the number of common shares outstanding before the issuance of the stock or securities; or (b)&nbsp;any director, officer or Substantial Shareholder (as defined by Nasdaq Listing Rule 5635(e)(3)) of the
company has a 5% or greater interest (or such persons collectively have a 10% or greater interest), directly or indirectly, in the company or assets to be acquired or in the consideration to be paid in the transaction or series of related
transactions and the present or potential issuance of common shares, or securities convertible into or exercisable for common shares, could result in an increase in outstanding common shares or voting power of 5% or more. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Nasdaq Listing Rule 5635(b), shareholder approval is required prior to the issuance of securities when the issuance or potential
issuance will result in a change of control. Although Nasdaq Listing Rules do not specifically discuss what constitutes a &#147;change of control&#148; for purposes of Rule 5635(b), related guidance with respect to Nasdaq Listing Rule 5635(b) has
indicated that the acquisition of, or right to acquire, by a single investor or affiliated investor group, as little as 20% of the common shares (or securities convertible into or exercisable for common shares) or voting power of an issuer could
constitute a change of control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Nasdaq Listing Rule 5635(d), shareholder approval is required for a transaction other than a public
offering involving the sale, issuance or potential issuance by an issuer of ordinary shares (or securities convertible into or exercisable for ordinary shares) at a price that is less than the lower of (1)&nbsp;the closing price immediately
preceding the signing of the binding agreement or (2)&nbsp;the average closing price of the ordinary shares for the five trading days immediately preceding the signing of the binding agreement, if the number of ordinary shares (or securities
convertible into or exercisable for ordinary shares) to be issued equals 20% or more of the ordinary shares, or 20% or more of the voting power, outstanding before the issuance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, because the number of New enGene Shares to be issued in the PIPE Financing and pursuant to Convertible Bridge Financing
(a)&nbsp;will constitute more than 20% of our outstanding FEAC Class&nbsp;A Shares and more than 20% of outstanding voting power prior to such issuance, (b)&nbsp;may result in a change of control of FEAC and (c)&nbsp;will be deemed an issuance lower
than the average closing price of the five trading days immediately preceding the date of the Business Combination Agreement, we are required to obtain shareholder approval of such issuance pursuant to Nasdaq Listing Rules 5635(a), (b) and (d). For
additional information relating to the PIPE Financing and Convertible Bridge Financing, see &#147;<I>Ancillary Agreements Related to the Business Combination</I> &#151; <I>Subscription Agreements and Side Letter Agreements</I>&#148; and
&#147;<I>Ancillary Agreements Related to the Business Combination</I> &#151; <I>Convertible Bridge Financing</I>.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Effect of Proposal on FEAC
Shareholders </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Nasdaq Proposal is adopted, New enGene would issue New enGene Shares representing more than 20% of the
outstanding FEAC Class&nbsp;A Shares in connection with the PIPE Financing and Convertible Bridge Financing. The issuance of such shares would result in significant dilution to the FEAC Shareholders and would afford such shareholders a smaller
percentage interest in the voting power, liquidation value and aggregate book value of FEAC. If the actual facts are different from the assumptions underlying the no redemption scenario (which they are likely to be), the voting power and implied
ownership of New enGene&#146;s shareholders will be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">239 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
different. For more information regarding post-Business Combination ownership and control, including the effects of various redemption scenarios and potential sources of dilution, see the section
titled &#147;<I></I><I>Proposal No. 1</I><B> &#151; </B><I>The Business Combination Proposal</I><B> &#151; </B><I>Sources and Uses for the Business Combination</I>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Nasdaq Proposal is not approved and we consummate the Business Combination on its current terms, FEAC would be in violation of Nasdaq
Listing Rule 5635(a), (b) and (d), which could result in the delisting of our securities from the Nasdaq Global Market. If Nasdaq delists our securities from trading on its exchange, we could face significant material adverse consequences,
including:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a limited availability of market quotations for our securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced liquidity with respect to our securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">determination that our shares are a &#147;penny stock,&#148; which will require brokers trading in our securities
to adhere to more stringent rules, possibly resulting in a reduced level of trading activity in the secondary trading market for our securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a limited amount of news and analyst coverage for the post-transaction company; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a decreased ability to issue additional securities or obtain additional financing in the future.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is a condition to the obligations of FEAC and enGene to close the Business Combination that New enGene Shares will
be approved for listing on The Nasdaq Stock Market LLC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vote Required for Approval </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The adoption and approval of the Nasdaq Proposal requires the affirmative vote of the holders of at least a majority of the FEAC Shares present
in person or represented by proxy and entitled to vote at the Special Meeting. Abstentions will have no effect on the outcome of the proposal. The Business Combination cannot be completed unless the Nasdaq Proposal is adopted by affirmative vote of
the holders of at least a majority of the votes cast by FEAC Shareholders present or represented by proxy at the Special Meeting and entitled to vote thereon. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Resolution </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The full text of the
resolution to be voted upon is as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;RESOLVED, as an ordinary resolution, that, for the purposes of complying with the
applicable provisions of Nasdaq Listing Rule 5635(a) and (b), the issuance of New enGene Shares pursuant to the PIPE Financing and Convertible Bridge Financing be approved in all respects.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Recommendation of FEAC Board </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THE FEAC BOARD RECOMMENDS THAT THE FEAC SHAREHOLDERS VOTE &#147;FOR&#148; THE NASDAQ PROPOSAL. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The existence of financial and personal interests of FEAC&#146;s directors may result in a conflict of interest on the part of one or more of
the directors between what they may believe is in the best interests of FEAC and its shareholders and what they may believe is best for themselves in determining to recommend that shareholders vote for the proposals. See the section entitled
&#147;<I>Proposal No.</I><I></I><I>&nbsp;1 &#151; The Business Combination Proposal &#151; Interests of FEAC&#146;s Sponsor, Directors and Executive Officers in the Business Combination</I>&#148; for a further discussion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">240 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom459793_23"></A>PROPOSAL NO. 4 &#151; THE INCENTIVE EQUITY PLAN PROPOSAL
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FEAC is asking FEAC
Shareholders to vote upon a proposal to approve the enGene Holdings Inc. 2023 Incentive Equity Plan (the &#147;Incentive Equity Plan&#148;), including the authorization of the initial share reserve under the Incentive Equity Plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Purpose of the Incentive Equity Plan </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
purpose of the Incentive Equity Plan is to attract and retain <FONT STYLE="white-space:nowrap">employees,&nbsp;non-employee&nbsp;directors,</FONT> and certain consultants and advisors of enGene. The Incentive Equity Plan provides for the issuance of
incentive stock <FONT STYLE="white-space:nowrap">options,&nbsp;non-qualified&nbsp;stock</FONT> options, stock appreciation rights, share awards, share units, and other <FONT STYLE="white-space:nowrap">share-based</FONT> awards. The Incentive Equity
Plan is intended to provide an incentive to participants to contribute to the growth of New enGene by aligning the economic interests of participants with those of the shareholders of New enGene. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Business Combination, the amended and restated equity incentive plan of enGene dated June&nbsp;30, 2021, and as may be
further amended and/or restated from time to time, and each other plan that provides for the award to any current or former director, manager, officer, employee, individual independent contractor or other individual service provider of New enGene,
enGene and any of their subsidiaries (the &#147;Group Company&#148;) of rights of any kind to receive equity securities of any Group Company or benefits measured in whole or in part by reference to equity securities of any Group Company (the
&#147;Prior Plans&#148;) will be converted and exchanged into rights to acquire shares of New enGene pursuant to the Business Combination, with such equity security rights to be merged into and converted into grants under the Incentive Equity Plan.
No additional grants shall be made under the Prior Plans after the effective date of the Incentive Equity Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Requested Share Authorization </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Incentive Equity Plan authorizes the compensation committee of the New enGene Board to provide incentive compensation in the form of stock
options, restricted shares and share units, performance shares and units, other share-based awards, and cash-based awards. Subject to adjustment as described below, New enGene will be authorized to issue or transfer up to approximately 4,392,533 New
enGene Shares under the Incentive Equity Plan. This authorized amount represents the sum of (i)&nbsp;approximately 6.7% of the fully diluted capitalization of New enGene after giving effect to the Business Combination (the &#147;Base Amount&#148;),
plus (ii)&nbsp;the number of New enGene Shares necessary to permit the exercise of all vested options to acquire enGene Common Shares that were granted under the Prior Plans and that are being assumed by New enGene in connection with the
Amalgamation and converted into options to acquire New enGene Shares. The aggregate number of New enGene Shares that may be issued or transferred under the Incentive Equity Plan pursuant to incentive stock options shall not exceed Base Amount. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary of the Incentive Equity Plan </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following is a summary of the material features of the Incentive Equity Plan. This summary is qualified in its entirety by the full text of the Incentive Equity Plan, a copy of which is included as Exhibit G to <B><U>Annex&nbsp;A</U></B> to this
proxy statement/prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Type of Awards </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Incentive Equity Plan provides for the issuance of stock options
<FONT STYLE="white-space:nowrap">(including&nbsp;non-statutory&nbsp;stock</FONT> options and incentive stock options), stock appreciation rights (&#147;SARs&#148;), restricted shares, restricted share units and other
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">241 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
share-based awards to <FONT STYLE="white-space:nowrap">employees,&nbsp;non-employee&nbsp;directors,</FONT> and certain consultants and advisors of New enGene or its subsidiaries. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Administration </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Incentive Equity Plan will be administered by the compensation committee of the New enGene Board or another committee appointed by the New enGene Board to administer the Incentive Equity Plan (and to the extent the New enGene Board does not appoint
a committee, the New enGene Board will serve as the committee) (for purposes of this Proposal No.&nbsp;4, the &#147;Committee&#148;); provided that any grants to members of the New enGene Board must be authorized by a majority of the New enGene
Board (counting all the New enGene Board members for purposes of a quorum, but only <FONT STYLE="white-space:nowrap">non-interested</FONT> New enGene Board members for purposes of such majority approval). The Committee (if other than the full New
enGene Board) must consist of directors who are <FONT STYLE="white-space:nowrap">&#147;non-employee</FONT> directors&#148; as defined under Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act and &#147;independent
directors,&#148; as determined in accordance with the independence standards established by the stock exchange on which the New enGene Shares is at the time primarily traded. The Committee may delegate authority under the Incentive Equity Plan to
one or more subcommittees as it deems appropriate. Subject to compliance with applicable law and stock exchange requirements, so long as the Chief Executive Officer is also a director on the New enGene Board, the Committee may delegate all or part
of its authority to the Chief Executive Officer (or if there is none then appointed, the President), as it deems appropriate, with respect to grants to employees or consultants who are not executive officers under Section&nbsp;16 of the Exchange
Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Committee will have full power and express discretionary authority to administer and interpret the Incentive Equity Plan, to
make factual determinations, and to adopt or amend such rules, regulations, agreements, and instruments for implementing the Incentive Equity Plan and for the conduct of its business as it deems necessary or advisable, in its sole discretion. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Shares Subject to the Incentive Equity Plan </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to adjustment, the Incentive Equity Plan authorizes the issuance or transfer of up to (i) the Base Amount, plus (ii)&nbsp;the number of
New enGene Shares necessary to permit the exercise of all vested options to acquire enGene Common Shares that were granted under the Prior Plans and that are being assumed by New enGene in connection with the Amalgamation and converted into options
to acquire New enGene Shares. FEAC estimates that the aggregate number of New enGene Shares that will be subject to the Incentive Equity Plan will be approximately 4,392,533&nbsp;million. The New enGene Shares issued pursuant to incentive stock
options shall not exceed the Base Amount. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Incentive Equity Plan contains an evergreen provision, pursuant to which, commencing
with the first business day of each calendar year beginning in 2024, the aggregate number of New enGene Shares that may be issued or transferred under the Incentive Equity Plan will be increased by a number of New enGene Shares equal to the lesser
of (x) 5% of the fully diluted capitalization of New enGene after giving effect to the Business Combination, or (y)&nbsp;such lesser number of shares as may be determined by the Committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any options or SARs granted under the Incentive Equity Plan (including options or SARs granted under the Prior Plans) expire or are
canceled, forfeited, exchanged, or surrendered without having been exercised, or if any share awards, share units, or other share-based awards granted under the Incentive Equity Plan (including options or SARs granted under the Prior Plans) are
forfeited, terminated, or otherwise not paid in full, the New enGene Shares subject to such awards will again be available for purposes of the Incentive Equity Plan. If New enGene Shares are surrendered in payment of the exercise price of an option,
the number of New enGene Shares available for issuance under the Incentive Equity Plan will be reduced only by the net number of shares actually issued by New enGene upon such exercise and not by the gross number of shares as to which such option is
exercised. Upon the exercise of any SAR under the Incentive Equity Plan, the number of New enGene Shares available for issuance will be reduced only by the net number of shares actually issued by New enGene upon such exercise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">242 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If New enGene Shares are withheld by New enGene in satisfaction of the withholding taxes
incurred in connection with the issuance, vesting or exercise of any grant or the issuance of New enGene Shares under the Incentive Equity Plan, the number of New enGene Shares available for issuance will be reduced by the net number of shares
issued, vested, or exercised under such grant, calculated in each instance after payment of such share withholding. If any awards are paid in cash, and not in New enGene Shares, any New enGene Shares subject to such awards will also be available for
future awards. If New enGene repurchases New enGene Shares on the open market with the proceeds from the exercise price New enGene receives from options, the repurchased shares will not be available for issuance under the Incentive Equity Plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Individual Limits for <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The maximum aggregate grant date value of New enGene Shares granted to any <FONT STYLE="white-space:nowrap">non-employee</FONT> director in any
one calendar year, taken together with any cash fees earned by such <FONT STYLE="white-space:nowrap">non-employee</FONT> director for services rendered during the calendar year, shall not exceed $500,000 in total value; provided, however, that with
respect to the year during which a <FONT STYLE="white-space:nowrap">non-employee</FONT> director is first appointed or elected to the New enGene Board, the maximum aggregate grant date value of New enGene Shares granted to such <FONT
STYLE="white-space:nowrap">non-employee</FONT> director, taken together with any cash fees earned by such <FONT STYLE="white-space:nowrap">non-employee</FONT> director for services rendered during such period, shall not exceed $750,000 in total
value during the initial annual period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Adjustments </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with stock splits, stock dividends, recapitalizations, and certain other events affecting New enGene Shares, the Committee will
make adjustments as it deems appropriate in: the maximum number of New enGene Shares reserved for issuance as grants; the maximum amount of awards that may be granted to any individual <FONT STYLE="white-space:nowrap">non-employee</FONT> director in
any year; the number and kind of shares covered by outstanding grants; the number and kind of shares that may be issued under the Incentive Equity Plan; the price per share or market value of any outstanding grants; the exercise price of options;
the base amount of SARs; and the performance goals or other terms and conditions as the Committee deems appropriate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Eligibility and
Vesting </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of the employees and <FONT STYLE="white-space:nowrap">non-employee</FONT> directors of New enGene will be eligible to
receive grants under the Incentive Equity Plan. In addition, consultants who perform certain services for New enGene may receive grants under the Incentive Equity Plan. The Committee will (i)&nbsp;select the employees,
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors, and consultants to receive grants and (ii)&nbsp;determine the number of New enGene Shares subject to a particular grant and the vesting and exercisability terms of awards granted under
the Incentive Equity Plan. As of the Closing Date, all employees (28 as of May 31, 2023) and six <FONT STYLE="white-space:nowrap">non-employee</FONT> directors would be eligible to participate in the Incentive Equity Plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Options </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the
Incentive Equity Plan, the Committee will determine the exercise price of the options granted and may grant options to purchase New enGene Shares in such amounts as it determines. The Committee may grant options that are intended to qualify as
incentive stock options under Section&nbsp;422 of the Code, or <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock options, which are not intended to so qualify. Incentive stock options may only be granted to employees. Anyone eligible to
participate in the Incentive Equity Plan may receive a grant of <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock options. The exercise price of a stock option granted under the Incentive Equity Plan cannot be less than the fair market
value of a New enGene Share on the date the option is granted. If an incentive stock option is granted to a 10% shareholder of the total combined voting power of all classes of New enGene securities, the exercise price cannot be less than 110% of
the fair market value of a New enGene Share on the date the option is granted. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">243 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The exercise price for any option is generally payable in cash. In certain circumstances as
permitted by the Committee, the exercise price may be paid: by the surrender of New enGene Shares with an aggregate fair market value, on the date the option is exercised, equal to the exercise price; by payment through a broker in accordance with
procedures established by the Federal Reserve Board; by, solely with respect to <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock options, New enGene Shares subject to the exercisable option that have a fair market value on the date of
exercise equal to the aggregate exercise price; or by such other method as the Committee approves. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term of an option cannot exceed 10
years from the date of grant, except that if an incentive stock option is granted to a 10% shareholder of the total combined voting power of all class of New enGene securities, the term cannot exceed five years from the date of grant. In the event
that on the last day of the term of a <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock option, the exercise is prohibited by applicable law, including a prohibition on purchases or sales of New enGene Shares under the New enGene insider
trading policy, or pursuant to any restrictions on transfer imposed by the Committee, the term of the <FONT STYLE="white-space:nowrap">non-qualified</FONT> option will be extended for a period of 30 days following the end of the legal prohibition,
or until the expiration of such restrictions on transfer, unless the Committee determines otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as provided in the grant
instrument, an option may only be exercised while a participant is employed by or providing service to us. The Committee will determine in the grant instrument under what circumstances and during what time periods a participant may exercise an
option after termination of employment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Share Awards </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Incentive Equity Plan, the Committee may grant share awards. A share award is an award of New enGene Shares that may be subject to
restrictions as the Committee determines. The restrictions, if any, may lapse over a specified period of employment or based on the satisfaction of <FONT STYLE="white-space:nowrap">pre-established</FONT> criteria, in installments or otherwise, as
the Committee may determine, including, but not limited to, restrictions based on the achievement of performance goals. Except to the extent restricted under the grant instrument relating to the share award, a participant will have all of the rights
of a shareholder as to those shares, including the right to vote and the right to receive dividends or distributions on the shares. Dividends with respect to share awards that vest based on performance shall vest if and to the extent that the
underlying share award vests, as determined by the Committee. All unvested share awards are forfeited if the participant&#146;s employment or service is terminated for any reason, unless the Committee determines otherwise. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Share Units </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the
Incentive Equity Plan, the Committee may grant share units to anyone eligible to participate in the Incentive Equity Plan. Share units represent hypothetical New enGene Shares. Share units become payable on terms and conditions determined by the
Committee, including specified performance goals, and will be payable in cash, New enGene Shares, or a combination thereof, as determined by the Committee. All unvested share units are forfeited if the participant&#146;s employment or service is
terminated for any reason, unless the Committee determines otherwise. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Stock Appreciation Rights </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Incentive Equity Plan, the Committee may grant SARs, which may be granted separately or in tandem with any option. SARs granted in
tandem with a <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock option may be granted either at the time the <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock option is granted or any time thereafter while the option remains
outstanding. SARs granted in tandem with an incentive stock option may be granted only at the time the grant of the incentive stock option is made. The Committee will establish the base amount of the SAR at the time the SAR is granted, which will be
equal to or greater than the fair market value of a New enGene Share as of the date of grant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">244 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a SAR is granted in tandem with an option, the number of SARs that are exercisable during
a specified period will not exceed the number of New enGene Shares that the participant may purchase upon exercising the related option during such period. Upon exercising the related option, the related SARs will terminate, and upon the exercise of
a SAR, the related option will terminate to the extent of an equal number of New enGene Shares. Generally, SARs may only be exercised while the participant is employed by, or providing services to, us. When a participant exercises a SAR, the
participant will receive the excess of the fair market value of the underlying New enGene Shares over the base amount of the SAR. The appreciation of a SAR will be paid in New enGene Shares, cash, or both. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term of a SAR cannot exceed 10 years from the date of grant. In the event that on the last day of the term of a SAR, the exercise is
prohibited by applicable law, including a prohibition on purchases or sales of New enGene Shares under New enGene&#146;s insider trading policy, or pursuant to any restrictions on transfer imposed by the Committee, the term of the SAR will be
extended for a period of 30 days following the end of the legal prohibition, or until the expiration of such restrictions on transfer, unless the Committee determines otherwise. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Other Share-Based Awards </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Incentive Equity Plan, the Committee may grant other types of awards that are based on, or measured by, New enGene Shares, and
granted to anyone eligible to participate in the Incentive Equity Plan. The Committee will determine the terms and conditions of such awards. Other share-based awards may be payable in cash, New enGene Shares or a combination of the two, as
determined by the Committee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Dividend Equivalents </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Incentive Equity Plan, the Committee may grant dividend equivalents in connection with grants of share units or other share-based
awards made under the Incentive Equity Plan. Dividend equivalents entitle the participant to receive amounts equal to ordinary dividends that are paid on the shares underlying a grant while the grant is outstanding. The Committee will determine
whether dividend equivalents will be paid currently or accrued as contingent cash obligations. Dividend equivalents may be paid in cash New enGene Shares. The Committee will determine the terms and conditions of the dividend equivalent grants,
including whether the grants are payable upon the achievement of specific performance goals. Dividend equivalents with respect to share units or other share-based awards that vest based on performance shall vest and be paid only if and to the extent
that the underlying share units or other share-based awards vest and are paid as determined by the Committee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Change of Control
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If New enGene experiences a change of control where New enGene is not the surviving company (or survives only as a subsidiary of
another company), unless the Committee determines otherwise, all outstanding grants that are not exercised or paid at the time of the change of control will be assumed, or replaced with grants (with respect to cash, securities or a combination
thereof) that have comparable terms, by the surviving company (or a parent or subsidiary of the surviving company). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If there is a change
of control and all outstanding grants are not assumed, or replaced with grants that have comparable terms, by the surviving company, the Committee may (but is not obligated to) make adjustments to the terms and conditions of outstanding grants,
including, without limitation, taking any of the following actions (or combination thereof) without the consent of any participant: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">determine that outstanding options and SARs will accelerate and become fully exercisable and the restrictions and
conditions on outstanding share awards, share units, and dividend equivalents immediately lapse; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pay participants, in an amount and form determined by the Committee, in settlement of outstanding share units or
dividend equivalents; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">245 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require that participants surrender their outstanding stock options and SARs in exchange for a payment by us, in
cash or New enGene Shares, equal to the difference between the exercise price and the fair market value of the underlying New enGene Shares; provided, however, if the per share fair market value of New enGene Shares does not exceed the per share
stock option exercise price or SARs base amount, as applicable, New enGene will not be required to make any payment to the participant upon surrender of the stock option or SAR and shall have the right to cancel any such option or SAR for no
consideration; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">after giving participants an opportunity to exercise all of their outstanding stock options and SARs, terminate
any unexercised stock options and SARs on the date determined by the Committee. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general terms, a change of control
under the Incentive Equity Plan occurs if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a person, entity or affiliated group, with certain exceptions, acquires more than 50% of the <FONT
STYLE="white-space:nowrap">then-outstanding</FONT> voting securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">New enGene merges into, or consummates an amalgamation or arrangement with, another entity unless the holders of
voting shares immediately prior to such transaction have at least 50% of the combined voting power of the securities in the combined entity or its parent; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">New enGene merges into, or consummates an amalgamation or arrangement with, another entity and the members of the
New enGene Board prior to such transaction would not constitute a majority of the board of the combined entity or its parent; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">New enGene sells or disposes of all or substantially all of the assets of New enGene; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">New enGene consummates a complete liquidation or dissolution; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a majority of the members of the New enGene Board are replaced during any
<FONT STYLE="white-space:nowrap">12-month</FONT> period by directors whose appointment or election is not endorsed by a majority of the incumbent directors. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Deferrals </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Committee
may permit or require participants to defer receipt of the payment of cash or the delivery of New enGene Shares that would otherwise be due to the participant in connection with a grant under the Incentive Equity Plan. The Committee will establish
the rules and procedures applicable to any such deferrals, consistent with the requirements of Section&nbsp;409A of the Code. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Withholding </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All grants
under the Incentive Equity Plan are subject to applicable U.S. federal (including taxes under FICA), state, and local, foreign or other tax withholding requirements. New enGene may require participants or other persons receiving grants or exercising
grants to pay an amount sufficient to satisfy such tax withholding requirements with respect to such grants, or New enGene may deduct from other wages and compensation paid by New enGene the amount of any withholding taxes due with respect to such
grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Committee may permit or require that tax withholding obligation with respect to grants paid in New enGene Shares be paid by
having shares withheld up to an amount that does not exceed the participant&#146;s minimum applicable withholding tax rate for U.S. federal (including FICA), state, and local tax liabilities, or as otherwise determined by the Committee. In addition,
the Committee may, in its discretion, and subject to such rules as the Committee may adopt, allow participants to elect to have such share withholding applied to all or a portion of the tax withholding obligation arising in connection with any
particular grant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">246 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Transferability </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as permitted by the Committee with respect to <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock options, only a participant
may exercise rights under a grant during the participant&#146;s lifetime. Upon death, the personal representative or other person entitled to succeed to the rights of the participant may exercise such rights. A participant cannot transfer those
rights except by will or by the laws of descent and distribution or, with respect to grants other than incentive stock options, pursuant to a domestic relations order. The Committee may provide in a grant instrument that a participant may transfer <FONT
STYLE="white-space:nowrap">non-qualified</FONT> stock options for no consideration to a permitted assign in compliance with applicable securities laws. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Amendment; Termination </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The New enGene Board may amend or terminate the Incentive Equity Plan at any time, except that New enGene Shareholders must approve an
amendment if such approval is required in order to comply with the Code, applicable laws or applicable stock exchange requirements. Unless terminated sooner by the New enGene Board or extended with shareholder approval, the Incentive Equity Plan
will terminate on the day immediately preceding the tenth anniversary of the effective date of the Incentive Equity Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Shareholder
Approval </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except in connection with certain corporate transactions, including stock dividends, stock splits, a recapitalization, a
change in control, a reorganization, a merger, an amalgamation, a consolidation, and a <FONT STYLE="white-space:nowrap">spin-off,</FONT> shareholder approval is required (i)&nbsp;to reduce the exercise price or base price of outstanding stock
options or SARs, (ii)&nbsp;to cancel outstanding stock options or SARs in exchange for the same type of grant with a lower exercise price or base price, and (iii)&nbsp;to cancel outstanding stock options or SARs that have an exercise price or base
price above the current price of a New enGene Share, in exchange for cash or other securities, each as applicable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Establishment of <FONT
STYLE="white-space:nowrap">Sub-Plans</FONT> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The New enGene Board may, from time to time, establish one or more <FONT
STYLE="white-space:nowrap">sub-plans</FONT> under the Incentive Equity Plan to satisfy applicable blue sky, securities or tax laws of various jurisdictions outside the United States or Canada. The New enGene Board may establish such <FONT
STYLE="white-space:nowrap">sub-plans</FONT> by adopting supplements to the Incentive Equity Plan setting forth limitations on the Committee&#146;s discretion and such additional terms and conditions not otherwise inconsistent with the Incentive
Equity Plan as the New enGene Board deems necessary or desirable. All such supplements will be deemed part of the Incentive Equity Plan, but each supplement will only apply to participants within the affected jurisdiction, and New enGene will not be
required to provide copies of any supplement to such unaffected participants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Clawback </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All grants under the Incentive Equity Plan (including any proceeds, gains or other economic benefit actually or constructively received upon
receipt of any grant or receipt or resale of any New enGene Shares underlying the grant) will be subject to any applicable policies implemented by the New enGene Board, which may be adopted in future and be amended from time to time, including any
clawback or recoupment policies and share trading policies.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Performance Measures </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Incentive Equity Plan, the grant, vesting, exercisability or payment of certain awards, or the receipt of New enGene Shares subject
to certain awards, may be made subject to the satisfaction of performance measures. The performance goals applicable to a particular award will be determined by the Committee at the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">247 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
time of grant. One or more of the following business criteria for New enGene may be used by the Committee in establishing performance measures under the Incentive Equity Plan: cash flow; free
cash flow; earnings (including gross margin, earnings before interest and taxes, earnings before taxes, earnings before interest, taxes, depreciation, amortization and charges for share-based compensation, earnings before interest, taxes,
depreciation and amortization, adjusted earnings before interest, taxes, depreciation and amortization and net earnings); earnings per share; growth in earnings or earnings per share; book value growth; share price; return on equity or average
shareholder equity; total shareholder return or growth in total shareholder return either directly or in relation to a comparative group; return on capital; return on assets or net assets; revenue, growth in revenue or return on sales; sales;
expense reduction or expense control; expense to revenue ratio; income, net income or adjusted net income; operating income, net operating income, adjusted operating income or net operating income after tax; operating profit or net operating profit;
operating margin; gross profit margin; return on operating revenue or return on operating profit; regulatory filings; regulatory approvals, litigation and regulatory resolution goals; other operational, regulatory or departmental objectives; budget
comparisons; growth in shareholder value relative to established indexes, or another peer group or peer group index; development and implementation of strategic plans and/or organizational restructuring goals; development and implementation of risk
and crisis management programs; improvement in workforce diversity; compliance requirements and compliance relief; safety goals; productivity goals; workforce management and succession planning goals; economic value added (including typical
adjustments consistently applied from generally accepted accounting principles required to determine economic value added performance measures); measures of customer satisfaction, employee satisfaction or staff development; development or marketing
collaborations, formations of joint ventures or partnerships or the completion of other similar transactions intended to enhance the New enGene&#146;s revenue or profitability or enhance its customer base; merger and acquisitions; and other similar
criteria as determined by the Committee. Performance goals may be established on an absolute or relative basis and may be established on a corporate-wide basis or with respect to one or more business units, divisions, subsidiaries or business
segments. Relative performance may be measured against a group of peer companies, a financial market index or other objective and quantifiable indices. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary of U.S. Federal Income Tax Consequences </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of certain U.S. federal income tax consequences of awards under the Incentive Equity Plan. It does not purport to be
a complete description of all applicable rules, and those rules (including those summarized here) are subject to change. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Options
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An optionee generally will not recognize taxable income upon the grant of a <FONT STYLE="white-space:nowrap">non-statutory</FONT>
option. Rather, at the time of exercise of the option, the optionee will recognize ordinary income for income tax purposes in an amount equal to the excess, if any, of the fair market value of vested shares purchased over the exercise price. New
enGene generally will be entitled to a tax deduction at such time and in the same amount, if any, that the optionee recognizes as ordinary income. The optionee&#146;s tax basis in any shares received upon exercise of an option will be the exercise
price paid plus the amount of compensation recognized by the participant as ordinary income (generally, fair market value of the shares on the date of exercise), and if the shares are later sold or exchanged, then the difference between the amount
received upon such sale or exchange and the fair market value of such shares on the date of exercise will generally be taxable as long-term or short-term capital gain or loss (if the shares are a capital asset of the optionee) depending upon the
length of time such shares were held by the optionee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Incentive stock options are eligible for favorable U.S. federal income tax
treatment if certain requirements are satisfied. An incentive stock option must have an option price that is not less than the fair market value of the stock at the time the option is granted, and must not be exercisable after the expiration of 10
years from the date of grant; further restrictions apply to employees who are <FONT STYLE="white-space:nowrap">greater-than-10%</FONT> shareholders. An employee granted an incentive stock option generally does not realize compensation income for
U.S. federal income tax purposes upon </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">248 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the grant of the option. At the time of exercise of an incentive stock option, no compensation income is realized by the optionee other than tax preference income for purposes of the federal
alternative minimum tax on individual income. If the shares acquired on exercise of an incentive stock option are held for at least two years after grant of the option and one year after exercise, then (i)&nbsp;the excess (if any) of the amount
realized on the disposition over the exercise price will be taxed as capital gain and (ii)&nbsp;the amount (if any) by which the exercise price exceeds the amount realized upon the disposition will be treated as capital loss. If the shares acquired
on exercise of an incentive stock option are disposed of within less than two years after grant or one year of exercise, the optionee will realize taxable compensation income in the year of the disposition equal to the lesser of (i)&nbsp;the excess
of the fair market value of the shares on the date of exercise over the option price or (ii)&nbsp;the excess of the amount realized on the disposition over the option price, and New enGene generally will be entitled to a tax deduction in such
amount. Any additional amount realized will be taxed as capital gain. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Share Awards </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A participant generally will not be taxed upon the grant of share awards subject to restrictions, but rather will recognize ordinary income in
an amount equal to the fair market value of the shares at the time the shares are no longer subject to a &#147;substantial risk of forfeiture&#148; (within the meaning of the Code). New enGene generally will be entitled to a deduction at the time
when, and in the amount that, the participant recognizes ordinary income on account of the lapse of the restrictions. A participant&#146;s tax basis in the shares will equal their fair market value at the time the restrictions lapse, and the
participant&#146;s holding period for capital gains purposes will begin at that time. Any cash dividends paid on the restricted shares before the restrictions lapse will be taxable to the participant as additional compensation (and not as dividend
income). Under Section&nbsp;83(b) of the Code, a participant may elect to recognize ordinary income at the time the shares are awarded in an amount equal to their fair market value at that time (less any amount paid by the participant for the
shares), notwithstanding the fact that such shares are subject to restrictions and a substantial risk of forfeiture. If such an election is made, no additional taxable income will be recognized by such participant at the time the restrictions lapse,
the participant will have a tax basis in the shares equal to their fair market value on the date of their award, and the participant&#146;s holding period for capital gains purposes will begin at that time. New enGene generally will be entitled to a
tax deduction at the time when, and to the extent that, ordinary income is recognized by such participant. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Share Units </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, the grant of share units will not result in income for the participant or in a tax deduction for us. Upon the settlement of such an
award in cash or shares, the participant will recognize ordinary compensation income equal to the aggregate value of the payment received, and New enGene generally will be entitled to a tax deduction at the same time and in the same amount. A gain
or loss recognized upon a subsequent sale or exchange of the shares (if settled in shares) is treated as capital gain or loss for which New enGene will not be entitled to a deduction. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Stock Appreciation Rights (SARs) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A participant who is granted a SAR generally will not recognize ordinary income upon receipt of the SAR. Rather, at the time of exercise of
such SAR, the participant will recognize ordinary income for U.S. federal income tax purposes in an amount equal to the value of any cash received and the fair market value on the date of exercise of any shares received. New enGene generally will be
entitled to a tax deduction at such time and in the same amount, if any, that the participant recognizes as ordinary income. The participant&#146;s tax basis in any shares received upon exercise of a SAR will be the fair market value of the shares
on the date of exercise, and if the shares are later sold or exchanged, then the difference between the amount received upon such sale or exchange and the fair market value of such shares on the date of exercise will generally be taxable as
long-term or short-term capital gain or loss (if the shares are a capital asset of the participant) depending upon the length of time such shares were held by the participant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">249 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Other Awards </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to other share-based awards granted under the Incentive Equity Plan (including, e.g., dividend equivalents), generally when the
participant receives payment with respect to an award, the amount of cash and/or the fair market value of any shares or other property received in excess of the amount paid (if any) will be ordinary income to the participant, and New enGene
generally will be entitled to a tax deduction at the same time and in the same amount. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>New Plan Benefits </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Future benefits under the Incentive Equity Plan generally will be granted at the discretion of the Committee and are therefore not currently
determinable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Compensation Plan Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the consummation of the Business Combination, FEAC has no equity compensation plans or outstanding equity awards. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration with the SEC </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the
Incentive Equity Plan is approved by FEAC Shareholders and becomes effective, New enGene intends to file a registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> registering the shares reserved for issuance under the Incentive
Equity Plan as soon as reasonably practicable after New enGene becomes eligible to use such form. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vote Required for Approval </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The adoption and approval of the Incentive Equity Plan Proposal requires the affirmative vote of the holders of at least a majority of the FEAC
Shares present in person or represented by proxy and entitled to vote at the Special Meeting. Abstentions will have no effect on the outcome of the proposal. The Business Combination cannot be completed unless the Incentive Equity Plan Proposal is
adopted by affirmative vote of the holders of at least a majority of the votes cast by FEAC Shareholders present or represented by proxy at the Special Meeting and entitled to vote thereon. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Resolution to be Voted Upon </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The full
text of the resolution to be passed is as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;RESOLVED, as an ordinary resolution, that the enGene Holdings Inc. 2023
Incentive Equity Plan, a copy of which is attached to the proxy statement/prospectus as Exhibit G to <B><U>Annex A</U></B>, be adopted and approved.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recommendation of the FEAC Board </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THE
FEAC BOARD RECOMMENDS THAT FEAC SHAREHOLDERS VOTE &#147;FOR&#148; THE APPROVAL OF THE INCENTIVE EQUITY PLAN PROPOSAL. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The existence
of financial and personal interests of FEAC&#146;s directors may result in a conflict of interest on the part of one or more of the directors between what they may believe is in the best interests of FEAC and its shareholders and what they may
believe is best for themselves in determining to recommend that shareholders vote for the proposals. See the section entitled &#147;<I>Proposal No.</I><I></I><I>&nbsp;1 </I><B><I>&#151;</I></B><I> The Business Combination Proposal &#151; Interests
of FEAC</I><I>&#146;</I><I>s Sponsor, Directors and Executive Officers in the Business Combination</I>&#148; for a further discussion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">250 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom459793_24"></A>PROPOSAL NO. 5 &#151; THE ADJOURNMENT PROPOSAL </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Adjournment Proposal, if adopted, will allow the FEAC Board to adjourn, at their sole discretion, the Special Meeting, or any postponement
thereof, to a later date or dates, if necessary. In no event will FEAC solicit proxies to adjourn the Special Meeting or consummate the Business Combination beyond the date by which it may properly do so under its Current Articles and Cayman Islands
law. The purpose of the Adjournment Proposal is to provide more time for the FEAC officers, directors, initial shareholders, enGene, and the enGene Shareholders to make purchases of public shares or other arrangements that would increase the
likelihood of obtaining a favorable vote on the Business Combination proposal and to meet the requirements that are necessary to consummate the Business Combination, See the section titled &#147;<I>Proposal No.</I><I></I><I>&nbsp;1 </I><B><I>&#151;
</I></B><I>The</I> <I>Business Combination</I> <I>Proposal &#151; Interests of FEAC&#146;s Sponsor, Directors and Executive Officers in the Business Combination</I>.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consequences If the Adjournment Proposal Is Not Approved </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Adjournment Proposal is presented to the meeting and is not approved by the FEAC Shareholders, the FEAC Board may not be able to adjourn
the Special Meeting to a later date or dates. In such event, the Business Combination may not be completed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vote Required for Approval </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The adoption and approval of the Adjournment Proposal requires the affirmative vote of the holders of at least a majority of the FEAC Shares
present in person or represented by proxy and entitled to vote at the Special Meeting. Abstentions will have no effect on the outcome of the proposal. The Business Combination cannot be completed unless the Adjournment Proposal is adopted by
affirmative vote of the holders of at least a majority of the votes cast by FEAC Shareholders present or represented by proxy at the Special Meeting and entitled to vote thereon. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THE FEAC BOARD OF DIRECTORS RECOMMENDS THAT FEAC SHAREHOLDERS VOTE &#147;FOR&#148; THE APPROVAL OF THE ADJOURNMENT PROPOSAL. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">251 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom459793_25"></A>UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION
</B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following unaudited pro forma condensed combined balance sheet as of April&nbsp;30, 2023 and the unaudited pro forma
condensed combined statements of operations for the six months ended April&nbsp;30, 2023 and for the fiscal year ended October&nbsp;31, 2022 present the combination of the financial information of FEAC, New enGene and enGene, after giving effect to
the Transactions, including Business Combination, PIPE Financing, the <FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreement, the Convertible Bridge Financing, the Working Capital Loans, the Sponsor and Insiders Letter Agreement, and the
Extension Loan and related adjustments described in the accompanying notes. Subsequent to the Business Combination, FEAC, New enGene and enGene are collectively referred to herein as the &#147;Combined Company.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FEAC is a blank check company incorporated on August&nbsp;9, 2021, as a Cayman Islands exempted company for the purpose of effecting a merger,
share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. Prior to executing the Business Combination Agreement, FEAC&#146;s efforts were limited to organizational
activities, completion of its IPO and the evaluation of possible business combinations. As of March&nbsp;31, 2023, there was $132.9&nbsp;million in investments and cash held in the Trust Account and $474,437 of cash held outside the Trust Account
available for general corporate purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">enGene Inc., is a clinical-stage biotechnology company developing <FONT
STYLE="white-space:nowrap">non-viral</FONT> gene therapies based on localized delivery of nucleic acid payloads to mucosal tissues. enGene&#146;s proprietary DDX platform has a high degree of payload flexibility, including DNA and various forms of
RNA with broad tissue and disease application. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined balance sheet as of April&nbsp;30, 2023,
reflects adjustments that depict the accounting of the Transactions as if they had been consummated on April&nbsp;30, 2023. The unaudited pro forma condensed combined statements of operations for the six months ended April&nbsp;30, 2023 and the
fiscal year ended October&nbsp;31, 2022, give pro forma effect to the Transactions as if they had occurred on November&nbsp;1, 2021, which is the beginning of the earliest period presented. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial information are based on and should be read in conjunction with the historical financial
statements of each of FEAC, New enGene, and enGene and the notes thereto, as well as the disclosures contained in the sections titled &#147;<I>FEAC&#146;s Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations,</I>&#148; and &#147;<I>enGene&#146;s Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</I>&#148; included elsewhere in this proxy statement/prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial statements have been presented for illustrative purposes only and do not necessarily
reflect what the Combined Company&#146;s financial condition or results of operations would have been had the Transactions occurred on the dates indicated, nor are they indicative of the future consolidated results of operations or financial
position of the Combined Company. The actual financial position and results of operations may differ significantly from the pro forma amounts reflected herein due to a variety of factors. The unaudited pro forma adjustments represent
management&#146;s estimates based on information available as of the date of these unaudited pro forma condensed combined financial statements and are subject to change as additional information becomes available and analyses are performed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial statements present two redemption scenarios as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">No Redemption Scenario: This presentation assumes that no FEAC public shareholders exercise redemption rights to
have their FEAC Class&nbsp;A Shares converted into their pro rata share of the Trust Account and thus the full amount held in the Trust Account as of the Closing is available for the Business Combination; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">252 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Maximum Redemption Scenario: This presentation assumes that 10,483,335 FEAC Class&nbsp;A Shares are redeemed,
resulting in an aggregate cash payment of approximately $111.2&nbsp;million out of the Trust Account based on an assumed redemption price of $10.61 per share that is calculated using the sum of approximately $132.9&nbsp;million cash in the Trust
Account as at March&nbsp;31, 2023 and the $1.3&nbsp;million Extension Loan (as defined in Note 1) deposited into the Trust Account on June&nbsp;6, 2023, divided by 12,650,000 FEAC Class&nbsp;A Shares subject to redemption assuming the pro forma
maximum redemptions scenario pursuant to the Business Combination Agreement. The number of FEAC Class&nbsp;A Shares that are redeemed is derived by reducing the total of 12,650,000 FEAC Class&nbsp;A Shares outstanding by 2,000,000 FEAC Class&nbsp;A
Shares held by the Sponsor that are subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements and 166,665 FEAC Class&nbsp;A Shares held by public shareholders that are subject to <FONT STYLE="white-space:nowrap">non-redemption</FONT>
agreements. After a redemption of approximately $111.2&nbsp;million out of approximately $134.2&nbsp;million Trust Account, including the $1.3&nbsp;million Extension Loan, the available cash from the Trust Account at Closing would be approximately
$23.0&nbsp;million. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination will result in the combination of enGene and New enGene, with a fiscal
year end of October&nbsp;31, with FEAC, with a fiscal year end of December 31. The pro forma statement of operations for the six months ended April&nbsp;30, 2023 and the year ended October&nbsp;31, 2022, presents the combination of financial
information of New enGene, FEAC and enGene, after giving effect to the Transactions described in the accompanying notes. The unaudited pro forma statement of operations for the six months ended April&nbsp;30, 2023 includes enGene&#146;s results of
operations for the six months ended April&nbsp;30, 2023, FEAC&#146;s results of operations for the six months ended March&nbsp;31, 2023, and New enGene&#146;s results of operations for the period from April&nbsp;24, 2023 (inception) to July&nbsp;31,
2023. The unaudited pro forma statement of operations for the year ended October&nbsp;31, 2022 includes enGene&#146;s results of operations for the year ended October&nbsp;31, 2022, and FEAC&#146;s statement of operations for the year ended
December&nbsp;31, 2022. The unaudited pro forma balance sheet as of April&nbsp;30, 2023 is based on a historical New enGene balance sheet as of July&nbsp;31, 2023, historical enGene balance sheet as of April&nbsp;30, 2023, and a historical FEAC
balance sheet as of March&nbsp;31, 2023. FEAC&#146;s results of operations for the three months ended December&nbsp;31, 2022 are included in the unaudited pro forma statement of operations for both the six months ended April&nbsp;30, 2023 and the
year ended October&nbsp;31, 2022. FEAC&#146;s loss from operations and other income for the three months ended December&nbsp;31, 2022 were $491,000 and $1.1&nbsp;million, respectively, resulting in net income for the three months ended
December&nbsp;31, 2022 of $621,000. The operations of New enGene are nominal in the unaudited pro forma condensed combined statements of operations for the period from April 24, 2023 (inception) to July&nbsp;31, 2023 and had not commenced in the
unaudited pro forma condensed combined statements of operations for the fiscal year ended October&nbsp;31, 2022. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">253 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNAUDITED PRO FORMA CONDENSED </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMBINED BALANCE SHEET </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AS OF APRIL 30, 2023 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(In
thousands, except share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Historical</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Scenario 1</B><br><B>Assuming No</B><br><B>Redemptions into Cash</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Scenario 2</B><br><B>Assuming Maximum</B><br><B>Redemptions into Cash</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(A)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(B)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(C)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Transaction<BR>Accounting<BR>Adjustments</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD COLSPAN="2" ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma<BR>Balance<BR>Sheet</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Transaction<BR>Accounting<BR>Adjustments</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD COLSPAN="2" ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma<BR>Balance<BR>Sheet</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>enGene<BR>Holdings<BR>Inc.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>enGene,<BR>Inc.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FEAC</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(a)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">211,477</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(111,228</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(v)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,600</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(c)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(600</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(e)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,254</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(f)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(912</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(j)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(l)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(965</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(n)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(48</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(o)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,710</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(p)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,014</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(q)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(r)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">130,483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(s)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(u)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Restricted certificate of deposit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Investment tax credit receivable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,057</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,057</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,057</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,080</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,080</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,641</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">193,505</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">214,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(111,228</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">103,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cash and securities held in trust account</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">132,946</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,728</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(k)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(m)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(130,483</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(s)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,299</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(f)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">133,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59,260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">215,947</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(111,228</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">104,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Liabilities and shareholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,786</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(f)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,155</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(f)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accrued offering costs and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(912</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(j)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,352</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(q)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Due to related party</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(m)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,265</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(n)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(48</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(o)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Promissory note&#151;related party</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(l)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,200</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(n)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Current portion of debt</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(b)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,762</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11,929</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Note payable, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Convertible debentures</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(a)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16,252</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(b)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(30,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(b)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,622</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(c)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">254 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="41%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Historical</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Scenario 1</B><br><B>Assuming No</B><br><B>Redemptions into Cash</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Scenario 2</B><br><B>Assuming Maximum</B><br><B>Redemptions into Cash</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(A)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(B)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(C)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Transaction<BR>Accounting<BR>Adjustments</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD COLSPAN="2" ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma<BR>Balance<BR>Sheet</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Transaction<BR>Accounting<BR>Adjustments</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD COLSPAN="2" ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma<BR>Balance<BR>Sheet</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>enGene<BR>Holdings<BR>Inc.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>enGene,<BR>Inc.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FEAC</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Convertible debenture embedded derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,126</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(b)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(348</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(c)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(13,003</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(g)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Deferred underwriting commissions</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,728</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(k)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Total Liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,490</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(51,008</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,801</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,801</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">FEAC Class&nbsp;A ordinary shares, subject to possible redemption</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">132,946</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(132,946</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(t)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">enGene Inc. Class&nbsp;A redeemable convertible preferred shares, no par value; unlimited shares
authorized</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,899</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(h)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">enGene Inc. Class&nbsp;B redeemable convertible preferred shares, no par value; unlimited shares
authorized</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,554</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(h)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">enGene Inc. Class&nbsp;C redeemable convertible preferred shares, no par value; unlimited shares
authorized</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(49,665</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(h)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">enGene Holdings Inc. Redeemable Class&nbsp;B common shares, no par value; unlimited shares
authorized</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Shareholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">FEAC Preference shares, $0.0001 par value; 5,000,000 shares authorized; none issued and
outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">FEAC Class&nbsp;A ordinary shares, $0.0001 par value; 500,000,000 shares authorized; none
outstanding (excluding 12,650,000 shares subject to possible redemption issued)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">FEAC Class&nbsp;B ordinary shares, $0.0001 par value; 50,000,000 shares authorized; 3,162,500
shares issued and outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(n)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">enGene Holdings Inc. common shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">122,398</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(i)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">174,774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(v)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">174,773</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(r)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(t)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(u)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">enGene Inc. common shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(b)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(b)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,532</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(f)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(h)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(122,398</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(i)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,897</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(d)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">131,809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(111,227</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(v)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(13,248</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(t)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(n)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">132,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(t)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accumulated other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,016</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,016</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,016</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">255 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Historical</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Scenario 1</B><br><B>Assuming No</B><br><B>Redemptions into Cash</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Scenario 2</B><br><B>Assuming Maximum</B><br><B>Redemptions into Cash</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(A)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(B)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(C)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Transaction<BR>Accounting<BR>Adjustments</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD COLSPAN="2" ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma<BR>Balance<BR>Sheet</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Transaction<BR>Accounting<BR>Adjustments</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD COLSPAN="2" ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma<BR>Balance<BR>Sheet</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>enGene<BR>Holdings<BR>Inc.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>enGene,<BR>Inc.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FEAC</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(72</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(112,371</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,876</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(630</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(c)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(104,421</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(104,421</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,897</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(d)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(600</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(e)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(854</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(f)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(g)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(t)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,710</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(p)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,662</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5(q)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Total shareholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(72</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(89,238</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,876</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">296,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">201,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(111,228</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">89,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Total liabilities and shareholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">133,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59,260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">215,947</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(111,228</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">104,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">256 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE SIX MONTHS ENDED APRIL&nbsp;30, 2023 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(In thousands, except share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Historical</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Scenario 1</B><br><B>Assuming No</B><br><B>Redemptions into Cash</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Scenario 2</B><br><B>Assuming Maximum<BR>Redemptions&nbsp;into&nbsp;Cash</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(A)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(B)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(C)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Transaction<BR>Accounting<BR>Adjustments</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma<BR>Statement&nbsp;of<BR>Operations</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD COLSPAN="2" ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Transaction<BR>Accounting<BR>Adjustments</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma<BR>Statement&nbsp;of<BR>Operations</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD COLSPAN="2" ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>enGene<BR>Holdings<BR>Inc.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>enGene,<BR>Inc.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FEAC</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(60</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6(g)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6(e)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Formation and operating costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(72</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,628</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,628</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(72</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9,370</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,258</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11,628</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11,628</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(316</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(316</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(316</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,352</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,341</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6(a)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">890</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">890</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(121</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6(c)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Interest earned from trust account</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,527</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6(h)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Change in fair value of derivative liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(318</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6(a)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Change in fair value of warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,526</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,526</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6(b)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,330</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(660</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(660</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(72</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,700</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,288</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,288</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Basic and diluted, net income (loss) for the period attributable to equity holders</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(72</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15,089</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,288</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,288</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Weighted average common shares outstanding used in basic and diluted net loss per share</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,768,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,162,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,621,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,552,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6(k)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,137,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,068,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6(k)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net income (loss) per share of Combined Company&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,200</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4.00</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.37</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.53</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">257 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE YEAR ENDED OCTOBER&nbsp;31, 2022 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(In thousands, except share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Historical</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Scenario 1</B><br><B>Assuming No</B><br><B>Redemptions into Cash</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Scenario 2</B><br><B>Assuming Maximum<BR>Redemptions&nbsp;into&nbsp;Cash</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(D)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(E)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(F)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Transaction<BR>Accounting<BR>Adjustments</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD COLSPAN="2" ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma<BR>Statement&nbsp;of<BR>Operations</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD COLSPAN="2" ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Transaction<BR>Accounting<BR>Adjustments</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma<BR>Statement&nbsp;of<BR>Operations</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD COLSPAN="2" ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>enGene<BR>Holdings<BR>Inc.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>enGene,<BR>Inc.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FEAC</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6(d)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6(d)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(120</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6(g)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6(e)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6(f)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6(i)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,624</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6(j)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Formation and operating costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,831</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,831</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,831</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,831</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,577</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19,427</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,831</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,577</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(33,835</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(33,835</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other income (expense), net:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(129</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(129</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(129</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(61</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6(a)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6(c)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Interest earned from trust account</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,862</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6(h)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Change in fair value of derivative liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(269</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6(a)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Change in fair value of warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,326</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6(b)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">662</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">662</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">662</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,013</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">938</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,213</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,213</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net income (loss) before provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(24,440</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11,639</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(36,048</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(36,048</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(22</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(22</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(22</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(24,462</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11,639</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(36,070</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(36,070</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Basic and diluted, net income (loss) for the period attributable to equity holders</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(29,024</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11,639</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(36,070</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(36,070</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Weighted average common shares outstanding used in basic and diluted net loss per share</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,640,030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,162,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,749,499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,552,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6(k)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,266,164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,068,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6(k)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss per share of Combined Company&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7.97</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1.08</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1.56</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">258 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Description of the Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;16, 2023, FEAC entered into the Business Combination Agreement. Under the terms of the proposed Business Combination Agreement the
business combination of FEAC, enGene, and New enGene will be completed through a series of transactions including Business Combination, PIPE Financing, the <FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreement, the Convertible Bridge
Financing, the Working Capital Loans, the Sponsor and Insiders Letter Agreement, and the Extension Loan. The principal steps of the Transactions are described below; please see &#147;<I>Proposal No.</I><I></I><I>&nbsp;1 &#151; The Business
Combination Proposal</I>&#148; for a full description of the proposed Transactions. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Assuming maximum redemptions, it is expected
that FEAC will combine with enGene and New enGene with the steps of the Transactions at an estimated combined enterprise value of approximately $236.4&nbsp;million. Assuming maximum redemptions, the cash components of the transaction (excluding
transaction expenses) will be funded by: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FEAC cash in trust of $23.0 million (which includes <FONT STYLE="white-space:nowrap">non-redemption</FONT>
agreements of $1.7 million), and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">private placements of common shares and warrants from various investors in convertible bridge and PIPE Financing
of $113.3 million, as described below. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Assuming no redemptions, it is expected that FEAC will combine with enGene and
New enGene with the steps of the transactions at an estimated combined enterprise value of approximately $343.9&nbsp;million. Assuming no redemptions, the cash components of the transaction (excluding transaction expenses) will be funded by: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FEAC cash in trust of $134.2&nbsp;million (which includes <FONT STYLE="white-space:nowrap">non-redemption</FONT>
agreements of $1.7 million), and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">private placements of common shares and warrants from various investors in convertible bridge and PIPE Financing
of $113.3&nbsp;million, as described below. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination remains subject to closing conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Business Combination Agreement, two entities will be incorporated to effect the Transactions, Can Merger Sub, a Canadian
corporation and a wholly owned subsidiary of FEAC and Cayman Merger Sub, a Cayman Islands exempt company and a direct wholly owned subsidiary of New enGene. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>PIPE Financing </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the
Business Combination Agreement, FEAC and New enGene entered into Subscription Agreements with the PIPE Investors, pursuant to which Subscription Agreements, as modified by the Side Letter Agreements, PIPE Investors have agreed to purchase FEAC
Class&nbsp;A Shares and FEAC Warrants (or after the Assumption, New enGene Shares and New enGene Warrants) for an aggregate commitment amount of $56.9&nbsp;million. The Subscription Agreements are subject to certain conditions, including, among
other things, completing the steps of the Transactions. The purpose of the PIPE Financing is to fund general corporate expenses of New enGene. Refer to note 5(u) below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Sponsor and Insiders Letter Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrent with the execution of the Business Combination Agreement, FEAC, the Sponsor, Forbion Growth Opportunities Fund I Cooperatief U.A.
and the other holders of FEAC Class&nbsp;B Shares, enGene, New enGene and the other parties named therein (collectively, other than enGene and New enGene, the &#147;Sponsor Parties&#148;) entered into the Sponsor and Insiders Letter Agreement,
pursuant to which the Sponsor has agreed to surrender and in effect issue to PIPE Investors, after giving effect to the conversion of all or part of the principal </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">259 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
amount outstanding under loans made by the Sponsor to FEAC into FEAC Private Placement Warrants, 1,789,004 FEAC Class&nbsp;B Shares and 5,463,381 FEAC Private Placement Warrants, effective
immediately prior to the Class&nbsp;B Conversion on the day which is two business days prior to the Closing Date (the &#147;Surrender&#148;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT
STYLE="white-space:nowrap">Non-Redemption</FONT> Agreement </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the execution of the Business Combination Agreement,
FEAC and a FEAC shareholder that is the beneficial owner of 166,665 FEAC Class&nbsp;A Shares entered into a <FONT STYLE="white-space:nowrap">non-redemption</FONT> agreement (the <FONT STYLE="white-space:nowrap">&#147;Non-Redemption</FONT>
Agreement&#148;), pursuant to which, FEAC will agree to issue additional FEAC Class&nbsp;A Shares and FEAC Warrants (which commitment will be assumed by New enGene as part of the Transactions such that New enGene will issue additional New enGene
Shares and New enGene Warrants) to such FEAC shareholder in consideration of such FEAC shareholder&#146;s commitment (i)&nbsp;to vote or cause to be voted all of its FEAC Shares in favor of the Transaction Proposals and (ii)&nbsp;not to redeem its
FEAC Class&nbsp;A Shares in connection with the approval of the Business Combination by the shareholders of FEAC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Convertible Bridge Financing
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the execution and delivery of the Business Combination Agreement, enGene agreed to certain modifications of existing
convertible indebtedness in an aggregate principal amount of $18.4&nbsp;million (the &#147;Amended 2022 Convertible Notes&#148; and, together with the enGene warrants to be issued by enGene as consideration for such modifications, the &#147;Amended
2022 Financing&#148;). Concurrently with the execution and delivery of the Business Combination Agreement, enGene entered into agreements pursuant to which it will issue new convertible indebtedness and enGene warrants (i)&nbsp;for cash in an
aggregate principal amount of $30.0&nbsp;million (which amount was funded in May 2023 and June 2023), of which Forbion Growth Sponsor FEAC I B.V. funded an aggregate amount of $20.0&nbsp;million, and (ii)&nbsp;in repayment of certain outstanding
indebtedness in an aggregate principal amount of $8.0&nbsp;million (collectively, the &#147;2023 Convertible Notes&#148; and, together with the enGene warrants purchased concurrently, the &#147;2023 Financing&#148;; the 2023 Financing together with
the Amended 2022 Financing, the &#147;Convertible Bridge Financing&#148;). The Convertible Bridge Financing indebtedness will be converted in the Transactions into that number of enGene Common Shares that, when exchanged at the enGene Exchange
Ratio, shall equal that number of FEAC Class&nbsp;A Shares (or after the Assumption, New enGene Shares) that the holders of such indebtedness would have received if they subscribed for FEAC Class&nbsp;A Shares (or after the Assumption, New enGene
Shares) on the same terms as the PIPE Financing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Working Capital Loans </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;24, 2023, the Sponsor and FEAC entered into an unsecured promissory note (the &#147;Note&#148;) under which the Sponsor agreed to
extend to FEAC a Working Capital Loan of up to $900,000, to be used for FEAC&#146;s general corporate purposes, which was increased to $1.2&nbsp;million on June&nbsp;6, 2023. The Sponsor funded the initial principal amount of $450,000 under the Note
on March&nbsp;24, 2023, and additionally funded $450,000 on April&nbsp;26, 2023 and $300,000 on June&nbsp;6, 2023. The Note bears no interest and will be due and payable on the earlier of (i)&nbsp;the date of consummation of a business combination
and (ii)&nbsp;December&nbsp;14, 2023. If FEAC completes the Business Combination, FEAC may repay the Note out of the proceeds of the Trust Account released to FEAC. Otherwise, no proceeds from the Trust Account can be used to repay the Note. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Extension Loan </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;6, 2023,
FEAC extended the period of time to consummate a business combination which required the Sponsor or its affiliates or designees to deposit into the Trust Account, $1.3&nbsp;million ($0.10 per FEAC Class&nbsp;A Shares in either case). The payment was
made in the form of a <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing, unsecured promissory note. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of
the Business Combination Agreement, the Sponsor will be (i)&nbsp;repaid only from funds held outside the Trust Account or from funds released to FEAC or (ii)&nbsp;converted at the option of the lender
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">260 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
into FEAC Private Placement Warrants at an exercise price of $1.50 to be issued by FEAC up to an aggregate amount of $1.5&nbsp;million in each case upon completion of the Business Combination.
The Sponsor has elected to convert the $1.5&nbsp;million to be repaid through the issuance of FEAC Private Placement Warrants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Basis of Pro Forma
Presentation </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial statements were prepared in accordance with Article 11 of SEC
Regulation <FONT STYLE="white-space:nowrap">S-X,</FONT> as amended by the final rule, Release <FONT STYLE="white-space:nowrap">No.&nbsp;33-10786,</FONT> Amendments to Financial Disclosures about Acquired and Disposed Businesses. Release <FONT
STYLE="white-space:nowrap">No.&nbsp;33-10786</FONT> replaced the previous pro forma adjustment criteria with simplified requirements to depict the accounting for business combinations (&#147;Transaction Accounting Adjustments&#148;) and permitted
the presentation of reasonably estimable synergies and other transaction effects that have occurred or are reasonably expected to occur (&#147;Management&#146;s Adjustments&#148;). Management of enGene and FEAC (collectively &#147;Management&#148;)
has elected not to present Management&#146;s Adjustments and will only be presenting Transaction Accounting Adjustments in the unaudited pro forma condensed combined financial information. The transaction accounting adjustments presented in the pro
forma financial information are made to provide relevant information necessary for an understanding of the Combined Company reflecting the accounting for the Business Combination, the PIPE Financing, the
<FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreement, the Convertible Bridge Financing, the Working Capital Loans, the Sponsor and Insiders Letter Agreement, and the Extension Loan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial statements are based on the FEAC historical financial statements, the New enGene
historical financial statements, and the enGene historical consolidated financial statements as adjusted to give effect to the Transactions. The unaudited pro forma condensed combined balance sheet gives pro forma effect to the Transactions as if
they had been consummated on April&nbsp;30, 2023. The unaudited pro forma condensed combined statement of operations for the six months ended April&nbsp;30, 2023 and for the year ended October&nbsp;31, 2022, gives effect to the Transactions as if
they had occurred on November&nbsp;1, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination will result in the combination of enGene and New enGene, with a
fiscal year end of October&nbsp;31, with FEAC, with a fiscal year end of December 31. The pro forma statement of operations for the six months ended April&nbsp;30, 2023 and for the year ended October&nbsp;31, 2022, present the combination of
financial information of New enGene, FEAC and enGene, after giving effect to the Business Combination and related adjustments described in the accompanying notes. The unaudited pro forma statement of operations for the six months ended
April&nbsp;30, 2023 includes enGene&#146;s statement of operations for the six months ended April&nbsp;30, 2023, FEAC&#146;s results of operations for the six months ended March&nbsp;31, 2023, and New enGene&#146;s results of operations for the
period from April&nbsp;24, 2023 (inception) to July&nbsp;31, 2023. The unaudited pro forma annual statement of operations includes enGene&#146;s statement of operations for the year ended October&nbsp;31, 2022, and FEAC&#146;s statement of
operations for the year ended December&nbsp;31, 2022. FEAC&#146;s results of operations for the three months ended December&nbsp;31, 2022 are included in the unaudited pro forma statement of operations for both the six months ended April&nbsp;30,
2023 and the year ended October&nbsp;31, 2022. FEAC&#146;s loss from operations and other income for the three months ended December&nbsp;31, 2022 were $491,000 and $1.1&nbsp;million, respectively, resulting in net income for the three months ended
December&nbsp;31, 2022 of $621,000. The operations of New enGene are nominal in the unaudited pro forma condensed combined statements of operations for the period from April&nbsp;24, 2023 (inception) to July&nbsp;31, 2023 and had not commenced in
the unaudited pro forma condensed combined statement of operations for the fiscal year ended October&nbsp;31, 2022. The unaudited pro forma balance sheet as of April&nbsp;30, 2023 is based on a historical New enGene balance sheet as of July&nbsp;31,
2023, historical enGene balance sheet as of April&nbsp;30, 2023, and a historical FEAC balance sheet as of March&nbsp;31, 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Management has made significant estimates and assumptions in its determination of the pro forma adjustments. The pro forma adjustments
reflecting the Transactions are based on certain currently available information and certain assumptions and methodologies that Management believes are reasonable under the circumstances. The pro forma adjustments, which are described in the
accompanying notes, may be revised as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">261 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
additional information becomes available and is evaluated. Therefore, it is likely that the actual adjustments will differ from the pro forma adjustments, and it is possible the difference may be
material. Management believes that its assumptions and methodologies provide a reasonable basis for presenting all of the significant effects of the Transactions based on information available at this time and that the pro forma adjustments give
appropriate effect to those assumptions and are properly applied in the unaudited pro forma condensed combined financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
unaudited pro forma condensed combined financial statements do not give effect to any operating efficiencies or cost savings that may be associated with the Business Combination. FEAC and enGene have not had any historical relationship prior to the
Business Combination, with the exception of a shareholder investment in enGene by Forbion Capital Fund III, an affiliate of the Sponsor. Accordingly, no pro forma adjustments were required to eliminate activities between the companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial information presents two redemption scenarios as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">No Redemption Scenario: This presentation assumes that no FEAC public shareholders exercise redemption rights for
their right to have their FEAC Class&nbsp;A Shares converted into their pro rata share of the Trust Account and thus the full amount held in the Trust Account as of the Closing is available for the Business Combination; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Maximum Redemption Scenario: This presentation assumes that 10,483,335 FEAC Class&nbsp;A Shares are redeemed,
resulting in an aggregate cash payment of approximately $111.2&nbsp;million out of the Trust Account based on an assumed redemption price of $10.61 per share that is calculated using the sum of approximately $132.9&nbsp;million cash in the Trust
Account and the $1.3&nbsp;million Extension Loan deposited into the Trust Account on June&nbsp;6, 2023, divided by 12,650,000 FEAC Class&nbsp;A Shares subject to redemption assuming the pro forma maximum redemptions scenario pursuant to the Business
Combination Agreement. The number of FEAC Class&nbsp;A Shares that are redeemed is derived by reducing the total of 12,650,000 FEAC Class&nbsp;A Shares outstanding by 2,000,000 FEAC Class&nbsp;A Shares held by the Sponsor that are subject to <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements and 166,665 FEAC Class&nbsp;A Shares held by public shareholders that are subject to <FONT STYLE="white-space:nowrap">non-redemption</FONT> agreements. After a redemption of approximately
$111.2&nbsp;million out of approximately $134.2&nbsp;million Trust Account, including the $1.3&nbsp;million Extension Loan, the available cash from the Trust Account at Closing would be approximately $23.0&nbsp;million. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Assuming no FEAC public shareholders elect to redeem their shares for cash, enGene shareholders (including shares owned by Forbion Capital
Fund III, an existing enGene shareholder) will own approximately 29% of the shares of New enGene Shares, FEAC public shareholders (excluding Sponsor shares) will own approximately 32% of the shares of New enGene Shares, the Sponsor and FGOF will
together own approximately 17% of the shares of New enGene Shares, and PIPE investors (excluding Sponsor portion) will own approximately 22% of the shares of New enGene Shares. These percentages are based on the number of FEAC Class&nbsp;A Shares
outstanding as of March&nbsp;31, 2023, and do not include the impact of warrants or other dilutive instruments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If 10,483,335 shares of
FEAC Class&nbsp;A Shares are redeemed for cash, which assumes the maximum redemption of FEAC Class&nbsp;A Shares, enGene shareholders (including shares owned by Forbion Capital Fund III) will own approximately 42% of the shares of New enGene Shares,
FEAC public shareholders will own approximately 1% of the shares of New enGene Shares, the Sponsor and FGOF will together own approximately 25% of the New enGene Shares, and PIPE investors will own approximately 32% of the shares of New enGene
Shares. These percentages are based on the number of FEAC Class&nbsp;A Shares outstanding as of March&nbsp;31, 2023, and do not include the impact of warrants or other dilutive instruments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">262 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These unaudited pro forma condensed combined financial statements and related notes have
been derived from and should be read in conjunction with: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the accompanying notes to the unaudited pro forma condensed combined financial statements, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the historical unaudited condensed financial statements of FEAC as of and for the three months ended
March&nbsp;31, 2023, and the related notes not included in this proxy statement/prospectus, </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the historical unaudited consolidated financial statements of enGene Inc. as of and for the six months ended
April&nbsp;30, 2023, and the related notes included elsewhere in this proxy statement/prospectus, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the historical audited financial statements of FEAC as of and for the year ended December&nbsp;31, 2022, and the
related notes included elsewhere in this proxy statement/prospectus, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the historical unaudited condensed financial statements of FEAC as of and for the nine months ended
September&nbsp;30, 2022 (used to determine the results of operations of FEAC for the six months ended March&nbsp;31, 2023) not included in this proxy statement/prospectus, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the historical audited consolidated financial statements of enGene Inc. as of and for the year ended
October&nbsp;31, 2022, and the related notes included elsewhere in this proxy statement/prospectus, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the historical audited financial statements of enGene Holdings Inc. as of July&nbsp;31, 2023 and for the period
from April&nbsp;24, 2023 (inception) to July&nbsp;31, 2023 and the related notes included elsewhere in this proxy statement/prospectus, and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the sections entitled &#147;<I>FEAC&#146;s Management&#146;s Discussion and Analysis of Financial Condition and
Results of Operations</I>,&#148; &#147;<I>enGene&#146;s Management&#146;s Discussion and Analysis of Financial Condition and Results of Operation</I>,&#148; and other financial information relating to FEAC and enGene included elsewhere in this proxy
statement/prospectus. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial statements are provided for illustrative
purposes only and are not necessarily indicative of what the actual results of operations and financial position would have been had the Transactions taken place on the dates indicated, nor are they indicative of the future consolidated results of
operations or financial position of the Combined Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Accounting for the Business Combination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the legal form, the Business Combination will be accounted for as a reverse recapitalization in accordance with US&nbsp;GAAP.
Under this method of accounting, FEAC will be treated as the acquired company for financial reporting purposes, whereas enGene will be treated as the accounting acquirer. In accordance with this accounting method, New enGene is considered to be a
continuation of enGene, with the net identifiable assets of FEAC deemed to have been acquired by enGene in exchange for enGene Common Shares accompanied by a recapitalization. The net assets of FEAC will be stated at historical cost, with no
goodwill or other intangible assets recorded, and operations prior to the Business Combination will be those of enGene. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">enGene has been
determined to be the accounting acquirer based on an evaluation of the following facts and circumstances, and accordingly the Business Combination is treated as an equivalent to an acquisition of FEAC accompanied by a recapitalization. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Senior management of enGene will continue as senior management of the Combined Company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enGene will identify a majority of the members of the Board of Directors of the Combined Company;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The name of the Combined Company will be enGene Holdings Inc. and it will utilize enGene&#146;s current
headquarters; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enGene&#146;s operations will comprise the ongoing operations of the Combined Company. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">263 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Common shares of enGene Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preliminary estimated enGene Exchange Ratio is calculated in accordance with the terms of the Business Combination Agreement as a quotient
obtained by dividing the enGene Per Share Value by the Reference Price of $10.25. The enGene Per Share Value is determined as (i) $96,590,230, which is the reference value of $90,000,000 plus the exercise value of enGene Inc.&#146;s outstanding
share-based awards, divided by (ii) 52,197,346, which is the sum of enGene&#146;s outstanding common shares immediately prior to the closing of the Business Combination and the number of common shares issued or issuable upon exercise or settlement
of enGene Inc.&#146;s outstanding share-based awards and excludes any shares issuable for the conversion of enGene Inc.&#146;s convertible debt. The defined terms are presented in full in the Business Combination Agreement and included elsewhere in
the proxy statement/prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>enGene Inc.<BR>shares as of<BR>April&nbsp;30,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>shares<BR>esitmated&nbsp;to<BR>be&nbsp;issued on<BR>conversion<BR>of enGene<BR>Inc. 2022<BR>and 2023<BR>Convertible<BR>Notes (2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>enGene common<BR>shares assumed<BR>outstanding<BR>prior&nbsp;to the<BR>closing of the<BR>Business<BR>Combination</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,885,897</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,338,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39,224,397</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred shares (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,152,399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,152,399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37,038,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,338,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72,376,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">enGene Inc. common shares outstanding prior to the closing of the Business Combination</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72,376,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed enGene Exchange Ratio</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.1805347941</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated New enGene common shares issued to enGene shareholders upon closing of the
Transactions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,066,517</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">enGene Inc.&#146;s outstanding classes of preferred shares convert to Engene Inc.&#146;s common shares at a
ratio of 1:1 immediately prior to the close of the Business Combination. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Refer to Note 5(b) for the calculation of the number of shares estimated to be issued on conversion of
enGene&#146;s 2022 and 2023 Convertible Notes. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Adjustments to Unaudited Pro Forma Condensed Combined Balance Sheet </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pro forma notes and adjustments, based on preliminary estimates that could change materially as additional information is obtained, are as
follows: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Pro forma notes: </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5(A) Derived from
the audited balance sheet of New enGene as of July&nbsp;31, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5(B) Derived from the unaudited condensed consolidated balance sheet of enGene as of
April&nbsp;30, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5(C) Derived from the unaudited condensed balance sheet of FEAC as of March&nbsp;31, 2023. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Pro forma Transaction Accounting Adjustments: </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To record adjustments for debt financing obtained by enGene in May 2023. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">On April&nbsp;4, 2023, enGene entered into an interest-free debt agreement for aggregate cash proceeds of $8.0&nbsp;million (the &#147;2023
Subordinated Notes&#148;), which was included as a component of current portion of debt in enGene&#146;s historical financial statements. On May&nbsp;16, 2023, enGene entered into an amendment to their existing 2022 convertible notes issued in the
year ended October&nbsp;31, 2022, in an aggregate amount of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">264 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">
$18.4&nbsp;million (the &#147;2022 Convertible Notes&#148; and the &#147;Amended Note Purchase Agreement&#148;) pursuant to which enGene Inc. also received additional aggregate debt financing in
the amount of $30.0&nbsp;million (the &#147;2023 Convertible Notes&#148;). The additional financing is funded in two tranches, comprising an initial $20.0&nbsp;million on May&nbsp;17, 2023, and a subsequent $10.0&nbsp;million on June&nbsp;15, 2023.
As part of the Amended Note Purchase Agreement, the 2023 Subordinated Notes were repaid by way of additional 2023 Convertible Notes, for an aggregate amount of $38.0&nbsp;million. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The 2023 Convertible Notes, and the 2022 Convertible Notes as amended on May&nbsp;16, 2023, automatically convert at the time of the Business
Combination into the number of enGene Common Shares that, when exchanged in the Business Combination for shares of New enGene are in an equal to the number of New enGene Shares that the holder would have received had it invested in the PIPE
Financing, including any warrants issued. These transactions result in no pro forma adjustments in the pro forma statement of operations for six months ended April&nbsp;30, 2023 and the year ended October&nbsp;31, 2022, because the debt is converted
into New enGene Shares and no interest expense on the debt is expected. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">In accordance with the Amended Note Purchase Agreement, the
holders of the 2022 Convertible Notes received warrants to purchase enGene Common Shares and the holders of the 2023 Convertible Notes were issued warrants in connection with the issuance of the 2023 Convertible Notes. These warrants will convert
through the transaction to warrants to purchase common shares of the Combined Company. There is no pro forma adjustment related to the issuance of enGene warrants and the conversion to Combined Company warrants as the classification and valuation of
the warrants has not yet been determined. These warrants shall have substantially similar terms as the warrants received by the PIPE investors and are expected to be equity classified (refer to Note 5(u)). </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect the ultimate conversion of the outstanding principal balance of $18.4&nbsp;million of the 2022
Convertible Notes and $38.0&nbsp;million of the 2023 Convertible Notes issued by enGene, including the associated derivative liability, into 35,338,500 enGene Common Shares as follows: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="95%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022 Convertible<BR>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023 Convertible<BR>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands, except share amounts<BR>and ratios)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Principal balance of the convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 18,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 38,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated purchase price paid for the warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,805</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated purchase price allocated to the convertible notes (A)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 18,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 36,195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">enGene Inc. common shares issued at redemption price of $10.25</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,795,122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,707,317</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional enGene Inc. common shares issued in connection with PIPE financing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">286,241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">591,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total enGene Inc. shares issued upon conversion of the convertible notes prior to reflecting the
conversion ratio (B)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,081,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,298,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion ratio (C=A*1000/B)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed enGene Exchange Ratio (D)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.1805347941</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.1805347941</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated enGene common shares issued to enGene convertible note holders upon conversion of 2022
Convertible Notes and 2023 Convertible Notes (E=A*1000/(C*D))</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,528,872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,809,628</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">These enGene Common Shares convert to 6,379,822 New enGene Shares after exchange pursuant to the terms of
the Business Combination Agreement. The corresponding offsets related to the conversion have been recorded as the derecognition of the 2022 Convertible Notes of $16.3&nbsp;million and $3.1 million of the related derivative liability, totaling $19.4
million, the derecognition of the 2023 Convertible Notes of $38.0&nbsp;million, and increases in New enGene Shares of $57.4 million. The fair value of the warrants has not been finalized as of the date of this proxy statement/prospectus, therefore
the value of the warrants has been included in common shares. When determined, the fair value of the warrants will be reclassified from common shares to additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">265 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect the repayment of term notes entered into by enGene Inc. that are to be repaid, with the proceeds of
the Transactions, with outstanding principal of $3.0&nbsp;million, as of April&nbsp;30, 2023, and associated fees of $600,000 through cash payment and the recognition of the remaining deferred issuance costs. The corresponding offsets related to the
repayment are the derecognition of $2.6&nbsp;million of convertible debt liability, $348,000 of derivative liability and an increase in accumulated deficit of $630,000. The transaction is not expected to have a recurring impact.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect the automatic acceleration of vesting of enGene&#146;s unvested share options as of April&nbsp;30,
2023. Unvested share-based compensation expense relating to options existing at April&nbsp;30, 2023, is $378,213. In addition, of the 5.8&nbsp;million options issued July&nbsp;7, 2023, 4.4&nbsp;million options will vest upon closing of the
Transactions and the balance will vest over time. For the 4.4&nbsp;million options that will vest upon closing of the Transactions, the stock-based compensation expense is preliminarily estimated at $2.5&nbsp;million, determined assuming a fair
value of common shares at grant date of C$1.06 ($0.79), and the following assumptions based on preliminary estimates: expected life of 6.08 years from the most recent prior grant in February 2023, volatility of 82.7% and risk-free interest rate of
3.56%. The valuation analysis for the share-based compensation expense relating to the options issued on July&nbsp;7, 2023 is preliminary and, upon finalization of the valuation, the actual results may be materially different than those disclosed in
these unaudited pro forma condensed combined financial information. For the 1.4&nbsp;million options that will vest over time, no pro forma adjustment is included. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect the payment of $600,000 for the Directors&nbsp;&amp; Officers (&#147;D&amp;O&#148;) insurance tail
policy of enGene that is required to be purchased pursuant to the Business Combination Agreement. The policy does not cover any claims incurred after the consummation of the Business Combination. The transaction is not expected to have a recurring
impact. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect the remaining payment of $5.3 million for estimated transaction costs, including banking, printing,
legal and accounting services. $4.5&nbsp;million of the total estimated transaction costs to be incurred by enGene were deemed to be direct and incremental costs of the Business Combination and recorded as an offset to common shares as the shares
issued have no par value and $854,000 (allocated based upon relative fair value of shares invested, assuming maximum redemption) were deemed as related to issuance costs of the 2023 Subordinated Notes and the 2023 Convertible Notes, expected to be
accounted for in accordance with the fair value option election, and therefore were recorded to accumulated deficit. Additionally, the corresponding remaining offset has been recorded as a $1.3&nbsp;million decrease in deferred costs which was
included in other assets on the pro forma balance sheet, a decrease in accounts payable of $12,000, and a decrease in accrued expenses and other current liabilities of $1.2&nbsp;million. This estimate may change as additional information becomes
known and there may also be increased costs not directly related to the Transactions. The transaction is not expected to have a recurring impact. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect the cancellation of warrants to purchase enGene Class&nbsp;C preferred shares through the
derecognition of the remaining warrant liability, and recognition of offsetting amount in accumulated deficit of $13.0 million. As part of the Transactions, all warrants to purchase Class&nbsp;C preferred shares are either cancelled or are not
expected to be exercised because the exercise price of the warrants are below the expected share price. The transaction is not expected to have a recurring impact. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect the automatic conversion, on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-to-one</FONT></FONT> basis, of all outstanding shares of enGene Preferred Shares, with a carrying amount of $53.1&nbsp;million, into 33,152,399 enGene Common Shares. enGene
Preferred Shares outstanding shares are comprised the following: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Preferred Shares Classes Shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;A preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,477,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;B preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">864,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;C preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,810,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Preferred Shares issued and outstanding converted to enGene Common Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,152,399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">266 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect the recapitalization of enGene and New enGene pursuant to the Business Combination Agreement, the
recapitalization of enGene through the contribution of all the common shares of enGene of 72,376,796 to New enGene and the issuance of 13,066,517 shares of New enGene Shares, reflecting the exchange ratio of 0.1805347941. The recapitalization amount
is determined as follows: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common shares of enGene Inc. as of April&nbsp;30, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 16,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of 2022 Convertible Notes per Note 5(b)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of 2023 Convertible Notes per Note 5(b)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">enGene estimated transaction costs per Note 5(f)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,532</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total enGene Inc. preferred shares issued and outstanding converted to enGene Inc. common shares
per Note 5(h)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total amount of enGene Inc. common shares contributed to New enGene as part of the
recapitalization entry</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">122,398</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To record the cash settlement of $0.9&nbsp;million related to FEAC&#146;s accounts payable and accrued
expenses. Upon the close of the Business Combination, FEAC is obligated to pay these balances off pursuant to the Business Combination Agreement and reflect the settlement as an elimination of the accounts payable and accrued expenses. The
transaction is not expected to have a recurring impact. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5(k)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To record the cash settlement of $3.7&nbsp;million from the funds available in the Trust Account related to
deferred underwriting commissions incurred during FEAC&#146;s IPO. FEAC recorded these costs in 2021 by crediting its deferred underwriting commissions liability accounts and debiting expenses. Upon the close of the Business Combination, FEAC is
obligated to settle the balances pursuant to the Business Combination Agreement and reflect the settlement as an elimination of the deferred legal costs liabilities. The transaction is not expected to have a recurring impact. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5(l)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On March&nbsp;24, 2023, the Sponsor and FEAC entered into an unsecured promissory note (the &#147;Working
Capital Loan&#148;) under which the Sponsor agreed to extend up to $900,000, to be used for general corporate purposes, which was increased to $1.2&nbsp;million on June&nbsp;6, 2023. The Sponsor funded an initial principal amount of $450,000 on
March&nbsp;24, 2023 which was included as promissory note&#151;related party in the March&nbsp;31, 2023 FEAC historical financial statements, and additionally funded $450,000 on April&nbsp;26, 2023 and $300,000 on June&nbsp;6, 2023. This adjustment
is to record the issuance of Working Capital Loans subsequent to March&nbsp;31, 2023 in the aggregate of $750,000. The Working Capital Loans will be settled upon the consummation of the Business Combination, through the issuance of 600,000 FEAC
Private Placement Warrants valued at $1.50 per warrant; see Note 5(m). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5(m)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect the required deposit into the Trust Account made by the Sponsor in connection with FEAC&#146;s
decision to extend the period of time to consummate a business combination. On June&nbsp;6, 2023 the Sponsor made a deposit into the Trust Account of $1.3&nbsp;million in connection with FEAC&#146;s decision to initially extend the period of time to
consummate a business combination from June 14, 2023 to September 14, 2023 (the &#147;Sponsor Extension Loan&#148;). The deposit was funded as a <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing, unsecured promissory note. Upon
consummation of the Business Combination, the note may, at the election of the Sponsor, be converted into 400,000 additional FEAC Private Placement Warrants and repayment from cash of $965,000. FEAC currently intends, in accordance with its
obligations under the Business Combination Agreement, to extend the time available to it to consummate its initial business combination from September 14, 2023, to December 14, 2023, by depositing an additional $1,265,000 (or $0.10 per FEAC Class A
Share) into the Trust Account on or before September 14, 2023, and the Sponsor is expected to fund such amount in the form of an additional extension note on the same terms. There is no pro forma adjustment recorded for the additional
$1.3&nbsp;million that the Sponsor is expected to deposit into the Trust Account before September 14, 2023 to further extend the period of time to consummate a business combination from September 14, 2023 to December 14, 2023. </P></TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">267 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5(n)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To record the settlement of the Working Capital Loans of $1.2&nbsp;million and the Sponsor Extension Loan of
$1.3&nbsp;million through the issuance of 1.0&nbsp;million FEAC Private Placement Warrants of $1.5&nbsp;million and $965,000 of cash. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5(o)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect the settlement of $48,000 representing amounts due to related parties for FEAC&#146;s independent
board members and FEAC&#146;s office space, secretarial, and administrative fees. The transaction is not expected to have a recurring impact. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5(p)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect the payment of $1.7&nbsp;million for the D&amp;O insurance tail policy of FEAC that is required to
be purchased pursuant to the Business Combination Agreement. The policy does not cover any claims incurred after the consummation of the business combination. The transaction is not expected to have a recurring impact. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5(q)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect FEAC&#146;s total estimated advisory, legal, accounting and auditing fees and other professional
fees in consummating the Business Combination of $7.0 million, as accrued offering costs and expenses and subsequently reclassify to accumulated deficit upon the close of the Business Combination. Costs of $1.4&nbsp;million have been accrued in the
historical financial statements. This estimate may change as additional information becomes known and there may also be increased costs not directly related to the Transactions. The transaction is not expected to have a recurring impact.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5(r)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect the redemption of the initial shares issued at inception of New enGene at the consummation of the
Business Combination for an amount equal to the capital initially contributed of $7. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5(s)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect the release of $130.5&nbsp;million from the Trust Account to cash upon the completion of the
Business Combination, assuming no FEAC Class&nbsp;A shareholders exercise their rights to have their ordinary shares redeemed for their pro rata share of the Trust Account. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5(t)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect the reclassification of 12,650,000 shares, or $132.9&nbsp;million, FEAC&#146;s Class&nbsp;A Shares
subject to redemption from temporary equity to equity upon the Business Combination for those shareholders that have not elected to redeem and the conversion of those shares into New enGene Shares in Scenario 1, which assumes no FEAC public
shareholders exercise their redemption rights. The share balance is converted to the legal par value of FEAC&#146;s Class&nbsp;A Shares. The offsetting adjustment to issued equity is recorded in additional
<FONT STYLE="white-space:nowrap">paid-in</FONT> capital. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The accumulated deficit of FEAC has been derecognized and
reversed to additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital, comprising the historical accumulated deficit of $5.9&nbsp;million and the impact to accumulated deficit of pro forma adjustments related to the $1.7&nbsp;million
purchase of D&amp;O insurance tail policy for FEAC and recognition of $5.7 million of FEAC transaction costs (see adjustments 5(p) and 5(q)). </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5(u)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect the issuance and sale of 6,435,441 New enGene Shares to the PIPE investors pursuant to Subscription
Agreements entered into concurrent with the completion of the Business Combination (as modified by the Side Letter Agreements), for an aggregate commitment amount of $56.9&nbsp;million. Warrants issued with the PIPE Financing are to have terms that
are substantially similar to the terms of the FEAC Public Warrants, which have been determined to be equity classified by FEAC and accounted for as such within FEAC&#146;s previously issued financial statements, as they do not meet the liability
classification requirements under ASC 480, and are considered to be indexed to the issuer&#146;s stock and meet all other conditions for equity classification under ASC 815-40. The proceeds of the PIPE investment are recorded net of transaction
costs deemed to be direct and incremental costs of the equity financing in the amount of approximately $4.5 million. FEAC will enter into the subscription agreements and the commitment to issue shares will be assumed by New enGene as part of the
Business Combination. The PIPE Financing is recorded as the issuance of New enGene Shares, with no par value, accordingly. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect, in Scenario 2, the assumption that FEAC public shareholders exercise their redemption rights with
respect to a maximum of 10,483,335 FEAC Class&nbsp;A Shares subject to redemption prior to the consummation of the Business Combination at a redemption price of approximately $10.61 per share, or $111.2&nbsp;million in cash, using the redemption
amount at March&nbsp;31, 2023, per FEAC&#146;s financial statements </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">268 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
of $10.51 plus $0.10 for the Extension Loan of $1.3&nbsp;million. The $111.2&nbsp;million or 10,483,335 common shares represents the maximum redemption amount upon the consummations of the
Business Combination on April&nbsp;30, 2023, and contractual limitations on shareholders&#146; right to redeem through FEAC Sponsor&#146;s <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement related to 2,000,000 FEAC Class&nbsp;A Shares and
the <FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreement relating to 166,665 FEAC Class&nbsp;A Shares. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Adjustments to
Unaudited Pro Forma Condensed Combined Statement of Operations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pro forma notes and adjustments, based on preliminary estimates
that could change materially as additional information is obtained, are as follows: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Pro forma notes: </I></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Derived from the statement of operations and comprehensive loss of New enGene for the period from
April&nbsp;24, 2023 (incorporation) to July&nbsp;31, 2023. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Derived from the unaudited condensed consolidated statement of operations and comprehensive loss of enGene for
the six months ended April 30, 2023. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The results of operations of FEAC for the six months ended March&nbsp;31, 2023 are derived from the unaudited
condensed statement of operations for the three months ended March&nbsp;31, 2023 and the results of operations for the three months ended December&nbsp;31, 2022, calculated using the statement of operations for the year ended December&nbsp;31, 2022
and unaudited condensed statement of operations for the nine months ended September&nbsp;30, 2022. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6(D)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">There was no statement of operations prepared for New enGene as it was incorporated on April&nbsp;24, 2023, and
had no operations in the period ended October&nbsp;31, 2022. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6(E)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Derived from the consolidated statement of operations and comprehensive loss of enGene for the year ended
October&nbsp;31, 2022. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6(F)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Derived from the statement of operations of FEAC for the year ended December&nbsp;31, 2022.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">enGene and FEAC are both <FONT STYLE="white-space:nowrap">non-taxable</FONT> entities and no pro forma adjustments have an impact on
associated income tax. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Pro forma Transaction Accounting Adjustments: </I></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To eliminate the interest expense and to reflect the derecognition of change in fair value of the derivative
liability associated with the 2022 Convertible Notes as it is assumed that the 2022 Convertible Notes were converted to equity as if the Business Combination had occurred on November&nbsp;1, 2021. The interest adjustment was based on the total
interest expense on the 2022 Convertible Notes recorded for the six months ended April&nbsp;30, 2023 and the year ended October&nbsp;31, 2022. The transaction is not expected to have a recurring impact. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To eliminate the change in fair value of enGene Warrants to purchase Class&nbsp;C preferred shares as the
warrants are cancelled as part of the Transactions, as if the Business Combination had occurred on November&nbsp;1, 2021. The transaction is not expected to have a recurring impact. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect the fees associated with the repayment of the convertible debenture to the Business Development Bank
of Canada and eliminate the interest expense recognized on the convertible debenture, given the convertible debenture to the Business Development Bank of Canada will be repaid at the time of closing of the Business Combination. The transaction is
not expected to have a recurring impact. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect the automatic acceleration of vesting of enGene&#146;s unvested share options as of April&nbsp;30,
2023. Unvested share-based compensation expense relating to options existing at April&nbsp;30, 2023, is $378,213. In </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">269 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
addition, of the 5.8&nbsp;million options issued July&nbsp;7, 2023, 4.4&nbsp;million options will vest upon closing of the Transactions and the balance will vest over time. For the
4.4&nbsp;million options that will vest upon closing of the Transactions, the stock-based compensation expense is preliminarily estimated at $2.5&nbsp;million. For purposes of the preliminary estimation, the stock-based compensation expense was
determined assuming a fair value of common shares at grant date of C$1.06 ($0.79), and the following assumptions based on preliminary estimates: expected life of 6.08 years from the most recent prior grant in February 2023, volatility of 82.7% and
risk-free interest rate of 3.56%. The valuation analysis for the share-based compensation expense relating to the options issued on July&nbsp;7, 2023 is preliminary and, upon finalization of the valuation, the actual results may be materially
different than those disclosed in these unaudited pro forma condensed combined financial information. For the 1.4&nbsp;million options that will vest over time, no pro forma adjustment is included. Any share-based compensation expense recognized in
the historical financial statements is not adjusted. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect enGene&#146;s issuance costs of the 2023 Subordinated Notes and the 2023 Convertible Notes. Issuance
costs associated with the 2023 Subordinated Notes of $12,000 included in the historical financial statements are derecognized in the pro forma statement of operations for the six months ended April&nbsp;30, 2023. Total issuance costs of $865,871,
inclusive of the $12,000 associated with the 2023 Subordinated Notes are recognized as expense in the pro forma statement of operations for the year ended October&nbsp;31, 2022 as the notes are expected to be accounted for in accordance with the
fair value option election. The transaction is not expected to have a recurring impact. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect an adjustment to recognize $600,000 for the D&amp;O insurance tail policy of enGene that is required
to be purchased pursuant to the Business Combination Agreement. The policy does not cover any claims incurred after the consummation of the business combination. The transaction is not expected to have a recurring impact. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect an adjustment to eliminate FEAC&#146;s administrative support fees of $10,000 per month as if the
Business Combination had occurred on November&nbsp;1, 2021. The transaction is not expected to have a recurring impact. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect the derecognition of investment income related to the investments held in the Trust Account in as if
the Business Combination had occurred on November&nbsp;1, 2021. The transaction is not expected to have a recurring impact. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect an adjustment to recognize $1.7&nbsp;million of general and administrative expense in the pro forma
statement of operations for the year ended October&nbsp;31, 2022 related to the D&amp;O insurance tail policy of FEAC that is required to be purchased pursuant to the Business Combination Agreement. The policy does not cover any claims incurred
after the consummation of the business combination. The transaction is not expected to have a recurring impact. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect FEAC&#146;s estimated incremental advisory, legal, accounting, and other professional fees related
to the Business Combination that are not recorded in its historical financial statements as an increase to general and administrative expense in the pro forma statement of operations for the year ended October&nbsp;31, 2022 as if the transactions
had occurred on November&nbsp;1, 2021. The transaction is not expected to have a recurring impact. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">270 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6(k)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The pro forma basic and diluted net loss per share amounts presented in the unaudited pro forma condensed
combined statement of operations are based upon the number of New enGene Shares outstanding at the closing of the Transactions, assuming the Transactions occurred on November&nbsp;1, 2021. The calculation of weighted-average shares outstanding for
pro forma basic and diluted net loss per share assumes that the shares issuable in connection with the Transactions have been outstanding for the entirety of the period presented. Pro forma basic and diluted net loss per share is calculated as
follows for the six months ended April&nbsp;30, 2023 and year ended October&nbsp;31, 2022: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended April&nbsp;30, 2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Scenario 1<BR>(Assuming No<BR>Redemptions<BR>for Cash)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Scenario 2<BR>(Assuming<BR>Full<BR>Redemptions<BR>for Cash)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Numerator:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,288</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,288</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Denominator:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New enGene common shares owned by public shareholders that were subject to redemption upon
closing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,483,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New enGene common shares owned by public shareholders that were not subject to redemption upon
closing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,373,496</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,373,496</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New enGene common shares owned by enGene shareholders (excluding the conversion of the 2022
Convertible Notes and the 2023 Convertible Notes)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,686,695</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,686,695</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New enGene common shares owned by enGene shareholders derived from the conversion of the 2022
Convertible Notes and the 2023 Convertible Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,379,822</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,379,822</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New enGene common shares owned by PIPE investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,435,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,435,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New enGene common shares owned by shareholders that were subject to
<FONT STYLE="white-space:nowrap">non-redemption</FONT> agreement (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">193,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">193,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average common shares outstanding used in basic and diluted net loss per share
(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,552,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,068,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share of Combined Company&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.37</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.53</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">271 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended October&nbsp;31, 2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Scenario 1<BR>(Assuming No<BR>Redemptions<BR>for Cash)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Scenario 2<BR>(Assuming<BR>Full<BR>Redemptions<BR>for Cash)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Numerator:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(36,070</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(36,070</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Denominator:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New enGene common shares owned by public shareholders that were subject to redemption upon
closing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,483,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New enGene common shares owned by public shareholders that were not subject to redemption upon
closing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,373,496</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,373,496</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New enGene common shares owned by enGene shareholders (excluding the conversion of the 2022
Convertible Notes and the 2023 Convertible Notes)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,686,695</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,686,695</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New enGene common shares owned by enGene shareholders derived from the conversion of the 2022
Convertible Notes and the 2023 Convertible Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,379,822</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,379,822</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New enGene common shares owned by PIPE investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,435,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,435,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New enGene common shares owned by shareholders that were subject to
<FONT STYLE="white-space:nowrap">non-redemption</FONT> agreement (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">193,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">193,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average common shares outstanding used in basic and diluted net loss per share
(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,552,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,068,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share of Combined Company&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1.08</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1.56</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents 166,665 FEAC Class&nbsp;A Shares associated with the
<FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreement and 26,575 additional FEAC Class&nbsp;A Shares that will be issued to the same FEAC shareholder in consideration for the <FONT STYLE="white-space:nowrap">Non-Redemption</FONT>
Agreement. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents the total number of outstanding New enGene Shares that New enGene would issue as of the consummation
of the Transactions. Under Scenario 1, the number of outstanding New enGene Warrants of 10,411,667 and New enGene share options of 6,090,357&nbsp;to be issued or available to be issued, respectively, upon the consummation of the Transactions have
been excluded from the computation of diluted net loss per share attributable to common shareholders for the six months ended April&nbsp;30, 2023 and the year ended October&nbsp;31, 2022 because including them would have been antidilutive. Under
Scenario 2, the numbers of outstanding New enGene Warrants of 10,411,667 and New enGene share options of 5,337,534&nbsp;to be issued or available to be issued, respectively, upon the consummation of the Transactions have been excluded from the
computation of diluted net loss per share attributable to common shareholders for the six months ended April&nbsp;30, 2023 and the year ended October&nbsp;31, 2022 because including them would have been antidilutive. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">272 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom459793_26"></A>SELECTED HISTORICAL FINANCIAL INFORMATION OF FEAC </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FEAC is providing the following selected historical financial information to assist the analysis of the financial aspects of the Business
Combination Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following selected historical statements of operations and cash flows data of FEAC for the year ended
December&nbsp;31, 2022 and the period from August&nbsp;9, 2021 (inception) through December&nbsp;31, 2021, and the historical balance sheet data of FEAC as of December&nbsp;31, 2022 and 2021 are derived from FEAC&#146;s audited financial statements
included elsewhere in this proxy statement/prospectus. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following selected historical statements of operations and cash flows data
of FEAC for the six months ended June&nbsp;30, 2023 and June&nbsp;30, 2022, and the historical balance sheet data of FEAC as of June&nbsp;30, 2023 are derived from FEAC&#146;s unaudited interim consolidated financial statements included elsewhere in
this proxy statement/prospectus. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information below is only a summary and should be read in conjunction with the sections
entitled &#147;<I>FEAC&#146;s</I> <I>Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</I>&#148; and the financial statements, and the notes and schedules related thereto, which are included elsewhere in this
proxy statement/prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The historical results included below and elsewhere in this proxy statement/prospectus are not indicative of
the future performance of FEAC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Statement of Operations </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the six</B><br><B>months&nbsp;ended</B><br><B>June&nbsp;30,&nbsp;2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the six</B><br><B>months&nbsp;ended</B><br><B>June&nbsp;30,&nbsp;2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the year</B><br><B>ended&nbsp;December&nbsp;31,</B><br><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;period</B><br><B>from</B><br><B>August&nbsp;9,&nbsp;2021</B><br><B>(inception)</B><br><B>through</B><br><B>December&nbsp;
31,</B><br><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Operating costs <SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,050,505</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">816,351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,831,421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">232,346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Loss from operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(6,050,505</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(816,351</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(1,831,421</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(232,346</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Other Income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Interest earned from Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,989,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">154,482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,861,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Bank interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Total other income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,989,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">154,538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,862,147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Net (loss)/income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(3,060,575</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(661,813</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>30,726</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(225,437</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Basic and diluted weighted average shares outstanding, Class&nbsp;A ordinary shares subject to
possible redemption</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,650,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,650,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,650,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,558,966</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Basic and diluted net (loss)/income per share, Class&nbsp;A ordinary shares subject to possible
redemption</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(0.19</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(0.04</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>0.00</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(0.05</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Basic and diluted, weighted average shares outstanding &#151; Class&nbsp;B ordinary shares</P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,162,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,162,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,162,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,162,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Basic and diluted net (loss)/income per share, Class&nbsp;B ordinary shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(0.19</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(0.04</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>0.00</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(0.05</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the period from August&nbsp;9, 2021 through December&nbsp;31, 2021 and the year ended December&nbsp;31,
2022, the description of this line item was &#147;Formation and Operating Costs.&#148; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">273 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Statements of Cash Flows Data </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;six</B><br><B>months&nbsp;ended</B><br><B>June&nbsp;30,&nbsp;2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the six</B><br><B>months&nbsp;ended</B><br><B>June&nbsp;30,&nbsp;2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the year</B><br><B>ended&nbsp;December&nbsp;31,</B><br><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the period</B><br><B>from</B><br><B>August&nbsp;9, 2021</B><br><B>(inception)</B><br><B>through</B><br><B>December&nbsp;31,</B><br><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,245,013</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>294,385</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(755,147</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(796,248</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,265,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(129,662,500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2,465,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>131,528,046</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net change in cash</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(45,013</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>294,385</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(755,147</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,069,298</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, beginning of the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">314,151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,069,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,069,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash, end of the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>269,138</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>774,913</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>314,151</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,069,298</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">274 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Balance Sheets </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30, 2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">269,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">314,151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,069,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,668</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">197,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">498,591</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>309,806</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>511,804</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,567,889</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses <FONT STYLE="white-space:nowrap">&#151;&nbsp;non-current</FONT> portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">209,052</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and securities held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">135,786,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">131,531,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">129,669,409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>136,095,976</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>132,043,138</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>131,446,350</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities, Shares Subject to Redemption and Shareholders&#146; Deficit:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current liabilities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued offering costs and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,493,223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">844,605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">316,651</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Due to related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48,699</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48,904</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Promissory note &#151; related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">965,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Convertible Note &#151; Related Party</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>8,006,922</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>893,509</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>327,447</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred underwriting commissions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,727,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,727,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,727,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>11,734,422</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>4,621,009</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>4,054,947</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Commitments and Contingencies</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;A ordinary shares subject to possible redemption, 12,650,000 shares at redemption value
of approximately $10.73, $10.40 and $10.25 at June&nbsp;30, 2023 and December&nbsp;31, 2022 and 2021, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">135,786,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">131,531,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">129,669,409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Shareholders&#146; Deficit:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preference shares, $0.0001&nbsp;par value; 5,000,000&nbsp;shares authorized; none issued and
outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;A ordinary shares, $0.0001&nbsp;par value;&nbsp;500,000,000&nbsp;shares authorized;
none outstanding (excluding&nbsp;12,650,000&nbsp;shares subject to possible redemption issued) at June&nbsp;30, 2023, December&nbsp;31, 2022 and 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;B ordinary shares, $0.0001&nbsp;par value;&nbsp;50,000,000&nbsp;shares
authorized;&nbsp;3,162,500&nbsp;shares issued and outstanding at June&nbsp;30, 2023, December&nbsp;31, 2022 and December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Additional&nbsp;paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,424,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,109,521</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,278,322</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total shareholders&#146; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>11,424,616</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(4,109,205</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(2,278,006</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Liabilities, Shares Subject to Redemption and Shareholders&#146; Deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>136,095,976</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>132,043,138</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>131,446,350</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">275 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom459793_27"></A>SELECTED HISTORICAL FINANCIAL DATA OF ENGENE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selected statement of consolidated operations and comprehensive loss and cash flow data of enGene for the three for the years ended
October&nbsp;31, 2022, 2021, and 2020, and the balance sheet data as of October&nbsp;31, 2022 and 2021, were derived from the audited historical consolidated financial statements of enGene included elsewhere in this proxy statement/prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selected statement of consolidated operations and comprehensive loss of enGene for the three and six months ended April&nbsp;30, 2023 and
2022 and statement of cash flows for the six months ended April&nbsp;30, 2023 and 2022, and the balance sheet data as of April&nbsp;30, 2023, were derived from the unaudited historical interim consolidated financial statements of enGene included
elsewhere in this proxy statement/prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information below is only a summary and should be read in conjunction with the sections
entitled &#147;<I>enGene&#146;s Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</I>&#148; and in enGene&#146;s consolidated financial statements, and the notes related thereto, which are included elsewhere
in this proxy statement/prospectus. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Statements of Operations and Comprehensive Loss Data </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Three Months Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Six Months Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>Year Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>April&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>April&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>October&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(dollar amounts in<BR>thousands, except<BR>share and per share<BR>data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(dollar amounts in<BR>thousands, except<BR>share and per share<BR>data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="10" ALIGN="center"><B>(dollar amounts in<BR>thousands, except<BR>share and per share<BR>data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;9,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,853</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total other (income) expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,767</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net loss per share of common shares, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Weighted average number of common shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,849,767</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,622,186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,768,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,616,193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,640,030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,562,638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,763,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Statements of Balance Sheet Data </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>As of</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>April&nbsp;30,</B><br><B>2023</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>October&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(dollar&nbsp;amounts<BR>in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(dollar&nbsp;amounts<BR>in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,641</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,517</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-current</FONT> liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42,301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shareholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">89,238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">76,614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53,442</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">276 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Statements of Cash Flows Data </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Six Months Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>Year Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>April&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>October&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(dollar amounts<BR>in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(dollar amounts in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10,667</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,186</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(17,592</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15,984</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(13,061</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(23</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(115</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(153</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(247</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(192</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of exchange rate changes on cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(342</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(805</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(51</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase (decrease) in cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,936</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,039</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(456</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">277 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom459793_28"></A>INFORMATION ABOUT FEAC </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Unless the context otherwise requires, all references in this section to &#147;we,&#148; &#147;us&#148; and &#147;ours&#148; refer to FEAC
prior to the consummation of the Business Combination, which will be the business of New enGene and its subsidiaries following the consummation of the Business Combination. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FEAC is a blank check company
incorporated on August&nbsp;9, 2021 as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or
entities. Prior to executing the Business Combination Agreement, FEAC&#146;s efforts were limited to organizational activities, completion of its IPO and the evaluation of possible business combinations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Sponsor is Forbion Growth Sponsor FEAC I B.V., a Dutch private limited liability company. On August&nbsp;12, 2021, Forbion European
Sponsor LLP paid $25,000, or approximately $0.009 per share, in consideration for 2,875,000 FEAC Class&nbsp;B Shares. On November&nbsp;23, 2021, Forbion European Sponsor LLP transferred 2,875,000 FEAC Class&nbsp;B Shares to the Sponsor in exchange
for $25,000, or approximately $0.009 per share. The registration statement for our IPO was declared effective on December&nbsp;9, 2021. On December&nbsp;9, 2021, FEAC issued an additional 287,500 FEAC Class&nbsp;B Shares to the Sponsor resulting
from a 1.1 for 1 share dividend. As a result, the Sponsor owned 3,162,500 FEAC Class&nbsp;B Shares as of the date of the Business Combination Agreement. The FEAC Class&nbsp;B Shares will be exchanged for FEAC Class&nbsp;A Shares, on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis, on the day that is two business days prior to the Closing of the Business Combination. The number of FEAC Class&nbsp;B Shares issued was determined based on
the expectation that the FEAC Class&nbsp;B Shares would represent 20% of the issued and outstanding ordinary shares of FEAC upon completion of the IPO. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Initial Public Offering </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
December&nbsp;14, 2021, we completed our IPO of 11,000,000 FEAC Units at a price of $10.00 per unit, generating gross proceeds of $110,000,000. On December&nbsp;15, 2021, the underwriters of our IPO exercised their full over-allotment option and
purchased the additional FEAC Units available to them. The aggregate amount of FEAC Units sold in our IPO and subsequent exercise of the over-allotment option was 12,650,000 and generated gross proceeds of $126,500,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Simultaneously with the closing of the IPO, the Sponsor purchased in a private placement 4,700,000 FEAC Private Placement Warrants (5,195,000
FEAC Private Placement Warrants when the underwriters&#146; over-allotment option was fully exercised on December&nbsp;15, 2021), each exercisable to purchase one FEAC Class&nbsp;A Share at $11.50 per share, at a price of $1.50 per FEAC Private
Placement Warrants. The sale of the FEAC Private Placement Warrants in connection with the IPO and subsequent over-allotment option exercise generated gross proceeds of $7,792,500. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Transaction costs related to our IPO amounted to $5,793,160 consisting of $1,800,000 of underwriting commissions, $3,150,000 of deferred
underwriting commissions, and $843,160 of other offering costs. The underwriters&#146; exercise of their full over-allotment option generated an additional $907,500 in transaction costs for aggregate transaction costs of $6,700,660 consisting of
$2,130,000 of underwriting commissions, $3,727,500 of deferred underwriting commissions and $843,160 of other offering costs. In addition, $1,641,236 of cash was held outside of the Trust Account and is available for general corporate purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the closing of our IPO on December&nbsp;14, 2021, $113,492,500 from the net proceeds of the sale of the FEAC Units in our IPO and
the sale of the FEAC Private Placement Warrants was deposited into the Trust Account. This amount was comprised of $10.25 per unit for the 11,000,000 FEAC Units sold in our IPO in addition to a $742,500 deposit in advance from the Sponsor related to
the underwriters&#146; exercise of the full over-</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">278 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
allotment option which took place the following day on December&nbsp;15, 2021. Following the closing of our IPO and the exercise of the underwriters&#146; full over-allotment option, $129,662,500
($10.25 per unit) was held in the Trust Account. The amount in the Trust Account will be invested only in U.S. government treasury obligations with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule <FONT
STYLE="white-space:nowrap">2a-7</FONT> under the Investment Company Act which invest only in direct U.S. government treasury obligations. As of June&nbsp;30, 2023, there was $135,786,170 in investments and cash held in the Trust Account and $269,138
of cash held outside the Trust Account available for general corporate purposes. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management has broad discretion with respect to
the specific application of the net proceeds of the IPO and the sale of the FEAC Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a business combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;1, 2022, we announced that, commencing February&nbsp;1, 2022, holders of the 12,650,000 FEAC Units sold in our IPO and
subsequent over-allotment option exercise may elect to separately trade the FEAC Class&nbsp;A Shares and the FEAC Warrants included in the FEAC Units. Those FEAC Units not separated continued to trade on Nasdaq under the symbol &#147;FRBNU&#148; and
the FEAC Class&nbsp;A Shares and FEAC Warrants that were separated trade under the symbols &#147;FRBN&#148; and &#147;FRBNW,&#148; respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>June
2023 Combination Period Extension </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FEAC may extend the period of time to consummate a business combination by up to two additional
three-month periods (for a total of 24 months to complete an initial business combination). In order to extend the time available for FEAC to consummate an initial business combination, the Sponsor or its affiliates or designees must deposit into
the Trust Account, for each additional three-month period, $1,265,000 ($0.10 per FEAC Class&nbsp;A Shares in either case), on or prior to the date of the applicable deadline, the first of which was on June&nbsp;14, 2023. Any such payments would be
made in the form of a <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing, unsecured promissory note (each such note, an &#147;Extension Loan&#148;). The Sponsor and its affiliates or designees are not obligated to fund the Trust Account to
extend the time for FEAC to complete an initial business combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;6, 2023, FEAC extended the time available to
consummate its initial business combination from June&nbsp;14, 2023 to September&nbsp;14, 2023 by having the Sponsor deposit an additional $1,265,000, or $0.10 per unit, into the Trust Account (the &#147;Extension Funding&#148;), in accordance with
FEAC&#146;s Current Articles and the Investment Management Trust Agreement by and between the Company and Continental Stock Transfer&nbsp;&amp; Trust Company, dated as of December&nbsp;9, 2021. In connection with the Extension Funding, on
June&nbsp;6, 2023, FEAC issued an unsecured promissory note (the &#147;Extension Note&#148;) in the total principal amount of $1,265,000 to the Sponsor. The Sponsor funded the principal amount of $1,265,000 by depositing such amount into the Trust
Account on June&nbsp;6, 2023. The Extension Note bears no interest and shall be due and payable on the Loan Note Maturity Date. In the event that FEAC does not consummate an initial business combination, the Extension Note will be repaid only from
amounts remaining outside of the Trust Account, if any. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently with the consummation of an initial business combination, the
Sponsor will have the option, but not the obligation, to convert up to $600,000 total principal amount of the Extension Note, in whole or in part, into additional warrants of FEAC at a price of $1.50 per warrant, each warrant exercisable for one
FEAC Class&nbsp;A Share. The warrants will be identical to the FEAC Private Placement Warrants (see also &#147;<I>The Business Combination Agreement &#151; Repayment of the Working Capital Loan Note and Extension Loan Notes</I>&#148;). A failure to
pay the principal outstanding amount of the Extension Note within five business days following the date when due or the commencement of a voluntary or involuntary bankruptcy action of FEAC shall be deemed an event of default, in which case the
Sponsor may declare the Extension Note due and payable immediately. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FEAC currently intends, in accordance with its obligations under
the Business Combination Agreement, to extend the time available to it to consummate its initial business combination from September 14, 2023, to December 14, 2023, by depositing an additional $1,265,000 (or $0.10 per FEAC Class A Share) into the
Trust Account on or before September 14, 2023, and the Sponsor is expected to fund such amount in the form of an additional extension note on the same terms. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">279 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Effecting the Business Combination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Redemption of FEAC Class&nbsp;A Shares and Liquidation If No Business Combination </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FEAC&#146;s Governing Documents provide that we will have only 18 months from the closing of our IPO (or up to 24 months from the closing of
our IPO if we extend the period of time to consummate a business combination, subject to the Sponsor depositing additional funds in the Trust Account) (the &#147;Combination Period&#148;) to consummate our initial business combination. If we have
not consummated an initial business combination within the Combination Period, we will: (i)&nbsp;cease all operations except for the purpose of winding up; (ii)&nbsp;as promptly as reasonably possible but not more than ten business days thereafter,
redeem the FEAC Class&nbsp;A Shares, at a per share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (which interest will be net of taxes payable) earned on the funds held in the Trust
Account and not previously released to us to pay our income taxes, if any (less up to $100,000 of interest to pay dissolution expenses) divided by the number of the then-outstanding FEAC Class&nbsp;A Shares, which redemption will completely
extinguish public shareholders&#146; rights as shareholders (including the right to receive further liquidation distributions, if any); and (iii)&nbsp;as promptly as reasonably possible following such redemption, subject to the approval of our
remaining shareholders and its board of directors, liquidate and dissolve, subject in the case of clauses (ii)&nbsp;and (iii), to our obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable
law. There will be no redemption rights or liquidating distributions with respect to the FEAC Warrants, which will expire worthless if we fail to consummate an initial business combination within the Combination Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Sponsor and each member of its management team have entered into an agreement with FEAC, pursuant to which they have agreed to
(i)&nbsp;waive their redemption rights with respect to their FEAC Class&nbsp;B Shares, (ii)&nbsp;to waive their redemption rights with respect to their FEAC Class&nbsp;B Shares and FEAC Class&nbsp;A Shares in connection with a shareholder vote to
approve an amendment to our Governing Documents (A)&nbsp;that would modify the substance or timing of our obligation to provide holders of the FEAC Class&nbsp;A Shares the right to have their FEAC Class&nbsp;A Shares redeemed in connection with the
initial business combination or to redeem 100% of the FEAC Class&nbsp;A Shares if we do not complete the initial business combination within the Combination Period or (B)&nbsp;with respect to any other provision relating to the rights of holders of
the FEAC Class&nbsp;A Shares, and (iii)&nbsp;waive their rights to liquidating distributions from the Trust Account with respect to any FEAC Class&nbsp;B Shares they hold if we fail to consummate an initial business combination within the
Combination Period (although they will be entitled to liquidating distributions from the Trust Account with respect to any FEAC Class&nbsp;A Shares they hold if we fail to complete the initial business combination within the Combination Period).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Sponsor and our officers and directors have agreed, pursuant to a letter agreement with us, that they will not propose any amendment
to our Governing Documents (A)&nbsp;that would modify the substance or timing of our obligation to provide holders of our FEAC Class&nbsp;A Shares the right to have their FEAC Class&nbsp;A Shares redeemed in connection with our initial business
combination or to redeem 100% of our FEAC Class&nbsp;A Shares if we do not complete our initial business combination within the Combination Period or (B)&nbsp;with respect to any other provision relating to the rights of holders of our FEAC
Class&nbsp;A Shares, unless we provide such FEAC Shareholders with the opportunity to redeem their FEAC Class&nbsp;A Shares upon approval of any such amendment at a per share price, payable in cash, equal to the aggregate amount then on deposit in
the Trust Account, including interest (which interest will be net of taxes payable) earned on the funds held in the Trust Account and not previously released to us to pay our income taxes, if any, divided by the number of the then-outstanding FEAC
Class&nbsp;A Shares. However, we may not redeem our FEAC Class&nbsp;A Shares in an amount that would cause our net tangible assets to be less than $5,000,001 (so that we do not then become subject to the SEC&#146;s &#147;penny stock&#148; rules). If
this optional redemption right is exercised with respect to an excessive number of FEAC Class&nbsp;A Shares such that we cannot satisfy the net tangible asset requirement, we would not proceed with the amendment or the related redemption of FEAC
Class&nbsp;A Shares at such time. This redemption right shall apply in the event of the approval of any such amendment, whether proposed by our Sponsor, any executive officer or director, or any other person. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">280 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we were to expend all of the net proceeds of our IPO and the sale of the FEAC Private
Placement Warrants, other than the funds held in the Trust Account, and without taking into account interest, if any, earned on the Trust Account, the per share redemption amount received by shareholders upon our dissolution would be $10.35
(including the Extension Funding on June&nbsp;6, 2023 and assuming the period of time to consummate an initial business combination is not extended a second time as provided for herein). The proceeds funds held in the Trust Account could, however,
become subject to the claims of our creditors which would have higher priority than the claims of holders of FEAC Class&nbsp;A Shares. We cannot assure you that the actual per share redemption amount received by shareholders will not be less than
$10.35. While we intend to pay such amounts, if any, we cannot assure you that we will have funds sufficient to pay or provide for all creditors&#146; claims. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we will seek to have all vendors, service providers, prospective target businesses and other entities with which we do business
execute agreements with us waiving any right, title, interest or claim of any kind in or to any monies held in the Trust Account for the benefit of holders of FEAC Class&nbsp;A Shares, there is no guarantee that they will execute such agreements or
even if they execute such agreements that they would be prevented from bringing claims against the Trust Account including, but not limited, to fraudulent inducement, breach of fiduciary responsibility or other similar claims, as well as claims
challenging the enforceability of the waiver, in each case in order to gain an advantage with respect to a claim against our assets, including the funds held in the Trust Account. If any third-party refuses to execute an agreement waiving such
claims to the monies held in the Trust Account, our management will perform an analysis of the alternatives available to it and will only enter into an agreement with a third-party that has not executed a waiver if management believes that such
third-party&#146;s engagement would be significantly more beneficial to us than any alternative. Examples of possible instances where we may engage a third-party that refuses to execute a waiver include the engagement of a third-party consultant
whose particular expertise or skills are believed by management to be significantly superior to those of other consultants that would agree to execute a waiver or in cases where management is unable to find a service provider willing to execute a
waiver. UBS Securities and Kempen&nbsp;&amp; Co. USA, Inc. (now called Van Lanschot Kempen) have not executed an agreement with us waiving such claims to the monies held in the Trust Account in connection with our IPO. In addition, there is no
guarantee that such entities will agree to waive any claims they may have in the future as a result of, or arising out of, any negotiations, contracts or agreements with us and will not seek recourse against the Trust Account for any reason. In
order to protect the amounts held in the Trust Account, our Sponsor has agreed that it will be liable to us if and to the extent any claims by a third-party (other than Marcum LLP, our independent registered public accounting firm) for services
rendered or products sold to us (other than our independent registered public accounting firm), or a prospective target business with which we have discussed entering into a transaction agreement, reduce the amounts in the Trust Account to below the
lesser of (i) $10.25 per FEAC Class&nbsp;A Share and (ii)&nbsp;the actual amount per FEAC Class&nbsp;A Share held in the Trust Account as of the date of the liquidation of the Trust Account if less than $10.25 per FEAC Class&nbsp;A Share due to
reductions in the value of the trust assets, in each case net of the interest that may be withdrawn to pay our tax obligations (less up to $100,000 of interest to pay dissolution expenses), provided that such liability will not apply to any claims
by a third-party or prospective target business that executed a waiver of any and all rights to seek access to the Trust Account nor will it apply to any claims under our indemnity of the underwriters of our IPO against certain liabilities,
including liabilities under the Securities Act. In the event that an executed waiver is deemed to be unenforceable against a third-party, our Sponsor will not be responsible to the extent of any liability for such third-party claims. However, we
have not asked our Sponsor to reserve for such indemnification obligations, nor have we independently verified whether our Sponsor has sufficient funds to satisfy its indemnity obligations and we believe that our Sponsor&#146;s only assets are
securities of our company. Therefore, we cannot assure you that our Sponsor would be able to satisfy those obligations. None of our officers or directors will indemnify us for claims by third parties including, without limitation, claims by vendors
and prospective target businesses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that the proceeds in the Trust Account are reduced below the lesser of (i) $10.25 per
FEAC Class&nbsp;A Share and (ii)&nbsp;the actual amount per FEAC Class&nbsp;A Share held in the Trust Account as of the date of the liquidation of the Trust Account if less than $10.25 per FEAC Class&nbsp;A Share due to reductions in the value of
the trust assets, in each case net of the amount of interest which may be withdrawn to pay our income tax obligations, and our Sponsor asserts </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">281 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that it is unable to satisfy its indemnification obligations or that it has no indemnification obligations related to a particular claim, our independent directors would determine whether to take
legal action against our Sponsor to enforce its indemnification obligations. While we currently expect that our independent directors would take legal action on our behalf against our Sponsor to enforce its indemnification obligations to us, it is
possible that our independent directors in exercising their business judgment may choose not to do so in any particular instance. Accordingly, we cannot assure you that due to claims of creditors the actual value of the per share redemption price
will not be less than $10.35 per FEAC Class&nbsp;A Share (excluding interest earned in the Trust Account). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will seek to reduce the
possibility that our Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers, prospective target businesses or other entities with which we do business execute agreements with
us waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account. Our sponsor will also not be liable as to any claims under our indemnity of the underwriters of our IPO against certain liabilities, including
liabilities under the Securities Act. We will have access to up to $1,641,236 following our IPO and the sale of the FEAC Private Placement Warrants with which to pay any such potential claims (including costs and expenses incurred in connection with
our liquidation, currently estimated to be no more than approximately $100,000). In the event that we liquidate and it is subsequently determined that the reserve for claims and liabilities is insufficient, shareholders who received funds from our
Trust Account could be liable for claims made by creditors, however such liability will not be greater than the amount of funds from our Trust Account received by any such shareholder. In the event that our offering expenses exceed our estimate of
$620,000, we may fund such excess with funds from the funds not to be held in the Trust Account. In such case, the amount of funds we hold outside the Trust Account would decrease by a corresponding amount. Conversely, in the event that the offering
expenses are less than our estimate of $620,000, the amount of funds we hold outside the Trust Account would increase by a corresponding amount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we file a bankruptcy or <FONT STYLE="white-space:nowrap">winding-up</FONT> petition or an involuntary bankruptcy or <FONT
STYLE="white-space:nowrap">winding-up</FONT> petition is filed against us that is not dismissed, the funds held in the Trust Account could be subject to applicable bankruptcy or insolvency law, and may be included in our bankruptcy estate and
subject to the claims of third parties with priority over the claims of our shareholders. To the extent any bankruptcy claims deplete the Trust Account, we cannot assure you we will be able to return $10.35 per FEAC Class&nbsp;A Share (excluding
interest earned in the Trust Account) to holders thereof. Additionally, if we file a bankruptcy or <FONT STYLE="white-space:nowrap">winding-up</FONT> petition or an involuntary bankruptcy or <FONT STYLE="white-space:nowrap">winding-up</FONT>
petition is filed against us that is not dismissed, any distributions received by shareholders could be viewed under applicable debtor/creditor and/or bankruptcy or insolvency laws as either a &#147;preferential transfer&#148; or a &#147;fraudulent
conveyance.&#148; As a result, a bankruptcy or insolvency court could seek to recover some or all amounts received by our shareholders. Furthermore, our board of directors may be viewed as having breached its fiduciary duty to our creditors and/or
may have acted in bad faith, and thereby exposing itself and our company to claims of punitive damages, by paying holders of FEAC Class&nbsp;A Shares from the Trust Account prior to addressing the claims of creditors. We cannot assure you that
claims will not be brought against us for these reasons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of FEAC Class&nbsp;A Shares are entitled to receive funds from the Trust
Account only (i)&nbsp;in the event of the redemption of our FEAC Class&nbsp;A Shares if we do not complete our initial business combination within the Combination Period, (ii)&nbsp;in connection with a shareholder vote to amend our Current Articles
(A)&nbsp;to modify the substance or timing of our obligation to provide holders of our FEAC Class&nbsp;A Shares the right to have their shares redeemed in connection with our initial business combination or to redeem 100% of FEAC Class&nbsp;A Shares
if we do not complete our initial business combination within the Combination Period, or (B)&nbsp;with respect to any other provision relating to the rights of holders of our FEAC Class&nbsp;A Shares, or (iii)&nbsp;if they redeem their respective
shares for cash upon the completion of the initial business combination. FEAC Shareholders who redeem their FEAC Class&nbsp;A Shares in connection with a shareholder vote described in clause (ii)&nbsp;in the preceding sentence shall not be entitled
to funds from the Trust Account upon the subsequent completion of an initial business combination or liquidation if we have not consummated an initial business combination within 18 months from the closing of our IPO (or up to 24 months from the
closing of our IPO if we extend the period of time to consummate a business combination, subject to our Sponsor depositing additional funds in the Trust </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">282 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Account), with respect to such FEAC Class&nbsp;A Shares so redeemed. In no other circumstances does a shareholder have any right or interest of any kind to or in the Trust Account. In the event
we seek shareholder approval in connection with our initial business combination, a shareholder&#146;s voting in connection with the business combination alone will not result in a shareholder&#146;s redeeming its shares to us for an applicable pro
rata share of the Trust Account. Such shareholder must have also exercised its redemption rights described above. These provisions of our Current Articles, like all provisions of our Current Articles, may be amended with a shareholder vote. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Fair Market Value of enGene&#146;s Business </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rules of Nasdaq require that FEAC&#146;s initial business combination must occur with one or more target businesses that together have an
aggregate fair market value of at least 80% of the assets held in the Trust Account (excluding the deferred underwriting commissions and taxes payable on the income earned on the Trust Account) at the time of the agreement to enter into the business
combination. The FEAC Board determined that this test was met in connection with the proposed Business Combination. The fair market value of enGene has been determined by the FEAC Board based upon standards generally accepted by the financial
community (such as actual and potential sales, earnings, cash flow and/or book value). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting Restrictions in Connection with Shareholder Meeting
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with FEAC&#146;s IPO, FEAC&#146;s initial shareholder (consisting of the Sponsor) and its directors at the time of its
IPO entered into a letter agreement to vote their shares in favor of the initial business combination. As of the date hereof, the Sponsor owns approximately 20%, and FGOF, together with the Sponsor, owns approximately 32.7%, of the total outstanding
FEAC Shares (excluding, for the avoidance of doubt, the FEAC Class&nbsp;A Shares underlying the FEAC Private Placement Warrants). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At any
time prior to the Special Meeting, during a period when they are not then aware of any material nonpublic information regarding FEAC or its securities, the Sponsor, enGene and/or its affiliates may purchase shares and/or warrants from investors, or
they may enter into transactions with such investors and others to provide them with incentives to acquire shares of FEAC Class&nbsp;A Shares or vote their shares in favor of the Business Combination. The purpose of such share purchases and other
transactions would be to increase the likelihood that the proposals presented to shareholders for approval at the Special Meeting are approved. Any such share purchases and other transactions may thereby increase the likelihood of obtaining
shareholder approval of the Business Combination. This may result in the completion of the Business Combination in a way that may not otherwise have been possible. While the exact nature of any such incentives has not been determined as of the date
of this proxy statement/prospectus, they might include, without limitation, arrangements to protect such investors or holders against potential loss in value of their shares, including the granting of put options and the transfer to such investors
or holders of shares or rights owned by the Sponsor for nominal value. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Properties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Commencing on the date of the IPO and through the earlier of consummation of the initial business combination and the liquidation, FEAC agreed
to pay the Sponsor a total of $10,000 per month for office space, utilities, secretarial and administrative support and to reimburse the Sponsor for any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT>
expenses related to identifying, investigating and completing an initial business combination. FEAC currently maintains its executive offices at 4001 Kennett Pike, Suite 302 Wilmington, Delaware 19807. The cost for the use of this space is included
in the $10,000 per month fee FEAC pays to the Sponsor for office space, administrative and support services. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently have two executive officers. These individuals are not obligated to devote any specific number of hours to our matters but they
intend to devote as much of their time as they deem necessary to our affairs until </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">283 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
we have completed our initial business combination. The amount of time they will devote in any time period will vary based on whether a target business has been selected for our initial business
combination and the stage of the business combination process we are in. We do not intend to have any full time employees prior to the completion of our initial business combination. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Directors and Executive Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FEAC&#146;s directors and executive officers are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="46%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Position</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jasper Bos</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Executive Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cyril Lesser</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Financial Officer</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sander Slootweg</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wouter Joustra</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Philip Astley-Sparke</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hilde Steineger</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ton Logtenberg</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Jasper Bos, Ph.D.</I></B>, our Chief Executive Officer, is a former Merck executive and joined Forbion
Growth as a General Partner in May 2021. Before joining Forbion&#146;s Naarden-based headquarters, Jasper was Senior Vice President and Managing Director at M Ventures, leading the venture capital arm of pharmaceutical company Merck, which he joined
in 2009. At M Ventures, he led a team of 21 investment professionals and with a fund size of &#128;400&nbsp;million invested in over 50 portfolio companies spanning biotech, life sciences tools, and tech companies with investment activities ranging
from seed-stage to cross-over and IPO. In addition, as Country Speaker Merck Netherlands, he assumed responsibility and liaised between all Merck activities in the Netherlands. His track record as an investor includes the successful exits of Prexton
Therapeutics, Epitherapeutics, Galecto, ObsEva, Translate Bio, and <FONT STYLE="white-space:nowrap">F-Star,</FONT> and has served on multiple boards of privately-owned biotech companies. He has experience in several operational roles in portfolio
companies and played a key role in the creation of multiple successful <FONT STYLE="white-space:nowrap">spin-out</FONT> companies out of Merck. Jasper holds a Ph.D. in Pharmacy from the University of Groningen, the Netherlands. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Cyril Lesser</I></B>, our Chief Financial Officer, joined Forbion in 2009 as a Controller. Prior to joining Forbion, Cyril was a Senior
Account Manager at a trust office where he was responsible for a team dealing with the accounting, financial and tax aspects of several companies. Cyril holds a M.Sc. in International Financial Economics from the University of Amsterdam and a M.Sc.
in Fiscal Law from the Free University of Amsterdam, The Netherlands. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Sander Slootweg</I></B>, who is a <FONT
STYLE="white-space:nowrap">non-independent</FONT> member of our board of directors, is the Managing Partner and <FONT STYLE="white-space:nowrap">Co-Founder</FONT> of Forbion. In addition to his leading role in the investment team and the portfolio,
he is responsible for fundraising, investor and public relations. On the portfolio management side, he currently serves on the boards of portfolio companies NewAmsterdam Pharma (Chair, NAMS), Azafaros, Replimune (REPL), NorthSea (Chair), Xention and
Oxyrane. Significant transactions for which Sander was responsible include Dezima Pharma, acquired by Amgen in 2015 for up to $1.55&nbsp;billion, and Biovex, sold to Amgen in March of 2011 for up to $1&nbsp;billion. In recent years, Sander has also
served on the boards of Ario Pharma, Pulmagen, Fovea (sold to Sanofi in 2009), uniQure (QURE, IPO on Nasdaq in 2014), Argenta (sold to Galapagos in 2010), Alantos Pharmaceuticals, Inc. (sold to Amgen in 2007), Impella (sold to Abiomed in 2005),
Pieris (IPO on Nasdaq in 2015) and has acted as the Chairman of the Board of AMT (IPO on Euronext in 2007). Before <FONT STYLE="white-space:nowrap">co-founding</FONT> Forbion, he was an Investment Director at ABN AMRO Capital Life Sciences. His
other activities at ABN AMRO included <FONT STYLE="white-space:nowrap">buy-out/growth</FONT> equities at ABN AMRO Capital, Equity Capital Markets Syndications and Financial Institutions Relationship Management Latin America. Sander holds degrees in
Business and Financial Economics from the Free University of Amsterdam and Business Administration from Nyenrode University, The Netherlands. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">284 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Wouter Joustra</I></B>, who is a
<FONT STYLE="white-space:nowrap">non-independent</FONT> member of our board of directors, joined Forbion in 2019 as a partner, currently serving as a General Partner for the Forbion Growth Fund. At Forbion, Mr.&nbsp;Joustra is responsible for deal
origination, general portfolio management and divestment strategies, and focuses on Forbion&#146;s Growth Opportunities Funds, which principally invests in late-stage life sciences companies. Previously Mr.&nbsp;Joustra was a Senior Trader as well
as Executive Board member of the Life Sciences&nbsp;&amp; Healthcare Franchise at Kempen, a European boutique investment bank. In this role, Mr.&nbsp;Joustra managed Kempen&#146;s trading portfolio and was involved in deal structuring, equity
capital markets transactions as well as larger block trades. Before Gyroscope Therapeutics was acquired by Novartis, Mr.&nbsp;Joustra served as a member of Gyroscope Therapeutics&#146; board of directors. Mr.&nbsp;Joustra currently serves as a board
member of VectivBio (Nasdaq: VECT) and holds a position as a board observer at NewAmsterdam Pharma N.V. (Nasdaq: NAMS). Mr.&nbsp;Joustra holds an M.Sc. in Business Administration from the University of Groningen and a B.Sc. in International Business
and Management from the same university. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Philip Astley-Sparke</I></B>, who is an independent
<FONT STYLE="white-space:nowrap">non-executive</FONT> member of our board of directors, is a <FONT STYLE="white-space:nowrap">co-founder</FONT> of Replimune Group Inc. (REPL) and has served as a member of the Board since the company&#146;s formation
in 2015 and served as Chief Executive Officer since January 2020. Previously, Philip served as Replimune&#146;s Executive Chairman from 2015 to January 2020. From 2016 until June 2021, Philip served as Chairman of uniQure N.V. (QURE), a Nasdaq
listed gene therapy company. From 2013 to 2015, Mr.&nbsp;Astley Sparke served as uniQure N.V.&#146;s President of United States operations, where he established its United States infrastructure. Philip served as Vice President and General Manager at
Amgen, Inc. until December 2011, following Amgen Inc.&#146;s acquisition of BioVex Group, Inc. in March 2011. Philip was previously President and Chief Executive Officer of BioVex Group, Inc. Prior to BioVex Group, Inc., Philip was a healthcare
investment banker at Chase H&amp;Q and qualified as a Chartered Accountant with Arthur Andersen LLP. Philip previously served as Chairman of the board of directors of Oxyrane Limited, a biotechnology company, from 2012 to 2020. Philip received a
B.Sc. in Cellular and Molecular Pathology from Bristol University. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Hilde Steineger, Ph.D.</I></B>, who is an independent <FONT
STYLE="white-space:nowrap">non-executive</FONT> member of our board of directors, is Chief Executive Officer at Staten Biotechnology B.V. and Chief Operating Officer and <FONT STYLE="white-space:nowrap">Co-founder</FONT> of NorthSea Therapeutics
B.V. Dr.&nbsp;Steineger previously served as Head of Strategic Innovation Management in Nutrition&nbsp;&amp; Health Division of BASF (BASF), and as Head of Global <FONT STYLE="white-space:nowrap">Omega-3</FONT> Innovation Management at Pronova
BioPharma ASA (PRON), from 2013 to 2015. From 2007 to 2010, Dr.&nbsp;Steineger was Head of Investor Relations and subsequently Vice President Business Development at Pronova BioPharma from 2010 to 2013. She has previously held positions as Senior
Associate with Neomed Management and as an equity analyst at Nordea Securities. Dr.&nbsp;Steineger served as a board member of Strongbridge BioPharma PLC (SBBP) from 2013 to 2021 and has previously served as a member of the board of directors of
Nordic Nanovector ASA, PCI Biotech AS (PCIB), Algeta ASA, Afiew AS, Weifa AS, Inven2AS, Alertis AS, Clavis Pharma ASA and Biotech Pharmacon ASA. Dr.&nbsp;Steineger holds a Ph.D. in Medical Biochemistry from University of Oslo and an M.Sc. in
Molecular Biology/Biotechnology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Ton Logtenberg, Ph.D.</I></B>, who is an independent
<FONT STYLE="white-space:nowrap">non-executive</FONT> member of our board of directors, is a <FONT STYLE="white-space:nowrap">co-founder</FONT> of Crucell N.V. (CRXL), where he served as the Chief Scientific Officer from 2000-2003 and a founder of
Merus N.V. (MRUS), where he served as the CEO since 2003 and post IPO, from 2016-2020 as the President, CEO and Principal Financial Officer. In 2022, Ton <FONT STYLE="white-space:nowrap">co-founded</FONT> Gyes B.V. and since then serves as the
company&#146;s Chief Executive Officer. Ton has extensive experience in founding biotech companies and taking them from <FONT STYLE="white-space:nowrap">start-up</FONT> to public listing on the Nasdaq and Euronext exchanges. Since 2021, Ton is a <FONT
STYLE="white-space:nowrap">non-executive</FONT> director and Chairman of the Board of Synox Therapeutics Ltd. and Mestag Therapeutics Ltd. Ton holds a M.Sc. in Medical Biology and a Ph.D. in Molecular Immunology from the University of Utrecht, The
Netherlands. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Number and Terms of Office of Officers and Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors is divided into three classes, with only one class of directors being appointed in each year, and with each class
(except for those directors appointed prior to our first annual general meeting) serving a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">285 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
three-year term. In accordance with the Nasdaq corporate governance requirements, we are not required to hold an annual meeting until one year after our first fiscal year end following our
listing on Nasdaq. The term of office of the first class of directors, consisting of Philip Astley-Sparke and Ton Logtenberg, will expire at our first annual general meeting. The term of office of the second class of directors, consisting of Sander
Slootweg and Hilde Steineger, will expire at our second annual general meeting. The term of office of the third class of directors, consisting of Wouter Joustra, will expire at our third annual general meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the completion of an initial business combination, any vacancy on the board of directors may be filled by a nominee chosen by holders
of a majority of our FEAC Class&nbsp;B Shares. In addition, prior to the completion of an initial business combination, holders of a majority of FEAC Class&nbsp;B Shares may remove a member of the board of directors for any reason. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to an agreement entered into in connection with our IPO, our Sponsor, upon and following consummation of an initial business
combination, is entitled to nominate three individuals for appointment to our board of directors, as long as our Sponsor holds any securities covered by the registration and shareholder rights agreement. This agreement will be terminated by virtue
of FEAC and the Sponsor entering into a new registration rights agreement on or around the Closing Date. See &#147;<I>Ancillary Agreements Related to the Business Combination &#151; Registration Rights Agreement</I>&#148; for further information.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our officers are appointed by the board of directors and serve at the discretion of the board of directors, rather than for specific
terms of office. Our board of directors is authorized to appoint persons to the offices set forth in our Current Articles as it deems appropriate. Our Current Articles provide that our officers may consist of one or more chairman of the board, chief
executive officer, president, chief financial officer, vice presidents, secretary, treasurer and such other offices as may be determined by the board of directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Independence </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nasdaq listing
standards require that a majority of our board of directors be independent. An &#147;independent director&#148; is defined generally as a person other than an officer or employee of the company or its subsidiaries or any other individual having a
relationship which in the opinion of the company&#146;s board of directors, would interfere with the director&#146;s exercise of independent judgment in carrying out the responsibilities of a director. Our board of directors has determined that
Philip Astley-Sparke, Hilde Steineger and Ton Logtenberg are &#147;independent directors&#148; as defined in the Nasdaq listing standards. Our independent directors will have regularly scheduled meetings at which only independent directors are
present. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officer and Director Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For services rendered to FEAC prior to or in connection with the completion of FEAC&#146;s initial business combination, each of our
independent board members will receive an annual salary of $25,000 from our Sponsor. Other than these payments, none of our executive officers or directors have received any cash compensation for services rendered to us. Until the earlier of
consummation of our initial business combination and our liquidation, we agreed to reimburse our Sponsor for office space, secretarial and administrative services provided to us in the amount of $10,000 per month. In addition, our Sponsor, executive
officers and directors, or their respective affiliates will be reimbursed for any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in connection with activities on our behalf such as
identifying potential target businesses and performing due diligence on suitable business combinations. Our audit committee will review on a quarterly basis all payments that were made by us to our Sponsor, executive officers or directors, or their
affiliates. Any such payments prior to an initial business combination will be made using funds held outside the Trust Account. Other than quarterly audit committee review of such reimbursements, we do not expect to have any additional controls in
place governing our reimbursement payments to our directors and executive officers for their <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in connection with our activities on our
behalf in connection with identifying and consummating an initial business combination. Other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">286 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
than these payments and reimbursements, no compensation of any kind, including finder&#146;s and consulting fees, will be paid by the company to our Sponsor, executive officers and directors, or
their respective affiliates, prior to completion of our initial business combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the completion of our initial business
combination, directors or members of our management team who remain with us may be paid consulting or management fees from the combined company. All of these fees will be fully disclosed to FEAC Shareholders, to the extent then known, in the proxy
solicitation materials or tender offer materials furnished to FEAC Shareholders in connection with a proposed business combination. We have not established any limit on the amount of such fees that may be paid by the combined company to our
directors or members of management. It is unlikely the amount of such compensation will be known at the time of the proposed business combination, because the directors of the post-combination business will be responsible for determining executive
officer and director compensation. Any compensation to be paid to our executive officers will be determined, or recommended to the board of directors for determination, either by a compensation committee constituted solely by independent directors
or by a majority of the independent directors on our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not intend to take any action to ensure that members of
our management team maintain their positions with us after the consummation of our initial business combination, although it is possible that some or all of our executive officers and directors may negotiate employment or consulting arrangements to
remain with us after our initial business combination. The existence or terms of any such employment or consulting arrangements to retain their positions with us may influence our management&#146;s motivation in identifying or selecting a target
business but we do not believe that the ability of our management to remain with us after the consummation of our initial business combination will be a determining factor in our decision to proceed with any potential business combination. We are
not party to any agreements with our executive officers and directors that provide for benefits upon termination of employment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Committees of the
Board of Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Nasdaq listing rules, we have three standing committees&#151;an audit committee in compliance with
Section&nbsp;3(a)(58)(A) of the Exchange Act, a compensation committee, and a nominating committee, each comprised of independent directors. Under Nasdaq listing rule 5615(b)(1), a company listing in connection with its IPO is permitted to phase in
its compliance with the independent committee requirements. We do not rely on the <FONT STYLE="white-space:nowrap">phase-in</FONT> schedules set forth in Nasdaq listing rule 5615(b)(1). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Audit Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have established an audit committee of the board of directors. The members of our audit committee are Philip Astley-Sparke, Hilde Steineger
and Ton Logtenberg. Hilde Steineger serves as Chairman of our audit committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors has determined that each of Philip
Astley-Sparke, Hilde Steineger and Ton Logtenberg are independent under the Nasdaq listing standards and applicable SEC rules. Each member of the audit committee is financially literate and our board of directors has determined that Hilde Steineger
qualifies as an &#147;audit committee financial expert&#148; as defined in applicable SEC rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audit committee is responsible for:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">meeting with our independent registered public accounting firm regarding, among other issues, audits, and
adequacy of our accounting and control systems; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">monitoring the independence of the independent registered public accounting firm; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">verifying the rotation of the lead (or coordinating) audit partner having primary responsibility for the audit
and the audit partner responsible for reviewing the audit as required by law; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">287 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inquiring and discussing with management our compliance with applicable laws and regulations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">pre-approving</FONT> all audit services and permitted <FONT
STYLE="white-space:nowrap">non-audit</FONT> services to be performed by our independent registered public accounting firm, including the fees and terms of the services to be performed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">appointing or replacing the independent registered public accounting firm; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">determining the compensation and oversight of the work of the independent registered public accounting firm
(including resolution of disagreements between management and the independent registered public accounting firm regarding financial reporting) for the purpose of preparing or issuing an audit report or related work; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing procedures for the receipt, retention and treatment of complaints received by us regarding
accounting, internal accounting controls or reports which raise material issues regarding our financial statements or accounting policies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">monitoring compliance on a quarterly basis with the terms of our IPO and, if any noncompliance is identified,
immediately taking all action necessary to rectify such noncompliance or otherwise causing compliance with the terms of our IPO; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving all payments made to our existing shareholders, executive officers or directors and their
respective affiliates. Any payments made to members of our audit committee will be reviewed and approved by our board of directors, with the interested director or directors abstaining from such review and approval. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Compensation Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have established a compensation committee of the board of directors. The members of our compensation committee are Philip Astley-Sparke,
Hilde Steineger and Ton Logtenberg, and Philip Astley-Sparke serves as chairman of the compensation committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have adopted a
compensation committee charter, which details the principal functions of the compensation committee, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving on an annual basis the corporate goals and objectives relevant to our Chief Executive
Officer&#146;s compensation, evaluating our Chief Executive Officer&#146;s performance in light of such goals and objectives and determining and approving the remuneration (if any) of our Chief Executive Officer based on such evaluation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving the compensation of all of our other Section&nbsp;16 executive officers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing our executive compensation policies and plans; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">implementing and administering our incentive compensation equity-based remuneration plans; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assisting management in complying with our proxy statement and annual report disclosure requirements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approving all special perquisites, special cash payments and other special compensation and benefit arrangements
for our executive officers and employees; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">producing a report on executive compensation to be included in our annual proxy statement; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing, evaluating and recommending changes, if appropriate, to the remuneration for directors.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The charter also provides that the compensation committee may, in its sole discretion, retain or obtain the advice of a
compensation consultant, legal counsel or other adviser and will be directly responsible for the appointment, compensation and oversight of the work of any such adviser. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">288 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, before engaging or receiving advice from a compensation consultant, external legal
counsel or any other adviser, the compensation committee will consider the independence of each such adviser, including the factors required by Nasdaq and the SEC. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Nominating Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have established a nominating committee of the board of directors. The members of our nominating committee are Philip Astley-Sparke, Hilde
Steineger and Ton Logtenberg, and Ton Logtenberg serves as Chairman of the nominating committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The nominating committee is responsible
for overseeing the selection of persons to be nominated to serve on our board of directors. The nominating committee considers persons identified by its members, management, shareholders, investment bankers and others. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We adopted a nominating committee charter, which provides that persons to be nominated: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">should have demonstrated notable or significant achievements in business, education or public service;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">should possess the requisite intelligence, education and experience to make a significant contribution to the
board of directors and bring a range of skills, diverse perspectives and backgrounds to its deliberations; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">should have the highest ethical standards, a strong sense of professionalism and intense dedication to serving
the interests of the shareholders. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The nominating committee considers a number of qualifications relating to management
and leadership experience, background and integrity and professionalism in evaluating a person&#146;s candidacy for membership on the board of directors. The nominating committee may require certain skills or attributes, such as financial or
accounting experience, to meet specific board needs that arise from time to time and will also consider the overall experience and makeup of its members to obtain a broad and diverse mix of board members. The nominating committee does not
distinguish among nominees recommended by shareholders and other persons. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Compensation Committee Interlocks and Insider
Participation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of our executive officers currently serves, and in the past year has not served, as a member of the
compensation committee of any entity that has one or more executive officers serving on our board of directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Code of Ethics
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have adopted a code of ethics applicable to our directors, officers and employees (our &#147;Code of Ethics&#148;). Our Code of
Ethics is a &#147;code of ethics,&#148; as defined in Item 406(b) of Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT> A copy of the Code of Ethics will be provided without charge upon request from us. We intend to disclose any amendments to
or waivers of certain provisions of our Code of Ethics in a Current Report on Form <FONT STYLE="white-space:nowrap">8-K.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Conflicts of Interest </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Cayman Islands law, directors and officers owe the following fiduciary duties: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">duty to act in good faith in what the director or officer believes to be in the best interests of the company as
a whole; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">duty to exercise powers for the purposes for which those powers were conferred and not for a collateral purpose;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">289 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">directors should not improperly fetter the exercise of future discretion; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">duty to exercise powers fairly as between different sections of shareholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">duty not to put themselves in a position in which there is a conflict between their duty to the company and their
personal interests; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">duty to exercise independent judgment. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the above, directors also owe a duty of care which is not fiduciary in nature. This duty has been defined as a requirement to
act as a reasonably diligent person having both the general knowledge, skill and experience that may reasonably be expected of a person carrying out the same functions as are carried out by that director in relation to the company and the general
knowledge skill and experience of that director. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As set out above, directors have a duty not to put themselves in a position of conflict
and this includes a duty not to engage in self-dealing, or to otherwise benefit as a result of their position. However, in some instances what would otherwise be a breach of this duty can be forgiven and/or authorized in advance by the shareholders
provided that there is full disclosure by the directors. This can be done by way of permission granted in the Current Articles or alternatively by shareholder approval at general meetings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our founders, officers and directors presently have, and any of them in the future may have additional, fiduciary and contractual
duties to other entities, including MP and its affiliates. As a result, if any of our founders, officers or directors becomes aware of a business combination opportunity which is suitable for an entity to which they have then-current fiduciary or
contractual obligations, then, subject to their fiduciary duties under Cayman Islands law, they will need to honor such fiduciary or contractual obligations to present such business combination opportunity to such entity, before we can pursue such
opportunity. If these other entities decide to pursue any such opportunity, we may be precluded from pursuing the same. However, we do not expect these duties to materially affect our ability to complete our initial business combination. Our Current
Articles provide that we renounce our interest in any business combination opportunity offered to any director or officer unless such opportunity is expressly offered to such person solely in their capacity as a director or officer of the company
and it is an opportunity that we are able to complete on a reasonable basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Below is a table summarizing the entities to which our
executive officers and directors currently have fiduciary duties, contractual obligations or other material management relationships: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Individual</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Entity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Entity&#146;s Business</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Affiliation</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sander Slootweg</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Replimune Group Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Biotechnology</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NewAmsterdam Pharma Company N.V.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Biotechnology</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Director, Board Chairman</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NorthSea Therapeutics B.V.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Biotechnology</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Director, Board Chairman</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Azafaros B.V.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Biotechnology</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Oxyrane UK Ltd</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Biotechnology</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wouter Joustra</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vectiv Bio</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Biotechnology</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New Amsterdam Pharma Company N.V.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Biotechnology</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Board observer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Philip Astley-Sparke</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Replimune Group Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Biotechnology</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="white-space:nowrap">Co-founder,</FONT> Director, Chief Executive Officer</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hilde Steineger</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Staten Biotechnology B.V.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Biotechnology</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Chief Executive Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NorthSea Therapeutics B.V.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Biotechnology</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="white-space:nowrap">Co-founder,</FONT> Chief Operating Officer</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">290 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Individual</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Entity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Entity&#146;s Business</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Affiliation</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ton Logtenberg</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SynOx Therapeutics Ltd</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Biotechnology</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Director, Board Chairman</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Merus N.V.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Biotechnology</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Founder, Chief Executive Officer</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gyes B.V.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Biotechnology</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Founder, Chief Executive Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mestag Therapeutics Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Biotechnology</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Director, Board Chairman</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should also be aware of the following other potential conflicts of interest: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Forbion Capital Fund III, an affiliate of Forbion, the Sponsor and FGOF, is a significant shareholder of enGene
(currently holding an equity interest in enGene of approximately 26%) and an investor in both of enGene&#146;s Amended 2022 Convertible Notes and the 2023 Convertible Notes, and as a result, a conflict of interest may exist in determining whether
the Business Combination is appropriate as FEAC&#146;s initial business combination. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our executive officers and directors are not required to, and will not, commit their full time to our affairs,
which may result in a conflict of interest in allocating their time between our operations and our search for a business combination and their other businesses. We do not intend to have any full-time employees prior to the completion of our initial
business combination. Each of our executive officers is engaged in several other business endeavors for which they may be entitled to substantial compensation, and our executive officers are not obligated to contribute any specific number of hours
per week to our affairs. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Sponsor subscribed for FEAC Class&nbsp;B Shares prior to the date of our IPO prospectus and purchased FEAC
Private Placement Warrants in a transaction that closed simultaneously with the closing of our IPO. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Sponsor and each member of our management team have entered into an agreement with us, pursuant to which they
have agreed to waive their redemption rights with respect to any FEAC Class&nbsp;B Shares and FEAC Class&nbsp;A Shares held by them in connection with (i)&nbsp;the completion of our initial business combination and (ii)&nbsp;a shareholder vote to
approve an amendment to our Current Articles (A)&nbsp;that would modify the substance or timing of our obligation to provide holders of our FEAC Class&nbsp;A Shares the right to have their shares redeemed in connection with our initial business
combination or to redeem 100% of our FEAC Class&nbsp;A Shares if we do not complete our initial business combination within the Combination Period or (B)&nbsp;with respect to any other provision relating to the rights of holders of our FEAC
Class&nbsp;A Shares. Additionally, our Sponsor has agreed to waive its rights to liquidating distributions from the Trust Account with respect to its FEAC Class&nbsp;B Shares if we fail to complete our initial business combination within the
prescribed time frame. If we do not complete our initial business combination within the required time period, the FEAC Private Placement Warrants will expire worthless. Except as described herein, our Sponsor and our directors and executive
officers have agreed not to transfer, assign or sell any of their FEAC Class&nbsp;B Shares until the earliest of (A)&nbsp;one year after the completion of our initial business combination and (B)&nbsp;subsequent to our initial business combination,
(x)&nbsp;if the closing price of our FEAC Class&nbsp;A Shares equals or exceeds $12.00 per share (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any <FONT
STYLE="white-space:nowrap">30-trading</FONT> day period commencing at least 150 days after our initial business combination, or (y)&nbsp;the date on which we complete a liquidation, merger, share exchange or other similar transaction that results in
all of the holders of FEAC Class&nbsp;A Shares having the right to exchange their ordinary shares for cash, securities or other property. With certain limited exceptions, the FEAC Private Placement Warrants and the FEAC Class&nbsp;A Shares
underlying such warrants, will not be transferable until 30 days following the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">291 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
completion of our initial business combination. Because each of our executive officers and director nominees will own ordinary shares or warrants directly or indirectly, they may have a conflict
of interest in determining whether a particular target business is an appropriate business with which to effectuate our initial business combination. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our officers and directors may have a conflict of interest with respect to evaluating a particular business
combination if the retention or resignation of any such officers and directors is included by a target business as a condition to any agreement with respect to our initial business combination. In addition, our founders, sponsor, officers and
directors may sponsor, form or participate in other blank check companies similar to ours during the period in which we are seeking an initial business combination. Any such companies may present additional conflicts of interest in pursuing an
acquisition target, particularly in the event there is overlap among investment mandates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are not prohibited from pursuing an initial business combination with a company that is affiliated with our
Sponsor, officers or directors. In the event we seek to complete our initial business combination with a company that is affiliated with our Sponsor or any of our officers or directors, we, or a committee of independent directors, will obtain an
opinion from an independent investment banking firm or another independent entity that commonly renders valuation opinions that such initial business combination is fair to our company from a financial point of view. We are not required to obtain
such an opinion in any other context. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot assure you that any of the above mentioned conflicts will be resolved
in our favor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we seek shareholder approval, we will complete our initial business combination only if we obtain the approval by way of
an ordinary resolution under Cayman Islands law, which requires the affirmative vote of a majority of the shareholders who attend and vote at a general meeting of the company. In such case, our Sponsor and each member of our management team have
agreed to vote their FEAC Class&nbsp;B Shares and FEAC Class&nbsp;A Shares in favor of our initial business combination. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitation on Liability and
Indemnification of Officers and Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cayman Islands law does not limit the extent to which a company&#146;s memorandum and
articles of association may provide for indemnification of officers and directors, except to the extent any such provision may be held by the Cayman Islands courts to be contrary to public policy, such as to provide indemnification against willful
default, willful neglect, civil fraud or the consequences of committing a crime. Our Current Articles provide for indemnification of our officers and directors to the maximum extent permitted by law, including for any liability incurred in their
capacities as such, except through their own actual fraud, willful default or willful neglect. We entered into agreements with our directors and officers to provide contractual indemnification in addition to the indemnification provided for in our
Current Articles. We also purchased a policy of directors&#146; and officers&#146; liability insurance that insures our officers and directors against the cost of defense, settlement or payment of a judgment in some circumstances and insures us
against our obligations to indemnify our officers and directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our officers and directors have agreed to waive any right, title,
interest or claim of any kind in or to any monies in the Trust Account, and have agreed to waive any right, title, interest or claim of any kind they may have in the future as a result of, or arising out of, any services provided to us and will not
seek recourse against the Trust Account for any reason whatsoever (except to the extent they are entitled to funds from the Trust Account due to their ownership of FEAC Class&nbsp;A Shares). Accordingly, any indemnification provided will only be
able to be satisfied by us if (i)&nbsp;we have sufficient funds outside of the Trust Account or (ii)&nbsp;we consummate an initial business combination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">292 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our indemnification obligations may discourage shareholders from bringing a lawsuit against
our officers or directors for breach of their fiduciary duty. These provisions also may have the effect of reducing the likelihood of derivative litigation against our officers and directors, even though such an action, if successful, might
otherwise benefit us and our shareholders. Furthermore, a shareholder&#146;s investment may be adversely affected to the extent we pay the costs of settlement and damage awards against our officers and directors pursuant to these indemnification
provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that these provisions, the insurance and the indemnity agreements are necessary to attract and retain talented and
experienced officers and directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Proceedings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is no material litigation, arbitration or governmental proceeding currently pending against us or any members of our management team in
their capacity as such, and FEAC and the members of its management team have not been subject to any such proceeding in the 12&nbsp;months preceding the date of this proxy statement/prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Periodic Reporting and Audited Financial Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FEAC has registered its securities under the Exchange Act and has reporting obligations, including the requirement to file annual and quarterly
reports with the Securities and Exchange Commission. In accordance with the requirements of the Exchange Act, FEAC has filed with the SEC its Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended June&nbsp;30,
2023. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">293 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom459793_29"></A>FEAC&#146;S MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following discussion and analysis should be read in conjunction with the
financial statements and related notes of FEAC included elsewhere in this proxy statement/prospectus. This discussion contains <FONT STYLE="white-space:nowrap">forward-looking</FONT> statements reflecting our current expectations, estimates and
assumptions concerning events and financial trends that may affect our future operating results or financial position. Actual results and the timing of events may differ materially from those contained in these forward-looking statements due to a
number of factors, including those discussed in the sections entitled &#147;Risk Factors&#148; and &#147;Cautionary Statement Regarding Forward-Looking Statements&#148; appearing elsewhere in this proxy statement/prospectus. Unless the context
otherwise requires, all references in this section to &#147;FEAC,&#148; &#147;we,&#148; &#147;us&#148; and &#147;ours&#148; refer to FEAC prior to the consummation of the Business Combination, which will be the business of New enGene and its
subsidiaries following the consummation of the Business Combination. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FEAC is a blank check company incorporated on August&nbsp;9, 2021 as a Cayman Islands exempted company for the purpose of effecting a merger,
share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. Prior to executing the Business Combination Agreement, FEAC&#146;s efforts were limited to organizational
activities, completion of its IPO and the evaluation of possible business combinations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2023, we had not commenced any operations. All activity through June&nbsp;30, 2023 related to our formation, IPO and
identifying a business combination target. We have neither engaged in any operations nor generated any revenues to date. We will not generate any operating revenues until after the completion of our initial business combination, at the earliest. We
will generate <FONT STYLE="white-space:nowrap">non-operating</FONT> income in the form of interest income on cash and cash equivalents from the proceeds derived from the IPO held in the Trust Account. We expect to incur increased expenses as a
result of being a public company (for legal, financial reporting, accounting and auditing compliance), as well as for due diligence expenses in connection with the Business Combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the six months ended June&nbsp;30, 2023, we had a net loss of $3,060,575, which consisted of operating costs of $6,050,505, partly offset
by interest income of $2,989,930. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the six months ended June&nbsp;30, 2022, we had a net loss of $661,813, which consisted of
operating costs of $816,351, partly offset by interest income of $154,538. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2022, we had a net
income of $30,726, which consisted of interest income of $1,861,925 and bank interest income of $222, partially offset by operating costs of $1,831,421. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the period from August&nbsp;9, 2021 (inception) to December&nbsp;31, 2021, we had a net loss of $225,437, which consisted of formation and
operating costs of $232,346, partially offset by interest income of $6,909. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At June&nbsp;30, 2023, we had $269,138 in our operating bank account and a working capital deficit of approximately $7,697,116. In addition, in
order to finance transaction costs in connection with a Business Combination, our Sponsor or an affiliate of the Sponsor or certain of our officers and directors may, but are not obligated to, provide our Working Capital Loans. As of June&nbsp;30,
2023 and December&nbsp;31, 2022, there was $1,200,000 and $0 outstanding under the Working Capital Loans, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">294 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with our assessment of going concern considerations in accordance with FASB
ASC <FONT STYLE="white-space:nowrap">205-40</FONT> &#147;Presentation of Financial Statements &#151; Going Concern,&#148; management has determined that we have and will continue to incur significant costs in pursuit of its acquisition plans which
raises substantial doubt about our ability to continue as a going concern. Moreover, we may need to obtain additional financing either to complete our initial business combination or because we become obligated to redeem a significant number of FEAC
Class&nbsp;A Shares upon consummation of our initial business combination, in which case we may issue additional securities or incur debt in connection with such initial business combination. Subject to compliance with applicable securities laws, we
would only complete such financing simultaneously with the completion of our initial business combination. If we are unable to complete our initial business combination because we do not have sufficient funds available to us, we will be forced to
cease operations and liquidate the Trust Accounts. In addition, following our initial business combination, if cash on hand is insufficient, we may need to obtain additional financing in order to meet our obligations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks and Uncertainties and Factors That May Adversely Affect Our Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Management is currently evaluating the impact of the current global economic uncertainty, the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
pandemic, rising interest rates, rising inflation, increases in energy prices, supply chain disruptions and the Russia-Ukraine armed conflict (including the impact of any sanctions imposed in response thereto) and has concluded that while it is
reasonably possible that any of these could have a negative effect on our financial position, results of operations and/or search for a target company, the specific impact is not readily determinable as of the date of these financial statements. The
financial statements do not include any adjustments that might result from the outcome of this uncertainty. We cannot at this time fully predict the likelihood of one or more of the above events, their duration or magnitude or the extent to which
they may negatively impact our business and our ability to complete an initial business combination. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Financing Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2023, we did not have any <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual Obligations </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not
have any long-term debt obligations, capital lease obligations, operating lease obligations, purchase obligations or long-term liabilities other than the deferred commission fees, legal fees and related party payables of $3,727,500, $3,884,759 and
$48,699 as of June&nbsp;30, 2023, respectively, payable upon the consummation of a business combination. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies and
Estimates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of the condensed financial statements in conformity with GAAP requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a
condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the
actual results could differ significantly from those estimates. We have identified the following as our critical accounting policies and estimates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Ordinary Shares Subject to Redemption </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
account for our ordinary shares subject to possible redemption in accordance with the guidance in ASC Topic 480 &#147;Distinguishing Liabilities from Equity.&#148; Ordinary shares subject to mandatory redemption (if any)
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">295 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
are classified as a liability instrument and measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares that feature redemption rights that are either within the
control of the holder or subject to redemption upon the occurrence of uncertain events not solely within our control) are classified as temporary equity. At all other times, ordinary shares are classified as shareholders&#146; equity. Our FEAC
Class&nbsp;A Shares feature certain redemption rights that are considered to be outside of our control and subject to the occurrence of uncertain future events. Accordingly, 12,650,000 FEAC Class&nbsp;A Shares subject to possible redemption are
presented at redemption value as temporary equity, outside of the shareholders&#146; deficit section of our balance sheets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognize
changes in redemption value immediately as they occur and adjust the carrying value of FEAC Class&nbsp;A Shares to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable ordinary
shares are affected by charges against additional paid in capital and accumulated deficit. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Net Loss Per Ordinary Share </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We comply with the accounting and disclosure requirements of FASB ASC Topic 260 &#147;Earnings Per Share.&#148; Net loss per ordinary share is
computed by dividing net loss by the weighted average number of shares of ordinary shares outstanding during the period, excluding ordinary shares subject to forfeiture. At June&nbsp;30, 2023, we did not have any dilutive securities and other
contracts that could, potentially, be exercised or converted into ordinary shares and then share in our losses. As a result, diluted loss per ordinary share is the same as basic loss per ordinary share for the periods presented. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Accounting Pronouncements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
August 2020, the FASB issued ASU Topic <FONT STYLE="white-space:nowrap">2020-06</FONT> &#147;Debt-Debt with Conversion and Other Options (Subtopic <FONT STYLE="white-space:nowrap">470-20)</FONT> and Derivatives and Hedging-Contracts in Entity&#146;s
Own Equity (Subtopic <FONT STYLE="white-space:nowrap">815-40):</FONT> Accounting for Convertible Instruments and Contracts in an Entity&#146;s Own Equity&#148; (&#147;ASU<B> </B><FONT STYLE="white-space:nowrap">2020-06&#148;),</FONT> which
simplifies accounting for convertible instruments by removing major separation models required under current US&nbsp;GAAP. ASU <FONT STYLE="white-space:nowrap">2020-06</FONT> also removes certain settlement conditions that are required for
equity-linked contracts to qualify for scope exception, and it simplifies the diluted earnings per share calculation in certain areas. ASU <FONT STYLE="white-space:nowrap">2020-06</FONT> is effective January&nbsp;1, 2022 and should be applied on a
full or modified<B> </B>retrospective basis, with early adoption permitted beginning on January&nbsp;1, 2021. We adopted ASU <FONT STYLE="white-space:nowrap">2020-06</FONT> effective January&nbsp;1, 2021. The adoption of ASU <FONT
STYLE="white-space:nowrap">2020-06</FONT> did not have an impact on our unaudited condensed financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Management does not
believe that any other recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the accompanying unaudited condensed financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">296 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom459793_30"></A>FEAC&#146;S EXECUTIVE AND DIRECTOR COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For services rendered to FEAC prior to or in connection with the completion of FEAC&#146;s initial business combination, each of our
independent board members will receive an annual salary of $25,000 from our Sponsor. Other than these payments, none of our executive officers or directors have received any cash compensation for services rendered to us. Until the earlier of
consummation of our initial business combination and our liquidation, we agreed to reimburse our Sponsor for office space, secretarial and administrative services provided to us in the amount of $10,000 per month. In addition, our Sponsor, executive
officers and directors, or their respective affiliates will be reimbursed for any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in connection with activities on our behalf such as
identifying potential target businesses and performing due diligence on suitable business combinations. Our audit committee will review on a quarterly basis all payments that were made by us to our Sponsor, executive officers or directors, or their
affiliates. Any such payments prior to an initial business combination will be made using funds held outside the Trust Account. Other than quarterly audit committee review of such reimbursements, we do not expect to have any additional controls in
place governing our reimbursement payments to our directors and executive officers for their <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in connection with our activities on our
behalf in connection with identifying and consummating an initial business combination. Other than these payments and reimbursements, no compensation of any kind, including finder&#146;s and consulting fees, will be paid by the company to our
Sponsor, executive officers and directors, or their respective affiliates, prior to completion of our initial business combination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">297 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom459793_31"></A>BUSINESS OF ENGENE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Throughout this section, unless otherwise noted, &#147;we,&#148; &#147;us,&#148; &#147;our&#148; and similar words refer to, for periods
prior to the Closing, enGene and its subsidiary, and for periods following the Closing, to New enGene and its consolidated subsidiaries. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a
clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. We are developing <FONT STYLE="white-space:nowrap">non-viral</FONT> gene therapies based on our novel and proprietary dually derived
chitosan, or &#147;DDX&#148;, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs. We believe our DDX platform, with its broad tissue and disease application, has the potential
to take gene therapy beyond rare genetic diseases into oncology and other underserved therapeutic areas. We have established integrated capabilities with this platform to support the clinical development and potential commercialization of our gene
therapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead product candidate, detalimogene voraplasmid, or <FONT STYLE="white-space:nowrap">&#147;EG-70,&#148;</FONT> which is
comprised of three gene cargos delivered via our proprietary DDX platform, is a therapy designed to generate a local immune reaction in proximity to tumors. We believe this enables the immune system to reduce or clear the tumor and develop memory to
resist recurrence. Because this treatment does not need to deliver the therapeutic gene directly into tumor cells, it is applicable to many tumor types. We are currently developing <FONT STYLE="white-space:nowrap">EG-70</FONT> as a monotherapy to
treat <FONT STYLE="white-space:nowrap">non-muscle</FONT> invasive bladder cancer (&#147;NMIBC&#148;) with carcinoma in situ (&#147;Cis&#148;) in patients that have been unresponsive to treatment with Bacillus Calmette-Guerin, or &#147;BCG,&#148; or
what is referred to as &#147;BCG-unresponsive NMIBC with Cis.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In NMIBC, carcinoma in situ, or Cis, is a flat, high-grade, sessile
tumor that has a high likelihood of invading the deeper layers of the bladder wall. A &#147;high-&#148; or &#147;low-&#148; tumor risk describes the degree to which the tumor pathology appears more likely to grow quickly and invade non-cancerous
tissue. NMIBC with Cis is typically initially treated with a solution containing the bacterium BCG that is instilled into the bladder multiple times over the course of several months. Despite this treatment, many of these cancers recur and are
unresponsive to additional BCG, allowing the cancer to spread throughout and deeper into the bladder and often requiring surgical removal of the bladder (radical cystectomy). We believe BCG-unresponsive NMIBC with Cis is currently an underserved
therapeutic segment with limited treatment options, and that there is a market opportunity for EG-70 as a monotherapy for this condition. While the potential market for EG-70 may not be limited to these patients, that is our current initial focus in
working to bring EG-70 to market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate there are approximately 60,000 new patients globally each year with BCG-unresponsive NMIBC,
of which up to 70% have Cis at the time of diagnosis of BCG-unresponsiveness. We derived this estimate from the overall global bladder cancer incidence of 550,000 patients per year, estimating the percentage of such patients with NMIBC, and further
estimating the percentage of such patients who later develop BCG-unresponsiveness. See <I>&#147;</I><I>&#151;</I><I> Product and Pipeline Development </I><I>&#151;</I><I> Lead Program: NMIBC Background and Unmet Need</I>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">EG-70</FONT> program is enrolling patients in a combined Phase 1/2 open label registrational study, referred
to as &#147;LEGEND&#148; (ClinicalTrials.gov identifier NCT04752722). In addition, our preclinical research is focused on expanding the cancer indications that can be treated with <FONT STYLE="white-space:nowrap">EG-70.</FONT> We are also in early
stages of developing a second product candidate referred to as <FONT STYLE="white-space:nowrap">EG-i08</FONT> for treatment of Cystic Fibrosis. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our
Competitive Strengths </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Proprietary &#147;Next-Generation&#148; DDX Platform &#151;</B> We believe our DDX platform has the potential
to be the next generation platform that takes gene therapy beyond rare diseases. It has a high degree of payload flexibility, by which we mean the capacity to include multiple genes per drug product (including DNA and RNA) and has been demonstrated
in preclinical animal and in vitro models to </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">298 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
effectively induce expression of therapeutic genes in mucosal tissues following delivery to the urinary tract, lung, and gastrointestinal tract, among other organs. We believe products developed
using the DDX platform can overcome many of the significant challenges that have historically faced gene therapy, including the inability to <FONT STYLE="white-space:nowrap">re-dose,</FONT> safety concerns, limited efficacy, high cost of goods, lack
of commercially viable manufacturing technology, limited ability to effectively target localize diseases, systemic toxicity, and difficulties with effective administration. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Fast Tracked Product Candidate in Underserved Market</B> &#151; We are developing EG-70, which has received
FDA Fast Track designation, as a monotherapy for <FONT STYLE="white-space:nowrap">BCG-unresponsive</FONT> NMIBC with Cis, which currently is an underserved therapeutic segment with limited drug and other treatment options. Although Fast Track
designation may expedite the development or review process, there can be no assurance accelerated approval designation will lead to a faster development, regulatory review or approval process or increase the likelihood EG-70 will receive marketing
approval. The <FONT STYLE="white-space:nowrap">3-month</FONT> data collected from all patients in the Phase 1 portion of the ongoing LEGEND trial demonstrate that EG-70 is well-tolerated across all tested doses. Across all dose levels tested in the
Phase 1 study, a <FONT STYLE="white-space:nowrap">3-month</FONT> complete response, or &#147;CR,&#148; rate of 68% (N=22) was observed. Importantly, 70% of patients (7 out of 10) treated in the recommended dose planned for Phase 2 (RP2D) experienced
a <FONT STYLE="white-space:nowrap">3-month</FONT> CR. Phase 1 patients who were treated in the RP2D cohort and who elected to continue treatment and receive an additional <FONT STYLE="white-space:nowrap">12-week</FONT> cycle had a 60% CR rate at
6-months (6 out of 10). While we are encouraged by these results, the Phase 1 portion of this study was designed to evaluate safety and was not designed to evaluate efficacy in a statistically meaningful way. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Product Profile Tailored to the Practical Needs of Clinicians and Patients</B> &#151; Gene therapies and gene
therapy products such as oncolytic viruses have historically been associated with specific handling or dosing requirements designed for safety reasons to minimize patient, physician, or environmental exposure or risk. These include use of enhanced
personal protective equipment during preparation and administration, required virucidal decontamination of drug product-exposed bodily fluids such as urine after exposure to the gene therapy product, preparative treatment of tissues with a solvent
or wash agent, enhanced refrigeration/cold chain storage requirements, and guidance to avoid close personal contact with the patient during the treatment period. By contrast, EG-70 can be handled in accordance with biosafety level 1 guidelines, does
not require the aforementioned precautions in handling or decontamination of fluids or bodily surfaces following dosing, and has no ultra cold chain storage requirements. We believe these product characteristics will position EG-70 as a preferred
choice among both physicians and patients. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
<P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;Pipeline-in-a-Product&#148;</FONT></FONT>
</FONT> Potential</B> &#151; Through the LEGEND study, we have demonstrated that <FONT STYLE="white-space:nowrap">EG-70</FONT> is able to traverse and transfect mucosal epithelia, express multiple cargos in the mucosal tissue and simultaneously
activate multiple arms of the immune system. We have demonstrated in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> models the potential for expanding <FONT STYLE="white-space:nowrap">EG-70</FONT> to treat multiple additional solid tumors.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Scalable, Proprietary Manufacturing Process</B> &#151; We developed the DDX platform <FONT
STYLE="white-space:nowrap">in-house,</FONT> and in addition, have developed manufacturing processes to produce <FONT STYLE="white-space:nowrap">EG-70</FONT> that we believe are robust, cost-effective and scalable. These manufacturing processes which
involve incorporation of plasmid DNA (API) with the DDX carrier at a defined concentrations and mixing rate using commercially available equipment, are patent-protected and involve proprietary <FONT STYLE="white-space:nowrap">know-how.</FONT> We
also have a global, royalty-bearing, <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license to use certain patents and <FONT STYLE="white-space:nowrap">know-how</FONT> relating to a proprietary plasmid DNA backbone for high-yield production
and efficient expression of transgene in target tissues. We believe we have scaled up our manufacturing processes to a level that will be able to meet the needs of commercial launch for <FONT STYLE="white-space:nowrap">EG-70.</FONT> We believe our
manufacturing process is in accordance with Good Manufacturing Practice (cGMP) and quality system regulations for drugs and biologics. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Experienced Management Team &#151;</B> Our management team has extensive experience across oncology,
respiratory and multiple other therapeutic areas and modalities and are well-equipped to lead our drug development and commercialization efforts. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">299 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Focus on advancing our lead product candidate <FONT STYLE="white-space:nowrap">EG-70</FONT> through late-stage
clinical development and seek regulatory marketing approval in the United States. </B>We are focused on bringing <FONT STYLE="white-space:nowrap">EG-70</FONT> to market as a monotherapy for <FONT STYLE="white-space:nowrap">BCG-unresponsive</FONT>
NMIBC with Cis, which currently is an underserved therapeutic segment with limited treatment options. According to published reports, currently available drug options have been characterized by limited effectiveness and durability, unfavorable
toxicity, manufacturing challenges, and/or practical limitations including lack of re-dosability and tropism for particular organ systems such as the liver. As a result, the primary treatment option available for most
<FONT STYLE="white-space:nowrap">BCG-unresponsive</FONT> NMIBC is a radical cystectomy, which can often result in negative outcomes, mortality, and a reduced quality of life. In response to this urgent unmet medical need, the FDA has issued guidance
for the design of clinical studies for development of novel NMIBC treatments, with a goal of encouraging development of alternative treatments to this drastic surgery. We have followed this guidance and discussed our
<FONT STYLE="white-space:nowrap">EG-70</FONT> development plan with the FDA, and subsequent to these discussions, the FDA cleared us to initiate the pivotal, Phase 2 portion of the LEGEND clinical trial. In this trial, we are evaluating the safety
and efficacy of <FONT STYLE="white-space:nowrap">EG-70</FONT> in a single arm, open label, multicenter, Phase 2 pivotal portion of our LEGEND trial using the RP2D, given to patients in multiple cycles. We currently aim to file a Biologics License
Application (&#147;BLA&#148;) in 2025 with the FDA for approval to market <FONT STYLE="white-space:nowrap">EG-70</FONT> in the United States as a monotherapy for <FONT STYLE="white-space:nowrap">BCG-unresponsive</FONT> NMIBC with Cis, and we believe
<FONT STYLE="white-space:nowrap">EG-70&#146;s</FONT> product profile will integrate seamlessly into community urology clinics where the vast majority of NMIBC patients are treated. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Build a fully integrated company by independently commercializing approved products in indications and key
geographies where we believe we can maximize our product candidates&#146; value.</B> We currently own all development and commercialization rights for our product candidates and programs. To maximize the potential of
<FONT STYLE="white-space:nowrap">EG-70,</FONT> we currently plan to retain commercial rights to <FONT STYLE="white-space:nowrap">EG-70</FONT> in the United States and commercialize <FONT STYLE="white-space:nowrap">EG-70</FONT> independently, while
selectively partnering outside of the United States, with the goal of leveraging a potential partner&#146;s regional expertise and existing sales force to the extent appropriate. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Expand the application of <FONT STYLE="white-space:nowrap">EG-70</FONT> to additional bladder cancer
indications. </B>Given the high unmet need in NMIBC, we plan to enroll a cohort of patients in the Phase 2 LEGEND trial to assess <FONT STYLE="white-space:nowrap">EG-70</FONT> in the <FONT STYLE="white-space:nowrap">BCG-na&iuml;ve</FONT> patient
population to evaluate its ultimate potential as a monotherapy in first line patients and expanding <FONT STYLE="white-space:nowrap">EG-70&#146;s</FONT> opportunity. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>We also believe we could potentially develop <FONT STYLE="white-space:nowrap">EG-70</FONT> as a treatment for
locally advanced muscle invasive bladder cancer (MIBC).</B> Preclinically, we have shown in an orthotopic model of locally advanced bladder cancer that mice receiving <FONT STYLE="white-space:nowrap">EG-70</FONT> exhibit profound and durable
anti-tumor immunity, with cured mice developing resistance to subsequent local or distal <FONT STYLE="white-space:nowrap">re-challenge</FONT> with bladder tumor cells. This <FONT STYLE="white-space:nowrap">pre-clinical</FONT> observation supports
the potential clinical evaluation of <FONT STYLE="white-space:nowrap">EG-70</FONT> in patients with intact bladders diagnosed with locally advanced or metastatic bladder cancer. Furthermore, based on the well-defined mechanism of action of <FONT
STYLE="white-space:nowrap">EG-70,</FONT> we expect that to the extent <FONT STYLE="white-space:nowrap">EG-70</FONT> proves to be both safe and effective in the high-risk NMIBC population, we could potentially also study its use in the earlier stage <FONT
STYLE="white-space:nowrap">low-</FONT> and intermediate-grade NMIBC populations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Pursue
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;pipeline-in-a-product&#148;</FONT></FONT></FONT> strategy in expanding <FONT STYLE="white-space:nowrap">EG-70</FONT> as immuno-oncology therapy
to address unmet needs in a wide range of solid tumors.</B> The demonstrated mechanism of action of <FONT STYLE="white-space:nowrap">EG-70,</FONT> namely, synergistic activation of innate and adaptive immune system to turn &#147;cold&#148; tumor
microenvironments &#147;hot,&#148; stimulates cancer antigen recognition, creates a pro tumor-killing environment in the local milieu, and induces immunological memory against the cancer. We believe it is therefore potentially applicable across a
wide range of indications in oncology and enables us to pursue a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;pipeline-in-a-product&#148;</FONT></FONT></FONT> development strategy for <FONT
STYLE="white-space:nowrap">EG-70.</FONT> We have already demonstrated strong <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> data for <FONT STYLE="white-space:nowrap">EG-70</FONT> in other solid tumor
models, and plan to advance <FONT STYLE="white-space:nowrap">EG-70</FONT> to other cancer indications with significant unmet needs. We are evaluating <FONT STYLE="white-space:nowrap">EG-70&#146;s</FONT> potential application
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">300 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
in genitourinary (prostate, upper urinary tract) and gynecological (cervical, ovarian, endometrial, vaginal vulvar) cancers. This potentially would allow for rapid entry of <FONT
STYLE="white-space:nowrap">EG-70</FONT> into new areas of clinical development. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Apply our proprietary DDX platform to other mucosal tissues.</B> We believe that our early clinical data
combined with our preclinical <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> studies demonstrate the value and the breadth of our DDX platform in delivering genetic medicines to mucosal tissues. We
believe this could potentially allow us to use this DDX platform to develop effective new agents beyond <FONT STYLE="white-space:nowrap">EG-70,</FONT> thereby unlocking better outcomes for historically <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">difficult-to-treat</FONT></FONT> conditions. Our belief is driven by our DDX platform&#146;s several key advantages and points of differentiation relative to others in the gene therapy field, which we believe will enable
us to bring gene therapy to tissues beyond the liver, muscle, and central nervous system, and will enable repeat dosing of such genetic medicines. For example, our platform&#146;s lack of significant vector-based immune response supports the ability
to dose repeatedly. Furthermore, the tolerability of DDX in the clinic is bolstered by the lack of genomic integration concerns. Importantly, we have also developed a streamlined,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-to-end</FONT></FONT> cGMP manufacturing process that can support commercial launch of <FONT STYLE="white-space:nowrap">EG-70</FONT> and that can be readily applied to new drug
products. </P></TD></TR></TABLE>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Gene Therapy Platform for Mucosal Tissues </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Historically, gene therapy has been hampered by several significant challenges associated with the use of viral vectors as gene delivery
vehicles. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Early gene therapies using viral vectors (i.e., viruses used as carriers and delivery agents in gene therapies)
were found to have led to cancers in patients due to insertional mutagenesis, and in at least one case, a severe innate immune response that led to multiple-organ failure and death. More recently, high doses of the frequently used adeno-associated
virus (AAV) viral vector have been found to lead to many serious adverse events, including hepatotoxicity, hemolytic anemia, acute kidney failure, neurotoxicity and myocarditis. These safety issues received significant attention and we believe they
negatively influenced public perception of gene therapy&#146;s overall safety. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In addition, because patients&#146; immune systems react to the proteins in the vector shell, most viral-based
gene therapies can only be applied once. This limit on the ability to <FONT STYLE="white-space:nowrap">re-dose</FONT> the therapy or titrate it to a patient&#146;s needs impedes the ability to achieve long-term consistent expression of delivered
genes in the target tissues. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Constraints on the size of genetic cargos that can be delivered by viral vectors, such as AAV, limit the number
of indications for which they may be applicable and can often require the use of truncated, <FONT STYLE="white-space:nowrap">non-natural</FONT> proteins to overcome this packaging limitation. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Finally, the high manufacturing costs of viral vectors and historical lack of scalable manufacturing systems
capable of withstanding regulatory scrutiny and meeting possible market demand limits patient access to and market adoption of many gene therapies. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe our proprietary DDX platform can overcome these limitations of traditional viral gene delivery platforms. As described in more
detail below, unlike viral vectors, we believe the delivery vehicle we have developed is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">non-viral,</FONT> consisting of synthetic polymeric carriers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">non-immunogenic,</FONT> and therefore, as has already been demonstrated in human
clinical trial, <FONT STYLE="white-space:nowrap">re-dosable;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">able to carry large genetic payload &#151; our <FONT STYLE="white-space:nowrap">EG-70</FONT> leverages a DNA
payload that comprises three distinct expressed genes delivered as a single drug product; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">manufactured based entirely on synthetic chemistry (rather than complex biological production systems), in a
process that is highly controlled, reproducible, cost-effective and scalable; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">able to traverse mucosal barriers, allowing the targeting of organs traditionally intractable for gene therapy.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">301 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mucosal tissues such as the bladder, lungs, and gut, comprise a vast surface area across the
human body. Their relative ease of accessibility makes these tissues attractive targets for modalities that have the potential to be locally targeted such as tissue-localized gene therapy. In spite of these properties, gene therapies have struggled
in mucosal tissues, as the biological barrier function of the tissues has rendered them an inhospitable environment to most drug products or gene delivery modalities. Thus, although gene therapy has revolutionized other fields of medicine, it has
left behind many patients suffering from illnesses that manifest in mucosal tissues. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">enGene was founded to seek to address these
underserved patients with novel genetic medicines. Our DDX platform allows <FONT STYLE="white-space:nowrap">non-viral</FONT> gene therapies to be dosed directly into the lumen of the targeted mucosal tissue. Once inside the lumiral cavity, the DDX
nanoparticles transport nucleic acid medicines (DNA or RNA) into the mucosal epithelial cells. For example, the transported genetic medicines can encode for proteins, peptides, antibodies, and other <FONT STYLE="white-space:nowrap">non-coding</FONT>
RNA molecules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Product and Pipeline Development </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead product candidate program is <FONT STYLE="white-space:nowrap">EG-70</FONT> (detalimogene voraplasmid), which we are developing as a
monotherapy for the treatment of BCG-unresponsive NMIBC with Cis. This lead program is currently enrolling in a combined Phase 1/2 open label registrational study, &#147;LEGEND&#148; (ClinicalTrials.gov identifier NCT04752722), the data from which
we will incorporate in a Biologics License Application to be submitted at the conclusion of the Phase 2 portion of the trial. This trial also includes a <FONT STYLE="white-space:nowrap">BCG-treatment</FONT> na&iuml;ve arm to assess <FONT
STYLE="white-space:nowrap">EG-70</FONT> as a potential first-line therapeutic for high-risk NMIBC. We currently expect to make an additional Investigational New Drug application (&#147;IND&#148;) in 2024 for the application of <FONT
STYLE="white-space:nowrap">EG-70</FONT> to an additional <FONT STYLE="white-space:nowrap">as-yet</FONT> unnamed indication, most likely in the gynecological or genitourinary cancer space. Until such time as we finalize and announce this second
indication, it will be difficult to forecast or predict further clinical development timelines, as we expect they will be determined by the ultimate indication we elect to pursue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A second product candidate, <FONT STYLE="white-space:nowrap">EG-i08,</FONT> is in preclinical development for cystic fibrosis, with
development candidate nomination expected in 2024 subject to a multifactor <FONT STYLE="white-space:nowrap">go/no-go</FONT> assessment involving technical review and assessment of grant support availability. As above, given the early stage of this
program, it will be difficult to forecast or predict further clinical development timelines at this time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following chart shows the
current status of our product development to the extent we can estimate key actions and milestones at this time: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g459793g00a01.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">302 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">EG-70</FONT> (detalimogene voraplasmid):
Immuno-oncology </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Mechanism of action </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our <FONT STYLE="white-space:nowrap">EG-70</FONT> drug product candidate comprises nanoparticles, with a DNA nanoplasmid encapsulated by a <FONT
STYLE="white-space:nowrap">non-viral,</FONT> DDX polymer-based delivery vehicle. The DDX delivery vehicle consists of a highly derivatized chitosan backbone and includes reversible PEGylation (where PEG stands for polyethylene glycol) to facilitate
diffusion through protective epithelial shields, such as mucous in the lung and the GAG (glycosaminoglycan) layer in the bladder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <FONT
STYLE="white-space:nowrap">EG-70</FONT> drug substance plasmid DNA encodes multiple open reading frames expressing three distinct transcripts: a single-chain <FONT STYLE="white-space:nowrap">interleukin-12</FONT> protein <FONT
STYLE="white-space:nowrap">(IL-12)</FONT> and two <FONT STYLE="white-space:nowrap">non-protein</FONT> coding RNA products, eRNA11a and VA1, which coordinate to stimulate the retinoic acid-inducible gene I
<FONT STYLE="white-space:nowrap">(RIG-I)</FONT> pathway. Together, this combination of <FONT STYLE="white-space:nowrap">RIG-I</FONT> activation and <FONT STYLE="white-space:nowrap">IL-12</FONT> secretion serves to activate both innate and adaptive
immunity, creating a <FONT STYLE="white-space:nowrap">pro-inflammatory,</FONT> tumor-killing environment: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g459793g00a02.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">RIG-I</FONT> is expressed in most cell types and highly expressed in
epithelial cells. It is also expressed in tumor cells and recognizes double stranded RNA molecules with an uncapped 5&acute; triphosphate (5&acute;PPP) or 5&acute;&nbsp;diphosphate (5&acute;PP) end to initiate a signaling cascade that results in the
production of Type I interferons (IFN) and proinflammatory cytokines. The activation of <FONT STYLE="white-space:nowrap">RIG-I</FONT> stimulates a potent inflammatory response that results in direct tumor cell killing, cytokine-mediated activation
of innate immune cells, and the recruitment and cross-priming of T cells. <FONT STYLE="white-space:nowrap">IL-12</FONT> is an immunomodulatory cytokine primarily produced by antigen presenting cells, such
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">303 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
as dendritic cells (DCs) and macrophages, following bacterial or viral infection. Signaling through the <FONT STYLE="white-space:nowrap">IL-12</FONT> receptor complex, expressed on natural killer
(NK), <FONT STYLE="white-space:nowrap">NK-T,</FONT> and activated effector CD4+ and CD8+ T cells, enhances the cytotoxicity of effector cells and results in T cell proliferation, polarization to a type 1 helper (Th1) phenotype, and interferon-gamma
(IFN<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>) production. The production of IFN<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT> is central to the potent anti-tumor and anti-angiogenic functions of <FONT STYLE="white-space:nowrap">IL-12.</FONT>
In summary, the activation of <FONT STYLE="white-space:nowrap">RIG-I</FONT> is intended to induce an innate immune response that will trigger T cell recruitment and cross-presentation of tumor antigens to T cells through induction of mediators such
as <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">C-X-C</FONT></FONT> motif chemokine ligand 10 (CXCL10) and Type I IFNs, respectively. The expression of <FONT STYLE="white-space:nowrap">IL-12</FONT> protein is intended to augment
the anti-tumor activity of indwelling effector T cells. Together, <FONT STYLE="white-space:nowrap">RIG-I</FONT> agonism and <FONT STYLE="white-space:nowrap">IL-12</FONT> receptor stimulation function in a
<FONT STYLE="white-space:nowrap">two-step</FONT> mechanism to recruit and activate immune cells to the tumor microenvironment (&#147;TME&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials using systemic or subcutaneous administration of <FONT STYLE="white-space:nowrap">IL-12</FONT> to treat various solid
malignancies have resulted in severe dose-limiting toxicities, resulting in a marginal therapeutic window. In contrast, local delivery of <FONT STYLE="white-space:nowrap">IL-12</FONT> has emerged as a clinical strategy to enhance immunological
activity within the TME, promote systemic immunity, and minimize systemic toxicity. Using preclinical models, we have demonstrated a therapeutic benefit of <FONT STYLE="white-space:nowrap">co-expression</FONT> of
<FONT STYLE="white-space:nowrap">RIG-I</FONT> activators and <FONT STYLE="white-space:nowrap">IL-12</FONT> in bladder urothelium to localize therapeutic effect and exposure within the bladder TME without systemic toxicity. We believe these clinical
trials demonstrated that coupling the potent stimulation of the innate immune system by <FONT STYLE="white-space:nowrap">RIG-I</FONT> agonism to stimulation of the adaptive immune response by <FONT STYLE="white-space:nowrap">IL-12</FONT> provides
robust and persistent anti-tumor activity in a murine orthotopic bladder cancer model. Moreover, we also demonstrate translatable expression across multiple species, including humans. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Lead Program: NMIBC Background and Unmet Need </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Disease Background </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Bladder cancer represents a serious, life-threatening condition. Based on data reported through 2020, bladder cancer is expected to result in
an estimated 2.7% of all cancer deaths in 2023 while comprising an estimated 4.2% of all new cancer cases according to the National Institute of Health. Overall, according to the American Cancer Society and the National Institute of Health, the
chance men will develop this cancer during their life is about 1 in 28; and for women, the chance is about 1 in 91. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Fortunately, due to
early warning signals such as hematuria, many instances of bladder cancer are diagnosed while still localized to the bladder urothelium, and these NMIBCs represent approximately 80% of newly diagnosed bladder tumors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Unmet Medical Need </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since
NMIBC is often diagnosed early, it can be treated in its early stage to prevent invasive therapy or organ removal. The initial treatment plan for these patients involves local therapy to the inside of the bladder to treat the disease before it can
become invasive, while limiting systemic side effects. Since the 1970s, the primary therapy for high-risk NMIBC has been intravesical BCG therapy, despite the adverse effects with which it is associated and a &#062;50% failure rate.<B><I>
</I></B>Due to the increased use of BCG in this setting and loss of several manufacturers of BCG, supply constraints have resulted in a shortage of the BCG for commercial use. To manage the limited supply available in the United States, as of
February 2019 the American Urological Association and their collaborative physician groups revised their treatment guidelines to recommend that BCG should be prioritized for patients with high-risk disease and they should receive full-strength BCG
induction, but subsequent maintenance doses could be <FONT STYLE="white-space:nowrap">one-half</FONT> to <FONT STYLE="white-space:nowrap">one-third</FONT> the standard dose. This situation is projected to continue into 2026 and has brought urgency
to the unmet medical need for effective intravesical treatments for patients with high grade NMIBC, according to the American Urological Association. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, while most patients are free of recurrence at 1 year with induction and maintenance full-dose BCG, as many as 75% develop a new
tumor in 5 years and unfortunately a second course of BCG is unlikely to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">304 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
provide further benefit. This population represents a population of patients with a profound medical need to keep their cancer from becoming invasive while being able to preserve their bladders.
In addition, patients receiving local salvage therapy for NMIBC with Cis who failed BCG induction and maintenance generally do not respond to more BCG, or to other intravesical chemotherapy agents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate there are approximately 60,000 new patients globally each year with BCG-unresponsive NMIBC, of which up to 70% have Cis at the
time of diagnosis of BCG-unresponsiveness. We derived this estimate from the overall global bladder cancer incidence of 550,000 patients per year, estimating the percentage of such patients with NMIBC, and further estimating the percentage of such
patients who later develop BCG-unresponsiveness. At the anticipated time of EG-70&#146;s BLA application in 2025, we estimate that there will be approximately 9,800 new NMIBC patients with BCG-unresponsive NMIBC in the United States per year, of
which up to 70% will have Cis at time of diagnosis. Outside of the United States, we believe the market will be comparable on a population-adjusted basis, although per-capita bladder cancer incidence has been known to vary across countries. Of note,
these are only our current estimates and have been derived from a variety of sources, including scientific literature, input from key opinion leaders, patient foundations or secondary market research databases and may prove to be incorrect. For
individuals with BCG-unresponsive NMIBC with Cis, treatment options are currently quite limited. In the case of papillary bladder tumors, a frequent precursor condition to BCG-unresponsive NMIBC with Cis, gemcitabine and mitomycin are given as a
single-dose of intravesical chemotherapy shortly after surgical removal of the tumor to reduce the recurrence rate; however, they are not <FONT STYLE="white-space:nowrap">FDA-approved</FONT> to be used for NMIBC with Cis. VALSTAR<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (valrubicin) was approved by the FDA for salvage therapy in <FONT STYLE="white-space:nowrap">BCG-unresponsive</FONT> NMIBC patients with Cis, but is not recommended by the National Comprehensive
Cancer Network (NCCN) in their guidelines due to the low CR rate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA approval of Keytruda<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (pembrolizumab) in 2020 for the treatment of patients with BCG-unresponsive NMIBC with Cis (with or without papillary tumors) provided a systemic, intravenous option for therapy. However, we
believe the adverse event profile of Keytruda combined with its relatively limited durability and its systemic route of administration, typically by medical oncologists rather than urology clinics, may limit its widespread adoption as a treatment
option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Adstiladrin<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (nadofaragene firadenovec-vncg) was recently approved by
the FDA for patients with <FONT STYLE="white-space:nowrap">BCG-unresponsive</FONT> NMIBC with Cis. However, Adstiladrin<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> has faced manufacturing challenges which limited its availability at
its product launch. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In summary, despite these recent FDA approvals, for patients with
<FONT STYLE="white-space:nowrap">BCG-unresponsive</FONT> NMIBC, treatment options are limited, and so the standard therapy has been radical cystectomy, which is associated with significant complications, including a lower quality of life, and risk
of death. Therefore, we believe the development and discovery of new treatment options for BCG-unresponsive NMIBC with Cis is still a high priority to decrease the morbidity, burden of health-care expenditures, and mortality related to bladder
cancer. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In response to this urgent unmet medical need due to the lack of treatment options and BGC shortage, the FDA has issued
guidance for the design of clinical studies for development of novel NMIBC treatments, with a goal of encouraging development of alternative treatments to radical cystectomy. We have followed this guidance and discussed with the FDA our <FONT
STYLE="white-space:nowrap">EG-70</FONT> development plan, and subsequent to these discussion, the FDA cleared us to initiate the pivotal, Phase 2 portion of the LEGEND study. We believe <FONT STYLE="white-space:nowrap">EG-70</FONT> has the potential
to serve as a safe and effective immuno-oncology therapy to directly address this unmet need. We are encouraged by these results; however, the Phase 1 portion of this study was designed to evaluate safety and was not designed to evaluate efficacy in
a statistically meaningful way. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>LEGEND: A Phase 1/2 Study of <FONT STYLE="white-space:nowrap">EG-70</FONT> in NMIBC
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Study Design </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">LEGEND is a Phase 1/2, open-label, multicenter, safety and dose-finding study conducted in the United States and initiated in February 2021 to
determine the safety, tolerability, and efficacy of <FONT STYLE="white-space:nowrap">EG-70</FONT> in adult patients </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">305 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with NMIBC with Cis who have failed BCG therapy and are recommended for radical cystectomy, or high-risk NMIBC patients with Cis who are <FONT STYLE="white-space:nowrap">BCG-na&iuml;ve</FONT> or
have received incomplete BCG treatment. The study consists of two phases, beginning with a Dose-Escalation Phase (Phase 1). The key objective for the Phase 1&nbsp;portion of the study is evaluation of safety and tolerability. While not statistically
powered for efficacy, an evaluation of efficacy was a secondary objective, with a Phase 2 study to be conducted at the RP2D. Eligible <FONT STYLE="white-space:nowrap">BCG-unresponsive</FONT> NMIBC patients with Cis have been enrolled in Phase 1 and
will continue to be enrolled in Cohort 1 of Phase 2, which has already begun. Eligible high-risk NMIBC patients with Cis who have been incompletely treated or are <FONT STYLE="white-space:nowrap">BCG-na&iuml;ve</FONT> will be enrolled starting in
Phase 2 in a separate <FONT STYLE="white-space:nowrap">single-arm</FONT> cohort (Cohort 2). The schema, with key design features, for the cohorts that are unresponsive to BCG is defined below. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g459793g60i15.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All patients in Phase 1 received at least one cycle of treatment with
<FONT STYLE="white-space:nowrap">EG-70.</FONT> A cycle is 12 weeks in duration. Those patients who have complete response or stable disease (SD) at the end of Cycle 1 (Week 10) may (in association and consultation with their physician) choose to
continue receiving treatment for up to a total of 4&nbsp;cycles, provided they do not have progressive disease (PD) on evaluation for response at the end of each cycle. Patients who complete cycle 1 and the additional 3 cycles without PD are
followed until PD or for approximately 2 years following their <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">End-of-Treatment</FONT></FONT> Visit, whichever occurs first. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Study Endpoints </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
primary endpoint of the Phase 1 study is safety (i.e., characterizing the nature, incidence, relatedness and severity of all observed adverse events (&#147;AEs&#148;) and severe adverse events (&#147;SAEs&#148;)), with complete response and
pharmacodynamics of biomarkers assessed as exploratory endpoints. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Result: Safety </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Twenty-four</FONT> patients have received at least one dose of <FONT STYLE="white-space:nowrap">EG-70</FONT>
in the Phase 1 study, with the total number of AEs and most commonly reported AEs across all 22 patients defined in the table below. The majority (97%) of AEs have been Grade 1 or 2 and largely consistent with the same events seen with
instrumentation, catheterization, and intravesical instillation of any agent. Four Grade 3 SAEs have been observed in Phase 1. However, on review, it was observed that the renal failure was present at baseline before treatment with <FONT
STYLE="white-space:nowrap">EG-70.</FONT> The other three Grade 3 SAEs were considered unrelated to the study drug. There was no association between the severity or incidence of AEs and the dose level. In addition, AEs were not more frequent or
severe later cycles of dosing. The following table summarizes the Phase 1 safety results. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">306 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g459793g16a85.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Results: Efficacy </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Efficacy was assessed by the standard three criteria evaluation used for NMIBC, namely urinary cytology, cystoscopic appearance (i.e., an
inspection with a cystoscope - a thin tube with video camera that is inserted into the bladder), and biopsy results of suspicious areas. Biopsies in the former area of Cis were required even if the appearance was normal. In Phase 1, patients without
progressive disease were allowed to electively continue on study drug after the <FONT STYLE="white-space:nowrap">3-month</FONT> visit. In total, 22 patients were dosed with the study drug and evaluable for efficacy at the <FONT
STYLE="white-space:nowrap">3-month</FONT> visit. One patient included in evaluations for safety evaluation was excluded from efficacy, see the footnote to the table below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The plot below captures individual subjects in each row, organized chronologically from the first patient enrolled (#1) to the last enrolled
in Phase 1 (#22). The dose group is captured on the left-hand side of the plot, with DL1, DL2, DL3 reflecting half-log increments in amount of plasmid DNA instilled, as dose. Each of these three regimens reflects delivery of a dose on Weeks 1 and 2
of each <FONT STYLE="white-space:nowrap">3-month</FONT> cycle, whereas the &#145;prime&#146; dosing schedule indicated as DL2&#146; reflects 4 instillations of <FONT STYLE="white-space:nowrap">EG-70</FONT> in each
<FONT STYLE="white-space:nowrap">3-month</FONT> cycle, namely at Weeks 1, 2, 5, and 6. Expansion cohorts after safety had been demonstrated in the initial cohort of 3 patients is indicated by the suffix &#145;E&#146;. Overall, across all doses, 16
of 22 patients dosed with <FONT STYLE="white-space:nowrap">EG-70</FONT> achieved a Complete Response, or &#147;CR,&#148; for a best overall CR rate of 73%. Specifically, at the <FONT STYLE="white-space:nowrap">3-month</FONT> timepoint, this CR rate
was 68% (15 of 22), with 82% (18 of 22) of patients continuing to receive additional doses of the study drug beyond 3 months. Within the dose selected for the pivotal portion of the study (DL2&#146;), the CR rate at 3 and 6 months was 70% and 60%,
respectively, with 90% of patients continuing on the study drug beyond 3 months. Of note, patient #1 has maintained a CR for 18 months after the first dose of <FONT STYLE="white-space:nowrap">EG-70.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">307 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g459793g27q68.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Pharmacodynamics </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Urine was monitored during the Phase 1 study to assess expression of our secreted, therapeutic transgene protein product, <FONT
STYLE="white-space:nowrap">IL-12.</FONT> As can be seen in the figure below, <FONT STYLE="white-space:nowrap">IL-12</FONT> was not detected in any patient at the baseline, <FONT STYLE="white-space:nowrap">pre-treatment</FONT> timepoint. By contrast,
after treatment, <FONT STYLE="white-space:nowrap">IL-12</FONT> was detected in the urine of all patients dosed, with dose levels (DL) 2 and 3 (800 and 2500 mg of plasmid DNA, respectively) demonstrating an order of magnitude higher levels of <FONT
STYLE="white-space:nowrap">IL-12</FONT> than dose level 1. Together, we believe these data demonstrate: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> that the <FONT
STYLE="white-space:nowrap">EG-70</FONT> drug product is transfecting human cells and expressing therapeutic products; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> that the route
of administration drives local expression, without the liability of systemic exposure to immune-modulating agents. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">308 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g459793g00a06.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Phase 2 Trial </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Phase 2 portion of the study is open-label and is comprised of two independent single arm cohorts of patients with <FONT
STYLE="white-space:nowrap">Cis-containing</FONT> NMIBC (with or without papillary disease). Cohort 1 is <FONT STYLE="white-space:nowrap">BCG-unresponsive</FONT> patients. Cohort 2 is <FONT STYLE="white-space:nowrap">BCG-na&iuml;ve</FONT> or <FONT
STYLE="white-space:nowrap">BCG-incompletely</FONT> treated patients. Although the treatment is the same for each cohort, an independent set of analysis will occur for each cohort. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In Phase 2, cycles will be 12 weeks in duration. Patients in either cohort who have exhibited SD or CR at Week 12 will continue treatment with
<FONT STYLE="white-space:nowrap">EG-70</FONT> until Week 24, whereas patients with PD will discontinue treatment. Patients who experience and maintain CR at Week 24 will receive additional cycles every 12 weeks until Week 48. Percentage of patients
with CR at 48 weeks, based on cystoscopic appearance, urine cytology, and appropriate biopsies will be the <FONT STYLE="white-space:nowrap">co-primary</FONT> endpoint together with the nature, incidence, relatedness, and severity of treatment
emergent adverse events. Secondary endpoints will include progression free survival, CR rates at 12, 24, 36, and 96 weeks, as well as CR rate by 24 weeks, and the duration of response of the responding patients. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Preclinical Validation of Mechanism of Action: <FONT STYLE="white-space:nowrap">EG-70</FONT> for bladder cancer </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have characterized <FONT STYLE="white-space:nowrap">EG-70</FONT> preclinically so as to validate that the combination of <FONT
STYLE="white-space:nowrap">RIG-1</FONT> agonism and <FONT STYLE="white-space:nowrap">IL-12</FONT> secretion eradicates preclinical tumor models. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">309 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Preparation and characterization of polymer-based nanoparticles loaded with plasmid DNA
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">EG-70</FONT> contains a <FONT STYLE="white-space:nowrap">non-integrative</FONT> plasmid DNA (pDNA)
packaged in our proprietary DDX delivery platform that is further combined with the excipient polyethylene
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">glycol-b-poly-L-glutamic</FONT></FONT></FONT></FONT> acid <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">(PEG-b-PLE),</FONT></FONT> a <FONT STYLE="white-space:nowrap">di-block</FONT> <FONT STYLE="white-space:nowrap">co-polymer.</FONT> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g459793g00a07.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pDNA of <FONT STYLE="white-space:nowrap">EG-70</FONT> encodes the two subunits (p40 and p35) of the
human <FONT STYLE="white-space:nowrap">(h)&nbsp;IL-12</FONT> cytokine. Encoded within the same plasmid are two RNA products (adenoviral VA RNA1 (VA1) and eRNA11a; annotated together as eRNA41H) that coordinate to activate <FONT
STYLE="white-space:nowrap">RIG-I.</FONT> The dsRNA directly induces the intracellular protein <FONT STYLE="white-space:nowrap">RIG-I,</FONT> while VA1 is an inhibitor of adenosine deaminase acting on RNA (ADAR), an RNA editing enzyme, and the
double-stranded RNA-dependent protein kinase (PKR), a protein translation inhibitor. Together, VA1 and eRNA11a synergistically boost <FONT STYLE="white-space:nowrap">RIG-I</FONT> activity and increase transgene expression. Of note, the eRNA11a and
VA1 sequences are not species specific and thus identical in the plasmids encoding for either human or mouse <FONT STYLE="white-space:nowrap">IL-12</FONT> protein. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g459793g00a08.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Formulating DDX with pDNA results in mostly spherical nanoparticles, as shown in the figure below (left)
with an average diameter <FONT STYLE="white-space:nowrap">(Z-average</FONT> &plusmn; SD) of 115 &plusmn; 9 nm and an average polydispersity index (PDI &plusmn; SD) of 0.15 &plusmn; 0.03 (figure below, right panel, left and right axes, respectively).
The near-neutral zeta potential following <FONT STYLE="white-space:nowrap">non-covalent</FONT> PEGylation by adsorption of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PEG-b-PLE</FONT></FONT> to the core nanoparticle surface
(average 3.4 &plusmn; 0.9 mV) significantly improved nanoparticle colloidal stability following instillation and incubation for 1 hour in mouse bladder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">310 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g459793g00a09.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">IL-12</FONT> expression and function: Nanoparticles mediate the
expression of transgene products and bioactivity in cultured cells </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Given that human <FONT STYLE="white-space:nowrap">hIL-12</FONT>
lacks biological activity in mice, a surrogate plasmid that encodes murine <FONT STYLE="white-space:nowrap">IL-12</FONT> <FONT STYLE="white-space:nowrap">(mIL-12)</FONT> was used to generate nanoparticles for preclinical studies in mice (referred to
herein as <FONT STYLE="white-space:nowrap">&#147;mEG-70&#148;</FONT> to indicate the mouse proxy for <FONT STYLE="white-space:nowrap">EG-70</FONT> drug product). To evaluate the dose-dependent expression of transgene
<FONT STYLE="white-space:nowrap">mIL-12</FONT> protein, secreted <FONT STYLE="white-space:nowrap">mIL-12</FONT> was measured in murine urothelial carcinoma cells (MB49) transfected with increasing DNA concentration. As shown in the left panel of the
figure below, a dose-dependent increase in secreted <FONT STYLE="white-space:nowrap">mIL-12</FONT> protein was observed following dosing of MB49 cells. Similarly, <FONT STYLE="white-space:nowrap">hIL-12</FONT> protein was expressed in a
dose-dependent manner following transfection of human primary bladder epithelial cells with <FONT STYLE="white-space:nowrap">EG-70</FONT> (right panel). <FONT STYLE="white-space:nowrap">No&nbsp;IL-12</FONT> protein was detected in supernatants of
cells transfected with control nanoparticles containing an empty plasmid (&#145;Vector&#146; negative controls), demonstrating transgene-specific <FONT STYLE="white-space:nowrap">IL-12</FONT> production. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g459793g00a10.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The production of IFN<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT> is central to the potent anti-tumor
activity of <FONT STYLE="white-space:nowrap">IL-12.</FONT> The figures below demonstrate the downstream function of the <FONT STYLE="white-space:nowrap">IL-12</FONT> produced from the in vitro transfections described above, with mouse and human
experiments captured in the left and right panels, respectively. Transgene <FONT STYLE="white-space:nowrap">mIL-12</FONT> protein recovered from supernatant of transfected cells as described in the above figure elicited a dose-dependent increase in
IFN<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT> production that was comparable to IFN<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT> levels observed with recombinant <FONT STYLE="white-space:nowrap">IL-12</FONT> protein, both in the presence <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(RIG-I/mIL-12)</FONT></FONT> or absence <FONT STYLE="white-space:nowrap">(mIL-12)</FONT> of transgene <FONT STYLE="white-space:nowrap">RIG-I</FONT> agonists. In contrast, only baseline IFN<FONT
STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT> was produced from cells exposed to an equivalent volume of supernatant from cells transfected with control plasmids lacking <FONT STYLE="white-space:nowrap">IL-12</FONT> (left panel). Similarly, <FONT
STYLE="white-space:nowrap">hIL-12</FONT> protein stimulated human peripheral blood mononuclear cells (PBMCs) to produce IFN<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT> in a dose-dependent manner with comparable potency to recombinant <FONT
STYLE="white-space:nowrap">hIL-12</FONT> protein (right panel). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">311 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g459793g00a11.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">RIG-I</FONT> agonist expression and function: Nanoparticles mediate the
expression of transgene products and bioactivity in cultured cells </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dose-dependent expression of both
<FONT STYLE="white-space:nowrap">RIG-I</FONT> agonists was also observed in MB49 cells by <FONT STYLE="white-space:nowrap">RT-qPCR</FONT> (figure below). Similar to <FONT STYLE="white-space:nowrap">IL-12,</FONT> no eRNA11a or VA1 expression detected
in cells transfected with negative control nanoparticles. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g459793g00a12.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">RIG-I</FONT> agonists eRNA11a and VA1 RNA stimulate the production of IFN<FONT
STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>. Consequently, IFN<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> production was measured in MB49 cells transfected with <FONT STYLE="white-space:nowrap">mEG-70</FONT> or control plasmids to confirm
bioactivity of <FONT STYLE="white-space:nowrap">EG-70</FONT> encoded <FONT STYLE="white-space:nowrap">RIG-I</FONT> agonists. Transfection of cells with nanoparticles containing pDNA encoding <FONT STYLE="white-space:nowrap">RIG-I</FONT> agonists
(either <FONT STYLE="white-space:nowrap">mEG-70</FONT> or <FONT STYLE="white-space:nowrap">RIG-I)</FONT> resulted in a dose-dependent production of IFN<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> (figure below, left panel) and IFN<FONT
STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> (figure below, right panel) confirming <FONT STYLE="white-space:nowrap">RIG-I</FONT> activation. Conversely, production of IFN<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> and IFN<FONT
STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> was not observed in cells transfected with control nanoparticles- including those encapsulating plasmids with only <FONT STYLE="white-space:nowrap">mIL-12</FONT> without
<FONT STYLE="white-space:nowrap">RIG-I</FONT> agonists (labeled <FONT STYLE="white-space:nowrap">&#145;mIL-12&#146;</FONT> in plots). We believe this demonstrates that the <FONT STYLE="white-space:nowrap">RIG-I</FONT> activation was not due to
stimulation of <FONT STYLE="white-space:nowrap">DNA-sensing</FONT> pathways or signaling of <FONT STYLE="white-space:nowrap">mIL-12</FONT> protein through the <FONT STYLE="white-space:nowrap">IL-12</FONT> receptor but driven specifically by <FONT
STYLE="white-space:nowrap">RIG-I</FONT> agonism. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g459793g00a13.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">312 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>In vivo expression of transgene products in mouse bladder </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We evaluated the expression of transgene products in murine bladder following intravesical instillation (IVI) of
<FONT STYLE="white-space:nowrap">mEG-70.</FONT> As shown in the figure below, and assessed by MSD immunoassay from bladder tissue, <FONT STYLE="white-space:nowrap">mIL-12</FONT> protein expression peaked 48 hours after a single IVI, with sustained
levels through the end of assessment at 7 days (168 hours; right panel). Transgene <FONT STYLE="white-space:nowrap">RIG-I</FONT> agonists were expressed as early as 4 hours post-administration, reaching peak expression levels by 24 hours that were
sustained through 7 days (middle and left panels). Of note, these levels of expression were obtained without the use of a mucolytic agent and surfactant, as required for adenoviral-mediated gene therapies in the bladder. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g459793g62a10.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IVI administration of <FONT STYLE="white-space:nowrap">mEG-70</FONT> also stimulated a dose-dependent
increase in transgene mIL 12 protein expression, reaching a plateau at doses exceeding 10 &micro;g of plasmid DNA (Figure below, left panel). Expression of transgene <FONT STYLE="white-space:nowrap">RIG-I</FONT> agonists exhibited a similar
dose-dependent expression pattern in murine bladders (middle and right panels). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g459793g62b20.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Analysis of intravesical <FONT STYLE="white-space:nowrap">mEG-70</FONT> treatment in an orthotopic
bladder cancer model </I></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To evaluate the therapeutic benefit of <FONT STYLE="white-space:nowrap">mEG-70,</FONT> an orthotopic model of
murine bladder cancer was established by implanting syngeneic MB49 urothelial carcinoma cells that stably express luciferase (MB49luc) into murine bladders, utilizing <FONT STYLE="white-space:nowrap">non-invasive</FONT> imaging (IVIS) to measure
luciferase activity as a proxy for tumor burden. Baseline tumor burden was confirmed by bioluminescence using in vivo imaging before two weekly IVI of <FONT STYLE="white-space:nowrap">mEG-70,</FONT> with the study design captured in the top panel of
the figure below. Only animals with successful tumor engraftment were used in subsequent analyses, with the level of bioluminescence used to randomize mice across treatment groups (bottom panels). Mouse <FONT STYLE="white-space:nowrap">EG-70</FONT>
mediated a dose-dependent reduction of <FONT STYLE="white-space:nowrap">pre-existing</FONT> tumor burden as evidenced by diminished bioluminescent signal on Day 29 of the study. Note in the figure below, the right panel displays individual animals,
with the color scale indicating the intensity of the tumor signal, from blue (lowest) to red (highest), and areas without color indicating a lack of tumor. The graph on the left displays the geometric mean across all animals, &plusmn; 95% confidence
interval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">313 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g459793g65a10.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Bladder weights were assessed post-necropsy on Day 29 as an additional surrogate readout for tumor
burden (figure below, top left panel). Microscopic evaluation revealed that sham-treated animals had carcinoma in the bladder, which extended to the urethra. In mEG <FONT STYLE="white-space:nowrap">70-</FONT> treated animals, a dose-dependent
reduction in the number of tumor-bearing animals was observed, with no visible lesions observed in animals treated at the highest dose level (figure below, bottom panel displaying H&amp;E staining). These data recapitulated the dose-dependent
anti-tumor activity of <FONT STYLE="white-space:nowrap">mEG-70</FONT> observed by in vivo imaging. Consistent with the dose-dependent therapeutic benefit of <FONT STYLE="white-space:nowrap">mEG-70,</FONT> we also detected dose-dependent expression
of mouse <FONT STYLE="white-space:nowrap">IL-12</FONT> protein in tumor-bearing bladders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We further examined the durability of the
anti-tumor response by monitoring long-term survival until all mice succumbed to bladder cancer or were deemed cured, which was defined as no evidence of bioluminescent signal with no clinical signs of bladder cancer, including palpable bladder mass
and hematuria. Over 90% of mice treated with <FONT STYLE="white-space:nowrap">mEG-70</FONT> had durable anti-tumor responses as demonstrated by long-term disease-free survival with no disease relapse during the
<FONT STYLE="white-space:nowrap">100-day</FONT> monitoring period (figure below, top right panel). In contrast, about 90% of sham-treated animals had succumbed to disease during the same period. We believe these data demonstrate the rapid, robust,
and durable anti-tumor effects of <FONT STYLE="white-space:nowrap">mEG-70</FONT> in the orthotopic model of bladder cancer. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g459793g65b20.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">314 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Immune profiling following <FONT STYLE="white-space:nowrap">mEG-70</FONT> treatment of
tumor-bearing mice </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Given that <FONT STYLE="white-space:nowrap">mEG-70</FONT> mediated the induction of
<FONT STYLE="white-space:nowrap">IL-12</FONT> and <FONT STYLE="white-space:nowrap">RIG-I</FONT> signaling, we assessed the immune cell repertoires of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mEG-70-treated</FONT></FONT>
animals to further explore the mechanistic basis for anti-tumor activity. Flow cytometry analyses revealed a higher frequency of NK cells <FONT STYLE="white-space:nowrap">(CD3-NK1.1+)</FONT> (3 days post first IVI of
<FONT STYLE="white-space:nowrap">mEG-70;</FONT> figure below, left panel; Average &plusmn; StDev) and an increased proportion of activated CD69+ NK cells (figure below, right panel) in the bladders of <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">mEG-70-treated</FONT></FONT> mice compared to sham-treated mice. Further evidence of NK cell activation in the bladder was demonstrated by an increase in mature CD11b+CD27+ NK cells. This was accompanied by a decrease in
immature CD11b-CD27- NK cells in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mEG-70-treated</FONT></FONT> mice compared to sham controls. Assessment of the proportion of cells expressing CD69 and KLRG1 markers further suggested
that NK cells had a mature phenotype in the TME. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g459793g68a11.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These changes in the bladders of mEG <FONT STYLE="white-space:nowrap">70-treated</FONT> mice were followed
by a significant decrease in myeloid cells (CD11b+) homing to the bladder in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mEG-70-treated</FONT></FONT> mice compared to sham-treated mice (3 days post second IVI of <FONT
STYLE="white-space:nowrap">mEG-70,</FONT> figure below, left panel). In addition, a decreased frequency of CD11b+Ly6C+Ly6G+ cells was observed in mouse bladders, consistent with a myeloid-derived suppressor cell (MDSC) phenotype (Figure below,
middle panel). The proportion of tumor-associated macrophages (CD11b+F4/80+Ly6C+) was also reduced in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mEG-70-treated</FONT></FONT> bladders compared to sham controls (Figure below,
right panel). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g459793g68b22.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We analyzed tumor-bearing bladders for changes in T cell populations following <FONT
STYLE="white-space:nowrap">mEG-70</FONT> treatment. Frequencies of both CD4+ and CD8+ T cells were strongly enhanced in mEG <FONT STYLE="white-space:nowrap">70-treated</FONT> bladders compared to sham controls (13 days after initiation of <FONT
STYLE="white-space:nowrap">mEG-70</FONT> treatment, figure below, top left panel). The spatial localization of these T cells was analyzed by immunohistochemistry and revealed pervasive infiltration in <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">mEG-70-treated</FONT></FONT> animals. In contrast, in sham-treated animals, there was poor T cell infiltration, with a marginal localization of cells in the tumor periphery (figure below, bottom panel comparison of
&#145;Sham&#146; and <FONT STYLE="white-space:nowrap">&#145;EG-70&#146;).</FONT> Both CD4+ and CD8+ T cells were also present at increased proportions in the tumor-draining lymph nodes of <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">mEG-70-treated</FONT></FONT> mice compared to sham-treated controls (figure below, top right panel). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">315 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g459793g71a71.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Long-term effects, immunological memory, and systemic immunity mediated by <FONT
STYLE="white-space:nowrap">mEG-70</FONT> </I></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe the long-term survival benefit and lack of relapse in <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mEG-70-treated</FONT></FONT> animals suggested that immunological memory may have been established. To further explore this, we examined protective immunity against tumor <FONT
STYLE="white-space:nowrap">re-challenge,</FONT> wherein <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mEG-70-treated</FONT></FONT> mice with complete disease regression and no relapse <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">(&#145;mEG-70-cured&#146;),</FONT></FONT> were <FONT STYLE="white-space:nowrap">re-challenged</FONT> orthotopically with MB49luc cells to assess protection from recurring disease. All <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">mEG-70-</FONT></FONT> cured mice were resistant to tumor recurrence, as shown by negative bioluminescence signal up to 3 weeks after <FONT STYLE="white-space:nowrap">re-challenge.</FONT> In contrast, indicative of tumor
burden, all <FONT STYLE="white-space:nowrap">age-matched</FONT> na&iuml;ve controls had positive bioluminescence signal following cell implantation (figure below; bottom panel displays luminescence from each individual animal reflecting tumor burden
from luciferase expression with the color scale indicating the intensity of the tumor signal, from blue (lowest) to red (highest), and areas without color indicating a lack of tumor; top panel reflects geometric means &plusmn; 95% confidence
interval). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">316 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g459793g73a10.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As shown in the figure below, to determine if local treatment to the bladder results in systemic
anti-tumor immunity, mice cured of orthotopic bladder cancer by <FONT STYLE="white-space:nowrap">mEG-70</FONT> were challenged with MB49luc cells subcutaneously on the flank and tumor growth was monitored. Although
<FONT STYLE="white-space:nowrap">age-matched</FONT> na&iuml;ve controls showed rapid tumor growth, all <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mEG-70-cured</FONT></FONT> mice remained tumor free up to 50 days
post-rechallenge. To investigate whether the abscopal anti-tumor immunity was specific to MB49luc cells, a separate cohort of mice was <FONT STYLE="white-space:nowrap">re-challenged</FONT> with antigenically distinct melanoma tumor cells <FONT
STYLE="white-space:nowrap">(B16-F10).</FONT> Although <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mEG-70-cured</FONT></FONT> mice were resistant to <FONT STYLE="white-space:nowrap">re-challenge</FONT> with MB49luc cells, the <FONT
STYLE="white-space:nowrap">B16-F10</FONT> tumors grew on the mouse flank, suggesting that long-term anti-tumor effect is antigen-driven and specific to the primary tumor. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g459793g73b20.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">317 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Expression of Transgene Products in Cynomolgus Monkey Bladders </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To evaluate the translation of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">EG-70-mediated</FONT></FONT> expression of
transgene products from mouse to <FONT STYLE="white-space:nowrap">non-human</FONT> primate (NHP) bladders, expression was evaluated in bladders of cynomolgus monkeys treated with two IVI of <FONT STYLE="white-space:nowrap">EG-70</FONT> separated by
one week (Study Days 1 and 8), the same dosing paradigm established in mice. For each harvest timepoint, two monkeys were dosed, and bladders were harvested on study days 10, 15, 22, and 36 (2, 7, 14, and 28 days after the second dose,
respectively). Bladder tissue from each monkey was divided into multiple fragments and pulverized to assess protein or RNA expression at the indicated timepoints. Robust levels of <FONT STYLE="white-space:nowrap">hIL-12</FONT> protein were detected
up to 14 days following the second dose of <FONT STYLE="white-space:nowrap">EG-70</FONT> and cleared by 28 days after the second <FONT STYLE="white-space:nowrap">EG-70</FONT> administration (figure below, left panel). Expression of the <FONT
STYLE="white-space:nowrap">RIG-I</FONT> agonists was observed in the bladder up to 28 days after the second administration (figure below, middle and left panels). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g459793g76a10.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Expression of <FONT STYLE="white-space:nowrap">hIL-12</FONT> protein was dose-dependent and there was no
expression of transgene products observed in NHPs dosed with vector control formulations (figure below, left panel). Human <FONT STYLE="white-space:nowrap">IL-12</FONT> protein was also detected in the urine of NHP following a single <FONT
STYLE="white-space:nowrap">EG-70</FONT> administration and the level of <FONT STYLE="white-space:nowrap">IL-12</FONT> in the urine trended higher at a dose of 1.0 mg/mL than the level measured following administration of a low dose of <FONT
STYLE="white-space:nowrap">EG-70</FONT> (0.0625 mg/mL) or empty vector control nanoparticles. Furthermore, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">EG-70-encoded</FONT></FONT> <FONT STYLE="white-space:nowrap">hIL-12</FONT>
protein expression is restricted to the bladder, as no <FONT STYLE="white-space:nowrap">IL-12</FONT> protein was quantified in the plasma of NHPs treated with <FONT STYLE="white-space:nowrap">EG-70.</FONT> Transgene-specific upregulation of
downstream cytokines was also observed in an NHP bladder following administration of <FONT STYLE="white-space:nowrap">EG-70</FONT> compared to an NHP bladder dosed with empty vector control nanoparticles (Figure below, boxed panels). We believe
these data show translation of expression of transgene products from mouse to NHP. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g459793g76b20.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Fast Follower Programs: Bladder, Gynecological, and Genitourinary Cancers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe these preclinical and Phase 1 data demonstrate the following, which we believe significantly
<FONT STYLE="white-space:nowrap">de-risk</FONT> the DDX platform and <FONT STYLE="white-space:nowrap">EG-70</FONT> as drug product: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">EG-70</FONT> has been demonstrated to be well tolerated when instilled
intravesically. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Redosability of <FONT STYLE="white-space:nowrap">EG-70</FONT> has been demonstrated, with <FONT
STYLE="white-space:nowrap">EG-70</FONT> administered up to 16 times to individual patients and with repeated expression of the transgene observed even after multiple doses. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The mechanism of anti-tumor activity driven by agonism of <FONT STYLE="white-space:nowrap">RIG-I</FONT> and
secretion of <FONT STYLE="white-space:nowrap">IL-12</FONT> has been successfully demonstrated clinically with the high rate of complete response observed in the LEGEND trial. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">318 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Together, we believe these data support broader utilization of <FONT
STYLE="white-space:nowrap">EG-70</FONT> for multiple additional oncology indications. As a result, we are exploring advancing <FONT STYLE="white-space:nowrap">EG-70</FONT> into additional bladder cancer indications and have performed preclinical
experiments that support application of <FONT STYLE="white-space:nowrap">EG-70</FONT> to additional organs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Other Bladder Cancer
Indications </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our preclinical data package utilizes the MB49 cancer cell line, which when instilled into the bladder, can generate
tumors reflective of muscle invasive bladder cancer. We believe that this preclinical data could potentially support the use of <FONT STYLE="white-space:nowrap">EG-70</FONT> in advanced bladder cancer, such as muscle invasive disease. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Gynecological, Genitourinary </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In preclinical in vitro and in vivo studies, we have delivered <FONT STYLE="white-space:nowrap">EG-70</FONT> to multiple additional organs via
multiple routes of administration and have demonstrated expression of <FONT STYLE="white-space:nowrap">IL-12</FONT> in multiple additional organs, as indicated in the figure below. In addition to demonstration of expression, we have also
demonstrated anti-tumor effect in models of ovarian cancer and glioblastoma. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt; text-indent:4%">


<IMG SRC="g459793g79a79.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Illustrative examples of these data are displayed in the chart below. In the left panel, <FONT
STYLE="white-space:nowrap">IL-12</FONT> can be measured in intraperitoneal lavage fluid after intraperitoneal delivery of <FONT STYLE="white-space:nowrap">mEG-70</FONT> (which encodes the murine surrogate of
<FONT STYLE="white-space:nowrap">IL-12).</FONT> Because this murine surrogate is physiologically active in mice, we can also detect expression of downstream pharmacodynamic markers, as evinced by expression of
<FONT STYLE="white-space:nowrap">IFN-gamma</FONT> in the <FONT STYLE="white-space:nowrap">mEG-70</FONT> treated animals (right panel), in contrast to the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PEG-RXG-N9</FONT></FONT>
negative control animals, which are dosed with &#145;empty&#146; plasmids. We believe that local delivery of <FONT STYLE="white-space:nowrap">EG-70</FONT> could be an effective treatment for cancers of multiple intraperitoneal organs, including
ovarian cancer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">319 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g459793g81a10.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similarly, as shown in the figure below, direct injection of <FONT STYLE="white-space:nowrap">mEG-70</FONT>
into the prostate results in expression of <FONT STYLE="white-space:nowrap">IL-12</FONT> (left panel) and <FONT STYLE="white-space:nowrap">IFN-gamma</FONT> (right panel). These results demonstrate that direct injection into a solid organ may be
another approach for targeting solid tumors of multiple organs. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g459793g81b20.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">EG-i08:</FONT> Cystic Fibrosis </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The LEGEND study has demonstrated that the RXG backbone contained in detalimogene voraplasmid can successfully traverse extracellular barriers
of mucosal organs and transfect epithelial cells. Cystic fibrosis is caused by genetic lesions in the cystic fibrosis conductance transmembrane regulator (cftr) gene, resulting in malfunction in the corresponding protein product (&#147;CFTR&#148;).
Cystic fibrosis remains a significant unmet medical need for a subset of patients whose underlying genetics preclude treatment with CFTR modulators. When CFTR is missing or not functional, the lack of CFTR in the airways results in fluid imbalance
that manifests as dehydrated mucus, and ultimately, inflammation and infection. CFTR modulators, which can affect the function or quantity of CFTR proteins with certain genetic defects, have emerged as effective treatment options for a subset of
patients. According to the Cystic Fibrosis Foundation, it is estimated that 10% of patients have mutations that are not amenable to CFTR modulators, such as frameshift or truncation mutations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This estimate notwithstanding, EG-i08 remains at an early stage in development and is challenging or impossible for enGene to provide
additional specificity with respect to possible treatable patients or markets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are leveraging our mucous permeable delivery vehicle to
develop a medicine for cystic fibrosis by encoding the full length <I>cftr</I> gene in a plasmid. As shown in the figure below, we have demonstrated with an in vitro membrane depolarization assay that the CFTR protein encoded within plasmid is
functional, and wherein the membrane depolarization can be inhibited in a dose-dependent manner with the addition of a CFTR inhibitor <FONT STYLE="white-space:nowrap">(Inh-172).</FONT> Further, we have demonstrated that after intratracheal
instillation when delivering this plasmid in our proprietary delivery vehicle that we can detect CFTR mRNA expression in all animals dosed (left panel, displaying 2 separate nucleotide variants of <I>cftr</I>). We believe these data support our
ability to deliver and express a functional CFTR protein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">320 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g459793g84a84.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commercialization Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with our clinical development plan, we are currently working towards the filing of a BLA for
<FONT STYLE="white-space:nowrap">EG-70</FONT> for the treatment of patients with BCG-unresponsive with Cis in 2025 based on the Phase II results from the pivotal LEGEND study. If the FDA grants us marketing approval for <FONT
STYLE="white-space:nowrap">EG-70</FONT> in the United States, we currently plan to commercialize <FONT STYLE="white-space:nowrap">EG-70</FONT> in the United States ourselves. Our current plan is to establish a U.S.-focused sales and marketing
organization to coordinate with high-prescribing urology centers in the United States. Our plan is to have a specialty urologic medical science liaison team coupled with a commercial sales force to simultaneously educate physicians and scientists
about <FONT STYLE="white-space:nowrap">EG-70</FONT> while marketing the drug for the approved label. To proactively support these efforts, we will seek to continue expanding our relationships with key opinion leaders as well as our trial
investigators while expanding physician and patient education about the potential benefits of <FONT STYLE="white-space:nowrap">EG-70</FONT> versus alternative therapies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to explore selective partnerships with third parties to commercialize <FONT STYLE="white-space:nowrap">EG-70</FONT> outside of the
United States, both in Europe and the rest of the world, with the goal of leveraging a potential partner&#146;s regional expertise and existing salesforce to the extent appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The second open-label cohort in Phase 2 of the LEGEND study, in which we propose to treat
<FONT STYLE="white-space:nowrap">BCG-na&iuml;ve</FONT> (or incompletely treated) NMIBC patients with Cis, provides an additional opportunity to demonstrate the potential use of <FONT STYLE="white-space:nowrap">EG-70</FONT> in an indication grappling
with critical drug shortages and unmet need and thus represents another important component of our commercialization plan. To the extent that <FONT STYLE="white-space:nowrap">EG-70</FONT> shows promise in this patient population, we will share the
results of the study with key opinion leaders and urology community leaders, with the aim of building credibility and support for our therapy and increasing interest in its use among urologists and healthcare providers in <FONT
STYLE="white-space:nowrap">FDA-approved</FONT> indications. We believe the urology community will benefit from <FONT STYLE="white-space:nowrap">EG-70&#146;s</FONT> relative ease of use and handling as, among other benefits, it does not require the
containment procedures that are required for BCG. If supported by the data, we may choose to pursue further trials in first line <FONT STYLE="white-space:nowrap">BCG-na&iuml;ve</FONT> NMIBC patients, some of which may be registrational. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also believe we could potentially develop <FONT STYLE="white-space:nowrap">EG-70</FONT> as a treatment for locally advanced muscle invasive
bladder cancer (MIBC). We have shown in an orthotopic model of locally advanced bladder cancer that mice receiving <FONT STYLE="white-space:nowrap">EG-70</FONT> exhibit profound and durable anti-tumor immunity, with cured mice developing resistance
to subsequent local or distal <FONT STYLE="white-space:nowrap">re-challenge</FONT> with bladder tumor cells, which we believe was driven primarily by <FONT STYLE="white-space:nowrap">T-cell</FONT> mediated immune activity. This promising <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> observation supports the potential clinical evaluation of <FONT STYLE="white-space:nowrap">EG-70</FONT> in patients with intact bladders diagnosed with locally advanced or metastatic bladder cancer.
Furthermore, based on the well-defined mechanism of action of <FONT STYLE="white-space:nowrap">EG-70,</FONT> we expect that to the extent <FONT STYLE="white-space:nowrap">EG-70</FONT> proves to be both safe and effective in the high-risk NMIBC
population, we could also study its use in the earlier stage <FONT STYLE="white-space:nowrap">low-</FONT> and intermediate-grade NMIBC population. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">321 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Manufacture and Supply </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Detalimogene voraplasmid is a nanoparticle suspension containing the plasmid deoxyribonucleic acid (pDNA) drug substance or active
pharmaceutical ingredients (API) encapsulated in a proprietary polymer, DDX, and further combined with a custom-manufactured methoxy-poly(ethylene <FONT STYLE="white-space:nowrap">glycol)-block-poly(L-glutamic</FONT> acid) diblock copolymer
(abbreviated as <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PEG-b-PLE).</FONT></FONT> DDX and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PEG-b-PLE</FONT></FONT> are novel excipients. The drug product is
formulated as an aqueous nanoparticle dispersion, filter sterilized, lyophilized to a dry powder, and stored at <FONT STYLE="white-space:nowrap">-20&deg;C.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not currently own or operate any manufacturing facilities for the clinical or commercial production of drug product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have leveraged our internal expertise and <FONT STYLE="white-space:nowrap">know-how</FONT> to develop and scale up the manufacturing
processes for our proprietary DDX and drug product before transferring them to qualified external contract manufacturers or CMOs. Additionally, we have conducted studies to understand and establish controls for all critical process parameters and
critical quality attributes for our drug product. The <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PEG-b-PLE</FONT></FONT> excipient and pDNA drug substance are custom manufactured and purchased from qualified cGMP manufacturers
located in the European Union. All critical excipients, drug substance and drug product are currently manufactured at cGMP-compliant CMOs at a scale that we believe can meet our needs for a commercial launch of
<FONT STYLE="white-space:nowrap">EG-70</FONT> for the <FONT STYLE="white-space:nowrap">BCG-unresponsive</FONT> NIMBC indication in the U.S. following FDA approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe our manufacturing processes are robust, cost-effective and scalable. These manufacturing processes are patent-protected and involve
significant proprietary <FONT STYLE="white-space:nowrap">know-how.</FONT> We also have a global, royalty-bearing, <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license to use certain patents and
<FONT STYLE="white-space:nowrap">know-how</FONT> relating to a proprietary plasmid DNA backbone for high-yield production and efficient expression of transgene in target tissues. Our manufacturing process is in accordance with Good Manufacturing
Practice (cGMP) and quality system regulations for drugs and biologics. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently rely on individual purchase orders with
independent CMOs to supply our clinical trials. We have performed detailed quality audits in the past and will continue to conduct periodic quality audits of their facilities per existing quality agreements. We believe that our current suppliers of
excipients, API and finished products will be capable to provide sufficient quantities of each component to meet our clinical trial supply needs. We have supply agreements in place with multiple CMOs to support manufacturing, release testing,
stability analysis, clinical labeling and packaging of <FONT STYLE="white-space:nowrap">EG-70</FONT> for the pivotal Phase 2 trial of LEGEND study. We will enter into long term commercial supply agreements with selected qualified CMOs to supply <FONT
STYLE="white-space:nowrap">EG-70</FONT> in the event that we are granted marketing approval in the United States. Other CMOs may be used in the future for commercial manufacturing. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial
success depends in part on our ability to protect, obtain, enforce and maintain exclusivity around our gene delivery technology and product candidates through intellectual property protection, as well as our ability to operate without infringing,
misappropriating or otherwise violating the proprietary rights of others and to prevent others from infringing, misappropriating or otherwise violating our proprietary rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We strive to protect, maintain, enforce and enhance the proprietary technology, inventions and improvements that are commercially material to
our business, including by seeking, maintaining and defending our patent rights. We have and are expecting to maintain granted patents, and we continue to file and prosecute patent applications, directed to our modified oligomeric chitosan-based
nanoparticle gene delivery technology independently or in combination with therapeutic genes in an effort to establish intellectual property positions relating to new compositions of matter and novel treatments of various indications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also rely, in part, on trade secrets and <FONT STYLE="white-space:nowrap">know-how</FONT> to maintain exclusivity to our technology. We
strive to protect our proprietary information that is not covered by registered intellectual property instruments by entering </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">322 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
into confidentiality and invention assignment agreements with employees, collaborators and consultants. While protecting trade secrets and <FONT STYLE="white-space:nowrap">know-how</FONT>
presents challenges due to, for example, movement of personnel and the natural evolution of the knowledge in the field of our technology over time, we strive to actively manage exchanges of information with third parties to minimize the risks of
dissemination. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Patent Portfolio </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our patent portfolio includes composition of matter, method of treatment and manufacturing process protection for our lead product candidate <FONT
STYLE="white-space:nowrap">EG-70.</FONT> We have taken a multi-tiered approach to our patent strategy, and in doing so we have captured a series of sequential technical developments leading to and incorporated within
<FONT STYLE="white-space:nowrap">EG-70.</FONT> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">First, as of July&nbsp;31, 2023, we own two patent families comprising six granted U.S. patents, two pending U.S.
<FONT STYLE="white-space:nowrap">non-provisional</FONT> applications, and 85 corresponding granted foreign patents and pending foreign patent applications in jurisdictions including Australia, Brazil, Canada, China, Eurasian Patent Organization, the
European Patent Office, Austria, Belgium, Switzerland, Czech Republic, Germany, Denmark, Estonia, Spain, Finland, France, United Kingdom, Greece, Hong Kong, Hungary, Ireland, Italy, Luxembourg, Latvia, Macedonia, Netherlands, Norway, Poland,
Portugal, Sweden, Slovenia, Slovakia, Turkey, Israel, India, Japan, Philippines, Republic of Korea, Mexico, New Zealand, Singapore and South Africa with claims directed to the dual-derivatization scheme that constitutes the core of our <FONT
STYLE="white-space:nowrap">DDX-based</FONT> gene delivery platform, including granted and pending composition of matter claims relating to the nature of the hydrophilic polyol used in the dual derivatization scheme, as well as methods of use and
treatment.&nbsp;The U.S. and foreign patents directed to this subject matter will expire between 2033 and 2034, absent any applicable patent term extension or patent term adjustment. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Second, as of July&nbsp;31, 2023, we own one patent family comprising one U.S.
<FONT STYLE="white-space:nowrap">non-provisional</FONT> application and 15 corresponding foreign patent applications pending in jurisdictions including Australia, Brazil, Canada, China, the European Patent Office, Hong Kong, Israel, India, Japan,
Republic of Korea, Mexico, New Zealand, Philippines, Singapore and South Africa with claims directed to the <FONT STYLE="white-space:nowrap">non-covalent,</FONT> reversible coating of our nanoparticle technology for enhanced delivery, which we have
recently developed and incorporated into <FONT STYLE="white-space:nowrap">EG-70,</FONT> which enhances transfection and gene expression.&nbsp;The pending claims include compositions of matter and methods of use, and the patents issuing from this
patent family, if any, will expire in 2040, absent any applicable patent term extension or patent term adjustment. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Third, as of July&nbsp;31, 2023, we own one patent family comprising one U.S.
<FONT STYLE="white-space:nowrap">non-provisional</FONT> application and 15 corresponding foreign patent applications pending in jurisdictions including Australia, Brazil, Canada, China, the European Patent Office, Hong Kong, Israel, India, Japan,
Republic of Korea, Mexico, New Zealand, Philippines, Singapore and South Africa with claims directed to the unique combination of immunological cargos, <FONT STYLE="white-space:nowrap">IL-12</FONT> and <FONT STYLE="white-space:nowrap">RIG-1</FONT>
agonists, that are delivered in <FONT STYLE="white-space:nowrap">EG-70,</FONT> including composition of matter claims relating to alternatives to our <FONT STYLE="white-space:nowrap">RIG-I</FONT> agonists, as well as methods of using same in the
treatment of mucosal cancers.&nbsp;The patents issuing from this patent family, if any, will also expire in 2040, absent any applicable patent term extension or patent term adjustment. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Fourth, as of July&nbsp;31, 2023, we own one patent family comprising one granted U.S. patent, one pending U.S. <FONT
STYLE="white-space:nowrap">non-provisional</FONT> application, and six corresponding foreign patent applications pending in jurisdictions including Australia, Canada, China, the European Patent Office, Israel and Japan with claims directed to the
use of our chitosan-based nanoparticle gene delivery technology in the treatment of various inflammatory gut disorders. The patents issuing from this patent family will expire in 2037, absent any applicable patent term extension or patent term
adjustment. In this patent family, U.S. Patent No.&nbsp;11,603,398 received a patent term adjustment of 154 days thereby extending the expiry date to at least April&nbsp;12, 2038. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">323 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Fifth, as of July&nbsp;31, 2023, we own one patent family comprising one U.S.
<FONT STYLE="white-space:nowrap">non-provisional</FONT> application and four corresponding foreign patent applications pending in jurisdictions including Australia, Canada, the European Patent Office and Hong Kong with claims directed to the use of
our chitosan-based nanoparticle gene delivery technology in the treatment of various lung disorders. The patents issuing from this patent family, if any, will expire in 2041, absent any applicable patent term extension or patent term adjustment.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Sixth, we have one pending PCT application directed to the use of <FONT STYLE="white-space:nowrap">EG-70</FONT>
in the treatment of various metastatic cancers, based on data obtained in one of the cancer models.&nbsp;The patents issuing from this patent family, if any, will expire in 2042, absent any applicable patent term extension or patent term adjustment.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Seventh, as of July&nbsp;31, 2023, we own one patent family comprising two granted U.S. patents and corresponding
granted foreign patents in jurisdictions including Australia, the European Patent Office, Belgium, Switzerland, Germany, France, United Kingdom, Ireland, Liechtenstein, Netherlands, Hong&nbsp;Kong, and New Zealand with claims directed to the use of
low molecular weight chitosan in oral gene delivery, including composition of matter and method of use claims. The US and foreign patents directed to this subject matter will generally expire in 2027, absent any applicable patent term extension or
patent term adjustment. In this patent family, U.S. Patent No.&nbsp;8,846,102 received a patent term adjustment of 1737 days thereby extending the expiry date to at least December&nbsp;31, 2031, and U.S. Patent No.&nbsp;9,404,088 received a patent
term adjustment of 736 days thereby extending the expiry date to at least April&nbsp;4, 2029. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Finally, as of July&nbsp;31, 2023, we own one patent family comprising three granted U.S. patents and 28
corresponding granted foreign patents in jurisdictions including Australia, Canada, China, the European Patent Office, Austria, Belgium, Switzerland, Germany, Denmark, Spain, Finland, France, United Kingdom, Ireland, Iceland, Italy, Netherlands,
Norway, Poland, Portugal, Sweden, Slovenia, Hong Kong, Israel, Japan, Republic of Korea, Mexico, India and Singapore with claims directed to certain methods of manufacturing our nanoparticles, including composition of matter, methods of making, and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-process</FONT></FONT> claims.&nbsp;The US and foreign patents directed to this subject matter will expire in 2028, absent any applicable patent term extension or patent term
adjustment. In this patent family, U.S. Patent No.&nbsp;8,722,646 received a patent term adjustment of 327 days thereby extending the expiry date to at least August&nbsp;19, 2029. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in
which we file, the patent term is 20 years from the date of filing of the first <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application to which priority is claimed. In the U.S., patent term may be lengthened by patent term
adjustment, which compensates a patentee for administrative delays by the USPTO in granting a patent or may be shortened if a patent is terminally disclaimed over an earlier-filed patent. In the U.S., the term of a patent that covers an <FONT
STYLE="white-space:nowrap">FDA-approved</FONT> drug may also be eligible for a patent term extension of up to five years beyond the expiration of the patent under the Hatch-Waxman Act, which is designed to compensate for the patent term lost during
the FDA regulatory review process. The length of the patent term extension involves a complex calculation based on the length of time it takes for regulatory review. A patent term extension under the Hatch-Waxman Act cannot extend the remaining term
of a patent beyond a total of 14 years from the date of product approval and only one patent applicable to an approved drug may be extended. Moreover, a patent can only be extended once, and thus, if a single patent is applicable to multiple
products, it can only be extended based on one product. Similar provisions are available in Europe and certain other foreign jurisdictions to extend the term of a patent that covers an approved drug. There is no guarantee that the applicable
authorities will agree with our assessment of whether any extensions should be granted, and if granted, the length of these extensions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our general filing strategy regarding registrable intellectual property is to seek patent protection in major markets. For example, our core <FONT
STYLE="white-space:nowrap">DDX-based</FONT> gene delivery technology is protected by issued patents in the United States, Europe (with country coverage within Europe), Japan, China, Hong Kong, India, Eurasia, South Korea, Canada, Australia, New
Zealand, Brazil, Mexico and several other jurisdictions. Our filing strategy typically </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">324 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
involves the filing of an international PCT patent application followed by national filings in specific countries. The selection of countries is made on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our patent portfolio currently comprises nine patent families, which include
approximately 133 issued patents and 49 pending patent applications, including 12 issued U.S. patents, four issued European patents (with country coverage within Europe), six <FONT STYLE="white-space:nowrap">non-provisional</FONT> pending U.S.
applications, five European pending applications and one pending PCT application. enGene exclusively owns all nine patent families in its patent portfolio. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent positions of companies like us are generally uncertain and involve complex legal, scientific, and factual questions. Changes in the
patent laws and rules, either by legislation, judicial decisions, or regulatory interpretation in other countries may diminish our ability to protect our inventions and enforce our intellectual property rights, and more generally could affect the
value of our intellectual property. In particular, our ability to stop third parties from making, using, selling, offering to sell, importing or otherwise commercializing any of our patented inventions, either directly or indirectly, will depend in
part on our success in obtaining, defending and enforcing patent claims that cover our technology, inventions, and improvements. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and
its scope can be reinterpreted after issuance. Consequently, we do not know whether any of our product candidates will be protectable or remain protected by enforceable patents or will be commercially useful in protecting our commercial products and
methods of using and manufacturing the same. We also cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient
proprietary protection from competitors. Any patents that we hold or control may be challenged, circumvented or invalidated by third parties. In addition, our agreements and security measures protecting our trade secrets and <FONT
STYLE="white-space:nowrap">know-how</FONT> may be breached, and we may not have adequate remedies for any such breach. Further, our trade secrets may otherwise become known or independently discovered by competitors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See &#147;<I>Risk Factors &#151; Risks Related to Our Intellectual Property</I>&#148; for important information about risk respecting our
intellectual property. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Strategic License Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April 10, 2020, we entered into a non-exclusive license agreement (the &#147;License Agreement&#148;) with Nature Technology Corporation
(&#147;NTC&#148;) pursuant to which NTC granted enGene a worldwide <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> royalty-bearing and sublicensable license to certain patents and <FONT STYLE="white-space:nowrap">know-how</FONT> relating to
the Nanoplasmid<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> vector backbone that is used in detalamogene voraplasmid to research, develop, make, use, import, sell and offer to sell, any gene and cell therapy products incorporating the
Nanoplasmid<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> vector backbone (excluding any such products in the field of dermatology). The licensed intellectual property includes 10 patent families (inclusive of all related divisional,
continuation, <FONT STYLE="white-space:nowrap">continuation-in</FONT> part, substitutes, counterparts and/or any foreign equivalents filed in any country within such family) and certain <FONT STYLE="white-space:nowrap">know-how.</FONT> NTC is solely
responsible for the preparation, filing, prosecution, cost and maintenance of all patent applications and patents included in the licensed intellectual property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless terminated earlier, the License Agreement will continue until no valid claim of any licensed patent exists in any country. NTC may
terminate the License Agreement if we fail to make any payments within a specified period after receiving written notice of such failure. Either party may terminate the License Agreement in the event either party commits a material breach and fails
to cure such breach within a certain period. We can terminate the License Agreement for convenience with prior notice to NTC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the
License Agreement, we are obligated to make annual payments of $50,000 until the first sale of a product for which a royalty is due and make a payment to NTC of $50,000 upon assigning the License Agreement to a third-party. We are also required to
make a one-time payment of $50,000 for the first dose of a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">325 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
product covered by a valid claim of a licensed patent (a &#147;Milestone Product&#148;) in the first patient in a Phase&nbsp;I clinical trial or, if there is no Phase&nbsp;I clinical trial, in a
Phase&nbsp;II clinical trial, as well as a one-time payment of $450,000 upon regulatory approval of a Milestone Product by the U.S. Food and Drug Administration. The first milestone related to the first dose of a Milestone Product, was achieved
during the year ended October&nbsp;31, 2021. The second milestone, regulatory approval of a Milestone Product, has not yet been achieved as of the year ended October&nbsp;31, 2022. We are also required to pay NTC a royalty percentage in the low
single digits of the aggregate net product sales in a calendar year by us, our affiliates or sublicensees on a product-by-product and country-by-country basis, as long as the composition or use of the applicable product is covered by a valid claim
in the country where the net sales occurred. Royalty obligations under the License Agreement will continue until the expiration of the last valid claim of a licensed patent covering such licensed product in such country. In the event that we or any
of our affiliates or sublicensees manufacture any GMP lot of a licensed product, then we or any such affiliate or sublicensee will be obligated to pay NTC an amount per manufactured gram of GMP (or its equivalent) lot of product, which varies based
on the volume manufactured. Such manufacturing payment will expire on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> basis upon receipt of regulatory approval to market a product in any country
in the licensed territory. Under the License Agreement, enGene is permitted to sublicense our rights to third parties and we are not required to share any of the license revenue with NTC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NTC was acquired by Aldevron, LLC in January 2022. The terms of the existing License Agreement described above remained the same. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The biotechnology and
pharmaceutical industries are characterized by rapid innovation of new technologies, fierce competition, and strong defense of intellectual property. While we believe that <FONT STYLE="white-space:nowrap">EG-70</FONT> and our knowledge, experience
and scientific resources provide us with competitive advantages, we may face competition from pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions, among other things.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of our competitors, either independently or with strategic partners, have substantially greater financial, technical and human
resources than we do. Accordingly, our competitors may be more successful than we are in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approval for treatments and achieving widespread
market acceptance. Merger and acquisition activity in the biotechnology and biopharmaceutical industries may result in resources being concentrated among a smaller number of our competitors. These companies also compete with us in recruiting and
retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials and acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may
also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
commercial opportunity could be substantially limited if our competitors develop and commercialize products that are more effective, safer, less toxic, more convenient or less expensive than products we may develop. In geographies that are critical
to our commercial success, competitors may also obtain regulatory approvals before us, resulting in our competitors building a strong market position in advance of the entry of our products. In addition, our ability to compete may be affected in
many cases by insurers or other third-party payers seeking to encourage the use of other drugs. The key competitive factors affecting the success of any products we may develop are likely to be their efficacy, safety, convenience, price and
availability of reimbursement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are three <FONT STYLE="white-space:nowrap">FDA-approved</FONT> products, as well as multiple
companies that have drugs in clinical development for the treatment of high risk NMIBC patients that are unresponsive to BCG. While many of these products represent a different modality and may not be either intravesical or monotherapy, they may
nonetheless compete with us for patient recruitment in our clinical trials as well as for commercial sales. Competing products include, among other things, the following: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">326 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">FDA-Approved:</FONT> </I></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Adstiladrin<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (nadofaragene firadenovec) is a <FONT
STYLE="white-space:nowrap">non-replicating</FONT> adenoviral vector-based gene therapy that is manufactured and marketed by Ferring Pharmaceuticals A/S. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Keytruda<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (pembrolizumab), a Merck product, for the
treatment of patients with high-risk BGG- unresponsive NMIBC with Cis with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">VALSTAR<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (valrubicin), marketed by Endo Pharmaceuticals,
is an anthracycline topoisomerase inhibitor for intravesical treatment of <FONT STYLE="white-space:nowrap">BCG-refractory</FONT> Cis of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or
mortality. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Multiple companies have reported drugs in clinical development, including the following: </I></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Aura Biosciences is developing <FONT STYLE="white-space:nowrap">AU-011</FONT> for patients with intermediate or
high-risk NMIBC. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ImmunityBio has submitted a BLA for their drug Anktiva<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>
in combination with BCG in patients with BCG unresponsive high grade NMIBC based on the results of their QUILT 3.032 study. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Sesen Bio presented Phase 3 data for their lead candidate,
Vicineum<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>, as a treatment for <FONT STYLE="white-space:nowrap">BCG-unresponsive</FONT> NMIBC. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">UroGen Pharma has <FONT STYLE="white-space:nowrap">UGN-301,</FONT> an
<FONT STYLE="white-space:nowrap">anti-CTLA-4</FONT> immunotherapy that it is developing for the treatment of patients with recurrent NMIBC gel as both a single agent and in combination with <FONT STYLE="white-space:nowrap">UGN-201,</FONT>
Urogen&#146;s investigational TLR7 agonist. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">CG Oncology has CG0070 that is being investigated in a global Phase 3 clinical trial as a monotherapy for the
treatment of <FONT STYLE="white-space:nowrap">BCG-unresponsive</FONT> NMIBC, as well as in Phase 2 studies in combination with pembrolizumab. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Seagen has Padcev<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (enfortumab vedotin), a <FONT
STYLE="white-space:nowrap">NECTIN-4</FONT> targeted antibody-drug conjugate, which it is developing in NMIBC. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Protara has <FONT STYLE="white-space:nowrap">TARA-002,</FONT> an investigational cell therapy in development for
the treatment of NMIBC and lymphatic malformations (LMs). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Janssen has <FONT STYLE="white-space:nowrap">TAR-200,</FONT> an investigational drug delivery system enabling
controlled release of gemcitabine into the bladder. Janssen is also developing <FONT STYLE="white-space:nowrap">TAR-200</FONT> and cetrelimab as a combination therapy. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Theralase has <FONT STYLE="white-space:nowrap">TLD-1433,</FONT> a light-activated photodynamic compound that is
activated in the bladder via the proprietary <FONT STYLE="white-space:nowrap">TLC-3200</FONT> medical laser system. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Bristol Myers Squibb has Opdivo<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (nivolumab or nivolumab
plus) the experimental medication <FONT STYLE="white-space:nowrap">BMS-986205</FONT> with or without BCG. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Roche is developing Tecentriq<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (atezolizumab plus) BCG
bladder instillation in <FONT STYLE="white-space:nowrap">BCG-naive</FONT> high-risk NMIBC patients via the ALBAN trial. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Janssen Pharmaceuticals (part of Johnson &amp; Johnson) is developing Balversa<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (erdafitinib) versus investigator choice of intravesical chemotherapy in participants who received BCG and recurred with HR NMIBC. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Pfizer has sasanlimab, an
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibody. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">AstraZeneca is evaluating the efficacy and safety of
Imfinzi<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (durvalumab plus BCG) compared to standard therapy with BCG in NMIBC. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Intravesical BCG vs GEMDOCE in NMIBC is being investigated via the BRIDGE trial to determine the event free
survival of <FONT STYLE="white-space:nowrap">BCG-na&iuml;ve</FONT> high grade NMIBC patients treated with intravesical BCG vs Gemcitabine + Docetaxel; the estimated study completion date is October 2030. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">327 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I></I>See &#147;<I>Risk Factors &#151; Risks Related to enGene and New enGene&#146;s
Business Following the Business Combination &#151; Risks Relating to Our Business &#151; We face significant competition from other biotechnology and pharmaceutical companies, which may result in our competitors discovering, developing or
commercializing products before us or more successfully than we do. Our business and results of operations could be adversely affected if we fail to compete effectively</I>&#148;<I></I> for important information about risks respecting
competition.<I> </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Regulatory Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The development, production, testing, distribution, and marketing of biologics like the ones we are developing are subject to strict
regulations by various federal, state, and local agencies in addition to foreign regulatory authorities. These regulations cover a wide range of aspects, including research, safety, efficacy, labeling, packaging, storage, distribution, and
advertising, as well as post-approval monitoring and reporting. Our company, as well as our vendors, partners, CROs, and manufacturers, will need to comply with these regulations. To gain approval for our product candidate, we need to comply with
the regulatory requirements of various governing agencies, including those related to preclinical and clinical trials, manufacturing, and commercialization. This process requires a significant investment of time and financial resources. In the
United&nbsp;States, our focus market, the FDA regulates biologics under the FDCA and PHSA, and other federal, state, and local regulations also apply. Our product candidate, <FONT STYLE="white-space:nowrap">EG-70</FONT> is not yet approved for
marketing in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I></I>See &#147;<I>Risk Factors &#151; Risks Related to enGene and New enGene&#146;s Business Following
the Business Combination &#151; Risks Relating to Our Business &#151; Regulatory Risks</I>&#148; for important information about risks respecting regulatory matters<I>. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To obtain approval for our product candidates for therapeutic use in the United States, we must follow a series of steps regulated by the FDA.
This includes conducting preclinical studies in compliance with regulations, meetings with the FDA, submitting an IND to the FDA, obtaining institutional review board, or &#147;IRB,&#148; or ethics committee approval at each clinical trial site,
conducting clinical trials in compliance with GCP requirements, preparing and submitting a BLA accompanied by fees, undergoing FDA <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspections of manufacturing facilities, and having potential FDA
audits of the clinical trial sites. Finally, the FDA will review and approve the BLA and provide any recommendations before the biologic drug can be sold commercially in the United States. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Preclinical and clinical testing of biological drug products </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to test a drug or biologic in humans, it must first undergo extensive preclinical testing, which includes laboratory evaluations and
animal studies to determine safety and efficacy. These studies must comply with federal and state regulations, including Good Laboratory Practices (&#147;GLP&#148;) requirements for safety and toxicology studies. The results of these studies, as
well as manufacturing and analytical data, must be submitted to the FDA as part of an IND. The IND is a request for authorization to administer the product to humans and must be approved before clinical trials can begin. The IND submission focuses
on the protocol for the initial clinical study and includes results of animal and <I>in vitro</I> studies, as well as any available human data to support the use of the investigational product. The IND becomes effective 30 days after receipt by the
FDA, unless the FDA raises concerns or questions about the study, in which case a clinical hold is imposed until the concerns are resolved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the clinical stage of development, the product candidate is administered to patients or healthy volunteers under the supervision of
qualified investigators in accordance with GCP requirements. Each clinical trial must be reviewed and approved by an IRB to ensure that the risks to individuals participating in the clinical trial are minimized and reasonable in relation to the
anticipated benefits. The FDA, IRB, or sponsor may suspend or discontinue a clinical trial at any time on various grounds. Some studies also include oversight by a data safety monitoring board. Clinical trials must be reported to public registries
within specific timeframes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">328 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While international clinical trials can be conducted under an IND, the FDA does not require
that all foreign clinical trials be conducted under United States INDs. The FDA will accept a well-designed and conducted foreign clinical study not conducted under an IND if the study was conducted in accordance with GCP requirements and the FDA is
able to validate the data through an onsite inspection if necessary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials that are carried out to determine the efficacy of a
drug for the purpose of obtaining marketing approval through a BLA are typically carried out in three phases that can occur simultaneously, in combination, or staggered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Phase 1</I>: Phase 1 of clinical trials involves administering the investigational product to healthy human volunteers or patients with the
target disease or condition for the first time. The primary objective of these studies is to evaluate the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, identify any side effects
associated with increasing doses, and potentially gather preliminary evidence of effectiveness. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Phase 2</I>: Phase 2 clinical trials
usually involve giving the investigational product to a small group of patients with a particular disease or condition to assess its effectiveness, determine the best dosage and dosing schedule, and detect any potential risks or side effects. To
gather data before conducting more extensive and costly Phase 3 trials, several Phase 2 studies may be conducted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Phase 3</I>: Phase 3
trials usually involve testing the investigational product in a larger group of patients to confirm its efficacy and safety. The trials are conducted at multiple locations and aim to establish the overall risk-benefit profile of the product.
Typically, the FDA requires two well-controlled Phase 3 clinical trials to approve a BLA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After marketing approval, Phase 4 clinical
trials, also known as post-approval trials, may be conducted to gain more experience with the product in its intended use and to gather additional safety data. The FDA may require these trials as a condition of approval. The results of clinical
trials and safety reports for serious adverse events must be submitted to the FDA annually and within 15 days of the sponsor&#146;s determination. Fatal or life-threatening adverse reactions must be reported within seven days. Along with clinical
trials, companies must complete additional animal studies, develop information about the product&#146;s biological characteristics, and establish a commercial manufacturing process that adheres to cGMP requirements. The manufacturing process must
consistently produce quality batches of the product, and appropriate packaging and storage conditions must be identified through stability studies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Expanded Access </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Expanded access, also known as &#147;compassionate use,&#148; refers to the use of investigational products outside of their intended clinical
development to treat patients suffering from serious or life-threatening diseases or conditions when no satisfactory alternative treatment options are available. FDA regulations permit access to investigational products through an IND by the
treating physician or the company for treatment purposes, including individual patients, <FONT STYLE="white-space:nowrap">intermediate-size</FONT> patient populations, and larger populations for use under a treatment protocol or treatment IND
application. It is important to note that companies are not obligated to provide expanded access to their investigational products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>BLA Submission and marketing authorization by the FDA </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to apply for either data exclusivity or market exclusivity for our product candidates. If the necessary clinical testing is completed
successfully, we will submit the results of preclinical studies and clinical trials, as well as detailed information on the product&#146;s manufacturing, labeling, and other aspects, to the FDA in the form of a BLA. This application seeks approval
to market a new biologic for one or more specific indications. The BLA must contain all relevant data from both positive and negative studies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">329 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The BLA should incorporate all important information accessible from relevant preclinical
and clinical examinations, including negative or questionable outcomes as well as certain discoveries, along with itemized data connecting with the item&#146;s science, assembling, controls, and proposed naming, in addition to other things.
Information might come from organization supported clinical preliminaries planned to test the wellbeing and viability of an item&#146;s utilization or from various elective sources, including review started by examiners. The data submitted must be
of sufficient quality and quantity to satisfy the FDA regarding the investigational product&#146;s safety, purity, and potency in order to support marketing approval. A BLA must be approved by the FDA before a biologic can be sold in the United
States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A BLA or supplement to a BLA must also include data to assess the biological product candidate&#146;s safety and effectiveness
for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective, as required by the Pediatric Research Equity Act, or PREA. An
initial Pediatric Study Plan (PSP) must be submitted within sixty days of an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-of-Phase</FONT></FONT> 2 meeting or as agreed upon between the sponsor and FDA by a sponsor planning
to submit a marketing application for a biological product that includes a new clinically active component, new indication, new dosage form, new dosing regimen, or new route of administration. PREA does not apply to any biological product for an
indication for which an orphan designation has been granted, unless otherwise required by regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some cases, the FDA may also
request additional information before deciding whether or not to accept the BLA for filing. Within 60 days of receiving a BLA, the FDA must decide whether or not to accept it for filing. This decision may include refusing to file. The FDA begins a
comprehensive substantive review of the BLA as soon as the submission is accepted for filing. A BLA is reviewed by the FDA to see, among other things, if the product is safe, pure, and effective, and if the facility where it is manufactured,
processed, packaged, or stored satisfies standards designed to guarantee the product&#146;s continued safety, quality, and purity. Under the objectives and polices consented to by the FDA under the Physician Endorsed Medication Client Expense Act,
or PDUFA, the FDA targets ten months from the documenting date in which to finish its underlying survey of a unique BLA and answer the candidate, and a half year from the recording date of a unique BLA petitioned for need audit. The FDA doesn&#146;t
generally meet its PDUFA objective dates for standard or need BLAs, and the survey interaction is frequently stretched out by FDA demands for extra data or explanation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, under PDUFA, as changed, each BLA should be joined by a client charge, and the patron of an endorsed BLA is likewise dependent upon a
yearly program expense. FDA changes the PDUFA client expenses on a yearly premise. In some cases, fees may be reduced or waived. For example, a small business may not have to pay the application fee for the first time. In addition, unless the
product also includes a <FONT STYLE="white-space:nowrap">non-orphan</FONT> indication, there are no user fees associated with BLAs for products designated as orphan drugs. See &#147;<I>Orphan drug designation</I>&#148; below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA might allude an application for a biologic to a warning board of trustees. A panel of independent experts, such as clinicians and
other scientific experts, is known as an advisory committee. It reviews, evaluates, and offers a recommendation, such as whether the biologic is sufficiently safe and effective in a particular indication for a particular population and under what
conditions. While an advisory committee&#146;s recommendations do not bind the FDA, they are carefully taken into consideration when deciding whether or not to grant marketing approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA will typically conduct an inspection of the facility or facilities where the product is manufactured prior to approving a BLA. The FDA
will not approve an application unless it finds that the manufacturing facilities and processes are adequate to guarantee consistent product production in accordance with the required specifications. Furthermore, prior to approving a BLA, the FDA
might investigate at least one clinical preliminary destination to guarantee consistence with GCP and different necessities and the uprightness of the clinical information submitted to the FDA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">330 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may require a Risk Evaluation and Mitigation Strategy (REMS) to be submitted as a
condition for approving a Biologics License Application (BLA) to ensure that the product&#146;s benefits outweigh its risks. The REMS may include medication guides, communication plans, assessment plans, or other risk-minimization tools. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once the BLA and all related information, including advisory committee recommendations and inspection reports, have been evaluated, the FDA
may issue an approval letter or a Complete Response Letter. A Complete Response Letter indicates that the application is not ready for approval and lists all deficiencies found in the BLA. The FDA may recommend actions the applicant can take to
improve the BLA&#146;s chances of approval. Even with additional information, the FDA may still reject the application. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the FDA
approves a product, they may impose restrictions, require additional studies, or limit approved indications for use. The FDA can also impose distribution and use restrictions or other risk management mechanisms under a REMS, which may affect the
product&#146;s market and profitability. Post-marketing studies or surveillance programs may result in the FDA limiting or preventing further marketing of the product. Changes to the approved product may also require further testing and FDA review
and approval. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Expedited drug development and review programs at the FDA </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA has programs to speed up the development and review of new drugs and biologics for serious or life-threatening diseases. These programs
include Fast Track designation, Breakthrough Therapy designation, priority review, and Accelerated Approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A biologic can get Fast
Track designation if it is meant to treat a serious or life-threatening disease and has the potential to address unmet medical needs for that disease. This applies to the product and the specific indication for which it is being studied. Fast Track
designation allows sponsors to interact more with the FDA during preclinical and clinical development. There is also potential for rolling review, where the FDA can review parts of the Biologics License Application (BLA) on a rolling basis if the
sponsor provides a schedule, the FDA accepts the schedule, and the sponsor pays required fees when submitting the first section of the BLA. Our lead product candidate, <FONT STYLE="white-space:nowrap">EG-70,</FONT> has been granted Fast Track
designation by the FDA. There can be no assurance that EG-70&#146;s Fast Track designation will lead to a faster development, regulatory review or approval process or increase the likelihood EG-70 will receive marketing approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Breakthrough Therapy designation is given to drugs that demonstrate a substantial improvement over existing therapies on clinically
significant endpoints, and this designation provides intensive guidance for an efficient development program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Products with Fast Track or
Breakthrough Therapy designation may also be eligible for priority review and Accelerated Approval. Priority review is given to drugs that provide significant improvement in safety or effectiveness for serious or life-threatening diseases or
conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accelerated Approval is given when a drug has an effect on a surrogate or early clinical endpoint that is likely to predict
clinical benefit. Sponsors must agree to conduct additional post-approval studies to verify clinical benefit, and the FDA may withdraw approval if those studies fail. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While these programs may expedite the development or review process, they do not change the scientific or medical standards for approval or
the quality of evidence necessary to support approval. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Post Approval Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA heavily regulates drugs and biologics that are manufactured or distributed with their approval. This includes requirements related to
recordkeeping, reporting, and product distribution. Companies must </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">331 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
comply with promotion and advertising restrictions and are prohibited from promoting products for unapproved uses. Although physicians can prescribe drugs for
<FONT STYLE="white-space:nowrap">off-label</FONT> use, companies cannot market or promote them for these purposes. Failure to comply with these requirements can result in penalties and liability under the False Claims Act. Post-approval requirements
may include post-market testing and surveillance to assess the product&#146;s safety and effectiveness. Manufacturers and their subcontractors must register with the FDA and undergo periodic inspections for compliance. Changes to the manufacturing
process may require FDA approval. Failure to comply can result in legal or regulatory action, and the FDA can withdraw approval if regulatory standards are not maintained. Revisions to approved labeling and other restrictions may also be imposed.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, post approval, a pediatric study is typically required unless a waiver is granted. In the case of <FONT
STYLE="white-space:nowrap">EG-70,</FONT> due to the rare incidence of bladder cancer in children, we may request a waiver of this requirement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consequences of failing to comply with FDA regulations include various restrictions such as limitations on marketing or manufacturing,
product recalls, safety alerts, and mandated modifications of promotional materials and labeling. Companies may also face fines, warning letters, or untitled letters, as well as holds on clinical trials and refusal of FDA approvals. The FDA can also
take more serious actions such as product seizure or detention, injunctions, or civil or criminal penalties. In addition, companies may face consent decrees, corporate integrity agreements, debarment, or exclusion from federal healthcare programs.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Orphan drug designation and exclusivity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Orphan Drug Act allows the FDA to give orphan drug designation (&#147;ODD&#148;) to drugs or biologics meant to treat rare diseases or
conditions, which are defined as having a patient population of fewer than 200,000 individuals in the United States or a patient population greater than 200,000 individuals in the United States when it is not reasonable to expect that the cost of
developing and making the drug available in the United States will be recovered from sales in the United States. To receive ODD, it must be requested before submitting a BLA, and the identity of the therapeutic agent and its potential orphan use are
publicly disclosed after ODD is granted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a product receives ODD and later becomes the first
<FONT STYLE="white-space:nowrap">FDA-approved</FONT> drug for a particular clinically active component for the disease it was designated for, it is entitled to orphan drug exclusivity, meaning the FDA cannot approve any other applications, including
a full BLA, to market the same biologic for the same indication for seven years from the approval of the BLA, except under specific circumstances. These circumstances include showing clinical superiority to the product with orphan drug exclusivity
or if the holder of the exclusivity cannot assure the availability of sufficient quantities of the drug for patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Orphan drug
exclusivity does not prevent the FDA from approving a different drug or biologic for the same disease or condition, or the same drug or biologic for a different disease or condition. ODD also offers benefits like tax credits for certain research and
a waiver of the BLA application user fee. However, a product with ODD may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received ODD. Moreover, the exclusive marketing rights in the
United States may be lost if the FDA later finds that the request for designation was materially defective or if the manufacturer can&#146;t assure sufficient quantities of the product for patients with the rare disease or condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that one or more indications for which we may develop a drug product based on the DDX platform may qualify for ODD. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Biosimilars and Exclusivity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Patent Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA, signed
into law in 2010, includes a subtitle called the Biologics Price Competition and Innovation Act (&#147;BPCIA&#148;), which simplified approval process for biological products that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">332 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
are similar to an <FONT STYLE="white-space:nowrap">FDA-licensed</FONT> reference biological product. The FDA has issued several guidance documents outlining how to review and approve biosimilars.
Biosimilarity requires that the biological product and the reference product be the same in terms of safety, purity, and potency. This can be proven through analytical studies, animal studies, and clinical studies. Interchangeability requires that a
product be biosimilar to the reference product and that the biologic, and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An application for a biosimilar product cannot be submitted to the FDA until four years after the reference product was licensed by the FDA.
Also, the approval of a biosimilar product cannot be made effective until 12&nbsp;years after the reference product was licensed. During this period, another company may still market a competing version of the reference product if the FDA approves a
full BLA for the competing product that shows the safety, purity, and potency of its product. The BPCIA also created exclusivity periods for biosimilars approved as interchangeable products. It is not yet clear if products deemed
&#147;interchangeable&#148; by the FDA will be readily substituted by pharmacies, which are governed by state pharmacy law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United
States, a biological product may receive additional market exclusivity for six months if the manufacturer voluntarily completes a pediatric study in accordance with an <FONT STYLE="white-space:nowrap">FDA-issued</FONT> &#147;Written Request.&#148;
The BPCIA, which created an abbreviated approval pathway for biosimilar products, is complex and continues to be interpreted and implemented by the FDA. Recently, government proposals have sought to decrease the
<FONT STYLE="white-space:nowrap">12-year</FONT> reference product exclusivity period. Some aspects of the BPCIA, which could affect its exclusivity provisions, have been the subject of litigation. Therefore, the impact, implementation, and
regulatory interpretation of the BPCIA remain uncertain. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Regulation of combination drug products in the US </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Combination products are those that are made up of different components, such as biological and device components, that are typically regulated
by different FDA centers. According to FDA regulations, a combination product can be a single entity made up of two or more regulated components that are combined in some way, two or more separate products packaged together, or a product that
requires the use of an approved drug, device or biological product to achieve the intended effect. The FDA assigns a lead center for review of combination products based on the product&#146;s primary mode of action. The Office of Combination
Products has been established to address issues related to combination products and provide guidance and regulations for their regulation. Combination products with a biologic primary mode of action are generally reviewed through the biologic
approval process, with input from the device center to ensure the device component meets safety and performance requirements. Combination products are subject to current Good Manufacturing Practice (cGMP) regulations for drugs, biologics, and
devices, including quality system regulations for medical devices. Our manufacturing process is cGMP compliant. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Other regulatory
considerations for drug products </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After a product candidate has been approved or commercialized, its manufacturing, sales,
promotion, and other related activities are subject to regulation by various regulatory bodies in the United States. In addition to the FDA, these regulatory authorities may include the Centers for Medicare&nbsp;&amp; Medicaid Services (CMS), other
divisions of the Department of Health and Human Services (HHS), the Drug Enforcement Administration (DEA), the Consumer Product Safety Commission, the Federal Trade Commission (FTC), the Occupational Safety&nbsp;&amp; Health Administration (OSHA),
the Environmental Protection Agency, as well as state and local governments and agencies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Drug coverage and reimbursement
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States and many other countries, patients rely on third-party payers to cover part or all of the costs of their
treatment. Having sufficient coverage and reimbursement from government healthcare programs and private insurers is critical for the success of new products. The availability of coverage and reimbursement
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">333 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
will impact our ability to commercialize our product candidates, and the amount of reimbursement provided may not be enough for us to make a profit. Government authorities and third-party payers
determine which medications they will pay for and at what level. New products may not be covered or may have limited coverage, and the reimbursement level may be lower than necessary to cover our costs. The
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic has also caused uncertainty regarding insurance coverage, as many people have lost their employer-based coverage. The factors that payers consider when determining reimbursement include
whether the product is covered by the plan, safe, effective, medically necessary, appropriate for the patient, and cost-effective. Discounts and rebates required by government programs and private payers may reduce the net price for drugs, and there
is increasing pressure on drug companies to offer predetermined discounts. We cannot be certain that reimbursement will be available for our products or what the reimbursement level will be, and we may be subject to penalties if we do not report
pricing metrics accurately and in a timely manner. We also cannot be certain that if we obtain reimbursement arrangements with payors that such arrangements will not be subject to recoupment actions or overpayment challenges, which can be time
consuming and expensive to resolve. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Health care laws and regulations in the United States </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pharmaceutical companies must comply with various healthcare regulations enforced by the federal government and state and foreign authorities
where they do business. These regulations limit financial arrangements and relationships involving the research, sale, marketing, and distribution of products authorized for sale. The laws include the federal Anti-Kickback Statute, which prohibits
offering or receiving remuneration for referrals or purchases that may be paid under federal and state healthcare programs. The False Claims Act and Civil Monetary Penalties Law prohibit submitting false claims for payment to the government. The
federal Health Insurance Portability and Accountability Act of 1996 imposes liability for executing schemes to defraud healthcare benefit programs or falsifying information related to healthcare delivery and payment. The &#147;Sunshine Act&#148;
requires manufacturers of reimbursable drugs, devices, biologics, and medical supplies to report physician payments and other transfers of value. HIPAA imposes privacy and security obligations on certain healthcare providers, health plans, and
healthcare clearinghouses. Similar state laws may apply to sales and marketing arrangements involving healthcare items or services reimbursed by <FONT STYLE="white-space:nowrap">non-governmental</FONT> third-party payors, reporting requirements
related to financial arrangements with clinicians, and state privacy and security laws governing health information can be different from HIPAA. Noncompliance with these laws can lead to significant penalties, including administrative, civil, and
criminal penalties, damages, fines, disgorgement, restructuring of operations, oversight and reporting obligations, and exclusion from participation in federal and state healthcare programs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Healthcare legislative development </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Healthcare payors, whether they are government or private entities, are using more sophisticated methods to control costs, but these methods
are not always suitable for new technologies like gene therapy and treatments for rare diseases. Legislative and regulatory changes to the healthcare system in the United States and many other countries could affect our ability to sell our products
profitably. The Affordable Care Act, which became law in 2010, introduced a range of changes, including subjecting biologic products to competition from lower-cost biosimilars, increasing minimum Medicaid rebates, and imposing new annual fees and
taxes on certain branded prescription drugs. The ACA has faced legal and political challenges, and the Biden administration has initiated a special enrollment period and ordered reviews of policies and rules that limit access to healthcare. Other
healthcare reform measures may also impact our business. Since the ACA was enacted, other legislative changes have been proposed and adopted in the United States, including spending reductions under the Budget Control Act of 2011 and the Right to
Try Act, which provides a federal framework for certain patients to access investigational new drug products. There has also been growing interest in specialty drug pricing practices and efforts to control pharmaceutical and biological product
pricing at the federal and state levels, including transparency measures and importation from other countries. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Facilities</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our corporate headquarters are located in Montreal, Canada, where we lease and occupy approximately 10,000 square feet of laboratory and office
space at 7171 Rue Frederick Banting, Montreal, QC H4S 1Z9. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">334 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
current term of our lease expires on September&nbsp;30, 2023. We signed a new lease on December&nbsp;29, 2022, for a 10,620 sq. feet of new laboratory and office space at 4868 Rue Levy, Montreal,
QC. We plan to move into the new facility after the current lease is expired. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe our current facilities are sufficient for our
need in the foreseeable future. However, if we need more space for our business in the future, we may choose to rent or lease additional or different space. We expect that there will be appropriate options available to us at reasonable prices if we
need to expand our operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of July 31, 2023, we had 33 employees, including 30 full-time employees, 25 of whom were primarily engaged in research and development
activities. <FONT STYLE="white-space:nowrap">Twenty-four</FONT> of our employees are based in Canada and nine in the United States. None of our employees are represented by a labor organization or are party to a collective bargaining arrangement. We
consider our relationship with our employees to be excellent. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Proceedings</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we may be involved in legal proceedings that arise in the regular course of our business. Our management believes that we
are not currently involved in any legal proceedings that are likely to have a significant negative effect on our business. However, legal proceedings can negatively affect our business, financial condition, results, and future prospects, regardless
of the outcome, due to costs associated with defense and settlement, as well as the diversion of management resources, among other factors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">335 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom459793_32"></A>ENGENE&#146;S MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AND RESULTS OF OPERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Throughout this section, unless otherwise noted, &#147;we,&#148; &#147;us,&#148; &#147;enGene&#148; and the &#147;Company&#148; refer to
enGene Inc. and its consolidated subsidiary. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>You should read the following discussion and analysis of our financial condition and
results of operations together with our consolidated financial statements as of April&nbsp;30, 2023 and October&nbsp;31, 2022 and for the three and six months ended April&nbsp;30, 2023 and 2022 and for the fiscal years ended October&nbsp;31, 2022,
2021, 2020 and the related notes and other financial information included elsewhere in this proxy statement/prospectus. Some of the information contained in this discussion and analysis or set forth elsewhere in this proxy statement/prospectus,
including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. See the sections titled &#147;Special Note Regarding Forward-Looking
Statements&#148; and &#147;Risk Factors&#148; for a discussion of forward-looking statements and important factors that could cause actual results to differ materially from the results described in or implied by these forward-looking statements.
</I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>We operate as a single operating segment focused on research, discovery, and clinical development of human gene therapy products.
Our fiscal year is the year ended October 31. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. We are developing <FONT
STYLE="white-space:nowrap">non-viral</FONT> gene therapies based on our novel and proprietary dually derived chitosan, or &#147;DDX&#148;, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues
and other organs. We believe our DDX platform, with its broad tissue and disease application, has the potential to take gene therapy beyond rare genetic diseases into oncology and other underserved therapeutic areas. We have established integrated
capabilities with this platform to support the clinical development and potential commercialization of our gene therapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our
inception, we have devoted substantially all of our efforts to organizing and staffing our company, business planning, raising capital, establishing our intellectual property portfolio, acquiring or discovering product candidates, research and
development activities for our primary program, <FONT STYLE="white-space:nowrap">EG-70,</FONT> <FONT STYLE="white-space:nowrap">EG-i08</FONT> and other compounds. We do not have any products approved for sale and have not generated any revenue from
product sales except we have had collaboration agreements resulting in recovery of R&amp;D costs with various past partners. The Company operates as a single operating segment focused on research, discovery, and clinical development of human gene
therapy products. To date, we have financed our operations primarily with the issuance of convertible debt and proceeds from sales of preferred shares. From inception, we have raised aggregate gross proceeds of approximately $77.8 million through
the sale and issuance of our preferred shares, warrants, and convertible debentures, and $19.0&nbsp;million through our term loan and April 2023 note financings. Our primary uses of capital are, and we expect will continue to be, research and
development activities, compensation and related expenses, and general overhead costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have incurred significant operating losses
since our inception. Our net losses were $24.5&nbsp;million, $23.4&nbsp;million and $15.1&nbsp;million for the years ended October&nbsp;31, 2022, 2021 and 2020, respectively. Our net losses were $5.3&nbsp;million and $12.7&nbsp;million for the three
and six months ended April&nbsp;30, 2023, respectively, and $5.3&nbsp;million and $9.3&nbsp;million for the three and six months ended April&nbsp;30, 2022, respectively. As of April&nbsp;30, 2023 and October&nbsp;31, 2022, we had an accumulated
deficit of $112.4&nbsp;million and $99.7&nbsp;million, respectively, and cash and cash equivalents of $17.5&nbsp;million and $20.4&nbsp;million, respectively. We expect to continue to incur net operating losses for at least the next several years,
as we advance our product candidates through preclinical and clinical development and seek regulatory approvals, manufacture drug product and drug supply, maintain, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">336 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
enforce, defend and expand our intellectual property portfolio, as well as hire additional personnel, pay for accounting, audit, legal, regulatory and consulting services, and pay costs
associated with maintaining compliance with listing rules and the requirements of the SEC, director and officer liability insurance, investor and public relations activities and other expenses associated with operating as a public company. Our net
losses may fluctuate significantly from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">quarter-to-quarter</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-year,</FONT></FONT> depending on
the timing of our preclinical studies, our clinical trials and our expenditures on other research and development activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Giving pro
forma effect to the Business Combination, including the PIPE Financing and other transactions and assumptions set forth in the &#147;<I>Unaudited Pro Forma Financial Information</I>&#148; and further assuming the maximum redemption scenario, as of
April&nbsp;30, 2023, pro forma cash and cash equivalents would have been $100.2&nbsp;million. With the funds to be received as a result of the Business Combination, we may be able to reach significant clinical milestones for <FONT
STYLE="white-space:nowrap">EG-70.</FONT> We could use our available capital resources sooner than we currently expect, in which case we would be required to obtain additional financing, which may not be available to us on acceptable terms, or at
all. Our failure to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. See the subsection titled &#147;<I>Liquidity and Capital Resources</I>&#148; and
&#147;<I>Unaudited Pro Forma Financial Information</I>&#148;. In addition, if we obtain regulatory approval for a product candidate and do not enter into a third-party commercialization partnership, we expect to incur significant expenses related to
developing our commercialization capability to support product sales, marketing, manufacturing and distribution activities. As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy.
Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of public or private equity offerings and debt financings, or other capital sources, which could include
potential collaboration agreements, strategic alliances, or additional licensing arrangements. We may be unable to raise additional funds or enter into such arrangements when needed, on favorable terms, or at all. Our failure to raise capital or
enter into such agreements as, and when, needed, could have a material adverse effect on our business, results of operations and financial condition, including requiring us to have to delay, reduce or eliminate product development or future
commercialization efforts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Components of Our Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Revenue </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not
have any product candidates approved for sale and have not generated any revenue since our inception and do not expect to generate any revenue from the sale of products or from other sources in the near future, if at all. We will not generate
revenue from product sales unless and until we successfully complete clinical development and obtain regulatory approval for a product candidate, if ever. If our development efforts for our current lead product candidate, <FONT
STYLE="white-space:nowrap">EG-70,</FONT> <FONT STYLE="white-space:nowrap">EG-i08</FONT> or additional product candidates that we may develop in the future are successful and result in marketing approval or if we enter into collaboration or license
agreements with third parties, we may generate revenue in the future from a combination of product sales or payments from such collaboration or license agreements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Operating Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Research and Development </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses account for a significant portion of our operating expenses and consist primarily of costs incurred for our
research activities, including our drug discovery efforts and the development of our product candidates. We expense research and development costs as incurred, which include: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Direct Costs: </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses incurred under agreements with Contract Research Organization (CROs) that are primarily engaged in the
oversight and conduct of our clinical trials; Contract Development and Manufacturing </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">337 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
Organization (CDMOs) that are primarily engaged to provide drug substance and product for our clinical trials, research and development programs, as well as investigative sites and consultants
that conduct our clinical trials, nonclinical studies and other scientific development services; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of acquiring and manufacturing nonclinical and clinical trial materials, including manufacturing
registration and validation batches; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs of outside consultants, including their fees, share-based compensation and related travel expenses;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs related to compliance with quality and regulatory requirements; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">payments made under third-party licensing agreements. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Indirect Costs: </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">personnel-related expenses including salaries, benefits, share-based compensation and other related costs for
individuals involved in research and development activities; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">facilities and other expenses not directly tied to a program. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expense research and development costs as incurred. We recognize direct development costs based on an evaluation of the progress to
completion of specific tasks using information provided to us by our vendors or our estimate of the level of service that has been performed at each reporting date. Payments for these development activities are based on the terms of the individual
agreements, which may differ from the pattern of costs incurred, and are reflected in our financial statements as prepaid expenses or accrued expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A significant portion of our research and development costs to date have been third-party costs, which we track on an individual product
candidate basis after a clinical product candidate has been identified. Currently, our main clinical product candidate is <FONT STYLE="white-space:nowrap">EG-70.</FONT> Our indirect research and development costs are primarily personnel-related
costs and facilities and other costs. Employees and infrastructure are not directly tied to any one program and are deployed across our programs. As such, we do not track these costs on a specific program basis. We utilize third-party contractors
for our research and development activities and CDMOs for our manufacturing activities and we do not have our own laboratory or manufacturing facilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development activities are central to our business model. Currently, the Company&#146;s sole research and development facility is
located in Montreal, Quebec, Canada, and as such, the majority of the Company&#146;s research and development and other operating expenses are incurred in Canada and denominated in the Canadian dollar. We expect that our research and development
expenses will continue to increase for the foreseeable future as we progress our ongoing Phase 1/2 clinical trial, continue to discover and develop additional product candidates, expand our headcount and maintain, expand and enforce our intellectual
property portfolio. If <FONT STYLE="white-space:nowrap">EG-70</FONT> or any future product candidates enter into later stages of clinical development, they will generally have higher development costs than those in earlier stages of clinical
development, primarily due to the increased size and duration of later-stage clinical trials. There are numerous factors associated with the successful development and commercialization of any product candidates we may develop in the future,
including future trial design and various regulatory requirements, many of which cannot be determined with accuracy at this time based on our stage of development. Additionally, future commercial and regulatory factors beyond our control will impact
our clinical development program and plans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Our research and development expenses may vary significantly in the future based on factors,
such as: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number and scope of
<FONT STYLE="white-space:nowrap">nonclinical&nbsp;and&nbsp;IND-enabling&nbsp;studies;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">per patient trial costs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of trials required for approval; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">338 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of sites included in the trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the countries in which the trials are conducted; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the length of time required to enroll eligible patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of patients that participate in the trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">the&nbsp;drop-out&nbsp;or&nbsp;discontinuation</FONT> rates of patients;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential additional safety monitoring requested by regulatory agencies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the duration of patient participation in the
<FONT STYLE="white-space:nowrap">trials&nbsp;and&nbsp;follow-up;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost and timing of manufacturing our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the phase of development of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the efficacy and safety profile of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which we establish additional collaboration or license agreements; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether we choose to partner any of our product candidates and the terms of such partnership.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any changes in the outcome of any of these variables with respect to the development of
<FONT STYLE="white-space:nowrap">EG-70</FONT> or any future product candidates in nonclinical and clinical development could mean a significant change in the costs and timing associated with the development of these product candidates. For example,
if the FDA or another regulatory authority were to delay our planned start of clinical trials or require us to conduct clinical trials or other testing beyond those that we currently expect, or if we experience significant delays in enrollment in
any clinical trials following the applicable regulatory authority&#146;s acceptance and clearance, we could be required to expend significant additional financial resources and time to complete clinical development than we currently expect. We may
never obtain regulatory approval for any product candidates that we develop. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The successful development of
<FONT STYLE="white-space:nowrap">EG-70,</FONT> <FONT STYLE="white-space:nowrap">EG-i08</FONT> or any product candidates we may develop in the future is highly uncertain. Therefore, we cannot reasonably estimate or know the nature, timing and
estimated costs of the efforts that will be necessary to complete the development and commercialization of <FONT STYLE="white-space:nowrap">EG-70,</FONT> <FONT STYLE="white-space:nowrap">EG-i08</FONT> and any other product candidates we may develop.
We are also unable to predict when, if ever, material net cash inflows will commence from the sale of <FONT STYLE="white-space:nowrap">EG-70,</FONT> <FONT STYLE="white-space:nowrap">EG-i08</FONT> or any future product candidate, if approved. This is
due to the numerous risks and uncertainties associated with product development. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>General and Administrative </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses consist primarily of personnel-related expenses, including salaries, benefits, and share-based compensation
expenses for personnel in executive and other administrative functions. Other significant general and administrative expenses include professional services, including legal, accounting and audit services and other consulting fees as well as facility
costs not otherwise included in research and development expenses, insurance, and other operating costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that our general and
administrative expenses will continue to increase in the foreseeable future as our business expands to support our continued research and development activities, including our clinical trials. These increases will likely include increased costs
related to the hiring of additional personnel and fees for outside consultants, among other expenses. We also anticipate increased expenses associated with operating as a public company, including costs for accounting, audit, legal, regulatory, and <FONT
STYLE="white-space:nowrap">tax-related</FONT> services related to compliance with the rules and regulations of the SEC, listing standards applicable to companies listed on a national securities exchange, director and officer insurance premiums and
investor relations costs. In addition, if we obtain regulatory approval for our current product candidate or any product candidates we may develop in the future and do not enter into a third-party commercialization collaboration, we expect to incur
significant expenses related to building a sales and marketing team to support product sales, marketing and distribution activities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">339 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Other (Income) Expense, Net </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Change in fair value of convertible debenture embedded derivative liabilities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our convertible debentures consist of a debt instrument, a minimum interest obligation, and a share conversion feature. We identified embedded
derivatives related to share conversion features within the convertible notes that required bifurcation as a single compound derivative instrument and are classified as liabilities on our consolidated balance sheets. The convertible debenture
embedded derivative liabilities were initially recorded at fair value upon the date of issuance using a probability weighted expected return model and are subsequently remeasured to fair value at each reporting date. The estimated probability and
timing of underlying events triggering the conversion features contained within the convertible debentures are inputs used to determine the estimated fair value of the embedded derivative. Changes in the fair value of the convertible debenture
embedded derivative liabilities were recognized in change in fair value of convertible embedded derivative liabilities as a component of other expense in our consolidated statements of operations and comprehensive loss. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Change in fair value of warrant liabilities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We issued warrants to purchase redeemable convertible preferred shares as part of the issuance of certain redeemable convertible preferred
shares and convertible debentures. We account for the redeemable convertible preferred shares warrants issued based upon the characteristics and provisions of the instrument and determined that the warrants are liability classified. The redeemable
convertible preferred share warrants are recognized at their fair value on the date of issuance and remeasured to fair value at each reporting period, with the changes in fair value recognized in the change in fair value of warrant liabilities as a
component of other expense in our consolidated statements of operations and comprehensive loss. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Interest Expense </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense is made of interest paid on our convertible notes and third-party debt and <FONT STYLE="white-space:nowrap">non-cash</FONT>
interest expense for amortization of our debt discounts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Interest Income </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest income is associated with our interest-bearing cash and cash equivalents. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Other expense, net </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other
expense, net primarily consists mainly of foreign exchange gains and losses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception, we have not recorded any income tax benefits for the net losses we have incurred in each period or for our earned research
and development tax credits, as we believe, based upon the weight of available evidence, that it is more likely than not that all of our net operating loss carryforwards and tax credits will not be realized. As of April&nbsp;30, 2023 and
October&nbsp;31, 2022, we have recorded a full valuation allowance against our deferred tax assets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">340 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the three and six months ended April&nbsp;30, 2023, and 2022 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our results of operations for each of the periods presented (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>Three months ended<BR>April 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>Six months ended<BR>April 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$&nbsp;Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$&nbsp;Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(unaudited) </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(212</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">807</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense (income), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(625</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(625</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(318</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(408</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(389</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,526</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(58</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(149</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(130</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(316</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(30</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(286</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,352</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,842</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other (income) expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(199</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(265</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other expense (income), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(545</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,767</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,563</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(42</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our research and development expenses for each of the periods presented (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>&nbsp;</B><BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8pt; font-family:Times New Roman"><B></B></P></TD>
<TD VALIGN="bottom" COLSPAN="9" ALIGN="center"><B>Three Months Ended</B><BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>April&nbsp;30,</B></P></TD>
<TD VALIGN="bottom"><B>&nbsp;</B><BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>&nbsp;</B><BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8pt; font-family:Times New Roman"><B></B></P></TD>
<TD VALIGN="bottom" COLSPAN="9" ALIGN="center"><B>Six Months Ended</B><BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>April&nbsp;30,</B></P></TD>
<TD VALIGN="bottom"><B>&nbsp;</B><BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$&nbsp;Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$&nbsp;Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Direct costs:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">EG-70-</FONT></FONT>
INT02</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,078</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,703</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Early stage/Other discovery R&amp;D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(78</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(293</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(178</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Indirect costs:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel-related</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">821</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(164</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(299</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patent and licensing fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(163</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facilities and depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(108</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(217</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Refundable tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(363</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(315</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(48</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(722</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(830</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(212</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses decreased by $0.2 million from $3.4 million for the three months ended
April&nbsp;30, 2022 to $3.2&nbsp;million for the three months ended April 30, 2023. The decreases in research and development expenses were driven by: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $0.1&nbsp;million increase in direct costs related to the nonclinical development of our main program, <FONT
STYLE="white-space:nowrap">EG-70</FONT> &#150; INT02, as it further progressed into the further stages of drug development process; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">341 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $0.2&nbsp;million increase in indirect costs relating to professional fees, primarily relating to third-party
CMC research and development costs; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $0.1&nbsp;million increase in other expenses primarily attributable to an increase in laboratory supplies.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The increases were offset by the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $0.3&nbsp;million decrease in direct costs relating to the research and nonclinical development of early stage
and other discovery programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $0.2&nbsp;million reduction in personnel-related costs primarily due to a reduction in research and development
employee headcount. Included within personnel-related costs is $7,000 of share-based compensation, for each of the three months ended April&nbsp;30, 2023 and 2022; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $0.1&nbsp;million decrease in facilities expense primarily attributable to a decrease in rent expense, as the
Company&#146;s lease in Waltham, MA expired during the year ended October&nbsp;31, 2022. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development
expenses increased by $0.9&nbsp;million from $6.0&nbsp;million for the six months ended April&nbsp;30, 2022 to $6.9&nbsp;million for the six months ended April&nbsp;30, 2023. This increase was attributable to the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $0.6&nbsp;million increase in direct costs related to the nonclinical development of our main program, <FONT
STYLE="white-space:nowrap">EG-70</FONT> &#150; INT02, as it further progressed into the further stages of drug development process; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $0.8&nbsp;million increase in indirect costs relating to professional fees, primarily relating to third party
CMC research and development costs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $0.2&nbsp;million increase in other expenses primarily attributable to an increase in laboratory supplies; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $0.1&nbsp;million decrease in amounts recorded for government assistance which are recorded as contra research
and development expense. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The increases were partially offset by the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $0.3&nbsp;million reduction in personnel-related costs primarily due to a reduction in employee headcount.
Included within personnel-related costs is $12,000 and $13,000 of share-based compensation, for the six months ended April&nbsp;30, 2023 and 2022, respectively; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $0.2&nbsp;million decrease in direct costs relating to the research and nonclinical development of early stage
and other discovery programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $0.2&nbsp;million decrease in patent and licensing fees expenses primarily attributable to a decrease in patent
applications; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $0.2&nbsp;million decrease in facilities expense primarily attributable to a decrease in rent expense, as the
Company&#146;s lease in Waltham, MA expired during the year ended October&nbsp;31, 2022. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>General and Administrative
Expenses </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our general and administrative expenses for each of the periods presented (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>&nbsp;</B><BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8pt; font-family:Times New Roman"><B></B></P></TD>
<TD VALIGN="bottom" COLSPAN="9" ALIGN="center"><B>Three Months Ended</B><BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>April&nbsp;30,</B></P></TD>
<TD VALIGN="bottom"><B>&nbsp;</B><BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>&nbsp;</B><BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8pt; font-family:Times New Roman"><B></B></P></TD>
<TD VALIGN="bottom" COLSPAN="9" ALIGN="center"><B>Six Months Ended</B><BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>April&nbsp;30,</B></P></TD>
<TD VALIGN="bottom"><B>&nbsp;</B><BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:8pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$&nbsp;Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$&nbsp;Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" COLSPAN="9" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" COLSPAN="9" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel-related expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">606</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">505</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">976</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">572</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patent maintenance and legal fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(26</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(65</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">807</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">342 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses increased by $0.7&nbsp;million from $0.8&nbsp;million
for three months ended April&nbsp;30, 2022 to $1.5&nbsp;million for the three months ended April&nbsp;30, 2023. This increase was primarily attributable to the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $0.1&nbsp;million increase in personnel-related expenses primarily driven by an increase in employee salaries.
Included within personnel-related costs is $32,000 and $21,000 of share-based compensation, for the three months ended April&nbsp;30, 2023 and 2022, respectively; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $0.6&nbsp;million increase in costs related to professional fees primarily driven by accounting and audit
related fees. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses increased by $0.9&nbsp;million from $1.6&nbsp;million for six months
ended April&nbsp;30, 2022 to $2.5&nbsp;million for the six months ended April&nbsp;30, 2023. This increase was primarily attributable to the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $0.7&nbsp;million increase in costs related to professional fees primarily driven by accounting and audit
related fees; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $0.2&nbsp;million increase in personnel-related expenses primarily driven by an increase in an increase in
employee salaries. Included within personnel-related costs is $47,000 and $41,000 of share-based compensation, for the six months ended April&nbsp;30, 2023 and 2022, respectively. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Total Other Expense (Income), Net </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total other expense (income), net decreased by approximately $0.5&nbsp;million from expense of $1.1&nbsp;million for the three months ended
April&nbsp;30, 2022 to $0.5&nbsp;million for the three months ended April&nbsp;30, 2023. This decrease is attributable to a $0.6&nbsp;million increase on the gain recorded on the change in fair value of the convertible debenture embedded derivative
liabilities due to change in the probability percentage of a SPAC transaction occurring in three months ended April&nbsp;30, 2023 and due to the embedded derivative liabilities associated with the 2022 Notes which were not outstanding during the
three months ended April 30, 2022, a $0.4&nbsp;million decrease on the loss recorded on the change fair value of warrant liabilities due to changes in the valuation assumption such as volatility and the risk-free rate, a $0.1&nbsp;million increase
in interest income, and a $0.3&nbsp;million increase in other income which were primarily driven by foreign exchange gains. These were partially offset by a $0.9&nbsp;million increase in interest expense due to interest expense associated with the
2022 Notes which were not outstanding during the three&nbsp;months ended April&nbsp;30, 2022 and additional interest associated with the Hercules term loan as a result of the additional draw down that occurred in June 2022 and an increase in the
interest rate due to the increasing prime rate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total other expense (income), net increased by approximately $1.6 million from expense of
$1.8&nbsp;million for the six months ended April&nbsp;30, 2022 to expense of $3.3&nbsp;million for the six months ended April&nbsp;30, 2023. This increase is attributable to a $0.1&nbsp;million decrease in the gain recorded on the changes in the
fair value of the convertible debenture embedded derivative liabilities, and a $1.8&nbsp;million increase in interest expense due to interest associated with the 2022 Notes which were not outstanding during the six months ended April&nbsp;30, 2022
and additional interest associated with the Hercules term loan as a result of the additional draw down that occurred in June 2022 and an increase in the interest rate due to the increasing prime rate. These were partially offset by a
$0.1&nbsp;million decrease in the loss on the change in the fair value recorded for warrant liabilities due to changes in the valuation assumption such as volatility and the risk-free rate, and an increase in interest income of $0.3&nbsp;million.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">343 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the Years Ended October&nbsp;31, 2022, and 2021 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our results of operations for each of the periods presented (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;October&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other (income) expense, net:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of convertible debenture embedded derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(269</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(278</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(845</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(129</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(104</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,601</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on extinguishment and modifications of debentures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,727</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">662</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,558</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss before provision for income tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for income tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our research and development expenses for each of the periods presented (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;October&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Direct costs:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">EG-70</FONT> - INT02</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,660</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Early stage/Other discovery R&amp;D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Indirect costs:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel-related</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,801</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(835</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">904</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patent and licensing fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">661</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facilities and depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(21</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">887</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">871</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Refundable tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,413</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,592</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Government assistance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(584</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Private research grants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(264</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;15,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;12,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses increased by $3.0&nbsp;million from $12.5&nbsp;million for the year ended
October&nbsp;31, 2021 to $15.5&nbsp;million for the year ended October&nbsp;31, 2022. This increase was attributable to the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $1.7&nbsp;million increase in direct costs related to the nonclinical development of our main program, <FONT
STYLE="white-space:nowrap">EG-70</FONT> &#150; INT02, as it further progressed into the further stages of drug development process; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">344 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $0.1&nbsp;million increase in direct costs relating to the research and nonclinical development of early stage
and other discovery programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $0.8&nbsp;million increase in indirect costs relating to professional fees, primarily relating to third-party
CMC research and development costs; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $1.1&nbsp;million increase as a result of a reduction in various incentives including (i)&nbsp;a
$0.2&nbsp;million decrease in refundable tax credits received from the Canadian federal and Quebec provincial government; (ii)&nbsp;a $0.6&nbsp;million decrease in amounts received from Canadian government assistance related to <FONT
STYLE="white-space:nowrap">COVID-19</FONT> relief programs, and (iii)&nbsp;a $0.3&nbsp;million decrease in amounts received from private institution grants for research activities. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The increases were partially offset by the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $0.8&nbsp;million reduction in personnel-related costs primarily due to a reduction in employee headcount.
Included within personnel-related costs is $31&nbsp;thousand and $75&nbsp;thousand of share-based compensation, for the years ended October&nbsp;31, 2022 and 2021, respectively. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>General and Administrative Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our general and administrative expenses for each of the periods presented (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended<BR>October&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel-related expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(169</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">477</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">386</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patent maintenance and legal fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(112</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total general and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses increased by $0.6&nbsp;million from $3.4&nbsp;million for the year ended
October&nbsp;31, 2021 to $4.0&nbsp;million for the year ended October&nbsp;31, 2022. This increase was primarily attributable to the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $0.4&nbsp;million increase in costs related to professional fees primarily driven by accounting and audit
related fees; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $0.4&nbsp;million increase in patent maintenance and legal expenses. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The increases were partially offset by the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $0.2&nbsp;million decrease in personnel-related expenses primarily driven by a decrease in headcount; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $0.1&nbsp;million decrease in other expenses primarily driven by a decrease in office and IT expenses.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Personnel-related expenses were consistent year-over-year. Included within personnel-related costs is $0.1&nbsp;million
and $0.3&nbsp;million of share-based compensation, for the years ended October&nbsp;31, 2022 and 2021, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Other (Income)
Expense, Net </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other expenses, net decreased by approximately $2.6&nbsp;million from expense of $7.6&nbsp;million for the year ended
October&nbsp;31, 2021 to expense of $5.0&nbsp;million for the year ended October&nbsp;31, 2022. This decrease is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">345 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
attributable to a $0.3&nbsp;million decrease in expense due to the changes in the fair value of the embedded derivative liabilities, $0.8&nbsp;million decrease in expense due to changes in the
fair value of warrant liabilities, a $3.6&nbsp;million decrease in interest expense and a $1.7&nbsp;million increase attributable to gain on extinguishment and modifications of convertible notes, both of which was driven by modifications and
conversions of outstanding convertible debentures into preferred shares during the year ended October&nbsp;31, 2021. These were partially offset by an increase in other expenses, net of $0.5&nbsp;million which were primarily driven by foreign
exchange losses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the Years Ended October&nbsp;31, 2021, and 2020 </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our results of operations for each of the periods presented (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;October&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,853</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,853</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other (income) expense, net:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of convertible debenture embedded derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(701</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(234</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(56</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,699</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on extinguishment and modifications of debentures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,727</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,558</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(169</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss before provision for income tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for income tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">346 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our research and development expenses for each of the periods presented (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;October&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Direct costs:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">EG-70</FONT> - INT02</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,936</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Early stage/Other discovery R&amp;D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">780</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(399</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Indirect costs:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel-related</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(289</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">904</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patent and licensing fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facilities and depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">871</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Refundable tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,592</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,765</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Government assistance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(584</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(293</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(291</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Private research grants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(264</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(264</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;12,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;10,614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses increased by $1.8&nbsp;million from $10.6&nbsp;million for the year ended
October&nbsp;31, 2020 to $12.5&nbsp;million for the year ended October&nbsp;31, 2021. This increase was attributable to the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $2.5&nbsp;million increase in direct costs related to the nonclinical development of our main program, <FONT
STYLE="white-space:nowrap">EG-70</FONT> &#150; INT02 as it further progressed into the further stages of drug development process; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $0.2&nbsp;million increase in indirect costs relating to professional fees, primarily relating to third-party
CMC R&amp;D consultants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $0.2&nbsp;million increase in other indirect costs such as lab supplies and insurance; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $0.2&nbsp;million increase due to a decrease in refundable tax credit. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The increases were partially offset by the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $0.4&nbsp;million decrease in direct costs related to early stage and other discovery R&amp;D programs;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $0.3&nbsp;million reduction in personnel-related costs primarily driven by a decrease in headcount. Included
within personnel-related costs is $75,000 and $17,000 of share-based compensation, for the years ended October&nbsp;31, 2022 and 2021, respectively; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $0.6&nbsp;million decrease in costs due to an increase in various incentives received including (i)&nbsp;a
$0.3&nbsp;million increase in amounts received from Canadian government assistance related to <FONT STYLE="white-space:nowrap">COVID-19</FONT> relief programs, and (ii)&nbsp;a $0.3&nbsp;million increase in amounts received from a <FONT
STYLE="white-space:nowrap">one-time</FONT> private institution grants for research activities. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">347 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>General and Administrative Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our general and administrative expenses for each of the periods presented (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended<BR>October&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel-related expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,936</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">477</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patent maintenance and legal fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(170</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(37</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total general and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses increased by $0.2&nbsp;million from $3.2&nbsp;million for the year ended
October&nbsp;31, 2020 to $3.4&nbsp;million for the year ended October&nbsp;31, 2021. This increase was primarily attributable to the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $0.3&nbsp;million increase in costs related to personnel-related expenses primarily driven by an increase in
share-based compensation expense, as included within personnel-related costs is $0.4&nbsp;million and $0.1&nbsp;million in share-based compensation, for the years ended October&nbsp;31, 2021 and 2020, respectively; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $0.1&nbsp;million increase in costs related to professional fees primarily driven by accounting and audit
related fees. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The increases were partially offset by the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $0.2&nbsp;million decrease in patent maintenance and legal expenses. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Other (Income) Expense, Net </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other expense, net increased by approximately $6.4&nbsp;million from $1.2&nbsp;million of expense for the year ended October&nbsp;31, 2020 to
$7.6&nbsp;million of expense for the year ended October&nbsp;31, 2021. This increase is primarily attributable to a $4.4&nbsp;million increase in the expense due to the change in the fair value of liability classified warrants for our redeemable
convertible preferred stock, a $1.3&nbsp;million increase in interest expense due to interest incurred on our convertible debentures issued in 2020 and 2021, and a $0.7&nbsp;million increase in the expense due to the change in the fair value of
convertible debentures embedded derivative liabilities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Sources of Liquidity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception, we have incurred significant losses in each period and on an aggregate basis. We have not yet commercialized any product
candidates, and we do not expect to generate revenue from sales of any product candidates or from other sources for several years, if at all. As of April&nbsp;30, 2023, we had $17.5&nbsp;million in cash and cash equivalents, and we had an
accumulated deficit of $112.4&nbsp;million. To date, we have funded our operations primarily with the issuance of convertible debt and proceeds from sales of preferred shares. From inception, we have raised aggregate gross proceeds of approximately
$77.8&nbsp;million through the sale and issuance of our preferred shares, warrants and convertible debentures, and $19.0&nbsp;million through our term loan and April 2023 note financings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will need substantial additional funding to support our continuing operations and pursue our development strategy. Until such time as we
can generate significant revenue from sales of our product </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">348 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
candidates, if ever, we expect to finance our operations through the sale of equity, debt financings or other capital sources, including potential collaborations with other companies or other
strategic transactions. Adequate funding may not be available to us on acceptable terms, if at all. Should we fail to raise capital or enter into such agreements as, and when, needed, we may have to significantly delay, scale back, or discontinue
the development and commercialization of our product candidates or delay our efforts to expand our product pipeline. We may also be required to sell or license to other parties&#146; rights to develop or commercialize our product candidates that we
would prefer to retain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s ability to continue as a going concern depends on its ability to successfully develop and
commercialize its products, achieve and maintain profitable operations, as well as its ability to obtain additional financing and on the continued financial support of its shareholders and debt holders. While we have historically been successful in
securing financing, raising additional funds is dependent on a number of factors outside of the Company&#146;s control, and as such there is no assurance that it will be able to do so in the future. These conditions indicate the existence of a
material uncertainty that raise substantial doubt on the Company&#146;s ability to continue as a going concern and, therefore, that it may be unable to realize its assets and discharge its liabilities in the normal course of business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Giving pro forma effect to the Business Combination, including the PIPE Financing and other transactions and assumptions set forth in the
&#147;<I>Unaudited Pro Forma Condensed Combined Financial Information</I>&#148; and further assuming the maximum redemption scenario, as of April&nbsp;30, 2023, pro forma cash and cash equivalents would have been $100.2&nbsp;million. See
&#147;<I>Unaudited Pro Forma Condensed Combined Financial Information</I>.&#148; With the funds to be received as a result of the Business Combination, we may be able to reach significant clinical milestones for
<FONT STYLE="white-space:nowrap">EG-70.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Cash Flows </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the three and six months ended April&nbsp;30, 2023, and 2022 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table provides information regarding our cash flows for each of the periods presented (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months&nbsp;Ended</B><br><B>April&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10,667</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,186</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(23</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(115</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of exchange rate changes on cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(342</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net decrease in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,936</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,039</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Net Cash Used in Operating Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities for the six months ended April&nbsp;30, 2023 was $10.7&nbsp;million and was primarily due to our net loss
of $12.7&nbsp;million, partially offset by adjustments for <FONT STYLE="white-space:nowrap">non-cash</FONT> charges totaling $3.2&nbsp;million which was primarily driven by <FONT STYLE="white-space:nowrap">non-cash</FONT> interest expense of
$1.7&nbsp;million and changes in fair value of convertible debenture embedded derivative liabilities and warrant liabilities of $1.5&nbsp;million, share-based compensation expense of $0.1&nbsp;million, and depreciation of property and equipment of
$0.1&nbsp;million. Further there were changes in operating assets and liabilities of $1.1&nbsp;million, which was primarily associated with a $2.3&nbsp;million decrease in accrued expenses and other liabilities, a $2.0&nbsp;million increase in
accounts payable, $0.7&nbsp;million increase in the investment tax credit receivable, and a $0.2&nbsp;million increase in prepaid expenses and other assets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">349 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities for the six months ended April&nbsp;30, 2022 was
$7.2&nbsp;million and was primarily due to our net loss of $9.4&nbsp;million, partially offset by adjustments for <FONT STYLE="white-space:nowrap">non-cash</FONT> charges totaling $1.6&nbsp;million which was primarily driven by <FONT
STYLE="white-space:nowrap">non-cash</FONT> interest expense on convertible notes of $0.2&nbsp;million, changes in fair value on warrant liabilities of $1.6&nbsp;million, changes in fair value on embedded derivative liabilities of $0.4&nbsp;million,
share-based compensation expense of $0.1&nbsp;million, and depreciation of property and equipment of $0.1&nbsp;million. Additionally, there were changes in in operating assets and liabilities of $0.6&nbsp;million, primarily driven by a decrease in
the investment tax credit receivable of $0.8&nbsp;million and a increase in prepaid expenses of $.0.2 million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Net Cash Used in
Investing Activities </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities for each of the six months ended April&nbsp;30, 2023 and 2022 was
$23&nbsp;thousand and $115&nbsp;thousand, respectively related to purchases of property and equipment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Net Cash Provided by Financing
Activities </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities for the six months ended April&nbsp;30, 2023 was $7.8&nbsp;million, resulting
from proceeds of $8.0&nbsp;million received from the issuance of the April 2023 notes, partially offset by the payment of FEAC merger and PIPE financing transaction costs of $0.1&nbsp;million and payment of issuance costs associated with the April
2023 Notes of $0.1 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities for the six months ended April&nbsp;30, 2022 was $5.6&nbsp;million,
resulting from proceeds of $7.0&nbsp;million received from the issuance of our term loan, partially offset by the payment of debt issuance costs of $0.4&nbsp;million, and $1.0&nbsp;million of repayments related to short term debt obligations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the years ended October&nbsp;31, 2022, 2021, and 2020 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table provides information regarding our cash flows for each of the periods presented (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended</B><br><B>October&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(17,592</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15,984</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(13,061</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(153</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(247</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(192</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of exchange rate changes on cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(805</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(51</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase (decrease) in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(456</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Net Cash Used in Operating Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities for the fiscal year ended October&nbsp;31, 2022 was $17.6&nbsp;million and was primarily due to our net
loss of $24.5&nbsp;million, partially offset by adjustments for <FONT STYLE="white-space:nowrap">non-cash</FONT> charges totaling $4.7&nbsp;million which was primarily driven by <FONT STYLE="white-space:nowrap">non-cash</FONT> interest expense of
$0.6&nbsp;million and changes in fair value of warrant liabilities of $3.3&nbsp;million, as well as changes in operating assets and liabilities of $2.2&nbsp;million, which was primarily associated with a $2.3&nbsp;million increase in accrued
expenses and other liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities for the fiscal year ended October&nbsp;31, 2021 was
$16.0&nbsp;million and was primarily due to our net loss of $23.4&nbsp;million, partially offset by adjustments for <FONT STYLE="white-space:nowrap">non-cash</FONT> charges totaling $8.5&nbsp;million which was primarily driven by <FONT
STYLE="white-space:nowrap">non-cash</FONT> interest expense on convertible notes of $5.0&nbsp;million, changes in fair value on warrant liabilities of $4.2&nbsp;million, a net gain on extinguishment and modifications of convertible debentures of
$1.7&nbsp;million, share-based compensation expense of $0.4&nbsp;million, and depreciation of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">350 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
property and equipment of $0.3&nbsp;million. Additionally, there were changes in operating assets and liabilities of $1.1&nbsp;million, primarily driven by an increase in prepaid expenses and
other current assets of $1.5&nbsp;million and a decrease in the investment tax credit receivable of $0.3&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in
operating activities for the fiscal year ended October&nbsp;31, 2020 was $13.1&nbsp;million and was primarily due to our net loss of $15.1&nbsp;million, partially offset by adjustments for <FONT STYLE="white-space:nowrap">non-cash</FONT> charges
totaling $1.6&nbsp;million which was primarily driven by <FONT STYLE="white-space:nowrap">non-cash</FONT> interest expense on convertible notes of $3.7&nbsp;million, changes in fair value on warrant liabilities of $0.2&nbsp;million, changes in fair
value of convertible debenture embedded derivative liabilities of $0.7&nbsp;million, a gain on modifications of convertible debentures of $1.6&nbsp;million, share-based compensation expense of $0.2&nbsp;million, and depreciation of property and
equipment of $0.3&nbsp;million. Additionally, there were changes in operating assets and liabilities of $0.4&nbsp;million, primarily driven by an increase in accounts payable of $0.2&nbsp;million and accrued expenses and other liabilities of
$0.2&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Net Cash Used in Investing Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities for each of the fiscal years ended October&nbsp;31, 2022, 2021, and 2020 was $0.2&nbsp;million, for
purchases of property and equipment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Net Cash Provided by Financing Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities for the fiscal year ended October&nbsp;31, 2022 was $28.0&nbsp;million, resulting from proceeds of
$18.4&nbsp;million received from the issuance of convertible debentures, and $11.0&nbsp;million gross proceeds received from the issuance of our term loan, partially offset by the repayment of debt of $1.0&nbsp;million and payment of debt issuance
costs of $0.4&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities for the fiscal year ended October&nbsp;31, 2021 was
$22.5&nbsp;million, resulting from gross proceeds of $15.6&nbsp;million received from the issuance of our Series C Preferred Shares and warrants, $6.1&nbsp;million gross proceeds received from the issuance of convertible debentures, and
$2.0&nbsp;million received from the issuance of debt, partially offset by $0.1&nbsp;million of payments related to issuance costs associated with our Series C Preferred Shares, and $1.0&nbsp;million of repayments related to short term debt
obligations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities for the fiscal year ended October&nbsp;31, 2020 was $12.8&nbsp;million, resulting
from gross proceeds of $13.0&nbsp;million received from the issuance of convertible debentures, partially offset by $0.2&nbsp;million of payments related to issuance costs associated with our convertible debentures. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Hercules Loan Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;30, 2021, we entered into a Loan and Security Agreement (the &#147;Loan Agreement&#148;) with Hercules Capital, Inc.
(&#147;Hercules&#148; or the &#147;Bank&#148; or the &#147;Lender&#148;) for the issuance of a term loan facility of up to an aggregate principal amount of up to $20.0&nbsp;million (the &#147;Term Loans&#148;). The Loan Agreement will remain in
place upon consummation of the Business Combination. The Loan Agreement provides for (i)&nbsp;an initial term loan advance of $7.0&nbsp;million, which closed on December&nbsp;30, 2021, (ii) subject to the achievement of certain Clinical Milestones
(the &#147;Clinical Milestone&#148;), a right of the Company to request that the Lender make additional term loan advances to us in an aggregate principal amount of up to $4.0&nbsp;million from the achievement of the Clinical Milestone through
June&nbsp;15, 2022, which was drawn in June 2022, and (iii)&nbsp;subject to the achievement of certain financial milestones (the &#147;Financial Milestone&#148;), a right of the Company to request that the Lender make additional term loan advances
to the Company in an aggregate principal amount of up to $9.0&nbsp;million from achievement of the Financial Milestone through December&nbsp;15, 2022, which was not achieved. We are required to pay an end of term fee (the &#147;End of Term
Charge&#148;) equal to 6.35% of the aggregate principal amount of the Term Loans advances upon repayment. The financing agreement contains negative covenants that, among other things and subject to certain exceptions, could restrict our ability to
incur additional liens, incur additional indebtedness, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">351 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
make investments, including acquisitions, engage in fundamental changes, sell or dispose of assets that constitute collateral, including certain intellectual property, pay dividends or make any
distribution or payment on or redeem, retire or purchase any equity interests, amend, modify or waive certain material agreements or organizational documents and make payments of certain subordinated indebtedness. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Term Loans mature on July&nbsp;1, 2025, with no option for extension (the &#147;Maturity Date&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Term Loan bears interest at an annual rate equal to the greater of (i) 8.25% plus the prime rate of interest as reported in the Wall
Street Journal minus 3.25% and (ii) 8.25% provided, that, from and after the date we achieve the financial milestone, as defined within the agreement, the reference to 8.25% in clauses (i)&nbsp;and (ii) is reduced to 8.15%. Borrowings under the Loan
Agreement are repayable in monthly interest-only payments through June 2023. After the interest-only payment period, borrowings under the Loan Agreement are repayable in equal monthly payments of principal and accrued interest until the Maturity
Date. At the our option, we may elect to prepay all, but not less than all, of the outstanding term loan by paying the entire principal balance and all accrued and unpaid interest thereon plus a prepayment charge equal to the following percentage of
the principal amount being prepaid: (i) 3.0% of the principal amount outstanding if the prepayment occurs in any of the first twelve months following the closing date of the last draw down; (ii) 2.0% of the principal amount outstanding if the
prepayment occurs after the first twelve months following the closing date of the last draw down, but on or prior to twenty-four months following the closing date of the last draw down; and 1.0% of the principal amount outstanding at any time
thereafter but prior to the Maturity Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Loan Agreement, we granted Hercules a security interest senior to any
current and future debts and to any security interest, in all of the Company&#146;s right, title, and interest in, to and under all of Company&#146;s property and other assets, and certain equity interests and accounts of enGene, subject to limited
exceptions including the borrower&#146;s intellectual property. The Loan Agreement also contains certain events of default, representations, warranties and <FONT STYLE="white-space:nowrap">non-financial</FONT> covenants of the Company. The Company
has been in compliance with the financial covenants and <FONT STYLE="white-space:nowrap">non-financial</FONT> covenants since inception of the loan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The debt discount and issuance costs are being accreted to the principal amount of debt and being amortized from the date of issuance through
the Maturity Date to interest expense using the effective-interest rate method. The effective interest rate of the outstanding debt under the Loan Agreement is approximately 17.8% as of April&nbsp;30, 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of April&nbsp;30, 2023 the carrying value of the note payable consists of the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Note payable, including End of Term Charge</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,699</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Debt discount, net of accretion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(696</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Note payable, net of discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of October&nbsp;31, 2022 the carrying value of the note payable consists of the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Note payable, including End of Term Charge</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,699</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Debt discount, net of accretion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(891</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Note payable, net of discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the three months ended April&nbsp;30, 2023 and 2022, we recognized $0.4 and $0.2&nbsp;million of interest expense
related to the Loan Agreement. During the six months ended April&nbsp;30, 2023 and 2022, we recognized $0.9 and $0.3&nbsp;million of interest expense related to the Loan Agreement. There were no outstanding note payable balances in the fiscal years
ended October&nbsp;31, 2021 or 2020. During the fiscal year ended October&nbsp;31, 2022, the Company recognized $1.0&nbsp;million of interest expense related to the Loan Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">352 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Through April&nbsp;30, 2023, we borrowed $11.0&nbsp;million under the Loan Agreement and
incurred $1.1&nbsp;million of debt discount and issuance costs inclusive of facility fees, legal fees, End of Term Charge and fair value of the warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Estimated future principal payments due under the Loan Agreement, including the contractual End of Term Charge are as follows as of
April&nbsp;30, 2023: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,586</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total principal payments, including End of Term Charge</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,699</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>April 2023 Notes </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;4, 2023, we entered into a note purchase agreement (the &#147;April 2023 Notes&#148;) for a principal amount of $8.0&nbsp;million
with Merck Lumira Biosciences Fund, L.P., Merck Lumira Biosciences Fund (Quebec), L.P., Lumira Ventures III, L.P., Lumira Ventures III (International), L.P., Lumira Ventures IV, L.P., Lumira Ventures IV (International), L.P., Fond de
solidarit&eacute; des travailleurs du Qu&eacute;bec (F.T.Q.), and Forbion Capital Fund III Cooperatief U.A. (collectively the &#147;April 2023 Investors&#148;). The April 2023 Notes had an interest free period of 45 days from the date of issuance,
and commencing on the 46th day, is to accrue interest at a rate of 15% per annum. The April 2023 Notes are classified as current as they mature on the earlier of (i)&nbsp;July 31, 2023; or (ii)&nbsp;the date the Company completes a qualified
financing, as defined within the April 2023 Notes as a financing pursuant to which the Company sells convertible promissory notes, warrants, preferred shares, common shares, or a combination thereof of the Company for an aggregate amount of at least
$20.0&nbsp;million. Upon the completion of the financing in May 2023, we issued convertible debentures and warrants of the Company to the April 2023 Note Investors, on the same terms and conditions of the convertible debentures and warrants that
were issued to the investors of the 2023 Financing, as repayment of the April 2023 Notes. Refer to Note 17 of our condensed consolidated financial statements for the period ending April&nbsp;30, 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We elected the fair value option of accounting of ASC 825 for the April 2023 Notes. We recorded the April 2023 Notes at fair value upon the
date of issuance, which was determined to be $8.0&nbsp;million, and subsequently remeasured the April 2023 Notes to fair value at each reporting period. No change in fair value was recorded on the April 2023 Notes during the three and <FONT
STYLE="white-space:nowrap">six-months</FONT> ended April&nbsp;30, 2023, given the close proximity between the issuance date of the notes and the period end. As a result of applying the fair value option of accounting, direct costs and fees related
to the April 2023 Notes were expensed as incurred and were not deferred. We incurred issuance costs of $0.1 million associated within the April 2023 Notes, which was reflected within general and administrative expense within the three and <FONT
STYLE="white-space:nowrap">six-months</FONT> consolidated statement of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Funding Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our primary uses of capital are, and we expect will continue to be, research and development activities, compensation and related expenses and
general overhead costs. We expect to continue to incur significant expenses and operating losses for the foreseeable future. In addition, upon the closing of the Business Combination, we expect to incur additional costs associated with operating as
a public company. We anticipate that our expenses will increase significantly in connection with our ongoing activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Without giving
effect to the Business Combination, we believe that our cash is not sufficient to fund our operations for twelve months from the date of authorization of our financial statements. Giving pro forma effect to the Business Combination, including the
PIPE Financing other transactions and assumptions set forth in the &#147;<I>Unaudited Pro Forma Condensed Combined Financial Informatio</I>n&#148; and further and assuming the maximum redemption scenario, as of April&nbsp;30, 2023, pro forma cash
and cash equivalents would have been $100.2&nbsp;million. We could use our available capital resources sooner than we currently expect, in which case we would be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">353 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
required to obtain additional financing, which may not be available to us on acceptable terms, or at all. Our failure to raise capital as and when needed would have a negative impact on our
financial condition and our ability to pursue our business strategy. See &#147;<I>Unaudited Pro Forma Condensed Combined Financial Information</I>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the numerous risks and uncertainties associated with research, development and commercialization of product candidates, we are
unable to estimate the exact amount of our working capital requirements. Our future funding requirements will depend on, and could increase significantly as a result of, many factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the initiation, timing, costs, progress and results of our planned clinical trials of <FONT
STYLE="white-space:nowrap">EG-70;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, progress, results and costs of our earlier-stage research programs, including the progress of
preclinical development and possible clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, progress, results and costs of our research programs and preclinical development of any future product
candidates we may pursue; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of regulatory submissions and timing of regulatory approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the progress of the development efforts of parties with whom we may in the future enter into collaborations
and/or research and development agreements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and amount of milestone and other payments we are obligated to make under our Nature Technology
Corporation Agreement or any future license agreements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cash requirements of any future acquisitions or discovery of product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish and maintain collaborations, strategic partnerships or marketing, distribution,
licensing or other strategic arrangements with third parties on favorable terms, if at all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs involved in prosecuting and enforcing patent and other intellectual property claims;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of manufacturing our product candidates by third parties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of commercialization activities if our lead candidates or any future product candidates are approved for
sale, including marketing, sales and distribution costs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our efforts to enhance operational systems and hire additional personnel, including personnel to support
development of our product candidates; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of operating as a public company. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is currently eligible to claim Canadian federal and provincial tax credits as a Canadian controlled private corporation
(&#147;CCPC&#148;) on eligible research and development expenditures (&#147;SR&amp;ED&#148;). To the extent the Company ceases to be a CCPC for tax purposes (which will be the case as a result of consummation of the Business Combination), it will no
longer be eligible for cash refunds on federal tax credit earned with respect to federally eligible SR&amp;ED expenditures. Following the loss of CCPC status, the Company&#146;s federal SR&amp;ED tax credits will be earned at a lower rate and may
only be used to offset future federal taxes payable. Provincial tax credits earned in Qu&eacute;bec in relation to SR&amp;ED are anticipated to continue to result in a cash refund to the Company, albeit at a reduced rate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A change in the outcome of any of these or other variables with respect to the development of our lead candidates or any product or
development candidate we may develop in the future could significantly change the costs and timing associated with our development plans. Further, our operating plans may change in the future, and we may need additional funds to meet operational
needs and capital requirements associated with such operating plans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until such time, if ever, as we can generate substantial product
revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings or other capital sources, which could include </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">354 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
collaborations, strategic alliances or licensing arrangements. Adequate additional financings, if available, funds may not be available to us on acceptable terms, or at all. To the extent that we
raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our existing shareholders may be diluted, and the terms of these securities may include liquidation or other preferences that could
adversely affect the rights of such shareholders. Debt financing, if available, may involve agreements that include restrictive covenants that limit our ability to take specific actions, such as incurring additional debt, making capital expenditures
or declaring dividends, that could adversely impact our ability to conduct our business. If we raise additional funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights
to our technologies, future revenue streams, research program or product candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be
required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. Our ability to raise
additional funds may be adversely impacted by potential worsening global economic conditions and disruptions to and volatility in the credit and financial markets in the United States and worldwide. Because of the numerous risks and uncertainties
associated with product development, there is no assurance that we will ever be profitable or generate positive cash flow from operating activities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual Obligations and Other Commitments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>License Agreement with Nature Technology Corporation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;10, 2020, we entered into the License Agreement with NTC pursuant to which NTC granted us a worldwide <FONT
STYLE="white-space:nowrap">non-exclusive,</FONT> royalty-bearing and sublicensable license to certain patents and <FONT STYLE="white-space:nowrap">know-how</FONT> relating to the Nanoplasmid<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>
vector backbone that is used in detalamogene voraplasmid to research, develop, make, use, import, sell and offer and sell, any gene and cell therapy products incorporating the Nanoplasmid<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>
vector backbone (excluding any such products in the field of dermatology). Unless terminated earlier, the License Agreement will continue until no valid claim of any licensed patent exists in any country. We can voluntarily terminate the License
Agreement with prior notice to NTC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We paid NTC an initial, upfront fee of $50,000 which was recorded as research and development expense
upon entering into the License Agreement. Beginning on the first anniversary of the effective date of the License Agreement and on each subsequent anniversary, we are required to pay NTC a $50,000 annual maintenance fee until the first sale of a
product for which a royalty is due. We are also required to make a payment to NTC of $50,000 upon assigning the License Agreement to a third-party. The License Agreement provides for a <FONT STYLE="white-space:nowrap">one-time</FONT> payment of
$50,000 for the first dose of a product covered by a valid claim of a licensed patent (a &#147;Milestone Product&#148;) in the first patient in a Phase I clinical trial or, if there is no Phase I clinical trial, in a Phase II clinical trial, as well
as a <FONT STYLE="white-space:nowrap">one-time</FONT> payment of $450,000 upon regulatory approval of a Milestone Product by the U.S. Food and Drug Administration. The first milestone related to the first dose of a Milestone Product, was achieved
during the year ended October&nbsp;31, 2021. The second milestone, regulatory approval of a Milestone Product, has not yet been achieved as of the year ended October&nbsp;31, 2022. We are also required to pay NTC a royalty percentage in the low
single digits of the aggregate net product sales in a calendar year by us, our affiliates or sublicensees on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, as long as the composition or use of the applicable product is covered by a valid claim in the country where the net sales occurred. Royalty obligations under the License Agreement
will continue until the expiration of the last valid claim of a licensed patent covering such licensed product in such country. In the event that we or any of our affiliates or sublicensees manufactures any GMP lot of a licensed product, then we or
any such affiliate or sublicensee will be obligated to pay NTC an amount per manufactured gram of GMP (or its equivalent) lot of product, which varies based on the volume manufactured. Such manufacturing payment will expire on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> basis upon receipt of regulatory approval to market a product in any country in the licensed territory. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">355 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a more detailed description of this agreement, see the section titled Business of enGene
&#150; Intellectual Property &#150; Strategic License Agreement and Note 6 to our consolidated financial statements included elsewhere in this proxy statement/prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Lease Obligations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our leases are comprised of all operating leases for office and lab space. We have a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">month-to-month</FONT></FONT> office and lab space lease located in Montreal, Quebec, Canada, which commenced in November 2021 and had an initial term of 12 months that expired on October&nbsp;31, 2022. The lease includes
options to renew for consecutive twelve-month periods upon landlord consent, at new lease rates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;29, 2022, we signed a
new lease for approximately 10,620 square feet of new laboratory and office space at 4868 Rue Levy, Montreal, QC. The term of the lease is for 10 years beginning on the commencement date and requires an annual initial base rent of $36.50 Canadian
Dollar (&#147;CAD&#148;) per square foot, which is subject to annual increases of 2%. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Purchase and Other Obligations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We enter into contracts in the normal course of business with CROs, CDMOs and other third-party vendors for nonclinical research studies and
testing, clinical trials and testing and manufacturing services. Most contracts do not contain minimum purchase commitments and are cancellable by us upon written notice. Payments due upon cancellation consist of payments for services provided or
expenses incurred, including those incurred by subcontractors of our suppliers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company does not have material capital expenditure
commitments at April&nbsp;30, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has committed to pay transaction costs in connection with the Business Combination. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Estimates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This
management&#146;s discussion and analysis is based on our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles or GAAP. The preparation of our consolidated financial statements
and related disclosures requires us to make judgments and estimates that affect the reported amounts of assets, liabilities and expenses, as well as related disclosures during the reported periods. We base our estimates on historical experience,
known trends and events, and various other factors that we believe are reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions. On an ongoing basis, we evaluate our judgments and
estimates in light of changes in circumstances, facts and experience. The effects of material revisions in estimates, if any, will be reflected in the financial statements prospectively from the date of change in estimates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While our accounting policies are described in more detail in the notes to our consolidated financial statements included elsewhere in this
proxy statement/prospectus, we believe the following accounting policies used in the preparation of our financial statements require the most significant judgments and estimates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Accrued and Prepaid Research and Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of the process of preparing our financial statements, we are required to estimate our accrued and prepaid third-party research and
development expenses as of each balance sheet date. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf, and estimating the level of service
performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. The majority of our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">356 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
service providers invoice us monthly in arrears for services performed or when contractual milestones are met. We make estimates of our accrued and prepaid expenses as of each balance sheet date
based on facts and circumstances known to us at that time. We periodically confirm the accuracy of our estimates with the service providers and make adjustments if necessary. The significant estimates in our accrued and prepaid research and
development expenses include the costs incurred for services performed by our vendors in connection with research and development activities for which we have not yet been invoiced. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We base our expenses related to research and development activities on our estimates of the services received and efforts expended pursuant to
quotes and contracts with vendors that conduct research and development activities on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be
instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the research and development expense. In accruing service fees, we estimate the time period over which services will be
performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or prepaid balance accordingly. <FONT
STYLE="white-space:nowrap">Non-refundable</FONT> advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather
than when the payment is made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we do not expect our estimates to be materially different from amounts incurred, if our estimates
of the status and timing of services performed differ from the actual status and timing of services performed, it could result in us reporting amounts that are too high or too low in any particular period. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Warrant Liabilities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We issued warrants to purchase shares of redeemable convertible preferred shares as part of the issuance of certain of our redeemable
convertible preferred shares, convertible debentures, and term loan. We account for our redeemable convertible preferred shares warrants issued in connection with our various financing transactions based upon the characteristics and provisions of
the instrument. Redeemable convertible preferred share warrants classified as liabilities are recorded on the consolidated balance sheets at their fair value on the date of issuance and remeasured to fair value at each reporting period, with the
changes in fair value recognized in the change in fair value of warrant liabilities, net in the consolidated statements of operations and comprehensive loss. We adjusted the liability for changes in the fair value of these warrants until the earlier
of the exercise of the warrants, the expiration of the warrants, or until such time as the warrants were no longer considered liability. We estimated the fair value of our warrant liabilities using a Modified Black-Scholes option-pricing model,
which includes assumptions that are based on the individual characteristics of the warrants on the valuation date, and assumptions related to the fair value of the underlying redeemable convertible preferred shares, expected volatility, expected
life, dividends, and risk-free interest rate and discount for lack of marketability (&#147;DLOM&#148;). The weighted average expected life was estimated based on the weighting of scenarios considering the probability of different terms up to the
contractual term of 10 years in light of the expected timing of a future exit event. We determine the expected volatility based on an analysis of reported data for a group of guideline companies that have issued instruments with substantially
similar terms. The expected volatility has been determined using a weighted average of the historical volatility measures of this group of guideline companies. The risk-free interest rate is determined by reference to the Canadian Treasury yield
curve in effect at the time of measurement of the warrant liabilities for time periods approximately equal to the weighted average expected life of the warrant. We have not paid, and do not anticipate paying, cash dividends on our redeemable
convertible preferred shares; therefore, the expected dividend yield is assumed to be zero. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because there is no public market for the
underlying redeemable convertible preferred shares, our Board of Directors has determined their fair value based on third-party valuations. Initially, the enterprise equity value of the Company was determined using a market approach and/or cost
approach by considering the weighting of scenarios estimated using a back-solve method based on recent financing transactions of the Company. This </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">357 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
value was then allocated towards the Company&#146;s various securities of its capital structure using an option pricing method, or OPM, and a waterfall approach based on the order of the
superiority of the rights and preferences of the various securities relative to one another. Significant assumptions used in the OPM to determine the fair value of preferred shares include volatility, DLOM, and the expected timing of a future
liquidity event such as an initial public offering or sale of the Company, in light of prevailing market conditions. This valuation process creates a range of equity values both between and within scenarios. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to considering the results of these valuations, our Board of Directors considered various objective and subjective factors to
determine the fair value of our redeemable convertible preferred shares as of each valuation date, including the prices at which the Company sold redeemable convertible preferred in the most recent transactions, external market conditions, the
progress of the Company&#146;s research and development programs, our financial position, including cash on hand, and our historical and forecasted performance and operating results, and the lack of an active public market for the our redeemable
convertible preferred shares, among other factors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to the nature of these inputs, the warrants represent a Level&nbsp;3 measurement
within the fair value hierarchy. The assumptions underlying these valuations represented management&#146;s best estimate, which involved inherent uncertainties and the application of management&#146;s judgment and these valuations are sensitive to
changes in the unobservable inputs. As a result, if we had used different assumptions or estimates, or if there are changes to the unobservable inputs, the fair value of the warrants could have been materially different. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Convertible Debentures Embedded Derivative Liabilities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our convertible debentures contain equity conversion options, extension features, and certain repayment features, that have been identified as
a single compound embedded derivative requiring bifurcation from the host contract. The convertible debenture embedded derivative liabilities is initially measured at fair value on issuance and is subject to remeasurement at each reporting period
with changes in fair value recognized in the change in fair value of derivative liabilities, net in the consolidated statements of operations and comprehensive loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimated the fair value of the convertible debenture embedded derivative liabilities on issuance using a probability weighted scenario
expected return model. The estimated probability and timing of underlying events triggering the conversion and liquidity repayment features and probability of exercise of the extension features within the convertible debentures, as well as discount
rates, volatility and share prices, are inputs used to determine the estimated fair value of the embedded derivative. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Share-Based
Compensation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We measure all share-based awards granted to employees, officers, directors and
<FONT STYLE="white-space:nowrap">non-employees</FONT> based on the fair value on the date of the grant and recognize compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective
award. Our share-based payments related only to stock options to date. We account for forfeitures of our share-based awards as they occur. We issue share-based awards with only service-based vesting conditions to date. For share-based awards with
service-based vesting conditions, we record the expense using the straight-line method including when such awards have graded vesting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For all stock options granted at fair value of the underlying common shares at the time of the grant with service-based vesting, the fair
value of each stock option is estimated on the date of grant using the Black- Scholes option-pricing model, which requires inputs based on certain subjective assumptions, including the fair value of our common shares, expected share price
volatility, the expected term of the award, the risk-free interest rate for a period that approximates the expected term of the option, and our expected dividend yield. We determine the volatility for awards granted based on an analysis of reported
data for a group of guideline companies that have issued options with substantially similar terms. The expected volatility has been determined </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">358 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
using a weighted average of the historical volatility measures of this group of guideline companies. The expected option term was calculated based on the simplified method, which uses the
midpoint between the vesting date and the contractual term, as we do not have sufficient historical data to develop an estimate based on participant behavior. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in
effect at the time of grant of the award for time periods approximately equal to the expected term of the award. We have not paid, and do not anticipate paying, cash dividends on our common shares; therefore, the expected dividend yield is assumed
to be zero. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because there has been no public market for our common shares, our Board of Directors have determined the fair value of our
common share based on third-party valuations of our common shares. Initially, the enterprise equity value of the Company was determined using a market approach and/or cost approach by considering the weighting of scenarios estimated using a
back-solve method based on recent financing transactions of the Company. This value was then allocated towards the Company&#146;s various securities of its capital structure using an option pricing method, or OPM, and a waterfall approach based on
the order of the superiority of the rights and preferences of the various securities relative to one another. Significant assumptions used in the OPM to determine the fair value of common shares include volatility, discount for lack of
marketability, and the expected timing of a future liquidity event such as an initial public offering, or sale of our Company in light of prevailing market conditions. This valuation process creates a range of equity values both between and within
scenarios. In addition, our Board of Directors considered various objective and subjective factors to determine the fair value of our common shares as of each grant date of stock options, including, among other factors: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prices at which we sold shares of preferred shares and the superior rights and preferences of the preferred
shares relative to its common shares at the time of each grant, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the estimated value of each security both outstanding and anticipated, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the anticipated capital structure that will directly impact the value of the currently outstanding securities,
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial position, including cash on hand, and our historical and forecasted performance and operating
results, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the progress of our research and development programs, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our stage of development and business strategy and the material risks related to our business and industry,
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the likelihood of achieving a liquidity event for the holders of our common stock, such as an initial public
offering or a sale of our company, given prevailing market conditions, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">external market conditions affecting the biotechnology industry sectors, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">local and global economic conditions, and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the lack of an active public market for our common shares and convertible preferred shares.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assumptions underlying these valuations represented management&#146;s best estimate, which involved inherent
uncertainties and the application of management&#146;s judgment and these valuations are sensitive to changes in the unobservable inputs. As a result, if we had used different assumptions or estimates, or if there are changes to the unobservable
inputs, the fair value of its common shares and share-based compensation expense could have been materially different. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our share-based
compensation expense is recorded in general and administrative and research and development expenses in the Company&#146;s consolidated statements of operations and comprehensive loss. We recorded share-based compensation expense of
$39&nbsp;thousand and $28&nbsp;thousand and $59&nbsp;thousand and $54&nbsp;thousand for the three and six months ended April&nbsp;30, 2023 and 2022, respectively. As of April&nbsp;30, 2023, there was $0.4&nbsp;million of unrecognized stock-based
compensation expense related to unvested stock options, to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">359 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
be recognized over a weighted-average period of 3.05 years. We recorded share-based compensation expense of $0.1&nbsp;million, $0.4&nbsp;million and $0.2&nbsp;million for the fiscal years ended
October&nbsp;31, 2022, 2021 and 2020, respectively. As of October&nbsp;31, 2022, there was $0.3&nbsp;million of unrecognized stock-based compensation expense related to unvested stock options, to be recognized over a weighted-average period of 2.8
years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subsequent to April&nbsp;30, 2023, our Board of Directors granted additional options to employees on July&nbsp;7, 2023 for <FONT
STYLE="white-space:nowrap">non-voting</FONT> common shares at an exercise price of $1.06 CAD ($0.79 USD). As with previously granted options, the exercise price was set at the fair value of the underlying common shares on the grant date as
determined by our Board of Directors based on a third-party valuation. In the case of these granted stock options, the methodology used to arrive at the fair value of our common shares on the grant date was determined using a
Probability-Weighted-Expected Return Method, which differs from the previous methodology used to value our common shares as a result of our having entered into the Business Combination Agreement with respect to the contemplated Business Combination
on May&nbsp;16, 2023, prior to the grant of these options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In future periods, we expect our stock-based compensation expense to increase,
due in part to our existing unrecognized stock-based compensation expense and as we grant additional stock-based awards to continue to attract and retain our employees. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Recoverability of Investment Tax Credits Receivable </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are eligible to claim Canadian federal and provincial tax credits on eligible research and development expenditures. The Canadian federal
government offers a tax incentive to companies performing research and development activities in Canada and this tax incentive can be refunded or used to reduce federal income taxes in Canada otherwise payable. Such credits, if not refunded or used
in the year earned, can be carried forward for a period of twenty years. The Quebec provincial government offers a similar refundable incentive. The investment tax credits recorded are based on management&#146;s estimates of amounts expected to be
recovered and are subject to audit by the taxation authorities, the resulting adjustments of which could be significant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the three
months ended April&nbsp;30, 2023 and 2022, we recorded $0.4&nbsp;million and $0.3&nbsp;million, respectively, as a reduction of research and development expense associated with research and development investment tax credits. During the six months
ended April&nbsp;30, 2023 and 2022, we recorded $0.7&nbsp;million and $0.8&nbsp;million, respectively, as a reduction of research and development expense associated with research and development investment tax credits. During the fiscal years ended
October&nbsp;31, 2022, 2021 and 2020, we recorded $1.4&nbsp;million, $1.6&nbsp;million and $1.8&nbsp;million, respectively, as a reduction of research and development expense associated with research and development investment tax credits. We have
outstanding investment tax credits receivable of $2.1&nbsp;million and $1.3&nbsp;million as of April&nbsp;30, 2023 and October&nbsp;31, 2022, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Internal Controls Over Financial Reporting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A company&#146;s internal control over financial reporting is a process designed by, or under the supervision of, a company&#146;s principal
executive and principal financial officers, or persons performing similar functions, and effected by a company&#146;s Board of Directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting
and the preparation of financial statements in accordance with generally accepted accounting principles. A material weakness is a significant deficiency, or a combination of significant deficiencies, in internal control over financial reporting such
that it is reasonably possible that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In preparing our financial statements as of and for the year ended October&nbsp;31, 2022, management and our independent registered public
accounting firm identified a material weakness or identified material weaknesses in our internal control over financial reporting. The material weaknesses identified related to: lack of formal </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">360 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
policies, procedures and controls related to the design of internal controls over financial reporting including risk assessment process and control activities for certain key financial reporting
processes;&nbsp;lack of sufficient accounting and financial reporting personnel with requisite knowledge and experience in the application of complex areas of US&nbsp;GAAP; general information technology controls that were not designed appropriately
(access and system changes); and lack of appropriate segregation of duties in the preparation and review of account reconciliations and journal entries.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to implement in the near term measures designed to improve our internal control over financial reporting to remediate these material
weaknesses, including formalizing our processes and internal control documentation and strengthening supervisory reviews by our financial management; hiring additional qualified accounting and finance personnel with requisite knowledge and
experience in the application of complex areas of US&nbsp;GAAP, engaging financial consultants to enable the implementation of internal control over financial reporting and improving segregation of duties among accounting and finance personnel in
the preparation and review of account reconciliations and journal entries. We will also review and improve the design of our general information technology controls including managing user access and privileged access, managing changes in the
information system and segregation of duties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While we are implementing these measures, we cannot assure you that these efforts will
remediate our material weaknesses in a timely manner, or at all, or prevent restatements of our financial statements in the future. If we are unable to successfully remediate our material weaknesses, or identify any future material weaknesses, the
accuracy and timing of our financial reporting may be adversely affected, we may be unable to maintain compliance with securities law requirements regarding timely filing of periodic reports, and the market price of our common stock may decline as a
result. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Emerging Growth Company and Smaller Reporting Company Status </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Section&nbsp;107(b) of the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, an &#147;emerging growth company&#148; can delay
the adoption of new or revised accounting standards until such time as those standards would apply to private companies. We have elected this exemption to delay adopting new or revised accounting standards until such time as those standards apply to
private companies. Where allowable we have early adopted certain standards as described in Note 2 of our consolidated financial statements included elsewhere in this proxy statement/prospectus. As a result, our consolidated financial statements may
not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. We will continue to remain an &#147;emerging growth company&#148; until the earliest of the following: (i)&nbsp;the
last day of the fiscal year following the fifth anniversary of the date of the completion of this offering; (ii)&nbsp;the last day of the fiscal year in which our total annual gross revenue is equal to or more than $1.07&nbsp;billion; (iii)&nbsp;the
date on which we have issued more than $1&nbsp;billion in nonconvertible debt during the previous three years; or (iv)&nbsp;the date on which we are deemed to be a large accelerated filer under the rules of the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also a &#147;smaller reporting company,&#148; meaning that the market value of our stock held by
<FONT STYLE="white-space:nowrap">non-affiliates</FONT> plus the proposed aggregate amount of gross proceeds to us as a result of this offering is less than $700.0&nbsp;million and our annual revenue is less than $100.0&nbsp;million during the most
recently completed fiscal year. We may continue to be a smaller reporting company after this offering if either (i)&nbsp;the market value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250.0&nbsp;million or
(ii)&nbsp;our annual revenue is less than $100.0&nbsp;million during the most recently completed fiscal year and the market value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700.0&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from
certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on
Form <FONT STYLE="white-space:nowrap">10-K</FONT> and, similar to emerging growth </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">361 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
companies, smaller reporting companies have reduced disclosure obligations including regarding executive compensation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Accounting Pronouncements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have
reviewed all recently issued accounting pronouncements and have determined that, other than as disclosed in Note&nbsp;2 to our annual consolidated financial statements included elsewhere in this proxy statement/ prospectus, such standards will not
have a material impact on our financial statements or do not otherwise apply to our operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Off-Balance&nbsp;Sheet</FONT> Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We did not have during the periods presented, and we do not currently have,
<FONT STYLE="white-space:nowrap">any&nbsp;off-balance&nbsp;sheet</FONT> arrangements, as defined in the rules and regulations of the SEC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quantitative
and Qualitative Disclosures About Market Risk </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Interest Rate Risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates,
resulting from the Federal Reserve&#146;s rising of interest rates. Our Term Loan has a variable interest rate that fluctuates with the U.S. prime rate. Interest rate risk also arises from the possibility that changes in market interest rate will
affect the fair value of notes measured at fair value. In general, if interest rates rise, then the value of the notes will decrease. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Credit Risk </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
primary exposure to credit risk is through financial instruments and consist primarily of cash and cash equivalents. We regularly maintain deposits in accredited financial institutions in excess of federally insured limits. As of April&nbsp;30,
2023, we held cash deposits in Canada at the National Bank of Canada, or NBC in excess of CDIC insured limits, and in the United States at Silicon Valley Bank, or SVB, in excess of FDIC insured limits. On March&nbsp;10, 2023, SVB was closed by the
California Department of Financial Protection and Innovation, and the Federal Deposit Insurance Corporation, or FDIC, was appointed as receiver. No losses have been incurred by us on deposits that were held at SVB to date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are dependent on third-party CDMO&#146;s (&#147;Contract Development and Manufacturing Organization&#148;) and CRO&#146;s (&#147;Contract
Research Organization&#148;) with whom we do business. In particular, we rely and expect to continue to rely on a small number of manufacturers to supply us with the requirements of active pharmaceutical ingredients and formulated drugs in order to
perform research and development activities in its programs. We also rely on a limited number of third-party CROs to perform research and development activities on its behalf. These programs could be adversely affected by significant interruption
from these providers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Foreign Currency Exchange Risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to November&nbsp;1, 2022, the functional currency of enGene Inc. was the Canadian dollar and the functional currency of the
Company&#146;s subsidiary, enGene U.S., Inc. is the U.S.&nbsp;Dollar (&#147;USD&#148;). During the current reporting period, the Company reassessed its functional currency and determined that the&nbsp;functional currency of enGene Inc.
changed&nbsp;from the Canadian dollar to the U.S. dollar based on management&#146;s analysis as a result of evaluating criteria within Accounting Standards Codification (&#147;ASC&#148;) 830, and considering our increased exposure to the USD through
increased research and development activities in the United States, the recent financings in USD and contemplated future financings in USD, and the business combination with FEAC. The change in functional currency is accounted for prospectively from
November&nbsp;1, 2022, and prior year </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">362 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
financial statements have not been restated for the change in functional currency. All assets and liabilities were reported using the same USD values as previously reported under the USD
reporting currency described above. As a result, the cumulative translation adjustment balance as of October&nbsp;31, 2022, is carried forward and will remain unchanged. The reporting currency of enGene Inc. is the US&nbsp;Dollar throughout all
periods presented. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-monetary</FONT> assets and liabilities denominated in foreign currencies are
translated into the functional currency at the exchange rates prevailing at the date of the transaction. Exchange gains or losses arising from foreign currency transactions that are conducted in a currency other than the Company&#146;s functional
currency are included in other expenses, net in the Consolidated Statements of Operations and Comprehensive Loss. Prior to November&nbsp;1, 2022, the financial statements of subsidiaries which had a functional currency other than the Canadian Dollar
were translated from their functional currency into the parent company&#146;s functional currency of CAD, and then into the reporting currency as follows: assets and liabilities were translated at the exchange rates at the balance sheet dates,
revenue and expenses were translated at the average exchange rates and shareholders&#146; (deficit) equity was translated based on historical exchange rates. Translation adjustments were not included in determining net loss but were included as a
foreign exchange adjustment to accumulated other comprehensive income, a component of shareholders&#146; (deficit) equity. Beginning on November&nbsp;1, 2022, due to the change in functional currency of the parent company to USD, all entities in the
reporting group have a functional currency in USD and the cumulative translation adjustment balance as of October&nbsp;31, 2022, is carried forward and will remain unchanged. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operating expenses are denominated in the currencies of the countries in which its operations are located, which are primarily in Canada
and the U.S. Our consolidated results of operations and cash flows are, therefore, subject to fluctuations due to changes in foreign currency exchange rates and may be adversely affected in the future due to changes in foreign exchange rates. To
date, we have not entered into any hedging arrangements with respect to foreign currency risk or other derivative financial instruments, although we may choose to do so in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Effects of Inflation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Inflation generally affects us by increasing our cost of labor and clinical trial costs. We believe that inflation has not had a material
effect on our consolidated financial statements included elsewhere in this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">363 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom459793_33"></A>DIRECTORS AND EXECUTIVE OFFICERS OF ENGENE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following persons currently serve as enGene&#146;s executive officers and directors. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="46%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Position</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Executive Officers</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jason D. Hanson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Executive Officer and Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Alex Nichols</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>President and Chief Operating Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Anthony&nbsp;T. Cheung</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Technology Officer and Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;James&nbsp;C. Sullivan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Scientific Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Executive</FONT> Directors</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Marco Boorsma</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gerry Brunk</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Richard Glickman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dennis Langer, M.D., J.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a biographical summary of the experience of our executive officers and directors: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Jason D. Hanson
</I></B>has served as Chief Executive Officer and a Director of enGene since July 2018. From August 2016 to November, 2017, Mr.&nbsp;Hanson served as President and Chief Executive Officer of Ohana Biosciences, a biotechnology company based in
Cambridge, MA, and as member of the Ohana Board of Directors and consultant to Ohana from November 2017 to June 2018. Mr.&nbsp;Hanson previously served as Executive Vice President and Chief Strategy Officer for NuVasive, Inc. from November 2015 to
August 2016. Mr.&nbsp;Hanson served as Corporate Vice President of General Electric Company and member of the senior executive team of GE Healthcare, a global pharmaceutical, medical device and healthcare services business from May 2014 to October
2015. In January 2013, Mr.&nbsp;Hanson served as Company Group Chairman and Executive Vice President of Valeant Pharmaceuticals International, Inc. (now Bausch Health Companies Inc.). Previously, he served in various roles at Medicis Pharmaceutical
Corporation, including as Executive Vice President and Chief Operating Officer between July 2006 and December 2012. Mr.&nbsp;Hanson also served in numerous roles at GE Healthcare, including General Counsel roles, from April 1999 to July 2006.
Mr.&nbsp;Hanson holds a B.S. from Cornell University and a J.D. from Duke University School of Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Dr. Alex Nichols</I></B> has
served as President and Chief Operating Officer of enGene since January 2023. Prior to joining enGene, Dr. Nichols served as President, CEO, and co-founder of Mythic Therapeutics, Inc., a clinical-stage product-platform company developing a pipeline
of antibody-drug conjugates (&#147;ADCs&#148;). In this role, Dr.&nbsp;Nichols co-invented the company&#146;s technology platform and lead program, raised more than $130&nbsp;million across several financing rounds and helped grow the company into
an emerging ADC innovator. From November 2014 to September 2016, Dr.&nbsp;Nichols worked as an associate at Flagship Pioneering Inc., where he was part of the co-founding team of Cogen Therapeutics (now Repertoire Immune Medicines). Alex holds a
B.A. in Biochemistry from Oberlin College and Ph.D. in Biophysics from Harvard University. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Dr. Anthony T. Cheung</I></B> co-founded
enGene and has served enGene in various capacities since the company&#146;s inception. Since July 2018, Dr.&nbsp;Cheung has served as Chief Technology Officer. From February 2013 to July 2018, Dr.&nbsp;Cheung served as the President and Chief
Executive Officer of enGene. From May 2011 to February 2013, Dr.&nbsp;Cheung served as Interim Chief Executive Officer. From March 2004 to May 2011, Dr.&nbsp;Cheung served as the Chief Scientific Officer of enGene. From November 1999 to February
2015, Dr.&nbsp;Cheung served as the Corporate Secretary of enGene. From November 1999 to March 2004, Dr.&nbsp;Cheung served as the President and Chief Executive Officer of enGene. Dr.&nbsp;Cheung has co-authored numerous book chapters, review
articles and peer-reviewed journals, and is named investor on numerous patents, in the areas of gene therapy and polymer chemistry. Dr.&nbsp;Cheung holds a B.Sc. from University of British Columbia and a Ph.D. in Physiology from the Tulane
University School of Medicine. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">364 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Dr. James C. Sullivan</I></B> has served as Chief Scientific Officer at enGene since
February 2022. In this role, Dr. Sullivan oversees Research and Preclinical Development. From January 2021 to January 2022, Dr.&nbsp;Sullivan served as Vice President, Head of Pulmonary Discovery at Translate Bio, Inc. Before joining Translate Bio,
Dr.&nbsp;Sullivan was Executive Director, Head of Translational Biology at Sana Biotechnology, Inc from August 2019 to January 2021. He also served at Vertex Pharmaceuticals, Inc. from January 2008 to August 2019, where he where he was an IND and/or
s/NDA team member for several products, including, for cystic fibrosis, Kalydeco<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, Orkambi<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> and Symdeko<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, as well as Incivek<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> for Hepatitis C. Dr.&nbsp;Sullivan was also an IND team member for multiple assets currently in clinical development
to treat alpha-1-antitrypsin (AAT) deficiency and the first-ever CRISPR-based gene editing therapeutic product for the treatment of certain hemoglobinopathies (exagamglogene autotemcel). Dr.&nbsp;Sullivan holds a B.S. in Biology from Boston College,
a M.Sc. from University College Dublin, and a Ph.D. from Boston University. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Dr. Marco Boorsma </I></B>has served as a member of enGene&#146;s Board since August 2017. Dr.&nbsp;Boorsma has served as a General
Partner at Forbion Capital Partners since April 2017, after joining the firm in July 2007. Dr.&nbsp;Boorsma currently also serves on the boards of Inversago, Rectify Pharma, Oxitope Pharma, VectorY Therapeutics, Sitala, and Escalier Biosciences. He
served on the Board of both NorthSea Therapeutics and Milestone Pharmaceuticals from November 2017 to December 2019 and served as an observer to the Boards of Exosome Diagnostics and Oxyrane from April 2010 to June 2018 and August 2011 to January
2011, respectively. Dr.&nbsp;Boorsma previously served on the Board of Dezima Pharma (sold to Amgen in September 2015), Akarna Therapeutics (sold to Allergan in August 2016), Inflazome (sold to Roche in September 2020), Prexton Therapeutics (sold to
Lundbeck in March 2018), and RSPR Pharma from February 2014 to March 2018. Before joining Forbion, Dr.&nbsp;Boorsma was a Scientist, Project Manager, and Business Development Director, respectively, at DSM Pharmaceutical Products from June 2001 to
July 2007. Prior to DSM, Dr.&nbsp;Boorsma was a scientist at Cytos Biotechnology from August 1998 to May 2001. Dr.&nbsp;Boorsma holds an M.S. in molecular biology from the University of Groningen, The Netherlands, and received his Ph.D. in
biotechnology from the ETH Institute for Technology in Z&#252;rich, Switzerland. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Gerry Brunk</I></B> has served as a member of
enGene&#146;s Board since October 2017. Mr. Brunk is a co-founder and Managing Director at Lumira Ventures, a healthcare venture capital firm. Prior to beginning his venture capital career in 2002, Mr. Brunk was an entrepreneur and co-founder of
several venture-capital funded healthcare companies and served as an Engagement Manager in the healthcare practice of The Boston Consulting Group from July 1994 to May 1999. Earlier, Mr. Brunk was a member of the investment banking group of Credit
Suisse First Boston in New York from June 1990 to June 1992. Mr. Brunk received an MBA from Stanford University Graduate School of Business and a B.A. from the University of Virginia. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Dennis H. Langer, M.D., J.D. </I></B>has served as a member of enGene&#146;s Board since December 2015, and as Vice-Chair since 2017.
Dr. Langer has served as a Director of several public and private health care companies, and served in executive roles in several pharmaceutical and biotechnology companies. Dr. Langer held several high level positions at GlaxoSmithKline from
September 1994 to January 2004, including most recently as a Senior Vice President of Research and Development. He was also a Founder and Director of Ception Therapeutics, Inc. from December 2004 until April 2010, when it was acquired by Cephalon,
Inc. Dr. Langer was President and CEO of Neose Technologies, Inc. from June 1991 to August 1994. He also held Research &amp; Development and Marketing positions at Lilly, Abbott and Searle. Dr. Langer has served as a Director of Quoin
Pharmaceuticals (Nasdaq: QNRX) since October 2021. During the past five years, he has served as a Director of Myriad Genetics, Inc. (Nasdaq: MYGN) from May 2004 to June 2022; Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) from February 2011 to
September 2019; Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) from May 2021 <B>t</B>o June 2022, now known as Eterna Therapeutics, Inc. (Nasdaq: ERNA); and Pernix Therapeutics Holdings, Inc. (Nasdaq: PTX) from November 2016 to May 2019.
Previously, he was a Director of Sirna Therapeutics, Inc. (Nasdaq: RNAI) from April 2005 until December 2006, when it was acquired by Merck &amp; Co., Inc. and a Director of Pharmacopeia, Inc. (Nasdaq: PCOP) from May 2007 until December 2008, when
it </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">365 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
was acquired by Ligand Pharmaceuticals, Inc. Dr. Langer has also served as a Director of the Whitehead Institute for Biomedical Research, a non-profit affiliated with the Massachusetts Institute
of Technology, since May 2020. Dr. Langer holds a J.D. from Harvard Law School, an M.D. from Georgetown University School of Medicine, and a B.A. in Biology from Columbia University. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Dr. Richard M. Glickman </I></B>has served as the Chair of enGene&#146;s Board since January 2015, and has served as a member of the
enGene Board since October 2011. Dr. Glickman was a co-founder of Aurinia Pharma Corp. where he served as its Chairman and CEO since February 2017. He was also the founding and current Chairman of the Board of Essa Pharmaceuticals Inc. Previously,
Dr. Glickman was a co-founder of Apsreva Pharmaceuticals where he served as its Chairman and CEO from 2001 to 2006. Dr Glickman is the recipient of numerous awards including the Ernst and Young Entrepreneur of the Year and Canada&#146;s Top 40 under
40. Dr. Glickman holds a B.S. in Microbiology and Immunology from the McGill University. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">366 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom459793_34"></A>ENGENE&#146;S EXECUTIVE AND DIRECTOR COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Unless otherwise indicated or the context otherwise requires, references in this section to &#147;we,&#148; &#147;us,&#148;
&#147;our,&#148; and other similar terms refer to enGene and its subsidiary. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Compensation Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following discussion contains forward-looking statements that are based on our current plans, considerations, expectations and
determinations regarding future compensation programs. The actual amount and form of compensation and the compensation policies and practices that we adopt in the future may differ materially from currently planned programs as summarized in this
discussion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The compensation provided to our named executive officers for the fiscal year ended October&nbsp;31, 2022 is detailed in the
2022 Summary Compensation Table and accompanying footnotes and narrative that follow this section. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our named executive officers for the
fiscal year ended October&nbsp;31, 2022 are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Jason D. Hanson, our Chief Executive Officer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Anthony Cheung, our Chief Technology Officer; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">James Sullivan, our Chief Scientific Officer. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2022 Summary Compensation Table </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following table presents information regarding the total compensation awarded to, earned by, and paid to our named executive officers for services rendered to us in all capacities for the fiscal year ended October&nbsp;31, 2022. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name And <BR>Principal Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fiscal<BR>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Base</B><br><B>Salary<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<BR><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP><BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nonequity&nbsp;Incentive<BR>Plan Compensation</B><br><B>($)<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jason D. Hanson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">446,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">193,638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,150</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">649,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anthony Cheung<B><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">225,580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">112,790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,384</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">341,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Technology Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James Sullivan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">279,250</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57,517</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">97,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,362</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">439,866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Scientific Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts paid Dr.&nbsp;Cheung were converted from Canadian dollar to U.S. dollar using an exchange rate of
C$1.00 = US$0.7327, which was the Bank of Canada closing rate on October&nbsp;31, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Sullivan began employment on February&nbsp;15, 2022, and, as such, this number represents his prorated
base salary. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Hanson and Dr.&nbsp;Cheung did not receive any option grants in 2022 but Dr.&nbsp;Sullivan did receive
an option grant in connection with his hiring. The amount reported represents the aggregate grant date fair value of the stock option awarded to Dr.&nbsp;Sullivan during the 2022 fiscal year, calculated in accordance with Financial Accounting
Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic 718. Such grant date fair value does not take into account any estimated forfeitures. The assumptions used in calculating the grant date fair value of the stock option
reported in this column are set forth in Note 12 to our consolidated financial statements as of October&nbsp;31, 2022 and 2021 and for the years ended October&nbsp;31, 2022, 2021 and 2020 (the &#147;Audited Financial Statements&#148;). The amount
reported in this column reflects the grant date accounting cost for these stock option awards and does not correspond to the actual economic value that may be received by Mr.&nbsp;Sullivan upon the vesting of his stock options or any sale of the
shares, which depends on the market value of our common stock on a date in the future. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">367 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts in the &#147;Nonequity incentive plan compensation&#148; column represent annual bonus amounts
awarded to the named executive officers by enGene&#146;s compensation committee, as detailed in &#147;&#151; Cash Incentive Compensation&#148; below. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This amount represents 401K employer contributions to Mr. Hanson. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This amount represents RRSP employer contributions and supplemental private healthcare benefit to
Dr.&nbsp;Cheung. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This amount represents 401K employer contributions made for Dr.&nbsp;Sullivan. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Narrative to Summary Compensation Table </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Base
Salaries </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We use base salaries to recognize the experience, skills, knowledge and responsibilities required of all our employees,
including our named executive officers. Base salaries are reviewed annually, typically in connection with our annual performance review process, and adjusted from time to time to realign salaries with market levels after taking into account
individual responsibilities, performance and experience. For fiscal year ended October&nbsp;31, 2022, the base salary for each of Mr.&nbsp;Hanson, Dr.&nbsp;Cheung and Dr.&nbsp;Sullivan was $446,419, 225,580, and 279,250, respectively. The amounts
paid of C$390,000 to Dr.&nbsp;Cheung were converted from Canadian dollar to U.S. dollar using an exchange rate of C$1.00 = US$0.7327, which was the Bank of Canada closing rate on October&nbsp;31, 2022. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash Incentive Compensation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
seek to motivate and reward our executives for achievements relative to our corporate goals and expectations for each fiscal year. For the fiscal year ending October&nbsp;31, 2022, the target cash bonus, subject to the achievement of overall company
performance criteria, for Mr.&nbsp;Hanson, Dr.&nbsp;Cheung, and Dr.&nbsp;Sullivan was 45%, 50%, and 35% of their base salaries, respectively. The company performance criteria for 2022 included operational goals in the areas of the clinical
development of <FONT STYLE="white-space:nowrap">EG-70,</FONT> technology advances in the DDX platform, financing activity and building the corporate organization and corporate brand. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Equity Compensation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we
do not have a formal policy with respect to the grant of equity incentive awards to our executive officers, we believe that equity grants provide our executive officers with a strong link to our long-term performance, create an ownership culture and
help to align the interests of our executive officers and our stockholders. In addition, we believe that equity grants with a time-based vesting feature promote executive retention because this feature incentivizes our executive officers to remain
in our employment during the vesting period.&nbsp;Executive grants are typically negotiated in connection with their hiring. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Employment
Arrangements with Our Named Executive Officers </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Jason D. Hanson </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;9, 2018, enGene and Jason Hanson<I> </I>entered into an employment agreement (the &#147;Hanson Employment Agreement&#148;), which
provides for an annual base salary, an annual bonus opportunity and eligibility to participate in our employee benefit plans. In addition, the Hanson Employment Agreement provided for equity stock option grant, representing 4.5% of our fully-diluted
capitalization as of the date of the Hanson Employment Agreement, and also provided for enGene&#146;s agreement to grant to Mr.&nbsp;Hanson an additional stock option following the closing of the first equity financing after the date of the Hanson
Employment Agreement in which the gross proceeds raised by enGene are at least C$10,000,000 (the &#147;Subsequent Financing&#148;), which additional stock option would be exercisable for a number of shares sufficient to <FONT
STYLE="white-space:nowrap">true-up</FONT> Mr.&nbsp;Hanson&#146;s aggregate equity ownership in enGene represented by both stock option grants contemplated under the Hanson Employment Agreement to 4.5% of our fully diluted capitalization immediately
after the Subsequent Financing. Subject to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">368 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Mr.&nbsp;Hanson&#146;s continued employment, both of such stock option awards would vest as follows: 25% vesting on the first anniversary of the start date of Mr.&nbsp;Hanson&#146;s employment
with enGene, and the remaining 75% vesting in 36 equal monthly installments after the date of such first anniversary. Mr.&nbsp;Hanson&#146;s vesting schedule was subsequently amended in 2020 to provide for 33.3% vesting on each anniversary over
three years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Hanson Employment Agreement provides that, subject to Mr.&nbsp;Hanson&#146;s continued employment, fifty percent (50%)
of any unvested stock options held by Mr.&nbsp;Hanson at the time that enGene consummates a liquidity event shall accelerate and become fully vested immediately upon consummation of such liquidity event. In addition, subject to
Mr.&nbsp;Hanson&#146;s continued employment, in the case of any liquidity event consummated by enGene that consists of or involves a change of control transaction, all unvested stock options held by Mr.&nbsp;Hanson shall accelerate and become fully
vested (i)&nbsp;at the time of consummation of such change of control transaction if the acquiror (or its ultimate parent entity) does not assume all of Mr.&nbsp;Hanson&#146;s unvested options outstanding at such time, or (ii)&nbsp;upon termination
by enGene or any of its affiliates without &#147;cause&#148; or termination by Mr.&nbsp;Hanson for &#147;good reason&#148; of Mr.&nbsp;Hanson&#146;s employment at any time following the consummation of such change of control transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Hanson Employment Agreement, in the event that Mr.&nbsp;Hanson&#146;s employment with enGene is terminated by enGene without
cause or by Mr.&nbsp;Hanson for good reason, Mr.&nbsp;Hanson is entitled to receive post-termination severance benefits from enGene consisting of twelve months&#146; base salary and six months of continued coverage under enGene&#146;s medical and
dental benefit plans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Hanson Employment Agreement, Mr.&nbsp;Hanson has agreed to a twelve-month <FONT
STYLE="white-space:nowrap">non-compete</FONT> and a twelve-month <FONT STYLE="white-space:nowrap">non-solicitation</FONT> covenant with respect to customers or employees. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Anthony Cheung </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;26, 2013,
enGene and Anthony Cheung entered into an offer letter (the &#147;Cheung Offer Letter&#148;), which provides for an annual base salary, an annual bonus opportunity, and eligibility to participate in our employee benefit plans generally. In addition,
the Cheung Offer Letter provided for an equity grant representing 5% of our then fully diluted capitalization, which such award would vest as follows: 33.3% vesting on the first anniversary of Dr.&nbsp;Cheung&#146;s start date, followed by equal
yearly vesting for two years thereafter, subject to acceleration of 50% of unvested options upon a change of control. In connection with the Cheung Offer Letter, enGene and Dr.&nbsp;Cheung also entered into a
<FONT STYLE="white-space:nowrap">Non-Competition</FONT> and <FONT STYLE="white-space:nowrap">Non-Solicitation</FONT> Agreement, which includes a nine-month <FONT STYLE="white-space:nowrap">non-compete</FONT> and a nine-month <FONT
STYLE="white-space:nowrap">non-solicitation</FONT> of customers or employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Cheung Offer Letter, in the event that
Dr.&nbsp;Cheung&#146;s employment with enGene is terminated by enGene without &#147;cause&#148;, Dr.&nbsp;Cheung is entitled to receive post-termination severance benefits from enGene consisting of eighteen months&#146; base salary and continuation
of coverage under enGene&#146;s benefits plan for the minimum period required by applicable employment standards legislation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>James Sullivan </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;14, 2022, enGene and James Sullivan entered into an offer letter (the &#147;Sullivan Offer Letter&#148;), which provides for
an annual base salary, an annual bonus opportunity, and eligibility to participate in our employee benefit plans generally. In addition, the Sullivan Offer Letter provided for an equity grant representing .75% of our then fully diluted
capitalization, which such award would vest as follows: 25% vesting on the first anniversary of Dr.&nbsp;Sullivan&#146;s start date, followed by equal monthly vesting for three years thereafter, subject to acceleration in connection with a change of
control. In connection with the Sullivan Offer Letter, enGene and Dr.&nbsp;Sullivan also entered into a <FONT STYLE="white-space:nowrap">Non-Competition</FONT> and <FONT STYLE="white-space:nowrap">Non-Solicitation</FONT> Agreement, which includes a
nine-month <FONT STYLE="white-space:nowrap">non-compete</FONT> and a nine-month <FONT STYLE="white-space:nowrap">non-solicitation</FONT> of customers and employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the case of enGene&#146;s termination of Dr.&nbsp;Sullivan&#146;s employment other than for cause, Dr.&nbsp;Sullivan is entitled to any
Accrued Obligations (as defined in the Sullivan Offer Letter), an additional nine months&#146; base </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">369 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
salary, prorated bonus, and continued coverage for nine months under enGene group benefit plans in place and as amended from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Dr.&nbsp;Sullivan is terminated for &#147;cause&#148;, he will not be entitled to any severance pay, notice or compensation in lieu of
notice, nor to any payment, other than any minimum entitlements to which he would be entitled under applicable law. He will, however, be entitled to payment of any unpaid base salary. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Equity Awards at 2022 Fiscal <FONT STYLE="white-space:nowrap">Year-End</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information concerning outstanding equity awards held by each of our named executive officers as of
October&nbsp;31, 2022. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant</B><br><B>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number Of<BR>Securities&nbsp;Underlying<BR>Unexercised&nbsp;Options<BR>(#)</B><br><B>Exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number Of<BR>Securities</B><br><B>Underlying</B><br><B>Unexercised</B><br><B>Options (#)</B><br><B>Unexercisable<SUP
STYLE="font-size:75%; vertical-align:top">(5)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option</B><br><B>Exercise</B><br><B>Price</B><br><B>($)<SUP STYLE="font-size:75%; vertical-align:top">(1) </SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option</B><br><B>Expiration</B><br><B>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jason D. Hanson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7/9/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">759,374</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7/9/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7/30/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">171,429</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7/30/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8/20/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,877,041</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,029,345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8/20/2031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8/20/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39,027</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(3) </SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,402</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8/20/2031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anthony Cheung</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12/4/2013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">293,333</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12/4/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5/21/2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">160,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5/21/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/11/2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">126,667</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/11/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3/16/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">202,897</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3/16/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12/14/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,020</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(2) </SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12/14/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8/20/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">556,347</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">305,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8/20/2031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8/20/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,073</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(3) </SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8/20/2031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James Sullivan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3/18/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">492,582</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3/18/2032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts in the &#147;Option Exercise Price&#148; column are denominated in Canadian currency.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">33.3% of the shares are subject to the award vesting on the first anniversary of the grant date, followed by
equal yearly installments for two years thereafter, subject to the named executive officer&#146;s continuous service relationship. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">50% of the shares are subject to the award were vested as of the grant date, with the remaining 50% of the
shares subject to the award vesting on the first anniversary of the grant date, followed by equal monthly installments for 36 months thereafter, subject to the named executive officer&#146;s continuous service relationship. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">25% of the shares are subject to the award vesting on the first anniversary of the grant date, followed by
equal monthly installments for 36 months thereafter, subject to the named executive officer&#146;s continuous service relationship. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Upon the Closing of the Business Combination, all outstanding enGene Options will be assumed by New enGene and
enGene Options that were issued or available to be issued as of May 16, 2023 will accelerate and become vested and exercisable (if not previously vested and exercisable). For additional information, see &#147;<I>Proposal No.</I><I></I><I>&nbsp;1</I>
&#151; <I>The Business Combination Proposal</I> &#151; <I>Cancellation of Certain Warrants of enGene</I><I>; Assumption of enGene Options</I>.&#148; </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Employee Benefit and Equity Compensation Plans </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stock Option Plan and Equity Incentive Plan </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have an employee stock option plan (the &#147;ESOP&#148;) and an equity incentive plan (the &#147;EIP&#148;, and together with the ESOP, the
&#147;Plans&#148;), whereby options to purchase <FONT STYLE="white-space:nowrap">non-voting</FONT> common shares of enGene stock may be granted to directors, officers, employees, consultants and members of the scientific advisory board. The Plans
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">370 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
provide for the issuance of common stock options up to a maximum of 15% of the aggregate issued and outstanding common shares and <FONT STYLE="white-space:nowrap">non-voting</FONT> common shares
of enGene calculated on an <FONT STYLE="white-space:nowrap">as-converted</FONT> and fully diluted basis. Our Board of Directors administers the Plans. The Board of Directors determines the number of options to be granted, the vesting period and the
exercise price of new options. It is our policy to establish the exercise price at an amount that approximates (and is no less than) the fair value of the underlying shares on the date of grant as determined by the Board of Directors. As of
July&nbsp;31, 2023, there were 15,638,946&nbsp;shares reserved for issuance in the Plans, of which 297,036&nbsp;shares remain available for future grants under the Plans. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Retirement Plans </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain a <FONT
STYLE="white-space:nowrap">US&nbsp;tax-qualified&nbsp;retirement</FONT> plan that provides eligible employees with an opportunity to save for retirement on a <FONT STYLE="white-space:nowrap">US&nbsp;tax-advantaged&nbsp;basis.</FONT> All
participants&#146; interests in their contributions are 100% vested when contributed. Contributions are allocated to each participant&#146;s individual account and are then invested in selected investment alternatives according to the
participants&#146; directions. The retirement plan is intended to qualify under Section&nbsp;401(a) of the Code. We contribute 3% of an individual&#146;s eligible compensation to the 401(k) Plan irrespective of employee contribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain a Canadian <FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plan that provides eligible employees with an
opportunity to save for retirement on a <FONT STYLE="white-space:nowrap">Canadian&nbsp;tax-advantaged&nbsp;basis.</FONT> All participants&#146; interests in their contributions are 100% vested when contributed. Contributions are allocated to each
participant&#146;s individual account and are then invested in selected investment alternatives according to the participants&#146; directions. We contribute 1.5% to the Registered Retirement Savings Plan (RRSP) irrespective of employee
contribution. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We did not make any equity or <FONT STYLE="white-space:nowrap">non-equity</FONT> awards to any of the
<FONT STYLE="white-space:nowrap">non-employee</FONT> members of our Board of Directors in 2022. During fiscal year 2022, Jason Hanson and Anthony Cheung, served as our Chief Executive Officer and Chief Technology Officer respectively, as well as a
members of our Board of Directors, and received no additional compensation for their services as members of our Board of Directors. See the section titled &#147;Executive Compensation&#148; for more information about Mr.&nbsp;Hanson&#146;s and
Dr.&nbsp;Cheung&#146;s compensation for fiscal year 2022. We reimburse <FONT STYLE="white-space:nowrap">non-employee</FONT> members of our Board of Directors for reasonable travel expenses incurred in attending meetings of our Board of Directors and
committees of our Board of Directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2022 <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Table </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees&nbsp;Earned&nbsp;Or<BR>Paid In&nbsp;Cash<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard Glickman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48,725</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48,725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dennis Langer, M.D., J.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54,136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54,136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steve&nbsp;Gannon</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,972</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marco Boorsma, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gerry Brunk</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts paid Dr.&nbsp;Glickman and Mr.&nbsp;Gannon were converted from Canadian dollar to U.S. dollar using
an exchange rate of C$1.00 = US$.7327, which was the Bank of Canada closing rate on October&nbsp;31, 2022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Boorsma and Mr.&nbsp;Brunk do not receive compensation for their services as members of our board of
directors. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">371 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom459793_34a"></A>DESCRIPTION OF ENGENE&#146;S MATERIAL INDEBTEDNESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2021 Loan and Security Agreement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
December&nbsp;30, 2021, enGene entered into the Loan Agreement with Hercules for Term Loans of up to an aggregate principal amount of up to $20.0&nbsp;million. The Loan Agreement provides for (i)&nbsp;an initial term loan advance of
$7.0&nbsp;million, which closed on December&nbsp;30, 2021, (ii) subject to the achievement of the Clinical Milestone, a right of enGene to request that Hercules make additional term loan advances to enGene in an aggregate principal amount of up to
$4.0&nbsp;million from the achievement of the Clinical Milestone through June&nbsp;15, 2022, which was drawn in June 2022, and (iii)&nbsp;subject to the achievement of the &#147;Financial Milestone&#148;, a right of enGene to request that Hercules
make additional term loan advances to enGene in an aggregate principal amount of up to $9.0&nbsp;million from achievement of the Financial Milestone through December&nbsp;15, 2022, which was not achieved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">enGene is required to pay the End of Term Charge equal to 6.35% of the aggregate principal amount of the Term Loans advance upon repayment.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Maturity Date of the Term Loan is July&nbsp;1, 2025, with no option for extension. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Term Loans bear interest at an annual rate equal to the greater of (i) 8.25% and (ii) 8.25% plus the prime rate of interest minus 3.25%.
Borrowings under the Loan Agreement are repayable in monthly interest-only payments through June 2023. After the interest-only payment period, borrowings under the Loan Agreement are repayable in equal monthly payments of principal and accrued
interest until the Maturity Date. The amount outstanding under the Term Loans (including the End of Term Charge) as of October&nbsp;31, 2022 and October&nbsp;31, 2021 was $11.699&nbsp;million, with a carrying value of $10.914&nbsp;million, and zero,
respectively. Total interest expense incurred in the fiscal year ended October&nbsp;31, 2022 on the Term Loans was $1.0&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At
enGene&#146;s option, enGene may elect to prepay all, but not less than all, of the outstanding Term Loans by paying the entire principal balance and all accrued and unpaid interest thereon plus a prepayment charge equal to the following percentage
of the principal amount being prepaid: (i) 3.0% of the principal amount outstanding if the prepayment occurs in any of the first twelve months following the closing date of the last draw down; (ii) 2.0% of the principal amount outstanding if the
prepayment occurs after the first twelve months following the closing date of the last draw down, but on or prior to twenty-four months following the closing date of the last draw down; and (iii) 1.0% of the principal amount outstanding at any time
thereafter but prior to the Maturity Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Loan Agreement, enGene granted Hercules a security interest senior to
any current and future debts and to any security interest, in all of enGene&#146;s right, title, and interest in, to and under all of enGene&#146;s property and other assets, and certain equity interests and accounts of enGene, subject to limited
exceptions including enGene&#146;s intellectual property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Loan Agreement also contains certain customary events of default,
representations and warranties, voluntary <FONT STYLE="white-space:nowrap">pre-payment</FONT> provisions, and affirmative and negative covenants of enGene. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Loan Agreement will remain in effect following completion of the Business Combination. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>BDC Notes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2020, enGene
issued a convertible debenture to BDC Capital Inc., an affiliate of the Business Development Bank of Canada, in the amount of $2.2&nbsp;million (the &#147;BDC Notes&#148;). The BDC Notes bear interest at rate of 8% per annum and mature on
September&nbsp;29, 2025. The BDC Notes will be paid off in full in connection with the Business Combination in accordance with their terms. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">372 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2022 Convertible Notes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;20, 2022, enGene entered into a Note Purchase Agreement with, and issued an aggregate amount of $18.4&nbsp;million of
convertible promissory notes (the &#147;2022 Convertible Notes&#148;) to, existing shareholders including Forbion Capital Fund III Cooperatief U.A. (&#147;Forbion Capital Fund III&#148;), Fonds de Solidarit&eacute; des Travailleurs du Qu&eacute;bec
(F.T.Q.) (&#147;FSTQ&#148;), Lumira Ventures III, L.P. (&#147;Lumira III&#148;), Lumira Ventures III (International), L.P. (&#147;Lumira International&#148;), Merck Lumira Biosciences Fund, L.P. (&#147;Merck-Lumira L.P.&#148;), Merck Lumira
Biosciences Fund (Qu&eacute;bec), L.P. (&#147;Merck-Lumira Qu&eacute;bec&#148; and together with, Merck-Lumira L.P. FSTQ, Lumira III, Lumira International and Forbion Capital Fund III, collectively the &#147;2022 Noteholders&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the execution and delivery of the Business Combination Agreement, enGene and the 2022 Noteholders entered into amended and restated
convertible promissory notes (the &#147;Amended 2022 Convertible Notes&#148; and together with the enGene warrants issued by enGene as consideration for such modifications, the &#147;Amended 2022 Financing&#148;) to amend and restate the 2022
Convertible Notes in their entirety and to issue to each 2022 Noteholder warrants of enGene in consideration of those amendments set forth in each Amended 2022 Convertible Note. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Amended 2022 Financing indebtedness will be converted in the Transactions into that number of enGene Common Shares that, when exchanged at
the enGene Exchange Ratio, shall equal that number of FEAC Class&nbsp;A Shares (or after the Assumption, New enGene Shares) that the holders of such indebtedness would have received if they had subscribed for FEAC Class&nbsp;A Shares (or after the
Assumption, New enGene Shares) on the same terms as the PIPE Financing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2023 Convertible Notes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;4, 2023, enGene entered into a Note Purchase Agreement with, and issued the 2023 Subordinated Notes to, existing shareholders,
including Forbion Capital Fund III, FSTQ, Lumira III, Lumira International, Lumira Ventures IV, L.P., Lumira Ventures IV (International), L.P., Merck-Lumira L.P., Merck-Lumira Qu&eacute;bec (collectively, the &#147;2023 Noteholders&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;16, 2023, enGene agreed to issue convertible promissory notes (the &#147;2023 Convertible Notes&#148; and together with the
warrants purchased concurrently, the &#147;2023 Financing&#148;) and warrants with an aggregate value of $38&nbsp;million, to existing and new shareholders. The existing shareholders that participated in this financing included Merck-Lumira L.P.,
Merck-Lumira Quebec, FSTQ, Lumira III, Lumira International, Lumira Ventures IV, L.P., Lumira Ventures IV (International), L.P., and Forbion Capital Fund III. The new investors included FEAC&#146;s Sponsor and Investissement Quebec. These new
convertible promissory notes and warrants that were issued to the 2023 Noteholders repaid enGene&#146;s obligations under the 2023 Subordinated Notes in full. This financing was completed in two tranches: the first tranche with an aggregate value of
$28 million in convertible promissory notes and warrants was issued on May&nbsp;17, 2023, with the second tranche was issued on June&nbsp;15, 2023 for an additional $10.0&nbsp;million in convertible promissory notes and warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2023 Financing indebtedness will be converted in the Transactions into that number of enGene Common Shares that, when exchanged at the
enGene Exchange Ratio, shall equal that number of FEAC Class&nbsp;A Shares (or after the Assumption, New enGene Shares) that the holders of such indebtedness would have received if they had subscribed for FEAC Class&nbsp;A Shares (or after the
Assumption, New enGene Shares) on the same terms as the PIPE Financing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IQ Letter Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with IQ&#146;s investment in the 2023 Convertible Notes, IQ, New enGene, FEAC and enGene entered into a letter agreement (the
&#147;IQ Letter Agreement&#148;) pursuant to which New enGene agreed to comply with certain covenants that from the time that IQ first holds New enGene Shares until the earlier of (1)&nbsp;the date </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">373 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
IQ ceases to hold at least 2% of New enGene&#146;s outstanding shares on a fully-diluted basis, and (2)&nbsp;the date that is five years after the date of the Letter Agreement, unless New enGene
receives prior written consent from IQ: (i)&nbsp;New enGene must maintain its head office in the Province of Qu&eacute;bec, and (ii)&nbsp;New enGene shall cause enGene Inc. to (A)&nbsp;maintain operations in the Province of Qu&eacute;bec,
(B)&nbsp;maintain a research and development center in the Province of Qu&eacute;bec, and (C)&nbsp;engage at least 20 employees who are residents and work in the Province of Qu&eacute;bec (the &#147;Employment Threshold&#148;), provided that, if in
good faith, the New enGene Board determines that maintaining the Employment Threshold puts enGene Inc. at risk of bankruptcy, insolvency or determines that it is in the best interests of enGene Inc. to effect a general reduction in workforce, IQ
shall not unreasonably withhold consent to reduce the Employment Threshold. Additionally, after the consummation of the Transactions, IQ will, for so long as IQ holds shares representing, in the aggregate, ownership of greater than 2% of New enGene
on a fully diluted basis, be permitted to have an observer attend any meeting of the New enGene Board subject to the terms and conditions of a board observer agreement to be negotiated in good faith between New enGene and IQ. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">374 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom459793_34b"></A>CURRENT DIRECTORS AND EXECUTIVE OFFICERS OF NEW ENGENE
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of August&nbsp;7, 2023, the following persons currently serve as New enGene&#146;s executive officers and directors. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="59%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Age</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Position</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Executive Officers</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jason D. Hanson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">54</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Executive Officer and Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dr. Anthony T. Cheung</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">52</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Technology Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alexandre Grassin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">45</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Interim Chief Financial Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Non-Executive Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jasper Bos</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">47</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gerry Brunk</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">55</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dr. Richard Glickman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">65</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For biographical summaries of the experience of Jason D. Hanson, Gerry Brunk, Dr.&nbsp;Anthony Cheung and Dr.
Richard Glickman, see &#147;<I>Directors and Executive Officers of enGene.</I>&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a biographical summary of the experience of
Jasper Bos, see &#147;<I>Information About FEAC &#151; Directors and Executive Officers</I>.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Alexandre Grassin</I></B> has
served as New enGene&#146;s Interim Chief Financial Officer since July 2023. Mr.&nbsp;Grassin has served as Interim Chief Financial Officer at enGene USA Inc. since October 2022. Mr. Grassin served as Consulting CFO at Danforth Advisors since
October 2022. Mr. Grassin also serves as CFO for Aleva Neurotherapeutics, Lausanne, Switzerland, since June 2021. Additionally, Mr. Grassin served as CFO/VP Finance and Administration for Genkyotex, Geneva, Switzerland, from April 2012 to May 2021.
Mr. Grassin has more than 20 years of cross industry experience, primarily in the Pharmaceuticals, Biotechnology and Medical Technology sectors in France, Switzerland and in the United States. Mr. Grassin also served a financial auditor at KPMG,
Paris, France, from September 2000 to May 2004. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">375 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom459793_35"></A>DIRECTORS AND EXECUTIVE OFFICERS OF NEW ENGENE AFTER THE
BUSINESS COMBINATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board of Directors and Management After the Business Combination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following completion of the Business Combination, the existing management of enGene will initially continue to serve in their current positions
as executive officers of New enGene. See &#147;<I>Executive Officers and Directors of enGene &#151; Executive Officers</I>&#148; for biographical information about these individuals. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Directors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Business Combination Agreement, New enGene anticipates that its board of directors will initially consist of seven
(7)&nbsp;directors, including (i)&nbsp;one (1) independent director and one (1)&nbsp;other director (whether or not independent), each to be identified by FEAC, (ii)&nbsp;Jason D. Hanson, the Chief Executive Officer of enGene, and (iii)&nbsp;three
(3) independent directors and one (1)&nbsp;other director to be identified by enGene. The New enGene Board of Directors will be divided into three classes, Class&nbsp;I, II and III, each to serve a three-year term, except for the initial term after
the Closing, for which the Class&nbsp;I directors will be up for reelection at the first annual meeting of shareholders occurring after the Closing, and for which the Class&nbsp;II directors will be up for reelection at the second annual meeting of
shareholders occurring after the Closing. At each annual meeting of shareholders, the successors to directors whose terms then expire will be elected to serve from the time of election and qualification until the third annual meeting following the
election. Details regarding the New enGene Board of Directors will be provided in a subsequent amendment to the Registration Statement on Form <FONT STYLE="white-space:nowrap">S-4,</FONT> of which this proxy statement/prospectus forms a part. </P>
 <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Governance </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Rule 5600
Series of the Nasdaq Listing Rules generally requires that a listed company&#146;s constating documents provide for a quorum for any meeting of the holders of the company&#146;s common shares that is greater than
<FONT STYLE="white-space:nowrap">33-1/3%</FONT> of the outstanding shares of the company&#146;s common shares that provide voting rights. New enGene&#146;s articles that will be in force immediately prior to the closing of this offering will provide
that a quorum of shareholders is the holders of at least <FONT STYLE="white-space:nowrap">33-1/3%</FONT> of the shares entitled to vote at the meeting, present in person or represented by proxy, and at least two persons entitled to vote at the
meeting, present in person or represented by proxy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as stated above, New enGene intends to comply with the rules generally
applicable to U.S. domestic companies listed on the Nasdaq. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Canadian Securities Administrators has issued corporate governance
guidelines pursuant to National Policy <FONT STYLE="white-space:nowrap">58-201</FONT> &#151; <I>Corporate Governance Guidelines</I> (the &#147;Corporate Governance Guidelines&#148;), together with certain related disclosure requirements pursuant to
National Instrument <FONT STYLE="white-space:nowrap">58-101</FONT> &#151; <I>Disclosure of Corporate Governance Practices</I> (&#147;NI <FONT STYLE="white-space:nowrap">58-101&#148;).</FONT> The Corporate Governance Guidelines are recommended as
guidelines for issuers to consider in developing their own corporate governance practices. New enGene recognizes that good corporate governance plays an important role in its overall success and in enhancing shareholder value and, accordingly, New
enGene has adopted, or will be adopting in connection with the closing of this offering, certain corporate governance policies and practices which reflect its consideration of the recommended Corporate Governance Guidelines. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The disclosure set out below includes disclosure required by NI <FONT STYLE="white-space:nowrap">58-101</FONT> describing New enGene&#146;s
approach to corporate governance in relation to the Corporate Governance Guidelines. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">376 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Composition and Election of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Board Composition </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">New enGene&#146;s Board of Directors currently consists of one (1)&nbsp;director. Effective upon consummation of the Business Combination, New
enGene anticipates that its board of directors will initially consist of seven (7)&nbsp;directors.<B> </B>Under the BCBCA, a director may be removed with or without cause by a resolution passed by a special majority of the votes cast by shareholders
present in person or by proxy at a meeting and who are entitled to vote. Following the continuance of New enGene under the BCBCA, the director residency requirements in the CBCA will cease to apply. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Staggered Board Provisions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Proposed Articles, for the purposes of facilitating staggered terms of the directors on the board, the following provisions, or the
staggered board provisions, shall apply: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">(i)&nbsp;&nbsp;&nbsp;&nbsp;one-third</FONT> of
the directors (or if the number of directors is not divisible by three, then that number of directors that is <FONT STYLE="white-space:nowrap">one-third</FONT> of the directors rounded up to the next whole number) shall initially hold office for a
three-year term expiring on the third annual general meeting of New enGene following the date noted at the end of the Proposed Articles; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">(ii)&nbsp;&nbsp;&nbsp;&nbsp;one-third</FONT> of the directors (or if the number of directors
is not divisible by three, then that number of directors that is <FONT STYLE="white-space:nowrap">one-third</FONT> of the directors rounded up to the next whole number) shall initially hold office for a
<FONT STYLE="white-space:nowrap">two-year</FONT> term expiring on the second annual general meeting of New enGene following the date noted at the end of the Proposed Articles; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;the remaining number of directors shall initially hold office for a
<FONT STYLE="white-space:nowrap">one-year</FONT> term expiring on the first annual general meeting of New enGene following the date noted at the end of the Proposed Articles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While the staggered board provisions apply, at every annual general meeting and in every unanimous shareholder resolution in lieu thereof, all
of the directors whose terms expire shall cease to hold office immediately before the election or appointment of directors, but are eligible for <FONT STYLE="white-space:nowrap">re-election</FONT> or
<FONT STYLE="white-space:nowrap">re-appointment.</FONT> The shareholders entitled to vote at the annual general meeting for the election of directors may elect, or in a unanimous resolution appoint, the number of directors required to fill any
vacancies created. The directors will hold office for the applicable terms contemplated in the staggered board provisions. Upon resignations of a director, the remaining directors may fill the casual vacancy resulting from such resignation for the
remainder of the unexpired term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the expiry of the directors&#146; initial terms of office as set out above, the directors may
be elected in the manner provided in Article 14.2 of the Proposed Articles to hold office for three-year terms expiring on the third annual general meeting following their election. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When New enGene continues as a British Columbia company, New enGene anticipates that the initial terms of office for each of the directors
will be as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;two individuals will have one year terms expiring on the first annual general meeting
following the date New enGene continues as a British Columbia company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;three individuals will have two year
terms expiring on the second annual general meeting following the date New enGene continues as a British Columbia company; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;Jason D. Hanson and two other individuals will have three year terms expiring on the third annual general meeting
following the date New enGene continues as a British Columbia company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">377 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Replacement or Removal of Directors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the BCBCA and the Proposed Articles, a director may be removed with or without cause by a special resolution passed by a special majority
(being two-thirds) of the votes cast by shareholders present in person or by proxy at a duly convened meeting and who are entitled to vote. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent directors are elected or appointed to fill casual vacancies or vacancies arising from the removal of directors, in both
instances whether by shareholders or directors, the directors shall hold office until the remainder of the unexpired portion of the term of the departed director that was replaced. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Proposed Articles, the number of directors of New enGene will be set at a minimum of three (3). The directors will be authorized to
determine the actual number of directors to be elected from time to time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Diversity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">New enGene does not have a formal policy nor measurable objectives (such as a target) regarding board diversity or for the representation of
women on their board of directors, management team or executive officers. New enGene expects that its priority in the selection of New enGene&#146;s Board members will be to identify members who will further the interests of its shareholders through
their established record of professional accomplishment, the ability to contribute positively to the collaborative culture among board members, knowledge of New enGene&#146;s business and understanding of the competitive landscape. New enGene&#146;s
nominating and corporate governance committee and management team are expected to take gender and other diversity representation into consideration as part of their overall recruitment and selection process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">New enGene expects to facilitate the representation of women on its board and in executive officer positions by ensuring that diversity
considerations are taken into account in senior management, monitoring the level of female representation on the board and in senior management positions, continuing to broaden recruiting efforts to attract and interview qualified female candidates,
and committing to retention and training to ensure that New enGene&#146;s most talented employees are promoted from within the organization. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director
Term Limits and Other Mechanisms of Board Renewal </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">New enGene&#146;s Board of Directors has not adopted director term limits or other
automatic mechanisms of board renewal. Rather than adopting formal term limits, mandatory <FONT STYLE="white-space:nowrap">age-related</FONT> retirement policies and other mechanisms of board renewal, New enGene expects that the Nominating and
Corporate Governance Committee of its board of directors will develop a skills and competencies matrix for New enGene&#146;s Board of Directors as a whole and for individual directors. New enGene further expects that the Nominating and Corporate
Governance Committee will also conduct a process for the assessment of its board of directors, each committee and each director regarding their or its effectiveness and contribution, and will report evaluation results to its board of directors on a
regular basis. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Independence of the Members of the Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Director Independence </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Applicable Nasdaq rules require a majority of a listed company&#146;s board of directors to be comprised of independent directors. Under
applicable Nasdaq rules, a director will only qualify as an &#147;independent director&#148; if, in the opinion of the listed company&#146;s board of directors, that person does not have a relationship that would interfere with the exercise of
independent judgment in carrying out the responsibilities of a director. Under NI <FONT STYLE="white-space:nowrap">58-101,</FONT> a director is considered to be independent if that person is independent within the meaning of National Instrument <FONT
STYLE="white-space:nowrap">52-110</FONT> &#151; <I>Audit Committees</I> (&#147;NI <FONT STYLE="white-space:nowrap">52-110&#148;).</FONT> Pursuant to NI <FONT STYLE="white-space:nowrap">52-110,</FONT> an independent director is a director who is free
from any direct or indirect relationship which could, in the view of New enGene&#146;s Board of Directors, be reasonably expected to interfere with a director&#146;s independent judgment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">378 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The independent directors of New enGene&#146;s Board of Directors will<B> </B>hold regularly
scheduled meetings at which <FONT STYLE="white-space:nowrap">non-independent</FONT> directors and members of management are not in attendance. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Mandate of the Board of Directors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">New enGene&#146;s Board of Directors will be responsible for the stewardship of the Company and providing oversight as to the management of New
enGene and affairs, including providing guidance and strategic oversight to management. Effective upon consummation of the Business Combination, New enGene&#146;s Board will adopt a formal mandate that New enGene expects will include the following:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">appointing New enGene&#146;s Chief Executive Officer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing the corporate goals and objectives that New enGene&#146;s Chief Executive Officer is responsible for
meeting and reviewing the performance of New enGene&#146;s Chief Executive Officer against such corporate goals and objectives; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">taking steps to satisfy itself as to the integrity of New enGene&#146;s Chief Executive Officer and other
executive officers and that New enGene&#146;s Chief Executive Officer and other executive officers create a culture of integrity throughout the organization; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving New enGene&#146;s Code of Conduct (as defined herein) and reviewing and monitoring
compliance with the Code of Conduct and New enGene&#146;s enterprise risk management processes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adopting a strategic planning process to establish objectives and goals for New enGene&#146;s business and
reviewing, approving, and modifying, as appropriate, the strategies proposed by management to achieve such objectives and goals; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving material transactions not in the ordinary course of business. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Meetings of Directors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">New enGene&#146;s Board of Directors may meet together for the conduct of business, adjourn and otherwise regulate their meetings as they think
fit, and meetings of the directors held at regular intervals may be held at the place, at the time and on the notice, if any, as the directors may from time to time determine. The independent members of New enGene&#146;s Board of Directors will also
meet, as required, without the <FONT STYLE="white-space:nowrap">non-independent</FONT> directors and members of management before or after each regularly scheduled board meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A director who has a material interest in a matter before New enGene&#146;s Board of Directors or any committee on which they serve is
required to disclose such interest as soon as the director becomes aware of it. In situations where a director has a material interest in a matter to be considered by New enGene&#146;s Board of Directors or any committee on which they serve, such
director may be required to absent themselves from the meeting while discussions and voting with respect to the matter are taking place. Directors will also be required to comply with the relevant provisions of the BCBCA regarding conflicts of
interest. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Committees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective upon consummation of the Business Combination, New enGene expects that its board of directors will establish an audit committee, a
compensation committee and a nominating and corporate governance committee. It is expected that the initial members of New enGene&#146;s respective committees will be determined prior to the closing of the Business Combination. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Compensation Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective upon consummation of the Business Combination, it is expected that New enGene will establish a compensation committee. <B></B>Under
SEC and the Nasdaq rules, there are heightened independence standards for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">379 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
members of the compensation committee. New enGene expects that its compensation committee members will meet this heightened standard and are also expected to be independent for purposes of NI <FONT
STYLE="white-space:nowrap">58-101.</FONT> The functions of the compensation committee are expected to include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and making recommendations with respect to compensation policy and programs and determining and
recommending option grants under New enGene&#146;s incentive stock plan; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and recommending to New enGene&#146;s Board of Directors the manner in which executive compensation
should be tied to corporate goals and objectives; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving annually the corporate goals and objectives applicable to the compensation of the Chief
Executive Officer, evaluating at least annually the Chief Executive Officer&#146;s performance in light of those goals and objectives and determining and approving the Chief Executive Officer&#146;s compensation level based on this evaluation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">making recommendations to New enGene&#146;s Board of Directors regarding the compensation of all other executive
officers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and making recommendations to New enGene&#146;s Board of Directors regarding incentive compensation
plans and equity-based plans; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authority to oversee New enGene&#146;s <FONT STYLE="white-space:nowrap">non-executive</FONT> incentive
compensation plans and equity-based plans, including the discharge of any duties imposed on the compensation committee by any of those plans; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing director compensation for service on New enGene&#146;s Board of Directors and board committees at least
once a year and to recommending any changes to its Board of Directors. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is expected that New enGene&#146;s Board of
Directors will establish a written charter that will be effective immediately prior to the consummation of the Business Combination setting forth the purpose, composition, authority and responsibility of New enGene&#146;s compensation committee
consistent with the rules of the Nasdaq, the SEC and the guidance of the Canadian Securities Administrators. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Audit Committee
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective upon consummation of the Business Combination, it is expected that New enGene will establish an audit committee
comprised of independent directors as required by applicable SEC, Nasdaq rules and <FONT STYLE="white-space:nowrap">NI&nbsp;52-110.</FONT> At least one member of the audit committee will qualify as an &#147;audit committee financial expert&#148;, as
such term is defined the rules and regulation established by the SEC, and all members of the audit committee will be &#147;financially literate&#148;, as such term is defined in NI <FONT STYLE="white-space:nowrap">52-110</FONT> (except as may be
permitted by NI <FONT STYLE="white-space:nowrap">52-110).</FONT> The expected principal purpose of New enGene&#146;s audit committee will be to assist its Board of Directors in its oversight of: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the quality and integrity of New enGene&#146;s financial statements and related information;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the independence, qualifications, appointment and performance of New enGene&#146;s external auditor;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">New enGene&#146;s disclosure controls and procedures, internal control over financial reporting and
management&#146;s responsibility for assessing and reporting on the effectiveness of such controls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">New enGene&#146;s compliance with applicable legal and regulatory requirements; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">New enGene&#146;s enterprise risk management processes. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is expected that New enGene&#146;s Board of Directors will establish a written charter that will be effective immediately prior to the
consummation of the Business Combination setting forth the purpose, composition, authority and responsibility of its audit committee, consistent with the rules of the Nasdaq, the SEC and <FONT STYLE="white-space:nowrap">NI&nbsp;52-110.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">380 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">New enGene&#146;s audit committee will have access to all of its books, records, facilities
and personnel and may request any information about us as it may deem appropriate. It will also have the authority in its sole discretion and at New enGene&#146;s expense, to retain and set the compensation of outside legal, accounting or other
advisors as necessary to assist in the performance of its duties and responsibilities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Nominating and Corporate Governance
Committee </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective upon consummation of the Business Combination, it is expected that New enGene will establish a nominating and
governance committee of the board of directors. The members of the nominating and governance committee will be independent for purposes of NI <FONT STYLE="white-space:nowrap">58-101.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is expected that New enGene&#146;s Board of Directors will establish a written charter that will be effective immediately prior to the
consummation of the Business Combination setting forth the purpose, composition, authority and responsibility of New enGene&#146;s nominating and corporate governance committee. The nominating and corporate governance committee&#146;s expected
purpose will be to assist New enGene&#146;s Board of Directors in: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identifying individuals qualified to become members of New enGene&#146;s Board of Directors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">selecting or recommending that New enGene&#146;s Board of Directors select director nominees for the next annual
meeting of shareholders and determining the composition of its Board of Directors and its committees; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing and overseeing a process to assess New enGene&#146;s Board of Directors, the Chair of the board, the
committees of the board, the chairs of the committees, individual directors and management; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing and implementing New enGene&#146;s corporate governance guidelines. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In identifying new candidates for New enGene&#146;s Board of Directors, the nominating and corporate governance committee will consider what
competencies and skills its board of directors, as a whole, should possess and assess what competencies and skills each existing director possesses, considering New enGene&#146;s board of directors as a group, and the personality and other qualities
of each director, as these may ultimately determine the boardroom dynamic. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It will be the responsibility of the nominating and corporate
governance committee to regularly evaluate the overall efficiency of New enGene&#146;s Board of Directors and its Chair and all board committees and their chairs. As part of its anticipated mandate, the nominating and corporate governance committee
will conduct the process for the assessment of New enGene&#146;s Board of Directors, each committee and each director regarding their or its effectiveness and contribution, and report evaluation results to its board of directors on a regular basis.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of Business Conduct and Ethics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective upon consummation of the Business Combination, it is expected that New enGene will establish a code of conduct and ethics (the
&#147;Code of Conduct&#148;) applicable to all of New enGene&#146;s directors, officers and employees, including its Chief Executive Officer, Chief Financial Officer, controller or principal accounting officer, or other persons performing similar
functions, which will be a &#147;code of ethics&#148; as defined in Item 406(b) of Form <FONT STYLE="white-space:nowrap">10-K</FONT> promulgated by the SEC and which will be a &#147;code&#148; under NI <FONT STYLE="white-space:nowrap">58-101.</FONT>
The Code of Conduct is expected to set out the fundamental values and standards of behavior that will be expected from New enGene&#146;s directors, officers, employees, consultants and contractors with respect to all aspects of its business. The
objective of the Code of Conduct is expected to provide guidelines to promote integrity and deter wrongdoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the effectiveness of
the registration statement of which this proxy statement/prospectus forms a part, the full text of the Code of Conduct will be posted on New enGene&#146;s website at <U>www.engene.com</U>. The written Code of Conduct will also be filed with the
Canadian securities regulatory authorities on SEDAR at </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">381 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<U>www.sedar.com</U>. Information contained on, or that can be accessed through, New enGene&#146;s website does not constitute a part of this proxy statement/prospectus and is not incorporated by
reference herein. If New enGene makes any amendment to the Code of Conduct or grant any waivers, including any implicit waiver, from a provision of the code of ethics, New enGene will disclose the nature of such amendment or waiver on its website to
the extent required by the rules and regulations of the SEC and the Canadian Securities Administrators. New enGene intends to satisfy the disclosure requirement&nbsp;under&nbsp;Item 5.05 of
<FONT STYLE="white-space:nowrap">Form&nbsp;8-K&nbsp;regarding</FONT> an amendment to, or a&nbsp;waiver&nbsp;from, a provision of its Code of Ethics that applies to its principal executive officer, principal financial officer, principal accounting
officer or controller or persons performing similar functions, by posting such information on New enGene&#146;s internet website. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Monitoring
Compliance with the Code of Conduct </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is expected that New enGene&#146;s nominating and corporate governance committee will be
responsible for reviewing and evaluating the Code of Conduct at least annually and will recommend any necessary or appropriate changes to its board of directors for consideration. New enGene expects that the nominating and corporate governance
committee will assist its board of directors with the monitoring of compliance with the Code of Conduct, and will be responsible for considering any waivers of the Code of Conduct (other than waivers applicable to members of the nominating and
corporate governance committee, which shall be considered by the audit committee, or waivers applicable to New enGene&#146;s directors or executive officers, which shall be subject to review by its board of directors as a whole). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Committee Interlocks and Insider Participation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of the members of New enGene&#146;s compensation committee will at any time have been one of its officers or employees. None of the
individuals who is expected to become New enGene&#146;s executive officers currently serves, or in the past year has served, as a member of the board of directors or compensation committee of any entity that has one or more executive officers on New
enGene&#146;s Board of Directors or compensation committee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Position Descriptions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective upon consummation of the Business Combination, it is expected that New enGene&#146;s Board of Directors will adopt a written position
description for the Chair of the board of directors which is expected to set out the Chair&#146;s key responsibilities, including, among other things, duties relating to setting board of director meeting agendas, chairing board of director and
shareholder meetings, director development and ensuring the board of directors is provided with timely and relevant information to effectively discharge its duties and responsibilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective upon consummation of the Business Combination, it is expected that New enGene&#146;s Board of Directors will adopt a written
position description for each of its committee chairs which is expected to set out each of the committee chair&#146;s key responsibilities, including, among other things, duties relating to setting committee meeting agendas, chairing committee
meetings and working with the respective committee and management to ensure, to the greatest extent possible, the effective functioning of the committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective upon consummation of the Business Combination, it is expected that New enGene&#146;s Board of Directors will adopt a written
position description for its Chief Executive Officer which is expected to set out the key responsibilities of New enGene&#146;s Chief Executive Officer, including, among other duties in relation to providing overall leadership, working with the
board of directors to develop New enGene&#146;s strategic direction and the annual corporate plan and budget, and managing the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> business and affairs of the
Company and carrying out such duties and responsibilities as is customary for a Chief Executive Officer of a company in a similar industry and stage of development. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">382 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Orientation and Continuing Education </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective upon consummation of the Business Combination, New enGene expect that it will implement an orientation program for new directors
under which a new director will meet separately with the Chair of New enGene&#146;s Board of Directors, its lead director, if applicable, members of the senior executive team and the secretary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is expected that the chair of each committee will be responsible for providing leadership to enable each committee to effectively carry out
the committee&#146;s mandate. New enGene expect that the board of directors, in conjunction with the Nominating and Corporate Governance Committee, will provide an orientation program for new directors and continuing education opportunities for all
directors. New enGene expects that the Nominating and Corporate Governance Committee will assist new directors in becoming acquainted with the Company and its governance processes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">383 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXECUTIVE OFFICER AND DIRECTOR COMPENSATION OF NEW ENGENE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officer Compensation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
policies of New enGene with respect to the compensation of its executive officers following the Business Combination will be administered by the New enGene Board of Directors in consultation with its compensation committee (as described above). The
compensation policies followed by New enGene will be intended to provide for compensation that is sufficient to attract, motivate and retain executives of New enGene and potentially other individuals and to establish an appropriate relationship
between executive compensation and the creation of shareholder value. To meet these goals, the compensation committee will be charged with recommending executive compensation packages to New enGene&#146;s Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is anticipated that performance-based and equity-based compensation will be an important foundation in executive compensation packages as
New enGene believes it is important to maintain a strong link between executive incentives and the creation of shareholder value. New enGene believes that performance and equity-based compensation can be an important component of the total executive
compensation package for maximizing shareholder value while, at the same time, attracting, motivating and retaining high-quality executives. Upon consummation of the Business Combination, New enGene will adopt the Incentive Equity Plan which will
reflect what New enGene believes is a focus on performance- and equity-based compensation. Since New enGene will not have a compensation committee until completion of the Business Combination, it has not yet adopted any formal guidelines for
allocating total compensation between equity compensation and cash compensation for executives hired in the future. For a description of the terms of the Incentive Equity Plan, see the section entitled &#147;<I>The Incentive Equity Plan
Proposal</I>.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">New enGene intends to be competitive with other similarly situated companies in its industry following completion of
the Business Combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The compensation decisions regarding New enGene&#146;s executives will be based on New enGene&#146;s need to
attract individuals with the skills necessary for New enGene to achieve its business plan, to reward those individuals fairly over time, and to retain those individuals who continue to perform at or above New enGene&#146;s expectations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the guidance provided by its compensation committee, New enGene may utilize the services of third parties from time to time in
connection with the hiring and compensation awarded to executive employees. This could include subscriptions to executive compensation surveys and other databases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">New enGene&#146;s compensation committee will be charged with performing an annual review of New enGene&#146;s executive officers&#146; cash
compensation and equity holdings to determine whether they provide adequate incentives and motivation to executive officers and whether they adequately compensate the executive officers relative to comparable officers in other companies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employment Agreements </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior
completion of the Business Combination, New enGene or a subsidiary thereof will enter into employment agreements with Jason D. Hanson, Chief Executive Officer of enGene who will become Chief Executive Officer of New enGene, and certain other
executive officers. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">New enGene currently does not have a definitive compensation plan for its future directors. New enGene, working with the compensation
committee, anticipates setting director compensation at a level comparable with those directors with similar positions at comparable companies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">384 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom459793_36"></A>DESCRIPTION OF NEW ENGENE SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following description of
the material terms of the New enGene&#146;s share capital upon the completion of the Business Combination includes a summary of specified provisions of the Proposed Articles that will be adopted pursuant to the continuation of New enGene under the
BCBCA. This description is qualified by reference to the Proposed Articles. You are encouraged to read the forms of Proposed Articles for greater detail with respect to the description of material terms, copies of which are attached to this proxy
statement/prospectus as Exhibit G to </I><B><I><U>Annex A</U></I></B><I>, and each is incorporated in this proxy statement/prospectus by reference. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Share Capital </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the completion
of this offering, New enGene&#146;s authorized share capital will consist of an unlimited number of common shares and an unlimited number of blank cheque preferred shares, issuable in series, all of which preferred shares will be undesignated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of May&nbsp;31, 2023, 10 Class&nbsp;B common shares were outstanding and held of record by 1 shareholder. On the date that is one business
day prior to the Closing Date, in connection with the merger of Cayman Merger Sub with and into FEAC, New enGene will redeem these initial 10 Class&nbsp;B common shares for an aggregate amount of C$10.00, which represents the amount of capital that
such shareholder contributed upon the incorporation of New enGene. Upon the consummation of the Business Combination, there will be 33,552,029 New enGene Shares outstanding, assuming, among other things, that none of the holders of FEAC Class&nbsp;A
Shares exercise their redemption rights. See &#147;<I>Security Ownership of Certain Beneficial Owners and Management of New enGene</I>&#148;<I> </I>for information about anticipated share ownership of New enGene following completion of the Business
Combination. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under
the Proposed Articles, the holders of New enGene common shares are entitled to one vote for each share held on all matters submitted to a vote of the shareholders. Holders of New enGene&#146;s common shares are entitled to receive ratably any
dividends declared by New enGene&#146;s Board of Directors out of funds legally available for that purpose, subject to any preferential dividend rights of any outstanding preferred shares. New enGene common shares have no preemptive rights,
conversion rights or other subscription rights or redemption or sinking fund provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of New enGene&#146;s liquidation,
dissolution or winding up, holders of New enGene common shares will be entitled to share ratably in all assets remaining after payment of all debts and other liabilities and any liquidation preference of any outstanding preferred shares. The shares
to be issued by New enGene in this offering will be, when issued and paid for, validly issued, fully paid <FONT STYLE="white-space:nowrap">and&nbsp;non-assessable.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Proposed
Articles, New enGene&#146;s Board of Directors will have the authority, without further action by New enGene&#146;s shareholders, to issue an unlimited number of preferred shares in one or more series and to fix the rights, preferences, privileges
and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting, or the
designation of, such series, any or all of which may be greater than the rights of common shares. The issuance of New enGene preferred shares could adversely affect the voting power of holders of common shares and the likelihood that such holders
will receive dividend payments and payments upon New enGene&#146;s liquidation, dissolution or winding up. In addition, the issuance of preferred shares could have the effect of delaying, deferring or preventing a change in control of New enGene or
other corporate action. Immediately after consummation of this offering, no preferred shares will be outstanding, and New enGene has no present plan to issue any preferred shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">385 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>New enGene Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Assumption of FEAC Warrants </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Business Combination, New enGene will assume the FEAC Warrants and the FEAC Warrant Agreement pursuant to the Warrant
Assignment, Assumption and Amendment Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>PIPE Warrants </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Business Combination, the PIPE Investors will receive New enGene Warrants upon the consummation of the PIPE Financing in
accordance with the terms of the Subscription Agreement as amended by the Side Letter Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Automatic Exchange of Certain enGene
Warrants </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Business Combination, the enGene Warrants that were issued to the holders of the enGene Convertible Notes
will automatically be exchanged in accordance with the Plan of Arrangement for that number of New enGene Warrants that, when exchanged at the enGene Exchange Ratio, shall equal that number of New enGene Warrants that the holders of the enGene
Convertible Notes would have received if they had participated in the PIPE Financing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Terms of the New enGene Warrants </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each whole warrant will entitle the registered holder to purchase one New enGene Share at a price of $11.50&nbsp;per share, subject to
adjustment as discussed below. Pursuant to the terms of the New enGene Warrant Agreement, a warrant holder may exercise its New enGene Warrants only for a whole number of New enGene Shares. This means only a whole New enGene Warrant may be exercised
at a given time by a warrant holder. The New enGene Warrants will expire five years after the completion of the Business Combination, at 5:00 p.m., New York City time, or earlier upon redemption or liquidation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">New enGene will not be obligated to deliver any New enGene Shares pursuant to the exercise of a warrant and will have no obligation to settle
such warrant exercise unless a registration statement under the Securities Act with respect to the New enGene Shares underlying the New enGene Warrants is then effective and a prospectus relating thereto is current, subject to New enGene satisfying
its obligations described below with respect to registration, or a valid exemption from registration is available. No warrant will be exercisable and New enGene will not be obligated to issue a New enGene Share upon exercise of a warrant unless the
New enGene Share issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of the jurisdiction of residence of the registered holder of the warrants. In the event that the conditions in the
two immediately preceding sentences are not satisfied with respect to a warrant, the holder of such warrant will not be entitled to exercise such warrant and such warrant may have no value and expire worthless. In no event will New enGene be
required to net cash settle any warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">New enGene has agreed that as soon as practicable, but in no event later than 15 business days
after the Closing of the Business Combination, it will use its commercially reasonable efforts to file with the SEC a registration statement for the registration, under the Securities Act, of the New enGene Shares issuable upon exercise of the
warrants, and New enGene will use its commercially reasonable efforts to cause the same to become effective within 60 business days after the Closing of the Business Combination, and to maintain the effectiveness of such registration statement and a
current prospectus relating to those New enGene Shares until the New enGene Warrants expire or are redeemed, as specified in the New enGene Warrant Agreement; provided that if the New enGene Shares are at the time of any exercise of a warrant not
listed on a national securities exchange such that they satisfy the definition of a &#147;covered security&#148; under Section&nbsp;18(b)(1) of the Securities Act, New enGene may, at its option, require holders of New enGene Warrants who exercise
their New enGene Warrants to do so on a &#147;cashless basis&#148; in accordance with Section&nbsp;3(a)(9) of the Securities Act and, in the event </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">386 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
New enGene so elects, it will not be required to file or maintain in effect a registration statement, but New enGene will use its commercially reasonable efforts to register or qualify the shares
under applicable blue sky laws to the extent an exemption is not available. If a registration statement covering the New enGene Shares issuable upon exercise of the New enGene Warrants is not effective by the 60th day after the Closing of the
Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when New enGene will have failed to maintain an effective registration statement, exercise New enGene Warrants on a
&#147;cashless basis&#148; in accordance with Section&nbsp;3(a)(9) of the Securities Act or another exemption, but New enGene will use its commercially reasonable efforts to register or qualify the shares under applicable blue sky laws to the extent
an exemption is not available. In such event, each holder would pay the exercise price by surrendering the New enGene Warrants for that number of New enGene Shares equal to the quotient obtained by dividing (x)&nbsp;the product of the number of New
enGene Shares underlying the New enGene Warrants, multiplied by the excess of the &#147;fair market value&#148; (defined below) less the exercise price of the New enGene Warrants by (y)&nbsp;the fair market value. The &#147;fair market value&#148;
as used in this paragraph shall mean the volume weighted average price of the New enGene Shares for the 10 trading days ending on the trading day prior to the date on which the notice of exercise is received by the warrant agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Redemption of New enGene Warrants. </I>Once the redeemable New enGene Warrants become exercisable, New enGene may redeem the outstanding
New enGene Warrants (except as described herein): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in whole and not in part; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at a price of $0.01 per New enGene Warrant; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon a minimum of 30 days&#146; prior written notice of redemption to each warrant holder; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if, and only if, the closing price of the New enGene Shares equals or exceeds $18.00 per share (as adjusted as
described below) for any 20 trading days within <FONT STYLE="white-space:nowrap">a&nbsp;30-trading&nbsp;day</FONT> period ending three trading days before New enGene send the notice of redemption to the warrant holders. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">New enGene will not redeem the New enGene Warrants as described above unless a registration statement under the Securities Act covering the
issuance of the New enGene Shares issuable upon exercise of the New enGene Warrants is then effective and a current prospectus relating to those New enGene Shares is available throughout
<FONT STYLE="white-space:nowrap">the&nbsp;30-day&nbsp;redemption</FONT> period. If and when the New enGene Warrants become redeemable by New enGene, New enGene may exercise its redemption right even if it is unable to register or qualify the
underlying securities for sale under all applicable state securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The last of the redemption criterion discussed above is
designed to prevent a redemption call unless there is at the time of the call a significant premium to the warrant exercise price. If the foregoing conditions are satisfied and New enGene issues a notice of redemption of the New enGene Warrants,
each warrant holder will be entitled to exercise his, her or its warrant prior to the scheduled redemption date. However, the price of the New enGene Shares may fall below the $18.00 redemption trigger price (as adjusted for adjustments to the
number of shares issuable upon exercise or the exercise price of a warrant as described under the heading &#147;<I>New enGene Warrants &#151; Redemption Procedures &#151; Anti-dilution Adjustments</I>&#148;) as well as the $11.50 (for whole shares)
warrant exercise price after the redemption notice is issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If New enGene calls the New enGene Warrants for redemption as described
above, New enGene will have the option to require any holder that wishes to exercise its New enGene Warrant to do so on a &#147;cashless basis.&#148; In determining whether to require all holders to exercise their New enGene Warrants on a
&#147;cashless basis,&#148; New enGene will consider, among other factors, its cash position, the number of New enGene Warrants that are outstanding and the dilutive effect on its shareholders of issuing the maximum number of New enGene Shares
issuable upon the exercise of its New enGene Warrants. If New enGene takes advantage of this option, all holders of New enGene Warrants would pay the exercise price by surrendering their New enGene Warrants for that number of New enGene Shares equal
to the quotient obtained by dividing (x)&nbsp;the product of the number of New enGene Shares underlying the New enGene Warrants, multiplied by the difference between the exercise </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">387 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
price of the New enGene Warrants and the &#147;fair market value&#148; (defined below) by (y)&nbsp;the fair market value. The &#147;fair market value&#148; means
<FONT STYLE="white-space:nowrap">the&nbsp;10-day&nbsp;average</FONT> closing price as of the date on which the notice of redemption is sent to the holders of the New enGene Warrants. If New enGene takes advantage of this option, the notice of
redemption will contain the information necessary to calculate the number of New enGene Shares to be received upon exercise of the New enGene Warrants, including the &#147;fair market value&#148; in such case. Requiring a cashless exercise in this
manner will reduce the number of New enGene Shares to be issued and thereby lessen the dilutive effect of a warrant redemption. We believe this feature is an attractive option to New enGene if it does not need the cash from the exercise of the New
enGene Warrants after the Business Combination. If New enGene calls its New enGene Warrants for redemption and does not take advantage of this option, FEAC&#146;s Sponsor and its permitted transferees would still be entitled to exercise their New
enGene Warrants for cash or on a cashless basis using the same formula described above that other warrant holders would have been required to use had all warrant holders been required to exercise their New enGene Warrants on a cashless basis, as
described in more detail below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No fractional New enGene Shares will be issued upon exercise. If, upon exercise, a holder would be
entitled to receive a fractional interest in a share, New enGene will round down to the nearest whole number of the number of New enGene Shares to be issued to the holder. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Redemption Procedures </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A holder of a warrant may notify New enGene in writing in the event it elects to be subject to a requirement that such holder will not have the
right to exercise such warrant, to the extent that after giving effect to such exercise, such person (together with such person&#146;s affiliates), to the warrant agent&#146;s actual knowledge, would beneficially own in excess of 9.8% (or such other
amount as a holder may specify) of the New enGene Shares issued and outstanding immediately after giving effect to such exercise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Anti-dilution Adjustments.</I> If the number of outstanding New enGene Shares is increased by a capitalization or share dividend payable in
New enGene Shares, or by a <FONT STYLE="white-space:nowrap">sub-division</FONT> of common shares or other similar event, then, on the effective date of such capitalization or share dividend, <FONT STYLE="white-space:nowrap">sub-division</FONT> or
similar event, the number of New enGene Shares issuable on exercise of each warrant will be increased in proportion to such increase in the outstanding common shares. A rights offering made to all or substantially all holders of common shares
entitling holders to purchase New enGene Shares at a price less than the &#147;historical fair market value&#148; (as defined below) will be deemed a share dividend of a number of New enGene Shares equal to the product of (i)&nbsp;the number of New
enGene Shares actually sold in such rights offering (or issuable under any other equity securities sold in such rights offering that are convertible into or exercisable for New enGene Shares) and (ii)&nbsp;one minus the quotient of (x)&nbsp;the
price per New enGene Share paid in such rights offering and (y)&nbsp;the historical fair market value. For these purposes, (i)&nbsp;if the rights offering is for securities convertible into or exercisable for New enGene Shares, in determining the
price payable for New enGene Shares, there will be taken into account any consideration received for such rights, as well as any additional amount payable upon exercise or conversion and (ii) &#147;historical fair market value&#148; means the volume
weighted average price of the New enGene Shares as reported during the 10 trading day period ending on the trading day prior to the first date on which the New enGene Shares trade on the applicable exchange or in the applicable market, regular way,
without the right to receive such rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if New enGene, at any time while the New enGene Warrants are outstanding and
unexpired, pays a dividend or make a distribution in cash, securities or other assets to all or substantially all of the holders of New enGene Shares on account of such New enGene Shares (or other securities into which the New enGene Warrants are
convertible), other than (a)&nbsp;as described above, (b)&nbsp;any cash dividends or cash distributions which, when combined on a per share basis with all other cash dividends and cash distributions paid on the New enGene Shares during the <FONT
STYLE="white-space:nowrap">365-day</FONT> period ending on the date of declaration of such dividend or distribution does not exceed $0.50 (as adjusted to appropriately reflect any other adjustments and excluding cash dividends or cash distributions
that resulted in an adjustment to the exercise price or to the number of New enGene Shares issuable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">388 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
on exercise of each warrant) but only with respect to the amount of the aggregate cash dividends or cash distributions equal to or less than $0.50 per share, (c)&nbsp;to satisfy the redemption
rights of the holders of New enGene Shares in connection with the Business Combination, or (d)&nbsp;to satisfy the redemption rights of the holders of the New enGene Shares in connection with a shareholder vote to amend New enGene&#146;s articles
(A)&nbsp;to modify the substance or timing of New enGene&#146;s obligation to provide holders of the New enGene Shares the right to have their shares redeemed in connection with the Business Combination or (B)&nbsp;with respect to any other
provision relating to the rights of holders of the New enGene Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the number of New enGene Shares is decreased by a consolidation,
combination, reverse share <FONT STYLE="white-space:nowrap">sub-division</FONT> or reclassification of the New enGene Shares or other similar event, then, on the effective date of such consolidation, combination, reverse share <FONT
STYLE="white-space:nowrap">sub-division,</FONT> reclassification or similar event, the number of New enGene Shares issuable on exercise of each warrant will be decreased in proportion to such decrease in outstanding New enGene Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever the number of New enGene Shares purchasable upon the exercise of the New enGene Warrants is adjusted, as described above, the warrant
exercise price will be adjusted by multiplying the warrant exercise price immediately prior to such adjustment by a fraction (x)&nbsp;the numerator of which will be the number of New enGene Shares purchasable upon the exercise of the New enGene
Warrants immediately prior to such adjustment and (y)&nbsp;the denominator of which will be the number of New enGene Shares so purchasable immediately thereafter. The FEAC Warrant Agreement provides that no adjustment to the number of New enGene
Shares issuable upon exercise of a warrant will be required until cumulative adjustments amount to 1% or more of the number of New enGene Shares issuable upon exercise of a warrant as last adjusted. Any such adjustments that are not made will be
carried forward and taken into account in any subsequent adjustment. All such carried forward adjustments will be made (i)&nbsp;in connection with any subsequent adjustment that (taken together with such carried forward adjustments) would result in
a change of at least 1% in the number of New enGene Shares issuable upon exercise of a warrant and (ii)&nbsp;on the exercise date of any warrant. In addition, if (i)&nbsp;New enGene issues additional New enGene Shares or equity-linked securities for
capital raising purposes in connection with the closing of the Business Combination at a newly issued price of less than $9.20 per New enGene Share (with such issue price or effective issue price to be determined in good faith by New enGene&#146;s
Board of Directors and, in the case of any such issuance to FEAC&#146;s Sponsor or its affiliates, without taking into account any founder shares held by FEAC&#146;s Sponsor or such affiliates, as applicable, prior to such issuance) (the &#147;Newly
Issued Price&#148;), (ii) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the Business Combination on the date of the completion of the
Business Combination (net of redemptions), and (iii)&nbsp;the volume weighted average trading price of the New enGene Shares during the 20 trading day period starting on the trading day prior to the day on which the Business Combination is
consummated is below $9.20 per share (such price, the &#147;Market Value&#148;), then the exercise price of the New enGene Warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued
Price, and the $18.00 per share redemption trigger price will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price, respectively. This provision of the New enGene Warrants makes it
possible that the exercise price and redemption price trigger of the New enGene Warrants would be adjusted downward as a result of the PIPE Financing. Following the PIPE Financing, the New enGene Board of Directors will evaluate the terms of the
PIPE Financing and determine whether the foregoing conditions have been satisfied that would result in adjustments to the exercise price and redemption trigger price of the New enGene Warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In case of any reclassification or reorganization of the outstanding New enGene Shares (other than those described above or that solely
affects the par value of such New enGene Shares), or in the case of any merger or consolidation of New enGene with or into another corporation (other than a consolidation or merger in which New enGene is the continuing corporation and that does not
result in any reclassification or reorganization of the outstanding New enGene Shares), or in the case of any sale or conveyance to another corporation or entity of the assets or other property of New enGene as an entirety or substantially as an
entirety in connection with which it is dissolved, the holders of the New enGene Warrants will thereafter have the right to purchase and receive, upon </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">389 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the basis and upon the terms and conditions specified in the New enGene Warrants and in lieu of New enGene Shares immediately theretofore purchasable and receivable upon the exercise of the
rights represented thereby, the kind and amount of New enGene Shares or other securities or property (including cash) receivable upon such reclassification, reorganization, merger or consolidation, or upon a dissolution following any such sale or
transfer, that the holder of the New enGene Warrants would have received if such holder had exercised their New enGene Warrants immediately prior to such event. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The New enGene Warrants will be issued in registered form under a warrant agreement between Continental Stock Transfer&nbsp;&amp; Trust
Company, as warrant agent, and New enGene. The New enGene Warrant Agreement provides that the terms of the New enGene Warrants may be amended without the consent of any holder for the purpose of (i)&nbsp;curing any ambiguity or correct any mistake,
including to conform the provisions of the New&nbsp;enGene Warrant Agreement to the description of the terms of the New enGene Warrants and the New&nbsp;enGene Warrant Agreement set forth in the prospectus for FEAC&#146;s IPO, or defective provision
(ii)&nbsp;amending the provisions relating to cash dividends on common shares as contemplated by and in accordance with the New enGene Warrant Agreement, (iii)&nbsp;providing for the delivery of certain alternative issuances in the case of certain
reorganizations or other events or (iv)&nbsp;adding or changing any provisions with respect to matters or questions arising under the New enGene Warrant Agreement as the parties to the New enGene Warrant Agreement may deem necessary or desirable and
that the parties deem to not adversely affect the rights of the registered holders of the New enGene Warrants, provided that the approval by the holders of at least 65% of the then-outstanding New enGene Warrants is required to make any change that
adversely affects the interests of the registered holders. You should review a copy of the New enGene Warrant Agreement and the Warrant Assignment, Assumption and Amendment Agreement, which will be filed as an exhibit to the registration statement
of which this proxy statement/prospectus is a part, for a complete description of the terms and conditions applicable to the New enGene Warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The warrant holders do not have the rights or privileges of holders of New enGene Shares and any voting rights until they exercise their New
enGene Warrants and receive New enGene Shares. After the issuance of New enGene Shares upon exercise of the New enGene Warrants, each holder will be entitled to one vote for each share held of record on all matters to be voted on by shareholders.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If, upon exercise of the New enGene Warrants, a holder would be entitled to receive a fractional interest in a share, New enGene will,
upon exercise, round down to the nearest whole number the number of New enGene Shares to be issued to the warrant holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">New enGene has
agreed that, subject to applicable law, any action, proceeding or claim against New enGene arising out of or relating in any way to the New enGene Warrant Agreement or the Warrant Assignment, Assumption and Amendment Agreement will be brought and
enforced in the courts of the State of New York or the United States District Court for the Southern District of New York, and New enGene irrevocably submit to such jurisdiction, which jurisdiction will be the exclusive forum for any such action,
proceeding or claim. This provision applies to claims under the Securities Act but does not apply to claims under the Exchange Act or any claim for which the federal district courts of the United States of America are the sole and exclusive forum.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">390 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom459793_37"></A>SECURITIES ACT RESTRICTIONS ON RESALE OF COMMON SHARES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon completion of the Business Combination, New enGene will have unlimited common shares authorized and, based on the assumptions set out
elsewhere in this proxy statement/prospectus, 33,552,029 common shares issued and outstanding, assuming no common shares are redeemed in connection with the Business Combination. All of New enGene&#146;s common shares issued in connection with the
Business Combination will be freely transferable by persons other than by New enGene&#146;s &#147;affiliates&#148; without restriction or further registration under the Securities Act. Sales of substantial amounts of New enGene&#146;s common shares
in the public market could adversely affect prevailing market prices of New enGene&#146;s common shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights and <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Business Combination, on or around the Closing Date, New
enGene, FEAC, the Sponsor Holders (as defined in the Registration Rights Agreement) and the enGene Holders (as defined in the Registration Rights Agreement) will enter into the Registration Rights Agreement. Pursuant to the terms of the Registration
Rights Agreement, among other things, the Sponsor Holders and the enGene Holders will be granted certain customary registration rights with respect to their respective equity securities of New enGene, in each case, on the terms and subject to the
conditions therein. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Subscription Agreements relating to the PIPE, FEAC (or subject to and in accordance with the
Assumption, New enGene) agreed that, as soon as practicable, but in no event later than 15 business days after the Closing Date, it shall use its commercially reasonable efforts to file with the SEC a registration statement (the &#147;Registration
Statement&#148;) registering the resale of the Subscribed Shares (as defined in the Subscription Agreements) and/or any other equity security (of FEAC, any successor entity or otherwise) issued or issuable with respect to the Subscribed Shares by
way of share split, dividend, distribution, recapitalization, merger, exchange, replacement or similar event or otherwise, and FEAC shall use its commercially reasonable efforts to have the Registration Statement declared effective as soon as
practicable after the filing thereof, but no later than the 60<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> calendar day (or 90<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> calendar day if the Staff of the SEC notifies FEAC that
it will &#147;review&#148; the Registration Statement) following the Closing Date. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently with the execution and delivery of
the Business Combination Agreement, FEAC, New enGene, enGene, the directors of enGene and certain shareholders of enGene (collectively, other than FEAC, the &#147;enGene Parties&#148;) entered into voting agreements (the &#147;enGene Voting
Agreements&#148;) and <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements (the &#147;enGene <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements&#148;) pursuant to which the enGene Parties agreed to, among other things, (i)&nbsp;vote or
cause to be voted all of its enGene Shares in favor of the enGene Arrangement Resolution and the Transactions; (ii)&nbsp;be bound by certain other covenants and agreements related to the Business Combination and (iii)&nbsp;be bound by certain
transfer restrictions with respect to the enGene Shares and New enGene Shares, as applicable, in each case, on the terms and subject to the conditions set forth in the enGene Voting Agreements and the enGene
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, concurrently with the execution and delivery of the Business
Combination Agreement, enGene, New enGene and the Sponsor Parties entered into a voting agreement (the &#147;FEAC Voting Agreement&#148;) pursuant to which the Sponsor Parties agreed to, among other things, (i)&nbsp;vote or cause to be voted all of
its FEAC Shares in favor of the Transaction Proposals; (ii)&nbsp;be bound by certain other covenants and agreements related to the Business Combination and (iii)&nbsp;be bound by certain transfer restrictions with respect to the FEAC Shares, in each
case, on the terms and subject to the conditions set forth in the FEAC Voting Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 144 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Rule 144 under the Securities Act (&#147;Rule 144&#148;), a person who has beneficially owned restricted common shares or warrants
of New enGene for at least six months would be entitled to sell their securities </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">391 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
provided that (i)&nbsp;such person is not deemed to have been one of New enGene&#146;s affiliates at the time of, or at any time during the three months preceding, a sale and (ii)&nbsp;New enGene
is subject to the Exchange Act periodic reporting requirements for at least three months before the sale and have filed all required reports under Section&nbsp;13 or 15(d) of the Exchange Act during the 12 months (or such shorter period as New
enGene is required to file reports) preceding the sale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Persons who have beneficially owned restricted common shares or warrants of New
enGene for at least six months but who are New enGene&#146;s affiliates at the time of, or at any time during the three months preceding a sale, would be subject to additional restrictions, by which such person would be entitled to sell within any
three-month period only a number of securities that does not exceed the greater of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1% of the total number of New enGene Shares then outstanding (as of the date of this proxy statement/prospectus,
FEAC has 12,650,000 Class A ordinary shares, no par value, and 3,162,500 Class&nbsp;B ordinary shares, no par value, issued and outstanding); or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the average weekly reported trading volume of New enGene Shares during the four calendar weeks preceding the
filing of a notice on Form 144 with respect to the sale. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales by New enGene&#146;s affiliates under Rule 144 are also
limited by manner of sale provisions and notice requirements and by the availability of current public information about us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Restrictions on the Use
of Rule 144 by Shell Companies or Former Shell Companies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Rule 144 is not available for the resale of securities initially issued by
shell companies (other than business-combination related shell companies) or issuers that have been at any time previously a shell company. However, Rule 144 also includes an important exception to this prohibition if the following conditions are
met: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the issuer of the securities that was formerly a shell company has ceased to be a shell company;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the issuer of the securities is subject to the reporting requirements of Section&nbsp;13 or 15(d) of the Exchange
Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the issuer of the securities has filed all Exchange Act reports and material required to be filed, as applicable,
during the preceding 12 months (or such shorter period that the issuer was required to file such reports and materials) other than Form <FONT STYLE="white-space:nowrap">8-K</FONT> reports; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at least one year has elapsed from the time that the issuer filed current Form
<FONT STYLE="white-space:nowrap">10-type</FONT> information with the SEC reflecting its status as an entity that is not a shell company. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, New enGene&#146;s initial shareholders will be able to sell their founder shares, private placement shares and private placement
warrants, as applicable, pursuant to Rule 144 without registration one year after New enGene has completed its initial business combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the Closing, FEAC will no longer be a shell company, and so, once the conditions listed above are satisfied, Rule 144 will become
available for the resale of the above-noted restricted securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">392 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom459793_38"></A>CANADIAN SECURITIES LAW MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Distribution and Resale of New enGene Shares and New enGene Warrants Received in the Transaction and New enGene Shares underlying New enGene Warrants under
Canadian Securities Laws </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The New enGene Shares and New enGene Warrants issued in connection with the consummation of the Transactions,
and the New enGene Shares issued upon the exercise of the New enGene Warrants in accordance with the terms and conditions thereof, will not be legended and may be resold through registered dealers in each of the provinces and territories of Canada,
provided that: (i)&nbsp;the trade is not a &#147;control distribution&#148; (as defined in National Instrument <FONT STYLE="white-space:nowrap">45-102</FONT> &#151; <I>Resale of Securities of the Canadian Securities Administrators</I>); (ii) no
unusual effort is made to prepare the market or create a demand for those securities; (iii)&nbsp;no extraordinary commission or consideration is paid in respect of that trade; (iv)&nbsp;if the selling securityholder is an insider or officer of New
enGene (as defined under applicable Canadian securities legislation), the insider or officer has no reasonable grounds to believe that New enGene is in default of applicable Canadian securities legislation; and (v)&nbsp;New enGene is and has been a
reporting issuer in a jurisdiction of Canada for the four months immediately preceding the trade (subject to the abridgment of such four month period upon New enGene becoming a reporting issuer in a jurisdiction of Canada after the Closing and being
a reporting issuer at the time of the trade). New enGene is expected to become a reporting issuer in the province of Quebec by filing a <FONT STYLE="white-space:nowrap">non-offering</FONT> prospectus therein. Each New enGene securityholder is urged
to consult the holder&#146;s professional advisors with respect to restrictions applicable to trades in New enGene Shares (including New enGene Shares underlying New enGene Warrants) and New enGene Warrants under applicable Canadian securities
legislation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Ongoing Canadian Reporting Obligations of New enGene </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following Closing, New enGene is expected to become a reporting issuer in the province of Quebec by filing a
<FONT STYLE="white-space:nowrap">non-offering</FONT> prospectus therein and as a result, will be subject to Canadian continuous disclosure and other reporting obligations under applicable Canadian securities laws in the province of Quebec. Among
these reporting obligations is the requirement that its reporting insiders file reports with respect to, among other things, their beneficial ownership of, or control or direction over, securities of New enGene and their interests in, and rights and
obligations associated with, related financial instruments. New enGene will be an &#147;SEC issuer&#148; (as such term is defined under Canadian securities laws) and, therefore, in certain instances, may rely on available exemptions to satisfy its
Canadian continuous disclosure and other reporting obligations by filing in Canada its periodic and current reports filed with the SEC, but New enGene will not be a foreign issuer under applicable Canadian securities law and, therefore, will not be
entitled to additional exemptions available to foreign issuers under Canadian securities laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">393 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom459793_39"></A>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
OF ENGENE </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding the beneficial ownership of enGene Shares as of August&nbsp;11, 2023, for each of:
</P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each person who is known to enGene to be the beneficial owner of more than 5% of the outstanding shares of any
class of shares of enGene; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the current named executive officers and directors of enGene; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the current executive officers and directors of enGene as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, enGene believes that all persons named in the table have sole voting and investment power with respect to all
shares beneficially owned by them. Except as otherwise noted herein, the number and percentage of enGene Shares beneficially owned is determined in accordance with Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> of the Exchange Act, and the
information is not necessarily indicative of beneficial ownership for any other purpose. Under such rule, a person is deemed to be a beneficial owner of a security if that person has sole or shared voting power, which includes the power to vote or
to direct the voting of the security, or investment power, which includes the power to dispose of or to direct the disposition of the security. In determining beneficial ownership percentages, enGene deems shares that a person has the right to
acquire, including the enGene Shares issuable pursuant to derivative securities that are currently exercisable or exercisable within 60 days of May&nbsp;31, 2023, if any, to be outstanding and to be beneficially owned by the person with such right
to acquire additional enGene Shares for the purposes of computing the percentage ownership of that person (including in the total when calculating the applicable beneficial owner&#146;s percentage of ownership), but we do not treat them as
outstanding for the purpose of computing the percentage ownership of any other person. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The calculation of the percentage of
beneficial ownership of enGene Shares is presented prior to the Business Combination, and is based on enGene having issued and outstanding as of August&nbsp;11, 2023, 3,524,045&nbsp;enGene Common Shares, 1,477,715 enGene Class&nbsp;A Preferred
Shares, 864,570 enGene Class&nbsp;B Preferred Shares, and 30,810,114 enGene Class&nbsp;C Preferred Shares. The presentation of enGene beneficial ownership excludes the impact of (i)&nbsp;issued and outstanding warrants for the acquisition of enGene
Class&nbsp;C Preferred Shares, which are expected to be canceled and no longer outstanding immediately prior to (but conditioned upon) the consummation of the Business Combination, (ii)&nbsp;outstanding promissory notes of enGene that are
convertible into enGene Common Shares upon the happening of certain events (none of which are expected by enGene management to occur prior to the consummation of the Business Combination), and which will convert into 35,338,500 enGene Common Shares
immediately prior to, and contingent upon, the consummation of the Business Combination, (iii)&nbsp;issued and outstanding warrants for the acquisition of approximately 14,841,640 enGene Common Shares issued to investors in the enGene Convertible
Notes, which are not exercisable until after the closing of the Business Combination, (iv)&nbsp;361,852 issued and outstanding <FONT STYLE="white-space:nowrap">non-voting</FONT> enGene Common Shares of enGene that will be exchanged for voting Common
Shares of New enGene in connection with the consummation of the Business Combination, and (v)&nbsp;options granted under the enGene Equity Plan, all of which are exercisable for non-voting enGene Common Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The enGene Board, acting as the committee under the enGene Equity Plan, has determined that all options to acquire enGene Common Shares issued
under the enGene Equity Plan in respect of shares issued or authorized to be issued under such plan as of May&nbsp;16, 2023, will accelerate and become vested and exercisable (if not previously vested and exercisable) as of immediately prior to the
consummation of the Business Combination. In July 2023, the enGene Board authorized the grant to enGene employees of options to acquire an additional 5.8 million non-voting enGene Common Shares, which options will vest according to their respective
terms, subject to the additional requirement that the Business Combination is consummated and a registration statement on Form S-8 is filed with the SEC in respect of the New enGene Shares underlying such granted options (after giving effect to the
Business Combination) and becomes effective. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">394 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Security ownership of certain beneficial owners of enGene </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Title of Class</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name and Address of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent&nbsp;of&nbsp;class</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>enGene Common</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10K Lakes Fund II LP (1)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,523,809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>enGene Class&nbsp;A Preferred</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>396419 B.C. Ltd and affiliate (2)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">963,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Epic Ventures Inc. (3)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80,139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Scott Hawthorn (4)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80,139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>enGene Class&nbsp;B Preferred</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10K Lakes Fund II LP (1)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">864,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>enGene Class&nbsp;C Preferred</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Lumira Ventures III, L.P. and affiliates (5)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,423,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Forbion Capital Fund III Co&ouml;perarief U.A. (6)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,695,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Fonds de Solidarit&eacute; des Travailleurs du Qu&eacute;bec (7)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,691,901</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Security ownership of management of enGene </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>enGene</B><br><B>Common Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>enGene Class&nbsp;A</B><br><B>Preferred Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>enGene Class&nbsp;B</B><br><B>Preferred Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>enGene Class&nbsp;C</B><br><B>Preferred Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and Address<BR>of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B><br><B>of shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B><br><B>of class</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number<BR>of shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B><br><B>of class</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B><br><B>of&nbsp;shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent<BR>of class</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B><br><B>of shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B><br><B>of class</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jason D. Hanson (8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp; </TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp; </TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Anthony&nbsp;T.&nbsp;Cheung&nbsp;(8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">162,507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">114,164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;James&nbsp;C. Sullivan (8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp; </TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp; </TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marco Boorsma (9)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,695,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Gerry Brunk (10)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,423,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Richard Glickman (8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">136,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dennis Langer M.D., J.D.&nbsp;(8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp; </TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>enGene directors and executive officers as a group (9 persons)</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">457,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">114,164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,118,213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Less than 1%. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, the business address of each person named below is c/o enGene Inc., 7171 Rue Frederick Banting, Saint-Laurent,
QC&nbsp;H4S&nbsp;1Z9, Canada. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">10K Lakes Fund II LP is controlled by its general partner, 10K Lakes Management II, LLC. 10K Lakes Management
II, LLC is managed by 10K Lakes Capital, LLC. 10K Lakes Capital, LLC is managed by its members, none of which is deemed a beneficial owner of enGene Shares held by 10K Lakes Fund II LP based on the commonly referred-to &#147;rule of three.&#148; 10K
Lakes Management II, LLC and 10K Lakes Capital, LLC may be deemed to beneficially own the shares held by 10K Lakes Fund II LP, but each disclaims beneficial ownership except to the extent of its respective pecuniary interests therein, if any.
</P></TD></TR></TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 850,052 shares held by 396419 B.C. Ltd (&#147;B.C. Ltd.&#148;) and 113,307 shares held by Mr. Paul
Erickson. Mr. Erickson and his spouse are the sole owners of B.C. Ltd. and may be deemed to have investment and/or voting power over the shares held by B.C. Ltd. The business address of B.C. Ltd is 2157 Crescent Road, Victoria, British Columbia,
Canada VSB&nbsp;1A4. </P></TD></TR></TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr. Peter Barrang is the sole shareholder and the President of Epic Ventures Inc. Mr.&nbsp;Barrang and his
spouse, together with other members of Mr. Barrang&#146;s extended family, comprise the board of directors of Epic Ventures Inc. Mr.&nbsp;Barrang and his spouse may be deemed to have investment and/or voting power over the shares held by Epic
Ventures Inc. The business address of Epic Ventures Inc. is 10217 Surfside Place, Sidney, B.C. V8L 3R6 Canada. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">395 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The business address of Mr. Hawthorn is 46 Water Street, Vancouver, British Columbia, Canada V8S 2H4.
</P></TD></TR></TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 5,918,132 shares held by Lumira Ventures III, L.P. (&#147;Lumira III&#148;), 196,928 shares held by
Lumira Ventures III (International), L.P. (&#147;Lumira III Int&#146;l&#148;), 1,412,616 shares held by Lumira Ventures IV, L.P. (&#147;Lumira IV&#148;), 339,562 shares held by Lumira Ventures IV (International), L.P. (&#147;Lumira IV
Int&#146;l&#148;), 3,989,393 shares held by Merck Lumira Biosciences Fund, L.P. (&#147;Merck-Lumira&#148;), and 566,444 shares held by Merck Lumira Biosciences Fund (Qu&#233;bec), L.P. (&#147;Merck-Lumira B&#148; and, together with Lumira&nbsp;III,
Lumira III Int&#146;l, and Merck-Lumira, the &#147;Lumira entities&#148;). Lumira III and Lumira III Int&#146;l are controlled by their general partner, Lumira Ventures III GP, L.P., and managed by Lumira Capital Investment Management Inc.
(&#147;Lumira Mgmt&#148;). Lumira Ventures III GP, L.P. is controlled by its general partners, Lumira III GP Inc. and Lumira III GP Holdings Co. Lumira IV and Lumira IV Int&#146;l are controlled by their general partner, Lumira IV GP 2020 Inc., and
managed by Lumira Mgmt. Merck-Lumira and Merck-Lumira B are controlled by their general partner, Lumira Capital GP, L.P., and managed by Lumira Mgmt. Lumira Capital GP, L.P. is controlled by its general partners, Lumira GP Inc. and Lumira GP
Holdings Co. Mr. Brunk is an executive officer of each of Lumira III Inc., Lumira III GP Holdings Co., Lumira IV GP 2020 Inc., Lumira GP Inc., Lumira GP Holdings Co. and Lumira Mgmt. Each of Lumira III Inc., Lumira III GP Holdings Co., Lumira IV GP
2020 Inc., Lumira GP Inc., Lumira GP Holdings Co., Lumira Mgmt and Mr. Brunk may be deemed to beneficially own the shares held by the respective Lumira entities, but each disclaims beneficial ownership except to the extent of their respective
pecuniary interests therein, if any. The business address of Merck-Lumira and Merck-Lumira B is 141 Adelaide Street West, Suite 770, Toronto, Ontario, Canada M5H 3L5. The business address of the other Lumira entities is c/o 303 Wyman Street, Suite
300, Waltham, MA 02451. </P></TD></TR></TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Forbion III Management B.V. (&#147;Forbion III&#148;) is the director, and Forbion Capital Fund III C.V.
(&#147;FCF&nbsp;III&#148;) is the sole member, of Forbion Capital Fund III Co&ouml;peratief U.A. (&#147;Forbion III COOP&#148;). Forbion&nbsp;III has voting and investment power over the shares held by Forbion III COOP. Such voting and investment
power are exercised by Forbion III through its investment committee, consisting of H. A. Slootweg, M. A. van Osch, G. J. Mulder, H.N. Reithinger, M. Boorsma and S.&nbsp;J.&nbsp;H. van Deventer. None of the members of the investment committee have
individual voting and investment power with respect to such shares, and the members of the investment committee, including M. Boorsma, who is a director of enGene, disclaim beneficial ownership of such shares except to the extent of their
proportionate pecuniary interests therein. Forbion III COOP disclaims any affiliation with FEAC, Sponsor, or any of FEAC&#146;s or Sponsor&#146;s direct or indirect directors, officers or other affiliates. The business address of Forbion III COOP
and Forbion III is Gooimeer 2-35, 1411 DC Naarden, The Netherlands. </P></TD></TR></TABLE>  <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fonds de solidarit&#233; des travailleurs du Qu&#233;bec (the &#147;Fonds&#148;) is managed by a 19-member
board of directors, which is majority independent and includes Mr. Claude S&#233;guin, the chair of the board, and Ms. Janie C. B&#233;&iuml;que, who is also the President and Chief Executive Officer of the Fonds. Investment power over the enGene
shares held by the Fonds is exercised either by its board of directors or by a 9-member investment committee of the Fonds&#146; board of directors, which is majority independent and includes Pierre-Maurice Vachon, who is also a President of the
Fonds, and Magali Picard, who is also first vice-chair of the board. None of the members of the Fonds&#146; board of directors or investment committee have individual voting or investment power over the enGene shares held by the Fonds. Mr.
S&#233;guin, Ms. B&#233;&iuml;que, Mr. Vachon and Ms.&nbsp;Picard each disclaim beneficial ownership of such shares except to the extent of their pecuniary interests therein. The business address of FSTQ is 545 Cr&#233;mazie Blvd. East, Suite 200,
Montr&#233;al, Qu&#233;bec, Canada H2M 2W4. </P></TD></TR></TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As of August&nbsp;11, 2023, Mr.&nbsp;Hanson is the holder of options to acquire 6,739,079 non-voting enGene
Common Shares, Dr. Cheung is the holder of options to acquire 2,690,135 non-voting enGene Common Shares, Dr.&nbsp;Sullivan is the holder of options to acquire 1,149,219 non-voting enGene Common Shares, Dr.&nbsp;Glickman is the holder of options to
acquire 365,062 non-voting enGene Common Shares and Mr. Langer is the holder of options to acquire 308,975 non-voting enGene Common Shares, which non-voting shares are not represented in the above table. Upon consummation of the Business
Combination, such options will accelerate and be fully vested and exercisable (to the extent not previously vested and exercisable) and will be assumed by New enGene and represent the right to acquire New enGene Shares (which will be voting shares).
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">396 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of enGene Shares held by Forbion III COOP. See footnote (6) above. Dr. Boorsma is a member of the
investment committee of Forbion. Dr. Boorsma disclaims beneficial ownership of the enGene Shares held by Forbion COOP, except to the extent of his pecuniary interest therein, if any. </P></TD></TR></TABLE>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of enGene Shares held by the Lumira entities. See footnote (5) above. Dr. Brunk is an executive
officer of certain entities controlling and/or managing the Lumira entities. Dr. Brunk disclaims beneficial ownership of the enGene Shares held by the Lumira entities, except to the extent of his pecuniary interest therein, if any.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">397 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom459793_40"></A>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
OF FEAC </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding the actual beneficial ownership of FEAC Shares as of August 11,
2023, prior to the consummation of the Business Combination, by: </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each person who is known to us to be the beneficial owner of more than 5% of our issued and outstanding FEAC
Shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our current named executive officers and directors; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all of our current executive officers and directors as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined according to the rules of the SEC, which generally provide that a person has beneficial ownership of a
security if they possess sole or shared voting or investment power over that security, and includes shares underlying options that are currently exercisable or exercisable within 60 days. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, FEAC believes that all persons named in the table below have, or may be deemed to have, sole voting and investment
power with respect to all FEAC Shares beneficially owned by them. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and Address of Beneficial Owner<SUP
STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of FEAC Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage&nbsp;of<BR>FEAC&nbsp;Shares<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;B<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;A</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>FEAC Officers, Directors and Five Percent (5%) or Greater Holders <FONT
STYLE="white-space:nowrap">Pre-Business</FONT> Combination</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forbion Growth Sponsor FEAC I B.V.
(Sponsor)<SUP STYLE="font-size:75%; vertical-align:top">(4)(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,162,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forbion Growth Opportunities Fund I Cooperatief U.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Citadel<SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,075,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Highbridge<SUP STYLE="font-size:75%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">893,152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jasper Bos</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cyril Lesser</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sander Slootweg</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wouter Joustra</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Philip Astley-Sparke</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hilde Steineger</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ton Logtenberg</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>All FEAC officers and directors as a group (7&nbsp;individuals)</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Less than 1%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unless otherwise noted, the business address of each of FEAC&#146;s Shareholders is 4001 Kennett Pike,
Suite&nbsp;302 Wilmington, Delaware 19807. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Interests shown consist solely of FEAC Class&nbsp;B Shares. Such FEAC Class&nbsp;B Shares will be exchanged for
FEAC Class&nbsp;A Shares on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-to-one</FONT></FONT> basis at the time of FEAC&#146;s initial business combination or earlier at the option of the holders thereof. Excludes forward
purchase shares that will only be issued, if at all, at the time of FEAC&#146;s initial business combination. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The percentages reported herein are based upon 15,812,500 of FEAC Shares outstanding as of August&nbsp;11,
2023, which is the sum of 12,650,000 FEAC Class&nbsp;A Shares and 3,162,500 FEAC Class&nbsp;B Shares (which will be exchanged for FEAC Class&nbsp;A Shares at the time of FEAC&#146;s initial business combination or earlier at the option of the
holders thereof, and exclude forward-purchase shares that will only be issued, if at all, at the time of FEAC&#146;s initial business combination. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Forbion Growth Sponsor FEAC I B.V., FEAC&#146;s Sponsor, is the record holder of the FEAC Class&nbsp;B Shares
reported herein. Jasper Bos, Cyril Lesser, Sander Slootweg and Wouter Joustra, who are directors of the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">398 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Sponsor, have voting and investment discretion with respect to the FEAC Shares owned by the Sponsor and may be deemed to have indirect shared beneficial ownership of the FEAC Shares owned by the
Sponsor. Jasper Bos, Cyril Lesser, Sander Slootweg and Wouter Joustra each disclaim beneficial ownership over the FEAC Class&nbsp;B Shares except to the extent of their pecuniary interest therein. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Forbion Growth Opportunities Fund I Cooperatief U.A. (&#147;FGOF&#148;) wholly owns the Sponsor and therefore
the Sponsor and FGOF have shared voting and investment power over the FEAC Class&nbsp;B Shares held by the Sponsor. Together with the 2,000,000 FEAC Class&nbsp;A Shares underlying the 2,000,000 FEAC Units held by it, FGOF has shared voting and
investment power over 5,162,500 FEAC Shares in the aggregate, representing approximately 32.7% of issued and outstanding FEAC Shares as of March&nbsp;31, 2023. Forbion Growth Management B.V. (&#147;Forbion Management&#148;) is the sole director of
FGOF and therefore shares voting and investment power (i)&nbsp;with FGOF over the 2,000,000 FEAC Class&nbsp;A Shares underlying the FEAC Units held by FGOF and (ii)&nbsp;with FGOF and, indirectly, the Sponsor, over the 3,162,500 FEAC Class&nbsp;B
Shares held by the Sponsor. Forbion Management exercises voting and investment power through its investment committee (the &#147;Investment Committee&#148;) consisting of Sander Slootweg, Martien van Osch,
<FONT STYLE="white-space:nowrap">Geert-Jan</FONT> Mulder, Vincent van Houten, Dirk Kersten, Nanna L&uuml;neborg, Wouter Joustra and Jasper Bos. None of the members of the Investment Committee has individual voting and investment power with respect
to the FEAC Shares, and each such member disclaims beneficial ownership of the FEAC Shares except to the extent of his or her proportionate pecuniary interest therein. FGOF, the Sponsor, Forbion Management and such members of the Investment
Committee each disclaims any affiliation with Forbion III and its directors, officers or other affiliates. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on information reported on a Schedule 13G/A filed on February&nbsp;14, 2023 by Citadel Advisors LLC
(&#147;Citadel Advisors&#148;), Citadel Advisors Holdings LP (&#147;CAH&#148;), Citadel GP LLC (&#147;CGP&#148;), Citadel Securities LLC (&#147;Citadel Securities&#148;), Citadel Securities Group LP (&#147;CALC4&#148;), Citadel Securities GP LLC
(&#147;CSGP&#148;) and Mr.&nbsp;Kenneth Griffin with respect to the FEAC Class&nbsp;A Shares owned by Citadel Multi-Strategy Equities Master Fund Ltd., a Cayman Islands company (&#147;CM&#148;), and Citadel Securities. Citadel Advisors is the
portfolio manager for CM. CAH is the sole member of Citadel Advisors. CGP is the general partner of CAH. CALC4 is the <FONT STYLE="white-space:nowrap">non-member</FONT> manager of Citadel Securities. CSGP is the general partner of CALC4.
Mr.&nbsp;Griffin is the President and Chief Executive Officer of CGP, and owns a controlling interest in CGP and CSGP. Each of Citadel Advisors, CAH and CGP may be deemed to beneficially own 1,075,000 shares. Citadel Securities may be deemed to
beneficially own 58 shares. Each of CALC4 and CSGP may be deemed to beneficially own 58 shares. Mr.&nbsp;Griffin may be deemed to beneficially own 1,075,058 shares. Each of Citadel Advisors, CGP, Citadel Securities and CSGP is organized as a limited
liability company under the laws of the State of Delaware. Each of CALC4 and CAH is organized as a limited partnership under the laws of the State of Delaware. Mr.&nbsp;Griffin is a U.S. citizen. The address of each of such persons and entities is
Southeast Financial Center, 200 S. Biscayne Blvd., Suite 3300, Miami, Florida 33131. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on information reported on a Schedule 13G filed on February&nbsp;2, 2023 by Highbridge Capital
Management, LLC, a Delaware limited liability company (&#147;Highbridge&#148;), Highbridge is the investment adviser to certain funds and accounts (the &#147;Highbridge Funds&#148;) with respect to the FEAC Class&nbsp;A Shares directly held by the
Highbridge Funds. The address of the business office of Highbridge is 277 Park Avenue, 23rd Floor, New York, New York 10172. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Underwriting Fees as a Percentage of Amount in Trust Net of Redemptions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding the effective underwriting fee payable to the underwriters of FEAC&#146;s IPO upon
completion of the Business Combination under the following scenarios: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">No Redemption Scenario: assumes that no holder of FEAC Class&nbsp;A Shares exercises redemption rights to have
its FEAC Class&nbsp;A Shares converted into their pro rata share of the Trust Account; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Maximum Redemption Scenario: assumes that 10,483,335 FEAC Class&nbsp;A Shares are redeemed, resulting in an
aggregate cash payment of approximately $112.5&nbsp;million out of the Trust Account based on an assumed redemption price of $10.73 per share that is calculated using the $135.8 million cash in the Trust Account as at June 30, 2023, divided by
12,650,000 FEAC Class A Shares subject to </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">399 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
redemption assuming the pro forma maximum redemptions scenario pursuant to the Business Combination Agreement. The number of FEAC Class&nbsp;A Shares that are redeemed in this scenario is derived
by reducing the total of 12,650,000 FEAC Class&nbsp;A Shares outstanding by 2,000,000, FEAC Class&nbsp;A Shares held by the Sponsor that are subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements and 166,665 FEAC Class&nbsp;A Shares
held by a FEAC Shareholder that are subject to a <FONT STYLE="white-space:nowrap">non-redemption</FONT> agreement. </P></TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>No Redemption<BR>scenario</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Maximum<BR>Redemption<BR>scenario</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IPO underwriting fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,727,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,727,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amount in Trust Account net of redemptions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$<BR></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">135,786,170<BR></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,299,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting fees as a % of Amount in Trust Account net of redemptions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.75</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">400 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom459793_41"></A>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AND MANAGEMENT OF NEW ENGENE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding the expected beneficial ownership of New enGene Shares immediately following consummation
of the PIPE and the Business Combination, assuming that no FEAC Class A Shares are redeemed, and alternatively that the maximum number of FEAC Class A Shares are redeemed, by: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each person who is expected to be the beneficial owner of more than 5% of New enGene Shares upon giving effect to
the proposed Business Combination; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each person who is expected to be a named executive officer or director of New enGene upon giving effect to the
proposed Business Combination; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the persons expected to be executive officers and directors of New enGene upon giving effect to the proposed
Business Combination, as a group. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, we believe that all persons named in the below table will
have sole voting and investment power with respect to all New enGene Shares beneficially owned by them. Except as otherwise noted herein, the number and percentage of New enGene Shares beneficially owned is determined in accordance with Rule 13d-3
of the Exchange Act, and the information is not necessarily indicative of beneficial ownership for any other purpose. Under such rule, a person is deemed to be a beneficial owner of a security if that person has sole or shared voting power, which
includes the power to vote or to direct the voting of the security, or investment power, which includes the power to dispose of or to direct the disposition of the security. In determining beneficial ownership percentages, we deem shares that a
person will have the right to acquire within 60 days following the date of the proposed Business Combination, if any, to be outstanding and to be beneficially owned by the person with such right to acquire additional New enGene Shares for the
purposes of computing the percentage ownership of that person (including in the total when calculating the applicable beneficial owner&#146;s percentage of ownership), but we do not treat them as outstanding for the purpose of computing the
percentage ownership of any other person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The calculation of the percentage of beneficial ownership of New enGene Shares is based on the
following assumptions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prior surrender by Sponsor of 1,789,004 FEAC Class B Shares pursuant to the Sponsor and Insiders Letter
Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an estimated enGene Exchange Ratio of approximately 0.1805 and an estimated enGene Per Share Value of
approximately $1.85; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that all options issued or available to be issued under the enGene Equity Plan that remain outstanding as of the
Closing Date are exercisable within 60 days following the Closing Date (notwithstanding that no registration statement on Form S-8 will be available during such 60-day period to allow for any such exercise and notwithstanding any applicable exercise
blackout periods that may apply in respect of such 60-day period); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no new or additional grants of options for the purchase of enGene shares to any of the current executive officers
or directors of enGene appearing in the table below after August&nbsp;11, 2023 and prior to the consummation of the Business Combination; </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no separation of employment or association with enGene by any of the executive officers or directors of enGene
appearing in the table below prior to the consummation of the Business Combination; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all outstanding convertible promissory notes of enGene will convert into 6,379,822 New enGene Shares upon the
consummation of the Business Combination. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">401 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The presentation of New enGene beneficial ownership excludes the impact of warrants for the
acquisition of New enGene Shares that will be issued in connection with the consummation of the Business Combination, all of which will be exercisable 30 days following the consummation of the Business Combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The &#147;Maximum Redemption Scenario&#148; presented in the table below takes into account a non-redemption agreement provided by a FEAC
shareholder for the benefit of FEAC and enGene whereby such FEAC shareholder agreed not to redeem 166,665 FEAC Class A Shares in connection with the approval of the Business Combination by the shareholders of FEAC. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>No<BR>Redemption<BR>Scenario</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Maximum<BR>Redemption<BR>Scenario</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and Address of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent<BR>of class</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent<BR>of class</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>New enGene greater than 5% holders</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forbion Growth (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,765,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lumira Ventures III, L.P. and affiliates (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,049,984</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forbion Capital Fund III Co&#246;perarief U.A. (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,894,735</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fonds de Solidarit&#233; des Travailleurs du Qu&#233;bec (4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,642,590</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Biotechnology Value Fund, L.P. and affiliates (5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,251,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>New enGene directors and named executive officers</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jason D. Hanson (6)<I></I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,216,638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dr. Anthony T. Cheung (7)<I></I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">538,946</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dr. James C. Sullivan (6)<I></I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">207,474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dr. Gerry Brunk (8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,049,984</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jasper Bos (9)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dr. Richard Glickman (6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>New enGene directors and executive officers as a group (8 persons)</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I></I>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I></I>2,308,908</TD>
<TD NOWRAP VALIGN="bottom"><I></I>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Less than 1%. </P></TD></TR></TABLE>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, the address of each person named below is c/o enGene Holdings Inc., 7171 Rue Frederick Banting, Saint-Laurent, QC
H4S 1Z9, Canada. </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Forbion Growth Sponsor FEAC I B.V., or Sponsor, will be the record holder of 3,765,932 of the New enGene Shares
reported herein. Forbion Growth Opportunities Fund I Cooperatief U.A. (&#147;FGOF&#148;) will be the record holder of the remaining 2,000,000 New enGene Shares reported herein. FGOF wholly owns the Sponsor and therefore the Sponsor and FGOF have
shared voting and investment power over the New enGene Shares held by the Sponsor. Forbion Growth Management B.V. (&#147;Forbion Management&#148;) is the sole director of FGOF and therefore shares voting and investment power (i) with FGOF over the
New enGene Shares that will be held by FGOF and (ii) with FGOF and, indirectly, the Sponsor, over the New enGene Shares that will be held by the Sponsor. Forbion Management exercises voting and investment power through its investment committee (the
&#147;Investment Committee&#148;) consisting of Sander Slootweg, Martien van Osch, Geert-Jan Mulder, Vincent van Houten, Dirk Kersten, Nanna L&uuml;neborg, Wouter Joustra and Jasper Bos. None of the members of the Investment Committee has individual
voting and investment power with respect to the FEAC Shares, and each such member disclaims beneficial ownership of the FEAC Shares except to the extent of his or her proportionate pecuniary interest therein. Jasper Bos, Cyril Lesser, Sander
Slootweg and Wouter Joustra, who are directors of the Sponsor, have voting and investment discretion with respect to the New enGene Shares owned by the Sponsor and may be deemed to have indirect shared beneficial ownership of the New enGene Shares
owned by the Sponsor. Jasper Bos, Cyril Lesser, Sander Slootweg and Wouter Joustra each disclaim beneficial ownership over the New enGene Shares except to the extent of their pecuniary interest therein. FGOF, Sponsor, Forbion Management and such
members of the Investment Committee each disclaims any affiliation with Forbion III and its directors, officers or other affiliates. The business address of the above-named Forbion persons is c/o Forbion, Gooimeer 2-35, 1411 DC Naarden, The
Netherlands. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">402 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 1,342,114&nbsp;shares that will be held by Lumira Ventures III, L.P. (&#147;Lumira III&#148;),
44,658 shares that will be held by Lumira Ventures III (International), L.P. (&#147;Lumira III Int&#146;l&#148;), 348,764 shares that will be held by Lumira Ventures IV, L.P. (&#147;Lumira IV&#148;), 88,835 shares that will be held by Lumira
Ventures IV (International), L.P. (&#147;Lumira IV Int&#146;l&#148;), 1,077,608 shares that will be held by Merck Lumira Biosciences Fund, L.P. (&#147;Merck-Lumira&#148;), and 153,005 shares that will be held by Merck Lumira Biosciences Fund
(Qu&eacute;bec), L.P. (&#147;Merck-Lumira B&#148; and, together with Lumira III, Lumira III Int&#146;l, and Merck-Lumira, the &#147;Lumira entities&#148;). Lumira III and Lumira III Int&#146;l are controlled by their general partner, Lumira Ventures
III GP, L.P., and managed by Lumira Capital Investment Management Inc. (&#147;Lumira Mgmt&#148;). Lumira Ventures III GP, L.P. is controlled by its general partners, Lumira III GP Inc. and Lumira III GP Holdings Co. Lumira IV and Lumira IV
Int&#146;l are controlled by their general partner, Lumira IV GP 2020 Inc., and managed by Lumira Mgmt. Merck-Lumira and Merck-Lumira B are controlled by their general partner, Lumira Capital GP, L.P., and managed by Lumira Mgmt. Lumira Capital GP,
L.P. is controlled by its general partners, Lumira GP Inc. and Lumira GP Holdings Co. Mr. Brunk is an executive officer of each of Lumira III Inc., Lumira III GP Holdings Co., Lumira IV GP 2020 Inc., Lumira GP Inc., Lumira GP Holdings Co. and Lumira
Mgmt. Each of Lumira III Inc., Lumira III GP Holdings Co., Lumira IV GP 2020 Inc., Lumira GP Inc., Lumira GP Holdings Co., Lumira Mgmt and Mr. Brunk may be deemed to beneficially own the shares held by the respective Lumira entities, but each
disclaims beneficial ownership except to the extent of their respective pecuniary interests therein, if any. The business address of Merck-Lumira and Merck-Lumira B is 141 Adelaide Street West, Suite 770, Toronto, Ontario, Canada M5H 3L5. The
business address of the other Lumira entities is c/o 303 Wyman Street, Suite 300, Waltham, MA 02451. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Forbion III Management B.V. (&#147;Forbion III&#148;) is the director of Forbion Capital Fund III
Co&ouml;peratief U.A. (&#147;Forbion III COOP&#148;) with voting and investment power over the shares that will be held by Forbion III COOP. Such voting and investment power are exercised by Forbion III through its investment committee, consisting
of H. A. Slootweg, M. A. van Osch, G. J. Mulder, H.N. Reithinger, Dr. M. Boorsma and S. J. H. van Deventer. None of the members of the investment committee have individual voting and investment power with respect to such shares, and the members of
the investment committee, including Dr. Boorsma, who is currently a director of enGene, disclaim beneficial ownership of such shares except to the extent of their proportionate pecuniary interests therein. Forbion III COOP disclaims any affiliation
with FEAC, Sponsor, or any of FEAC&#146;s or Sponsor&#146;s direct or indirect directors, officers or other affiliates. The business address of Forbion III COOP and Forbion III is Gooimeer 2-35, 1411 DC Naarden, The Netherlands.
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fonds de solidarit&#233; des travailleurs du Qu&#233;bec (the &#147;Fonds&#148;) is managed by a 19-member
board of directors, which is majority independent and includes Mr. Claude S&#233;guin, the chair of the board, and Ms. Janie C. B&#233;&iuml;que, who is also the President and Chief Executive Officer of the Fonds. Investment power over the enGene
shares held by the Fonds is exercised either by its board of directors or by a 9-member investment committee of the Fonds&#146; board of directors, which is majority independent and includes Pierre-Maurice Vachon, who is also a President of the
Fonds, and Magali Picard, who is also first vice-chair of the board. None of the members of the Fonds&#146; board of directors or investment committee have individual voting or investment power over the enGene shares held by the Fonds. Mr.
S&#233;guin, Ms. B&#233;&iuml;que, Mr. Vachon and Ms.&nbsp;Picard each disclaim beneficial ownership of such shares except to the extent of their pecuniary interests therein. The business address of the Fonds is 545 Cr&eacute;mazie Blvd. East, Suite
200, Montr&eacute;al, Qu&eacute;bec, Canada H2M 2W4. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 1,204,412 New enGene Shares that will be held by Biotechnology Value Fund, L.P. (&#147;BVF&#148;),
912,776 New enGene Shares that will be held by Biotechnology Value Fund II, L.P. (&#147;BVF2&#148;), 104,257 New enGene Shares that will be held by Biotechnology Value Trading Fund OS LP (&#147;Trading Fund OS&#148;) and 29,592 New enGene Shares
that will be held by MSI BVF SPV, LLC (&#147;MSI BVF&#148;). BVF I GP LLC (&#147;BVF GP&#148;) is the general partner of BVF, and may be deemed to beneficially own the New enGene Shares held by BVF; BVF II GP LLC (&#147;BVF2 GP&#148;) is the general
partner of BVF2, and may be deemed to beneficially own the New enGene Shares held by BVF2; BVF Partners OS Ltd. (&#147;Partners OS&#148;) is the general partner of Trading Fund OS, and may be deemed to beneficially own the New enGene Shares held by
Trading Fund OS. BVF GP Holdings LLC (&#147;BVF GPH&#148;) is the sole member of each of BVF GP and BVF2 GP, and may be deemed to beneficially own the New enGene Shares beneficially owned by BVF and
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">403 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
BVF2. BVF Partners L.P. (&#147;Partners&#148;) is the investment manager of BVF, BVF2, Trading Fund OS and MSI BVF and the sole member of Partners OS, and may be deemed to beneficially own the
New enGene Shares beneficially owned by BVF, BVF2, Trading Fund OS, and MSI BVF. BVF Inc. is the general partner of Partners, and may be deemed to beneficially own the New enGene Shares beneficially owned by Partners. Mark N. Lampert is a director
and officer of BVF Inc., and may be deemed to beneficially own the New enGene Shares beneficially owned by BVF Inc. Each of BVF GP, BVF2 GP, Partners OS, BVF GPH, Partners, BVF Inc. and Mr. Lampert disclaims beneficial ownership of the shares
beneficially owned by BVF, BVF2, Trading Fund OS and MSI BVF. The business address of BVF, BVF GP, BVF2, BVF2 GP, BVF GPH, MSI BVF, Partners, BVF Inc. and Mark N. Lampert is 44 Montgomery St., 40th Floor, San Francisco, California 94104. The
business address of Trading Fund OS and Partners OS is PO Box 309 Ugland House, Grand Cayman, KY1-1104, Cayman Islands. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents options to acquire New enGene Shares (after giving effect to the assumption of outstanding options
under the enGene Option Plan that will occur upon the Closing of the Business Combination). </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 53,283 New enGene Shares and options to acquire 485,663 New enGene Shares (after giving effect to
the assumption of outstanding options under the enGene Option Plan that will occur upon the Closing of the Business Combination). </P></TD></TR></TABLE>  <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of enGene Shares held by the Lumira entities. See footnote (2) above. Dr. Brunk is an executive
officer of certain entities controlling and/or managing the Lumira entities. Dr. Brunk disclaims beneficial ownership of the enGene Shares held by the Lumira entities, except to the extent of his pecuniary interest therein, if any.
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Bos is a director of Sponsor, and a member of the investment committee of Forbion Management.
Mr.&nbsp;Bos disclaims beneficial ownership over the New enGene Shares held by Sponsor and FGOF, except to the extent of his proportionate pecuniary interest therein. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">404 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom459793_42"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FEAC </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>FEAC Class&nbsp;B Shares
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&nbsp;12, 2021, Forbion European Sponsor LLP paid $25,000, or approximately $0.009 per share, in consideration for 2,875,000
FEAC Class&nbsp;B Shares. On November&nbsp;23, 2021, Forbion European Sponsor LLP transferred 2,875,000 FEAC Class&nbsp;B Shares to the Sponsor in exchange for $25,000, or approximately $0.009 per share. On December&nbsp;9, 2021, FEAC issued an
additional 287,500 FEAC Class&nbsp;B Shares to the Sponsor resulting from a 1.1 for 1 share dividend. As a result, the Sponsor owned 3,162,500 FEAC Class&nbsp;B Shares as of the date of the Business Combination Agreement. The FEAC Class&nbsp;B
Shares will be exchanged for FEAC Class&nbsp;A Shares, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis, on the day that is two business days prior to the Closing of the Business Combination. The
number of FEAC Class&nbsp;B Shares issued was determined based on the expectation that the FEAC Class&nbsp;B Shares would represent 20% of the issued and outstanding ordinary shares of FEAC upon completion of the IPO. Such FEAC Class&nbsp;B Shares
were issued pursuant to the exemption from registration contained in Section&nbsp;4(a)(2) of the Securities Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Private Placement
Warrants </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Simultaneously with the closing of the IPO, the Sponsor purchased in a private placement 4,700,000 FEAC Private Placement
Warrants (5,195,000 FEAC Private Placement Warrants when the underwriters&#146; over-allotment option was fully exercised on December&nbsp;15, 2021), each exercisable to purchase one FEAC Class&nbsp;A Share at $11.50 per share, at a price of $1.50
per FEAC Private Placement Warrants. The sale of the FEAC Private Placement Warrants in connection with the IPO and subsequent over-allotment option exercise generated gross proceeds of $7,792,500. Except as described below, the FEAC Private
Placement Warrants have terms and provisions that are identical to those of the FEAC Warrants. The FEAC Private Placement Warrants are not transferable, assignable or salable (and the FEAC Class&nbsp;A Shares issuable upon exercise of the FEAC
Private Placement Warrants will not be transferable, assignable or salable until 30 days after the completion of the Business Combination), except pursuant to limited exceptions, and they are not redeemable by FEAC. The Sponsor, or its permitted
transferees, have the option to exercise the FEAC Private Placement Warrants on a cashless basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There will be no redemption rights or
liquidating distributions with respect to the FEAC Class&nbsp;B Shares or FEAC Private Placement Warrants. Also, the FEAC Private Placement Warrants will expire worthless if FEAC fails to consummate a business combination within the Combination
Period (as such term is defined in FEAC&#146;s IPO prospectus). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Working Capital Loans </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to finance transaction costs in connection with an intended business combination, the Sponsor or an affiliate of the Sponsor, or
certain of FEAC&#146;s officers and directors may, but are not obligated to, loan to FEAC funds as may be required (&#147;Working Capital Loans&#148;). If FEAC completes such business combination, FEAC may repay the Working Capital Loans out of the
proceeds of the Trust Account released to FEAC. Otherwise, the Working Capital Loans may be repaid only out of funds held outside the Trust Account. In the event that the business combination does not close, FEAC may use a portion of the working
capital held outside the Trust Account to repay the Working Capital Loans but no proceeds from the Trust Account would be used to repay the Working Capital Loans. Up to an aggregate amount of $1,500,000 in Working Capital Loans and Extension Loans
may be converted, at the option of the Sponsor, into additional FEAC Warrants at a price of $1.50 per warrant on terms identical to the FEAC Private Placement Warrants, concurrently with the consummation of an initial business combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;24, 2023, the Sponsor and FEAC entered into an unsecured promissory note (the &#147;First Loan Note&#148;) under which the
Sponsor agreed to extend to FEAC a Working Capital Loan of up to $900,000, to be used </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">405 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
for FEAC&#146;s general corporate purposes. The Sponsor funded the initial principal amount of $450,000 under the First Loan Note on March&nbsp;24, 2023 and an additional $450,000 under the First
Loan Note on April&nbsp;26, 2023. The First Loan Note bears no interest and will be due and payable on the earlier of (i)&nbsp;the date of consummation of FEAC&#146;s initial merger, share exchange, asset acquisition, share purchase, reorganization
or similar business combination with one or more businesses or entities (an &#147;initial business combination&#148;) and (ii)&nbsp;December&nbsp;14, 2023 (such earlier date, the &#147;Loan Note Maturity Date&#148;). If FEAC completes an initial
business combination, FEAC may repay the First Loan Note out of the proceeds of the Trust Account released to FEAC. In the event that FEAC does not consummate an initial business combination, the First Loan Note will be repaid only from amounts
remaining outside of the Trust Account, if any. Concurrently with the consummation of an initial business combination, the Sponsor will have the option, but not the obligation, to convert up to the total principal amount of the First Loan Note, in
whole or in part, into additional warrants of FEAC at a price of $1.50&nbsp;per warrant and on terms identical to the FEAC Private Placement Warrants (see also &#147;<I>The Business Combination Agreement &#151; Repayment of the Working Capital Loan
Note and Extension Loan Notes</I>&#148;). A failure to pay the principal outstanding amount of the First Loan Note within five business days following the date when due or the commencement of a voluntary or involuntary bankruptcy action of FEAC
shall be deemed an event of default, in which case the Sponsor may declare the First Loan Note due and payable immediately. The issuance of the First Loan Note was made pursuant to the exemption from registration contained in Section&nbsp;4(a)(2) of
the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;6, 2023, FEAC issued an additional unsecured promissory note (the &#147;Second Loan Note&#148;) under
which the Sponsor agreed to extend to FEAC a Working Capital Loan in the total principal amount of $300,000 to the Sponsor. The proceeds of the Second Loan Note will be used by FEAC for general corporate purposes. The Sponsor funded the principal
amount of $300,000 on June&nbsp;6, 2023. The Second Loan Note bears no interest and shall be due and payable on the Loan Note Maturity Date. If FEAC completes an initial business combination, FEAC may repay the Second Loan Note out of the proceeds
of the Trust Account released to FEAC. In the event that FEAC does not consummate an initial business combination, the Second Loan Note will be repaid only from amounts remaining outside of the Trust Account, if any. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Extension Loans; Business Combination Deadline Extension </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FEAC may extend the period of time to consummate a business combination by up to two additional three-month periods (for a total of 24 months
to complete an initial business combination). In order to extend the time available for FEAC to consummate an initial business combination, the Sponsor or its affiliates or designees must deposit into the Trust Account, for each additional
three-month period, $1,265,000 ($0.10 per FEAC Class&nbsp;A Shares in either case), on or prior to the date of the applicable deadline, the first of which was on June&nbsp;14, 2023. Any such payments would be made in the form of a <FONT
STYLE="white-space:nowrap">non-interest</FONT> bearing, unsecured promissory note (each such note, an &#147;Extension Loan&#148;). The Sponsor and its affiliates or designees are not obligated to fund the Trust Account to extend the time for FEAC to
complete an initial business combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;6, 2023, FEAC extended the time available to consummate its initial business
combination from June&nbsp;14, 2023 to September&nbsp;14, 2023 by having the Sponsor deposit an additional $1,265,000, or $0.10 per unit, into the Trust Account (the &#147;Extension Funding&#148;), in accordance with FEAC&#146;s Current Articles and
the Investment Management Trust Agreement by and between the Company and Continental Stock Transfer&nbsp;&amp; Trust Company, dated as of December&nbsp;9, 2021. In connection with the Extension Funding, on June&nbsp;6, 2023, FEAC issued an unsecured
promissory note (the &#147;Extension Note&#148;) in the total principal amount of $1,265,000 to the Sponsor. The Sponsor funded the principal amount of $1,265,000 by depositing such amount into the Trust Account on June&nbsp;6, 2023. The Extension
Note bears no interest and shall be due and payable on the Loan Note Maturity Date. In the event that FEAC does not consummate an initial business combination, the Extension Note will be repaid only from amounts remaining outside of the Trust
Account, if any. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently with the consummation of an initial business combination, the Sponsor will have the option, but not the
obligation, to convert up to $600,000 total principal amount of the Extension Note, in whole or in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">406 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
part, into additional warrants of FEAC at a price of $1.50 per warrant, each warrant exercisable for one FEAC Class&nbsp;A Share. The warrants will be identical to the FEAC Private Placement
Warrants (see also &#147;<I>The Business Combination Agreement &#151; Repayment of the Working Capital Loan Note and Extension Loan Notes</I>&#148;). A failure to pay the principal outstanding amount of the Extension Note within five business days
following the date when due or the commencement of a voluntary or involuntary bankruptcy action of FEAC shall be deemed an event of default, in which case the Sponsor may declare the Extension Note due and payable immediately. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FEAC currently intends, in accordance with its obligations under the Business Combination Agreement, to extend the time available to it to
consummate its initial business combination from September 14, 2023, to December 14, 2023, by depositing an additional $1,265,000 (or $0.10 per FEAC Class A Share) into the Trust Account on or before September 14, 2023, and the Sponsor is expected
to fund such amount in the form of an additional extension note on the same terms. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Sponsor and Insiders Letter Agreement;
Surrender; Sponsor Loans Conversion </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;16, 2023, concurrently with the execution of the Business Combination Agreement, FEAC,
the Sponsor, FGOF and the other holders of FEAC Class&nbsp;B Shares, enGene, New enGene and the other parties named therein (collectively, other than enGene and New enGene, the &#147;Sponsor Parties&#148;) entered into the Sponsor and Insiders
Letter Agreement, pursuant to which the Sponsor has agreed to surrender, after giving effect to the conversion of all or part of the principal amount outstanding under loans made by the Sponsor to FEAC into FEAC Private Placement Warrants, 1,789,004
FEAC Class&nbsp;B Shares and 5,463,381 FEAC Private Placement Warrants, as a contribution to the capital of FEAC and for no consideration, effective immediately prior to the Class&nbsp;B Conversion on the day which is two business days prior to the
Closing Date (the &#147;Surrender&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Sponsor Parties agreed to (i)&nbsp;be bound by certain other covenants and
agreements related to the Business Combination, (ii)&nbsp;waive the anti-dilution protection with respect to the FEAC Class&nbsp;B Shares (whether resulting from the PIPE Financing or otherwise) and (iii)&nbsp;be bound by certain transfer
restrictions with respect to the FEAC Shares and the FEAC Private Placement Warrants held by them (including the New enGene Shares and New enGene Warrants received in exchange therefore in connection with the Business Combination and the
Transactions), in each case, on the terms and subject to the conditions set forth in the Sponsor and Insiders Letter Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also,
FEAC, the Sponsor and each Insider that is a Lender under the Sponsor Loans (each such term as defined in the Sponsor and Insiders Letter Agreement), each on its own behalf and on behalf of its affiliates (including the officers and directors of
FEAC and each Lender ), assuming that the aggregate principal amount outstanding under the Sponsor Loans exceeds $1,500,000 on the day which is two business days prior to the Closing Date, have agreed to elect to convert, and will take such
necessary or appropriate actions so as to ensure the conversion of, an amount equal to $1,500,000 of the aggregate principal amount outstanding under the Sponsor Loans, taken together, into additional FEAC Private Placement Warrants immediately
prior to the Surrender on the day that is two&nbsp;business days prior to the Closing Date, in each case in accordance with the FEAC Warrant Agreement and the relevant promissory note governing each such Sponsor Loan (the &#147;Sponsor Loans
Conversion&#148;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>FEAC Voting Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently with the execution and delivery of the Business Combination Agreement, enGene, New enGene and the Sponsor Parties entered into the
FEAC Voting Agreement, pursuant to which the Sponsor Parties agreed to, among other things, (i)&nbsp;vote or cause to be voted all of their FEAC Shares in favor of the Transaction Proposals; (ii)&nbsp;be bound by certain other covenants and
agreements related to the Business Combination, and (iii)&nbsp;be bound by certain transfer restrictions with respect to the FEAC Shares, in each case, on the terms and subject to the conditions set forth in the FEAC Voting Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">407 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Registration Rights Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On or around the Closing Date, New enGene, FEAC, the Sponsor Holders (as defined in the Registration Rights Agreement) and the enGene Holders
(as defined in the Registration Rights Agreement) will enter into the Registration Rights Agreement, pursuant to which, among other things, the Sponsor Holders and the enGene Holders will be granted certain customary registration rights with respect
to their respective Equity Securities (as defined in the Registration Rights Agreement) of New enGene, in each case, on the terms and subject to the conditions therein. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Office Space, Secretarial and Administrative Services </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Commencing on the date of the IPO and through the earlier of consummation of the initial business combination and the liquidation, FEAC agreed
to pay the Sponsor a total of $10,000 per month for office space, utilities, secretarial and administrative support and to reimburse the Sponsor for any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT>
expenses related to identifying, investigating and completing an initial business combination. FEAC currently maintains its executive offices at 4001 Kennett Pike, Suite 302 Wilmington, Delaware 19807. The cost for the use of this space is included
in the $10,000 per month fee FEAC pays to the Sponsor for office space, administrative and support services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, the Sponsor
has agreed to pay an annual salary of $25,000 to each of the independent board members of FEAC for services rendered prior to or in connection with the completion of the business combination. Board members are entitled to reimbursement for any <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses related to identifying, investigating, negotiating and completing the business combination as well. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FEAC&#146;s audit committee reviews on a quarterly basis all payments that were made to the Sponsor, FEAC&#146;s officers, directors or its or
their affiliates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>enGene </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I></I><B><I>2022 Convertible Notes</I></B><I> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;20, 2022, enGene entered into a note purchase agreement with, and issued the 2022 Convertible Notes to, existing shareholders,
including the 2022 Noteholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the execution and delivery of the Business Combination Agreement, enGene and the 2022
Noteholders entered into the Amended 2022 Convertible Notes to amend and restate the 2022 Convertible Notes, pursuant to which (i)&nbsp;the Amended 2022 Convertible Notes are, among other things, convertible into that number of enGene Common Shares
that, when exchanged at the enGene Exchange Ratio, shall equal that number of FEAC Class&nbsp;A Shares (or after the Assumption, New enGene Shares) that the holders of the Amended 2022 Convertible Notes would have received if they had subscribed for
FEAC Class&nbsp;A Shares (or after the Assumption, New enGene Shares) on the same terms as the PIPE Financing, and (ii)&nbsp;each 2022 Noteholder received warrants of enGene in consideration of certain amendments set forth in each Amended 2022
Convertible Note. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I></I><B><I>2023 Convertible Notes</I></B><I> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;4, 2023, enGene entered into a Note Purchase Agreement with, and issued the 2023 Subordinated Notes to, existing shareholders,
including, the 2023 Noteholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently with the execution and delivery of the Business Combination Agreement, enGene and the 2023
Noteholders entered into agreements, pursuant to which enGene repaid the 2023 Subordinated Notes by issuing to each 2023 Noteholder (i)&nbsp;an amount of convertible promissory notes of enGene substantially in the same form and on the same terms as
certain convertible promissory notes issued concurrently to the Sponsor and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">408 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Investissement Qu&eacute;bec (&#147;IQ&#148;), and (ii)&nbsp;a number of warrants to acquire enGene Common Shares substantially in the same form and on the same terms as certain warrants issued
concurrently with the Sponsor and IQ, corresponding, in the aggregate, to the principal amount of 2023 Subordinated Notes held by such 2023 Noteholder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;17, 2023 pursuant to the agreements described immediately above, enGene issued an aggregate amount of $38.0&nbsp;million
convertible debentures and warrants to the 2023 Noteholders, the Sponsor and IQ. This financing was completed in two tranches, with the second tranche closing on June&nbsp;15, 2023. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I></I><B><I>Other Transactions with Significant Shareholders</I></B><I> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Fiscal year ended October 31, 2021 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June 30, 2021, the enGene completed the sale of 3,662,813 shares of Class C Preferred Shares at a price of $2.12376 (C$2.6320) to existing
shareholders including Merck-Lumira L.P., Merck-Lumira Quebec, FSTQ, Lumira, Lumira International, and Forbion Capital Fund III for an aggregate amount of $7.8 million. Included within the Class C Agreement was one additional closing for the Class C
Second Tranche which obligated the Company to sell and Class C investors to purchase additional Class C redeemable convertible preferred shares upon the achievement of certain milestone events. The Class C Second Tranche obligated the Company to
sell and the Class C investors to purchase 3,662,810 Series 3 Class C Shares at a price of $2.13192 ($2.6320 CAD) per share for total proceeds of $7.8 million. The Class C Second Tranche closed on October 29, 2021. Additionally, on June 30, 2021,
shares of Class A and Class B Preferred Shares held by the same existing shareholders were exchanged for Class C Preferred Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
June 30, 2021, the holders of the 2019 Notes, 2020 Notes, and 2021 Notes elected to convert the notes and all accrued interest into Class B redeemable convertible preferred shares at a conversion price of $2.175315&nbsp;CAD per share, resulting in
an issuance of 16,464,646 Class B redeemable convertible preferred shares. Additionally, on June 30, 2021, shares of Class A and Class B Preferred Shares held by the same existing shareholders were exchanged for Class C Preferred Shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Fiscal year ended October 31, 2020 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;14, 2020, enGene issued convertible debentures for an aggregate amount of $5.1&nbsp;million to existing shareholders including
FSTQ, Merck-Lumira L.P., Merck-Lumira Qu&eacute;bec, Lumira III and Lumira International. As part of the issuance of the 2020 Notes enGene also issued 3,088,188 warrants to purchase enGene&#146;s Class&nbsp;B redeemable convertible preferred shares
to the same shareholders. Additionally, on June&nbsp;30, 2021, shares of Class&nbsp;A and Class&nbsp;B Preferred Shares held by the same existing shareholders were exchanged for Class&nbsp;C Preferred Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;25, 2020, enGene issued convertible debentures for an aggregate amount of $5.7&nbsp;million to existing shareholders including
FSTQ, Forbion Capital Fund III, Merck-Lumira L.P., Merck-Lumira Quebec, Lumira III and Lumira International. As part of the issuance of the 2020 Notes the Company also issued 3,576,971 warrants to purchase enGene&#146;s Class&nbsp;B redeemable
convertible preferred shares to the same shareholders. Additionally, on June&nbsp;30, 2021, shares of Class&nbsp;A and Class&nbsp;B Preferred Shares held by the same existing shareholders were exchanged for Class&nbsp;C Preferred Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For additional information relating to the transactions described under &#147;&#151; <I>Other Transactions with Significant
Shareholders</I>,&#148; see Notes 9 and 10 to enGene&#146;s Audited Financial Statements. Unless otherwise defined, defined terms used in this section will have the meaning assigned to such term in the Audited Financial Statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">409 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Registration Rights Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Business Combination, on or around the Closing Date, New enGene, FEAC, the Sponsor Holders (as defined in the
Registration Rights Agreement) and the enGene Holders (as defined in the Registration Rights Agreement) will enter into the Registration Rights Agreement. Pursuant to the terms of the Registration Rights Agreement, among other things, the Sponsor
Holders and the enGene Holders will be granted certain customary registration rights with respect to their respective equity securities of New enGene, in each case, on the terms and subject to the conditions therein. For additional information, see
&#147;<I>Securities Act Restrictions on Resale of Common Shares &#151; Registration Rights and <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements</I>.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Director Indemnification </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">enGene has entered into indemnification agreements with each of its directors, which require enGene to indemnify these individuals and, in
certain cases, affiliates of such individuals, to the fullest extent permissible under Canadian law and the Canada Business Corporations Act against liabilities that may arise by reason of their service to enGene or at enGene&#146;s direction, and
to advance expenses incurred as a result of any proceeding against them as to which they could be indemnified. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective upon the
consummation of the Business Combination, New enGene intends to enter into indemnification agreements with its directors and certain of its executive officers. The indemnification agreements will require New enGene to indemnify its directors and
officers to the fullest extent permitted under Canadian law and the Canada Business Corporations Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Related Party Policy
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">enGene, as a private company, does not have a formal written related party transaction policy. It is anticipated that New enGene
will implement policies and procedures with respect to the approval of related party transactions in connection with the Closing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">410 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom459793_43"></A>MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following are material U.S. federal income tax consequences of (i)&nbsp;the Business Combination generally applicable to U.S. Holders
(defined below) of FEAC Class&nbsp;A Shares and FEAC Warrants (together, &#147;FEAC Securities&#148;), (ii) the exercise of redemption rights by U.S. Holders of FEAC Class&nbsp;A Shares and (iii)&nbsp;the ownership and disposition of New enGene
Shares and New enGene Warrants (together, &#147;New enGene Securities&#148;) received by U.S. Holders of FEAC Class&nbsp;A Shares and FEAC Warrants, respectively, in the Business Combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This summary is limited to U.S. federal income tax considerations relevant to U.S. Holders that hold FEAC Securities and, after the completion
of the Business Combination, will hold New enGene Securities, as &#147;capital assets&#148; within the meaning of Section&nbsp;1221 of the Code (generally, property held for investment). This discussion does not address all aspects of U.S. federal
income taxation that may be relevant to particular holders in light of their individual circumstances or status, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Sponsor or any member thereof; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">banks or financial institutions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">dealers or electing traders in securities that are subject to <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">mark-to-market</FONT></FONT> tax accounting rules; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> entities; &#147;individual retirement accounts&#148; or
&#147;Roth IRAs&#148;; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">insurance companies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulated investment companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">real estate investment trusts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">partnerships or other entities or arrangements treated as partnerships for U.S. federal income tax purposes (and
investors therein); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that acquired FEAC Securities as compensation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that actually or constructively own or owned five percent or more of the shares of FEAC, or, following
the Business Combination, will own five percent or more of the shares of New enGene, by vote or value; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that hold FEAC Securities, or will hold New enGene Securities, in connection with a trade or business,
permanent establishment, or fixed place of business conducted outside the United States; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that hold FEAC Securities, or will hold New enGene Securities, as part of a straddle, constructive sale,
hedging, conversion or other integrated or similar transaction; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. Holders (as defined below) whose functional currency is not the U.S. dollar. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to the consequences of holding New enGene Shares or New enGene Warrants, this discussion is limited to U.S. Holders that will
acquire such New enGene Shares or own New enGene Warrants by virtue of the Business Combination or that will acquire such New enGene Shares as a result of the exercise of New enGene Warrants owned by virtue of the Business Combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a partnership (or any entity so characterized for U.S. federal income tax purposes) holds FEAC Securities or New enGene Securities, the tax
treatment of such partnership and its partners will generally depend on the status of the partners and the activities of the partnership and the partner and certain determinations made at the partner level. Partnerships holding any FEAC Securities
or New enGene Securities and their partners should consult their tax advisors as to the particular U.S. federal income tax consequences of the Business Combination, the ownership and disposition of New enGene Securities, or the exercise of
redemption rights with respect to the FEAC Class&nbsp;A Shares. This discussion also does not consider the tax treatment of other pass-through entities or persons who hold FEAC Securities or New enGene Securities through such entities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">411 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion is based on the Code, proposed, temporary and final Treasury regulations
promulgated under the Code, judicial and administrative interpretations thereof, the income tax treaty between the United States and Canada (the &#147;Treaty&#148;) and practices of the U.S. Internal Revenue Service (the &#147;IRS&#148;), all as of
the date hereof and all of which are subject to differing interpretations. All of the foregoing is subject to change, which change could apply retroactively and could affect the tax considerations described herein. This discussion does not address
alternative minimum or Medicare contribution tax considerations, the special tax accounting rules under Section 451(b) of the Code, or U.S. federal taxes other than those pertaining to U.S. federal income taxation (such as estate or gift taxes), nor
does it address any aspects of U.S. state, local or non-U.S. taxation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not and do not intend to seek any ruling from the IRS
regarding any aspect of the Business Combination or the exercise of redemption rights. There can be no assurance that the IRS will not take positions that are inconsistent with those discussed below or that any such positions would not be sustained
by a court. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used herein, the term &#147;U.S. Holder&#148; means a person that is, for U.S. federal income tax purposes, a beneficial
owner of FEAC Securities or New enGene Securities received pursuant to the Business Combination and: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a citizen or individual resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation or other entity taxable as a corporation for U.S. federal income tax purposes, created or organized
in or under the laws of the United States, any state thereof or the District of Columbia; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an estate the income of which is included in gross income for U.S. federal income tax purposes regardless of its
source; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust (A)&nbsp;the administration of which is subject to the primary supervision of a U.S. court and which has
one or more U.S. persons (within the meaning of the Code) who have the authority to control all substantial decisions of the trust or (B)&nbsp;that has in effect a valid election under applicable Treasury regulations to be treated as a U.S. person.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS SUMMARY DOES NOT PURPORT TO BE A COMPREHENSIVE ANALYSIS OR DESCRIPTION OF ALL POTENTIAL U.S. FEDERAL INCOME TAX
CONSEQUENCES OF THE BUSINESS COMBINATION. HOLDERS AND OWNERS OF FEAC SECURITIES SHOULD CONSULT THEIR TAX ADVISERS REGARDING THE PARTICULAR TAX CONSEQUENCES TO THEM OF THE BUSINESS COMBINATION AND OF THE OWNERSHIP AND DISPOSITION OF NEW ENGENE
SECURITIES AFTER THE BUSINESS COMBINATION, OR THE REDEMPTION OF THEIR FEAC CLASS A SHARES, INCLUDING THE APPLICABILITY AND EFFECTS OF U.S. FEDERAL, STATE, LOCAL, AND <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> TAX LAWS. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Consequences of the Business Combination to U.S. Holders of FEAC Securities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the qualifications, assumptions and limitations set forth in this section entitled &#147;&#151;&nbsp;<I>Consequences of the Business
Combination to U.S. Holders of FEAC Securities</I>,&#148; in the opinion of Davis Polk &amp; Wardwell LLP, the following are the material U.S. federal income tax consequences of the Business Combination to U.S. Holders of FEAC Securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Separation of the Units </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The separation of one FEAC Class&nbsp;A Share and <FONT STYLE="white-space:nowrap">one-third</FONT> of one FEAC Warrant comprising a unit
should not be a taxable event for U.S. federal income tax purposes. However, the tax treatment of instruments like&nbsp;units is not clear. As such, there can be no assurance that the IRS or any court will agree that such separation should not be
taxable. U.S. Holders should consult their tax advisors regarding the tax consequences in their particular circumstances. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Treatment of
the FEAC Reorganization </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although the treatment of the FEAC Reorganization for U.S. federal income tax purposes is not free from doubt,
the FEAC Reorganization should be treated as a &#147;reorganization&#148; described in Section&nbsp;368(a)(1)(F) of the Code (an &#147;F Reorganization&#148;). However, because there are no legal authorities that directly address the same facts as
the FEAC Reorganization, there is no assurance that the IRS or any court will agree with this position. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">412 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">U.S. Holders should be aware that the completion of the Business Combination is not
conditioned on the receipt of an opinion of counsel that the FEAC Reorganization (or any other aspect of the Business Combination) qualifies as a <FONT STYLE="white-space:nowrap">tax-free</FONT> transaction. Neither FEAC nor New enGene has requested
or will request a ruling from the IRS with respect to any aspect of the U.S. federal income tax treatment of the Business Combination (including the FEAC Reorganization). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Assuming that the FEAC Reorganization qualifies as an F Reorganization: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a U.S. Holder that exchanges its FEAC Securities pursuant to the FEAC Reorganization generally will not recognize
gain or loss on the exchange of such FEAC Securities for New enGene Securities, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the adjusted tax basis of a U.S. Holder in New enGene Shares received as a result of the FEAC Reorganization will
equal the adjusted tax basis of the FEAC Class&nbsp;A Shares surrendered in exchange therefor, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the adjusted tax basis of a U.S. Holder in New enGene Warrants owned as a result of the FEAC Reorganization will
equal the adjusted tax basis of the corresponding FEAC Warrants, and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a U.S. Holder&#146;s holding period in New enGene Securities received in the exchange will include the holding
period in the corresponding FEAC Securities. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the FEAC Reorganization does not qualify as an F Reorganization, the
tax consequences of the FEAC Reorganization will depend on whether the FEAC Reorganization or any component thereof would qualify for tax-free treatment under other provisions of the Code, and may be affected by FEAC&#146;s status as a passive
foreign investment company (a &#147;PFIC&#148;) and whether New enGene is also a PFIC (see the discussion below under &#147;&#151; <I>Passive Foreign Investment Company Rules</I>&#148;). U.S. Holders should consult their tax advisors regarding the
U.S. federal income tax consequences of the FEAC Reorganization if it does not qualify as an F Reorganization or otherwise as a tax-free transaction (including the requirement to recognize gain in that event or any required information reporting).
In addition, U.S. Holders should consult their tax advisors regarding the application of the PFIC rules to the exchange of their FEAC Securities pursuant to the FEAC Reorganization if the FEAC Reorganization does not qualify as an F Reorganization.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because the FEAC Reorganization will occur prior to the redemption of FEAC Class A Shares by U.S. Holders that exercise redemption
rights, U.S. Holders exercising such redemption rights will be subject to the potential tax consequences of the FEAC Reorganization described above (including any tax consequences if the FEAC Reorganization does not qualify as an F Reorganization).
All U.S. Holders considering exercising redemption rights are urged to consult their tax advisors with respect to the potential tax consequences to them of the FEAC Reorganization and an exercise of redemption rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>The remainder of this disclosure entitled &#147;Material U.S. Federal Income Tax Considerations&#148; assumes that the FEAC Reorganization
qualifies as an F Reorganization.</B> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Redemption by U.S. Holders of FEAC Class A Shares </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that a U.S. Holder of FEAC Class A Shares elects to exercise its redemption rights pursuant to the redemption provisions described
in this proxy statement/prospectus under &#147;<I>Information about the Special Meeting </I><I>&#151; </I><I>Redemption Rights</I>,&#148; the treatment of the redemption for U.S. federal income tax purposes will generally depend on whether the
redemption qualifies as a sale under Section 302 of the Code or as a distribution, the consequences of which will be impacted by the PFIC rules, as discussed below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, whether a redemption qualifies for sale treatment will depend largely on the total number of FEAC Class&nbsp;A Shares treated as
held by the U.S. Holder (including any shares constructively owned by the U.S. Holder described below) relative to all FEAC Class&nbsp;A Shares outstanding both before and after such redemption, taking into account other transactions occurring in
connection with the redemption (including the Business Combination (treating New enGene Shares as FEAC Class&nbsp;A Shares for this purpose)). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The redemption of FEAC Class&nbsp;A Shares generally will be treated as a sale of the shares (rather than as a corporate distribution) if such
redemption (i)&nbsp;is &#147;substantially disproportionate&#148; with respect to the U.S. Holder, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">413 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(ii)&nbsp;results in a &#147;complete termination&#148; of the U.S. Holder&#146;s interest in FEAC or (iii)&nbsp;is &#147;not essentially equivalent to a dividend&#148; with respect to the U.S.
Holder. These tests are explained more fully below. </P> <P STYLE="margin-top:11pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In determining whether any of the tests are satisfied, a U.S. Holder generally takes
into account not only shares actually owned by the U.S. Holder, but also any shares that are constructively owned by such U.S. Holder. A U.S. Holder may constructively own, in addition to shares owned directly, shares owned by certain related
individuals and entities in which the U.S. Holder has an interest or that have an interest in such U.S. Holder, as well as any shares the U.S. Holder has a right to acquire by exercise of an option, which would generally include FEAC Class&nbsp;A
Shares which could be acquired pursuant to the exercise of the FEAC Warrants (and, after the completion of the Business Combination, the New enGene Shares which could be acquired by exercise of the New enGene Warrants). </P>
<P STYLE="margin-top:11pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to meet the substantially disproportionate test, the percentage of outstanding voting shares of FEAC (including the FEAC Class&nbsp;A
Shares and the New enGene Shares received in exchange therefor) actually and constructively owned by the U.S. Holder immediately following the redemption of FEAC Class&nbsp;A Shares must, among other requirements, be less than 80% of the percentage
of FEAC outstanding voting shares actually and constructively owned by the U.S. Holder immediately before the redemption. Before the Business Combination, the FEAC Class&nbsp;A Shares (and immediately after the FEAC Reorganization, the corresponding
redeemed New enGene Shares) may not be treated as voting shares for this purpose and, consequently, this substantially disproportionate test may not be applicable. There will be a complete termination of a U.S. Holder&#146;s interest if either
(i)&nbsp;all FEAC Class&nbsp;A Shares actually and constructively owned by the U.S. Holder are redeemed or (ii)&nbsp;all FEAC Class&nbsp;A Shares actually owned by the U.S. Holder are redeemed, the U.S. Holder is eligible to waive, and effectively
waives in accordance with specific rules, the attribution of shares owned by certain family members, the U.S. Holder does not constructively own any other shares of FEAC or New enGene, and certain other requirements are met. The redemption of the
FEAC Class&nbsp;A Shares will not be essentially equivalent to a dividend with respect to a U.S. Holder if it results in a &#147;meaningful reduction&#148; of the U.S. Holder&#146;s proportionate interest in FEAC. Whether the redemption will result
in a meaningful reduction in a U.S. Holder&#146;s proportionate interest in FEAC will depend on the particular facts and circumstances. However, the IRS has indicated in a published ruling that even a small reduction in the proportionate interest of
a small minority shareholder in a publicly held corporation who exercises no control over corporate affairs may constitute such a &#147;meaningful reduction.&#148; </P>
<P STYLE="margin-top:11pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of the foregoing tests is satisfied, the redemption will be treated as a sale and taxed as described in &#147;<I>Consequences of
Ownership and Disposition of New enGene Shares or New enGene Warrants</I> &#151; <I>Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of New enGene Shares and New enGene Warrants</I>&#148;<I> </I>below.<I> </I>If none of the
foregoing tests is satisfied, then the redemption will be treated as a corporate distribution and taxed as described under &#147;<I>Consequences of Ownership and Disposition of New enGene Shares or New enGene Warrants</I> &#151; <I>Dividends and
Other Distributions on New enGene Shares</I>&#148; below. After the application of those rules, any remaining tax basis of the U.S. Holder in the redeemed FEAC Class&nbsp;A Shares will be added to the U.S. Holder&#146;s adjusted tax basis in its
remaining shares, or, if it has none, to the U.S. Holder&#146;s adjusted tax basis in other shares constructively owned by such U.S. Holder. </P>
<P STYLE="margin-top:11pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any income or gain recognized with respect to the redemption of FEAC Class&nbsp;A Shares will be subject to the PFIC rules described in
&#147;<I>Passive Foreign Investment Company Rules&#148;</I><B><I> </I></B>below. For example, if, as FEAC believes, it was a PFIC for its taxable year ended December&nbsp;31, 2022, any amount treated as a dividend paid to a <FONT
STYLE="white-space:nowrap">non-corporate</FONT> U.S. Holder of FEAC Class&nbsp;A Shares (or after the FEAC Reorganization, New enGene Shares) would not be eligible for the lower long-term capital gains rate that applies to qualified dividend income,
and any gain or &#147;excess distribution&#148; may be subject to additional taxes, charges and reporting obligations under the PFIC rules described below. </P>
<P STYLE="margin-top:11pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As discussed below under &#147;<I>Material Dutch Tax Consequences of the Business Combination</I>,&#148; redemption proceeds may be subject to
Dutch dividend withholding tax. U.S. Holders should consult their tax advisors regarding the creditability or deductibility of any such Dutch withholding taxes in general (taking into account Treasury regulations that in most cases effectively
prohibit U.S. taxpayers from claiming foreign tax credits with respect to taxes imposed on dispositions of shares) as well as in their particular circumstances. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">414 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">U.S. HOLDERS OF FEAC CLASS A SHARES CONTEMPLATING THE EXERCISE OF THEIR REDEMPTION RIGHTS
SHOULD CONSULT THEIR TAX ADVISERS CONCERNING THE U.S. FEDERAL, STATE, LOCAL, AND <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> TAX CONSEQUENCES THEREOF. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Consequences to U.S. Holders of New enGene Securities of the Ownership and Disposition of New enGene Shares or New enGene Warrants
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the qualifications, assumptions and limitations set forth in this section entitled &#147;<I>&#151;Consequences to U.S.
Holders of New enGene Securities of the Ownership and Disposition of New enGene Shares or New enGene Warrants</I>,&#148; in the opinion of Morgan, Lewis &amp; Bockius LLP, the following are the material U.S. federal income tax consequences to U.S.
Holders of New enGene Securities<I> </I>of the ownership and disposition of New enGene Share or New enGene Warrants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Dividends and
Other Distributions on New enGene Shares </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the PFIC rules discussed below under the heading &#147;&#151; <I>Passive Foreign
Investment Company Rules</I>,&#148; distributions on New enGene Shares will generally be taxable as a dividend for U.S. federal income tax purposes to the extent paid from New enGene&#146;s current or accumulated earnings and profits, as determined
under U.S. federal income tax principles. Distributions in excess of New enGene&#146;s current and accumulated earnings and profits will constitute a return of capital that will be applied against and reduce (but not below zero) the U.S.
Holder&#146;s adjusted tax basis in its New enGene Shares. Any remaining excess will be treated as gain realized on the sale or other disposition of the New enGene Shares and will be treated as described below under the heading &#147;&#151; <I>Gain
or Loss on Sale, Taxable Exchange or Other Taxable Disposition of New enGene Shares and New enGene Warrants</I>.&#148; Because New enGene may not maintain calculations of earnings and profits under U.S. federal income tax principles, it is expected
that the full amount of distributions (if any) paid by New enGene will be reported as dividends for U.S. federal income tax purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Amounts treated as dividends that New enGene pays to a U.S. Holder that is a taxable corporation generally will be taxed at regular rates and
will not qualify for the dividends received deduction generally allowed to domestic corporations in respect of dividends received from other domestic corporations. With respect to <FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. Holders,
under tax laws currently in effect and subject to certain exceptions (including, but not limited to, dividends treated as investment income for purposes of investment interest deduction limitations), dividends generally will be taxed at the lower
applicable long-term capital gains rate only if (i) New enGene Shares are readily tradable on an established securities market in the United States or New enGene is eligible for the benefits of the Treaty, (ii)&nbsp;New enGene is not treated as a
PFIC with respect to such U.S. Holder for the taxable year in which the dividend was paid nor for the preceding taxable year and (iii) certain holding period and other requirements are met. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of the foreign tax credit rules, dividends will be treated as foreign-source income. As discussed below under &#147;<I>Certain
Canadian Federal Income Tax Consideration &#151; Non-Canadian Resident Holders &#151; Dividends on New enGene Shares</I>,&#148; dividends paid by New enGene will be subject to Canadian withholding tax. For U.S. federal income tax purposes, the
amount of dividend income will include any amounts withheld in respect of Canadian taxes. Subject to applicable limitations that vary depending upon a U.S. Holder&#146;s particular circumstances and the discussion below regarding certain Treasury
regulations, Canadian taxes withheld from dividend payments (at a rate not exceeding the applicable rate provided in the Treaty with respect to a U.S. Holder eligible for the benefits of the Treaty) generally will be creditable against such U.S.
Holder&#146;s U.S. federal income tax liability. The rules governing foreign tax credits are complex. For example, Treasury regulations provide that, in the absence of an election to apply the benefits of an applicable income tax treaty, in order
for non-U.S. income taxes to be creditable, the relevant non-U.S. income tax rules must be consistent with certain U.S. federal income tax principles, and we have not determined whether the Canadian income tax system meets these requirements. A
recent IRS notice indicated the Treasury Department and the IRS are considering amendments to these Treasury regulations and provided some temporary relief from certain of their provisions. U.S. Holders should consult their tax advisors regarding
the creditability of Canadian taxes in their particular </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">415 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
circumstances. In lieu of claiming a credit, a U.S. Holder may be able to elect to deduct non-U.S. income taxes, including Canadian taxes, in computing such U.S. Holder&#146;s taxable income,
subject to applicable limitations. An election to deduct creditable non-U.S. taxes instead of claiming foreign tax credits applies to all creditable non-U.S. taxes paid or accrued in the taxable year. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of New enGene Shares and New enGene Warrants </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the PFIC rules discussed below under the heading &#147;&#151; <I>Passive Foreign Investment Company Rules</I>,&#148; upon any sale,
exchange or other taxable disposition of a New enGene Share or New enGene Warrant, a U.S. Holder generally will recognize gain or loss in an amount equal to the difference between (i)&nbsp;the sum of (x)&nbsp;the amount of the cash and (y)&nbsp;the
fair market value of any other property, received in such sale, exchange or other taxable disposition and (ii)&nbsp;the U.S. Holder&#146;s adjusted tax basis in such New enGene Share or New enGene Warrant (determined as described above or below), in
each case as calculated in U.S. dollars. Any such gain or loss generally will be capital gain or loss and will be long-term capital gain or loss if the U.S. Holder&#146;s holding period for such New enGene Share or New enGene Warrant exceeds one
year. Long-term capital gain realized by a <FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. Holder generally will be taxable at a reduced rate. The deductibility of capital losses is subject to limitations. This gain or loss generally will
be treated as U.S. source gain or loss. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Exercise, Lapse or Redemption of a New enGene Warrant </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the PFIC rules and except as discussed below with respect to the cashless exercise of a New enGene Warrant, a U.S. Holder generally
will not recognize taxable gain or loss on the acquisition of a New enGene Share upon exercise of a New enGene Warrant with cash. The U.S. Holder&#146;s tax basis in the New enGene Share received upon exercise of a New enGene Warrant generally will
be an amount equal to the sum of the U.S. Holder&#146;s initial investment in a New enGene Warrant (i.e., its tax basis, calculated in U.S. dollars) and the exercise price. The U.S. Holder&#146;s holding period for a New enGene Share received upon
exercise of a New enGene Warrant with cash will begin on the date following the date of exercise (or possibly the date of exercise) of the New enGene Warrant and will not include the period during which the U.S. Holder held the New enGene Warrant
(or any FEAC Warrant exchanged therefor). If a New enGene Warrant is allowed to lapse unexercised, a U.S. Holder generally will recognize a capital loss equal to such U.S. Holder&#146;s tax basis in the warrant (calculated in U.S. dollars). Such
loss will be long-term if the warrant has been held for more than one year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The tax consequences of a cashless exercise of a New enGene
Warrant are not clear under current law. Subject to the PFIC rules discussed below, a cashless exercise may not be taxable, either because the exercise is not a realization event or because the exercise is treated as a &#147;recapitalization&#148;
for U.S. federal income tax purposes. In either <FONT STYLE="white-space:nowrap">tax-free</FONT> situation, a U.S. Holder&#146;s tax basis in the New enGene Share received generally would equal the U.S. Holder&#146;s tax basis in the New enGene
Warrant. If the cashless exercise is not treated as a realization event, it is unclear whether a U.S. Holder&#146;s holding period for the New enGene Share will commence on the date of exercise of the warrant or the day following the date of
exercise of the warrant. If the cashless exercise is treated as a recapitalization, the holding period of the New enGene Share would include the holding period of the warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is also possible that a cashless exercise may be treated in part as a taxable exchange in which gain or loss would be recognized. In such
event, a portion of the New enGene Warrants to be exercised on a cashless basis could, for U.S. federal income tax purposes, be deemed to have been surrendered in consideration for the exercise price of the remaining portion of the New enGene
Warrants, which would be deemed to be exercised. For this purpose, a U.S. Holder may be deemed to have surrendered a number of New enGene Warrants having an aggregate value equal to the exercise price for the total number of warrants to be deemed
exercised. Subject to the PFIC rules discussed below, the U.S. Holder would recognize capital gain or loss in an amount equal to the difference between the exercise price for the total number of New enGene Warrants deemed exercised and the U.S.
Holder&#146;s tax basis in the warrants deemed surrendered. In this case, a U.S. Holder&#146;s tax basis in the New </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">416 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
enGene Shares received would equal the U.S. Holder&#146;s tax basis in the New enGene Warrants exercised plus (or minus) the gain (or loss) recognized with respect to the surrendered warrants. It
is unclear whether a U.S. Holder&#146;s holding period for the New enGene Shares would commence on the date of exercise of the warrants or the day following the date of exercise of the warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to the absence of authority on the U.S. federal income tax treatment of a cashless exercise, there can be no assurance which, if any, of
the alternative tax consequences and holding periods described above would be adopted by the IRS or a court of law. Accordingly, a U.S. Holder should consult the U.S. Holder&#146;s tax advisor regarding the tax consequences of a cashless exercise.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the PFIC rules described below, if New enGene redeems New enGene Warrants for cash or purchases New enGene Warrants in an
open-market transaction, such redemption or purchase generally will be treated as a taxable disposition to the U.S. Holder, taxed as described above under &#147;&#151; <I>Gain or Loss on the Sale, Taxable Exchange or Other Taxable Disposition of New
enGene Shares and New enGene Warrants.</I>&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Adjustment to Exercise Price of New enGene Warrants </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms of each New enGene Warrant provide for an adjustment to the number of New enGene Shares for which a New enGene Warrant may be
exercised or to the exercise price of the warrant in certain events, as discussed in the section of this proxy statement/prospectus captioned &#147;<I>Description of New enGene Securities &#151; Warrants &#151; New enGene Warrants Redemption
Procedures &#151; Anti-dilution Adjustments</I>.&#148; An adjustment which has the effect of preventing dilution generally is not taxable. The U.S. Holders of the New enGene Warrants would, however, be treated as receiving a constructive
distribution from New enGene if, for example, the adjustment increases such U.S. Holders&#146; proportionate interest in the assets or earnings and profits of New enGene (e.g. through an increase in the number of New enGene Shares that would be
obtained upon exercise or through a decrease to the exercise price of a New enGene Warrant) as a result of a distribution of cash or other property to the holders of New enGene Shares which is taxable to the U.S. Holders of such New enGene Shares as
described under &#147;&#151; <I>Dividends and Other Distributions on New enGene Shares</I>&#148; above. Such constructive distribution would be subject to tax as described under that section in the same manner as if the U.S. Holders of the warrants
received a cash distribution from New enGene equal to the fair market value of such increased interest, and would increase a U.S. Holder&#146;s adjusted tax basis in such U.S. Holder&#146;s New enGene Warrants to the extent that such distribution is
treated as a dividend. New enGene cannot ensure that it will be able to provide U.S. Holders with the information needed to determine the U.S. federal income tax impact of any constructive distribution received by such U.S. Holder pursuant to these
rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Passive Foreign Investment Company Rules </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The treatment of U.S. Holders of FEAC Securities and New enGene Securities could be (and generally will be, in the case of U.S. Holders of FEAC
Class&nbsp;A Shares) materially different from that described above due to the application of the PFIC rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general and as relevant
here, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> corporation is a PFIC for U.S. federal income tax purposes for any taxable year in which (i) 50% or more of the value of its assets (generally determined on the basis of a weighted quarterly
average) consists of assets, including its pro rata share of the assets of any corporation in which it is considered to own at least 25% of the shares by value, that produce, or are held for the production of, passive income, or (ii) 75% or more of
its gross income, including its pro rata share of the gross income of any corporation in which it is considered to own at least 25% of the shares by value, consists of passive income. Passive income generally includes dividends, interest, rents and
royalties (other than rents or royalties derived from the active conduct of a trade or business) and gains from the disposition of passive assets. Cash and cash equivalents are generally passive assets. The value of goodwill will generally be
treated as an active or passive asset based on the nature of the income produced in the activity to which the goodwill is attributable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">417 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the <FONT STYLE="white-space:nowrap">start-up</FONT> exception, a corporation
will not be a PFIC for the first taxable year the corporation has gross income (the <FONT STYLE="white-space:nowrap">&#147;start-up</FONT> year&#148;), if (1)&nbsp;no predecessor of the corporation was a PFIC, (2)&nbsp;it is established to the
satisfaction of the IRS that the corporation will not be a PFIC for either of the first two taxable years following the <FONT STYLE="white-space:nowrap">start-up</FONT> year, and (3)&nbsp;the corporation is not in fact a PFIC for either of those
years (the <FONT STYLE="white-space:nowrap">&#147;start-up</FONT> exception&#148;). FEAC believes that it did not qualify for the <FONT STYLE="white-space:nowrap">start-up</FONT> exception for its taxable year ended December&nbsp;31, 2021.
Therefore, because FEAC is a blank check company with no current active business, based on the composition of FEAC&#146;s income and assets, FEAC believes that it was a PFIC for its taxable years ended December&nbsp;31, 2021 and December&nbsp;31,
2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, the income and assets of FEAC may affect the PFIC status of New enGene for New enGene&#146;s taxable year in which the
FEAC Reorganization occurs because New enGene will be treated, subject to the U.S. Holder&#146;s making one or more of the applicable elections described below, as the same corporation as FEAC for purposes of the corporation&#146;s qualification as
a PFIC. Consequently, FEAC&#146;s income and assets in its current taxable year may affect the PFIC status of New enGene for New enGene&#146;s current taxable year (<I>i.e.</I>, the year in which the FEAC Reorganization occurs). New enGene&#146;s
PFIC status for any taxable year is a factual annual determination that can be made only after the end of that year and will depend on the composition of New enGene&#146;s income and assets and the value of its assets from time to time and, for the
taxable year in which the Business Combination occurs, the composition of the income and assets, and the value of the assets, of FEAC, its predecessor for this purpose. The value of New enGene&#146;s assets includes the value of its goodwill and
other intangible assets not shown on its financial statements, which may be determined, in large part, by reference to the market price of the New enGene Shares from time to time, which is subject to change and may be particularly volatile while the
business is at the pre-commercialization stage. In addition, prior to the commercialization of any of New enGene&#146;s drug candidates its income may be primarily passive. Accordingly, there is a significant risk that New enGene will be a PFIC for
its current or any future taxable year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If FEAC is or was a PFIC (as FEAC believes to be the case for its 2021 and 2022 taxable years)
for any taxable year during the holding period of a U.S. Holder in its FEAC Class A Shares, then, New enGene will also be treated as a PFIC as to such U.S. Holder with respect to New enGene Shares received in exchange for FEAC Class A Shares
pursuant to the FEAC Reorganization, even if New enGene does not meet the test for PFIC status in its own right, unless the U.S. Holder made an applicable PFIC election (or elections). In addition, if this rule were to apply, such U.S. Holder would
be treated for purposes of the PFIC rules as if such U.S. Holder held such New enGene Shares (treated as shares of a PFIC as to such holder) for a period that includes such holder&#146;s holding period for the FEAC Class A Shares exchanged therefor.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If New enGene is a PFIC (or is treated as a PFIC with respect to a U.S. Holder, <I>e.g. </I>due to prior ownership of FEAC Class A Shares
in the absence of an applicable election (or elections)) for any taxable year (or portion thereof) that is included in the holding period of a U.S. Holder of New enGene Shares and the U.S. Holder did not make an applicable PFIC election (or
elections) discussed below, such U.S. Holder generally will be subject to special and adverse rules with respect to (i) any gain recognized by the U.S. Holder on the sale or other disposition of its New enGene Shares and (ii) any &#147;excess
distribution&#148; made to the U.S. Holder (generally, any distributions to such U.S. Holder during a taxable year of the U.S. Holder to the extent greater than 125% of the average annual distributions received by such U.S. Holder in respect of the
New enGene Shares during the three preceding taxable years of such U.S. Holder or, if shorter, such U.S. Holder&#146;s holding period for the New enGene Shares). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under these rules (the &#147;interest charge rules&#148;): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. Holder&#146;s gain or excess distribution will be allocated ratably over the U.S. Holder&#146;s holding
period for the New enGene Shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount allocated to the U.S. Holder&#146;s taxable year in which the U.S. Holder recognized the gain or
received the excess distribution, or to the period in the U.S. Holder&#146;s holding period before the first day of New enGene&#146;s first taxable year in which New enGene is a PFIC, will be taxed as ordinary income; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">418 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount allocated to other taxable years (or portions thereof) of the U.S. Holder and included in the U.S.
Holder&#146;s holding period will be taxed at the highest tax rate in effect for that year and applicable to the U.S. Holder; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an additional tax equal to the interest charge generally applicable to underpayments of tax will be imposed on
the U.S. Holder with respect to the tax attributable to each taxable year described in the preceding bullet of the U.S. Holder. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is not entirely clear how various aspects of the PFIC rules apply to the FEAC Warrants and New enGene Warrants. Under proposed Treasury
regulations relating to PFICs (the &#147;proposed Treasury regulations&#148;), which have a retroactive effective date, the PFIC rules may apply to rights to acquire shares of a PFIC as if they were shares, and thus could apply to dispositions
(other than exercises) of the FEAC Warrants or New enGene Warrants. As a result, under the proposed Treasury regulations, if a U.S. Holder sells or otherwise disposes of such New enGene Warrants (other than upon exercise of such New enGene Warrants)
and New enGene (or FEAC) was a PFIC at any time during the U.S. Holder&#146;s holding period of such New enGene Warrants (or FEAC Warrants), any gain recognized generally will be treated as an excess distribution, taxed as described above. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>PFIC Elections </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
general, if New enGene (or FEAC) is a PFIC, a U.S. Holder may avoid the adverse PFIC tax consequences under the interest charge rules described above in respect of New enGene Shares (or FEAC Class A Shares), but not New enGene Warrants or FEAC
Warrants (a) by making or having made a qualified electing fund (&#147;QEF&#148;) election or a mark-to-market election for the first taxable year for which New enGene (or FEAC) is or was a PFIC and in which such U.S. Holder held (or was deemed to
hold) such New enGene Shares (or FEAC Class A Shares) and maintain such election or (b) by making and maintaining a QEF election along with an applicable purging election (collectively, the &#147;PFIC Elections&#148;). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I></I></B><I>QEF and Purging Elections</I><B><I> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of making and maintaining a timely and valid QEF election (if eligible to do so), a U.S. Holder of New enGene Shares must include
in income such U.S. Holder&#146;s pro rata share of New enGene&#146;s net capital gains (as long-term capital gain) and other earnings and profits (as ordinary income), on a current basis, whether or not distributed. A U.S. Holder generally may make
a separate election to defer the payment of taxes on undistributed income inclusions under the QEF rules, but if deferred, any such taxes will be subject to an interest charge. A subsequent distribution of such earnings and profits that were
previously included in income should generally not be taxable as a dividend to such U.S. Holder. The tax basis of a U.S. Holder&#146;s shares in a PFIC with respect to which a QEF election has been made will be increased by amounts that are included
in income, and decreased by amounts distributed but not taxed as dividends, under the above rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A U.S. Holder may not make a QEF
election with respect to its New enGene Warrants. If a U.S. Holder that exercises New enGene Warrants properly makes and maintains a QEF election with respect to the newly acquired New enGene Shares (or has previously made a QEF election with
respect to its New enGene Shares or FEAC Class A Shares, as applicable), the QEF election will apply to the newly acquired New enGene Shares. Notwithstanding a QEF election, the adverse tax consequences relating to PFIC shares under the interest
charge rules described above, adjusted to take into account the current income inclusions resulting from the QEF election, may continue to apply with respect to the New enGene Shares (because under the proposed Treasury regulations, the New enGene
Shares generally would be deemed to have a holding period for purposes of the interest charge rules that includes the period the U.S. Holder held the corresponding New enGene Warrants (and the FEAC Warrants)), unless the U.S. Holder made a purging
election under the PFIC rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the type of purging election most likely relevant, the U.S. Holder will be deemed to have sold such
shares at their fair market value and any gain recognized on such deemed sale will be treated as an excess distribution, as described above. As a result of this election, the U.S. Holder will have additional basis (to the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">419 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
extent of any gain recognized in the deemed sale) and, for purposes of the interest charge rules, a new holding period in such holder&#146;s New enGene Shares. Because after the purging election
takes effect the QEF election will be in effect for the entirety of the new holding period, the interest charge rules will not apply with respect to the New enGene Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the absence of a purging election, a U.S. Holder would be treated for purposes of the interest charge rules as if the U.S. Holder held such
New enGene Shares and New enGene Warrants for a period that includes a period when the QEF election was not in effect, including such U.S. Holder&#146;s holding period for the FEAC Class&nbsp;A Shares and FEAC Warrants exchanged therefor,
respectively. U.S. Holders are urged to consult their tax advisors regarding the application of the purging elections rules to their particular circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The QEF election is made on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">shareholder-by-shareholder</FONT></FONT> basis
and, once made, can be revoked only with the consent of the IRS. A U.S. Holder generally makes a QEF election by attaching a completed IRS Form 8621 (Information Return by a Shareholder of a Passive Foreign Investment Company or Qualified Electing
Fund), including the information provided in a PFIC Annual Information Statement from FEAC or New enGene, as the case may be, to a timely filed U.S. federal income tax return for the tax year to which the election relates. In the event that New
enGene determines after the completion of the Business Combination that New enGene is a PFIC for U.S. federal income tax purposes for any taxable year, New enGene will, upon request of a holder of New enGene Shares, provide a PFIC Annual Information
Statement to such holder. Retroactive QEF elections generally may be made only by filing a protective statement with such federal income tax return and if certain other conditions are met or with the consent of the IRS. U.S. Holders are urged to
consult their tax advisors regarding the availability and tax consequences of a retroactive QEF election under their particular circumstances. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Mark-to-Market Election </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As an alternative to a QEF election, if a U.S. Holder owns shares in a company that is a PFIC and the shares are &#147;regularly traded&#148;
on a &#147;qualified exchange,&#148; such U.S. Holder could make a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election that would result in tax treatment different from that under the interest
charge rules described above. The FEAC Class&nbsp;A Shares and New enGene Shares will be treated as regularly traded for any calendar year in which more than a <I>de minimis </I>quantity of the FEAC Class&nbsp;A Shares or New enGene Shares, as
applicable, are traded on a qualified exchange on at least 15 days during each calendar quarter. Nasdaq, where the FEAC Class&nbsp;A Shares are listed and the New enGene Shares are expected to be listed, is a qualified exchange for this purpose.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Such electing U.S. Holder generally will include for each of its taxable years as ordinary income the excess, if any, of the fair market
value of its New enGene Shares at the end of such year over its adjusted basis in its New enGene Shares. The U.S. Holder also will recognize an ordinary loss in respect of the excess, if any, of its adjusted basis of its New enGene Shares over the
fair market value of its New enGene Shares at the end of its taxable year (but only to the extent of the net amount of previously included in income as a result of the mark-to-market election). The U.S. Holder&#146;s basis in its New enGene Shares
will be adjusted to reflect any such income or loss amounts. Any gain recognized on a sale or other taxable disposition of its New enGene Shares will be treated as ordinary income, and any loss will be treated as an ordinary loss (but only to the
extent of the net amount previously included in income as a result of the mark-to-market election, with any excess treated as a capital loss). If a U.S. Holder makes the mark-to-market election, distributions paid on New enGene Shares will be
treated as discussed under &#147;<I>Consequences of Ownership and Disposition of New enGene Shares and New enGene Warrants &#151; </I><I>Dividends and Other Distributions on New enGene Shares</I>&#148; above. A mark-to-market election may not be
made with respect to the New enGene Warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If made, a mark-to-market election will be effective for the taxable year for which the
election is made and for all subsequent taxable years in which New enGene is a PFIC, unless the New enGene Shares cease to qualify as &#147;regularly traded&#148; on a &#147;qualified exchange&#148; for purposes of the PFIC rules or the IRS consents
to the revocation of the election. U.S. Holders are urged to consult their tax advisors regarding the availability and tax </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">420 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
consequences of a mark-to-market election with respect to New enGene Shares under their particular circumstances (including the possible recognition of income or gain under the PFIC interest
charge rules in the case that the mark-to-market election is not made for the first taxable year in which the U.S. Holders own (or are treated as owning) the New enGene Shares). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Other PFIC Rules </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If New
enGene is a PFIC and, at any time, has a non-U.S. subsidiary that is a PFIC, a U.S. Holder generally would be deemed to own a proportionate amount of the shares of such lower-tier PFIC and generally could incur liability for the deferred tax and
interest charge under the interest charge rules described above if New enGene receives an excess distribution from, or disposes of all or part of its interest in, the lower-tier PFIC, or the U.S. Holder otherwise was deemed to have disposed of an
interest in the lower-tier PFIC, in each case as if the U.S. Holder held such shares directly, even though the U.S. Holder will not receive any proceeds of that distribution or disposition. A mark-to-market election cannot be made with respect to a
lower-tier PFIC. U.S. Holders are urged to consult their tax advisors regarding the tax issues raised by lower-tier PFICs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A U.S. Holder
that owns (or is deemed to own) shares in a PFIC during any taxable year of the U.S. Holder may have to file an IRS Form 8621 (whether or not a QEF or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT>
election is made) and to provide such other information as may be required by the U.S. Treasury Department. Failure to do so, if required, will extend the statute of limitations applicable to such U.S. Holder until such required information is
furnished to the IRS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THE RULES DEALING WITH PFICS ARE VERY COMPLEX AND ARE IMPACTED BY VARIOUS FACTORS IN ADDITION TO THOSE DESCRIBED ABOVE. ALL U.S.
HOLDERS ARE URGED TO CONSULT THEIR TAX ADVISORS REGARDING THE CONSEQUENCES TO THEM OF THE PFIC RULES, INCLUDING, WITHOUT LIMITATION, WHETHER A QEF ELECTION (OR A QEF ELECTION ALONG WITH A PURGING ELECTION), A <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">MARK-TO-MARKET</FONT></FONT> ELECTION, OR ANY OTHER ELECTION IS AVAILABLE AND THE CONSEQUENCES TO THEM OF ANY SUCH ELECTION, THE APPLICATION OF THE PFIC RULES TO WARRANTS, AND THE IMPACT OF ANY PROPOSED OR FINAL PFIC
TREASURY REGULATIONS. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Information Reporting and Backup Withholding </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividend payments (including constructive dividends) with respect to New enGene Shares and proceeds from the sale, exchange or redemption of
FEAC Securities or New enGene Securities may be subject to information reporting to the IRS and possible United States backup withholding. Backup withholding (currently at a rate of 24 percent) will not apply, however, to a U.S. Holder who furnishes
a correct taxpayer identification number (generally on an IRS Form <FONT STYLE="white-space:nowrap">W-9</FONT> provided to the relevant paying agent) and makes other required certifications, or who is otherwise exempt from backup withholding and
establishes such exempt status if required to do so. Any amounts withheld under the backup withholding rules may be allowed as a refund or credit against a holder&#146;s U.S. federal income tax liability, if any, provided the required information is
timely furnished to the IRS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, certain U.S. Holders holding specified foreign financial assets with an aggregate value in
excess of the applicable dollar thresholds are required to report information to the IRS relating to New enGene Shares or the non-U.S. financial accounts through which they are held, subject to certain exceptions (including an exception for New
enGene Shares held in accounts maintained by U.S. financial institutions), by attaching a complete IRS Form 8938 (Statement of Specified Foreign Financial Assets) with their tax return for each year in which they hold New enGene Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">421 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom459793_44"></A>MATERIAL DUTCH TAX CONSEQUENCES OF THE BUSINESS COMBINATION
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summary of material Dutch tax consequences of the Business Combination is based on the presumption that FEAC is, and
will during its existence, continue to be effectively managed in the Netherlands and, consequently, that FEAC will at all times during its existence be considered a Dutch tax resident under Dutch tax law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This summary solely addresses the principal Dutch tax consequences, for a holder of FEAC Class&nbsp;A Shares or FEAC Warrants (other than the
Sponsor), of the ownership and/or disposal of such FEAC Class&nbsp;A Shares and/or FEAC Warrants and does not purport to describe every aspect of taxation that may be relevant to a particular holder of FEAC Class&nbsp;A Shares or FEAC Warrants. Tax
matters are complex, and the tax consequences of the ownership and/or disposal of FEAC Class&nbsp;A Shares or FEAC Warrants to a particular holder of such FEAC Class&nbsp;A Shares or FEAC Warrants will depend in part on such holder&#146;s
circumstances. Accordingly, a holder of FEAC Class&nbsp;A Shares or FEAC Warrants is urged to consult its own tax advisor for a full understanding of the tax consequences of the ownership and disposal of FEAC Class&nbsp;A Shares or FEAC Warrants,
including the applicability and effect of Dutch tax laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that in this summary English terms and expressions are used to
refer to Dutch concepts, the meaning to be attributed to such terms and expressions shall be the meaning to be attributed to the equivalent Dutch concepts under Dutch tax law. In addition, the terms &#147;the Netherlands&#148; and &#147;Dutch&#148;
shall refer solely to the European part of the Kingdom of the Netherlands. This summary assumes that FEAC is organized, and that its business will be conducted, in the manner outlined in this proxy statement/prospectus. A change to such
organizational structure or to the manner in which FEAC conducts its business may invalidate the contents of this summary, which will not be updated to reflect any such change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This summary is based on the tax law of the Netherlands (not including unpublished case law) as it stands at the date of this proxy
statement/prospectus. The tax law upon which this summary is based is subject to changes, including with retroactive effect. Any such change may invalidate the contents of this summary, which will not be updated to reflect such change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This summary does not address the Dutch tax consequences for a holder of FEAC Class&nbsp;A Shares or FEAC Warrants who: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">is a person who may be deemed an owner of FEAC Class&nbsp;A Shares or FEAC Warrants for Dutch tax purposes
pursuant to specific statutory attribution rules in Dutch tax law; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">is, although in principle subject to Dutch corporation tax, in whole or in part, specifically exempt from that
tax in connection with income from FEAC Class&nbsp;A Shares or FEAC Warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">is an &#147;investment institution&#148; as defined in the Dutch Corporation Tax Act 1969; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">is an entity that, although in principle subject to Dutch corporation tax, is fully or partly exempt from Dutch
corporation tax; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">owns FEAC Class&nbsp;A Shares or FEAC Warrants in connection with a membership of a management board or a
supervisory board, an employment relationship, a deemed employment relationship or management role; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">has a substantial interest in FEAC or a deemed substantial interest in FEAC for Dutch tax purposes. Generally, a
person holds a substantial interest if (a)&nbsp;such person &#151; either alone or, in the case of an individual, together with its partner or any of its relatives by blood or by marriage in the direct line (including foster-children) or of those of
its partner for Dutch tax purposes &#151; owns or is deemed to own, directly or indirectly, 5% or more of the FEAC Class&nbsp;A Shares or of any other class of FEAC Shares, including any rights to acquire, directly or indirectly, an interest in the
FEAC Shares (such as the right to acquire an interest in the FEAC Shares underlying the FEAC Warrants) or profit </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">422 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
participating certificates relating to 5% or more of the annual profits or to 5% or more of the liquidation proceeds of FEAC, or (b)&nbsp;such person&#146;s FEAC Shares, rights to acquire FEAC
Shares or profit participating certificates of FEAC are held by him following the application of a <FONT STYLE="white-space:nowrap">non-recognition</FONT> provision; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">is for Dutch tax purposes taxable as a corporate entity and resident of Aruba, Cura&ccedil;ao or Sint Maarten.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Taxes on income and capital gains </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Dutch resident holders of FEAC Class&nbsp;A Shares or FEAC Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A holder of FEAC Class&nbsp;A Shares or FEAC Warrants who is resident or deemed to be resident in the Netherlands for Dutch tax purposes is
fully subject to Dutch income tax if he is an individual or fully subject to Dutch corporation tax if it is a corporate entity, or an entity, including an association, a partnership or a mutual fund, taxable as a corporate entity, as described in
the summary below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Individuals deriving profits or deemed to be deriving profits from an enterprise </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any benefits derived or deemed to be derived from or in connection with FEAC Class&nbsp;A Shares or FEAC Warrants that are attributable to an
enterprise from which an individual derives profits, whether as an entrepreneur or pursuant to a <FONT STYLE="white-space:nowrap">co-entitlement</FONT> to the net value of an enterprise, other than as a shareholder, are generally subject to Dutch
income tax at progressive rates up to 49.5%. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Individuals deriving benefits from miscellaneous activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any benefits derived or deemed to be derived from or in connection with FEAC Class&nbsp;A Shares or FEAC Warrants that constitute benefits from
miscellaneous activities by an individual are generally subject to Dutch income tax at progressive rates up to 49.5%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An individual may,
<I>inter alia</I>, derive, or be deemed to derive, benefits from or in connection with FEAC Class&nbsp;A Shares or FEAC Warrants that are taxable as benefits from miscellaneous activities if its investment activities go beyond regular active
portfolio management. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Other individuals </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a holder of FEAC Class&nbsp;A Shares or FEAC Warrants is an individual whose situation has not been discussed above in this section
&#147;<I>&#151; Dutch resident holders of FEAC Class</I><I></I><I>&nbsp;A Shares or FEAC Warrants</I>,&#148; the value of its FEAC Class&nbsp;A Shares or FEAC Warrants forms part of the yield basis for purposes of tax on benefits from savings and
investments. A deemed benefit, which is calculated on the basis of a holder&#146;s actual bank savings plus its actual other investments (including the value of its FEAC Class&nbsp;A Shares or FEAC Warrants), minus its actual liabilities whilst
taking into account a deemed benefit for each of these categories, is taxed at the rate of 32%. For the year 2023, the estimated deemed benefit rate for actual bank savings is 0.36%, the estimated deemed benefit rate for actual other investments is
6.17% and the deemed benefit rate for actual liabilities is 2.57%. The estimated deemed return percentages are expected to be confirmed by the Dutch government at a later stage. Actual benefits derived from or in connection with its FEAC
Class&nbsp;A Shares or FEAC Warrants are not subject to Dutch income tax. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Corporate entities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any benefits derived or deemed to be derived from or in connection with FEAC Class&nbsp;A Shares or FEAC Warrants that are held by a corporate
entity, or an entity, including an association, a partnership or a mutual fund, taxable as a corporate entity, are generally subject to Dutch corporation tax. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">423 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>General </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A holder of FEAC Class&nbsp;A Shares or FEAC Warrants will not be deemed to be resident in the Netherlands for Dutch tax purposes only by
reason of the execution and/or enforcement of the documents relating to the Transactions or the performance by FEAC of its obligations under such documents or under the FEAC Class&nbsp;A Shares or FEAC Warrants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-Dutch</FONT> resident holders of FEAC Class&nbsp;A Shares or FEAC Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Individuals </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a holder
of FEAC Class&nbsp;A Shares or FEAC Warrants is an individual who is neither resident nor deemed to be resident in the Netherlands for purposes of Dutch income tax, it will not be subject to Dutch income tax in respect of any benefits derived or
deemed to be derived from or in connection with the FEAC Class&nbsp;A Shares or FEAC Warrants, except if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it derives profits from an enterprise, whether as an entrepreneur or pursuant to a
<FONT STYLE="white-space:nowrap">co-entitlement</FONT> to the net value of such enterprise, other than as a shareholder, and such enterprise is carried on, in whole or in part, through a permanent establishment or a permanent representative in the
Netherlands, and its holding of FEAC Class&nbsp;A Shares or FEAC Warrants are attributable to such permanent establishment or permanent representative; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it derives benefits or is deemed to derive benefits from or in connection with FEAC Class&nbsp;A Shares or FEAC
Warrants that are taxable as benefits from miscellaneous activities performed in the Netherlands; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it derives profits pursuant to the entitlement to a share in the profits of an enterprise, other than as a holder
of securities, which is effectively managed in the Netherlands and to which enterprise its FEAC Class&nbsp;A Shares or FEAC Warrants are attributable. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Corporate entities </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a
holder of FEAC Class&nbsp;A Shares or FEAC Warrants is a corporate entity, or an entity including an association, a partnership and a mutual fund, taxable as a corporate entity, which is neither resident, nor deemed to be resident in the Netherlands
for purposes of Dutch corporation tax, it will not be subject to Dutch corporation tax in respect of any benefits derived or deemed to be derived from or in connection with the FEAC Class&nbsp;A Shares or FEAC Warrants, except if: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it derives profits from an enterprise directly which is carried on, in whole or in part, through a permanent
establishment or a permanent representative in the Netherlands, and to which permanent establishment or permanent representative its FEAC Class&nbsp;A Shares or FEAC Warrants are attributable; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it derives profits pursuant to a <FONT STYLE="white-space:nowrap">co-entitlement</FONT> to the net value of an
enterprise which is managed in the Netherlands, other than as a holder of securities, and to which enterprise its FEAC Class&nbsp;A Shares or FEAC Warrants are attributable. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>General </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a holder of
FEAC Class&nbsp;A Shares or FEAC Warrants is neither resident nor deemed to be resident in the Netherlands, such holder will for Dutch tax purposes not carry on or be deemed to carry on an enterprise, in whole or in part, through a permanent
establishment or a permanent representative in the Netherlands only by reason of the execution and/or enforcement of the documents relating to the Transactions or the performance by FEAC of its obligations under such documents or under the FEAC
Class&nbsp;A Shares or FEAC Warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">424 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Dividend withholding tax </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>General </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FEAC is generally
required to withhold Dutch dividend withholding tax at a rate of 15% from dividends distributed by it, subject to possible relief under Dutch domestic law, the Treaty on the Functioning of the European Union or an applicable Dutch income tax treaty
depending on a holder&#146;s individual circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The concept &#147;dividends distributed by FEAC&#148; as used in this summary
includes, but is not limited to, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">distributions in cash or in kind, deemed and constructive distributions and repayments of capital not recognized
as <FONT STYLE="white-space:nowrap">paid-in</FONT> for Dutch dividend withholding tax purposes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">liquidation proceeds and proceeds of repurchase or redemption of FEAC Class&nbsp;A Shares in excess of the
average capital recognized as <FONT STYLE="white-space:nowrap">paid-in</FONT> for Dutch dividend withholding tax purposes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the par value of FEAC Class&nbsp;A Shares issued by FEAC to a FEAC Shareholder or an increase of the par value of
FEAC Class&nbsp;A Shares, as the case may be, to the extent that it does not appear that a contribution, recognized for Dutch dividend withholding tax purposes, has been made or will be made; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">partial repayment of capital, recognized as <FONT STYLE="white-space:nowrap">paid-in</FONT> for Dutch dividend
withholding tax purposes, if and to the extent that there are net profits, unless (a)&nbsp;the general meeting of FEAC Shareholders has resolved in advance to make such repayment and (b)&nbsp;the par value of the FEAC Shares concerned has been
reduced by an equal amount by way of an amendment to FEAC&#146;s Current Articles. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the above, the
concept &#147;dividends distributed by FEAC&#148; may, for the purposes of Dutch dividend withholding tax, include proceeds of any amounts paid in respect of a repurchase or redemption of redeemable FEAC Warrants or of a cash settlement of FEAC
Warrants, and consequently, Dutch dividend withholding tax at a rate of 15% may be due in respect of (a part of) such proceeds. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Registration taxes and duties </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No Dutch registration tax, transfer tax, stamp duty or any other similar documentary tax or duty, other than court fees, is payable in the
Netherlands in respect of or in connection with the execution and/or enforcement (including by legal proceedings and including the enforcement of any foreign judgment in the courts of the Netherlands) of the documents relating to the Transactions,
the performance by FEAC of its obligations under such documents, or the transfer of FEAC Class&nbsp;A Shares or FEAC Warrants, except that Dutch real property transfer tax may be due upon an acquisition in connection with FEAC Class&nbsp;A Shares or
FEAC Warrants of real property situated in the Netherlands, (an interest in) an asset that qualifies as real property situated in the Netherlands, or (an interest in) a right over real property situated in the Netherlands, for the purposes of Dutch
real property transfer tax. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">425 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom459793_45"></A>CERTAIN CANADIAN FEDERAL INCOME TAX CONSIDERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a general summary, as of the date hereof, of the principal Canadian federal income tax considerations under the Income Tax
Act (Canada) and the regulations thereunder (collectively, the &#147;Tax Act&#148;) generally applicable to a beneficial owner (other than the Sponsor) of New enGene Shares or New enGene Warrants (collectively, the &#147;Securities&#148;) following
the Transactions and who at all relevant times, for purposes of the Tax Act, (a)&nbsp;holds such Securities as capital property, (b)&nbsp;deals at arm&#146;s length with New enGene, and (c)&nbsp;is not affiliated with New enGene (a
&#147;Holder&#148;). Generally, the Securities will be considered to be capital property to a Holder unless they are held or acquired in the course of carrying on a business of trading in or dealing in securities or as part of an adventure or
concern in the nature of trade. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This summary assumes that, at all relevant times, New enGene is a resident of Canada for purposes of the
Tax Act and any applicable income tax treaty or convention. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This summary is based on the facts set out in this proxy
statement/prospectus, the provisions of the Tax Act in force as of the date prior to the date hereof, the Canada-United States Tax Convention (1980)&nbsp;as amended (the &#147;Treaty&#148;) and counsel&#146;s understanding of the current
administrative policies and assessing practices of the Canada Revenue Agency (the &#147;CRA&#148;) published in writing by the CRA prior to the date hereof. This summary takes into account all specific proposals to amend the Tax Act publicly
announced by or on behalf of the Minister of Finance (Canada) prior to the date hereof (the &#147;Tax Proposals&#148;) and assumes that the Tax Proposals will be enacted in the form proposed, although no assurance can be given that the Tax Proposals
will be enacted in their current form or at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This summary does not otherwise take into account or anticipate any changes in law or in
the administrative policies or assessing practices of the CRA, whether by way of judicial, legislative or governmental decision or action. This summary is not exhaustive of all possible Canadian federal income tax considerations and does not take
into account other federal or any provincial, territorial or foreign income tax legislation or considerations, which may differ materially from those described in this summary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This summary does not address the deducibility of interest by a Holder who has borrowed money or otherwise incurred debt in connection with
the acquisition of enGene Shares, enGene Warrants or the Securities. This summary is not applicable to a Holder who acquired enGene Shares or New enGene Shares on the exercise of an employee stock option or other employee compensation arrangement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This summary is of a general nature only and is not, and is not intended to be, and should not be construed to be, legal or tax advice to
any particular Holder, and no representations concerning the tax consequences to any particular Holder are made. The tax consequences of acquiring, holding and disposing of the Securities will vary according to the Holder&#146;s particular
circumstances. Holders should consult their own tax advisors regarding the tax considerations applicable to them having regard to their particular circumstances. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Currency Conversion </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, for purposes of the Tax Act, all amounts relating to the acquisition, holding or disposition of the Securities must be converted
into Canadian dollars based on the relevant exchange rate as determined in accordance with the Tax Act. The amount of dividends required to be included in the income of, and capital gains or capital losses realized by, a Canadian Resident Holder (as
defined below) may be affected by fluctuations in the Canadian / U.S. dollar exchange rate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Exercise of New enGene Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No gain or loss will be realized by a Holder of a New enGene Warrant upon the exercise of such New enGene Warrant. When a New enGene Warrant is
exercised, the Holder&#146;s cost of the New enGene Share acquired thereby will be equal to the adjusted cost base of the New enGene Warrant to such Holder, plus the amount paid on the exercise of the New enGene Warrant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">426 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Holders Resident in Canada </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following portion of the summary applies to a Holder who, for purposes of the Tax Act and any applicable income tax treaty or convention,
is, or is deemed to be, resident in Canada and no other country at all relevant times (a &#147;Canadian Resident Holder&#148;). This summary is not applicable to a Canadian Resident Holder (a)&nbsp;that is a &#147;financial institution&#148; for
purposes of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> rules contained in the Tax Act, (b)&nbsp;that is a &#147;specified financial institution&#148; as defined in the Tax Act, (c)&nbsp;an
interest in which is a &#147;tax shelter investment&#148; as defined in the Tax Act, (d)&nbsp;that reports its &#147;Canadian tax results&#148; as defined in the Tax Act in a currency other than Canadian currency, (e)&nbsp;that will receive
dividends on the New enGene Shares under or as part of a &#147;dividend rental arrangement&#148; as defined in the Tax Act, (f)&nbsp;that has entered or will enter into, with respect to the Securities, a &#147;derivative forward agreement&#148; or
&#147;synthetic disposition arrangement&#148;, each as defined in the Tax Act, or (g)&nbsp;that is exempt from tax under the Tax Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A
Canadian Resident Holder to whom the New enGene Shares might not constitute capital property may make, in certain circumstances, an irrevocable election permitted by subsection 39(4) of the Tax Act to have their New enGene Shares, and every other
&#147;Canadian security&#148;, as defined in the Tax Act, held by such Canadian Resident Holder in the taxation year of the election and in all subsequent taxation years, treated as capital property. Canadian Resident Holders should consult their
own tax advisors regarding this election. New enGene Warrants will not be &#147;Canadian securities&#148; for purposes of this election. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This summary does not address the possible application of the &#147;foreign affiliate dumping&#148; rules that may be applicable to a Canadian
Resident Holder that is a corporation resident in Canada (for the purposes of the Tax Act) and is, or becomes, or does not deal at arm&#146;s length with a corporation resident in Canada that is, or that becomes as part of a transaction or event or
series of transactions or events that includes the acquisition of the Securities, controlled by a <FONT STYLE="white-space:nowrap">non-resident</FONT> person, or a group of <FONT STYLE="white-space:nowrap">non-resident</FONT> persons not dealing
with each other at arm&#146;s length, in each case for purposes of the rules in section 212.3 of the Tax Act. Any such Canadian Resident Holder to which this summary does not apply should consult its own tax advisor with respect to the tax
consequences applicable to the acquisition, holding and disposition of the Securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Expiry of New enGene Warrants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, the expiry of an unexercised New enGene Warrant will give rise to a capital loss equal to the adjusted cost base to the Canadian
Resident Holder of such expired New enGene Warrant. See &#147;<I>Holders Resident in Canada </I><B><I>&#151;</I></B><I> Dispositions of Securities</I>&#148; below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Dividends on New enGene Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends (including deemed dividends) received on the New enGene Shares by a Canadian Resident Holder who is an individual (other than certain
trusts) will be included in the individual&#146;s income and will be subject to the <FONT STYLE="white-space:nowrap">gross-up</FONT> and dividend tax credit rules applicable to taxable dividends received by individuals from &#147;taxable Canadian
corporations&#148;, as defined in the Tax Act, including the enhanced dividend tax credit rules applicable to any dividends designated by New enGene as &#147;eligible dividends&#148; in accordance with the Tax Act. There may be limitations on the
ability of New enGene to designate dividends as eligible dividends. Dividends received by individuals (other than certain trusts) may give rise to alternative minimum tax under the Tax Act, depending on the individual&#146;s circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends (including deemed dividends) received on the New enGene Shares by a Canadian Resident Holder that is a corporation will be included
in computing the corporation&#146;s income and will generally be deductible in computing its taxable income. In certain circumstances, subsection 55(2) of the Tax Act will treat a taxable dividend received by a Canadian Resident Holder that is a
corporation as proceeds of disposition or a capital gain. Canadian Resident Holders that are corporations are urged to consult their own tax advisors having regard to their particular circumstances. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">427 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A Canadian Resident Holder that is a &#147;private corporation&#148; or a &#147;subject
corporation&#148;, each as defined in the Tax Act, may be liable to pay a refundable tax under Part IV of the Tax Act on dividends received (or deemed to be received) on the New enGene Shares to the extent that such dividends are deductible in
computing the Canadian Resident Holder&#146;s taxable income. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A Canadian Resident Holder that is throughout the relevant taxation year a
&#147;Canadian-controlled private corporation&#148;, as defined in the Tax Act, may be liable for an additional tax (refundable in certain circumstances) in respect of its &#147;aggregate investment income&#148;, as defined in the Tax Act, for the
year, which includes dividends received or deemed to be received in respect of New enGene Shares, but not dividends or deemed dividends that are deductible in computing the dividend recipient&#146;s taxable income. Tax Proposals released on
August&nbsp;9, 2022, are intended to extend this additional tax and refund mechanism in respect of &#147;aggregate investment income&#148; to &#147;substantive CCPCs&#148; as defined in such Tax Proposals. Canadian Resident Holders are advised to
consult their own tax advisors regarding the possible implications of these Tax Proposals in their particular circumstances. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Dispositions of Securities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, upon a disposition (or a deemed disposition) of a New enGene Share or a New enGene Warrant (other than upon the exercise of a New
enGene Warrant or a disposition of a New enGene Share to New enGene unless purchased by New enGene in the open market in the manner in which shares are normally purchased by any member of the public in the open market), a Canadian Resident Holder
will realize a capital gain (or a capital loss) equal to the amount by which the Canadian Resident Holder&#146;s proceeds of disposition are greater (or less) than the Canadian Resident Holder&#146;s adjusted cost base of the New enGene Share or the
New enGene Warrant, respectively, and any reasonable costs of disposition. The adjusted cost base to the Canadian Resident Holder of a New enGene Share or a New enGene Warrant acquired will be determined by averaging the cost of the New enGene Share
or the New enGene Warrant, respectively, with the adjusted cost base of all other New enGene Shares or New enGene Warrants, respectively, owned by the Canadian Resident Holder as capital property immediately before the time of acquisition, if any.
The treatment of capital gains and capital losses is discussed below under &#147;<I>Holders Resident in Canada &#151; Taxation of Capital Gains and Capital Losses</I>.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Taxation of Capital Gains and Capital Losses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, <FONT STYLE="white-space:nowrap">one-half</FONT> of any capital gain (a &#147;taxable capital gain&#148;), realized by a Canadian
Resident Holder in a taxation year must be included in the Canadian Resident Holder&#146;s income for that year and <FONT STYLE="white-space:nowrap">one-half</FONT> of any capital loss (an &#147;allowable capital loss&#148;) realized by a Canadian
Resident Holder in a taxation year must be deducted against taxable capital gains realized by the Canadian Resident Holder in that year. Allowable capital losses in excess of taxable capital gains realized in a particular taxation year generally may
be carried back and deducted in any of the three preceding taxation years or carried forward and deducted in any subsequent taxation year against net taxable capital gains realized by the Canadian Resident Holder in such years, to the extent and in
the circumstances described in the Tax Act. Capital gains realized by an individual (other than certain trusts) may give rise to alternative minimum tax. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amount of any capital loss realized by a Canadian Resident Holder that is a corporation on the disposition (or deemed disposition) of a
New enGene Share may be reduced by the amount of any dividends received (or deemed to be received) by the Canadian Resident Holder on such New enGene Shares (or a share substituted for such New enGene Shares) to the extent and under the
circumstances described in the Tax Act. Similar rules may apply where a New enGene Shares is owned by a partnership or trust of which a corporation, trust or partnership is a member or beneficiary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A Canadian Resident Holder that is throughout the relevant taxation year a &#147;Canadian-controlled private corporation&#148;, as defined in
the Tax Act, may be liable for an additional tax (refundable in certain circumstances) in respect of its &#147;aggregate investment income&#148;, as defined in the Tax Act, for the year, which includes an amount in respect of taxable capital gains.
Tax Proposals released on August&nbsp;9, 2022, are intended to extend this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">428 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
additional tax and refund mechanism in respect of &#147;aggregate investment income&#148; to &#147;substantive CCPCs&#148; as defined in such Tax Proposals. Canadian Resident Holders are advised
to consult their own tax advisors regarding the possible implications of these Tax Proposals in their particular circumstances. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Eligibility for Investment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Provided that on the Closing Date the Securities are listed on a &#147;designated stock exchange&#148; as defined in the Tax Act (which
currently includes the Nasdaq), the Securities will be, at that time, qualified investments under the Tax Act for trusts governed by registered retirement savings plans (&#147;RRSPs&#148;), registered retirement income funds (&#147;RRIFs&#148;),
registered disability savings plans (&#147;RDSPs&#148;), deferred profit sharing plans, registered education savings plans (&#147;RESPs&#148;), <FONT STYLE="white-space:nowrap">tax-free</FONT> savings accounts (&#147;TFSAs&#148;) and first home
savings accounts (&#147;FHSAs&#148;) each as defined in the Tax Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding that the Securities may be qualified investments for
a trust governed by a TFSA, RRSP, RRIF, RDSP, RESP or FHSA, a holder of a TFSA, RDSP or FHSA, an annuitant of an RRSP or RRIF, or a subscriber of an RESP, as applicable, will be subject to a penalty tax under the Tax Act with respect to the
Securities if the Securities are &#147;prohibited investments&#148; for the TFSA, RRSP, RRIF, RDSP, RESP or FHSA. A Security will not be a prohibited investment for a trust governed by a TFSA, RRSP, RRIF, RDSP, RESP or FHSA provided that the
annuitant under the RRSP or RRIF, the holder of the TFSA, RDSP or FHSA or the subscriber of the RESP, as the case may be, deals at arm&#146;s length with New enGene for purposes of the Tax Act, and does not have a &#147;significant interest&#148;
(as defined in the Tax Act for purposes of the prohibited investment rules) in New enGene. In addition, a Security will not be a prohibited investment if the Security is &#147;excluded property&#148; (as defined in the Tax Act for purposes of the
prohibited investment rules) for the TFSA, RRSP, RRIF, RDSP, RESP or FHSA. Holders, annuitants and subscribers should consult their own tax advisors with respect to whether the Securities would be &#147;prohibited investments&#148; in their
particular circumstances. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-Canadian</FONT> Resident Holders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This portion of the summary is applicable to a Holder who, at all relevant times, is neither resident in Canada nor deemed to be resident in
Canada for purposes of the Tax Act and any applicable income tax treaty or convention, and who does not use or hold (and is not deemed to use or hold) the Securities in the course of carrying on, or otherwise in connection with, a business in Canada
(a <FONT STYLE="white-space:nowrap">&#147;Non-Canadian</FONT> Resident Holder&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Special rules, which are not discussed in this
summary, may apply to a <FONT STYLE="white-space:nowrap">Non-Canadian</FONT> Resident Holder that is an &#147;authorized foreign bank&#148; as defined in the Tax Act, or an insurer carrying on business in Canada and elsewhere. Such <FONT
STYLE="white-space:nowrap">Non-Canadian</FONT> Resident Holders should consult their own tax advisors with respect to an investment in the Securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Dividends on New enGene Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends paid or credited (or deemed to be paid or credited) on a New enGene Share to a <FONT STYLE="white-space:nowrap">Non-Canadian</FONT>
Resident Holder by New enGene will be subject to Canadian withholding tax at the rate of 25%, subject to a reduction of such rate under the terms of an applicable income tax treaty or convention. For example, in the case of a <FONT
STYLE="white-space:nowrap">Non-Canadian</FONT> Resident Holder who is a resident of the United States for purposes of the Treaty, who is the beneficial owner of the dividend, and who qualifies for full benefits of the Treaty, the rate of such
withholding tax will generally be reduced to 15% (or 5% if the beneficial owner of such dividend is a corporation that owns at least 10% of the voting stock of New enGene). <FONT STYLE="white-space:nowrap">Non-Canadian</FONT> Resident Holders are
urged to consult their own tax advisors to determine their entitlement to relief under an applicable income tax treaty or convention. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Dispositions of Securities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A <FONT STYLE="white-space:nowrap">Non-Canadian</FONT> Resident Holder generally will not be subject to tax under the Tax Act in respect of a
capital gain or entitled to deduct any capital loss, realized on the disposition or deemed disposition of a Security </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">429 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
unless the Security constitutes (or is deemed to constitute) &#147;taxable Canadian property&#148; of such <FONT STYLE="white-space:nowrap">Non-Canadian</FONT> Resident Holder for purposes of the
Tax Act, and the gain is not exempt from tax pursuant to the terms of an applicable income tax treaty or convention. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Provided the New
enGene Shares are listed on a &#147;designated stock exchange&#148; as defined in the Tax Act (which currently includes the Nasdaq) at the time of disposition, the Securities generally will not constitute taxable Canadian property of a <FONT
STYLE="white-space:nowrap">Non-Canadian</FONT> Resident Holder unless, at any time during the <FONT STYLE="white-space:nowrap">60-month</FONT> period immediately preceding the disposition the following two conditions are met concurrently: (i) 25% or
more of the issued shares of any class or series of the capital stock of New enGene were owned by or belonged to one or any combination of (a)&nbsp;the <FONT STYLE="white-space:nowrap">Non-Canadian</FONT> Resident Holder, (b)&nbsp;persons with whom
the <FONT STYLE="white-space:nowrap">Non-Canadian</FONT> Resident Holder did not deal at arm&#146;s length, and (c)&nbsp;partnerships in which the <FONT STYLE="white-space:nowrap">Non-Canadian</FONT> Resident Holder or a person described in
(b)&nbsp;holds a membership interest directly or indirectly through one or more partnerships; and (ii)&nbsp;more than 50% of the fair market value of the New enGene Shares was derived, directly or indirectly, from one or any combination of
(a)&nbsp;real or immovable property situated in Canada, (b) &#147;Canadian resource property&#148; (as defined in the Tax Act), (c) &#147;timber resource property&#148; (as defined in the Tax Act), or (d)&nbsp;options in respect of, interests in, or
for civil law rights in, such properties, whether or not such property exists. Notwithstanding the foregoing, a Security may be deemed to be taxable Canadian property in certain circumstances specified in the Tax Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Securities are taxable Canadian property of a <FONT STYLE="white-space:nowrap">Non-Canadian</FONT> Resident Holder, any capital gain
realized on the disposition or deemed disposition of such Security may not be subject to tax under the Tax Act pursuant to the terms of an applicable income tax treaty or convention. <FONT STYLE="white-space:nowrap">Non-Canadian</FONT> Resident
Holders whose Securities may constitute taxable Canadian property should consult their own tax advisors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">430 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom459793_46"></A>CAYMAN ISLAND APPRAISAL RIGHTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FEAC Shareholders that dissent from a merger are entitled to be paid the fair market value of their shares, which if necessary may ultimately
be determined by the court. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom459793_47"></A>SHAREHOLDER COMMUNICATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shareholders and interested parties may communicate with FEAC&#146;s board of directors, any committee chairperson or the <FONT
STYLE="white-space:nowrap">non-management</FONT> directors as a group by writing to the board or committee chairperson in care of Forbion European Acquisition Corp., 4001 Kennett Pike, Suite 302, Wilmington, Delaware 19807. Following the Business
Combination, such communications should be sent to New enGene, 7171 Rue Frederick Banting, Saint-Laurent, QC H4S 1Z9, Canada, Attention: Investor Relations. Each communication will be forwarded, depending on the subject matter, to the board of
directors, the appropriate committee chairperson or all <FONT STYLE="white-space:nowrap">non-management</FONT> directors. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom459793_48">
</A>VALIDITY OF COMMON SHARES AND WARRANTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the New enGene Shares to be issued in connection with the Business
Combination will be passed upon by Blake, Cassels&nbsp;&amp; Graydon LLP. The validity of the New enGene Warrants to be issued in connection with the Business Combination will be passed upon by Morgan, Lewis&nbsp;&amp; Bockius LLP. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom459793_49"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements of Forbion European Acquisition Corp. for the year ended December&nbsp;31, 2022 and the period from August&nbsp;9,
2021 (inception) through December&nbsp;31, 2021, and as of December&nbsp;31, 2022 and December&nbsp;31, 2021, included in the registration statement of which this proxy statement/prospectus forms a part, have been audited by Marcum LLP, independent
registered public accounting firm, as stated in their report appearing herein which contains an explanatory paragraph relating to substantial doubt about the ability of Forbion European Acquisition Corp. to continue as a going concern as described
in Note 1 to the financial statements. Such financial statements have been so included in reliance upon the report of such firm given upon their authority as experts in accounting and auditing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of enGene Inc. as of October&nbsp;31, 2022 and 2021, and for each of the years in the three-year period
ended October&nbsp;31, 2022, have been included in the registration statement of which this proxy statement/prospectus forms a part, in reliance upon the report of KPMG LLP, independent registered public accounting firm, appearing elsewhere herein,
and upon the authority of said firm as experts in accounting and auditing. The audit report covering the October&nbsp;31, 2022 consolidated financial statements contains an explanatory paragraph that states enGene Inc. has incurred a net loss and
negative cash flows from operating activities for the year ended October&nbsp;31, 2022, has an accumulated deficit at October&nbsp;31, 2022, and will need additional financing in order to meets its obligations and fund its future expected negative
cash flows, that raise substantial doubt about its ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements of enGene Holdings Inc. as of July 31, 2023 and for the period from April 24, 2023 (inception) to July 31, 2023, have
been included in the registration statement of which this proxy statement/prospectus forms a part in reliance upon the report of KPMG LLP, independent registered public accounting firm, appearing elsewhere herein, and upon the authority of said firm
as experts in accounting and auditing. The audit report covering the July 31, 2023 financial statements contains an explanatory paragraph that states enGene Holdings Inc. has incurred net losses since its inception and requires financing to meet its
liabilities, that raise substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">431 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom459793_50"></A>HOUSEHOLDING; DELIVERY OF DOCUMENTS TO SHAREHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the rules of the SEC, FEAC and services that it employs to deliver communications to its shareholders are permitted to deliver to
two or more shareholders sharing the same address a single copy of each of FEAC&#146;s annual report to shareholders and FEAC&#146;s proxy statement. Upon written or oral request, FEAC will deliver a separate copy of the annual report to
shareholders and/or proxy statement to any shareholder at a shared address to which a single copy of each document was delivered and who wishes to receive separate copies of such documents. Shareholders receiving multiple copies of such documents
may likewise request that FEAC delivers single copies of such documents in the future. Shareholders may notify FEAC of their requests by calling or writing FEAC at its principal executive offices at 4001 Kennett Pike, Suite 302, Wilmington, Delaware
19807. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom459793_51"></A>ENFORCEABILITY OF CIVIL LIABILITY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FEAC </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FEAC is a Cayman Islands exempted
company. You may have difficulty serving legal process within the United States upon FEAC. The Cayman Islands has a different body of securities laws as compared to the United States and provides less protection to investors. Additionally, Cayman
Islands companies may not have standing to sue before the Federal courts of the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FEAC has been advised by Maples, its
Cayman Islands legal counsel, that the courts of the Cayman Islands are unlikely (i)&nbsp;to recognize or enforce against FEAC judgments of courts of the United States predicated upon the civil liability provisions of the federal securities laws of
the United States or any state; and (ii)&nbsp;in original actions brought in the Cayman Islands, to impose liabilities against FEAC predicated upon the civil liability provisions of the federal securities laws of the United States or any state, so
far as the liabilities imposed by those provisions are penal in nature. In those circumstances, although there is no statutory enforcement in the Cayman Islands of judgments obtained in the United States, the courts of the Cayman Islands will
recognize and enforce a foreign money judgment of a foreign court of competent jurisdiction without retrial on the merits based on the principle that a judgment of a competent foreign court imposes upon the judgment debtor an obligation to pay the
sum for which judgment has been given provided certain conditions are met. For a foreign judgment to be enforced in the Cayman Islands, such judgment must be final and conclusive and for a liquidated sum, and must not be in respect of taxes or a
fine or penalty, inconsistent with a Cayman Islands judgment in respect of the same matter, impeachable on the grounds of fraud or obtained in a manner, and or be of a kind the enforcement of which is, contrary to natural justice or the public
policy of the Cayman Islands (awards of punitive or multiple damages may well be held to be contrary to public policy). A Cayman Islands Court may stay enforcement proceedings if concurrent proceedings are being brought elsewhere. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">432 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom459793_52"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">New enGene has filed a registration statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> to register the issuance of securities
described elsewhere in this proxy statement/prospectus. This proxy statement/prospectus is a part of that registration statement. This proxy statement/prospectus does not contain all of the information included in the registration statement. For
further information pertaining to New enGene and its securities, you should refer to the registration statement and to its exhibits. Whenever reference is made in this proxy statement/prospectus to any of New enGene or FEAC&#146;s contracts,
agreements or other documents, the references are not necessarily complete, and you should refer to the annexes to the proxy statement/prospectus and the exhibits attached to the registration statement for copies of the actual contract, agreement or
other document. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the effectiveness of the registration statement of which this proxy statement/prospectus forms a part, New enGene
will be subject to the information and periodic reporting requirements of the Exchange Act and will file annual, quarterly and current reports, proxy statements and other information with the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FEAC files reports, proxy statements and other information with the SEC as required by the Exchange Act. You may access information on FEAC at
the SEC web site containing reports, the registration statement and other information at: http://www.sec.gov. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you would like
additional copies of this proxy statement/prospectus or any document incorporated by reference herein, or if you have questions about the Business Combination, you should contact via phone or in writing: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Morrow Sodali LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">333 Ludlow
Street, 5th Floor, South Tower </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Stamford, CT 06902 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Individuals call toll-free <FONT STYLE="white-space:nowrap">(800)&nbsp;662-5200</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Banks and brokers call <FONT STYLE="white-space:nowrap">(203)&nbsp;658-9400</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Email: FEAC.info@investor.morrowsodali.com<B> </B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>If you are a shareholder of FEAC and would like to request documents, please do so no later than </B><B>four</B><B> business days before
the Special Meeting in order to receive them before the Special Meeting</B>. If you request any documents from Morrow, Morrow will mail them to you by first class mail, or another equally prompt means. Information and statements contained in this
proxy statement/prospectus or any annex to this proxy statement/prospectus are qualified in all respects by reference to the copy of the relevant contract or other annex filed as an exhibit to the registration statement of which this proxy
statement/prospectus forms a part, which includes exhibits incorporated by reference from other filings made with the SEC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">433 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom459793_53"></A>INDEX TO FINANCIAL STATEMENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="94%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B><I>enGene Inc.</I></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin459793_300">Condensed Consolidated Balance Sheets as of April 30, 2023 and October&nbsp;31,
 2022 (Unaudited)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin459793_301">Condensed Consolidated Statements of Operations and Comprehensive Loss for the
 Three and Six Months Ended April 30, 2023 and 2022 (Unaudited)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin459793_302">Condensed Consolidated Statements of Redeemable Convertible Preferred Shares
 and Shareholders&#146; Deficit for the Three and Six Months Ended April 30, 2023 and 2022 (Unaudited)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin459793_303">Condensed Consolidated Statements of Cash Flows for the Six Months Ended April
 30, 2023 and 2022 (Unaudited)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin459793_304">Notes to Condensed Consolidated Financial Statements </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fintoc459793_1">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fintoc459793_2">Consolidated Balance Sheets as of October 31, 2022 and 2021</A></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fintoc459793_3">Consolidated Statements of Operations and Comprehensive Loss for the Years
 Ended October&nbsp;31, 2022, 2021 and 2020</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin459793_200">Consolidated Statements of Redeemable Convertible Preferred Shares and Shareholders&#146;
 Deficit for the Years Ended October 31, 2022, 2021 and 2020 </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fintoc459793_4">Consolidated Statement of Cash Flows for the Years ended October 31, 2022,
 2021 and 2020</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fintoc459793_5">Notes to Consolidated Financial Statements </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Forbion European Acquisition Corp.</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fintoc459793_6">Condensed Balance Sheets as of June 30, 2023 (Unaudited) and December 31, 2022
 (Audited)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fintoc459793_7">Condensed Statements of Operations for the Three and Six Months Ended June
 30, 2023 and 2022 (Unaudited)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fintoc459793_8">Condensed Statements of Changes in Shareholders&#146; Deficit for the Three
 and Six Months Ended June&nbsp;30, 2023 and 2022 (Unaudited)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fintoc459793_9">Condensed Statements of Cash Flows for the Six Months Ended June 30, 2023 and
 2022 (Unaudited)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fintoc459793_10">Notes to Condensed Financial Statements (Unaudited)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fintoc459793_11">Report of Independent Registered Public Accounting Firm (PCAOB ID No. 688)
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fintoc459793_12">Balance Sheets as of December 31, 2022 and 2021</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fintoc459793_13">Statements of Operations for the Year Ended December 31, 2022 and for the
 Period from August&nbsp;9, 2021 (Inception) through December 31, 2021</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fintoc459793_14">Statements of Changes in Shareholders&#146; Deficit for the Year Ended December
 31, 2022 and for the Period from August 9, 2021 (Inception) through December 31, 2022</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fintoc459793_15">Statements of Cash Flows for the Year Ended December 31, 2022 and for the
 Period from August&nbsp;9, 2021 (Inception) through December 31, 2021</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fintoc459793_16">Notes to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>enGene Holdings Inc.</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fintoc459793_171">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fintoc459793_172">Balance Sheet as of July 31, 2023</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fintoc459793_172a">Statement of Operations and Comprehensive Loss for April 24, 2022 (inception)
 to July 31, 2023 </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fintoc459793_172b">Statement of Redeemable Common Shares and Shareholder&#146;s Deficit for
 April 24, 2022 (inception) to July&nbsp;31, 2023 </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fintoc459793_172c">Statement of Cash Flows for April 24, 2022 (inception) to July 31, 2023
 </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fintoc459793_173">Notes to Financial Statements </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin459793_300"></A>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDENSED CONSOLIDATED BALANCE SHEETS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(UNAUDITED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>April&nbsp;30,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>October&nbsp;31,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted certificate of deposit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investment tax credits receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,057</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,641</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities, redeemable convertible preferred shares and shareholders&#146;
deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,786</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">723</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of notes payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Note payable, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible debentures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible debenture embedded derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,791</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;A redeemable convertible preferred shares, no par value; unlimited shares authorized,
1,477,715, and 1,477,715 shares issued and outstanding as of April&nbsp;30, 2023, and October&nbsp;31, 2022, respectively. Redemption amount of $3,777 and $3,634 as of April&nbsp;30, 2023, and October&nbsp;31, 2022, respectively.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;B redeemable convertible preferred shares, no par value; unlimited shares authorized,
864,570 and 864,570 shares issued and outstanding as of April&nbsp;30, 2023, and October&nbsp;31, 2022, respectively. Redemption amount of $1,593 and $1,533 as of April&nbsp;30, 2023, and October&nbsp;31, 2022, respectively.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;C redeemable convertible preferred shares, no par value; unlimited shares authorized,
30,810,114, and 30,810,114 issued and outstanding as of April&nbsp;30, 2023 and October&nbsp;31, 2022, respectively. Redemption amount of $109,717 and $107,462, as of April&nbsp;30, 2023, and October&nbsp;31, 2022, respectively.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shareholders&#146; deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common shares, no par value, unlimited shares authorized, 3,885,897 and 3,688,872 shares issued
and outstanding as of April&nbsp;30, 2023, and October&nbsp;31, 2022, respectively.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,683</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,016</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,016</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(112,371</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(99,671</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total shareholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(89,238</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(76,614</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities, redeemable convertible preferred shares and shareholders&#146; deficit</P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these condensed consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin459793_301"></A>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(UNAUDITED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended&nbsp;April&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended April&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2023&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2022&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">807</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other (income) expense, net:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of convertible debentures embedded derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">(625</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">(318</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">(408</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,526</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(149</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(316</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(30</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,352</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense (income), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(199</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other expense (income), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,767</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividends to redeemable convertible preferred shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,457</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,089</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,698</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive loss (gain):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency translation adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(64</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(55</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share of common shares, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average common shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,849,767</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,622,186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,768,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,616,193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these condensed consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin459793_302"></A>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS&#146; DEFICIT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(UNAUDITED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;A<BR>Redeemable<BR>Convertible</B><br><B>Preferred&nbsp;Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;B</B><br><B>Redeemable<BR>Convertible<BR>Preferred&nbsp;Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;C</B><br><B>Redeemable</B><br><B>Convertible</B><br><B>Preferred&nbsp;Shares</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common&nbsp;Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR>Paid in<BR>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Other</B><br><B>Comprehensive<BR>Loss</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Shareholders&#146;</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Balance at October&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,477,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">864,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,810,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49,665</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,606,261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,183</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(75,209</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(53,442</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Share-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Foreign currency translation adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,025</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,025</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Balance at January&nbsp;31, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,477,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">864,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,810,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49,665</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,612,492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,194</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(79,234</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(57,452</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Share-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Foreign currency translation adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,324</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,324</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Balance at April&nbsp;30, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,477,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">864,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,810,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49,665</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,624,340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,130</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(84,558</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(62,679</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these condensed consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS&#146; DEFICIT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(UNAUDITED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="29%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;A</B><br><B>Redeemable<BR>Convertible</B><br><B>Preferred Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;B</B><br><B>Redeemable<BR>Convertible<BR>Preferred&nbsp;Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;C</B><br><B>Redeemable</B><br><B>Convertible</B><br><B>Preferred Shares</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR>Paid in<BR>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Other</B><br><B>Comprehensive<BR>Loss</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Shareholders&#146;</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Balance at October&nbsp;31, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,477,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">864,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,810,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49,665</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,688,872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,683</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,016</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(99,671</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(76,614</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Share-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,418</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,418</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Balance at January&nbsp;31, 2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,477,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">864,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,810,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49,665</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,698,872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,016</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(107,089</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(84,012</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Issuance of common shares upon cashless exercise of options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Share-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,282</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,282</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Balance at April&nbsp;30, 2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,477,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">864,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,810,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49,665</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,885,897</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,016</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(112,371</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(89,238</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these condensed consolidated financial statements.</I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin459793_303"></A>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(UNAUDITED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended</B><br><B>April&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from operating activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,700</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9,349</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,526</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of convertible debenture embedded derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(318</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(408</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Debt issuance costs expensed upon issuance of debt recorded at the fair value option</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> lease expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(39</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investment tax credit receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(722</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">752</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(190</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(244</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,271</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(78</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10,667</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,186</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(23</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(115</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(23</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(115</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of April 2023 Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment of issuance costs associated with April 2023 Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(132</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of term loan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payments of issuance costs associated with term loan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(391</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repayment of short-term debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,010</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payments of FEAC merger and PIPE financing transaction costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(132</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of exchange rate changes on cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(342</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net decrease in cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,936</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,039</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash at beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash at end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,978</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental <FONT STYLE="white-space:nowrap">non-cash</FONT> investing and financing
activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant liability recognized upon issuance of term loan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FEAC merger and PIPE financing transaction costs included within accrued expenses and accounts
payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash paid for interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">676</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these condensed consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin459793_304"></A>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(UNAUDITED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Description of Business </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">enGene Inc. (&#147;enGene&#148; or the &#147;Company&#148;) is a biopharmaceutical company located in Montreal, Quebec, Canada, with its head
office in Canada, and incorporated pursuant to the Canada Business Corporations Act on November&nbsp;9, 1999. The Company is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is
developing <FONT STYLE="white-space:nowrap">non-viral</FONT> gene therapies based on its novel and proprietary dually derived chitosan, or &#147;DDX&#148;, gene delivery platform, which allows localized delivery of multiple gene cargos directly to
mucosal tissues and other organs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Going Concern </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which
presumes the Company will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities and commitments in the ordinary course of business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has incurred a net loss of $5.3&nbsp;million and $12.7&nbsp;million for the three and six months ended April&nbsp;30, 2023, and
negative cash flows from operating activities of $10.7&nbsp;million during the six months ended April&nbsp;30, 2023, and, as of that date, has an accumulated deficit of $112.4&nbsp;million. To date, the Company has not generated any revenues and has
financed its liquidity needs primarily through the issuance of redeemable convertible Preferred Shares and warrants, debt and convertible debentures and the Company will need additional financing in order to meets its obligations and fund its future
expected negative cash flows. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s ability to continue as a going concern depends on its ability to successfully develop
and commercialize its product, achieve and maintain profitable operations, as well as its ability to obtain additional financing and on the continued financial support of its shareholders and debt holders. Management&#146;s plans are to raise
additional financing. While the Company has historically been successful in securing financing, raising additional funds is dependent on a number of factors outside of the Company&#146;s control, and as such there is no assurance that it will be
able to do so in the future. These conditions indicate the existence of a material uncertainty that raise substantial doubt on the Company&#146;s ability to continue as a going concern and, therefore, that it may be unable to realize its assets and
discharge its liabilities in the normal course of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is seeking to complete an equity financing and business
combination transaction with a special purpose acquisition company (&#147;SPAC&#148;) (see Business Combination with Forbion European Acquisition Corp. below). As part of the transaction, the Company&#146;s outstanding convertible Preferred Shares
and the majority of its convertible debt would be exchanged for common shares of the combined company. These plans are intended to mitigate the relevant conditions that raise substantial doubt about the Company&#146;s ability to continue as a going
concern; however, as the plans are not within the Company&#146;s control, it is not assured that they will be effectively implemented. In the event the Company does not complete a SPAC merger, the Company expects to seek additional funding in order
to repay debt, as needed, and successfully develop and commercialize its products through private equity financings, debt financings, collaborations, licensing arrangements, and/or strategic alliances. The Company may not be able to obtain financing
on acceptable terms, or at all, and the Company may not be able to enter into collaborations or other such arrangements. The terms of any financing may adversely affect the holdings or the rights of the Company&#146;s shareholders. If the Company is
unable to raise capital when needed, or on attractive terms, it could be forced to delay, reduce or eliminate its research or drug development programs or any future commercialization efforts. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(UNAUDITED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These consolidated financial statements do not include any adjustments to the amounts and
classification of assets and liabilities that results from the outcome of this uncertainty. Such adjustments could be material. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Business
Combination with Forbion European Acquisition Corp. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;16, 2023, the Company entered into a business combination
agreement with Forbion European Acquisition Corp. (&#147;FEAC&#148;), a publicly traded SPAC. Under the terms of the proposed transaction, the combined company will be named enGene Holdings Inc. (&#147;Newco&#148;) whose common shares are expected
to be listed on Nasdaq. The cash components of the transaction will be funded by FEAC&#146;s cash in trust that is not used for redemptions, as well as investments consisting of private placements of common shares, other private investments and a
FEAC shareholder <FONT STYLE="white-space:nowrap">non-redemption</FONT> commitment of approximately $115&nbsp;million which includes the $18.4&nbsp;million received from the 2022 Notes (as defined in Note 8), $8.0&nbsp;million received from the
April 2023 Notes (as defined in Note 7) and the $30.0&nbsp;million received from the 2023 Financing (as defined in Note 17). Refer to Note 17 Subsequent Events for additional information. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Summary of Significant Accounting Policies </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s significant accounting policies are disclosed in the audited consolidated annual financial statements for the years ended
October&nbsp;31, 2022, 2021 and 2020, and notes thereto. These interim consolidated financial statements should be read in conjunction with the consolidated annual financial statements. Since the date of those annual financial statements, there have
been no changes to the Company&#146;s significant accounting policies, except as noted below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unaudited Interim Financial Information </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying unaudited interim condensed consolidated financial statements have been prepared in conformity with accounting principles
generally accepted in the United States of America (&#147;GAAP&#148;) for interim financial reporting and accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The condensed
consolidated balance sheet at October&nbsp;31, 2022 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. These
interim financial statements include the accounts of the Company and its wholly owned subsidiary, enGene USA, Inc. All intercompany accounts and transactions have been eliminated in consolidation. The unaudited interim condensed consolidated
financial statements have been prepared on the same basis as the audited consolidated annual financial statements as of October, 31 2022 and 2021 and for the years ended October&nbsp;31, 2022, 2021, and 2020 and, in the opinion of management,
reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the Company&#146;s condensed consolidated balance sheet as of April&nbsp;30, 2023, the condensed consolidated statements of operations for
the three and <FONT STYLE="white-space:nowrap">six-</FONT> months ended April&nbsp;30, 2023 and 2022, the condensed consolidated statement of redeemable convertible preferred shares and shareholders&#146; deficit for the three and <FONT
STYLE="white-space:nowrap">six-months</FONT> ended April&nbsp;30, 2023 and 2022, and condensed consolidated statements of cash flows for the six months ended April&nbsp;30, 2023 and 2022. The financial data and other information disclosed in these
notes related to the three and <FONT STYLE="white-space:nowrap">six-months</FONT> ended April&nbsp;30, 2023, and 2022 are unaudited. The results for the six months ended April&nbsp;30, 2023, are not necessarily indicative of results to be expected
for the year ending October&nbsp;31, 2023, any other interim periods, or any future year or period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(UNAUDITED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Functional Currency Change </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to November&nbsp;1, 2022, the Company&#146;s functional currency was the Canadian dollar (&#147;CAD&#148;), and its reporting currency
was the U.S. dollar (&#147;USD&#148;). During the period, the Company reassessed its functional currency and determined that its&nbsp;functional currency be changed&nbsp;from the Canadian dollar to the USD based on management&#146;s analysis as a
result of evaluating criteria within Accounting Standards Codification (&#147;ASC&#148;) 830. The change in functional currency is accounted for prospectively from November&nbsp;1, 2022, and prior year financial statements have not been restated for
the change in functional currency. All assets and liabilities were reported using the same USD values as previously reported under the USD reporting currency described above. As a result, the cumulative translation adjustment balance as of
October&nbsp;31, 2022, is carried forward and will remain unchanged. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company reported net realized and unrealized foreign currency
transaction gains of $0.2&nbsp;million for the three-month period ended April&nbsp;30, 2023 and net realized and unrealized foreign currency transaction losses of $0.1&nbsp;million for the <FONT STYLE="white-space:nowrap">six-month</FONT> period
ended April&nbsp;30, 2023. The Company reported net realized and unrealized foreign currency transaction losses of $0.1&nbsp;million for the three and six months ended April&nbsp;30, 2022, which were reflected within other expense (income), net in
the Company&#146;s consolidated statements of operations and comprehensive loss. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Deferred Transaction Costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with the <FONT
STYLE="white-space:nowrap">in-process</FONT> business combination with FEAC as deferred transaction costs until such transaction is consummated. After consummation of such transaction, these costs are recorded as a reduction of the proceeds received
from the transaction within equity. Should the business combination be abandoned, the deferred transaction costs, currently recorded as deferred transaction costs, will be expensed immediately as a charge to operating expenses in the statements of
operations. The Company did not record any deferred transaction costs as of October&nbsp;31, 2022, and recorded deferred transaction costs of $1.3&nbsp;million as of April&nbsp;30, 2023, which are presented within Other Assets on the Company&#146;s
condensed consolidated balance sheet. Transaction costs of $0.1&nbsp;million related to the April 2023 notes for which the fair value option is elected are not deferred and are included in general and administrative expenses in the Company&#146;s
consolidated statements of operations and comprehensive loss. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value Option </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company elected the fair value option of accounting of ASC 825 for the certain notes from their issuance date in order to not have to
bifurcate any embedded derivatives in accordance with ASC 815. The notes for which the fair value option of accounting is elected are recorded at fair value upon the date of issuance and subsequently remeasured to fair value at each reporting
period. Changes in the fair value of the notes, which include accrued interest, if any, are recorded as a component of other expense (income), net in the consolidated statement of operations and comprehensive loss. The Company has not elected to
present interest expense separately from changes in fair value and therefore will not present interest expense associated with the notes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Government Assistance Programs for Research and Development Expenditures </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is currently eligible to claim Canadian federal and provincial tax credits as a Canadian controlled private corporation
(&#147;CCPC&#148;) on eligible research and development expenditures. The Canadian federal government offers a tax incentive to companies performing research and development activities in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(UNAUDITED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Canada and this tax incentive can be refunded or used to reduce federal income taxes in Canada otherwise payable. Such credits, if not refunded or used in the year earned, can be carried forward
for a period of twenty years. The Quebec provincial government offers a similar refundable incentive. The investment tax credits recorded are based on management&#146;s estimates of amounts expected to be recovered and are subject to audit by the
taxation authorities, the resulting adjustments of which could be significant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Amounts received or receivable resulting from government
assistance programs, including investment tax credits for research and development, are recognized when there is reasonable assurance that the amount will be received, and all attached conditions will be complied with. Reimbursements of eligible
research and development expenditures pursuant to government assistance programs are received in cash and recorded as reductions of research and development costs when the related costs have been incurred and there is reasonable assurance regarding
collection of the claim. During the three and six months ended April&nbsp;30, 2023, the Company recorded $0.4&nbsp;million, and $0.7&nbsp;million, respectively, as a reduction of research and development expense associated with research and
development investment tax credits. During the three and six months ended April&nbsp;30, 2022, the Company recorded $0.3&nbsp;million, and $0.8&nbsp;million, respectively, as a reduction of research and development expense associated with research
and development investment tax credits. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently Adopted and Issued Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There have been no changes from the financial statements for the year ended October&nbsp;31, 2022. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Fair Value Measurements </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents the Company&#146;s fair value hierarchy for financial assets and liabilities measured as of April&nbsp;30, 2023,
and October&nbsp;31, 2022: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>April&nbsp;30, 2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Quoted&nbsp;Prices&nbsp;in<BR>Active Markets<BR>for Identical<BR>Assets (Level 1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant&nbsp;Other<BR>Observable<BR>Inputs (Level 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant&nbsp;Other<BR>Observable<BR>Inputs (Level 3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B></B><I>Liabilities</I><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible debenture embedded derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 3,474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">April 2023 Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total financial liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,477</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,477</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="12"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>October&nbsp;31, 2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Quoted&nbsp;Prices&nbsp;in<BR>Active Markets<BR>for Identical<BR>Assets (Level 1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant&nbsp;Other<BR>Observable<BR>Inputs (Level 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant&nbsp;Other<BR>Observable<BR>Inputs (Level 3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B></B><I>Liabilities</I><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible debenture embedded derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,791</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,791</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total financial liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(UNAUDITED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of April&nbsp;30, 2023, and October&nbsp;31, 2022, the Company had no financial assets
that required fair value measurement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of April&nbsp;30, 2023, and October&nbsp;31, 2022, the Company had Level&nbsp;3 financial
liabilities that were measured at fair value on a recurring basis. The Company&#146;s convertible debenture embedded derivative liabilities, April 2023 Notes and warrant liabilities were carried at fair value determined using Level&nbsp;3 inputs in
the fair value hierarchy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the three and <FONT STYLE="white-space:nowrap">six-months</FONT> ended April&nbsp;30, 2023, and the year
ended October&nbsp;31, 2022, there were no transfers or reclassifications between fair value measure levels of liabilities. The carrying values of all financial current assets, accounts payable and accrued expenses approximate their fair values due
to the short-term nature of these assets and liabilities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Convertible Debentures Embedded Derivative Liabilities</I><B><I> </I></B><I> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s convertible debentures contain equity conversion options, extension features, and certain repayment features, that have been
identified as a single compound embedded derivative requiring bifurcation from the host contract. The Company estimated the fair value of the convertible debenture embedded derivative liabilities on issuance using a probability weighted scenario
expected return model. The estimated probability and timing of underlying events triggering the conversion and liquidity repayment features and probability of exercise of the extension features within the convertible debentures as well as discount
rates, volatility and share prices are inputs used to determine the estimated fair value of the embedded derivative. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assumptions
ranges that the Company used to determine the fair value of the convertible debentures embedded derivative liabilities for the notes that were outstanding as of each respective period (refer to Note 8 for description of notes) were as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>April&nbsp;30,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>October&nbsp;31,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Probability of qualified financing*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share price (CAD)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 2.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 2.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Discount rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">10.4-18.4</FONT></TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">10.4-18.4</FONT></TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected time to respective scenarios</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.4&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.4 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The probability represents the cumulated probabilities of conversion at various dates before maturity. The
probability includes the probability of a SPAC transaction (which corresponds to a listing event for the 2022 Notes and to a liquidity event for the BDC Notes). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(UNAUDITED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table provides a summary of the change in the estimated fair value of the
Company&#146;s convertible debentures embedded derivative liabilities for the three and <FONT STYLE="white-space:nowrap">six-months</FONT> ended April&nbsp;30, 2023, and 2022 are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>


<TR STYLE="font-size:1px; "></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of October&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of convertible debenture embedded derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(408</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign exchange rate translation adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of January&nbsp;31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of convertible debenture embedded derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign exchange rate translation adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of April&nbsp;30, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>


<TR STYLE="font-size:1px; "></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of October&nbsp;31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,791</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of convertible debenture embedded derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign exchange (gain)/loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of January&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of convertible debenture embedded derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(625</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign exchange (gain)/loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of April&nbsp;30, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>April 2023 Notes </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company elected the fair value option of accounting for the April 2023 Notes. The Company recorded the April 2023 Notes at fair value upon
the date of issuance, which was determined to be the total cash proceeds received of $8.0&nbsp;million and will subsequently remeasure the notes to fair value at each reporting period. No change in fair value was recorded on the April 2023 Notes
during the three and <FONT STYLE="white-space:nowrap">six-months</FONT> ended April&nbsp;30, 2023, given the close proximity between the issuance date of the notes and the period end. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Warrant Liabilities</I><B><I> </I></B><I> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company issued warrants to purchase shares of redeemable convertible preferred shares as part of the issuance of certain redeemable
convertible preferred shares, convertible debentures, and term loan. The Company estimates the fair value of its warrant liabilities using a Modified Black-Scholes option-pricing model, which includes assumptions that are based on the individual
characteristics of the warrants on the valuation date, and assumptions related to the fair value of the underlying redeemable convertible<B><I> </I></B>preferred shares, expected volatility, expected life, dividends, risk-free interest rate and
discount for lack of marketability (&#147;DLOM&#148;). Due to the nature of these inputs, the warrants are considered a Level&nbsp;3 liability. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(UNAUDITED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The weighted average expected life was estimated based on the weighting of scenarios
considering the probability of different terms up to the contractual term of 10 years in light of the expected timing of a future exit event. The Company determines the expected volatility based on an analysis of reported data for a group of
guideline companies that have issued instruments with substantially similar terms. The expected volatility has been determined using a weighted average of the historical volatility measures of this group of guideline companies. The risk-free
interest rate is determined by reference to the Canadian treasury yield curve in effect at the time of measurement of the warrant liabilities for time periods approximately equal to the weighted average expected life of the warrants. The Company has
not paid, and does not anticipate paying, cash dividends on its redeemable convertible preferred shares; therefore, the expected dividend yield is assumed to be zero. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because there is no public market for the underlying redeemable convertible<B><I> </I></B>preferred shares, the Company has determined their
fair value based on third-party valuations. Initially, the estimated enterprise equity value of the Company was determined using a market approach and/or cost approach by considering the weighting of scenarios estimated using a back-solve method
based on recent financing transactions of the Company. This value was then allocated towards the Company&#146;s various securities of its capital structure using an option pricing method, or OPM, and a waterfall approach based on the order of the
superiority of the rights and preferences of the various securities relative to one another. Significant assumptions used in the OPM to determine the fair value of redeemable convertible preferred shares include volatility, DLOM, and the expected
timing of a future liquidity event such as an IPO or sale of the Company, in light of prevailing market conditions. This valuation process creates a range of equity values both between and within scenarios. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to considering the results of these valuations, the Company considered various objective and subjective factors to determine the
fair value of the Company&#146;s preferred shares as of each valuation date, including the prices at which the Company sold redeemable convertible preferred in the most recent transactions, external market conditions, the progress of the
Company&#146;s research and development programs, the Company&#146;s financial position, including cash on hand, and its historical and forecasted performance and operating results, and the lack of an active public market for the Company&#146;s
redeemable convertible preferred shares, among other factors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assumptions underlying these valuations represented management&#146;s
best estimate, which involved inherent uncertainties and the application of management&#146;s judgment, and these valuations are sensitive to changes in the unobservable inputs. As a result, if we had used different assumptions or estimates, or if
there are changes to the unobservable inputs, the fair value of the warrants shares could have been materially different. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assumptions
that the Company used to determine the fair value of the warrant liabilities as of each period end were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>April&nbsp;30,</B><br><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>October&nbsp;31,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average expected life (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.67</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.92</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred share price &#150; Class&nbsp;C (CAD)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 2.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 2.20</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise price &#150; Class&nbsp;C (CAD)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.632</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(UNAUDITED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table provides a summary of the change in the estimated fair value of the
Company&#146;s warrant liabilities for the three and <FONT STYLE="white-space:nowrap">six-months</FONT> ended April&nbsp;30, 2023, and 2022: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>


<TR STYLE="font-size:1px; "></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of October&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 9,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant liabilities recognized upon issuance of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">854</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign exchange rate translation adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(312</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of January&nbsp;31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign exchange rate translation adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(43</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of April&nbsp;30, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>


<TR STYLE="font-size:1px; "></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of October&nbsp;31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign exchange (gain)/loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of January&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign exchange (gain)/loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(196</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of April&nbsp;30, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Property and Equipment, Net </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of April&nbsp;30, 2023, and October&nbsp;31, 2022, property and equipment, consisted of the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>April&nbsp;30,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>October&nbsp;31,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lab equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,472</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,472</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office furniture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Accumulated depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,553</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depreciation and amortization expense related to property and equipment was $37 and $83 for the three and <FONT
STYLE="white-space:nowrap">six-months</FONT> ended April&nbsp;30, 2023, respectively, and $61 and $133 for the three and <FONT STYLE="white-space:nowrap">six-months</FONT> ended April&nbsp;30, 2022, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(UNAUDITED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Accrued Expenses and Other Current Liabilities </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of April&nbsp;30, 2023, and October&nbsp;31, 2022, accrued expenses and other current liabilities consisted of the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>April&nbsp;30,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>October&nbsp;31,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,845</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">573</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employee compensation and related benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">676</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued income tax payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>License Agreement and Clinical Research Organization </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>License Agreement &#150; Nature Technology Corporation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;10, 2020, the Company entered into a <FONT STYLE="white-space:nowrap">Non-Exclusive</FONT> License Agreement (the &#147;License
Agreement&#148;) with Nature Technology Corporation (&#147;NTC&#148;) whereby the Company licenses certain rights to the technology of radiopharmaceutical products from NTC for commercialization. Under the terms of the License Agreement, NTC granted
to the Company and its affiliates a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> royalty-bearing, sublicensable license to research, have researched, develop, have developed, make, have made, use, have used, import, have imported, sell,
offer to sell, and have sold or offered for sale any product in the defined license field. Unless terminated earlier, the NTC license agreement will continue until no valid claim of any licensed patent exists in any country. The Company can
voluntarily terminate the license agreement with prior notice to NTC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company paid NTC an initial, upfront fee of $50 which was
recorded as research and development expense upon entering into the License Agreement. Beginning on the first anniversary of the effective date of the License Agreement and on each subsequent anniversary, the Company is required to pay NTC a $50
annual maintenance fee. The Company is also required to make a payment to NTC of $50 upon assigning the License Agreement to a third party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The License Agreement provides for a <FONT STYLE="white-space:nowrap">one-time</FONT> payment of $50 for the first dose of a milestone
product, as defined in the License Agreement, in the first patient in a Phase I clinical trial or, if there is no Phase I clinical trial, in a Phase II clinical trial, as well as a <FONT STYLE="white-space:nowrap">one-time</FONT> payment of $450
upon regulatory approval of a milestone product by the U.S. Food and Drug Administration. The first milestone related to the first dose of a milestone product, was achieved during the year ended October&nbsp;31, 2021. The second milestone,
regulatory approval of a milestone product, has not yet been achieved as of the year ended October&nbsp;31, 2022. The Company is also required to pay NTC a royalty percentage in the low single digits of the aggregate net product sales in a calendar
year by the Company, its affiliates or sublicensees on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, as long as the composition or use of the applicable product is covered by a valid claim in the country where the net sales occurred. Royalty
obligations under the license agreement will continue until the expiration of the last valid claim of a licensed patent covering such licensed product in such country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that the Company or any of its affiliates or sublicensees manufactures any Good Manufacturing Practice (&#147;GMP&#148;) lot of a
product, then the Company or any such affiliate or sublicensee will be obligated to pay NTC an amount per manufactured gram of GMP (or its equivalent) lot of product, which varies based on the volume manufactured.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(UNAUDITED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
The payment will expire on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> basis upon receipt of regulatory approval to market a product in
any country in the licensed territory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During each of the three and six months ended April&nbsp;30, 2023 and 2022, the Company incurred
$13 and $25, respectively, of expenses related to the annual maintenance fee under the License Agreement which is recorded within research and development expenses. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Notes Payable </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>2021 Loan and Security Agreement </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
December&nbsp;30, 2021, the Company entered into a Loan and Security Agreement with Hercules Capital, Inc. (&#147;Hercules&#148; or the &#147;Lender&#148;) for the issuance of a term loan facility of up to an aggregate principal amount of up to
$20.0&nbsp;million (the &#147;Term Loans&#148;). The Loan Agreement provides for (i)&nbsp;an initial term loan advance of $7.0&nbsp;million, which closed on December&nbsp;30, 2021, (ii) subject to the achievement of certain Clinical Milestones
(&#147;Clinical Milestone&#148;), a right of the Company to request that the Lender make additional term loan advances to the Company in an aggregate principal amount of up to $4.0&nbsp;million from the achievement of the Clinical Milestone through
June&nbsp;15, 2022, which was drawn in June 2022, and (iii)&nbsp;subject to the achievement of certain financial milestones (&#147;Financial Milestone&#148;), a right of the Company to request that the Lender make additional term loan advances to
the Company in an aggregate principal amount of up to $9.0&nbsp;million from achievement of the Financial Milestone through December&nbsp;15, 2022, which was not achieved. The Company is required to pay an end of term fee (&#147;End of Term
Charge&#148;) equal to 6.35% of the aggregate principal amount of the Term Loans advances upon repayment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Term Loans mature on
July&nbsp;1, 2025, with no option for extension (the &#147;Maturity Date&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Term Loan bears interest at an annual rate equal to
the greater of (i) 8.25% plus the prime rate of interest as reported in the Wall Street Journal minus 3.25% and (ii) 8.25% provided, that, from and after the date the Company achieves the financial milestone, as defined within the agreement, the
reference to 8.25% in clauses (i)&nbsp;and (ii) is reduced to 8.15%. Borrowings under the Loan and Security Agreement are repayable in monthly interest-only payments through June 2023. After the interest-only payment period, borrowings under the
Loan and Security Agreement are repayable in equal monthly payments of principal and accrued interest until the Maturity Date. At the Company&#146;s option, the Company may elect to prepay all, but not less than all, of the outstanding term loan by
paying the entire principal balance and all accrued and unpaid interest thereon plus a prepayment charge equal to the following percentage of the principal amount being prepaid: (i) 3.0% of the principal amount outstanding if the prepayment occurs
in any of the first twelve months following the closing date of the last draw down; (ii) 2.0% of the principal amount outstanding if the prepayment occurs after the first twelve months following the closing date of the last draw down, but on or
prior to twenty-four months following the closing date of the last draw down; and 1.0% of the principal amount outstanding at any time thereafter but prior to the Maturity Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Loan Agreement, the Company granted Hercules a security interest senior to any current and future debts and to any
security interest, in all of the Company&#146;s right, title, and interest in, to and under all of Company&#146;s property and other assets, and certain equity interests and accounts of enGene, subject to limited exceptions including the
Borrower&#146;s intellectual property. The Loan Agreement also contains certain events of default, representations, warranties and <FONT STYLE="white-space:nowrap">non-financial</FONT> covenants of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(UNAUDITED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The debt discount and issuance costs are being accreted to the principal amount of debt and
being amortized from the date of issuance through the Maturity Date to interest expense using the effective-interest rate method. The effective interest rate of the outstanding debt under the Loan Agreement is approximately 17.8% as of
April&nbsp;30, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of April&nbsp;30, 2023 and October&nbsp;31, 2022, the carrying value of the Term Loan consists of the following:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>April&nbsp;30,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>October&nbsp;31,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Note payable, including End of Term Charge</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,699</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,699</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Debt discount, net of accretion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(696</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(891</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Note payable, net of discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of April&nbsp;30, 2023, and October&nbsp;31, 2022, the Company classified $3.6&nbsp;million and
$1.3&nbsp;million of the note payable as current which represents the principal payments due and amortization of the debt discount to be recorded within twelve months from the balance sheet date. During the three and
<FONT STYLE="white-space:nowrap">six-months</FONT> ended April&nbsp;30, 2023, the Company recognized $0.4&nbsp;million and $0.9&nbsp;million of interest expense related to the Loan Agreement, respectively, of which $0.1&nbsp;million and
$0.2&nbsp;million was related to the amortization of the debt discount, respectively. During the three and <FONT STYLE="white-space:nowrap">six-months</FONT> ended April&nbsp;30, 2022, the Company recognized $0.2&nbsp;million and $0.3&nbsp;million
of interest expense related to the Loan Agreement, respectively, of which $0.1&nbsp;million and $0.1&nbsp;million was related to the amortization of the debt discount, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Through April&nbsp;30, 2023, the Company borrowed $11.0&nbsp;million under the Loan Agreement and incurred $1.1&nbsp;million of debt discount
and issuance costs inclusive of facility fees, legal fees, End of Term Charge and initial fair value of the warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Estimated future
principal payments due under the Loan Agreement, including the contractual End of Term Charge are as follows as of April&nbsp;30, 2023: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="26%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Note&nbsp;Principal&nbsp;Payments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023 (remaining 6 months)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,586</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total principal payments, including End of Term Charge</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,699</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of April&nbsp;30, 2023, based on borrowing rates available to the Company for loans with similar terms and
consideration of the Company&#146;s credit risk, the carrying value of the Company&#146;s variable interest rate debt, excluding unamortized debt issuance costs, approximates fair value. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Hercules Warrants </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under
the Loan and Security Agreement, the Company agreed to issue to Hercules warrants (the &#147;Hercules Warrants&#148;) to purchase a number of shares of the Company&#146;s Preferred Shares at the exercise price equal to 2.5% of the aggregate amount
of the Term Loans that are funded, as such amounts are funded. On the Closing Date, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(UNAUDITED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Company issued a warrant to purchase 84,714 Class&nbsp;C Preferred Shares which were determined to have a fair value of $34 upon issuance. On the second tranche closing, in June 2022, the
Company issued an additional warrant to purchase 48,978 Class&nbsp;C Preferred Shares which were determined to have a fair value of $23 upon issuance. The initial Hercules Warrant values are recorded as a discount to the term loan and are being
amortized to interest expense using the effective interest method over the life of the Term Loans. The Company remeasures the fair value of the warrants at each reporting date with changes being recorded as a change in the fair value of the warrant
liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Hercules Warrants will be exercisable for a period of ten years from the date of the issuance of each warrant at a <FONT
STYLE="white-space:nowrap">per-share</FONT> exercise price equal to $2.632 Canadian Dollars, subject to certain adjustments as specified in the warrants. In addition, the Company has granted to the holders of the Hercules Warrants certain
registration rights on a pari passu basis with the holders of outstanding Preferred Shares and warrants to purchase Preferred Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company accounted for the warrants as a liability since they were indexed to the Company&#146;s Preferred Shares classified as temporary equity. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>April 2023 Notes </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
April&nbsp;4, 2023, the Company entered into a note purchase agreement (the &#147;April 2023 Notes&#148;) for a principal amount of $8.0&nbsp;million with Merck Lumira Biosciences Fund, L.P., Merck Lumira Biosciences Fund (Quebec), L.P., Lumira
Ventures III, L.P., Lumira Ventures III (International), L.P., Lumira Ventures IV, L.P., Lumira Ventures IV (International), L.P., Fond de solidarit&eacute; des travailleurs du Qu&eacute;bec (F.T.Q.), and Forbion Capital Fund III Cooperatief U.A.
(collectively the &#147;April 2023 Investors&#148;). The April 2023 Notes had an interest free period of 45 days from the date of issuance, and commencing on the 46th day, is to accrue interest at a rate of 15% per annum. The April 2023 Notes are
classified as current as they mature on the earlier of (i)&nbsp;July 31, 2023; or (ii)&nbsp;the date the Company completes a qualified financing, as defined within the April 2023 Notes as a financing pursuant to which the Company sells convertible
promissory notes, warrants, preferred shares, common shares, or a combination thereof of the Company for an aggregate amount of at least $20.0&nbsp;million. Upon the completion of the 2023 Financing in May 2023 (as defined within Note 17), the
Company issued convertible debentures and warrants of the Company to the April 2023 Note Investors, on the same terms and conditions of the convertible debentures and warrants that were issued to the investors of the 2023 Financing, as repayment of
the April 2023 Notes. Refer to Note 17. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company elected the fair value option of accounting for the April 2023 Notes. The Company
recorded the April 2023 Notes at fair value upon the date of issuance, which was determined to be $8.0&nbsp;million, and subsequently remeasured the April 2023 Notes to fair value at each reporting period. No change in fair value was recorded on the
April 2023 Notes during the three and <FONT STYLE="white-space:nowrap">six-months</FONT> ended April&nbsp;30, 2023, given the close proximity between the issuance date of the April 2023 Notes and the period end. Additionally, the April 2023 Notes
had an interest free period of 45 days and as such there was no interest expense recorded on the April 2023 Notes for the three and six months ended April&nbsp;30, 2023. As a result of applying the fair value option of accounting, direct costs and
fees related to the April 2023 Notes were expensed as incurred and were not deferred. The Company incurred issuance costs of $0.1&nbsp;million associated within the April 2023 Notes, which was reflected within general and administrative expense
within the three and <FONT STYLE="white-space:nowrap">six-months</FONT> consolidated statement of operations for the period ended April&nbsp;30, 2023. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(UNAUDITED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Convertible Debentures </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has issued convertible debentures to various investors. The outstanding principal, accrued interest, and unamortized deferred
financing costs of the convertble debentures recorded on the balance sheet as of each period end are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>April&nbsp;30,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>October&nbsp;31,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BDC Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,497</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022 Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,908</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Convertible debentures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>BDC Notes </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2020, the Company issued a convertible debenture to the Business Development Bank of Canada (&#147;BDC&#148;) in the amount of
$2.2&nbsp;million (the &#147;BDC Notes&#148;). The debt bears interest at rate of 8% per annum and had an initial maturity date of September&nbsp;28, 2023. In December 2021 the Company amended the agreement which resulted in the maturity date
extending to September&nbsp;29, 2025. The BDC Notes are convertible at the option of the Holder into the Company&#146;s Class&nbsp;B redeemable convertible preferred shares at a price of 80% of the price paid per share in qualified financing, as
defined within the BDC convertible debenture agreement. The issuance of the Term Loan in 2021 met the definition of a qualified financing per the BDC convertible debenture agreement. As the conversion option was not exercised upon the issuance of
the Term Loan, the conversion rights upon a qualified financing were waived. There are optional conversion options that still exist if the Company is in default, as defined under the terms of the BDC Notes, or in the event of certain liquidation
events, as defined within the BDC Notes, which allow for conversion of the BDC Note into the most senior share outstanding at the time of the event. If a liquidation event, as defined within the BDC Note agreement, and which includes a SPAC
transaction, is consummated after a qualified financing, and optional conversion is not elected, the Company is required to pay the investor in cash, the outstanding principal and the accrued but unpaid interest and in addition an amount equal to
20% of the principal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon issuance of the BDC Notes, the Company identified embedded derivatives related to the equity conversion
features and liquidity event repayment features which required bifurcation as a single compound derivative instrument. The Company estimated the fair value of the embedded derivative liabilities upon issuance at $0.2&nbsp;million. The Company
remeasured the fair value of the embedded derivatives in effect at each reporting period, with the subsequent changes in the fair value of the derivative being recognized in changes in fair value of derivatives within the Company&#146;s consolidated
statements of operations and comprehensive loss. The estimated fair value of the embedded derivative liabilities at April&nbsp;30, 2023 was $0.3&nbsp;million, resulting in $0.2&nbsp;million and $0.1&nbsp;million recorded in change in fair value of
convertible debentures embedded derivative liabilities in the consolidated statement of operations and comprehensive loss for the three and six months ended April&nbsp;30, 2023, respectively. Total interest expense, including the amortization of
debt discounts, was $60 and $0.1&nbsp;million was recorded for the three and six months ended April&nbsp;30, 2023, respectively. The estimated fair value of the embedded derivative liabilities at April&nbsp;30, 2022 was $0.2&nbsp;million, resulting
in zero and $0.4&nbsp;million recorded in change in fair value of convertible debentures embedded derivative liabilities in the consolidated statement of operations and comprehensive loss for the three and six months ended April&nbsp;30, 2022,
respectively. Total interest expense, including the amortization of debt discounts, was $0.1&nbsp;million and $0.2&nbsp;million for the three and six months ended April&nbsp;30, 2022, respectively. As part of the issuance of the BDC Notes, the
Company incurred an aggregate of $36 of debt issuance costs of which a portion were recorded as a reduction of the carrying value of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(UNAUDITED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the BDC Notes, and a portion was allocated to the embedded derivative liabilities which were expensed as incurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of April&nbsp;30, 2023, based on borrowing rates available to the Company for loans with similar terms and consideration of the
Company&#146;s credit risk, the carrying value of the Company&#146;s BDC Notes, excluding unamortized debt issuance costs, approximates fair value. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>2022 Notes </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended
October&nbsp;31, 2022, the Company issued convertible debentures for an aggregate amount of $18.4&nbsp;million on October&nbsp;20, 2022 (the &#147;2022 Notes&#148;). The 2022 Notes had an initial maturity that is the later of (i)&nbsp;three years
from the date of issuance; or (ii)&nbsp;the maturity date of the Term Loan (see Note 8). The 2022 Notes bear interest at 10% per annum commencing on the date of issuance. The 2022 Notes are automatically convertible into common shares or redeemable
convertible preferred shares (&#147;Captial Shares&#148;) of the Company, which ever is issued by the Company in a qualified financing of Capital Shares that is not a listing event with an aggregate consideration of $50.0&nbsp;million. The
outstanding principal and accrued interest will convert at a price of 85% of the price paid in such qualified financing. In the event of a <FONT STYLE="white-space:nowrap">non-qualified</FONT> financing, the noteholder majority has the option to
convert the debentures to Capital Shares issued in the <FONT STYLE="white-space:nowrap">non-qualified</FONT> financing event, at a price equal to 85% of the price paid per share in the <FONT STYLE="white-space:nowrap">non-qualified</FONT> financing.
Additionally, upon a listing event such as an initial public offering, the 2022 Notes will be automatically converted into the number of common shares equal to the quotient by dividing the outstanding principal and interest by the listing price,
except if the listing event is a SPAC business combination, following which the 2022 Notes will be automatically converted into common shares based on the outstanding principal excluding interest. In the event of default, the noteholder majority has
the option to require payment of the principal and accrued interest amounts or to convert the outstanding principal and accrued interest into the number of the then most senior share class of the Company or common shares at the issue price of such
shares at that date. Further, upon maturity of the 2022 Notes, at the option of a noteholder majority, the principal amount and accrued and unpaid interest shall be repaid in full or converted into the number of the then most senior share class or
the Company or common shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon issuance of the 2022 Notes, the Company identified embedded derivatives related to the equity
conversion features which required bifurcation as a single compound derivative instrument. The Company estimated the fair value of the embedded derivative liabilities upon issuance at $3.5&nbsp;million. Given the close proximity between the issuance
date of the notes and the Company&#146;s year ended October&nbsp;31, 2022, no change in fair value was recorded related to the embedded derivative liabilities identified as part of the issuance of the 2022 Notes. The estimated fair value of the
embedded derivative liabilities at April&nbsp;30, 2023 was $3.1&nbsp;million, resulting in $0.8&nbsp;million and $0.4&nbsp;million recorded in change in fair value of convertible debentures embedded derivative liabilities in the consolidated
statement of operations and comprehensive loss for the three and six months ended April&nbsp;30, 2023, respectively. Total interest expense, including the amortization of debt discounts, was $0.6&nbsp;million and $1.3&nbsp;million was recorded for
the three and six months ended April&nbsp;30, 2023, respectively. As part of the issuance of the 2022 Notes, the Company incurred an aggregate of $44 of debt issuance costs of which a portion were recorded as a reduction of the carrying value of the
2022 Notes, and a portion was allocated to the embedded derivative liabilities which were expensed as incurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of April&nbsp;30,
2023, based on borrowing rates available to the Company for loans with similar terms and consideration of the Company&#146;s credit risk, the carrying value of the Company&#146;s 2022 Notes, excluding unamortized debt issuance costs, approximates
fair value. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(UNAUDITED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Redeemable Convertible Preferred Shares </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of April&nbsp;30, 2023 and October&nbsp;31, 2022, the Company&#146;s Articles of Amendment had an unlimited number of authorized shares of
each class of redeemable convertible preferred shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Class&nbsp;A Redeemable Convertible Preferred Shares </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;26, 2013, the Company entered into a subscription agreement (the &#147;Class&nbsp;A Agreement&#148;) with multiple investors,
whereby the Company agreed to sell to the investors an initial aggregate amount of 610,333 Class&nbsp;A redeemable convertible preferred shares at a price of $1.5929 ($1.63845 CAD) per share for total aggregate proceeds of $1.0&nbsp;million (the
&#147;Class&nbsp;A Initial Closing&#148;). Included within the Class&nbsp;A Agreement were three additional future tranche obligations (the &#147;Class&nbsp;A Second Tranche,&#148; &#147;Class&nbsp;A Third Tranche&#148; and &#147;Class&nbsp;A Fourth
Tranche&#148;) for the Company to issue and sell shares of Class&nbsp;A redeemable convertible preferred shares upon the achievement of certain milestone events. Only the Class&nbsp;A Second Tranche closed under the Class&nbsp;A Agreement. The
Class&nbsp;A Second Tranche obligated the Company to sell and the Class&nbsp;A Investors to purchase 1,830,999 shares of Class&nbsp;A redeemable convertible preferred shares at a price of $1.56967 ($1.63845 CAD) per share for total proceeds of
$2.9&nbsp;million, upon the establishment of the Company&#146;s headquarters in Montreal Quebec and completion of experiments required to bolster a patent application for dually-derivatized chitosan (the &#147;Second Closing Milestone Event&#148;),
which occurred in 2013. Additionally, upon completing the Class&nbsp;A redeemable convertible preferred share financing, convertible notes of the Company held by multiple investors converted into Class&nbsp;A redeemable convertible preferred shares.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Class&nbsp;B Redeemable Convertible Preferred Shares </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;6, 2015, the Company entered into a subscription agreement (the &#147;Class&nbsp;B Agreement&#148;) with multiple investors,
where the Company agreed to sell to the investors an initial aggregate amount of 2,758,221 Class&nbsp;B redeemable convertible preferred shares at a price of $1.85032 ($2.17532 CAD) per share for total proceeds of $5.1&nbsp;million (the
&#147;Class&nbsp;B Initial Closing&#148;). Included within the Class&nbsp;B Agreement were two additional closings (the &#147;Class&nbsp;B Second Tranche,&#148; and the &#147;Class&nbsp;B Third Tranche,&#148; respectively) which obligated the
Company to sell and Class&nbsp;B investors to purchase additional Class&nbsp;B redeemable convertible preferred shares upon certain events. The Class&nbsp;B Second Tranche obligated the Company to sell and the Class&nbsp;B Investors to purchase
1,838,815 Class&nbsp;B Shares at a price of $1.63419 ($2.17532 CAD) per share for total proceeds of $3.0&nbsp;million and the Class&nbsp;B Third Tranche obligated the Company the sell and the Class&nbsp;B Investors to purchase 1,608,963 Class&nbsp;B
Shares at a price of $1.63419 ($2.17532 CAD) per share for total proceeds of $2.6&nbsp;million. The Class&nbsp;B Second Tranche and Class&nbsp;B Third Tranche closed on March&nbsp;1, 2017. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Class&nbsp;B-1</FONT> Redeemable Convertible Preferred Shares </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;10, 2015, the Company entered into a Subscription Agreement (the Class <FONT STYLE="white-space:nowrap">&#147;B-1</FONT>
Agreement&#148;), in which the Company was to issue 1,523,809 <FONT STYLE="white-space:nowrap">Class&nbsp;B-1</FONT> redeemable convertible preferred shares for a purchase price of $1.98345 ($2.625 CAD) per share, resulting in aggregate proceeds of
$2.5&nbsp;million. During the year ended October&nbsp;31, 2020, the <FONT STYLE="white-space:nowrap">Class&nbsp;B-1</FONT> redeemable convertible preferred shares converted to common shares on a 1:1 basis. Therefore, as of each of the years ended
October&nbsp;31, 2020, October&nbsp;31, 2021, and October&nbsp;31, 2022, no shares of the <FONT STYLE="white-space:nowrap">Class&nbsp;B-1</FONT> redeemable convertible preferred shares remained outstanding. The Company has presented these shares
within temporary equity as of October&nbsp;31, 2019 within the consolidated statements of redeemable convertible preferred shares and shareholder deficit, as they contained the same redemption features as the Class&nbsp;B redeemable convertible
preferred shares (further described above). Upon conversion to common </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(UNAUDITED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shares, the carrying value of the <FONT STYLE="white-space:nowrap">Class&nbsp;B-1</FONT> redeemable convertible preferred shares was reclassified to additional paid in capital within
shareholders&#146; deficit. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Class&nbsp;C Redeemable Convertible Preferred Shares </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Class&nbsp;C redeemable convertible preferred shares are issuable in series, of which an unlimited number are designated as Series 1
Class&nbsp;C redeemable convertible preferred shares with an issue price per share of $1.5929 ($1.63845 CAD); an unlimited number are designated as Series 2 Class&nbsp;C redeemable convertible preferred shares with an issue price per share of
$1.85032 ($2.175315 CAD); an unlimited number are designated as Series 3 Class&nbsp;C redeemable convertible preferred shares with an issue price per share of $2.12376 ($2.6320 CAD); and an unlimited number are designated as Series 4 Class&nbsp;C
redeemable convertible preferred shares that is reserved for the potential conversion of the BDC Notes, and will each have an issue price per share of $1.69901 ($2.10559 CAD). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;30, 2021, the Company entered into a subscription agreement (the &#147;Class&nbsp;C Agreement&#148;) with multiple investors,
where the Company agreed to sell to the Investors an initial aggregate amount of 3,662,813 Series 3 Class&nbsp;C redeemable convertible preferred shares (the &#147;Series 3 Class&nbsp;C Shares&#148;) at a price of $2.12376 ($2.6320 CAD) per share
for total proceeds of $7.8&nbsp;million (the &#147;Class&nbsp;C Initial Closing&#148;). Included within the Class&nbsp;C Agreement was one additional closing (the &#147;Class&nbsp;C Second Tranche&#148;) which obligated the Company to sell and
Class&nbsp;C investors to purchase additional Class&nbsp;C redeemable convertible preferred shares upon the achievement of certain milestone events. The Class&nbsp;C Second Tranche obligated the Company to sell and the Class&nbsp;C investors to
purchase 3,662,810 Series 3 Class&nbsp;C Shares at a price of $2.13192 ($2.6320 CAD) per share for total proceeds of $7.8&nbsp;million. The Class&nbsp;C Second Tranche closed on October&nbsp;29, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of each of the Class&nbsp;C Initial Closing and Class&nbsp;C Second Tranche, each Class&nbsp;C investor received 3,662,813 and
3,662,810 warrants, respectively, to purchase Class&nbsp;C redeemable convertible preferred shares (the &#147;Class&nbsp;C Warrants&#148;), resulting in an aggregate issued amount of 7,325,623 Class&nbsp;C Warrants. The Class&nbsp;C Warrants have an
exercise price of $2.12376 ($2.6320 CAD) per share and a term of 10 years. The Class&nbsp;C Warrants were determined to be liabilities. The Company estimated the fair value of the warrant liabilities upon issuance and remeasured the fair value of
the warrant liabilities at each reporting period, with the subsequent changes in the fair value of the warrant liabilities being recognized in changes in fair value of warrant liabiliities within the Company&#146;s consolidated statements of
operations and comprehensive loss. Upon the completion of the business combination with FEAC, all existing Class&nbsp;C Warrants of the Company will be extinguished. Refer to Note 17. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the Class&nbsp;C Agreement, certain convertible notes held by various Class&nbsp;C investors and other investors were
exchanged for an aggregate amount of 16,464,646 Class&nbsp;B redeemable convertible preferred shares. Additionally, upon entering into the Class&nbsp;C Agreement, the Company also entered into a share exchange agreement (the &#147;Share Exchange
Agreement&#148;) with the Class&nbsp;A investors and the Class&nbsp;B investors. As part of the Share Exchange Agreement, certain of the Class&nbsp;A redeemable convertible preferred shares issued to Class&nbsp;A investors were exchanged for Series
1 Class&nbsp;C redeemable convertible preferred shares and certain of the Class&nbsp;B redeemable convertible preferred shares issued to the Class&nbsp;B investors were exchanged for Series 2 Class&nbsp;C redeemable convertible preferred shares.
This exchange resulted in the derecognition of Class&nbsp;A and B redeemable convertible preferred shares and the recognition of Class&nbsp;C redeemable convertible preferred shares at the fair value of the Class&nbsp;C redeemable convertible
preferred shares. The difference between the carrying value of the Class&nbsp;A and Class&nbsp;B redeemable convertible preferred shares and the fair value of the Class&nbsp;C redeemable convertible preferred shares for which they converted into was
recorded within additional paid in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(UNAUDITED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
capital and no gain or loss on extinguishment was recorded within the consolidated statements of operations and comprehensive loss. Further, the February 2020 Warrants, June 2020 Warrants, and
2021 Warrants, which consisted of warrants to purchase the Company&#146;s Class&nbsp;B redeemable convertible preferred shares and were issued as part of the convertible debentures were cancelled and replaced by the terms of the Class&nbsp;C
Warrants. The aggregate amount of outstanding warrants of 10,242,130 from the February 2020 Warrants, the June 2020 Warrants, and the 2021 Warrants converted into 10,242,130 Class&nbsp;C Warrants, which have an exercise price of $2.12376 ($2.6320
CAD) per share and a term expiring on February&nbsp;14, 2030. Immediately prior to conversion, the warrants were marked to fair value, with the change in the fair value of the warrant liabilities being recognized in changes in fair value of warrant
liabilities within the Company&#146;s consolidated statements of operations and comprehensive loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon issuance of each series of
Class&nbsp;A, Class&nbsp;B, and Class&nbsp;C Preferred Shares, the Company assessed the embedded conversion and liquidation features of the shares and determined that such features did not require the Company to separately account for these
features. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of April&nbsp;30, 2023, and October&nbsp;31, 2022, the redeemable convertible Preferred Shares consisted of the following:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>April&nbsp;30, 2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred&nbsp;Shares&nbsp;Issued<BR>and Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Redemption</B><br><B>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common&nbsp;Shares&nbsp;Issuable<BR>Upon Conversion</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;A Preferred Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,477,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 3,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,477,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;B Preferred Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">864,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,593</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">864,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;C Preferred Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,810,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">109,717</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,810,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,152,399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">115,087</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,152,399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>October&nbsp;31, 2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred Shares Issued<BR>and Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Redemption<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Shares Issuable<BR>Upon Conversion</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;A Preferred Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,477,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 1,899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 3,634</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,477,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;B Preferred Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">864,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">864,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;C Preferred Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,810,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">107,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,810,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,152,399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">112,629</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,152,399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of each class of Preferred Shares have the following rights and preferences: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Voting Rights </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of the redeemable
convertible preferred shares will vote together with the holders of common shares as a single class upon any matter submitted to the shareholders for a vote. Holders of redeemable convertible preferred shares may cast the number of votes equal to
the number of shares of common shares to which such shares of the redeemable convertible preferred shares are convertible into, including fractions of shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(UNAUDITED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Liquidation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a liquidation event, as defined in the Company&#146;s Articles of Amendment, each holder of Class&nbsp;C redeemable convertible
preferred shares will be entitled to ratably receive, in priority to any distribution of the property or assets of the Company to the holders of other classes of shares, an amount equal to two times the applicable issue price for each Class&nbsp;C
redeemable convertible preferred share, subject to adjustment for shares splits, consolidations and similar events, plus all accrued or declared but unpaid dividends for such redeemable convertible preferred shares (the &#147;Class&nbsp;C Preferred
Liquidation Preference&#148;). After any conversion of Class&nbsp;C redeemable convertible preferred shares into common shares, the holders of such common shares will not be entitled to any preferential payment of distribution in the case of a
liquidation event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the Class&nbsp;C redeemable convertible preferred shares liquidation preferences, in the event of a
liquidation event, each holder of Class&nbsp;A and/or Class&nbsp;B redeemable convertible preferred shares will be entitled to ratably receive, in priority to any distribution of the property or assets of the Company to the holders of voting and <FONT
STYLE="white-space:nowrap">non-voting</FONT> common shares, out of the liquidation proceeds, an amount equal to one times the issue price of each Class&nbsp;A and/or Class&nbsp;B redeemable convertible preferred shares, subject to adjustment for
shares splits, consolidations and similar events, plus all accrued or declared but unpaid dividends for such Class&nbsp;A and/or Class&nbsp;B redeemable convertible preferred shares (the &#147;Class&nbsp;A and Class&nbsp;B Preferred Liquidation
Preference&#148;). After any conversion of Class&nbsp;A and/or Class&nbsp;B redeemable convertible preferred shares into common shares, the holders of such common shares will not be entitled to any preferential payment or distribution in case of a
liquidation event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After payment has been made in full to the holders of Class&nbsp;A, Class&nbsp;B, and Class&nbsp;C redeemable
convertible preferred shareholders, any assets remaining available will be distributed ratably and on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis among the preferred shareholders and holder of voting and <FONT
STYLE="white-space:nowrap">non-voting</FONT> common shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a sale transaction, each holder of Class&nbsp;C redeemable
convertible preferred shares will be entitled to receive, out of the liquidation proceeds, regardless of any other dispositions among the parties, prior to and in preference to any distribution to holders of voting and
<FONT STYLE="white-space:nowrap">non-voting</FONT> common shares, Class&nbsp;A redeemable convertible preferred shares and/or Class&nbsp;B redeemable convertible preferred shares , an amount equal to the Class&nbsp;C Preferred Liquidation Preference
for each Class&nbsp;C redeemable convertible preferred shares then held. Once all amounts payable to the holders of Class&nbsp;C redeemable convertible preferred shares have been made, then each holder of Class&nbsp;A redeemable convertible
preferred shares and Class&nbsp;B redeemable convertible preferred shares will be entitled to receive, out of the liquidation proceeds, regardless of any other dispositions among the parties, prior to and in preference to any distribution to holders
of voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common shares, an amount equal to the Class&nbsp;A and Class&nbsp;B Preferred Liquidation Preference for each holder of Class&nbsp;A or Class&nbsp;B redeemable convertible preferred
shares then held. Once all amounts payable to the redeemable convertible preferred shareholders have been made, then any remaining liquidation proceeds received as part of the sale transaction will be distributed ratably and on an <FONT
STYLE="white-space:nowrap">as-converted</FONT> basis among all redeemable convertible preferred shareholders and holders of voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Conversion </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the Class&nbsp;A,
Class&nbsp;B, <FONT STYLE="white-space:nowrap">Class&nbsp;B-1</FONT> and Class&nbsp;C redeemable convertible preferred shares is automatically converted into common shares at the applicable conversion price upon (i)&nbsp;the closing of a qualified
IPO having a price per share not less than three times the issue price of the Series 3 Class&nbsp;C redeemable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(UNAUDITED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
convertible preferred shares, and with gross proceeds for the Company of not less than $50.0&nbsp;million or (ii)&nbsp;the election to convert by a special majority approval, which is defined as
approval of holders of at least 54% of the Class&nbsp;C redeemable convertible preferred shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each redeemable convertible preferred
share may also be converted at the option of the shareholder, without the payment of any additional consideration, at any time after the original issue date, into a number of fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT>
common shares as determined by multiplying each such share by the conversion ratio in accordance with the Company&#146;s Articles of Amendment. The conversion ratio is determined by dividing the issue price by the conversion price. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Dividends </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of Class&nbsp;A
Preferred Shares are entitled to receive, at the same rate as the holders of Class&nbsp;B and <FONT STYLE="white-space:nowrap">Class&nbsp;B-1</FONT> Preferred Shares, and in priority to holders of common shares, an annual fixed cumulative
preferential dividend of 8% calculated on the issue price of $1.5929 ($1.63845 CAD) per share. The undeclared cumulative dividend on Class&nbsp;A Preferred Shares as of April&nbsp;30, 2023 and October&nbsp;31, 2022, was $2.0&nbsp;million, and
$1.9&nbsp;million, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of Class&nbsp;B Preferred Shares are entitled to receive, at the same rate as the holders of
Class&nbsp;A and <FONT STYLE="white-space:nowrap">Class&nbsp;B-1</FONT> Preferred Shares, and in priority to common shares, an annual fixed cumulative preferential dividend of 8% of the issue price of $1.85032 ($2.175315 CAD) per share. The
Class&nbsp;B shares are subject to an anti-dilution adjustment in the event of a common share issuance at a price per share lower than $1.85032 ($2.17532 CAD). The undeclared cumulative dividend on Class&nbsp;B shares as of April&nbsp;30, 2023, and
October&nbsp;31, 2022, was $210&nbsp;thousand, and $151&nbsp;thousand, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of Class&nbsp;C redeemable convertible
preferred shares are entitled to receive in priority to all other classes of shares an annual fixed cumulative preferential dividend in the amount of 8% of the issue price of $2.12376 ($2.6320 CAD) per share. The Class&nbsp;C redeemable convertible
preferred shares are subject to an anti-dilution adjustment in the event of a common share issuance at a price per share lower than $2.12376 ($2.6320 CAD). The undeclared cumulative dividend on Class&nbsp;C redeemable convertible preferred shares as
of April&nbsp;30, 2023, and October&nbsp;31, 2022, was $7.6&nbsp;million, and $4.9&nbsp;million, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Redemption </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Preferred Shares are automatically redeemable upon a deemed liquidation event, as defined in the Company&#146;s Articles of Amendment. Upon
such event, the preferred shareholders would be paid their preference amounts according to the liquidation priority set forth in the Articles of Amendment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(UNAUDITED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Common Shares </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has an unlimited number of authorized shares of common shares, with no par value. The voting and
<FONT STYLE="white-space:nowrap">non-voting</FONT> common shares issued and outstanding as of April&nbsp;30, 2023 and October&nbsp;31, 2022 are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>April&nbsp;30,&nbsp;2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>October&nbsp;31,&nbsp;2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Voting common shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,524,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,524,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-voting</FONT> common shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">361,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">164,827</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total outstanding common shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,885,897</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,688,872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Dividend Rights </I>&#150; Holders of voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common
shares are entitled to receive <FONT STYLE="white-space:nowrap">non-cumulative</FONT> dividends, subject to the rights, privileges, conditions and restrictions attaching to the Preferred Shares, if, as and when declared by the Board of Directors out
of the money legally available for the payment of dividends. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Voting Rights</I> &#150; At all meetings of the shareholders of the
Company, the holders of the voting common shares are entitled to one vote for each common share held. <FONT STYLE="white-space:nowrap">Non-voting</FONT> shares of common shares are not entitled to vote, except as otherwise provided in the Canada
Business Corporations Act. Shares acquired through stock options are <FONT STYLE="white-space:nowrap">non-voting</FONT> shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Liquidation Rights</I> &#150; Subject to the rights, privileges, conditions and restrictions attaching to the redeemable convertible
preferred shares, in the event of liquidation event, the holders of common shares will be entitled to receive ratably and pari passu among the holders of common shares, the holders of <FONT STYLE="white-space:nowrap">non-voting</FONT> common shares
and the holders of redeemable convertible preferred shares, on an as converted basis, monies, securities and other assets distributable in connection with the liquidation event. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of April&nbsp;30, 2023, and October&nbsp;31, 2022, the Company has reserved the following shares of common shares for the potential
conversion of outstanding redeemable convertible preferred shares and the exercise of shares options: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>April&nbsp;30,&nbsp;2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>October&nbsp;31,&nbsp;2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred shares, as converted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,152,399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,152,399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants to purchase shares of Class&nbsp;C redeemable convertible preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,701,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,701,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options to purchase common shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,979,615</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,731,309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59,833,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59,585,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company also had convertible notes outstanding as of April&nbsp;30, 2023 and October&nbsp;31, 2022, which
could obligate the Company to issue shares of redeemable convertible preferred shares upon the occurrence of various future events at prices and in amounts that are not determinable until the occurrence of those future events. Because the necessary
conditions for the conversion of these instruments had not been satisfied during each of the periods ended April&nbsp;30, 2023 and October&nbsp;31, 2022, the Company has excluded these instruments from the table above. See Note 8 for additional
details. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(UNAUDITED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Share-Based Compensation </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The ESOP and EIP Plans </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has an
employee shares option plan (the &#147;ESOP&#148;) and an equity incentive plan (the &#147;EIP&#148;) (collectively, the &#147;Plans&#148;) which was adopted by the Board of Directors, and approved by the shareholders, effective July&nbsp;5, 2018.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Plans, options to purchase <FONT STYLE="white-space:nowrap">non-voting</FONT> common shares of the Company&#146;s shares may be
granted to directors, officers, employees, consultants and members of the scientific advisory board. The Plans provide for the issuance of common stock options up to a maximum of 15% of the aggregate issued and outstanding common shares and <FONT
STYLE="white-space:nowrap">non-voting</FONT> common shares of the Company calculated on an as converted and fully diluted basis. The Company&#146;s stock option plans are administered by the Board of Directors. The Board of Directors determines the
number of options to be granted, the vesting period and the exercise price of new options. It is the Company&#146;s policy to establish the exercise price at an amount that approximates the fair value of the underlying shares on the date of grant as
determined by the Board of Directors. As of April&nbsp;30, 2023, there were 9,838,946 shares reserved for issuance in the Plans, of which 379,435 shares remain available for future grants under the Plans. The options vest in accordance with the
vesting terms determined for each grant by the Board of Directors. The vesting terms of the Company&#146;s granted stock options are typically 100% vesting immediately upon grant date, or over a three- or four-year service period. The Company does
not have any performance awards. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stock Options </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assumptions that the Company used to determine the grant-date fair value of stock options, were as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;months&nbsp;ended</B><br><B>April&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six months ended<BR>April&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.08</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.08</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.08</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.08</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">81.39</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">81.39</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.56</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.16</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.56</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.16</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of common shares and exercise price of options (CAD)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 0.38</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 0.38</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of common shares and exercise price of options (USD)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 0.28</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 0.28</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(UNAUDITED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the Company&#146;s stock option activity: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Exercise<BR>Price*(USD)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Remaining<BR>Contractual<BR>Term<BR>(in years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Intrinsic<BR>Value<BR></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of October&nbsp;31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,731,309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,065,899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(315,069</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited or expired</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(502,524</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of April&nbsp;30, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,979,615</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">933</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options vested and exercisable as of April&nbsp;30, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,103,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options unvested as of April&nbsp;30, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,876,519</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">- All options outstanding at October&nbsp;31, 2022 were issued in Canadian dollars at $0.22. All options
granted during the three and <FONT STYLE="white-space:nowrap">six-months</FONT> ended April&nbsp;30, 2023 were issued in Canadian dollars at $0.38. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the three and six months ended April&nbsp;30, 2023, included within the stock options exercised are 85,850 shares of common shares
issued upon cashless exercise of the stock options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate intrinsic value of share options is calculated as the difference
between the exercise price of the share options and the fair value of the Company&#146;s common share for those share options that had exercise prices lower than the fair value of the Company&#146;s common shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The weighted-average grant-date fair value per share of share options granted during the three and six months ended April&nbsp;30, 2023 and
2022 was $0.20 and $0.11, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Share-based Compensation Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Share-based compensation expense included in the Company&#146;s condensed consolidated statements of operations and comprehensive loss was as
follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended</B><br><B>April&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended</B><br><B>April&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total share-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of April&nbsp;30, 2023, there was $0.4&nbsp;million of unrecognized compensation expense related to
outstanding stock options, which is expected to be recognized over a weighted-average period of 3.05 years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(UNAUDITED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Net Loss Per Share </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the computation of the Company&#146;s basic and diluted net loss per share for the periods presented: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three Months Ended<BR>April&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended</B><br><B>April&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Add: Deemed dividend attributable to redeemable convertible Preferred Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common shareholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,457</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,089</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,698</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of common shares used in net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,849,767</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,622,186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,768,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,616,193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per common share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company excluded the following shares from the computation of diluted net loss per share attributable to
common shareholders during the three months and six months ended April&nbsp;30, 2023, and 2022 because including them would have had an anti-dilutive effect: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended&nbsp;April&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended April&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2023&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2022&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,152,399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,152,399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,152,399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,152,399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants to purchase redeemable convertible Preferred Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,701,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,701,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,701,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,701,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options to purchase common shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,979,615</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,120,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,979,615</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,120,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59,833,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59,974,533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59,833,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59,974,533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company also had convertible notes outstanding for the three and
<FONT STYLE="white-space:nowrap">six-months</FONT> ended April&nbsp;30, 2023 and 2022, which could obligate the Company to issue preferred shares upon the occurrence of various future events at prices and in amounts that are not determinable until
the occurrence of those future events. Because the necessary conditions for the conversion of these instruments had not been satisfied during each of the three and <FONT STYLE="white-space:nowrap">six-months</FONT> ended April&nbsp;30, 2023 and
2022, the Company has excluded these instruments from the table above and the calculation of diluted net loss per share. See Note 8 for additional details. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(UNAUDITED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Income Taxes </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the three and <FONT STYLE="white-space:nowrap">six-months</FONT> ended April&nbsp;30, 2023 and 2022, the Company recorded no income tax
provision or benefit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has evaluated the positive and negative evidence bearing upon its ability to realize its deferred tax
assets, which primarily consist of net operating loss carryforwards. The Company has considered its history of cumulative net losses, estimated future taxable income and prudent and feasible tax planning strategies and has concluded that it is more
likely than not that the Company will not realize the benefits of its deferred tax assets. As a result, as of April&nbsp;30, 2023, the Company has maintained a full valuation allowance against its remaining net deferred tax assets. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Leases </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s leases are comprised of all operating leases for office and lab space. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2019, the Company entered into an office space lease approximating 12,271 of rentable square feet or a portion of an office building
located at 201 Jones Road, Waltham, Massachusetts. The lease commenced in April 2019 and the lease term is to expire on March&nbsp;30, 2022, with no options to renew. The lease expired on March&nbsp;30, 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2021, the Company entered into an office and lab space lease approximating 9,360 of rentable square feet for designated office and
lab spaces located at 7171 Frederick-Banting, City of Montreal, judicial district of Montreal, Province of Quebec. The leased commenced in November 2021 and had an initial term of 12 months that expires on October&nbsp;31, 2022, and includes options
to renew for consecutive twelve-month periods upon landlord consent at new lease rates. As the Company has elected to not recognize leases with a lease term of 12 months or less on the balance sheet, this was considered short-term leases, and no
operating lease right of use assets and liabilities were recognized. In October 2022, the Company entered into a lease amendment to extend the lease for an additional term of six months through April 2023, with an option to extend the lease through
September 2023. The amendment resulted in $0.4&nbsp;million of additional lease commitments to be paid during the extended term, inclusive of the option period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;29, 2022, the Company signed a new lease for approximately 10,620 square feet of new laboratory and office space at 4868 Rue
Levy, Montreal, QC. The term of the lease is for 10 years beginning on the commencement date, and requires an annual initial base rent of $36.50 CAD per square foot, which is subject to annual increases of 2%. The lease has not commenced as of
April&nbsp;30, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the three and six months ended April&nbsp;30, 2023, and 2022, the components of operating lease cost were as
follows, and are reflected in general and administrative expenses and research and development expenses, as determined by the underlying activities: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended&nbsp;April&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended&nbsp;April&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2023&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2022&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2023&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2022&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease Cost:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Variable operating lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term operating lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(UNAUDITED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the cash paid for amounts included in the measurement of the
Company&#146;s operating lease liabilities for the three and six months ended April&nbsp;30, 2023, and 2022: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended&nbsp;April&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended&nbsp;April&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2023&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2022&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2023&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2022&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash paid for amounts included in the measurement of operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:10pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of April&nbsp;30, 2023, the Company does not have any operating lease liabilities recorded on the balance
sheet. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>15.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Commitments and Contingencies </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Legal Proceedings </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to
time, in the ordinary course of business, the Company is subject to litigation and regulatory examinations as well as information gathering requests, inquiries and investigations. As of April&nbsp;30, 2023, and October&nbsp;31, 2022, there were no
matters which would have a material impact on the Company&#146;s financial results. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>16.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Related Party Transactions </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the three and six months ended April&nbsp;30, 2023, the Company had the following transactions with shareholders that hold more than 10%
of the total outstanding shares of the Company: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;4, 2023, the Company entered into the April 2023 Notes for a principal
amount of $8.0&nbsp;million with the April 2023 Investors, as described in Note 7. The April 2023 Notes had an interest free period of 45 days from the date of issuance, and commencing on the 46th day, is to accrue interest at a rate of 15% per
annum. The April 2023 Notes mature on the earlier of (i)&nbsp;July 31, 2023; or (ii)&nbsp;the date the Company completes a qualified financing, as defined within the April 2023 Notes as a financing pursuant to which the Company sells convertible
promissory notes, warrants, preferred shares, common shares, or a combination thereof of the Company for an aggregate amount of at least $20.0&nbsp;million. Upon the completion of the 2023 Financing (as defined within Note 17) the Company issued
convertible debentures and warrants of the Company to the April 2023 Note Investors, on the same terms and conditions of the convertible debentures and warrants that were issued to the investors of the 2023 Financing, as repayment of the April 2023
Notes. Refer to Note 17. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company did not have any transactions with related parties during the three and six months ended
April&nbsp;30, 2022. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>17.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Subsequent Events </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has evaluated subsequent events through August 9, 2023, the date these financial statements were available to be issued. Except as
noted below, the Company concluded that no additional subsequent events have occurred that require disclosure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;16, 2023, the
Company entered into a business combination agreement with FEAC, a publicly traded SPAC. Under the terms of the proposed transaction, the combined company will be named enGene Holdings Inc. (&#147;Newco&#148;) whose common shares are expected to be
listed on Nasdaq. The cash components of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(UNAUDITED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
transaction will be funded by FEAC&#146;s cash in trust that is not used for redemptions, as well as investments consisting of private placements of common shares, other private investments and a
FEAC shareholder <FONT STYLE="white-space:nowrap">non-redemption</FONT> commitment, totaling approximately $115&nbsp;million, which includes $18.4&nbsp;million received from the 2022 Notes, and the $38.0&nbsp;million received from the 2023 Financing
(as defined below), which includes $8.0&nbsp;million in repayment of the April 2023 Notes. The parties to the business combination agreement will amalgamate under Section&nbsp;192 of the Canada Business Corporations Act pursuant to a plan of
arrangement (the &#147;Amalgamation&#148;, the date of the Amalgamation being the &#147;Closing Date&#148;). The closing of the business combination is subject to the affirmative vote of FEAC shareholders and the Company&#146;s shareholders, amongst
other conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;16, 2023, FEAC, Newco, and certain investors (the &#147;PIPE Investors&#148;) entered into subscription
agreements (the &#147;Subscription Agreements&#148; and each a &#147;Subscription Agreement&#148;) pursuant to which, among other things, the PIPE Investors have agreed, subject to the completion of each element of the transactions (other than those
that are scheduled to be completed following the Closing Date), to subscribe for and purchase, and FEAC has agreed that it will issue and sell to the PIPE Investors (which obligation will be assumed (the &#147;Assumption&#148;) by Newco after the
completion of the FEAC Reorganization and prior to the consummation of the PIPE Financing (as defined below),) the number of FEAC Class&nbsp;A shares (or after the Assumption, Newco Shares) provided for in the applicable Subscription Agreement in
exchange for FEAC Class&nbsp;A share (or after the Assumption, Newco Share) (as amended by the Side Letter Agreements (as defined below, the &#147;PIPE Financing&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately following the execution and delivery of the Subscription Agreements, FEAC and Newco entered into a side letter with each PIPE
Investor (the &#147;Side Letter Agreement&#148; and collectively, the &#147;Side Letter Agreements&#148;) to amend the relevant Subscription Agreement and which, together with the relevant Subscription Agreement, reflects the total number of FEAC
Class&nbsp;A shares and FEAC warrants to be issued by FEAC (or after the Assumption, the total number of Newco Shares and Newco Warrants to be issued by Newco) pursuant to the PIPE Financing in consideration of the purchase price set forth in the
relevant Subscription Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Subscription Agreements and Side Letter Agreements, the PIPE Investors have collectively
subscribed for FEAC Class&nbsp;A shares and FEAC warrants (or after the Assumption, Newco Shares and Newco Warrants) for an aggregate purchase price equal to $56.9&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the Closing Date, all of the Company&#146;s existing redeemable convertible preferred shares outstanding immediately prior to the
Amalgamation will be exchanged for shares of Newco&#146;s common shares, with no dividends or distributions being declared or paid on the Company&#146;s&#146; redeemable convertible preferred shares, and certain of the Company&#146;s existing
convertible notes will convert to common shares of the Company at the conversion ratio in place at the time of conversion. Further, all of the Company&#146;s existing outstanding Class&nbsp;C Warrants will be terminated. Pursuant to the
Amalgamation, all of the Company&#146;s common shares outstanding immediately prior to the Amalgamation will be exchanged for common shares of Newco at an agreed upon exchange ratio set out in the Amalgamation plan of arrangement (the &#147;Company
Exchange Ratio&#148;) and each of the Company&#146;s outstanding warrants immediately prior to the Amalgamation shall be exchanged for warrants of Newco at the Company Exchange Ratio. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the execution and delivery of the business combination agreement with FEAC, the Company agreed to certain modifications of the 2022
Notes having an aggregate principal amount of $18.4&nbsp;million (the &#147;Amended 2022 Notes&#148; and, together with the Company warrants to be issued by the Company as consideration for such modifications, the &#147;Amended 2022
Financing&#148;). On May&nbsp;12, 2023, the Company also consented to certain </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(UNAUDITED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
modifications of the BDC Notes pursuant to which the Company will be required on the Closing Date to repay in cash (i)&nbsp;the outstanding principal and the accrued but unpaid interest; and
(ii)&nbsp;an amount equal to 20% of the principal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently with the execution and delivery of the business combination agreement,
the Company also entered into agreements pursuant to which it will issue new convertible indebtedness and warrants (i)&nbsp;for cash in an aggregate principal amount of $30.0&nbsp;million and (ii)&nbsp;in repayment of the April 2023 Notes in an
aggregate principal amount of $8.0 million (collectively, the &#147;2023 Notes&#148; and, together with the warrants purchased concurrently, the &#147;2023 Financing&#148;; the 2023 Financing together with the Amended 2022 Financing, the
&#147;Convertible Bridge Financing&#148;). As part the 2023 financing, the terms of the April 2023 Notes were modified, in which the repayment of the April 2023 Notes resulted in the Company issuing convertible debentures and warrants of the Company
to the April 2023 Note Investors, on the same terms and conditions of the convertible debentures and warrants that were issued to the investors of the 2023 Financing. As part the 2023 Financing, the terms of the April 2023 Notes were modified, in
which the repayment of the April 2023 Notes resulted in the Company issuing convertible debentures and warrants of the Company to the April 2023 Note Investors, on the same terms and conditions of the convertible debentures and warrants that were
issued to the investors of the 2023 Financing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2023 Financing occurred in two separate issuances with $20.0&nbsp;million received in
May 2023, and the additional $10.0&nbsp;million received in June 2023, of which Forbion Growth Sponsor FEAC I B.V. funded an aggregate amount of $20.0&nbsp;million. The 2023 Notes issued as part of the 2023 Financing have an initial maturity date of
three years from the closing date and are to accrue interest at 10% per annum, which is payable upon maturity. The 2023 Notes have the same conversion terms as the 2022 Notes (as described in Note 8). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the completion of the business combination, the Convertible Bridge Financing indebtedness will be converted into that number of common
shares of the Company, that, when exchanged at the agreed upon exchange ratio, shall equal that number of FEAC Class&nbsp;A shares (or after the assumption of FEAC by Newco, Newco Shares) that the holders of such indebtedness would have received if
they subscribed for FEAC Class&nbsp;A shares (or after the assumption of FEAC by, Newco Shares) on the same terms as the investors who have participated in the PIPE Financing. Further, pursuant to the Amalgamation plan of arrangement, immediately
prior to the Closing Date, all of the Company&#146;s unvested stock options issued and outstanding under its&#146; Plans as of May&nbsp;16, 2023 will be immediately vested and exercisable and will be exchanged for options of the Newco at the Company
Exchange Ratio on the Closing Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;7, 2023, the Board of Directors approved the reservation of an additional 5,800,000 <FONT
STYLE="white-space:nowrap">non-voting</FONT> common shares for issuance under the Company&#146;s employee equity incentive plan, revising the number of shares reserved from 9,838,946 to 15,638,946. Also on July&nbsp;7, 2023, the Company granted
5,800,000 options to employees at an exercise price of $1.06 CAD ($0.79 USD), of which 4,402,977 of the issued options vest immediately upon grant, and the remaining 1,397,023 options vest over varying terms up to four years. These options are not
exercisable unless and until the completion of the business combination agreement and there is an effective registration statement for the shares underlying such granted options, and will terminate automatically in the event of the termination of
the business combination agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g459793g77a10.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="28%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>KPMG LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">600&nbsp;de&nbsp;Maisonneuve&nbsp;Blvd.&nbsp;West</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Suite 1500, Tour
KPMG</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Montr&eacute;al (Qu&eacute;bec) H3A 0A3</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">Canada</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Telephone</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Fax</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">Internet</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">(514)&nbsp;840-2100</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">(514) <FONT STYLE="white-space:nowrap">840-2187</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">www.kpmg.ca</P></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fintoc459793_1"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Shareholders and Board of Directors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">enGene Inc.: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Opinion on the Consolidated Financial Statements </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have
audited the accompanying consolidated balance sheets of enGene Inc. (the &#147;Company&#148;) as of October&nbsp;31, 2022 and 2021, the related consolidated statements of operations and comprehensive loss, redeemable convertible preferred shares and
shareholders&#146; deficit, and cash flows for each of the years in the three-year period ended October&nbsp;31, 2022, and the related notes (collectively, the &#147;consolidated financial statements&#148;). In our opinion, the consolidated
financial statements present fairly, in all material respects, the financial position of the Company as of October&nbsp;31, 2022 and 2021, and the results of its operations and its cash flows for each of the years in the three-year period ended
October&nbsp;31, 2022, in conformity with U.S. generally accepted accounting principles. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Going Concern </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note&nbsp;1
to the consolidated financial statements, the Company has incurred a net loss and negative cash flows from operating activities for the year ended October&nbsp;31, 2022, has an accumulated deficit at October&nbsp;31, 2022, and will need additional
financing in order to meets its obligations and fund its future expected negative cash flows, that raise substantial doubt about its ability to continue as a going concern. Management&#146;s plans in regard to these matters are also described in
Note&nbsp;1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Basis for
Opinion </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These consolidated financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion
on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#147;PCAOB&#148;) and are required to be independent with respect to the
Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable
assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial
statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our
audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable
basis for our opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ KPMG LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have served as the
Company&#146;s auditor since 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Montreal, Canada </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">August&nbsp;9,&nbsp;2023 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fintoc459793_2"></A>CONSOLIDATED BALANCE SHEETS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>October&nbsp;31,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>October&nbsp;31,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted certificate of deposit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investment tax credits receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">797</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,517</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Right of use assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities, redeemable convertible preferred shares and shareholders&#146;
deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">723</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 1,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of notes payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,048</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Note payable, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible debentures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible debenture embedded derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,791</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;A redeemable convertible preferred shares, no par value; unlimited shares authorized,
1,477,715 and 1,477,715 shares issued and outstanding as of October&nbsp;31, 2022 and 2021, respectively. Redemption amount of $3,634 and $3,709 as of October&nbsp;31, 2022 and 2021, respectively.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;B redeemable convertible preferred shares, no par value; unlimited shares authorized,
864,570 and 864,570 shares issued and outstanding as of October&nbsp;31, 2022 and 2021, respectively. Redemption amount of $1,533 and $1,564 as of October&nbsp;31, 2022 and 2021, respectively.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;C redeemable convertible preferred shares, no par value; unlimited shares authorized,
30,810,114 and 30,810,114 shares issued and outstanding as of October&nbsp;31, 2022 and 2021, respectively. Redemption amount of $107,462 and $113,708 as of October&nbsp;31, 2022 and 2021, respectively.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shareholders&#146; deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common shares, no par value, unlimited shares authorized 3,688,872 and 3,606,261 shares issued and
outstanding as of October&nbsp;31, 2022 and 2021, respectively.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,683</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,016</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,183</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(99,671</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(75,209</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total shareholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(76,614</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(53,442</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities, redeemable convertible preferred shares and</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">shareholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 15,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fintoc459793_3"></A>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended October&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,853</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,853</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other (income) expense, net:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of convertible debentures embedded <BR>derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(269</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(701</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(234</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(129</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(56</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,699</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on extinguishment and modifications of debentures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,727</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,558</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">662</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other (income) expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss before provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividends to redeemable convertible preferred shareholders*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,562</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,577</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on conversion of Class&nbsp;A and Class&nbsp;B redeemable convertible preferred shares to
Class&nbsp;C redeemable convertible preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,817</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common shareholders*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,645</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive loss (gain):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency translation adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,167</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,365</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share of common shares, basic and diluted*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average common shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,640,030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,562,638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,763,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts previously presented were revised due to the correction of an immaterial error.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin459793_200"></A>CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS&#146; DEFICIT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;A Redeemable<BR>Convertible<BR>Preferred Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;B Redeemable<BR>Convertible Preferred</B><br><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Class&nbsp;B-1</FONT><BR>Redeemable<BR>Convertible<BR>Preferred Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;C Redeemable<BR>Convertible<BR>Preferred Shares</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR>Paid in<BR>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Other</B><br><B>Comprehensive<BR>Loss</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Shareholders&#146;</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Balance at October&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,156,131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,205,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,523,809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,009</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,000,236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,323</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(509</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(36,700</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(19,684</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Conversion of <FONT STYLE="white-space:nowrap">Class&nbsp;B-1</FONT> redeemable convertible
preferred shares to common shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,523,809</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,009</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,523,809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,009</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,009</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Share-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Foreign currency translation adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(309</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(309</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,068</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,068</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Balance at October&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,156,131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,205,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,525,295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,352</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(818</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(51,768</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(31,902</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Conversion of convertible debentures to redeemable convertible Class&nbsp;B preferred
shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,464,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of Class&nbsp;C redeemable convertible preferred shares, net of issuance costs of $110
and warrants</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,325,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,721</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Conversion of Class&nbsp;A and Class&nbsp;B redeemable convertible preferred shares to
Class&nbsp;C redeemable convertible preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,678,416</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,939</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,806,075</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37,957</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,484,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,944</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,817</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,817</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,966</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Share-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Foreign currency translation adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,365</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,365</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,441</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,441</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Balance at October&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,477,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">864,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,810,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">49,665</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,606,261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,183</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(75,209</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(53,442</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Share-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Foreign currency translation adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,462</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,462</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Balance at October&nbsp;31, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,477,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">864,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,810,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">49,665</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,688,872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,683</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,016</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(99,671</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(76,614</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these consolidated financial statements.</I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fintoc459793_4"></A>CONSOLIDATED STATEMENTS OF CASH FLOWS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended October&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Cash flows from operating activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(24,462</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(23,441</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15,068</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">644</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,699</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Change in fair value of warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(234</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Change in fair value of convertible debenture embedded derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(269</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(701</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Gain on extinguishment and modification of convertible debentures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,727</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,558</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> lease expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(22</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Unrealized foreign currency losses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Share-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Depreciation of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">259</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Investment tax credit receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(149</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Prepaid expenses and other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(113</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,462</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(197</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Accrued expenses and other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(17,592</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15,984</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(13,061</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(153</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(248</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(192</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Proceeds from disposal of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(153</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(247</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(192</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Proceeds from issuance of common shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Proceeds of issuance of redeemable convertible preferred shares and warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Payment of issuance costs associated with redeemable convertible preferred shares and
warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(110</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Proceeds from issuance of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,057</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Payment of issuance costs associated with convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(44</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(162</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Proceeds from issuance of debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Payments of debt issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(391</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Repayment of debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,010</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(964</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Effect of exchange rate changes on cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(805</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(51</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net increase (decrease) in cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(456</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Cash at beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,081</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Cash at end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 20,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 11,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 4,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Supplemental <FONT STYLE="white-space:nowrap">non-cash</FONT> investing and financing
activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Conversion of redeemable convertible preferred shares to common shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,009</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Warrant liability recognized upon issuance of redeemable convertible preferred shares and
convertible debentures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Derivative liability recognized upon issuance and modification of convertible debentures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Conversion of convertible debentures and embedded derivatives into redeemable convertible preferred
shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,534</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Gain recorded to additional paid in capital upon conversion of Series A and Series B redeemable
convertible preferred shares to Series C redeemable convertible preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,817</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Warrant liability recognized upon issuance of term loan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Cash paid for interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">615</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fintoc459793_5"></A>NOTES TO THE FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Description of Business </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">enGene Inc. (&#147;enGene&#148; or the &#147;Company&#148;) is a biopharmaceutical company located in Montreal, Quebec, Canada, with its head
office in Canada, and incorporated pursuant to the Canada Business Corporations Act on November&nbsp;9, 1999. The Company is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is
developing <FONT STYLE="white-space:nowrap">non-viral</FONT> gene therapies based on our novel and proprietary dually derived chitosan, or &#147;DDX&#148;, gene delivery platform, which allows localized delivery of multiple gene cargos directly to
mucosal tissues and other organs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Going Concern </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s consolidated financial statements have been prepared assuming the Company will continue as a going concern, which presumes
the Company will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities and commitments in the ordinary course of business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has incurred a net loss of $24.5 million and negative cash flows from operating activities of $17.6&nbsp;million during the year
ended October&nbsp;31, 2022 and, as of that date, has an accumulated deficit of $99.7&nbsp;million. To date, the Company has not generated any operating revenues and has financed its liquidity needs primarily through the issuance of redeemable
convertible Preferred Shares and warrants, debt and convertible debentures and the Company will need additional financing in order to meets its obligations and fund its future expected negative cash flows. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s ability to continue as a going concern depends on its ability to successfully develop and commercialize its products,
achieve and maintain profitable operations, as well as its ability to obtain additional financing and on the continued financial support of its shareholders and debt holders. Management&#146;s plans are to raise additional financing. While the
Company has historically been successful in securing financing, raising additional funds is dependent on a number of factors outside of the Company&#146;s control, and as such there is no assurance that it will be able to do so in the future. These
conditions indicate the existence of a material uncertainty that raise substantial doubt on the Company&#146;s ability to continue as a going concern and, therefore, that it may be unable to realize its assets and discharge its liabilities in the
normal course of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is seeking to complete an equity financing and business combination transaction with a special
purpose acquisition company (&#147;SPAC&#148;) (see Business Combination with Forbion European Acquisition Corp. below). As part of the transaction, the Company&#146;s outstanding convertible Preferred Shares and the majority of its convertible debt
would be exchanged for common shares of the combined company. These plans are intended to mitigate the relevant conditions that raise substantial doubt about the Company&#146;s ability to continue as a going concern; however, as the plans are not
within the Company&#146;s control, it is not assured that they will be effectively implemented. In the event the Company does not complete a SPAC merger, the Company expects to seek additional funding in order to repay debt, as needed, and
successfully develop and commercialize its products through private equity financings, debt financings, collaborations, licensing arrangements, and/or strategic alliances. The Company may not be able to obtain financing on acceptable terms, or at
all, and the Company may not be able to enter into collaborations or other such arrangements. The terms of any financing may adversely affect the holdings or the rights of the Company&#146;s shareholders. If the Company is unable to raise capital
when needed, or on attractive terms, it could be forced to delay, reduce or eliminate its research or drug development programs or any future commercialization efforts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These consolidated financial statements do not include any adjustments to the amounts and classification of assets and liabilities that
results from the outcome of this uncertainty. Such adjustments could be material. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Business Combination with Forbion European Acquisition Corp. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;16, 2023, the Company entered into a business combination agreement with Forbion European Acquisition Corp. (&#147;FEAC&#148;), a
publicly traded SPAC. Under the terms of the proposed transaction, the combined company will be named enGene Holdings Inc. (&#147;Newco&#148;) whose common shares are expected to be listed on Nasdaq. The cash components of the transaction will be
funded by FEAC&#146;s cash in trust that is not used for redemptions, as well as investments consisting of private placements of common shares, other private investments and a FEAC shareholder <FONT STYLE="white-space:nowrap">non-redemption</FONT>
commitment of approximately $115&nbsp;million. Refer to Note 18 Subsequent Events for additional information. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Summary of Significant Accounting Policies </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
accompanying consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (&#147;GAAP&#148;) and include the accounts of the Company and its wholly owned subsidiary,
enGene USA, Inc. All intercompany accounts and transactions have been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification
(&#147;ASC&#148;) and as amended by Accounting Standards Updates (&#147;ASU&#146;s&#148;) of the Financial Accounting Standards Board (&#147;FASB&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements are expressed in US dollars. The consolidated financial statements have been prepared on a historical
cost basis, except for items that are required to be accounted for at fair value. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of the Company&#146;s consolidated financial statements in conformity with GAAP requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these
consolidated financial statements include but are not limited to the accrual of research and development expenses, the recoverability of investment tax credits receivable and the valuations of common shares, redeemable convertible preferred shares,
warrants to purchase redeemable convertible preferred shares, convertible debentures, embedded derivatives on convertible debt and share-based compensation. The Company bases its estimates on historical experience, known trends and other
market-specific or other relevant factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. Actual results could differ from those estimates and such differences may
be material to the consolidated financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Segment Information </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief
operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company operates as a single business segment focused on research, discovery, and clinical development of human gene therapy
products. The majority of the Company&#146;s tangible assets are held in Canada. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Foreign Currency Translation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company maintains its consolidated financial statements in the Company&#146;s functional currency, which is the Canadian Dollar. Monetary
assets and liabilities denominated in currencies other than the functional </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
currency are translated into the functional currency at rates of exchange prevailing at the balance sheet dates. <FONT STYLE="white-space:nowrap">Non-monetary</FONT> assets and liabilities
denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing at the date of the transaction. Exchange gains or losses arising from foreign currency transactions are included in other (income)
expense, net in the consolidated statement of operations and comprehensive loss. The Company reported net realized and unrealized foreign currency transaction losses for the years ended October 31, 2022, 2021, and 2020 of $0.7&nbsp;million,
$0.1&nbsp;million, and $0.1&nbsp;million, respectively, which was reflected within other expense, net in the Company&#146;s consolidated statements of operations and comprehensive loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For financial reporting purposes, the consolidated financial statements of the Company have been presented in the U.S. dollar, the reporting
currency. The financial statements are translated from their functional currency into the reporting currency as follows: assets and liabilities are translated at the exchange rates at the balance sheet dates, expenses and other (income) expense, net
are translated at the average exchange rates and shareholders&#146; deficit is translated based on historical exchange rates. Translation adjustments are not included in determining net loss but are included as a foreign exchange adjustment to other
comprehensive loss, a component of shareholders&#146; deficit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risk of Concentrations of Credit and
<FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Risk </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially expose the Company to
concentrations of credit risk consist primarily of cash. The Company regularly maintains deposits in accredited financial institutions in excess of federally insured limits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of October&nbsp;31, 2022, the Company held cash deposits at Silicon Valley Bank, or SVB, in excess of Federal Deposit Insurance Corporation
(FDIC) insured limits. On March&nbsp;10, 2023, SVB was closed by the California Department of Financial Protection and Innovation, and the FDIC, was appointed as receiver. No losses were incurred by the Company on deposits that were held at SVB.
Management believes that the Company is not currently exposed to significant credit risk as the Company&#146;s deposits were held in custody at third-party financial institutions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is dependent on third-party CDMOs (&#147;Contract Development and Manufacturing Organization&#148;) and CRO (&#147;Contract
Research Organization&#148;) with whom it does business. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements of active pharmaceutical ingredients and formulated
drugs in order to perform research and development activities in its programs. The Company also relies on a limited number of third-party CROs to perform research and development activities on its behalf. These programs could be adversely affected
by significant interruption from these providers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash and Cash Equivalents </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company considers all short-term, highly liquid investments purchased with an original maturity of three months or less at the date of
purchase to be cash equivalents. The Company&#146;s cash and cash equivalents include bank balances, demand deposits and other short-term, highly liquid investments. Cash and cash equivalents have been measured at amortized cost. The Company had no
cash equivalents as of the years ended October&nbsp;31, 2022 and 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restricted Certificate of Deposit </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Restricted certificate of deposits consist of temporary holdings of highly liquid Canadian guaranteed investment certificates held with a bank
and is used as a guarantee of the Company&#146;s short term borrowings. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Property and Equipment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment are comprised mainly of research and development equipment, computer hardware and software, office furniture and
equipment, and leasehold improvements. Property and equipment are stated at cost less accumulated depreciation and accumulated impairment losses, if applicable. Depreciation expense is recognized using the straight-line method over the estimated
useful life of each asset, as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated Useful Life</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lab equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5 years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3 years</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5 years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office furniture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5 years</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Shorter&nbsp;of&nbsp;remaining&nbsp;lease&nbsp;term&nbsp;or&nbsp;useful&nbsp;life</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Estimated useful lives are periodically assessed to determine if changes are appropriate. Maintenance and
repairs are charged to expense as incurred. When assets are retired or otherwise disposed of, the cost of these assets and related accumulated depreciation or amortization are eliminated from the consolidated balance sheet and any resulting gains or
losses are included in the consolidated statements of operations and comprehensive loss in the period of disposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company reviews
long-lived assets, such as property and equipment, for impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. If indicators of impairment are present, the assets are tested for
recoverability by comparing the carrying amount of the assets to the related estimated future undiscounted cash flows that the assets are expected to generate. If the expected undiscounted cash flows are less than the carrying value of the assets,
then the assets are considered to be impaired and its carrying value is written down to fair value, based on the related estimated discounted future cash flows. To date, no such impairment losses have been recorded. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Leases </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company adopted FASB
ASC 842 with an effective date of November&nbsp;1, 2019, using the modified retrospective transition approach which uses the effective date as the date of initial application. In accordance with ASC 842, the Company determines whether an arrangement
is or contains a lease at inception. A contract is or contains a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Company classifies leases at the lease
commencement date, when control of the underlying asset is transferred from the lessor to the lessee, as operating or finance leases and records a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT>
(&#147;ROU&#148;) asset and a lease liability on the consolidated balance sheet for all leases with an initial lease term of greater than 12 months. The Company has elected to not recognize leases with a lease term of 12&nbsp;months or less on the
balance sheet. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company enters into contracts that contain both lease and <FONT STYLE="white-space:nowrap">non-lease</FONT>
components. <FONT STYLE="white-space:nowrap">Non-lease</FONT> components may include maintenance, utilities, and other operating costs. For leases of real estate, the Company combines the lease and associated
<FONT STYLE="white-space:nowrap">non-lease</FONT> components in its lease arrangements as a single lease component. Variable costs, such as utilities or maintenance costs, are not included in the measurement of <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets and lease liabilities, but rather are expensed when the event determining the amount of variable consideration to be paid occurs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lease assets and liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease
term using the discount rate implicit in the lease if readily determinable. If the rate </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
implicit is not readily determinable, the Company utilizes an estimate of its incremental borrowing rate based upon the available information at the lease commencement date. ROU assets are
further adjusted for initial direct costs, prepaid rent, or incentives received. Operating lease payments are expensed using the straight-line method as an operating expense over the lease term. The Company&#146;s lease terms may include options to
extend or terminate the lease when it is reasonably certain that the Company will exercise that option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value Measurements of Financial
Instruments </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain assets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the
exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.
Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following
three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level 1&#151;Quoted prices in active markets for identical assets or liabilities. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level 2&#151;Observable inputs (other than Level&nbsp;1 quoted prices), such as quoted prices in active markets
for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level 3&#151;Unobservable inputs that are supported by little or no market activity that are significant to
determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of
fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&nbsp;3. A financial instrument&#146;s level within the fair value hierarchy is
based on the lowest level of any input that is significant to the fair value measurement. The Company&#146;s convertible debt embedded derivative and warrant liabilities are carried at fair value, determined according to Level&nbsp;3 inputs in the
fair value hierarchy described above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Convertible Debentures </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s convertible debentures consist of a debt instrument, a minimum interest obligation, and a share conversion feature. Certain
of the convertible debentures issued by the Company also included warrants to purchase redeemable convertible preferred shares, which were classified as liabilities. The Company identified embedded derivatives related to certain share conversion,
extension and repayment features within the convertible notes that required bifurcation as a single compound derivative instrument. At inception, the Company utilized the residual method to determine the value of the debt instrument based on the
difference between gross proceeds and the estimated fair value of the embedded derivative and any warrants that were issued. The discounts on debt resulting from any issuance costs, embedded derivatives and warrants are amortized over the life of
the debt using the effective interest method. The issuance costs allocated to the embedded derivatives and warrants are expensed at inception. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Debt
Issuance Costs </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company capitalizes certain legal, accounting, and other third-party fees that are directly associated with the
issuance of debt as debt issuance costs. Debt issuance costs are recorded as a direct reduction of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
carrying amount of the associated debt on the Company&#146;s consolidated balance sheets and amortized as interest expense on the Company&#146;s consolidated statements of operations and
comprehensive loss using the effective interest method. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Convertible Debenture Embedded Derivative Liabilities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s convertible debentures contain certain features that meet the definition of embedded derivatives requiring bifurcation from
the convertible debenture instrument as a separate compound derivative. The convertible debenture embedded derivative liabilities is initially measured at fair value on issuance and is subject to remeasurement at each reporting period with changes
in fair value recognized in the change in fair value of derivative liabilities, net in the consolidated statements of operations and comprehensive loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Warrant Liabilities </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company
accounts for its redeemable convertible preferred shares warrants issued in connection with its various financing transactions based upon the characteristics and provisions of the instrument. Redeemable convertible preferred share warrants
classified as liabilities are recorded on the consolidated balance sheets at their fair value on the date of issuance and remeasured to fair value at each reporting period, with the changes in fair value recognized in the change in fair value of
warrant liabilities, net in the consolidated statements of operations and comprehensive loss. The Company adjusted the liability for changes in the fair value of these warrants until the earlier of the exercise of the warrants, the expiration of the
warrants, or until such time as the warrants were no longer considered liability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Redeemable Convertible Preferred Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company records redeemable convertible preferred shares upon issuance at its respective fair value or original issuance price less issuance
costs. When warrants to purchase redeemable convertible preferred shares are issued in conjunction with the redeemable convertible preferred shares, the proceeds are allocated to the warrants based on their fair value with the residual amounts being
allocated to the redeemable convertible preferred shares. The Company classifies its redeemable convertible preferred shares outside of shareholders&#146; equity within the temporary equity section of the balance sheet as the redemption of such
shares is outside the Company&#146;s control. The Company does not adjust the carrying values of the redeemable convertible preferred shares to redemption value unless it becomes probable that the instrument will become redeemable. As of
October&nbsp;31, 2022, the Company&#146;s redeemable convertible preferred shares was not adjusted to redemption value since the occurrence of these events was not considered probable as of October&nbsp;31, 2022. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Government Assistance Programs for Research and Development Expenditures </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is currently eligible to claim Canadian federal and provincial tax credits as a Canadian controlled private corporation (CCPC) on
eligible research and development expenditures. The Canadian federal government offers a tax incentive to companies performing research and development activities in Canada and this tax incentive can be refunded or used to reduce federal income
taxes in Canada otherwise payable. Such credits, if not refunded or used in the year earned, can be carried forward for a period of twenty years. The Quebec provincial government offers a similar refundable incentive. The investment tax credits
recorded are based on management&#146;s estimates of amounts expected to be recovered and are subject to audit by the taxation authorities, the resulting adjustments of which could be significant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Amounts received or receivable resulting from government assistance programs, including investment tax credits for research and development,
are recognized when there is reasonable assurance that the amount will be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
received and all attached conditions will be complied with. Reimbursements of eligible research and development expenditures pursuant to government assistance programs are received in cash and
recorded as reductions of research and development costs when the related costs have been incurred and there is reasonable assurance regarding collection of the claim. During the years ended October&nbsp;31, 2022, 2021, and 2020, the Company
recorded $1.4&nbsp;million, $1.6&nbsp;million, and $1.8&nbsp;million, respectively, as a reduction of research and development expense associated with research and development investment tax credits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended October&nbsp;31, 2021, the Company also recorded $0.6&nbsp;million related to government
<FONT STYLE="white-space:nowrap">COVID-19</FONT> relief programs and $0.3&nbsp;million from private institutional research grants, which were recorded as a reduction of research and development expense. Additionally during the year ended
October&nbsp;31, 2020, the Company received $0.3&nbsp;million related to government <FONT STYLE="white-space:nowrap">COVID-19</FONT> relief programs which was recorded as a reduction of research and development expense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses are comprised primarily of costs incurred for our drug discovery efforts and development of our product
candidates. These expenses include salaries, employee benefits, and share-based compensation expense for our research and development personnel, materials, supplies, depreciation on and maintenance of research equipment, the cost of services
provided by outside CROs and consultants to conduct research and development activities including costs of clinical trials and manufacturing, and the allocable portions of facility costs, such as rent, utilities, and general support services. All
costs associated with research and development are expensed as incurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Management estimates the Company&#146;s accrued research and
development expenses as of each balance sheet date in the Company&#146;s financial statements based on facts and circumstances known to the Company at that time. If the actual timing of the performance of services or the level of effort varies from
the estimate, the Company will adjust the accrual accordingly. Nonrefundable advance payments for goods and services are deferred and recognized as expense in the period that the related goods are consumed or services are performed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent Costs </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All patent-related
costs incurred in connection with filing and prosecuting patent applications such as direct application fees, and legal and consulting expenses are expensed as incurred due to the uncertainty about the recovery of the expenditure. Patent-related
costs are classified as general and administrative expenses within the Company&#146;s consolidated statements of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Share-Based
Compensation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has an employee stock option plan (the &#147;ESOP&#148;) and an equity incentive plan (the
&#147;EIP&#148;) (collectively, the &#147;Plans&#148;) whereby employees render services as consideration for equity instruments. The Company measures all share-based awards granted to employees, officers, directors and <FONT
STYLE="white-space:nowrap">non-employees</FONT> based on their fair value on the date of the grant and recognizes compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective award.
The Company accounts for forfeitures of its share-based awards as they occur. The Company issues share-based awards with service-based vesting conditions. For share-based awards with service-based vesting conditions the Company records the expense
using the straight-line method including when such awards have graded vesting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For all stock options granted at fair value of the <FONT
STYLE="white-space:nowrap">non-voting</FONT> common shares at the time of the grant with service-based vesting, the fair value of each stock option is estimated on the date of grant using the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap">Black-Scholes</FONT> option-pricing model, which requires inputs based on certain subjective assumptions, including the fair value of the Company&#146;s common
shares, expected share price volatility, the expected term of the award, the risk-free interest rate for a period that approximates the expected term of the option, and the Company&#146;s expected dividend yield. The Company determines the
volatility for awards granted based on an analysis of reported data for a group of guideline companies that have issued options with substantially similar terms. The expected volatility has been determined using a weighted average of the historical
volatility measures of this group of guideline companies. The expected option term was calculated based on the simplified method, which uses the midpoint between the vesting date and the contractual term, as the Company does not have sufficient
historical data to develop an estimate based on participant behavior. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the
expected term of the award. The Company has not paid, and does not anticipate paying, cash dividends on its common shares; therefore, the expected dividend yield is assumed to be zero. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because there has been no public market for the Company&#146;s common shares, the Board of Directors has determined the fair value of the
Company&#146;s common stock based on third-party valuations of the Company&#146;s common shares. Initially, the estimated enterprise equity value of the Company was determined using a market approach and/or cost approach by considering the weighting
of scenarios estimated using a back-solve method based on recent financing transactions of the Company. This value was then allocated towards the Company&#146;s various securities of its capital structure using an option pricing method, or OPM, and
a waterfall approach based on the order of the superiority of the rights and preferences of the various securities relative to one another. Significant assumptions used in the OPM to determine the fair value of common shares include volatility,
discount for lack of marketability, and the expected timing of a future liquidity event such as an initial public offering (&#147;IPO&#148;), or sale of the Company in light of prevailing market conditions. This valuation process creates a range of
equity values both between and within scenarios. In addition , the Company&#146;s Board of Directors considered various objective and subjective factors to determine the fair value of the Company&#146;s common shares as of each grant date, including
the prices at which the Company sold shares of redeemable convertible preferred shares and the superior rights and preferences of the redeemable convertible preferred shares relative to its common shares at the time of each grant, external market
conditions, the progress of the Company&#146;s research and development programs, the Company&#146;s financial position, including cash on hand, and its historical and forecasted performance and operating results, and the lack of an active public
market for the Company&#146;s common shares and redeemable convertible preferred shares, among other factors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assumptions underlying
these valuations represented management&#146;s best estimate, which involved inherent uncertainties and the application of management&#146;s judgment and these valuations are sensitive to changes in the unobservable inputs. As a result, if the
Company had used different assumptions or estimates or if there are changes to the unobservable inputs, the fair value of its common shares and share-based compensation expense could have been materially different. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s share-based compensation expense is recorded in general and administrative and research and development expenses in the
Company&#146;s consolidated statements of operations and comprehensive loss. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the
Company&#146;s consolidated financial statements. Under this method, deferred tax assets and liabilities are determined based on differences between the consolidated financial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
statement carrying amounts and the tax bases of the assets and liabilities using the enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation
allowance against deferred tax assets is recorded if, based on the weight of the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accounts for uncertainty in income taxes recognized in the financial statements by applying a
<FONT STYLE="white-space:nowrap">two-step</FONT> process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing
authorities. If the tax position is deemed <FONT STYLE="white-space:nowrap">more-likely-than-not</FONT> to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of
benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits,
that are considered appropriate as well as the related net interest and penalties. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comprehensive Loss </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Comprehensive loss includes net loss as well as other changes in shareholders&#146; deficit that result from transactions and economic events
other than those with shareholders. The Company&#146;s comprehensive loss includes foreign currency translation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Loss Per Share </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period.
Diluted net loss per share is computed using the weighted-average number of common shares outstanding during the period and, if dilutive, the weighted-average number of potential shares of common shares. Net loss per share attributable to common
shareholders is calculated using the <FONT STYLE="white-space:nowrap">two-class</FONT> method, which is an earnings allocation formula that determines net loss per share for the holders of the Company&#146;s common shares and participating
securities. Net loss attributable to common shareholders is allocated first based on dividend rights and then to common and preferred shareholders based on ownership interests on <FONT STYLE="white-space:nowrap">an&nbsp;as-converted</FONT> basis as
if all the earnings for the period had been distributed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When considering the impact of the convertible equity instruments, diluted net
loss per share is computed using the more dilutive of (a)&nbsp;the <FONT STYLE="white-space:nowrap">two-class&nbsp;method</FONT> or (b)&nbsp;the <FONT STYLE="white-space:nowrap">if-converted&nbsp;method.</FONT> The Company allocates earnings first
to preferred shareholders and warrant holders based on dividend rights and then to common and preferred shareholders and warrant holders based on ownership interests. The weighted-average number of common shares included in the computation of
diluted net loss gives effect to all potentially dilutive common equivalent shares, including outstanding stock options, warrants, and the potential issuance of common shares upon the conversion of the convertible notes. Common stock equivalent
shares are excluded from the computation of diluted net loss per share if their effect is antidilutive. In periods in which the Company reports a net loss attributable to common shareholders, diluted net loss per share attributable to common
shareholders is generally the same as basic net loss per share attributable to common shareholders because dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. See Note 13, <I>Net Loss per Share</I>, for
further detail. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently Adopted Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-02</FONT><I>, Leases (Topic 842) </I>(&#147;ASU <FONT
STYLE="white-space:nowrap">2016-02&#148;),</FONT> which sets out the principles for the recognition, measurement, presentation, and disclosure of leases for both parties to a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
contract (i.e., lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not
the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also
required to record a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term
of 12 months or less may be accounted for similar to existing guidance for operating leases today. For nonpublic entities, this guidance is effective for annual periods beginning after December&nbsp;15, 2021 and interim periods with fiscal years
beginning after December&nbsp;15, 2022. In July 2018, the FASB issued <I>ASU No.</I><I></I><I><FONT STYLE="white-space:nowrap">&nbsp;2018-11,</FONT> Leases (Topic 842)</I>, which added an optional transition method under which financial statements
may be prepared under the revised guidance for the year of adoption, but not for prior years. Under the latter method, entities will recognize a cumulative <FONT STYLE="white-space:nowrap">catch-up</FONT> adjustment to the opening balance of
retained earnings in the period of adoption. The Company adopted this guidance on November&nbsp;1, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2019, the FASB
issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2019-12,</FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ASU-2019-12,</FONT></FONT> <I>Simplifying the Accounting for Income Tax</I>, which contains several provisions
that reduce financial statement complexity including removing the exception to the incremental approach for intra-period tax expense allocation when a company has a loss from continuing operations and income from other items not included in
continuing operations. The Company adopted this accounting standard as of November&nbsp;1, 2021 with no material impact on its consolidated financial statements and related disclosures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2020, the FASB issued&nbsp;ASU <FONT STYLE="white-space:nowrap">2020-06,</FONT> <I>Accounting for Convertible Instruments and
Contracts in an Entity&#146;s Own Equity </I>(&#147;ASU <FONT STYLE="white-space:nowrap">2020-06&#148;),</FONT> which simplifies and clarifies certain calculation and presentation matters related to convertible and equity and debt instruments.
Specifically,&nbsp;ASU <FONT STYLE="white-space:nowrap">2020-06&nbsp;removes</FONT> requirements to separately account for conversion features as a derivative under ASC Topic 815 and removing the requirement to account for beneficial conversion
features on such instruments. ASU <FONT STYLE="white-space:nowrap">2020-06</FONT> also provides clearer guidance surrounding disclosure of such instruments and provides specific guidance for how such instruments are to be incorporated in the
calculation of Diluted EPS. The Company adopted this standard on November&nbsp;1, 2020 with no material impact on the consolidated financial statements and related disclosures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November&nbsp;2021, the FASB issued <FONT STYLE="white-space:nowrap">ASU&nbsp;2021-10,</FONT><I>&nbsp;Government Assistance</I> <I>(Topic
832): Disclosure by Business Entities about Government Assistance</I><FONT STYLE="white-space:nowrap">&nbsp;(&#147;ASU&nbsp;2021-10&#148;),</FONT> which improves the transparency of government assistance received by most business entities by
requiring the disclosure of: (1)&nbsp;the types of government assistance received; (2)&nbsp;the accounting for such assistance; and (3)&nbsp;the effect of the assistance on a business entity&#146;s financial statements. This guidance is effective
for financial statements issued for annual periods beginning after December&nbsp;15, 2021. The Company <FONT STYLE="white-space:nowrap">adopted&nbsp;ASU&nbsp;2021-10&nbsp;effective</FONT> November&nbsp;1, 2021 and included incremental financial
statement disclosures, and the adoption did not have a material impact on its consolidated financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently Issued Accounting
Pronouncements&#151;Not Yet Adopted </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-13,</FONT>
<I>Financial Instruments&#151;Credit Losses (Topic 326)</I>&#151;<I>Measurement of Credit Losses on Financial Instruments </I>(&#147;ASU <FONT STYLE="white-space:nowrap">2016-13&#148;).</FONT> This new standard changes the impairment model for most
financial assets and certain other instruments. Entities will be required to use a model that will result in the earlier recognition of allowances for losses for trade and other receivables, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">held-to-maturity</FONT></FONT> debt securities, loans, and other instruments. For <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> debt securities with unrealized losses,
the losses will be recognized as allowances rather than reductions in the amortized cost of the securities. In November 2019, the FASB issued ASU <FONT STYLE="white-space:nowrap">2019-10,</FONT> <I>Financial Instruments &#150; Credit Losses (Topic
326), Derivatives and Hedging (Topic 815), and Leases (Topic 842)</I> (&#147;ASC <FONT STYLE="white-space:nowrap">2019-10&#148;),</FONT> which defers the effective date of ASU </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap">2016-13</FONT> to fiscal years beginning after December&nbsp;15, 2022, including interim periods within those fiscal years, for entities meeting the definition of
a smaller reporting company. The Company will adopt ASU <FONT STYLE="white-space:nowrap">2016-13</FONT> effective November&nbsp;1, 2023. The Company is currently evaluating the effect of the adoption of ASU
<FONT STYLE="white-space:nowrap">2016-13</FONT> on the consolidated financial statements. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Fair Value Measurements </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents the Company&#146;s fair value hierarchy for financial assets and liabilities measured as of October&nbsp;31, 2022
and 2021: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>October&nbsp;31, 2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Quoted&nbsp;Prices&nbsp;in<BR>Active Markets<BR>for Identical<BR>Assets (Level 1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant&nbsp;Other<BR>Observable<BR>Inputs (Level 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant&nbsp;Other<BR>Observable<BR>Inputs (Level 3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B></B><I>Liabilities</I><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible debenture embedded derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,791</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,791</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total financial liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>October&nbsp;31, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Quoted&nbsp;Prices&nbsp;in<BR>Active Markets<BR>for Identical<BR>Assets (Level 1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant&nbsp;Other<BR>Observable<BR>Inputs (Level 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant&nbsp;Other<BR>Observable<BR>Inputs (Level 3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B></B><I>Liabilities</I><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible debenture embedded derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total financial liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of October&nbsp;31, 2022, and 2021, the Company had no financial assets that required fair value
measurement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of October&nbsp;31, 2022 and 2021, the Company had Level&nbsp;3 financial liabilities that were measured at fair value on
a recurring basis. The Company&#146;s convertible debenture embedded derivative liabilities and warrant liabilities were carried at fair value determined using Level&nbsp;3 inputs in the fair value hierarchy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the years ended October&nbsp;31, 2022 and 2021, there were no transfers or reclassifications between fair value measure levels of
liabilities. The carrying values of all financial current assets, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Convertible Debentures Embedded Derivative Liabilities</I><B><I> </I></B><I> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s convertible debentures contain equity conversion options, extension features, and certain repayment features, that have been
identified as a single compound embedded derivative requiring bifurcation from the host contract. The Company estimated the fair value of the convertible debenture embedded derivative </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
liabilities on issuance using a probability weighted scenario expected return model. The estimated probability and timing of underlying events triggering the conversion and liquidity repayment
features and probability of exercise of the extension features within the convertible debentures as well as discount rates, volatility and share prices are inputs used to determine the estimated fair value of the embedded derivative. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assumptions ranges that the Company used to determine the fair value of the convertible debentures embedded derivative liabilities for the
notes that were outstanding during each respective year (refer to Note 9 for description of notes) were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended October&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Probability of qualified financing*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60%**</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50%&nbsp;&#150;&nbsp;95%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75%&nbsp;&#150;&nbsp;80%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70%&nbsp;&#150;&nbsp;80%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share price (CAD)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.02&nbsp;&#150;&nbsp;$2.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Discount rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.4%&nbsp;&#150;&nbsp;18.4%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12.6%&nbsp;&#150;&nbsp;35.0%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12.6%&nbsp;&#150;&nbsp;35.0%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected time to respective scenarios</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.4 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.5&nbsp;&#150;&nbsp;1.9 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.3&nbsp;&#150;&nbsp;3.0&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The probability represents the cumulated probabilities of conversion at various dates before maturity.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For 2022, the probability includes the probability of a SPAC transaction (which corresponds to a listing event
for the 2022 Notes and to a liquidity event for the BDC Notes). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June of 2021, certain of the outstanding convertible
debentures converted into shares of the Company&#146;s redeemable convertible Preferred Shares, and thus the associated derivative liabilities were marked to fair value immediately prior to conversion, upon which they were settled. Refer to Note 9
for further discussion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table provides a summary of the change in the estimated fair value of the Company&#146;s
convertible debentures embedded derivative liabilities: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of October&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of convertible debenture embedded derivative liabilities recognized upon issuance and
modification of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">676</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of convertible debenture embedded derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Extinguishment of convertible debenture embedded derivative liabilities upon conversion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,038</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in convertible debenture embedded derivative due to modification of convertible
debentures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign exchange rate adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of October&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of convertible debenture embedded derivative liabilities recognized upon
issuance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of convertible debenture embedded derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(269</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign exchange rate adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(42</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of October&nbsp;31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,791</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Warrant Liabilities</I><B><I> </I></B><I> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company issued warrants to purchase shares of redeemable convertible preferred shares as part of the issuance of certain redeemable
convertible preferred shares, convertible debentures, and term loan. The Company estimates the fair value of its warrant liabilities using a Modified Black-Scholes option-pricing model, which includes assumptions that are based on the individual
characteristics of the warrants on the valuation date, and assumptions related to the fair value of the underlying redeemable convertible<B><I> </I></B>preferred shares, expected volatility, expected life, dividends, risk-free interest rate and
discount for lack of marketability (&#147;DLOM&#148;). Due to the nature of these inputs, the warrants are considered a Level&nbsp;3 liability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The weighted average expected life was estimated based on the weighting of scenarios considering the probability of different terms up to the
contractual term of 10 years in light of the expected timing of a future exit event. The Company determines the expected volatility based on an analysis of reported data for a group of guideline companies that have issued instruments with
substantially similar terms. The expected volatility has been determined using a weighted average of the historical volatility measures of this group of guideline companies. The risk-free interest rate is determined by reference to the Canadian
treasury yield curve in effect at the time of measurement of the warrant liabilities for time periods approximately equal to the weighted average expected life of the warrants. We have not paid, and do not anticipate paying, cash dividends on our
redeemable convertible preferred shares; therefore, the expected dividend yield is assumed to be zero. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because there is no public market
for the underlying redeemable convertible<B><I> </I></B>preferred shares, the Company has determined their fair value based on third-party valuations. Initially, the estimated the enterprise equity value of the Company was determined using a market
approach and/or cost approach by considering the weighting of scenarios estimated using a back-solve method based on recent financing transactions of the Company. This value was then allocated towards the Company&#146;s various securities of its
capital structure using an option pricing method, or OPM, and a waterfall approach based on the order of the superiority of the rights and preferences of the various securities relative to one another. Significant assumptions used in the OPM to
determine the fair value of redeemable convertible preferred shares include volatility, DLOM, and the expected timing of a future liquidity event such as an IPO or sale of the Company, in light of prevailing market conditions. This valuation process
creates a range of equity values both between and within scenarios. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to considering the results of these valuations, the
Company considered various objective and subjective factors to determine the fair value of the Company&#146;s preferred shares as of each valuation date, including the prices at which the Company sold redeemable convertible preferred in the most
recent transactions, external market conditions, the progress of the Company&#146;s research and development programs, the Company&#146;s financial position, including cash on hand, and its historical and forecasted performance and operating
results, and the lack of an active public market for the Company&#146;s redeemable convertible preferred shares, among other factors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
assumptions underlying these valuations represented management&#146;s best estimate, which involved inherent uncertainties and the application of management&#146;s judgment and these valuations are sensitive to changes in the unobservable inputs. As
a result, if we had used different assumptions or estimates, or if there are changes to the unobservable inputs, the fair value of the warrants shares could have been materially different. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assumptions that the Company used to determine the fair value of the warrant liabilities
as of each period end were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended October&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average expected life (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.0</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.92</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.24</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred share price &#150; Class&nbsp;B (CAD)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred share price &#150; Class&nbsp;C (CAD)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise price &#150; Class&nbsp;B (CAD)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.175</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise price &#150; Class&nbsp;C (CAD)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.632</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.632</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table provides a summary of the change in the estimated fair value of the Company&#146;s warrant
liabilities: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>


<TR STYLE="font-size:1px; "></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of October&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant liabilities recognized upon issuance of Preferred Shares and convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign exchange rate translation adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of October&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 9,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant liabilities recognized upon issuance of term loan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of warrant liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign exchange rate translation adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,048</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of October&nbsp;31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Property and Equipment, Net </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of October&nbsp;31, 2022 and 2021, property and equipment, consisted of the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>October&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>October&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lab equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,472</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office furniture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,978</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: accumulated depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,553</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depreciation and amortization expense related to property and equipment was $0.2&nbsp;million,
$0.3&nbsp;million and $0.3&nbsp;million for the years ended October&nbsp;31, 2022, 2021 and 2020, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Accrued Expenses and Other Current Liabilities </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of October&nbsp;31, 2022 and 2021, accrued expenses consisted of the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>October&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>October&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,845</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">573</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employee compensation and related benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">676</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">829</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued income tax payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>License Agreement </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>License Agreement &#150; Nature Technology Corporation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;10, 2020, the Company entered into a <FONT STYLE="white-space:nowrap">Non-Exclusive</FONT> License Agreement (the &#147;License
Agreement&#148;) with Nature Technology Corporation (&#147;NTC&#148;) whereby the Company licenses certain rights to the technology of radiopharmaceutical products from NTC for commercialization. Under the terms of the License Agreement, NTC granted
to the Company and its affiliates a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> royalty-bearing, sublicensable license to research, have researched, develop, have developed, make, have made, use, have used, import, have imported, sell,
offer to sell, and have sold or offered for sale any product in the defined license field. Unless terminated earlier, the NTC license agreement will continue until no valid claim of any licensed patent exists in any country. The Company can
voluntarily terminate the license agreement with prior notice to NTC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company paid NTC an initial, upfront fee of $50 which was
recorded as research and development expense upon entering into the License Agreement. Beginning on the first anniversary of the effective date of the License Agreement and on each subsequent anniversary, the Company is required to pay NTC a $50
annual maintenance fee. The Company is also required to make a payment to NTC of $50 upon assigning the License Agreement to a third party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The License Agreement provides for a <FONT STYLE="white-space:nowrap">one-time</FONT> payment of $50 for the first dose of a milestone
product, as defined in the License Agreement, in the first patient in a Phase I clinical trial or, if there is no Phase I clinical trial, in a Phase II clinical trial, as well as a <FONT STYLE="white-space:nowrap">one-time</FONT> payment of $450
upon regulatory approval of a milestone product by the U.S. Food and Drug Administration. The first milestone related to the first dose of a milestone product, was achieved during the year ended October&nbsp;31, 2021. The second milestone,
regulatory approval of a milestone product, has not yet been achieved as of the year ended October&nbsp;31, 2022. The Company is also required to pay NTC a royalty percentage in the low single digits of the aggregate net product sales in a calendar
year by the Company, its affiliates or sublicensees on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, as long as the composition or use of the applicable product is covered by a valid claim in the country where the net sales occurred. Royalty
obligations under the license agreement will continue until the expiration of the last valid claim of a licensed patent covering such licensed product in such country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that the Company or any of its affiliates or sublicensees manufactures any Good Manufacturing Practice (&#147;GMP&#148;) lot of a
product, then the Company or any such affiliate or sublicensee is obligated to pay NTC an amount per manufactured gram of GMP (or its equivalent) lot of product, which varies based on the volume manufactured. The payment will expire on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> basis upon receipt of regulatory approval to market a product in any country in the licensed territory. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During each of the years ended October&nbsp;31, 2022, 2021 and 2020, the Company incurred $50
of expenses related to the annual maintenance fee under the License Agreement recorded within research and development expenses. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Current portion of notes payable </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;22, 2021, the Company entered into a short-term borrowing contract for $2.0&nbsp;million as an advance on the Company&#146;s
expected Investment Tax Credit claims for the fiscal years ended October&nbsp;31, 2021 and 2020. The loan bears interest at an annual fixed rate of 7.95% and the total amount was payable at the earliest of (i) 18 months after the end of the last
financed fiscal year; (ii)&nbsp;the date of the receipt of the last reimbursement from the government authorities; or (iii)&nbsp;the occurrence of an event of default, as defined by the short-term borrowing contract. On May&nbsp;27, 2021, the
Company made a partial principal repayment of $1.0&nbsp;million The remaining principal amount of $1.0&nbsp;million was paid on December&nbsp;29, 2021. There are no outstanding amounts associated with the short-term borrowing contract as of
October&nbsp;31, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The current portion of notes payable of $1.3&nbsp;million as of October&nbsp;31, 2022 represents the current
portion of the Note Payable, as further described in Note 8. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Note Payable </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>2021 Loan and Security Agreement </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
December&nbsp;30, 2021, the Company entered into a Loan and Security Agreement with Hercules Capital, Inc. (&#147;Hercules&#148; or the &#147;Lender&#148;) for the issuance of a term loan facility of up to an aggregate principal amount of up to
$20.0&nbsp;million (the &#147;Term Loans&#148;). The Loan Agreement provides for (i)&nbsp;an initial term loan advance of $7.0&nbsp;million, which closed on December&nbsp;30, 2021, (ii) subject to the achievement of certain Clinical Milestones
(&#147;Clinical Milestone&#148;), a right of the Company to request that the Lender make additional term loan advances to the Company in an aggregate principal amount of up to $4.0&nbsp;million from the achievement of the Clinical Milestone through
June&nbsp;15, 2022, which was drawn in June 2022, and (iii)&nbsp;subject to the achievement of certain financial milestones (&#147;Financial Milestone&#148;), a right of the Company to request that the Lender make additional term loan advances to
the Company in an aggregate principal amount of up to $9.0&nbsp;million from achievement of the Financial Milestone through December&nbsp;15, 2022, which was not achieved. The Company is required to pay an end of term fee (&#147;End of Term
Charge&#148;) equal to 6.35% of the aggregate principal amount of the Term Loans advances upon repayment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Term Loans mature on
July&nbsp;1, 2025, with no option for extension (the &#147;Maturity Date&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Term Loan bears interest at an annual rate equal to
the greater of (i) 8.25% plus the prime rate of interest as reported in the Wall Street Journal minus 3.25% and (ii) 8.25% provided, that, from and after the date the Company achieves the financial milestone, as defined within the agreement, the
reference to 8.25% in clauses (i)&nbsp;and (ii) is reduced to 8.15%. Borrowings under the Loan and Security Agreement are repayable in monthly interest-only payments through June 2023. After the interest-only payment period, borrowings under the
Loan and Security Agreement are repayable in equal monthly payments of principal and accrued interest until the Maturity Date. At the Company&#146;s option, the Company may elect to prepay all, but not less than all, of the outstanding term loan by
paying the entire principal balance and all accrued and unpaid interest thereon plus a prepayment charge equal to the following percentage of the principal amount being prepaid: (i) 3.0% of the principal amount outstanding if the prepayment occurs
in any of the first twelve months following the closing date of the last draw down; (ii) 2.0% of the principal amount outstanding if the prepayment occurs after the first </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
twelve months following the closing date of the last draw down, but on or prior to twenty-four months following the closing date of the last draw down; and 1.0% of the principal amount
outstanding at any time thereafter but prior to the Maturity Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Loan Agreement, the Company granted Hercules a
security interest senior to any current and future debts and to any security interest, in all of the Company&#146;s right, title, and interest in, to and under all of Company&#146;s property and other assets, and certain equity interests and
accounts of enGene, subject to limited exceptions including the Borrower&#146;s intellectual property. The Loan Agreement also contains certain events of default, representations, warranties and <FONT STYLE="white-space:nowrap">non-financial</FONT>
covenants of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The debt discount and issuance costs are being accreted to the principal amount of debt and being amortized
from the date of issuance through the Maturity Date to interest expense using the effective-interest rate method. The effective interest rate of the outstanding debt under the Loan Agreement is approximately 15.9%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of October&nbsp;31, 2022 the carrying value of the note payable consists of the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Note payable, including End of Term Charge</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,699</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Debt discount, net of accretion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(891</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Note payable, net of discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There were no outstanding note payable balances in the year ended October&nbsp;31, 2021. During the year ended
October&nbsp;31, 2022, the Company recognized $1.0&nbsp;million of interest expense related to the Loan Agreement, of which $0.3&nbsp;million was related to the amortization of the debt discount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Through October&nbsp;31, 2022, the Company borrowed $11.0&nbsp;million under the Loan Agreement and incurred $1.1&nbsp;million of debt
discount and issuance costs inclusive of facility fees, legal fees, End of Term Charge and fair value of the warrants (described below). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Estimated future principal payments due under the Loan Agreement, including the contractual End of Term Charge are as follows as of
October&nbsp;31, 2022: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="24%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Note&nbsp;Principal&nbsp;Payments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,586</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total principal payments, including End of Term Charge</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,699</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of October&nbsp;31, 2022, based on borrowing rates available to the Company for loans with similar terms
and consideration of the Company&#146;s credit risk, the carrying value of the Company&#146;s variable interest rate debt, excluding unamortized debt issuance costs, approximates fair value. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Hercules Warrants </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Loan and
Security Agreement, the Company agreed to issue to Hercules warrants (the &#147;Hercules Warrants&#148;) to purchase a number of shares of the Company&#146;s Preferred Shares at the exercise price equal to 2.5%
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the aggregate amount of the Term Loans that are funded, as such amounts are funded. On the Closing Date, the Company issued a warrant to purchase 84,714 Class&nbsp;C Preferred Shares which
were determined to have a fair value of $34&nbsp;thousand upon issuance. On the second tranche closing, in June 2022, the Company issued an additional warrant to purchase 48,978 Class&nbsp;C Preferred Shares which were determined to have a fair
value of $23&nbsp;thousand upon issuance. The initial Hercules Warrant values are recorded as a discount to the term loan and are being amortized to interest expense using the effective interest method over the life of the Term Loans. The Company
remeasures the fair value of the warrants at each reporting date with changes being recorded as a change in the fair value of the warrant liabilities. During the year ended October&nbsp;31, 2022 the Company recorded a change in fair value of
$9&nbsp;thousand related to the warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Hercules Warrants will be exercisable for a period of ten years from the date of the
issuance of each warrant at a <FONT STYLE="white-space:nowrap">per-share</FONT> exercise price equal to $2.632 Canadian Dollars, subject to certain adjustments as specified in the warrants. In addition, the Company has granted to the holders of the
Hercules Warrants certain registration rights on a pari passu basis with the holders of outstanding Preferred Shares and warrants to purchase Preferred Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accounted for the warrants as a liability since they were indexed to the Company&#146;s Preferred Shares classified as temporary
equity. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Convertible Debentures </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has issued convertible debentures to various investors. The outstanding principal, accrued interest, and unamortized deferred
financing costs of the convertible debentures recorded on the balance sheet as of each year end are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>October&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>October&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2019 Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2020 Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2021 Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BDC Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,497</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022 Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,908</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Convertible debentures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>2019 Notes </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended October&nbsp;31, 2019 the Company issued convertible debentures for an aggregate principal amount of $7.6&nbsp;million in
three separate issuances: $2.2&nbsp;million in January 2019 (the &#147;January 2019 Notes&#148;), $2.3&nbsp;million in April 2019 (the &#147;April 2019 Notes&#148;), and $3.1&nbsp;million in July 2019 (the &#147;July 2019 Notes&#148;) (collectively,
the &#147;2019 Notes). The 2019 Notes had an original maturity of twelve months from the issuance date and accrued interest at a rate of 8% per annum. The 2019 Notes are automatically convertible into the Company&#146;s shares issued as part of an
equity financing of at least $35.0&nbsp;million Canadian Dollars (a &#147;Qualified Financing&#148;) at a price of 80% of the price of the qualified financing shares. In the event of a <FONT STYLE="white-space:nowrap">non-qualified</FONT> financing
event in which the Company does not raise $35.0&nbsp;million Canadian Dollars <FONT STYLE="white-space:nowrap">(&#147;Non-qualified</FONT> Financing&#148;), the noteholder majority has the option to convert the debentures into the <FONT
STYLE="white-space:nowrap">Non-qualified</FONT> Financing shares, at a price equal to 80% of the price paid per share in the <FONT STYLE="white-space:nowrap">Non-qualified</FONT> Financing. In the event of a Qualified Financing or <FONT
STYLE="white-space:nowrap">Non-Qualified</FONT> Financing, the noteholder majority may elect </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to convert the debentures into the Company&#146;s Class&nbsp;B redeemable convertible preferred shares at price equal to the issue price of the Class&nbsp;B redeemable convertible preferred
shares of $2.17315 CAD, instead of being converted into Qualified Financing shares or <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Financing shares. Additionally, upon a change of control, the noteholder majority has the option to require
repayment of the debentures at an amount equal to two times the principal and accrued interest. In the event of default, the noteholder majority has the option to require payment of the principal and accrued interest amounts. Further, upon maturity
of the 2019 Notes, at the option of a noteholder majority, the principal amount and accrued and unpaid interest shall be converted into Class&nbsp;B redeemable convertible preferred shares equal to the issue price (as defined in the Company&#146;s
articles) in effect as of the maturity date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon issuance of the 2019 Notes, the Company identified embedded derivatives related to
equity conversion and extension features which required bifurcation as a single compound derivative instrument. The Company estimated the fair value of the embedded derivative liabilities upon each issuance, establishing an aggregate initial
derivative liability of $0.9&nbsp;million upon issuance. The Company remeasured the fair value of the embedded derivatives at each reporting period, with the subsequent changes in the fair value of the derivative being recorded in the changes in
fair value of derivative liabilities in the statement of operations and comprehensive loss. The Company incurred an aggregate of $131 of debt issuance costs associated with the issuance of the 2019 Notes, of which a portion were recorded as a
reduction of the carrying value and amortized to interest expense over the term of the note, and a portion of which was allocated to the embedded derivative liabilities which were expensed as incurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2020, in conjunction with the issuance of the February 2020 Notes (as defined below), the terms of the 2019 Notes were modified to
extend the maturity date of each of the 2019 Notes to February&nbsp;14, 2021. The modification was accounted for as an extinguishment, resulting in a gain on modification of the 2019 and 2020 Notes of $1.6&nbsp;million, which is recognized in other
(income) expense, net, within the Company&#146;s consolidated statements of operations and comprehensive loss and was recorded during the year ended October&nbsp;31, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2020 the terms of the 2019 and 2020 Notes were further modified to extend the maturity date for all of the 2019 Notes to
December&nbsp;31, 2021, or such later date, determined by the majority shareholder. The modification was accounted for as an extinguishment, resulting in a gain on modification of the 2019 and 2020 Notes of $1.7&nbsp;million, which is recognized in
in other (income) expense, net within the Company&#146;s consolidated statements of operations and comprehensive loss and was recorded during the year ended October&nbsp;31, 2021. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>2020 Notes </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended
October&nbsp;31, 2020, the Company issued convertible debentures for an aggregate amount of $10.8&nbsp;million to certain of its shareholders in two separate issuances: $5.1&nbsp;million in February 2020 (the &#147;February 2020 Notes&#148;) and
$5.7&nbsp;million in June 2020 (the &#147;June 2020 Notes&#148;) (collectively, the &#147;2020 Notes&#148;). The February 2020 Notes had an initial maturity of February&nbsp;14, 2021, with an option to extend the maturity date to February&nbsp;14,
2022 upon the election of a 65% majority of the noteholders, and the June 2020 Notes had an initial maturity date of December&nbsp;31, 2020, with an option to extend the maturity date to December&nbsp;31, 2021, upon the election of a 65% majority of
the noteholders. The 2020 Notes bear interest at 8% per annum. The 2020 Notes are automatically convertible into the Company&#146;s shares issued as part of an equity financing of at least $35.0&nbsp;million Canadian Dollars (a &#147;Qualified
Financing&#148;) at a price of 80% of the price of the qualified financing shares. In the event of a <FONT STYLE="white-space:nowrap">non-qualified</FONT> financing event in which the Company does not raise $35.0&nbsp;million Canadian Dollars <FONT
STYLE="white-space:nowrap">(&#147;Non-qualified</FONT> Financing&#148;), the noteholder majority has the option to convert the debentures into the <FONT STYLE="white-space:nowrap">Non-qualified</FONT> Financing shares, at a price equal to 80% of the
price paid per share in the <FONT STYLE="white-space:nowrap">Non-qualified</FONT> Financing. In the event of a Qualified Financing or <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Financing, the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
noteholders majority may elect to convert the debentures into the Company&#146;s Class&nbsp;B redeemable convertible preferred shares at price equal to the issue price of the Class&nbsp;B
redeemable convertible preferred shares of $2.17315 CAD, instead of being converted into Qualified Financing shares or <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Financing shares. Additionally, upon a change of control, the noteholder
majority has the option to require repayment of the debentures at an amount equal to two times the principal and accrued interest. In the event of default, the noteholder majority has the option to require payment of the principal and accrued
interest amounts. Further, upon maturity of the 2020 Notes, at the option of a noteholder majority, the principal amount and accrued and unpaid interest shall be converted into Class&nbsp;B redeemable convertible preferred shares equal to the issue
price (as defined in the Company&#146;s articles) in effect as of the maturity date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon issuance of the 2020 Notes, the Company
identified embedded derivatives related to equity conversion and extension features which required bifurcation as a single compound derivative instrument. The Company estimated the fair value of the embedded derivative liabilities upon each
issuance, establishing an initial aggregate derivative liability of $0.8&nbsp;million upon issuance. The Company remeasured the fair value of the embedded derivatives at each reporting period, with the subsequent changes in the fair value of the
derivative being recognized in change in fair value of derivative liability, within the Company&#146;s consolidated statements of operations and comprehensive loss. The Company incurred an aggregate amount of $162 of debt issuance costs associated
with the issuance of the 2020 Notes, of which a portion were recorded as a reduction of the carrying value and are amortized to interest expense over the term of the note, and a portion of which was allocated to the embedded derivative liabilities
and warrant liabilities which were expensed as incurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of the issuance of the February 2020 Notes the Company issued 3,088,188
warrants to purchase the Company&#146;s Class&nbsp;B redeemable convertible preferred shares, respectively (the &#147;February 2020 Warrants&#148;). The February 2020 Notes Warrants were issued at an exercise price of $2.17315 Canadian Dollars per
share and are exercisable at any time until February&nbsp;14, 2030. Additionally, as part of the issuance of the June 2020 Notes, the Company issued 3,576,971 warrants to purchase the Company&#146;s Class&nbsp;B redeemable convertible preferred
shares (the &#147;June 2020 Warrants&#148;) at an exercise price of $2.175315 Canadian Dollars per share, which are exercisable at any time until June&nbsp;25, 2030. The February 2020 Warrants and the June 2020 Warrants were determined to be
liabilities. The Company estimated the fair value of the warrant liabilities upon each issuance, establishing an aggregate warrant liability of $1.7&nbsp;million at issuance. The Company remeasured the fair value of the warrant liabilities at each
reporting period, with the subsequent changes in the fair value of the warrant liabilities being recognized as change in fair value of warrant liabilities within the Company&#146;s consolidated statements of operations and comprehensive loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2020 the terms of the 2019 and 2020 Notes were modified to extend the maturity date through December&nbsp;31, 2021. The
modification was accounted for as an extinguishment, resulting in a gain on modification of the 2019 and 2020 Notes of $1.7&nbsp;million, which is recognized in other (income) expense, net, within the Company&#146;s consolidated statements of
operations and comprehensive loss that was recorded during the year ended October&nbsp;31, 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>2021 Notes </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended October&nbsp;31, 2021, the Company issued convertible debentures for an aggregate amount of $6.1&nbsp;million in February
2021 (the &#147;2021 Notes&#148;). The 2021 Notes had an initial maturity of December&nbsp;31, 2021, with an option to extend the maturity date upon the election of a 65% majority of the noteholders. The 2021 Notes bear interest at 8% per annum. The
2021 Notes are automatically convertible into the Company&#146;s shares issued as part of an equity financing of at least $35.0&nbsp;million Canadian Dollars (a &#147;Qualified Financing&#148;) at a price of 80% of the price of the qualified
financing shares. In the event of a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap">non-qualified</FONT> financing event in which the Company does not raise $35.0&nbsp;million Canadian Dollars
<FONT STYLE="white-space:nowrap">(&#147;Non-qualified</FONT> Financing&#148;), the noteholder majority has the option to convert the debentures into the <FONT STYLE="white-space:nowrap">Non-qualified</FONT> Financing shares, at a price equal to 80%
of the price paid per share in the <FONT STYLE="white-space:nowrap">Non-qualified</FONT> Financing. In the event of a Qualified Financing or <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Financing, the noteholders majority may elect to
convert the debentures into the Company&#146;s Class&nbsp;B redeemable convertible preferred shares at price equal to the issue price of the Class&nbsp;B redeemable convertible preferred shares of $2.17315 CAD, instead of being converted into
Qualified Financing shares or <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Financing shares. Additionally, upon a change of control, the noteholder majority has the option to require repayment of the debentures at an amount equal to two
times the principal and accrued interest. In the event of default, the noteholder majority has the option to require payment of the principal and accrued interest amounts. Further, upon maturity of the 2021 Notes, at the option of a noteholder
majority, the principal amount and accrued and unpaid interest shall be converted into Class&nbsp;B redeemable convertible preferred shares equal to the issue price (as defined in the Company&#146;s articles) in effect as of the maturity date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon issuance of the 2021 Notes, the Company identified embedded derivatives related to the equity conversion and extension features which
required bifurcation as a single compound derivative instrument. The Company estimated the fair value of the embedded derivative liabilities upon issuance at $0.6&nbsp;million. The Company remeasured the fair value of the embedded derivatives at
each reporting period, with the subsequent changes in the fair value of the derivative within the Company&#146;s consolidated statements of operations and comprehensive loss. As part of the issuance of the 2021 Notes, the Company incurred an
aggregate of $24 of debt issuance costs of which a portion were recorded as a reduction of the carrying value of the 2021 Notes, and a portion was allocated to the embedded derivative liabilities and warrant liabilities which were expensed as
incurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of the issuance of the 2021 Notes the Company issued 3,576,971 warrants to purchase the Company&#146;s Class&nbsp;B
redeemable convertible preferred shares, respectively (the &#147;2021 Warrants&#148;). The 2021 Warrants were issued at an exercise price of $2.175315 CAD per share and are exercisable at any time until February&nbsp;14, 2030. The 2021 Warrants were
determined to be liabilities. The Company estimated the fair value of the warrant liabilities upon issuance, establishing a warrant liability of $0.8&nbsp;million. The Company remeasured the fair value of the warrant liabilities at each reporting
period, with the subsequent changes in the fair value of the warrant liabilities being recognized in change in fair value of warrant liabilities within the Company&#146;s consolidated statements of operations and comprehensive loss. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>2019 Notes, 2020 Notes, and 2021 Notes Conversion </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;30, 2021, the holders of the 2019 Notes, 2020 Notes, and 2021 Notes (the &#147;Notes&#148;) elected to convert the notes and all
accrued interest into Class&nbsp;B redeemable convertible preferred shares at a conversion price of $2.175315&nbsp;CAD per share, resulting in an issuance of 16,464,646 Class&nbsp;B redeemable convertible preferred shares. Immediately following the
conversion of the Notes into Class&nbsp;B redeemable convertible preferred shares, they were exchanged into Class&nbsp;C redeemable convertible preferred shares with the exception of one holder who retained 864,570 shares of Class&nbsp;B redeemable
convertible preferred shares as they did not participate in the share exchange. The conversion of the Notes into Series&nbsp;B redeemable convertible preferred shares was accounted for as a conversion, with the carrying value of the Notes recorded
into Class&nbsp;B redeemable convertible preferred shares. Upon the exchange of the Class&nbsp;B redeemable convertible preferred shares into Class&nbsp;C redeemable convertible preferred shares, the Company recorded the Class&nbsp;C redeemable
convertible preferred shares at their fair value. The difference between the carrying value of the Class&nbsp;B redeemable convertible preferred shares and the fair value of the Class&nbsp;C redeemable convertible preferred shares that were
exchanged resulted in a gain of $2.8&nbsp;million which was recorded to additional paid in capital. </P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>BDC Notes </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2020, the Company issued a convertible debenture to the Business Development Bank of Canada (&#147;BDC&#148;) in the amount of
$2.2&nbsp;million (the &#147;BDC Notes&#148;). The debt bears interest at rate of 8% per </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">annum and had an initial maturity date of September 28, 2023. In
December 2021 the Company amended the agreement which resulted in the maturity date extending to September&nbsp;29, 2025. The BDC Notes are convertible at the option of the Holder into the Company&#146;s Class&nbsp;B redeemable convertible preferred
shares at a price of 80% of the price paid per share in qualified financing, as defined within the BDC convertible debenture agreement. The issuance of the Term Loan in 2021 met the definition of a qualified financing per the BDC convertible
debenture agreement. As the conversion option was not exercised upon the issuance of the Term Loan, the conversion right upon a qualified financing were waived. There are optional conversion options that still exist if the Company is in default, as
defined under the terms of the BDC Notes, or in the event of certain liquidation events, as defined within the BDC Notes, which allow for conversion of the BDC Note into the most senior share outstanding at the time of the event. If a liquidation
event, as defined within the BDC Note agreement, and which includes a SPAC transaction, is consummated after a qualified financing, and optional conversion is not elected, the Company is required to pay the investor in cash, the outstanding
principal and the accrued but unpaid interest and in addition an amount equal to 20% of the principal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon issuance of the BDC Notes,
the Company identified embedded derivatives related to the equity conversion features and liquidity event repayment features which required bifurcation as a single compound derivative instrument. The Company estimated the fair value of the embedded
derivative liabilities upon issuance at $0.2&nbsp;million. The Company remeasured the fair value of the embedded derivatives in effect at each reporting period, with the subsequent changes in the fair value of the derivative being recognized in
changes in fair value of derivatives within the Company&#146;s consolidated statements of operations and comprehensive loss. As part of the issuance of the BDC Notes, the Company incurred an aggregate of $36 of debt issuance costs of which a portion
were recorded as a reduction of the carrying value of the BDC Notes, and a portion was allocated to the embedded derivative liabilities which were expensed as incurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of October&nbsp;31, 2022, based on borrowing rates available to the Company for loans with similar terms and consideration of the
Company&#146;s credit risk, the carrying value of the Company&#146;s BDC Notes, excluding unamortized debt issuance costs, approximates fair value. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>2022 Notes </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended
October&nbsp;31, 2022, the Company issued convertible debentures for an aggregate amount of $18.4&nbsp;million on October&nbsp;20, 2022 (the &#147;2022 Notes&#148;). The 2022 Notes had an initial maturity that is the later of (i)&nbsp;three years
from the date of issuance; or (ii)&nbsp;the maturity date of the 2021 Loan and Security Agreement (see Note 8). The 2022 Notes bear interest at 10% per annum commencing on the date of issuance. The 2022 Notes are automatially convertible into common
shares or redeemable convertible preferred shares (&#147;Captial Shares&#148;) of the Company, which ever is issued by the Company in a qualified financing of Capital Shares that is not a listing event with an aggregate consideration of
$50.0&nbsp;million. The outstanding principal and accrued interest will convert at a price of 85% of the price paid in such qualified financing. In the event of a <FONT STYLE="white-space:nowrap">non-qualified</FONT> financing, the noteholder
majority has the option to convert the debentures to Capital Shares issued in the <FONT STYLE="white-space:nowrap">non-qualified</FONT> financing event, at a price equal to 85% of the price paid per share in the
<FONT STYLE="white-space:nowrap">non-qualified</FONT> Financing. Additionally, upon a listing event such as an initial public offering, the 2022 Notes will be automatically converted into the number of common shares equal to the quotient by dividing
the outstanding principal and interest by the listing price, except if the listing event is a SPAC business combination, following </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which the 2022 Notes will be automatically converted into common shares based on the outstanding principal excluding interest. In the event of default, the noteholder majority has the option to
require payment of the principal and accrued interest amounts or to convert the outstanding principal and accrued interest into the number of the then most senior share class of the Company or common shares at the issue price of such shares at that
date. Further, upon maturity of the 2022 Notes, at the option of a noteholder majority, the principal amount and accrued and unpaid interest shall be repaid in full or converted into the number of the then most senior share class or the Company or
common shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon issuance of the 2022 Notes, the Company identified embedded derivatives related to the equity conversion features
which required bifurcation as a single compound derivative instrument. The Company estimated the fair value of the embedded derivative liabilities upon issuance at $3.5&nbsp;million. Given the close proximity between the issuance date of the notes
and the Company&#146;s year ended October&nbsp;31, 2022, no change in fair value was recorded related to the embedded derivative liabilities identified as part of the issuance of the 2022 Notes. As part of the issuance of the 2022 Notes, the Company
incurred an aggregate of $44 of debt issuance costs of which a portion were recorded as a reduction of the carrying value of the 2022 Notes, and a portion was allocated to the embedded derivative liabilities which were expensed as incurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of October&nbsp;31, 2022, based on borrowing rates available to the Company for loans with similar terms and consideration of the
Company&#146;s credit risk, the carrying value of the Company&#146;s 2022 Notes, excluding unamortized debt issuance costs, approximates fair value. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Redeemable Convertible Preferred Shares </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of October&nbsp;31, 2022 and 2021, the Company&#146;s Articles of Amendment had an unlimited number of authorized shares of each class of
redeemable convertible preferred shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Class&nbsp;A Redeemable Convertible Preferred Shares </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;26, 2013, the Company entered into a subscription agreement (the &#147;Class&nbsp;A Agreement&#148;) with multiple investors,
whereby the Company agreed to sell to the investors an initial aggregate amount of 610,333 Class&nbsp;A redeemable convertible preferred shares at a price of $1.5929 ($1.63845 CAD) per share for total aggregate proceeds of $1.0&nbsp;million (the
&#147;Class&nbsp;A Initial Closing&#148;). Included within the Class&nbsp;A Agreement were three additional future tranche obligations (the &#147;Class&nbsp;A Second Tranche,&#148; &#147;Class&nbsp;A Third Tranche&#148; and &#147;Class&nbsp;A Fourth
Tranche&#148;) for the Company to issue and sell shares of Class&nbsp;A redeemable convertible preferred shares upon the achievement of certain milestone events. Only the Class&nbsp;A Second Tranche closed under the Class&nbsp;A Agreement. The
Class&nbsp;A Second Tranche obligated the Company to sell and the Class&nbsp;A Investors to purchase 1,830,999 shares of Class&nbsp;A redeemable convertible preferred shares at a price of $1.56967 ($1.63845 CAD) per share for total proceeds of
$2.9&nbsp;million, upon the establishment of the Company&#146;s headquarters in Montreal Quebec and completion of experiments required to bolster a patent application for dually-derivatized chitosan (the &#147;Second Closing Milestone Event&#148;),
which occurred in 2013. Additionally, upon completing the Class&nbsp;A redeemable convertible preferred share financing, convertible notes of the Company held by multiple investors converted into Class&nbsp;A redeemable convertible preferred shares.
</P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Class&nbsp;B Redeemable Convertible Preferred Shares </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;6, 2015, the Company entered into a subscription agreement (the &#147;Class&nbsp;B Agreement&#148;) with multiple investors,
where the Company agreed to sell to the investors an initial aggregate amount of 2,758,221 Class&nbsp;B redeemable convertible preferred shares at a price of $1.85032 ($2.17532 CAD) per share for total proceeds of $5.1&nbsp;million (the
&#147;Class&nbsp;B Initial Closing&#148;). Included within the Class&nbsp;B Agreement were two additional closings (the &#147;Class&nbsp;B Second Tranche,&#148; and the &#147;Class&nbsp;B Third Tranche,&#148; respectively) which obligated the
Company to sell and Class&nbsp;B investors to purchase additional Class&nbsp;B redeemable convertible preferred shares upon certain events. The Class&nbsp;B Second Tranche obligated the Company to sell and the Class&nbsp;B Investors to purchase
1,838,815 Class&nbsp;B Shares at a price of $1.63419 ($2.17532 CAD) per share for total proceeds of $3.0&nbsp;million and the Class&nbsp;B Third Tranche obligated the Company the sell and the Class&nbsp;B Investors to purchase 1,608,963 Class&nbsp;B
Shares at a price of $1.63419 ($2.17532 CAD) per share for total proceeds of $2.6&nbsp;million. The Class&nbsp;B Second Tranche and Class&nbsp;B Third Tranche closed on March&nbsp;1, 2017. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Class&nbsp;B-1</FONT> Redeemable Convertible Preferred Shares </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;10, 2015, the Company entered into a Subscription Agreement (the Class <FONT STYLE="white-space:nowrap">&#147;B-1</FONT>
Agreement&#148;), in which the Company was to issue 1,523,809 <FONT STYLE="white-space:nowrap">Class&nbsp;B-1</FONT> redeemable convertible preferred shares for a purchase price of $1.64367 ($2.17532 CAD) per share, resulting in aggregate proceeds
of $2.5&nbsp;million. During the year ended October&nbsp;31, 2020, the <FONT STYLE="white-space:nowrap">Class&nbsp;B-1</FONT> redeemable convertible preferred shares converted to common shares on a 1:1 basis. Therefore, as of each of the years ended
October&nbsp;31, 2020, October&nbsp;31, 2021, and October&nbsp;31, 2022, no shares of the <FONT STYLE="white-space:nowrap">Class&nbsp;B-1</FONT> redeemable convertible preferred shares remained outstanding. The Company has presented these shares
within temporary equity as of October&nbsp;31, 2019 within the consolidated statements of redeemable convertible preferred shares and shareholder deficit, as they contained the same redemption features as the Class&nbsp;B redeemable convertible
preferred shares (further described above). Upon conversion to common shares, the carrying value of the <FONT STYLE="white-space:nowrap">Class&nbsp;B-1</FONT> redeemable convertible preferred shares was reclassified to additional paid in capital
within shareholders&#146; deficit. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Class&nbsp;C Redeemable Convertible Preferred Shares </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Class&nbsp;C redeemable convertible preferred shares are issuable in series, of which an unlimited number are designated as Series 1
Class&nbsp;C redeemable convertible preferred shares with an issue price per share of $1.5929 ($1.63845 CAD); an unlimited number are designated as Series 2 Class&nbsp;C redeemable convertible preferred shares with an issue price per share of
$1.85032 ($2.17532 CAD); an unlimited number are designated as Series 3 Class&nbsp;C redeemable convertible preferred shares with an issue price per share of $2.12376 ($2.6320 CAD); and an unlimited number are designated as Series 4 Class&nbsp;C
redeemable convertible preferred shares that is reserved for the potential conversion of the BDC Notes, and will each have an issue price per share of $1.69901 ($2.10559 CAD). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;30, 2021, the Company entered into a subscription agreement (the &#147;Class&nbsp;C Agreement&#148;) with multiple investors,
where the Company agreed to sell to the Investors an initial aggregate amount of 3,662,813 Series 3 Class&nbsp;C redeemable convertible preferred shares (the &#147;Series 3 Class&nbsp;C Shares&#148;) at a price of $2.12376 ($2.6320 CAD) per share
for total proceeds of $7.8&nbsp;million (the &#147;Class&nbsp;C Initial Closing&#148;). Included within the Class&nbsp;C Agreement was one additional closing (the &#147;Class&nbsp;C Second Tranche&#148;) which obligated the Company to sell and
Class&nbsp;C investors to purchase additional Class&nbsp;C redeemable convertible preferred shares upon the achievement of certain milestone events. The Class&nbsp;C Second Tranche obligated the Company to sell and the Class&nbsp;C investors to
purchase 3,662,810 Series 3 Class&nbsp;C Shares at a price of $2.13192 ($2.6320 CAD) per share for total proceeds of $7.8&nbsp;million. The Class&nbsp;C Second Tranche closed on October&nbsp;29, 2021. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of each of the Class&nbsp;C Initial Closing and Class&nbsp;C Second Tranche, each
Class&nbsp;C investor received 3,662,813 and 3,662,810 warrants, respectively, to purchase Class&nbsp;C redeemable convertible preferred shares (the &#147;Class&nbsp;C Warrants&#148;), resulting in an aggregate issued amount of 7,325,623
Class&nbsp;C Warrants. The Class&nbsp;C Warrants have an exercise price of $2.12376 ($2.6320 CAD) per share and a term of 10 years. The Class&nbsp;C Warrants were determined to be liabilities. The Company estimated the fair value of the warrant
liabilities upon issuance and remeasured the fair value of the warrant liabilities at each reporting period, with the subsequent changes in the fair value of the warrant liabilities being recognized in changes in fair value of warrant liabiliities
within the Company&#146;s consolidated statements of operations and comprehensive loss. Upon the completion of the business combination with FEAC, all existing Class&nbsp;C Warrants of the Company will be extinguished. Refer to Note 18. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the Class&nbsp;C Agreement, certain convertible notes held by various Class&nbsp;C investors and other investors were
exchanged for an aggregate amount of 16,464,646 Class&nbsp;B redeemable convertible preferred shares (see Note 9). Additionally, upon entering into the Class&nbsp;C Agreement, the Company also entered into a share exchange agreement (the &#147;Share
Exchange Agreement&#148;) with the Class&nbsp;A investors and the Class&nbsp;B investors. As part of the Share Exchange Agreement, certain of the Class&nbsp;A redeemable convertible preferred shares issued to Class&nbsp;A investors were exchanged
for Series 1 Class&nbsp;C redeemable convertible preferred shares and certain of the Class&nbsp;B redeemable convertible preferred shares issued to the Class&nbsp;B investors were exchanged for Series 2 Class&nbsp;C redeemable convertible preferred
shares. This exchange resulted in the derecognition of Class&nbsp;A and B redeemable convertible preferred shares and the recognition of Class&nbsp;C redeemable convertible preferred shares at the fair value of the Class&nbsp;C redeemable
convertible preferred shares. The difference between the carrying value of the Class&nbsp;A and Class&nbsp;B redeemable convertible preferred shares and the fair value of the Class&nbsp;C redeemable convertible preferred shares for which they
converted into was recorded within additional paid in capital and no gain or loss on extinguishment was recorded within the consolidated statements of operations and comprehensive loss. Further, the February 2020 Warrants, June 2020 Warrants, and
2021 Warrants, which consisted of warrants to purchase the Company&#146;s Class&nbsp;B redeemable convertible preferred shares and were issued as part of the convertible debentures were cancelled and replaced by the terms of the Class&nbsp;C
Warrants. The aggregate amount of outstanding warrants of 10,242,130 from the February 2020 Warrants, the June 2020 Warrants, and the 2021 Warrants converted into 10,242,130 Class&nbsp;C Warrants, which have an exercise price of $2.12376 ($2.6320
CAD) per share and a term expiring on February&nbsp;14, 2030. Immediately prior to conversion, the warrants were marked to fair value, with the change in the fair value of the warrant liabilities being recognized in changes in fair value of warrant
liabilities within the Company&#146;s consolidated statements of operations and comprehensive loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon issuance of each series of
Class&nbsp;A, Class&nbsp;B, and Class&nbsp;C Preferred Shares, the Company assessed the embedded conversion and liquidation features of the shares and determined that such features did not require the Company to separately account for these
features. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of October&nbsp;31, 2022 and 2021, the redeemable convertible Preferred Shares consisted
of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>October&nbsp;31, 2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred&nbsp;Shares&nbsp;Issued<BR>and Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Redemption</B><br><B>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common&nbsp;Shares<BR>Issuable<BR>Upon&nbsp;Conversion</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;A Preferred Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,477,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 1,899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 3,634</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,477,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;B Preferred Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">864,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">864,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;C Preferred Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,810,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">107,462</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,810,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,152,399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">112,629</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,152,399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amount previously presented was revised due to the correction of an immaterial error. This revision is also
reflected in the disclosure of the redemption value on the consolidated balance sheet. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>October&nbsp;31, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred&nbsp;Shares&nbsp;Issued<BR>and Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Redemption</B><br><B>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common&nbsp;Shares<BR>Issuable<BR>Upon&nbsp;Conversion</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;A Preferred Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,477,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 1,899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 3,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,477,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;B Preferred Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">864,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,564</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">864,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;C Preferred Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,810,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">113,708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,810,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,152,399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">118,981</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,152,399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of each class of Preferred Shares have the following rights and preferences: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Voting Rights </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of the redeemable
convertible preferred shares will vote together with the holders of common shares as a single class upon any matter submitted to the shareholders for a vote. Holders of redeemable convertible preferred shares may cast the number of votes equal to
the number of shares of common shares to which such shares of the redeemable convertible preferred shares are convertible into, including fractions of shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Liquidation </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a
liquidation event, as defined in the Company&#146;s Articles of Amendment, each holder of Class&nbsp;C redeemable convertible preferred shares will be entitled to ratably receive, in priority to any distribution of the property or assets of the
Company to the holders of other classes of shares, an amount equal to two times the applicable issue price for each Class&nbsp;C redeemable convertible preferred share, subject to adjustment for shares splits, consolidations and similar events, plus
all accrued or declared but unpaid dividends for such redeemable convertible preferred shares (the &#147;Class&nbsp;C Preferred Liquidation Preference&#148;). After any conversion of Class&nbsp;C redeemable convertible preferred shares into common
shares, the holders of such common shares will not be entitled to any preferential payment of distribution in the case of a liquidation event. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the Class&nbsp;C redeemable convertible preferred shares liquidation preferences, in the event of a liquidation event, each holder
of Class&nbsp;A and/or Class&nbsp;B redeemable convertible preferred shares will be entitled to ratably receive, in priority to any distribution of the property or assets of the Company to the holders of voting and
<FONT STYLE="white-space:nowrap">non-voting</FONT> common shares, out of the liquidation proceeds, an amount equal to one times the issue price of each Class&nbsp;A and/or Class&nbsp;B redeemable convertible preferred shares, subject to adjustment
for shares splits, consolidations and similar events, plus all accrued or declared but unpaid dividends for such Class&nbsp;A and/or Class&nbsp;B redeemable convertible preferred shares (the &#147;Class&nbsp;A and Class&nbsp;B Preferred Liquidation
Preference&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
After any conversion of Class&nbsp;A and/or Class&nbsp;B redeemable convertible preferred shares into common shares, the holders of such common shares will not be entitled to any preferential
payment or distribution in case of a liquidation event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After payment has been made in full to the holders of Class&nbsp;A, Class&nbsp;B,
<FONT STYLE="white-space:nowrap">Class&nbsp;B-1,</FONT> and Class&nbsp;C redeemable convertible preferred shareholders, any assets remaining available will be distributed ratably and on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis
among the preferred shareholders and holder of voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event
of a sale transaction, each holder of Class&nbsp;C redeemable convertible preferred shares will be entitled to receive, out of the liquidation proceeds, regardless of any other dispositions among the parties, prior to and in preference to any
distribution to holders of voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common shares, Class&nbsp;A redeemable convertible preferred shares and/or Class&nbsp;B redeemable convertible preferred shares , an amount equal to the
Class&nbsp;C Preferred Liquidation Preference for each Class&nbsp;C redeemable convertible preferred shares then held. Once all amounts payable to the holders of Class&nbsp;C redeemable convertible preferred shares have been made, then each holder
of Class&nbsp;A redeemable convertible preferred shares and Class&nbsp;B redeemable convertible preferred shares will be entitled to receive, out of the liquidation proceeds, regardless of any other dispositions among the parties, prior to and in
preference to any distribution to holders of voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common shares, an amount equal to the Class&nbsp;A and Class&nbsp;B Preferred Liquidation Preference for each holder of Class&nbsp;A or
Class&nbsp;B redeemable convertible preferred shares then held. Once all amounts payable to the redeemable convertible preferred shareholders have been made, then any remaining liquidation proceeds received as part of the sale transaction will be
distributed ratably and on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis among all redeemable convertible preferred shareholders and holders of voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Conversion </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the Class&nbsp;A,
Class&nbsp;B, <FONT STYLE="white-space:nowrap">Class&nbsp;B-1</FONT> and Class&nbsp;C redeemable convertible preferred shares is automatically converted into common shares at the applicable conversion price upon (i)&nbsp;the closing of a qualified
IPO having a price per share not less than three times the issue price of the Series 3 Class&nbsp;C redeemable convertible preferred shares, and with gross proceeds for the Company of not less than $50.0&nbsp;million or (ii)&nbsp;the election to
convert by a special majority approval, which is defined as approval of holders of at least 54% of the Class&nbsp;C redeemable convertible preferred shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each redeemable convertible preferred share may also be converted at the option of the shareholder, without the payment of any additional
consideration, at any time after the original issue date, into a number of fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> common shares as determined by multiplying each such share by the conversion ratio in accordance with
the Company&#146;s Articles of Amendment. The conversion ratio is determined by dividing the issue price by the conversion price. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Dividends </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of Class&nbsp;A Preferred Shares are entitled to receive, at the same rate as the holders of Class&nbsp;B and <FONT
STYLE="white-space:nowrap">Class&nbsp;B-1</FONT> Preferred Shares, and in priority to holders of common shares, an annual fixed cumulative preferential dividend of 8% calculated on the issue price of $1.5929 ($1.63845 CAD) per share. The undeclared
cumulative dividend on Class&nbsp;A Preferred Shares as of October&nbsp;31, 2022, 2021 and 2020 was $1.9&nbsp;million, $1.7&nbsp;million and $2.4&nbsp;million, respectively. </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of Class&nbsp;B Preferred Shares are entitled to receive, at the same rate as the
holders of Class&nbsp;A and <FONT STYLE="white-space:nowrap">Class&nbsp;B-1</FONT> Preferred Shares, and in priority to common shares, an annual fixed cumulative preferential dividend of 8% of the issue price of $1.85032 ($2.17532 CAD) per share.
The Class&nbsp;B shares are subject to an anti-dilution adjustment in the event of a common share issuance at a price per share lower than $1.85032 ($2.17532 CAD). The undeclared cumulative dividend on Class&nbsp;B shares as of October&nbsp;31,
2022, 2021 and 2020 was $151&nbsp;thousand, $41&nbsp;thousand and $4.4&nbsp;million, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of <FONT
STYLE="white-space:nowrap">Class&nbsp;B-1</FONT> Preferred Shares are entitled to receive, at the same rate as the holders of Class&nbsp;A and Class&nbsp;B Preferred Shares, and in priority to common shares, an annual fixed cumulative preferential
dividend in the amount of 8% of the issue price of $1.64367 ($2.17532 CAD) per share. The <FONT STYLE="white-space:nowrap">Class&nbsp;B-1</FONT> Preferred Shares are subject to an anti-dilution adjustment in the event of a common share issuance at a
price per share lower than $1.64367 ($2.17532 CAD). The undeclared cumulative dividend on <FONT STYLE="white-space:nowrap">Class&nbsp;B-1</FONT> Preferred Shares as of October&nbsp;31, 2022, 2021 and 2020 was $0. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of Class&nbsp;C redeemable convertible preferred shares are entitled to receive in priority to all other classes of shares an annual
fixed cumulative preferential dividend in the amount of 8% of the issue price of $2.12376 ($2.6320 CAD) per share. The Class&nbsp;C redeemable convertible preferred shares are subject to an anti-dilution adjustment in the event of a common share
issuance at a price per share lower than $2.12376 ($2.6320 CAD). The undeclared cumulative dividend on Class&nbsp;C redeemable convertible preferred shares as of October&nbsp;31, 2022, 2021 and 2020 was $4.9&nbsp;million, $1.2&nbsp;million and $0,
respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Redemption </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Preferred Shares are automatically redeemable upon a deemed liquidation event, as defined in the Company&#146;s Articles of Amendment. Upon such event, the preferred shareholders would be paid their preference amounts according to the liquidation
priority set forth in the Articles of Amendment. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Common Shares </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has an unlimited number of authorized shares of common shares, with no par value. The voting and non-voting common shares issued
and outstanding as of October&nbsp;31, 2022 and 2021 are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>October&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Voting common shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,524,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,524,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-voting</FONT> common shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">164,827</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82,216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total outstanding common shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,688,872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,606,261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Dividend Rights </I>&#150; Holders of voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common
shares are entitled to receive <FONT STYLE="white-space:nowrap">non-cumulative</FONT> dividends, subject to the rights, privileges, conditions and restrictions attaching to the Preferred Shares, if, as and when declared by the Board of Directors out
of the money legally available for the payment of dividends. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Voting Rights</I> &#150; At all meetings of the shareholders of the
Company, the holders of the voting common shares are entitled to one vote for each common share held. <FONT STYLE="white-space:nowrap">Non-voting</FONT> shares of common shares are not entitled to vote, except as otherwise provided in the Canada
Business Corporations Act. Shares acquired through stock options are <FONT STYLE="white-space:nowrap">non-voting</FONT> shares. </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Liquidation Rights</I> &#150; Subject to the rights, privileges, conditions and
restrictions attaching to the redeemable convertible preferred shares, in the event of liquidation event, the holders of common shares will be entitled to receive ratably and pari passu among the holders of common shares, the holders of <FONT
STYLE="white-space:nowrap">non-voting</FONT> common shares and the holders of redeemable convertible preferred shares, on an as converted basis, monies, securities and other assets distributable in connection with the Liquidation Event. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of October&nbsp;31, 2022 and 2021, the Company has reserved the following common shares for the potential conversion of outstanding
redeemable convertible preferred shares and the exercise of warrants and share options: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>October&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred shares, as converted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,152,399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,152,399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants to purchase shares of Class&nbsp;C redeemable convertible preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,701,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,567,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options to purchase common shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,731,309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,675,432</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59,585,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59,395,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company also had convertible notes outstanding for the fiscal year ended October&nbsp;31, 2022, and 2021,
which could obligate the Company to issue shares of preferred stock upon the occurrence of various future events at prices and in amounts that are not determinable until the occurrence of those future events. Because the necessary conditions for the
conversion of these instruments had not been satisfied during each of the fiscal years ended October&nbsp;31, 2022, and 2021, the Company has excluded these instruments from the table above. See Note&nbsp;9, &#147;Convertible Debentures,&#148; for
additional details. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Share-Based Compensation </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The ESOP and EIP Plans </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has an
employee shares option plan (the &#147;ESOP&#148;) and an equity incentive plan (the &#147;EIP&#148;) (collectively, the &#147;Plans&#148;) which was adopted by the Board of Directors, and approved by the shareholders, effective July&nbsp;5, 2018.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Plans, all options to purchase <FONT STYLE="white-space:nowrap">non-voting</FONT> common shares of the Company&#146;s shares
may be granted to directors, officers, employees, consultants and members of the scientific advisory board. The Plans provide for the issuance of <FONT STYLE="white-space:nowrap">non-voting</FONT> common share options up to a maximum of 15% of the
aggregate issued and outstanding common shares and <FONT STYLE="white-space:nowrap">non-voting</FONT> common shares of the Company calculated on an as converted and fully diluted basis. The Company&#146;s stock option plans are administered by the
Board of Directors. The Board of Directors determines the number of options to be granted, the vesting period and the exercise price of new option. It is the Company&#146;s policy to establish the exercise price at an amount that approximates the
fair value of the underlying shares on the date of grant as determined by the Board of Directors. As of October&nbsp;31, 2022, there were 9,838,946 shares reserved for issuance in the Plans, of which 942,810 shares remain available for future grants
under the Plans. The options vest in accordance with the vesting terms determined for each grant by the Board of Directors. The vesting terms of the Company&#146;s granted stock options are typically 100% vesting immediately upon grant date, or over
a three- or four-year service period. The Company does not have any performance awards. </P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stock Options </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assumptions that the Company used to determine the grant-date fair value of stock options, were as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended October&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.08</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.0&nbsp;&#150;&nbsp;6.08</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.08&nbsp;&#150;&nbsp;6.11</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71.8%&nbsp;&#150;&nbsp;77.8%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77.9%&nbsp;&#150;&nbsp;78%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.16</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.37 &#150; 1.11</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.67 &#150; 0.83</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of <FONT STYLE="white-space:nowrap">non-voting</FONT> common shares and exercise price
of options (CAD)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.22</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 0.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 0.22</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of <FONT STYLE="white-space:nowrap">non-voting</FONT> common shares and exercise price
of options (USD)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.17</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 0.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 0.16</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the Company&#146;s stock option activity: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Exercise<BR>Price*<BR>(USD)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Remaining<BR>Contractual<BR>Term<BR>(in years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Intrinsic<BR>Value<BR>(in<BR>thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of October&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,626,533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,366,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(80,966</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited or expired</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(236,315</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of October&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,675,432</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">492,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(82,611</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited or expired</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(354,094</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of October&nbsp;31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,731,309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options vested and exercisable as of October&nbsp;31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,075,403</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options unvested as of October&nbsp;31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,655,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#150; All options were issued in Canadian dollars at $0.22. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate intrinsic value of share options is calculated as the difference between the exercise price of the share options and the fair
value of the Company&#146;s <FONT STYLE="white-space:nowrap">non-voting</FONT> common share for those share options that had exercise prices lower than the fair value of the Company&#146;s common shares. The fair value of the <FONT
STYLE="white-space:nowrap">non-voting</FONT> common shares exercised during the year ended October&nbsp;31, 2022, October&nbsp;31, 2021 and October&nbsp;31, 2020 was determined to be equal to the exercise price of the share option, and therefore
there is no aggregate intrinsic value for options exercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The weighted-average grant-date fair value per share of share options
granted during the year ended October&nbsp;31, 2022, October&nbsp;31, 2021, and October&nbsp;31, 2020 was $0.11, $0.11, and $0.12, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Share-based Compensation Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Share-based compensation expense included in the Company&#146;s condensed consolidated statements of operations and comprehensive loss was as
follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended October&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total share-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of October&nbsp;31, 2022, there was $0.3&nbsp;million of unrecognized compensation expense related to
outstanding stock options, which is expected to be recognized over a weighted-average period of 2.8 years. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Net Loss Per Share </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the computation of the Company&#146;s basic and diluted net loss per share for the periods presented (in
thousands, except share and per share amounts): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended October&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 24,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 23,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 15,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deemed dividend attributable to redeemable convertible Preferred Shares*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,562</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,577</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on conversion of preferred shares recorded within additional paid in capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,817</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common shareholders, basic and diluted*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 29,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 16,645</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of common shares used in net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,640,030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,562,638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,763,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per common share, basic and diluted*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 7.97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 6.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts previously presented were revised due to the correction of an immaterial error.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company excluded the following shares from the computation of diluted net loss per share attributable to common
shareholders during the year ended October&nbsp;31, 2022, 2021 and 2020 because including them would have had an anti-dilutive effect: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended October&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,152,399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,152,399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,362,130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants to purchase redeemable convertible Preferred Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,701,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,567,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,665,159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options to purchase common shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,731,309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,675,432</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,626,533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59,585,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59,395,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,653,822</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company also had convertible notes outstanding for the fiscal year ended October 31,
2022, 2021, and 2020, which could obligate the Company to issue shares of redeemable convertible preferred shares upon the occurrence of various future events at prices and in amounts that are not determinable until the occurrence of those future
events. Because the necessary conditions for the conversion of these instruments had not been satisfied during each of the fiscal years ended October 31, 2022, 2021, and 2020 the Company has excluded these instruments from the table above and the
calculation of diluted net loss per share. See Note 9, &#147;Convertible Debentures,&#148; for additional details. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Income Taxes </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Loss before provision for income taxes consisted of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended October&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Domestic (Canada)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(23,965</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(22,872</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,475</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign (US)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(475</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(569</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(593</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(24,440</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(23,441</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15,068</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The components of the provision for income taxes is as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended October&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current expense (benefit):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Domestic (Canada)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign (US)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current expense (benefit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred expense (benefit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Domestic (Canada)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign (US)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax expense (benefit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total income tax expense (benefit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">$&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A reconciliation of the Company&#146;s statutory income tax rate to the Company&#146;s effective income tax
rate is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended October&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income at Canada statutory rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26.50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26.50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26.50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State taxes, net of federal benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.12</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.21</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.12</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Permanent differences</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3.90</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5.22</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.36</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.29</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.41</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.36</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign rate differential</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.11</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.13</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.22</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of debentures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3.62</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(22.86</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(18.29</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(29.13</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.14</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.14</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.09</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The net deferred income tax balances related to the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>October&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non-Deductible R&amp;D Expenditures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating loss (NOL) carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Credits, Net of Tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible Debenture Embedded derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible Debentures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accruals</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease Liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,706</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(22,048</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(18,429</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible Debentures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Right of Use Assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(65</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(263</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(74</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(277</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax assets (liability)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The calculation of the Company&#146;s tax liabilities involves dealing with uncertainties in the application
of complex tax laws and regulations for both federal taxes and the provinces and states in which the Company operates or does business in. ASC&nbsp;740 states that a tax benefit from an uncertain tax position may be recognized when it is more likely
than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, on the basis of the technical merits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company records uncertain tax positions as liabilities in accordance with ASC&nbsp;740 and adjusts these liabilities when the
Company&#146;s judgment changes as a result of the evaluation of new information not previously available. Because of the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from
the current estimate of the unrecognized tax benefit liabilities. These differences will be reflected as increases or decreases to income tax expense in the period in which new information is available. As of October&nbsp;31, 2022 and 2021, no
uncertain tax positions have been recorded in the consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes interest and penalties
related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statement of operations and comprehensive loss. As of October&nbsp;31, 2022 and 2021, no accrued interest or penalties are included on the related
tax liability line in the consolidated balance sheet. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of October&nbsp;31, 2022, the Company has Canadian NOL carry-forwards of
$53.0&nbsp;million, that expire between 2028 and 2042. As of October&nbsp;31, 2022, the Company had a U.S. Federal NOL carry-forward of $0.8&nbsp;million, that may be carried forward indefinitely. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of October&nbsp;31, 2022, the Company also has Canadian investment tax credits of
$1.6&nbsp;million that expire between 2028 and 2042. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>15.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Leases </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s leases are comprised of all operating leases for office and lab space. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2019, the Company entered into an office space lease approximating 12,271 of rentable square feet or a portion of an office building
located at 201 Jones Road, Waltham, Massachusetts. The lease commenced in April 2019 and the lease term is to expire on March&nbsp;30, 2022, with no options to renew. The lease expired on March&nbsp;30, 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2021, the Company entered into an office and lab space lease approximating 9,360 of rentable square feet for designated office and
lab spaces located at 7171 Frederick-Banting, City of Montreal, judicial district of Montreal, Province of Quebec. The leased commenced in November 2021 and had an initial term of 12 months that expires on October&nbsp;31, 2022, and includes options
to renew for consecutive twelve-month periods upon landlord consent at new lease rates. As the Company has elected to not recognize leases with a lease term of 12 months or less on the balance sheet, this was considered short-term leases, and no
operating lease right of use assets and liabilities were recognized. In October 2022, the Company entered into a lease amendment to extend the lease for an additional term of six months through April 2023, with an option to extend the lease through
September 2023. The amendment resulted in $0.4&nbsp;million of additional lease commitments to be paid during the extended term, inclusive of the option period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended October&nbsp;31, 2022, 2021, and 2020, the components of operating lease cost were as follows, and are reflected in
general and administrative expenses and research and development expenses, as determined by the underlying activities: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended October&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease Cost:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Variable operating lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term operating lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes information related to the measurement of the Company&#146;s operating leases
for the years ended October&nbsp;31, 2022, 2021 and 2020: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended October&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average remaining lease term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average discount rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15.34</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15.34</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash paid for amounts included in the measurement of operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of October&nbsp;31, 2022, the Company does not have any operating lease liabilities recorded on the balance
sheet. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>16.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Commitments and Contingencies </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Legal Proceedings </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to
time, in the ordinary course of business, the Company is subject to litigation and regulatory examinations as well as information gathering requests, inquiries and investigations. As of October&nbsp;31, 2022 and 2021, there were no matters which
would have a material impact on the Company&#146;s financial results. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>17.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Related Party Transactions </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended October&nbsp;31, 2022, the Company had the following transactions with shareholders that hold more than 10% of the total
outstanding shares of the Company: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;20, 2022, the Company issued an aggregate amount of $18.4&nbsp;million of convertible
debentures to existing shareholders including Forbion Capital Fund III Cooperatief U.A. (&#147;Forbion Capital Fund III&#148;), Fonds de Solidarit&eacute; des Travailleurs du Qu&eacute;bec (F.T.Q.) (&#147;FSTQ&#148;), Lumira Ventures III, L.P.
(&#147;Lumira III&#148;), Lumira Ventures III (International), L.P. (&#147;Lumira International III&#148;), Merck Lumira Biosciences Fund, L.P. (&#147;Merck&#148;), Merck Lumira Biosciences Fund (Qu&eacute;bec), L.P. (&#147;Merck Quebec&#148;) Refer
to Note 9. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended October&nbsp;31, 2021, the Company had the following transactions with shareholders that hold more than
10% of the total outstanding shares of the Company: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;2, 2021, the Company issued convertible debentures for an aggregate
amount of $6.1&nbsp;million to existing shareholders including Merck, Merck Quebec, FSTQ, Lumira III, Lumira International III, Forbion Capital Fund III, and Pharmstandard International S.A. As part of the issuance of the 2021 Notes the Company also
issued 3,576,971 warrants to purchase the Company&#146;s Class&nbsp;B redeemable convertible preferred shares to the same shareholders. Refer to Note 9. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;30, 2021, the Company completed the sale of 3,662,813 shares of Class&nbsp;C Preferred Shares at a price of $2.12376 ($2.6320
CAD) to existing shareholders including Merck, Merck Quebec, FSTQ, Lumira III, Lumira International III, and Forbion Capital Fund III for an aggregate amount of $7.7&nbsp;million. Included within the Class&nbsp;C Agreement was one additional closing
for the Class&nbsp;C Second Tranche which obligated the Company to sell and Class&nbsp;C investors to purchase additional Class&nbsp;C redeemable convertible preferred shares upon the achievement of certain milestone events. The Class&nbsp;C Second
Tranche obligated the Company to sell and the Class&nbsp;C investors to purchase 3,662,810 Series 3 Class&nbsp;C Shares at a price of $2.13192 ($2.6320 CAD) per share for total proceeds of $7.8&nbsp;million. The Class&nbsp;C Second Tranche closed on
October&nbsp;29, 2021. Refer to Note 10. Additionally, on June&nbsp;30, 2021, shares of Class&nbsp;A and Class&nbsp;B Preferred Shares held by the same existing shareholders were exchanged for Class&nbsp;C Preferred Shares. Refer to Note 9. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;30, 2021, the holders of the 2019 Notes, 2020 Notes, and 2021 Notes elected to convert the notes and all accrued interest into
Class&nbsp;B redeemable convertible preferred shares at a conversion price of $2.175315&nbsp;CAD per share, resulting in an issuance of 16,464,646 Class&nbsp;B redeemable convertible preferred shares. Additionally, on June&nbsp;30, 2021, shares of
Class&nbsp;A and Class&nbsp;B Preferred Shares held by the same existing shareholders were exchanged for Class&nbsp;C Preferred Shares. Refer to Note 9. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended October&nbsp;31, 2020, the Company had the following transactions with shareholders that hold more than 10% of the total
outstanding shares of the Company: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;14, 2020, the Company issued convertible debentures for an aggregate amount of
$5.1&nbsp;million to existing shareholders including FSTQ, Merck, Merck Quebec, Lumira III and Lumira International III. As part </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the issuance of the 2020 Notes the Company also issued 3,088,188 warrants to purchase the Company&#146;s Class&nbsp;B redeemable convertible preferred shares to the same shareholders.
Additionally, on June&nbsp;30, 2021, shares of Class&nbsp;A and Class&nbsp;B Preferred Shares held by the same existing shareholders were exchanged for Class&nbsp;C Preferred Shares. Refer to Note 9. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;25, 2020, the Company issued convertible debentures for an aggregate amount of $5.7&nbsp;million to existing shareholders
including FSTQ, Forbion, Merck, Merck Quebec, Lumira III and Lumira International III. As part of the issuance of the 2020 Notes the Company also issued 3,576,971 warrants to purchase the Company&#146;s Class&nbsp;B redeemable convertible preferred
shares to the same shareholders. Additionally, on June&nbsp;30, 2021, shares of Class&nbsp;A and Class&nbsp;B Preferred Shares held by the same existing shareholders were exchanged for Class&nbsp;C Preferred Shares. Refer to Note 9. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>18.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Subsequent Events </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has evaluated subsequent events through August&nbsp;9, 2023, the date these financial statements were available to be issued.
Except as noted below, the Company concluded that no additional subsequent events have occurred that require disclosure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
December&nbsp;29, 2022, the Company signed a new lease for approximately 10,620 square feet of new laboratory and office space at 4868 Rue Levy, Montreal, QC. The term of the lease is for 10 years beginning on the commencement date, and requires an
annual initial base rent of $36.50 CAD per square foot, which is subject to annual increases of 2%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the first quarter of fiscal
year 2023, the Company determined that the functional currency of the parent company, enGene Inc., be changed from the Canadian Dollar to the United States Dollar, as a result of evaluating criteria within ASC 830 and the contemplated future
financing and business combination with FEAC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the first six months of the Company&#146;s fiscal year end October&nbsp;31, 2023,
the Company issued an aggregate 1,065,899 stock options under its current Plans, which were issued in connection with new hire employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;4, 2023, the Company entered into a note purchase agreement (the &#147;April 2023 Notes&#148;) for a principal amount of
$8.0&nbsp;million with Merck, Merck Quebec, FSTQ, Lumira, Lumira International, Lumira Ventures IV, L.P., Lumira Ventures (International) L.P., and Forbion (collectively the &#147;April 2023 Investors&#148;). The April 2023 Notes had an interest
free period of 45 days from the date of issuance, and commencing on the 46th date, was to accrue interest at a rate of 15% per annum. The April 2023 Notes mature on the earlier of (i)&nbsp;July&nbsp;31, 2023; or (ii)&nbsp;the date the Company
completes a qualified financing, as defined within the April 2023 Notes as a financing pursuant to which the Company sells convertible promissory notes, warrants, preferred shares, common shares, or a combination thereof of the Company for an
aggregate amount of at least $20.0&nbsp;million. Upon the 2023 Financing (as defined below) the Company issued convertible debentures and warrants of the Company to the April 2023 Note Investors, at the same terms and conditions of the convertible
debentures and warrants that were issued to the investors of the 2023 Financing, as repayment of the April 2023 Notes. Refer below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
May&nbsp;16, 2023, the Company entered into a business combination agreement with FEAC, a publicly traded SPAC. Under the terms of the proposed transaction, the combined company will be named enGene Holdings Inc. (&#147;Newco&#148;), whose common
shares are expected to be listed on Nasdaq. The cash components of the transaction will be funded by FEAC&#146;s cash in trust that is not used for redemptions, as well as investments </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
consisting of private placements of common shares, other private investments and a FEAC shareholder <FONT STYLE="white-space:nowrap">non-redemption</FONT> commitment, totaling approximately
$115&nbsp;million, which includes $18.4&nbsp;million received from the 2022 Notes, which includes $8.0 million in repayment of the April 2023 Notes and the $38.0&nbsp;million received from the 2023 Financing (as defined below). The parties to the
business combination agreement will amalgamate under Section&nbsp;192 of the Canada Business Corporations Act pursuant to a plan of arrangement (the &#147;Amalgamation&#148;, the date of the Amalgamation being the &#147;Closing Date&#148;). The
closing of the business combination is subject to the affirmative vote of FEAC shareholders and the Company&#146;s shareholders, amongst other conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;16, 2023, FEAC, Newco, and certain investors (the &#147;PIPE Investors&#148;) entered into subscription agreements (the
&#147;Subscription Agreements&#148; and each a &#147;Subscription Agreement&#148;) pursuant to which, among other things, the PIPE Investors have agreed, subject to the completion of each element of the transactions (other than those that are
scheduled to be completed following the Closing Date), to subscribe for and purchase, and FEAC has agreed that it will issue and sell to the PIPE Investors (which obligation will be assumed (the &#147;Assumption&#148;) by Newco after the completion
of the FEAC Reorganization and prior to the consummation of the PIPE Financing (as defined below)), the number of FEAC Class&nbsp;A shares (or after the Assumption, Newco Shares) provided for in the applicable Subscription Agreement in exchange for
FEAC Class&nbsp;A share (or after the Assumption, Newco Share) (as amended by the Side Letter Agreements (as defined below, the &#147;PIPE Financing&#148;)). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately following the execution and delivery of the Subscription Agreements, FEAC and Newco entered into a side letter with each PIPE
Investor (the &#147;Side Letter Agreement&#148; and collectively, the &#147;Side Letter Agreements&#148;) to amend the relevant Subscription Agreement and which, together with the relevant Subscription Agreement, reflects the total number of FEAC
Class&nbsp;A shares and FEAC warrants to be issued by FEAC (or after the Assumption, the total number of Newco Shares and Newco Warrants to be issued by Newco) pursuant to the PIPE Financing in consideration of the purchase price set forth in the
relevant Subscription Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Subscription Agreements and Side Letter Agreements, the PIPE Investors have collectively
subscribed for FEAC Class&nbsp;A shares and FEAC warrants (or after the Assumption, Newco Shares and Newco Warrants) for an aggregate purchase price equal to $56.9&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the Closing Date, all of the Company&#146;s existing redeemable convertible preferred shares outstanding immediately prior to the
Amalgamation will be exchanged for shares of the Newco&#146;s common shares, with no dividends or distributions being declared or paid on the Company&#146;s&#146; redeemable convertible preferred shares, and certain of the Company&#146;s existing
convertible notes will convert to common shares of the Company at the conversion ratio in place at the time of conversion. Further, all of the Company&#146;s existing outstanding Class&nbsp;C Warrants will be terminated. Pursuant to the
Amalgamation, all of the Company&#146;s common shares outstanding immediately prior to the Amalgamation will be exchanged for common shares of Newco at an agreed upon exchange ratio set out in the Amalgamation plan of arrangement (the &#147;Company
Exchange Ratio&#148;) and each of the Company&#146;s outstanding warrants immediately prior to the Amalgamation shall be exchanged for warrants of Newco at the Company Exchange Ratio. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the execution and delivery of the business combination agreement with FEAC, the Company agreed to certain modifications of the 2022
Notes having an aggregate principal amount of $18.4&nbsp;million (the &#147;Amended 2022 Notes&#148; and, together with the Company warrants to be issued by the Company as consideration for such modifications, the &#147;Amended 2022
Financing&#148;). On May&nbsp;12, 2023, the Company also consented to certain modifications of the BDC Notes pursuant to which the Company will be required on the Closing Date to repay in cash (i)&nbsp;the outstanding principal and the accrued but
unpaid interest; and (ii)&nbsp;an amount equal to 20% of the principal. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN THOUSANDS OF USD, EXCEPT FOR SHARE AND PER SHARE DATA) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently with the execution and delivery of the business combination agreement, the
Company also entered into agreements pursuant to which it will issue new convertible indebtedness and warrants (i)&nbsp;for cash in an aggregate principal amount of $30.0&nbsp;million and (ii)&nbsp;in repayment of the April 2023 Notes in an
aggregate principal amount of $8.0&nbsp;million (collectively, the &#147;2023 Notes&#148; and, together with the warrants purchased concurrently, the &#147;2023 Financing&#148;; the 2023 Financing together with the Amended 2022 Financing, the
&#147;Convertible Bridge Financing&#148;). As part the 2023 Financing, the terms of the April 2023 Notes were modified, in which the repayment of the April 2023 Notes resulted in the Company issuing convertible debentures and warrants of the Company
to the April 2023 Note Investors, on the same terms and conditions of the convertible debentures and warrants that were issued to the investors of the 2023 Financing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2023 Financing occurred in two separate issuances with $20.0&nbsp;million received in May 2023, and the additional $10.0&nbsp;million
received in June 2023, of which Forbion Growth Sponsor FEAC I B.V. funded an aggregate amount of $20.0&nbsp;million. The 2023 Notes issued as part of the 2023 Financing have an initial maturity date of three years from the closing date and are to
accrue interest at 10% per annum, which is payable upon maturity. The 2023 Notes have the same conversion terms as the 2022 Notes (as described in Note 9). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the completion of the business combination, the Convertible Bridge Financing indebtedness will be converted into that number of common
shares of the Company, that, when exchanged at the agreed upon exchange ratio, shall equal that number of FEAC Class&nbsp;A shares (or after the assumption of FEAC by Newco, Newco Shares) that the holders of such indebtedness would have received if
they subscribed for FEAC Class&nbsp;A shares (or after the assumption of FEAC by, Newco Shares) on the same terms as the investors who have participated in the PIPE Financing. Further, pursuant to the Amalgamation plan of arrangement, immediately
prior to the Closing Date, all of the Company&#146;s unvested stock options issued and outstanding under its&#146; Plans as of May&nbsp;16, 2023 will be immediately vested and exercisable and will be exchanged for options of the Newco at the Company
Exchange Ratio on the Closing Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, prior to the Closing Date, all of the Company&#146;s existing redeemable convertible
preferred shares outstanding immediately prior to the Amalgamation will be exchanged for shares of the Newco&#146;s common shares with no dividends or distributions being declared or paid on the Company&#146;s redeemable convertible preferred
shares, and certain of the Company&#146;s existing convertible notes will convert to common shares of the Company at the conversion ratio in place at the time of conversion. Further, all of the Company&#146;s existing outstanding Class&nbsp;C
Warrants will be terminated. Pursuant to the Amalgamation, all of the Company&#146;s common shares outstanding immediately prior to the Amalgamation will be exchanged for common shares of Newco at an agreed upon exchange ratio set out in the
Amalgamation plan of arrangement (the &#147;Company Exchange Ratio&#148;) and each of the Company&#146;s outstanding warrants immediately prior to the Amalgamation shall be exchanged for warrants of Newco at the Company Exchange Ratio. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;7, 2023, the Board of Directors approved the reservation of an additional 5,800,000
<FONT STYLE="white-space:nowrap">non-voting</FONT> common shares for issuance under the Company&#146;s employee equity incentive plan, revising the number of shares reserved from 9,838,946 to 15,638,946. Also on July&nbsp;7, 2023, the Company
granted 5,800,000 options to employees at an exercise price of $1.06 CAD ($0.79 USD), of which 4,402,977 of the issued options vest immediately upon grant, and the remaining 1,397,023 options vest over varying terms up to four years. These options
are not exercisable unless and until the completion of the business combination agreement and there is an effective registration statement for the shares underlying such granted options, and will terminate automatically in the event of the
termination of the business combination agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART I. FINANCIAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;1. Financial Statements </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORBION EUROPEAN ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fintoc459793_6"></A>CONDENSED BALANCE SHEETS </B></P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">269,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">314,151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,668</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">197,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>309,806</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>511,804</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and securities held in trust account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">135,786,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">131,531,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>136,095,976</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>132,043,138</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities, Shares Subject to Redemption and Shareholders&#146; Deficit:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current liabilities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued offering costs and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,493,223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">844,605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Due to Related Party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48,699</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48,904</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Promissory Note - Related Party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">965,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible Note - Related Party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>8,006,922</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>893,509</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred underwriting commissions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,727,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,727,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>11,734,422</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>4,621,009</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Commitments and Contingencies (Note 6)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;A ordinary shares subject to possible redemption,&nbsp;12,650,000&nbsp;shares at
redemption value of approximately $10.73 and $10.40 at June&nbsp;30, 2023 and December&nbsp;31, 2022, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">135,786,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">131,531,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Shareholders&#146; Deficit:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preference shares, $0.0001&nbsp;par value; 5,000,000&nbsp;shares authorized; none issued and
outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;A ordinary shares, $0.0001&nbsp;par value;&nbsp;500,000,000&nbsp;shares authorized;
none outstanding (excluding&nbsp;12,650,000&nbsp;shares subject to possible redemption issued) at June&nbsp;30, 2023 and December&nbsp;31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;B ordinary shares, $0.0001&nbsp;par value;&nbsp;50,000,000&nbsp;shares
authorized;&nbsp;3,162,500&nbsp;shares issued and outstanding at June&nbsp;30, 2023 and December&nbsp;31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Additional&nbsp;paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11,424,932</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,109,521</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total shareholders&#146; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(11,424,616</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(4,109,205</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Liabilities, Shares Subject to Redemption and Shareholders&#146; Deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>136,095,976</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>132,043,138</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these unaudited condensed financial statements. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORBION EUROPEAN ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fintoc459793_7"></A>UNAUDITED CONDENSED STATEMENTS OF OPERATIONS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Three&nbsp;Months&nbsp;Ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Six Months Ended</B><br><B>June&nbsp;30</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,283,705</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">371,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,050,505</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">816,351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss from operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(4,283,705</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(371,332</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(6,050,505</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(816,351</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest earned from Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,575,269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">113,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,989,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">154,482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bank interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total other income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,575,320</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>113,051</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2,989,930</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>154,538</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(2,708,385</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(258,281</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(3,060,575</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(661,813</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted weighted average shares outstanding, Class&nbsp;A ordinary shares subject to
possible redemption</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,650,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,650,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,650,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,650,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Basic and diluted net loss per share, Class&nbsp;A ordinary shares subject to possible
redemption</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(0.17</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(0.02</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(0.19</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(0.04</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted, weighted average shares outstanding &#150; Class&nbsp;B&nbsp;ordinary
shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,162,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,162,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,162,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,162,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Basic and diluted net loss per share, Class&nbsp;B ordinary shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(0.17</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(0.02</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(0.19</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(0.04</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these unaudited condensed financial statements. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORBION EUROPEAN ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fintoc459793_8"></A>UNAUDITED CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDERS&#146; DEFICIT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE THREE AND SIX MONTHS ENDED JUNE&nbsp;30, 2023 </B></P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Times; font-size:10pt" ALIGN="center">


<TR STYLE="visibility:hidden; line-height:0pt; color:white">

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD nowrap ><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD nowrap ><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD nowrap ><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD nowrap ><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD nowrap ><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD nowrap ><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD nowrap ><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>Class&nbsp;A<BR>Ordinary<BR>Share</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>Class&nbsp;B<BR>Ordinary Share</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman; "><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-In</FONT></B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman; "><B>Accumulated</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman; "><B>Shareholders&#146;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>Shares</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>Amount</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>Shares</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>Amount</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>Capital</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>Deficit</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>Deficit</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of January&nbsp;1, 2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>$</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B></B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>3,162,500</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>$</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>316</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>$</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B></B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>$</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>(4,109,521</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>$</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>(4,109,205</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>)&nbsp;</B></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Re-measurement</FONT> of Class&nbsp;A ordinary shares subject
to possible redemption to redemption amount</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">(1,414,567</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">(1,414,567</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">(352,190</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">(352,190</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of March&nbsp;31, 2023 (unaudited)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>3,162,500</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>316</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>(5,876,278</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>(5,875,962</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>)&nbsp;</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Re-measurement</FONT> of Class&nbsp;A ordinary shares subject
to possible redemption to redemption amount</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">(2,840,269</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">(2,840,269</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">(2,708,385</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">(2,708,385</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of June&nbsp;30, 2023 (unaudited)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>$</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B></B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>3,162,500</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>$</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>316</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>$</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B></B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>$</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>(11,424,932</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>$</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>(11,424,616</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>)&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE THREE AND SIX MONTHS ENDED JUNE&nbsp;30, 2022 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Times; font-size:10pt" ALIGN="center">


<TR STYLE="visibility:hidden; line-height:0pt; color:white">

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD nowrap ><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD nowrap ><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD nowrap ><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD nowrap ><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD nowrap ><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD nowrap ><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD nowrap ><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>Class&nbsp;A<BR>Ordinary<BR>Share</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>Class&nbsp;B<BR>Ordinary Share</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman; "><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-In</FONT></B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman; "><B>Accumulated</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman; "><B>Shareholders&#146;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>Shares</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>Amount</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>Shares</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>Amount</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>Capital</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>Deficit</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>Deficit</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as January&nbsp;1, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>$</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B></B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>3,162,500</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>$</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>316</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>$</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B></B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>$</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>(2,278,322</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>$</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>(2,278,006</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>)&nbsp;</B></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Re-measurement</FONT> of Class&nbsp;A ordinary shares subject
to possible redemption to redemption amount</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">(41,453</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">(41,453</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">(403,532</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">(403,532</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of March&nbsp;31, 2022 (unaudited)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>3,162,500</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>316</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>(2,723,307</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>(2,722,991</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>)&nbsp;</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Re-measurement</FONT> of Class&nbsp;A ordinary shares subject
to possible redemption to redemption amount</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">(113,029</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">(113,029</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">(258,281</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">(258,281</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of June&nbsp;30, 2022 (unaudited)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>$</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B></B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>3,162,500</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>$</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>316</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>$</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B></B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>$</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>(3,094,617</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>$</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; "><B>(3,094,301</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; "><B>)&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these unaudited condensed financial statements. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORBION EUROPEAN ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fintoc459793_9"></A>UNAUDITED CONDENSED STATEMENTS&nbsp;OF CASH FLOWS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Six Months Ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from operating activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,060,575</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(661,813</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss&nbsp;to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest earned on cash and marketable securities held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,989,836</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(154,482</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">156,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">246,724</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued offering costs and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,648,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">237,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Due to related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(205</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37,903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash used in operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(1,245,013</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(294,385</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from investing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Principal deposited in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,265,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash used in investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(1,265,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of promissory note to related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">965,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of convertible note to related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash provided by financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>2,465,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net change in cash</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(45,013</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(294,385</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, beginning of the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">314,151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,069,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash, end of the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>269,138</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>774,913</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosure of cash flow information:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Remeasurement Adjustment of Class&nbsp;A ordinary shares subject to possible redemption</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,254,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these unaudited condensed financial statements. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORBION EUROPEAN ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fintoc459793_10"></A>NOTES TO CONDENSED FINANCIAL STATEMENTS (UNAUDITED) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 1&nbsp;&#151;&nbsp;Organization, Business Operation, Going Concern and Liquidity </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Forbion European Acquisition Corp. (the &#147;Company&#148;) was incorporated as a Cayman Islands exempted company on&nbsp;August 9, 2021. The Company was
incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar Business Combination with one or more businesses or entities (the &#147;Business Combination&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2023, the Company had not commenced any operations. All activity through June&nbsp;30, 2023 relates to the Company&#146;s formation and
the Initial Public Offering (the &#147;IPO&#148; or &#147;Public Offering&#148;) which is described below, and the Company&#146;s completion of a Business Combination. The Company will not generate any operating revenues until after the completion
of its initial Business Combination, at the earliest. The Company will generate <FONT STYLE="white-space:nowrap">non-operating</FONT> income the form of interest income on cash and cash equivalents from the proceeds derived from the Public Offering.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s Sponsor is Forbion Growth Sponsor FEAC I B.V., a Dutch private limited liability company (the&nbsp;&#147;Sponsor&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The registration statement for the Company&#146;s IPO was declared effective on December&nbsp;9, 2021 (the &#147;Effective Date&#148;). On December&nbsp;14,
2021, the Company&#146;s commenced the IPO of&nbsp;11,000,000&nbsp;units (or&nbsp;12,650,000&nbsp;units if the underwriters&#146; over-allotment option is exercised in full) at $10.00&nbsp;per unit (the &#147;Units&#148;), which is discussed in Note
3. Each Unit consists of&nbsp;one&nbsp;Class&nbsp;A ordinary <FONT STYLE="white-space:nowrap">share&nbsp;and&nbsp;one-third&nbsp;of</FONT> one redeemable warrant (the &#147;Public Warrants&#148;). Each whole warrant entitles the holder to
purchase&nbsp;one&nbsp;Class&nbsp;A ordinary share at a price of $11.50&nbsp;per share. On December&nbsp;15, 2021, the underwriters exercised their full over-allotment option and purchased the additional Units available to them. The aggregate Units
sold in the IPO and subsequent over-allotment were 12,650,000&nbsp;and generated gross proceeds of $126,500,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Simultaneously with the consummation of
the IPO, the Company consummated the private placement of&nbsp;4,700,000 warrants (or&nbsp;5,195,000&nbsp;warrants when the underwriters&#146; over-allotment option was fully exercised on December&nbsp;15, 2021) (the &#147;Private Placement
Warrants&#148;) to the Sponsor, at a price of $1.50&nbsp;per Private Placement Warrant. The sale of the Private Placement Warrants in connection with the IPO and subsequent over-allotment option exercise generated gross proceeds of $7,792,500. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Transaction costs related to the IPO amounted to $5,793,160&nbsp;consisting of $1,800,000&nbsp;of underwriting commissions, $3,150,000&nbsp;of deferred
underwriting commissions, and $843,160&nbsp;of other offering costs. The underwriters&#146; exercise of their full over-allotment option generated an additional $907,500&nbsp;in transaction costs for aggregate transaction costs of
$6,700,660&nbsp;consisting of $2,130,000&nbsp;of underwriting commissions, $3,727,500&nbsp;of deferred underwriting commissions and $843,160&nbsp;of other offering costs. In addition, $1,641,236&nbsp;of cash was held outside of the Trust Account (as
defined below) and is available for working capital purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;15, 2021, the underwriter fully exercised the over-allotment option and
purchased an additional 1,650,000 Units for additional gross proceeds of $16,500,000. Simultaneously with the exercise of the over-allotment option, the Sponsor purchased an additional&nbsp;495,000&nbsp;Private Placement Warrants for additional
gross proceeds of $742,500.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters&#146; exercise of their full over-allotment option generated an additional $907,500&nbsp;in transaction costs
for aggregate transaction costs of $6,700,660&nbsp;consisting of $2,130,000&nbsp;of underwriting commissions, $3,727,500&nbsp;of deferred underwriting commissions and $843,160&nbsp;of other offering costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the closing of the exercise of the underwriters&#146; full over-allotment option, an additional $16,170,000 was placed in the Trust Account for
aggregate proceeds in the Trust Account of $129,662,500 ($10.25 per Unit). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
As a result of the underwriters&#146; over-allotment option exercise, 412,500 Founder Shares are no longer subject to forfeiture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s management has broad discretion with respect to the specific application of the net proceeds of the IPO and the sale of Private Placement
Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company
must complete one or more initial Business Combinations having an aggregate fair market value of at least&nbsp;80% of the net assets held in the Trust Account (as defined below) (excluding the deferred underwriting commissions and taxes payable on
the interest earned on the Trust Account) at the time of signing a definitive agreement in connection with the initial Business Combination. However, the Company will complete the initial Business Combination only if the post-Business Combination
company in which its public shareholders own shares will own or acquire&nbsp;50% or more of the outstanding voting securities of the target or is otherwise not required to register as an investment company under the Investment Company Act (the
&#147;Investment Company Act&#148;). There is no assurance that the Company will be able to complete a Business Combination successfully. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the
closing of the IPO on December&nbsp;14, 2021, $113,492,500&nbsp;from the net proceeds of the sale of the Units in the IPO and the sale of the Private Placement Warrants was deposited into a trust account (the &#147;Trust Account&#148;). This amount
was comprised of $10.25&nbsp;per Unit for the&nbsp;11,000,000&nbsp;Units sold in the IPO in addition to a $742,500 Deposit in Advance from the Sponsor related to the underwriters&#146; exercise of the full over-allotment option which took place the
following day on December&nbsp;15, 2021. Following the closing of the IPO and the exercise of the underwriters&#146; full over-allotment option, $129,662,500&nbsp;($10.25&nbsp;per Unit) was held in the Trust Account and will only be invested in
United States &#147;government securities&#148; within the meaning of Section&nbsp;2(a)(16) of the Investment Company Act having a maturity of&nbsp;185&nbsp;days or less or in money market funds meeting certain conditions under <FONT
STYLE="white-space:nowrap">Rule&nbsp;2a-7&nbsp;promulgated&nbsp;under</FONT> the Investment Company Act which invest only in direct U.S. government treasury obligations. Pursuant to the trust agreement, the trustee is not permitted to invest in
other securities or assets. Except with respect to interest earned on the funds held in the Trust Account that may be released to the Company to pay its income taxes, if any, the Company&#146;s amended and restated memorandum and articles of
association, as discussed below and subject to the requirements of law and regulation, will provide that the proceeds from the Public Offering and the sale of the Private Placement Warrants held in the Trust Account will not be released from the
Trust Account (1)&nbsp;to the Company, until the completion of the initial Business Combination, or (2)&nbsp;to its public shareholders, until the earliest of (a)&nbsp;the completion of the initial Business Combination, and then only in connection
with those Class&nbsp;A ordinary shares that such shareholders properly elected to redeem, subject to the limitations described herein, (b)&nbsp;the redemption of any public shares properly tendered in connection with a shareholder vote to amend the
Company&#146;s amended and restated memorandum and articles of association (A)&nbsp;to modify the substance or timing of the Company&#146;s obligation to provide holders of the Class&nbsp;A ordinary shares the right to have their shares redeemed in
connection with the initial Business Combination or to redeem&nbsp;100% of the public shares if the Company does not complete the initial Business Combination within Combination Period or (B)&nbsp;with respect to any other provision relating to the
rights of holders of the Class&nbsp;A ordinary shares, and (c)&nbsp;the redemption of the public shares if the Company has not consummated the Company&#146;s Business Combination within Combination Period, subject to applicable law. Public
shareholders who redeem their Class&nbsp;A ordinary shares in connection with a shareholder vote described in clause (b)&nbsp;in the preceding sentence shall not be entitled to funds from the Trust Account upon the subsequent completion of an
initial Business Combination or liquidation if the Company has not consummated an initial Business Combination within Combination Period, with respect to such Class&nbsp;A ordinary shares so redeemed. The funds held in the Trust Account could become
subject to the claims of the Company&#146;s creditors, if any, which could have priority over the claims of its public shareholders. As it is expected that we are and will continuously be considered a Dutch tax resident, any redemption proceeds
(including interest income on the trust account) distributed to our shareholders in excess of the <FONT STYLE="white-space:nowrap">paid-up&nbsp;capital&nbsp;for</FONT> Dutch tax purposes may be subject to&nbsp;15% Dutch dividend withholding tax.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company will provide holders (the &#147;Public Shareholders&#148;) of its Class&nbsp;A ordinary
shares, par value $0.0001, sold in the IPO (the &#147;Public Shares&#148;), with the opportunity to redeem all or a portion of their Class&nbsp;A ordinary shares upon the completion of a Business Combination either (i)&nbsp;in connection with a
general meeting called to approve the Business Combination or (ii)&nbsp;by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a proposed Business Combination or conduct a tender offer will be made by
the Company, solely in its discretion, and will be based on a variety of factors such as the timing of the transaction and whether the terms of the transaction would require the Company to seek shareholder approval under applicable law or stock
exchange listing requirement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company will provide its Public Shareholders with the opportunity to redeem all or a portion of their Public Shares
upon the completion of the initial Business Combination, regardless of whether such shareholder votes on such proposed Business Combination, and if they do vote, regardless of whether they vote for or against such proposed Business Combination, at <FONT
STYLE="white-space:nowrap">a&nbsp;per-share&nbsp;price,&nbsp;payable&nbsp;in</FONT> cash, equal to the aggregate amount then on deposit in the Trust Account calculated as of two business days prior to the consummation of the initial Business
Combination, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its income taxes, if any, divided by the number of then-outstanding Public Shares, subject to the limitations described
herein. The amount in the Trust Account is initially anticipated to be $10.25&nbsp;per public share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The per share amount that the Company will
distribute to investors who properly redeem their shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters. The redemption rights will include the requirement that a beneficial holder must identify
itself in order to validly redeem its shares. There will be no redemption rights upon the completion of the initial Business Combination with respect to the Company&#146;s warrants. Further, the Company will not proceed with redeeming the Public
Shares, even if a Public Shareholder has properly elected to redeem its Public Shares if a Business Combination does not close. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ordinary shares
subject to redemption were recorded at a redemption value and classified as temporary equity upon the completion of the Public Offering, in accordance with Financial Accounting Standards Board&#146;s (&#147;FASB&#148;) Accounting Standards
Codification (&#147;ASC&#148;) Topic 480 &#147;Distinguishing Liabilities from Equity.&#148; In such case, the Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a
Business Combination and, if the Company seeks shareholder approval, a majority of the issued and outstanding shares voted are voted in favor of the Business Combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s amended and restated memorandum and articles of association provides that the Company will have only&nbsp;18&nbsp;months from the closing
of the Public Offering (or up to&nbsp;24&nbsp;months from the closing of the IPO if the Company extends the period of time to consummate a Business Combination, subject to the Sponsor depositing additional funds in the Trust Account) (the
&#147;Combination Period&#148;) to consummate its initial Business Combination. On June&nbsp;6, 2023, the Company extended the period of time to consummate a Business Combination from June&nbsp;14, 2023 to September&nbsp;14, 2023 by having the
Sponsor deposit an additional $1,265,000, or $0.10 per unit, into the Trust Account, in accordance with the Company&#146;s amended and restated memorandum and articles of association and the Investment Management Trust Agreement by and between the
Company and Continental Stock Transfer&nbsp;&amp; Trust Company, dated as of December&nbsp;9, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Company has not consummated an initial
Business Combination within Combination Period, the Company will: (i)&nbsp;cease all operations except for the purpose of winding up; (ii)&nbsp;as promptly as reasonably possible but not more than 10 business days thereafter, redeem the public
shares, <FONT STYLE="white-space:nowrap">at&nbsp;a&nbsp;per-share&nbsp;price,&nbsp;payable</FONT> in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not
previously released to the Company to pay its income taxes, if any (less up to $100,000&nbsp;of interest to pay dissolution expenses) divided by the number of the then-outstanding public shares, which redemption will completely extinguish public
shareholders&#146; rights as shareholders (including the right to receive further liquidation distributions, if any); and (iii)&nbsp;as promptly as reasonably possible following such redemption, subject to the approval of the Company&#146;s
remaining shareholders and its board of directors, liquidate and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
dissolve, subject in the case of clauses (ii)&nbsp;and (iii), to the Company&#146;s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other
applicable law. There will be no redemption rights or liquidating distributions with respect to the Company&#146;s warrants, which will expire worthless if the Company fails to consummate an initial Business Combination within Combination Period.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Sponsor and each member of its management team have entered into an agreement with the Company, pursuant to which they have agreed to (i)&nbsp;waive
their redemption rights with respect to their Founder Shares (ii)&nbsp;waive their redemption rights with respect to their Founder Shares and public shares in connection with a shareholder vote to approve an amendment to the Company&#146;s amended
and restated memorandum and articles of association (A)&nbsp;that would modify the substance or timing of the Company&#146;s obligation to provide holders of the Class&nbsp;A ordinary shares the right to have their shares redeemed in connection with
the initial Business Combination or to redeem 100% of the public shares if the Company does not complete the initial Business Combination within Combination Period or (B)&nbsp;with respect to any other provision relating to the rights of holders of
the Class&nbsp;A ordinary shares and (iii)&nbsp;waive their rights to liquidating distributions from the Trust Account with respect to any Founder Shares they hold if the Company fails to consummate an initial Business Combination within Combination
Period (although they will be entitled to liquidating distributions from the Trust Account with respect to any Public Shares they hold if the Company fails to complete the initial Business Combination within the prescribed time frame). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s amended and restated memorandum and articles of association provides that the Company will have only until&nbsp;18&nbsp;months from the
closing of the Public Offering to complete a Business Combination. However, if the Company anticipates that it may not be able to consummate a Business Combination within 18 months, the Company may extend the period of time to consummate a Business
Combination by up to two additional three-month periods for a total of&nbsp;24&nbsp;months to complete a Business Combination (the &#147;Combination Period&#148;). In order to extend the time available for the Company to consummate a Business
Combination, the Sponsor or its affiliate or designees must deposit into the Trust Account, for each additional three-month period, $1,265,000&nbsp;($0.10&nbsp;per Public Share in either case), on or prior to the date of the applicable deadline. On
June&nbsp;6, 2023, the Company extended the period of time to consummate a Business Combination from June&nbsp;14, 2023 to September&nbsp;14, 2023 by having the Sponsor deposit an additional $1,265,000, or $0.10 per unit, into the Trust Account, in
accordance with the Company&#146;s amended and restated memorandum and articles of association and the Investment Management Trust Agreement by and between the Company and Continental Stock Transfer&nbsp;&amp; Trust Company, dated as of
December&nbsp;9, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a third party (other than the
Company&#146;s independent auditors) for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account
to below (1) $10.25&nbsp;per public share or (2)&nbsp;such lesser amount per public share held in the Trust Account as of the date of the liquidation of the Trust Account due to reductions in the value of the trust assets, in each case net of the
interest which may be withdrawn to pay taxes, except as to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account and except as to any claims under the Company&#146;s indemnity of the underwriters
of the Public Offering against certain liabilities, including liabilities under the Securities Act. Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent
of any liability for such third-party claims. The Company has not independently verified whether the Sponsor has sufficient funds to satisfy its indemnity obligations and believes that the Sponsor&#146;s only assets are securities of the Company
and, therefore, the Sponsor may not be able to satisfy those obligations. The Company has not asked the Sponsor to reserve for such obligations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
May&nbsp;16, 2023, the Company entered into a Business Combination Agreement (as it may be amended and/or restated from time to time, the &#147;Business Combination Agreement&#148;) with enGene, Inc., a corporation incorporated under the laws of
Canada (&#147;enGene&#148;) and enGene Holdings Inc., a corporation incorporated under the laws of Canada (&#147;Newco&#148;), contemplating the proposed business combination among the Company, enGene
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and Newco (the &#147;Business Combination&#148;). See Note 6 for further information relating to the Business Combination Agreement and the Business Combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;9, 2023, Newco filed a registration statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> with the U.S. Securities and Exchange
Commission in connection with the contemplated Business Combination with the Company and enGene. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity, Capital Resource and Going Concern
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At June&nbsp;30, 2023, the Company had&nbsp;$269,138 in its operating bank account and working capital deficit of approximately $7,697,116. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, in order to finance transaction costs in connection with a Business Combination, the Company&#146;s Sponsor or an affiliate of the Sponsor or
certain of the Company&#146;s officers and directors may, but are not obligated to, provide the Company Working Capital Loans. As of June&nbsp;30, 2023 and December&nbsp;31, 2022, there was $1,200,000 and $0 outstanding under the Working Capital
Loans, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Company&#146;s assessment of going concern considerations in accordance with FASB <FONT
STYLE="white-space:nowrap">ASC&nbsp;205-40,</FONT> Presentation of Financial Statements&#151;Going Concern&#148;, management has determined that the Company has and will continue to incur significant costs in pursuit of its acquisition plans which
raises substantial doubt about the Company&#146;s ability to continue as a going concern. Moreover, the Company may need to obtain additional financing either to complete the initial Business Combination or because the Company becomes obligated to
redeem a significant number of the Company&#146;s Public Shares upon consummation of the initial Business Combination, in which case the Company may issue additional securities or incur debt in connection with such Business Combination. Subject to
compliance with applicable securities laws, the Company would only complete such financing simultaneously with the completion of the initial Business Combination. If the Company is unable to complete the initial Business Combination because the
Company does not have sufficient funds available, the Company will be forced to cease operations and liquidate the Trust Account. In addition, following the initial Business Combination, if cash on hand is insufficient, the Company may need to
obtain additional financing in order to meet certain obligations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, management has determined that if the Company is unable to complete a Business
Combination by September&nbsp;14, 2023 (or by December&nbsp;14, 2023 if the Company further extends the period of time to consummate a Business Combination, by resolution of the Company&#146;s board of directors and if requested by the
Company&#146;s sponsor subject to the Sponsor depositing additional funds in the Trust Account, as further described herein), then the Company will cease all operations except for the purpose of liquidating. The date for mandatory liquidation and
subsequent dissolution as well as the Company&#146;s liquidity condition raise substantial doubt about the Company&#146;s ability to continue as a going concern. No adjustments have been made to the carrying amounts of assets or liabilities should
the Company be required to liquidate after the Combination Period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks and Uncertainties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management is currently evaluating the impact of the current global economic uncertainty, the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, rising
interest rates, rising inflation, increases in energy prices, supply chain disruptions and the Russia-Ukraine armed conflict (including the impact of any sanctions imposed in response thereto) and has concluded that while it is reasonably possible
that any of these could have a negative effect on the Company&#146;s financial position, results of operations and/or search for a target company, the specific impact is not readily determinable as of the date of these financial statements. The
financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company cannot at this time fully predict the likelihood of one or more of the above events, their duration or magnitude or the extent to
which they may negatively impact the Company&#146;s business and its ability to complete an initial Business Combination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 2&nbsp;&#151;&nbsp;Significant Accounting Policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis of Presentation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying unaudited
condensed financial statements are presented in conformity with accounting principles generally accepted in the United States of America (&#147;US GAAP&#148;) and in accordance with the instructions on
<FONT STYLE="white-space:nowrap">Form&nbsp;10-Q&nbsp;and</FONT> Article 8 of <FONT STYLE="white-space:nowrap">Regulation&nbsp;S-X&nbsp;of</FONT> the SEC. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP. In
the opinion of management, the unaudited condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. The interim
results for the three and six&nbsp;months ended June&nbsp;30, 2023 are not necessarily indicative of the results to be expected for the year ending December&nbsp;31, 2023 or for any future interim periods. The accompanying unaudited condensed
financial statements should be read in conjunction with the Company&#146;s audited financial statements and notes thereto included in the Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> for the year ended December&nbsp;31,
2022&nbsp;filed with the SEC on March&nbsp;30, 2023. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Emerging Growth Company Status </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is an &#147;emerging growth company,&#148; as defined in Section&nbsp;2(a) of the Securities Act, as modified by the Jumpstart our Business
Startups Act of 2012, (the &#147;JOBS Act&#148;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to,
not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from
the requirements of holding a <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, Section&nbsp;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting
standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised
financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <FONT STYLE="white-space:nowrap">non-emerging</FONT> growth companies but any
such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the
Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#146;s unaudited condensed financial statements with another
public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Use of Estimates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of the unaudited
condensed financial statements in conformity with U.S. GAAP requires the Company&#146;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at
the unaudited condensed financial statements and the reported amounts of expenses during the reporting period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Making estimates requires management to
exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the unaudited condensed financial statements, which management considered
in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cash and Cash Equivalents </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not
have any cash equivalents as of June&nbsp;30, 2023 and December&nbsp;31, 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Fair Value of Financial Instruments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of the Company&#146;s assets and liabilities, which qualify as financial instruments under FASB ASC&nbsp;820, &#147;Fair Value Measurements and
Disclosures,&#148; approximates the carrying amounts represented in the balance sheets, primarily due to its short-term nature. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company follows the
guidance in ASC 820,&nbsp;&#147;Fair Value Measurement,&#148;&nbsp;for its financial assets and liabilities that <FONT STYLE="white-space:nowrap">are&nbsp;re-measured</FONT> and reported at fair value at each reporting period, <FONT
STYLE="white-space:nowrap">and&nbsp;non-financial&nbsp;assets</FONT> and liabilities that <FONT STYLE="white-space:nowrap">are&nbsp;re-measured&nbsp;and</FONT> reported at fair value at least annually. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of the Company&#146;s financial assets and liabilities reflects management&#146;s estimate of amounts that the Company would have received in
connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and
liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and
liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Level&nbsp;1&nbsp;&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Valuation adjustments and block discounts are not being applied. Since valuations are
based on quoted prices that are readily and regularly available in an active market, valuation of these securities does not entail a significant degree of judgment.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Level&nbsp;2&nbsp;&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Valuations based on (i)&nbsp;quoted prices in active markets for similar assets and liabilities, (ii)&nbsp;quoted prices in markets that are not active for identical or similar assets, (iii)&nbsp;inputs other than quoted prices for
the assets or liabilities, or (iv)&nbsp;inputs that are derived principally from or corroborated by market through correlation or other means.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Level&nbsp;3&nbsp;&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Valuations based on inputs that are unobservable and significant to the overall fair value measurement.</TD></TR>
</TABLE>   <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cash and Securities Held in Trust Account </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2023, investment in the Company&#146;s Trust Account consisted of $1,227 in cash and $135,784,943 in&nbsp;U.S. Treasury Securities. As of
December&nbsp;31, 2022, investment in the Company&#146;s Trust Account consisted of $1,375 in cash and $131,529,959 in&nbsp;U.S. Treasury Securities. All of the U.S. Treasury Securities will mature on September&nbsp;5, 2023. The Company classified
its U.S. Treasury Securities as <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">held-to-maturity</FONT></FONT> in accordance with FASB ASC Topic 320 &#147;Investments&#151;Debt and Equity Securities&#148;. <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Held-to-maturity</FONT></FONT> securities are those securities which the Company has the ability and intent to hold until maturity. <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Held-to-maturity</FONT></FONT> treasury securities are recorded at amortized cost and adjusted for the amortization or accretion of premiums or&nbsp;discounts. The carrying value approximates the fair value due to its
short-term maturity. The carrying value, excluding </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
gross unrealized holding loss and fair value of held to maturity securities at June&nbsp;30, 2023 and December&nbsp;31, 2022 are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Times; font-size:10pt" ALIGN="center">


<TR STYLE="visibility:hidden; line-height:0pt; color:white">

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD nowrap ><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD nowrap ><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD nowrap ><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>Carrying<BR>Value&nbsp;as&nbsp;of<BR>June&nbsp;30,<BR>2023</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>Quoted Prices<BR>in&nbsp;Active<BR>Markets<BR>(Level 1)</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>Gross<BR>Unrealized<BR>Gains</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. Treasury Securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">135,784,943</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">135,833,058</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">48,115</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">1,227</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">135,786,170</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">135,833,058</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">48,115</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Def.-Times; font-size:10pt" ALIGN="center">


<TR STYLE="visibility:hidden; line-height:0pt; color:white">

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD nowrap >&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD nowrap >&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD nowrap >&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>Carrying<BR>Value as of<BR>December&nbsp;31,<BR>2022</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>Quoted Prices<BR>in Active<BR>Markets<BR>(Level 1)</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-family:Times New Roman; "><B>Gross<BR>Unrealized<BR>Losses</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. Treasury Securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">131,529,959</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">130,537,313</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">(992,646</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">1,375</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">130,531,334</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">130,537,313</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman; ">(992,646</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman; ">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Concentration of Credit Risk </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at
times, may exceed the federal depository insurance coverage of $250,000. The Company has not experienced losses on these accounts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Class&nbsp;A
Ordinary Shares Subject to Possible Redemption </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for its ordinary shares subject to possible redemption in accordance with the
guidance in ASC Topic 480 &#147;Distinguishing Liabilities from Equity.&#148; Ordinary shares subject to mandatory redemption (if any) are classified as a liability instrument and measured at fair value. Conditionally redeemable ordinary shares
(including ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#146;s control) are classified as temporary
equity. At all other times, ordinary shares are classified as shareholders&#146; deficit. The Company&#146;s Class&nbsp;A ordinary shares feature certain redemption rights that are considered to be outside of the Company&#146;s control and subject
to the occurrence of uncertain future events. Accordingly,&nbsp;12,650,000&nbsp;Class&nbsp;A ordinary shares subject to possible redemption are presented at redemption value as temporary equity, outside of the shareholders&#146; deficit&nbsp;section
of the Company&#146;s balance sheets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of
Class&nbsp;A ordinary shares to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable ordinary shares are affected by charges against additional paid in capital and accumulated
deficit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Class&nbsp;A ordinary shares subject to possible redemption reflected on the balance sheets as of June&nbsp;30, 2023 and December&nbsp;31,
2022 is reconciled in the following table: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Class&nbsp;A ordinary shares subject to possible redemption, December&nbsp;31,
2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>131,531,334</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deposit in connection with Extension Funding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,265,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Remeasurement of carrying value to redemption value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,989,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Class&nbsp;A ordinary shares subject to possible redemption, June&nbsp;30, 2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>135,786,170</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Offering Costs associated with the Initial Public Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Offering costs consist of underwriting, legal, accounting and other expenses incurred through the balance sheet date that are directly related to the IPO. The
Company complies with the requirements of the ASC <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">340-10-S99-1.</FONT></FONT></FONT> Offering costs are allocated ratably with the redeemable and <FONT
STYLE="white-space:nowrap">non-redeemable</FONT> shares they are allocated to. Offering costs associated with warrant liabilities are expensed, and offering costs associated with the Class&nbsp;A ordinary shares are charged to shareholders&#146;
equity. The Company incurred offering costs amounting to $5,793,160 consisting of $1,800,000 of underwriting commissions, $3,150,000 of deferred underwriting commissions, and $843,160 of other offering costs. The underwriters&#146; exercise of their
full over-allotment option generated an additional $907,500 in transaction costs for aggregate transaction costs of $6,700,660 consisting of $2,130,000 of underwriting commissions, $3,727,500 of deferred underwriting commissions and $843,160 of
other offering costs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Net Loss Per Share </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company complies with accounting and disclosure requirements of ASC Topic 260, &#147;Earnings Per Share.&#148; The statements of operations include a presentation of loss per Class&nbsp;A ordinary share and loss per Class&nbsp;B ordinary share
following <FONT STYLE="white-space:nowrap">the&nbsp;two-class&nbsp;method</FONT> of income per share. At June&nbsp;30, 2023 and 2022, the Company did&nbsp;not have any dilutive securities and other contracts that could, potentially, be exercised or
converted into ordinary shares and then share in the losses of the Company.&nbsp;As a result, diluted loss per share is the same as basic loss per share for the periods&nbsp;presented. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The tables below presents a reconciliation of the numerator and denominator used to compute basic and diluted loss per share for each category for the three
and six months ended June&nbsp;30, 2023 and for 2022: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Three&nbsp;Months&nbsp;Ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Six Months Ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;A</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;B</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;A</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;B</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;A</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;B</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;A</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;B</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Basic and diluted net loss per share:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Allocation of net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,166,708</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(541,677</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(206,625</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(51,656</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,448,460</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(612,115</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(529,450</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(132,363</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Denominator:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Weighted-average shares outstanding including ordinary shares subject to redemption</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,650,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,162,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,650,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,162,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,650,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,162,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,650,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,162,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Basic and diluted net loss per share</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.17</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.17</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.02</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.02</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.19</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.19</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.04</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.04</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Income Taxes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company follows the asset and liability method of accounting for income taxes under Financial Accounting Standards Board (&#147;FASB&#148;) ASC 740,
&#147;Income Taxes.&#148; Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their
respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax
assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASC Topic 740 prescribes a recognition threshold and a measurement attribute for the financial statements recognition and measurement of tax positions taken
or expected to be taken in a tax return. For those benefits to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company&#146;s management determined that the Cayman Islands is the
Company&#146;s major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. As of June&nbsp;30, 2023 and December&nbsp;31, 2022, there were no unrecognized tax benefits and
no amounts accrued for interest and penalties. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company&#146;s management does not expect
that the total amount of unrecognized tax benefits will materially change over the next twelve months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s tax provision was zero for all
periods presented. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Business Combination Costs </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Costs
incurred in relation to a potential Business Combination may include legal, accounting, and other expenses. Any such costs are expensed as incurred. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Accounting Pronouncements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2020, the
Financial Accounting Standards Board (&#147;FASB&#148;) issued Accounting Standards <FONT STYLE="white-space:nowrap">Update&nbsp;(&#147;ASU&#148;)&nbsp;2020-06,&nbsp;Debt&#151;Debt&nbsp;with</FONT> Conversion and Other
<FONT STYLE="white-space:nowrap">Options&nbsp;(Subtopic&nbsp;470-20)&nbsp;and&nbsp;Derivatives</FONT> and Hedging&#151;Contracts in Entity&#146;s Own Equity <FONT STYLE="white-space:nowrap">(Subtopic&nbsp;815-40)</FONT> <FONT
STYLE="white-space:nowrap">(&#147;ASU&nbsp;2020-06&#148;)&nbsp;to&nbsp;simplify</FONT> accounting for certain financial <FONT STYLE="white-space:nowrap">instruments.&nbsp;ASU&nbsp;2020-06&nbsp;eliminates&nbsp;the</FONT> current models that require
separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity&#146;s own equity. The new standard
also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity&#146;s own equity. <FONT STYLE="white-space:nowrap">ASU&nbsp;2020-06&nbsp;amends&nbsp;the</FONT> diluted earnings
per share guidance, including the requirement to <FONT STYLE="white-space:nowrap">use&nbsp;the&nbsp;if-converted</FONT> method for all convertible
<FONT STYLE="white-space:nowrap">instruments.&nbsp;ASU&nbsp;2020-06&nbsp;is&nbsp;effective&nbsp;January&nbsp;1,</FONT> 2022 and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January&nbsp;1,
2021. The guidance was adopted starting January&nbsp;1, 2022. Adoption of the ASU did not impact the Company&#146;s financial position, results of operations or cash flows. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management does not believe that any other recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the
Company&#146;s unaudited condensed financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 3&nbsp;&#151; Initial Public Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;14, 2021, the Company consummated its IPO of 11,000,000 Units at a purchase price of $10.00 per Unit. Each Unit was sold at a price of $10.00
and consists of one Class&nbsp;A ordinary share and <FONT STYLE="white-space:nowrap">one-third</FONT> of one redeemable warrant. Each whole warrant entitles the holder to purchase one Class&nbsp;A ordinary share at a price of $11.50 per share,
subject to adjustment (see Note 7). On December&nbsp;15, 2021, the underwriters exercised their full over-allotment option and purchased the additional Units available to them. The aggregate Units sold in the IPO and subsequent over-allotment were
12,650,000 and generated gross proceeds of $126,500,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the closing of the IPO on December&nbsp;14, 2021, $113,492,500 from the net proceeds
of the sale of the Units in the IPO and the sale of the Private Placement Warrants was deposited into a trust account (the &#147;Trust Account&#148;). This amount was comprised of $10.25 per Unit for the 11,000,000 Units sold in the IPO in
addition&nbsp;to a $742,500 Deposit in Advance from the Sponsor related to the underwriters&#146; exercise of the full over-allotment option which took place the following day on December&nbsp;15, 2021. Following the closing of the IPO and the
exercise of the underwriters&#146; full over-allotment option, $129,662,500 ($10.25 per Unit) was placed in a Trust Account and will be invested only in U.S. government treasury obligations with a maturity of 185 days or less or in money market
funds meeting certain conditions under Rule <FONT STYLE="white-space:nowrap">2a-7</FONT> under the Investment Company Act which invests only in direct U.S. government treasury obligations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 4 &#151; Private Placement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Simultaneously with the closing of the IPO, the Company&#146;s Sponsor purchased an aggregate of 4,700,000 Private Placement Warrants (5,195,000 Private
Placement Warrants when the underwriters&#146; over-allotment option was fully exercised on December&nbsp;15, 2021), each exercisable to purchase one Class&nbsp;A ordinary share at $11.50 per share, at a price of $1.50&nbsp;per Unit. The sale of the
Private Placement Warrants in connection with the IPO and subsequent over-allotment option exercise generated gross proceeds of $7,792,500. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Private
Placement Warrants are not transferable, assignable or salable (and the Class&nbsp;A ordinary shares issuable upon exercise of the Private Placement Warrants are not transferable, assignable or salable until&nbsp;30&nbsp;days after the completion of
the initial Business Combination), except as described herein under &#147;Principal Shareholders&#151;Transfers of Founder Shares and Private Placement Warrants.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any amendment to the terms of the Private Placement Warrants or any provision of the warrant agreement with respect to the Private Placement Warrants require
a vote of holders of at least 50% of the number of the then outstanding Private Placement Warrants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 5&nbsp;&#151;&nbsp;Related Party Transactions
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Founder Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;12, 2021, Forbion
European Sponsor LLP paid $25,000, or approximately $0.009&nbsp;per share, to cover certain offering costs in consideration for&nbsp;2,875,000&nbsp;Class&nbsp;B ordinary shares (the &#147;Founder Shares&#148;), par value $0.0001. On
November&nbsp;23, 2021, Forbion European Sponsor LLP transferred&nbsp;2,875,000&nbsp;Class&nbsp;B ordinary shares to&nbsp;the Sponsor in exchange for $25,000, or approximately $0.009&nbsp;per share. On December&nbsp;9, 2021, the Company
issued&nbsp;287,500&nbsp;Class&nbsp;B ordinary shares to the Sponsor resulting from a 1.1 for 1 share dividend. Up to&nbsp;412,500 Founder Shares are subject to forfeiture by the Sponsor depending on the extent to which the underwriters&#146;
over-allotment option is exercised. Prior to the Business Combination, only holders of Class&nbsp;B ordinary shares will be able to vote on the appointment of directors and to continue the Company in a jurisdiction outside the Cayman Islands. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;15, 2021, the underwriters fully exercised their over-allotment and as a result,&nbsp;412,500&nbsp;Founder Shares are&nbsp;no&nbsp;longer
subject to forfeiture. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Convertible Note &#150; Related Party </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to finance transaction costs in connection with an intended Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the
Company&#146;s officers and directors may, but are not obligated to, loan the Company funds as may be required (&#147;Working Capital Loans&#148;). If the Company completes the initial Business Combination, the Company may repay the Working Capital
Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans may be repaid only out of funds held outside the Trust Account. In the event that the initial Business Combination does not close. The
Company may use a portion of the working capital held outside the Trust Account to repay the Working Capital Loans but no proceeds from the Trust Account would be used to repay the Working Capital Loans. Up to $1,500,000&nbsp;of such Working Capital
Loans may be convertible into warrants of the post-Business Combination entity at a price of $1.50&nbsp;per warrant at the option of the lender. The warrants would be identical to the Private Placement Warrants. The Company has evaluated the
accounting treatment of convertible note under ASC 815. The Company has determined that due to the convertible loan meeting the derivative scope exception provided in ASC 815, this note did not require a bifurcation of proceeds. Thus, the proceeds
in connection to the convertible note are reported at par on the condensed balance sheets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;24, 2023, the Sponsor and the Company entered
into an unsecured convertible promissory note (the &#147;Note&#148;) under which the Sponsor agreed to extend to the Company a Working Capital Loan of up to $900,000, to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
be used for the Company&#146;s general working capital purposes. The Sponsor funded the initial principal amount of $450,000&nbsp;under the Note on March&nbsp;24, 2023. On April&nbsp;26, 2023,
the Company made an additional drawdown on the Note for aggregate $450,000. The Note bears no interest and will be due and payable on the earlier of (i)&nbsp;the date of consummation of a Business Combination and (ii)&nbsp;December&nbsp;14, 2023
(the &#147;Maturity Date&#148;). If the Company completes a Business Combination, the Company may repay the Note out of the proceeds of the Trust Account released to the Company. Otherwise, no proceeds from the Trust Account can be used to repay the
Note. Concurrently with the consummation of a Business Combination, the Sponsor will have the option, but not the obligation, to convert up to the total principal amount of the Note, in whole or in part, into additional warrants of the post-Business
Combination entity at a price of $1.50 per warrant. The warrants will be identical to the Private Placement Warrants. As of June&nbsp;30, 2023, the Company had&nbsp;$900,000 and $600,000 outstanding under the Note and Extension Note (as defined
below), respectively, totaling $1,500,000 in borrowings which are recorded as convertible note &#150; related party on the condensed balance sheets. As of December 31, 2022, there were no borrowings outstanding. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Promissory Note &#150; Related Party </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;6,
2023, the Company issued an additional unsecured promissory note (the &#147;Working Capital Note&#148;) in the total principal amount of $300,000 to the Sponsor. The proceeds of the Working Capital Note will be used by the Company for general
working capital purposes. The Sponsor funded the principal amount of $300,000 on June&nbsp;6, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Working Capital Note bears no interest and shall
be due and payable on the Maturity Date. In the event that the Company does not consummate a Business Combination, the Working Capital Note will be repaid only from amounts remaining outside of the Trust Account, if any. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A failure to pay the principal outstanding amount of the Working Capital Note within five business days following the date when due or the commencement of a
voluntary or involuntary bankruptcy action of the Company shall be deemed an event of default, in which case the Sponsor may declare the Working Capital Note due and payable immediately. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2023, the Company had&nbsp;$300,000 and $665,000 outstanding under the Working Capital Note and Extension Note, respectively, totaling
$965,000 in borrowings which are recorded as promissory note &#150; related party on the condensed balance sheets. As of December 31, 2022, there were no borrowings outstanding. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Extension Note &#150; Related Party </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company may
extend the period of time to consummate a Business Combination by up to&nbsp;two additional three-month periods&nbsp;(for a total of&nbsp;24&nbsp;months to complete a Business Combination). In order to extend the time available for the Company to
consummate a Business Combination, the Sponsor or its affiliates or designees must deposit into the Trust Account, for each additional three-month period, $1,265,000, ($0.10&nbsp;per Public Share in either case), on or prior to the date of the
applicable deadline (the &#147;Extension Funding&#148;). Any such payments would be made in the form <FONT STYLE="white-space:nowrap">of&nbsp;a&nbsp;non-interest</FONT> bearing,&nbsp;unsecured promissory note. Such note would either be paid upon
consummation of a Business Combination or, at the relevant insider&#146;s discretion, converted upon consummation of a Business Combination into additional Private Placement Warrants at a price of $1.50&nbsp;per Private Placement Warrant. The
Sponsor and its affiliates or designees are not obligated to fund the Trust Account to extend the time for the Company to complete a Business Combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Extension Funding, the Sponsor funded the principal amount of $1,265,000 by depositing such amount into the Trust Account on
June&nbsp;6, 2023 and extended the period of time to consummate a Business Combination from June&nbsp;14, 2023 to September&nbsp;14, 2023, in accordance with the Company&#146;s Amended and Restated Memorandum and Articles of Association and the
Investment Management Trust Agreement by and between the Company and Continental Stock Transfer&nbsp;&amp; Trust Company, dated as of December&nbsp;9, 2021. On </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
June&nbsp;6, 2023 the Company issued an unsecured promissory note (the &#147;Extension Note&#148;) in the total principal amount of $1,265,000 to the Sponsor. The Extension Note bears no interest
and shall be due and payable on the earlier of (i)&nbsp;the date of consummation of the Business Combination and (ii)&nbsp;the Maturity Date. In the event that the Company does not consummate a Business Combination, the Extension Note will be repaid
only from amounts remaining outside of the Trust Account, if any. Up to $600,000 of the total principal amount under such Extension Note can be converted, at the Sponsor&#146;s discretion, in whole or in part, into additional warrants of the Company
at a price of $1.50 per warrant, each warrant exercisable for one Class&nbsp;A ordinary share, $0.0001 par value per share, of the Company. The warrants will be identical to the Private Placement Warrants. At June&nbsp;30, 2023, the convertible
portion of the Extension Note, or $600,000, has been included in convertible note &#150; related party on the condensed balance sheets. The nonconvertible portion, or $665,000 of the Extension Note, has been included in promissory note &#150;
related party on the condensed balance sheets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Office Space, Secretarial and Administrative Services </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Commencing on the date that the Company&#146;s securities are first listed on the NASDAQ through the earlier of consummation of the initial Business
Combination and the liquidation, the Company agreed to pay the Sponsor a total of $10,000&nbsp;per month for office space, utilities, secretarial and administrative support and to reimburse the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Sponsor&nbsp;for&nbsp;any&nbsp;out-of-pocket&nbsp;expenses&nbsp;related</FONT></FONT> to identifying, investigating and completing an initial Business Combination. For the three and six months ended June&nbsp;30, 2023, the
Company expensed $30,000 and $60,000&nbsp;in administrative support&nbsp;services, respectively. For the three and six months ended June&nbsp;30, 2022, the Company expensed $30,000 and $60,000, respectively,&nbsp;in administrative support services.
At June&nbsp;30, 2023 and December&nbsp;31, 2022, the Company had accrued $30,000&nbsp;and $30,000, respectively, in administrative fees payable to the Sponsor which are included in due to related party on the condensed balance sheets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, the Sponsor has agreed to pay an annual salary of $25,000&nbsp;to each of the independent Board Members for services rendered prior to or in
connection with the completion of the Business Combination. Board members are entitled to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">reimbursement&nbsp;for&nbsp;any&nbsp;out-of-pocket&nbsp;expenses&nbsp;related</FONT></FONT>
to identifying, investigating, negotiating and completing the Business Combination as well. For the three and six months ended June&nbsp;30, 2023, the Company expensed&nbsp;$18,699 and $37,192, respectively, for services rendered by the independent
Board&nbsp;Members. For the three and six months ended June&nbsp;30, 2022, the Company expensed&nbsp;$18,699 and $37,198, respectively,&nbsp;for services rendered by the independent Board Members. At June&nbsp;30, 2023 and December&nbsp;31, 2022,
the Company had accrued&nbsp;approximately $18,699&nbsp;and $18,904, respectively, in compensation expense to the independent board members which are included in due to related party on the condensed balance sheets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 6&nbsp;&#151;&nbsp;Commitments&nbsp;&amp; Contingencies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration and Shareholder Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of the
Founder Shares, Private Placement Warrants, Class&nbsp;A ordinary shares underlying the Private Placement Warrants and any warrants that may be issued upon conversion of Working Capital Loans and extension loans (and any Class&nbsp;A ordinary shares
issuable upon the exercise of the Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans and extension loans) will be entitled to registration rights pursuant to a registration and shareholder rights
agreement to be signed prior to or on the effective date of the Public Offering. The holders of these securities are entitled to make up to&nbsp;three&nbsp;demands, excluding short form demands, that the Company register such securities. In
addition, the holders have certain &#147;piggy-back&#148; registration rights with respect to registration statements filed subsequent to the Company&#146;s completion of the initial Business Combination. However, the registration and shareholder
rights agreement provide that the Company will not permit any registration statement filed under the Securities Act to become effective until termination of the applicable <FONT STYLE="white-space:nowrap">lock-up</FONT> period, which occurs
(i)&nbsp;in&nbsp;the case of the Founder Shares, as described in the following paragraph, and (ii)&nbsp;in the case of the Private Placement Warrants and the respective Class&nbsp;A ordinary shares underlying such warrants, 30&nbsp;days after the
completion of the initial Business </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as described herein, the Sponsor and the Company&#146;s directors and executive officers have agreed not to transfer, assign or sell (i)&nbsp;their
Founder Shares until the earliest of (A)&nbsp;one&nbsp;year after the completion of the initial Business Combination and (B)&nbsp;subsequent to the initial Business Combination, (x)&nbsp;if the closing price of the Class&nbsp;A ordinary shares
equals or exceeds $12.00&nbsp;per share (as <FONT STYLE="white-space:nowrap">adjusted&nbsp;for&nbsp;share&nbsp;sub-divisions,</FONT> share capitalizations, reorganizations, recapitalizations and the like) for any&nbsp;20&nbsp;trading <FONT
STYLE="white-space:nowrap">days&nbsp;within&nbsp;any&nbsp;30-trading&nbsp;day</FONT> period commencing at least&nbsp;150&nbsp;days after the initial Business Combination, or (y)&nbsp;the date on which the Company complete a liquidation, merger,
share exchange or other similar transaction that results in all of its public shareholders having the right to exchange their ordinary shares for cash, securities or other property, and (ii)&nbsp;any of their Private Placement Warrants and
Class&nbsp;A ordinary shares issued upon conversion or exercise thereof until 30&nbsp;days after the completion of the initial Business Combination. Any permitted transferees will be subject to the same restrictions and other agreements of the
Sponsor with respect to any Founder Shares, Private Placement Warrants and Class&nbsp;A ordinary shares issued upon conversion or exercise thereof.&nbsp;The Company refers&nbsp;to such transfer restriction
<FONT STYLE="white-space:nowrap">herein&nbsp;as&nbsp;the&nbsp;lock-up.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, pursuant to the registration and shareholder rights agreement,
the Sponsor, upon and following consummation of an initial Business Combination, will be entitled to nominate&nbsp;three&nbsp;individuals for appointment to the Company&#146;s board of directors, as long as the Sponsor holds any securities covered
by the registration and shareholder rights agreement. Prior to the Business Combination, only holders of Class&nbsp;B ordinary shares will be able to vote on the appointment of directors and to continue the Company in a jurisdiction outside the
Cayman Islands. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Underwriting Agreement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
underwriters <FONT STYLE="white-space:nowrap">had&nbsp;a&nbsp;45-day&nbsp;option&nbsp;from</FONT> the date of the IPO to purchase up to an additional&nbsp;1,650,000&nbsp;Units to cover over-allotments, if any. On December&nbsp;15, 2021, the
underwriters fully exercised the over-allotment option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters were paid underwriting commission of $0.20&nbsp;per Unit sold in the IPO,
excluding Units sold to&nbsp;Forbion Cooperatief, or $1,800,000, upon the closing of the IPO. Following the exercise of the underwriters&#146; over-allotment option on December&nbsp;15, 2021, the underwriters earned an additional $330,000&nbsp;for
an aggregate of $2,130,000&nbsp;in underwriting commissions related to the IPO and over-allotment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, $3,150,000&nbsp;is payable to the
underwriters for deferred underwriting commissions related to the Units sold in the IPO, excluding those Units sold to&nbsp;Forbion Cooperatief. Following the exercise of the underwriters&#146; over-allotment option on December&nbsp;15, 2021, the
underwriters earned an additional $577,500&nbsp;for an aggregate of $3,727,500 in deferred underwriting commissions related to the IPO and over-allotment. The deferred underwriting commission will become payable to the underwriters from the amounts
held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Purchase Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has entered
into&nbsp;two&nbsp;forward purchase agreements (the &#147;Forward Purchase Agreements&#148;) with the Sponsor, pursuant to which the Sponsor has agreed to purchase (1)&nbsp;an aggregate of&nbsp;1,000,000&nbsp;Class&nbsp;A ordinary shares for
$10.00&nbsp;per share (the &#147;firm forward purchase shares&#148;), or an aggregate amount of $10,000,000 and (2)&nbsp;in addition, an aggregate of up to&nbsp;1,000,000&nbsp;Class&nbsp;A ordinary shares for $10.00&nbsp;per share (the
&#147;additional forward purchase shares&#148;), or an aggregate maximum amount of up to $10,000,000, in each case in a private placement that may close simultaneously with the closing of the Company&#146;s initial Business Combination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Deferred Legal Fees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has incurred $3,884,759 in deferred legal fees, of which $125,000 are associated with the Company&#146;s Initial Public Offering and are contingent
upon the consummation of the Business Combination. Deferred legal fees are included in accrued offering costs and expenses on the Company&#146;s condensed balance sheets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Business Combination Agreement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;16, 2023, the
Company entered into the Business Combination Agreement with enGene and Newco. The Business Combination Agreement contemplates that the proposed Business Combination among the Company, enGene and Newco will be completed through, among others, the
following series of transactions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company shall incorporate or cause to be incorporated Can Merger Sub as a corporation under the laws of
Canada and a direct wholly owned subsidiary of the Company (&#147;Can Merger Sub&#148;) and Newco shall incorporate or cause to be incorporated Cayman Merger Sub as a Cayman Islands exempted company and a direct wholly-owned subsidiary of Newco
(&#147;Cayman Merger Sub&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pursuant to a Sponsor and Insiders Letter Agreement entered into concurrently with the execution and delivery of
the Business Combination Agreement (the &#147;Sponsor and Insiders Letter Agreement&#148;), the Sponsor has agreed to surrender, after giving effect to the conversion of all or part of the principal amount outstanding under loans made by the Sponsor
to the Company into Private Placement Warrants, 1,789,004 Founder Shares and 5,463,381 Private Placement Warrants, as a contribution to the capital of the Company and for no consideration (the &#147;Surrender&#148;), effective immediately prior to
the Class&nbsp;B Conversion (as defined below) on the day which is two (2)&nbsp;business days prior to the Closing Date (as defined below); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on the day which is two (2)&nbsp;business days prior to the Closing Date, each Founder Share that remains
outstanding following the Surrender shall be exchanged for one Class&nbsp;A ordinary share of the Company (the &#147;Class&nbsp;B Conversion&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on the day which is one (1)&nbsp;business day prior to the Closing Date, Cayman Merger Sub will merge with and
into the Company with the Company as the surviving entity pursuant to a plan of merger under the laws of the Cayman Islands (the &#147;Cayman Merger&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">concurrently with the Cayman Merger, and effective at the same time the Cayman Merger becomes effective under
Cayman Islands law, (i)&nbsp;Newco will assume the warrants of the Company to purchase one Class&nbsp;A ordinary share of the Company at an exercise price of $11.50 per share (as so assumed, &#147;Newco Warrants&#148;) pursuant to a warrant
assignment, assumption and amendment agreement to be entered into on or around the Closing Date, and (ii)&nbsp;Newco will redeem the initial Class&nbsp;A common shares of Newco (the &#147;Newco Shares&#148;) held by the sole shareholder of Newco for
an amount equal to the amount of capital that the sole shareholder of Newco contributed for purposes of the incorporation of Newco (such transactions, together with the Cayman Merger, the &#147;Cayman Reorganization&#148;); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">following the Cayman Reorganization, the Company will file an election to change its classification for U.S.
federal income tax purposes from a corporation to an entity disregarded as separate from its owner Newco, to be effective as of the beginning of the Closing Date (the &#147;U.S. Entity Classification Election&#148; and, together with the Cayman
Reorganization, the &#147;FEAC Reorganization&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on the Closing Date, subsequent to the FEAC Reorganization becoming effective, the Company will sell to Newco,
and Newco will purchase, all&nbsp;of the outstanding common shares of Can Merger Sub (the &#147;Can Merger Sub Share Sale&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subsequent to the Can Merger Sub Share Sale, Can Merger Sub and the Company will amalgamate under
Section&nbsp;192 of the Canada Business Corporations Act pursuant to a plan of arrangement (the &#147;Amalgamation&#148;; the date of the Amalgamation being the &#147;Closing Date&#148;), and pursuant to the
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
Amalgamation, (i)&nbsp;each enGene share outstanding immediately prior to the Amalgamation shall be exchanged for Newco Shares at an agreed upon exchange ratio set out in the Amalgamation plan of
arrangement (the &#147;Company Exchange Ratio&#148;) and each enGene warrant outstanding immediately prior to the Amalgamation shall be exchanged for Newco Warrants per the Company Exchange Ratio; (ii)&nbsp;each Can Merger Sub share outstanding
immediately prior to the Amalgamation shall be exchanged for one common share in the authorized share capital of the amalgamated entity; (iii)&nbsp;in consideration for the issuance of Newco Shares, the amalgamated entity shall issue its common
shares to Newco; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">following the Amalgamation, Newco will continue from being a corporation incorporated under and governed by the
<I>Canada Business Corporations Act</I> to a company continued to and governed by the <I>Business Corporations Act (British Columbia)</I>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transactions described above, together with the other transactions contemplated by the Business Combination Agreement, are hereinafter referred to as the
&#147;Transactions&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrently with the execution and delivery of the Business Combination Agreement, the Company, Newco and enGene, among other
parties, entered into the enGene Voting Agreement (the &#147;enGene Voting Agreement&#148;), the enGene <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement (the &#147;enGene <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement&#148;), and
the FEAC Voting Agreement (the &#147;FEAC Voting Agreement&#148;) pursuant to which certain shareholders of enGene and the Company, respectively, agreed to&nbsp;vote in favor of the Transactions and to certain transfer restrictions in respect of
such shareholders&#146; shares of the Company and of Newco, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Business Combination Agreement contains customary representations and
warranties and covenants. The Business Combination is expected to close in the second half of 2023, subject to the satisfaction of customary closing conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Business Combination Agreement and the Transactions were approved by the boards of directors of each of the Company and enGene. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sponsor and Insiders Letter Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
May&nbsp;16, 2023, the Sponsor and Insiders Letter Agreement was entered into between the Company, the Sponsor, Forbion Growth Opportunities Fund I Cooperatief U.A., enGene, Newco and the other parties named therein (collectively, other than enGene
and Newco, the &#147;Sponsor Parties&#148;), pursuant to which the Sponsor has agreed to surrender, after giving effect to the conversion of all or part of the principal amount outstanding under loans made by the Sponsor to the Company into Private
Placement Warrants, 1,789,004 of Founder Shares and 5,463,381 of Private Placement Warrants, as a contribution to the capital of the Company and for no consideration, effective immediately prior to the Class&nbsp;B Conversion (as defined therein) on
the day which is two&nbsp;(2)&nbsp;business days prior to the Closing Date (as defined therein). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the Sponsor Parties agreed to (i)&nbsp;be
bound by certain other covenants and agreements related to the Business Combination, (ii)&nbsp;waive the anti-dilution protection with respect to the Founder Shares (whether resulting from the PIPE Financing or otherwise) and (iii)&nbsp;be bound by
certain transfer restrictions with respect to the shares of the Company and the Private Placement Warrants held by it (including the Newco Shares (as defined therein) and Newco Warrants (as defined therein) received in exchange therefore in
connection with the Business Combination and the Transactions), in each case, on the terms and subject to the conditions set forth in Sponsor and Insiders Letter Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Transaction Support Agreements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrently with
the execution and delivery of the Business Combination Agreement, the Company, Newco, enGene, the directors of enGene and certain shareholders of enGene (collectively, other than the Company, the &#147;enGene Parties&#148;) entered into voting
agreements (the &#147;enGene Voting Agreements&#148;) <FONT STYLE="white-space:nowrap">and&nbsp;lock-up&nbsp;agreements</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(the <FONT STYLE="white-space:nowrap">&#147;enGene&nbsp;Lock-Up&nbsp;Agreements&#148;)</FONT> pursuant to which the enGene Parties agreed to, among other things, (i)&nbsp;vote or cause to be
voted all of its Company Shares (as defined therein) in favor of the Company Arrangement Resolution (as defined therein) and the Transactions; (ii)&nbsp;be bound by certain other covenants and agreements related to the Business Combination; and
(iii)&nbsp;be bound by certain transfer restrictions with respect to the Company Shares and Newco Shares, as applicable, in each case, on the terms and subject to the conditions set forth in the enGene Voting Agreements and the <FONT
STYLE="white-space:nowrap">enGene&nbsp;Lock-Up&nbsp;Agreements.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, concurrently with the execution and delivery of the Business
Combination Agreement, enGene, Newco and the Sponsor Parties entered into <FONT STYLE="white-space:nowrap">a&nbsp;lock-up&nbsp;agreement</FONT> (the &#147;FEAC Voting Agreement&#148;) pursuant to which the Sponsor Parties agreed to, among other
things, (i)&nbsp;vote or cause to be voted all of their shares of the Company (the &#147;FEAC Shares&#148;) in favor of the Transaction Proposals (as defined therein); (ii)&nbsp;be bound by certain other covenants and agreements related to the
Business Combination and (iii)&nbsp;be bound by certain transfer restrictions with respect to the FEAC Shares, in each case, on the terms and subject to the conditions set forth in the FEAC Voting Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Subscription Agreements and Side Letter Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;16, 2023, the Company, Newco and certain investors (the &#147;PIPE Investors&#148;) entered into subscription agreements (the &#147;Subscription
Agreements&#148; and each a &#147;Subscription Agreement&#148;) pursuant to which, among other things, the PIPE Investors have agreed, subject to the completion of each element of the Transactions (other than those Transactions that are scheduled to
be completed following the Closing Date (as defined therein)), to subscribe for and purchase, and the Company has agreed that it will issue and sell to the PIPE Investors (which obligation will be assumed (the &#147;Assumption&#148;) by Newco after
the completion of the FEAC Reorganization and prior to the consummation of the PIPE Financing (as defined below)) the number of Class&nbsp;A ordinary shares of the Company (or after the Assumption, Newco Shares) provided for in the applicable
Subscription Agreement in exchange for the purchase price of $10.25 per Class&nbsp;A ordinary shares of the Company (or after the Assumption, Newco Share) (as amended by the Side Letter Agreements (as defined below, the &#147;PIPE Financing&#148;).
Pursuant to the Subscription Agreements, the PIPE Investors have collectively subscribed for 5,550,408 Class&nbsp;A ordinary shares of the Company (or after the Assumption, Newco Shares) for an aggregate purchase price equal to $56,891,682. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immediately following the execution and delivery of the Subscription Agreements, the Company and Newco entered into a side letter with each PIPE Investor (the
&#147;Side Letter Agreement&#148; and collectively, the &#147;Side Letter Agreements&#148;) to amend the relevant Subscription Agreement and which, together with the relevant Subscription Agreement, reflects the total number of the Class&nbsp;A
ordinary shares of the Company and the warrants of the Company to be issued by the Company (or after the Assumption, the total number of Newco Shares and Newco Warrants to be issued by Newco) pursuant to the PIPE Financing in consideration of the
purchase price set forth in the relevant Subscription Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;16, 2023, Newco, the Company and a shareholder of the Company that is the beneficial owner of 166,665 Class&nbsp;A ordinary shares of the Company
entered into a <FONT STYLE="white-space:nowrap">non-redemption</FONT> agreement (the <FONT STYLE="white-space:nowrap">&#147;Non-Redemption</FONT> Agreement&#148;), pursuant to which, among others, the Company will issue additional Class&nbsp;A
ordinary shares of the Company and warrants of the Company (or after the Assumption, Newco will issue additional Newco Shares and Newco Warrants) to such shareholder of the Company in consideration of such shareholder&#146;s commitment not to redeem
its Class&nbsp;A ordinary shares of the Company in connection with the approval of the Business Combination by the shareholders of the Company (the <FONT STYLE="white-space:nowrap">&#147;Non-Redemption</FONT> Transaction&#148;). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Registration Rights Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On or around the
Closing Date, Newco, the Company, the Sponsor Holders (as defined in the Registration Rights Agreement) and the enGene Holders (as defined in the Registration Rights Agreement) will enter into a </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
registration rights agreement (the &#147;Registration Rights Agreement&#148;), pursuant to which, among other things, the Sponsor Holders and the enGene Holders will be granted certain customary
registration rights with respect to their respective Equity Securities (as defined therein) of Newco, in each case, on the terms and subject to the conditions therein. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Certain enGene Indebtedness </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the
execution and delivery of the Business Combination Agreement, enGene agreed to certain modifications of existing convertible indebtedness in an aggregate principal amount of $18,400,000 (the &#147;Amended 2022 Convertible Notes&#148; and, together
with the enGene warrants to be issued by enGene as consideration for such modifications, the &#147;Amended 2022 Financing&#148;). Concurrently with the execution and delivery of the Business Combination Agreement, enGene entered into agreements
pursuant to which it will issue new convertible indebtedness and enGene warrants (i)&nbsp;for cash in an aggregate principal amount of $30,000,000 and (ii)&nbsp;in repayment of certain outstanding indebtedness in an aggregate principal amount of
$8,000,000 (collectively, the &#147;2023 Convertible Notes&#148; and, together with the enGene warrants purchased concurrently, the &#147;2023 Financing&#148;; the 2023 Financing together with the Amended 2022 Financing, the &#147;Convertible Bridge
Financing&#148;). The Convertible Bridge Financing indebtedness will be converted in the Transactions into that number of common shares of enGene that, when exchanged at the Company Exchange Ratio, shall equal that number of Class&nbsp;A ordinary
shares of the Company (or after the Assumption, Newco Shares) that the holders of such indebtedness would have received if they subscribed for Class&nbsp;A ordinary shares of the Company (or after the Assumption, Newco Shares) on the same terms as
the PIPE Financing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Business Combination Deadline Extension and Extension Loan Note </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;6, 2023, the Company extended the time available to consummate its Business Combination from June&nbsp;14, 2023 to September&nbsp;14, 2023 by
having the Sponsor deposit an additional $1,265,000, or $0.10 per unit, into the Trust Account (the &#147;Extension Funding&#148;), in accordance with the Company&#146;s Amended and Restated Memorandum and Articles of Association and the Investment
Management Trust Agreement by and between the Company and Continental Stock Transfer&nbsp;&amp; Trust Company, dated as of December&nbsp;9, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
connection with the Extension Funding, on June&nbsp;6, 2023, the Company issued an unsecured promissory note (the &#147;Extension Note&#148;) in the total principal amount of $1,265,000 to the Sponsor. The Sponsor funded the principal amount of
$1,265,000 under the Extension Note by depositing such amount into the Trust Account on June&nbsp;6, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Extension Note bears no interest and shall
be due and payable on the earlier of (i)&nbsp;the date of consummation of the Business Combination and (ii)&nbsp;the Maturity Date. In the event that the Company does not consummate a Business Combination, the Extension Note will be repaid only from
amounts remaining outside of the Trust Account, if any. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrently with the consummation of a Business Combination, the Sponsor will have the option,
but not the obligation, to convert up to $600,000 total principal amount of the Extension Note, in whole or in part, into additional warrants of the Company at a price of $1.50 per warrant, each warrant exercisable for one Class&nbsp;A ordinary
share, $0.0001 par value per share, of the Company. The warrants will be identical to the private placement warrants issued by the Company to the Sponsor at the time of the Company&#146;s IPO. A failure to pay the principal outstanding amount of the
Extension Note within five business days following the date when due or the commencement of a voluntary or involuntary bankruptcy action of the Company shall be deemed an event of default, in which case the Sponsor may declare the Extension Note due
and payable immediately. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 7&nbsp;&#151;&nbsp;Shareholders&#146; Deficit </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preference shares</B>&nbsp;&#151;The Company is authorized to issue 5,000,000 preference shares with a par value of $0.0001&nbsp;and with such designations,
voting and other rights and preferences as may be determined from time to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
time by the Company&#146;s board of directors. As of June&nbsp;30, 2023 and December&nbsp;31, 2022, there were&nbsp;no&nbsp;preference shares issued or outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Class</B><B></B><B>&nbsp;A ordinary shares</B>&nbsp;&#151;&nbsp;The Company is authorized to issue&nbsp;500,000,000&nbsp;Class&nbsp;A ordinary shares with
a par value of $0.0001&nbsp;per share. As of June&nbsp;30, 2023 and December&nbsp;31, 2022, there were&nbsp;no&nbsp;Class&nbsp;A ordinary shares outstanding, excluding&nbsp;12,650,000&nbsp;Class&nbsp;A ordinary shares subject to possible redemption
issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Class</B><B></B><B>&nbsp;B ordinary shares</B>&nbsp;&#151;&nbsp;The Company is authorized to issue&nbsp;50,000,000&nbsp;Class&nbsp;B ordinary
shares with a par value of $0.0001&nbsp;per share. Holders are entitled to&nbsp;one&nbsp;vote for each share of Class&nbsp;B ordinary shares. As of August&nbsp;13, 2021, there were&nbsp;2,875,000&nbsp;Class&nbsp;B ordinary shares issued and
outstanding. Of the&nbsp;2,875,000&nbsp;Class&nbsp;B ordinary shares, an aggregate of up to&nbsp;375,000&nbsp;shares are subject to forfeiture to the Company for&nbsp;no consideration to the extent that the underwriters&#146; over-allotment option
is not exercised in full or in part. On December&nbsp;9, 2021, the Company effected a stock dividend of&nbsp;1.1&nbsp;shares for each outstanding share, resulting in there being an aggregate of&nbsp;3,162,500&nbsp;Founder Shares outstanding, of
which&nbsp;412,500&nbsp;are subject to forfeiture to the extent that the underwriters&#146; over-allotment option is not exercised in full or in part. All share and per share amounts have been retroactively restated to reflect the share dividend.
The forfeiture amounts were determined such that the initial shareholders will collectively own&nbsp;20%&nbsp;of the Company&#146;s issued and outstanding ordinary shares after the Public Offering. At June&nbsp;30, 2023 and December&nbsp;31, 2022,
there were&nbsp;3,162,500&nbsp;shares of Class&nbsp;B ordinary shares issued and outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of Class&nbsp;A ordinary shares and holders of
Class&nbsp;B ordinary shares will vote together as a single class on all matters submitted to a vote of the Company&#146;s shareholders except as required by law. Unless specified in the Company&#146;s amended and restated memorandum and articles of
association, or as required by applicable provisions of the Companies Act or applicable stock exchange rules, the affirmative vote of a majority of the Company&#146;s ordinary shares that are voted is required to approve any such matter voted on by
the Company&#146;s shareholders. Approval of certain actions will require a special resolution under Cayman Islands law, being the affirmative vote
<FONT STYLE="white-space:nowrap">of&nbsp;at&nbsp;least&nbsp;two-thirds&nbsp;of&nbsp;the&nbsp;Company&#146;s</FONT> ordinary shares that are voted, and pursuant to the Company&#146;s amended and restated memorandum and articles of association; such
actions include amending the Company&#146;s amended and restated memorandum and articles of association and approving a statutory merger or consolidation with another company. The Company&#146;s board of directors is divided into three classes, each
of which will generally serve for a term of&nbsp;three years&nbsp;with only&nbsp;one&nbsp;class of directors being appointed in each year. There is no cumulative voting with respect to the appointment of directors, with the result that the holders
of more than&nbsp;50% of the shares voted for the appointment of directors can appoint all of the directors. Prior to the Business Combination, only holders of Class&nbsp;B ordinary shares will be able to vote on the appointment of directors and to
continue the Company in a jurisdiction outside the Cayman Islands. The Company&#146;s shareholders are entitled to receive ratable dividends when, as and if declared by the board of directors out of funds legally available therefor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Class&nbsp;B ordinary shares will automatically convert into Class&nbsp;A ordinary shares, which such Class&nbsp;A ordinary shares delivered upon
conversion will not have any redemption rights or be entitled to liquidating distributions, if the Company does not consummate an initial Business Combination, at the time of the initial Business Combination or earlier at the option of the holders
thereof at a ratio such that the number of Class&nbsp;A ordinary shares issuable upon conversion of all Founder Shares equal, in the <FONT STYLE="white-space:nowrap">aggregate,&nbsp;on&nbsp;an&nbsp;as-converted</FONT> basis, 20% of the sum of
(i)&nbsp;the total number of ordinary shares issued and outstanding upon completion of the Public Offering, plus (ii)&nbsp;the total number of Class&nbsp;A ordinary shares issued or deemed issued or issuable upon conversion or exercise of any
equity-linked securities (as defined herein) or rights issued or deemed issued, by the company in connection with or in relation to the consummation of the initial Business Combination, excluding any Class&nbsp;A ordinary shares or equity-linked
securities exercisable for or convertible into Class&nbsp;A ordinary shares issued, deemed issued, or to be issued, to any seller in the initial Business Combination and any Private Placement Warrants issued to the Sponsor, its affiliates or any
member of its management team upon conversion of Working Capital Loans and extension loans. Any conversion of Class&nbsp;B ordinary shares described herein will take effect as a compulsory redemption of Class&nbsp;B ordinary shares and an issuance
of Class&nbsp;A </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
ordinary shares as a matter of Cayman Islands law. In no event will the Class&nbsp;B ordinary shares convert into Class&nbsp;A ordinary shares at a rate <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">of&nbsp;less&nbsp;than&nbsp;one-to-one.</FONT></FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Public Warrants</B>&nbsp;&#151;&nbsp;Each whole warrant entitles the
holder to purchase&nbsp;one&nbsp;Class&nbsp;A ordinary share at a price of $11.50&nbsp;per share, subject to adjustment as discussed herein. In addition, if (x)&nbsp;the Company issue additional Class&nbsp;A ordinary shares or equity-linked
securities for capital raising purposes in connection with the closing of the initial Business Combination at an issue price or effective issue price of less than $9.20&nbsp;per ordinary share (with such issue price or effective issue price to be
determined in good faith by the Company&#146;s board of directors and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any Founder Shares held by the Sponsor or such affiliates, as applicable, prior to
such issuance) (the &#147;Newly Issued Price&#148;), (y) the aggregate gross proceeds from such issuances represent more than&nbsp;60% of the total equity proceeds, and interest thereon, available for the funding of the initial Business Combination
on the date of the consummation of the initial Business Combination (net of redemptions), and (z)&nbsp;the volume weighted average trading price of the Class&nbsp;A ordinary shares during the&nbsp;20&nbsp;trading day period starting on the trading
day prior to the day on which the Company consummate the initial Business Combination (such price, the &#147;Market Value&#148;) is below $9.20&nbsp;per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal
to&nbsp;115% of the higher of the Market Value and the Newly Issued Price, the $18.00&nbsp;per share redemption trigger price described adjacent to &#147;Redemption of public warrants&#148; will be adjusted (to the nearest cent) to be equal
to&nbsp;180% of the higher of the Market Value and the Newly Issued Price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The warrants will become exercisable on the later of&nbsp;30&nbsp;days after
the completion of the Company&#146;s initial Business Combination and will expire&nbsp;five years&nbsp;after the completion of the Company&#146;s initial Business Combination, at 5:00 p.m., New York City time, or earlier upon redemption or
liquidation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has agreed that as soon as practicable, but in no event later than&nbsp;twenty&nbsp;business days after the closing of the
initial Business Combination, the Company will use its commercially reasonable efforts to file with the SEC a registration statement for the registration, under the Securities Act, of the Class&nbsp;A ordinary shares issuable upon exercise of the
warrants, and the Company will use its commercially reasonable efforts to cause the same to become effective within&nbsp;60&nbsp;business days after the closing of the initial Business Combination, and to maintain the effectiveness of such
registration statement and a current prospectus relating to those Class&nbsp;A ordinary shares until the warrants expire or are redeemed, as specified in the warrant agreement; provided that if the Class&nbsp;A ordinary shares are at the time of any
exercise of a warrant not listed on a national securities exchange such that they satisfy the definition of a &#147;covered security&#148; under Section&nbsp;18(b)(1) of the Securities Act, the Company may, at its option, require holders of public
warrants who exercise their warrants to do so on a &#147;cashless basis&#148; in accordance with Section&nbsp;3(a)(9) of the Securities Act and, in the event the Company so elect, the Company will not be required to file or maintain in effect a
registration statement, but the Company will use its commercially reasonably efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available. If a registration statement covering the Class&nbsp;A
ordinary shares issuable upon exercise of the warrants is not effective by the&nbsp;60th day after the closing of the initial Business Combination, warrant holders may, until such time as there is an effective registration statement and during any
period when the Company will have failed to maintain an effective registration statement, exercise warrants on a &#147;cashless basis&#148; in accordance with Section&nbsp;3(a)(9) of the Securities Act or another exemption, but the Company will use
its commercially reasonable&nbsp;efforts to register or qualify the shares under applicable <FONT STYLE="white-space:nowrap">blue-sky</FONT> laws to the extent an exemption is not available. In such event, each holder would pay the exercise price by
surrendering the warrants for that number of Class&nbsp;A ordinary shares equal to the quotient obtained by dividing (x)&nbsp;the product of the number of Class&nbsp;A ordinary shares underlying the warrants, multiplied by the excess of the
&#147;fair market value&#148; (defined below) less the exercise price of the warrants by (y)&nbsp;the fair market value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Redemption of public
warrants</I></B>. Once the warrants become exercisable, the Company may redeem the outstanding warrants (except as described herein with respect to the Private Placement Warrants): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in whole and not in part; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at a price of $0.01&nbsp;per warrant; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon a minimum of&nbsp;30&nbsp;days&#146; prior written notice of redemption, which the Company refer to as the <FONT
STYLE="white-space:nowrap">&#147;30-day</FONT> redemption period&#148;; and</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if, and only if, the last reported sale price (the &#147;closing price&#148;) of the Class&nbsp;A ordinary shares
equals or exceeds $18.00&nbsp;per share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant as described under the heading &#147;Description of Securities&#151;Warrants&#151;Public
Shareholders&#146; Warrants&#151;Redemption Procedures&#151;Anti-dilution Adjustments&#148;) for any&nbsp;20&nbsp;trading days within <FONT STYLE="white-space:nowrap">a&nbsp;30-trading&nbsp;day</FONT> period ending on the third trading day prior to
the date on which the Company send the notice of redemption to the warrant holders. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company will not redeem the warrants as
described above unless a registration statement under the Securities Act covering the issuance of the Class&nbsp;A ordinary shares issuable upon exercise of the warrants is then effective and a current prospectus relating to those Class&nbsp;A
ordinary shares is available <FONT STYLE="white-space:nowrap">throughout&nbsp;the&nbsp;30-day</FONT> redemption period.&nbsp;If and when the warrants become redeemable by the Company, it may exercise its redemption right even if it is unable to
register or qualify the underlying securities for sale under all applicable state securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has established the last of the redemption
criterion discussed above to prevent a redemption call unless there is at the time of the call a significant premium to the warrant exercise price. If the foregoing conditions are satisfied and the Company issues a notice of redemption of the
warrants, each warrant holder will be entitled to exercise his, her or its warrant prior to the scheduled redemption date. However, the price of the Class&nbsp;A ordinary shares may fall below the $18.00&nbsp;redemption trigger price (as adjusted
for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant as described under the heading &#147;Description of Securities&#151;Warrants &#151;Public Shareholders&#146; Warrants&#151;Redemption
Procedures&#151;Anti-dilution Adjustments&#148;) as well as the $11.50&nbsp;(for whole shares) warrant exercise price after the redemption notice is issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Company calls the Public Warrants for redemption as described above, it will have the option to require any holder that wishes to exercise its public
warrant to do so on a &#147;cashless basis.&#148; In determining whether to require all holders to exercise their public warrants on a &#147;cashless basis,&#148; the Company will consider, among other factors, its cash position, the number of
public warrants that are outstanding and the dilutive effect on shareholders of issuing the maximum number of Class&nbsp;A ordinary shares issuable upon the exercise of the Public Warrants. If the Company takes advantage of this option, all holders
of Public Warrants would pay the exercise price by surrendering their public warrants for that number of Class&nbsp;A ordinary shares equal to the quotient obtained by dividing (x)&nbsp;the product of the number of Class&nbsp;A ordinary shares
underlying the warrants, multiplied by the difference between the exercise price of the warrants and the &#147;fair market value&#148; (defined below) by (y)&nbsp;the fair market value. The &#147;fair market
<FONT STYLE="white-space:nowrap">value&#148;&nbsp;means&nbsp;the&nbsp;10-day&nbsp;average&nbsp;closing</FONT> price as of the date on which the notice of redemption is sent to the holders of the warrants. If the Company takes advantage of this
option, the notice of redemption will contain the information necessary to calculate the number of Class&nbsp;A ordinary shares to be received upon exercise of the warrants, including the &#147;fair market value&#148; in such case. Requiring a
cashless exercise in this manner will reduce the number of shares to be issued and thereby lessen the dilutive effect of a warrant redemption. The Company believes this feature is an attractive option if it does not need the cash from the exercise
of the warrants after the Business Combination. If the Company calls the warrants for redemption and does not take advantage of this option, the Sponsor and its permitted transferees would still be entitled to exercise their private placement
warrants for cash or on a cashless basis using the same formula described above that other warrant holders would have been required to use had all warrant holders been required to exercise their warrants on a cashless basis, as described in more
detail below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No fractional Class&nbsp;A ordinary shares will be issued upon exercise. If, upon exercise, a holder would be entitled to receive a
fractional interest in a share, the Company will round down to the nearest whole number of the number of Class&nbsp;A ordinary shares to be issued to the holder. If, at the time of redemption, the warrants are exercisable for a security other than
the Class&nbsp;A ordinary shares pursuant to the warrant agreement (for instance, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
if the Company is not the surviving company in the Business Combination), the warrants may be exercised for such security. At such time as the warrants become exercisable for a security other
than the Class&nbsp;A ordinary shares, the Company (or surviving company) will use its commercially reasonable efforts to register under the Securities Act the security issuable upon the exercise of the warrants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 8&nbsp;&#151;&nbsp;Subsequent Events </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company
evaluated subsequent events and transactions that occurred after the balance sheet date through the date that the unaudited condensed financial statements were issued. Based on this, the Company did not identify any subsequent events that would have
required adjustment or disclosure in the unaudited condensed financial statements. </P>  <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fintoc459793_11"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Shareholders and Board of Directors of </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Forbion
European Acquisition Corp. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Opinion on the Financial Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have audited the accompanying balance sheets of Forbion European Acquisition Corp. (the &#147;Company&#148;) as of December&nbsp;31, 2022 and 2021, the
related statements of operations, changes in shareholders&#146; deficit and cash flows for the year ended December&nbsp;31, 2022, and for the period from August&nbsp;9, 2021 (inception) through December&nbsp;31, 2021, and the related notes
(collectively referred to as the &#147;financial statements&#148;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December&nbsp;31, 2022 and 2021, and the results of
its operations and its cash flows for the year ended December&nbsp;31, 2022 , and for the period from August&nbsp;9, 2021 (inception) through December&nbsp;31, 2021, in conformity with accounting principles generally accepted in the United States of
America. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>E</B><B>xplanatory Paragraph</B><B> &#150; Going Concern</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As more fully described in Note&nbsp;1 to
the financial statements, the Company&#146;s ability to execute its business plan is dependent upon the consummation of a business combination and it lacks the financial resources it needs to sustain operations for a reasonable period of time, which
is considered to be one year from the issuance date of the financial statements. Further, if the Company does not complete a business combination by June&nbsp;14, 2023, or obtain approval for an extension of this deadline, it will be required to
cease all operations except for the purpose of liquidating. These conditions raise substantial doubt about the Company&#146;s ability to continue as a going concern. Management&#146;s plans with regard to these matters are also described in
Note&nbsp;1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis for Opinion
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the Company&#146;s
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#147;PCAOB&#148;) and are required to be independent with respect to the Company in accordance
with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our
audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.
The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for
the purpose of expressing an opinion on the effectiveness of the Company&#146;s internal control over financial reporting. Accordingly, we express no such opinion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and
performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used
and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/s/ Marcum LLP</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marcum LLP</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have served as the Company&#146;s auditor since 2021. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New York, NY</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March&nbsp;30, 2023</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fintoc459793_12"></A>FORBION EUROPEAN ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BALANCE SHEETS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">314,151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,069,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">197,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">498,591</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>511,804</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,567,889</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid <FONT STYLE="white-space:nowrap">expenses&#150;&nbsp;non-current</FONT> portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">209,052</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and securities held in trust account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">131,531,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">129,669,409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>132,043,138</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$131,446,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities, Shares Subject to Redemption and Shareholders&#146; Deficit:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current liabilities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued offering costs and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">844,605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">316,651</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Due to related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48,904</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>893,509</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>327,447</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred underwriting commissions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,727,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,727,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,621,009</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,054,947</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Commitments and Contingencies (Note 6)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;A ordinary shares subject to possible redemption,&nbsp;12,650,000&nbsp;shares at
redemption value of approximately $10.40 and $10.25 at December&nbsp;31, 2022 and 2021, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">131,531,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">129,669,409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Shareholders&#146; Deficit:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preference shares, $0.0001&nbsp;par value; 5,000,000&nbsp;shares authorized; none issued and
outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;A ordinary shares, $0.0001&nbsp;par value;&nbsp;500,000,000&nbsp;shares authorized;
none outstanding (excluding&nbsp;12,650,000&nbsp;shares subject to possible redemption issued) at December&nbsp;31, 2022 and 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;B ordinary shares, $0.0001&nbsp;par value;&nbsp;50,000,000&nbsp;shares
authorized;&nbsp;3,162,500&nbsp;shares issued and outstanding at December&nbsp;31, 2022 and 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Additional&nbsp;paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,109,521</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,278,322</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total shareholders&#146; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(4,109,205</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2,278,006</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Liabilities, Shares Subject to Redemption and Shareholders&#146; Deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>132,043,138</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom"><B>$131,446,350</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fintoc459793_13"></A>FORBION EUROPEAN ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STATEMENTS OF OPERATIONS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Year<BR>Ended<BR>December&nbsp;31,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Period<BR>from<BR>August&nbsp;9,&nbsp;2021<BR>(Inception)<BR>through<BR>December&nbsp;31,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Formation and operating costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,831,421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">232,346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss from operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,831,421</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(232,346</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bank Interest Income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest earned from Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,861,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total other income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,862,147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net income (loss)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>30,726</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(225,437</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted weighted average shares outstanding, Class&nbsp;A ordinary shares subject to
possible redemption</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,650,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,558,966</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net income (loss) per share, Class&nbsp;A ordinary shares subject to possible
redemption</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.05</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted, weighted average shares outstanding &#150; Class&nbsp;B&nbsp;ordinary
shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,162,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,162,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net income (loss) per share, Class&nbsp;B ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.05</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:300pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fintoc459793_14"></A>FORBION EUROPEAN ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STATEMENTS OF CHANGES IN SHAREHOLDERS&#146; DEFICIT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE YEAR ENDED DECEMBER&nbsp;31, 2022 AND </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE PERIOD FROM AUGUST&nbsp;9, 2021 (INCEPTION) THROUGH DECEMBER&nbsp;31, 2021 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;A<BR>Ordinary<BR>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;B<BR>Ordinary Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional</B><br><B><FONT STYLE="white-space:nowrap">Paid-In</FONT><BR>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shareholders&#146;</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of August&nbsp;9, 2021 (Inception)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;B ordinary share issued to initial shareholder</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,162,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sale of 5,195,000 Private Placement Warrants, net of fair value of warrant</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,792,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,792,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Allocated proceeds to public warrants</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,493,159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,493,159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriters&#146; discount and deferred underwriter discount allocated to warrants</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(161,749</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(161,749</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other offering expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(23,283</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(23,283</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(225,437</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(225,437</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Remeasurement of Class&nbsp;A ordinary shares subject to possible redemption to redemption
amount</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11,125,311</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,052,885</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(13,178,196</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of December&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,162,500</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>316</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2,278,322</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2,278,006</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Remeasurement of Class&nbsp;A ordinary shares subject to possible redemption to redemption
amount</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,861,925</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,861,925</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of December&nbsp;31, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,162,500</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>&nbsp;316</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(4,109,521</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(4,109,205</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:200pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fintoc459793_15"></A>FORBION EUROPEAN ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STATEMENTS OF CASH FLOWS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Year<BR>Ended<BR>December&nbsp;31,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Period<BR>from<BR>August&nbsp;9, 2021<BR>(Inception)<BR>through<BR>December&nbsp;31,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from operating activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(225,437</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net income (loss) to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Formation cost paid by Sponsor</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,941</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest earned on cash and marketable securities held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,861,925</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,909</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">509,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(707,643</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued offering costs and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">527,954</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">126,004</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Due from related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.60em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash used in operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(755,147</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(796,248</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from investing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Principal deposited in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(129,662,500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.60em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash used in investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(129,662,500</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from initial public offering, net of costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">123,735,546</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from private placement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,792,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of promissory note to related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">124,577</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment of promissory note to related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(124,577</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.60em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash provided by financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>131,528,046</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net change in cash</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(755,147</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,069,298</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, beginning of the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,069,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash, end of the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>314,151</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,069,298</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosure of cash flow information:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred offering costs paid by Sponsor in exchange for issuance of Class&nbsp;B ordinary
shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred underwriters&#146; discount payable charged to additional paid in capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,727,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Remeasurement Adjustment of Class&nbsp;A ordinary shares subject to possible redemption</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,861,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,178,196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">190,647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:80pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fintoc459793_16"></A>FORBION EUROPEAN ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DECEMBER&nbsp;31, 2022 and 2021 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note
1&nbsp;&#151;&nbsp;Organization, Business Operation and Going Concern </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Forbion European Acquisition Corp. (the &#147;Company&#148;) was incorporated as
a Cayman Islands exempted company on August&nbsp;9, 2021. The Company was incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar Business Combination with one or more
businesses or entities (the &#147;Business Combination&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022, the Company had not commenced any operations. All activity
through December&nbsp;31, 2022 relates to the Company&#146;s formation and the Initial Public Offering (the &#147;IPO&#148; or &#147;Public Offering&#148;) which is described below, and the Company&#146;s completion of a Business Combination. The
Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company <FONT STYLE="white-space:nowrap">will&nbsp;generate&nbsp;non-operating&nbsp;income</FONT> in the form of
interest income on cash and cash equivalents from the proceeds derived from the Public Offering. The Company has selected December&nbsp;31 as its fiscal year end. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s Sponsor is Forbion Growth Sponsor FEAC I B.V., a Cayman Islands limited liability company (the &#147;Sponsor&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The registration statement for the Company&#146;s IPO was declared effective on December&nbsp;9, 2021 (the &#147;Effective Date&#148;). On December&nbsp;14,
2021, the Company consummated the IPO of 11,000,000 units (or 12,650,000 units if the underwriters&#146; over-allotment option is exercised in full) at $10.00 per unit (the &#147;Units&#148;), which is discussed in Note 3. Each Unit consists of one
Class&nbsp;A ordinary share <FONT STYLE="white-space:nowrap">and&nbsp;one-third&nbsp;of</FONT> one redeemable warrant (the &#147;Public Warrants&#148;). Each whole warrant entitles the holder to purchase one Class&nbsp;A ordinary share at a price of
$11.50 per share. On December&nbsp;15, 2021, the underwriters exercised their full over-allotment option and purchased the additional Units available to them. The aggregate Units sold in the IPO and subsequent over-allotment option exercise were
12,650,000 and generated gross proceeds of $126,500,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Simultaneously with the consummation of the IPO, the Company consummated the private placement
of&nbsp;4,700,000 warrants (or&nbsp;5,195,000&nbsp;warrants when the underwriters&#146; over-allotment option was fully exercised on December&nbsp;15, 2021) (the &#147;Private Placement Warrants&#148;) to the Sponsor, at a price of $1.50&nbsp;per
Private Placement Warrant. The sale of the Private Placement Warrants in connection with the IPO and subsequent over-allotment option exercise generated gross proceeds of $7,792,500. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Transaction costs related to the IPO amounted to $5,793,160&nbsp;consisting of $1,800,000&nbsp;of underwriting commissions, $3,150,000&nbsp;of deferred
underwriting commissions, and $843,160&nbsp;of other offering costs. The underwriters&#146; exercise of their full over-allotment option generated an additional $907,500&nbsp;in transaction costs for aggregate transaction costs of
$6,700,660&nbsp;consisting of $2,130,000&nbsp;of underwriting commissions, $3,727,500&nbsp;of deferred underwriting commissions and $843,160&nbsp;of other offering costs. In addition, $1,641,236&nbsp;of cash was held outside of the Trust Account (as
defined below) and is available for working capital purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;15, 2021, the underwriter fully exercised the over-allotment option and
purchased an additional 1,650,000 Units for additional gross proceeds of $16,500,000. Simultaneously with the exercise of the over-allotment option, the Sponsor purchased an addition 495,000 Private Placement Warrants for additional gross proceeds
of $742,500, which was already included in the Trust Account and shown as a Deposit in Advance in this financial statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the closing of the
exercise of the underwriters&#146; full over-allotment option, an additional $16,170,000 was placed in the Trust Account for aggregate proceeds in the Trust Account of $129,662,500 ($10.25 per Unit). As a result of the underwriters&#146;
over-allotment option exercise, 412,500 Founder Shares are no longer subject to forfeiture. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s management has broad discretion with respect to the specific application of the net
proceeds of the IPO and the sale of Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company must complete one or more initial Business Combinations having an aggregate fair market value of at least&nbsp;80% of the net assets held in the
Trust Account (as defined below) (excluding the deferred underwriting commissions and taxes payable on the interest earned on the Trust Account) at the time of signing a definitive agreement in connection with the initial Business Combination.
However, the Company will complete the initial Business Combination only if the post-Business Combination company in which its public shareholders own shares will own or acquire&nbsp;50% or more of the outstanding voting securities of the target or
is otherwise not required to register as an investment company under the Investment Company Act (the &#147;Investment Company Act&#148;). There is no assurance that the Company will be able to complete a Business Combination successfully. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the closing of the IPO on December&nbsp;14, 2021, $113,492,500&nbsp;from the net proceeds of the sale of the Units in the IPO and the sale of the
Private Placement Warrants was deposited into a trust account (the &#147;Trust Account&#148;). This amount was comprised of $10.25&nbsp;per Unit for the&nbsp;11,000,000&nbsp;Units sold in the IPO in addition to a $742,500 Deposit in Advance from the
Sponsor related to the underwriters&#146; exercise of the full over-allotment option which took place the following day on December&nbsp;15, 2021. Following the closing of the IPO and the exercise of the underwriters&#146; full over-allotment
option, $129,662,500&nbsp;($10.25&nbsp;per Unit) was held in the Trust Account and will only be invested in United States &#147;government securities&#148; within the meaning of Section&nbsp;2(a)(16) of the Investment Company Act having a maturity
of&nbsp;185&nbsp;days or less or in money market funds meeting certain conditions under <FONT STYLE="white-space:nowrap">Rule&nbsp;2a-7&nbsp;promulgated&nbsp;under</FONT> the Investment Company Act which invest only in direct U.S. government
treasury obligations. Pursuant to the trust agreement, the trustee is not permitted to invest in other securities or assets. Except with respect to interest earned on the funds held in the Trust Account that may be released to the Company to pay its
income taxes, if any, the Company&#146;s amended and restated memorandum and articles of association, as discussed below and subject to the requirements of law and regulation, will provide that the proceeds from the Public Offering and the sale of
the Private Placement Warrants held in the Trust Account will not be released from the Trust Account (1)&nbsp;to the Company, until the completion of the initial Business Combination, or (2)&nbsp;to its public shareholders, until the earliest of
(a)&nbsp;the completion of the initial Business Combination, and then only in connection with those Class&nbsp;A ordinary shares that such shareholders properly elected to redeem, subject to the limitations described herein, (b)&nbsp;the redemption
of any public shares properly tendered in connection with a shareholder vote to amend the Company&#146;s amended and restated memorandum and articles of association (A)&nbsp;to modify the substance or timing of the Company&#146;s obligation to
provide holders of the Class&nbsp;A ordinary shares the right to have their shares redeemed in connection with the initial Business Combination or to redeem&nbsp;100% of the public shares if the Company does not complete the initial Business
Combination within Combination Period or (B)&nbsp;with respect to any other provision relating to the rights of holders of the Class&nbsp;A ordinary shares, and (c)&nbsp;the redemption of the public shares if the Company has not consummated the
Company&#146;s Business Combination within Combination Period, subject to applicable law. Public shareholders who redeem their Class&nbsp;A ordinary shares in connection with a shareholder vote described in clause (b)&nbsp;in the preceding sentence
shall not be entitled to funds from the Trust Account upon the subsequent completion of an initial Business Combination or liquidation if the Company has not consummated an initial Business Combination within Combination Period, with respect to such
Class&nbsp;A ordinary shares so redeemed. The funds held in the Trust Account could become subject to the claims of the Company&#146;s creditors, if any, which could have priority over the claims of its public shareholders. As it is expected that we
are and will continuously be considered a Dutch tax resident, any redemption proceeds (including interest income on the trust account) distributed to our shareholders in excess of the
<FONT STYLE="white-space:nowrap">paid-up&nbsp;capital&nbsp;for</FONT> Dutch tax purposes may be subject to&nbsp;15% Dutch dividend withholding tax. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company will provide holders (the &#147;Public Shareholders&#148;) of its Class&nbsp;A ordinary shares, par value $0.0001, sold in the IPO (the &#147;Public Shares&#148;), with the opportunity to redeem all or a portion of their Class&nbsp;A
ordinary shares upon the completion of a Business Combination either (i)&nbsp;in connection with a general meeting called to approve the Business Combination or (ii)&nbsp;by means of a tender offer. The decision as to whether the Company
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
will seek shareholder approval of a proposed Business Combination or conduct a tender offer will be made by the Company, solely in its discretion, and will be based on a variety of factors such
as the timing of the transaction and whether the terms of the transaction would require the Company to seek shareholder approval under applicable law or stock exchange listing requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company will provide its Public Shareholders with the opportunity to redeem all or a portion of their Public Shares upon the completion of the initial
Business Combination, regardless of whether such shareholder votes on such proposed Business Combination, and if they do vote, regardless of whether they vote for or against such proposed Business Combination, at
<FONT STYLE="white-space:nowrap">a&nbsp;per-share&nbsp;price,&nbsp;payable&nbsp;in</FONT> cash, equal to the aggregate amount then on deposit in the Trust Account calculated as of two business days prior to the consummation of the initial Business
Combination, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its income taxes, if any, divided by the number of then-outstanding Public Shares, subject to the limitations described
herein. The amount in the Trust Account is initially anticipated to be $10.25&nbsp;per public share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The per share amount that the Company will
distribute to investors who properly redeem their shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters. The redemption rights will include the requirement that a beneficial holder must identify
itself in order to validly redeem its shares. There will be no redemption rights upon the completion of the initial Business Combination with respect to the Company&#146;s warrants. Further, the Company will not proceed with redeeming the Public
Shares, even if a Public Shareholder has properly elected to redeem its Public Shares if a Business Combination does not close. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ordinary shares
subject to redemption were recorded at a redemption value and classified as temporary equity upon the completion of the Public Offering, in accordance with Financial Accounting Standards Board&#146;s (&#147;FASB&#148;) Accounting Standards
Codification (&#147;ASC&#148;) Topic 480 &#147;Distinguishing Liabilities from Equity.&#148; In such case, the Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a
Business Combination and, if the Company seeks shareholder approval, a majority of the issued and outstanding shares voted are voted in favor of the Business Combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s amended and restated memorandum and articles of association provides that the Company will have only&nbsp;18&nbsp;months from the closing
of the Public Offering (or up to&nbsp;24&nbsp;months from the closing of the IPO if the Company extends the period of time to consummate a Business Combination, subject to the Sponsor depositing additional funds in the Trust Account) (the
&#147;Combination Period&#148;) to consummate its initial Business Combination. If the Company has not consummated an initial Business Combination within Combination Period, the Company will: (i)&nbsp;cease all operations except for the purpose of
winding up; (ii)&nbsp;as promptly as reasonably possible but not more than 10 business days thereafter, redeem the public shares, <FONT STYLE="white-space:nowrap">at&nbsp;a&nbsp;per-share&nbsp;price,&nbsp;payable</FONT> in cash, equal to the
aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its income taxes, if any (less up to $100,000&nbsp;of interest to pay
dissolution expenses) divided by the number of the then-outstanding public shares, which redemption will completely extinguish public shareholders&#146; rights as shareholders (including the right to receive further liquidation distributions, if
any); and (iii)&nbsp;as promptly as reasonably possible following such redemption, subject to the approval of the Company&#146;s remaining shareholders and its board of directors, liquidate and dissolve, subject in the case of clauses (ii)&nbsp;and
(iii), to the Company&#146;s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the Company&#146;s
warrants, which will expire worthless if the Company fails to consummate an initial Business Combination within Combination Period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Sponsor and each
member of its management team have entered into an agreement with the Company, pursuant to which they have agreed to (i)&nbsp;waive their redemption rights with respect to their Founder Shares (ii)&nbsp;waive their redemption rights with respect to
their Founder Shares and public shares in connection with a shareholder vote to approve an amendment to the Company&#146;s amended and restated memorandum and articles of association (A)&nbsp;that would modify the substance or timing of the
Company&#146;s obligation to provide holders of the Class&nbsp;A ordinary shares the right to have their shares redeemed in connection with the initial Business </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Combination or to redeem 100% of the public shares if the Company does not complete the initial Business Combination within Combination Period or (B)&nbsp;with respect to any other provision
relating to the rights of holders of the Class&nbsp;A ordinary shares and (iii)&nbsp;waive their rights to liquidating distributions from the Trust Account with respect to any Founder Shares they hold if the Company fails to consummate an initial
Business Combination within Combination Period (although they will be entitled to liquidating distributions from the Trust Account with respect to any Public Shares they hold if the Company fails to complete the initial Business Combination within
the prescribed time frame). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has until&nbsp;18&nbsp;months from the closing of the Public Offering to complete a Business Combination.
However, if the Company anticipates that it may not be able to consummate a Business Combination within 18 months, the Company may extend the period of time to consummate a Business Combination by up to two additional three-month periods for a total
of&nbsp;24&nbsp;months to complete a Business Combination (the &#147;Combination Period&#148;). In order to extend the time available for the Company to consummate a Business Combination, the Sponsor or its affiliate or designees must deposit into
the Trust Account, for each additional three-month period, $1,265,000&nbsp;($0.10&nbsp;per Public Share in either case), on or prior to the date of the applicable deadline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a third party (other than the Company&#146;s independent
auditors) for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below (1)
$10.25&nbsp;per public share or (2)&nbsp;such lesser amount per public share held in the Trust Account as of the date of the liquidation of the Trust Account due to reductions in the value of the trust assets, in each case net of the interest which
may be withdrawn to pay taxes, except as to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account and except as to any claims under the Company&#146;s indemnity of the underwriters of the Public
Offering against certain liabilities, including liabilities under the Securities Act. Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any
liability for such third-party claims. The Company has not independently verified whether the Sponsor has sufficient funds to satisfy its indemnity obligations and believes that the Sponsor&#146;s only assets are securities of the Company and,
therefore, the Sponsor may not be able to satisfy those obligations. The Company has not asked the Sponsor to reserve for such obligations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Going
Concern, Liquidity and Capital Resources </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s liquidity needs up to December&nbsp;14, 2021 had been satisfied through a payment from the
Sponsor of $25,000&nbsp;(see Note 5 of the Financial Statements) for the Founder Shares to cover certain offering costs and the loan under an unsecured promissory note from the Sponsor of up to $500,000. At December&nbsp;31, 2022, the Company had
approximately&nbsp;$0.3&nbsp;million in its operating bank account and a working capital deficit of approximately&nbsp;$0.4&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, in
order to finance transaction costs in connection with a Business Combination, the Company&#146;s Sponsor or an affiliate of the Sponsor or certain of the Company&#146;s officers and directors may, but are not obligated to, provide the Company
Working Capital Loans, as defined below (see Note 5 of the Financial Statements). As of December&nbsp;31, 2022 and, 2021, there were no amounts outstanding under any Working Capital Loans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Company&#146;s assessment of going concern considerations in accordance with FASB <FONT STYLE="white-space:nowrap">ASC205-40,</FONT>
Presentation of Financial Statements&#151;Going Concern&#148;, management has determined that the Company has and will continue to incur significant costs in pursuit of its acquisition plans which raises substantial doubt about the Company&#146;s
ability to continue as a going concern. Moreover, we may need to obtain additional financing either to complete our initial Business Combination or because we become obligated to redeem a significant number of our Public Shares upon consummation of
our initial Business Combination, in which case we may issue additional securities or incur debt in connection with such Business Combination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Subject to compliance with applicable securities laws, we would only complete such financing simultaneously with the completion of the Company&#146;s initial Business Combination. If the Company
is unable to complete its initial Business Combination because it does not have sufficient funds available to it, the Company will be forced to cease operations and liquidate the Trust Accounts. In addition, following the Company&#146;s initial
Business Combination, if cash on hand is insufficient, the Company may need to obtain additional financing in order to meet its obligations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further,
management has determined that if the Company is unable to complete a Business Combination by June&nbsp;14, 2023 (the &#147;Combination Period&#148;), then the Company will cease all operations except for the purpose of liquidating. However, the
Company may, by resolution of its board of directors if requested by the Company&#146;s sponsor, extend the Combination Period two times by an additional three months each time (for a total of up to 24 months to complete a Business Combination),
subject to the sponsor depositing additional funds into the trust account as further described herein. The date for mandatory liquidation and subsequent dissolution as well as the Company&#146;s liquidity condition raise substantial doubt about the
Company&#146;s ability to continue as a going concern. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be required to liquidate after the Combination Period. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks and Uncertainties </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management is currently
evaluating the impact of the current global economic uncertainty, the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, rising interest rates, rising inflation, increases in energy prices, supply chain disruptions and the Russia-Ukraine
armed conflict (including the impact of any sanctions imposed in response thereto) and has concluded that while it is reasonably possible that any of these could have a negative effect on the Company&#146;s financial position, results of operations
and/or search for a target company, the specific impact is not readily determinable as of the date of these financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. The
Company cannot at this time fully predict the likelihood of one or more of the above events, their duration or magnitude or the extent to which they may negatively impact the Company&#146;s business and its ability to complete an initial Business
Combination. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 2&nbsp;&#151;&nbsp;Significant Accounting Policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis of Presentation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying financial
statements are presented in conformity with accounting principles generally accepted in the United States of America (&#147;US GAAP&#148;) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the
&#147;SEC&#148;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Emerging Growth Company Status </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is an &#147;emerging growth company,&#148; as defined in Section&nbsp;2(a) of the Securities Act, as modified by the Jumpstart our Business
Startups Act of 2012, (the &#147;JOBS Act&#148;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to,
not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from
the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, Section&nbsp;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting
standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised
financial accounting standards. The JOBS Act </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
provides that a company can elect to opt out of the extended transition period and comply with the requirements that
<FONT STYLE="white-space:nowrap">apply&nbsp;to&nbsp;non-&nbsp;emerging&nbsp;growth</FONT> companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a
standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard.
This may make comparison of the Company&#146;s financial statements with those of another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult
or impossible because of the potential differences in accounting standards used. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Use of Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of the financial statements in conformity with GAAP requires the Company&#146;s management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition,
situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual
results could differ significantly from those estimates.</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cash and Cash Equivalents </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not
have any cash equivalents as of December&nbsp;31, 2022 and 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Fair Value of Financial Instruments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of the Company&#146;s assets and liabilities, which qualify as financial instruments under FASB ASC&nbsp;820, &#147;Fair Value Measurements and
Disclosures,&#148; approximates the carrying amounts represented in the balance sheets, primarily due to its short-term nature. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company follows the
guidance in ASC 820,&nbsp;&#147;Fair Value Measurement,&#148;&nbsp;for its financial assets and liabilities that are <FONT STYLE="white-space:nowrap">re-measured</FONT> and reported at fair value at each reporting period, and <FONT
STYLE="white-space:nowrap">non-financial</FONT> assets and liabilities that are <FONT STYLE="white-space:nowrap">re-measured</FONT> and reported at fair value at least annually. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of the Company&#146;s financial assets and liabilities reflects management&#146;s estimate of amounts that the Company would have received in
connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and
liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and
liabilities). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used
in order to value the assets and liabilities: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Level&nbsp;1&nbsp;&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Valuation adjustments and block discounts are not being applied. Since valuations are
based on quoted prices that are readily and regularly available in an active market, valuation of these securities does not entail a significant degree of judgment.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-114 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="89%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Level&nbsp;2&nbsp;&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Valuations based on (i)&nbsp;quoted prices in active markets for similar assets and liabilities, (ii)&nbsp;quoted prices in markets that are not active for identical or similar assets, (iii)&nbsp;inputs other than quoted prices for
the assets or liabilities, or (iv)&nbsp;inputs that are derived principally from or corroborated by market through correlation or other means.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Level&nbsp;3&nbsp;&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Valuations based on inputs that are unobservable and significant to the overall fair value measurement.</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cash and Securities Held in Trust Account </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December 31, 2022, investment in the Company&#146;s Trust Account consisted of $1,375 in cash and $131,529,959 in U.S. Treasury Securities. As of
December 31, 2021, investment in the Company&#146;s Trust Account consisted of $1,485 cash and $129,667,924 in U.S. Treasury Securities. All of the U.S. Treasury Securities will mature on June 15, 2023. The Company classified its U.S. Treasury
Securities as <FONT STYLE="white-space:nowrap">held-to-maturity</FONT> in accordance with FASB ASC Topic 320 &#147;Investments&#151;Debt and Equity Securities&#148;. <FONT STYLE="white-space:nowrap">Held-to&#150;maturity</FONT> securities are those
securities which the Company has the ability and intent to hold until maturity. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Held-to-maturity</FONT></FONT> treasury securities are recorded at amortized cost and adjusted for the
amortization or accretion of premiums of discounts. The carrying value approximates the fair value due to its short-term maturity. The carrying value, excluding gross unrealized holding loss and fair value of held to maturity securities at
December&nbsp;31, 2022 and 2021 are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying<BR>Value as of<BR>December&nbsp;31,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Quoted Prices<BR>in Active<BR>Markets<BR>(Level 1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Gross<BR>Unrealized<BR>Losses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. Treasury Securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">131,529,959</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">130,537,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(992,646</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">131,531,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">130,537,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(992,646</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying<BR>Value as of<BR>December&nbsp;30,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Quoted Prices<BR>in Active<BR>Markets</B><br><B>(Level&nbsp;1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Gross<BR>Unrealized<BR>Losses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. Treasury Securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">129,667,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">129,665,154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,770</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">129,669,409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">129,665,154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,770</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Concentration of Credit Risk </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at
times, may exceed the federal depository insurance coverage of $250,000. The Company has not experienced losses on these accounts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Class&nbsp;A
Ordinary Shares Subject to Possible Redemption </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for its ordinary shares subject to possible redemption in accordance with the
guidance in ASC Topic 480 &#147;Distinguishing Liabilities from Equity.&#148; Ordinary shares subject to mandatory redemption (if any) are classified as a liability instrument and measured at fair value. Conditionally redeemable ordinary shares
(including ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#146;s control) are classified as temporary
equity. At all other times, ordinary shares are classified as shareholders&#146; deficit. The Company&#146;s Class&nbsp;A ordinary shares feature certain redemption rights that are considered to be outside of the Company&#146;s
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-115 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
control and subject to the occurrence of uncertain future events. Accordingly,&nbsp;12,650,000&nbsp;Class&nbsp;A ordinary shares subject to possible redemption are presented at redemption value
as temporary equity, outside of the shareholders&#146; deficit section of the Company&#146;s balance sheets. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes changes in redemption
value immediately as they occur and adjusts the carrying value of Class&nbsp;A ordinary shares to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable ordinary shares are
affected by charges against additional paid in capital and accumulated deficit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Class&nbsp;A ordinary shares subject to possible redemption reflected
on the balance sheets as of December&nbsp;31, 2022 and 2021 is reconciled in the following table: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross Proceeds from IPO</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">129,662,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds allocated to Public Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,493,159</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;A ordinary shares issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9,678,128</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Plus:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Remeasurement of carrying value to redemption value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,171,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Class&nbsp;A ordinary shares subject to possible redemption, December&nbsp;31,
2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>129,669,409</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Remeasurement of carrying value to redemption value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,861,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Class&nbsp;A ordinary shares subject to possible redemption, December&nbsp;31,
2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>131,531,334</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Offering Costs associated with the Initial Public Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Offering costs consist of underwriting, legal, accounting and other expenses incurred through the balance sheet date that are directly related to the IPO. The
Company complies with the requirements of the ASC 340-10-S99-1. Offering costs are allocated ratably with the redeemable and non-redeemable shares they are allocated to. Offering costs associated with warrant liabilities are expensed, and offering
costs associated with the Class A ordinary shares are charged to shareholders&#146; deficit. The Company incurred offering costs amounting to $5,793,160 consisting of $1,800,000 of underwriting commissions, $3,150,000 of deferred underwriting
commissions, and $843,160 of other offering costs. The underwriters&#146; exercise of their full over-allotment option generated an additional $907,500 in transaction costs for aggregate transaction costs of $6,700,660 consisting of $2,130,000 of
underwriting commissions, $3,727,500 of deferred underwriting commissions and $843,160 of other offering costs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Net Income (Loss) Per Share </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company complies with accounting and disclosure requirements of ASC Topic 260, &#147;Earnings Per Share.&#148; The statements of operations include a
presentation of income (loss) per Class&nbsp;A ordinary share and income (loss) per Class&nbsp;B ordinary share following <FONT STYLE="white-space:nowrap">the&nbsp;two-class&nbsp;method</FONT> of income (loss) per share. At December&nbsp;31, 2022
and 2021, the Company did&nbsp;not have any dilutive securities and other contracts that could, potentially, be exercised or converted into ordinary shares and then share in the earnings of the Company.&nbsp;As a result, diluted income (loss) per
share is the same as basic income (loss) per share for the periods&nbsp;presented. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-116 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The tables below present a reconciliation of the numerator and denominator used to compute basic and diluted
income (loss) per share for each category for the year ended December&nbsp;31, 2022 and for the period from August&nbsp;9, 2021 (inception) through December&nbsp;31, 2021: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Year Ended</B><br><B>December&nbsp;31, 2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;period&nbsp;from</B><br><B>August&nbsp;9,&nbsp;2021<BR>(inception)&nbsp;through</B><br><B>December&nbsp;31,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;A</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;B</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;A</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;B</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net income (loss) per share:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Allocation of net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,581</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(74,394</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(151,043</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares outstanding including ordinary shares subject to redemption</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,650,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,162,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,558,966</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,162,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net income (loss) per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.05</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.05</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Income Taxes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company
follows the asset and liability method of accounting for income taxes under Financial Accounting Standards Board (&#147;FASB&#148;) ASC 740, &#147;Income Taxes.&#148; Deferred tax assets and liabilities are recognized for the estimated future tax
consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply
to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment
date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASC Topic 740 prescribes
a recognition threshold and a measurement attribute for the financial statements recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than
not to be sustained upon examination by taxing authorities. The Company&#146;s management determined that the Cayman Islands is the Company&#146;s major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized
tax benefits as income tax expense. As of December&nbsp;31, 2022 and 2021, there were no unrecognized tax benefits and no amounts accrued for interest and penalties. The Company is currently not aware of any issues under review that could result in
significant payments, accruals or material deviation from its position. The Company&#146;s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is considered to be an exempted Cayman Islands company with no connection to any other taxable jurisdiction and is presently not subject to income
taxes or income tax filing requirements in the Cayman Islands or the United States. As such, the Company&#146;s tax provision was zero for the period presented. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Business Combination Costs </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Costs incurred in relation to
a potential Business Combination may include legal, accounting, and other expenses. Any such costs are expensed as incurred. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-117 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Accounting Pronouncements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2020, the Financial Accounting Standards Board (&#147;FASB&#148;) issued Accounting Standards
<FONT STYLE="white-space:nowrap">Update&nbsp;(&#147;ASU&#148;)&nbsp;2020-06,&nbsp;Debt&#151;Debt&nbsp;with</FONT> Conversion and Other <FONT STYLE="white-space:nowrap">Options&nbsp;(Subtopic&nbsp;470-20)&nbsp;and&nbsp;Derivatives</FONT> and
Hedging&#151;Contracts in Entity&#146;s Own Equity <FONT STYLE="white-space:nowrap">(Subtopic&nbsp;815-40)</FONT> <FONT STYLE="white-space:nowrap">(&#147;ASU&nbsp;2020-06&#148;)&nbsp;to&nbsp;simplify</FONT> accounting for certain financial <FONT
STYLE="white-space:nowrap">instruments.&nbsp;ASU&nbsp;2020-06&nbsp;eliminates&nbsp;the</FONT> current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative
scope exception guidance pertaining to equity classification of contracts in an entity&#146;s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an
entity&#146;s own equity. <FONT STYLE="white-space:nowrap">ASU&nbsp;2020-06&nbsp;amends&nbsp;the</FONT> diluted earnings per share guidance, including the requirement to <FONT STYLE="white-space:nowrap">use&nbsp;the&nbsp;if-converted</FONT> method
for all convertible <FONT STYLE="white-space:nowrap">instruments.&nbsp;ASU&nbsp;2020-06&nbsp;is&nbsp;effective&nbsp;January&nbsp;1,</FONT> 2022 and should be applied on a full or modified retrospective basis, with early adoption permitted beginning
on January&nbsp;1, 2021. The guidance was adopted starting January&nbsp;1, 2022. Adoption of the ASU did not impact the Company&#146;s financial position, results of operations or cash flows. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management does not believe that any other recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on
the Company&#146;s financial statements.</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 3&nbsp;&#151;&nbsp;Initial Public Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;14, 2021, the Company consummated its IPO of 11,000,000 Units at a purchase price of $10.00 per Unit. Each Unit that the Company is offering
has a price of $10.00 and consists of one Class&nbsp;A ordinary share and <FONT STYLE="white-space:nowrap">one-third</FONT> of one redeemable warrant. Each whole warrant entitles the holder to purchase one Class&nbsp;A ordinary share at a price of
$11.50 per share, subject to adjustment (see Note 7). On December&nbsp;15, 2021, the underwriters exercised their full over-allotment option and purchased the additional Units available to them. The aggregate Units sold in the IPO and subsequent
over-allotment option exercise were 12,650,000 and generated gross proceeds of $126,500,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the closing of the IPO on December&nbsp;14, 2021,
$113,492,500 from the net proceeds of the sale of the Units in the IPO and the sale of the Private Placement Warrants were deposited into a trust account (the &#147;Trust Account&#148;). This amount was comprised of $10.25 per Unit for the
11,000,000 Units sold in the IPO in addition to a $742,500 Deposit in Advance from the Sponsor related to the underwriters&#146; exercise of the full over-allotment option which took place the following day on December&nbsp;15, 2021. Following the
closing of the IPO and the exercise of the underwriters&#146; full over-allotment option, $129,662,500 ($10.25 per Unit) was placed in a Trust Account and will be invested only in U.S. government treasury obligations with a maturity of 185 days or
less or in money market funds meeting certain conditions under <FONT STYLE="white-space:nowrap">Rule&nbsp;2a-7&nbsp;under</FONT> the Investment Company Act which invest only in direct U.S. government treasury obligations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 4&nbsp;&#151; Private Placement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Simultaneously with
the closing of the IPO, the Company&#146;s Sponsor purchased an aggregate of 4,700,000 Private Placement Warrants (5,195,000 Private Placement Warrants when the underwriters&#146; over-allotment option was fully exercised on December&nbsp;15, 2021),
each exercisable to purchase one Class&nbsp;A ordinary share at $11.50 per share, at a price of $1.50 per Unit. The sale of the Private Placement warrants in connection with the IPO and subsequent over-allotment option exercise generated gross
proceeds of $7,792,500. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Private Placement Warrants are not transferable, assignable or salable (and the Class&nbsp;A ordinary shares issuable upon
exercise of the Private Placement Warrants are not transferable, assignable or salable until 30 days after the completion of the initial Business Combination), except as described herein under &#147;Principal Shareholders&#151;Transfers of Founder
Shares and Private Placement Warrants.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any amendment to the terms of the Private Placement Warrants or any provision of the warrant agreement with
respect to the Private Placement Warrants require a vote of holders of at least 50% of the number of the then outstanding Private Placement Warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-118 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 5&nbsp;&#151;&nbsp;Related Party Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Founder Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;12, 2021, Forbion European
Sponsor LLP paid $25,000, or approximately $0.009&nbsp;per share, to cover certain offering costs in consideration for&nbsp;2,875,000&nbsp;Class&nbsp;B ordinary shares (the &#147;Founder Shares&#148;), par value $0.0001. On November&nbsp;23, 2021,
Forbion European Sponsor LLP transferred&nbsp;2,875,000&nbsp;Class&nbsp;B ordinary shares to&nbsp;the Sponsor in exchange for $25,000, or approximately $0.009&nbsp;per share. On December&nbsp;9, 2021, the Company
issued&nbsp;287,500&nbsp;Class&nbsp;B ordinary shares to the Sponsor resulting from a 1.1 for 1 share dividend. Up to&nbsp;412,500 Founder Shares are subject to forfeiture by the Sponsor depending on the extent to which the underwriters&#146;
over-allotment option is exercised. Prior to the Business Combination, only holders of Class&nbsp;B ordinary shares will be able to vote on the appointment of directors and to continue the Company in a jurisdiction outside the Cayman Islands. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;15, 2021, the underwriters fully exercised their over-allotment and as a result, 412,500 Founder Shares are no longer subject to forfeiture.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Promissory Note&nbsp;&#151;&nbsp;Related Party </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
August&nbsp;12, 2021, Forbion European Sponsor LLP agreed to loan the Company up to $500,000 to be used for a portion of the expenses of the Public Offering. These loans <FONT STYLE="white-space:nowrap">are&nbsp;non-interest&nbsp;bearing,</FONT>
unsecured and were due at the earlier of December&nbsp;31, 2021 or the closing of the Public Offering. The Company had outstanding borrowings of $0&nbsp;under the promissory note as of December&nbsp;31, 2022 and 2021. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Working Capital Loans </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to finance transaction
costs in connection with an intended Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company&#146;s officers and directors may, but are not obligated to, loan the Company funds as may be required (&#147;Working
Capital Loans&#148;). If the Company completes the initial Business Combination, the Company may repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans may be repaid
only out of funds held outside the Trust Account. In the event that the initial Business Combination does not close, the Company may use a portion of the working capital held outside the Trust Account to repay the Working Capital Loans but no
proceeds from the Trust Account would be used to repay the Working Capital Loans. Up to $1,500,000&nbsp;of such Working Capital Loans may be convertible into warrants of the post-Business Combination entity at a price of $1.50&nbsp;per warrant at
the option of the lender. The warrants would be identical to the Private Placement Warrants. As of December&nbsp;31, 2022 and 2021, the Company had&nbsp;no&nbsp;borrowings under the Working Capital Loans. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Related Party Extension Loans </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company may extend the
period of time to consummate a Business Combination by up to two additional three-month periods (for a total of 24 months to complete a Business Combination). In order to extend the time available for the Company to consummate a Business
Combination, the Sponsor or its affiliates or designees must deposit into the trust account, for each additional three-month period, $1,265,000, ($0.10 per Public Share in either case), on or prior to the date of the applicable deadline. Any such
payments would be made in the form of <FONT STYLE="white-space:nowrap">a&nbsp;non-interest&nbsp;bearing,</FONT> unsecured promissory note. Such notes would either be paid upon consummation of a Business Combination, or, at the relevant
insider&#146;s discretion, converted upon consummation of a Business Combination into additional Private Placement Warrants at a price of $1.50 per Private Warrant. The Sponsor and its affiliates or designees are not obligated to fund the trust
account to extend the time for the Company to complete a Business Combination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-119 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Office Space, Secretarial and Administrative Services </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Commencing on the date that the Company&#146;s securities are first listed on the NASDAQ through the earlier of consummation of the initial Business
Combination and the liquidation, the Company agreed to pay the Sponsor a total of $10,000&nbsp;per month for office space, utilities, secretarial and administrative support and to reimburse the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Sponsor&nbsp;for&nbsp;any&nbsp;out-of-pocket&nbsp;expenses&nbsp;related</FONT></FONT> to identifying, investigating and completing an initial Business Combination. For the year ended December&nbsp;31, 2022, the Company
expensed $120,000&nbsp;in administrative support&nbsp;services. For the period from August&nbsp;9, 2021 (inception) through December&nbsp;31, 2021, the Company expensed $7,097 in administrative support&nbsp;services. At December&nbsp;31, 2022 and
2021, the Company had accrued $30,000&nbsp;and $7,097, respectively, in administrative fees payable to the Sponsor which are included in due to related party on the balance sheets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, the Sponsor has agreed to pay an annual salary of $25,000&nbsp;to each of the independent Board Members for services rendered prior to or in
connection with the completion of the Business Combination. Board members are entitled to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">reimbursement&nbsp;for&nbsp;any&nbsp;out-of-pocket&nbsp;expenses&nbsp;related</FONT></FONT>
to identifying, investigating, negotiating and completing the Business Combination as well. For the year ended December&nbsp;31, 2022, the Company expensed $75,000&nbsp;for services rendered by the independent Board&nbsp;Members. For the period from
August&nbsp;9, 2021 (inception) through December&nbsp;31, 2021, the Company expensed $3,699 for the services rendered by the independent Board Members. At December&nbsp;31, 2022 and 2021, the Company had accrued&nbsp;approximately $18,904&nbsp;and
$3,699, respectively, in compensation expense to the independent board members which are included in due to related party on the balance sheets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note
6&nbsp;&#151;&nbsp;Commitments&nbsp;&amp; Contingencies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration and Shareholder Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of the Founder Shares, Private Placement Warrants, Class&nbsp;A ordinary shares underlying the Private Placement Warrants and any warrants that may
be issued upon conversion of Working Capital Loans and extension loans (and any Class&nbsp;A ordinary shares issuable upon the exercise of the Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans and
extension loans) will be entitled to registration rights pursuant to a registration and shareholder rights agreement to be signed prior to or on the effective date of the Public Offering. The holders of these securities are entitled to make up
to&nbsp;three&nbsp;demands, excluding short form demands, that the Company register such securities. In addition, the holders have certain &#147;piggy-back&#148; registration rights with respect to registration statements filed subsequent to the
Company&#146;s completion of the initial Business Combination. However, the registration and shareholder rights agreement provide that the Company will not permit any registration statement filed under the Securities Act to become effective until
termination of the applicable <FONT STYLE="white-space:nowrap">lock-up</FONT> period, which occurs (i)&nbsp;in&nbsp;the case of the Founder Shares, as described in the following paragraph, and (ii)&nbsp;in the case of the Private Placement Warrants
and the respective Class&nbsp;A ordinary shares underlying such warrants, 30&nbsp;days after the completion of the initial Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration
statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as described herein, the Sponsor and the Company&#146;s directors and executive officers have agreed not to transfer, assign or sell
(i)&nbsp;their Founder Shares until the earliest of (A)&nbsp;one&nbsp;year after the completion of the initial Business Combination and (B)&nbsp;subsequent to the initial Business Combination, (x)&nbsp;if the closing price of the Class&nbsp;A
ordinary shares equals or exceeds $12.00&nbsp;per share (as <FONT STYLE="white-space:nowrap">adjusted&nbsp;for&nbsp;share&nbsp;sub-divisions,</FONT> share capitalizations, reorganizations, recapitalizations and the like) for any&nbsp;20&nbsp;trading
<FONT STYLE="white-space:nowrap">days&nbsp;within&nbsp;any&nbsp;30-trading</FONT> day period commencing at least&nbsp;150&nbsp;days after the initial Business Combination, or (y)&nbsp;the date on which the Company complete a liquidation, merger,
share exchange or other similar transaction that results in all of its public shareholders having the right to exchange their ordinary shares for cash, securities or other property, and (ii)&nbsp;any of their Private Placement Warrants and
Class&nbsp;A ordinary shares issued upon conversion or exercise thereof until 30&nbsp;days after the completion of the initial Business Combination. Any permitted transferees will be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-120 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
subject to the same restrictions and other agreements of the Sponsor with respect to any Founder Shares, Private Placement Warrants and Class&nbsp;A ordinary shares issued upon conversion or
exercise thereof.&nbsp;The Company refers&nbsp;to such transfer restrictions <FONT STYLE="white-space:nowrap">herein&nbsp;as&nbsp;the&nbsp;lock-up.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, pursuant to the registration and shareholder rights agreement, the Sponsor, upon and following consummation of an initial Business Combination,
will be entitled to nominate&nbsp;three&nbsp;individuals for appointment to the Company&#146;s board of directors, as long as the Sponsor holds any securities covered by the registration and shareholder rights agreement. Prior to the Business
Combination, only holders of Class&nbsp;B ordinary shares will be able to vote on the appointment of directors and to continue the Company in a jurisdiction outside the Cayman Islands. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Underwriting Agreement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters had <FONT
STYLE="white-space:nowrap">a&nbsp;45-day&nbsp;option</FONT> from the date of the IPO to purchase up to an additional 1,650,000 Units to cover over-allotments, if any. On December&nbsp;15, 2021, the underwriters fully exercised the over-allotment
option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters were paid underwriting commission of $0.20 per Unit sold in the IPO, excluding Units sold to&nbsp;Forbion Cooperatief, or
$1,800,000, upon the closing of the IPO. Following the exercise of the underwriters&#146; over-allotment option on December&nbsp;15, 2021, the underwriters earned an additional $330,000 for an aggregate of $2,130,000 in underwriting commissions
related to the IPO and over-allotment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, $3,150,000 is payable to the underwriters for deferred underwriting commissions related to the Units
sold in the IPO, excluding those Units sold to&nbsp;Forbion Cooperatief. Following the exercise of the underwriters&#146; over-allotment option on December&nbsp;15, 2021, the underwriters earned an additional $577,500 for an aggregate of $3,727,500
in deferred underwriting commissions related to the IPO and over-allotment. The deferred underwriting commission will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a
Business Combination, subject to the terms of the underwriting agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Purchase Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has entered into two forward purchase agreements with an affiliate of the Sponsor (the &#147;FPA Purchaser&#148;), pursuant to which the FPA
Purchaser has agreed to purchase (1)&nbsp;an aggregate of 1,000,000 Class&nbsp;A ordinary shares for $10.00 per share (the &#147;firm forward purchase shares&#148;), or an aggregate amount of $10,000,000 and (2)&nbsp;in addition, an aggregate of up
to 1,000,000 Class&nbsp;A ordinary shares for $10.00 per share (the &#147;additional forward purchase shares&#148;), or an aggregate maximum amount of up to $10,000,000, in each case in a private placement that may close simultaneously with the
closing of the Company&#146;s initial Business Combination. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Deferred Legal Fees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has incurred&nbsp;$581,265 in legal fees associated with the Company&#146;s Initial Public Offering. These fees are deferred and will become
payable upon the consummation of the Business Combination and are included in accrued offering costs and expenses on the Company&#146;s balance sheets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 7&nbsp;&#151;&nbsp;Shareholders&#146; Deficit </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preference shares</B>&nbsp;&#151; The Company is authorized to issue 5,000,000 preference shares with a par value of $0.0001&nbsp;and with such
designations, voting and other rights and preferences as may be determined from time to time by the Company&#146;s board of directors. As of December&nbsp;31, 2022 and 2021, there were&nbsp;no&nbsp;preference shares issued or outstanding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-121 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Class</B><B></B><B>&nbsp;A ordinary shares</B>&nbsp;&#151;&nbsp;The Company is authorized to
issue&nbsp;500,000,000&nbsp;Class&nbsp;A ordinary shares with a par value of $0.0001&nbsp;per share. As of December&nbsp;31, 2022 and 2021, there were&nbsp;no&nbsp;Class&nbsp;A ordinary shares outstanding, excluding&nbsp;12,650,000&nbsp;Class&nbsp;A
ordinary shares subject to possible redemption issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Class</B><B></B><B> B ordinary shares</B> &#151; The Company is authorized to issue 50,000,000
Class B ordinary shares with a par value of $0.0001 per share. Holders are entitled to one vote for each share of Class B ordinary shares. As of August 13, 2021, there were 2,875,000 Class B ordinary shares issued and outstanding. Of the 2,875,000
Class B ordinary shares, an aggregate of up to 375,000 shares are subject to forfeiture to the Company for no consideration to the extent that the underwriters&#146; over-allotment option is not exercised in full or in part. On December 9, 2021, the
Company effected a stock dividend of 1.1 shares for each outstanding share, resulting in there being an aggregate of 3,162,500 Founder Shares outstanding, of which 412,500 are subject to forfeiture to the extent that the underwriters&#146;
over-allotment option is not exercised in full or in part. All share and per share amounts have been retroactively restated to reflect the share dividend. The forfeiture amounts were determined such that the initial shareholders will collectively
own 20% of the Company&#146;s issued and outstanding ordinary shares after the Public Offering. As of December 31, 2022 and 2021, there were 3,162,500 shares of class B ordinary shares issued and outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of Class&nbsp;A ordinary shares and holders of Class&nbsp;B ordinary shares will vote together as a single class on all matters submitted to a vote of
the Company&#146;s shareholders except as required by law. Unless specified in the Company&#146;s amended and restated memorandum and articles of association, or as required by applicable provisions of the Companies Act or applicable stock exchange
rules, the affirmative vote of a majority of the Company&#146;s ordinary shares that are voted is required to approve any such matter voted on by the Company&#146;s shareholders. Approval of certain actions will require a special resolution under
Cayman Islands law, being the affirmative vote of&nbsp;at&nbsp;least two&#151;thirds&nbsp;of&nbsp;the&nbsp;Company&#146;s ordinary shares that are voted, and pursuant to the Company&#146;s amended and restated memorandum and articles of association;
such actions include amending the Company&#146;s amended and restated memorandum and articles of association and approving a statutory merger or consolidation with another company. The Company&#146;s board of directors is divided into three classes,
each of which will generally serve for a term of&nbsp;three years&nbsp;with only&nbsp;one&nbsp;class of directors being appointed in each year. There is no cumulative voting with respect to the appointment of directors, with the result that the
holders of more than&nbsp;50% of the shares voted for the appointment of directors can appoint all of the directors. Prior to the Business Combination, only holders of Class&nbsp;B ordinary shares will be able to vote on the appointment of directors
and to continue the Company in a jurisdiction outside the Cayman Islands. The Company&#146;s shareholders are entitled to receive ratable dividends when, as and if declared by the board of directors out of funds legally available therefor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Class&nbsp;B ordinary shares will automatically convert into Class&nbsp;A ordinary shares, which such Class&nbsp;A ordinary shares delivered upon
conversion will not have any redemption rights or be entitled to liquidating distributions, if the Company does not consummate an initial Business Combination, at the time of the initial Business Combination or earlier at the option of the holders
thereof at a ratio such that the number of Class&nbsp;A ordinary shares issuable upon conversion of all Founder Shares equal, in the <FONT STYLE="white-space:nowrap">aggregate,&nbsp;on&nbsp;an&nbsp;as-converted</FONT> basis, 20% of the sum of
(i)&nbsp;the total number of ordinary shares issued and outstanding upon completion of the Public Offering, plus (ii)&nbsp;the total number of Class&nbsp;A ordinary shares issued or deemed issued or issuable upon conversion or exercise of any
equity-linked securities (as defined herein) or rights issued or deemed issued, by the company in connection with or in relation to the consummation of the initial Business Combination, excluding any Class&nbsp;A ordinary shares or equity-linked
securities exercisable for or convertible into Class&nbsp;A ordinary shares issued, deemed issued, or to be issued, to any seller in the initial Business Combination and any Private Placement Warrants issued to the Sponsor, its affiliates or any
member of its management team upon conversion of Working Capital Loans and extension loans. Any conversion of Class&nbsp;B ordinary shares described herein will take effect as a compulsory redemption of Class&nbsp;B ordinary shares and an issuance
of Class&nbsp;A ordinary shares as a matter of Cayman Islands law. In no event will the Class&nbsp;B ordinary shares convert into Class&nbsp;A ordinary shares at a rate
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">of&nbsp;less&nbsp;than&nbsp;one-to-one.</FONT></FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-122 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Public Warrants</B>&nbsp;&#151; Each whole warrant entitles the holder to
purchase&nbsp;one&nbsp;Class&nbsp;A ordinary share at a price of $11.50&nbsp;per share, subject to adjustment as discussed herein. In addition, if (x)&nbsp;the Company will issue additional Class&nbsp;A ordinary shares or equity-linked securities
for capital raising purposes in connection with the closing of the initial Business Combination at an issue price or effective issue price of less than $9.20&nbsp;per ordinary share (with such issue price or effective issue price to be determined in
good faith by the Company&#146;s board of directors and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any Founder Shares held by the Sponsor or such affiliates, as applicable, prior to such issuance)
(the &#147;Newly Issued Price&#148;), (y) the aggregate gross proceeds from such issuances represent more than&nbsp;60% of the total equity proceeds, and interest thereon, available for the funding of the initial Business Combination on the date of
the consummation of the initial Business Combination (net of redemptions), and (z)&nbsp;the volume weighted average trading price of the Class&nbsp;A ordinary shares during the&nbsp;20&nbsp;trading day period starting on the trading day prior to the
day on which the Company consummate the initial Business Combination (such price, the &#147;Market Value&#148;) is below $9.20&nbsp;per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to&nbsp;115% of the
higher of the Market Value and the Newly Issued Price, the $18.00&nbsp;per share redemption trigger price described adjacent to &#147;Redemption of public warrants&#148; will be adjusted (to the nearest cent) to be equal to&nbsp;180% of the higher
of the Market Value and the Newly Issued Price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The warrants will become exercisable on the later of&nbsp;30&nbsp;days after the completion of the
Company&#146;s initial Business Combination and will expire&nbsp;five years&nbsp;after the completion of the Company&#146;s initial Business Combination, at 5:00 p.m., New York City time, or earlier upon redemption or liquidation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has agreed that as soon as practicable, but in no event later than&nbsp;twenty&nbsp;business days after the closing of the initial Business
Combination, the Company will use its commercially reasonable efforts to file with the SEC a registration statement for the registration, under the Securities Act, of the Class&nbsp;A ordinary shares issuable upon exercise of the warrants, and the
Company will use its commercially reasonable efforts to cause the same to become effective within&nbsp;60&nbsp;business days after the closing of the initial Business Combination, and to maintain the effectiveness of such registration statement and
a current prospectus relating to those Class&nbsp;A ordinary shares until the warrants expire or are redeemed, as specified in the warrant agreement; provided that if the Class&nbsp;A ordinary shares are at the time of any exercise of a warrant not
listed on a national securities exchange such that they satisfy the definition of a &#147;covered security&#148; under Section&nbsp;18(b)(1) of the Securities Act, the Company may, at its option, require holders of public warrants who exercise their
warrants to do so on a &#147;cashless basis&#148; in accordance with Section&nbsp;3(a)(9) of the Securities Act and, in the event the Company so elect, the Company will not be required to file or maintain in effect a registration statement, but the
Company will use its commercially reasonably efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available. If a registration statement covering the Class&nbsp;A ordinary shares issuable upon
exercise of the warrants is not effective by the&nbsp;60th day after the closing of the initial Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company will
have failed to maintain an effective registration statement, exercise warrants on a &#147;cashless basis&#148; in accordance with Section&nbsp;3(a)(9) of the Securities Act or another exemption, but the Company will use its commercially
reasonable&nbsp;efforts to register or qualify the shares under applicable <FONT STYLE="white-space:nowrap">blue-sky</FONT> laws to the extent an exemption is not available. In such event, each holder would pay the exercise price by surrendering the
warrants for that number of Class&nbsp;A ordinary shares equal to the quotient obtained by dividing (x)&nbsp;the product of the number of Class&nbsp;A ordinary shares underlying the warrants, multiplied by the excess of the &#147;fair market
value&#148; (defined below) less the exercise price of the warrants by (y)&nbsp;the fair market value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Redemption of public warrants</I></B>. Once
the warrants become exercisable, the Company may redeem the outstanding warrants (except as described herein with respect to the Private Placement Warrants): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in whole and not in part; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at a price of $0.01 per warrant; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon a minimum of 30 days&#146; prior written notice of redemption, which the Company refer to as the <FONT
STYLE="white-space:nowrap">&#147;30-day</FONT> redemption period&#148;; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-123 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if, and only if, the last reported sale price (the &#147;closing price&#148;) of the Class&nbsp;A ordinary shares
equals or exceeds $18.00 per share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant as described under the heading &#147;Description of Securities&#151;Warrants&#151;Public
Shareholders&#146; Warrants&#151;Redemption Procedures&#151;Anti-dilution Adjustments&#148;) for any 20 trading days within a <FONT STYLE="white-space:nowrap">30-trading</FONT> day period ending on the third trading day prior to the date on which
the Company send the notice of redemption to the warrant holders. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company will not redeem the Warrants as described above unless a
registration statement under the Securities Act covering the issuance of the Class A ordinary shares issuable upon exercise of the warrants is then effective and a current prospectus relating to those Class A ordinary shares is available throughout
the 30-day redemption period. If and when the warrants become redeemable by the Company, it may exercise its redemption right even if it is unable to register or qualify the underlying securities for sale under all applicable state securities laws.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has established the last of the redemption criterion discussed above to prevent a redemption call unless there is at the time of the call a
significant premium to the warrant exercise price. If the foregoing conditions are satisfied and the Company issues a notice of redemption of the warrants, each warrant holder will be entitled to exercise his, her or its warrant prior to the
scheduled redemption date. However, the price of the Class&nbsp;A ordinary shares may fall below the $18.00 redemption trigger price (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant as
described under the heading &#147;Description of Securities&#151;Warrants &#151;Public Shareholders&#146; Warrants&#151;Redemption Procedures&#151;Anti-dilution Adjustments&#148;) as well as the $11.50 (for whole shares) warrant exercise price after
the redemption notice is issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Company calls the Public Warrants for redemption as described above, it will have the option to require any
holder that wishes to exercise its public warrant to do so on a &#147;cashless basis.&#148; In determining whether to require all holders to exercise their public warrants on a &#147;cashless basis,&#148; the Company will consider, among other
factors, its cash position, the number of public warrants that are outstanding and the dilutive effect on shareholders of issuing the maximum number of Class&nbsp;A ordinary shares issuable upon the exercise of the Public Warrants. If the Company
takes advantage of this option, all holders of Public Warrants would pay the exercise price by surrendering their public warrants for that number of Class&nbsp;A ordinary shares equal to the quotient obtained by dividing (x)&nbsp;the product of the
number of Class&nbsp;A ordinary shares underlying the warrants, multiplied by the difference between the exercise price of the warrants and the &#147;fair market value&#148; (defined below) by (y)&nbsp;the fair market value. The &#147;fair market
value&#148; <FONT STYLE="white-space:nowrap">means&nbsp;the&nbsp;10-day&nbsp;average&nbsp;closing</FONT> price as of the date on which the notice of redemption is sent to the holders of the warrants. If the Company takes advantage of this option,
the notice of redemption will contain the information necessary to calculate the number of Class&nbsp;A ordinary shares to be received upon exercise of the warrants, including the &#147;fair market value&#148; in such case. Requiring a cashless
exercise in this manner will reduce the number of shares to be issued and thereby lessen the dilutive effect of a warrant redemption. The Company believes this feature is an attractive option if it does not need the cash from the exercise of the
warrants after the Business Combination. If the Company calls the warrants for redemption and does not take advantage of this option, the Sponsor and its permitted transferees would still be entitled to exercise their private placement warrants for
cash or on a cashless basis using the same formula described above that other warrant holders would have been required to use had all warrant holders been required to exercise their warrants on a cashless basis, as described in more detail below.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No fractional Class&nbsp;A ordinary shares will be issued upon exercise. If, upon exercise, a holder would be entitled to receive a fractional interest
in a share, the Company will round down to the nearest whole number of the number of Class&nbsp;A ordinary shares to be issued to the holder. If, at the time of redemption, the warrants are exercisable for a security other than the Class&nbsp;A
ordinary shares pursuant to the warrant agreement (for instance, if the Company is not the surviving company in the Business Combination), the warrants may be exercised for such security. At such time as the warrants become exercisable for a
security other than the Class&nbsp;A ordinary shares, the Company (or surviving company) will use its commercially reasonable efforts to register under the Securities Act the security issuable upon the exercise of the warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-124 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 8&nbsp;&#151;&nbsp;Subsequent Events </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company evaluated subsequent events and transactions that occurred after the balance sheet date through the date that the financial statements were issued.
Based on this, other than as disclosed below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March 24, 2023, the Sponsor and the Company entered into an unsecured promissory note (the &#147;Note&#148;) under which the Sponsor agreed to extend to
the Company a Working Capital Loan of up to $900,000, to be used for the Company&#146;s general working capital purposes. The Sponsor funded the initial principal amount of $450,000 under the Note on March 24, 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Note bears no interest and will be due and payable on the earlier of (i)&nbsp;the date of consummation of a Business Combination and
(ii)&nbsp;December&nbsp;14, 2023. If the Company completes a Business Combination, the Company may repay the Note out of the proceeds of the Trust Account released to the Company. Otherwise, no proceeds from the Trust Account can be used to repay
the Note. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrently with the consummation of a Business Combination, the Sponsor will have the option, but not the obligation, to convert up to the
total principal amount of the Note, in whole or in part, into additional warrants of the post-Business Combination entity at a price of $1.50 per warrant. The warrants will be identical to the Private Placement Warrants. </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-125 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g459793g77a10.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">

<TR>

<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="28%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>KPMG LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">600&nbsp;de&nbsp;Maisonneuve&nbsp;Blvd.&nbsp;West</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Suite 1500, Tour
KPMG</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Montr&eacute;al (Qu&eacute;bec) H3A 0A3</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">Canada</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Telephone</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Fax</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">Internet</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">(514)&nbsp;840-2100</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">(514) <FONT STYLE="white-space:nowrap">840-2187</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">www.kpmg.ca</P></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman"><B><A NAME="fintoc459793_171"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman">To the Shareholder and Directors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman">of enGene Holdings Inc. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman"><B><I>Opinion on the Financial Statements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman">We have
audited the accompanying balance sheet of enGene Holdings Inc. (the &#147;Company&#148;) as of July&nbsp;31, 2023, the related statements of operations and comprehensive loss, redeemable common shares and shareholder&#146;s deficit, and cash flows
for the period from April&nbsp;24, 2023 (inception) to July&nbsp;31, 2023 and the related notes (collectively, the &#147;financial statements&#148;). In our opinion, the financial statements present fairly, in all material respects, the financial
position of the Company as of July&nbsp;31, 2023, and the results of its operations and its cash flows for the period from April&nbsp;24, 2023 (inception) to July&nbsp;31, 2023, in conformity with U.S. generally accepted accounting principles. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman"><B><I>Going Concern </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman">The accompanying financial
statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has incurred net losses since its inception and requires financing to meet its liabilities,
that raise substantial doubt about its ability to continue as a going concern. Management&#146;s plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the
outcome of this uncertainty. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman"><B><I>Basis for Opinion </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman">These financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on these financial statements
based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#147;PCAOB&#148;) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman">We conducted our audit in accordance
with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audit included
performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence
regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial
statements. We believe that our audit provides a reasonable basis for our opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman">/s/ KPMG LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman">We have served as the Company&#146;s auditor since 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman">Montr&eacute;al, Canada </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman">August&nbsp;9, 2023 </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="76%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">KPMG LLP, an Ontario limited liability partnership and member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. KPMG Canada
provides services to KPMG LLP.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-126 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE HOLDINGS INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fintoc459793_172"></A>BALANCE SHEET </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN USD) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>July&nbsp;31,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities and Shareholder&#146;s deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,830</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Due to related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42,660</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72,490</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable Class&nbsp;B common shares, no par value; unlimited shares authorized, 10 shares issued
and outstanding, redemption amount of $7</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shareholder&#146;s deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;A common shares, no par value; unlimited shares authorized, no shares issued and
outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(72,490</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total shareholder&#146;s deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(72,490</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities and shareholder&#146;s deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:300pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-127 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE HOLDINGS INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fintoc459793_172a"></A>STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN USD) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the period<BR>April&nbsp;24, 2023<BR>(Inception)through<BR>July&nbsp;31, 2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency losses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72,490</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share of common shares, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average common shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:340pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-128 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE HOLDINGS INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fintoc459793_172b"></A>STATEMENT OF REDEEMABLE COMMON SHARES AND SHAREHOLDER&#146;S DEFICIT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN USD) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Redeemable<BR>Class&nbsp;B Common<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shareholder&#146;s<BR>Deficit</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at April&nbsp;24, 2023 (Inception)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Redeemable Class&nbsp;B Common Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(72,490</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(72,490</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at July&nbsp;31, 2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>10</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B> 7</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(72,490</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(72,490</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:400pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-129 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE HOLDINGS INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fintoc459793_172c"></A>STATEMENT OF CASH FLOWS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN USD) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Period&nbsp;ended<BR>April&nbsp;24,&nbsp;2023<BR>(Inception)<BR>through<BR>July&nbsp;31, 2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash Flows from operating activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 72,490</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized foreign currency losses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(394</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(29,436</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Due to related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(42,660</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of redeemable Class&nbsp;B common shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of exchange rate changes on cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase in cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash at beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash at end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:250pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-130 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE HOLDINGS INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fintoc459793_173"></A>NOTES TO THE FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN USD) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Organization </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">enGene Holdings Inc. (the &#147;Company&#148;) was incorporated as 14963148 Canada Inc. Inc. under the federal laws of Canada on April&nbsp;24,
2023 and changed its name to enGene Holdings Inc. on May&nbsp;9, 2023. The Company was incorporated to facilitate the business combination between enGene Inc. (&#147;enGene&#148;) and Forbion European Acquisition Corp (&#147;FEAC&#148;), a publicly
traded special purpose acquisition company pursuant to the Business Combination Agreement (the &#147;BCA&#148;) dated May&nbsp;16, 2023 among the Company, enGene and FEAC, which is subject to closing conditions. The Company has commitments in
connection with the business combination (see below). The Company&#146;s intended business activity is holding the shares of enGene. enGene&#146;s intended businesses activity is the research and development of next generation <FONT
STYLE="white-space:nowrap">non-viral,</FONT> locally administered gene therapies. To date, the Company has not commenced operations and is expected to commence operations concurrent with the closing of the business combination (the
&#147;Closing&#148;) in accordance with the BCA. The Company&#146;s registered address is Suite 2600, Three Bentall Centre, 595 Burrard Street, Vancouver, BC, V7X&nbsp;1L3, Canada. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has authorized an unlimited amount of Class&nbsp;A common shares and Class&nbsp;B common shares, with no par value. The holders of
the Class&nbsp;A and B Common shares each shall be entitled to receive, subject to the rights of the holders of any other class of shares, any dividend declared by the Corporation in their absolute discretion, in such amount and in such form as the
board of directors of the Corporation may from time to time determine. The holders of the Class&nbsp;A and B Common shares each shall be entitled to receive notice of, and to attend, all meetings of the shareholders of the Corporation and shall have
one (1)&nbsp;vote for each Common share held. The Company issued ten Class&nbsp;B common shares for an aggregate purchase price of $10 Canadian Dollars (&#147;CAD&#148;) upon incorporation to a single shareholder of the Company, which is converted
to $7 United States Dollars (&#147;USD&#148;) using the exchange rate in effect on the date the shares were issued. The Class&nbsp;B common shares are redeemable at the original purchase price of $1.00 CAD per share at the option of the Company or
the holder at any time. The Company classifies its redeemable common shares outside of shareholder&#146;s equity within the temporary equity section of the balance sheet as the redemption of such shares is outside the Company&#146;s control. No
Class&nbsp;A common shares have been issued as of May&nbsp;16, 2023. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Going Concern </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s financial statements have been prepared assuming the Company will continue as a going concern, which presumes the Company
will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities and commitments in the ordinary course of business. The Company has incurred net losses since its inception and requires
financing to meet its liabilities. These conditions indicate the existence of a material uncertainty that raise substantial doubt about the Company&#146;s ability to continue as a going concern and, therefore, that it may be unable to realize its
assets and discharge its liabilities in the normal course of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is seeking to complete an equity financing and
business combination transaction with a special purpose acquisition company (&#147;SPAC&#148;) (see Business Combination with FEAC and related financing. above). These plans are intended to mitigate the relevant conditions that raise substantial
doubt about the Company&#146;s ability to continue as a going concern; however, as the plans are not within the Company&#146;s control, it is not assured that they will be effectively implemented. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Business Combination with FEAC and related financing </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;16, 2023, the Company entered into the BCA with enGene and FEAC. Upon closing of the proposed transaction contemplated by the BCA,
the Company will be the holding company of enGene and its common shares are expected to be listed on the Nasdaq. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-131 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE HOLDINGS INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN USD) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;16, 2023, the Company, FEAC, and certain investors (the &#147;PIPE
Investors&#148;) entered into subscription agreements as amended by certain Side Letter Agreements entered into immediately thereafter, among other things, the PIPE Investors have agreed, subject to the completion of each element of the business
combination, to subscribe for and purchase, and FEAC has agreed that it will issue and sell to the PIPE Investors (which obligation will be assumed (the &#147;Assumption&#148;) by the Company, after the completion of the FEAC reorganization and
prior to the consummation of the PIPE Financing (as defined below) FEAC Class&nbsp;A shares (the &#147;FEAC Class&nbsp;A Shares&#148;) (or after the Assumption, Class&nbsp;A Common shares of the Company) and warrants to acquire FEAC Class&nbsp;A
Shares (or after the Assumption, warrants to acquire Class&nbsp;A Common shares of the Company) for an aggregate purchase price equal to $56.8&nbsp;million (the &#147;PIPE Financing&#148;). Prior to the execution of the BCA, enGene agreed to certain
modifications of existing convertible indebtedness in an aggregate principal amount of $18.4&nbsp;million, where, among other things, enGene issued warrants to the existing noteholders. Concurrently with the execution and delivery of the BCA, enGene
entered into an agreement pursuant to which issued new convertible indebtedness and enGene warrants (i)&nbsp;for cash in an aggregate principal amount of $30.0&nbsp;million in May and June 2023 and (ii)&nbsp;in repayment of certain outstanding
indebtedness in an aggregate principal amount of $8.0&nbsp;million, which indebtedness was received in April 2023. Such indebtedness will be converted in the transactions to be completed as part of the BCA into that number of common shares of enGene
that, when exchanged at the agreed upon exchange ratio, shall equal that number of FEAC Class&nbsp;A Shares (or after the Assumption, Class&nbsp;A Common shares of the Company) that the holders of such convertible notes would have received if they
subscribed for FEAC Class&nbsp;A Shares (or after the Assumption, Class&nbsp;A Common shares of the Company) in the PIPE Financing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective the day before Closing, the Company will issue to the holders of FEAC Class&nbsp;A Shares and FEAC Class&nbsp;B shares
(collectively, the &#147;FEAC Shares&#148;) Class&nbsp;A common shares in the capital of the Company in exchange for such holders&#146; FEAC Shares. FEAC will thereby become a wholly-owned subsidiary of the Company. The Company will also assume the
FEAC Warrants to purchase one FEAC Share, pursuant to a warrant assignment, assumption and amendment agreement to be entered into at closing. The Company will then redeem its Class&nbsp;B common shares held by its sole shareholder for an amount
equal to the amount of capital that the sole shareholder of the Company subscribed to. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On the date the Closing occurs, enGene will
amalgamate with a subsidiary of the Company (&#147;Can Merger Sub&#148;) in accordance with the terms of the plan of arrangement (the &#147;Amalgamation&#148;), and pursuant to the Amalgamation, each share outstanding of Can Merger Sub immediately
prior to the Amalgamation shall be exchanged for one common share in the authorized share capital of the amalgamated entity at an agreed upon exchange ratio set out in the in Amalgamation. Additionally, each enGene share and warrant outstanding
immediately prior to the Amalgamation will be exchanged for Class&nbsp;A common shares and warrants of the Company at an agreed upon exchange ratio set out in the Amalgamation. Upon the completion of the Amalgamation, enGene will become a wholly
owned subsidiary of the Company and the Company will continue from being a corporation under and governed by the Canada Business Corporations Act to a company continued to and governed by the Business Corporation Act (British Columbia). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Business Combination Agreement, as described above, there is a commitment for enGene Holdings, Inc. to issue its own common
shares and warrants upon the consummation of the Business Combination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-132 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE HOLDINGS INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN USD) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Summary of Significant Accounting Policies </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
accompanying financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (&#147;GAAP&#148;). Any reference in these notes to applicable guidance is meant to refer to the authoritative
GAAP as found in the Accounting Standards Codification (&#147;ASC&#148;) and as amended by Accounting Standards Updates (&#147;ASU&#146;s&#148;) of the Financial Accounting Standards Board (&#147;FASB&#148;). The financial statements are expressed
in US dollars. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company&#146;s cash consists of cash received for the issuance of the Class&nbsp;B redeemable common shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Foreign Currency Translation
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company maintains its financial statements in the Company&#146;s functional currency, which is the United States Dollar
(&#147;USD&#148;). Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency at rates of exchange prevailing at the balance sheet dates.
<FONT STYLE="white-space:nowrap">Non-monetary</FONT> assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing at the date of the transaction. Exchange gains or losses
arising from foreign currency transactions are included in other (income) expense, net in the statement of operations and comprehensive loss. The Company reported no realized and $394 unrealized foreign currency transaction losses for the period
ended July&nbsp;31, 2023. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Loss Per Share </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period.
Diluted net loss per share is computed using the weighted-average number of common shares outstanding during the period and, if dilutive, the weighted-average number of potential shares of common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accrued expenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">Accrued
expenses recorded on the Company&#146;s balance sheet represent legal, accounting, and audit fees incurred as part of the formation of the entity and regulatory requirements for the preparation of the Company&#146;s financial statements, which are
unpaid as of July&nbsp;31, 2023. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the
Company&#146;s financial statements. Under this method, deferred tax assets and liabilities are determined based on differences between the financial statement carrying amounts and the tax bases of the assets and liabilities using the enacted tax
rates in effect in the years in which the differences are expected to reverse. A valuation allowance against deferred tax assets is recorded if, based on the weight of the available evidence, it is more likely than not that some or all of the
deferred tax assets will not be realized. The Company has recorded a valuation allowance against its deferred tax assets as of July&nbsp;31, 2023 because the Company&#146;s management believes that it is more likely than not that these assets will
not be fully realized. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-133 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE HOLDINGS INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO THE FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(AMOUNTS IN USD) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accounts for uncertainty in income taxes recognized in the financial statements
by applying a <FONT STYLE="white-space:nowrap">two-step</FONT> process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination
by the taxing authorities. If the tax position is deemed <FONT STYLE="white-space:nowrap">more-likely-than-not</FONT> to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The
amount of benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax
benefits, that are considered appropriate as well as the related net interest and penalties. As of July&nbsp;31, 2023 no accrued interest or penalties have been recorded. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Related Party Transactions </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is a related party to enGene Inc., as the Company&#146;s sole director is also an executive of enGene Inc. enGene Inc. has paid
certain expenses on the Company&#146;s behalf. The amounts owed to enGene Inc. bear no interest, are due on demand and are presented within Due to related party on the Company&#146;s Balance Sheet. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Subsequent events </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has evaluated subsequent events through August 9, 2023, the date these financial statements were available to be issued. The
Company concluded that no additional subsequent events have occurred that require disclosure. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-134 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="ii459793_1"></A>Annex A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B><I>Execution Version</I></B><B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MAY&nbsp;16, 2023 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORBION EUROPEAN ACQUISITION CORP. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>and </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE INC.
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>and </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE
HOLDINGS INC. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Business Combination Agreement </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">PAGE</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP>Certain Definitions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>1.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Definitions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>1.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Construction; Interpretation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP>Business Combination</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>The Arrangement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>The Interim Order</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>The Company Shareholders Meeting</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>The Company Information Circular</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>The Final Order</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Court Proceedings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>The Sponsor Loans Conversion</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>The Class&nbsp;B Conversion</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>The Cayman Reorganization</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Notice to FEAC Shareholders Delivering Written Objection</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>FEAC Shareholder Dissent Rights</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>The FEAC Reorganization</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>The Notes <FONT STYLE="white-space:nowrap">Set-Off</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.14</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>FEAC Liquidation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Allocation Schedule</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.16</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Exchange Agent</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.17</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Withholding</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.18</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Transfer Taxes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.19</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Transaction Structure</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP>Representations and Warranties Relating to the Group Companies</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Organization and Qualification</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Capitalization of the Group Companies</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Authority</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Financial Statements; Undisclosed Liabilities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Consents and Requisite Governmental Approvals; No Violations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Permits</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Material Contracts</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Absence of Changes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Litigation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Compliance with Applicable Law</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Employee Plans</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Environmental Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Intellectual Property</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.14</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Labor Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Insurance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.16</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tax Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.17</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Brokers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.18</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Real and Personal Property</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.19</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Transactions with Affiliates</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.20</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Suppliers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.21</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Data Privacy and Security</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.22</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Compliance with Sanctions Laws, Anti-Corruption Laws and Anti-Money Laundering Laws</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.23</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Information Supplied</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.24</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Investigation; No Other Representations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.25</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Regulatory Compliance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.26</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>EXCLUSIVITY OF REPRESENTATIONS AND WARRANTIES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP>Representations and Warranties Relating to FEAC and Can Merger Sub</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Organization and Qualification</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Capitalization</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Authority</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Board Approval; Vote Required</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Consents and Requisite Governmental Approvals; No Violations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>SEC Filings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Internal Controls; Listing; Financial Statements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Trust Account</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Listing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Contracts</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Absence of Changes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Litigation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Compliance with Applicable Law</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.14</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Compliance with Sanctions Laws, Anti-Corruption Laws and Anti-Money Laundering Laws</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Employees</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.16</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Not an Investment Company</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.17</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Business Activities; Assets</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.18</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Undisclosed Liabilities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.19</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tax Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.20</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Brokers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.21</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Transactions with Affiliates</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.22</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Information Supplied</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.23</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Investigation; No Other Representations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.24</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>EXCLUSIVITY OF REPRESENTATIONS AND WARRANTIES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP>Covenants</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Conduct of Business of the Company and FEAC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Efforts to Consummate</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Confidentiality and Access to Information</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Public Announcements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tax Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Exclusive Dealing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Preparation of Registration Statement / Proxy Statement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>FEAC Shareholder Approval</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>FEAC Board Recommendation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Exchange Listing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Trust Account</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>FEAC Indemnification; Directors&#146; and Officers&#146; Insurance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Company Indemnification; Directors&#146; and Officers&#146; Insurance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.14</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Resignations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Post-Closing Governance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.16</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Financials</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.17</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Newco Equity Incentive Plan</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.18</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Newco Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.19</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Subscription Agreements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.20</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Privacy Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.21</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>FEAC Related Party Agreements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.22</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section&nbsp;16 Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.23</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Disclosure of Certain Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.24</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Repayment of the Working Capital Loan Note and Extension Loan Notes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.25</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Can Merger Sub Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.26</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Cayman Merger Sub Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP>Conditions to Consummation of the Transactions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Conditions to the Obligations of the Parties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Other Conditions to the Obligations of FEAC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Other Conditions to the Obligations of the Company</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>6.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Frustration of Closing Conditions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-iii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP>Termination</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Termination</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Effect of Termination</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP>Miscellaneous</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>8.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap">Non-Survival</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>8.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Entire Agreement; Assignment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>8.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Amendment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>8.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Notices</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>8.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Governing Law</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>8.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Fees and Expenses</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>8.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Exhibits and Schedules</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>8.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Parties in Interest</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>8.9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Severability</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>8.10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Counterparts; Electronic Signatures</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>8.11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Knowledge of Company; Knowledge of FEAC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>8.12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Recourse</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>8.13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Extension; Waiver</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>8.14</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Waiver of Jury Trial</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>8.15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Submission to Jurisdiction</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>8.16</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Remedies</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>8.17</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Trust Account Waiver</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certain schedules and other similar attachments to this exhibit have been omitted. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="5%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company Arrangement Resolution</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">A-1</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Plan of Arrangement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">B-1</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit <FONT STYLE="white-space:nowrap">C-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Form of Subscription Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">C-1-1</FONT></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit <FONT STYLE="white-space:nowrap">C-2</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Form of Side Letter Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">C-2-1</FONT></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Exhibit&nbsp;C-3&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Form of <FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">C-3-1</FONT></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Form of Registration Rights Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">D-1</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit <FONT STYLE="white-space:nowrap">E-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Form of Company Voting Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">E-1-1</FONT></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit <FONT STYLE="white-space:nowrap">E-2</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Form of Company <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">E-2-1</FONT></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit <FONT STYLE="white-space:nowrap">E-3</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Form of FEAC Voting Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">E-3-1</FONT></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit F</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Form of Newco Articles</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">F-1</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit G</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Form of Newco Equity Incentive Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">G-1</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exhibit H</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capitalization Table</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">H-1</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-iv </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BUSINESS COMBINATION AGREEMENT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This BUSINESS COMBINATION AGREEMENT (this &#147;<B>Agreement</B>&#148;), dated as of May&nbsp;16, 2023, is made by and among Forbion European
Acquisition Corp., a Cayman Islands exempted company (&#147;<B>FEAC</B>&#148;), enGene Inc., a corporation existing under the laws of Canada (the &#147;<B>Company</B>&#148;; prior to the Amalgamation, references to the &#147;<B>Company</B>&#148;
shall be to enGene Inc., and following the Amalgamation, references to the &#147;<B>Company</B>&#148; shall be to the corporation resulting from the amalgamation of enGene Inc. and Can Merger Sub (as defined below) pursuant to the Plan of
Arrangement) and enGene Holdings Inc., a corporation incorporated under the laws of Canada (&#147;<B>Newco</B>&#148;). FEAC, the Company and Newco shall be referred to herein from time to time collectively as the &#147;<B>Parties</B>&#148; and each,
a &#147;<B>Party</B>&#148;. Capitalized terms used but not otherwise defined herein have the meanings set forth in Section&nbsp;1.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, FEAC is a blank check company incorporated as a Cayman Islands exempted company on August&nbsp;9, 2021 and incorporated for the
purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the sole shareholder of Newco (the &#147;<B>Formation Shareholder</B>&#148;) holds 10 Class&nbsp;B common shares of Newco temporarily
merely to facilitate the incorporation of Newco in anticipation of the Transactions and not for the purpose of having any economic or other interest in Newco; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, prior to the date that is two Business Days prior to the Closing Date, (i)&nbsp;FEAC shall (a)&nbsp;incorporate or cause to be
incorporated Can Merger Sub as a corporation under the laws of Canada and a direct wholly owned subsidiary of FEAC incorporated solely for purposes of effecting the Transactions (&#147;<B>Can Merger Sub</B>&#148;) and (b)&nbsp;after the
incorporation of Can Merger Sub, cause Can Merger Sub to execute a Joinder Agreement (as defined below) and become a party to this Agreement as a &#147;<B>Party</B>&#148; hereto and (ii)&nbsp;Newco shall (a)&nbsp;incorporate or cause to be
incorporated Cayman Merger Sub as a Cayman Islands exempted company and a direct wholly-owned subsidiary of Newco incorporated solely for purposes of effecting the Transactions (&#147;<B>Cayman Merger Sub</B>&#148;) and (b)&nbsp;after completion of
the incorporation of Cayman Merger Sub, cause Cayman Merger Sub to execute a Joinder Agreement and become a party to this Agreement as a &#147;<B>Party</B>&#148; hereto; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, pursuant to the Governing Documents of FEAC, FEAC is required to provide an opportunity for its public shareholders to have their
outstanding FEAC Class&nbsp;A Shares redeemed on the terms and subject to the conditions set forth therein in connection with obtaining the FEAC Shareholder Approval; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, as of the date of this Agreement, Forbion Growth Sponsor FEAC I B.V., a private limited liability company incorporated in The
Netherlands (the &#147;<B>Sponsor</B>&#148;), owns 3,162,500 FEAC Class&nbsp;B Shares and 5,195,000 FEAC Private Placement Warrants; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company entered into a Note Purchase Agreement dated as of October&nbsp;20, 2022 by and among the Company, Forbion Capital Fund
III Cooperatief U.A. (&#147;<B>Forbion Capital Fund III</B>&#148;), Fonds de Solidarit&eacute; des Travailleurs du Qu&eacute;bec (F.T.Q.) (&#147;<B>FSTQ</B>&#148;), Lumira Ventures III, L.P. (&#147;<B>Lumira III</B>&#148;), Lumira Ventures III
(International), L.P. (&#147;<B>Lumira International III</B>&#148;), Merck Lumira Biosciences Fund, L.P. (&#147;<B>Merck</B>&#148;), Merck Lumira Biosciences Fund (Qu&eacute;bec), L.P. (&#147;<B>Merck Qu&eacute;bec</B>&#148; and together with,
Merck, FSTQ, Lumira III, Lumira International III and Forbion Capital Fund III, collectively the &#147;<B>2022 Noteholders</B>&#148;) (the &#147;<B>2022 Note Purchase Agreement</B>&#148;) pursuant to which the Company issued $18.4&nbsp;million of
convertible promissory notes (each a &#147;<B>2022 Convertible Note</B>&#148; and collectively, the &#147;<B>2022 Convertible Notes</B>&#148;) to the 2022 Noteholders in substantially the form attached to the 2022 Note Purchase Agreement on the
terms and conditions set forth therein (the &#147;<B>2022 Financing</B>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company and each 2022 Noteholder have
entered into amended and restated convertible promissory notes on or about the date hereof, to amend and restate the 2022 Convertible Notes (each an &#147;<B>Amended 2022 Convertible Note</B>&#148; and collectively, the &#147;<B>Amended 2022
Convertible Notes</B>&#148;) pursuant to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which (i)&nbsp;the Amended 2022 Convertible Notes are, among other things, convertible into that number of common shares of the Company that, when exchanged at the Company Exchange Ratio, shall
equal that number of FEAC Class&nbsp;A Shares (or after the Assumption (as defined below), Newco Shares) that the holders of the Amended 2022 Convertible Notes would have received if they subscribed for FEAC Class&nbsp;A Shares (or after the
Assumption, Newco Shares) on the same terms as the PIPE Financing, and (ii)&nbsp;each 2022 Noteholder received warrants of the Company in consideration of certain amendments set forth in each Amended 2022 Convertible Note (the &#147;<B>2022
Warrants</B>&#148; and, together with the Amended 2022 Convertible Notes, the &#147;<B>Amended 2022 Financing</B>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS,
concurrently with the execution and delivery of this Agreement, the Sponsor and Investissement Qu&eacute;bec (&#147;<B>IQ</B>&#148;) are entering into agreements with the Company, pursuant to which the Sponsor and IQ will purchase, in one or more
closings, (i)&nbsp;convertible promissory notes of the Company (the &#147;<B>Original 2023 Convertible Notes</B>&#148;) that will, among other things, convert into that number of common shares of the Company that, when exchanged at the Company
Exchange Ratio, shall equal that number of FEAC Class&nbsp;A Shares (or after the Assumption, Newco Shares) that the holders of the Original 2023 Convertible Notes would have received if they subscribed for FEAC Class&nbsp;A Shares (or after the
Assumption, Newco Shares) on the same terms as the PIPE Financing, and (ii)&nbsp;warrants to acquire common shares of the Company (the &#147;<B>Original 2023 Warrants</B>&#148; and, together with the Original 2023 Convertible Notes, the
&#147;<B>Original 2023 Financing</B>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company entered into a Note Purchase Agreement dated as of April&nbsp;4, 2023
by and among the Company, Forbion Capital Fund III, FSTQ, Lumira III, Lumira International III, Lumira Ventures IV, L.P., Lumira Ventures IV (International), L.P., Merck, Merck Qu&eacute;bec (collectively, with respect to the 2023 Subordinated
Financing (as defined below), the &#147;<B>2023 Noteholders</B>&#148;) (the &#147;<B>2023 Subordinated Note Purchase Agreement</B>&#148;) pursuant to which the Company issued $8.0&nbsp;million of subordinated promissory notes (each a &#147;<B>2023
Subordinated Note</B>&#148; and collectively, the &#147;<B>2023 Subordinated Notes</B>&#148;) to the 2023 Noteholders in substantially the form attached to the 2023 Subordinated Note Purchase Agreement on the terms and conditions set forth therein
(the &#147;<B>2023 Subordinated Financing</B>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, concurrently with the execution and delivery of this Agreement, the
Company is entering into agreements with the 2023 Noteholders pursuant to which the Company will repay the 2023 Subordinated Notes by issuing to each 2023 Noteholder (i)&nbsp;an amount of convertible promissory notes of the Company substantially in
the same form and on the same terms as the Original 2023 Convertible Notes (the &#147;<B>Additional 2023 Convertible Notes</B>&#148; and, together with the Original 2023 Convertible Notes, the &#147;<B>2023 Convertible Notes</B>&#148;), and
(ii)&nbsp;a number of warrants to acquire common shares of the Company substantially in the same form and on the same terms as the Original 2023 Warrants (the &#147;<B>Additional 2023 Warrants</B>&#148; and, together with the Original 2023 Warrants,
the &#147;<B>2023 Warrants</B>&#148;), corresponding, in the aggregate, to the principal amount of 2023 Subordinated Notes held by such 2023 Noteholder (the &#147;<B>Additional 2023 Financing</B>&#148; and, together with the Original 2023 Financing,
the &#147;<B>2023 Financing</B>&#148;; and the 2023 Financing together with the Amended 2022 Financing, the &#147;<B>Convertible Bridge Financing</B>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, concurrently with the execution and delivery of this Agreement, certain investors (the &#147;<B>PIPE Investors</B>&#148;) are each
entering into a subscription agreement, substantially in the form attached hereto as Exhibit <FONT STYLE="white-space:nowrap">C-1</FONT> (the &#147;<B>Subscription Agreement</B>&#148; and collectively, the &#147;<B>Subscription Agreements</B>&#148;)
with FEAC and Newco, pursuant to which, among other things, the PIPE Investors have agreed, subject to the completion of each element of the Transactions (other than those Transactions that are scheduled to be completed following the Closing), to
subscribe for and purchase, and FEAC has agreed that it will issue and sell to the PIPE Investors (which obligation will be assumed (the &#147;<B>Assumption</B>&#148;) by Newco after the completion of the FEAC Reorganization and prior to the
consummation of the PIPE Financing) the number of FEAC Class&nbsp;A Shares (or after the Assumption, Newco Shares) provided for in the applicable Subscription Agreement (as amended by the applicable Side Letter Agreement (as defined below)) in
exchange for the purchase price set forth therein (the aggregate purchase price under the Subscription Agreements and the Side Letter Agreements, the &#147;<B>PIPE Financing Amount</B>&#148;, and the equity financing under the Subscription
Agreements and the Side Letter </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Agreements is hereinafter referred to as the &#147;<B>PIPE Financing</B>&#148;), in each case on the terms and subject to the conditions set forth in the relevant Subscription Agreement and Side
Letter Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, concurrently with the execution and delivery of this Agreement, each PIPE Investor is entering into a side
letter agreement, substantially in the form attached hereto as Exhibit <FONT STYLE="white-space:nowrap">C-2</FONT> (the &#147;<B>Side Letter Agreement</B>&#148; and collectively, the &#147;<B>Side Letter Agreements</B>&#148;) with FEAC and Newco to
amend the relevant Subscription Agreement and which, together with the relevant Subscription Agreement, will reflect the total number of FEAC Class&nbsp;A Shares and FEAC Warrants to be issued by FEAC (or after the Assumption, the total number of
Newco Shares and Newco Warrants to be issued by Newco) pursuant to the PIPE Financing in consideration of the purchase price set forth in the relevant Subscription Agreement, in each case on the terms and subject to the conditions set forth in the
relevant Subscription Agreement and Side Letter Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, concurrently with the execution and delivery of this Agreement,
Newco, FEAC and a FEAC Shareholder are entering into a <FONT STYLE="white-space:nowrap">non-redemption</FONT> agreement, substantially in the form attached hereto as Exhibit <FONT STYLE="white-space:nowrap">C-3</FONT> (the &#147;<B><FONT
STYLE="white-space:nowrap">Non-Redemption</FONT> Agreement</B>&#148;), pursuant to which, among others, FEAC will issue additional FEAC Class A Shares and FEAC Warrants (or after the Assumption, Newco will issue additional Newco Shares and Newco
Warrants) to such FEAC Shareholder (the &#147;<B><FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Transaction</B>&#148;) in consideration of such FEAC Shareholder&#146;s commitment not to redeem its FEAC Class&nbsp;A Shares in connection with
the FEAC Shareholder Approval, on the terms and subject to the conditions set forth in the <FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, assuming that the aggregate principal amount outstanding under the Working Capital Loan Note and any Extension Loan Notes exceeds
$1,500,000 on the day which is two (2)&nbsp;Business Days prior to the Closing Date, FEAC shall cause the Sponsor (or its Affiliate or designee, as applicable), as payee of the Working Capital Loan Note and any Extension Loan Notes, to elect to
convert an amount equal to $1,500,000 of the aggregate principal amount outstanding under the Working Capital Loan Note and any Extension Loan Notes, taken together, into additional FEAC Private Placement Warrants which upon such election will be
issued by FEAC to the Sponsor (or its Affiliate or designee, as applicable) immediately prior to the Surrender on the day which is two (2)&nbsp;Business Days prior to the Closing Date, in each case in accordance with the FEAC Warrant Agreement and
the relevant promissory note governing the Working Capital Loan Note and/or any Extension Loan Notes, as applicable (the &#147;<B>Sponsor Loans Conversion</B>&#148;, following which the Sponsor is expected to own 6,195,000 FEAC Private Placement
Warrants); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, concurrently with the execution and delivery of this Agreement, the Sponsor, FEAC and the other parties thereto are
entering into the sponsor and insiders letter agreement (the &#147;<B>Sponsor and Insiders Letter Agreement</B>&#148;), pursuant to which, among other things, the Sponsor has agreed to surrender, after giving effect to the Sponsor Loans Conversion,
1,789,004 FEAC Class&nbsp;B Shares and 5,463,381 FEAC Private Placement Warrants, as a contribution to the capital of FEAC and for no consideration, effective immediately prior to the Class&nbsp;B Conversion on the day which is two (2)&nbsp;Business
Days prior to the Closing Date, in each case, on the terms and conditions set forth in this Agreement and the Sponsor and Insiders Letter Agreement (the &#147;<B>Surrender</B>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, on the day which is two (2)&nbsp;Business Days prior to the Closing Date, each FEAC Class&nbsp;B Share that remains outstanding
following the Surrender of the 1,789,004 FEAC Class&nbsp;B Shares held by the Sponsor, as provided in the Sponsor and Insiders Letter Agreement, shall be exchanged (the &#147;<B>Class</B><B></B><B>&nbsp;B Conversion</B>&#148;) for one FEAC
Class&nbsp;A Share; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, on the day which is one (1)&nbsp;Business Day prior to the Closing Date, Cayman Merger Sub will merge with
and into FEAC with FEAC as the surviving entity pursuant to a plan of merger under the laws of the Cayman Islands (the &#147;<B>Cayman Merger</B>&#148;), as follows: (i)&nbsp;Newco will issue to the holders of FEAC Shares (including the Sponsor but
excluding the holders of any Dissenting FEAC Shares) Newco Shares in exchange for such holders&#146; FEAC Shares and such FEAC Shares will not be cancelled but will be transferred to Newco, (ii)&nbsp;FEAC will thereby become a wholly-owned
subsidiary of Newco, and (iii)&nbsp;each issued share of Cayman </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Merger Sub will be exchanged for a FEAC Class&nbsp;A Share of FEAC as the surviving entity and Cayman Merger Sub (having merged into FEAC) will cease to exist as a separate entity by virtue of
the Cayman Merger; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS concurrently with the Cayman Merger, and effective at the same time the Cayman Merger becomes effective under
the Cayman Islands law, (i)&nbsp;Newco will assume the FEAC Warrants (as so assumed, Newco Warrants) pursuant to the Warrant Assignment, Assumption and Amendment Agreement, (ii)&nbsp;FEAC as the entity surviving the Cayman Merger will issue to Newco
a <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing demand promissory note payable denominated in CDN$ having a principal amount equal to the fair market value of the FEAC Warrants assumed by Newco (as so assumed, Newco Warrants)
(&#147;<B>Note 3</B>&#148;) in consideration of the assumption by Newco of obligations under the FEAC Warrants (as so assumed, Newco Warrants), and (iii)&nbsp;Newco will redeem the initial Newco Shares held by the Formation Shareholder for an amount
equal to the amount of capital that the Formation Shareholder contributed for purposes of the incorporation of Newco (such transactions, together with the Cayman Merger, the &#147;<B>Cayman Reorganization</B>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, following the Cayman Reorganization, FEAC will file an election to change its classification for U.S. federal income tax purposes
from a corporation to an entity disregarded as separate from its owner Newco, to be effective as of the beginning of the Closing Date (the &#147;<B>U.S. Entity Classification Election</B>&#148; and, together with the Cayman Reorganization, the
&#147;<B>FEAC Reorganization</B>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, on the Closing Date and pursuant to the Plan of Arrangement, subsequent to the FEAC
Reorganization becoming effective and prior to the consummation of the PIPE Financing, FEAC will loan to Newco an amount equal to the total funds held in its Trust Account (after deducting the amounts owed to public shareholders of FEAC who have
properly exercised their redemption rights, a reasonable estimate of the amounts to be paid for any Dissenting FEAC Shares, and the deferred discount owed to the underwriters of FEAC&#146;s IPO), less the principal amount of Note 3 (together, the
&#147;<B>Loan Amount</B>&#148;) in consideration for which Newco will issue a CDN$ denominated <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing demand promissory note to FEAC having a principal amount equal to the Loan Amount converted
to its Canadian dollar equivalent based on the C$:U.S.$ Bank of Canada daily exchange rate on the Business Day immediately prior to the Closing Date (&#147;<B>Note 1</B>&#148;), following which FEAC will sell to Newco, and Newco will purchase, all
of the outstanding common shares of Can Merger Sub for a purchase price of CDN$10 (the &#147;<B>Can Merger Sub Share Sale</B>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, on the Closing Date and pursuant to the Plan of Arrangement, following the Can Merger Sub Share Sale but prior to the Amalgamation,
the PIPE Financing shall be consummated pursuant to the Subscription Agreements and the Side Letter Agreements and the <FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Transaction shall be consummated in accordance with the <FONT
STYLE="white-space:nowrap">Non-Redemption</FONT> Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, on the Closing Date and pursuant to the Plan of Arrangement, the
Amended 2022 Convertible Notes and 2023 Convertible Notes will automatically convert, concurrent with the consummation of the PIPE Financing, into that number of common shares of the Company that, when exchanged at the Company Exchange Ratio shall
equal that number of FEAC Class&nbsp;A Shares (or after the Assumption, Newco Shares) that the holders of the Amended 2022 Convertible Notes and 2023 Convertible Notes would have received if they subscribed for FEAC Class&nbsp;A Shares (or after the
Assumption, Newco Shares) on the same terms as the PIPE Financing; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, on the Closing Date and pursuant to the Plan of Arrangement,
after the consummation of the PIPE Financing and the conversion of the Company Convertible Notes, Can Merger Sub and the Company will amalgamate in accordance with the terms of the Plan of Arrangement (the &#147;<B>Amalgamation</B>&#148;), and
pursuant to the Amalgamation, (i)&nbsp;each Company Share outstanding immediately prior to the Amalgamation shall be exchanged for Newco Shares per the Company Exchange Ratio and each Company Warrant outstanding immediately prior to the Amalgamation
shall be exchanged for Newco Warrants per the Company Exchange Ratio; (ii)&nbsp;each Can Merger Sub share outstanding immediately prior to the Amalgamation shall be exchanged for one common share in the authorized share capital of the amalgamated
entity; (iii)&nbsp;in consideration for the issuance of Newco Shares, the amalgamated entity shall issue its common shares to Newco, in each case upon and subject to the other terms </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and conditions set forth in this Agreement, the Plan of Arrangement and in accordance with the provisions of applicable Law; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, on the Closing Date and pursuant to the Plan of Arrangement, following the Amalgamation, Newco will continue from being a corporation
incorporated under and governed by the <I>Canada Business Corporations Act</I> to a company continued to and governed by the <I>Business Corporations Act </I>(British Columbia) (the &#147;<B>Continuance</B>&#148;) and, in connection with the
Continuance, the articles of Newco shall be amended to reflect the requirements of the continued jurisdiction, among other things; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, on the Closing Date, and prior to the Amalgamation, the Newco Shares and Newco Warrants shall have been approved for listing on
Nasdaq or such other Exchange as agreed to by FEAC and the Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, immediately following the Closing Date, FEAC will repurchase
shares held by Newco in an aggregate amount equal to Note 1 and in consideration therefor issue to Newco a CDN$ denominated <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing demand promissory note in a principal amount equal to the
outstanding principal amount of Note 1 (&#147;<B>Note 2</B>&#148;), following which Note 1 and Note 2 (each having the same outstanding principal amount) will be set off by FEAC and Newco in full repayment of their respective principal amounts (the
&#147;<B>Notes <FONT STYLE="white-space:nowrap">Set-Off</FONT></B>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, following the Notes
<FONT STYLE="white-space:nowrap">Set-Off</FONT> becoming effective, Newco will transfer Note 3 to the Company in consideration for the issuance by the Company from treasury of additional common shares of the Company, following which FEAC will repay
the outstanding principal amount of Note 3, and subsequently be placed in liquidation in accordance with applicable Cayman law (the &#147;<B>Liquidation</B>&#148; and together with the Sponsor Loans Conversion, the Surrender, the Class&nbsp;B
Conversion, the Cayman Merger, the Cayman Reorganization, the FEAC Reorganization, the Assumption, the Can Merger Sub Share Sale, the Amalgamation, the PIPE Financing, the <FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Transaction and the
other transactions described above and contemplated by this Agreement, the Plan of Arrangement, the Subscription Agreements, the Side Letter Agreements, the <FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreement and the other Ancillary
Documents, the &#147;<B>Transactions</B>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, on or around the Closing Date, Newco, FEAC, the Sponsor Holders (as defined in
the Registration Rights Agreement) and the enGene Holders (as defined in the Registration Rights Agreement) will enter into an investor rights agreement, substantially in the form attached hereto as Exhibit D (the &#147;<B>Registration Rights
Agreement</B>&#148;), pursuant to which, among other things, the Sponsor Holders and the enGene Holders will be granted certain registration rights with respect to their respective Equity Securities of Newco, in each case, on the terms and subject
to the conditions therein; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the board of directors of FEAC (the &#147;<B>FEAC Board</B>&#148;) has (a)&nbsp;determined that the
Transactions are in the best interests of FEAC and fair to its shareholders, (b)&nbsp;approved this Agreement, the Ancillary Documents to which FEAC is or will be a party and the Transactions and (c)&nbsp;resolved to recommend, among other things,
approval of this Agreement and the Transactions by the holders of FEAC Shares entitled to vote thereon; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the board of directors
of the Company has (a)&nbsp;determined that the Transactions are in the best interests of the Company and fair to the Company Shareholders, (b)&nbsp;approved this Agreement, the Ancillary Documents to which the Company is or will be a party and the
Transactions, and (c)&nbsp;resolved to recommend, among other things, that the Company Shareholders vote in favor of the approval of this Agreement, the Transactions and the Company Arrangement Resolution; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the board of directors of Newco has unanimously (a)&nbsp;determined that the Transactions are fair to, and in the best interests of,
the Formation Shareholder and (b)&nbsp;approved this Agreement, the Ancillary Documents to which Newco is or will be a party and the Transactions; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Formation Shareholder has, as the sole shareholder of Newco, approved this Agreement, the Ancillary Documents to which Newco is
or will be a party and the Transactions; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, concurrently with the execution of this Agreement, certain Company Shareholders
(collectively, the &#147;<B>Supporting Company Shareholders</B>&#148;) will duly execute and deliver to FEAC and Newco a voting agreement, substantially in the form attached hereto as Exhibit <FONT STYLE="white-space:nowrap">E-1</FONT> and a <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreement substantially in the form attached hereto as Exhibit <FONT STYLE="white-space:nowrap">E-2</FONT> (collectively, the &#147;<B>Company Transaction Support Agreements</B>&#148;), pursuant to which,
among other things, each such Supporting Company Shareholder will agree to vote in favor of the Transactions, the entering into and execution by the Company of this Agreement and the Company Arrangement Resolution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, concurrently with the execution of this Agreement, the Sponsor and the directors and officers of FEAC have duly executed and
delivered to the Company and Newco a voting agreement, substantially in the form attached hereto as Exhibit <FONT STYLE="white-space:nowrap">E-3</FONT> (collectively, the &#147;<B>FEAC Transaction Support Agreement</B>&#148; and, together with the
Company Transaction Support Agreements, the &#147;<B>Transaction Support Agreements</B>&#148;), pursuant to which, among other things, each such person agrees to vote in favor of the Transactions and the entering into and execution by FEAC of this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:Times New Roman">WHEREAS the resulting Newco ownership following the Transactions is directionally set out in the capitalization table attached
hereto as Exhibit H, which exhibit may be amended by mutual written agreement of the Parties from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">time-to-time</FONT></FONT> to reflect any updates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the premises and the mutual promises set forth herein and for other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the Parties, each intending to be legally bound, hereby agree as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>C<SMALL>ERTAIN</SMALL> D<SMALL>EFINITIONS</SMALL> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Definitions</I><I>. </I>As used in this Agreement, the following terms have the respective meanings set
forth below. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>2022 Convertible Note</B>&#148; and &#147;<B>2022 Convertible Notes</B>&#148; has the meaning set
forth in the recitals to this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>2022 Financing</B>&#148; has the meaning set forth in the recitals to this Agreement.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>2022 Note Purchase Agreement</B>&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>2022 Noteholders</B>&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>2022 Warrants</B>&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>2023 Convertible Notes</B>&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>2023 Financing</B>&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>2023 Noteholders</B>&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>2023 Subordinated Financing</B>&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>2023 Subordinated Note</B>&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>2023 Subordinated Note Purchase Agreement</B>&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>2023 Warrants</B>&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Additional 2023 Convertible Notes</B>&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Additional 2023 Financing</B>&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Additional 2023 Warrants</B>&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Additional FEAC SEC Reports</B>&#148; has the meaning set forth in Section&nbsp;4.6. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Adjournment Proposal</B>&#148; has the meaning set forth in Section&nbsp;5.8. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Affiliate</B>&#148; means, with respect to any Person, any other Person who
directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, such Person. The term &#147;control&#148; means the possession, directly or indirectly, of the power to direct or cause the
direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise, and the terms &#147;controlled&#148; and &#147;controlling&#148; have meanings correlative thereto. Notwithstanding
the foregoing or anything to the contrary herein, any portfolio company or entity managed or controlled by any investment vehicle owned, controlled or managed by Forbion Group Holding B.V. or any of its Affiliates (other than Can Merger Sub and the
Sponsor) shall not be considered an Affiliate of FEAC. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Aggregate Closing PIPE Proceeds</B>&#148; means the sum of the cash
proceeds to be received by Newco in respect of the PIPE Financing on the Closing Date and the cash proceeds actually received by the Company in respect of the Convertible Bridge Financing prior to the Closing Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Aggregate Exercise Price</B>&#148; means the aggregate exercise price of the Company Options that will be exchanged for Rollover
Equity Awards, converted to its U.S. dollar equivalent based on the C$:US$ Bank of Canada daily exchange rate on the Business Day immediately prior to the Closing Date, and rounding the resulting exercise price up to the nearest whole cent. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Aggregate Transaction Proceeds</B>&#148; means an amount equal to (a)&nbsp;the sum (without duplication) of (i)&nbsp;the aggregate
cash proceeds available for release to FEAC from the Trust Account in connection with the Transactions (after, for the avoidance of doubt, giving effect to all of the FEAC Shareholder Redemptions), (ii) the unrestricted cash on the balance sheet of
FEAC as of the Closing Date, and (iii)&nbsp;the Aggregate Closing PIPE Proceeds, minus (b)&nbsp;the sum (without duplication) of the Unpaid FEAC Expenses and the Unpaid FEAC Liabilities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Agreement</B>&#148; has the meaning set forth in the introductory paragraph to this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Allocation Schedule</B>&#148; has the meaning set forth in Section&nbsp;2.15(a). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Amalgamation</B>&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Amended 2022 Convertible Note</B>&#148; and &#147;<B>Amended 2022 Convertible Notes</B>&#148; has the meaning set forth in the
recitals to this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Amended 2022 Financing</B>&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Ancillary Documents</B>&#148; means the Plan of Arrangement, the Registration Rights Agreement, the Sponsor and Insiders Letter
Agreement, the Subscription Agreements, the Side Letter Agreements, the <FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreement, the Convertible Bridge Financing Documents, the Letter of Transmittal, the Transaction Support Agreements, the
Joinder Agreements, the Warrant Assignment, Assumption and Amendment Agreement, the Newco Warrant Agreement, the Working Capital Loan Note, any Extension Loan Note and each other agreement, document, instrument and/or certificate contemplated by
this Agreement executed or to be executed by the Parties in connection with the Transactions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Anti-Corruption Laws</B>&#148;
means, collectively, (a)&nbsp;the U.S. Foreign Corrupt Practices Act (FCPA), (b) the <I>Corruption of Foreign Public Officials Act</I> (Canada) and (c)&nbsp;any other applicable anti-bribery or anti-corruption Laws related to combatting bribery and
corruption. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Anti-Money Laundering Laws</B>&#148; means any applicable anti-money laundering and counter-terrorism Laws in all
applicable jurisdictions, the rules and regulations thereunder and any applicable related or similar rules, regulations or guidelines, issued, administered or enforced by any Governmental Entity, including without limitation, the <I>Criminal
Code</I> (Canada); the <I>Proceeds of Crime (Money Laundering) and Terrorist Financing Act </I>(Canada), the Bank Secrecy Act as amended by the USA Patriot Act, 18 U.S.C. &#167;&#167; 1956-1957, Cayman Islands Proceeds of Crime Act (As Revised) and
regulations and guidance thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Arrangement</B>&#148; means the arrangement under Section&nbsp;192 of the CBCA on the terms
and subject to the conditions set out in the Plan of Arrangement, subject to any amendments or variations to the Plan of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">
Arrangement made in accordance with the terms of this Agreement and the Plan of Arrangement or made at the direction of the Court in the Final Order with the prior written consent of FEAC and the
Company, such consent not to be unreasonably withheld, conditioned or delayed. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Arrangement Dissent Rights</B>&#148; means the
rights of dissent in respect of the Arrangement described in the Plan of Arrangement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Articles of Arrangement</B>&#148; means the
articles of arrangement of the Company in respect of the Arrangement, required by the CBCA to be sent to the Director after the Final Order is made, which shall include the Plan of Arrangement and otherwise be in a form and content satisfactory to
the Company and FEAC, each acting reasonably. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Assumption</B>&#148; has the meaning set forth in the recitals to this Agreement.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Audited Company Financial Statements</B>&#148; has the meaning set forth in Section&nbsp;3.4(a). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>BCA Proposal</B>&#148; has the meaning set forth in Section&nbsp;5.8. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Bridge Consideration</B>&#148; means (A)&nbsp;with respect to the Newco Shares, the number of Newco Shares equal to (i)&nbsp;the
number of Company Common Shares issued upon the conversion of the Company Convertible Notes in accordance with their terms, multiplied by (ii)&nbsp;the Company Exchange Ratio, and (B)&nbsp;with respect to the Newco Warrants, the number of Newco
Warrants equal to (i)&nbsp;the number of Company Warrants multiplied by (ii)&nbsp;the Company Exchange Ratio. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Business
Day</B>&#148; means a day, other than a Saturday or Sunday, on which commercial banks in New York, New York and Vancouver, British Columbia are open for the general transaction of business. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Canadian Prospectus</B>&#148; has the meaning set forth in Section&nbsp;5.7(b). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>CARES Act</B>&#148; means Coronavirus Aid, Relief, and Economic Security Act (Pub. L. <FONT STYLE="white-space:nowrap">116-136)</FONT>
and any administrative or other guidance published with respect thereto by any Governmental Entity. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Cayman Act</B>&#148; means
the Cayman Islands Companies Act (As Revised). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Cayman Exchange Ratio</B>&#148; means one for one (1:1). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Cayman Merger</B>&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Cayman Merger and Reorganization Proposal</B>&#148; has the meaning set forth in Section&nbsp;5.8. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Cayman Reorganization</B>&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>CBA</B>&#148; has the meaning set forth in Section&nbsp;3.14(d). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>CBCA</B>&#148; means the <I>Canada Business Corporations Act</I>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Change in Recommendation</B>&#148; has the meaning set forth in Section&nbsp;5.9. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Change in Recommendation Notice</B>&#148; has the meaning set forth in Section&nbsp;5.7(b). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Change in Recommendation Notice Period</B>&#148; has the meaning set forth in Section&nbsp;5.7(b). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Change of Control Transaction</B>&#148; means any transaction or series of related transactions (a)&nbsp;under which any Person(s),
directly or indirectly, acquires or otherwise purchases (i)&nbsp;another Person or any of its Affiliates or (ii)&nbsp;all or substantially all of the assets, businesses or equity securities of another Person, or (b) that results, directly or
indirectly, in the shareholders of a Person as of immediately prior to such transaction holding, in the aggregate, less than fifty percent (50%) of the voting shares of such Person (or any successor or parent company of such Person) immediately
after the consummation thereof (in the case of each of clause (a)&nbsp;and (b), whether by merger, consolidation, tender offer, recapitalization, purchase or issuance of equity securities, tender offer or otherwise). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Class</B><B></B><B>&nbsp;B Conversion</B>&#148; has the meaning set forth in the recitals to this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Closing</B>&#148; has the meaning set forth in Section&nbsp;2.1. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Closing Date</B>&#148; has the meaning set forth in Section&nbsp;2.1. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Closing Filing</B>&#148; has the meaning set forth in Section&nbsp;5.4(b). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Closing Press Release</B>&#148; has the meaning set forth in Section&nbsp;5.4(b). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>COBRA</B>&#148; means Part 6 of Subtitle B of Title I of ERISA, Section&nbsp;4980B of the Code and any similar state Law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Code</B>&#148; means the U.S. Internal Revenue Code of 1986, as amended. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company</B>&#148; means, prior to the Amalgamation, enGene Inc., and following the Amalgamation, the corporation resulting from the
amalgamation of enGene Inc. and Can Merger Sub pursuant to the Plan of Arrangement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Acquisition Proposal</B>&#148; means
(a)&nbsp;any transaction or series of related transactions under which any Person(s), directly or indirectly, acquires or otherwise purchases (i)&nbsp;the Company or any of its controlled Affiliates or (ii)&nbsp;all or a material portion of the
assets or business of the Company and its controlled Affiliates (in the case of each of clause (i)&nbsp;and (ii), whether by merger, consolidation, recapitalization, purchase or issuance of equity securities, tender offer or otherwise), or
(b)&nbsp;any equity investment in the Company or any of its controlled Affiliates pursuant to which any such Person would own or control, directly or indirectly, twenty percent (20%) or more of the voting power of the Company or any of its
controlled Affiliates immediately following such transaction. Notwithstanding the foregoing or anything to the contrary herein, none of this Agreement, the Ancillary Documents or the Transactions (including the PIPE Financing and the Convertible
Bridge Financing) shall constitute a Company Acquisition Proposal. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Arrangement Resolution</B>&#148; means the special
resolutions of the Company Shareholders approving the Plan of Arrangement, which is to be considered at the Company Shareholders Meeting, in substantially the form attached to this Agreement as Exhibit&nbsp;A. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Certificates</B>&#148; has the meaning set forth in Section&nbsp;2.16(a). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Change of Control Payment</B>&#148; means (a)&nbsp;any success, change of control, retention, transaction bonus or other
similar payment or amount to any Person as a result of or in connection with this Agreement or the Transactions or any other Change of Control Transaction (including any such payments or similar amounts that may become due and payable based upon the
occurrence of one or more additional circumstances, matters or events) or (b)&nbsp;any payments made or required to be made pursuant to or in connection with or upon termination of, and any fees, expenses or other payments owing or that will become
owing in respect of, any Company Related Party Transaction (in the case of each of clause (a)&nbsp;and (b), regardless of whether paid or payable prior to, at or after the Closing or in connection with or otherwise related to this Agreement or any
Ancillary Document). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Class</B><B></B><B>&nbsp;A Preferred Shares</B>&#148; means Class&nbsp;A Preferred shares in the
Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Class</B><B></B><B>&nbsp;B Preferred Shares</B>&#148; means Class&nbsp;B Preferred shares in the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Class</B><B></B><B>&nbsp;C Preferred Shares</B>&#148; means Class&nbsp;C Preferred shares in the Company issuable in series,
one series being designated Series 1 Class&nbsp;C Preferred Shares, one series being designated Series 2 Class&nbsp;C Preferred Shares, one series designated Series 3 Class&nbsp;C Preferred Shares and one series being designated Series 4
Class&nbsp;C Preferred Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Common Shareholder Agreements</B>&#148; means the common shareholder agreements of the
Company in the form attached to the Company Majority Shareholder Agreement, as amended, modified, restated, replaced or supplemented by the board of directors of the Company from time to time; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Common Shares</B>&#148; means common shares of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Consideration</B>&#148; means (A)&nbsp;with respect to the Newco Shares,
the number of Newco Shares equal to the portion of the Reference Value divided by the Reference Price that is attributable to the aggregate number of Company Shares issued and outstanding immediately prior to the Closing (not including, for the
avoidance of doubt, the number of Company Common Shares issuable upon conversion of the Convertible Bridge Financing) including any Company Equity Awards exercised prior to or in connection with Closing, and (B)&nbsp;with respect to the Rollover
Equity Awards, the number of Rollover Equity Awards equal to the portion of the Reference Value divided by the Reference Price that is attributable to the aggregate number of Company Equity Awards (whether vested or unvested), and in each case
without duplication of the Company Shares taken into account for calculating the Company Consideration in respect of the Newco Shares and Rollover Equity Awards. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Convertible Notes</B>&#148; means the Amended 2022 Convertible Notes and the 2023 Convertible Notes. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company D&amp;O Persons</B>&#148; has the meaning set forth in Section&nbsp;5.13(a). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Disclosure Schedules</B>&#148; means the disclosure schedules to this Agreement delivered to FEAC by the Group Companies on
the date of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Equity Award</B>&#148; means, as of any determination time, each Company Option, restricted
stock unit, stock appreciation, phantom equity, and each other award to any current or former director, manager, officer, employee, individual independent contractor or other individual service provider of any Group Company of rights of any kind to
receive any Equity Security of any Group Company or benefits measured in whole or in part by reference to any Equity Security of any Group Company, in each case, under any Company Equity Plan or otherwise that is outstanding. For the avoidance of
doubt, the Company Warrants shall not be considered a Company Equity Award. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Equity Plan</B>&#148; means, collectively,
(a)&nbsp;the amended and restated equity incentive plan of the Company dated June&nbsp;30, 2021 and as may be further amended and/or restated from time to time, and (b)&nbsp;each other plan that provides for the award to any current or former
director, manager, officer, employee, individual independent contractor or other individual service provider of any Group Company of rights of any kind to receive Equity Securities of any Group Company or benefits measured in whole or in part by
reference to Equity Securities of any Group Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Exchange Ratio</B>&#148; means the quotient obtained by dividing
(a)&nbsp;the Company Per Share Value, by (b)&nbsp;the Reference Price. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Expenses</B>&#148; means, as of any determination
time, the aggregate amount of fees, expense, commissions or other amounts incurred by or on behalf of, or otherwise payable by, whether or not due, any Group Company in connection with the negotiation, preparation or execution of this Agreement or
any Ancillary Documents, the performance of its covenants or agreements in this Agreement or any Ancillary Document or the consummation of the Transactions (including the PIPE Financing, Convertible Bridge Financing and the <FONT
STYLE="white-space:nowrap">Non-Redemption</FONT> Transaction), including (a)&nbsp;the fees and expenses of outside legal counsel, accountants, advisors, brokers, investment bankers, consultants, or other agents or service providers of any Group
Company, and (b)&nbsp;any other fees, expenses, commissions or other amounts that are expressly allocated to any Group Company pursuant to this Agreement or any Ancillary Document; <I>provided</I> that, notwithstanding the foregoing or anything to
the contrary herein, Company Expenses shall not include any FEAC Expenses or FEAC Liabilities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Financial
Statements</B>&#148; has the meaning set forth in Section&nbsp;3.4(b). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Fully Diluted Shares</B>&#148; means the sum of
(without duplication)&nbsp;(a) the aggregate number of Company Shares issued and outstanding immediately prior to the Closing (not including, for the avoidance of doubt, the number of Company Common Shares issuable upon conversion of the Convertible
Bridge Financing), and (b)&nbsp;the aggregate number of Company Shares issued or issuable upon exercise of all issued and outstanding Company Equity Awards (whether vested or unvested), including Company Equity Awards exercised prior to or in
connection with the Closing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Fundamental Representations</B>&#148; means the representations and
warranties set forth in Section&nbsp;3.1(a), and Section&nbsp;3.1(b), Section&nbsp;3.1(d) (Organization and Qualification), Section&nbsp;3.2(b) through Section&nbsp;3.2(c) (Capitalization of the Group Companies), Section&nbsp;3.3 (Authority),
Section&nbsp;3.8 (Absence of Changes), and Section&nbsp;3.17 (Brokers). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Information Circular</B>&#148; means the notice
of the Company Shareholders Meeting to be sent to the Company Shareholders, and the accompanying management information circular, including all schedules, appendices and exhibits to, and information incorporated by reference in such management
information circular, to be prepared in connection with the Company Shareholders Meeting, together with any amendments thereto or supplements thereof in accordance with the terms of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Intellectual Property</B>&#148; means the Company Owned Intellectual Property and the Company Licensed Intellectual Property.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company IT Systems</B>&#148; means any and all computers, Software, firmware, middleware, hardware, systems, workstations,
routers, hubs, switches, networks, communication systems and data communication lines, servers, network equipment and databases (including those that are used to Process data) and other information technology equipment and related systems and
services, including any outsourced systems, and all associated documentation, in each case, to the extent owned or controlled by (or purported to be owned or controlled by) or licensed or leased to (or purported to be licensed to or leased to) any
Group Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Licensed Intellectual Property</B>&#148; means any and all Intellectual Property Rights owned by any third
party that is licensed or sublicensed (or purported to be licensed or sublicensed) to any Group Company or for which any Group Company has obtained (or purported to have obtained) a covenant not to be sued. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Majority Shareholder Agreement</B>&#148; means the third amended and restated majority shareholders agreement dated
June&nbsp;29, 2021 between the Company, the holders of Company Class&nbsp;A Preferred Shares, the holders of Company Class&nbsp;B Preferred Shares and the holders of Company Class&nbsp;C Preferred Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Material Adverse Effect</B>&#148; means any change, event, effect or occurrence that, individually or in the aggregate with
any other change, event, effect or occurrence, has had or would reasonably be expected to have a material adverse effect on (i)&nbsp;the business, results of operations or financial condition of the Group Companies, taken as a whole or (ii)&nbsp;the
ability of the Company to consummate the Transactions, <I>provided, however</I>, that in the case of clause (i)&nbsp;none of the following, either alone or in combination, shall constitute or be taken into account in determining whether a Company
Material Adverse Effect has occurred or is reasonably expected to occur: any adverse change, event, effect or occurrence resulting from or related to (a)&nbsp;any change, development, condition or event generally affecting the industries or markets
in which the Group Companies operate, (b)&nbsp;general business or economic conditions in or affecting the United States, Canada or elsewhere, or changes therein, (c)&nbsp;any outbreak or escalation of war or hostilities, whether or not pursuant to
the declaration of a national emergency or war, or the occurrence in any place of any military or terrorist attack, sabotage, civil unrest, cyberterrorism, riots, prolonged demonstrations or public disorders, or changes in global, national,
regional, provincial, state or local political conditions, or any escalation or worsening thereof, (d)&nbsp;changes in the financial, banking, capital or securities markets generally in the United States, Canada or any other country or region in the
world, or changes therein, including changes in interest rates in the United States, Canada or any other country and changes in exchange rates for the currencies of any countries, (e)&nbsp;changes or proposed changes in, or changes or proposed
changes in the interpretation of, any applicable Laws, regulatory framework, IFRS or GAAP, (f)&nbsp;the negotiation, execution or delivery of this Agreement, public announcement of this Agreement or the pendency or consummation of the Transactions
(<I>provided</I> that the exception in this clause (f)&nbsp;shall not apply to the representations and warranties set forth in Section&nbsp;3.5(b) to the extent that its purpose is to address the consequences resulting from the public announcement
or pendency or consummation of the Transactions or the condition set forth in Section&nbsp;6.2(a) to the extent it relates to such representations and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">warranties), (g) any failure by any Group Company to meet, or changes to, any internal or
published budgets, projections, forecasts, estimates or predictions, including, but not limited to any predictions or results (expressly excluding any treatment-related severe adverse events, grade 4 or higher, as that such terms are used by the
FDA) related to any clinical studies or trials (although the underlying facts and circumstances resulting in such failure may be taken into account to the extent not otherwise excluded from this definition pursuant to clauses (a)&nbsp;through (f),
(h) or (i)), (h) any hurricane, tornado, flood, earthquake, tsunami, natural disaster, mudslides, wild fires, acts of God or other natural disasters or comparable events in the United States, Canada or any other country or region in the world, or
any escalation of the foregoing, (i)&nbsp;any epidemics, pandemics, disease outbreaks or quarantines, including <FONT STYLE="white-space:nowrap">COVID-19</FONT> or any <FONT STYLE="white-space:nowrap">COVID-19</FONT> Measures or any change in such <FONT
STYLE="white-space:nowrap">COVID-19</FONT> Measures or interpretations thereof following the date of this Agreement, (j)&nbsp;the taking of any action required by the terms of this Agreement or any Ancillary Document, (k)&nbsp;any actions taken or
omitted to be taken by a Group Company at the written request or with the prior written consent of FEAC, (l) ordinary course deterioration of the Company&#146;s cash position (although the underlying facts and circumstances resulting in such failure
may be taken into account to the extent not otherwise excluded from this definition pursuant to clauses (a)&nbsp;through (f), (h) or (i)), (m) any material breach of this Agreement or any Ancillary Document by FEAC or (n)&nbsp;any matter set forth
on Section&nbsp;1.1 of the Company Disclosure Schedules; <I>provided, however</I>, that if any change, event, effect or occurrence resulting from a matter described in any of the foregoing clauses (a)&nbsp;through (f), (h) or (i)&nbsp;materially and
disproportionately adversely effects the Group Companies, taken as a whole, relative to other comparable companies and entities operating in the industries or markets in which the Group Companies operate, such change, event, effect or occurrence may
be taken into account in determining whether a Company Material Adverse Effect has occurred but only to the extent of the disproportionate effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company <FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliates</B>&#148; means, collectively, each Company Related Party and
each former, current or future Affiliates, Representatives, successors or permitted assigns of any Company Related Party (other than, for the avoidance of doubt, the Company). As it relates to the Company, the term &#147;<B><FONT
STYLE="white-space:nowrap">Non-Party</FONT> Affiliates</B>&#148; means &#147;<B>Company <FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliates.</B>&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Shares</B>&#148; means the
<FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common shares in the capital of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Option</B>&#148; means,
as of any determination time, each option to purchase Company Shares that are outstanding and unexercised (whether vested or unvested), whether granted under a Company Equity Plan or otherwise. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Owned Intellectual Property</B>&#148; means any and all Intellectual Property Rights that are owned or purported to be owned
by any Group Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Per Share Value</B>&#148; means the quotient obtained by dividing (a)&nbsp;the Reference Value, by
(b)&nbsp;the Company Fully Diluted Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Product</B>&#148; means (i)&nbsp;each product from which any Group Company has
derived within the two (2)&nbsp;years preceding the date hereof, is currently deriving or is scheduled to derive within the next two (2)&nbsp;years, revenue from the sale, license or other provision thereof, and (ii)&nbsp;each product candidate that
is being researched, tested, developed or manufactured by or on behalf of the Group Companies. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Registered Intellectual
Property</B>&#148; means any and all Registered Intellectual Property included in the Company Owned Intellectual Property. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Registration Rights Agreement</B>&#148; means the second amended and rested registration rights agreement of the Company dated
June&nbsp;30, 2021. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Related Party</B>&#148; has the meaning set forth in Section&nbsp;3.19. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Related Party Transactions</B>&#148; has the meaning set forth in Section&nbsp;3.19. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Required Approval</B>&#148; means approval by the affirmative vote of the
holders of not less than <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the Company Shares, voting together as a single class, present in person or represented by proxy at the Company Shareholders Meeting. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Shares</B>&#148; means the Company Common Shares, Company <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Shares,
Company Class&nbsp;A Preferred Shares, Company Class&nbsp;B Preferred Shares, and Company Class&nbsp;C Preferred Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company
Shareholders</B>&#148; means, collectively, the holders of Company Shares as of any determination time prior to the Closing. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Shareholders Agreements</B>&#148; means the Company Majority Shareholder Agreement and the Company Common Shareholder
Agreements. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Shareholders Meeting</B>&#148; means the special meeting of the Company Shareholders, including any
adjournment or postponement thereof in accordance with the terms of this Agreement, that is to be convened as provided by the Interim Order to consider, and if deemed advisable approve, the Company Arrangement Resolution and, with the prior written
consent of FEAC, for any other purpose as may be set out in the Company Information Circular. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Tax Counsel</B>&#148; has
the meaning set forth in Section&nbsp;5.5(b). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Transaction Support Agreements</B>&#148; has the meaning set forth in the
recitals to this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Warrant Holders</B>&#148; means, collectively, the holders of Company Warrants as of any
determination time prior to the Closing. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Warrants</B>&#148; means the 2022 Warrants and the 2023 Warrants. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Confidentiality Agreement</B>&#148; means that certain Confidentiality Agreement, dated as of April&nbsp;14, 2022, by and between the
Company and FEAC. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Consent</B>&#148; means any notice, authorization, qualification, registration, filing, notification, waiver,
order, consent or approval to be obtained from, filed with or delivered to, a Governmental Entity or other Person. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Continuance</B>&#148; shall have the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Contract</B>&#148; or &#147;<B>Contracts</B>&#148; means any written agreement, contract, license, lease, obligation, undertaking or
other commitment or arrangement that is legally binding upon a Person or any of his, her or its properties or assets. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Convertible
Bridge Financing</B>&#148; has the meaning set forth in the recitals to this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Convertible Bridge Financing
Documents</B>&#148; means the documents governing the Convertible Bridge Financing. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Copyrights</B>&#148; has the meaning set
forth in the definition of Intellectual Property Rights. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Court</B>&#148; means the Supreme Court of British Columbia or other
competent court, as applicable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B><FONT STYLE="white-space:nowrap">COVID-19</FONT></B>&#148; means
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> or <FONT STYLE="white-space:nowrap">COVID-19,</FONT> and any evolutions, mutations or strains thereof or related or associated epidemics, pandemic or disease
outbreaks. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B><FONT STYLE="white-space:nowrap">COVID-19</FONT> Measures</B>&#148; means any quarantine, &#147;<B>shelter in
place,</B>&#148; &#147;<B>stay at home,</B>&#148; social distancing, delay, shut down (including, the shutdown of air cargo routes), closure, sequester, safety or similar Law, directive, guidelines or recommendations promulgated by the applicable
Governmental Entity, in each case, in connection with or in response to <FONT STYLE="white-space:nowrap">COVID-19.</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>COVID
Program</B>&#148; has the meaning set forth in Section&nbsp;3.14(j). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Dissenting FEAC Shares</B>&#148; has the meaning set forth
in Section&nbsp;2.11(a). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Dissenting FEAC Shareholders</B>&#148; has the meaning set forth in
Section&nbsp;2.11(a). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Employee Benefit Plan</B>&#148; means each (i) &#147;<B>employee benefit plan</B>&#148; (as such term is
defined in Section&nbsp;3(3) of ERISA, whether or not subject to ERISA)&nbsp;(ii) compensation, employment, consulting, severance, termination protection, change in control, transaction bonus, retention or similar agreement, and (iii)&nbsp;any other
benefit or compensatory plan, program, policy or Contract that any Group Company maintains, sponsors, administers, contributes to or has entered into, including for the benefit of its current or former employees, officers, directors or other
individual service providers, or under or with respect to which any Group Company has any Liability, other than any plan sponsored or maintained exclusively by a Governmental Entity. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Environmental Laws</B>&#148; means all Laws and Orders concerning pollution, the storage, use, treatment, transportation, handling,
importation, exportation, sale, distribution, labeling, recycling, processing or testing of Hazardous Substance, the protection of the environment, or the protection of human health or safety (to the extent relating to exposure to Hazardous
Substances). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Equity Securities</B>&#148; means any share, share capital, capital stock, partnership, membership, joint venture or
similar interest in any Person (including any stock appreciation, phantom stock, profit participation or similar rights), and any option, warrant, right or security (including debt securities) convertible, exchangeable or exercisable therefor. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>ERISA</B>&#148; means the Employee Retirement Income Security Act of 1974, as amended, and any rules or regulations promulgated
thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Ex-Im Laws</B>&#148; means all applicable Laws relating to export, <FONT STYLE="white-space:nowrap">re-export,</FONT>
transfer and import controls, including the Export and Import Permits Act and the regulations thereunder and the Export Administration Regulations and the customs and import Laws administered by U.S. Customs and Border Protection. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchange</B>&#148; means a national securities exchange registered under the Exchange Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchange Act</B>&#148; means the Securities Exchange Act of 1934, as amended. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchange Agent</B>&#148; has the meaning set forth in Section&nbsp;2.16(a). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchange Consideration</B>&#148; means the Company Consideration and the Bridge Consideration, taken together. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Extension Loan Note</B>&#148; means any unsecured promissory note to be issued by FEAC to the Sponsor (or any of the Sponsor&#146;s
Affiliates or designees, as applicable), in connection with the deposit of funds in the Trust Account for purposes of the extension of the time available to FEAC to consummate an initial business combination in accordance with FEAC&#146;s Governing
Documents and the Trust Agreement, in an amount not exceed $1,265,000 per note for each applicable three-month period. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>FDA</B>&#148; means the U.S. Food and Drug Administration, or any successor agency thereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>FEAC</B>&#148; has the meaning set forth in the introductory paragraph to this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>FEAC Acquisition Proposal</B>&#148; means (a)&nbsp;any transaction or series of related transactions under which FEAC or any of its
controlled Affiliates, directly or indirectly, (i)&nbsp;acquires or otherwise purchases, or is acquired by or purchased by, any other Person(s), (ii) engages in a business combination with any other Person(s) or (iii)&nbsp;acquires or otherwise
purchases, or divests or otherwise sells, all or substantially all of the assets or businesses of any other Person(s) (in the case of each of clause (i), (ii) and (iii), whether by merger, consolidation, recapitalization, purchase or issuance of
equity securities, tender offer or otherwise) or (b)&nbsp;any equity, debt or similar investment in FEAC or any of its controlled Affiliates. Notwithstanding the foregoing or anything to the contrary herein, none of this Agreement, the Ancillary
Documents or the Transactions (including the PIPE Financing and Convertible Bridge Financing) shall constitute a FEAC Acquisition Proposal. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>FEAC Board</B>&#148; has the meaning set forth in the recitals to this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>FEAC Board Recommendation</B>&#148; has the meaning set forth in Section&nbsp;5.8.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>FEAC Certificates</B>&#148; has the meaning set forth in Section&nbsp;2.16(a). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>FEAC Change of Control Payment</B>&#148; means (a)&nbsp;any success, change of control, retention, transaction bonus or other similar
payment or amount to any Person as a result of or in connection with this Agreement or the Transactions or any other Change of Control Transaction (including any such payments or similar amounts that may become due and payable based upon the
occurrence of one or more additional circumstances, matters or events), or (b)&nbsp;any payments made or required to be made pursuant to or in connection with or upon termination of, and any fees, expenses or other payments owing or that will become
owing in respect of, any FEAC Related Party Transaction (in the case of each of clause (a)&nbsp;and (b), regardless of whether paid or payable prior to, at or after the Closing or in connection with or otherwise related to this Agreement or any
Ancillary Document), in each case, for the avoidance of doubt, other than the payment of fees of legal and other advisors in connection with the Transactions. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>FEAC Class</B><B></B><B>&nbsp;A Shares</B>&#148; means FEAC&#146;s Class&nbsp;A ordinary shares, $0.0001 par value. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>FEAC Class</B><B></B><B>&nbsp;B Shares</B>&#148; means FEAC&#146;s Class&nbsp;B ordinary shares, $0.0001 par value. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>FEAC D&amp;O Persons</B>&#148; has the meaning set forth in Section&nbsp;5.12(a). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>FEAC Disclosure Schedules</B>&#148; means the disclosure schedules to this Agreement delivered to the Company by FEAC on the date of
this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>FEAC Expenses</B>&#148; means, as of any determination time, the aggregate amount of fees, expense, commissions
or other amounts incurred by or on behalf of, or otherwise payable by, whether or not due, FEAC in connection with the negotiation, preparation or execution of this Agreement or any Ancillary Documents, the performance of its covenants or agreements
in this Agreement or any Ancillary Document or the consummation of the Transactions (including the PIPE Financing and Convertible Bridge Financing), including (a)&nbsp;the fees and expenses of outside legal counsel, accountants, advisors, brokers,
investment bankers, placement agents, underwriters, capital markets advisors, consultants, or other agents or service providers of FEAC and (b)&nbsp;any other fees, expenses, commissions or other amounts that are expressly allocated to FEAC pursuant
to this Agreement or any Ancillary Document; <I>provided that</I>, notwithstanding the foregoing or anything to the contrary herein, FEAC Expenses shall not include any Company Expenses. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>FEAC Financial Statements</B>&#148; means all of the financial statements of FEAC included in the FEAC SEC Reports. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>FEAC Fundamental Representations</B>&#148; means the representations and warranties set forth in Section&nbsp;4.1 (Organization and
Qualification), Section&nbsp;4.2 (Capitalization), Section&nbsp;4.3 (Authority), Section&nbsp;4.4 (Board Approval), Section&nbsp;4.8 (Trust Account), Section&nbsp;4.11(a) (Absence of Changes), Section&nbsp;4.17 (Business Activities), and
Section&nbsp;4.20 (Brokers). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>FEAC Information</B>&#148; has the meaning set forth in Section&nbsp;2.4(d). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>FEAC Liabilities</B>&#148; means, as of any determination time, the aggregate amount of Liabilities of FEAC, whether or not such
Liabilities are due and payable as of such time. Notwithstanding the foregoing or anything to the contrary herein, FEAC Liabilities shall not include any FEAC Expenses. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>FEAC Material Adverse Effect</B>&#148; means any change, event, effect or occurrence that, individually or in the aggregate with any
other change, event, effect or occurrence, has had or would reasonably be expected to have a material adverse effect on the business, results of operations or financial condition of FEAC; <I>provided, however</I>, that none of the following, either
alone or in combination, shall constitute or be taken into account in determining whether a FEAC Material Adverse Effect has occurred or is reasonably expected to occur: any adverse change, event, effect or occurrence resulting from or related to
(a)&nbsp;general business or economic conditions in or affecting the United States, Canada or elsewhere, or changes therein, or the global economy generally, (b)&nbsp;any outbreak or escalation of war or hostilities, whether or not
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">
pursuant to the declaration of a national emergency or war, or the occurrence in any place of any military or terrorist attack, sabotage, civil unrest, cyberterrorism, riots, prolonged
demonstrations or public disorders, or changes in global, national, regional, provincial, state or local political conditions, or any escalation or worsening thereof, (c)&nbsp;changes in the financial, banking, capital or securities markets
generally in the United States, Canada or any other country or region in the world, or changes therein, including changes in interest rates in the United States, Canada or any other country and changes in exchange rates for the currencies of any
countries, (d)&nbsp;changes, or proposed changes in or changes or proposed changes in interpretation of any applicable Laws, regulatory framework, IFRS or GAAP, (e)&nbsp;any change, event, effect or occurrence that is generally applicable to the
industries or markets in which FEAC operates, (f)&nbsp;the negotiation, execution or delivery of this Agreement, public announcement of this Agreement or the pendency or consummation of the Transactions (<I>provided</I> that the exception in this
clause (f)&nbsp;shall not apply to the representations and warranties set forth in Section&nbsp;4.5(b) to the extent that its purpose is to address the consequences resulting from the public announcement or pendency or consummation of the
Transactions or the condition set forth in Section&nbsp;6.3(a) to the extent it relates to such representations and warranties), (g) any failure by FEAC to meet, or changes to, any internal or published budgets, projections, forecasts, estimates or
predictions (although the underlying facts and circumstances resulting in such failure may be taken into account to the extent not otherwise excluded from this definition pursuant to clauses (a)&nbsp;through (f) or (h)), (h) any hurricane, tornado,
flood, earthquake, tsunami, natural disaster, mudslides, wild fires, acts of God or other natural disasters or comparable events in the United States, Canada or any other country or region in the world, or any escalation of the foregoing,
(i)&nbsp;any epidemics, pandemics, disease outbreaks or quarantines, including <FONT STYLE="white-space:nowrap">COVID-19</FONT> or any <FONT STYLE="white-space:nowrap">COVID-19</FONT> Measures or any change in such
<FONT STYLE="white-space:nowrap">COVID-19</FONT> Measures or interpretations thereof following the date of this Agreement, (j)&nbsp;the taking of any action required by the terms of this Agreement or any Ancillary Document, (k)&nbsp;any actions
taken or omitted to be taken by FEAC at the written request or with the prior written consent of the Company (l)&nbsp;any material breach of this Agreement or any Ancillary Document by the Company or (m)&nbsp;any matter set forth on Section&nbsp;1.1
of the FEAC Disclosure Schedules; <I>provided, however</I>, that if any change, event, effect or occurrence resulting from a matter described in any of the foregoing clauses (a)&nbsp;through (f), (h) or (i)&nbsp;materially and disproportionately
adversely effects FEAC relative to other &#147;<B>SPACs</B>&#148; comparable to FEAC on the basis of its listing, share conditions, obligations and assets, such change, event, effect or occurrence may be taken into account in determining whether a
FEAC Material Adverse Effect has occurred but only to the extent of the disproportionate effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>FEAC <FONT
STYLE="white-space:nowrap">Non-Controlled</FONT> Affiliates</B>&#148; has the meaning set forth in Section&nbsp;5.6(b). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>FEAC <FONT
STYLE="white-space:nowrap">Non-Party</FONT> Affiliates</B>&#148; means, collectively, each FEAC Related Party and each of the former, current or future Affiliates, Representatives, successors or permitted assigns of any FEAC Related Party (other
than, for the avoidance of doubt, FEAC). As it relates to FEAC, the term &#147;<B><FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliates</B>&#148; means &#147;<B>FEAC <FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliates.</B>&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>FEAC Private Placement Warrants</B>&#148; means the warrants (each entitling the holder thereof to purchase one FEAC Class&nbsp;A
Share) issued by FEAC to the Sponsor in a private placement simultaneously with the closing of its IPO and to be issued by FEAC to the Sponsor (or the Sponsor&#146;s Affiliates or designees, as applicable), upon the conversion of all or part of the
principal outstanding amount of the Working Capital Loan Note and any Extension Loan Note in connection with the consummation of the Business Combination. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>FEAC Registration Rights Agreement</B>&#148; means the Registration and Shareholder Rights Agreement dated December&nbsp;9, 2021,
between FEAC and the Sponsor. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>FEAC Related Party</B>&#148; has the meaning set forth in Section&nbsp;4.21. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>FEAC Related Party Transactions</B>&#148; has the meaning set forth in Section&nbsp;4.21. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>FEAC Reorganization</B>&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>FEAC SEC Reports</B>&#148; has the meaning set forth in Section&nbsp;4.6. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>FEAC Shareholder</B>&#148; means any holder of any FEAC Shares; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>FEAC Shareholder Approval</B>&#148; means (i)&nbsp;with respect to the BCA Proposal, the Governing Documents Proposal, the Share
Issuance Proposal, the Incentive Plan Proposal and the Adjournment Proposal, the affirmative vote of the holders of at least a majority of the FEAC Shares present in person or represented by proxy and entitled to vote at the FEAC Shareholders
Meeting, in each case, in accordance with the Governing Documents of FEAC and applicable Law; and (ii)&nbsp;with respect to the Cayman Merger and Reorganization Proposal, the affirmative vote of the holders of at least
<FONT STYLE="white-space:nowrap">two-thirds</FONT> of the FEAC Shares present in person or represented by proxy and entitled to vote at the FEAC Shareholders Meeting, in each case, in accordance with the Governing Documents of FEAC and applicable
Law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>FEAC Shareholder Redemptions</B>&#148; means the redemption by the holders of FEAC Class&nbsp;A Shares of all or a portion
of their FEAC Class&nbsp;A Shares (in connection with the Transactions or otherwise), as set forth in Governing Documents of FEAC. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>FEAC Shareholders Meeting</B>&#148; has the meaning set forth in Section&nbsp;5.7(b). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>FEAC Shares</B>&#148; means (a)&nbsp;prior to the Class&nbsp;B Conversion, collectively, the FEAC Class&nbsp;A Shares and the FEAC
Class&nbsp;B Shares, and (b)&nbsp;from and after the Class&nbsp;B Conversion, the FEAC Class&nbsp;A Shares after giving effect to the Class&nbsp;B Conversion. Any reference to the FEAC Shares in this Agreement or any Ancillary Document shall be
deemed to refer to clause (a)&nbsp;and/or clause (b)&nbsp;of this definition as the context so requires. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>FEAC Tax
Counsel</B>&#148; has the meaning set forth in Section&nbsp;5.5(b). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>FEAC Transaction Support Agreement</B>&#148; has the meaning
set forth in the recitals to this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>FEAC Unit</B>&#148; means each outstanding unit consisting of one FEAC Class&nbsp;A
Share and <FONT STYLE="white-space:nowrap">one-third</FONT> of one FEAC Warrant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>FEAC Warrants</B>&#148; means each warrant to
purchase one FEAC Class&nbsp;A Share at an exercise price of $11.50 per share, subject to adjustment, upon the terms and conditions in the FEAC Warrant Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>FEAC Warrant Agreement</B>&#148; means the warrant agreement, dated as of December&nbsp;9, 2021, by and between FEAC and the Trustee.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Federal Securities Laws</B>&#148; means the Exchange Act, the Securities Act and the other U.S. federal securities laws and the
rules and regulations of the SEC promulgated thereunder or otherwise. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Final Order</B>&#148; means the final order of the Court
pursuant to Section&nbsp;192 of the CBCA, in the form and substance satisfactory to FEAC and the Company (each acting reasonably), approving the Arrangement, as such order may be amended, modified, supplemented or varied by the Court at any time
prior to the Closing or, if appealed, then, unless such appeal is withdrawn, abandoned or dismissed, at such time which the Arrangement is affirmed or as amended, on appeal, <I>provided</I> that any such amendment is acceptable to each of FEAC and
the Company, each acting reasonably. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Forbion Capital Fund III</B>&#148; has the meaning set forth in the recitals to this
Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Foreign Antitrust Laws</B>&#148; has the meaning set forth in Section&nbsp;3.5(a). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Foreign Benefit Plan</B>&#148; means each Employee Benefit Plan maintained by any of the Group Companies for its current or former
employees, officers, directors or other individual service providers located outside of the United States. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>FSTQ</B>&#148; has the
meaning set forth in the recitals to this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>GAAP</B>&#148; means United States generally accepted accounting principles
as in effect from time to time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Governing Documents</B>&#148; means the legal document(s) by which any Person (other than an
individual) establishes its legal existence or which govern its internal affairs. For example, the &#147;<B>Governing</B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">
<B>Documents</B>&#148; of a U.S. or Canadian corporation are its certificate or articles of incorporation and, as the case may be, its certificates or articles of amendment, certificates or
articles of merger or amalgamations, and its <FONT STYLE="white-space:nowrap">by-laws,</FONT> the &#147;<B>Governing Documents</B>&#148; of a U.S. or Canadian limited partnership are its limited partnership agreement and certificate or articles of
limited partnership, the &#147;<B>Governing Documents</B>&#148; of a U.S. limited liability company are its operating or limited liability company agreement and certificate or articles of formation and the &#147;<B>Governing Documents</B>&#148; of a
Cayman Islands exempted company are its memorandum and articles of association. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Governing Documents Proposal</B>&#148; has the
meaning set forth in Section&nbsp;5.7(b). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Governmental Entity</B>&#148; means any United States, Canadian or other
(a)&nbsp;federal, state, provincial, local, municipal or other government, (b)&nbsp;governmental or quasi-governmental entity of any nature (including any governmental agency, branch, department, official, or entity and any court or other tribunal)
or (c)&nbsp;body exercising or entitled to exercise any administrative, executive, judicial, legislative, police, regulatory, or taxing authority or power of any nature, including any arbitral tribunal (public or private), securities regulator,
self-regulatory organization or stock exchange. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Group Company</B>&#148; and &#147;<B>Group Companies</B>&#148; means,
collectively, the Company and its Subsidiaries and Newco and its Subsidiaries (including, for the avoidance of doubt, upon the execution of a Joinder Agreement pursuant to Section&nbsp;5.26, Cayman Merger Sub). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Hazardous Substance</B>&#148; means any (a)&nbsp;pollutant, contaminant, chemical, (b)&nbsp;industrial, solid, liquid or gaseous toxic
or hazardous substance, material or waste, (c)&nbsp;petroleum or any fraction or product thereof, (d)&nbsp;asbestos or asbestos-containing material, (e)&nbsp;polychlorinated biphenyl, (f)&nbsp;chlorofluorocarbons, (g)
<FONT STYLE="white-space:nowrap">per-</FONT> and polyfluoroalkyl substances (including PFAs, PFOA, PFOS, Gen X, and PFBs) and (h)&nbsp;other substance, material or waste, in each case of (a) - (h), which are regulated under any Environmental Law
because of its dangerous or deleterious properties or characteristics or as to which Liability may be imposed pursuant to Environmental Law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Healthcare Laws</B>&#148; means all Laws relating to healthcare regulatory matters applicable to the Group Companies, including all
Laws relating to any federal health care program (as such term is defined in 42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7b(f)),</FONT> including the federal Anti-Kickback Statute (42 U.S.C. &#167;
<FONT STYLE="white-space:nowrap">1320a-7b(b)),</FONT> the Stark Anti-Self-Referral Law (42 U.S.C. &#167; 1395nn), the civil False Claims Act (31 U.S.C. &#167; 3729 et seq.), the administrative False Claims Law (42 U.S.C. &#167; <FONT
STYLE="white-space:nowrap">1320a-7b(a)),</FONT> Sections <FONT STYLE="white-space:nowrap">1320a-7,</FONT> <FONT STYLE="white-space:nowrap">1320a-7a,</FONT> and <FONT STYLE="white-space:nowrap">1320a-7b</FONT> of Title 42 of the United States Code
and any comparable self-referral or fraud and abuse laws promulgated by any Governmental Entity, the 21<SUP STYLE="font-size:75%; vertical-align:top">st</SUP> Century Cures Act (Pub. L. <FONT STYLE="white-space:nowrap">114-255),</FONT> the health
care fraud criminal provisions under <U>HIPAA</U>, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (42 U.S.C. &#167; 17921 et seq.), and any state or federal Law the purpose of which is to protect
the privacy of individually-identifiable patient information, Medicare (Title XVIII of the Social Security Act) and Medicaid (Title XIX of the Social Security Act), the Affordable Care Act, as amended by the Health Care and Education Affordability
Reconciliation Act of 2010, TRICARE (10 U.S.C. Section&nbsp;1071 et seq.), the Sunshine/Open Payments Law (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7h)</FONT> and similar federal, state or foreign Laws related to the reporting of
manufacturer payments or transfers of value to health care professionals, in each case including their foreign equivalents. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>HIPAA</B>&#148; means the Health Insurance Portability and Accountability Act of 1996 (42 U.S.C. &#167; 1320d et seq.). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>IFRS</B>&#148; means the International Financial Reporting Standards, as adopted by the International Accounting Standards Board, as
in effect from time to time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Incentive Plan Proposal</B>&#148; has the meaning set forth in Section&nbsp;5.8. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Indebtedness</B>&#148; means, as of any time, without duplication, with respect to any Person, the outstanding principal amount of,
accrued and unpaid interest on, fees and expenses arising under or in respect of (a)&nbsp;indebtedness for borrowed money, (b)&nbsp;other obligations evidenced by any note, bond, debenture or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">
other debt security, (c)&nbsp;obligations for the deferred purchase price of property or assets, including &#147;<B>earn-outs</B>&#148; and &#147;<B>seller notes</B>&#148; (but excluding any
trade payables arising in the ordinary course of business), (d) reimbursement and other obligations with respect to letters of credit, bank guarantees, bankers&#146; acceptances or other similar instruments, in each case, solely to the extent drawn,
(e)&nbsp;leases required to be capitalized under IFRS or GAAP as applicable, (f)&nbsp;derivative, hedging, swap, foreign exchange or similar arrangements, including swaps, caps, collars, hedges or similar arrangements, valued at the termination
value thereof, and (g)&nbsp;any of the obligations of any other Person of the type referred to in clauses (a)&nbsp;through (f) above directly or indirectly guaranteed by such Person or secured by any assets of such Person, whether or not such
Indebtedness has been assumed by such Person. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Intellectual Property Rights</B>&#148; means any and all intellectual property or
proprietary rights throughout the world including any and all United States and foreign (a)&nbsp;patents, patent applications, industrial designs and design patent rights, including any continuations, divisionals, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">continuations-in-part,</FONT></FONT> provisional and <FONT STYLE="white-space:nowrap">non-provisional</FONT> applications and statutory invention registrations, and any patents issuing on any of the foregoing and any
reissues, renewals, reexaminations, substitutes, supplementary protection certificates, extensions of any of the foregoing and all improvements to the inventions disclosed in each such registration, patent and patent application (collectively,
&#147;<B>Patents</B>&#148;); (b) trademarks, service marks, trade names, service names, brand names, trade dress rights, logos, slogans, Internet domain names, social media identifiers and accounts, corporate names and other source or business
identifiers (whether or not registered), together with all goodwill associated with any of the foregoing, and all applications, registrations, extensions and renewals of any of the foregoing (collectively, &#147;<B>Marks</B>&#148;); (c) copyrights,
works of authorship, data, database and design rights, and mask work rights, whether or not registered or published, and all registrations, applications, renewals, extensions, restorations, reversions, derivative rights and moral rights of any of
the foregoing, now or hereafter provided by applicable Law, regardless of the medium of fixation or means of expression (collectively, &#147;<B>Copyrights</B>&#148;); (d) trade secrets, <FONT STYLE="white-space:nowrap">know-how</FONT> (including
manufacturing and production processes), confidential or proprietary information, including invention disclosures, inventions, ideas, algorithms, formulae, processes, methods, techniques, technical data, and models, technologies, protocols,
methodologies, formulations, layouts, specifications, discoveries, compositions, industrial models, architectures, drawings, plans, ideas, research and development, customer and supplier lists, pricing and cost information, and business and
marketing plans and proposals, in each case whether patentable or not and whether reduced to practice or not (collectively, &#147;<B>Trade Secrets</B>&#148;); (e) rights in Software, and (f)&nbsp;any other intellectual or proprietary rights. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Intended Tax Treatment</B>&#148; has the meaning set forth in Section&nbsp;5.5(a). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Interim Order</B>&#148; means the interim order of the Court contemplated by Section&nbsp;2.2 of this Agreement and made pursuant to
Section&nbsp;192(4) of the CBCA, in a form acceptable to each of the Company and FEAC (each acting reasonably), providing for, among other things, the calling and holding of the Company Shareholders Meeting, as the same may be amended, modified,
supplemented or varied by the Court with the consent of FEAC and the Company, such consent not to be unreasonably withheld, conditioned or delayed, <I>provided</I> that any such amendment is acceptable to each of the Company and FEAC, each acting
reasonably. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Investment Company Act</B>&#148; means the Investment Company Act of 1940, as amended. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>IPO</B>&#148; has the meaning set forth in Section&nbsp;8.17. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>IQ</B>&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>JOBS Act</B>&#148; means the Jumpstart Our Business Startups Act of 2012. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Joinder Agreement</B>&#148; and &#147;<B>Joinder Agreements</B>&#148; means the joinder agreements, in form and substance reasonably
satisfactory to FEAC and the Company, by virtue of which Can Merger Sub and Cayman Merger Sub will each become a party to this Agreement as a &#147;<B>Party</B>&#148; hereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Latest Balance Sheet</B>&#148; has the meaning set forth in Section&nbsp;3.4(a). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Law</B>&#148; means any federal, state, provincial, local, foreign, national or
supranational statute, law (including common law), act, statute, ordinance, treaty, rule, Order, code, regulation or other binding directive or guidance issued, promulgated or enforced by a Governmental Entity having jurisdiction over a given
matter. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Letter of Transmittal</B>&#148; means the letter of transmittal in the form or forms mutually agreed to by each of Newco,
FEAC, the Exchange Agent and the Company (in any case, such agreement not to be unreasonably withheld, conditioned or delayed). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Liability</B>&#148; or &#147;<B>liability</B>&#148; means any and all debts, liabilities and obligations, whether accrued or fixed,
absolute or contingent, known or unknown, matured or unmatured or determined or determinable, including those arising under any Law (including any Environmental Law or Public Health Law), Proceeding or Order and those arising under any Contract,
agreement, arrangement, commitment or undertaking. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Lien</B>&#148; means any mortgage, pledge, security interest, encumbrance,
lien, license or <FONT STYLE="white-space:nowrap">sub-license,</FONT> charge, or other similar encumbrance or interest (including, in the case of any Equity Securities, any voting, transfer or similar restrictions). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Liquidation</B>&#148; has the meaning set forth in the recitals of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Loan Amount</B>&#148; has the meaning set forth in the recitals of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Lumira III</B>&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Lumira International III</B>&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Marks</B>&#148; has the meaning set forth in the definition of Intellectual Property Rights. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Material Contracts</B>&#148; has the meaning set forth in Section&nbsp;3.7(a). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Material Permits</B>&#148; has the meaning set forth in Section&nbsp;3.6. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Merck</B>&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Merck Qu&eacute;bec</B>&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Misrepresentation</B>&#148; means an untrue statement of a material fact or an omission to state a material fact that is required to
be stated or that is necessary to make a statement not misleading in light of the circumstances in which it was made. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Multiemployer Plan</B>&#148; has the meaning set forth in Section&nbsp;3(37) or Section&nbsp;4001(a)(3) of ERISA. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Nasdaq</B>&#148; means The Nasdaq Stock Market LLC. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Newco</B>&#148; has the meaning set forth in the introductory paragraph to this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Newco</B><B> Articles</B>&#148; has the meaning set forth in Section&nbsp;5.18. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Newco</B><B> Equity Incentive Plan</B>&#148; has the meaning set forth in Section&nbsp;5.17. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Newco Shares</B>&#148; means Class&nbsp;A common shares of Newco. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Newco Warrant Agreement</B>&#148; means the FEAC Warrant Agreement as amended and assumed by Newco pursuant to the Warrant Assignment,
Assumption and Amendment Agreement setting forth the terms and conditions of the Newco Warrants. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Newco Warrants</B>&#148; means
each warrant of Newco to purchase one Newco Share at an exercise price of $11.50 per share, subject to adjustment, upon the terms and conditions in the Newco Warrant Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B><FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreement</B>&#148; has the meaning set forth in the recitals to this
Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B><FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Transaction</B>&#148; has the meaning set forth in the recitals
to this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Note 1</B>&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Note 2</B>&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Note 3</B>&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Notes <FONT STYLE="white-space:nowrap">Set-Off</FONT></B>&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Off-the-Shelf</FONT></FONT> Software</B>&#148; means any Software
that is made generally and widely available to the public on an &#147;<B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">off-the-shelf</FONT></FONT></B>&#148; and commercial basis and is licensed to any of the Group Companies on a <FONT
STYLE="white-space:nowrap">non-exclusive</FONT> basis under <FONT STYLE="white-space:nowrap">non-discriminatory</FONT> terms and conditions. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Order</B>&#148; means any writ, order, judgment, injunction, decision, determination, award, ruling, subpoena, verdict or decree
entered, issued or rendered by any Governmental Entity having jurisdiction over such matter. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Original 2023 Convertible
Notes</B>&#148; has the meaning set forth in the recitals to this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Original 2023 Financing</B>&#148; has the meaning
set forth in the recitals to this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Original 2023 Warrants</B>&#148; has the meaning set forth in the recitals to this
Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Parties</B>&#148; has the meaning set forth in the introductory paragraph to this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Patents</B>&#148; has the meaning set forth in the definition of Intellectual Property Rights. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>PCAOB</B>&#148; means the Public Company Accounting Oversight Board. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Permits</B>&#148; means any approvals, authorizations, clearances, licenses, registrations, permits or certificates of a Governmental
Entity. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Permitted Liens</B>&#148; means (a)&nbsp;mechanic&#146;s, materialmen&#146;s, carriers&#146;, repairers&#146; and other
similar statutory Liens arising or incurred in the ordinary course of business for amounts that are not yet delinquent or are being contested in good faith by appropriate proceedings and for which sufficient reserves have been established in
accordance with GAAP or IFRS, as applicable, (b)&nbsp;Liens for Taxes, assessments or other governmental charges not yet due and payable as of the Closing Date or which are being contested in good faith by appropriate proceedings and for which
sufficient reserves have been established in accordance with GAAP or IFRS, as applicable, (c)&nbsp;encumbrances and restrictions on real property (including easements, covenants, conditions, rights of way and similar restrictions) that do not
prohibit or materially interfere with any of the Group Companies&#146; use or occupancy of such real property, (d)&nbsp;zoning, building codes and other land use Laws regulating the use or occupancy of real property or the activities conducted
thereon which are imposed by any Governmental Entity having jurisdiction over such real property and which are not violated by the use or occupancy of such real property or the operation of the businesses of the Group Company and do not prohibit or
materially interfere with any of the Group Companies&#146; use or occupancy of such real property, (e)&nbsp;cash deposits or cash pledges to secure the payment of workers&#146; compensation, unemployment insurance, social security benefits or
obligations arising under similar Laws or to secure the performance of public or statutory obligations, surety or appeal bonds, and other obligations of a like nature, in each case in the ordinary course of business and which are not yet due and
payable, <FONT STYLE="white-space:nowrap">(f)&nbsp;non-exclusive</FONT> licenses to Intellectual Property Rights granted in the ordinary course of business consistent with past practice, (g)&nbsp;restrictions on transfer of securities after the
Closing Date arising under applicable securities&#146; laws, and (h)&nbsp;the Liens listed and described on Section&nbsp;1.1 of the Company Disclosure Schedules. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Person</B>&#148; means an individual, partnership, corporation, limited liability company, joint stock company, unincorporated
organization or association, trust, joint venture or other similar entity, whether or not a legal entity. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Personal Data</B>&#148;
means, in addition to any definition for any similar term (e.g., &#147;<B>personal information</B>&#148;, &#147;<B>personally identifiable information</B>&#148;, &#147;<B>PII</B>&#148; or &#147;<B>personal data</B>&#148;) provided by or included in
any applicable Law, any and all data or information that identifies, or could be reasonably used to identify, an individual or natural person. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>PIPE Financing</B>&#148; has the meaning set forth in the recitals to this
Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>PIPE Financing Amount</B>&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>PIPE Investors</B>&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Plan of Arrangement</B>&#148; means the Plan of Arrangement in substantially the form attached hereto as Exhibit B, subject to any
amendments or variations to such plan made in accordance with this Agreement and the Plan of Arrangement or made at the direction of the Court in the Final Order with the prior written consent of the Company and FEAC, each acting reasonably. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>PPP Loan</B>&#148; has the meaning set forth in Section&nbsp;3.16(d). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B><FONT STYLE="white-space:nowrap">Pre-Closing</FONT> FEAC Holders</B>&#148; means the holders of FEAC Shares at any time prior to the
Cayman Merger. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B><FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Period</B>&#148; means any period that ends on or before the
Closing Date or, with respect to a period that includes but does not end on the Closing Date, the portion of such period through and including the Closing Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B><FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Reorganization</B>&#148; has the meaning set forth in Section&nbsp;2.19(a). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Privacy and Security Requirements</B>&#148; means any and all (i)&nbsp;applicable Laws, (ii)&nbsp;Group Companies&#146; published
internal and external facing privacy policies, (iii)&nbsp;contractual obligations and (iv)&nbsp;industry standards, in each case, relating to the Processing of Personal Data. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Proceeding</B>&#148; means any lawsuit, litigation, action, audit, examination, claim, cause of action, complaint, charge, proceeding,
investigation, inquiry, administrative enforcement proceeding, suit or arbitration (in each case, whether civil, criminal or administrative and whether public or private) pending by or before or otherwise involving any Governmental Entity. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Process</B>&#148; (or &#147;<B>Processing</B>&#148; or &#147;<B>Processes</B>&#148;) means the collection, use, storage, recording,
distribution, transfer, import, export, protection (including security measures), disposal or disclosure, performance of operations or set of operations on data or on sets of data, or other processing activity regarding data (whether electronically
or in any other form or medium). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Prospectus</B>&#148; has the meaning set forth in Section&nbsp;8.17. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Public Health Laws</B>&#148; means all applicable Laws relating to the development, testing, research (including preclinical,
nonclinical and clinical research or studies), manufacture, production, analysis, distribution, approval, importation, exportation, use, handling, quality, packaging, labeling sale or promotion of any drug (including any ingredient or component of
the foregoing products), including the Federal Food, Drug, and Cosmetic Act (21 U.S.C. &#167; 301 <I>et seq</I>.), the Public Health Service Act (42 U.S.C. &#167; 201 <I>et seq</I>.), the Canadian Food and Drugs Act (R.S.C. 1985, <FONT
STYLE="white-space:nowrap">c.F-27)</FONT> or similar federal, state or foreign Laws. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Public Shareholders</B>&#148; has the
meaning set forth in Section&nbsp;8.17. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Real Property Leases</B>&#148; means all leases,
<FONT STYLE="white-space:nowrap">sub-leases,</FONT> licenses or other agreements, in each case, pursuant to which any Group Company leases or <FONT STYLE="white-space:nowrap">sub-leases</FONT> any real property. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Recipient</B>&#148; has the meaning set forth in Section&nbsp;5.19. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Reference Price</B>&#148; means $10.25. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Reference Value</B>&#148; means the sum of: (i) $90,000,000, plus (ii)&nbsp;the Aggregate Exercise Price. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Registered Intellectual Property</B>&#148; means all issued Patents, pending Patent applications, registered Marks, pending
applications for registration of Marks, registered Copyrights, pending applications for registration of Copyrights and Internet domain name registrations. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Registration Statement / Proxy Statement</B>&#148; means a registration statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT>
relating to the Transactions and containing a prospectus of Newco and proxy statement of FEAC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Registration Rights Agreement</B>&#148; has the meaning set forth in the recitals
to this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Regulatory Permits</B>&#148; means all Permits granted by FDA, Health Canada or any comparable Governmental
Entity to any Group Company, including investigational new drug applications, new drug applications, manufacturing approvals and authorizations, <FONT STYLE="white-space:nowrap">no-objection</FONT> letters, or their national or foreign equivalents.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Representatives</B>&#148; means, with respect to any Person, such Person&#146;s Subsidiaries and its and such Subsidiaries&#146;
respective directors, managers, officers, employees, accountants, consultants, advisors, attorneys, agents and other representatives. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Rollover Equity Award</B>&#148; means an equity award with respect to Newco Shares that is outstanding on the day following the
Closing Date and that is received in exchange for a Company Equity Award upon disposition and cancellation of such Company Equity Award. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Sanctions Laws</B>&#148; means any applicable economic or financial sanctions Laws, including those administered by the Office of
Foreign Assets Control of the U.S. Department of the Treasury, the U.S. Department of State, any other agency of the US government, the government of Canada, His Majesty&#146;s Treasury or applicable anti-boycott measures. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Sanctioned Person</B>&#148; means any person, organization or vessel (a)&nbsp;designated on the OFAC list of Specially Designated
Nationals and Blocked Persons, the Consolidated List of Financial Sanctions Targets maintained by His Majesty&#146;s Treasury, and person listed by Canada under the regulations to the <I>Special Economic Measures Act</I>, the <I>Freezing Assets of
Corrupt Foreign Officials Act</I>, the <I>Justice for Victims of Corrupt Foreign Officials Act (Sergei </I><I>Magnitsky</I><I> Law)</I>, the <I>United Nations Act</I>, the <I>Criminal Code</I>, or any other similar Canadian law, or on any list of
targeted persons issued under the Sanctions Law of any other country with jurisdiction over the Parties, (b)&nbsp;that is, or is part of, a government of a Sanctioned Territory, (c)&nbsp;owned or controlled by, or acting on behalf of, any of the
foregoing, (d)&nbsp;located or resident in or organized under the laws of a Sanctioned Territory, or (e)&nbsp;otherwise targeted under any Sanctions Law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Sanctioned Territory</B>&#148; means any country or other territory subject to a general export, import, financial or investment
embargo under Sanctions Law, which countries and territories, as of the date of this Agreement, are the Crimea territory, the <FONT STYLE="white-space:nowrap">so-called</FONT> Donetsk People&#146;s Republic, the
<FONT STYLE="white-space:nowrap">so-called</FONT> Luhansk People&#146;s Republic, Cuba, Iran, North Korea, and Syria. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Sarbanes-Oxley Act</B>&#148; means the Sarbanes-Oxley Act of 2002, as amended. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Schedules</B>&#148; means, collectively, the Company Disclosure Schedules and the FEAC Disclosure Schedules. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>SEC</B>&#148; means the U.S. Securities and Exchange Commission. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Securities Act</B>&#148; means the U.S. Securities Act of 1933, as amended. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Securities Laws</B>&#148; means Federal Securities Laws and other applicable foreign and domestic securities or similar Laws,
including the <I>Securities Act</I> (Qu&eacute;bec) and any other applicable Canadian provincial and territorial securities laws. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Share Issuance Proposal</B>&#148; has the meaning set forth in Section&nbsp;5.7(b). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Side Letter Agreement</B>&#148; and &#147;<B>Side Letter Agreements</B>&#148; has the meaning set forth in the recitals to this
Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Signing Filing</B>&#148; has the meaning set forth in Section&nbsp;5.4(b). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Signing Press Release</B>&#148; has the meaning set forth in Section&nbsp;5.4(b). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Software</B>&#148; means any and all (a)&nbsp;computer programs and software, applications, systems, specifications and embedded
versions thereof, including any and all software implementations of algorithms, models and methodologies, development and design tools, compilers and assemblers, whether in (and including all) source code or object code; and (b)&nbsp;all
documentation related to any of the foregoing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Sponsor</B>&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Sponsor and Insiders Letter Agreement</B>&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Sponsor Loans Conversion</B>&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Subscription Agreement</B>&#148; and &#147;<B>Subscription Agreements</B>&#148; has the meaning set forth in the recitals to this
Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Subsidiary</B>&#148; means, with respect to any Person, any corporation, limited liability company, partnership or
other legal entity of which (a)&nbsp;if a corporation, a majority of the total voting power of shares of stock entitled (without regard to the occurrence of any contingency) to vote in the election of directors, managers or trustees thereof is at
the time owned or controlled, directly or indirectly, by such Person or one or more of the other Subsidiaries of such Person or a combination thereof, or (b)&nbsp;if a limited liability company, partnership, association or other business entity
(other than a corporation), a majority of the limited liability company, partnership or other similar ownership interests thereof is at the time owned or controlled, directly or indirectly, by such Person or one or more Subsidiaries of such Person
or a combination thereof and for this purpose, a Person or Persons own a majority ownership interest in such a business entity (other than a corporation) if such Person or Persons shall be allocated a majority of such business entity&#146;s gains or
losses or shall be a, or control any, managing director or general partner of such business entity (other than a corporation). The term &#147;<B>Subsidiary</B>&#148; shall include all Subsidiaries of such Subsidiary. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Supporting Company Shareholders</B>&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Surrender</B>&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Tax</B>&#148; means (a)&nbsp;any U.S., Canadian or other federal, national, state, local or provincial taxes, duties, levies or other
governmental charges, fees or assessments of any kind (including income, gross receipts, franchise, estimated, alternative minimum, sales, use, transfer, value added, excise, stamp, customs, duties, ad valorem, real property, personal property
(tangible and intangible), capital stock, social security, unemployment, payroll, wage, employment, severance, occupation, registration, environmental, communication, mortgage, profits, license, lease, service, goods and services, withholding,
premium, unclaimed property, escheat, turnover or windfall profits taxes), whether computed on a separate or combined, unitary or consolidated basis or in any other manner, together with any interest, deficiencies, penalties, additions to tax, or
additional amounts imposed by any Governmental Entity with respect thereto, whether disputed or not, and (b)&nbsp;any Liability for any amounts of the type described in clause (a)&nbsp;of another Person by operation of Law, as a transferee or
successor, by Contract or otherwise. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Tax Act</B>&#148; means the Income Tax Act (Canada) and the regulations promulgated
thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Tax Authority</B>&#148; means any Governmental Entity responsible for the collection or administration of Taxes or
Tax Returns. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Tax Contest</B>&#148; means any audit, hearing, proposed adjustment, arbitration, deficiency, assessment, suit,
dispute, claim, or other Proceeding commenced, filed or otherwise initiated or convened to investigate or resolve the existence and extent of a Liability for Taxes. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Tax Grant</B>&#148; means any Tax exemption, Tax holiday, reduced Tax rate or other Tax benefit granted by a Taxing Authority with
respect to the Company or any other Group Company that is not generally available without specific application therefor. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Tax
Return</B>&#148; means returns, information returns, notices, designations, statements, declarations, claims for refund, and reports relating to Taxes filed or required to be filed with any Tax Authority or other Governmental Entity, including any
schedules and attachments thereto and any amendments thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Termination Date</B>&#148; has the meaning set forth in
Section&nbsp;7.1(d). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Transaction Proposals</B>&#148; has the meaning set forth in Section&nbsp;5.8. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Transaction Support Agreements</B>&#148; has the meaning set forth in the recitals
to this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Transaction Personal Information</B>&#148; has the meaning set forth in Section&nbsp;5.19. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Transactions</B>&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Transfer Tax</B>&#148; has the meaning set forth in Section&nbsp;2.18. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Transferor</B>&#148; has the meaning set forth in Section&nbsp;5.19. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Treasury Regulations</B>&#148; means the U.S. Treasury Department regulations promulgated under the Code, as amended from time to time
(including any successor regulations). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Trust Account</B>&#148; has the meaning set forth in Section&nbsp;8.17. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Trust Account Released Claims</B>&#148; has the meaning set forth in Section&nbsp;8.17. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Trust Agreement</B>&#148; has the meaning set forth in Section&nbsp;4.8. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Trustee</B>&#148; has the meaning set forth in Section&nbsp;4.8. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Unaudited Company Financial Statements</B>&#148; has the meaning set forth in Section&nbsp;3.4(b). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Unpaid FEAC Expenses</B>&#148; means the FEAC Expenses that are unpaid as of immediately prior to the Closing. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Unpaid Company Expenses</B>&#148; means the Company Expenses that are unpaid as of immediately prior to the Closing. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>WARN</B>&#148; means the Worker Adjustment Retraining and Notification Act of 1988, as well as similar applicable foreign, state or
local Laws. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Warrant Assignment, Assumption and Amendment Agreement</B>&#148; means the warrant assignment, assumption and
amendment agreement to be entered into on or around the Closing Date between FEAC, Newco and the Trustee to amend the FEAC Warrant Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Working Capital Loan Note</B>&#148; means the unsecured promissory note issued by FEAC to the Sponsor on March&nbsp;24, 2023 in a
total principal amount of up to $900,000. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Written Objection</B>&#148; has the meaning set forth in Section&nbsp;2.10. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Construction; Interpretation</I>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The term &#147;<B>this Agreement</B>&#148; means this Business Combination Agreement together with the
Schedules and Exhibits hereto, as the same may from time to time be amended, modified, supplemented or restated in accordance with the terms hereof. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The headings set forth in this Agreement are inserted for convenience only and shall not affect in any way the
meaning or interpretation of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No Party, nor its respective counsel, shall be deemed the drafter of this Agreement for purposes of construing
the provisions hereof, and all provisions of this Agreement shall be construed according to their fair meaning and not strictly for or against any Party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Prior to the Amalgamation, references to the &#147;<B>Company</B>&#148; shall be to enGene Inc., and following
the Amalgamation, references to the &#147;<B>Company</B>&#148; shall be to the corporation resulting from the amalgamation of enGene Inc. and Can Merger Sub pursuant to the Plan of Arrangement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unless otherwise indicated to the contrary herein by the context or use thereof: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the words, &#147;herein,&#148; &#147;hereto,&#148; &#147;hereof&#148; and words of similar import refer to this
Agreement as a whole, including the Schedules and Exhibits, and not to any particular section, subsection, paragraph, subparagraph or clause set forth in this Agreement; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">masculine gender shall also include the feminine and neutral genders, and vice versa; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">words importing the singular shall also include the plural, and vice versa; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the words &#147;include,&#148; &#147;includes&#148; or &#147;including&#148; shall be deemed to be followed by
the words &#147;without limitation&#148;; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">unless otherwise indicated, references to &#147;<B>$</B>&#148; or &#147;<B>dollar</B>&#148; or
&#147;<B>US$</B>&#148; shall be references to United States dollars; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the word &#147;or&#148; is disjunctive but not necessarily exclusive; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the words &#147;writing&#148;, &#147;written&#148; and comparable terms refer to printing, typing and other
means of reproducing words (including electronic media) in a visible form; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(viii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the word &#147;day&#148; means calendar day unless Business Day is expressly specified; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ix)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the word &#147;extent&#148; in the phrase &#147;to the extent&#148; means the degree to which a subject or
other thing extends, and such phrase shall not mean simply &#147;if&#148;; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(x)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all references to Articles, Sections, Exhibits or Schedules are to Articles, Sections, Exhibits and Schedules
of this Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(xi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any statement in this Agreement to the effect that any information, document or other material has been
&#147;made available&#148; to FEAC, shall mean such information, documents or other materials posted to the virtual data room hosted by ShareVault at www.sharevault.net and labeled &#147;enGene Inc.&#148; as of 5:00 p.m., Eastern Time, on the date
that is one (1)&nbsp;Business Day prior to the date of this Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(xii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all references to any Law will be to such Law as amended, supplemented or otherwise modified or <FONT
STYLE="white-space:nowrap">re-enacted</FONT> from time to time; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all references to any Contract are to that Contract as amended or modified from time to time in accordance with
the terms thereof (subject to any restrictions on amendments or modifications set forth in this Agreement). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If any action under this Agreement is required to be done or taken on a day that is not a Business Day, then
such action shall be required to be done or taken not on such day but on the first succeeding Business Day thereafter. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>B<SMALL>USINESS</SMALL> C<SMALL>OMBINATION</SMALL> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>The Arrangement</I><I>. </I>On the terms and subject to the conditions set forth in this Agreement, Can
Merger Sub, the Company and Newco shall proceed to effect the Arrangement under Section&nbsp;192 of the CBCA beginning at the Arrangement Effective Time (as defined in the Plan of Arrangement), on the terms contained in the Plan of Arrangement. On
the terms and subject to the conditions set forth in this Agreement and the Plan of Arrangement, including the completion of each element of the Transactions (other than those Transactions that are scheduled to be completed following the Closing),
the closing of the Arrangement (the &#147;<B>Closing</B>&#148;) shall take place electronically by exchange of the closing deliverables by the means provided in Section&nbsp;8.10 as promptly as reasonably practicable, but in no event shall the
Closing occur on a date which is later than the third (3rd) Business Day following the satisfaction (or, to the extent permitted by applicable Law, waiver) of the conditions set forth in Article 6 (other than those conditions that by their nature
are to be satisfied at the Closing, but subject to satisfaction or waiver of such conditions) (the date on which the Arrangement occurs, the &#147;<B>Closing Date</B>&#148;) or at such other place, date and/or time as FEAC and the Company may agree
in writing. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>The Interim Order</I><I>. </I>No later than three (3)&nbsp;Business Days after the filing with the SEC of
the Registration Statement / Proxy Statement by Newco, the Company shall apply in a manner reasonably acceptable to FEAC pursuant to Section&nbsp;192 of the CBCA and, in cooperation with FEAC, prepare, file and diligently
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
pursue an application to the Court for the Interim Order in respect of the Arrangement, which shall provide, among other things: </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">for the class of persons to whom notice is to be provided in respect of the Arrangement, the Company
Shareholders Meeting and for the manner in which such notice is to be provided; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that the required level of approval for the Company Arrangement Resolution shall be the Company Required
Approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that, in all other respects, the terms, restrictions and conditions of the Governing Documents of the Company,
including quorum requirements and all other matters, shall apply in respect of the Company Shareholders Meeting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">for the notice requirements with respect to the presentation of the application to the Court for the Final
Order; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that the Company Shareholders Meeting may be adjourned or postponed from time to time by the Company in
accordance with the terms of this Agreement without the need for additional approval of the Court; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">for the confirmation of the record date and that the record date for the Company Shareholders entitled to
notice of and to vote at the Company Shareholders Meeting will not change in respect of any adjournment(s) or postponement(s) of the Company Shareholders Meeting; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">for the grant of Arrangement Dissent Rights to those Company Shareholders who are registered Company
Shareholders as contemplated in the Plan of Arrangement; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">for such other matters as FEAC and the Company may agree are reasonably necessary to complete the Transactions.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>The Company Shareholders Meeting</I>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On the terms and subject to the conditions set forth in this Agreement, the Interim Order and the provision of
the FEAC Information, the Company shall convene and conduct the Company Shareholders Meeting in accordance with the Governing Documents of the Company, applicable Laws and the Interim Order as soon as reasonably practicable following the
effectiveness of the Registration Statement/Proxy Statement, the Company Shareholders Meeting without the prior written consent of FEAC (not to be unreasonably withheld, delayed or conditioned), except in the case of an adjournment as required for
quorum purposes, as required by Law or by a Governmental Entity. The Company shall consult with FEAC in fixing the record date for the Company Shareholders Meeting and the date of the Company Shareholders Meeting, give notice to FEAC of the Company
Shareholders Meeting and allow FEAC&#146;s representatives and legal counsel to attend the Company Shareholders Meeting. The Company shall use its reasonable best efforts to obtain the Company Required Approval in respect of the Company Arrangement
Resolution, including instructing the management proxyholders named in the Company Information Circular to vote any discretionary or blank proxy submitted by shareholders in favor of such action, and, at the Company&#146;s option, acting reasonably,
using dealer and proxy solicitation services firms engaged by the Company to solicit proxies in favour of the approval of the Company Arrangement Resolution, and shall take all other action reasonably necessary or advisable to secure the Company
Required Approval in respect of the Company Arrangement Resolution. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall provide FEAC with (i)&nbsp;updates with respect to the aggregate tally of the proxies
received by the Company in respect of the Company Arrangement Resolution, (ii)&nbsp;updates with respect to any communication (written or oral) from any Company Shareholder in opposition to the Arrangement and/or any purported exercise or withdrawal
of Arrangement Dissent Rights by Company Shareholders, (iii)&nbsp;the right to demand postponement or adjournment of the Company Shareholders Meeting if, based on the tally of proxies, the Company will not receive the Company
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Required Approval in respect of the Company Arrangement Resolution; <I>provided</I>, that the Company Shareholders Meeting, so postponed or adjourned, shall not be later than (A)&nbsp;five (5)
Business Days prior to the Termination Date or (B)&nbsp;ten (10) days from the date of the first Company Shareholders Meeting, and (iv)&nbsp;the right to review and comment on all communications sent to Company Shareholders in connection with the
Company Shareholders Meeting. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall not (i)&nbsp;make any payment or settlement offer, or agree to any payment or settlement
prior to the Arrangement Effective Time with respect to Arrangement Dissent Rights, or (ii)&nbsp;waive any failure by any Company Shareholder to timely deliver a notice of exercise of Arrangement Dissent Rights, in each case without the prior
written consent of FEAC, which will not be unreasonably withheld, conditioned or delayed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>The Company Information Circular</I>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall promptly prepare and complete, in good faith consultation with FEAC, the Company Information
Circular together with any other documents required by applicable Law in connection with the Company Shareholders Meeting and the Arrangement, and the Company shall, as promptly as practicable after obtaining the Interim Order, cause the Company
Information Circular and such other documents to be sent to each Company Shareholder and other person as required by the Interim Order and applicable Law, provided that FEAC shall have complied with Section&nbsp;2.4(d). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall ensure that the Company Information Circular (i)&nbsp;complies with the Governing Documents
of the Company, the Interim Order and applicable Law, (ii)&nbsp;does not contain any Misrepresentation, except with respect to FEAC Information included in the Company Information Circular, which FEAC will ensure does not contain a
Misrepresentation, (iii)&nbsp;provides the Company Shareholders with sufficient information (explained in sufficient detail) to permit them to form a reasoned judgement concerning the matters to be placed before the Company Shareholders Meeting and
(iv)&nbsp;states any material interest of each director and officer, whether as director, officer, securityholder or creditor of the Company, as and to the extent required by applicable Law, in each case provided that FEAC shall have complied with
Section&nbsp;2.4(d). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall, subject to the terms of this Agreement, ensure that the Company Information Circular
includes a statement that the board of directors of the Company has unanimously (i)&nbsp;determined that the Plan of Arrangement and the Transactions are in the best interests of the Company and fair to the Company Shareholders and
(ii)&nbsp;recommended that the Company Shareholders vote in favor of the Company Arrangement Resolution. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">FEAC shall assist the Company in the preparation of the Company Information Circular, including obtaining and
furnishing to the Company on a timely basis any information with respect to FEAC or its securityholders required to be included under applicable Laws in the Company Information Circular (the &#147;<B>FEAC Information</B>&#148;), and ensuring that
the FEAC Information does not contain any Misrepresentation. The Company shall give FEAC and its legal counsel a reasonable opportunity to review and comment on drafts of the Company Information Circular and other related documents, and shall accept
the reasonable comments made by FEAC and its counsel, and agrees that all information relating to FEAC included in the Company Information Circular must be in a form and content reasonably satisfactory to FEAC. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Party shall promptly notify the other Parties if it becomes aware that the Company Information Circular
contains a Misrepresentation, or otherwise requires an amendment or supplement. The Parties shall cooperate in the preparation of any such amendment or supplement as required or appropriate, and the Company shall promptly deliver or otherwise
disseminate any such amendment or supplement to the Company Shareholders, and file the same with any Governmental Entity, in each case as required by the Court or applicable Law. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>The Final Order</I><I>. </I>The Company shall take all steps necessary or desirable to submit the
Arrangement to the Court and diligently pursue an application for the Final Order pursuant to Section&nbsp;192 of the CBCA, as </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
soon as reasonably practicable, but in any event not later than five (5)&nbsp;Business Days after the date on which the Company Arrangement Resolution is passed at the Company Shareholders
Meeting as provided for in the Interim Order. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Court Proceedings</I>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In connection with all Court proceedings relating to obtaining the Interim Order and the Final Order, the
Company shall: (i)&nbsp;diligently pursue the Interim Order and the Final Order; (ii)&nbsp;provide FEAC&#146;s legal counsel with a reasonable opportunity to review and comment upon drafts of all material to be filed with the Court in connection
with the Arrangement, and accept the reasonable comments of FEAC and its legal counsel; (iii)&nbsp;provide FEAC copies of any notice of appearance, evidence or other documents served on it or its legal counsel in respect of the application for the
Interim Order or the Final Order or any appeal from them, and any notice, written or oral, indicating the intention of any person to appeal, or oppose the granting of, the Interim Order or the Final Order; (iv)&nbsp;ensure that all material filed
with the Court in connection with the Arrangement is consistent in all material respects with this Agreement and the Plan of Arrangement; (v)&nbsp;not file any material with the Court in connection with the Arrangement or serve any such material,
and will not agree to modify or amend any materials so filed or served, except as contemplated by this Agreement or with FEAC&#146;s prior written consent, such consent not to be unreasonably withheld, conditioned or delayed, <I>provided</I> that
FEAC is not required to agree or consent to any increase or variation in the form of the Exchange Consideration or other modification or amendment to such filed or served materials that expands or increases its obligations, or diminishes or limits
its rights, set forth in any such filed or served materials or under this Agreement or the Arrangement; (vi)&nbsp;subject to this Agreement, oppose any proposal from any person that the Final Order contain any provision inconsistent with the
Arrangement or this Agreement, and if at any time after the issuance of the Final Order and prior to the Closing, the Company is required by the terms of the Final Order or by applicable Law to return to Court with respect to the Final Order, it
will do so only after notice to, and in good faith consultation and cooperation with, FEAC; and (vii)&nbsp;not object to legal counsel to FEAC making such submissions on the hearing of the motion for the Interim Order and the application for the
Final Order as such counsel considers appropriate, provided FEAC advises the Company of the nature of any such submissions reasonably in advance of the hearing and such submissions are consistent with this Agreement and the Plan of Arrangement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the terms of this Agreement, FEAC will cooperate with, and assist the Company, in seeking the
Interim Order and the Final Order, including by providing the Company on a timely basis any information reasonably required or requested to be supplied by FEAC in connection therewith. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>The Sponsor Loans Conversion</I>. The Sponsor Loans Conversion shall be consummated immediately prior to the
Surrender on the day which is two (2)&nbsp;Business Days prior to the Closing Date, on the terms and subject to the conditions of this Agreement, the FEAC Warrant Agreement and the relevant promissory note governing the Working Capital Loan Note
and/or any Extension Loan. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>The Class</I><I></I><I>&nbsp;B Conversion</I><I>. </I>On the terms and subject to the conditions set forth
in this Agreement and the Sponsor and Insiders Letter Agreement, on the day which is two (2)&nbsp;Business Days prior to the Closing Date, each FEAC Class&nbsp;B Share that remains outstanding following the Surrender of the 1,789,004 FEAC
Class&nbsp;B Shares held by the Sponsor, as provided in the Sponsor and Insiders Letter Agreement, shall be exchanged for one (1)&nbsp;FEAC Class&nbsp;A Share. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>The Cayman Reorganization</I>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On the terms and subject to the conditions set forth in this Agreement, on the day which is one
(1)&nbsp;Business Day prior to the Closing Date (the &#147;<B>Initial </B><B>Merger Effective Time</B>&#148;), Cayman Merger Sub will merge with and into FEAC with FEAC as the surviving entity pursuant to the Cayman Merger, as follows:
(i)&nbsp;Newco will issue to the holders of FEAC Shares (including the Sponsor but </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
excluding the holders of any Dissenting FEAC Shares) Newco Shares in exchange for such holders&#146; FEAC Shares and such FEAC Shares will not be cancelled but will be transferred to Newco,
(ii)&nbsp;FEAC will thereby become a wholly-owned subsidiary of Newco and (iii)&nbsp;each issued share of Cayman Merger Sub will be exchanged for a FEAC Class&nbsp;A Share of FEAC as the surviving entity and Cayman Merger Sub (having merged into
FEAC) will cease to exist as a separate entity by virtue of the Cayman Merger. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Concurrently with the Cayman Merger, and effective at the same time the Cayman Merger becomes effective under
the Cayman Islands law, (i)&nbsp;Newco will assume the FEAC Warrants (as so assumed, Newco Warrants) pursuant to the Warrant Assignment, Assumption and Amendment Agreement, (ii)&nbsp;FEAC as the entity surviving the Cayman Merger will issue Note 3
to Newco in consideration of the assumption by Newco of obligations under the FEAC Warrants (as so assumed, Newco Warrants) and (iii)&nbsp;Newco will redeem the initial Newco Shares held by the Formation Shareholder for an amount equal to the amount
of capital that the Formation Shareholder contributed for purposes of the incorporation of Newco. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Notice to FEAC Shareholders Delivering Written Objection. </I>If any FEAC Shareholder gives to FEAC, before
the FEAC Shareholder Approval is obtained at the FEAC Shareholders Meeting, written objection to the Cayman Merger (each, a &#147;<B>Written Objection</B>&#148;) in accordance with Section&nbsp;238(2) and 238(3) of the Cayman Act, FEAC shall,
following the FEAC Shareholder Approval, in accordance with Section&nbsp;238(4) of the Cayman Act, promptly give written notice of the authorization of the Cayman Merger to each such FEAC Shareholder who has made a Written Objection.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>FEAC Shareholder Dissent Rights</I>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to Section&nbsp;2.9 but notwithstanding any other provision of this Agreement to the contrary and to
the extent available under the Cayman Act, FEAC Shares that are issued and outstanding immediately prior to the Initial Merger Effective Time and that are held by FEAC Shareholders who shall have validly exercised their dissenters&#146; rights for
such FEAC Shares in accordance with Section&nbsp;238 of the Cayman Act and otherwise complied with all of the provisions of the Cayman Act relevant to the exercise and perfection of dissenters&#146; rights (the &#147;<B>Dissenting FEAC
Shares</B>&#148;, and the holders of such Dissenting FEAC Shares being the &#147;<B>Dissenting FEAC Shareholders</B>&#148;) shall not be converted into, and no Dissenting FEAC Shareholder shall be entitled to receive, the applicable consideration or
any Newco Warrants unless and until such Dissenting FEAC Shareholder fails to perfect or withdraws or otherwise loses his, her or its right to dissenters&#146; rights under the Cayman Act. The FEAC Shares owned by any FEAC Shareholder who fails to
perfect or who effectively withdraws or otherwise loses his, her or its dissenters&#146; rights pursuant to the Cayman Act shall cease to be Dissenting FEAC Shares and shall thereupon automatically be cancelled and cease to exist in exchange for the
right to receive the applicable number of Newco Shares on the basis of the Cayman Exchange Ratio, without any interest thereon. The FEAC Warrants owned by any FEAC Shareholder who fails to perfect or who effectively withdraws or otherwise loses his,
her or its dissenters&#146; rights pursuant to the Cayman Act shall thereupon automatically be cancelled and cease to exist in exchange for the right to receive the applicable number of Newco Warrants on the basis of the Cayman Exchange Ratio,
without any interest thereon. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Prior to the Closing Date, FEAC shall give the Company (i)&nbsp;prompt written notice of any demands for
dissenters&#146; rights received by FEAC from FEAC Shareholders (including any notices received by FEAC pursuant to Section&nbsp;238(2) or Section&nbsp;238 (5) of the Cayman Act) and any withdrawals of such demands, and (ii)&nbsp;the opportunity to
consult with FEAC in connection with all negotiations and proceedings with respect to any such notice or demand for dissenters&#146; rights under the Cayman Act. FEAC shall not, except with the prior written consent of the Company, make any offers
or payment or otherwise agree or commit to any payment or other consideration with respect to any exercise by a FEAC Shareholder of its rights to dissent from the Cayman Merger or any demands for appraisal or offer or agree or commit to settle or
settle any such demands or approve any withdrawal of any such dissenter rights or demands. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>The FEAC Reorganization</I>. Following the Cayman Reorganization, FEAC will file an election to change its
classification for U.S. federal income tax purposes from a corporation to an entity disregarded as separate from its owner Newco, to be effective as of the beginning of the Closing Date. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>The Notes <FONT STYLE="white-space:nowrap">Set-Off</FONT></I><I>. </I>Immediately following the Closing
Date, FEAC will repurchase shares held by Newco in an aggregate amount equal to Note 1 and in consideration therefor issue to Newco a CDN$ denominated <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing demand promissory note in a principal
amount equal to the outstanding principal amount of Note 1 (&#147;<B>Note 2</B>&#148;), following which Note 1 and Note 2 (each having the same outstanding principal amount) will be set off by FEAC and Newco in full repayment of their respective
principal amounts. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.14</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>FEAC Liquidation</I><I>. </I>Immediately following the Notes <FONT STYLE="white-space:nowrap">Set-Off</FONT>
becoming effective, Newco will transfer Note 3 to the Company in consideration for the issuance by the Company from treasury of additional common shares of the Company, following which FEAC will repay the outstanding principal amount of Note 3, and
subsequently be placed in Liquidation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.15</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Allocation Schedule</I>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No later than five (5)&nbsp;Business Days prior to the Closing Date, the Company shall deliver to FEAC and
Newco (and Newco shall thereafter deliver to the Exchange Agent) an allocation schedule (the &#147;<B>Allocation Schedule</B>&#148;) setting forth (i)&nbsp;the number of Company Shares held by each Company Shareholder, the number of Company Common
Shares that will be issued to the holders of the Company Convertible Notes as set out in the Plan of Arrangement, the number of Company Warrants and the number of Company Shares subject to each Company Equity Award held by each holder thereof and,
in the case of each Company Option, the exercise price thereof, (ii)&nbsp;(x) the number of Newco Shares that will be issued to each Company Shareholder, (y)&nbsp;the number of Newco Shares that will be subject to each Rollover Equity Award, which
shall be determined by multiplying the number of Company Shares subject to the corresponding Rollover Equity Award immediately prior to the Closing by the Company Exchange Ratio and rounding the resulting number down to the nearest whole number of
Newco Shares, and (z)&nbsp;the number of Newco Warrants that will be issued to each Company Warrant Holder, (iii)&nbsp;the portion of the Exchange Consideration allocated to each Company Shareholder, Company Equity Award holder and Company Warrant
Holder, and (iv)&nbsp;a certification, duly executed by an authorized officer of the Company, that the information delivered pursuant to clauses (i), (ii), and (iii)&nbsp;is, and will be as of immediately prior to the Closing, true and correct in
all respects. The Company will review any comments to the Allocation Schedule provided by FEAC or any of its Representatives and consider and incorporate in good faith any reasonable comments proposed by FEAC or any of its Representatives.
Notwithstanding the foregoing or anything to the contrary herein, (A)&nbsp;the aggregate number of Newco Shares that each Company Shareholder will have a right to receive pursuant to the Plan of Arrangement will be rounded down to the nearest whole
share, (B)&nbsp;in no event shall the aggregate number of Newco Shares set forth on the Allocation Schedule that are allocated in respect of Company Shares, the aggregate number of Rollover Equity Awards that are allocated in respect of the
aggregate number of Company Equity Awards, and the Newco Warrants that are allocated in respect of the aggregate number of Company Warrants, in aggregate exceed the portion of the Exchange Consideration issuable in respect of such Company Shares,
Company Equity Awards and Company Warrants pursuant to the Plan of Arrangement, and (C)&nbsp;the Allocation Schedule (and the calculations or determinations therein) shall be prepared in accordance with any applicable Law, the Governing Documents of
the Company, the Company Shareholders Agreements, the Company Equity Plan and any other Contract to which the Company is a party or bound to the extent applicable thereto. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No later than five (5)&nbsp;Business Days prior to the Closing Date, FEAC shall deliver to the Company and
Newco a statement setting forth (i)&nbsp;the number of FEAC Class&nbsp;A Shares expected to be outstanding after giving effect to the Class&nbsp;B Conversion and the FEAC Shareholder Redemptions,
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
(ii)&nbsp;the amount of the Unpaid FEAC Expenses and Unpaid FEAC Liabilities, (iii)&nbsp;the amount expected to remain in Trust Account after giving effect to the FEAC Shareholder Redemptions,
(iv)&nbsp;the Aggregate Transaction Proceeds, and (v)&nbsp;a certification, duly executed by an authorized officer of FEAC, that the information delivered pursuant to clauses (i), (ii), (iii) and (iv)&nbsp;is, and will be as of immediately prior to
the Closing Date, true and correct in all respects. FEAC will review any comments to the statement provided by the Company or any of its Representatives and consider and incorporate in good faith any reasonable comments proposed by the Company or
any of its Representatives. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.16</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Exchange Agent</I>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As promptly as reasonably practicable following the date of this Agreement, but in no event later than ten
(10)&nbsp;Business Days prior to the Closing Date, Newco shall appoint an exchange agent reasonably acceptable (such acceptance, not to be unreasonably withheld, conditioned or delayed) to FEAC and the Company (the &#147;<B>Exchange Agent</B>&#148;)
and enter into an exchange agent agreement with the Exchange Agent for the purpose of exchanging (i)&nbsp;certificates, if any, representing all of the Company Shares, the Convertible Notes, the Company Equity Awards and Company Warrants
(&#147;<B>Company Certificates</B>&#148;) for the portion of the Exchange Consideration issuable in respect of such Company Shares, Company Equity Awards and Company Warrants pursuant to the Plan of Arrangement and on the terms and subject to the
other conditions set forth in this Agreement, and (ii)&nbsp;certificates, if any, representing the FEAC Shares or FEAC Warrants (&#147;<B>FEAC Certificates</B>&#148;) and each FEAC Share or FEAC Warrant held in book-entry form on the stock transfer
books of FEAC immediately prior to the Closing, in either case, for such Newco Shares issuable in the Cayman Merger or Newco Warrants assumed in the Cayman Reorganization and on the terms and subject to the other conditions set forth in this
Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">At least three (3)&nbsp;Business Days prior to the Closing Date, the Company shall mail or otherwise deliver,
or shall cause to be mailed or otherwise delivered, a Letter of Transmittal to the Company Shareholders, holders of Company Convertible Notes and Company Warrant Holders. At least three (3)&nbsp;Business Days prior to the Closing Date, FEAC shall
mail or otherwise deliver, or shall cause to be mailed or otherwise delivered, a Letter of Transmittal to the holders of FEAC Shares and FEAC Warrants. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In accordance with the Plan of Arrangement, Newco shall deposit, or cause to be deposited, with the Exchange
Agent, (i)&nbsp;for the benefit of the Company Shareholders, Company Equity Award holders and Company Warrant Holders and for exchange in accordance with this Section&nbsp;2.16(c) through the Exchange Agent, evidence of Newco Shares, Rollover Equity
Awards and Newco Warrants in book-entry form representing the portion of the Exchange Consideration issuable pursuant to the Plan of Arrangement, and (ii)&nbsp;for the benefit of the holders of FEAC Shares and FEAC Warrants and for exchange in
accordance with this Section&nbsp;2.16(c) through the Exchange Agent, evidence of Newco Shares and Newco Warrants in book-entry form representing the Newco Shares issuable in the Cayman Merger and Newco Warrants assumed in the Cayman Reorganization
in exchange for the FEAC Shares and FEAC Warrants outstanding immediately prior to the Cayman Reorganization. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.17</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Withholding</I><I>. </I>Notwithstanding anything in this Agreement to the contrary, FEAC, any Group Company
and the Exchange Agent shall be entitled to take such actions as are reasonably necessary to deduct and withhold (or cause to be deducted and withheld) from any amounts payable or otherwise deliverable to any Person pursuant to the Arrangement or
this Agreement such Taxes, source deductions and other amounts as are required to be deducted and withheld under applicable Tax Law. Any amounts so deducted and withheld shall be timely remitted to the applicable Tax Authority. To the extent that
amounts are so deducted and withheld and timely remitted to the applicable Tax Authority, such amounts shall be treated for all purposes of the Arrangement and this Agreement as having been paid to the Person in respect of which such deduction and
withholding was made. Each of FEAC, the Group Companies and the Exchange Agent, as applicable, is hereby authorized to sell or otherwise dispose of, on behalf of such Person, such </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
portion of any share or other security deliverable to such Person as is necessary to provide sufficient funds to FEAC, a Group Company or the Exchange Agent, as the case may be, to enable it to
comply with such deduction and withholding requirement and FEAC, the Group Company or the Exchange Agent shall use commercially reasonable efforts to notify such Person thereof and remit the applicable portion of the net proceeds of such sale to the
appropriate Tax Authority and, if applicable, any portion of such net proceeds that is not required to be so remitted shall be paid to such Person. The Parties shall cooperate reasonably and in good faith to eliminate or reduce any such deduction or
withholding to the extent permitted by applicable Law (including, where it is reasonable to do so, through the request and provision of any statements, forms or other documents to reduce or eliminate any such deduction or withholding).
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.18</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Transfer Taxes</I>. Newco shall bear and pay (or, following the Closing, cause any Group Company to pay) any
transfer, documentary, sales, use, stamp, registration, value added or other similar Taxes imposed on a Party as a result of the Transactions (for the avoidance of doubt, other than Taxes imposed on an investor in a Party) (&#147;<B>Transfer
Taxes</B>&#148;) and shall file (or cause to be filed) all necessary Tax Returns with respect to all such Transfer Taxes; <I>provided</I> that if the Closing does not occur, each Party will be bear and pay any Transfer Taxes, and file any related
Tax Returns, to the extent such Transfer Taxes are imposed on such Party under applicable Law. The Parties agree to reasonably cooperate to (a)&nbsp;sign and deliver such resale and other certificates or forms as may be necessary or appropriate to
establish an exemption from (or otherwise reduce) any such Transfer Taxes and (b)&nbsp;prepare and file (or cause to be prepared and filed) all Tax Returns in respect of any such Transfer Taxes. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.19</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Transaction Structure</I>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If requested by any other Party to implement any reorganization transactions or implement any changes to the
structure of the Transactions (each, a &#147;<B><FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Reorganization</B>&#148;), each Party shall consider such <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Reorganization in good faith and
cooperate with the other Parties to the extent it determines in good faith that such reorganization transactions or transaction structure changes are advisable, in the best interests of the Company and will not (i)&nbsp;have an adverse impact on
such Party or its direct or indirect Subsidiaries or securityholders, (ii)&nbsp;alter or change the amount or kind of the consideration to be received or paid by any of its or any of its securityholders in connection with the Transactions,
(iii)&nbsp;have an adverse effect on the Tax consequences of the Transactions to the Party or any of its Subsidiaries or its direct or indirect securityholders, (iv)&nbsp;materially impede or delay consummation of any of the Transactions, and
(v)&nbsp;result in any breach by any Party or any of its Subsidiaries of any Material Contract in the case of the Company and its Subsidiaries or any Contract in the case of FEAC and its Subsidiaries or, in each case, any Contract with a
Governmental Entity, Order, Governing Document or Law. Any such changes to the structure of the Transactions that are agreed upon by FEAC and the Company shall be set forth in writing in an amendment to this Agreement pursuant to the terms hereof.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Party hereby waives any breach of a representation, warranty or covenant by any other Party, where such
breach is a result of an action taken by that other Party or any Affiliate thereof pursuant to a request by the Party in accordance with this Section&nbsp;2.19. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Party shall provide written notice to the other Parties of any proposed
<FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Reorganization at least 15 Business Days prior to the Closing Date. Upon receipt of such notice, each Party shall, to the extent it determines in good faith that such proposed <FONT
STYLE="white-space:nowrap">Pre-Closing</FONT> Reorganization is advisable in accordance with Section&nbsp;2.19(a), cooperate and use commercially reasonable efforts to prepare prior to the Closing Date all documentation necessary and do all such
other acts and things as are reasonably necessary, including making amendments to this Agreement or the Plan of Arrangement, to give effect to such <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Reorganization and to complete such <FONT
STYLE="white-space:nowrap">Pre-Closing</FONT> Reorganization as closely as reasonably practicable prior to the Closing Date. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>R<SMALL>EPRESENTATIONS</SMALL> <SMALL>AND</SMALL> W<SMALL>ARRANTIES</SMALL> R<SMALL>ELATING</SMALL>
<SMALL>TO</SMALL> <SMALL>THE</SMALL> G<SMALL>ROUP</SMALL> C<SMALL>OMPANIES</SMALL> </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Subject to Section&nbsp;8.7,
except as set forth in the Company Disclosure Schedules, the Company hereby represents and warrants to FEAC as follows, it being understood that representations and warranties with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
respect to Group Companies shall be deemed to include Cayman Merger Sub, as applicable, upon and with effect from the date of the execution of a Joinder Agreement by Cayman Merger Sub: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Organization and Qualification</I>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Group Company is a corporation, limited liability company or other applicable business entity duly
organized or formed, as applicable, validly existing and in good standing (or the equivalent thereof, if applicable, in each case, with respect to the jurisdictions that recognize the concept of good standing or any equivalent thereof) under the
Laws of its jurisdiction of formation, incorporation or organization (as applicable). Section&nbsp;3.1(a) of the Company Disclosure Schedules sets forth the jurisdiction of formation or organization (as applicable) for each Group Company. Each Group
Company has the requisite corporate, limited liability company or other applicable business entity power and authority to own, lease and operate its properties and to carry on its businesses as presently conducted, except where the failure to have
such power or authority would not have a Company Material Adverse Effect or prevent, materially delay or materially impair the ability of any Group Company to timely consummate the Transactions. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">True, complete and correct copies of the Governing Documents of each Group Company, the Company Majority
Shareholder Agreement, the form of Company Common Shareholder Agreement and Company Registration Rights Agreement have been made available to FEAC, in each case, as amended and in effect as of the date of this Agreement. The Governing Documents of
each Group Company, the Company Shareholders Agreements and Company Registration Rights Agreement are in full force and effect, no Group Company is in breach or violation of any provision set forth in its Governing Document, and the Company is not
in material breach of the Company Shareholders Agreements or the Company Registration Rights Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Group Company is duly qualified or licensed to transact business and is in good standing (or the
equivalent thereof, if applicable, in each case, with respect to the jurisdictions that recognize the concept of good standing or any equivalent thereof) in each jurisdiction in which the property and assets owned, leased or operated by it, or the
nature of the business conducted by it, makes such qualification or licensing necessary, except where the failure to be so duly qualified or licensed and in good standing would not have a Company Material Adverse Effect or prevent, materially delay
or materially impair the ability of any Group Company to timely consummate the Transactions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Newco was incorporated solely for purposes of entering into the Transactions and, since the date of its
incorporation, Newco has not owned any assets, carried on any business, conducted any operations or incurred any liabilities or obligations or has hired any employee or independent contractor, other than the execution of this Agreement and any
Ancillary Documents, the performance of its obligations hereunder and matters ancillary thereto. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Upon the execution of a Joinder Agreement pursuant to Section&nbsp;5.26, Cayman Merger Sub was incorporated
solely for purposes of entering into the Transactions and, since the date of its incorporation, Cayman Merger Sub has not owned any assets, carried on any business, conducted any operations or incurred any liabilities or obligations or has hired any
employee or independent contractor, other than the execution of the Joinder Agreement pursuant to Section&nbsp;5.26 and any Ancillary Documents, the performance of its obligations hereunder and matters ancillary thereto. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Capitalization of the Group Companies</I>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Section&nbsp;3.2(a) of the Company Disclosure Schedules sets forth a true, complete and correct statement as of
the date of this Agreement of (i)&nbsp;the number and class or series (as applicable) of all of the Equity Securities of each Group Company issued and outstanding, (ii)&nbsp;the identity of the Persons that are the registered owners thereof and
(iii)&nbsp;with respect to each Company Equity Award, (A)&nbsp;the date of grant, (B)&nbsp;any applicable exercise (or similar) price, (C)&nbsp;the expiration date, and (D)&nbsp;any applicable vesting schedule (including acceleration provisions).
All of the Equity Securities of each Group Company have been duly authorized and validly issued and are fully paid and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
<FONT STYLE="white-space:nowrap">non-assessable.</FONT> Except for the Company Equity Awards set forth on Section&nbsp;3.2(a) of the Company Disclosure Schedules or as set forth in the Governing
Documents of the Group Companies, as of the date of this Agreement, no Group Company has outstanding (x)&nbsp;equity appreciation, phantom equity or profit participation rights or (y)&nbsp;options, restricted stock, restricted stock units, phantom
stock, warrants, purchase rights, subscription rights, conversion rights, exchange rights, calls, puts, rights of first refusal or first offer or other Contracts to which a Group Company is a party that require such Group Company to issue, sell or
otherwise cause to become outstanding or to acquire, repurchase or redeem any Equity Securities or securities convertible into or exchangeable for Equity Securities of such Group Company. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The outstanding Equity Securities of the Group Companies (1)&nbsp;were not issued in violation of the Governing
Documents of the Group Companies or the Company Shareholders Agreements, (2)&nbsp;were not issued in violation of any <FONT STYLE="white-space:nowrap">pre-emptive</FONT> rights, call option, right of first refusal or first offer, subscription rights
or similar rights of any Person granted by the Group Companies and (3)&nbsp;have been offered, sold and issued in compliance with applicable Law, including applicable Securities Laws. Except for the Company Shareholders Agreements, there are no
voting trusts, proxies or other Contracts to which a Group Company is a party with respect to the voting or transfer of such Group Company&#146;s Equity Securities. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">None of the Group Companies owns or holds (of record, beneficially, legally or otherwise), directly or
indirectly, any Equity Securities in any Person (other than another Group Company), or the right to acquire any such Equity Security, and none of the Group Companies are a partner or member of any partnership, limited liability company or joint
venture (other than another Group Company). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Authority</I><I>. </I>Subject to the Company Required Approval of the Company Arrangement Resolution, each
Group Company has the requisite corporate power and authority to execute and deliver this Agreement and each Ancillary Document to which it is or will be a party, to perform its obligations hereunder and thereunder, and to consummate the
Transactions. Subject to the Company Required Approval of the Company Arrangement Resolution, the execution and delivery of this Agreement, the Ancillary Documents to which a Group Company is or will be a party and the consummation of the
Transactions have been (or, in the case of any Ancillary Document entered into after the date of this Agreement, will be upon execution thereof) duly authorized by all necessary corporate action on the part of the relevant Group Company. This
Agreement and each Ancillary Document to which a Group Company is or will be a party has been or will be, upon execution thereof, as applicable, duly and validly executed and delivered by the relevant Group Company and constitutes or will
constitute, upon execution and delivery thereof, as applicable, a valid, legal and binding agreement of the relevant Group Company (assuming that this Agreement and the Ancillary Documents to which such Group Company is or will be a party are or
will be, upon execution thereof, as applicable, duly authorized, executed and delivered by the other Persons party hereto or thereto), enforceable against such Group Company in accordance with their terms (subject to applicable bankruptcy,
insolvency, reorganization, moratorium or other Laws affecting generally the enforcement of creditors&#146; rights and subject to general principles of equity). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Financial Statements; Undisclosed Liabilities</I>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The audited consolidated balance sheets of the Company and its Subsidiaries as of October&nbsp;31, 2022 (the
&#147;<B>Latest Balance Sheet</B>&#148;) and the related audited consolidated statements of operations, changes in shareholders&#146; equity and cash flows of the Company and its Subsidiaries for each of the years ended October&nbsp;31, 2020,
October&nbsp;31, 2021 and October&nbsp;31, 2022, including the notes thereto (the &#147;<B>Audited Company Financial Statements</B>&#148;), when delivered following the date of this Agreement in accordance with Section&nbsp;5.16, (A) will be
prepared in accordance with GAAP applied on a consistent basis throughout the periods indicated (except as may be indicated in the notes thereto), (B) will fairly present, in all material respects, the financial position, results of operations and
cash flows of the Company and its Subsidiaries as of the dates thereof and for the periods indicated therein, except as otherwise specifically noted therein, (C)&nbsp;will have been audited in accordance with
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
the standards of the PCAOB and contain an unqualified report of the Company&#146;s auditors, and (D)&nbsp;will comply in all material respects with the applicable accounting requirements and with
the rules and regulations of the SEC, the Exchange Act and the Securities Act in effect as of the respective dates thereof (including Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> or Regulation <FONT STYLE="white-space:nowrap">S-K,</FONT>
as applicable). </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The unaudited consolidated balance sheets of the Company and its Subsidiaries as of April&nbsp;30, 2023 and the
related unaudited consolidated statements of operations and changes in shareholders&#146; equity and cash flows of the Company and its Subsidiaries for each of the <FONT STYLE="white-space:nowrap">six-month</FONT> periods ended April&nbsp;30, 2022
and April&nbsp;30, 2023 (the &#147;<B>Unaudited Company Financial Statements</B>&#148; and together with the Audited Company Financial Statements, the &#147;<B>Company Financial Statements</B>&#148;), when delivered following the date of this
Agreement in accordance with Section&nbsp;5.16, (i) will be prepared in accordance with GAAP applied on a consistent basis throughout the periods indicated (except as may be indicated in the notes thereto), (ii) will fairly present, in all material
respects, the financial position, results of operations and cash flows of the Company and its Subsidiaries as of the dates thereof and for the periods indicated therein (subject to normal <FONT STYLE="white-space:nowrap">year-end</FONT> audit
adjustments (none of which is expected to be material) and the absence of footnotes), except as otherwise specifically noted therein and (iii)&nbsp;will comply in all material respects with the applicable accounting requirements and with the rules
and regulations of the SEC, the Exchange Act and the Securities Act in effect as of the respective dates thereof (including Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> or Regulation <FONT STYLE="white-space:nowrap">S-K,</FONT> as
applicable). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The accounts receivable of the Company and its Subsidiaries reflected on the Latest Balance Sheet arose in the
ordinary course of business from bona fide transactions and in accordance with GAAP and none of such accounts receivable are subject to any set offs, counterclaims, credits or other offsets, and are current and collectible and will be collected in
accordance with their terms and their recorded amounts, subject only to the reserve for bad debts set forth in the Company Financial Statements. The accounts payable of the Company and its Subsidiaries reflected on the Latest Balance Sheet arose in
the ordinary course of business from bona fide transactions and in accordance with GAAP. Since the date of the Latest Balance Sheet, and other than in accordance with, related to or arising out of the negotiation and consummation of the
Transactions, the accounts receivable and accounts payable of the Company and its Subsidiaries have arisen in the ordinary course of business from bona fide transactions. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Except for Liabilities (i)&nbsp;set forth in Section&nbsp;3.4(d) of the Company Disclosure Schedules,
(ii)&nbsp;incurred in connection with the negotiation, preparation or execution of this Agreement or any Ancillary Documents, the performance of its covenants or agreements in this Agreement or any Ancillary Document or the consummation of the
Transactions (including, for the avoidance of doubt, the Company Expenses and any Liabilities arising out of, or related to, any Proceeding related to this Agreement, the Ancillary Documents or the Transactions, including any shareholder demand or
other shareholder Proceedings (including derivative claims) arising out of, or related to, any of the foregoing), (iii) set forth or disclosed in the Company Financial Statements, (iv)&nbsp;that have arisen since the Latest Balance Sheet in the
ordinary course of business (and not as a result of a breach of any Contract by any Group Company), (v) that are incurred with the consent of FEAC or (vi)&nbsp;that are not, and would not reasonably be expected to be, individually or in the
aggregate, material to the Group Companies, taken as a whole, the Company and its Subsidiaries do not have any Liabilities that would be required to be included in a balance sheet prepared in accordance with GAAP or disclosed in the notes thereto,
except in connection with the Transactions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company has established and maintain systems of internal accounting controls with respect to the Company
and its Subsidiaries that are designed to provide, in all material respects, reasonable assurance that (i)&nbsp;all transactions are executed in accordance with management&#146;s authorization and (ii)&nbsp;all transactions are recorded as necessary
to permit preparation of proper and accurate financial statements in accordance with GAAP and to maintain accountability for the Company and its Subsidiaries&#146; assets. The Company and its Subsidiaries maintain and, for all periods covered by the
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Company Financial Statements, have maintained books and records of the Company and its Subsidiaries in the ordinary course of business that are accurate and complete and reflect the revenues,
expenses, assets and liabilities of the Company and its Subsidiaries, in each case in all material respects. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Neither the Company nor any of its Subsidiaries has received any written complaint, allegation, assertion or
claim that there is (i)&nbsp;to the Company&#146;s knowledge, &#147;<B>significant deficiency</B>&#148; in the internal controls over financial reporting of the Company and its Subsidiaries, (ii)&nbsp;to the Company&#146;s knowledge, a
&#147;<B>material weakness</B>&#148; in the internal controls over financial reporting of the Company and its Subsidiaries or (iii)&nbsp;fraud or corporate misappropriation, whether or not material, that involves management or other employees of the
Company or its Subsidiaries who have a significant role in the internal controls over financial reporting of the Company and its Subsidiaries. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Consents and Requisite Governmental Approvals; No Violations</I>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No consent, approval or authorization of, or designation, declaration or filing with, any Governmental Entity
is required on the part of any Group Company with respect such Group Company&#146;s execution, delivery or performance of its obligations under this Agreement or the Ancillary Documents to which the Group Company is or will be party or the
consummation of the Transactions, except for (i)&nbsp;compliance with and filings under any applicable antitrust or other competition Laws of any <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions (collectively, &#147;<B>Foreign
Antitrust Laws</B>&#148;), (ii) the filing with the SEC of (A)&nbsp;the Registration Statement / Proxy Statement and the declaration of the effectiveness thereof by the SEC and (B)&nbsp;such reports under Section&nbsp;13(a) or 15(d) of the Exchange
Act as may be required in connection with this Agreement, the Ancillary Documents or the Transactions, (iii)&nbsp;the filing of the Canadian Prospectus with the Autorit&eacute; des march&eacute;s financiers du Qu&eacute;bec, (iv)&nbsp;the filing of
any documents required by the Final Order, the Interim Order, and filings required pursuant to the Plan of Arrangement, (v)&nbsp;the Company Required Approval in respect of the Company Arrangement Resolutions, or (vi)&nbsp;any other consents,
approvals, authorizations, designations, declarations, waivers or filings, the absence of which would not have a Company Material Adverse Effect. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Neither the execution, delivery or performance by a Group Company of this Agreement nor the Ancillary Documents
to which such Group Company is or will be a party nor the consummation by the Group Company of the Transactions will, directly or indirectly (with or without due notice or lapse of time or both)&nbsp;(i) result in any breach of any provision of the
relevant Group Company&#146;s Governing Documents or the Company Shareholders Agreements, (ii)&nbsp;result in, other than as set out in Section&nbsp;3.5(b) of the Company Disclosure Schedules, a violation or breach of, or constitute a default or
give rise to any right of termination, Consent, cancellation, amendment, modification, suspension, revocation or acceleration under, any of the terms, conditions or provisions of (A)&nbsp;any Material Contract to which any Group Company is a party
or (B)&nbsp;any Material Permits, (iii)&nbsp;violate, or constitute a breach under, any Order or applicable Law to which any Group Company or any of its properties or assets are bound, or (iv)&nbsp;result in the creation of any Lien (other than
Permitted Liens) upon any of the assets or properties of any Group Company, except, in the case of clauses (i)&nbsp;through (iv) above, as would not have a Company Material Adverse Effect or prevent, materially delay or materially impair the ability
of any Group Company to timely consummate the Transactions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Permits</I><I>. </I>Each of the Group Companies has all Permits (the &#147;<B>Material Permits</B>&#148;)
that are required to own, lease or operate its properties and assets and to conduct its business as currently conducted, except where the failure to hold the same would not result in a Company Material Adverse Effect. (a)&nbsp;Each Material Permit
is in full force and effect in accordance with its terms and (b)&nbsp;no written notice of revocation, cancellation or termination of any Material Permit has been received by the Group Companies, except, in each case, as would not reasonably be
expected to be, individually or in the aggregate, material to the Group Companies, taken as a whole. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Material Contracts</I>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company has made available to FEAC, true, correct and complete copies of the following Contracts to which a
Group Company is, as of the date of this Agreement, a party (such contracts, collectively, the &#147;<B>Material Contracts</B>&#148;): </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any Contract relating to Indebtedness of any Group Company or to the placing of a Lien (other than any
Permitted Lien) on any material assets or properties of any Group Company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any Contract under which any Group Company is lessee of or holds or operates, in each case, any tangible
property (other than real property), owned by any other Person, except for any lease or agreement under which the aggregate annual rental payments do not exceed $50,000; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any Contract under which any Group Company is lessor of or permits any third party to hold or operate, in each
case, any tangible property (other than real property), owned or controlled by such Group Company, except for any lease or agreement under which the aggregate annual rental payments do not exceed $50,000; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any joint venture, profit-sharing, partnership, collaboration,
<FONT STYLE="white-space:nowrap">co-promotion,</FONT> commercialization or research or development Contract; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any material Contract pursuant to which any Group Company licenses or sublicenses from or to any third party
(or receives from or grants to any third party a covenant not to sue with respect to) any Intellectual Property Right, including any (A)&nbsp;license, royalty, indemnification, covenant not to sue, escrow,
<FONT STYLE="white-space:nowrap">co-existence,</FONT> concurrent use, consent to use, assignment, development or other Contract relating to any Intellectual Property Rights, in each case, other than <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Off-the-Shelf-Software</FONT></FONT> licenses with aggregate annual payments of less than $150,000 and (B)&nbsp;other Contracts that have any material effect on any of the Group Companies&#146; ability to own, enforce,
defend, use, license or disclose any Intellectual Property Rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any Contract that (A)&nbsp;limits in any material respect the freedom of any Group Company to engage or compete
in any line of business or with any Person or in any area or that would so limit, in any material respect, the operations of any Group Company, or following the Closing, FEAC, (B)&nbsp;contains any exclusivity, &#147;most favored nation&#148; or
similar provisions, obligations or restrictions or (C)&nbsp;contains any other provisions restricting the ability of any Group Company to sell, manufacture, develop, commercialize, test or research products, directly or indirectly through third
parties, or to solicit any potential employee or customer, all in any material respect or that would so limit, in any material respect, the operations of the Company, other than in respect of <FONT STYLE="white-space:nowrap">non-disclosure</FONT>
agreements entered into by any Group Company in the ordinary course of business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any Contract requiring any future capital commitment or capital expenditure (or series of capital expenditures)
by any Group Company in an amount in excess of (A) $150,000 annually or (B) $300,000 over the term of the agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(viii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any Contract requiring any Group Company to guarantee the Liabilities of any Person (other than the Company or
a Subsidiary of the Company) or pursuant to which any Person (other than the Company or a Subsidiary of the Company) has guaranteed the Liabilities of a Group Company, in each case in excess of $50,000; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ix)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any Contract under which any Group Company has, directly or indirectly, made or agreed to make any loan,
advance, or assignment of payment to any Person or made any capital contribution to, or other investment in, any Person (other than the Company or a Subsidiary of the Company); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(x)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any Contract required to be disclosed on Section&nbsp;3.19 of the Company Disclosure Schedules;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(xi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any Contract (A)&nbsp;governing the terms of, or otherwise related to, the employment, engagement or services
of any current director, manager, officer, employee, individual independent </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
contractor or other individual service provider of a Group Company whose annual base salary (or, in the case of an individual independent contractor, annual base compensation) is in excess of
$180,000, except for Contracts with independent contractors where such Contract is for a fixed term and the compensation paid during that term does not exceed $180,000, or (B)&nbsp;providing for any Company Change of Control Payment;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(xii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any CBA; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(xiii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any Contract for the disposition of any portion of the assets or business of any Group Company or for the
acquisition by any Group Company of the assets or business of any other Person (other than acquisitions or dispositions made in the ordinary course of business), or under which any Group Company has any continuing obligation with respect to an <FONT
STYLE="white-space:nowrap">&#147;earn-out&#148;,</FONT> contingent purchase price or other contingent or deferred payment obligation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(xiv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any settlement, conciliation or similar Contract (A)&nbsp;the performance of which would be reasonably likely
to involve any payments in excess of $50,000 after the date of this Agreement, (B)&nbsp;with a Governmental Entity or (C)&nbsp;that imposes or is reasonably likely to impose, at any time in the future, any material,
<FONT STYLE="white-space:nowrap">non-monetary</FONT> obligations on any Group Company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(xv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any Contract regarding any material indemnification obligations incurred or provided by any Group Company other
than in the ordinary course of business; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(xvi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any other Contract the performance of which requires either (A)&nbsp;annual payments to or from any Group
Company in excess of $150,000 or (B)&nbsp;aggregate payments to or from any Group Company in excess of $300,000 over the term of the agreement and, in each case, that is not terminable by the applicable Group Company without penalty upon less than
thirty (30)&nbsp;days&#146; prior written notice. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Except as disclosed in Section&nbsp;3.7(b) of the Company Disclosure Schedule, (i)&nbsp;each Material Contract
is valid and binding on the applicable Group Company and, to the knowledge of the Company, the counterparty thereto, and is in full force and effect, (ii)&nbsp;the applicable Group Company and, to the knowledge of the Company, the counterparties
thereto are not in material breach of, or material default under, any Material Contract, (iii)&nbsp;to the Company&#146;s knowledge, no event or omission has occurred that, through the passage of time or the giving of notice, or both, would
constitute a default in any material respect thereunder or cause the acceleration of any Group Company&#146;s obligations thereunder or result in the creation of any Lien, other than Permitted Liens, (iv)&nbsp;the Company has delivered or made
available to FEAC true, complete and accurate copies of each Material Contract, including all material amendments, schedules, ancillary documents, annexes, exhibits or certificates related thereto, and (v)&nbsp;as of the date hereof, no Group
Company has received written, or to the Company&#146;s knowledge, oral, notice of termination, cancellation or <FONT STYLE="white-space:nowrap">non-renewal</FONT> of any Material Contract. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Absence of Changes</I><I>. </I>During the period beginning on November&nbsp;1, 2022 and ending on the date
of this Agreement, (a)&nbsp;no Company Material Adverse Effect has occurred, and (b)&nbsp;except as otherwise reflected in the Company Financial Statements, or as expressly contemplated by this Agreement, any Ancillary Document or otherwise in
connection with the Transactions, (i)&nbsp;the Company has conducted its business in the ordinary course in all material respects and (ii)&nbsp;no Group Company has taken any action that would require the consent of FEAC if taken during the period
from the date of this Agreement until the Closing pursuant to Section&nbsp;5.1(b). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Litigation</I><I>. </I>There is (and since April&nbsp;1, 2020, there has been) no Proceeding pending or, to
the Company&#146;s knowledge, threatened by or against any Group Company that, if adversely decided or resolved, has been or would reasonably be expected to be, individually or in the aggregate, material to the Group Companies, taken as a whole or
prevent, materially delay or materially impair the ability of any Group Company to timely consummate the Transactions. Neither the Group Companies nor any of their respective properties
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
or assets is subject to any material Order (including any Order that would prevent, materially delay or materially impair the ability of the Company to timely consummate the Transactions). As of
the date of this Agreement, there are no material Proceedings by a Group Company pending against any other Person. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Compliance with Applicable Law</I><I>. </I>Each Group Company (a)&nbsp;conducts, and since April&nbsp;1,
2020 has conducted, its business in accordance with all Laws and Orders applicable to such Group Company and is not in violation of any such Law or Order, including any Law or Order related to <FONT STYLE="white-space:nowrap">COVID-19,</FONT> and
(b)&nbsp;has not received any written communications from a Governmental Entity that alleges that such Group Company is not in compliance with any such Law or Order, except in the case of each of clauses (a)&nbsp;and (b), as is not and would not
reasonably be expected to result in a Company Material Adverse Effect. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Employee Plans</I>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company has made available to FEAC a true, complete and correct list of, and corresponding copies of, all
material Employee Benefit Plans (including, for each such Employee Benefit Plan, its jurisdiction). With respect to each material Employee Benefit Plan, the Group Companies have made available to FEAC true, complete and correct copies of the
material documents pursuant to which the plan is maintained, funded and administered including, for each material Employee Benefit Plan, (i)&nbsp;the most recent plan text and amendments, (ii)&nbsp;the most recently prepared actuarial valuation
report, (iii)&nbsp;all material correspondence with any applicable Governmental Entity for the current year and the previous three (3)&nbsp;years, and (iv)&nbsp;the most recent employee booklet. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No Group Company has any Liability with respect to or under: (i)&nbsp;a Multiemployer Plan; (ii)&nbsp;a
&#147;defined benefit plan&#148; (as defined in Section&nbsp;3(35) of ERISA, whether or not subject to ERISA) or a plan that is or was subject to Title IV of ERISA or Section&nbsp;412 of the Code; (iii)&nbsp;a &#147;multiple employer plan&#148;
within the meaning of Section of 413(c) of the Code or Section&nbsp;210 of ERISA; or (iv)&nbsp;a &#147;multiple employer welfare arrangement&#148; as defined in Section&nbsp;3(40) of ERISA. No Group Company has any Liabilities to provide any
retiree, post-ownership or post-termination health or life insurance or other welfare-type benefits to any Person other than (A)&nbsp;health continuation coverage pursuant to COBRA for which the recipient pays the entire cost of coverage (other than
as provided in employment agreements made available to FEAC), and (B)&nbsp;to the minimum extent required by any applicable employment standards Laws of Canada. No Group Company has any Liabilities by reason of at any time being considered a single
employer under Section&nbsp;414 of the Code with any other Person. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Employee Benefit Plan that is intended to be qualified under Section&nbsp;401(a) of the Code (i)&nbsp;has
timely received a favorable determination or opinion or advisory letter from the Internal Revenue Service, (ii)&nbsp;has been established under a standardized master and prototype or volume submitter plan for which a current favorable Internal
Revenue Service advisory letter or opinion letter has been obtained by the plan sponsor and is valid as to the adopting employer or (iii)&nbsp;has time remaining under applicable Laws to apply for a determination or opinion letter or to make any
amendments necessary to obtain a favorable determination or opinion letter, and, to the knowledge of the Company, nothing has occurred that would reasonably be expected to adversely affect the qualified status of such Employee Benefit Plan. None of
the Group Companies has incurred (whether or not assessed), or is reasonably expected to incur or be subject to, any Liability, penalty or Tax under Section&nbsp;4980H, 4980B, 4980D, 6721 or 6722 of the Code. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">There are no pending or, to the Company&#146;s knowledge, threatened material claims or Proceedings with
respect to any Employee Benefit Plan (other than routine claims for benefits). There have been no material <FONT STYLE="white-space:nowrap">non-exempt</FONT> &#147;prohibited transactions&#148; within the meaning of Section&nbsp;4975 of the Code or
Sections 406 or 407 of ERISA and no breaches of fiduciary duty (as determined under ERISA) with respect to any Employee Benefit Plan. With respect to each Employee Benefit Plan, all contributions, distributions, reimbursements and premium payments
that are due have been timely made in all material respects in accordance with the terms of the Employee Benefit Plan and in all material respects in compliance with the requirements of applicable Laws; and all such contributions,
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
distributions, reimbursements and premium payments for any period ending on or before the Closing Date that are not yet due have been made or properly accrued under applicable accounting
principles. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The execution and delivery of this Agreement and the consummation of the Transactions will not (alone or in
combination with any other event)&nbsp;(i) result in any payment or benefit becoming due to or result in the forgiveness of any indebtedness of any current or former director, manager, officer, employee, individual independent contractor or other
individual service providers of any of the Group Companies, (ii)&nbsp;increase the amount or value of any compensation or benefits payable to any current or former director, manager, officer, employee, individual independent contractor or other
individual service providers of any of the Group Companies, (iii)&nbsp;except as disclosed in Section&nbsp;3.11(e)(iii) of the Company Disclosure Schedules, result in the acceleration of the time of payment or vesting, or trigger any payment or
funding of any compensation or benefits to any current or former director, manager, officer, employee, individual independent contractor or other individual service providers of any of the Group Companies or (iv)&nbsp;limit or restrict the right of
any of the Group Companies to merge, amend or terminate any Employee Benefit Plan after Closing. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No amount that could be received (whether in cash or property or the vesting of property) by any
&#147;disqualified individual&#148; (as defined in Section&nbsp;280G of the Code) under any Employee Benefit Plan or otherwise as a result of the consummation of the Transactions could, separately or in the aggregate, be nondeductible under
Section&nbsp;280G of the Code or subjected to an excise tax under Section&nbsp;4999 of the Code. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Group Companies have no obligation to make a <FONT STYLE="white-space:nowrap">&#147;gross-up&#148;</FONT>
or similar payment in respect of any taxes that may become payable under Section&nbsp;4999, 409A or 457A of the Code. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Employee Benefit Plan that constitutes in any part a &#147;nonqualified deferred compensation plan&#148;
(as defined under Section&nbsp;409A(d)(1) of the Code) subject to Section&nbsp;409A of the Code has been operated and administered in all material respects in operational compliance with, and is in all material respects in documentary compliance
with, Section&nbsp;409A of the Code and its purpose, and no amount under any such plan, agreement or arrangement is or has been subject to the interest and additional Tax set forth under Section&nbsp;409A(a)(1)(B) of the Code. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Foreign Benefit Plan that is required to be registered or intended to be tax exempt has been registered
(and, where applicable, accepted for registration) and is tax exempt and has been maintained in good standing, to the extent applicable, with each Governmental Entity. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No Foreign Benefit Plan is (A)&nbsp;a &#147;defined benefit plan&#148; (as defined in ERISA, whether or not
subject to ERISA); (B) a &#147;registered pension plan&#148; (within the meaning of subsection 248(1) of the Tax Act); (C) a &#147;retirement compensation arrangement&#148; (within the meaning of subsection 248(1) of the Tax Act); or (D)&nbsp;has
any material unfunded or underfunded Liabilities. No Foreign Benefit Plan is intended to be, or has ever been determined or alleged by a Governmental Entity to be, a &#147;salary deferral arrangement&#148; within the meaning of subsection 248(1) of
the Tax Act. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(k)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All material contributions required to have been made by or on behalf of the Group Companies with respect to
plans or arrangements maintained or sponsored a Governmental Entity (including severance, termination indemnities or other similar benefits; Canada Pension Plan and Qu&eacute;bec Pension Plan contributions; unemployment insurance premiums;
workers&#146; compensation premiums and assessments; maintained for employees outside of the U.S.) have been timely made or fully accrued. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Environmental Matters</I>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">None of the Group Companies have received any written notice, report, Order, communication or other information
from any Governmental Entity or any other Person regarding any actual, alleged, or potential violation in any material respect of, failure to comply in any material respect with, or material Liability under, any Environmental Laws.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Except as would not be material to the Group Companies, taken as a whole: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Group Companies are (and, since April&nbsp;1, 2020, have been) in compliance with all Environmental Laws,
which compliance has included obtaining, maintaining and complying with all Permits that are required pursuant to Environmental Laws for the ownership or occupation of their facilities and the operation of their business. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">There is no Proceeding pending or, to the Company&#146;s knowledge, threatened against any Group Company
pursuant to Environmental Laws. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">There has been no manufacture, release, treatment, storage, disposal, arrangement for disposal, transport or
handling of, contamination by, or exposure of any Person to, any Hazardous Substances, in each case in a manner that has given or would give rise to Liabilities of the Group Companies under Environmental Law. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Group Companies have not assumed, undertaken, provided an indemnity with respect to or otherwise knowingly
become subject to any Liabilities of any other Person under Environmental Law. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Group Companies have made available to FEAC copies of all written environmental reports, audits, and
assessments and all other material environmental, health and safety documents that are in any Group Company&#146;s possession or control relating to the current or former operations, properties or facilities of the Group Companies.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Intellectual Property</I>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company has made available to FEAC a true, complete and correct list of all currently issued or pending
Company Registered Intellectual Property. For each item of Company Registered Intellectual Property, (x)&nbsp;a Group Company is the sole and exclusive registered owner of such item and (y)&nbsp;the Company has made available to FEAC a list
including (1)&nbsp;the jurisdictions in which such item has been issued or registered or filed, (2)&nbsp;the issuance, registration or application date, as applicable, for such item, (3) the issuance, registration or application number, as
applicable, for such item and (4)&nbsp;the title of such item. All material Company Registered Intellectual Property (i)&nbsp;has been duly maintained (including the timely payment of registration, maintenance and renewal fees and timely filing of
statements of use), (ii) is subsisting, in full force and effect and not expired, abandoned or cancelled, (iii)&nbsp;to the knowledge of the Company, is valid and enforceable and (iv)&nbsp;has not been adjudged invalid or unenforceable, in whole or
in part. No Group Company has received written notice of any Proceedings pending, including litigation, interference, <FONT STYLE="white-space:nowrap">re-examination,</FONT> inter parties review, reissue, opposition, nullity, or cancellation
Proceedings, that relate to any of the Company Registered Intellectual Property and, to the Company&#146;s knowledge, no such Proceedings are threatened by any Governmental Entity or any other Person. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A Group Company solely and exclusively owns all right, title and interest in and to the Company Owned
Intellectual Property and a Group Company holds a valid and enforceable license to all Company Licensed Intellectual Property, in each case, free and clear of all Liens (other than Permitted Liens). With respect to each item of Company Registered
Intellectual Property that is held by any Group Company related to a Company Product or, to the knowledge of the Company, any of their respective licensors by assignment, such assignment has been duly recorded with the applicable Governmental Entity
from which such Company Registered Intellectual Property was issued or granted or before which such Company Registered Intellectual Property is pending. The Group Companies have, and, to the knowledge of the Company, the Group Companies&#146;
licensors have, complied with, in all material respects, all necessary and applicable Laws regarding the duty of disclosure, candor and good faith in connection with each Patent included in the Company Registered Intellectual Property.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No Group Company has (i)&nbsp;transferred ownership of, or granted any exclusive license with respect to, any
material Company Owned Intellectual Property to any other Person or (ii)&nbsp;granted any </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
customer the right to use any material Company Product or service on anything other than a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> basis. The Group Companies own or have a valid and
enforceable written license to use, all Intellectual Property Rights used in, held for use in or otherwise necessary for the operation of the businesses of the Group Companies as currently conducted. No Company Owned Intellectual Property or, to the
knowledge of the Company, no Company Licensed Intellectual Property is subject to any outstanding Order that restricts in any material respect the use, sale, transfer, licensing or exploitation thereof by the Group Companies or affects the validity,
use or enforceability of any such Company Intellectual Property. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All current and former employees and independent contractors who independently or jointly contributed to or
otherwise participated in the authorship, invention, creation, improvement, modification or development of any material Intellectual Property Right for or on behalf of any Group Company have executed and delivered to the Group Company a written
contract providing for (i)&nbsp;the <FONT STYLE="white-space:nowrap">non-disclosure</FONT> by such Person of all Trade Secrets of the Group Companies, (ii)&nbsp;the present assignment by such Person to a Group Company of all such Intellectual
Property Rights authored, invented, created, improved, modified or developed, as applicable, by such Person in the course of their employment or other engagement with such Group Company and (iii)&nbsp;the irrevocable waiver of moral rights that such
Person may possess in and to any Intellectual Property Right. To the knowledge of the Company, no such agreement has been breached or otherwise violated. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Group Company has taken commercially reasonable steps, to maintain, defend and enforce all material
Company Owned Intellectual Property and their respective rights in all material Company Licensed Intellectual Property, including reasonable steps to maintain and protect the confidentiality of any Trade Secrets included in the Company Intellectual
Property, and to the knowledge of the Company, no such Trade Secrets have been disclosed to any other Person unless such disclosure was under an appropriate written <FONT STYLE="white-space:nowrap">non-disclosure</FONT> agreement containing
appropriate limitations on use, reproduction and disclosure, which have not been breached or otherwise violated. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To the knowledge of the Company, none of the Group Companies or any of the Company Products have infringed,
misappropriated, or otherwise violated, or are infringing, misappropriating or otherwise violating any Intellectual Property Rights of any other Person. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">There is no Proceeding pending, or to the knowledge of the Company, threatened, against any Group Company
(i)&nbsp;alleging that a Group Company has infringed, used without authorization, misappropriated or otherwise violated any Intellectual Property Rights of any other Person, or (ii)&nbsp;challenging the validity, enforceability, patentability,
registrability, use or any Group Company&#146;s right, title or interest in, to or under any Company Intellectual Property. No Group Company has received any written or, to the knowledge of the Company, threatened invitation from any Person to take
a license under any Patent or consider the applicability of any Patents to any products or services of the Group Companies or to the conduct of the business of the Group Companies. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To the Company&#146;s knowledge, no Person is infringing, misappropriating or otherwise violating, or has
infringed, misappropriated or otherwise violated any Company Owned Intellectual Property or any of the Group Company&#146;s rights under any Company Licensed Intellectual Property. No Group Company has made any written claim against any Person
alleging any infringement, misappropriation or other violation of any Company Intellectual Property. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Group Companies and, to the knowledge of the Company, the Group Companies&#146; licensors, have taken any
and all actions necessary to obtain, secure, maintain, enforce and protect the applicable Group Company&#146;s, or such licensors&#146;, as applicable, right, title and interest in, to and under any and all material Company Intellectual Property
that was created, developed or reduced to practice, or is being created, developed or reduced to practice, (i)&nbsp;pursuant to, or in connection with, any Contract with any Governmental Entity or Governmental Entity-affiliated entity, or
university, college or other educational institution or (ii)&nbsp;using any funding or facilities of any Governmental Entity or Governmental Entity-affiliated entity, or university, college or other educational institution
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
(collectively, &#147;<B>Government Funded IP</B>&#148;), and the Group Companies, and, to the knowledge of the Company, the Group Company&#146;s licensors, have complied with any and all any
Intellectual Property Rights disclosure and/or licensing obligations under any applicable Contract referenced in clause (i)&nbsp;above. The consummation of the Transactions will not necessitate the repayment of any funds received from any
Governmental Entity. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The execution and delivery of this Agreement and the consummation of the Transactions will not alter, encumber,
impair or extinguish any material Company Intellectual Property. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.14</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Labor Matters</I>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Group Companies are and since April&nbsp;1, 2020 have been in compliance in all material respects with all
applicable Laws respecting labor, employment and employment practices, including, without limitation, all laws respecting terms and conditions of employment, health and safety, <FONT STYLE="white-space:nowrap">COVID-19,</FONT> wages and hours
(including the classification of individual independent contractors and exempt and <FONT STYLE="white-space:nowrap">non-exempt</FONT> employees), immigration (including the completion of <FONT STYLE="white-space:nowrap">I-9s</FONT> for all
applicable employees and the proper confirmation of employee visas), harassment, discrimination and retaliation, disability rights or benefits, equal opportunity (including compliance with any affirmative action plan obligations), plant closures and
layoffs (including WARN), workers&#146; compensation, labor relations, employee leave issues, pay equity, French language, termination, affirmative action and affirmative action plan requirements and unemployment insurance. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Since April&nbsp;1, 2020, (i) none of the Group Companies (A)&nbsp;except as disclosed in Section&nbsp;3.14(b)
of the Company Disclosure Schedules, have or has had any material Liability for any arrears of or unpaid wages or other compensation for services to their current or former officer, directors, employees and individual independent contractors
(including salaries, overtime, wage premiums, commissions, fees or bonuses) under applicable Law, Contract or company policy, or any penalty, fines, Taxes, interest or other sums for failure to comply with any of the foregoing, or (B)&nbsp;has or
has had any material Liability for any payment to any trust or other fund governed by or maintained by or on behalf of any Governmental Entity with respect to unemployment compensation benefits, social security, social insurances or other benefits
or obligations for any current or former employees of any Group Company (other than routine payments to be made in the normal course of business and consistent with past practice); and (ii)&nbsp;the Group Companies have withheld all amounts required
by applicable Law or by agreement to be withheld from wages, salaries and other payments to employees or individual independent contractors or other individual service providers of each Group Company, except as has not resulted in material Liability
to the Group Companies, taken as a whole. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Since April&nbsp;1, 2020, there has been no &#147;<B>mass layoff</B>&#148;, &#147;<B>collective
dismissal</B>&#148;, &#147;<B>mass termination</B>&#148; or &#147;<B>plant closing</B>&#148; as defined by applicable Laws, including WARN related to any Group Company, and the Group Companies have not incurred any material Liability under WARN nor
will they incur any Liability under WARN as a result of the Transactions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No Group Company is negotiating, a party to or bound by any collective bargaining agreement or other agreement
with any labor organization, labor union, works council or other employee representative or any other Contract with a labor union, labor organization, works council, employee delegate, representative or other employee collective group (each, a
&#147;<B>CBA</B>&#148;) nor is there any duty on the part of any Group Company to bargain with any labor union, labor organization, works council, employee delegate, representative or other employee collective group. There are no CBAs or any other
labor-related agreements or arrangements that pertain to any of the employees of the Group Companies, and no employees of the Group Companies are represented by any labor union, labor organization, works council, employee delegate, representative or
employee collective group with respect to their employment with the Group Companies. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Since April&nbsp;1, 2020, there has been no actual or, to the Company&#146;s knowledge, threatened unfair labor
practice complaints or charges, material grievances, arbitrations, strikes, lockouts, work </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
stoppages, slowdowns, picketing, hand billing or other material labor disputes against any Group Company. No trade union, council of trade unions, employee bargaining agency or affiliated
bargaining agent holds bargaining rights with respect to any of the employees of any Group Company by way of certification, interim certification, voluntary recognition, or succession rights, or has applied or, to the knowledge of the Company,
threatened to apply to be certified as the bargaining agent of any employees of any Group Company. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To the Company&#146;s knowledge, since April&nbsp;1, 2020, (i) no labor union, works council, other labor
organization, or group of employees of any Group Company has made a demand for recognition, and there are no representation proceedings presently pending or, to the knowledge of the Company, threatened to be brought or filed with the National Labor
Relations Board or any other labor relations tribunal or authority and (ii)&nbsp;to the knowledge of the Company, there have been no labor organizing activities with respect to any employees of any Group Company. No trade union has applied to have
any Group Company declared a common or related employer pursuant to applicable legislation in any jurisdiction in which any Group Company carries on business. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To the knowledge of the Company, no current or former employee or individual independent contractor of any
Group Company is in any material respect in violation of any term of any employment agreement, nondisclosure agreement, common law nondisclosure obligation, fiduciary duty, legal duty of loyalty, noncompetition agreement, restrictive covenant or
other similar obligation: (i)&nbsp;owed to any Group Company; or (ii)&nbsp;owed to any third party with respect to such person&#146;s right to be employed or engaged by the applicable Group Company. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To the knowledge of the Company, no current employee with aggregate annual compensation in excess of $75,000,
intends to terminate his or her employment prior to the one (1)&nbsp;year anniversary of the Closing Date. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No employee layoff, facility closure or shutdown (whether voluntary or by Order), <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">reduction-in-force,</FONT></FONT> furlough, temporary layoff, material work schedule change or reduction in hours, or reduction in salary or wages, or other material workforce changes
affecting employees of the Group Companies has occurred within the past twelve (12)&nbsp;months or is currently contemplated, planned or announced by the Group Companies, including as a result of <FONT STYLE="white-space:nowrap">COVID-19</FONT> or
any Law, Order, directive, guidelines or recommendations by any Governmental Entity in connection with or in response to <FONT STYLE="white-space:nowrap">COVID-19.</FONT> The Group Companies have not otherwise experienced any material
employment-related liability with respect to or arising out of <FONT STYLE="white-space:nowrap">COVID-19</FONT> or any Law, Order, directive, guidelines or recommendations by any Governmental Entity in connection with or in response to <FONT
STYLE="white-space:nowrap">COVID-19.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company has made available to FEAC a true, correct and complete list of each of the business support
measures or government programs (including any supplemental employment plan or wage subsidy program) any Group Company has, as of the date of this Agreement, applied for with any Governmental Entity as a result of the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic (each a &#147;<B>COVID Program</B>&#148;), including the date of the application and status of the application. Each Group Company has performed all of the obligations required to be
performed by it in all material respects and is entitled to all benefits pursuant to such COVID Program. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(k)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Group Companies have promptly, thoroughly and impartially investigated all harassment (including
psychological or sexual harassment), or other discrimination, retaliation or policy violation allegations of which they are aware or ought to have been aware. With respect to each such allegation with potential merit, the Group Companies have taken
prompt corrective action that is reasonably calculated to prevent further improper conduct. The Group Companies do not reasonably expect any material Liability with respect to any such allegations and are not aware of any allegations relating to
officers, directors, employees, contractors, or agents of any Group Company, that, if known to the public, would bring such Group Company into material disrepute. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(l)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Except as set forth in the employment agreements that have been made available to FEAC, no executive level
employee or other employee to be named in the Registration Statement / Proxy </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Statement of any Group Company has any agreement as to length of notice, termination or severance payment required to terminate his or her employment, other than such as results by Law from the
employment of an employee without an agreement as to notice, termination or severance payment. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(m)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No audit of a Group Company by a Governmental Entity is being conducted, or to the knowledge of the Company is
pending, in respect of any foreign workers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(n)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">There are no outstanding assessments, penalties, fines, liens, charges, surcharges, or other amounts due or
owing pursuant to any workplace safety and insurance legislation and no Group Company has been reassessed in any material respect under such legislation since April&nbsp;1, 2020 and, to the knowledge of the Company, no audit of any Group Company is
currently being performed pursuant to any applicable workplace safety and insurance legislation. There are no claims or potential claims which may materially adversely affect any Group Company&#146;s accident cost experience in respect of its
business. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(o)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company has provided to FEAC all orders and inspection reports under applicable occupational health and
safety legislation (&#147;<B>OHSA</B>&#148;) together with the minutes of the joint health and safety committee meetings of the Group Companies for the period beginning on April&nbsp;1, 2020 and ending on the date of this Agreement. There are no
charges pending under OHSA. Each Group Company has complied in all material respects with any orders issued under OHSA and there are no appeals of any orders under OHSA currently outstanding. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.15</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Insurance</I><I>. </I>The Company has made available to FEAC true, complete and correct copies of all
material policies of fire, liability, workers&#146; compensation, property, casualty and other forms of insurance owned or held by any Group Company as of the date of this Agreement. All such policies are in full force and effect, all premiums due
and payable thereon as of the date of this Agreement have been paid in full as of the date of this Agreement, and true, complete and correct copies of all such policies have been made available to FEAC. As of the date of this Agreement, no claim by
any Group Company is pending under any such policies as to which coverage has been denied or disputed, or rights reserved to do so, by the underwriters thereof, except as is not and would not reasonably be expected to be, individually or in the
aggregate, material to the Group Companies, taken as a whole. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.16</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Tax Matters</I>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No Group Company is currently the subject of a Tax Contest. No Group Company has been informed in writing of
the commencement or anticipated commencement of any Tax audit or examination that has not been resolved or completed, and to the knowledge of each Group Company, no such audit or examination has been threatened. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Group Company has prepared and timely filed all material Tax Returns required to have been filed by it
(after giving effect to any valid extensions of time in which to make such filings), all such Tax Returns are true, complete and correct in all material respects and prepared in compliance in all material respects with all applicable Laws and
Orders, and each Group Company has timely paid all material Taxes required to have been paid or deposited by it regardless of whether shown on a Tax Return (except with respect to matters contested in good faith by appropriate proceedings and with
respect to which adequate reserves have been made in accordance with GAAP). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Group Company has timely withheld, collected and paid to the appropriate Tax Authority all material
amounts required to have been withheld, collected and paid. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No Group Company (i)&nbsp;has made an election to defer the payment of any &#147;applicable employment
taxes&#148; (as defined in Section&nbsp;2302(d)(1) of the CARES Act) pursuant to Section&nbsp;2302 of the CARES Act nor has any Group Company made any such deferral or election pursuant to the presidential memorandum regarding Deferring Payroll Tax
Obligations in Light of the Ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> Disaster signed on August&nbsp;8, 2020 or (ii)&nbsp;has applied for a loan under 15 U.S.C. 636(a)(36) (a &#147;<B>PPP Loan</B>&#148;). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No Group Company has consented to extend or waive the time in which any material Tax may be assessed or
collected by any Tax Authority, other than any such extensions or waivers that are no longer in effect or that were automatic extensions of time to file Tax Returns obtained in the ordinary course of business. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No &#147;<B>closing agreement</B>&#148; as described in Section&nbsp;7121 of the Code (or any corresponding or
similar provision of U.S., Canadian or other <FONT STYLE="white-space:nowrap">non-U.S.</FONT> state, local or provincial income Tax Law), private letter rulings, technical advice memoranda or similar agreements or rulings have been entered into or
issued by any Tax Authority with respect to a Group Company which agreement or ruling would be effective after the Closing Date, and there is no such request outstanding relating to any of the foregoing. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No Group Company will be required to include any item in taxable income, or exclude any item of deduction, for
any period ending after the Closing Date by reason of (i)&nbsp;a change in method of accounting for any period (or portion thereof) ending on or before the Closing Date, (ii)&nbsp;a use of an improper method of accounting for any period (or portion
thereof) ending on or before the Closing Date, (iii)&nbsp;an installment sale or open transaction disposition made on or prior to the Closing Date, (iv)&nbsp;an election made pursuant to Section&nbsp;965(h) of the Code (or any corresponding or
similar provision of state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Law), or (v)&nbsp;any prepaid amount received or deferred revenue accrued on or prior to the Closing Date. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The unpaid Taxes of the Group Companies (i)&nbsp;for all periods ending on or before the date of the Latest
Balance Sheet do not, in the aggregate, materially exceed the reserve for Tax liability (other than any reserve for deferred Taxes established to reflect timing differences between book and Tax income) set forth on the Company Financial Statements
and (ii)&nbsp;will not, in the aggregate, materially exceed that reserve as adjusted for operations and transactions through the Closing Date that occur in the ordinary course of business. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No Group Company is or has been a party to any &#147;listed transaction&#148; as defined in Section&nbsp;6707A
of the Code and Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.6011-4</FONT> (or any corresponding or similar provision of U.S. state or local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Tax Law). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">There are no Liens for Taxes on any assets of the Group Companies or any Equity Securities of any Group Company
other than Permitted Liens. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(k)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No Group Company was a &#147;distributing corporation&#148; or a &#147;controlled corporation,&#148; each
within the meaning of Section&nbsp;355(a)(1)(A) of the Code, in a distribution intended to qualify under Section&nbsp;355 of the Code (i)&nbsp;within the past two (2)&nbsp;years or (ii)&nbsp;as part of a &#147;plan&#148; or &#147;series of related
transactions&#148; (within the meaning of Section&nbsp;355(e) of the Code) in conjunction with the Transactions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(l)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No Group Company (i)&nbsp;is currently or has ever been a member of an affiliated group filing a consolidated,
combined or unitary income Tax Return (other than a group the common parent of which was a Group Company or any of its current Affiliates) or (ii)&nbsp;has any Liability for the Taxes of any Person (other than another Group Company) under
Section&nbsp;160 of the Tax Act or <FONT STYLE="white-space:nowrap">Section&nbsp;1.1502-6</FONT> of the Treasury Regulations (or any similar provision of U.S. state or local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Law), or as a
transferee or successor. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(m)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No written claims have ever been made by any Tax Authority in a jurisdiction (other than the jurisdiction under
the laws of which a Group Company is organized) where a Group Company does not file Tax Returns that such Group Company is or may be subject to taxation by that jurisdiction, which claims have not been resolved or withdrawn. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(n)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No Group Company is a party to any Tax allocation, Tax sharing or Tax indemnity or similar agreements (other
than a Contract entered into in the ordinary course of business the principal purpose of which does not relate to Taxes) and no Group Company is a party to any joint venture, partnership or other arrangement that is treated as a partnership for U.S.
federal income Tax purposes. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(o)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To the knowledge of the Company, other than as listed in Section&nbsp;3.16(o) of the Company Disclosure
Schedules, each Group Company is tax resident only in its jurisdiction of organization, incorporation or formation, as applicable. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(p)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company is, and has been since its formation, (i)&nbsp;organized under the laws of Canada,
(ii)&nbsp;treated as a foreign corporation for United States federal income tax purposes and (iii)&nbsp;treated solely as a Canadian tax resident for any income tax purposes. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(q)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">enGene USA, Inc. (i)&nbsp;has been owned by the Company since its formation and (ii)&nbsp;has not been at any
time during the five (5)&nbsp;year period ending on the Closing Date, a &#147;United States real property holding corporation&#148; within the meaning of Section&nbsp;897(c)(2) of the Code. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(r)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company is not a &#147;surrogate foreign corporation&#148; within the meaning of Section&nbsp;7874(a)(2)(B)
of the Code and is not subject to Section&nbsp;7874(b) of the Code. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(s)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company has not, since its formation, been treated as a &#147;passive foreign investment company&#148;
within the meaning of Section&nbsp;1297(a) of the Code. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(t)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To the knowledge of the Company, no Group Company has a permanent establishment (within the meaning of an
applicable Tax treaty) or otherwise has an office or fixed place of business in a country other than the country in which it is organized. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(u)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To the knowledge of the Company, there are no facts, circumstances or plans that, either alone or in
combination, could reasonably be expected to prevent the Transactions from qualifying for the Intended Tax Treatment. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No Group Company has, or has ever been deemed to have, for purposes of the Tax Act or any relevant provincial
legislation, acquired or had the use of property for proceeds greater than the fair market value thereof from, or disposed of property for proceeds less than the fair market value thereof to, or received or performed services or had the use of
property for other than the fair market value from or to, or paid or received interest or any other amount other than at a fair market value rate to or from, any Person with whom it does not deal at arm&#146;s length within the meaning of the Tax
Act. Each Group Company has complied in all material respects with the transfer pricing provisions of applicable Tax Laws. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(w)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company Shares are not &#147;taxable Canadian property&#148; within the meaning of the Tax Act.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(x)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All Group Companies have complied in all material respects with the conditions stipulated in any Tax Grant
granted to any Group Company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(y)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No Group Company has received a refund of Taxes to which it was not entitled including any refund resulting
from a deemed payment or overpayment of Taxes pursuant to section 125.7 of the Tax Act or any equivalent provision under any applicable Tax Laws. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.17</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Brokers</I><I>. </I>Except for fees due to the brokers, finders, investment bankers or other Persons set
forth on Section&nbsp;3.17 of the Company Disclosure Schedules (which fees shall be the sole responsibility of the Company, except as otherwise provided in Section&nbsp;8.6), no broker, finder, investment banker or other Person is entitled to any
brokerage fee, finders&#146; fee or other commission in connection with the Transactions based upon arrangements made by or on behalf of the Company or any of its Affiliates for which any of the Group Companies has any obligation.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.18</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Real and Personal Property</I>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Owned Real Property. </I>No Group Company owns any real property other than real property acquired by a
Group Company after the date of this Agreement that is either permitted pursuant to Section&nbsp;5.1(b) or entered into in accordance with Section&nbsp;5.1(b). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Leased Real Property. </I>The Company has made available to FEAC true, correct and complete copies of all
Real Property Leases pursuant to which any Group Company is a tenant or landlord as of the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
date of this Agreement together with all amendments. Each Real Property Lease is in full force and effect and is a valid, legal and binding obligation of the applicable Group Company party
thereto, enforceable in accordance with its terms against such Group Company and, to the Company&#146;s knowledge, each other party thereto (subject to applicable bankruptcy, insolvency, reorganization, moratorium or other Laws affecting generally
the enforcement of creditors&#146; rights and subject to general principles of equity). There is no material breach or material default by any Group Company or, to the Company&#146;s knowledge, any third party under any Real Property Lease, and, to
the Company&#146;s knowledge, no event has occurred which (with or without notice or lapse of time or both) would constitute a material breach or material default or would permit termination of, or a material modification or material acceleration
thereof by any party to such Real Property Leases. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Personal Property. </I>Each Group Company has good, marketable and indefeasible title to, or a valid
leasehold interest in or license or right to use, all of the material assets and properties of the Group Companies reflected in the Company Financial Statements as owned by the Group Companies or thereafter acquired by the Group Companies, except
for assets disposed of in the ordinary course of business. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.19</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Transactions with Affiliates</I><I>. </I>The Company has made available to FEAC true, complete and correct
copies of all Contracts between (a)&nbsp;any Group Company, on the one hand, and (b)&nbsp;any officer, director, partner, member, manager, registered equityholder or Affiliate of any Group Company (other than, for the avoidance of doubt, any other
Group Company) or any immediate family member of any of the foregoing Persons, on the other hand (each Person identified in this clause (b), a &#147;<B>Company Related Party</B>&#148;), other than (i)&nbsp;Contracts with respect to a Company Related
Party&#146;s employment with any of the Group Companies entered into in the ordinary course of business (including benefit plans, indemnification arrangements and other ordinary course compensation), (ii) the Company Shareholders Agreements,
(iii)&nbsp;any Ancillary Document, and (iv)&nbsp;Contracts entered into after the date of this Agreement that are either permitted pursuant to Section&nbsp;5.1(b) or entered into in accordance with Section&nbsp;5.1(b). No Company Related Party
(A)&nbsp;owns any interest in any material asset used in any Group Company&#146;s business, (B)&nbsp;possesses, directly or indirectly, any material financial interest in, or is a director or executive officer of, any Person which is a supplier,
lender, partner, lessor, lessee or other material business relation of any Group Company or (C)&nbsp;owes any material amount to, or is owed any material amount by, any Group Company (other than ordinary course accrued compensation, employee
benefits, employee or director expense reimbursement or other transactions entered into after the date of this Agreement that are either permitted pursuant to Section&nbsp;5.1(b) or entered into in accordance with Section&nbsp;5.1(b)). All
Contracts, arrangements, understandings, interests and other matters that are required to be disclosed pursuant to this Section&nbsp;3.19 are referred to herein as &#147;<B>Company Related Party Transactions</B>&#148;. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.20</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Suppliers. </I>There are no suppliers of products or services to the Group Companies that are material to
the business of the Group Companies with respect to which practical alternative sources of supply are not generally available on comparable terms and conditions in the marketplace. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.21</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Data Privacy and Security</I>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Group Company is presently in compliance with, and has at all times been in compliance with, in all
material respects, all applicable Privacy and Security Requirements. Each Group Company has implemented policies relating to the Processing of Personal Data as and to the extent required by applicable Privacy and Security Requirements.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">There is no pending, and since April&nbsp;1, 2020, there has not been any Proceedings asserted or, to the
Company&#146;s knowledge, threatened against any Group Company initiated by (i)&nbsp;any Person; (ii)&nbsp;the United States Federal Trade Commission, any state attorney general or similar state official; (iii)&nbsp;any other Governmental Entity,
foreign or domestic; or (iv)&nbsp;any regulatory or self-regulatory entity alleging any breach or violation of any Privacy and Security Requirement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To the Company&#146;s knowledge, since April&nbsp;1, 2020 (i) there has been no unauthorized access or other
Processing of Personal Data in the possession or control of any Group Company or any of its </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
contractors with regard to any Personal Data obtained from or on behalf of a Group Company, (ii)&nbsp;there have been no unauthorized use, access, intrusions, interruptions, modifications,
corruptions or breaches (including any ransomware attacks) of security into, or other cyber or security incidents with respect to, any Company IT System, (iii)&nbsp;no Group Company has notified or been required to notify any Person of any
(A)&nbsp;loss, theft or damage of, or (B)&nbsp;other unauthorized or unlawful access to, or Processing of, Personal Data. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Group Company owns or has a license to use the Company IT Systems as necessary to operate the business of
each Group Company as currently conducted. The Group Companies have taken commercially reasonable precautions, to protect the confidentiality, integrity and security of the material Company IT Systems (and all information and transactions stored or
contained therein or transmitted thereby). All Company IT Systems are (i)&nbsp;to the Company&#146;s knowledge, free from any &#147;Trojan horse&#148;, &#147;virus&#148;, &#147;ransomware&#148;, or other malicious code, material defect, bug, or
programming, design or documentation error and (ii)&nbsp;in sufficiently good working condition to operate and perform in all material respects in accordance with their documentation and functional specifications and otherwise in the manner
necessary for the operation of the business (except for ordinary wear and tear). To the Company&#146;s knowledge, since April&nbsp;1, 2020, there have not been any material failures or breakdowns of any Company IT Systems. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The consummation of the Transactions shall not breach or otherwise cause any violation of any Privacy and
Security Requirements, or result in any Group Company being prohibited from receiving or using any Personal Data in the manner currently received or used by such Group Company in all material respects. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.22</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Compliance with Sanctions Laws, Anti-Corruption Laws and Anti-Money Laundering Laws</I>.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Except as disclosed in Section&nbsp;3.21(a) of the Company Disclosure Schedules, for the past five years,
neither the Group Companies nor to the Company&#146;s knowledge any of their directors or officers, employees, agents, or other third-party representatives acting for or on behalf of any of the foregoing is or has been a Sanctioned Person or
otherwise is engaging or has engaged in dealings with a person who at the time of such dealing is or was Sanctioned Person or in a country or territory that at the time of such dealing is or was a Sanctioned Territory. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the past five years, the Group Companies have not violated in any material respect any Sanctions Laws,
Anti-Corruption Laws, Ex-Im Laws, or Anti-Money Laundering Laws. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the past five years, neither the Group Companies nor, to the Company&#146;s knowledge, any of their
directors, officers, employees, agents, or any third-party representatives acting for or on behalf of any of the foregoing has, in contravention of any Anti-Corruption Laws, (i)&nbsp;made, offered, promised, paid or received any unlawful bribes,
kickbacks or other similar payments to or from any Person, (ii)&nbsp;made or paid any contributions, directly or indirectly, to a domestic or foreign political party or candidate which was not in compliance with domestic Law or (iii)&nbsp;otherwise
made, offered, received, authorized, promised or paid any improper payment under any Anti-Corruption Laws. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the past five years, none of the Group Companies has been the subject of any voluntary disclosure,
prosecution or, to the Company&#146;s knowledge, allegation or investigation related to any Sanctions Laws, Anti-Corruption Laws, Ex-Im Laws, or Anti-Money Laundering Laws. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding anything in this Agreement, including but not limited to the representations made under
Section&nbsp;3.22 of this Agreement, nothing in this Agreement shall require the Company or its Affiliates, or any director, officer, employee or agent of the foregoing, to commit an act or omission that contravenes the <I>Foreign Extraterritorial
Measures Act </I>(Canada), or any Order promulgated thereunder. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.23</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Information Supplied</I><I>. </I>None of the information supplied or to be supplied by or on behalf of the
Group Companies in writing expressly for inclusion or incorporation by reference prior to the Closing in the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Registration Statement / Proxy Statement and the Canadian Prospectus will, when the Registration Statement / Proxy Statement is declared effective and the Canadian Prospectus is filed or when the
Registration Statement / Proxy Statement is mailed to the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> FEAC Holders or at the time of the FEAC Shareholders Meeting, and in the case of any amendment thereto, at the time of such amendment,
contain any Misrepresentation. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.24</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Investigation; No Other Representations</I>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Group Company, on its own behalf and on behalf of its Representatives, acknowledges, represents, warrants
and agrees that (i)&nbsp;it has conducted its own independent review and analysis of, and, based thereon, has formed an independent judgment concerning, the business, assets, condition, operations and prospects of, FEAC and (ii)&nbsp;it has been
furnished with or given access to such documents and information about FEAC and its business and operations as it and its Representatives have deemed necessary to enable it to make an informed decision with respect to the execution, delivery and
performance of this Agreement, the Ancillary Documents and the Transactions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In entering into this Agreement and the Ancillary Documents to which it is or will be a party, each Group
Company has relied solely on its own investigation and analysis and the representations and warranties expressly set forth in Article 4 and in the Ancillary Documents to which it is or will be a party and no other representations or warranties of
FEAC, any FEAC <FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliate or any other Person, either express or implied, and the Company, on its own behalf and on behalf of its Representatives, acknowledges, represents, warrants and agrees that,
except for the representations and warranties expressly set forth in Article 4 and in the Ancillary Documents to which it is or will be a party, none of FEAC, any FEAC <FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliate or any other Person
makes or has made any representation or warranty, either express or implied, in connection with or related to this Agreement, the Ancillary Documents or the Transactions. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.25</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Regulatory Compliance</I>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company has made available to FEAC a true and complete list of all material Regulatory Permits held by the
Group Companies. The Group Companies and the Company Products are in compliance in all material respects with all Regulatory Permits and, to the Company&#146;s knowledge, no event, circumstance or state of facts has occurred which (with or without
due notice or lapse of time or both) would reasonably be expected to result in the failure of a Group Company to be in compliance in all material respects with the terms of any such Regulatory Permit. To the knowledge of the Company, (i)&nbsp;no
Governmental Entity is considering limiting, suspending or revoking any Regulatory Permit and (ii)&nbsp;each third party that is a manufacturer, contractor or agent for the Group Companies is in compliance in all material respects with all
Regulatory Permits required by all Public Health Laws insofar as they reasonably pertain to the Company Products. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">There is no act, omission, event or circumstance of which the Company has knowledge that would reasonably be
expected to give rise to or lead to any material Proceeding against any Group Company related to compliance with Public Health Laws, and to the Company&#146;s knowledge, no such Proceedings have been threatened. To the Company&#146;s knowledge, the
Group Companies do not have any Liability for failure to comply with any Public Health Laws. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All Company Products are being, whether by the Company or a third party, researched, developed, tested,
investigated, manufactured, prepared, packaged, labeled, stored and distributed in compliance in all material respects with the Public Health Laws. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To the knowledge of the Company, all preclinical studies and clinical trials conducted by or on behalf of the
Group Companies or involving any Company Products are being and have been conducted in all material respects in accordance with all applicable clinical trial protocols, research ethics board or other similar approvals, informed consents and
applicable requirements and Public Health Laws, including those of the FDA, Health Canada and any comparable Governmental Entity. The Company has not received any written or, to the Company&#146;s knowledge, oral notice that the
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
FDA, Health Canada or any other Governmental Entity has recommended, initiated, or threatened to initiate any action to suspend, terminate, or otherwise restrict any preclinical studies and
clinical trials conducted by or on behalf of the Company or involving any Company Products. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To the knowledge of the Company, as of the date of this Agreement, no Group Company, nor any clinical trial
site conducting a clinical trial of any Company Product, is undergoing or has undergone any inspection or any other Governmental Entity investigation related to any Company Product, and the Group Companies have not identified or received written
notice of instances or allegations of research misconduct, research fraud, or improper or inaccurate data collection or recording with respect to a Company Product that would compromise or materially affect the integrity, reliability, completeness,
or accuracy of the resulting data, or the rights, safety, or welfare of the research participants. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Since the incorporation of the Company, the Group Companies have not distributed any Company Products that were
upon their shipment by any Group Company adulterated or misbranded in violation of 21 U.S.C. &#167; 331 or any other Governmental Entity&#146;s jurisdiction. No Company Products have been seized, withdrawn, recalled, detained or subject to a
suspension (other than in the ordinary course of business) of research, development, testing, manufacturing or distribution, and, to the Company&#146;s knowledge, there are no facts or circumstances reasonably likely to cause (i)&nbsp;the seizure,
denial, withdrawal, recall, or detention, or public health notification or safety alert or suspension of manufacturing or other activity relating to any Company Product or (ii)&nbsp;a termination, seizure or suspension of research, development,
testing, clinical investigation, manufacturing, distributing or other activity of any Company Product, in either case ((i) or (ii)), except as would not have a Company Material Adverse Effect. To the Company&#146;s knowledge, there are no pending or
threatened Proceedings against the Group Companies in the United States, Canada or any other jurisdiction seeking the withdrawal, recall, revocation, suspension, import detention or seizure of any Company Product. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Except as would not have a Company Material Adverse Effect, none of the Group Companies nor, to the
Company&#146;s knowledge, any of the Company&#146;s equityholders with five percent (5%) or greater interest, nor any of their respective directors, managers, officers, employees, individual independent contractors or other service providers,
including clinical trial investigators, coordinators, monitors, Company Products or services, have been or are currently disqualified, excluded or debarred from, or threatened with or currently subject to an investigation or Proceeding that could
result in disqualification, exclusion or debarment under any applicable Law, or assessed or threatened with assessment of civil monetary penalties regarding any health care programs of any Governmental Entity, or convicted of any crime regarding
health care products or services, or engaged in any conduct that would reasonably be expected to result in any such debarment, exclusion, disqualification, or ineligibility, including, without limitation, (A)&nbsp;debarment under 21 U.S.C.
Section&nbsp;335a or any similar Law, (B)&nbsp;exclusion under 42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7</FONT> or any similar Law or (C)&nbsp;exclusion under 48 CFR Subpart Section&nbsp;9.4, the System for Award Management
Nonprocurement Common Rule. None of the Group Companies nor, to the Company&#146;s knowledge, any of their current or former members, officers, partners, employees, contractors or agents have been subject to any consent decree of, or criminal or
civil fine or penalty imposed by, any Governmental Entity related to fraud, theft, embezzlement, breach of fiduciary responsibility, financial misconduct, or obstruction of an investigation of controlled substances. None of the Group Companies nor,
to the Company&#146;s knowledge, any of their current or former members, officers, partners, employees, contractors or agents has been (i)&nbsp;subject to any enforcement, regulatory or administrative Proceedings against or affecting the Company or
any of its Affiliates relating to or arising under any Healthcare Law and, to the Company&#146;s knowledge, no such enforcement, regulatory or administrative Proceeding has been threatened, or (ii)&nbsp;a party to any corporate integrity agreement,
monitoring agreement, deferred prosecution agreement, consent decree, settlement order, or similar agreement imposed by any Governmental Entity. None of the Group Companies nor, to </P></TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
the Company&#146;s knowledge, any of their officers, directors, employees, agents or contractors have received written notice from the FDA, any other Governmental Entity or any health insurance
institution with respect to debarment, disqualification or restriction. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All material reports, documents, claims, permits and notices required to be filed, maintained or furnished to
the FDA, Health Canada or any other Governmental Entity by the Company or any third party involving Company Products have been so filed, maintained or furnished. To the knowledge of the Company, all such reports, documents, claims, permits and
notices were complete and accurate in all material respects on the date filed (or were corrected or supplemented by a subsequent filing). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Group Companies and, to the Company&#146;s knowledge, their employees, are and have been, since the
incorporation of the Company, in compliance in all material respects with all Healthcare Laws and Public Health Laws. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To the knowledge of the Company, no officer or other employee or agent of any Group Company has (i)&nbsp;made
any untrue statement of material fact or fraudulent statement to the FDA or any other Governmental Entity; (ii)&nbsp;failed to disclose a material fact required to be disclosed to the FDA or any other Governmental Entity, or (iii)&nbsp;committed an
act, made a statement or failed to make a statement that would reasonably be expected to provide the basis for the FDA or any other Governmental Entity to refuse to grant a Regulatory Permit for any Company Product. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(k)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">There have been no Proceedings, and no such Proceedings are pending or, to the Company&#146;s knowledge,
threatened in writing against any Group Company related to product liability for the Company Products. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.26</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>EXCLUSIVITY OF REPRESENTATIONS AND WARRANTIES</I>. NOTWITHSTANDING THE DELIVERY OR DISCLOSURE TO FEAC OR ANY
OF ITS REPRESENTATIVES OF ANY DOCUMENTATION OR OTHER INFORMATION (INCLUDING ANY FINANCIAL PROJECTIONS OR OTHER SUPPLEMENTAL DATA), EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS ARTICLE 3 OR THE ANCILLARY DOCUMENTS, NONE OF THE COMPANY, ANY COMPANY
<FONT STYLE="white-space:nowrap">NON-PARTY</FONT> AFFILIATE OR ANY OTHER PERSON MAKES, AND THE COMPANY EXPRESSLY DISCLAIMS, ANY REPRESENTATIONS OR WARRANTIES OF ANY KIND OR NATURE, EXPRESS OR IMPLIED, IN CONNECTION WITH THIS AGREEMENT, THE ANCILLARY
DOCUMENTS OR ANY OF THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY, INCLUDING AS TO THE MATERIALS RELATING TO THE BUSINESS AND AFFAIRS OR HOLDINGS OF THE GROUP COMPANIES THAT HAVE BEEN MADE AVAILABLE TO FEAC OR ANY OF ITS REPRESENTATIVES OR IN ANY
PRESENTATION OF THE BUSINESS AND AFFAIRS OF THE GROUP COMPANIES BY THE MANAGEMENT OF THE COMPANY OR OTHERS IN CONNECTION WITH THE TRANSACTIONS CONTEMPLATED HEREBY OR BY THE ANCILLARY DOCUMENTS, AND NO STATEMENT CONTAINED IN ANY OF SUCH MATERIALS OR
MADE IN ANY SUCH PRESENTATION SHALL BE DEEMED A REPRESENTATION OR WARRANTY HEREUNDER OR OTHERWISE OR DEEMED TO BE RELIED UPON BY FEAC OR ANY FEAC <FONT STYLE="white-space:nowrap">NON-PARTY</FONT> AFFILIATE IN EXECUTING, DELIVERING AND PERFORMING
THIS AGREEMENT, THE ANCILLARY DOCUMENTS OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY. EXCEPT FOR THE REPRESENTATIONS AND WARRANTIES EXPRESSLY SET FORTH IN ARTICLE 3 OR THE ANCILLARY DOCUMENTS, IT IS UNDERSTOOD THAT ANY COST ESTIMATES,
PROJECTIONS OR OTHER PREDICTIONS, ANY DATA, ANY FINANCIAL INFORMATION OR ANY MEMORANDA OR OFFERING MATERIALS OR PRESENTATIONS, INCLUDING ANY OFFERING MEMORANDUM OR SIMILAR MATERIALS MADE AVAILABLE BY ANY GROUP COMPANY ARE NOT AND SHALL NOT BE DEEMED
TO BE OR TO INCLUDE REPRESENTATIONS OR WARRANTIES OF THE COMPANY, ANY COMPANY <FONT STYLE="white-space:nowrap">NON-PARTY</FONT> AFFILIATE OR ANY OTHER PERSON, AND ARE NOT AND SHALL NOT BE DEEMED TO BE RELIED UPON BY FEAC OR ANY FEAC <FONT
STYLE="white-space:nowrap">NON-PARTY</FONT> AFFILIATE IN EXECUTING, DELIVERING OR PERFORMING THIS AGREEMENT, THE ANCILLARY DOCUMENTS OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>R<SMALL>EPRESENTATIONS</SMALL> <SMALL>AND</SMALL> W<SMALL>ARRANTIES</SMALL> R<SMALL>ELATING</SMALL>
<SMALL>TO</SMALL> FEAC <SMALL>AND</SMALL> C<SMALL>AN</SMALL> M<SMALL>ERGER</SMALL> S<SMALL>UB</SMALL> </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Subject to
Section&nbsp;8.7, except as set forth on the FEAC Disclosure Schedules, or except as set forth in any FEAC SEC Reports (excluding any disclosures in any &#147;risk factors&#148; section that do not constitute statements of fact, disclosures in any
forward-looking statements disclaimers and other disclosures that are generally cautionary, predictive or forward-looking in nature), FEAC hereby represents and warrants to the Company as follows, <I>provided </I>that any representations and
warranties with respect to Can Merger Sub will only be deemed to be made upon and with effect from the date of the execution of a Joinder Agreement by Can Merger Sub: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Organization and Qualification</I>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each of FEAC and Can Merger Sub is duly incorporated, validly existing and in good standing (or the equivalent
thereof, if applicable, in each case, with respect to the jurisdictions that recognize the concept of good standing or any equivalent thereof) under the Laws of its jurisdiction of incorporation. Each of FEAC and Can Merger Sub has the requisite
corporate power and authority to own, lease and operate its properties and to carry on its businesses as presently conducted, except where the failure to have such power or authority would not have a FEAC Material Adverse Effect or prevent,
materially delay or materially impair the ability of FEAC or Can Merger Sub to timely consummate the Transactions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">True, complete and correct copies of the Governing Documents of each of FEAC and Can Merger Sub and the FEAC
Registration Rights Agreement have been made available to the Company (to the extent such information or document is not publicly available prior to 5:00 p.m. Eastern time on the date that is one (1)&nbsp;Business Day prior to the date of this
Agreement in the Electronic Data Gathering, Analysis and Retrieval (EDGAR) database of the SEC), in each case, as amended and in effect as of the date of this Agreement. The Governing Documents of FEAC and Can Merger Sub are in full force and
effect, and none of FEAC or Can Merger Sub is in breach or violation of any provision set forth in its Governing Documents or, in the case of FEAC, in material breach of the FEAC Registration Rights Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each of FEAC and Can Merger Sub is duly qualified or licensed to transact business and is in good standing (or
the equivalent thereof, if applicable, in each case, with respect to the jurisdictions that recognize the concept of good standing or any equivalent thereof) in each jurisdiction in which the property and assets owned, leased or operated by it, or
the nature of the business conducted by it, makes such qualification or licensing necessary, except where the failure to be so duly qualified or licensed and in good standing would not have a FEAC Material Adverse Effect or prevent, materially delay
or materially impair the ability of FEAC or Can Merger Sub to timely consummate the Transactions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Can Merger Sub was incorporated solely for purposes of entering into the Transactions and, since the date of
its incorporation, Can Merger Sub has not owned any assets, carried on any business, conducted any operations or incurred any liabilities or obligations or has hired any employee or independent contractor, other than the execution of this Agreement
and any Ancillary Documents to which it is a party, the performance of its obligations hereunder and matters ancillary thereto. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Capitalization</I>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Section&nbsp;4.2(a) of the FEAC Disclosure Schedules sets forth a true, complete and correct statement of the
number and class or series (as applicable) of the issued and outstanding FEAC Shares and FEAC Warrants as of the date hereof. All outstanding Equity Securities of FEAC (except to the extent such concepts are not applicable under the applicable Law
of FEAC&#146;s jurisdiction of incorporation or other applicable Law) and of Can Merger Sub as of the date hereof and as of immediately prior to the consummation of the Cayman Merger are or will be duly authorized and validly issued, fully paid and <FONT
STYLE="white-space:nowrap">non-assessable.</FONT> Except for the FEAC Shares and FEAC Warrants set forth on Section&nbsp;4.2(a) of the FEAC Disclosure Schedules (assuming that no FEAC Shareholder
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Redemptions are effected and no FEAC Class&nbsp;B Shares and FEAC Private Placement Warrants are surrendered by the Sponsor pursuant to the Sponsor and Insiders Letter Agreement), as of the date
hereof and as of immediately prior to the Cayman Merger, there are and shall be no other outstanding Equity Securities of FEAC. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The outstanding Equity Securities of FEAC and Can Merger Sub (1)&nbsp;were not issued in violation of the
Governing Documents of FEAC or Can Merger Sub, as applicable, (2)&nbsp;were not issued in violation of any preemptive rights, call option, right of first refusal or first offer, subscription rights or similar rights of any Person granted by FEAC or
Can Merger Sub, as applicable, and (3)&nbsp;have been offered, sold and issued in compliance with applicable Law, including applicable Securities Laws. Other than the Ancillary Documents and except as set forth on Section&nbsp;4.2(b) of the FEAC
Disclosure Schedules, there are no voting trusts, proxies or other Contracts to which FEAC is a party with respect to the voting or transfer of FEAC&#146;s Equity Securities. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Other than the FEAC Warrants and FEAC Shareholder Redemptions, there are no outstanding (A)&nbsp;equity
appreciation, phantom equity or profit participation rights or (B)&nbsp;options, restricted stock, restricted stock units, phantom stock, warrants, purchase rights, subscription rights, conversion rights, exchange rights, calls, puts, rights of
first refusal or first offer or other Contracts that could require FEAC or Can Merger Sub to issue, sell or otherwise cause to become outstanding or to acquire, repurchase or redeem any Equity Securities or securities convertible into or
exchangeable for Equity Securities of FEAC or Can Merger Sub. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">None of FEAC or Can Merger Sub owns or holds (of record, beneficially, legally or otherwise), directly or
indirectly, any Equity Securities in any other Person or the right to acquire any such Equity Security, and none of FEAC or Can Merger Sub is a partner or member of any partnership, limited liability company or joint venture. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">None of FEAC or Can Merger Sub directly or indirectly owns any equity or similar interest in, or any interest
convertible into or exchangeable or exercisable for any equity or similar interest in, any other Person. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Authority</I><I>. </I>Each of FEAC and Can Merger Sub has the requisite power and authority to execute and
deliver this Agreement and each Ancillary Document to which it is or will be a party, to perform its obligations hereunder and thereunder, and to consummate the Transactions. Subject to the receipt of the FEAC Shareholder Approval, the execution and
delivery of this Agreement, the Ancillary Documents to which FEAC or Can Merger Sub is or will be a party and the consummation of the Transactions have been (or, in the case of any Ancillary Document entered into after the date of this Agreement,
will be upon execution thereof) duly authorized by all necessary corporate action on the part of FEAC and Can Merger Sub, as applicable. This Agreement and each Ancillary Document to which FEAC or Can Merger Sub is or will be a party has been or
will be, upon execution thereof, as applicable, duly and validly executed and delivered by FEAC and Can Merger Sub, as applicable, and constitutes or will constitute, upon execution and delivery thereof, as applicable, a valid, legal and binding
agreement of FEAC and Can Merger Sub (assuming that this Agreement and the Ancillary Documents to which FEAC or Can Merger Sub is or will be a party are or will be, upon execution thereof, as applicable, duly authorized, executed and delivered by
the other Persons party hereto or thereto, as applicable), enforceable against FEAC and Can Merger Sub, as applicable, in accordance with their terms (subject to applicable bankruptcy, insolvency, reorganization, moratorium or other Laws affecting
generally the enforcement of creditors&#146; rights and subject to general principles of equity). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Board Approval; Vote Required</I><I>. </I>The FEAC Board (including any required committee or subgroup of
such board), by resolutions duly adopted by unanimous vote of those voting at a meeting duly called and held and not subsequently rescinded or modified in any way, has (a)&nbsp;determined that the Transactions are in the best interests of FEAC and
its shareholders and declared it advisable, to enter into this Agreement and the Ancillary Documents to which FEAC and to consummate the Transactions, (b)&nbsp;approved the execution, delivery and performance by FEAC of this Agreement, the Ancillary
Documents to which FEAC is or will </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
be a party and the Transactions and (c)&nbsp;resolved to recommend, among other things, the holders of FEAC Shares vote in favor of the approval of this Agreement and the Transactions, and
directed that this Agreement and the Transactions be submitted for consideration by the shareholders of FEAC at the FEAC Shareholders Meeting. The FEAC Shareholder Approval is the only vote of the holders of any class or series of shares of FEAC
necessary to approve the Transactions. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Consents and Requisite Governmental Approvals; No Violations</I>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No consent, approval or authorization of, or designation, declaration or filing with, any Governmental Entity
is required on the part of FEAC or Can Merger Sub with respect to FEAC and Can Merger Sub&#146;s execution, delivery or performance of its obligations under this Agreement or the Ancillary Documents to which FEAC or Can Merger Sub is or will be
party or the consummation of the Transactions, except for (i)&nbsp;compliance with and filings under any Foreign Antitrust Laws, (ii)&nbsp;the filing with the SEC of (A)&nbsp;the Registration Statement / Proxy Statement and the declaration of the
effectiveness thereof by the SEC and (B)&nbsp;such reports under Section&nbsp;13(a) or 15(d) of the Exchange Act as may be required in connection with this Agreement, the Ancillary Documents or the Transactions, (iii)&nbsp;the filing of the Canadian
Prospectus with the Autorit&eacute; des march&eacute;s financiers du Qu&eacute;bec, (iv)&nbsp;such filings with and approvals of Nasdaq or other relevant Exchange, as applicable, to permit the Newco Shares to be issued in connection with the
Transactions to be listed on Nasdaq or other relevant Exchange, as applicable, (v)&nbsp;the FEAC Shareholder Approval or (vi)&nbsp;any other consents, approvals, authorizations, designations, declarations, waivers or filings, the absence of which
would not have a FEAC Material Adverse Effect. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Neither the execution, delivery or performance by FEAC or Can Merger Sub of this Agreement nor the Ancillary
Documents to which FEAC or Can Merger Sub is or will be a party nor the consummation by FEAC or Can Merger Sub of the Transactions will, directly or indirectly (with or without due notice or lapse of time or both)&nbsp;(i) result in any breach of
any provision of FEAC&#146;s Governing Documents or Can Merger Sub&#146;s Governing Documents, (ii)&nbsp;result in a violation or breach of, or constitute a default or give rise to any right of termination, Consent, cancellation, amendment,
modification, suspension, revocation or acceleration under, any of the terms, conditions or provisions of any Contract to which FEAC or Can Merger Sub is a party, (iii)&nbsp;violate, or constitute a breach under, any Order or applicable Law to which
FEAC or Can Merger Sub or any of their properties or assets are bound or (iv)&nbsp;result in the creation of any Lien (other than Permitted Liens) upon any of the assets or properties of FEAC or Can Merger Sub, except in the case of clauses
(ii)&nbsp;through (iv) above, as would not have a FEAC Material Adverse Effect or prevent, materially delay or materially impair the ability of FEAC or Can Merger Sub to timely consummate the Transactions. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">FEAC is a trade agreement investor within the meaning of the <I>Investment Canada Act</I>.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>SEC Filings</I><I>. </I>FEAC has timely filed or furnished all statements, forms, reports and documents
required to be filed or furnished by it prior to the date of this Agreement with the SEC pursuant to Federal Securities Laws since its IPO (collectively, including all of the statements, forms, reports and documents filed or furnished by it in
connection with and subsequent to its IPO, and together with any exhibits and schedules thereto and other information incorporated therein, and as they have been supplemented, modified or amended since the time of filing, the &#147;<B>FEAC SEC
Reports</B>&#148;), and, as of the Closing, will have filed or furnished all other statements, forms, reports and other documents required to be filed or furnished by it subsequent to the date of this Agreement with the SEC pursuant to Federal
Securities Laws through the Closing (collectively, and together with any exhibits and schedules thereto and other information incorporated therein, and as they have been supplemented, modified or amended since the time of filing, but excluding the
Registration Statement / Proxy Statement, the &#147;<B>Additional FEAC SEC Reports</B>&#148;). Each of the FEAC SEC Reports, as of their respective dates of filing, and as of the date of any amendment or filing that superseded the initial filing,
complied and each of the Additional FEAC SEC Reports, as of their respective dates of filing, and as of the date of any amendment or filing that superseded the initial filing, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
will comply, in all material respects with the applicable requirements of the Federal Securities Laws (including, as applicable, the Sarbanes-Oxley Act and any rules and regulations promulgated
thereunder) applicable to the FEAC SEC Reports or the Additional FEAC SEC Reports (for purposes of the Additional FEAC SEC Reports, assuming that the representation and warranty set forth in Section&nbsp;3.23 is true and correct in all respects with
respect to all information supplied by or on behalf of Group Companies expressly for inclusion or incorporation by reference therein). As of their respective dates of filing, the FEAC SEC Reports did not contain any Misrepresentation (for purposes
of the Additional FEAC SEC Reports, assuming that the representation and warranty set forth in Section&nbsp;3.23 is true and correct in all respects with respect to all information supplied by or on behalf of Group Companies expressly for inclusion
or incorporation by reference therein). As of the date of this Agreement, there are no outstanding or unresolved comments in comment letters received from the SEC with respect to the FEAC SEC Reports. To the knowledge of FEAC, none of the FEAC SEC
Reports or the Additional FEAC SEC Reports is subject to ongoing SEC review or investigation. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Internal Controls; Listing; Financial Statements</I>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Except as is not required in reliance on exemptions from various reporting requirements by virtue of
FEAC&#146;s status as an &#147;<B>emerging growth company</B>&#148; within the meaning of the Securities Act, as modified by the JOBS Act, or &#147;<B>smaller reporting company</B>&#148; within the meaning of the Exchange Act, since its IPO,
(i)&nbsp;FEAC has established and maintained a system of internal controls over financial reporting (as defined in Rule <FONT STYLE="white-space:nowrap">13a-15</FONT> and Rule <FONT STYLE="white-space:nowrap">15d-15</FONT> under the Exchange Act)
sufficient to provide reasonable assurance regarding the reliability of FEAC&#146;s financial reporting and the preparation of FEAC&#146;s financial statements for external purposes in accordance with GAAP and (ii)&nbsp;FEAC has established and
maintained disclosure controls and procedures (as defined in Rule <FONT STYLE="white-space:nowrap">13a-15</FONT> and Rule <FONT STYLE="white-space:nowrap">15d-15</FONT> under the Exchange Act) designed to ensure that material information relating to
FEAC is made known to FEAC&#146;s principal executive officer and principal financial officer by others within FEAC. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">FEAC has not taken any action prohibited by Section&nbsp;402 of the Sarbanes-Oxley Act. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Since its IPO, FEAC has complied in all material respects with all applicable listing and corporate governance
rules and regulations of Nasdaq. The classes of securities representing issued and outstanding FEAC Class&nbsp;A Shares are registered pursuant to Section&nbsp;12(b) of the Exchange Act and are listed for trading on Nasdaq. As of the date of this
Agreement, there is no Proceeding pending or, to the knowledge of FEAC, threatened against FEAC by Nasdaq or the SEC with respect to any intention by such entity to deregister FEAC Class&nbsp;A Shares or prohibit or terminate the listing of FEAC
Class&nbsp;A Shares on Nasdaq. FEAC has not taken any action that is designed to terminate the registration of FEAC Class&nbsp;A Shares under the Exchange Act. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The FEAC SEC Reports contain true and complete copies of the applicable FEAC Financial Statements. The FEAC
Financial Statements (i)&nbsp;fairly present in all material respects the financial position of FEAC as at the respective dates thereof, and the results of its operations, shareholders&#146; equity and cash flows for the respective periods then
ended (subject, in the case of any unaudited interim financial statements, to normal <FONT STYLE="white-space:nowrap">year-end</FONT> audit adjustments (none of which is expected to be material) and the absence of footnotes), (ii) were prepared in
conformity with GAAP applied on a consistent basis during the periods involved (except, in the case of any audited financial statements, as may be indicated in the notes thereto and subject, in the case of any unaudited financial statements, to
normal year- end audit adjustments (none of which is expected to be material) and the absence of footnotes), (iii) in the case of the audited FEAC Financial Statements, were audited in accordance with the standards of the PCAOB and (iv)&nbsp;comply
in all material respects with the applicable accounting requirements and with the rules and regulations of the SEC, the Exchange Act and the Securities Act in effect as of the respective dates thereof (including Regulation <FONT
STYLE="white-space:nowrap">S-X</FONT> or Regulation <FONT STYLE="white-space:nowrap">S-K,</FONT> as applicable). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">FEAC has established and maintains systems of internal accounting controls that are designed to provide, in all
material respects, reasonable assurance that (i)&nbsp;all transactions are executed in accordance with management&#146;s authorization and (ii)&nbsp;all transactions are recorded as necessary to permit preparation of proper and accurate financial
statements in accordance with GAAP and to maintain accountability for FEAC&#146;s assets. FEAC maintains and, for all periods covered by the FEAC Financial Statements, has maintained books and records of FEAC in the ordinary course of business that
are accurate and complete and reflect the revenues, expenses, assets and liabilities of FEAC in all material respects. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Other than as set forth in Section&nbsp;4.7(f) of the FEAC Disclosure Schedules, since its incorporation, FEAC
has not received any written complaint, allegation, assertion or claim that there is, and to FEAC&#146;s knowledge there has been no, and there is not, (i)&nbsp;any &#147;significant deficiency&#148; in the internal controls over financial reporting
of FEAC to FEAC&#146;s knowledge, (ii)&nbsp;any &#147;material weakness&#148; in the internal controls over financial reporting of FEAC or (iii)&nbsp;fraud or corporate misappropriation, whether or not material, that involves management or other
employees of FEAC who have a significant role in the internal controls over financial reporting of FEAC. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Trust Account</I><I>. </I>As of March&nbsp;31, 2023, FEAC has an amount in cash and securities in the Trust
Account equal to $132,945,901. The funds held in the Trust Account are (a)&nbsp;invested in United States &#147;government securities&#148; within the meaning of Section&nbsp;2(a)(16) of the Investment Company Act, having a maturity of 180 days or
less or in money market funds meeting certain conditions under Rule <FONT STYLE="white-space:nowrap">2a-7</FONT> promulgated under the Investment Company Act which invest only in direct U.S. government treasury obligations and (b)&nbsp;held in trust
pursuant to, and in accordance with, that certain Investment Management Trust Agreement, dated as of December&nbsp;9, 2021 (the &#147;<B>Trust Agreement</B>&#148;), between FEAC and Continental Stock Transfer&nbsp;&amp; Trust Company, as trustee
(the &#147;<B>Trustee</B>&#148;). The Trust Agreement has not been amended or modified and is valid and in full force and effect and is enforceable in accordance with its terms, except as limited by applicable bankruptcy, insolvency, reorganization,
moratorium and other Laws of general application affecting enforcement of creditors&#146; rights generally, by general equitable principles. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">There are no separate agreements, side letters or other agreements or understandings (whether written or unwritten, express or implied) that
would cause the description of the Trust Agreement in the FEAC SEC Reports or the Additional FEAC SEC Reports to be inaccurate in any material respect or, to FEAC&#146;s knowledge, that would entitle any Person to any portion of the funds in the
Trust Account (other than (i)&nbsp;in respect of deferred underwriting commissions or Taxes, (ii)&nbsp;the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> FEAC Holders who shall have elected to redeem their FEAC Class&nbsp;A Shares pursuant to
the Governing Documents of FEAC or (iii)&nbsp;if FEAC fails to complete a business combination within the allotted time period set forth in the Governing Documents of FEAC and liquidates the Trust Account, subject to the terms of the Trust
Agreement, FEAC (in limited amounts to permit FEAC to pay the expenses of the Trust Account&#146;s liquidation, dissolution and winding up of FEAC) and then the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> FEAC Holders). Prior to the Closing,
none of the funds held in the Trust Account are permitted to be released, except in the circumstances described in the Governing Documents of FEAC and the Trust Agreement. FEAC has performed all material obligations required to be performed by it to
date under, and is not in material default or delinquent in performance or any other respect (claimed or actual) in connection with the Trust Agreement, and, to the knowledge of FEAC, no event has occurred which, with due notice or lapse of time or
both, would constitute such a material default thereunder. As of the date of this Agreement, there are no claims or proceedings pending with respect to the Trust Account. Since December&nbsp;9, 2021, FEAC has not released any money from the Trust
Account (other than interest income earned on the funds held in the Trust Account as permitted by the Trust Agreement). Upon the consummation of the Transactions, including the distribution of assets from the Trust Account (A)&nbsp;in respect of
deferred underwriting commissions or Taxes or (B)&nbsp;to the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> FEAC Holders who have elected to redeem their FEAC Class&nbsp;A Shares pursuant to the Governing Documents of FEAC, each in accordance
with the terms of and as set forth in the Trust Agreement, FEAC shall have no further obligation under either the Trust Agreement or the Governing Documents of FEAC to liquidate or distribute any assets held in the Trust Account, and the Trust
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">
Agreement shall terminate in accordance with its terms. As of the date hereof, assuming the accuracy of the representations and warranties of the Company contained herein or in any Ancillary
Document and the compliance by the Company with its obligations hereunder, FEAC has no reason to believe that any of the conditions to the use of funds in the Trust Account will not be satisfied or funds available in the Trust Account will not be
available to FEAC on the Closing Date. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Listing</I><I>. </I>The issued and outstanding FEAC Units are registered pursuant to Section&nbsp;12(b) of
the Exchange Act and are listed for trading on the Nasdaq under the symbol &#147;<B>FRBNU.</B>&#148; The issued and outstanding FEAC Class&nbsp;A Shares are registered pursuant to Section&nbsp;12(b) of the Exchange Act and are listed for trading on
the Nasdaq under the symbol &#147;<B>FRBN.</B>&#148; As of the date hereof, FEAC has no reason to believe that the FEAC Class&nbsp;A Shares will not continue to be listed on the Nasdaq through the Closing. The issued and outstanding FEAC Warrants
are registered pursuant to Section&nbsp;12(b) of the Exchange Act and are listed for trading on the Nasdaq under the symbol &#147;<B>FRBNW.</B>&#148; There is no Proceeding pending or, to the knowledge of FEAC, threatened in writing against FEAC by
the Nasdaq or the SEC with respect to any intention by such entity to deregister the FEAC Units, the FEAC Class&nbsp;A Shares or the FEAC Warrants or terminate the listing of FEAC on the Nasdaq. None of FEAC or any of its Affiliates has taken any
action in an attempt to terminate the registration of the FEAC Units, the FEAC Class&nbsp;A Shares or the FEAC Warrants under the Exchange Act. FEAC is not in violation of any of the rules and regulations or applicable continuing listing
requirements of the Nasdaq. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Contracts</I><I>. </I>Section&nbsp;4.10 of the FEAC Disclosure Schedules lists all material Contracts
currently in effect, other than this Agreement and the Ancillary Documents, to which FEAC is a party or by which FEAC or any of its assets or properties is bound, including without limitation any Contract requiring any future capital commitment or
capital expenditure (or series of capital expenditures) by FEAC, any Contract relating to Indebtedness of FEAC, any Contract requiring FEAC to guarantee the Liabilities of any Person and any Contract regarding any material indemnification
obligations incurred or provided by FEAC, and full and accurate copies of all such Contracts have been provided to the Company, including any Contract providing for any FEAC Change of Control Payment of the type described in clause (a)&nbsp;of the
definition thereof, in each case, for the avoidance of doubt, other than Contracts with legal and other advisors in connection with the Transactions. (a)&nbsp;Each Contract required to be listed in Section&nbsp;4.10 of the FEAC Disclosure Schedules
is valid and binding on FEAC and, to the knowledge of FEAC, the counterparty thereto, and is in full force and effect, (b)&nbsp;FEAC and, to the knowledge of FEAC, the counterparties thereto are not in material breach of, or material default under,
any such Contract, (c)&nbsp;to FEAC&#146;s knowledge, no event or omission has occurred that, through the passage of time or the giving of notice, or both, would constitute a default in any material respect thereunder or cause the acceleration of
FEAC&#146;s obligations thereunder or result in the creation of any Lien, other than Permitted Liens, (d)&nbsp;FEAC has delivered or made available to the Company (to the extent such information or document is not publicly available prior to 5:00
p.m. Eastern time on the date that is one (1)&nbsp;Business Day prior to the date of this Agreement in the Electronic Data Gathering, Analysis and Retrieval (EDGAR) database of the SEC) true, complete and accurate copies of such Contracts, including
all material amendments, schedules, ancillary documents, annexes, exhibits or certificates related thereto, and (e)&nbsp;as of the date hereof, FEAC has not received written, or, to FEAC&#146;s knowledge, oral notice of termination, cancellation or <FONT
STYLE="white-space:nowrap">non-renewal</FONT> of any such Contract. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Absence of Changes</I><I>. </I>Since the IPO to the date of this Agreement, (a)&nbsp;no FEAC Material
Adverse Effect has occurred and (b)&nbsp;except as otherwise reflected in the FEAC Financial Statements, actions or omissions taken as a result of <FONT STYLE="white-space:nowrap">COVID-19</FONT> and <FONT STYLE="white-space:nowrap">COVID-19</FONT>
Measures or as expressly contemplated or permitted by this Agreement, (i)&nbsp;FEAC has conducted its business in the ordinary course and in a manner consistent with past practice in all material respects and (ii)&nbsp;FEAC has not taken any action
that would require the consent of the Company if taken during the period from the date of this Agreement until the Closing pursuant to Section&nbsp;5.1(b). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Litigation</I><I>. </I>There is (and since FEAC&#146;s incorporation, there has been) no Proceeding pending
or, to FEAC&#146;s knowledge, threatened by or against FEAC that, if adversely decided or resolved, has been or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
would reasonably be expected to be, individually or in the aggregate, material to FEAC, taken as a whole or prevent, materially delay or materially impair the ability of FEAC to timely consummate
the Transactions. None of FEAC nor any of its properties or assets is subject to any material Order (including any Order that would prevent, materially delay or materially impair the ability of FEAC to timely consummate the Transactions). As of the
date of this Agreement, there are no material Proceedings by FEAC pending against any other Person. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Compliance with Applicable Law</I><I>. </I>FEAC (a)&nbsp;conducts, and since its incorporation has
conducted, its business in accordance with all Laws and Orders applicable to FEAC and is not in violation of any such Law or Order, and (b)&nbsp;has not received any written communications from a Governmental Entity that alleges that FEAC is not in
compliance with any such Law or Order, except in the case of each of clauses (a)&nbsp;and (b), as is not and would not reasonably be expected to be, individually or in the aggregate, material to FEAC, taken as a whole. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.14</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Compliance with Sanctions Laws, Anti-Corruption Laws and Anti-Money Laundering Laws</I>.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Since its incorporation, neither FEAC nor, to FEAC&#146;s knowledge, any of its directors or officers,
employees, agents, or other third-party representatives acting for or on behalf of any of the foregoing, is or has been a Sanctioned Person or otherwise is engaging or has engaged in dealings with a person who at the time of such dealing is or was
Sanctioned Person or in a country or territory that at the time of such dealing is or was a Sanctioned Territory. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Since its incorporation, FEAC has not violated in any material respect any Sanctions Laws, Anti-Corruption
Laws, Ex-Im Laws or Anti-Money Laundering Laws. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Since its incorporation, neither FEAC nor, to FEAC&#146;s knowledge, any of its directors or officers,
employees, agents, or any third-party representatives acting for or on behalf of any of the foregoing has, in contravention of any Anti-Corruption Laws (i)&nbsp;made, offered, promised, paid or received any unlawful bribes, kickbacks or other
similar payments to or from any Person, (ii)&nbsp;made or paid any contributions, directly or indirectly, to a domestic or foreign political party or candidate which was not in compliance with domestic Law or (iii)&nbsp;otherwise made, offered,
received, authorized, promised or paid any improper payment under any Anti-Corruption Laws. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Since its incorporation, FEAC has not been the subject of any voluntary disclosure, prosecution or enforcement
action or, to FEAC&#146;s knowledge, allegation or investigation related to any Sanctions Laws, Anti-Corruption Laws, Ex-Im Laws or Anti-Money Laundering Laws. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding anything in this Agreement, including but not limited to the representations made under
Section&nbsp;4.14 of this Agreement, nothing in this Agreement shall require FEAC or its Affiliates, or any director, officer, employee or agent of the foregoing, to commit an act or omission that contravenes the <I>Foreign Extraterritorial Measures
Act</I> (Canada), or any Order promulgated thereunder. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.15</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Employees</I><I>. </I>Other than the officers and directors listed in the FEAC SEC Reports, FEAC has never
employed any employees or retained any contractors. Other than reimbursement of any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred by FEAC&#146;s officers and directors in connection
with activities on FEAC&#146;s behalf in an aggregate amount not in excess of the amount of cash held by FEAC outside of the Trust Account, FEAC has no unsatisfied liabilities with respect to any employee. FEAC does not currently maintain or have
any liability under any employment or employee benefit plan, program, agreement, policy or arrangement, and neither the execution and delivery of this Agreement nor the Ancillary Documents nor the consummation of the Transactions will
(a)&nbsp;result in any payment (including severance, unemployment compensation, golden parachute, bonus or otherwise) becoming due to any director, officer or employee of FEAC, or (b)&nbsp;result in the acceleration of the time of payment or vesting
of any such benefits. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.16</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Not an Investment Company</I><I>. </I>FEAC is not an &#147;investment company&#148; or a Person directly or
indirectly &#147;controlled&#148; by or acting on behalf of an &#147;investment company&#148; within the meaning of the Investment Company Act, and the rules and regulations promulgated thereunder. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.17</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Business Activities; Assets</I><I>. </I>Since its incorporation, FEAC has not conducted any business
activities other than activities (a)&nbsp;in connection with or incident or related to its incorporation or continuing corporate (or similar) existence, (b)&nbsp;directed toward the accomplishment of a business combination, including those incident
or related to or incurred in connection with the negotiation, preparation or execution of this Agreement or any Ancillary Documents, the performance of its covenants or agreements in this Agreement or any Ancillary Document or the consummation of
the Transactions or (c)&nbsp;those that are administrative, ministerial or otherwise immaterial in nature. Except as set forth in FEAC&#146;s Governing Documents, there is no Contract binding upon FEAC or to which FEAC is a party which has or would
reasonably be expected to have the effect of prohibiting or materially impairing any business practice of it or its Subsidiaries, any acquisition of property by it or its Subsidiaries or the conduct of business by it or its Subsidiaries (including,
in each case, following the Closing). FEAC does not own any real property. FEAC does not own any material property or assets, other than its interest in the Trust Account. All property and assets owned by FEAC is owned free and clear of any Lien.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.18</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>No Undisclosed Liabilities</I><I>. </I>Except for Liabilities (a)&nbsp;set forth in Section&nbsp;4.18 of the
FEAC Disclosure Schedules, (b)&nbsp;incurred in connection with the negotiation, preparation or execution of this Agreement or any Ancillary Documents, the performance of its covenants or agreements in this Agreement or any Ancillary Document or the
consummation of the Transactions (including, for the avoidance of doubt, the FEAC Expenses and any Liabilities arising out of, or related to, any Proceeding related to this Agreement, the Ancillary Documents or the Transactions, including any
shareholder demand or other shareholder Proceedings (including derivative claims) arising out of, or related to, any of the foregoing), (c) set forth or disclosed in the FEAC Financial Statements included in the FEAC SEC Reports, (d)&nbsp;that have
arisen since the date of the most recent balance sheet included in the FEAC SEC Reports in the ordinary course of business (and not as a result of a breach of any Contract by FEAC), (e) that are incurred with the consent of the Company or
(f)&nbsp;that are not, and would not reasonably be expected to be, individually or in the aggregate, material to FEAC, FEAC does not have any Liabilities that would be required to be included in a balance sheet prepared in accordance with GAAP or
disclosed in the notes thereto. Immediately prior to the Closing, FEAC shall have no Indebtedness outstanding other than Indebtedness incurred as permitted under Section&nbsp;5.1(b). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.19</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Tax Matters</I>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">FEAC has prepared and timely filed all material Tax Returns required to have been filed by it, all such Tax
Returns are true, complete and correct in all material respects and prepared in compliance in all material respects with all applicable Laws and Orders, and FEAC has timely paid all material Taxes required to have been paid or deposited by it
regardless of whether shown on a Tax Return (except with respect to matters contested in good faith by appropriate proceedings and with respect to which adequate reserves have been made in accordance with GAAP). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">FEAC has timely withheld, collected and paid to the appropriate Tax Authority all material amounts required to
have been withheld, collected and paid. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">FEAC is not currently the subject of a Tax Contest. FEAC has not been informed in writing of the commencement
or anticipated commencement of any Tax audit or examination that has not been resolved or completed, and to the knowledge of FEAC, no such audit or examination has been threatened. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">FEAC has not consented to extend or waive the time in which any material Tax may be assessed or collected by
any Tax Authority, other than any such extensions or waivers that are no longer in effect or that were automatic extensions of time to file Tax Returns obtained in the ordinary course of business. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No &#147;closing agreement&#148; as described in Section&nbsp;7121 of the Code (or any corresponding or similar
provision of U.S., Canadian or other <FONT STYLE="white-space:nowrap">non-U.S.</FONT> state, local or provincial income Tax Law), private letter rulings, technical advice memoranda or similar agreements or rulings have been entered into or
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
issued by any Tax Authority with respect to FEAC which agreement or ruling would be effective after the Closing Date, and there is no such request outstanding relating to any of the foregoing.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">FEAC will not be required to include any item in taxable income, or exclude any item of deduction, for any
period ending after the Closing Date by reason of (i)&nbsp;a change in method of accounting for any period (or portion thereof) ending on or before the Closing Date, (ii)&nbsp;a use of an improper method of accounting for any period (or portion
thereof) ending on or before the Closing Date, (iii)&nbsp;an installment sale or open transaction disposition made on or prior to the Closing Date, (iv)&nbsp;an election made pursuant to Section&nbsp;965(h) of the Code (or any corresponding or
similar provision of state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Law), or (v)&nbsp;any prepaid amount received or deferred revenue accrued on or prior to the Closing Date. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">FEAC is not and has not been a party to any &#147;listed transaction&#148; as defined in Section&nbsp;6707A of
the Code and Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.6011-4</FONT> (or any corresponding or similar provision of U.S. state or local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Tax Law). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">There are no Liens for Taxes on any assets of FEAC or any Equity Securities of FEAC other than Permitted Liens.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">FEAC was not a &#147;distributing corporation&#148; or a &#147;controlled corporation,&#148; each within the
meaning of Section&nbsp;355(a)(1)(A) of the Code, in a distribution intended to qualify under Section&nbsp;355 of the Code (i)&nbsp;within the past two (2)&nbsp;years or (ii)&nbsp;as part of a &#147;plan&#148; or &#147;series of related
transactions&#148; (within the meaning of Section&nbsp;355(e) of the Code) in conjunction with the Transactions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To the knowledge of FEAC, FEAC is tax resident only in the Cayman Islands and the Netherlands.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(k)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">FEAC is, and has been since its formation organized under the laws of the Cayman Islands. Until the effective
time of the U.S. Entity Classification Election, FEAC has been treated since its formation as a foreign corporation for United States federal income tax purposes. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(l)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No written claims have ever been made by any Tax Authority in a jurisdiction where FEAC does not file Tax
Returns that FEAC is or may be subject to taxation by that jurisdiction, which claims have not been resolved or withdrawn. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(m)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To the knowledge of FEAC, FEAC does not have a permanent establishment (within the meaning of an applicable Tax
treaty) nor otherwise have an office or fixed place of business in a country other than a country in which it is organized or tax resident. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(n)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">FEAC (i)&nbsp;is not currently nor has ever been a member of an affiliated group filing a consolidated,
combined or unitary income Tax Return (other than a group the common parent of which was FEAC or any of its current Affiliates) and (ii)&nbsp;does not have any Liability for the Taxes of any Person under Section&nbsp;160 of the Tax Act or <FONT
STYLE="white-space:nowrap">Section&nbsp;1.1502-6</FONT> of the Treasury Regulations (or any similar provision of U.S. state or local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Law), or as a transferee or successor. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(o)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">FEAC has not, and has never been deemed to have, for purposes of the Tax Act or any relevant provincial
legislation, acquired or had the use of property for proceeds greater than the fair market value thereof from, or disposed of property for proceeds less than the fair market value thereof to, or received or performed services or had the use of
property for other than the fair market value from or to, or paid or received interest or any other amount other than at a fair market value rate to or from, any Person with whom it does not deal at arm&#146;s length within the meaning of the Tax
Act. FEAC has complied in all material respects with the transfer pricing provisions of applicable Tax Laws. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(p)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">FEAC is not a party to any Tax allocation, Tax sharing or Tax indemnity or similar agreements (other than a
Contract entered into in the ordinary course of business the principal purpose of which does not relate to Taxes) and FEAC is not a party to any joint venture, partnership or other arrangement that is treated as a partnership for U.S. federal income
Tax purposes. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(q)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To the knowledge of FEAC, there are no facts, circumstances or plans that, either alone or in combination,
could reasonably be expected to prevent the Transactions from qualifying for the Intended Tax Treatment. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(r)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">FEAC has complied in all material respects with the conditions stipulated in any Tax Grant granted to FEAC.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(s)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The FEAC Shares are not &#147;taxable Canadian property&#148; within the meaning of the Tax Act.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.20</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Brokers</I><I>. </I>Except for fees (including the amounts due and payable assuming the Closing occurs) set
forth on Section&nbsp;4.20 of the FEAC Disclosure Schedules (which fees shall be deemed FEAC Expenses for purposes of this Agreement), no broker, finder, investment banker or other Person is entitled to any brokerage fee, finders&#146; fee or other
commission in connection with the Transactions based upon arrangements made by or on behalf of FEAC, Can Merger Sub or any of their Affiliates for which FEAC or Can Merger Sub has any obligation. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.21</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Transactions with Affiliates</I><I>.</I><I> </I>Section&nbsp;4.21 of the FEAC Disclosure Schedules sets
forth all Contracts between (a)&nbsp;FEAC, on the one hand, and (b)&nbsp;any officer, director, partner, member, manager, registered equityholder (including the Sponsor) or Affiliate of either FEAC or the Sponsor, on the other hand (each Person
identified in this clause (a), a &#147;<B>FEAC Related Party</B>&#148;), other than (i)&nbsp;Contracts with respect to a FEAC Related Party&#146;s employment with, or the provision of services to, FEAC entered into in the ordinary course of business
(including benefit plans, indemnification arrangements and other ordinary course compensation), (ii) Contracts with respect to a <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> FEAC Holder&#146;s or a holder of FEAC Warrants&#146; status as a
holder of FEAC Shares or FEAC Warrants, as applicable, (iii)&nbsp;any Ancillary Document, and (iv)&nbsp;Contracts entered into after the date of this Agreement that are either permitted pursuant to Section&nbsp;5.1(b) or entered into in accordance
with Section&nbsp;5.1(b). Other than as set forth in Section&nbsp;4.21 of the FEAC Disclosure Schedules, no FEAC Related Party (A)&nbsp;owns any interest in any material asset used in FEAC&#146;s business, (B)&nbsp;possesses, directly or indirectly,
any material financial interest in, or is a director or executive officer of, any Person which is a material client, supplier, lender, partner, lessor or lessee or other material business relation of FEAC or (C)&nbsp;owes any material amount to, or
is owed any material amount by, FEAC. All Contracts, arrangements, understandings, interests and other matters that are required to be disclosed pursuant to this Section&nbsp;4.21 are referred to herein as &#147;<B>FEAC Related Party
Transactions</B>&#148;. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.22</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Information Supplied</I><I>. </I>None of the information supplied or to be supplied by or on behalf of FEAC
in writing expressly for inclusion or incorporation by reference prior to the Closing in the Registration Statement / Proxy Statement will, when the Registration Statement / Proxy Statement is declared effective or when the Registration Statement /
Proxy Statement is mailed to the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> FEAC Holders or at the time of the FEAC Shareholders Meeting, and in the case of any amendment thereto, at the time of such amendment, contain any
Misrepresentation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.23</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Investigation; No Other Representations</I>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">FEAC and Can Merger Sub, on their own behalf and on behalf of its Representatives, acknowledge, represent,
warrant and agree that (i)&nbsp;they have conducted their own independent review and analysis of, and, based thereon, have formed an independent judgment concerning, the business, assets, condition, operations and prospects, of the Group Companies
and (ii)&nbsp;they have been furnished with or given access to such documents and information about the Group Companies and their respective businesses and operations as they and their Representatives have deemed necessary to enable them to make an
informed decision with respect to the execution, delivery and performance of this Agreement, the Ancillary Documents and the Transactions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In entering into this Agreement and the Ancillary Documents to which they are or will be a party, FEAC and Can
Merger Sub have relied solely on their own investigation and analysis and the representations and warranties expressly set forth in Article 3 and in the Ancillary Documents to which they are or will be a party and no other representations or
warranties of the Company, any </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Company <FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliate or any other Person, either express or implied, and FEAC and Can Merger Sub, on their own behalf and on behalf of their
Representatives, acknowledges, represents, warrants and agrees that, except for the representations and warranties expressly set forth in Article 3 and in the Ancillary Documents to which they are or will be a party, none of the Company, any Company
<FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliate or any other Person makes or has made any representation or warranty, either express or implied, in connection with or related to this Agreement, the Ancillary Documents or the
Transactions. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.24</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>EXCLUSIVITY OF REPRESENTATIONS AND WARRANTIES</I><I>. </I>NOTWITHSTANDING THE DELIVERY OR DISCLOSURE TO THE
COMPANY OR ANY OF ITS REPRESENTATIVES OF ANY DOCUMENTATION OR OTHER INFORMATION (INCLUDING ANY FINANCIAL PROJECTIONS OR OTHER SUPPLEMENTAL DATA), EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS ARTICLE 4 AND THE ANCILLARY DOCUMENTS, NONE OF FEAC,
CAN MERGER SUB, ANY FEAC <FONT STYLE="white-space:nowrap">NON-PARTY</FONT> AFFILIATE OR ANY OTHER PERSON MAKES, AND EACH OF FEAC AND CAN MERGER SUB EXPRESSLY DISCLAIMS, ANY REPRESENTATIONS OR WARRANTIES OF ANY KIND OR NATURE, EXPRESS OR IMPLIED, IN
CONNECTION WITH THIS AGREEMENT, THE ANCILLARY DOCUMENTS OR ANY OF THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY, INCLUDING AS TO THE MATERIALS RELATING TO THE BUSINESS AND AFFAIRS OR HOLDINGS OF FEAC OR CAN MERGER SUB THAT HAS BEEN MADE AVAILABLE
TO THE COMPANY OR ANY OF ITS REPRESENTATIVES OR IN ANY PRESENTATION OF THE BUSINESS AND AFFAIRS OF FEAC BY OR ON BEHALF OF THE MANAGEMENT OF FEAC OR OTHERS IN CONNECTION WITH THE TRANSACTIONS CONTEMPLATED HEREBY OR BY THE ANCILLARY DOCUMENTS, AND NO
STATEMENT CONTAINED IN ANY OF SUCH MATERIALS OR MADE IN ANY SUCH PRESENTATION SHALL BE DEEMED A REPRESENTATION OR WARRANTY HEREUNDER OR OTHERWISE OR DEEMED TO BE RELIED UPON BY THE COMPANY OR ANY COMPANY
<FONT STYLE="white-space:nowrap">NON-PARTY</FONT> AFFILIATE IN EXECUTING, DELIVERING AND PERFORMING THIS AGREEMENT, THE ANCILLARY DOCUMENTS OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY. EXCEPT FOR THE REPRESENTATIONS AND WARRANTIES EXPRESSLY
SET FORTH IN THIS ARTICLE 4 OR THE ANCILLARY DOCUMENTS, IT IS UNDERSTOOD THAT ANY COST ESTIMATES, PROJECTIONS OR OTHER PREDICTIONS, ANY DATA, ANY FINANCIAL INFORMATION OR ANY MEMORANDA OR OFFERING MATERIALS OR PRESENTATIONS, INCLUDING, BUT NOT
LIMITED TO, ANY OFFERING MEMORANDUM OR SIMILAR MATERIALS MADE AVAILABLE BY OR ON BEHALF OF FEAC ARE NOT AND SHALL NOT BE DEEMED TO BE OR TO INCLUDE REPRESENTATIONS OR WARRANTIES OF FEAC, CAN MERGER SUB, ANY FEAC
<FONT STYLE="white-space:nowrap">NON-PARTY</FONT> AFFILIATE OR ANY OTHER PERSON, AND ARE NOT AND SHALL NOT BE DEEMED TO BE RELIED UPON BY THE COMPANY OR ANY COMPANY <FONT STYLE="white-space:nowrap">NON-PARTY</FONT> AFFILIATE IN EXECUTING, DELIVERING
OR PERFORMING THIS AGREEMENT, THE ANCILLARY DOCUMENTS OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>C<SMALL>OVENANTS</SMALL> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Conduct of Business of the Company and FEAC</I>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">From and after the date of this Agreement until the earlier of the Closing and the termination of this
Agreement in accordance with its terms, each of the Company, Newco and FEAC shall, and shall cause their respective Subsidiaries to, except (w)&nbsp;as expressly contemplated by this Agreement or any Ancillary Document, (x)&nbsp;as required by
applicable Law or any Governmental Entity, (y)&nbsp;in the case of the Company and its Subsidiaries only, as set forth on Section&nbsp;5.1(a) of the Company Disclosure Schedules, or (z)&nbsp;as consented to in writing by, in the case of the Group
Companies, FEAC and in the case of FEAC, the Company (it being agreed that any request for a consent shall not be unreasonably withheld, conditioned or delayed), (i) operate their respective business (including, in the case of the Company and Newco,
that of the Group Companies) in the ordinary </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
course and consistent with past practice and (ii)&nbsp;use commercially reasonable efforts to maintain and preserve intact their respective business organization, assets, properties and material
business relations (including, in the case of the Company and Newco, those of the Group Companies), taken as a whole. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Without limiting the generality of the foregoing, from and after the date of this Agreement until the earlier
of the Closing or the termination of this Agreement in accordance with its terms, each of the Company, Newco and FEAC shall, and shall cause their respective Subsidiaries to, except (v)&nbsp;as expressly contemplated by this Agreement or any
Ancillary Document and required in connection with the consummation of the Transactions, (w)&nbsp;as required by applicable Law or any Governmental Entity, (x)&nbsp;in the case of the Company and its Subsidiaries only, as set forth on
Section&nbsp;5.1(b) of the Company Disclosure Schedules or (y)&nbsp;as consented to in writing by, in the case of the Group Companies, FEAC and in the case of FEAC, the Company (it being agreed that any request for a consent shall not be
unreasonably withheld, conditioned or delayed) not to do any of the following: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">declare, set aside, make or pay a dividend on, or make any other distribution or payment in respect of, any
Equity Securities of any Group Company or repurchase any outstanding Equity Securities of any Subsidiary, other than, in the case of the Company only, (A)&nbsp;dividends or distributions, declared, set aside or paid by any of the Company&#146;s
Subsidiaries to the Company or any Subsidiary that is, directly or indirectly, wholly owned by the Company, and (B)&nbsp;the withholding of shares of the applicable class of capital stock of the Company in connection with the payment of taxes or the
exercise price upon the exercise or conversion of any Company Equity Awards outstanding on the date of this Agreement in accordance with the terms of the applicable Company Equity Plan and the underlying grant, award or similar agreement;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">(A) merge, consolidate, combine or amalgamate with any Person or (B)&nbsp;purchase or otherwise acquire
(whether by merging or consolidating with, purchasing any Equity Security in or a substantial portion of the assets of, or by any other manner) any corporation, partnership, association or other business entity or organization or division thereof;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">adopt any amendments, supplements, restatements or modifications to any (A)&nbsp;Governing Documents,
(B)&nbsp;in the case of the Company, the Company Shareholders Agreements (other than as agreed with IQ, the Sponsor and the Company Shareholders in connection with the 2023 Financing) or, any Company Equity Plan, other than (x)&nbsp;amendments of
solely an administrative nature which will not impact the terms of any Rollover Equity Award or (y)&nbsp;in accordance with the Company growth plan described on Section&nbsp;5.1(b)(viii) of the Company Disclosure Schedules, or (C)&nbsp;in the case
of FEAC, the Trust Agreement or the FEAC Warrant Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">(A) sell, assign, abandon, let lapse, lease, license, transfer or otherwise dispose of any material assets or
properties, other than (x)&nbsp;inventory or obsolete equipment in the ordinary course of business or <FONT STYLE="white-space:nowrap">(y)&nbsp;non-exclusive</FONT> licenses to Intellectual Property Rights granted in the ordinary course of business
consistent with past practice, (B)&nbsp;create, subject to or incur any Lien on any material assets or properties (other than Permitted Liens) or (C)&nbsp;disclose any Trade Secrets of the Group Companies (other than pursuant to a written
confidentiality agreement entered into in the ordinary course of business with reasonable protections of such Trade Secrets); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">(A) other than in accordance with the Company growth plan described on Section&nbsp;5.1(b)(viii) of the Company
Disclosure Schedules, issue, sell or grant (1)&nbsp;any Equity Securities of itself or any Subsidiary or (2)&nbsp;any options, warrants, rights of conversion or other rights, agreements, arrangements or commitments obligating itself or any
Subsidiary to issue, deliver or sell any Equity Securities of itself or any Subsidiary, other than, in the case of the Company only, the issuance of shares of the applicable class of capital stock of the Company upon the exercise, vesting or
conversion of any Company Equity Awards outstanding on the date of this </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Agreement in accordance with the terms of the applicable Company Equity Plan and the underlying grant, award or similar agreement, (B)&nbsp;in the case of the Company only, consent to the
transfer of any Company Shares, or (C)&nbsp;transfer or otherwise directly or indirectly dispose of, agree or consent to the transfer of, or subject to a Lien (other than a Permitted Lien), (1) any Equity Securities of any Subsidiary or (2)&nbsp;any
options, warrants, rights of conversion or other rights, agreements, arrangements or commitments obligating itself or any Subsidiary to issue, deliver or sell any Equity Securities of any of its Subsidiaries; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">incur, create or assume any Indebtedness, other than, (x)&nbsp;in the case of the Company and its Subsidiaries
only, in connection with the 2023 Financing or ordinary course trade payables and, (y)&nbsp;in the case of FEAC only, Indebtedness under (A)&nbsp;the Working Capital Loan Note, (B)&nbsp;any Extension Loan Note or (C)&nbsp;any other indebtedness owed
to the Sponsor, its Affiliates or designees in an aggregate outstanding amount not to exceed $600,000; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">make any loans, advances or capital contributions to, or guarantees for the benefit of, or any investments in,
any Person, other than, (A)&nbsp;in the case of the Company only, intercompany loans or capital contributions between the Company and any of its wholly owned Subsidiaries and (B)&nbsp;the reimbursement of expenses of employees in the ordinary course
of business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(viii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of the Group Companies only, except as required under the terms of any Employee Benefit Plan of any
Group Company that is set forth on Section&nbsp;3.11(a) of the Company Disclosure Schedules or in accordance with the Company growth plan described on Section&nbsp;5.1(b)(viii) of the Company Disclosure Schedules, (A)&nbsp;establish, amend, modify,
adopt, enter into or terminate any Employee Benefit Plan or any other benefit or compensation plan, policy, program, agreement, arrangement or Contract that would be an Employee Benefit Plan if in effect as of the date of this Agreement, other than
amendments of health or welfare benefit plans in connection with the annual renewal and reenrollment of such plans in the ordinary course of business and consistent with past practice that would not increase the aggregate cost to the Group Companies
of maintaining all Employee Benefit Plans that are health or welfare plans by more than 5% in the aggregate for all such amendments, (B)&nbsp;make, promise or grant any salary, bonus, benefit, incentive or any other compensation increase or decrease
payable to any current or former director, manager, officer, employee, individual independent contractor or other individual service provider receiving annual compensation equal to or greater than $180,000, other than (i)&nbsp;salary increases in
the ordinary course of business to such individuals that, in the aggregate, represent an increase of less than $180,000 on an annual basis, or (ii)&nbsp;Contracts with independent contractors where such Contract is for a fixed term and the
compensation paid during that term does not exceed $180,000, or (C)&nbsp;take any action other than as agreed herein to accelerate any payment, right to payment, or benefit, or the funding of any payment, right to payment or benefit, payable or to
become payable to any current or former director, manager, officer, employee, individual independent contractor or other individual service provider; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ix)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">waive or release any noncompetition, <FONT STYLE="white-space:nowrap">non-solicitation,</FONT> <FONT
STYLE="white-space:nowrap">no-hire,</FONT> nondisclosure, noninterference, <FONT STYLE="white-space:nowrap">non-disparagement</FONT> or other restrictive covenant obligation of any current or former director, manager, officer, employee, individual
independent contractor or other individual service provider other than in connection with Section&nbsp;5.22; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(x)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of the Company only, modify, extend, or enter into any CBA, or recognize or certify any labor
union, labor organization, works council, or group of employees of any Group Company as the bargaining representative for any employees of any Group Company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(xi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of the Company only, implement any employee layoffs, plant closings, reductions in force,
furloughs, temporary layoffs, salary or wage reductions, work schedule changes or other such actions to the extent that such actions that could implicate WARN; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(xii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of the Company only, enter into or terminate any executive employment agreements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(xiii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of FEAC and Newco only, hire any employees or retain any contractors or establish, amend, modify,
adopt, enter into or terminate any employee benefit plan, program, agreement, policy or arrangement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(xiv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">make, change or revoke any material election concerning Taxes, change any method of Tax accounting or Tax
accounting period, amend any Tax Return, enter into any material Tax closing agreement, seek any ruling from any Tax Authority with respect to material taxes, settle or compromise any material Tax Contest, or consent to any extension or waiver of
the limitation period applicable to or relating to any material Tax Contest, other than any such extension or waiver that is an extension of time to file a Tax Return obtained in the ordinary course of business; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(xv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">enter into any settlement, conciliation or similar Contract outside of the ordinary course of business other
than, in the case of the Company only, any settlement, conciliation or similar Contract the performance of which would involve the payment by the Group Companies of less than $150,000 in the aggregate, or that imposes, or by its terms will impose at
any point in the future, any material, <FONT STYLE="white-space:nowrap">non-monetary</FONT> obligations on any Group Company (or FEAC or any of its Affiliates after the Closing), in the case of the Company, or on FEAC, in the case of FEAC;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(xvi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">waive, release or assign, compromise or settle any Proceeding, outside of the ordinary course of business,
other than, in the case of the Company only, the settlement of any proceeding involving only the payment of money (not covered by insurance) by any Group Company of any amount not exceeding $100,000 in the aggregate; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(xvii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">authorize or incur any capital expenditures or commitments, outside of the ordinary course of business, other
than, in the case of the Company only, capital expenditures or commitments not exceeding $180,000 individually; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(xviii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">authorize, recommend, propose or announce an intention to adopt, or otherwise effect, a plan of complete or
partial liquidation, dissolution, restructuring, recapitalization, reorganization or similar transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(xix)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">change any method of accounting in any material respect, other than changes that are made in accordance with
GAAP or IFRS, as the case may be; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(xx)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">enter into any Contract with any broker, finder, investment banker or other Person under which such Person is
or will be entitled to any brokerage fee, finders&#146; fee or other commission in connection with the Transactions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(xxi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">make or promise any Company Change of Control Payment or FEAC Change of Control Payment, other than (A)&nbsp;in
the case of the Company only, those set forth in the employment agreements, offer letters or similar Contracts made available to FEAC and (B)&nbsp;in the case of FEAC only, those in connection with the Working Capital Loan or any Extension Loan;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(xxii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">(A) in the case of the Company only, other than in the ordinary course of business, (1)&nbsp;amend, modify or
terminate any Material Contract (excluding, for the avoidance of doubt, any expiration or automatic extension or renewal of any such Material Contract pursuant to its terms), (2) waive any material benefit or right under any Material Contract or
(3)&nbsp;enter into any Contract that would constitute a Material Contract, and (B)&nbsp;in the case of FEAC only, (1)&nbsp;amend, modify or terminate any material Contract (excluding, for the avoidance of doubt, any expiration or automatic
extension or renewal of any such material Contract pursuant to its terms), (2) waive any material benefit or right under any material Contract or (3)&nbsp;other than in the ordinary course of business, enter into any Contract; </P></TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(xxiii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of the Company only, fail to maintain in full force and effect in all material respects, or fail to
replace or renew, the material insurance policies of the Company and its Subsidiaries to the extent commercially reasonable in the Company&#146;s business judgment in light of prevailing conditions in the insurance market; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(xxiv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">agree to take any of the actions set forth in this Section&nbsp;5.1(b). </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything in this Section&nbsp;5.1 or this Agreement to the contrary, (a)&nbsp;any action taken, or omitted to be taken, by any
Party or its respective Subsidiaries to the extent such act or omission is necessary, based on the advice of outside legal counsel, to comply with any Law, Order, directive, pronouncement or guideline issued by a Governmental Entity providing for
business closures, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;sheltering-in-place&#148;</FONT></FONT> or other restrictions that relates to, or arises out of, <FONT STYLE="white-space:nowrap">COVID-19</FONT> (including
any <FONT STYLE="white-space:nowrap">COVID-19</FONT> Measure) shall in no event be deemed to constitute a breach of Section&nbsp;5.1 and (b)&nbsp;any action taken, or omitted to be taken, by any Party or its respective Subsidiaries to the extent
that the board of directors of such Party reasonably determines that such act or omission is necessary in response to <FONT STYLE="white-space:nowrap">COVID-19</FONT> to maintain and preserve in all material respects the business organization,
assets, properties and material business relations of such Party and its Subsidiaries, taken as a whole, shall not be deemed to constitute a breach of Section&nbsp;5.1; <I>provided, however</I>, (i)&nbsp;in the case of a material action or omission
taken in reliance on either clause (a)&nbsp;or (b), the Party taking or refraining from taking such action shall give the other Parties prompt written notice of any such act or omission, which notice shall describe in reasonable detail the act or
omission and the reason(s) that such act or omission is being taken, or omitted to be taken, pursuant to clause (a)&nbsp;or (b) and in no event shall clause (a)&nbsp;or (b) be applicable to any act or omission of the type described in
Section&nbsp;5.1(b)(i), Section&nbsp;5.1(b)(ii), Section&nbsp;5.1(b)(iii), Section&nbsp;5.1(b)(iv), Section&nbsp;5.1(b)(v), Section&nbsp;5.1(b)(vi), Section&nbsp;5.1(b)(viii), Section&nbsp;5.1(b)(xi), Section&nbsp;5.1(b)(xiv),
Section&nbsp;5.1(b)(xviii), (xx)(xx), Section&nbsp;5.1(b)(xxi), or Section&nbsp;5.1(b)(xxiv) (to the extent related to any of the foregoing). </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Nothing contained in this Section&nbsp;5.1 shall be deemed to give FEAC, directly or indirectly, the right to
control or direct the Company or any operations of the Company prior to the Closing. Prior to the Closing, the Company shall exercise, consistent with the terms and conditions of this Agreement, control over its businesses and operations.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Nothing contained in this Section&nbsp;5.1 shall be deemed to give the Company, directly or indirectly, the
right to control or direct FEAC or any operations of FEAC prior to the Closing. Prior to the Closing, FEAC shall exercise, consistent with the terms and conditions of this Agreement, control over its businesses and operations. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Efforts to Consummate</I>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the terms and conditions herein provided, each of the Parties shall use reasonable best efforts to
take, or cause to be taken, all actions and to do, or cause to be done, all things reasonably necessary or advisable to consummate and make effective as promptly as reasonably practicable the Transactions (including (i)&nbsp;the satisfaction, but
not waiver, of the closing conditions set forth in Article 6 and, in the case of any Ancillary Document to which such Party will be a party after the date of this Agreement, to execute and deliver such Ancillary Document when required pursuant to
this Agreement, (ii)&nbsp;using reasonable best efforts to obtain the PIPE Financing and the Convertible Bridge Financing on the terms and subject to the conditions set forth in the Subscription Agreements and Side Letter Agreements (with respect to
the PIPE Financing) and the Convertible Bridge Financing Documents (with respect to the Convertible Bridge Financing) and (iii)&nbsp;FEAC taking, or causing to be taken, all actions necessary or advisable to extend the period of time to consummate
an initial business combination by (x)&nbsp;a first additional three-month period (up to 21 months from FEAC&#146;s IPO) if FEAC anticipates that it may not be able to consummate the Transactions within 18 months from its IPO and (y)&nbsp;a second
additional three-month period (up to 24 months from FEAC&#146;s IPO) if FEAC anticipates that it may not be able to consummate the Transactions within 21 months from its IPO, in each in accordance with FEAC&#146;s Governing Documents and the Trust
Agreement). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Without limiting the generality of the foregoing, each of the Parties shall use reasonable best efforts to obtain, file with or deliver to, as applicable, any Consents of any Governmental
Entities or other Persons necessary, proper or advisable to consummate the Transactions. Each Party shall bear its own costs incurred in connection with obtaining such Consents. Each Party shall (i)&nbsp;make any appropriate filings or take, or
cause to be taken, any required actions pursuant to any Foreign Antitrust Laws with respect to the Transactions promptly following the date of this Agreement and (ii)&nbsp;respond as promptly as reasonably practicable to any requests by any
Governmental Entity for additional information and documentary material that may be requested under any Foreign Antitrust Laws. FEAC shall promptly inform the Company of any substantive communication between FEAC, on the one hand, and any
Governmental Entity, on the other hand, and the Company shall promptly inform FEAC of any substantive communication between the Company, on the one hand, and any Governmental Entity, on the other hand, in either case, regarding any of the
Transactions and to the extent permitted by law. Without limiting the foregoing, each Party and their respective Affiliates shall not extend any waiting period, review period or comparable period under any applicable Foreign Antitrust Laws or enter
into any agreement with any Governmental Entity not to consummate the Transactions, except with the prior written consent of FEAC and the Company. Nothing in this Section&nbsp;5.2 obligates any Party or any of its Affiliates to agree to
(i)&nbsp;sell, license or otherwise dispose of, or hold separate and agree to sell, license or otherwise dispose of, any entities, assets or facilities of any Group Company or any entity, facility or asset of such Party or any of its Affiliates,
(ii)&nbsp;terminate, amend or assign existing relationships and contractual rights or obligations, (iii)&nbsp;amend, assign or terminate existing licenses or other agreements, or (iv)&nbsp;enter into new licenses or other agreements. No Party shall
agree to any of the foregoing measures with respect to any other Party or any of its Affiliates, except with FEAC&#146;s and the Company&#146;s prior written consent. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">From and after the date of this Agreement until the earlier of the Closing or termination of this Agreement in
accordance with its terms, FEAC, on the one hand, and the Company, on the other hand, shall give counsel for the Company (in the case of FEAC) or FEAC (in the case of the Company), a reasonable opportunity to review in advance, and consider in good
faith the views of the other in connection with, any proposed written substantive communication to any Governmental Entity relating to the Transactions. Any materials exchanged in connection with this Section&nbsp;5.2 may be redacted or withheld as
necessary to address reasonable privilege or confidentiality concerns of legal counsel (including <FONT STYLE="white-space:nowrap">in-house</FONT> counsel) of any Party, and to remove competitively sensitive material; <I>provided</I>, that such
Party may, as it deems advisable and necessary, designate any materials provided to under this Section&nbsp;5.2 as &#147;outside counsel only.&#148; Each of the Parties agrees not to participate in any substantive meeting or discussion, either in
person or by telephone with any Governmental Entity in connection with the Transactions unless it consults with, in the case of FEAC, the Company, or, in the case of the Company, FEAC in advance and, to the extent reasonably practicable and not
prohibited by such Governmental Entity, gives, in the case of FEAC, the Company, or, in the case of the Company, FEAC, the opportunity to attend and participate in such meeting or discussion. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding anything to the contrary in the Agreement, in the event that this Section&nbsp;5.2 conflicts
with any other covenant or agreement in this Article 5 that is intended to specifically address any subject matter, then such other covenant or agreement shall govern and control solely to the extent of such conflict. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">From and after the date of this Agreement until the earlier of the Closing or termination of this Agreement in
accordance with its terms, FEAC, on the one hand, and the Company, on the other hand, shall each notify the other in writing promptly after learning of any shareholder demands or other shareholder Proceedings (including derivative claims and
Arrangement Dissent Rights) relating to this Agreement, any Ancillary Document or any matters relating thereto (collectively, the &#147;<B>Transaction Litigation</B>&#148;) commenced against, in the case of FEAC, FEAC, Can Merger Sub or any of their
Representatives (in their capacity as a representative of FEAC) or, in the case of the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Company, any Group Company or any of their respective Representatives (in their capacity as a representative of a Group Company). Subject and in addition to Section&nbsp;2.3 with respect to
Arrangement Dissent Rights, FEAC and the Company shall each (i)&nbsp;keep the other reasonably informed regarding any Transaction Litigation, (ii)&nbsp;give the other the opportunity to, at its own cost and expense, participate in the defense,
settlement and compromise of any such Transaction Litigation and reasonably cooperate with the other in connection with the defense, settlement and compromise of any such Transaction Litigation, (iii)&nbsp;consider in good faith the other&#146;s
advice with respect to any such Transaction Litigation, (iv)&nbsp;reasonably cooperate with each other and (v)&nbsp;refrain from settling or compromising any Transaction Litigation without the prior written consent of, in the case of the Group
Companies, FEAC and in the case of FEAC or Can Merger Sub, the Company (such consent not to be unreasonably withheld, conditioned or delayed). </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Confidentiality and Access to Information</I>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding Clause 8 (<I>Term</I>) of the Confidentiality Agreement, the Company and FEAC acknowledge and
agree that as of the date hereof, and continuing through the Closing Date and terminating thereafter, the Company, FEAC and each of their respective Affiliates and Representatives remain bound to the Confidentiality Agreement, the terms of which are
incorporated herein by reference. Notwithstanding the foregoing or anything to the contrary in this Agreement, in the event that this Section&nbsp;5.3(a) or the Confidentiality Agreement conflicts with any other covenant or agreement contained
herein or any Ancillary Document that contemplates the disclosure, use or provision of information or otherwise, then such other covenant or agreement contained herein shall govern and control to the extent of such conflict. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">From and after the date of this Agreement until the earlier of the Closing Date and the termination of this
Agreement in accordance with its terms, upon reasonable advance written notice, each Party shall provide, or cause to be provided, to each other Party and its Representatives during normal business hours reasonable access to its and its Subsidiaries
properties, directors, officers, books and records (in a manner so as to not interfere with normal business operations). Notwithstanding the foregoing, neither a Party nor its Subsidiaries shall be required to provide to each other Party or any of
its Representatives any information (i)&nbsp;if and to the extent doing so would (A)&nbsp;violate any Law to which such Party is subject, (B)&nbsp;result in the disclosure of any Trade Secrets of third parties in breach of any Contract with such
third party, (C)&nbsp;violate any legally-binding obligation of any Party with respect to confidentiality, <FONT STYLE="white-space:nowrap">non-disclosure</FONT> or privacy or (D)&nbsp;jeopardize protections afforded to any Party or its Subsidiaries
under the attorney-client privilege or the attorney work product doctrine (<I>provided</I> that, in case of each of clauses (A)&nbsp;through (D), the so affected Party shall, and shall cause its Subsidiaries to, use commercially reasonable efforts
to (x) provide such access as can be <I>provided</I> (or otherwise convey such information regarding the applicable matter as can be conveyed) without violating such privilege, doctrine, Contract, obligation or Law and (y)&nbsp;provide such
information in a manner without violating such privilege, doctrine, Contract, obligation or Law), or (ii)&nbsp;if any Group Company, on the one hand, and FEAC, any FEAC <FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliate or any of their
respective Representatives, on the other hand, are adverse parties in a litigation and such information is reasonably pertinent thereto; <I>provided</I> that each Party shall, in the case of clause (i)&nbsp;or (ii), provide prompt written notice of
the withholding of access or information on any such basis. For the avoidance of doubt, this Section&nbsp;5.3 shall not permit any unreasonably invasive or intrusive investigations or other testing, sampling or analysis by a Party of any properties,
facilities or equipment of another Party without the prior written consent of, in the case of the Group Companies, FEAC and in the case of FEAC, the Company (which may be withheld, conditioned or delayed by such Party in its sole discretion).
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Public Announcements</I>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to Section&nbsp;5.4(b), Section&nbsp;2.4, Section&nbsp;5.7 and Section&nbsp;5.7(b), none of the Parties
or any of their respective Representatives shall issue any press releases or make any public announcements </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
with respect to this Agreement or the Transactions prior to the Closing without the prior written consent of, in the case of the Group Companies, FEAC and in the case of FEAC or Can Merger Sub,
the Company; <I>provided, however</I>, that each Party may make any such announcement or other communication (i)&nbsp;if such announcement or other communication is required by applicable Law or by a Governmental Entity, in which case the disclosing
Party and its Representatives shall use reasonable best efforts to consult with the Company, if the disclosing party is FEAC, or FEAC, if the disclosing party is the Company, to review such announcement or communication and the opportunity to
comment thereon and the disclosing Party shall consider such comments in good faith, (ii)&nbsp;to the extent such announcements or other communications contain only information previously disclosed in a public statement, press release or other
communication previously approved in accordance with this Section&nbsp;5.4 and (iii)&nbsp;subject to and in accordance with Section&nbsp;5.2(b), to Governmental Entities in connection with any Consents required to be made under this Agreement, the
Ancillary Documents or in connection with the Transactions. Notwithstanding anything to the contrary in this Section&nbsp;5.4 or otherwise in this Agreement, the Parties agree that, following the Closing, Forbion Group Holding B.V., the Sponsor and
their respective Representatives and Affiliates may provide general information about the subject matter of this Agreement and the Transactions to any direct or indirect current investor or potential investors who enter into a separate
confidentiality agreement with the Company or in connection with informational or reporting activities. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The initial press release concerning this Agreement and the Transactions shall be a joint press release in the
form agreed by the Company and FEAC prior to the execution of this Agreement and such initial press release (the &#147;<B>Signing Press Release</B>&#148;) shall be released as promptly as reasonably practicable after the execution of this Agreement
on the day thereof. Promptly after the execution of this Agreement, FEAC shall file a current report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (the &#147;<B>Signing Filing</B>&#148;) with the Signing Press Release and a description of this
Agreement as required by, and in compliance with, the Securities Laws, which the Company shall have the opportunity to review and agree upon prior to filing (such agreement not to be unreasonably withheld, conditioned or delayed by either the
Company or FEAC, as applicable). The Company, on the one hand, and FEAC, on the other hand, shall mutually agree upon (such agreement not to be unreasonably withheld, conditioned or delayed by either the Company or FEAC, as applicable) a press
release announcing the consummation of the Transactions (the &#147;<B>Closing Press Release</B>&#148;) prior to the Closing, and, on the Closing Date, the Parties shall cause the Closing Press Release to be released. Promptly after the Closing (but
in any event within four (4)&nbsp;Business Days after the Closing), Newco shall file a current report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (the &#147;<B>Closing Filing</B>&#148;) with the Closing Press Release and a description of the
Closing as required by Securities Laws. In connection with the preparation of each of the Signing Press Release, the Signing Filing, the Closing Press Release and the Closing Filing, each Party shall, upon written request by any other Party, furnish
such other Party with all information concerning itself, its directors, officers and securityholders, and such other matters as may be reasonably necessary for such press release or filing. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Tax Matters</I>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Tax Treatment. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For U.S. federal income tax purposes, the Parties intend that (A)&nbsp;the Class&nbsp;B Conversion shall
constitute a transaction treated as a &#147;reorganization&#148; within the meaning of Section&nbsp;368(a)(1)(E) of the Code, (B)&nbsp;the surrender of 1,789,004 FEAC Class&nbsp;B Shares and 5,463,381 FEAC Private Placement Warrants shall be treated
as a contribution to the capital of FEAC for no consideration that is not taxable, (C)&nbsp;the FEAC Reorganization shall constitute a transaction treated as a &#147;reorganization&#148; within the meaning of Section&nbsp;368(a)(1)(F) of the Code,
(D)&nbsp;the assumption of the FEAC Warrants by Newco pursuant to the Warrant Assignment, Assumption and Amendment Agreement shall be treated as a <FONT STYLE="white-space:nowrap">non-taxable</FONT> exchange of the FEAC Warrants for Newco Warrants
that occurs at the same time as the Cayman Merger and as part of the FEAC </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Reorganization and (E)&nbsp;the Amalgamation shall constitute a transaction treated as a &#147;reorganization&#148; within the meaning of Section&nbsp;368(a)(1)(A) and 368(a)(2)(E) of the Code
(collectively, the &#147;<B>Intended Tax </B><B>Treatment</B>&#148;), and each Party shall, and shall cause its respective Affiliates to, file all U.S. Tax Returns consistent with, and take no position inconsistent with (whether in U.S. audits, U.S.
Tax Returns or otherwise with respect to U.S. federal income tax matters), the treatment described in this Section&nbsp;5.5(a)(i) unless required to do so pursuant to a &#147;determination&#148; that is final within the meaning of
Section&nbsp;1313(a) of the Code. Each of the Parties acknowledges and agrees that (i)&nbsp;it has had the opportunity to obtain independent legal and Tax advice with respect to the Transactions, and (ii)&nbsp;none of the Company, FEAC, Newco or any
other Person shall have any liability or obligation to any Person if any Transaction is determined not to qualify for the Intended Tax Treatment or otherwise not to qualify as a nontaxable Transaction to FEAC&#146;s or Company&#146;s shareholders or
securityholders for any tax purposes. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Parties hereby adopt this Agreement as a &#147;plan of reorganization&#148; within the meaning of Treasury
Regulations Sections 1.368-2(g) and 1.368-3(a). From the date hereof through the Closing, and following the Closing, the Parties shall not, and shall not permit or cause their respective Affiliates to, take any action, or knowingly fail to take any
action, which action or failure to act would reasonably be expected to prevent or impede the Transactions from qualifying for the Intended Tax Treatment. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If, in connection with the preparation and filing of the Registration Statement / Proxy Statement, the SEC
requests or requires that tax opinions be prepared and submitted with respect to the Tax consequences of (i)&nbsp;the FEAC Reorganization, or the redemption of FEAC Shares for the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> FEAC Holders or
FEAC, then FEAC will use reasonable best efforts to cause Davis Polk&nbsp;&amp; Wardwell London LLP or other counsel to FEAC (&#147;<B>FEAC Tax Counsel</B>&#148;) to deliver such tax opinions or (ii)&nbsp;the Amalgamation, or the ownership of Newco
Shares or Newco Warrants following the Amalgamation, for the Company Shareholders, Newco Shareholders or the Company, then the Company will use reasonable best efforts to cause Morgan, Lewis&nbsp;&amp; Bockius LLP or other counsel to the Company
(&#147;<B>Company Tax Counsel</B>&#148;) to deliver such tax opinions and, in either case, each Party will use reasonable best efforts to execute and deliver to FEAC Tax Counsel and Company Tax Counsel customary Tax representation letters reasonably
satisfactory to FEAC Tax Counsel or Company Tax Counsel, as applicable, at such time or times as may be reasonably requested by FEAC Tax Counsel or Company Tax Counsel, as applicable, in connection with the delivery of any such tax opinions with
respect to the Tax treatment of the Transactions. For the avoidance of doubt, a tax opinion regarding the Intended Tax Treatment is not a condition to Closing. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For Canadian income tax purposes, the Parties intend that (1)&nbsp;the Amalgamation qualify as an amalgamation
within the meaning of section 87 of the Tax Act and be governed by subsections 87(1), 87(2), 87(4), 87(5) and 87(9) of the Tax Act, (2)&nbsp;subsection 7(1.4) of the Tax Act apply to the exchange of certain employee options as described in the Plan
of Arrangement, and (3)&nbsp;an election pursuant to subsection 85(1) of the Tax Act will be filed jointly by Newco and the Company in respect of the transfer from Newco to the Company of Note 3 in consideration for the issuance of additional shares
from treasury at an elected amount to be determined at the Company&#146;s discretion (but in all cases within the limits set out in the Tax Act). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event that Newco determines after the Closing that Newco is a passive foreign investment company for
U.S. federal income tax purposes for any taxable year, Newco shall provide upon request from any Newco shareholder, sufficient information to allow such requesting shareholders to make a timely &#147;qualified electing fund&#148; election and to
comply with the requirements of such election within the meaning of Section&nbsp;1295 of the Code with respect to Newco. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Newco shall retain (or cause the Group Company to retain) all books and records with respect to Tax matters of
the Group Company for <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> Periods for at least seven (7)&nbsp;years following the Closing Date and to abide by all record retention agreements entered into by or with respect to the Group Company with
any Tax Authority. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Parties acknowledge that any shareholder of FEAC that is treated as owning five percent (5%) or more of the
FEAC Shares, as determined under Section&nbsp;367 of the Code and Treasury Regulations promulgated thereunder, may enter into a gain recognition agreement in accordance with Treasury Regulations Section&nbsp;1.367(a)-8. Upon a written request of any
such shareholder following the Closing Date, Newco shall use reasonable best efforts to furnish to such shareholder such information as the shareholder may reasonably request in connection with such shareholder&#146;s (i)&nbsp;preparation of a gain
recognition agreement, and (ii)&nbsp;determination as to whether there has been a gain &#147;triggering event&#148; under the gain recognition agreement, in each case, at the sole cost and expense of the requesting shareholder. For the avoidance of
doubt, none of FEAC, Newco, the Company, or any Group Company shall be required to operate in a manner that avoids or mitigates the likelihood of a triggering event. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Cayman Merger Sub will elect to be disregarded as an entity separate from Newco for U.S. federal income tax
purposes effective as of the day of its formation and will not subsequently change such classification. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Exclusive Dealing</I>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">From the date of this Agreement until the earlier of the Closing or the termination of this Agreement in
accordance with its terms, neither Newco nor the Company shall, and each of Newco and the Company shall cause the other Group Companies, its controlled Affiliates and its and their respective Representatives not to, directly or indirectly:
(i)&nbsp;solicit, initiate, knowingly encourage (including by means of furnishing or disclosing information), knowingly facilitate, directly or indirectly, any inquiry, proposal or offer (written or oral) with respect to a Company Acquisition
Proposal; (ii)&nbsp;furnish or disclose any <FONT STYLE="white-space:nowrap">non-public</FONT> information to any Person in connection with, or that could reasonably be expected to lead to, a Company Acquisition Proposal; (iii)&nbsp;discuss or
negotiate with any Person a Company Acquisition Proposal (other than to inform such Person of the restrictions set forth in this Section&nbsp;5.6), (iv) enter into any Contract or other arrangement or understanding regarding a Company Acquisition
Proposal; (v)&nbsp;take meaningful steps in preparation for, or conduct, a public offering of any Equity Securities of any Group Company (or any Affiliate or successor of any Group Company); or (vi)&nbsp;otherwise cooperate in any way with, or
knowingly assist or participate in, or knowingly facilitate or encourage any effort or attempt by any Person to do or seek to do any of the foregoing. The Company agrees to (A)&nbsp;notify FEAC promptly upon receipt of any such inquiry, proposal,
offer or Company Acquisition Proposal by any Group Company, and to provide copies of material documents, correspondence or other material received in respect of, from or on behalf of any such Person if in writing or electronic form, and if not in
writing or electronic form, a description of the material terms and conditions of any such inquiry, proposal, offer or Company Acquisition Proposal in reasonable detail (including the identity of the Persons making such inquiry, proposal, offer or
Company Acquisition Proposal) and (B)&nbsp;keep FEAC reasonably informed on a current basis of any modifications to such inquiry, proposal, offer or Company Acquisition Proposal and shall provide to FEAC copies of all material correspondence if in
writing or electronic form and if not in writing or electronic form, a description of the material terms of such correspondence or communication to the Company by or on behalf of any Person making such inquiry, proposal, offer or Company Acquisition
Proposal. Notwithstanding anything to the contrary in this Section&nbsp;5.6(a), this Agreement shall not prevent the Company or its board of directors from, prior to obtaining the Company Required Approval in respect of the Company Arrangement
Resolution, disclosing to Company Shareholders the receipt, existence or terms of a bona fide Company Acquisition Proposal received after the date hereof that did not result from a material breach of this Section&nbsp;5.6(a). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">From the date of this Agreement until the earlier of the Closing or the termination of this Agreement in
accordance with its terms, FEAC shall not, and shall cause its Representatives and Affiliates not to, directly or indirectly: (i)&nbsp;solicit, initiate, knowingly encourage (including by means of furnishing or disclosing information), knowingly
facilitate, directly or indirectly, any inquiry, proposal or offer (written or oral) with respect to a FEAC Acquisition Proposal; (ii)&nbsp;furnish or disclose any <FONT STYLE="white-space:nowrap">non-public</FONT> information to any Person in
connection with, or that could reasonably be expected to lead to, a FEAC Acquisition Proposal; (iii)&nbsp;discuss or negotiate with any Person a FEAC Acquisition Proposal (other than to inform such Person of the restrictions set forth in this
Section&nbsp;5.6), (iv) enter into any Contract or other arrangement or understanding regarding a FEAC Acquisition Proposal; (v)&nbsp;take meaningful steps in preparation for, or conduct, an offering of any securities of FEAC (or any Affiliate or
successor of FEAC); or (vi)&nbsp;otherwise cooperate in any way with, or knowingly assist or participate in, or knowingly facilitate or encourage any effort or attempt by any Person to do or seek to do any of the foregoing. FEAC agrees to
(A)&nbsp;notify the Company promptly upon receipt of any such inquiry, proposal, offer or FEAC Acquisition Proposal by FEAC, and to provide copies of material documents, correspondence or other material received in respect of, from or on behalf of
any such Person if in writing or electronic form, and if not in writing or electronic form, a description of the material terms and conditions of any such inquiry, proposal, offer or FEAC Acquisition Proposal in reasonable detail (including the
identity of any person or entity making such inquiry, proposal, offer or FEAC Acquisition Proposal) and (B)&nbsp;keep the Company reasonably informed on a current basis of any modifications to such inquiry, proposal, offer or FEAC Acquisition
Proposal and shall provide to the Company copies of all material correspondence if in writing or electronic form and if not in writing or electronic form, a description of the material terms of such correspondence or communication to FEAC by or on
behalf of any Person making such inquiry, proposal, offer or FEAC Acquisition Proposal. Notwithstanding any other provision to the contrary contained in this Agreement, none of the provisions of this Section&nbsp;5.6(b) (including without limitation
any of the foregoing regarding exclusivity) shall in any way apply to or limit the activities of any <FONT STYLE="white-space:nowrap">non-controlled</FONT> Affiliate of FEAC, including Forbion Group Holding B.V., any investment funds or entities
owned, controlled or managed by Forbion Group Holding B.V. and the direct or indirect portfolio companies thereof (each, a &#147;<B>FEAC <FONT STYLE="white-space:nowrap">Non-Controlled</FONT> Affiliate</B>&#148;), but only if Confidential
Information (as defined in the Confidentiality Agreement) of the Company has not been, and is not, made available to any such FEAC <FONT STYLE="white-space:nowrap">Non-Controlled</FONT> Affiliate. Should any individual who is employed by a FEAC <FONT
STYLE="white-space:nowrap">Non-Controlled</FONT> Affiliate and who is not employed by FEAC or the Sponsor receive Confidential Information (as defined in the Confidentiality Agreement) of the Company in his or her capacity as a director, officer or
other representative of FEAC, such individual will be bound by the terms of this Agreement applicable to FEAC, but the activities of such FEAC <FONT STYLE="white-space:nowrap">Non-Controlled</FONT> Affiliate may continue without limitation as set
forth herein and this Agreement shall not apply to such FEAC <FONT STYLE="white-space:nowrap">Non-Controlled</FONT> Affiliate so long as such FEAC <FONT STYLE="white-space:nowrap">Non-Controlled</FONT> Affiliate does not disclose or use any such
Confidential Information (as defined in the Confidentiality Agreement) in connection with such activities and is not otherwise directed to take, or refrain from taking such actions, by such individuals. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Preparation of Registration Statement / Proxy Statement</I>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As promptly as reasonably practicable following the date of this Agreement, the Parties shall prepare and Newco
shall file with, or confidentially submit to, the SEC, the Registration Statement / Proxy Statement (it being understood that the Registration Statement / Proxy Statement shall include a prospectus of Newco and a proxy statement of FEAC which will
be used for the FEAC Shareholders Meeting to adopt and approve the Transaction Proposals and other matters reasonably related to the Transaction Proposals, all in accordance with and as required by FEAC&#146;s Governing Documents, applicable Law,
and any applicable rules and regulations of the SEC and Nasdaq or other relevant Exchange, as applicable). No filing with or submission to the SEC of the Registration Statement / Proxy Statement shall be made unless approved by FEAC and the Company,
each acting reasonably. Each Party shall use its reasonable best efforts to (a)&nbsp;cause the Registration Statement / Proxy&nbsp;Statement to comply in all material respects with </P></TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
the applicable rules and regulations promulgated by the SEC (including, with respect to the Group Companies and FEAC, the provision of financial statements of, and any other information with
respect to, the Group Companies and FEAC for all periods, and in the form, required to be included in the Registration Statement / Proxy Statement under Securities Laws (after giving effect to any waivers received) or in response to any comments
from the SEC); (b) promptly notify the others of, reasonably cooperate with each other with respect to and respond promptly to any comments of the SEC and its staff; (c)&nbsp;have the Registration Statement / Proxy Statement declared effective under
the Securities Act as promptly as reasonably practicable after it is filed with the SEC; and (d)&nbsp;keep the Registration Statement / Proxy Statement effective through the Closing in order to permit the consummation of the Transactions. FEAC, on
the one hand, and the Company and Newco, on the other hand, shall promptly furnish, or cause to be furnished, to the other all information concerning such Party, its <FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliates and their respective
Representatives that may be required or reasonably requested in connection with any action contemplated by this Section&nbsp;5.7 or for including in any other statement, filing, notice or application made by or on behalf of FEAC or Newco to the SEC
or Nasdaq or other relevant Exchange, as applicable, in connection with the Transactions, including delivering customary tax representation letters to counsel to enable counsel to deliver any tax opinions requested or required by the SEC to be
submitted in connection therewith as described in Section&nbsp;5.5(b). If any Party becomes aware of any information that should be disclosed in an amendment or supplement to the Registration Statement / Proxy Statement, then (i)&nbsp;such Party
shall promptly inform, in the case of FEAC, the Company and Newco, or, in the case of the Company, FEAC and Newco thereof; (ii)&nbsp;the Parties shall prepare an amendment or supplement to the Registration Statement / Proxy Statement;
(iii)&nbsp;Newco shall file such amendment or supplement with the SEC; and (iv)&nbsp;FEAC shall mail, if appropriate, such amendment or supplement to the <FONT STYLE="white-space:nowrap">Pre-Closing</FONT> FEAC Holders. Newco shall as promptly as
reasonably practicable advise FEAC of the time of effectiveness of the Registration Statement / Proxy Statement, the issuance of any stop order relating thereto or the suspension of the qualification of Newco Shares for offering or sale in any
jurisdiction, and the Parties shall each use its reasonable best efforts to have any such stop order or suspension lifted, reversed or otherwise terminated. Each of the Parties shall use reasonable best efforts to ensure that none of the information
related to it or any of its <FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliates or its or their respective Representatives, supplied by or on its behalf for inclusion or incorporation by reference in the Registration Statement / Proxy
Statement will, at the time the Registration Statement / Proxy Statement is initially filed with the SEC, at each time at which it is amended, or at the time it becomes effective under the Securities Act contain any Misrepresentation. Filing and
registration fees associated with the Registration Statement/Proxy Statement, and all associated financial printer and proxy solicitation expenses, shall be deemed FEAC Expenses for purposes of this Agreement. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Parties shall prepare and Newco shall file with the Autorit&eacute; des march&eacute;s financiers du
Qu&eacute;bec and the securities regulator of each other province or as the Parties may mutually agree, a preliminary and final <FONT STYLE="white-space:nowrap">non-offering</FONT> prospectus (the &#147;<B>Canadian Prospectus</B>&#148;) in
sufficient time for Newco to become a reporting issuer in the Province of Qu&eacute;bec promptly following the Closing Date. Each Party shall use its reasonable best efforts to cause each of the preliminary and final
<FONT STYLE="white-space:nowrap">non-offering</FONT> prospectus to comply as to form in all material respects with applicable Canadian securities Laws. The Company and Newco shall allow FEAC and its counsel to review the preliminary and final <FONT
STYLE="white-space:nowrap">non-offering</FONT> prospectus a reasonable amount of time prior to their respective filings and shall consider for inclusion in the preliminary and final <FONT STYLE="white-space:nowrap">non-offering</FONT> prospectus
and/or any amendment or supplement thereto any reasonable comments proposed by FEAC. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>FEAC Shareholder Approval</I><I>. </I>As promptly as reasonably practicable following the time at which the
Registration Statement / Proxy Statement is declared effective under the Securities Act, FEAC shall (a)&nbsp;duly give notice of and (b)&nbsp;use reasonable best efforts to duly convene and promptly hold a meeting of its shareholders (the
&#147;<B>FEAC Shareholders Meeting</B>&#148;) in accordance with the Governing Documents of FEAC, for the purposes of obtaining the FEAC Shareholder Approval and, if applicable, any approvals related thereto and providing its shareholders with the
opportunity to elect to effect FEAC Shareholder Redemptions. FEAC shall, through unanimous approval of the FEAC Board, recommend to its </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
shareholders (the &#147;<B>FEAC Board Recommendation</B>&#148;), (i) the adoption and approval of this Agreement and the Transactions including the Plan of Arrangement (the &#147;<B>BCA
Proposal</B>&#148;); (ii) the approval and adoption of the Newco Articles (the &#147;<B>Governing Documents Proposal</B>&#148;); (iii) the approval of the Cayman Merger and the Cayman Reorganization (the &#147;<B>Cayman Merger and Reorganization
Proposal</B>&#148;); (iv) the approval of the issuance of the Newco Shares in connection with the Transactions as required by the listing requirements of Nasdaq or other relevant Exchange, as applicable (the &#147;<B>Share Issuance
Proposal</B>&#148;); (v) the adoption and approval of the Newco Equity Incentive Plan (the &#147;<B>Incentive Plan Proposal</B>&#148;); and (vi)&nbsp;the adoption and approval of a proposal for the adjournment of the FEAC Shareholders Meeting, if
necessary, to permit further solicitation of proxies because there are not sufficient votes to approve and adopt any of the foregoing (the &#147;<B>Adjournment Proposal</B>&#148;) (such proposals in clauses (i)&nbsp;through (iv) together, the
&#147;<B>Transaction Proposals</B>&#148;); <I>provided</I>, that FEAC may postpone or adjourn the FEAC Shareholders Meeting, after reasonable consultation with the Company (and after taking into account the Company&#146;s good faith input), (A) to
solicit additional proxies for the purpose of obtaining the FEAC Shareholder Approval, (B)&nbsp;for the absence of a quorum, or (C)&nbsp;to allow reasonable additional time for the filing or mailing of any supplemental or amended disclosures that
FEAC has determined, based on the advice of outside legal counsel, is reasonably likely to be required under applicable Law and for such supplemental or amended disclosure to be disseminated and reviewed by the
<FONT STYLE="white-space:nowrap">Pre-Closing</FONT> FEAC Holders prior to the FEAC Shareholders Meeting; <I>provided</I> that, without the consent of the Company, in no event shall FEAC adjourn the FEAC Shareholders Meeting for more than ten
(10)&nbsp;Business Days later than the original date of the FEAC Shareholders Meeting or to a date that is less than five (5)&nbsp;Business Days beyond the Termination Date. The FEAC Board Recommendation shall be included in the Registration
Statement / Proxy Statement. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>FEAC Board Recommendation. </I>The FEAC Board shall not (and no committee or subgroup thereof shall) change,
withdraw, withhold, qualify or modify, or publicly propose to change, withdraw, withhold, qualify or modify, the FEAC Board Recommendation (a &#147;<B>Change in Recommendation</B>&#148;); <I>provided</I> that the FEAC Board may make a Change in
Recommendation (although the resolutions approving this Agreement as of the date hereof may not be rescinded or amended) prior to the receipt of the FEAC Shareholder Approval if, and only if, the FEAC Board determines in good faith, after
consultation with its outside legal counsel, that a failure to make a Change in Recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable Law; <I>provided, further</I>, that the FEAC Board shall not be
entitled to make, or agree or resolve to make, a Change in Recommendation unless (x)&nbsp;FEAC delivers to the Company a written notice (a &#147;<B>Change in Recommendation Notice</B>&#148;) advising the Company that the FEAC Board proposes to take
such action and containing the material facts underlying the FEAC Board&#146;s determination that a Change in Recommendation is required (in each case, it being acknowledged that such Change in Recommendation Notice shall not itself constitute a
breach of this Agreement) and (y)&nbsp;at or after 10:00 a.m., New York City time, on the fifth (5th) Business Day immediately following the day on which FEAC delivered the Change in Recommendation Notice (such period from the time the Change in
Recommendation Notice is provided until 10:00 a.m. on the fifth (5th) Business Day immediately following the day on which FEAC delivered the Change in Recommendation Notice (the &#147;<B>Change in Recommendation Notice Period</B>&#148;)), the FEAC
Board again determines in good faith, after consultation with its outside legal counsel, that a failure to make a Change in Recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable Law. If requested
by the Company, FEAC will and will use its reasonable best efforts to cause its Representatives to, during the Change in Recommendation Notice Period, engage in good faith negotiations with the Company and its Representatives to make such
adjustments in the terms and conditions of this Agreement so as to obviate the need for a Change in Recommendation. FEAC acknowledges that its obligations hereunder to furnish the Proxy Statement, convene the FEAC Shareholders Meeting and solicit
the FEAC Shareholder Approval as provided hereunder shall apply notwithstanding any withdrawal or modification of the FEAC Board Recommendation in accordance with the terms hereof, unless this Agreement shall have been terminated in accordance with
its terms prior to the FEAC Shareholders&#146; Meeting. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Exchange Listing</I><I>. </I>Each of FEAC and the Company shall use its reasonable best efforts to cause:
(a)&nbsp;Newco&#146;s initial listing application with the Nasdaq or other Exchange as mutually agreed between the Parties, as applicable, in connection with the Transactions to have been approved; (b)&nbsp;Newco to satisfy all applicable initial
and continuing listing requirements of Nasdaq or other relevant Exchange, as applicable; and (c)&nbsp;the Newco Shares and Newco Warrants issuable pursuant to the Transactions in accordance with this Agreement to be approved for listing on the
Nasdaq or other relevant Exchange, as applicable, subject to official notice of issuance, in each case, as promptly as reasonably practicable after the date of this Agreement, and in any event prior to the Closing. From the date hereof through the
Closing, each Party shall notify the other Parties of any communications or correspondence from Nasdaq or other relevant Exchange, as applicable, with respect to the listing of Newco Shares, Newco Warrants or other securities of Newco, compliance
with the rules and regulations of the Nasdaq or other relevant Exchange, as applicable, and any potential suspension of listing or delisting action contemplated or threatened by the Nasdaq or other relevant Exchange, as applicable.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Trust Account</I><I>. </I>Upon satisfaction or, to the extent permitted by applicable Law, waiver of the
conditions set forth in Article 6 and provision of notice thereof to the Trustee, (a)&nbsp;FEAC shall make all appropriate arrangements, prior to the FEAC Shareholder Redemptions, to cause the Trustee to pay as and when due all amounts, if any,
payable to the Public Shareholders of FEAC pursuant to the FEAC Shareholder Redemptions, (b)&nbsp;at, and prior to, the Closing, FEAC shall (i)&nbsp;cause the documents, certificates and notices required to be timely delivered to the Trustee
pursuant to the Trust Agreement to be so delivered, and (ii)&nbsp;make all appropriate arrangements to cause the Trustee to (A)&nbsp;pay the amounts due to the underwriters of FEAC&#146;s IPO for their deferred underwriting commissions as set forth
in the Trust Agreement and (B)&nbsp;immediately thereafter, pay all remaining amounts then available in the Trust Account to FEAC (or its successor, as applicable) in accordance with the Trust Agreement, and (c)&nbsp;thereafter, the Trust Account
shall terminate, except as otherwise provided therein. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>FEAC Indemnification; Directors</I><I>&#146;</I><I> and Officers</I><I>&#146;</I><I> Insurance</I>.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Party agrees that (i)&nbsp;all rights to indemnification or exculpation now existing in favor of the
directors and officers of FEAC, as provided in the applicable FEAC Governing Documents or otherwise in effect as of immediately prior to the Closing as disclosed in Section&nbsp;5.12 of the FEAC Disclosure Schedules, in either case, solely with
respect to any matters occurring on or prior to the Closing shall survive the Transactions and shall continue in full force and effect from and after the Closing for a period of six (6)&nbsp;years and (ii)&nbsp;FEAC (or its successor, as applicable)
will perform and discharge, or cause to be performed and discharged, all obligations to provide such indemnity and exculpation during such six (6)-year period, in each case to the extent permitted by applicable Law. To the maximum extent permitted
by applicable Law, during such six (6)-year period, FEAC (or its successor, as applicable) shall advance, or cause to be advanced, expenses in connection with such indemnification as provided in the applicable FEAC Governing Documents or other
applicable agreements disclosed in Section&nbsp;5.12 of the FEAC Disclosure Schedules as in effect immediately prior to the Closing. The indemnification and liability limitation or exculpation provisions of FEAC&#146;s Governing Documents shall not,
during such six (6)-year period, be amended, repealed or otherwise modified after the Closing in any manner that would materially and adversely affect the rights thereunder of individuals who, as of immediately prior to the Closing, or at any time
prior to such time, were directors or officers of FEAC (the &#147;<B>FEAC D&amp;O Persons</B>&#148;) entitled to be so indemnified, have their liability limited or be exculpated with respect to any matters occurring on or prior to the Closing and
relating to the fact that such FEAC D&amp;O Person was a director or officer of FEAC immediately prior to the Closing, unless such amendment, repeal or other modification is required by applicable Law. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">FEAC (or its successor, as applicable) shall not have any obligation under this Section&nbsp;5.12 to any FEAC
D&amp;O Person when and if a court of competent jurisdiction shall ultimately determine (and such determination shall have become final and <FONT STYLE="white-space:nowrap">non-appealable)</FONT> that the indemnification of such FEAC D&amp;O Person
in the manner contemplated hereby is prohibited by applicable Law. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For a period of six (6)&nbsp;years after the Closing, Newco shall maintain, or cause to be maintained, without
any lapses in coverage, a &#147;tail&#148; policy providing directors&#146; and officers&#146; liability insurance coverage for the benefit of those Persons who are currently covered by any comparable insurance policies of FEAC as of the date of
this Agreement with respect to matters occurring on or prior to the Closing. Such &#147;tail&#148; policy shall provide coverage on terms (with respect to coverage and amount) that are substantially the same as (and no less favorable in the
aggregate to the insured than) the coverage provided under FEAC&#146;s directors&#146; and officers&#146; liability insurance policies as of the date of this Agreement; <I>provided</I> that Newco (or its successor, as applicable) shall not be
obligated to pay a premium for such &#147;tail&#148; policy in excess of three hundred percent (300%) of the most recent annual premium paid by FEAC prior to the date of this Agreement and, in such event, Newco (or its successor, as applicable)
shall purchase the maximum coverage available for three hundred percent (300%) of the most recent annual premium paid by FEAC prior to the date of this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If FEAC or any of its successors or assigns (i)&nbsp;shall merge or consolidate with or merge into any other
corporation or entity and shall not be the surviving or continuing corporation or entity of such consolidation or merger or (ii)&nbsp;shall transfer all or substantially all of their respective properties and assets as an entity in one or a series
of related transactions to any Person, then in each such case, proper provisions shall be made so that the successors or assigns of FEAC shall assume all of the obligations set forth in this Section&nbsp;5.12. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The FEAC D&amp;O Persons entitled to the indemnification, liability limitation, exculpation and insurance set
forth in this Section&nbsp;5.11 are intended to be third-party beneficiaries of this Section&nbsp;5.12. This Section&nbsp;5.12 shall survive the consummation of the Transactions and shall be binding on all successors and assigns of the Company and
Newco, respectively. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Company Indemnification; Directors</I><I>&#146;</I><I> and Officers</I><I>&#146;</I><I> Insurance</I>.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Party agrees that (i)&nbsp;all rights to indemnification or exculpation now existing in favor of the
directors and officers of the Group Companies, as provided in the Group Companies&#146; Governing Documents or otherwise in effect as of immediately prior to the Closing as disclosed in Section&nbsp;5.13 of the Company Disclosure Schedules, in
either case, solely with respect to any matters occurring on or prior to the Closing, shall survive the Transactions and shall continue in full force and effect from and after the Closing for a period of six (6)&nbsp;years and (ii)&nbsp;the Company
(or its successor, as applicable) will cause the applicable Group Companies to perform and discharge all obligations to provide such indemnity and exculpation during such six (6)-year period to the extent permitted by applicable Law. To the maximum
extent permitted by applicable Law, during such six (6)-year period, Newco shall cause the applicable Group Companies to advance expenses in connection with such indemnification as provided in the Group Companies&#146; Governing Documents or other
applicable agreements in effect as of immediately prior to the Closing as disclosed in Section&nbsp;5.13 of the Company Disclosure Schedules. The indemnification and liability limitation or exculpation provisions of the Group Companies&#146;
Governing Documents shall not, during such six (6)-year period, be amended, repealed or otherwise modified after the Closing in any manner that would materially and adversely affect the rights thereunder of individuals who, as of immediately prior
to the Closing, or at any time prior to such time, were directors or officers of the Group Companies (the &#147;<B>Company D&amp;O Persons</B>&#148;) entitled to be so indemnified, have their liability limited or be exculpated with respect to any
matters occurring on or prior to the Closing and relating to the fact that such Company D&amp;O Person was a director or officer of any Group Company immediately prior to the Closing, unless such amendment, repeal or other modification is required
by applicable Law. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">None of the Group Companies shall have any obligation under this Section&nbsp;5.13 to any Company D&amp;O
Person when and if a court of competent jurisdiction shall ultimately determine (and such determination shall have become final and <FONT STYLE="white-space:nowrap">non-appealable)</FONT> that the indemnification of such Company D&amp;O Person in
the manner contemplated hereby is prohibited by applicable Law. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall purchase, or cause to be purchased, at or prior to the Closing, and Newco shall maintain, or
cause to be maintained, in effect for a period of six (6)&nbsp;years after the Closing Date, without any lapses in coverage, a &#147;tail&#148; policy providing directors&#146; and officers&#146; liability insurance coverage for the benefit of those
Persons who are currently covered by any comparable insurance policies of the Group Companies as of the date of this Agreement with respect to matters occurring on or prior to the Closing and for all directors and officers of Newco effective as of
the incorporation of Newco. Such &#147;tail&#148; policy shall provide coverage on terms (with respect to coverage and amount) that are substantially the same as (and no less favorable in the aggregate to the insured than) the coverage provided
under the Group Companies&#146; directors&#146; and officers&#146; liability insurance policies as of the date of this Agreement; <I>provided</I> that none of the Company, Newco or any of their respective Affiliates shall pay a premium for such
&#147;<B>tail</B>&#148; policy in excess of three hundred percent (300%) of the most recent annual premium paid by the Group Companies prior to the date of this Agreement and, in such event, the Company, Newco or one of their respective Affiliates
shall purchase the maximum coverage available for three hundred percent (300%) of the most recent annual premium paid by the Group Companies prior to the date of this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If Newco or any of its successors or assigns (i)&nbsp;shall merge or consolidate with or merge into any other
corporation or entity and shall not be the surviving or continuing corporation or entity of such consolidation or merger or (ii)&nbsp;shall transfer all or substantially all of their respective properties and assets as an entity in one or a series
of related transactions to any Person, then in each such case, proper provisions shall be made so that the successors or assigns of Newco shall assume all of the obligations set forth in this Section&nbsp;5.12(a). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company D&amp;O Persons entitled to the indemnification, liability limitation, exculpation and insurance
set forth in this Section&nbsp;5.12(a) are intended to be third-party beneficiaries of this Section&nbsp;5.12(a). This Section&nbsp;5.12(a) shall survive the consummation of the Transactions and shall be binding on all successors and assigns of FEAC
and Newco. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.14</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Resignations</I><I>. </I>Prior to the Closing, all of the directors and officers of FEAC shall have executed
written resignations effective as of the Closing in form and substance satisfactory to each Party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.15</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Post-Closing Governance</I><I>. </I>The Parties shall take all such action within its power as may be
necessary or appropriate such that effective immediately after the Closing (a)&nbsp;the members of the board of directors of Newco shall initially be comprised of the individuals set forth on Section&nbsp;5.15(a) of the Company Disclosure Schedule,
(b)&nbsp;the officers of Newco are the individuals set forth on Section&nbsp;5.15(b) of the Company Disclosure Schedules and (c)&nbsp;all other actions set forth on Section&nbsp;5.15(c) of the Company Disclosure Schedules are taken.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.16</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Financials</I>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company will (i)&nbsp;as promptly as reasonably practicable and with efforts to do so, within twenty
(20)&nbsp;Business Days of the date of this Agreement deliver to Newco and FEAC the Audited Company Financial Statements for the years ended October&nbsp;31, 2021 and 2022, (ii) as promptly as reasonably practicable, deliver to Newco and FEAC
(A)&nbsp;the Unaudited Company Financial Statements, and (B)&nbsp;any other audited or unaudited consolidated balance sheets and the related audited or unaudited consolidated statements of operations, changes in shareholders&#146; equity and cash
flows of the Group Companies that are required to be included in the Registration Statement / Proxy Statement or the Canadian Prospectus, and (iii)&nbsp;as promptly as reasonably practicable, deliver to Newco and FEAC the Audited Company Financial
Statements for the year ended October&nbsp;31, 2020 that are required to be included in the Canadian Prospectus. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.17</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Newco</I><I> Equity Incentive Plan</I>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Prior to the effectiveness of the Registration Statement / Proxy Statement, the Newco board of directors shall
approve, and the Newco board of directors shall adopt an equity incentive plan, in substantially the form attached hereto as Exhibit G and with any changes or modifications thereto as
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
the Company and FEAC may mutually agree (such agreement not to be unreasonably withheld, conditioned or delayed by either the Company or FEAC, as applicable) (the &#147;<B>Newco</B><B> Equity
Incentive Plan</B>&#148;), in the manner prescribed under applicable Laws, effective as of the Closing Date, reserving an amount of Newco Shares for grant thereunder equal to (i)&nbsp;six and seven-tenths percent (6.7%) of the fully diluted equity
of the post-Closing parent company, plus (ii)&nbsp;the number of Newco Shares subject to any Rollover Equity Awards. The Newco Equity Incentive Plan will provide that the number of Newco Shares reserved for issuance thereunder will automatically
increase annually on the first day of each fiscal year beginning with the 2024 fiscal year in an amount equal to five percent (5%) of the Newco Shares outstanding on the last day of the immediately preceding fiscal year or such lesser amount as
determined by the Newco board of directors. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Newco will, upon a resolution of the following the Closing, grant equity awards under the Newco Equity
Incentive Plan to those officers and employees of the Company immediately prior to the Closing that become officers or employees of Newco or any of its subsidiaries at Closing to the extent necessary to bring the equity percentage interest of such
officers and employees in Newco immediately after the Closing to levels consistent with the equity ownership interests of management and employees of comparable biotech companies immediately after their initial public offering, as determined by the
Newco compensation committee after Closing based on market-based survey data and recommendations from a third party compensation consultant. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.18</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Newco</I><I> Matters</I><I>. </I>The Company and FEAC have caused Newco (i)&nbsp;to be incorporated under
the laws of Canada solely for the purpose of entering into the Transactions and (ii)&nbsp;to not own any assets other than the C$10 received as the subscription price for the Newco Share issued to the Company, carry on any business, conduct any
operations, incur any liabilities or obligations, or hire any employee or independent contractor since the date of its formation, other than the execution of this Agreement and any Ancillary Documents, the performance of its obligations hereunder
and matters ancillary thereto. The Company and FEAC shall take, and shall cause Newco to take, all requisite action to cause the Continuance to be effected and in connection therewith, the articles of Newco to be amended in substantially the form
attached hereto as Exhibit F (the &#147;<B>Newco</B><B> Articles</B>&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.19</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Subscription Agreements</I><I>. </I>FEAC shall not permit any amendment or modification to be made to, or
any waiver of any provision or remedy under, or any replacements or terminations of, the Subscription Agreements in any manner other than (a)&nbsp;as expressly provided for by the terms of the Subscription Agreements or (b)&nbsp;to reflect any
permitted assignments or transfers of the Subscription Agreements by the PIPE Investors pursuant to the Subscription Agreements, without the prior written consent of the Company (such consent not to be unreasonably withheld, conditioned or delayed;
<I>provided</I> that the parties acknowledge that any proposed amendment, modification or waiver of the Subscription Agreements that affects the offering price of the Newco Shares pursuant to the Subscription Agreements, that reduces the PIPE
Financing Amount or that adds additional conditions to the obligations of the PIPE Investors to consummate the transactions contemplated by the Subscription Agreements and the Side Letter Agreements may be rejected by the Company in its sole
discretion). FEAC shall use its reasonable best efforts to take, or cause to be taken, all actions and do, or cause to be done, all things necessary, proper or advisable to consummate the transactions contemplated by the Subscription Agreements and
the Side Letter Agreements on the terms and conditions described therein. Without limiting the generality of the foregoing, FEAC shall give the Company prompt (and, in any event within three (3)&nbsp;Business Days) written notice: (i)&nbsp;of any
proposed amendment to any Subscription Agreement; (ii)&nbsp;of any breach or default (or any event or circumstance that, with or without notice, lapse of time or both, could give rise to any breach or default) by any party to any Subscription
Agreement known to FEAC; and (iii)&nbsp;of the receipt of any written notice or other written communication from any party to any Subscription Agreement with respect to any actual, potential or claimed expiration, lapse, withdrawal, breach, default,
termination or repudiation by any party to any Subscription Agreement or any provisions of any Subscription Agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.20</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Privacy Matters</I>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the purposes of this Section&nbsp;5.20, &#147;<B>Transaction Personal Information</B>&#148; means the
Personal Data transferred, disclosed or conveyed to one Party or any of its representatives or agents (a &#147;<B>Recipient</B>&#148;) by or on behalf of another Party (a &#147;<B>Transferor</B>&#148;) as a result of or in conjunction with the
Transactions, and includes all such Personal Data transferred, disclosed or conveyed to the Recipient prior to the execution of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Transferor acknowledges and confirms that the transfer, disclosure, communication or conveyance of
Transaction Personal Information is necessary for the purposes of determining if the Parties shall proceed with the Transactions and, if the determination is made to proceed with the Transactions, to carry on the business of the Company and complete
the Transactions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In addition to its other obligations hereunder, the Recipient covenants and agrees to, prior to the completion
of the Transactions: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">collect, use and disclose the Transaction Personal Information solely for the purpose of reviewing, determining
whether to proceed with and completing the Transactions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">where required by applicable Law (including applicable privacy Laws), not communicate Transaction Personal
Information to third parties without the consent of the individual concerned, unless authorized to do so by applicable Law; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">protect and safeguard the confidentiality of the Transaction Personal Information using security safeguards
appropriate to the sensitivity of the Transaction Personal Information and in accordance with applicable privacy Laws; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">within a reasonable time, return to the Transferor or destroy the Transaction Personal Information, at the
option of the Recipient, should the Transactions not be completed; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">where required by applicable privacy Law, securely destroy the Transaction Personal Information when it is no
longer necessary for concluding the Transactions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Should the Transactions be completed, in addition to its other obligations hereunder, the Recipient covenants
and agrees to, following the completion of the Transactions: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">use and disclose the Transaction Personal Information solely for the purposes for which the information was
collected, permitted to be used or disclosed before the Arrangement was completed, unless the Recipient provides notice and/or obtains consent, in accordance with applicable Law, to use or disclose the Transaction Personal Information for other
purposes, or the use or disclosure of the Transaction Personal Information is otherwise required or permitted by applicable Law; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">protect the Transaction Personal Information by security safeguards appropriate to its sensitivity;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">give effect to withdrawals of consent to collect, use or disclose the Transaction Personal Information, subject
to and in accordance with applicable privacy Law; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">where required by applicable privacy Law, within a reasonable time after the Arrangement is completed, notify
the individuals to whom the Transaction Personal Information pertains that the Transactions have been completed and that their personal information has been disclosed to and is now held by the Recipient because of the Transactions.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.21</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>FEAC Related Party Agreements. </I>FEAC shall take, or shall cause to be taken, all actions necessary or
advisable to cause the agreements set forth on Section&nbsp;5.21 of the FEAC Disclosure Schedules to be terminated on or around the Closing Date without any further obligations or liabilities to FEAC or any of its Affiliates, in each case in
accordance with the terms of those agreements. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.22</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Section</I><I></I><I>&nbsp;16</I><I> Matters</I>. Prior to the Effective Time, the Newco board shall take
all reasonable steps as may be required or permitted to cause any receipt of Newco Shares by any person that is or will become at the Closing an officer or director of Newco subject to the reporting requirements of Section&nbsp;16(a) of the Exchange
Act that occurs or is deemed to occur by reason of or pursuant to the Transactions to be exempt under Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act, including by taking steps in accordance with the <FONT
STYLE="white-space:nowrap">No-Action</FONT> Letter, dated January&nbsp;12, 1999. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.23</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Disclosure of Certain Matters. </I>Each Party shall promptly provide the other Parties with written notice
of: (a)&nbsp;any event, development or condition of which it obtains knowledge that is reasonably likely to cause any of the conditions set forth in Article 6 not to be satisfied or (b)&nbsp;the receipt of notice from any Person alleging that the
consent of such Person may be required in connection with the Transactions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.24</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Repayment of the Working Capital Loan Note and Extension Loan Notes</I>. Notwithstanding anything to the
contrary in the promissory notes governing the Working Capital Loan Note and any Extension Loan Notes, FEAC shall cause the Sponsor (or its Affiliate or designee, as applicable), as payee of the Working Capital Loan Note and any Extension Loan
Notes, to elect to convert an amount equal to $1,500,000 of the aggregate principal amount outstanding under the Working Capital Loan Note and any Extension Loan Notes, taken together, into additional FEAC Private Placement Warrants which upon such
election will be issued by FEAC to the Sponsor (or its Affiliate or designee, as applicable) immediately prior to the Surrender on the day which is two (2)&nbsp;Business Days prior to the Closing Date, in each case in accordance with the FEAC
Warrant Agreement and the relevant promissory note governing the Working Capital Loan Note and/or any Extension Loan Notes, as applicable. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.25</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Can Merger Sub Matters</I>. Prior to the date that is two Business Days prior to the Closing Date, FEAC
shall (i)&nbsp;incorporate Can Merger Sub as a corporation incorporated under the laws of Canada that will be a direct wholly-owned subsidiary of FEAC incorporated solely for purposes of effecting the Transactions and (ii)&nbsp;following the
formation, as the sole shareholder of Can Merger Sub, approve and adopt (and cause that Can Merger Sub approve, adopt and execute, as applicable) this Agreement, the Joinder Agreement, the Ancillary Documents to which Can Merger Sub is or will be a
party and the transactions contemplated hereby and thereby (including the Transactions). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.26</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Cayman Merger Sub Matters</I>. Prior to the date that is two Business Days prior to the Closing Date, Newco
shall (i)&nbsp;incorporate Cayman Merger Sub as a Cayman Islands exempted company that will be a direct wholly-owned subsidiary of Newco incorporated solely for purposes of effecting the Transactions and (ii)&nbsp;following the formation, as the
sole shareholder of Cayman Merger Sub, approve and adopt (and cause that Cayman Merger Sub approve, adopt and execute, as applicable) this Agreement, the Joinder Agreement, the Ancillary Documents to which Cayman Merger Sub is or will be a party and
the transactions contemplated hereby and thereby (including the Transactions). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>C<SMALL>ONDITIONS</SMALL> <SMALL>TO</SMALL> C<SMALL>ONSUMMATION</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL>
T<SMALL>RANSACTIONS</SMALL> </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Conditions to the Obligations of the Parties</I><I>. </I>The obligations of each Party to consummate the
Transactions are subject to the satisfaction or, if permitted by applicable Law, waiver by FEAC and the Company of the following conditions: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Company Required Approval of the Company Arrangement Resolution shall have been approved at the Company
Shareholders Meeting in accordance with the Interim Order and applicable Law; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Interim Order and the Final Order shall have been granted in form and substance satisfactory to FEAC and
the Company, each acting reasonably, and shall not have been set aside or modified in a manner unacceptable to FEAC and the Company, each acting reasonably, on appeal or otherwise; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">each applicable waiting period or Consent under each Foreign Antitrust Law set forth on Section&nbsp;6.1(c) of
the FEAC Disclosure Schedules relating to the Transactions, and any agreement with any Governmental Entity not to consummate the Transactions, shall have expired, been terminated or obtained (or deemed, by applicable Law, to have been obtained), as
applicable; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">no Order or Law issued by any court of competent jurisdiction or other Governmental Entity or other legal
restraints or prohibition preventing the consummation of the Transactions shall be in effect; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Registration Statement / Proxy Statement shall have become effective in accordance with the provisions of
the Securities Act, no stop order shall have been issued by the SEC and shall remain in effect with respect to the Registration Statement / Proxy Statement, and no proceeding seeking such a stop order shall have been threatened or initiated by the
SEC and remain pending; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the FEAC Shareholder Approval shall have been obtained; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">after giving effect to the Transactions (including the PIPE Financing and the Convertible Bridge Financing),
Newco shall have at least $5,000,001 of net tangible assets (as determined in accordance with Rule <FONT STYLE="white-space:nowrap">3a51-1(g)(1)</FONT> of the Exchange Act) immediately after the Closing Date; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Articles of Arrangement to be filed with the Director under the CBCA in accordance with the Arrangement
shall be in a form and content satisfactory to the Company and FEAC, each acting reasonably; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Arrangement Dissent Rights have not been validly exercised, and not withdrawn or deemed to have been withdrawn,
with respect to more than 10% of the issued and outstanding Company Shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Newco&#146;s initial listing application with Nasdaq or other Exchange as mutually agreed between FEAC and the
Company, as applicable, in connection with the Transactions shall have been approved and, immediately following the Closing, Newco shall satisfy any applicable initial and continuing listing requirements of the Nasdaq or other relevant Exchange, as
applicable, and no Party shall have received any notice of <FONT STYLE="white-space:nowrap">non-compliance</FONT> therewith that has not been cured or would not be cured at or immediately following the Closing, and the Newco Shares and Newco
Warrants to be issued pursuant to the Transactions shall have been approved for listing on the Nasdaq or other relevant Exchange, as applicable; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(k)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Transaction Support Agreements shall continue to be in full force an effect. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Other Conditions to the Obligations of FEAC</I><I>. </I>The obligations of FEAC to consummate the
Transactions are subject to the satisfaction or, if permitted by applicable Law, waiver by FEAC of the following further conditions: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">(i) the Company Fundamental Representations shall be true and correct in all material respects as of the date
of this Agreement and as of the Closing Date, as though made on and as of the Closing Date (except to the extent that any such representation and warranty is made as of an earlier date, in which case such representation and warranty shall be true
and correct in all material respects as of such earlier date, other than failures to be true and correct that result from actions that are expressly required by the terms of this Agreement or approved in writing by FEAC), (ii) the representations
and warranties set forth in Section&nbsp;3.2(a) shall be true and correct in all respects (except for <I>de </I><I>minimis</I><I> </I>inaccuracies) as of the date of this Agreement and as of the Closing Date, as though made on and as of the Closing
Date (except to the extent that any such representation and warranty is made as of an earlier date, in which case such representation and warranty shall be true and correct in all respects (except for <I>de </I><I>minimis</I><I> </I>inaccuracies) as
of such earlier date), and (iii)&nbsp;the representations and warranties of the Company set forth in Article 3 (other than the Company Fundamental Representations and the representations and warranties of the Company set forth in
Section&nbsp;3.2(a)) shall be true and correct (without giving effect to any limitation as to &#147;<B>materiality</B>&#148; or &#147;<B>Company Material Adverse Effect</B>&#148; or any similar limitation set forth herein) in all respects as of the
date of this Agreement and as of the Closing Date, as though made on and as of the Closing Date (except to the extent that any such representation and warranty is made as of an earlier date, in which case such representation and warranty shall be
true and correct in all respects as of such earlier date), except where the failure of such representations and warranties to be true and correct, taken as a whole, does not cause a Company Material Adverse Effect; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Company shall have performed and complied in all material respects with the covenants and agreements
required to be performed or complied with by the Company under this Agreement at or prior to the Closing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">since the date of this Agreement, no Company Material Adverse Effect has occurred that is continuing; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at or prior to the Closing, the Company shall have delivered, or caused to be delivered, to FEAC the following
documents: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a certificate duly executed by an authorized officer of the Company (without personal liability), dated as of
the Closing Date, to the effect that the conditions specified in Section&nbsp;6.2(a), Section&nbsp;6.2(b) and Section&nbsp;6.2(c) are satisfied, in a form and substance reasonably satisfactory to FEAC; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Registration Rights Agreement duly executed by the applicable Company Shareholders. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Other Conditions to the Obligations of the Company</I><I>. </I>The obligations of the Company to consummate
the Transactions are subject to the satisfaction or, if permitted by applicable Law, waiver by the Company of the following further conditions: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">(i) the FEAC Fundamental Representations and the representations and warranties of FEAC set forth in
Section&nbsp;4.19(q) shall be true and correct in all respects as of the date of this Agreement and as of the Closing Date, as though made on and as of the Closing Date (except to the extent that any such representation and warranty is made as of an
earlier date, in which case such representation and warranty shall be true and correct in all material respects as of such earlier date), (ii) the representations and warranties set forth in Section&nbsp;4.2(a) shall be true and correct in all
respects (except for <I>de </I><I>minimis</I><I> </I>inaccuracies) as of the date of this Agreement and as of the Closing Date, as though made on and as of the Closing Date (except to the extent that any such representation and warranty is made as
of an earlier date, in which case such representation and warranty shall be true and correct in all respects (except for <I>de </I><I>minimis</I><I> </I>inaccuracies) as of such earlier date), (iii) the representations and warranties of FEAC
contained in Article 4 (other than the FEAC Fundamental Representations and the representations and warranties of FEAC set forth in Section&nbsp;4.2(a) and Section&nbsp;4.19(q) of this Agreement) shall be true and correct (without giving effect to
any limitation as to &#147;materiality&#148; or &#147;<B>FEAC Material Adverse Effect</B>&#148; or any similar limitation set forth herein) in all respects as of the date of this Agreement and the Closing Date, as though made on and as of the
Closing Date (except to the extent that any such representation and warranty is made as of an earlier date, in which case such representation and warranty shall be true and correct as of such earlier date), except where the failure of such
representations and warranties to be true and correct, taken as a whole, does not cause a FEAC Material Adverse Effect; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">FEAC shall have performed and complied in all material respects with the covenants and agreements required to
be performed or complied with by it under this Agreement at or prior to the Closing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">since the date of this Agreement, no FEAC Material Adverse Effect has occurred that is continuing;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at or prior to the Closing, FEAC shall have delivered, or caused to be delivered, the following documents to
the Company: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a certificate duly executed by an authorized officer of FEAC (without personal liability), dated as of the
Closing Date, to the effect that the conditions specified in Section&nbsp;6.3(a), Section&nbsp;6.3(b) and Section&nbsp;6.3(c) are satisfied in a form and substance reasonably satisfactory to the Company; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Investors and Registration Rights Agreement duly executed by FEAC and the Sponsor. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Frustration of Closing Conditions</I><I>. </I>The Company may not rely on the failure of any condition set
forth in this Article 6 to be satisfied if such failure was proximately caused by the Company&#146;s failure to use </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
reasonable best efforts to cause the Closing to occur, as required by Section&nbsp;5.2 or a breach of this Agreement. FEAC may not rely on the failure of any condition set forth in this Article 6
to be satisfied if such failure was proximately caused by FEAC&#146;s failure to use reasonable best efforts to cause the Closing to occur, as required by Section&nbsp;5.2 or a breach of this Agreement. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>T<SMALL>ERMINATION</SMALL> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Termination</I><I>. </I>This Agreement may be terminated and the Transactions may be abandoned at any time
prior to the Closing, notwithstanding any requisite approval and adoption of this Agreement and the Transactions by the Company or FEAC, as follows: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by mutual written consent of FEAC and the Company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by FEAC, if any of the representations or warranties set forth in Article 3 shall not be true and correct or if
the Company has failed to perform any covenant or agreement set forth in this Agreement (including an obligation to consummate the Closing) such that the condition to Closing set forth in either Section&nbsp;6.2(a) or Section&nbsp;6.2(b) could not
be satisfied and the breach or breaches causing such representations or warranties not to be true and correct, or the failures to perform any covenant or agreement, as applicable, is (or are) not cured or cannot be cured within the earlier of
(i)&nbsp;thirty (30) days after written notice thereof is delivered to the Company by FEAC, and (ii)&nbsp;the Termination Date; <I>provided, however</I>, that FEAC is not then in breach of this Agreement so as to prevent the condition to Closing set
forth in either Section&nbsp;6.3(a) or Section&nbsp;6.3(b) from being satisfied; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by the Company, if any of the representations or warranties set forth in Article 4 shall not be true and
correct or if FEAC has failed to perform any covenant or agreement set forth in this Agreement (including an obligation to consummate the Closing) such that the condition to Closing set forth in either Section&nbsp;6.3(a) or Section&nbsp;6.3(b)
could not be satisfied and the breach or breaches causing such representations or warranties not to be true and correct, or the failures to perform any covenant or agreement, as applicable, is (or are) not cured or cannot be cured within the earlier
of (i)&nbsp;thirty (30) days after written notice thereof is delivered to FEAC by the Company and (ii)&nbsp;the Termination Date; <I>provided, however</I>, the Company is not then in breach of this Agreement so as to prevent the condition to Closing
set forth in Section&nbsp;6.2(a) or Section&nbsp;6.2(b) from being satisfied; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by either FEAC or the Company, if the Transactions shall not have been consummated on or prior to
December&nbsp;14, 2023 (the &#147;<B>Termination Date</B>&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by either FEAC or the Company, if any Governmental Entity shall have issued an Order permanently enjoining,
restraining or otherwise prohibiting the Transactions and such Order shall have become final and <FONT STYLE="white-space:nowrap">non-appealable;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by either FEAC or the Company if the FEAC Shareholders Meeting has been held (including any adjournment or
postponement thereof), has concluded, FEAC&#146;s shareholders have duly voted and the FEAC Shareholder Approval was not obtained; provided, however, that neither FEAC nor the Company may terminate this Agreement pursuant to this Section&nbsp;7.1(f)
if the failure to obtain the FEAC Shareholder Approval has been caused by, or is a result of, a breach by such Party of any of its representations or warranties or the failure of such Party to perform any of its covenants or agreements under this
Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by either FEAC or the Company, if the Company Required Approval in respect of the Company Arrangement
Resolution shall not have been obtained at the Company Shareholders Meeting in accordance with the Interim Order and applicable Law; provided, however, that neither FEAC nor the Company may terminate this Agreement pursuant to this
Section&nbsp;7.1(g) if the failure to obtain the Company Required Approval has been caused by, or is a result of, a breach by such Party of any of its representations or warranties or the failure of such Party to perform any of its covenants or
agreements under this Agreement; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by the Company prior to receipt of the FEAC Shareholder Approval, in the event of a Change in Recommendation.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Effect of Termination</I><I>. </I>In the event of the termination of this Agreement pursuant to
Section&nbsp;7.1, this entire Agreement shall forthwith become void (and there shall be no Liability or obligation on the part of the Parties and their respective <FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliates) with the exception of
(a)&nbsp;Section&nbsp;5.3(a), this Section&nbsp;7.2, Article 8 and any corresponding definitions set forth in Article 1 (to the extent related to the foregoing), each of which shall survive such termination and remain valid and binding obligations
of the Parties and (b)&nbsp;the Confidentiality Agreement, which shall survive such termination and remain valid and binding obligations of the Parties thereto in accordance with its terms. Notwithstanding the foregoing or anything to the contrary
herein, the termination of this Agreement pursuant to Section&nbsp;7.1 shall not affect any Liability on the part of any Party for any willful or material breach of any covenant or agreement set forth in this Agreement or fraud (involving scienter)
prior to such termination. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>M<SMALL>ISCELLANEOUS</SMALL> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I><FONT STYLE="white-space:nowrap">Non-Survival</FONT></I><I>. </I>The representations, warranties, agreements
and covenants in this Agreement or in any certificate, statement or instrument delivered pursuant to this Agreement shall terminate at the Closing, except for (a)&nbsp;those covenants and agreements that by their terms expressly contemplate
performance in whole or in part after the Closing and (b)&nbsp;this Article 8 and any corresponding definitions set forth in Article 1. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Entire Agreement; Assignment</I><I>. </I>This Agreement, together with the Confidentiality Agreement and the
Ancillary Documents including any exhibits and schedules attached hereto or thereto, constitutes the entire agreement among the Parties with respect to the subject matter hereof and supersedes all other prior agreements and understandings, both
written and oral, among the Parties with respect to the subject matter hereof. This Agreement may not be assigned by any Party (whether by operation of law or otherwise) without the prior written consent of FEAC and the Company. Any attempted
assignment of this Agreement not in accordance with the terms of this Section&nbsp;8.2 shall be void. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Amendment</I><I>. </I>This Agreement may be amended or modified only by a written agreement executed and
delivered by FEAC and the Company. This Agreement may not be modified or amended except as provided in the immediately preceding sentence and any purported amendment by any Party or Parties effected in a manner which does not comply with this
Section&nbsp;8.3 shall be void, <I>ab initio</I>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Notices.</I><I> </I>All notices, requests, claims, demands and other communications hereunder shall be in
writing and shall be given (and shall be deemed to have been duly given) by delivery in person, by <FONT STYLE="white-space:nowrap">e-mail</FONT> (having obtained electronic delivery confirmation thereof), or by registered or certified mail (postage
prepaid, return receipt requested) (upon receipt thereof) to the respective Parties at the following addresses: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If to FEAC or, following the execution of a Joinder Agreement, Can Merger Sub, to: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">c/o Forbion European Acquisition Corp. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">Gooimeer 2-35 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">1411 DC Naarden
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">The Netherlands </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">Attention: Cyril Lesser </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">E-mail:</FONT> Cyril.Lesser@forbion.com </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman"><I>with a copy (which shall not constitute notice) to:</I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">Davis Polk&nbsp;&amp; Wardwell London LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">5 Aldermanbury Square </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">London
EC2V 7HR </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">United Kingdom </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">Attention: Leo Borchardt </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">Email: leo.borchardt@davispolk.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman"><I>with a copy (which shall not constitute notice) to:</I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">Stikeman Elliot LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">5300
Commerce Court West </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">199 Bay Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">Toronto Ontario M5L 1B9 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">Canada
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">Attention: Daniel Borlack </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">Email: dborlack@stikeman.com </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If to the Company, Newco or, following the execution of a Joinder Agreement, Cayman Merger Sub, to:
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">enGene Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">7171 Rue Frederick Banting </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">Saint-Laurent, QC H4S 1Z9 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">Canada </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">Attn: Jason Hanson </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">Email: jhanson@engeneinc.com </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman"><I>with a copy (which shall not constitute notice) to:</I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">Morgan, Lewis&nbsp;&amp; Bockius LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">101 Park Ave. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">New York, NY
10178-0060 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">United States </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">Attn: Howard A. Kenny </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">Email:
howard.kenny@morganlewis.com </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman"><I>with a copy (which shall not constitute notice) to:</I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">Blake, Cassels&nbsp;&amp; Graydon LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">595 Burrard Street, Suite </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">2600, Three Bentall Centre, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">Vancouver, British Columbia V7X 1L3 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">Canada </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">Attn: Joseph Garcia
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">Email: <U>joseph.garcia@blakes.com</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">or to such other address as the Party to whom notice is given may have previously furnished to the others in writing in the manner set forth
above. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Governing Law</I><I>. </I>This Agreement shall be governed by and construed in accordance with the laws of
the State of Delaware applicable to contracts executed in and to be performed in that State, except to the extent mandatorily governed by the federal laws of Canada, including the provisions relating to the Arrangement and the Plan of Arrangement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Fees and Expenses</I><I>. </I>Except as otherwise set forth in this Agreement, all fees and expenses
incurred in connection with this Agreement, the Ancillary Documents and the Transactions, including the fees and disbursements of counsel, financial advisors and accountants, shall be paid by the Party incurring such fees or expenses;
<I>provided</I> that, for the avoidance of doubt, (a)&nbsp;if this Agreement is terminated in accordance with its terms, the Company shall pay, or cause to be paid, all Unpaid Company Expenses and FEAC shall pay, or cause to be paid, all Unpaid FEAC
Expenses and (b)&nbsp;if the Closing occurs, then Newco shall pay, or cause to be paid, all Unpaid FEAC Expenses and all Unpaid Company Expenses. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Exhibits and </I><I>Schedules</I><I>. </I>All Exhibits and Schedules, or documents expressly incorporated
into this Agreement, are hereby incorporated into this Agreement and are hereby made a part hereof as if set out in </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
full in this Agreement. The Schedules shall be arranged in sections and subsections corresponding to the numbered and lettered Sections and subsections set forth in this Agreement. Any item
disclosed in the Company Disclosure Schedules or in the FEAC Disclosure Schedules corresponding to any Section or subsection of Article 3 (in the case of the Company Disclosure Schedules) or Article 4 (in the case of the FEAC Disclosure Schedules)
shall be deemed to have been disclosed with respect to every other section and subsection of Article 3 (in the case of the Company Disclosure Schedules) or Article 4 (in the case of the FEAC Disclosure Schedules), as applicable, where the relevance
of such disclosure to such other Section or subsection is reasonably apparent on the face of the disclosure. The information and disclosures set forth in the Schedules that correspond to the section or subsections of Article 3 or Article 4&nbsp;may
not be limited to matters required to be disclosed in the Schedules, and any such additional information or disclosure is for informational purposes only and does not necessarily include other matters of a similar nature. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Parties in Interest</I><I>.</I><I> </I>This Agreement shall be binding upon and inure solely to the benefit
of each Party and its successors and permitted assigns and, except as provided in Section&nbsp;5.12, Section&nbsp;5.12(a) and the subsequent sentence of this Section&nbsp;8.8, nothing in this Agreement, express or implied, is intended to or shall
confer upon any other Person any rights, benefits or remedies of any nature whatsoever under or by reason of this Agreement. Each of the <FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliates shall be an express third-party beneficiary of
Section&nbsp;8.12 and this Section&nbsp;8.8 (to the extent related to the foregoing). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Severability</I><I>. </I>Whenever possible, each provision of this Agreement will be interpreted in such a
manner as to be effective and valid under applicable Law, but if any term or other provision of this Agreement is held to be invalid, illegal or unenforceable under applicable Law, all other provisions of this Agreement shall remain in full force
and effect so long as the economic or legal substance of the Transactions is not affected in any manner materially adverse to any Party. Upon such determination that any term or other provision of this Agreement is invalid, illegal or unenforceable
under applicable Law, the Parties shall negotiate in good faith to modify this Agreement so as to effect the original intent of the Parties as closely as possible in an acceptable manner in order that the Transactions are consummated as originally
contemplated to the greatest extent possible. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Counterparts; Electronic Signatures</I><I>. </I>This Agreement and each Ancillary Document (including any of
the closing deliverables contemplated hereby) may be executed in one or more counterparts, each of which shall be deemed to be an original, but all of which shall constitute one and the same agreement. Delivery of an executed counterpart of a
signature page to this Agreement or any Ancillary Document (including any of the closing deliverables contemplated hereby) by <FONT STYLE="white-space:nowrap">e-mail,</FONT> or scanned pages shall be effective as delivery of a manually executed
counterpart to this Agreement or any such Ancillary Document. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Knowledge of Company; Knowledge of FEAC</I><I>. </I>For all purposes of this Agreement, the phrase &#147;to
the Company&#146;s knowledge&#148; and &#147;known by the Company&#148; and any derivations thereof shall mean as of the applicable date, the actual knowledge of the individuals set forth on Section&nbsp;8.11 of the Company Disclosure Schedules. For
all purposes of this Agreement, the phrase &#147;to FEAC&#146;s knowledge&#148; and &#147;to the knowledge of FEAC&#148; and any derivations thereof shall mean as of the applicable date, the actual knowledge of the individuals set forth on
Section&nbsp;8.11 of the FEAC Disclosure Schedules. <I>For the avoidance of doubt</I>, none of the individuals set forth on Section&nbsp;8.11 of the Company Disclosure Schedules or Section&nbsp;8.12(b) of the FEAC Disclosure Schedules shall have any
personal Liability or obligations regarding such knowledge. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>No Recourse</I><I>. </I>This Agreement may only be enforced against, and any action for breach of this
Agreement may only be made against, the Parties, and none of the Representatives of FEAC (including the Sponsor) or the Company (including directors, officers, employees and shareholders) shall have any Liability arising out of or relating to this
Agreement or the Transactions, including with respect to any claim (whether in tort, contract or otherwise) for breach of this Agreement or in respect of any written or oral representations made or alleged to be made in connection herewith, as
expressly provided herein. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Extension; Waiver</I><I>. </I>At any time prior to the Closing (and in the case of FEAC, prior to receipt of
the FEAC Shareholder Approval), (a) the Company may (i)&nbsp;extend the time for the performance of any of the obligations or other acts of FEAC set forth herein, (ii)&nbsp;waive any inaccuracies in the representations and warranties of FEAC set
forth herein or in any document delivered by FEAC or (iii)&nbsp;waive compliance by FEAC with any of the agreements or conditions set forth herein and FEAC may (i)&nbsp;extend the time for the performance of any of the obligations or other acts of
the Company set forth herein, (ii)&nbsp;waive any inaccuracies in the representations and warranties of the Company set forth herein or in any document delivered by the Company or (iii)&nbsp;waive compliance by the Company with any of the agreements
or conditions set forth herein. Any such extension or waiver shall be valid if set forth in a written instrument signed by the Party to be bound thereby. Any waiver of any term or condition shall not be construed as a waiver of any subsequent breach
or a subsequent waiver of the same term or condition, or a waiver of any other term or condition of this Agreement. The failure of any Party to assert any of its rights hereunder shall not constitute a waiver of such rights. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.14</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Waiver of Jury Trial</I><I>. </I>THE PARTIES EACH HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY
RIGHT TO TRIAL BY JURY OF ANY PROCEEDING (I)&nbsp;ARISING UNDER THIS AGREEMENT OR UNDER ANY ANCILLARY DOCUMENT OR (II)&nbsp;IN ANY WAY CONNECTED WITH OR RELATED OR INCIDENTAL TO THE DEALINGS OF THE PARTIES IN RESPECT OF THIS AGREEMENT OR ANY
ANCILLARY DOCUMENT OR ANY OF THE TRANSACTIONS RELATED HERETO OR THERETO OR ANY FINANCING IN CONNECTION WITH THE TRANSACTIONS CONTEMPLATED HEREBY OR ANY OF THE TRANSACTIONS CONTEMPLATED THEREBY, IN EACH CASE, WHETHER NOW EXISTING OR HEREAFTER
ARISING, AND WHETHER IN CONTRACT, TORT, EQUITY, OR OTHERWISE. THE PARTIES EACH HEREBY AGREES AND CONSENTS THAT ANY SUCH PROCEEDING SHALL BE DECIDED BY COURT TRIAL WITHOUT A JURY AND THAT THE PARTIES MAY FILE AN ORIGINAL COUNTERPART OF A COPY OF THIS
AGREEMENT WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT OF THE PARTIES HERETO TO THE WAIVER OF THEIR RIGHT TO TRIAL BY JURY. EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (A)&nbsp;NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS
REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, (B)&nbsp;EACH SUCH PARTY UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (C)&nbsp;EACH SUCH PARTY
MAKES THIS WAIVER VOLUNTARILY AND (D)&nbsp;EACH SUCH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 8.14. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.15</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Submission to Jurisdiction</I><I>. </I>Except as it relates to the Arrangement and the Plan of Arrangement,
each of the Parties irrevocably and unconditionally submits to the exclusive jurisdiction of the Chancery Court of the State of Delaware (or, if the Chancery Court of the State of Delaware declines to accept jurisdiction, any other state or federal
court located in the State of Delaware), for the purposes of any Proceeding (a)&nbsp;arising under this Agreement or under any Ancillary Document or (b)&nbsp;in any way connected with or related or incidental to the dealings of the Parties in
respect of this Agreement or any Ancillary Document or any of the Transactions, and irrevocably and unconditionally waives any objection to the laying of venue of any such Proceeding in any such court, and further irrevocably and unconditionally
waives and agrees not to plead or claim in any such court that any such Proceeding has been brought in an inconvenient forum. Each Party hereby irrevocably and unconditionally waives, and agrees not to assert, by way of motion or as a defense,
counterclaim or otherwise, in any Proceeding against such Party (i)&nbsp;arising under this Agreement or under any Ancillary Document or (ii)&nbsp;in any way connected with or related or incidental to the dealings of the Parties in respect of this
Agreement or any Ancillary Document or any of the Transactions, (A)&nbsp;any claim that such Party is not personally subject to the jurisdiction of the courts as described in this Section&nbsp;8.15 for any reason, (B)&nbsp;that such Party or such
Party&#146;s property is exempt or immune from the jurisdiction of any such court or from any legal process commenced in such courts (whether through service of notice, attachment prior to judgment, attachment in aid of execution of
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
judgment, execution of judgment or otherwise) and (C)&nbsp;that (x) the Proceeding in any such court is brought against such Party in an inconvenient forum, (y)&nbsp;the venue of such Proceeding
against such Party is improper or (z)&nbsp;this Agreement, or the subject matter hereof, may not be enforced against such Party in or by such courts. Each Party agrees that service of any process, summons, notice or document by registered mail or
internationally recognized courier service to such party&#146;s respective address set forth in Section&nbsp;8.4 shall be effective service of process for any such Proceeding. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.16</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Remedies</I><I>. </I>Except as otherwise expressly provided herein, any and all remedies provided herein
will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by law or equity upon such Party, and the exercise by a Party of any one remedy will not preclude the exercise of any other remedy. The Parties agree that
irreparable damage for which monetary damages, even if available, would not be an adequate remedy, would occur in the event that the Parties do not perform their respective obligations under the provisions of this Agreement (including failing to
take such actions as are required of them hereunder to consummate the Transactions) in accordance with their specific terms or otherwise breach such provisions. It is accordingly agreed that the Parties shall be entitled to an injunction or
injunctions, specific performance and other equitable relief to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement, in each case, without posting a bond or undertaking and without proof of
damages and this being in addition to any other remedy to which they are entitled at law or in equity. Each of the Parties agrees that it will not oppose the granting of an injunction, specific performance and other equitable relief when expressly
available pursuant to the terms of this Agreement on the basis that the other parties have an adequate remedy at law or an award of specific performance is not an appropriate remedy for any reason at law or equity. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.17</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Trust Account Waiver</I><I>. </I>Reference is made to the final prospectus of FEAC, filed with the SEC (File
<FONT STYLE="white-space:nowrap">No.&nbsp;333-261308)</FONT> on December&nbsp;9, 2021 (the &#147;<B>Prospectus</B>&#148;). Each Party other than FEAC (each an &#147;<B>Other Party</B>&#148; and, collectively, the &#147;<B>Other Parties</B>&#148;)
acknowledges and agrees and understands that FEAC has established a trust account (the &#147;<B>Trust Account</B>&#148;) containing the proceeds of its initial public offering (the &#147;<B>IPO</B>&#148;) and from certain private placements
occurring simultaneously with the IPO (including interest accrued from time to time thereon) for the benefit of FEAC&#146;s public shareholders (including overallotment shares acquired by FEAC&#146;s underwriters, the &#147;<B>Public
Shareholders</B>&#148;), and FEAC may disburse monies from the Trust Account only in the express circumstances described in the Prospectus. For and in consideration of FEAC entering into this Agreement, and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, each Other Party hereby agrees that, notwithstanding the foregoing or anything to the contrary in this Agreement, no Other Party, does now or shall at any time hereafter have any right,
title, interest or claim of any kind in or to any monies in the Trust Account or distributions therefrom, or make any claim against the Trust Account (including any distributions therefrom), regardless of whether such claim arises as a result of, in
connection with or relating in any way to, this Agreement or any proposed or actual business relationship between FEAC, on the one hand, and, such Other Party, on the other hand, or any other matter, and regardless of whether such claim arises based
on contract, tort, equity or any other theory of legal liability (any and all such claims are collectively referred to hereafter as the &#147;<B>Trust Account Released Claims</B>&#148;). Each Other Party, hereby irrevocably waives any Trust Account
Released Claims that it or any of its Representatives may have against the Trust Account (including any distributions therefrom) now or in the future as a result of, or arising out of, any negotiations, or Contracts with FEAC or its Representatives
and will not seek recourse against the Trust Account (including any distributions therefrom) for any reason whatsoever (including for an alleged breach of any agreement with FEAC or its Affiliates). The foregoing notwithstanding, (a)&nbsp;nothing
herein shall serve to limit or prohibit the Company&#146;s or Newco&#146;s right to pursue a claim against FEAC pursuant to this Agreement for legal relief against monies or other assets of FEAC held outside the Trust Account or for specific
performance or other equitable relief in connection with the Transactions, or for fraud in the making of the representations and warranties in Article 4; and (b)&nbsp;nothing herein shall serve to limit or prohibit any claims that the Company or
Newco may have in the future pursuant to this Agreement against FEAC&#146;s assets or funds that are not held in (or are released from) the Trust Account. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, each of the Parties has caused this Agreement to be duly executed on its behalf
as of the day and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">FORBION EUROPEAN ACQUISITION CORP.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Sander Slootweg</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-3.00em; font-size:10pt; font-family:Times New Roman">Name:&#8201;&#8202;Sander Slootweg</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-3.00em; font-size:10pt; font-family:Times New Roman">Title:&#8194;&#8201;&#8202;Authorized Signatory</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">ENGENE INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Anthony Cheung</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-3.00em; font-size:10pt; font-family:Times New Roman">Name:&#8201;&#8202;Anthony Cheung</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-3.00em; font-size:10pt; font-family:Times New Roman">Title:&#8194;&#8201;&#8202;Chief Technology Officer</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">ENGENE HOLDINGS INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Richard Glickman</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-3.00em; font-size:10pt; font-family:Times New Roman">Name:&#8201;&#8202;Richard Glickman</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-3.00em; font-size:10pt; font-family:Times New Roman">Title:&#8194;&#8201;&#8202;Director</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to Business Combination Agreement</I>] </P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Company Arrangement Resolution </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:36pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Arrangement Resolution </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>BE IT RESOLVED THAT: </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The arrangement (the &#147;<B>Arrangement</B>&#148;) under Section 192 of the <I>Canada </I><I>Business
Corporations Act</I> (the &#147;<B>CBCA</B>&#148;) involving enGene Inc. (the &#147;<B>Company</B>&#148;), enGene Holdings Inc. (&#147;<B>Newco</B>&#148;), a to be incorporated wholly owned subsidiary (&#147;<B>Can Merger Sub</B>&#148;) of Forbion
European Acquisition Corp. (&#147;<B>FEAC</B>&#148;) and an entity to be formed by the amalgamation between the Company and Can Merger Sub, pursuant to the business combination agreement dated {{business-combination-date}} between Newco, FEAC and
the Company (as it may be amended, modified or supplemented from time to time, the &#147;<B>Business Combination Agreement</B>&#148;) all as more particularly described and set forth in the management information circular of the Company dated
&#9679;, 2023 (as it may be amended, modified or supplemented in accordance with the Business Combination Agreement, the &#147;<B>Circular</B>&#148;) is hereby authorized, approved and adopted. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The (i) Business Combination Agreement and all the transactions and related actions contemplated therein,
including the Ancillary Documents (as defined in the Business Combination Agreement); (ii) actions of the board of directors of the Company (the &#147;<B>Board</B>&#148;) in approving the Arrangement, the Business Combination Agreement and the
Ancillary Documents to which the Company is or will be a party; and (iii) actions of the directors and officers of the Company in executing and delivering the Business Combination Agreement and the Ancillary Documents to which the Company is or will
be a party (and, in each case, any amendments, modifications or supplements thereto) and causing the performance by the Company of its obligations thereunder, in each case be and are hereby confirmed, ratified, authorized and approved.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The plan of arrangement (as it may be amended, supplemented, restated or otherwise modified in accordance with
its terms, the &#147;<B>Plan of Arrangement</B>&#148;), the full text of which is set out in Appendix <B>[</B><B></B>&#9679;<B></B><B>]</B> to the Circular, is hereby authorized, approved and adopted.<B> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company is hereby authorized to apply for a final order from the Supreme Court of British Columbia (the
&#147;<B>Court</B>&#148;) to approve the Arrangement on the terms set forth in the Business Combination Agreement and the Plan of Arrangement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding that this resolution has been duly passed (and the Arrangement approved) by the shareholders of
the Company or that the Arrangement has been approved by the Court, the Board is hereby authorized and empowered, without further notice to, or the approval of, the shareholders of the Company (i) to determine when to file the articles of
arrangement in respect of the Arrangement; (ii) to amend the Business Combination Agreement or the Plan of Arrangement (or both); and (iii) not to proceed with the Arrangement and any related transactions or revoke this resolution at any time prior
to the issue of a certificate giving effect to the Arrangement, in each case subject to the terms of the Business Combination Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any officer or director of the Company be, and is hereby, authorized, empowered and directed, acting for, in
the name and on behalf of the Company, to execute or cause to be executed, under the seal of the Company or otherwise, and to deliver or to cause to be delivered, for filing with the Director under the CBCA, articles of arrangement and such other
documents as are necessary or desirable to give effect to the Arrangement in accordance with the Business Combination Agreement or the Plan of Arrangement, such determination to be conclusively evidenced by the execution and delivery of such
articles of arrangement and any such other documents. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any officer or director of the Company be, and is hereby, authorized, empowered and directed, acting for, in
the name and on behalf of the Company, to execute or cause to be executed, under the seal of the Company or otherwise, and to deliver or to cause to be delivered, all such other documents and instruments and to perform or cause to be performed all
such other acts and things as such person determines may be necessary or desirable to give full force and effect to the foregoing resolutions and the matters authorized thereby, such determination to be conclusively evidenced by the execution and
delivery of such document or instrument or the doing of any such act or thing. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Plan of Arrangement </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE A </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PLAN OF ARRANGEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNDER SECTION 192 OF THE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B><B><I>CANADA </I></B><B></B><B><I>BUSINESS CORPORATIONS ACT</I></B><B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 1 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INTERPRETATION </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In this Plan of Arrangement, any capitalized terms used herein and not defined in this Section 1.1 have the
meaning ascribed thereto in the Business Combination Agreement. Unless the context otherwise requires, the following words and phrases used in this Plan of Arrangement will have the meanings hereinafter set out: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Affected Securities</B>&#148; means, collectively, the Company Shares, the Company Warrants, the Company Convertible Notes, and the<B>
</B>Company Options; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Affected Securityholders</B>&#148; means, collectively, the Company Shareholders, the Company Optionholders,
the Company Warrant Holders, the Company Convertible Noteholders, and the holders of Can Merger Sub Common Shares; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Aggregate
Exercise Price</B>&#148; means the aggregate exercise price of the Company Options that will be exchanged for Newco Options, converted to its U.S. dollar equivalent based on the C$:US$ Bank of Canada daily exchange rate on the Business Day
immediately prior to the Effective Date, and rounding the resulting exercise price up to the nearest whole cent; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Amalgamation</B>&#148; has the meaning ascribed thereto in Section 3.1(g) of this Plan of Arrangement; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Arrangement</B>&#148; means the arrangement under Section 192 of the CBCA on the terms and subject to the conditions set out in this
Plan of Arrangement, subject to any amendments or variations thereto made in accordance with the terms of the Business Combination Agreement or Article 7 of this Plan of Arrangement or made at the direction of the Court in the Final Order with the
consent of the Company, and FEAC, such consent not to be unreasonably withheld, conditioned or delayed; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Arrangement Effective
Time</B>&#148; means <B>[</B>&#9679;<B></B><B>]</B> on the Effective Date or such other time as the Company, FEAC and Newco may agree upon in writing; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>BCBCA</B>&#148; means the <I>Business Corporations Act </I>(British Columbia); </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Business Combination Agreement</B>&#148; means the business combination agreement made as of {{signing-date}} by and among Newco, the
Company, and FEAC, including all exhibits and schedules annexed thereto, as the same may be amended, supplemented or otherwise modified from time to time in accordance with the terms thereof, which provides for, among other things, this Arrangement;
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Business Day</B>&#148; means a day, other than a Saturday or Sunday, on which commercial banks in New York, New York and
Vancouver, British Columbia are open for the general transaction of business. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Can Merger Sub</B>&#148; means
<B>[</B>&#9679;<B></B><B>]</B>, a corporation incorporated under the laws of Canada and a wholly-owned subsidiary of FEAC; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Can
Merger</B><B> </B><B>Sub Common Shares</B>&#148; means the common shares of Can Merger Sub; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Cayman Merger Sub</B>&#148; means
<B>[</B>&#9679;<B></B><B>]</B>, a Cayman Islands exempted company and a wholly-owned subsidiary of Newco; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>CBCA</B>&#148; means
the <I>Canada Business Corporations Act</I>; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Certificate of Arrangement</B>&#148; means the certificate of arrangement to be
issued by the Director pursuant to subsection 192(7) of the CBCA in respect of the Articles of Arrangement; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Code</B>&#148; means the United States Internal Revenue Code of 1986, as amended;
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company</B>&#148; means prior to the Amalgamation, enGene Inc., a corporation existing under the laws of Canada. Following the
Amalgamation, the Company means the corporation resulting from the amalgamation of enGene Inc. and Can Merger Sub pursuant to this Plan of Arrangement and such resulting corporation will be named enGene Inc.; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company </B><B>Arrangement Resolution</B>&#148; means the special resolution of the Company Shareholders approving the Plan of
Arrangement, which is to be considered at the Company Shareholders Meeting, substantially in the form of Exhibit A attached to the Business Combination Agreement; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Common Shareholder</B><B>s</B>&#148; means, at any time, the holders of Company Common Shares issued and outstanding at such
time and &#147;<B>Company Common Shareholder</B>&#148; means any one of them; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Common Shares</B>&#148; means common shares
of the Company; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Convertible Note</B><B>h</B><B>olders</B>&#148; means, at any time, the holders of Company Convertible
Notes outstanding at such time and &#147;<B>Company Convertible Note</B><B>h</B><B>older</B>&#148; means any one of them; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company
Convertible Notes</B>&#148; means the Amended 2022 Convertible Notes and the 2023 Convertible Notes; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Company Equity Award&#148;
</B>means, as of any determination time, each Company Option, restricted stock unit, stock appreciation, phantom equity, and each other award to any current or former director, manager, officer, employee, individual independent contractor or other
individual service provider of any Group Company of rights of any kind to receive any Equity Security of any Group Company or benefits measured in whole or in part by reference to any Equity Security of any Group Company, in each case, under any
Company Equity Plan or otherwise that is outstanding. For the avoidance of doubt, the Company Warrants shall not be considered a Company Equity Award. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Equity Plan</B>&#148; means, collectively, (a) the amended and restated equity incentive plan of the Company dated
June&nbsp;30, 2021 and as may be further amended and/or restated from time to time, and (b) each other plan that provides for the award to any current or former director, manager, officer, employee, individual independent contractor or other
individual service provider of any Group Company of rights of any kind to receive Equity Securities of any Group Company or benefits measured in whole or in part by reference to Equity Securities of any Group Company.; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Company Exchange Ratio</B>&#148; means the quotient obtained by dividing (a) the Company Per Share Value, by (b) the Reference Price.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Fully Diluted Shares</B>&#148; means the sum of (without duplication) (a) the aggregate number of Company Shares issued
and outstanding immediately prior to the Effective Date (not including, for the avoidance of doubt, the number of Company Common Shares issuable upon (i) the conversion of the Company Convertible Notes and (ii) the exercise of the Company Warrants),
and (b) the aggregate number of Company Shares issued or issuable upon exercise of all issued and outstanding Company Equity Awards (whether vested or unvested), including Company Equity Awards exercised prior to or in connection with the
Arrangement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Information Circular</B>&#148; means the notice of the Company Shareholders Meeting to be sent to the
Company Shareholders, and the accompanying management information circular, including all schedules, appendices and exhibits to, and information incorporated by reference in such management information circular, to be prepared in connection with the
Company Shareholders Meeting, together with any amendments thereto or supplements thereof in accordance with the terms of the Business Combination Agreement; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Option</B>&#148; means, as of any determination time, each option to purchase Company Shares that is outstanding and
unexercised (whether vested or unvested), whether granted under a Company Equity Plan; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Optionholders</B>&#148; means, at
any time, the holders of Company Options granted under the Company Equity Plan outstanding at such time and &#147;<B>Company Optionholder</B>&#148; means any one of them; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Per Share Value</B>&#148; means the quotient obtained by dividing (a) the
Reference Value, by (b) the Company Fully Diluted Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Preferred Shareholders</B>&#148; means, at any time, the
holders of Company Preferred Shares issued and outstanding at such time and &#147;<B>Company Preferred Shareholder</B>&#148; means any one of them; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Preferred Shares</B>&#148; means the Class A Preferred shares, the Class B Preferred shares and the Class C Preferred shares
of the Company; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Shareholder Consideration</B>&#148; means the Newco Shares and the Newco Warrants to be issued to the
Company Shareholders and the Company Warrant Holders pursuant to the Arrangement and in accordance with and subject to the terms of this Plan of Arrangement; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Shareholders</B>&#148; means, at any time, the holders of Company Common Shares, Company Non-Voting Common Shares, and Company
Preferred Shares, or both, in each case issued and outstanding at such time and &#147;<B>Company Shareholder</B>&#148; means any one of them; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Shareholders Agreement</B><B>s</B>&#148; means the third amended and restated majority shareholders agreement dated June 30,
2021, by and among the Company and the shareholders listed thereto, as amended from time to time, and each of the Company&#146;s common shareholder agreements between the Company and each Company Common Shareholder; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Shareholders Meeting</B>&#148; means the special meeting of the Company Shareholders, including any adjournment or
postponement thereof in accordance with the terms of the Business Combination Agreement, to be called and held in accordance with the Interim Order for the purpose of considering and, if thought fit, approving the Company Arrangement Resolution and,
with the prior written consent of FEAC, for any other purpose as may be set out in the Company Information Circular; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company
Shares</B>&#148; means, collectively, the Company Common Shares, the Company Non-Voting Common Shares, and the Company Preferred Shares; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company</B><B> Transmittal Letter</B>&#148; means the letter of transmittal to be provided by the Company to the Company Shareholders
and the Company Warrant Holders, which provides a means for the delivery of any certificates representing Company Shares or Company Warrants to the Exchange Agent and for instructions to be given by such Company Shareholder to the Exchange Agent for
the delivery of the Company Shareholder Consideration; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Warrant Holders</B>&#148; means, at any time, the holders of
Company Warrants outstanding at such time and &#147;<B>Company Warrant Holder</B>&#148; means any one of them; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company
Warrants</B>&#148; means, as of any determination time, each warrant to purchase Company Shares that is outstanding and unexercised, whether vested or unvested; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Continuance</B>&#148; has the meaning ascribed thereto in Section 3.1(k) of this Plan of Arrangement; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Court</B>&#148; means the Supreme Court of British Columbia, or other competent court, as applicable; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Director</B>&#148; means the Director appointed pursuant to Section 260 of the CBCA; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Dissent Rights</B>&#148; means the right of any Company Shareholder to exercise the right of dissent with respect to their Company
Shares in connection with this Arrangement and in accordance with Section 190 of the CBCA, as the same may be modified by the Interim Order, any order of the Court and Section 4.1 of this Plan of Arrangement; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Dissenting Shareholders</B>&#148; means any Company Shareholder as of the record date for the Company Shareholders Meeting who has
properly and validly exercised its Dissent Rights in respect of the Company Arrangement Resolution in strict compliance with the Dissent Rights and has not withdrawn or been deemed to have withdrawn such exercise of Dissent Rights, but only in
respect of the Company Shares for which the Dissent Rights are validly exercised by such Company Shareholder; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Effective
Date</B>&#148; means the date shown on the Certificate of Arrangement giving effect to the Arrangement; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Equity Securities&#148; </B>means any share, share capital, capital stock,
partnership, membership, joint venture or similar interest in any Person (including any stock appreciation, phantom stock, profit participation or similar rights), and any option, warrant, right or security (including debt securities) convertible,
exchangeable or exercisable therefor. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchange Agent</B>&#148; means such trust company, bank, or other financial institution as
Newco may appoint in accordance with the terms of the Business Combination Agreement, with the consent of FEAC and the Company, such consent not to be unreasonably withheld, conditioned or delayed; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>FEAC</B>&#148; means Forbion European Acquisition Corp., a Cayman Islands exempted company; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Final Order</B>&#148; means the final order of the Court pursuant to Section 192 of the CBCA, in the form and substance satisfactory
to FEAC and the Company (each acting reasonably), approving the Arrangement, as such order may be amended, modified, supplemented or varied by the Court at any time prior to the Effective Date, or if appealed, then unless such appeal is withdrawn,
abandoned, or dismissed, at such time which the Arrangement is affirmed, or as amended, on appeal, provided that any such amendment is reasonably acceptable to each of FEAC and the Company, each acting reasonably; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Group Company&#148; </B>and<B> &#147;Group Companies&#148; </B>means, collectively, the Company and its Subsidiaries and Newco and its
Subsidiaries (including, for the avoidance of doubt, Cayman Merger Sub). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>h</B><B>older</B>&#148;, when used with reference to any
securities of a company, means the holder of such securities shown from time to time in the central securities register maintained by or on behalf of that company in respect of such securities; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Interim Order</B>&#148;<B> </B>means the interim order of the Court contemplated by Section&nbsp;2.2<B> </B>of the Business
Combination Agreement and made pursuant to Section&nbsp;192(4) of the CBCA, in a form acceptable to each of the Company and FEAC (each acting reasonably), providing for, among other things, the calling and holding of the Company Shareholders
Meeting, as the same may be amended, modified, supplemented or varied by the Court with the consent of FEAC and the Company, such consent not to be unreasonably withheld, conditioned or delayed, provided that any such amendment is acceptable to each
of the Company and FEAC, each acting reasonably; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Newco</B>&#148; means enGene Holdings Inc., a corporation incorporated under the
CBCA; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Newco</B> <B>Common Shares</B>&#148; means the Class&nbsp;A Common shares of Newco; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Newco Option</B>&#148; means an option to purchase Newco Common Shares, on terms and conditions substantially similar to the Company
Options, as described in Section&nbsp;3.1(h)(xiv); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Newco Shares</B>&#148; means the shares in the capital of Newco; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Newco Warrants</B>&#148; means each warrant of Newco to purchase one Newco Share at an exercise price of $11.50 per share, subject to
adjustment, upon the terms and conditions in the Newco Warrant Agreement; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Person</B>&#148; means an individual, partnership,
corporation, limited liability company, joint stock company, unincorporated organization or association, trust, joint venture or other similar entity, whether or not a legal entity. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>PIPE Subscription</B>&#148; has the meaning ascribed thereto in Section&nbsp;3.1(e) of this Plan of Arrangement; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Plan of Arrangement</B>&#148; means this plan of arrangement and any amendments, supplements, modifications or variations hereto made
in accordance with this Plan of Arrangement, the applicable provisions of the Business Combination Agreement, or upon the direction of the Court in the Final Order with the consent of the Company and FEAC, each acting reasonably; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Reference Price</B>&#148; means $10.25. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Reference Value</B>&#148; means the sum of: (i) $90,000,000, plus (ii)&nbsp;the Aggregate Exercise Price </P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Registration Rights Agreement</B>&#148; means the second amended and restated
registration rights agreement dated June&nbsp;30, 2021, by and among the Company and the shareholders listed thereto; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Subscription Agreements</B>&#148; means the subscription agreements, substantially in the form attached to Exhibit <FONT
STYLE="white-space:nowrap">C-1</FONT><B> </B>of the Business Combination Agreement, between each of the PIPE Investors, Newco and FEAC, as amended by the Side Letter Agreements and &#147;<B>Subscription Agreement</B>&#148; means any of the of
Subscription Agreements; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Subsidiary&#148;</B> means, with respect to any Person, any corporation, limited liability company,
partnership or other legal entity of which (a)&nbsp;if a corporation, a majority of the total voting power of shares of stock entitled (without regard to the occurrence of any contingency) to vote in the election of directors, managers or trustees
thereof is at the time owned or controlled, directly or indirectly, by such Person or one or more of the other Subsidiaries of such Person or a combination thereof, or (b)&nbsp;if a limited liability company, partnership, association or other
business entity (other than a corporation), a majority of the limited liability company, partnership or other similar ownership interests thereof is at the time owned or controlled, directly or indirectly, by such Person or one or more Subsidiaries
of such Person or a combination thereof and for this purpose, a Person or Persons own a majority ownership interest in such a business entity (other than a corporation) if such Person or Persons shall be allocated a majority of such business
entity&#146;s gains or losses or shall be a, or control any, managing director or general partner of such business entity (other than a corporation). The term &#147;Subsidiary&#148; shall include all Subsidiaries of such Subsidiary. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Tax Act</B>&#148; means the <I>Income Tax Act </I>(Canada) and the regulations made thereunder, as now in effect and as they may be
promulgated or amended from time to time; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Trust Account Amount</B>&#148; means an amount equal to the total funds held in
FEAC&#146;s Trust Account (after deducting the amounts owed to public shareholders of FEAC who have properly exercised their redemption rights, a reasonable estimate of the amounts to be paid for any Dissenting FEAC Shares (as that term is defined
in the BCA) and the deferred discount owed to the underwriters of FEAC&#146;s IPO), less the principal amount of Note 3. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In this Plan of Arrangement, unless otherwise expressly stated or the context otherwise requires:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the division of this Plan of Arrangement into Articles and Sections and the further division thereof into
subsections and the insertion of headings are for convenience of reference only and will not affect the construction or interpretation of this Plan of Arrangement. Unless otherwise indicated, any reference in this Plan of Arrangement to an Article,
Section or subsection refers to the specified Article, Section or subsection in this Plan of Arrangement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">time periods within or following which any payment is to be made or act is to be done will be calculated by
excluding the day on which the period commences and including the day on which the period ends. Where the last day of any such time period is not a Business Day, such time period will be extended to the next Business Day following the day on which
it would otherwise end; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the terms &#147;hereof&#148;, &#147;herein&#148;, &#147;hereunder&#148; and similar expressions refer to this
Plan of Arrangement and not to any particular section or other portion hereof and include any agreement or instrument supplementary or ancillary hereto; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">words importing the singular number only will include the plural and vice versa and words importing the use of
any gender will include all genders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the word &#147;including&#148; means &#147;including, without limiting the generality of the foregoing&#148;;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a reference to a statute is to that statute as now enacted or as the statute may from time to time be amended, <FONT
STYLE="white-space:nowrap">re-enacted</FONT> or replaced and includes any regulation, rule or policy made thereunder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all references to cash or currency in this Plan of Arrangement are to United States dollars unless otherwise
indicated; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all references to time herein or in any letter of transmittal are to local time, Vancouver, British Columbia,
unless otherwise specified. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Time shall be of the essence in this Plan of Arrangement, and the transactions contemplated hereto, in all
respects. </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 2 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BUSINESS COMBINATION AGREEMENT </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Plan of Arrangement is made pursuant to and subject to the provisions of the Business Combination
Agreement and constitutes an arrangement as referred to in Section&nbsp;192 of the CBCA. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Plan of Arrangement and the Arrangement, upon the filing of the Articles of Arrangement and the issuance
of the Certificate of Arrangement, will become effective as of the Arrangement Effective Time and will be binding without any further authorization, act or formality on the part of the Court or any Person, on the Affected Securityholders, including
Dissenting Shareholders, FEAC, Can Merger Sub, the Company, Newco, Cayman Merger Sub and the Exchange Agent from and after the Arrangement Effective Time. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 3 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARRANGEMENT
</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Commencing at the Arrangement Effective Time, the following transactions will occur and will be deemed to occur
at the times and in the order set out below without any further authorization, act or formality required on the part of any Person, except as otherwise expressly provided herein: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at the Arrangement Effective Time; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Company Shareholders Agreements will terminate and the parties to the Company Shareholders Agreements will
cease to have any rights or obligations under the Company Shareholders Agreements; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Registration Rights Agreement<B> </B>will terminate<B> </B>and the parties to the Registration Rights
Agreement will cease to have any rights or obligations under the Registration Rights Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">one minute after the steps in Section&nbsp;3.1(a), the Dissenting Shareholders will be deemed to exercise their
Dissent Rights and: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">such Dissenting Shareholder will cease to be entitled to the rights of a Company Shareholder in respect of the
Company Shares in relation to which such Dissenting Shareholder has exercised the Dissent Rights, other than the right to be paid value as set out in Section&nbsp;4.1(a); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the securities register of the Company shall be amended to reflect that such Dissenting Shareholder is no
longer the holder of such Company Shares as at and from the Arrangement Effective Time; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">each Company Share so surrendered by a Dissenting Shareholder shall be cancelled; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">one minute after the steps in Section&nbsp;3.1(b), FEAC will loan to Newco an amount equal to the Trust Account
Amount in exchange for a CDN$ denominated <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing<B> </B>demand promissory note in an amount equal to the Trust Account Amount converted to its Canadian dollar equivalent based on the C$:U.S.$
Bank of Canada daily exchange rate on the Business Day immediately prior to the Effective Date; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">one minute after the step in Section&nbsp;3.1(c), FEAC will sell to Newco, and Newco will purchase from FEAC,
all the shares of Can Merger Sub for CAD$10; </P></TD></TR></TABLE> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">one minute after the steps in Section&nbsp;3.1(d) Newco will sell, and the PIPE Investors will purchase, the
Newco Common Shares and the Newco Warrants in accordance with the terms of the Subscription Agreements (the &#147;<B>PIPE Subscription</B>&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">one minute after the step in Section&nbsp;3.1(e): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Company Convertible Notes will be converted pursuant to the terms of the Company Convertible Notes and the
Company will issue to such Company Convertible Noteholders the amount of Company Common Shares that are issuable under their respective Company Convertible Notes; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Company will add to the stated capital of the Company Common Shares an amount equal to the aggregate
principal amount of the Company Convertible Notes converted to its Canadian dollar equivalent based on the C$:U.S.$ Bank of Canada daily exchange rate on the date that the 2022 Convertible Notes or the 2023 Convertible Notes, as applicable, were
issued. For greater clarity, the aggregate principal amount of the Company Convertible Notes will not include any accrued but unpaid interest; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">one minute after the step in Section&nbsp;3.1(f), Can Merger Sub and the Company will amalgamate to continue as
one corporate entity with the same effect as if they were amalgamated under Section&nbsp;181 of the CBCA (the &#147;<B>Amalgamation</B>&#148;), except that the separate legal existence of the Company shall not cease and the Company shall survive the
Amalgamation as the Company post-Amalgamation notwithstanding the Director issuing a certificate of amalgamation and for the avoidance of doubt, the Amalgamation will qualify as an amalgamation within the meaning of Section&nbsp;87 of the Tax Act
and be governed by Subsections 87(1), 87(2), 87(4), 87(5) and 87(9) of the Tax Act, as applicable; provided further that the Amalgamation is intended to qualify as a statutory merger that is a &#147;reorganization&#148; within the meaning of
Sections 368(a)(1)(A) and 368(a)(2)(E) of the Code. On and after the Amalgamation, pursuant to the CBCA: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Company shall survive the Amalgamation as the Company post-Amalgamation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the property, rights, interests and obligations of the Company pre-Amalgamation shall continue to be the
property, rights interests and obligations of the Company post-Amalgamation and the Amalgamation shall not constitute an assignment by operation of law, a transfer, or any other disposition of the property, rights, interests or obligations of the
Company <FONT STYLE="white-space:nowrap">pre-Amalgamation</FONT> to the Company post-Amalgamation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">simultaneously, the separate legal existence of Can Merger Sub will cease without Can Merger Sub being
liquidated or wound up, and the property, rights, interests, and obligations of Can Merger Sub will become the property, rights, interests and obligations of the Company post-Amalgamation and the Amalgamation shall not constitute an assignment by
operation of law, a transfer, or any other disposition of the property, rights, interests or obligations of Can Merger Sub to the Company post-Amalgamation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Company post-Amalgamation will continue to be liable for the obligations of the Company <FONT
STYLE="white-space:nowrap">pre-Amalgamation</FONT> and will become liable for the obligations of Can Merger Sub; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any existing cause of action, claim or liability to prosecution will be unaffected; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a civil, criminal or administrative action or proceeding pending by or against the Company pre-Amalgamation or
Can Merger Sub may be continued by or against the Company post-Amalgamation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a conviction against, or ruling, order or judgment in favour of or against, the Company pre-Amalgamation or Can
Merger Sub may be enforced by or against the Company post-Amalgamation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(viii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the name of the Company post-Amalgamation will be enGene Inc.; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ix)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">there shall be no restrictions on the business of the Company post-Amalgamation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(x)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Company post-Amalgamation shall have a minimum of one director and a maximum of ten directors, until
changed in accordance with the CBCA. Until changed by shareholders of the Company post-Amalgamation, or by the directors of the Company post-Amalgamation if so authorized by the shareholders, the numbers of directors of the Company post-Amalgamation
shall be <B>[</B><B>&#149;</B><B>]</B>; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(xi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the registered office of the Company post-Amalgamation will be the same as the registered office of the Company
<FONT STYLE="white-space:nowrap">pre-Amalgamation;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(xii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Articles of Arrangement shall be deemed to be the articles of incorporation of the Company pre-Amalgamation
and the Certificate of Arrangement shall be deemed to be the certificate of incorporation of the Company post-Amalgamation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(xiii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the <FONT STYLE="white-space:nowrap">by-laws</FONT> of the Company post-Amalgamation will be in the form of the
<FONT STYLE="white-space:nowrap">by-laws</FONT> of the Company <FONT STYLE="white-space:nowrap">pre-Amalgamation,</FONT> <I>mutatis mutandis</I>; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(xiv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Company post-Amalgamation shall be authorized to issue an unlimited number of common shares;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(xv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the first directors and officers of the Company post-Amalgamation will be: </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="22%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Address for Service</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Canadian Resident</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Director or Officer</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(xvi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">each Company Share outstanding immediately prior to the Amalgamation will be exchanged for Newco Common Shares
at the Company Exchange Ratio, following which each such Company Share shall be cancelled; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(xvii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in consideration for the issuance of the Newco Common Shares pursuant to Section&nbsp;3.1(g)(xvi), the Company
post-Amalgamation shall issue to Newco the number of common shares of the Company post-Amalgamation with an aggregate fair market value equal to the aggregate fair market value of the Newco Common Shares so issued and delivered;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(xviii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">each Company Warrant outstanding immediately prior to the Amalgamation will be exchanged for Newco Warrants at
the Company Exchange Ratio; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(xix)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">each Can Merger Sub Common Share outstanding immediately prior to the Amalgamation will be exchanged for one
common share of the Company post-Amalgamation, following which each such Can Merger Sub Common Share shall be cancelled; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(xx)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the stated capital of the Company post-Amalgamation will be an amount equal to the <FONT
STYLE="white-space:nowrap">paid-up</FONT> capital for purposes of the Tax Act of the Can Merger Sub Common Shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(xxi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an amount equal to the lesser of (A)&nbsp;the aggregate <FONT STYLE="white-space:nowrap">paid-up</FONT> capital
for purposes of the Tax Act of the Company Shares outstanding immediately prior to the Amalgamation (less the <FONT STYLE="white-space:nowrap">paid-up</FONT> capital for purposes of the Tax Act of any Company Shares held by Dissenting Shareholders);
and (B)&nbsp;the aggregate fair market value of the Company Shares outstanding immediately prior to the Amalgamation (less the fair market value of any Company Shares held by Dissenting Shareholders) will be added to the stated capital of the Newco
Common Shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(xxii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">each Company Option which is an outstanding option to purchase Company
<FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Shares or an Incentive Stock Option (as defined in the Company Equity Plan) shall be, to the extent not already vested in accordance with the terms of the Company Equity Plan, deemed to be
vested and exercisable, and exchanged for a Newco Option at the Company Exchange Ratio, in accordance with subsection 7(1.4) of the Tax Act on terms and conditions </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
otherwise identical to the terms of the Company Option. For certainty, the parties agree and acknowledge that the Company Optionholder shall not receive, and shall not be entitled to receive, any
consideration in respect of the disposition of such Company Options hereunder other than the Newco Options. If necessary for purposes of meeting the requirements of paragraph 7(1.4)(c) of the Tax Act, the exercise price of each Newco Option and/or
the number of Newco Common Shares subject to the Newco Option shall be, and shall be deemed to be, adjusted at the time of the exchange by the amount, and only to the extent necessary, to ensure that the aggregate fair market value of the Newco
Common Shares subject to the Newco Options immediately after the exchange less the aggregate exercise price for such Newco Common Shares does not exceed the excess of the aggregate fair market value of the Company
<FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Shares subject to the Company Options immediately before the exchange less the aggregate exercise price for such Company <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Shares under
the Company Options; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(xxiii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Company Equity Plan will terminate; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(xxiv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Company pre-Amalgamation is a corporate entity and the Company post-Amalgamation will be a corporate
entity; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(xxv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Company post-Amalgamation will continue to be a corporation existing under the CBCA. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">one minute after the step in Section&nbsp;3.1(g), Richard M. Glickman will resign as a director of Newco.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">one minute after the step in Section&nbsp;3.1(h), the following directors and officers will be elected and
appointed to Newco: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="22%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Address for Service</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Canadian Resident</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Director or Officer</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">one minute after the step in Section&nbsp;3.1(i), <B>[</B><B>&#149;</B><B>]</B> will be appointed as the
auditor of Newco; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(k)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">one minute after the step in Section&nbsp;3.1(j) Newco will be authorized to apply to the Director to continue
from being a corporation governed by the CBCA and the laws of Canada to a company governed by the BCBCA and the laws of British Columbia (the &#147;<B>Continuance</B>&#148;); and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(l)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at the time that a certificate of continuation for Newco is issued by the Province of British Columbia
Registrar of Companies under the BCBCA, Newco shall be discontinued from the CBCA. </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 4 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DISSENT RIGHTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pursuant to the Interim Order, each Company Shareholder, who is a registered holder of Company Shares, as of
the record date of the Company Shareholders Meeting may exercise the Dissent Rights; provided that, notwithstanding section 190(5) of the CBCA, the written notice of objection to the Company Arrangement Resolution contemplated by section 190(5) of
the CBCA must be sent to and received by the Company not later than [10:00 a.m.] ([Eastern] time) on the Business Day that is two (2)&nbsp;Business Days before the Company Shareholders Meeting (as it may be adjourned or postponed from time to time).
Dissenting Shareholders who: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">are ultimately determined to be entitled to be paid fair value for the Company Shares in respect of which they
have exercised the Dissent Rights, will, notwithstanding anything to the contrary contained in Section&nbsp;190 of the CBCA: (i)&nbsp;be deemed to have irrevocably surrendered such Company Shares, for cancellation; (ii)&nbsp;shall be entitled to a
payment from the Company post-Amalgamation of cash equal to </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
the fair value of the Company Shares; and (iii)&nbsp;will not be entitled to any other payment or consideration, including any payment that would be payable under the Arrangement in respect of
such Company Shares had such Company Shareholders not validly exercised their Dissent Rights; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">are ultimately not entitled, for any reason, to be paid fair value for the Company Shares in respect of which
they have exercised the Dissent Rights, will be deemed to have participated in the Arrangement on the same basis as a Company Shareholder who has not exercised Dissent Rights and shall receive Newco Common Shares in respect of such Company Shares on
the basis set forth in Section&nbsp;3.1(g)(xvi). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In no case will the Company, Newco or any other Person be required to recognize Dissenting Holders as holders
of Company Shares after the Arrangement Effective Time. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For greater certainty, in addition to any other restrictions in the Interim Order and under Section&nbsp;190 of
the CBCA, none of the following shall be entitled to exercise Dissent Rights: (i)&nbsp;Company Shareholders who vote or have instructed a proxyholder to vote such Company Shares in favour of the Company Arrangement Resolution; (ii)&nbsp;the Company
Optionholders; (iii)&nbsp;Company Warrant Holders; (iv)&nbsp;Company Convertible Noteholders; and (v)&nbsp;any other Person who is not a registered holder of Company Shares as of the record date for the Company Shareholders Meeting.
</P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 5 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATES AND PAYMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On or prior to the Effective Date (i)&nbsp;each Company Shareholder, Company Warrant Holder and Company
Convertible Noteholder will deposit or cause to be deposited with the Exchange Agent for the benefit of and to be held on behalf of the Company Shareholders, the Company Warrant Holders and the Company Convertible Noteholders entitled to receive
Newco Shares and Newco Warrants pursuant to Section&nbsp;3.1(g), certificates representing, or evidence in book-entry form of, the Company Shares, the Company Warrants and the Company Convertible Notes; and (ii)&nbsp;promptly following the
Amalgamation, Newco will deposit or cause to be deposited with the Exchange Agent (a)&nbsp;for the benefit of and to be held on behalf of the Company Shareholders and the Company Warrant Holders entitled to receive Newco Shares and Newco Warrants
pursuant to Section&nbsp;3.1(g), certificates representing, or evidence in book-entry form of, the Company Shareholder Consideration. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Following the deposit with the Exchange Agent of the certificates or other evidence representing or evidencing
the Company Shareholder Consideration specified in Section&nbsp;5.1, Newco will be fully and completely discharged from its obligation to pay the Company Shareholder Consideration to the Company Shareholders and Company Warrant Holders pursuant to
Section&nbsp;3.1(g) and the rights of such holders will be limited to receiving, from the Exchange Agent, the Newco Shares or Newco Warrants, as applicable, to which they are entitled in accordance with this Plan of Arrangement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Until such time as a Company Shareholder or a Company Warrant Holder deposits with the Exchange Agent a duly
completed Company Transmittal Letter, and the documents, certificates and instruments contemplated by the Company Transmittal Letter, and such other documents and instruments as the Exchange Agent, the Company or Newco, as the case may be, may
reasonably require, the payment or delivery to which such Company Shareholder or Company Warrant Holder is entitled will, in each case, be delivered or paid to the Exchange Agent to be held as agent on behalf of and for the benefit of such Company
Shareholder or Company Warrant Holder for delivery to such Company Shareholder or Company Warrant Holder, without interest and net of all applicable withholdings and other taxes, if any, upon delivery of the Company Transmittal Letter, and the
documents, certificates and instruments contemplated by the Company Transmittal Letter, and such other documents, certificates and instruments as the Exchange Agent, the Company<B> </B>or Newco, as the case may be, may reasonably require.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Upon surrender to the Exchange Agent for cancellation of a certificate that immediately prior to the
Arrangement Effective Time represented one or more Company Shares or Company Warrants, a duly </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
completed and executed Company Transmittal Letter and such additional documents, certificates and instruments as the Exchange Agent, the Company or Newco, as the case may be, may reasonably
require, the holder of such surrendered certificate, or the deliverer of such Company Transmittal Letter will be entitled to receive, and the Exchange Agent will, as promptly as practicable after the Arrangement Effective Time, deliver to such
holder, the certificate(s) representing or other evidence of Newco Shares or Newco Warrants that such Company Shareholder or Company Warrant Holder is entitled to receive under the Arrangement, and any certificate so surrendered will forthwith be
cancelled. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If any former Company Shareholder or former Company Warrant Holder fails to deliver to the Exchange Agent the
certificates, documents or instruments required to be delivered to the Exchange Agent under this Article 5 in order for such former Company Shareholder or former Company Warrant Holder to receive the consideration which such former holder is
entitled to receive pursuant to Section&nbsp;3.1 on or before the day immediately prior to the sixth anniversary of the Arrangement Effective Time, and any right or claim to payment hereunder that remains outstanding, on the day before the sixth
anniversary of the Arrangement Effective Time, (i)&nbsp;will cease to represent a right or claim of any kind or nature and the right of the holder to receive the applicable consideration pursuant to this Plan of Arrangement will terminate and any
applicable consideration held by the Exchange Agent in trust for such former holder will be deemed to be surrendered and forfeited to Newco or its successors for no consideration, and (ii)&nbsp;any certificate representing Company Shares or Company
Warrants formerly held by such former holder will cease to represent a claim of any nature whatsoever and will be deemed to have been surrendered to Newco and will be cancelled. Neither the Company nor Newco, nor any of their respective predecessor,
successors or affiliates will be liable to any Person in respect of any consideration (including any consideration previously held by the Exchange Agent in trust for any such former holder) which is forfeited to the Company or Newco or delivered to
any public official pursuant to any applicable abandoned property, escheat or similar law. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">After the Arrangement Effective Time and until surrendered as contemplated by this Article 5, each certificate
that immediately prior to the Arrangement Effective Time represented one or more Company Shares or Company Warrants will be deemed at all times to represent only the right to receive certificate(s) representing or other evidence of, the Newco Shares
or Newco Warrants that such Company Shareholder or Company Warrant Holder is entitled to receive in accordance with this Article 5, less any amounts withheld pursuant to Section&nbsp;6.2. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If any certificate that immediately prior to the Arrangement Effective Time represented one or more outstanding
Company Shares or Company Warrants that were exchanged pursuant to Article 3 has been lost, stolen or destroyed, upon the making of an affidavit of that fact by the Person claiming such certificate to be lost, stolen or destroyed, the Exchange Agent
will issue in exchange for such lost, stolen or destroyed certificate, the Newco Shares or Newco Warrants that such Person is entitled to receive pursuant to Article 3, deliverable in accordance with such holder&#146;s Company Transmittal Letter.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">When authorizing the delivery of such consideration in exchange for any lost, stolen or destroyed certificate,
the Person to whom the consideration is being delivered must, as a condition precedent to the delivery of such consideration, give a bond satisfactory to the Company or Newco and the Exchange Agent in such sum as the Company, Newco and the Exchange
Agent may direct or otherwise indemnify the Company, Newco and the Exchange Agent in a manner satisfactory to <B></B>the Company, Newco and the Exchange Agent against any claim that may be made against the Company, Newco or the Exchange Agent with
respect to the certificate alleged to have been lost, stolen or destroyed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In no event will any Person be entitled to a fractional Newco Share. Where the aggregate number of Newco Shares
to be issued to a Person pursuant to the Plan of Arrangement would result in a fraction of a Newco Share being issuable, the number of Newco Shares to be received by such Person will be rounded down to the nearest whole Newco Share.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any exchange or transfer of securities pursuant to this Plan of Arrangement shall be free and clear of any
Liens or other claims of third parties at any time. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 6 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EFFECT OF THE ARRANGEMENT; WITHHOLDINGS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">From and after the Arrangement Effective Time: (a)&nbsp;this Plan of Arrangement will take precedence and
priority over any and all Affected Securities issued prior to the Arrangement Effective Time, (b)&nbsp;the rights and obligations of the Affected Securityholders, the Company, Can Merger Sub, the Company, Newco, the Exchange Agent and any transfer
agent or other exchange agent therefor in relation thereto, will be solely as provided for in this Plan of Arrangement, and (c)&nbsp;all actions, causes of action, claims or proceedings (actual or contingent and whether or not previously asserted)
based on or in any way relating to any Affected Securities will be deemed to have been settled, compromised, released and determined without liability except as set forth in this Plan of Arrangement. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company, Newco and the Exchange Agent shall be entitled to take such actions as are reasonably necessary to
deduct and withhold (or cause to be deducted and withheld) from any amounts payable or otherwise deliverable to any Person pursuant to this Plan of Arrangement such Taxes, source deductions and other amounts as are required to be deducted and
withheld under applicable Tax Law. Any amounts so deducted and withheld shall be timely remitted to the applicable Tax Authority. To the extent that amounts are so deducted and withheld and timely remitted to the applicable Tax Authority, such
amounts shall be treated for all purposes of this Plan of Arrangement as having been paid to the Person in respect of which such deduction and withholding was made. Each of the Company, Newco and the Exchange Agent, as applicable, is hereby
authorized to sell or otherwise dispose of, on behalf of such Person, such portion of any share or other security deliverable to such Person as is necessary to provide sufficient funds to the Company, Newco and the Exchange Agent, as the case may
be, to enable it to comply with such deduction and withholding requirement and the Company,<B> </B>Newco or the Exchange Agent shall use commercially reasonable efforts to notify such Person thereof and remit the applicable portion of the net
proceeds of such sale to the appropriate Tax Authority and, if applicable, any portion of such net proceeds that is not required to be so remitted will be paid to such Person. The Parties shall cooperate reasonably and in good faith to eliminate or
reduce any such deduction or withholding to the extent permitted by applicable Law (including, where it is reasonable to do so, through the request and provision of any statements, forms or other documents to reduce or eliminate any such deduction
or withholding). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 7 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to Sections 7.3 and 7.4, the Company and FEAC may amend, modify and/or supplement this Plan of
Arrangement at any time and from time to time prior to the Arrangement Effective Time, provided that such amendment, modification and/or supplement must (i)&nbsp;be set out in writing, (ii)&nbsp;be approved by the Company and FEAC, each acting
reasonably, (iii)&nbsp;be filed with the Court and, if made following the Company Shareholders Meeting, approved by the Court, subject to such conditions as the Court may impose, and (iv)&nbsp;be communicated to the Affected Securityholders if and
as required by the Court. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any amendment, modification or supplement to this Plan of Arrangement may be proposed by the Company or FEAC at
any time prior to the Company Shareholders Meeting (provided that the Company or FEAC will have consented thereto in writing) with or without any other prior notice or communication, and if so proposed and accepted by the Persons voting at the
Company Shareholders Meeting (other than as may be required under the Interim Order), will become part of this Plan of Arrangement for all purposes. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any amendment, modification or supplement to this Plan of Arrangement that is approved or directed by the Court
following the Company Shareholders Meeting will be effective only if (i)&nbsp;it is consented to in writing by each of the Company and FEAC (in each case, acting reasonably), (ii) it is filed with the Court, other than amendments contemplated in
Section&nbsp;7.4, which do not require such filing, and (iii)&nbsp;if required by the Court, it is consented to by some or all of the Company Shareholders in the manner directed by the Court. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any amendment, modification or supplement to this Plan of Arrangement may be made following the Effective Date
by the Company without the approval of the former Company Shareholders, provided that (i)&nbsp;it is not adverse to the financial or economic interests of the former Company Shareholders; and (ii)&nbsp;it concerns a matter which, in the reasonable
opinion of the Company, is of an administrative or ministerial nature required to better give effect to the implementation of this Plan of Arrangement. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 8 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FURTHER
ASSURANCES </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding that the transactions and events set out herein will occur and be deemed to occur in the order
set out in this Plan of Arrangement without any further act or formality, each of the parties to the Business Combination Agreement, including those persons deemed to be party to the Arrangement under </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">this Plan of Arrangement, will make, do and execute, or cause to be made, done and executed, all such further acts, deeds, agreements, transfers, assurances, instruments or documents as may reasonably be required by any
of them in order to implement this Plan of Arrangement and to further document or evidence any of the transactions or events set out herein. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit <FONT STYLE="white-space:nowrap">C-1</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form of Subscription Agreement </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-1-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B><I>Final Form</I></B><B> </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF SUBSCRIPTION AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This SUBSCRIPTION AGREEMENT (this &#147;<B>Subscription Agreement</B>&#148;) is entered into this 16<SUP
STYLE="font-size:75%; vertical-align:top">th</SUP> day of May 2023, by and between Forbion European Acquisition Corp., a Cayman Islands exempted company (&#147;<B>FEAC</B>&#148;), enGene Holdings Inc., a company incorporated under the laws of Canada
(&#147;<B>Newco</B>&#148;) and the undersigned (&#147;<B>Subscriber</B>&#148; or &#147;<B>you</B>&#148;). Defined terms used but not otherwise defined herein shall have the respective meanings ascribed thereto in the Business Combination Agreement
(as defined below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Can Merger Sub, a company to be incorporated under the laws of Canada (&#147;<B>Can Merger Sub</B>&#148;),
will be a wholly-owned subsidiary of FEAC incorporated solely for purposes of effecting the Transactions (as defined below), and Cayman Merger Sub, a company to be incorporated as a Cayman Island exempted company (&#147;<B>Cayman Merger
Sub</B>&#148;) will be a wholly-owned subsidiary of Newco incorporated solely for purposes of effecting the Transactions; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, enGene
Inc., a corporation incorporated and existing under the laws of Canada (&#147;<B>enGene</B>&#148;) entered into a Note Purchase Agreement dated as of October&nbsp;20, 2022 by and among enGene, Forbion Capital Fund III Cooperatief U.A.
(&#147;<B>Forbion Capital Fund III</B>&#148;), Fonds de Solidarit&eacute; des Travailleurs du Qu&eacute;bec (F.T.Q.) (&#147;<B>FSTQ</B>&#148;), Lumira Ventures III, L.P. (&#147;<B>Lumira III</B>&#148;), Lumira Ventures III (International), L.P.
(&#147;<B>Lumira International III</B>&#148;), Merck Lumira Biosciences Fund, L.P. (&#147;<B>Merck</B>&#148;), Merck Lumira Biosciences Fund (Qu&eacute;bec), L.P. (&#147;<B>Merck Qu</B><B>&eacute;</B><B>bec</B>&#148; and together with, Merck, FSTQ,
Lumira III, Lumira International III and Forbion Capital Fund III, collectively the &#147;<B>2022</B> <B>Noteholders</B>&#148;) (the &#147;<B>2022 Note Purchase Agreement</B>&#148;) pursuant to which enGene issued $18.4&nbsp;million of convertible
promissory notes (each a &#147;<B>2022</B> <B>Convertible Note</B>&#148; and collectively, the &#147;<B>2022</B> <B>Convertible Notes</B>&#148;) to the 2022 Noteholders in substantially the form attached to the 2022 Note Purchase Agreement on the
terms and conditions set forth therein; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, enGene and each 2022 Noteholder have entered into amended and restated convertible
promissory notes on or about the date hereof, to amend and restate the 2022 Convertible Notes (each an &#147;<B>Amended 2022</B> <B>Convertible Note</B>&#148; and collectively, the &#147;<B>Amended</B> <B>2022</B> <B>Convertible Notes</B>&#148;)
pursuant to which (i)&nbsp;the Amended 2022 Convertible Notes are, among other things, convertible into that number of common shares of enGene that, when exchanged at the Company Exchange Ratio (as defined in the Business Combination Agreement),
shall equal that number of Ordinary Shares (as defined below) (or, after the Assumption (as defined below), Newco Common Shares (as defined below)) that the holders of the Amended 2022 Convertible Notes would have received if they subscribed for
Ordinary Shares (or, after the Assumption, Newco Common Shares) on the same terms as the PIPE Financing (as defined below) and (ii)&nbsp;each 2022 Noteholder received warrants to acquire common shares of enGene in consideration of certain amendments
set forth in each Amended 2022 Convertible Note (the &#147;<B>2022 Warrants</B>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, concurrently with the execution and
delivery of this Subscription Agreement and the Business Combination Agreement, the Sponsor (as defined below) and Investissement Qu&eacute;bec (&#147;<B>IQ</B>&#148;) are entering into agreements with enGene, pursuant to which the Sponsor and IQ
will purchase, in one or more closings, (i)&nbsp;convertible promissory notes of enGene (the &#147;<B>Original</B> <B>2023 Convertible Notes</B>&#148; and, together with the Amended 2022 Convertible Notes, the &#147;<B>Company Convertible
Notes</B>&#148;) that will, among other things, convert into that number of common shares of enGene that, when exchanged at the Company Exchange Ratio, shall equal that number of Ordinary Shares (or, after the Assumption, Newco Common Shares) that
the holders of the Original 2023 Convertible Notes would have received if they subscribed for Ordinary Shares on the same terms as the PIPE Financing, and (ii)&nbsp;warrants to acquire common shares of enGene (the &#147;<B>Original</B> <B>2023
Warrants</B>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company entered into a Note Purchase Agreement dated as of April&nbsp;4, 2023 by and among the Company,
Forbion Capital Fund III, FSTQ, Lumira III, Lumira International III, Lumira Ventures IV, L.P., </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-1-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Lumira Ventures IV (International), L.P., Merck, Merck Qu&eacute;bec (collectively, with respect to the 2023 Subordinated Financing (as defined below), the &#147;<B>2023 Noteholders</B>&#148;)
(the &#147;<B>2023 Subordinated Note Purchase Agreement</B>&#148;) pursuant to which the Company issued $8.0&nbsp;million of subordinated promissory notes (each a &#147;<B>2023 Subordinated Note</B>&#148; and collectively, the &#147;<B>2023
Subordinated Notes</B>&#148;) to the 2023 Noteholders in substantially the form attached to the 2023 Subordinated Note Purchase Agreement on the terms and conditions set forth therein (the &#147;<B>2023 Subordinated Financing</B>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, concurrently with the execution and delivery of this Agreement, the Company is entering into agreements with the 2023 Noteholders
pursuant to which the Company will repay the 2023 Subordinated Notes by issuing to each 2023 Noteholder (i)&nbsp;an amount of convertible promissory notes of the Company substantially in the same form and on the same terms as the Original 2023
Convertible Notes (the &#147;<B>Additional 2023 Convertible Notes</B>&#148; and, together with the Original 2023 Convertible Notes, the &#147;<B>2023 Convertible Notes</B>&#148;), and (ii)&nbsp;a number of warrants to acquire common shares of the
Company substantially in the same form and on the same terms as the Original 2023 Warrants, corresponding, in the aggregate, to the principal amount of 2023 Subordinated Notes held by such 2023 Noteholder; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, FEAC, Newco and enGene have, concurrently with the execution and delivery of this Subscription Agreement, entered into that certain
Business Combination Agreement, dated as of the date hereof (as amended, modified, supplemented or waived from time to time in accordance with its terms, the &#147;<B>Business Combination Agreement</B>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, concurrently with the execution and delivery of this Subscription Agreement, Newco, FEAC and a certain FEAC Shareholder (as defined
in the Business Combination Agreement) are entering into a <FONT STYLE="white-space:nowrap">non-redemption</FONT> agreement, substantially in the form attached to the Business Combination Agreement (the
&#147;<B><FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreement</B>&#148;), pursuant to which, among others, FEAC will issue additional Ordinary Shares and FEAC Warrants (or, after the Assumption, Newco will issue additional Newco Common
Shares and Newco Warrants) to such FEAC Shareholder (the &#147;<B><FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Transaction</B>&#148;) in consideration of such FEAC Shareholder&#146;s commitment not to redeem an amount of its Ordinary
Shares set out in such <FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreement in connection with the FEAC Shareholder Approval (as defined in the Business Combination Agreement), on the terms and subject to the conditions set forth in the <FONT
STYLE="white-space:nowrap">Non-Redemption</FONT> Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, as of the date of this Subscription Agreement, Forbion Growth
Sponsor FEAC I B.V., a private limited liability company incorporated in The Netherlands (the &#147;<B>Sponsor</B>&#148;), owns 3,162,500 FEAC Class&nbsp;B ordinary shares (&#147;<B>FEAC Class</B><B></B><B>&nbsp;B Shares</B>&#148; and, together with
the Ordinary Shares, the &#147;<B>FEAC Shares</B>&#148;) and 5,195,000 FEAC private placement warrants (each whole warrant entitling the holder thereof to purchase one Ordinary Share, the &#147;<B>FEAC Private Placement Warrants</B>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, assuming that the aggregate principal amount outstanding under the Working Capital Loan Note and any Extension Loan Notes (each as
defined in the Business Combination Agreement) equals or exceeds $1,500,000 on the day which is two (2)&nbsp;Business Days (as defined below) prior to the Closing Date (as defined below), FEAC shall cause the Sponsor (or its Affiliate or designee,
as applicable), as payee of the Working Capital Loan Note and any Extension Loan Notes, to elect to convert an amount equal to $1,500,000 of the aggregate principal amount outstanding under the Working Capital Loan Note and any Extension Loan Notes,
taken together, into additional FEAC Private Placement Warrants at a price of $1.50 per FEAC Private Placement Warrant, which upon such election will be issued by FEAC to the Sponsor (or its Affiliate (as defined in the Business Combination
Agreement) or designee, as applicable) immediately prior to the Surrender (as defined below) on the day which is two (2)&nbsp;Business Days prior to the Closing Date, in each case in accordance with the FEAC Warrant Agreement and the relevant
promissory note governing the Working Capital Loan Note and/or any Extension Loan Notes, as applicable, following which the Sponsor is expected to own 6,195,000 FEAC Private Placement Warrants (the &#147;<B>Sponsor Loan Conversion</B>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, concurrently with the execution and delivery of this Subscription Agreement, the Sponsor, FEAC and the other parties thereto are
entering into the sponsor and insiders letter agreement (the &#147;<B>Sponsor and</B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-1-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<B>Insiders Letter Agreement</B>&#148;), pursuant to which, among other things, the Sponsor has agreed to surrender, after giving effect to the Sponsor Loans Conversion, 1,789,004 FEAC
Class&nbsp;B Shares and 5,463,381 FEAC Private Placement Warrants, as a contribution to the capital of FEAC and for no consideration, effective immediately prior to the Class&nbsp;B Conversion (as defined below) and on the day which is two
(2)&nbsp;Business Days prior to the Closing Date, in each case, on the terms and conditions set forth in Business Combination Agreement and the Sponsor and Insiders Letter Agreement (the &#147;<B>Surrender</B>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, on the day which is two (2)&nbsp;Business Days (as defined below) prior to the Closing Date, each FEAC Class&nbsp;B Share that
remains outstanding following the Surrender of the 1,789,004 FEAC Class&nbsp;B Shares held by the Sponsor, as provided in the Sponsor and Insiders Letter Agreement, shall be exchanged (the &#147;<B>Class</B><B></B><B>&nbsp;B Conversion</B>&#148;)
for one Ordinary Share (as defined below); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, on the day which is one (1)&nbsp;Business Day prior to the Closing Date, Cayman
Merger Sub will merge with and into FEAC with FEAC as the surviving entity pursuant to a plan of merger under the laws of the Cayman Islands (the &#147;<B>Cayman Merger</B>&#148;), as follows: (i)&nbsp;Newco will issue to the holders of Ordinary
Shares (including the Sponsor but excluding the holders of any Dissenting FEAC Shares (as defined in the Business Combination Agreement)) Newco common shares (&#147;<B>Newco Common Shares</B>&#148;) in exchange for such holders&#146; Ordinary Shares
and such Ordinary Shares will not be cancelled but will be transferred to Newco, (ii)&nbsp;FEAC will thereby become a wholly-owned subsidiary of Newco and (iii)&nbsp;each issued share of Cayman Merger Sub will be exchanged for an Ordinary Share of
FEAC as the surviving entity and Cayman Merger Sub (having merged into FEAC) will cease to exist as a separate entity by virtue of the Cayman Merger; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS concurrently with the Cayman Merger, and effective at the same time the Cayman Merger becomes effective under the Cayman Islands law,
(i)&nbsp;Newco will assume the FEAC Private Placement Warrants and FEAC&#146;s warrants to purchase one Ordinary Share at an exercise price of $11.50 per share, subject to adjustment, upon the terms and conditions in the FEAC Warrant Agreement (as
defined in the Business Combination Agreement) (the &#147;<B>FEAC Public Warrants</B>&#148; and, together with the Private Placement Warrants, the &#147;<B>FEAC Warrants</B>&#148; and, the FEAC Warrants as so assumed, the &#147;<B>Newco
Warrants</B>&#148;) pursuant to the Warrant Assignment, Assumption and Amendment Agreement (as defined below), (ii) FEAC as the entity surviving the Cayman Merger will issue to Newco a <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing
demand promissory note payable denominated in CDN$ having a principal amount equal to the fair market value of the FEAC Warrants assumed by Newco (as so assumed, Newco Warrants) (&#147;<B>Note 3</B>&#148;) in consideration of the assumption by Newco
of obligations under the FEAC Warrants (as so assumed, Newco Warrants) and (iii)&nbsp;Newco will redeem the initial Newco Common Shares held by its formation shareholder for an amount equal to the amount of capital that such formation shareholder
contributed for purposes of the incorporation of Newco (such transactions, together with the Cayman Merger, the &#147;<B>Cayman Reorganization</B>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, following the Cayman Reorganization, FEAC will file an election to change its classification for U.S. federal income tax purposes
from a corporation to an entity disregarded as separate from its owner Newco, to be effective as of the beginning of the Closing Date (the &#147;<B>U.S. Entity Classification Election</B>&#148; and, together with the Cayman Reorganization, the
&#147;<B>FEAC Reorganization</B>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, on the Closing Date and pursuant to the Plan of Arrangement (as defined below),
subsequent to the FEAC Reorganization becoming effective and prior to the consummation of the PIPE Financing (as defined below), FEAC will loan to Newco an amount equal to the total funds held in its Trust Account (as defined below) on the Closing
Date (after deducting the amounts owed to FEAC Shareholders who have properly exercised their redemption rights, a reasonable estimate of the amounts to be paid for any Dissenting FEAC Shares and the deferred discount owed to the underwriters of
FEAC&#146;s initial public offering), less the principal amount of Note 3 (together, the &#147;<B>Loan Amount</B>&#148;), in consideration for which Newco will issue a CDN$ denominated <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing
demand promissory note to FEAC having a principal amount equal to the Loan Amount converted to its Canadian dollar equivalent based on the C$:U.S.$ Bank of Canada daily exchange rate on the Business Day
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-1-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
immediately prior to the Closing Date (&#147;<B>Note 1</B>&#148;), following which FEAC will sell to Newco, and Newco will purchase, all of the outstanding common shares of Can Merger Sub for a
purchase price of CDN$ 10 (the &#147;<B>Can Merger Sub Share Sale</B>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, on the Closing Date and pursuant to the Plan of
Arrangement, following the Can Merger Sub Share Sale but prior to the Amalgamation (as defined below), the PIPE Financing shall be consummated on the terms and subject to the conditions set forth in this Subscription Agreement and the Other
Subscription Agreements (as defined below), as may be amended from time to time, and the <FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Transaction shall be consummated in accordance with the
<FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, on the Closing Date and pursuant to the Plan of Arrangement,
the Amended 2022 Convertible Notes and 2023 Convertible Notes will automatically convert, concurrent with the consummation of the PIPE Financing, into that number of common shares of enGene that, when exchanged at the Company Exchange Ratio shall
equal that number of Ordinary Shares (or, after the Assumption, Newco Common Shares) that the holders of the Amended 2022 Convertible Notes and 2023 Convertible Notes would have received if they subscribed for Ordinary Shares (or, after the
Assumption, Newco Common Shares) on the same terms as the PIPE Financing; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, on the Closing Date and pursuant to the Plan of
Arrangement, after the consummation of the PIPE Financing and the conversion of the Company Convertible Notes, Can Merger Sub and enGene will amalgamate in accordance with the terms of the plan of arrangement (the &#147;<B>Plan of
Arrangement</B>&#148;) substantially in the form attached to the Business Combination Agreement (the &#147;<B>Amalgamation</B>&#148;) and pursuant to the Amalgamation, (i)&nbsp;each enGene common share outstanding immediately prior to the
Amalgamation shall be exchanged for Newco Common Shares per the Company Exchange Ratio, each Company Equity Award (as defined in the Business Combination Agreement) outstanding immediately prior to the Amalgamation shall be exchanged for Rollover
Equity Awards (as defined in the Business Combination Agreement) per the Company Exchange Ratio and each enGene warrant outstanding immediately prior to the Amalgamation shall be exchanged for Newco Warrants per the Company Exchange Ratio,
(ii)&nbsp;each Can Merger Sub share outstanding immediately prior to the Amalgamation shall be exchanged for one common share in the authorized share capital of the amalgamated entity, and (iii)&nbsp;in consideration for the issuance of Newco Common
Shares, the amalgamated entity shall issue its common shares to Newco, in each case upon and subject to the other terms and conditions set forth in the Business Combination Agreement, the Plan of Arrangement and in accordance with the provisions of
applicable Law (the time at which the Amalgamation is completed, the &#147;<B>Amalgamation Closing</B>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, on the Closing
Date and pursuant to the Plan of Arrangement, following the Amalgamation, Newco will continue from being a corporation incorporated under and governed by the <I>Canada Business Corporations Act</I> to a company continued to and governed by the
<I>Business Corporations Act </I>(British Columbia) (the &#147;<B>Continuance</B>&#148;)<B> </B>and, in connection with the Continuance, the articles of Newco shall be amended to reflect the requirements of the continued jurisdiction, among other
things; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, on the Closing Date, and prior to the Amalgamation, the Newco Common Shares and Newco Warrants will be listed on Nasdaq
or such other Exchange as agreed to by FEAC and enGene; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, immediately following the Closing Date, FEAC will repurchase shares held
by Newco in an aggregate amount equal to Note 1 and in consideration therefor issue to Newco a CDN$ denominated <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing demand promissory note in a principal amount equal to the outstanding
principal amount of Note 1 (&#147;<B>Note 2&#148;</B>), following which Note 1 and Note 2 (each having the same outstanding principal amount) will be set off by FEAC and Newco in full repayment of their respective principal amounts (the
&#147;<B>Notes <FONT STYLE="white-space:nowrap">Set-Off</FONT></B>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, following the Notes
<FONT STYLE="white-space:nowrap">Set-Off</FONT> becoming effective, Newco will transfer Note 3 to enGene in consideration for the issuance by enGene from treasury of additional common shares of enGene, following which FEAC will repay the outstanding
principal amount of Note 3, and subsequently be placed in liquidation in accordance with applicable Cayman law (the &#147;<B>Liquidation</B>&#148; and together with the Sponsor Loans Conversion, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-1-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Surrender, the Class&nbsp;B Conversion, the Cayman Merger, the Cayman Reorganization, the FEAC Reorganization, the Assumption, the Can Merger Sub Share Sale, the Amalgamation, the PIPE
Financing, the <FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Transaction and the other transactions described above and contemplated by the Sponsor and Insiders Letter Agreement, Business Combination Agreement, the Plan of Arrangement, this
Subscription Agreement, the Other Subscription Agreements, the <FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreement and the other Ancillary Documents (as defined in the Business Combination Agreement), the
&#147;<B>Transactions</B>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, in connection with the Transactions, Subscriber desires to subscribe for and purchase from
FEAC (or following the Assumption, Newco) that number of FEAC&#146;s Class&nbsp;A ordinary shares, $0.0001 par value each (the &#147;<B>Ordinary Shares</B>&#148;) (or following the Assumption, Newco Common Shares) set forth on the signature page
hereto (giving effect to the Assumption, the &#147;<B>Subscribed Shares</B>&#148;) for a purchase price of $10.25 per share (the &#147;<B>Per Share Price</B>&#148;), and for the aggregate purchase price set forth on the signature page hereto (the
&#147;<B>Purchase Price</B>&#148;), and FEAC (or following the Assumption, Newco) desires to issue and sell to Subscriber the Subscribed Shares in consideration of the payment of the Purchase Price therefor by or on behalf of Subscriber to FEAC, all
on the terms and subject to the conditions set forth herein; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, certain other &#147;qualified institutional buyers&#148; (as
defined in Rule 144A under the Securities Act of 1933, as amended (the &#147;<B>Securities Act</B>&#148;)) or institutional &#147;accredited investors&#148; (within the meaning of Rule 501(a)(1), (2), (3) or (7)&nbsp;under the Securities Act) have,
severally and not jointly, entered into separate subscription agreements with FEAC and Newco substantially in the form hereof (each, an &#147;<B>Other Subscriber</B>&#148;), pursuant to which such Other Subscribers have agreed to purchase Ordinary
Shares from FEAC (or after the Assumption, Newco Common Shares) on the Closing Date (as defined below) at the Per Share Price (the &#147;<B>Other Subscription Agreements</B>&#148;; the equity financing under this Subscription Agreement and the Other
Subscription Agreements, each as may be amended from time to time, the &#147;<B>PIPE Financing</B>&#148;), and the aggregate amount of securities to be sold by FEAC (or after the Assumption, Newco) pursuant to this Subscription Agreement and the
Other Subscription Agreements equals, as of the date hereof, 5,550,408 Ordinary Shares (or, following the Assumption, Newco Common Shares); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, subsequent to the FEAC Reorganization becoming effective and prior to the consummation of the PIPE Financing, all rights, covenants
and obligations of FEAC, including the rights, covenants and obligations under this Subscription Agreement and the Other Subscription Agreements, will be assumed by Newco (the &#147;<B>Assumption</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the foregoing and the mutual representations, warranties and covenants, the payment of the Purchase Price
by the Subscriber, and subject to the conditions, herein contained, and intending to be legally bound hereby, the parties hereto hereby agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated or the context otherwise requires, by virtue of, and with effect from, the FEAC Reorganization and the Assumption
becoming effective, all references herein (i)&nbsp;to FEAC, shall refer to Newco, and (ii)&nbsp;to the Subscribed Shares shall refer to Newco Common Shares of the corresponding number rather than Ordinary Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Subscription</U>. Subject to the terms and conditions hereof, at the Closing (as defined below), Subscriber hereby agrees, to subscribe
for and purchase, and FEAC (or following the Assumption, Newco) hereby agrees to issue and sell to Subscriber, upon the payment of the Purchase Price, the Subscribed Shares (such subscription and issuance, the &#147;<B>Subscription</B>&#148;).
Notwithstanding anything herein to the contrary, the consummation of the Subscription contemplated hereby (the &#147;<B>Closing</B>&#148;) is contingent upon the completion of each element of the Transactions (other than those Transactions that are
scheduled to be completed following the Amalgamation Closing), including the substantially concurrent occurrence of the Amalgamation Closing (the date of the Closing, the &#147;<B>Closing Date</B>&#148;). For the avoidance of doubt, each of the
parties hereto acknowledges and agrees that the Subscribed Shares that will be issued pursuant hereto at the Closing shall be Newco common shares issued by Newco. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-1-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Representations, Warranties and Agreements</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1. <U>Subscriber</U><U>&#146;</U><U>s Representations, Warranties and Agreements</U>. To induce the issuance of the Subscribed Shares,
Subscriber hereby represents and warrants to each of FEAC and Newco and acknowledges and agrees with each of FEAC and Newco, as of the date hereof and as of the Closing Date, as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1.1. Subscriber has been duly formed or incorporated and is validly existing in good standing under the laws of its
jurisdiction of incorporation or formation, with power and authority to enter into, deliver and perform its obligations under this Subscription Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1.2. This Subscription Agreement has been duly authorized, validly executed and delivered by Subscriber. Assuming that this
Subscription Agreement constitutes the valid and binding agreement of FEAC and Newco, this Subscription Agreement is the valid and binding obligation of Subscriber, and is enforceable against Subscriber in accordance with its terms, except as may be
limited or otherwise affected by (i)&nbsp;bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium or other laws relating to or affecting the rights of creditors generally, and (ii)&nbsp;principles of equity, whether considered at
law or equity. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1.3. The execution, delivery and performance by Subscriber of this Subscription Agreement and the
consummation of the transactions contemplated herein do not and will not (i)&nbsp;result in any violation of the provisions of the organizational documents of Subscriber or any of its subsidiaries, (ii)&nbsp;result in any violation of any statute or
any judgment, order, rule or regulation of any court or governmental agency or body, domestic or foreign, having jurisdiction over Subscriber that would reasonably be expected to have a material adverse effect on the legal authority and ability of
Subscriber to enter into and timely perform its obligations under this Subscription Agreement (a &#147;<B>Subscriber Material Adverse Effect</B>&#148;) or (iii)&nbsp;conflict with or result in a breach or violation of any of the terms or provisions
of, or constitute a default under, or result in the creation or imposition of any lien, charge or encumbrance upon any of the property or assets of Subscriber or any of its subsidiaries pursuant to the terms of any indenture, mortgage, deed of
trust, loan agreement, lease, license or other agreement or instrument to which Subscriber or any of its subsidiaries is a party or by which Subscriber or any of its subsidiaries is bound or to which any of the property or assets of Subscriber or
any of its subsidiaries is subject, which would reasonably be expected to have a Subscriber Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1.4. Subscriber (i)&nbsp;(a) is a &#147;qualified institutional buyer&#148; (as defined in Rule 144A under the Securities
Act) or an institutional &#147;accredited investor&#148; (within the meaning of Rule 501(a)(1), (2), (3), (7), (8), (9), (12) or (13)&nbsp;of Regulation D under the Securities Act), (b) is not an entity formed for the specific purpose of acquiring
the Subscribed Shares, unless such newly formed entity is an entity in which all of the investors are institutional accredited investors, and under the Securities Act), (b) is an Institutional Account as defined in FINRA Rule 4512(c) and (c)&nbsp;is
a sophisticated institutional investor, experienced in investing in transactions of the type contemplated by this Subscription Agreement and capable of evaluating investment risks independently, both in general and with regard to all transactions
and investment strategies involving a security or securities, including its participation in the Subscription, in each case, satisfying the applicable requirements set forth on <U>Schedule I</U>, (ii)&nbsp;has exercised independent judgment in
evaluating its participation in the purchase of the Subscribed Shares, (iii)&nbsp;is acquiring the Subscribed Shares only for its own account and not for the account of others, or if Subscriber is subscribing for the Subscribed Shares as a fiduciary
or agent for one or more investor accounts, each owner of such account is a qualified institutional buyer, and Subscriber has full investment discretion with respect to each such account, and the full power and authority to make the
acknowledgements, representations, warranties and agreements herein on behalf of each owner of each such account, for investment purposes only and not with a view to any distribution of the Subscribed Shares in any manner that would violate the
securities laws of the United States or any other applicable jurisdiction and (iv)&nbsp;is not acquiring the Subscribed Shares with a view to, or for offer or sale in connection with, any distribution thereof in violation of the Securities Act or
any securities laws of the United States or any other jurisdiction (and shall provide the requested information on <U>Schedule I</U> following the signature page hereto). Subscriber understands that the offering of the Subscribed Shares meets
(i)&nbsp;the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-1-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
exemptions from filing under FINRA Rule 5123(b)(1)(A) and (C)&nbsp;or (J) and (ii)&nbsp;the institutional customer exemption under FINRA Rule 2111(b). Subscriber acknowledges that it is aware
that there are substantial risks incident to the purchase and ownership of the Subscribed Shares, including those set forth in the investor presentation provided by FEAC (as amended and supplemented through the date hereof) and in the SEC Documents
(as defined below). Subscriber is able to fend for itself in the transactions contemplated herein, has such knowledge and experience in financial and business matters as to be capable of evaluating the merits and risks of an investment in the
Subscribed Shares, and has sought such accounting, legal and tax advice as Subscriber has considered necessary to make an informed investment decision. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1.5. Subscriber understands that the Subscribed Shares are being offered in a transaction not involving any public offering
within the meaning of the Securities Act and that the Subscribed Shares have not been registered under the Securities Act or the securities laws of any other jurisdiction. Subscriber understands that the Subscribed Shares may not be offered, resold,
transferred, pledged or otherwise disposed of by Subscriber absent an effective registration statement under the Securities Act, except (i)&nbsp;to Newco or a subsidiary thereof, (ii)&nbsp;to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> persons
pursuant to offers and sales that occur solely outside the United States within the meaning of Regulation S under the Securities Act or (iii)&nbsp;pursuant to another applicable exemption from the registration requirements of the Securities Act, and
in each of cases (i)&nbsp;and (iii), in accordance with any applicable securities laws of the states and other jurisdictions of the United States, and that the Subscribed Shares (i)&nbsp;will be &#147;restricted securities&#148; within the meaning
of Rule 144 under the Securities Act (&#147;<B>Rule 144</B>&#148;) and accordingly are subject to restrictions on transferability and resale and may not be transferred or resold except as permitted under the Securities Act and applicable state
securities laws pursuant to registration or exemption therefrom and (ii)&nbsp;shall be subject to a legend to such effect (<U>provided</U> that such legends will be eligible for removal upon compliance with the relevant resale provisions of Rule 144
and as set forth in Section&nbsp;10 of this Subscription Agreement). Subscriber acknowledges that the Subscribed Shares will not be immediately eligible for offer, resale, transfer, pledge or disposition pursuant to Rule 144 until at least one year
from the filing by Newco of the &#147;Form 10 information&#148; after the Closing Date and that the provisions of Rule 144(i) will generally apply to the Subscribed Shares. Subscriber understands and agrees that the Subscribed Shares will be subject
to the foregoing restrictions and, as a result, Subscriber may not be able to readily resell the Subscribed Shares and may be required to bear the financial risk of an investment in the Subscribed Shares for an indefinite period of time. Subscriber
understands that it has been advised to consult independent legal counsel prior to making any offer, resale, pledge or transfer of any of the Subscribed Shares. Subscriber has determined based on its own independent review and such professional
advice as it deems appropriate that the Subscribed Shares are a suitable investment for Subscriber, notwithstanding the substantial risks inherent in investing in or holding the Subscribed Shares, and that Subscriber is able at this time and in the
foreseeable future to bear the economic risk of a total loss of Subscriber&#146;s investment. Subscriber acknowledges specifically that a possibility of total loss exists. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1.6. Subscriber understands and agrees that, pursuant to the Assumption, Subscriber will purchase the Subscribed Shares
directly from Newco. Subscriber further acknowledges that there have been no representations, warranties, covenants or agreements made to Subscriber by FEAC, Newco, enGene, the Placement Agents or any of their respective affiliates or any control
persons, officers, directors, employees, partners, agents or representatives, expressly or by implication, other than, in the case of FEAC and Newco only, those representations, warranties, covenants and agreements expressly set forth in this
Subscription Agreement. Subscriber understands that certain financial information (whether historical or in the form of financial forecasts or projections) of FEAC, Newco and enGene have been prepared and reviewed solely by FEAC, Newco, enGene and
their respective officers, directors and employees, as applicable, and have not been reviewed by the Placement Agents or any outside party or, except for the financial statements as expressly set forth in the Registration Statement (as defined
below), certified or audited by an independent third-party auditor or audit firm. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1.7. Subscriber does not have, as of
the date hereof, and during the <FONT STYLE="white-space:nowrap">30-day</FONT> period immediately prior to the date hereof such Subscriber has not, and during the period beginning as of the date hereof until
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-1-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
the Closing Date or the earlier termination of this Subscription Agreement such Subscriber will not have, entered into, any &#147;put equivalent position&#148; as such term is defined in Rule <FONT
STYLE="white-space:nowrap">16a-1</FONT> under the Securities Exchange Act of 1934, as amended (the &#147;<B>Exchange Act</B>&#148;) or short sale positions with respect to the securities of FEAC. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1.8. If Subscriber is or is acting on behalf of (i)&nbsp;an employee benefit plan that is subject to Title I of the Employee
Retirement Income Security Act of 1974, as amended (&#147;<B>ERISA</B>&#148;), (ii) a plan, an individual retirement account or other arrangement that is subject to Section&nbsp;4975 of the Internal Revenue Code of 1986, as amended (the
&#147;<B>Code</B>&#148;), (iii) an employee benefit plan (such as a governmental plan (as defined in Section&nbsp;3(32) of ERISA), a church plan (as defined in Section&nbsp;3(33) of ERISA) or a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> plan
(as described in Section&nbsp;4(b)(4) of ERISA)) that is subject to any federal, state, local, <FONT STYLE="white-space:nowrap">non-U.S.</FONT> or other laws or regulations that are similar to such provisions of ERISA or the Code (collectively,
&#147;<B>Similar Laws</B>&#148;) or (iv)&nbsp;an entity whose underlying assets are considered to include &#147;plan assets&#148; of any such plan, account or arrangement described in (i), (ii) and (iii)&nbsp;above (each of the foregoing described
in (i), (ii)&nbsp;(iii) and (iv) above, a &#147;<B>Plan</B>&#148;), Subscriber represents and warrants that its acquisition and holding of the Subscribed Shares will not constitute or result in a <FONT STYLE="white-space:nowrap">non-exempt</FONT>
prohibited transaction under Section&nbsp;406 of ERISA or Section&nbsp;4975 of the Code or violate any Similar Laws. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1.9. If Subscriber is or is acting on behalf of a Plan, Subscriber represents and warrants that none of FEAC, Newco, enGene
or any of their respective affiliates (the &#147;<B>Transaction Parties</B>&#148;) has acted as the Plan&#146;s fiduciary, or has been relied on for advice, with respect to its decision to acquire and hold the Subscribed Shares, and none of the
Transaction Parties shall at any time be relied upon as the Plan&#146;s fiduciary with respect to any decision to acquire, continue to hold or transfer the Subscribed Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1.10. Subscriber acknowledges that no disclosure or offering document has been prepared or reviewed by SVB Securities LLC and
UBS Securities LLC (collectively, in their capacity as placement agents, the &#147;<B>Placement Agents</B>&#148;) or any of their respective affiliates or any control persons, officers, directors, employees, partners, agents or representatives of
any of the foregoing in connection with the offer and sale of the Subscribed Shares. In making its decision to purchase the Subscribed Shares, Subscriber represents that it has relied solely upon independent investigation made by Subscriber and the
representations, warranties and covenants of FEAC and Newco contained in this Subscription Agreement. Without limiting the generality of the foregoing, Subscriber has not relied on any statements or other information provided by anyone (including
the Placement Agents), other than FEAC, Newco, enGene and their respective representatives concerning FEAC, Newco, enGene or the Subscribed Shares or the offer and sale of the Subscribed Shares. Subscriber acknowledges and agrees that Subscriber has
received access to and has had an adequate opportunity to review such information as Subscriber deems necessary in order to make an investment decision with respect to the Subscribed Shares, including with respect to FEAC, Newco, enGene, and the
Transactions. Subscriber represents and agrees that Subscriber and Subscriber&#146;s professional advisor(s), if any, received, reviewed and understood the offering materials made available to them in connection with the Subscription and the
Transactions, have had the full opportunity to ask such questions, including on the financial information, receive such answers and obtain such information as Subscriber and Subscriber&#146;s professional advisor(s), if any, have deemed necessary to
make an investment decision with respect to the Subscribed Shares. Subscriber represents and warrants it is relying exclusively on its own investment analysis and due diligence (including professional advice it deems appropriate) with respect to the
Subscription, the Transactions, the Subscribed Shares and the business, condition (financial and otherwise), management, operations, properties and prospects of FEAC, Newco and enGene including but not limited to all business, legal, regulatory,
accounting, credit and tax matters. Subscriber further acknowledges that Subscriber has not relied upon the Placement Agents in connection with Subscriber&#146;s due diligence review of the offering of the Subscribed Shares and of FEAC, Newco and
enGene. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1.11. Subscriber acknowledges and agrees that (a)&nbsp;it has been informed that each of the Placement Agents is
acting solely as placement agent in connection with the Subscription and is not acting as an underwriter or in any other capacity in connection with the Subscription and is not and shall not be construed as a fiduciary for Subscriber, FEAC, Newco,
enGene or any other person or entity in connection </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-1-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
with the Transactions, (b)&nbsp;the Placement Agents have not made and will not make any representation or warranty, whether express or implied, of any kind or character and have not provided any
advice or recommendation in connection with the Subscription and the Transactions, in each case, to Subscriber and such advice or recommendation is not necessary or desired (c)&nbsp;the Placement Agents will have no responsibility to Subscriber with
respect to (i)&nbsp;any representations, warranties or agreements made by any person or entity under or in connection with the Subscription and the Transactions or any of the documents furnished pursuant thereto or in connection therewith, or the
execution, legality, validity or enforceability (with respect to any person) or any thereof, or (ii)&nbsp;the business, condition (financial and otherwise), management, operations, properties or prospects of, or any other matter concerning, FEAC,
Newco, enGene, the Subscription or the Transactions, (d)&nbsp;the Placement Agents, their respective affiliates or any control persons, officers, directors, employees, partners, agents or representatives of the Placement Agents or their respective
affiliates, shall have no liability or obligation (including without limitation, for or with respect to any losses, claims, damages, obligations, penalties, judgments, awards, liabilities, costs, expenses or disbursements incurred by Subscriber,
FEAC, Newco, enGene or any other person or entity) to the maximum extent permitted by applicable law, whether in contract, tort or otherwise, to Subscriber, FEAC, Newco, enGene or any other person or entity or to any person claiming through each of
them, in respect of the Subscription and the Transactions and (e)&nbsp;the Placement Agents and their respective affiliates and any control persons, officers, directors, employees, partners, agents or representatives of the Placement Agents and
their respective affiliates have made no independent investigation with respect to FEAC, Newco, enGene, the Subscribed Shares, the Subscription or the Transactions or the accuracy, completeness or adequacy of any information supplied to the
Placement Agents by FEAC, Newco or enGene. Subscriber further acknowledges that SVB Securities LLC and UBS Securities LLC are acting as capital markets and financial advisors to FEAC in connection with the Transactions. Subscriber waives and
releases any claim that it or its affiliates may have against any Placement Agent and its affiliates and any control persons, officers, directors, employees, partners, agents or representatives of that Placement Agent and its affiliates with respect
to any actual or perceived conflict of interest that may arise from such Placement Agent&#146;s engagements as indicated in the immediately preceding sentence, in the context of such Placement Agent&#146;s engagement by FEAC as FEAC&#146;s placement
agent in connection with the Subscription. FEAC and Newco are solely responsible for paying any fees or other commission owed to the Placement Agents in connection with the Subscription or the Transactions. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1.12. Subscriber became aware of this offering of the Subscribed Shares solely by means of direct contact between Subscriber
or one of its representatives, on the one hand, and FEAC, one of its representatives or the Placement Agents (collectively, the &#147;<B>Issuer Parties</B>&#148;) on behalf of FEAC, as the case may be, on the other hand, as a result of a <FONT
STYLE="white-space:nowrap">pre-existing</FONT> relationship between the Subscriber and one or more of the Issuer Parties. Subscriber did not become aware of this offering of the Subscribed Shares, nor were the Subscribed Shares offered to the
Subscriber, by any general solicitation or general advertising, and none of FEAC, Newco, the Placement Agents or their respective representatives or any person acting on behalf of any of them acted as investment advisor, broker or dealer to the
Subscriber. The Subscriber acknowledges that FEAC represents and warrants that the Subscribed Shares (i)&nbsp;were not offered by any form of general solicitation or general advertising, including methods described in section 502(c) of Regulation D
under and (ii)&nbsp;are not being offered in a manner involving a public offering under, or in a distribution in violation of, the Securities Act, or any state securities laws. The Subscriber acknowledges that it is not relying upon, and has not
relied upon, any statement, representation or warranty made by any person, firm or corporation (including, without limitation, FEAC, Newco, the Placement Agents, any of their respective affiliates or any control persons, officers, directors,
employees, partners, agents or representatives of any of the foregoing), other than the representations and warranties of FEAC and Newco contained in <U>Section</U><U></U><U>&nbsp;2.2</U> and <U>Section</U><U></U><U>&nbsp;2.3</U>, respectively, of
this Subscription Agreement, in making its investment or decision to invest in FEAC. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1.13. Subscriber acknowledges that
it is aware that there are substantial risks incident to the purchase and ownership of the Subscribed Shares, including those set forth in the SEC Documents (as defined below) and the investor presentation provided by FEAC (as amended and
supplemented as of the date hereof). Subscriber, alone, or together with any professional advisor(s), has analyzed and considered </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-1-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
the risks of an investment in the Subscribed Shares and determined that the Subscribed Shares are a suitable investment. Subscriber further acknowledges that Subscriber shall be responsible for
any of Subscriber&#146;s tax liabilities that may arise as a result of the transactions contemplated by this Subscription Agreement or the Business Combination Agreement, and that neither FEAC, Newco or enGene, nor any of their respective agents or
affiliates or the Placement Agents, have provided any tax advice or any other representation or guarantee, whether written or oral, regarding the tax consequences of the transactions contemplated by this Subscription Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1.14. Subscriber understands and agrees that no federal or state agency has passed upon or endorsed the merits of the
offering of the Subscribed Shares or made any findings or determination as to the fairness of an investment in the Subscribed Shares and the foregoing authorities have not confirmed the accuracy or determined the adequacy of any representation (and
any representation to the contrary is a criminal offense). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1.15. Subscriber represents and warrants that none of
Subscriber or any of its officers, directors, managers, managing members, general partners or any other person acting in a similar capacity or carrying out a similar function on its behalf is (i)&nbsp;a person or entity named on the List of
Specially Designated Nationals and Blocked Persons administered by the U.S. Treasury Department&#146;s Office of Foreign Assets Control (&#147;<B>OFAC</B>&#148;) or in any Executive Order issued by the President of the United States and administered
by OFAC or any similar list of sanctioned persons administered by the United Nations Security Council, the European Union, Canada, His Majesty&#146;s Treasury (&#147;<B>HMT</B>&#148;), any individual European Union member state or the United Kingdom
or any other relevant sanctions authority (collectively, &#147;<B>Sanctions Lists</B>&#148;) or a person or entity designated by any OFAC sanctions program, (ii)&nbsp;directly or indirectly 50% or more owned or otherwise controlled by, or acting on
behalf of, one or more persons on a Sanctions List, (iii)&nbsp;organized, incorporated, established, located or resident in, a country or territory that is the target of country-wide or territory-wide economic or trade sanctions (currently Cuba,
Iran, North Korea, Syria, the Crimea region of Ukraine, the <FONT STYLE="white-space:nowrap">so-called</FONT> Donetsk People&#146;s Republic, the <FONT STYLE="white-space:nowrap">so-called</FONT> Luhansk People&#146;s Republic and any other Covered
Region of Ukraine identified pursuant to Executive Order 14065, and <FONT STYLE="white-space:nowrap">non-government</FONT> controlled areas of the Kherson and Zaporizhia region of Ukraine), or (iv)&nbsp;a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> shell bank or providing banking services indirectly to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> shell bank. The representations, warranties and undertakings in this
<U>Section</U><U></U><U>&nbsp;2.1.15</U> will not apply to any party hereto to which Council Regulation (EC) No.&nbsp;2271/96, as amended (the &#147;<B>Blocking Regulation</B>&#148;) applies, if and to the extent that such representation, warranty
or undertaking is or would be invalid or unenforceable by reason of breach of any provision of the Blocking Regulation (or any law or regulation implementing such Blocking Regulation or any similar measure in any member state of the European Union
or the United Kingdom). If Subscriber is a financial institution subject to the Bank Secrecy Act (31 U.S.C. Section&nbsp;5311 et seq.), as amended by the USA PATRIOT Act of 2001, and its implementing regulations (collectively, the
&#147;<B>BSA/PATRIOT Act</B>&#148;), Subscriber represents that it maintains policies and procedures reasonably designed to comply with applicable obligations under the BSA/PATRIOT Act. Subscriber also represents that, to the extent required, it
maintains policies and procedures reasonably designed to ensure compliance with sanctions programs administered by OFAC, the United Nations Security Council, the European Union, Canada, HMT, any European Union member state and the United Kingdom,
including for the screening of its investors against the Sanctions Lists and the OFAC sanctions programs. Subscriber further represents and warrants that, to the extent required, it maintains policies and procedures reasonably designed to ensure
that the funds held by Subscriber and used to purchase the Subscribed Shares were legally derived. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1.16. Except as
expressly disclosed in a Schedule 13D or Schedule 13G (or amendments thereto) filed by Subscriber with the Commission with respect to the beneficial ownership of FEAC&#146;s securities, Subscriber is not currently (and at all times through the
Closing Date will refrain from being or becoming) a member of a &#147;group&#148; (within the meaning of Section&nbsp;13(d)(3) or Section&nbsp;14(d)(2) of the Exchange Act, or any successor provision) acting for the purpose of acquiring, holding or
disposing of equity securities of FEAC or Newco, as applicable (within the meaning of Rule <FONT STYLE="white-space:nowrap">13d-5(b)(1)</FONT> under the Exchange Act). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-1-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1.17. On each date the Purchase Price would be required to be funded to
FEAC (or, following the Assumption, Newco) pursuant to <U>Section</U><U></U><U>&nbsp;3.1,</U> Subscriber will have sufficient immediately available funds to pay the Purchase Price pursuant to <U>Section</U><U></U><U>&nbsp;3.1</U> and will be able to
consummate the subscription of the Subscribed Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1.18. No broker, finder or other financial consultant has acted on
behalf of Subscriber in connection with this Subscription Agreement or the transactions contemplated hereby in such a way as to create any liability on FEAC, Newco or enGene. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1.19. Subscriber agrees that, from the date of this Subscription Agreement until the Closing or the earlier termination of
this Subscription Agreement, none of Subscriber, its controlled affiliates, or any person or entity acting on behalf of Subscriber or any of its controlled affiliates or pursuant to any understanding with Subscriber or any of its controlled
affiliates will engage in any Short Sales with respect to securities of FEAC or Newco, as applicable. For the purposes hereof, &#147;<B>Short Sales</B>&#148; shall include, without limitation, all &#147;short sales&#148; as defined in Rule 200
promulgated under Regulation SHO under the Exchange Act, and all types of direct and indirect stock pledges (other than pledges in the ordinary course of business as part of prime brokerage arrangements), forward sale contracts, options, puts,
calls, swaps and similar arrangements (including on a total return basis), including through <FONT STYLE="white-space:nowrap">non-U.S.</FONT> broker dealers or foreign regulated brokers. Notwithstanding the foregoing, (a)&nbsp;nothing herein shall
prohibit any entities under common management or that share an investment advisor with Subscriber (including Subscriber&#146;s controlled affiliates and/or affiliates) that have no knowledge of this Subscription Agreement or of Subscriber&#146;s
participation in the transactions contemplated hereby from entering into any Short Sales and (b)&nbsp;in the case of a Subscriber that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such
Subscriber&#146;s assets, this <U>Section</U><U></U><U>&nbsp;2.1.19</U> shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Subscribed Shares covered by this
Subscription Agreement. For the avoidance of doubt, this <U>Section</U><U></U><U>&nbsp;2.1.19</U> shall not apply to (i)&nbsp;any sale (including the exercise of any redemption right) of securities of FEAC or Newco, as applicable (A)&nbsp;held by
Subscriber, its controlled affiliates or any person or entity acting on behalf of Subscriber or any of its controlled affiliates prior to the execution of this Subscription Agreement or (B)&nbsp;purchased by Subscriber, its controlled affiliates or
any person or entity acting on behalf of Subscriber or any of its controlled affiliates in an open market transaction after the execution of this Subscription Agreement or (ii)&nbsp;ordinary course,
<FONT STYLE="white-space:nowrap">non-speculative</FONT> hedging transactions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1.20. Subscriber acknowledges that it is
aware that in connection with, and immediately upon completion of, the Cayman Merger, each Ordinary Share of FEAC issued and outstanding immediately prior to the effective time of the Cayman Merger shall automatically be cancelled and cease to exist
in exchange for the right to receive, without interest, one Newco Common Share. Subscriber acknowledges that the above will be effected as part of the Transactions without any further consent, vote, or approvals from Subscriber, and to the extent
that Subscriber may have any such rights under Cayman Islands law, Canadian law or otherwise, Subscriber effectively forfeits such rights hereby. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1.21. The funds being used to purchase the Subscribed Shares which will be paid by the Subscriber to FEAC (or following the
Assumption, Newco) in accordance with the terms hereunder will not represent proceeds of crime for the purposes of the <I>Proceeds of Crime (Money Laundering) and Terrorist Financing Act</I> (Canada) (the &#147;<B>PCMLTFA</B>&#148;) and the
Subscriber and the beneficial subscriber, if any, acknowledges that FEAC (or following the Assumption, Newco) may in the future be required by law to disclose the Subscriber&#146;s or beneficial subscriber&#146;s name and other information relating
to this Subscription Agreement and the Subscriber&#146;s subscription hereunder, on a confidential basis, pursuant to the PCMLTFA. To the best of its knowledge,&nbsp;none of the subscription funds to be provided by the Subscriber or the beneficial
subscriber have been or will be derived from or related to any activity that is deemed criminal under the laws of Canada or any other jurisdiction or are being tendered on behalf of a person or entity who has not been identified to the Subscriber.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1.22. Subscriber acknowledges and agrees that the sale and delivery of the Subscribed Shares is subject to applicable
requirements under the securities laws and regulations of the provinces and territories </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-1-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
of Canada (&#147;<B>Canadian Securities Laws</B>&#148;) and is conditional upon such sale being exempt from the requirements of Canadian Securities Laws of the province or territory in which it
resides or may be deemed to reside as to the filing and delivery of a prospectus and that the Subscribed Shares have not been qualified under a prospectus under Canadian Securities Laws. The Subscriber acknowledges and agrees that FEAC and Newco may
rely on the prospectus exemption available in respect of the Subscription under Section&nbsp;2.11 (<I>Business combination and reorganization</I>) of National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> &#150; Prospectus Exempt
Distributions, or such other exemption or exemption ruling as it determines, upon the advice of counsel, to be advisable, in respect of the issuance and sale of the Subscribed Shares. The Subscriber acknowledges that FEAC and Newco, as of the date
hereof, are not &#147;reporting issuers&#148; in any jurisdiction in Canada, that the Subscribed Shares are subject to statutory resale restrictions under applicable Canadian Securities Laws of the province or territory in which Subscriber resides
or may be deemed to reside, which resale restrictions may apply outside of Canada, and Subscriber covenants that it will not resell the Subscribed Shares except in compliance with such laws. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1.23. Subscriber is eligible to purchase the Subscribed Shares pursuant to an exemption from the registration and prospectus
requirements of Canadian Securities Laws </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1.24. The Subscriber acknowledges and agrees that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) the Subscriber is not entitled, and will not take any action to acquire any entitlement, to vote, consent or otherwise
approve in respect of the Transactions, whether arising under this Subscription Agreement, in respect of the right to acquire the Subscribed Shares, or otherwise, and notwithstanding the foregoing, to the extent that it is so entitled to vote,
consent or otherwise approve, shall exercise such entitlement to vote, consent or otherwise right of approval in favour of the approval, consent, ratification and adoption of any resolution in respect of the Transactions (and any other matters or
actions necessary for the consummation of the Transactions contemplated by the Business Combination Agreement), including without limitation at any meeting of securityholders of FEAC, Newco or any other person or entity (including in connection with
any separate vote of any <FONT STYLE="white-space:nowrap">sub-group</FONT> of securityholders of FEAC, Newco or any other person or entity that may be required to be held and of which <FONT STYLE="white-space:nowrap">sub-group</FONT> the Subscriber
forms part) called to vote upon the Transactions or at any adjournment or postponement thereof or in any other circumstances upon which a vote, consent or other approval (including written consent in lieu of a meeting) with respect to the
Transactions is sought; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) the Subscriber shall not take any other action of any kind which would reasonably be expected
to prevent or materially delay the consummation of any of the Transactions or any other transactions contemplated by the Business Combination Agreement; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) the Subscriber waives to the fullest extent permitted by law any and all rights of appraisal, rights of dissent or similar
rights that the Subscriber may have or acquire with respect to any resolution in respect of the Transactions or any other matters or actions necessary for the consummation of the Transactions contemplated by the Business Combination Agreement, and
will not exercise any such right with respect to any such resolution which is waived hereby. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1.25. The Subscriber
acknowledges that the Placement Agents: (i)&nbsp;have not provided the Subscriber with any information or advice with respect to the Subscribed Shares, (ii)&nbsp;have not made or make any representation, express or implied as to FEAC, Newco,
Newco&#146;s credit quality, the Subscribed Shares or the Subscriber&#146;s purchase of the Subscribed Shares, (iii)&nbsp;have not acted as the Subscriber&#146;s financial advisor or fiduciary in connection with the issue and purchase of Subscribed
Shares, (iv)&nbsp;may have acquired, or during the term of this Subscription Agreement may acquire, <FONT STYLE="white-space:nowrap">non-public</FONT> information with respect to the Newco, which, subject to the requirements of applicable law, the
Subscriber agrees need not be provided to it, and (v)&nbsp;may have existing or future business relationships with FEAC and Newco (including, but not limited to, lending, depository, risk management, advisory and banking relationships) and will
pursue actions and take steps that it deems or they deem necessary or appropriate to protect its or their interests arising therefrom without regard to the consequences for a holder of Subscribed Shares, and that certain of these actions may have
material and adverse consequences for a holder of Subscribed Shares. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-1-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Subscriber acknowledges that FEAC, Newco and/or the Placement Agents and/or their respective affiliates may now or in the future own securities of FEAC and may purchase securities in connection
with the Transactions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1.26. The Subscriber acknowledges that it has not relied on the Placement Agents in connection
with its determination as to the legality of its acquisition of the Subscribed Shares or as to the other matters referred to herein and the Subscriber has not relied on any investigation that the Placement Agents, any of their affiliates or any
person acting on their behalf have conducted with respect to the Subscribed Shares, FEAC or Newco. The Subscriber further acknowledges that it has not relied on any information contained in any research reports prepared by the Placement Agents or
any of their affiliates. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1.27. The Subscriber acknowledges that neither the Placement Agents, nor any of their
respective affiliates nor any control persons, officers, directors, employees, partners, agents or representatives of any of the foregoing have made any independent investigation with respect to FEAC, Newco or its subsidiaries or any of their
respective businesses, or the Subscribed Shares or the accuracy, completeness or adequacy of any information supplied to the Subscriber by FEAC. Each Placement Agent has not made and does not make any representations as to FEAC, Newco or the quality
or value of the Subscribed Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.2. <U>FEAC</U><U>&#146;</U><U>s Representations, Warranties and Agreements</U>. To induce Subscriber
to purchase the Subscribed Shares, FEAC hereby represents and warrants to Subscriber and agrees with Subscriber, as of the date hereof and as of the Closing Date, as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.2.1. FEAC has been duly incorporated and is validly existing and in good standing under the laws of the Cayman Islands and
has all requisite power and authority to own, lease and operate its properties and conduct its business as presently conducted and to enter into, deliver and perform its obligations under this Subscription Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.2.2. This Subscription Agreement, the Other Subscription Agreements, the Business Combination Agreement and the Ancillary
Documents (collectively, the &#147;<B>Transaction Documents</B>&#148;) to which FEAC is a party have been duly authorized, validly executed and delivered by FEAC and, assuming that the Transaction Documents to which FEAC is a party constitute valid
and binding obligations of the other parties thereto, are valid and binding obligations of FEAC, and are enforceable against FEAC in accordance with their terms, except as may be limited or otherwise affected by (i)&nbsp;bankruptcy, insolvency,
fraudulent conveyance, reorganization, moratorium or other laws relating to or affecting the rights of creditors generally and (ii)&nbsp;principles of equity, whether considered at law or equity. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.2.3. Assuming the accuracy of the Subscriber&#146;s representations and warranties in <U>Section</U><U></U><U>&nbsp;2.1</U>
hereof and Newco&#146;s representations and warranties in <U>Section</U><U></U><U>&nbsp;2.3</U> hereof, the execution, delivery and performance of the Transaction Documents to which FEAC is a party (including compliance by FEAC with all of the
provisions hereof), the issuance and sale of the Subscribed Shares and the consummation of the other transactions contemplated under the Transaction Documents, including the Transactions, do not and will not (i)&nbsp;conflict with or result in a
breach or violation of any of the terms or provisions of, or constitute a default under, or result in the creation or imposition of any lien, charge or encumbrance upon any of the property or assets of FEAC or any of its subsidiaries pursuant to the
terms of any indenture, mortgage, charge, deed of trust, loan agreement, lease, license or other agreement or instrument to which FEAC or any of its subsidiaries is a party or by which FEAC or any of its subsidiaries is bound or to which any of the
property or assets of FEAC or any of its subsidiaries is subject, which would reasonably be expected to have a material adverse effect on the business, properties, financial condition, stockholders&#146; equity or results of operations of FEAC,
Newco or enGene and their respective subsidiaries, taken as a whole, or materially and adversely affects the ability of FEAC to timely perform its obligations under the Transaction Documents to which it is a party, in each case subject to the
exceptions in the definition of Company Material Adverse Effect in the Business Combination Agreement<I> mutatis mutandis </I>(collectively, a &#147;<B>FEAC Material Adverse Effect</B>&#148;), (ii) result in any violation of the provisions of the
organizational documents of FEAC or any of its subsidiaries or (iii)&nbsp;result in any violation of any statute or any judgment, order, rule or regulation of any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-1-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
court or governmental agency or body, domestic or foreign, having jurisdiction over FEAC or any of its subsidiaries or any of its properties that would, individually or in the aggregate,
reasonably be expected to have a FEAC Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.2.4. Neither FEAC, nor any person acting on its behalf
has, directly or indirectly, made any offers or sales of any security of FEAC nor solicited any offers to buy any security under circumstances that would adversely affect reliance by FEAC on Section&nbsp;4(a)(2) of the Securities Act for the
exemption from registration for the transactions contemplated hereby or would require registration or qualification of the issuance of the Subscribed Shares under the Securities Act or a prospectus under Canadian Securities Laws. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.2.5. Except for the Placement Agents, no broker or finder is entitled to any brokerage or finder&#146;s fee or commission
from FEAC solely in connection with the sale of the Subscribed Shares to the Subscriber. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.2.6. Neither FEAC, nor any
person acting on its behalf has conducted any general solicitation or general advertising, including methods described in section 502(c) of Regulation D under the Securities Act, in connection with the offer or sale of any of the Subscribed Shares
and neither FEAC, nor any person acting on its behalf has offered any of the Subscribed Shares in a manner involving a public offering under, or in a distribution in violation of, the Securities Act, any state securities laws or any Canadian
Securities Laws. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.2.7. Concurrently with the execution and delivery of this Subscription Agreement, FEAC is entering into
the Other Subscription Agreements containing substantially similar terms (including the Per Share Price term) as this Subscription Agreement, providing for the sale of an aggregate of 5,550,408 Ordinary Shares (or, following the Assumption, Newco
Common Shares) for an aggregate purchase price of $56,891,682.00 (including the Subscribed Shares purchased and sold under this Subscription Agreement). No Other Subscription Agreement, side letter or similar agreement with an Other Subscriber
contains terms (including the Per Share Price term) that are materially more advantageous to such Other Subscriber thereunder than the terms of this Subscription Agreement (other than terms particular to the regulatory requirements of such Other
Subscriber or its affiliates or related funds that are mutual funds or are otherwise subject to regulations related to the timing of funding and the issuance of the related Ordinary Shares (or, following the Assumption, Newco Common Shares)). The
Other Subscription Agreements have not been amended in any material respect following the date of this Subscription Agreement to include terms that are materially more advantageous to any Other Subscriber thereunder than the terms of this
Subscription Agreement (other than terms particular to the regulatory requirements of such Other Subscriber or its affiliates or related funds that are mutual funds or are otherwise subject to regulations related to the timing of funding and the
issuance of the related Ordinary Shares (or, following the Assumption, Newco Common Shares)). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.2.8. Assuming the accuracy
of Subscriber&#146;s representations and warranties set forth in <U>Section</U><U></U><U>&nbsp;2.1</U>, no registration or qualification under the Securities Act or a prospectus under applicable Canadian Securities Laws is required for the offer and
sale of the Subscribed Shares by FEAC to Subscriber. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.2.9. There are no pending or, to the knowledge of FEAC, threatened,
suits, claims, actions, or proceedings, which, if determined adversely, would, individually or in the aggregate, reasonably be expected to have a FEAC Material Adverse Effect. There is no unsatisfied judgment, any open injunction, or any decree,
ruling or order of any governmental authority or arbitrator outstanding against or binding upon FEAC, which would, individually or in the aggregate, reasonably be expected to have a FEAC Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.2.10. Assuming the accuracy of Subscriber&#146;s representations and warranties set forth in
<U>Section</U><U></U><U>&nbsp;2.1</U>, FEAC is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental
authority, self-regulatory organization or other person in connection with the execution, delivery and performance by FEAC of this Subscription Agreement (including, without limitation, the issuance of the Subscribed Shares), other than
(i)&nbsp;filings with the United States Securities and Exchange Commission (the &#147;<B>Commission</B>&#148;), (ii) filings required by applicable state or federal securities laws, including filings pursuant
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-1-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
to Regulation D under the Securities Act, (iii)&nbsp;filings required in accordance with <U>Section</U><U></U><U>&nbsp;4</U>, (iv) filings required by applicable Canadian Securities Laws,
(v)&nbsp;filings required to consummate the Transactions as provided under the Business Combination Agreement, (vi)&nbsp;those required by The Nasdaq Stock Market LLC (the &#147;<B>Nasdaq</B>&#148;) or other national securities exchange registered
under the Exchange Act (an &#147;<B>Exchange</B>&#148;), as applicable, and (vii)&nbsp;filings, the failure of which to obtain would not be reasonably be expected to have, individually or in the aggregate, a FEAC Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.2.11. FEAC made available to Subscriber (including via the Commission&#146;s EDGAR system) a true, correct and complete copy
of each form, report, statement, schedule, prospectus, proxy, registration statement and other documents filed by FEAC with the Commission prior to the date of this Subscription Agreement (the &#147;<B>SEC Documents</B>&#148;), which SEC Documents,
as of their respective filing dates, complied in all material respects with the requirements of the Exchange Act applicable to the SEC Documents and the rules and regulations of the Commission promulgated thereunder and applicable to the SEC
Documents. As of their respective dates, all SEC Documents required to be filed by FEAC with the Commission prior to the date hereof complied in all material respects with the applicable requirements of the Securities Act and the Exchange Act and
the rules and regulations of the Commission promulgated thereunder. None of the SEC Documents filed under the Exchange Act, contained, when filed or, if amended prior to the date of this Subscription Agreement, as of the date of such amendment with
respect to those disclosures that are amended, any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were
made, not misleading; <U>provided</U> that FEAC makes no such representation or warranty with respect to the registration statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> to be filed with respect to the Transactions or any other
information relating to Newco, enGene or any of their affiliates included in any SEC Document or filed as an exhibit thereto. FEAC has filed each report, statement, schedule, prospectus, and registration statement that FEAC was required to file with
the Commission since its inception and through the date hereof. There are no material outstanding or unresolved comments in comment letters from the Commission staff with respect to any of the SEC Documents. The financial statements of FEAC included
in the SEC Documents complied in all material respects with applicable accounting requirements and the rules and regulations of the Commission with respect thereto as in effect at the time of filing and fairly present in all material respects the
financial condition of FEAC as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, <FONT STYLE="white-space:nowrap">year-end</FONT> audit
adjustments, and such financial statements have been prepared in conformity with GAAP applied on a consistent basis during the periods involved (except as may be disclosed therein or in the notes thereto, and except that the unaudited financial
statements may not contain all footnotes required by GAAP); except, in each case, as set forth in any subsequent SEC Document filed or furnished with the Commission on or prior to the date hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.2.12. FEAC is not, and immediately after receipt of payment for the Subscribed Shares will not be, an &#147;investment
company&#148; within the meaning of the Investment Company Act of 1940, as amended. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.2.13. FEAC is not (i)&nbsp;a person
or entity named on any Sanctions List, (ii)&nbsp;directly or indirectly 50% or more owned or otherwise controlled by, or acting on behalf of, one or more persons on a Sanctions List, (iii)&nbsp;organized, incorporated, established or located in a
country or territory that is the target of country-wide or territory-wide economic or trade sanctions (currently Cuba, Iran, North Korea, Syria, the Crimea region of Ukraine, the <FONT STYLE="white-space:nowrap">so-called</FONT> Donetsk
People&#146;s Republic, the <FONT STYLE="white-space:nowrap">so-called</FONT> Luhansk People&#146;s Republic and any other Covered Region of Ukraine identified pursuant to Executive Order 14065, and
<FONT STYLE="white-space:nowrap">non-government</FONT> controlled areas of the Kherson and Zaporizhia region of Ukraine) or (iv)&nbsp;a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> shell bank or providing banking services indirectly to a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> shell bank. The representations, warranties and undertakings in this <U>Section</U><U></U><U>&nbsp;2.2.13</U> will not apply to any party hereto to which the Blocking Regulation applies, if and to the
extent that such representation, warranty or undertaking is or would be invalid or unenforceable by reason of breach of any provision of the Blocking Regulation (or any law or regulation implementing such Blocking Regulation or any similar measure
in any member state of the European Union or the United Kingdom). If FEAC is a financial institution subject to the BSA/PATRIOT Act, FEAC represents that it maintains policies and procedures reasonably designed to comply with applicable obligations
under the BSA/</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-1-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
PATRIOT Act. FEAC also represents that, to the extent required, it maintains policies and procedures reasonably designed to ensure compliance with sanctions programs administered by OFAC, the
United Nations Security Council, the European Union, Canada, HMT, any European Union member state and the United Kingdom, including for the screening of its investors against the Sanctions List and the OFAC sanctions programs. FEAC further
represents and warrants that, to the extent required, it maintains policies and procedures reasonably designed to ensure that the funds held by FEAC were legally derived. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.2.14. FEAC is not in default or violation (and no event has occurred which, with notice or the lapse of time or both, would
constitute a default or violation) of any term, condition or provision of (i)&nbsp;the organizational documents of FEAC, (ii)&nbsp;any loan or credit agreement, guarantee, note, bond, mortgage, indenture, lease or other agreement, permit, franchise
or license to which, as of the date of this Subscription Agreement, FEAC is a party or by which FEAC&#146;s properties or assets are bound or (iii)&nbsp;any statute or any judgment, order, rule or regulation of any court or governmental agency,
taxing authority or regulatory body, domestic or foreign, having jurisdiction over FEAC or any of its properties, except, in the case of clauses (ii)&nbsp;and (iii), for defaults or violations that have not had and would not be reasonably likely to
have, individually or in the aggregate, a FEAC Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.2.15. FEAC is in compliance with all applicable
laws, except where such <FONT STYLE="white-space:nowrap">non-compliance</FONT> would not be reasonably likely to have a FEAC Material Adverse Effect. FEAC has not received any written communication from a governmental entity that alleges that FEAC
is not in compliance with or is in default or violation of any applicable law, except where such <FONT STYLE="white-space:nowrap">non-</FONT> compliance, default or violation would not, individually or in the aggregate, reasonably be expected to
have a FEAC Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.2.16. As of the date hereof, the issued and outstanding Ordinary Shares are
registered pursuant to Section&nbsp;12(b) of the Exchange Act, and are listed for trading on Nasdaq under the symbol &#147;FRBN&#148;. There is no suit, action, proceeding or investigation pending or, to the knowledge of FEAC, threatened against
FEAC by Nasdaq or the Commission with respect to any intention by such entity to deregister the Ordinary Shares or prohibit or terminate the listing of the Ordinary Shares on Nasdaq. FEAC has taken no action that is designed to terminate the
registration of the Ordinary Shares under the Exchange Act or the listing of the Ordinary Shares on Nasdaq. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.2.17. All
issued and outstanding FEAC Shares have been duly authorized and validly issued, are fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and are not subject to preemptive or similar rights and all outstanding FEAC Warrants have
been duly authorized and validly issued, are fully paid and are not subject to preemptive or similar rights.&nbsp;There are no shareholder agreements, voting trusts or other agreements or understandings to which FEAC is a party or by which it is
bound relating to the voting of any securities of FEAC, other than as contemplated by or described in, as applicable, the Transactions, the Transaction Documents or the SEC Documents. Except as contemplated by or described in, as applicable, the
Transactions, the Transaction Documents or the SEC Documents, there are no securities or instruments issued by or to which FEAC is a party containing anti-dilution or similar provisions that will be triggered, and not fully waived by the holder of
such securities or instruments pursuant to a written agreement or consent, by the issuance of (i)&nbsp;the Subscribed Shares, (ii)&nbsp;the shares to be issued pursuant to any Other Subscription Agreement or (iii)&nbsp;the consummation of the
Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.3. <U>Newco</U><U>&#146;</U><U>s Representations, Warranties and Agreements</U>. To induce Subscriber to purchase the
Subscribed Shares, Newco hereby represents and warrants to Subscriber and agrees with Subscriber, as of the date hereof and as of the Closing Date, as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.3.1. Newco has been duly incorporated and is validly existing and in good standing under the laws of Canada (provided that,
following the Continuance, Newco shall be validly continued and validly existing and in good standing under the laws of the Province of British Columbia), and has all requisite power and authority to own, lease and operate its properties and conduct
its business as presently conducted and to enter into, deliver and perform its obligations under the Transaction Documents to which it is party. At the Closing Date, the Subscribed Shares will be duly authorized and, when issued and delivered to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-1-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Subscriber against full payment for the Subscribed Shares, will be free and clear of any liens or other restrictions (other than arising under applicable securities laws) in accordance with the
terms of this Subscription Agreement and registered with Newco&#146;s transfer agent, and the Subscribed Shares will be validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and will not have been issued in violation
of or subject to any preemptive or similar rights under Newco&#146;s constitutive agreements, under any agreement or instrument to which Newco is a party or by which Newco is bound, or under applicable law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.3.2. The Transaction Documents to which Newco is a party have been duly authorized, validly executed and delivered by Newco
and, assuming that the Transaction Documents to which Newco is a party constitute valid and binding obligations of the other parties thereto, are valid and binding obligations of Newco, and are enforceable against Newco in accordance with their
terms, except as may be limited or otherwise affected by (i)&nbsp;bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium or other laws relating to or affecting the rights of creditors generally and (ii)&nbsp;principles of equity,
whether considered at law or equity. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.3.3. Assuming the accuracy of the Subscriber&#146;s representations and warranties
in <U>Section</U><U></U><U>&nbsp;2.1</U> hereof and FEAC&#146;s representations and warranties in <U>Section</U><U></U><U>&nbsp;2.2</U> hereof, the execution, delivery and performance of the Transaction Documents to which Newco is a party (including
compliance by Newco with all of the provisions hereof), the issuance and sale of the Subscribed Shares and the consummation of the other transactions contemplated herein, including the Transactions, do not and will not (i)&nbsp;conflict with or
result in a breach or violation of any of the terms or provisions of, or constitute a default under, or result in the creation or imposition of any lien, charge or encumbrance upon any of the property or assets of Newco or any of its subsidiaries
pursuant to the terms of any indenture, mortgage, charge, deed of trust, loan agreement, lease, license or other agreement or instrument to which Newco or any of its subsidiaries is a party or by which Newco or any of its subsidiaries is bound or to
which any of the property or assets of Newco or any of its subsidiaries is subject, which would reasonably be expected to have a material adverse effect on the business, properties, financial condition, shareholders&#146; equity or results of
operations of Newco, FEAC or enGene and their respective subsidiaries, taken as a whole, or materially and adversely affects the ability of Newco to timely perform its obligations under the Transaction Documents to which it is a party, in each case
subject to the exceptions in the definition of Company Material Adverse Effect in the Business Combination Agreement<I> mutatis mutandis </I>(collectively, a &#147;<B>Newco Material Adverse Effect</B>&#148;), (ii) result in any violation of the
provisions of the organizational documents of Newco or any of its subsidiaries or (iii)&nbsp;result in any violation of any statute or any judgment, order, rule or regulation of any court or governmental agency or body, domestic or foreign, having
jurisdiction over Newco or any of its subsidiaries or any of its properties that would, individually or in the aggregate, reasonably be expected to have a Newco Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.3.4. Neither Newco, nor any person acting on its behalf has, directly or indirectly, made any offers or sales of any security
of Newco nor solicited any offers to buy any security under circumstances that would adversely affect reliance by Newco on Section&nbsp;4(a)(2) of the Securities Act for the exemption from registration for the transactions contemplated hereby or
would require registration or qualification of the issuance of the Subscribed Shares under the Securities Act or a prospectus under Canadian Securities Laws. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.3.5. Except for the Placement Agents, no broker or finder is entitled to any brokerage or finder&#146;s fee or commission
from Newco solely in connection with the sale of the Subscribed Shares to the Subscriber. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.3.6. Neither Newco, nor any
person acting on its behalf has conducted any general solicitation or general advertising, including methods described in section 502(c) of Regulation D under the Securities Act, in connection with the offer or sale of any of the Subscribed Shares
and neither Newco, nor any person acting on its behalf has offered any of the Subscribed Shares in a manner involving a public offering under, or in a distribution in violation of, the Securities Act, any state securities laws or any Canadian
Securities Laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-1-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.3.7. Concurrently with the execution and delivery of this Subscription
Agreement, Newco is entering into the Other Subscription Agreements containing substantially similar terms (including the Per Share Price term) as this Subscription Agreement, providing for the sale of an aggregate of 5,550,408 Ordinary Shares (or,
following the Assumption, Newco Common Shares) for an aggregate purchase price of $56,891,682.00 (including the Subscribed Shares purchased and sold under this Subscription Agreement). No Other Subscription Agreement, side letter or similar
agreement with a similarly situated Other Subscriber contains terms (including the Per Share Price term) that are materially more advantageous to such similarly situated Other Subscriber thereunder than the terms of this Subscription Agreement
(other than terms particular to the regulatory requirements of such Other Subscriber or its affiliates or related funds that are mutual funds or are otherwise subject to regulations related to the timing of funding and the issuance of the related
Ordinary Shares (or, following the Assumption, Newco Common Shares)). The Other Subscription Agreements have not been amended in any material respect following the date of this Subscription Agreement to include terms that are materially more
advantageous to any similarly situated Other Subscriber thereunder than the terms of this Subscription Agreement (other than terms particular to the regulatory requirements of such Other Subscriber or its affiliates or related funds that are mutual
funds or are otherwise subject to regulations related to the timing of funding and the issuance of the related Ordinary Shares (or, following the Assumption, Newco Common Shares)). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.3.8. As of the date of this Subscription Agreement and as of the date immediately prior to the Cayman Merger, Newco has two
classes of authorized common shares, class A common shares and class B common shares, of which 10 (ten) class B common shares have been issued and are outstanding. All issued and outstanding common shares of Newco have been duly authorized and
validly issued, are fully paid, <FONT STYLE="white-space:nowrap">non-assessable</FONT> and are not subject to preemptive or similar rights. There are no shareholder agreements, voting trusts or other agreements or understandings to which Newco is a
party or by which it is bound relating to the voting of any securities of Newco, other than as contemplated by the Transaction Documents to which Newco is a party. Except as described in&nbsp;the Transaction Documents, there are no securities or
instruments issued by or to which Newco is a party containing anti-dilution or similar provisions that will be triggered, and not fully waived by the holder of such securities or instruments pursuant to a written agreement or consent, by the
issuance of (i)&nbsp;the Subscribed Shares,&nbsp;(ii) the shares to be issued pursuant to any Other Subscription Agreement or (iii)&nbsp;the consummation of the Transactions. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.3.9. There are no pending or, to the knowledge of Newco, threatened, suits, claims, actions, or proceedings, which, if
determined adversely, would, individually or in the aggregate, reasonably be expected to have a Newco Material Adverse Effect. There is no unsatisfied judgment, any open injunction, or any decree, ruling or order of any governmental authority or
arbitrator outstanding against or binding upon Newco, which would, individually or in the aggregate, reasonably be expected to have a Newco Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.3.10. Assuming the accuracy of Subscriber&#146;s representations and warranties set forth in
<U>Section</U><U></U><U>&nbsp;2.1</U>, Newco is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental
authority, self-regulatory organization or other person in connection with the execution, delivery and performance by Newco of this Subscription Agreement (including, without limitation, the issuance of the Subscribed Shares), other than
(i)&nbsp;filings with the Commission, (ii)&nbsp;filings required by applicable state or federal securities laws, including filings pursuant to Regulation D under the Securities Act, (iii)&nbsp;filings required in accordance with
<U>Section</U><U></U><U>&nbsp;4</U>, (iv) filings required by applicable Canadian Securities Laws, (v)&nbsp;filings required to consummate the Transactions as provided under the Business Combination Agreement, (vi)&nbsp;those required by Nasdaq or
other Exchange, as applicable, and (vii)&nbsp;filings, the failure of which to obtain would not be reasonably be expected to have, individually or in the aggregate, a Newco Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.3.11. Newco is not, and immediately after receipt of payment for the Subscribed Shares will not be, an &#147;investment
company&#148; within the meaning of the Investment Company Act of 1940, as amended. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-1-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.3.12. Newco is not (i)&nbsp;a person or entity named on any Sanctions
List, (ii)&nbsp;directly or indirectly 50% or more owned or otherwise controlled by, or acting on behalf of, one or more persons on a Sanctions List, (iii)&nbsp;organized, incorporated, established or located in a country or territory that is the
target of country-wide or territory-wide economic or trade sanctions (currently Cuba, Iran, North Korea, Syria, the Crimea region of Ukraine, the <FONT STYLE="white-space:nowrap">so-called</FONT> Donetsk People&#146;s Republic, the <FONT
STYLE="white-space:nowrap">so-called</FONT> Luhansk People&#146;s Republic and any other Covered Region of Ukraine identified pursuant to Executive Order 14065, and <FONT STYLE="white-space:nowrap">non-government</FONT> controlled areas of the
Kherson and Zaporizhia region of Ukraine) or (iv)&nbsp;a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> shell bank or providing banking services indirectly to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> shell bank. The representations,
warranties and undertakings in this <U>Section&nbsp;2.3.12</U> will not apply to any party hereto to which the Blocking Regulation applies, if and to the extent that such representation, warranty or undertaking is or would be invalid or
unenforceable by reason of breach of any provision of the Blocking Regulation (or any law or regulation implementing such Blocking Regulation or any similar measure in any member state of the European Union or the United Kingdom). If Newco is a
financial institution subject to the BSA/PATRIOT Act, Newco represents that it maintains policies and procedures reasonably designed to comply with applicable obligations under the BSA/PATRIOT Act. Newco also represents that, to the extent required,
it maintains policies and procedures reasonably designed to ensure compliance with sanctions programs administered by OFAC, the United Nations Security Council, the European Union, Canada, HMT, any European Union member state and the United Kingdom,
including for the screening of its investors against the Sanctions List and the OFAC sanctions programs. Newco further represents and warrants that, to the extent required, it maintains policies and procedures reasonably designed to ensure that the
funds held by Newco were legally derived. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.3.13. Newco is not in default or violation (and no event has occurred which,
with notice or the lapse of time or both, would constitute a default or violation) of any term, condition or provision of (i)&nbsp;the organizational documents of Newco, (ii)&nbsp;any loan or credit agreement, guarantee, note, bond, mortgage,
indenture, lease or other agreement, permit, franchise or license to which, as of the date of this Subscription Agreement, Newco is a party or by which Newco&#146;s properties or assets are bound or (iii)&nbsp;any statute or any judgment, order,
rule or regulation of any court or governmental agency, taxing authority or regulatory body, domestic or foreign, having jurisdiction over Newco or any of its properties, except, in the case of clauses (ii)&nbsp;and (iii), for defaults or violations
that have not had and would not be reasonably likely to have, individually or in the aggregate, a Newco Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.3.14. Newco is in compliance with all applicable laws, except where such
<FONT STYLE="white-space:nowrap">non-compliance</FONT> would not be reasonably likely to have a Newco Material Adverse Effect. Newco has not received any written communication from a governmental entity that alleges that Newco is not in compliance
with or is in default or violation of any applicable law, except where such <FONT STYLE="white-space:nowrap">non-compliance,</FONT> default or violation would not, individually or in the aggregate, reasonably be expected to have a Newco Material
Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Settlement Date and Delivery</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.1. <U>Closing</U>. The Closing shall occur on the Closing Date, subject to the completion of the other parts of the Transactions (other than
those Transactions that are scheduled to be completed following the Amalgamation Closing), including the substantially concurrent occurrence of the Amalgamation Closing. Upon written notice from (or on behalf of) FEAC to Subscriber (the
&#147;<B>Closing Notice</B>&#148;) at least five (5)&nbsp;Business Days prior to the date that FEAC reasonably expects all conditions to the Amalgamation Closing to be satisfied (the &#147;<B>Expected Closing Date</B>&#148;), Subscriber shall
deliver to FEAC no later than two (2)&nbsp;Business Days prior to the Expected Closing Date (i)&nbsp;the Purchase Price for the Subscribed Shares by wire transfer of United States dollars in immediately available funds to the account specified by
FEAC in the Closing Notice, such funds to be held by FEAC in escrow, segregated from and not <FONT STYLE="white-space:nowrap">co-mingled</FONT> with the other funds of FEAC (and in no event will such funds be held in the Trust Account) for the
benefit of Subscriber until the Closing at which point the funds shall be released to Newco at the time of the PIPE Financing; and (ii)&nbsp;any other information that is reasonably requested in the Closing Notice in order for FEAC (or, following
the Assumption, Newco) to issue the Subscribed Shares including, without limitation, the legal name of the person in whose name such Subscribed Shares are to be issued, and if applicable, a duly executed Internal Revenue Service Form <FONT
STYLE="white-space:nowrap">W-9</FONT> or the applicable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-1-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Internal Revenue Service Form <FONT STYLE="white-space:nowrap">W-8,</FONT> as applicable. On the Closing Date, following and subject to the Assumption, Newco shall issue to Subscriber (or the
funds and accounts designated by Subscriber if so designated by Subscriber, or its nominee in accordance with its delivery instructions) or to a custodian designated by Subscriber, as applicable, the Subscribed Shares, free and clear of any liens or
other restrictions whatsoever (other than those arising under state or federal securities laws or Canadian securities laws), which Subscribed Shares, unless otherwise determined by FEAC (or following the Assumption, Newco), shall be uncertificated,
with record ownership reflected only in the register of shareholders of Newco and shall provide evidence of such issuance from Newco&#146;s transfer agent showing Subscriber as the owner of the Subscribed Shares on and as of the Closing Date within
two (2)&nbsp;Business Days of the Closing Date. If the Transactions (other than those Transactions that are scheduled to be completed following the Amalgamation Closing) are not consummated within two (2)&nbsp;Business Days after the Expected
Closing Date, FEAC shall promptly (but no later than one (1)&nbsp;Business Day thereafter) return the Purchase Price to Subscriber by wire transfer of United States dollars in immediately available funds to an account specified by Subscriber, and
any Subscribed Shares that had been issued shall be cancelled. Notwithstanding such return, (i)&nbsp;a failure to close on the Expected Closing Date shall not, by itself, be deemed to be a failure of any of the conditions to Closing set forth in
this <U>Section</U><U></U><U>&nbsp;3</U> to be satisfied or waived on or prior to the Closing Date, and (ii)&nbsp;unless and until this Subscription Agreement is terminated in accordance with <U>Section</U><U></U><U>&nbsp;5</U> hereof, Subscriber
shall remain obligated (A)&nbsp;to redeliver funds on the new Closing Date to FEAC following FEAC&#146;s delivery to Subscriber of a new Closing Notice and (B)&nbsp;to consummate the Closing upon satisfaction of the conditions set forth in this
<U>Section</U><U></U><U>&nbsp;3</U>. For purposes of this Subscription Agreement, &#147;<B>Business Day</B>&#148; means a day, other than a Saturday or Sunday, on which commercial banks in New York, New York and Toronto, Ontario are open for the
general transaction of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.2. <U>Conditions to Closing of FEAC and Newco</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">FEAC&#146;s (or following the Assumption, Newco&#146;s) obligations to sell and issue the Subscribed Shares at the Closing are subject to the
fulfillment or (to the extent permitted by applicable law) written waiver by FEAC (or following the Assumption, Newco), on or prior to the Closing Date, of each of the following conditions: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.2.1. <U>Representations and Warranties Correct</U>. The representations and warranties made by Subscriber in
<U>Section</U><U></U><U>&nbsp;2.1</U> hereof shall be true and correct in all material respects when made (unless they specifically speak as of another date in which case they shall be true and correct in all material respects as of such date)
(other than representations and warranties that are qualified as to materiality or Subscriber Material Adverse Effect, which representations and warranties shall be true and correct in all respects), and shall be true and correct in all material
respects on and as of the Closing Date (unless they specifically speak as of another date in which case they shall be true and correct in all material respects as of such date) (other than representations and warranties that are qualified as to
materiality or Subscriber Material Adverse Effect, which representations and warranties shall be true in all respects) with the same force and effect as if they had been made on and as of said date, but in each case without giving effect to the
Amalgamation Closing. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.2.2. <U>Compliance with Covenants</U>. Subscriber shall have performed, satisfied and complied in
all material respects with the covenants, agreements and conditions required by this Subscription Agreement to be performed, satisfied or complied with by Subscriber at or prior to the Closing. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.2.3. <U>Closing of the Transactions</U>. All conditions precedent to the Amalgamation Closing set forth in the Business
Combination Agreement shall have been satisfied or waived by the party entitled to the benefit thereof under the Business Combination Agreement, and the Cayman Merger has been consummated. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.2.4. <U>Legality</U>. There shall not be in force any order, judgment, injunction, decree, writ, stipulation, determination
or award, in each case, entered by or with any governmental authority, statute, rule or regulation enjoining or prohibiting the consummation of the transactions contemplated by this Subscription Agreement or the Transactions and no such governmental
authority shall have instituted or threatened in writing a proceeding seeking to impose any such restraint or prohibition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-1-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.2.5. <U>Regulatory Approvals</U>. FEAC shall have obtained all required
regulatory approvals (including those that may be required under the securities laws of the United States or Canadian Securities Laws) to permit the completion of the transactions contemplated hereby. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.2.6. <U>No Registration or Prospectus Requirements</U>. The offer, issue, sale and delivery of the Subscribed Shares shall be
exempt from any applicable requirements to file a registration statement or prospectus or deliver an offering memorandum (as defined in applicable securities laws, including securities laws of the United States or Canadian Securities Laws) or any
similar document under applicable securities laws, including securities laws of the United States or Canadian Securities Laws, or FEAC or Newco shall have received such orders, consents or approvals as may be required to permit such sale without the
requirement of filing a registration statement or prospectus or delivering an offering memorandum or any similar document. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.3.
<U>Conditions to Closing of Subscriber</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subscriber&#146;s obligation to purchase the Subscribed Shares at the Closing is subject to
the fulfillment or (to the extent permitted by applicable law) written waiver by Subscriber, on or prior to the Closing Date, of each of the following conditions: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.3.1. <U>Representations and Warranties Correct</U>. The representations and warranties made by FEAC in
<U>Section</U><U></U><U>&nbsp;2.2</U> and Newco in <U>Section</U><U></U><U>&nbsp;2.3</U> hereof shall be true and correct in all material respects when made (unless they specifically speak as of another date in which case they shall be true and
correct in all material respects as of such date) (other than representations and warranties that are qualified as to materiality or FEAC Material Adverse Effect or Newco Material Adverse Effect, which representations and warranties shall be true
and correct in all respects), and shall be true and correct in all material respects on and as of the Closing Date (unless they specifically speak as of another date in which case they shall be true and correct in all material respects as of such
date) (other than representations and warranties that are qualified as to materiality or FEAC Material Adverse Effect or Newco Material Adverse Effect, which representations and warranties shall be true and correct in all respects) with the same
force and effect as if they had been made on and as of said date, but in each case without giving effect to the Amalgamation Closing. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.3.2. <U>Compliance with Covenants</U>. Each of FEAC and Newco shall have performed, satisfied and complied in all respects
with the covenants, agreements and conditions required by this Subscription Agreement to be performed, satisfied or complied with by FEAC and Newco at or prior to the Closing, except where the failure of such performance or compliance would not or
would not reasonably be expected to prevent, materially delay, or materially impair the ability of FEAC and Newco to consummate the Closing. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.3.3. <U>Closing of the Transactions</U>. All conditions precedent to the Transactions (other than those Transactions that are
scheduled to be completed following the Amalgamation Closing) set forth in the Business Combination Agreement or other relevant transaction agreements shall have been satisfied or waived by the party entitled to the benefit thereof under the
Business Combination Agreement. Except to the extent consented to in writing by Subscriber (which consent is not to be unreasonably withheld, conditioned or delayed), the Business Combination Agreement (as filed with the Commission on or shortly
after the date hereof) shall not have been amended, modified, supplemented or waived in a manner that would reasonably be expected to materially and adversely affect the economic benefits that Subscriber would reasonably expect to receive under this
Subscription Agreement in a manner disproportionate to other shareholders of FEAC or Newco. Newco shall have assumed all of the obligations of FEAC hereunder in accordance with Section&nbsp;6.6 hereof (including, for the avoidance of doubt, standing
in the place of the &#147;FEAC&#148; for purposes of <U>Section</U><U></U><U>&nbsp;4</U> hereunder). There shall have been no amendment, waiver or modification to the Other Subscription Agreements that materially benefits any such Other Subscriber
thereunder (other than terms particular to the legal or regulatory requirements of such Other Subscriber or its affiliates or related persons) unless Subscriber has been offered substantially the same benefits. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-1-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.3.4. <U>Legality</U>. There shall not be in force any order, judgment,
injunction, decree, writ, stipulation, determination or award, in each case, entered by or with any governmental authority, statute, rule or regulation enjoining or prohibiting consummation of the transactions contemplated by this Subscription
Agreement or the Transactions and no such governmental authority shall have instituted or threatened in writing a proceeding seeking to impose any such restraint or prohibition. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.3.5. <U>Listing</U>. No suspension of the qualification of the Ordinary Shares for offering or sale or trading in any
jurisdiction, and no suspension or removal from listing of the Ordinary Shares on Nasdaq or other Exchange, as applicable, and no initiation or threatening of any proceedings for any of such purposes or delisting, shall have occurred, and the
Subscribed Shares shall be approved for listing on Nasdaq or other Exchange, as applicable, subject to official notice of issuance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.4.
From the date hereof until the Closing Date, FEAC shall provide prompt written notice to Subscriber of any (i)&nbsp;amendment, modification or waiver of any provision of the Business Combination Agreement that would reasonably be expected to
materially and adversely affect the economic benefits that Subscriber, FEAC or Newco would reasonably expect to receive under this Subscription Agreement or (ii)&nbsp;any declaration by FEAC of a FEAC Material Adverse Effect or Newco of a Company
Material Adverse Effect (as defined in the Business Combination Agreement) under the Business Combination Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Registration
Statement</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.1. FEAC (or subject to and in accordance with the Assumption, Newco) agrees that, as soon as practicable, but in no
event later than fifteen (15)&nbsp;Business Days after the Closing Date (the date on which the Registration Statement is filed, the &#147;<B>Filing Date</B>&#148;), it shall use its commercially reasonable efforts to file with the Commission (at
FEAC&#146;s sole cost and expense) a registration statement (the &#147;<B>Registration Statement</B>&#148;) registering the resale of the Subscribed Shares and/or any other equity security (of FEAC, any successor entity or otherwise) issued or
issuable with respect to the Subscribed Shares by way of share split, dividend, distribution, recapitalization, merger, exchange, replacement or similar event or otherwise (the &#147;<B>Registrable Securities</B>&#148;), and FEAC shall use its
commercially reasonable efforts to have the Registration Statement declared effective as soon as practicable after the filing thereof, but no later than the 60th calendar day (or 90th calendar day if the Staff of the Commission notifies FEAC that it
will &#147;review&#148; the Registration Statement) following the Closing Date (the date on which the Registration Statement is declared effective, the &#147;<B>Effectiveness Date</B>&#148;); <U>provided</U>, <U>however</U>, that FEAC&#146;s
obligations to include the Registrable Securities in the Registration Statement are contingent upon Subscriber furnishing a completed and executed selling shareholders questionnaire in customary form to FEAC that contains the information required by
Commission rules for a Registration Statement regarding Subscriber, the securities of FEAC held by Subscriber and the intended method of disposition of the Registrable Securities to effect the registration of the Registrable Securities, and
Subscriber shall execute such documents in connection with such registration as FEAC may reasonably request that are customary of a selling stockholder in similar situations, including providing that FEAC shall be entitled to postpone and suspend
the effectiveness or use of the Registration Statement, if applicable, as permitted hereunder; <U>provided</U>, that Subscriber shall not in connection with the foregoing be required to execute any <FONT STYLE="white-space:nowrap">lock-up</FONT> or
similar agreement or otherwise be subject to any contractual restriction on the ability to transfer the Registrable Securities, and unless otherwise agreed to in writing by Subscriber prior to the filing of the Registration Statement, Subscriber
shall not be identified as a statutory underwriter in the Registration Statement; <U>provided</U>, that if the Commission requests that Subscriber be identified as a statutory underwriter in the Registration Statement, Subscriber will have the
opportunity to withdraw from the Registration Statement upon its prompt written request to FEAC. For purposes of clarification, any failure by FEAC to file the Registration Statement by the Filing Date or to effect such Registration Statement by the
Effectiveness Date shall not otherwise relieve FEAC of its obligations to file or effect the Registration Statement as set forth above in this <U>Section</U><U></U><U>&nbsp;4</U>. For purposes of this <U>Section</U><U></U><U>&nbsp;4</U>,
&#147;Subscriber&#148; shall include any person to which the rights under this <U>Section</U><U></U><U>&nbsp;4</U> shall have been duly assigned. FEAC will use its commercially reasonable efforts to provide a draft of the Registration Statement to
Subscriber for review at least two (2)&nbsp;Business Days in advance of filing the Registration Statement; <U>provided</U><I> </I>that, for the avoidance of doubt, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-1-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in no event shall FEAC be required to delay or postpone the filing of such Registration Statement as a result of or in connection with the Subscriber&#146;s review. Notwithstanding the foregoing,
if the Commission prevents FEAC from including any or all of the Registrable Securities proposed to be registered for resale under the Registration Statement due to limitations on the use of Rule 415 of the Securities Act for the resale of the
Registrable Securities by the applicable shareholders or otherwise, (i)&nbsp;such Registration Statement shall register for resale such number of Subscribed Shares which is equal to the maximum number of Subscribed Shares as is permitted by the
Commission and (ii)&nbsp;the number of Subscribed Shares to be registered for each selling shareholder named in the Registration Statement shall be reduced pro rata among all such selling shareholders; and as promptly as practicable after being
permitted to register additional Subscribed Shares under Rule 415 under the Securities Act, FEAC shall amend the Registration Statement or file a new Registration Statement to register such Subscribed Shares not included in the initial Registration
Statement and cause such amendment or Registration Statement to become effective as promptly as practicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.2. In the case of the
registration effected by FEAC pursuant to this Subscription Agreement, FEAC shall, upon reasonable request, inform Subscriber as to the status of such registration. At its expense FEAC shall: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.2.1. except for such times as FEAC is permitted hereunder to suspend the use of the prospectus forming part of a Registration
Statement, use its commercially reasonable efforts to keep such registration, and any qualification, exemption or compliance under state securities laws which FEAC determines to obtain, continuously effective, and to keep the applicable Registration
Statement or any subsequent shelf registration statement free of any material misstatements or omissions, until the earlier of the following: (i)&nbsp;the third anniversary of the effectiveness of the Registration Statement, (ii)&nbsp;when
Subscriber has sold all of its Registrable Securities pursuant to the Registration Statement or Rule 144 and (iii)&nbsp;the date all Registrable Securities held by the Subscriber may be sold without restriction under Rule 144, including without
limitation, any volume and manner of sale restrictions which may be applicable to affiliates under Rule 144 and without the requirement for FEAC to be in compliance with the current public information required under Rule 144(c)(1) (or Rule
144(i)(2), if applicable); <U>provided</U>, that for as long as the Registration Statement shall remain effective pursuant to the immediately preceding sentence, FEAC will (a)&nbsp;use commercially reasonable efforts to file all reports, and
(b)&nbsp;provide all customary and reasonable cooperation, necessary to update or amend the Registration Statement as necessary to include the Registrable Securities; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.2.2. use commercially reasonable efforts to advise Subscriber within five (5)&nbsp;Business Days: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) when a Registration Statement or any post-effective amendment thereto has become effective; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) of any request by the Commission for amendments or supplements to any Registration Statement or the prospectus included
therein or for additional information; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) of the issuance by the Commission of any stop order suspending the
effectiveness of any Registration Statement or the initiation of any proceedings for such purpose; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) of the receipt by
FEAC of any notification with respect to the suspension of the qualification of the Registrable Securities included therein for sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) subject to the provisions in this Subscription Agreement, of the occurrence of any event that requires the making of any
changes in any Registration Statement or prospectus so that, as of such date, the statements therein are not misleading and do not omit to state a material fact required to be stated therein or necessary to make the statements therein (in the case
of a prospectus, in the light of the circumstances under which they were made) not misleading; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything to the contrary
set forth herein, FEAC shall not, when so advising Subscriber of such events, provide Subscriber with any material, <FONT STYLE="white-space:nowrap">non-public</FONT> information regarding FEAC or subject Subscriber to any duty of confidentiality;
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-1-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.2.3. use its commercially reasonable efforts to obtain the withdrawal of
any order suspending the effectiveness of any Registration Statement as soon as reasonably practicable; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.2.4. upon the
occurrence of any event contemplated in <U>Section</U><U></U><U>&nbsp;4.2.2(e)</U>, except for such times as FEAC is permitted hereunder to suspend, and has suspended, the use of a prospectus forming part of a Registration Statement, FEAC shall use
its commercially reasonable efforts to as soon as reasonably practicable prepare a post-effective amendment to such Registration Statement or a supplement to the related prospectus, or file any other required document so that, as thereafter
delivered to purchasers of the Registrable Securities included therein, such prospectus will not include any untrue statement of a material fact or omit to state any material fact necessary to make the statements therein, in the light of the
circumstances under which they were made, not misleading; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.2.5. use its commercially reasonable efforts to cause all
Subscribed Shares to be listed on each securities exchange or market, if any, on which FEAC&#146;s Ordinary Shares are then listed; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.2.6. use its commercially reasonable efforts to take all other steps reasonably necessary to effect the registration of the
Registrable Securities and to enable the sale of the Registrable Securities under Rule 144; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.2.7. use its
commercially reasonable efforts to cause FEAC&#146;s transfer agent to remove any restrictive legend, at Subscriber&#146;s request, as provided in Section&nbsp;10.3 hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.3. Notwithstanding anything to the contrary in this Subscription Agreement, FEAC shall be entitled to delay or postpone the effectiveness of
the Registration Statement, and from time to time to require Subscriber not to sell under the Registration Statement or to suspend the effectiveness thereof, (i)&nbsp;as may be necessary in connection with the preparation and filing of a
post-effective amendment to the Registration Statement following the filing of FEAC&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> or <FONT STYLE="white-space:nowrap">20-F,</FONT> as applicable, or (ii)&nbsp;if the filing,
effectiveness or continued use of any Registration Statement would require FEAC to make any public disclosure of material <FONT STYLE="white-space:nowrap">non-public</FONT> information, which disclosure, in the good faith determination of the board
of directors of FEAC, after consultation with counsel to FEAC, (a)&nbsp;would be required to be made in any Registration Statement in order for the applicable Registration Statement not to contain any untrue statement of a material fact or omit to
state a material fact necessary to make the statements contained therein not misleading, (b)&nbsp;would not be required to be made at such time if the Registration Statement were not being filed, and (c)&nbsp;FEAC has a bona fide business purpose
for not making such information public (each such circumstance, a &#147;<B>Suspension Event</B>&#148;); <U>provided</U>, <U>however</U>, that FEAC may not delay or suspend the Registration Statement on more than two occasions or for more than sixty
(60)&nbsp;consecutive calendar days, or more than one hundred twenty (120)&nbsp;total calendar days, in each case, during any three hundred sixty (360)&nbsp;day period. Upon receipt of any written notice from FEAC (which notice shall not contain any
material <FONT STYLE="white-space:nowrap">non-public</FONT> information regarding FEAC and which notice shall not be subject to any duty of confidentiality) of the happening of any Suspension Event during the period that the Registration Statement
is effective or if as a result of a Suspension Event the Registration Statement or related prospectus contains any untrue statement of a material fact or omits to state any material fact required to be stated therein or necessary to make the
statements therein, in light of the circumstances under which they were made (in the case of the prospectus) not misleading, Subscriber agrees that it will immediately discontinue offers and sales of the Subscribed Shares under the Registration
Statement (excluding, for the avoidance of doubt, sales conducted pursuant to Rule 144) until Subscriber receives copies of a supplemental or amended prospectus (which FEAC agrees to promptly prepare) that corrects the misstatement(s) or omission(s)
referred to above and receives notice that any post-effective amendment has become effective or unless otherwise notified by FEAC that it may resume such offers and sales (which notice shall not contain any material
<FONT STYLE="white-space:nowrap">non-public</FONT> information regarding FEAC and which notice shall not be subject to any duty of confidentiality). If so directed by FEAC, Subscriber will deliver to FEAC or, in Subscriber&#146;s sole discretion
destroy, all copies of the prospectus covering the Subscribed Shares in Subscriber&#146;s possession; <U>provided</U>, <U>however</U>, that this obligation to deliver or destroy all copies of the prospectus covering the Subscribed Shares shall not
apply (i)&nbsp;to the extent Subscriber is required to retain a copy of such prospectus (a)&nbsp;in order to comply with applicable legal, regulatory, self-regulatory or professional requirements or (b)&nbsp;in accordance with a bona fide <FONT
STYLE="white-space:nowrap">pre-existing</FONT> document retention policy or (ii)&nbsp;to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-1-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
copies stored electronically on archival servers as a result of automatic data <FONT STYLE="white-space:nowrap">back-up.</FONT> Subscriber may deliver written notice (an <FONT
STYLE="white-space:nowrap">&#147;Opt-Out</FONT> Notice&#148;) to FEAC requesting that Subscriber not receive notices from FEAC otherwise required by this <U>Section</U><U></U><U>&nbsp;4</U>; <U>provided</U>, <U>however</U>, that Subscriber may later
revoke any such <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Notice in writing. Following receipt of an <FONT STYLE="white-space:nowrap">Opt-Out</FONT> Notice from Subscriber (unless subsequently revoked), (i) FEAC shall not deliver any such
notices to Subscriber and Subscriber shall no longer be entitled to the rights associated with any such notice and (ii)&nbsp;each time prior to Subscriber&#146;s intended use of an effective Registration Statement, Subscriber will notify FEAC in
writing at least two (2)&nbsp;business days in advance of such intended use, and if a notice of a Suspension Event was previously delivered (or would have been delivered but for the provisions of the preceding sentence) and the related suspension
period remains in effect, FEAC will so notify Subscriber, within one (1)&nbsp;business day of Subscriber&#146;s notification to FEAC, by delivering to Subscriber a copy of such previous notice of Suspension Event, and thereafter will provide
Subscriber with the related notice of the conclusion of such Suspension Event promptly following its availability. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.4.
The parties agree that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.4.1. FEAC shall, notwithstanding the termination of this Subscription Agreement, indemnify and
hold harmless, to the extent permitted by law, Subscriber (to the extent Subscriber is named as a selling shareholder under any Registration Statement), the officers, directors, agents, partners, members, managers, shareholders, affiliates,
employees of each Subscriber, each person who controls such Subscriber (within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act), and the officers, directors, partners, members, managers, shareholders,
agents, affiliates and employees of each such controlling person from and against any and all losses, claims, damages, liabilities, costs and expenses (including, without limitation, any reasonable and documented attorneys&#146; fees of one law firm
and one local counsel in each applicable jurisdiction and expenses incurred in connection with defending or investigating any such action or claim) (collectively, &#147;<B>Losses</B>&#148;), as incurred, that arise out of or are based upon
(i)&nbsp;any untrue or alleged untrue statement of material fact contained in any Registration Statement (or incorporated by reference therein), prospectus included in any Registration Statement or preliminary prospectus or any amendment thereof or
supplement thereto or arising out of or relating to any omission or alleged omission to state a material fact required to be stated therein or necessary to make the statements therein (in the case of any prospectus or form of prospectus or
supplement thereto, in the light of the circumstances under which they were made) not misleading or (ii)&nbsp;any violation or alleged violation by FEAC of the Securities Act, Exchange Act or any state securities law or any rule or regulation
thereunder, in connection with the performance of its obligations under this <U>Section</U><U></U><U>&nbsp;4</U>, except insofar as the same are caused by or contained in any information furnished in writing to FEAC by or on behalf of Subscriber
expressly for use therein or Subscriber has omitted a material fact from such information; <U>provided</U>, <U>however</U>, that the indemnification contained in this <U>Section</U><U></U><U>&nbsp;4.4</U> shall not apply to amounts paid in
settlement of any Losses if such settlement is effected without the consent of FEAC (which consent shall not be unreasonably withheld, conditioned or delayed), nor shall FEAC be liable for any Losses to the extent they arise out of or are based upon
a violation which occurs (A)&nbsp;in reliance upon and in conformity with written information furnished by Subscriber expressly for use in such Registration Statement or preliminary prospectus or any amendment thereof or supplement thereto,
(B)&nbsp;in connection with any failure of such person to deliver or cause to be delivered a prospectus made available by FEAC in a timely manner, (C)&nbsp;as a result of offers or sales effected by or on behalf of any person by means of a
&#147;free writing prospectus&#148; (as defined in Rule 405 under the Securities Act) that was not authorized by FEAC or (D)&nbsp;in connection with any offers or sales effected by or on behalf of Subscriber in violation of
<U>Section</U><U></U><U>&nbsp;4.3</U> hereof. FEAC shall notify Subscriber promptly of the institution, threat or assertion of any proceeding arising from or in connection with the transactions contemplated by this
<U>Section</U><U></U><U>&nbsp;4</U> of which FEAC is aware. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.4.2. Subscriber agrees, severally and not jointly with any
person that is a party to the Other Subscription Agreements, to indemnify and hold harmless, to the extent permitted by law, FEAC and each Placement Agent and each of FEAC&#146;s and each Placement Agent&#146;s respective directors, officers,
employees and agents and each person who controls FEAC and such Placement Agent, as applicable (within the meaning of Section&nbsp;15 of the Securities Act and Section&nbsp;20 of the Exchange Act) against any and all Losses,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-1-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
as incurred, that arise out of or result from any untrue or alleged untrue statement of material fact contained in any Registration Statement, prospectus included in any Registration Statement or
preliminary prospectus or any amendment thereof or supplement thereto or any omission of a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not
misleading, but only to the extent that such untrue statement or omission is contained in any information or affidavit so furnished in writing by such Subscriber expressly for use therein; <U>provided</U>, <U>however</U>, that the indemnification
contained in this <U>Section</U><U></U><U>&nbsp;4.4</U> shall not apply to amounts paid in settlement of any Losses if such settlement is effected without the consent of Subscriber (which consent shall not be unreasonably withheld, conditioned or
delayed). Notwithstanding anything to the contrary herein, in no event shall the liability of Subscriber be greater in amount than the dollar amount of the net proceeds received by Subscriber upon the sale of the Subscribed Shares purchased pursuant
to this Subscription Agreement giving rise to such indemnification obligation. Subscriber shall notify FEAC promptly of the institution, threat, or assertion of any proceeding arising from or in connection with the transactions contemplated by this
<U>Section</U><U></U><U>&nbsp;4</U> of which the Subscriber is aware. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.4.3. Any person entitled to indemnification herein
shall (1)&nbsp;give prompt written notice to the indemnifying party of any claim with respect to which it seeks indemnification (<U>provided</U> that the failure to give prompt notice shall not impair any person&#146;s right to indemnification
hereunder to the extent such failure has not prejudiced the indemnifying party) and (2)&nbsp;unless in such indemnified party&#146;s reasonable judgment a conflict of interest between such indemnified and indemnifying parties may exist with respect
to such claim, permit such indemnifying party to assume the defense of such claim with counsel reasonably satisfactory to the indemnified party. If such defense is assumed, the indemnifying party shall not be subject to any liability for any
settlement made by the indemnified party without its consent (which consent shall not be unreasonably withheld, conditioned or delayed). An indemnifying party who elects not to assume the defense of a claim shall not be obligated to pay the fees and
expenses of more than one counsel for all parties indemnified by such indemnifying party with respect to such claim, unless in the reasonable judgment of legal counsel to any indemnified party a conflict of interest exists between such indemnified
party and any other of such indemnified parties with respect to such claim. No indemnifying party shall, without the consent of the indemnified party (which consent shall not be unreasonably withheld, conditioned or delayed), consent to the entry of
any judgment or enter into any settlement which cannot be settled in all respects by the payment of money (and such money is so paid by the indemnifying party pursuant to the terms of such settlement) or which settlement includes a statement or
admission of fault and culpability on the part of such indemnified party or which settlement does not include as an unconditional term thereof the giving by the claimant or plaintiff to such indemnified party of a release from all liability in
respect to such claim or litigation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.4.4. The indemnification provided for under this Subscription Agreement shall
remain in full force and effect regardless of any investigation made by or on behalf of the indemnified party and shall survive the transfer of the Subscribed Shares purchased pursuant to this Subscription Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.4.5. If the indemnification provided under this <U>Section</U><U></U><U>&nbsp;4.4</U> from the indemnifying party is
unavailable or insufficient to hold harmless an indemnified party in respect of any Losses referred to herein, then the indemnifying party, in lieu of indemnifying the indemnified party, shall contribute to the amount paid or payable by the
indemnified party as a result of such losses, claims, damages, liabilities and expenses in such proportion as is appropriate to reflect the relative fault of the indemnifying party and the indemnified party, as well as any other relevant equitable
considerations. The relative fault of the indemnifying party and indemnified party shall be determined by reference to, among other things, whether any action in question, including any untrue or alleged untrue statement of a material fact or
omission or alleged omission to state a material fact, was made by (or not made by, in the case of an omission), or relates to information supplied by (or not supplied by, in the case of an omission), such indemnifying party or indemnified party,
and the indemnifying party&#146;s and indemnified party&#146;s relative intent, knowledge, access to information and opportunity to correct or prevent such action. The amount paid or payable by a party as a result of the Losses or other liabilities
referred to above shall be deemed to include, subject to the limitations set forth above, any legal or other fees, charges or expenses reasonably incurred by such party in connection with any investigation or proceeding. No person guilty of
fraudulent misrepresentation (within </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-1-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
the meaning of Section&nbsp;11(f) of the Securities Act) shall be entitled to contribution pursuant to this <U>Section</U><U></U><U>&nbsp;4.4</U> from any person who was not guilty of such
fraudulent misrepresentation. Each indemnifying party&#146;s obligation to make a contribution pursuant to this <U>Section</U><U></U><U>&nbsp;4.4</U> shall be individual, not joint and several, and in no event shall the liability of Subscriber be
greater in amount than the dollar amount of the net proceeds received by Subscriber upon the sale of the Subscribed Shares purchased pursuant to this Subscription Agreement giving rise to such contribution obligation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Termination</U>. This Subscription Agreement shall terminate and be void and of no further force and effect, and all rights and
obligations of the parties hereunder shall terminate without any further liability on the part of any party in respect thereof, upon the earliest to occur of (i)&nbsp;such date and time as the Business Combination Agreement is validly terminated in
accordance with its terms without being consummated, (ii)&nbsp;upon the mutual written agreement of each of the parties hereto to terminate this Subscription Agreement, (iii)&nbsp;the Termination Date (as defined in the Business Combination
Agreement), (iv) if the conditions to Closing set forth in <U>Section</U><U></U><U>&nbsp;3.3</U> hereof are not satisfied or (to the extent permitted by applicable law) waived in writing, or are not capable of being satisfied or (to the extent
permitted by applicable law) waived in writing, on or prior to the Closing Date and, as a result thereof, the transactions contemplated by this Subscription Agreement will not be or are not consummated on the Closing Date and (v)&nbsp;FEAC&#146;s
notification to the Subscriber in writing that it has, with the prior written consent of Newco and enGene, abandoned its plans to move forward with the Transactions and/or terminated the Subscriber&#146;s obligations with respect to the subscription
without the issuance of the Subscribed Shares having occurred. FEAC shall promptly notify Subscriber in writing of the termination of the Business Combination Agreement promptly after the termination of such agreement. Upon the termination hereof in
accordance with this <U>Section</U><U></U><U>&nbsp;5</U>, any monies paid by Subscriber to FEAC in connection herewith shall promptly (and in any event within two (2)&nbsp;Business Days) be returned in full to Subscriber by wire transfer of U.S.
dollars in immediately available funds to the account specified by Subscriber, without any deduction for or on account of any tax withholding, charges or <FONT STYLE="white-space:nowrap">set-off,</FONT> whether or not the Transactions shall have
been consummated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Miscellaneous</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.1. <U>Further Assurances</U>. At the Closing, the parties hereto shall execute and deliver such additional documents and take such
additional actions as the parties reasonably may deem to be practical and necessary in order to consummate the Subscription as contemplated by this Subscription Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.1.1. Subscriber acknowledges that FEAC, Newco and the Placement Agents will rely on the acknowledgments, understandings,
undertakings, agreements, representations and warranties made by Subscriber contained in this Subscription Agreement. Prior to the Closing, Subscriber agrees to promptly notify FEAC, Newco and the Placement Agents if any of the acknowledgments,
understandings, undertakings, agreements, representations and warranties made by Subscriber set forth herein are no longer accurate in all material respects. Each of FEAC and Newco acknowledges that Subscriber and the Placement Agents will rely on
the acknowledgments, understandings, undertakings, agreements, representations and warranties made by FEAC and Newco contained in this Subscription Agreement. Prior to the Closing, each of FEAC and Newco agrees to promptly notify Subscriber and the
Placement Agents if any of the acknowledgments, understandings, undertakings, agreements, representations and warranties made by FEAC and Newco set forth herein are no longer accurate in all material respects (other than those acknowledgments,
understandings, agreements, undertakings, representations and warranties qualified by materiality, in which case FEAC or Newco shall notify Subscriber and the Placement Agents if they are no longer accurate in any respect). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.1.2. Each of FEAC, Newco, Subscriber and each of the Placement Agents is entitled to rely upon this Subscription Agreement
and is irrevocably authorized to produce this Subscription Agreement or a copy hereof to any interested party in any administrative or legal proceeding or official inquiry with respect to the matters covered hereby. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.1.3. FEAC may request from Subscriber such additional information as FEAC may reasonably deem necessary to evaluate the
eligibility of Subscriber to acquire the Subscribed Shares, and Subscriber </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-1-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
shall provide such information as may be reasonably requested, to the extent within Subscriber&#146;s possession and control or otherwise readily available to Subscriber, <U>provided</U> that
FEAC agrees to keep confidential any such information provided by Subscriber. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.1.4. Each of Subscriber, FEAC and Newco
shall pay all of its own respective expenses in connection with this Subscription Agreement and the transactions contemplated herein (it being agreed that all expenses related to any Registration Statement are for the account of FEAC to the extent
provided in <U>Section</U><U></U><U>&nbsp;4</U>, and FEAC shall be responsible for the fees of its transfer agent and all of DTC&#146;s fees associated with the issuance of the Subscribed Shares). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.1.5. Each of Subscriber, FEAC and Newco shall take, or cause to be taken, all actions and do, or cause to be done, all things
necessary, proper or advisable to consummate the transactions contemplated by this Subscription Agreement on the terms and conditions described therein no later than immediately prior to the Amalgamation Closing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.2. Subscriber hereby acknowledges and agrees that, except in respect of any stock lending program, it will not, nor will any person acting
at Subscriber&#146;s direction or pursuant to any understanding with Subscriber (including Subscriber&#146;s controlled affiliates), directly or indirectly, offer, sell, pledge, contract to sell, sell any option in, or engage in hedging activities
or execute any &#147;short sales&#148; (as defined in Rule 200 of Regulation SHO under the Exchange Act) with respect to, any Subscribed Shares or any securities of FEAC or any instrument exchangeable for or convertible into any Subscribed Shares or
any securities of FEAC until the Amalgamation Closing (or such earlier termination of this Subscription Agreement in accordance with its terms). Notwithstanding the foregoing, (i)&nbsp;nothing herein shall prohibit any entities under common
management or that share an investment advisor with Subscriber (including Subscriber&#146;s controlled affiliates and/or affiliates) that have no knowledge of this Subscription Agreement or of Subscriber&#146;s participation in the transactions
contemplated hereby from entering into any Short Sales; (ii)&nbsp;in the case of a Subscriber that is a multimanaged investment vehicle whereby separate portfolio managers manage separate portions of such Subscriber&#146;s assets and the portfolio
managers have no knowledge of the investment decisions made by the portfolio managers managing other portions of such Subscriber&#146;s assets, this <U>Section</U><U></U><U>&nbsp;6.2</U> shall only apply with respect to the portion of assets managed
by the portfolio manager that made the investment decision to purchase the Subscribed Shares covered by this Subscription Agreement. For the avoidance of doubt, this <U>Section</U><U></U><U>&nbsp;6.2</U> shall not apply to (i)&nbsp;any sale
(including the exercise of any redemption right) of securities of FEAC (A)&nbsp;held by Subscriber, its controlled affiliates or any person or entity acting on behalf of Subscriber or any of its controlled affiliates prior to the execution of this
Subscription Agreement or (B)&nbsp;purchased by Subscriber, its controlled affiliates or any person or entity acting on behalf of Subscriber or any of its controlled affiliates in an open market transaction after the execution of this Subscription
Agreement or (ii)&nbsp;ordinary course, <FONT STYLE="white-space:nowrap">non-speculative</FONT> hedging transactions. FEAC acknowledges and agrees that, notwithstanding anything herein to the contrary, the Subscribed Shares may be pledged by
Subscriber in connection with a bona fide margin agreement, <U>provided</U> that such pledge shall be (i)&nbsp;pursuant to an available exemption from the registration requirements of the Securities Act or (ii)&nbsp;pursuant to, and in accordance
with, a registration statement that is effective under the Securities Act at the time of such pledge, and Subscriber effecting a pledge of the Subscribed Shares shall not be required to provide FEAC with any notice thereof; <U>provided</U>,
<U>however</U>, that neither FEAC nor its counsel shall be required to take any action (or refrain from taking any action) in connection with any such pledge, other than providing any such lender of such margin agreement with an acknowledgment that
the Subscribed Shares are not subject to any contractual lock up or prohibition on pledging, the form of such acknowledgment to be subject to review and comment by FEAC in all respects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.3. <U>Notices</U>. Any notice or communication required or permitted hereunder shall be in writing and either delivered personally, emailed
or sent by overnight mail via a reputable overnight carrier, or sent by certified or registered mail, postage prepaid, and shall be deemed to be given and received (i)&nbsp;when so delivered personally, (ii)&nbsp;when sent, with no mail
undeliverable or other rejection notice, if sent by email, or (iii)&nbsp;three (3) Business Days after the date of mailing to the address below or to such other address or addresses as such person may hereafter designate by notice given hereunder:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) if to Subscriber, to such address or addresses set forth on the signature page hereto; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-1-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="91%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">(ii) if to FEAC, to:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Forbion European Acquisition Corp.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gooimeer <FONT STYLE="white-space:nowrap">2-35</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">1411 DC Naarden</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">The Netherlands</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attention:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Cyril Lesser</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Cyril.Lesser@forbion.com</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><I>with a required copy (which copy shall not constitute notice) to:</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Davis Polk&nbsp;&amp; Wardwell London LLP</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">5 Aldermanbury Square</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">London EC2V 7HR</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">United Kingdom</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attention:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Leo Borchardt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">leo.borchardt@davispolk.com;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">(iii) if to Newco, to:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">enGene Holdings Inc. 7171 Rue Frederick Banting</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Saint-Laurent, QC H4S 1Z9</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Canada</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Attn: Jason Hanson</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Email: jhanson@engeneinc.com</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><I>with a required copy (which copy shall not constitute notice) to:</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Morgan, Lewis&nbsp;&amp; Bockius LLP</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">101 Park Ave.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">New York, NY 10178-0060</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">United States</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Attention: Howard A. Kenny</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Email: howard.kenny@morganlewis.com</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.4. <U>Entire Agreement</U>. This Subscription Agreement and any amendments hereto constitute the
entire agreement, and supersede all other prior agreements, understandings, representations and warranties, both written and oral, among the parties, with respect to the subject matter hereof, including any commitment letter entered into relating to
the subject matter hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.5. <U>Modifications and Amendments</U>. This Subscription Agreement may not be amended, modified,
supplemented or waived except by an instrument in writing, signed by the party against whom enforcement of such amendment, modification, supplement or waiver is sought. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.6. <U>Newco Assumptions of Obligations.</U> Subject to the terms and conditions hereof applicable to FEAC&#146;s obligations hereunder,
Newco acknowledges that, by virtue of and with effect from the FEAC Reorganization becoming effective, and without further action by FEAC, Newco or the Subscriber, the Assumption shall become effective so that Newco shall assume all of FEAC&#146;s
obligations under this Subscription Agreement, including, without limitation, the obligation to issue the Subscribed Shares and the obligations of FEAC set forth in <U>Section</U><U></U><U>&nbsp;4</U> hereof and FEAC shall assign all of its rights
under this Subscription Agreement to Newco. By virtue of, and with effect from, the FEAC Reorganization becoming effective, and without further action by FEAC, Newco or the Subscriber, (i)&nbsp;all surviving rights, covenants, and obligations of
FEAC under this Subscription Agreement shall be rights, covenants, and obligations of Newco; and (ii)&nbsp;Newco shall be liable for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-1-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any breach of any representation or warranty by FEAC set forth in this Subscription Agreement. The Subscriber hereby expressly agrees to and acknowledges the Assumption in accordance with the
foregoing and the other terms hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.7. <U>Assignment</U>. Except pursuant to the Assumption, neither this Subscription Agreement nor
any rights, interests or obligations that may accrue to Subscriber (including Subscriber&#146;s rights to purchase the Subscribed Shares) may be transferred or assigned without the prior consent of FEAC (or, following the Assumption, Newco);
<U>provided</U> that Subscriber&#146;s rights and obligations hereunder may be assigned to any fund or account managed by the same investment manager as Subscriber, without the prior consent of FEAC, <U>provided</U><I> </I>that such assignee(s)
agrees in writing to be bound by the terms hereof, and upon such assignment by a Subscriber, the assignee(s) shall become Subscriber hereunder and have the rights and obligations and be deemed to make the representations and warranties of Subscriber
provided for herein to the extent of such assignment; <U>provided further</U> that, no assignment shall relieve the assigning party of any of its obligations hereunder, including any assignment to any fund or account managed by the same investment
manager as Subscriber. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.8. <U>Benefit</U>. Except as otherwise provided herein, this Subscription Agreement shall be binding upon, and
inure to the benefit of the parties hereto and their heirs, executors, administrators, successors, legal representatives, and permitted assigns, and the agreements, representations, warranties, covenants and acknowledgments contained herein shall be
deemed to be made by, and be binding upon, such heirs, executors, administrators, successors, legal representatives and permitted assigns. This Subscription Agreement shall not confer rights or remedies upon any person other than the parties hereto
and their respective successors and assigns, except that the Placement Agents shall be third-party beneficiaries to the representations, warranties, understandings and undertakings made by FEAC, Newco and Subscriber in this Subscription Agreement
and as provided in Section&nbsp;4.4.2, Section&nbsp;6.15 and Section&nbsp;9 and enGene shall be a third-party beneficiary with respect to the entirety of this Subscription Agreement and as provided in Section&nbsp;4.4. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.9. <U>Governing Law</U>. This Subscription Agreement, and any claim or cause of action hereunder based upon, arising out of or related to
this Subscription Agreement (whether based on law, in equity, in contract, in tort or any other theory) or the negotiation, execution, performance or enforcement of this Subscription Agreement, shall be governed by and construed in accordance with
the laws of the State of Delaware, without giving effect to the principles of conflicts of law thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.10. <U>Consent to Jurisdiction;
Waiver of Jury Trial</U>. Each of the parties irrevocably consents to the exclusive jurisdiction and venue of the Court of Chancery of the State of Delaware, provided that if subject matter jurisdiction over the matter that is the subject of the
legal proceeding is vested exclusively in the U.S. federal courts, such legal proceeding shall be heard in the U.S. District Court for the District of Delaware (together with the Court of Chancery of the State of Delaware, &#147;<B>Chosen
Courts</B>&#148;), in connection with any matter based upon or arising out of this Subscription Agreement. Each party hereby waives, and shall not assert as a defense in any legal dispute, that (i)&nbsp;such person is not personally subject to the
jurisdiction of the Chosen Courts for any reason, (ii)&nbsp;such legal proceeding may not be brought or is not maintainable in the Chosen Courts, (iii)&nbsp;such person&#146;s property is exempt or immune from execution, (iv)&nbsp;such legal
proceeding is brought in an inconvenient forum or (v)&nbsp;the venue of such legal proceeding is improper. Each party hereby consents to service of process in any such proceeding in any manner permitted by Delaware law, further consents to service
of process by nationally recognized overnight courier service guaranteeing overnight delivery, or by registered or certified mail, return receipt requested, at its address specified pursuant to <U>Section</U><U></U><U>&nbsp;6.3</U> and waives and
covenants not to assert or plead any objection which they might otherwise have to such manner of service of process. Notwithstanding the foregoing in this <U>Section</U><U></U><U>&nbsp;6.10</U>, a party may commence any action, claim, cause of
action or suit in a court other than the Chosen Courts solely for the purpose of enforcing an order or judgment issued by the Chosen Courts. TO THE EXTENT NOT PROHIBITED BY APPLICABLE LAW WHICH CANNOT BE WAIVED, EACH OF THE PARTIES WAIVES ANY RIGHT
TO TRIAL BY JURY ON ANY CLAIMS OR COUNTERCLAIMS ASSERTED IN ANY LEGAL DISPUTE RELATING TO THIS SUBSCRIPTION AGREEMENT WHETHER NOW EXISTING OR HEREAFTER ARISING. IF THE SUBJECT MATTER OF </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-1-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
ANY SUCH LEGAL DISPUTE IS ONE IN WHICH THE WAIVER OF JURY TRIAL IS PROHIBITED, NO PARTY SHALL ASSERT IN SUCH LEGAL DISPUTE A NONCOMPULSORY COUNTERCLAIM ARISING OUT OF OR RELATING TO THIS
SUBSCRIPTION AGREEMENT. FURTHERMORE, NO PARTY SHALL SEEK TO CONSOLIDATE ANY SUCH LEGAL DISPUTE WITH A SEPARATE ACTION OR OTHER LEGAL PROCEEDING IN WHICH A JURY TRIAL CANNOT BE WAIVED. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.11. <U>Severability</U>. If any provision of this Subscription Agreement shall be invalid, illegal or unenforceable, the validity, legality
or enforceability of the remaining provisions of this Subscription Agreement shall not in any way be affected or impaired thereby and shall continue in full force and effect. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.12. <U>No Waiver of Rights, Powers and Remedies</U>. No failure or delay by a party hereto in exercising any right, power or remedy under
this Subscription Agreement, and no course of dealing between the parties hereto, shall operate as a waiver of any such right, power or remedy of such party. No single or partial exercise of any right, power or remedy under this Subscription
Agreement by a party hereto, nor any abandonment or discontinuance of steps to enforce any such right, power or remedy, shall preclude such party from any other or further exercise thereof or the exercise of any other right, power or remedy
hereunder. The election of any remedy by a party hereto shall not constitute a waiver of the right of such party to pursue other available remedies. No notice to or demand on a party not expressly required under this Subscription Agreement shall
entitle the party receiving such notice or demand to any other or further notice or demand in similar or other circumstances or constitute a waiver of the rights of the party giving such notice or demand to any other or further action in any
circumstances without such notice or demand. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.13. <U>Remedies</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.13.1. The parties agree that irreparable damage would occur if this Subscription Agreement is not performed or the Closing is
not consummated in accordance with its specific terms or is otherwise breached and that money damages or other legal remedies would not be an adequate remedy for any such damage. It is accordingly agreed that the parties hereto shall be entitled to
equitable relief, including in the form of an injunction or injunctions, to prevent breaches or threatened breaches of this Subscription Agreement and to enforce specifically the terms and provisions of this Subscription Agreement in an appropriate
court of competent jurisdiction as set forth in <U>Section</U><U></U><U>&nbsp;6.10</U>, this being in addition to any other remedy to which any party is entitled at law or in equity, including money damages. The right to specific enforcement shall
include the right of the parties hereto to cause the other parties hereto to cause the transactions contemplated hereby to be consummated on the terms and subject to the conditions and limitations set forth in this Subscription Agreement. The
parties hereto further agree (i)&nbsp;to waive any requirement for the security or posting of any bond in connection with any such equitable remedy, (ii)&nbsp;not to assert that a remedy of specific enforcement pursuant to this
<U>Section</U><U></U><U>&nbsp;6.13</U> is unenforceable, invalid, contrary to applicable law or inequitable for any reason and (iii)&nbsp;to waive any defenses in any action for specific performance, including the defense that a remedy at law would
be adequate. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.13.2. The parties acknowledge and agree that this <U>Section</U><U></U><U>&nbsp;6.13</U> is an integral
part of the transactions contemplated hereby and without that right, the parties hereto would not have entered into this Subscription Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.14. <U>Survival of Representations and Warranties and Covenants</U>. All representations and warranties made by the parties hereto, and all
covenants and other agreements of the parties hereto, in this Subscription Agreement shall survive the Closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.15. <U>No
Liability</U>. Subscriber agrees that none of the Placement Agents shall be liable to it (including in contract, tort, under federal or state securities laws or otherwise) for any action heretofore or hereafter taken or omitted to be taken by any of
them in good faith in connection with the Transactions and the purchase and sale of the Subscribed Shares hereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-1-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
On behalf of Subscriber and its affiliates, Subscriber releases the Placement Agents in respect of any Losses related to the Transactions and the purchase and sale of the Subscribed Shares
hereunder. Subscriber agrees not to commence any litigation or bring any claim against any of the Placement Agents in any court or any other forum which relates to, may arise out of, or is in connection with, the Transactions and the purchase and
sale of the Subscribed Shares hereunder. This undertaking is given freely and after obtaining independent legal advice, except for such party&#146;s own gross negligence, willful misconduct or bad faith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.16. <U>Headings and Captions</U>. The headings and captions of the various subdivisions of this Subscription Agreement are for convenience
of reference only and shall in no way modify or affect the meaning or construction of any of the terms or provisions hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.17.
<U>Counterparts</U>. This Subscription Agreement may be executed in one or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party
and delivered to the other parties, it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or any other form of electronic delivery, such signature shall create
a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such signature page were an original thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.18. <U>Construction</U>. The words &#147;<I>include</I>,&#148; &#147;<I>includes</I>,&#148; and &#147;<I>including</I>&#148; will be deemed
to be followed by &#147;without limitation.&#148; Pronouns in masculine, feminine, and neuter genders will be construed to include any other gender, and words in the singular form will be construed to include the plural and vice versa, unless the
context otherwise requires. The words &#147;<I>this </I><I>Subscription Agreement</I>,&#148; &#147;<I>herein</I>,&#148; &#147;<I>hereof</I>,&#148; &#147;<I>hereby</I>,&#148; &#147;<I>hereunder</I>,&#148; and words of similar import refer to this
Subscription Agreement as a whole and not to any particular subdivision unless expressly so limited. The parties hereto intend that each representation, warranty, and covenant contained herein will have independent significance. If any party hereto
has breached any representation, warranty, or covenant contained herein in any respect, the fact that there exists another representation, warranty or covenant relating to the same subject matter (regardless of the relative levels of specificity)
which such party hereto has not breached will not detract from or mitigate the fact that such party hereto is in breach of the first representation, warranty, or covenant. All references in this Subscription Agreement to numbers of shares, per share
amounts and purchase prices shall be appropriately adjusted to reflect any stock split, stock dividend, stock combination, recapitalization or the like occurring after the date hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.19. <U>Mutual Drafting</U>. This Subscription Agreement is the joint product of the parties hereto and each provision hereof has been
subject to the mutual consultation, negotiation and agreement of the parties and shall not be construed for or against any party hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Cleansing Statement; Disclosure</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.1. Newco shall use commercially reasonable efforts to publicly file a registration statement on Form
<FONT STYLE="white-space:nowrap">S-4</FONT> with respect to the Transactions with the Commission as soon as reasonably practicable following the date of this Subscription Agreement (the &#147;<B>Disclosure Document</B>&#148;) disclosing all material
terms of the transactions contemplated hereby and by the Other Subscription Agreements and the Transactions and any other material nonpublic information that FEAC or its officers, directors, employees or agents has provided to Subscriber prior to
the filing of the Disclosure Document. Upon the issuance of the Disclosure Document, to the actual knowledge of FEAC, Subscriber shall not be in possession of any material, <FONT STYLE="white-space:nowrap">non-public</FONT> information received from
FEAC, Newco, enGene or any of their officers, directors, employees or agents, and Subscriber shall no longer be subject to any confidentiality or similar obligations under any current agreement, whether written or oral, with FEAC, Newco, enGene, the
Placement Agents or any of their respective affiliates, relating to the transactions contemplated by this Subscription Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.2.
Notwithstanding anything in this Subscription Agreement to the contrary, FEAC and Newco shall not (and shall cause their officers, directors, employees and agents not to) publicly disclose the name of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-1-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Subscriber or any affiliate or investment adviser of Subscriber, or include the name of Subscriber or any affiliate or investment adviser of Subscriber without the prior written consent
(including by <FONT STYLE="white-space:nowrap">e-mail)</FONT> of Subscriber (i)&nbsp;in any press release or marketing materials, or (ii)&nbsp;in any filing with the Commission or any regulatory agency or trading market, except as required by the
federal securities laws, rules or regulations and to the extent such disclosure is required by other laws, rules or regulations, at the request of the staff of the Commission or regulatory agency or under regulations of Nasdaq or other Exchange, as
applicable, in which case FEAC and Newco shall provide Subscriber with prior written notice (including by <FONT STYLE="white-space:nowrap">e-mail)</FONT> of such permitted disclosure, and shall reasonably consult with Subscriber regarding such
disclosure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Trust Account Waiver</U>. In addition to the waiver of Newco pursuant to Section&nbsp;8.17 of the Business Combination
Agreement, and notwithstanding anything to the contrary set forth herein, Subscriber acknowledges that FEAC has established a trust account containing the proceeds of its initial public offering and from certain private placements (collectively,
with interest accrued from time to time thereon, the &#147;<B>Trust Account</B>&#148;). Subscriber acknowledges that (i)&nbsp;it has no right, title, interest or claim of any kind in or to any monies held in the Trust Account, and (ii)&nbsp;it shall
have no right of <FONT STYLE="white-space:nowrap">set-off</FONT> or any right, title, interest or claim of any kind (&#147;<B>Claim</B>&#148;) to, or to any monies in, the Trust Account, in each case in connection with this Subscription Agreement,
and hereby irrevocably waives any Claim to, or to any monies in, the Trust Account that it may have in connection with this Subscription Agreement; <U>provided</U>, <U>however</U>, that nothing in this <U>Section</U><U></U><U>&nbsp;8</U> shall
(x)&nbsp;serve to limit or prohibit Subscriber&#146;s right to pursue a claim against FEAC for legal relief against assets held outside the Trust Account, for specific performance or other equitable relief, (y)&nbsp;serve to limit or prohibit any
claims that Subscriber may have in the future against FEAC&#146;s assets or funds that are not held in the Trust Account (including any funds that have been released from the Trust Account and any assets that have been purchased or acquired with any
such funds) or (z)&nbsp;be deemed to limit Subscriber&#146;s right, title, interest or claim to the Trust Account by virtue of such Subscriber&#146;s record or beneficial ownership of securities of FEAC, including, but not limited to, any redemption
right with respect to any such securities of FEAC. In the event Subscriber has any Claim against FEAC under this Subscription Agreement, Subscriber shall pursue such Claim solely against FEAC and its assets outside the Trust Account and not against
the property or any monies in the Trust Account. Subscriber agrees and acknowledges that such waiver is material to this Subscription Agreement and has been specifically relied upon by FEAC to induce FEAC to enter into this Subscription Agreement
and Subscriber further intends and understands such waiver to be valid, binding and enforceable under applicable law. Notwithstanding the foregoing, in no event shall the terms of this <U>Section</U><U></U><U>&nbsp;8</U> apply to any money or other
assets held outside the Trust Account. In the event Subscriber, in connection with this Subscription Agreement, commences any action which seeks, in whole or in part, relief against the funds held in the Trust Account or distributions therefrom or
any of FEAC&#146;s or Newco&#146;s shareholders, whether in the form of monetary damages or injunctive relief, Subscriber shall be obligated to pay to FEAC and Newco all of their legal fees and costs in connection with any such action in the event
that FEAC and Newco prevail in such action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U><FONT STYLE="white-space:nowrap">Non-Reliance</FONT></U>. Subscriber acknowledges that
it is not relying upon, and has not relied upon, any statement, representation or warranty made by any person, firm or corporation, (including, without limitation, enGene, any Placement Agent, any of their respective affiliates or any of their
respective control persons, officers, directors or employees), other than the representations and warranties of FEAC and Newco expressly set forth in this Subscription Agreement, in making its investment or decision to invest in FEAC. Subscriber
acknowledges and agrees that none of (i)&nbsp;an Other Subscriber pursuant to any Other Subscription Agreement or any other agreement related to the PIPE Financing (including the controlling persons, officers, directors, partners, agents or
employees of any such Other Subscriber) or (ii)&nbsp;enGene, the Placement Agents, their respective affiliates or any of their respective control persons, officers, directors, partners, agents or employees, shall be liable to Subscriber pursuant to
this Subscription Agreement or any other agreement related to the PIPE Financing for any action heretofore or hereafter taken or omitted to be taken by any of them in connection with the PIPE Financing or with respect to any claim (whether in tort,
contract, under federal or state securities laws or otherwise) for breach of this Subscription Agreement or in respect of any written or oral representations made or alleged to be made in connection herewith, except as expressly provided herein, or
for any actual or alleged inaccuracies, misstatements or omissions with respect to any information or materials of any kind furnished by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-1-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
FEAC, the Newco, the Placement Agents or any <FONT STYLE="white-space:nowrap">Non-Party</FONT> Affiliate (as defined below) concerning FEAC, Newco, the Placement Agents, any of their controlled
affiliates, this Subscription Agreement or the transactions contemplated hereby. For purposes of this Subscription Agreement, <FONT STYLE="white-space:nowrap">&#147;Non-Party</FONT> Affiliates&#148; means each former, current or future officer,
director, employee, partner, member, manager, direct or indirect equityholder or affiliate of FEAC, Newco, the Placement Agents or any of FEAC&#146;s, Newco&#146;s or the Placement Agents&#146; controlled affiliates or any family member of the
foregoing. The obligations of Subscriber under this Subscription Agreement are several and not joint with the obligations of any Other Subscriber or any other investor under the Other Subscription Agreements, and Subscriber shall not be responsible
in any way for the performance of the obligations of any Other Subscriber under this Subscription Agreement or any Other Subscriber or other investor under the Other Subscription Agreements. The decision of Subscriber to purchase Subscribed Shares
pursuant to this Subscription Agreement has been made by Subscriber independently of any Other Subscriber or any other investor and independently of any information, materials, statements or opinions as to the business, affairs, operations, assets,
properties, liabilities, results of operations, condition (financial or otherwise) or prospects of FEAC or Newco or any of their respective affiliates or subsidiaries which may have been made or given by any Other Subscriber or investor or by any
agent or employee of any Other Subscriber or investor, and neither Subscriber nor any of its agents or employees shall have any liability to any Other Subscriber or investor (or any other person) relating to or arising from any such information,
materials, statements or opinions. Nothing contained herein or in any Other Subscription Agreement, and no action taken by Subscriber or Other Subscriber or other investor pursuant hereto or thereto, shall be deemed to constitute Subscriber and any
Other Subscribers or other investors as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that Subscriber and any Other Subscribers or other investors are in any way acting in concert or as a group
with respect to such obligations or the transactions contemplated by this Subscription Agreement and the Other Subscription Agreements. Subscriber acknowledges that no Other Subscriber has acted as agent for Subscriber in connection with making its
investment hereunder and no Other Subscriber will be acting as agent of Subscriber in connection with monitoring its investment in the Subscribed Shares or enforcing its rights under this Subscription Agreement. Subscriber shall be entitled to
independently protect and enforce its rights, including without limitation the rights arising out of this Subscription Agreement, and it shall not be necessary for any Other Subscriber or investor to be joined as an additional party in any
proceeding for such purpose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Rule 144</U>. From and after such time as the benefits of Rule 144 promulgated under the Securities
Act or any other similar rule or regulation of the Commission that may allow Subscriber to sell securities of FEAC to the public without registration are available to holders of FEAC&#146;s shares of common stock and for so long as Subscriber holds
the Subscribed Shares, FEAC agrees to: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.1. make and keep public information available, as those terms are understood and defined in
Rule 144; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.2. file with the Commission in a timely manner all reports and other documents required of FEAC under the Securities Act
and the Exchange Act so long as FEAC remains subject to such requirements and the filing of such reports and other documents is required for the applicable provisions of Rule 144; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.3. furnish to Subscriber so long as it owns Subscribed Shares, as promptly as practicable upon request, (x)&nbsp;a written statement by
FEAC, if true, that it has complied with the reporting requirements of Rule 144, the Securities Act and the Exchange Act, and (y)&nbsp;such other information as may be reasonably requested to permit Subscriber to sell such securities pursuant to
Rule 144 without registration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">FEAC (or following the Assumption, Newco) shall, if requested by Subscriber, use commercially reasonable
efforts to (i)&nbsp;cause the removal of any restrictive legend related to compliance with the federal securities laws set forth on the Subscribed Shares, (ii)&nbsp;request its legal counsel to deliver an opinion, if necessary, to the transfer agent
in connection with the instruction under subclause (i)&nbsp;to the effect that removal of such legends in such circumstances may be effected in compliance under the Securities Act, and (iii)&nbsp;issue Subscribed Shares without any such legend in
certificated or book-entry form or by electronic delivery through The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-1-35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Depository Trust Company, at Subscriber&#146;s option, if (a)&nbsp;Subscriber has sold or transferred Subscribed Shares pursuant to the effective Registration Statement or in compliance with Rule
144, or (b)&nbsp;Subscriber intends to sell or transfer Subscribed Shares pursuant to the effective Registration Statement or in compliance with Rule 144 promptly after such request to FEAC. FEAC&#146;s obligation to remove legends under this
paragraph may be conditioned upon Subscriber providing such undertakings, representations and documentation (including broker representation letters) as are reasonably necessary and customarily required in connection with the removal of restrictive
legends related to compliance with the federal securities laws. Subscriber agrees to disclose its beneficial ownership, as determined in accordance with Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> of the Exchange Act, of Ordinary Shares to
FEAC (or its successor) upon reasonable request to assist FEAC in making the determination described above. Notwithstanding the foregoing, FEAC will not be required to deliver any such opinion, authorization, certificate, or direction if it
reasonably believes that removal of the legend could result in or facilitate transfers of securities in violation of applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page Follows</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-1-36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, each of FEAC, Newco and Subscriber has executed or caused this
Subscription Agreement to be executed by its duly authorized representative as of the date set forth below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>FORBION EUROPEAN ACQUISITION CORP.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ENGENE HOLDINGS INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title:</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-1-37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accepted and agreed this 16<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> day of May 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SUBSCRIBER: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Signature of Subscriber:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Signature of Joint Subscriber, if applicable:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: May&nbsp;16, 2023 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name of Subscriber:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name of Joint Subscriber, if applicable:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(Please print. Please indicate name and</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(Please print. Please indicate name and</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Capacity of person signing above)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Capacity of person signing above)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name in which securities are to be registered</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(if different from the name of Subscriber listed directly above):</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email Address: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If there are
joint investors, please check one: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Joint Tenants with Rights of Survivorship </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Tenants-in-Common</FONT></FONT>
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Community Property </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="27%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Subscriber&#146;s&nbsp;EIN:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Joint&nbsp;Subscriber&#146;s</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">EIN:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Business Address-Street:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Mailing Address-Street (if different):</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">City, State, Zip:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">City, State, Zip:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Attn:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Telephone No.: _________________________</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Telephone No.: _____________________</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Facsimile No.: __________________________</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Facsimile No.: ______________________</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aggregate Number of Subscribed Shares subscribed for: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aggregate Purchase Price: $ </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You must pay the Purchase Price by
wire transfer of U.S. dollars in immediately available funds to the account specified by FEAC in the Closing Notice. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-1-38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ELIGIBILITY REPRESENTATIONS OF SUBSCRIBER </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">QUALIFIED INSTITUTIONAL BUYER STATUS </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(Please check the applicable subparagraphs): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#9744; We are a &#147;qualified institutional buyer&#148; (as defined in Rule 144A under the Securities Act of
1933, as amended (the &#147;<U>Securities Act</U>&#148;) (a &#147;<B>QIB</B>&#148;)). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#9744; We are subscribing for the Subscribed Shares as a fiduciary or agent for one or more investor accounts,
and each owner of such account is a QIB. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** OR *** </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">INSTITUTIONAL ACCREDITED INVESTOR STATUS (Please check the applicable subparagraphs): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#9744; We are an &#147;accredited investor&#148; (within the meaning of Rule 501(a) under the Securities Act)
or an entity in which all of the equity holders are accredited investors within the meaning of Rule 501(a) under the Securities Act, and have marked and initialed the appropriate box on the following page indicating the provision under which we
qualify as an &#147;accredited investor.&#148; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#9744; We are not a natural person. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** AND *** </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">C.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">AFFILIATE STATUS </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(Please check the applicable box) SUBSCRIBER: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is not: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">an &#147;affiliate&#148; (as defined in Rule 144 under the Securities Act) of FEAC or Newco or acting on behalf of an affiliate of FEAC or
Newco. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>This page should be completed by Subscriber </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>and constitutes a part of the Subscription Agreement. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-1-39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rule 501(a) under the Securities Act, in relevant part, states that an &#147;accredited investor&#148; shall
mean any person who comes within any of the below listed categories, or who the issuer reasonably believes comes within any of the below listed categories, at the time of the sale of the securities to that person. Subscriber has indicated, by
marking and initialing the appropriate box below, the provision(s) below which apply to Subscriber and under which Subscriber accordingly qualifies as an &#147;accredited investor.&#148; </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any bank as defined in section 3(a)(2) of the Securities Act, or any savings and loan association or other
institution as defined in section 3(a)(5)(A) of the Securities Act whether acting in its individual or fiduciary capacity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any broker or dealer registered pursuant to section 15 of the Securities Exchange Act of 1934, as amended;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any insurance company as defined in section 2(a)(13) of the Securities Act; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any investment company registered under the Investment Company Act of 1940, as amended (the &#147;<U>Investment
Company Act</U>&#148;) or a business development company as defined in section 2(a)(48) of the Investment Company Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any Small Business Investment Company licensed by the U.S. Small Business Administration under section 301(c)
or (d)&nbsp;of the Small Business Investment Act of 1958, as amended; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any plan established and maintained by a state, its political subdivisions, or any agency or instrumentality of
a state or its political subdivisions, for the benefit of its employees, if such plan has total assets in excess of $5,000,000; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any employee benefit plan within the meaning of the Employee Retirement Income Security Act of 1974, as amended
(&#147;<B>ERISA</B>&#148;), if (i)&nbsp;the investment decision is made by a plan fiduciary, as defined in section 3(21) of ERISA, which is either a bank, a savings and loan association, an insurance company, or a registered investment adviser,
(ii)&nbsp;the employee benefit plan has total assets in excess of $5,000,000 or, (iii)&nbsp;such plan is a self-directed plan, with investment decisions made solely by persons that are &#147;accredited investors&#148;; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any private business development company as defined in section 202(a)(22) of the Investment Advisers Act of
1940, as amended; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any (i)&nbsp;corporation, limited liability company or partnership, (ii)&nbsp;Massachusetts or similar business
trust, or (iii)&nbsp;organization described in section 501(c)(3) of the Internal Revenue Code of 1986, as amended, not formed for the specific purpose of acquiring the securities offered, and with total assets in excess of $5,000,000; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any trust, with total assets in excess of $5,000,000, not formed for the specific purpose of acquiring the
securities offered, whose purchase is directed by a sophisticated person as described in Section&nbsp;230.506(b)(2)(ii) of Regulation D. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-1-40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit <FONT STYLE="white-space:nowrap">C-2</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form of Side Letter Agreement </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-2-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Final Form </I></B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF SUBSCRIPTION AGREEMENT SIDE LETTER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">THIS SUBSCRIPTION AGREEMENT SIDE LETTER (this &#147;<U>Agreement</U>&#148;) is made and entered into as of May 16<SUP
STYLE="font-size:75%; vertical-align:top">th</SUP>, 2023 by and between Forbion European Acquisition Corp., a Cayman Islands exempted company (&#147;<U>FEAC</U>&#148;), enGene Holdings Inc., a company incorporated under the laws of Canada
(&#147;<U>Newco</U>&#148;) and [&#149;] (the &#147;<U>Investor</U>&#148;). Each of the FEAC, Newco and the Investor will individually be referred to herein as a &#147;<U>Party</U>&#148; and, collectively, as the &#147;<U>Parties</U>&#148;. Defined
terms used but not otherwise defined herein shall have the respective meanings ascribed thereto in the Subscription Agreement (as defined below). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, Can Merger Sub, a company to be incorporated under the laws of Canada (&#147;<U>Can Merger Sub</U>&#148;), will be a wholly-owned
subsidiary of FEAC incorporated solely for purposes of effecting the Transactions (as defined in the Subscription Agreement), and Cayman Merger Sub, a company to be incorporated as a Cayman Island exempted company (&#147;<U>Cayman Merger
Sub</U>&#148;) will be a wholly-owned subsidiary of Newco incorporated solely for purposes of effecting the Transactions; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, enGene
Inc., a corporation incorporated and existing under the laws of Canada (&#147;<U>enGene</U>&#148;) entered into a Note Purchase Agreement dated as of October&nbsp;20, 2022 by and among enGene, Forbion Capital Fund III Cooperatief U.A.
(&#147;<U>Forbion Capital Fund III</U>&#148;), Fonds de Solidarit&eacute; des Travailleurs du Qu&eacute;bec (F.T.Q.) (&#147;<U>FSTQ</U>&#148;), Lumira Ventures III, L.P. (&#147;<U>Lumira III</U>&#148;), Lumira Ventures III (International), L.P.
(&#147;<U>Lumira International III</U>&#148;), Merck Lumira Biosciences Fund, L.P. (&#147;<U>Merck</U>&#148;), Merck Lumira Biosciences Fund (Qu&eacute;bec), L.P. (&#147;<U>Merck Qu</U><U>&eacute;</U><U>bec</U>&#148; and together with, Merck, FSTQ,
Lumira III, Lumira International III and Forbion Capital Fund III, collectively the &#147;<U>2022</U> <U>Noteholders</U>&#148;) (the &#147;<U>2022 Note Purchase Agreement</U>&#148;) pursuant to which enGene issued $18.4&nbsp;million of convertible
promissory notes (each a &#147;<U>2022 Convertible Note</U>&#148; and collectively, the &#147;<U>2022 Convertible Notes</U>&#148;) to the 2022 Noteholders in substantially the form attached to the 2022 Note Purchase Agreement on the terms and
conditions set forth therein; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, enGene and each 2022 Noteholder have entered into amended and restated convertible promissory
notes on or about the date hereof, to amend and restate the 2022 Convertible Notes (each an &#147;<U>Amended 2022 Convertible Note</U>&#148; and collectively, the &#147;<U>Amended 2022 Convertible Notes</U>&#148;) pursuant to which (i)&nbsp;the
Amended 2022 Convertible Notes are, among other things, convertible into that number of common shares of enGene that, when exchanged at the Company Exchange Ratio (as defined in the Business Combination Agreement (as defined below)), shall equal
that number of Class&nbsp;A ordinary shares of FEAC (&#147;<U>Ordinary Shares</U>&#148;) (or, after the Assumption (as defined below), Newco Common Shares (as defined below)) that the holders of the Amended 2022 Convertible Notes would have received
if they subscribed for Ordinary Shares (or, after the Assumption, Newco Common Shares) on the same terms as the PIPE Financing and (ii)&nbsp;each 2022 Noteholder received warrants to acquire common shares of enGene in consideration of certain
amendments set forth in each Amended 2022 Convertible Note (the &#147;<U>2022 Warrants</U>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, concurrently with the
execution and delivery of this Agreement and the Business Combination Agreement, the Sponsor (as defined below) and Investissement Qu&eacute;bec (&#147;<U>IQ</U>&#148;) are entering into agreements with enGene, pursuant to which the Sponsor and IQ
will purchase, in one or more closings, (i)&nbsp;convertible promissory notes of enGene (the &#147;<U>Original</U> <U>2023 Convertible Notes</U>&#148; and, together with the Amended 2022 Convertible Notes, the &#147;<U>Company Convertible
Notes</U>&#148;) that will, among other things, convert into that number of common shares of enGene that, when exchanged at the Company Exchange Ratio, shall equal that number of Ordinary Shares (or, after the Assumption, Newco Common Shares) that
the holders of the Original Convertible Notes would have received if they subscribed for Ordinary Shares on the same terms as the PIPE Financing and (ii)&nbsp;warrants to acquire common shares of enGene (the &#147;<U>Original 2023
Warrants</U>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company entered into a Note Purchase Agreement dated as of April&nbsp;4, 2023 by and among the Company,
Forbion Capital Fund III, FSTQ, Lumira III, Lumira International III, Lumira Ventures IV, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-2-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
L.P., Lumira Ventures IV (International), L.P., Merck, Merck Qu&eacute;bec (collectively, with respect to the 2023 Subordinated Financing (as defined below), the &#147;<U>2023
Noteholders</U>&#148;) (the &#147;<U>2023 Subordinated Note Purchase Agreement</U>&#148;) pursuant to which the Company issued $8.0&nbsp;million of subordinated promissory notes (each a &#147;<U>2023 Subordinated Note</U>&#148; and collectively, the
&#147;<U>2023 Subordinated Notes</U>&#148;) to the 2023 Noteholders in substantially the form attached to the 2023 Subordinated Note Purchase Agreement on the terms and conditions set forth therein (the &#147;<U>2023 Subordinated
Financing</U>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, concurrently with the execution and delivery of this Agreement, the Company is entering into agreements
with the 2023 Noteholders pursuant to which the Company will repay the 2023 Subordinated Notes by issuing to each 2023 Noteholder (i)&nbsp;an amount of convertible promissory notes of the Company substantially in the same form and on the same terms
as the Original 2023 Convertible Notes (the &#147;<U>Additional 2023 Convertible Notes</U>&#148; and, together with the Original 2023 Convertible Notes, the &#147;<U>2023 Convertible Notes</U>&#148;), and (ii)&nbsp;a number of warrants to acquire
common shares of the Company substantially in the same form and on the same terms as the Original 2023 Warrants, corresponding, in the aggregate, to the principal amount of 2023 Subordinated Notes held by such 2023 Noteholder; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, FEAC, Newco and enGene have, concurrently with the execution and delivery of this Agreement, entered into that certain Business
Combination Agreement, dated as of the date hereof (as amended, modified, supplemented or waived from time to time in accordance with its terms, the &#147;<U>Business Combination Agreement</U>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, concurrently with the execution and delivery of this Agreement and the Business Combination Agreement, Newco, FEAC and a certain
shareholder of FEAC (the &#147;<U>FEAC Shareholder</U>&#148;) are entering into a <FONT STYLE="white-space:nowrap">non-redemption</FONT> agreement, substantially in the form attached to the Business Combination Agreement (the &#147;<U><FONT
STYLE="white-space:nowrap">Non-Redemption</FONT> Agreement</U>&#148;), pursuant to which, among others, FEAC will issue additional Ordinary Shares and FEAC Warrants (or after the Assumption, Newco will issue additional Newco Shares and Newco
Warrants) to such FEAC Shareholder in consideration of such FEAC Shareholder&#146;s commitment not to redeem an amount of its Ordinary Shares set out in such <FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreement in connection with the
FEAC Shareholder Approval, on the terms and subject to the conditions set forth in the <FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, immediately prior to the execution and delivery of this Agreement, the Investor, FEAC and Newco have entered into that certain
Subscription Agreement, dated as of the date hereof (as amended, modified, supplemented or waived from time to time in accordance with its terms, the &#147;<U>Subscription Agreement</U>&#148;), pursuant to which, among other things, Investor has
agreed, contingent upon the substantial concurrent occurrence of the Amalgamation Closing, to subscribe for and purchase, and FEAC (or after the Assumption, Newco) has agreed that it will issue and sell to the Investor, the number of Ordinary Shares
(as defined below) (or, after the Assumption, Newco Common Shares) provided for in the Subscription Agreement in exchange for the purchase price set forth therein (the &#147;<U>Purchase Price</U>&#148;), in each case on the terms and subject to the
conditions set forth in the Subscription Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, as of the date of this Agreement, Forbion Growth Sponsor FEAC I B.V., a
private limited liability company incorporated in The Netherlands (the &#147;<U>Sponsor</U>&#148;), owns 3,162,500 FEAC Class&nbsp;B ordinary shares (&#147;<U>FEAC Class</U><U></U><U>&nbsp;B Shares</U>&#148; and, together with the Ordinary Shares,
the &#147;<U>FEAC Shares</U>&#148;) and 5,195,000 FEAC private placement warrants (each whole warrant entitling the holder thereof to purchase one Ordinary Share, the &#147;<U>FEAC Private Placement Warrants</U>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, assuming that the aggregate principal amount outstanding under the Working Capital Loan Note and any Extension Loan Notes (each as
defined in the Business Combination Agreement) equals or exceeds $1,500,000 on the day which is two (2)&nbsp;Business Days (as defined in the Subscription Agreement) prior to the Closing Date (as defined in the Subscription Agreement), FEAC shall
cause the Sponsor (or its Affiliate or designee, as applicable), as payee of the Working Capital Loan Note and any Extension Loan Notes, to elect to convert an amount equal to $1,500,000 of the aggregate principal amount outstanding under the
Working Capital </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-2-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Loan Note and any Extension Loan Notes, taken together, into additional FEAC Private Placement Warrants at a price of $1.50 per FEAC Private Placement Warrant, which upon such election will be
issued by FEAC to the Sponsor (or its Affiliate (as defined in the Business Combination Agreement) or designee, as applicable) immediately prior to the Surrender (as defined below) on the day which is two (2)&nbsp;Business Days prior to the Closing
Date, in each case in accordance with the FEAC Warrant Agreement and the relevant promissory note governing the Working Capital Loan Note and/or any Extension Loan Notes, as applicable, following which the Sponsor is expected to own 6,195,000 FEAC
Private Placement Warrants; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, immediately prior to the execution and delivery of this Agreement, the Sponsor, FEAC and the other
parties thereto entered into the sponsor and insiders letter agreement (the &#147;<U>Sponsor and Insiders Letter Agreement</U>&#148;), pursuant to which, among other things, the Sponsor has agreed to surrender, after giving effect to the Sponsor
Loans Conversion 1,789,004 FEAC Class&nbsp;B Shares and 5,463,381 FEAC Private Placement Warrants, as a contribution to the capital of FEAC and for no consideration, effective immediately prior to the Class&nbsp;B Conversion (as defined below) and
on the day which is two (2)&nbsp;Business Days prior to the Closing Date, in each case, on the terms and conditions set forth in Business Combination Agreement and the Sponsor and Insiders Letter Agreement (the &#147;<U>Surrender</U>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, on the day which is two (2)&nbsp;Business Days prior to the Closing Date, each FEAC Class&nbsp;B Share that remains outstanding
following the Surrender of the 1,789,004 FEAC Class&nbsp;B Shares held by the Sponsor, as provided in the Sponsor and Insiders Letter Agreement, shall be exchanged (the &#147;<U>Class</U><U></U><U>&nbsp;B Conversion</U>&#148;) for one Ordinary
Share; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, on the day which is one (1)&nbsp;Business Day prior to the Closing Date, Cayman Merger Sub will merge with and into FEAC
with FEAC as the surviving entity pursuant to a plan of merger under the laws of the Cayman Islands (the &#147;<U>Cayman Merger</U>&#148;), as follows: (i)&nbsp;Newco will issue to the holders of Ordinary Shares (including the Sponsor but excluding
the holders of any Dissenting FEAC Shares (as defined in the Business Combination Agreement)) Newco common shares (&#147;<U>Newco Common Shares</U>&#148;) in exchange for such holders&#146; Ordinary Shares and such Ordinary Shares will not be
cancelled but will be transferred to Newco, (ii)&nbsp;FEAC will thereby become a wholly-owned subsidiary of Newco and (iii)&nbsp;each issued share of Cayman Merger Sub will be exchanged for an Ordinary Share of FEAC as the surviving entity and
Cayman Merger Sub (having merged into FEAC) will cease to exist as a separate entity by virtue of the Cayman Merger; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS concurrently
with the Cayman Merger, and effective at the same time the Cayman Merger becomes effective under the Cayman Islands law, (i)&nbsp;Newco will assume the FEAC Private Placement Warrants and FEAC&#146;s warrants to purchase one Ordinary Share at an
exercise price of $11.50 per share, subject to adjustment, upon the terms and conditions in the FEAC Warrant Agreement (as defined in the Business Combination Agreement) (the &#147;<U>FEAC Public Warrants</U>&#148; and, together with the Private
Placement Warrants, the &#147;<U>FEAC Warrants</U>&#148; and, the FEAC Warrants as so assumed, the &#147;<U>Newco Warrants</U>&#148;) pursuant to the Warrant Assignment, Assumption and Amendment Agreement (as defined below), (ii) FEAC as the entity
surviving the Cayman Merger will issue to Newco a <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing demand promissory note payable denominated in CDN$ having a principal amount equal to the fair market value of the FEAC Warrants assumed
by Newco (as so assumed, Newco Warrants) (&#147;<U>Note 3</U>&#148;) in consideration of the assumption by Newco of obligations under the FEAC Warrants (as so assumed, Newco Warrants) and (iii)&nbsp;Newco will redeem the initial Newco Common Shares
held by its formation shareholder for an amount equal to the amount of capital that such formation shareholder contributed for purposes of the incorporation of Newco (such transactions, together with the Cayman Merger, the &#147;<U>Cayman
Reorganization</U>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, following the Cayman Reorganization, FEAC will file an election to change its classification for U.S.
federal income tax purposes from a corporation to an entity disregarded as separate from its owner Newco, to be effective as of the beginning of the Closing Date (the &#147;<U>U.S. Entity Classification Election</U>&#148; and, together with the
Cayman Reorganization, the &#147;<U>FEAC Reorganization</U>&#148;); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-2-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, on the Closing Date and pursuant to the Plan of Arrangement (as defined below),
subsequent to the FEAC Reorganization becoming effective and prior to the consummation of the PIPE Financing (as defined below), FEAC will loan to Newco an amount equal to the total funds held in its Trust Account (as defined in the Subscription
Agreement) on the Closing Date (after deducting the amounts owed to FEAC Shareholders who have properly exercised their redemption rights, a reasonable estimate of the amounts to be paid for any Dissenting FEAC Shares and the deferred discount owed
to the underwriters of FEAC&#146;s initial public offering), less the principal amount of Note 3 (together, the &#147;<U>Loan Amount</U>&#148;), in consideration for which Newco will issue a CDN$ denominated
<FONT STYLE="white-space:nowrap">non-interest</FONT> bearing demand promissory note to FEAC having a principal amount equal to the Loan Amount converted to its Canadian dollar equivalent based on the C$:U.S.$ Bank of Canada daily exchange rate on
the business day immediately prior to the Closing Date (&#147;<U>Note 1</U>&#148;), following which FEAC will sell to Newco, and Newco will purchase, all of the outstanding common shares of Can Merger Sub for a purchase price of CDN$ 10 (the
&#147;<U>Can Merger Sub Share Sale</U>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, on the Closing Date and pursuant to the Plan of Arrangement (as defined below),
following the Can Merger Sub Share Sale but prior to the Amalgamation, the Investor and the Other Subscribers (as defined in the Subscription Agreement), on the terms and conditions set forth in the Subscription Agreement, this Agreement, the Other
Subscription Agreements (as defined in the Subscription Agreement) and the side letters that the Other Subscribers have, severally and not jointly, entered into with FEAC and Newco in substantially the form hereof (the &#147;<U>Other Side
Letters</U>&#148;; the equity financing under the Subscription Agreement, this Agreement, the Other Subscription Agreements and the Other Side Letters, the &#147;<U>PIPE Financing</U>&#148;) shall purchase Ordinary Shares (or after the Assumption,
Newco Common Shares), for an aggregate subscription price of $56,891,682.00; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, on the Closing Date and pursuant to the Plan of
Arrangement, the Amended 2022 Convertible Notes and 2023 Convertible Notes will automatically convert, concurrent with the consummation of the PIPE Financing, into that number of common shares of enGene that, when exchanged at the Company Exchange
Ratio shall equal that number of Ordinary Shares (or after the Assumption, Newco Common Shares) that the holders of the Amended 2022 Convertible Notes and 2023 Convertible Notes would have received if they subscribed for Ordinary Shares (or after
the Assumption, Newco Common Shares) on the same terms as the Subscription Agreement as amended by this Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, on the
Closing Date and pursuant to the Plan of Arrangement, after the consummation of the PIPE Financing and the conversion of the Company Convertible Notes, Can Merger Sub and enGene will amalgamate in accordance with the terms of the plan of arrangement
(the &#147;<U>Plan of Arrangement</U>&#148;) substantially in the form attached to the Business Combination Agreement (the &#147;<U>Amalgamation</U>&#148;) and pursuant to the Amalgamation, (i)&nbsp;each enGene common share outstanding immediately
prior to the Amalgamation shall be exchanged for Newco Common Shares per the Company Exchange Ratio, each Company Equity Award (as defined in the Business Combination Agreement) outstanding immediately prior to the Amalgamation shall be exchanged
for Rollover Equity Awards (as defined in the Business Combination Agreement) per the Company Exchange Ratio and each enGene warrant outstanding immediately prior to the Amalgamation shall be exchanged for Newco Warrants per the Company Exchange
Ratio, (ii)&nbsp;each Can Merger Sub share outstanding immediately prior to the Amalgamation shall be exchanged for one common share in the authorized share capital of the amalgamated entity, and (iii)&nbsp;in consideration for the issuance of Newco
Common Shares, the amalgamated entity shall issue its common shares to Newco, in each case upon and subject to the other terms and conditions set forth in the Business Combination Agreement, the Plan of Arrangement and in accordance with the
provisions of applicable law (the time at which the Amalgamation is completed, the &#147;<U>Amalgamation Closing</U>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, on
the Closing Date and pursuant to the Plan of Arrangement, following the Amalgamation, Newco will continue from being a corporation incorporated under and governed by the <I>Canada Business Corporations Act</I> to a company continued to and governed
by the <I>Business Corporations Act</I> (British Columbia) (the &#147;<U>Continuance</U>&#148;) and, in connection with the Continuance, the articles of Newco shall be amended to reflect the requirement of the continued jurisdiction, among other
things; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-2-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, on the Closing Date, and prior to the Amalgamation, the Newco Common Shares and
Newco Warrants will be listed on Nasdaq or such other Exchange as agreed to by FEAC and enGene; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, immediately following the
Closing Date, FEAC will repurchase shares held by Newco in an aggregate amount equal to Note 1 and in consideration therefor issue to Newco a CDN$ denominated <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing demand promissory note in a
principal amount equal to the outstanding principal amount of Note 1 (&#147;<U>Note 2</U>&#148;), following which Note 1 and Note 2 (each having the same outstanding principal amount) will be set off by FEAC and Newco in full repayment of the
respective principal amounts (the &#147;<U>Notes <FONT STYLE="white-space:nowrap">Set-Off</FONT></U>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, following the Notes
<FONT STYLE="white-space:nowrap">Set-Off</FONT> becoming effective, Newco will transfer Note 3 to enGene in consideration for the issuance by enGene from treasury of additional common shares of enGene, following which FEAC will repay the outstanding
principal amount of Note 3 to Newco, and subsequently FEAC will be placed in liquidation in accordance with applicable Cayman law; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, to rationalize the capital structure of Newco and to satisfy the valuation objectives of FEAC and Newco, on the one hand, and of the
Investor, on the other hand, FEAC (or after the Assumption, Newco) desires to issue and sell and Investor desires to subscribe for and purchase the Additional Securities (as defined below) and the Subscribed Shares (as defined in the Subscription
Agreement), for total consideration equal to the Purchase Price; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">WHEREAS, subsequent to the FEAC Reorganization becoming effective and
prior to the consummation of the PIPE Financing, all rights, covenants and obligations of FEAC, including the rights, covenants and obligations under the Subscription Agreement and under this Agreement, will be assumed by Newco (the
&#147;<U>Assumption</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the premises and the mutual promises contained herein and for other
good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each of the Parties, intending to be legally bound, hereby agrees as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. Unless otherwise indicated or the context otherwise requires, by virtue of, and with effect from, the FEAC Reorganization and the
Assumption becoming effective, all references herein (i)&nbsp;to FEAC, shall refer to Newco, and (ii)&nbsp;to the Subscribed Shares shall refer to Newco Common Shares of the corresponding number rather than ordinary shares of FEAC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Issuance and Subscription</U>. (a)&nbsp;In connection with the Subscription Agreement and in consideration of the Purchase Price to be
paid by Investor set forth in the Subscription Agreement, FEAC (or after the Assumption, Newco) agrees to issue and sell and Investor agrees to subscribe for and purchase, on the Closing Date following the Can Merger Sub Share Sale and contingent
upon the completion of each element of the Transactions (as defined in the Subscription Agreement) (other than those Transactions that are scheduled to be completed following the Amalgamation Closing), including the substantially concurrent
occurrence of the Amalgamation Closing, an additional [&#149;] Ordinary Shares (or after the Assumption, Newco Common Shares, the &#147;<U>Additional Shares</U>&#148;) and [&#149;] FEAC warrants (which shall be on terms substantially similar to the
terms of the FEAC Public Warrants, the &#147;<U>FEAC PIPE Warrants</U>&#148;) or after the Assumption, warrants of Newco (which shall be on terms substantially similar to the FEAC PIPE Warrants, as adjusted for a Canadian public company, the
&#147;<U>Newco Warrants</U>&#148; and, together with the Additional Shares, the &#147;<U>Additional Securities</U>&#148;), in each case on the terms and subject to the conditions set forth in the Subscription Agreement and this Agreement, resulting
in an aggregate amount of [&#149;] Ordinary Shares (or after the Assumption, Newco Common Shares) and [&#149;] FEAC PIPE Warrants (or after the Assumption, Newco Warrants) to be issued and sold by FEAC (or after the Assumption, Newco) to Investor in
consideration of the Purchase Price to be paid by Investor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) References in the Subscription Agreement to &#147;Subscribed Shares&#148;
shall be deemed to include the Additional Securities and the Subscription Agreement together with this Agreement comprises the legal and economic arrangement between the parties and shall govern the Investor&#146;s investment in the Subscribed
Shares </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-2-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and the Additional Securities. To the extent of any inconsistency between this Agreement and the Subscription Agreement, this Agreement shall prevail. After the Assumption, the Parties
acknowledge and agree that the Investor is subscribing for and purchasing, and Newco is issuing and selling, the Subscribed Shares and the Additional Securities as a single transaction, in exchange for aggregate consideration equal to the Purchase
Price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Representations, Warranties and Agreements</U>. Sections 2 and 3 of the Subscription Agreement shall apply to this
Agreement, <I>mutatis mutandis</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Registration Rights</U>. Section&nbsp;4 of the Subscription Agreement shall apply to this
Agreement with respect to the Additional Securities, and the shares underlying the FEAC PIPE Warrants or the Newco Warrants, as the case may be, <I>mutatis mutandis</I>. For the avoidance of doubt, the Additional Securities, and the shares
underlying the FEAC PIPE Warrants or the Newco Warrants, as the case may be, shall be deemed to be &#147;Registrable Securities&#148; as such term is defined in, and for all purposes under, the Subscription Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Termination</U>. Section&nbsp;5 of the Subscription Agreement shall apply to this Agreement, <I>mutatis mutandis</I>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Miscellaneous, Other</U>. Sections 6, 7, 9 and 10 of the Subscription Agreement shall apply to this Agreement, <I>mutatis mutandis</I>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Trust Account Waiver</U>. Section&nbsp;8 of the Subscription Agreement (including Section&nbsp;6.6 &#147;<I>Newco Assumption of
Obligations</I>&#148;) shall apply to this Agreement, <I>mutatis mutandis</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[signature page follows] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-2-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, each of FEAC, Newco and Investor has executed or caused this Agreement to be
executed by its duly authorized representative as of the date first mentioned above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>FORBION EUROPEAN ACQUISITION CORP.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ENGENE HOLDINGS INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Subscription Agreement Side Letter] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-2-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accepted and agreed: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INVESTOR: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Subscription Agreement Side Letter] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-2-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit <FONT STYLE="white-space:nowrap">C-3</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form of <FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreement </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-3-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Final Form </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF <FONT STYLE="white-space:nowrap">NON-REDEMPTION</FONT> AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS <FONT STYLE="white-space:nowrap">NON-REDEMPTION</FONT> AGREEMENT (this &#147;<U>Agreement</U>&#148;) is made and entered into as of May
16<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>, 2023 by and among Forbion European Acquisition Corp., a Cayman Islands exempted company (&#147;<U>FEAC</U>&#148;), [&#149;], a [&#149;] and a holder of certain FEAC Class&nbsp;A Shares and
certain FEAC Public Warrants (as defined below) (the &#147;<U>FEAC Shareholder</U>&#148;) and enGene Holdings Inc., a company incorporated under the laws of Canada (&#147;<U>Newco</U>&#148;). Each of FEAC, the FEAC Shareholder and Newco will
individually be referred to herein as a &#147;<U>Party</U>&#148; and, collectively, as the &#147;<U>Parties</U>&#148;. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the Business Combination
Agreement (as defined below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this agreement: (i) &#147;<U>FEAC Class</U><U></U><U>&nbsp;A Shares</U>&#148; means FEAC
Class&nbsp;A ordinary shares, $0.0001 par value; (ii) &#147;<U>FEAC Class</U><U></U><U>&nbsp;B Shares</U>&#148; means FEAC&#146;s Class&nbsp;B ordinary shares, $0.0001 par value; (iii) &#147;<U>FEAC Shares</U>&#148; means (a)&nbsp;prior to the
Class&nbsp;B Conversion (as defined below), collectively, the FEAC Class&nbsp;A Shares and the FEAC Class&nbsp;B Shares, and (b)&nbsp;from and after the Class&nbsp;B Conversion, the FEAC Class&nbsp;A Shares after giving effect to the Class&nbsp;B
Conversion; and (iv)&nbsp;a &#147;<U>FEAC Public Warrant</U>&#148; means each warrant to purchase one FEAC Class&nbsp;A Share at an exercise price of $11.50 per share, subject to adjustment, upon the terms and conditions in the FEAC Warrant
Agreement (as defined in the Business Combination Agreement). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Can Merger Sub, a company to be incorporated under the laws of
Canada (&#147;<U>Can Merger Sub</U>&#148;), will be a wholly-owned subsidiary of FEAC incorporated solely for purposes of effecting the Transactions (as defined in the Business Combination Agreement), and Cayman Merger Sub, a company to be
incorporated as a Cayman Island exempted company (&#147;<U>Cayman Merger Sub</U>&#148;) will be a wholly-owned subsidiary of Newco incorporated solely for purposes of effecting the Transactions; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, enGene Inc., a corporation existing under the laws of Canada (&#147;<U>enGene</U>&#148;) entered into a Note Purchase Agreement dated
as of October&nbsp;20, 2022 by and among enGene, Forbion Capital Fund III Cooperatief U.A. (&#147;<U>Forbion Capital Fund III</U>&#148;), Fonds de Solidarit&eacute; des Travailleurs du Qu&eacute;bec (F.T.Q.) (&#147;<U>FSTQ</U>&#148;), Lumira
Ventures III, L.P. (&#147;<U>Lumira III</U>&#148;), Lumira Ventures III (International), L.P. (&#147;<U>Lumira International III</U>&#148;), Merck Lumira Biosciences Fund, L.P. (&#147;<U>Merck</U>&#148;), Merck Lumira Biosciences Fund
(Qu&eacute;bec), L.P. (&#147;<U>Merck Qu</U><U>&eacute;</U><U>bec</U>&#148; and together with, Merck, FSTQ, Lumira III, Lumira International III and Forbion Capital Fund III, collectively the &#147;<U>2022</U> <U>Noteholders</U>&#148;) (the
&#147;<U>2022 Note Purchase Agreement</U>&#148;) pursuant to which enGene issued $18.4&nbsp;million of convertible promissory notes (each a &#147;<U>2022 Convertible Note</U>&#148; and collectively, the &#147;<U>2022 Convertible Notes</U>&#148;) to
the 2022 Noteholders in substantially the form attached to the 2022 Note Purchase Agreement on the terms and conditions set forth therein; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, enGene and each 2022 Noteholder have entered into amended and restated convertible promissory notes on or about the date hereof, to
amend and restate the 2022 Convertible Notes (each an &#147;<U>Amended 2022 Convertible Note</U>&#148; and collectively, the &#147;<U>Amended 2022 Convertible Notes</U>&#148;) pursuant to which (i)&nbsp;the Amended 2022 Convertible Notes are, among
other things, convertible into that number of common shares of enGene that, when exchanged at the Company Exchange Ratio (as defined in the Business Combination Agreement), shall equal that number of FEAC Class&nbsp;A Shares (or after the Assumption
(as defined below), Newco Shares (as defined below)) that the holders of the Amended 2022 Convertible Notes would have received if they subscribed for FEAC Class&nbsp;A Shares or, after the Assumption, Newco Shares) on the same terms as the PIPE
Financing, and (ii)&nbsp;each 2022 Noteholder received warrants to acquire common shares of enGene in consideration of certain amendments set forth in each Amended 2022 Convertible Note (the &#147;<U>2022 Warrants</U>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, concurrently with the execution and delivery of this Agreement and the Business Combination Agreement, Forbion Growth Sponsor FEAC I
B.V., a private limited liability company incorporated in The Netherlands (the &#147;<U>Sponsor</U>&#148;) and Investissement Qu&eacute;bec (&#147;<U>IQ</U>&#148;) are entering into agreements with enGene, pursuant to which the Sponsor and IQ will
purchase, in one or more closings, (i)&nbsp;convertible promissory notes of enGene (the &#147;<U>Original</U> <U>2023 Convertible Notes</U>&#148; and, together with the Amended 2022 Convertible Notes, the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-3-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
&#147;<U>Company Convertible Notes</U>&#148;) that will, among other things, convert into that number of common shares of enGene that, when exchanged at the Company Exchange Ratio, shall equal
that number of FEAC Class&nbsp;A Shares (or, after the Assumption, Newco Shares) that the holders of the Original 2023 Convertible Notes would have received if they subscribed for FEAC Class&nbsp;A Shares (or, after the Assumption, Newco Shares) on
the same terms as the PIPE Financing, and (ii)&nbsp;warrants to acquire common shares of enGene (the &#147;<U>Original 2023 Warrants</U>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company entered into a Note Purchase Agreement dated as of April&nbsp;4, 2023 by and among the Company, Forbion Capital Fund III,
FSTQ, Lumira III, Lumira International III, Lumira Ventures IV, L.P., Lumira Ventures IV (International), L.P., Merck, Merck Qu&eacute;bec (collectively, with respect to the 2023 Subordinated Financing (as defined below), the &#147;<U>2023
Noteholders</U>&#148;) (the &#147;<U>2023 Subordinated Note Purchase Agreement</U>&#148;) pursuant to which the Company issued $8.0&nbsp;million of subordinated promissory notes (each a &#147;<U>2023 Subordinated Note</U>&#148; and collectively, the
&#147;<U>2023 Subordinated Notes</U>&#148;) to the 2023 Noteholders in substantially the form attached to the 2023 Subordinated Note Purchase Agreement on the terms and conditions set forth therein (the &#147;<U>2023 Subordinated
Financing</U>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, concurrently with the execution and delivery of this Agreement, the Company is entering into agreements
with the 2023 Noteholders pursuant to which the Company will repay the 2023 Subordinated Notes by issuing to each 2023 Noteholder (i)&nbsp;an amount of convertible promissory notes of the Company substantially in the same form and on the same terms
as the Original 2023 Convertible Notes (the &#147;<U>Additional 2023 Convertible Notes</U>&#148; and, together with the Original 2023 Convertible Notes, the &#147;<U>2023 Convertible Notes</U>&#148;), and (ii)&nbsp;a number of warrants to acquire
common shares of the Company substantially in the same form and on the same terms as the Original 2023 Warrants, corresponding, in the aggregate, to the principal amount of 2023 Subordinated Notes held by such 2023 Noteholder; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, FEAC, Newco and enGene have, concurrently with the execution and delivery of this Agreement, entered into that certain Business
Combination Agreement, dated as of the date hereof (as amended, modified, supplemented or waived from time to time in accordance with its terms, the &#147;<U>Business Combination Agreement</U>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, concurrently with the execution and delivery of this Agreement, certain investors (the &#147;<U>PIPE Investors</U>&#148;) are each
entering into a subscription agreement, substantially in the form attached to the Business Combination Agreement (the &#147;<U>Subscription Agreement</U>&#148; and collectively, the &#147;<U>Subscription Agreements</U>&#148;) with FEAC and Newco,
pursuant to which, among other things, the PIPE Investors have agreed, subject to the completion of each element of the Transactions (other than those Transactions that are scheduled to be completed following the Closing Date (as defined below)), to
subscribe for and purchase, and FEAC has agreed that it will issue and sell to the PIPE Investors (which obligation will be assumed (the &#147;<U>Assumption</U>&#148;) by Newco upon the completion of the FEAC Reorganization (as defined below) and
prior to the consummation of the PIPE Financing (as defined below)) the number of FEAC Class&nbsp;A Shares (or, after the Assumption, Newco Shares) provided for in the applicable Subscription Agreement (as amended by the applicable Side Letter
Agreement (as defined below)) in exchange for the purchase price set forth therein (the equity financing under the Subscription Agreements and the Side Letter Agreements is hereinafter referred to as the &#147;<U>PIPE Financing</U>&#148;), in each
case on the terms and subject to the conditions set forth in the relevant Subscription Agreement and Side Letter Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS,
concurrently with the execution and delivery of this Agreement, each PIPE Investor is entering into a side letter agreement, substantially in the form attached to the Business Combination Agreement (the &#147;<U>Side Letter Agreement</U>&#148; and
collectively, the &#147;<U>Side Letter Agreements</U>&#148;) with FEAC and Newco to amend the relevant Subscription Agreement and which, together with the relevant Subscription Agreement, will reflect the total number of FEAC Class&nbsp;A Shares and
FEAC warrants on terms substantially similar as the FEAC Public Warrants (the &#147;<U>FEAC PIPE Warrants</U>&#148;) to be issued by FEAC (or after the Assumption, the total number of common shares of Newco (the &#147;<U>Newco Shares</U>&#148;) and
warrants to acquire Newco Shares (the &#147;<U>Newco Warrants</U>&#148;) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-3-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to be issued by Newco) pursuant to the PIPE Financing in consideration of the purchase price set forth in the relevant Subscription Agreement, in each case on the terms and subject to the
conditions set forth in the relevant Subscription Agreement and Side Letter Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, as of the date of this Agreement, the
Sponsor owns 3,162,500 FEAC Class&nbsp;B Shares and 5,195,000 FEAC private placement warrants (each whole warrant entitling the holder thereof to purchase one FEAC Class&nbsp;A Share, the &#147;<U>FEAC Private Placement Warrants</U>&#148; and,
together with the FEAC Public Warrants, the &#147;<U>FEAC Warrants</U>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, assuming that the aggregate principal amount
outstanding under the Working Capital Loan Note and any Extension Loan Notes (as defined in the Business Combination Agreement) equals or exceeds $1,500,000 on the day which is two (2)&nbsp;Business Days (as defined in the Business Combination
Agreement) prior to the Closing Date (as defined below), FEAC shall cause the Sponsor (or its Affiliate (as defined in the Business Combination Agreement) or designee, as applicable), as payee of the Working Capital Loan Note and any Extension Loan
Notes, to elect to convert an amount equal to $1,500,000 of the aggregate principal amount outstanding under the Working Capital Loan Note and any Extension Loan Notes, taken together, into additional FEAC Private Placement Warrants at a price of
$1.50 per FEAC Private Placement Warrant, which upon such election will be issued by FEAC to the Sponsor (or its Affiliate or designee, as applicable) immediately prior to the Surrender (as defined below) on the day which is two (2)&nbsp;Business
Days prior to the Closing Date, in each case in accordance with the FEAC Warrant Agreement and the relevant promissory note governing the Working Capital Loan Note and/or any Extension Loan Notes, as applicable, following which the Sponsor is
expected to own 6,195,000 FEAC Private Placement Warrants); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, concurrently with the execution and delivery of this Agreement, the
Sponsor, FEAC and the other parties thereto are entering into the sponsor and insiders letter agreement (the &#147;<U>Sponsor and Insiders Letter Agreement</U>&#148;), pursuant to which, among other things, the Sponsor has agreed to surrender, after
giving effect to the Sponsor Loans Conversion, 1,789,004 FEAC Class&nbsp;B Shares and 5,463,381 FEAC Private Placement Warrants, as a contribution to the capital of FEAC and for no consideration, effective immediately prior to the Class&nbsp;B
Conversion (as defined below) on the day which is two (2)&nbsp;Business Days prior to the Closing Date, in each case, on the terms and conditions set forth in Business Combination Agreement and the Sponsor and Insiders Letter Agreement (the
&#147;<U>Surrender</U>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, on the day which is two (2)&nbsp;Business Days prior to the Closing Date, each FEAC Class&nbsp;B
Share that remains outstanding following the Surrender of the 1,789,004 FEAC Class&nbsp;B Shares held by the Sponsor, as provided in the Sponsor and Insiders Letter Agreement, shall be exchanged (the &#147;<U>Class</U><U></U><U>&nbsp;B
Conversion</U>&#148;) for one FEAC Class&nbsp;A Share; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, on the day which is one (1)&nbsp;Business Day prior to the Closing Date,
Cayman Merger Sub will merge with and into FEAC with FEAC as the surviving entity pursuant to a plan of merger under the laws of the Cayman Islands (the &#147;<U>Cayman Merger</U>&#148;), as follows: (i)&nbsp;Newco will issue to the holders of FEAC
Shares (including the Sponsor but excluding the holders of any Dissenting FEAC Shares (as defined in the Business Combination Agreement)) Newco Shares in exchange for such holders&#146; FEAC Shares and such FEAC Shares will not be cancelled but will
be transferred to Newco, (ii)&nbsp;FEAC will thereby become a wholly-owned subsidiary of Newco and (iii)&nbsp;each issued share of Cayman Merger Sub will be exchanged for a FEAC Class&nbsp;A Share of FEAC as the surviving entity and Cayman Merger
Sub (having merged into FEAC) will cease to exist as a separate entity by virtue of the Cayman Merger; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS concurrently with the
Cayman Merger, and effective at the same time the Cayman Merger becomes effective under the Cayman Islands law, (i)&nbsp;Newco will assume the FEAC Warrants (as so assumed, Newco Warrants) pursuant to the Warrant Assignment, Assumption and Amendment
Agreement, (ii)&nbsp;FEAC as the entity surviving the Cayman Merger will issue to Newco a <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing demand promissory note payable denominated in CDN$ having a principal amount equal to the fair
market value of the FEAC Warrants </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-3-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
assumed by Newco (as so assumed, Newco Warrants) (&#147;<U>Note 3</U>&#148;) in consideration of the assumption by Newco of obligations under the FEAC Warrants (as so assumed, Newco Warrants) and
(iii)&nbsp;Newco will redeem the initial Newco Shares held by its formation shareholder for an amount equal to the amount of capital that such formation shareholder contributed for purposes of the incorporation of Newco (such transactions, together
with the Cayman Merger, the &#147;<U>Cayman Reorganization</U>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, following the Cayman Reorganization, FEAC will file an
election to change its classification for U.S. federal income tax purposes from a corporation to an entity disregarded as separate from its owner Newco, to be effective as of the beginning of the Closing Date (the &#147;<U>U.S. Entity Classification
Election</U>&#148; and, together with the Cayman Reorganization, the &#147;<U>FEAC Reorganization</U>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, on the Closing
Date and pursuant to the Plan of Arrangement (as defined below), subsequent to the FEAC Reorganization becoming effective and prior to the consummation of the PIPE Financing, FEAC will loan to Newco an amount equal to the total funds held in its
Trust Account on the Closing Date (after deducting the amounts owed to the holders of FEAC Class&nbsp;A Shares who have properly exercised their redemption rights, a reasonable estimate to be paid for any Dissenting FEAC Shares and the deferred
discount owed to the underwriters of FEAC&#146;s initial public offering), less the principal amount of Note 3 (together, the &#147;<U>Loan Amount</U>&#148;) in consideration for which Newco will issue a CDN$ denominated <FONT
STYLE="white-space:nowrap">non-interest</FONT> bearing demand promissory note to FEAC having a principal amount equal to the Loan Amount converted to its Canadian dollar equivalent based on the C$:U.S.$ Bank of Canada daily exchange rate on the
Business Day immediately prior to the Closing Date (&#147;<U>Note 1</U>&#148;), following which FEAC will sell to Newco, and Newco will purchase, all of the outstanding common shares of Can Merger Sub for a purchase price of CDN$ 10 (the
&#147;<U>Can Merger Sub Share Sale</U>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, on the Closing Date and pursuant to the Plan of Arrangement, following the Can
Merger Sub Share Sale but prior to the Amalgamation, the PIPE Financing shall be consummated pursuant to the Subscription Agreements and the Side Letter Agreements and the transactions contemplated by Section&nbsp;4 of this Agreement shall be
consummated pursuant to this Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, on the Closing Date and pursuant to the Plan of Arrangement, the Amended 2022
Convertible Notes and 2023 Convertible Notes will automatically convert, concurrent with the consummation of the PIPE Financing and the transactions contemplated by Section&nbsp;4 of this Agreement, into that number of common shares of enGene that,
when exchanged at the Company Exchange Ratio shall equal that number of FEAC Class&nbsp;A Shares (or, after the Assumption, Newco Shares) that the holders of the Amended 2022 Convertible Notes and 2023 Convertible Notes would have received if they
subscribed for FEAC Class&nbsp;A Shares (or, after the Assumption, Newco Shares) on the same terms as the PIPE Financing; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, on the
Closing Date and pursuant to the Plan of Arrangement, after the consummation of the PIPE Financing and the conversion of the Company Convertible Notes, Can Merger Sub and enGene will amalgamate in accordance with the terms of the plan of arrangement
(the &#147;<U>Plan of Arrangement</U>&#148;) substantially in the form attached to the Business Combination Agreement (the &#147;<U>Amalgamation</U>&#148;) and pursuant to the Amalgamation, (i)&nbsp;each enGene common share outstanding immediately
prior to the Amalgamation shall be exchanged for Newco Shares per the Company Exchange Ratio, each Company Equity Award (as defined in the Business Combination Agreement) outstanding immediately prior to the Amalgamation shall be exchanged for
Rollover Equity Awards (as defined in the Business Combination Agreement) per the Company Exchange Ratio and each enGene warrant outstanding immediately prior to the Amalgamation shall be exchanged for Newco Warrants per the Company Exchange Ratio,
(ii)&nbsp;each Can Merger Sub share outstanding immediately prior to the Amalgamation shall be exchanged for one common share in the authorized share capital of the amalgamated entity, and (iii)&nbsp;in consideration for the issuance of Newco
Shares, the amalgamated entity shall issue its common shares to Newco, in each case upon and subject to the other terms and conditions set forth in the Business Combination Agreement, the Plan of Arrangement and in accordance with the provisions of
applicable Law (the time at which the Amalgamation is completed, the &#147;<U>Amalgamation Closing</U>&#148;); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-3-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, on the Closing Date and pursuant to the Plan of Arrangement, following the
Amalgamation, Newco will continue from being a corporation incorporated under and governed by the <I>Canada Business Corporations Act</I> to a company continued to and governed by the <I>Business Corporations Act</I> (British Columbia) (the
&#147;<U>Continuance</U>&#148;) and, in connection with the Continuance, the articles of Newco shall be amended to reflect the requirements of the continued jurisdiction, among other things; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, on the Closing Date, and prior to the Amalgamation, the Newco Shares and Newco Warrants will be listed on Nasdaq or such other
Exchange as agreed to by FEAC and enGene; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, immediately following the Closing Date, FEAC will repurchase shares held by Newco in
an aggregate amount equal to Note 1 and in consideration therefor issue to Newco a CDN$ denominated <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing demand promissory note in a principal amount equal to the outstanding principal amount
of Note 1 (&#147;<U>Note 2</U>&#148;), following which Note 1 and Note 2 (each having the same outstanding principal amount) will be set off by FEAC and Newco in full repayment of their respective principal amounts (the &#147;<U>Notes <FONT
STYLE="white-space:nowrap">Set-Off</FONT></U>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, following the Notes <FONT STYLE="white-space:nowrap">Set-Off</FONT>
becoming effective, Newco will transfer Note 3 to enGene in consideration for the issuance by enGene from treasury of additional common shares of enGene, following which FEAC will repay the outstanding principal amount of Note 3 and subsequently be
placed in liquidation in accordance with applicable Cayman law; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, as of the date hereof, the FEAC Shareholder is the beneficial
owner of [&#149;] FEAC Class&nbsp;A Shares (collectively, the &#147;<U>Subject FEAC Equity Securities</U>&#148; and, each, a &#147;<U>Subject FEAC Equity Security</U>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the FEAC Shareholder acknowledges and agrees that FEAC and the other parties to the Business Combination Agreement would not have
entered into and agreed to consummate the transactions contemplated by the Business Combination Agreement without the FEAC Shareholder entering into this Agreement and agreeing to be bound by the agreements, covenants and obligations contained in
this Agreement; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, to rationalize the capital structure of Newco and to satisfy the valuation objectives of FEAC and Newco, on
the one hand, and of the FEAC Shareholder, on the other hand, and in consideration of the FEAC Shareholder&#146;s commitment to, among other things, not redeem the Subject FEAC Equity Securities, and subject to the conditions set forth herein, FEAC
(or, after the Assumption, Newco) desires to issue and sell and the FEAC Shareholder desires to subscribe for the Additional Securities (as defined below); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, subsequent to the FEAC Reorganization becoming effective and prior to the consummation of the PIPE Financing and the transactions
contemplated in Section&nbsp;4 of this Agreement, all rights, covenants and obligations of FEAC, including the rights, covenants and obligations under this Agreement, will be assumed by Newco pursuant to the Assumption. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the premises and the mutual promises contained herein and for other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, each of the Parties, intending to be legally bound, hereby agrees as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Agreement to Vote</U>. The FEAC Shareholder hereby unconditionally and irrevocably agrees, with effect from
the date hereof and until the earlier of (x)&nbsp;the date on which this Agreement is terminated in accordance with Section&nbsp;7 hereof and (y)&nbsp;the Closing Date (the &#147;<U>Voting and <FONT STYLE="white-space:nowrap">Lock-Up</FONT>
Period</U>&#148;), to be present at any meeting of the shareholders of FEAC, and to vote (in person or by proxy), or consent to any action by written consent or resolution with respect to, all of the Subject FEAC Equity Securities (i)&nbsp;in favor
of the Transaction Proposals (as defined in the Business Combination Agreement) and any other matter reasonably necessary to the consummation of the Transactions (as defined in the Business Combination Agreement) and the other matters contemplated
by the Business Combination Agreement and considered and voted upon by the shareholders of FEAC, and (ii)&nbsp;in opposition to: (A)&nbsp;any and all other proposals (1)&nbsp;that could
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-3-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
reasonably be expected to delay or impair the ability of FEAC to consummate the transactions contemplated by the Business Combination Agreement or any Ancillary Agreement (as defined in the
Business Combination Agreement) or (2)&nbsp;which are in competition with or materially inconsistent with the Business Combination Agreement, any Transaction and the transactions contemplated thereby, or (B)&nbsp;any other action, proposal,
transaction or agreement involving FEAC or any of its subsidiaries that is intended, or would reasonably be expected, to prevent, impede, interfere with, delay, postpone or adversely affect in any material respect the transactions contemplated by
the Business Combination Agreement or any Ancillary Agreement or would reasonably be expected to result in (x)&nbsp;any breach of any representation, warranty, covenant, obligation or agreement of FEAC in the Business Combination Agreement or any
Ancillary Agreement or (y)&nbsp;any of the conditions to FEAC&#146;s obligations under the Business Combination Agreement or any Ancillary Agreement not being fulfilled. The FEAC Shareholder shall deliver to FEAC and Newco evidence of its compliance
with its obligations hereunder as may be reasonably requested. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>No Redemption</U>. The FEAC Shareholder hereby agrees that it shall not redeem, or submit a request to
FEAC&#146;s transfer agent or otherwise exercise any right to redeem, any Subject FEAC Equity Security. Prior to the Closing and after the last date for redemption of FEAC Class&nbsp;A Shares, the FEAC Shareholder shall deliver to FEAC and Newco
evidence that it continues to hold the Subject FEAC Equity Securities and that such Subject FEAC Equity Securities have not been submitted for redemption. For the avoidance of doubt, the restrictions set forth in this Section&nbsp;2 shall not apply
to any FEAC Class&nbsp;A Shares held by the FEAC Shareholder other than the Subject FEAC Equity Securities. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U><FONT STYLE="white-space:nowrap">Lock-Up</FONT> of Subject FEAC Equity Securities</U>. The FEAC Shareholder
hereby agrees that, with effect from the date hereof and during the Voting and <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period, it shall not, directly or indirectly (including by operation of law), (i) sell, assign, transfer, exchange, offer,
assign, swap, convert, place a lien on, pledge, or otherwise dispose or encumber any of the Subject FEAC Equity Securities, (ii)&nbsp;deposit any of the Subject FEAC Equity Securities into a voting trust or enter into a voting agreement or
arrangement or grant any proxy or power of attorney with respect to any of the Subject FEAC Equity Securities that conflicts with any of the covenants or agreements set forth in this Agreement, (iii)&nbsp;publicly announce any intention to effect,
or enter into any contract, option or other arrangement or undertaking with respect to, any transaction specified in clause (i)&nbsp;or (ii) with respect to the Subject FEAC Equity Securities, (iv)&nbsp;engage in any hedging or other transaction
which is designed to, or which would (either alone or in connection with one or more events, developments or events (including the satisfaction or waiver of any conditions precedent)), lead to or result in a sale or disposition of the Subject FEAC
Equity Securities even if such Subject FEAC Equity Securities would be disposed of by a Person (as defined in the Business Combination Agreement) other than the FEAC Shareholder or (v)&nbsp;take any action that would have the effect of preventing or
materially delaying the performance of its obligations under this Agreement (the covenants under (i)-(v) hereof, the &#147;<U><FONT STYLE="white-space:nowrap">Lock-Up</FONT></U>&#148;); <U>provided</U> that the
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> shall not be applicable in case of transfers of the Subject FEAC Equity Securities by the FEAC Shareholder to any fund or account managed by the same investment manager as the FEAC Shareholder in
accordance with Section&nbsp;8(b) hereof. For the avoidance of doubt, the restrictions set forth in this Section&nbsp;3 shall not apply to any FEAC Class&nbsp;A Shares held by the FEAC Shareholder other than the Subject FEAC Equity Securities.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Issuance and Subscription</U>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In consideration of the FEAC Shareholder&#146;s performance of its obligations described herein, FEAC (or after
the Assumption, Newco) agrees to issue and sell and the FEAC Shareholder agrees to subscribe for, on the Closing Date following the Can Merger Sub Share Sale and contingent upon the completion of each element of the Transactions (other than those
Transactions that are scheduled to be completed following the Amalgamation Closing), including the substantially concurrent occurrence of the Amalgamation Closing, an additional [&#149;] FEAC Class&nbsp;A Shares (or after the Assumption, Newco
Shares, the &#147;<U>Additional Shares</U>&#148;) and [&#149;] FEAC warrants (which shall be on terms substantially similar to the terms of the FEAC Public Warrants, the &#147;<U>FEAC PIPE Warrants</U>&#148;) or after the Assumption, warrants of
Newco (which shall be on terms substantially similar to the FEAC PIPE Warrants, as adjusted for a Canadian public company, the &#147;<U>Newco Warrants</U>&#148; and, together with the Additional Shares, the &#147;<U>Additional Securities</U>&#148;),
in each case on the terms </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-3-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
and subject to the conditions set forth in this Agreement. Each of the Parties hereto acknowledges and agrees that the Additional Securities will be issued in accordance with the terms of this
Agreement and pursuant to the Plan of Arrangement. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The consummation of the transactions contemplated in this Section&nbsp;4 shall occur on the Closing Date,
subject to the completion of each element of the Transactions (other than those Transactions that are scheduled to be completed following the Amalgamation Closing), including the substantially concurrent occurrence of the Amalgamation Closing. Upon
written notice from (or on behalf of) FEAC to the FEAC Shareholder (the &#147;<U>Closing Notice</U>&#148;) at least five (5)&nbsp;Business Days prior to the date that FEAC reasonably expects all conditions to the Amalgamation Closing to be satisfied
(the &#147;<U>Expected Closing Date</U>&#148;), the FEAC Shareholder shall deliver to FEAC no later than two (2)&nbsp;Business Days prior to the Expected Closing Date any other information that is reasonably requested in the Closing Notice in order
for FEAC (or, following the Assumption, Newco) to issue the Additional Securities including, without limitation, the legal name of the person in whose name such Additional Securities are to be issued, and if applicable, a duly executed Internal
Revenue Service Form <FONT STYLE="white-space:nowrap">W-9</FONT> or the applicable Internal Revenue Service Form <FONT STYLE="white-space:nowrap">W-8,</FONT> as applicable. On the Closing Date, following and subject to the Assumption, Newco shall
issue to the FEAC Shareholder (or the funds and accounts designated by the FEAC Shareholder if so designated by the FEAC Shareholder, or its nominee in accordance with its delivery instructions) or to a custodian designated by the FEAC Shareholder,
as applicable, the Additional Securities, net of Additional Securities withheld by Newco in respect of Canadian withholding tax and in respect of any additional expenses or costs reasonably expected to be incurred by Newco in connection with the
obligation to pay such Canadian withholding tax (including any fees paid to any agent to sell such withheld Additional Securities), free and clear of any liens or other restrictions whatsoever (other than those arising under state or federal
securities laws or Canadian securities laws), which Additional Securities, unless otherwise determined by FEAC (or following the Assumption, Newco), shall be uncertificated, with record ownership reflected only in the register of shareholders of
Newco and shall provide evidence of such issuance from Newco&#146;s transfer agent showing the FEAC Shareholder as the owner of the Additional Securities on and as of the Closing Date within two (2)&nbsp;Business Days of the Closing Date. If the
Transactions (other than those Transactions that are scheduled to be completed following the Amalgamation Closing) are not consummated within two (2)&nbsp;Business Days after the Expected Closing Date, any Additional Securities that had been issued
shall be cancelled. Notwithstanding anything in this Agreement to the contrary, Newco shall be entitled to take such actions as are reasonably necessary to deduct and withhold (or cause to be deducted and withheld) any shares or other securities
otherwise deliverable to the FEAC Shareholder pursuant to this Agreement on account, and in satisfaction of, any Taxes (as defined in the Business Combination Agreement), and other amounts as are required to be deducted and withheld under applicable
Tax Law (each as defined in the Business Combination Agreement) in respect of the consideration payable to the FEAC Shareholder hereunder as well as any additional expenses or costs incurred or reasonably expected to be incurred by Newco in
connection with the obligation to pay any such Taxes (including any fees paid to any agent to sell such withheld Additional Securities). Newco is thus hereby authorized to retain, sell, and/or otherwise dispose of such shares or other securities
otherwise deliverable to the FEAC Shareholder as are necessary to enable Newco to comply with such deduction and withholding requirement. The Parties shall cooperate reasonably and in good faith to consider any further arrangements that will enable
Newco to satisfy its deduction and withholding obligations under applicable Tax Law in respect of the consideration payable to the FEAC Shareholder under this Agreement in a manner that is most commercially efficient and expedient for each Party.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The obligations of FEAC (or, following the Assumption, Newco) pursuant to this Section&nbsp;4 shall be subject
to the satisfaction, or valid waiver by FEAC, of the following conditions: (i)&nbsp;the FEAC Shareholder shall have fully complied with, performed and satisfied its obligations set out in Sections 1-3 hereof, and shall have performed, satisfied and
complied in all material respects with all other covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by it at or prior to the Closing Date, (ii)&nbsp;the completion of each element of the
Transactions (other than those Transactions that are scheduled to be completed following the Amalgamation Closing), including the substantially concurrent </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-3-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
occurrence of the Amalgamation Closing, and (iii)&nbsp;all representations and warranties of the FEAC Shareholder contained in this Agreement shall be true and correct in all material respects
(other than representations and warranties that are qualified as to materiality, which representations and warranties shall be true and correct in all respects) at and as of the Closing Date (except for representations and warranties made as of a
specific date, which shall be true and correct in all material respects (other than representations and warranties that are qualified as to materiality, which representations and warranties shall be true and correct in all respects) as of such
date). </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Additional Securities, and the shares underlying the FEAC PIPE Warrants or the Newco Warrants, as the case
may be, shall be deemed to be &#147;Registrable Securities&#148; as such term is defined in, and for all purposes under, the form of Subscription Agreement attached to the Business Combination Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Representations and Warranties</U>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>FEAC Representations and Warranties</U>. FEAC represents and warrants as of the date hereof and as of the
Closing Date to the FEAC Shareholder as follows: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">FEAC has been duly incorporated and is validly existing and in good standing under the laws of the Cayman
Islands and has all requisite power and authority to own, lease and operate its properties and conduct its business as presently conducted and to enter into, deliver and perform its obligations under this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Agreement and the Business Combination Agreement (the &#147;<U>Transaction Documents</U>&#148;) have been
duly authorized, validly executed and delivered by FEAC and, assuming that the Transaction Documents constitute valid and binding obligations of the other parties thereto, are valid and binding obligations of FEAC, and are enforceable against FEAC
in accordance with their terms, except as may be limited or otherwise affected by (i)&nbsp;bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium or other laws relating to or affecting the rights of creditors generally and
(ii)&nbsp;principles of equity, whether considered at law or equity. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Assuming the accuracy of the FEAC Shareholder&#146;s representations and warranties in Section&nbsp;5.3 hereof
and Newco&#146;s representations and warranties in Section&nbsp;5.2 hereof, the execution, delivery and performance of the Transaction Documents (including compliance by FEAC with all of the provisions hereof), the issuance of the Additional
Securities and the consummation of the other transactions contemplated under the Transaction Documents, including the Transactions, do not and will not (a)&nbsp;conflict with or result in a breach or violation of any of the terms or provisions of,
or constitute a default under, or result in the creation or imposition of any lien, charge or encumbrance upon any of the property or assets of FEAC or any of its subsidiaries pursuant to the terms of any indenture, mortgage, charge, deed of trust,
loan agreement, lease, license or other agreement or instrument to which FEAC or any of its subsidiaries is a party or by which FEAC or any of its subsidiaries is bound or to which any of the property or assets of FEAC or any of its subsidiaries is
subject, which would reasonably be expected to have a material adverse effect on the business, properties, financial condition, stockholders&#146; equity or results of operations of FEAC, Newco or enGene and their respective subsidiaries, taken as a
whole, or materially and adversely affects the ability of FEAC to timely perform its obligations under this Agreement, in each case subject to the exceptions in the definition of FEAC Material Adverse Effect in the Business Combination Agreement
<I>mutatis mutandis</I> (collectively, a &#147;<U>FEAC Material Adverse Effect</U>&#148;), (b) result in any violation of the provisions of the organizational documents of FEAC or any of its subsidiaries or (c)&nbsp;result in any violation of any
statute or any judgment, order, rule or regulation of any court or governmental agency or body, domestic or foreign, having jurisdiction over FEAC or any of its subsidiaries or any of its properties that would, individually or in the aggregate,
reasonably be expected to have a FEAC Material Adverse Effect. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Newco Representations and Warranties.</U> Newco represents and warrants as of the date hereof and as of the
Closing Date to the FEAC Shareholder as follows: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Newco has been duly incorporated and is validly existing and in good standing under the laws of Canada
(provided that, following the Continuance, Newco shall be validly continued and validly </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-3-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
existing and in good standing under the laws of the Province of British Columbia), and has all requisite power and authority to own, lease and operate its properties and conduct its business as
presently conducted and to enter into, deliver and perform its obligations under this Agreement. At the Closing Date, the Additional Securities will be duly authorized and, when issued and delivered to the FEAC Shareholder, will be free and clear of
any liens or other restrictions (other than arising under applicable securities laws) in accordance with the terms of this Agreement and registered with Newco&#146;s transfer agent, the Additional Securities will be validly issued, fully paid and <FONT
STYLE="white-space:nowrap">non-assessable</FONT> and will not have been issued in violation of or subject to any preemptive or similar rights under Newco&#146;s constitutive agreements, under any agreement or instrument to which Newco is a party or
by which Newco is bound, or under applicable law. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Transaction Documents have been duly authorized, validly executed and delivered by Newco and, assuming that
the Transaction Documents constitute valid and binding obligations of the other parties thereto, are valid and binding obligations of Newco, and are enforceable against Newco in accordance with their terms, except as may be limited or otherwise
affected by (a)&nbsp;bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium or other laws relating to or affecting the rights of creditors generally and (b)&nbsp;principles of equity, whether considered at law or equity.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Assuming the accuracy of the FEAC Shareholder&#146;s representations and warranties in Section&nbsp;5.3 hereof
and FEAC&#146;s representations and warranties in Section&nbsp;5.1 hereof, the execution, delivery and performance of the Transaction Documents (including compliance by Newco with all of the provisions hereof), the issuance and sale of the
Additional Securities and the consummation of the other transactions contemplated herein, including the Transactions, do not and will not (c)&nbsp;conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a
default under, or result in the creation or imposition of any lien, charge or encumbrance upon any of the property or assets of Newco or any of its subsidiaries pursuant to the terms of any indenture, mortgage, charge, deed of trust, loan agreement,
lease, license or other agreement or instrument to which Newco or any of its subsidiaries is a party or by which Newco or any of its subsidiaries is bound or to which any of the property or assets of Newco or any of its subsidiaries is subject,
which would reasonably be expected to have a material adverse effect on the business, properties, financial condition, shareholders&#146; equity or results of operations of Newco, FEAC or enGene and their respective subsidiaries, taken as a whole,
or materially and adversely affects the ability of Newco to timely perform its obligations under this Agreement, in each case subject to the exceptions in the definition of FEAC Material Adverse Effect in the Business Combination Agreement
<I>mutatis mutandis</I> (collectively, a &#147;<U>Newco Material Adverse Effect</U>&#148;), (d) result in any violation of the provisions of the organizational documents of Newco or any of its subsidiaries or (e)&nbsp;result in any violation of any
statute or any judgment, order, rule or regulation of any court or governmental agency or body, domestic or foreign, having jurisdiction over Newco or any of its subsidiaries or any of its properties that would, individually or in the aggregate,
reasonably be expected to have a Newco Material Adverse Effect. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>FEAC Shareholder Representations and Warranties</U>. The FEAC Shareholder hereby represents and warrants as
of the date hereof and as of the Closing Date to FEAC and Newco as follows: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The FEAC Shareholder has been duly formed or incorporated and is validly existing in good standing under the
laws of its jurisdiction of incorporation or formation, with power and authority to enter into, deliver and perform its obligations under this Agreement. The FEAC Shareholder is and will be through the Closing Date or termination of this Agreement
in accordance with Section&nbsp;7 hereof the beneficial owner of the Subject FEAC Equity Securities, free and clear of all liens and has provided FEAC and Newco with evidence thereof. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Agreement has been duly authorized, validly executed and delivered by the FEAC Shareholder. Assuming that
this Agreement constitutes the valid and binding agreement of FEAC and Newco, this Agreement is the valid and binding obligation of the FEAC Shareholder, and is enforceable against the FEAC Shareholder in accordance with its terms, except as may be
limited or otherwise affected by </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-3-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
(i)&nbsp;bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium or other laws relating to or affecting the rights of creditors generally, and (ii)&nbsp;principles of equity,
whether considered at law or equity. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The execution, delivery and performance by the FEAC Shareholder of this Agreement and the consummation of the
transactions contemplated herein do not and will not (i)&nbsp;result in any violation of the provisions of the organizational documents of the FEAC Shareholder or any of its subsidiaries, (ii)&nbsp;result in any violation of any statute or any
judgment, order, rule or regulation of any court or governmental agency or body, domestic or foreign, having jurisdiction over the FEAC Shareholder that would reasonably be expected to have a material adverse effect on the legal authority and
ability of the FEAC Shareholder to enter into and timely perform its obligations under this Agreement (a &#147;<U>FEAC Shareholder Material Adverse Effect</U>&#148;) or (iii)&nbsp;conflict with or result in a breach or violation of any of the terms
or provisions of, or constitute a default under, or result in the creation or imposition of any lien, charge or encumbrance upon any of the property or assets of the FEAC Shareholder or any of its subsidiaries pursuant to the terms of any indenture,
mortgage, deed of trust, loan agreement, lease, license or other agreement or instrument to which the FEAC Shareholder or any of its subsidiaries is a party or by which the FEAC Shareholder or any of its subsidiaries is bound or to which any of the
property or assets of the FEAC Shareholder or any of its subsidiaries is subject, which would reasonably be expected to have a FEAC Shareholder Material Adverse Effect. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the FEAC Shareholder (i)&nbsp;(a) is a &#147;qualified institutional buyer&#148; (as defined in Rule 144A under
the Securities Act of 1933, as amended (the &#147;<U>Securities Act</U>&#148;)) or an institutional &#147;accredited investor&#148; (within the meaning of Rule 501(a)(1), (2), (3), or (7)&nbsp;under the Securities Act), (b) is an Institutional
Account as defined in FINRA Rule 4512(c) and (c)&nbsp;is a sophisticated institutional investor, experienced in investing in transactions of the type contemplated by this Agreement and capable of evaluating investment risks independently, both in
general and with regard to all transactions and investment strategies involving a security or securities, including its participation in the transactions of the type contemplated by this Agreement, in each case, satisfying the applicable
requirements set forth on <U>Schedule I</U>, (ii)&nbsp;has exercised independent judgment in evaluating its investment in the Additional Securities, (iii)&nbsp;is acquiring the Additional Securities only for its own account and not for the account
of others, or if the FEAC Shareholder is acquiring the Additional Securities as a fiduciary or agent for one or more investor accounts, each owner of such account is a qualified institutional buyer, and the FEAC Shareholder has full investment
discretion with respect to each such account, and the full power and authority to make the acknowledgements, representations, warranties and agreements herein on behalf of each owner of each such account, for investment purposes only and not with a
view to any distribution of the Additional Securities in any manner that would violate the securities laws of the United States or any other applicable jurisdiction and (iv)&nbsp;is not acquiring the Additional Securities with a view to, or for
offer or sale in connection with, any distribution thereof in violation of the Securities Act or any other securities laws of the United States or any other jurisdiction (and shall provide the requested information on <U>Schedule I</U> following the
signature page hereto). The FEAC Shareholder has determined based on its own independent review and such professional advice as it deems appropriate that acquiring the Additional Securities and its participation in the transactions contemplated by
this Agreement (i)&nbsp;are fully consistent with its financial needs, objectives and condition, and (ii)&nbsp;comply and are fully consistent with all investment policies, guidelines and other restrictions applicable to it (if any). The FEAC
Shareholder is not an entity formed for the specific purpose of acquiring the Additional Securities. The FEAC Shareholder understands that the transfer of the Additional Securities meets (i)&nbsp;the exemptions from filing under FINRA Rule
5123(b)(1)(A) and (C)&nbsp;or (J) and (ii)&nbsp;the institutional customer exemption under FINRA Rule 2111(b). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The FEAC Shareholder understands that the Additional Securities are being transferred in a transaction not
involving any public offering within the meaning of the Securities Act, that the transfer to the FEAC Shareholder is being made in reliance on a private placement exemption from registration under the Securities Act, and that the Additional
Securities have not been registered under the Securities Act or the securities laws of any other jurisdiction. Except in respect of any stock lending program, the FEAC Shareholder understands that the Additional Securities may not be offered, sold,
resold, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-3-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
transferred, pledged or otherwise disposed of by the FEAC Shareholder absent an effective registration statement under the Securities Act, except (i)&nbsp;to Newco or a subsidiary thereof,
(ii)&nbsp;to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> persons pursuant to offers and sales that occur solely outside the United States within the meaning of Regulation S under the Securities Act or (iii)&nbsp;pursuant to another applicable
exemption from the registration requirements of the Securities Act, and in each of cases (i)&nbsp;and (iii), in accordance with any applicable securities laws of the states and other jurisdictions of the United States, and that the Additional
Securities (i)&nbsp;will be &#147;restricted securities&#148; within the meaning of Rule 144 under the Securities Act (&#147;<U>Rule 144</U>&#148;) and accordingly are subject to restrictions on transferability and resale and may not be transferred
or resold except as permitted under the Securities Act and applicable state securities laws pursuant to registration or exemption therefrom and (ii)&nbsp;shall be subject to a legend to such effect (provided that such legends will be eligible for
removal upon compliance with the relevant resale provisions of Rule 144 and as set forth in this Agreement). The FEAC Shareholder acknowledges that the Additional Securities will not be immediately eligible for offer, resale, transfer, pledge or
disposition pursuant to Rule 144 until at least one year from the filing by FEAC of the &#147;Form 10 information&#148; after the Closing Date and that the provisions of Rule 144(i) will generally apply to the Additional Securities. The FEAC
Shareholder understands and agrees that the Additional Securities will be subject to the foregoing restrictions and, as a result, the FEAC Shareholder may not be able to readily resell the Additional Securities and may be required to bear the
financial risk of an investment in the Additional Securities for an indefinite period of time. The FEAC Shareholder understands that it has been advised to consult independent legal counsel prior to making any transfer of any of the Additional
Securities. The FEAC Shareholder has determined based on its own independent review and such professional advice as it deems appropriate that the Additional Securities are a suitable investment for the FEAC Shareholder, notwithstanding the
substantial risks inherent in investing in or holding the Additional Securities, and that the FEAC Shareholder is able at this time and in the foreseeable future to bear the economic risk of a total loss of the FEAC Shareholder&#146;s investment.
The FEAC Shareholder acknowledges specifically that a possibility of total loss exists. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The FEAC Shareholder understands and agrees that the FEAC Shareholder is acquiring the Additional Securities
directly from FEAC (or, after the Assumption, Newco). The FEAC Shareholder further acknowledges that there have been no representations, warranties, covenants or agreements made to the FEAC Shareholder by Sponsor, FEAC, Newco, enGene or any of their
respective affiliates or any control persons, officers, directors, employees, partners, agents or representatives, expressly or by implication, other than, in the case of Sponsor only, those representations, warranties, covenants and agreements
expressly set forth in this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The FEAC Shareholder does not have, as of the date hereof, and during the
<FONT STYLE="white-space:nowrap">30-day</FONT> period immediately prior to the date hereof the FEAC Shareholder has not, and during the period beginning as of the date hereof until the Closing Date or the earlier termination of this Agreement the
FEAC Shareholder will not have, entered into, any &#147;put equivalent position&#148; as such term is defined in Rule <FONT STYLE="white-space:nowrap">16a-1</FONT> under the Securities Exchange Act of 1934, as amended (the &#147;<U>Exchange
Act</U>&#148;) or short sale positions with respect to the securities of FEAC. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the FEAC Shareholder is or is acting on behalf of (i)&nbsp;an employee benefit plan that is subject to Title
I of the Employee Retirement Income Security Act of 1974, as amended (&#147;<U>ERISA</U>&#148;), (ii) a plan, an individual retirement account or other arrangement that is subject to Section&nbsp;4975 of the Internal Revenue Code of 1986, as amended
(the &#147;<U>Code</U>&#148;), (iii) an employee benefit plan (such as a governmental plan (as defined in Section&nbsp;3(32) of ERISA), a church plan (as defined in Section&nbsp;3(33) of ERISA) or a <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
plan (as described in Section&nbsp;4(b)(4) of ERISA)) that is subject to any federal, state, local, <FONT STYLE="white-space:nowrap">non-U.S.</FONT> or other laws or regulations that are similar to such provisions of ERISA or the Code (collectively,
&#147;<U>Similar Laws</U>&#148;) or (iv)&nbsp;an entity whose underlying assets are considered to include &#147;plan assets&#148; of any such plan, account or arrangement described in (i), (ii) and (iii)&nbsp;above (each of the foregoing described
in (i), (ii)&nbsp;(iii) and (iv) above, a &#147;<U>Plan</U>&#148;), the FEAC Shareholder represents and warrants that its acquisition and holding of the Additional Securities will not constitute or result in a
<FONT STYLE="white-space:nowrap">non-exempt</FONT> prohibited transaction under Section&nbsp;406 of ERISA or Section&nbsp;4975 of the Code or violate any Similar Laws. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-3-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the FEAC Shareholder is or is acting on behalf of a Plan, the FEAC Shareholder represents and warrants that
none of FEAC, Newco, enGene or any of their respective affiliates (the &#147;<U>Transaction Parties</U>&#148;) has acted as the Plan&#146;s fiduciary, or has been relied on for advice, with respect to its decision to acquire and hold the Additional
Securities, and none of the Transaction Parties shall at any time be relied upon as the Plan&#146;s fiduciary with respect to any decision to acquire, continue to hold or transfer the Additional Securities. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The FEAC Shareholder became aware of the transactions contemplated by this Agreement solely by means of direct
contact between the FEAC Shareholder or one of its representatives, on the one hand, and FEAC and Newco or their representatives, on the other hand, as a result of a <FONT STYLE="white-space:nowrap">pre-existing</FONT> relationship between the FEAC
and one of the FEAC Shareholder&#146;s representatives. The FEAC Shareholder did not become aware of the transfer of the Additional Securities, nor were the Additional Securities transferred to the FEAC Shareholder, by any general solicitation or
general advertising. The FEAC Shareholder acknowledges that the Additional Securities were not transferred by any form of general solicitation or general advertising, including methods described in section 502(c) of Regulation D under the Securities
Act. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(k)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The FEAC Shareholder acknowledges that it is aware that there are substantial risks incident to the ownership
of the Additional Securities, including those set forth in the investor presentation provided by FEAC (as amended and supplemented as of the date hereof) and in each form, report, statement, schedule, prospectus, proxy, registration statement and
other documents filed by FEAC with the U.S. Securities and Exchange Commission (the &#147;<U>Commission</U>&#148;). The FEAC Shareholder is able to fend for itself in the transactions contemplated herein, has such knowledge and experience in
financial and business matters as to be capable of evaluating the merits and risks of an investment in the Additional Securities, has the ability at this time and in the foreseeable future to bear the economic risks of its prospective investment and
can afford the complete loss of such investment, and the FEAC Shareholder has sought such accounting, legal and tax advice as the FEAC Shareholder has considered necessary to make an informed investment decision. The FEAC Shareholder, alone, or
together with any professional advisor(s), has analyzed and considered the risks of an investment in the Additional Securities and determined that the Additional Securities are a suitable investment. The FEAC Shareholder further acknowledges that
the FEAC Shareholder shall be responsible for any of the FEAC Shareholder&#146;s tax liabilities that may arise as a result of the transactions contemplated by this Agreement, and that neither, FEAC or Newco, nor any of their respective agents or
affiliates, have provided any tax advice or any other representation or guarantee, whether written or oral, regarding the tax consequences of the transactions contemplated by this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(l)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The FEAC Shareholder understands and agrees that no federal or state agency has passed upon or endorsed the
merits of the transfer of the Additional Securities or made any findings or determination as to the fairness of an investment in the Additional Securities and the foregoing authorities have not confirmed the accuracy or determined the adequacy of
any representation (and any representation to the contrary is a criminal offense). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(m)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The FEAC Shareholder represents and warrants that none of the FEAC Shareholder or any of its officers,
directors, managers, managing members, general partners or any other person acting in a similar capacity or carrying out a similar function on its behalf is a. a person or entity named on the List of Specially Designated Nationals and Blocked
Persons administered by the U.S. Treasury Department&#146;s Office of Foreign Assets Control (&#147;<U>OFAC</U>&#148;) or in any Executive Order issued by the President of the United States and administered by OFAC or any similar list of sanctioned
persons administered by the United Nations Security Council, the European Union, Canada, His Majesty&#146;s Treasury (&#147;<U>HMT</U>&#148;), any individual European Union member state or the United Kingdom or any other relevant sanctions authority
(collectively, &#147;<U>Sanctions Lists</U>&#148;) or a person or entity designated by any OFAC sanctions program, b. directly or indirectly 50% or more owned or otherwise controlled by, or acting on behalf of, one or more persons on a Sanctions
List, c. organized, incorporated, established, located or resident in, a country or territory that is the target of country-wide or territory-wide </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-3-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
economic or trade sanctions (currently Cuba, Iran, North Korea, Syria, the Crimea region of Ukraine, the <FONT STYLE="white-space:nowrap">so-called</FONT> Donetsk People&#146;s Republic, the <FONT
STYLE="white-space:nowrap">so-called</FONT> Luhansk People&#146;s Republic and any other Covered Region of Ukraine identified pursuant to Executive Order 14065, and <FONT STYLE="white-space:nowrap">non-government</FONT> controlled areas of the
Kherson and Zaporizhia region of Ukraine), or d. a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> shell bank or providing banking services indirectly to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> shell bank. The representations, warranties
and undertakings in this Section&nbsp;5.3(m) will not apply to any party hereto to which Council Regulation (EC) No.&nbsp;2271/96, as amended (the &#147;<U>Blocking Regulation</U>&#148;) applies, if and to the extent that such representation,
warranty or undertaking is or would be invalid or unenforceable by reason of breach of any provision of the Blocking Regulation (or any law or regulation implementing such Blocking Regulation or any similar measure in any member state of the
European Union or the United Kingdom). If the FEAC Shareholder is a financial institution subject to the Bank Secrecy Act (31 U.S.C. Section&nbsp;5311 et seq.), as amended by the USA PATRIOT Act of 2001, and its implementing regulations
(collectively, the &#147;<U>BSA/PATRIOT Act</U>&#148;), the FEAC Shareholder represents that it maintains policies and procedures reasonably designed to comply with applicable obligations under the BSA/PATRIOT Act. The FEAC Shareholder also
represents that, to the extent required, it maintains policies and procedures reasonably designed to ensure compliance with sanctions programs administered by OFAC, the United Nations Security Council, the European Union, Canada, HMT, any European
Union member state and the United Kingdom, including for the screening of its investors against the Sanctions Lists and the OFAC sanctions programs. The FEAC Shareholder further represents and warrants that, to the extent required, it maintains
policies and procedures reasonably designed to ensure that the funds held by the FEAC Shareholder and used to purchase the Additional Securities were legally derived. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(n)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Except as expressly disclosed in a Schedule 13D or Schedule 13G (or amendments thereto) filed by the FEAC
Shareholder with the Commission with respect to the beneficial ownership of FEAC&#146;s securities, the FEAC Shareholder is not currently (and at all times through the Closing Date will refrain from being or becoming) a member of a &#147;group&#148;
(within the meaning of Section&nbsp;13(d)(3) or Section&nbsp;14(d)(2) of the Exchange Act, or any successor provision) acting for the purpose of acquiring, holding or disposing of equity securities of FEAC or Newco, as applicable (within the meaning
of Rule <FONT STYLE="white-space:nowrap">13d-5(b)(1)</FONT> under the Exchange Act). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(o)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No broker, finder or other financial consultant has acted on behalf of the FEAC Shareholder in connection with
this Agreement or the transactions contemplated hereby in such a way as to create any liability on FEAC or Newco. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(p)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The FEAC Shareholder agrees that, from the date of this Agreement until the Closing Date or the earlier
termination of this Agreement, none of the FEAC Shareholder, its controlled affiliates, or any person or entity acting on behalf of the FEAC Shareholder or any of its controlled affiliates or pursuant to any understanding with the FEAC Shareholder
or any of its controlled affiliates will engage in any Short Sales with respect to securities of FEAC or Newco, as applicable. For the purposes hereof, &#147;Short Sales&#148; shall include, without limitation, all &#147;short sales&#148; as defined
in Rule 200 promulgated under Regulation SHO under the Exchange Act, and all types of direct and indirect stock pledges (other than pledges in the ordinary course of business as part of prime brokerage arrangements), forward sale contracts, options,
puts, calls, swaps and similar arrangements (including on a total return basis), including through <FONT STYLE="white-space:nowrap">non-U.S.</FONT> broker dealers or foreign regulated brokers. Notwithstanding the foregoing, (a)&nbsp;nothing herein
shall prohibit any entities under common management or that share an investment advisor with the FEAC Shareholder (including the FEAC Shareholder&#146;s controlled affiliates and/or affiliates) that have no knowledge of this Agreement or of the FEAC
Shareholder&#146;s participation in the transactions contemplated hereby from entering into any Short Sales and (b)&nbsp;in the case the FEAC Shareholder is a multi-managed investment vehicle whereby separate portfolio managers manage separate
portions of the FEAC Shareholder&#146;s assets, this Section&nbsp;5.3(p) shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision to acquire the Additional Securities covered by this
Agreement. For the avoidance of doubt, this Section&nbsp;5.3(p) shall not apply to (i)&nbsp;any sale (including the exercise of any redemption right) of securities of FEAC or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-3-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Newco, as applicable (A)&nbsp;held by the FEAC Shareholder, its controlled affiliates or any person or entity acting on behalf of the FEAC Shareholder or any of its controlled affiliates prior to
the execution of this Agreement or (B)&nbsp;purchased by the FEAC Shareholder, its controlled affiliates or any person or entity acting on behalf of the FEAC Shareholder or any of its controlled affiliates in an open market transaction after the
execution of this Agreement or (ii)&nbsp;ordinary course, <FONT STYLE="white-space:nowrap">non-speculative</FONT> hedging transactions. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(q)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The FEAC Shareholder acknowledges that it is aware that in connection with, and immediately upon completion of,
the Cayman Merger, each FEAC Class&nbsp;A Share issued and outstanding immediately prior to the effective time of the Cayman Merger shall be exchanged for one Newco Share. The FEAC Shareholder acknowledges that the above will be effected as part of
the Transactions without any further consent, vote, or approvals from the FEAC Shareholder, and to the extent that the FEAC Shareholder may have any such rights under Cayman Islands law, Canadian law or otherwise, the FEAC Shareholder effectively
forfeits such rights hereby. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(r)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The FEAC Shareholder and the beneficial subscriber, if any, acknowledges that FEAC (or following the
Assumption, Newco) may in the future be required by law to disclose the FEAC Shareholder&#146;s or beneficial subscriber&#146;s name and other information relating to this Agreement and the FEAC Shareholder&#146;s subscription hereunder, on a
confidential basis, pursuant to the <I>Proceeds of Crime (Money Laundering) and Terrorist Financing Act</I> (Canada). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(s)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The FEAC Shareholder acknowledges and agrees that the sale and delivery of the Additional Securities is subject
to applicable requirements under the securities laws and regulations of the provinces and territories of Canada (&#147;<U>Canadian Securities Laws</U>&#148;) and is conditional upon such sale being exempt from the requirements of Canadian Securities
Laws of the province or territory in which it resides or may be deemed to reside as to the filing and delivery of a prospectus and that the Additional Securities have not been qualified under a prospectus under Canadian Securities Laws. The FEAC
Shareholder acknowledges and agrees that FEAC and Newco may rely on the prospectus exemption available in respect of the transactions hereunder under Section&nbsp;2.11 (<I>Business combination and reorganization</I>) of National Instrument <FONT
STYLE="white-space:nowrap">45-106</FONT> &#150; Prospectus Exempt Distributions, or such other exemption or exemption ruling as it determines, upon the advice of counsel, to be advisable, in respect of the issuance of the Additional Securities. The
FEAC Shareholder acknowledges that FEAC and Newco, as of the date hereof, are not &#147;reporting issuers&#148; in any jurisdiction in Canada, that the Additional Securities are subject to statutory resale restrictions under applicable Canadian
Securities Laws of the province or territory in which the FEAC Shareholder resides or may be deemed to reside, which resale restrictions may apply outside of Canada, and the FEAC Shareholder covenants that it will not resell the Additional
Securities except in compliance with such laws. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(t)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The FEAC Shareholder is eligible to acquire the Additional Securities pursuant to an exemption from the
registration and prospectus requirements of Canadian Securities Laws. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(u)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The FEAC Shareholder acknowledges and agrees that: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the FEAC Shareholder is not entitled, and will not take any action to acquire any entitlement, to vote, consent
or otherwise approve in respect of the Transactions, whether arising under this Agreement, in respect of the right to acquire the Additional Securities, or otherwise, and notwithstanding the foregoing, to the extent that it is so entitled to vote,
consent or otherwise approve, shall exercise such entitlement to vote, consent or otherwise right of approval in favour of the approval, consent, ratification and adoption of any resolution in respect of the Transactions (and any other matters or
actions necessary for the consummation of the Transactions contemplated by the Business Combination Agreement), including without limitation at any meeting of securityholders of FEAC, Newco or any other person or entity (including in connection with
any separate vote of any <FONT STYLE="white-space:nowrap">sub-group</FONT> of securityholders of FEAC, Newco or any other person or entity that may be required to be held and of which <FONT STYLE="white-space:nowrap">sub-group</FONT> the FEAC
Shareholder forms part) called to vote upon the Transactions or at any </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-3-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
adjournment or postponement thereof or in any other circumstances upon which a vote, consent or other approval (including written consent in lieu of a meeting) with respect to the Transactions is
sought; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the FEAC Shareholder shall not take any other action of any kind which would reasonably be expected to prevent
or materially delay the consummation of any of the Transactions or any other transactions contemplated by the Business Combination Agreement; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the FEAC Shareholder waives to the fullest extent permitted by law any and all rights of appraisal, rights of
dissent or similar rights that the FEAC Shareholder may have or acquire with respect to any resolution in respect of the Transactions or any other matters or actions necessary for the consummation of the Transactions contemplated by the Business
Combination Agreement, and will not exercise any such right with respect to any such resolution which is waived hereby. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Newco Assumption of Obligations</U>. Subject to the terms and conditions hereof applicable to FEAC&#146;s
obligations hereunder, Newco acknowledges that, by virtue of and with effect from the FEAC Reorganization becoming effective, and without further action by FEAC, Newco or the FEAC Shareholder, the Assumption shall become effective so that Newco
shall assume all of FEAC&#146;s obligations under this Agreement, including, without limitation, the obligation to issue the Additional Securities and the obligations of FEAC set forth in Section&nbsp;4 hereof and FEAC shall assign all of its rights
under this Agreement to Newco. By virtue of, and with effect from, the FEAC Reorganization becoming effective, and without further action by FEAC, Newco or the FEAC Shareholder, (i)&nbsp;all surviving rights, covenants, and obligations of FEAC under
this Agreement shall be rights, covenants, and obligations of Newco; and (ii)&nbsp;Newco shall be liable for any breach of any representation or warranty by FEAC set forth in this Agreement. The FEAC Shareholder hereby expressly agrees to and
acknowledges the Assumption in accordance with the foregoing and the other terms hereof. Unless otherwise indicated or the context otherwise requires, by virtue of, and with effect from, the FEAC Reorganization and the Assumption becoming effective,
all references herein (i)&nbsp;to FEAC, shall refer to Newco, and (ii)&nbsp;to the Additional Shares and FEAC PIPE Warrants shall refer to Newco Shares and Newco Warrants, respectively, of the corresponding number, rather than FEAC Class&nbsp;A
Shares and FEAC PIPE Warrants, respectively. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Termination</U>. This Agreement shall terminate and be void and of no further force and effect, and all
rights and obligations of the parties hereunder shall terminate without any further liability on the part of any party in respect thereof, upon the earliest to occur of (i)&nbsp;such date and time as the Business Combination Agreement is validly
terminated in accordance with its terms without being consummated, (ii)&nbsp;upon the mutual written agreement of each of the parties hereto to terminate this Agreement, (iii)&nbsp;the Termination Date (as defined in the Business Combination
Agreement), (iv) if the conditions set forth in Section&nbsp;4.3 hereof are not satisfied or (to the extent permitted by applicable law) waived in writing, or are not capable of being satisfied or (to the extent permitted by applicable law) waived
in writing, on or prior to the Closing Date and, as a result thereof, the transactions set forth in Section&nbsp;4 hereof will not be or are not consummated on the Closing Date and (v)&nbsp;FEAC&#146;s notification to the FEAC Shareholder in writing
that it has, with the prior written consent of Newco and enGene, abandoned its plans to move forward with the Transactions and/or terminated the FEAC Shareholder&#146;s obligations with respect to the subscription without the issuance of the
Additional Securities having occurred. FEAC shall promptly notify the FEAC Shareholder in writing of the termination of the Business Combination Agreement promptly after the termination of such agreement. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8. <U>Miscellaneous.</U> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Agreement constitutes the entire agreement among the Parties relating to the transactions contemplated by
this Agreement and supersede any other agreements, whether written or oral, that may have been made or entered into by or among any of the Parties or any of their respective subsidiaries relating to the transactions contemplated by this Agreement.
No representations, warranties, covenants, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-3-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
understandings, agreements, oral or otherwise, relating to the transactions contemplated by this Agreement exist between the Parties except as expressly set forth or referenced in this Agreement.
enGene shall be a third-party beneficiary hereof. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Except pursuant to the Assumption, no Party shall assign this Agreement or any part hereof without the prior
written consent of the other Party. Subject to the foregoing, this Agreement shall be binding upon and inure to the benefit of the Parties and their respective permitted successors and assigns; <U>provided</U> that the FEAC Shareholder&#146;s rights
and obligations hereunder may be assigned to any fund or account managed by the same investment manager as the FEAC Shareholder, without the prior consent of FEAC or Newco, provided that such assignee(s) agrees in writing to be bound by the terms
hereof, and upon such assignment by the FEAC Shareholder, the assignee(s) shall become the FEAC Shareholder hereunder and have the rights and obligations and be deemed to make the representations and warranties of the FEAC Shareholder provided for
herein to the extent of such assignment; <U>provided further</U> that, no assignment shall relieve the assigning party of any of its obligations hereunder, including any assignment to any fund or account managed by the same investment manager as the
FEAC Shareholder. Any attempted assignment in violation of the terms of this Section&nbsp;8(b) shall be null and void, <I>ab initio</I>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Agreement may be amended or modified in whole or in part, only by a duly authorized agreement in writing
executed by each of the Parties in the same manner as this Agreement and which makes reference to this Agreement. The approval of this Agreement by the stockholders of any of the Parties shall not restrict the ability of the board of directors or
managers (or other body performing similar functions) of any of the Parties to terminate this Agreement in accordance with Section&nbsp;7 or to cause such Party to enter into an amendment to this Agreement pursuant to this Section&nbsp;8(c).
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Agreement, and any claim or cause of action hereunder based upon, arising out of or related to this
Agreement (whether based on law, in equity, in contract, in tort or any other theory) or the negotiation, execution, performance or enforcement of this Agreement, shall be governed by and construed in accordance with the laws of the State of
Delaware, without giving effect to the principles of conflicts of law thereof. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each of the Parties irrevocably consents to the exclusive jurisdiction and venue of the Court of Chancery of
the State of Delaware, provided that if subject matter jurisdiction over the matter that is the subject of the legal proceeding is vested exclusively in the U.S. federal courts, such legal proceeding shall be heard in the U.S. District Court for the
District of Delaware (together with the Court of Chancery of the State of Delaware, &#147;<U>Chosen Courts</U>&#148;), in connection with any matter based upon or arising out of this Agreement. Each party hereby waives, and shall not assert as a
defense in any legal dispute, that (i)&nbsp;such person is not personally subject to the jurisdiction of the Chosen Courts for any reason, (ii)&nbsp;such legal proceeding may not be brought or is not maintainable in the Chosen Courts,
(iii)&nbsp;such person&#146;s property is exempt or immune from execution, (iv)&nbsp;such legal proceeding is brought in an inconvenient forum or (v)&nbsp;the venue of such legal proceeding is improper. Each Party hereby consents to service of
process in any such proceeding in any manner permitted by Delaware law, further consents to service of process by nationally recognized overnight courier service guaranteeing overnight delivery, or by registered or certified mail, return receipt
requested, at its address specified pursuant to Section&nbsp;8(h) and waives and covenants not to assert or plead any objection which they might otherwise have to such manner of service of process. Notwithstanding the foregoing in this
Section&nbsp;8(e), a Party may commence any action, claim, cause of action or suit in a court other than the Chosen Courts solely for the purpose of enforcing an order or judgment issued by the Chosen Courts. TO THE EXTENT NOT PROHIBITED BY
APPLICABLE LAW WHICH CANNOT BE WAIVED, EACH OF THE PARTIES WAIVES ANY RIGHT TO TRIAL BY JURY ON ANY CLAIMS OR COUNTERCLAIMS ASSERTED IN ANY LEGAL DISPUTE RELATING TO THIS AGREEMENT WHETHER NOW EXISTING OR HEREAFTER ARISING. IF THE SUBJECT MATTER OF
ANY SUCH LEGAL DISPUTE IS ONE IN WHICH THE WAIVER OF JURY TRIAL IS PROHIBITED, NO PARTY SHALL ASSERT IN SUCH LEGAL DISPUTE A </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-3-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
NONCOMPULSORY COUNTERCLAIM ARISING OUT OF OR RELATING TO THIS AGREEMENT. FURTHERMORE, NO PARTY SHALL SEEK TO CONSOLIDATE ANY SUCH LEGAL DISPUTE WITH A SEPARATE ACTION OR OTHER LEGAL PROCEEDING IN
WHICH A JURY TRIAL CANNOT BE WAIVED. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If any provision of this Agreement shall be invalid, illegal or unenforceable, the validity, legality or
enforceability of the remaining provisions of this Agreement shall not in any way be affected or impaired thereby and shall continue in full force and effect. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Agreement may be executed in one or more counterparts, all of which when taken together shall be
considered one and the same agreement and shall become effective when counterparts have been signed by each Party and delivered to the other Party, it being understood that the Parties need not sign the same counterpart. In the event that any
signature is delivered by facsimile transmission or any other form of electronic delivery, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and
effect as if such signature page were an original thereof. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any notice or communication required or permitted hereunder shall be in writing and either delivered
personally, emailed or sent by overnight mail via a reputable overnight carrier, or sent by certified or registered mail, postage prepaid, and shall be deemed to be given and received (i)&nbsp;when so delivered personally, (ii)&nbsp;when sent, with
no mail undeliverable or other rejection notice, if sent by email, or (iii)&nbsp;three (3) Business Days after the date of mailing to the address below or to such other address or addresses as such person may hereafter designate by notice given
hereunder: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(i) if to the FEAC Shareholder, to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">[&#149;] </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><I>with a required
copy (which copy shall not constitute notice) to: </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">[&#149;] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(ii) if to FEAC, to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Forbion
European Acquisition Corp. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Gooimeer <FONT STYLE="white-space:nowrap">2-35</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">1411 DC Naarden </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">The
Netherlands </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cyril Lesser </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cyril.Lesser@forbion.com </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><I>with a required copy (which copy shall not constitute notice) to: </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Davis Polk&nbsp;&amp; Wardwell London LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">5 Aldermanbury Square </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">London
EC2V 7HR </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">United Kingdom </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Leo Borchardt </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; leo.borchardt@davispolk.com </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(iii) if to Newco, to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">enGene
Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">7171 Rue Frederick Banting </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Saint-Laurent, QC H4S 1Z9 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Canada </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Jason Hanson
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email: jhanson@engeneinc.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-3-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><I>with a required copy (which shall not constitute notice) to: </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Morgan, Lewis&nbsp;&amp; Bockius LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">101 Park Ave. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">New York, NY
10178-0060 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">United States </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Howard A. Kenny </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email: howard.kenny@morganlewis.com </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In addition to the waiver of Newco pursuant to Section&nbsp;8.17 of the Business Combination Agreement, and
notwithstanding anything to the contrary set forth herein, the FEAC Shareholder acknowledges that FEAC has established a trust account containing the proceeds of its initial public offering and from certain private placements (collectively, with
interest accrued from time to time thereon, the &#147;<U>Trust Account</U>&#148;). The FEAC Shareholder acknowledges that (i)&nbsp;it has no right, title, interest or claim of any kind in or to any monies held in the Trust Account, and (ii)&nbsp;it
shall have no right of <FONT STYLE="white-space:nowrap">set-off</FONT> or any right, title, interest or claim of any kind (&#147;<U>Claim</U>&#148;) to, or to any monies in, the Trust Account, in each case in connection with this Agreement, and
hereby irrevocably waives any Claim to, or to any monies in, the Trust Account that it may have in connection with this Agreement; <U>provided</U>, <U>however</U>, that nothing in this Section&nbsp;8(i) shall (x)&nbsp;serve to limit or prohibit the
FEAC Shareholder&#146;s right to pursue a claim against FEAC for legal relief against assets held outside the Trust Account, for specific performance or other equitable relief, (y)&nbsp;serve to limit or prohibit any claims that the FEAC Shareholder
may have in the future against FEAC&#146;s assets or funds that are not held in the Trust Account (including any funds that have been released from the Trust Account and any assets that have been purchased or acquired with any such funds) or
(z)&nbsp;be deemed to limit the FEAC Shareholder&#146;s right, title, interest or claim to the Trust Account by virtue of the FEAC Shareholder&#146;s record or beneficial ownership of securities of FEAC. In the event the FEAC Shareholder has any
Claim against FEAC under this Agreement, the FEAC Shareholder shall pursue such Claim solely against FEAC and its assets outside the Trust Account and not against the property or any monies in the Trust Account. The FEAC Shareholder agrees and
acknowledges that such waiver is material to this Agreement and has been specifically relied upon by FEAC to induce FEAC to enter into this Agreement and the FEAC Shareholder further intends and understands such waiver to be valid, binding and
enforceable under applicable law. Notwithstanding the foregoing, in no event shall the terms of this Section&nbsp;8(i) apply to any money or other assets held outside the Trust Account. In the event the FEAC Shareholder, in connection with this
Agreement, commences any action which seeks, in whole or in part, relief against the funds held in the Trust Account or distributions therefrom or any of FEAC&#146;s or Newco&#146;s shareholders, whether in the form of monetary damages or injunctive
relief, the FEAC Shareholder shall be obligated to pay to FEAC and Newco all of their legal fees and costs in connection with any such action in the event that FEAC and Newco prevail in such action. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All representations and warranties made by the parties hereto, and all covenants and other agreements of the
parties hereto, in this Agreement shall survive the consummation of the Transactions. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[signature page follows]
</I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-3-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, each of the Parties has caused this Agreement to be duly executed on its behalf
as of the day and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>FORBION EUROPEAN ACQUISITION CORP.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ENGENE HOLDINGS INC.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[&#149;]</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to <FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreement] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-3-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE I </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ELIGIBILITY </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REPRESENTATIONS OF </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FEAC
SHAREHOLDER </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">QUALIFIED INSTITUTIONAL BUYER STATUS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(Please check the applicable subparagraphs): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#9744; We are a &#147;qualified institutional buyer&#148; (as defined in Rule 144A under the Securities Act of
1933, as amended (the &#147;<U>Securities Act</U>&#148;) (a &#147;<B>QIB</B>&#148;)). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#9744; We are subscribing for the Additional Securities as a fiduciary or agent for one or more investor
accounts, and each owner of such account is a QIB. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** OR *** </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">INSTITUTIONAL ACCREDITED INVESTOR STATUS (Please check the applicable subparagraphs): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#9744; We are an &#147;accredited investor&#148; (within the meaning of Rule 501(a) under the Securities Act)
or an entity in which all of the equity holders are accredited investors within the meaning of Rule 501(a) under the Securities Act, and have marked and initialed the appropriate box on the following page indicating the provision under which we
qualify as an &#147;accredited investor.&#148; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#9744; We are not a natural person. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** AND *** </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">C.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">AFFILIATE STATUS </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(Please check the applicable box) FEAC SHAREHOLDER: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is not: </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">an &#147;affiliate&#148; (as defined in Rule 144 under the Securities Act) of FEAC or Newco or acting on behalf of an affiliate of FEAC or
Newco. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>This page should be completed by the FEAC Shareholder </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>and constitutes a part of the Non Redemption Agreement </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-3-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rule 501(a) under the Securities Act, in relevant part, states that an &#147;accredited investor&#148; shall
mean any person who comes within any of the below listed categories, or who the issuer reasonably believes comes within any of the below listed categories, at the time of the sale of the securities to that person. The FEAC Shareholder has indicated,
by marking and initialing the appropriate box below, the provision(s) below which apply to the FEAC Shareholder and under which the FEAC Shareholder accordingly qualifies as an &#147;accredited investor.&#148; </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any bank as defined in section 3(a)(2) of the Securities Act, or any savings and loan association or other
institution as defined in section 3(a)(5)(A) of the Securities Act whether acting in its individual or fiduciary capacity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any broker or dealer registered pursuant to section 15 of the Securities Exchange Act of 1934, as amended;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any insurance company as defined in section 2(a)(13) of the Securities Act; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any investment company registered under the Investment Company Act of 1940, as amended (the &#147;<U>Investment
Company Act</U>&#148;) or a business development company as defined in section 2(a)(48) of the Investment Company Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any Small Business Investment Company licensed by the U.S. Small Business Administration under section 301(c)
or (d)&nbsp;of the Small Business Investment Act of 1958, as amended; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any plan established and maintained by a state, its political subdivisions, or any agency or instrumentality of
a state or its political subdivisions, for the benefit of its employees, if such plan has total assets in excess of $5,000,000; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any employee benefit plan within the meaning of the Employee Retirement Income Security Act of 1974, as amended
(&#147;<B>ERISA</B>&#148;), if (i)&nbsp;the investment decision is made by a plan fiduciary, as defined in section 3(21) of ERISA, which is either a bank, a savings and loan association, an insurance company, or a registered investment adviser,
(ii)&nbsp;the employee benefit plan has total assets in excess of $5,000,000 or, (iii)&nbsp;such plan is a self-directed plan, with investment decisions made solely by persons that are &#147;accredited investors&#148;; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any private business development company as defined in section 202(a)(22) of the Investment Advisers Act of
1940, as amended; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any (i)&nbsp;corporation, limited liability company or partnership, (ii)&nbsp;Massachusetts or similar business
trust, or (iii)&nbsp;organization described in section 501(c)(3) of the Internal Revenue Code of 1986, as amended, not formed for the specific purpose of acquiring the securities offered, and with total assets in excess of $5,000,000; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any trust, with total assets in excess of $5,000,000, not formed for the specific purpose of acquiring the
securities offered, whose purchase is directed by a sophisticated person as described in Section&nbsp;230.506(b)(2)(ii) of Regulation D. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-3-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit D </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form of Registration Rights Agreement </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-1-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Final Form </I></B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>REGISTRATION RIGHTS AGREEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Registration Rights Agreement (this &#147;<B>Agreement</B>&#148;), dated effective as of [&#149;], 2023 (the &#147;<B>Effective
Date</B>&#148;), is made by and among enGene Holdings Inc., a company incorporated under the laws of Canada that intends to continue to a company governed by the <I>Business Corporations Act</I> (British Columbia) (the &#147;<B>Company</B>&#148;),
Forbion European Acquisition Corp., a Cayman Islands exempted company (&#147;<B>FEAC</B>&#148;), each of the parties listed on <U>Schedule A</U> hereto as a &#147;Sponsor Holder&#148; (each, a &#147;<B>Sponsor Holder</B>&#148; and collectively, the
&#147;<B>Sponsor Holders</B>&#148;), and each of the parties listed on <U>Schedule A</U> hereto as an &#147;enGene Holder&#148; (each, an &#147;<B>enGene</B> <B>Holder</B>&#148; and collectively, the &#147;<B>enGene</B> <B>Holders</B>&#148;, and,
together with the Sponsor Holders, each, a &#147;<B>Holder</B>&#148; and collectively, the &#147;<B>Holders</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, pursuant
to that certain Business Combination Agreement, dated as of May&nbsp;16, 2023 (the &#147;<B>Business Combination Agreement</B>&#148;), by and among FEAC and enGene Inc., a corporation incorporated and existing under the laws of Canada
(&#147;<B>enGene</B>&#148;), the Cayman Merger Sub and the Can Merger Sub referred to therein, and the Company, among other things, (a) all of the issued and outstanding Class&nbsp;B ordinary shares of FEAC following the surrender of a portion
thereof (the &#147;<B>Founder Shares</B>&#148;) were converted into Class&nbsp;A ordinary shares of FEAC (the &#147;<B>Class</B><B></B><B>&nbsp;B Conversion</B>&#148;), (b) Cayman Merger Sub merged with and into FEAC with FEAC surviving the merger
(the &#147;<B>Cayman Merger</B>&#148;) and all of the issued and outstanding Class&nbsp;A ordinary shares of FEAC (after giving effect to the Class&nbsp;B Conversion) were exchanged for common shares of the Company (the &#147;<B>Common
Shares</B>&#148;), and all of the issued and outstanding warrants to purchase (at an exercise price of $11.50 per share) Class&nbsp;A ordinary shares of FEAC were assumed by the Company, and thereby became exercisable for warrants to purchase Common
Shares at an exercise price of $11.50 per share (the &#147;<B>FEAC-Derived Warrants</B>&#148;), in each case on a on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis, and (c)&nbsp;Can Merger Sub and
enGene amalgamated (the &#147;<B>Amalgamation</B>&#148;) in accordance with the terms of the plan of arrangement substantially in the form attached to the Business Combination Agreement and pursuant to the Amalgamation, each enGene common share
outstanding immediately prior to the Amalgamation was exchanged for Common Shares the Company Exchange Ratio (as defined in the Business Combination Agreement) and each enGene warrant outstanding immediately prior to the Amalgamation was exchanged
for warrants to acquire Common Shares per the Exchange Ratio (the &#147;<B>enGene-Derived Warrants</B>&#148; and collectively with the FEAC-Derived Warrants, the &#147;<B>Warrants</B>&#148;), all as further described in the Business Combination
Agreement (such transactions and the other transactions consummated pursuant to the Business Combination Agreement, the &#147;<B>Transactions</B>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, FEAC and each of the Sponsor Holders are parties to that certain Registration Rights Agreement dated as of December&nbsp;9, 2021 (the
&#147;<B>Prior Agreement</B>&#148;); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the parties to the Prior Agreement desire to terminate the Prior Agreement, and the
Company and the Holders desire to provide for certain rights and obligations included herein with respect to the Registrable Securities (as defined below) held by the Holders, in each case contingent upon the occurrence of, and effective as of,
Closing (as defined below). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-1-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the foregoing, the parties hereby agree as follows: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE I </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEFINITIONS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;1.1 Definitions</B>. For purposes of this Agreement, the following terms and variations thereof have
the meanings set forth below: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Adverse Disclosure</B>&#148; means any public disclosure of material <FONT
STYLE="white-space:nowrap">non-public</FONT> information, which disclosure, in the good faith judgment of the Chief Executive Officer or Chief Financial Officer of the Company, after consultation with outside counsel to the Company, (i)&nbsp;would
be required to be made in any Registration Statement or Prospectus in order for the applicable Registration Statement or Prospectus not to contain a Misstatement, (ii)&nbsp;would not be required to be made at such time if the Registration Statement
were not being filed, and (iii)&nbsp;the Company has a bona fide business purpose for not making public. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Affiliate</B>&#148;
means, with respect to any specified Person, a Person that directly or indirectly Controls or is Controlled by, or is under common Control with, such specified Person. For purposes of this Agreement, no party to this Agreement shall be deemed to be
an Affiliate of the Company or another party to this Agreement solely by reason of the execution and delivery of this Agreement. Notwithstanding the foregoing or anything to the contrary herein, any portfolio company or entity managed or controlled
by any investment vehicle owned, controlled or managed by Forbion Capital Partners B.V. or any of its Affiliates (other than the Sponsor) shall not be considered an Affiliate of FEAC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Agreement</B>&#148; is defined in the Preamble. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Amalgamation</B>&#148; is defined in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Beneficial Owner</B>&#148; of a security is a Person who directly or indirectly, through any contract, arrangement, understanding,
relationship or otherwise, has or shares (a)&nbsp;voting power, which includes the power to vote, or to direct the voting of, such security and/or (b)&nbsp;investment power, which includes the power to dispose of, or to direct the disposition of,
such security. The term &#147;<B>Beneficially Own</B>&#148; shall have a correlative meaning. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Board</B>&#148; means the Board of
Directors of the Company or a duly authorized committee thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Business Combination Agreement</B>&#148; is defined in the
Recitals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Business Day</B>&#148; means a day, other than a Saturday or Sunday, on which commercial banks in New York, New York
and Vancouver, British Columbia are open for the general transaction of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Cayman Merger</B>&#148; is defined in the
Recitals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Class</B><B></B><B>&nbsp;B Conversion</B>&#148; is defined in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Closing</B>&#148; means the date on which the closing of the Arrangement (as defined in the Business Combination Agreement) occurs
under the Business Combination Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Commission</B>&#148; means the U.S. Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Common Shares</B>&#148; is defined in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company</B>&#148; is defined in the Preamble. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Control</B>&#148; (including the terms &#147;<B>Controls</B>,&#148; &#147;<B>Controlled by</B>&#148; and &#147;<B>under common
Control with</B>&#148;) means the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-1-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Demand Registration</B>&#148; is defined in
<U>Section</U><U></U><U>&nbsp;2.1.1</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Demand Requesting Holder</B>&#148; is defined in
<U>Section</U><U></U><U>&nbsp;2.1.1</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Demanding Holders</B>&#148; is defined in <U>Section</U><U></U><U>&nbsp;2.1.1</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Effective Date</B>&#148; is defined in the Preamble. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Effective Time</B>&#148; means the moment in time at which the closing of the Arrangement (as defined in the Business Combination
Agreement) occurs under the Business Combination Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>enGene</B>&#148; is defined in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>enGene</B><B><FONT STYLE="white-space:nowrap">-Derived</FONT> Common Shares</B>&#148; means the Common Shares issued by the Company
pursuant to the Amalgamation in exchange for the issued and outstanding common shares in the capital of enGene. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>enGene-Derived
Warrants</B>&#148; is defined in the Recitals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>enGene Holder</B>&#148; and &#147;<B>enGene Holders</B>&#148; are defined in the
Preamble. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>enGene Holder Lock</B><B><FONT STYLE="white-space:nowrap">-Up</FONT> Period&#146;</B> means the period starting on the
Effective Date and ending at 12:01 am, US eastern time, on the enGene <FONT STYLE="white-space:nowrap">Lock-Up</FONT> End Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>enGene Lock</B><B><FONT STYLE="white-space:nowrap">-Up</FONT> End Date</B>&#148; means the earlier of (x)&nbsp;the <FONT
STYLE="white-space:nowrap">six-month</FONT> anniversary of the Effective Date and (y)&nbsp;the date (after the date of the Closing) on which the Company completes a liquidation, merger, amalgamation, arrangement, share exchange or other similar
transaction that results in all of the Company&#146;s shareholders having the right to exchange their Common Shares for cash, securities or other property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchange Act</B>&#148; means the Securities Exchange Act of 1934, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>FEAC</B>&#148; is defined in the Preamble. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>FEAC-Derived Warrants</B>&#148; is defined in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Form</B><B></B><B>&nbsp;S</B><B><FONT STYLE="white-space:nowrap">-1</FONT></B>&#148; means a Registration Statement on <FONT
STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> or any comparable successor form or forms thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Form</B><B></B><B>&nbsp;S</B><B><FONT STYLE="white-space:nowrap">-3</FONT></B>&#148; means a Registration Statement on <FONT
STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> or any comparable successor form or forms thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Founder Shares</B>&#148; is
defined in the Recitals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Founder Shares</B><B><FONT STYLE="white-space:nowrap">-Derived</FONT> Common Shares</B>&#148; means the
Common Shares issued by the Company pursuant to the Cayman Merger in exchange for the Class&nbsp;A ordinary shares of FEAC that were issued by FEAC pursuant to the Class&nbsp;B Conversion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Governmental Entity</B>&#148; means any United States, Canadian or other (a)&nbsp;federal, state, provincial, local, municipal or
other government, (b)&nbsp;governmental or <FONT STYLE="white-space:nowrap">quasi-governmental</FONT> entity of any nature (including any governmental agency, branch, department, official, or entity and any court or other tribunal) or (c)&nbsp;body
exercising or entitled to exercise any administrative, executive, judicial, legislative, police, regulatory, or taxing authority or power of any nature, including any arbitral tribunal (public or private). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Holder</B>&#148; and &#147;<B>Holders</B>&#148; are defined in the Preamble. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Law</B>&#148; means any federal, state, provincial, local, foreign, national or supranational statute, law (including common law),
act, statute, ordinance, treaty, rule, Order, code, regulation or other binding directive or guidance issued, promulgated or enforced by a Governmental Entity having jurisdiction over a given matter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-1-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Lock</B><B><FONT STYLE="white-space:nowrap">-Up</FONT> Period</B>&#148; means the
enGene Holder <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period, the Sponsor <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period, and/or the <FONT STYLE="white-space:nowrap">lock-up</FONT> period set forth in <U>Article V</U> hereof, as
applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Maximum Number of Securities</B>&#148; is defined in <U>Section</U><U></U><U>&nbsp;2.1.5</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Misstatement</B>&#148; means an untrue statement of a material fact or an omission to state a material fact required to be stated in
a Registration Statement or Prospectus, or necessary to make the statements in a Registration Statement or Prospectus in the light of the circumstances under which they were made not misleading. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>New Registration Statement</B>&#148; is defined in <U>Section</U><U></U><U>&nbsp;2.3.3</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Order</B>&#148; means any writ, order, judgment, injunction, decision, determination, award, ruling, subpoena, verdict or decree
entered, issued or rendered by any Governmental Entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Person</B>&#148; means any individual, corporation, firm, partnership,
joint venture, limited liability company, estate, trust, business association, organization, any court, administrative agency, regulatory body, commission or other governmental authority, board, bureau or instrumentality, domestic or foreign and any
subdivision thereof or other entity, and also includes any managed investment account. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Piggyback Registration</B>&#148; is
defined in <U>Section</U><U></U><U>&nbsp;2.2.1</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Prior Agreement</B>&#148; is defined in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Pro Rata</B>&#148; is defined in <U>Section</U><U></U><U>&nbsp;2.1.5</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Prospectus</B>&#148; means the prospectus included in any Registration Statement, as supplemented by any and all prospectus
supplements and as amended by any and all <FONT STYLE="white-space:nowrap">post-effective</FONT> amendments and including all material incorporated by reference in such prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Registrable Security</B>&#148; and &#147;<B>Registrable Securities</B>&#148; means (a)&nbsp;the Founder <FONT
STYLE="white-space:nowrap">Shares-Derived</FONT> Common Shares held by a Sponsor Holder at the Effective Time, immediately after giving effect to the Closing of the Transactions, (b)&nbsp;the FEAC-Derived Warrants held by a Sponsor Holder at the
Effective Time, immediately after giving effect to the Closing of the Transactions, (c)&nbsp;all Common Shares issuable upon the exercise of a FEAC-Derived Warrant by a Sponsor Holder, (d)&nbsp;the
<FONT STYLE="white-space:nowrap">enGene-Derived</FONT> Common Shares held by an enGene Holder or Sponsor Holder at the Effective Time, immediately after giving effect to the Closing of the Transactions, (e)&nbsp;the enGene-Derived Warrants held by
an enGene Holder or Sponsor Holder at the Effective Time, immediately after giving effect to the Closing of the Transactions, (f)&nbsp;all Common Shares issuable upon the exercise of an enGene-Derived Warrant by an enGene Holder or Sponsor Holder
and (g)&nbsp;any other equity security of the Company issued or issuable with respect to any such Common Shares by way of a stock dividend or stock split or in connection with a combination of shares, recapitalization, merger, consolidation or
reorganization; <U>provided</U>, <U>however</U>, that, as to any Registrable Securities, such securities shall cease to be Registrable Securities when: (i)&nbsp;a Registration Statement with respect to the sale of such securities shall have become
effective under the Securities Act and such securities shall have been Transferred in accordance with such Registration Statement; (ii)&nbsp;such securities shall have been otherwise Transferred, new certificates (or book entry position) for such
securities not bearing a legend restricting further Transfer shall have been delivered by the Company to the Transferee, and subsequent public distribution of such securities shall not require registration under the Securities Act; (iii)&nbsp;such
securities shall have ceased to be outstanding; (iv)&nbsp;such securities have been sold under Rule 144 (or other similar exemption under the Securities Act then in force); (v) such securities have been sold to, or through, a broker, dealer or
underwriter in a public distribution or other public securities transaction; or (vi)&nbsp;Rule 144 (or other similar exemption under the Securities Act then in force) is available for the sale of all of such Holder&#146;s Common Shares without
regard to volume limitations, manner of sale requirements or registration requirement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-1-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Registration</B>&#148; means a registration effected by preparing and filing a
registration statement or similar document in compliance with the requirements of the Securities Act, and the applicable rules and regulations promulgated thereunder, and such registration statement becoming effective. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Registration Expenses</B>&#148; means the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses of a Registration or Underwritten Offering, as applicable, including, without limitation, the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) all registration and filing fees (including fees with respect to filings required to be made with the Financial Industry
Regulatory Authority, Inc.) and any fees of the securities exchange on which Common Shares are then listed; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) fees and
expenses of compliance with securities or blue sky laws (including reasonable fees and disbursements of counsel for the Underwriters in connection with blue sky qualifications of Registrable Securities); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C) printing, messenger, telephone and delivery expenses; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(D) reasonable fees and disbursements of counsel for the Company; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(E) reasonable fees and disbursements of all independent registered public accountants of the Company incurred specifically in
connection with such Registration or Underwritten Offering; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(F) reasonable fees and expenses, not to exceed $100,000
in connection with any Registration Statement or Underwritten Offering, of one (1)&nbsp;legal counsel selected by the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">majority-in-interest</FONT></FONT> of the Demanding Holders or
the <FONT STYLE="white-space:nowrap">majority-in</FONT> interest of the Takedown Requesting Holders, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Registration
Statement</B>&#148; means any registration statement under the Securities Act that covers the Registrable Securities pursuant to the provisions of this Agreement, including the Prospectus included in such registration statement, amendments
(including <FONT STYLE="white-space:nowrap">post-effective</FONT> amendments) and supplements to such registration statement, and all exhibits to and all material incorporated by reference in such registration statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Required Information</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;6.1</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Resale Shelf Registration</B>&#148; is defined in <U>Section</U><U></U><U>&nbsp;2.1.1</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Resale Shelf Registration Statement</B>&#148; is defined in <U>Section</U><U></U><U>&nbsp;2.3.1</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Rule 144</B>&#148; means such rule promulgated under the Securities Act, as the same shall be amended from time to time, or any
successor rule then in force. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>SEC Guidance</B>&#148; is defined in <U>Section</U><U></U><U>&nbsp;2.3.3</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Securities Act</B>&#148; means the Securities Act of 1933, as amended from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Sponsor</B>&#148; means Forbion Growth Sponsor FEAC I B.V., a Dutch private limited liability company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Sponsor Holder</B>&#148; and &#147;<B>Sponsor Holders</B>&#148; are defined in the Preamble. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Sponsor Holder Lock</B><B><FONT STYLE="white-space:nowrap">-Up</FONT> Period</B>&#148; means the period starting on the Effective
Date and ending at 12:01 am, US eastern time, on the Sponsor <FONT STYLE="white-space:nowrap">Lock-Up</FONT> End Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Sponsor
Lock</B><B><FONT STYLE="white-space:nowrap">-Up</FONT> End Date</B>&#148; means the earlier of (A) 12:01 am, U.S. eastern time, on the twelve-month anniversary of the date of the Closing and (B)&nbsp;following the Closing, (x)&nbsp;if the closing
price of the Common Shares equals or exceeds $12.00 per share (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any
<FONT STYLE="white-space:nowrap">30-trading</FONT> day period commencing at least 150 days after the Closing (provided, however that any transfer restrictions applicable to Sponsor Holders shall not be lifted pursuant to this clause (B)(x) prior to
the date that is one hundred and eighty </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-1-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
one (181)&nbsp;days following the Closing) and (y)&nbsp;the date on which the Company completes a liquidation, merger, amalgamation, arrangement, share exchange or other similar transaction that
results in all of the Company&#146;s shareholders having the right to exchange their Common Shares for cash, securities or other property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Takedown Requesting Holder</B>&#148; is defined in <U>Section</U><U></U><U>&nbsp;2.3.4</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Transactions</B>&#148; is defined in the Recitals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Transfer</B>&#148; means to, directly or indirectly, sell, transfer, assign, pledge, encumber, hypothecate, exchange or similarly
dispose of, either voluntarily or involuntarily, or to enter into any contract, option or other arrangement or understanding with respect to the sale, transfer, assignment, pledge, encumbrance, hypothecation, exchange or similar disposition of, any
interest owned by a person or any interest (including a beneficial interest) in, or the ownership, control or possession of, any interest owned by a person. The terms &#147;<B>Transferred</B>&#148;, &#147;<B>Transferee</B>&#148; and similar shall be
construed accordingly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Underwriter</B>&#148; means a securities dealer who purchases any Registrable Securities as principal in
an Underwritten Offering and not as part of such dealer&#146;s <FONT STYLE="white-space:nowrap">market-making</FONT> activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Underwritten Registration</B>&#148; or &#147;<B>Underwritten Offering</B>&#148; means a Registration in which securities of the
Company are sold to an Underwriter in a firm commitment underwriting for distribution to the public, including for the avoidance of doubt an Underwritten Shelf Takedown. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Underwritten Shelf Takedown</B>&#148; is defined in <U>Section</U><U></U><U>&nbsp;2.3.4</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Warrants</B>&#148; is defined in the Recitals. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE II </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2.1 Demand Registration</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1.1 <U>Request for Registration</U>. Subject to the provisions of <U>Section</U><U></U><U>&nbsp;2.1.5</U> and
<U>Section</U><U></U><U>&nbsp;2.4</U> hereof, at any time and from time to time following the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period applicable to any Holder, (i)&nbsp;Sponsor Holders who hold at least a majority in interest of the <FONT
STYLE="white-space:nowrap">then-outstanding</FONT> number of Registrable Securities held by all Sponsor Holders at such time, or (ii)&nbsp;enGene Holders holding at least a majority in interest of the
<FONT STYLE="white-space:nowrap">then-outstanding</FONT> number of Registrable Securities held by all enGene Holders at such time (such Holders described in clauses (i)&nbsp;and (ii), the &#147;<B>Demanding Holders</B>&#148;) may make a written
demand for Registration of all or part of their Registrable Securities on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> (or, if <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> is not available to be used by the Company at such time, on
<FONT STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> or another appropriate form permitting Registration of such Registrable Securities for resale by such Demanding Holders), which written demand shall describe the amount and type of securities to
be included in such Registration and the intended method(s) of distribution thereof (such written demand a &#147;<B>Demand Registration</B>&#148;). The Holders making a Demand Registration may request that the registration be made pursuant to Rule
415 under the Securities Act (a &#147;<B>Resale Shelf Registration</B>). The Company shall, within five (5)&nbsp;days of the Company&#146;s receipt of the Demand Registration, notify, in writing, all other Holders of Registrable Securities of such
demand, and each such Holder of Registrable Securities who thereafter wishes to include all or a portion of such Holder&#146;s Registrable Securities in a Registration pursuant to a Demand Registration (each such Holder that includes all or a
portion of such Holder&#146;s Registrable Securities in such Registration, a &#147;<B>Demand Requesting Holder</B>&#148;) shall so notify the Company, in writing, within five (5)&nbsp;days after the receipt by the Holder of the notice from the
Company. Upon receipt by the Company of any such written notification from a Demand Requesting Holder(s) to the Company, such Demand Requesting Holder(s) shall be entitled to have their Registrable Securities included in a Registration pursuant to a
Demand Registration and the Company shall </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-1-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
effect, as soon thereafter as practicable, the Registration of all Registrable Securities requested by the Demanding Holders and Demand Requesting Holders pursuant to such Demand Registration.
Under no circumstances shall the Company be obligated to effect more than two Registrations for the enGene Holders and two Registrations for the Sponsor Holders pursuant to a Demand Registration under this <U>Section</U><U></U><U>&nbsp;2.1.1.]</U>
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1.2 <U>Holder Information</U>. The Company&#146;s obligations to include the Registrable Securities held by a Holder in any
Registration Statement are contingent upon such Holder furnishing in writing to the Company such information regarding the Holder, the securities of the Company held by the Holder and the intended method of disposition of the Registrable Securities
as shall be reasonably requested by the Company to effect the registration of the Registrable Securities, and the Holder shall execute such documents in connection with such registration as the Company may reasonably request that are customary of a
selling shareholder in similar situations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1.3 <U>Effective Registration</U>. Notwithstanding the provisions of
<U>Section</U><U></U><U>&nbsp;2.1.1</U> above or any other part of this Agreement, a Registration pursuant to a Demand Registration shall not count as a Registration unless and until (a)&nbsp;the Registration Statement filed with the Commission with
respect to a Registration pursuant to a Demand Registration has been declared effective by the Commission and remains effective for not less than 180 days (or such shorter period as shall terminate when all Registrable Securities covered by such
Registration Statement have been sold or withdrawn), or if such Registration Statement relates to an Underwritten Offering, such longer period as, in the opinion of counsel for the Underwriter or Underwriters, a Prospectus is required by law to be
delivered in connection with sales of Registrable Securities by an Underwriter or dealer and (b)&nbsp;the Company has complied with all of its obligations under this Agreement with respect thereto; <U>provided</U>, <U>further</U>, <U>however</U>,
that if, after such Registration Statement has been declared effective, an offering of Registrable Securities in a Registration pursuant to a Demand Registration is subsequently interfered with by any stop order or injunction of the Commission,
federal or state court or any other governmental agency, the Registration Statement with respect to such Registration shall be deemed not to have been declared effective for purposes of counting Registrations under
<U>Section</U><U></U><U>&nbsp;2.1.1</U> above unless and until (i)&nbsp;such stop order or injunction is removed, rescinded or otherwise terminated, and (ii)&nbsp;a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">majority-in-interest</FONT></FONT> of the Demanding Holders initiating such Demand Registration thereafter affirmatively elect to continue with such Registration and accordingly
notify the Company in writing, but in no event later than five (5)&nbsp;days, of such election; <U>provided</U>, <U>further</U>, <U>however</U>, that the Company shall not be obligated or required to file another Registration Statement until the
Registration Statement that has been previously filed with respect to a Registration pursuant to a Demand Registration becomes effective or has been terminated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1.4 <U>Underwritten Offering</U>. Subject to the provisions of <U>Section</U><U></U><U>&nbsp;2.1.5</U> and
<U>Section</U><U></U><U>&nbsp;2.4</U> hereof, if a Demanding Holder advises the Company as part of their Demand Registration that the offering of the Registrable Securities pursuant to such Demand Registration shall be in the form of an Underwritten
Offering, then the right of such Demanding Holder or Demand Requesting Holder (if any) to include its Registrable Securities in such Registration shall be conditioned upon such Holder&#146;s participation in such Underwritten Offering and the
inclusion of such Holder&#146;s Registrable Securities in such Underwritten Offering to the extent provided herein. All such Holders proposing to distribute their Registrable Securities through an Underwritten Offering under this
<U>Section</U><U></U><U>&nbsp;2.1.4</U> shall enter into an underwriting agreement in customary form with the Underwriter(s) selected for such Underwritten Offering by the Demanding Holder initiating the Demand Registration, which Underwriter(s)
shall be reasonably acceptable to the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1.5 <U>Reduction of Underwritten Offering</U>. If the managing Underwriter or
Underwriters in an Underwritten Registration pursuant to a Demand Registration, in good faith, advises the Company, the Demanding Holder(s) and the Demand Requesting Holders (if any) in writing that the dollar amount or number of Registrable
Securities that the Demanding Holder(s) and the Demand Requesting Holders (if any) desire to sell, taken together with all other Common Shares or other equity securities that the Company desires to sell, if any, as to which a Registration has been
requested pursuant to separate written contractual <FONT STYLE="white-space:nowrap">piggy-back</FONT> registration rights held by any other shareholders who desire to sell, exceeds the maximum dollar amount or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-1-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
maximum number of equity securities that can be sold in the Underwritten Offering without adversely affecting the proposed offering price, the timing, the distribution method, or the probability
of success of such offering (such maximum dollar amount or maximum number of such securities, as applicable, the &#147;<B>Maximum Number of Securities</B>&#148;), then the Company shall include in such Underwritten Offering, as follows:
(i)&nbsp;first, the Registrable Securities of the Demanding Holder(s) (pro rata based on the respective number of Registrable Securities that each Demanding Holder has requested be included in such Underwritten Registration and the aggregate number
of Registrable Securities that the Demanding Holders requested be included in such Underwritten Registration (such proportion is referred to herein as &#147;<B>Pro Rata</B>&#148;)) that can be sold without exceeding the Maximum Number of Securities;
(ii)&nbsp;second, to the extent that the Maximum Number of Securities has not been reached under the foregoing clause (i), the Registrable Securities that each Demand Requesting Holding (if any) has requested to be included in such Underwritten
Registration (pro rata based on the respective number of Registrable Securities that each Demand Requesting Holding (if any) has requested to be included in such Underwritten Registration) and the aggregate number of Registrable Securities that the
Demand Requesting Holders have requested to be included in such Underwritten Registration that can be sold without exceeding the Maximum Number of Securities; (iii)&nbsp;third, to the extent that the Maximum Number of Securities has not been reached
under the foregoing clauses (i)&nbsp;and (ii), Common Shares or other equity securities that the Company desires to sell, which can be sold without exceeding the Maximum Number of Securities; and (iv)&nbsp;fourth, to the extent that the Maximum
Number of Securities has not been reached under the foregoing clauses (i), (ii) and (iii), Common Shares or other equity securities of other persons or entities that the Company is obligated to register in a Registration pursuant to separate written
contractual arrangements with such persons and that can be sold without exceeding the Maximum Number of Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1.6 <U>Demand
Registration Withdrawal</U>. A Holder shall have the right to withdraw from a Registration pursuant to such Demand Registration for any or no reason whatsoever upon written notification to the Company and the Underwriter(s) (if any) of their
intention to withdraw from such Registration (i)&nbsp;in the case of an Underwritten Offering, prior to the launch of the roadshow for the offering, and (ii)&nbsp;otherwise, prior to the effectiveness of the Registration Statement filed with the
Commission with respect to the Registration of their Registrable Securities pursuant to such Demand Registration. If a Demanding Holder initiating a Demand Registration or a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">majority-in-interest</FONT></FONT> of the Demand Requesting Holders (if any) withdraws from a proposed offering pursuant to this <U>Section</U><U></U><U>&nbsp;2.1.6,</U> then such
registration shall not count as a Demand Registration provided for in <U>Section</U><U></U><U>&nbsp;2.1</U>. Notwithstanding anything to the contrary in this Agreement, the Company shall be responsible for the Registration Expenses incurred in
connection with a Registration pursuant to a Demand Registration prior to its withdrawal under this <U>Section</U><U></U><U>&nbsp;2.1.6</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2.2 Piggyback Registration</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.2.1 <U>Piggyback Rights</U>. If at any time or from time to time following the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period
applicable to any Holder hereof the Company proposes to file a Registration Statement under the Securities Act with respect to an offering of equity securities, or securities or other obligations exercisable or exchangeable for, or convertible into
equity securities, for its own account or for the account of shareholders of the Company, other than a Registration Statement (i)&nbsp;filed pursuant to <U>Section</U><U></U><U>&nbsp;2.1</U>, (ii) filed in connection with any employee stock option
or other benefit plan, (iii)&nbsp;for an exchange offer or offering of securities solely to the Company&#146;s existing shareholders, (iv)&nbsp;for an offering of debt that is convertible into equity securities of the Company, (v)&nbsp;to register
the offering of securities in connection with a transaction to be registered on <FONT STYLE="white-space:nowrap">Form&nbsp;S-4</FONT> or (vi)&nbsp;for a dividend reinvestment plan, then the Company shall give written notice of such proposed filing
to all of the Holders of Registrable Securities as soon as practicable but not less than ten (10)&nbsp;days before the anticipated filing date of such Registration Statement, which notice shall (A)&nbsp;describe the amount and type of securities to
be included in such offering, the intended method(s) of distribution, and the name of the proposed managing Underwriter(s), if any, in such offering, and (B)&nbsp;offer to all of the Holders of Registrable Securities the opportunity to register the
sale of such number of Registrable Securities as such Holders may request in writing within five (5)&nbsp;days after receipt of such written notice (such Registration a &#147;<B>Piggyback Registration</B>&#148;). The Company shall, in good faith,
cause such Registrable Securities to be included in such Piggyback Registration and shall use its reasonable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-1-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
best efforts to cause the managing Underwriter(s) of a proposed Underwritten Offering to permit the Registrable Securities requested by a Holder pursuant to this
<U>Section</U><U></U><U>&nbsp;2.2.1</U> (to the extent that such Holder is not then subject to a <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period) to be included in a Piggyback Registration on the same terms and conditions as any similar
securities of the Company included in such Registration and to permit the sale or other disposition of such Registrable Securities in accordance with the intended method(s) of distribution thereof. All such Holders proposing to distribute their
Registrable Securities through an Underwritten Offering under this <U>Section</U><U></U><U>&nbsp;2.2.1</U> shall enter into an underwriting agreement in customary form with the Underwriter(s) selected for such Underwritten Offering by the Company.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.2.2 <U>Reduction of Piggyback Registration</U>. If the managing Underwriter(s) in an Underwritten Registration that is to be a
Piggyback Registration, in good faith, advises the Company and the Holders of Registrable Securities participating in the Piggyback Registration in writing that the dollar amount or number of Common Shares that the Company desires to sell, taken
together with (a)&nbsp;Common Shares, if any, as to which Registration has been demanded pursuant to separate written contractual arrangements with persons or entities other than the Holders of Registrable Securities hereunder, (b)&nbsp;the
Registrable Securities as to which registration has been requested pursuant to <U>Section</U><U></U><U>&nbsp;2.2</U> hereof, and (c)&nbsp;Common Shares, if any, as to which Registration has been requested pursuant to separate written contractual <FONT
STYLE="white-space:nowrap">piggy-back</FONT> registration rights of other shareholders of the Company, exceeds the Maximum Number of Securities, then: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) If the Registration is undertaken for the Company&#146;s account, the Company shall include in any such Registration
(A)&nbsp;first, Common Shares or other equity securities that the Company desires to sell, which can be sold without exceeding the Maximum Number of Securities; (B)&nbsp;second, to the extent that the Maximum Number of Securities has not been
reached under the foregoing section (A), the Registrable Securities of Holders exercising their rights to register their Registrable Securities pursuant to <U>Section</U><U></U><U>&nbsp;2.2.1</U> hereof, pro rata, based on the respective number of
Registrable Securities that each Holder has so requested, which can be sold without exceeding the Maximum Number of Securities; and (C)&nbsp;third, to the extent that the Maximum Number of Securities has not been reached under the foregoing clauses
(A)&nbsp;and (B), Common Shares, if any, as to which Registration has been requested pursuant to written contractual <FONT STYLE="white-space:nowrap">piggy-back</FONT> registration rights of other shareholders of the Company, which can be sold
without exceeding the Maximum Number of Securities; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) If the Registration is pursuant to a request by persons or
entities other than the Holders of Registrable Securities, then the Company shall include in any such Registration (A)&nbsp;first, Common Shares or other equity securities, if any, of such requesting persons or entities, other than the Holders of
Registrable Securities, which can be sold without exceeding the Maximum Number of Securities; (B)&nbsp;second, to the extent that the Maximum Number of Securities has not been reached under the foregoing section (A), the Registrable Securities of
Holders exercising their rights to register their Registrable Securities pursuant to <U>Section</U><U></U><U>&nbsp;2.2.1</U>, pro rata based on the respective number of Registrable Securities that each Holder has requested be included in such
Underwritten Registration and the aggregate number of Registrable Securities that the Holders have requested to be included in such Underwritten Registration, which can be sold without exceeding the Maximum Number of Securities; (C)&nbsp;third, to
the extent that the Maximum Number of Securities has not been reached under the foregoing clauses (A)&nbsp;and (B), Common Shares or other equity securities that the Company desires to sell, which can be sold without exceeding the Maximum Number of
Securities; and (D)&nbsp;fourth, to the extent that the Maximum Number of Securities has not been reached under the foregoing clauses (A), (B) and (C), Common Shares or other equity securities for the account of other persons or entities that the
Company is obligated to register pursuant to separate written contractual arrangements with such persons or entities, which can be sold without exceeding the Maximum Number of Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.2.3 <U>Piggyback Registration Withdrawal</U>. Any Holder of Registrable Securities shall have the right to withdraw from a Piggyback
Registration for any or no reason whatsoever upon written notification to the Company and the Underwriter or Underwriters (if any) of his, her or its intention to withdraw from such Piggyback Registration prior to (i)&nbsp;in the case of an
Underwritten Offering, the date on which the roadshow for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-1-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the offering is launched, and (ii)&nbsp;otherwise, the effectiveness of the Registration Statement filed with the Commission with respect to such Piggyback Registration. the Company (whether on
its own good faith determination or as the result of a request for withdrawal by persons pursuant to separate written contractual obligations) may withdraw a Registration Statement filed with the Commission in connection with a Piggyback
Registration at any time prior to the effectiveness of such Registration Statement. Notwithstanding anything to the contrary in this Agreement, the Company shall be responsible for the Registration Expenses incurred in connection with the Piggyback
Registration prior to its withdrawal under this <U>Section</U><U></U><U>&nbsp;2.2.3</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.2.4 <U>Unlimited Piggyback Registration
Rights</U>. For purposes of clarity, any Registration effected pursuant to <U>Section</U><U></U><U>&nbsp;2.2</U> hereof shall not be counted as a Registration pursuant to a Demand Registration effected under <U>Section</U><U></U><U>&nbsp;2.1</U>
hereof, and there shall be no limit on the number of Piggyback Registrations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.2.5 <U>Right to Terminate Registration</U>. The Company
shall have the right to terminate or withdraw any registration initiated by it under this <U>Section</U><U></U><U>&nbsp;2.2</U> prior to the effectiveness of such registration whether or not any Holder of Registrable Securities has elected to
include securities in such registration. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2.3 Resale Shelf Registrations</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.3.1 <U>Registration Statement Covering Resale of Registrable Securities</U>. Notwithstanding the right of any Holder to request a Resale
Shelf Registration pursuant to <U>Section</U><U></U><U>&nbsp;2.1.1</U>, the Company shall prepare and file or cause to be prepared and filed with the Commission as soon as practicable (but in any case no later than 15 calendar days after the
Effective Date) a Registration Statement for an offering to be made on a continuous basis pursuant to Rule 415 of the Securities Act or any successor thereto registering the resale from time to time by Holders of all of the Registrable Securities
held by the Holders (the &#147;<B>Resale</B> <B>Shelf Registration Statement</B>&#148;). The Company shall use its commercially reasonable efforts to cause such Registration Statement to become effective as soon as practicable after filing, but no
later than the earlier of (i)&nbsp;sixty (60) calendar days after the Closing (or ninety (90)&nbsp;calendar days after the Closing if the Commission notifies the Company that it will &#147;review&#148; the Registration Statement) and
(ii)&nbsp;fifteen (15) Business Days after the Company is notified (orally or in writing, whichever is earlier) by the Commission that the Registration Statement will not be &#147;reviewed&#148; or will not be subject to further review. The Resale
Shelf Registration Statement shall be filed on any then applicable form. If the Resale Shelf Registration Statement is initially filed on <FONT STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> and thereafter the Company becomes eligible to use <FONT
STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> for secondary sales, the Company shall, as promptly as practicable, cause such Resale Shelf Registration Statement to be amended, or shall file a new replacement Resale Shelf Registration Statement,
such that the Resale Shelf Registration Statement is on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3.</FONT> If any Resale Shelf Registration Statement filed pursuant to <U>Section</U><U></U><U>&nbsp;2.3.1</U> is filed on <FONT
STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> and thereafter the Company becomes ineligible to use <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> for secondary sales, the Company shall promptly notify the Holders of such ineligibility and
use its best efforts to file a shelf registration on an appropriate form as promptly as practicable to replace the shelf registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> and have such replacement Resale Shelf
Registration Statement declared effective as promptly as practicable and to cause such replacement Resale Shelf Registration Statement to remain effective, and to be supplemented and amended to the extent necessary to ensure that such Resale Shelf
Registration Statement is available or, if not available, that another Resale Shelf Registration Statement is available, for the resale of all the Registrable Securities held by the Holders until all such Registrable Securities have ceased to be
Registrable Securities; <U>provided,</U> <U>however</U>, that at any time the Company once again becomes eligible to use <FONT STYLE="white-space:nowrap">Form&nbsp;S-3,</FONT> the Company shall cause such replacement Resale Shelf Registration
Statement to be amended, or shall file a new replacement Resale Shelf Registration Statement, such that the Resale Shelf Registration Statement is once again on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3.</FONT> Once effective, the Company shall
use commercially reasonable efforts to keep the Resale Shelf Registration Statement that is required to be filed pursuant to this <U>Section</U><U></U><U>&nbsp;2.3.1</U> and Prospectus included therein continuously effective and to be supplemented
and amended to the extent necessary to ensure that such Registration Statement is available at all times until the earlier of (i)&nbsp;the third anniversary of the Closing, and (ii)&nbsp;as to any particular Holder, the date on which the Holder
ceases to hold any Registrable Securities. The Registration Statement filed with the Commission pursuant to this <U>Section</U><U></U><U>&nbsp;2.3.1</U> shall contain a Prospectus in such form as to permit any Holder to sell such Registrable
Securities pursuant to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-1-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Rule&nbsp;415 under the Securities Act (or any successor or similar provision adopted by the Commission then in effect) at any time beginning on the effective date for such Registration Statement
(subject to the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period applicable to such Holder, which shall control), and shall provide that such Registrable Securities may be sold pursuant to any method or combination of methods legally available
to, and requested by, Holders. The Resale Shelf Registration Statement filed hereunder may also register Common Shares other than Registrable Securities, including shares sold by the Company in one or more PIPE transactions and shares issuable upon
the exercise of warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.3.2 <U>Notification and Distribution of Materials</U>. The Company shall notify the Holders in writing of the
effectiveness of the Resale Shelf Registration Statement as soon as practicable, and in any event within three (3)&nbsp;Business Days after the Resale Shelf Registration Statement becomes effective (which may be accomplished by the issuance of a
press release with such information), and shall furnish to any Holder, without charge, at its request, such number of copies of the Resale Shelf Registration Statement (including any amendments, supplements and exhibits), the Prospectus contained
therein (including each preliminary prospectus and all related amendments and supplements) and any documents incorporated by reference in the Resale Shelf Registration Statement or such other documents as the Holders may reasonably request in order
to facilitate the sale of the Registrable Securities in the manner described in the Resale Shelf Registration Statement (to the extent any of such documents are not available on EDGAR). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.3.3 <U>SEC Cutback</U>. Notwithstanding the registration obligations set forth in this <U>Section</U><U></U><U>&nbsp;2.3</U>, in the event
the Commission informs the Company that all of the Registrable Securities cannot, as a result of the application of Rule 415, be registered for resale as a secondary offering on a single registration statement, the Company agrees to promptly
(i)&nbsp;inform each of the Holders thereof and use its reasonable best efforts to file amendments to the Resale Shelf Registration Statement as required by the Commission and/or (ii)&nbsp;withdraw the Resale Shelf Registration Statement and file a
new registration statement (a &#147;<B>New Registration Statement</B>&#148;) on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3,</FONT> or if <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> is not then available to the Company for such
registration statement, on such other form available to register for resale the Registrable Securities as a secondary offering; <U>provided</U>, <U>however</U>, that prior to filing such amendment or New Registration Statement, the Company shall use
its reasonable best efforts to advocate with the Commission for the registration of all of the Registrable Securities in accordance with any <FONT STYLE="white-space:nowrap">publicly-available</FONT> written or oral guidance, comments, requirements
or requests of the Commission staff (the &#147;<B>SEC Guidance</B>&#148;). Notwithstanding any other provision of this Agreement, if any SEC Guidance sets forth a limitation on the number of Registrable Securities permitted to be registered on a
particular Registration Statement as a secondary offering (and notwithstanding that the Company used diligent efforts to advocate with the Commission for the registration of all or a greater number of Registrable Securities), unless otherwise
directed in writing by a Holder as to further limit its Registrable Securities to be included on the Registration Statement, the number of Registrable Securities to be registered on such Registration Statement will be reduced on a pro rata basis
based on the total number of Registrable Securities held by the Holders, subject to a determination by the Commission that certain Holders must be reduced first based on the number of Registrable Securities held by such Holders. In the event the
Company amends the Resale Shelf Registration Statement or files a New Registration Statement, as the case may be, under clauses (i)&nbsp;or (ii) above, the Company will use its reasonable best efforts to file with the Commission, as promptly as
allowed by Commission or SEC Guidance provided to the Company or to registrants of securities in general, one or more registration statements on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> or such other form available to register for
resale those Registrable Securities that were not registered for resale on the Resale Shelf Registration Statement, as amended, or the New Registration Statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.3.4 <U>Underwritten Shelf Takedown</U>. At any time and from time to time after a Resale Shelf Registration Statement has been declared
effective by the Commission, to the extent such Resale Shelf Registration may be used for an underwritten offering, any of the Demanding Holders may request to sell all or any portion of the Registrable Securities in an underwritten offering that is
registered pursuant to the Resale Shelf Registration Statement (each, an &#147;<B>Underwritten Shelf Takedown</B>&#148;); <U>provided</U>, <U>however</U>, that the Company shall only be obligated to effect an Underwritten Shelf Takedown if such
offering shall include securities with a total offering price (including piggyback securities and before deduction of underwriting discounts) reasonably </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-1-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
expected to exceed, in the aggregate, $10,000,000. All requests for Underwritten Shelf Takedowns shall be made by giving written notice to the Company, which shall specify the approximate number
of Registrable Securities proposed to be sold in the Underwritten Shelf Takedown. Within five (5)&nbsp;days of receipt of this notice, the Company must notify all of the Holders of Registrable Securities of the Underwritten Shelf Takedown. Within
five (5)&nbsp;days of delivery of this notice, Holders of Registrable Securities must notify the Company if they wish to participate in the Underwritten Shelf Takedown. The Company shall include in any Underwritten Shelf Takedown the securities
requested to be included by any Holder within such specified timeframe (each a &#147;<B>Takedown Requesting Holder</B>&#148;). All such Holders proposing to distribute their Registrable Securities through an Underwritten Shelf Takedown under this
<U>Section</U><U></U><U>&nbsp;2.3.4</U> shall enter into an underwriting agreement in customary form with the Underwriter(s) selected for such Underwritten Offering by the Takedown Requesting Holder (who must be reasonably acceptable to the
Company). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.3.5 <U>Reduction of Underwritten Shelf Takedown</U>. If the managing Underwriter(s) in an Underwritten Shelf Takedown, in
good faith, advise the Company and the Takedown Requesting Holders in writing that the dollar amount or number of Registrable Securities that the Takedown Requesting Holders desire to sell, taken together with all other Common Shares or other equity
securities that the Company desires to sell, exceeds the Maximum Number of Securities, then the Company shall include in such Underwritten Shelf Takedown, as follows: (i)&nbsp;first, the Registrable Securities of the Demanding Holders, on a Pro Rata
basis, (ii)&nbsp;second, to the extent that the Maximum Number of Securities has not been reached under the foregoing section (i), the Registrable Securities of the Takedown Requesting Holders, on a Pro Rata basis, that can be sold without exceeding
the Maximum Number of Securities; and (iii)&nbsp;third, to the extent that the Maximum Number of Securities has not been reached under the foregoing clauses (i)&nbsp;and (ii), Common Shares or other equity securities that the Company desires to
sell, which can be sold without exceeding the Maximum Number of Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.3.6 Registrations effected by the Company pursuant to
<U>Section</U><U></U><U>&nbsp;2.3.1</U> shall not be counted as Demand Registrations effected pursuant to <U>Section</U><U></U><U>&nbsp;2.1</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.3.7 Under no circumstances shall the Company be obligated to effect more than three Underwritten Shelf Takedowns for the enGene Holders and
three Underwritten Shelf Takedowns for the Sponsor Holders pursuant to <U>Section</U><U></U><U>&nbsp;2.3.4</U>]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2.4 Restrictions on Registration Rights</B>. Notwithstanding anything to the contrary contained herein, the
Company shall not be obligated to (but may, at its sole option) file a Registration Statement pursuant to a Demand Registration request made under <U>Section</U><U></U><U>&nbsp;2.1</U> during the period starting with the date thirty (30)&nbsp;days
prior to Company&#146;s good faith estimate of the date of the filing of, and ending on a date ninety (90)&nbsp;days after the effective date of, a Company initiated Registration and provided that Company has delivered written notice to the Holders
prior to receipt of a Demand Registration pursuant to <U>Section</U><U></U><U>&nbsp;2.1.1</U> and that New Holdco continues to actively employ, in good faith, all reasonable efforts to cause the applicable Registration Statement to become effective.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2.5 Other Registration Rights</B>. The Company represents that, as of the date hereof and other than as set
forth herein, no Person has the right to request or require it to register any equity securities issued by it, other than (i)&nbsp;such registration rights granted pursuant to the PIPE Financing, the Convertible Bridge Financing and the <FONT
STYLE="white-space:nowrap">Non-Redemption</FONT> Agreement, each as defined in the Business Combination Agreement, and (ii)&nbsp;such registration rights as applicable under the terms of the Warrants. The Company will not grant any Person any
registration rights with respect to the equity of the Company that are prior in right or in conflict or inconsistent with the rights of the Holders as set forth in this <U>Article II</U> in any material respect (it being understood that this shall
not preclude the grant of additional demand and piggyback registration rights in and of themselves so long as such rights are not prior in right to the rights under this Agreement). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-1-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE III </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMPANY PROCEDURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.1 General Procedures</B>. If at any time on or after the Effective Time the Company is required to effect the
Registration of Registrable Securities, the Company shall use its reasonable best efforts to effect such Registration to permit the sale of such Registrable Securities in accordance with the intended plan of distribution thereof, and pursuant
thereto the Company shall, as expeditiously as possible: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.1.1 prepare and file with the Commission as soon as practicable a Registration
Statement with respect to such Registrable Securities and use its commercially reasonable efforts to cause such Registration Statement to become effective and remain effective until all Registrable Securities covered by such Registration Statement
have been sold or are no longer outstanding; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.1.2 prepare and file with the Commission such amendments and <FONT
STYLE="white-space:nowrap">post-effective</FONT> amendments to the Registration Statement, and such supplements to the Prospectus, as may be reasonably requested by the Holders or any Underwriter of Registrable Securities or as may be required by
the rules, regulations or instructions applicable to the registration form used by the Company or by the Securities Act or rules and regulations thereunder to keep the Registration Statement effective until all Registrable Securities covered by such
Registration Statement are sold in accordance with the intended plan of distribution set forth in such Registration Statement or supplement to the Prospectus or are no longer outstanding; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.1.3 prior to filing a Registration Statement or Prospectus, or any amendment or supplement thereto, furnish without charge to the
Underwriter(s), if any, and the Holders of Registrable Securities included in such Registration, and such Holders&#146; legal counsel, copies of such Registration Statement as proposed to be filed, each amendment and supplement to such Registration
Statement (in each case including all exhibits thereto and documents incorporated by reference therein), the Prospectus included in such Registration Statement (including each preliminary Prospectus), and such other documents as the Underwriters and
the Holders of Registrable Securities included in such Registration or the legal counsel for any such Holders may reasonably request in order to facilitate the disposition of the Registrable Securities owned by such Holders; provided, that the
Company will not have any obligation to provide any document pursuant to this clause that is available on the Commission&#146;s EDGAR system; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.1.4 prior to any public offering of Registrable Securities, use its reasonable best efforts to: (i)&nbsp;register or qualify the Registrable
Securities covered by the Registration Statement under such securities or &#147;blue sky&#148; laws of such jurisdictions in the United States as the Holders of Registrable Securities included in such Registration Statement (in light of their
intended plan of distribution) may request and (ii)&nbsp;take such action necessary to cause such Registrable Securities covered by the Registration Statement to be registered with or approved by such other governmental authorities as may be
necessary by virtue of the business and operations of the Company and do any and all other acts and things that may be necessary or advisable to enable the Holders of Registrable Securities included in such Registration Statement to consummate the
disposition of such Registrable Securities in such jurisdictions; provided, however, that the Company shall not be required to qualify generally to do business in any jurisdiction where it would not otherwise be required to qualify or take any
action to which it would be subject to general service of process or taxation in any such jurisdiction where it is not then otherwise so subject; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.1.5 cause all such Registrable Securities to be listed on each securities exchange or automated quotation system on which similar securities
issued by the Company are then listed; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.1.6 provide a transfer agent or warrant agent, as applicable, and registrar for all such
Registrable Securities no later than the effective date of such Registration Statement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.1.7 advise each seller of such Registrable
Securities, promptly after it shall receive notice or obtain knowledge thereof, of the issuance of any stop order by the Commission suspending the effectiveness of such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-1-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Registration Statement or the initiation or threatening of any proceeding for such purpose and promptly use its reasonable best efforts to prevent the issuance of any stop order or to obtain its
withdrawal if such stop order should be issued; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.1.8 advise each Holder of Registrable Securities covered by such Registration
Statement, promptly after the Company receives notice thereof, of the time when such registration statement has been declared effective or a supplement to any Prospectus forming a part of such registration statement has been filed (provided that any
such notice may be made by the issuance of a press release including such information); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.1.9 at least five (5)&nbsp;days prior to the
filing of any Registration Statement or Prospectus or any amendment or supplement to such Registration Statement or Prospectus, furnish a copy thereof to each seller of such Registrable Securities or its counsel; <U>provided</U>, that the Company
will not have any obligation to provide any document pursuant to this clause that is or will become available on the Commission&#146;s EDGAR system; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.1.10 notify the Holders at any time when a Prospectus relating to such Registration Statement is required to be delivered under the
Securities Act, of the happening of any event as a result of which the Prospectus included in such Registration Statement, as then in effect, includes a Misstatement, and then to correct such Misstatement as set forth in
<U>Section</U><U></U><U>&nbsp;3.4</U> hereof; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.1.11 permit a representative of the Holders, the Underwriter(s), if any, and any attorney
or accountant retained by such Holders or Underwriter(s) to participate in the preparation of the Registration Statement, and cause the Company&#146;s officers, directors and employees to supply all information reasonably requested by any such
representative, Underwriter(s), attorney or accountant in connection with the Registration; <U>provided</U>, <U>however</U>, that such representatives or Underwriter(s) enter into a confidentiality agreement, in form and substance reasonably
satisfactory to the Company, prior to the release or disclosure of any such information; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.1.12 in the event of an Underwritten Offering,
request a customary &#147;comfort&#148; letter from the Company&#146;s independent registered public accounting firm, addressed to the Underwriter(s) and in customary form and covering such matters of the type customarily covered by
&#147;comfort&#148; letters as the managing Underwriter(s) may reasonably request, and reasonably satisfactory to a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">majority-in-interest</FONT></FONT> of the participating Holders and
such managing Underwriter; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.1.13 in the event of an Underwritten Offering, request one or more customary legal opinions of counsel
representing the Company for the purposes of such Registration, addressed to the Underwriter(s) and &#147;negative assurance letters&#148; covering such matters with respect to the Registration in respect of which such opinions and letters are being
given as the Underwriter(s) may reasonably request and as are customarily included in such opinions and negative assurance letters; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.1.14 in the event of any Underwritten Offering, enter into and perform its obligations under an underwriting agreement, in usual and
customary form, with the managing Underwriter(s) of such offering; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.1.15 make available to its security holders, as soon as reasonably
practicable, an earnings statement covering the period of at least twelve (12)&nbsp;months beginning with the first day of the Company&#146;s first full calendar quarter after the effective date of the Registration Statement which satisfies the
provisions of Section&nbsp;11(a) of the Securities Act and Rule 158 thereunder (or any successor rule promulgated thereafter by the Commission); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.1.16 if a Registration, including an Underwritten Offering, use its commercially reasonable efforts to make available senior executives of
the Company to participate in customary &#147;road show&#148; presentations that may be reasonably requested by the Underwriter(s) in any Underwritten Offering; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.1.17 otherwise, in good faith, use commercially reasonable efforts to cooperate reasonably with, and take such customary actions as may
reasonably be requested by the Holders, in connection with such Registration. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-1-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.2 Registration Expenses</B>. All Registration Expenses shall
be borne by the Company. It is acknowledged by the Holders that the Holders shall bear all incremental selling expenses relating to the sale of Registrable Securities, such as Underwriters&#146; commissions and discounts, brokerage fees, Underwriter
marketing costs and, other than as set forth in the definition of &#147;<B>Registration Expenses</B>,&#148; all reasonable fees and expenses of any legal counsel representing the Holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.3 Requirements for Participation in Underwritten Offerings</B>. No person may participate in any Underwritten
Offering for equity securities of the Company pursuant to a Registration initiated by the Company hereunder unless such person (i)&nbsp;agrees to sell such person&#146;s securities on the basis provided in any underwriting arrangements approved by
the Company and (ii)&nbsp;completes and executes all customary questionnaires, powers of attorney, indemnities, <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements, underwriting agreements and other customary documents as may be reasonably
required under the terms of such underwriting arrangements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.4 Suspension of Sales; Adverse
Disclosure</B>. The Company shall promptly notify each of the Holders in writing if a Registration Statement or Prospectus contains a Misstatement and, upon receipt of such written notice from the Company, each of the Holders shall forthwith
discontinue disposition of Registrable Securities until he, she or it has received copies of a supplemented or amended Prospectus correcting the Misstatement, provided that the Company hereby covenants promptly to prepare and file any required
supplement or amendment correcting any Misstatement promptly after the time of such notice and, if necessary, to request the immediate effectiveness thereof. If the filing, initial effectiveness or continued use of a Registration Statement or
Prospectus included in any Registration Statement at any time (a)&nbsp;would require the Company to make an Adverse Disclosure, (b)&nbsp;would require the inclusion in such Registration Statement of financial statements that are unavailable to the
Company for reasons beyond the Company&#146;s control, (c)&nbsp;requires the Company to update the financial statements contained in such Registration Statement pursuant to the rules and regulations of the Commission through the filing of a <FONT
STYLE="white-space:nowrap">post-effective</FONT> amendment which is subject to potential Commission review, or (d)&nbsp;in the good faith judgment of the Chief Executive Officer or Chief Financial Officer of the Company, which judgment shall be
documented in writing and provided to the Holders in the form of a written certificate signed by such officer, such filing, initial effectiveness or continued use of a Registration Statement would be materially detrimental to the Company. the
Company shall have the right to defer the filing, initial effectiveness or continued use of any Registration Statement pursuant to (a), (b) or (c)&nbsp;for a period of not more than ninety (90)&nbsp;days in any three hundred and sixty <FONT
STYLE="white-space:nowrap">(360)-day</FONT> period. In the event the Company exercises its rights under the preceding sentence, the Holders agree to suspend, immediately upon their receipt of the notice referred to above, their use of the Prospectus
relating to any Registration in connection with any sale or offer to sell Registrable Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.5
Reporting Obligations</B>. As long as any Holder shall own Registrable Securities, the Company, at all times while it shall be a reporting company under the Exchange Act, shall expend commercially reasonable efforts to (i)&nbsp;file timely (or
obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed by the Company after the date hereof pursuant to Sections 13(a) or 15(d) of the Exchange Act (and upon the request of any Holder, the
Company shall deliver to such Holder a written certification of a duly authorized officer as to whether it has complied with such requirements), and (ii)&nbsp;take such further action as any Holder may reasonably request, all to the extent required
from time to time to enable such Holder to sell Common Shares held by such Holder without registration under the Securities Act within the limitation of the exemptions provided by Rule 144 promulgated under the Securities Act (or any successor rule
promulgated thereafter by the Commission), including using commercially reasonable efforts to cause any legal opinions to be delivered. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-1-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IV </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEMNIFICATION AND CONTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.1 Indemnification</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.1.1 The Company agrees to indemnify, to the extent permitted by law, each Holder of Registrable Securities, its officers and directors and
agents and each person who controls such Holder (within the meaning of the Securities Act) against all losses, claims, damages, liabilities and expenses (including reasonable attorneys&#146; fees) caused by any untrue or alleged untrue statement of
material fact contained in any Registration Statement, Prospectus or preliminary Prospectus or any amendment thereof or supplement thereto or any omission or alleged omission of a material fact required to be stated therein or necessary to make the
statements therein, in the light of the circumstances in which they were made, not misleading, except insofar as the same are caused by or contained in any information furnished in writing to the Company by such Holder expressly for use therein. The
Company shall indemnify the Underwriter(s), their officers and directors and each person who controls (within the meaning of the Securities Act) such Underwriter(s) to the same extent as provided in the foregoing with respect to the indemnification
of the Holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.1.2 In connection with any Registration Statement in which a Holder of Registrable Securities is participating, such
Holder shall furnish to the Company in writing such information and affidavits as the Company reasonably requests for use in connection with any such Registration Statement or Prospectus and, to the extent permitted by law, shall, severally and not
jointly, indemnify the Company, its directors and officers and agents and each person who controls (within the meaning of the Securities Act) the Company against any losses, claims, damages, liabilities and expenses (including without limitation
reasonable attorneys&#146; fees) resulting from any untrue statement of material fact contained in the Registration Statement, Prospectus or preliminary Prospectus or any amendment thereof or supplement thereto or any omission of a material fact
required to be stated therein or necessary to make the statements therein not misleading, but only to the extent that such untrue statement or omission is contained in any information or affidavit so furnished in writing by such Holder expressly for
use therein; <U>provided</U>, <U>however</U>, that the obligation to indemnify shall be several, not joint and several, among such Holders of Registrable Securities, and the liability of each such Holder of Registrable Securities shall be in
proportion to and limited to the net proceeds received by such Holder from the sale of Registrable Securities pursuant to such Registration Statement. The Holders of Registrable Securities shall indemnify the Underwriter(s), their officers,
directors and each person who controls (within the meaning of the Securities Act) such Underwriter(s) to the same extent as provided in the foregoing with respect to indemnification of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.1.3 Any person entitled to indemnification herein shall (i)&nbsp;give prompt written notice to the indemnifying party of any claim with
respect to which it seeks indemnification (<U>provided</U>, <U>however</U>, that the failure to give prompt notice shall not impair any person&#146;s right to indemnification hereunder to the extent such failure has not materially prejudiced the
indemnifying party) and (ii)&nbsp;unless in such indemnified party&#146;s reasonable judgment a conflict of interest between such indemnified and indemnifying parties may exist with respect to such claim, permit such indemnifying party to assume the
defense of such claim with counsel reasonably satisfactory to the indemnified party. If such defense is assumed, the indemnifying party shall not be subject to any liability for any settlement made by the indemnified party without its consent (but
such consent shall not be unreasonably withheld, conditioned or delayed). An indemnifying party who is not entitled to, or elects not to, assume the defense of a claim shall not be obligated to pay the fees and expenses of more than one counsel for
all parties indemnified by such indemnifying party with respect to such claim, unless in the reasonable judgment of any indemnified party a conflict of interest may exist between such indemnified party and any other of such indemnified parties with
respect to such claim. No indemnifying party shall, without the consent of the indemnified party, consent to the entry of any judgment or enter into any settlement which cannot be settled in all respects by the payment of money (and such money is so
paid by the indemnifying party pursuant to the terms of such settlement) or which settlement does not include as an unconditional term thereof the giving by the claimant or plaintiff to such indemnified party of a release from all liability in
respect to such claim or litigation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-1-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.1.4 The indemnification provided for under this Agreement shall remain in full force and
effect regardless of any investigation made by or on behalf of the indemnified party or any officer, director or Affiliate of such indemnified party and shall survive the transfer of securities. The Company and each Holder of Registrable Securities
participating in an offering also agrees to make such provisions as are reasonably requested by any indemnified party for contribution (pursuant to <U>Section</U><U></U><U>&nbsp;4.1.5</U>) to such party in the event the Company&#146;s or such
Holder&#146;s indemnification is unavailable for any reason. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.1.5 If the indemnification provided under
<U>Section</U><U></U><U>&nbsp;4.1</U> hereof from the indemnifying party is unavailable or insufficient to hold harmless an indemnified party in respect of any losses, claims, damages, liabilities and expenses referred to herein, then the
indemnifying party, in lieu of indemnifying the indemnified party, shall to the extent permitted by law contribute to the amount paid or payable by the indemnified party as a result of such losses, claims, damages, liabilities and expenses in such
proportion as is appropriate to reflect the relative fault of the indemnifying party and the indemnified party, as well as any other relevant equitable considerations. The relative fault of the indemnifying party and indemnified party shall be
determined by a court of law by reference to, among other things, whether any action in question, including any untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact, was made by, or relates
to information supplied by, such indemnifying party or indemnified party, and the indemnifying party&#146;s and indemnified party&#146;s relative intent, knowledge, access to information and opportunity to correct or prevent such action;
<U>provided</U>, <U>however</U>, that the liability of any Holder under this <U>Section</U><U></U><U>&nbsp;4.1.5</U> shall be limited to the amount of the net proceeds received by such Holder in such offering giving rise to such liability. The
amount paid or payable by a party as a result of the losses or other liabilities referred to above shall be deemed to include, subject to the limitations set forth in <U>Sections 4.1.2</U>, <U>4.1.2</U> and <U>4.1.3</U> above, any legal or other
fees, charges or expenses reasonably incurred by such party in connection with any investigation or proceeding. The parties hereto agree that it would not be just and equitable if contribution pursuant to this <U>Section</U><U></U><U>&nbsp;4.1.5</U>
were determined by pro rata allocation or by any other method of allocation, which does not take account of the equitable considerations referred to in this <U>Section</U><U></U><U>&nbsp;4.1.5</U>. No person guilty of fraudulent misrepresentation
(within the meaning of Section&nbsp;11(f) of the Securities Act) shall be entitled to contribution pursuant to this <U>Section</U><U></U><U>&nbsp;4.1.5</U> from any person who was not guilty of such fraudulent misrepresentation. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE V </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT
STYLE="white-space:nowrap">LOCK-UP</FONT> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.1
Lock</B><B><FONT STYLE="white-space:nowrap">-Up</FONT></B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.1.1 Each Holder agrees, and the Company agrees and shall cause each director
and officer of the Company to agree, that, in connection with each Registration or sale of Registrable Securities pursuant to <U>Section</U><U></U><U>&nbsp;2.1</U>, <U>Section</U><U></U><U>&nbsp;2.2 </U>or <U>Section</U><U></U><U>&nbsp;2.3</U>
conducted as an Underwritten Offering, if requested, to become bound by and to execute and deliver a customary <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement with the underwriter(s) of such Underwritten Offering restricting such
applicable person or entity&#146;s right to (a)&nbsp;Transfer, directly or indirectly, any equity securities of the Company held by such person or entity or (b)&nbsp;enter into any swap or other arrangement that Transfers to another any of the
economic consequences of ownership of such securities during the period commencing on the date of the final Prospectus relating to the Underwritten Offering and ending on the date specified by the underwriters (such period not to exceed ninety
(90)&nbsp;days). The terms of such <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements shall be negotiated among the applicable Holders requested to enter into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements in accordance with the
immediately preceding sentence, the Company and the underwriters and shall include customary exclusions from the restrictions on Transfer set forth therein, including that such restrictions on the applicable Holders shall be conditioned upon all
officers and directors of the Company, as well as all such applicable Holders, being subject to the same restrictions; <U>provided</U>, <U>however</U>, to the extent any Holder is granted a release or waiver from the restrictions contained in this
<U>Section</U><U></U><U>&nbsp;5.1.</U> and in such Holder&#146;s <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement prior to the expiration of the period set forth in such Holder&#146;s <FONT STYLE="white-space:nowrap">lock-up</FONT>
agreement, then all applicable Holders shall be automatically granted a release or waiver from the restrictions contained in this <U>Section</U><U></U><U>&nbsp;5.1</U> and the applicable <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-1-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which they are party to the same extent, on substantially the same terms as and on a pro rata basis with, the Holder to which such release or waiver is granted. The provisions of this
Section&nbsp;5.1 shall not apply to any Holder that then holds less than one percent (1%) of then total issued and outstanding Common Shares. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VI </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TERMINATION
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;6.1 Prior Agreement Termination</B>. By execution and delivery of this Agreement and contingent upon
the occurrence of, and effective as of, Closing, FEAC and Sponsor (who represents and warrants that it holds at least a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">majority-in-interest</FONT></FONT> of the &#147;Registrable
Securities&#148; under the Prior Agreement), hereby terminate in its entirety the Prior Agreement pursuant to the power and authority granted to FEAC and the holders of at least a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">majority-in-interest</FONT></FONT> of such &#147;Registrable Securities&#148; in Section&nbsp;6.5 of the Prior Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;6.2 Termination</B>. This Agreement shall terminate in the case of any Holder, the date on which neither the
Holder nor any of its permitted assignees holds any Registrable Securities. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VII </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GENERAL PROVISIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7.1 Notices</B>. All notices, requests, claims, demands and other communications hereunder shall be in writing
and shall be given (and shall be deemed to have been duly given upon receipt) by delivery in person, by <FONT STYLE="white-space:nowrap">e-mail</FONT> or by registered or certified mail (postage prepaid, return receipt requested) to the respective
parties at the following addresses or <FONT STYLE="white-space:nowrap">e-mail</FONT> addresses (or at such other address or email address for a party as shall be specified in a notice given in accordance with this Section&nbsp;7.1): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If to the Company, to it at: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><U>with a copy (which shall not constitute notice) to</U>: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If to a Holder, to the address or email address set forth for such Holder on the signature page hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7.2 Severability</B>. If any term or other provision of this Agreement is invalid, illegal or incapable of being
enforced by any rule of law or public policy, all other conditions and provisions of this Agreement shall nevertheless remain in full force and effect so long as the economic or legal substance of the transactions contemplated hereby is not affected
in any manner materially adverse to any party. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the parties hereto shall negotiate in good faith to modify this Agreement so as to effect the
original intent of the parties as closely as possible in a mutually acceptable manner in order that the transactions contemplated hereby be consummated as originally contemplated to the fullest extent possible. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7.3 Entire Agreement; Assignment</B>. This Agreement constitutes the entire agreement among the parties with
respect to the subject matter hereof and supersedes all prior agreements and undertakings, both written and oral, among the parties, or any of them, with respect to the subject matter hereof. This Agreement shall not be assigned (whether pursuant to
a merger, by operation of law or otherwise), by any party without the prior express written consent of the other parties hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7.4 Parties in Interest</B>. This Agreement shall be binding upon and inure solely to the benefit of each party
hereto (and its respective permitted assigns), and nothing in this Agreement, express or implied, is intended to or shall confer upon any other person any right, benefit or remedy of any nature whatsoever under or by reason of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-1-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7.5 Governing Law</B>. This Agreement shall be governed by,
and construed in accordance with, the laws of the State of Delaware applicable to contracts executed in and to be performed in that State. All legal actions and proceedings arising out of or relating to this Agreement shall be heard and determined
exclusively in any Delaware Chancery Court; <U>provided</U>, <U>however</U>, that if jurisdiction is not then available in the Delaware Chancery Court, then any such legal action may be brought in any federal court located in the State of Delaware
or any other Delaware state court. The parties hereto hereby (a)&nbsp;irrevocably submit to the exclusive jurisdiction of the aforesaid courts for themselves and with respect to their respective properties for the purpose of any action arising out
of or relating to this Agreement brought by any party hereto, and (b)&nbsp;agree not to commence any action relating thereto except in the courts described above in Delaware, other than actions in any court of competent jurisdiction to enforce any
judgment, decree or award rendered by any such court in Delaware as described herein. Each of the parties further agrees that notice as provided herein shall constitute sufficient service of process and the parties further waive any argument that
such service is insufficient. Each of the parties hereby irrevocably and unconditionally waives, and agrees not to assert, by way of motion or as a defense, counterclaim or otherwise, in any action arising out of or relating to this Agreement or the
transactions contemplated hereby, (i)&nbsp;any claim that it is not personally subject to the jurisdiction of the courts in Delaware as described herein for any reason, (ii)&nbsp;that it or its property is exempt or immune from jurisdiction of any
such court or from any legal process commenced in such courts (whether through service of notice, attachment prior to judgment, attachment in aid of execution of judgment, execution of judgment or otherwise) and (iii)&nbsp;that (x) the action in any
such court is brought in an inconvenient forum, (y)&nbsp;the venue of such action is improper or (z)&nbsp;this Agreement, or the subject matter hereof, may not be enforced in or by such courts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7.6 Waiver of Jury Trial</B>. EACH OF THE PARTIES HERETO HEREBY WAIVES TO THE FULLEST EXTENT PERMITTED BY
APPLICABLE LAW ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY WITH RESPECT TO ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT. EACH OF THE PARTIES HERETO (I)&nbsp;CERTIFIES THAT NO REPRESENTATIVE, AGENT OR
ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THAT FOREGOING WAIVER AND (II)&nbsp;ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED
TO ENTER INTO THIS AGREEMENT AND THE TRANSACTIONS CONTEMPLATED HEREBY, AS APPLICABLE, BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS <U>SECTION 7.6</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7.7 Headings; Interpretation</B>. The descriptive headings contained in this Agreement are included for
convenience of reference only and shall not affect in any way the meaning or interpretation of this Agreement. The parties have participated jointly in the negotiation and drafting of this Agreement. If any ambiguity or question of intent arises,
this Agreement will be construed as if drafted jointly by the parties and no presumption or burden of proof will arise favoring or disfavoring any party because of the authorship of any provision of this Agreement. Unless the context of this
Agreement clearly requires otherwise, use of the masculine gender shall include the feminine and neutral genders and vice versa, and the definitions of terms contained in this Agreement are applicable to the singular as well as the plural forms of
such terms. The words &#147;includes&#148; or &#147;including&#148; means &#147;including without limitation.&#148; The words &#147;hereof,&#148; &#147;hereby,&#148; &#147;herein,&#148; &#147;hereunder&#148; and similar terms in this Agreement shall
refer to this Agreement as a whole and not any particular section or article in which such words appear, the word &#147;extent&#148; in the phrase &#147;to the extent&#148; means the degree to which a subject or other thing extends and such phrase
shall not mean simply &#147;if.&#148; Any reference to a law shall include any rules and regulations promulgated thereunder, and means such law as from time to time amended, modified or supplemented. References herein to any contract (including this
Agreement) mean such contract as amended, supplemented or modified from time to time in accordance with the terms thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7.8 Counterparts</B>. This Agreement may be executed and delivered (including by facsimile or portable document
format (pdf) transmission) in counterparts, and by the different parties hereto in separate counterparts, each of which when executed shall be deemed to be an original but all of which taken together shall constitute one and the same agreement.<B>
</B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-1-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7.9 Specific Performance</B>. The parties hereto agree that
irreparable damage would occur in the event any provision of this Agreement was not performed in accordance with the terms hereof and that the parties shall be entitled to specific performance of the terms hereof, in addition to any other remedy at
law or in equity. Each of the parties hereby further waives (i)&nbsp;any defense in any action for specific performance that a remedy at law would be adequate and (ii)&nbsp;any requirement under any Law to post security or a bond as a prerequisite
to obtaining equitable relief. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7.10 Expenses</B>. Except as otherwise provided herein, all costs and
expenses incurred in connection with this Agreement and the transactions contemplated hereby shall be paid by the party incurring such costs and expenses, whether or not the transactions contemplated hereby are consummated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7.11 Amendment</B>. This Agreement may not be amended, and no provision herein may be waived, except by an
instrument in writing signed by (i)&nbsp;the Company, (ii)&nbsp;Sponsor Holders who hold at least a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">majority-in-interest</FONT></FONT> of the
<FONT STYLE="white-space:nowrap">then-outstanding</FONT> number of Registrable Securities held by all Sponsor Holders at such time and (iii)&nbsp;enGene Holders holding at least a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">majority-in-interest</FONT></FONT> of the <FONT STYLE="white-space:nowrap">then-outstanding</FONT> number of Registrable Securities held by all enGene Holders at such time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7.12 Waiver</B>. At any time, the Company may (a)&nbsp;extend the time for the performance of any obligation or
other act of any Holder, (b)&nbsp;waive any inaccuracy in the representations and warranties of any Holder contained herein or in any document delivered by such Holder pursuant hereto and (c)&nbsp;waive compliance with any agreement of such Holder
or any condition to its own obligations contained herein. At any time, upon the affirmative vote or written consent of (x)&nbsp;a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">majority-in-interest</FONT></FONT> of the Sponsor
Holders and (y)&nbsp;a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">majority-in-interest</FONT></FONT> of the enGene Holders, such Holders may (i)&nbsp;extend the time for the performance of any obligation or other act of the
Company, (ii)&nbsp;waive any inaccuracy in the representations and warranties of the Company contained herein or in any document delivered by the Company pursuant hereto and (iii)&nbsp;waive compliance with any agreement of the Company or any
condition to their own obligations contained herein. Any such extension or waiver shall be valid if set forth in an instrument in writing signed by the party or parties to be bound thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7.13 Further Assurances</B>. At the request of the Company, in the case of any Holder, or at the request of any
Holder, in the case of the Company, and without further consideration, each party shall execute and deliver or cause to be executed and delivered such additional documents and instruments and take such further action as may be reasonably necessary
to consummate the transactions contemplated by this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7.14 Corporate Opportunities</B>. It is
hereby acknowledged that the Sponsor Holders and their Affiliates participate in, and own and will own substantial equity interests in other entities (existing and future) that participate in, similar industries to the Company (the
&#147;<B>Portfolio Companies</B>&#148;) and may make investments and enter into advisory service agreements and other agreements from time to time with such Portfolio Companies. Any individual who serves as a director, officer, employee, agent,
partner, shareholder, member or manager of a Sponsor Holder may also serve as a director, officer, employee, agent, partner, shareholder or member of (i)&nbsp;such Sponsor Holder&#146;s Affiliate or Portfolio Company or (ii)&nbsp;a different Sponsor
Holder or such different Sponsor Holder&#146;s Affiliate or Portfolio Company and, at any given time, such Sponsor Holder, its Affiliates or Portfolio Companies may be in direct or indirect competition with the Company and/or its Affiliates. The
Company waives, to the maximum extent permitted by Law, the application of the doctrine of corporate opportunity (or any analogous doctrine) with respect to any Sponsor Holders, their Affiliates or Portfolio Companies or any of their directors
(subject to compliance by such director with his or her fiduciary duties as a director of the Company (as such, a &#147;<B>Sponsor Director</B>&#148;) and Laws applicable to the Company or its directors). As a result of such waiver, none of Sponsor
Holders, their Affiliates or Portfolio Companies, nor any of their directors (subject to compliance by a Sponsor Director with his or her fiduciary duties as a director of the Company) and Laws applicable to the Company or its directors), shall have
any obligation to refrain from: (A)&nbsp;engaging in or managing the same or similar activities or lines of business as the Company or any of its Affiliates or developing or marketing any products or services that compete (directly or indirectly)
with those of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-1-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Company or any of its subsidiaries; (B)&nbsp;acquiring assets in the same or similar areas of operation and lines of business of the Company; (C)&nbsp;investing in, owning or disposing of any
(public or private) interest in any person engaged in the same or similar activities or lines of business as, or otherwise in competition with, the Company or any of its Affiliates (including a Sponsor Holder or their Affiliates, a
&#147;<B>Competing Person</B>&#148;); (D) developing a business relationship with any Competing Person; or (E)&nbsp;entering into any agreement to provide any service(s) to any Competing Person or acting as director, officer, employee, agent,
partner, shareholder, member, manager or advisor to, or other principal of, any Competing Person, regardless (in the case of each of clauses (A)&nbsp;through (E)) of whether such activities are in direct or indirect competition with the business or
activities of the Company or any of its subsidiaries (the activities described in clauses (A)&nbsp;through (D) are referred to herein as &#147;<B>Specified Activities</B>&#148;). To the fullest extent permitted by law, the Company hereby renounces
(for itself and on behalf of its subsidiaries) any interest or expectancy in, or in being notified of or offered an opportunity to participate in, any Specified Activity that may be presented to or become known to Sponsor, its Affiliates or
Portfolio Companies or any Sponsor Director, other than any such Specified Activity that was learned, discovered or sourced solely in the course of a Sponsor Director acting in such Sponsor Director&#146;s capacity as a director of the Company or
any of its Affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;7.15 No Strict Construction</B>. The language used in this Agreement shall be deemed
to be the language chosen by the parties to express their mutual intent and no rule of strict construction shall be applied against any party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(Next Page is Signature Page) </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-1-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Final Form </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, each of the undersigned has caused its duly authorized representative to execute and deliver this Agreement as of the date
first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ENGENE HOLDINGS INC</B>.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>FORBION EUROPEAN ACQUISITION CORP.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Company Signature Page to Registration Rights Agreement</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-1-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Final Form </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, each of the undersigned has caused its duly authorized representative to execute and deliver this Agreement as of the date
first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SPONSOR HOLDERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>[&#149;]</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Sponsor Holders Signature Page to Registration Rights Agreement</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-1-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Final Form </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, each of the undersigned has caused its duly authorized representative to execute and deliver this Agreement as of the date
first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ENGENE HOLDERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>[&#149;]</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>enGene Holders Signature Page to Registration Rights Agreement</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-1-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Final Form </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule A </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Sponsor Holders
</U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Holder</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number of Shares</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>enGene Holders </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Holder</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number of Shares</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Schedule A </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-1-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit <FONT STYLE="white-space:nowrap">E-1</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form of Company Voting Agreement </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-1-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Final Form </I></B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE VOTING AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This enGene Voting Agreement (this &#147;<U>Agreement</U>&#148;) is made as of May&nbsp;16, 2023, by and among enGene Holdings Inc., a company
incorporated under the laws of Canada that intends to continue to a company governed by the <I>Business Corporations Act</I> (British Columbia) (the &#147;<U>Company</U>&#148;), Forbion European Acquisition Corp., a Cayman Islands exempted company
(&#147;<U>FEAC</U>&#148;), and the undersigned shareholders (collectively, the &#147;<U>Voting Parties</U>&#148; and each a &#147;<U>Voting Party</U>&#148;) of enGene Inc., a company incorporated under the laws of Canada (&#147;<U>enGene</U>&#148;).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS,</B> concurrently with the execution and delivery of this Agreement, FEAC, enGene, the Company and certain other persons party
thereto are entering into a Business Combination Agreement (as the same may be amended or modified from time to time, the &#147;<U>Business Combination Agreement</U>&#148;), pursuant to which, on the terms and subject to the conditions set forth
therein, among other things FEAC, enGene and the Company agreed to effect the Transactions set forth therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE,</B> in
consideration of the premises and for other good and valuable consideration, the receipt, sufficiency and adequacy of which are hereby acknowledged, the parties hereto agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Definitions</U>. As used herein, the term &#147;<U>Voting Shares</U>&#148; shall mean, taken together, all securities of enGene
beneficially owned (as such term is defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act, excluding shares of stock underlying unexercised options or warrants, but including any shares of stock acquired upon exercise
of such options or warrants) (&#147;<U>Beneficially Owned</U>&#148; or &#147;<U>Beneficial Ownership</U>&#148;) by any Voting Party, including any and all securities of enGene acquired and held in such capacity subsequent to the date hereof.
Capitalized terms used and not defined herein have the respective meanings assigned to them in the Business Combination Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.
<U>Representations and Warranties of the Voting Parties</U>. Each Voting Party on its own behalf hereby represents and warrants to FEAC, severally and not jointly, with respect to such Voting Party and such Voting Party&#146;s Beneficial Ownership
of its Voting Shares set forth on <U>Annex</U><U></U><U>&nbsp;A</U> as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <I>Authority</I>. Voting Party has all requisite
power and authority and legal capacity to enter into this Agreement, to perform fully Voting Party&#146;s obligations hereunder and to consummate the transactions contemplated hereby. This Agreement has been duly authorized, executed and delivered
by Voting Party. This Agreement constitutes a valid and binding obligation of Voting Party enforceable in accordance with its terms, except as enforcement may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar
laws affecting creditors&#146; rights generally and by principles governing the availability of equitable remedies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <I>No
Consent</I>. No consent, approval or authorization of, or designation, declaration or filing with, any Governmental Entity or other Person on the part of Voting Party is required in connection with the execution, delivery and performance of this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <I>No Conflicts</I>. Neither the execution and delivery of this Agreement, nor the consummation of the transactions
contemplated hereby, nor compliance with the terms hereof, will violate, conflict with or result in a breach of, or constitute a default (with or without notice or lapse of time or both) under any provision of, Voting Party&#146;s Governing
Documents, any trust agreement, loan or credit agreement, note, bond, mortgage, indenture, lease or other agreement, instrument, permit, concession, franchise, license, judgment, order, notice, decree, statute, law, ordinance, rule or regulation
applicable to Voting Party or to Voting Party&#146;s property or assets (including the Voting Shares) that would reasonably be expected to prevent or delay the consummation of the Transactions or that would reasonably be expected to prevent Voting
Party from fulfilling its obligations under this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-1-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <I>Ownership of Shares</I>. Except pursuant to the arrangements referred to in the
following sentence, each Voting Party (i)&nbsp;Beneficially Owns its Voting Shares free and clear of all Liens (other than transfer restrictions under applicable securities laws) and (ii)&nbsp;has the sole power to vote or cause to be voted its
Voting Shares. Except pursuant hereto and pursuant to (A)&nbsp;enGene&#146;s Governing Documents, (B)&nbsp;that certain Third Amended and Restated Majority Shareholders Agreement, dated as of June&nbsp;30, 2021, by and between enGene and the
shareholders named therein (the &#147;<U>Shareholders Agreement</U>&#148;), (C) that certain Second Amended and Restated Registration Rights Agreement, dated as of June&nbsp;30, 2021, by and between enGene and the shareholders named therein (the
&#147;<U>Registration Rights Agreement</U>&#148;), (D) the enGene <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement, dated as of even date herewith, by and between enGene, the Company, FEAC and the Voting Parties (the &#147;<U>enGene <FONT
STYLE="white-space:nowrap">Lock-up</FONT> Agreement</U>&#148;) and (E)&nbsp;any agreement granting equity or equity-based compensation awards (collectively with the Shareholders Agreement and the Registration Rights Agreement, the &#147;<U>Company
Affiliate Agreements</U>&#148;), there are no options, warrants or other rights, agreements, arrangements or commitments of any character to which Voting Party is a party relating to the pledge, acquisition, disposition, transfer or voting of Voting
Shares prior to the consummation of the Transactions and there are no voting trusts or voting agreements with respect to the Voting Shares. Voting Party does not Beneficially Own or otherwise have any direct or indirect interest in (i)&nbsp;any
Voting Shares, other than the Voting Shares set forth on <U>Annex</U><U></U><U>&nbsp;A</U> or (ii)&nbsp;any options, warrants or other rights to acquire any additional common shares, or vote any common shares, or any other equity interests, of
enGene (&#147;<U>enGene Shares</U>&#148;) or any security exercisable or exchangeable for or convertible into enGene Shares, other than as set forth on <U>Annex</U><U></U><U>&nbsp;A</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <I>No Litigation</I>. There is no Proceeding pending against, or, to the knowledge of Voting Party, threatened against, Voting Party that
would reasonably be expected to impair or adversely affect the ability of Voting Party to perform Voting Party&#146;s obligations hereunder or to consummate the transactions contemplated by this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <I>Business Combination Agreement</I>. Each Voting Party understands and acknowledges that FEAC, enGene and the Company are entering into
the Business Combination Agreement in reliance upon such Voting Party&#146;s execution and delivery of this Agreement. Such Voting Party has received a copy of the Business Combination Agreement and is familiar with the provisions of the Business
Combination Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Agreement to Vote Shares;</U><U> Irrevocable Proxy; </U><U>Further Assurances</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Prior to the earlier of (x)&nbsp;date on which this Agreement is terminated in accordance with its terms and (y)&nbsp;the Closing Date (the
&#147;<B>Voting Period</B>&#148;), each Voting Party shall, at any meeting (or in connection with any request for action by written consent) of the shareholders of enGene at which the matters described in clauses (i)&nbsp;and (ii) below are
considered and at every adjournment or postponement thereof, (x)&nbsp;cause the Voting Shares that such Voting Party Beneficially Owns to be counted as present thereat for the purpose of establishing a quorum, (y)&nbsp;vote or cause to be voted the
Voting Shares that such Voting Party Beneficially Owns and (z)&nbsp;execute a written consent or consents if shareholders of enGene are requested to vote their shares through the execution of an action by written consent, in each case to the extent
such Voting Shares are entitled to vote thereon pursuant to enGene&#146;s Governing Documents: (i)&nbsp;in favor of (A)&nbsp;the approval, consent, ratification and adoption of the Company Arrangement Resolution and the Transactions, (B)&nbsp;any
proposal to adjourn or postpone the Company Shareholders Meeting to a later date if there are not sufficient votes for approval, consent, ratification and adoption of the Company Arrangement Resolution and the Transactions, and (C)&nbsp;any other
matter reasonably necessary to the consummation of the Transactions and the other matters contemplated by the Business Combination Agreement and considered and voted upon by the shareholders of enGene; and (ii)&nbsp;against (other than as
contemplated by the Transactions)&nbsp;(A) any proposal or offer from any Person (other than FEAC or any of its Affiliates) concerning (1)&nbsp;a merger, consolidation, liquidation, recapitalization, share exchange or other business combination
transaction involving enGene, (2)&nbsp;the issuance or acquisition of shares of capital stock or other equity securities of enGene, or (3)&nbsp;the sale, lease, exchange or other disposition of any significant portion of enGene&#146;s properties or
assets; (B)&nbsp;any action, proposal, transaction or agreement that could reasonably be expected to result in a breach of any covenant or obligation of enGene set forth in the Business Combination </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-1-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Agreement, or in any representation or warranty of enGene set forth in the Business Combination Agreement becoming inaccurate; and (C)&nbsp;any action, proposal, transaction or agreement that
could reasonably be expected to impede, interfere with, delay, discourage, adversely affect or inhibit the timely consummation of the Transactions or the fulfillment of enGene&#146;s conditions under the Business Combination Agreement or change in
any manner the voting rights of any class of shares of enGene (including any amendments to the Governing Documents), except as contemplated by this Agreement, the Business Combination Agreement or the Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) During the term of this Agreement, each Voting Party irrevocably and unconditionally consents to the details of this Agreement being set
out in the materials to be submitted to the Court in connection with the Arrangement and in the Company Information Circular to be prepared in connection with the Company Shareholders Meeting and for the form of this Agreement to be filed with the
SEC and any other Governmental Entity, in connection with the Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Each Voting Party hereby appoints each of Jason Hanson
and Anthony Cheung, acting individually, and any designee of either of them, and each of them individually, as its proxies and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact,</FONT></FONT> with full power of
substitution and resubstitution, to vote or act by written consent during the term of this Agreement with respect to the Voting Shares in accordance with <U>Section</U><U></U><U>&nbsp;3(a)</U> hereof. This proxy and power of attorney is given to
secure the performance of the duties of Voting Party under this Agreement. Each Voting Party shall take such further action or execute such other instruments as may be necessary to effectuate the intent of this proxy. This proxy and power of
attorney granted by Voting Party shall be irrevocable during the term of this Agreement, shall be deemed to be coupled with an interest sufficient in law to support an irrevocable proxy and shall revoke any and all prior proxies granted by Voting
Party with respect to the Voting Shares. The power of attorney granted by Voting Party herein is a durable power of attorney and shall survive the dissolution, bankruptcy, death or incapacity of Voting Party. The proxy and power of attorney granted
hereunder shall terminate upon the termination of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>No Voting Trusts or Other Arrangement</U>. During the Voting
Period, each Voting Party will not, and will not permit any entity under Voting Party&#146;s control to, deposit any Voting Shares in a voting trust, grant any proxies with respect to the Voting Shares or subject any of the Voting Shares to any
arrangement with respect to the voting of the Voting Shares except as contemplated in this Agreement or the Business Combination Agreement. Each Voting Party hereby revokes any and all previous proxies and attorneys in fact with respect to the
Voting Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Certain Covenants of Voting Party; Transfer and Encumbrance</U>. During the Voting Period, each Voting Party will
not, (a)&nbsp;directly or indirectly, transfer (including by operation of law), sell, offer, exchange, assign, hedge, swap, convert, pledge or otherwise dispose of or encumber (&#147;<U>Transfer</U>&#148;) any of such Voting Party&#146;s Voting
Shares or enter into any contract, option or other agreement with respect to, or consent to, a Transfer of, any of such Voting Party&#146;s Voting Shares or Voting Party&#146;s voting or economic interest therein, (b)&nbsp;publicly announce any
intention to effect any transaction specified in clause (a), (c)&nbsp;knowingly take any action that would make any representation or warranty of such Voting Party contained herein untrue or inaccurate, or have the effect of preventing or disabling
such Voting Party from performing its obligations under this Agreement, or (d)&nbsp;take any action, nor permit its representatives to take any action, to contest, oppose or interfere with the Company&#146;s application pursuant to Section&nbsp;192
of the CBCA for the Interim Order or the Final Order or to otherwise contest or oppose the Arrangement before any Governmental Entity, or to solicit proxies or become a participant in a solicitation in opposition to or competition with the Company
Arrangement Resolution or the Transactions. Any attempted Transfer of Voting Shares or any interest therein in violation of this <U>Section</U><U></U><U>&nbsp;5</U> shall be null and void. Notwithstanding the foregoing, this
<U>Section</U><U></U><U>&nbsp;5</U> shall not prohibit a Transfer of Voting Shares by any Voting Party in compliance with Section&nbsp;2(b) of the enGene <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement; <U>provided</U>, <U>however</U>,
that in each case, the applicable transferees enter into a written joinder to this Agreement in form and substance reasonably acceptable to FEAC and enGene by which such applicable transferees agree to be bound by this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-1-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Appraisal and Dissenters&#146; Rights</U>. Each Voting Party hereby (a)&nbsp;waives to
the fullest extent permitted by Law, and agrees not to assert or perfect, any rights of appraisal or rights to dissent (as applicable, or any similar rights) from the Transactions that Voting Party may have by virtue of ownership of the Voting
Shares, including the Dissent Rights, and (b)&nbsp;agrees not to commence or participate in any claim, derivative or otherwise, against FEAC, the Company or enGene or the members of their respective Boards of Directors relating to the negotiation,
execution or delivery of this Agreement or the Business Combination Agreement or the consummation of the Transactions, including any claim (i)&nbsp;challenging the validity of, or seeking to enjoin the operation of, any provision of this Agreement
or (ii)&nbsp;alleging a breach of any fiduciary duty of the Board of Directors of FEAC, the Company or enGene in connection with this Agreement, the Business Combination Agreement or the Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Exercise of Rights</U>. Each Voting Party shall not exercise any registration rights or other rights (solely to the extent such right
would prevent, impede, or delay or be inconsistent with the Transactions) granted pursuant to the Company Affiliate Agreements with respect to any Voting Shares Beneficially Owned as of the date hereof or acquired and held in such capacity
subsequent to the date hereof, other than in compliance with this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Additional Matters</U>. Each Voting Party shall, from
time to time, (i)&nbsp;execute and deliver, or cause to be executed and delivered, such additional or further consents, documents and other instruments as FEAC, enGene or the Company may reasonably request for the purpose of effectively carrying out
the transactions contemplated by this Agreement and the Business Combination Agreement and (ii)&nbsp;refrain from exercising any veto right, consent right or similar right (whether under the Governing Documents of enGene or the CBCA which would
impede, disrupt, prevent or otherwise adversely affect the consummation of the Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Termination</U>. This Agreement shall
automatically terminate upon the earliest to occur of (a)&nbsp;the Closing Date and (b)&nbsp;the date on which the Business Combination Agreement is terminated for any reason in accordance with its terms. Upon termination of this Agreement, no party
shall have any further rights, obligations or liabilities under this Agreement; <U>provided</U>, that nothing in this <U>Section</U><U></U><U>&nbsp;9</U> shall relieve any party of liability for any breach of this Agreement occurring prior to
termination and the provisions of <U>Sections 11</U> through <U>14</U> shall survive any termination of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>No
Agreement as Director or Officer</U>. Nothing in this Agreement will limit or affect any actions or omissions taken by a Voting Party (or any Affiliate, securityholder, partner, director, officer or employee of Voting Party) in his, her or its
capacity as a director or officer of enGene or the Company. Nothing in this Agreement will be construed to prohibit, limit or restrict a Voting Party (or any Affiliate, partner or employee of Voting Party) from exercising his or her fiduciary duties
as an officer or director to enGene, the Company or their respective Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Specific Enforcement</U>. The parties hereto
agree that (a)&nbsp;irreparable damage would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached, (b)&nbsp;each party shall be entitled to seek
specific performance of the terms hereof and immediate injunctive relief and other equitable relief to prevent breaches, or threatened breaches, of this Agreement, without the necessity of proving the inadequacy of money damages as a remedy and
without bond or other security being required, this being in addition to any other remedy to which they are entitled at law or in equity, (c)&nbsp;it may be difficult to prove damages with reasonable certainty, that it may be difficult to procure
suitable substitute performance, and that injunctive relief and/or specific performance will not cause an undue hardship to the parties, (d)&nbsp;the existence of any other remedy contemplated by this Agreement does not diminish the availability of
specific performance of the obligations hereunder or any other injunctive relief, and (e)&nbsp;in the event of any action by any other party for specific performance or injunctive relief, the first party will not assert that a remedy at law or other
remedy would be adequate or that specific performance or injunctive relief in respect of such breach or violation should not be available on the grounds that money damages are adequate or any other grounds. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-1-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>Entire Agreemen</U>t. This Agreement and the Business Combination Agreement (and the
agreements delivered concurrently herewith pursuant to the Business Combination Agreement) together constitute the entire agreement and understanding of the parties hereto in respect of the subject matter hereof and supersedes all prior
understandings, agreements or representations, both written and oral, by or among the parties hereto with respect to the subject matter hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <U>Notices</U>. All notices and other communications hereunder shall be in writing and shall be deemed given: (a)&nbsp;on the date
established by the sender as having been delivered personally; (b)&nbsp;one (1) Business Day after being sent by a nationally recognized overnight courier guaranteeing overnight delivery; (c)&nbsp;on the date delivered, if delivered by email of a
pdf document; or (d)&nbsp;on the fifth (5th) Business Day after the date mailed, by certified or registered mail, return receipt requested, postage prepaid. Such communications, to be valid, must be addressed as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">if to the Voting Parties, to such person&#146;s address </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">of record a set forth on Annex A hereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">with a copy to (which shall not constitute notice): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Morgan, Lewis&nbsp;&amp; Bockius LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">101 Park Ave. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">New York, NY
10178-0060 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">United States </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attn: Howard A. Kenny </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email:
howard.kenny@morganlewis.com </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">and with a copy (which shall not constitute notice) to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Blake, Cassels&nbsp;&amp; Graydon LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">595 Burrard Street, Suite </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">2600, Three Bentall Centre, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Vancouver, British Columbia V7X 1L3 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Canada </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attn: Joseph Garcia
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email: joseph.garcia@blakes.com </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">if to FEAC to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Forbion European
Acquisition Corp. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Gooimeer <FONT STYLE="white-space:nowrap">2-35</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">1411 DC Naarden </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">The
Netherlands </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Cyril Lesser </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> Cyril.Lesser@forbion.com </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">with a copy to (which shall not constitute notice): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Davis Polk&nbsp;&amp; Wardwell London LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">5 Aldermanbury Square </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">London
EC2V 7HR </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">United Kingdom </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Leo Borchardt </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email: <U>leo.borchardt@davispolk.com</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">and with a copy (which shall not constitute notice) to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Stikeman Elliot LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">5300
Commerce Court West </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-1-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">199 Bay Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Toronto Ontario M5L 1B9 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Canada
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Daniel Borlack </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email: dborlack@stikeman.com </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <U>Miscellaneous</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)
<U>Section 8.3</U> (Amendment), <U>Section</U><U></U><U>&nbsp;8.5</U> (Governing Law), <U>Section</U><U></U><U>&nbsp;8.13</U> (Extension; Waiver), <U>Section</U><U></U><U>&nbsp;8.14</U> (Waiver of Jury Trial), <U>Section</U><U></U><U>&nbsp;8.15</U>
(Submission to Jurisdiction) and <U>Section</U><U></U><U>&nbsp;8.17</U> (Trust Account Waiver) of the Business Combination Agreement are incorporated herein by reference, <I>mutatis mutandis</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) In the event that any term, provision, covenant or restriction of this Agreement, or the application thereof, is held to be illegal,
invalid or unenforceable under any present or future Law: (i)&nbsp;such provision will be fully severable; (ii)&nbsp;this Agreement will be construed and enforced as if such illegal, invalid or unenforceable provision had never comprised a part
hereof; (iii)&nbsp;the remaining provisions of this Agreement will remain in full force and effect and will not be affected by the illegal, invalid or unenforceable provision or by its severance herefrom; and (iv)&nbsp;in lieu of such illegal,
invalid or unenforceable provision, there will be added automatically as a part of this Agreement a legal, valid and enforceable provision as similar in terms of such illegal, invalid or unenforceable provision as may be possible. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Each Voting Party acknowledges that it has been advised to seek independent legal advice with respect to this Agreement and that it has
either obtained such advice or consciously determined that it does not need such advice and that, in either case, it is entering into this Agreement of its own free will, under no compulsion or duress and that it understands and is aware of the
terms and conditions hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) This Agreement may be executed in multiple counterparts, all of which shall be considered one and the
same document and shall become effective when multiple counterparts have been signed by each of the parties and delivered to the other parties, it being understood that all parties hereto need not sign the same counterpart. Delivery by electronic
transmission to counsel for the other parties of a counterpart executed by a party shall be deemed to meet the requirements of the previous sentence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The titles and captions in this Agreement are for reference purposes only, and shall not affect in any way the meaning or interpretation
of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Other than Transfers permitted by a Voting Party pursuant to <U>Section</U><U></U><U>&nbsp;5</U>, and then only on
the terms therein, no party hereto may assign, directly or indirectly, including by operation of law, either this Agreement or any of its rights, interests, or obligations hereunder without the prior written approval of the other parties. Subject to
the foregoing sentence, this Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors and permitted assigns, and nothing herein, express or implied, is intended to or shall confer upon any
other Person any legal or equitable right, benefit or remedy of any nature whatsoever under or by reason of this Agreement. Any purported assignment or delegation made in violation of this provision shall be void and of no force or effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Remainder of page intentionally left blank</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-1-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, each of the undersigned has caused its duly authorized representative to
execute and deliver this Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>COMPANY:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ENGENE HOLDINGS INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>FEAC:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>FORBION EUROPEAN ACQUISITION CORP.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I></I>[<I>Signature Page to enGene Voting Agreement</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-1-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, each of the undersigned has caused its duly authorized representative to
execute and deliver this Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>VOTING PARTIES:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>[NAME]</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I></I>[<I> Voting Parties Signature Page to Company Voting Agreement</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-1-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Annex&nbsp;A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Voting Interests </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Annexed</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-1-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit <FONT STYLE="white-space:nowrap">E-2</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form of Company <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement </B></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-2-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Final Form </I></B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">LOCK-UP</FONT> AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement (the &#147;<U>Agreement</U>&#148;) is made as May 16, 2023, by and among enGene
Inc., a company incorporated under the laws of Canada (&#147;<U>enGene</U>&#148;), enGene Holdings Inc., a company incorporated under the laws of Canada that intends to continue to a company governed by the <I>Business Corporations Act</I> (British
Columbia) (the &#147;<U>Company</U>&#148;), each of the parties listed on <U>Schedule I</U> hereto (each, an &#147;<U>enGene Equity Holder</U>&#148; and collectively, the &#147;<U>enGene Equity Holders</U>&#148;), and Forbion European Acquisition
Corp., a Cayman Islands exempted company (&#147;<U>FEAC</U>&#148;). Capitalized terms used but not defined herein have the respective meanings given to such terms in the Business Combination Agreement (as defined below).<SUP
STYLE="font-size:75%; vertical-align:top"> </SUP> </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, enGene, the Company, FEAC and certain other persons party thereto have entered into a Business Combination Agreement (as the
same may be amended or modified from time to time, the &#147;<U>Business Combination Agreement</U>&#148;), pursuant to which, on the terms and subject to the conditions set forth therein, among other things, FEAC, enGene, the Company and the other
parties thereto agreed, among other things, to combine their respective businesses and consummate the Transactions; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>,
pursuant to the Business Combination Agreement, the enGene Equity Holders are entering into this Agreement substantially concurrently with the consummation of the Transactions to provide for the imposition on the Closing Date at the effective time
of the Amalgamation pursuant to the Plan of Arrangement (the &#147;<U>Closing</U>&#148;) of certain transfer restrictions with respect to the Restricted Securities (as defined below). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW,
THEREFORE,</B> in consideration of the foregoing and the mutual agreements contained herein, and intending to be legally bound hereby, the parties hereto hereby agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1. <U>Definitions</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) &#147;<U>Excluded Securities</U>&#148; means, with respect to any enGene Equity Holder, (i)&nbsp;any Newco Shares issued to such enGene
Equity Holder in connection with the Closing of the Transactions in respect of such enGene Equity Holder&#146;s participation in the Convertible Bridge Financing or the PIPE Financing, and (ii)&nbsp;any Newco Warrants issued to such enGene Equity
Holder in connection with the Closing of the Transactions in respect of such enGene Equity Holder&#146;s participation in the Convertible Bridge Financing or the PIPE Financing, together with the Newco Shares issuable to such enGene Equity Holder
upon exercise of any such Newco Warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) &#147;<U>Restricted Securities</U>&#148; means, with respect to any enGene Equity Holder,
any Newco Shares (other than Excluded Securities) issued to such enGene Equity Holder in connection with the Closing of the Transactions in exchange for or in consideration of such enGene Equity Holder&#146;s ownership interests in enGene (the
&#147;<U>enGene Original Interests</U>&#148;), and (ii)&nbsp;any Newco Shares issued or issuable upon exercise of any derivative securities (including options) for the purchase of Newco Shares issued to such enGene Equity Holder in connection with
the Closing of the Transactions in exchange for or in consideration of such enGene Equity Holder&#146;s ownership of derivative securities (including options) in enGene. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) &#147;<U>Transfer</U>&#148; means mean the (i)&nbsp;sale of, offer to sell, contract or agreement to sell, hypothecate, pledge, grant of
any option to purchase or otherwise dispose of or agreement to dispose of, directly or indirectly, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-2-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or establishment or increase of a put equivalent position or liquidation with respect to or decrease of a call equivalent position within the meaning of Section&nbsp;16 of the Exchange Act, and
the rules and regulations of the SEC promulgated thereunder with respect to, any security, (ii)&nbsp;entry into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any
security, whether any such transaction is to be settled by delivery of such securities, in cash or otherwise, or (iii)&nbsp;public announcement of any intention to effect any transaction specified in clause (i)&nbsp;or (ii). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2. <U>Transfer Restrictions</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Effective as of and conditioned upon the occurrence of the Closing, each of the enGene Equity Holders agrees that it, he or she shall not,
until the earlier of (x) 12:01 am, U.S. eastern time, on the <FONT STYLE="white-space:nowrap">six-month</FONT> anniversary of the date of the Closing and (y)&nbsp;the date (after the date of the Closing) on which the Company completes a liquidation,
merger, share exchange or other similar transaction that results in all of the Company&#146;s shareholders having the right to exchange their Newco Shares for cash, securities or other property, Transfer any Restricted Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Notwithstanding anything herein to the contrary, from and after the Closing, Transfers of the Restricted Securities held by any enGene
Equity Holder or any of their permitted transferees (that have complied with this <U>Section</U><U></U><U>&nbsp;2(b)</U>), are permitted (i)&nbsp;to the officers or directors of enGene or the Company, any affiliate or family member of any of the
officers or directors of enGene or the Company, any affiliate of such enGene Equity Holder, enGene or the Company or to any direct or indirect equityholders of such enGene Equity Holder, enGene or the Company or any affiliates of such equityholders,
or any employees of such affiliates; (ii)&nbsp;in the case of an individual, by gift to a member of such individual&#146;s immediate family or to a trust, the beneficiary of which is such individual, a member of such individual&#146;s immediate
family, an affiliate of such individual or to a charitable organization; (iii)&nbsp;in the case of an individual, by virtue of laws of descent and distribution upon death of such individual; (iv)&nbsp;in the case of an individual, pursuant to a
qualified domestic relations order; (v)&nbsp;to the Company in connection with the &#147;net&#148; or &#147;cashless&#148; exercise of options or other rights to purchase shares of Company Common Stock held by such enGene Equity Holder in
satisfaction of any tax withholding or exercise price obligations through cashless surrender or otherwise, provided that any shares of Company Common Stock issued upon exercise of such option or other rights shall remain subject to the terms of this
Letter Agreement; <U>provided</U>, <U>however</U>, that these permitted transferees must enter into a written agreement with the Company agreeing to be bound by the transfer restrictions herein in substantially the form of
<U>Exhibit</U><U></U><U>&nbsp;A</U> attached hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) This <U>Section</U><U></U><U>&nbsp;2</U> shall continue to apply to Restricted
Securities following their transfer to a permitted transferee under <U>Section</U><U></U><U>&nbsp;2(b)</U> above. Each holder of Restricted Securities shall be entitled to vote its Restricted Securities and receive dividends and other distributions
with respect to such Restricted Securities (to the extent such concepts are applicable) during any period of time that such shares are subject to restrictions on transfer hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Any Transfer of Restricted Securities made or attempted in violation of or contrary to the terms of this Agreement shall be null and void
<I>ab initio</I>, and the Company shall refuse to recognize any such purported transferee of the Restricted Securities as one of the Company&#146;s equity holders for any purpose. The Company may impose stop-transfer instructions with respect to the
Restricted Securities during the period of the restrictions on transfer applicable thereto under this <U>Section</U><U></U><U>&nbsp;2</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Each certificate (if any) evidencing any Restricted Securities shall be stamped or otherwise imprinted with a legend in substantially the
following form, in addition to any other applicable legends: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO
RESTRICTIONS ON TRANSFER SET FORTH IN A <FONT STYLE="white-space:nowrap">LOCK-UP</FONT> AGREEMENT, DATED AS OF MAY [16], 2023, BY AND AMONG THE ISSUER OF SUCH SECURITIES (THE &#147;ISSUER&#148;), THE ISSUER&#146;S SECURITY HOLDER NAMED THEREIN AND
CERTAIN OTHER PARTIES NAMED THEREIN. A COPY OF </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-2-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
SUCH SPONSOR WAIVER AND SHARE RESTRICTION AGREEMENT WILL BE FURNISHED WITHOUT CHARGE BY THE ISSUER TO THE HOLDER HEREOF UPON WRITTEN REQUEST.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3. <U>Representations and Warranties of each </U><U>enGene</U><U> Equity Holder</U>. Each enGene Equity Holder (each on its own
behalf and not on behalf of any other enGene Equity Holder) represents and warrants as of the date hereof to FEAC, the Company and enGene as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Organization; Due Authorization</U>. Each enGene Equity Holder is duly organized, validly existing and in good standing under the laws
of the jurisdiction in which it is incorporated, formed, organized or constituted, and the execution, delivery and performance of this Agreement and the consummation of the transactions contemplated hereby are within the such corporate, limited
liability company or organizational powers and have been duly authorized by all necessary corporate, limited liability company or organizational actions on the part of such enGene Equity Holder. This Agreement has been duly executed and delivered by
each enGene Equity Holder and, assuming due authorization, execution and delivery by the other parties to this Agreement, this Agreement constitutes a legally valid and binding obligation of such enGene Equity Holder, enforceable against such enGene
Equity Holder in accordance with the terms hereof (except as enforceability may be limited by bankruptcy laws, other similar laws affecting creditors&#146; rights and general principles of equity affecting the availability of specific performance
and other equitable remedies). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Ownership</U>. Each enGene Equity Holder is the record and beneficial owner (within the meaning of
Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act) of, and has good title to, the respective enGene Original Interests, and there exist no Liens or any other limitation or restriction (including any restriction on the right
to vote, sell or otherwise dispose, other than transfer restrictions under the Securities Act or other applicable securities laws) affecting any enGene Original Interests other than pursuant to this Agreement, the Business Combination Agreement and
the Ancillary Documents. Other than the enGene Original Interests, the Restricted Securities and the Excluded Securities, each enGene Equity Holder does not hold or own any rights to acquire (directly or indirectly) any equity securities of enGene
or outstanding options, warrants, rights, convertible or exchangeable securities, &#147;phantom&#148; stock rights, stock appreciation rights, stock-based performance units or commitments for shares of enGene. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>No Conflicts</U>. The execution and delivery of this Agreement by each enGene Equity Holder does not, and the performance by such
enGene Equity Holder of its obligations hereunder will not, (i)&nbsp;conflict with or result in a violation of the organizational documents of such enGene Equity Holder or (ii)&nbsp;require any consent or approval that has not been given or other
action that has not been taken by any Person (including under any contract binding upon such enGene Equity Holder or its enGene Original Interests), in each case to the extent such consent, approval or other action would prevent, enjoin or
materially delay the performance by such enGene Equity Holder of its obligations under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Litigation</U>. There are
no Proceedings pending against each enGene Equity Holder, or to the knowledge of such enGene Equity Holder, threatened against such enGene Equity Holders, before (or, in the case of threatened Proceedings, that would be before) any Governmental
Entity, which in any manner challenges or seeks to prevent, enjoin or materially delay the performance by such enGene Equity Holder of its obligations under this Agreement. Each enGene Equity Holder has never been suspended or expelled from
membership in any securities or commodities exchange or association or had a securities or commodities license or registration denied, suspended or revoked. Each enGene Equity Holder (i)&nbsp;is not subject to or a respondent in any legal action
for, any injunction, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">cease-and-desist</FONT></FONT> order or order or stipulation to desist or refrain from any act or practice relating to the offering of securities in any
jurisdiction, (ii)&nbsp;has never been convicted of, or pleaded guilty to, any crime involving fraud, relating to any financial transaction or handling of funds of another person, or pertaining to any dealings in any securities and (iii)&nbsp;is not
currently a defendant in any such criminal proceeding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Acknowledgment</U>. Each enGene Equity Holder understands and acknowledges
that each of the Company, enGene and FEAC is entering into the Business Combination Agreement in reliance upon such enGene Equity Holders&#146;s execution and delivery of this Agreement. Each enGene Equity Holders has had the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-2-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
opportunity to read the Business Combination Agreement and this Agreement and acknowledges that it has been advised to seek independent legal advice with respect to this Agreement and that it has
either obtained such advice or consciously determined that it does not need such advice and that, in either case, it is entering into this Agreement of its own free will, under no compulsion or duress and that it understands and is aware of the
terms and conditions hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4. <U>Termination</U>. This Agreement shall be binding upon each enGene Equity Holder upon such
enGene Equity Holder&#146;s execution and delivery of this Agreement, but this Agreement shall only become effective upon the Closing. Notwithstanding anything to the contrary contained herein, in the event that the Business Combination Agreement is
terminated in accordance with its terms prior to the Closing, this Agreement and all rights and obligations of the parties hereunder shall automatically terminate and be of no further force or effect. If the Closing takes place, the provisions of
this Agreement, other than this <U>Section</U><U></U><U>&nbsp;4</U> and <U>Section</U><U></U><U>&nbsp;5</U>, shall terminate and be of no further force or effect upon the first to occur of (i)&nbsp;the six (6)&nbsp;month anniversary of the Closing
Date and (ii)&nbsp;the date that all of the Restricted Securities are no longer subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> restrictions set forth in <U>Section</U><U></U><U>&nbsp;2(a)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5. <U>Miscellaneous</U>. Article 8 of the Business Combination Agreement is incorporated herein by reference, <I>mutatis
mutandis</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[ <I>remainder of page intentionally left blank; signature page follows </I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-2-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, each of the undersigned has caused its duly authorized
representative to execute and deliver this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B>COMPANY:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">ENGENE HOLDINGS INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Company Signature Page to <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-2-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, each of the undersigned has caused its duly authorized
representative to execute and deliver this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B>FEAC:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">FORBION EUROPEAN ACQUISITION CORP.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Company Signature Page to <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-2-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, each of the undersigned has caused its duly authorized
representative to execute and deliver this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">[NAME]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">[NAME], individually</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>enGene Equity Holders&#146; Signature Page to <FONT STYLE="white-space:nowrap">Lock-Up</FONT>
Agreement</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-2-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form of Joinder to <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">[DATE], 20__ </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reference is made
to that certain <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement, dated as of May 16, 2023, by and among enGene Holdings Inc., a company incorporated under the laws of Canada (the &#147;<U>Company</U>&#148;), and the enGene Equity Holders
named therein (as amended from time to time, the &#147;<U><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement</U>&#148;). Capitalized terms used but not otherwise defined herein have the meanings given to such terms in the <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned transferee of [<I>describe securities transferred</I>] (a
&#147;<U>New Holder</U>&#148;) agrees that this joinder to the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement (this &#147;<U>Joinder</U>&#148;) is being executed and delivered for good and valuable consideration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned New Holder hereby agrees to and does become party to the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement as an
&#147;enGene Equity Holder&#148; thereunder. This Joinder shall serve as a counterparty signature page to the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement and by executing below, the undersigned New Holder is deemed to have executed the
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement with the same force and effect as if originally named a party thereto effective from and after the date hereof; <U>provided</U>, however, that the terms and conditions of the <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Agreement shall apply only with respect to the Restricted Shares transferred to New Holder from the transferor that was a party to the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Joinder may be executed in multiple counterparts, including by means of facsimile or electronic signature, each of which shall be deemed
an original, but all of which together shall constitute the same instrument. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[ <I>remainder of page intentionally left blank; signature
page follows</I> ] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-2-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, each of the undersigned has caused its duly authorized
representative to execute and deliver this Joinder as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>[NEW HOLDER]</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><U>Notice Address</U>:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">ENGENE HOLDINGS INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-2-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SCHEDULE I </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>enGene Equity Holders </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Attached</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-2-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit <FONT STYLE="white-space:nowrap">E-3</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form of FEAC Voting Agreement </B></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-3-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Execution Version </I></B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FEAC VOTING AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This FEAC Voting Agreement (this &#147;<U>Agreement</U>&#148;) is made as of May 16, 2023, by and among Forbion European Acquisition Corp., a
Cayman Islands exempted company (&#147;<U>FEAC</U>&#148;), Forbion Growth Sponsor FEAC I B.V., a Dutch private limited liability company (&#147;<U>Sponsor</U>&#148;), Forbion Growth Opportunities Fund I Cooperatief U.A., a cooperative association
(<I>co</I><I>&ouml;</I><I>peratie</I>) with exempted liability incorporated in the Netherlands (&#147;<U>FGOF</U>&#148;), each of the directors and officers of FEAC (together with Sponsor and FGOF, the &#147;<U>Voting Parties</U>&#148; and each a
&#147;<U>Voting Party</U>&#148;), enGene Inc., a corporation incorporated under the laws of Canada (&#147;<U>enGene</U>&#148;) and enGene Holdings Inc., a company incorporated under the laws of Canada that intends to continue to a company governed
by the <I>Business Corporations Act</I> (British Columbia) (the &#147;<U>Company</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS,</B> concurrently with the
execution and delivery of this Agreement, FEAC, enGene, the Company and certain other persons party thereto are entering into a Business Combination Agreement (as the same may be amended or modified from time to time, the &#147;<U>Business
Combination Agreement</U>&#148;), pursuant to which, on the terms and subject to the conditions set forth therein, among other things, FEAC, enGene, the Company and the other parties thereto agreed to effect the Transactions set forth therein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE,</B> in consideration of the premises and for other good and valuable consideration, the receipt, sufficiency and adequacy
of which are hereby acknowledged, the parties hereto agree as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Definitions</U>. As used herein, the term &#147;<U>Voting
Shares</U>&#148; shall mean, taken together, all securities of FEAC beneficially owned (as such term is defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act, excluding shares of stock underlying unexercised options or
warrants, but including any shares of stock acquired upon exercise of such options or warrants) (&#147;<U>Beneficially Owned</U>&#148; or &#147;<U>Beneficial Ownership</U>&#148;) by any Voting Party, including any and all securities of FEAC acquired
and held in such capacity subsequent to the date hereof. Capitalized terms used and not defined herein have the respective meanings assigned to them in the Business Combination Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Representations and Warranties of the Voting Parties</U>. Each Voting Party on its own behalf hereby represents and warrants to each of
enGene and the Company, severally and not jointly, with respect to such Voting Party and such Voting Party&#146;s Beneficial Ownership of its Voting Shares set forth on <U>Annex</U><U></U><U>&nbsp;A</U> as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <I>Authority</I>. Voting Party has all requisite power and authority to enter into this Agreement, to perform fully Voting Party&#146;s
obligations hereunder and to consummate the transactions contemplated hereby. This Agreement has been duly authorized, executed and delivered by Voting Party. This Agreement constitutes a valid and binding obligation of Voting Party enforceable in
accordance with its terms, except as enforcement may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors&#146; rights generally and by principles governing the availability of equitable
remedies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <I>No Consent</I>. No consent, approval or authorization of, or designation, declaration or filing with, any Governmental
Entity or other Person on the part of Voting Party is required in connection with the execution, delivery and performance of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <I>No Conflicts</I>. Neither the execution and delivery of this Agreement, nor the consummation of the transactions contemplated hereby,
nor compliance with the terms hereof, will violate, conflict with or result in a breach of, or constitute a default (with or without notice or lapse of time or both) under any provision of, Voting Party&#146;s Governing Documents, any trust
agreement, loan or credit agreement, note, bond, mortgage, indenture, lease or other agreement, instrument, permit, concession, franchise, license, judgment, order, notice, decree, statute, law, ordinance, rule or regulation applicable to Voting
Party or to Voting Party&#146;s property or assets (including the Voting Shares) that would reasonably be expected to prevent or delay the consummation of the Transactions or that would reasonably be expected to prevent Voting Party from fulfilling
its obligations under this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-3-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <I>Ownership of Shares</I>. Except pursuant to the arrangements referred to in the
following sentence, each Voting Party (i)&nbsp;Beneficially Owns its Voting Shares free and clear of all Liens (other than transfer restrictions under applicable securities laws) and (ii)&nbsp;has the sole power to vote or cause to be voted its
Voting Shares. Except pursuant hereto and pursuant to (A)&nbsp;that certain Letter Agreement, dated as of December&nbsp;9, 2021 (the &#147;<U>Insider Letter</U>&#148;), by and among FEAC and the Voting Parties other than FGOF, (B)&nbsp;that certain
Warrant Agreement, dated as of December&nbsp;9, 2021, by and between FEAC and Continental Stock Transfer&nbsp;&amp; Trust Company, (C)&nbsp;that certain Registration Rights Agreement dated as of December&nbsp;9, 2021, by and between FEAC and Sponsor
(the &#147;<U>Registration Rights Agreement</U>&#148;), and (D)&nbsp;the Sponsor and Insider Letter, dated as of even date herewith, by and between FEAC, the Company and the Voting Parties (the &#147;<U>Sponsor and Insider Letter</U>&#148;), there
are no options, warrants or other rights, agreements, arrangements or commitments of any character to which Voting Party is a party relating to the pledge, acquisition, disposition, transfer or voting of Voting Shares prior to the consummation of
the Transactions and there are no voting trusts or voting agreements with respect to the Voting Shares. As of the date hereof, Voting Party does not Beneficially Own or otherwise have any direct or indirect interest in (i)&nbsp;any Voting Shares,
other than the Voting Shares set forth on <U>Annex</U><U></U><U>&nbsp;A</U> or (ii)&nbsp;any options, warrants or other rights to acquire any additional ordinary shares, or vote any ordinary shares, or any other equity interests, of FEAC
(&#147;<U>FEAC Shares</U>&#148;) or any security exercisable or exchangeable for or convertible into FEAC Shares, other than as set forth on <U>Annex</U><U></U><U>&nbsp;A</U> and except for any Voting Shares underlying any FEAC Private Placement
Warrants to be issued by FEAC to a Voting Party as payee under the Working Capital Loan Note and/or any Extension Loan Note following the election by such Voting Party to convert all or part of the outstanding principal amount of the Working Capital
Loan Note or any Extension Loan Note in FEAC Private Placement Warrants in connection with the consummation of the Transactions, in each case in accordance with FEAC&#146;s Governing Documents and the Trust Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <I>No Litigation</I>. There is no Proceeding pending against, or, to the knowledge of Voting Party, threatened against, Voting Party that
would reasonably be expected to impair or adversely affect the ability of Voting Party to perform Voting Party&#146;s obligations hereunder or to consummate the transactions contemplated by this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <I>Business Combination Agreement</I>. Each Voting Party understands and acknowledges that FEAC, enGene and the Company are entering into
the Business Combination Agreement in reliance upon such Voting Party&#146;s execution and delivery of this Agreement. Such Voting Party has received a copy of the Business Combination Agreement and is familiar with the provisions of the Business
Combination Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Agreement to Vote Shares;</U><U> </U><U>Further Assurances</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Prior to the earlier of (x)&nbsp;date on which this Agreement is terminated in accordance with its terms and (y)&nbsp;the Closing Date
(the &#147;<B>Voting Period</B>&#148;), each Voting Party irrevocably agrees that it shall, at any meeting (or in connection with any request for action by written consent) of the shareholders of FEAC at which the matters described in clauses
(i)&nbsp;and (ii) below are considered and at every adjournment or postponement thereof, (x)&nbsp;cause the Voting Shares that such Voting Party Beneficially Owns to be counted as present thereat for the purpose of establishing a quorum,
(y)&nbsp;vote or cause to be voted the Voting Shares that such Voting Party Beneficially Owns and (z)&nbsp;execute a written consent or consents if shareholders of FEAC are requested to vote their shares through the execution of an action by written
consent, in each case to the extent such Voting Shares are entitled to vote thereon pursuant to FEAC&#146;s Governing Documents: (i)&nbsp;in favor of (A)&nbsp;the Transaction Proposals and (B)&nbsp;any other matter reasonably necessary to the
consummation of the Transactions and the other matters contemplated by the Business Combination Agreement and considered and voted upon by the shareholders of FEAC; and (ii)&nbsp;against (other than as contemplated by the Transactions)&nbsp;(A) any
proposal or offer from any Person (other than enGene or any of its Affiliates) concerning (1)&nbsp;a merger, consolidation, liquidation, recapitalization, share exchange or other business combination transaction involving FEAC, (2)&nbsp;the issuance
or acquisition of shares or other equity securities of FEAC, or (3)&nbsp;the sale, lease, exchange or other disposition of any significant portion of FEAC&#146;s properties or assets; (B)&nbsp;any action, proposal, transaction or agreement that
could reasonably be expected to result in a breach of any covenant or obligation of FEAC set forth in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-3-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Business Combination Agreement, or in any representation or warranty of FEAC set forth in the Business Combination Agreement becoming inaccurate; and (C)&nbsp;any action, proposal, transaction or
agreement that could reasonably be expected to impede, interfere with, delay, discourage, adversely affect or inhibit the timely consummation of the Transactions or the fulfillment of FEAC&#146;s conditions under the Business Combination Agreement
or change in any manner the voting rights of any class of shares of FEAC (including any amendments to the Governing Documents), except as contemplated by this Agreement, the Business Combination Agreement or the Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) During the term of this Agreement, each Voting Party irrevocably and unconditionally consents to the details of this Agreement being set
out in the materials to be submitted to FEAC&#146;s shareholders or otherwise to be prepared in connection with the FEAC Shareholders Meeting and for the form of this Agreement to be filed with the SEC and any other Governmental Entity, in
connection with the Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>No Voting Trusts or Other Arrangement</U>. During the Voting Period, each Voting Party will not,
and will not permit any entity under Voting Party&#146;s control to, deposit any Voting Shares in a voting trust, grant any proxies with respect to the Voting Shares or subject any of the Voting Shares to any arrangement with respect to the voting
of the Voting Shares except as contemplated in this Agreement or the Business Combination Agreement. Each Voting Party hereby revokes any and all previous proxies and attorneys in fact with respect to the Voting Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Certain Covenants of Voting Party; Transfer and Encumbrance</U>. During the Voting Period, each Voting Party will not, in each case
other than as contemplated by the Transactions, (a)&nbsp;directly or indirectly, transfer (including by operation of law), sell, offer, exchange, assign, hedge, swap, convert, pledge or otherwise dispose of or encumber (&#147;<U>Transfer</U>&#148;)
any of such Voting Party&#146;s Voting Shares or enter into any contract, option or other agreement with respect to, or consent to, a Transfer of, any of such Voting Party&#146;s Voting Shares or Voting Party&#146;s voting or economic interest
therein, (b)&nbsp;publicly announce any intention to effect any transaction specified in clause (a), (c)&nbsp;knowingly take any action that would make any representation or warranty of such Voting Party contained herein untrue or inaccurate, or
have the effect of preventing or disabling such Voting Party from performing its obligations under this Agreement or (d)&nbsp;take any action, nor permit its Representatives to take any action, to contest, oppose or interfere with the Cayman Merger
or to otherwise contest or oppose any of the Transactions before any Governmental Entity, or to solicit proxies or become a participant in a solicitation in opposition to or competition with the FEAC Shareholder Approval or any of the Transactions.
Any attempted Transfer of Voting Shares or any interest therein in violation of this <U>Section</U><U></U><U>&nbsp;5</U> shall be null and void. Notwithstanding the foregoing, this <U>Section</U><U></U><U>&nbsp;5</U> shall not prohibit a Transfer of
Voting Shares by any Voting Party in compliance with Section&nbsp;2(a) of the Sponsor and Insider Letter; <U>provided</U>, <U>however</U>, that in each case, the applicable transferees enter into a written joinder to this Agreement in form and
substance reasonably acceptable to the Company and FEAC by which such applicable transferees agree to be bound by this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.
<U>Termination of Certain Agreements</U>. Prior to the Closing Date, the Voting Parties shall take such actions as may be necessary or appropriate to terminate the Registration Rights Agreement, effective as of and contingent upon the Transactions
and the occurrence of the Closing Date, without any liability being imposed on FEAC, the Company or enGene following such termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.
<U>Appraisal and Dissenters&#146; Rights</U>. Each Voting Party hereby (a)&nbsp;waives, to the fullest extent permitted by Law, and agrees not to assert or perfect, any rights of appraisal or rights to dissent (as applicable, or any similar rights)
from the Transactions that Voting Party may have by virtue of ownership of the Voting Shares, including any dissenters&#146; rights under Section&nbsp;238 of the Cayman Act, and (b)&nbsp;agrees not to commence or participate in any claim, derivative
or otherwise, against FEAC, the Company or enGene or the members of their respective Boards of Directors relating to the negotiation, execution or delivery of this Agreement or the Business Combination Agreement or the consummation of the
Transactions, including any claim (i)&nbsp;challenging the validity of, or seeking to enjoin the operation of, any provision of this Agreement or (ii)&nbsp;alleging a breach of any fiduciary duty of the Board of Directors of FEAC, the Company or
enGene in connection with this Agreement, the Business Combination Agreement or the Transactions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-3-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Redemption Rights</U>. During the Voting Period, if FEAC seeks shareholder approval
for the Transactions, each Voting Party shall not (a)&nbsp;exercise any right to redeem any Voting Shares Beneficially Owned as of the date hereof or acquired and held in such capacity subsequent to the date hereof or (b)&nbsp;make any public
statements with the intent to encourage any of FEAC&#146;s shareholders to exercise any right to redeem any FEAC Class&nbsp;A Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.
<U>Insider Letter</U>. Each party hereto that is a party to the Insider Letter hereby agrees that from the date hereof until the termination of this Agreement, none of them shall, or shall agree to, amend, modify or vary paragraphs 9(c) or 11 of the
Insider Letter, except as otherwise expressly provided for by this Agreement and the other agreements entered into concurrently herewith in connection with the Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Additional Matters</U>. Each Voting Party shall, from time to time, (i)&nbsp;execute and deliver, or cause to be executed and
delivered, such additional or further consents, documents and other instruments as FEAC, enGene or the Company may reasonably request for the purpose of effectively carrying out the transactions contemplated by this Agreement and the Business
Combination Agreement and (ii)&nbsp;refrain from exercising any veto right, consent right or similar right (whether under the Governing Documents of FEAC or the Cayman Act) which would impede, disrupt, prevent or otherwise adversely affect the
consummation of the Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Termination</U>. This Agreement shall automatically terminate upon the earliest to occur of
(a)&nbsp;the Closing Date and (b)&nbsp;the date on which the Business Combination Agreement is terminated for any reason in accordance with its terms. Upon termination of this Agreement, no party shall have any further rights, obligations or
liabilities under this Agreement; <U>provided</U>, that nothing in this <U>Section</U><U></U><U>&nbsp;11</U> shall relieve any party of liability for any breach of this Agreement occurring prior to termination and the provisions of <U>Sections
13</U> through <U>16</U> shall survive any termination of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>No Agreement as Director or Officer</U>. Nothing in this
Agreement will limit or affect any actions or omissions taken by a Voting Party (or any Affiliate, securityholder, partner, director, officer or employee of Voting Party) in his, her or its capacity as a director or officer of FEAC. Nothing in this
Agreement will be construed to prohibit, limit or restrict a Voting Party (or any Affiliate, partner or employee of Voting Party) from exercising his or her fiduciary duties as an officer or director to FEAC or its Subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <U>Specific Enforcement</U>. The parties hereto agree that (a)&nbsp;irreparable damage would occur in the event that any of the provisions
of this Agreement were not performed in accordance with their specific terms or were otherwise breached, (b)&nbsp;each party shall be entitled to seek specific performance of the terms hereof and immediate injunctive relief and other equitable
relief to prevent breaches, or threatened breaches, of this Agreement, without the necessity of proving the inadequacy of money damages as a remedy and without bond or other security being required, this being in addition to any other remedy to
which they are entitled at law or in equity, (c)&nbsp;it may be difficult to prove damages with reasonable certainty, that it may be difficult to procure suitable substitute performance, and that injunctive relief and/or specific performance will
not cause an undue hardship to the parties, (d)&nbsp;the existence of any other remedy contemplated by this Agreement does not diminish the availability of specific performance of the obligations hereunder or any other injunctive relief, and
(e)&nbsp;in the event of any action by any other party for specific performance or injunctive relief, the first party will not assert that a remedy at law or other remedy would be adequate or that specific performance or injunctive relief in respect
of such breach or violation should not be available on the grounds that money damages are adequate or any other grounds. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <U>Entire
Agreemen</U>t. This Agreement and the Business Combination Agreement (and the agreements delivered concurrently herewith pursuant to the Business Combination Agreement) together constitute the entire agreement and understanding of the parties hereto
in respect of the subject matter hereof and supersedes all prior understandings, agreements or representations, both written and oral, by or among the parties hereto with respect to the subject matter hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <U>Notices</U>. All notices and other communications hereunder shall be in writing and shall be deemed given: (a)&nbsp;on the date
established by the sender as having been delivered personally; (b)&nbsp;one (1) Business Day after </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-3-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
being sent by a nationally recognized overnight courier guaranteeing overnight delivery; (c)&nbsp;on the date delivered, if delivered by email of a pdf document; or (d)&nbsp;on the fifth (5th)
Business Day after the date mailed, by certified or registered mail, return receipt requested, postage prepaid. Such communications, to be valid, must be addressed as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">if to the Voting Parties, to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Forbion European Acquisition Corp. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Gooimeer 2-35 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">1411 DC Naarden
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">The Netherlands </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Cyril Lesser </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">E-mail:</FONT> Cyril.Lesser@forbion.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">with a copy to (which shall not constitute notice): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Davis Polk&nbsp;&amp; Wardwell London LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">5 Aldermanbury Square </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">London
EC2V 7HR </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">United Kingdom </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Leo Borchardt </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email: <U>leo.borchardt@davispolk.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">and with a copy (which shall not constitute notice) to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Stikeman Elliot LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">5300
Commerce Court West </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">199 Bay Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Toronto Ontario M5L 1B9 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Canada
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Daniel Borlack </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email: dborlack@stikeman.com </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">if
to enGene or the Company to: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">enGene Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">7171 Rue Frederick Banting </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Saint-Laurent, QC H4S 1Z9 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Canada </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attn: Jason Hanson </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email: jhanson@engeneinc.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">with a copy (which shall not constitute notice) to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Morgan, Lewis&nbsp;&amp; Bockius LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">101 Park Ave. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">New York, NY
10178-0060 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">United States </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attn: Howard A. Kenny </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email:
howard.kenny@morganlewis.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">and with a copy (which shall not constitute notice) to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Blake, Cassels&nbsp;&amp; Graydon LLP </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-3-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">595 Burrard Street, Suite </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">2600, Three Bentall Centre, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Vancouver, British Columbia V7X 1L3 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Canada </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attn: Joseph Garcia
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email: joseph.garcia@blakes.com </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. <U>Miscellaneous</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)
<U>Section 8.3</U> (Amendment), <U>Section</U><U></U><U>&nbsp;8.5</U> (Governing Law), <U>Section</U><U></U><U>&nbsp;8.13</U> (Extension; Waiver), <U>Section</U><U></U><U>&nbsp;8.14</U> (Waiver of Jury Trial), <U>Section</U><U></U><U>&nbsp;8.15</U>
(Submission to Jurisdiction) and <U>Section</U><U></U><U>&nbsp;8.17</U> (Trust Account Waiver) of the Business Combination Agreement are incorporated herein by reference, <I>mutatis mutandis</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) In the event that any term, provision, covenant or restriction of this Agreement, or the application thereof, is held to be illegal,
invalid or unenforceable under any present or future Law: (i)&nbsp;such provision will be fully severable; (ii)&nbsp;this Agreement will be construed and enforced as if such illegal, invalid or unenforceable provision had never comprised a part
hereof; (iii)&nbsp;the remaining provisions of this Agreement will remain in full force and effect and will not be affected by the illegal, invalid or unenforceable provision or by its severance herefrom; and (iv)&nbsp;in lieu of such illegal,
invalid or unenforceable provision, there will be added automatically as a part of this Agreement a legal, valid and enforceable provision as similar in terms of such illegal, invalid or unenforceable provision as may be possible. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Each Voting Party acknowledges that it has been advised to seek independent legal advice with respect to this Agreement and that it has
either obtained such advice or consciously determined that it does not need such advice and that, in either case, it is entering into this Agreement of its own free will, under no compulsion or duress and that it understands and is aware of the
terms and conditions hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) This Agreement may be executed in multiple counterparts, all of which shall be considered one and the
same document and shall become effective when multiple counterparts have been signed by each of the parties and delivered to the other parties, it being understood that all parties hereto need not sign the same counterpart. Delivery by electronic
transmission to counsel for the other parties of a counterpart executed by a party shall be deemed to meet the requirements of the previous sentence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The titles and captions in this Agreement are for reference purposes only, and shall not affect in any way the meaning or interpretation
of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Other than Transfers permitted by a Voting Party pursuant to <U>Section</U><U></U><U>&nbsp;5</U>, and then only on
the terms therein, no party hereto may assign, directly or indirectly, including by operation of law, either this Agreement or any of its rights, interests, or obligations hereunder without the prior written approval of the other parties. Subject to
the foregoing sentence, this Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors and permitted assigns, and nothing herein, express or implied, is intended to or shall confer upon any
other Person any legal or equitable right, benefit or remedy of any nature whatsoever under or by reason of this Agreement. Any purported assignment or delegation made in violation of this provision shall be void and of no force or effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Remainder of page intentionally left blank</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-3-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, each of the undersigned has caused its duly authorized representative to
execute and deliver this Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>FEAC:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>FORBION EUROPEAN ACQUISITION CORP.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I></I>[<I> FEAC Signature Page to FEAC Voting Agreement</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-3-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, each of the undersigned has caused its duly authorized representative to
execute and deliver this Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>VOTING PARTIES:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FORBION GROWTH SPONSOR FEAC I B.V.,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>a Dutch private limited company</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>FORBION GROWTH OPPORTUNITIES FUND I COOPERATIEF U.A., a Dutch cooperative association (</B><B><I>co&ouml;peratie</I></B><B>) with exempted liability</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I></I>[<I> Voting Parties Signature Page to FEAC Voting Agreement</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-3-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, each of the undersigned has caused its duly authorized representative to
execute and deliver this Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">JASPER BOS</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CYRIL LESSER</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">SANDER SLOOTWEG</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">WOUTER JOUSTRA</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">PHILIP ASTLEY-SPARKE</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">HILDE STEINEGER</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">TON LOGTENBERG</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I></I>[<I> Voting Parties Signature Page to FEAC Voting Agreement</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-3-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, each of the undersigned has caused its duly authorized representative to
execute and deliver this Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>COMPANY:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ENGENE HOLDINGS INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ENGENE:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ENGENE INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>enGene Signature Page to FEAC Voting Agreement</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-3-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Annex&nbsp;A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Voting Interests </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Voting Interests</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Warrants</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Indirect&nbsp;Interests</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Class&nbsp;A<br>ordinary&nbsp;shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Class&nbsp;B<br>ordinary&nbsp;shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Class&nbsp;A&nbsp;ordinary&nbsp;shares<BR>subject to Warrants</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">in Class&nbsp;A<br>ordinary&nbsp;shares</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sponsor</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">-0-</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">3,162,500</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">5,195,000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">8,357,500</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FGOF</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">2,000,000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">-0-</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">-0-</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">10,357,500</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jasper Bos</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">-0-</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">-0-</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">-0-</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cyril Lesser</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">-0-</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">-0-</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">-0-</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sander Slootweg</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">-0-</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">-0-</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">-0-</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wouter Joustra</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">-0-</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">-0-</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">-0-</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Philip Astley-Sparke</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">-0-</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">-0-</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">-0-</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hilde Steineger</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">-0-</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">-0-</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">-0-</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ton Logtenberg</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">-0-</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">-0-</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">-0-</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-3-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit F </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form of Newco Articles </B></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I>Final Form </I></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>BUSINESS CORPORATIONS ACT </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLES </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>of </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE HOLDINGS INC. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD COLSPAN="3" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>ARTICLE 1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>INTERPRETATION</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Definitions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Business Corporations Act and Interpretation Act Definitions Applicable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>ARTICLE 2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>SHARES AND SHARE CERTIFICATES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Authorized Share Structure</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Form of Share Certificate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shareholder Entitled to Certificate or Acknowledgement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Delivery by Mail</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Replacement of Worn Out or Defaced Certificate or Acknowledgement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Replacement of Lost, Stolen or Destroyed Certificate or Acknowledgement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Splitting Share Certificates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Certificate Fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Recognition of Trusts</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>ARTICLE 3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>ISSUE OF SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Directors Authorized</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commissions and Discounts</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brokerage</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conditions of Issue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share Purchase Warrants and Rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>ARTICLE 4</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>SHARE REGISTERS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Central Securities Register</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Closing Register</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>ARTICLE 5</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>SHARE TRANSFERS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Registering Transfers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Form of Instrument of Transfer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transferor Remains Shareholder</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Signing of Instrument of Transfer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Enquiry as to Title Not Required</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer Fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><B>ARTICLE 6</B></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><B>TRANSMISSION OF SHARES</B></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal Personal Representative Recognized on Death</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rights of Legal Personal Representative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><B>ARTICLE 7</B></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><B>PURCHASE OF SHARES</B></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company Authorized to Purchase or Otherwise Acquire Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase When Insolvent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sale and Voting of Purchased, Redeemed, or Otherwise Acquired Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><B>ARTICLE 8</B></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><B>BORROWING POWERS</B></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Borrowing Powers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><B>ARTICLE 9</B></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><B>ALTERATIONS</B></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alteration of Authorized Share Structure by the Shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alteration of Authorized Share Structure by the Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Special Rights and Restrictions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No Interference with Class&nbsp;or Series Rights without Consent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change of Name</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other Alterations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><B>ARTICLE 10</B></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><B>MEETINGS OF SHAREHOLDERS</B></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Annual General Meetings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Resolution Instead of Annual General Meeting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Calling of Meetings of Shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notice for Meetings of Shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Record Date for Notice</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Record Date for Voting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Failure to Give Notice and Waiver of Notice</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notice of Special Business at Meetings of Shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;Meetings and Series Meetings of Shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Meetings by Telephone or Other Communications Medium</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Advance Notice of Nominations of Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><B>ARTICLE 11</B></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><B>PROCEEDINGS AT MEETINGS OF SHAREHOLDERS</B></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Special Business</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Special Majority</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Quorum</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">One Shareholder May Constitute Quorum</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other Persons May Attend</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Requirement of Quorum</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lack of Quorum</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lack of Quorum at Succeeding Meeting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selection of Alternate Chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjournments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- ii - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notice of Adjourned Meeting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.13</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decision by Show of Hands or Poll</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.14</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Declaration of Result</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.15</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Motion Need Not be Seconded</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.16</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No Casting Vote</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.17</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Manner of Taking Poll</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.18</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Demand for Poll on Adjournment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.19</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chair Must Resolve Dispute</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.20</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Casting of Votes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.21</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No Demand for Poll on Election of Chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.22</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Demand for Poll Not to Prevent Continuance of Meeting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.23</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Retention of Ballots and Proxies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><B>ARTICLE 12</B></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><B>VOTES OF SHAREHOLDERS</B></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of Votes by Shareholder or by Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Votes of Persons in Representative Capacity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Votes by Joint Holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal Personal Representatives as Joint Shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Representative of a Corporate Shareholder</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proxy Provisions Do Not Apply to All Companies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Appointment of Proxy Holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alternate Proxy Holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">When Proxy Holder Need Not Be Shareholder</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deposit of Proxy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Validity of Proxy Vote</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Form of Proxy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.13</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revocation of Proxy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.14</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revocation of Proxy Must Be Signed</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.15</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chair May Determine Validity of Proxy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.16</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Production of Evidence of Authority to Vote</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><B>ARTICLE 13</B></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><B>DIRECTORS</B></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First Directors; Number of Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in Number of Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Directors&#146; Acts Valid Despite Vacancy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Qualifications of Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Remuneration of Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reimbursement of Expenses of Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Special Remuneration for Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gratuity, Pension or Allowance on Retirement of Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><B>ARTICLE 14</B></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><B>ELECTION AND REMOVAL OF DIRECTORS</B></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Staggered Terms</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Election at Annual General Meeting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Election or Appointment between Annual General Meetings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consent to be a Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Failure to Elect or Appoint Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Places of Retiring Directors Not Filled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Directors May Fill Casual Vacancies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- iii - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Remaining Directors Power to Act</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shareholders May Fill Vacancies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ceasing to be a Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Removal of Director by Shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.13</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Removal of Director by Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><B>ARTICLE 15</B></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><B>POWERS AND DUTIES OF DIRECTORS</B></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Powers of Management</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Appointment of Attorney of Company</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><B>ARTICLE 16</B></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><B>DISCLOSURE OF INTEREST OF DIRECTORS</B></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Obligation to Account for Profits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restrictions on Voting by Reason of Interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interested Director Counted in Quorum</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disclosure of Conflict of Interest or Property</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director Holding Other Office in the Company</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No Disqualification</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Professional Services by Director or Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director or Officer in Other Corporations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><B>ARTICLE 17</B></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><B>PROCEEDINGS OF DIRECTORS</B></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">17.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Meetings of Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">17.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Voting at Meetings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">17.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chair of Meetings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">17.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Meetings by Telephone or Other Communications Medium</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">17.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Calling of Meetings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">17.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notice of Meetings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">17.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">When Notice Not Required</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">17.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Meeting Valid Despite Failure to Give Notice</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">17.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Waiver of Notice of Meetings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">17.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Quorum</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">17.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Validity of Acts Where Appointment Defective</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">17.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consent Resolutions in Writing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><B>ARTICLE 18</B></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><B>EXECUTIVE AND OTHER COMMITTEES</B></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">18.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Appointment and Powers of Executive Committee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">18.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Appointment and Powers of Other Committees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">18.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Obligations of Committees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">18.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Powers of Board</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">18.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Committee Meetings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><B>ARTICLE 19</B></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><B>OFFICERS</B></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">19.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Directors May Appoint Officers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">19.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Functions, Duties and Powers of Officers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">19.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Qualifications</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">19.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Remuneration and Terms of Appointment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- iv - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><B>ARTICLE 20</B></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><B>INDEMNIFICATION</B></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">20.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Definitions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">20.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mandatory Indemnification of Eligible Parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">20.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Indemnification of Other Persons</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">20.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-Compliance</FONT> with <I>Business Corporations
Act</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">20.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Company May Purchase Insurance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><B>ARTICLE 21</B></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><B>DIVIDENDS</B></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">21.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment of Dividends Subject to Special Rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">21.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Declaration of Dividends</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">21.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No Notice Required</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">21.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Record Date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">21.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Manner of Paying Dividend</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">21.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Settlement of Difficulties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">21.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">When Dividend Payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">21.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividends to be Paid in Accordance with Number of Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">21.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Receipt by Joint Shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">21.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend Bears No Interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">21.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Fractional Dividends</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">21.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Payment of Dividends</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">21.13</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Capitalization of Surplus</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">21.14</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Unclaimed Dividends</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><B>ARTICLE 22</B></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><B>DOCUMENTS, RECORDS AND REPORTS</B></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">22.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Recording of Financial Affairs</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">22.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Inspection of Accounting Records</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><B>ARTICLE 23</B></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><B>NOTICES</B></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">23.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Method of Giving Notice</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">23.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Deemed Receipt</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">23.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Certificate of Sending</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">23.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Notice to Joint Shareholders</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">23.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Notice to Legal Personal Representatives and Trustees</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">23.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Undelivered Notices</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><B>ARTICLE 24</B></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><B>SEAL AND EXECUTION OF DOCUMENTS</B></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">24.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Who May Attest Seal</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">24.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Sealing Copies</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">24.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Mechanical Reproduction of Seal</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">24.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Execution of Documents Generally</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><B>ARTICLE 25</B></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><B>PROHIBITIONS</B></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">25.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Definitions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">25.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Application</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">25.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Consent Required for Transfer of Shares or Designated Securities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- v - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><B>ARTICLE 26</B></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><B>FORUM SELECTION</B></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">26.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Forum for Adjudication of Certain Disputes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><B>ARTICLE 27</B></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><B>SPECIAL RIGHTS AND RESTRICTIONS ATTACHED TO COMMON SHARES</B></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><B>ARTICLE 28</B></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><B>SPECIAL RIGHTS AND RESTRICTIONS ATTACHED TO THE PREFERRED SHARES</B></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- vi - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I>Final Form </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Incorporation number: _______________ </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>BUSINESS CORPORATIONS ACT </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLES </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>of </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE HOLDINGS INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INTERPRETATION </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.1</B>
<B>Definitions</B><B>.</B> In these Articles (the &#147;<B>Articles</B>&#148;), unless the context otherwise requires: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Applicable
Securities Laws</B>&#148; means the applicable securities legislation of the United States and each relevant province and territory of Canada, as amended from time to time, the written rules, regulations and forms made or promulgated under any such
statute and the published national instruments, multilateral instruments, policies, bulletins and notices of the securities commissions and similar regulatory authorities of the United States and each province and territory of Canada; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>board of directors</B>&#148;, &#147;<B>directors</B>&#148; and &#147;<B>board</B>&#148; mean the directors of the Company for the time
being; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Business Corporations Act</I></B>&#148; means the <I>Business Corporations Act</I> (British Columbia) from time to time
in force and all amendments thereto and includes all regulations and amendments thereto made pursuant to that Act; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>business
day</B>&#148; means a day, other than a Saturday or Sunday, on which commercial banks in New York, New York and Vancouver, British Columbia are open for the general transaction of business; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Interpretation Act</I></B>&#148; means the <I>Interpretation Act</I> (British Columbia) from time to time in force and all
amendments thereto and includes all regulations and amendments thereto; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>legal personal representative</B>&#148; means the
personal or other legal representative of a shareholder; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>registered address</B>&#148; of a shareholder means the
shareholder&#146;s address as recorded in the central securities register; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>seal</B>&#148; means the seal of the Company, if any;
and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Securities Act</I></B>&#148; means the <I>Securities Act</I> (British Columbia) from time to time in force and all
amendments thereto and includes all regulations and amendments thereto made pursuant to that Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.2</B> <B>Business Corporations Act and
Interpretation Act Definitions Applicable</B><B>.</B> The definitions in the <I>Business Corporations Act</I> and the definitions and rules of construction in the <I>Interpretation Act</I>, with the necessary changes, so far as applicable, and
unless the context requires otherwise, apply to these Articles as if they were an enactment. If there is a conflict between a definition in the <I>Business Corporations Act</I> and a definition or rule in the <I>Interpretation Act</I> relating to a
term used in these Articles, the definition in the <I>Business Corporations Act</I> will prevail in relation to the use of the term in these Articles. If there is a conflict between these Articles and the <I>Business Corporations Act</I>, the
<I>Business Corporations Act</I> will prevail. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 2 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SHARES AND SHARE CERTIFICATES </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.1</B>
<B>Authorized Share Structure</B><B>.</B> The authorized share structure of the Company consists of shares of the class or classes and series, if any, described in the Notice of Articles of the Company. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.2</B> <B>Form of Share Certificate</B><B>.</B> Each share certificate issued by the Company must comply
with, and be signed as required by, the <I>Business Corporations Act</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.3</B> <B>Shareholder Entitled to Certificate or
Acknowledgement</B><B>.</B> Except in respect of shares that are uncertificated shares within the meaning of the <I>Business Corporations Act</I>, each shareholder is entitled, without charge, to (a)&nbsp;one share certificate representing the
shares of each class or series of shares registered in the shareholder&#146;s name or (b)&nbsp;a <FONT STYLE="white-space:nowrap">non-transferable</FONT> written acknowledgement of the shareholder&#146;s right to obtain such a share certificate,
provided that in respect of a share held jointly by several persons, the Company is not bound to issue more than one share certificate and delivery of a share certificate for a share to one of several joint shareholders or to one of the
shareholders&#146; duly authorized agents will be sufficient delivery to all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.4</B> <B>Delivery by Mail</B><B>.</B> Any share certificate or <FONT
STYLE="white-space:nowrap">non-transferable</FONT> written acknowledgement of a shareholder&#146;s right to obtain a share certificate may be sent to the shareholder by mail at the shareholder&#146;s registered address and neither the Company nor
any director, officer or agent of the Company (including the Company&#146;s transfer agent or legal counsel) is liable for any loss to the shareholder because the share certificate or acknowledgement is lost in the mail or stolen. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.5</B> <B>Replacement of Worn Out or Defaced Certificate or Acknowledgement</B><B>.</B> If the directors are satisfied that a share certificate or a <FONT
STYLE="white-space:nowrap">non-transferable</FONT> written acknowledgement of the shareholder&#146;s right to obtain a share certificate is worn out or defaced, they must, on production to them of the share certificate or acknowledgement, as the
case may be, and on such other terms, if any, as they think fit: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">order the share certificate or acknowledgement, as the case may be, to be cancelled; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">issue a replacement share certificate or acknowledgement, as the case may be. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.6</B> <B>Replacement of Lost, Stolen or Destroyed Certificate or Acknowledgement</B><B>.</B> If a share certificate or a
<FONT STYLE="white-space:nowrap">non-transferable</FONT> written acknowledgement of a shareholder&#146;s right to obtain a share certificate is lost, stolen or destroyed, a replacement share certificate or acknowledgement, as the case may be, must
be issued to the person entitled to that share certificate or acknowledgement, as the case may be, if the directors receive: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">proof satisfactory to them that the share certificate or acknowledgement is lost, stolen or destroyed; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any indemnity the directors consider adequate. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.7</B> <B>Splitting Share Certificates</B><B>.</B> If a shareholder surrenders a share certificate to the Company with a written request that the Company
issue in the shareholder&#146;s name two or more share certificates, each representing a specified number of shares and in the aggregate representing the same number of shares as the share certificate so surrendered, the Company must cancel the
surrendered share certificate and issue replacement share certificates in accordance with that request. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.8</B> <B>Certificate Fee</B><B>.</B> There
must be paid to the Company, in relation to the issue of any share certificate under Articles 2.5, 2.6 or 2.7, the amount, if any and which must not exceed the amount prescribed under the <I>Business Corporations Act</I>, determined by the
directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.9</B> <B>Recognition of Trusts</B><B>.</B> Except as required by law or statute or these Articles, no person will be recognized by the
Company as holding any share upon any trust, and the Company is not bound by or compelled in any way to recognize (even when having notice thereof) any equitable, contingent, future or partial interest in any share or fraction of a share or (except
as provided by law or statute or these Articles or as ordered by a court of competent jurisdiction) any other rights in respect of any share except an absolute right to the entirety thereof in the shareholder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 2 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 3 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ISSUE OF SHARES </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.1</B> <B>Directors
Authorized</B><B>.</B> Subject to the <I>Business Corporations Act</I> and the rights of the holders of issued shares of the Company, the Company may issue, allot, sell or otherwise dispose of the unissued shares, and issued shares held by the
Company, at the times, to the persons, including directors, in the manner, on the terms and conditions and for the issue prices (including any premium at which shares with par value may be issued) that the directors may determine. The issue price
for a share with par value must be equal to or greater than the par value of the share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.2</B> <B>Commissions and Discounts</B><B>.</B> The Company
may at any time, pay a reasonable commission or allow a reasonable discount to any person in consideration of that person purchasing or agreeing to purchase shares of the Company from the Company or any other person or procuring or agreeing to
procure purchasers for shares of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.3</B> <B>Brokerage</B><B>.</B> The Company may pay such brokerage fee or other consideration as may be
lawful for or in connection with the sale or placement of its securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.4</B> <B>Conditions of Issue</B><B>.</B> Except as provided for by the
<I>Business Corporations Act</I>, no share may be issued until it is fully paid. A share is fully paid when: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">consideration is provided to the Company for the issue of the share by one or more of the following:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">past services performed for the Company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">property; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">money; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the value of the consideration received by the Company equals or exceeds the issue price set for the share
under Article 3.1. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.5</B> <B>Share Purchase Warrants and Rights</B><B>.</B> Subject to the <I>Business Corporations Act</I>, the
Company may issue share purchase warrants, options and rights upon such terms and conditions as the directors determine, which share purchase warrants, options and rights may be issued alone or in conjunction with debentures, debenture stock, bonds,
shares or any other securities issued or created by the Company from time to time. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 4 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SHARE REGISTERS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.1</B> <B>Central
Securities Register</B><B>.</B> As required by and subject to the <I>Business Corporations Act</I>, the Company must maintain a central securities register, which may be kept in electronic form. The directors may, subject to the <I>Business
Corporations Act</I>, appoint an agent to maintain the central securities register. The directors may also appoint one or more agents, including the agent which keeps the central securities register, as transfer agent for its shares or any class or
series of its shares, as the case may be, and the same or another agent as registrar for its shares or such class or series of its shares, as the case may be. The directors may terminate such appointment of any agent at any time and may appoint
another agent in its place. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.2</B> <B>Closing Register</B><B>.</B> The Company must not at any time close its central securities register. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 5 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SHARE
TRANSFERS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.1</B> <B>Registering Transfers</B><B>.</B> A transfer of a share of the Company must not be registered unless: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a duly signed instrument of transfer in respect of the share has been received by the Company or the transfer
agent or registrar for the class or series of shares to be transferred; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 3 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if a share certificate has been issued by the Company in respect of the share to be transferred, that share
certificate has been surrendered to the Company or the transfer agent or registrar for the class or series of shares to be transferred; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">such other evidence, if any, as the Company or the transfer agent or registrar for the class or series of
shares to be transferred may require to prove the title of the transferor or the transferor&#146;s right to transfer the share, that the written instrument of transfer is genuine and authorized and that the transfer is rightful or to a protected
purchaser has been provided. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.2</B> <B>Form of Instrument of Transfer</B><B>.</B> The instrument of transfer in respect of any
share of the Company must be either in the form, if any, on the back of the Company&#146;s share certificates or in any other form satisfactory to the Company or the transfer agent or registrar for the class or series of shares to be transferred.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.3</B> <B>Transferor Remains Shareholder</B><B>.</B> Except to the extent that the <I>Business Corporations Act</I> otherwise provides, the
transferor of shares is deemed to remain the holder of the shares until the name of the transferee is entered in a securities register of the Company in respect of the transfer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.4</B> <B>Signing of Instrument of Transfer</B><B>.</B> If a shareholder, or the shareholder&#146;s duly authorized attorney, signs an instrument of
transfer in respect of shares registered in the name of the shareholder, the signed instrument of transfer constitutes a complete and sufficient authority to the Company and its directors, officers and agents to register the number of shares
specified in the instrument of transfer or specified in any other manner, or, if no number is specified, all the shares represented by the share certificates or set out in the written acknowledgements deposited with the instrument of transfer: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the name of the person named as transferee in that instrument of transfer; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if no person is named as transferee in that instrument of transfer, in the name of the person on whose behalf
the instrument is deposited for the purpose of having the transfer registered. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.5</B> <B>Enquiry as to Title Not
Required</B><B>.</B> Neither the Company nor any director, officer or agent of the Company is bound to inquire into the title of the person named in the instrument of transfer as transferee or, if no person is named as transferee in the instrument
of transfer, of the person on whose behalf the instrument is deposited for the purpose of having the transfer registered or is liable for any claim related to registering the transfer by the shareholder or by any intermediate owner or holder of the
shares, of any interest in the shares, of any share certificate representing such shares or of any written acknowledgement of a right to obtain a share certificate for such shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.6</B> <B>Transfer Fee</B><B>.</B> There must be paid to the Company, in relation to the registration of any transfer, the amount, if any, determined by
the directors. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 6 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TRANSMISSION OF SHARES </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.1</B> <B>Legal
Personal Representative Recognized on Death</B><B>.</B> In case of the death of a shareholder, the legal personal representative, or if the shareholder was a joint holder, the surviving joint holder, will be the only person recognized by the Company
as having any title to the shareholder&#146;s interest in the shares. Before recognizing a person as a legal personal representative, the directors may require proof of appointment by a court of competent jurisdiction, a grant of letters probate,
letters of administration or such other evidence or documents as the directors consider appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.2</B> <B>Rights of Legal Personal
Representative</B><B>.</B> The legal personal representative has the same rights, privileges and obligations that attach to the shares held by the shareholder, including the right to transfer the shares in accordance with these Articles, provided
the documents required by the <I>Business Corporations Act</I> and the directors have been deposited with the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 4 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 7 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PURCHASE OF SHARES </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.1</B> <B>Company
Authorized to Purchase or Otherwise Acquire Shares</B><B>.</B> Subject to Article 7.2, the special rights and restrictions attached to the shares of any class or series, the <I>Business Corporations Act</I> and the Applicable Securities Laws, the
Company may, if authorized by the directors, purchase or otherwise acquire any of its shares at the price and upon the terms determined by the directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.2</B> <B>Purchase When Insolvent</B><B>.</B> The Company must not make a payment or provide any other consideration to purchase, redeem or otherwise
acquire any of its shares if there are reasonable grounds for believing that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Company is insolvent; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">making the payment or providing the consideration would render the Company insolvent. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.3</B> <B>Sale and Voting of Purchased, Redeemed, or Otherwise Acquired Shares</B><B>.</B> If the Company retains a share purchased, redeemed, or
otherwise acquired by it, the Company may sell, gift or otherwise dispose of the share, but, while such share is held by the Company, it: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is not entitled to vote the share at a meeting of its shareholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">must not pay a dividend in respect of the share; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">must not make any other distribution in respect of the share. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 8 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BORROWING
POWERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8.1</B> <B>Borrowing Powers</B><B>.</B> The Company, if authorized by the directors, may: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">borrow money in the manner and amount, on the security, from the sources and on the terms and conditions that
the directors consider appropriate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">issue bonds, debentures and other debt obligations either outright or as security for any liability or
obligation of the Company or any other person and at such discounts or premiums and on such other terms as the directors consider appropriate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">guarantee the repayment of money by any other person or the performance of any obligation of any other person;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">mortgage, charge, whether by way of specific or floating charge, grant a security interest in, or give other
security on, the whole or any part of the present and future assets and undertaking of the Company. </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 9
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ALTERATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9.1</B>
<B>Alteration of Authorized Share Structure by the Shareholders</B><B>.</B> Subject to Articles 9.3 and 9.4, the <I>Business Corporations Act </I>and the special rights and restrictions attached to the shares of any class or series, the Company may
by special resolution:<B> </B> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">create one or more classes or series of shares or, if none of the shares of a class or series of shares are
allotted or issued, eliminate that class or series of shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">increase, reduce or eliminate the maximum number of shares that the Company is authorized to issue out of any
class or series of shares or establish a maximum number of shares that the Company is authorized to issue out of any class or series of shares for which no maximum is established; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 5 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the Company is authorized to issue shares of a class of shares with par value: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">decrease the par value of those shares; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if none of the shares of that class of shares are allotted or issued, increase the par value of those shares;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">change all or any of its unissued, or fully paid issued, shares with par value into shares without par value or
any of its unissued shares without par value into shares with par value; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">otherwise alter its shares or authorized share structure when required or permitted to do so by the <I>Business
Corporations Act</I>; </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">and, if applicable, alter its Notice of Articles and Articles accordingly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9.2</B> <B>Alteration of Authorized Share Structure by the Directors</B><B>.</B><SUP STYLE="font-size:75%; vertical-align:top"> </SUP>Subject to Articles
9.3 and 9.4, the Company may by directors&#146; resolution: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">subdivide or consolidate all or any of its unissued, or fully paid issued, shares; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">alter the identifying name of any of its shares; </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">and, if applicable, alter its Notice of Articles and Articles accordingly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9.3</B> <B>Special Rights and Restrictions</B><B>.</B> Subject to Article 9.4, the special rights or restrictions attached to any class or series of shares
and the <I>Business Corporations Act</I>, the Company may by special resolution: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">create special rights or restrictions for, and attach those special rights or restrictions to, the shares of
any class or series of shares, whether or not any or all of those shares have been issued; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">vary or delete any special rights or restrictions attached to the shares of any class or series of shares,
whether or not any or all of those shares have been issued; </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">and alter its Articles or Notice of Articles accordingly.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9.4</B> <B>No Interference with Class</B><B></B><B>&nbsp;or Series Rights without Consent</B><B>.</B> A right or special right attached to issued
shares must not be prejudiced or interfered with under the <I>Business Corporations Act</I>, the Notice of Articles or these Articles unless the holders of shares of the class or series of shares to which the right or special right is attached
consent by a special separate resolution of the holders of such class or series of shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9.5</B> <B>Change of Name</B><B>.</B> The Company may by
directors&#146;<B> </B>resolution authorize an alteration of its Notice of Articles in order to change its name. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9.6</B> <B>Other
Alterations</B><B>.</B> If the <I>Business Corporations Act</I> does not specify the type of resolution and these Articles do not specify another type of resolution, the Company may by special resolution alter these Articles. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 10 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MEETINGS OF
SHAREHOLDERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.1</B> <B>Annual General Meetings</B><B>.</B> Unless an annual general meeting is deferred or waived in accordance with the
<I>Business Corporations Act</I>, the Company must hold its first annual general meeting within 18 months after the date on which it was incorporated or otherwise recognized, and after that must hold an annual general meeting at least once in each
calendar year and not more than 15 months after the last annual reference date at such time and, subject to Article 10.10, at such place as may be determined by the directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.2</B> <B>Resolution Instead of Annual General Meeting</B><B>.</B> If all the shareholders who are entitled to vote at an annual general meeting consent
by a unanimous resolution under the <I>Business Corporations Act</I> to all of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 6 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
business that is required to be transacted at that annual general meeting, the annual general meeting is deemed to have been held on the date of the unanimous resolution. The shareholders must,
in any unanimous resolution passed under this Article 10.2, select as the Company&#146;s annual reference date a date that would be appropriate for the holding of the applicable annual general meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.3</B> <B>Calling of Meetings of Shareholders</B><B>.</B> The directors may, whenever they think fit, call a meeting of shareholders, to be held at such
time and, subject to Article 10.10, at such place as may be determined by the directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.4</B> <B>Notice for Meetings of Shareholders</B><B>.</B>
The Company must send notice of the date, time and, unless the meeting is a fully electronic meeting, the location of any meeting of shareholders, in the manner provided in these Articles, or in such other manner, if any, as may be prescribed by
ordinary resolution (whether previous notice of the resolution has been given or not), to each shareholder entitled to attend the meeting, to each director and to the auditor of the Company, unless these Articles otherwise provide, at least the
following number of days before the meeting: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if and for so long as the Company is a public company, 21 days; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">otherwise, 10 days. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.5</B> <B>Record Date for Notice</B><B>.</B> The directors may set a date as the record date for the purpose of determining shareholders entitled to
notice of any meeting of shareholders. The record date must not precede the date on which the meeting is to be held by more than two months or, in the case of a general meeting requisitioned by shareholders under the <I>Business Corporations
Act</I>, by more than four months. The record date must not precede the date on which the meeting is held by fewer than: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if and for so long as the Company is a public company, 21 days; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">otherwise, 10 days. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If no record date is set, the record date is 5 p.m. on the day immediately preceding the first date on which the notice is sent or, if no notice is sent, the
beginning of the meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.6</B> <B>Record Date for Voting</B><B>.</B> The directors may set a date as the record date for the purpose of
determining shareholders entitled to vote at any meeting of shareholders. The record date must not precede the date on which the meeting is to be held by more than two months or, in the case of a general meeting requisitioned by shareholders under
the <I>Business Corporations Act</I>, by more than four months. If no record date is set, the record date is 5 p.m. on the day immediately preceding the first date on which the notice is sent or, if no notice is sent, the beginning of the meeting.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.7</B> <B>Failure to Give Notice and Waiver of Notice</B><B>.</B> The accidental omission to send notice of any meeting to, or the <FONT
STYLE="white-space:nowrap">non-receipt</FONT> of any notice by, any of the persons entitled to notice does not invalidate any proceedings at that meeting. Any person entitled to notice of a meeting of shareholders may, in writing or otherwise, waive
or reduce the period of notice of such meeting. Attendance of a person at a meeting of shareholders is a waiver of entitlement to notice of the meeting unless that person attends the meeting for the express purpose of objecting to the transaction of
any business on the grounds that the meeting is not lawfully called. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.8</B> <B>Notice of Special Business at Meetings of Shareholders</B><B>.</B> If
a meeting of shareholders is to consider special business within the meaning of Article 11.1, the notice of meeting must: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">state the general nature of the special business; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the special business includes considering, approving, ratifying, adopting or authorizing any document or the
signing of or giving of effect to any document, have attached to it a copy of the document or state that a copy of the document will be available for inspection by shareholders: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at the Company&#146;s records office, or at such other reasonably accessible location in British Columbia as is
specified in the notice; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 7 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">during statutory business hours on any one or more specified days before the day set for the holding of the
meeting. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, any special business that is not set out in the notice of meeting shall not be approved at that
meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.9</B> <B>Class Meetings and Series Meetings of Shareholders</B><B>.</B> Unless otherwise specified in these Articles, the provisions of
these Articles relating to a meeting of shareholders will apply, with the necessary changes and so far as they are applicable, to a class meeting or series meeting of shareholders holding a particular class or series of shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.10</B> <B>Meetings by Telephone or Other Communications Medium</B><B>.</B><B> </B>The directors may determine that a meeting of shareholders shall be
held entirely by means of telephonic, electronic or other communication facilities that permit all participants to participate in the meeting, whether by telephone, electronic or other communications medium. A meeting of shareholders may also be
held at which some, but not necessarily all, persons entitled to attend may participate by means of such communications facilities, if the directors determine to make them available. A person participating in a meeting by such means is deemed to be
present at the meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.11 Advance Notice of Nominations of Directors. </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Nomination Procedures</U> - Subject only to the <I>Business Corporations Act</I>, Applicable Securities Law
and these Articles, only persons who are nominated in accordance with the following procedures shall be eligible for election as directors of the Company. Nominations of persons for election to the board may be made at any annual meeting of
shareholders, or at any special meeting of shareholders if the election of directors is a matter specified in the notice of meeting, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by or at the direction of the board, including pursuant to a notice of meeting; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by or at the direction or request of one or more shareholders pursuant to a proposal made in accordance with
the provisions of the <I>Business Corporations Act</I>, or a requisition of the shareholders made in accordance with the provisions of the <I>Business Corporations Act</I>; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by any person (a &#147;<B>Nominating Shareholder</B>&#148;) who (A)&nbsp;at the close of business on the date
of the giving of the notice provided for in this Article 10.11 and on the record date for notice of such meeting, is entered in the securities register as a holder of one or more shares carrying the right to vote at such meeting, or who beneficially
owns shares that are entitled to be voted at such meeting and provides evidence of such beneficial ownership to the Company, and (B)&nbsp;has given timely notice in proper written form as set forth in this Article 10.11. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Manner of timely notice</U> - To be timely, a Nominating Shareholder&#146;s notice must be received by the
corporate secretary of the Company at the principal executive office or registered office of the Company: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of an annual meeting (including an annual and special meeting) of shareholders, not later than the
close of business on the 30th day prior to the date of the meeting; provided, however, that in the event that the meeting is to be held on a date that is less than 50 days after the date (the &#147;<B>Notice Date</B>&#148;) on which the first public
announcement of the date of the meeting was made, notice by the Nominating Shareholder may be made not later than the close of business on the tenth (10th) day following the Notice Date; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of a special meeting (which is not also an annual meeting) of shareholders called for the purpose
of electing directors (whether or not called for other purposes), not later than the close of business on the fifteenth (15th) day following the day on which the first public announcement of the date of the meeting was made. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 8 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Proper form of notice</U> - To be in proper written form, a Nominating Shareholder&#146;s notice must comply
with this Article 10.11 and must set forth: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as to each person whom the Nominating Shareholder proposes to nominate for election as a director:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">their name, age, business and residential address, and principal occupation or employment for the past five
years; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">their direct or indirect beneficial ownership in, or control or direction over, any class or series of
securities of the Company, including the number or principal amount; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any other information that would be required to be disclosed in a dissident proxy circular or other filings
required to be made in connection with the solicitation of proxies for election of directors pursuant to the <I>Business Corporations Act</I> and as required by Applicable Securities Laws; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as to each Nominating Shareholder giving the notice: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">their name, business and residential address; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any direct or indirect beneficial ownership in, or control or direction over, any class or series of securities
of the Company, including the number or principal amount; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any proxy, contract, arrangement, agreement or understanding pursuant to which such person, or any of its
Affiliates or Associates, or any person acting jointly or in concert with such person, has any interests, rights or obligations relating to the voting of any securities of the Company or the nomination of directors to the board; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(D)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any other information relating to such person that would be required to be included in a dissident proxy
circular or other filings required to be made in connection with solicitations of proxies for election of directors pursuant to the <I>Business Corporations Act</I> and as required by Applicable Securities Laws. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">References to &#147;Nominating Shareholder&#148; in this Article 10.11 shall be deemed to refer to each shareholder that nominates a person for
election as a director in the case of a nomination proposal where more than one shareholder is involved in making such nomination proposal. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Currency of information</U> - All information to be provided in a timely notice pursuant to this Article
10.11 shall be provided as of the record date for determining shareholders entitled to vote at the meeting (if such date shall then have been publicly announced) and as of the date of such notice. The Nominating Shareholder shall update such
information to the extent necessary so that it is true and correct as of the date that is ten (10)&nbsp;business days prior to the date of the meeting, or any adjournment or postponement thereof. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Power of the chair</U> - The chair of the meeting shall have the power and duty to determine whether a
nomination was made in accordance with the procedures set forth in the foregoing provisions and, if any proposed nomination is not in compliance with such foregoing provisions, to declare that such defective nomination shall be disregarded.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Delivery of notice</U> - Notwithstanding any other provision of these Articles, notice given to the
corporate secretary of the Company pursuant to this Article 10.11 may only be given by personal delivery, facsimile transmission or by email (at such email address as may be stipulated from time to time on the Company&#146;s website for general
inquiries), and shall be deemed to have been given and made only at the time it is served by personal delivery to the corporate secretary at the address of the principal executive offices of the Company, email (at the address as aforesaid and
provided that confirmation of receipt of such email has been received) or sent by facsimile transmission (provided that receipt of the confirmation of such transmission has been received); provided that if such delivery or electronic communication
is made on a day which is not a business day or later than 5:00 p.m. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 9 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
(Vancouver time) on a day which is a business day, then such delivery or electronic communication shall be deemed to have been made on the subsequent day that is a business day.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Exclusive Means</U> &#150; For the avoidance of doubt, this Article 10.11 shall be the exclusive means for
any person to bring nominations for election to the board at or in connection with any annual or special meeting of the shareholders of the Company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Waiver</U> - Notwithstanding the foregoing, the board may, in its sole discretion, waive any requirement in
this Article 10.11. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Definitions</U> - For purposes of this Article 10.11, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Affiliate</B>&#148;, when used to indicate a relationship with a specific person, shall mean a person that directly, or indirectly
through one or more intermediaries, controls, or is controlled by, or is under common control with, such specified person; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Associate</B>&#148;, when used to indicate a relationship with a specified person, shall mean (i)&nbsp;any body corporate or trust of
which such person beneficially owns, directly or indirectly, voting securities carrying more than 10% of the voting rights attached to all voting securities of such body corporate or trust for the time being outstanding, (ii)&nbsp;any partner of
that person, (iii)&nbsp;any trust or estate in which such person has a substantial beneficial interest or as to which such person serves as trustee or in a similar capacity, (iv)&nbsp;a spouse of such specified person, (v)&nbsp;any person of either
sex with whom such specified person is living in conjugal relationship outside marriage or (vi)&nbsp;any relative of such specified person or of a person mentioned in clauses (iv)&nbsp;or (v) of this definition if that relative has the same
residence as the specified person; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>beneficially owns</B>&#148; or &#147;<B>beneficially owned</B>&#148; means, in connection with
the ownership of shares in the capital of the Company by a person, (i)&nbsp;any such shares as to which such person or any of such person&#146;s Affiliates or Associates owns at law or in equity, or has the right to acquire or become the owner at
law or in equity, where such right is exercisable immediately or after the passage of time and whether or not on condition or the happening of any contingency or the making of any payment, upon the exercise of any conversion right, exchange right or
purchase right attaching to any securities, or pursuant to any agreement, arrangement, pledge or understanding whether or not in writing; (ii)&nbsp;any such shares as to which such person or any of such person&#146;s Affiliates or Associates has the
right to vote, or the right to direct the voting, where such right is exercisable immediately or after the passage of time and whether or not on condition or the happening of any contingency or the making of any payment, pursuant to any agreement,
arrangement, pledge or understanding whether or not in writing; (iii)&nbsp;any such shares which are beneficially owned, directly or indirectly, by a Counterparty (or any of such Counterparty&#146;s Affiliates or Associates) under any Derivatives
Contract (without regard to any short or similar position under the same or any other Derivatives Contract) to which such person or any of such person&#146;s Affiliates or Associates is a Receiving Party; provided, however that the number of shares
that a person beneficially owns pursuant to this clause (iii)&nbsp;in connection with a particular Derivatives Contract shall not exceed the number of Notional Securities with respect to such Derivatives Contract; provided, further, that the number
of securities owned beneficially by each Counterparty (including their respective Affiliates and Associates) under a Derivatives Contract shall for purposes of this clause be deemed to include all securities that are owned beneficially, directly or
indirectly, by any other Counterparty (or any of such other Counterparty&#146;s Affiliates or Associates) under any Derivatives Contract to which such first Counterparty (or any of such first Counterparty&#146;s Affiliates or Associates) is a
Receiving Party and this proviso shall be applied to successive Counterparties as appropriate; and (iv)&nbsp;any such shares which are owned beneficially within the meaning of this definition by any other person with whom such person is acting
jointly or in concert with respect to the Company or any of its securities; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>close of business</B>&#148; means 5:00 p.m.
(Vancouver time) on a business day in British Columbia, Canada; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Derivatives Contract</B>&#148; shall mean a contract between two
parties (the &#147;<B>Receiving Party</B>&#148; and the &#147;<B>Counterparty</B>&#148;) that is designed to expose the Receiving Party to economic benefits and risks that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 10 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
correspond substantially to the ownership by the Receiving Party of a number of shares in the capital of the Company or securities convertible into such shares specified or referenced in such
contract (the number corresponding to such economic benefits and risks, the &#147;<B>Notional Securities</B>&#148;), regardless of whether obligations under such contract are required or permitted to be settled through the delivery of cash, shares
in the capital of the Company or securities convertible into such shares or other property, without regard to any short position under the same or any other Derivatives Contract. For the avoidance of doubt, interests in broad-based index options,
broad-based index futures and broad-based publicly traded market baskets of stocks approved for trading by the appropriate governmental authority shall not be deemed to be Derivatives Contracts; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>public announcement</B>&#148; shall mean disclosure in a press release reported by a national news service in Canada or the United
States, or in a document publicly filed by the Company under its profile on the System for Electronic Document Analysis and Retrieval at <U>www.sedar.com</U> or on the Electronic Data Gathering, Analysis and Retrieval system
at&nbsp;https://<U>www.sec.gov/edgar/searchedgar/companysearch.html</U>. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 11 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROCEEDINGS AT MEETINGS OF SHAREHOLDERS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.1</B> <B>Special Business</B><B>.</B> At a meeting of shareholders, the following business is special business: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at a meeting of shareholders that is not an annual general meeting, all business is special business except
business relating to the conduct of or voting at the meeting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at an annual general meeting, all business is special business except for the following: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">business relating to the conduct of or voting at the meeting; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">consideration of any financial statements of the Company presented to the meeting; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">consideration of any reports of the directors or auditor; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the setting or changing of the number of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the election or appointment of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the appointment of an auditor; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the setting of the remuneration of an auditor; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(viii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">business arising out of a report of the directors not requiring the passing of a special resolution or an
exceptional resolution; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ix)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any other business which, under these Articles or the <I>Business Corporations Act</I>, may be transacted at a
meeting of shareholders without prior notice of the business being given to the shareholders. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.2</B> <B>Special
Majority</B><B>.</B> The majority of votes required for the Company to pass a special resolution at a meeting of shareholders is <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the votes cast on the resolution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.3</B> <B>Quorum</B><B>.</B> Subject to the special rights and restrictions attached to the shares of any class or series of shares and Article 11.4, the
quorum for the transaction of business at a meeting of shareholders is two persons who are, or who represent by proxy, shareholders who, in the aggregate, hold at least
33<SUP STYLE="vertical-align:top">1</SUP>&#8260;<SUB STYLE="vertical-align:bottom">3</SUB> of the issued shares entitled to be voted at the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.4</B> <B>One Shareholder May Constitute Quorum</B><B>.</B> If there is only one shareholder entitled to vote at a meeting of shareholders: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the quorum is one person who is, or who represents by proxy, that shareholder, and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that shareholder, present in person or by proxy, may constitute the meeting. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 11 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.5</B> <B>Other Persons May Attend</B><B>.</B> In addition to those persons who are entitled to vote at
a meeting of shareholders, the only other persons entitled to be present at the meeting are the directors, the officers, any lawyer for the Company, the auditor of the Company, any other persons invited to be present at the meeting by the directors
or by the chair of the meeting and any persons entitled or required under the <I>Business Corporations Act</I> or these Articles to be present at the meeting; but if any of those persons does attend the meeting, that person is not to be counted in
the quorum and is not entitled to vote at the meeting unless that person is a shareholder or proxy holder entitled to vote at the meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.6</B>
<B>Requirement of Quorum</B><B>.</B> No business, other than the election of a chair of the meeting and the adjournment of the meeting, may be transacted at any meeting of shareholders unless a quorum of shareholders entitled to vote is present at
the commencement of the meeting, but such quorum need not be present throughout the meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.7</B> <B>Lack of Quorum</B><B>.</B> If, within <FONT
STYLE="white-space:nowrap">one-half</FONT> hour from the time set for the holding of a meeting of shareholders, a quorum is not present: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of a general meeting requisitioned by shareholders, the meeting is dissolved, and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of any other meeting of shareholders, the meeting stands adjourned to the same day in the next week
at the same time and place. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.8</B> <B>Lack of Quorum at Succeeding Meeting</B><B>.</B> If, at the meeting to which the meeting
referred to in Article 11.7(b) was adjourned, a quorum is not present within <FONT STYLE="white-space:nowrap">one-half</FONT> hour from the time set for the holding of the meeting, the person or persons present and being, or representing by proxy,
one or more shareholders entitled to attend and vote at the meeting constitute a quorum. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.9</B> <B>Chair</B><B>.</B> The following individual is
entitled to preside as chair at a meeting of shareholders: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the chair of the board, if any; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the chair of the board is absent or unwilling to act as chair of the meeting, the president, if any.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.10</B> <B>Selection of Alternate Chair</B><B>.</B> If, at any meeting of shareholders, there is no chair of the board or
president present within 15 minutes after the time set for holding the meeting, or if the chair of the board and the president are unwilling to act as chair of the meeting, or if the chair of the board and the president have advised the secretary,
if any, or any director present at the meeting, that they will not be present at the meeting, the directors present must choose one of their number to be chair of the meeting or if all of the directors present decline to take the chair or fail to so
choose or if no director is present, the shareholders entitled to vote at the meeting who are present in person or by proxy may choose any person present at the meeting to chair the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.11</B> <B>Adjournments</B><B>.</B> The chair of a meeting of shareholders may, and if so directed by the meeting must, adjourn the meeting from time to
time and from place to place, but no business may be transacted at any adjourned meeting other than the business left unfinished at the meeting from which the adjournment took place. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.12</B> <B>Notice of Adjourned Meeting</B><B>.</B> It is not necessary to give any notice of an adjourned meeting of shareholders or of the business to
be transacted at an adjourned meeting of shareholders except that, when a meeting is adjourned for 30 days or more, notice of the adjourned meeting must be given as in the case of the original meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.13</B> <B>Decision by Show of Hands or Poll</B><B>.</B> Subject to the <I>Business Corporations Act</I>, every motion put to a vote at a meeting of
shareholders will be decided on a show of hands, or the functional equivalent of a show of hands by means of electronic, telephonic or other communications facility unless a poll, before or on the declaration of the result of the vote by show of
hands or the functional equivalent of a show of hands, is directed by the chair or demanded by at least one shareholder entitled to vote who is present in person or by proxy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 12 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.14</B> <B>Declaration of Result</B><B>.</B> The chair of a meeting of shareholders must declare to the
meeting the decision on every question in accordance with the result of the show of hands (or its functional equivalent) or the poll, as the case may be, and that decision must be entered in the minutes of the meeting. A declaration of the chair
that a resolution is carried by the necessary majority or is defeated is, unless a poll is directed by the chair or demanded under Article 11.13, conclusive evidence without proof of the number or proportion of the votes recorded in favour of or
against the resolution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.15</B> <B>Motion Need Not be Seconded</B><B>.</B> No motion proposed at a meeting of shareholders need be seconded unless
the chair of the meeting rules otherwise, and the chair of any meeting of shareholders is entitled to propose or second a motion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.16</B> <B>No
Casting Vote</B><B>.</B> In the case of an equality of votes, the chair of a meeting of shareholders does not, either on a show of hands (or its functional equivalent) or on a poll, have a second or casting vote in addition to the vote or votes to
which the chair may be entitled as a shareholder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.17</B> <B>Manner of Taking Poll</B><B>.</B> Subject to Article 11.18, if a poll is duly demanded
at a meeting of shareholders: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the poll must be taken: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at the meeting, or within seven days after the date of the meeting, as the chair of the meeting directs; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the manner, at the time and at the place that the chair of the meeting directs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the result of the poll is deemed to be the decision of the meeting at which the poll is demanded; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the demand for the poll may be withdrawn by the person who demanded it. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.18</B> <B>Demand for Poll on Adjournment</B><B>.</B> A poll demanded at a meeting of shareholders on a question of adjournment must be taken immediately
at the meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.19</B> <B>Chair Must Resolve Dispute</B><B>.</B> In the case of any dispute as to the admission or rejection of a vote given on a
poll, the chair of the meeting must determine the dispute, and the chair&#146;s determination made in good faith is final and conclusive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.20</B>
<B>Casting of Votes</B><B>.</B> On a poll, a shareholder entitled to more than one vote need not cast all the votes in the same way. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.21</B> <B>No
Demand for Poll on Election of Chair</B><B>.</B> No poll may be demanded in respect of the vote by which a chair of a meeting of shareholders is elected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.22</B> <B>Demand for Poll Not to Prevent Continuance of Meeting</B><B>.</B> The demand for a poll at a meeting of shareholders does not, unless the
chair of the meeting so rules, prevent the continuation of a meeting for the transaction of any business other than the question on which a poll has been demanded. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.23</B> <B>Retention of Ballots and Proxies</B><B>.</B> The Company or its agent must, for at least three months after a meeting of shareholders, keep
each ballot cast on a poll and each proxy voted at the meeting, and, during that period, make them available for inspection during normal business hours by any shareholder or proxy holder entitled to vote at the meeting. At the end of such three
month period, the Company may destroy such ballots and proxies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 13 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 12 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VOTES OF SHAREHOLDERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12.1</B>
<B>Number of Votes by Shareholder or by Shares</B><B>.</B> Subject to any special rights or restrictions attached to any shares and to the restrictions imposed on joint shareholders under Article 12.3: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">on a vote by show of hands (or its functional equivalent), every person present who is a shareholder or proxy
holder and entitled to vote on the matter has one vote; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">on a poll, every shareholder entitled to vote on the matter has one vote in respect of each share entitled to
be voted on the matter and held by that shareholder and may exercise that vote either in person or by proxy. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12.2</B> <B>Votes of
Persons in Representative Capacity</B><B>.</B> A person who is not a shareholder may vote at a meeting of shareholders, whether on a show of hands (or its functional equivalent) or on a poll, and may appoint a proxy holder to act at the meeting, if,
before doing so, the person satisfies the chair of the meeting, or the directors, that the person is a legal personal representative or a trustee in bankruptcy for a shareholder who is entitled to vote at the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12.3</B> <B>Votes by Joint Holders</B><B>.</B> If there are joint shareholders registered in respect of any share: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any one of the joint shareholders may vote at any meeting of shareholders, personally or by proxy, in respect
of the share as if that joint shareholder were solely entitled to it; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if more than one of the joint shareholders is present at any meeting of shareholders, personally or by proxy,
and more than one of them votes in respect of that share, then only the vote of the joint shareholder present whose name stands first on the central securities register in respect of the share will be counted. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12.4</B> <B>Legal Personal Representatives as Joint Shareholders</B><B>.</B> Two or more legal personal representatives of a shareholder in whose sole name
any share is registered are, for the purposes of Article 12.3, deemed to be joint shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12.5</B> <B>Representative of a Corporate
Shareholder</B><B>.</B> If a corporation, that is not a subsidiary of the Company, is a shareholder, that corporation may appoint a person to act as its representative at any meeting of shareholders of the Company, and: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">for that purpose, the instrument appointing a representative must be received: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at the registered office of the Company or at any other place specified, in the notice calling the meeting, for
the receipt of proxies, at least the number of business days specified in the notice for the receipt of proxies, or if no number of days is specified, two business days before the day set for the holding of the meeting or adjourned or postponed
meeting; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at the meeting or any adjourned or postponed meeting, to the chair of the meeting or adjourned or postponed
meeting or by a person designated by the chair of the meeting or adjourned or postponed meeting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if a representative is appointed under this Article 12.5: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the representative is entitled to exercise in respect of and at that meeting the same rights on behalf of the
corporation that the representative represents as that corporation could exercise if it were a shareholder who is an individual, including, without limitation, the right to appoint a proxy holder; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the representative, if present at the meeting, is to be counted for the purpose of forming a quorum and is
deemed to be a shareholder present in person at the meeting. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 14 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Evidence of the appointment of any such representative may be sent to the Company or its transfer agent by
written instrument, fax or any other method of transmitting legibly recorded messages. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12.6</B> <B>Proxy Provisions Do Not Apply to All
Companies</B><B>.</B> Articles 12.7 to 12.15 do not apply to the Company if and for so long as it is a public company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12.7</B> <B>Appointment of
Proxy Holders</B><B>.</B> Every shareholder of the Company, including a corporation that is a shareholder but not a subsidiary of the Company, entitled to vote at a meeting of shareholders of the Company may, by proxy, appoint one or more (but not
more than five) proxy holders to attend and act at the meeting in the manner, to the extent and with the powers conferred by the proxy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12.8</B>
<B>Alternate Proxy Holders</B><B>.</B> A shareholder may appoint one or more alternate proxy holders to act in the place of an absent proxy holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12.9</B> <B>When Proxy Holder Need Not Be Shareholder</B><B>.</B> A person must not be appointed as a proxy holder unless the person is a shareholder,
although a person who is not a shareholder may be appointed as a proxy holder if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the person appointing the proxy holder is a corporation or a representative of a corporation appointed under
Article 12.5; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Company has at the time of the meeting for which the proxy holder is to be appointed only one shareholder
entitled to vote at the meeting; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the shareholders present in person or by proxy at and entitled to vote at the meeting for which the proxy
holder is to be appointed, by a resolution on which the proxy holder is not entitled to vote but in respect of which the proxy holder is to be counted in the quorum, permit the proxy holder to attend and vote at the meeting. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12.10</B> <B>Deposit of Proxy</B><B>.</B> A proxy for a meeting of shareholders must: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">be received at the registered office of the Company or at any other place specified, in the notice calling the
meeting, for the receipt of proxies, at least the number of business days specified in the notice, or if no number of days is specified, two business days before the day set for the holding of the meeting or any adjourned meeting;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">unless the notice provides otherwise, be provided, at the meeting or any adjourned meeting, to the chair of the
meeting or to a person designated by the chair of the meeting; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">be received in any other manner determined by the board or the chair of the meeting. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A proxy may be sent to the Company by written instrument, fax or any other method of transmitting legibly recorded messages or by using such available
internet or telephone voting services as may be approved by the directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12.11</B> <B>Validity of Proxy Vote</B><B>.</B> A vote given in accordance
with the terms of a proxy is valid notwithstanding the death or incapacity of the shareholder giving the proxy and despite the revocation of the proxy or the revocation of the authority under which the proxy is given, unless notice in writing of
that death, incapacity or revocation is received: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at the registered office of the Company, at any time up to and including the last business day before the day
set for the holding of the meeting or any adjourned meeting at which the proxy is to be used; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at the meeting or any adjourned meeting by the chair of the meeting or adjourned meeting, before any vote in
respect of which the proxy has been given has been taken. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 15 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12.12</B> <B>Form of Proxy</B><B>.</B> A proxy, whether for a specified meeting or otherwise, must be
either in the following form or in any other form approved by the directors or the chair of the meeting: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>ENGENE HOLDINGS INC. </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(the &#147;Company&#148;) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The
undersigned, being a shareholder of the Company, hereby appoints <I>[name]</I> or, failing that person, <I>[name]</I>, as proxy holder for the undersigned to attend, act and vote for and on behalf of the undersigned at the meeting of shareholders of
the Company to be held on <I>[month, day, year]</I> and at any adjournment of that meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Number of shares in respect of which this
proxy is given (if no number is specified, then this proxy if given in respect of all shares registered in the name of the shareholder): _______________. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Signed this ______ day of __________, _____. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Signature of
shareholder)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(Name of shareholder - printed)</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12.13</B> <B>Revocation of Proxy</B><B>.</B> Subject to Article 12.14, every proxy may be revoked by an instrument in
writing that is received: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at the registered office of the Company at any time up to and including the last business day before the day
set for the holding of the meeting at which the proxy is to be used; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at the meeting or any adjourned meeting, by the chair of the meeting or any adjourned meeting, before any vote
in respect of which the proxy has been given has been taken. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12.14</B> <B>Revocation of Proxy Must Be Signed</B><B>.</B> An
instrument referred to in Article 12.13 must be signed as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the shareholder for whom the proxy holder is appointed is an individual, the instrument must be signed by
the shareholder or the shareholder&#146;s legal personal representative or trustee in bankruptcy; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the shareholder for whom the proxy holder is appointed is a corporation, the instrument must be signed by
the corporation or by a representative appointed for the corporation under Article 12.5. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12.15</B> <B>Chair May Determine Validity
of Proxy</B><B>.</B> The chair of any meeting of shareholders may determine whether or not a proxy deposited for use at the meeting, which may not strictly comply with the requirements of this Article 12 as to form, execution, accompanying
documentation, time of filing or otherwise, shall be valid for use at the meeting, and any such determination made in good faith shall be final, conclusive and binding upon the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12.16</B> <B>Production of Evidence of Authority to Vote</B><B>.</B> The directors or the chair of any meeting of shareholders may, but need not, inquire
into the authority of any person to vote at the meeting and may, but need not, demand from that person production of evidence as to the existence of the authority to vote. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 16 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 13 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DIRECTORS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13.1</B> <B>First Directors;
Number of Directors</B><B>.</B> The first directors are the persons designated as directors of the Company in the Notice of Articles that applies to the Company when it is recognized under the <I>Business Corporations Act</I>. The number of
directors, excluding additional directors appointed under Article 14.10, is set at: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">subject to paragraphs (b)&nbsp;and (c), the number of directors that is equal to the number of the
Company&#146;s first directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the Company is a public company, a number that is no less than three (3)&nbsp;and no greater than ten (10),
and which shall be the most recently set of: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the number of directors set by the board of directors of the Company; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the number of directors set under Article 14.6; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the Company is not a public company, the most recently set of: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the number of directors set by the board of directors of the Company; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the number of directors set under Article 14.6. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13.2</B> <B>Change in Number of Directors</B><B>.</B> If the number of directors is set under Article 13.1(b)(i) or 13.1(c)(i): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the shareholders may elect the directors needed to fill any vacancies in the board of directors up to that
number at the first meeting of shareholders following the setting of that number, subject to these Articles (including Article 10.11); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the shareholders do not elect the directors needed to fill any vacancies in the board of directors up to
that number at the first meeting of shareholders following the setting of that number, then the directors may appoint directors to fill those vacancies, subject to these Articles. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13.3</B> <B>Directors</B><B>&#146;</B><B> Acts Valid Despite Vacancy</B><B>.</B> An act or proceeding of the directors is not invalid merely because fewer
than the number of directors set or otherwise required under these Articles is in office. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13.4</B> <B>Qualifications of Directors</B><B>.</B>
Notwithstanding any other provision of these Articles, a director is not required to hold a share in the capital of the Company as qualification for the director&#146;s office but must be qualified as required by the <I>Business Corporations Act</I>
to become, act or continue to act as a director. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13.5</B> <B>Remuneration of Directors</B><B>.</B> The directors are entitled to the remuneration for
acting as directors, if any, as the directors may from time to time determine. If the directors so decide, the remuneration of the directors, if any, will be determined by the shareholders. That remuneration may be in addition to any salary or other
remuneration paid to any officer or employee of the Company as such, who is also a director. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13.6</B> <B>Reimbursement of Expenses of
Directors</B><B>.</B> The Company must reimburse each director for the reasonable expenses that he or she may incur in and about the business of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13.7</B> <B>Special Remuneration for Directors</B><B>.</B> If any director performs any professional or other services for the Company that in the opinion
of the directors are outside the ordinary duties of, or not in that individual&#146;s capacity as, a director, or if any director is otherwise specially occupied in or about the Company&#146;s business, he or she may be paid remuneration fixed by
the directors, or, at the option of that director, fixed by ordinary resolution, and such remuneration may be either in addition to, or in substitution for, any other remuneration that he or she may be entitled to receive. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 17 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13.8</B> <B>Gratuity, Pension or Allowance on Retirement of Director</B><B>.</B> Unless otherwise
determined by ordinary resolution, the directors on behalf of the Company may pay a gratuity or pension or allowance on retirement to any director who has held any salaried office or place of profit with the Company or to that director&#146;s spouse
or dependants and may make contributions to any fund and pay premiums for the purchase or provision of any such gratuity, pension or allowance. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 14 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ELECTION AND
REMOVAL OF DIRECTORS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14.1</B> <B>Staggered Terms</B>. For purposes of facilitating staggered terms on the board, the following provisions shall
apply: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">one-third</FONT> of the directors (or if the number of directors is not
divisible by three, then that number of directors that is <FONT STYLE="white-space:nowrap">one-third</FONT> of the directors rounded up to the next whole number) shall initially hold office for a three-year term expiring on the third annual general
meeting of the Company following the date noted at the end of these Articles; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">one-third</FONT> of the directors (or if the number of directors is not
divisible by three, then that number of directors that is <FONT STYLE="white-space:nowrap">one-third</FONT> of the directors rounded up to the next whole number) shall initially hold office for a <FONT STYLE="white-space:nowrap">two-year</FONT> term
expiring on the second annual general meeting of the Company following the date noted at the end of these Articles; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the remaining number of directors shall initially hold office for a
<FONT STYLE="white-space:nowrap">one-year</FONT> term expiring on the first annual general meeting of the Company following the date noted at the end of these Articles, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and upon the expiry of the directors&#146; initial terms of office as set forth above, the directors shall be elected in the manner provided in Article 14.2
to hold office for three-year terms expiring on the third annual general meeting following their election. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14.2</B> <B>Election at Annual General
Meeting</B><B>.</B> At every annual general meeting and in every unanimous resolution contemplated by Article 10.2: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all of the directors whose terms expire shall cease to hold office immediately before the election or
appointment of directors under Article 14.2(b) below, but are eligible for <FONT STYLE="white-space:nowrap">re-election</FONT> or <FONT STYLE="white-space:nowrap">re-appointment;</FONT> and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the shareholders entitled to vote at the annual general meeting for the election of directors may elect, or in
the unanimous resolution appoint, the number of directors required to fill the following vacancies, such that the staggered terms are maintained as contemplated in Article 14.1: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the vacancies created by the expiry of any directors&#146; terms under these Articles, to hold office for
three-year terms expiring on the third annual general meeting following their election; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any vacancies created before the expiry of any directors&#146; terms under these Articles, which vacancies have
not already been filled as otherwise permitted in these Articles, to hold office for the remainder of the unexpired portion of the term of the departed directors whom the new directors are replacing. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14.3</B> <B>Election or Appointment between Annual General Meetings</B><B>.</B> A director may be: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">elected or appointed under Articles 14.7, 14.9, 14.12 or 14.13 to hold office until the remainder of the
unexpired portion of the term of the departed director whom the new director is replacing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">appointed under Article 14.10 for a term expiring on the first annual general meeting of the Company following
the director&#146;s appointment under Article 14.10. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For greater certainty, following the expiry of the term of any director appointed
under Articles 14.7, 14.9, 14.10, 14.12 or 14.13, that director is eligible for <FONT STYLE="white-space:nowrap">re-election</FONT> or <FONT STYLE="white-space:nowrap">re-appointment</FONT> under these Articles for a three-year term. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 18 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14.4</B> <B>Consent to be a Director</B><B>.</B> No election, appointment or designation of an individual
as a director is valid unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that individual consents to be a director in the manner provided for in the <I>Business Corporations Act</I>;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that individual is elected or appointed at a meeting at which the individual is present and the individual does
not refuse, at the meeting, to be a director; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">with respect to first directors, the designation is otherwise valid under the <I>Business Corporations Act</I>.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14.5</B> <B>Failure to Elect or Appoint Directors</B><B>.</B> If: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Company fails to hold an annual general meeting, and all the shareholders who are entitled to vote at an
annual general meeting fail to pass the unanimous resolution contemplated by Article 10.2 on or before the date by which the annual general meeting is required to be held under the <I>Business Corporations Act</I>; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the shareholders fail, at the annual general meeting or in the unanimous resolution contemplated by Article
10.2, to elect or appoint any directors; </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">then each director then in office continues to hold office until the earlier
of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the date on which that director&#146;s successor is elected or appointed; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the date on which that director otherwise ceases to hold office under Section&nbsp;128(1)(b) or (c)&nbsp;of the
<I>Business Corporations Act</I>, or under any one of Articles 14.11(b) to (d). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14.6</B> <B>Places of Retiring Directors Not
Filled</B><B>.</B> If, at any meeting of shareholders at which there should be an election of directors, the places of any of the retiring directors are not filled by that election, then those retiring directors who are not <FONT
STYLE="white-space:nowrap">re-elected</FONT> and who are asked by the newly elected directors under this Article 14.6 to continue in office will, if willing to do so, continue in office to complete the number of directors for the time being set
pursuant to these Articles until further new directors are elected at a meeting of shareholders convened for that purpose, and any such election by the shareholders shall be for the remainder of the three-year term that would have commenced at the
meeting of shareholders at which the places of such directors were not filled. If any such election or continuance of directors does not result in the election or continuance of the number of directors for the time being set pursuant to these
Articles, then the number of directors of the Company is deemed to be set at the number of directors actually elected or continued in office. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14.7</B>
<B>Directors May Fill Casual Vacancies</B><B>.</B> Any casual vacancy occurring in the board of directors may be filled by the remaining directors, subject to these Articles (including Article 14.3). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14.8</B> <B>Remaining Directors Power to Act</B><B>.</B> The directors may act notwithstanding any vacancy in the board of directors, but if the Company
has fewer directors in office than the number set pursuant to these Articles as the quorum of directors, then the directors may only act for the purpose of appointing directors up to that number or of summoning a meeting of shareholders for the
purpose of filling any vacancies on the board of directors or, subject to the <I>Business Corporations Act</I>, for any other purpose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14.9</B>
<B>Shareholders May Fill Vacancies</B><B>.</B> If the Company has no directors or fewer directors in office than the number set pursuant to these Articles as the quorum of directors, then the shareholders may elect or appoint directors to fill any
vacancies on the board of directors, subject to these Articles (including Articles 10.11 and 14.3). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14.10</B> <B>Additional Directors</B><B>.</B>
Notwithstanding Articles 13.1 and 13.2, between annual general meetings or unanimous resolutions contemplated by Article 10.2, the directors may appoint one or more additional directors subject to these Articles, but the number of additional
directors appointed under this Article 14.10 must not at any time exceed: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">one-third</FONT> of the number of first directors, if, at the time of the
appointments, one or more of the first directors have not yet completed their first term of office; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 19 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in any other case, <FONT STYLE="white-space:nowrap">one-third</FONT> of the number of the current directors who
were elected or appointed as directors other than under this Article 14.10. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as provided otherwise under these Articles or the
<I>Business Corporations </I>Act, any director so appointed shall cease to hold office at the end of a term expiring on the first annual general meeting of the Company following the director&#146;s appointment but is eligible for <FONT
STYLE="white-space:nowrap">re-election</FONT> or <FONT STYLE="white-space:nowrap">re-appointment</FONT> for a subsequent three-year term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14.11</B>
<B>Ceasing to be a Director</B><B>.</B> A director ceases to be a director when: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the term of office of the director expires; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the director dies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the director resigns as a director by notice in writing provided to the Company or a lawyer for the Company; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the director is removed from office pursuant to Articles 14.12 or 14.13. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14.12</B> <B>Removal of Director by Shareholders</B><B>.</B> The Company may remove any director before the expiration of that director&#146;s term of
office by special resolution. In that event, the shareholders may elect, or appoint by ordinary resolution passed at a meeting of shareholders, a director to fill the resulting vacancy, subject to these Articles (including Articles 10.11 and 14.3).
If the shareholders do not elect or appoint a director to fill the resulting vacancy contemporaneously with the removal, then the directors may appoint a director to fill that vacancy, subject to these Articles (including Article 14.3). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14.13</B> <B>Removal of Director by Directors</B><B>.</B> The directors may remove any director before the expiration of his or that director&#146;s term
of office if the director is convicted of an indictable offence, or if the director ceases to be qualified to act as a director of a company and does not promptly resign, and the directors may appoint a director to fill the resulting vacancy,
subject to these Articles (including Article 14.3). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 15 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>POWERS AND DUTIES OF DIRECTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15.1</B> <B>Powers of Management</B><B>.</B> The directors must, subject to the <I>Business Corporations Act</I> and these Articles, manage or supervise
the management of the business and affairs of the Company and have the authority to exercise all such powers of the Company as are not, by the <I>Business Corporations Act</I> or by these Articles, required to be exercised by the shareholders of the
Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15.2</B> <B>Appointment of Attorney of Company</B><B>.</B> The directors may from time to time, by power of attorney or other instrument,
under seal if so required by law, appoint any person to be the attorney of the Company for such purposes, and with such powers, authorities and discretions (not exceeding those vested in or exercisable by the directors under these Articles and
excepting the power to fill vacancies in the board of directors, to remove a director, to change the membership of, or fill vacancies in, any committee of the directors, to appoint or remove officers appointed by the directors and to declare
dividends) and for such period, and with such remuneration and subject to such conditions as the directors may think fit. Any such power of attorney may contain such provisions for the protection or convenience of persons dealing with such attorney
as the directors think fit. Any such attorney may be authorized by the directors to <FONT STYLE="white-space:nowrap">sub-delegate</FONT> all or any of the powers, authorities and discretions for the time being vested in such attorney. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 16 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DISCLOSURE
OF INTEREST OF DIRECTORS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16.1</B> <B>Obligation to Account for Profits</B><B>.</B> A director or senior officer who holds a disclosable interest
(as that term is used in the <I>Business Corporations Act</I>) in a contract or transaction into which the Company has entered or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 20 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
proposes to enter is liable to account to the Company for any profit that accrues to the director or senior officer under or as a result of the contract or transaction only if and to the extent
provided in the <I>Business Corporations Act</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16.2</B> <B>Restrictions on Voting by Reason of Interest</B><B>.</B> A director who holds a
disclosable interest in a contract or transaction into which the Company has entered or proposes to enter is not entitled to vote on any directors&#146; resolution to approve that contract or transaction, unless all the directors have a disclosable
interest in that contract or transaction, in which case any or all of those directors may vote on such resolution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16.3</B> <B>Interested Director
Counted in Quorum</B><B>.</B> A director who holds a disclosable interest in a contract or transaction into which the Company has entered or proposes to enter and who is present at the meeting of directors at which the contract or transaction is
considered for approval may be counted in the quorum at the meeting whether or not the director votes on any or all of the resolutions considered at the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16.4</B> <B>Disclosure of Conflict of Interest or Property</B><B>.</B> A director or senior officer who holds any office or possesses any property, right
or interest that could result, directly or indirectly, in the creation of a duty or interest that materially conflicts with that individual&#146;s duty or interest as a director or senior officer, must disclose the nature and extent of the conflict
as required by the <I>Business Corporations Act.</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16.5</B> <B>Director Holding Other Office in the Company</B><B>.</B> A director may hold any
office or place of profit with the Company, other than the office of auditor of the Company, in addition to their office of director for the period and on the terms (as to remuneration or otherwise) that the directors may determine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16.6</B> <B>No Disqualification</B><B>.</B> No director or intended director is disqualified by that director&#146;s or intended director&#146;s office
from contracting with the Company either with regard to the holding of any office or place of profit the director holds with the Company or as vendor, purchaser or otherwise, and no contract or transaction entered into by or on behalf of the Company
in which a director is in any way interested is liable to be voided for that reason. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16.7</B> <B>Professional Services by Director or
Officer</B><B>.</B> Subject to the <I>Business Corporations Act</I>, a director or officer, or any person in which a director or officer has an interest, may act in a professional capacity for the Company, except as auditor of the Company, and the
director or officer or such person is entitled to remuneration for professional services as if that director or officer were not a director or officer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16.8</B> <B>Director or Officer in Other Corporations</B><B>.</B> A director or officer may be or become a director, officer or employee of, or otherwise
interested in, any person in which the Company may be interested as a shareholder or otherwise, and, subject to the <I>Business Corporations Act</I>, the director or officer is not accountable to the Company for any remuneration or other benefits
received by that individual as director, officer or employee of, or from that individual&#146;s interest in, such other person. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE
17 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROCEEDINGS OF DIRECTORS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17.1</B> <B>Meetings of Directors</B><B>.</B> The directors may meet together for the conduct of business, adjourn and otherwise regulate their meetings as
they think fit, and meetings of the directors held at regular intervals may be held at the place, at the time and on the notice, if any, as the directors may from time to time determine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17.2</B> <B>Voting at Meetings</B><B>.</B> Questions arising at any meeting of directors are to be decided by a majority of votes and, in the case of an
equality of votes, the chair of the meeting does not have a second or casting vote. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17.3</B> <B>Chair of Meetings</B><B>.</B> The following individual
is entitled to preside as chair at a meeting of directors: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the chair of the board, if any; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 21 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the absence of the chair of the board, the president, if any, if the president is a director; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any other director chosen by the directors if: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">neither the chair of the board nor the president, if a director, is present at the meeting within 15 minutes
after the time set for holding the meeting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">neither the chair of the board nor the president, if a director, is willing to chair the meeting; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the chair of the board and the president, if a director, have advised the secretary, if any, or any other
director, that they will not be present at the meeting. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17.4</B> <B>Meetings by Telephone or Other Communications Medium</B><B>.</B>
A director may participate in a meeting of the directors or of any committee of the directors in person or by telephone if all directors participating in the meeting, whether in person or by telephone or other communications medium, are able to
communicate with each other. A director may participate in a meeting of the directors or of any committee of the directors by a communications medium other than telephone if all directors participating in the meeting, whether in person or by
telephone or other communications medium, are able to communicate with each other and if all directors who wish to participate in the meeting agree to such participation. A director who participates in a meeting in a manner contemplated by this
Article 17.4 is deemed for all purposes of the <I>Business Corporations Act</I> and these Articles to be present at the meeting and to have agreed to participate in that manner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17.5</B> <B>Calling of Meetings</B><B>.</B> A director may, and the corporate secretary or an assistant corporate secretary of the Company, if any, on the
request of a director must, call a meeting of the directors at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17.6</B> <B>Notice of Meetings</B><B>.</B> Other than for meetings held at
regular intervals as determined by the directors pursuant to Article 17.1, reasonable notice of each meeting of the directors, specifying the place, day and time of that meeting must be given to each of the directors by any method set out in Article
23.1 or orally or by telephone. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17.7</B> <B>When Notice Not Required</B><B>.</B> It is not necessary to give notice of a meeting of the directors to a
director if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the meeting is to be held immediately following a meeting of shareholders at which that director was elected or
appointed, or is the meeting of the directors at which that director is appointed; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the director has waived notice of the meeting. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17.8</B> <B>Meeting Valid Despite Failure to Give Notice</B><B>.</B> The accidental omission to give notice of any meeting of directors to, or the <FONT
STYLE="white-space:nowrap">non-receipt</FONT> of any notice by, any director does not invalidate any proceedings at that meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17.9</B> <B>Waiver
of Notice of Meetings</B><B>.</B> Any director may send to the Company a document signed by that director waiving notice of any past, present or future meeting or meetings of the directors and may at any time withdraw that waiver with respect to
meetings held after that withdrawal. After sending a waiver with respect to all future meetings and until that waiver is withdrawn, no notice of any meeting of the directors need be given to such director and all meetings of the directors so held
are deemed not to be improperly called or constituted by reason of notice not having been given to such director. Attendance of a director at a meeting of the directors is a waiver of notice of the meeting, unless that director attends the meeting
for the express purpose of objecting to the transaction of any business on the grounds that the meeting is not lawfully called. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17.10</B>
<B>Quorum</B><B>.</B> The quorum necessary for the transaction of the business of the directors is a majority of the number of directors in office or such greater number as the directors may by resolution determine from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17.11</B> <B>Validity of Acts Where Appointment Defective</B><B>.</B> Subject to the <I>Business Corporations Act</I>, an act of a director or officer is
not invalid merely because of an irregularity in the election or appointment or a defect in the qualification of that director or officer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 22 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17.12</B> <B>Consent Resolutions in Writing</B><B>.</B> A resolution of the directors or of any committee
of the directors consented to in writing by all of the directors entitled to vote on it, whether by signed document (which may include an electronic signature, as permitted by the <I>Electronic Transactions Act</I> (British Columbia)), fax, email or
any other method of transmitting legibly recorded messages, is as valid and effective as if it had been passed at a meeting of the directors or of the committee of the directors duly called and held. Such resolution may be in two or more
counterparts which together are deemed to constitute one resolution in writing. A resolution passed in that manner is effective on the date stated in the resolution or on the latest date stated on any counterpart. A resolution of the directors or of
any committee of the directors passed in accordance with this Article 17.12 is deemed to be a proceeding at a meeting of directors or of the committee of the directors and to be as valid and effective as if it had been passed at a meeting of the
directors or of the committee of the directors that satisfies all the requirements of the <I>Business Corporations Act</I> and all the requirements of these Articles relating to meetings of the directors or of a committee of the directors. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 18 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXECUTIVE
AND OTHER COMMITTEES </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18.1</B> <B>Appointment and Powers of Executive Committee</B><B>.</B> The directors may, by resolution, appoint an executive
committee consisting of the director or directors that they consider appropriate, and this committee has, during the intervals between meetings of the board of directors, all of the directors&#146; powers, except: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the power to fill vacancies in the board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the power to remove a director; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the power to change the membership of, or fill vacancies in, any committee of the directors; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">such other powers, if any, as may be set out in the resolution or any subsequent directors&#146; resolution.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18.2</B> <B>Appointment and Powers of Other Committees</B><B>.</B> The directors may, by resolution: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">appoint one or more committees (other than the executive committee) consisting of the director or directors
that they consider appropriate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">delegate to a committee appointed under paragraph (a)&nbsp;any of the directors&#146; powers, except:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the power to fill vacancies in the board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the power to remove a director; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the power to change the membership of, or fill vacancies in, any committee of the directors; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the power to appoint or remove officers appointed by the directors; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">make any delegation referred to in paragraph (b)&nbsp;subject to the conditions set out in the resolution or
any subsequent directors&#146; resolution. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18.3</B> <B>Obligations of Committees</B><B>.</B> Any committee appointed under Articles
18.1 or 18.2, in the exercise of the powers delegated to it, must: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">conform to any rules that may from time to time be imposed on it by the directors; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">report every act or thing done in exercise of those powers at such times as the directors may require.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18.4</B> <B>Powers of Board</B><B>.</B> The directors may, at any time, with respect to a committee appointed under Articles 18.1 or
18.2: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">revoke or alter the authority given to the committee, or override a decision made by the committee, except as
to acts done before such revocation, alteration or overriding; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 23 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">terminate the appointment of, or change the membership of, the committee; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">fill vacancies in the committee. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18.5</B> <B>Committee Meetings</B><B>.</B> Subject to Article 18.3(a) and unless the directors otherwise provide in the resolution appointing the committee
or in any subsequent resolution, with respect to a committee appointed under Articles 18.1 or 18.2: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the committee may meet and adjourn as it thinks proper; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the committee may elect a chair of its meetings but, if no chair of a meeting is elected, or if at a meeting
the chair of the meeting is not present within 15 minutes after the time set for holding the meeting, the directors present who are members of the committee may choose one of their number to chair the meeting; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a majority of the members of the committee constitutes a quorum of the committee; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">questions arising at any meeting of the committee are determined by a majority of votes of the members present,
and in case of an equality of votes, the chair of the meeting does not have a second or casting vote. </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 19
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OFFICERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>19.1</B>
<B>Directors May Appoint Officers</B><B>.</B> The directors may, from time to time, appoint such officers, if any, as the directors determine and the directors may, at any time, terminate any such appointment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>19.2</B> <B>Functions, Duties and Powers of Officers</B><B>.</B> The directors may, for each officer: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">determine the functions and duties of the officer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">entrust to and confer on the officer any of the powers exercisable by the directors on such terms and
conditions and with such restrictions as the directors think fit; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">revoke, withdraw, alter or vary all or any of the functions, duties and powers of the officer.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>19.3</B> <B>Qualifications</B><B>.</B> No officer may be appointed unless that officer is qualified in accordance with the
<I>Business Corporations Act</I>. One person may hold more than one position as an officer of the Company. Any person appointed as the chair of the board or as the managing director must be a director. Any other officer need not be a director. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>19.4</B> <B>Remuneration and Terms of Appointment</B><B>.</B> All appointments of officers are to be made on the terms and conditions and at the
remuneration (whether by way of salary, fee, commission, participation in profits or otherwise) that the directors think fit and are subject to termination at the pleasure of the directors, and an officer may in addition to such remuneration be
entitled to receive, after he or she ceases to hold such office or leaves the employment of the Company, a pension or gratuity. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE
20 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEMNIFICATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>20.1</B>
<B>Definitions</B><B>.</B> In this Article 20: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>eligible party</B>&#148;, in relation to a Company, means an individual who: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is or was a director or officer of the Company, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 24 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is or was a director or officer of another corporation (A)&nbsp;at a time when the corporation is or was an
affiliate of the Company, or (B)&nbsp;at the request of the Company, or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at the request of the Company, is or was, or holds or held a position equivalent to that of, a director of
officer of a partnership, trust, joint venture or other unincorporated entity, </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">and includes, to the extent permitted by
the Act, the heirs and personal or other legal representatives of that individual; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>eligible penalty</B>&#148; means a judgment, penalty or fine awarded or imposed in, or an amount paid
in settlement of, an eligible proceeding; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>eligible proceeding</B>&#148; means a proceeding in which an eligible party or any of the heirs and
personal or other legal representatives of the eligible party, by reason of the eligible party being or having been a director or officer of, or holding or having held a position equivalent to that of a director or officer of, the Company or an
associated corporation: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is or may be joined as a party; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is or may be liable for or in respect of a judgment, penalty or fine in, or expenses related to, the
proceeding; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>expenses</B>&#148; has the meaning set out in the <I>Business Corporations Act</I>.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>20.2</B> <B>Mandatory Indemnification of Eligible Parties</B><B>.</B> Subject to the <I>Business Corporations Act</I>, the Company
must indemnify an eligible party against all eligible penalties to which such person is or may be liable, and the Company must, after the final disposition of an eligible proceeding, pay the expenses actually and reasonably incurred by such person
in respect of that proceeding. Each director is deemed to have contracted with the Company on the terms of the indemnity contained in this Article 20.2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>20.3</B> <B>Indemnification of Other Persons</B><B>.</B> Subject to any restrictions in the <I>Business Corporations Act</I>, the Company may indemnify any
person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>20.4</B> <B><FONT STYLE="white-space:nowrap">Non-Compliance</FONT> with </B><B><I>Business Corporations Act</I></B><B>.</B> The failure of a
director or officer of the Company to comply with the <I>Business Corporations Act</I> or these Articles does not invalidate any indemnity to which he or she is entitled under this Article 20. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>20.5</B> <B>Company May Purchase Insurance</B><B>.</B> The Company may purchase and maintain insurance for the benefit of any person (or that person&#146;s
heirs or legal personal representatives) who: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is or was a director, officer, employee or agent of the Company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is or was a director, officer, employee or agent of a corporation at a time when the corporation is or was an
affiliate of the Company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at the request of the Company, is or was a director, officer, employee or agent of a corporation or of a
partnership, trust, joint venture or other unincorporated entity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at the request of the Company, holds or held a position equivalent to that of a director or officer of a
partnership, trust, joint venture or other unincorporated entity; </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">against any liability incurred by that person as such director,
officer, employee or agent or person who holds or held such equivalent position. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 21 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DIVIDENDS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21.1</B> <B>Payment of
Dividends Subject to Special Rights</B><B>.</B> The provisions of this Article 21 are subject to the rights, if any, of shareholders holding shares with special rights as to dividends. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 25 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21.2</B> <B>Declaration of Dividends</B><B>.</B> Subject to the <I>Business Corporations Act</I> and the
rights of the holders of issued shares of the Company, the directors may from time to time declare and authorize payment of such dividends as they consider appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21.3</B> <B>No Notice Required</B><B>.</B> The directors need not give notice to any shareholder of any declaration under Article&nbsp;21.2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21.4</B> <B>Record Date</B><B>.</B> The directors may set a date as the record date for the purpose of determining shareholders entitled to receive payment
of a dividend. The record date must not precede the date on which the dividend is to be paid by more than two months. If no record date is set, the record date is 5 p.m. on the date on which the directors pass the resolution declaring the dividend.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21.5</B> <B>Manner of Paying Dividend</B><B>.</B> A resolution declaring a dividend may direct payment of the dividend wholly or partly in money or by
the distribution of specific assets or of fully paid shares or of bonds, debentures or other securities of the Company or any other corporation, or in any one or more of those ways. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21.6</B> <B>Settlement of Difficulties</B><B>.</B> If any difficulty arises in regard to a distribution under Article 21.5, the directors may settle the
difficulty as they deem advisable, and, in particular, may: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">set the value for distribution of specific assets; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">determine that cash payments in substitution for all or any part of the specific assets to which any
shareholders are entitled may be made to any shareholders on the basis of the value so fixed in order to adjust the rights of all parties; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">vest any such specific assets in trustees for the persons entitled to the dividend. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21.7</B> <B>When Dividend Payable</B><B>.</B> Any dividend may be made payable on such date as is fixed by the directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21.8</B> <B>Dividends to be Paid in Accordance with Number of Shares</B><B>.</B> All dividends on shares of any class or series of shares must be declared
and paid according to the number of such shares held. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21.9</B> <B>Receipt by Joint Shareholders</B><B>.</B> If several persons are joint shareholders
of any share, any one of them may give an effective receipt for any dividend, bonus or other money payable in respect of the share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21.10</B>
<B>Dividend Bears No Interest</B><B>.</B> No dividend bears interest against the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21.11</B> <B>Fractional Dividends</B><B>.</B> If a dividend
to which a shareholder is entitled includes a fraction of the smallest monetary unit of the currency of the dividend, that fraction may be disregarded in making payment of the dividend and that payment represents full payment of the dividend. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21.12</B> <B>Payment of Dividends</B><B>.</B> Any dividend or other distribution payable in money in respect of shares may be paid by cheque or by
electronic means or by such other method as the directors may determine. The payment will be made to or to the order of each registered shareholder in respect of which the payment is to be made. Cheques will be sent to the registered address of the
shareholder, unless the shareholder otherwise directs. In the case of joint shareholders, the payment will be made to the order of all such joint shareholders and, if applicable, sent to them at the registered address of the joint shareholder who is
first named on the central securities register, unless such joint shareholders otherwise direct. The sending of the cheque or the sending of the payment by electronic means or the sending of the payment by a method determined by the directors in an
amount equal to the dividend or other distribution to be paid less any tax that the Company is required to withhold will satisfy and discharge the liability for the payment, unless payment is not made upon presentation, if applicable, or the amount
of tax so deducted is not paid to the appropriate taxing authority. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 26 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21.13</B> <B>Capitalization of Surplus</B><B>.</B> Notwithstanding anything contained in these Articles,
the directors may from time to time capitalize any surplus of the Company and may from time to time issue, as fully paid, shares or any bonds, debentures or other securities of the Company as a dividend representing the surplus or any part of the
surplus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21.14</B> <B>Unclaimed Dividends</B><B>.</B> Any dividend unclaimed after a period of three years from the date on which the same has been
declared to be payable shall be forfeited and shall revert to the Company. The Company shall not be liable to any person in respect of any dividend which is forfeited to the Company or delivered to any public official pursuant to any applicable
abandoned property, escheat or similar law. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 22 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DOCUMENTS, RECORDS AND REPORTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>22.1</B> <B>Recording of Financial Affairs</B><B>.</B> The directors must cause adequate accounting records to be kept to record properly the financial
affairs and condition of the Company and to comply with the <I>Business Corporations Act</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>22.2</B> <B>Inspection of Accounting Records</B><B>.</B>
Unless the directors determine otherwise, or unless otherwise determined by ordinary resolution, no shareholder of the Company is entitled to inspect or obtain a copy of any accounting records of the Company. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 23 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICES
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>23.1</B> <B>Method of Giving Notice</B><B>.</B> Unless the <I>Business Corporations Act</I> or these Articles provide otherwise, a notice,
statement, report or other record required or permitted by the <I>Business Corporations Act</I> or these Articles to be sent by or to a person may be sent by any one of the following methods: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">mail addressed to the person at the applicable address for that person as follows: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">for a record mailed to a shareholder, the shareholder&#146;s registered address; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">for a record mailed to a director or officer, the prescribed address for mailing shown for the director or
officer in the records kept by the Company or the mailing address provided by the recipient for the sending of that record or records of that class; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in any other case, the mailing address of the intended recipient; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">delivery at the applicable address for that person as follows, addressed to the person: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">for a record delivered to a shareholder, the shareholder&#146;s registered address; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">for a record delivered to a director or officer, the prescribed address for delivery shown for the director or
officer in the records kept by the Company or the delivery address provided by the recipient for the sending of that record or records of that class; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in any other case, the delivery address of the intended recipient; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">sending the record by fax to the fax number provided by the intended recipient for the sending of that record
or records of that class; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">sending the record by email to the email address provided by the intended recipient for the sending of that
record or records of that class; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">physical delivery to the intended recipient; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 27 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">creating and providing a record posted on or made available through a generally-accessible electronic source
and providing written notice by any of the foregoing methods of the availability of such record; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as otherwise permitted by Applicable Securities Laws. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>23.2</B> <B>Deemed Receipt</B><B>.</B> A notice, statement, report or other record that is: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">mailed to a person by ordinary mail to the applicable address for that person referred to in Article 23.1 is
deemed to be received by the person to whom it was mailed on the day, Saturdays, Sundays and holidays excepted, following the date of mailing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">faxed to a person to the fax number provided by that person referred to in Article 23.1 is deemed to be
received by the person to whom it was faxed on the day it was faxed; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">e-mailed</FONT> to a person to the
<FONT STYLE="white-space:nowrap">e-mail</FONT> address provided by that person referred to in Article 23.1 is deemed to be received by the person to whom it was <FONT STYLE="white-space:nowrap">e-mailed</FONT> on the day it was <FONT
STYLE="white-space:nowrap">e-mailed;</FONT> and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">delivered in accordance with Article 23.1(f), is deemed to be received by the person on the day such written
notice is sent. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>23.3</B> <B>Certificate of Sending</B><B>.</B> A certificate signed by the corporate secretary, if any, or other
officer of the Company or of any other corporation acting in that capacity on behalf of the Company stating that a notice, statement, report or other record was sent in accordance with Article 23.1 is conclusive evidence of that fact. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>23.4</B> <B>Notice to Joint Shareholders</B><B>.</B> A notice, statement, report or other record may be provided by the Company to the joint shareholders
of a share by providing such record to the joint shareholder first named in the central securities register in respect of the share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>23.5</B>
<B>Notice to Legal Personal Representatives and Trustees</B><B>.</B> A notice, statement, report or other record may be provided by the Company to the persons entitled to a share in consequence of the death, bankruptcy or incapacity of a shareholder
by: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">mailing the record, addressed to them: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by name, by the title of the legal personal representative of the deceased or incapacitated shareholder, by the
title of trustee of the bankrupt shareholder or by any similar description; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at the address, if any, supplied to the Company for that purpose by the persons claiming to be so entitled; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if an address referred to in paragraph (a)(ii) has not been supplied to the Company, by giving the notice in a
manner in which it might have been given if the death, bankruptcy or incapacity had not occurred. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>23.6</B> <B>Undelivered
Notices</B><B>.</B> If, on two consecutive occasions, a notice, statement, report or other record is sent to a shareholder pursuant to Article 23.1 and on each of those occasions any such record is returned because the shareholder cannot be located,
then, subject to the <I>Business Corporations Act</I>, the Company shall not be required to send any further records to the shareholder until the shareholder informs the Company in writing of that shareholder&#146;s new address. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 24 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEAL AND
EXECUTION OF DOCUMENTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>24.1</B> <B>Who May Attest Seal</B><B>.</B> Except as provided in Articles 24.2 and 24.3, the Company&#146;s seal, if any,
must not be impressed on any record except when that impression is attested by the signatures of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any two directors; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 28 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any officer, together with any director; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the Company only has one director, that director; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any one or more directors or officers or persons as may be determined by the directors. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>24.2</B> <B>Sealing Copies</B><B>.</B> For the purpose of certifying under seal a certificate of incumbency of the directors or officers of the Company or
a true copy of any resolution or other document, despite Article 24.1, the impression of the seal may be attested by the signature of any director or officer or the signature of any other person as may be determined by the directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>24.3</B> <B>Mechanical Reproduction of Seal</B><B>.</B> The directors may authorize the seal to be impressed by third parties on share certificates or
bonds, debentures or other securities of the Company as they may determine appropriate from time to time. To enable the seal to be impressed on any share certificates or bonds, debentures or other securities of the Company, whether in definitive or
interim form, on which facsimiles of any of the signatures of the directors or officers of the Company are, in accordance with the <I>Business Corporations Act</I> or these Articles, printed or otherwise mechanically reproduced, there may be
delivered to the person employed to engrave, lithograph or print such definitive or interim share certificates or bonds, debentures or other securities one or more unmounted dies reproducing the seal and such persons as are authorized to attest the
Company&#146;s seal may in writing authorize such person to cause the seal to be impressed on such definitive or interim share certificates or bonds, debentures or other securities by the use of such dies. Share certificates or bonds, debentures or
other securities to which the seal has been so impressed are for all purposes deemed to be under and to bear the seal impressed on them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>24.4</B>
<B>Execution of Documents Generally</B><B>.</B> The directors may from time to time by resolution appoint any one or more persons, officers or directors for the purpose of executing any instrument, document or agreement in the name of and on behalf
of the Company for which the seal need not be affixed, and if no such person, officer or director is appointed, then any one officer or director of the Company may execute such instrument, document or agreement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 25 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROHIBITIONS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>25.1</B> <B>Definitions</B><B>.</B> In this Article 25: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>designated security</B>&#148; means: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a voting security of the Company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a security of the Company that is not a debt security and that carries a residual right to participate in the
earnings of the Company or, on the liquidation or winding up of the Company, in its assets; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a security of the Company convertible, directly or indirectly, into a security described in paragraph
(i)&nbsp;or (ii); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>security</B>&#148; has the meaning assigned in the <I>Securities Act</I>; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>voting security</B>&#148; means a security of the Company that: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is not a debt security, and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">carries a voting right either under all circumstances or under some circumstances that have occurred and are
continuing. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>25.2</B> <B>Application</B><B>.</B> Article 25.3 does not apply to the Company if and for so long as it is a public
company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 29 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>25.3</B> <B>Consent Required for Transfer of Shares or Designated Securities</B><B>.</B> No share or
designated security may be sold, transferred or otherwise disposed of without the consent of the directors and the directors are not required to give any reason for refusing to consent to any such sale, transfer or other disposition. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 26 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORUM
SELECTION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>26.1</B> <B>Forum for Adjudication of Certain Disputes</B><B>.</B> Unless the Company consents in writing to the selection of an
alternative forum, the Supreme Court of British Columbia, Canada and the appellate Courts therefrom, shall, to the fullest extent permitted by law, be the sole and exclusive forum for (i)&nbsp;any derivative action or proceeding brought on behalf of
the Company; (ii)&nbsp;any action or proceeding asserting a claim of breach of a fiduciary duty owed by any director, officer, or other employee of the Company to the Company; (iii)&nbsp;any action or proceeding asserting a claim arising pursuant to
any provision of the <I>Business Corporations Act </I>or these Articles (as either may be amended from time to time); or (iv)&nbsp;any action or proceeding asserting a claim otherwise related to the affairs of the Company. Unless the Company
consents in writing to the selection of an alternative forum, and without limiting the generality of the foregoing sentence, the United States District Court for the District of Delaware shall be the sole and exclusive forum for resolving any
complaint filed in the United States asserting a cause of action arising under the <I>Securities Act of 1933</I>, as amended and the <I>Securities Exchange Act of 1934</I>, as amended. If any action or proceeding, the subject matter of which is
within the scope of the preceding sentence, is filed other than with the designated court (a &#147;<B>Foreign Action</B>&#148;) in the name of any securityholder, such securityholder shall be deemed to have consented to (x)&nbsp;the personal
jurisdiction of the Supreme Court of British Columbia, Canada or the United States District Court for the District of Delaware, as the case may be, in connection with any action or proceeding brought in any such court to enforce the preceding
sentence, and (y)&nbsp;having service of process made upon such securityholder in any such action or proceeding by service upon such securityholder&#146;s counsel in the Foreign Action as agent for such securityholder. Any person or entity
purchasing or otherwise acquiring any interest in common shares in the capital of the Company shall be deemed to have notice of and consented to the provisions of this Section&nbsp;26.1. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 27 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPECIAL
RIGHTS AND RESTRICTIONS ATTACHED TO COMMON SHARES </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>27.1</B> The Common Shares without par value (the &#147;<B>Common Shares</B>&#148;) have attached
to them the special rights and restrictions set out in this Article 27. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Dividends </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>27.2</B> Except as otherwise provided in these Articles, each holder of a Common Share is entitled, as such, to receive, on the date fixed for payment
thereof, and the Company will pay thereon, such dividends as the directors may in their sole and absolute discretion declare from time to time out of the money or other property of the Company properly applicable to the payment of dividends. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>27.3</B> No holder of a Common Share will be entitled, as such, to any dividend other than or in excess of the dividends, if any, declared pursuant to
Article 27.2. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>27.4</B> The directors may, in their sole and absolute discretion, declare and pay or set apart for payment dividends on the Common
Shares independently of any dividend on, and without also declaring or paying or setting apart for payment any dividend (whether or not of a similar amount) on, any one or more other classes of shares in the Company and may, in their sole and
absolute discretion, declare and pay or set apart for payment dividends on shares of any one or more classes of shares in the Company other than the Common Shares independently of any dividend on, and without also declaring or paying or setting
apart for payment any dividend (whether or not of a similar amount) on, the Common Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 30 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Winding Up </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>27.5</B> In the event of the liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up</FONT> of the Company or other distribution of property
or assets of the Company among its shareholders for the purpose of winding up its affairs, no amount will be paid and no property or asset of the Company will be distributed to the holders of the Common Shares, as such, until the holders of any
other class or series of shares entitled to receive assets of the Company upon such a distribution in priority to the holders of the Common Shares, as such, have first received from the property and assets of the Company the amount to which they are
entitled pursuant to these Articles, but thereafter, the holders of the Common Shares will be entitled to all remaining property and assets of the Company on a share for share basis. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Votes </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>27.6</B> Each holder of a Common Share,
as such, is entitled to receive notice of and to attend and vote in person or by proxy at all meetings of the shareholders of the Company and is entitled to one vote for each such share held. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 28 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPECIAL
RIGHTS AND RESTRICTIONS ATTACHED TO THE PREFERRED SHARES </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Preferred Shares </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>28.1</B> The special rights or restrictions attached to the Preferred Shares without par value (the &#147;<B>Preferred Shares</B>&#148;) shall be as
follows: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Issuable in Series </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>28.2</B> The
Preferred Shares may at any time and from time to time be issued in one or more series. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>28.3</B> Subject to Article 9.4 and the <I>Business
Corporations Act</I>, the board may from time to time, by directors&#146; resolution, if none of the Preferred Shares of any particular series are issued, alter these Articles and authorize the alteration of the Notice of Articles of the Company, as
the case may be, to do one or more of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">determine the maximum number of shares of any of those series of Preferred Shares that the Company is
authorized to issue, determine that there is no such maximum number, or alter any determination made under this paragraph (a)&nbsp;or otherwise in relation to a maximum number of those shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">create an identifying name by which the shares of any of those series of Preferred Shares may be identified, or
alter any identifying name created for those shares; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">attach special rights or restrictions to the shares of any of those series of Preferred Shares or alter any
special rights or restrictions attached to those shares, including, but without limiting or restricting the generality of the foregoing, special rights or restrictions with respect to: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the rate, amount, method of calculation and payment of any dividends, whether cumulative, partly cumulative or <FONT
STYLE="white-space:nowrap">non-cumulative,</FONT> and whether such rate, amount, method of calculation or payment is subject to change or adjustment in the future; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any rights upon a dissolution, liquidation or <FONT STYLE="white-space:nowrap">winding-up</FONT> of the Company
or upon any other return of capital or distribution of the assets of the Company among its shareholders for the purpose of winding up its affairs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any rights of redemption, retraction or purchase for cancellation and the prices and terms and conditions of
any such rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any rights of conversion, exchange or reclassification and the terms and conditions of any such rights;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any voting rights and restrictions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the terms and conditions of any share purchase plan or sinking fund; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 31 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any other special rights or restrictions, not inconsistent with these share provisions, attaching to such
series of Preferred Shares. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>28.4</B> No special rights or restrictions attached to any series of Preferred Shares will confer upon
the shares of that series a priority over the shares of any other series of Preferred Shares in respect of dividends or a return of capital in the event of the dissolution of the Company or on the occurrence of any other event that entitles the
shareholders holding the shares of all series of the Preferred Shares to a return of capital. The Preferred Shares of each series will, with respect to the payment of dividends and the distribution of assets or return of capital in the event of
dissolution or on the occurrence of any other event that entitles the shareholders holding the shares of all series of the Preferred Shares to a return of capital, rank on a parity with the shares of every other series. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Class&nbsp;Rights or Restrictions </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>28.5</B>
Holders of Preferred Shares will be entitled to preference with respect to payment of dividends over the Common Shares and any other shares ranking junior to the Preferred Shares with respect to payment of dividends. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>28.6</B> In the event of the liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up</FONT> of the Company, whether voluntary or
involuntary, or any other distribution of the assets of the Company among its shareholders for the purpose of winding up its affairs, the holders of the Preferred Shares will be entitled to preference over the Common Shares and any other shares
ranking junior to the Preferred Shares with respect to the repayment of capital paid up on and the payment of unpaid dividends accrued on the Preferred Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>28.7</B> The Preferred Shares may also be given such other preferences over the Common Shares and any other shares ranking junior to the Preferred Shares
as may be fixed by directors&#146; resolution as to the respective series authorized to be issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DATED _______________________, 2023. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">SIGNATURE OF A DIRECTOR OF THE COMPANY</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 32 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit G </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form of Newco Equity Incentive Plan </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B><I>Final Form</I></B><B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>FORM OF </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE
HOLDINGS INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2023 INCENTIVE EQUITY PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective as of the Effective Date (as defined below), the enGene Holdings Inc. 2023 Incentive Equity Plan (as in effect from time to time,
the &#147;<U>Plan</U>&#148;) is hereby established. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of the Plan is to provide employees, certain consultants and advisors,
and the <FONT STYLE="white-space:nowrap">non-employee</FONT> members of the Board of Directors, of enGene Holdings Inc., a company organized under the laws of Canada that that intends to continue as a company governed by the <I>Business Corporations
Act</I> (British Columbia) (together with its successors, the &#147;<U>Company</U>&#148;), and its subsidiaries, with the opportunity to receive grants of incentive stock options, nonqualified stock options, stock appreciation rights, share awards,
share units, and other share-based awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company believes that the Plan will encourage the participants to contribute materially to
the growth of the Company, thereby benefitting the Company&#146;s shareholders, and will align the economic interests of the participants with those of the shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the consummation of the transactions contemplated under the Business Combination Agreement, (i)&nbsp;the amended and
restated equity incentive plan of enGene Inc. (the &#147;<U>Corporation</U>&#148;) dated June&nbsp;30, 2021 and as may be further amended and/or restated from time to time, and (ii)&nbsp;each other plan that provides for the award to any current or
former director, manager, officer, employee, individual independent contractor or other individual service provider of the Company, the Corporation and any of their subsidiaries (the &#147;<U>Group Company</U>&#148;) of rights of any kind to receive
equity securities of any Group Company or benefits measured in whole or in part by reference to equity securities of any Group Company (the &#147;<U>Prior Plans</U>&#148;), will be converted and exchanged into rights to acquire shares of the Company
as set forth in the Business Combination Agreement, with such equity security rights to be merged into and converted into grants under the Plan. No additional grants shall be made under the Prior Plans after the Effective Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section&nbsp;1. Definitions </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following terms has the meanings set forth below for purposes of the Plan: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) &#147;<U>409A</U>&#148; means Section&nbsp;409A of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) &#147;<U>Board</U>&#148; means the Board of Directors of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) &#147;<U>Business Combination Agreement</U>&#148; means that certain Business Combination Agreement, dated as of May&nbsp;16, 2023, by and
among Forbion European Acquisition Corp., a Cayman Islands exempted company, enGene Inc., a corporation existing under the laws of Canada, the Company, and the other persons named therein and party thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) &#147;<U>Canadian Employees</U>&#148; means officers, employees, and <FONT STYLE="white-space:nowrap">non-employee</FONT> members of the
Board, or a corporation that does not deal at arm&#146;s length with the Company for purposes of the Tax Act, who are residents of Canada for purposes of the Tax Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) &#147;<U>Cause</U>&#148; has the meaning given to that term in any written employment agreement, offer letter or severance or termination
agreement between the Employer and the Participant, or if no such agreement exists or if such term is not defined therein, and unless otherwise defined in the Grant Instrument, Cause means a finding by the Committee that the Participant (i)&nbsp;has
breached his or her employment or service contract with the Employer, (ii)&nbsp;has engaged in disloyalty to the Employer, including, without limitation, fraud, embezzlement, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
theft, commission of a felony, indictable offence or proven dishonesty, (iii)&nbsp;has disclosed trade secrets or confidential information of the Employer to persons not entitled to receive such
information, (iv)&nbsp;has breached any written <FONT STYLE="white-space:nowrap">non-competition,</FONT> <FONT STYLE="white-space:nowrap">non-solicitation,</FONT> invention assignment or confidentiality agreement between the Participant and the
Employer or (v)&nbsp;has engaged in such other behavior detrimental to the interests of the Employer as the Committee determines. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)
&#147;<U>CEO</U>&#148; means the Chief Executive Officer of the Company (or if there is none then appointed, the President of the Company). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) &#147;<U>Change of Control</U>&#148;, unless otherwise set forth in a Grant Instrument, shall be deemed to have occurred if: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Any &#147;person&#148; (as such term is used in <U>Section</U>s 13(d) and 14(d) of the Exchange Act) becomes a &#147;beneficial
owner&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act), directly or indirectly, of securities of the Company representing more than 50% of the voting power of the then outstanding securities of the
Company; <U>provided</U> that a Change of Control shall not be deemed to occur as a result of a transaction in which the Company becomes a direct or indirect subsidiary of another Person and in which the shareholders of the Company, immediately
prior to the transaction, will beneficially own, immediately after the transaction, shares of such other Person representing more than 50% of the voting power of the then outstanding securities of such other Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) The consummation of (A)&nbsp;an amalgamation, arrangement, merger, consolidation or other form of business combination of the Company
with another Person where, immediately after such transaction, the shareholders of the Company, immediately prior to such transaction, will not beneficially own, in substantially the same proportion as ownership immediately prior to such
transaction, shares entitling such shareholders to more than 50% of all votes to which all shareholders of the surviving Person would be entitled in the election of directors, or where the members of the Board, immediately prior to such transaction,
will not, immediately after such transaction, constitute a majority of the board of directors of the surviving Person or (B)&nbsp;a sale or other disposition of all or substantially all of the assets of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) A change in the composition of the Board over a period of 12 consecutive months or less such that a majority of the Board members
ceases, by reason of one or more contested elections, or threatened election contests, for Board membership, to be comprised of individuals who either (A)&nbsp;have been Board members continuously since the beginning of such period or (B)&nbsp;have
been elected or nominated for election as Board members during such period by at least a majority of the Board members described in clause (A)&nbsp;who were still in office at the time the Board approved such election or nomination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) The consummation of a complete dissolution or liquidation of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Committee may modify the definition of Change of Control for a particular Grant as the Committee deems appropriate to comply with 409A or otherwise.
Notwithstanding the foregoing, if a Grant constitutes deferred compensation subject to 409A and the Grant provides for payment upon a Change of Control, then, for purposes of such payment provisions, no Change of Control shall be deemed to have
occurred upon an event described in items (i) &#150; (iv) above unless the event would also constitute a change in ownership or effective control of, or a change in the ownership of a substantial portion of the assets of, the Company under 409A.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) &#147;<U>Common Share</U>&#148; shall mean the common shares of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) &#147;<U>Code</U>&#148; means the Internal Revenue Code of 1986, as amended, and the regulations promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) &#147;<U>Committee</U>&#148; means the Compensation Committee of the Board or another committee appointed by the Board to administer the
Plan and to the extent the Board does not appoint a committee, the Board can serve as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Committee. The Committee shall consist of Directors who are <FONT STYLE="white-space:nowrap">&#147;non-employee</FONT> directors&#148; as defined under Rule
<FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act and &#147;independent directors,&#148; as determined in accordance with the independence standards established by the stock exchange on which the Common Shares are at
the time primarily traded. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) &#147;<U>Consultant</U>&#148; means a person other than an Employee, officer or Director of the Company or
of any of its subsidiaries that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) is engaged to provide bona fide services to the Company or a Related Entity of the Company, other
than services provided in relation to a distribution, the offer and sale of securities in a capital-raising transaction, or, directly or indirectly, to promote or maintain a market for the Company&#146;s securities; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) provides the services under a written contract with the Company or a Related Entity of the Company; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) spends or will spend a significant amount of time and attention on the affairs and business of the Company or a Related Entity of the
Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">and includes </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) for an individual consultant, a corporation of which the individual consultant is an employee or shareholder, and a partnership of which
the individual consultant is an employee or partner; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) for a consultant that is not an individual, an employee, executive officer,
or director of the consultant, provided that the individual employee, executive officer, or director spends or will spend a significant amount of time and attention on the affairs and business of the Company or a Related Entity of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) &#147;<U>Director</U>&#148; means a member of the Board of the Company or any of its subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) &#147;<U>Disability</U>&#148; or &#147;<U>Disabled</U>&#148; means, unless otherwise set forth in the Grant Instrument, a
Participant&#146;s becoming disabled within the meaning of the Employer&#146;s <FONT STYLE="white-space:nowrap">long-term</FONT> disability plan applicable to the Participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) &#147;<U>Dividend Equivalent</U>&#148; means an amount determined by multiplying the number of Common Shares subject to a Share Unit or
Other Share-Based Award by the <FONT STYLE="white-space:nowrap">per-share</FONT> cash dividend paid by the Company on its outstanding Common Shares, or the <FONT STYLE="white-space:nowrap">per-share</FONT> Fair Market Value of any dividend paid on
its outstanding Common Shares in consideration other than cash. If interest is credited on accumulated divided equivalents, the term &#147;Dividend Equivalent&#148; shall include the accrued interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) &#147;<U>Effective Date</U>&#148; means the effective date of the consummation of the merger contemplated by the Business Combination
Agreement, subject to approval of the Plan by the shareholders of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) &#147;<U>Employed by, or providing service to, the
Employer</U>&#148; means employment or service as an Employee, Consultant or member of the Board (so that, for purposes of exercising Options and SARs and satisfying conditions with respect to Share Awards, Share Units, and Other Share-Based Awards,
a Participant shall not be considered to have terminated employment or service until the Participant ceases to be an Employee, Consultant or member of the Board), unless the Committee determines otherwise. If a Participant&#146;s relationship is
with a subsidiary of the Company and that entity ceases to be a subsidiary of the Company, the Participant will be deemed to cease employment or service when the entity ceases to be a subsidiary of the Company, unless the Participant transfers
employment or service to an Employer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) &#147;<U>Employee</U>&#148; means an employee of the Employer (including an officer or Director
who is also an employee), but excluding any person who is classified by the Employer as a &#147;contractor&#148; or &#147;consultant,&#148; no </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
matter how characterized by the Internal Revenue Service, other governmental agency or a court. Any change of characterization of an individual by the Internal Revenue Service or any court or
government agency shall have no effect upon the classification of an individual as an Employee for purposes of this Plan, unless the Committee determines otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) &#147;<U>Employer</U>&#148; means the Company and its subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) &#147;<U>Exchange Act</U>&#148; means the Securities Exchange Act of 1934, as amended. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) &#147;<U>Exercise Price</U>&#148; means the per share price at which Common Shares may be purchased under an Option, as designated by the
Committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n) &#147;<U>Fair Market Value</U>&#148; means: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) For so long as the Common Shares are publicly traded, the Fair Market Value per share shall be determined as follows: (A)&nbsp;if the
principal trading market for the Common Shares is a national securities exchange, the closing sales price during regular trading hours on the relevant date or, if there were no trades on that date, the latest preceding date upon which a sale was
reported, or (B)&nbsp;if the Common Shares are not principally traded on any such exchange, the last reported sale price of a share of Common Shares during regular trading hours on the relevant date, as reported by the OTC Bulletin Board. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) If the Common Shares are not publicly traded or, if publicly traded, is not subject to reported transactions as set forth above, the Fair
Market Value per share shall be determined in good faith by the Committee through any reasonable valuation method authorized under the Code or Tax Act, if applicable, and commonly used to value privately held stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(o) &#147;<U>GAAP</U>&#148; means United States generally accepted accounting principles. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(p) &#147;<U>Grant</U>&#148; means an Option, SAR, Share Award, Share Unit or Other Share-Based Award granted under the Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(q) &#147;<U>Grant Instrument</U>&#148; means the written agreement that sets forth the terms and conditions of a Grant, including all
amendments thereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(r) &#147;<U>Incentive Stock Option</U>&#148; means an Option that is intended to meet the requirements of an
incentive stock option under Section&nbsp;422 of the Code. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(s) &#147;<U><FONT STYLE="white-space:nowrap">Non-Employee</FONT>
Director</U>&#148; means a Director who is not an Employee. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(t) &#147;<U>Nonqualified Stock Option</U>&#148; means an Option that is not
intended to be taxed as an incentive stock option under Section&nbsp;422 of the Code. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(u) &#147;<U>Option</U>&#148; means an option to
purchase Common Shares, as described in <U>Section</U><U></U><U>&nbsp;6</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) &#147;<U>Other Share-Based Award</U>&#148; means any
Grant based on, measured by or payable in Common Shares (other than an Option, Share Unit, Share Award, or SAR), as described in <U>Section</U><U></U><U>&nbsp;10</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(w) &#147;<U>Participant</U>&#148; means an Employee, Consultant or <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director designated by
the Committee to participate in the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(x) &#147;<U>Performance Goals</U>&#148; means performance goals that may include, but are not
limited to, one or more of the following criteria: cash flow; free cash flow; earnings (including gross margin, earnings before interest and taxes, earnings before taxes, earnings before interest, taxes, depreciation, amortization and charges for
share-based compensation, earnings before interest, taxes, depreciation and amortization, adjusted earnings before interest, taxes, depreciation and amortization and net earnings); earnings per share; growth in earnings or earnings per share; book
value growth; share price; return on equity or average shareholder equity; total shareholder return or growth in total shareholder return either directly or in relation to a comparative group; return on capital; return on assets or net assets;
revenue, growth in revenue or return on sales; sales; expense </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reduction or expense control; expense to revenue ratio; income, net income or adjusted net income; operating income, net operating income, adjusted operating income or net operating income after
tax; operating profit or net operating profit; operating margin; gross profit margin; return on operating revenue or return on operating profit; regulatory filings; regulatory approvals, litigation and regulatory resolution goals; other operational,
regulatory or departmental objectives; budget comparisons; growth in shareholder value relative to established indexes, or another peer group or peer group index; development and implementation of strategic plans and/or organizational restructuring
goals; development and implementation of risk and crisis management programs; improvement in workforce diversity; compliance requirements and compliance relief; safety goals; productivity goals; workforce management and succession planning goals;
economic value added (including typical adjustments consistently applied from generally accepted accounting principles required to determine economic value added performance measures); measures of customer satisfaction, employee satisfaction or
staff development; development or marketing collaborations, formations of joint ventures or partnerships or the completion of other similar transactions intended to enhance the Company&#146;s revenue or profitability or enhance its customer base;
merger and acquisitions; and other similar criteria as determined by the Committee. Performance Goals applicable to a Grant shall be determined by the Committee, and may be established on an absolute or relative basis and may be established on a
corporate-wide basis or with respect to one or more business units, divisions, subsidiaries or business segments. Relative performance may be measured against a group of peer companies, a financial market index or other objective and quantifiable
indices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(y) &#147;<U>Person</U>&#148; means any natural person, corporation, limited liability company, partnership, trust, joint stock
company, business trust, unincorporated association, joint venture, governmental authority or other legal entity of any nature whatsoever. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(z) &#147;<U>Related Entity</U>&#148; means, for the Company, a person that controls or is controlled by the Company or that is controlled by
the same person that controls the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(aa) &#147;<U>Restriction Period</U>&#148; has the meaning given that term in
<U>Section</U><U></U><U>&nbsp;7(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(bb) &#147;<U>SAR</U>&#148; means a stock appreciation right, as described in
<U>Section</U><U></U><U>&nbsp;9</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(cc) &#147;<U>Share Award</U>&#148; means an award of Common Shares, as described in
<U>Section</U><U></U><U>&nbsp;7</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(dd) &#147;<U>Share Unit</U>&#148; means an award of a phantom unit representing a Common Share, as
described in <U>Section</U><U></U><U>&nbsp;8</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ee) &#147;<U>Substitute Awards</U>&#148; has the meaning given that term in
<U>Section</U><U></U><U>&nbsp;4(c)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ff) &#147;<U>Tax Act</U>&#148; means the Income Tax Act (Canada), as amended, including any
applicable regulations and guidance thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(gg) &#147;<U>Termination Date</U>&#148; means, in respect of a Canadian Employee, the
date that an Employee ceases to provide services to, or otherwise ceases its relationship with, the Employer on a permanent basis, for any reason, whether lawful or otherwise (including, without limitation by reason of termination for Cause,
termination without Cause, resignation, death or disability), without regard to any applicable period of notice, payment in lieu of notice, severance pay, termination pay, benefits continuation, or similar compensation and/or benefits to which the
Employee may then be entitled, subject only to the express minimum requirements of applicable employment or labour standards legislation (if applicable). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section&nbsp;2. Administration </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Committee</U>. The Plan shall be administered and interpreted by the Committee; <U>provided</U>, however, that any Grants to members of
the Board must be authorized by a majority of the Board (counting all Board members for purposes of a quorum, but only <FONT STYLE="white-space:nowrap">non-interested</FONT> Board members for purposes of such majority
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approval). The Committee may delegate authority to one or more subcommittees, as it deems appropriate. Subject to compliance with applicable law and the applicable stock exchange rules, the
Board, in its discretion, may perform any action of the Committee hereunder in any individual instance (without any need for any formal assumption of authority from the Committee). To the extent that the Board, a subcommittee or the CEO, as
described below administers the Plan, references in the Plan to the &#147;<U>Committee</U>&#148; shall be deemed to refer to the Board or such subcommittee or the CEO. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Delegation to CEO</U>. Subject to compliance with applicable law and applicable stock exchange requirements, so long as the CEO is also
a Director, the Committee may delegate all or part of its authority and power to the CEO, as it deems appropriate, with respect to Grants to Employees or Consultants who are not executive officers under Section&nbsp;16 of the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Committee Authority</U>. The Committee shall have the sole authority to (i)&nbsp;determine the individuals to whom Grants shall be made
under the Plan, (ii)&nbsp;determine the type, size, terms and conditions of the Grants to be made to each such individual, (iii)&nbsp;determine the time when the Grants will be made and the duration of any applicable exercise or Restriction Period,
including the criteria for exercisability and the acceleration of exercisability, (iv)&nbsp;amend the terms of any previously issued Grant, subject to the provisions of <U>Section</U><U></U><U>&nbsp;17</U> below, (v)&nbsp;determine and adopt terms,
guidelines, and provisions, not inconsistent with the Plan and applicable law, that apply to individuals residing outside of the United States who receive Grants under the Plan, and (vi)&nbsp;deal with any other matters arising under the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Committee Determinations</U>. The Committee shall have full power and express discretionary authority to administer and interpret the
Plan, to make factual determinations and to adopt or amend such rules, regulations, agreements and instruments for implementing the Plan and for the conduct of its business as it deems necessary or advisable, in its sole discretion. The
Committee&#146;s interpretations of the Plan and all determinations made by the Committee pursuant to the powers vested in it hereunder shall be conclusive and binding on all Persons having any interest in the Plan or in any awards granted
hereunder. All powers of the Committee shall be executed in its sole discretion, in the best interest of the Company, not as a fiduciary, and in keeping with the objectives of the Plan and need not be uniform as to similarly situated individuals.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Indemnification</U>. No member of the Committee or the Board, and no employee of the Company shall be liable for any act or
failure to act with respect to the Plan, except in circumstances involving his or her bad faith or willful misconduct, or for any act or failure to act hereunder by any other member of the Committee or employee or by any agent to whom duties in
connection with the administration of this Plan have been delegated. The Company shall indemnify members of the Committee and the Board and any agent of the Committee or the Board who is an employee of the Company or a subsidiary against any and all
liabilities or expenses to which they may be subjected by reason of any act or failure to act with respect to their duties on behalf of the Plan, except in circumstances involving such Person&#146;s bad faith or willful misconduct. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section&nbsp;3. Grants </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Grants under the Plan may consist of Options as described in <U>Section</U><U></U><U>&nbsp;6</U>, Share Awards as described in
<U>Section</U><U></U><U>&nbsp;7</U>, Share Units as described in <U>Section</U><U></U><U>&nbsp;8</U>, SARs as described in <U>Section</U><U></U><U>&nbsp;9</U>, and Other Share-Based Awards as described in <U>Section</U><U></U><U>&nbsp;10</U>. All
Grants shall be subject to the terms and conditions set forth herein and to such other terms and conditions consistent with this Plan as the Committee deems appropriate and as are specified in writing by the Committee to the individual in the Grant
Instrument. All Grants shall be made conditional upon the Participant&#146;s acknowledgement, in writing or by acceptance of the Grant, that all decisions and determinations of the Committee shall be final and binding on the Participant, his or her
beneficiaries and any other person having or claiming an interest under such Grant. Grants under a particular Section&nbsp;of the Plan need not be uniform as among the Participants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section&nbsp;4. Shares Subject to the Plan </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Shares Authorized</U>. Subject to adjustment as described below in <U>Sections 4(b)</U> and <U>4(e)</U> below, the aggregate number of
Common Shares that may be issued or transferred under the Plan shall be [&#149;]<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> Common Shares, plus [&#149;]<SUP STYLE="font-size:75%; vertical-align:top">2</SUP> Common Shares subject to
outstanding grants under the Prior Plan as of the Effective Date. The aggregate number of Common Shares that may be issued or transferred under the Plan pursuant to Incentive Stock Options shall not exceed [&#149;]<SUP
STYLE="font-size:75%; vertical-align:top">3</SUP> Common Shares. Commencing with the first business day of each calendar year beginning in 2024, the aggregate number of Common Shares that may be issued or transferred under the Plan shall be
increased by a number equal to the lesser of (x) [&#149;]<SUP STYLE="font-size:75%; vertical-align:top">4</SUP> million Common Shares, or (y)&nbsp;such lesser number of Common Shares as may be determined by the Committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Source of Shares; Share Counting</U>. Shares issued or transferred under the Plan may be authorized but unissued Common Shares or
reacquired Common Shares, including shares purchased by the Company on the open market for purposes of the Plan. If and to the extent Options or SARs granted under the Plan (including options or SARs granted under the Prior Plan, if any), expire or
are canceled, forfeited, exchanged or surrendered without having been exercised, or if any Share Awards, Share Units or Other Share-Based Awards (including options or SARs granted under the Prior Plan, if any) are forfeited, terminated or otherwise
not paid in full, the shares subject to such Grants shall again be available for purposes of the Plan. If Common Shares otherwise issuable under the Plan are surrendered in payment of the Exercise Price of an Option, then the number of Common Shares
available for issuance under the Plan shall be reduced only by the net number of shares actually issued by the Company upon such exercise and not by the gross number of shares as to which such Option is exercised. Upon the exercise of any SAR under
the Plan, the number of Common Shares available for issuance under the Plan shall be reduced by only by the net number of shares actually issued by the Company upon such exercise. If Common Shares otherwise issuable under the Plan are withheld by
the Company in satisfaction of the withholding taxes incurred in connection with the issuance, vesting or exercise of any Grant or the issuance of Common Shares thereunder, then the number of Common Shares available for issuance under the Plan shall
be reduced by the net number of shares issued, vested or exercised under such Grant, calculated in each instance after payment of such share withholding. To the extent any Grants are paid in cash, and not in Common Shares, any shares previously
subject to such Grants shall again be available for issuance or transfer under the Plan. For the avoidance of doubt, if shares are repurchased by the Company on the open market with the proceeds of the Exercise Price of Options, such shares may not
again be made available for issuance under the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Substitute Awards</U>. Shares issued or transferred under Grants made
pursuant to an assumption, substitution or exchange for previously granted awards of a company acquired by the Company in a transaction (&#147;<U>Substitute Awards</U>&#148;) shall not reduce the number of Common Shares available under the Plan and
available shares under a shareholder approved plan of an acquired company (as appropriately adjusted to reflect the transaction) may be used for Grants under the Plan and shall not reduce the Plan&#146;s share reserve (subject to applicable stock
exchange listing and Code or Tax Act requirements). </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Note to Draft</U>: Number to be inserted in connection with the closing of the transactions contemplated by
the Business Combination Agreement equal to 6.7% of the fully diluted capitalization of the Company immediately after giving effect to the transactions contemplated by the Business Combination Agreement. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Note to Draft</U>: Number to be equal to the number of shares underlying outstanding stock option awards
under the Prior Plans, after giving effect to exchange and conversion as contemplated under the Business Combination Agreement. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">3</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Note to Draft</U>: Number to be inserted in connection with the closing of the transactions contemplated by
the Business Combination Agreement equal to 6.7% of the fully diluted capitalization of the Company immediately after giving effect to the transactions contemplated by the Business Combination Agreement. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">4</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Note to Draft</U>: Number to be inserted in connection with the closing of the transactions contemplated by
the Business Combination Agreement equal to 5% of the fully diluted capitalization of the Company immediately after giving effect to the transactions contemplated by the Business Combination Agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Individual Limits for <FONT STYLE="white-space:nowrap">Non-Employee</FONT>
Directors</U>. Subject to adjustment as described below in <U>Section</U><U></U><U>&nbsp;4(e)</U>, the maximum aggregate grant date value of Common Shares subject to Grants granted to any <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director
during any calendar year, taken together with any cash fees earned by such <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director for services rendered during the calendar year, shall not exceed $500,000 in total value; provided, however,
that with respect to the year during which the <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director is first appointed or elected to the Board, the maximum aggregate grant date value of Common Shares granted to such <FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Director during the initial annual period, taken together with any cash fees earned by such <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director for services rendered during such period, shall
not exceed $750,000 in total value during the initial annual period. For purposes of this limit, the value of such Grants shall be calculated based on the grant date fair value of such Grants for financial reporting purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Adjustments</U>. If there is any change in the number or kind of Common Shares outstanding by reason of (i)&nbsp;a stock dividend,
spinoff, recapitalization, stock split, or combination or exchange of shares, (ii)&nbsp;a merger, amalgamation, reorganization or consolidation, (iii)&nbsp;a reclassification or change in par value, or (iv)&nbsp;any other extraordinary or unusual
event affecting the outstanding Common Shares as a class without the Company&#146;s receipt of consideration, or if the value of outstanding Common Shares is substantially reduced as a result of a spinoff or the Company&#146;s payment of an
extraordinary dividend or distribution, the maximum number and kind of Common Shares available for issuance under the Plan, the maximum amount of Grants which a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director may receive in any year,
the number and kind of shares covered by outstanding Grants, the number and kind of shares issued and to be issued under the Plan, and the price per share or the applicable market value of such Grants shall be equitably adjusted by the Committee to
reflect any increase or decrease in the number of, or change in the kind or value of, the issued Common Shares to preclude, to the extent practicable, the enlargement or dilution of rights and benefits under the Plan and such outstanding Grants;
<U>provided</U>, however, that any fractional shares resulting from such adjustment shall be eliminated. In addition, in the event of a Change of Control, the provisions of <U>Section</U><U></U><U>&nbsp;12</U> shall apply. Any adjustments to
outstanding Grants to individuals subject to U.S. income tax shall be consistent with Section&nbsp;409A or Section&nbsp;424 of the Code, to the extent applicable. The adjustments of Grants under this <U>Section</U><U></U><U>&nbsp;4(e)</U> shall
include adjustment of shares, Exercise Price of Stock Options, base amount of SARs, Performance Goals or other terms and conditions, as the Committee deems appropriate. The Committee shall have the sole discretion and authority to determine what
appropriate adjustments shall be made and any adjustments determined by the Committee shall be final, binding and conclusive. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section&nbsp;5. Eligibility for Participation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Eligible Persons</U>. All Employees, <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors and Consultants shall be eligible to
participate in the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Selection of Participants</U>. The Committee shall select the Employees,
<FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors and Consultants to receive Grants and shall determine the number of Common Shares subject to a particular Grant in such manner as the Committee determines. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Voluntary Participation</U>. Participation in the Plan will be entirely voluntary and any decision not to participate will not affect
any Employee&#146;s, <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director&#146;s or Consultant&#146;s employment or other service relationship with the Company or any of its subsidiaries. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section&nbsp;6. Options </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Committee may grant Options to an Employee, <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director or Consultant upon such terms as
the Committee deems appropriate. The following provisions are applicable to Options: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Number of Shares</U>. The Committee shall
determine the number of Common Shares that will be subject to each Grant of Options to Employees, <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors and Consultants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Type of Option and Exercise Price</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) The Committee may grant Incentive Stock Options or Nonqualified Stock Options or any combination of the two, all in accordance with the
terms and conditions set forth herein. Incentive Stock Options may be granted only to employees of the Company or its parent or subsidiary corporations, as defined in Section&nbsp;424 of the Code, who are subject to U.S. income tax. Nonqualified
Stock Options may be granted to Employees, <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors and Consultants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) The
Exercise Price of Common Shares subject to an Option shall be determined by the Committee and shall be equal to or greater than the Fair Market Value of the Common Shares on the date the Option is granted. However, an Incentive Stock Option may not
be granted to an Employee who, at the time of grant, owns securities possessing more than 10% of the total combined voting power of all classes of securities of the Company, or any parent or subsidiary corporation of the Company, as defined in
Section&nbsp;424 of the Code, unless the Exercise Price per share is not less than 110% of the Fair Market Value of the Common Shares on the date of grant. Notwithstanding the foregoing, the Exercise Price of any Option granted to a Canadian
Employee shall under no circumstances be less than 100% of the Fair Market Value on the date the Option is granted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Option
Term</U>. The Committee shall determine the term of each Option. The term of any Option shall not exceed ten years from the date of grant. However, an Incentive Stock Option that is granted to an Employee who, at the time of grant, owns securities
possessing more than 10% of the total combined voting power of all classes of securities of the Company, or any parent or subsidiary corporation of the Company, as defined in Section&nbsp;424 of the Code, may not have a term that exceeds five years
from the date of grant. Notwithstanding the foregoing, in the event that on the last business day of the term of an Option (other than an Incentive Stock Option), the exercise of the Option is prohibited by applicable law, including a prohibition on
purchases or sales of Common Shares under the Company&#146;s insider trading policy, the term of the Option shall be extended for a period of 30 days following the end of the legal prohibition, unless the Committee determines otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Exercisability of Options</U>. Options shall become exercisable in accordance with such terms and conditions, consistent with the Plan,
as may be determined by the Committee and specified in the Grant Instrument. The Committee may accelerate the exercisability of any or all outstanding Options at any time for any reason. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Grants to <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Employees</U>. Notwithstanding the foregoing, Options granted to persons
who are <FONT STYLE="white-space:nowrap">non-exempt</FONT> employees under the Fair Labor Standards Act of 1938, as amended, may not be exercisable for at least six months after the date of grant (except that such Options may become exercisable, as
determined by the Committee, upon the Participant&#146;s death, Disability or retirement, or upon a Change of Control or other circumstances permitted by applicable regulations). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Termination of Employment or Service</U>. Except as provided in the Grant Instrument, an Option may only be exercised while the
Participant is employed by, or providing services to, the Employer (and in the case of a Canadian Employee, prior to a Termination Date). The Committee shall determine in the Grant Instrument under what circumstances and during what time periods a
Participant may exercise an Option after termination of employment or service. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <U>Exercise of Options</U>. A Participant may exercise
an Option that has become exercisable, in whole or in part, by delivering a notice of exercise to the Company. The Participant shall pay the Exercise Price for an Option as specified by the Committee (i)&nbsp;in cash, (ii)&nbsp;unless the Committee
determines otherwise, by delivering Common Shares owned by the Participant and having a Fair Market Value on the date of exercise at least equal to the Exercise Price or by attestation (on a form prescribed by the Committee) to ownership of Common
Shares having a Fair Market Value on the date of exercise at least equal to the Exercise Price, (iii)&nbsp;by payment through a broker in accordance with procedures permitted by Regulation T of the Federal Reserve Board, (iv)&nbsp;if permitted by
the Committee, and solely with respect to Nonqualified Stock Options, by withholding Common Shares subject to the exercisable Option, which have a Fair Market Value on the date of exercise equal to the Exercise
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Price, or (v)&nbsp;by such other method as the Committee may approve. Common Shares used to exercise an Option shall have been held by the Participant for the requisite period of time necessary
to avoid adverse accounting consequences to the Company with respect to the Option. Payment for the shares to be issued or transferred pursuant to the Option, and any required withholding taxes, must be received by the Company by the time specified
by the Committee depending on the type of payment being made, but in all cases prior to the issuance or transfer of such shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h)
<U>Limits on Incentive Stock Options</U>. Each Incentive Stock Option shall provide that, if the aggregate Fair Market Value of the Common Shares on the date of the grant with respect to which Incentive Stock Options are exercisable for the first
time by a Participant during any calendar year, under the Plan or any other stock option plan of the Company or a parent or subsidiary, exceeds $100,000, then the Option, as to the excess, shall be treated as a Nonqualified Stock Option. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section&nbsp;7. Share Awards </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Committee may issue or transfer Common Shares to an Employee, <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director or Consultant
under a Share Award, upon such terms as the Committee deems appropriate. The following provisions are applicable to Share Awards: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)
<U>General Requirements</U>. Common Shares issued or transferred pursuant to Share Awards may be issued or transferred subject to restrictions or no restrictions, as determined by the Committee. The Committee may, but shall not be required to,
establish conditions under which restrictions on Share Awards shall lapse over a period of time or according to such other criteria as the Committee deems appropriate, including, without limitation, restrictions based on the achievement of specific
Performance Goals. The period of time during which the Share Awards will remain subject to restrictions will be designated in the Grant Instrument as the &#147;<U>Restriction Period</U>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Number of Shares</U>. The Committee shall determine the number of Common Shares to be issued or transferred pursuant to a Share Award
and the restrictions applicable to such shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Requirement of Employment or Service</U>. If the Participant ceases to be employed
by, or provide service to, the Employer (or in the case of a Canadian Employee, a Termination Date occurs) during a period designated in the Grant Instrument as the Restriction Period, or if other specified conditions are not met, the Share Award
shall terminate as to all shares covered by the Grant as to which the restrictions have not lapsed, and those Common Shares must be immediately returned to the Company. The Committee may, however, provide for complete or partial exceptions to this
requirement as it deems appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Restrictions on Transfer and Legend on Share Certificate</U>. During the Restriction Period,
a Participant may not sell, assign, transfer, pledge or otherwise dispose of the shares of a Share Award except under <U>Section</U><U></U><U>&nbsp;15</U>. Unless otherwise determined by the Committee, the Company will retain possession of
certificates for shares of Share Awards until all restrictions on such shares have lapsed. Each certificate for a Share Award, unless held by the Company, shall contain a legend giving appropriate notice of the restrictions in the Grant. The
Participant shall be entitled to have the legend removed from the share certificate covering the shares subject to restrictions when all restrictions on such shares have lapsed. The Committee may determine that the Company will not issue
certificates for Share Awards until all restrictions on such shares have lapsed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Right to Vote and to Receive Dividends</U>.
Unless the Committee determines otherwise, during the Restriction Period, the Participant shall have the right to vote shares of Share Awards and to receive any dividends or other distributions paid on such shares, subject to any restrictions deemed
appropriate by the Committee, including, without limitation, the achievement of specific Performance Goals.<B><I> </I></B>Dividends with respect to Share Awards that vest based on performance shall vest if and to the extent that the underlying Share
Award vests, as determined by the Committee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Lapse of Restrictions</U>. All restrictions imposed on Share Awards shall lapse upon
the expiration of the applicable Restriction Period and the satisfaction of all conditions, if any, imposed by the Committee. The Committee may determine, as to any or all Share Awards, that the restrictions shall lapse without regard to any
Restriction Period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section&nbsp;8. Share Units </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Committee may grant Share Units, each of which shall represent one hypothetical Common Share, to an Employee, <FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Director or Consultant upon such terms and conditions as the Committee deems appropriate. The following provisions are applicable to Share Units: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Crediting of Units</U>. Each Share Unit shall represent the right of the Participant to receive a Common Share or an amount of cash
based on the value of a Common Share, if and when specified conditions are met. All Share Units shall be credited to bookkeeping accounts established on the Company&#146;s records for purposes of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Terms of Share Units</U>. The Committee may grant Share Units that vest and are payable if specified Performance Goals or other
conditions are met, or under other circumstances. Share Units may be paid at the end of a specified performance period or other period, or payment may be deferred to a date authorized by the Committee. The Committee may accelerate vesting or
payment, as to any or all Share Units at any time for any reason, <U>provided</U> such acceleration complies with 409A. The Committee shall determine the number of Share Units to be granted and the requirements applicable to such Share Units.
Notwithstanding anything to the contrary, the vesting period for Share Units granted to a Canadian Employee shall, in all cases, be in compliance with the requirements pertaining to the exception to the application of the salary deferral arrangement
rules in paragraph (k)&nbsp;of the definition of &#147;salary deferral arrangement&#148; in subsection 248(1) of the Tax Act, as such subsection may be amended or enacted from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Requirement of Employment or Service</U>. If the Participant ceases to be employed by, or provide service to, the Employer (or in the
case of a Canadian Employee, a Termination Date occurs) prior to the vesting of Share Units, or if other conditions established by the Committee are not met, the Participant&#146;s Share Units shall be forfeited. The Committee may, however, provide
for complete or partial exceptions to this requirement as it deems appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Payment With Respect to Share Units</U>. Payments
with respect to Share Units shall be made in cash, Common Shares or any combination of the foregoing, as the Committee shall determine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Canadian Employees</U>. All Share Units granted to Canadian Employees shall be in compliance with the requirements pertaining to the
exception to the application of the salary deferral arrangement rules in paragraph (k)&nbsp;of the definition of &#147;salary deferral arrangement&#148; in subsection 248(1) of the Tax Act, as such subsection may be amended or enacted from time to
time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section&nbsp;9. Stock Appreciation Rights </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Committee may grant SARs to an Employee, <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director or Consultant separately or in
tandem with any Option. The following provisions are applicable to SARs: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>General Requirements</U>. The Committee may grant SARs to
an Employee, <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director or Consultant separately or in tandem with any Option (for all or a portion of the applicable Option). Tandem SARs may be granted either at the time the Option is granted or
at any time thereafter while the Option remains outstanding; <U>provided</U>, however, that, in the case of an Incentive Stock Option, SARs may be granted only at the time of the grant of the Incentive Stock Option. The Committee shall establish the
base amount of the SAR at the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
time the SAR is granted. The base amount of each SAR shall be equal to or greater than the Fair Market Value of a Common Share as of the date of grant of the SAR. The term of any SAR shall not
exceed ten years from the date of grant. Notwithstanding the foregoing, in the event that on the last business day of the term of a SAR, the exercise of the SAR is prohibited by applicable law, including a prohibition on purchases or sales of Common
Shares under the Company&#146;s insider trading policy, the term shall be extended for a period of 30 days following the end of the legal prohibition, unless the Committee determines otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Tandem SARs</U>. In the case of tandem SARs, the number of SARs granted to a Participant that shall be exercisable during a specified
period shall not exceed the number of Common Shares that the Participant may purchase upon the exercise of the related Option during such period. Upon the exercise of an Option, the SARs relating to the Common Shares covered by such Option shall
terminate. Upon the exercise of SARs, the related Option shall terminate to the extent of an equal number of Common Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)
<U>Exercisability</U>. A SAR shall be exercisable during the period specified by the Committee in the Grant Instrument and shall be subject to such vesting and other restrictions as may be specified in the Grant Instrument. The Committee may
accelerate the exercisability of any or all outstanding SARs at any time for any reason. SARs may only be exercised while the Participant is employed by, or providing service to, the Employer (and in the case of a Canadian Employee, prior to a
Termination Date) or during the applicable period after termination of employment or service (or in the case of a Canadian Employee, after Termination Date) as specified by the Committee. A tandem SAR shall be exercisable only during the period when
the Option to which it is related is also exercisable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Grants to Non</U><U><FONT STYLE="white-space:nowrap">-Exempt</FONT>
Employees</U>. Notwithstanding the foregoing, SARs granted to persons who are <FONT STYLE="white-space:nowrap">non-exempt</FONT> employees under the Fair Labor Standards Act of 1938, as amended, may not be exercisable for at least six months after
the date of grant (except that such SARs may become exercisable, as determined by the Committee, upon the Participant&#146;s death, Disability or retirement, or upon a Change of Control or other circumstances permitted by applicable regulations).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Value of SARs</U>. When a Participant exercises SARs, the Participant shall receive in settlement of such SARs an amount equal to
the value of the stock appreciation for the number of SARs exercised. The stock appreciation for a SAR is the amount by which the Fair Market Value of the underlying Common Shares on the date of exercise of the SAR exceeds the base amount of the SAR
as described in subsection&nbsp;(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Form of Payment</U>. The appreciation in a SAR shall be paid in Common Shares, cash or any
combination of the foregoing, as the Committee shall determine. For purposes of calculating the number of Common Shares to be received, Common Shares shall be valued at their Fair Market Value on the date of exercise of the SAR. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section&nbsp;10. Other Share-Based Awards </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Committee may grant Other Share-Based Awards, which are awards (other than those described in <U>Sections 6</U> through <U>9</U>) that are
based on or measured by Common Shares, to any Employee, <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director or Consultant, on such terms and conditions as the Committee shall determine. Other Share-Based Awards may be awarded subject to
the achievement of Performance Goals or other criteria or other conditions and may be payable in cash, Common Shares or any combination of the foregoing, as the Committee shall determine. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section&nbsp;11. Dividend Equivalents </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Committee may grant Dividend Equivalents in connection with Share Units or Other Share-Based Awards. Dividend Equivalents may be paid
currently or accrued as contingent cash obligations and may be payable in cash or Common Shares, and upon such terms and conditions as the Committee shall determine. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Dividend Equivalents with respect to Share Units or Other Share-Based Awards that vest based on performance shall vest and be paid only if and to the extent the underlying Share Units or Other
Share-Based Awards vest and are paid, as determined by the Committee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section&nbsp;12. Consequences of a Change of Control </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Assumption of Outstanding Grants</U>. Upon a Change of Control where the Company is not the surviving corporation (or survives only as a
subsidiary of another corporation), unless the Committee determines otherwise, all outstanding Grants that are not exercised or paid at the time of the Change of Control shall be assumed by, or replaced with grants (with respect to cash, securities,
or a combination thereof) that have comparable terms by, the surviving corporation (or a parent or subsidiary of the surviving corporation). An assumption or substitution of any Grants shall be done in a manner consistent with the provisions of
Sections 409A and, if applicable, 424 of the Code, for individuals subject to U.S. income tax. After a Change of Control, references to the &#147;Company&#148; or &#147;Employer&#148; as they relate to employment matters shall include the successor
employer in the transaction, subject to applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Other Alternatives</U>. In the event of a Change of Control, if any
outstanding Grants are not assumed by, or replaced with grants that have comparable terms by, the surviving corporation (or a parent or subsidiary of the surviving corporation), the Committee may (but is not obligated to) make adjustments to the
terms and conditions of outstanding Grants, including, without limitation, taking any of the following actions (or combination thereof) with respect to any or all outstanding Grants, without the consent of any Participant: (i)&nbsp;the Committee may
determine that outstanding Stock Options and SARs shall automatically accelerate and become fully exercisable and the restrictions and conditions on outstanding Share Awards, Share Units and Dividend Equivalents shall immediately lapse;
(ii)&nbsp;the Committee may determine that Participants shall receive a payment in settlement of outstanding Share Units or Dividend Equivalents, in such amount and form as may be determined by the Committee; (iii)&nbsp;the Committee may require
that Participants surrender their outstanding Stock Options and SARs in exchange for a payment by the Company, in cash or Common Shares as determined by the Committee, in an amount equal to the amount, if any, by which the then Fair Market Value of
the Common Shares subject to the Participant&#146;s unexercised Stock Options and SARs exceeds the Stock Option Exercise Price or SAR base amount, and (iv)&nbsp;after giving Participants an opportunity to exercise all of their outstanding Stock
Options and SARs, the Committee may terminate any or all unexercised Stock Options and SARs at such time as the Committee deems appropriate. Such surrender, termination or payment shall take place as of the date of the Change of Control or such
other date as the Committee may specify. Without limiting the foregoing, if the per share Fair Market Value of the Common Shares does not exceed the per share Stock Option Exercise Price or SAR base amount, as applicable, the Company shall not be
required to make any payment to the Participant upon surrender of the Stock Option or SAR and shall have the right to cancel any such Stock Option or SAR for no consideration. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section&nbsp;13. Deferrals </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Committee may permit or require a Participant to defer receipt of the payment of cash or the delivery of shares that would otherwise be due
to such Participant in connection with any Grant. If any such deferral election is permitted or required, the Committee shall establish rules and procedures for such deferrals and may provide for interest or other earnings to be paid on such
deferrals. The rules and procedures for any such deferrals shall be consistent with applicable requirements of 409A. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section&nbsp;14.
Withholding of Taxes </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Required Withholding</U>. All Grants under the Plan shall be subject to applicable United States federal
(including taxes under FICA), state and local, foreign country or other tax withholding requirements. The Employer may require that the Participant or other person receiving Grants or exercising Grants pay to the Employer an amount sufficient to
satisfy such tax withholding requirements with respect to such Grants, or the Employer may deduct from other wages and compensation paid by the Employer the amount of any withholding taxes due with respect to such Grants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Share Withholding</U>. The Committee may permit or require the Employer&#146;s tax
withholding obligation with respect to Grants paid in Common Shares to be satisfied by having shares withheld up to an amount that does not exceed the Participant&#146;s applicable withholding tax rate for United States federal (including FICA),
state and local, foreign country or other tax liabilities. The Committee may, in its discretion, and subject to such rules as the Committee may adopt, allow Participants to elect to have such share withholding applied to all or a portion of the tax
withholding obligation arising in connection with any particular Grant. Unless the Committee determines otherwise, share withholding for taxes shall not exceed the Participant&#146;s minimum applicable tax withholding amount. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section&nbsp;15. Transferability of Grants </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Nontransferability of Grants</U>. Except as described in subsection&nbsp;(b) below, only the Participant may exercise rights under a
Grant during the Participant&#146;s lifetime. A Participant may not transfer those rights except (i)&nbsp;by will or by the laws of descent and distribution or (ii)&nbsp;with respect to Grants other than Incentive Stock Options, pursuant to a
domestic relations order. When a Participant dies, the personal representative or other person entitled to succeed to the rights of the Participant may exercise such rights. Any such successor must furnish proof satisfactory to the Company of his or
her right to receive the Grant under the Participant&#146;s will or under the applicable laws of descent and distribution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)
<U>Transfer of Nonqualified Stock Options</U>. Notwithstanding the foregoing, the Committee may provide, in a Grant Instrument, that a Participant may transfer Nonqualified Stock Options to a permitted assign in compliance with the applicable
securities laws, according to such terms as the Committee may determine; <U>provided</U> that the Participant receives no consideration for the transfer of an Option and the transferred Option shall continue to be subject to the same terms and
conditions as were applicable to the Option immediately before the transfer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section&nbsp;16. Requirements for Issuance or Transfer of
Shares </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No Common Shares shall be issued or transferred in connection with any Grant hereunder unless and until all legal requirements
applicable to the issuance or transfer of such Common Shares have been complied with to the satisfaction of the Committee. The Committee shall have the right to condition any Grant on the Participant&#146;s undertaking in writing to comply with such
restrictions on his or her subsequent disposition of the Common Shares as the Committee shall deem necessary or advisable, and certificates representing such shares may be legended to reflect any such restrictions. Certificates representing Common
Shares issued or transferred under the Plan may be subject to such stop-transfer orders and other restrictions as the Committee deems appropriate to comply with applicable laws, regulations and interpretations, including any requirement that a
legend be placed thereon. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section&nbsp;17. Amendment and Termination of the Plan </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Amendment</U>. The Board may amend or terminate the Plan at any time; <U>provided</U>, however, that the Board shall not amend the Plan
without shareholder approval if such approval is required in order to comply with the Code, the Tax Act or other applicable law, or to comply with applicable stock exchange requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>No Repricing of Options or SARs</U>. Except in connection with a corporate transaction involving the Company (including, without
limitation, any stock dividend, distribution (whether in the form of cash, Common Shares, other securities or property), stock split, extraordinary cash dividend, recapitalization, change in control, reorganization, merger, consolidation, <FONT
STYLE="white-space:nowrap">split-up,</FONT> <FONT STYLE="white-space:nowrap">spin-off,</FONT> combination, repurchase or exchange of Common Shares or other securities, or similar transactions), the Company may not, without obtaining shareholder
approval, (i)&nbsp;amend the terms of outstanding Stock Options or SARs to reduce the Exercise Price of such outstanding Stock Options or base price of such SARs, (ii)&nbsp;cancel outstanding Stock Options or SARs in exchange for Stock Options or
SARs with an Exercise Price or base price, as applicable, that is less than the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Exercise Price or base price of the original Stock Options or SARs or (iii)&nbsp;cancel outstanding Stock Options or SARs with an Exercise Price or base price, as applicable, above the current
stock price in exchange for cash or other securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Termination of Plan</U>. The Plan shall terminate on the day immediately
preceding the tenth anniversary of its Effective Date, unless the Plan is terminated earlier by the Board or is extended by the Board with the approval of the shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Termination and Amendment of Outstanding Grants</U>. A termination or amendment of the Plan that occurs after a Grant is made shall not
materially impair the rights of a Participant with respect to such Grant unless the Participant consents or unless the Committee acts under <U>Section</U><U></U><U>&nbsp;18(f)</U>. The termination of the Plan shall not impair the power and authority
of the Committee with respect to an outstanding Grant. Whether or not the Plan has terminated, an outstanding Grant may be terminated or amended under <U>Section</U><U></U><U>&nbsp;18(f)</U> or may be amended by agreement of the Company and the
Participant consistent with the Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section&nbsp;18. Miscellaneous </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Grants in Connection with Corporate Transactions and Otherwise</U>. Nothing contained in the Plan shall be construed to (i)&nbsp;limit
the right of the Committee to make Grants under the Plan in connection with the acquisition, by purchase, lease, merger, consolidation or otherwise, of the business or assets of any corporation, firm or association, including Grants to employees
thereof who become Employees, or (ii)&nbsp;limit the right of the Company to grant stock options or make other awards outside of the Plan. The Committee may make a Grant to an employee of another corporation who becomes an Employee by reason of a
corporate merger, consolidation, acquisition of securities or property, reorganization or liquidation involving the Company, in substitution for a stock option or Share Awards grant made by such corporation. Notwithstanding anything in the Plan to
the contrary, the Committee may establish such terms and conditions of the new Grants as it deems appropriate, including setting the Exercise Price of Options or the base price of SARs at a price necessary to retain for the Participant the same
economic value as the prior options or rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Governing Document</U>. The Plan shall be the controlling document. No other
statements, representations, explanatory materials or examples, oral or written, may amend the Plan in any manner. The Plan shall be binding upon and enforceable against the Company and its successors and assigns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Funding of the Plan</U>. The Plan shall be unfunded. The Company shall not be required to establish any special or separate fund or to
make any other segregation of assets to assure the payment of any Grants under the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Rights of Participants</U>. Nothing in
the Plan shall entitle any Employee, <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director, Consultant or other person to any claim or right to receive a Grant under the Plan. Any Grant under the Plan shall be a <FONT
STYLE="white-space:nowrap">one-time</FONT> award that does not constitute a promise of future grants nor will it form part of a Participant&#146;s standard compensation or be considered for the purpose of calculating any entitlements to vacation,
benefits, notice of termination or payment in lieu of notice or as otherwise required by any other contract or applicable law. The Company, in its sole discretion, maintains the right to make available future Grants under the Plan. Neither the Plan
nor any action taken hereunder shall be construed as giving any individual any rights to be retained by or in the employ of the Employer or any other employment rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>No Fractional Shares</U>. No fractional Common Shares shall be issued or delivered pursuant to the Plan or any Grant. Except as
otherwise provided under the Plan, the Committee shall determine whether cash, other awards or other property shall be issued or paid in lieu of such fractional shares or whether such fractional shares or any rights thereto shall be forfeited or
otherwise eliminated. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Compliance with Law</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) The Plan, the exercise of Options and SARs and the obligations of the Company to issue or transfer Common Shares under Grants shall be
subject to all applicable laws and regulations, and to approvals by any governmental or regulatory agency as may be required. With respect to persons subject to Section&nbsp;16 of the Exchange Act, it is the intent of the Company that the Plan and
all transactions under the Plan comply with all applicable provisions of Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> or its successors under the Exchange Act. In addition, it is the intent of the Company that Incentive Stock Options comply
with the applicable provisions of Section&nbsp;422 of the Code, and that, to the extent applicable, Grants comply with the requirements of 409A, to the extent applicable. To the extent that any legal requirement of Section&nbsp;16 of the Exchange
Act, 409A or Section&nbsp;422 of the Code as set forth in the Plan ceases to be required under Section&nbsp;16 of the Exchange Act, 409A or Section&nbsp;422 of the Code, that Plan provision shall cease to apply. The Committee may revoke any Grant if
it is contrary to law or modify a Grant to bring it into compliance with any valid and mandatory government regulation. The Committee may also adopt rules regarding the withholding of taxes on payments to Participants. The Committee may, in its sole
discretion, agree to limit its authority under this Section. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) The Plan is intended to comply with the requirements of 409A, to the
extent applicable. Each Grant shall be construed and administered such that the Grant either (A)&nbsp;qualifies for an exemption from the requirements of 409A or (B)&nbsp;satisfies the requirements of 409A. If a Grant is subject to 409A,
(I)&nbsp;distributions shall only be made in a manner and upon an event permitted under 409A, (II)&nbsp;payments to be made upon a termination of employment or service shall only be made upon a &#147;separation from service&#148; under 409A,
(III)&nbsp;unless the Grant specifies otherwise, each installment payment shall be treated as a separate payment for purposes of 409A, and (IV)&nbsp;in no event shall a Participant, directly or indirectly, designate the calendar year in which a
distribution is made except in accordance with 409A. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) Any Grant that is subject to 409A and that is to be distributed to a Key
Employee (as defined below) upon separation from service shall be administered so that any distribution with respect to such Grant shall be postponed for six months following the date of the Participant&#146;s separation from service, if required by
409A. If a distribution is delayed pursuant to 409A, the distribution shall be paid within 15 days after the end of the <FONT STYLE="white-space:nowrap">six-month</FONT> period. If the Participant dies during such
<FONT STYLE="white-space:nowrap">six-month</FONT> period, any postponed amounts shall be paid within 90 days of the Participant&#146;s death. The determination of Key Employees, including the number and identity of persons considered Key Employees
and the identification date, shall be made by the Committee or its delegate each year in accordance with Section&nbsp;416(i) of the Code and the &#147;specified employee&#148; requirements of 409A. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) Notwithstanding anything in the Plan or any Grant agreement to the contrary, each Participant shall be solely responsible for the tax
consequences of Grants under the Plan, and in no event shall the Company or any subsidiary or affiliate of the Company have any responsibility or liability if a Grant does not meet any applicable requirements of 409A. Although the Company intends to
administer the Plan to prevent taxation under 409A, the Company does not represent or warrant that the Plan or any Grant complies with any provision of federal, state, local or other tax law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <U>Establishment of Subplans</U>. The Board may from time to time establish one or more <FONT STYLE="white-space:nowrap">sub-plans</FONT>
under the Plan for purposes of satisfying applicable blue sky, securities or tax laws of various jurisdictions outside the United States or Canada. The Board shall establish such <FONT STYLE="white-space:nowrap">sub-plans</FONT> by adopting
supplements to the Plan setting forth (i)&nbsp;such limitations on the Committee&#146;s discretion under the Plan as the Board deems necessary or desirable and (ii)&nbsp;such additional terms and conditions not otherwise inconsistent with the Plan
as the Board shall deem necessary or desirable. All supplements adopted by the Board shall be deemed to be part of the Plan, but each supplement shall apply only to Participants within the affected jurisdiction and the Employer shall not be required
to provide copies of any supplement to Participants in any jurisdiction that is not affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) <U>Clawback Rights</U>. All Grants
(including any proceeds, gains or other economic benefit actually or constructively received by the Participant upon any receipt of any Grant or upon the receipt or resale of any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shares of Company Stock underlying the Grant) under the Plan shall be subject to the provisions of any applicable policies implemented by the Board from time to time, including, any clawback or
recoupment policies, share trading policies and other policies that may be implemented by the Board from time to time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) <U>Tax Act
Elections</U>. In the sole discretion of the Committee, the Company may make an election under subsection 110(1.1) of the Tax Act where applicable. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) <U>Waiver of Damages</U>. A grantee, who is a Canadian Employee, waives any and all rights to any Grants and to any compensation or damages
in respect or in lieu thereof as a consequence of termination of the Participant&#146;s employment or service to the Employer for any reason, or otherwise for any reason whatsoever insofar as those rights arise or may arise from the Participant
ceasing to have rights with respect to such Grants upon a termination such Participant&#146;s employment or service to the Employer. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k)
<U>Governing Law</U>. The validity, construction, interpretation and effect of the Plan and Grant Instruments issued under the Plan shall be governed and construed by and determined in accordance with the laws of the Province of British Columbia and
the federal laws of Canada applicable therein, without giving effect to the conflict of laws provisions thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/// end </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">G-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit H </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Capitalization Table </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Omitted </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">H-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="rom459793_101"></A>ANNEX B </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g459793g01g05.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">May&nbsp;14, 2023 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Board of
Directors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Forbion European Acquisition Corp. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4001 Kennett
Pike, Suite 302 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Wilmington, Delaware 19807 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Members of the
Board of Directors: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You have requested that Lincoln International LLC (&#147;Lincoln&#148;) render an opinion (the &#147;Opinion&#148;) as to whether the
Company Consideration (as defined in the Agreement (as defined below)) to be issued in connection with the Transaction (as defined below) is fair from a financial point of view to the FEAC Unaffiliated Shareholders (defined as holders of
Class&nbsp;A ordinary shares, par value $0.0001 per share (the &#147;FEAC Class&nbsp;A Shares&#148;) of Forbion European Acquisition Corp. (&#147;FEAC&#148;) prior to the consummation of the Transaction, other than (i)&nbsp;holders of FEAC
Class&nbsp;A Shares who elect to redeem their FEAC Class&nbsp;A Shares prior to or in connection with the Transaction, (ii)&nbsp;officers, directors, or affiliates of FEAC, or (iii)&nbsp;Forbion Growth Sponsor FEAC I B.V. (the &#147;Sponsor&#148;)
or any affiliates of the Sponsor). Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Agreement (as defined below). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Background of the Transaction</U> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We understand that,
in connection with the Transaction, FEAC proposes to enter into a Business Combination Agreement (the &#147;Agreement&#148;) by and among FEAC, enGene, Inc. (the &#147;Company&#148;) and enGene Holdings Inc. (&#147;Newco&#148;). Pursuant to, and as
more fully described in, the Agreement, on the Closing Date, Can Merger Sub and the Company will amalgamate in accordance with the terms of the Plan of Arrangement (the &#147;Plan&#148; and such amalgamation, the &#147;Amalgamation&#148;), and
pursuant to the Plan, (i)&nbsp;each Company Share outstanding immediately prior to the Amalgamation shall be exchanged for Newco Shares at the Company Exchange Ratio and each Company Warrant outstanding immediately prior to the Amalgamation shall be
exchanged for Newco Warrants at the Company Exchange Ratio; (ii)&nbsp;each Can Merger Sub share outstanding immediately prior to the Amalgamation shall be exchanged for one common share in the authorized share capital of the amalgamated entity;
(iii)&nbsp;in consideration for the issuance of Newco Shares, the amalgamated entity shall issue its common shares to Newco, in each case upon and subject to the other terms and conditions set forth in the Agreement, the Plan and in accordance with
the provisions of applicable Law (the transactions described in this paragraph, together with the other transactions contemplated by the Agreement, including but not limited to the FEAC Reorganization and Can Merger Sub Share Sale, the
&#147;Transaction&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lincoln compared the enterprise value of the Company implied from the Company Consideration to enterprise values observed in
our analyses to determine whether the Company Consideration to be issued in the Transaction is fair from a financial point of view to the FEAC Unaffiliated Shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also understand that, in connection with the Transaction, FEAC has completed the Amended 2022 Financing and intends to pursue the PIPE Financing and the
2023 Financing (together with the Amended 2022 Financing </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Lincoln International LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">110 N Upper Wacker </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">51<SUP STYLE="font-size:75%; vertical-align:top">st</SUP> Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Chicago, Illinois 60606 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><FONT COLOR="#33ea54"><B>www.lincolninternational.com </B></FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g459793g01g05.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and PIPE Financing, the &#147;Financings&#148;). The
terms and conditions of the Financings have or will be set forth in those certain note purchase or subscription agreements entered into in connection therewith, as to which terms and conditions we express no opinion. Furthermore, Lincoln expresses
no opinion with respect to the <FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Transaction or the Sponsor Loans Conversion. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Scope of
Analysis</U> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with this Opinion, Lincoln has, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reviewed the following documents: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Cash and debt balances for the Company as of January&nbsp;31, 2023; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The pro forma equity ownership table of FEAC and an estimated Transaction sources and uses schedule provided to
us by FEAC; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A draft of the Agreement, dated as of May&nbsp;14, 2023; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company&#146;s Corporate Presentation dated May 2023; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">e.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Other documents relating to the history, past and current operations, financial condition, and probable future
outlook of the Company provided to Lincoln by the management of each of the Company and FEAC; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Discussed the business, financial outlook and prospects of the Company and its addressable market, as well as
the terms and circumstances surrounding the Transaction, with management of the Company and FEAC; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reviewed certain financial and other information for the Company, and compared that data and information with
certain stock trading and corresponding data and information for companies with publicly traded securities that we deemed relevant, none of which is directly comparable to the Company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reviewed certain financial and other information for the Company and the Transaction, and compared that data
and information with certain financial and corresponding data and information for companies that have been subject to change of control M&amp;A transactions and capital raise transactions that we deemed relevant, none of which is directly comparable
to the Company and the Transaction; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Considered such other information and financial, economic and market criteria and analyses that we deemed
relevant. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Assumptions, Qualifications, and Limiting Conditions</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In performing its analyses and rendering this Opinion with respect to the Company Consideration, Lincoln has, with FEAC management&#146;s consent: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Relied upon and assumed the accuracy and completeness of all of the financial, accounting, legal, tax and other
information we reviewed, and we have not assumed any responsibility for the independent verification of, nor independently verified, any of such information; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Relied upon the assurances of the management of FEAC that the information provided is complete and correct in
all material respects and do not contain any untrue statement of a material fact or omit to state a material fact necessary that would make such information materially incomplete or misleading; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Assumed that the Transaction will be consummated in a timely manner that complies in all respects with all
applicable federal and state statutes, rules and regulations; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g459793g01g05.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Assumed that in the course of obtaining any necessary regulatory and third-party consents, approvals and
agreements for the Transaction, no modification, delay, limitation, restriction, or condition will be imposed that will have an adverse effect on FEAC, the Company or the Transaction; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Assumed that the Transaction will be consummated in accordance with the terms outlined by FEAC and other
documents made available to Lincoln, without waiver, modification or amendment of any term, condition or agreement therein that is material to Lincoln&#146;s analysis; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Assumed that there has been no material change in the assets, liabilities, business, condition (financial or
otherwise), results of operations, or prospects of the Company since the date of the most recent information was made available to Lincoln; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Assumed that the final terms of the Transaction will not vary materially from those set forth in the copies or
drafts, as applicable, reviewed by Lincoln; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Assumed that the final versions of all documents reviewed by Lincoln conform in all material respects to the
drafts reviewed by Lincoln. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lincoln has prepared this Opinion as of the date hereof. This Opinion is necessarily based on financial,
economic, market and other conditions as they exist on and the information made available to us as of the date hereof. Although subsequent developments may affect this Opinion, Lincoln does not have any obligation to update, revise or reaffirm this
Opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lincoln did not evaluate FEAC&#146;s or the Company&#146;s solvency and was not requested to make, and did not make, an independent evaluation
or appraisal of the assets or liabilities (contingent, derivative, <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet or otherwise) of FEAC or the Company or any of their respective subsidiaries, nor was Lincoln furnished with any such
evaluations or appraisals. Lincoln did not perform any financial analyses to evaluate the value of FEAC or to derive valuation reference ranges for shares of FEAC for purposes of comparison with the Company Consideration or otherwise. Lincoln was
not requested to, nor did Lincoln participate in the negotiation or structuring of the Transaction. Lincoln was not requested to, nor did Lincoln seek alternative candidates for the Transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Opinion (i)&nbsp;does not address the underlying business decision of the Board of Directors of FEAC (the &#147;Board&#148;) or FEAC to proceed with or
effect the Transaction or the relative merits of the Transaction as compared to other transaction structures, transactions or business strategies that may be available to FEAC or the effect of any other transaction in which FEAC might engage, and
does not address whether the Company Consideration to be issued by FEAC pursuant to the Agreement is the best possibly attainable under the circumstances, (ii)&nbsp;does not address the capital structure of FEAC, whether FEAC should be issuing debt
or equity securities or a combination of both in connection with the Transaction, the Financings, the <FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Transaction or the Sponsor Loans Conversion, or the form, structure or any aspect or terms
of any debt or equity financing for the Transaction, the Financings, the <FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Transaction or the Sponsor Loans Conversion or the likelihood of closing such financings, (iii)&nbsp;does not constitute
advice or a recommendation to the Board, FEAC or any security holder as to how they should act, elect to redeem or vote with respect to any matter relating to the Transaction, (iv)&nbsp;does not constitute advice or a recommendation to the Board,
FEAC or any security holder as to how they should act, elect to redeem or vote with respect to any matter relating to the Transaction, (v)&nbsp;only addresses the fairness from a financial point of view to the FEAC Unaffiliated Shareholders of the
Company Consideration to be issued pursuant to the Agreement in the Transaction and does not address any other terms, aspects or implications of the Transaction, or any agreements, arrangements or understandings entered into in connection with the
Transaction or otherwise, (vi)&nbsp;does not address the individual circumstances of specific shareholders of FEAC with respect to rights or aspects which may distinguish such holders or equity securities held by such holders, and (vii)&nbsp;does
not address, take into consideration or give effect to any existing or future </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g459793g01g05.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">rights, preferences, restrictions or limitations or
other attributes of any such securities or holders (including the Sponsor). We express no opinion as to the fairness of any portion or aspect of the Transaction to (i)&nbsp;the holders of any class of securities, creditors or other constituencies of
FEAC, the Company or any other party, except as expressly set forth below, or (ii)&nbsp;any one class or group of FEAC&#146;s or the Company&#146;s security holders, creditors or other constituencies <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">vis-&agrave;-vis</FONT></FONT> any other class or group of FEAC&#146;s or the Company&#146;s security holders, creditors or other constituents (including, without limitation, the allocation of any Company Consideration
among or within such classes or groups of security holders, creditors or other constituents). The decision as to whether to proceed with the Transaction or any related transaction depends on an assessment of various factors, many of which are
unrelated to the financial analyses on which this Opinion is based. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lincoln expresses no opinion as to what the market price or value of the stock of
FEAC will be after the announcement or consummation of the Transaction (including as compared to the amount which holders of FEAC Class&nbsp;A Shares may receive on redemption of their FEAC Class&nbsp;A Shares in connection with the FEAC Shareholder
Redemptions). This Opinion should not be construed as a valuation opinion, credit rating, solvency opinion, an analysis of FEAC&#146;s credit worthiness, as tax advice, or as accounting advice. We also express no opinion about the amount or nature
of any compensation or equity arrangement to be given to FEAC&#146;s officers, directors or employees, or class of such persons, in connection with the Transaction relative to the Company Consideration in the Transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is understood that this Opinion is for the use and benefit of the Board in connection with the Transaction. This Opinion may not be used for any other
purpose and is not intended to, and does not confer, any rights or remedies upon any other person. Except as contemplated by the Engagement Letter, dated as of March 1, 2023, among Lincoln and FEAC, neither this Opinion nor any other advice or
information provided by Lincoln, whether oral or written, may be disclosed, reproduced, disseminated, summarized, quoted from or referred to, in whole or in part, without our prior written consent. This Opinion does not create any fiduciary duty on
the part of Lincoln to FEAC, the Board, the shareholders of FEAC or any other party. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Disclosure of Relationships</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lincoln will receive a customary fee from FEAC for our services, a portion of which was payable upon our retention, and the balance upon the earlier of
termination of the Transaction in accordance with the Agreement or the consummation of the Transaction. In addition, FEAC has agreed to indemnify us and certain related parties against certain liabilities, and to reimburse us for certain expenses,
arising in connection with or as a result of our engagement. During the two years preceding the date of this Opinion, we and our affiliates have not had other investment banking relationships with the Company or its affiliates, or any investment
banking relationships with FEAC or its affiliates, for which we were paid for our services. We and our affiliates provide a range of investment banking and financial services and, in that regard, we and our affiliates may in the future provide,
investment banking and other financial services to FEAC and each of its respective affiliates, for which we and our affiliates would expect to receive compensation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Conclusion</U> </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on and subject to the foregoing,
and in reliance thereon, we are of the opinion that, as of the date hereof, the Company Consideration to be issued in connection with the Transaction is fair from a financial point of view to the FEAC Unaffiliated Shareholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g459793g01g05.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Opinion has been authorized for issuance by the
Opinion Review Committee of Lincoln. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Very truly yours, </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g459793g00b19.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LINCOLN INTERNATIONAL LLC </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="ii459793_2"></A>ANNEX C </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Execution Version </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPONSOR AND INSIDERS LETTER AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Sponsor and Insiders Letter Agreement (the &#147;<U>Agreement</U>&#148;) is made as of May 16<SUP
STYLE="font-size:75%; vertical-align:top">th</SUP>, 2023, by and among enGene Inc., a corporation incorporated under the laws of Canada (&#147;<U>enGene</U>&#148;), enGene Holdings Inc., a company incorporated under the laws of Canada that intends
to continue to a company governed by the <I>Business Corporations Act</I> (British Columbia) (the &#147;<U>Company</U>&#148;), Forbion European Acquisition Corp., a Cayman Islands exempted company (&#147;<U>FEAC</U>&#148;), Forbion Growth Sponsor
FEAC I B.V., a Dutch private limited liability company (the &#147;<U>Sponsor</U>&#148;), each of the other parties to the Insider Letter (as defined below) set forth on the signature pages hereto (the &#147;<U>Insiders</U>&#148;), and Forbion Growth
Opportunities Fund I Cooperatief U.A., a cooperative association (<I>co&ouml;peratie</I>) with exempted liability incorporated in the Netherlands (&#147;<U>Sponsor Parent</U>&#148; and, together with Sponsor, the &#147;<U>Sponsor Parties</U>&#148;).
Capitalized terms used but not defined herein have the respective meanings given to such terms in the Business Combination Agreement (as defined below). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>,
as of the date hereof, the Sponsor is the holder of record and the &#147;beneficial owner&#148; (within the meaning of Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act) of (i) 3,162,500 FEAC Class&nbsp;B Shares (the
&#147;<U>Sponsor Shares</U>&#148;) and (ii)&nbsp;FEAC Private Placement Warrants for the purchase of 5,195,000 shares of FEAC Class&nbsp;A Shares in the aggregate (the &#147;<U>Sponsor Warrants</U>&#148;), and Sponsor Parent is the holder of record
and the &#147;beneficial owner&#148; (within the meaning of Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act) of 2,000,000 FEAC Class&nbsp;A Shares (the &#147;<U>Sponsor IPO Shares</U>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, concurrently with the execution and delivery of this Agreement, FEAC, enGene, the Company and certain other persons party
thereto are entering into a Business Combination Agreement (as the same may be amended or modified from time to time, the &#147;<U>Business Combination Agreement</U>&#148;), pursuant to which, on the terms and subject to the conditions set forth
therein, FEAC, enGene, the Company and the other parties thereto agreed, among other things, to consummate the Transactions set forth therein; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, as an inducement to FEAC, enGene and the Company to enter into the Business Combination Agreement and to consummate the
Transactions, the Sponsor Parties and the Insiders are entering into this Agreement to provide for, among other things, (i)&nbsp;the waiver of any adjustment to the conversion ratio set forth in the FEAC Articles (as defined below) or any other
anti-dilution or similar protection with respect to the Sponsor Shares that would otherwise result from or be triggered by the Transactions, (ii)&nbsp;the imposition on the Closing Date at the effective time of the Amalgamation pursuant to the Plan
of Arrangement (the &#147;<U>Closing</U>&#148;) of certain transfer restrictions with respect to the Restricted Securities (as defined below), and (iii)&nbsp;the forfeiture by the Sponsor of certain Sponsor Shares and Sponsor Warrants in connection
with the consummation of the Transactions. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE,</B> in consideration of the foregoing and the mutual agreements contained herein, and intending to be legally bound hereby,
the parties hereto hereby agree as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1. <U>Surrender</U>. On the day that is two (2)&nbsp;Business Days prior to the
Closing Date, effective immediately prior to the Class&nbsp;B Conversion and contingent upon the substantially concurrent completion of each element of the Transactions (other than those Transactions that are scheduled to be completed following the
completion of the Amalgamation), automatically, and without any further action of the Sponsor, FEAC, or any other person, 1,789,004 of Sponsor&#146;s FEAC Class&nbsp;B Shares and 5,463,381 of Sponsor&#146;s FEAC Private Placement
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Warrants (together, the &#147;<U>Surrendered Securities</U>&#148;) are hereby surrendered to FEAC and forfeited as a contribution to the capital of FEAC for no consideration and cancelled and no
longer outstanding, in each case subject to the terms and conditions of this Agreement and the Business Combination Agreement and in accordance with FEAC&#146;s Governing Documents, each as in effect immediately prior to the Class&nbsp;B Conversion.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2. <U>Insider Letter; Transfer Restrictions</U>. Capitalized terms used in this <U>Section</U><U></U><U>&nbsp;2</U> and not
otherwise defined have the meanings set forth in that certain letter agreement, dated as of December&nbsp;9, 2021 (the &#147;<U>Insider Letter</U>&#148;), among FEAC, the Sponsor and the Insiders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Insider Letter provides in Section&nbsp;9 thereof for certain restrictions on transfer of (i)&nbsp;Founder Shares and Class&nbsp;A
Ordinary Shares issuable upon conversion thereof, and (ii)&nbsp;Private Placement Warrants, Working Capital Warrants and Extension Loan Warrants, and Class&nbsp;A Ordinary Shares issuable upon exercise thereof, until the expiration of certain time
periods or the happening of certain prior events. Notwithstanding the provisions of the Insider Letter, and in precedence thereto, effective as of and conditioned upon the Closing, each of the Sponsor Parties and each Insider agrees that it, he or
she shall not, until the earlier of (A) 12:01 am, U.S. eastern time, on the twelve-month anniversary of the date of the Closing and (B)&nbsp;following the Closing, (x)&nbsp;if the closing price of the Company Common Shares (as defined below) equals
or exceeds $12.00 per share (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any <FONT STYLE="white-space:nowrap">30-trading</FONT> day period commencing at
least 150 days after the Closing (<I>provided, however</I> that the transfer restrictions applicable to Sponsor Parties and the Insiders shall not be lifted pursuant to this clause (a)(B)(x) prior to the date that is one hundred and eighty one
(181)&nbsp;days following the Closing) and (y)&nbsp;the date on which the Company completes a liquidation, merger, amalgamation, arrangement, share exchange or other similar transaction that results in all of the Company&#146;s shareholders having
the right to exchange their common shares of the Company (&#147;<U>Company Common Shares</U>&#148;) for cash, securities or other property, Transfer (as such term is defined in the Insider Letter)&nbsp;(i) any Sponsor IPO Shares, (ii)&nbsp;any
Founder Shares, any Class&nbsp;A Ordinary Shares issuable upon conversion of such Founder Shares, or any Company Common Shares issued in exchange for or in consideration of such Class&nbsp;A Ordinary Shares in connection with the Closing or
(iii)&nbsp;any Private Placement Warrants, Working Capital Warrants or Extension Loan Warrants, any Class&nbsp;A Ordinary Shares issued or issuable upon exercise of such Private Placement Warrants, Working Capital Warrants or Extension Loan
Warrants, or any Company Common Shares issued or issuable upon exercise of such warrants in the form assumed by the Company and amended in connection with the Closing; <I>provided</I>, <I>however</I>, that the foregoing restrictions shall not apply
to any Transfer of Restricted Securities (as defined below) effected in compliance with Section&nbsp;9(c) of the Insider Letter (it being understood that the &#147;written agreement with the Company&#148; in the <I>proviso</I> to Section&nbsp;9(c)
of the Insider Letter will be in substantially the form of Exhibit&nbsp;A attached hereto). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Notwithstanding anything herein or in the
Insider Letter to the contrary, from and after the Closing, references in the Insider Letter to the Founder Shares or Class&nbsp;A Ordinary Shares issuable upon conversion thereof shall include the Company Common Shares issued upon conversion and
exchange of such Founder Shares and Class&nbsp;A Ordinary Shares in connection with the Closing of the Transactions, and references in the Insider Letter to the Private Placement Warrants, Working Capital Warrants or Extension Loan Warrants or
Class&nbsp;A Ordinary Shares issuable upon exercise thereof shall include the Company Common Shares issued or issuable following the assumption by the Company of such warrants and the amendment of such warrants in connection with the Closing of the
Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The Sponsor IPO Shares, the Founder Shares, the FEAC Class&nbsp;A Ordinary Shares issuable upon conversion of such
Founder Shares, the Private Placement Warrants, Working Capital Warrants and Extension Loan Warrants, the Class&nbsp;A Ordinary Shares issuable upon exercise of such warrants, and the shares of the Company&#146;s common stock issuable in exchange
for such Sponsor IPO Shares, Founder Shares and FEAC Class&nbsp;A Ordinary Shares in connection with the Closing of the Transactions or issued or issuable upon exercise of such Private Placement Warrants, Working Capital Warrants and Extension Loan
Warrants following the assumption by the Company of such warrants and the amendment of such warrants in connection with the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Closing of the Transactions, are collectively referred to in this Agreement from time to time as the &#147;Restricted Securities&#148;. This Section&nbsp;2 shall continue to apply to Restricted
Securities following their transfer to a permitted transferee under the Insider Letter. Each holder of Restricted Securities shall be entitled to vote its Restricted Securities and receive dividends and other distributions with respect to such
Restricted Securities (to the extent such concepts are applicable) during any period of time that such shares are subject to restrictions on transfer hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Any Transfer of Restricted Securities made or attempted in violation of or contrary to the terms of this Agreement shall be null and void
<I>ab initio</I>, and FEAC and the Company shall refuse to recognize any such purported transferee of the Restricted Securities as one of FEAC&#146;s or the Company&#146;s equity holders for any purpose. Any of FEAC, enGene or the Company may impose
stop-transfer instructions with respect to the Restricted Securities during the period of the restrictions on transfer applicable thereto under this Section&nbsp;2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Each certificate (if any) evidencing any Restricted Securities shall be stamped or otherwise imprinted with a legend in substantially the
following form, in addition to any other applicable legends: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO
RESTRICTIONS ON TRANSFER SET FORTH IN A SPONSOR AND INSIDERS LETTER AGREEMENT, DATED AS OF MAY 16<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>, 2023, BY AND AMONG THE ISSUER OF SUCH SECURITIES (THE &#147;ISSUER&#148;), THE ISSUER&#146;S
SECURITY HOLDER NAMED THEREIN AND CERTAIN OTHER PARTIES NAMED THEREIN. A COPY OF SUCH SPONSOR WAIVER AND SHARE RESTRICTION AGREEMENT WILL BE FURNISHED WITHOUT CHARGE BY THE ISSUER TO THE HOLDER HEREOF UPON WRITTEN REQUEST.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) The Company and enGene are hereby made express third party beneficiaries of the Insider Letter with the power and authority to enforce the
Insider Letter on behalf of and against each other party to the Insider Letter. FEAC shall not terminate, amend or modify, or waive compliance with, the Insider Letter absent the prior written consent of the Company and enGene (not to be
unreasonably withheld). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) In the event and to the extent that there shall be a conflict between the provisions of this Agreement and
the provisions of the Insider Letter, this Agreement shall control with respect to the subject matter hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3. <U>Waiver
of Anti-Dilution Protection</U>. With effect as of immediately prior to, and conditioned upon the consummation of, the Closing, the Sponsor, who is the holder of all of the outstanding FEAC Class&nbsp;B Shares as of the date hereof, in compliance
with and pursuant to the Memorandum and Articles of Association of the FEAC adopted by special resolution dated 8&nbsp;December 2021 and effective on 9&nbsp;December 2021 (as the same may be amended or modified from time to time, the &#147;<U>FEAC
Articles</U>&#148;), hereby waives, and agrees not to assert, perfect or seek to enforce, any rights to adjustment or other anti-dilution protections that would otherwise result from or be triggered by the Transactions (including the PIPE Financing)
with respect to the FEAC Class&nbsp;B Shares under the FEAC Articles or under any applicable law; <I><U>provided</U></I>, that, for the avoidance of doubt, the foregoing waiver does not waive the Sponsor&#146;s rights under Section&nbsp;17.8 of the
FEAC Articles, which provides that in no event may any FEAC Class&nbsp;B Share convert into FEAC Class&nbsp;A Shares at a ratio that is less than <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one.</FONT></FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4. <U>Underwriting Agreement</U>. UBS Securities LLC and Kempen&nbsp;&amp; Co. USA, Inc. (now called Van Lanschot Kempen (USA)
Inc.), being the &#147;Representatives&#148; and the &#147;Underwriters&#148; (the &#147;<U>Underwriters</U>&#148;) under that certain Underwriting Agreement dated December&nbsp;9, 2021, entered into by FEAC in favor of such Underwriters (the
&#147;<U>Underwriting Agreement</U>&#148;), by execution and delivery of a consent letter agreement entered into concurrently with the execution and delivery of this Agreement, consent, including pursuant to Section&nbsp;16(g) of the Underwriting
Agreement, to the amendments of the Underwriting Agreement and the Insider Letter effected by this Agreement, including as provided in this <U>Section</U><U></U><U>&nbsp;4</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Section 4 of the Underwriting Agreement provides for certain representations and warranties and agreements of FEAC in relation to Shares,
Warrants, Founders Shares and the Amended and Restated </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Memorandum and Articles of Association (as such terms are defined in the Underwriting Agreement) that continue for a period of five (5)&nbsp;years from the date of the consummation of a Business
Combination. From and after the time and date of the Closing of the Transactions, such terms shall be deemed to refer to the Company Common Shares and the Governing Documents of the Company adopted in connection with the Closing of the Transactions,
respectively. In furtherance thereof, the Transactions, and the listing and registration of the Company Common Shares in connection therewith, are hereby expressly permitted and agreed to by the parties to the Underwriting Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) From and after the Closing of the Transactions, all communications under the Underwriting Agreement sent to FEAC (as &#147;the
Company&#148; thereunder) shall be delivered to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">enGene Holdings Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">7171 Rue Frederick Banting </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Saint-Laurent, QC H4S 1Z9 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Canada </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attn: Jason Hanson </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email: jhanson@engeneinc.com </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">with a copy (which shall not constitute notice) to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Morgan, Lewis&nbsp;&amp; Bockius LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">101 Park Ave. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">New York, NY
10178-0060 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">United States </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attn: Howard A. Kenny </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email:
howard.kenny@morganlewis.com </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">and with a copy (which shall not constitute notice) to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Blake, Cassels&nbsp;&amp; Graydon LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">595 Burrard Street, Suite </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">2600, Three Bentall Centre, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Vancouver, British Columbia V7X 1L3 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Canada </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attn: Joseph Garcia
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email: joseph.garcia@blakes.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The Company and enGene are hereby made express third party beneficiaries of the Underwriting Agreement with the power and authority to
enforce the Underwriting Agreement on behalf of and against each other party to the Underwriting Agreement. FEAC and the Underwriters shall not terminate, amend or modify, or waive compliance with, the Underwriting Agreement absent the prior written
consent of the Company and enGene. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5. <U>Fairness Opinion</U>. FEAC represents and warrants to the Sponsor, the Insiders,
enGene and the Company that a majority of FEAC&#146;s disinterested independent directors have approved the Transactions, and that FEAC has obtained, prior to entering into this Agreement and the Business Combination Agreement, an opinion from
Lincoln International LLC that the Company Consideration to be issued in connection with the Business Combination is fair from a financial point of view to the unaffiliated FEAC Shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6. <U>Sponsor Loans</U>. The Prospectus (as such term is defined in the Underwriting Agreement) permits loans made by the Sponsor
or an affiliate of the Sponsor or any of FEAC&#146;s officers or directors (each, a &#147;<U>Lender</U>&#148;), on such terms as to be determined by FEAC from time to time, to finance FEAC&#146;s needs for working capital and obligations to make
extension payments (&#147;<U>Sponsor Loans</U>&#148;). The Prospectus, and the agreements entered into by FEAC at the time of its initial public offering, contemplate that such Sponsor Loans are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
convertible into private placement warrants at a price of $1.50 per warrant, at the option of the Lender. FEAC, Sponsor and each Insider that is a Lender under the Sponsor Loans, each on its own
behalf and on behalf of its affiliates (including the officers and directors of FEAC and each Lender), hereby, assuming that the aggregate principal amount outstanding under the Sponsor Loans exceeds $1,500,000 on the day which is two
(2)&nbsp;Business Days prior to the Closing Date, agrees to elect to convert, and shall take such necessary or appropriate actions so as to ensure the conversion of, an amount equal to $1,500,000 of the aggregate principal amount outstanding under
the Sponsor Loans, taken together, into additional FEAC Private Placement Warrants immediately prior to the Surrender on the day that is two (2)&nbsp;Business Days prior to the Closing Date, in each case in accordance with the Warrant Agreement and
the relevant promissory note governing each such Sponsor Loan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7. <U>Representations and Warranties of the Sponsor</U>. Each
Sponsor Party (as to itself and not as to any other Sponsor Party) represents and warrants as of the date hereof to enGene, the Company and FEAC as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Organization; Due Authorization</U>. Such Sponsor Party is duly organized, validly existing and in good standing under the laws of the
jurisdiction in which it is incorporated, formed, organized or constituted, and the execution, delivery and performance of this Agreement and the consummation of the transactions contemplated hereby are within such Sponsor Party&#146;s corporate,
limited liability company or organizational powers and have been duly authorized by all necessary corporate, limited liability company or organizational actions on the part of such Sponsor Party&#146;s. This Agreement has been duly executed and
delivered by such Sponsor Party and, assuming due authorization, execution and delivery by the other parties to this Agreement, this Agreement constitutes a legally valid and binding obligation of such Sponsor Party, enforceable against such Sponsor
Party in accordance with the terms hereof (except as enforceability may be limited by bankruptcy laws, other similar laws affecting creditors&#146; rights and general principles of equity affecting the availability of specific performance and other
equitable remedies). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Ownership</U>. Such Sponsor Party is the record and beneficial owner (within the meaning of Rule <FONT
STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act) of, and has good title to, all of the Sponsor Shares and Sponsor Warrants as set forth in the Recitals to this Agreement as being owned by such Sponsor Party and there exist no Liens or
any other limitation or restriction (including any restriction on the right to vote, sell or otherwise dispose of such Sponsor Shares and Sponsor Warrants (other than transfer restrictions under the Securities Act or other applicable securities
laws)) affecting any Sponsor Shares and Sponsor Warrants, other than any Permitted Liens or pursuant to this Agreement, the Business Combination Agreement and the Ancillary Documents. Other than the Sponsor Warrants, pursuant to the FEAC Articles or
pursuant to an Ancillary Document, such Sponsor Party does not hold or own any rights to acquire (directly or indirectly) any equity securities of FEAC or outstanding options, warrants, rights, convertible or exchangeable securities,
&#147;phantom&#148; stock rights, stock appreciation rights, stock-based performance units or commitments for shares of FEAC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>No
Conflicts</U>. The execution and delivery of this Agreement by such Sponsor Party does not, and the performance by such Sponsor Party of its obligations hereunder will not, (i)&nbsp;conflict with or result in a violation of the organizational
documents of such Sponsor Party or (ii)&nbsp;require any consent or approval that has not been given or other action that has not been taken by any Person (including under any contract binding upon such Sponsor Party or such Sponsor Party&#146;s
Sponsor Shares or Sponsor Warrants), in each case to the extent such consent, approval or other action would prevent, enjoin or materially delay the performance by such Sponsor Party of its obligations under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Litigation</U>. There are no Proceedings pending against such Sponsor Party, or to the knowledge of such Sponsor Party, threatened
against such Sponsor Party, before (or, in the case of threatened Proceedings, that would be before) any Governmental Entity, which in any manner challenges or seeks to prevent, enjoin or materially delay the performance by such Sponsor Party of its
obligations under this Agreement. Such Sponsor Party has never been suspended or expelled from membership in any securities or commodities exchange or association or had a securities or commodities license or registration denied, suspended or
revoked. Such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Sponsor Party (i)&nbsp;is not subject to or a respondent in any legal action for, any injunction, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">cease-and-desist</FONT></FONT>
order or order or stipulation to desist or refrain from any act or practice relating to the offering of securities in any jurisdiction, (ii)&nbsp;has never been convicted of, or pleaded guilty to, any crime involving fraud, relating to any financial
transaction or handling of funds of another person, or pertaining to any dealings in any securities and (iii)&nbsp;is not currently a defendant in any such criminal proceeding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Acknowledgment</U>. Such Sponsor Party understands and acknowledges that each of the Company, enGene and FEAC is entering into the
Business Combination Agreement in reliance upon such Sponsor Party&#146;s execution and delivery of this Agreement. Such Sponsor Party has had the opportunity to read the Business Combination Agreement and this Agreement and has had the opportunity
to consult with its tax and legal advisors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8. <U>Termination</U>. This Agreement and all of its provisions shall
automatically terminate and be of no further force or effect upon the termination of the Business Combination Agreement in accordance with its terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;9. <U>Miscellaneous</U>. Article 8 of the Business Combination Agreement is incorporated herein by reference, <I>mutatis
mutandis</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;10. <U>Legal Representation</U>. The Sponsor and the Insiders each hereby agrees on behalf of its directors,
members, partners, officers, employees and Affiliates and each of their respective successors and assigns (all such parties, the &#147;<U>Waiving Parties</U>&#148;), that Blake, Cassels&nbsp;&amp; Graydon LLP (&#147;<U>BCG</U>&#148;) and Morgan
Lewis&nbsp;&amp; Bockius LLP (&#147;<U>MLB</U>&#148;) may represent the shareholders or holders of other equity interests of the Company and its Subsidiaries or any of their respective directors, members, partners, officers, employees or Affiliates
(including after the Closing, FEAC), in each case, solely in connection with any Proceeding or obligation arising out of or relating to the Transactions, notwithstanding their prior representation of enGene, its Subsidiaries and the Company. The
Sponsor and each Insider, on behalf of itself and the Waiving Parties, hereby consents thereto and irrevocably waives (and will not assert) any conflict of interest, breach of duty or any other objection arising from or relating to BCG&#146;s or
MLB&#146;s prior representation of enGene, its Subsidiaries or the Company (including, after the Closing, FEAC). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[ <I>remainder of page
intentionally left blank; signature page follows </I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, each of the undersigned has caused its duly authorized
representative to execute and deliver this Sponsor and Insiders Letter Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ENGENE:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">ENGENE INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Anthony Cheung</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Anthony Cheung</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Technology Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>COMPANY:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">ENGENE HOLDINGS INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Richard Glickman</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Richard Glickman</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to Sponsor and Insiders Letter Agreement</I>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, each of the undersigned has caused its duly authorized
representative to execute and deliver this Sponsor and Insiders Letter Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">FORBION EUROPEAN ACQUISITION CORP.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Jasper Bos</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Jasper Bos</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">FORBION GROWTH SPONSOR FEAC I B.V.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Jasper Bos</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Jasper Bos</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Cyril Lesser</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Cyril Lesser</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">FORBION GROWTH OPPORTUNITIES FUND I COOPERATIEF U.A.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Sander Slootweg</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Sander Slootweg</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Authorized Signatory</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Wouter Joustra</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Wouter Joustra</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Authorized Proxy</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>FEAC and Sponsor Parties&#146; Signature Page to Sponsor and Insiders Letter Agreement</I>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, each of the undersigned has caused its duly authorized
representative to execute and deliver this Sponsor and Insiders Letter Agreement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jasper Bos</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">JASPER BOS, individually</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Cyril Lesser</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CYRIL LESSER, individually</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Sander Slootweg</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">SANDER SLOOTWEG, individually</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Wouter Joustra</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">WOUTER JOUSTRA, individually</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Philip Astley-Sparke</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">PHILIP ASTLEY-SPARKE, individually</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Hilde Steineger</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">HILDE STEINEGER, individually</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Ton Logtenberg</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">TON LOGTENBERG, individually</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Underwriter Signature Page to Sponsor and Insiders Letter Agreement</I>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form of Joinder to Insider Letter and </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Sponsor and Insiders Letter Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">[DATE], 20__ </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reference is made
to (i)&nbsp;that certain that certain letter agreement, dated as of December&nbsp;9, 2021 (the &#147;<U>Insider Letter</U>&#148;), among Forbion European Acquisition Corp., a Cayman Islands exempted company (&#147;<U>FEAC</U>&#148;), Forbion Growth
Sponsor FEAC I B.V., a Dutch private limited liability company (the &#147;<U>Sponsor</U>&#148;) and the other individuals party thereto (the &#147;<U>Insiders</U>&#148;), and (ii)&nbsp;that certain Sponsor and Insiders Letter Agreement, dated as of
May 16<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>, 2023, by and among enGene Inc., a company incorporated under the laws of Canada (&#147;<U>enGene</U>&#148;), enGene Holdings Inc., a company incorporated under the laws of Canada (the
&#147;<U>Company</U>&#148;), FEAC, Sponsor and the Insiders (as amended from time to time, the &#147;<U>Securities Restriction Agreement</U>&#148;). Capitalized terms used but not otherwise defined herein have the meanings given to such terms in the
Insider Letter or the Securities Restriction Agreement, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned transferee of [<I>describe securities
transferred</I>] (a &#147;<U>New Holder</U>&#148;) agrees that this joinder to the Insider Letter and the Securities Restriction Agreement (this &#147;<U>Joinder</U>&#148;) is being executed and delivered for good and valuable consideration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned New Holder hereby agrees to and does become party to the Insider Letter as an &#147;Insider&#148; thereunder and to the
Securities Restriction Agreement as a &#147;Sponsor&#148; or an &#147;Insider&#148; thereunder, as applicable. This Joinder shall serve as a counterparty signature page to the Insider Letter and the Securities Restriction Agreement and by executing
below, the undersigned New Holder is deemed to have executed each of the Insider Letter and the Securities Restriction Agreement with the same force and effect as if originally named a party thereto effective from and after the date hereof;
<I><U>provided</U></I>, <I><U>however</U></I>, that the terms and conditions of the Insider Letter and the Securities Restriction Agreement shall apply only with respect to the Restricted Shares transferred to New Holder from the transferor that was
a party to the Insider Letter and the Securities Restriction Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Joinder may be executed in multiple counterparts, including
by means of facsimile or electronic signature, each of which shall be deemed an original, but all of which together shall constitute the same instrument. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[ <I>remainder of page intentionally left blank; signature page follows</I> ] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, each of the undersigned has caused its duly authorized
representative to execute and deliver this Joinder as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">[NEW HOLDER]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman"><U>Notice Address</U>: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">FORBION EUROPEAN ACQUISITION CORP.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">ENGENE HOLDINGS INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="ii459793_5"></A>ANNEX D </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WARRANT
ASSIGNMENT, ASSUMPTION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AND AMENDMENT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Warrant Assignment, Assumption and Amendment Agreement (this &#147;<U>Agreement</U>&#148;) is made as of [&#9679;], 2023, by and among
Forbion European Acquisition Corp., a Cayman Islands exempted company (the &#147;<U>Company</U>&#148;), enGene Inc., a company incorporated under the laws of Canada (&#147;<U>enGene</U>&#148;), enGene Holdings Inc., a company incorporated under the
laws of Canada that intends to continue to a company governed by the <I>Business Corporations Act</I> (British Columbia) (&#147;<U>New enGene</U>&#148;), and Continental Stock Transfer&nbsp;&amp; Trust Company, a New York corporation (the
&#147;<U>Warrant Agent</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Company and the Warrant Agent are parties to that certain warrant agreement, dated
as of December&nbsp;9, 2021 (the &#147;<U>Original Warrant Agreement</U>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Company consummated, on
December&nbsp;14, 2021, an initial public offering (including the associated over-allotment offering, the &#147;<U>Offering</U>&#148;) of units of the Company&#146;s equity securities, each such unit comprised of one Class&nbsp;A ordinary share of
the Company, par value $0.0001 per share (&#147;<U>Ordinary Shares</U>&#148;) and <FONT STYLE="white-space:nowrap">one-third</FONT> of a redeemable Public Warrant (as defined below) and, in connection therewith, issued and delivered warrants for the
purchase of 4,216,666 Ordinary Shares to public investors in the Offering (the &#147;<U>FEAC Public Warrants</U>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>,
Forbion Growth Sponsor FEAC I B.V., a Dutch limited liability company (the &#147;<U>Sponsor</U>&#148;), substantially concurrently with the Offering, purchased from the Company warrants for the purchase of an 5,195,000 Ordinary Shares, each bearing
the legend set forth in <U>Exhibit A</U> hereto (the &#147;<U>Private Placement Warrants</U>&#148;), at a purchase price of $1.50 per Private Placement Warrant; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, in order to finance the Company&#146;s transaction costs in connection with an intended initial Business Combination (as
defined below), the Sponsor or an affiliate of the Sponsor or certain of the Company&#146;s officers and directors may, but are not obligated to, from time to time loan to the Company funds as the Company may require (&#147;<U>Working Capital
Loans</U>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, in order to extend the period of time the Company has to consummate a Business Combination (as defined
below) by up to two additional three month periods, the Sponsor or its affiliates or designees must deposit into the trust account additional funds of $1,265,000 ($0.10 per unit) for each respective available three-month extension, for a total
payment of up to $2,530,000 ($0.20 per unit), in exchange for one or more <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing, unsecured promissory notes (&#147;<U>Extension Loans</U>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, up to $1,500,000 of the Working Capital Loans and Extension Loans, taken together, are convertible (at a rate of a warrant for
one share for every $1.50 of such loans) into warrants for the purchase of Ordinary Shares at a price of $1.50 per warrant, which warrants will be identical to the Private Placement Warrants (the &#147;<U>Sponsor Loan Warrants</U>&#148; and,
together with the Private Placement Warrants, the &#147;<U>FEAC Private Placement Warrants</U>&#148; and, together with the FEAC Public Warrants, the &#147;<U>FEAC Warrants</U>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, all of the FEAC Warrants are governed by the Original Warrant Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Company, enGene, New enGene and certain other persons party thereto have entered into a Business Combination Agreement (as
the same may be amended or modified from time to time, the &#147;<U>Business Combination Agreement</U>&#148;), pursuant to which, on the terms and subject to the conditions set forth therein, among other things, at the time of consummation (the
&#147;<U>Closing</U>&#148;) of the Transactions (as defined therein), the Company, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
enGene and New enGene will, among other things, combine their respective businesses (the transactions contemplated by the Business Combination Agreement are referred to herein as the
&#147;<U>Business Combination</U>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, at the Initial Merger Effective Time and as part of the Cayman Merger (each as
defined in the Business Combination Agreement), each outstanding Ordinary Share will be converted into the right to receive one common share of New enGene (each, a &#147;<U>Common Share</U>&#148; and together, the &#147;<U>Common Shares</U>&#148;);
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, pursuant to each of the Business Combination Agreement and Section&nbsp;4.4 of the Original Warrant Agreement, as part of
the Cayman Reorganization (as defined in the Business Combination Agreement), concurrently with the Cayman Merger, and effective at the same time the Cayman Merger becomes effective under the Cayman Islands law (the &#147;<U>Effective
Time</U>&#148;), each of the FEAC Public Warrants issued and outstanding immediately prior thereto will be assumed by New enGene and amended as provided herein to reflect that such warrants will thereupon become warrants to purchase Common Shares on
substantially the same terms as the FEAC Public Warrants (&#147;<U>New enGene Public Warrants</U>&#148;), and the rights and obligations of the Company under the Original Warrant Agreement shall be assigned to and assumed by New enGene; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Sponsor, the Company, enGene, New enGene and certain other parties thereto named therein have entered into a Sponsor and
Insiders Letter Agreement, dated May&nbsp;16, 2023 (the &#147;<U>Sponsor Letter Agreement</U>&#148;), pursuant to which, among other things, the Sponsor has agreed to surrender FEAC Private Placement Warrants for the purchase of 5,463,381 Ordinary
Shares (the &#147;<U>Forfeited Warrants</U>&#148;) as a contribution to the capital of FEAC and for no consideration, effective at the time specified in the Business Combination Agreement, on the terms and conditions set forth in the Business
Combination Agreement and the Sponsor Letter Agreement (the &#147;<U>Warrant Forfeiture</U>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, as part of the Cayman
Reorganization, concurrently with the Cayman Merger, and effective at the same time the Cayman Merger becomes effective under the Cayman Islands law, the FEAC Private Placement Warrants remaining after giving effect to the Warrant Forfeiture are
being assumed by New enGene, and amended as provided herein to reflect that such warrants will thereupon become warrants to purchase Common Shares on substantially the same terms as the FEAC Private Placement Warrants (&#147;<U>New enGene Private
Placement Warrants</U>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, following the Cayman Reorganization, the Company will file an election to change its
classification for U.S. federal income tax purposes from a corporation to an entity disregarded as separate from its owner New enGene, to be effective as of the beginning of the Closing Date (the &#147;<U>U.S. Entity Classification
Election</U>&#148; and, together with the Cayman Reorganization, the &#147;<U>FEAC Reorganization</U>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, following
the Closing of the Business Combination, the Company will be liquidated; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, in connection with the Closing of the Business
Combination, New enGene has issued (i)&nbsp;to its PIPE Investors (as defined in the Business Combination Agreement) certain warrants for the purchase of Common Shares on substantially the same terms as the New enGene Public Warrants and
(ii)&nbsp;to a Company shareholder party to a <FONT STYLE="white-space:nowrap">non-redemption</FONT> agreement with the Company certain warrants for the purchase of Common Shares on substantially the same terms as the New enGene Public Warrants
(such warrants, together with the New enGene Private Placement Warrants and the New enGene Public Warrants, being &#147;<U>New enGene Warrants</U>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, enGene has issued to its 2022 Noteholders and its 2023 Noteholders (as such terms are defined in the Business Combination
Agreement) certain warrants of enGene (the &#147;<U>enGene Warrants</U>&#148;) for the purchase of common shares of enGene (&#147;<U>enGene Common Shares</U>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, on the Closing Date, pursuant to the Amalgamation (as defined in the Business Combination Agreement), (i) each enGene Warrant
outstanding immediately prior to the Amalgamation will be exchanged for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
New enGene Private Placement Warrants for the purchase of such number of Common Shares as is determined as per the Exchange Ratio (as defined in the Business Combination Agreement), upon and
subject to the other terms and conditions set forth in Business Combination, the Plan of Arrangement (as defined in the Business Combination Agreement) and in accordance with the provisions of applicable law; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, as part of the Cayman Reorganization the Company desires to assign all of its right, title and interest in the Original
Warrant Agreement to New enGene and New enGene wishes to accept such assignment, and the parties hereto desire to amend the Original Warrant Agreement in the form of this Agreement to reflect such assignment and assumption; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, Section&nbsp;9.8 of the Original Warrant Agreement provides that the Company and the Warrant Agent may amend the Original
Warrant Agreement without the consent of any registered holders for the purpose of curing any ambiguity, or curing, correcting or supplementing any defective provision contained therein or adding or changing any other provisions with respect to
matters or questions arising under the Original Warrant Agreement as the Company and the Warrant Agent may deem necessary or desirable and that the Company and the Warrant Agent deem shall not adversely affect the interest of the registered holders;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the parties hereto desire to enter into this Agreement to provide for the Warrant Agent to act following the Closing on
behalf of New enGene hereunder, and the Warrant Agent is willing to so act, including in connection with the issuances, surrenders, assignments, assumptions and amendments in respect of the FEAC Warrants, the enGene Warrants and the New enGene
Warrants described herein, and in connection with the issuance, registration, transfer, exchange, redemption and exercise of the New enGene Warrants; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, New enGene desires to provide for the form and provisions of the New enGene Warrants, the terms upon which they shall be
issued and exercised, and the respective rights, limitation of rights, and immunities of New enGene, the Warrant Agent, and the holders of the Warrants; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, all acts and things have been done and performed which are necessary to make the New enGene Warrants, when executed on behalf
of New enGene and countersigned by or on behalf of the Warrant Agent, if a physical certificate is issued, as provided herein, the valid, binding and legal obligations of New enGene, and to authorize the execution and delivery of this Agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE</B>, in consideration of the foregoing and of the mutual covenants and agreements contained herein, the receipt and
sufficiency of which is hereby acknowledged, and intending to be legally bound, the parties hereto hereby agree as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">1.
&nbsp;&nbsp;&nbsp;&nbsp;<U>Assignment and Assumption; Consent</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Assignment and Assumption</U>. The
Company hereby assigns to New enGene all of the Company&#146;s right, title and interest in and to the Original Warrant Agreement (as amended hereby) as of the Effective Time. New enGene hereby assumes, and agrees to pay, perform, satisfy and
discharge in full, as the same become due, all of the Company&#146;s liabilities and obligations under the Original Warrant Agreement (as amended hereby). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Consent</U>. The Warrant Agent hereby consents to the assignment of the Original Warrant Agreement by the
Company to New enGene pursuant to <U>Section</U><U></U><U>&nbsp;1.1</U> hereof effective as of the Effective Time, and the assumption of the Original Warrant Agreement by New enGene from the Company pursuant to <U>Section</U><U></U><U>&nbsp;1.1</U>
hereof effective as of the Effective Time, and to the continuation of the Original Warrant Agreement in full force and effect from and after the Effective Time, subject at all times to the Original Warrant Agreement (as amended hereby) and to all of
the provisions, covenants, agreements, terms and conditions of the Original Warrant Agreement and this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.
&nbsp;&nbsp;&nbsp;&nbsp;<U>Warrant Forfeiture</U>. Sponsor hereby confirms the prior surrender, pursuant to and effected by the Sponsor Letter Agreement, of the Forfeited Warrants to the Company as a contribution to the capital of FEAC and for no
consideration, effective as of the time and date set forth in the Sponsor Letter Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendment of Original Warrant Agreement</U>. The Company and
the Warrant Agent hereby amend the Original Warrant Agreement as provided in this <U>Section</U><U></U><U>&nbsp;3</U>, effective as of the Effective Time, and acknowledge and agree that the amendments to the Original Warrant Agreement set forth in
this <U>Section</U><U></U><U>&nbsp;3</U> are necessary or desirable and that such amendments do not adversely affect the interests of the registered holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.1 &nbsp;&nbsp;&nbsp;&nbsp;<U>Defined Terms</U>. Unless the context otherwise requires, from and after the Effective Time: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;All references to the &#147;Company&#148; in the Original Warrant Agreement shall mean and refer to enGene
Holdings Inc. as the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successor-in-interest</FONT></FONT> to Forbion European Acquisition Corp. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;All references to &#147;Ordinary Shares&#148; in the Original Warrant Agreement shall mean and refer to the Common
Shares. As a result thereof, all such references shall be references to the Common Shares of enGene Holdings Inc. rather than the Ordinary Shares of Forbion European Acquisition Corp. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;All references to &#147;Public Warrants&#148;, &#147;Private Placement Warrants&#148; and &#147;Warrants&#148; in
the Original Warrant Agreement shall mean and refer to the New enGene Public Warrants, the New enGene Private Placement Warrants and the New enGene Warrants, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;All references to &#147;Warrants&#148; in the Original Warrant Agreement shall mean and refer to the New enGene
Warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;All references to the &#147;Board of Directors&#148; or any committee thereof in the Original
Warrant Agreement shall mean the board of directors or committee thereof, as applicable, of enGene Holdings Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;All references to the Company&#146;s &#147;Charter&#148; shall mean the Articles of New enGene after giving effect
to the continuation of New enGene to a company governed by the <I>Business Corporations Act</I> (British Columbia). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;The term &#147;Business Day&#148; as used in the Original Warrant Agreement shall mean a day, other than a
Saturday, Sunday or federal holiday, on which banks in Toronto, Ontario and New York, New York are generally open for normal business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Detachability of Warrants</U>. Section&nbsp;2.4 and Section&nbsp;5.6 of the Original Warrant Agreement are each
hereby deleted and replaced with the following: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">&#147;INTENTIONALLY OMITTED&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>. Section&nbsp;9.2 of the Original Warrant Agreement is hereby deleted and replaced with the
following: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Any notice, statement or demand authorized by this Agreement to be given or made by the Warrant Agent or by the holder of any
Warrant to or on the Company shall be sufficiently given when so delivered if by hand or overnight delivery or if sent by certified mail or private courier service within five (5)&nbsp;days after deposit of such notice, postage prepaid, addressed
(until another address is filed in writing by the Company with the Warrant Agent), as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">enGene Holdings Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7171 Rue Frederick Banting </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Saint-Laurent, QC H4S 1Z9 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Canada
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Attn: Jason Hanson </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Email:
jhanson@engeneinc.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">with a copy to (which will not constitute notice): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Morgan, Lewis&nbsp;&amp; Bockius LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">101 Park Ave. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">New York, NY
10178-0060 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">United States </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Attn: Howard A. Kenny </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Email:
howard.kenny@morganlewis.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">with a copy (which shall not constitute notice) to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Blake, Cassels&nbsp;&amp; Graydon LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">595 Burrard Street, Suite 2600, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Three Bentall Centre, </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Vancouver,
British Columbia V7X 1L3 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Canada </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Attn: Joseph Garcia </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Email:
joseph.garcia@blakes.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any notice, statement or demand authorized by this Agreement to be given or made by the holder of any Warrant or by the Company
to or on the Warrant Agent shall be sufficiently given when so delivered if by hand or overnight delivery or if sent by certified mail or private courier service within five (5)&nbsp;days after deposit of such notice, postage prepaid, addressed
(until another address is filed in writing by the Warrant Agent with the Company), as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Continental Stock Transfer&nbsp;&amp; Trust
Company </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">1 State Street, 30<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>&nbsp;Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">New York, New York 10004 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: Compliance Department </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.4 &nbsp;&nbsp;&nbsp;&nbsp;<U>Legend</U>. The restricted legend contained in Exhibit A of the Original Warrant Agreement is hereby deleted
and replaced with the Legend contained in <U>Exhibit A</U> hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.5 &nbsp;&nbsp;&nbsp;&nbsp;<U>Warrant Certificate</U>. The Warrant
Certificate contained in Exhibit B of the Original Warrant Agreement is hereby deleted and replaced with the Warrant Certificate contained in <U>Exhibit B</U> hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[ <I>Signature Page Follows </I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF, </B>each of the parties has caused this Agreement to be duly executed
by its duly authorized representative as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">FORBION EUROPEAN ACQUISITION CORP.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">ENGENE INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">ENGENE HOLDINGS INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">CONTINENTAL STOCK TRANSFER&nbsp;&amp; TRUST COMPANY</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LEGEND </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THE SECURITIES REPRESENTED BY
THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS, AND MAY NOT BE OFFERED, SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED,
AND ANY APPLICABLE STATE SECURITIES LAWS OR AN EXEMPTION FROM REGISTRATION IS AVAILABLE. IN ADDITION, SUBJECT TO ANY ADDITIONAL LIMITATIONS ON TRANSFER DESCRIBED IN THE WARRANT AGREEMENT BY AND AMONG NEW ENGENE HOLDINGS INC. (AS SUCCESSOR TO FORBION
EUROPEAN ACQUISITION CORP.), CONTINENTAL STOCK TRANSFER&nbsp;&amp; TRUST COMPANY AND THE OTHER PARTIES THERETO, THE SECURITIES REPRESENTED BY THIS CERTIFICATE MAY NOT BE SOLD OR TRANSFERRED PRIOR TO THE DATE THAT IS THIRTY (30)&nbsp;DAYS AFTER THE
DATE UPON WHICH FORBION EUROPEAN ACQUISITION CORP. COMPLETES THE BUSINESS COMBINATION (AS DEFINED IN THE RECITALS OF THE WARRANT AGREEMENT, AS AMENDED, REFERRED TO HEREIN) EXCEPT TO A PERMITTED TRANSFEREE (AS DEFINED IN <U>SECTION 2</U> OF THE
WARRANT AGREEMENT, AS AMENDED) WHO AGREES IN WRITING WITH THE COMPANY TO BE SUBJECT TO SUCH TRANSFER PROVISIONS. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECURITIES EVIDENCED BY THIS CERTIFICATE
AND COMMON SHARES OF THE COMPANY ISSUED UPON EXERCISE OF SUCH SECURITIES ARE ENTITLED TO REGISTRATION RIGHTS UNDER CERTAIN AGREEMENTS BY AND AMONG THE COMPANY AND THE RESPECTIVE PARTIES THERETO. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form of Warrant Certificate </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Face </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Number </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Warrants </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THIS WARRANT
SHALL BE VOID IF NOT EXERCISED PRIOR TO </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE EXPIRATION OF THE EXERCISE PERIOD PROVIDED FOR IN THE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WARRANT AGREEMENT DESCRIBED BELOW </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE HOLDINGS INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Organized under the laws of the Province of British Colombia, Canada </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>CUSIP </B>&#9679; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Warrant
Certificate </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>This Warrant Certificate certifies
that</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, or registered assigns, is the registered holder
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; warrants evidenced hereby (the<B>&nbsp;&#147;Warrants&#148;</B>&nbsp;and each, a <B>&#147;Warrant&#148;</B>) to purchase Class&nbsp;A Ordinary Shares,
$0.0001 par value per share (the <B>&#147;Common Shares&#148;</B>), of enGene Holdings Inc., a company organized under the laws of the Province of British Colombia, Canada<I> </I>(the<B>&nbsp;&#147;Company&#148;</B>). Each Warrant entitles the
holder, upon exercise during the Exercise Period set forth in the Warrant Agreement referred to below, to receive from the Company that number of fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> Common Shares as set forth below,
at the exercise price (the<B>&nbsp;&#147;Warrant Price&#148;</B>) as determined pursuant to the Warrant Agreement, payable in US dollars, by bank wire or certified check (or through &#147;<B>cashless exercise</B>&#148; as provided for in the Warrant
Agreement) of the United&nbsp;States of America upon surrender of this Warrant Certificate and payment of the Warrant Price at the office or agency of the Warrant Agent referred to below, subject to the conditions set forth herein and in the Warrant
Agreement. Defined terms used in this Warrant Certificate but not defined herein shall have the meanings given to them in the Warrant Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each whole Warrant is initially exercisable for one fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> Common Share. No
fractional shares will be issued upon exercise of any Warrant. If, upon the exercise of Warrants, a holder would be entitled to receive a fractional interest in a Common Share, the Company will, upon exercise, round down to the nearest whole number
the number of Common Shares to be issued to the Warrant holder. The number of Common Shares issuable upon exercise of the Warrants is subject to adjustment upon the occurrence of certain events set forth in the Warrant Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The initial Warrant Price per Common Share for any Warrant is equal to $11.50 per share. The Warrant Price is subject to adjustment upon the
occurrence of certain events set forth in the Warrant Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the conditions set forth in the Warrant Agreement, the
Warrants may be exercised only during the Exercise Period and to the extent not exercised by the end of such Exercise Period, such Warrants shall become void. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reference is hereby made to the further provisions of this Warrant Certificate set forth on the reverse hereof and such further provisions
shall for all purposes have the same effect as though fully set forth at this place. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Warrant Certificate shall not be valid unless
countersigned by the Warrant Agent, as such term is used in the Warrant Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Warrant Certificate shall be governed by and
construed in accordance with the internal laws of the State of New York, without regard to conflicts of laws principles thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[
<I>Signature Page Follows</I> ] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ENGENE HOLDINGS INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">[&#9679;]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">[&#9679;]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CONTINENTAL STOCK TRANSFER&nbsp;&amp; TRUST COMPANY, as Warrant Agent</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">[&#9679;]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">[&#9679;]</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form of Warrant Certificate </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Reverse </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Warrants
evidenced by this Warrant Certificate are part of a duly authorized issue of Warrants entitling the holder on exercise to receive Common Shares and are issued or to be issued pursuant to a Warrant Agreement dated as of [&#9679;], 2023
(the&nbsp;&#147;<B>Warrant Agreement</B>&#148;), duly executed and delivered by the Company to Continental Stock Transfer&nbsp;&amp; Trust Company, a New York corporation, as warrant agent (the&nbsp;&#147;<B>Warrant Agent</B>&#148;), which Warrant
Agreement is hereby incorporated by reference in and made a part of this instrument and is hereby referred to for a description of the rights, limitation of rights, obligations, duties and immunities thereunder of the Warrant Agent, the Company and
the holders (the words&nbsp;&#147;<B>holders</B>&#148;&nbsp;or&nbsp;&#147;<B>holder</B>&#148;&nbsp;meaning the Registered Holders or Registered Holder, respectively) of the Warrants. A copy of the Warrant Agreement may be obtained by the holder
hereof upon written request to the Company. Defined terms used in this Warrant Certificate but not defined herein shall have the meanings given to them in the Warrant Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Warrants may be exercised at any time during the Exercise Period set forth in the Warrant Agreement. The holder of Warrants evidenced by this
Warrant Certificate may exercise them by surrendering this Warrant Certificate, with the form of election to purchase set forth hereon properly completed and executed, together with payment of the Warrant Price as specified in the Warrant Agreement
(or through &#147;<B>cashless exercise</B>&#148; as provided for in the Warrant Agreement) at the principal corporate trust office of the Warrant Agent. In the event that upon any exercise of Warrants evidenced hereby the number of Warrants
exercised shall be less than the total number of Warrants evidenced hereby, there shall be issued to the holder hereof or his, her or its assignee, a new Warrant Certificate evidencing the number of Warrants not exercised. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything else in this Warrant Certificate or the Warrant Agreement, no Warrant may be exercised unless at the time of exercise
(i)&nbsp;a registration statement covering the Common Shares to be issued upon exercise is effective under the Securities Act of 1933, as amended, and (ii)&nbsp;a prospectus thereunder relating to the Common Shares is current, except through
&#147;cashless exercise&#148; as provided for in the Warrant Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Warrant Agreement provides that upon the occurrence of
certain events the number of Common Shares issuable upon the exercise of the Warrants set forth on the face hereof may, subject to certain conditions, be adjusted. If, upon exercise of a Warrant, the holder thereof would be entitled to receive a
fractional interest in a Common Share, the Company shall, upon exercise, round down to the nearest whole number of Common Shares to be issued to the holder of the Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Warrant Certificates, when surrendered at the principal corporate trust office of the Warrant Agent by the Registered Holder thereof in person
or by legal representative or attorney duly authorized in writing, may be exchanged, in the manner and subject to the limitations provided in the Warrant Agreement, but without payment of any service charge, for another Warrant Certificate or
Warrant Certificates of like tenor evidencing in the aggregate a like number of Warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon due presentation for registration of
transfer of this Warrant Certificate at the office of the Warrant Agent, a new Warrant Certificate or Warrant Certificates of like tenor and evidencing in the aggregate a like number of Warrants shall be issued to the transferee(s) in exchange for
this Warrant Certificate, subject to the limitations provided in the Warrant Agreement, without charge except for any tax or other governmental charge imposed in connection therewith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company and the Warrant Agent may deem and treat the Registered Holder(s) hereof as the absolute owner(s) of this Warrant Certificate
(notwithstanding any notation of ownership or other writing hereon made by anyone), for the purpose of any exercise hereof, of any distribution to the holder(s) hereof, and for all other purposes, and neither the Company nor the Warrant Agent shall
be affected by any notice to the contrary. Neither the Warrants nor this Warrant Certificate entitles any holder hereof to any rights of a shareholder of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Election to Purchase </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(To Be Executed Upon Exercise of Warrant) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned hereby irrevocably elects to exercise the right, represented by this Warrant Certificate, to
receive&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common Shares and herewith tenders payment for such Common Shares to the order of enGene Holdings Inc. (the&nbsp;&#147;<B>Company</B>&#148;) in
the amount of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in accordance with the terms hereof. The undersigned requests that a certificate for such Common Shares be registered in the name
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; whose address is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and that such Common Shares be
delivered to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; whose address is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; . If said number of shares
is less than all of the Common Shares purchasable hereunder, the undersigned requests that a new Warrant Certificate representing the remaining balance of such Common Shares be registered in the name
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , whose address is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and that such Warrant Certificate
be delivered to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , whose address is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; . </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that the Warrant may be exercised, to the extent allowed by the Warrant Agreement, through cashless exercise (i)&nbsp;the number
of Common Shares that this Warrant is exercisable for would be determined in accordance with the relevant section of the Warrant Agreement which allows for such cashless exercise and (ii)&nbsp;the holder hereof shall complete the following: The
undersigned hereby irrevocably elects to exercise the right, represented by this Warrant Certificate, through the cashless exercise provisions of the Warrant Agreement, to receive Common Shares. If said number of shares is less than all of the
Common Shares purchasable hereunder (after giving effect to the cashless exercise), the undersigned requests that a new Warrant Certificate representing the remaining balance of such Common Shares be registered in the name
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , whose address is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and that such Warrant Certificate
be delivered to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , whose address is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; . </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[ <I>Signature Page Follows </I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: [&#9679;], 202[&#9679;] </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Signature)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Address)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Tax Identification Number)</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Signature Guaranteed: </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THE SIGNATURE(S) SHOULD BE GUARANTEED BY
AN ELIGIBLE GUARANTOR INSTITUTION (BANKS, STOCKBROKERS, SAVINGS AND LOAN ASSOCIATIONS AND CREDIT UNIONS WITH MEMBERSHIP IN AN APPROVED SIGNATURE GUARANTEE MEDALLION PROGRAM, PURSUANT TO S.E.C. RULE <FONT STYLE="white-space:nowrap">17Ad-15</FONT>
UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="rom459793_102"></A>ANNEX E </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U STYLE="border-bottom:1pt double; padding-bottom:1pt">YOUR VOTE IS IMPORTANT. PLEASE VOTE TODAY.</U> </B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Vote by Internet &#150; QUICK


<IMG SRC="g459793g15g15.jpg" ALT="LOGO">
 EASY </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IMMEDIATE &#150; 24 Hours a Day, 7 Days a Week or by Mail </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ALIGN="center"><FONT STYLE="font-size:18pt"><B>FORBION EUROPEAN ACQUISITION CORP.</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0.50em; font-size:10pt; font-family:Times New Roman"><B>Your Internet vote authorizes the named proxies to vote your shares in the same manner as if you
marked, signed and returned your proxy card. Votes submitted electronically over the Internet must be received by 11:59 p.m., Eastern Time, on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">


<IMG SRC="g459793g15p01.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INTERNET &#150;</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>www.cstproxyvote.com</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Use the Internet to vote your proxy.
Have your proxy card available when you access the above website. Follow the prompts to vote your shares.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">


<IMG SRC="g459793g15p02.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vote at the Meeting &#150;</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you
plan to attend the virtual online extraordinary general meeting, you will need your 12 digit control number to vote electronically at the extraordinary general meeting. To attend the extraordinary general meeting, visit:</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B><U>https://www.cstproxy.com/feac/2023</U></B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">


<IMG SRC="g459793g15p03.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt"><B>MAIL &#150; </B>Mark, sign and date your proxy card and return it in the postage-paid envelope provided.</FONT></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0.50em; margin-right:0.50em; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PLEASE DO NOT RETURN THE PROXY CARD<BR>IF YOU ARE VOTING ELECTRONICALLY.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-size:8pt"><B>


<IMG SRC="g459793g15p04.jpg" ALT="LOGO">
 FOLD HERE &#149; DO NOT SEPARATE &#149; INSERT IN ENVELOPE PROVIDED


<IMG SRC="g459793g15p04.jpg" ALT="LOGO">
</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2" NOWRAP ALIGN="center"><FONT STYLE="font-size:6pt">Please mark<BR>your votes<BR>like this</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" ALIGN="center">


<IMG SRC="g459793g15p05.jpg" ALT="LOGO">
</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt"><B>PROXY</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THE BOARD OF DIRECTORS RECOMMENDS A VOTE &#147;FOR&#148; PROPOSALS
[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>]. </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:8pt; font-family:Times New Roman"><B>a)&#8195;&#8202;Proposal No. 1 - The Business Combination Proposal</B> <B>- </B>to consider and
vote upon a proposal</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="center">FOR</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">&#9744;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="center">&nbsp;AGAINST&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">&#9744;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="center">&nbsp;ABSTAIN&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">&#9744;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top" COLSPAN="7"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:8pt; font-family:Times New Roman">&nbsp;&nbsp;&#8195;&#8201;&#8201;to approve and adopt by special resolution the
Business Combination Agreement (the &#147;Business Combination Agreement&#148;), dated as of May&nbsp;16, 2023, by and among FEAC, enGene Inc. a corporation incorporated under the laws of Canada (&#147;enGene&#148;), and enGene Holdings Inc., a
corporation incorporated under the laws of Canada (&#147;New enGene&#148;), a copy of which is attached to the accompanying proxy statement/prospectus as <U>Annex A</U>, and the transactions contemplated therein (the &#147;Transactions&#148;),
whereby, among other things, FEAC, enGene and New enGene will complete a business combination (the &#147;Business Combination&#148;) (we refer to this proposal as the &#147;Business Combination Proposal&#148;).</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:8pt; font-family:Times New Roman"><B>b)&#8195;&#8202;Proposal No. 2 - The Governing Documents Proposal - </B>to consider and vote
upon a proposal</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="center">FOR</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">&#9744;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="center">&nbsp;AGAINST&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">&#9744;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="center">&nbsp;ABSTAIN&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">&#9744;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" COLSPAN="7" ROWSPAN="6"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:8pt; font-family:Times New Roman">&nbsp;&nbsp;&#8195;&#8201;&#8201;to approve the following material
differences between the articles of New enGene to be in effect following the Business Combination (the &#147;Proposed Articles&#148;) and FEAC&#146;s current Amended and Restated Memorandum and Articles of Association (the &#147;Current
Articles&#148;): (i) the name of the new public entity will be &#147;enGene Holdings Inc.&#148; as opposed to &#147;Forbion European Acquisition Corp.&#148;; (ii)New enGene will have an unlimited number of authorized common shares and an unlimited
number of authorized blank cheque preferred shares, as opposed to FEAC having 500,000,000 Class&nbsp;A ordinary shares authorized, 50,000,000 Class&nbsp;B ordinary shares authorized and 5,000,000 preference shares authorized; (iii)&nbsp;New
enGene&#146;s Proposed Articles would reduce the requisite quorum for a meeting of shareholders from a majority of votes as required under the Current Articles to 33 1/3% of the shares entitled to vote at such meeting; (iv)&nbsp;New enGene&#146;s
Proposed Articles would include an advance notice provision that requires a nominating shareholder to provide notice to New enGene in advance of a meeting of shareholders should such nominating shareholder wish to nominate a person for election to
the board of directors; (v)&nbsp;New enGene&#146;s corporate existence will be perpetual as opposed to FEAC&#146;s corporate existence terminating if the initial business</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"></TR>
</TABLE>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;
</P></DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" COLSPAN="7"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:8pt; font-family:Times New Roman">&nbsp;&nbsp;&#8195;&#8201;&#8201;combination is not consummated by FEAC within a
specified period of time; and (vi)&nbsp;New enGene&#146;s constitutional documents will not include the various provisions applicable only to special purpose acquisition corporations that FEAC&#146;s Current Articles contain (we refer to this
proposal as the &#147;Governing Documents Proposal&#148;).</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:8pt; font-family:Times New Roman"><B>c)</B>&#8195;&#8201;<B>Proposal No. 3 - The Nasdaq Proposal &#151; </B>to consider and vote upon
a proposal to approve, for</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="center">FOR</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">&#9744;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="center">&nbsp;AGAINST&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">&#9744;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="center">&nbsp;ABSTAIN&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">&#9744;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" COLSPAN="7"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:8pt; font-family:Times New Roman">&nbsp;&nbsp;&#8195;&#8201;&#8201;purposes of complying with Nasdaq Listing Rule
5635(a), (b) and (d), the issuance of more than 20% of the issued and outstanding FEAC Class&nbsp;A Shares and the resulting change in control in connection with the Business Combination (we refer to this proposal as the &#147;Nasdaq
Proposal&#148;).</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:8pt; font-family:Times New Roman"><B>d)&#8195;&#8202;Proposal No. 4 - The Incentive Equity Plan</B> <B>Proposal &#151; </B>to
consider and vote upon a proposal to</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="center">FOR</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">&#9744;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="center">&nbsp;AGAINST&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">&#9744;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="center">&nbsp;ABSTAIN&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">&#9744;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:8pt; font-family:Times New Roman">&nbsp;&nbsp;&#8195;&#8201;&#8201;approve the enGene Holdings Inc. 2023 Incentive Equity Plan (we
refer to this proposal as the &#147;Incentive Equity Plan Proposal&#148;).</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:8pt; font-family:Times New Roman"><B>c)&#8195;&#8201;</B><B>Proposal No. 5 - The Adjournment Proposal &#151; </B>to consider and vote
upon a proposal to approve the</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="center">FOR</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">&#9744;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="center">&nbsp;AGAINST&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">&#9744;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="center">&nbsp;ABSTAIN&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">&#9744;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" COLSPAN="7"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-2.00em; font-size:8pt; font-family:Times New Roman">&nbsp;&nbsp;&#8195;&#8201;&#8201;adjournment of the Special Meeting to a later date or
dates, if necessary, to permit further solicitation and vote of proxies if, based upon the tabulated vote at the time of the Special Meeting, any of the condition precedent proposals would not be duly approved and adopted by FEAC Shareholders or we
determine that one or more of the closing conditions under the Business Combination Agreement is not satisfied or waived (we refer to this proposal as the &#147;Adjournment
Proposal&#148;).</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONTROL NUMBER</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:20pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:20pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&#8194;&#8201;&#8201;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> </div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>
 <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"><B>Signature<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> Signature, if held
jointly<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
Date<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&nbsp;2023.</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">Note: Please sign exactly as name appears hereon. When shares are held by joint owners, both should sign. When signing as attorney, executor, administrator, trustee, guardian, or corporate officer, please give title as
such.</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:30pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Important Notice Regarding the Internet Availability of Proxy Materials </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>for the Extraordinary General Meeting to be held on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2023. </B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>To view the 2022 Proxy
Statement and to Attend </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>the Extraordinary General Meeting, please go to: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>https://www.cstproxy.com/feac/2023 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:30pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-size:8pt"><B>


<IMG SRC="g459793g15p04.jpg" ALT="LOGO">
&nbsp;FOLD HERE &#149; DO NOT SEPARATE &#149; INSERT IN ENVELOPE PROVIDED&nbsp;


<IMG SRC="g459793g15p04.jpg" ALT="LOGO">
</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD ROWSPAN="2" VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:3%; text-indent:-2%; font-size:12pt; font-family:Times New Roman"><B>PROXY </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORBION EUROPEAN ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>4001 KENNETT PIKE, SUITE 302, WILMINGTON, DELAWARE 19807 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO BE HELD ON &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2023
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">The undersigned appoints
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
and each of them, as proxies, each with the power to appoint their substitute, and authorizes each of them to represent and to vote, as designated on the reverse hereof, all of the ordinary shares of Forbion European Acquisition Corp., a Cayman
Islands exempted company (&#147;FEAC,&#148; &#147;we,&#148; &#147;us&#148; or &#147;our&#148;) held of record by the undersigned at the close of business on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2023 at the Extraordinary General Meeting of Forbion European Acquisition Corp., will be convened at 10:00 a.m., New York City
time, on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2023, and virtually at <B>https://www.cstproxy.com/feac/2023 </B>or at such other date, time and place to which such
meeting may be adjourned or postponed.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>THIS PROXY WHEN PROPERLY EXECUTED WILL BE
VOTED AS INDICATED. IF NO CONTRARY INDICATION IS MADE, THE PROXY WILL BE VOTED IN FAVOR OF PROPOSAL &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , AND IN ACCORDANCE WITH THE
JUDGMENT OF THE PERSONS NAMED AS PROXY HEREIN ON ANY OTHER MATTERS THAT MAY PROPERLY COME BEFORE THE EXTRAORDINARY GENERAL MEETING. THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS. PLEASE MARK, SIGN, DATE AND RETURN THE PROXY CARD
PROMPTLY.</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Continued and to be marked, dated and signed on the other side) </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom459793_54"></A>PART II </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;20.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Indemnification of Directors and Officers </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>New enGene </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following Closing, New enGene
will be governed by the&nbsp;Business Corporations Act<I></I>&nbsp;(British Columbia), or BCBCA. Under the BCBCA, and New enGene&#146;s Proposed Articles, New enGene may (or must, pursuant to the Proposed Articles) indemnify all eligible parties
against all eligible penalties to which such person is or may be liable, and we must, after the final disposition of an eligible proceeding, pay the expenses actually and reasonably incurred by such person in respect of that proceeding. As of
Closing each director shall be deemed to have contracted with New enGene on the terms of indemnity contained in the Proposed Articles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of such an indemnification: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;eligible party,&#148; in relation to New enGene, means an individual who </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">is or was a director or officer of New enGene; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">is or was a director or officer of another corporation </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at a time when the corporation is or was an affiliate of New enGene, or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at the request of New enGene; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at the request of New enGene, is or was, or holds or held a position equivalent to that of, a director or officer
of a partnership, trust, joint venture or other unincorporated entity and includes the heirs and personal or other legal representatives of that individual; </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;eligible penalty&#148; means a judgment, penalty or fine awarded or imposed in, or an amount paid in settlement of, an eligible
proceeding; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;eligible proceeding&#148; means a proceeding in which an eligible party or any of the heirs and personal or other legal
representatives of the eligible party, by reason of the eligible party being or having been a director or officer of, or holding or having held a position equivalent to that of a director or officer of, New enGene or an associated corporation: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">is or may be joined as a party, or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">is or may be liable for or in respect of a judgment, penalty or fine in, or expenses related to, the proceeding;
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;expenses&#148; includes costs, charges and expenses, including legal and other fees, but does not include
judgments, penalties, fines or amounts paid in settlement of a proceeding; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;proceeding&#148; includes any legal proceeding or
investigative action, whether current, threatened, pending or completed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, under the BCBCA, New enGene may pay, as they are
incurred in advance of the final disposition of an eligible proceeding, the expenses actually and reasonably incurred by an eligible party in respect of that proceeding, provided that New enGene first receives from the eligible party a written
undertaking that, if it is ultimately determined that the payment of expenses is prohibited by the restrictions noted below, the eligible party will repay the amounts advanced. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the provisions of New enGene&#146;s Proposed Articles noted above, New
enGene must not indemnify an eligible party or pay the expenses of an eligible party, if any of the following circumstances apply: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the indemnity or payment is made under an earlier agreement to indemnify or pay expenses and, at the time that
the agreement to indemnify or pay expenses was made, New enGene was prohibited from giving the indemnity or paying the expenses by its articles; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the indemnity or payment is made otherwise than under an earlier agreement to indemnify or pay expenses and,
at the time that the indemnity or payment is made, New enGene is prohibited from giving the indemnity or paying the expenses by its articles; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if, in relation to the subject matter of the eligible proceeding, the eligible party did not act honestly and in
good faith with a view to the best interests of New enGene or the associated corporation, as the case may be; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of an eligible proceeding other than a civil proceeding, if the eligible party did not have
reasonable grounds for believing that the eligible party&#146;s conduct in respect of which the proceeding was brought was lawful. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if an eligible proceeding is brought against an eligible party by or on behalf of New enGene or by or on behalf of an associated
corporation, New enGene must not do either of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">indemnify the eligible party in respect of the proceeding; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pay the expenses of the eligible party in respect of the proceeding. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding any of the foregoing, and whether or not payment of expenses or indemnification has been sought, authorized or declined under
the BCBCA or the Proposed Articles of New enGene, on the application of New enGene or an eligible party, the Supreme Court of British Columbia may do one or more of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">order New enGene to indemnify an eligible party against any liability incurred by the eligible party in respect
of an eligible proceeding; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">order New enGene to pay some or all of the expenses incurred by an eligible party in respect of an eligible
proceeding; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">order the enforcement of, or any payment under, an agreement of indemnification entered into by New enGene;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">order New enGene to pay some or all of the expenses actually and reasonably incurred by any person in obtaining
an order under this section; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make any other order the court considers appropriate. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The BCBCA and New enGene&#146;s articles authorize us to purchase and maintain insurance for the benefit of an eligible party against any
liability that may be incurred by reason of the eligible party being or having been a director or officer of, or holding or having held a position equivalent to that of a director or officer of, New enGene, a current or former affiliate of New
enGene or a corporation, partnership, trust, joint venture or other unincorporated entity at the request of New enGene. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, New
enGene has entered, or will enter, into separate indemnity agreements with each its directors and officers pursuant to which New enGene has or will agree to indemnify and hold harmless its directors and officers against any and all liability, loss,
damage, cost or expense in accordance with the terms and conditions of the BCBCA and the Proposed Articles. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FEAC </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cayman Islands law does not limit the extent to which a company&#146;s memorandum and articles of association may provide for indemnification
of officers and directors, except to the extent any such provision may be held by the Islands, courts to be contrary to public policy, such as to provide indemnification against willful default, willful neglect, civil fraud or the consequences of
committing a crime. FEAC&#146;s memorandum and articles of association will provide for indemnification of its officers and directors to the maximum extent permitted by law, including for any liability incurred in their capacities as such, except
through their own actual fraud, willful default or willful neglect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the
Securities Act may be permitted to directors, officers or persons controlling us pursuant to the foregoing provisions, we have been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities
Act and is theretofore unenforceable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;21.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Exhibits and Financial Statement Schedules </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="91%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit<BR>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;2.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1980845/000119312523207502/d459793ds4.htm#ii459793_1">Business Combination Agreement, dated May&nbsp;
16, 2023, by and among FEAC, enGene and New enGene (included as Annex A to the proxy statement/prospectus).***&#134; </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1980845/000119312523207502/d459793ds4.htm#ii459793_1">Proposed Articles of New enGene (included in Annex A to the proxy statement/prospectus).*** </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d459793dex41.htm">Specimen Class A Common Share Certificate of New enGene.* </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;4.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d459793dex42.htm">Specimen Class B Common Share Certificate of New enGene.* </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;4.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1980845/000119312523207502/d459793ds4.htm#ii459793_5">Specimen Warrant Certificate of New enGene (included in <U>Annex D</U> to the proxy statement prospectus).*** </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;5.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d459793dex51.htm">Opinion of Blake, Cassels &amp; Graydon LLP.*</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;5.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d459793dex52.htm">Opinion of Morgan, Lewis &amp; Bockius LLP.* </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;8.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d459793dex81.htm">Opinion of Davis Polk &amp; Wardwell LLP as to U.S. federal income tax matters.*</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;8.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d459793dex82.htm">Opinion of Morgan, Lewis &amp; Bockius LLP as to U.S. federal income tax matters.* </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1980845/000119312523207502/d459793ds4.htm#ii459793_2">Sponsor and Insiders Letter Agreement, dated May&nbsp;
16, 2023, by and among FEAC, the Sponsor, Forbion Growth Opportunities Fund I Cooperatief U.A., enGene, New enGene and the other parties named therein (included as <U>Annex C</U> to the proxy statement/prospectus).*** </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1980845/000119312523207502/d459793ds4.htm#ii459793_1">Form of Subscription Agreement (included in <U>Annex A</U> to the proxy statement/prospectus).*** </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1980845/000119312523207502/d459793ds4.htm#ii459793_1">Form of Subscription Agreement Side Letter Agreement (included in <U>Annex A</U> to the proxy statement/prospectus).***
</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1980845/000119312523207502/d459793ds4.htm#ii459793_1">Form of enGene <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement (included in <U>Annex A</U> to the proxy statement/prospectus).***
 </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1980845/000119312523207502/d459793ds4.htm#ii459793_1">Form of enGene Voting Agreement (included in <U>Annex A</U> to the proxy statement/prospectus).*** </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1874495/000119312523150633/d455771dex104.htm">FEAC Voting Agreement, dated May<U></U>&nbsp;
16, 2023, by and among, the Sponsor Parties, enGene and New enGene (incorporated by reference to Exhibit 10.4 of FEAC&#146;s <FONT STYLE="white-space:nowrap">Form&nbsp;
8-K/A</FONT> (No. <FONT STYLE="white-space:nowrap">001-41148)</FONT> filed with the SEC on May<U></U>&nbsp;22, 2023.*** </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1980845/000119312523207502/d459793ds4.htm#ii459793_1">Form of Subscription Agreement Side Letter Agreement (included in <U>Annex A</U> to the proxy
statement/prospectus).***</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1980845/000119312523207502/d459793ds4.htm#ii459793_1">Form of <FONT STYLE="white-space:nowrap">Non-Redemption</FONT> Agreement (included in <U>Annex A</U> to the proxy statement/prospectus).***
 </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1980845/000119312523207502/d459793ds4.htm#ii459793_1">Form of Registration Rights Agreement (included in <U>Annex A</U> to the proxy statement/prospectus).*** </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1980845/000119312523207502/d459793ds4.htm#ii459793_5">Form of Warrant Assignment, Assumption and Amendment Agreement, by and among, FEAC, enGene and Continental Stock Transfer&nbsp;
&amp; Trust Company, as Trustee (included in <U>Annex D</U> to the proxy statement/prospectus).*** </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1980845/000119312523207502/d459793ds4.htm#ii459793_1">Form of enGene Holdings Inc. 2023 Incentive Equity Plan (included in <U>Annex A</U> to the proxy statement/prospectus).***-
</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1874495/000119312521356920/d251150dex104.htm">Private Placement Warrants Purchase Agreement, dated December&nbsp;
9, 2021, by and between FEAC and the Company and the Sponsor (incorporated by reference to Exhibit&nbsp;10.4 to FEAC&#146;s Current Report on Form&nbsp;8-K filed on December&nbsp;14, 2021).*** </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1980845/000119312523207502/d459793dex1013.htm">Loan and Security Agreement, dated December&nbsp;30, 2021, by and among enGene, enGene USA and Hercules Capital Inc.***+&#134;
</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.14</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d459793dex1014.htm"><FONT STYLE="white-space:nowrap">Non-Exclusive</FONT> License Agreement, dated April&nbsp;10, 2020, by and between enGene and Nature Technology Corporation.*+&#134; </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1980845/000119312523207502/d459793dex1015.htm">Master Service Agreement, dated November&nbsp;11, 2019, by and between enGene and BioAgilytix Labs, LLC.***+&#134;
</A></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="91%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit<BR>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.16</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1980845/000119312523207502/d459793dex1016.htm">Letter Agreement, dated May&nbsp;16, 2023, by and among enGene<B>, </B>IQ<B>, </B>FEAC<B> </B>and New enGene.***+&#134; </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.17</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1980845/000119312523207502/d459793dex1017.htm">Lease Agreement, dated November&nbsp;1, 2021, by and between enGene and NeoMed Institute, as amended.*** </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.18</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1980845/000119312523207502/d459793dex1018.htm">Lease Amendment Agreement, dated October&nbsp;1, 2022, by and between enGene and NeoMed Institute.*** </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.19</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1980845/000119312523207502/d459793dex1019.htm">Lease Amendment Agreement No. 2, dated April 1, 2023, by and between enGene and NeoMed Institute.*** </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.20</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1980845/000119312523207502/d459793dex1020.htm">Lease Amendment Agreement No.&nbsp;3, dated September&nbsp;1, 2023, by and between enGene and NeoMed Institute.*** </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.21</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1980845/000119312523207502/d459793dex1021.htm">Lease Agreement, dated December&nbsp;29, 2022, by and between enGene and <FONT STYLE="white-space:nowrap">Are-Canada</FONT> No.&nbsp;
5 Holdings, ULC.*** </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.22</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Employment Agreement between New enGene and Jason D. Hanson.**-</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.23</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Employment Agreement between New enGene and Dr.&nbsp;Alex Nichols.**-</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.24</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Employment Agreement between New enGene and Dr.&nbsp;Anthony&nbsp;T. Cheung.**-</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.25</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Employment Agreement between New enGene and James C. Sullivan.**-</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;23.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d459793dex231.htm">Consent of KPMG LLP.* </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;23.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d459793dex232.htm">Consent of Marcum LLP.* </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;23.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d459793dex51.htm">Consent of Blake, Cassels &amp; Graydon LLP (included in Exhibit 5.1).* </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;23.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d459793dex52.htm">Consent of Morgan, Lewis&nbsp;&amp; Bockius LLP (included in Exhibit 5.2).* </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;23.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d459793dex81.htm">Consent of Davis Polk &amp; Wardwell LLP (included in Exhibit&nbsp;8.1).* </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;23.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d459793dex82.htm">Consent of Morgan, Lewis &amp; Bockius LLP (included in Exhibit 8.2).* </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>107</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d459793dexfilingfees.htm">Filing Fee Exhibit.* </A></TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Filed herewith. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be filed by amendment. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Filed previously. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top"><FONT STYLE="font-size:6.5pt">&#134;</FONT></SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Certain of the exhibits and schedules to these exhibits have been omitted in accordance with <FONT
STYLE="white-space:nowrap">Regulation&nbsp;S-K</FONT> Item&nbsp;601(a)(5). The registrant agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">+</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Portions of this exhibit are redacted in accordance with Regulation S-K Item 601(b)(10)(iv).
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">-</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Indicates a management contract or compensatory plan or arrangement. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;22.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Undertakings </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The undersigned registrant undertakes as follows: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To file, during any period in which offers or sales are being made, a post-effective amendment to this
registration statement: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To include any prospectus required by Section&nbsp;10(a)(3) of the Securities Act of 1933;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">ii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect in the prospectus any facts or events arising after the effective date of the registration statement
(or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in
volume of securities offered (if the total dollar value of securities offered would not exceed </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule
424(b) if, in the aggregate, the changes in volume and price represent no more than 20&nbsp;percent change in the maximum aggregate offering price set forth in the &#147;Calculation of Registration Fee&#148; table in the effective registration
statement; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">iii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To include any material information with respect to the plan of distribution not previously disclosed in the
registration statement or any material change to such information in the registration statement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective
amendment will be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time will be deemed to be the initial bona fide offering thereof. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To remove from registration by means of a post-effective amendment any of the securities being registered which
remain unsold at the termination of the offering. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser, each
prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, will be deemed to be part of and
included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document
incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any
statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">That, for the purpose of determining any liability under the Securities Act of 1933 to any purchaser in the
initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the
securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such
securities to such purchaser: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be
filed pursuant to Rule 424; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">ii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or
used or referred to by the undersigned registrant; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">iii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The portion of any other free writing prospectus relating to the offering containing material information about
the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">iv.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that prior to any public reoffering of the securities registered hereunder through use of a prospectus which is
a part of this registration statement, by any person or party who is deemed to be an underwriter within the meaning of Rule 145(c), the issuer undertakes that such reoffering prospectus will contain the information called for by the applicable
registration form with respect to reofferings by persons who may be deemed underwriters, in addition to the information called for by the other items of the applicable form. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that every prospectus (i)&nbsp;that is filed pursuant to paragraph (1)&nbsp;immediately preceding, or
(ii)&nbsp;that purports to meet the requirements of Section&nbsp;10(a)(3) of the Securities Act of 1933 and is used in connection with an offering of securities subject to Rule 415, will be filed as a part of an amendment to the registration
statement and will not be used until such amendment is effective, and that, for purposes of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to
the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to respond to requests for information that is incorporated by reference into this proxy
statement/prospectus/information statement pursuant to Item 4, 10(b), 11, or 13 of Form <FONT STYLE="white-space:nowrap">S-4,</FONT> within one business day of receipt of such request, and to send the incorporated documents by first class mail or
other equally prompt means. This includes information contained in documents filed subsequent to the effective date of the registration statement through the date of responding to the request. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to supply by means of a post-effective amendment all information concerning a transaction, and the company
being acquired involved therein, that was not the subject of and included in the registration statement when it became effective. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to
directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public
policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer
or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the
opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act of 1933 and will
be governed by the final adjudication of such issue. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom459793_55"></A>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act, the registrant has duly caused this Amendment No. 1 to the Registration Statement to be
signed on its behalf by the undersigned, thereunto duly authorized, in the City of Saint-Laurent, Quebec, Canada, on the 29th day of August, 2023. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>ENGENE HOLDINGS INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jason D. Hanson</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jason D. Hanson</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD></TR>
</TABLE></DIV>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, this Amendment No. 1 to the Registration
Statement has been signed by the following persons in the capacities and on the dates indicated. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Date</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Jason D. Hanson</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Jason D. Hanson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Chief&nbsp;Executive&nbsp;Officer&nbsp;and&nbsp;Director</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(<I>Principal&nbsp;Executive&nbsp;Officer</I>)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">August&nbsp;29,&nbsp;2023</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Alexandre Grassin</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Alexandre Grassin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Interim Chief Financial Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(<I>Principal&nbsp;Financial&nbsp;Officer&nbsp;and&nbsp;Principal Accounting Officer</I>)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">August&nbsp;29,&nbsp;2023</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Jasper Bos</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Jasper Bos</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">August&nbsp;29,&nbsp;2023</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Gerry Brunk</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Gerry Brunk</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">August&nbsp;29,&nbsp;2023</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Dr. Richard Glickman</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Dr. Richard Glickman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">August&nbsp;29,&nbsp;2023</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-8 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>d459793dex41.htm
<DESCRIPTION>EX-4.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="21%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">COMPANY <B>enGene</B><B> Holdings Inc.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">CERTIFICATE RECEIVED</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">NUMBER OF SHARES</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">REGISTERED HOLDER</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">ALLOTTED/TRANSFERRED&nbsp;FROM</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">DATE &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">CERTIFICATE NUMBER</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">CLASS&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Class&nbsp;A Common</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ROWSPAN="3" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD ROWSPAN="3" VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">PAR VALUE</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">DATE OF ISSUE</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Signature</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">INCORPORATED UNDER THE CANADA BUSINESS CORPORATIONS ACT </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">Class&nbsp;A Common&nbsp;&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">TRANSFER OF THESE SHARES IS RESTRICTED </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE HOLDINGS INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">THIS CERTIFIES THAT </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">is the
registered holder of the number and class of shares described hereon, such shares being fully paid up and <FONT STYLE="white-space:nowrap">non-assessable</FONT> in the capital of the Corporation. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>THERE ARE SPECIAL RIGHTS AND RESTRICTIONS ATTACHED TO THESE SHARES, AND A COPY OF THE FULL TEXT THEREFORE IS OBTAINABLE FROM THE REGISTERED OR RECORDS OFFICE OF THE CORPORATION ON DEMAND AND WITHOUT CHARGE.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">IN WITNESS WHEREOF the Corporation has caused this Certificate to be signed by its duly authorized officer(s), and, where required, to be sealed with its common seal, on the date of issue.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Authorized Signatory</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>3
<FILENAME>d459793dex42.htm
<DESCRIPTION>EX-4.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="21%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">COMPANY <B>enGene</B><B> Holdings Inc.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">CERTIFICATE RECEIVED</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">NUMBER OF SHARES</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">REGISTERED HOLDER</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">ALLOTTED/TRANSFERRED FROM</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">DATE &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">CERTIFICATE NUMBER</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">CLASS&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Class&nbsp;B Common</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ROWSPAN="3" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD ROWSPAN="3" VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">PAR VALUE</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">DATE OF ISSUE</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Signature</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">INCORPORATED UNDER THE CANADA BUSINESS CORPORATIONS ACT </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">Class B Common </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">TRANSFER OF
THESE SHARES IS RESTRICTED </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGENE HOLDINGS INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">THIS CERTIFIES THAT </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">is the
registered holder of the number and class of shares described hereon, such shares being fully paid up and <FONT STYLE="white-space:nowrap">non-assessable</FONT> in the capital of the Corporation. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>THERE ARE SPECIAL RIGHTS AND RESTRICTIONS ATTACHED TO THESE SHARES, AND A COPY OF THE FULL TEXT THEREFORE IS OBTAINABLE FROM THE REGISTERED OR RECORDS OFFICE OF THE CORPORATION ON DEMAND AND WITHOUT CHARGE.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">IN WITNESS WHEREOF the Corporation has caused this Certificate to be signed by its duly authorized officer(s), and, where required, to be sealed with its common seal, on the date of issue.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Authorized Signatory</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>4
<FILENAME>d459793dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g459793g0830051411016.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">


<IMG SRC="g459793g0830051411178.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Reference: 99472/5</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">August&nbsp;29, 2023</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">enGene Holdings Inc.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7171 Frederick Banting</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Saint-Laurent, Qu&eacute;bec</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">H4S 1Z9</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>RE: enGene Holdings Inc.&#151;Registration Statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Sirs and Mesdames: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have acted as Canadian counsel to
enGene Holdings Inc., a corporation governed by the <I>Canada</I> <I>Business Corporations Act</I> (the &#147;<B>Corporation</B>&#148;), in connection with the transactions contemplated by a business combination agreement dated May&nbsp;16, 2023
(the &#147;<B>Business Combination Agreement</B>&#148;) by and among Forbion European Acquisition Corp., (&#147;<B>FEAC</B>&#148;), Can Merger Sub, Cayman Merger Sub, and the Corporation. The Corporation filed a registration statement on Form <FONT
STYLE="white-space:nowrap">S-4</FONT> with the United States Securities and Exchange Commission (the &#147;<B>SEC</B>&#148;) on<B> </B>August&nbsp;9, 2023<B> </B>(the &#147;<B>Registration Statement</B>&#148;), relating to the registration under the
<I>U.S. Securities Act of 1933</I>, as amended (the &#147;<B>Securities Act</B>&#148;), of (i) 27,090,013 common shares in the capital of the Corporation (&#147;<B>Common Shares</B>&#148;), 14,023,496 of which<B> </B>are issuable pursuant to the
Cayman Merger and 13,066,517 are issuable pursuant to the Plan of Arrangement (the &#147;<B>Arrangement Shares</B>&#148;); (ii) 6,896,099 Common Shares (the &#147;<B>Warrant Shares</B>&#148;) issuable pursuant to and in accordance with the warrants
to purchase Common Shares (the &#147;<B>Warrants</B>&#148;), 4,216,666 of which are issuable in respect of 4,216,666 FEAC Public Warrants, and 2,679,432 are issuable in respect of enGene Warrants issued to the lenders of the Convertible Bridge
Financing and governed by the warrant agreement dated as of December&nbsp;9, 2021 (the &#147;<B>Warrant Agreement</B>&#148;) by and between FEAC and Continental Stock Transfer&nbsp;&amp; Trust Company, as trustee (the &#147;<B>Trustee</B>&#148;), as
the same will be as amended, assigned and assumed pursuant to the warrant assignment, assumption and amendment agreement (the &#147;<B>Warrant Amendment Agreement</B>&#148; and, together with the warrant agreement, the &#147;<B>Warrant
Documents</B>&#148;) to be entered into by and among the Corporation and the Trustee to be effective following the closing (the &#147;<B>Closing</B>&#148;) of the transactions contemplated by the Business Combination Agreement; and (iii)&nbsp;the
Warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Terms used in this opinion that are defined in the Business Combination Agreement, and are not otherwise defined herein, have the same meanings
herein as in the Business Combination Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Materials Reviewed </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with this opinion, we have examined originals or copies, certified or otherwise identified to our satisfaction, of each of the following
documents: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Registration Statement and such matters of fact and questions of law as we have considered appropriate for
the purposes of this letter; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Business Combination Agreement included in the Registration Statement; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g459793g0830051845982.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g459793g0830051411016.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> Page
 2
</TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the form of Plan of Arrangement attached as a schedule to the Business Combination Agreement included in the
Registration Statement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">resolutions of the directors of the Corporation approving, among other things, the Business Combination
Agreement and the transactions contemplated thereby; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">resolutions of the directors of the Corporation approving various issuances in connection with the Plan of
Arrangement and the Business Combination Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Arrangement Resolution; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the form of Warrant Amendment Agreement included in the Registration Statement; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the articles of incorporation of the Corporation and the form of BCBCA articles of the Corporation to be
effective at Closing. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have also examined originals or copies, certified or otherwise identified to our satisfaction, of such public
and corporate records, certificates, instruments and other documents. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Assumptions and Fact Reliance </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have assumed that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all information contained in all documents reviewed by us is true and correct; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the genuineness of all signatures on all documents reviewed by us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the authenticity and completeness of all documents submitted to us as originals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the conformity to authentic originals of all documents submitted to us as certified or photostatic copies,
whether facsimile, electronic, photostatic, certified or otherwise, and the authenticity of the originals of such copies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the accuracy, currency and completeness of the indices and filing systems maintained at the public offices,
registries and websites where we have searched or made inquiries or have caused searches or enquiries to be made and of the information and advice provided to us by appropriate government, regulatory and other like officials with respect to those
matters referred to herein; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">each natural person signing any document reviewed by us had the legal capacity to do so, none of which facts we
have independently verified; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the enGene Exchange Ratio not changing between the filing of the Registration Statement and Closing;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the effectiveness of the Plan of Arrangement in the form previously reviewed; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g459793g0830051845982.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g459793g0830051411016.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> Page
 3
</TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the due authorization, execution and delivery of all documents in drafts previously reviewed where
authorization, execution and delivery are prerequisites to the effectiveness of such documents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Warrant Agreement has been duly authorized, executed and delivered by, and constitutes, a valid and legally
binding obligation of, each of the parties thereto enforceable against each of them in accordance with its terms under the laws of the State of New York; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(k)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Warrant Amendment Agreement will, at the relevant time for the purposes of the opinions expressed in
paragraphs (a)&nbsp;and (c) below, be duly authorized, executed and delivered by, and constitute, a valid and legally binding obligation of, each of the parties thereto enforceable against each of them in accordance with its terms under the laws of
the State of New York; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(l)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Warrant Amendment Agreement is approved in substantially the same form and substance as the draft of the
Warrant Amendment Agreement previously provided; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(m)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the articles of arrangement giving effect to the Arrangement (the &#147;<B>Articles of Arrangement</B>&#148;)
will be in the form prescribed under the <I>Canada Business Corporations Act</I>; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(n)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the effectiveness of the Plan of Arrangement in the same form appended to the Business Combination Agreement;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(o)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that insofar as any obligation under any of the Warrant Documents is to be performed in any jurisdiction
outside of the Province of British Columbia, its performance will not be illegal or unenforceable by virtue of the laws of that other jurisdiction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(p)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the terms used in any of the Warrant Documents have the same meanings under the laws of the Province of British
Columbia as they do under the laws of the State of New York and would be interpreted and understood under the laws of the Province of British Columbia in the same way as they are interpreted and understood under the laws of the State of New York;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(q)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the provisions of any instrument evidencing the Warrants will be consistent in all respects with the provisions
of the Warrant Documents; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(r)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Registration Statement will be effective and comply with all applicable laws. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not undertaken any special or independent investigation to determine the existence or absence of any facts or circumstances relating to the Business
Combination Agreement, Warrant Agreement, the Warrants or the Common Shares. No inference as to our knowledge as to such facts and circumstances should be drawn merely from our specific representation of the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Whenever our opinion refers to the Corporation&#146;s Arrangement Shares and Warrant Shares as being &#147;fully paid and
<FONT STYLE="white-space:nowrap">non-assessable&#148;,</FONT> such opinion indicates that the holder of such Common Shares cannot be required to contribute any further amounts to the Corporation by virtue of its status as holder of such Common
Shares of the Corporation, either in order to complete payment for such Common Shares, to satisfy claims of creditors of the Corporation, or otherwise. No opinion is expressed as to the actual receipt by the Corporation of the consideration for the
issuance of such Common Shares or as to the adequacy of any consideration received. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g459793g0830051845982.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g459793g0830051411016.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> Page
 4
</TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Applicable Laws </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are qualified to carry on the practice of law in the Province of British Columbia. Our opinion below is expressed only with respect to the laws of the
Province of British Columbia and the federal laws of Canada applicable therein, in each case, in effect on the date hereof. We express no opinion with respect to the laws of any other jurisdiction. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Opinions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based upon the foregoing, and subject to the
qualifications, assumptions and limitations stated herein, we are of the opinion that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">following the Articles of Arrangement becoming effective and the completion of each of the other transactions
contemplated by the Plan of Arrangement to occur prior to or at the Closing Date in accordance with the terms thereof, the execution, delivery, and performance of the Warrant Amendment Agreement by the Corporation will not violate the Articles of
Arrangement or any provincial statute or regulation in force in the Province of British Columbia or any federal statue or regulation of Canada applicable in the Province of British Columbia. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">following the Articles of Arrangement becoming effective and the completion of each of the other transactions
contemplated by the Plan of Arrangement to occur prior to or at the Closing Date in accordance with the terms thereof, the Arrangement Shares registered under the Registration Statement, will be validly issued as fully paid and <FONT
STYLE="white-space:nowrap">non-assessable;</FONT> and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">following the Articles of Arrangement becoming effective and the completion of each of the other transactions
contemplated by the Plan of Arrangement to occur prior to or at the Closing Date in accordance with the terms thereof, the Warrant Shares registered under the Registration Statement and issuable upon the due exercise of the Warrants and payment of
the exercise price therefor in accordance with the terms of the Warrant Agreement, as amended by the Warrant Amendment Agreement, will be validly issued as fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Qualifications and Liabilities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This opinion letter has
been prepared for your use in connection with the Registration Statement and is expressed as of the date hereof. Our opinion is expressly limited to the matters set forth above and we render no opinion, whether by implication or otherwise, as to any
other matters relating to the Corporation, the Registration Statement or the Common Shares and does not take into account any proposed rules, policies or legislative changes that may come into force following the date hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the filing of this opinion letter as an exhibit to the Registration Statement and to the reference to this firm on the cover page and
under the caption &#147;Validity of Common Shares and Warrants&#148; in the Registration Statement. In giving this consent, we do not hereby agree that we are within the category of persons whose consent is required under Section&nbsp;7 of the
Securities Act or the rules and regulations of the SEC promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yours very truly, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(signed) <I>&#147;Blake, Cassels and Graydon LLP&#148;</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g459793g0830051845982.jpg" ALT="LOGO">
 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.2
<SEQUENCE>5
<FILENAME>d459793dex52.htm
<DESCRIPTION>EX-5.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g459793snap1.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">August&nbsp;29, 2023 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">enGene Holdings Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7171 Rue Frederick Banting </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Saint-Laurent, Qu&eacute;bec </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">H4S 1Z9, Canada </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Re: <U>Registration Statement of enGene
Holdings Inc. on Form <FONT STYLE="white-space:nowrap">S-4</FONT> (Registration No.</U><U></U><U><FONT STYLE="white-space:nowrap">&nbsp;333-273851)</FONT></U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have acted as United
States federal and State of New York counsel to enGene Holdings Inc., a corporation incorporated under the laws of Canada (&#147;<U>New enGene</U>&#148;), in connection with the preparation and filing of the Registration Statement on Form <FONT
STYLE="white-space:nowrap">S-4</FONT> originally filed under the Securities Act of 1933, as amended (the &#147;<U>Act</U>&#148;), with the U.S. Securities and Exchange Commission on August&nbsp;9, 2023 (File
<FONT STYLE="white-space:nowrap">No.&nbsp;333-273851)</FONT> (as amended, the &#147;<U>Registration Statement</U>&#148;), relating to the registration of an aggregate of (i) 27,090,013 Class&nbsp;A common shares of New enGene (each, a &#147;<U>New
enGene Share</U>&#148;), (ii) 6,896,099 warrants to purchase New enGene Shares at a price of USD $11.50 per New enGene Share, subject to adjustment (the &#147;<U>New enGene Warrants</U>&#148;), and (iii) 6,896,099 New enGene Shares issuable upon
exercise of the New enGene Warrants, each to be issued by New enGene in connection with the proposed business combination (the &#147;<U>Business Combination</U>&#148;) and the related transactions contemplated by the Business Combination Agreement,
dated May&nbsp;16, 2023 (as it may be amended and supplemented, the &#147;<U>Business Combination Agreement</U>&#148;) by and among Forbion European Acquisition Corp., a Cayman Islands exempted company (&#147;<U>FEAC</U>&#148;), enGene Inc., a
company incorporated under the laws of Canada (&#147;<U>enGene</U>&#148;), and New enGene. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The New enGene Warrants will be governed by the Warrant
Agreement (as defined below), dated December&nbsp;9, 2021, by and between FEAC and Continental Stock Transfer&nbsp;&amp; Trust Company, a New York corporation (the &#147;<U>Warrant Agent</U>&#148;), pursuant to which FEAC&#146;s warrants to purchase
one Class&nbsp;A ordinary share of FEAC common stock at a price of USD $11.50 per share, subject to adjustment (the &#147;<U>FEAC Public Warrants</U>&#148;) were issued (the &#147;<U>Original Warrant Agreement</U>&#148;), as amended by the Warrant
Assignment, Assumption and Amendment Agreement (the &#147;<U>Warrant Assignment, Assumption and Amendment Agreement</U>&#148;), to be entered into by and among FEAC, enGene, New enGene and the Warrant Agent. Upon consummation of the Business
Combination and related transactions contemplated by the Business Combination Agreement, and the execution and delivery of the Warrant Assignment, Assumption and Amendment Agreement (the &#147;<U>Assignment and Assumption</U>&#148;), (i) each of the
4,216,667 outstanding FEAC Public Warrants will be assumed by New enGene and become New enGene Warrants, and (ii) 2,679,432 New enGene Warrants will be issued in respect of certain warrants issued by enGene to certain lenders as part of the
Convertible Bridge Financing described in the Registration Statement. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Morgan, Lewis&nbsp;&amp; Bockius <SMALL>LLP</SMALL></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:10pt">101 Park Avenue New York,</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">


<IMG SRC="g459793snap1a.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">+1.212.309.6000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NY 10178-0060</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">United States</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt;margin-bottom:1pt">


<IMG SRC="g459793snap1b.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">+1.212.309.6001</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">August 29, 2023 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 2
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this opinion letter, we have examined originals, or copies certified or
otherwise identified to our satisfaction, of (i)&nbsp;the Original Warrant Agreement, (ii)&nbsp;the form of Warrant Assignment, Assumption and Amendment Agreement, (iii)&nbsp;the Registration Statement and the exhibits thereto, (iv)&nbsp;the
Business Combination Agreement, and (v)&nbsp;such other documents, and we have considered such legal matters as we have deemed necessary and relevant as the basis for the opinion set forth below. With respect to such examination, we have assumed the
genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as reproduced or certified copies, and the authenticity of the originals of those
latter documents. As to questions of fact material to this opinion, we have, to the extent deemed appropriate, relied upon certain representations of certain officers and employees of New enGene and enGene. We have assumed that each of the Warrant
Agent and FEAC is validly existing, has duly authorized, executed and delivered the Original Warrant Agreement, will duly authorize, execute and deliver the Warrant Assignment, Assumption and Amendment Agreement, and had and/or has all requisite
legal ability to do so. We have also assumed that pursuant to the laws of Canada, each of New enGene and enGene is validly existing, has the power to execute the Warrant Assignment, Assumption and Amendment Agreement and issue the New enGene
Warrants, and will duly authorize, execute and deliver the Warrant Assignment, Assumption and Amendment Agreement and issue the New enGene Warrants, and has all requisite legal ability to do so. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based upon the foregoing, we are of the opinion that, when issued as described in the Registration Statement, the New enGene Warrants will be
legally binding obligations of New enGene except: (a)&nbsp;as enforceability may be limited by bankruptcy, insolvency, reorganization or similar laws affecting creditors&#146; rights generally and by general equitable principles (regardless of
whether enforceability is considered in a proceeding in equity or at law); (b) as enforceability of any indemnification or contribution provision may be limited under the Federal and state securities laws; and (c)&nbsp;that the remedy of specific
performance and injunctive and other forms of equitable relief may be subject to the equitable defenses and to the discretion of the court before which any proceeding therefor may be brought. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are opining solely on the laws of the State of New York. Our opinion is based on these laws as in effect on the date hereof, and we assume
no obligation to revise or supplement this opinion should the law be changed by legislative action, judicial decision, or otherwise. We express no opinion as to whether the laws of any other jurisdiction are applicable to the subject matter hereof.
We are not rendering any opinion as to compliance with any other international, Federal or state law, rule or regulation relating to securities, or to the sale or issuance thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We hereby consent to the use of this opinion as an exhibit to the Registration Statement, to the use of our name as your counsel, and to all
references made to us in the Registration Statement and in the prospectus forming a part thereof. In giving this consent, we do not hereby admit that we are in the category of persons whose consent is required under Section&nbsp;7 of the Act or the
rules and regulations promulgated thereunder.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">/s/ Morgan, Lewis&nbsp;&amp; Bockius LLP</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-8.1
<SEQUENCE>6
<FILENAME>d459793dex81.htm
<DESCRIPTION>EX-8.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-8.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 8.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="51%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="middle"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em">


<IMG SRC="g459793g40d42.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; line-height:12pt; font-size:8pt; font-family:ARIAL">Davis&nbsp;Polk&nbsp;&amp;&nbsp;Wardwell <SMALL>LLP</SMALL></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; line-height:12pt; font-size:8pt; font-family:ARIAL">450 Lexington Avenue</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; line-height:12pt; font-size:8pt; font-family:ARIAL">New York, NY 10017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:48pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">August&nbsp;29, 2023 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Re:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Material U.S. Federal Income Tax Considerations </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Forbion European Acquisition Corp. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4001 Kennett Pike, Suite 302
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Wilmington, Delaware, 19807 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have acted as United States counsel to Forbion European Acquisition Corp., a Cayman Islands exempted company (&#147;<B>FEAC</B>&#148;), in connection with
the transactions contemplated by the business combination agreement, executed on May&nbsp;16, 2023 (as it may be amended and/or restated from time to time, the &#147;<B>BCA</B>&#148;), by and among FEAC, enGene Inc., a corporation incorporated under
the laws of Canada (the &#147;<B>Company</B>&#148;) and enGene Holdings Inc., a corporation incorporated under the laws of Canada (&#147;<B>Newco</B>&#148;) (the &#147;<B>Business Combination</B>&#148;), including (i)&nbsp;the merger of Cayman
Merger Sub, a&nbsp;Cayman Islands exempted company and a direct wholly-owned subsidiary of Newco (&#147;<B>Cayman Merger Sub</B>&#148;), with and into FEAC, with FEAC surviving (the &#147;<B>Cayman Merger</B>&#148;), (ii)&nbsp;concurrently with the
Cayman Merger, and effective at the same time the Cayman Merger becomes effective under the Cayman Islands law, the assumption by Newco of the warrants of FEAC (the &#147;<B>FEAC Warrants</B>&#148; and, after the assumption, the &#147;<B>Newco
Warrants</B>&#148;) (iii)&nbsp;concurrently with the Cayman Merger, and effective at the same time the Cayman Merger becomes effective under the Cayman Islands law, the redemption by Newco of the initial Newco Shares held by the Formation
Shareholder (the Cayman Merger, the assumption by Newco of the FEAC Warrants and the redemption of the Formation Shareholder&#146;s Newco Shares are together referred to as the &#147;<B>Cayman Reorganization</B>&#148;); (iv)&nbsp;following (and to
be effective the beginning of the day after) the Cayman Reorganization, the election by FEAC to be treated, for U.S. federal income tax purposes, as an entity disregarded as separate from its owner Newco (the &#147;<B>U.S. Entity Classification
Election</B> &#148; and, together with the Cayman Reorganization, the &#147;<B>FEAC Reorganization</B>&#148;)<B> </B>and (v)&nbsp;one day following the Cayman Reorganization, the amalgamation of Can Merger Sub, a&nbsp;corporation incorporated under
the laws of Canada and a direct wholly owned subsidiary of FEAC with and into the Company with the Company surviving (the amalgamation, and together with the FEAC Reorganization, the &#147;<B>Transactions</B>&#148;). Unless otherwise indicated, each
capitalized term used herein has the meaning ascribed to it in the Registration Statement (defined below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This opinion is being delivered in connection
with the Registration Statement (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-273851)</FONT> of Newco on Form <FONT STYLE="white-space:nowrap">S-4,</FONT> filed with the Securities and Exchange Commission, as amended and supplemented through
the date hereof (the &#147;<B>Registration Statement</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In preparing the opinion set forth below, we have examined and reviewed originals or
copies, certified or otherwise identified to our satisfaction, of: (i)&nbsp;the Registration Statement; (ii)&nbsp;the BCA; (iii)&nbsp;representation letters delivered to us by each of FEAC and Newco for purposes of this opinion (together, the
&#147;<B>Representation Letters</B>&#148;) and (iii)&nbsp;such other documents, certificates and records as we have deemed necessary or appropriate as a basis for our opinion. In such examination, we have assumed the genuineness of all signatures,
the legal capacity of natural persons, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as duplicates or certified or conformed copies, and the authenticity of the
originals of such latter documents. </P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g459793g00u16.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:16pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In rendering our opinion, we have assumed, without any independent investigation or examination thereof, that
(i)&nbsp;the Business Combination (including the FEAC Reorganization and each of the other Transactions) will be consummated in the manner described in the Registration Statement and the BCA, each will be effective under applicable law, and none of
the terms or conditions contained in either the Registration Statement or the BCA will be waived or modified, (ii)&nbsp;the facts relating to the Transactions and Business Combination are accurately and completely reflected in the Registration
Statement and the BCA, (iii)&nbsp;any representations made in the Representation Letters are true, complete and correct and will remain true, complete and correct at all times up to and including the Initial Merger Effective Time and the Closing
Date (each as defined in the BCA), as applicable, and (iv)&nbsp;any representations made in the Representation Letters subject to qualification relating to the knowledge, belief, expectation or intent of any party are true, complete and correct and
will remain true, complete and correct at all times up to and including the Initial Merger Effective Time and the Closing Date, as applicable, in each case, without such qualification. Our opinion assumes and is expressly conditioned on, among other
things, the initial and continuing accuracy of the facts, information, covenants, representations and warranties set forth in the documents referred to above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our opinion is based on the Internal Revenue Code of 1986, as amended, Treasury regulations promulgated thereunder, judicial decisions, published positions of
the Internal Revenue Service (the &#147;<B>Service</B>&#148;), and such other authorities as we have considered relevant, all as in effect on the date of this opinion and all of which are subject to change or differing interpretations, possibly with
retroactive effect. A change in the authorities upon which our opinion is based could affect the conclusions expressed herein. Moreover, there can be no assurance that positions contrary to our opinion will not be taken by the Service or, if
challenged, by a court. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based upon the foregoing, and subject to the qualifications, assumptions and limitations stated herein and in the Registration
Statement, we hereby confirm that the statements set forth in the Registration Statement under the heading &#147;Material U.S. Federal Income Tax Considerations&#151;Consequences of the Business Combination to U.S. Holders of FEAC Securities&#148;
constitute the opinion of Davis Polk&nbsp;&amp; Wardwell LLP as to the material U.S. federal income tax consequences of the Business Combination to U.S. Holders of FEAC Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This opinion is being delivered prior to the consummation of the Transactions and therefore is prospective and dependent on future events. This opinion is
expressed as of the date hereof, and we are under no obligation to supplement or revise our opinion to reflect any legal developments, any factual matters arising subsequent to the date hereof, or the impact of any information, document,
certificate, record, statement, representation, covenant, or assumption relied upon herein that becomes incorrect or untrue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as expressly set
forth above, we express no other opinion. This opinion has been prepared solely in connection with the Registration Statement and may not be relied upon for any other purpose without our prior written consent. We hereby consent to the filing of this
opinion as Exhibit 8.1 to the Registration Statement. In giving this consent, we do not thereby admit that we are in the category of persons whose consent is required under Section&nbsp;7 of the Securities Act of 1933, as amended, or the rules and
regulations of the Securities Exchange Commission thereunder. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Very truly yours, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Davis Polk &amp; Wardwell LLP </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">2 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-8.2
<SEQUENCE>7
<FILENAME>d459793dex82.htm
<DESCRIPTION>EX-8.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-8.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 8.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g459793snap1.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">August&nbsp;29, 2023 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">enGene
Holdings Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7171 Rue Frederick Building </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Saint-Lauren, QC
H4S 1Z9, Canada </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Board of Directors </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and
Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have acted as counsel to enGene Holdings Inc., a corporation incorporated under the laws of Canada
(&#147;<I><U>Newco</U></I>&#148;), in connection with the transactions contemplated by the business combination agreement , executed on May&nbsp;16, 2023 (as it may be amended and/or restated from time to time, the &#147;<I><U>BCA</U></I>&#148;), by
and among Forbion European Acquisition Corp., a Cayman Islands exempted company (&#147;<I><U>FEAC</U></I><B><I>&#148;</I></B>), enGene Inc., a corporation incorporated under the laws of Canada (the &#147;<I><U>Company</U></I>&#148;) and Newco (the
&#147;<I><U>Business Combination</U></I>&#148;), including (i)&nbsp;the merger of Cayman Merger Sub, a Cayman Islands exempted company and a direct wholly-owned subsidiary of Newco (&#147;<I><U>Cayman Merger Sub</U></I>&#148;), with and into FEAC,
with FEAC surviving (the &#147;<I><U>Cayman Merger</U></I>&#148;), (ii) concurrently with the Cayman Merger, and effective at the same time the Cayman Merger becomes effective under the Cayman Islands law, the assumption by Newco of the warrants of
FEAC (the &#147;<I><U>FEAC Warrants</U></I>&#148; and, after the assumption, the &#147;<I><U>Newco Warrants</U></I>&#148;) (iii) concurrently with the Cayman Merger, and effective at the same time the Cayman Merger becomes effective under the Cayman
Islands law, the redemption by Newco of the initial Newco Shares held by the Formation Shareholder (the Cayman Merger, the assumption by Newco of the FEAC Warrants and the redemption of the Formation Shareholder&#146;s Newco Shares are together
referred to as the &#147;<I><U>Cayman Reorganization</U></I>&#148;); (iv) following (and to be effective the beginning of the day after) the Cayman Reorganization, the election by FEAC to be treated, for U.S. federal income tax purposes, as an
entity disregarded as separate from its owner Newco (the &#147;<I><U>U.S. Entity Classification Election</U></I>,&#148; and, together with the Cayman Reorganization, the &#147;<I><U>FEAC Reorganization</U></I>&#148;) and (v)&nbsp;one day following
the Cayman Reorganization, the amalgamation of Can Merger Sub, a corporation incorporated under the laws of Canada and a direct wholly owned subsidiary of FEAC with and into the Company with the Company surviving (the amalgamation, and together with
the FEAC Reorganization, the &#147;<I><U>Transactions</U></I>&#148;). Unless otherwise indicated, each capitalized term used herein has the meaning ascribed to it in the Registration Statement (defined below). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At your request, and in connection with the filing of the registration statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT>
(Registration No. _________) (as amended to the date hereof, the &#147;<I><U>Registration Statement</U></I>&#148;) with the Securities and<B> </B>Exchange Commission under the Securities Act of 1933, as amended, relating to certain proposed
transactions pursuant to the BCA, we are rendering our opinion regarding the accuracy of certain disclosures provided in the Registration Statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In preparing the opinion set forth below, we have examined and reviewed originals or copies, certified or otherwise identified to our
satisfaction, of: (i)&nbsp;the Registration Statement; (ii)&nbsp;the BCA; and (iii)&nbsp;such other documents, certificates and records as we have deemed necessary or appropriate as a basis for our opinion. In such examination, we have assumed the
genuineness of all signatures, the legal capacity of natural persons, the authenticity of all documents submitted to </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Morgan, Lewis&nbsp;&amp; Bockius <SMALL>LLP</SMALL></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">1111&nbsp;Pennsylvania&nbsp;Avenue,&nbsp;NW</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Washington, DC 20004</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g459793snap1a.jpg" ALT="LOGO">
+1.202.739.3000</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">United States</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g459793snap1b.jpg" ALT="LOGO">
+1.202.739.3001</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">enGene Holdings Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">August&nbsp;29, 2023 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 2
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">us as originals, the conformity to original documents of all documents submitted to us as duplicates or
certified or conformed copies, and the authenticity of the originals of such latter documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In rendering this opinion, we have
assumed, with your permission and without any independent investigation or examination thereof, that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(1) all parties to the BCA have
acted and will act in accordance with the terms of the BCA and any other documents reviewed by us; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(2) the facts relating to the
Transactions and Business Combination are accurately and completely reflected in the Registration Statement and the BCA; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(3) the
Transactions will be consummated pursuant to and in accordance with the terms and conditions set forth in the BCA and the Registration Statement and the documents referenced therein, without the waiver or modification of any such terms and
conditions, and each such Transaction will be effective under applicable law; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(4) all facts, information, statements, covenants,
representations, warranties, and agreements made by or on behalf of any Person in the BCA, the documents referenced therein, or the Registration Statement are and, at all times up to and including the Closing, will continue to be true, complete, and
correct, and all such facts, information, statements, covenants, representations, warranties, and agreements can be established to the Internal Revenue Service or courts, if necessary, by clear and convincing evidence; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(5) all facts, information, statements, covenants, representations, warranties, and agreements made or stated by or on behalf of any Person in
the BCA, the documents referenced therein, or the Registration Statement that are qualified by the knowledge, intention, expectation, and/or belief of any person or entity are and, at all times up to and including the Closing, will continue to be
true, complete, and correct as though not so qualified; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(6) as to all matters as to which any Person represents that it is not a party to,
does not have, or is not aware of any plan, intention, understanding, or agreement, there is in fact no plan, intention, understanding, or agreement and, at all times up to and including the Closing, there will be no plan, intention, understanding,
or agreement; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(7) FEAC, the Company, Newco, and their respective affiliates will report the Transactions for all U.S. federal income tax
reporting purposes in a manner consistent with the BCA, the Registration Statement, and this opinion; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(8) the FEAC Reorganization will
qualify as a reorganization under Section&nbsp;368(a)(1)(F) of the Internal Revenue Code of 1986, as amended (the <I>&#147;</I><I><U>Code</U></I><I>&#148;).</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of the assumptions described above are untrue for any reason, or if the Transactions are consummated other than in accordance with the
terms and conditions set forth in the BCA, the documents referenced therein, or the Registration Statement, our opinion as expressed below may be adversely affected. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">enGene Holdings Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">August&nbsp;29, 2023 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 3
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our opinion is based on the Code, the Treasury Regulations, case law, and published rulings
and other pronouncements of the Internal Revenue Service, as in effect on the date hereof. No assurances can be given that such authorities will not be amended or otherwise changed at any time, possibly with retroactive effect. We assume no
obligation to advise you of any such subsequent changes, or to update or supplement this opinion to reflect any change in facts, circumstances, or law after the date hereof. Any change in the applicable law or regulations, or any new administrative
or judicial interpretation of the applicable law or regulations, may affect the continuing validity of our opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based upon and
subject to the foregoing and to the assumptions, exceptions, limitations, and qualifications set forth herein, it is our opinion that the discussion in the section of the Registration Statement entitled &#147;Material U.S. Federal Income Tax
Consideration &#150; Consequences to U.S. Holders of New enGene Securities of the Ownership and Disposition of New enGene Shares or New enGene Warrants&#148; addresses the material U.S. federal income tax consequences to U.S. Holders of New enGene
Securities of the ownership and disposition of New enGene Shares or New enGene Warrants (as such terms are defined in the Registration Statement) and is accurate in all material respects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our opinion relates solely to the specific matter set forth above, and no opinion is expressed, or should be inferred, as to any other U.S.
federal, state, local, or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> income, estate, gift, transfer, sales, use, or other tax consequences that may result from the Transactions. Our opinion is limited to legal rather than factual matters and
has no official status or binding effect of any kind. Accordingly, we cannot assure you that the Internal Revenue Service or a court will agree with our opinion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The opinion expressed herein is being furnished in connection with the filing of the Registration Statement and may not be used or relied upon
for any other purpose without our prior written consent. We hereby consent to the filing of this opinion with the Securities and Exchange Commission as Exhibit 8.1 to the Registration Statement and to the references to this opinion in the
Registration Statement. In giving this consent, we do not admit that we are within the category of persons whose consent is required under Section&nbsp;7 of the Securities Act of 1933, as amended, or the rules or regulations of the Securities and
Exchange Commission promulgated thereunder. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Very truly yours,</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/s/ Morgan, Lewis&nbsp;&amp; Bockius LLP</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.14
<SEQUENCE>8
<FILENAME>d459793dex1014.htm
<DESCRIPTION>EX-10.14
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.14</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.14 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EXECUTED VERSION </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTAIN
INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">NON-EXCLUSIVE</FONT> LICENSE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This <FONT STYLE="white-space:nowrap">NON-EXCLUSIVE</FONT> LICENSE AGREEMENT (&#147;Agreement&#148;) is entered into as of April&nbsp;10, 2020
(&#147;Effective Date&#148;) between enGene, Inc., a corporation formed under Canadian law having its principal place of business at 7171 Frederick Banting, Suite 3232, Laurent, Quebec, Canada, H4S, 1Z9 (&#147;ENGENE&#148;) and Nature Technology
Corporation, a Delaware corporation with a place of business at 4701 Innovation Drive, Suite 103, Lincoln, NE 68521 (&#147;NTC&#148;), each referred to herein individually as &#147;Party&#148; and collectively as &#147;Parties.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, NTC designs and develops gene encoded therapy vectors and methods for making such vectors; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, NTC is the owner of certain Patent Rights and Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> (each defined below)
regarding such vectors and methods and desires to grant a license to the same; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, ENGENE is engaged in the development and
commercialization of gene and cell therapy products and desires to license such Patent Rights and Licensed <FONT STYLE="white-space:nowrap">Know-How.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of good and valuable consideration, the receipt and sufficiency of which are herein acknowledged, the Parties
hereby agree as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 1 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>DEFINITIONS </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As
used in this Agreement, the following terms shall have the meanings set out in this Article I unless otherwise specifically provided herein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.1
&#147;<U>Affiliate</U>&#148; with respect to either Party shall mean any corporation or other legal entity other than that Party in whatever country organized, controlling, controlled by or under common control with that Party. The term
&#147;control&#148; shall mean direct or indirect ownership of fifty percent (50%) or more of the voting securities having the right to elect directors. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.2 &#147;<U>Confidential Information</U>&#148; means, other than Exempt Information, all information, in whatever form or manner presented, which is disclosed
or provided by or on behalf of the Disclosing Party to the Receiving Party during the Term and either (a)&nbsp;relates to the Disclosing Party&#146;s business or business plans, including but not limited to suppliers, customers, prospective
customers, contractors, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> or clinical data, grant proposals, the content and format of various clinical and medical databases, utilization data, cost and pricing data, disease management data,
software products, programming techniques, data warehouse and methodologies, <FONT STYLE="white-space:nowrap">know-how,</FONT> trade secrets, technical and <FONT STYLE="white-space:nowrap">non-technical</FONT> materials, processes, sales and
marketing plans and strategies, designs, and any discussions and proceedings relating to any of the foregoing, or (b)&nbsp;is information which a reasonable person would deem as confidential. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EXECUTED VERSION </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.3 &#147;<U>Disclosing Party</U>&#148; means the Party that discloses Confidential Information to the
Receiving Party. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.4 &#147;<U>Exempt Information</U>&#148; means information that the Receiving Party can demonstrate (a)&nbsp;was in its possession prior
to the time of disclosure by the Disclosing Party, as shown by documents or other competent evidence; (b)&nbsp;is or becomes publicly known or publicly available through no fault, omission, or other act of the Receiving Party; (c)&nbsp;is obtained
by the Receiving Party from a Third Party under no obligation of confidentiality to the Disclosing Party; (d)&nbsp;is independently developed by the Receiving Party without use or reference to the Confidential Information, as shown by documents or
other competent evidence in the Receiving Party&#146;s possession; or (e)&nbsp;is required to be disclosed by law or order of a court, governmental or regulatory agency of competent jurisdiction. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.5 &#147;<U>License Field</U>&#148; shall mean any ENGENE gene therapy products and/or ENGENE cell therapy products in which ENGENE possesses rights of
development or commercialization, and the manufacturing of such products. The use of [***] in the field of dermatology is excluded from the License Field. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.6 &#147;<U>Licensed IP</U>&#148; shall mean the Patent Rights and the Licensed <FONT STYLE="white-space:nowrap">Know-How.</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.7 &#147;<U>Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT></U>&#148; shall mean the information set forth in <B>Exhibit B,</B> as updated and in
effect from time to time. As of the date of this Agreement, <B>Exhibit B</B> only includes the <FONT STYLE="white-space:nowrap">know-how</FONT> that has been transferred upon the execution of this Agreement. <B>Exhibit B</B> will be updated on an
ongoing basis upon any new transfer of <FONT STYLE="white-space:nowrap">know-how</FONT> by NTC to ENGENE by a written amendment signed by both parties. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.8 &#147;<U>License Territory</U>&#148; shall mean worldwide. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.9 &#147;<U>Net Sales</U>&#148; shall mean: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the gross amount billed or invoiced, or if no such bill or invoice is issued the amount received, whichever is
greatest, by ENGENE and/or its Affiliates or sublicensees for or on account of sales of Products to a Third Party; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">less the following deductions from such gross amounts to the extent actually allowed or paid as shown in
documentation by ENGENE, its Affiliates or sublicensees (as the case may be) including, without limitation in effecting such sale: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">amounts repaid or credited by reason of rejection, return or recall or allowances granted for damaged goods,
defects, recalls, returns or rejections of the of Products; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EXECUTED VERSION </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">trade, quantity or cash rebates or discounts, retroactive price reductions or adjustments in each case actually
granted, or billing corrections actually corrected and bad debts with respect to sales of Product to the extent taken; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">commercially reasonable allowances for <FONT STYLE="white-space:nowrap">non-collectible</FONT> receivables
and/or actual write-offs or write-downs taken for <FONT STYLE="white-space:nowrap">non-collectible</FONT> receivables; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(D)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">amounts for outbound transportation, insurance, packaging, handling and shipping, that clearly specifies the
charges applicable to the applicable Products; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(E)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">taxes, customs duties, import/export duties or other similar governmental taxes or charges imposed on sales of
the Product(s) and other governmental or regulatory authority charges levied on or measured by production, sale, transportation, or delivery of Products, to the extent separately stated on purchase orders, invoices or other documents of sale that
are paid by or on behalf of ENGENE, its Affiliates or sublicensees, but not franchise or income taxes of any kind whatsoever. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, amounts received or invoiced by ENGENE and/or any of its Affiliates or sublicensees in connection with the sale
of a Product among ENGENE and/or its Affiliates or sublicensees (as well as affiliates of sublicensees) for resale to Third Parties shall not be included in the computation of Net Sales hereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.10 &#147;<U>Material Breach</U>&#148; means a breach of this Agreement that results in the loss of a substantial benefit which the <FONT
STYLE="white-space:nowrap">non-breaching</FONT> Party would otherwise derive from this Agreement. ENGENE challenging the validity of any Patent Rights shall be considered a Material Breach solely for purposes of Article 10.4 hereof (it being
understood and agreed that the sole remedy of NTC for any challenge by ENGENE of the validity of any Patent Rights shall be for NTC to terminate this Agreement pursuant to Article 10.4 hereof). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.11 &#147;<U>Milestone Product</U>&#148; shall mean a Product, the composition, manufacture or use of which in the United States is covered by a Valid Claim
in the United States. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.12 &#147;<U>Patent Right</U>&#148; shall mean, inclusively, (i)&nbsp;any patent or patent application identified in <B>Exhibit
A,</B> (ii)&nbsp;any patent application that is entitled to claim priority from any such patent or patent application identified in <B>Exhibit A</B>, including any divisional, continuation, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">continuation-in-part,</FONT></FONT> substitutes, counterparts and/or any foreign equivalents filed in any country of any patent or patent application referred to in the foregoing clause (i)&nbsp;and this clause (ii), and
(iii)&nbsp;any letters patent and/or the equivalent thereof issuing on any patent application referred to in any of the foregoing clauses (i)&nbsp;and (ii) and/or any reissue, reexamination or extension of any such letters patent and/or the
equivalent thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.13 &#147;<U>Permitted User</U>&#148; means any person who (1) (a) is the Receiving Party&#146;s director, officer, consultant,
professional advisor, agent or employee, or (b)&nbsp;is party to an effective confidentiality agreement with Receiving Party which is consistent with the terms of this Agreement; and (2)&nbsp;has a need to know the Confidential Information in
connection with this Agreement, the exercise of any rights under this Agreement or the performance of any obligations under this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EXECUTED VERSION </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.14 &#147;<U>Phase I clinical trial</U>&#148; means a study of a pharmaceutical product in healthy human
volunteers, which trial is designed to ascertain initial tolerance, safety, metabolism, pharmacological and/or pharmacokinetic information regarding such product in a manner that is generally consistent with 21 CFR &#167; 312.21(a), as amended (or
its successor regulation), for the purpose of enabling the design of a well-controlled, scientifically valid, Phase 2 clinical trial. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.15 &#147;<U>Phase
II clinical trial</U>&#148; means a study of a pharmaceutical product in human patients, which trial is designed to evaluate the initial effectiveness and dose range of the pharmaceutical product for a particular indication or indications in
patients with the disease or condition under study and to determine the common short-term side effects and risks associated with the drug, in a manner that is generally consistent with 21 CFR &#167; 312.21(b), as amended (or its successor
regulation), for the purpose of enabling the design of further clinical trials. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.16 &#147;<U>Preferred Manufacturer</U>&#148; means a Third-Party
contract manufacturer that has separate rights to manufacture under some or all of the Licensed IP. A list of Preferred Manufacturers as of the Effective Date is set forth in <B>Exhibit C</B>. NTC shall update <B>Exhibit C</B> on an annual basis by
giving written notice thereof to ENGENE and upon such update <B>Exhibit C</B>_shall be deemed amended without further action of the Parties. [***] </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.17
&#147;<U>Product</U>&#148; shall mean any article, device or composition, the manufacturing, having manufactured, selling, offering to sell, use, or importation of which, in whole or in part, (1)&nbsp;would infringe, or is covered by, one or more
Valid Claims absent the license granted hereunder, or (2)&nbsp;makes use of any of the Licensed <FONT STYLE="white-space:nowrap">Know-How.</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.18
&#147;<U>Receiving Party</U>&#148; means the Party who receives Confidential Information from the Disclosing Party. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.19 &#147;<U>Reporting
Period</U>&#148; shall mean a period of twelve (12)&nbsp;months commencing on the Effective Date and each subsequent anniversary of that date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.20
&#147;<U>Third Party</U>&#148; shall mean any individual or entity which is neither a Party, an Affiliate of a Party, a direct or indirect sublicensee of ENGENE or any of its Affiliates, or an affiliate of any such direct or indirect sublicensee.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.21 &#147;<U>Valid Claim</U>&#148; shall mean any claim from (a)&nbsp;an issued, unexpired, unlapsed patent included in any Patent Right to the extent
that it has not been held invalid or unenforceable by a decision of a court or other government agency of competent jurisdiction from which no appeal can be taken, or to the extent an appeal is not taken within the time allowed for appeal or that it
has not been disclaimed, denied or admitted to be invalid or unenforceable through reissue or disclaimer or otherwise; or (b)&nbsp;a patent application included within any Patent Right to the extent that such patent application has not been
canceled, withdrawn, abandoned, or pending for more than [***] after the earliest applicable priority date thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EXECUTED VERSION </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 2 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>LICENSE GRANTS </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2.1 <U>Grant of
License</U>. Subject to the terms of this Agreement and the rights of NTC and NTC&#146;s Affiliates in Patent Rights, NTC hereby grants to ENGENE and its Affiliates in the License Territory a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT>
royalty-bearing, sublicenseable (subject to Article 2.2, through multiple tiers of sublicensees) license under the Licensed IP to research, have researched, develop, have developed, make, have made, use, have used, import, have imported, sell, offer
to sell, and have sold or offered for sale any Product in the License Field. In the event that any of the Licensed IP is owned or licensed by any Affiliate of NTC, such Affiliate hereby grants the foregoing license with respect to such Licensed IP
and, solely for this purpose, the any reference in the foregoing sentence to NTC shall be deemed a reference to such Affiliate. NTC hereby covenants and agrees that NTC shall cause any such Affiliate to grant such license and that NTC shall be
liable for any failure of any such Affiliate to grant such license. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2.2 <U>Sublicenses</U>. Each sublicense granted hereunder shall be consistent with and
comply with all terms of this Agreement and shall incorporate terms and conditions sufficient to enable ENGENE to comply with this Agreement. ENGENE shall ensure that any sublicensee to which it grants a sublicense will not exceed the scope of the
rights granted to ENGENE under this Agreement including, but not limited to, the License Field. ENGENE will provide or cause to be provided to NTC a fully signed copy of any sublicense agreement (other than any sublicense agreement with a contract
manufacturer or other contractor pursuant to which such contract manufacturer or contractor shall practice or use the Licensed IP solely for the benefit of, or to provide services to, ENGENE or any of its Affiliates or sublicensees) within thirty
(30)&nbsp;days of executing the same and ENGENE may redact, or cause to be redacted, from such copy any proprietary or confidential technical information of it or the sublicensee. Any sublicense which is not in accordance with the foregoing shall be
null and void. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2.3 <U>Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> and Consulting</U>. Promptly (but in any event within thirty
(30)&nbsp;days) following the Effective Date, NTC shall complete the transfer to ENGENE of all Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> identified on <B>Exhibit B</B> as of the date of this Agreement. Such Licensed <FONT
STYLE="white-space:nowrap">Know-How</FONT> to be transferred by NTC to ENGENE pursuant to the immediately preceding sentence shall include all <FONT STYLE="white-space:nowrap">know-how</FONT> owned or licensed by NTC or any of its Affiliates as of
the date of this Agreement that is necessary or useful for ENGENE to acquire, setup, implement, use, operate and <FONT STYLE="white-space:nowrap">carry-on</FONT> [***]. In the event that, at any time and from time to time during the Term, NTC or any
of its Affiliates acquires, licenses, generates or develops <FONT STYLE="white-space:nowrap">know-how</FONT> that is necessary or useful for ENGENE or any of its Affiliates [***], NTC shall give written notice thereof to ENGENE and shall promptly
(but in any event within 90 days after such acquisition, license, generation or development) transfer such <FONT STYLE="white-space:nowrap">know-how</FONT> to ENGENE, and ENGENE and NTC shall amend this Agreement for purposes of updating <B>Exhibit
B</B> to reflect that any such transferred <FONT STYLE="white-space:nowrap">know-how</FONT> pursuant to this sentence shall be included in Licensed <FONT STYLE="white-space:nowrap">Know-How.</FONT> Except to the extent otherwise provided below in
this Article 2.3 to the contrary, all activities undertaken by NTC in connection with the transfer of the Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> pursuant to the foregoing provisions of this Article 2.3 shall be at the sole cost
and expense of NTC. ENGENE shall pay to NTC a <FONT STYLE="white-space:nowrap">one-time</FONT> fee of [***] plus reimbursement of reasonable NTC personnel travel costs for the transfer contemplated under this Article 2.3 which includes NTC providing
all reasonable assistance required by ENGENE onsite at the facility of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EXECUTED VERSION </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
ENGENE or at the facility of any contract manufacturer of ENGENE or any of its Affiliates. If ENGENE requires further consulting by NTC regarding any additional Licensed <FONT
STYLE="white-space:nowrap">Know-How</FONT> transferred under this Agreement, ENGENE shall pay NTC a consulting rate of [***] per hour for a senior NTC consultant and, when applicable, reasonable travel and lodging expenses. To the extent NTC
provides any consulting services in accordance with this Article 2.3, any intellectual property developed by NTC will be owned by NTC and will automatically be included in <B><U>Exhibit A or B</U></B> of this Agreement, as applicable. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 3 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>PAYMENTS;
ROYALTIES; SUBLICENSE INCOME </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3.1 <U>License Issue Fee</U>. Within ten (10)&nbsp;days of Effective Date, ENGENE shall pay NTC a <FONT
STYLE="white-space:nowrap">one-time,</FONT> <FONT STYLE="white-space:nowrap">non-refundable,</FONT> license issue fee in the amount of [***]. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3.2
<U>Annual Maintenance Fee</U>. Beginning on the first anniversary of the Effective Date and each subsequent anniversary of the Effective Date, ENGENE shall pay to NTC fifty thousand United States dollars (50,000 USD). The obligation of ENGENE to
make payment of the fee owed under this Article 3.2 will terminate on the date of the first sale of a Product for which a royalty is due to NTC pursuant to Article 3.5. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3.3 <U>Assignment Fee</U>. ENGENE shall pay NTC fifty thousand United States dollars (50,000 USD) if ENGENE assigns this Agreement to a Third Party. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3.4 <U>Milestone Payments</U>. ENGENE shall pay NTC milestone payments for each different Milestone Product in the Licensed Field as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a <FONT STYLE="white-space:nowrap">one-time</FONT> payment of fifty thousand United States dollars (50,000 USD)
for the first dose of a Milestone Product in the first patient in a Phase I clinical trial or, if there is no Phase I clinical trial, in a Phase II clinical trial; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a <FONT STYLE="white-space:nowrap">one-time</FONT> payment of four hundred-fifty thousand United States dollars
(450,000 USD) upon regulatory approval of a Milestone Product by the Food&nbsp;&amp; Drug Administration (FDA) in the U.S. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For clarity,
(i)&nbsp;the milestone payments under this Article 3.4 shall be paid to NTC regardless of whether ENGENE, its Affiliate, or its sublicensee achieves the milestone, and (ii)&nbsp;the milestone payments contemplated above in this Article 3.4 shall be
paid only once with respect to a Milestone Product (regardless of the number of different clinical trials and regulatory approvals applicable to such Milestone Product) and the maximum amount of aggregate milestone payments for a Milestone Product
under this Article 3.4 shall be five hundred thousand United States dollars (500,000 USD). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3.5 <U>Product Royalty</U>. Subject to Article 3.11, ENGENE
shall pay NTC a royalty equal to [***] of the aggregate Net Sales of Product in a calendar year by ENGENE, its Affiliates or sublicensees on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Product</FONT></FONT> and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis so long as the composition or use of the applicable Product is covered by a Valid Claim in the country where such Net Sales occurred. Upon there being
no Valid Claim remaining in a country that covers the composition, manufacture or use of the applicable Product in such country, ENGENE shall have a fully <FONT STYLE="white-space:nowrap">paid-up,</FONT> royalty-free, irrevocable, perpetual license
to the Licensed IP in such country with respect to such applicable Product and have the right to grant sublicenses under such Licensed IP in such country through multiple tiers of sublicensees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EXECUTED VERSION </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3.6 <U>Manufacturing Payment</U>. In the event that ENGENE or any of its Affiliates or sublicensees
manufactures any GMP (or its equivalent) lot of a Product, then ENGENE or any such Affiliate or sublicensee shall pay NTC per GMP (or its equivalent) manufactured lot of Product according to the following schedule: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[***]; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[***]; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[***]; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[***]. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The payment under this Article 3.6 shall expire on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Product</FONT></FONT> basis
upon receipt of regulatory approval to market a Product in any country in the Territory. No payment is due under this Article 3.6 for manufacturing performed by a Preferred Manufacturer for and on behalf of ENGENE or any of its Affiliates or
sublicensees. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3.8 <U>Payment Schedule</U>. Unless otherwise stated, all payments due to NTC under this Article 3 shall be due and payable by ENGENE within
sixty-five (65)&nbsp;days after the following dates: (i)&nbsp;achieving a specific milestone for the payments due under Article 3.4; or (ii)&nbsp;the end of each Reporting Period for the royalty or payments due under Article 3.5 or 3.6,
respectively. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3.9 <U>Form of Payment</U>. All payments due under this Agreement shall be drawn on a United States bank and shall be payable in United
States dollars. Each payment shall reference this Agreement and identify the obligation under this Agreement that the payment satisfies. Conversion of foreign currency to U.S. dollars shall be made at the conversion rate existing in the United
States, as reported in The Wall Street Journal on the last working day of the applicable Reporting Period. Such payments shall be without deduction of exchange, collection or other charges, and, specifically, without deduction of withholding or
similar taxes or other government-imposed fees or taxes imposed on ENGENE, except as permitted in the definition of Net Sales or as otherwise required under applicable law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Checks for all payments due to NTC under this Agreement shall be made in immediately available funds payable to NTC and addressed as set forth
below or by wire transfer to a United States based account to be identified by NTC: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">[***] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3.10 <U>Overdue Payment</U>. The payments due under this Agreement shall, if overdue, bear interest beginning on the first day following the day the payment
was due and until payment thereof at a per annum rate equal to [***], not to exceed the maximum permitted by law. Any such overdue payment when made shall be accompanied by all interest so accrued. NTC shall be entitled to recover, in addition to
all other remedies, reasonable attorneys&#146; fees and costs related to the administration or enforcement of this Agreement, including collection of payments, following ENGENE&#146;s such failure to pay. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EXECUTED VERSION </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3.11 <U>Royalty Reduction</U>. If ENGENE is required or deems it reasonably necessary to obtain a license
from a person (other than an Affiliate of ENGENE) under any intellectual property rights of such person that cover the manufacture, use or sale of a Product in a country, or are necessary to manufacture, use or sell a Product in a country, ENGENE
shall have the right to deduct, from the royalties due to NTC under Article 3.5, [***] of the aggregate payments made by ENGENE or any of its Affiliates or sublicensees to such person in exchange for such license on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> and a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Product</FONT></FONT> basis, except that in no instance shall the
reduction in the royalty under Article 3.5 reduce NTC&#146;s aggregate royalties under Article 3.5 with respect to Net Sales of a Product throughout the Licensed Territory in a calendar year to an amount less than [***] of aggregate Net Sales of
such Product throughout the Licensed Territory in such calendar year. For avoidance of doubt, the royalty reduction under this Article 3.11 only applies to Net Sales that are also subject to payment of royalties pursuant to Article 3.5. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 4 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>RECORDS
</U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.1 <U>Reports</U>. ENGENE will deliver to NTC a written report setting forth a full accounting showing how any amounts due by ENGENE to NTC
under Article 3.5 and Article 3.6 have been calculated, including an accounting of total Net Sales, and amounts of Product manufactured for such Reporting Period (including amounts of Product manufactured by a Preferred Manufacturer even though no
accompanying payment would be due). Each Reporting Period report involving a sale of a Product will include Product names and quantity sold for each country in which Product was sold. If no sale of a Product has occurred and no other amount is due
to NTC, ENGENE will submit a report confirming the same. All reports under this Article 4.1 shall be provided to NTC with any payment pursuant to the payment schedule in Article 3.8. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.2 <U>Audits</U>. During the Term, ENGENE will keep adequate books and records of accounting for the purpose of calculating all amounts payable by ENGENE to
NTC under Article 3.5 and Article 3.6. For the [***] following the end of the calendar year to which each will pertain, such books and records of accounting will be kept at ENGENE&#146;s or one of its Affiliates&#146; principal place of business and
will be open for inspection and copying at reasonable times and upon reasonable notice by an independent certified accountant selected by NTC, and which is reasonably acceptable to ENGENE, for inspecting the amounts due by ENGENE to NTC under
Article 3.5 and Article 3.6. In no event will such inspections be conducted hereunder more frequently than once every twelve (12)&nbsp;months and no record shall be audited more than once. Such accountant will have executed and delivered to ENGENE a
customary confidentiality agreement as reasonably requested by ENGENE. The accountant shall share its analysis and report with ENGENE, and may only share with NTC its conclusion as to whether there has been underpayment or overpayment and if so, the
amount of such underpayment or overpayment. Any undisputed underpayments will be paid by ENGENE to NTC within sixty (60)&nbsp;days of notification of the results of such inspection. Any undisputed overpayments will be offset by the next payment due
by ENGENE to NTC. NTC will pay for any such inspections, except that in the event there is any upward adjustment in aggregate amounts payable for any calendar year shown by such inspection of more than [***] of the amount paid, ENGENE will reimburse
NTC for any reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs of such accountant or related to such inspection. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EXECUTED VERSION </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 5 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIALITY </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.1 The Parties
will treat Confidential Information as strictly confidential and proprietary and will safeguard its confidential and proprietary nature with at least the same degree of care as it holds its own confidential or proprietary information. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.2 The Receiving Party may use Confidential Information only in connection with this Agreement and the exercise by the Receiving Party of its rights under
this Agreement or the performance by the Receiving Party of its obligations under this Agreement, and for no other purpose whatsoever. Subject to the foregoing provisions of this Article 5.2, the Receiving Party will not use the Confidential
Information for the personal benefit of itself or a Permitted User, or for the benefit of any Third Party. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.3 The Receiving Party will not disclose
(directly or indirectly) any Confidential Information to, or permit it to be accessed by, any person except a Permitted User. The Receiving Party will cause any Permitted User to whom Confidential Information is disclosed to abide by the
confidentiality provisions of this Agreement. On a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis, either Party may, in its sole discretion, waive the restrictions of this Article 5.3 to provide
for specific disclosures to specific third parties; provided, however, that such waiver must be in a writing signed by the Disclosing Party and such Third Party must execute a confidentiality agreement with the Disclosing Party which is consistent
with the terms of this Agreement. Each Receiving Party shall be responsible to Disclosing Party for any disclosure or misuse of Confidential Information that results from a failure to comply with this provision. A Receiving Party, as applicable,
shall promptly report to Disclosing Party any actual or suspected violation of the terms of this Article 5 and will take all reasonable further steps requested by Disclosing Party to prevent, control or remedy any such violation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.4 If the Receiving Party is requested or required to disclose the Confidential Information or the substance of this Agreement in connection with a legal or
administrative proceeding or otherwise to comply with a requirement under the law, the Receiving Party will give the Disclosing Party prompt notice of such request so that the Disclosing Party may seek an appropriate protective order or other
remedy, or waive compliance with the relevant provisions of this Agreement. If the Disclosing Party seeks a protective order or other remedy, the Receiving Party, at Disclosing Party&#146;s expense, will cooperate with and assist the Disclosing
Party in such efforts. If the Disclosing Party fails to obtain a protective order or waives compliance with the relevant provisions of this Agreement, the Receiving Party will disclose only that portion of Confidential Information, which the
Receiving Party&#146;s legal counsel determines the Receiving Party is required to disclose. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.5 All obligations of confidentiality will terminate [***]
years after expiration or early termination of this Agreement (any obligations relating to any trade secret shall survive until such time as such trade secret enters the public domain through no fault of Receiving Party and without breach of this
Agreement). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EXECUTED VERSION </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.6 The Parties agree to treat all information related to prosecution and maintenance of any intellectual
property right as Confidential Information. In addition, Parties acknowledge and agree that, with regard to filing, prosecution and maintenance of any intellectual property right, the interests of the Parties are aligned and legal in nature. The
Parties agree and acknowledge that they have not waived, and nothing in this Agreement constitutes a waiver of, any legal privilege concerning any intellectual property right or a Party&#146;s Confidential Information, including privilege under the
common interest doctrine and similar or related doctrines. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.7 Notwithstanding any of the foregoing in this Article 5, either Party may share a copy of
this Agreement and any report under Article 4.1 with a Third Party that is under a written confidentiality agreement with a Party for the sole purpose of the Third Party performing diligence in connection with a potential acquisition, merger, asset
purchase, stock purchase, or similar transaction involving such Party and Third Party. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 6 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>INTELLECTUAL PROPERTY </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6.1
<U>Prosecution</U>. NTC shall be solely responsible for the preparation, filing, prosecution, cost and maintenance of all patent applications and patents included in Patent Rights. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 7 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>THIRD
PARTY INFRINGEMENT AND LEGAL ACTION </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7.1 <U>NTC&#146;s Right to Prosecute</U>. NTC shall have the sole and exclusive right to enforce its Patent
Rights at NTC&#146;s sole cost and expense, against Third Party infringers and will do so, when, in its sole judgment, enforcement is reasonable under the circumstances. Both Parties shall promptly inform the other Party of any third-party
infringement of the Patent Rights of which it is aware. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 8 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>REPRESENTATIONS; WARRANTIES </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8.1
<U>Mutual Representations and Warranties</U>. Each Party represents and warrants to the other Party the following as of the Effective Date: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">it is a company duly organized, validly existing and in good standing under the laws of the jurisdiction in
which it is formed; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that the execution, delivery and performance of this Agreement by it, and the transactions contemplated hereby,
do not and will not conflict with or result in a breach of any provision of the corporate charter, certificate of incorporation, <FONT STYLE="white-space:nowrap">by-laws</FONT> or organizational documents of such Party or any of its affiliates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">it has the power and authority and the legal right to enter into this Agreement and to perform its obligations
hereunder; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(D)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">it has taken all necessary company action on its part required to authorize the execution and delivery of this
Agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EXECUTED VERSION </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8.2 <U>Employee/Contractor Agreements</U>. Each Party represents and warrants that its Permitted Users acting
on its behalf pursuant to this Agreement will be obligated under a binding written agreement of confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> consistent in scope with those set forth in Article 5. It is understood and agreed
that any agreement required by this Article 8.2 does not need to be specific to this Agreement as long as the said agreement provides for the binding obligations of the Permitted User as described herein. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8.3 <U>Representations and Warranties of NTC</U>. NTC represents and warrants to ENGENE the following as of the Effective Date: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NTC is the sole owner of each of the patent applications and patents set forth on <B>Exhibit A</B>, as well as
all inventions claimed under each of such patent applications and patents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NTC has not granted any rights in, to or under the Licensed IP to any person that are inconsistent with the
rights and licenses granted by NTC to ENGENE pursuant to this Agreement; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NTC does not own, is the licensee, or has the right to use, any patent application, any patent, any invention
claimed in any patent application or patent, or any <FONT STYLE="white-space:nowrap">know-how,</FONT> that, in each case, is not included in the Licensed IP [***]. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8.4 <U>Warranty Disclaimer</U>. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, OR ANY OTHER AGREEMENT CONTEMPLATED HEREUNDER, NEITHER PARTY MAKES
REPRESENTATIONS OR EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, AND EXPRESSLY DISCLAIMS ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND OF FITNESS FOR A PARTICULAR PURPOSE OR USE,
<FONT STYLE="white-space:nowrap">NON-INFRINGEMENT,</FONT> VALIDITY AND ENFORCEABILITY OF PATENT RIGHTS, OR THE PROSPECTS OR LIKELIHOOD OF DEVELOPMENT OR COMMERCIAL SUCCESS OF PRODUCT. NOTHING IN THIS AGREEMENT SHALL LIMIT OR EXCLUDE THE LIABILITY OF
EITHER PARTY FOR FRAUD OR FRAUDULENT MISREPRESENTATION; AND ANY BREACH OF THIS AGREEMENT THAT RESULTS FROM THE WILFUL ACT OR WILFUL OMISSION OF EITHER PARTY OR ITS AFFILIATES, EMPLOYEES, AGENTS OR
<FONT STYLE="white-space:nowrap">SUB-CONTRACTORS.</FONT> </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 9 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>INDEMNIFICATION </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9.1
<U>Indemnification of NTC</U>. ENGENE agrees to indemnify, hold harmless and defend NTC or any NTC agent or employee from and against any liability, loss, damage, cost, fee, and expense, including any reasonable legal expense and attorney fee
(collectively, &#147;Losses&#148;) arising out of any suit, claim, action, or demand, brought or made by a Third Party (&#147;Third-Party Claim&#148;) against NTC or any NTC agent or employee based on (a)&nbsp;ENGENE&#146;s breach of this Agreement
or (b)&nbsp;the manufacture, use, handling, storage, sale or other disposition of any Product by ENGENE or any ENGENE Affiliate, agent, or employee, all except to the extent such Losses and/or Third-Party Claim results from (i)&nbsp;the negligence,
fraud or willful misconduct of NTC or any NTC agent or employee, and (ii)&nbsp;a breach by NTC of any provision of this Agreement, including, without limitation, any NTC warranty under Article 8. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EXECUTED VERSION </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9.2 <U>Indemnification of ENGENE</U>. NTC agrees to indemnify, hold harmless and defend ENGENE, any Affiliate
of ENGENE or any ENGENE agent or employee from and against any Losses arising out of any Third-Party Claim against ENGENE or any ENGENE Affiliate, agent or employee based on NTC&#146;s or any NTC&#146;s Affiliates breach of this Agreement, except to
the extent such any Losses and/or Third-Party Claim result from the negligence or willful misconduct of ENGENE or any ENGENE Affiliate or a breach by NTC of any provision of this Agreement, including, without limitation, of any ENGENE warranty under
Article 8. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9.3 <U>Procedure</U>. A Party that intends to claim indemnification under this Article 9 (&#147;Indemnitee&#148;) shall promptly notify the
indemnifying Party (&#147;Indemnitor&#148;) in writing of any Third-Party Claim with full details of the action, claim, proceeding, or demand, in respect of which the Indemnitee intends to claim such indemnification, and the Indemnitor shall have
sole control of the defense and/or settlement thereof. The indemnity arrangement in this Article 9 shall not apply to amounts paid in settlement of any action with respect to a Third-Party Claim, if such settlement is executed without the consent of
the Parties, which consent shall not be withheld or delayed unreasonably. The failure to deliver written notice to the Indemnitor within a reasonable time after the commencement of any action with respect to a Third-Party Claim shall only relieve
the Indemnitor of its indemnification obligations under this Article 9 if and to the extent the Indemnitor is actually prejudiced thereby. The Indemnitee shall cooperate fully with the Indemnitor and Indemnitor&#146;s legal representatives in the
investigation of any action with respect to a Third-Party Claim covered by this indemnification. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9.4 <U>Limited Liability</U>. IN NO EVENT SHALL EITHER
PARTY BE LIABLE TO THE OTHER PARTY OR ANY OF ITS AFFILIATES FOR ANY SPECIAL, PUNITIVE, INDIRECT, INCIDENTAL, OR CONSEQUENTIAL DAMAGES, INCLUDING LOST PROFITS OR LOST REVENUES, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. FOR CLARITY,
THIS ARTICLE 9.4 SHALL NOT LIMIT A PARTY&#146;s INDEMNIFICATION OBLIGATION WITH RESPECT TO THIRD-PARTY CLAIMS UNDER THIS ARTICLE 9. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9.5 <U>Insurance</U>.
Each Party shall, at its own expense, procure and maintain during the Term and for a period of three (3)&nbsp;years thereafter, insurance (including self-insurance) policy/policies adequate to cover its obligations hereunder and which are consistent
with normal business practices of prudent companies similarly situated. Such insurance shall not be construed to create a limit of a Party&#146;s liability with respect to its obligations hereunder, including the indemnification obligations under
this Article 9. Each Party shall provide the other Party with written evidence of such insurance or self-insurance upon request. Each Party shall provide the other Party with written notice at least thirty (30)&nbsp;days prior to the cancellation, <FONT
STYLE="white-space:nowrap">non-renewal</FONT> or material change in such insurance or self-insurance which could materially and adversely affect the rights of such other Party hereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EXECUTED VERSION </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 10 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>TERM AND TERMINATION </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10.1
<U>Agreement Term</U>. The term of this Agreement shall commence on Effective Date and shall remain in effect until no Valid Claim exists in any country unless this Agreement is terminated earlier in accordance with any of the other provisions of
this Article 10 (&#147;Term&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10.2 <U>Termination by ENGENE</U>. ENGENE may terminate this Agreement by giving NTC written notice at least 30 days
in advance of the effective date of termination selected by ENGENE. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10.3 <U>Termination for Failure to Pay</U>. If ENGENE fails to make any payment due
hereunder and NTC is not in Material Breach in the performance of any of NTC&#146;s obligations under this Agreement, NTC shall have the right to terminate this Agreement upon sixty (60)&nbsp;days written notice, unless ENGENE makes such payment
plus any interest due, as set forth in Article 3.10, within said notice period. If payments are not made and NTC is not in Material Breach in the performance of any of NTC&#146;s obligations under this Agreement, NTC may immediately terminate this
Agreement at the end of said notice period. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10.4 <U>Termination for Material Breach</U>. In the event that either Party shall be in Material Breach in the
performance of any of its obligations under this Agreement (the &#147;Breaching Party&#148;), in addition to any other right and remedy the other Party (the &#147;Complaining Party&#148;) may have, the Complaining Party may terminate this Agreement
by giving notice in writing specifying the Material Breach and its claim of right to terminate; provided, however, that if the Material Breach is remediable, the Breaching Party shall have ninety (90)&nbsp;days (or sixty (60)&nbsp;days for any
payment breach) (the &#147;Notice Period&#148;) to rectify the Material Breach, and the termination(s) shall become effective at the end of the Notice Period only if the Breaching Party fails to cure the Material Breach complained about during
(i)&nbsp;the Notice Period or, (ii)&nbsp;if such Material Breach (other than any payment breach) has not been cured within such ninety (90)&nbsp;day period, if the Breaching Party has commenced actions to cure such Material Breach within the Notice
Period and thereafter uses reasonable efforts to cure such Material Breach, such longer period as is reasonably required to cure such Material Breach, but in any event, not to exceed ninety (90)&nbsp;days following expiration of the Notice Period.
Notwithstanding the foregoing, a Complaining Party may not terminate this Agreement pursuant to this Article 10.4 if such Complaining Party itself is in Material Breach of any of its performance obligations under this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10.5 <U>Special Provisions Regarding Breaches by Sublicensees</U>. Notwithstanding anything in this Article 10 to the contrary, if a Material Breach by ENGENE
under Articles 10.3 or 10.4 arises as a result of a Material Breach by a sublicensee of the terms of a sublicense and ENGENE has notified NTC in writing of such Material Breach and is using commercially reasonable efforts to cure such Material
Breach or terminate such sublicense, NTC may not terminate this Agreement for a period of one hundred eighty (180)&nbsp;days after receiving the written notice of such sublicensee Material Breach to allow cure by ENGENE, which may include
termination of the sublicense. Thereafter, NTC may terminate this Agreement or may terminate the sublicensing rights hereunder as to such sublicensee. For clarity, any such termination of the sublicensed rights as to the breaching sublicensee shall
not affect the rights hereunder held by ENGENE or any other sublicensee, and this Agreement and such other sublicenses shall remain in full force and effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EXECUTED VERSION </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10.6 <U>Rights of Certain Sublicensees Upon Termination</U>. Upon termination of this Agreement pursuant to
Article 10.2, Article 10.3 or Article 10.4, NTC shall offer to each sublicensee under a sublicense granted directly by ENGENE or any of its Affiliates that remains in effect on the effective date of termination of this Agreement the right to enter
into a license agreement directly with NTC on substantially the same terms and conditions under which such sublicense was granted to such sublicensee, provided that (i)&nbsp;such sublicensee is not then in breach of its sublicense, (ii)&nbsp;such
sublicensee agrees to comply with all the terms of this Agreement to the extent applicable to the rights sublicensed to it by ENGENE or any of its Affiliates, and (iii)&nbsp;such license agreement does not impose any obligations upon NTC that exceed
the obligations of NTC under this Agreement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 11 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>DISPUTE RESOLUTION AND GOVERNING LAW </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11.1 <U>Resolution by Negotiation</U>. The Parties shall first attempt in good faith to resolve any dispute, controversy or claim arising under, out of or
relating to this contract and any subsequent amendments of this contract, including, without limitation, its formation, validity, binding effect, interpretation, performance, breach or termination, and/or
<FONT STYLE="white-space:nowrap">non-contractual</FONT> claims (&#147;Dispute&#148;) by negotiation between senior executives of each Party. If the Dispute is not resolved within thirty (30)&nbsp;business days following the first meeting between the
senior executives (&#147;Negotiation Period&#148;), the Parties may proceed to arbitration pursuant to Article 11.2. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11.2 <U>Resolution by
Arbitration</U>. Following the Negotiation Period, either Party may request arbitration to resolve any Dispute by providing written notice to the other Party (&#147;Arbitration Notice&#148;). Arbitration shall be settled by one arbitrator in an
arbitration administered by the American Arbitration Association (&#147;AAA&#148;) in accordance with its Commercial Arbitration Rules. The Parties shall endeavor to agree upon the arbitrator, and if they fail to do so within <FONT
STYLE="white-space:nowrap">twenty-one</FONT> (21)&nbsp;days of the Arbitration Notice, the appointment shall be made by the AAA. The place, or legal seat of arbitration, shall be New York, New York, and the language of the arbitration shall be
English. The arbitrator shall issue a reasoned award. The arbitrator shall have the power to grant any interim or provisional measures that the arbitrator deems appropriate, including, but not limited to, injunctive relief and specific performance,
and any interim or provisional measures ordered by the arbitrator may be specifically enforced by any court of competent jurisdiction as a final award. The arbitrator shall not have power to award damages in excess of actual compensatory damages and
shall not multiply actual damages or award punitive damages. Nothing herein shall authorize the arbitrator to act as <I>amiable compositeurs</I> or to proceed <I>ex aequo et bono</I>. Each Party hereto retains the right to seek interim measures from
a judicial authority, and any such request shall not be deemed incompatible with the agreement to arbitrate or a waiver of the right to arbitrate. The arbitrator shall award the prevailing Party, if any as determined by the arbitrator, its
reasonable costs, including reasonable attorney&#146;s fees. Judgment on any award rendered by the arbitrator may be entered in any court of competent jurisdiction. All information concerning an arbitration shall be treated as Confidential
Information of each Party. Any documentary or other evidence given by any Party or witness in any arbitration shall be treated as confidential by any Party whose access to such evidence arises exclusively because of its participation in the
arbitration and shall not be disclosed to any Third Party (other than a witness or expert), except as may be required by law. Any Party who commences any judicial proceeding in connection with an arbitration initiated hereunder shall endeavor to
have the judicial record of any such proceeding sealed to the extent permitted by law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EXECUTED VERSION </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11.3 <U>Governing Law</U>. This Agreement, and all questions regarding the existence, validity,
interpretation, breach or performance of this Agreement, shall be governed by, and construed and enforced in accordance with, the laws of the State of New York. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 12 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>GENERAL
PROVISIONS </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">12.1 <U>Intervening Events</U>. If either Party&#146;s performance of any obligation under this Agreement is prevented, restricted,
interfered with or delayed by reason of any force majeure cause such as floods, fires, riots, insurrections, explosions, other natural disasters or serious labor disputes beyond the reasonable control of the Party required to perform, the Party so
affected, upon giving written notice and written evidence of such force majeure to the other Party, shall be excused from such performance to the extent of such prevention, restriction, interference, or delay; provided that the affected Party shall
use its commercial reasonable efforts to avoid or remove such causes of <FONT STYLE="white-space:nowrap">non-performance</FONT> and shall continue performance with the utmost dispatch whenever the force majeure is removed. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">12.2 <U>Waiver of Breach</U>. The failure of either Party at any time or times to require performance of any provision of this Agreement shall in no manner
affect its rights at a later time to enforce such rights. No waiver by either Party of any condition or term in any one or more instances shall be construed as a further or continuing waiver of such condition or term or of another condition or term.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">12.3 <U>Modification</U>. No amendment or modification of any provision of this Agreement shall be effective unless in a prior writing signed by Parties.
No provision of this Agreement shall be varied, contradicted or explained by any oral agreement, course of dealing or performance or any other matter not set forth in an agreement in writing and signed by Parties. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">12.4 <U>Severability</U>. In the event any provision of this Agreement should be held invalid, illegal, or unenforceable in any jurisdiction, Parties shall
negotiate, in good faith, and enter into a valid, legal and enforceable substitute provision that most nearly reflects the original intent of Parties. All other provisions of this Agreement shall remain in full force and effect in such jurisdiction.
Such invalidity, illegality, or unenforceability shall not affect the validity, legality, or enforceability of such provision in any other jurisdiction. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">12.5 <U>Entire Agreement</U>. This Agreement constitutes the entire agreement between Parties relating to the subject matter hereof and thereof and supersedes
all previous express or implied agreements and understandings, negotiations, writings and commitments, either oral or written, with respect to the subject matter hereof and thereof. In entering into this Agreement, each Party acknowledges and agrees
it does not rely on, and shall have no remedy in respect of, any statement, representation, warranty or understanding, whether negligently or innocently made, of any person, whether a Party or not, other than as expressly set out in this Agreement.
Nothing in this clause shall, however, operate to limit or exclude any liability for fraud. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EXECUTED VERSION </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">12.6 <U>Notices</U>. Any notice or communication required or permitted under this Agreement shall be
delivered personally, sent electronically by <FONT STYLE="white-space:nowrap">e-mail</FONT> (and promptly confirmed by personal delivery, registered or certified mail or overnight courier), sent by internationally-recognized courier, or sent by
registered or certified mail, postage prepaid to the following addresses of Parties (or such other address for a Party as may be at any time thereafter specified by like notice): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To NTC:</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To ENGENE:</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">[***]</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any such notice shall be deemed to have been given: (a)&nbsp;when delivered if personally delivered; (b)&nbsp;on the next
business day after dispatch if sent by confirmed electronic <FONT STYLE="white-space:nowrap">e-mail</FONT> or by internationally-recognized overnight courier; and/or (c)&nbsp;on the fifth business day following the date of mailing if sent by mail or
nationally recognized courier. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">12.7 <U>Assignmen</U>t. ENGENE may assign or transfer this Agreement: (a)&nbsp;without the consent of NTC to an ENGENE
Affiliate without the requirement of payment of the Assignment Fee set forth in Article 3.3; or (b)&nbsp;in connection with the transfer or sale of all or substantially all of ENGENE&#146;s assets or business related to any Product and/or this
Agreement, whether by merger, consolidation, sale of assets, change in control or other transaction. ENGENE shall require such assignee or transferee to agree in writing to assume the obligations to NTC that are being assigned or transferred, and
pay the Assignment Fee set forth in Article 3.3 upon closing of the transaction leading to the assignment. ENGENE shall provide a copy of the assignment and assumption agreement or other documentary evidence sufficient to demonstrate ENGENE&#146;s
compliance with this Article 12.7 within thirty (30)&nbsp;days after such assignment. Failure of an assignee to agree to be bound by the terms hereof or failure of ENGENE to notify NTC and provide copies of assignment documentation shall be grounds
for termination of this Agreement under Article 10.4 following the giving of any notice and expiration of any applicable cure period provided for in Article 10.4. For clarity, if ENGENE merges with another person and ENGENE is the surviving entity
of such merger and there is otherwise no assignment by ENGENE of this Agreement in connection with such merger, then it is hereby acknowledged and agreed that the provisions of this Article 12.7 that impose obligations on ENGENE or an assignee or
transferee shall not be applicable in connection with such merger. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">12.8 <U>No Partnership or Joint Venture</U>. Nothing in this Agreement or any action
which may be taken pursuant to its terms is intended, or shall be deemed, to establish a joint venture or partnership between Parties. Neither Party shall have any express or implied right or authority to assume or create any obligations on behalf
of, or in the name of, the other Party, or to bind the other Party to any contract, agreement or undertaking with any Third Party. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">12.9
<U>Interpretation</U>. The captions to the several Articles of this Agreement are not a part of this Agreement but are included for convenience of reference and shall not affect its meaning or interpretation. In this Agreement: (a)&nbsp;the word
&#147;including&#148; shall be deemed to be followed by the phrase &#147;without limitation&#148; or like expression; (b)&nbsp;the words &#147;herein,&#148; &#147;hereof&#148; and &#147;hereunder&#148; and other words of similar import refer to this
Agreement as a whole and not to any particular Article or other subdivision; (c)&nbsp;references in this Agreement to &#147;days&#148; shall mean calendar days. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">12.10 <U>Counterparts; Electronic or Facsimile Signatures</U>. This Agreement may be executed in any number of counterparts, each of which shall be an
original, but all of which together shall constitute one instrument. This Agreement may be executed and delivered electronically or by facsimile and upon such delivery such electronic or facsimile signature will be deemed to have the same effect as
if the original signature had been delivered to the other Party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EXECUTED VERSION </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">12.11 <U><FONT STYLE="white-space:nowrap">Non-solicitation</FONT></U>. During the Term, and for one
(1)&nbsp;year immediately following the end of the Term, neither Party shall solicit or cause to be solicited the employment of any key employee of the other Party to whom such other Party may be introduced or with whom such other Party otherwise
had contact with as a result of this Agreement; provided that this provision shall not apply to: (a)&nbsp;the use of general solicitations not targeted at employees of the other Party or the employment of any person who responds to such
solicitations; (b)&nbsp;the use of search firms, or the hiring of any persons solicited by such search firms, so long as such firms are not advised by the Party to solicit employees of the other Party; or (c)&nbsp;the hiring, employing or discussing
of employment with any person who contacts the Party independently without any solicitation by the Party. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">12.12 <U>Section 365(n) of the Bankruptcy
Code</U>. All rights and licenses granted pursuant to any Section of this Agreement are, and shall be deemed to be, for purposes of Section&nbsp;365(n) of the U.S. Bankruptcy Code or comparable provision of applicable bankruptcy or insolvency laws,
rights and licenses to &#147;intellectual property&#148; (as defined in Section&nbsp;101(35A) of title 11 of the Bankruptcy Code of the United States and of any comparable provisions of the applicable bankruptcy or insolvency laws of any country).
Each Party agrees that a Party that is a licensee of rights and licenses under this Agreement shall retain and may fully exercise all of its rights and elections under the U.S. Bankruptcy Code or comparable provision of applicable bankruptcy or
insolvency laws. The Parties further agree that, in the event of the commencement of a bankruptcy proceeding under the U.S. Bankruptcy Code or comparable provisions of applicable bankruptcy or insolvency laws by or against a Party that is a licensor
of rights and licenses under this Agreement (a &#147;Licensor Party&#148;), the other Party (a &#147;Licensee Party&#148;) shall be entitled to a complete duplicate of (or complete access to, as appropriate) any such intellectual property licensed
to such Licensee Party and all embodiments of such intellectual property, which, if not already in such Licensee Party&#146;s possession, shall be promptly delivered to it (a)&nbsp;upon any such commencement of a bankruptcy or insolvency proceeding
upon such Licensee Party&#146;s written request therefor, unless the Licensor Party in the bankruptcy proceeding elects to continue to perform all of its obligations under this Agreement or (b)&nbsp;if not delivered under clause (a), following the
rejection of this Agreement by the Licensor Party in the bankruptcy proceeding upon written request therefor by the Licensee Party. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">12.12 <U>Survival</U>.
Expiration or termination of this Agreement shall not relieve Parties of any rights or obligation accruing prior to such expiration or termination (including, without limitation, any irrevocable and perpetual licensees to which ENGENE may have
become entitled pursuant to Article 3.5 prior to the expiration or termination of this Agreement). In addition, upon expiration or termination of this Agreement, all other rights and obligations of Parties under this Agreement shall terminate,
except (i)&nbsp;those that may pertain to any Product (including obligations to pay royalties or payments under Articles 3.5 or 3.6 that accrued prior to termination or expiration) that exists at the time of this Agreement termination or expiration,
and (ii)&nbsp;those in Articles 1, 5, 9, 11, and 12 and Articles 3.10, 4.1, 4.2 and 10.6. Notwithstanding the foregoing or anything in Article 10 express or implied to the contrary, in the event that the Term expires pursuant to Article 10.1 if and
when no Valid Claim exists in any country in the License Territory, then ENGENE shall have a fully <FONT STYLE="white-space:nowrap">paid-up,</FONT> royalty-free, irrevocable, perpetual license to the Licensed IP in the License Territory to research,
have researched, develop, have developed, make, have made, use, have used, import, have imported, sell, offer to sell, and have sold or offered for sale any Product in the License Field, and ENGENE shall have the right to grant sublicenses under
such Licensed IP in the License Territory through multiple tiers of sublicensees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EXECUTED VERSION </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF,</B> the Parties have executed this
<FONT STYLE="white-space:nowrap">Non-Exclusive</FONT> License Agreement as of the Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>NATURE TECHNOLOGY CORPORATION</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>ENGENE, INC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Clague Hodgson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jason D. Hanson</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Clague Hodgson</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Jason D. Hanson</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">President</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">President</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EXECUTED VERSION </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Exhibit A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Patent Rights </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EXECUTED VERSION </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Exhibit B </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EXECUTED VERSION </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Exhibit C </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Preferred Manufacturers </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>9
<FILENAME>d459793dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g459793g49u48.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KPMG LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">600 de Maisonneuve
Blvd West </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Suite 1500, Tour KPMG </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Montr&eacute;al
(Qu&eacute;bec) H3A 0A3 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tel. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">514-840-2100</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fax. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">514-840-2187</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">www.kpmg.ca </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consent of Independent Registered
Public Accounting Firm </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the use of our report dated August&nbsp;9, 2023 with respect to the consolidated balance sheets as at
October&nbsp;31, 2022 and 2021, the related consolidated statements of operations and comprehensive loss, redeemable convertible preferred shares and shareholders&#146; deficit and cash flows for the three years ended October&nbsp;31, 2022, and the
related notes, of enGene Inc., included herein; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the use of our report dated August&nbsp;9, 2023 with respect to the balance sheet as at July&nbsp;31, 2023, the
related statements of operations and comprehensive loss, redeemable common shares and shareholder&#146;s deficit and cash flows for the period from April&nbsp;24, 2023 (inception) to July&nbsp;31, 2023 and the related notes, of enGene Holdings Inc.,
included herein; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the reference to our firm under the heading &#147;Experts&#148; in the prospectus. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/s/ KPMG LLP</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">August&nbsp;29, 2023</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Montr&eacute;al, Canada</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><SUP
STYLE="font-size:75%; vertical-align:top">&copy;</SUP> 2023 KPMG LLP, an Ontario limited liability partnership and a member firm of the KPMG global organization of independent </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved. </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>10
<FILENAME>d459793dex232.htm
<DESCRIPTION>EX-23.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM&#146;S CONSENT </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the inclusion in this Registration Statement of enGene Holdings Inc on Amendment No.&nbsp;1 to Form&nbsp;S-4 of our report dated March&nbsp;30,
2023, which includes an explanatory paragraph as to Forbion European Acquisition Corp.&#146;s ability to continue as a going concern, with respect to our audits of the financial statements of Forbion European Acquisition Corp.<B> </B>as of
December&nbsp;31, 2022 and 2021 and for the years ended December&nbsp;31, 2022, and for the period from August&nbsp;9, 2021 (inception) through December&nbsp;31, 2021, which report appears in the Prospectus, which is part of this Registration
Statement. We also consent to the reference to our Firm under the heading &#147;Experts&#148; in such proxy statement/prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Marcum
<SMALL>LLP</SMALL> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Marcum <SMALL>LLP</SMALL> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">August 29, 2023 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>11
<FILENAME>d459793dexfilingfees.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<HTML><HEAD>
<TITLE>EX-FILING FEES</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 107 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Calculation of Filing Fee Tables </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT STYLE="white-space:nowrap">S-4</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Form Type) </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>enGene Holdings
Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Exact Name of Registrant as Specified in its Charter) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Table 1: Newly Registered and Carry Forward Securities </U></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="99" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Security</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Type</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Security</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Class</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Title</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Fee</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Calculation</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">or Carry</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Forward</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Rule</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Amount</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Registered(1)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Proposed</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Maximum</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Offering</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Price Per</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Unit</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Maximum</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Aggregate</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Offering</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Price</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Fee</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Rate</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Amount of</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Registration</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Fee</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Carry</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Forward</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Form</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Type</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Carry</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Forward</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">File</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Number</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Carry</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Forward</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Initial</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Effective</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Date</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Filing Fee</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Previously</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Paid In</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Connection</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">with</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Unsold</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Securities</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">to be</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Carried</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Forward</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="1" COLSPAN="25" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="25" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt; padding-right:2pt">Newly Registered Securities</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Fees previously</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Paid<SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Equity</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Class&nbsp;A Common Shares</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Rule 457(c) (Based on the market prices on August&nbsp;4, 2023 on the Nasdaq Stock Market LLC of the FEAC Class&nbsp;A ordinary shares</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">27,090,013</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$10.78(2)(5)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$292,030,340</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$0.00011020</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$32,182</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Fees previously</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Paid<SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Equity</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Warrants to Acquire Class&nbsp;A Common Shares</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Rule 457(c) (Based on the market prices on August&nbsp;4, 2023 on the Nasdaq Stock Market LLC of FEAC Warrants)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">6,896,099</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$0.5642(3)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$3,890,779</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$0.00011020</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$429</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Equity</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Class&nbsp;A Common Shares (issuable on exercise of Warrants)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Rule 457(g) (No separate registration fee required)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">6,896,099</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$11.50(4)(5)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$0</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" COLSPAN="25" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="25" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt; padding-right:2pt">Carry Forward Securities</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Carry</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Forward</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Securities</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">N/A</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="right" STYLE="padding-bottom:1pt ;">Total Offering Amounts&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">$295,921,119</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">$0.00011020</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">$32,611</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="right" STYLE="padding-bottom:1pt ;">Total Fees Previously Paid&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">$32,611</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="right" STYLE="padding-bottom:1pt ;">Total Fee Offsets&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">$0</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="right" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000">Net Fee Due&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000">$0</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All securities being registered will be issued by enGene Holdings Inc., a corporation incorporated under the
laws of Canada (&#147;New enGene&#148;) in connection with the consummation of the Business Combination pursuant to Business Combination Agreement, dated as of May&nbsp;16, 2023 (as it may be amended and/or restated from time to time, the
&#147;Business Combination Agreement&#148;) among (i)&nbsp;New enGene, (ii)&nbsp;enGene Inc., a corporation incorporated under the laws of Canada (&#147;enGene&#148;), and (iii)&nbsp;Forbion European Acquisition Corp., a Cayman Islands exempted
company (&#147;FEAC&#148;). For information relating to the Business Combination and the transactions pursuant to which the securities registered hereunder will be issued, see &#147;<I>Proposal No.</I><I></I><I>&nbsp;1 &#151; The Business
Combination Proposal &#151; Transaction Structure</I>&#148; in the proxy statement/prospectus included herein. All capitalized terms used but not defined in this Exhibit 107 will have the meanings assigned to such terms in the proxy
statement/prospectus. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on the market prices on August&nbsp;4, 2023 on the Nasdaq Stock Market LLC (&#147;Nasdaq&#148;) of the
FEAC Class&nbsp;A Shares (FEAC is the company to which the registrant will succeed after the transactions described in this registration statement and the proxy statement/prospectus included herein). Consists of (i) 12,650,000 New enGene Shares to
be issued in respect of FEAC Class&nbsp;A Shares, (ii) 1,373,496 New enGene Shares to be issued in respect FEAC Class&nbsp;B Shares that will convert into FEAC Class&nbsp;A shares in connection with the consummation of the Business Consummation, and
(iii) 13,066,517 New enGene Shares to be issued to holders of enGene Shares (inclusive of 6,379,822 New enGene Shares to be issued in respect of enGene Shares that will be issued upon conversion of enGene Convertible Notes immediately prior to the
Business Combination). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on the market prices on August&nbsp;4, 2023 on Nasdaq of the FEAC Public Warrants (FEAC is the company to
which the registrant will succeed after the transactions described in this registration statement and the proxy statement/prospectus included herein). Consists of (i) 4,216,666 New enGene Warrants to be issued in respect of 4,216,666 FEAC Public
Warrants, and (ii) 2,679,432 New enGene Warrants to be issued in respect of enGene Warrants issued to the lenders of the Convertible Bridge Financing. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of New enGene Shares issuable upon exercise of New enGene Warrants. Each warrant will entitle the
warrant holder to purchase one New enGene Share at a price of $11.50 per share (subject to adjustment). Pursuant to Rule 457(g), no separate registration fee required for these securities. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pursuant to Rule 416(a), there are also being registered an indeterminable number of additional securities as
may be issued to prevent dilution resulting from stock splits, stock dividends or similar transactions. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Registrant previously paid the required registration fee in connection with the initial filing of this
registration statement on August&nbsp;9, 2023. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g459793g00a01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g459793g00a01.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1>^4&AO=&]S:&]P(#,N,  X0DE-! 0
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M<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F
M"7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT3W5T
M<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !2
M9W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O
M;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M      !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M    4G-L=%5N=$8C4'AL0'P@           *=F5C=&]R1&%T86)O;VP!
M %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M          !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F-
M60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1"
M;W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P
M4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE-
M ^T      !  E,S,  $  0"4S,P  0 !.$))300F       .
M #^    X0DE- _(       H  /_______P  .$))300-       $    6CA"
M24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M   *  $          3A"24T#]0      2  O9F8  0!L9F8 !@       0 O
M9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M!@       3A"24T#^       <   _____________________________P/H
M     /____________________________\#Z     #_________________
M____________ ^@     _____________________________P/H   X0DE-
M! @      !     !   "0    D      .$))301$       0     @   D
M  )      #A"24T$'@      !      X0DE-!!H      T$    &
M      56   +%@    8 9P P #  80 P #$    !
M      $             "Q8   56                      $
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M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     0X0DE-! P     #-L    !    H
M $T   '@  "08   #+\ &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D
M@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4
M% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,#/_  !$( $T H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
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M(M^]O_D$OLS_ /N1;][?
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
M !$( 2,"70,!$0 "$0$#$0'_Q  ?  $  00# 0$!            !@0%!P@!
M PD""@O_Q !N$  !! (! 0(("04*! P0#P$% @,$!@$'  @)$1(3%!46&5C6
M&"%65Y*5EI?5%QHB,54C05%488&1DYC2"B5Q\"0F,C,X0D1T=Z&QP2<T-3=%
M4E-R=79XE+6VM\4H1TB#A8:'LK/&Q]'3U_'A_\0 ' $! 0 " P$!
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M%>[#J/H##;&M5/([=M00&#H-K*PK/"./72,8O/<)9H];&M5K6<R+%Q-8>EV
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M9]"WH=ALNS\E9H^XZ=CS* NUS)];<:*$-(Q]I09EO@5<,6.5,3"MNV"44P"
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M@J]MK7!PT3DIK.(XX0)N(:>2G/Y185K\3$A1WY#O@(6OQ;:O!2K/=C)8DBQ
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M+)N+97^FV\G]*:'J]$S<G=$4U374;;:-T;C9SV*&6.6"&"1ANV5LD<D4T;7
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M*\+OGWE.4I2K&,TZ1GPLJ4XG*<91,6G&4X;\+.592C.%)PA:EI<2B?1_2/\
M+%U_6$6RZVCA;*^?E%Y])=&VN3*!>WV6WV@;,?7OL.O,)ZS7I?\  \+,Z\]_
M>G&$>B#WA9RK.<=WA9FX:QE/=G*OW3N_[7*OC[K]'](WMABX?;/P7_)/I+HW
M^:3(7^RSB!_/U[[9;AE?Y]9OTO\ @K5Y;>^]"\(PCT/=[U]_@=V4J\N\4G&<
M+QGN=<;5W8S^CW^#A3Z/Z0O:T7KN^#/RBXZT^DFC;7O(,KV+6WW_ //8;#M-
M^(!O:2U7M%>EJT$V1:K@7K;TEYN/'E6BMDQPU;KF>['CB<=$Z"/:3G_5R";\
M*,C'Z2GL)QE6-4N@](QMQ:IL@%[B-X<[*YR:0TNN!D&AQW6N0%MAY0Z,E=A,
MQB.6<K0UOA$ 7<"X-&8N7X0 =JW7'$AY>%&)"IL4B/F,HD1)L)]J3%DL.IPM
MMYA]E2VW6W$9PI"T*RE2<XSC.<9QGG4D%I+7 M<"000001M!!S!&\%=TUS7M
M#FD.:X AP((((N"",B"#<=2K>15.$3A$X1.$3A$X1.$3A$X1.$7&,XSCOQG&
M<9_5G&>_']..$7/")PBXQG&<8SC.,XSC&<9QGOQG&?CQG&<?%G&<?'C./U\(
MN>$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1?C4
M_P *3ZP;X*L6G>B:J%YX2E'*3'W=M1J!(>C)N;DVSGJU0ZX36RXA4D, EU ]
M89(I]+L*:7EU\BZWF6!@K:]A_AAHB!\=9IJ5C7S1S&BI<0!U-HHY)Y&@C)[Q
M*R,.'A!HD:,GF_A'\8].U,;Z#D_ ]\<$T'/ZW"2W7@RR14\+R"+QQNADE<PW
M:YYB<<XQ;\L^N^F7<.UZ2Y?Z'78AJOLV]JDNK6;$"GVC+LZD#%+=\\2X$1H?
M'G;%J*)DQV6A,.'/FF9*&@8&P$Q?I]3I2CI)Q3U$ICD,)G P/<"P-G=E@#B7
M%M-,0T DEK6#PY(VO\>H]!:2KZ7GE+$R2'G'-B3*R,B3%3L).L+6AC754.)Q
M<+-<YY&KCD<R/G=*6^OUB;<9D^G2*^PO*ALL=<J_.>LL%N7!'23%;'L3<D"0
MB(3(-BGYN8K"5%H1X5'0^1JMIC!=D==#)*(0V82'[8?#(T1.+7/#)7$86O+&
MX@+FS71N-A-$7Z9=%5,4#JDR4KH@? ,=3$]T[0YC"^%C27/8U[Q&20V\C96-
M!=#,&4832&YK-A>:YJ;8Y[#0A-@=R&I5C)^ "6.J9=!A?D8Y[P1C@N^T<@U.
MSW1G(=QJ\A#BFCPM4K)]=11_WE731^'@\.>)OAXI6X/"</"Q03-MMO%(-K'6
MPCT7I*;^ZT?62_5ZWZNFF?\ 5!D,FL\%A\#!40.Q;,,T1OX;;UC?3_O5Y+:V
MM-;1=0\Z)8:6W0K0M#CIZ)"GA4)6D7E.<E8),9-@?'_HJ(3&R6?#9GQ%O8]T
M: $@UM(" XD&HB! 87-><W_X'-<'?REK@;%IMF-#Z6(!&C:X@F, BEF()F:'
M19AG_>-<US>+2",B%V,=/6^Y61:8NE-KR<FX$TJ&PQKVV/9+#1N!'E\\;XL2
MKRV)#S8 *)#\;QC;3IL0TM6'"<)#\.D='MQ%U;2# YK'WJ(A@>['A:Z[O!<=
M6^P-B<#_ .4V#0VEG8,.C*\ZUCI([4DYQL9@QN;9GA!NLCN1LUC/YFWYC=/>
M\9#X1IS4VPX#-ACU6<)($Z?81XR4,N\Y@;4RZ2$D<W&R)L$J2RD202M48@A?
MC8BWF_TN':2H&AYYY3.,9E:]K)HW/#H6E\K,(=?&QHNYNUN^RK=#:5<Z-O<^
ML;K1$YCGT\K&%D[Q'%)C<P-P/<0&NO8[KJQOZ?VQ&@'BLC6=]8&59#CEE(.U
M(\W" -LOS(KKAB4J!A@<AJ0.(,N+EK:2A<"=A6<>22/%[!6T9=&P55.736$3
M1-&72$AI 8 Z[KAS2+7R<T_XA?4[1FD6LFD=0U8CIK\X>:>4-A <YI,KL%F
M%K@2X@#"[@;9;%]&_4"94&0.I\.3FQZ^K^SJ]X-GK6,&ZK9]?W?9018[PBN/
M'&)M=UW;8[=>SA)S-@'QZ[B!DL3&1I?#=IK1S,9=,X:N>2FDO%+X$D4\%.\N
M\#*-LE1$3)]C5ETF+"QY;SF<G-+2"(LIVD3TL57#]=%];%-35%7&&>'G(Z*E
MF:(OMZUHBMC>P.NM8Z(>HFV^BGFFICN^ZU:IW&O)D60(VY,!WE)Y55?=9;EO
M/0WBN:X1QF/+;9<'I\0Z5\A8<4ZWA-IW1L!D#YG?4RS026B>0V2GU>N%R "&
M:QIN"0[,,Q$6.ZGY*Z9J1$8J=EIJ>"JCQ31@F*I,HA);<N:YYA>"T@%F1?A!
MN,%7'6=FH40&_9G ,.8=@#2K(.-9 A*P0!9P;&- ")@..G2I@V(>"S(A@4[(
M1CQXV7"EN89;GP<R>?!515!D$0D<V-SVF0Q2-C<Z-Q9(UCW-#7ECVEC@#DX.
M&9:ZW55-!/2-B,[H6.E#'"(31OF8R1H?%))$QQ<QDD9$C"=K'-) QMOG,U1.
MF8CZ3$J]M"<'A#K!81U9$$(4QN<8KXD#:9 @N3>4T=<;GECHRMQGY$&.S&EP
MK*RZ-KD*5!,0A/61U.F&"%DM$V1SXHGS/8YI;'*^2$/8P7C\%D;Y3A<XEKHG
M!TSFN8YW>247)R37R0Z1DA8R6=D$<@(?)'%%,8Y)#AF(=+*R$8HV@/9,W! Q
M[96QQIT-H!DMLT-@R22"@WPS#UY9G9DDF>ETL4)MT@=(E,CXD &_(L!R!2!R
M9^0V5#QIZQ3D#)CPZ"TWN$FE#'1R:N,RNIF.JX0 R)L[WPAP:7N=(!%&ZH?A
MQ^&^.)N-H>XKC&'00DKX=;((FULK:*I+W23.I(XIRQQ#&,A<9IF4S \Q LCF
MF?@)8VTNGZSZ91+MFQ&W+)L*!P \^&5Y&[%;*'(U? R0XJ,EF&VYB:1,&IT-
M,^0YBN"7Z[-\=,L,1:'%\=M9IEXBQ:.;$72QA_AAQ9&99&R/==Q&%D;&NPCZ
MV02M(;$0N6_1W)V(SVTJZ?!!.8O\(?.V&(Q1M#6!Q<^61P$A^HC,+@XS-.=O
M&T/ISFU6"X=V/,"65%;%SVV:VAH])*%"@6MO3&C\<^_70@- .S%S(CR04<F%
MWQ5=F$) AMEZ 4(YOJM+-G<(J1LD.N>PF6\88QDDH:8C&)9)-9"R.3$^-K ^
M5K&O)#F-UQ4.@)*:,S:0?!4""-]H<,QDDDBA<\3-F,,4(AGDDC#(Y3(Z.%[G
MQ@%DCI(K2W3FV!S89.[',C(UK-U'+PN/A]XC)BCR%B!D8L4D.@E7Q)0:X-"D
MSB0L%FO&&FTNB">2:,1](TCI<RZD:. >88Y[/-FL:7,BD:YS7E@D8_'(R/&\
MRQWM(W ;\@Z(T (><'2SM4VHDIB682Y[VB2:-S6OB9(YCXC'&^41-;#( 3')
MK !88^N.F=N(-:?W(1?FE&JVZ^44.>:@UU@V!N#Q+) "R,7/($@9^#6(<F!"
M-HC1H<WS@[.FN3G1(C::O3!<XMT>QK6&:S"Z[I3'+ &!DI>&,9)$Z4ASHRYS
MFX0UN$/?I&C^3@:QITM*Y\@B)EP860B2.IQ%\ B,CWQRLIVNC;* UKM87NQ.
MCBAMMH&HH8"3.INQG31N(R&?F"R+PV%%C.%)TP22'1)KK41TZ[6R#8Q]Z<+B
M9;. R<@Y#AP((28M[?!55[I0VHHQ'&XR!KV![G' UKVO<T%PB$K<8:U[@8Y&
MMC<YSI&@<2JH-%-A>^DKW32LU9<R1T3&-UCW1N:UQ#73&%XC+G1L^MB>Z5K&
M,B<3.I^N.F%+@AT7MV<3C305@@SD-^4AE#+0!KYYD.;F^>ZMF4L%>+% &%HX
MB%#>EUP2^Z%F%)9 B+FIXS:O3-GA] QCFR1N:3:0.ADEC+XVB.<#64\3GQN>
M7 22 2-8&->T\QVC^3EXW1Z4?(UT4K'-&*$LJ(H)@R5^MIBXPU4[(Y&QL:70
MQ$QN>Y\D;A]1]>]+[*I!;&UCMB6MF%/%4N !<'+S,E")1157+%B,N'*4M<YA
M%?BD@2"26Y\ACSNZ+87B<LZKTR<,?,8XA=S7U#I<0#6R-8)F1M:X6##K7,EP
M$M:[5AYLT5E!R;NZ3NG/-<L=%2-BP&[HR_422/+'DEXU+7PAX#G-,A8+O,;1
MK70@^TVL&9W+-(# !PN,%FJL&BRF+)#K86*HD2$N%I(Z Y%/6&<MJFO29\)H
MJ$ F)$G,4G. P"&XUFDW0PRQZ/:U\L<;W1S2.:8G3/.!D@8US@8HFWJ &$LD
MEC NULKF\9NC]"-J*F&;2KW1PRR1QRP1L(G;!$TO?&9"UA;+.\MIB7M#XH92
M;/?$UU7C673TN>2%)W7)87 CFWHQZ0*RL&61#5&CUYV,S'B.$8SME>:FRY(M
MY#DRL1B 6/.<GYC6"<,QYYI; Q_<YIQ%@=&'_6QEUS("2[ X1 M:)!X,Q;(6
MM;>-K\^YV@2]T?==[<+9'"9S 8GX2UL6%K6%X=,0]YC-W0-?$'E^&9\=W:UW
MTT6,D''"MEFZPLZ4$P6')S"3R1^3M.#$TRR*6H0WR: (N.#57DC6US";&) ^
M<\5G16W7\:^=Z8B8]\E'%,(V/<X-)B+A'/(S"R[GW>^GU<P<0UALYH8UUFG=
MW/Y.SR1QPZ1FIS+)&QI>!,&F6FB>"\"./"QE3K8',!?("YA+W,&(^N_8N]49
MWH]Z[ 73U7+N]:-,[U;(0; %381AX,&O <+,DQS,-0A6(D<PS/K9NJR928\%
M5D 2ZV<D0FX[0A,?XSEQ0-TIR?.F)8!!6Z.?'9PC?&Z6DFF9&8W"3PBRTT4[
M1=VIE9-$UQO(3]Y_#S23M"\J&Z @JC4:/TK'.<!GBF9!6P0/D;(S5#"V3%!-
M3O-F&>)T$KF -C _H$L/(D,,OMY[VWFFW49_A2XG"TY_GQG'/$%^B ;CY]'F
M7;PJG")PBU"ZY-Q&=*]/5FL-9EOCK38)XREUTI'PGQHN:<\H>FD6EY6E3$J*
M#'EUCI+>%N1R?D3V$]R%*3V>B*5E56L9( Z.-KIGL/\ C#+!K;;P7N9B!L"P
M."ZK3-4^EH)'Q$MDD<V%CQM9CN7.OG8X&N#3;)Y;LVC\OLA6):W'IGA2W7'L
MOK>=<5AQ<A2W%9>6O*L9<<4K/A*\+*LJSWJ5WYSWY]!MA!L+;!87R%S8#POT
MV[/)YPW$ZQ<XN(#B3EML/_5[>-B>)W69SX:D*=[G%X<2I"N[#?@NI_32K"<*
MQC/@/*==QCN[E>'XO]+"<8QD+7:0#MWYV&$?\PVC(>;83EK(=X=W.)P=0%Q(
M2/\ !?)USLL;[]][K( K;[ #K AMB26,$HX\0W(D1H#")DE&&&U/3)3[,9II
M+:G$N.R'$M(1X3BO]3C.=;WLC89' AK/"=8.<;!F(^""2<P,A<DY#=;<UDLK
MS&QUW/ # 2QHN97 7<6 #;:YR%K]9D_Y+[4GSO)+CVA,:LKK"[#+)RVV,UYN
MX/9B02$^"RX^16TWC$9LFQ&A2I(I>&FI<5J7);9<QYQ%=H:<>-KL :UQQZL.
MNT$D-SS()+0X7+76!*:B;"2^[=4]@D+BT&/6O9A<YN O-KYC"YS38.;F%&#8
MB.)EL>3F@YQQ_$AU$T.Y.6VQXHD0'J1)9GPX#C+\IN"V089PVYX(^;!=6M$A
MQYAG8QV(GP',&)MP0. <"+2.N!>V1VAP&5BL'M<T?W@?=CLQ?;CPV(,0(/@W
ML<\+FDW)LK+C/[HEWO\ ]$-+2F.[C'=XI&,)QA&&\*\%S]%3N/"5G*N_NSW_
M !)\++*YRL,6=L]N'BZ^WJL=BEG6'A9X#AR&5M9E?5_N#=HVFV+A6$*SA:T8
M4ZC*DMKSGN\%K*5Y<1X.%XQGOS^EX2L=^.[N3WXSW9GYC&;C,9@$WOBOZ!OW
M*@.N?"-PP9Y<1>XP'8-MS<DY Y+UQ[,S?AV#8INFSD]R8!EI<)5]M]QQQ8^4
MZZYDC&8RIYQMF&N1EN2S&0AO#;TB8K&7$.8RW\CRBI6,=#5,;A=*YT4MADYS
M;F-V\XBP%KB=S6Y Y'['DU52.;/22.N(@V6*YN6M<&B5NP ,#W-<T 9%SCF"
M O<[GS"^L3A$X1.$3A$X18(ZDM3EMW:HEZY#DA MXG>].G",D]!;*"GJU1]Q
M4.]6\9*$R()&$8R:JM;,AXX<I$<#%I4]D<:6P*DS'VB+2^%TF=6NIZ:<IF@]
M[BG8<\KG(HAMNTV@J6%0@\!V%6[(J> IK3A&Y$'8XLC>6"^"=8L\[$Q) ;-'
M>('8(LQT+5?6,,W>(LUXW-526EQI&UO+I8N>4E62?%*/75\>JP2R%)BBS;DE
M1FEMY@B/0V!3<49O-5PN%8[&+)$5A=Z4KS:M6[<H=D<HE&?VGU-4[;K\.C$&
M+A51M%JMLUD](&0P6P=4N 56.RU+7."%N@6&LVP)9]C62SG9<^*.,,PQ)%W:
MBZ0+=K#:[NS\7],IP[LK?MKLH"*^Y%KS0.]7C:]@UB^/!Q 8^*6N@T'L(6'N
MYPZ^I;@ZI52LAGWP-.!^&18SUQTG]0D6N5F!/M\?6DQS1_0543]H 7]^S7P;
ML#IHLUJ.;9(0*Y;-=7'6K$:Z0+1@8/EXD'(EAEBG2MC#1)IR1-@D5D#]%F\X
MX>L#;.SI^ZXJ&J=*Z\-,DM@W$9&Z@9%'$ &[C/W>L?I]:GEMGH$<AKR1#CG8
MP)BKN-8"#D[1LS%8(NSX%6]95/M@<J5UQ)NDTCHID'?8M[L#:3+VE@]E9=W#
M>J\8TR?G_E@V$>L9&5?2E.N-=N$^I.UBHU7<5)):X#70V1>@6CJR>J6O_,]B
MAY&3';SMH\.$*D19"@E6MFV+M:J4!6J!(EP&5@Z<:!"50A\J1 '*AY'PGG8L
M9I:B++O")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB\O86F.M6!KD*%7
MLRX,O!TT*"_6JW:->LSUA*B.TW9CDL);#=;=-2+I9K4!V?55YM%KDU*<#.-,
M%($.#*03C?2&LT.Z=S^;Q'%KG"22*?#CE?5Q,$D;) T0Q1/II0(XM8'L\$N(
M+3\QS+30@#.<S##J0(XI8 _!"RCE<8Y7QEYFEG951'6RF)S'@.:UI#Q?;#2N
MT!1:AOHGLU_S+)(;C.D'3[.I)P:,B3(W.[J.H*8A580?'!QN8.@67Y$5JUE3
M(TOL+SQ8JS/"L9MV$4V@M4_74X+\-(QNK-4UYL*054HO(Z-SW!U<0"8FL<R#
M R4/^JSEAT^)F:FH.K)JGOUG-7,!//.:Q>#&R5C&EM!<C7.>V2HQ21.8-;2R
M*EVAR_RC3YVS/%RB=3KQ*@UNG5'4<@,&L)"=K([8:P]:;58A19,P(78VQ2FB
M,JL$A:]7E:[:(QHYL,8S7N!+H'^SM;3W#99&SR32U0<^-HJ61R"*)CFV>PTL
MQ:)6NYRV2-S60.+U##RA)J'.J<..&)T$4$5(6LD<ZF?)$9II6.Q,>*N'$8BP
MTKXY&O?4-$:DY.I]8PZ->HX(F5@ND9-EFTQJGS=.KKHEFQ=0MVL!><3@6FOB
M3AV\YU<9KD@"G!NMUDIB$2AGBE;M;[Y8IK;+HEQ@+VL(:(Q-K6U>-Q900L:U
MICD>QD/.62!_@22MQ L;)$ UNQT.F&LG#'/#G.F=!JGTAC8V32$\A+Q+&U\D
M_-7Q%GAQ1.PN#WQ2DO=G/I?J.WJK3K'(WA(A2]@VRP5FS') V9$E0'B^=.:K
MKUK=ALP$-01\5V]5ZUN1H,-AB(F.MJ3&9;8DMXYPM)2TLLT8HP1!%')&P.!#
M@WG50^,$NNYQU+X[N))O<$D@KL-&15<4+^>D&HDD9(\M+2TN--3LD(#?!:#*
MR2S186S&16RO.O78IPB_'1_A171E>K&3U)ULTL00/5FJTI&G-MH'QGI*JF.A
M6,U9*/;)C;*7%-A9I"UV$$7(.):CCIN*XTXI>2F5,^N_PRTU!$*K0D[VQR3S
M<[HRXANN>8V1SP@FUY V*.2-N9<T2VMAS\,_C!R?JJCF7*"FC?+%30&BKFL!
M<88A*^6"H+1>T>.62.5]@&DPWN"2/RF:VZD]O:CK+M4U]8H0$8^=78'EJKM>
M*S793Q6@')4)Z29&$,OAIY75]'DD0[R'($]H*L?*9=&%C4(CZI5:,HZR775$
M;GO$>J%I)&  -J&-< QS;/:VJG#7@W:7AP\)C'-\9HM.:1T?3FEI)61Q&4S&
M\,4CBYSZ:1["Z1CKQO=1TY>P@AP86GP'R-=4L=3FWX%9-U$(;#UD(;8C0E-5
M>IUBNSQ N)9*W<61%>-"1,4R#&(MM3"V=N,/GM99L&#!EA;)&TVJ2;Q.BZ-T
MK)GL?+(PD_732RM>\QR0E\C'N+'OU,KXKEMC'@81ABB#+W=TBV"2GB?#!%)8
M 4]/#"^)@EBGU<,C&"2./70LFPM=<2F21I#IIC)>8G5YOF%#KD2/:QJ<U? #
M(^>NI5-TM*>JY+41(!)-%G RR!Z2,5HG54-ATO(EYR/JJ(COC$%CN2>#M#4#
MG2N,3_KM9B;KI0P"5E6R01L#\,8<*ZJ)#0/"EN+8&8=C>4>E6M@:)V?4:K X
MP0E[C!+12Q.E>68I7-=H^D:'/))9%A-\;RZB#]5N] 0MP(.NCK EVY(OJX+0
M\>PSFSIA5. N?WQ8\=S]T8HM14EK+F40Y0*/-&^12Y!!^9D_1%!(\/=#=X@-
M.'%SB1$72NP^$2,C-+NS#R'8@&AJ/E%I6-I8VH&$U#:DC5L'UH9"P_9 LUPI
MH"0+6=&',+2YY=-B'7'OA^='EBY]/!-(&U-B;!@Z\HCL,L<I\77GFBUDF)==
M>;D'(!G6%4.!593B'6UQ'@X*+"K\X@+EZ&Z!H TA[9I#CF+7.J)PYD<SJ@OA
M:1(+1N94S1R#;('8WDR!KQO?RITJYS2QU-$T,IP]C:2F+99J=E((ZB0&*QE9
M)1PRQ?X82W!&!&2PPT'U9;SKK3;0NU0FTLR TIK$BLUN8E$@"Q2HPQU34H4Z
MR^N,UKVJ*;5);>RW*&)(,^*(NN2U;GZ'H)+XHG9M<TVEE;D\SEPN'@@$U,Q(
M! (?A-V -&F/E)I:(>!/']IKP74\+K.:*9H=9S"";4D&T&Q9B;A<2Y4Q#JIW
MH4I<S7TV[/+J4ZET[7[XI@:*A(76*'#LHZN0UOP8<:2^\S!N-FCD)<IU^09R
M7=DEUS9L:!)B5NB:!DPJ&P 3-GFJ0\N<?K9S&Z0V)( Q0Q%H  9@ 9A#GAVM
M^G]*R4SZ1]3B@?30TA9@8VT-.V5D8#F@.O@GE:\DG6!]WW<UA;5A>K;?M=%"
M0H:\>0P0,X 3"8: 5Q4D40K&M!NH@TF%.<$KF-*BT0..&Y;\>IAV;'R<=:6;
M?DSWH_0VCI'O>^#$Z1LC)+R26>V6J?6/#FX[&\[W.O:^$B.^ !HRCY1:7BCC
MBCJ0UD)B=%]5%BC=#1LH(RQQ9B%J9C6D7PEX,A&L)<;M\,[J!7.G3I5I#SED
M94Z9+C2:94?(%/3[9=+NK#,&.&8C1(\6S7^S$!T*&W'A#VI,,;$CM"A8Z%%U
MG0>CBUK1$]N  -+9I0X 0P0?:+R2714\37.==SB'/)QO<X[F\J=,M<]VOB=K
M+X@ZGAPD&HJ*D  ,&$-FJIG-#;!H+66P,:T8FV+MZ[;8E12-^EB#1IE,5N59
M6JO6A=F*L0(;0P:P8."A4&>49%"F(XP<S+><;CP(D&+X*FH$),?FTU'!2 MI
MP]D9OAB,LKXF%QQ.+(WN<&8G$N=AM=Q<[:YU^MK-)5.D',=5F*21N$.G;!"R
MHD:T86"25C&N>&,LQ@<;!K6@W#6VV>);2Z/HJL>CVK;-.CYM$F4J+9 E9QF/
M46Z_)9' QLP609GJ(QC"(;+)8[+,OR(Q X0LN;*2BUA\/TC*+3[A];71,=J0
MV\,DI!G,@+I'M>S#@P%UV1-C +8VQ:MAEQ_3.TGR58?JM&S2-UY);-! +4S8
M7!D;'1RM<7ZP,!DF<\G%*^76D0F/'HV^=/ LF0FIIAF8/<N-K(^:)%>K<EV9
M4FZB'3K8",+EIQ=FNJ"WF*9?LL]\"<G6,#,%8/.6!:2PV1R74VEGL8TU#&OY
MM PR":48:C7R&LE=&QK#*)*=T8A:)8FQ2!^KU7@/'!97: CED>*.5\9JZB00
MNIX'%]**:,4,,<CY'BGU54V1T[S%,^>)S-<93K&&U1[)TW2R-QFF:;9&L$RU
M\*UQH5'?9'#(I>8352PC EB[P,PH==;9#.N+?)%5O,$S,)]R6H2*D3]CH=+M
M93MCJ(261TS)C(X%SW,:SG$A>:9V-TA,@ P1CP6. ;C>&:F5')U[ZM\])4M,
MDM7+3B$$1L;)))S6%L8JV8&PL$9)+Y+XY&$D,8YU;.L/2O-O@:>W2+L*I+?G
M>;8!\"8_+<GRB1V&[&%CQTRRQIHH4! K,Q@3V+9.G2IB*ZZ?<E(:,MRL6Q:;
M;32-YQ3OJ+QMB>YH:&M9&X.>]S87![Y91&9!J6M:TRB+"2PMR?-R:=60O%)6
M1T@$SYV,<7%[WRM+(V,=.UT<4,6L$3A.YSG:DS8@) 8_FU:.::V;A--,+CFJ
M]20U#&0&H<%X<2#S:F[9;+,/'IEP)!29R$.L^7VA>2 Y,\NU&2.>%/-X![1#
MI,\SO/'BCEJ)*I[BXM>R1L^JA;%$V%LC(W.AL7X786$EV,'6:><Z$'=+^RS8
M)HJ2*AC8U@?$^)U.9YW33/G?%)*&3XA'C872!H9JR-5,WSG1PZUAMFG;3BKC
M0+/';D>4,2'"4O)YEJK3I;:[:VS$DNU+PG)N(B/(1%O3)GK@6BOR8E<'\<1\
MH ;FHHC=T)(PD!C1&3,UIU!+AK_LXO"?!A;B@E:Z5_+,W)(BPI-)-+63M#L8
M<9#K0('N'.&ACW4^;@T8(ZC$XLGB+(VU2KOTD)&6D=$U;:V//$.S00D^5+DD
M38)<L5KR;6"*9[MK;@9>$V*N6Z!+0T)PY-A6R42<>R,PU38TYMIW'"\UL!P.
MB=(P-#8Y,+ZMLS"T0XK/BE@<WPS9T#6_;O.<A6<EA'/&W1U4-:V=D;W$R318
MF4;H'AYJ0T%DT$[7 ,N1.]V(QD4XUGNC]6E6RP2*1"FC:B\4E.5T>24MR?"%
M*7WQ(TQYR9.7(D,M]S;LK+^/*EIS(Q&A8=Q#8[BG$S8(FU+FOG#&B5[  US[
M>$YH#6@ G,-MX(RNZV(_.UAIG54[J)KV4ID<8&27+VQW\%KB7O+B-A<7>%]K
M"R^!L8YN7&3_ #_R<(G")PB]I.Q%Z5KSN?JXI6T(HB:W2M8S9[_G9<9S$,G9
M2 N2)9%Q7<I2AU0V 4DE9SK2E^1O-BV7DXS/;SCS?^(^FJ>ET2[1#'M=6:0=
M$7QM=X4-+%*V8R/ /@ZV2)L3 X>&TR$?8*]:_A-R?J:S3;=.R1OCH-%LF;'*
MYI#*BLFA? (HR<G"&*5\LKFWP.U+3_>!?TD1\;,.##B9SWYC16&,Y_ARTTE&
M<_TIYX.OTJ/1O\YS*J^%4X1.$6H_6]I\KNGI\L]<KT?RNS Y@^X5Z'XSQ>9T
M\)E]$F"VK*T(Q(G")I.)$\<I+'E;S&75-HQEU'9:)JVT=;'+)E&YKHI#GX+7
M@6=EG9KPUQMGA!V[%U>F*1];0R11WUC'-EC:+7<YMP69@MNYCG-%P1B(S;;$
M/R_RXST"1)AEHS\.9%?7%DQ):'(DJ+.8==:<CR(\CN=:?9<3E#T=Q*7FUX4E
M6$Y[\<]#!Q#$RSFG"YI:\EKFD$@@AYN"-A&5L\EYL&AKL+R]KFAS7-+&AP<
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MJ<'V];JGZO!;/%CMAMOLO+BSR]V5^@ Y:!74-?QXK45K,5D)7G.N6E3K1O\
M@V0;*D5R\3G"]FW^'BSZ1B"-U[+L9%[2;EC>N4P@U$=:",Q_I6-HGSR#'00%
M]7&R1\G<:9L5 YC@)(1@CHGN;-=TXC K!&(FM)&,GY>1U<R"-Q97SAM',]C(
MQIJ RZ0:]I,<Q+I:^-KH0&P.D=S(R&9QL< &YV[ZMLW82]= <"[E3#)3<@L3
M"MNH]T[8'BZYJ$/A%YM=JV5$KT770)H_:P]0D:S!UXO#V#!"6B[AY8XT1'K.
MJC]11R4T'.),<4S64CW&*JI*8NDJGG4Q1TY>9WF.)THJ'R-,#G1PN!8UV"_=
M5L=5/S>,,FA?)5M8)J:KJ0V*D8-?++4!@@C$DC8C3,8YL[6RS,(>YFLMC_HP
MQN==ALLC97Y7$+?U1K'.R6=H*O'F5OJ3Q:]JXVMC5+5RSYM:H^!/H@F)C6B4
MZK6&Q55U;PYV3R\[]+\SP,%-S6PJJCF_-M3C.C]52\VYT8<S-BUI/./[3C,H
MD\' N-H;GID>:GG=S24_.15:_ -)":J%5S77>"(0W5 <V_LI9J3%=VL*]!>=
M$OH$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$
MX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$
M3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A%C;<NQ8NH-0[3VQ-A+)1-9:
MZNNP) UMS#+A%FGULE8%CVWLI7AIR;@?Y*VYE*L(6ZE64YQCNYR:.G-75TU*
MTX75-1# '6N&F61L>(C*X;BN1<;%QJVI;1T=55N&)M+3S5!;>V(0QND(ONOA
MM?K6J%XZZZQK2YOU^WU4XU4JH#OD>Z[/0T$&4XOL2COZI#RZ;K]PO:69:EYM
M6SH5:FE+RS4ZW#)(5AJSS((FPD1O9PZ%EJ(1)%*S6RO@,-,2YTK:>85+Q-/@
MC( U5,Z0-A,DA;MC:71M=U4^G8J>?52Q2:J)L[9ZD-:V)U3#S1NH@QRW),M4
MV.\PCCQ;)7-9(YOR([02@FFK@=A:YN^*'4=;TB^N7B=;M%@P1&=<-L[&T\NI
MQBUEVZ#JN9<"SZTL+HZR,VF33;7 'S95;/SX\NG/W,_04[!"UU1#KIJB: 0M
MBK'O:V&EIJO6N;'2OELZ*ICQ1F(2QD@2,:6RB*LT] ]T]J><104\$YF=)1L8
MYTU7546I:Z2J9'B;-22!K]88I1G$]P,9DI@/7U33!,N0;KQ(E1'VZ\2HTX%&
MDRK;:0MSU]T<VNHN) 2_)($<@2-=68P5)B/EXN8D43'D(Q)==F(CU^@YFM8W
M&ULXUK9VO($43X:C2L4OU@)<6MCT8YX(8;N<1D,-\(]/P/>\X'&!PC?3N8'&
M66.:#1$L1P&S0YTFE8V$%[;  Y^%:3".NW7IF<FO1M9[F9O9(NBNT_7LP-0X
MUGOUD@V'8E6N(.LRE;%S4X\C7AS4FR(UKGVNSUD&_#J<LW4BUI D09,KK?H6
MH8#(:BD,+6:R:=KYS'!&Z."6%\@YOK2)V55.8VQQR/#I6LE;$\/:W:S3M,]P
MC%/6"=[S%#3ED(EGE9+40S1QGG&J!IY*2I$KI9(V%L3I(GR1EKG157:6=/*\
MSY$.'>98072A%S)6)QBC!!PS)\3J F&K9>#9[Z"L8,Q/D;XU6"\ZFP0ZC0SE
MCEQB-PAQ:M;YH#9]'J_($PA[I71!@,SR0QU6U\K71POC>QHH:E^%CW3%D8<V
M(ZR(/P^D>CC<MUSF-B9(7VB8 Z04A9$YLDS)&2.=74L=WL;$))<+I0(Y2R5A
M^OG2QB76?%"+]'KYT+&,%;LL969].IBITK<(X>./E@EN+/&'B)/1.Q8(\MKZ
M%=ZK+Q $E&;"L%8@96=J=H.L:V0XX"]CRQL0?()9L(I7.<QKXFX0UM;3N<V<
MPR#$YN#''(UNQNGJ(NC!94-8]H+YBR,Q0DFL:ULCFRN+BY]!4M:Z%LT1PM=K
M,$D;G2O6O65J+:6M96U:^@^Q5AVRJ3JTH\^JJ%O-A[84JBQ:T0D$ZA:[/6WP
M2U;'JJC,P>>FRZPX^3@60>**@3<"!JJ-$U5-4"F>8S(ZGFJ6@:QN)E.)C(T-
MECCD$G]GE#&N8T2V:8G/;(QSMU/I>DJ*=U2W6,C9404SR\,.%]1J-4XNBDEC
M+#SF+&YKSJKN$H86/#<?O=HCHUFOS[ID#M%RA11165"N[56%J#G; +TQGJ)3
M1@@WTDQ;)-I)Z0QC8@MR16XE6D0,N 'K-'ND:968_(&@*TO$0?3:\N8##K78
MV,?6<PUSW8-4V-M9_9W#6&4.L_5ZDB0\<\H*$1F;!4\WP/<V?4C!(]E'W0U+
M&X]:Z1U$#.TZL1$ QZP3 QB]D.NC6H:VV/7QRE;#&[$K@FED7J!'G:AL]ME3
M;S=]7:Y&5U8ND[8L_HX;BW'<5$%R?3AZJB)\<C+.5PL=KPV86:P;H6I?%'.R
M6!T#W2MUY%5'$&PPU50Z3%-31ZQAAHZAPU(E>"P,D8R1S6'-^FZ:.62G?%.V
MH8V)VH!II)7.EGI:9L>&&IDU<@FK:9IUQB86R:QCW1ASA$;)VA.MZ2-N=QN-
M;/!*/4 E3?*-D"NO@-R!6638^H&L[$KAD9:KZ !&"%"*Z$-C5"M>G[J=LLY4
ME=/&64>EB:O;'H*>5T,44D;YII)0TM;.^%\8CH)*>1CHH'O8V=M<QV*H9"R,
M6UKHW7 U/T_3Q"HEFC?'!!'$78G0,F9+K*^.IC>V69C'NIW4$@PP/F?)9QB$
MC '*96[KGU?4/3%+]/V4;?I5XM]$)0*]$H9 P],H%0MU^N)E0)[8$0V !"J9
M1S]E'.W0=5RES#^9Y]!$VJ-9*\X3TQ:&J93#:6G8)H(IVND=,UF&>6*")FLU
M)8][IIF1N$3I&PO#VSNB,<F'=+INEA$Q,=0_4S30O;&R)S\5/%-/,[5ZX/8Q
ML,$DK3*V-TS,#H&RB6/'T.];M,048'8HU^:)>'8@3]'EP03&Q)-YC6OIUKU-
MK8R)BQ+HZF;I!ZDJ&>C$RE[%Q@@\BC%FR#DC+)'"4:&F+2[70%O@/UP<_FXA
M,5?)-(YQC$UX3H^=A:V!V-S3JR\.C+\>[<&(#4S@G&S4EK14.GUU!%#&QN,P
MVF&D('ASYF!C7?68"R4,O_3=U,$MXF2@@U4L5&0BDQ;P*A.N/9*-Q%;@W5JH
MD(-1U./LQBHE6K@Y*9XA]3.)-FD#VO&H%>62M>D-'-HV->R76C7&%YRPWYI2
M5+7L.1+7\Y>T7%[1AQMBL,]&:3?7.<V2'4G4B=@N<5N>5M*YCP2;/9S5CG6-
MKREHO@N=NN=6NW3A$X1.$3A$X1.$3A$X1.$7CQVP_:FB^S7TW7U5(.&N74)M
MI\G U=5CBWW  4:&3&](+];XL&5#(20HAR=!'C!4:7!?/FIJ&6I;4$:8>C_7
M\D.2[^4=9()7OAT?2!KJJ5@&L>YY.KIXBX%H>\!SG/(<(V-)L7.8#\-RZY8Q
M\DZ"(PQLGTG6E[**"2YC8V,#65,X:YKS%&7,:UK2#(]P:"&M>1^%787:T=I/
MLNPS;(=ZTNH -,FONO9'Z]V":U=7HV'%J7AB'6]<R*N#C,-85XMI*('AX0E/
MAK6K&59]PI^2?)NEC;$S0U \  8JB!E5(;#:9*@2O).T^%YE^<ZKEQRMJY72
MR:>TC&7$G!2SNI(FW-[-BIM4P ;!D2!O4$]9'VA?MS=77]HK;?O;S?\ 1OD]
MXCT3^'TO9+C_ $PY5?YBTS^(U7:)ZR/M"_;FZNO[16V_>WCZ-\GO$>B?P^E[
M)/IARJ_S%IG\1JNT3UD?:%^W/U=?VBMM^]O'T;Y/^(]$_A]+V2?3#E5_F+3/
MXC5=HGK(^T+]N;JZ_M%;;][>/HWR>\1Z)_#Z7LD^F'*K_,6F?Q&J[1/61]H7
M[<W5U_:*VW[V\?1OD]XCT3^'TO9)],.57^8M,_B-5VB>LC[0OVY^KK^T7MOW
MMX^C?)[Q'HG\/I>R3Z7\JO\ ,6F?Q&J[5/61]H7[<W5U_:*VW[V\?1OD]XCT
M3^'TO9)],.57^8M,_B-5VB>LC[0OVYNKK^T5MOWMX^C?)[Q'HG\/I>R3Z8<J
MO\Q:9_$:KM$]9'VA?MS=77]HK;?O;Q]&^3WB/1/X?2]DGTPY5?YBTS^(U7:)
MZR/M"_;GZNO[16V_>WCZ-\GO$>B?P^E[)/IARJ_S%IG\1JNT3UD?:%^W-U=?
MVBMM^]O'T;Y/>(]$_A]+V2?3#E5_F+3/XC5=HGK(^T+]N;JZ_M%;;][>/HWR
M>\1Z)_#Z7LD^F'*K_,6F?Q&J[1/61]H7[<W5U_:*VW[V\?1OD]XCT3^'TO9)
M],.57^8M,_B-5VB>LC[0OVYNKK^T5MOWMX^C?)[Q'HG\/I>R3Z8<JO\ ,6F?
MQ&J[1/61]H7[<W5U_:*VW[V\?1OD]XCT3^'TO9)],.57^8M,_B-5VB>LC[0O
MVYNKK^T5MOWMX^C?)[Q'HG\/I>R3Z7\JO\Q:9_$:KM4]9'VA?MS=77]HK;?O
M;Q]&^3WB/1/X?2]DGTPY5?YBTS^(U7:+NC]I5VAT9YI]OKEZM5.-+PM"7^H/
M:DIG*DY[\8=C2K0]'?1G_;-O-.-JQ\2DYQ\7(>3?)X@@Z#T5GEE04H/F(B!'
ME!!0<L.50(/TBTQD0<](5)&1N+@R$'R$$+WY[)3_  @+=J]KT[IVZV;0QLBG
MWPK%K5,W&1@CAMQJED).M10@FWRQC,"!8:X6F9;'L&9<'S^,*3F7BI0B)<6L
M1Y]RPY!T<5'-I30D1@?3,=+4T37.=%)"P%TDL <7.CEC;=[HPXQO8TAC6O $
MGJ/(3^)=?/7T^AN4,K:EE7((:32#FMCFCJ'FT4-26!K)(I76C9)@$C)'-QN>
MPDL_;+$E,3HS$R*XEZ/):0\RZC/>E;;B<*0K&<?KQG&>>-KWQ5'")PB<(G")
MPB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(H?>[Y5]:UJ1;;C.ECP<<G
M7 OC8 4Y8R,DQ;K&)J-9%#@5:&ESI4B;LIT0&'PA@V7)?F3V$8;PG*EI(HG1
M=]Z8V77\6JC[*J1ZO*EBH*"C15F%'<DG6FG@*&L$O(G74'FGFU@WVVUL&,95
M@:[*RVYA)%/HUIK$R8P.AV,#+(29!:)&@QBX]^9(E '4,'8S$5J0M]V0%>=;
M9+,MH4X-=<0W,2RM:<9(L=R]]ZN@@K989!DWB%2+R&UM983-%OTFR0[M8G:R
MU7@46GQJP];##I]-SJTL),"A2(TL--P2H^9(&.*EI(J6I]1>F;O<9NOZW=69
M=T@%; &?KDP-8PI)R75S%LKQU^$T<#CDDA$*P4.[@4GQRY0*6;J%E$P2,D@$
M(QXQ%\!.H[35@?KD<;<<Y5<0-0L]/?G5ZTBH%NK][F@!M9+U4F4"0QMDA2Y]
MKK$2<Z%ESL 9%A"M6# M9.'AXBMDCJFT7&ACY[ESE+BFZP%N5:7&IM[F.7*N
M'W S4$A0X\.L/R+XJ.NQ DFX-.:.$:UYW'YL<04F2UE1%4.=3FD$,E)6+FZ]
M#"QJ44)D(E5NDT;&K6Q?/N*3>_.,2NOP7M:6%=7LC4+9\>0[KU+P$NQ(LS+P
M^4AHBRW6;0#N(AL[79OEXQ<XR+R]F/*AO,$ZZ9(5T\-EPYS$:9$GB#HHD)(1
M)+#3\:="D,.(PIO/"*CO=,!;'H]RUY:&')59OE4L-,L49EW++L@%:!$P(68:
M>QA667'8$Z0VAW&,Y;4K"\8SG'=S;!,^GFAJ(B!)!+'-&2+@/B>'L)&\!S0;
M+540QU,$U/*"8IXI(9 #8EDK"QX!W'"XV.XYK$$GI3T:5*%[#8Z;BQV>QC),
M"PGR)@ZP\0FDXM28.V. *%DX%?JMI/R*)3RQ>QTT37R\DU6@9;$M! 5 D1^6
M-)UK6L9',8XXW!T;&M80T,,ICC<YS7/ECC$TK&1RN>QK)'L PN<#PSHJA>]\
MDD DED8YLDCG/!<7B(22-:US612R&"%SY(FQO+XXW8L3&D70MTUZ>.R(L\P"
ML)(K##5X$R>E['V8[9%P:E:B5TJSTJR*N'GZ<8K=B-G90*PS2,@^*AV"PA8)
M-@(?,#IN#-(U; 6LD8UA?(\L$%.(\4L389;1ZK ULD;(P^,-#'&.-Y:7L8X9
M.T;1O(<^-[GAD;-8:BI,I;#*Z>(NEUVL<^.1\A9(YQD:))&!P9(]KN173-H<
M&R-CB=9UZ"R(8K\8:TSY?X$-BJP=3#*\TRE4U6,(%0-%ZDBQL*\+]RHPC#GA
MYS,S*/TE7/+B^ID<7F0N)P^$9G53I"<O\;JVJ)ZYGVME8W1E S"&TL8P"-K?
MM>"(FTC8P/"V-;0T@'_P&7WW^C/37I$ZYY3-HL:.11/G%89P*8L=;LHDJ3N5
MEOY H L]=,"[!7B<VVW*UE)! &2'S'6[$8&*>R)GR("S-(UC,A,2W"UI8]D<
MD;FMAC@:U\<C',D:(H8FAKVN U;76Q .5?HVADS=  [$YX>Q\D<C7NGDJ'/9
M)&]DD;C-+*\N8YKCK'MOA<6G"P'H*TU7KU;;*/DV6+4+;"#0Y6JQ9!->I<1N
MLTW7U(I[,5-=;%$FV*"/UI6C.OY#<MH]4K9B78H!Y4IL0@3S)--U<D,4;A&9
M8B\BI<-9,3)-//*29,0O.ZIE94"QCEB(C=& 7E_"9H&C9/+*#((96M::5AU<
M0#(J>&(?5X76@;31OIR"V2&7%()"<.'8!>B=4R5M/%*FBPRVHU<B.$;88L%O
M+3H]25<E5ULN7LY8N3-^;,;!N;;:S$N<X\R?FL2E/LXCML\#GM4 0V75B\A#
M8F1Q-:9=3K,#8V-:S%J(;X T Q@BQO?L.84AL71:P@1C%,^29[A%KM7C?*][
MWX.<36QN=E(0;@"W+>C-8?DP/:9F@)Q[6=F$3J^8JUKM=PN##P$@-9$/!(I"
MU'S!@6(8'1V8XT:*(0H8?+>'A+,*1WNY<]J><LJVR".HC<'LEBBBA(>UQ>'E
ML3&-<\N)+G.:7.V.)&2<QI3324;HW24TK'1OBEEFF!C<T,+ 99'N8P- #6L<
MUK+> &E1TITNZ#,DC1,EK81)781+P<N.\M-LUR2S(I<'6[Y%NJ1RC58AV5W7
M8T?07+?!$1K4JE0X]5R9R";3 QL;I*N8UC6U#AJW!['86&0$3.J TR%ID=&*
MASIQ$YQB$Q,N#&<2UNT70/>][J9A,C2U[;OU9O"VF+M4':H2FG:V S-8)3"-
M5CU?@J/[ Z0M);">/3YU?("#5GLU6LAHR&L-ABREN5_9^L-KE(89C)54"IIN
M=DU%37;42J40&9GR!Z#*2+1]MHHC.GTK64X8UKVO9''+&QCXXRWZRFJ:5KGG
M#>74QU<VJ;*7L:'8,)9=JUU&B:*H+W.C<U\DL4KWLDD#KQU5+5N#/#M%KI:.
M RNB#'N+0\.$GA*N*](W3L:#QP1+6T-\>P-\T.9;/VR(1)#'8E\A$81XU#/Q
MS-CCV%C9^P?2U!Z>2],7K<:E6G)B5*R\F-TK7L>7MJ"'8L8\"(M:X&!S7,86
M%L98::#5%C6ZH1,$>$"RR=HC1SVACJ9I ;AN))0YS2V=KA(\2!\@D%34:T2.
M=K3*]TN-QNI'/Z==-ES)ZPFJ:D\;LJ2+)4E8#UG/2<P"@.ZUN6%'*,&IN E<
M2%V/?(<*M!$C@ S-N/21HV)+(R)"];:^K:QD;)L#(\)8UC(V#$U\,@>["P8Y
M"^G@+I'XI':I@<XAH"V.T=1O?(]\.L?*'![I))9#A='-$6-QO=JX\%1.T1QX
M8VZUY:T%Q*X.=.6E;&^5F%*)!40,RL$)I: 2.AC39-#^K94<L--!BD J%,0I
M>DM431I<-,@$ADVC YH^5&E-/.O&:0K(PT-G=A8,(:YK'L+2*D%KF/:YKVN;
M6537->'->V9X<"" #]'44F(N@;=YN7-<]CPX&F<',>QS7L>UU'2N:]A:YCH(
MW-((NJK6^B-=:F.DS5%%+"M3ZA6:/%#-/>-%!@%9LU_N++(SQZ72'E)6R[*M
M!0S*FSYCDQUR VG#+4%I.945U15,:R=V,MEDF+[6<]\D<$)+K6;9L5-$QH:T
M  $YDDJTU!34DCGP,U>*&. ,&;61QRU$]FWNZ[I:F5[R7&Y(V668^<1<Q.$3
MA%Y<P^HOJ_3K@,2D4"'#(-M4,>8L1G5VP#AUB6L=IJXWZU%:16L D/UV+6[A
M?@#(\#F.48L595EG+CP^<.7])W/T5KWMYP7-O,6QLJ8&-<,57%!$R:3%:1TD
M4$A<^[3')N!#A\SW1TL(&GFS6N&I:Z5]/.YPLRBFGD=#'@NP,FJ(FAA#A+%O
M+2TWJP=5_4X M@X%'Z?IMF:+3MR3XJ!%'OT6!&J>NI&YDU=N5<)<UR+BY71G
M3PUN*'76HHGRC<>OLLF5(Q!3;\(]&:.DB<\UPC+&TC3CF@+C-.*3688@ XQ0
MFJ?=PD+R*2>[1X6JSETKI&.5K&T!E#S4N 9%, (H.>%EYB<.ME%& &&,-#JN
MG&,Y&6FF=7W4QE&R9K736:#CJS4*];ZFQ/J=S-'+$+LL_69:!Y$,'OCT&+/'
MJMYM%:)T5R56%#MDZU*1Y5M:"%IRZB;HO1UZ=IT@U[I)7Q2ELD+61NC;4,<'
M.<'%D9EABE;,!*#3U#2(W/:-8.E=)?VAPT<6-CCCDB:Z.9TDC)33/#FM :'/
M$4\L1A)B(JJ9[3(&.=JI,6ZE]X5V->^_6]FE* R;.NM1IFJ+[:;#8VY_43=-
M?ABD+-=C4NH,56FT@;7BDX04/0[9. %(EFDEY42.P4M^#='43S!:HC&L$>L+
M:J"-D>&@AG>UP>993++,Y[6N:PQA[71!@==L69TE6L;.332 QNE$;74T\CY
M=(34[)!JQ%$(8H&QO<USQ*6.$A<6X72YZZ7]A;(V?3K';]EUHW39Y:P5DD"J
M!X0\)EU8*?TYJNTSJXA4L2'G%$ [B>M8N01(153O.,6</D*84/\ (8G!TC!3
MT\S(J:1DS6LD:^5CP\2/955,8DR<YK<<3(W!K3;"6D7O<\_1L]14POFJ8WPN
M?(QS(GM+3&Q]-3R&/-C'.P2/D:7.&+$' V(PC97G7KL4X1?@T_PJ$-:8_6SH
MT_/:E^AY7IE#BJW(5E?D"C0/9NR)5IBQ\9_<\3(\8]6)$WP<>'XB:.\/.<>+
MPGW3^%SXCH:NC:6ZYFDG/D'^(,DIJ<1$_P#*3'*&Y[6N\_YO_C+',-/:-E<'
M:A^BA'$XWP&2.JJ'3-:-F("2(N.\.9PR\B.F^Y])X'34P9O(=7BUNSM%HC%@
MN5,@5LZ02;)H>3 (**0*(AR54H@()MV$= (W %7)BEYD2/K\X7-!+-6OJ])0
MZ7DK@Z@=*R'FI:2)FLBQZNN#AA=/9LQD?2&-_-'V+ XSQL8^.7X[0U3R?BT6
M6:4;"^IY]C#33OEGU9ET<8W%S8 74[(HZ[6QBLCN'%HIYI)8WQ6\J>Z?)NMK
M? /W>@S;>V]!62=UCJ". ([".+N527@IKR:>T=7XM%I8W7&"<)X,R1T^0<O
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M4&9)M=>AL'FM]#9MH4&/2R:A\"IW_6FO![>Q;Y3%S#"8]9MFM6A9V><O401
M(MX-;7AO8=8=L"1RA+T.U[!IA"!F5B<VR8UO?[-KLVN+,\GB*E0))>K390Y]
MR)%>=@/1EOQH[V5M((IYPB<(G")PB<(G")PB<(G")PB<(G")PB<(G"+"'412
M#6Q-63:N"""[-*7<]3'I]8-3(\$59ZW3MM4BXV^M37YD:7!4S8*H!-!\Q"$=
MP=/5-3!(>#"DOK3S*"9E/4B1[W1C4U3&R,!<Z.2:EFBBD !!O'*]C[M.)ML3
M;N "X.D8)*FE,4;6O=KZ.1T;W86R105D$T\1)#A:2&.2/"X878L+K-)(U!@=
M//5B$B%6J1L.O:_<74]@.52) +)-CP9^69VX;TW23Y$G3UF[#0M6Q[C2:^S&
M95#BX@5=R&/&X NR0Y'M37Z+>6&:G?.-; )268'21AM*RKF8ULN".>I,4S[G
M$;R7<['9S>I;H_2S&2"&I93G55!@:UXD;'(7U+Z2&1SX<<E/3-EACL"W^ZLU
MHC\%UPG:;ZN#-:\TV*_&RZF@],)#O,NR'-?2V)U<W89O-AJQ-\0)L)>>1-T%
MNETT):G+K*4W$"SXQ^8XN>?G7'%M7HMDF*.!C+OF#L=/KP1)2,A9(P.>QK6L
MF,LKHM2,W QAMF-BS=1Z6?'@DJ)'6;$YICJ>;D&.K?-)$\M8][R^'51-D,Q\
M%I#R29'3]W4OK'JP?NM^W=I:RBHSU:TC<]:4:B1Y!:79B?G37%UL"[6 =DNR
MZC"N$W=#^J66X!>HFI$H#JYK+!J*U8IH>0T=4Z+$,%'61N(DK8:F:<A@C;AJ
M(8]5( &RF$4@J27,F8 ^IS83&UPPTI2Z7,U374$K Z.@GIH*>[W2O<ZGGDUL
M9),(F-8:0!LD+R64V4C1(YCL?6O4'6Y=%W6A/VR:U5#&I;D)CY/WD3/!93??
MA6A8-4.R86MXQ2XVB -+Z"S,L$,D!9JT4.W(0NP/-%,7C?%5Z&A$,PB&M;4Q
M.)C@<V0&#N8\RL!J2V*)SFUUHRQYE+B/ !9J-<M)IJ8SP&9PB?2R-;K)F.C^
MO.E&:IY;3-=-(UKZ&\C71ZH-!^L+7"?)9G5G5Y!A;2@U*Q!([IVPV:=KQV%;
M$UZNUZNV/=1:V2&IU9"5<01F7ERM$%S7[1BV1FGVY3HB:B?,;ER"O';5:*<:
M9TD3R&,C;4!T1DDDDCHV1 B1\KVB$2-L(]4;$!XPBP;R'4NE@VJ$<K09))#3
MX9=7''%)6/EL8V1-<9]4X$R"4 @ECL1!QV$3HSJQ%/R"\FTLDS4PC:"%G(1;
M_EL\7'6\[T]GR]<UZ<,50C^30>IJG;*%>:A4>$%5E8Y4#S/)FBK!6LWUNBW@
M,$1:QK8FQAT%V,=$RN8V2=C)6\X=>6G=C<2_(XL8:Z.36RATNUQ>9@YSG3.F
M+9[/>V5] \QT[WQ/YLT:FI;@:T, <,.%SQ)%FC0NO>J&K7-DSNO:#-W%2Z5Y
MI-CH<P<H*FTCJ#TZCQQ@"-B5&N.0\3KR(ZBS!61C$3$UFT ,K&1H3(</6N'7
M5&CI8L%'3:EPE+V.+7!^K=/7$L>XS27M Z@:T>%8QR>$7%[I.=04^DHI<=;5
M:X.B#7L#FF,2-@H&A[&B&(C%.RN>X^"'"5G@- 8R+</G5+ME^$+_  J.AVT?
MUC:&V5,ARLTBU=.D&G "64NYA9LE)V)>R]F%H7E/B428X^\UF<XA*O#6U/0K
M*>Y&<\]R_A=40NT17TK7#7Q:0,\C<L6JFIX&1OXD%T$C;[B+;U^<?XS4T[=-
MZ,JW,/-YM&\WCDSMKJ>HFDE9?8"&5$3AO(<>"\#*%K+?A[5L@CKD[-=HE\L\
MVIV"EA=AQ@RRY"OF]4@(LJTT]\R-CD1;MDW-0Q0J=+8G)CS)TB3*0/@1DSGO
MNZBJT?'5AM3$W7T\398YWTQ?@$D=7*6Q3!CBUPBHYWN +;@ #$XV7G%'1:6F
MH'NHIG&EJ93#/2Q58CUCF2T<+734YD8U[#-74S&EP=8NNX-: Y9 KVD^L,=D
M1L&O2Y?CR/B[^@@QN77LZ>AHW#UI>R5HMP9^]29HV"N#9M5V*[SKD.BPH#)"
ML/W%4;Q#.&./)7Z&>'T\C18?4831U#6G :F!D43Q &N=BCJHH6PN+B6RMB!\
M*_,CT5RDC+*J-[\9/.'.[HTSWM$K:6IDFJ8W5)+&%DE%-4.G:&870.FR PQN
M7JCJHI%/*P<%30FF"1_Y9"( )N*LR!GFT4<@AQ^SV*T"NTC!".^:1 35[A!'
MR<&\L,3:X0GQXZ9#>P5FB:B9AP1R3.?S)LCZ*0.QOC<]U*99(!A+6!VNA<X:
MNY;(UI-CI?H_3]-3RM,LD=/&SND^*/2,);@9*UK*UL,50<37283#4-8=:0'1
M.=8%:U'["?M1B?8;0<,60^4>Q()G#Y.:8,$9&&T-8?GDR+\F;,>PTVVWAV0^
MXO#;:$>%X*4XQVD<4<+&Q11LBC8+,CC:UC&BY-FM: T"Y)R&TDKHIIIJB1\T
M\LDTKS=\LKW22/-K7<]Y+G&P S)R "M',UK3A%ZA]CA6[4<[072!2L-2LIJ,
MBR'SDF-A?=&%2:T4KB?'+3\7@229X=%PA>?TO&J5C&? SW?$?Q#J(8>2]9%*
MX!]5+2PP-WND;41U#K#;X,4,CB1LL!M(7HO\+*6>?EC0RQ-.KHX*VHJ7"]FQ
M/I):9MSL\*:HB:!ON2-A7]/*!XSR&'X[O\;Y*QXSO_7X?BD^%W_J^/O[_P![
MGYVV+]5#, \0JOA5.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$
M3A$X1.$3A$X1.$3A$X1.$3A%B8GH71QHO;SYC3>K2IW8#4)B]&B5!JLTM<F1
MK@)X<U:",D4[,/-P'JM67H:";TI,9ZN G6<(<$#U1R+ODZ-TK,2PF7J+6,E,
M4T L<9+]$J[N(]AJE<CTZL'&,+%J\27KM1B1:L#(M^#+%5R.R#@O,#&T1<$4
M2L'2GTT6AA^*<T-J6;'F8JS1)CT"K4=HQ"I+8MFIB#B(HYE)L$ 8! XXT"6Q
M,#QXX4.PB%XD7!1'(IL_IK4,EJ6Q)U9KJ0Q/@S1DYA^E5MUF:-)>F7G$?+:6
M-4W(@S_RB[ \LB/)6Q)].+?XYM?I(8\L(J)W1&D7Q: ;^G]7O!FD9;;$NT*K
M.#FT*0%;4E$)8M4=.%-UNNI5W-XSG $-W]_FR%X@BZK-H'1-T,S;'<-+ZIM5
M@)$A)DB<L>O:D;,3RX 5( @RLPD2$29DDD'!RY089.>>7)@BI#PZ,ZU#<4SD
MBX(Z T28> R"VE]4E)%6F#B-9?(:]J<UZO3P[85H3-".R1+BQ<H6U6ZZ@?(@
MJ8=AI A<1U-^:X/B"+4K>3G0[H&U5*MWOICUY)>OLL,8?-@=)ZT(B ,.JJG5
MYNY6^1)9@SH@?7E=L=G*$#,>"1<K5,=M<IA*8[TZ-)(JC0^\.EVYW>FV2B:!
M_)P3V,&B)J.U)U!U:#R8*WS3U=ZMRU&=)56Q%KD/-/TK:!:Y'G28F+5)]D@W
MG#5B($Y$%VP$42I>Y>CJA#]=6E.BX.O!)_2W3(<JVR30#6DE475-EL-3KNCA
M=DL[EIG7@#"H9LY!;K\*\0A269=<M4G7RK"Y5R4A!%:XNR^C:S"Z_P"8^C4?
M;VM^ZGU/=ZH%&:RZ=I:]IT\I#K*J-7R;$^]11XMVK"ZM#= Q]E/UD#-A:N+H
MUV3L7H4VTT17J'U%]'M=%V<R+Z?_ #5!V44Z?+2I0K6VK&ORS+WP2/'Z-<7D
M#[%E$@I4PX,YL^XC]B9KUYK%96,,QP4TQ::V,+D6[FF)U6GT7"Z>'F 1D.Y;
M0#D1I"6Z0FIN('9UP";!F223\J8\4=*7P?9"BBKLA;A3RWS@O#:I.6D$65.$
M3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1:5=>70
MQIWK^T81TQMR#(;\1,0>I=N$K8CV2D6J,P_'C&P<Q]B2RE2X\A^$0A2H\B 2
M@2'XLIA6<M.L]OH735=H*M;6T3P' 8)8GW,-1$2"Z*5H+26DM!:YKFN8X!S3
MD0>CY0<G]'<I-'OT?I&-SF$B2&6,ALU/,T$-FA<00'@.<TAP+'L<YCA8@C\A
MEB[!OM+.GX\Z'T%O,!)IP\\3. "40W<:60;GD6!T)\JX'$@[-#B$Y4,("S(D
MQ2SBLR@8>8CQ<D2->C>GC^(O)^L9BTGH6KUQC;&_5LI:J,M:7.#0^2:G?A!D
M?8&/(2/:20]U_'N]9RHH'NCT/RBI&TPD?(S6/JZ24.>&-<YT<,-3&'$,CNYL
MOVHXW !S&$8H$]BOVKX)Z'(#;"K8M^ S&BPW8-^V#&7'BQ(U'AQXJ%-T5/\
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M7^*6A6L)AH-)R26.%LC*6%A/_-(VIF+0>(C>>K:MD/\ !G3SI&B?2FB(HO\
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M /G/C_R=^._^'E5#W7L7NM_[SO+YAYCY%SYQ(?OSIG_G3_\ !_W^/B_>[O\
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M5OLH^V3TR>^1EU^JX'XKQJA][%ZQ^%.>.Z%6^RC[9/3)[Y&77ZK@?T_]5O\
M_O\ )QJA][%ZQ^%.>.Z%6^RC[9/3)[Y&W7ZK@?BO&J'WL7K'X4YX[H5;[*/M
MD],GOD9=?JN!^*\:H?>Q>L?A3GCNA5OLH^V3TR>^1EU^JX'XKQJA][%ZQ^%.
M>.Z%6^RC[9/3)[Y&W7ZK@?BO&J'WL7K'X4YX[H5;[*/MD],GOD9=?JN!^*\:
MH?>Q>L?A3GCNA5OLH^V3TR>^1EU^JX'XKQJA][%ZQ^%.>.Z%6^RC[9/3)[Y&
M77ZK@?BO&J'WL7K'X4YX[H5;[*/MD],GOD9=<_\ T7 _YRW&J'WL7K'X4YX[
MH5;[*/MD],GOD;=?JN#^*\:H?>Q>L?A3GCNA5OLH^V3TR>^1EU^JX'XKQJA]
M[%ZQ^%.>.Z%6^RC[9/3)[Y&7;ZK@?BW&J'WL7K'X4YX[H5;[*/MD],GOD;=?
MJN!^*\:H?>Q>L?A3GCNA5OLH^V3TR>^1EU^JX'XKQJA][%ZQ^%.>.Z%6^RC[
M9/3)[Y&W7ZK@?BO&J'WL7K'X4YX[H5;[*/MD],GOD;=?JN!^*\:H?>Q>L?A3
MGCNA5OLH^V3TR>^1MU^JX'XKQJA][%ZQ^%.>.Z%6^RC[9/3)[Y&W7ZK@_BO&
MJ'WL7K'X4YX[H5;[*/MD],GOD9=OJN!^+<:H?>Q>L?A3GCNA5OLH^V3TR>^1
MEV^JX'XMQJA][%ZQ^%.>.Z%6^RC[9/3)[Y&W7ZK@?BO&J'WL7K'X4YX[H5;[
M*/MD],GOD9=?JN!^+<:H?>Q>L?A3GCNA5OLH^V3TR>^1MU^JX'XKQJA][%ZQ
M^%.>.Z%6^RC[9/3)[Y&W7ZK@?BO&J'WL7K'X4YX[H5;[*/MD],GOD9=?JN!^
M*\:H?>Q>L?A3GCNA5OLH^V3TR>^1EV^JX'XMQJA][%ZQ^%.>.Z%6^RC[9/3)
M[Y&W7ZK@?BO&J'WL7K'X4YX[H5;[*/MD],GOD9=?JN!^*\:H?>Q>L?A3GCNA
M5OLH^V3TR>^1EU^JX'XKQJA][%ZQ^%.>.Z%6^RC[9/3)[Y&W7ZK@?BO&J'WL
M7K'X4YX[H5;[*/MD],GOD;=?JN#^*\:H?>Q>L?A3GCNA5OLH^V3TR>^1EU^J
MX'XKQJA][%ZQ^%.>.Z%6^RC[9/3)[Y&77ZK@?BO&J'WL7K'X4YX[H5;[*/MD
M],GOD9=OJN!^+<:H?>Q>L?A3GCNA5OLH^V3TR>^1MU^JX'XKQJA][%ZQ^%.>
M.Z%6^RC[9/3)[Y&W7ZK@?BO&J'WL7K'X4YX[H5;[*/MD],GOD;=?JN!^*\:H
M?>Q>L?A3GCNA5OLH^V3TR>^1EU^JX'XKQJA][%ZQ^%.>.Z%6^RC[9/3)[Y&7
M;ZK@?P?^%OYO\O\ )\?&J'WL7K'X4YX[H5;[*/MD],GOD9=?JN!^+<:H?>Q>
ML?A3GCNA5OLH^V3TR>^1MU^JX'XKQJA][%ZQ^%.>.Z%6^RC[9/3)[Y&W7ZK@
M?BO&J'WL7K'X4YX[H5;[*/MD],GOD9=?JN!^*\:H?>Q>L?A3GCNA5OLH^V3T
MR>^1EU^JX'XKQJA][%ZQ^%.>.Z%6^RC[9/3)[Y&77ZK@?BO&J'WL7K'X4YX[
MH5;[*/MEQZ9/?(R[?5<#\6XU0^]B]8_"G/'="K?91]LN?3)[Y&77ZK@?BO&J
M'WL7K'X4YX[H5;[*/MD],GOD;=?JN#^*\:H?>Q>L?A3GCNA5OLH^V51$M3LJ
M2Q&S5+;%P^ZAK,F6.AMQF,+5A.77W$$G%(:1W^$M26UJPG&<X2K/Q<AC !.L
MC-MP<23Y/!63*HO<UO-*MF(@8GQL#6WWN(E) &\@'R*6\UKEIPB<(G")PB<(
MG")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")P
MB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G
M")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB
M<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(F<XQ^O.,?Y>$7'?C
M^'']..$3OQ_#C^G'")WX_AQ_3CA$[\?PX_IQPBY[\9_5G&>$3A$X1.$3A$X1
M.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A
M$X1891U":=S<K;0I5VB";'1DD56;T@&':V @Y#BZ>:,MQKB?%C:>8?#"K_3)
MQF.%.D7Q+%B'9(MQLN+2@BG3U]HT=$%R1<ZFPV3G1Q@U;UB#M(($I9"4)BCX
M*ES$IESI)6#-&QXC&7)#Q"'*AMMJDQWFT$48#[OU"<K<&W0]CT^.!GU>MW-$
MHP=@5^1#K%OA((5HP8&G7AQ(%&,Q',.0L&8D!UU27&O%X>:<;017[&RM<Y*2
M >+_ $K)J(F<J6'Q:@7G2*D7%?FDU2!_E_E;*1T*-)ESLN,IQ$BQWY$C+;33
MBTD5C,[OTU7AZ"QO:VNQHUQNMOHG2;E7T1E1;@<"5JKS?&X(93@>>/60 *&$
M,YQ"E3# YIN1GRIK*B*1D[_0PI%0<S=JB)+(EAH"Q9.R!H!%$ZQJD(KT)4*5
M-:DIEGEPY: T?+6'BBHLA,%#^6'<)(HG9=\:<J0>">-;(J:1A.Z5W78YT:7C
M'7Y]WM1T%7 U9AP0:B,Z25=)V4+F;&8C+4)'3<&2WD0=B3.9(N@?U :7)'55
MJ/LFK-'$"::9>'D"*!+T=C8*YZ*9 E^=,0TP[#8,#9;D&K2E,V7+"&WW1+;,
MB.MTBD=/VKK+8+,!^C;!IEN05'SRPU->L@@J].%BRSX$D2BQX<MU]Z! -QI
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MVWN[&<,O90=&YH!< +VRQ-+A<7%V@ES;C/,#=Q"D55#.]S(B]V'%=^IF;$[
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MQO%N^ YA_&4*SAK*,+6C&'$)4VI*LTM<TV((-K[-QW^3_91DT4C0YDC2TN+
M;VN\$C#8V.*X-A:Y&8N,U2LVBO/CH19)B @>1;%NPY$A],7#R#2VVQ/[G)\4
M\VL@XZVW&;=;0XXXKP,(\+"L8IC>"6X3<7N +_9%W;,L@"3P6 JJ=T;)1-&(
MY!&6.<[#?7$"+)UG R$@-! ))MM5='*CI,=J4U+:2R]$CSD^/RJ*\B)*QC,=
MY^/*2S(C)<[_  <8D--*PO"FU)PM*DXQ+2"01L):;9BXV@$7!\Q/'8MC98W-
M#@\6+6O&+P2&N^R2UUG-OL\( WRM?)5Z5)6E*T*PI*L84E2<X4E258[\*3G'
M?C.,XSC.,XSG&<9[\<BV @BX-P<P1L(XKGA$X1:#]:?4#8]<,AM?4>>Z'L%@
M'+,F#L;.$SAH54E^%#C#'OC5%ED942;EZ:WA,B)'BIQ%6AV3AYGL]'TK)<4L
M@Q-:<+6G876!)/$ $6&PDY[++X;EAIZHT>(:"CD,,\\>NFG8;21PESF,;$[_
M  OD<Q^)^3FM:,.;L3?*R5FVD8CMEGRC,V._(<0\4F3Y$AZ2^E2,/.J6^^N5
M(2AQQ"'Y7<XTV\M#3CN'',)5W0P X &BPOA &0\@R%]PW@=2\Q?SE[34/=*]
MKG&\KWN<YQRN27.Q. ) +K$7< 2'6 HF&CTE#CK&":VF<XP\]X4A++2E-RGD
MH=>5G#;;BVH$U33:U)6[Y+(2WA2FEX3E9HRL,]UAY/W\UU@&S$$@2$ V)NZP
M.%[@";AN88\C.YP&P-B#VP8E@)(G.0U2W$#8OELU;DW$=,>-E2$(<4J1(9PO
M+JW$)::;RIYY2TI:;7G/=R'"+7 S-AEM/H_T",9-)C+2XB-N-]WX0UMP-KB,
MR2 &BY<3D"NJ:T<&OYBS53V'\--R,HR^XON9>9;D-N^$VXM&4*9>:7WX5GP<
M+3A7@Y^+%&%V8L<SG;>"0?SOYU'B9CBU^-I :;7.QS0YIN"1FT@WOY<UTMK+
M.J6A#T[*FVWG5XR\\CP4,1G9;N<Y6M..],9EUW",_I+2C/@)5GNQD0-X'HXG
M^I4!E)-B\V!)N3L:TO.=QL:TGB0,ED+7NY-C:N+QR%<L16.RR\E4P'+ER7A$
M]&,XPXS+'/.*9PM2/"0F0VA$EGOSEMU/QXSIFIXIV%KVB]O!> ,33N(.VP)V
M;#O79:-TS7Z*F;)3SR%@<-93O>\PRM!S:YA-FN(%A( )&'81F#[F:@V4/VM1
MQ-M@I\2J6UA$R-G.,JC2T8QAYK/=G/\ J5]^/X._&>[.<=W/F'M+'O8;78]S
M#;9<&V74=HWVVYKW*EJ&5=-!517U=1#',S$+.PR,#P'#8'"]G ;"%E#F*Y"<
M(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")
MPB<(G")PBTSV%T.ZKV>=OYRUV;8DKTXM V]01#1"H8"4*\#4ZI3Z64^%(I4E
M<LI,QIFD(DQ[[(NX=F,V<@#A< =9#<2:111SLW^FS$L;-@C#8IX45HTV)%@M
M4Q==9$46DEJ-&IL:DSZ9.HHVHG(=CM1LX-$5D?*39+4?) 2 )N:B(R14\KL\
M-7QHPN/4[]LNJ*"HK$<-(;51#SP&.$&ZL$&Y(=-@I!!A\Q<1^E];M%9%K9M8
M80X!<>JE? 9*E$RR*ZI[.SIN:!SZY$%V>$)G4\I1<M,'(ZY,>O%8_4!$=8:)
M2A<DD_)8A]2-^B-2R$N:\]'A5=N?F;@9,R4(KI&Z#=,P8HOR E<AIH.7CV.%
M9A?H*)*8LL4KK6P1S[PP918E1?F)LNJJS8WX3M94$GF7S<@B*EMEGV$D5YV7
MT9T/9Y"[R2.P-NUL9L.^!MB6RMTZRU\,%+GA>O8.L)\6<X]49YPA7K+5 U;0
M:K9,U.#QS%8"'ZY$ &69<V8118AV?6CIKM57&*7\.W5Y%4<S&&%:WABP1:>8
MTQ8Q@\YB?4I[J6I%ET#K$Z2( W0AV9+#3(F2[8<R4&2B+#5EZ*.D[7<>OZQ/
M[XV30&+B_5*O6:H[LFG5M^RCO/EZBQZ(GOIT>?;1-SO>X[$4EC#\DW-S;"0&
M/5I(.(% "X1%/M*:QZ0U[NAV_6^VHM^V JCR)X>O2BE .L^AUM@9N(8O69K%
M.BV9J,,H&W @^$]7;.VB32+-7"-Q:.%CV;"6(H[KW1'2B:$ :J1W3&V\##:9
MZ)M>R]?V%S6\VHS:AK>PV STQ&RU9D5!^Q9D[(/O6^?%;.6"<-MZ24M8@?'A
M0Z_D811L?K'HZI N,^%ZK;!6!=(U9I&#KY^):-1JSJ^AU$:) :\,:XF3M7S9
MSD&Q0K+)8,#Y<BRUPD_LF1,6!A3)5.D!2+Z_(?T+N,3:*2W@>LL=5\U+$HM<
MB;'BQC.NB(&I6<=JNHZ_+Z_# [J3IJJ!4+J' Q;:<NX= P!?R(R?%L4B^F)Y
M%O[ID0!#41+-</IL\(E<=G6><83$='I<LMQV;;[9<8"1LAQZ4*2%MIHV%2)F
MO.SQ21^!\]UR9&?6HBRIPB<(G")PB<(H+::6FQFZN<P\+2_6%$%,1RX9TQ'4
MLA(#R<2XV&2HIR&1AK#MXB2\KDMMXD/>'&7GP<XVQRX&R,LZS\.;782,(<+?
M9==IQ9C*]AFN#547.9Z6>\6*FUF%LT!F:=8Z%V-H$L19(PPC ^[@,1NTY*P
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MA$X1.$3A$X1.$3A$X1.$3A$X1.$3A%'[3;:K1@<NSW6R@*A6Q[D%F?8+08'
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MQW):R14=$Z.]?Z_O\798@L=>MRKENFU&RTX@5(2R\/;=VV9=X%7CN%"Y!NO
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M7VR$1#SLYF$Z54!^%50G8\%Z=K^V0630[)8,LNU284<C(%#H5D/1I$J5:4Q
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M9>1J%/9/#18AQFP;MJHE4V;+F#9$%1=6'HZ77'HI.JWZ=77U_.5_H9U2TZ7
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M@BLF8PR4X#M=L#U0TPV;DY*%U1JG8<PXE?8L(V,0\CPN?'2;%/SB*(YV+1H
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M'W[JO$\41B51 @3,A"2$VQ%1((>K%(E>A8JFV>)F'+E.M!'W-CU=QN ;6(.
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MOD'2:[CFW>;6&H$R=7)I"V4RR"B676\S+"\TT<PS,@D8+\LGS_5=3.SM#!$
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M6)=7=PU'C);?!NP7FLQHRFUI5'9R@BM)/3^N3#U!=(5F&^C6++3%(B9<DIA
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MJ0F4+&CU^3XS$@C9"?&CXK'@,0E+=\F0UAY["R*W-ZBU8UD3EO7E-1D"1>+
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MS0(:B4TR*(0"HY#;Z8^'$XAD10N:PK"L*3(&CW/"RJ%&\410W;-2JPO69HO
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:(G")PB<(G")PB<(G")PB<(G")PB<(G"+_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g459793g00a02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g459793g00a02.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2#X4&AO=&]S:&]P(#,N,  X0DE-! 0
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M<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F
M"7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT3W5T
M<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !2
M9W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O
M;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M      !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M    4G-L=%5N=$8C4'AL0':            *=F5C=&]R1&%T86)O;VP!
M %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M          !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F-
M60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1"
M;W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P
M4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE-
M ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M #^    X0DE- _(       H  /_______P  .$))300-       $    6CA"
M24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M   *  $          3A"24T#]0      2  O9F8  0!L9F8 !@       0 O
M9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M!@       3A"24T#^       <   _____________________________P/H
M     /____________________________\#Z     #_________________
M____________ ^@     _____________________________P/H   X0DE-
M! @      !     !   "0    D      .$))300>       $     #A"24T$
M&@     #-0    8             !S,   C>          $
M             0             (W@  !S,                      0
M                       0     0       &YU;&P    "    !F)O=6YD
M<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE
M9G1L;VYG          !"=&]M;&]N9P  !S,     4F=H=&QO;F<   C>
M!G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '<VQI
M8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE;G5M
M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M
M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M0G1O;6QO;F<   <S     %)G:'1L;VYG   (W@    -U<FQ415A4     0
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M24T$$0       0$ .$))3004       $    !#A"24T$#      6/P    $
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M)DXC[F"K+9=OC8T.;!W#U&N9^^[TQO\ ;^8H9.)AOM#K6T-?D$,_255N=8\
M^W=8W<]WI,_S*TV*S%LBW'./D'']U(:QK0T
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M^D\CYN!FHJ09(+,RG64K*LQBD*8YS%(0A1,<YA I2E* B8QC"( 4I0 1$1$
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M6NP=KEJ3)A6'=F>/7$@Y59/9UFI-7:2CHBM3MPN4_:[%8RHU\K."81,Q6ZE
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MS'.H<)&3&H8$*A*C"\5?5)))!)-%!--%%$A$DD4B%32233*!2)IID "$(0H
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M:7@/;M,6]/'# )W YRQ5O!7<]WLQ!7#V R(@D>6(!ADVG0WDY(BB CV4C?\
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MJ-/?BR=)H$#WJ1AZ*D.*@]D##[W[ #A/M*%&YG&?N1^-_P"&.=I 'X/KY/\
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M/0(D  ZE.=;J@#RF;/-HXY(SO7U)N]GK[?T9.0(&D:<0#Y\M^51OVM+^%<&
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MKXJ/&3SL'B;U-Q\H>^3ZW[<_E!XK@@I"8G9!00$[82=!+\ IF[CT= $"@':
M0'KU'T^D/1@8R._=?9[./=ZZENIALE<E9@W![AAU/7C=VYP!CZ^_4HH]D/0I
M_%^CJ8O7H+GH3TB'3KWH]0^\ =/1\&1QCU^B?9VW?B[Y]WJYHW4SR5]/GANX
MB&[/.?0X(/KSVH84??\ : X>\.)NHE^T!8 7_P"Z(  J" ^G_< %#TC.!SDG
MMSD@_A<XX]O;CG/J]4J)/#@KZ0Q@$C.P]/N?W&?R>VO41)U-U X^_<]KTEZ
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MO?U9\7U8![^W\7-0H?P[=@]'&0>Y1C'Z1_<9Q]7J8\UWZI]1#[('0[KKZ2]
M$$@[W[P#T G3H'PB/P_>QX><Y[M[/9S]?;]=/'@8*XVPXP&[;_!Z\ YSD_60
M#F@=CT=D#]K[" >^*'O^Y,(#[XH!_$=0'T>D/O /4<G XP3GCL?7C@G([8^K
M\F:C#^LKCY3U$^'J 'L?7)C'.0/61Q74HH]HO9 _VZ'9Z"'3LB!P0Z"(= (
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M4Q\N3@-C&\!L<]BWHC@@=^]<@*/4/0;IWB0_"'P"<01 >H?:]OKT^_U^_P!
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MQC%=#"EV#=0.  W#J B7[0%@ _7M%ZB/>=!'IZ!_F >F1X<>O&WZNV[^G/\
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M4YF]8/I9VG))]I9?!7)*HB0Z9AV7+&!-6.4[(R3'H;Q!F9H(>E0?XX3=Z81
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MT)<#K0I%QA1Z.S<<8SGPA&\5<&J*1DU">V;+@)T%T0,$DRZE%:0(^ X=%0,
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M<Y4HN4/1*I(I D'MERQNZ+' /618]#^(+G6'J!E##T5 _8Z")NG3[,+@H@0
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MA=5*A!^Q^T.P6HST)N?)BW/(/+[B"3GVOU#@CL-62$QC>V9+^^574'K),/\
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M03F3=@Y+=O'U.,<C54>V)_;+EN@JJ*B R3'J/>1X,0 1[8 (D$.^*/9[(#Z
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MK-I@ZY;+M;85@_;Q=6\9@ROW+MC,N7]6=1KEHA*^4H5^^(Q&#5CY-Y)@D&S
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MR0H#1<[2#.\LS@IA)WK%/Q:.[8"("'CKL"'4+U#T*-FSA(X>^(<Q>@C[&V^
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M*E2YZV66!:%C1>>(I.T)>[6%=P_21*Y=$<HH+',DV0*2OGW1MH7SQI> 2?\
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M+NZ(1%B3B@9]B,AH=M3&C88HPN26Z[>$X&Y490P/.6/I]O2QD?C.<YK$-/B
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M'CC_ )\[JSM6_P!YC_@_WFO#:E^W;K^-']6MR&9JT*TO>&#^X#Q,_.4\*_\
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M5Z;NF0,@KD'()P2/5ZO7ZJT+F:=TZ06-)%NK>&4"20*R2E&38ZJKJKYVR=F
M#!=P.:RE\(U.R6IM3\)Z@RL^[:/59KE'J_6%^;<;9S:K_9TO1T-,;==N:M7'
MU(!]M*S-SR]=@W:@IIOIJ03BTY"3!19-PJ%80"920K$1LPW!<!MRC//A'<_4
M*SWAV);+NE16N$1^@9#(4$4I*KL!D;E0> 2<9-8;ZUWSN-[ 5N9H6V-^2G'*
M5\*CQUTQIJ=W=,2C;>,K36K%]7>0VN-A!+ILKXK3&>V(J9A8B%VDU1N0H,I!
MM+-SQ2,,H>^U><JNX0.S;1X<Y!1AZL[2#E>.V*UEEDV@I)*8C?PQ1M*3U2N=
MLR/GQ[1(" ) '&"&&,5'/MJ.IC2=OYN;>YB<HM&721Y&[XA=>*T*I;JVUQOT
M[0=![SL.NHZH;0TAJ:K3-->UJ=JM*$UTN&SAB):0FK').X6TQB\:S0:L ,(Q
M&C#8N=Q579F0'(9B#P3P%SP.Q)J2_P FUS)<SQ,9I@FU9)(8TBF:,+)%&I4@
MJGB:3!RQ((Q69_-KE4Q/086 T[<]B5J\U/E]PVI5V?MZ-M+7[%U7KER>UW3K
M7!1=OL=6@:U<82Q1#J5AY1&K3DZR?P[Q0%CJL'9%5<<:88%@"&1R.5/(0GD
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M6W.-=LZ2V:1SN+>1YW)YQ"-06:';%< 8I2#7HM&H\*JB@  %  O  "@\ #
M X%<47T5Q(6ZSRRRNY9V65F>0L2[-(R^)BVXLS,<G)))J9UKGAQ'N&SVNGJU
MNVMRMZD;1,4B'11CK.E5K!=:^5V,U3:SL5S!(:ZL]LC1CY!)U6Z_:Y*:3<1[
M]MXD+ADZ22DQ2!=Q4@ 9/;(!]97.X#D<D>L&H6ZMV<1K*I8L5& VTLO=5?'3
M9AR"JL6R",<5<K<W(K4O']"ON-J3D_"I6A611A306O-D7\SA2*(S.^!RGKRI
M6I2,!,K]J*1Y4C(CH3G*T,N9!P"551GSM ..^2!_215Y9HX<=0D;LXPCMVQG
MT%;'<=\9]56=\X9P\'7T3L\FXDE*G/7NSZS@P2HFS5K7,7JD-5'MSKL7KQ*E
MGV#(.JBT167L[AI5UF,"1!?RJZ:"@L!+=*3=MV\X#=UQ@]CG..?5SS6/RNWV
M"3J>$N4'A<L77EE"!=Y*_A87 ]=6AW_8=?2+'2?,/1M]8G4V#.4""87VO2H)
MT.]4@OEJWQC>W/F(-50A90(MQ5I26EY%K$5B*E7<M8FCE6K1[%//;M/&UV$+
MW5P]A+9V6D/%%<"^O)I&2VCMA)&\]K+:O=3:D\EBR2R1VCB59(P2G3MC97UO
M:VEW'#::7#J:ZYJ7PEBN+FTET6P@A@\ON+CHS)9ZC%J$-E::+!;:K#-''=7T
M(M);>XE EV5IJ$63352.11)4A5$U$S@HFH0Y0,0Z9RB)3D.40,4Y1$#%$! >
M@YJD$$@@@@D$$8((X((/((/<5J @@$$$$ @@Y!!Y!!'!!'8UV$0#X1 /]X@&
M1@GL*FN@K)!\*J8?[SE#^T<G:Q[*3^0U&1[1[Q77QAO^'1^-)]+)V/\ N6_F
MG[*C<H[LH_*/MIXPW_#H_&D^EC8_[EOYI^RF]/W2_P X?;4@M4R:(K%AE62S
M87D9"2C]J"AB*)BX:,EUT0.F!RB<G>)E[10$!,'4.H=<W=-M1=ZC8VLJR"*X
MO+:"0J"&V2S(C[200#M8X.#@\UJ7]R;:QO+B)D,D%K/-&"007CB=UR 02,J,
MC/(K''7W*VL3G<1]V:^Q>2-V2>4D>\=02YQZ!VCFZ'=QPF,/VJQ7#=,.IE'A
M #/>:W_X;:C9[Y](D\XVXR>@VV.]1>^ .(KC ]:&.1CPL)KQ>C_#^PN]D.II
MY!.<#K+F2T=NW?F2')]3AT7\*7'-94LGK.1:HO8]VV?,W! 4;NFBZ;ANLF8.
MI3I+(F.FH40^ 2F$,^<2Q2P2/#/')#+&2KQ2HT<B,.X9& 92/80#7OHY(YD6
M6)TDC<;DDC8.CJ>Q5E)5A]8)%168ZO5H=Y:2I?(+7SO75X-,M(\\U6+5"SM:
MD"Q5GJ=PI5@C[54+96Y)5L];MIBOS\4Q?MR/V$C%/TTUHR:C).'>OH]S96*G
M(P>""",@@C!!^HBL<L:RH4;.,JP*G#*RD,K*?458 ^L'L002#:.N\-=:1L]7
M+1;+-?\ :T[!ZSW9JB3=;(E*Y),[?4]_3NO)R_-;%!0%6KE=;I".LJY$PD35
MHBM5N+AU)5MY#<+OA=)27/. %!96\((P4# 8Y)_").<G-4$" AF9Y"$EC)<J
M0RS,C,&4*J@>  !0J@$@@DYJD8GP>^A&M!V5K:QN[YL*L[5T/K+CK:0O=D:2
M\J- TZK?%-=NF$RTAXV0;W"N>S]X9G;%EW,L5Y UJ7[T)M@ZDG\]5L@C *LS
M# ];8SP<C'';ZR.V *BUBV/&Q9U>)(6WD$[(]^PYP#N&\X;OD*?2&3+(7P:?
M$AK5)FI7#7<9MMM)ZDU[H^-F=LPU0N-FINM]9ZZ2UQ7(2C3R]8:OJLH=L>5M
M<A(1ATWJ]UGI6:07:HEC&$<,LGJ8KRS>$D ECDDC.#ZA^( 5 LK?:5=!)\FD
M0,@#,J1IL4*< KZV)&#O8MD< 7_@N/50A;GI78"\_<9^V:,T[;=*5J6GI6.=
M+3U;NRVL7-@F;?XM$,PE+2Z<ZGK3@LDQ\E,RK.IHYXU3QQN#.I8D,,#Q,&/U
M$;L ?5XC^JLPC ,;;F)CC:,%B"6#=,DMQRQ,:G(QSGCGBE]B<1]6;,B.0$18
M'UO;$Y&2^O+%<'L/-,V3Z!L6JXRJ,*--4]0\6X09.(=U2J]-*-)QM8(F2DFB
MJ,I'/(=VYBE9$C+LQCP;@,CU-G.?QY/LJCV\;B4'<.L4+$'!#(%"%>"!C:IP
M002.002*J+C[QVK_ !Y8;%0B+OL784OM78BVT;M:=G2\',6"4MSFG4ZD.7"*
ME>KE7BX^.4AZ/">+Q#&*;QT8H"S:);L(HK.-9PS;L< !1M 4$#&2?62<Y)R<
MY/<\Y-6BB$0?#.YD<R,SD$EBJKQ@  808   ]6!@##B8_EH:1^;8O'_[DZGF
M3_Z?_P#;?_H5K'_W)?Y"W_YPE9N;\T'2^1-*84ZX/K1 .*];:YL&D7:BS0UV
M\Z_O]2<J.:[<:E,F;/VK668 X>,EF\G&RD-*Q,C)PTU%R,5(O&:V-6*'(P<@
M@@C((/<$>S]8/(P16S+$LRA6+##!U93AT=>S*><$<CD$$$@@@D58B)X!:?95
MYM&3%JVK=+4XY&ZSY2W#:-PM$3)[#V)M74CF"&D*6Q\VK;" 1JT3$UF!K3:K
M52N5B*8U^-3;1:;!VL[?.+=5LGA0-A0*!@!3G..<Y)).22<GGC K&+2/&"79
MC,D[2,P+O)&5V;CM VJ%"A5"@ < $DG(/:^D:AN.5TY,6IS-MW6C]N1.Z*>6
M&>-6B+FVPU6M]0:-YPCE@],\A31=UEU%F;4[!R=XFQ5*^(DBJ@XJK%=V,>)2
MIS["0>/KX%9GC5S&S9S%()5P?P@K(,\'(PYXXYQ5CI7@CIJ3OECO24G>XCV3
M\C=5\K7]0B)B';4Q#=>JX;R$E9X^*5KSAXR+>V2,:KL5JG)]+!)1+26:J1<D
MXE74C82L!C@^!H\G.=K'.,Y_!_!]@XY  &$VL99FRXW31SE01M$L8QN QD;\
M#?SXBH(P<YH2_P#@V-.WY]LR-'96_J?J+==JD+MN/CQ2=A1\1IO8=EGGB$C;
MG[U@ZJ\E=:LC>9!N60ND;KV[T^,L,@L_D';3QV5E%WDB5@%X4E1A6*^(#U>O
M!QZL@D>ZJO9QMU!OE6.5M\D2N!&[$Y8\J77>>7".H8Y)&2<Y1;OT-2=^TZMT
M>YKSC*%JVRM4;3BQKSUJQ>#8M.WRO[$JC9PL]822:D2M.5J/0EVQ$4W+N-,Y
M;MWC-=0CI*BL5.1CL1S[""#_ $^^L\D:RJ%;( >.08.#NC<.O<'C*@'ZLX(/
M-7KRM9*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*HK86N:/M
M>J/:/L:LQEOJ4B\A9!] RZ9UF#E[7)N.LD&Y53342,*D9.Q,;)MA X 5TS1.
M(& HE&02IR#@^T?7P?U55T612CJ&4D$@]B5(8>X@'\E4-L;C;HK;DM+SVR=8
M5>W3,_KYQJB<DI1JL+N8UPYL3"VJ4V45;KH"_@T[-&,YMJT==Z#*0(LNS,@9
MV[[^5=EX!(&=WXCC&1[#CCZQWJCPQ2$ET5B4,9)[E"P;:<=QN (]ASC&3FF-
MP\.N+^_Y]G:MQ:2HM[LS.$&L!/RL:HA+OJN+@SKV+34A&KL75@K .5%ERUV=
M5D84BKAT<C$IG;D5961T!"L0#W _I^H_6/J]E1+;03$-+$CL!@$CG'?:2,$K
MG\$Y7OQS5U9K5.MK#K&1TM*TBMK:FE::OKQ[KQO%MHZIFHSB)&"4J;>'C2-&
MC*""&'R8E'L2-V[=D!6[<B29"@%0Q#;LG<#NSZ\YSG/MSS5S&A0Q%%Z94H4P
M NPC!7 P ,<8'JKULFL:#<(>K0%GJL5-0U)L53MM3CGJ1SMX*R45X@_J$PP*
M50@IO(!XV;N(\YC'*FHD03%. =!!B"2#R00?Q'@^^I9%8*&4$*RLH/J9#E2/
MK!&1]=6MN_$/C)LG9;'<5ZTAKZS[+8*5]4+;*0:*K^06J3H7M37GT2&(PLSB
MJO.CJM.+$TE%H!<B:L2=F=),Q+"1U!4,0#D8^H]Q]6?7CO6-K>!Y!*\2-(,8
M8CGP^B3ZF*_@E@=IY&*]F/$OC3&[?<;\8:3U^UW ZE'D\M>4H) LH%DD8T(:
M1M:* B,:VM\C$ :*?VULQ2LCV.478NI15LX724=1]NS<=OLSQCV?B^KM06\(
MDZPB02$D[P.<D$%O9N()!;&X@X)Q5A]I>#BXU6/6'(:K:GU=KK4&PM[:BVYJ
MTFQ(>J%=>Q$-O0S]C8Y&$@$GK)C#M9.4=(3%BC*P:O$L3AJF,BL=0"*DLLSA
MD+,S*C*V,]]IR!GGMV&<X]58WLX"DRQQI&\T;QEPOH[P02!D  G!8+MW$<\X
M(N?JGA'Q>U#4+;4JII/73!KLFC,->[0%"O)'0O%4:Q+N*5J\@W?*O?%J<=&2
ME?%J@R.A7V)))T5JP3%4YC5:1V()8\$E>>Q)SG\?U]ZO';01JRK$@#KM?PCQ
MKC&TYSX<$@+Z(!( J&G^!?#JU1E%A[/QZUW88[6U?]B5/0FXQQ*'8U'RJ,Z%
M0D'#UVNZL=2+,&/(DK%F6F((CM154L>!EE>V$L@SAV&[OSW/;/U' [C!J#:6
MS! T*,(QM3<,X7.=ISG<N>=K97ZJR#KVN*+5+1<;I6ZO%0MIV"6LDN<RP0%!
MW824V)/!58CX -W(D@X<YHY@1%)(J38>QT-T 0J22 ">!G ]F>_OK,$569@
M&?;N/MVC"^X<"JVR*M3%*8I3%*8I3%*8I6#^D/Y9C?WYN'CC_GSNK.U;_>8_
MX/\ >:\-J7[=NOXT?U:W(9FK0K2]X8/[@/$S\Y3PK_S1+E9?O;_Q9_J5EM/O
M\?\ 'Q_VJ5GCG!KZ'3%*8I3%*8I3%*8I6#=<26A^==W;$2)/,;;KLUA6D%^B
MQJ-,1$5KV"\B13$Z95(PT[%)-92Q6%LJLVGB.:I!N4V;FNHFD=P/))9L+,/!
M:6TD:ZRK1Q)%>ZE.7?3IX9U^Z+B>*QCDAN+68&WM8HK>>V/5N[H5GEC@BM[5
M]4*7&IW3RGX+-'-<2W%CH%L677+>[M&!L[2TFUJ:.XT^\@*WM]<S:G;7@:VL
M=/-:F/!A[GA":FU]IX/"(ZW9VZ6E^1%5@^'3JM:QB;JPM%@V%MDM;C0MR*_M
MCD>HR3YA=6Y@;^-+MQ29@0T><!-69?$6Z1P A+\XP%7)QV[<>RN#82#I1Q^5
MIN)E M\('!+R8&<]3()W=NWU5+=/<C6%,XZ^#NXKUUOH2?V_JJ_\;]1[RX@;
M4U3<K!R)JFU*ILF AM@;HJ*,1<H-M56M$0)9=NL-D2U+LD',-1;VA*P WDCD
M4EER\SG?A@[+(K (5(.U&X.<\+@,/Q5$4P6&S@40F2-X(Y;:2-C,KJZAY4PX
MV[/%()"C CQ[N<5MKW;NOD1QZX[[:OFQ&^I;9M)_*PU#XXU;5,5<V2-EV-L>
M6:4G64!94+7)S3ETZ7N4W$.IIW$$29,:ZTF)%5MW3,YBX55&=0-P7NY8CA5&
M6(P!Z@<9[G K>DDFBAD=^FTA(6%8PPW.Y"1JP8G)+D9Q@!<GU5AG+U'7G@^]
MR^#KE=P7%G!ZEH6@N5^N+MNVW&.UK9^1NTY72^RIVWW&PKD,SA9_<,E6]JRC
M%Y(KH!)RJSN$:JG=/6K5>^3*LNT>(NC!1ZT =< >L+E?;BL!5+62T,C (D5P
MC2MPO6D,,A9F/"M*5E(R>3E1WKWT,A.5GP5%.<NZK(-4[?L_:=QKC>51<5F:
MKFN=J<HME7>CV:+=/F*SZERY]=66%>U5Z6./*Q;F4BV<7'K2BK)BJW6JWD(N
M;>*Z9YX8;1)Y&AM%U*3;%827D\?RL%K%=F-II(LR8&Q?3S74T.*_DMYFLKZX
MTU(K+4KS4I+2V2\U";0H1-<ZK:Z=I\VV"^O+C31*L%M=%;;&Z:8B.$UM]U?%
MMX/6FO(5I+)SS6)H]3C&LXDW%HE,MF,"P:H2B;4PF,V3D$DB.B(&,)DBJ@0P
MB)1S%+Y5U)/+G,E[O?RR0JJ&2ZW'RARB81"\N]BJ>%<X7@"H=["5FDTNW\DT
MR0E].M1(\PMK%CNM(!-+\I+TK<QQ]23QOMW-XB:CK'#O9-,2M"IB;L]/LBG8
MZ^D1Z=>@^CI_;F]8W,5N<R;N_!"Y_O\ 76C>023)MCQGV$X'K_V]U8^6;45T
ME>]\328>_$>G>2!$_O??'LB/_A_O_P!F>VT[X3:5;%3*9N.^V#//'JR!CU>W
M'Y*\??\ P?U&XW=)8N<XS*%]1&>!GU_J]56-E>,FUG;D54$(4"CUZB::3*/P
M]0_]5GM+?_Q#^#4:;6:[S]5H3_\ IUY.Y^ VORR%D6UQ]=R ?R> _P#8J5^Y
M9V[^!A/_ ,<)_P#\LS_&-\&/W5Y^AG_'6M^P'X1>RT_2O_\ BH"5XU[4B(R0
MEGJ,,#.,8NG[H4YDBB@-FB)UUA(3N@$Y^[3,)2@("8?>@(=<SVWP_P#@Y=7$
M%M"UWU;B:."+=:E5ZDKA$RV_@;F&3ZN]8I_@1KUO!-<2"U$<$4DTFVYRVR)2
M[8&SEL*<#/)X[58J-BY*9>(QT2P=R3]P;L(,V+=5TX5-_,1)$ISB ?"8>G0H
M=1,(  CGL;BXM[2)Y[J:*W@C&7EFD6.-1ZLNY"C)X SDG &2:\G!;SW4JPVT
M,D\SG"1Q(TCL?J503_<*SNT7I7:%3<H2\O:W-4C5#D77JC)1&3._ 0 3$D45
MP7B6)S%]Z*R!7;XI>T4IVJ@ 8/C/PQ^%GP>U.-[6UTV/4;A0434YE:W$/?!@
M9-ES, <D)(8H<X)64<5]9^"GP9UW3F6XN=0>Q@8AFTZ(K/U0>XF5]UO"Q!QN
M022CD9C;MF7GRNOI-,4K#*TT$[V3O*K;1DR^5E+Y5I:)DDTM?%(I"QRU=-9^
M[.XN*+E!.948S:_BYT$Q? _$SPB*CI<A/:6NHJD5@KZU$@AL+R&>,^7D]>47
M/DF0MH58P"2!=X8]/I^ L$4GU-M>!([0-J\2B.SGCDC)O21*XF$ .+5E)B#Q
MKN#'9L\.<#,,\H"*JLL+?CY.)D<;"K<TP#Q;6Q 0J3%"N$F8L +=A!(KI5E,
M&&/)U;N?&A,H<HN% +:/4=JP[]>A8KIMU!)SJ!W7LCW)@E/W%EMBO .J1N0I
MP#M!-ENV C!UN D64\;^.].;EVF,<F3:8)4.@W^DN.!@ UY*Z^*8ZPDX^S8%
M-LQI/)AXOK8.S3$T6I'$3T]FW0"G537,,:'\%/VQ,)^IQ# U+T<Z]%_[4]L>
M=1YOB7VS?M/U H.KZ8QP.*>6,>//4/[1,)\=\/NHEOE1]R]\''4'B^KM0FO2
M@=B)N/LX)4MFR4\Y#Q?6X][2UT94K*)$/9MT.1)1PP,$:;HU3[D!*<12)UGS
MDN)/_/8>=)CMTYU#B_4PEI_VGP2%D^5],[N1XC3RMO%_YU!S8+"OBO>+D&/=
M)^U>"0K_ "GI'<<^D:F5<H0M9BIKFT9,QJC#9MCG'LFJE0.[;5I^>R>QQ-0S
M6X.'2B4.J_@G LD4%@9 P[30BRK5 A\=SJ*O#=J-:AD$FEVMO'&/+LM=1BW\
MJ8;[154SA)UWLRF3J>/:'8C'/=[HKD#5X7#V,,2Q@WA+3*(>N1FU"@R*LJ[R
MPW%\,0&;&8JJJ2"2BZZB:***9U5EE3E32223*)U%%%#B!$TTR )CG,(%*4!,
M80 !'/&5YBM2FM;E5=^^%KM^RM13T9?->:(X5!I2^WFM.T9BHMMI7S<;"]Q]
M+CK$Q.M%2LS&U>"5D)M".=.@BC.4&;TR#T%&Y<[ K  PP6E+*#P=H7!./83P
M,X['N*YT;K-J+O&0Z16O2=UY42/*'"!NQ(5<G&<9Y(/!VWY@KHTQ2F*4Q2F*
M4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*
M4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*5@_I#^68W]^;AXX_Y\[JSM6_W
MF/\ @_WFO#:E^W;K^-']6MR&9JT*TO>&#^X#Q,_.4\*_\T2Y67[V_P#%G^I6
M6T^_Q_Q\?]JE9XYP:^ATQ2F*4Q2F*4Q2F*5@7R39(:KW1I[>\*_F()W9;34M
M<;!>(1SJ2@)JJ-7TDDQA9@L.W+*,UDFEJLEB:/Y9VZJS,E97'R4:RN815;8#
M+<)#;S0F.WL$U34Y-1B:<20*EB MM-%&S03Q7MU'91AIH&>':W3GB9U(WK%9
MDAU3R:>.ZO-4\R:/9:'<K9%+B>751))J5E<70CN+2XTRP\X,T=E=(;HW,?6M
M[B&.=6SAB9*(G8V/G(1XPE8F5:-Y&,E(Y9%TR?LG:15VSQHZ0$Z2[=PD<JB2
MR9S$.0P&*(@.:J.DB+)&RNCJ&1T(964C(96&001R"#6O<6\]I/-;7,,EO<6\
MCPSP3(T<L4L;%7CD1@&1T8$,K $$8-3'L$[0G[)>V( 43]D.T)0](%$W3KT
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M ,DG"@*!GU!0  !Z@  !P!BO;%13%*8I3%*E\M&-YF+DHAV*@-91BZCW(HF
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MLU>ZVEM8K FYF(BOR;>4:TZ-!%DQFG/CKEHPQR,K;=HY .YMH3<23^""0,#
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MJX1=$EM704K8MI;6OZ=9UG,3%<GEM>U2.O\ =;-&5>E,)6J0CF"K4 SCHBO
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M)*@E2P4D[BH[D<8]1P"03@X%9#=('*A)659%B:554QJ[XPI.X.>64,RHRJ2
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MQ=43$+8+[);!JLGKVC1]NAI37LAJ]],RE=@@6L]F=VRHKD86^6<S) L 9!*
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M:(%J=5M#.$5@7< Q7=% 4R=X5,5.A@*)P'F:E($-H&G>WB>X*RNDAB.T12$
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M9/OKZ>-=2:LO38%^L(BHO'MCG$?A$QD2"(_^?7/(5Z2M/7A4OX^I_P!),O\
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MV^2\DUJ)=R\@5LX>JH-2E[+9DT*!W3YXX5,FV9,FY1**[MVLBW2$Y"G5*8Y
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M6OV38%23NU4CSO?*5?41:.RN!<,7+=JX!E(&)'OC,G2J3HK-\<C=84@ QR&
MA@UKR*::WDCMY3!*VW;("P(PP)&Y?$NX C*\C-;%K)%%.DDT?5C7.Y, YRI
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M4JW30L@)9BH'JC& O8 9K6O-YNI@RA#U7"^ 1Y7J-M8X W$^MSDMZR:R)N%
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M2;)J*'.1ND951<R:!#&$J29EE55C$3 I15444$!.<PC; &< #)R?K. ,GVG
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M46M-S+@C(CB7DUR1HD-'$6?NE2,#)B IBR*=4P-1()2B04 3$H@ EZ" 9 1
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MOGH1OTPL9*&/)9(T=R$9E&]CP26W-AAL2732"3$<:--CK.IDR^&#XPSLB@L
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MHNGDO*.G+=,46[ES(.UUT$3$%,4D5E5CJ))B0QB"F0Q2B0PE$.@B& B $!%
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M28&.HH<P@4I"%$QA$  !$<$@ DD  9)/  '<D^H"@!)P!DG@ =R?97F(" B
M@(" B @(=! 0] @(#Z0$!] @/P8I7&*5$LV;N1=MF$>U<OGSUPBU9LF:"KEV
M[=.%"I(-FS9 IUEW"ZIBIHHI$.HHH8I"%,80 8)"@LQ"JH)9B0  !DDD\  <
MDG@"I +$*H)8D   DDDX  '))/  Y)KP.0Z1SIJ$,FHF8Q%$SE$AR'((E.0Y
M3 !BF*8!*8I@ 2B @( (9-1V[UV115<*IH()*+KK*$2111(915550P%(FFF0
M#'.H<P@4A"@)C&$  !$0#!( ))P!R2>P'M- "3@#)/  [D^RNABF(8Q#E$IB
MB)3%, E,4Q1Z"4P#T$! 0$! 0 0$.@XI7&*4Q2F*4Q2HL\>_28MY-1D[3C7;
MART:2!VRQ&+IVR(W4>-F[LQ 06<-$WC11RBFH91 CIN94I"KI":-REBH8;@
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MV[!\[1>N&C-VZ0C6Y7DBLW;K+(L&AW+=D1T]43(8C5N=XZ:M"KKF32,Y<MT
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M&KV=]YUC#UXQNMO*=P@!*,&VF-07P4)(.7W/@$9!(*MEJ(NKT7.VX,&TS'#
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MTI'JK)+(MVB:::JZ[QN5%XNJX/C%I;J' CX<QLY9W9G:%]\99F8LQ1@""2>
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M D1),F58T1I&5<-*P=SD^)@JH"<GC"HHP,#CMDDUC9V8(K'(C4J@X\*EF;'
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M#JRM&"&DZQP6!ZO'RBL"&1N.ZD$<X[FH6XF5E8.<K'TAD*1T\YV%2"K+GG#
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M[AYU.6"C)!3<F=CM&>59E)4X*D8K9DO)&2.-"458$A(PI)P"'VMC<JN#AE#
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M$I1!C(.72I#NN];HS4FF0B:Q$3%="!TS=TAW6188E,;*@4Q(T<>,@*C%"R@
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M44&P*.G+B;2%>&3.P3.=\U&60**\89VV0*_1 56IE4_?9(NK<LZB9,QAB_/
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M8+K.%6K<SU BAW#5J[<HJ(,GRZ2;)\J4"-'"PF(!D=U;RL$CF1V8%E"G.X
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MGG..:M52K%$PU/V_$R#DR+ZV4R"AX)(J"ZH.W[+9%(L+E$ZJ29TVP$B8:1<
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MG= (.L&WA-R@,5N>L!N!VY91W)P">2.:@SQ&^ZQ8](@+NVDX!@Z9.WTL*QY
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MG33_ )U%[S]E/-U]\UE_F_[T]L6C^LT7\</T,>=-/^=1>\_93S=??-9?YO\
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MK%TZ<JG7<.7#M5=PNLH83J+++*@91550XB8ZAS&.<PB8PB(B.0-3TX  74(
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M=U^9B^VGQJ:A]%6?YZ?[*><<-^(.G_*NP?LN/BVLOI.Z_,Q?;3XU-0^BK/\
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MTH-(U"YMC=0P"2(1RR@">W$[Q0%A-)%:M*+J:.+8_4>*%U0*Q8@*<1D#Q)Y
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M[W7GUK2[::2">[2.2&2.*8%)2D#RK&\77E$9BA202H$EE=(V8E Y=64;-O\
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M(26>145$@C-NBQ[B7)=V9$V@-GLM0TK2?([>&\FOHVUW3=3N9S:O EO;V!E
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M-.,>MMM5S9JC2(>**QDU<MK;RM42$(1)0II4B\'>:THZ<M.R"*JBS903'9J
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M,L9HE4.TL:HREE8NH4J!DL&)P5 Y)!P!SG%56"=V9%AE9T8(R+&Y97+;0K*
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M0,15HMQ3"4FUJS&"I6)L@2-D;J&27K[$3,0!W-H*E,FM%-^\?IJ%,0[<I@$
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MV[3;ZR7&ZV&8M=JL,DH560F[%8)!Q*S,J].0I"&<OY!TX<K=V1-,#JB":9"
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M.GI8&3DC0C]5:-=@O!3@1T^R*1-1]&-DW+8ZUHIXI^KTRQZ,SP2;D=,2H%+
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M(Q</>2VP6 =.>8B%6R$8,VS1T^';8RWES83MJ;:MT;Z"V^#MA>R16ZVEN]M
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M:2%Q9UJZ=,7+=ZR<N&;QHLFX:NVJRC=RV<(G Z2[==$Q%45DCE*=-5,Y3D.
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M165ED=6081@[!D S@*0<J.3P"!R?;7'EJ9ZD'RM)]4T9!L0?'W74C>7!<)5
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M#L6L2X76*X77C&XK=TP667(1955J1(ZBQ"J',8Y0,&WTTRS;$W.,.=HRX P
MQQE@!Q@YXK3ZDF$7J/MC),8W-A"3DE!G"DGDE<$GGO7J\L=AD7;^0D)Z9?/Y
M5L#*4>O)1\Z=R3,HH&*T?N5USK/&P"V;""#@ZB0"W0$"=4D^S CC4*JHBJIR
MJA5 4\\J , \GD8/)]M2TLK,S-)(S.NUV9V+.N0=K$DEERH.#D9 ]@J'-+RQ
MVP,CRDB9F#,L<#0SUR9L$>1\,H1B" JBD#,DF89$K4"=P5\(NP(#@14R=JYS
MM7.=V<#.[;MW9QG.WPY[[>.U5ZC[=N]]NW;MW';MW;]N,XV[_'CMN\6,\U$^
MR2Q=W#I>7IKNJ\H*L EY4?=W!JF5*N92')W_ &8Q05B$6$[($#"J0J@CVR@(
M1TX_&>FF9/OAVKX_5X^/%QQSFK=67"#J28B.8QO;$9SG*#/@.0#E<<UX-IN9
M9LW,>SEY-HP>N&KMXQ;/W2#-V[9*=ZR=.6R2I$5W#1414:K*D.HW4'MI&(;T
MY)1"0Q12R@@$J"0&&" 2,@$<$#@CO4"215**[JC$%E#,%8J<J2H."5/()&0>
MU1#"S62*>/I&+L$W&R$F1=.2?,)9^S>2";I3OG)'SINX37=D<*_95RKG4*LI
M[]0#&].0T<;*JM&C*N"JLBE5(& 5!! P.!CL.!4K-,C,Z2R([YWLKLK-DY.Y
M@06R>3DG)Y->"4W-(Q;J#1EY1&%?.$W;V'2D':<6\=H]CNG+J/(L#1PX2[M/
MNUED3J$[!.R8.R7I.Q"P<HI=055]HW*I[@-C(!]8!Q4"60(T8D<1L=S1AV",
MP[,RYVDC Y()XJ%9/WT:X*\CGCM@[(19,CIDX6:N")N$3MUR%70.FJ4BZ"JJ
M"Q0,!5$5#IG Q#F*,E5888!AP<$ C(.0<'V'D?74*S(0R,RL,@,I*D @@@$$
M'D$@^T$@\&N3R#]1JU8J/79V3%5=PR9G<K&:LUW0I"Z6:MQ.*3=5R*" KJ(D
M(=844N\,;NR=EM7);:-S !C@9(&< GN0,G /;)IN8J%+,54DJN3M4MC<0,X!
M.!D@9.!GL*]%9646-(F6DGZIIA4%I8RKQPH:46!QXV"TB)E!%\J#H1<@HY[T
MX.![[KWGOL@*HVX51L&$P!X1C&%X\(QQ@8XX[4+N=^78]0Y?+$[SG=E^?$=W
MBR<\\]ZB7%BL#MA'13J=F',7$'%2)C7$F]681B@B(BI',U%S-V1Q$QA$[9-(
MW41'KZ1R!'&&9PB!G&'8*H9A[&.,L/QDU8RRLJHTDC(G*(78JA]JJ3A?R 5"
MJ2DFMY0[Z1?*^5ERNI7O';@_E-R591P5Q(=I0?'5RN%55RJN>\4!9114#=LY
MC#;:HVX51M&%X'A&,87V#  P,<#%5+N=^78]0[GRQ.]LDY?GQ'))R<G))[FO
M5K-S+%@_BF4O)LXN5[H)2-:OW;=A) @;MH _9HJD;O.Y/[Y+QA-3NS>^)T'T
MY!1&979%+)G:Q4%ESWVDC(SZ\$9J1)(JLBNZH^-Z!F"OCMN4'#8]60<5<BQ[
MEM%DT[K/1RK.$BZ1K"R;!N<>2):NV\E8[?LD:VWGK':W*[]RWD9)M!T^KUJ(
M,T:1Z#&$AT4>Y6=.'CMQKQV<<=W<WH9VFN8[>%MQ!6.*VZACCB  *J7FED?)
M8L[D\  #:EOI9;&TL-L:06DMQ,NP,'EFN3&'DF)8AF5(HXH]JJ%1>Q8LQMX^
ML,_*.6+R3G)B1>1B+=M&NGTF]=N8]NT.*C5!BNX745:(ME!$[=) Z9$3B)DR
ME,/7,ZQHH951%#$E@J@!B>Y8 8)/K)[^NM5I97*L\DC,@ 0L[,5"]@I))4#U
M 8QZJBF]OMC23?S36T6)M,2B:B,G+-YJ21DY%);L=ZD_?IN2NG::O=D[PCA5
M0I^P3M /9#I!BB*JABC*+@JI12JD=BJD8&/5@#%6$\ZNT@FE$CC#N)'#L/8S
M [F' [D]JE))&032;HIOWA$6;Q21:(D=+E2:R"Q6Q5GS=,IP(@\5*S:%4=)
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M5-(H.1*45@/T#I'3CW%]B;SC+;5W'';+8R<>KGCU4ZLFT)U'V#< F]MH#<L
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M!K][C)!:O.9!S<R2280J)W""KF<CMU]4U9)[JU-C8]>WLDU'=Y9,8O)V,R=
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MQ2F*4Q2F*4Q2F*4Q2F*5>OCC]W35W];8[^U3.!\*?^'M6_DC_P!9:])\#_\
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M$>OI[ .B&C1,0OP%[:(GZ= ,<P@)A]Y#_P")-^B!9]/M9I .9(WFA#?64(E
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M_DT^*NT^FIOT2/\ U%/-PO/6RQ_)5']Y8^,NY^B8?TB7_)I\5=I]-3?HD?\
MJ*>;A>>MEC^2J/[RQ\9=S]$P_I$O^33XJ[3Z:F_1(_\ 44\W"\];+'\E4?WE
MCXR[GZ)A_2)?\FGQ5VGTU-^B1_ZBGFX7GK98_DJC^\L?&7<_1,/Z1+_DT^*N
MT^FIOT2/_44\W"\];+'\E4?WECXR[GZ)A_2)?\FGQ5VGTU-^B1_ZBGFX7GK9
M8_DJC^\L?&7<_1,/Z1+_ )-/BKM/IJ;]$C_U%/-PO/6RQ_)5']Y8^,NY^B8?
MTB7_ ":?%7:?34WZ)'_J*>;A>>MEC^2J/[RQ\9=S]$P_I$O^33XJ[3Z:F_1(
M_P#44\W"\];+'\E4?WECXR[GZ)A_2)?\FGQ5VGTU-^B1_P"HIYN%YZV6/Y*H
M_O+'QEW/T3#^D2_Y-/BKM/IJ;]$C_P!13S<+SULL?R51_>6/C+N?HF'](E_R
M:?%7:?34WZ)'_J*>;A>>MEC^2J/[RQ\9=S]$P_I$O^33XJ[3Z:F_1(_]13S<
M+SULL?R51_>6/C+N?HF'](E_R:?%7:?34WZ)'_J*>;A>>MEC^2J/[RQ\9=S]
M$P_I$O\ DT^*NT^FIOT2/_44\W"\];+'\E4?WECXR[GZ)A_2)?\ )I\5=I]-
M3?HD?^HIYN%YZV6/Y*H_O+'QEW/T3#^D2_Y-/BKM/IJ;]$C_ -13S<+SULL?
MR51_>6/C+N?HF'](E_R:?%7:?34WZ)'_ *BGFX7GK98_DJC^\L?&7<_1,/Z1
M+_DT^*NT^FIOT2/_ %%/-PO/6RQ_)5']Y8^,NY^B8?TB7_)I\5=I]-3?HD?^
MHIYN%YZV6/Y*H_O+'QEW/T3#^D2_Y-/BKM/IJ;]$C_U%/-PO/6RQ_)5']Y8^
M,NY^B8?TB7_)I\5=I]-3?HD?^HIYN%YZV6/Y*H_O+'QEW/T3#^D2_P"33XJ[
M3Z:F_1(_]13S<+SULL?R51_>6/C+N?HF'](E_P FGQ5VGTU-^B1_ZBGFX7GK
M98_DJC^\L?&7<_1,/Z1+_DT^*NT^FIOT2/\ U%/-PO/6RQ_)5']Y8^,NY^B8
M?TB7_)I\5=I]-3?HD?\ J*>;A>>MEC^2J/[RQ\9=S]$P_I$O^33XJ[3Z:F_1
M(_\ 44\W"\];+'\E4?WECXR[GZ)A_2)?\FGQ5VGTU-^B1_ZBGFX7GK98_DJC
M^\L?&7<_1,/Z1+_DT^*NT^FIOT2/_44\W"\];+'\E4?WECXR[GZ)A_2)?\FG
MQ5VGTU-^B1_ZBGFX7GK98_DJC^\L?&7<_1,/Z1+_ )-/BKM/IJ;]$C_U%/-P
MO/6RQ_)5']Y8^,NY^B8?TB7_ ":?%7:?34WZ)'_J*>;A>>MEC^2J/[RQ\9=S
M]$P_I$O^33XJ[3Z:F_1(_P#44\W"\];+'\E4?WECXR[GZ)A_2)?\FGQ5VGTU
M-^B1_P"HIYN%YZV6/Y*H_O+'QEW/T3#^D2_Y-/BKM/IJ;]$C_P!13S<+SULL
M?R51_>6/C+N?HF'](E_R:?%7:?34WZ)'_J*>;A>>MEC^2J/[RQ\9=S]$P_I$
MO^33XJ[3Z:F_1(_]13S<+SULL?R51_>6/C+N?HF'](E_R:?%7:?34WZ)'_J*
M>;A>>MEC^2J/[RQ\9=S]$P_I$O\ DT^*NT^FIOT2/_44\W"\];+'\E4?WECX
MR[GZ)A_2)?\ )I\5=I]-3?HD?^HJ<P7@Y&Y'Z)I68M\PV*<HF9,XEM$F6'KZ
M"*.1&1.5,W00/W2:2@EZ]A4ANALPW'_B3J#QLMO86L#D<22--/M^L)B(%AZM
MQ90>2I&16S:_^%VF)(&N=2N[F-2"8HXXK?=_\6?,S;3Z]NQL=F!YK=1PKX$2
M\C)P#!C4PK50BUTEBH%;JD*H/;*91==9<3KNG*O9 5G3E15PL8 %10P@4,\%
M>7MUJ-P]U>3//-)@M(Y&2!V557"HB_@HBJHS@*!D'Z)9V5IIEM':6,$=O;1#
M"11C')QEW8DN[MP7D=F=CRQ8G(^JFB5%E2JQ%UYDF4B+!JBCV2E  ZD(!1]'
M^T>H_P"SX,UJRGDD^VJQQ2J<GZM 6)N=&9C&KY,0$!*ND0_^S_O%'IZ!^$.@
MXI5G'?'[4BBQCGIT88QC"(B*)/\ 9_,0/Y\5.3[3[ZA?<]ZA]3(OXHOT<4R?
M:?>:>Y[U#ZF1?Q1?HXID^T^\T]SWJ'U,B_BB_1Q3)]I]YI[GO4/J9%_%%^CB
MF3[3[S3W/>H?4R+^*+]'%,GVGWFGN>]0^ID7\47Z.*9/M/O-/<]ZA]3(OXHO
MT<4R?:?>:>Y[U#ZF1?Q1?HXID^T^\T]SWJ'U,B_BB_1Q3)]I]YI[GO4/J9%_
M%%^CBF3[3[S3W/>H?4R+^*+]'%,GVGWFGN>]0^ID7\47Z.*9/M/O-/<]ZA]3
M(OXHOT<4R?:?>:>Y[U#ZF1?Q1?HXID^T^\T]SWJ'U,B_BB_1Q3)]I]YI[GO4
M/J9%_%%^CBF3[3[S3W/>H?4R+^*+]'%,GVGWFGN>]0^ID7\47Z.*9/M/O-/<
M]ZA]3(OXHOT<4R?:?>:>Y[U#ZF1?Q1?HXID^T^\T]SWJ'U,B_BB_1Q3)]I]Y
MI[GO4/J9%_%%^CBF3[3[S3W/>H?4R+^*+]'%,GVGWFGN>]0^ID7\47Z.*9/M
M/O-/<]ZA]3(OXHOT<4R?:?>:>Y[U#ZF1?Q1?HXID^T^\T]SWJ'U,B_BB_1Q3
M)]I]YI[GO4/J9%_%%^CBF3[3[S3W/>H?4R+^*+]'%,GVGWFGN>]0^ID7\47Z
M.*9/M/O-/<]ZA]3(OXHOT<4R?:?>:>Y[U#ZF1?Q1?HXID^T^\T]SWJ'U,B_B
MB_1Q3)]I]YI[GO4/J9%_%%^CBF3[3[S3W/>H?4R+^*+]'%,GVGWFGN>]0^ID
M7\47Z.*9/M/O-/<]ZA]3(OXHOT<4R?:?>:>Y[U#ZF1?Q1?HXID^T^\T]SWJ'
MU,B_BB_1Q3)]I]YI[GO4/J9%_%%^CBF3[3[S3W/>H?4R+^*+]'%,GVGWFGN>
M]0^ID7\47Z.*9/M/O-/<]ZA]3(OXHOT<4R?:?>:>Y[U#ZF1?Q1?HXID^T^\T
M]SWJ'U,B_BB_1Q3)]I]YI[GO4/J9%_%%^CBF3[3[S3W/>H?4R+^*+]'%,GVG
MWFGN>]0^ID7\47Z.*9/M/O-/<]ZA]3(OXHOT<4R?:?>:>Y[U#ZF1?Q1?HXID
M^T^\T]SWJ'U,B_BB_1Q3)]I]YI[GO4/J9%_%%^CBF3[3[S3W/>H?4R+^*+]'
M%,GVGWFGN>]0^ID7\47Z.*9/M/O-/<]ZA]3(OXHOT<4R?:?>:>Y[U#ZF1?Q1
M?HXID^T^\T]SWJ'U,B_BB_1Q3)]I]YI[GO4/J9%_%%^CBF3[3[S3W/>H?4R+
M^*+]'%,GVGWFGN>]0^ID7\47Z.*9/M/O-/<]ZA]3(OXHOT<4R?:?>:>Y[U#Z
MF1?Q1?HXID^T^\T]SWJ'U,B_BB_1Q3)]I]YI[GO4/J9%_%%^CBF3[3[S3W/>
MH?4R+^*+]'%,GVGWFGN>]0^ID7\47Z.*9/M/O-/<]ZA]3(OXHOT<4R?:?>:>
MY[U#ZF1?Q1?HXID^T^\T]SWJ'U,B_BB_1Q3)]I]YI[GO4/J9%_%%^CBF3[3[
MS46ST!J1%8JB=.BRG*8! 01)U ?A^^7_ &?VXP.^.?;3<>V3_P!_]_\ >:O+
@!5J#K[8B,/&M6*8%  *@D0G3]$H?_/\ XXJ*J#%*_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g459793g00a06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g459793g00a06.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2)^4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (F*^B (X0DE-! 0      %<< 5H  QLE1QP"   "&  < G@ $U5P9&%T
M960@1FEG=7)E(#4M,#(< @4 $U5P9&%T960@1FEG=7)E(#4M,#(< C< "#(P
M,C,P-S(X' (\  8Q,S4T,34 .$))300E       0E<Y*]/3QB^TY%:3:TC;?
M#CA"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /<')I
M;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M#W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4
M<       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0
M<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P
M<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O
M;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
M3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O
M;VP      $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B
M0&_@            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M         $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M             %)S;'15;G1&(U!X;$!Y,&Z0        "G9E8W1O<D1A=&%B
M;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C
M4FQT                5&]P(%5N=$8C4FQT                4V-L(%5N
M=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R
M;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M   -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M    .$))30/M       0 [_^-0 "  (#O_XU  (  CA"24T$)@      #@
M           _@   .$))300-       $    'CA"24T$&0      !    !XX
M0DE- _,       D           $ .$))32<0       *  $          CA"
M24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M 0 R     0!:    !@       0 U     0 M    !@       3A"24T#^
M    <   _____________________________P/H     /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H   X0DE-! @      !     !   "
M0    D      .$))300>       $     #A"24T$&@     #-0    8
M        !D8   G3          $                          0
M       )TP  !D8                      0
M   0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"
M=&]M;&]N9P  !D8     4F=H=&QO;F<   G3    !G-L:6-E<U9L3',    !
M3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M!V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I
M;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
M    26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O
M<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   9&
M %)G:'1L;VYG   )TP    -U<FQ415A4     0       &YU;&Q415A4
M 0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .
M8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       )
M:&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=
M  EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.
M;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M      QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
M     #A"24T$*       #     (_\        #A"24T$$0       0$ .$))
M3004       $    !3A"24T$#      /%P    $   "@    9@   >   +]
M   .^P 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_; (0
M# @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,
M# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\  $0@
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M ,L.UV@<]2ZW_P C9_\ X6N_\]O69]1_^06?\;;_ -4B(CVS+K8"J])/BO\
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MN3^OK]SL(1'IV6-!\?;2_=_TEH_4NRRSIMYL>ZP_:7:O<7'Z%1Y>F3\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M[G\)_%5B_, #W-*X^Y_"?Q58OS  ]S2N/N?PG\56+\P /<TKC[G\)_%5B_,
M#W-*X^Y_"?Q58OS  ]S2N/N?PG\56+\P /<TKC[G\)_%5B_, #W-*X^Y_"?Q
M58OS  ]S2N/N?PG\56+\P /<TKC[G\)_%5B_, #W-*X^Y_"?Q58OS  ]S2N/
MN?PG\56+\P /<TKC[G\)_%5B_, #W-*X^Y_"?Q58OS  ]S2N/N?PG\56+\P
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M,G?T)"1)(&50J;BGR+2 I$W;/L5>&1V4M30K6*&I&%_@(*I]\QF^8LF^L$2
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M9RXQM22*)22,DFQRPH*K+VU<T[<POZTZS/%Y41]^_G^KG\7.WD [
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MJ:_)8PRF(Y)RSK69^K /;>^A8+R\7^*TN\8MX@
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M*8CDG+.M9GZL ]M[Z%@O+Q?XK2[QBWB
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M!Q'%'BCMSLS <@                ""J??,9OF+)OK!$@$Z
M                 4S=G(2G>.C U2FZ)JF@["^/&&!J<%34_NVBMWV1*W'"
M/4F/M3LI+VRB0JC_ %4\@HCH3G3U7U3;33;)Y7D^99U>N8?+,+5BKUJU-ZY1
M3<LVYIMQ531-6MZY;IF.%53&D3,[]=-(F7LP> Q>85UV\'9F]711\)53%=NC
M2CA13KK<KHB=]41I$S._BTU8(QKM)^$B&WK4D2J]6LEE?XY6")H7[1"Q=BUJ
MIBQ-O98G0O2'['EY1^RB#R]CBB]-_7&OJ.QGDF>1*[^Q.U%66X"S3E5R;MK$
M8^NY1\9P6M--V,'%N9GXSI/"^#KTTG6.#OB-8US=W9[.*L+A;<8.9KM58B:Z
M?AL-^C%=5N:=\WM)UBF?DS/%OTUALBKVP8?:L,C]A0!Z*D4.E*++BP/9*5>B
M*<46#SDV3]$KHE0KR,8/3G%^0J2$&==,Y\CR<ZYS"L9@\3@,3>P>+M39Q.'K
MX%ZU-5%<T5:15I-5NJNB=TQ.M-4QOXT>Q%B[A;US#WZ/@[UJK@W*.%35P9TB
M=.%1-5,[IB=8F83(>9\0                           %?E&$DS">FJ2\
MFIBHG$3#RM<8VV,(T,F>QI>-=MM=<YWTQMKC&<ZZYZXQG;&.N<=J.%PZ>#.E
M7"IX,Z\56L:3SZ:3X/J<Q3PYBG=^E,4[^+?NW^!SK_HS>Q__ ,2&7?N<UI_]
M5Q?7\E]U/_QC;_X[&_\ ZYEO^BZS_9LH^W$?^W/T9O8__P")#+OW.:T_^JX?
MR7W4_P#QC;_X[&__ *X_Z+K/]FRC[<1_[=L_OW]#G).,O&.[%-CRCBXVUZ\5
MK/N,4LB4:;9+/8S(I?7KQ"6*M&2KT[!8VEDFR^N9C(H:[UHQ,,F7.*$PYS83
M$SI'FU_;:3S:C%6\TS&C'7OC.-HQN*IQ>(BJJKX?$Q>KB_>X55-%57PESA5Z
MU4TS.NLTQ.YC+N$C 7+F!B*(C"5U8:(MZ_!Q%F9MQ%'"BF>!'!TIUB)TTW0]
MRBJCKB;\=BG>C.6-DN$!L7/))^MRU4"*OVJ6VC9UJ^SD<F4XFYSS736Y5C-Z
M6EB9<3'8E'VB!$P57%6Z$RN/*FJ-^PY>/[2^:FN#VU>O<;<:1X[=HW:-A,$*
MHS1@K>)**(X]UXDB,17Z%QN#WI5/D\9("1:L89%[:<0R2]N.G]121R5;Z/GL
MX>K2^4&;5)<95%963/+LL*W9K>MRSZ)Q&O%,SE[/"8LWQ>N(0Y2-]8X5#(E
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MU!)QV="S=-M@VZ@                   @JGWS&;YBR;ZP1(!.@
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M,<?9S]ONW^(9>CD                  !!5/OF,WS%DWU@B0"=
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ML-83Y(V,?(2D[&-S9%2)GQH)*-;9<V/\\CF%SHQI'7V%(>$2W8-GX
M(*I]\QF^8LF^L$2 3H                            !I [=?X.U1?323
M]1I<+1[E7+.8^C)]ZPZ8[&?3L7U3]M:<MPO?P]NT?NU6.[=>S@^ _P <_F,9
M_'[T-7ML^^C.NM_LK:G]H.6<?YZ/9T,VQ&&'
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M9M'(OQZK*MURY4;"Y!)&;R#'V)..2L%N&=_4=RO+TQOY>,<ZZ_X3'K&WX
M    $%4^^8S?,63?6") )T                             T@=NO\':H
MOII)^HTN%H]RKEG,?1D^]8=,=C/IV+ZI^VM.6X7Q.G3S=M>+P\W1QZZK'=NO
M9P? ?XY_,8S^/WH:N[:=].==;GV5M3^T'+./\]'LZ&;8C##@
M               (2U_;_,?F]"?V_74Q_P!73^F<@)L
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MU[.#X#_'/YC&?Q^]#5S;/OHSKK?[*VI_:#EG'^>CV=#-L1AAP
M                $):_M_F/S>A/G_XU,/-XX_)Z/. FP
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MW7LX/@/\<_F,9_'[T-7-M.^G.NMS[*VI_:#EG'^>CV=#-L1AAP
M                 $):_M^F/S>A/\*F'X?Z>'=UR$V
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MB=5K<>H39-)SMC!I>#,[EYSC&^N,YP(PP[[0
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M* MX   %)OOPC:L^A._?KWQL&3M<C8_TGE/NN=/;;Y.Q77<![#,EV#&/$
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M_=K"H=HN6L?YRW[&TSH[.OX:= ]^,_W4N?AYNL3D'_5Z,9\^?'.!%6%=D
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MMZ?CR/@                    A+7C'M_F.?3'H3U_SJ8>8.W;M FP
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MH=HN6L?YRW[&TSG[.OK^C4H'KU^VESZ_+[4Y#T^/PZ]?CSU\/&*L*[(0
M%(4/^H,^^F^[/Y2) ,IFWSV$]%Y7[E9>['_+P_4<%[O0N\8MX0
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M                    A+7]OTQS_P GH3_"IA_W_P!.H=NW\1-@
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ML@     4A0_Z@S[Z;[L_E(D RF;?/83T7E?N5E[L?\O#]1P7N]"[QBWA
M                0EK^W^8>CVNPG^%3'\(";
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M^C]X0B+S)HK7L?A\)B:*+5XS,L9BR%B@K4UZ$(B"5*E5D[=2<JP3E*E2AML
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M':+EK'^<M^QM,Z.SK^&I077_ ,Z73IGPS]JDASX=V?/GS=/1T[^L585V0
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M.CJ                  "$M?V_3#YO0G^%3#O\ Z>@!-@
M         <?/:37<UQCGM.E_)KE'9=+RREN9W9IN/$6GW>TWFHZ!D/$I_L&F
M5/(&XR&HE8Q1.V79/*5%LLUHO$G7/!D"CD7+).2HF-MRH1G'[^WW_<W2]FIR
M(4\EK4[0R?5]8\IMWB7KR9C#=QIL%\='I]C3@H2TM B+T9JG?'O.^[A5#';A
M+SK&/84PV)IEJUZ(C!F6O4O30YZ?N^R&V$       $%4^^8S?,63?6") )T
M         *WN3WH;5^C><_5AT'MRWE' ==POM[;T83Z7A>L6?:4OS]QMYV[<
M^[C]<;EX);%N_*['_JW_ ,Q^WCIYO.*=[K?S>0>7FGJR]!=MOD9;Y6+]6'2[
MITQG/7/?UZ]^.N?P=^>[QS^'KT\],("[E^/GO"4A]$%:_4QE 6\  -<_:R_
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M5]CHZ@                  A+7]OTP^;T)^3^^IA_3/X/2 FP
M             -,;/=])6?S9YQ<7N?CMQ_=$E8RZF9EQ,J/D-"Z@):3*1D-(
MQ99)++KMVGC&6Y3U4Y6WK8+/,EF'1[S#54=0LZ<MF2[[E*';MVYA;79W<C\7
MW97.IAKB4Q6?<3Z0OJ%5EQCF4$CL398,2V)Z4@;M:M>0QSA3.S,4NC%=6:N>
M6YJDA6KH8<6X[-^'UU2-Z0_ ;0@       053[YC-\Q9-]8(D G0
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MVL*AVBY:Q_G+?L;3.?LZL?[]2@OG2YYZ=?-[4Y!TZ=,Y]/G\W3IYQ%6%=D(
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M=736                  (4U_;],/F]"OX5, _,34
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M,/ZMF5&9@\C];99V]:WZ::>ST4]4P?JM<W+8S;.WDYTV+W*QKC&V-M=LYQG
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MACNQ^UT=736                  (2U]?;],>OA[7H3T_SJ8=0$V
M               '^9SC&,YSG&,8[\YSGIC&/3G.? !HXE3[RA[/_F-S M:+
M\*+:YDT3S.E-6VPU3+CBZ0%?:M83R#4_$:<>*TGL'G$DB:YUB*A/!T<MB,I8
MW)0V,I;\YM*M,8O.,R4&079OUA?I4IYB<K^1-5)N/4OYDW)#)Q'^/6DE9Y:]
M5K ZPJ6)5-%U\]>HYN;'M[*G::-FR>6H6A0K):M#FIM5JLN*98E2!M&
M  !!5/OF,WS%DWU@B0'/]GCY^T?6G0        #D1[:[X:6?HE@G\+D8VW[B
M_>73Z5Q_X;"J-L.6:NK6/56U'Z?I]?V6OY<"U;WS5WS=?X98;*>5<L](8+WF
MT]X5Y]W\?R_>WH2V+9[UWAX)N_T9QZXZ9[OCQC_2*=[K7R,@W?\ :S3?T[LO
M]7YH-MM\C+=__;Q>[ZL-O^O\DOZ]^,],XQW9\.OCUQXX[_/Y^_\ )FF$ =RW
M'SWA*0^B&M?J8R@+>  &N?M9?@!7O]\JW^66O1,^Y]WW95XL?^K<9T\7CYF>
MV8Y<P/\ >?<\0XQQLMNW^+C[<\\71Q\:VD[C6.K?OX_WT;X=,>)9&._S]/#P
MQGITS\F-?NZE.NT=CT3A?M^,8S7GGGW\W3ISS6>V7*EGJ-KV^)6U5WOFUU\<
M[B&<=^?_ #@;^O3KWYQG.>[KU[NOGZBMT3=W8#QG?8C?O>_[W(YIXX\<>MQ5
MQ3XI]3\Z<[[*;]\W_?9'Z'J ?V1X[?)C\HP6?_1K/G_V=:Y.XKR_FOH>KWW"
M/9$5CGU\.GAG=]G']FYLHLAF[FQ'X8ZE;=>[_P!)OGQ[^_/3/3N\?-USU&L&
MV_?5G/6+?NUGQ>I4.T7+6/\ .6_8VF<_9U]?T:E!=^/MJ<\YQXYZ^U.0?+X9
M[NO7O_+%6%=D(  HVV/? XR?35(O^CI?0SF4\G[3>A<-_P"H\A>+%?2,MZW=
M]PQK07V\?OHT!\P9;]8D(M3N3_0,XZWAYU_V-?KZ?$M#8KZ-CO/VO9RT*BVH
MXXW1QQKT=I^Q-5M:].FGR8QW9Z8\,>'?USG'GQC'?G/3T==.+GSESRZOQ2HF
MOY=7E5>N6XOL5,9QR3LCXJ0>,>'_ "[@&?3GT]_FSX]^1T=736
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M3NZ8[O'S]_05NB;NZ >,[[$;][W_ 'N1S3QQXX];BKBGQ3ZGYTYWV4W[YO\
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M7XI?7'S= !"6OK[?YCZ/:]">G^=3#^GF 38
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M !2^%SYRYY=7XI?7'S= !"6O[?IC\WH3_"IA_3K_ *.[KD)L
M                      (*I]\QF^8LF^L$2 3H        !R(]M=\-+/T2
MP3^%R,;;]Q?O+I]*X_\ #851MARS5U:QZJVH_3]/K^RU_+@6K>^:N^;K_#+#
M93RKEGI#!>\VGO"O/']O/IZNW&WH2V+>*[_)>O?C'=U/]/=GY/2*>[K?S>0>
M5FGX<NX^W[Y@NVWR,M\K%^K#I;W>G'Q8SU[O#N\^/3WYQYNOG%+H"[F./GO"
M4A]$-:_4QE 6\ XU.=O)CDA&.7?(*,1CD%=\9CC+8[NB9V&-VQ/6%H:D9.A'
MJ2-N;VE_1I424ORMO(3)BBR=<YSG&G4;C[#[-[.XG9+9_$XG(,DQ.(O9;8KO
M7\1E6 OWKM=43K7<N7</7775//57,U=,JASK,<PM9KC[=K'XRW;HQ-RFBBWB
MK]%%-,3NBFFFN*:8CHB(AA$OO6\'V(XKI_N>VI! ,HFIM]I#_9,T>XEAO83$
MA[(AUCKH]JVC5&T'MZ YM3:I,$HC420Q-H7NF(VTD>99'DEBUB,PL9-E-C'\
M/X7X[8RW!6<7\)?O4TW[GQFU8HO<.]3<N4W:N'PKD5UQ5,Q5.LF[F6.QMS;3
M)+%S&8JNQ-.8T_ UXB[5:X-&48Z:*?@YKFC@T333-,<'2F:8F(B8C2MQ'>WY
M]NAM@G<:S_M>9_ZT9TZ^?/J9.>[&//W].O\ IQY]?^ZEWQV)Z<JPWO.,C?\
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M7(N(\YA_;4.Q0:WJI $):\?W?3'XX]"?X5,,?)YOE]/F 38
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MV(W[WO\ O<CFGCCQQZW%7%/BGU/SISOLIOWS?]]D?H>H!_9'CM\F/RC!9_\
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MQ'G,/[:AV*#7!5( A37]OTP^;T)_A4P_#_J]'G 34
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MYZ]1T=736             X(N3_PEN0_TYVU]?I -M,BY$R;3_567:Z\4_\
M5+,_9NXEUY;R=@.I87V%MF3V/WPZ:Z^:]D?4IW$:[HW>IC?/X+WJTQ6U7(N(
M\YA_;4.Q0:X*I $):_M^F'A]KT)^7^^IAX_Z@$V
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MBE1-?RZO*J]<MQG8J=<\D['SG[B#SW]V>O\ =Y .OAYO1^4='5TU@
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M-:8DB)/=6)[8<GJ49TF-5%D$/B!N4'X(+6)<F&DD[DXR=IIZIG?&VN L4
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M11LK*TJ./!RQET<W+"+UX<&7@
M       Q>Y>5*ZW/5,;BC0_QF-*&3D)Q3M!4YRQ:H;VDQIIODQ4]KO+22I3(
MUN_LX_M4.5L493&%%IELC<6M&K5HDR@U62&4(       -<-R<<KDN7D)7,LQ
M5O'"MFBLKGKVQ$G*"-322NG):0U[ UQ+PMJ;VJZ4W&TK&W6&7JKKZ:X777*X
MSF!N;NI3QM:[+D21E#8\       #3A7? N\(O<%;'N3=0**,UCR]NKE&KY1,
M3U)S^4-L1ZU'6UG9)3LOC!]<-[8U)RT-D-$ E\D.N.6LSS Z]CZ5F@[,>H;4
ML/#<>      ,:>3%+2.ZD5'IHXYLC9O6/)>E[I>MGLU<5JNCE;2 YV>&QK]8
M(5^3'M:09@MM*5X2(=SL9PJ7)=.F^0Q'G'#V^'B47E5+ NJO;C)R/Y+5MR2F
MDO=9)*$MNPDB.J*C=;+J9@@"2#K8K*T5CO50%9:IXOL>,JX@UV%)"S(L^*XP
MQF/ ;3@     !C=(::D3ORZJ/D$G<F4N*5_QVY!5 ZM!QJ[$A5R"VK'XV3)A
M<6\G1 8V[L[>W4S(DSN:I<DJTI:Y,NJ)$M(-7'H0QLK+C':BOEQ$.2,WJCC;
M0".N*VMJOC":!E#[+Y9>RBSG^$.29?93DOI^GDC+%(EI##'YGBZG%@.>\OD!
MRTJ0M29K4YDP;)     'KK$^RI(J2Z*5"+=2F/3Z+$F2M5:38XK8O52EV/*/
M(U4$9VP:1DX@XK!NFN3"C-.NFP:E*Q[-2=<?+[I"TZJY.6[/H32]+<HHFG@%
MTO558,D\^O"4U!,4'M@D<%X[-,C=HW+I1"'^8V],WE]<[,<9HBASV@7NQ*V;
MH'L+MXO\<+&@=[V/>,KK2A>.K-,*UC$!S2G'*4/,OBTKD[-*'V1N%PSQY6U1
M2349+\(W5/$F$E! U;MHPEKC7Z7NFA[.RQT-@P    #'GEI0J/E'QEO7CNM=
M2V$NXJQEL$(?#T>SBF9G)\:E"=H=EC;H>FV<D+<Z^LUBYMU4IMG!(2<CPH(R
M=ZKH&O3^IQ3V]I]([(O%VCG%,S:-<;HPQP'A-+F>11V2K>-\BL^71R5V0?<'
M'QMBS^V$2&P6DR%0!76;KI#R(%'%ITN=5'J+<TAEMP<XN3SBO$+@CL^N:57*
MML3D)<-M-#I)S8D:>UL4_FKO(6S"G,4K>N$^DH=TR\ISFY6J%>RER4Q7I%]T
M+)A.DU#-L                                          <CG^RH^5=
MX--!-'&#CDTS'*-I<:WN[E1:46W/;FJL(@=8S7%J A;G*-#4R9ODUCW!E')F
MYF2+2Y,4WU\D>=$6T;5.2],<3]F_M]_@G\XWY=F[R7G7)_BK")+=,/>:VY*5
MZ8?4/)VM9(V[L[[#KP@B9&CDQJALVTU*(:)RWJ&:S(B:B,5MJF(31C.0KUI6
M?5]CEGB             _G?;737;??;73337.V^^^<:ZZZZXSG;;;;.<8UUU
MQC.<YSG&,8QG.<] ',[V>_;Q1;F%VL_++AT8[M/N,*R\-G#=])T2EXE3Q2Z-
MQ1VQGV0*\HQWULXK1UL2%;FY)+11*([)=M/9!=C0TXUWS'BTZ9\73'\73(#D
M
M                   !H2_V2.V-R'LC^1RM$WHD:IXLWC(O=E*5*0G4.BXG
MD#4;84M<3BB]#%JLIM;T#>6H4[&G:(421)KO@A,27H&^ EM;TZU:Y$($9#BX
MEI"7!>2E(+6KRD&#]4)2Q5IIJ>J+184J<)-#S-]4^%!V"<:8-W\H/=
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MVQG.-M=L9QG&<9SC.,XSC/0!_0  ^))9-&X9'GN73"0,D3BD::USY(Y/)75
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MHB%;N]8.UQ2J1\IYSS&J#C!:%@'3OCTKX[0!!,*TM+D$MG'%.>):Z2QR(J+
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M59H[LQ<==M%;4A4:ND?*]>^I,3CJ<1OA:S%^R3CZFV*<&HM/7ZWR2,>NC_5
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MG&IU24XH\DS<O?7;(?:
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M@G8K!#>;NE*+R#EE(
-              __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g459793g00a07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g459793g00a07.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1R$4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '&B^<G(X0DE-! 0      $<< 5H  QLE1QP"   "&  < G@ "T9I9W5R
M92 V+3 R' (%  M&:6=U<F4@-BTP,AP"-P (,C R,S W,C@< CP !C$S-34S
M-  X0DE-!"4      !"75$L7+-+]\+XG\4W5^D0J.$))300Z      #E
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M<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
M    0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T
M=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,
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M;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT
M;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #
MO_XU  (  @.__C4  @ ".$))300F       .             #^    X0DE-
M! T       0    >.$))3009       $    'CA"24T#\P      "0
M     0 X0DE-)Q        H  0         ".$))30/U      !( "]F9@ !
M &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M   ! #4    ! "T    &       !.$))30/X      !P  #_____________
M________________ ^@     _____________________________P/H
M /____________________________\#Z     #_____________________
M________ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M      0     .$))300:      ,U    !@             !Y@  "=D
M     0                         !              G9   !Y@
M               !                         !     !        ;G5L
M;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @
M;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   !Y@    !2
M9VAT;&]N9P  "=D    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L
M:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M    !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T
M960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD
M<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE
M9G1L;VYG          !"=&]M;&]N9P   >8     4F=H=&QO;F<   G9
M W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G951%6%0
M   !       &86QT5&%G5$585     $       YC96QL5&5X=$ES2%1-3&)O
M;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M
M#T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N=6T
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M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  ? * # 2(  A$! Q$!_]T
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M.ROV;F6W @8U)>2>Y<]K3!_E>JA:XA__T/2<[T+V/Q<C%LR*70'PV6\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
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M6<*%0;I&65,1!NFJX7."9#"5%!)190P 1),YS%*-=5+,JC&6(49( R3@9)(
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M%-%7&O20IRG+$J#*3:6=G/1\BX\\$6#V.*@^1=&268G(X*D8-%_&G_Y30_\
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M^73OWJP6[>-CXNU86CT&6^.4=&=JJE4\_;OM0_@R%6,F00!+"9.#B!>H2FY
M?D(!J>.^D<^\B=<<$CMGN3^^U5I-*A4X$TGU"'&<X_\ 4>GQX[$]8]L/CQ>,
M##W6,JK?>T\<)R<6T=IJ'VZ[5_:/:W2CH"I ),+@D*8IMPX 2]93F'D3!QJR
M;@A2<+QGOC]X_7ZBJQLDWA=[\C/0$YQD=!R"?KBNR3\=/Q?V[]:/D]\#DCA
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M=$@O(R-B0C_VEB5A%*W8M)&S$<$D51FTO3[B8SS6D4DIQN=@?>P, NH(5S@
M992<  \ 5<E$1$3 1C&%@HN/A8>,;),XV)B63:.C8]H@4"(M63%FFBU:MTB
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M>OR'IFIV^B4&*;Q$,_&+R'5LQM(B ]7YWY;\(B80ZOXPB(_?]_/;75'W_?\
M7U_MTKAR]0<]03CTY_8^GT'T+-9J*FE*:4II2FE*:4II2FE*:4K2Y^F%<?5[
MP[Q'T+>-Q)A["/8L)AX1Y !+SV#T$0 1X ?7G4<API^8^7UZ_H,GH.M2P\2
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MUR/J,$>G!Z=>!UQ1B>U)@A(@$G38V405<B4ZZ<2U?(J(K+"FD<?,0!;R!(<
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M178'I[I;'Z' )/?MSQ5,2=:;'>G.=RFZ2.4#@[!)5J!A'DP]2:Y!6,H8H?$
M@)0-W%0_(FTK0(2,DE3Z=Q]0:P]>*Y*,H;;+F7RC" -\;W @ F;C^$- R92'
M'A-0.!5Z/,'^"$2%*3S>.HIX@_\ .0#_ %J/ED@$XY'/)_4U.BD0R\\#/4?
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MJ:'R[B1_76^Z3+"13+XVA<!2:HSZV!LKQK<R*61,C7AJ]&Q8AIR#^.L^(E9
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M'+;Y688QEL8P1C/4$?UXZGX5WF&V.(=&4#&1@\#&3R<\_OFL["=@X*(<^O\
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M*F4PAD<?[TJB?#*CKJFURI-T%%[";%)][&2.URLVM!R69-)N'4JXR%;,/-5
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M1UZ_/ Z=/ECXXJU')F)V$I:I^2*P5/[2_<G*)DP.H!05.4A3FZ0*8X% .H0
M"B/< #U'L0!DA(X/ SCC.,# P,=NAS\..G(FDS+G;P"?D.IZ^GIZ'/IBHD<8
M3*Z $DXY<H*""9A%,2IB01[D,)@ G B =S" =^.?0!K3!@6;;QU///Z@Y^@^
M_-68F!P,X&?AUY([=<? <\]JDVE;88<CEHZFO*8H <BB#1HEYRSL2J" CYP(
M@V*F!@ AS]:A@$!#H$.=<B::3)7RB<]P>N0<=OCTQ5^.)<!A,,-R<#(X/0C(
MS\?[5=]88.!H.&+K!1B -8]S6IN<DT2K*J"Z6AH9T\:,TP5 IDD5EVJ2L@X
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MMTD1;MF\^DU9,&+-$")((IIH-FZ12)D(F0I0R 6(5026(  ZDDX 'Q)XK!(
M)/  R3Z 5U=5V&>'A>J]6;73\.8[LE<NE>C;94YF)L=G=L;#69=BRDXR=B54
M[*/MD8]CY*/>(.T0,D9!ZU4Z@!9/JDEAF@DEBFC>.2&1HI592#'*C,K(WHP9
M6!'JI]*PK*P!5@0P#+@]00"".^,$&J/@-H_AGVB]63&L#AVL2-RIT].5>S1B
M;3*B;6&GZY5L:W27BWDZX=)5\KA"L9?QW*M^B4.G)$L!F\8=X]AI]O%S26-U
M%!'<R1;89HXY8G,D67CDDN84=4#F3!DM+A3[GNF/+8#H6U$T;.4#992RD8;
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M=)I6,*HU2A)[(]=96BV4:PMF;M!")FHEY).4G,<Q4,Q7K+AD]C7"8N'[2/\
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MW[KD#<P=0W !YT-OI%[-%;)87<,:0OY4C)-!%/&KJ[QL2WF2C>V<RCDAAG(
M.:6/8,8I@RBXQFVCXV-:-F$>P9(IMF;%BS1(W:,VC=$I$F[9LW331012(5-)
M(A$R%*4H 'TQ$6-%C151$541% 5550%55 X"J   . !@5ZA5"J%4!54!54#
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MA$D0FU!M-A6:,2MM9[C8IVLZ*S.I<F&7;F.]B?.X,A!(&58AML7G,5.!T3)
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<I32E-*4TI32E-*4TI32E-*4TI32E-*4TI7__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g459793g00a08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g459793g00a08.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2^>4&AO=&]S:&]P(#,N,  X0DE-! 0
M    +X*^$A8CA"24T$!       1QP!6@ #&R5'' (   (8 !P">  +1FEG=7
M)E(#<M,#(< @4 "T9I9W5R92 W+3 R' (W  @R,#(S,#<R.!P"/  &,3,U-C
M4T #A"24T$)0      $!1LX\JD "[P,G2^--DV80TX0DE-!#H      .4
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MYS    %P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L
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M1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M  $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F
M<         #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'
M1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $
M$NBX4  0 " 2Z+A0 !  (X0DE-!"8       X             /X   #A"24
MT$#0      !    !XX0DE-!!D       0    >.$))30/S       )
M     ! #A"24TG$       "@ !          (X0DE- _4      $@ +V9F
M$ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M    $ -0    $ +0    8       $X0DE- _@      '   /____________
M________________\#Z     #_____________________________ ^@
M  _____________________________P/H     /____________________
M________\#Z   .$))300(       0     0   D    )      #A"24T$'@
M      !      X0DE-!!H      S4    &              )O   #P0
M     !                          $              \$   )O
M                $                         $     $       !N=6
MQL     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"
M!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   )O     %
M)G:'1L;VYG   #P0    9S;&EC97-6;$QS     4]B:F,    !       %<V
MQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M     &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R87
M1E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F
M1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&
M5F=&QO;F<          $)T;VUL;VYG   ";P    !29VAT;&]N9P   \$
M #=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$585
M    $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F
M]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T
M /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0
M    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP96
M5N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S97
M1L;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V
M5T;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@
MP    "/_         X0DE-!!$       $! #A"24T$%       !     4X0D
ME-! P     '%     !    H    &@   '@  ##    '#0 &  !_]C_X@Q824
M-#7U!23T9)3$4  0$   Q(3&EN;P(0  !M;G1R4D="(%A96B 'S@ "  D !@
M Q  !A8W-P35-&5     !)14,@<U)'0@               0  ]M8  0
M#3+4A0("
M           !%C<')T   !4    #-D97-C   !A    &QW='!T   !\    !
M1B:W!T   "!    !1R6%E:   "&    !1G6%E:   "+    !1B6%E:   "0
M   !1D;6YD   "5    '!D;61D   "Q    (AV=65D   #3    (9V:65W
M #U    "1L=6UI   #^    !1M96%S   $#    "1T96-H   $,     QR5%
M)#   $/   " QG5%)#   $/   " QB5%)#   $/   " QT97AT     $-O<'
MER:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P
M         2<U)'0B!)14,V,3DV-BTR+C$              !)S4D="($E%0S
M8Q.38V+3(N,0
M                  6%E:(        /-1  $    !%LQ865H@
M           %A96B        !OH@  ./4   .06%E:(        &*9  "WA0
M  &-I865H@        )*    ^$  "VSV1E<V,         %DE%0R!H='1P.B
M\O=W=W+FEE8RYC:               %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M
M!D97-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B
M!S<&%C92 M('-21T(              "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'
M0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M  9&5S8P         L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($
ME%0S8Q.38V+3(N,0              +%)E9F5R96YC92!6:65W:6YG($-O;F
M1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M   '9I97<      !.D_@ 47RX $,\4  /MS  $$PL  UR>     5A96B
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MO^W/]M____[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@     '_VP"$  P("
M@)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,#
MP,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1
M$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( &@ H
M,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0         #  $"! 4&!P
M@)"@L!  $% 0$! 0$!          $  @,$!08'" D*"Q   00! P($ @4'!@
M@% PPS 0 "$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#!R624_
M#A\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;
M7%U>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0 " @$"! 0#! 4&!P<&!3
M4!  (1 R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A
M:BLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]5
M9F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@ , P$  A$#$0 _ /54DDDE*22224
MI))))3@]8^L]G2\N[$&$[(L92W(IV%Q]1KB<9E8%=-OZ;]H/Q,?T_TGZ')^T
M_X'TE9Z']8,;K-F4VAH:,;T2/=+RV^FO*;ZM>UOH6,=8^GT_?_ #2U55?G5^
MK955ML?40+ '#VDC<UKVMW/;[?WT@+02 ++:25-F7=N@M]0F2&MT=_TO;_ )
MVQ2Q\N^^L.LQK,,
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
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MR37;.FYU$%T5"_D15)0Y#A\E,(8!R\ 8 P!@# & , 8 P!@# & , 8 P!@#
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M*=#*S1B\^S6E[3YTX--3+?1' 2G0VV3[<1Y"<P7K\]@DK"-)E^15OE-9"I)
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MN #@&JYSHT+O>=]3:_[Z@=:6M35^N[]Z=02&Y:2PVT]W/0J^O:II&[O=&P$
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MI6.GG"[!%*28JIM"MUT!+]&@?S 1"^7,R1X)& , 8 P!@# & , 8 P!@# &
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M!%L[>"\!\Y63=H423CC+RLX]W-+YOEXK?&4V5*6<],=<[^_D7:#X  _Q@J&
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MXVZQ<N./.GV,2BR-$[<V!4I4ZVVMN3)5&QE92+@K&B&NJ@HT>H$<-HJP//=
MRZ ENK6]KV[7 ^*GUISWB_\ IZPSE[IK.V5XXK4='LM23=6'=W"6(W%)*-1>
M"G^S5CS7#43PL\#BWE9(Z954:E#D8>\1X_74,ZE)$J/L?6.U/CLB0J*F1;-T
M_%NU1,JH*:) $QSJG4.>FZN)75:562X5A1A'.>&"Y+.%E[MMX66V\'MINGTM
M-M86U-\<LN=6JUAU:LL<4VLRX5LHPCQ/@A&,<O&75N6Y?C & , 8 P!@# &
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M*"8P 03 8H@!A#L# (?L, ]DU$U2%42.11,X=E.F8IR&#]=E,41*(=_'8".
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M9W!-WSE;/T:/>\V=?:V8O^.YJ"VWDS@D*I-<=IOE+K=IKYLOJ%7:SM"Q5?\
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MQSLB2JB"AFSQHHJW6*FNDJB<4U# 55,Z9NC%, 5 [7 & , 8 P!@# & , 8
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M_!'D;:]@VB3EL=554C4Q%S 9 B'(H0JB9BG(<I3D.40,4Y# !BF*8.P,4P"
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M(]?KZ9DW             .@  ^   #X  #X  _62#S@# & , 8 P!@# & ,
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M4)QE"<).,X33C*,HMJ491:3C*+3332::::R;[SY'*RD# & , 8 P!@# & ,
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M<X5(YVG![Y33Z8<<XDDUA9%/3[]63:G$ \;KJ_HR.U-!&< 0M<6>=VJ@I+'
M575$D7JGM'8$,<RR]3DE$XU=3LT:\A5E'"SGGG;_ .BG3>UG>ZEILJ6EZ]C,
MJW"U9Z@URC?4X)N%5I*,;NE%U$O[VG72CPYS1NT=:Q4;>[4J]KE*,O\ &HIX
M^ZVWQP7[DGE8Q%I83V_= \D]*\G:4VOFEKU$7"&4(F$@T;J_33U?>*$ QHVQ
MP+GVY2%?IB(A[3UNF1< ]YHJX;F36/\ )>N=G]8[.7LK#6;&M97$<N'&LTJ\
M$\=[;UXYI5Z3_?IREA^S)1DG%=#MKJWNZ2K6]6-6G+K%[I^$D]XR76,DFO O
MIF&/<8 P!@# & , 8 P"$G,#G[Q[X8UY5SL>RIR][=LE7-:U96E47URGE #I
M Z[<IC(5Z)44$ /-3AVC02%4!D5\Y(#4^X]D^PVO]L;E4],MG"SA4C"ZU.X3
MIV5LFWQ>WC->JDGBA04ZF<<:A%\:Q]_J=IIU/CN:B4FFX4H^U5J/HHP6^&]N
M)XBNK--?FKSZW=S;M_W.]/PKFO8AVHM3=5P3QP:L5X@BH1)\_,H"1K%9C-U#
M(NI]\W3. &42C&48S4%IGU_V+[!:+V+M."SA]:U&M!1O-5KTX*YK\FZ5)+B5
MM:J2S"A"4F]G6J5II3.;ZMK5SJDFI_96T7FG;IOA>.4JC_;GOC=)1Y1CU?!X
M4<&]N<V]C(U>CLEH:CP[MH;86S'S85(&G1JOFI[:8&50^]6%\DD<D3!,U175
M5.1P]491I'#Y*OMKVXTKL7ISN+N4:^H5X2_L_3(3Q6NJB:3E)I2[BVIN2=6O
M-8PG"FJE5Q@XTG1Z^J54DG3MH27?5VMEUX8)[3J-<DLJ.SEA8SO(\:>,^J>*
M&K(?4^I(3[;"1XB[E95V*2]@M<ZN0A7UALDB1)(7\F[$A2AT1)JR:IH,(]NU
M8MD&Z?Q3VB[1ZIVHU2MJNK5^]KU<1ITX\4:%K1C_ '=O;4W*7=TH+IERG)RJ
M5)3J2E)]0M+2A94(6]O!0IP7OE*3YSF^<I2ZM^Y8224@,P1<C & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8!%7ECPXTES(H)Z1MRO@J]8D<*5*[Q((M
M;A2I%<I0,]@Y,R:@&;K&(E]PAWR;F)DR)I@[:'41;K([-V7[6ZUV1OU?:1<<
M*EPJZLZN9V=[2BW]G<4DUEK+[NM!QK4FVZ<TI24K.]L;;4*+HW--2CSC);3I
MR_>A+FGXKD^331IK<V/32W_PPE7<I-1:M^U"JY,2'VS5X]R>)21.( V:V^/)
M]2XJ$J83E2$CU52*>+=EC91X;R33^ONQ?TE:#VQIPHTZBT[6%'[72KFI%3FT
MLRG957PQO*2PWB"5:"WJTHK$I<XU7L_=Z<Y5()W%MG*K0C[<$EMWL$I.+Z<2
MS%K+RGL6XXPR;O7I7VRZ/NJY:EV9#L+#--[!371#1M8KE>;LF\>VO,(""KBU
MI;$NDQ!U>%K[47!60(N)B3BY1HLV12R7:BA3U+N]-OM%L]5TVM4MZ+H7D7&K
M<7-Q*<JD[&X4DK1Z?94J]Q6N)</&Y1HTZM*2;DTE]S3G6I7M6WKJ-2IFFU.G
M2I4^&$?K-*2;J.XJSC3IPC[:QQ[I[9^=!^L)LZFM75<Y642%O(U^YW2AK;!U
M"96/LDN;7, G8;?:75!FF<7".HB!C5FZM@?1T]7W;)TY1:HU0RQS(I<&UWZ(
M["ZE&X[+7]6U^L6=G?1T[5\3HT5J%=V]K:1U"C*K55:O5C)6\*MO6C4A&4YW
M:BN*6X6NM5(J<+ZG!RIUZU#O;?BQ-6])5:M;NIJ.*<(O[1J;<9>RH-M(RSZ/
MYX<2>0[9F?6&\:1(2KTI!+5)R33JEQ25.8"?3GK%C&-EE504$">31NY04$2F
M1653.0YN5:UV*[4]GY36J:)?4*4&\W5.C*YLVEU5W;][02?A*I&2Y-)[&8MK
M^SNXJ5O<TJN5GA4TIKWPEB<?C%$N"F*<I3D,4Y# !BF*(&*8HAV!BF 1 0$/
MD! 1 0^0S5_TV?O\"[/; & , XSMZSCVZKM^[;,FB!#*+NG:Z39NBF0HF.HJ
MLL<B:9"E 3&,<P%*4!$1  ')C&4FHQ3E)[)13;;\$ENP8_M]>J3PHX_).F]@
MW##76R-_=(%0U:=&^39G"(#Y-W2\0X-!1*GF'@/WF9CP P&#Y,40S>M#^C7M
MEK\HNUT:XM;>36;O4U*PMU']Z/?Q5:M'P[BC5;RGRW,;=ZOIUGE5[JGQK_#I
MOO*C\N&&6O\ NX5YF ?E-Z[N^-HI/ZOQWKZ&B:LN=9 ;2Z59639<@T'R*447
M*S8\#5C+)B JEC&DG)-5.A:3R8E\C=W[,?09HNG.G<]H[F6M7"49?4Z2G;:;
M3FMVIM25S=I/EQRH4IKV:E"2;3U&_P"UM:HG3L*7<1>5WU7$JG_;%9A#R;XV
MO)X,&D[/3UKFY"P669E;%8IEVH\E)J:?/)67E'S@_:CAX_>JKNWBZIC?)UE3
MJ'-T CX]!G;[>WM[.A3M[6C1M;:C!0I4:%.%&C2A%;1A3@HPA%+HDD:G4JUK
MBHYU9SJU9O#E)RG*3SLEG=[MI+&_3H9E>!WHV[;Y'*P^Q-Z)S.G=+*&1>MV;
MQF+/8MZ9^2:A$X2)?(@:N0SQ(1\;#,H"LHF)5(J(>)*D>H\=[<_3#I>@*MIV
M@.CJ^L+BISK1EQZ;8SPTW4JPE_O5>$L?849*$6FJM:$HNG+:-)[,5KGAKWZE
M0H/#5'E6JKGB6=Z4&L\_;WV4>9MVZCT]K71%#A-::FJ,32Z9 (^TQB(I$2@H
ML8 %Q(2+M4RCR4E7R@>\_E)!=R^>KB95PNH8>P^4-4U74=:OJVHZI=UKV]N)
M9J5ZTLO"^["$4E"E2@MJ=*G&-.G':$4MC?Z-&E;TX4:-.-*G!)1A!822_%M]
M6VVWNVV7+S'GJ, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & <20
MCV$LQ>1<HR:24;(-EF3^/?MD7C%\S<IF2<-7;1P11!RV72.9)9!9,Z2J9C$.
M4Q1$!JA.=.<:E.4H3A*,X3A)PG"<6I1E"46I1E%I.,HM--)IIH-)IIK*>S3Y
M->#,)7*CT0M%[4D'E]X[S*W'G9!7(2C6-BT#.]:.Y5%7ZI!<D$@*<C4UOJ2I
MG3<UMT6/9B7S2@5#_(=D[+_3/KVDPA8Z]37:'3''NIRN)<.I0HN/ XJY?%"Z
MCP93A=0E4GG#N(K9Z]?=G+.YEWUNW9W":E&=)+NW-/*<J>R332>8.+RL[F$C
M=W$?F3QM:2D7O#2,_=]>M*'+T-OM;2IQF6L=&35U+=)NTR$@TBGZP2\Z[%:*
MGW]T@85]+03LT:K*)J)I."=GT7M?V.[15*531M:HZ?J,[^C?/2];CW+JU:-D
M[.A:4E*K"#I4(8JT*5E<UX4J\.\C2:<HO7[BPU.TC.G<VTKJ@[>=NJ]B_M8Q
MJ5N]J591E&3E4JR6*LI03E%[SRB!>I'%%>6A%[8&5'A&M3HMY=*M+69]),+U
M9F];F$ZNP,PD@D8UE,NIU:+(/]:+C&X(*.TP3<)%06WW5HWT;5PH3O:\KN]L
M8QG:=W3G8VTKBB[JIWE/NZE2C&@JK6U2I+*@\IMK"V+H*XC*=.A0=O0KYC7E
M+%>JJ<E1]BIQ0A4<^%RQ*,5NXI/9R.@-_P#)+06C:W)UC<VRJW+6"5AWE,D*
M/LFV3%?85\S254DHB[)&L<O0&LT=-.)"'IK:';V6':-';B?".(+=D_UJX[.]
MF->UNYI7&B:;7I6]*O"\A=Z=:V]Q.OQ484ZUC*-O1U!TE]HJMY*N[>K*<(V_
M>-.=/(J_U&RTVE4=Q4XZDZ;H5(5)UHQIXG*<;B4YU**DUP\%**4XI-SQNI5K
M6?6+]0>M 4IMWI6(J:9DREM-(I4D(@)2 4QSH0;%954@%^#J*F,(F,8XJ&-W
MEG<_0[V!N9<2TBK;;)8M=0O::Z])UJF[SN^>RQ@\X=J=5AGBG1GX\=)+I_E<
M5MY+'/.2N#^M_P"H"*9"!>: 4P=B*Q=95P5%._[&*8ID@*4 _9$RC\_WRT_V
M)]@LMNSU%K;"_M2X27Q23?Q?S/3_ %LU/]VVQMOW3W_\^75[+WEJK;ZMOJ!V
MTJZ2W(*9@&[@ZASHU.N5"OF3!0Q3 DW=LX+[B@1/Q$J7MO2F\1,!C'_8Y&T^
MB3L#:8?]AJY:DI)W=W>U]XK9.+KJ#B^<HN+C)\TUA'A4[3ZM/E6IT\Y^Y2@L
M>2XN/?PQOSW\8=;#WWO';@*EVEN#9FP$5% 5,TM]UL4['@<#>0&3C9"06CT?
M$WR0J+<A""/X%+FX:=V=T#2&GI>BZ7I\HYQ4M+&VHU=\YS5A351MY>7*;;R\
MMY,97U+4+E-5KRXDGS3J24'EX:X$U'PPGS3\BU[!@]E'K6+BV+N1D'JR;=C'
M1[99V\=KJ"!4D&S5LFHX<+*"( 1)%-0YQ$H% 1^,RU6K3HPG5K5(4J<$Y3J5
M9QA"$5NY3G)J,4ENVVDNK+6G3J59*%.$ZDGRC",IREGEA)-M^.SYK<RD<;_1
MYYE\@%&,E,TPND*2Y%-52R[72=PLHJT/T/N15((B:T.UC)F\T/N32%8J@ &*
M_ HE$W+NT7TP=C]#4Z=M=O7;Q<2C0TMQJVZDLX[V_;^K*.<)]Q*XFM_8V9L5
MEV8U"Y:E72M*>V>]WJX\J:W3QC*FXX-DOB)Z2?%WBJO&VIS$*[@VFQ%NY2O.
MP6;!XUA)!$?/ZFH58J1XJ!.FJ ';/EQE)QN)"BE+E_(!^=.UGTI]I^U4:EK*
MO'2M+GQ1EI^GSJ05:#_9O+AR[ZY6,J4/LK>>7FARQNFGZ'8:=PRIT^]K+#[^
MMB4T\8S!84::YXX5G'.3,H^<V,P, 8 P!@# & , 8 P!@# & , 8 P!@# &
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HQ\*<(P^;23?QR7SS#GL, 8 P!@# & , 8 P!@# & , 8 P!@# /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g459793g00a09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g459793g00a09.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2,\4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (R"^B9(X0DE-! 0      $<< 5H  QLE1QP"   "&  < G@ "T9I9W5R
M92 X+3 R' (%  M&:6=U<F4@."TP,AP"-P (,C R,S W,C@< CP !C$S-3@Q
M,@ X0DE-!"4      !!FK&]ME70J=XV)7*+0T+G\.$))300Z      #E
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M<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
M    0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T
M=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,
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M;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT
M;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #
MO_XU  (  @.__C4  @ ".$))300F       .             #^    X0DE-
M! T       0    >.$))3009       $    'CA"24T#\P      "0
M     0 X0DE-)Q        H  0         ".$))30/U      !( "]F9@ !
M &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M   ! #4    ! "T    &       !.$))30/X      !P  #_____________
M________________ ^@     _____________________________P/H
M /____________________________\#Z     #_____________________
M________ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M      0     .$))300:      ,U    !@             "F   !]4
M     0                         !              ?5   "F
M               !                         !     !        ;G5L
M;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @
M;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   "F     !2
M9VAT;&]N9P  !]4    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L
M:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M    !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T
M960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD
M<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE
M9G1L;VYG          !"=&]M;&]N9P   I@     4F=H=&QO;F<   ?5
M W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G951%6%0
M   !       &86QT5&%G5$585     $       YC96QL5&5X=$ES2%1-3&)O
M;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M
M#T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N=6T
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M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  U * # 2(  A$! Q$!_]T
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M4
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M5$:#RXP5&3@@Y(.:F9NB.DIB/ T&V ([B2Y(_C,WU.<=L?3.RIW?IXKN.(N
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M!M<<8_>7.?J#_I'KZ<?CGBHBS'BO[SI;(2%48[E+/78M)1TY6D$65,5.LFF
MD!DIYM9<$2,BJ4W6/)3'Y(4H]Q$)%M>M_B!;:2U]+U#J5[.R1H(F6$!&."9!
MB)2P92".Y'.:\CT+T<9/#_8=J!C.1)<^AQC_ %YQSZ\#'K[X;:/&0WQLWDU
M5G/-AEW,>5!*+>F@:JBX?NG9BI-T5RJ5P"%*981(9<J?07TY 0XU?6?4_7,B
M075YU3JL"R[FFA$EN4B1 6=D*Q9X49"DD\9&0:^'Z(Z/#,JZ#:DC:!E[KDL<
M>LXX!QSR.><5L.H^+MO:J,FT:94S!8"/#@BJI'/HVJI@L51(3=+<S:!3!1(Y
MA "FZA,7IY,(<"&L7J'5_7NH0M+H76>IJ@+*LL:VTBJ0V,R"6!AN !X( .>!
MZU]'H3I#:5DT*UC9AW$MSD'OY?WYS[ X^G>K8]KOB+6K(T!-R5ZS,[;/U0,K
M&MW(0+=-%$I1#H0\N,3Y5 >!$%!.(CZ<]]1'K7Q6^,>B7K6\O6&L-%X:[)19
M6#!GQY__ "!@K=BH& 1CC.:U[6^@=(0VQTS186C)(EVM.SY_XP9R<?4  9]>
M*KXW!^([N_KMPM2%"W'W'Y#$ZZ<*FQ84Q0S;@3E252!>N+'6+Y@ 7DYCE$!#
M@.![[_TE\3OB)>V%H^I=0WYGWEIFFCA0R1EL@.$A18R8R"0H&"#C&,#/Q= ]
M*>!$9M"M1,8EW@2W7E?'/'S&3ZY)SR.:A-&;]?& OTJY5KNZB^1L'$MGBC@4
M8;'GM3M1(.GD4G%+'R2IJ%$"$,(&/R/(@' ZD>?XO7&CP*MYK$TMQ</$(_$"
MLL8)S@%1YBP(R><8XY-6Y^'O33NI&D6\:+NR!)+^\)&%',K=N^,C.>3Q@X50
M_%>\4)NK88FX;FLCF=LG<@DU?2-;H#/DB0&!N=(@4]- Q2&*('(113K'T$HZ
MR.J==ZY*+6>QUR54>.$O% Z,"6QOR=A8$]P2 !G'-4@Z#Z7 9)=%MV;+[7+7
M"\9)7 64 [0=OKDKSDU);"7B.^*%;UF$G9,UW5]&(&ZGK>+@J6<CIB!BF2<G
M4)60,DNHD(BHF0X=)@,4OH(AIG4OQ/UK3HY8;?J^Z@GD&(7GDA4I*1@HJF(@
MJK$8)X(P2 <U<Q=!=*%=TFA6@&<#,MR<YX!.+C )SD@?W58K!;NMV^16\E*1
MFXFTU%G%QI^IHY9U CM1X1/S#*JD7@%N@I #]CR4#>O;UU#=S\<?B9H[QV\_
M4UYJ,TLF_P 0"W6/P0VT1QE;==\C=\ 9]_2OF;HGH^V\-7T""5I'QE&NB%!.
M.3\P<X]\_?Z9A:\\4/=12UK='V_==<%5XYFL$>Y)&THGEG RA$U@*E5Q*H8!
M #B)NH. ^<4/?)R?$+XG:DFFSZ?JU\B32(T\;>%DIA2RDF,8!Y'8'OR*]ST'
MT8F=VAVHX]9+KC/_ .\$Y'N,"H:9/\:_?O68U(:ON,M,L05@27D/D:GE70\P
MA>E-1,M6%/KY^^)',0@' PDX$0[2%H_4'6=Y.1=]1:A"2I98BT&P[222-T>0
M,###<<=QBK*XZ,Z/C7<FA6K#N2'NR<-@=A-@]^#CC@ 9S6LT?%3\761D$Y%/
M=C=5JZY=L$$%XRO4($2(R(%.@JX%.DN%$/9^HB;KJ!3@!4/R($YUG&Z_O8;;
MP/VI="]5)'<3F%FS$<,J9"!]_+(3M((5<'=5LO0?3S2[CHUIX.0%"O<[CNP0
M6)EP"O8J,@Y)RIP*VWF+Q!_%EQ77H*T.MY607$=.@5%PJSKF.W:45Y@>858B
M!:+[6L) *)15$!+P(B<A0#DN T#XM:EK5W<V45[()K1MVV7;&TP&5*%R1&H/
M< 8;(&"<@5<3] =,0KO_ &3;^;RD*9V"$\@@&0D^V2<#V/&(1S'C=>++&6XD
M.&\"YK13,Q'0K?:KCT%7S;@IR^8J6F=()& P H %(IP;CD!+SJ4;77+R?1WO
M#J-TMW*&AV>(FR&3)&40C(<CS+DLN0<<8!U"YZ7TR/7([-=&LA8*!,S;;@RR
MI@>7Q!,R*H8@,0%8YQD>BH^,/XS-YRI&U@N[F^5Y&>=IBP:NJWCI%G["X,;R
ME42+4LRZG44HF3*!C'$ #N(" C[:CU=:Z5TY)>+J4]_-;(5EE1MTOC*N6#E1
ML51P<@8/;&<BL79=%RWO4;1S:/;V.G$M(D;;C$T ;:NTM(TC2,!DJ6RI/(&!
M5SL/O1\2%+&LM&_JMK?-Y!BHY=T67<P5#034.=,54P621JI4  H_-2$J8&*!
M0\PI^3#KF>Z^-?4K:W;S?M6]MM*N9EC\",H=I#;3MS&6P>Y!8@Y)S4GK\/ND
MEAVG1K5Y N [27(RV,Y.V8*.V3P!WP/2MQ>#-OWW]9SWE57$NY++MAR)57U3
MR?+S#5>(JL?$-5H*(*:# RD578IVJN1Z'4045S$$3??P,'S=3UT=U1=ZOU/:
MP_MJZFL7M92EE<M&[7$HM9)6?RKE1'M\0$D'R@#()%1_UQTMH^D=,SW5MI5O
M;WJ7=NHN87GPL4DVW:!)(RG<N%.0?4C%65[<L,5O)6#L9WZYW7/TO;+=6F\]
M8),NZ/<M&$?2L@X<K.UTXZ'RRQBF"1E!'RF4<Q:,6R?2BU;(HD(F7GWK?XI]
M?:9UCU/IUEU+>6UG8:]JMK:VZ1VFR&W@O9HH8EW6Y8K&BJ@+LS$#S$DDG0++
M3+&6TMY)+<%Y(D9FW/R2HR>&P,D^F/>MU_J8<:_]H\_]O3_C8[I^_P .WW8^
M/SZU;_NP_$?_ -;+[_Z.R_\ PU77[(T[M\N.?^)_Y[N.WZS3]3#C7O\ UQY_
M_P ['=/_ +XOY!_CK_W8?B/_ .ME[_\ 1V7_ .&I^Q]._P#1Q_\ .D/O_P 7
MZ]>XK.MG<"%&W+;DJ%$67(<K4F6&=LEJCX>]Y1R3DY*+G[%;]S<7/2$0YR1:
MK6^B32["K5UO((1SEJU=!#LE%4#*I=8]5_ KJ;7.J>E]3OM>U&74KJ#79K6*
M:98E9(%L+"41CP8XU*B261LD$Y8\XQ6L:S;PVURD<""-#"K$ DY)9LDEB3V
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M 01V'..>_)JT;$.W&*K>$HA:7D&[^*]B:.Y8RB:8NW*)RE.H(*CR/5TF X]
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MQM>PB'5Q_6)&?_[K_P GK_$/?G[XC_\ 7_K3_P"4^M_A_P!(7''X=JBO3_\
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M Q%C]LR=P;IUI!K\AC33K/%K,4D*_'&[NK+IW0Y[:22/9U)"9FB^WX:Z3JS
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MG_94Z%YY/#1I5*2*0=TJER051NP8DJ?4@Y%>=XD<,T<UP&\.%6<A"2#V"L4
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M'./3 'L?7G^3[R8^A4L::[@G)'$@X2,"29TSN?-<G**3<H&3(!#]9P,90QP
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MS,5#3$L"IPS8<8X'(LLP=MNO^1G"-=5M!X*D(NS"6UU_J+%R92E("+CV(QB
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M-YK,P$.;NW1X3R7,LFT.IR<#)R03G[Q6'[251+MJPP >ZD,/?\5G(^G''O\
MZ=]1]\5.?B5UV3C_ *U:V/P%]*/Z<U@],_\ !UC_ .RP?^[6I$^</P'\_P";
MT /R_'\W&@@8]!^ Q]_Z_G5[@#L /P% 6'GN CWY_9?S>GT:8'< 9]\?\J8&
M<^OW#^ZO.TXW5NZW.C\-OVTP!Y'G_P"_^[H?@'QUWY_DJ?\ 4/6__E7=?_XK
M2#6B=4?[?%_[*G_O9JLIUT[6MTTI32E-*4TI32E-*4TI6$Y'QMC_ #!1['C3
M*=-KF0<?7!A\EVFF6Z)9SM;L,;YZ+GV&7B'Z2S-\U]H;H+>2X2.3S4DS\=1
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MO$.>P:4H/'/(#]7T<#V'M^YP' =@#TTI4:=V&[;!^RK$$EF[/UF6KE-92D?
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M"G!R1R2!@\\#G&@_%//^:-R2,9N[#\<SCZ??ZD<\>M64;478$VXX=+W^;2V
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MT8!FNI%(!B0C+.R@$LQ7 7EMQ"BJ7$Z0A2X\S/MC4G:SOP0%SG(QDDXP ,G
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MFS-8QPJAQZ]OUWJX#'?X/Z-^TZL_O*R^O3]?KM5:S'2E-*5@F4N^,<C!_P#
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MRB4Z:B9R&(<ARB)3D, E,41 0$!TI7Z2E*4H%* %*4 *4I0 "E* <   '8
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M1[>@!R,#]>U/-&XVJT*4BJ'17MFJST7"4;)M8Y0&[,4TQ*J#14X$(Z !$YU
M3*H=-0#!U")@#7CU]TUTA>ZK!-JFHQVE]#M>:WFG'B,6;($BKG9G QN*Y4C
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M;VU$EQ//AE=5F>";/:'*A6"D$X)&TX.21ST7IENPL;6U67,,%NBAP&7Q8P
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MYR<>4RG+DQBF*NL8R1A*4H= \B ;9U3K^F6^@.UTP$K!FF>=MTA=@<*92!A
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M&I K&GCR!$E%F:9 4<&!0"F."0H]Q* B83%$O4/J @/I 70O4-SK5]<I>>'
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MZLM[61)!>.1&9(O+&F[L%!^TJ@_VCQGUS5ZCJJI'SEU)'8]^><<^Q&,X['&
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M<&\HQ"D+U&'D0'RQ(!>2@'/ B.)TJZ'5VB?LW49Y&E@01S2R$[MZ@,CA\D'
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MZ*OK&YDN9K-[B0K$JQ[UGECP=KO&HVJC..,<DGN1QJ&F]0ZYU39WD=O8VVU
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MS;3 O32#N2,*QTWAU2'^<4P"J0JIS<])B%ZC"  ;D0UMFLPWW6VBK9VMV6>
MQ&-8"$#1@$<'[)*@8R"0,'/:O<Q(H?G8K'.\'..1QZ  ^W'WU^BS;GY&>ND;
M(4X&\:1L+U1A(+E.R_J1(@K',D0@G541(/!1.=$2AR'4(=A#XT_H2VM-+FMM
M2+W!D$0FB!$GG;"@DG"AR.< Y]1DY%5#)M" ;@<\OSN ')YY]<?2I[[*+14M
MQEYCGN691A-$*S.JR0>JIE2!ZD<I 04%7I!0>D!$G]N''3ZCSH/5VD'IEDM;
M!9[.VFE*SR(S*9 4!0>(#N56)*D!@20!]#A]:FN;/29)=-C"R!AGPU)*J<[B
M!]"%&1G@D#TKY/BHT3$^.EH9U0H=@:;69+&?L$4T3LC)."F3(/ ]:::AB<F$
M1+TB0.X<B'&6^&4]Y/J%U:&ZF:Q6.)MSR.S1S;CA48DL5*@$H& 4XV\$@V73
M=YJ%YI\LU^-Q60I$67#,,#=GRC.#C!.2?<%<'F)<,HJQ9/B&E=(@1?R"LUGL
M<BHDI'.D%Q7<D:J('*F[.CSY7F\%Y!3L/! '75RR7%IH=P;II AE$JPRLI69
M&0JK.KC<@;&X8R,+R.17J4ADOXW18VE$;QF0 ETPZEE5APP#'#*QR W'JM23
MN>2+PQHS:AM?DY**E#>0N\=B#PZS=BOP];NTCE4Y>^0401*0Y^HA5"G$IP+S
MI]CI6FR:DVIR"9IH5+(B>0*TB'PF0@@>&6(+97(."!@G&3DEE$0C7;YN"6RQ
MP& ;C.2VW.,D '!)Q7LO&(6>6(3&47BN/7?3D>W63F(T\6W9Q9&K\$S+??00
M3 SLP%\PA"F5(8@AU]'8=5TW7Y-"GUJ?6IE@M92AMYQ.S3^)%G82-S812=I.
M%/?;FO.YM$N5MQ$%;8"&1XT*-'( K*>/;)P,@D<X&<PKRY@;+6WRXK*I-U6S
M.?2,W(=LX5:L0(N)D_9'1FQR 51$0ZE&JHG2,!NHHCR8 E'I_JWISJ_24BN)
M0\MD=VYU$DS^& WB1F0,?.. R@,2.<\&M OM#UC1-5EOM'$<D-]B-[=B8H(F
M;RJV(RN5C/(!&WDX[FOL4:T;A\6.*S$.$'=DK2KUE*UY!1N#N(.[(J+I1H@J
MLB &$H]95$B*@9-7KX^< \VNKV71?4$=Y=0NFG7J))#=<LD[1E=BR%$8XSP0
M0 "I&< 9J\TI^J])GBM+Y1JMK)M:&>(JIA8$N\;,RJS*OV06!.?LL>U3OF]P
M0[B(((&(I3UM88R(D%IN30.5!NFX(F"7L13I*HNR$,H54B/5P/60QA3 !$^H
MFMNE#TE<F>?4$>UGFA%M ^6<QMEO%PP,9.""_8\@9R *WA;M;U2L2/D!U8C
M 93M9!R"3G<.V/O!YM ^QX(Q^TWOT-9RF^>(*8[RLN59Z9X(PC@\*=$\>B*X
MF*HBL1,#$4.<ZIC&.(&Z>Q96Z)FC?KFS"M'&W@7JE8PG^E(+&1Q(P4#:P)Y
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M)%,3B5),A *0'@+P=Q]QQ]/[O[J?<?7'IQ].WIQC&>>#7QS^$?$*$.0VY._
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MW?()[<BOV9D@(%*^*10VJ>A7JCEB$2YE"O'S)T\!<_RB9=ZLJ!VOD")"$!
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M>':6:RAY9&\K;&B4EU"+]K@ C'VN<3S?7,:RPVX4EM^YI&0JD4>.#O(VEBQ
MP#G).?2HBY%S9GW;^Z9I*7."N!+6Q48LH=TCYSV%8'%(&#@Q$3$Z0>MQ(=$Z
M:AP.F*B9RF,3J+)6A=+])]71R'Y"[TUM/=9Y;J-P(;F0;A(H+IY6C;(8' !
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M&L%PMBK,N6[)5H/(2$Q5L?)N'#AC+.HQ5BE*.%A#E(QW2)53B8RAS%2.8$E
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M*;9F6=E\ *D +'(V>8O-]M@7Y=FJYJ+FK,V[%ZR)"MB-E.W\!_3^9_6*LO\
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M2S=XDD941!0A^@0, ]0&#CL4:I9:!IT5MIUDBGY8NTY=HS%>*I8$1C<CQDX
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M'X'OZ <<Y-5H-G9=WCZ)1GK"UC4*X0S8&8-2E5>-%FZB(]::ZARJ  %3.50
M,'4/6    !99:,=!PSO:6DDKW3>(7#G$<H8-PRC*]R/0^AJY(6] 5B-H!!
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M5^;G2J'^H_F/O_7MWJ][&/X-L>_M'J?[PQ^E5K.-*4TI32E<16R(?^+/0O\
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M@C%Y1RXM)I*-6"<@^F)6T(R#R7>R(!$LV230RTX=$W6D76ESOHD]S<64=X(
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M82!SN<9SP,8%=$&(+*ZP%AAF_3G4%(U[&@4S%0J?GMCG2ZRIE(4Q3=9 #H.
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MN4D "P )Y2", ')]1GGTP.PX_*XS(*F#+)@%ZL P!'*4/Y3)N8$D'J#XJ(<
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M:')"I=*G2/0<PCSD=.ETG67_ &=%I,K^$ D[+)CQ7#B*3PR<NK ,6/VLCU
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MQ[>X]>1]_(J=.0,BUFQ-X%C5(IVW1<1WE.BE$13<.3)@"9>$S"!@$W//5W,
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M;L=2:*SMHQ)M"0HN.> !CCCV^M:J^7EO[8_^4'_:UX?)C_='_P TU=_M5O\
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M1R#ZY!.:\\'[#KW7VK>ZWNTO*TW=*BY8*QW -I ZAQ."3PQBB8@*(F4 @<$
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MYRPD%HTP-%#'$K=!=)1,W2! ZRE.;I-TB7OSJ<KW2X+[1UBDM[>24011SI+
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M%'SSB3R4!.FL'G&+R4/?UQT98P-HFFO=B66.*2$S&( ED(SM<,=^T [F&5.
M<$\5+UZ\BF418$AB;P]Y(!;'<$ XY[G!X/8\@:"K-BW14-M&LIH; E&.RGDX
MEU(F%NF0J!04.F5PL)45T^3<\=1A,F/!" (<AMNHVO0^J--)9"V\>,B"XB0>
M)OSD!MHRT9*C!4XPW<G.*Q%BVM0>2\998V_>)+D*\?'^J8$;9-IR0Z@#  *U
M:_M3S107%&F&^5YQJXN"[4'CM(ZQ?-53.4?+,DBDH<O253@!5$0[@'7T]M0%
MU]TYK7[3LY.GK=DL$?8"$&%()SN) .2#V]AQ6?CE=T3$BAP?W@;N1]W/IC@
M$GD8J7_A'YG6R)XN>,Z^U3(:#@\3YL]@E$4RE)+E^UP@!YBH<@L+0O2F!DQ
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MY:]1.YZ^5)V\D%G<2SC,1;9)56MM#E,DWBXVQ6;"\U;'+9FV,+5!>4G'SXR
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M1TX_=(+SJL:D@^U/7.A]/U^VN+6^U#5UCG9F_<W,"F,/G*1E[63R<]GWD
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MD3JI,H>/4;L&*:S@C-! KA<%%*E FFFBFFBD0J:21")IID "D33(4"D(0H<
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M-9%8ATE452%42534*)3IJ)G 2'(<HB4Y# )3%$0$! 1#2E?V
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LTI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*5_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g459793g00a10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g459793g00a10.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1[44&AO=&]S:&]P(#,N,  X0DE-! 0
M    'KB^>&0X0DE-! 0      $<< 5H  QLE1QP"   "&  < G@ "T9I9W5R
M92 Y+3 R' (%  M&:6=U<F4@.2TP,AP"-P (,C R,S W,C@< CP !C$S-3DQ
M.  X0DE-!"4      !!1MUA#LC(4()!9B"9<6\$..$))300Z      #E
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M<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
M    0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T
M=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,
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M;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT
M;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #
MO_XU  (  @.__C4  @ ".$))300F       .             #^    X0DE-
M! T       0    >.$))3009       $    'CA"24T#\P      "0
M     0 X0DE-)Q        H  0         ".$))30/T       2 #4    !
M "T    &       !.$))30/W       <  #_________________________
M____ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M  0     .$))300:      ,U    !@             ""   !>,
M 0                         !              7C   ""
M           !                         !     !        ;G5L;
M  (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   ""     !29VAT
M;&]N9P  !>,    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M!F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
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M;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
M C_P        .$))3001       ! 0 X0DE-!!0       0    #.$))300,
M      P0     0   *     W   !X   9R    OT !@  ?_8_^T #$%D;V)E
M7T--  '_[@ .061O8F4 9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,
M#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,
M# P,# P,# P,# P,# P,# P,# S_P  1"  W * # 2(  A$! Q$!_]T !  *
M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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MFW8/](:&_P ZUG[JNLL:RNOU7,:]P TT!,"=F[\U5.OTB_I&32;&U"P!OJ.
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MXL^S?HRRQS['-KL]38DIUTE4]3JDCP
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M P # 0$            )"@8'" ,$!0(!_\0 1!   00# 0 ! @0!" <%!P4
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M//////5J>A.&>M[2Z1DEQS;@2G;AM,VYBK(=?E7?*IUOS#6Q$)!==6L(4G=
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M&A [?_GGGGGGGGGGGGGGGJ2G;58<D4[\E'0K]:H:BD(L;=O),DLN@KG[$ZM
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MS8UV5Q,&NAB.#QMG/FD"@\@$ZA9 @A&]'+K74,WF[YA_AKYY^O\ ]#:F_P
M@/?$Z*Y/HSJT3&@=XQJ120;$2+XJ!1CUF6A6JS5\1;),WBCEY6$RASTHFHW1
M3TT;%7#UJAMC*K=%)7???:#?DO\ DN/ /+5ZW7<JLMO:TQUG8(L8? #5F2Z
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M90Z8$Q9)BJNR(#WS55)RS>-%E6[E!1-9%3=/?7;.T.8OX:^>O^!U3?\ A_\
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M*1AH3811%PH1(%, H>Q,NGA9I#8LD03B\0;DG&SU&-!Q:;G1%779%/H+^;V
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M:P[FSYF:FG]B'(1D[&N(K^X(>\BV>M6P5A$(U*BLHL?:.S0<I(8X('L9$2L
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MJ-#6=_//17QG^NPN3^[!YZ_S2](>E0\\\\\\\]5W^?KYXKV^*>W.;J*YSH*
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M8<U1PC )"\VF\6B,T!QJ=.3"!!XM(X6<V:**) 9W///<H]X_P/\ 8_\ RL]
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MV!_%9VI%CD0K[$D&G;BUYF;U5%7S_9@U1/6)M".H#5@)0^.*$<%9!AA&6+[
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M9(Q)H&(2Y4=$/U-_(U5DT^IW/R4?REEM%F\M5YFY/_2W,#Z@L31%"F[%5,:
MN2YB.A%DM-A>>ALN-)%("Q-!W5 +?3\[9@9)R6C:;EFW4V]MJB^P/Y2QT0C9
MJM<UCQ.IFHK,=5'-T#\3T N6$U90J$3]RQ0;O.BL*N6Z,?L&.;*.<:IXT?*/
M66VF%6:GU@?Z'J[Y/9-\N<3Z,MJEZ18?)' ;$I.*5;6\/KQ'] M]ON- -XU?
M[8>]D$JC,N;5J!,$6SBT/W+B*5TYK$8WFGY1_&\-'&^_F@C/R97RK1O-/R&#
MK<:4X/DP^[IG-@,AYV847"\_MNT(%"WIFPJWY[77@A\A)EG@?*TZDQV-(L2X
M]HZ&M"A\"8;=D?&/6ME<C<L<EVFM\-[GI*PGL\*T]SO>]L=3/C4J#BY)/9[B
MMYI"JFMF!2S7F6%R $/2,D9-"AL!$%\&?W7JV%CI8T9(QR_"*.NOBWY%@\VI
MWD.6W5?'3E:7C6-W5*7M0E Q'.DVWD(:XU <QDQNKWC.JE-=JRDT>%QVUG\H
MDDNR@+? #NB:^71V7+Y'_F(^46J+ZD5:,*)>\;ZU73[&:1<0.D\,NT5T5<1M
M5T6$01C.S%$&P<_'-H_H'8/*7JI>!VL\(ER!/2?MF;1)$;V)TY\M?RB5]SU;
M*P+XQ]J^N"$\XTK<I.P]+K8VK$XFQNR8OX$B5!UX%K5$E-93$7X"1FC-;-S[
MTK%1V 122:DA3K9)[SU\:7S+?(E<-DS+G]?E0YUTD5?65(J,N^<734E+)2R+
MTNC4PBYA[>8Q.DHO7MFBX]++A@ZL7D49@$4438'GL>+[&2L<=O\ .-H?*?\
M,!M\A&:I_F";*S'/1CFME>"\RV"I@$>?4XQN12M/%GYI?$RTV^UKI,,=%*V.
MI3#K\>8$A66I_;5KIO[Y3ODK^4_G>*40N[Y'><C5G8%I*P^Q;WKZ]:DO0K&M
MG(O7$1&DC<EI"3P&H8Z2-K[O9!,IC Y7H1$AG<> Y#FW[9XITGS1WG\O,UXL
MA%O2SXT(U-YZ]JX_)=)6]Z5B]1/)SN*P<S&)8O2!NNEI/%U9>)8"#N8JJ68.
M77ZG]6"0-!ZU8L8T."/F&^4^5N[2FTAY^*=H06&<Q$+WNJ+H2>"U,=H"S0CE
M(@1J^*+1ZCPZS8N4!Z2!F)YVFFME7$U<QUN9<3]9D[RD6^+W_P#,7\N-3=,U
MQ#([S#+:">S6NX!*>>:4CCB(WK&K^EAS>3%Y$'LJ::TP\.%=7C04*@K&OJP/
M55,H$?*-)'*SI 28'JL9<A/RC]\%%(\VQ\2<@;NI#T7+>7F^KGK6*MTFUC0D
M5+BQDV^4WIC;1E63A&%%T@MB+;YC9=TY#-F;M10LT_'K-[\V?3\8#"9C8OQ:
MS2"5^X;X*')42Z3 J9CX-'IL%RH[<+"UZ>'[NC*EA2!F7!QW\VU?R&#_ /ZL
M'[_I.^KCUB3SU-KI_FR&&?DQO.&5KRW<2M>U!*N?=1"?#7QK_'=-8%%S<Q@T
M:L*4IW79/1T'86 [G3XF:Q*W!RN2!,*,A9D(V;.&TP&&6^ER7SV#)QFM8"\F
MUBHQZ#0L@<;:F['G:0D!''AAG'6*N=2\VD^C=FN0; QB:^=7YU\LD,8Z*YPJ
M@WUW^D6CSMWXPHI- GR0[=#.7[.\Z\D7+<=F0".V#+8.5@O,5LV(8GTP3!QB
M!%2X6&0*9R*2?O"Z#*K2L&L>5 D=CJ0M^.)D9@$E4ETDET%$UD%D]%45DM]5
M$E4E-<;IJ)J:9SINGOIMC;3?7.==M<XVUSG&<9]Y/>H^8,2;51D29-"#);*6
MRK1\V1=M5=D5=%T<J-W&BB6^4ETDUDL[:9RFJGHIK]-]-<X]OVKHU1]*PLI,
M3<.J"KXF:L0H@<L O&H!% 12=&FKG\XV+S%^+$M7<F)MWG_Q:#\TJ]=(N?JX
M35U5SG?WNV-4%37"P$B[;J^N[2& ##:0@AUBPJ-39B%/L\;8:&Q+22C";<<7
M:XVVPW),TT7B.-ML)K:XVSC.;LQHX?\ FLL![)CE\XR\>_DVJ#;\X[RBBVRZ
M=?93T_,.,MV[=OE=;\:N44$4L[?;2TUUP: 4]4E3[R-2K*MKJM=YB84D,NW@
M$)C4.WE)];\?W3<CVCHP=DV75_'O]PD3RZ>;_CW_ !+9_%GZ^G-J-I.R]PBM
MC4]5L_4C4A4EL<4FM?Q.5;@)6M]O[TF"[G1+_87(%?LH_=,L<H$5/M)?C<Y^
MWI],L-:0V/ \F9%I&0<;A(UX4R5,ZBQH2(B!PETV($?SS["+ ".8@MWJ#QW]
MUHV;"=G22RFC/977,,$ZZ$^&M>D^;;1#S6"5I2)_J)WT%4\@H2IST8CDQM'E
MV>/XG,K*G#"!5@[V;U7%)8XU8SFUI:Q!PK9F_!$%9RB-+"GKOM,3?? _3G3K
M^D-4JTM?I'G1>2'!.TNJ!^4=PPG#R<9$SMQ5-H2^%8BQ0[!34KB8N>(UE+21
M:'EC0EC)$QSQ71+7NIXS:$&CI@_:MGS%\W69O63Q!)RT>-'*>R+AJZ;+:[HN
M&[A'?=)9!73=)5/?9-37;7;.,X37%55?3L>S$:CK>!59%,OW93,8KF'QZ$1[
M)-_MKN^(Y"QH<,&Y?/=]--G3O\M^8<;:ZY64WSKCZ?-+TA2T@EL4GQZH:O-S
MJ!N7[V#S0O (H2ED->%7:[\F[BDC>"5C$><D7[ER]?KB'C-5V[<+N7&ZBRJF
M^VP"PD4>&$ AP8/,AB[)R-*B"S-L1&$QSU'=N\8$&#Q-9H]9.VZBB#EJY250
M71WW253WTVVUSC->UG7%1Q=G"*IK^$UE"QRKA<?$:^BH*&1ABL\5RN[69@8X
MP&BFRKI;;99RHBTTW75SE17;;?.<^^>4IZI#=A@K<-5;71>UXN.7$1FSBD)C
M3^PHZ)<X7PX& IH[&*R,0/7PZ=869,"3=LKARXQNGMA97\6=N1[!XLR<NV31
MTX&.-W8Y=RV176'NE&Z[/=RR55TVW:.-VCEPUW60V34V;N%T,[9254UV;L&.
M[Y$GNR:;DFS9PR;D-VR.SY!F[4;K.FB+O.F5TFSE9HT5<(:*:I+*-F^ZFFVR
M*>=?AGW,-BH25R>4+QF.1Q$8],S>0'E!8D*F'&#,Z$"DI*O\MV6HT>&:YT>/
M2R_Y9J-;YT64T:I?37@ O\H7QVCJJIZYG-X LUC=R%A1^JYJ$@%@EFKB)U_,
M6M=V+*7>0D*?OH)4T8EZ842=L>6-H]7#19Y&G2Y_+0D'<.,"HOLKXWN0*L-\
ME0N]WS*,<$5<E$)!K*XS894BG%JM/QNJ2S:/2EK V0.YI1&IU(XK7\I$U-^Z
M# R>R(+%7HAH=*,QRLA%&WG5_2%9@;?IV2;RF!R-P=8,2+D)((P4:%XK("D4
ME( _%Y8*!RF,2.,R<(7C\@CTB#"S(<N-=L7[)!=';3VV_/?/+?DOTHG^IHY<
MC?T]Y^H-\-U7>5V7Y93\VCAJAHHNYRJA]S3#=%-15;.WVT]-M]L:YI*<SUKP
M_+?D3CTRJFJ(YS=#HCU?5K;FV L/A>Z0P0F$2'-*Z+#I>:Z6F\8 _P TLC*3
M][*P;\\?!@A<#P#;GD/SP;\N6=W>_//:!ZGFM55]SM<4GO #))54J<&,A9[%
M(A%97-I-*H_+$<11W%PT8A#5W)R;R19-)AM/TS1#\EJ]W(/2 L>T=DFGEY8L
MF!7)S+SS;56 "\5K*S*2JV>5W&#^J&AV.0>5PD(;BH(QHU)FFVI02#>L6#[5
MN8*HX<H*X3(O=/HY4WSYYYY[3/0EZPOFFFYY=]@LY<2BE?AE"Y$7 H?()Y,"
MN^54FK(6 B\98ORA!\_>KMVNJNR3<6.344)G"(H,S?DFL:]1?(;Q[#;7KR'5
MK35MQK/<!#GR_K#LM ;&W4&B%P]JUV6S10"U]WMCO),QG-E1JCMH[]NNHI)H
M-'R ^-Z'2XG]R(OUYCO////:"Z@Z.@/)=%6)T#9C"9EH?6X!X=)!Z]AYN=3$
MOELENHB."1X"U<N%%W&^GT7)$5!T>"-,.#,D,A@3%^3:QUSCY(.+A?2-,S*;
MU?:"$D 4^,!LNC%1T?V@5)I=956ITNRI68-&MA:R9Q++#@/-HF3.WX&O)?&0
MCP3$PZLR%/)/LU<=>\7=Q5]VQ'IP5B< M*J9#7CZ!Z22 6^,B0Z6H1ZUZRBE
MQU7,6^8/,9W'5P,YKR:!BS%'!_4Z&(I%X_)0P8R)<M/=J>>>>Y*ZP[+JSCUA
M4[JR0UB'W5S6_7%-1%A (64DJ;,[9%@0^N6)^7GM=6D6A43#FIP!V(E9.<&+
M$-G20F,,S\@<M1*_-WR$]=<I5L^CG-'3-5V#;$,G8R!6?9RT49B-HA4$"9=
M5A7]>V;9;MU.H;*% ?\ /K((4W:#J\83.1:-Q!PV5 :QP.056UP.^:[G,[DR
MPC=2]!'I06/P<1SY$6H2LF9;JT78=S6/0T;EU-NRMICP0:.;S^IIUL1S=!>J
M3(Z*CA\I7#_IQP5^9W; ?E@XEGT%A<[;V:[CB$UB<<EJ$>E$>)LI*!1D8=F8
M3"R)FQ3),6AT7H\U8EVS,B0:H$$'"3=ZZ1TT74^_=GQ:\(]%7:OT9<=%:3"Y
MW",4;+3;%DV]'EU&T(333BS;(:+3X)'<-A&$\[I-\!\(KKJNG#O1PX=NE%I
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M\1,LA!J ON:9+E&L7R_-(.N;MM&^P43B0YW MQLX$NIA<,S#F7%EH2<J_A>
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2BVV$F(]J@EF?GGGGGGGGGO_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g459793g00a11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g459793g00a11.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2&F4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (8J^A88X0DE-! 0      $D< 5H  QLE1QP"   "&  < G@ #$9I9W5R
M92 Q,"TP,AP"!0 ,1FEG=7)E(#$P+3 R' (W  @R,#(S,#<R.!P"/  &,30P
M,#0P #A"24T$)0      $#R\ %FK@VLS1C'[9\:QBD\X0DE-!#H      .4
M   0     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $
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M=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M    $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO
M;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG
M:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0
M$ .__C4  @ " [_^-0 "  (X0DE-!"8       X             /X   #A"
M24T$#0      !    !XX0DE-!!D       0    >.$))30/S       )
M       ! #A"24TG$       "@ !          (X0DE- _4      $@ +V9F
M  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M      $ -0    $ +0    8       $X0DE- _@      '   /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H     /__________________
M__________\#Z   .$))300(       0     0   D    )      #A"24T$
M'@      !      X0DE-!!H      S4    &              '\   %K0
M       !                          $             !:T   '\
M                  $                         $     $       !N
M=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O
M<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   '\
M %)G:'1L;VYG   %K0    9S;&EC97-6;$QS     4]B:F,    !       %
M<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M       &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R
M871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U
M;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M3&5F=&QO;F<          $)T;VUL;VYG   !_     !29VAT;&]N9P  !:T
M   #=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$58
M5     $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,
M8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T
M   /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU
M;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP
M965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S
M971L;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T
M<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@
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M>0VYC^F=.PF_8K;=[6,=7B-WMJG;]+>_?Z;=W\XDI+T)K6]-:UH#6BR\!H$
M#UK= %H*AT,STYI@B;;]'"#_ #UOTF_FJ^DI2228F-3PDIJ]5SQ@8&1E!N]U
M%-EVT"3%;38\[1[G+-KQ<WJ61CW7X[
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "C =0# 1$  A$! Q$!_\0
M'@ !  (" P$! 0            @)!@<$!0H# @'_Q !$$  !!0 #  $# P$"
M"0D'!0 % @,$!@<  0@)$1(3%!46(1<B"A@9(R0Q.7>V,C9887F7M]?P)3-!
M45)6@2E&H:;!_\0 ' $! 0 " P$!              $$!@(%!P,(_\0 .1$
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M *SU8P/L%>-0'%*2W-$F1,B6.(Q%J0M*9$22\RI25)Z7WVGOKH#O^ . . .
M. . . . . . . . . . . . 8P=I%,M"Y3MEJ-8L+DX%-J\UPX!%%ES*R3D1
MY1&NRESXDA4@'/E1(LF:)>[7 E2(T=Y^.MQEM20,9%XIC0,0FOA<ES,0!0>B
M6E 070ZM $)L\!#3<&QI&Q!34-)V$VPRB(7Z9Z(1T,M)9D(2VGKH"%?R&?\
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M^MA=C";<".U8?U/743MTTTM4N!^B2STCII2$)FL=JF-\Y12BFI;[^OEOY?\
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M*>N?9.Y=4ET.8<C,F2L"M7.;1IWTF4N=?:I$!W:94I"&G*Y*/NA^V6.H?3*
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M/?;3O:/O;[[0KKGS!2Z&]Y>E)I*-<BM<SN+0+[@_D6[!ZH+=+2#E#L'IEWU
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MO[Z^TZ_"@06)*NGD.2%W[=?WUWOW,_N?FB&5MM1NV=W0CDY_.?.&S>=LX=
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M"-_I_0J)E]% W._89HV^PQ=W$]@JME>-/;?< %C6,-_HKC"K$6._*$,C(:2
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M*8PK?R(T@TTO[7^H\R%*CR&E+;1W]CJ/NZ3WW]. _P"/N6?< A'NGR"^;,,
MR2<RX1[X:C'?X\NG4*4-+6-F>TJ2F:J:S*FP8H^*.[B/HEO2Y+??4C\49I#C
MSJ4\V[1^Q&OZO=&N.++"IE3[=9>;&RO'<&HN"@XPG*<K.).*C%_IWDVDCRGM
M9^,W8;LIB3NGJ4-9RZ\MX<M,T>S'R,V%L./VSNC9=35373[.2LE99%\?#"$9
M2>RVKD'JO!]QC5KJ@:$#(';0)[+0Z?(ELQK;$0S%7+GQ"(;MQ;T>6-;:?_6)
M0IUGKIE;K+ST=3;R^NU3LWK.CRR'FX-T*<>SV<LJ,92Q9.4E&$J[MDI1L;7
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M(:;E]L,]RD1U*6PB1VVGM]#*UI0M;27?NZ;4M"5*1TGM24]]]]=8IVA]^ .
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M;UNFZUE.77XGC-WC4/7(=:T@AG1"%8^J$>>5 +.52"?_ "O]MR("9@MDB0@
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MT)>",#%I2RL_+E':=]M5,9-?J_+XE?#7![_\5D6Y=D%W;7.7_(M6YCF>. .
M. . . . . . . . . :)]03-&A><=X=QN1TQL7>.Z=UDO21$:Q27](;I!V13
MF8-<EH>CV&:HVQ$7'#/1Y+)!2.V'XS["G6U 5>?$QF$;.Y&@()TCW=2IDN#7
MC"1WL[%?).2U9JZ'^B7\MG9)WYQH--EDK(6ZC(9M[]@DD5R1$0)^%Q:DR%J
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M]O\ CO\ ^M8/^O\ CU:)WI&B?7Z"?_V@5[_0TO\ ^@?_ $-_NTC_ #_'T!K
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MFXI[J,GR??>./GWK%_\ ,%0U;8<8]'Z>7*=QQ<$YYQ\XW?0I=@<%]DAMG*7
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M;97_ $.5,6R)I.2UZ*/RK'6; $&5N!5[,7&.58E)S@V6_C+]G(JF=0!0%NW
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M*_,FS["7&@6ILQH#3N*6#X_JYZROM5Q.SU^J[1F6(+QZP9^"#&:CE]?SC+-
M(WNTPZC-D5H3G1DU1;IKZ.M+;IUF,3:=*L@D?;H ::^GIT"2>"^ILK]'G=F
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M^F4I2EO[>D]== 9#P"/^^^?PV^JQ/LS8"8#^Q/?\[W\5T,C19'[V9SMHZU"
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M-&.9.-4MIF8PA=7MI[]=&>_(/>C@6%< < < < < < < < < < < < < < <
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>,\5Z/]OY)X[>Y?O_  3KY2C@#@#@#@#@#@#@'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g459793g00a12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g459793g00a12.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2 <4&AO=&]S:&]P(#,N,  X0DE-! 0
M    ( "^@9(X0DE-! 0      $D< 5H  QLE1QP"   "&  < G@ #$9I9W5R
M92 Q,2TP,AP"!0 ,1FEG=7)E(#$Q+3 R' (W  @R,#(S,#<R.!P"/  &,30P
M,34V #A"24T$)0      $$+5:.3+2]#E=F^#_I^>]1PX0DE-!#H      .4
M   0     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $
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M=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M    $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO
M;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG
M:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0
M$ .__C4  @ " [_^-0 "  (X0DE-!"8       X             /X   #A"
M24T$#0      !    !XX0DE-!!D       0    >.$))30/S       )
M       ! #A"24TG$       "@ !          (X0DE- _0      !( -0
M  $ +0    8       $X0DE- _<      !P  /______________________
M______\#Z   .$))300(       0     0   D    )      #A"24T$'@
M    !      X0DE-!!H      S4    &              'N   $-P
M   !                          $             !#<   'N
M              $                         $     $       !N=6QL
M     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   'N     %)G
M:'1L;VYG   $-P    9S;&EC97-6;$QS     4]B:F,    !       %<VQI
M8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M   &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E
M9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG   ![@    !29VAT;&]N9P  !#<    #
M=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$585
M  $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O
M; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /
M15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0
M  ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N
M=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L
M;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T
M;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P
M   "/_         X0DE-!!0       0    #.$))300,      U?     0
M *    !)   !X   B.    U# !@  ?_8_^T #$%D;V)E7T--  '_[@ .061O
M8F4 9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,
M# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4
M#@X.%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,
M# P,# P,# S_P  1" !) * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$!
M 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&
M!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q
M0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$
MP]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G
M]Q$  @(! @0$ P0%!@<'!@4U 0 "$0,A,1($05%A<2(3!3*!D12AL4(CP5+1
M\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C
M\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!
M  (1 Q$ /P#T3#ZJ+NJ9?2_0+#AM8[U6AWID/&YE>]]=3?5],L>YE7K5_P#"
M[_46BN>Z<[;];^IM+'$V5538-Q8-K6;=P=8ZMC[&/V?HZ_\ M-ZEWH_:*/7Z
M%)3D8OU?&/:^PY5UOL#:-[B]U;AZNVYK[S=OL8R_]'ZC?]+ZOK>I^B/]7LJ_
M-Z!TS,R7>ID9.)1;<^ -SWULLL=M8&L;N>[\U2KZWTBVRJNK+JM=>6BK8[<'
M;Q8^N',W-][<>U0^KC2SZO=+:Z-S</'!@DB14S\Y_N_SDE.BDDDDI22222E)
M)))*4DF6=D==P6M+<1XSLC;N%6.0\#3<UU]^X8^+6^/8_)NI]7_ ^I8DITDE
M0Z%F9F=TJC*S65UY-F[>VDN=7H]S&;'6!K_<QK5?24Y+/K UW67=)^PY8+6[
MOM1J/H\M'\Y/T/?[+/Y%O^C4\SK/V.^RJS%ML%>P[J6EY+;?T=3AHUF_UF7U
M^EZF_P#1U_\ <FFM"9UCJKNMG /2;FX8D?;=S8@!D7<^EZ3W/>STV7_:_P!'
M_1O]&7-ZCU'&OL95@ORJV;'-->DML_1[ YYV^M797:ZW_!LJLQ?4V?I;:DI@
MSZP5OM],8MY+GL8P@,,[]ONTL]K:7NV9'^@_PB'D?6&YKK1C8%MOHN?639^B
M#K&ES*VM=MM;Z=[V?H['_OU?Z1BG7U?J3[A6>FO#7O:UKY> &G;OLL]2BO;Z
M+M^__K?H>LSUK*'=U'J_V@5-PB6"U]5EIT:  ?0O;[G.=5<^W&^@Q_H[,S_1
MUI*8U=?LNN=6S#LVAU;6O<'-DF_[)E-.ZKVNQ*[*+_I?IOTM?^ ]96<'JOVJ
M\XKZ+*;V5MM?.K!N+F>FVWV[GMV_N*UC/MLQJK+F^G:]C76,_=<1+F_V7(J2
MG__0ZRK,Z??F];RJL@O=3B_KE%3#590[TX=59GMLK_6/U9^ST/0LI_[4W?HL
M+T-#ZH5^ET&AD;7!]I>S>+7-<ZVQ[J[\AC*6Y&0S=MR+MGOM_P +D?S]N=B5
M6YG5>N#(KML!K=34+O7H8& OV58MH?<_:Y^^VW+QVUO_ */]E_T=.I]5GUOZ
M)0*\6S!96;*VXMKWV/8&/?7M-F1-GYO_ )!)3;KZ5TZI]SV4-G(8:[0Z7!S2
M7.>TL?N9^D]3]+_I?T?J?S52J_501]5NCCPP,;_SS6H8WUC;DW.JKP[VFIK;
M+P=KGL8?7:X^E0Z]UCFOQ]C?2_G_ -)]F];T+4;ZMEKOJ[TLL<7L.'CEKCR1
MZ3(=PW_J4E.DDDDDIC98RNMUCSM8P%SCX :E8U?UFQ^HX3<GHC'YC+@X4Y-C
M744;QN:T/LR6LNL_25NK_4\?+LW_ $ZUM$ @@\'0JMT_IN'T[&KQL9@:RENQ
MA@ AL[MOM#6M;N_-8DIQ>C.^M>9TB@]2O95DVL>+744!KFG<]M3A;?=Z?\WZ
M;_Z"B=(Z-U)O2ZL?-SLNUVQS2ZVZ+!N+OIV4TU7/<W=_W)70))*<#I?U6HQN
MG5X>3-C0US'5/MNN: \NW!OKW.J_._T"O=&Z%@]'P*,'&;^CQ]WIS) +G.L<
MYC7N?M]UCEHI)*6:UK&AK &M'  @)TDDE-8/S_M1::JOLNT0_>[?NG]ST]OT
M%5SW]=WV-PV5^E+ QPCU(]GJO_2O]+_2>QU:&RCZT_MQUK\O$/1O3]M(I?ZV
M_?,?SNW^9_[4>KL_[I(F?C];M?9]ER*ZZ26AC-0[:-AM_2;7?I'?I6I*83UP
M_:&AKM6.])Y=4 UP_H_I,:RS<][=OVOU_P!'ZOJ?9_T23K/K!74X5ULOL];8
M#86L_1!KOTU?IN_.>*?99^E]]_\ @_23MQ>L'[0WU&AMC'"MQ>\D.,_9]NW^
M:]%I_2O_ $GK[/\ A/T;_9.LBLM;DB?7^DYTDT$>D]V[T=M=[&GUJJ_3V?:*
MOY[TKDE-5W_.UH=6WTGEP]-EAV^QQ;=MRGGV^M3N=C;ZOL]-K+*O3_3U6?:%
M9?9U\5/N
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M         /_B Z9)0T-?4%)/1DE,10 ! ;[,_OX>   #D$%$0D4"$   <')T
M<D=205E865H@!\\ !@ #        86-S<$%04$P     ;F]N90
M          $  /;6  $     TRU!1$)%
M                                   %8W!R=    ,     R9&5S8P
M /0   !G=W1P=    5P    48FMP=    7     4:U120P   80   (,=&5X
M=     !#;W!Y<FEG:'0@,3DY.2!!9&]B92!3>7-T96US($EN8V]R<&]R871E
M9    &1E<V,         #41O="!'86EN(#(P)0
M
M                        6%E:(        /;6  $     TRU865H@
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M P0&!P$""  )$1(3%!46&2$Q"A<8(B19F-8CE]4E05=Q@<$F*#,T45*1_]H
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M)Y1=@FSZ(_$.6DL$GR,,&A)$Q7+*C:IM5YB_HQO&%71;8HP_5UV5MH.Y?%P
MMX9$.8Z2*!V+DJ!6?MG3P&^>LDE7PA4F)759N'(Q=55EN_&.E&RRJ&7#)?=+
M9-3-=W'3'0$*CL]Y\8O+)LNP?B>'=/WC=.V9C+=IM?4(K*#F"WQ\0"=R1!UM
M()KKT!")Z,FU@NW3@LK))7SW*F!M1^J47:ON%5ORF]13\@ KR53OF&G&<GF(
MAOKU=/P%<F:OCC4C1=AVUK6Q&#T_VY;,6:S R0AHUW$CDGO>,/25>$B^RL!4
MD0L63/\ Q6?R!]+O[/G,4D?6_(L2C=G6IB0QZYIO5TYUJ2IHH'X<Y<NP#!XV
M%FE\5X:<";K)V7)9/"GLP?0LK^D5C<I] 22*2)D'KS?'X\>N^BNO,V]9%B"J
M]AT#@(&E1 6IHS!Y4E.GDRLGE7GKHHR??3Z13C=ON#T)VL=CT9C&:Z%$]@V0
M;TP9T)-'J#Z'LG\DG7'7](-(N=CHV)+V7*N&YDV#5A;0[GN;P96Q^XZ/JZ2\
M^R6QJ%Z;NV[@ >71N3'X@;GDEKVBYT)>1B<-7E=;."'[+Q?N2SWK]&S4Z0J^
MXK'YAMH-\A%/QZ%<^S;J&\^J$0[&.<8=<6T)DDTMBYL_M18/,W6TCB$19D(*
M,6)QN+)5])=VFD;MMG(1D<]!+>R;[ZWBMY492#;K*)71;78,N<2.*5-(@@^[
M>5(5S+R1RLYL6-!7<YL" 185'179$J@<+D0T5)F4>L6+RZRBH9H?9GB&I#?5
M#H*T[]+?$5?X^S9I6HBR;XE%27]S8 P)&1[%Q1;F/K7^M^+6.6;:/)#(?ZK[
M<JY2-A(HF9;Q%$I'UI019R0IB+D([Y"T>CKNY.F?R'GC%[$;!--K)XA 59K9
M,7$DX+6R=]&S4>4AT$@(V9U#$!J3<4Y30'&)_:<28G)8W9G+(L7+';1HCO%\
M:O4<XZ[YDUM2Q4XO^U@FX+TJQ\_B#8(R#&V=46K*(,&._D8Q9-PQ9F2+!@X]
MV82BMH3B,*%=W;J/'G(APST2W\]4R^0TEV 2^2K4[3T?"2B*RZ.TI&:3G<9S
MQB\I\0,AE@5E9VQ?I"1V8\Q<^Y"*6I%9H[1'CMB =O"G8)>HAC>TU7AD=;-Q
M_+'_ +?R_P#3SSSST+O)4>4 _,G\HJZE?OX+B1<_<.2%)Z^G:TVTL))Q)^JA
M^)^/9K$'VL"8$-ANX)."H:#T6"\=<&\,$]S^Z[B:+SSSSSSSSSSSSSSSSSSS
MSSSSW7CQ H3AU@4,'C,/G:K][@>R;,\/'R^<97>.ORR2?YAVMG&,JN%OO64S
MC&=]\^[#W 0%"VSY^4;#6#<F5T9IE"*#-ND^))C]%4F";]VFGJX>:,4UUDV>
MKA135MHLKHCC353?&>DQ!(/@,YCF(;%,1YZ]V)/ .(\(P&=D=W&CS=^Y%X9_
MD5WNSM--ULZ50W7V<::+Y4RKKKMC]"$*AI;9]L5B49)[$]Q2A+8@!%/-B"@+
M;;8(H^RY:*9=[A]M]]A6SC\38?MOMEIE'.V?KW;8>P9K/G#-BS:N";A-V27;
M-D4%B#I%HV8).7RJ6FN[MPDP9LV2:R^RBFC1JV;:[8102TUZA.(1-%4@LC%X
MZDL7*LCI55,(-35)FQJZ+H<9(*:ML;/2K!RW;N&1%SE5VU701506342TVUY+
MB.1YV6;GW0$,Y.L]$$VAIP+8K%FNC;4CHVT;DE$-GB&C?0N6T0U26UPEJ3(Z
MIXUP]<X5^FL? ,23PRR!B&9@CG?) LU&LFY)_E35KHIEX^10T=.LJ:,6.N^5
MU=_NU9M==OKANCC0E'P*&4,HA!".6I9Z>:Y2&LD\MCA+#W4B90SHCC\$L_U)
M$=7I%/[7CK#][A=93#I?\3\R,:CA= LU+1\(3;'D6[8XW(BF#U RW:8SJU0+
M).4%4R*+;&VV&Z3S5;1'&V<)ZZXSGW*&"!(1MEF&%CA#/*NRV6HQDV8-LK;X
MUUW6R@T222RKOKIIKLIG7[]L::XSG.-<?3L?4A?D[AM%TEVS8R@[GBD8_M0_
M]F5QS_2T9^(\7T;"KWBLC(C9!:3RR^C!%4'I)6CZ)NR<G_+"*\+C'48$L!,@
M$-IA*3;Z/,[DM(W/!>A*MB5Q5HK)%H1-6S]V!4ET)F-<R+9$:7( W7ZG"Y^#
MC4O!J8("W>J*)D(P5=-<(/VVBK)TV<*Y5\]QE'K-++C"KMLGEHEHX=X472TR
MU04PIG19QC;?&44M\)*YT44^W3;":GTVS]FWT\3(+8JZ)R2"0V4V-!8Y+K17
M(M:UBYR5@A4@L%R(;MG95"%!WSY A*%AK5ZS<OTPK=[NT0=-U5\)Z+)[;1E<
MZ18G&OF*^19P1F\IF2<JY1X1E QI)OT#\O!QKJ>=A#$H3%/T,&&6_99BY$NC
M+7]?6.GOU,Z6_,&UV/Z>R82Z>>>>>>>>>>>>>>>>>ZDZ>!Q<,3D4F,BH['PK
M)P2,G3I%F)#B1S1+99V_)DWZS=DP9-4=-U7#ITND@BGKMNHIKKKG.*X?R@=Z
M2GL/CJ]ZF^,IUT&5<IK1-.0=_4\X=5E1U3:QJR(N0-,8%;Q240,Y<Q^0)CEH
M:Z8T3B5AD1YU\L8D::""@M_DW^CJ0SJF$\F7,.ZQZ*L?IF8+]&&UXO/;*FDI
MFI)G%$Z[KMMJ"$O)A)9(:8AD3")0DBS5W&I;.23IRFPQLNHX7L"^>>B9^7+I
MGL?FOE;HB9\P4/I*&L7YHM:;NNA$K@@,5(TE* 4</N69UC5TPBTA7L-:-MV;
M63),T=M6A-37 C=OOOC?;:"G@3Y-.]YYVC':WJV7'?D$!%>9+1F\NJ61]D\/
ME6,:/@)[2XH--TY[2'-%9XBCD>VDQL-I"I/L9=2),XJ28J-\1AY^/<D#+D2@
M 4YD C4$6(AV*YL!J12*:AR+QDDH2$:EFFB"!'4>Y4698(MDT4G>$<.4=$]%
M-=<5R'=\=#P>-V;SE%VDYLN=?$>+Z6O.8MG9N8.SUX1N+0@P2^-V!RTLT?MS
ML_86- )\YE5AZ_J3Y^=FO-SYB067=&_HMUE<?)OT?,TA\2F/1= U!7I*;.6;
MGM>5 Z5E\- D4J2)V:RI@HRJF_IY2@R3GRC5 V")%K&2DN8$U*0M_$T)XX 3
M$IUT![UZ"8SFQ([/NZJ*K&)S>QK(L%.\;$ITN,B%;-(WS'R=8M54P"@%F66%
M-Q )=#*T9W/8^&F&0TX*A*AGR4:9;2^1F249D;X!O3H;L\/?4LOK<17L08MZ
MKJ]O14>B!:-2B('K(X]YDOR<%B]A/3^91^KC9'>4LB(T2F'!N H\0)<N%OUY
MJ[4WT#B765VQ:&D8G*2<VE=B_$U7=AU580\@^(L'/4_94^-DN;^#!98BY<,4
M9/I;U9.D+BD XHJ['M)->57GWVVK\&W?H?M61SIN.<5=V\=VS..FZ"NBCZ.,
M='UU84TEM52>]K$J&>5M*"DU7;3J(S.[(X$22Z;B%OADEX[)F\P@%8G:X$Q_
M]C'2H-ZTL$U Y<O*EJYX]<+NWCJNH2Y=NG2JB[IRY7C0Q5=PY65VW56765WW
M4655WV444VVWWVVVSG.<B^>>>J@?(_6-AGOD#L:2#Y77KJ3MY1PRRI'I4SW,
M[I17XX])C+M0:\6D?.J3Y!I8+WH8Y&)F1C;?#=UFT<2!.%R35@&&#W+F</Y$
M/D1I_P"-RH(W;-O1F>2Y"<3D=6D,"PEM'&;=W,S#!^_&)RZ<3F11"O:VB^^@
MY;5_,9O)Q 0?G.OWJK*9PEG%7Q@]M=#=Z!+ON&R*DIFF*=BMEF*=JV*06W<7
ME8;R75L6+BK//3>PXLR9U&4C+]=6.:P/-<+GV;A)$T07DI9B[$J8E1]5WZ@X
M5N]&UOE%?06L;HMZM;DGOQ6V?)!4D/%IT2O^MJOOV33SJFI8-O,"^K$V("UI
MLI'&U2C%F -:.Y'P88+5V+ZM7FUG!_QX2_-8<CVE9A.QZ$E?.=M=?RVGJ;;Z
MBAC^,<_W9?LIG%.TQ-M&B[QU'H^"KQK &!^N!S_\FP"M6T%<(C' %%5GCOXO
M[1Z#L7Y8/E@C_2QFK))8M+U?QC3Z4CIZMYY5D-.QT07Z2EHU^G&K!F]B%%"'
MYF9D&KLH-E9$&ZT;((M?P735\GBQ!YYYYYYYYY[YQOIG/TQMKG/_ .,;8SG_
M /F,^^O0^6/\\?Q@5'UR^X>L?H-U$.A1=AQVKRP(U6MDLHB(ELH3$K"DB]E+
MQ;2 # ^$38]8A(GTB0!"T-UEB)!LDV<;I[!R_P"5KXT8-NH@>[NY64?IY^W8
M/'+J@LT/YV__ %3CT,,'S:VWU_A]J0_?;[LXU^GW;8QF$WOK^DTZ\ZVM%H?Q
MOQ98O=%=%X QDQRU0C>Z*K%!)0ZD$B&+1-D/D'/Q7,A;MQ(H69UD@I\L*7V+
M[CD]OS(UUZ5<-\D-WV ##$:@^*WOJ9NRHP>^V6G0[GSGR.(J/6J+C?"1&\;T
MADD79I;*;82=9AR2KA+7575IKG?"?H3_ )P>R/G5"U/13CF/F*3\9OS-IEQQ
M>40WH*G;JDLC'Z0PF0; )J/3@?[!0(4DJT4>LRZEA/E2A5OH)9MU]E-5,Y3^
M.JCY]VIR_0=K_(>YZ1[^Z+4'OWYGGR\-Q5<<>TT<"2\^Q"/)S"@T:CU?6;,\
M#F;(W@Q,1]M',-WK/(  %::(*JSISKE2<7#6I*&6+90H(V7%LA<:KBO(X]!4
MU#VK)9GEFBY!CC8.3S9<0W;8U#[D)$$ LGJ;-ZC%M-&FC7?(O)?."?+U9.J[
MT/C)1NZDCZ0JG&$?>1UP]4>L1K/.2;9W(I'AP\2U'ZIZN&BS!IAKANCH/T52
M6<N=H///?"B::R>Z2R>BJ2FNVBB2FFNZ:FFV,XVTWTVQG7?7;&<XVUVQG&<9
MSC.,X]Q&PP:R4RJS'L6BNVN=,J-FC=!3.F<XVSIG=)/3;.N<ZZYSKG/TSG7&
M<X^N,>YWORT;H)K+.$T$=%W&$\+K:)Z:K+X1QMJCA93&N-U<):[[X3QOMMA/
M&VV-?IC;/UZO5*/;)["M$PVR6Z^V^XW71CE/9SA;\?;?9GC'V[+X7U_&VVRG
ME3"VOXF<_?CZX8Q'WSUZRQ@,[(([M')%IC#)P]2W1_BP</4/[Z^FZ6,8RT57
MTQG3Z?5';'T]R\N!K1=1/*[%LY<J:JK)Y4;HKKK;)IHZ**:_=JHJILDDDEKO
MMC;;*:::>,_;IKC'U^5'J[N/\.S44V<MUW7_  4-]]G;;1'+59Q_=SMER@FD
MWRW44_XJ6B:.4]M==-/I].$66<*N'2+7Z?EE&ZR[A-'Z?E-\XV50554Q_P#;
M;YQC91/?;\+;.,9VUSG'U\1=,MTL;-W#7=#7;1'79%9+9+7?;.NB:.,Z;9TQ
MMG.VFFB>,XSG.VNNN/KG&/?MLJEK^)]RJ>OX.OWK?=OKC\+3.-ML;J?7/]S7
M.NNV?NV^F/IKMGZ_3&??6=]-=<;;;:ZZYSKC&V=L8USG?;&NF,9SGZ9SOMMK
MKKC^>VVV,8^N<XQ[^_=K]V-/NQ]V<9VQK]<?=G7&<8SMC'\\XQG;7&<_3Z8S
MG&,_SQ[^^AI[,^.RE9C8=GW;:'9D[YQY_O4]39GJJGG1.E@-57;(*=R '5_N
M0L.Q8F\G->N" V,1F.&6<#F 7<XT%(?IV@TPZ>$'.9OE4Z1SRWS0I8SVY>5J
MAC#@]B.R=#JJM)S<(*RF),.3_*5S7U:UY,HE)9C/3CU%%1H$:IGTW0EL3V7%
MIMTUB#30SX&JXL1FMT_?$UYTY#Y9$W>\KQW$ZPYFQ)X+*2HP K-M\6!<?/"-
MPVU5E'FY,W,,\!PL3="YB_T9E-+"1PZ'"6[:Q'YYZ!O@X5^F?-!\Q*GUB6?U
M:O\ BTK_ /"QNMS+G'XKKH=K])<C7T)ASX'+/\)_BPEDNIO8R O](>DIJ^CS
M^,AP<\GGGGGGGGN(^?L1C)V2)/6@\</;+/'[]\Y1:,F3-LGLLX=.W3C=-!LV
M;HZ;JK+K*:)))Z;;J;ZZZYSB,22?*E5$PD1BNN(JSLOY [+#/5@Y97GEL*2H
M.'&DL_A[-;%ZGE[P/28'5LMG&I$=%Y#.YDUTU6RA#WJR"C?%%+X/>;/DI"?)
ME*C=C6[='%X)>O[UWE-O35C%K*%QO.LC$-G485$VV^(0P.:*D]]$09N41Y=Q
MMJS5>BQ#G3=11"XXYYBH.Q=]&]K=V_)+VP_2442>QZN+HL. P<CMG.<[MWP;
MC*+T9!=FGW9V3^TP:51PGG":RVR>-?17N_B]H<?W_%VD*X_;?I"UF1"SP,'N
MJ*UE*"K^/@T&+TB+FME2Z$VM)WL/+G&V[@\[DLBE\VT;KZ 4#[)9PW'H6587
M4EOPU%-C7E6\=44+^F-=6\*B)TZJTT_C],)M @2JQRFVGUS_ '<9T3SGZXQM
M],_7T<_??%UX7)94&DK\.,NE^ZB&8;*3\;J*/@&8J'X//B*0!YJ1E1PA*&:;
M@@5??H11]ABEL\QNCC.Q![OI*FRYO1<#![*07)?1=NU9MF^C%I/L0-DF@BCJ
MFFUU85L,B239%%/&$=$$5<ZHIZ:IIJ9QKC;V/[3X%H*UHUH!+)3EB_0>H/VL
MI_K ELED""J6NZ:J7XLW*R=EN@[14WT<:99XWSMA-1-1/=/&<[/5G7<:J:!Q
M>N8>W7;1R)"TA8S1VOET[43TVW56<NW&==/QG;MRJLZ<[ZZ)IY66W_"223^Q
M/7W/GGGGL2642N]AMC^JB)5Q(V_Z2Y565FDUD$:?IE]<K?EV[)@*A<A9OFVV
MF$-OQ'1<7G9;;=';\%+'YGVAW*E@?(E(%K"Q:< C3Q!F4::!][17=U?LU<[*
M/\$&<:VBD&D>\@$):ZM?H[=M]6Z6/P<LRK_*Z^B,HC39ULT:[/DT$7VS=#9X
MBU64<-4G64M<N$VSA5%NJN@FMG?5%91N@HJGC7?=%+;;.FM;AU=/R,,ZK)V]
MOT=:SLPWX[EW4R=?)4/3* ;>RZ_NG>, JB1UTJ=22Z0^60%WJC+PV2:L])E&
M361Q:4Q1K^<%//+<DB($-LJUU6YKB@9U"XZ9[[Q70&8\?2#'6VLV,W;?VE1O
M?[2Q*Q]Q*35;\]%BXI_O6N[7>M=VT7:[Z:JHGD^1SU+ZM@LTX*&T%S;!)WUF
MRCF@CIUP_DUF5IVN N!]34^UN0EUHY0J XREM9%YZT'HOI3<U@[@2$],125P
M <92 1ITYWPM_GZ)]0==<FM;@Y>K&'S>+1^6=.W%,D(]%Y_(W+JEI7&(?S[4
M?]=^L1"&U@Q&62S:URHL:J.47;5@UB#]N]C)@\W(8$^,82\9W93^ T;F 2RQ
M/'MKB_DI*2"+3 "I)>R7%QTXZ@KV;&I&-9#YM/L;H=-/P!P2\+IHUH6"?E'N
ML-(P5/.DEY="=]WA!>Z:BLM)LZ'/JVZU#2&DEX[*S"M=#XE;8R.4*Z&A0W*D
M$T%CY;"\LW"ZDCZ<M=*Y@1U[,(,V%LQKE@)_G0G)DU#SVX:"DT:BO.[ZT+!^
M,T77['@FK992E43*L&_>E9:SOH!D41E$CT&]$5"4.Y"2%GL'%;0Z"K1"2K'I
MJ$D2J$/]H8E'7UN61UGRA/:;DTANVYI+QKS/<K]B\)5M6UFTK4T7O&?W];,(
MGR0TJ)B<1Z J!I'(AHBS2>D8-,+MTA*VK@S%E7'MA'PFZ9_Q-S7#K;5N"/WG
MQ'\@'&E%6#%04D*KQ^RF</Z\YP;12S)@0$"!B]I@'O/YX!-'1%7*$.0E!F4%
MS(A<Q%AKL%G[I_6>4-UMT?T+"R]YRDQGXSKAD4?9B!+JU1D+E<3L6 (QD155
M5.G 6&JE=-T7LJ?!EUM34O=[O%9 4)BAXQ@-PSR1W9TT0!6VTGAMU9+ ';OZ
M=7<RE W)IV7@KNIJGD.V64JC?/G,4>E@YK-CDT::E@=</!C%ZB^C+69RO2/_
M )[6"*SJVI2N.XZAZ2D/R&_'[\LC6NNCI!,7<"Z;ZU!Q+HP8"DD9F,'"U)&!
M%FV98?+ZP&LI9)Q,_CS,! *JD+N50T2@FJFXRU583_\ SRV+$(I5O+$(FI'C
MR$@K5OZ3B'EP=K4K +VJZK]890-N6.SW%1"R2H.,M)3/CD5"UPS.+%$';-C)
MWZ Y)P0=M=-<5?T?>P:]O2)VOT-$MOCCJXM:< HQX0Y)X)@-: )#1(A!K-W8
MXQT?+XGHVE)RQ)^0)%U&D,.,&8&M6P!X##[OC;F4NU+'7GGH>N9 $F!_,;\D
MZTB;5ZW;G^8>%3T8V@<=?@'KF-.)IURQ:N+$7?$2&DBL'8B/*)$)"/T&L'(%
M*.,$QR2XYPX<S"^>>>>>>T=^3& 3>U/CU[3KBM2;0+/IKS3;\<B!=^=S&&8T
M\3A99N.>N9#KMKL&1;K[:J;D=,XW;:ZY4U^NV,8]39^ KXVB8[/17[QF)3KJ
MYN0)5.M3O/XFS[ LZM#AH!M/5I!(K=KYR8$U219C,D(VE$W]MJO ;?\ .R/]
M-9*.]7V$[JD:KVYBX 1%6.L,Y8JT.P0&!*]J$:%*S 6(;:X3;BVL@R-;P&&M
M4DL?;HPBT2+9::YQHS-:9UPI[P].?'I0M-V,<LABD;F9 DDNF)%3W(:0C(ZH
M[<ING;YCJJ(27=%-U4OL;DGRJSEJ@HMIIMLLMNOG>E)))!/1%%--%)/7&B:2
M6FJ::>FN/IKKIIIC&NNN,?PQKKC&,8_ECV.G-.U,\EVD_=UI!',YT>M26DP7
MB@163:$&2:23-]J;49;$=7;5-!%-NXPXPJEHDGKIOKC37&,D>>>>>>>>>>>>
M>>ZA.0 %7OZ:D<$*$?Q=T/R"9)EN]_&3^[\1'\KJOE?\73[=OO3_  _OU^W;
M[L8^F?I\LY%'R!4D"8'0SXV&U0V,!V91DY*BM7.OW-MB0]%?=VQU<:XSLAET
MBEA77'U3^['OT<G0;)WHP>&131\IE/&C)R1:(.]\K9^U'&C=5;1;;*NV<83Q
MC3/WYS]-?KGW/2<MU]UTT5T5E&RF$7.B2NBF[=7.FJF$E]=-L[)*93WTWQHI
MC7;[-]=OI]NV,Y^,/&F4$G6'3;+9;9+1%QA=+*"N[A35%#5)7&WX:FRRN^B2
M6NFV<J*;ZZ:8VVVQC/Z)+H+Y5PBLDME!79!;"2FBF45],:[;HJ_9G/X:NNN^
MFVR>_P!-]<;:YSC&-L?7Z3435TPHEOHIIM]?MW3VUWTV^F<XS]-M<YQGZ9QG
M&?IG^&<9Q_/'OOSSU#XE?.TUZNF?1O2G5/QL=9%:?O /#>>^>)17O78B&PPW
M(9E(X?&W7,_/P.L1,<Z2LMR=B\H!HWB]7ME&/2"/NMVDIBK(:V=ZV^^TK72J
M"N@<H=\?61V,PP?6U(Q*MQ5*DW4&8M0A)^YG!W:\; KN-CPC9)MN-7?,"KHB
MBJ^3_$::L<N7"6#_ (^>OJLZ=+VN*K[DZ0\P/X2.A1 QK(2?++Q>8-)&ZE38
M=ENASE<-IO$4@JP-_C=67H!&RNY+&@)4BJD7T92;>UQEW7W,$#5NU&8WK6L>
M5YN%PTQ?&A&3,4MJJ9V'EUK!-)CC7??]+(R[=HHE'@^_W%RBRK)%HQ55(C]'
M73"^TN;I 3YR812PM9HQZOS*=*,ED+C\EE4$ECB' R,A.,7DX""'D7C)- :&
M-[("I.4$DG+D$<9)--G0<DDVTQYS@$4@WS%?(L]C ]RQ<V#RCPC/I9NY,G"^
MI"5$)YV$"=D&J1DD01"ME!D>$(:A@28T(BHW5=H#DWKU^X<RZ^>>>>>>Z621
MT++X\<BLC8(E8_)!) &:&KY4U1?BRC55D^:*;);IJZ:KMEE$_P 1)1-5/.WW
MI*:*:Z[8PW0G,]2\V"CXJK0KT?K)W[=^;?E2;@L2>[,M%DQS79TX^W[&0[1R
MZPT;IIZ8UV<N%5=EEE=U,Y^\\\\\\\\\\\\\]'7W^6^1X57D^6X:C/-AEHC2
M=@N5WMERRV1=SL["1!G]PNM21N%5U,(G("VB>@M:--9,4':/I7E)@]1T&[?F
M-JS_ ,+=D_TGZ2VI<Z'2T4=EH^VKX(M&T_D+$3ZFX2D8WD>NCG>OBE2U"9*&
M)3LR^[4BP*I(CT1/W.$U-G.--?77@.QS8&&VDZ0E"2["1VTA1 KO'0-$YEFC
MDLD&<D&S-^Y$IO\ +C0<N^:-7BS/"*CEL@MMNEK7*<S+Y(&=4DK3ST'TL]ER
M''$OZ03@6M,U D&6NZ"W3N"BE5)"D*,Q(M([(:\=Y:2:%)D_VND>[-K)QID0
MKHYU<^+Y@@S,/.+H0&_U Q?I4IT-\@>U8LI5\=5@I7XSF\NN'H':FY'_ &SG
MI!6,-1BRQ>)R<8?4C.X[]@5&\42<::*IEM/74,2B$,FW"4?YDY$@Y/H2&PYX
M!O-O-H1>M,=%U]9;FC+%3M.0]*WF)K4Q$Y7!II9#*."3QN?N+$UGL]D@JU8<
M,FA./Q\DENO;'.;#IOJWD_2].6Z:C<Q@\7F72]O3>.@!EIMWLPJ>31R&\XU-
MI?I^K*^E1H(B:E;^XR(#]'CZWZC680(LQ(QG<IL6P1\7,$(QRUZA4%5=,J]F
MD4X@/0KY")!):QED"5LWM->TZO( I!));(8^''W5-4%1W2DA6L *4E2>T9GX
M![DXH*DH+3/G1@6P:JM><\U2BLK0+<T<!6K>'R"Q$T)BY\L&MN$24$XL_FNA
M(@NW:.M)2<KF\K-NAN'B K#PC'M><*B<*H)IGQ6N_-X-IKK.IK"L*D.JXF1@
M(3O*J#U[2:P:(N">2E^%ZJ''4U^@7A&;)5G7;NBCEFP2Q(&+KP$ *F-0;&CY
M!^RTQT,)-5\24_&Y%B4(X6YDB!<2<!$(W68\.N'DNA?0^/U9/R"*#<M^O[;F
M]WNK?5+99<JHJ_<9V_'<JJJJ;*;;N^>>K6TM\)O6?/\ =-/VW#/D0IER:I"L
M)+2-3H3'@J+R4Y%JGE-J%[2D(H,>(WWAVVE;\E(R(5U-6+5N0V"/=AJC;+1=
M1NK(;\S<^JF"_&WU$VNA&VU(+/JXD%=O'-,5B7MB6,2$A$OUACEY&!R.1J<;
MW=CM6IQ]+B,?AN[9S@2=D0A$JDYQ'A\#M54Q7EX=W$>>@=AC*?D JB]X>K(.
M'9?QE%F[9Y/>G)NK%=]I\V"R&W;&A/[=)1HM*Q\4  !%4L*8 ?CFB[(@NSLJ
M>K\7S\6%FD[2[DGE 0ZG(@&MJQ_C<O\ JV'ID$X6%LFS.1;ZD=[W*(L10%&B
M.T>?6@4?:I)31R-D*[Z1%?UDPV42:.,[[7<:?'6QKRIJB?=%)N'=UP.]NFND
M10&"6=.]ZQKR8=)778%N(QY$(V<QN)V0O6+:;(B ,EEL+<8;'6Q8T!9#&Q7=
M#?13XG6-G1OY9?F!KRS;FMR^=ZOB''4'A-@7:K W,[<P5!?H ^.'.WU=1R'Q
MY\R9&9 ?V:.?V5 /L_F%4G##*:2#IS9$\\\\\\\\\\\\\\\\\\\\\\\\\\\\
M\\\\\\\\]2]^4V,?KORQG?V9NQ8RN^%4:"LDC&Z*[KMRW>3PZCBN)='XK6C[
MGZ$R>D1KLB6@HZ[(XWETH@)1C*YD_+3?2411(0QQ9+^3^8+0[@?J5P+O6'\Y
M2XS3DZ P2U9K,<P(<#ESV.$EAZ3*3MT79<08>-FKU(>4CPXF?";_ 'G18]PX
M%XUQ'%\).-1-G=<1F-LVM.UJA#.;3L=Y3=]OY[NDL*EQ):ZA]@7HZL9O*IT*
MA@2ZW0<*!%PQG+G9!Z\JHI,3("+[R%DU?6%///04\-L$&7S._+WNB6(E-G]8
M\5/ETR$7M2-Z"5U'_1R&PH:XLV2R$=*1R.C?1TG)ZI0C56.G#MR-%1MM)A4L
M($YUO////////////////////////////////////5!?D0Z1BE-?)U<K>*W'
MVG4"Z@RA%+>"TIU;S?3P*R)<S9U@/"MH/0<\H.=3JR"2M73?33]L%YJ+=6)*
M(PK3D0WW=@$]@-C/OT=S(MR)=\D[ J />=!5U!S=D3:NRL;!REX7:Q <Z(:9
MC R0$ S/$Q^W\5M&UT30<A^HNDV[$DV7<:YVC=X8[RX'B_0Z?)5/_'E>_P ?
M5DVOO%E%V<\Y#@_/T?F!DA"[+F]>CI(_@1XLYR0.Q*M+;=0EW)F" MXZATT"
M,">AQB0'9GI\\]#7ROL.V^9#Y-L#[==VJIKSAPSJ2&.B4+(:T^1_:[K'*E1L
MTX@'$NAC0.WRVE6@V:JF)FDM,5G#TNL(=!&C.93SSSSSSSSSSSSSSSSSSSSS
MSSSSSSSSSSSSSSSU1#Y6ZFZDFO>LQET#CG7;"UP;GG(/PG)*=X^YPN:GU1KS
M8/M;YJ4].6/4LMD5!R &87F*N1AB2#$(^F,%S0*TEJ4A5CS"42=3:WL?!U;L
MW[=JLA;UCLN9;F?697-F;-:;D,\BPLI+6\+)V9^P2+76L9>4K=K%)C/-(4U9
MDHE)-BZ<:8LRC%DT2TV^&SEBNI=:LLO&T+IY+ZLM^JGE?RV"69S_ /(;T#V[
M/X\N_AMN5\#'V[O:^@ED#C42B,YG@ZF1^H]VD@0F=GE%$]3'X+_6SIZ-(]\L
MO'P=]U(.&G9Q,7G),BIF"3]&'PE\3S+K.OJ<%ZSKFL:GRZ<CM9[+R-B"%86^
MW9Y:1D;(%OR;B1XP..JB,AUIWW6%PYY<>5W"K+)1[IV;7+6Z1\T'#QO6H;$H
MN/V.3GE=6F&?G=CH^<L3M5S.*:"@ X\)P_ %'RY]$=@.L;PI2 8.(^8/O944
M*&C%37&7!)DPH/8M62A8NM97:;-8J3W;));/R2K1DR:JOG6572C=HU0V5RDW
M2UTE5\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\]2Y^4FK!EG_ "@V*Q_K
M<L>:)Q<ISW-&L5K7F#LB[2?/MN.@M9QN+$3$LJ*+FZGC#^MZHTM.Y::;)D!I
M?%G7.N_L+[8LU9ND;F!T "E(4G&Y.%$R./&V+@8: GAS,N&+C7:>R+L>4%D$
M7#%^R=);;).&CM!5!9/;;15/;7.<>\57U+T[4JA56JZGK2LU3NC-,VI7T$B\
M,4,Z#LN=A^A7>."ANQ#1CL]>;,]7>5L-<NW.4,:975^_)?HF>AOC$<WE9/5M
MI,+E1ATFO4APE,ZU44@VQ]C6-D\)6$7LV&%Y$R_:D/F=QF82!VQ8R"/M743>
MMPB9!%D<T?.6SUGLWR#QW&^8Z0C%9R(J+M.:,++NB[I'8CJ+-P&'%N= S:?S
MBRS\+"J$#KN$"E5;+E$4 L&Y\D490Q?401.%5G!!V\AK^(2DXSSW\M7S.5?!
M1),!7X45R O!09.;ZSO])CKQ*\E-6C @Y-'Y$+'_ *IJ473"3 CO)&RZSAVL
MGH,?"\[67_////////////////////////////////////4N_E.Z4/4U\E%Q
M.ZP/]/5<W3(4!&+8/0KY X#R]6LJE^(-#3$9<)4COSS8\NL-XZ@<D609$DY*
MM*[+TKJQ(9#6BV]>MA:=T/'\L?\ ?_#'O[YYYZ#[BZ)O(O\ ,S\LKEW&9A'=
M9;3G$DK9N)8YKIPUD[-V9Z:%Z26':P%!%ZVA[E40L.9MK&V7L34L+-*$E]@*
ML;T3G!\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\]5[UZ8D?2=OO\ I&B>
MNOBP3HJZSU22D%SY\B+K]JK^I*P*;R3@+M6# XM:@T37I)^3:DY+&AF<&7["
M0&W<C:.Q[N1$V>]H3'\L?^W\O_3SSSST+/(Z-=I?,I\I.8$-EX]\M0/#JMC;
MRII8;5L2L/,EZHU(D8?M/<?D7<15 :1MNS=UU]:]W*MC*0[_ +>1D?IIO///
M/////////////////////////////////1X43\57!=$US#H SYDHZQGT.W(.
M4K)M.EJBE=GG2)"0DI)L6D4NS!F;HD5;/"6R+1]E))=%JU9Z?=LHC^)M(?YY
MYZ,.1?)Q"HUVUKR.^JN4XBK6VH7SD>O[>11Q&,A>BK$Y\.=.Q"N]X9MOM)70
M1_589+9Y.=%4F(Z6&1(%46HT4=FF>F=6_(?P*-^57LN=D>V>3F$)D7'G$<9
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MQI=6QV<K&R] 6S!N.?7LJ90/!$0/;J1%&9?D5V;5'+A15^BB^3F5_LY\]_\
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)>>>>>>>>>__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g459793g00a13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g459793g00a13.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2MP4&AO=&]S:&]P(#,N,  X0DE-! 0
M    *U2^$0DCA"24T$!       21P!6@ #&R5'' (   (8 !P">  ,1FEG=7
M)E(#$R+3 R' (%  Q&:6=U<F4@,3(M,#(< C< "#(P,C,P-S(X' (\  8Q-#
M S,C4 .$))300E       0A\#E2[/O]0(,T4(Z3ZZ-RSA"24T$.@      Y0
M   !     !       +<')I;G1/=71P=70    %     %!S=%-B;V]L 0
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MYU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M  5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M     08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&
M]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6
M=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M
M 0 2JX$  !  (!*K@0  $  CA"24T$)@      #@             _@   .$
M))300-       $    'CA"24T$&0      !    !XX0DE- _,       D
M        $ .$))32<0       *  $          CA"24T#]       $@ U
M   0 M    !@       3A"24T#]P      '   ______________________
M_______P/H   X0DE-! @      !     !   "0    D      .$))300>
M     $     #A"24T$&@     #-0    8              @D   8Z
M    $                          0             &.@   @D
M               0                         0     0       &YU;&
MP    "    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&
MQO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   @D     4F
M=H=&QO;F<   8Z    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&
MEC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M    9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&
M5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'
M-/8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,96
M9T;&]N9P          0G1O;6QO;F<   ()     %)G:'1L;VYG   &.@
M-U<FQ415A4     0       &YU;&Q415A4     0       $US9V5415A4
M   0      !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V
M]L 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0
M]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M
M  #T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96
MYU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&
MQO;F<         "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S97
M1L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #
M    (_\        #A"24T$$0       0$ .$))3004       $     SA"24
MT$#      8I0    $   "@    -    >   &&    8B0 8  '_V/_B#%A)0T
M-?4%)/1DE,10 ! 0  #$A,:6YO A   &UN=')21T(@6%E:( ?.  ( "0 & #
M$  &%C<W!-4T94     $E%0R!S4D="                  #VU@ !     -
M,M2% @(
M          $6-P<G0   %0    ,V1E<V,   &$    ;'=T<'0   'P    %&
M)K<'0   ($    %')865H   (8    %&=865H   (L    %&)865H   )
M  %&1M;F0   )4    <&1M9&0   +$    B'9U960   -,    AG9I97<
M/4    )&QU;6D   /X    %&UE87,   0,    )'1E8V@   0P    #')44D
M,   0\   (#&=44D,   0\   (#&)44D,   0\   (#'1E>'0     0V]P>7
M)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY  !D97-C
M       !)S4D="($E%0S8Q.38V+3(N,0              $G-21T(@245#-C
M$Y-C8M,BXQ
M                !865H@        \U$  0    $6S%A96B
M          6%E:(        &^B   X]0   Y!865H@        8ID  +>%
M 8VEA96B         DH   #X0  +;/9&5S8P         6245#(&AT=' Z+R
M]W=W<N:65C+F-H               6245#(&AT=' Z+R]W=W<N:65C+F-H
M                                                           &
M1E<V,         +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('
M-P86-E("T@<U)'0@              +DE%0R V,3DV-BTR+C$@1&5F875L="
M!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M!D97-C         "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@24
M5#-C$Y-C8M,BXQ               L4F5F97)E;F-E(%9I97=I;F<@0V]N9&
MET:6]N(&EN($E%0S8Q.38V+3(N,0
M  =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,  03"P #7)X    !6%E:(
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M^$?^6 1X"H@0J!:X'-@C""DH+T@U>#NH0=A("$XX5'A:N&#H9RAM>'.X>?B
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M[<_VW____M  Q!9&]B95]#30 !_^X #D%D;V)E &2      ?_; (0 # @("
MD(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,#
MP,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0
MP,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\  $0@ - "@ P
M$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,  0($!08'"
MD*"P$  04! 0$! 0$          0 " P0%!@<("0H+$  !! $# @0"!0<&"
M4###,!  (1 P0A$C$%05%@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MZ*N'&=W"FNVFB=>/R&\?71?<OJB:<[F1$7D,GB=C<B](&GIM2/DT./\ H#8
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M1<;J>D-CT5&;6A%&\'PRK"E=0@F*K+%H<(7M>%FQPP>K1B-C3",US:<5GD6
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MWWU7<I,L.FV7:B">^K;#A#\V=/S)_=X\=F40F&"F8E*HW*, R:X4WF.G!AO
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M05GFB8DJ] OW<8CQUQEP:%[1"O7XZNEUAG8T#J&G/QUB<K+Y-(3SC$A\TA#
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M_N_S>L0C7]G ']R"O\O^7_T%#_+[V_///////////:AO.Q)75%:R*P(E7O\
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M;ZQH[8PD?,HR+$#1 UPG/6*\W.M(-*PLK!.) 0:A<$U\P@GR!6MU>2L1YR/
M1]>1&IZBA]H&'/<-4771IZPE)XK.W$82A DJC''HVM78B"NUR%T+CI.!8OG:
M;(9'9%NS+Y&8/7'SD\Y6&DX$B>=?D%-3F-Q^#%K"BL-X2Z+F"T,<SZ-(2>.Z
MD%@$.(IZBY"+45*10OLI^@DP31,P&<O1ZJ;C;(QGS7\W&I=*H 'YT^1LI.8,
MPC)6:0X?\?/3;R3Q(9--3.\0(R0$W@RA,*RE.D=/[1YT1;-T#&H0KD?NXPP=
M?BQ'?Y[N-$X8\L92I>]-*_'S9>M7\WVX6Z(UB;*Q&TZ_JO<P5W(,P_\ :F\N
M0LG.("M'EG6A5.8YQ&]VN"^<-/#_ ,]W&D47G#63U-WG'7-9$("*L9N;X6Z)
M%K0,I:KUD-K(=,$WL.1VCCVPB)$>PA34OAHM)WCUHW#:/%7".N^YN<_F Y0Z
M;O<-SE"8UTQ$;-.'K$B3-I</--K5*$2F=41)A.K A+X_-00L<QF49BI<,9)Q
MAPIH8:LS0==PT22),]UK3?//////4!?,?V?TQSE,V4=H>Y6%%CZ\X4[ [9=$
M'D,@4MTNF><Y22CPL-HDIM/PIC1A$)$UL8XYE.L(W!S]WNH%V"201HU7U>_-
M\R7:*K'X^>SZB(<M=?D2<NX_E"KRT(M1I W0\?>3BK]#"_[O96#2"#-A%%B>
MXZ5.E!NV0[U@^04T5V;YSM*H!\G[1$$%1_Y/_P"4%7\(@:G^5'CTRHBI]C-'
M3[T5,2S&%$]_M^[3;&,?=KG7;Z8^['O6S\H;3'U_^;[^4;^7\_\ V.C6?_A]
M)9_/_P ,?S]I";?-)%,-[>AE?\C=M![?K&-1T@<TN+FTU$ZTJQ>PD2&D F-[
M2%I+-WL'JO?<:0.2:3ZI[J#HF#/%6Z:NS#.F<IN7Y)Y7P]9;" ]9@'-\#IV+
MIU*O9'Q90LT(/P4\MJ>DJTC4$M"+R&WIWD*K9,OV!BJ1+-#B:D^>I2\=L)9+
MQO"S_)B7R*6#94TJ&HZDYNZ$YXEMK6/K$L6EVUS9+H;3P<6QA$UFA!@,V%6)
M&GDGL4WI$TQ<,B6D@$)%7+EXNL]T38;IJ:]U^7%"HK;,<R7K1M]7#>#:Q[%A
M<)E/('/$HEM3VX.KV+1";2)>&_NU@GR;>50('-18VUHO^]F=8;)VQ =^Y.T$
M4W&_K4_\DLS[9M>SZVY5$M^?M*# 2)*UW';E%38/("%DARJ;!W"8?'8];\)S
MH,@:&S5U;TB>/R#B&YE4&;I!7NT@RHUTW ?Z0-SP7@<%,RCGSL4E(SDE6J0R
M4K+GDI**U,7K%ZV7LRP(=7$F5E6BLD'#8J*.30(Y4TT=OH*U0.KIZ:J;XQF4
M2^3BU;UH2Y>UJ)'P,+SA5AVN_P"%Z@MZIIT/Z5MJ&R> 55/G!43L.MP:%C4C
ML8?9.B7/4>S"Y,G8V^8SNN08IRA/<?('_E06?_X?_P H?\\YQ_[')[_-]?\
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M^["G589(Y^Y8*_D8EM@9$GE-[^F4B-7-1<&4U?&/D+J^]>=8!4Y.C"7*Y%\
MEE;L:SD4K(VL#FB9XI;_ /%F6!>9,MXTU@[.,OEG;QL/:MF35TW1&MQFD[IX
M:YSL@Q_Y.=G%J6GA^91W25?U%3I_!Y.8E439._S)R/%9GU7STW'VCYG^5,O@
M*Y'-W33\FCC19O\ =IFY*MZ],5Z0J4G!XF]JTM$GD!)5RO'Q6T(>P<@)5 OH
M>O%\-<!=XRZ"+*B%@GZ+]NW&J;LLM_T^<I^P.<\S<]V8UBC&?TS7,N908-_#
M43:'(J)>M0L7VT8)JQ-LW4;?BWB3G44+_615QHM'WN1@_9V-6V9-MDL_ UW
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M(%YLWCK-O+4E8INKB1)[C-=Y6QV1S%1M>UO:MKW'%87 +A<"F55R(C^Z.$;
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M*0A0.US+)9O)#>PM>4%AXA,RW:Z08H/X6^B^P?C=I5"SKSJ&"'"GQ30CD:D
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M&'1-[;LR0CR2$'A;TIN0#+3$X^;1]+574E"_#;TS:G*E/2RP^P$:MNK3X_\
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D_B:2FVFU64KS<''R<X1<ZCY$>.C7XG=1?]W9"+S?/////?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g459793g00b19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g459793g00b19.jpg
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M 1$  A$! Q$!_\0 '    @,! 0$!              @'"0H&!0,$_\0 +!
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MA)A]1\"\Q%B=LB0AD@QC<HO[K1VR1@T*EXENX2'2',2J"$.; 8X?HN]P!"2
MW#1-LJ156V36V.VN3H] WKU6K[)+9/$S*G[NZUZ#OJ[9EQ[ZZD(<VEE8NVPG
MI[L2Q0ZLJI_FLL_0T<IUO"HDV<LD[FZ(U&JX*.HAN1:0V XV'H3Y]N]?N1(U
M- !>7J'+WO@OW>.LXM;A7V<1M=5O7GN#G+T20RD4)J6[RU2$Z/:R-PW11,X"
MOQ*$68!8DLLVT=A(NW&*: _Y#IOA^^QMA?:5W3X_49?-ASA\9)_W>OQZ2X@@
M_9BF#XH0<)M6 UFY?OG2N?BDV9LT=W#EPIM_\IHHI[J;Y_\ 6NN<^68E2'H9
M8/&?J?Y0>OT%&[J5MKFL'*:N/LIEM9'0MLST?OM_OGY84'2)IOIM]_MLGMIM
MC[:YQC";S_.]J/@",W?MT<)JER#V].A:TB1SCJ:P"R95C/01&LB532F6-'[:
M IV0SB$XC*[X9-V*[UNSK^>H%XU-6BNB3V,EDMFV,ID,N!;TVN]MOMM.<GGM
M0]?U=1/H*:'NG:Y<A.82T>C5P* 7CP\J(F4N:&GD7@T?R-9KMIS,S6(Z>;I1
MV%N3S\>[#%VYM,7L*)9:I3#)H,76ZXNM]^G654O_ *J?UHIU4:G0YE>O]X14
MF+:+5 ;@@IE)Y&O'V+5>.D7YZ/2:6P^*QZ:D'?ZP:Y+F_P"R#OUQ4B4BB W4
M,Y-IL\+-:T];T].K7-#(:]6/?//T"O8U(>KK#(&O8I[+=E[YM41&V?\ -K#D
MGGNO:[D<VH^M+(DQ0LR'5Z*C-.M"$N()J)DI "9'1N;*2$),43KY&>+31].&
ME]5=7OJ^E5+I>4_:+S+V5>D]H2F6=MY/0RNF5O!)C-:U*PROK7JY_*=H6A/Z
MI,F'*9:115:1Z_PAY@F  -3Z6%7\:W-#FCUTV3#B@+UKN-72<-/[ZR8^\6U'
M%>.>D(KT?8<1JJG9W4,YK^73V:EV88+'4IK'G\='D$G3M33*QIL3(-%X^/9:
M."A TDQ:"VCI^JW041C?F/**W8':9$_7S[4+4Y?]>/:79)+G"WK0O"2V[5('
M>=?XPF9;G-T,I*HN>Z%RO85GB7#!S$R3IN(F)95%9IHR%R M'A2RZF7^&F4Z
MOACECC='EV4\VKDU7N$XSHJ_;M]A'K/[X]A.O=/6T&J-I?9CGVJ.-$D:UAL5
M-L)S(*H:"H%)SU>,QSZQ8KM$+>V8/1!9@B6<,0!!&1FY1HF],E$ 89XXN.*U
M?FU72VP6AT?M+=./.U?6GZU[WLCUWA6UB04E I'S=29VZI5-[!M\+;70,UBN
MK%A! ,?<D)43@PZ%I_E"DG8(+'Z\CR[14421!:HQW<VF,C++ZJW\V6P('+M[
M=:G9^Q?ZC;G7@CI9?F815$DZ(E4:BQAS99*#3(2#90:QEV&KJ#UCOJ\"E]#1
M4DKLWQ.WS1RBI &I(?J@+ED@3,1H4C'P\LCS6!?/3E]OOKTUY/O?ZEWG;BRV
MF]% :9EEVV6%BZ3JVV@*9@08:H;"?C4';>K29+]<;0E4LC[M;9E/D@RS1C%W
M6FHK1\2/HF X1+CX3D78'"\]_29\>+_=;2?*M?(_ZG^+I)?=M6W=\Q]@4UMB
M:NAT:)FNB"L\7!U)):4;&0!K"<1B4-:R)VA-=R+'5E(B4RC8 8JTT<.CB=,O
M#5^E *QKL#=UWXYO6EJ:P>,_=C273=K7)2%LUG->1K4JV LKP'0VV'[8Z].\
M^/H&-LO-ER@I$QCJ-5>5"PPY'CDH@<L._MA;.1"L,'QITD:;!DXN" B(M:64
M]-0]GUE8'5'14:]['3_K^Y Y_7G2'%Y!C*.R^IB<HC9.&+3"M:KM6353%0SY
MJZ4_)D#)95"I"$!_-1RDL0G\:/OF+0K$5V@^<U[_ ,ZUSZDT'X9DOYORE:TI
M;J/!OTTFG#I2]85RISO;_0,VUT1AU+5S(YL]'-MTFBI/$?%JJB(P)^^F4="<
MC*:CXX#0QI\%"9)DWUU^V^,>6<PM#JA\R(O7_4,PJ;F2'.K623_SU<KXWT+T
M4\U2W246NVYWG]RF ?XJ;[[ZCH B]%U?&$/OKHPB$'CPU+31%FGKA&6[6QH>
MAI]]XREKV9$J6J^QK@GQ# J$59!Y584N)9^&<LHW#@;Z0&G">N^Z>JBR8\>X
MR@C\]<K+?!+7/RWQX@+0.6OF(MZK*QE4:Y>1O*U!GZZ^.TIK).O;F26^6[H.
M5N-1N4@,!QLOIJ[:CZOJ-O H T$K;? >Z!$=M$D%7;C3Q_/YTERWKC'Z3VY]
MVWU9,?L'Z!,\K<0]2]"1I+565U92TWD4.PHAJZ;I3382L-ASIZVWUWT7'LY,
M_%.R*6VOQ48H.-=LZXSG;",2\@=E+].?M/5X?YEC_(G+U3T>&WW(F04=0-63
M+GBJCPW8MO2O_P AM*Q9$3<[JO2AJ831^7*JN7KAPLW9JLA:*N&(]HDDDR;5
M^.QP>T;#Q),<OL"OV\.^ZFL:TH!;-JQ:IK-MV1\<>KCF"A9N\@4L[&N43)EH
M/8O3ENR42]8/B5*0I8=+GP*-D7PZ&"AT;;/IRL%</_RR=.N)CBE@T>;.S3$_
MI!W;0=]="M8]]061[$GG'5$\/\<<969RQ8E2<\5_5=K=+]4C8F"@-:'H7!A\
M<DBE#Q<?)CSN_P"<2$R-)O8?)G6H.N&KUZ-,RQ]EJ]<MV3[3+7F51M4,;YVN
MS0^7BB[F?NM_IP/8Y=-#IR>]3;F.W%>74$6,S>+3NRQQEU75=K-)*I8G1UG*
M#31+%HVH]>.F@J%P],\3)!0<@F;UYEN:F+O>-IV?%P'Z30Q:TJW@"K#5MTOT
M-7M2^D/"NI&6'/\ MF7LJ?2NU22QN$,H,F2+Z5"Z9?!^S(E'AYD";7$Z31&1
M[69MHV\CZ8T7^X<1U[N]2CHM,_C._EQNJOW^:WTO?6Y.5X_2LT1K NG/]+EA
MZ1^Q[99UZ$I<?;K5X0A-)1@#+(F=G@]H?#(&966/S1A'%12<Q=CG)-D%(&(Z
MZ;/T9*8+Y2'BY:>;4+OJO%^G%5UD@T;],C3]>=01*W;+NHM:U/ :PB@R9U*Z
M!.Q9&]+:0(M)3.Y%=4FW./LRZOI18;92:;0A=IMN]:IQN$FR+Z,195*2)E\1
M<?* :[]#@#MU]7=N6S\N<C616?<_?G5MGJPU<;?&: KGGP;%WCERK#*1IJ +
MCG(=XR7%#4P#H_,"C@F2$LE2#'+L:FZ:.-6RB.GB97Z<<0VM>ZOZ 'S*K^M;
MFADT[']@M\]0*BB]/^G&KJI=\P\Z291):-6/U)?%:/)I$[BE,5=?],FD[F1.
M(_55.(/$R0T>Y>.9 *;BSZ#QTNF\1K$QT<UM-P';L?ZFM4JY"\$].O9=*>L[
MN&H ,[Q<13L[FBJ;2)T6<63'SR,=K_D!'[D3#R(P[%1-0%)D62 ]9P4>(%21
M@ ':YU'MQVJQ5#F.>+5&.6_]HE7I>AOOII$(*>E3VZ17FHUR!6E?UNM1=-7T
MV[?@^"=GPY([TE:4AC%0Q072[MIM(&.D54J *&L!9^:F#@%%Y2:613&$W6F
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I1004'<%I]8SOB2'B(>(AXB'B(>(AXB'B(>(AXB'B(>(AXB'B(>(G_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g459793g00u16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g459793g00u16.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1"\17AI9@  34T *@    @ " $Q  (
M   1   (>@,!  4    !   (C ,#  $    !     %$0  $    ! 0   %$1
M  0    !   .Q%$2  0    !   .Q(=I  0    !   (E.H<  <   @,
M;@     <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                     $UI8W)O
M<V]F="!/9F9I8V4    !AJ   +&/  'J'  '   (#   "*8     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  7 '$# 2(  A$! Q$!_\0 'P
M 04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%! 0
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FPYX'OO#/BJZO+&_B.E7).ZU93N'<8[<'@>QHHH [O(HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g459793g01a54.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g459793g01a54.jpg
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MOO#$0GV?.X+($G07$[M[Y:; GAXR$(G)CO5;>+$YUAL$NZUN]@<G=V;Y ['
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MSH!@.F]&!G$_#)I;HSKK6Q&:>>^,6M"'L6]=<"XQ))2<HH@@HL@@@L!1))(
ME%$E%AT LHHL&@@+++!K00  '00AUH(=:UK6L#DP& P& P& P(8J[_?CD?\
MUSL7ZO%#8$SX# 8# 8# 8# 8# 8$-<C/^'N]_P"IJS_\$/F!,N P& P& P&
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MOTYQ[^W? ><^;^KG<OTYQ[^W? ><^;^KG<OTYQ[^W? ><^;^KG<OTYQ[^W?
M><^;^KG<OTYQ[^W? ><^;^KG<OTYQ[^W? Q=V<YW.YG4/?IFP8@UQ2P5TI?7
MZ4O50&MJ1MU65C1LD $\2M.5OBE6I=Y(UIB2DS.:6$)IIZDY.02,S06-P& P
M& P& P& P& P& P& P& P& P& P& P& P& P& P& P(:HC_<A\_KEY&?K"6?
M@3+@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,#5E%WOFUR%N+ENCK?D_6=*P.B>1/F1B\4<N,::TW-:A14?2=F*7Y
MQE2JX(88-4M=+/7I/$0L^RDQ+>2,M2()_@$X27YC.T0]?ZI_J.-OWC,!YC.T
M0]?ZI_J.-OWC,!YC.T0]?ZI_J.-OWC,!YC.T0]?ZI_J.-OWC,!YC.T0]?ZI_
MJ.-OWC,#'HQQFY^Q)M4M31S]J[217(9;)C=*>$3:>9Y3FLK>ID]["/WQ0.ZG
MV\OR_:4GIOQ=+LDCO#\'WQ!D/F,[1#U_JG^HXV_>,P'F,[1#U_JG^HXV_>,P
M'F,[1#U_JG^HXV_>,P'F,[1#U_JG^HXV_>,P'F,[1#U_JG^HXV_>,P,_X%VW
M8]W<88C/[:=&-]L'W<WQ!Y ]QN/[BK,];J>_[0JEK=TL=VYO6F<QR984VK5B
M(#HM++7'J=E';+V (0N'@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,#7]PA_C2[2;^WVY?JB<1,#8#@?@M;$$0="$#>P[UH8>[
ML0=[UTT(.AA&#8@[].N\$0>NOC!WKKK8:PX[RNL2$SEKK&^W<368*T;]?H!8
M3"P->F^[J&J%JNMR>(VM1>2STC-<5:J(/'2ILR1TMKW+8NL9YQ$-)B7.7L$&
M#.Y?SM%!XH"92&E94E9'=JDR^#*RWHE1JQW!JKV.6A&XU#D)+*-]62&<197.
MTL>2+F5 G6R6JI:B;E;FP+HK*'X)Z=^1,=;JVC]DI$93PUSN=M\%K436O6.+
M=,3G^0J6"+/I3DTLCF<2PR,M(:^-BML;'TQ<S'-QC42YKG-(A&%8YWV@RZ%,
M<I7J>/DX)>HY'9%WXPMD,=/D0K%:.*5F<J$L"&UL)CT TPQHJ:609Q<D;@>8
MFE)T>TW-KLB<G$]C#)U7)/=2&5&Y6/8SU8)EIT(^VB!+'XC$$U?+W(B:\?8>
M4[1-[:-%RI@BZ&1WG&&="VOHI\M7QZ5H7LY^5GQ%]5.(=\WFT8T2H<9E],2N
M*!9U=1)I<X+GYH4C:$]TW)<=(PIU:&<A/IY>6YPDE3%24LAR1QI^3P>6(%KN
MQ,\K;5\,V$]41=>[PCIDK3PM[BK X-D1D\-='12G/23*&S>,H9(R/K<#9:-P
M3&$;4JV=U)/;QM6W)N.-CK])6DTISV$Z8# U]]E]_P 'C!_7MS._71Y X&P3
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8&O[A
M#_&EVDW]OMR_5$XB8&P' \9XD+.PB; .JT*<]Z</)+.D+)4*U[LY!0K70Q$V
MMZ(E0M7*"&ML<G12!,0;M,VMZYP4>"1I%!Q8075D]XV645#VVM=11< +2ON:
MO&TZ&KXT:I995IU9'JS8*ADK"SGN"%UU-W5ID$JCA*@O>YJ<B>%H-RD);@'G
M0DGBK!]-M<US#8!&V>-V6I0-#?"JR&B@;%;?B*MB7(VY_8XR&$-TY;T)RV,K
MDZ9U)>&8 %$84@1"2C;B@E:4UK4SO69U;S.#P-=434QM:(Z%R%A8S($U1^(:
M1K&0KR*N3>0VUMBNVAO6M @$$$L)C6B5H1)#$)!I01C FWC!)G^-+H+!(26^
M@;6VP(0[EU:HC6U33%8R76S),82].D8:DCD@981,2X:ROD;6*2$\+E&FAN4^
MYYY\$H#-B^/E%%('!JU3U:C:'2*O\$6LYT,8%#..#RP]"KE4+):3T!C<DB,H
M6-;8MD<:1IB&5]6MR!8ZH5:I&G-+#%9-6O&.I(P3*G^L*UC$;BPJ\;$[@CKM
M K\D>YJ;*'"M"R$[*QK5Y9<6GTO<'^.J"R-EQN0R!WDA)R!4N<W$89O%(73M
M$M1#!!H="*J8)1*?BMT2C39%&)PEK^/P9 E8&9"D;"7-Y4%$-C>8MV3M>N&V
ML: 1JQ2W(30E/ 8&OOLOO^#Q@_KVYG?KH\@<#8)@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#7]PA_C2[2;^WVY?JB<1,#8#@
M5VL.)28SD!0UF("5#I%HO$+M@+TTD>&&!!([)%5[Q#YDM+*)/$4@:RZVD<-4
M.)1!Y[=NPRSC"@M8G12F"HG&;B5>M#NM'2=6& .#E57%-50<G8C+>L.9-<OD
MJV75>[I7B%KIA6VATY&F5OB,H5.[;#F_::R5JZ%M<FCZ$NOXR]MP6/X]59:-
M&PYUJ<]LA4IC#78]N3:*3=1*G9.\OC19%GS&VV]#*(V.(J0H)>UO,M'''9[1
MOSNWN0$(9^2$MQ7FP=$'J6O YSR1I/DCQ_FS0DJQ+9M1/E7-,YB\H72_0%%H
M58>T2A>0E<8K!U&AP>1O2Y DVG$N;92SIFYQ$XLCRM?HG%P\><P^^K'K"/1I
MW@]0-$B0O=?BD[<DL25'QQS;6:1LKC*=QM?JMP@*;-)6S2IFC\RA\B97TP!+
M3)F M(E I6!3-@X9<LFF-PU:LDU=/-EQV'1&.NSXZ7-<VTLB-:>!UC<?)*D6
MOK+$F&7(VR57^[U[9;RI8G%F?5K?&"I<!U23R-QHC8<SIP[Y2N;(^QET/J:2
MQ=T>)(YQ*./=DR0A%62]9<L'M9J?6G3-2C:T*E*IM:WV(+$39'&4F-%-K<:P
M#6-\WEB%N#*S>-W(M.RW(SOQT8*-N!YX^!B1,*FLQE9,0F4'Y#SN?SBT5.Y/
M#F0]I\6@;G#9$0Z/TJDDF<GN%(H9I[7#30U*,-JF P-??9??\'C!_7MS._71
MY X&P3 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8&H6LKN?N+]X<Z&2:\9^7,P2V=RS%:\(E52\?I?8L,?8:X\<..D*)6(Y(S!
MT@-5$R*"R- K2%B&8E,1Z"=L)@A%@"=OA"6/U1.T$^J'8F ^$)8_5$[03ZH=
MB8#X0EC]43M!/JAV)@/A"6/U1.T$^J'8F ^$)8_5$[03ZH=B8'0([1Z(JE[@
MU)N*7/H]R:@(C')"5Q)L$:I"6X@.,0#5$AWL9(59:<\:?8]:T:$HS8>N@[P.
M_P#"$L?JB=H)]4.Q,!\(2Q^J)V@GU0[$P'PA+'ZHG:"?5#L3 ?"$L?JB=H)]
M4.Q,!\(2Q^J)V@GU0[$P/5[-6.2Z+\0(6AG$,EE?2%TLSDW,1Q"<LBJ-RUH9
MK Y17+.XMM]8EV@JVI8X1>1LSIXFHUHTHI:5H>NN\"]^ P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P(;A_P#')<__
M *75O_\ ER3 F3 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8$0
MS:=3=JG,8@L&AL5DRY]BDMEBU;+)Z[PE(W)(P[PYG E2A9Z[GQSDH7G2X)HM
MG ;"DA2#>M"5"4ZT0'!Y<Y"?-A37MWF_W<\!Y<Y"?-A37MWF_P!W/ >7.0GS
M84U[=YO]W/ >7.0GS84U[=YO]W/ >7.0GS84U[=YO]W/ >7.0GS84U[=YO\
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MM;#L.A:WK0>?\)'2CA\>(5)S:GR87^B7Q3@?RXTVGZ_\1+C(JACR,0/YC!'
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M$+E[:T,3(]Z,2TUR76NG*BD%I)&N\G9B'.<O23D##$8]:VF+4QFZAH&XD0#
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MIH#E[ KPD+Y6#S'9A27(6&MQ3G../=N($;)8+2U#4"1:E<75-ZYSBUH5TI7
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MTWH"A(H-*%L(M:'U#O6@R/ U^=G1_%SR0_O ^??ZU-F8&P/ 8# 8# 8# 8#
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MN*UO,VPZ_&,")EY#L\FT#KU[@#(H6I'KT^+!UO74/KX05I3^AUX?=H$TF?\
M,7[TZ:2'N[Z]-Z\+"U<G3BZ?SEG##O7XNQ8#X0V*#^*EXJ=H$J,W\A?O+;H0
M==_DUX9W9&U*'K\G>&>$&O\ F$'7IP/S?.R8./X.)=G[SYDR@?4)&EE;T[7B
M38]^@'C"NU;W@^TQ6]]-C,V08(L/7>RM[UL.!\[OCM Y9U30G@-#Z]V?\4IW
MY$\M(2SDH-"_%/5L-!PCD >NV#T>$1IWQ'L6][T%9KIK8@XA4[VAMGZV"SN7
M%64(QG_@54=XG4@6[S#:0S_6  M[D0\V V%*]@$(@A<V4DS'D= JB=E*-![H
M9]5G KCG64Q16DYL,ENNZD&M[27?R)F+[==G-A@A@%L<5=9JJ7M%=%]"RRPH
M:S8H8V *!HH"$(-BT(+F8# U'\'N3''"M(SR8B5C\@:2K^5(^?O/%2KC,VM:
M"120)4Z[E%92E$>I9GU^0.)!*Q,,"A*::F"!00,!I0AEBT+876]^MPV];7C+
M[>:L_>O >_6X;>MKQE]O-6?O7@/?K<-O6UXR^WFK/WKP'OUN&WK:\9?;S5G[
MUX#WZW#;UM>,OMYJS]Z\![];AMZVO&7V\U9^]> ]^MPV];7C+[>:L_>O >_6
MX;>MKQE]O-6?O7@/?K<-O6UXR^WFK/WKP'OUN&WK:\9?;S5G[UX%4N.EDUU:
MG:$\XI/6$^A5CQLOCKP.:QR&!2IBF#&!S22?FF<J;ANT>7N* *Y,4J3&J$FU
M&E!):@@9A80G%[$&S 4?81"V(3(T"$+>Q"$)M1[$(6]]=[WO9/7>][].][].
M]^G>!^>YY@_,;/\ 1B+]A@/<\P?F-G^C$7[# >YY@_,;/]&(OV& ]SS!^8V?
MZ,1?L,#YW&XZ+>MB8646]?)O;6AWO7_VWLCT?_Q@?7N>8/S&S_1B+]A@/<\P
M?F-G^C$7[# >YY@_,;/]&(OV& ]SS!^8V?Z,1?L,![GF#\QL_P!&(OV&!Z"9
M(E1%>!1IDZ0GO;%X),2605WA=.\+P900 [PNFNN^G7?377>!V,!@,!@,#QW6
M.Q]^!X)\8V=Y+Z=WP;JV(G$'=_F[BP@X/3_ITZ8&(ZIVHPF>&#5E<:.Z][PN
MH1&=&=[_ ,7A--?>Z_\ 7KUP,R:V-D9"O ,K.UM!/30? M;>D0%=W73IKP:0
MDH'3737373IZ-8'J8# 8# 8# 8# 8# 8# 8# 8# 8# 8$3.U!T4_.:]Z?*6J
M9Y>'14>N<W9VKF'N+FXKE)@C5*Q>O6,QRI8J4&B$8>H4&F'&F"$,P8A;WO \
M_P![;QV^8.EO99!O\BP'O;>.WS!TM[+(-_D6 ][;QV^8.EO99!O\BP'O;>.W
MS!TM[+(-_D6!$%^\=N/R.F;'5)*+IQ*I(C*TPE0GK&%$'DCULOH,HTID"86/
M7Y! %K>OR;P)?][;QV^8.EO99!O\BP'O;>.WS!TM[+(-_D6 ][;QV^8.EO99
M!O\ (L![VWCM\P=+>RR#?Y%@/>V\=OF#I;V60;_(L#-HA7->U\%>" P.&0@#
MJ),-T!$(NR1H+D-%H_2,2\+*A1:6"2:5*=)A*-&;(TH/T5L&C3.\&9X# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
MAKD-_$E9?_XLN_\ [+P)EP& P& P& P& P& P& P& P& P& P& P& P& P&
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E8?(,:5<GG1N,$@<GA^4[<!*9*X:4J/']%&E!3  G*$6,9H?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g459793g01g05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g459793g01g05.jpg
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M%8[NQL<LM[#I4R(DKI!'#+*S6WIK0;@EB$D):8[<( 7#* $?%7GCE>X'TA,
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MRPTC#;;+32,);;:;;2E"&T)PA",82G&$XQCTJ$DDDG9/DD^Y/YGK10
M- #P ![ #[ = )ZN^&]\>73E]+[,"Q-D\[6NQ3Y!2QP](F:V-HYHI,=4]-)+
MI%JJMG%@I,E:LK6Q3G:R)4^IR4Z+>DOOO.,U+NO*TXEA)AM1H J&RKM(JCP%
M$B.C,!^<G,Z\ @#I!ROPW[=R<[V46SCI9&+R+1DC6!V/[S>A-%*D9/OJ$Q)O
M;%"22=(<%>%3AWQ[V+&PM65:S[!W W%DPH6W-PF!MHMM?B3F%QB$>H01 2MU
M2JYFQW7X<@H)KK5D?&29(J4=DCY,F.]4R?<&1RB>E.Z10;!,$"E$8CR"Y9G=
M]'R%9R@(#!>0!Z)8'LK!]O2?,58I;%P JMRXZRS1AAIA"J)'#%L$J72,2%25
M,A4D$F6S]? ]M:TV'JJS/$8];V91K;KZPR [[$4LP#N8 A7"SPN5*BSHT8BU
M )2%P7Y$*8PS)2TX]%D-I4TL1#*T$T4R:+PR)*@8$J6C8.O( @D; V 02/N.
MF:U72W6L592PCLP2UY"A <)-&T;E"0P#!6)4E6 .B01XZ7=_HJGC;_O[UK_F
M;K3_ $6]-/\ +/+_ -72_P!#+_S^L\_L5]M_U^6_UJM_T76A.5/AZ>&^/>@=
M;=):LN'1Q&_ZL)DRU<A7.^40M6'Y):O&*U)26'"M6@2$EE(\W,6RF,7A+1*2
MPXI:VT+9<JW>Z,E?JS5)DJB*8*KF.*17TKJXXDS,!Y4;VI\;Z(8KX?8/#Y"M
MDJLV1:Q59VC6:Q \1+QO$>:I5C8CB[:TZ^='R/!(7W7PQISR%:09T%O(K?0]
M)9NH"^(EZX-!@-AR:KD0Q"@-*G':W:8.1ZV3<S,EC S#[CB6,MR6DH6EP7C<
MC8Q=CYFL(S)Z;1ZE5F7BY4GPK(=_2-'?Y^.F'.X.GW#1&/O-.D FCGW6=(Y.
M<8<*.3QRKQTYV..SXT1][[TAJ.L:!TUJC1E)D&)=.TYKFEZPJLJPRHLX_)KM
M$KHZLAGS4V#!&0I95T>,CK(28@V!&?E*=<9AQFU)916L3O9L3V9 HDGEDF<*
M"%#RN7;B"20NV.@22!]SU?HU(L?2J48"YAIUH:L1D(:0QP1K$A=E55+E5'(A
M5!.R /;H;7>/A+XD\A>S0^X]Q0-C4O9(\&BNFK3IZQ5RIS+P-A^RD(J[-':=
M;HA@C78S;@X078CP"N!3S8HC,(#A8*,*+8WN'(XN%H*[1/"6YJDZ,XC8_O>G
MQ="H<^6797E]0 )8E;SW9.$[AM)<N+9ALK'Z;RTY(XFG4:X>N)(9E=HQM4<!
M7X'@S,JQA"[>@?3=U/4ZG4]3J=3U.IU/4ZG65^GMOV_4Q7EV'4\C,,[;ZHH6
MH+;]R@YFKS4+'3-CG2.!BL/L_HB>9U7%^Q.SA_#3.)#?L*]["D7*D"3+<+[_
M )BG+.FCKZTDB4;\>1ISL>/.O/0O)W)JCXM8N.K>4@IS<EY?S,D%F1N/D<6Y
M1)IO.AL:\]8JW)Y ME:'ZVZ!H-_KU=8Y=INO-/"@6WF&'TS-2[UVO7+T3H\?
M:J5/YBKUALLQ6VZ>-MORAQJE>EU@(<7]ONS1,20@QD-FE6EC=OG))9V: D:F
MK0O&)##XWZT2OS*>><8=E^I.+!;O<%FAE[]>Q'&,7#6IJEP \JE^VD[0+:\Z
M^5M/$(4F^D0S^DDAXSAD^IN?H+IO/C?T3USKC9E,HNP2VD^?]@["&%-5QKH"
MMIS<T;5<*>@6S(M81VJ0P<^VFB,5EE1;,Q#D6"ZMA$;WW>L%:I^*V:4L,DD2
MSVHXBLQC9%K^N1L\&YE@B@DZUY/G?7-[(Y,=MT<O6LP06'I8^Q81ZHFCF>Z*
MBMP!E0Q+&TSL .?+84ZUL]?VKNGHWF?4?+0BM7MNW[/VGTJ%TY=[Y6^?G[V8
M)UXGJO>6PG9=/T@&O$!3QEJ70:Y 4RS;'D-#62Q%>,Y<]IGICX*MN>XSQ<(8
M:C3QQ/9]-0PFKQ:DL,GA=2N=E!YT/X^V:O9'&5,4D<XFLV\FE*>>/'F=VC:I
M?LEH:,<ZDN&KQ+H2GZ0[??QZ71G0&_=%\!0MR_OB2YMHKLWG^KN6RR<U6 .=
MKU=W#TIK;5QA<GFX1:+/:"]JK].MY-8NK"C<LW8S#$!(^'F9,9A*YJUJUG)M
M!Z0] 0VG$:6U96>O3FF4"VR*@1Y(QR=E"HI.SH;ZXR60OT< MWUS\VUG'Q&6
M3&RI)''<R5:J^\:LLLSRQPS-PB5S)(X7BO)@O7R=%];[GN/)O:NVR)X/L'//
MO^V6!IS<4G2-UT"K8T_6.IHY^QL6[1.PS$ZX5<GKC;S-IUJ<^X*!-6%57><C
M!AKC4F1*YL48([N/@"M%\U\N9X!8CL^D)IRB%+,2A'$L'"9=<BG,;9M@#I0R
M]R?$YJVTBV/P_P"=6G<:C/CS8:K4$D@FH66,T35K8EK2<O3$AB.D4@D\9S9Y
M#-G[9VIR/H;9=>K>O-YV0!L&9TE0H\9^5#,"8>H(&P-2;AU"2E2$27M5;0PY
M-GCWW6YDP&:'6?7!UQ%@IY%]_P!+>,AAANV86>6NCQ"I*?!4F<QSP3@>/6AT
M ?(#*5E4<777ACNX;5JWB,?:CBKWY([!R=< E75::V*ERFQ.S4M'D5)Y%'26
MLY]2%B?:V]Y,A>NO(U1.8TWK34/5D UK72^U0!FSAXNYGMW= @+;9];%:=7G
MC3!&;1J2H'J^JW>4R*DM_=.@ \G+S3=.*^W(,29<5)<].<S%9;$#*C>A\O6=
M$F$C<="23E,\8Y?NU6&MR+UVN=S)6[CKXOYBFM4/6I6HWE073>R$<TM9X8RX
M=H(>%6&8A#]>00[ A?JZ-SV;JD3VUHG4U(WU3:UJG=5-W+?7:V1T:.L9VM1=
M&)T7"F@(]K=O0UPIB\2]D')SA1\3$=KB68<2+$));4ZJO72FV/LSR5I'FKR5
MXN0L%%<V?F2&*",\?3$2C6SS\DD=7+LN53-T*D%^&.I=ANV#&U%9)(A1^15H
MQ*9UY>N;+MS* QZ4 -K?5SUG=]KE=7]3ZG+LQY="TOH'F'9]:B"A:G+(^;VF
M=ZCAW-EU_$C/W1+\+4-3;!CTLL*C2OU^/=>S/QAFN]=!2ISKL26+-R%RS:0+
M"M,Q_;Z=&=^1WY&O;75V*]*V6RM-P#7I8_%VHPJ_SI>W)E5G!._J!6G#Z:Z&
MCR\GEXQ2!ZGZU'<\:.[SMMST>=TWNHQH$H2YKK6OS,>QT_6725XI5+I<>H;J
M7L&:JZ;BI>-@5XE:AY&A0*M="4*Q56M#:J_D2960>G2-JQC8X["SUULJMMY5
M*R35(Y))"]?TAZ<$GI.J$2EXU*.[2#D.@L>5RPQU'/2S47I77Q[MC4KN)8:N
M3G@A@$5WYEO6N0BQ$\JM76*=EDAC2(E'ZL'H3N/8/.G;@ZBVJM!2'( KGO6]
MWW-?(C,A-OTK9-F[;V=0*YM(VK#JHL_3@Z12A8'8SF([4RDL'XE_?DYK .T>
MQY5<=%:QYD1V%YK4L=>(ZX6$AAAD>%?N+!$A:(;(D*F(#FR;L9'.6,=FE@EB
M1L.F/K3W9P#ZU*2S;LP1VW]PU)# L=DZ!@$BV&/HQRE?.YW84H_B]'=I["(4
MK%\+ZSCR@&)TJ)6*.9VE<[(Y2-:#ITN7/Q&#UB?;"=?_ '"47.4R'KN"YU]U
M,2 ^XB?APDR[8^(2>FLQ#:!>588U]24@ #DX0-Q76V?BH\D=<G.M!VPN:L/
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M'YCZ7)+PL*)'N.*B#8;+/C"3Z>!.SL7IE!^X46:S!0?L SLP \!F8^[$FU:
M$W>(  #8BJ[ #PSFA?0N1[%BD<:%CY*1HI.E4 ;/PS.V]K;,&]BC]D;-V%L&
M!3VN;X-1@W>Z62UPZM"EQ]WL2X=<C'B4]D)%DLB1;,B.,1%:>:&CVW$*1#CX
M;*=V00P_(-%#%$TC7#(8XT0N1\L07*@%B"S$%MZ+'\STM?#.W;M)F%LVK%A8
L?PU85GFDE6)2+H*QB1F$8(1 0N@0J@_NC33OI/ZU/J>IU.IZG4ZGJ=3K_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g459793g0830051411016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g459793g0830051411016.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !  ,\# 2(  A$! Q$!_\0
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M9)/:@"GJVK66AZ5<ZGJ,ZPVENA>1SV'MZD] *^<K"VU7X[?$-[V\$EOX>L2
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MT)?.!^\*_,..Q)4]*]>\/^)-)O/!BW7@#3+6\2$@'34E6V=,]0<@@-]>#ZT
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K$;I"Y)'0#@'\*^D+2UBL;*"T@7;#!&L:+Z*HP/Y5-10 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g459793g0830051411178.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g459793g0830051411178.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !I ,\# 2(  A$! Q$!_\0
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M,=VG:*-MV\+D;"NT#Y5Z#/'N:-0T*Z^+%^T37,:23VLD-MY,>478[F4-N8D
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MXZ<TX>'[ 7_VLK,["1I5C>9VC5V!!8(3@$Y/;N:-0T-2BBBF(**** "BBB@
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M1_*>!;4#,@E8B1M^_&-V[.[..,YYJS;:5I]I\EO;HA$7E$*3]PDGGZDDYZT
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M5;CL[6*S^QI;Q+;!=GDA!LV^F.F* .*U*./3+&^M;.WMM,U#["91+9<I)&K
M'(XVMEA@G/!.">:NWVL:S8C4I!/%,EM<06<:K;_,7=(B7/S#@%SA>/K6O]A\
M/:4KVGDZ=:B[78T3!$\X=,8/4<]*NKI=@EI):K9P"WE $D6P;6PH49'?A0/P
M% ')OXDUI&CL3#+Y[W!03_9EW[-F['E[\;L^_3G%3:?>:OJ.LZ:\UT(/]'N5
MDB$0PY21%#8W'!((.,G'([UT']@Z3]B^Q?V;:_9B^_RO*&W=ZX]?>G#2]+EC
MAC6TM62U)6)508B/0@>GO0!?HHHIB"BBHXYXI9)4CD5GB;9(H/*G .#^!!_&
M@"2BHX9XKF%)H9%DB<95U.01[5)0 4444 %%%% !6'KL-M+?:<\EU;Q74;.T
M"7*;HY.,,.V"!T.<]>#S6VS!5+,0% R2>U946I:%KI^RI<V5\<>9Y1*OD>N#
M_.@#(TK7;5;N.-#;65D8[IG5'!B:1)%RR-@9'+'MWXXK+6_OM5M+&6?5);?Y
M[!V>)(ADR("2=RGOT[<UUFI3Z'8Q00ZDUC%&.88Y@N!CNH/3'M5I+6PN;,!(
M+:6VE52 $4HZC[OL1Z4K#.4T[7M5N=:BWM)Y<EY);O [6X154L!MPWF[N 3D
M8// X-3^+1I[6>J^6UB+XVP%S]I)W^3AL;,]&R3CMGK721Q:?_:$KQ16_P!L
M11YC*@W@'ID]<<?I5*\U#P]]H@>]N-/,VXB%I2I8$-M.">F&X^M '.1W$^G7
M5U>QW=E(LNH0JMFR!IV#K&A!.<JX'.,=N>O&:Q0^&M(%AM_M<6]WY_E8\S=Y
M$GF;L<_ZW9U[XKM;C4O#\&K$3SV*Z@A"DL%\Q<@8&>O0C\ZO21V%@+B_>.W@
M^4M-.5"G [LW^-%@N<[I+::/$%@VF- +<:2?-,1&W&^/RMV._P#K,9]ZOZ]!
M$^HZ&6C0DW_)*CG]U)3;Z;PW!"MO<3V=LEP4N=J$)YH#!@QQU&15J;7=%6:%
M)KZU\TA9(@S#.&Z,/KS0!AVIOK*ZN+F*](MFU?R#:>4NPJQ"DYQNSDY&#CCI
M47A_7M5O]2LFN&D\NZ,GFP2-;A8L D! K>9D$!3N'<GCI79>1#C'E)@MO^Z/
MO>OU]ZS;>_T'^UI(;>XL/[0=BKB,KYC$<D'')(]*+ 9.L?V?;:AJMX\MA.WV
M=!=6EW\K;0"1L;L"#TP03W%4&OYK*;5KB'4+I6G:V6"W=8LQ[U7'W@,8Y7+$
MCU#&NSFL;.YF26>U@ED3[CO&&*_0GI1+8VD[N\UK!(SIL8O&"67.<'/;/:BP
M7.,T_7=0OI%LKK5ULEC>X#7@\EFD,93"Y*[. Q)PH^[VYJ?PQJ%Q<WLL#W:K
M \SRQS)%M^V$@9P&SM X.WKR.< YZ>XLM,BL7^T6MJMK$#(P>-=BX'WL8QP!
MU]JG-M;LN#!$5W;\%!U]?K18+DU%':LB#Q+IES>"TB>Y,Y*Y0V<RXR2 22N
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MJ@/$FD-:27'VK"(ZQLK1.'W-]T;"-Q)'3CF@#E;;47AU#39?[1LM*+:/$O\
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M#H#C'4=J2"UW>%M.E>W+3C5(F$[1%7D4W:L9,'E0WWL=J[:B@#G[_4);1O\
MB9K#9.X=+:]@4SB/ID-E!M)P..0<'T%<^MS%#X6:R9I]/O9X6/GFS+&\4N_
MXR"V=VW@KOXKT"B@#S\'RM,U'2)+26*_O+J"2WAVLWRE8L$-TPFP@GMMJ.*&
E[NKC3-)LKK,=I<2OL:U9)85V2#]XQ..K #'WLYKT2CO18+G_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g459793g0830051845982.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g459793g0830051845982.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  5 @<# 2(  A$! Q$!_\0
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M#;'%*S*/F)8H&3Y>> )"<?WA7744 8.E#4QJ\K7)F^QM&?+W$D$@)C((RO\
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M:^,]NORBBB@!7T&.9F^T74TR2-&TB.J88H01G"^V*LWL""RBAC58T2:':JC
M 613@#\*** *>L>'+76KRVN;B69&@&T+&5PPWH^#D$]47IBL@_#G29$6.:YO
MIHUA2 (\HX1=F "!D?<'YFBB@"4^ =.+2/\ :[OS))!(9!LWAAU*MMRN3Z?A
MQQ5FY\(V]W+/++?W9>9UE8XC^^H"AON?W1C'3OC/-%% %*Y^'.BW-C):%[A8
4W39D,NX#<C=2/^F:C\31110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g459793g15g15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g459793g15g15.jpg
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M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
M !$(  L )P,!$0 "$0$#$0'_Q  7  $! 0$                )"@@'_\0
M(Q   @(# 0$  04!        !08$!P$#" ()(0 2%!<B)/_$ !<! 0 #
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7@IC HC/FP1HC1 5*J95AYLZS/Y@K_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g459793g15p01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g459793g15p01.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[0SX4&AO=&]S:&]P(#,N,  X0DE-! 0
M    #-R^,I(X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RP
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 )3,S  !  $ E,S,
M  $  3A"24T$)@      #@             _@   .$))300-       $
M6CA"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]       $@ U     0 M    !@
M 3A"24T#]P      '   _____________________________P/H   X0DE-
M! @      !     !   "0    D      .$))301$       0     @   D
M  )      #A"24T$'@      !      X0DE-!!H      T$    &
M      !/    5@    8 9P Q #4 <  P #$    !
M      $              %8   !/                      $
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M;VYG    3P    !29VAT;&]N9P   %8    #=7)L5
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                _^%AU&AT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\
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M 0$! 0$! 0$! 0$! 0$! 0'_P  +"  9 !P! 1$ _\0 %P ! 0$!
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J P3"6)%B1,L3U %6%R.^0_Q^^?C!S?S1WC?]3GY,2-^Y^W^J-SBH\__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g459793g15p02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g459793g15p02.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[0V.4&AO=&]S:&]P(#,N,  X0DE-! 0
M    #7*^-$(X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RP
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 )3,S  !  $ E,S,
M  $  3A"24T$)@      #@             _@   .$))300-       $
M6CA"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]       $@ U     0 M    !@
M 3A"24T#]P      '   _____________________________P/H   X0DE-
M! @      !     !   "0    D      .$))301$       0     @   D
M  )      #A"24T$'@      !      X0DE-!!H      T$    &
M      !-    >P    8 9P Q #4 <  P #(    !
M      $              'L   !-                      $
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M     0      #F-E;&Q490
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  "P@
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AV'VH-BO[W6C_ +J:]#_ZGJ>C@ZXOMDU#_3L'_F$S]?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>g459793g15p03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g459793g15p03.jpg
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1>8/F78:FQIMYMXT@KCL__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>g459793g15p04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g459793g15p04.jpg
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M 0('              4#! 8'"  ""0H4&5B7U/_$ !8! 0$!
M       #!/_$ !\1  $# P4               $ $2$" S$B05&!D?_:  P#
M 0 "$0,1 #\ <RPYA@[%.-7"K&KV2D#.%N.3PYCC*(^%<J.Q5FPZ3F1K>[[0
M9,V^_>B6)-)0""&*[6;+],8%UA$U4EFC:4'$G!:*;3VRXU&1AXP)P^_2L1[B
1."GEK0GLF-_=HH,>#X5__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>g459793g15p05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g459793g15p05.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  @ !\# 1$
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HY]%ID;XR!-DQ&<H\V3'3$)?<4E^$:J <+O@+$6(JTM!!D^!E\E__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>g459793g16a85.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g459793g16a85.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1@T4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &!B^86@X0DE-! 0      "0< 5H  QLE1QP"   "   < @4 $$9I9W5R
M93-?,#@R-3(P,C,X0DE-!"4      ! @V+ 3JK15:;:Z[G"7^YV?.$))300Z
M      #E    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O
M;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E
M96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !       /<')I;G10
M<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *
M<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F
M"7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT3W5T
M<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !2
M9W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O
M;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M      !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M    4G-L=%5N=$8C4'AL0'P@           *=F5C=&]R1&%T86)O;VP!
M %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M          !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F-
M60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1"
M;W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P
M4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE-
M ^T      ! #O_XU  (  0.__C4  @ !.$))300F       .
M #^    X0DE- _(       H  /_______P  .$))300-       $    6CA"
M24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M   *  $          3A"24T#]0      2  O9F8  0!L9F8 !@       0 O
M9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M!@       3A"24T#^       <   _____________________________P/H
M     /____________________________\#Z     #_________________
M____________ ^@     _____________________________P/H   X0DE-
M! @      !     !   "0    D      .$))300>       $     #A"24T$
M&@     #00    8             !$T   L6    !@!3 %0 7P Q #  -@
M  $                          0             +%@  !$T
M             0                         0     0       &YU;&P
M   "    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P  !$T     4F=H
M=&QO;F<   L6    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC
M90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M  9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D
M     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/
M8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T
M;&]N9P          0G1O;6QO;F<   1-     %)G:'1L;VYG   +%@    -U
M<FQ415A4     0       &YU;&Q415A4     0       $US9V5415A4
M 0      !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L
M 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%
M4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M
M#T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU
M;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO
M;F<         "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L
M;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #
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M# P,# P,# P,# P,# P,# P,# P,_\  $0@ /@"@ P$B  (1 0,1 ?_=  0
M"O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M U\I\JBXE/1;\BWT<;%INN>2:ZF=2QGF&AKW-],
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$!_\  $0@ ZP)= P$1  (1 0,1 ?_$ !\  0 !! (# 0
M       !!08'" 0) @,*"__$ 'X0   % P$% P0("1 0$ T#!0$#! 4& @<1
M(0 (,4%1"6%Q$A6!D1,4%AFAL<'P&C-25%=8E]'6"A<B(S0U57*2DY25T]?A
M\1@D)3(W.$)#4V-E<W>#LK8F)R@V.45(8F1T=79XL[?21$9F9X*%AH>6H[3#
MU82FM4=6HJ?&_\0 ' $!  ,! 0$! 0            $" P0%!@<(_\0 5Q$
M 0," P,(!@4(!@4, @,! 0 " P01$B$Q!4%1!A-A<8&AT? 659&QP=,4(C*2
ME <5%U+2U.'Q(S1"<Y.S)$548W0E,S4V0U-B<H*#LK1$HW6$I,/_V@ , P$
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M/ETX#L(;?[+2-V61'9XY:%+GB?:5'G-R_1!=^RU'[IM%AP'L"7/$^TKEHS9
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M\N.TY9?RS-LKF^0MJ;Z[M44?/Y_>^_M7SY\/%%(?/Y\?''+:1Y\Z]=MR)\?
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MG?Q3T4Y0^JY_OP_-4>\W]IISW1Y_^W$#_"W:/2OD]OVI!]R;Y2>B?*'U7/\
M?@^;Y[0GO-_::?:CS_\ ;B"?A;L]*^3WK2#[LWRD]$^4/JN?[\'S4]YO[33[
M4>?_ +<03\+<? &STKY/>M(/NS?*MW!/1/E#K^:Y_OP>[G;H'8W]II]J//\
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ME#ZKG^_#\U/>;^TTU#^1'G_CYX@F1QP#_7;P^?(-GI9R>S'YT@Z\$]S;0?\
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MMR25B!Q0+"3DBU$J)*4I5)1I!Q5!I=5 79^3W8\C6O975[V/:',>V6E<US7
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M^D>(XG&CI9 6%[[3.#HVD3,Q@I^2[@POGDQ20ND,;WR-$+XS31.B?(3&PR3
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MO..B(<"7RB*)K UOD1MV(RIKVBSVB _16U!<(&31RTKG&&>*ID=(7,%3S;9
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M7?MJ [*[LS1X;G5L/V$[?_G]GI-RB]:U'M9\M/1OD]ZJIONN_;4^]6]F:/\
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MZ=897=T:U)")712J1E'C66F44TGDTT&@%6TCE1R@  %<P!I+F@4=  USA9Q
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MG@J[C XX^I#KJ/PYX<@S=GV1V^\JC_M'L]P7 [^F0#.?1C3CS#AZ-K*JG7@
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M/NXXV(F.G'KRX]X!CEKGGW[$4XX?)SSPXB&F@\ T#CD<X(GCX^OD& $.6G3
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M_:BD\U&M:78CV%6W.1:-PH3J6YRI35-CHVK%<-D8YSV--W1EH>+$8<30YNH
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M-0'4 P/74,B1.N,Z:\.'3IRUSRUP&,[//'?YZD4#RZ:=-- Z>G0>_GG8B:>
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M$7U:CGIY9?/_ !6GHQM&-UK7[=#W)@'$]W@GN?0Z_DU.H8^F4?N7=M.-W0F
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M=H))-RK  :+BJFA(K.$\SV2DRH "H2Z@ *AI   1"JFK7  &F,@&H9UVD.(
M' W_ (=2@M!-\UQ_<^A^J4?KE'[ELQN\A1@'$]W@GN?1 &/+4Z\?RRC]R_@Z
MYV!Y'#V=WG/I3 .)[O!3Y@1?5J..=3*/W+^/GM.-W1[$P#B>[P4>Y]#]6H_7
M"^[^U=WAJ.T8W>0F <3W>"GS B#^K4^DPL?_ +777QUY!AC=Y'?YRZ$P#B>[
MP4>Y]#Q\M1S_ *LOGRQ[%C'HV8W>1W^<NA, XGN\$&/H?JU(8Z&%\O\ %?/
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M'N\5'NB)^MC?U='C\PV8#T>>Q,8X'N\5R4SXF/,I*KH,(JK$ HJK&D:!$1P
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MISX:9Y:=< (:]VQ$S_ //T\Q]/#3TO/GS[45PJ3*JF%%Y50ZG^QCWT4"IIH
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M/!%46@1!Q2B XS56&G,!+K 0^^'> AM5WV3V>\*S/M#M]Q7*?A$5V!$< 06
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M)$Y\]![_ %=P]=1[LXU(@!D,\\\^?#OR(AG.@>.=A\VO\,T00UP(#IC/,0X
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M$MBKF1<Z@$'L%P;<<P=;#KT;%)()W'A8ZYC7CE:XL2+:9A-B$D6MEE87MD
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M?=;OOF.A077W9VL>&M_#VGH6]8].&._3GG''PXZXZCM?SY\_PJFG/(=0#3@
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MD5-5VBV\_P N Z?Y*I-^ \[^*S!IH.O=Q =.&!YCPX!RY!G,^?/>H4 (#Y0
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MZ$5=4?G A'_A5?AK4LR'J_CVH/MGJ\%;^P-?M?#=YXJA>@ X\@'4>0!QTR&
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M4%!$,BU=D$<^;FUW5%J7-ND:)FB%WVRMS:61F4R%/<!(Y&RA>Y)V%);V+/\
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MLT/7X*WG <+58!S4'#J']LK# <N.1R'KVNW[(\[]/AX+-VIZS[UQ<@/$0[A
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M(M;SO(^"SA\@?P:X -<CD!'PR([64+R$<#S#QX\<B/3P#AG4 SL11Z>FNO#
M]0SJ&. 8UV(J/[GF 7SW3^8V<9-YO\T!(/-:(7SS3[-[9%K\[>P>WP;@4#[8
M]I>S^U?9A$T"O+$:MHL-;"_&WG<ESI?+@JP&FH]<ZYX] UZ#G(]W7647I+2)
MB3SU1*<@M2K$D%2DLHN@]7[ 6):?VP=0 &'>P%B)9(&U5>QT5#31BFH:=B*K
MM7YX)N(_DQQ5KK@NOOQP\1#7T5?]D]GO"LS[0[?<5R'[\WC_ 'DOGQ_GL!Z^
M/=X;0S0]?P"E^HZOB51<8QZPY=._AT'YA=44ACIQSGCCNX?#Z. YVB_FW9YZ
M,T0!QZ.''7./# XYXY>&THI$1XYX:9#B(B 9Q@== [NFQ% "&G$ #GD<\O'G
MW!P#7.S(=")C/I[LXU[O0 8 /0'$B8QKKGGW:B'/D/#.H!J AJ&Q$ .& $=,
MZ!KG7'/(!ZLAKC@.Q$$-<<1X?%WCJ'# =/'9OOY\ZHIQG/#0!'3N#U\]!SC3
MGIL1>.0Y=W'D.F1# =V.NQ%=L=^DJ/[[1_D"/Q<>_;)^O9XK5FAZ_!6\O$?;
MRO\ XP< Z\O+J].,!PZ\.(#MHW[(ZEF[4]9]ZX@8$=<<@U^?=J.FF>&0VE0G
M#T<.'//,..OI# X$!#9Y\_P1!XZZYR.FG?D,AG&H\L>.Q%&.8<>.G( Y_P /
M#X@>?/DHIX<0Y#@-1$ '(AQTTY_?SL1.N?' <Q'7QX".O+CQXD3(X''=G' -
M,:\M0].>F-2*/A]?\&@Z_P >NQ%(>C'# ]X\L_/&=0'78B<M Z"(CJ/H#IW^
MOIL\^Q%YE#^3+X_S](<1US4'=RXXSW]<P38$]!**]'S\[C?TY7_6!\6V3?M#
MSN6S_LGL]X5D>H->\>F<:X\<CZ=MO/GSFL4SD>?'(CGPSPSH&-! .&Q$Z &-
M0'@ Y\!X],:<M> ZD4<PXZ<LXP/R8'7X]B*> XUT'7B&0^3.>O/UD4<.&F=.
M7 1YCZ!Z<-B((:]/$>F<\M=0T]6Q%.0 >/#IX]P!G0-1XZ\--B(&O'IG'#.
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MC=O38H-QT7%LCH=3J;6 !X<,M4V(3I8G?89C2V1T.=B!OOU+MW[%C^FNF/\
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M&0[AX^H--/#/CG4=GG^'GOS"('$!XX&G3^+APT#CX[$3AJ(!ICCD1[@' \@
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M/7&H<\CIIS#EIITP(;$5V1WZ2HP&/RRCF(_U&>?CMD_4=7Q*U9H>OX!6\O\
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MB#D,Z"&O?@>[C\0ZY[@V(GISGCG(]VG(>. X\,Y ,X(G+PXAD>..X Z\^.,
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M'GH([,;>/<?!,#N'>/%/,[ES3#^ND_NO/F/'9B;Q[CX>?>P.X=X\4\SN0_\
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MXTR 5 &0R&0R'/: ;$'@I(N".*LZME<::A " KQPJH,*\FK',/*KHJQS_)4
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M3KX_E@\>?CRV8V\??X)@=P[QXIYG<M?Y6'7G[(3UY?EH:?P:!C.S&WCW'P3
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M1.3E F1MN-$%SM-6YG4.Z5T7Q1O3.YJJ0(D"F/OY"I4U%*R"36-XHK,"IL7
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M#+QWNOC!H@U6\<FZ='SJ[T'(MDS+9C.5LR<FU8CM5:Q8_6JAS>RQ1K]GAOF
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M5@[T*M[!SOU<ZXML9Y F1$\LEEH*7;R5M4@LVQN[44A<E+ \&W'<(NOG$L/
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MYL3MYRYTKF",BV39=T.3PS=^W*;)1&?1X\S=5DEFWB7.<CB2LQJNT5;> /\
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M6\EU+#63OD0S);S6EMU=5+'JW.MD2W!A[%+DS9YY3%)'<M*G?$*TDLAS)3)
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@B)L1-B)L1-B)L1-B)L1-B)L1-B)L1-B)L1-B)L1?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>g459793g19s00.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g459793g19s00.jpg
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M(B0Q-T)15%=WDYG2U=;9,C-!=;@F-$-B4E9A_\0 & $! 0$! 0
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M:)!M(NR?6@(Z9-):YE;(>T$+7[U[P5=,0;FQG@$<-'6=510@&&VJT"B9)&3
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MWD_ I[@_5;[ _9-+>"V;UJNY,=2_P55E_5]#/S<&\$)!X X X X X X X X
MX X X X X X X!1JS_G%.G/U5N^7VB]#N3%:/O9+@]5VM%Y>4@X X X X X
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M)NL/XF()_DO EYO=C[F5X>'T)NL/XF()_DO EYO=C[F5X>'T)NL/XF()_DO
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MT.Q>L?=VZ P"$VQVRZQ/*^9VC2MCR(= .D-GPZ7%TJ8N*"W&/!AY4?[XS\0
MW.%H&P$.RCR&2/5H/>NU41JSC5+.H2E@[FJO-1DCT@X(. . . . . . . .
M. . . . . . . . . . . . . 4:L_YQ3IS]5;OE]HO0[DQ6C[V2X/5=K1>7
ME(. . . . . . . . . . . . . . . . . . . . . . . . . 4:L_YQ3I
MS]5;OE]HO0[DQ6C[V2X/5=K1>7E(. . . . . . . . . . . . . . . .
M. . . . . . . . . 4:L_YQ3IS]5;OE]HO0[DQ6C[V2X/5=K1>7E(. . .
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M22'B_).,(G*DQI,PY5U3U.C"$@:#MV<AT#X59.UV@M0,X)N$W(1MJFD,=/\
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<SJGNX8.DL;([BK^C9333M4:=ZPY'])S@Y#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>g459793g19s01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g459793g19s01.jpg
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M ?_$ !\  0$  @,! 0$! 0         (!@<$!0D# @$*"__$ %<0  $$ @(
M @0&"PD/ 0@#  4#! 8' 0( " D1$A,4%188(5AXEQ<B(S@Y69BWUM?8&20R
M-5=VEK;3,3,V-T%"5%56=[*UN-79N0HE-%%Q=)74<W6S_\0 & $! 0$! 0
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M!/=?;1%/7&B>-=<8QP:VOI_*O<L/XK_6GYO%&?5+ ?T?X,CXK_6GYO%&?5+
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MX:28.6[QD\;J*(.6RR2R6^VF^NV1D[K@#@$!VO8MF]BK4D_5SKG+"%=1>O\
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MM,4-5&^DVMIBH*F[ZUH7%6S._P AN]>RZ%U7V4C'8>PFTE$V2P<R&$6><FE
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M\"PYY4RS9^6/SGIR^PPF<?,-$I307;.\ 52QRT(4LV)CL92(-WA]^(P2V4+
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M&,2\L&8FCF^NZ800L^+JI[HL5,<%2E_+8FH&79Y]/>F3#M53-?FI\7D%4LK
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MK>NY<O!!P!P!P!P!P!P!P!P!P!P"&H3^$K[,?0<Z._GZ\0G@N"WOMLER\$'
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MG[EY_"/WEY^J^Y^?\#[7RX(XEQ::;B;?$Q^\'[5?[HS_ /QM>"%S< < < <
M< < < < < < AJV/P@W2WZ/G>'^L73_@N#WKMM%R\$' ' ' ' ' ' ' ' '
M' ' /(^C.UM&]?+![DPJX)))8?)"?<6RI8-9;U;:YM C&S,-K5 898%8W"#
MAXQ>+#WJ22K9^KY*-E==\:[:^7!I;+=4NJ*+_=(NF_\ *B?^IB]/U:<#T;67
M5>2%HA:O2N*MJO4"7[,HC,^O,QO%6F9Z$I*XBNKNJ+YEJ\ODE4SN,G:F<($0
M"&Z43$OL#W[$R^(UE"YJ+E 9R],1MN+Z=K%3,37*EYRX5M8R"S[AZ6VO-X1.
MI+VXN_)"#$JPD(P5K1\S>@$Y35EI+V>-/BQY;K^0WBSB2;N=8?,](NY$JR.)
M@H>T?.MGL<P^(!Z=I8*S5\^/\2:?$2'P^!NH6#C.Y5PHN(E4="UP<C32F9>X
M7D59U(1['(P?:=QDG1A9@58R5[=M@N%'! -J#5F%>0F0Q]@Q*PDHF4"-K)7;
MOG&NF^KJ?P$AT.C X $C?=/LM'PX0K")?CW-4$N9'<V/!^IRG3-I.Q<CQUT4
M?QTB0IUK&O:1X;#8>QED8928*F,?/BWMKY\_@1M/!<]9SS,LBT]Z1P[(0"S[
M#3R1QAYV1@?:&=+':)L,.LO-*KJ^%0:)AHN+A-%QMFP9%Y57L,GDA>$LD5L[
MB# M/9=>2;$1X>G:I2(47U>NL91@7]^Z1=-_Y43_ -3%Z?JTX)Z-K+JO)HLW
MV1J'L5W(Z/M*<.2*7;PF1=@#<L<*5O9D:'@19.B)0&'NWY66P\",3U>E7*#!
MLEJ[V76<*Z::)9SG@0TG-*1=9KP>K/!D< < \R[WN* T)W]K"?6H_.QZ&E>G
MUL1!E(F$(G,M';29Q=-0&D JZL,CDAV9/5Q0P@^03>Z-]5D&B^R>VV=,XX-I
M-[,*_JGH;/\ W2+IO_*B?^IB]/U:<$]&UEU7DXZGB+]+%7#=XK8Y=5VSU7T:
M.E*2O#=PUT=8TU<ZMU]JRRJAJXU22U7U2VUPKA/3"F-L::^0>C:RZKR<C]TB
MZ;_RHG_J8O3]6G ]&UEU7DZ\AXG'2,1JTW*W&_&:/R#,2QW(5+=C+5Z5(JX0
M'C&FSFN$L.2#Y?.$6;)'.[ETKG":">^^?+@>C:RZKR=A^Z1=-_Y43_U,7I^K
M3@>C:RZKR<=SXB_2UZGJB\L<N[2T<-7>B3FDKP73T=,7*3QDYUT5K+?75PS>
M((.FJV,84;N44ETMM%4]-\!Z-K+JO)R/W2+IO_*B?^IB]/U:<#T;675>23^]
M/=WK;;O4._ZRKB8RJ53N<5Z3CL4CC&G;J1=F31!=JDS8MUGU>-&:2BV_R84=
M.4$-,8SLHKIKC.<!Z=I8=5Y/97@R. . . . . . . . . 0U;'X0;I;]'SO#
M_6+I_P %P>]=MHN7@@X X X X X X X X X X X X X X X!#4)_"5]F/H.=
M'?S]>(3P7!;WVV2Y>"#@#@#@#@#@#@#@#@#@#@$-]Z_XAZP?3DZI?G):<&MG
MZOROV+DX,C@#@#@#@#@#@#@#@#@$)6?=/:!]V?D?7WKY%J$<,H70M67)(I%<
MI^PAKITZM"PKJA+,*%9PD$72RW&)5#N^<N7VZ*BBA?1)+7;5#.>"Q2=6N4>3
M[^U^);_J'HS_ $MOW]"N"#VOQ+?]0]&?Z6W[^A7 'M?B6_ZAZ,_TMOW]"N :
M9D]2^(Y)[UJ*\UM.DK4E4<$N6"L "4CO91B8;7&_JE^0?NW>\.PX;+A=JK9)
MLT44]TW6I=ULOLGELCC<6:1JGRGR;F]K\2W_ %#T9_I;?OZ%<$'M?B6_ZAZ,
M_P!+;]_0K@#VOQ+?]0]&?Z6W[^A7 -:VM=G?BB8V$L*Q8;U!,0C:U*.@$D9P
MJ67/F5)C[ANF 5!L1":'8FT$*O0RLZ2,:H/W**#A-BHAG?&RFO!4IY-\E)Z8
M<$' ' ' ' ' ' ' (@+=\:]:3*PH5':<[36.ZK"9OZ^EAZL^O\TF<2;RT4/%
MDR0EG(AB663Y9DT,CMW&4,YUTV<:Z9SYXSP6-W->3X_'K!_-=[R_DJV'_9<"
M'IS7D?'K!_-=[R_DJV'_ &7 AZ<UY--VQXNO6.AFB;Z\(?V&IUFOIA1NXM&G
MB,"3<Z[;9TT]ES*2@OVK913&4TM&^%-U5<>K3UVW\M>!#W[FGV9Y\0GQH>HJ
MO<J[;V'Q#M4<K2:]8.L571\]'>K5NR!)W+*MM;MW+)<EYAP#U'W:W#6]"EF!
M71=1D24=ODFJN^P]QG UZ-J%:[OM;*O"5WBTRJHYX]_0&5'D(H+?W0A+76^4
MV<0D%1F8E+GV^,XUS[!%I6\"GW^N,[:XSNS'+:8SMKY[?;:^8GHVKQ18RFN:
M<%>(=\HXZ01<M>L?>!RV<))KMW"'5FP%D%T%=,*)+(JII[)JI*Z;:[IJ:;;:
M;Z;8VUSG&<9X)#TYKR?7X]8/YKO>7\E6P_[+@0].:\CX]8/YKO>7\E6P_P"R
MX$/3FO)0=#WA#>Q-;L[0@C24C@;B4V+"78F;1M_$96$E=4V)*:KG8$]'"FNK
M\61!3>&2 0N@XUQG;++"VF<IJ:9R#44?F]<#<7!!P"7+I[:06DK B]7$(-=5
MBSJ60X[/F "G*KD=E.V<3CAL+'29@Q@%IMJ,;Z&)")9(Y<9QE=5UCT,9QKMY
M"PVII$Q5I5XLU[\>L'\UWO+^2K8?]EP(>G->1\>L'\UWO+^2K8?]EP(>G->1
M\>L'\UWO+^2K8?\ 9<"'IS7DE_M)V9)VH*I!I#^J?=ITM!NT%#6E(,/.L<\8
MZH1" S- W(W3?9=/&'3M!@GMNV8I>:[M3R22QG;/!52;535UY*@^/6#^:[WE
M_)5L/^RX)#TYKR/CU@_FN]Y?R5;#_LN!#TYKR/CU@_FN]Y?R5;#_ ++@0].:
M\G02GQ%ZY@L?*2Z<4#W+AT1!-\/3\ID?6.?C ($=A5-)4D7(*H^J9,&V5-=W
M+E3[1%/SWV^3&>!#TYKR>@G!!P!P!P!P!P"&XI^$JOOZ#?4?\_G=G@N"WOML
MER<$/YMC;.NV-,XUVSKG&NVVN=M==O+[7.VN-M<[8QGRSG7&VN<X^3&V//SP
M!XYI]XNPZW4^]>P2*U=;26G@-Z.,@GW76Y@\.(E:\[!2JKX>L'F!&U4F$X07
MBD".N9@$AKEX\9'SP!S@N(;ML C@U"E*M6L59I/*];]"Q)3>\TB5,VQ,]R\1
M?2]C(64"J3,]KJ=4'&W$]E >-LHJC,Q\^D121NH8RE,B2,2B7!TAN6T-'R'<
M:&>+1W<H5$CXH=K]C6D.[JO[M0Z3!ZM8AHV<[8P&T[(DY21-E9*VK!C1+"'B
M+8@#9@-+"6Q>Q1%H3H5!$MUBVX8:G'YB<59G=13<:]%B)G"$HC&6GNA=K%S0
MI"<M@Z[>PB48,'4C)O#8G$@Y( +=Q[<DX5CF5PY4U(7+,PV#;M&9O9,PZ9/2
MK9T18)#V;Q 8S&3+N 0WXBOWL>/I'=(/^MOKSP57X;79ER<$' ' ' ' ' '
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MQ><'93 9015:AX;;I^5$$(D@)$U6M,4LYB'T=Z)%\<$(:\/7_$;9/TY?$O\
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M!D4A&H&!U8]A9S+DVCIE%R>F'C*-O445\(ZN-DM5==^!$S#3A3CX+SX(. .
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M[',UO0:Q.$+UA$8I)C:JK\86)32-RIB4F32,E :2H6<0^2 ):*D(D24&M6Q
M66I_$^#=<>6/+A1:O2![7_F]ZM]E^P% /$//=K#I!-2O9"D7.WEYZL'U87Z1
MF92. ?3QJIL,IN?5"YUVUS[,3;:K.M5PG-)]'OE7>^3@Z=KK1Z^O683O/7\<
MA<2=NVXT9VTIY<T8ZX.';I9)LSUMD(>V=3SK.Z?N5TT$7\S>S>HFRF4FSR[T
MBSUF(5$A.W)WZ*'T>D27VBLBY12<-UDG#=PDFL@NBIHJBLBKIA1)9)5/.VBB
M2FFVNZ:FFVVF^FV-M<YQG&>"'UX!YXFK [FV7V6O^JJ/LSK%6,&I(=3^$<VM
MUOM6Y99(B=DQ,E)"#E0W$>V5&!QK$>HQT:LV&L8>.-M-]E5R6^V,:<&OPI*4
MVW6FTEBU]KRS,H^ WB6_.BZ,_D&W[_Y'N!.Q]NU_LOV#X#>);\Z+HS^0;?O_
M )'N!.Q]NU_LOV#X#>);\Z+HS^0;?O\ Y'N!.Q]NU_LOV&J;0ZS>(1;+VJGT
MB[8=-62M0VL#N"-ZA>BMVMTWTDCX"41UFQ-X?>(81V< U64L(JN6S#<:_P!W
M2#+=(DBDFN@X%3V5,;.U50_Q*W^IM;X#>);\Z+HS^0;?O_D>X).Q]NU_LOV#
MX#>);\Z+HS^0;?O_ )'N!.Q]NU_LOV#X#>);\Z+HS^0;?O\ Y'N!.Q]NU_LO
MV#X#>);\Z+HS^0;?O_D>X$['V[7^R_88N$L#N96O9>@:IO&S.L=G0:[15Q;*
MYJGK?:M-2R.DZUBXF1#W*9N7]LKT#DF!'<CNU>,-HPR<::IZJH$M,YSIP'Z6
MG":BM6GBEALK,]#N#(X!YA5X^[5]?9YV:&!^G<JMN,67V2FUN1&:QJZ*+C3)
M]'91&80+:MW 2934.?8/VSN.O=7"3MBGKG79+=+.VNWGP:26.U&D-FV/C&]M
M_P 7A9?Y0O6+]9' C9^[]+)[NL)8'8)T&-65X6UC+S>+(K(PRU(EV>H*NKC@
MNJ^_K5=83;L MR-6+%D%E\:.'; /)&HPBJFG@FR>)Z^KR+1?5^E]C2VCKQ>*
M\^Y4W#+0E@5#/[SB_;DGT^NC9HV_RCF<]I^\.M4[63TQY^S%IJ2L UIMG.Q!
MV6UQJGJ$;.<\UGIM:8+@<Q+LMX[K/&R"WAK=:9#MKCT="B7:J.0W"V<>?W78
M#N;G>6N,_)GU&)&[]'Y=?:-O/TL!'_GCM/'Z9W9<<]#C[7!XZDL^X%>KE)4V
M/5^1SM!']9V_*]-/+RS@1)9QVOKZ+CW'G]MJY*UG)&^,8]#(_?S]9A7YY]HX
MB-C-Z7ZJ+;GQI7^,Z4O&6$&)[L[TR[1=QS3!T@19B;\[0]1]Z?&$FZVCE!T-
MZZUS)X#0[E<>X31W"EY97\LE@K"">Z4G4=J.WCH/PV]26[9<XXWQM,%R-^PO
M:]HW0:M?#IL5LU;(I-VS9OV ZOHMV[='35-%!!%.QM4TD4D]=4TDD]==$]-=
M=--<:XQC D;/W?I9]OC&]M_Q>%E_E"]8OUD<"-G[OTLR7HU +'KJB"8ZV(?\
M )M+NPW<&XGD,WD &4.(V&OCMK=EU1$6^.QAZ1 /R3:(SX'J3V%OG+9 A[2V
MU5VV1VX(XFE:)<DD6!P0< < < < < < < < < < < \V@T<1[VW-*9=/$]2W
M43KG9A:"5;6[C&%HS?=^5><V%V!<5@M/3V9RF"TS8(LE7530PBFN#5LJ'S2S
M3+$J\%5<^ "VT><V3PX[[4S/27@A^-E$]-D]=]]--EM\II:[;:Z[*J83W5SH
MGC.<9WWPDDHIG77SVPFGOOY>CIMG &EY%UZJJ5R^QYT<"%W4FMFHQU%SQXC,
MIFP:EZO$O)B0'1UJ)'GVHD&X:/; F3A*1 6(R3>F>=8W,;:(L]6PLN$LG*M>
MGA:&%F.G="G9!%).0CTJR5AH.FHZ(V9VA9PUFX'=?)4;FE.Y/L!TO:LY0^A$
MCDLA>LR<B1)D"29E^Q..2C%7#;0):IOP6-&<V*=2J,A<E S0%&SB4RCLF>2Y
MM+'4\G;V1%#;^O(Q5+I:6%7,C4=35%Q H5$ CMM+]S:)%:.#CI/5[(L.2[D)
M^<_)27!#AD![ NP?"BK%F3%DV;D>2&D&R+U@08/4=VSQB^9N=%6[MF[;J*(.
M6RZ:B*Z*FZ2NF^FVVN0//&M!CGI1?,+Z[LW3I;JAV%<2)IUO8/G"KC'7VXXT
M )34[UX%/7:VZOV)IW!@<JG=+!-]]]*Z?PF;UT,42B+^M8Z &G5-XJ)C%6F.
M2<7E366_1K@R>.,VN*4U3W [$@H;LU&G;W["=#J'TE[YFD1:0(;+JEL(^=D^
MC!S^\'1Q8'$2,8A6A75R&3GLDBS@N+/#474?*C6"_*^[^>"N+MOTGU#C\@E=
M@E9!<49P*/31JGJC!@<SC42@,;U*SA'4;'1X7>:/UM=%"H)1A%A8<>VP00F<
MDC(\<V-E%B1-H7.M?;Y+.WKKMR-L"[WM,[5M*XYC0S>\;$RXH4C#L<8.=?SM
M=")6CJ+$E7Q)@Q,-;+#E(X]=ZZJ+IC3+0HS%.$AWO(&H4[NMNSGW)[4[7VS!
M;V[,45+G@8V7DGD>Z2D'8=JRR7=LV$,BMFUY)D!.&&\@:TO*)G";5.E6;?8^
MK4TX,++8?[0 D16"%"XSU:XN';3,^G7;O/()/0_7,S(X1.;>L&1]:^O-K7C(
MH8#&BV,:DMVTT[LIHY]DRS"1)E'E"8Q02OE8X+7#)R2+>R-I+HWEK^/ U>MF
M[Z<+U\P9M&>_360*U:T7HZ?"2UJ1V@IH! *G8>_-NX7V.D<KCL+D() >4782
M/$)UB+N1W:/:$F[NKXB5C\@=8,M2F-4 C58YX1IK"G$_@KOOF4-:H?PGK]:,
MI&7V3AJ%*G=G0"*1Z;"9]2%R7J!>Y*3=S&]V9!A&:8*MI.T'LS@0:M*(BY#R
M>1I/WV@X/3$U5)F](:66OQT/CVYONT*-GP\N2?2N'==<P01L3N"!12)V(,JJ
MR7<K,MUR792($1IB?AJ.-1]L%:@[)KEDB.A9)C/2%FD!P/0"4&@E*URSW8<'
M5T2EF&7[WH+#X%,Q=<@I#%K"8,^Q3P"<1VB1MOAUU2[)4K1TY&98R-KN,52G
M>]MC748<NT4<MQZ9;WDJ (-A[I9\^<R[.S+KI3.4W[5WT. K<V;C[B]1\$84
M<KR75?/>X]6SF)''P<OL/D(JG*WE#%X+. ';P6:"'X?+XM(QSQ+9NY03+;C"
M;%B5'O6J01$XSLS^I'JEP9' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
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& X X!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>g459793g19s02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g459793g19s02.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X51\:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 V+C M8S P,B W.2XQ
M-C0U,3DL(#(P,C O,#@O,C4M,3<Z-30Z,# @(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z>&UP1TEM9STB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(*(" @(" @(" @(" @
M>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(@H@(" @
M(" @(" @("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S
M+S$N,2\B"B @(" @(" @(" @('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @("!X;6QN<SIS=%)E9CTB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F
M(R(*(" @(" @(" @(" @>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"]S5'EP92]297-O=7)C945V96YT(R(*(" @(" @(" @(" @
M>&UL;G,Z>&UP5%!G/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O="]P
M9R\B"B @(" @(" @(" @('AM;&YS.G-T1&EM/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O<U1Y<&4O1&EM96YS:6]N<R,B"B @(" @(" @(" @('AM
M;&YS.G-T1FYT/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O
M1F]N=",B"B @(" @(" @(" @('AM;&YS.GAM<$<](FAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"]G+R(*(" @(" @(" @(" @>&UL;G,Z:6QL=7-T<F%T
M;W(](FAT=' Z+R]N<RYA9&]B92YC;VTO:6QL=7-T<F%T;W(O,2XP+R(^"B @
M(" @(" @(#QX;7 Z0W)E871E1&%T93XR,#(S+3 V+3 Y5#$V.C0Q.C0R*S U
M.C,P/"]X;7 Z0W)E871E1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O
M;#Y!9&]B92!);&QU<W1R871O<B R-2XP("A7:6YD;W=S*3PO>&UP.D-R96%T
M;W)4;V]L/@H@(" @(" @(" \>&UP.DUO9&EF>41A=&4^,C R,RTP-BTP.50Q
M-CHT,3HT,BLP-3HS,#PO>&UP.DUO9&EF>41A=&4^"B @(" @(" @(#QX;7 Z
M365T861A=&%$871E/C(P,C,M,#8M,#E4,38Z-#$Z-#(K,#4Z,S \+WAM<#I-
M971A9&%T841A=&4^"B @(" @(" @(#QX;7 Z5&AU;6)N86EL<SX*(" @(" @
M(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM
M9SIW:61T:#XR,3(\+WAM<$=);6<Z=VED=&@^"B @(" @(" @(" @(" @(" @
M(#QX;7!'26UG.FAE:6=H=#XR-38\+WAM<$=);6<Z:&5I9VAT/@H@(" @(" @
M(" @(" @(" @(" \>&UP1TEM9SIF;W)M870^2E!%1SPO>&UP1TEM9SIF;W)M
M870^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.FEM86=E/B\Y:B\T04%1
M4VM:2E)G04)!9T5!4T%"24%!1"\W44%S54=H=F1'.7IA1SEW241-=4U!0311
M:VQ.02LP04%!04%!0D%!4T%!04%!14$F(WA!.T%10DE!04%!05%!0B\K-$%$
M:T9K8C)*;$%'5$%!04%!068O8D%)44%"9U%%0D%514)G549"9VM'0E%92D-W
M9T="9V=,1$%O2T-W;TLF(WA!.T1"04U$07=-1$%W441!-%!%03A/1$)-5$9"
M451%>'=B1WAS8TAX.&9(>#AF2'@X9DAW14A"=V-.1$$P645"05E':%521E)O
M9DAX.&8F(WA!.TAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X
M9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9B\X04%%46="04%$54%W15(F(WA!
M.T%!25)!44U2068O14%A24%!04%(05%%0D%114%!04%!04%!04%!449!=TE'
M05%!2$-!:TM#=T5!06=)1$%114)!445!04%!04%!04$F(WA!.T%104-!=U%&
M0F=C24-1;TQ%04%#05%-1$%G44-"9V-$0D%)1T%N34)!9TU20D%!1DE227A1
M5D5'13)%:6-9155-<$=H0GA7>%%I4$(F(WA!.U5T2&A->%II.$-2>6=V16Q1
M>E)4:W%+>5DS4$-.55%N:S9/>DYH9%5:2%1$,'5)24IO34I#:&=::$I21E)Q
M4S!6=$Y62T)R>30O4$4F(WA!.S%/5#!:6%=&;&%7,7AD6&PY5UHR:'!A;71S
M8E<U=EDS4C%D;F0T95AP-V9(,2MF,T]%:%EA2&E);4MI-'E.:F\K0VLU4U9L
M<&59;5HF(WA!.W%B;DHR96XU2VIP2U=M<#9I<'%Q=7-R839V;U)!04E#05%)
M1$)1545"45E%0T%-1&)114%!:$5$0D-%4TU514954DYH26=:>&=:17DF(WA!
M.V]B2'=&34A2-%-.0T962FEC=D5Z2D121&=H85-5>5=I63=,0T(S4%-.94I%
M9WAD56MW9TI#:&=:2FI:1D=I9&MD1E4S.'%/>G=Y9W F(WA!.S K4'IH2E-K
M=$U453504FQD65=6<&)81C%E6#%2;%IM9&]A5W!R8D<Q=6(R4C%D;F0T95AP
M-V9(,2MF,T]%:%EA2&E);4MI-'E.:F\F(WA!.RM$;$I75VPU:5IM<'5C;EHV
M9FMQ3VMP86%N<4MM<7$V>71R<2MV+V%!07=$05%!0T5135)!1#A!.54T<3=&
M6%EQ-T9867$W1EA9<3<F(WA!.T9867$W1EA9<3=&6%EQ-T9867%P6&0U85=D
M=$ID6&,X9'1B46IL3%!+>7!':6IU>DU105!N:7%32C5N=DY1<"MG3DUK=31J
M,'8W<VTF(WA!.WIT0U!&4S9V4$HW1DEI<"]M>%9E3DHX>C-65&9A,SE653E)
M9$UT-#0Y=D)P3&XV,'IF3E%M2W0O-$\P9#9F5UAV3'<O=$,U=F)Q4D0F(WA!
M.S@T:DHV6#-,:7$T95-02G9F471063DR93%H6FEF17-Y:VLO4$982'E2-4Q)
M;V1!,#)N+TU*0B]Z4FER4CAL959H+V-A9$A:;G,Q;5<F(WA!.W1#4&-',TU:
M>%9O*U8U660Y3S%N56)-.6QE65AI;C4O6%9U2"LU9V9F1E9P;#@U,DER2D1A
M-C%#3W8Q971L8S O=T%M3U9P65I'*V,F(WA!.VM9>%9%-F(U;3!U*W546E9E
M,#%)06QT4'4P34TY04MK;W)B4W%/-WAL;#DX5E181EA9<6M&<C4P<TQU,6AU
M<F%X,4=7,W5%5U='4F(F(WA!.T]A:DDT1$MW,C=G-'%Q9C1Q9R\V='5P9CE)
M8S,Y359D+VEQ1"]Q,C9L+S!H>F8P>%8S*TMO4#A!<3(V;"]W0DEC,SE-5F0O
M:7%$+W$F(WA!.S(V;"\P:'IF,'A6,RM+;U K<F)Q6"]32$XO5$989C1Q9R\V
M='5P9CE)8S,Y359D+VEQ1"]!2W1U<&8X05-(3B]41EAF-'%G+S9T=7 F(WA!
M.V8Y26,S.4U69"]I<40O<3(V;"\P:'IF,'A65W-036QN96%G=6YI,W5R935E
M2U-E3F)M0U-%36M426IK37=P<UIL,CDX5E181EA9<3<F(WA!.T95=3%Z5V\Y
M3&=J-'A.9%@Q,"]O,D9J2%%03DQ1=%-P,E96549N8S=+;W)I<4-S=DQ4>C-#
M86HU9VM454Y143@T24%$.55T5#)%16(F(WA!.V9A668W.68T>C(T:C1C5E0W
M1E=!+VU2<#!T,S5K.&]35VQO:C,Q=&581')F>C9:4'%51G5J5WIR5U@P1$8V
M9DM5>#AA>7)U03(O2$8F(WA!.U='8690-78P5'EP85=V;'%W=3E--4YR17I#
M>3!74T581W O5V<Y:$108EA%3'9"851W3E0Q2VIG049-:3AC5E%0;E=$>DQ0
M;VYM=E(F(WA!.TQ44V12:G-D4G5T56YE3S P>5-:8FTY-%<S;W(K.&=9:4=3
M45130V%-9D4V9V@O-6EQ9%A0;68X,4=V9&1D;79R4S!3-E%A9$1B-F(F(WA!
M.V-4>7)B;2MJ4DAJ5G1..4YL87ED,VM";FMK1$%B2G5U0E=B959R=GI-4$TR
M<C9D<6,Y,64R5G-I1WAV2F]"0D5W*W=63&968E97;$HF(WA!.U%S,W!026TY
M9F="5D%Q."LQ83<X+V%V-5<Q0S$Q;S9S,&,O-E!&-V)285='84LU3C1F<FQR
M07$R<VXQ:3%7,UAN>DMU1'-P9'5246PF(WA!.UAS*VTR9'!:869B5VQN17-.
M<D)'<V--4U)R0W%Q;V]!23!61E0U0E)4=W=+=#%44TY.,5<Q*W$V:&)P8U$Q
M1'%',EI(6#=,>'-+36HF(WA!.W(K>7EK161J:7%3:3<Q2'DS2VM7<%1T9F%$
M2S9X=S9L2U(V.7%Z;6EP9$YS2DEI84MS=C)H*S-89#A66DQI<5,K4V8K54TP
M1"]T;E<F(WA!.VXO2FA-5E1R1EA9<3=&6%EQ-T9867$W1EA9<3=&56QU+W=$
M;$TY3"]!3S)D<5 X07EF<V-65')&6%EQ-T959S!725@R=F%P<D5V>$<F(WA!
M.S-K3VUA9411*VY&1'A--4AG,&LY43-I151&52]X5C)+=DU)9GIE,6E3>3$K
M9CE%86)*4#5E:3%#5R]S<F96;FQN439:2S!B*W%H<VLF(WA!.TUA>D-.;6E*
M,V)A;T%*2W%P.6]V;C(U,4AY+W%/<7!A,DXR8E8P9W,Q,')54')S1GAC>6A1
M:TAR=$)B.$<U>6]R9D-W2$QR545"5F$F(WA!.U!Z1&QV3E X=4YO*VUI-3%B
M>DI#.7AB,DYX3V)E2T),9%5.>C8X>7AZ35!385)5;W-:2F(R>%9-.5@X,50V
M3#5A3W)A<' W4EAX;%<F(WA!.S%H,#9'5EIF56YM;BMR,C9R3%)2>&Q:;&%P
M56-19'A557A61'DK6G9-=&I*<#9A=&\Q=&)I.74T8E(U24PU<#!8,6QL8FMN
M2S-I6FDF(WA!.VYP<GE$2W8R=&EA8G%R<D@X>69*,2MK5#)D-4Q0-C!O9VE6
M8E,W-49M:5=:5S0K;'DY3F\U55I:86-#1U=J8FI&53,P;EAT33%95&TF(WA!
M.W=K959B9'I(23=24WAQ5T)+;F<P:6]*1G%P*TI+:C-X5D@T<7 S1G9"8S(X
M='9C4G),0DUJ4GEX3TMQ>4U+37)!.5%18U996#9T.2LF(WA!.V<O.$%#,S%H
M+W)8-E,O478Q=FPK."MQ96PY8W)Z-BMP*VHO:#56<GHK3#)W<6XS:VXO;$1.
M02\W6C%P+WE95$%Q9%EQ-T971#9L-3$F(WA!.S%Z4R]-,35B-FIB>'<V5D9Z
M8E0T4%%K.6$Y:FIT1VY:<F4X859B6#%V555R-D5G43A15S5(1E=O=GIB,&E7
M1E!4,&Y5,G9P46MK1VTF(WA!.SA,8C$U3&53,F$V5V136B]2-&5K:#)-9V5V
M=SAA-UEQ=71V>F(X=C-.=UDT-TLO3G59:DY&94-/2F]P1BMO:E550T):5VM*
M:W1J>54F(WA!.V-/;V]A8E966'0K83)H0S!T3'-7;#-*0F-1:39N:VA.<DUT
M=&)T4#E813!R>%1U:F]:86HY>5I.9U0P,WA63R]++VUA4'I$850S8TXF(WA!
M.VAD5U5%33@Q<T=U=E%(3U,R;65#8F=)6EIT;&MI27%A5C=9<6Y/2W5X5DIB
M=B]L33E,+S=:,F\O.&XW2$95-GA6,DMU>%9)=DQS9W0F(WA!.W13,6I2-5!H
M:VAU5W9B9&8U<F4Y2FPU:B]O-#E65#AQ.3A65#-&6%EQ>$M,.'5B1F9+*W$K
M6'!D579R:4Q6>F1M-'8U0EII-E)D4F,F(WA!.WE885)S;'5K65=6,EEM<4=L
M9'%55VEQ,2]W071R3S8T2G$K<EAU<S)O;6IN=4Q'*VHP.3=A8WA2;4].6F]9
M-U-.1T-H<3%O1W%&<3,F(WA!.W=,4E92=%!Y<3!Q>71B94-W,5153$XW0S5N
M=71+;F<K<4DQ;70R>&5E,V=15R]P96<W2"LW:U)H<TM5<&EQ96%J-5=S3E,X
M=G9O=6\F(WA!.U181C%%-45H=3-K+S!G5$I)2E5M4C%!5DA344)L-'%&1DM!
M53)X5D)3*U(R=4ER3F)Z6'15=7!B2S=I=D9U2D=T43=M14U&:5I5=# F(WA!
M.VI62T]A;$56>C-B65564VDP+TIV>2]B5R]O3'%&.4I7-FAV;FQK1FTP>E1W
M27-9:T5V,6(Q160P4VIY259D='IY<5-C5EI(-64X<5<F(WA!.U=H,V5P6%9V
M4$Q,2G%K<7I4<39W4GAQ>3$S4T\S:6=3<F-I5V1G6&)U>&]-5E1R1EA%9T-P
M,D%X5F=N,6=F;R\O1B\O04(U9G!J.4HF(WA!.S$S<#E2*W(O04M-*W-F-FXQ
M9CA!,&XO5BLW0W))9DI0+TM'84(O,GIR5"]K=VU"539X5C)+<V,Q;GE,;RMO
M3F,S55-M3%5P5FU-13 F(WA!.W-L>$QB4C-%,%11+U=$6FEA3T8S0W14;%%.
M5%E-3593+U-F>7 X<U<S;"MZ,'$K:F4X=4Q94G1*<45C.3-"33!K8U Q97%3
M0V0U;S F(WA!.SE,-%!35UAG0G-"5&)&55=V-5HK5# Q3F13:70W;4,W4F<P
M6FAV-S9+3D=71#9S<%-&2C%I5VM(-W-C5C)88D96-"],:GEC1$$S,4HF(WA!
M.S)E,UHS-71C,TQ02UI*4D\T=5=-<$YW<&Q!9FI.>49C5E1843E",'I1-TIR
M3%15:VIT;FUL=4=34V%A8RMR3S5K;&)L33AJ1&LW1FDF(WA!.TLP<5-E*TMP
M:&ER<U935S<O=T-5>C!V+T%,6C)O+SA!2BMX>%9/<U9D:7)S5E-N6'1'=4QW
M=U@R;E1,8F%Z63AJ851U0UDS5C9E<$(F(WA!.TU"=5EP3TER5&-%0FAU359A
M,&9Z2&)8,#<R1GI',6AR34LX<#E.;4DU.&$P.5-*:#A-<U)04C K4F\R,DMP
M=FEQ>65E1T-'4V5E4EDF(WA!.V]9;$QY>751<7%Q:7)->DA9041Q8U9E6654
M=E!-<R]N>558.7I.1G!8;6TR3GHU95<V=4Q6;UI$87I'3F9Q85)44W5N<E<X
M:V)-<G$F(WA!.W U<3(Q831Q9W9-*W915T]V87I$8V$U3DTQ,TAF4$%,8E5,
M:3)K<VMT-TM156US-G%I47)*1V5&>D562FMO1%A#<5=T*V0K<%=N;#DF(WA!
M.VUT.5$P:2]U-T<U:6EE5E,X;VUT:EEW,TPP4#%H5D5K8E-323AH9F8P,C1X
M13AG<7%9-C$K8EAM:7ET<FTU<W!T279O4G%L,7!S37$F(WA!.W%K5558,5I8
M9$)C5#-&+T)#<E0O04%Q1'E(1VA)5GE19U9::C5-.#0S=70V,7)/;C-N,5I8
M<U1'.$U.<55M0WA31F=O:VYI;FY5=C@F(WA!.T<V<VMB1'-P54(R0W-V>%9:
M4%!"8G=V4&-33$1"17!A4U=29W%+;S-*6FI1041&5TUZ5%A(;3%28C)O93,X
M<TXO=E9E341(2F9*,V@F(WA!.V=";WEW4#A!='EM;DID:S)04$975&5J1#90
M;SA&.4AJ=SE/9S0X854T,#95<&EQ56539BM533!$+W1N5VXO2FA-5E1R1EA9
M<3=&6%DF(WA!.W$W1EA9<3=&6%EQ-T95;'4O=T1L33E,+T%/,F1Q4#A!>69S
M8U94<D9867$W1EA9<6=T53!B5$Y6:%-++W0Q;4548S1*2VQ*26YP5&XF(WA!
M.T9+:%=33C9F=$EW3TMP8CE2.#)A8B]V0F52879B1#=.='%*34TV:G=7-FA6
M9W=(65!#5U!D.%983#5R.4$X9%4P<2\P.78U+U%.,T4F(WA!.V9F,4Q-,T%5
M93AN2$954F$K8F9+.3(O<#(K<C)C:W9E251X*V]$-$9#95%0>D=+<&]R2WEH
M;$E+:U9"1S1)3TMT-'%H<GI5.4]S5C4F(WA!.S-T,41A<E-V2V%267A4>'%X
M1TMP6B]J8GDP-4ES-V\V:W<R-#9D2$QE-RM"3G5S:7(X,DE'2W)4<6YM<3E0
M2%0Y2E=W:E!7-C%/5F$F(WA!.V=F>DIB,GAL6B]K.&M:>%8P6&Q32V5E3S8Q
M>39F5TQM33@T;W!123=/3F=A9W@R<3%3<2]S=$E88V1M>%90<U9D:7%3+W=#
M0V9*;B\F(WA!.T%&64Y/+S9225 X06UJ1EAF-$HX;68X059G,#<O<$5G+W=#
M84U69"]G;GE:+W="5T14=BMK4T0O04IO>%8S*T-F2FXO04993D\O-E(F(WA!
M.TE0.$%M:D989C1*.&UF.$%69S W+W!%9R]W0V%-5E-F5"]*+VQ*=DTR<U).
M;VQG,%5C5F]9-'IA=VQ63$-8;%%C84-T3CA+<'@O9VXF(WA!.WE:+S%93D\O
M-E))4"MA34-U+W=4-4TO-G-';F8Y26M(+TY'2W4O=U0U32\V<T=N9CE):T@O
M3D=+=2]W5#5-+S9S1VYF.4EK2"].1TLF(WA!.V]R5"]!0S<U9C R6G Y3S!Y
M,'-P,E5O,'1V0DA%-5%K17%74E9.2V=B67%M1TMU>%8R2W5X5C)+=7A6,DMQ
M3C%:5V0R;G S545D=VXF(WA!.SAK<4LT*S5G8U93=RM39DIP67-D0C T<V5P
M3G!"52\X2FEQ5#9*-5 X<%-A;C5G4U123$(P:'8P4TI7=%E3154R1G$O1E%6
M,DA*:6$F(WA!.T1U5&EQ9C)F;&IY,5I-1W,Y2G,W6FAU1VAT-&]Z+W=Q:D95
M>7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W!*<'8O2U9A,R]X:'-V,5,F(WA!
M.S1Q;F5+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A62F1!+S0V
M=FU4+T%,84UF+V1/=$U65')&6%EQ-T9867$W1EA9<3<F(WA!.T9867$W1EA9
M<3=&56LP,R]!2E-R5R\X06I$6F9Q;'A63SA69&ER<U9D:7)S5F1I<G-69&ER
M<U9D:7)S5F1I<G-69&EQ4S9"+W@Q9DTF(WA!.VXO8E)J+S=P,7!I<619<3=&
M6%EQ-T9867$W1EA9<3=&6%EQ-T9867%K;6TO.'!6<F8O1T=Y+U9,:7%D-'$W
M1EA9<3=&6%EQ-T9867$F(WA!.S=&6%EQ-T9867$W1EA9<3=&56PP1"]J<2M:
M4"LR:D@O04XP-C!X5D]S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U935%1F
M*U5Q,78F(WA!.R]J1%IF<6QX5D\X5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER
M<U9D:7)S5F1I<5,V0B]W0618>DHO,C!9+RLV9&%9<6Y72W5X5C)+=7@F(WA!
M.U8R2W5X5C)+=7A6,DMU>%8R2W!*<'8X07EL5W0O=T1'1WDO5DQI<60T<3=&
M6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&56PF(WA!.S!$+VIQ*UI0
M*S)J2"]W0C V,'A63W-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5E-'83 X
M=S)U=5AT.7 Y=&%8548U2$%P1GAC>3(F(WA!.S=O,%!-2%I,931"0C4K3TMQ
M;C%V>FXO,6$Y3R\W:4TO+UI$:7)V<F9N4#A!-G1E;F8Y>$=F+W-H>%8S,79Z
M;B]!3E=V5'8X075)>B\F(WA!.T%06D1I<G9R9FY0+T%+=&5N9CA!8U)N+T%/
M>4A&6&97+T]F+T%&83E/+S=I32\X03)1-'$W-C,U>B\V=&5N9CEX1V8O04Q)
M8U91;'(F(WA!.W)N;38T=F(R,%A33E!$,DQ):VI(55IQ35I)>$E+9C9&-$YI
M<4PK="MC+SA!<3$V9"]W0GA'9CA!-TEC5F0Y8C@U+SA!5G(P-R]U27HF(WA!
M.R]W1%I$:7)V<F9N4"]Q,39D+S-%6B\X07-H>%8S,79Z;B\Q83E/+S=I32\O
M04=1-'$W-C,U>B\V=&5N9CEX1V8O<VAX5C,Q=GIN+S$F(WA!.V$Y3R\W:4TO
M+UI$:7)V<F9N4#A!-G1E;F8Y>$=F+W-H>%9F-69S=%5G;#%3-3%+3T-'8E5,
M<UA#4E<X<GIQ<4QA=U%!1C-J9TY364,F(WA!.V9S-'%M*TMU>%8R2W5X5C)+
M=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A62DY'+S531'I"+WAM
M='8K;UI-5E1V1EA9<3<F(WA!.T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&
M6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ:VUJ9CAP0C5G+W=#
M33%T+S$F(WA!.T1*:7%D-'$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T98
M67$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1E5K,&(O;$DF(WA!
M.U!-2"]!0FUT=BMO6DU65'9&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9
M<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3<F(WA!.T9867%K;6IF
M.'!"-6<O-'I7,R]536U+<#-I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S
M5F1I<G-69&ER<U9D:7)S5F1I<G-69&DF(WA!.W)S5F1I<G-69&ER<U935%)V
M*U5G.'=F.%IR8B]!2VAK>%9/.%9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-6
M9&ER<U9D:7)S5F1I<G,F(WA!.U9D:7)S5F1I<G-6635P970K8F13,'DP,4=$
M4V)"64PR0T\T:58Y46U$:$I51'%'07-I2S!B9F9&550Y8C@U+SE7=E1V*S1J
M4"]W0FLF(WA!.T]+=2MT*V,O*W)8<#,O8U)N+S=)8U9D.6(X-2\Y5W94=BLT
M:E O,E$T<3<V,S5Z+T%/<EAP,R]C4FXO-TEC5E%6;$(U>G1T43%#."\F(WA!
M.U(K;E Y965.*T@Q*V-C4%1I5T]L9G%7.65.8U92=C%V>FXO,6$Y3R\W:4TO
M+UI$:7)V<F9N4#A!-G1E;F8Y>$=F+W-H>%8S,79Z;B\F(WA!.T%.5W94=CA!
M=4EZ+T%06D1I<G9R9FY0+T%+=&5N9CA!8U)N+T%/>4A&55!Q1W0K8610="]R
M5C%P5FHY6%=32DI$1F9Z331%<VEX,58F(WA!.U=S,$)P>G)4:TU66D9I<G-6
M9&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U936'E4+W=!;UIO
M2"]!1WIR5"]K=VU+<#$F(WA!.VER<U915W18='I9-E)E6'1T0VQX4&)1=DUK
M16MH:%(K0VQU2FM62E-U=S8X1&ER>GA0>FIV;C!7,S%H8DQ25%E4,V-&:SDW
M*VTR*W$F(WA!.W=Y>G='8W!.3V),-$AJ6&IZ2$5G1F=+:SAG1E4X,5 X>%<P
M-WEF6659<&)'3V8V,F95:VAT8FXQ26MS,4IA4S=36F]K3'AR0T))2W@F(WA!
M.W)7;T(T-'%J<GIZ6'%C;FU'9E).1#!X3E%K<TQE2S8Q2V5E-4YR1VDS0F(P
M631327!V5FMC4G-A2&EO-W1V:7))<EHU<$QE2C5O+U(F(WA!.VUD1F%32&M'
M-$U25FPU1%DP3S%C5E9-5F1I<5-E8W8K569M+S1Z5S,O551(:494=D9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%DF(WA!.W$W1EA9<3=&6%EQ:W9K;B]!
M2E%Z45 X071N5VXO2FA-5E1R1EA9<6A.5S O.4DV6F170FYK=%)D4G1%,7A"
M-F9Q24A&0U8Y5DI%<E0F(WA!.WA5-'%K3C$U0FAM,')39%!I,64K=$@P:5=/
M94<Y:%=Y.6574TM,,%DR;3E3,F5*:7-F=S=)4&5U2V]7-2]+=E$W*T999%EU
M<#E99VDF(WA!.W1:-U<R:78T<D=625AU2#5T8W=R.5=6635L,E9/231"4E1H
M:7%P82]L>$)A4&)Z,FUU87!B,W-6=$A9,U8T:E=O:W4W949M34M80VTF(WA!
M.S--9DM.6$M,2D=I>54O87)V:7),630Q:FI73E-3<4%+0WI&;6]"5&1M2EEN
M,TIX5F1I<G-64U1Z;"]Y:C@S+T=A,B\V:5DX47%D-'$F(WA!.S=&6%EQ-T98
M67$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T95;#AK+SA!2T=A0B]W0G,V
M,"\U34II<619<6PO;4=B54ED03%/8E0F(WA!.U9,-FI(851V6DE">4IM5TYJ
M1TMD+VIP:7)Z2%0Y33AV<G%T=&1A;'!6>G)V;#8T,'4P4&QU-6=T-613:6EU
M6&%2-WAI66QK84LU;6LF(WA!.V1833<P+S%X=FA615!D9FU*8RM:3E<P5%-P
M<B]!169413 K95!2<%IB2TEW5SDS8DQA=&)R-C!K13AC:V-I=$MR35HS-55.
M06A51F<F(WA!.W%!,6)Z4#A!;4]L=%IA;F%83W)"3E,P-F9563='2%,T-S5)
M<%1C5S1S-UIP3&$Q96Y/07ET2E8V*S0K13165DQN>E@K62]P5U%S:'$F(WA!
M.S!W9S%/-5-A85A35VEA-'-K=3=F,'I+1&$W9C9,3$IX-%)X.'%6.51K:%(Q
M549&-6@X>C-E:&%W=754-G!*4&$V93DU<$9Z93982G F(WA!.S5J,4]#-6Q3
M,%='5#9T8DDX:W%'1W%64$EK9T%$:V]693%W;55W>&U:47-P54=24C!$53-!
M*VY!<2]&56LX-68X;R].+W=!6G)B+W$F(WA!.TIJ>$-P,VER<U9D:7)S5F1I
M<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5E-8>50O>6AM9V8Y<S8P+S5-
M2FEQ9%EQ-T963S)T8F$F(WA!.S%I.4LR:%-#3&MZ*VY';U)E56I&,V%I,$97
M6FEX.%-A-'%S=F)'>'8W5U,P=G)E2S=T6F%#5S-N4EI),F]14GE29U9.0TLT
M<7)G0E$F(WA!.T%"4419061+67$W1E9/93%T<"]4.65*2F928U-X8S%$8TI&
M<E(Q<C!95C9J1E941EA9<6MN;DPO04I2*V(O:DYB9CA!551(:494=D8F(WA!
M.UA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ:WIE4R]*
M>DU78E%D3TQ%,4I.<$%34V8Y:&ER6"M#9DIN+T%&64XF(WA!.T\O-E))4#A!
M;6I&6&8T2CAM9CA!5F<P-R]P16<O=T-A359D+V=N>5HO=T)71%1V*VM31"]!
M2F]X5C,K0V9*;B]!1EE.3R\V4DE0.$$F(WA!.VUJ1E5N,&YY9C539EAD8VIF
M4DQ";S1P8F-226)716A18F1#94DT-U9/*T95-"]W5#5-+S9S1VYF.4EK2"].
M1T)89C1*.&UF.5=$5'8F(WA!.RMK4T0O;6I&6&8T2CAM9CE71%1V*VM31"]M
M:D989C1*.&UF.5=$5'8K:U-$+VUJ1E8X6&LW>6I&2VMS5V@V9DA,1W=A3U)B
M5T975FPF(WA!.TY145%T45%C5E1F1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ
M-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&56LP8B]L25!-2"]'83(F(WA!
M.R]W0V]:3594=D9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867%K;6HF(WA!.V8X<$(U9R\T
M>E<S+T%&1$II<60T<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&
M6%EQ-T9867$W1EA9<3=&6%EQ-T97;F0F(WA!.T52;F1G<4M#5UEM9T%'-4I*
M>%9*1S@U-D%Z1DQ+8515,T=X1VY24UAA9RM$4U%Q.&%(+U=967$S*VY.9&PO
M,VXX=EA+1',Y,U!A>$LF(WA!.U(Q-E)36$0O04AQ359B1C,U,"\V=%=N1"]T
M-'HO=T1:1&EQ0W,T4$]D='%';UAN-E P-2]R>GAV=RMV>FIH-F-3>#!R.5-.
M83AA-'$F(WA!.VDO,#-R.%@K.5!L-C1F>&$P;G1:44\O*S=:3&1V=54T<35F
M3V5G;WEP9E-385<W1V=';U%Y5W%C=C56;&Q665A0*W$U>%9/-#5%:U(F(WA!
M.UI),D1O-$1)-FUO24\T24EX5G9&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<6M.,S5G=DQQ.6PP,WDF(WA!.R]!;#%C=TYW
M=DPK66M79'-W-F]X6#1P6E(O=G1/;C=42G165G%,>69:>FQ:=&1N:S%Y-4(U
M574V9E9L4&(P-U)A441J*WEZ2WHO-5(F(WA!.WA64&M215)54E%Q2T%&54-G
M04=W04%X5DIV3TYR6E1E6#=Q4SEV<#E0=&)61W5*8FDS=7!,26=2;S%/8SA4
M4G5Q5DY44F@P,S)X5C4F(WA!.VYO2&UB5TQ$5#E&=#E",7DS=EID6#AV4S8S
M4"ML2DQN5EIJ95=A44I*1D-X=30R5EI785-Q1#=,23%/-$-Q2W1V>F@Q1V9K
M-EAE;'DF(WA!.S(V86IB5WIY>$%.2CE8=DQ/,VUJ2U%09&\X:D-E9&\K569)
M;FIT2'53<%9M=C5D-GIQ;7-E6%1E86YE5SDS94,W=3183G1%65)'25HF(WA!
M.S-J151Q6DIF:EAJ-V)%8E8S259K>DMR2U9907%246<W9V<T<6M5=FLK=VA:
M<'1%;&LP3S9.5'ES<4-":65V<5=R07=06'4S05 T34TF(WA!.U9D8F$O93).
M,49P+VU'2DE*6FU%9'!Q8TY285A$:S!61'E*84-6=3!B:V<O<W-X,D-Q9EEQ
M-T9867$W1EA9<3=&6%EQ-T9867$W1E@F(WA!.UEQ-T9867$W1EA9<3=&56LX
M>C-6-E5T3DES2E=G=DY6;$U*=54K,T)B;W!E95IA+W1"4451.6Y:5#!X5DTY
M4# K>3 V>6AS<DM&64PF(WA!.U="94U54SE!3W9F8VMN8VLW:S=N1E52:7)S
M5E,O4B]-1VHV>70R,FU84S-)<TQM4WEU>6]98THT<48P4$E#=7I!9VI9:F]C
M5E1$1E@F(WA!.UEQ-&M+0U-A06)K;G!41E9S57-5,%-4475S:U5I:#0U14E:
M5U9H54UP1WA"1TMR<U953#9X<S<K>FUS-WE&6C=79%-K,$QI<7-P-F<F(WA!
M.VI&57$X=%A&,T4Q-V]T-TLP.7AP8F])8FE1,65A,&U"83-K8SDR2$9O;5 W
M5$E7-S1Q;FU+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8F(WA!.S)+=7A6,DMU
M>%8R2W!(<3!G=&9-*VE88VTP13AD,W!W8G-S='@V53AD9EEI>EI2+VQ%1'9I
M<659<3=&54AR4#98+U)6,$Y(5T9T54TF(WA!.V)#>BMS=3!C26M/=UHR4DI7
M;W979U4Q-F4K2W9/-%!Y,C@R5TU7=&%D85@P3C-P=7(R9&U';'9P9TIH9%=9
M0TY'>5=T<&)O,$4P2W F(WA!.T5Z:S@V0W4O5$95=W0O26UO<')%1C9U:C90
M85%I>49P87!B>4]7,&E13DU8;# O+T%%5TY'.5@Q9U=O<TIQ3W)$;W%X-GHO
M2GI7;W(F(WA!.T-0;F)A44QM2U,R5G)*5VMA,6Q33WIN=$QU-&1M9S5#5S9&
M=W)32GA)8F=!>FUV24960W@O2TQZ6$AE5TQZ5T=I;TEK=#1,>39J=34F(WA!
M.S-K:VAJ,'545'!L.4TR4TMW;&%26E-#,WAC1E4Y:498<"]K>E)P3D4X<396
M<$US1G9B5%=6=$A$3D9::VU$,49(>'5H2U)(-#)Q>'$F(WA!.V\S3T)5-7A6
M,DMP1G!C:3-(;3-7-VU+:E%W45=69S=J+V8X04-:-V@Q+S)+6&-F,#1Q;G5+
M=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8F(WA!.S)+=7A6,DMU>%8R2V]45G1,
M=$Y6,"M7>'5G,W!3,$ED1'AK4C!94$A*1S,W3&\V:&Q066I&57!S3F9U9%!N
M:C!R>DEY>%A434DW4%8F(WA!.TMC3%<X<G-O<CEM2V,O=%)(<60P-4-V1E9K
M3TMU>%9J9C5H83EF-D8U6&UV<D1G;'<P.71B9E=:0GEJ=#%U6C!G831C9$-)
M;&LU-S<F(WA!.V)B-UEQ:W9M6'I89BM33DAK=35,."MA6G%!:3)U2'0W861%
M4T=E-&54+U$T0U@U<D9X44Q"=%1K>$-H,T-Q13AY+VU$<EEM5S$P*S,F(WA!
M.TYH8W@S,FQM,D5J8C-T=&0S;'9"2W8W,C-A35)-3&YI6DEP1UI44W9%-UEQ
M>EAY=G)4-C-O5G)Q8VM!=%I:=W=L='<O<6A(:F1O,D,F(WA!.W9X:C5$:W!O
M94DK5TMP<&ER<U99+W%'=C-&-6-3-E8U9#181V])948Q9DU/9'):*U!Q145C
M-5%.>$-P<B].>$<K2W!P;RML5S)L868F(WA!.TA:5S5:,51K,&LP:#534WEU
M>&535U)U-WE/4WI(>'A61UEQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&
M6%EQ-T9867$W1E9+-G0F(WA!.V)7-W0U3&$V:%,T='!L2U114W%(4C%05E=6
M9U%19F9&56M8>3-Q3VYM=6<V;3EV0T]M;EAO83=T4G0P:DI:2C1V64-1;W9:
M35964# F(WA!.S$U9W1D=%$P3U-51')0<# P9'EG2&E5;"MR5%8Y;%)S5E=4
M*V)03$US36M';RMR0D)+<%-74%5,3S1G:EI72'A+5%!%<4U+9&1Y358F(WA!
M.U-T2E!Y8E-X6%0T,CAU<EE2>4=:3$Y466E&6E-V17E#369#2$MM;&%6<&EQ
M,C18.&QR9T]T=U!,8V]M0T-14V951S5I24@P=S%E=D,F(WA!.W T*T=+;S=3
M.60X:S986FEZ,$<S0S)A:W-L=G!&:DY*0T-X<5-"87A-9W)8<FEQ2T]U82]C
M,$=N849+9U!39E5:;S=72VYI1FHK<WHF(WA!.S$Y;6E8-31Q<V)Y-7%M<$$O
M<#=5,FQT>C$P-G=$5VQU4C133T=E951W4#=X5F)U;4MP,5HR9'!:5W-D<EIW
M<&)7<TMH25E);$-):6HF(WA!.W-Q<E%!67%R67$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6"\O6CPO>&UP1TEM9SII;6%G93X*(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]X;7 Z
M5&AU;6)N86EL<SX*(" @(" @(" @/'!D9CI0<F]D=6-E<CY!9&]B92!01$8@
M;&EB<F%R>2 Q-2XP,#PO<&1F.E!R;V1U8V5R/@H@(" @(" @(" \9&,Z9F]R
M;6%T/F%P<&QI8V%T:6]N+W!O<W1S8W)I<'0\+V1C.F9O<FUA=#X*(" @(" @
M(" @/&1C.G1I=&QE/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @(" @(" @
M(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UD969A=6QT(CYG,3ES,#(\+W)D
M9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+V1C.G1I
M=&QE/@H@(" @(" @(" \9&,Z9&5S8W)I<'1I;VX^"B @(" @(" @(" @(#QR
M9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI('AM;#IL86YG/2)X+7)E
M<&%I<B(^1FEL92!.86UE.B @(" @(" @(" @(" @(&<Q.7,P,BYA:28C>$$[
M57-E<FYA;64Z(" @(" @(" @(" @("!R<C8P-30Y.28C>$$[3&]C86P@5&EM
M93H@(" @(" @(" @(" @,#DM2G5N+3(P,C,@,30Z,S$Z-#@F(WA!.T535"!4
M:6UE.B @(" @(" @(" @(" @,#DM2G5N+3(P,C,@,#4Z,#$Z-#@F(WA!.U-C
M<FEP="!697)S:6]N.B @(" @(" @(#(N-B8C>$$[26QL=7-T<F%T;W(@5F5R
M<VEO;CH@(" @,C4N,"XP)B-X03M'<F%P:&EC('1Y<&4Z(" @(" @(" @($9L
M;W<@0VAA<G0F(WA!.R8C>$$[*BHJ5&AE('!R969L:6=H="!C:&5C:R!I<R!C
M;VUP;&5T92X@4&QE87-E(&5N<W5R92!M86YU86P@8VAE8VMS(&%R92!C;VUP
M;&5T960@<&5R('!R;V-E<W,N*BHJ)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@
M9F]N=',@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @(" @
M(" @(%1I;65S3F5W4F]M86Y04TU4)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@
M8V]L;W)S(&%R92!P<F5S96YT(&EN('1H92!D;V-U;65N=#HF(WA!.R @(" @
M(" @("!";&%C:R8C>$$[)B-X03LM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TF(WA!.T9I;&4@3F%M93H@(" @(" @
M(" @(" @("!G,3ES,#(N86DF(WA!.U5S97)N86UE.B @(" @(" @(" @(" @
M<G(V,#4T.3DF(WA!.TQO8V%L(%1I;64Z(" @(" @(" @(" @(# Y+4IU;BTR
M,#(S(#$U.C0W.C0Y)B-X03M%4U0@5&EM93H@(" @(" @(" @(" @(# Y+4IU
M;BTR,#(S(# V.C$W.C0Y)B-X03M38W)I<'0@5F5R<VEO;CH@(" @(" @(" R
M+C8F(WA!.TEL;'5S=')A=&]R(%9E<G-I;VXZ(" @(#(U+C N,"8C>$$[1W)A
M<&AI8R!T>7!E.B @(" @(" @("!&;&]W($-H87)T)B-X03LF(WA!.RHJ*E1H
M92!P<F5F;&EG:'0@8VAE8VL@:7,@8V]M<&QE=&4N(%!L96%S92!E;G-U<F4@
M;6%N=6%L(&-H96-K<R!A<F4@8V]M<&QE=&5D('!E<B!P<F]C97-S+BHJ*B8C
M>$$[)B-X03M4:&4@9F]L;&]W:6YG(&9O;G1S(&%R92!P<F5S96YT(&EN('1H
M92!D;V-U;65N=#HF(WA!.R @(" @(" @("!4:6UE<TYE=U)O;6%N4%--5"8C
M>$$[)B-X03M4:&4@9F]L;&]W:6YG(&-O;&]R<R!A<F4@<')E<V5N="!I;B!T
M:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @(" @0FQA8VLF(WA!.R8C>$$[+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M)B-X03M&:6QE($YA;64Z(" @(" @(" @(" @(" @9S$Y<S R+F%I)B-X03M5
M<V5R;F%M93H@(" @(" @(" @(" @(')R-C$S,CDW)B-X03M,;V-A;"!4:6UE
M.B @(" @(" @(" @(" P.2U*=6XM,C R,R Q-CHT,3HS-28C>$$[15-4(%1I
M;64Z(" @(" @(" @(" @(" P.2U*=6XM,C R,R P-SHQ,3HS-28C>$$[4V-R
M:7!T(%9E<G-I;VXZ(" @(" @(" @,BXV)B-X03M);&QU<W1R871O<B!697)S
M:6]N.B @(" R-2XP+C F(WA!.T=R87!H:6,@='EP93H@(" @(" @(" @1FQO
M=R!#:&%R="8C>$$[)B-X03LJ*BI4:&4@<')E9FQI9VAT(&-H96-K(&ES(&-O
M;7!L971E+B!0;&5A<V4@96YS=7)E(&UA;G5A;"!C:&5C:W,@87)E(&-O;7!L
M971E9"!P97(@<')O8V5S<RXJ*BHF(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!F
M;VYT<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @
M(" @5&EM97-.97=2;VUA;E!3350F(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!C
M;VQO<G,@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @(" @
M(" @($)L86-K)B-X03LF(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+28C>$$[/"]R9&8Z;&D^"B @(" @(" @
M(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SID97-C<FEP=&EO;CX*(" @
M(" @(" @/&1C.F-R96%T;W(^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @
M(" @(" @(" @(" \<F1F.FQI/G)R-C U-#DY/"]R9&8Z;&D^"B @(" @(" @
M(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]D8SIC<F5A=&]R/@H@(" @(" @
M(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N9&ED.C=C-#0Y-&8S+6,Y,F8M8C8T
M.2TX9# Y+6$Q,68T8F9A,68P-#PO>&UP34TZ1&]C=6UE;G1)1#X*(" @(" @
M(" @/'AM<$U-.DEN<W1A;F-E240^>&UP+FEI9#HW8S0T.31F,RUC.3)F+6(V
M-#DM.&0P.2UA,3%F-&)F83%F,#0\+WAM<$U-.DEN<W1A;F-E240^"B @(" @
M(" @(#QX;7!-33I/<FEG:6YA;$1O8W5M96YT240^=75I9#HW9F4U-#8S.2TT
M,V4V+30S838M.&1D8BTV.3 Q,S%A-#-D.&4\+WAM<$U-.D]R:6=I;F%L1&]C
M=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.E)E;F1I=&EO;D-L87-S/F1E9F%U
M;'0\+WAM<$U-.E)E;F1I=&EO;D-L87-S/@H@(" @(" @(" \>&UP34TZ1&5R
M:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" \<W12968Z:6YS=&%N8V5)1#YX;7 N:6ED.C5C-V9B.34S+3$V8V(M93 T
M82TX.3<S+3 V,C$W9C)B.69B-SPO<W12968Z:6YS=&%N8V5)1#X*(" @(" @
M(" @(" @/'-T4F5F.F1O8W5M96YT240^>&UP+F1I9#HU8S=F8CDU,RTQ-F-B
M+64P-&$M.#DW,RTP-C(Q-V8R8CEF8C<\+W-T4F5F.F1O8W5M96YT240^"B @
M(" @(" @(" @(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT240^=75I9#HW9F4U
M-#8S.2TT,V4V+30S838M.&1D8BTV.3 Q,S%A-#-D.&4\+W-T4F5F.F]R:6=I
M;F%L1&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.G)E;F1I=&EO;D-L
M87-S/F1E9F%U;'0\+W-T4F5F.G)E;F1I=&EO;D-L87-S/@H@(" @(" @(" \
M+WAM<$U-.D1E<FEV961&<F]M/@H@(" @(" @(" \>&UP34TZ2&ES=&]R>3X*
M(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z93 W9#@R8V(M9#9B
M92TT,31B+6$X-V0M934X-&(V.3DW-V8T/"]S=$5V=#II;G-T86YC94E$/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(S+3 V+3 Y5#$S.C(Q
M.C(V*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B R-2XP("A7:6YD
M;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @
M/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T
M:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#II;G-T86YC94E$/GAM<"YI:60Z-V,T-#DT9C,M8SDR9BUB-C0Y+3AD
M,#DM83$Q9C1B9F$Q9C T/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z=VAE;CXR,#(S+3 V+3 Y5#$V.C0Q.C0R*S U.C,P
M/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A
M<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B R-2XP("A7:6YD;W=S*3PO<W1%
M=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H
M86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(
M:7-T;W)Y/@H@(" @(" @(" \>&UP5%!G.DY086=E<SXQ/"]X;7!44&<Z3E!A
M9V5S/@H@(" @(" @(" \>&UP5%!G.DAA<U9I<VEB;&54<F%N<W!A<F5N8WD^
M1F%L<V4\+WAM<%109SI(87-6:7-I8FQE5')A;G-P87)E;F-Y/@H@(" @(" @
M(" \>&UP5%!G.DAA<U9I<VEB;&5/=F5R<')I;G0^5')U93PO>&UP5%!G.DAA
M<U9I<VEB;&5/=F5R<')I;G0^"B @(" @(" @(#QX;7!44&<Z36%X4&%G95-I
M>F4@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W1$
M:6TZ=SXV,3(N,# P,# P/"]S=$1I;3IW/@H@(" @(" @(" @(" \<W1$:6TZ
M:#XW.3(N,# P,# P/"]S=$1I;3IH/@H@(" @(" @(" @(" \<W1$:6TZ=6YI
M=#Y0;VEN=',\+W-T1&EM.G5N:70^"B @(" @(" @(#PO>&UP5%!G.DUA>%!A
M9V53:7IE/@H@(" @(" @(" \>&UP5%!G.D9O;G1S/@H@(" @(" @(" @(" \
M<F1F.D)A9SX*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT3F%M
M93Y4:6UE<TYE=U)O;6%N4%--5#PO<W1&;G0Z9F]N=$YA;64^"B @(" @(" @
M(" @(" @(" @(#QS=$9N=#IF;VYT1F%M:6QY/E1I;65S($YE=R!2;VUA;CPO
M<W1&;G0Z9F]N=$9A;6EL>3X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O
M;G1&86-E/E)E9W5L87(\+W-T1FYT.F9O;G1&86-E/@H@(" @(" @(" @(" @
M(" @(" \<W1&;G0Z9F]N=%1Y<&4^3W!E;B!4>7!E/"]S=$9N=#IF;VYT5'EP
M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.G9E<G-I;VY3=')I;F<^5F5R
M<VEO;B W+C P/"]S=$9N=#IV97)S:6]N4W1R:6YG/@H@(" @(" @(" @(" @
M(" @(" \<W1&;G0Z8V]M<&]S:71E/D9A;'-E/"]S=$9N=#IC;VUP;W-I=&4^
M"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1FEL94YA;64^=&EM97,N
M='1F/"]S=$9N=#IF;VYT1FEL94YA;64^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" \+W)D9CI"86<^"B @(" @(" @(#PO>&UP5%!G
M.D9O;G1S/@H@(" @(" @(" \>&UP5%!G.E!L871E3F%M97,^"B @(" @(" @
M(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI/D)L86-K/"]R
M9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!4
M4&<Z4&QA=&5.86UE<SX*(" @(" @(" @/'AM<%109SI3=V%T8VA'<F]U<',^
M"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M/'AM<$<Z9W)O=7!.86UE/D1E9F%U;'0@4W=A=&-H($=R;W5P/"]X;7!'.F=R
M;W5P3F%M93X*(" @(" @(" @(" @(" @(" @/'AM<$<Z9W)O=7!4>7!E/C \
M+WAM<$<Z9W)O=7!4>7!E/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<%109SI3=V%T8VA'
M<F]U<',^"B @(" @(" @(#QI;&QU<W1R871O<CI#<F5A=&]R4W5B5&]O;#Y!
M9&]B92!);&QU<W1R871O<CPO:6QL=7-T<F%T;W(Z0W)E871O<E-U8E1O;VP^
M"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D9CI21$8^"CPO>#IX
M;7!M971A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @"CP_>'!A8VME="!E;F0]
M(G<B/S[_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0'_P  1" #X ,P# 1$  A$! Q$!_\0 '@ ! 0$  @,! 0$
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M<[D4>()<^<'R:,5NYF4DC+[77;AK(!(U7?7R-=MM2QYZ[/MN\>CX.)@ D6C
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M_'X<^;UKNO9/LKX?_?S?&WAQQSSSX<<<\X*G^YB-8V\'YY[)DC7QUSUP[*V
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M,TS\-D(B3A=W;3G75TUT*!'CYCLY;;;ZZN$-5^54>=M>%-=>>>/$.U8# 8#
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MV%65C1L-&*.RA%*)5-4?OD<1*.I$SY,T<+DU",N-N#<@($N71=HWC3)XBJX
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M& P& P)8)7O*[%+E8EUDBXF;;AB+T')[KF+A^.HV'F!SI4<7%!7(OC@_=4O
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M:?'DB>+-GSX17%H1X<WY82.936(V=PF%+L[-+S<N?&.W\?4<JL'"& P& P&
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M,.L87RO>Z M(/R6J\L>SU*]>LS"4NUU'>Y@)VC! >63]>-0^'N20EH$LY@/
ME'D?KR!,7Q0,U'D'RL*BI!XY7)Q\4\:EKY95/2??9U>P,E?Y,D49:GHO;%$%
MI&VD$8E;=""W9[]#SR2Q G-3@$SM&XC,CA(T3T-V//#1!946^6D)F6G29[@H
M0(++["OEI/;3.=,(SP4!SVGCI?Q0KJH^Q]G$N>?%)D*HR;5N/=)<_'PX9S?L
M$SIJM7C??CC;;15K-5=5.-?D>5SNEPH2M\=;[7]O#L0[;6%^;&@*PZY1]QSS
MOJ4E)%U>%J[,U/S:C12&QI2'5A"CR.O.SAF93LRZ ::W"6CN-OTO.I;#",[G
MZCKG]0[9 .O$'A4D2L$T^DUK6UHT<L>+:M8DUDLR8,WVG"9)A#V;$<&A57AB
KNFB/!B/5/$8+'C2C=!V7%OGR?I7(OE&D?NV>=MXPA@,!@,!@,!@,!@?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>g459793g27q68.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g459793g27q68.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2#\4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (."^A!8X0DE-! 0      "P< 5H  QLE1QP!6@ #&R5'' (   (  !P"
M!0 01FEG=7)E-%\P.#(T,C R,SA"24T$)0      $ .R$=&1>Y;JLDWM#[U\
M\+HX0DE-!#H      .4    0     0      "W!R:6YT3W5T<'5T    !0
M  !0<W138F]O; $     26YT965N=6T     26YT90    !#;')M    #W!R
M:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $
M  ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U
M '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN
M4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2
M<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O
M;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
M $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B
M;V]L      !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U
M8D!OX            $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M          !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M              !2<VQT56YT1B-0>&Q >0            IV96-T;W)$871A
M8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&
M(U)L=                %1O<"!5;G1&(U)L=                %-C;"!5
M;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC
M<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M    #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<
M     #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-!"8       X
M            /X   #A"24T#\@      "@  ________   X0DE-! T
M  0   !:.$))3009       $    'CA"24T#\P      "0           0 X
M0DE-)Q        H  0         !.$))30/U      !( "]F9@ ! &QF9@ &
M       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4
M   ! "T    &       !.$))30/X      !P  #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@  #A"24T$"       $     $   )    "0      X0DE-!!X       0
M    .$))300:      ,U    !@             &%   "=H          0
M                       !              G:   &%
M       !                         !     !        ;G5L;     (
M   &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M        3&5F=&QO;F<          $)T;VUL;VYG   &%     !29VAT;&]N
M9P  "=H    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M$@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R
M:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
M5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,
M   !        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M          !"=&]M;&]N9P  !A0     4F=H=&QO;F<   G:     W5R;%1%
M6%0    !        ;G5L;%1%6%0    !        37-G951%6%0    !
M   &86QT5&%G5$585     $       YC96QL5&5X=$ES2%1-3&)O;VP!
M"&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M    #T53;&EC
M94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N=6T    /15-L
M:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M
M$453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M       *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M        "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M        .$))3001       ! 0 X0DE-!!0       0    $.$))300,
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M/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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MQ)#9<YSK/L;6.5P93<KIN9>WZ-U!M81,%CJW-0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M4?O&^)/0N[9OH=<%>]' /B_ISNK[9J/AI/WDU,78H_>-\2>A=VS?0ZX*]Z.
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ME]URK9QR%6"C2]-.MNF+E%C<%0^JAQ&>*HDDP^5\K-!KW284P1X>XV9;_=F
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M"VTKP&C*WHBVW3"T*OCJD:@C$<K$W !U'%KB)Q^L)5BPJ9@XW1LL2*/%>T!
MV0IB*&-5;U&S0>:5:(HVH-6%C3&KY38[7"I%5B$DHK&5+*D"*GC;,VKEHIZK
M3;%"P:51/AU%+*\ /?) 'N<7/D+U-@6$TFIYO11Q\W= ^ Z<KS&:6.IBI]$O
MD<;015E3'$TDM8R4M: UK VVR;:W@.8,T!\BQP+?LD?#BQ1M81/,42#;),D>
M3&<#35HXLTH>#2"5/W<@=!#7=XA$LK1ZS9-EDD;D]M+RLY143W24V*31O=S
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MOL+J=H:.EQ;4/<!Q+6.(&QI.1:4H^YL/0)#?O7C:+\+N XD*0H3,1$^BXJ6
M[7J3$I8YLO9%&MS N))#GKD4; FF%]U]S Y'S3$@$-,+KU*LBK!VUJI?5+EU
MUO88WECK7%LP;M<" YKFG>US2'-.\$%9-<'-#A>QW$6((-B"-Q!!!&X@K*M8
M+)<)^S6?H:?U9?VJM>@P+[Z]P_SESZ_[E[I^PNKFU/Y%W;;](/#OVO([KBU/
MKB?VZ7Y[E=C]3C_$;\T+!M^,@&Q79QN.D)G'<;RL'%XLD:Y:"31F1(0DP,N0
MM1?N9PP#V*%GD( M%%I%,6PNVA%:-"2B;*])S<DI9I6:XT=BANP/&-Q\<C>(
M@>R>:R4GC[>#%YM/=K..VD(D,5"X0W0CX5CV9NT062<BAA&),\0I_&TXQ'"K
MQ0NN<Q[X1 )1,!)([;'"+^DS1$T1-$31$T1-$31%;C#%P3$E!K0L1 NB YZQ
M;'1%@U0L%<.VRK=$L,3,CBX>\B.44M>,K"HDH-N<HI4?#GK6JK94BUOV: )C
M%=N\/CL]<SA[)@\CRLQ<O\D/2Q.;DAB.7IY2.$SY(Y^6A%P2C?>A\W(.>AZQ
M<-7+?\C*HZ(H795G'HBMR:\52**(",F8Y+6U8"FS]*A)7;G" M:+J+L75U*5
M'%G'!*R]/A?VI3II2ZV_8R5T;)V-M:>(1/OM#1-#."-U].%@S!&B3E>Q&#F!
M[HW&]XWE[;6S)C?'GELT9"<K&X&=K@S!X0YQZ?R.=]7P88\?6_*GA[/#6H[M
MO<RMW]I[XR6:IX0YQ^5SWZV&/W)U**M9#G'Y7/>KX,,?3\HG]BFH&T[>YEY\
M=Y^,(GA#G#H_(Q[T_P#2PQ]FGY4]?UM,^/2,OB.6SX^I$\(<X_*YWUXPR^OP
M$_8IIGQ/>M\5_P!91/"+./RL=_6PR^Y6ECQ/Q>)$\(<X?*Y[Q_ZV&/K5_F5Z
MW77U],^/#AWQL[^P=Y$K(<X\>AN>X>G&&/W)]GZVF=LSGT>?5\:+$,A2K<@R
M@$Y>1-I);Y4TALH=1FUG#AS]U?(6X-^L$L:L5@BZ3UQ<2L:VH-%6ZZ;E7DHW
MI*VJ5LNJ5[JAE!7/I=,U3*.I=3-:QLCS4-A>80UA:YKW&0-T6$.:XD-+2#9<
M;E'+B,')W'Y\';([%X<$Q67"FPQ-GF=B4=!4/H6Q0/9(R:0U38A'"^-[9'D,
M<QP<6GD0!RYV7(C+XLYD,:S#>R0)MQ[U9Q@**-T$@I5^.L-IKWI8\2MM06:M
M4ZJK774O0L2JHDHG=2Z[7S"CQGZHS7-@EAKM3-4TCY7NPNE86,A>\&SF4K0T
M%LK])Q!<VP+'--R?Q]A?*?\ VDI<4PUN(8?R@-(ZNI(ZJ23DEAD38Z.2HB%6
M'/9A,88Q\(.G(?3,:W28YAN5VA0-YK;(I-V[(T@@@FFB@BE%F":2**5M+$TD
MK+1%+;$T[+;;+++:<+;:4I;2E*:^N.+G.+G$N<XESB3<N<3<DDYDDYWOF=J_
M;(         V #( = "^OA#G'Y6.^KX,L?3X]0GQ]%/W.O6.?$_%^OAM\[*4
M\(LX=/Y&/>E3P88_<K]WUM,\LSTG*_5;Q99YHGA%G'Y6._K89?<K2QXD]X>+
MQ[43PBSC\K':_P#X89?<JFECQ(ZO%^LHGA#G'J[G.^KX,,O9_F3^QZE-,]N?
M<RZO,]THGA#G'Y6._K88_<KUO\O3IWS\7B[_ /"Z)X19P^5COZV&7W*TL>)_
M_'Q(GA#G'Y7/?K88_<KQ?A73O_)XM_F$6CN\+)G9!XT[@-NWT7D1TW>-I'=*
M:Q[$\?E5MBR"H6@BCNXA#RU65UUBI&J-J-4*.*44K=12J-O(\7RNJN4M,:#Z
MWVU+],5/.]11P50&CJ-3I:V"8LOI2V +2ZQO?1!'P?ZM&+_53PN;D\/J<0XG
M-'-'B1Q;T/P6CQ8-?&ZBYEK354-88"6OJ= ,,8DLXN#M 6^>S[)O9"I(1G:>
MX$7D5LT:,@%T7K(<31^*V7N%G!6TKW*HPAXBKVZU)-CVVQ6Y:B-*IW66I]MN
MK?AR2JN4]3)7#E VI:QC(#2Z^C@I;N)FUH:88(M,V$=P[2T<K 7-\/J,8O\
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M5V/U./\ $;\T+ -_,LD$$V9[CY?%PL7D!R/XND!!D+F402R#'5;4[$K7CE[
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M6776_BJ6UK6G3KY_#]3:BAFBF&)U3C%+'(&F&(!Q8\.L3I&U[6O8V7YRH/\
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MK3R5KUZJ^B]3_P!/Q^''RM:==5]@F^&I/HT[3N=^6-Q?Z_\ 9S]Y/3T7J?\
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M*#MH1C<<02@:LB]FY7(S (!!L'9[> '0;YJ!H\&[<A?,=VY^+=TE=.]F$ZW
MI0^6V994RV9C,?=9DF>.1V8\.RIAGF2X@=3URPP5X22YBRB\62G'>&)3A<IB
MLK#7F9:1R4XG*3JD4-4(,I7@\,RM8$V! ((!&1X96W[SOVK%P%\K;@;'*^=^
M]LSV;=ZY78KSEO\ 0(;!4LE-=]A6"34IM#)[GE9;MERL5EF.,L*S":9GW 0G
M%&/A&&FV87&&6D#AH? 4RD;2-&(&N5F\7\"SU2:TJ>-\R(S>V@"-+1S%B+6%
M\[7TLQT9[<SE9MC]J#F!8CA87^6^W8M]F<FSUN'WPY*BL R%NXPC@T;@4"]7
M)9!P',H5CZ1GI.KBPLU980+2K%$68!)5#!"LII,S$UR _P CK3*;D8T/QTO$
M,4E+T,/2M:+M:2'$9&_';8[[&PW6'%00 T7 O?C\MO'^L*(]WV5>R+/-QN9X
MSCS%>XJ$8BC>W.7Q3;>8PZ QW,Q.4-S,\FF*6&&LC3>2)R<@XC$9CY<9D9I-
M8M- \9C<%Q8.<3&:G%[\B"1@#)C6:-SHDWNZ^0MO  OF > W(W1L#D3?._ZA
MYW/>MJ;(,P=EL'KXFET3"[EY!DE;"F1LT9/QT6PL7%8V<YS>1;<D_(X3B[6L
M8(1(7C+%\KQ'B;$T1'RW)"4ZR.&RE$<LXW1F9R6EY!3("/,'1L+"X.[( DYV
MN<\CLVY7OEZ3.^CMMM_7W\[=PG)2GB69]DK)9EQ%#'![=$^Q@ZRU$)%CB;9"
MQ#=&[IWBRW+S,=G\AN9=$,8 +<=MV>*L9Y!,88Q[*;,<R9VXW(8^3"!2A"!!
M[(S!$=B?2WM8]'"W&Q(N0;Y6NH.C8VM_'=;]9'?Z)?W#YCW_ /AUN;A&!87F
MMUD@#G\OD#$K1]C*4M<*W;=<-[+!LMB@ =E4B :8ZE!3<%NU:HPDC"0$R>S+
MN20$VY9E'1,?*D&L!K+-+BVQ;8YBY).WCZ4?'O.^ &V!-MENZ3>^_=Q/&]]B
MV3['/*,X24[GRF1%]RQC'(NS$K?'LTW+C9)%)#/)8\"RA[E.0!<:SK;5MZEF
M,4['2L59FH@(=9'Q.Q(66-\:FQE6DE;O<9 T6L "=PW#8+V-N_:YSNH=;*UM
M^SXM^?=ROP6Z$;I2F[&=UI3A53;OBRBE:=%;Z(Y*S!5&E]:?R5$JKKU3I=Q[
M7597D\.V7\KGTO\ 3-5_\91?%5U]NJYZSQ56+^D)O[G3_%/56ZKGK*V;UVUT
M%PG[-9^AI_5E_:JUZ# OOKW#_.7/K_N7NG["ZN;4_D7=MOT@\._:\CNN+4>N
M)_;I?GN5V/U./\1OS0L*WV34!CS9UN/F$K@<5R;&1&*)5200:>+*-H(>#D65
M11%.=.4&C]VWA3)J^5)RUP/8O"B$>9$E1;5<C8V2NTK-<E=J4DP!@/>['B>0
M,V=C]R7-,YX'EY(1EG;[.YY!D<=^";O"$4J",0;)^Z7/L (J9D$(1%HVRC&+
MH+DK(#_%J*,J'S=%!V7CI1?B1^K9YGN=RZ_H;T4IHB:(FB+^;HAB'*-F!R;#
M"V%MP<0SF/QYO-]$O(%(-E*'M<F!Y#'\JHXQB8?OZU&M,RY)+9((XNE&/#V/
MV<K=QJ,1J7CDSX1&5HBI(\_/J4"_QGJOE\1'Q[PMY=TYQ?-KS#TOQ)C#<C;D
M2+Y"@+^$F3^%,Y0X.NC&,M0&0SR#TLD*\,MP<8F4=;MV!C.N1H$_A)/%U9[
M!!(T0(E0[(I76#1%BD\=1!C!YD\R"3&!H$UBT@<38N:+4 AQ<22$N[Y&0*G+
MG3&@8<S$6O'#TI5ZT[WMDU'?=*':NVV$6-89D>*9'C>,\R9F/F,;QQ@G"8[2
M-O+G8\*WA=EL;\&5+5K[WK%]'J#K13P:3HF29*MNU/4[5:5XD4)8XA\;D>=]
MV;DV-L?+M\B8S01OO<NT>0E7 F,[ZV4M;N$;;J5ONK6M;K;J]/#CPZ-$4^<U
MT ^9]#V\3^':6\[E$YK8!\SZ/1U?D\G3T_$^_P VHL,^G:BIS6P#YGT?;Y3X
M=J45>:V ?,^A[>)_#NOT^O2R*G-; /F?1]OD_AVB)S6P#YGT?;Q/X=^'K4T1
M5YK8!\SZ'MXG\._#UJ:(G-; /F?1]OD_AVB*V&L+8ND <L!,Q9N\$'!A .59
MWDS*-CL:4:+,G[:Y5N2172M7:KJI5415253I?6Y)1.^EMU-4T,=1#+!,W3BG
MB?#*PEP#XY&ECVW:0X:37$$M(<+Y$$!5:ZCI<1HJS#ZV(3T5?2U%%60.<]C9
MJ6JA?!41.=&YDC1)#(]A<Q[7M#KM<UP!&NPSL=FRH018%1N%!#8B,>M2#!S;
M,,@*7-WK)=-RU7M35ERB5]R2Z2:E+%$[T[JV\F^RZVM;:^?9R/Y-QO9(S"XF
MO8YKV.UU4;.:0YIL9R#8@',$<0OFU/\ 46^I=33PU-/R4I(YZ>6.:&05^+.+
M)87B2-X#L0<TEKVAUG @D6((R6QLKQ'")4,RDT4%MQI/,$3MA\TD#&WDE20U
MH(+!@URU]]U4U% ;4T_J/I6RVVVY>^BG+I7H]#+&)8Y(G$@2,<PD;0' BXZ1
M>Z^NT-7)05M)71 .DHZF"I8UWVKG02-D:UUL]%Q;8VSL398%M=V_L]MN,:P!
M&0>$[U[(BLG,&J,*BT'1$B@P'IVMA]SPA<V1;BQ(UM6ESQ:JRZ2SC\;HM1%.
MO0T@HX=4'EY+W2.=;1N76&0N; !H&TW-SO78Y3X^_E'B0KS3BF9'314L,.LU
MKFQQNDD)?(&1A[G2S2N!#&Z+2UF>CI'8SC3RT]FFKB\ZG&GEI[--$3C3RT]F
MFB)QIY:>S31$XT\M/9IHB<:>6GLTT1.-/+3V::(J54LMX<J^RWCU<;J4X^IQ
MKHH) VD#NJE%++OY&^R[AU\+J5X>Q71+@[""OUQIY:>S312G&GEI[--$3C3R
MT]FFB)QIY:>S31$XT\M/9IHB<:>6GLTT1.-/+3V::(G&GEI[--$3C3RT]FFB
M+\=M2IUJ)_V]O[NBBXXCK"_=+K:TXTNI6E>FE:5IPK3RZ*4XT\M/9IHB<:>6
MGLTT1.-/+3V::(G&GEI[--$3C3RT]FFB)QIY:>S31$XT\M/9IHB<:>6GLTT1
M4K?9;3C6ZVE/+6ZE*>S6NB*E%$[J\+;[+J^2EUM:^Q2O'11<<1UK]Z*4T1-$
M31$T1:SSCY*G"?TA=RG^/VUG7$K/Z9P__P",Q;_%8,N?4>OZ3^ZUWZ6@5\=8
M=B3QTY>+%\J6*NW"SE6QKG3-K%K8HX5N5OM;,660F[)DWMNOK1%HS;H-6R=+
M46Z*2-EB=M[3/ =7\59N>CJ'B4=9("82Q''J2K(DYRO' %7=S/N]3.&XLCP5
M2'$3+U6YJ'G1![8Q$@@YF0G25S:@X!' QB0FG3 **(/FTASW; #W!;]?GWD!
M)V =3?$L8F!K;)C\E-P\SR].XX3QQ$(=/9JS);@]P"2H.(9 D1N)0XXKR9_?
M:\;'I+'2P1JD.N>.K""+9!R@A<1&]UR"\VLT&][;]FW?U?%FI&D;6 SV9-\2
MDB['N)[;Z673R?6WU)K!:67;E<STOJ8;53M<":6URAQJ30N62M684IW4E55.
MEZ5M;[>,!SM@:.HCHXJ+G@/>CQ+"HA?MOGPTJ8AV894?$A+0*A4DQW-9IJQ9
MH2F/Q^51QW>Z5R8DA>Q-@95'WXU^E>HR=T)(MD5[G::[=*2YXRT1QV=[:/D4
MY\![T>+H6/Y+E.U_#I^%QK)>5\FQ,GD$MWBBBK[-FY5P&?EZ/N]U[!W)1\R>
M1P&X2=T4L7M/%1E$$V[MRM<FV9NED0+W D-:;=RXRVBYOL.T;4&D1< =3?$H
M[BFX+8M.%!2,3W$3,XY-BT2PQHSSGN7[M70>31+'HMG>R5EZ;IJ=/3!:T/&8
MT[10D4GY"[^/BR0MLX>I3]DL?2BPVFW1?;?9QW Y&Q4V=P'4WN\/C69R2>[5
MHD9D  [E',"!.,N4QI"QGE'=<8:/3UY<"!OB<9*!I&0%S.;M3,HCXTA!H@\.
M3 :[+-$B 1M=?7D@9"!9HL=E\NF^9R%AD3D<[;U%G'<.IOB64#W&WXI"6N06
M,ZS.O'7ALI&6R/.MNE2E*DG!NR;(S&*P):5)SM.3"5PIBI*/*QNPRQ;#'[QR
MR29M5E[(TGWM9MQGF 0+;[DVMG;;F<MMDSO:POW&_+:RQ%ED?:0\#!SRF9,D
MAQL@D:L.#W2G-&YN'O7LM2GC+%]T8L%2J7!BJ9^_(#ZR*MQ"S))^Z*-"Z;9N
MJF"-*CQ,GL0;&^P'8"1LW6SZ;7S3TV>0RVY-X7X++(N^VXS.0N8K&LGY*)GV
MQY_&NX*9TW%M*NRXU*2JN$A;E].6K,RS5I"IND/+"7#T06<P>;-!3YZZB$D1
M&-)X%["P_7T7_P!+A#<;0.IOB\[CB%,*.&8@@JDM88RO=>BI8K9:MGG.3A*M
MR=U+[:*MW&1%4%TZUI2EZ*R:B2MO&Q2R^RZZVN.F> ^/QJ+GHZAXE8XW\EC.
M/_EXQC]LG+>J-+_3-5_\91_XJN5:+^D)O[G3_IZE;-Z[:Z"X3]FL_0T_JR_M
M5:]!@7WU[A_G+GU_W+W3]A=7-J?R+NVWZ0>'?M>1W7%J/7$_MTOSW*['ZG'^
M(WYH6%;N]R>&MN&/5S&>8%DV;8R,AY*XEJT*P/.\WQ(%'HZV8.C#K)241C,C
M%1H(N@^LN9JRJQJS*U:$+6E5[A[JB6E9K7#"60=A>8\KA\3Q[9\4QQD(E 2N
M68TAF?8I(<'(EHI&3,9$%B<?,Y%QG&VKXF%*2V-VOA;!>\N*J38KO6K6UPWN
M4(NH&B+Y.%TVR"SE:M;46Z2BZMU+;KZVII67*7UI992Z^ZM+;:UI;;2MUU>B
MVE:UI31%R\C>ZC<?,7&UDY$+,/R>NX2"P'+M^"AT8EJV10F*,@7R:5FYI-,D
MIS&V)XPCN-H:1Q[#P1XK#Y,VRYE ?)PHA ,I(Q3**$6-/.R SS-&'8?F7:^,
MB E&5R>90#'V+\F1YY.\IYZRU%4XLV5Q_$1&/,@B1, A0"0<Y@;)>:3I:3@(
M@ A;3+# (:Q:29R,H16YUO*W-L<JKXLDHV%0(QE_+TJA^W!P9Q6PD,5NQ7#M
MPC;%QS)Y2:PG=5)GLQ+(Q$Q!EO N3X_P$\1F^2P+-@I)!\<DS5,BQB.]D5S1
MWG)Y,E(/'BL"Q-DQC@G*,.C\3D:$QR+*V\>R(]/Y8QC(2.0G(V*P5R1C<??Q
MN(FX_,W-L>:36A"=.W%@X@,(MAI]V1B-196;CHOB27SPYC[&TES-(1C220^/
MHW8N@^&<29EF9D85.$46#P\Q89M@<<"1I51K4X7>$'ZI03'Q;TLD191+"4UW
M7X=WG;?&"T= RAS'[X9#3!%FM8&(0G->&8U,(\E)K;;#]XLHT6E$G@A<J.8E
M%6K<*PF[ (JY() $BC:.[Y]*D?9_A>:X2@4X#3B@UF^F.6I=D09'V61YGFE]
M&!<D8@$5!,@S9D<#&L@Y6,.C8PS(:2"7"$G\>$'1..1SDA'(0$?N2E1H'QX:
MF6X'=2\%NAC=)I/,:-E;7RSI)2M]V"<:JTNLHW:.;:V\FZE/Q5UM>/'\3PX5
MU'G\O5W1GU(I.YC)=YS >VB/W,TSW@=?5NX]2)S&2WSF ]M$?N9Z>F? ;]Y\
M70$5>8R6TZ:$@''_ (T1K_\ M?X>MJ,SD0+'@3XO%\:)S&2[Q$P'I_DLE3_]
MLU-N('R_J")S&2WQD@'7\MD>KJ\U^/ZW13I\<9[K;/COW,[=Z]R43F,EWG,!
M[;(_<S4VWV%^[U;N/4B<QDNK^>8#Q_TT1\?7^=FH MN V;S?+O>>S8BIS&2Z
MGYY .'_&R/I?[U_APIZTYG<+]WN]'G<]\L/R'MLG<LQ_.XJ,+Q= C)X9*8Z/
M7>/BR31%\;!/AC15TH@&<+)MDW#I.]>]%!96Q*VZY-%2^EME:>(4\E705U+&
M6MDJ:2IIXW.<0UKYH9(VN<6M+@T.<+EH+@+D G(\7E)AT^,<G<?PBF?'%4XK
M@F+8;3R2N<V*.HK\/J*6%\KF,>]L;))6ND<QCWA@):QS@&GD?&>P\[G LDCY
MAUD##2K42;$DG*2,DG-RRB#%^W=+6)6J0%-.Y6]-*ZU.V]2RRM]:4NOMMXW4
M^54_U/<;AJ()78A0%L4T4C@)JLDM8]KB #3 7(! N0+[2%^.L*_V:^7E#BF&
MULV.<FWQ4=?1U4K&5N+%[HZ>HCF>U@=A36ESFL(:'.:TD@$@9KM!7!DM\Y /
M;9+V/YF5Z/PZ=?81?HOW=O3L&?>7[?2F#9;PI6A,!6E:=%:.R/5Z5:#/4X=/
M#[%8MT [\SOZ<CNW[3W<T5>8R6\>-20"O_W9'R</&,K^YXNK0@VL /,WW#N\
M#OVHG,9+O.8#VT1]C^9G5Z6IMP Z[=^UMO2BIS&2[Q$@%*?\;)>/KIP[U]7K
M^SI;B 3XMA)MM[W4B<QDN\Y@./7^:R/7Y?YF=/C\FAON MLS.[ALR1.8R7><
MP'J]UDN->/'CQ_*ST_7TMP ^2UK;,NA%7F-EWC)@*]71W61X?]U]/UN/3Y=1
M;@ .D;;'O=0\694YC)=7K) /;9'[F==:\=3F-@'7OX;-@&SY-Z+1G>/V/3->
MX1Y %X5+,<BDXJVDB)&DB,RAG<O>85"WM:M*#(H5HI2R@YQV^JUR%;:WI43H
MI2Z^MGBN5W)NOQ\T!HIZ:GYJ*D2:^29I?KM1H:.JADN&ZIU]*UKBU[FWP/ZM
M7U+>4/U1YN3TF!U^%T3<)BQ-E2,1GK(72&L?0NB,7-:.J#@T4S]/3++$MT0Z
MYM\]G78\<V;?",]=S268X+)2AC'VP^V/&90\O04%+EE7-75"<3%VIVWT?(=I
MJC<M6ZZQ3EVV4MMK?CR1Y,U^ 25SZVIIIQ4LIVQZA\SRPQ.E+R[6Q1V#A( -
M&][$&V2Q^HK]2OE%]3FJY03XYB&%UK<5@PZ*F&'3UDSHW4DE6^4R\ZHZ4-#A
M.P-T"\DM=I 6!.]7,9+?.8#VT1^YFO;Y\!TY]6[_ $7WY5YC);YS >7\UD>O
MR_S,TSX#AMMEPV>? (E,&RZG#\L@'1Y79'AU^+\K/)XOK^.D$$WN!GML;;NX
M=_GN)4YC)=YRC_33I_)1'TJ\/YE]7X<-3PRV=)Z1PX(G,9+O.8#HZOR41^YF
MF? 9WW_PW[T5>8R6]/Y9 .G^NB/V.]G#\/99]'7?X[7W=-]^ZQ4YC)=YR >V
MR/BZOSL\GX>/3/@.OCMW<?/<B<QDN\Y@/6=D?%U?G93\.C2VW(;]_'O9 [^N
MR*O,9+NG\LP'33Y;(]?1_O97KX=/[G1J+;,AD1^OH&R^7ZBBXR2[L/NYL_*Y
M.=9Y PVBS-2$T6:I.)).;%TFQ(DY>()KV)0)5.U:Q):RU6U-12RE]M:67WVT
MI=7Y#5_4^QJHJZJ=E?0-9-432L:Z6K#FLDD<]K2!3$ @. (!(!V$A?B+&O\
M9MY=XCC&*XA!C?)MD-=B==60LDK<6;(R*JJ99HVO#,*>UKVLD#7!KG-!! <1
MF>L6,ML\]AF-X#$"IB+."<6AL:CQ%=D^+JLEWP8,S'.EFBC@,W74;*+-[[D+
MUFZ"MR5;;E$4[ZW66_4L.II*/#Z&ED+'RTU)34[WL+M%SX861O+2YH<6ES26
MES02#F <E^O^2V%U&!\F>3V#5<D4M5A."87AM3+ Y[H9)Z&B@III(G2,CD=&
M^2)SF.?&QY:07-:;A9S7!DMK^>0#U.ZB/K_G9JYGP'=OGEQ]+YY[%WE2N#)=
MXB0#TN+LC]R]3GT=/=L//N6[B*O,9+O$3 =/7^2R7W,Z=+7V@9;-_P"I%3F,
MEWG,!ZO=1'C_ -V?7T[PMW=W<M\6Q%6N#);PZ"0#CX^+LCTU]S-0 Z^ZV[H[
MF7^O0BIS&2WA_-(!Q\?Y+(^IT?E7QZO9]+4YWV"V[;W<\K;=^Y$YC);U=\P'
MMHCU^YFF>VPZ]W4B<QDNZ*=\@'MLEY>-?SK]3R<?2X:6S)L/,6&[N\;=-T6N
M&ZC9=E3-^*[H1$I%"!I>LD#EZ.3I20-6%&HZQ_:LGVT?'23CMU]7*?:[.YJV
M5Y-_*4MZ./G.5&#U>-X7S&CFA@FYS#-K)7R,9HQAX>"8HWN+B7"PT0#;,BV?
MS+ZK?(S%>7G)%V 8/54=)6'$Z&M$U?)410:JF$XD;ITT%3+INUK=$:O1-C=P
MROK_ ++^QLYWV[;A8=EB<3#&1>-Q]A*FKUC&SDL>EU5#D8+!6ES9N4AXEE?:
MDZ?HJ+U5?)76(6J7IT54I:G?Y7DUR*Q;!L7I\0JJZDGAA9.UT<4E2YY,L$D3
M2!)"QF3G@F[AE>USDOD'U+OJ&<KN1/+3#>46+8K@=50T<&(1RPT55B,M0YU7
M0U%+&6,J,/@B(;)*US]*5I# XMTG6:>WFOIR_5B:(FB)HB:(M9YQ\E3A/Z0N
MY3_'[:SKB5G],X?_ /&8M_BL&7/J/7])_=:[]+0*<-6U84-9YQ%3.>-C>,W4
MF6C863(O!DELMCL;E#,]'B@@F&(AWXR2CWR%ER%"24A DQZK%\(EP&.DE[R8
M9J6CAO)KM$WM?AT&X-_U=PJ0;&_GY\>A:SY%['EB[(AQ^;(3O*]+BN/"6-C"
M!Z9E,@K&@C]M)7B"I8SD)Q)C[E<--BL;R#'VZ91N-!R&"@&XQBV#*/AJ^8E(
MW#;?OY;.&67?66F> VW\]N[+CFL;"=C1Q,,,CS;Z4&S+H#'0T2C=KB.PYM8.
M$QC(&,I_'3S^YN&HH:R;1SC5 3)<EN[[)!*1IA:Q[1O4:,M0"4C=ON<R>/&]
MA<[-V[.Y33/ ;;[_ !_P'!8PKV*W$?@HE'FDP--"" -&/]_FT> C';QBPBFV
M:%![R*\>M!&ZNA8';!%KD70B0!5E"4DD]REW>1[< O:PWO;O7RW_ "W-TTS>
M]AL ZK^-;/3/:9#,BC( "G!\Z8 0 1F(:U%,V@$"@8(9?AIK'+V7%4PXMJSI
M,@4%E<V#,C3!DRL=NYG(2SIEV]U8DE&G8D@6)+2<[[#>PRWFVV]ADHTK7(&V
MW>MN'1T<,EJVR[%?CL?C<9%6F4YHAD<?))),U,\L0D7CV5GLC(C@X:.,:R.'
MLHT3$P2-#0K!S?#HV1"5(RM@%G30V$EH(850G6F^0L+6M>XWWVWVW_5W)TSP
MZ+7.S]9/%3.ELD;*PQ+%9W-61)3B2V5"YX_A,A'0]^XE,QNR?',N3 A-Y/>#
MH8DHV838.<-+B;KF/<#Z=RFM[TBP;Q(=%XUF_1&EQ%]VS]6^^0S4:6=[9YY_
M)ELR[]UG<9VP",;A,11O'9*QI'L09WFF7(X%)-FS:QN)R/&LM1:01BXB-957
M)7 $LRR(Q'BA=N\,&%0P49*##QTX(R=2-/;<;0 <^!N+<,]OCVQ>][[Q\EO%
MG_!?,5M)APR#CX/X22%VU&1K;_&FY5S8.O*+4P%-WF0VAY\K<VNL=R>>RHL<
M?SDU6RQ<GWTNK9:DX1[H5%Y)O;>XD7VD][=NVH77^/X\OB&Q8O%-G+"%Y"A<
MQ&S,H5:127""35J42:M'(N"PP#N/0@<#'W"V:-Q%07(MS<T=$I02>)/"48#@
M8Z_'D'5Y0V]G3N",A<6MGF3:YZFC:I+KWR N#UDC/J'7FMV-:UBH,C?R6,X_
M^7C&/VR<MZJ4O],U7_QE'_BJY5XOZ0F_N=/^GJ5LWKMKH+A/V:S]#3^K+^U5
MKT&!??7N'^<N?7_<O=/V%U<VI_(N[;?I!X=^UY'=<6H]<3^W2_/<KL?J<?XC
M?FA8/ON=XQ8[0,_NLQC)P9QXEC]_WY&8R<M661W3]1TS3B]L!?D7; 4.F=DL
MO!JQDD;>M0 XRFR>GUTPR#ZZFE9K3?9AC/=L]S^SR3N^BVY@^0AF,IE%L6S;
M-&0-DBT6A+>7F84XDXMK!=I@6-/S<ZF;:,B*/9M*6I08(%QMX* (QZLA)6F2
M>=\L_/N!=?-$31%J?&=D&UZ/6QUPZP]!I6?B(1M$(M,)9%8X4F "  R1YU \
M>,)$F):$*1#&8<^XB<%8N%%W0N/-T;'CXB5<$RK\BO9O9IM,DC\:3.;;L*$B
M 5#N8.[<8WBO;A3?O'#XS5 ==8,L[B2NCF/8$!O3;43MO#PJ*#;Z7-(\)1:$
M5\6VM[<'%TXO5P=BZY7)+Q$E.5K88#3<2,DWDU\V0(O7";.U:T@A.%%9RD^;
M*(.DYPLM,;%:2594I>16N1[2=NDB'VM;<0P&/D&.,R.(HS(XS$8V)D$*@SV,
MR2(-14/>6"E$0EH&/S"5#(Y1)K>D$8R61,&**8^0&VA BU]R-V,#:G/<6BL/
MBX>PQK#&W?*R1-H'!\/7.INF9@K'&Q1>0K37&4S29'E(4-81T9,HBWB\TC89
MLF%C,A#A:5&U(I)S+$GVWW;KNIGF&#S:.9$,QV69.K,9>\C]&0,M&<> XD#4
M0<'V-D/$#(1 8, #QJLJ9K1=LX#(')ZJ4L?2@H0(K7L4RY,\Q8ZR68E!"22
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M0,@8^30:UFFYL8+]%K6Z1-F@9*_<U ?IXDR=>/\ Q3]EO7\.'BIPUM5]4YJ
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MJ8:K6TNJUNG ) UOV:.5FB=8=+TM\A8A1WA78ECS"&1 V2 $QFI<H%0+-V[
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MN'+MX\NI]?P<.9U/Q34OR7^-4Y?747]WF_207Z3N[G?4 9%V1X,S&9S@CEZ
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M?Y;Z7CTRXGJ'C1.=@3YL(=?#CRVW37ZK_DTRXGJ'C1.=@3YL(^/HY3;CT?\
M\3Z_[E>#+B>K^*)SL"O-9'IZOQ3;IIY?Y;U>KZO52O!EQ/4/'Y_*2F6!5>CO
M61\O\DU\O#]-\NF7$]0\:)SL"O-1'^V;?6_'>GUNK3+B>H>-%]4,IBUUD4:#
M"%MRRJ:5M;KFW"E5+[;*75X*<>%*W4X\.GAU4UIJ)F4]//4.#G-@AEF<UH&D
MYL3'/(%W6N0VPOE?:LF-+WL8#8O<UH)V N(%SUK(E)@T33O4JT<UI99??6E+
MDN-:64K=6E/Q7#CPIX_2UY6/EA1R2,C%)5 O>Q@)U5@7D-S]/N)[XNNB<+E
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MEGK>VH!&KC@<+9E\\D9TKG(!M/(+6MG<'HWK8'O%DKYU."/+_1ZFODX?0_\
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M75OK?^)I92VF!*UNK=QY-*4IQK6O"FN0W!:)KFN9A^$:8<TM(Q":^D"""/\
M<S<WS'$K'T:G=9HK<.<7>E ]$V^F)RL+4I))O:P!SR7V[PY*KT\U."/+_1ZF
MO\7_ %VM7B'8*/PR?R!9VK.PTWA4OD:=XLE<.'-3@CA]/J:^E_8_^E335XAV
M"C\,G\@2U9V&F\*E\C3O#DJG^Q1@CW^IKZOT/_EZ>&FKQ#L%'X9/Y EJSL--
MX5+Y'W?,Y.\62OG4X(]_J:_9]#_Q];35XAV"C\,G\@2U9OAIO"I3_P#\82H+
M)5>O%&"/?YFO'H]/T/\ QTU>(=@H_#)O($M6=AIO"I?(T[Q9*X\>:C!'O\S7
MV?D?^OT]-7B'8*/PR?R!+5G8:;PJ7R-.\62OG4X(]_J:]/J_^K_T^OIJ\0[!
M1^&3^0*+5G8:7PJ7R).\.2OG48(Z>O\ ]/4U_B_Z:O$.P4?AD_D"FU9V&F\*
ME\C3O%DKYU."??ZFO\7_ $U>(=@H_#)_($M6=AIO"I?(U^+[LAA.%JV/]OPR
MKGC6VCG<)+6U5NU5Z:V=OP%;6_D54_%5MX\GETX]=-4*W#^=&,UU'ALA8'"/
M6UTS2 [1TM'_ ')M[Z+;[=@6+JZIHK!TE#3:S,:RO,1?H\-.D&D&Z0O;9I=.
M>%2_,.5( M#4Q.%X!.+YO.0,#NNQQF.6RJD:<'J.ZLY!+[6^"++PD4;7M5+"
M!U:RYHQNO3JYN3MOMK7;AV$F(U!H:;"("(M9+;$9P9&QDZ+6_P"X/TG^F):S
M*^=B;+!V)5-3HAKJ.KLX-M!7.FU9?<!S]72'0:;?;'+;P6*3YF3#9<8Y)=88
MPS+MP,:@15U%H='-Q$@KD _'D:/6RMP&-&\,@ KTC1)Z68,")1VQMM;+D$N[
M[$&MU[63#/SICC#0<Z$;M &OG#]#,%P;S#==P#K7 )MLR]%%6<J68!4T<4 ]
M I*MAJ'A\I@%3]C>(C4\P)9I.;"]T0>&EPB) +[.]NU;<!N&W)8/A.8+]M\0
MQ<C+1(XBQCTWS42;O73)Z*'D4"PFV,X?E;2X"X[MO:,;WKYF2JLQ=T<#&Z5&
MZKBTZ.NTCHPTA;<Z)=63!Q&XD"A< 3O )MLN=JX9%7<Z,5.1<V)J96DC=<"D
M< >(!-N)6Q'=6X#YV^'??QFO\7C4:O$.P4?AD_D"BU9V&F\*E\C3NK<!\[?#
MOOXS7^+QIJ\0[!1^&S^0):L[#3>%2^1IW5N ^=OAWW\9K_%XTU>(=@H_#)_(
M$M6=AIO"I?(T[JW ?.WP[[^,U_B\::O$.P4?AD_D"6K-\--X5+Y&$[JW ?.W
MP[[^,U_B\::O$.P4?AD_D"6K.PTWA4OD:=U;@/G;X=]_&:_Q>--7B'8*/PV?
MR!1:L[#2^%2^1=SS&;NK<!\[?#OOXS7^+QIJ\0[!1^&S^0*;5G8:;PJ7R/N^
M9R=U;@/G;X=]_&:_Q>--7B'8*/PR?R!+5G8:;PJ7R-.ZMP'SM\.^_C-?XO&F
MKQ#L%'X9/Y EJSL--X5+Y&G=6X#YV^'??QFO\7C35XAV"C\,G\@2U9V&F\*E
M\C3NK<!\[?#OOXS7^+QIJ\0[!1^&3^0):L[#3>%2^1IW5N ^=OAWW\9K_%XT
MU>(=@H_#)_($M6=AIO"I?(T[JW ?.WP[[^,U_B\::O$.P4?AD_D"6K.PTWA4
MOD:=U;@/G;X=]_&:_P 7C35XAV"C\,G\@46K.PTOA4OD2=U;@/G;X=]_&:_Q
M>--7B'8*/PV?R!3:L[#3>%2^1IW5N ^=OAWW\9K_ !>--7B'8*/PR?R!+5G8
M:;PJ7R-.ZMP'SM\.^_C-?XO&FKQ#L%'X9/Y EJSL--X5+Y&G=6X#YV^'??QF
MO\7C35XAV"C\-G\@2U9V&F\*E\C3NK<!\[?#OOXS7^+QIJ\0[!1^&3^0):L[
M#3>%2^1IW5N ^=OAWW\9K_%XTU>(=@H_#)_($M6=AIO"I?(T[JW ?.WP[[^,
MU_B\::O$.P4?AD_D"BU;V"E\+E\B3NG<!\[?#OOXS7^+QIJ\0[!1^&S^0*;5
MG8:;PJ7R-7Z&P8^A)G.0)Z2%OY4H&7C@$/'TG5D=A,=?O&!,R-8/G]$R4C+'
MB8H.J=DCUF%;O6T?C[89& -6A%4QOIZ9[)#43N:Z8L,;&1WU<,;G->]K7. =
M(^1S(]9(YK X1QAL4=G%^R&%X>9IG-=(6F-C67T(F%P<YK2;.>Y[FL+WD-!#
M&!K&6<72QJZK*UDD-:DMREUCO\=LAV$1RX&WAT-5\ASHTC)U>'5>J[1QK%DD
ME+J<INFV<V)W4L>+TOL;*3+[I4$.Z1%&TL'>,KSTW' +0[.;/8V,6&0'IW.O
MG[FWIM>VU0Z>W+LX_N2GN'R;8.Q@^)ML0C<#DB9.7JU" =S+IM-0,."-VEM>
MY;FR\?Q/DTZ4JM=1]91B%JVLJW<.+Z5UD&W%]NX<+;"<QMVGNVRSLN<6->R4
M;HIEC/%$DD^#X; )IGUHW,041(H?F?O;#8Z!PS,LZY&(O!@AF:F&<3PR,1L7
M%X1"<4A1QJ;RDW<X:KM1@]>E2R(&SAF!?I_63:^[=O7V@?93<H9&DPUZ!QW!
M[L-PO"6+\N9LRF)CV93D;:5DP:<Y$F;2/$I-'L:OX8R8X? 0Z:QV[)479OEU
MI^Q9NVR[,;WP)$+1Q.5AM'>[^S@L/Q1V6_->:G^/<;!,,8TQCFLH8Q[CO+ /
M*DCDR48Q+E(E"-V.7LD)%GHM%NY=PN.8=V\P";!#5JZ=[U#/<(L(7-ZV+67D
M+6DV.VP[XV#CL SLNN>U/-CW<?MQPUG8C%[(:]RG! LO7CK<DL9'-+B2-;K7
M((TY'!W)J,ED[+3$7,.!(QP5CK\807'LU7-[=,L#8'+8.CY>.VV=N"V Z*5Z
MOK5X]%/+X^CH_P ^B9VM>V>8)&7>VC?\NY5T3//+/@!WM@' _*;YV5*4X>7K
MX_A]GU=%!-]PV6ZCEW,K#?W57['X</6_R:(>[G?;UWOTCQ[<E3_)3Q^EX_W>
MOC2GCT2QS/=.[Y.%]XV*NB7Z-UA?,7R'<V=&X=-VB<3LV[MQZ^YWQWL Q!^5
M^5L^A6U*)CW;W&\W41I3J.R"*+Q@HLGPX4L2<#X$"4N2MMI2Y[W:[NK<J[4K
MJQ+G!3..T"6,?BM?I =XR.[UAN2+[>4;CH.MTEI:>C8UN0&VYWK8_5=;UPG[
M-9^AI_5E_:JUZ# OOKW#_.7/K_N7NG["ZN;4_D7=MOT@\._:\CNN+4>N)_;I
M?GN5V/U./\1OS0M8^RI9#B\)V7Y;"RL3G%VTR,"6A+ [@?#L]S+)8<8?+-G
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M6V=LOL2K;9R[K;>56G*K2G&NOE=/]3?$8:B"8XA1$1312$!L]R&/:X@79:Y
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MCC_'4".Q'!\Z?8_)F)YD$M%5)9)@V.XI*[8M"1$;ATUDDFF<_GL[ 87Q]&!
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M53/GD$;78<]P8U[W!@<]S@VP<YQS6[T.QZ)A,3C$.%8DW"N!D4 "(X/7?G,
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MK=PDJV<HUK15LY25;KV)K)*66W8Y(YF-DB>V1CKZ+V.#FFQ(.8W@@@C:"""
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MGVRP,0Y),'$6"6QD_-8YD%M*(C4K!$&3=-6'1J*7S3'Q(:3F!XU/HOEB6,)
M69.([$RB!279#*VT=X6OM'F1OV+R0#87CJ#2*<'EI?-I'?/X7DN#FZ/BSL:J
MB%RF6H4/C!0\&\'0P4#8KT<$0 L?#&[@7)#,C.6%%$RB(P>0O/#81\5K[MM[
M=R^S>OID#973*[1ZED'+\C+O2,;+Q*\H+A\*CCX$&(1X3':7PE<4.36C10VU
M$UMR(0O6*VS<65*1--K'H8A'8['BDNMF;6[IOPM;+/;M &S/)1U..QMP.4'7
M" &2TA4#-QG)(LZ$C\9!,RHLU,IS")8++P5RV:-QT;7;A(LOC@^[58OURV,K
MTH2FB@S6M>C"C3V][N=(W'JN=N9"^1_L9&+#SLJ^<S*6+NBY.;OB-21.3O[3
MJ<XEN/Y@2NDR]DQ9E79!<ECT/88=QLK$V!])L'5>B+78!DX4*=/H^7O9VZ#N
MX=-NC8,2B "AP;9P^>-PHL>)0=E'BY$FZ0'-$F:3@B0=7J.7[Y:Q&U1V\<J7
MKNG%ZBZU]ZE]UU2UDDW/R#>=O6 =M_%BN+/Z-F<_^;V'?\&GFK$GK>G_ !I_
MEC2+[>3N1_M+8_5=;UPG[-9^AI_5E_:JUZ# OOKW#_.7/K_N7NG["ZN;4_D7
M=MOT@\._:\CNN+4>N)_;I?GN5V/U./\ $;\T*/=_A6 AMF.Y!YE"+FYM U<7
M'Q4BA\>E;B!DY0V.VI!&P&DY:JHK0Q@5?D&C(Q*Z7W)QT.L_,+I+H,U$%-*S
M6BVS''&:MM>Z.)XQW#%)6<,Y<PIDJ28S=A=^F[7<_"!#3&A_%S>9 9AC?<?1
MFU:F$D9O&U(CE@ U5M<6(R( 181E<V-1.$7:?1%&65I27C<<9LHQ>WLF<S.C
MX7#U7:'=39D7+)NG;XZX9UK9:_;Q*-#3\Q<#+U6]"K>/JC*.6U[NU=.I63/B
MA B($TTC8(202&O?<ND(&T0Q-DF+;C2$>C<:5U7J9'1Q@1VULKVQ17%P'.N2
M\C>(XVOE(N-(,T;W*^</AP6$![1 9->^JSA4B7+$%JO#DC-NK4Z$)#(B=]MJ
MY4V2O2LN=O5N'"RQ%JV3;L6S5JA6BB9"W1;<W)<][C=\CS]M)([:Y[CFYQZ
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M(E0PLG;PO6L;HM+GBEEM.-MMZE$[;J4IQI2Z[A3C2E>.KK7AT;9+$!S ^V\
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ML<LEQK@D@$7&T7S'=&Y7BF)7_1Q+LZT\?Y&6X\?5Y7'AZ]*^MT:Q4JO-,_\
M/#/Q\/R,MQI6M>GA^+KZO7U^3HX$5.:5_P"(PSZZUZ6RWL=%_57Q^MT:(J\T
MS_I_+=GU\?S.MZ_'\5UUIY.KQ4IPXU(J4Q*_\\-*T\G<RW5_;_7IPZ:4K7CX
MB)S2O^JA=GPX5X<6ZW'I_P#JZ*>IPKP]/1%6F)G_ $_EPS\7]++>+JZKZ>EX
M^OZY%3FE?^=V?13A^9UNGA7CT\;JTZ>NO17R>.NB+ZIXJ?IUN_+9G=RN'^H+
M6\.''Q4K7R^7Q>Q4JJ8U&A9P;H:6T$WTM'APT5W\%QB/"VU+9(7RZ]T1&@YK
M='5B0&]P;WUGQ+-(C$W$;6>JKNT7-':2*=M$K+[*VU2N4NK6[E]%>-+^%.'D
MTI:8T^G=X=I!H%@1:U^)Z?E4XUC,>*QT[(X'PZATCB7N#M+3#1E;9;1^-:J8
M#VNR;%.X[/&7RYH:\ Y ='+XJT:.'*I"]&6RA&7E;C"*K9%%HH(=-D!C+M2[
MSNQ.]=Q=5O2EEBNJFHW0U53.YP+92[0 )O\ 9'B1VD",M$@-%B=YR&WL8]RH
MIL5Y.8%A$,,C*B@; *ISVM$8=24KJ2+4D.)<)FN=*Z[6:%@WTUS;>3707ATT
M1-$31$T1-$31$T1-$7B3)#E2#D2D_9*%635H^>#$W2%Y!HR?JNT6#QRRM4JY
M0:O5F#Y)HX53L1<JLG::-]]S9:EDZ+@ X@Z)) =8V)%K@'82+B_=3S\^HKVZ
MA$T1-$31$T1-$31$T1-$31$T1-$31%%F<OZ#.5OI>3#_ +A?ZJUWK.J_N\WZ
M-RKU?K6H]ID^85/>NTN@M9"/R2TJ^D9C;_'[+&K!]:,_O$OZ.%:#ZL[VN/Y\
MO^O2<K'8M?8ON"SG-Q%LEB^%L171YX2.M1"D@W"302:<,@YTD%2=$A8S;/(&
M YT[[W5<J,FAPLBU[;1&T@ZY%5;O 5W+O"J"LJ:*6EQ!\M+,^%[HXZ<QN<PV
M)875+'%M]EVM/0NW!@-5411SQOA#)&A[0XN! .P$:/7FO09S]FR)5CI"7X;Q
M0WCA>?XQ@Q%Y&<^S$^<'<Y>1HMCEF49!2VV^*CRG>I_*FI%RR7D0CNAFU<)I
M/$U[DZ5V8;RXPO$ZZGH(*:O9+4O+&.ECIQ&"&.>=(LJ7N LT[&G.RBHP.JIH
M7SR20ED8N0TN+B";9>E%SGO('2KQ.-V\*QUDPGCF4Q"?LZ,2L# LI,B)'.!D
MD+3^1XZC(^V)B[2MLFE(L.^R6)NDY6/A2:4;H'D5AI)C>F I(?9KCZ!R^,?'
MOV$[,AEEMS6"V]D2VS.KZ*"9'("@95;'S-K)O ^3!XTH4GDVF\.N#/#,B%AV
M0,O%V^/I),#@^0*BG#F(,[RT?L-7)K()%.B<LQ<WOW/U]W;F.&6<.=W^.2\#
MB61,5"I)F0!+CDH"M$XFD,C9)I=#8>?FY]9VSR82@W:+T@X!6UBU<*-U7ZY
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M+#('+9EO%\]NZQ%KBUR+]U9MUU]3Q>K^'#C3TZ:*#<"U[@VV;,MWQYWMG\>
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MJ(-.YZ(6N;5N^II#;9:BF![_ /\ R!N;W(V#/8FJJ<OL\'@TGE?G\N3>!O9
M/F1V$^WLW_%;4\VJ^V:7P.;R_=_K=-34]G@\&D\J3P-[(!\R.PGV]F_XK:<V
MJ^V:7P.;R]-34]G@\&D\J3P-[(!\R.PGV]F_XK:CFM9VS3>!R^7)J:GL\'@T
MGE2>!O9 /F1V$^WLW_%;4\VJ^V:7P.;R]-34]G@\&D\J3P-[(!\R.PGV]F_X
MK=.HYK6=LTW@<OEW>_CFFIJ>SP>#2>5)X&]D ^9'83[>S?\ %;4\VJ^V:7P.
M;R]-34]G@\&D\J3P-[(!\R.PGV]F_P"*VG-JOMBE\#F\O34U/9X/!I/*D\#>
MR ?,CL)]O9O^*VG-JOMBE\#F\O34U/9X/!I/*D\#>R ='^E'85T=5:/LWTKZ
M73X+<?PXZ@TM600:BD((L0:.8@@[01S_ #!6365<;VO94PL>QS7L<VGD#FN:
M06N:15@@@@$$9@V6+SEMV0R$0F8S-AC39-+'T1BT@D[.+1MSG5W(I*[ "795
MN  -4HFJJY-&5FE@X6W22446?.4$[$[[KJ6UUC#Y0;ZRAW?_ ->_=O\ 7OGN
M5TU^-N!:[%I"UP(((J2""+$$<]S!&1"D7N7LD?F_9!Z7$[GFE?7_ -+=>G6S
MFU9VS2^!S>7JAJ:GL\'3_NTGE2=R]DC\W[(/=[//Q:TYK6=LTW@<N?Y]\EDU
M-3V>#P:3RI.Y>R1^;]D'N]GGXM:GFU7VS2^!S>7IJ:GL\'@TGE2=R]DC\W[(
M/=[//Q:TYM5]L4O@<WEZ:FI[/!X-)Y4G<O9(_-^R#W>SS\6M.;5?;-+X'-Y>
MFIJ>SP>#2>5)W+V2/S?L@]WL\_%K4<UK.VJ;P.7RY-34]G@\&D\J3N7LD?F_
M9![O9Y^+6IYM5]LTO@<WEZ:FI[/!X-)Y4G<O9(_-^R#W>SS\6M.;5?;-+X'-
MY>FIJ>SP>#2>5)W+V2/S?L@]WL\_%K3FU7VS2^!S>7][^.::FI[/!X-)Y4G<
MO9(_-^R#W>SS\6M1S6L[9IO Y?+DU-3V>#P:3RI8F\.=DL:SJ/0VV&[.G+0[
M$YE)EI8@4SY?'0SF*&((*:QTF\I%ZIHFI*E,WA(&VO5L4=,8G(54TU;6BMR,
M\VJ^V:7P.;R]-34]G@Z?]VD\J66=R]DC\W[(/=[//Q:TYM5]L4O@<WEZ:FI[
M/!X-)Y4G<O9(_-^R#W>SS\6M.;5?;-+X'-U^O_X=":FI[/!X-)Y4G<O9(_-^
MR#W>SS\6M1S6L[:IO Y?+DU-3V>#P:3RI.Y>R1^;]D'N]GGXM:GFU7VS2^!S
M9?G_ ,MTU-3V>#P:3RI.Y>R1^;]D'N]GGXM:CFU9;US2]WF<U_\ 'V^)-34]
MG@\&D\J3N7LD?F_9![O9Y^+6G-JR_KFE[G,YK?X^_P ::FI[/!X-)Y4G<O9(
M_-^R#W>SS\6M3S:K[8I? YO+TU-3V>#P:3RI.Y>R1^;]D'N]GGXM:<VJ^V*7
MP.;R]-34]G@\&D\J3N7LD?F_9![O9Y^+6G-JOMFE/_V<WZJ\)J:GL\'@TGE2
M=R]DC\W[(/=[//Q:U'-JSMFE\#F\O34U/9X/!I/*EAT"D'9+9K%V<C>0K9Y$
M7#I\>9W 9&4SZS+MK L@*!$7:[=6+)7VMRZ(Y,P.OK92BPU^T6MK?8I;?=/-
MJOMFE\#F\O34U/9X/!I/*EF/<O9)/-^R#W>SS\6].;5?;-+X'-Y?YV[J:FI[
M/!X-)Y4G<O9(_-^R#W>SS\6M.;5?;%+X'-Y>FIJ>SP>#2>5)W+V2/S?L@]WL
M\_%K4<VK.V:7P.;R]-34]G@\&D\J3N7LD?F_9![O9Y^+6IYM5]LTO@<WEZ:F
MI[/!X-)Y4G<O9)/-^R#W>SS\6].;5?;-+X'-Y>FIJ>SP>#2>5)W+V2/S?L@]
MWL\_%K3FU7VS2^!S>7[_ /1-34]G@\&D\J3N7LD?F_9![O9Y^+6HYK6=LTW@
M<O5Z^_CTIJ:GL\'@TGE2=R]DC\W[(/=[//Q:TYM6=LTO@<WEZ:FI[/!X-)Y4
MG<O9(_-^R#W>SS\6M3S:K[9I>YS.;R^_QIJ:GL\'@TGE2Q.4'.R61UU$6[>&
M[.3ULHEC6,N5Q!7/CA&.-G @T4ND)NZR+*4;!D%1"0U9RI5-.UZ48)54I<K;
M;='-:SMFF\#EZ_7W\.A-34]G@\&D\K66=R]DC\W[(/=[//Q:U/-JOMBE\#F\
MO34U/9X/!I/*D[E[))YOV0>[V>?BUIS:K[8I? YO+TU-3V>#P:3RI>1T"[(R
M5HFV?N=J01ERJW+N(++\DB3RE*<*VI)$)KAW(PANE?6G)6NI'%'-4[KJ-W+5
M;D+IP:.I?D^L:QM[DT],(WVL<M*>:J8 38WU=\LB+Y-1.[)U0UHOF88 U_<O
M+).T#CZ0FVP@YK:;#,.*0V&)-9)'HT!EY)^](RI2-RR23ZPT0JK5JS+%)O,0
M4=E,C**AVPY!98N-2H-2;HA1E:B!S"VVW#3Q4[2V)I&D=)[W.<^21]@-.21Q
M+WNL +N)LT!HLT #=%#'"TM8+:1TGN<2Y[W6 TGO<2Y[K  %Q-F@-%F@ 2QK
M<MJ:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HBX3]FL_0T_JR_M5:]!@7WU[
MA_G+GU_W+W3]A=7-J?R+NVWZ0>'?M>1W7%J?7$_MTOSW*['ZG'^(WYH4^:TK
M--$31$T1-$31$T1-$31$T1-$6E>'MU$FR5FB['Y>  P$-E'HJJ8TD@^7/S$D
M>W;0<^17;YD+PTCJ\6%C0=)5))6VD,+J&D1^J0)BZ;G:,R2K=*XBW4T1-$31
M$T1-$31$T1-$31%'>53\XB\%,G,=1<5+Y4QN'WMA!HD;&C4QMY)HG("ZU(S&
MY=)BRP$!<3-,(S'(X3.2PBQ:1H9:T=%;'[0BQ3;?F+G_ ,(8\R]>%;QQU,P[
MAR2CS<DN5L!&194@".!U7#X4!,-G8PP+?,GP>21Z-RP ]1< I=&H[)AQ8*Q(
MIOT1-$31$T1-$31$T1-$31%H5(]Z=PO=U9MM'Q%AX.A#>.8?-)X=KDEBFVF.
M4HA)9E&PH0L'Q<?Q:V<]P#8RT'C9QDV'%I>4DC\5'FG?8&&'S4BWUT1-$31$
MT1-$31$T1-$31%A&39@XQYC?(,_:1LQ,G<&A$KF#6(1Y*JQ^5.(R!?FD8V#1
MM36N5,'%&5HL8E:BK51ZZ0MHFI6O)J1:Z[0MTR&YL3DGMEN.7!;&4JC4>(',
M0SM]DG&L@1EF-H;D5DZCTM(1>(KNG(:^5/(F=95%W5:EXZX764:.7JX001;@
MZ(FB)HB:(FB)HB:(FB)HBU0FV?<E!LWR'"D1PGW]>I;?YWEG'\BD60 $8#9%
MF$0/8Z VQ!&C)M)2,4BZ+O(H]N<F<A')$V[ID4H$AIUBS:/BY%DNV+-1K/&/
M2LR, H^-L&SV80X/(H4=)27'V1PT7?V,$,@8].F ,;(DXH6==VC&[Q07<P<D
MPQ1>/EY)&E0TC+$6Q6B)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(F
MB+A/V:S]#3^K+^U5KT&!??7N'^<N?7_<O=/V%U<VI_(N[;?I!X=^UY'=<6H]
M<3^W2_/<KL?J<?XC?FA3YK2LTT1-$31$T1-$31$T1-$31$T10?"=N6(<=Y$D
M.4XG'23"8R3PS[H6=S&:F@0?G)E0Z=9'\#H>;D)&(P6N0YJ(%RV<UAH,%65R
M(>S+G.[7J":MI%.&B)HB:(FB)HB:(FB)HB:(L%R-CB*95BZ\/F*!=40J3!&D
M%X_)I+##XPU&3+&0 2X650XN"DH0B-+C6;M)T*+-%%;$U&;JJ[%RZ:KD7ZQO
MC>&XDA@F 0$2H&BX94LZ:M7!,N<(.2,@-$9)(C1D]('Y0_()!(Y&7+2&12 Z
M3(FCIPH0+%7SM^\<.%"+.-$31$T1-$31$T1-$31$T108>VWX>DV51N9S$;(K
MSL8XC;_MC>8S4=%2Q>&('&\-/R;'PZ0M8#+)'$DI&5I&I#)8T5,AK[AJS%ZB
MN CZHLBG/1$T1-$31$T1-$31$T1-$5M,B!T@#E0)=M1X)-C7P@HTJJLA1T.)
M-563UM59LHBX1HNV652[:W6263Y7+24L4I;=0BC[%&&(#A86=%P1F?MK*#J<
MEDQF6S::Y%E<B-MX^"B;-^<F.09!)Y24O'QB,1Z/CDGA=9NP$AV3-HDBFG6E
MQ%*>B)HB:(FB)HB:(FB)HB:(H8RMM]Q1FQL>:Y&CS\O9)L7S;#!I89*Y?%'K
MK&N1GT<(S2,ID(D>!OF:1YS$P5KH@R<-RR;5JLQ;/T&1 BW=$62XPQA%\0Q)
MG"(:O+EH^/4K<P2FF0I[DLFQ1[0W;(CVD@R-))2?;"&;=JBB.#(D[!0U.E]K
M!FWHJI2\BD+1$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31%PG[-9
M^AI_5E_:JUZ# OOKW#_.7/K_ +E[I^PNKFU/Y%W;;](/#OVO([KBU'KB?VZ7
MY[E=C]3C_$;\T*?-:5FFB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:
M(FB)HB:(FB)HB:(FB)HB_GY@$TC;[?EN'"S[-& PTI8;SF<?QY&\G[W,RPC,
M3-FMC?#:L.$X]VQ,C33'$S"O):0<^#0)Y8F/F1=X7&O6Z]U]Z:SY-_GN47%S
MG\G1YY[^\M7<!N\^XKFD#RP5F4VSK)26-]J)UE"RY')XZXC+\Y96WJ')RLT3
M1R8[$N)-)G>'HH()JE@K\4\8K1<>J&:C(P,:.2GX_/S_ (K:<QV1C)++&^/U
MA.Z3"\[E>0[H&0.R"&8DC$6CN+)5(<8S>6RG#1B=99SM&L3,)* D( ->ECUP
M8FFXL7'KGP(YCAP3D4<F3$BRW$^^G<KG8-%ZBLHX)Q/G&>XDP\2Q3MLDF*I=
M(3.5#F5]C\0S^ME5@X;31M*@>-H[GB4'<:/CKD<I!8X#Q3,XS*Y.E/#XLC'"
M+8 +OCR9.]E6:]VL0@JJ#N8'$(#LZQB3%J#)>:R ;;PS"T8CT\2*.6]B9(EN
MS)3"/+KJIBA;#'XD4<=WI-JOR52+14=NGW-;0<+DMO,F,G,?SO%67@+X9*]V
MTYQ5*<J3O;=EO'F3)G%"C+)AS,%VWMY.F6=(#D6"(BLE9SC%CO&,1' QAP?D
M"01=G0BRN3]D^W%A)/D!>.,HQ.W"FWQYD?&&(@^+Z-9P.*);5(QG)N5S5BXK
MET5G_&-R<F<R-=9Z/BV0L.FP:T5Q*/RH&RZ13?ORCSZ/D[RQF4]DSW+ ,5.)
MDVR/@E]&P62)T&:Y$'UQ)("N01\>Q-CJ;L8S%%D,X MMF0)('E$ID"!Z"PS/
M\:R;+XPF&CT$86SN*9"<(E/>MU?J)4CGNR(;CK<LYKQ_'I)CE<LV,)#\;@4<
M;I'D(",<[A<(XP#O,P19?*<0SUCR360_(IA\:$S[&3+'^1RJHXUA[*R($8BW
ME1%ZI_O3WNX8CF1)"Y?0+,J\=)[O<>@@K##[Z++LU=OT\@(F/9@D*S7(2J11
M$?$Y1)Y#/(VT<1>/EQ,::KAR<1O2*/711Y^+SXE>&);W]XF2P1YG"Y[AY!I$
MX+O)R (RJQA4?RJ/R0/V\P?:1*(<*H\QKDYYBE1RYFF;\@0J7D\>3"2C7@2+
M(L&MT1R*RD3*.%*BR;;^=Q>);,^2GGJ@#=1UGQS):0*9,HRYE\%AA#9]MLR3
M X3C<'D[*6+81(@1@])Y:M7'RF2,?9(R@K'Y64P]4C(/#A4(0KICNLRY,@DP
MP:L O("P[+;YNUW+-&SYL2$MY#E/#>-X"SQC 9:!N=-7SX>LSRW.)\XA[Q2Y
M>TWC(814JF[CMBR9%J.WW<;XH>YM/&S>/LKMA,MV[#*XWC>&R42+SB_<5@DC
M/GD:&2*L^/7B;X9-63$=#7M@QVZ>,'SH=+[S#NYH0:D7PQSO:W*91E.'\<8^
MS=A3(Z.6B^!$)AF:%XE=.@N&)5DS$.ZF=Y0PJM'T\BDAU)O!G&%800!!Y:6\
M,H,WD]C/*H0W0P#N?$\_/S_6H6$[@-U>7<R0@:_W #H/,)D(V+.Q,-'1@FA'
M;5VN<=X.-\R9(C>/G$]1=OQ)1.(12LN'K/2(%J4D^-A4K>$AX $Q,O/SXJ+]
M[N]VW^G%2]&NR![B6N9-OD&GLIQI<+D\SYJY("BL*$TR+/#XS>'G;;27G%N.
MYAD^)2=:%%8QCF&2GOO@1?+CS#A5W.)7ER%5QFE&UKRE=)]E4@,F,3S (3(N
M30W&FX?<QB"&&7:SATX<P'%N=9Y#(>(7?.U5W1)>"AA+?'+DH\<.7Y-S#EGY
M)PN1<.U+B+;O1$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$
M31$T1-$31$T1-$31$T1<)^S6?H:?U9?VJM>@P+[Z]P_SESZ_[E[I^PNKFU/Y
M%W;;](/#OVO([KBU'KB?VZ7Y[E=C]3C_ !&_-"YY3'>).(9*)5F![G(1X L]
MW$XP^!V_+1^#NVCK!&"Q2T6W$9*7+#0-N5!QK&\AQYFC)SZ1NI"_AZ ".#8H
MM'JN3 UU72LUC=O90<H%3B;"W#D+B-V.)9DE;+XLC-<E/7)&,Q' >+)F#B,<
M:E<!QR<CYV2RCN7P'&GS13'CYUW&594#CRKN4*LHX3S\^^MI(3O?/2K;Q(\N
MN,4"FDS%[B1>V,%$49T80B!W()[+,/PPP)/YE)<<QN31B- YK+5A\W[X8V<2
M0*O%)*P!QZ4E+0S$N11!,NR=*1" S:0*X^QP;D44=NHXPLB.<$Y9!Y+)8W@'
M)6YR?D0<J'P! @2@T5PK$89+D3S2.J$'Z^0V,?(A@),;3OB18#,>R#;CHKAF
M\:IC3$Z^;RT9R'B.)&&>2RSA1_N?QH'B\/D$A+XRKC*MX/#SW.$D0A,9>+R9
MV6+F#&.&:X=B'R0S,!"+/X3GG=%'-H.<\RSN2BY3DA[FLM@;;R*:J1&3#GA@
M=FUGM1@I2YX+Q;@H4^.95RO:O)4GTCJ/Q^DV-QXFJ[@D.J58#'GY[$4@13<=
M-2>S^_(DPRBE!9Q=F2<8W;%U8-'IQE!^.BFX:98R&PT)CZ#N",)EF=I2#AK^
M-AG$);2G&KF7=OE05A*(:P4H[(O%M-RYNDG.36@S*DMBDE @H@>$YE9A(B!C
M\5QMEAO2!I0C&D>F8TZ:MR'F%NTID$GN ;14G(,80@XN'B$>(BR0=1$^11<+
MW09Y*R1LT3S!%5,(9+E#A /N;N@4=C4<C G',$SOEC-Q;#0PX](-)UC <!AN
M)(3!<@SU(L@?>$\J9)"OYE# ()*KS\_/>BO&-MRFXK(+K'Q%7*&.HDN1P_CU
MUG!E)\<MQ>+=O&1,I8'BSJ"1F3GBDQ$2269[D.XN9QQ=+#X24L1@G"))F,E=
M(Q-Y'CR33TBV=V=Y9RSE&+GUI\FT(-8]DW.<&4+25U&@65QU<99!;0$*.EL.
MQPS/XK*N"1D/DB]W)X1.TA T2"A;"X06DQJ8VP\BB3+TOWZX1@F1,TRZ=[9B
M6-,/F-P>6)2&"P>>I2Z1X"B&/7YO&$0%+O3U1C#(RQAN_4DKN^JPY*]D!38/
MS2+DLQ<$5ZP[E3.N-\&9:S7N@LS18XQ3AMQ/I''\C"-JP8*2)Q6(%Y7,UH O
MMUE^0#*#%!0*NQ20R Y:.TFI 9<S9E7:9)1H^)%#$B[)KDC';X\SRCM:'!5
MTK*X\28P?-)K)!U_.DX1@N0"&Z(@?@L16^*-YSN"@N'IS)&+LB0B\^O>6 (S
M.0J5A.\BNJO9.W2#J #%,)H*%C&389CG(;5O*<JVMXK=D?<=?MM@I:,OB.W(
M:D\5,2H5-'*X/--FWHB@Y@,L!C^^[D4\=MB*U*]D^EZ4.=2M7;H"1J0QIA'-
M<3'69G/&7=^(LT#\Y'D9=-0T4P9(YL+=12+X73E$@CN,87F0F(C\X#')/2,
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MRV-5-6L43XA1Z19-,]VV#<>Y2D&(9E)W8*6QN&0F:O\ MX,NY8.FN13<O!1
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M$\<95Q8[9B&DNB9YJY8%HYE^5EFS<HB\N!3!94PR45%%C\>*D47Y0V5#BMV
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MK;9FA61;8<:8HD$GA>",18[@6,Y64AV0'$)+/(^)G6+9,7HU3$$&)])PVAF
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M:@@8BF<SMVRV/VNY3AK;&DNF4\RMO?>Y8R='ULD18B5FV'6N[ -,*^#Y*99
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M%V1B8V"I.0878RB+<;DV>Q.Z&HR@@^S3CEAMVR=-K<A2#)XBT"9BRD4R)C7
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M'ES*21\_ HA)O#\>Z@-9$R:$6)B^R0;926/@<SF=9A&@TI Y"G,23=XJR>>
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MX7CR<8W3V@2IV*GRT4(ER#_<0 =/FDAA.X&<[GHU(Q8R[;G;$$70_,$\>F5
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M"/14X'V\0_:Z/G@1NTV^MW:LU98A@<:##'YUZ:%@W;<F[ !A2<BD;8L^M?\
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M.&J)QM9TMR +HF1)LDK2O<+UB^M?\._-OYA0,2O]QW'[IP%^Q]"@>#;YMOD
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MJAMLH/>BJ0;+D_C3R0RP=)LCDVY<82(SIT>B$*+1Q]:_X=^;?S"R]$,Q]AW
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M7<VR!(.[4LN1?(DC)OFL/-$Y&\/8ZQX4BSZU_P ._-OYA1Z)97U.\#U3C?\
ML^A75CODP"R*C7=^V/*I$(")!RT=AI7=E<0C(4B,IAY!X^N[?@6Z02-_(!6$
M8E'C)&:'Y,2LC9&7 @KL.-DKU"CZU_P[\V_F%/HC_8[VCU3V0O[#<L[D/9)\
M/2S!</V\R3:S."T!A"&0FH953<JQ9R)5MDC&^5L4%["9<9@!C0@Y'0[,4K1#
ME5FO?JTTW"R<L2+R-DN3>OK7_#OS;^80XC8^HWV_=.DCL?0L_+]ELQD;#90
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MGEF V/X CPH&H=+SUXS>- C$<(9 (]#8^#&"!4:8MJ/K7_#OS;^83T2_L?\
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M_P F=/K7_#OS;^84>B7]C_Y/_6G^C_\ ]B9_V\?^3.GUK_AWYM_,)Z)?V/\
MY/\ UKGOOO[*'Z*OFK_]!W@'X!^''^R9X4=]?"CP/_\ =_'>X>X?!W^O.Z>[
M/Z7[G_'^A08-S+6_[SK=;H?<=#1T-/\ M7WOI]%K;[Y5YZO7Z'V/1T=+_CTK
,Z6C_ %1:UNG:O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>g459793g40d42.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g459793g40d42.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1"\17AI9@  34T *@    @ " $Q  (
M   1   (>@,!  4    !   (C ,#  $    !     %$0  $    ! 0   %$1
M  0    !   .Q%$2  0    !   .Q(=I  0    !   (E.H<  <   @,
M;@     <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                     $UI8W)O
M<V]F="!/9F9I8V4    !AJ   +&/  'J'  '   (#   "*8     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ? )P# 2(  A$! Q$!_\0 'P
M 04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%! 0
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/C/8\\>]>@_=&#SB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>g459793g49u48.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g459793g49u48.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M (?\$/L_B'_H*:=_X+W_ /CU%Z?9_?\ \ +3[_A_P2KJ4VOZ9I\MXU]I\JQ
M$H+)U+#([^:<?E505.4N6S^__@"DY15[_P!?>)97>MZI/?FWN[&WBM[IX%5[
M1Y&(7')(D7U]*)1IP2NGJN__   3D[V+?V?Q#_T%-._\%[__ !ZIO3[/[_\
M@#M/O^'_  0^S^(?^@IIW_@O?_X]1>GV?W_\ +3[_A_P3-N-7UBT^T6SRV3W
M*W5O"DHMW5 )" 25WDDC_>%:*G!V>MK/\/D2Y26AI?9_$/\ T%-._P#!>_\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>g459793g60i15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g459793g60i15.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1;B4&AO=&]S:&]P(#,N,  X0DE-! 0
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M<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F
M"7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT3W5T
M<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !2
M9W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O
M;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M      !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M    4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;VP!
M %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M          !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F-
M60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1"
M;W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P
M4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE-
M ^T      !  E,S,  $  0"4S,P  0 !.$))300F       .
M #^    X0DE- _(       H  /_______P  .$))300-       $    6CA"
M24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M   *  $          3A"24T#]0      2  O9F8  0!L9F8 !@       0 O
M9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M!@       3A"24T#^       <   _____________________________P/H
M     /____________________________\#Z     #_________________
M____________ ^@     _____________________________P/H   X0DE-
M! @      !     !   "0    D      .$))301$       0     @   D
M  )      #A"24T$'@      !      X0DE-!!H      T4    &
M      +^   '9     @ 4@!I &0 90!R #8 -P X     0
M           !              =D   "_@                     !
M                     !     !        ;G5L;     (    &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG   "_@    !29VAT;&]N9P  !V0    &
M<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC
M94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T
M   ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T
M   *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"
M=&]M;&]N9P   OX     4F=H=&QO;F<   =D     W5R;%1%6%0    !
M    ;G5L;%1%6%0    !        37-G951%6%0    !       &86QT5&%G
M5$585     $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT
M5$585     $       EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG
M;@    =D969A=6QT    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L
M:6=N    !V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'
M0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F
M=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<         "W)I
M9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P        .$))
M3001       ! 0 X0DE-!!0       0    $.$))300,      O[     0
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M]O/QU_!579.,:F 9%.YLR/4;W_M)SDXII ^T4[FDG;ZC>_\ :2HJM@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M7OQ'O[_U^B98@93W[@X>9\!1K[[1;"2%JL E6;"]:I.1;JE, &*J@*@I*%,
M&*<ABF # ( B77$1B)@V3O4Z656.U530:MG"B:;04B*)J)I',0?'/VBJH90
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MY2)E+VAVE*!C#W=QA((!B)*Z98%K%#F=N4#HN6KUQ'KF,04R.#M@3,#I(H@
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M?W5$%"*IC_J,03%_W<\AB)'I]1JH5$"J%,Y3.8.TA@,)4Q 1/W@ ]H"!BDX
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MGOD=JCW#P '<)%Y QB@*./OW9_E]\L?L_P"?^?\ GV_MQ$KZ80C"<K#M<_<
MSTR8QCF.)A-)/K'!,"$ 1Y 2%?,R=O'8"8"8O <&![^_U>^8FT.(C$1B(Q$8
MB,1&(C$1B(Q$8B,1&(C$1B(Q$UJNBAGUQ6!N<Q00=.57!"F$H*-H^&7:K"H
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M?+S#5@[+W&,#BNE Q2B0O=SSHET'_GCC_P!<1.Q4EA/7%4DU#&5F589900.
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M3< 4Q7<>_47Y#X0>7:F] XYLO$@<P"#](!_GQR.T2CGAGOX#Z?Z"7RVND64
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MD% E4 3X$>/!5[N.XF/7$E],J*M:5F7+IP@Y=22C%)-5 %2@2.8(*&;H*%4
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M "3! %D2)NS"Y66'M3%5,7CD[HR!E$Q,!@3[DTC=IS$,*)1 3<%',SQ)/?-
M, >H#ZI><28Q$8B,1&(GY]MS;4VA'[@VO'Q^R+\Q8,=E7IFR9,[E8FK1FT;6
MB41;-6K9"231;MFZ)"(H((D(DBD0J:9"D* !]_H]+IFT>D9M/0S-IJ"S&FLD
MDU(222N22>))XD\9\CJM1>NHU 6ZX 76@ 6/A0'8#@", 8Q@9  '#LF-?QP;
M;^5/8_UXL_\ -,Z?!-)\VT_V-?X9@=5J!@=?=W_WK@X[^)QGO_AG@_'!MOY4
M]C_7BS_S3'@FD^;:?[&O\,MX3J?^?</^Z^?_ ,B/H'=V\H_'!MOY4]C_ %XL
M_P#-,>":3YMI_L:_PR/"=3VWW#N/6MQ])\H]W9PXYQ@1^.#;?RI['^O%G_FF
M/!-)\VT_V-?X8&IU)_S[N_A:XSPSCBQ/:./#G];\<&V_E3V/]>+/_-,>":3Y
MMI_L:_PP=3J0/[^[EG^\LX=_^+ESXY^@\,OQP;;^5/8_UXL_\TQX)I/FVG^Q
MK_#)&IU!']_?RS_>/GCGLW9_GV9C\<&V_E3V/]>+/_-,>":3YMI_L:_PR/"=
M1P_VBX\/^8Y/KX/C'H&3],?C@VW\J>Q_KQ9_YICP32?-M/\ 8U_A@:G4]M]P
M_P"Z_ \,#GVY'>>?;'XX-M_*GL?Z\6?^:8\$TGS;3_8U_AD^$ZCC_M%XXX_O
M']'>>TG'T<.V/QP;;^5/8_UXL_\ -,>":3YMI_L:_P ,@:G4D<=1</\ NOGC
MV<\<^ /'(^N/QP;;^5/8_P!>+/\ S3'@FD^;:?[&O\,#4ZGC\?<>>/C;!V9X
M\< \N[ZQ'XX-M_*GL?Z\6?\ FF/!-)\VT_V-?X8\*U) Q?;ZC:X]1'E'LR>W
M'IP8_'!MOY4]C_7BS_S3'@FD^;:?[&O\,>$Z@YQ??VX^,?T8X9'T9^D\H_'!
MMOY4]C_7BS_S3'@FD^;:?[&O\,D:G48_O[CZ>L?GDC_BY?P[3'XX-M_*GL?Z
M\6?^:8\$TGS;3_8U_ACPG4'EJ+N![+7^KY1X]O+T=YC\<&V_E3V/]>+/_-,>
M":3YMI_L:_PRIU6I&/C[N>">M;.?_N( //EV=F8_'!MOY4]C_7BS_P TQX)I
M/FVG^QK_  R?"=3Q_P!HOX?^];F?6PY @\/K)C\<&V_E3V/]>+/_ #3'@FD^
M;:?[&O\ #'A.I_Y]W'@/C7&>\C))^CB,#/'(C\<&V_E3V/\ 7BS_ ,TQX)I/
MFVG^QK_#)&IU&/[^XG'/K7QQSQ^4.'OWF/QP;;^5/8_UXL_\TQX)I/FVG^QK
M_#(&IU/(WW9 _P";9QY<>?+TX]7+)?C@VW\J>Q_KQ9_YICP32?-M/]C7^&2=
M3J/^?=@<SUEA[.'^+OYXSP[1'XX-M_*GL?Z\6?\ FF/!-)\VT_V-?X9'A.I_
MY]V>SXUSPR 2<''KQRS](?C@VW\J>Q_KQ9_YICP32?-M/]C7^&/"=3C U%V>
M6>L<\CS^5CL/#L) X1^.#;?RI['^O%G_ )ICP32?-M/]C7^&/"M1G'7W<^VU
MQD<>7$]QX\.'KS'XX-M_*GL?Z\6?^:8\$TGS;3_8U_ACPG4]M]N>P=:_'M[P
M<XQZ..<1^.#;?RI['^O%G_FF/!-)\VT_V-?X8\)U/9==]J_+U[@..1C&<<>?
M8_'!MOY4]C_7BS_S3'@FD^;:?[&O\,>$ZGYQ=CL^-<Y..0.['?S XXYCA'XX
M-M_*GL?Z\6?^:8\$TGS;3_8U_AD^$Z@_Y]XY?YK]N?21]_\ 5^.#;?RI['^O
M%G_FF/!-)\VT_P!C7^&1X3J?G%W'./C'R#P]."!^\XSGC'XX-M_*GL?Z\6?^
M:8\$TGS;3_8U_ACPG4=NHNX8R.M;Z<Y/KXCZ.(C\<&V_E3V/]>+/_-,>":3Y
MMI_L:_PQX3J#_GWC_NMGCD=I[P,<LYC\<&V_E3V/]>+/_-,>":3YMI_L:_PQ
MX3J>S47=HR;7XGCV9[#]V>? Q^.#;?RI['^O%G_FF/!-)\VT_P!C7^&!J=1C
M/A%W+C\;8!]Y)Y?S[1'XX-M_*GL?Z\6?^:8\$TGS;3_8U_A@ZK4#_/N[<_&N
M/7VD\!Q^KGF/QP;;^5/8_P!>+/\ S3'@FD^;:?[&O\,#57G&+[O3\;9R_P#N
MY\1]\RIJKJ,M4#)2\#LFT7JVZYO,2YK%P:A<;,E8XJ-D$EFPSU/L#67;3=>G
MXL'"B[=W"R+!TJ7D$UT7J4>\9\FKZ.JL1'TU5%6IH<6TMU5?5LRD'9<A0K96
MV,$,K 'L*EE;>C6V(S)<]ME%JFNT&QA8H/\ BK8,&5EW<"A!)[0=I'Y[O=$Z
M]UX]#>VVT8TZPNI^[Z)V0V7M&B=L([SVDJPM=54,FJ:%E7;>R),4;I64W+5M
M8&* )%<(.(Z<;-FS.61:MOL^@'Z%Z9TI+=%='TZW3$5ZW3'1Z<-7:.&]5*9-
M3D$HW80R$DJ2?@NGJ^F>AM4%7I/7VZ*_-FCU U5Y#ISV,0^!;7G##F1AQP:?
M/?\ +3ZQ_G9]3'[]]I?>K/>\3]$^;.C_ &/3_ESP?&W2OG+7>UW_ (X_+3ZQ
M_G9]3'[]]I?>K)\3]$^;.C_8]/\ EQXWZ5\Y:_VN_P#,C\M/K'^=GU,?OWVE
M]ZLCQ/T3YLZ/]CT_Y<>-NE?.6N]KO_''Y:?6/\[/J8_?OM+[U8\3=$>:^C_8
M]/\ EQXVZ4\Y:[VN_P#''Y:?6/\ .SZF/W[[2^]6/$_1/FSH_P!CT_Y<>-NE
M?.6N]KO_ !Q^6GUC_.SZF/W[[2^]6/$_1/FSH_V/3_EQXVZ5\Y:[VN_\<?EI
M]8_SL^IC]^^TOO5CQ/T3YLZ/]CT_Y<>-NE?.6N]KO_''Y:?6/\[/J8_?OM+[
MU8\3=$>:^C_8]/\ EQXVZ4\XZ[VJ_P#''Y:?6/\ .SZF/W[[2^]6/$_1/FSH
M_P!CT_Y<>-^E?.6N]KO_ #(_+3ZQ_G9]3'[]]I?>K'B?HGS9T?W?[GI^7=_=
MQXWZ5\Y:[N_WN_EW?WD?EI]8_P [/J8_?OM+[U9/B?HD<NC.CQ_]'I_RX\;]
M*CETEKQ_]7?^9'Y:?6/\[/J8_?OM+[U9'B;HCS7T?['I_P N/&W2GG'7>U7_
M (X_+3ZQ_G9]3'[]]I?>K'B?HGS9T?['I_RX\;=*^<M=[7?^./RT^L?YV?4Q
M^_?:7WJR?$_1/FSH_P!CT_Y<>-^E?.6O]KO_ #(_+3ZQ_G9]3'[]]I?>K(\3
M=$>:^C_8]/\ EQXVZ4\Y:[VN_P#''Y:?6/\ .SZF/W[[2^]6/$_1/FSH_P!C
MT_Y<>-^E?.6N]KO_ #(_+3ZQ_G9]3'[]]I?>K'B?HGS9T?['I_RX\;=*^<M=
M[7?^./RT^L?YV?4Q^_?:7WJQXFZ(\U]'^QZ?\N/&W2GG+7>UW_CC\M/K'^=G
MU,?OWVE]ZLGQ/T3YLZ/]CT_Y<>-^E?.6O]KO_,C\M/K'^=GU,?OWVE]ZLCQ/
MT3YLZ/\ 8]/^7'C;I7SEKO:[_P <?EI]8_SL^IC]^^TOO5CQ-T1YKZ/]CT_Y
M<>-NE/.6N]KO_''Y:?6/\[/J8_?OM+[U9/B?HGS9H/8]/^7)\;]*^<M?[7?^
M9'Y:?6/\[/J8_?OM+[U9'B?HGS9T?['I_P N1XWZ5\Y:[VN_\R/RT^L?YV?4
MQ^_?:7WJQXGZ)\V='^QZ?\N/&W2OG+7>UW_CC\M/K'^=GU,?OWVE]ZL>)^B>
M7BSH_'=X'I_RX\;]*\O&6NQW>%W_ )D?EI]8_P [/J8_?OM+[U8\3]$\_%G1
M^>_P/3_EQXWZ5Y^,M=GO\+O_ #(_+3ZQ_G9]3'[]]I?>K'B;HCS7T?['I_RX
M\;=*><M=[7?^./RT^L?YV?4Q^_?:7WJQXGZ)\V='^QZ?\N/&W2OG+7>UW_CC
M\M/K'^=GU,?OWVE]ZL>)^B?-G1_L>G_+CQMTKYRUWM=_XX_+3ZQ_G9]3'[]]
MI?>K'B;HCS7T?['I_P N/&W2GG'7>U7_ (X_+3ZQ_G9]3'[]]I?>K'B?HGS9
MT?['I_RX\;=*^<M=[7?^./RT^L?YV?4Q^_?:7WJQXFZ(\U]'^QZ?\N/&W2GG
M+7>UW_CC\M/K'^=GU,?OWVE]ZL>)NB/-?1_L>G_+CQMTIYRUWM=_XX_+3ZQ_
MG9]3'[]]I?>K'B?HGS9T?['I_P N/&W2OG+7>UW_ (X_+3ZQ_G9]3'[]]I?>
MK'B?HGS9T?['I_RX\;]*\_&6NSW^%W_F3]-WN'7NNDK>7T5T;]5-V?S-S?.5
M$M&;8N$NJ_D[4NN8RI]86^=DE3NWUB,J)U:/,23IRZG?%4JJ[CWS1KC>5_._
M[8_V66@-TKT92%I SK-+4@"U ?\ M%2*,+7CA:J@!.%@&TN5_0O[(?VG-Y7H
MOI&TM<2?!-18V6MSQZBQV.6LSDUL>+CR"2P7/ZJL_-9^C1B)^;G>7_77N'_M
M2V#_ /=DOGZ-H?\ <M'_ .5T_P#Z*3XS5_[UJ,<^ON/HQUC#EGTY_C,6&'M*
M8?V (_\  .<ZIS^H9P. .3R)X@\?5@X[,&;@2W3G QUD&&4>VN(23G;K76XV
MM&/A4[&2O4"RVIE;J_)JMD&YJTWD89BSG#JM%V[9O*,S)2XG7.+;R%Z1L:L.
M!4^4IL/5%G-767U5M38@)/6E;&*88$LC H,#/I'1(KE2;%&ZU%%@50X2EW%B
M-C^[#( V1@!AY1)S,*):FE%9Z,@@LU0 )Z)835=ERNI]>*GV<@_=Q:(1X-*X
MXET549*/?L7WOK$QJ#!9DN9XNB@**RW:=6HK>SJK3U;LEB8K#UE5#DMFP(1M
M*L-KL6## )R!R#3DNJ[Z_+4.K9=D<,=GDD(7X%2#N50..6QC/D.H[8!*XD88
MPLQ;9UQ7Z_717=A+2#QI8'=7=JE<>0]X$4&DVQ<-'2:\XE(-TP3?K,"1JR3P
M\^%U9M^5LI06668&U0:UM QNWDE&!!"%2<J&W K).F?R!Y.YWV(F3N.&-9/%
M=@ <8(W XPQ&W$LEPHLM3/>I1\ZCI%C-(O%8Z2BQD@:+GCW/E7[84IB,AY%)
MPT4,B8X+,$T5D'+5TT6<METU37IO6[=A65D(W(^W< PRIRC.I##.,-D$$$ C
M$I94U84DJ58-M9=VW(.6^4JL".&,J!Q!&X$2X7VHPU:2H[BORLE--+;4"V$R
M\A'(1JQ79+39ZVLBV9-W;\2-#&KQ5VHK.5'2A''<LFW./ED:T6O8;Q8JHU5O
M5X5BPP:JK022%X_&8.!C((&0,F;:U04LK%^LK#@L-I^6Z$!03SV\.9)(Y< +
M7*Z\V! L%Y2<HESA8ML*0.9*7JT[&Q[<5U2-T07>O6"#9$5EU4D$@45+XBRB
M:1.XYRE&R:C3V,$2^EV.<*EJ,QP"3A0Q)P 2<#@ 3(:FY!N>JU%' LU3IZ!E
MF ';VG.<8XG$RP;3#!37K"U$4M+)T[H[2WISD@P;EHKV2=75:IDIK:2\)!5*
M>50(64:D(YD%URIK)GCT6_<]0Y1K&\):GXH@7FG8K$WJHI%W7,N2-F<H<A0"
M0=Q/DG?P;XD6 .":A;O('4EC<:^K#  [^ 8?*;A\D<2;".EYH7SNMMG\%*V5
M"\5NCJ+1<^!X2,FYM&X M#22KF(0!9Z@XJQS*R+"05BF2/*9S/577='W\-3:
M+"KI6:+;P'3RWKK-6'4!R0"+>"LH8GCY('E5.FLXH&5K!:E7DMY*NW6>0V5X
MMY&2P;8.&,YR+:^U!--(<\VWL=+EVAJZ^M4<E$S#Q=Y,PD1(N(N<=QK=Q%-1
M*$(]:.TWA9(T<+LC5RO"#+MT%%2V76(7V&NY#UBU,650$=U#5AB'.>L4@C;N
MVY ?83B5.G?;OW5,-IL4*S$LBL58J"HXH0<YQN )7<!/1'3-D>_@^I%R]6E&
M5B/9$6\HWD9!I%LG-4KQK1,MY!Y,1$8F!48<AET9!@$A#N#D432DC"DJ)!UE
M8ZS<EJ-7U1*%59V%UG5H55'<\7X%6VN/^'B,O!K#LPZ%7W@$$@ UH+'#,RKR
M3)!'DD\F[K,]UI.M4%7[=]"2L,G5I.X%GHUV[-%*P\78SU-7M.^8,7J+YQ/^
M48-&+QDU<*'DXPZA44W0&)==363M*NC]:M/5L!OWM6+?\+,I45DL6#$85L$D
M<:FAP"049=C6;U8[2BN:^&Y0V[>=JKM!XKG@>-'#421GJY,V*.E(548)D\DW
MT&964":"-8&2!V]()8D\(0B9%!7*U<S3:1<((K*M62Y"E$\O>M=B5LC_ !A"
MK8 NS<V< ^7OXXQD(5!(!80E9=&L#*-JEBA+;L+C)!"[,<<X+!B!R(X26/='
M6]H\;1R+^K2<BI98VJ2#*.FC**0$K+QS^7C1G%W+-HQ;,W,5%2;\[IJ[>D8)
MQ[M"3*Q?)"U'(:ZD@L5M514UJLR?WB(P1]@!+%@[*N"%+%E*;E.9HVDLW!<U
ML>L6M@KY*.PW+N.  "JDDC)4 AMIR!;+A1(JLQFO7*%CC97\+&DLYD)F+<N'
MT&BFSLCN(26:I+QL9+( @U0 [UH_:)O!6(<R214E$>ZU-[VOJ :V3J2@5& #
MG=6'()#,AR3@%6*XQQR#*6U+6*2'4]8K$LI\D8L*#&5# *!Q##F,D 8DLLVF
M%T[0M!5=K,H1+&+E9U2WV1PUD*U-U=A)M(IE<*^^J<<_.]BI5X_8M$XV+0L#
MYH^?LV1G3I8SCR^5>M!J%EA0NS)6*:P5M2UE+-38MK+AT"LVYS6&52VU1C.C
MZ8BS;6&"JI86/@UN@8#K$-:'*N2!M4.P8XR>8BLEJ2P0B$PYGI2MP;>,>C'L
M59-^]3+97HP,?9DT*_X$8X$XJ04O#2 *RX0[=,LO'M5UD7[@&@:KJZ["@K2Q
MRPW-M5?BEZQJLV98?XT=<)O)V,0"HS,VTSIN+-6@4X!9FP[%0X*>2=V4=6\O
M:/*5<ALB7#\2%N._91#5_67TTK982H2\.UE5Q>U2Q6$CLT7'V0R[!!F@"BC!
M\U<.XMW+,6#UJHR?N6SL4T5*^&U!6<K:J"I[D<IPMKKQN:O#%O\ $I"N$9@P
M*@CC+'2V;@H-;-O1&7><UNV2H<E<#)!!(+ $$,1P$H0U)-&.BN2P5!6 /7'E
MG<VY*3D5:W'1S">;U9VD]63AS2HODK$]CHA-LRB7OG%Y)BX8*.X]<'I;>%H.
M'5V]9U@J6G:@L9C6;05R^S::PS99UP%8, PQ*C3/D8LJV;#8;06-84.*R&PF
M[(9E7 #9)4KE2&$AEM+.%KA*52KSD*X>1T'5W[9@]D';IY..Y2APUJDQAWD5
M#.(CR NGKM*+>2KR*9N$1:-TWKEP)U#9KK *EMLK<*UEJE@JJ*U6]ZEWJ[A]
MV "P168'<=H'":/ILVM4CJ2%K8*3DL6I6P["JE<9+;=Q7/  MQS%76K)YK#A
M*FDZXLN:FMK\$$WDG"TZ%6=#&=D@=L5AY(BJ:4D9VNP/(%D$8^.D9$[8&)&C
MAYJ-56S[-M@'7&CK"H%?6C=E<[MW-<!MNTLRJ#NR!3P=PN[<A;JA=L#%FZL[
M<'&,<B6P6# !FXKQ-QJ6L%I'8ZE!L/FRNF<!8IEZT@5FRD@9W"T22N*4&DL]
M1,U0D3.&:4-(>,DJFR>>:3 5? *<U;=4%TXOKQAK*ZU-@(4![UIWD Y*X.]<
M$%EQRS)2AC>:G+9"NY"%>:4M9L!8<^&TY!"G(XD9-6VU!(S\H\1AG#&LM"6*
M)J#%C>II%.9=V>78%=L(A,8>*5;JJ2!RJ@V=&0;1S4ID"R3YJ"A5U*G5K6H+
M@VGJWN9J$.Q:D;#.=[Y\GM +,V"54\A(TY=B%/5@.M8%SX8NP)">0I!)XX.
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MK6L/8 E"4*<KD"ME=7/DX+;E&1C:1D;<&!J7WLY53NM>TCC@FP,A4$,#@JQ
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MZO8K7;^LXA [ EV*[G)7. <<!!O+(RE$#,E:.X+;F%138<%]H.$"G"C.#D9
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M8Q.7E&SA*-9/X^-B(%K%Z>)0S:[KM;J+J^D.L%Z,E 8*X85*EPJ%B)IP5ZE
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M<Y?!*A2"O":9JJ'65464$#**J'44,!2E 3J&$QA I *4H"81'M*4"A[
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MJKK;:55$52=0MH8NIS2]:[D#5!^3Y"L$))(. H8GHJK2PEF+!:#7M"D8M5R
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M+_KKW#_VI;!_^[)?/O\ 0_[EH_\ RNG_ /12?):H_P"UZ@$D?'W8!QC(L;'
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MDE(2YVJ/80HBF:2E9%X(J"<_BNU.#=G:4MPBJ7*C!L.YR/\ $VT)D^G:JCU
M2I<D#))V9502."EBQ4<NUBW'B"3GN.4+9O"^V>UN;.24-$@,].SL;&-D(]5J
MR//(KL'39Z88](MA+[RKF@3*SJ+XRT-W1IB%8*';#S4Z&BJH5;=_Q:5LQ+ D
M(=P*C<>K._XSR"OE^7\KC-K=5;987W!1O=E VG;N\D@^3\9A/((<'*DH/)X2
M*N]C71^,N+V;,Z+.Q#2!DT5V$6HV5B8\%"1S1NT,Q%M'>]B:JB,6O&HM',8@
MH=!BLW1.8@[#3TKLVIC8YL4AF!WM\HE@V6W\W#$ASQ8$R@NM;?N?(=51E(4J
M57Y( (PNT$A=H!4'R2 1/939MY70F6[F=.\3GY"1E9(7\?$OU1DY=(B$K(,%
MWK!=>&>2**223US#*1ZKDB*)53F*BF!8\&H!0A-IK547:SKY"<45@K .JY.T
M/N R<8R<SU]IW!G)#,Q.Y5)+,.+*<95F',IC(&#Q&39QM]F%1=7WY> JY3KB
M2ZA!3(HHG46S5G6@[R)E.08=LR:I-#D$IP! AE#*' 3#?J:L ;%P#80#Q_O2
M39S_ .,DEO7*FQ^)+'B*\G_X> F,\ 5 &.7(9SQQ=G^RKI)-IUHZED/"LJIU
MILS6%@8]P]%4&0.$?.,(MJ\;,WAH]FJ_8,UV[)^X2%R];KN%5E%*+IJ5-9"G
MXH )N>Q@N-V#AF(+*&(5B"R@X4@  2U]I#9;@Y)?"("1D=JJ& . 64>22,D!
MN,@N;S(DG'8",]_+'>,?220<^J,1P!Y@9XYX$XP>T\<8&>X'O$8CGQX=YX8Y
M'ER..TGF<\C@YC$ 'CGEZ1Q/9_#ESX\>R,223W<3V#ZN)QPX]O<!Z3&(Y =F
M#SY\^?$X/$\<XQRYC,8CU\\9&"1V#/J.?5P/KC$=_ ^D#//MYXY@]W'GG.(Q
M(X$\3CEP)(///+AV8QSP>_B2Q SR.#V\CWG./3G'=P/",1V9(/$XQV\_^KC@
M\ 1P[XQ& 3G&#D#C]?#O/=V$<)[-FSAXX0:-$%G3MTLDV:MFZ1UG#EPNH5)!
M!!%,IE%EEE3E3223*8ZAS%(0HF$ &"0H+,0  22>   R23V #B8"DD!?*RPX
M G).1@=OE$]PR>'JENZZ.KR+]S+T^?6NOY!@_P"NG==9[WC]N=L])TZ:YEBF
M*615Y!RW/=YGPS%@V9B@0'2:LXZ%2)A(A&U9]#]&M_:35]?<K+T+H[."D%3K
M[U_PCD12O^,]WD\'=NJPZ:Z67H#2]10RGI?55XX'<-%2W-SS'6L?D@\2?*^2
MH+_C[>O7DD\=R,B[<OY!^Y7>OGSU=5T\>O'2IUW+MVY7,=9PY<+J'6776.=5
M94YU%#&.81']45510J@*J@*JJ  H P  .  '  3\J9F=F9B69B69F))8DY))
M/$DGB2939,B,1&(C$1B(Q$8B,1&(C$1B(Q$G<)LV_5J-K,1 6B2AV--O0[-J
MQ(\R+5Q!WT6T(T"SQ[Y)$K]&230K<&5$?,B@@>.161136,JHI@^FHL:Q[*E=
MKJ/!K2V2'HRYZME)VE<V/GAD[CDXQC=-5J*DK2NUD6J_PFL+@%+\(O6 XSNP
MB#GCR>7.6Z\W:T[*NEMV)>9A>PW2]62:MULGG235!S,V.Q2+B6FI1=!B@U9(
MJOI%VX<J)-&S=LF942(()) 4A;445::FK3T(*Z::TJJ0$D)6BA54$DD@* .)
M)[S*WWVZFZW47.;+KK&MM<@ L[DLS$  #)).  !V"3G46_-H:*7L+G64M7H=
MQ:HU2&G%YK7NNKRL[B'#&3C'T4BI?:G9CQT;+1LQ(Q\XQC!9M9UBX\I,I/FZ
M+=-+#5Z#3:[JQJ%L85-N0)??3A@RLK'J;*]S(R*R%LE&&4(),WTFNU.B+G3,
MB&P;7+TTVDKAE*@VUOM#*S*P7 8$ALB7(W4ONXVN%=3A=S)4A6.<0?DF]=J3
M6;0K+JUC>G%-97-M I76/HJMS,:SC16-A;T\)LZD@6$*X4.<U?%FB\(&JZG-
MP8/DV6FLV"OJ1:U)<TM<*@*^N9#9L\G=B6\9:WP?P7KR*<%0 E8<5FSK34MH
M06K3UGE]4KBO=QVRFVSU%[EWBWCVFT+D-D;QTO*V/L1K]6KHRMIG6[!K.7&S
MJ5:#A%;A=9IO&,$9:YVL\U:9(C8@/)=;N4[YTG1VCT18Z:K861:\FRRS;4F2
ME-?6.XJI0DE:J@E:D\%$C5=(:S6JJZF[K%1F< )6FZQ@ UMG5HIMM8 !K;-S
MD#BTRW?.N7>UH6HB-8LBVO(;7=>Z=XVO,JZTK:<T$YTXZWJU'J$])W1I6HNU
MSS-.:@)&[PU4L4G,5^K2M@=-XYLX.V+(+\NGZ%T50N-M8U#WV:YG:PV%-FOU
M%EMB)4;&KK8HZU/96JO8J D\2)UZCIO6VFH56&A*:]$J!%K#[]'174C-:$%C
MJ'5K%K=F12WR<R#..K/?;J4)*JW"( J=$F-8I0*&NM8M:2E0)ZQIW"4JR.O6
MU-1HB,8O;T4+8B1*N$696A!"P,56TNBD\)L.B= %V"I_[Y-07-^H-QNK0U+9
MUYMZ[=U1-1._RJR4;*G$P;I;7L^\W#A4] 3J:.JZFQ@[5]3U?5%38JV %#BP
M!QAN,IH7JJWM! _(A<8^5;247KV)7CK=1-=WN(10U336FO=>/(V&NM3L$5#S
MM5I3%K7(^RQ#-C8SQR8D=RKE1150\OT7H7VDU,A5KV#577TN?";C?>K-58C.
MEES&PUN60-R42$Z4UR;L7!@RT*5MJIM0>#5K3252VMU1ZZE"!U 8@<29!#;A
MV4>-;PYK6\&-::Q6TTW:>5C>Q/62]N<WM:I ;R7B&8J6UXYFC.3G-)>86,B#
MT&@%;EV\"TVXMU0W-J?"R2S$^$=4*>M^5SZL!<?)P,XSQF/ANJP%ZYL+I_!
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ME7&/"#C_ .$/QXC\VO#_ "N27U-:_>/(_:1_FB_;'\N2.A4'^>3_ -I1W?\
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M=;K=8+ZJE*%0GQE5EAWY;<CJ*\D<1MXYR0#5=<A"NRFM#6[G<"6.UT0;".#
MEP.PYX <S+RZZIM6M6)7P_A0Z!%G89"6;QE><2RU>8U-^Q86)Y.*1BKMDT9Q
M8R3%VJ]2=N6:[)R@LS7<F7034S'1>J+%?BAQK"EK @L-JLU8K#A69FVLH7 8
M,""!@D7.NH"[O+/RRP5-Q05D!R^TD +N#$@D%2",YQ/1+J2K";NRM).N6EB:
M%V*.MX@R;)%9.SRPPQYPBD>NZ6CV;<YV*#ER5FY=@JJV/&';*.7,LU9@/1MN
M*BMM3;]/X2_E$=4F_9Y0 9B-Q"E@.#!PP"H6+PVL%PR6+MNZE?)X.VW=Y).
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MU8N+@UMN(\EBV%4L).^]U6UQ/NE6>L->WF;CG/33U!;Y1O=@A))K5:E+]/\
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MNIU/\'=FS$K++MZ_,P#*S,GB,7;VM@:1$ 2)1/5S[GQH$8RN-H8UVK4U2D:
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MU35@H1V])3-6IZ?AFMA>!.LOP-1LX6Y)-XT?('1=2:<T'C$D3D!4J7]B4H%
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M=B586#IV#=PNWBVYGDJLU1.Z28G0,F=38:*PJ7-FG5-S(CO<J+:R@%A46QN
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MKRN+MH-"E'D+ B;F;4Z;8+:% UI0D+I<M7M=53U;L]7=:N2I+!N65J=>DX&
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M1*Y63562;F4("ZJ*!DB+JII"8%#IHF70*J<I1*F99(#B J$ 9P<$X.!@$XX
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M3%->NQZG%E;%7 8!AC(#*5;F".*L1],JR*ZE64%202.PD$,"<=Q /T2\]I>
M#M#@! 0#@. $/8(!^H0_5QE):<XB<"4H\\E >0 !Y !Y !Y !Y_4 ^H?X^N(
MG.(C$1B)T%),04 4R""OHJ D*(*AV@3A3D/A_  "?"Y^" %]@<8B=Q ! 0$
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M"8PB8QA  #U,81,8?:(B(CZCF,U  Y#'JG)BE, E,4#%'VE, " _ZP'D!Q$
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M9-0@\&(8 1.Q)^'69.7[20;/VS5HL]5,P5(],+= [A,YTR-S*&4'QFCE A2
M)CKHJ)% 3E$ 1+7%W.)E735H@A*-U7,$6PF,^CEV:+./.MX!"OEU@!)L\,8#
M&\F<PN"ID.H<A2%$<1/(+Q"^/%('3DD332A"QIEV*B/F$%5F#9L\!%02N2MG
M*\DU33$R +I *RSI!NW;.%DD2^H346X<N6:;YKYIH5=5=N+A'QB-VRYFJ[DR
M8*"<K9)T15L=8X%*5=%5(W!DS!B)1!;:N)0/^$4*!3-Q=@89-F!1:@OY47 "
M*P!X/F/[#Q/[HJ@) $3!QB)RC;*NX*W.WL4*L1VX*T:F2DV:A7+HX-1*W0$J
MP@JL(/F0@F3N/_E3?T_M2=R)2MKM6'*<>;WW9HKR?D ;,EET@?%/)M%'S))P
MV3.H=NHLT247 %>TI4R&,8P &(EQ"Q0!FK9Z$U%"S>.S,6CH'[44'+TA5CG:
MH*^+V*N"$;N%#I$,8Y4T%5# !$SF!$\/PLJ_@F<?A#"^ 1(JQUO?)IX94CO#
M1Q#F/XO: &?E,R+R/)G0"W !5#MQ$X5MM60\;QK'")>7\'Q_$E&1?"\PDHNA
MXG*P=OC(HJJI\_WTTSG+R4HB")5!/P8K)MPEXT5U7BT>DB#UN*BCYL*97#0A
M 4[C.$#JI$51 !.FHJFF8 .<I11+OB(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8
MB,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1
MB(Q$8B,1&(C$1B(Q$8B1>5:URT'7A9$ >C%K+"Z0#S*:"#AW#+M5$5G!"D;&
M<>]4V9<K853+(E70>E3(9))4B)U6JL"LF1,H*-^)D\NL=LY\-5[)G<.'I1D#
M#W"^*BX<'7:MW7BD:J)MU6Y$SM6YDD<Y3I5NL%"6CC+&<*R+!TB_37E%5G24
M7+OGBKE-+E;O:-GS]1X*BJ0)G<KD$BBJIFR14D2F>5^FBS>Q$B*9FS59U/2!
M7;Q4B:2LXTE8=5XX6,<B"7F$EY I"@)!!T OA)YP?,'1*IO4ZT1PJ\;$5276
MD9%XL=-TNW47</7"Q)%-82F3570<NE%3"505"CW@FW.5J)$\1P]_?T_?*(M5
MJ$>Z10$%_.N2%4(<[QZNNL6-%E'$445 QP+Y/S,2B'>)"I^4CU!#_(043C']
M?3[_ ,NR)4JT6I*MSM5&8"V4;N43I ]<$(9JL,CXZ?<18I@2 91;^Z8 3%%E
MVB463;PYB=UJ365$6[=5 Q? \NHV,1R9N=,[$K_RRR14!23 R!I1^H  GX7>
MZ5$Y#%,)<1* M+IL>LDDF19!U,KM2HJD?O#OG3N/(64(X!]XAW@*BG$ NLL=
MP5)51 RAN7;@QUD2[*56L';B@JU0,D6 )6$S*+"8[>';(.D#-FRQCBHV.+=T
MN1RND<BRJ94P6.8$2=J):U:O3WQ7,AW*K(JE=NE3HO72[1?WP1D'KATBW RK
M9YXK2=?$(9-)PF5J[.W2* "8HHER;U*OLFDJT9"NS3F0!%XLW?K)O!'@QC%3
MD/$%Z"AP4.8QC+G5 #B!3%(!2E1.#5^N2S.),"XNH]I$+,6@M9#PV;V&?BP.
MJ@OY,Z:3EBY][60"4G:@HDF9 0,W66242.'?]_=S^KMEM1IU-DV#5PF"SJ/>
M-3+M#GD'I04CWK-TFBFB914CA)H1I(/!03(9/@KQR97O%93N2??WS+["(QD8
MJZB63TY@:IM1(P.F5%)BBJJ[1(*78@BFH=X^;OSJ'*)A,9,$R$(FD3N1+HNK
M'.P=1JZ[5;Q&@^;:"LF)_)NQ6:]RJ8' Y$5S)KH%./:4YTU"%-W$, (EE0JL
M$@Z9/C NX>Q@-D63MX_7<N&H-P>(I(IJ*JF$@'1?N6RQ0X%RDIV+^(;X0H]^
M?OWSD*I  >25%(YO?=I)1CSEVL!5&\L^<OI! IBJ%,4ZSQTX4)P83M3**E:>
M "JP*(EH7B:>G,M&SMTY<2SM9C)-T57K]SXCQBHS,VD#@03MTG*A(%%(#*"F
M51FP?)HI@W]\@.B=%*356RC-51RJV9(HLV;=H,DHB@HJ<8!DP$5/&*HJ8ZE=
M@RMT@/VK/&W>(*J.G!54>GLE6G0ZFV34;IM/!2,Z5='3([53-XCN.DXQ8BBI
M5"N#I+LY:1(":RIP)XP"AX8(HE31.$XBGOVQZ\3L<MHUI+QRJ"9E4FZ9)  9
MRR8N&Y$6@O$P7,U6!$_F&7F%43%1%4Y11/-S0J^LJR536=LQ9&11.#-X+45D
M$V[Y%)H?RXH@D'FWHOB"F4IR.B&%OX/F7/BHGL:AU3DR0M3E+P\310!\Y*1H
ME)-Y1N[19I@L'EDW!)J2,8J7:83N"<&[&S0B")[LZ?6V<JG,-T1-)%</5@64
M<F7$R[SM%SVIJ&,1(_) .<6Y43J*=Z[D5ECJ*&1)6"J0\<*)CW<]O!RCW<<<
M\<#Z\<ASQ[.0Y]N(CQ4AXX43'N !+\,OP@$0 !#U]0$3% !#T$3 'M$,1 JI
M![5$P]3%]3E#X1/[P>H^TO\ I![0_7QB)2LI./DBF.P>(.TR@B(*MS@HBH5=
MJ@]1,BL7E)<BC5TW7*=$ZA/#63$3!W &(E7XB8\\*$'M$0'X1?00$0$!]?00
M$! >?8("'ZAQ$X!5(>.%$QY$ #@Y1Y$P"8H!Z^HB4!$/V@ B'H&(GF#MJ*Y6
MH.4!<G247(W!9,5SH)*$256*D!N\4DU5")G4 HE*H<I#"!A ,1.%GC1NF"KA
MTW02$Z:8**K)ID$ZRQ&R1 ,8P%$RKA1-!,H#R=8Y$R@)S 443NFX05 !(H4>
MX1* #R0PB4QB#P0X%-P)B&[1XX, =Q1$H@(HG07C0JQ&YG3<%U$EETT163!4
MZ+8R1'"I4Q-WF30.NB58X )4S+)@<0$Y>43W$Y"B "<H"8!$H"8 $P!QR(<C
MZ@'(<B'LY#GVXB4RS]FW59(K.$R*R*YFK$G(F,Y7(U<O3D3[0-_=:LW*PF-P
M0"HF 3=PE 42H\5/_P#T)[3%_OE_O%Y$P>WVE !$P>T.!YXXQ$Y\0GP1[R<&
M#N*/<'PBAP(F+Z^H<" \AR'J'[0Q$I!D60*N$/'**S0K<SA,I3G,F#HXD0 >
MPINXQS!ZE)W&(!B&4 A5""9$]'#UFT04<NG3=NV1(H=5==9-)%,B7HJ<ZAS%
M(4J8^AQ,( 0?[W&(G(.VHKJ-@<H"X120650!9,5DT71U4VRJB?=WD3<'06(B
M<P 54R2A2"82& $3JZ>M692G=+D1*=9N@7N$1$57:Y&K<O:4!, *+J$3[Q "
M%Y$QS%(4Q@1/<54RB("H0!*( 8!.4! 1#D $!'T$0$! !]H#R'IB(\1/D0\0
MG(& HAWEY QAX*40Y]#&'T !]1'V!B)WQ$8B,1&(C$1B(Q$8B,1&(C$1B(Q$
M8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$Q\\U]'/G+YRY=J&%[.-I]
M<"LV *KKLR&1;LWC@[=15U'E:F!B=ORF99@46:JIVZSE-=$L<5JN*!K$N'$G
M(K.46X*J*)%:M"*.5F[$Y'Q46Z)2C(MGK3WP0?NQ>.@=.%SJ*J<-O+(ER=ZP
MAWI&J;ARKX:"<<BH@W:,&;=RA'DG$_+K(M&Z!3-5R3JYE&_(IF7:M%U@7,58
MJR/?]W\OO,KFFOXYHRE&GGG;@TJ^BWB[ERWC3JF"(E/?9NBN4C)--Z"[HS@S
MY=Z5=RY\TO\ VR9?!*BB4B.L()-=)VJLY=O$W;=X#MRDR.Y\9%Q NC]JH-0,
MF59Q"N%C@F)>P\Y+&2$@JH^"B4">HH$C,C,7TD8H-G;9983H&7= ]C'<2Y7<
MJ*(J&5<JM561C+"( 5>*8G2(DF04A>YB52^K854[XY73M+SB+E%$I"H 2,!S
M+N)<QHQ,I"I-!25=+IH"1/O3[Q/WF$1**)<9C7\5.21'[YPX.D1NV:BQ\!@9
M R"*2[59 53M#.2M7;%V^9N&B:Q&QBOG*OABJ*)D43I#Z\C(:0/(-WKXZ@LG
MC5(AR,2^5._18I.%VBR;0CEN!19J+MFA%@9MW$A(*E0$5R>$B6I'4L$FBHF=
MX[.H<I@*N1M&-SH"9J1J<S4B#$B3<3IM(D%!(GWK!$-0<'6\5V+A$K3:YBR*
MN77FUS>.@@1PB+6.\$0;'#DC;_)!48).V1"1CXC11(7+%!JB<X%0$%$2V1&J
MXMNVAUE))XLNU!@Z6,+2*(FZ7:C!.$EA3\B<45S+P;=9RZ3.+QTHNY!PY.BH
M"143V3U1#I)G*G(OBJ"UBVB2@HQZI&Z,:TCFH(HLW#19@#==2*9R!FYFIB!*
M)@\.*O:DDFB7.6UO 2Y69'!3@1A$MH9H7P6BH(,VL7.QB()BN@H)3 $X+L>!
M HNXZ./QVHF*=$\E=:Q2S]%^=_('.@]>/4VZAD#M 4=/U)1/E 4@(J9B^7<*
M,C./&*DFZ<IF34%0ATD2D/JJ'.S19#(/012;H->/+QJ@BU22L2!FW*[-8QD"
MIV-P9J58RRC9RRCG?BK+H',JB>ZFKX-1RFY%=T':\\ZX0[6_EWBXO95^=5VF
M5(OF%A6F':9%%Q5 C8W@"0Y1Y!$KPH$4,(R@E'#HS:/++G:JE*@19N\EF[QH
M1\V-X1O!<1C1^[;1A@[O 24+WBH=),X(D<;ZWB)%*09G<+M21[@(YLHQ(1NO
MV%CI8S@RRYO%65*\5MLL=RF"A!4*9$IU#G(*ID@=OHX>O@#_ !E^8Z\BV"Z*
MR3E8Y$)"/DB(+-8Y4GB,8U.-,@*IVAG7E%Q2+)> #C^RE14>D,)SF+B3*=[K
M&"D%I5=VLZ76E'KY\=98$%ED5'C.58E33.NDH7PF*,R\+'I@0I6X%:B(**MP
M5.B=7>LXUZ"A'$M+*-Q7!1-H*B!&WEQ=23P[5V1%%$[\@K2:ABJNE#K 9JR4
M5.LH5V=XB<JZO@57B+PRKG@KPKURT J!&;Y8'LR^,9VBDDGXR@GFWB)#J'."
M;7M0 @D#T1*Y_KZ%D95S,KG7"0<NDW8N4TVI5T545Z\J@*"YFYE4_ 3K3!ND
M(''L35>"'PW)S8B65'4L&DDJ7SSWQE2"0KI%"-;+-A,Q.P,=D#=D1-H<Z*<6
M*ATB =8T,Q,N=4QW8N$2/K:VCU[&$.$BY1;$A7TBL=NSC6RYW$BZLK0X-E&K
M5#R**:=D<)^"W*"2J#-FFJ0RJ0.,C Y]ON(DM)J^O%.DH;Q#*HG0.FIX+3Q"
M"@I"K"":IT#K$!16*=*"(JF4*I.2JH'\95)1*8GBTU7!M6K9L+IZN=J'*3Q8
M&JKT5S+QJRKP[A9!4QGC@(:)3<+>A3D9^&1--%4Z0(DD:U-DU?0[Y-91,\+#
M&AVZ2"+9!(Y%"%(HN<I$O@J"!0%,$A)X1NX"&!-5=-9$C :MCO";H#+R'@)1
M:,4Y23;1*!9!)NRGXY)=X*#!,ZCGREB> JJ!BF772;N%>Y1,,1*UWK6#<K(K
MI*+LSHJS*_\ DI&Z13+RJR"S=P*94BI&7A0:,D(HZI%2MV[5(G8*@ J5$J(_
M7T-%GES1ZB[,DO$KPYRM2-4#,4%G#Y8BL<HFW*9JJBD]*W*!>Y,Y6;-90AET
MSJ*(E(WUI$-A;BBY63!NC'I>&5!J=%;R$\G82F<$<)KBJ8[XJO!S'\4"NG'B
M*K#Y<6Z/IS]7\!/%OJN ;E1$KAZ9R@FU33?F!IY\@LR5])%4CKRPJ$6(C6HU
M(IRCP3_*C%*!G2O+T1*<NIH8J"Z(2#XIG)4O%.DA'M2@=%[&NB> FR:MA;HF
M1B63!9%$Y0<-D$CJF,Y\9=9$N4WKB(FW3-91TZ:-F46A$),&R,?X ,T&,W&^
M$119HJX03593KI)5)!5)(XHM#B03-R\HE3'4&+C)=*71<.#';^^"C9N9!@1-
MJO(G=F6.V62:$<H((E?O@;,DUBM$CO7:QTE%5$S(HEE0U/"HLUVAY!^L90A2
MI+BC'H*MQ\*N(+&(9FT;&Y>-ZQ'MGIP.5=RBL^ ZWB.CJ B7A]0(UV$45%TX
M8$AHMK%L"-468D(FU=M793*$605(H506B:2B7:4/!.NF0R97"X*(D;/KABP?
M1A2RL@X._<-&RSE=-B#TOO;'Q;HZY';9LW6%=T]K#-\(*&4:H.WTJJDUY<H
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F$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>g459793g62a10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g459793g62a10.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1UX4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '5R^=18X0DE-! 0      $D< 5H  QLE1QP"   "   < G@ #$9I9W5R
M92 Q,RTP,AP"!0 ,1FEG=7)E(#$S+3 R' (W  @R,#(S,#<R.!P"/  &,30P
M-#4Q #A"24T$)0      $'!4CYP,E:56'DN(%BPSJ9$X0DE-!#H      .4
M   0     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $
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M=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M    $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO
M;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG
M:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0
M$ "4S,P  0 ! )3,S  !  $X0DE-!"8       X             /X   #A"
M24T$#0      !    !XX0DE-!!D       0    >.$))30/S       )
M       ! #A"24TG$       "@ !          $X0DE- _0      !( -0
M  $ +0    8       $X0DE- _<      !P  /______________________
M______\#Z   .$))300(       0     0   D    )      #A"24T$1
M    $     (   )    "0      X0DE-!!X       0     .$))300:
M  -!    !@             !V0  ""D    & &< -@ R &$ ,0 P     0
M                       !              @I   !V0
M       !                         !     !        ;G5L;     (
M   &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M        3&5F=&QO;F<          $)T;VUL;VYG   !V0    !29VAT;&]N
M9P  ""D    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M$@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R
M:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
M5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,
M   !        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M          !"=&]M;&]N9P   =D     4F=H=&QO;F<   @I     W5R;%1%
M6%0    !        ;G5L;%1%6%0    !        37-G951%6%0    !
M   &86QT5&%G5$585     $       YC96QL5&5X=$ES2%1-3&)O;VP!
M"&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M    #T53;&EC
M94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N=6T    /15-L
M:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M
M$453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M       *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M        "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M        .$))3001       ! 0 X0DE-!!0       0    #.$))300,
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M/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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MHY/\S7ZJN49N0>HOPKQ2!L=;26O(L>UKFL/ZNP
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M<8@[FN6$-:R?)?%/H"XEN>$90*]M53N6(O%UWUKP^))"V9YMW+=A]EBEA-[
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M26":]4''W;H8B1/I-FS,X[Z&LDO>&K=8F,P=9K>.GRC:C>3NJT+!ULL,<3E
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M;**-\W2]^7''*0/*R]U;KA(G'XI?.K6CWD:W6@1VAZ-V;ET*;-+V+=*(CQ#
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MK4$YI@=&ZDDY4PSK]W1\ A4\K,@5<QJ)DV9*8H2JOC#XNDG(@^.]IVG;(_\
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M7#++O#K--)=5///'O/'+#K+''OKO+KO'KOT]=]<Q4L^K-LIE,R<AJ+<6,U=
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MCW_RC_X)Z"_PA;#_ ,V7'O\ Y1_\$]!?X0MA_P";'CW_ ,H_^">@O\(6P_\
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MNH3,"&$1-CIV(CLCCS@3&SW5H3M?Y=Y=.JKF,[J*SR3R41K3L^E1XFAK\J>
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FS*SCCCCCCCF-%N?7UJ;^UML_@Y*N<UI]K20?]'6(?B7..9%<_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>g459793g62b20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g459793g62b20.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1WL4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '="^=C(X0DE-! 0      $D< 5H  QLE1QP"   "   < G@ #&9I9W5R
M92 Q-"TP,AP"!0 ,9FEG=7)E(#$T+3 R' (W  @R,#(S,#<R.!P"/  &,30P
M-C$Q #A"24T$)0      $*?F=R&F;F^<*U90X7<5M_DX0DE-!#H      .4
M   0     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $
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M=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M    $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO
M;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG
M:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0
M$ "4S,P  0 ! )3,S  !  $X0DE-!"8       X             /X   #A"
M24T$#0      !    !XX0DE-!!D       0    >.$))30/S       )
M       ! #A"24TG$       "@ !          $X0DE- _0      !( -0
M  $ +0    8       $X0DE- _<      !P  /______________________
M______\#Z   .$))300(       0     0   D    )      #A"24T$1
M    $     (   )    "0      X0DE-!!X       0     .$))300:
M  -!    !@             !]P  "#8    & &< -@ R &( ,@ P     0
M                       !              @V   !]P
M       !                         !     !        ;G5L;     (
M   &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M        3&5F=&QO;F<          $)T;VUL;VYG   !]P    !29VAT;&]N
M9P  "#8    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M$@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R
M:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
M5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,
M   !        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M          !"=&]M;&]N9P   ?<     4F=H=&QO;F<   @V     W5R;%1%
M6%0    !        ;G5L;%1%6%0    !        37-G951%6%0    !
M   &86QT5&%G5$585     $       YC96QL5&5X=$ES2%1-3&)O;VP!
M"&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M    #T53;&EC
M94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N=6T    /15-L
M:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M
M$453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M       *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M        "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M        .$))3001       ! 0 X0DE-!!0       0    #.$))300,
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M/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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MLK]+W?X!^_\ MTV*5&1G>CC_ &H4C(O ]7TA8:V.&Z[Z3V![&?X/]/X
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M,35!M!DC,U%8=7BQL_ B)V%Q=-0D,D2!P>$E1U=GA)&5EIBALO_:  @! 0
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M]'??*)X_X@IE$SVOJ,4GE5QN U=>,[G1J-B(L88JQ6NT/)7UY!JKC-,HC\6
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M-/+T?FR[Y5YY!M'HIY&J\VPU ETN(5^RM6BZ$Q&3T4&82 C#Y%&;2M*4@C*
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MF8Q\"IU]_P"N^=G'ZQJWP3:_?MWR5SO]2&?]5$/[HMR&:E^J_6O]G_41$/N
M/Y[:G_HEJ[X=0G[M#.>*.?6=K+X%W=]_*"_]W_/YO[>3UQS%JS-,Z!MNYXIL
M%,@<[QM>&C8F&$2"(77=E<C78B#2@Q,HN*E$0KRPHO#)L-%R&0&WG3&91\\V
M>(%7PQ^DZ%N%&>64O'*6/,U$'AT-HS)F[)TX:PCR":8OG[I$P-8-V*9O;.@
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MZ>X_HBM3X<3C[L%.>+E?U7I)_;_U"&/X>..2C!?T(AOV5CW[H9\C1]]9F,?
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M!SL,/K(2KX)0'[]6/S_0?UBK)^#]/?>^Z.>GN/Z(K4^'$X^[!3GBI5]5V2?
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M$*82"<F6\BZ06DLA.S/N0HFNHR[!*8G+%N8 [I7+:U06EH4VA4;JLM"+9V[
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MQGM-NAY"J[N37V+.<;#JA>R[8)QR%0&*PO7PUG/@3SR'1*"CU+-93#.:RQT
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M;?71KZ"GX.TAU*1#:&.6/FP@!W7(9 $X.EM9MN<L$G>+U<VC<Q,JK5!;7!_
M(W6[I]$R %^=2F(1S*6YE ?X*Z-4MZ9#L1N&;J^I-@0,LFE\W_+85?F-\1H7
M44IU=D>@"M9Q.DPL%PN_LOU+#.SO8LW&$BU3@F,++,%)U\]!7L>DWL&NM&?,
MF>BUNZIFRD@F,/G)G42&B=D)1LB\JIR5H&A:PN.<+)GI1 V=C6-$[>RLHS3%
M46,?B]>/<;7<0D])2#UJ$E;HH+N(\>,BVB/VS:O>R$?/1*6,=5-(&-QQIV9;
MGHFPVZ&)[ @KM)PL@+>/X_TA+JZ#4),GC0*NG@W!GH:H3:-3;@FERV7CCCCC
MCCCCCCCD#7Q5=I6F* ,*MV9LK6A^*(.G94W6L*HZ:O9.T7;8HH"R;:\*NM 6
MQ:LEL<G:*X)B+?JJY]ING:[?K%''&;\D+;O]:UM1^P?0#^4GC\D+;O\ 6M;4
M?L'T _E)X_)"V[_6M;4?L'T _E)X_)"V[_6M;4?L'T _E)X_)"V[_6M;4?L'
MT _E)X_)"V[_ %K6U'[!] /Y2>/R0MN_UK6U'[!] /Y2>/R0MN_UK6U'[!]
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MLBEH6;:RP)T+"A9,0]X+[B1\/*-="(MTW#9LR\4L4,='.&LN&KNHX'544:R
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MDQ DB@UUEU:GC;GTDPTZ>5'LVTJF3:H:L67J=G(#5)-+)ZF\*M2)4Y$I#)&
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0..................?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>g459793g65a10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g459793g65a10.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2A.4&AO=&]S:&]P(#,N,  X0DE-! 0
M    *#*^$"D#A"24T$!       +1P!6@ #&R5'' %:  ,;)4<< @   @  '
M(% !%&:6=U<F4Q-5\P.#(T,C R,P X0DE-!"4      ! B?OQXL3S9[7CL+'
MW01MX9.$))300Z      #E    $     $       MP<FEN=$]U='!U=
M4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0
M]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M     /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '
M0 =0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'
M1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M  $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G
M)B;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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MP@56YT1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;
M .8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M        UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;V
MYG       X0DE- ^T      ! !7@    $  0%>     0 !.$))300F
M .             #^    X0DE- _(       H  /_______P  .$))300-
M     $    6CA"24T$&0      !    !XX0DE- _,       D
M$ .$))32<0       *  $          3A"24T#]0      2  O9F8  0!L9F
M8 !@       0 O9F8  0"AF9H !@       0 R     0!:    !@       0
M U     0 M    !@       3A"24T#^       <   __________________
M___________P/H     /____________________________\#Z     #___
M__________________________ ^@     __________________________
M___P/H   X0DE-! @      !     !   "0    D      .$))300>
M $     #A"24T$&@     #-0    8              W,   B>
M$                          0             (G@   W,
M           0                         0     0       &YU;&P
M "    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F
M<          $QE9G1L;VYG          !"=&]M;&]N9P   W,     4F=H=&
MQO;F<   B>    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90
M   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D
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MYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #
M(_\        #A"24T$$0       0$ .$))3004       $    !#A"24T$#
M     =BP    $   "@    0    >   '@    =;P 8  '_V/_B#%A)0T-?4%
M)/1DE,10 ! 0  #$A,:6YO A   &UN=')21T(@6%E:( ?.  ( "0 & #$  &
M%C<W!-4T94     $E%0R!S4D="               !  #VU@ !     -,M2%
M @(
M      $6-P<G0   %0    ,V1E<V,   &$    ;'=T<'0   'P    %&)K<'
M0   ($    %')865H   (8    %&=865H   (L    %&)865H   )     %&
M1M;F0   )4    <&1M9&0   +$    B'9U960   -,    AG9I97<   /4
M  )&QU;6D   /X    %&UE87,   0,    )'1E8V@   0P    #')44D,
M0\   (#&=44D,   0\   (#&)44D,   0\   (#'1E>'0     0V]P>7)I9V
MAT("AC*2 Q.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY  !D97-C
M   !)S4D="($E%0S8Q.38V+3(N,0              $G-21T(@245#-C$Y-C
M8M,BXQ
M            !865H@        \U$  0    $6S%A96B
M      6%E:(        &^B   X]0   Y!865H@        8ID  +>%   8VE
MA96B         DH   #X0  +;/9&5S8P         6245#(&AT=' Z+R]W=W
M<N:65C+F-H               6245#(&AT=' Z+R]W=W<N:65C+F-H
M                                                       &1E<V
M,         +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86
M-E("T@<U)'0@              +DE%0R V,3DV-BTR+C$@1&5F875L="!21T
M(@8V]L;W5R('-P86-E("T@<U)'0@                            !D97
M-C         "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C
M$Y-C8M,BXQ               L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6
M]N(&EN($E%0S8Q.38V+3(N,0                                  =F
MEE=P      $Z3^ !1?+@ 0SQ0  ^W,  03"P #7)X    !6%E:(       3
ME6 %    !7'^=M96%S          $                        "CP
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MJYPKH[NK6[+KNGO"&\F[T5O8^^
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M+O>_Z.H]DJ4#KNX;5AD0/O3I5@9I+FX8."M1E9A)2_T.J;/@J1>I$8[-B@3
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M>'*%)94MD@=]I:'67FEK;=;4E:%*2K&<^S7@+D\(G"*-[C=K56I)@&"T]?\
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M;5Z\CUZ$= AVDM"#L H9#$;8XH9,N&.*8(?KBI%$28HF=]T&(DPPN =V%H7
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MNM.)PMMQMU.4.(6C/V4A:592I.?LI.<XS]L\(ORDNY?4F_\ 2+LSLO0VR$X
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M*P:\$"0A$ EV195A$),J-)M"\BK>=BBF&PLN$-*953'$3 2Q,  &\\8($1B
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MG TPLIUB:5(2+XS30S;K"3B74-^\[AQ/O97[.$)8?0ZC+.<J,!8L;7 ZY/\
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ME&,)5A*$JSGPUPN"0 WXT86!<!PV;5JMH7A=]0ZIMO9$AN;89V&]::^&(%1
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MG'E$ "R].K(0M+>"8/)8,)B7Z^ *;GXS+PI'O*'P4+4+DDLU*T<\!7R+$Y-
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MTKJ+Y@-P*^FV-KTG:E0-MUVH. .R)%]#-LVV*:*B/&VC7Y2,,9L$[LR-(E\
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M!+0+TD/59^K/E#.">#B<1B<7&9^+FS<1/CB)BQ$^9'-G1NQ:*9,,41 =X7)
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MS8PTD;Y0!8IH_N>\*0P^A#B2+5CCP)/"PQY>76)6/+R\O_#+OSS^V,8\_/\
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M>+A9@61SDM(<8;)0P00VZ5;SHNA_W#3PO,^>/X-#GEG\_P#PQ[Y_GSYY\O\
MPG?;SS]\^7E]_O\ GCA1AIP]CE3E19C5?!R\.>DM6UFL=?7(MN\T^4H5H].U
MMTDKDJG-FQ9\K$X<,V(0X$DXB& P04 H4Y0Z'P_DX$,,9?)NBS46(*\#;PO5
M_976ES./_P 8]\8_T8\_ML['W\L8QY_Z//'Y9SYD84H*6]^ZU7\*\#+PNE_G
MUF5_-CSQN'>Z<^6//&,>:=FXS]O/[??[?GC[XQPC Y>S?D^>J[P;P4O#&')?
M+=ZNQ,D20)$ K=F=C;BF%-B04:Q#Q; ^)'81*1DC1HHHBLL8;4^V,QDA3JVD
MJP56=4KPF?#PUU/M6>F=9*K!S;($W%),9LNPRDN1=DAI"O3T:2&?<"P2P):$
ME9&-.#*&>'?&+=0IOS].4D;W?@L<3X-?AFHSC*>J%.QY?EC]*=E9Q]_+S\TY
MNV4Y\_+'J\\9]7E]_/A%E%J\*#P];L9&'VGK/59<F%K5;IT3EZR;!88CJQ48
MIB%KL*&();QQ& XZ/82A*6V$K)*=+D3%D2)QI1!1AH*6X+&%>#;X9R_LKJA3
MOR\OM:-E)SG'^O*;KC.<_P"O.<Y\_OY^?"  6HN:5X/WAMFPD97"NK%0>A8:
M6FYR, 59]C^V)*V,2!!FBVW$W/#RE'B5B!9<;<=6PVF/;RPTTMTA3U!8@AG!
M!#@$4K4$$$:@@@V((1AH/=.M-5V=G\);P[KGBMILW6*IRV*C4X:C5WWK)L)G
MZ95*]\KZ+#-Y%N#&7F8_!A"&7RLOEY;6EMPA;;324"26!)(% "20 [L!D')+
M#,DW)5TX6K:].532RQI/@R^&2GR]/4VG8\LY5C.+5LSSPK.,X]6,_IMYXSY9
MSCSQGS\OM_HY$63USPF/#PJ2YIRN]9*K&+L59FZ=-Y:LVPW<2%:L3&!IJ)>2
M3<'DI9.92E*W6L-DM*0AP=YIQ"5XI+M:@8, ,R:D!R7-RY9@[  /=*>8J_&]
MAD%CV?!N\,_/Y]4:?^:L_P#WHV5C[JSA2LY\KKCSSE6,*SY^?[7GG\\YSF*,
M'=JZ^_>2R.H^$WX>="M=<O-.ZTUJOVVI3478JY.Q]KV.@V)FH8QD^,D!LKN:
MVLO"ECM.X2ZVXT[Z5(>;<;<<0HC#0+IC_!Y\-62,+/+ZH4C)!I1!A'L3^P Q
M_?*><?=RR&';QPQ6L..+]D85AD89OTLC--,H0A-<EN 8<G)]255GP?AD="0Z
M#%ZN_@PZXD*#"6V>O<16YUF9L@<;;K/$04#/S@;U@EY,T<J4AZS @$H;*2/E
MF,&]#*%X6M8DFY)8 !R](0(81R   %@  *!/[=-%A-CZ$>&+UR@YS?UBZT:*
MUU"ZDBB[]-7]RI+RJIQM587+$3V,BI,,4Y%MCJ*82&*09EYMO C+A/M)S%*=
MNWL>2@F.ZZ^"[9=>7/<!6@M+PE ILK'QUKM&P]27W6S;<W,D#(AXX0+8M=K$
MM892;DC@H^(!@0)4J7FS1(>/9*EBF W"GTFOV(=_5_7BK-:FU=X>?8RKM"Z[
MU#JJVPNMI:,SBN6/5$I5YRGS&-=PVLH.7*I^PZU 6F+**UA4H:E0=E+B&\R-
M5KJ(>-DB0HQ]IDJ&R'&S<'95Q>UAX,@&UHW2!O6_1<5L62O*]8PT-)]5[9%0
MTE>&E&M8KT7<3]9#4<Y][$8<H0D.Q/1YHXKI 9;X^/<R2C\3P->ME).F]8^$
MO=;Y==3Z?TQUAEK:?79Z,LM>&TO$LPM\J=*O%?1:FZ_)3U2'J&U*[2MBQ%53
M92*;(6F-JEM$KZ9=Z.E,QN%$ &0\F_O?DLWV;K?PUZ\98:AM;0'6<>+Z\:LJ
MMOEG;1HN@'536=$V-:[3#5"$B77ZL4(!(W&T5>Q_2*97AW):8D&F5M1KQLQ%
M)/(2,\@]LJ_RHCS4_!L?U\;L=WKUU,Q78Z_LZK-B"^ID(QL)C9[L0U9A=>JU
M"3JIO:RKJ_6'6K@+644M4R13\_I>P&NMI5*))097X7>_/BK!:^ZJ^')NG7E.
MO&O>L74J]:XEA3Y&FRL;HK6!4.A!1RQIM 89-3;<B))J6CGH^Q1I H4H!,QI
M,;,B#R0#X[)593GP^>AJO/U=*^J*O/\ /SZ]ZGSY_G^?G4_]>?\ VY_T\*,-
M H6V^[I%WHEN&N=?ZC6J!0:3<I_71-%JE0C:'%U:YTS>HM>O,<FJ1(<>#'++
MLX<E,-&#BI'L 4H'9A7BPY@<Q_U&W\)^NV)M;!,_ZK9^*D-=_FR8X&\UU?QM
M'\OPCXCC_P!FR,:>TJ)OX/5/"["*#T5=L.E(=$=V[,Y#$2-AM8>4TVC8(RLG
M#JU%?)7E#B<*;:PQA.48]SU95CU_@W9W^4^&]F[/W=T888H ,U)N-Q,_S,TG
MJO3?"R><1X&V-&6($>U(8==T;7QQJ<SO$U84:F9V3\[.OH2<(M1/BY3!T/K7
M4TJ6&W#QM4V[!V>E7F*W)6-=71O9SU+V76<5FO5NS]7.T;5L230IRV2,@-&T
M[)V(MB3,>=!BH>1(?*$/W<=-+O1Z,OA?9:Q6OPO=7RCNMKMOM$W:>NV-@4F,
M MFQK].:R([*T4;:LO%"Z<UYUYLDY/U?6WZ2V6,<K>L:8VR_##O'5F3"8,;D
MRF5N=]:FP+YVO99[X7HE 1J^P2,)U?V[U>V9*"U5S;E9V31M]5&"DI-@NXMU
MUJBF[QDY9Z?&B8Y13LV[7#GT@$3 *)=?F3&)05!Y\7?[OV!5S=SZQU1LJ8T@
MYL^38$-H>VR;GK2*(G0(AJTWPK4>UJ 57E@FI4[9FWM=WN_2#L!'90=E$=F8
M]> X@M*BJ@+K!IOI]U?H![.JMBPMHJLWLJA4(>V7'9\+L5V/N=3AZMHS4FGX
M.PK(<8!-H\-&5K7=/JS:EV9LEQQ4J1)V&7DY$TI0>^GV9:KXOK\!K_\ $>1^
MVX :$A:]>^I5G@&Z[!QU5BAV):)@JZ9)RKPL3/KFE$R;KWND$R52BQR7?4XS
M*R#GJQ@LM]8.K^0]^[>D#A;3A$X15Y[=?R4.SW[O.Z?[-K+PB\J&J?\ )=K;
M[_\ F#3OM^?_ )NQWY_\W_M\_+GD*"PY!9XK\L_[,\*KT<^'M_((Z2?ND]<_
M[(*?SQT7Y>'C&?YTSOE^\KLG_IASA<$5SS*UK<*+]'?\)5_FS-C?OA[0_LKT
M7PN:#]J]/SCC;3:W75H:::0IQQQQ24-MMH3E2UK6K.$H0A.,J4I6<)2G&<YS
MC&.%I8!^MS5/_"=KW^NE;_\ U+A%G[;B'4(=:6AQIQ"7&W&U86AQ"\84A:%I
MSE*D*3G"DJ3G.%8SC.,YQGA%_?")PB<(G")PB<(G")PB<(G")PB<(G")PB<(
MG")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")P
MB<(G"+7OVETC([R[-];*W8XW94CH]K2_:].R&*?:K]3JF7:2Y7KDK6L==9>C
MS$$ITQQ8=MEJC'R!Z''#X0\X!"\QY7D4-2!E5^3,W5_):H[CUP['HZ2_':J?
M92V[8[!^#7M?'9&,M4EM'8%GM';$,+KJ[3(28KEJ+G6X7:X[-MW1"5ZIQ$5&
MR1,. ? -1!057#$CRE6%W,-ZT-.C^?VNU?"[=;H7K5M^ :[=]DJYU;[:M[6V
MK5-T];Y+4.W)FEV30NV-3Q,GK77+NB>OP>T&M/W2_P!?VFU&P54G[6]F)F\P
MTC)V>/JD!PJ:L:T.A'#/F_&RE'0EQ[@;/F][YIFQ+(+0HFUZVSJ>\=QNHUEI
M$U,11U9LQ>S:Y#:Z@E]3K@L&"L+U2'A;A9(P\=UIJ8!8S-NO*D(X@?6G%G\F
MX>?!2G/TNY;F[K5^4L4!/0^I>I6N"9VC3$E$F1T%L'LAO&(FJN99ZR^6TX/,
MAZ2T\S.5_P":(Z0$W/;RF(]Q;LK5GL"$SY>_[]-%2GIW2MB%$>&%K"5U)M2B
M6CHQH*_T?L19;MKNWU"H8MH.IZSI%NN4J\S4=&U+;0VS+<(5M".G-='W"%Q7
MJJ)+3TG"2<I% GE #]/ ,>VO2PX$V7#["5JYSUB\5&D@T^=NMCN%\Z'6:NMU
MJ-L<_=:#IPNN:YKR=U4.K4Z4B+E;K-I#8.NMR[;I-5JQXTO.W2EXCXQ)A9#@
M1)4O6C<?OJX\VHHYU/5MIZVW)3-YVJG]A=S:EI'<#94]-[TM.@-F1?8_9D?M
M/J$%KR#VG>^OT50XJYE1NHYN' Z_1=BUOJ&D0[U,*C)2-UP+#QMGMLH4#O:C
MOF]KL>WFP:O=ZJC]X:.M*=D3FH^Q?Z$;YIWB26&E:WH^O[M9IJH7G?';:O[=
MT=7]A5>%48%JJVVK7YDS.)GK\]4ZK2):0L%:LMFJYC) SA'.AS:^M ;@95?R
M55(,V[REVU0#O_\ 6G5ZIHF(\->K[,W-(RV_I*6T]9HS4&F;CL+2EBKFOVW:
MC#';BMM^C(#;,EM&1A;=6 K:Q;[ '8(7%"?@"I_%N=>5,WLMAIC3YVI?%&F1
M%^JGS_=J-9J7HSA0[C]6U]U/H.PW1,I::2EM.V*K>X\UO"G,IFP)93BLO..*
M7Y> PWZS&X7",#^IQ$J2QL1,C$)!X573/B%'\OP-XMCMN[$V@1TD1,:9OYT4
M\>&F%&AZFV/\8%(\DYMLSZH7@!T=1N$42B? PLY3#;4A\9A2VD^R\_D3"O:<
MPSE6$9Y]KX ;,Q\[! ;OR8)%!0 S)$N:6ZQGKV77_@M,^;\.=AQ_[IVV/+;.
M/AO71O5;&>>M7U1.$6K/Q98:;D-*:>F8.9(AR*9V%@+.2D&S]H*'*R@>=8;8
MKCD=$;"Z>:IVQO6C'>Y8FCLS-=CZY%'A F5FR6!Z%GRZU8BAM6@SO]E(FIK/
M8I[P\*C>M=[:73)(76#UU$VDRYM7L^^U"5N5.GIQT0OLN!KW;>R"9B C)&("
M,V)'04ZR^:RX,.X.#'^^3(%^I>W4^9?JH:\+7N'>>UF-UM7FW;"LS],!U?,P
MK.P=9=>]:FB0MTD-JQ;,D 'H7?.\DFASI.OR2!E7)^K&*C!8N:KX<Q!6!B44
M0/[_ +GA=OQ9CM3U37OW8W538T&JMP]GT+M^T6>5MTHY(-V>.UW;M ;NUC,P
M]"=%CSV6YHZY7RASQPI+\&$?'U;)!<LX7$1$>255.^I/A6C4'7T-7>Q[]:)F
MM>[-ZO;!UF+H*[[%K%9%LG4_3VL-45K9EF:P%2D3%SVCG7Q<O=X&5A)\"!B9
MMNMQMIGY '-N(+(!J3V!+<3U/LN54:EW_?T/^(?C.MMPW5L?:6C*1U>O.R]?
M1>PQM?+(KMNOL-7%6-F-E:;2*<:3'#BML@QXLK]0<&$;1[I1).5$**.=\#(>
M3@KTI<+:<(G"*O/;K^2AV>_=YW3_ &;67A++RH:I_P EVMO_ %!IN?\ 1_YN
MQO\ J_\ A_K^_P"?/(4AL.0]%GN?R5Y_Z,__ %__ -_F_P"+CWY^[Y=%5Z./
M#V_D$=)/W2>N?]D%/YXZ+\O#QC/\Z9WR_>5V3_TPYPN&+]Q6M;A97Z._X2K_
M #9FQOWP]H?V5Z+X7-!^T=?5>GDP,20$* /%'.!.'?#-",8:)$,$):4R2*4,
M\E;) Y#*UM/L.H6TZTM3;B5(5G&2TM/;/1OI3GQ$)"IYZ?\ 5S-53TOB+"BL
MYT!J?Z FP.;QG(UR<3#?HE].Q,.1S;0"Y+ _S5!-H%4]EA*48*,+,,LAQ [,
MMP@@@H HP((PX800[(@88C+8XH@H[:61QAAV4H:8'8:0AIEEI"&VFT)0A*4I
MQC!5<CA$X1.$3A$X1.$3A$X1.$6NWO[W3T-U,C];1NW^XD'U%F+\78SZS*3&
MK3MH9N49568L>? '!8@ID6+Q%E62"(=+>4,0]DEMEA+S?R,M%"0+D#FM<C'B
M[]0RC<QP_C-U%TU+^1E#IZB&^M)&'<,Y:5YTC"4KP[G#><*5CR7]L^6>$<7]
M*^_Q6R^F/&%Z58]*5>,Q6EN9RVA6&^J;^?XUWW,(1E"=;K4VXYEIW*&5Y]SR
M0K[9QCSX1QKI;MQS7P>\8'I8ZK"6_&A@QUM^[E:&.J*5K5AM>&EY6DC5I"DX
M9<3EO.4X1C"\J2O.58QA)'!SZ<O-?R5XNO38%W#!GC3Q@SRL-Y2V]U.$0M6'
M4)<;].,ZEQE7J0I.<>7GY>?EGRSC..$<#/WH^O#K9?+'B]],<H]S'C4Q?H]"
M'?7_  3A?3[:W$-(<]7ZI/+*%NN-MI7C/IRM:$XSZE8QDF\-;_Q^0N6OQ;>G
MK8")1SQH 41SCJ64&JZEC8'4ZK#F4MI<SJ3TY5G#3F?+&?R0KA-X:Y/5Q3JN
M]JOBD=5[N].CU7QE8^8?K55E[O-M,=58IIP"K00*9.5EUI*U8QEYD6/4DOV1
MO>+?9SZAAWO+.,$<:C^_OTU"Z/'B\]*L);]7C0B*4XXZPG".JX'FM\?VL$(2
MW^IE:TY:R\UZTYSG*,N)2K.<YX4=[$5X/]T,\6GIHRZE+WC3_#6YEE#0^.J\
M'A3JGL)RWAE#^CW7G5+]:,*PWE?H4I*580I6,9(7%21V/Y7 SXNW2I*4J5XV
MF$I4U[R5*ZK0"4J:RI*,.8SG16,91E;C;>%8SY96M",>:E8QDA=OW /8MZ57
M*_W6CIK\91>?&M<P,@AL13V>JL!A&"'6W7FVLYSHK_&4TPZO'V\O2WG.<X_G
M)74?^4Y=;<>/$+BH\77I4[C.6_&T]S"<-Y5E'5: 5A.'L^36593HK.,>YG.,
M(\\X]6<^6///".:5%?\ B?RN<%XL?3F26^V!XU#Q2QFG'GTL=4X)>66FGT#.
MN+_\!7[.&R'$,K\_\5Q6$YQC/"M1<OK2OE^.K+^4>+UT8PC&7?&J,4M*D,NJ
M3UFK+2,OK0M6$I0KKPXIO*\-.K0VIQ:O2A6/4KTY5PH]JBMJ=?,$:+([[XFG
M4K6]TM="NWC162M6ZFS,M!V6!>ZUZZ)5#RD,6H*4!44+UM.%)P"5C+"GQC2V
MEY].4/NX5A:BKM0D6TXL]^*QIOQ7^E+P_P MOQM['D7#S8^7\]9*"AI+KJ'7
M&TJ<7UB2E*<H8>5E:LX;3AM65+3Y?<E=1_Y3E?/M]UP\>+=T>RWEW_=OY_VD
MH;6IS^#)0O1A#JLH;7E7\&'RPEQ6,I0K\E9QG&,YSPCWJ.UN=>!T_/)&\6+I
M08[[(OC<6-]SS7CT-=8J&K./0K*%X5G'6+RQE"_V%>><>2L93GR5]L$OF/>E
M>>OYXO\ NM_1SU81_NX$_P"M2DI2C^#)0O7E2LK2E/I_@P^K*E9;<PG'EYYR
MA7EC[9X1\G#VMG7CPM^0N:GQ;^B6,-H<\;6UY=4A6?-'6_7J,+]M:VG%H;5U
M2<SA*'4+0KS6O"%H4E2O/&>$WAKK7^]/;V7\G^*KTCBS5QTCXX&P0SF_NX*1
MUKU2V\G&6O>\\HST^\__ !6,KS_H3C.<_EGA'#._?A>G31<Y'BA]+W0(V3;\
M;^Y_ EWGF(TA[0FCP\%O,/-CN(:;.ZGC/*\GWFVDJ]OT+6KTH4K.%>4/(GM]
MR$<7^QY?VUR7\#>*-TN-RO GC@6\GT,OOJRSHW0;B<-#,N$/K]6.J_ISAMAI
MQU7EG/["?/'GYX\W0^7Y1Q]E\L>*=TG4O#:?'&M:UY5Z,81H_0:_->&TNY1C
M*.J^<96EM6%J3C/J2G/FK&/OPYT/E^4<.V=O)_1?XUXIW2=]2$,>.+;'E.>W
MZ$M:.T&XI7NJ4AORPGJOG/DM2583GR\E>G/EG/EGCH?+\H"#;W[_ #H5]R_%
M+Z1"9=$,\<&[AEM^M+F<:6Z]MN-J1A:UY0V_U*(1^RAM2L^K#J?3C.<>?\UZ
M>GY1PSO37W8:E<+/BB](\)RO/CI[%PC"FDY5G2?6S"?4^EU3./5GIQC'FZEE
MY2/O^TEI>4^>$YY'X'R_*.&<TYT\KKDD^)STN"$&/+\<K98P9GO?%*>TAUN;
M8?\ CJ]#^&G%=.,)5EI?["_+/[*O-/YXSC!^!\ORC@^^#^BR" \1#J7:(B[3
ML#XWFS)*)US#@3UV,9TOUE2FOQ,G:("F F&-N]/4/J0_9[1 1.$CM/.-OR3"
MW4(8]QU#H?+\HX\VZ^O;T6+8\4;I'E;"$^.GL12B4Y6PE.E>M:LNIP\ZQE2,
M8Z<YSE.'F76\YQCR]3:\?^3GCH?+\H"#8^_?G1?1[Q0>DXZ\MO>.CL5MS"/<
M]M6E>M6',M^QDG+F$?P.O7[>&$J=RYY>C"$J5ZO).?(_ ^5//T=''OD_V-5\
M7O%%Z.J1AO/CL[-'=QEI65L:;ZP86K#WJPRC#972LI/D]Y9RCRQE:LMYRE6$
MX5C)^!\ORAYMVKW'I]PO]=\3+I4P(.>]X[NW6PRU$H&)7I?JJEIY0F6L$X0K
M/1W[^UEYK"L_EYKQC&<Y\^'.A\ORHX_W'L.3FE&U--5QF_$]Z0NYQAOQX]MN
M94M+>,(TOU57YN+PG*&\>GH[GS6O"DY0G'W5C.,X^W'0^7Y5&KGL/PZY(OB8
M]*S67B!/';W 2R.C#C[K.E.J[B&4*;<>2IQ2>CF<)3EIIQ>,Y^WI3G/Y8\^'
M.A\J^?OR4%;1'RSZ+E07B2],[--PM<@O'9VY(S5BEPX&% :TWU/;=D)>0)&#
M$!96_P!(6F</.DF#-YRZXVAKWD*=6A"L*XZ'R_/M^;'&I-V  +ME;[VJZ37B
M2],Z]*RT),>.SMT&4@S2HZ4#>TSU2PX(8&:N.(:<SCH_E.<H-;6/A2592MQ.
M?;RK'EG-Z=:?E_)''^X\F&K69_OJN&[XF'27X[1;GCQ;F887[B</(T[U+:96
MIOTY5C_".B;V4JQA:$IQZ\>XI6,-X5G.,8=/3\JVN3K4-]AVNN)_NF_1W[?_
M +>S=7W6RWC'ZGNH_GE9"4K83C'\ OS]3J%I6WCR\UI5A2<9QGD?@?+\Y_W0
MD:M[;C8D?V==,-XAGA^NV4RYB>.7M)5N<KC,"=:6-&=.LS[]3B3)"9&AR)E'
M0;Y[\%'2!\I)BQZR%A"F''%LLH>+?6X?@?+\I3[$\M?;/1=OCQ.NC2E80GQ[
M]SY6I7I2G&H.HV5*5Z,.>6,8Z%^><^C.%>7Y^7G_ *.'.A\ORCB[]-?)S<6X
M+D#>)ATC,('$&\>?=KQ12F$#,-Z<ZD*=>64OT#I;3CH7YJR\O]EOR_QE?;'G
MG[</P)[?<HXU]NWK^;*#K-V=\)FQ;'3L^W>+S+3.TA38.77=9SK!TD.MF92H
MH&76)HN6,\/EPTF5JC80:JW+%..G5] 8V8DD-([7H.=#Y?E*5[FFG]O3@MH:
M;IJ"U>&59+WHO<[W8+6LU.2=AC-L$5+7](?MDT=V":/NIA,!K'6VI*BV=FZ.
MV'$G)#4B./FY3)LS-&2\J<9*%]H\%888SQ=X:PL188G;6SI))_I$S$RX2:/8
M%^B^??%B=%AOAEX\Q$$)CCP_A7;>(@@A ,444G SIL,(%G)A #T>^:DKPQI<
MV:TE>3GA@VP'-N2N(XA@YX@LG**30VC,&AKCQF0?8>:2V/D<^1^4WG+KOPUI
MPRKWWQ7V?#LOQ[MO P1"*&2-FF&(6(F[*P,X$</]2EET[_#=C9VT?@WX3QN(
MDQ8>=.F^(1,DQMO012O$VV)!!8D%_E.[V(>JV/\ /G2^YIPBU3>*<[M+] ]<
M1U3E '(*P7@.$@J-4R>V,?O38>T<PEHE8^!H1/5/;>II^0@X^B1=SMEIC+++
MYK@<96C++*O,-P0SK)0^[N>3$>^"S?4T< =X8D,/J79CFEPFM"V"2@]EZ<J%
MHE9:C+C$R\O.&Q5-W^3:KX7;QB!)6/ML;L22(OJK4Y/9(F8JT89E 2,&:P;E
MZ_?JH \(FP6>:3M]S8]FNUCV/,:PZJWMPFP)ZXK@Y+5MOJFPV-2VM)/72LP,
M<G8D]%5Z:C[]%W64N%BAH>NZ_#!MD]7?I4L<09\6.5LM#WTS96V[=2O9*O[0
MZ>R6D[#)JIDMNZU57:U!AZ2W*M6.*(ZY;[L]:EKI=%NE.5>EQ=_JE)C/98!A
MF3;#-Q*#[(I2X^*?*Z>WH?[]%1WIJ[WLW]JJ#(O5PVS'3-)WSU3OD]9=W!7?
MKO:4N":CUK;NW&KHFH5?7=9;VIKR-V@??->5NJVN.9HKC\G*-"7^63K^"R@L
MBNM#KP!(MJ6;+)F $<0/9.2NOCQ4OKI>](#Z^VAK/KOLV\2%ZJ_9G9.VJ#;J
M9:X*LB50 '5UGU]K>HT"S"C,?,L$K7X4LXUYWZ<5-S [#9BRA/U :<3H<K9W
M7H4X6TX1.$5>>W7\E#L]^[SNG^S:R\(O*AJK[:NUM^?_ -P*=Y>>,?SUV._V
M^>/+\O\ X>7W\GW;O_'>A4AL.0]%GF?RS_LS_P V?^?D57HY\/;^01TD_=)Z
MY_V04_GCHOR\/&,_SIG?+]Y79/\ TPYPN"*YYGU6M;A1?H[_ (2K_-F;&_?#
MVA_97HOA<T'[1U]2O4#PM*B[/^<ODO\ 1_ 7A?[?I_\ ^7"F9Y#[_P J]'"J
M<(J@7_Q ^CNJ;?-:_P!E]M.OU#O%<D4Q$]4[7M.HP<_#RJF$$ICI"+D)1@L4
MU0[B'L#.M)=RVK"\(].?/A1Q9P^CJ?\ 5^U]9[LID;L74-\JFRJ',/2 \5;Z
M5. 6*NR+\2>1%R;(<K&/D!ON 20A0):&W5*8*'=9<PE:%8P54@<(G")PB<(G
M")PB\<GXL\7Y-?ZH^D?#[N*MV&2WY,8><1A4EI##BD_LY4G"4>:U93Y9_8PK
M/V1YX+,60>[TS--<O370^<;I5UQIN]:MW(O9MQ9@+-IF"M%SJ<1D4,IBX(Q:
MY0XQHE]Y*?,=&(L$%DMEW.6'CVWU8]II:V2 -<V'Y>_1V:M\E1 6,0NZ%CX#
M"^&/<:4.L'*!O6]G(MY(6\H!2OD$"L-^WAXM([HS&2!6W74**'2\4N='%L]7
M'%WO45+57+@8 ::V=7*N\$*AB58G@4(<:82-&_4KM)-_*6AW"616V6,Y.0E7
MIRMGVG&_4MQE*B %R2XH&R&1T#DF]-5>_P 3OK_K?K/VCUW2M>R34@&3#Z]L
M<K)9(84^W*DQKJ3E.+2VTH-#Z!1R\#YPIEAXE[(^&V\I':)%<#4@V?F!T#GS
MNM?,W'(BJS6E"QZ!<&T^ 1*X8#RRHQ"KC55/,EI0VGY'[:4+<0[A7DKTX\TK
MSC&"4H,J"IX/WL-;L!=;+=I=0J36?#1UMV?S88YNWV_:1T'^A"DQZ'\PT=&R
M(+CR6&TH-4>(:P@U_*\9;=8D6<(1A8QJ6"M&!-G/+-B YR#AG NV8A3HT",N
MS[K(4(TXO/4J7:;?='3G.?\ P'@9(:;<]*L*3A64^YY*SG/GC*L8_P#)+,((
M!H;?:S$\SQ=J5"KQ2ZK VO>]*I=G(9@X&Q[*G(Z:DBDH98@H.<M=;CWYE:U)
MPT$T-'^Z>DU>$,H;2A[*\M)\\D%"'+AKAJ/$#<UH=:A\E9?O9I:"T7V;$HU4
ML<59H%=KK$_%V/#\(V^B+D1(:4>#E30WG(ILX5+;[2"!C'&9)I8A;'ME%.!#
ME2'?N_"M*TIE4-TK2V?!;"IT<[]/8'45KZ*8(S@=##A3_P"L&DDY'<RE/J(>
M4RTX_E#F,KRPE;N4^EO/D0M3IQI3+1P!1Q4L%L%NNI=0Q?A^5+9XXP^=F2.S
M9/$F&I(N%,Q0L9*1[+;(2!$/-BD,.P\D-)/$.I*D"I<5E",I2G)6@ RN[AZ"
M]!1_3ZBUU0:KQS!=4E35A,%/L0>LF12G1T/+94V.&Z\VP1A&5M>TISS>PA>%
M-8SYN>6?/&"D)L'8U #VIF.8)&0MHK\^&+UWIG:G:]HU_L&2>KZ#*+M>P%69
M0K1)2),650L8U]"L9+*;&-(&->6E7EA+6%OJPTEQ#A6F09P:BGE<<2V@<T5"
M'JZ!%W.PUMID60&AMHP4?ZAF4$ $CA05N;^8TK"/1\9WVD/M+QZ4+;4K/EA/
MDG)2F\YT:I8OTI4$6Z*W'B8,LC=K>Q9*AT(:QL+;C7NX;;;;=?*V;"MML*<]
M*</+6S@A?M9]2G&T.+2C.&W%)*1<V#GJ;$,*TRJU&-&*EZ^=8=8U3P[-2=@X
M*QMR]UMMZEQ+76/./4)'IR#/AI;#$4TV8DF':C0<G9;2ZAXF7>20ZV^PRSDM
M=6=^U3=Q]V<M1:UJ]$+>ILG@@44LAJKTW+1"<"G?&]XPD]+*"6<NI9($8?;^
M:/AQ)(+[3HY;;3P[S393(N01R-V#.+49FRIF0K^>']UKJG924[$XF[/'U22I
M]*V!:(%TU 3V)J4Q9WGFO?4_Y/?3 &Q\*-(2I",>\/C#WR/BBEE0"S9U.8J]
M'-^>?*BH/% @$6N1C$#CN#-76B-O!^RRXRIH>/V MYQ;2$K0ZAGW&O<>\E(1
MEQ.,JQC*,X*-4DWH7K0E_(9&@ &H)605"M-V39U<IY# K$9(#SX0F2TLCQ42
MN7N<Z"X<\HCT"ALH] ZW%K4RUZ&&U*7A*,9P0&I&>>9NS]!=V;*%G>\7B=]8
MJ)UA[+5FLT>P9L,99:5#6,K) GQI*(E7ZM9(\P!UGX8B_B'_ $P>>BU+'3E;
M<NX,KR>$?0V2)J..37H*"U:FWV=5J(BQ1]*:37@)@;V[)!/F/X';:4*C%@AW
M2BGG5XPIA+:$Y4^ZM2$)1C+CGH\U*20O0V;("M-!V&88W9WFGH-UGA^P4!L6
M3G[M7Z'!T/54I/GR$H@1M\YPI!L:(TRV8U[+P[)J,*D'VUX7Z'&$)<1E]XH4
M@;5V Y/0DZT-2]GK0JGM0C4.V<A+PHCX;-GLC?P7&Q'5#K J42P^^^!^T^PR
MMXE#8QI+*&"GF"&AG7' R$-$8$O8$:WM7*Y(XG,5IF/7RC.W[<=0H@XL=@XY
M[7L6*])M8R%$X)M#S;JR\>TZZR,QDUOY(H[:BW/++8X[KR\-Y*9DBE6&AO9@
M7-#E<\*S+WJU!2]$]IK?JVESB;"+7JA;PI.9;S'*218B]6R;DW',.13I BFT
MR9ZPV@V"2\);] N"C,822Z0B@#UR%\M'U>IMEDJR6>-: -"!9 8$ -)UPV:.
MRPEEAY6(>[J2LI"6\I<^.\WA3CBT9RVMO.<X^V,J)9N6<.57S# :#@SA7LW1
MU^I#706!WZ3/1@=A<L%DKM(K Y<>ZN7ADS<@_,'884I)C#H:I)@ED,-I3 @;
M3IA)#KLE\8(J]'/]0MFP!-*G+^<@.NZIQ@F=9]^77 &U.NT6NMJ60+C"W6&N
MTW7/.659<;SA:&WV\I3YX_86UC/V5CR25!#9 $_=B7]#2X%%7WJ'0M<[![-Z
MAHVURTPU,-7[%A/P0. _$DHL5X/B!E%D,$-1/S);,,*\MUG/H'(POTXQE#B"
M@N="UVU+9M4Z"MZ7+M3KZLZT[%7S7E.>2Y7ZV]L6-C#S4"#OF@ T^P)9'R;E
ML4:1*2M]B*2_'IPW+E-8^GM.-E#MN$BIG<D@OH,W?.C"K4%R%#UU"&CU!-8
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M;MX^JR.(QT54E[+$,T#A<FL9I$MD)A*F<8:()P!A7L+]E2_1GL?QF!'Q'\0
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M'[\CU]0M.?AS:9;[ ]I]=0;B2%0-8'@;+-$BMM.9& A(\; V,?);>&<RY/R
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M;$/87:\R0OZ&J/R_'2TC&DFN(>7_ !8S^1UNN)9QDC5<G5NO>W!L]2JG+_#
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MG!QT.M1<#5X0?+A+C-:JT.HAQ)A)K:2U[_/\>E%&K?X8SLZCR\^QNB<^6/\
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F)PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(O_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>g459793g65b20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g459793g65b20.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2'44&AO=&]S:&]P(#,N,  X0DE-! 0
M    (;B^AC(X0DE-! 0      "T< 5H  QLE1QP!6@ #&R5'' (   (  !P"
M!0 11FEG=7)E,39?,#@R-#(P,C, .$))300E       0+;KFA$!K^Q8(?Q,)
M -DO3CA"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /
M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 [_^-0 "  $#O_XU  (  3A"24T$)@
M#@             _@   .$))30/R       *  #_______\  #A"24T$#0
M    !    %HX0DE-!!D       0    >.$))30/S       )           !
M #A"24TG$       "@ !          $X0DE- _4      $@ +V9F  $ ;&9F
M  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $
M-0    $ +0    8       $X0DE- _@      '   /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H     /__________________________
M__\#Z   .$))300(       0     0   D    )      #A"24T$'@
M!      X0DE-!!H      S4    &              2M   '90         !
M                          $             !V4   2M
M          $                         $     $       !N=6QL
M @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M          !,969T;&]N9P          0G1O;6QO;F<   2M     %)G:'1L
M;VYG   '90    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4
M   2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &
M;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9
M  !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J
M8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO
M;F<          $)T;VUL;VYG   $K0    !29VAT;&]N9P  !V4    #=7)L
M5$585     $       !N=6QL5$585     $       !-<V=E5$585     $
M      9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $
M   (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L
M:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%
M4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T
M   115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N
M9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "
M/_         X0DE-!!$       $! #A"24T$%       !     0X0DE-! P
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MQ $_   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
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M=HM8U\3S&\.\%G8^-C ]6BI@VWG;[1I^K8ODDI*RW)=U1MFVST',V&+:S2#
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M;0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MJUV=&U?J\P^$BPFD;H!BS;1MAF,D[M(XE'7B-:R10,H-K8-<.&V)98S:#R)
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M>6,>CQ$NFXB1OM.8?@ZW%F#VABHK?OVL(I4H1292_H+:FMBUB)=KB82((&*
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M7"%MM..(':RTEU]:$Y4EEM3SC3.''<XPA&776FL*5C+CB$>:L(E6UR\1_:]
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M/I..-J4KT4I2G'GGX)3A./+&,>69/Y1^OX?$Q)$]RPWS^Z(SY_\ ^P$^G_\
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M0<;&#)%"SQ$L4XB.(E;??G_;A\+O^R%1O\D;MKQ$LDXB1+NAZ'8J<,N<-U,
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MXB.(CB(XB.(CB)6SXQ/W+3OM^3'M'_!\CB)9(C^D3_P4_P!['$3RXB.(E?\
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M]\?^X6A_\4-3XE![M^?^!.OYQ*QQ$_M#]-OVH/53\F[1O^+"K\1.F]^K*_\
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M%_V+_751K-&X%5G]?3I_Z.-?.6EREHG??'Z^'N/TLV-M<?[LQ(^]<8Q[5D+
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MHWY^-=_7W$1]ML\,#\/_ *C?GXUW]?<1'VVSPP/P_P#J-^?C7?U]Q$?;;/#
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MB*&D$-<[\5>#<<XEF?TB@UWT/8U^-6'9+ZRY)>E3LI96.1\H;)K4$@-J<O\
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M!MGW@X$HQPD,E#7).O\ 2+.AYYP6#/4:Z[J+"=^8CKQ;3<4&Z[A94WH4L4Y
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M" H)+C])IK:NJGS;'!+%F_\ D4:W;<[$ EF(#%V/(#0!!Y 1-$/CSQV3#2Q
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M4Z>Z5*"OGL(>'?*4<\.A]X?G]U"NI5^2-IJ]M8K!T4.KJ;1R7RP%J0(RKZ6
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MF78[Q6JAKN*D8O45$L%OLCSS@,;.VP9NK58<AIUT<LY8,D6#8BAP"1W!\-R
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M"WW(ECV$J4=VLLK9&&CQ,\1K V"$*^.BR*FDCO)DHR;FHY^#EVBRFG/9XG"
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M2N192:GR[W>ZTU^@%2VPM8L6L&P5K4K%-:8JA6986!C=/+6XB,KZ>MK&92Y
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M(K4U465=TKN6JGF&X(O)"U]UO#>R=*2>//GR"Z\N<F[E>EQ THR40,_$GD=
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M&;=)4IV->7)9+(5#ED/^B46.J$2QZ8CBV62!FB$)40+[5X>I9N.U3U![&KJ
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MFQ:])KO7V\H%'(#<4"UL%"AU<IQ+>C&;B*,4G@@'%,8MO7$:5P=*W'?%0O\
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MK46&^S5;&M:U7ML+R8[8CN2YT .X3W7W8FURC5_=ZB+0+#:[D^Q6L\@.W;0
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M"0'DCD!&C)R*R7"RJG%QQX*B%H(C"DK>2^IXQ2N6]=Z1C95-Z/2ODO760-%
M4L5F5@Q9V\RL#D&T-.K %0*P.C<</Q#T2_IW4J5S</.KNIR\:TIV=?*"W8[<
M!]UN0:MQ; VDLK#:9E8GNK:#V_"[WU+2MIP6$,CVF'8*- 0]@C,1-,94+-PZ
MGL?[-[ME&"A6B?10DT=#)S2,,$M9S\_=0PK.GYF1B6[Y4V%58CCSK/JKLT>X
MYH58KWXG:GN#/BKQ'T2_P[USJ71LAN;8.2]==W$J,C';3XV0%/=?.I9'*_\
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MA7"\7MKKQT93Q\HKLF%QT6785B!K]4KTS9;<\^\EJ'J0LC*FR0YXD0H<\UJ
M'4R-ATN/>8ERI7!;<,.O+KTDRT::2+N%KQ<"DWWVUU4*J,;;BB+6Z-8&5 Y+
M.0K@HE6@[=E1BJ!M5F=2L>JW[U8G3.DHC@+DY3JUU36.PI2JW@O%!_(JU@MV
M5@Q&AQM[Q3JZRJFP+49;[P 8EZ<V<P7)_8+K\] \VLN"UV;$2N0;Z8\XTAZ9
MV"['MAXE AX*"&]HC/L@-R81RLBPYES-5B.I6C!*)][S%Y5J+<TV)RQ$4;"8
M?/EY;%[.S\%\N#=FYSMF<_N72*D-&'A6(@R+PW$?><H<!94PTP-*A.Q#.HWJ
M:X6.PPM8CVX\0X&-%)(:02<^PI,H?(/(P^;[.E9J<ONL^4:ALQ]H1H5YK! K
MIJ"@\/2&C&?(L\RU"[Z(6H$<$0'2;(70#G;%1RY \6"'F)FOZL^-D(K6E*-
M!W<AKG!TJJ=DE5/IX,.PT#IISL.<57*O-S9+Z(EY+4?#!$CLO21Q'O<4],OF
M-%49[4(.S&KP"ZX6Z/&MR3R'#I1T=P^+F<-R/D9-=-8%V]W.MA\NM!58HK%C
M\ K,65F"H7LT=BM=*Z:;K6:["JO'H4LW+)M!+Z5E_P#C:X^P)UR1/9AKT#TF
M074(F>,L4:]+&E,,&NOJEB9$N/  C6EF.RD.L=_$B2^W($K="> <<& $/?\
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MJ&2I5<I<*Z^I> L?H'5NE9O1.H])QJNHX#\+Q?26R+6L<)YG+0=70J>X.U"
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MX_8G5*<-J.S('7)$"F>5&RC]<V'KN\M',QY66&S3*/$O'V5<)*L90][9*54
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MXP!V+3)"%SH$776BY\>8-U%L=!1;2^+U>RL-]QQLD9CXU; *+\]Z*ZZ*::W
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M23K4W4!5KA*]:TGQ,%,B$-YM30[<Q%UZ>*&C5@"R,''*P2Z(2P2Y)D/ LNS
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M"6=2X4I?Y]9*D^@*A(!*D<0./AL\"= RPW&F_'UH*]-C(2[C9&[%LK<+L'9
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M18 :&@H[AT32*[">XFHT!L1BM1N8F%';4O# 0OLK 7]#0K.?)WV1C ^7//\
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MM.+]#T'L8]+'M'M&6'FEJ;QE[UC:7FF$^I>PTV.+G*$8:QZJ*J*!PK5:T4@
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M%;A,'))LLH0Z./\ T>*K^&#7W\!!I0HYXM!& ,*63AM8YS)*?3;D+2]7WA.
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M-8 "-!$9DV2M7@ ;,VB(W#;)M.CYFO@2SDO'!/O70X1!>%.,#&>QIK,>ZKT
MU*2F-/-.99R82VDM>&4+7H,GQIT;+K6K(Z;D959:JPU7I0R%ZP>#,OG,K-MF
M)=50'0)0\B!!>J?;KX1ZQ@TX75/#74NHT)95?;7ECIUOE7T,S5FE;#;CV#E8
MVS97KL-HW<R3PO \W*/&FI8W5JR-+%S'AP<3%UB?$AB(QALUIU!9; [3D.@3
M#S.8^-!B)(9W"G_6D"Y2WZ=Y\?8 9%_\=E&ON6+75L]; (%X(W9]JG%F9T(
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MR1=ZOXPR+1:.1VVK _,<C_-ZO5\=SCZ]7ZHN2V8O4^H+EL7Y9(S<E<AO-[V
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M,P[@D?D=?C\)4*%.UVI!WM20=CX[!'?MO?OOO/1'PD-$BI"BHJ.C0DJ4I(@
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M6VLJJ7;0]**$10J@*JJJA550%   $U61;9E7-?D,;;6X\G;0V%4*H 4!0 H
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AF(EIZQ4Z)]H)!<]9D?#K*VW6G'&EHEO'$1Q$<1'$3__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>47
<FILENAME>g459793g68a11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g459793g68a11.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[2).4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (C*^AU0X0DE-! 0      $D< 5H  QLE1QP"   "   < G@ #&9I9W5R
M92 Q-RTP,AP"!0 ,9FEG=7)E(#$W+3 R' (W  @R,#(S,#<R.!P"/  &,30Q
M,#$T #A"24T$)0      $%/<QVDZ?Z'G,+)5BA4!G&<X0DE-!#H      .4
M   0     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $
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M=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M    $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO
M;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG
M:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0
M$ "4S,P  0 ! )3,S  !  $X0DE-!"8       X             /X   #A"
M24T$#0      !    !XX0DE-!!D       0    >.$))30/S       )
M       ! #A"24TG$       "@ !          $X0DE- _0      !( -0
M  $ +0    8       $X0DE- _<      !P  /______________________
M______\#Z   .$))300(       0     0   D    )      #A"24T$1
M    $     (   )    "0      X0DE-!!X       0     .$))300:
M  -!    !@             !G0   Q@    & &< -@ X &$ ,0 Q     0
M                       !              ,8   !G0
M       !                         !     !        ;G5L;     (
M   &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M        3&5F=&QO;F<          $)T;VUL;VYG   !G0    !29VAT;&]N
M9P   Q@    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M$@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R
M:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
M5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,
M   !        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M          !"=&]M;&]N9P   9T     4F=H=&QO;F<   ,8     W5R;%1%
M6%0    !        ;G5L;%1%6%0    !        37-G951%6%0    !
M   &86QT5&%G5$585     $       YC96QL5&5X=$ES2%1-3&)O;VP!
M"&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M    #T53;&EC
M94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N=6T    /15-L
M:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M
M$453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M       *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M        "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M        .$))3001       ! 0 X0DE-!!0       0    #.$))300,
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M/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
M   !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3
M(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T
M-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=7
M9W>'EZ>WQ]?G]Q$  @(! @0$ P0%!@<'!@4U 0 "$0,A,1($05%A<2(3!3*!
MD12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T
M9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7
MI[?'_]H # ,!  (1 Q$ /P#U5))4:>M]+OM%-5X<\^J!HX-FA[Z+QZCF^G[;
M*;MGN_2LINMI]2JJQ)3>23 @@$&0=00H7V/JJ=8RIU[FB14PM#G>3?6?55_G
MV)*>8S\;ZS_MZV[&-[L"[,PJW5BP!K**O0R;<O';Z@VUOL;EX74,?;^L5VU6
M?X'])9^I='6Z,%[.NB\YVRB;;;396YHIK:&U5[G>C?58VUF?N_29&5^M>KZ-
MU-5&G^T<S_RKRO\ .Q?_ 'L56JWJE=C7OHZC:UIDUO/3PUVENCO3LK?_ (:O
MZ#_^TM'_ '8^T)3LI*E7GY3[&L=TW)K:X@&QSL?:T'\YVS+>_;_48KJ2E)))
M)*4DDDDI29V[:=L;HTGB53S.L=,P;/2R\AE5GIFX,,[BQI:QSFM;.[WO^BKC
M7-<T.:0YIU!&H(*2G@#C]>OP<)AQ^L-R&LNKZJ&9+JWNS34QM&1C6OROL_V'
M[1ZMC/0_R=_-^IC_ .#KF_$^M)OZDWJ-N7.RA[LC$^T%AV'!_5L&C&RJ/4JS
MO3S_ +2[$Q\3-POTGK7OJRJEWJ22GG/JY1];Z+<6OJME;\.OI^.V[>=]WVL>
MIZ\W->[U+/YOU[7[ZK?T?H^_U['XE&!]>Z\*BAMEQO;1CV5WW6E\76Y>'?EX
MV:T6;[FX3*<S](W^=Z9D?9/^,[/)ZE3C/<Q]5[RQNXFJBVP$;;K8:^JM[7OV
MXSV[&_X6S'J_G,FC>>B]M['/:U[0U[F$6,<PRQQK+FML#=U;MOZ.SZ%C/>DI
MJ="9=7T?$KO9?7<RIK;6Y5GK7!XTL];)^C>[?_A6>Q_^#KK_ )M7TDDE/__0
M]55,=(Z:,C[3Z -L6 DDD'U7&RW=6X^F]VY]FUSF_HO5MKJ_1VV*XDDIS^@M
M:SI&,Q@#6M:0UH$  .< UH"T%0Z'_P E4?!W_5.5])2DDEA?7G(R,7ZI=3R,
M:U]%]=.ZNVIQ8]IW-U8]FUS4E.AFXN,^ZA[Z6/<ZT!SBT$D!C_I&%;8QE; R
MMH8QN@:T0!\ %\UGZU_6@Q/6,XP9$Y-VA_[<7<?XH^N=:ZA]9<BC/ZAE9=+<
M.QXKONLL:'"S':'[+7N;NVN<DI]>22224I))9?7NIWX%6-]G(]6Z]C2#1D9$
MUM_2Y3:V8%=SVY'V=ECJ/4]B2DN=T/IO4+QDY5;G7-K-3;&665D-)W^ST7U[
M'[OHVM_2(6+BXN/UW(^STLI-F+27EC0TN(?D!N_;]/:H]4^LN!TS+&%:RRS(
M-0N:Q@: =SC552U]]E+/7N].][&;OYK'NLM]-2Q,K'R>MWFA^\-Q*"[0B-S\
MAS/I )*=14K.DXMECK'/R YYW$-R<AK9/[M;+FL9_8:KJ22FC^QL/]_)_P#8
MO)_]Z$.WI%#6@U?:+'$P0<S); \9]9RTDTA)35Z:][L6H^D:ZC6UU9?8;7D.
M&[](^S<_=_URQ6U6Z;IT[%_XFO\ ZEJLI*?_T?0Z<K,?UW(H)L^QLJ:UK#CN
M:P6"+'VMSW/V7^HRYC/397_@OWZ[?4TE@8^7?;]:[\9QN=7CL+@+!7Z#=S:M
MC<1[<7[0^_Z;LIMN97Z/K5_TEEGZ"[E]1S<?J;,:O%.10_'?;-1_2FQA&VK]
M-Z.)56YG^%MR_P"=_1^FS^<24SZ'_P E4?!W_5.1\RV^BE]U36.%;'/<'DB=
MHW #:'*OT$EW2,9Q:6%S22QT2TDN.QVPN9N9]'V/61=]<,;+PK&TX&61?6X5
MN/V< [@6M=KE[FI*>CJ]>#ZP:#.FPDZ?VEA?XP?_ !&=6_XC_OS5)OUPQ396
MQV#E,%ME=6\^@0#:]F.QSMF4]^S?:W?L8H_XP?\ Q&=6_P"(_P"_-24_.R[[
M_$M_XJ\G_P (V?\ GW&7 KOO\2W_ (J\G_PC9_Y]QDE/MB2222E+ ^MF=9B5
M8H%UU5=]CJK&4,H>; YCFLJM^VMLKQJ/4VONR]GHTU_SW\]ZE>^N;^NU>!9B
M8C<VQC:_M#-];W5,::B^ME]UCLBC)_0XS7-LM9^BIM_FLGU*_P!#8E.[?@X6
M2/UG'JNECJCZC&O_ $;]IMJ]X_FK/3KWL_X-5V?\N7?^%:O_ #Y>JO6^OY'3
M+V4TX5F0'T67'(BP4L<QU;&5VVT49/TVOMM?^YZ7\W9ZJGA9%M_6\DV8UN-M
MQJ0WU=GO!?>[=7Z-EKO;]%WK-IL24ZR2222E+YP^O  ^M_5X_P"Y5GY5]'KY
MQ^O'_BOZO_X:L_*DIPU]5+Y57U4DI__2[6BGIS/K?=?4ZZ[-MJ++Y;3Z5(:*
M75TM>:V96ZYKO6VT76[_ /L
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                      #_X4>L:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U
M33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@]
M(F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 W+C(M
M8S P," W.2XQ8C8U83<Y+" R,#(R+S V+S$S+3$W.C0V.C$T(" @(" @(" B
M/@H@(" \<F1F.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y
M.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@H@(" @(" \<F1F.D1E<V-R:7!T
M:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7 ](FAT=' Z
M+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B"B @(" @(" @(" @('AM;&YS.F1C
M/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(*(" @(" @(" @
M(" @>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M
M;2\B"B @(" @(" @(" @('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B"B @(" @(" @(" @
M('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y
M<&4O4F5S;W5R8V52968C(@H@(" @(" @(" @("!X;6QN<SIP:&]T;W-H;W ]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO<&AO=&]S:&]P+S$N,"\B"B @(" @(" @
M(" @('AM;&YS.G1I9F8](FAT=' Z+R]N<RYA9&]B92YC;VTO=&EF9B\Q+C O
M(@H@(" @(" @(" @("!X;6QN<SIE>&EF/2)H='1P.B\O;G,N861O8F4N8V]M
M+V5X:68O,2XP+R(^"B @(" @(" @(#QX;7 Z0W)E871E1&%T93XR,#(S+3 W
M+3(X5#$T.C$P.C$T/"]X;7 Z0W)E871E1&%T93X*(" @(" @(" @/'AM<#I-
M;V1I9GE$871E/C(P,C,M,#<M,CE4,#(Z,30Z,3,K,#4Z,S \+WAM<#I-;V1I
M9GE$871E/@H@(" @(" @(" \>&UP.DUE=&%D871A1&%T93XR,#(S+3 W+3(Y
M5# R.C$T.C$S*S U.C,P/"]X;7 Z365T861A=&%$871E/@H@(" @(" @(" \
M>&UP.D-R96%T;W)4;V]L/D%D;V)E(%!H;W1O<VAO<" R,RXU("A7:6YD;W=S
M*3PO>&UP.D-R96%T;W)4;V]L/@H@(" @(" @(" \9&,Z=&ET;&4^"B @(" @
M(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI('AM;#IL
M86YG/2)X+61E9F%U;'0B/F9I9W5R92 Q-RTP,CPO<F1F.FQI/@H@(" @(" @
M(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO9&,Z=&ET;&4^"B @(" @(" @
M(#QD8SID97-C<FEP=&EO;CX*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M9&5F875L="(^9FEG=7)E
M(#$W+3 R/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @
M(" @/"]D8SID97-C<FEP=&EO;CX*(" @(" @(" @/&1C.F9O<FUA=#YI;6%G
M92]E<'-F/"]D8SIF;W)M870^"B @(" @(" @(#QX;7!-33I);G-T86YC94E$
M/GAM<"YI:60Z,3DV-V9E-S$M93=F9"UD831A+6(W86,M9C4S,3%F-3)F9F$P
M/"]X;7!-33I);G-T86YC94E$/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)
M1#YA9&]B93ID;V-I9#IP:&]T;W-H;W Z-3%A93!D8C8M-F4V-BTU9#1A+6$W
M,6$M9CAA9F$S9&(Q9CEA/"]X;7!-33I$;V-U;65N=$E$/@H@(" @(" @(" \
M>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/G5U:60Z9F%F-6)D9#4M8F$S9"TQ
M,61A+6%D,S$M9#,S9#<U,3@R9C%B/"]X;7!-33I/<FEG:6YA;$1O8W5M96YT
M240^"B @(" @(" @(#QX;7!-33I(:7-T;W)Y/@H@(" @(" @(" @(" \<F1F
M.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V
M960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN
M<W1A;F-E240^>&UP+FEI9#IE8F0T-#5D92UB9CDV+3(U-#,M8C,W.2TY9F%A
M,&5B-#=F-C \+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IW:&5N/C(P,C,M,#<M,CE4,#(Z,3,Z-3DK,#4Z,S \+W-T179T
M.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT
M/D%D;V)E(%!H;W1O<VAO<" R,RXU("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A
M<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO
M<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F-O;G9E<G1E9#PO<W1%
M=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R
M<SYF<F]M(&EM86=E+W1I9F8@=&\@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H
M;W1O<VAO<#PO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F1E
M<FEV960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.G!A<F%M971E<G,^8V]N=F5R=&5D(&9R;VT@:6UA9V4O=&EF9B!T;R!A<'!L
M:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P/"]S=$5V=#IP87)A;65T97)S
M/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HT,3,U-&$T
M8BTY-#%D+3$X-#,M.&(Q-2UA864U-SDR,C@P-F8\+W-T179T.FEN<W1A;F-E
M240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C,M,#<M,CE4
M,#(Z,3,Z-3DK,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<" R,RXU("A7
M:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @
M(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @
M(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z865F,#8Q-S$M.&,X8RUA,30Q
M+6$R-6,M838Q-3<Q.6-C8C4Q/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(S+3 W+3(Y5# R.C$T.C$S*S U
M.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F
M='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @,C,N-2 H5VEN9&]W<RD\+W-T
M179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC
M:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYC;VYV
M97)T960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.G!A<F%M971E<G,^9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S
M:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.F%C=&EO;CYD97)I=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IP87)A;65T97)S/F-O;G9E<G1E9"!F<F]M(&%P<&QI8V%T
M:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO<W1%=G0Z
M<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I
M;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI
M:60Z,3DV-V9E-S$M93=F9"UD831A+6(W86,M9C4S,3%F-3)F9F$P/"]S=$5V
M=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR
M,#(S+3 W+3(Y5# R.C$T.C$S*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H
M;W @,C,N-2 H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^
M"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI3
M97$^"B @(" @(" @(#PO>&UP34TZ2&ES=&]R>3X*(" @(" @(" @/'AM<$U-
M.D1E<FEV961&<F]M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @/'-T4F5F.FEN<W1A;F-E240^>&UP+FEI9#IA968P-C$W,2TX8SAC
M+6$Q-#$M83(U8RUA-C$U-S$Y8V-B-3$\+W-T4F5F.FEN<W1A;F-E240^"B @
M(" @(" @(" @(#QS=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z-#$S-31A-&(M
M.30Q9"TQ.#0S+3AB,34M86%E-3<Y,C(X,#9F/"]S=%)E9CID;V-U;65N=$E$
M/@H@(" @(" @(" @(" \<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/G5U:60Z
M9F%F-6)D9#4M8F$S9"TQ,61A+6%D,S$M9#,S9#<U,3@R9C%B/"]S=%)E9CIO
M<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#PO>&UP34TZ1&5R:79E9$9R
M;VT^"B @(" @(" @(#QP:&]T;W-H;W Z0V]L;W)-;V1E/C$\+W!H;W1O<VAO
M<#I#;VQO<DUO9&4^"B @(" @(" @(#QP:&]T;W-H;W Z1&%T94-R96%T960^
M,C R,RTP-RTR.%0Q-#HQ,#HQ-#PO<&AO=&]S:&]P.D1A=&5#<F5A=&5D/@H@
M(" @(" @(" \=&EF9CI);6%G95=I9'1H/C@T-3PO=&EF9CI);6%G95=I9'1H
M/@H@(" @(" @(" \=&EF9CI);6%G94QE;F=T:#XT.3(\+W1I9F8Z26UA9V5,
M96YG=&@^"B @(" @(" @(#QT:69F.D)I='-097)386UP;&4^"B @(" @(" @
M(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI/C@\+W)D9CIL
M:3X*(" @(" @(" @(" @(" @/')D9CIL:3XX/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D^.#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F
M.FQI/C@\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @
M(" \+W1I9F8Z0FET<U!E<E-A;7!L93X*(" @(" @(" @/'1I9F8Z0V]M<')E
M<W-I;VX^-3PO=&EF9CI#;VUP<F5S<VEO;CX*(" @(" @(" @/'1I9F8Z4&AO
M=&]M971R:6-);G1E<G!R971A=&EO;CXR/"]T:69F.E!H;W1O;65T<FEC26YT
M97)P<F5T871I;VX^"B @(" @(" @(#QT:69F.D]R:65N=&%T:6]N/C$\+W1I
M9F8Z3W)I96YT871I;VX^"B @(" @(" @(#QT:69F.E-A;7!L97-097)0:7AE
M;#XT/"]T:69F.E-A;7!L97-097)0:7AE;#X*(" @(" @(" @/'1I9F8Z4&QA
M;F%R0V]N9FEG=7)A=&EO;CXQ/"]T:69F.E!L86YA<D-O;F9I9W5R871I;VX^
M"B @(" @(" @(#QT:69F.EA297-O;'5T:6]N/C,P,# P,# O,3 P,# \+W1I
M9F8Z6%)E<V]L=71I;VX^"B @(" @(" @(#QT:69F.EE297-O;'5T:6]N/C,P
M,# P,# O,3 P,# \+W1I9F8Z65)E<V]L=71I;VX^"B @(" @(" @(#QT:69F
M.E)E<V]L=71I;VY5;FET/C(\+W1I9F8Z4F5S;VQU=&EO;E5N:70^"B @(" @
M(" @(#QE>&EF.D-O;&]R4W!A8V4^-C4U,S4\+V5X:68Z0V]L;W)3<&%C93X*
M(" @(" @(" @/&5X:68Z4&EX96Q81&EM96YS:6]N/C<Y,CPO97AI9CI0:7AE
M;%A$:6UE;G-I;VX^"B @(" @(" @(#QE>&EF.E!I>&5L641I;65N<VEO;CXT
M,3,\+V5X:68Z4&EX96Q91&EM96YS:6]N/@H@(" @(" @(" \97AI9CI$871E
M5&EM94]R:6=I;F%L/C(P,C,M,#<M,CA4,30Z,3 Z,30\+V5X:68Z1&%T951I
M;65/<FEG:6YA;#X*(" @(" @(" @/&5X:68Z4W5B4V5C5&EM94]R:6=I;F%L
M/C P/"]E>&EF.E-U8E-E8U1I;65/<FEG:6YA;#X*(" @(" @(" @/&5X:68Z
M4W5B4V5C5&EM941I9VET:7IE9#XP,#PO97AI9CI3=6)396-4:6UE1&EG:71I
M>F5D/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\
M+W@Z>&UP;65T83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M/#]X<&%C:V5T(&5N9#TB=R(_/O_; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
M  L( (0 _0$!$0#_Q  >  $  04! 0$!            " 8'"0H+! 4# O_$
M %,0  $$ @(!  4%"0H(#@,   4#! 8' 0( " D1$A,4>!46-W:V&"$Q.#E7
MF+6X%S-8=Y>AM[G5V H906&5EK36&B(F15%55EEQ=)'!U_"DT_'_V@ ( 0$
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M@NF^FVVN^F\M :[:;:Y]&VNVN2&,Z[:Y^]MC.,9QG[V<8Y'5W9M;?=91]?\
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MEHTZ>=R"+31^*)(.6+S5J09M'S?5P@IA%XU;.D\:KH);ZZ\?W,G6W^#Y1_\
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M-8 &22>8!9+%4'01)P..")',#CX-(G[LM)@3-0;'PAH=& ((*-FCQR$_C_\
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M;&@FLJ@AN/21H/*-]=47R#(JWU<)ZZZJ>MC&/1KV_)TN_/\ =O\ ]-CMY_\
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MPU]W1*R7NZ_>A/7&RHU5MS0 5"3<N$R X"D;OJW-7]8.!T1ADIL26JKVZ'K
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%F!Y__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>48
<FILENAME>g459793g68b22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g459793g68b22.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[2&^4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (:*^AA X0DE-! 0      $D< 5H  QLE1QP"   "   < G@ #&9I9W5R
M92 Q."TP,AP"!0 ,9FEG=7)E(#$X+3 R' (W  @R,#(S,#<R.!P"/  &,30Q
M,C$V #A"24T$)0      $!NV?T-PKQ \4_[%K>RHH \X0DE-!#H      .4
M   0     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $
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M=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M    $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO
M;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG
M:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0
M$ "4S,P  0 ! )3,S  !  $X0DE-!"8       X             /X   #A"
M24T$#0      !    !XX0DE-!!D       0    >.$))30/S       )
M       ! #A"24TG$       "@ !          $X0DE- _0      !( -0
M  $ +0    8       $X0DE- _<      !P  /______________________
M______\#Z   .$))300(       0     0   D    )      #A"24T$1
M    $     (   )    "0      X0DE-!!X       0     .$))300:
M  -!    !@             "Q0  !T<    & &< -@ X &( ,@ R     0
M                       !              ='   "Q0
M       !                         !     !        ;G5L;     (
M   &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M        3&5F=&QO;F<          $)T;VUL;VYG   "Q0    !29VAT;&]N
M9P  !T<    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M$@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R
M:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
M5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,
M   !        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M          !"=&]M;&]N9P   L4     4F=H=&QO;F<   ='     W5R;%1%
M6%0    !        ;G5L;%1%6%0    !        37-G951%6%0    !
M   &86QT5&%G5$585     $       YC96QL5&5X=$ES2%1-3&)O;VP!
M"&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M    #T53;&EC
M94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N=6T    /15-L
M:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M
M$453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M       *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M        "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M        .$))3001       ! 0 X0DE-!!0       0    #.$))300,
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M/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M'AX@.QPS4!OTVI*<#K'_ "SG?\:S_P \8RL_5?\ Y8L_\*\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_   L( .,"5 $!$0#_Q  ?  $
M P$  P # 0          " D*!P4&"P(#! '_Q !;$   !@,  0 $"@,*" D)
M"0 " P0%!@<  0@)$1(3% H5&#@Y=WAYM[@6%R$9(B,Q.EA9EYC5)#)7=8&U
MU_ :-T%A=I:AL=8E0D=6:+;!T?$G16-QD97'V.'_V@ ( 0$  #\ W\8QC&,8
MQF5;R1?">8QXZ>_9OQC(>.I39L1JMNJ5\LRZ&2UT[,HC\?LUCAK\K>D<"W7+
MV6L2QXF<L;85IPF3/IZ?#0-P#$&U2,TZ]GM;N"JN*^)[;[@E.]3&NZXKA%.X
M^W,KB2C'8:^4&-;97,<978U.L)2;G$BD$>:4KL-$L);D[IMT.2*$Z4TL5;7A
MI\Y;=Y6U'3S7,><%7)[WS(JKHI_22>U$DU1N15@&RU(66M6K(/7PHZXM*^*&
M)E")4F6:4;7D:">2<4,@5\2YZ9FQL$].3LV-[.$L@X3LN7I4C8$I4(L"8T2\
M\TM+HM0,XH! ]F^J:(TL)>Q;&'6_7YE8U>URT$2"PIY#((PJE!*1,]S*4,D7
M:%*M0'8DZ4AR>UR%&<H/#K8B22SA&&AUO8 BUE>/E\[5L#AWQE=']F\_A@,K
MG591^M7>!F2U*LE$!="YS;M=P,Y>K3QU^8E+LC"QR]<O;1H'U*28L+1'C-4)
M0F$'=HX%Z7?^D.!.6>K;B-A\4DMO<]UW;%A'M.S8]"&5VDD81.[X<@^/75Q-
M:&,A2<<,@+D\K!)$_JA.6G>ILS<HX195<V:@4.M;S^$V"UHS_=5;E")4Q2Q
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MF4*Y!OW1>A5)UB72[>QB$'A7CZ\@'PEOR*<ER7LWG"0>.N61R)3B80DNEIQ
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M3^UQ---X@HE+XRCDK+&B)*S&O[O'"C-E&/[6S%K1.+@REFA$6-U2)CD(#-;
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M?C_CGOCHOR&U<KL);;W10I\:NBLC<(N?75<'VC,$$XGI]=-+3%&AW;#'MY0
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MH/M/5++#[46Q&^J .O:BWK0=B,]&OWXMAUH.]B].]ZUK6_V:S\@  6$("PA
M &M!"  =!"$.OV:"$(=:UK6M?LUK6M:UE0DA^GOJ7[HJ_P#\X_-^6^XQC&,8
MQC&,8QC&,8QE6=X>3MRI5P<D!/CO\DUMZ;K1LVLM+:<YR;Y>A7E5L7$!EV&W
MG&SQKV?6\_W+!@KN1; 6;(1QF4Z,0(=-@-J)=<J=%J.HZG)M-30_0/.9IT@>
M6#=;],0$BMK.*"S[3:T]'1I.]/Y8&)U]Y]+2N^,-B5Z(4;V25[/7K22_C_CS
M]6DY&B@DZ)*T2'U=A*T6#V0=A%H0=A+]7U->J+6A!]&M>@6M;UZ-_MS]N5!^
M.;YY_FH^W-5/Y(>9LM\QC&,8QC&,8QC&,8QC&4; _E))_P!RL1^=HW+R<]=E
M\J8X)$I1-Y,K&@C<-CKW*I"N+3*5AB-CCS8I=W96!(C*/5JAIT"-0<%,E(.4
MG[!HH@HPT00;I-;OA'/BN=V]"[--C= .;6YHTSBVN3=Q?URM;W!O6D@4HUR%
M8FI@U.K1JTYI:A,I3F&$GDF -*&,L81;_L_X13XOO_7CHS^Q+V!_L5R--0>>
M+QU1*\^M9L^2CH9+';6GM7/L)6%\9]9J37-MC-&P"$O!QZ1/39BIN&GD3"YH
MP$KRDYJ@HD"L@!B8XHT<EO\ A%/B^_\ 7CHS^Q+V!_L5SH5.^=SQP7I<E7T+
M!+&MPFR[EE 89735->8.CZZ;)!)1-ZUTTV DLZJ^/QU(=[@W+%.Q+7-.7HLD
M6]BUO>M;N&QC&,8QC&,8QC&,J"D/T]]2_=%7_P#G'YORWW&,B[*NJ62)R-ZC
M1]*=1OAS(XJ6XUWBO/=A2*..(TP]@$K97UN;34+JW';UZR9<D,&0>#>AEBV'
M?ISG#7W]6KW)I5#FJFNM5TGA &$R6,I',EH[6L0).C4.# )<#;.$ -.J)(H4
MI?4&/UBR1[%ZN]:UONU67PV6L\.#,AK.](08W-FW,;A:=0R^O&=6#2I.E]S;
MW21(DR5:Y[$IT?I 0,2C:4I0HT'V9 ]Z[GC&,8QC&,8QC&9(/*O(;)Z3[/K>
M.W-XW_)-;7)E'-%W0 R)U-<,3I"$VS9;M)(.*OKZACE%+RALBF[<ECK%+8^F
MCTK''CV]'*$#RA'[<+LT.-WOBK@$'K;E%%&J^Y;Z(X_CH; F2X%.]/SI=8=H
MD+%8FW:F2FR-PL&S% V!]]F6)G1?I.,M+I*I]1 D]IOVED6,94'XYOGG^:C[
M<U4_DAYFRWS&,8QC&,8QC&,8QC&,91L#^4DG_<K$?G:-R\G. ]7_ #6NE/J!
MN/\ #N1YA<Y!^:9R]]G:D_PUC.2)QC.;QSZ1SQ)?;4#^$-BYO@QC&,8QC&,8
MQC&,J"D/T]]2_=%7_P#G'YORWW&,9"VE/GD=O_YOY?\ P^E>32QC&,8QC&,8
MQC&8K>UN:HE7_77;EB]=\#\P>3$I]L(=SQJZ[.\F=<<Z2?FSG^1-<7CT#J"=
M5);$C: UQ%H.]!/11Z7QP&VR6&29 (H9CP>%+E_?A?JB;U#P/7;++YA")&TR
MB86=8E61BM+@4]!5[3--SF;NSY6]&0V\%:M:;:#'6#">4PD2<I2:A]L$]I:C
M3VMK1*#;5\8RH3QS?/.\U'VYZJ_)#S-_R_[^C_3EO>,_E7*1HT2Q84C5.)B1
M*H4EMZ'2?:U<,@D9H$:/2M0D2[5*1 T2GTI5)D^SA@]LH)+]8P,+?E?V)_,"
M[<__ &WEK_\ M-GI\%[]=[*839/".&NV'UB(DDUB!J\IDYH2 !(J[F;_ %],
MFWV+ATZD4[&R3",/K,:?HG:54:@&J0'JD)R=4=+>HK*>K0CZ]\?:=M6E52)W
M-:RHU;I%?D2!Q(+1HE87M "NK!L9GVT'&*S$)0E;PD<??$*W1C:6FTF4JNJX
MQC&,8QC&,9R&_+YJ7F"G+"OZ]9FWU]4M6QX^3S>7.9*U4G:FLDTE*4$E V)E
MKHZ.3BO5(VMG9VI$M=7AV6HFQM1JERL@@R #1YHN%'&E+2NURDUL0Y)3\_KN
MK)A5LYHFU8I?)EAW$E1+Z?B4;IMTC)4UE3K:3:X)G2%@86Y<2O;/>EZLY"F;
MW Q+,3E#KFD>T:P66M1;V^.#(QS24UI,X_+XE(X#/:[LN#JRD4PKRP(/+6]K
MD,5ET<4GIPN+4X(P[T4J2JDQJE(I(/,K/!_*23_N5B/SM&Y>3G >K_FM=*?4
M#<?X=R/,+G(/S3.7OL[4G^&L9R1.,9S>.?2.>)+[:@?PAL7-\&,8QC&,8QC(
M9=U]V4%X^:"FM\7M+F!K(CL5EC_#X"JE<8CDTMQZB;,-Y40:M4<F=&LB0RY>
M1HHI&V)31F;,4$;,T$ ];WTWF;IZDNNJG8+CH>Q(98L2=DS:4Z*(9+(_+RXI
M)EC S2%PA,C6QMP<D*"5L"-];@O+28HTI2#4$C&7HLXH0_8K\OBJN8:;L2_[
MPEB:#U15<<52J;RE4C<7$+6T)1E$:V0VM"1>[.B]:L4)6]L:VQ$K<7)Q5I4*
M),<I4%%B@+#_ #1\!S#F>Y^J]6+-XK7_ #[+HY +9BLYJ*R(G<,8G4V-:"8!
M$M5*Z1TN:N[S/Q/[/N(%,K8X)W4M689M20!N=MH)6<>=H4)W352ZW>?G]^<V
M%BF<@KB9,$RA\DKZ>U_8<4]S%(81.83+6]L?H[(FLEQ;E1R14EV4:D7I%*90
M>2<$>0ND/T]]2_=%7_\ G'YORWW&,9"VE/GD=O\ ^;^7_P /I7DTL8QC&,8Q
MC&,8QF"KO/F[FFNNR.G>@UO=7ABD4@J[IRPNN$M4]3,*N9="S*>GL#5')AR;
MT'N+2!WD;U3=?(VAX?ZJ@T7A<EE!5DML/)#%@GISMCTD^"F)0",^/^-.]>6_
M0]NM]I6M;]V/>^7TJ]HY]JV1W!+E$^74M5,5>2TTAA4:KA&^-S4*(R1O:']H
M=C7/3FS-1QWN)$R^S>Z.>N#(#%[ O]YEA),]F:2O*\A]>0*66?8L_FBMK='W
MXAB4(A36[/;F>E8V5U=UZH1"=N0HT0MJEA9YZ,E1&2R_-5X^JRY\Y\Z64V?+
MIM7?4B:6KZ2;JQJ>QY[8$L:ZY I':#J=7S%'#I0P-M7:1+03]5($#:"/'I#T
MQVC%(=%"L7J*V:\OBKJ_NBI9.AFE96E$6*=025MH5)2-^B\D;R'1H<2R%I"9
M<D&>D4%[/0KTJ5>A4:-1KDJ960<2761XYOGG^:C[<U4_DAYFRWS&,9"[@3YO
MCM]IWN;\[G0N31QC&,8QC&,8QE1_G1Y>N3L/Q=],4=0#4JD5N.B>MIG$(JA6
M-R%?+5%86Q"+&<8TVJ'<0&O;RZL\8<"F%,X# D7/H6U$H&$I0/>J!]4+Y'9>
MV+;O;ZD\@]K<N<L^2;Q]]>TM0W:[X@FG=$PC]4Q&5-/51$21OLA.<GAH;9%*
MV=VKB,.STF0K"V=RW$4Y -*$IMFW$O"%YWU1G<4ILB==D>.M3V!Y,+=Z_K9N
MJ*8QVH>CF*IET;8H3%FBQB5#18#?&#9V-K62>4PPPDYP)4M\=4&. = WH_G'
M'O+;KR;\('DL!=NG>HNJU#[XAC):"=]86(T65/60E5V"U-&HHQO3-%(@F1Q-
M*-G&[)6PQO/.+=G=X5;6# J 23IYS@/5_P UKI3Z@;C_  [D>87.0?FF<O?9
MVI/\-8SDB<8SF\<^D<\27VU _A#8N;X,8QC&,8QC&4K]_ H_NGI)M\1-@<VB
MM,F?\OV)<UL]&BU7 '7CZ!3(N3UK Y?5NYY%I4K5VQ-I\Q!8FX4<3HE4<:RO
MTF6?&B%"I2IO>_&A:E816<]0^/N-<FM_(<SXVD$*/VQL95?#8K^J&?M[M'ZA
MZ< X5O'XTR'RNS&&M3=SYJ6H53S&W]"!E<'9<:F$2AFWU]+;B@?-EM3*@J-8
M^E+:C4<+=XE1<A?TT9;[),1NC>:[L)3LM0.2,#M\0Z=%S A5)@D.[XC;F@Q6
M@TN]^3Y!&WDGNB?TMV->L6Y#ZD-A[7Y*^$.[ZWJCK#<//[TZ"*I 20GH>'/1
MZ%S+;GJ(Q5(!H#0<>>CB#"V-I<V1B"K5&D),MFX.XZOCH6GO(W8%H+NN?'.H
M[N[M=N@JQ:X+*(W5G4E>UK&HW7<<:E<A,"@G;3#7BQ5L2=B91'CTJ]6:Q;!Z
MJO92]*O-\'RSR.[\C^<>+1IWZQZUZQ-EOBHO)\)D?6UFLUFR2)EH^M^;D F2
M)+V6'P\IL8U@M>_K$9R588:OWLX*@ ?X/-(>,8R%U*?/([?_ &?_ '?S!_I_
M^SZ5Y-'&,8QC&,8QC&,9D*[[Y6\=?:LJM6VJ34H>2.O;2['L[Q4OLQF?/,2M
M>J>B.@5<-<U;FHGM?D%2'3*XB9A.KI!.E(^Y5]94:?T1:I]/=T^DK.JTN\<\
MW1?DGF6E.?XPQPEG'6]:P:,2E; 8LW1%CETW88DR,4JG)K8WI4FSG.6.C6:[
M+W)Q"<[KAG!,<E1ZC0A[B]Y2K!O2 4O&-5+S1>70T1F4@?8+<KOR;)VICZ\H
M^'R:'O3>V6MSJ@>4GNKK+V]_,2-*Y2E=6YS8&YRVZ)2E*<"Q2VYS*;YU[VXY
MJ;Q8]&2K@RU[;2T70GD"YL?.=:888B\WQ7D>Z"D@W[G^=6G%R'E PJYG+T24
M8;RD+":(UN6.RYXD"/4B<%3*=;9RGXHKD5^,WQX\[V3U]V?QI://%0O1%@M'
M(ER1F '/DALIS;Y8HB5BKUT-G2&2F58,L<>CAK0>G0H#UTEV0J<TJY*<3YWP
MPT^LH.[/+E4;A;EO7NLAO;=>)#K8OJ4(IG;<PVX\>\]/054RD[<S1]$ZJF\#
MF!F;C"&=%HAE;6U((!@R!'&WQXQC(7<"?-\=OM.]S?G<Z%R:.,8QC&,8QC*.
M//3USV[R%Q98%@\?U6:I,1MT-423HY%8E>MSI2"Y9<U91Q @15'-XG)S;*U/
MVY[<XLH5H %%14AS,>CP;&D*-+M9YYG%TV)5S/*>@*,3\YV:L7/)#O526T8Y
M<1+,B1.:A,SKPSR*MC0S..WIM+3N8DI"$LUMVHVA4",.)&/?;L8RC8'\I)/^
MY6(_.T;EY.<!ZO\ FM=*?4#<?X=R/,+G(/S3.7OL[4G^&L9R1.,9S>.?2.>)
M+[:@?PAL7-\&,8QC&,8QC,Y7E8EE3TYULEZ$J+NMWXP[7J;C-Z?K4"?SLZ=+
MU38O(1-L$-T58;)A"4MK CFJNZ7TUNIHY@EB*;/3PJ>V1$SN#8I.,*]C\'<L
MA-F3/L"UK,M#I&QO(--U-/&=-(^H^;P<F2Z&56V-DP3<^L=8T>B=)(SQ^G3D
MXYVL:'1#+9 Z/T@&\N,G$@=#2R!Z$L8RH*0_3WU+]T5?_P"<?F_+?<8QD+J4
M^>1V_P#YNY@_#Z5Y-'&,8QC&,8QC&,9B\\F/*E <G=%URLF7EQMNDW'H/R=Q
MOJ*&49%F3E,SY-]UW:EFS2DZ@DX;,-32TNH8:ULSG&W>0/0G2.%C4IMB9#UN
MS#2M27%,.E<.H&,AE77K]W)N4*EDTC?0S\TUHT[E$1D9214P)&;52MK7"G*/
MHDP!G-3N@(--7DK!&&JCPZ*WJ6.,94'XYOGG>:C[<U4__G\R'F;_ 'U_IRWS
M&,9"[@3YOCM]IWN;\[G0N31QC&,8QC&,9F@\W'D1BL+GU*<=,%X=?T.F%=43
M7]@3KE*B+3>;49Z$>ZQES^PF5;:Z.MY1"DQAD^.@)<UU&5;C-FYE-6 :FU8H
M1N32I[=X*K^EMQMO:,4(O'J'H/G^IKQAC-S78W:$3D#!T<YPR15BS.\P!*WE
M_B,.62J,)[!)D"6#KW1M+DZ=J3G@?DJ H]I(W?CC&4; _E))_P!RL1^=HW+R
M<X#U?\UKI3Z@;C_#N1YA<Y!^:9R]]G:D_P -8SDB<8SF\<^D<\27VU _A#8N
M;X,8QC&,8QC&4(>:[QS[Z0@3Q?=1L?5KS=PH?#Z:L6'\FV?5$$D]JT8RS\RQ
M6\EZC]U,CI"9F^5-,QFSBO26YTB$U1O:E1M@DI2C2<D/(?#[TWXZDMS6M R^
MM^DYYY([6%$(3<\.\C!A,'ZF3D5.WOQT7J6*1<F/QNO!L$3U(95("6"LE\H4
MKUCV[2)T<%^SRSB=)N,94%(?I[ZE^Z*O_P#./S?EON?SK%B1O2*EZ]4F0H$*
M8]8M6K#RDR1&D3%".4JE2DX0"4Z9.2 9IYYHP%%% $88(( [WJ/7RQ.1_P"=
M-SE_7?6?_B?'RQ.1_P"=-SE_7?6?_B?(?4YU;RXCZY[.=E?2=!)6MX0<V!:7
M)3<5=D-[H)N@<H(< MRPV1 3KMH#C2B5NDQANTII@"S_ &8QA#N8/RQ.1_YT
MW.7]=]9_^)\\U'>H.:)>]MD9B?1%&2B2/2H")GC\=MN O;V[+3-"V6D;&EMD
M"E>O5#T$6P)TJ<TT6@BV$&]:WG<\8QC&,8QC&,9G2O"J.</+K?/12I7Q"W35
M9XP>AH$EB5UNA-')G#LN]Z1BDQDTTXMDZJ=PQ^?FR@4#I.XBUR17(''<7?7Q
M]4+2DS:1'C#'BSOQL=,5MU/R=#)G6E*G<TIH"_3.BICS:<VL;5N@K$I>2+H+
M,*K3I8PA;(WMKCB]K )C4,;<WH5+$K;3MMK4J&I;$<\L8RH/QS?//\U'VYJI
M_)#S-EOF>'?I"P19L4/<G?&>.,R01(53N_.:)H;$PE)Q:9.%0O<#TZ0D1Z@T
MH@G1AH=FG&%E T(8PAWS_P#7U1G^6BI_ZQ8?_?&/U]49_EHJ?^L6'_WQD..$
M+LIENH)U3.%N5BA4"Z6[;5:(63V*ICMI5_:-_KD*G11[L >TZU"I3K$AV@^S
M4I3R5!(ADF@&*8_Z^J,_RT5/_6+#_P"^,]CC5E5S-%A[=#I_"98X)DHEJE!&
MI4Q/JQ.C :40)6>E:UZH\I*$\\@D2@P 2M&G%%['H9@-"]UQC&,8QC&4C]KM
M/F=,[0JR,\AWE44%Y%MV/O:!SE;WS&AN!\H.P8A&BG,L%D"46)#UKE![.4)U
MY$<E3.-0;'I()+''AA @4I7\R>7'U==KUXQS5+VCTG5G2#^Y.S4H@SK5U$[H
MQ'&&<A&I+=V]V;MS69_'ZEP6C2J4RWWA#[D4081[$[VWK@F-C&4; _E))_W*
MQ'YVC<O)S@/5_P UKI3Z@;C_  [D>87.0?FF<O?9VI/\-8SDB<8SF\<^D<\2
M7VU _A#8N;X,8QC&,8QC&1TZEYAKSKZIEM)6L\V4UUZ]/;&ZRA!5]CRFK7>6
MMC,J$J-AS[*(6N:I**'/^]Z3R1H;'5M-=4@ IQ+"B_6T*IJD>2^(FSNN?<,0
M7C"@:OK?BF&\8]OU!-*[CSE&K44WG()G>;*D>)M.DCK\>31(QI:];]%%2)6X
MGOA;FZI)0>](C$Z9/?AC&5!2'Z>^I?NBK_\ SC\WY;[G!>J?FO\ 2'U"W!^'
MLBSYW_$_-7.DGY)YXD,DH6FI _O%4Q)P=WMZK&%NCLZ+E+:48H6N+BN9#E:U
M6>/>QG*%)QAQ@M[$,8M_MW*'Y)O+/\VVAOZHH#_<&/DF\L_S;:&_JB@/]P8^
M2;RS_-MH;^J* _W!G[JOHZEJU[F\8+]7=1UE WQ3Y :L:E#Q#8)&(RZ*&Q17
M-O*CVXYP96M$J-0G*D2-2:D,-$G,/2)C1E[,(*$'Z">,8QC&,8QC&,R&]873
M\DF^^R)EX[/(5+8,NM[J))#+RY)9N#W_ +&D*WMAYK E\GCER^%([0(*V5!K
MN&)93;S,O=Y' (R^-P!O;PVNCFDCP;I/#6W<[(.%(4HYSL>Q;<;WV?VY)KDL
M:YHRLA%U2?I.06"^.=[JK=@[@D1*H9.$L[4.#<IC B#"&EG1LR="X/2#25Z<
M;3L8RH/QS?//\U'VYJI_)#S-EOF4#?";TJ9=X=K]1+$Y*I(LM+DY*J3*"PFD
M*$RCJFGBCR#BAZ$ PHXH8RS"QZV 8!""+6];]&\X'R)>/?YL%#_U6PW^Z,?(
MEX]_FP4/_5;#?[HQ\B7CW^;!0_\ 5;#?[HQ\B7CW^;!0_P#5;#?[HR>?@_J.
MK:A\PDW::KKR&5TUNWC6GKBYM\+CC5&T;@O+ZAI%,!8L3M25*4H4@3E@("<:
M$1FB@!+T+U=:UFT7&,8QC&,9GQ\DM1=N(.QZ?L.&^4Z6\A<5VHR/D4L]E+D/
M+D(%2,YBT:)51691=1>C1I38T7L)>G,9I3&FI6JE,8D#DC?T8E<<-4H&NRCA
M6D++I^#25PGO>5D][-<_7-#Y"Y_/VNIT2*-M")(K2*D,3<*D9&=F>6QY4&@5
MJ5:L:XP!Z, $QP"]FA%-=U=&QC;')[>G!$TL[.@6.CLZN2DE$W-C8WIS%:]P
M7K% RTZ1$B2DFJ52D\P!)!!9AIHP@ (6J&X!\("Y\MOFRVNCJHIJTY^C8NXH
M]P3SO 6M6PMDNZCMJ=((JZ5TZQ,4B,9VN#1J8-4D.D!2F8*RSFR-,ZER5EB6
MJ$S2*QGA/MB.]OUM84H35U+Z9L>D[KL'G.]Z;G2Z/O$AK.XZR/0!DL>_2**.
M#G&94SFHG=I=6.3L2PQM=V]>684$HTH\DN" /Y22?]RL1^=HW+R<X#U?\UKI
M3Z@;C_#N1YA<Y!^:9R]]G:D_PUC.2)QC.;QSZ1SQ)?;4#^$-BYO@QC. 7'\J
M;XR9OD_?J ^*/<5'Z0_KCW8NG+XR]XU[K\3?H3K:7W'W7UO>/?O\(]X]'L_X
M/TY#BPKB\C-?6/0E<JV3BAQ5WS-9A"FMS3JKT)31]3$*HG5K*%R\@TL1JPA:
MA@RIH)*3B+,*5KR% Q")*, *045_= ?TFC_Z;ZX[_0WXZ;/TJ_17=U?I-^CO
MOA/QQ^C_ ,;Z^*OCKXO]X^+/C+_ ??/8^]?P'KY,3&,8QF:'X0]6/C_KJG)+
MV%T;R=8O1/0J*H9;#*=<8XHZ<4ULSK8 W/4PCJ6ZMT58T):8/ =/$B7#<9B\
MFMIYA!ZD@3R$"$C2>2W@]IC@%NI)_P"E.+>8[2YRD=KMT(@]QD6PAOYD<Y(]
MPV-()<09$6F^9?*G);7J)?8CJ",2ED,TB>]&+"AK5IB#8B[/>M>DXOR#SI:G
M1\QBLZG+%5T?*>#(76<?.E$]EKBX.C>PL<=B[(2,K2IR=WMU;T03E)Z= WDG
M'.3DI3($BD\NI)!YZX.P59TZZ7?R#T)272G,T[YWK9=R4\N$"DU@V/,.LS/9
M\^M$$EK"]BABA1+PDN"MZ)<5B-5%T#4O//3+SPD)3[#.!NYF/N>N[)?C*IG=
M!VK1EQ2RA+WHVR5; Y2NM;.B*-H=5;:)[BZYP8)&RN3(_L[JRR%J/TC<"%)H
M"RPB3#V*-TA^GOJ7[HJ__P X_-^6^YP7JGYK_2'U"W!^'LBS!7P7\S'F;ZG8
M9_JHG);8QGJK)\]#Q=?>(5-^&-T9O"QC&,8QC&,8QF4GRH\#O5&]#0GK.@W?
MR9Q:NGRV[)Z0M]RX84479::A+K?X(VUO+K68:8LEA%91B>X*^<I(19VH&]22
M.JA,VUCO!U*U4V;!9IX<[S\<,VY]/K/@CIXWH=8U2"76G<3I94B6G]+2.QK-
ME"Q^G-EW5&Y(QQ"5$ODCDR\Q,H=M1)MCH/8(6IJ%[!,G"*2?=?;+CQPP5,EA
M/.-P]5W#>UACKBK*=IXIF0+7)R0L+C)GQ]EDUE2M!$H-%65I;1>\O#TKWLY<
ML0IDZ49.URQ!72N\_P!6[]1_-T\I/DGH>[+SZ(7]$)-<LL*B#Q^Q*V3<EJU2
M'H1TF,@?'H$5.11)2G 5'?B54O/F)ZI.@1$HG72EO3W%\N]&5WUUSO3G3-3'
M.)M>7; F&?Q@MX3%(WIO1O24)JAF>TA!ZI.F>V)>%6RO*=,K5IB7- J+3*U)
M 2SS*_?'-\\[S4;_ /;FJG_LXAYF_P#GEOF4'?"9?H?[U^MGDC\UM.?[_P#;
ME+&,8R2_B$^F4D_W94__ #3TIFP'&,8QC&,9DMZKG?#<=\N_94G\F_-%H=(Q
MF+T]RO .0T;CR#:G4E3Q*-+XA*)G=AL>:H] YE"6N2N<V?&+XS>5:?X\$ L;
M<E4$ITZPG<O?!@[5<JLWR8-_+U:633O%:B^J8FG.5:SFJK"IICC;C,*,8R;K
M_5_ +$9F-PCD=<++CRY88T-2!,QHU)GM&M*E1*DY665^1_DVQ>X.39[S+7-X
M%4$=92^-HIE+5$)43Y%(J[0/"=RF%:NK$AE\%<=Q^PT"4,:DYC=)VU2JC2QW
M9Q#&E=%(=YS83X??)] X_><W7O-%V)-JI\O50^1#GRHVI@C5*Q:_TE3QYGB\
MC5-TA9YM8#;2K38,./%&X;7$F:M_H.ZPPM>O?-MTC*$VV<\B>*EOL^B^JB/)
M3345<)!V/WG9/<#G0\=M&3NK93ICVQMD,KN&N%D5PYPG4ODL<BR!>-_=&8X,
M9<5KUOV"8\2(DTN/W*G''-O$_P (/D5:<PUH15T(D?B '-GEC3R>:RH"V4+.
MQ&UC4NNU\YDDG="!&M;$U)=I$RTE"'231P$H5!R@TW3)G >K_FM=*?4#<?X=
MR/,+G(/S3.7OL[4G^&L9R1.,9S>.?2.>)+[:@?PAL7-\&,8R$/2OSG_'5]?%
MU_D[Z"R;V,8QC&4:>0?I&ZK(OZ\O'?5M"U?<5<-'C1O#I>_6FQ4\R?'VRU4N
M;;'K:B:1K>(PUU95CN?)K)C"=3.MGKBC7"*'G,S$XL\@,1F+?P\/W6?8EAR>
MW>2.XJ_I^"6K1M#\?77 D-+12:0ED8ZEZ(KI[&WUC,XM/93*I RV)4DF@3Y#
MY 2I5IP*A$A&20,H@*E19AV;*.H(=S);;[Q?6<<MWJ F/$HJ>A$PD3'%HHJD
M[LZM[4)[D+M(GJ/->VJ)MBQ?*E+4:\(#G[XF"QI5!2AP+&',Y"O'5Y%;&XXL
M9JF_(3)57<$&ZUY5[Z#<]P]>5U=SMWI?E/2US<I;%YJZUY%FUKHJ(1^(HDL8
MJ:)IDOZ$Q=$\-#(B$B)0R62++)>+/&>^672W;:KR84U#4DB[]Z]<>FYGSK$+
M1D$B9*O8V!HA;%6</7V= ET1/D4D:APWX\>G2.+2&5<8M2I]E[ !4B*YASCP
M_P M\/\ G,B$2Y;JM/5<>F_BDO212AN3RR=RP+J\H.N>;VU(M$IG<HE"Q)LI
M%K1'L$"A*F'K^$,)&;^_S17G!>J?FO\ 2'U"W!^'LBS!7P7\S'F;ZG87_JHG
M);8QGJK)\]#Q=?>(5-^&5T9O"QC&,8QC&,8QD'^O/'MSGW6[5OOII-8\\@-;
M:?SBJ10VI.(;2TZ=7LYE/2O=IP>&.[""PUT9$RZ!&$LA7J61 4Z/12EI7%N)
M@0PV\8=3\TSZ;6[T/ ^7Z8YXL#E6]NQ_'E7Q=#QS4 C3E1<!N.-*23)1&FD1
M#0]25V>(BUO1SBJ3&!:URAXVR%H2WER"IZ)Y>C?)(\T)&*T\;E8"F$NLN6#9
M+KG37;U<4[.ZYIQ,G('($U4RBQSSFQCLR=!4F,4>FY<<EP8$D3NST4Q[?#(\
MN254J^'^_*QB?!70W)'C^J2G['Y9J7K+E)_XBE76,4E*?5=7Z0UK8[=R:_TS
M&4PR>3?IX@73NR6QU]2320QV6E%+#75Q5+DMA?/_ (4>8#N!>'>3NU*X8[XE
M7)=8.S(E=FR:V9%V-KFED+6^36G\0*(=)H4M>&15(D*-&TJ7](-1IM:$B@A&
MV&K%I _6?#E155<TWOY>:/I&)EP:K8%V[7**)14IW?WTMH3.G'/.\@7E!=I0
MZO;ZL]X=W9P6;$X.BLPO:CV!0BTQ1!)=ZV4'?"9?H?[U^MGDC\UM.92QC&,D
MOXA/IE)/]V5/_P T]*9L!QC&,8QC&4&N?3#%6WG NYDZ\ZK4<^UE"^/*E-XX
MJR=V:UUC0=NH9X\R8WH2Q7+4E7-\8F-KPR6QJ.1IM3&KBGQ@BVMJDB,] J5G
MZ\YX3K(>I>Y>0:$0KH2Q.K^/ZCZP313DR_K+EI]C.S\TNM91636[ X]9AY8-
M3V"UC9;JOCT4?$IBMN]S--3-BY0@*3Z+O6QC*-@?RDD_[E8C\[1N7DYP'J_Y
MK72GU W'^'<CS"YR#\TSE[[.U)_AK&<D3C&<WCGTCGB2^VH'\(;%S?!C(N6%
MW%Q54DO>*]M;K_ERLI]'A(P/\'L+H"IX7+V,;@WI79 !XC4DEK:]-@ES6N0N
M2,*U$1M2WK$JPG0TZ@DP?IG[I3XY_P"?YQ3_ &J*+_\ '>0XZ%\A' SMT?P.
M[M?<'(#DTQ:Z[@<I,Z-_2U,+&Z.MSARA>K$@7OJU--3$S0B6O;FVLZ14X&IR
M%+JX(6\DP:M6029,?]TI\<_\_P XI_M447_X[Q^Z4^.?^?YQ3_:HHO\ \=Y+
MV.2./3&/,,NB+\RRJ*2EF:Y'&)/''1"^1Z1QY[0D.;*_,+TV'JFUW9G=M5)G
M!K=&]2H0N"%00K2'G$&EF"\SC&,S5^8&8<VQKIC]83%<W9G,O9W-W&[E9$@O
M7D6'Q*8(W.@9W<C57]<<_6=&[!(6PZ</=L74K5"J&-K$:4#7(FMV?720,Z0*
M39_2?" KA;1,>OX?9,'[*B_D!=%M/V;U-)^YU=>N]MV1!9*S2A@HY[B#G5"D
M^OFZJV%/&)I'V*%L924V(.Y3PB6Z4Z.3&EZ"\8RH*0_3WU+]T5?_ .<?F_+?
M<X+U3\U_I#ZA;@_#V19@KX+^9CS-]3L,_P!5$Y+;&,]59/GH>+K[Q"IOPQNC
M-X6,8QC&,8QC&,Q5^;:N?&;S%U34)THX:Z;MZU>F>HZN=[_G4?5]K/5>/-<V
MXX6 ;.VNE7"L;JB<.6]'F.<<2*HC5+4W*R1-JA6:",J"-D:(TX>.FB>9:$Y4
M@#5R35$]I6G;(T?<R&O[3%8)=D-3Y8J="YNXYPVV@]R"9L4G-V2F"[L;JXB,
M;EA1I6RBS-F;%.3&,J#\<WSSO-1]N:J?R0\S?[_Z,M\R@[X3+]#_ 'K];/)'
MYK:<_P#KE+&,8R2_B$^F4D_W94__ #3TIFP'&,8QC&,9'#IVFN3[6KAW>>O:
MFHZT*NJQJ?I^ZJ[T@$.GD8@S5'V=0ZR.4^K,&AW3,I;>R(E"MR7I@$F:0)Q[
M-$(H/JYRKASJ[B;HB$NT+XI=6)%#:83L#4KK=GJ*9463"621EN2J*JFBNIK!
MZ_5IXE(0-;P8P/;(QCCKF:WN1:-::H2*P%SDQC*-@?RDD_[E8C\[1N7DYP'J
M_P":UTI]0-Q_AW(\PN<@_-,Y>^SM2?X:QG)$XQG-XY](YXDOMJ!_"&Q<WP8S
MX]_PG'Z<3N3_ #M2'Y:Z<RA?&,9]P7Q7?1A>./[!W(7Y?:]R>>,8RCSS2>."
M,]<U&NMR$U<_3*_8G'&Z!2 J&]3//(SQ97._Z1BE4OJ]_L039(ZZ=4*!X"7+
M8JWVK%7*--;^2I5E.;&-6>I,@UX:/('XHXC:<TYUBKU?U<=SV[.8Q7MH.W7M
MK*>FYW<$YAC(O3PR",'6</D5@5!+6F.-RAY006+MLAAABL]0Y?%<3-<51VS-
M5&,94%(?I[ZE^Z*O_P#./S?EON<%ZI^:_P!(?4+<'X>R+,%?!?S,>9OJ=AG^
MJB<EMC&>JLGST/%U_P _D0J;\,KHS>%C&,8QC&,8QC,X'E;ZX:)UU3R?R+5%
M^>.*M'B"/L\Z?=KQZ^E:6=MU.WSSNYQJ/P6"QB#Q.T(-N,W$6FL&3R'7ZQG1
M(E-CC2_@9V]2ZM"Q.*QKQ3=>V)VMR:5;-J*:>?9K&[>N:G7.?T YN*^F;7(J
M:>NL1;[3KI(^+W.1,<9FJ!$G<T#2_KE"W8-[=4A@F5T:M[LEQC*@_'-\\_S4
M?;FJG\D/,V6^90=\)E^A_O7ZV>2/S6TYE+&,8R2_B$^F4D_W94__ #3TIFP'
M&,8QC&,9DQ\I?05>(/(>?RY7C9;-07%>Z6BZ8M>:M%UP=U@?0L>Z%VEJUF;9
M-X^+(TN2=6UI#HX\C8;)F]<.5761&F!+*6EHGA&HT9K+9?%UR+*N0B[BA<_Y
MWA\#FBX$#*5=#P/H&V;QBE^1]E!*"(XSLK1T'*I;=%,(ZT(5J2PU:YODDA36
M=*CED2F,B,5.XD=M.,91L#^4DG_<K$?G:-R\G. ]7_-:Z4^H&X_P[D>87.0?
MFF<O?9VI/\-8SDB<8SF\<^D<\27VU-?A#8N;X,9\>_X3C].)W)_G:D/RUTYE
M"^,8S[@OBN^C"\<?V#N0OR^U[D\\8QD/.OZ]XMZ"@P:#[(<*K?H,M=X[-U5:
M6'9":&IGP^/KE"A@6.S83)XZX/;"!R(.&-M7"4L+H>D$0X)%I1!A.H&<_*N=
M;0[FM_B6OZNYF5<G\=5-QCU)0$?IV*11K9X)T \SN^$ATF2K8$K(8MN,>)@\
M=5LZ/2$HY"I4K5*W:S3AK0+ML8RH*0_3WU+]T5?_ .<?F_+?<X+U3\U_I#ZA
M;@_#V19@KX+^9CS-]3L+_P!5$Y+;&,]59/GH>+K[Q"IOPRNC-X6,8QC&,8QC
M&,R-]$,$QG'D7Z(YR9/@[GC)O2Q"VM7T P75=,JJ"/R'H>JY'+E$=.M<QZ?N
M<Y&)=+2)*-.WV''W.0JY(Q/#FB//VXMCBB=U-_/CLKR7UCSFEB\WXNY\X+?
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MQ- 4+BY(RI2]LY;&F5N)$I_1CXV11=S)*T)D>U:-Z+&$]O)]-'M6>&+M"/\
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M-\\SD?[3E"?BK%,^ZYC&,8RJ[RR=-W=SW5/-D'YRDK) +C[$[4Y^XYB]J/\
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MH4]7&*FI6XI# *D*9<40<K3C <G 86+0M^9%U_4X-'B''.@P!2A]94(7*G3
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M+%850()@W%&SU)+1C$])"?>#PJ%"+8T TX]UZZ\L_P )"$(H(;O[D$(\L1Q
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M<:F6M;8C>G.+IZQFQTB;F9P-,(0.RYD+9!.:1L7'%&DHUZA*6E4FE&%DFC&
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MAY7V)\F>5SF&9\F<;-M_]SU*[= ]91!V@]>V)$(;.ZO_ %S3QHL!ZI)5+(!
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>49
<FILENAME>g459793g70s01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g459793g70s01.jpg
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MEI>W"18Q6)33UB,U-W5WF+37,C,V05'_Q  6 0$! 0
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M. X#@3'5/IF;[^S'U'_-7NSPN$:SXX5.<(<!P' <!P' <#$G_P"XC7^4D?\
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MAM+K$F.ZA]A]I>/*0XR\TI3;C:\9QE*T*4E6,^.,YQPCVX#@. X#@. X#@.
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*"' <!P' <#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>50
<FILENAME>g459793g70s02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g459793g70s02.jpg
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
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M(C@Y5UAXF+?8&2-6=Y:XUPH:,4)TE]88,G6HM3?_Q  6 0$! 0
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MC2G?0MZ6C 3/HVT6BM?AXZT;-DAV4\BVOU-4A.%&2[WSB4G>Z4#E,"/T[.)
M^"HW9&Y+7B"84<Y+GW Z0#L CCL<Q;"S&B"(YJ:1PZ,$V.X,2H\9JE5-45=-
M%1G7(F:1]8NO%W-V$_;60_S%)+&R9F+L&Q".Z !\=E5.B*8'.&0L^(4=H-X@
MU8#)3!]3*>Y*"V0_DCE)9+$B(A4Q9:T>U5'E>%QBIOIWU^E\@EH#6XI"'5T!
M62:DD: 8@(L+H*O)W8<<?F?/(1!Z@Y:"4#9R%B\,WZK1BTC<8$25)\Z!"<X"
M?^[1'"-S@-=7NNTV?%0KRZ9GZ_+'W8@DV9NE@S-(0IB9C83:*8M(C%T6(D'
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MMWN3:' ' ' ' (;ZX?*S\1']ZG7_ /E:JO@T_P!-G^74N3@R. . . . . .
M. . . 0T%^<KLG[#5)?CYV!X!<O ' ' ' ' ' (;ZX?*S\1']ZG7_P#E:JO@
MT_TV?Y=2Y.#(X X X X X X X X X!#07YRNR?L-4E^/G8'@%R\ < < < <
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MP!P!P!P!P!P!P!P!P!P!P"&@OSE=D_8:I+\?.P/ +EX X X X X X X X X
MX X X X X!,UO=QNM-#S-O7EL6L'B,V=1@;,THTJ+DI<IB*F"IT&*.+(@ I7
M5LP(EXQ(&#-5SNCEPX#O]4]=L(;9X+$_ZTNIK3])-TE^G0;_  =8_P#P[@0]
M.*[C])-TE^G0;_!UC_\ #N!#TXKN2(*[W]4D>^D\LE6UM-(*2ZB5-!V,GVA5
MB^RW4M"7+=)XJ!25]R/GY?L0Y\,073RGC75N1;;8WSG;.NH0].*[E=_I)NDO
MTZ#?X.L?_AW AZ<5W'Z2;I+].@W^#K'_ .'<"'IQ7<WE2O96C>Q2<H4I>PQ4
MZ]Q3L8QE:+%F9'NP3HTT6?"4B#(X-%O$O:#1NNX:*80V2632WVUWSYN> U'D
M]#>7!!P!P!P!P!P!P!P!P!P!P"&X=\Y5V*^PWTP_'SOIP7!;OI9,MLJ&]N3$
MV,$*WM*(Q:&)F6+J."'>0RF[@*E6Q=FZ$R%F2IJ5$4W*EL9#&5B0J9XR\A:C
MP<V:!28]/<P)XS6@BENX,6#QL7&++KUD_:P:MHU-)9@DY6DT[FL1TG2LOM(L
MI**FFPW#BP'SZ)*&(GE@H720?2#1I9K;,<CWM85Q7UY^N%8IUIDC&INV,E@U
MPP6TK;C!%.95?:T-@T@CRS-DZ$'IH\+,X::D# 3540(:DH0 V'91/QR5#FSM
M<@08N8:Y)!1LS(A3FO*S?MV/1/4_>*]F"+3BKZ @G[-<JZ>0PG*SYR%*^M0#
MW+,46J:5=B3+ HU,BP[[:0!R 4>^"E#0V40V6O0<))@Q///-3:]&Q6TZ\"N(
M#/BK&;B A*1N(E8V\A*OI.7CY.0.2P(%*PA<;E9D2C(\GM&VQ%O)Y+H3$@!I
M!ZZ1)/W35N'GGGJS25&?+;[X?^(ZH?A[-N"NZSM^67'P0< < < < < < < <
M < < AN'?.5=BOL-],/Q\[Z<%P6[Z62Y."&K+SA:UD4K;M=-R@\(YG]9SJ$-
M317.V!HAU+(P3 -B;[S/UF6S!<@FZ5U3SJIOJEG1/;7?;7; $^Q6%W+&IQD\
M]O"*'H@]/V*<%PHA+2Z2+965D%359BV;_#57#R/QN&C\Q3,;U9)C5V[UW8 _
M38T"]4.@6K_C_AP!P"'*,^6WWP_\1U0_#V;<%=UG;\LN/@@X X X X X X X
M X X X!\0^S'B+=-_#^\2*R7?;FXO>E;VITAZL-X$I[WUISSV\M#+X[JJR73
MS*RA$SW%^S=)0"V\XSJ.T>>O>1ALZRV>8;C=FQ:M+Y5,-S5*]+-K(_G^\>>#
M']<G_P!>>U?]#>"_"]I]/.SW-;V/_:"O!TF.D*PQ[L^KMHU.Q,E-!U>OG:U-
ME)Q" TT)5&O=]:+5QC<,\,,IN&U41425DL3!HK;-4E-WS4/A>T^GG9[DTC/&
M$\'P8-I#7](<SP;I-C7(!H:$=3.W#%621"N]Z\]-'"(8C 2D:=(S5O!W?M78
MZ,-YC9I_%)7"UP$JKP:<+B_#]I7Y;_W*^&L]?4I^J?[0?X.L#K.!0HSW<U,E
M8K$@($@2TZ]]K]T7+H6.;M%?5=UZ*3<[LD=DLH,=W>OKF[-)#=YMNYRKOL)\
M+VGT\[/<S_\ O'G@Q_7)_P#7GM7_ $-X'PO:?3SL]S9OAS=MNOG=;L)WHN_K
M+8'OEU>[7ZTQAO)_<I-H;Z0Y'X!+DR['V+8$;BDAT]4W<H8]9W$ZLW'G^5JX
16QKOG49M679A-0XT>+R/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>51
<FILENAME>g459793g70s03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g459793g70s03.jpg
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M,C8X03,U475VEK2UN-79-#>Y"E)4<9'!_\0 %P$! 0$!
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MJ=NC:Q":6^*T&MEB&*3ICAOR;.C4YB4Q/=D\8?43R:R'Z3N6D>S1 )%M6X(
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M5:,_0@A%H\9XC?.UH7G^.M;PDS,Q29F8TF9HIXLL!0 %%  666$("RRPZ
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M-^4$[1^C_P 0?\_Z\PN4<Y]N%<F$,!@,!@,!@,!@,!@,"&^W/_5<;_3DH_\
MY//L+&/IQ>TKDPA@,!@,!@,!@,!@,!@,"&N+O[6]V_3EG7[DJ!PLX</+[RN7
M"& P& P& P& P& P& P(:KK\I%UW]#+R?G[YO*/X7*.<^W"N7"& P& P& P&
M P/,-YMLCGSN?I64S:JND9!%;+HSE%LA\IJ/F2^KNC;@Z0%]Z5'+6I0^U+7T
MQ;&MS9RYG&CCV]S5)%8R75.<2287H8@FJ5B+QC.<1E&K;'M_U/\ (WW)]7UV
MI]AN$I.W6/)[?]3_ "-]R?5]=J?8;@I.W6/)[?\ 4_R-]R?5]=J?8;@I.W6/
M)[?]3_(WW)]7UVI]AN"D[=8\GM_U/\C?<GU?7:GV&X*3MUCR>W_4_P C?<GU
M?7:GV&X*3MUCR>W_ %/\C?<GU?7:GV&X*3MUCR>W_4_R-]R?5]=J?8;@I.W6
M/)[?]3_(WW)]7UVI]AN"D[=8\GM_U/\ (WW)]7UVI]AN"D[=8\GM_P!3_(WW
M)]7UVI]AN"D[=8\GM_U/\C?<GU?7:GV&X*3MUCRECJ'K.-64?S:.'4/W YAK
MSJ>K;,EFS."NPV_W-AD:;I<G>70O3A2R7:XQ*:ZH0A;T&E+BH]-L2=*:$LW8
M"Q%-,)SC.)C54_M_U/\ (WW)]7UVI]AN$I.W6/)[?]3_ "-]R?5]=J?8;@I.
MW6/)[?\ 4_R-]R?5]=J?8;@I.W6/)[?]3_(WW)]7UVI]AN"D[=8\GM_U/\C?
M<GU?7:GV&X*3MUCR>W_4_P C?<GU?7:GV&X*3MUCR>W_ %/\C?<GU?7:GV&X
M*3MUCRQ\[RE= )I4VP517G99,T>(^]RQIBAO!?9()"Y1B-.4?9Y#(4+0*DM+
ME3,R.LKC#:ZN1) TB%=(&=*I-+.<4H#1],TK:F&,9UIGM+(/;_J?Y&^Y/J^N
MU/L-P4G;K'D]O^I_D;[D^KZ[4^PW!2=NL>3V_P"I_D;[D^KZ[4^PW!2=NL>3
MV_ZG^1ON3ZOKM3[#<%)VZQY/;_J?Y&^Y/J^NU/L-P4G;K'E+',W6<:KF0]6K
MY=1'<#:EL_JB5V;"S"^"NPU^W6&.E85'&T3H8!!2RD;<8:\15\2[;W$*5P+"
MD"H,2A3J4QII9C#"T:QK.ZI_;_J?Y&^Y/J^NU/L-PE)VZQY/;_J?Y&^Y/J^N
MU/L-P4G;K'D]O^I_D;[D^KZ[4^PW!2=NL>3V_P"I_D;[D^KZ[4^PW!2=NL>3
MV_ZG^1ON3ZOKM3[#<%)VZQY/;_J?Y&^Y/J^NU/L-P4G;K'D]O^I_D;[D^KZ[
M4^PW!2=NL>3V_P"I_D;[D^KZ[4^PW!2=NL>3V_ZG^1ON3ZOKM3[#<%)VZQY/
M;_J?Y&^Y/J^NU/L-P4G;K'D]O^I_D;[D^KZ[4^PW!2=NL>3V_P"I_D;[D^KZ
M[4^PW!2=NL>3V_ZG^1ON3ZOKM3[#<%)VZQY85S+,S[<[4ZMN)GKF[897[OS3
MQ573&\W-1MLT<=()= [*[FD4P;8\U6W$(<ZOA<>:+*@ZES7M:)4@3"D2 @:G
M2@8B@EF*1%XQG"8G+AT^6>C.&3 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M;];VPV-QWJKL? )BPR@UD6Z$( VY_1M*Y2M8'0DP RE#6\IT+@F. ,E0F*-
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M&@TK0EL4EZ=T0;.*:W?:0M+5WB.M?#\']4<^IF5VD1UG,8&9C3:<G-=I,\#
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M*1:<+3OG:-ZTJL_"(;\HM_=BW](SB+_K9YZPL8^G%[2N3"& P& P& P& P&
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MY,(8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>52
<FILENAME>g459793g71a71.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g459793g71a71.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[2OR4&AO=&]S:&]P(#,N,  X0DE-! 0
M    *]:^$2(CA"24T$!       21P!6@ #&R5'' (   (  !P">  ,9FEG=7
M)E(#$Y+3 R' (%  QF:6=U<F4@,3DM,#(< C< "#(P,C,P-S(X' (\  8Q,S
M S,C4 .$))300E       0MVVEC@FQQ( T_Q9<]0Z<G3A"24T$.@      Y0
M   !     !       +<')I;G1/=71P=70    %     %!S=%-B;V]L 0
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MYU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M  5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M     08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&
M]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6
M=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M
M 0 9     !  $!D     $  3A"24T$)@      #@             _@   .$
M))300-       $    'CA"24T$&0      !    !XX0DE- _,       D
M        $ .$))32<0       *  $          3A"24T#]0      2  O9F
M8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:    !@
M       0 U     0 M    !@       3A"24T#^       <   __________
M___________________P/H     /____________________________\#Z
M    #_____________________________ ^@     __________________
M___________P/H   X0DE-! @      !     !   "0    D      .$))30
M1$       0     @   D    )      #A"24T$'@      !      X0DE-!!
MH      T$    &              :A   )V@    8 9P W #$ 80 W #$
M !                          $             "=H   :A
M            $                         $     $       !N=6QL
M   @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;V
MYG          !,969T;&]N9P          0G1O;6QO;F<   :A     %)G:'
M1L;VYG   )V@    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V
M4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9
M    !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V
M)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F=&
MQO;F<          $)T;VUL;VYG   &H0    !29VAT;&]N9P  "=H    #=7
M)L5$585     $       !N=6QL5$585     $       !-<V=E5$585
M$       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O;
M$    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15
M-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0
M]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6
MT    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;V
MYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&
M]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P
M "/_         X0DE-!!$       $! #A"24T$%       !     4X0DE-!
MP     &',    !    H    &P   '@  #*@   &%< &  !_]C_[0 ,061O8F
M5?0TT  O_N  Y!9&]B90!D@     '_VP"$  P(" @)" P)"0P1"PH+$14/#
MP/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,#
MP!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,#
MP,# P,# P,# P,# P,# P,# P,#/_  !$( &P H ,!(@ "$0$#$0'_W0 $
MK_Q $_   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
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M;#?L>V?UCU-G\YZOZ/[9_W3]-*SW4[OV+%_P!&$+*Q<=F-<]K US6.+2)D$
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M9_XINB?^&:OR%>^YG]#O\ ^+?_ -25XQ]5_JE]9\+K_3,G*Z9D548E];[K"
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MVL=]%[D*JCI%6+;ALQ[_0O<'6--CW$D;8/JOO=;^8W\]6&Y6
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( 9<"70,!$0 "$0$#$0'_Q  ?  $
M 0,% 0$             " 8'"0$$!0H+ P+_Q !W$   !@$#  4$" L0"PL)
M! L! @,$!08'  @1"1(3(3$4%4%1%Q@X87B8M]86&2(W6%EQ=X&7UPHC)R@Y
M5%97D92AL;:XTO R-39&1V9G=9:TP20F2&AT=H:(T>'Q&B5"4G*'M=78,T29
MIJ<I-$E398*5J+/(_\0 ' $!  (# 0$!              ,$ 0(%!@<(_\0
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MVU;-(U=\I&,VK-)2K8X\Z(+HS\46%C;,>[.,05FS1.2JEEV%GFD?+N9: O\
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MH1%0YB!SW<F  Y[O'2E;AT[:LD3.'CENT0*)0,NZ6301*)A I0,JJ8A $QA
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M#H5]N6)(FX5I;.^]?*U-L>%<F8 KE%S)N2G+M1\4XWRS57-*M3#%U4+"Q<+
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M)JE(Z;(+E.D52ME[:O=5]K#W-?COV)?_ %5Z4JS!K#<S.A>CT,^6_+#93)G
MSD,D]'\5<V82 <I<F&5+ND YKJ"9SHC81$9$6YA;"N*'">E*K.DYES=C9K.L
MJ!T2N>J<TL]GF+K86U>RYL)BT)JW6$Z*D[9)%-KNH3*ZFIE9!)>3D%0,Y?."
MBX<J*+G44,I5:>VKW5?:P]S7X[]B7_U5Z4J^^$,LY9R8O8TLF;6LH;<DH=*+
M4AW.1;U@.Y)VU1\=^5\A$DPKEG)J\>>%*U:J/#6)*'2<EDVP1BCXZ#XK52I
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M2E4U;:;5+Y"K5VYU^*L\$X6;N%XF:9HOF"J[50%6RIVZY3)F405 %$C"')#
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MJL?F<K]1EV8_\CSM_.;S1I2LW&E*:4II2FE*:4II2FE*@KM$^OATE/PV*O\
MS$ME6E*G5I2FE*:4II2FE*A3TD_ZG?OM^![N3^1ZXZ4KQQ=*4TI32E>LYT#7
MZD3L=^]?,_*+=-*5ETTI32E-*5!R8]V#F+X.FV/Y1]VFO3IZ7-F^W.W/D7)Z
MN0_HGBOV+ ?OMHU7=6]VMF_X,NV7Y3MU>H,1Z5]D^WFW?D.P*GM^BF+_ &'
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MR2KEVZ<+(H-VZ2BJJJ:9#'!2L4'1TYYN^0,J;FJCDK?/M%W0O)6[>R?B6EX
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M^I+:4KIQ[10$=J.V;T?I?\.#X>@,=UWQ'GT\B/''O^ ZL<%_57^Z*5(80$.
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M4J!O3,L64EA[:\RD6C5^R<;RZ(5=H]02=-5BEPWG@Y2K(+D424*4Y2G #D,
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M_P#DI+:4KJ?[=O<^X)]/Z#>,/0'II,( ]_B/( /=W?=[M6!N'ZJ_$*5>3N\
M'WQ'T@ !X<^GCWA[@'P'2E:>//H /2'AP(>L>/#N#CD.[N  XTI66_H>?<*U
MCX0&]K^>MN!U =Y\)^.E7HZ2?]3OWV_ ]W)_(]<=8I7CBZ4II2FE*]9SH&OU
M(G8[]Z^9^46Z:4K+II2FE*:4J#DQ[L',7P=-L?RC[M->G3TN;-]N=N?(N3U<
MA_1/%?L6 _?;1JNZM[M;-_P9=LORG;J]08CTK[)]O-N_(=@58M^B>+'_  6
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M>' !QX^D0$0] CI2@<<>\7GU^/'H[P[^_P![[A1\5*S ]$/[@7%/WP]T?O\
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MP5*A!?.AID9:RL+%3\FX159169+OE*.H65L 7*VXZ;,[KMGVR[?%89.$QSN
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MX9;SOS@O,Q*X6R!! 6#IK4F'Q.RL/<NW?]*V;URZMM&>_C<.Y"6C<**N7(
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M-.X.4/Z!K[Q[7^OISVSO9]O/\)_!3V4-I/VTZ1^,S@#YJ:=P<H?T#7WCVO\
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M"GLH[2?MITC\9G 'S4T[@Y0_H&OO'M?Z^G/;.]GV\_PG\%/91VD_;3I'XS.
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M;-U>U2(IU><G;JN>KURFXYX#GCCG@.?#7+ODCDOLJ"1.W-NS!(_\#L#JJY;
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M:$$;Q6\#>-BX>>*GGL>J82CQMWS+W&*/!@_N,\0'QTYF]_9O[DUBM?;BXO\
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M T'?D@ZD:3!X7^Q]!-$ZPS21:/F9UC%;NG[A-PR>KN!.1PLJ91PV27<J%,J
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MHMLH]D7*35LF)2G65-U2]=0Q2)ID#O,HLLH)4D4DP.HLJ8B29#*& HZI)8
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MO)UT,DZSX:@NJ0LCO<T[])UG01XP-VM7%4[3LE.Q%,%>H?LNT 13[7JF[,5
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MN$%#?G1\%,,K9F1E)))N( 6.55U8H<Q""2JF8=,NC'(-SSA5H*D:+E.F740
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M9PV%N2S80VN=OYSB5LW.:SW#**UXLR-;7$%KKO<Y\J+:'.U%HD:D0,DHDBN
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M4BV\1HC^0@[AP&^!KOU/54.BON(RS/E&@/:=3&GC!K+[KAU6J"N:AXW4X_\
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M:D!!VS!D\=B<BPO73U<LBJ78*@50Y:2V:3DG+<;,= ,LZ/$]*3+#2HG8@SE
M@ ;V +" 2>D2 21N(6# (TJ:N-7ZSFLHM776!S&.%F)BF, D*1+J*)$0 Q"*
ME;E25(1$%@$Z9  G"12%;H[(1TE0DJC%06C,P60#"]A!(UDSJ29//Q*%;F:
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MS;RV">G7.43N$VINHB?KE.81*+!=!,HG$%0 OYX &[QX&TK(L8Z^B@*N8.@
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MNC13QR1L9)MV2,J5^JB+IK(JJ2!7K=X@X)UU$@, 6\,+99$M.C*3<%S*TD&
M03 R@,S YYRJ6*9UD1!<+969P1H(D1(.\23.@6 (DQF@P:D-MSMTN7*U;3!Z
MK(-'9G4(LBJZ7?BW279 V7ZBJBCPZ"2#]AVXMTE0:^5*.%S"BJJH52MMO!BW
M@BQ4*ZNEPRN5I):WF"C*%%Q"N4$$D "3E$XP]W.2LF"I41!!CI $P22L'O9W
MZ$362NQP%>E$?.<^F8J<.S?*&=D=NV@H,3)D</.V,U62[5 "-4U1*J!^S%+K
MI"0P")O(H]Q=$8C,5D0#)'>Z$'=.GT&K:B=)&^!NF3/AF=T<8D'0$QF7L-<B
MXV<F9-Q#UFMO7K8&@OW8)L80CAHDQ8+.)-ZZ*DI8GQ4TG3UNDHH8CIR=LJY,
MN!G*MEU;,J#,]Q8+$&2S9@0 L&;:DGPP6 *E:W DR1$C0 1.\L=)@Z0/$-XJ
MQ'G7,E4PM8HJKS)<G7:+7,O77@LFB+Z>AC2X/'C*-4(Z5+)=C$.#H(=JLB\9
MK!YM<)=Y72MC&%+H-VS8%EPJEK<ME+(H4PK9@&)5FU:' !$,<HT&901F+:Z&
M!(!;L !B8@"!NTB3.;%-K0DRE:HJ+&92C5*6C"N43ME6JJB*2LC%JH+%353=
MI'5*NND4ARIN@D2F4 "$ :@ R@@RPT81!&@(.@B((70Q 6"9).7&@,:$2" -
M^N8'CH09'7)T$5>T ^K+X^/K$0]'C]W^/U^.M ((@'CNF.R9\7C'DBJK]E?N
M.]JGP<\*_)Q7-<&E2:TI32E-*4TI32E-*4TI76F_-!O]MMJ7^;LT?ZSBW7V_
M[CWY/E!^OLO^[CZ\-RSW[.\&+^/#5FQJWNULW_!EVR_*=NKU\PQ'I7V3[>;=
M^0[ KU5OT3Q?[%@-?_6VA4J->?J_32E-*4TI32E8T\O=(/,T[>U!['<48&#+
M61$L8U/,=Y?3>:*#A]9E0K9;Y.K%/BRNW1NN]S%9:^WA):Q6:'CGE:C8J*;(
MH#8%I=T2.*I5-;=^E?V[99SYF+:_D6Y4;%>>*5NRS'MNQMCE>?E)67R3$XQ2
MC%(BV*O3P+*%KDW<C'GR0U1?R?ELD:OO20*LR=%P"*E7SK'21;'KBXRDVKNX
MJE/3X9QY9<N9 57:V2,:1^+*<Y596G(T$^E8)DRO%(@7J)F<G:**XLD*U=G;
MMCO 7=-DU5*M@?IC.C#(=XF.]##8F86>%J;H224NH0CZPBB6'F2*IPYDUZ([
M.X;)#DMN=7'3==RV0=6E!9R@112LE93%.4IR&*<AR@8ARB!BF*8 $IBF 1 Q
M3 (" @(@(" @/&E*Q,;?@#V%<=^''T-,_1Z.NKX\"'J#P][N[N0]!A_R&'Z^
M;3K]2)[9ZO')X&==PXZ#?X.PUC%Z8G)DS4L>8PI;9J*\%>'UV=RQRHMU>J_K
MD7$I0R1CK)J]B7K3[USW)G!46O'YV<A%T?IGW/<);O8O'X@LRW;"6$MLL@J+
MIO.[2"!(%A!J?$0<I^C\A<*+F+Q.)YKGGPB6+G-YL@-MKC,_:QS6[2PIS@.6
M (4UCAZ27,]2RID7%K"ES+&Q5IA@RKQWG*.<H*M!E7TM:D9^,24*LLW%TS)&
M),)LB0E3 Y$6JASBDF&O0\EL#=P5O&C%6S;O7<=>;*\AVMA;1MM$?D]6=20<
MV;C,#Z1]SRSW'A-O[-QV"C$;2QUEXN6T+]SV$OE KW81<YNW&MJQ!N*'=3*@
MKA2R,!?HX?';BF#02HI]JD4_^Y4R$43.V4[04"DY*816 "\"<"%2 B9RAKU3
MECJI@@:D0=0!PUCLUU.@WBO,\LUMCE7B"C)W,J6;4V\\6K85E:S<YTKE.\W3
M! : G0*UPCM)N/EI%'C:.61%)($G+)^X564 IA,Y'R5L*8)E[(054,8SD@]F
M/9+%%11.]< S$A.EE SP1,Z;Q&:1)X]Z Q$@'QV)N,AN6EA K#HE2TL 27@9
M=2%TN96(RDDS4Q-D#?%UGRC['V6[!#0V,\@0ZU9N\M9Y^KU!M7#&<D?5FZ5-
M[<'/D*=MJ=B:MRH.")NGDC7IJ<AC10L'TDF[X/*#NJWA%Q6%#W<7AC-BS;LW
M;JWU8L+V'O):DM9NH=9R@.J-FE1EQ8Q!LNN,L$+?PC6WL(]N\5NL68&T BL%
M:6!MLS6P!N</D4U9<^CWW2S>0)7&E7QDEYPBV-NGXT$;! .(Z7B*_P!F[$T9
M*M'1R/Y"3)(Q)X=HJ1K(2*,TR=J-&C=4@I&Y2[,[BM8DX@);9K2/%NZ'2Y<!
M!-Q&65 97%P@LJE64,T";FU\38Q%BS=PQMK9#2RBWD9+EP9CS@RDK%PD9F9B
M2S#,<H SK=#[L.O.V"KW/+&98TD!E')3-I!1]5(_:R*]8I+1V23XEG#4RZ"<
MS/29&[M>/;NURQ[./8D="1^LZ9L/FO*_;UK:ERUAL*^?#8=C<-P9LMZ\05E,
MP!*(I*J2.DS,5E8)\KCKZM92PD&'%RZRLSH[C,%"SH0@N/JLJQ<Y>B%F_P#O
M1EH3=;CZ[;3<#YRPPURV]L, C?("?N %DHRJ5B42L5C9MXZ'9RS][*HNXF,:
M2+!-MV+1HH_1E7+$0$!I;#6[LG$X?:V,P.+;#HCMAG2UT6O7,J6F<LRA48,Q
M5C!8Y,D@B;^ LW\!S>T,1@\2;-M4>RW-E4+O<MY2[$'+;>T7R,RD,S)E#!JZ
MN.;<.7_$/G";K^1(W(= KK6DB\E54(T\=$V6WLI55.K.:RZ7E#^?6CFI6GRE
M)= B_D, =TY!KY0U25^N8/:;XLBUB+5W"8IPY&'N(KL;-AK3<^CA65K8+VV!
MD-SC*%)T>O4XK'XZVQRXMC=-EYL7K3,;5A2%+ FRI970HPN@ MGYN<ZW0.8Q
M"]AK1 A8E"&@K?&2JCV-(S?>2 I()%3.+MBIPE*QJR;OLWPN6BIR'=.5RM%&
MRK<"DZ%]7>WD8<YA[@:W=5D!@$QK"Y6 4G+ # @!I4FNSL;:+3@[URU;>RC8
MBS=LWT-RV4OJZW;#+%L7+5ZT7709T%QAJK-F[A.TVUV&Z8$Q;9+%(^>GDG5F
M"H32[H',C)MB)]1JI+J)E*F>=:ID\W3S@P)G>2S)V^%NT\I%JC\&V_8M8?:F
M+M6$%M$NN#;B%5A&;FYUYIFE[<ZJC*DDC7YURDPMO [;VAA+=HV$LXJZBVH8
M! "" N<E^;8'/;#%BJ, 6?+G:L=S ?I;\[CW?6INX\>_]#\@'=[WHX_A'7FL
M40;5S?(1O(1]._=U<*\XYT;P&-X[/FC=Y8FLP&N#5:H)YK]U3C_GP]K[D7GU
M_7'QK_MX]7=SWZNX+OW\ ^/7X.KCV36C[AX?F-4'E>S)UZO)$4! PR\@G'F(
MX$O9E;'*H=1<Q3 8ITR+ U043.42+>4D;&ZIG!3ENN5"D2/A_-WS )CPZ<"8
M@5)A+>>[,D91,C?,@ #4:G6.J"8,5#K(=LA;#C1G7VK-!]')5]6<>L4ILL"[
ML,U$3U?37(Y>JIBP3CG3AS&2*TRLL+EJFT\D:]L9R<A9[##.+C,%5B +K+*A
M2K,8"@;U4H .B2\;I(NFVZW&,$G-"KI($MEU).Z#IO$3V'#9GN3D)[),>[=1
M3BJP0P\+"J,^T: XJOT.P39NJNX!HMY6B>.08E<*+LS2,63M&+@BBPJ]5"W=
M4-9N9'8L;[YE)"@HX(+),!02=(UTS9,T3>PQRZ$:9';- ,M.89A!F1/1/$Q,
M#23$;97DM!0Q:6_C).*7AVSD9V0EUV3-XY4.8XE:$8QKI1Z4Z0KG;.EABTP(
MFT274*"STC#V6"OMBDLWK-H7<R@/==B %'-K(5%9KI5"V8=!2S*))(%<'$V1
M9=[=YF0@M%M%#:Q(DD@("0H! 8D R(%7@I3Y5E:8;RB>B4'$?-'0=&DG3=6&
M5*+4A7D7,/),6-=DR/F[LZ!3K+HD:G45< _2?$237DQ"M?LXQ>8:Y;* "VEM
ME< @.MRPJJ]U1;Z+,J!M!S9!0$K7 RE(:#)).:>L09Z,DR 3$D#C$RER[BI-
MZGYU:W2F0.-9.QH/EW90+(&6&23*V%DU9QYF_ETF#!VL=CV"SP5D6R;A95(3
M*N"^3V?BKMNZ%&'OWL59#&#,"TDNRMF.:VO7F&19T684W7*E8E>D -P$L0 '
M!.F\=AG0Z5=/;IMQ98I7=VF0L3.WR\@1=*&DX]N9NQ1AWW9*]NFF8ZGY^[3(
M0#$254;() ()*+F.=0,;5VM=V@53FVL6T +6BQ):ZH(+L %4.9)8*@ .D+I5
M4 (I4""3J8 C_=$$D@<"29!UW29#9 KD1<:S(5":E%HIE8P08J*MG#1N]6*#
ME%RHT:"[263%9P1 4OJ45%"E.8R8 8"CKDVW-ATNIE+*<RR"1F4R#OU ,2)U
MC4'45LD@D@3P.AT!!4DD;M_9K!!D5BDSOABL-YF7+$PY:@O56#*,7C'Z2<D:
MW-)"92809G+A5PJ19JZ;J(F,Y;@JX3.W,#U!59)5-6[A>>Q+Q<-N\ETF,UI&
M*H%G$*3E&4.BJJJ65#&93$UT>=%M$*E@VC AR(:94Q)S$-))B9(\=+X:7O$/
M=(K'PMEU*[$0"LB\<BY;-F]9CIPST61DU7Z"LG*+HN&(I,50=IMV1)F:\K6?
MM6XL&5+:-H6+R); 9&5PH77IVV(,Z$%C"R<Q598 G*0)U=;EIG/?3(!A2VFD
MP1I)C5228W3F.2G'UJ18V(D4HX4%E/))IM1461ZI7S,HH)&,4XIG\I5%%1DL
M9%$I%UO).H51-(RB=:V0".L@J09,-+:MIIZF#J28.H%5,1;+6RT:H9UF<L"8
MX$:ANP S!T,C" (AW<]P!W^G]SGG[G?W\=W=QJ?<3.G'B!Y=>R3IPD:D#GUN
M=I0\W#=J/^7JJ_S9=O\ KEXO\N_@7^Z!\0J9>]'VXU5^\'ZRS;[^&U7^=+AO
M4"=^OZR_&*VJDB'  X$0#TA]ST^ON#N[_#O]7&NTXW&-_P /5X^P^*=:A3?U
MZ'3K^WCJ$V4;M#.+J\-+LCS*4!)'9)0B#1,';QJUZH]5,'8M"*INGZ'"BIG*
MB()(E6;D!0BG4M89+XSFUF4LK0T@2R[P(G4(680,PEM2NE3@ (,P!W;]8!@3
MH=TCKC=V5C5SC=+:+@].BZF*47/X]=O9.RJ/&Y&)E7%.FW$%4VB4,S9/(]ZL
MZ0:2[ S! %K1.1AXF/0(=L9=AV["VRJ-=NF3?"\RF<7%/.S<O0&N+<:.<6#K
M:0YB892<L-\#<!TCE((R@!9(4A0& C0$Z$ @S9_;!.OW;=).VOG+*S/HA^BM
M"23UR>:19-[',+MUVZ2C@3]NDT=(-%P18E*T%PT%=RLHJW,,R7K9VA>MV\P4
MFZML7&#/S8N/S*LY)EK>7IJP##HD,0REL8FVPPR,0-"A8J(7/S:AR!  #22K
M21O$"#$P3HORIIJ.#I V<',@@"K^-0*LIV:CE("=J]*5(Y#D6/US@C^>D.<Q
M5$CI*!TG:VK$(27"CHA682LAB87,2% !Z4%3K!TKG@-O(@:&9 (U,=0)CKF-
M-3,U(?"U%>2L5/"W6J%A?0AXI>"1<*F3DD)1NL4YG0G;%12?LSH NW;NY-=R
M[,L@ ]MY$Z)QP-I7QSEIV7$6"Y?.5[TVG,E0K7&56F"R(%2#!!93-NP#!$JZ
MB(T!,@$"2%!W;B3,[HDQ3ULP5?[W;EBMVM2CIAN[Z\TT:23$%XXR[1JN6;,Q
M;$.U2*?AH1P@W756,]41759=@L40O83;5C X9K?X^Y;=0+1*1F@N&0L\ Y1F
M". 80E94KK#<PK76S@J""<\&=2 1&422PU(:-1OU(J?6/*8RH55BJRS.546:
M9CN7($$@.WJQ@.Z<=01,)0.?Z@G)A-V9"=83'ZQA\QB;SXN_=Q#  W')@1H.
M X20($QK\%3=X50:@"-=^\ZSKX="1J1U183<30G\Q+L+0ZMYZ_"(PRL$5HQ9
MN5I!X[5%TZ*V%R*B+1L5R<012='?,%D^W.9$P*-B*&GPUU!::R; O%KBLRMF
MRM9("75A'5Y*EX89LNC9"0 ) #GS!BI )#@@$.(*L"P( ! T($G0D FL9[^
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M$VSR<4\ROX[!D!-&*NUO*X#$R1F)R$F00K$YA-?9\%;PNU>3=R\;:J^(5R
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M%8K%0ZH$A%C#C%6\84RX@!.=,FV7(0YN<+9OQ): 750ZH0P&0 TS$(4!,;@
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M$S,]PIHGCR$.B &5ZPMGZR3951R8P]GRF=;L&9R *8F<"4ZH 8XRWR!E74L
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M>/D^"8E'!*++0D*JX-UUU8J.57-U13$RQVJ!E3"0PF$@F,8QNH(B)!'@1,(
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M#I-P$BXS%X>U=2U<<&0PMA;91RQ @DH&A54#OC*B %(#G<)AW"&XH?2 23*
M$DQD<*-6) ('2;5FU%7.8;?6)$W+WZ.)Z.=)BUA9)S)#$I-SG:J&;-UY!-K%
MIIL15452<23TKQJ91,B!S1XF4;)&FPNW=HO<56NBYD!8!K081!#0J9&9Q(*D
MRNI)"9(J"]A+")T;>7/KHY$R,RZM( T((C@0"TQ4XL/;?*YC1)K-.WSBT6GL
M/SB6D2-!2BB+I"5=*'2;((E(*R:IDUGRHJNG!#&*!TTU5$C:8S:.(QA(=B$)
M$H( 8J  6RP#JH;* %!B!"K$"64MK*J 8.NI.IWZL9,'4Z'0$@F:O/(6&#AU
MD$):8C(Y9P'*2+Y^W;+*  #P9))90IC@(@ <]Q>0$>?J1XH $C0$P=8$[S F
M!USO\ H$)>8T[0(T/9U=A\!ZHJQ@,95H^=/U!;$FYZR3*2QCFC2=FI,KOVCD
MCDJ@>3]=<1?(F(XXY6 BBY#@44K>(N/:YEI6;>'M(ZN 02R92K R5*@%-5 $
M$ -QD1 6===7)4@R=#H=XF=-)UD1N-5\X=34G'HH2ME</XSEBHX2729@F^;*
M(%>$%N+%BW5D#J$ ITDEG:Z)@Y77*N4J934PYD!+:JW7G<Y9( ()($J9U),&
M- =:ERB#F/7&@62 -&$M UW0)'&-VUD'?+$K9N!V\>FH@"9$U"@11<# 'EC@
M2JMB.#@Y*(J$ 3 JB11)$3B4W6WMH)Z4RBEB"3/1D<%8B5 $GO209&^M')@Q
M!F8ZA.I $@:$G=K TWFKK8QC2(13R74;'0>RKLQ#G42.D<[)D=4&8%!01,*7
M6<.52F#@IA6,(=80ZYHS!9FUU.76#HNFD:0VI\<:$$#1FD*O 28&Z6[),'AP
MT K?K!QG_;'W?WZ9(]/^1/(??W_@#_OYU7QG>6I.H;L.]# D=6IXC7?Q,*;V
M\/TUD%U0K>L<E3+ULD[EN>\/9[D.[U<8QQ?SX^/(B #W=W'OZZF%$V5G=F8G
M6!I/Q\8X"MA(&FL[^/&((\6GA-5M+P<7/L3L99B@_;<E4*DX3*?LU2 8I%TA
M'DR2Q ,;JJ$$#  F*(]4QP-=1F0YD9D,0"I((\8,0=-./&:S/PGPGAIKU=9T
MWG4@5:4V)VL3!2+.#DW2<FN\92#=ZN1$P&-&NEU2,%2?4 #=\P6-%NC@<@!U
M@?))D6**9MKF(:XX-U0PR%8!(U8=^-#JK@/!!F,I)!FME)0C2-021!T_.GA,
M='2.L:Q,?+)2H6:*0KEHB@Z%&1CEXQRBT3(_:.U &29/TE"I=HFSD7"KHXE4
M!RT= +ADJ595$P2NURXL%F)!5@R,_190461J2"@ D=+H@'<P,JD(<P B-.]!
M(G@8WR#IKO.^ 1:"]XE7D8B$KE41-'HM'B9DW9'3Y[YH8).4VJS!'RN4!=V1
MQUE#"F)%W3,O:-F3-N8Q#(W<-C;N%NFX2SKEAD8J X@Y9 4$ !F*$-D/1+R.
ME45Q$NC4 $R=VHDB=1QE8(,3J09F:Q9;>*Z2%;IOG\Z].,<#(RQ7;YH(F4*+
M51VDFL5T[_/BKG41[9ZH4R2J1!:E I2I5;VU\6S,JDVU-P1$,4 T$,<P,#*)
M*DL1+YVEJD2Q:.\*84F&T!ZY41&_2#X"!$5!C;:S3)V1/.S<L\G:\S41;M:X
M91N5,SMF\66=HS*R3=JZ(8KA-LH9@FFB44^H<SA4SIZ0TUW:^,91;%QLYC.[
M*JD, (-L   98 <EBR@1 4$PFS;!@6QJ3N)*Y3H=9,D'4@$0QU!U G #:*KL
M0"35%I%Q4<W,5%$@IM6;9$G(E3*)A*DD0!'JEY$I2B)2AW< '*N26DL6+;RQ
M))/63J23/^9K;+O UTB -9\' #AJ(  X58V_R[>=L5):13R/?M$&\Q,/BHK%
M<)HE4:$CT%#NTC&;F*DLY$#(F41/R4%#F*02&"?#'(+[DD1;""('29PQ'$R5
M0C0$"=9D0*P L?\ > P0=P4SXND-=#O XSNHDDM'G4&'FY)@$@LBX=L$C1+Q
MHW=.E3>4KD1?MWX->U4 XKJHK$!<_7,FB=0!$(FN EBR$D+!8$K(  4L- =-
M)A>HDP!6X&H70B- =XU)W@@[Q(F3OCA7']BVAW"I6;M)Q+OY)R[<OA21*)GK
MXW:O7!RI%*DK(&50567,5)JV Q5 *U3,D!R:A2PG(509CE$P9.;\[I=+- ,M
MOG<8&VD:D:" -.$Z") CP23/&36WCFGGF=81"Z29DW#I)!9=,?\ =8MPY>.4
MS=0"JH]HW12-]4KR!BG.4@E(4Q)S"H I))AB-ZB.B# ,&#G TZM9!%1]9/"=
MQ UX:F8!Z)(XQNUUE*0A2 FFF4"ID*4A2%[BE(4 *4H '@!0   .!  ]6HSO
M'CD?8Z[M-#QJ*=_E.@/@\&N_XJK'97[CO:I\'/"OR<US7 .I)ZZQ4FM*4TI3
M2E-*4TI32E-*5UIOS0;_ &VVI?YNS1_K.+=?;_N/?D^4'Z^R_P"[CZ\-RSW[
M.\&+^/#5FQJWNULW_!EVR_*=NKU\PQ'I7V3[>;=^0[ KU5OT3Q?[%@/WVT*E
M1KS]7Z:4II2FE*:4II2FE*:4II2FE*Q,[?A V%\<!R(\5ED @'A_9*=X_='U
M=WI#W_08<'F+,"/Q5O?^KN'$1UD<3IPJP-P_57XA-7=%+DWJ#QX\ X\/NA]S
M@1]_TZGW]?V^;CH9\>E9#$;C'V^VM:.FC=VV6:.4B.&ZI.JHBH'6(< $# 42
MCW<=8 'O](=_.B,PRL#!$$$3/ADGR@S._72@)!!!U$0?M&X<?\ZP1=*)LL.H
MQG-R>/5IQV=5VV5RS7S*D? UCD@5*TNL6LHT6DR-8A<6K2>9.73ME'P*<<M'
M%A82!=E+](Y%\H!-O8V*RP2PP%X%I%QV![G825AR9MD!>F65A<:XL_6_N>\K
M[V&*[ QM\I@<2_\ V:X;BJ;-\%[ENR;CALEB[?*L/S+=W,<DWKERL";$&$T5
M"27;>3NB&43!R+SA234;=7M2.4UA5.58RHJ "SH#-EW"3D@HN2(J**_4 [89
MW2U+( IG@"VAAA C2"=)!DZ[OL-O"8/E-A[&*Q5H83'KGMVL8,L77MZ\U>6\
M'2Y-RW=1UNLI:X+P967)B+DA:#D=E464A'OU?*89\8IDX]ZNN59F==@*#9TS
M;JM7A%%S/$U'$D[:.(MK(-EEX]VS:M5T#MX<1:MXID='RWE2&_%B;@#YHYP,
MA58;(HN*^4@.'#*T^(VUR6VS9QW=SX>RS@6"<3@@]OG$)8LUVS>NAP[!H54+
M9%Z2FZJ9ZVUDR;9'%*C\5(6>WV'%L6Z([C,:NIUZI6&8/79I5-1=FW!LQ<D%
M_(+NV<?*NW*#!Z8ZY$6RID5!U7"8-<2^-.%L=V.C!\9;7#AW91E"_C;@;,R(
M%+H@4J "YRUG"[%Q#WEO_P"A"FT' 4O?V?BC=RE#EN,G-O;87$"J%804:WD0
MA>C11I&*$48J.BHJ%*!4#.^QC4#'13.Z(V%8H+(IBJX;H&!TH!GG^Z#D<IHF
M,8R9@N<[;LH]P9L1=4,R6%N!"W19@H)8(#<>$E5R)F&9A!%=6SLSE'FYD6KN
M"12I%NPAMDYCD%Q[>&MD);)#:W<MPI)%O.2J_%^I$(/@\RHR*C7A!19Q,^:E
M'[QS]4=8S6-AVJ:$6P7/U$CM%WMA65%LB\([; H[8ZJ#%7+EO/B[5EGTRV;>
M8V[(!5T5VN.YOW;3C,MQ5LJ6&B]Z]=W!<BL?B#=;'8^[AUSE,N'NM>Q5VV6>
MV[<X+0>W;Q%O,AL9;EP6WRL6@NE0BO<;<9=BT0?R$8P3;D5[5T"L5%-&2:<=
M'A(R*B*#9N+5%R@T;G>%(JB@8&3< !1NBM6YRTA@+;YQFN-DLH%+77+7;A"@
MZ-<(SN"-6S,[%@2>W9P^P.2)!-FP<7=064O7+O=&+NJ5;\781WNX@J[Y!DLJ
MZ*$*EC;",9=T'8O,6NU8N@[59%(@E]>M'"LHO7Y=M"-HH@5\S5LR;KHLYFQ+
MS*\HHU:NB(0\2_!HXE6LP,5'RLFUX.*V_:P]G&W+:)<;#H\65N([E@+I;G+@
M8I;YL(&=99U4Y#:#E5?YSMO[H^(==H=P8<6UPI8.+N*1\1<<,QS,JEK5I;(L
MJ_-\[=97"J$EEMUV?*;4HBCU:O4^ ; TA:S#1L'&( 4J8)L8QJDT;EZI"@0#
M"FD!C]4H%ZYC"   @&OCN*Q#XF]<Q%PC/==[MPC=F<R0/!H!,F(%?G[%8BYB
M;MR]<8M<NN]VX[$RSNV=B6WDDG>9)UJWFYL>-M^=0_\ 6Q5=Q]_@*\_[P[_#
M5#$*.9N]ENYU]1WGXQUSPJDQZ+#@9/;QW_;?67W7GZKU!7-/NJL?_!\R-Z_V
MQL:^KW]7L#WUS]4?']O\-]:/N'A^8US)BB ]WH'GCCCG@1[_ %]_A_#KHD1K
MV$<2?I/ETJ*OT4G)>1\??#GTAX^O@.[GUASQW<" C=';'EC?IOI5C<MT*5GE
MFED@#B=\PCG43(Q*0$16F8]^_C^S62>JO6:"#F#;>=G*;=<P-Y(CLZ"JK9=%
MD[;0W$)*LI AAFF>D)&\ZZ*-0"""=T R+F%OK;S(^YM5)U"L)X1N;0$@@C>)
MU%1R>L"ODT&T@JNP1DW1XA C1<Z*B)E4E"I-#G I.R<+*)K'4<@F<A$W*;=$
M%P%-QJ9%5K;,N5F10T$#6&Z1);,=.CH0!,L9.AMEBI [3J>J =#H8B -1&[3
M6N:A&;)J9 R;]^P21_W.,>9/KH?[I3<)+C)QC]R5LNW=.W#9R[;N7#9ZNBB<
MIG*3LH.$ZEQ"6!($PQ#@*9$1&A&8:$<8(Z,#5=\T B)F-Y(UF9# $J1J)&AX
M@Q#?0HR;&3=3-9>.(1=U'BD],T=1[KA/M4U2L5O*$W"RRA3%$/+D3MSF$2F.
M<53)E&O8:XC%0LH[!LC:D$F"PR.%4Y2JB,RG*"0"#,CY'4*_3*Z PPC0ZF0"
M1O;4SJ0-  /FWB#=J*Y$V[=R=?M73HZ(NI!X94Y7"YE#.1*9PHHX3 KE=<SK
MM52.$@X$2"79K>)=P;M^XR;@F8A0P&490 $T76#I!!DB36H>TJY5MJ#UP-^D
M3O([((UTF#!Y_A1XB9,A3)]59<5BLU2@)NKU4T@2=CU5!.)S>3 FJ0%"B4Q@
M62;E6 MA4  (B  ,I!4F3(S!=($ DB5.[4D Q$[R28$$:_XG?J(T'$:U]VS6
M4D!,P9(.')4FQCJ@W,JNJUZARI(*@T0*LV*U$K8W>Z6.)C@HD*)A/U=2!5Z3
M YB#P4A3(ECG+3F!(B%&A!F16I<+EF%!ZV&I!W1$$ C4$DD\(WW&BL?&1C6R
M[UJ[DI%VN=H@V #-H]HB"#AP5S)@95N95$ZG6-UT5DP[95($2'4 $QQ!,,%D
MDF .]4@R#J1IH!I)(TTW"NUT9BH8*@&IDDGL$29&HR[N/&:N_"0K:"C6L<T0
M11!(A15\F3*FDHN8H=LH0A"E I#GY[,I2%(DF!$R%(4H%"4"-3O.^.)CM\$
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M]\")@DQBX%@  CU,:'<1((EAF&H.D#<!NJ&,;2,FZ0:,$B&%4")I("54Z:*
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MA@5.3M!2[0Z8ECR SZZJ9Q.W;*+F%$025ZXJ7,H=(5@0))R +T<Q&<09=LT
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M%^^8Y%3/<:(9[F9ST07TBJ5S$7KMNW:=AS=K-D0*B@%N^8Y5!=S EW+/H!,
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MW Z]9J%G'6.2;2GFB'4=&;MS \7[%1V6/<K(D.5DN$48A'*[)-%/RDY7)P,
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M*VO9%,!B'(4Q# )1*)>2F*8.!*)1Y P" \" @(#X:B\'BZZV/ACJ(W220/!
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MC/5&I.NF_?VUDSBF$8V29,&Q$&J1C&21*)C@4YC"<3]94QSB(G'K<F,/5[@
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M'LS](EZ/^"90/5X^Y,]7\8C]S7NW$>K'N5\'5OCCOK)YT[U^#Q=?V-?L*ZU
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M_P"-:_1+6>_]'7?S\4RD_A_X*7H]/W-9S8SJN>X'\/AI"'J\L?$:U^B>M#R
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MK][3 XN.[8/\O=5_FR[?]<G%_EV\"_W14R=Z/'\9JNMW7UA+3_SDQ7\K5&U
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MK.'GJW!+NW"Z@K"@LVE&4>NX<^4I%!$2<,.J98YQ6DU 62*3P.U>1G.,MS9
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M@'W>[EQ&AF=-Y TCJW:G=XR-P $F!J35ME\KU0KLK5GYVDC=<"BJTCU$6Y1
MYRG."\B=@FN4H)G5$S85P,D4#I=<#I@?0NH_/21HR@YO% F-.!CM)-61A;Q$
MD!>,,8)TG0">%<&YS1&HG)V4,Z[$RPH@N]>-VH%'ZH2@/8IO$2G,8""4IE@
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M?K^LOQBMJHPP];D![P'GN'@0$/?#P\!X'GG76^WV^VM:.8'C'7X=_B\-:
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M?*KKM1+U$!2LG#J48L0+BHKE7+P@((1&N*<JWK@(9;)U74$@K!CS"0!.68D
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M*9EP$729SVDM$ R"" +@"D21)5F(.I9-!ET8C.!JLBWE4$! #F(774DP8WZ
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M<L]^SO!B_CPU9L:M[M;-_P &7;+\IVZO7S#$>E?9/MYMWY#L"O56_1/%_L6
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M]E',Y:'"*<:U1,\>/$'4VS;'4259+*.EE+2VV*K:LJJY%900(55@*I:X27(
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M\(,>".,P!5HCJIJM1=-VRJX*LUW1014.G]4*1E"@U[$4UBMR+G*)^&AR+"
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M68Q5,4RBAR)D 2D$.L<Y"%#O,8I>L(=;!@FT -Y9@.)F>KQC=OW=5:-WPW1
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M =HJNHN78)+%CE5(Y!4SY3E(RQ>0**Y2_P"Z0[0Z7!L8*[B+%Y;Z6GNJ0Z.
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MW%8QB,HYNJX<JLXI@1K%,3.''D#)L590@_FK&8W$8^X][$OG<YG)@ 9F$%C
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MMKEO2#6>GT50UPR%;"KP1W:[:3+!L+ >%!&;AV1.S38N'K&QV"<:%="<73&
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MY:1E.LW-V#5BV[$B)VIDEME-BV_-W+;7%N@YF@DZYBRVR2&53;9<^8LSB5(
MZ;7U<W+0:<IM1T9._H@.P ,D.L+$ 2#J9 OC$9+BB6N'I4%+-(Q@\B(J*7E/
M*&+PCZ:C%7($CV(&3(LU3?&4=Q(2$BR$[EOYO!B7RTQU#:KB#;OY;1%HVX('
M1YIW#=(*H.=2!FML[#<MO0'.!JU@-99W!N9F<QT@ZJ4$%B1E(D+<"*9DM),
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MDD0LS,7%^9)"-L,ADZC2*]IA9]A&5\8=B1*0?LE6*$:T=1[X2M%EFHBJ^C)
MC=^H9VF=)59)XE'B[*-*^]MY0NQ0.K6KBHQ,LJ\X"N4L>Q9>Z2,S=%692VNB
M%90I$YP6 'YQ4J9@2"9: D- EHJ+=UR!.I#=(ZV23F1C(B6L4^<8Q5.#B89@
M,S*V*$AUUXD#QZ$G&(%9L"'/&("Z4!TQ?%DG/:OGDEE;',WD9H'.%D:X,EU
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M8N &!8=.V$C[)L_$[(VG86VU^U:.(MHJX>[<4W<RG);;", .>MVPKL H8D
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MH#,,R2B$J0JKF#=(DYF9@0!J 3 J;_0-FV9++<8M;S<TT,^5U+NVEL,JB$0
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M&2#+SI,NDTTDNL"2(),8YHDWBXAH!&$6T;-2%3U,$R@ 3 TEB28DG4P#OG@
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M$PQ;.6<*2-$B3T0?)H('!0D@L\&/&N]QM0I"@D& _0!&5'S%B))&4P"21!@
M34A4@)F@$+E$P&*R7$+ZF2PGKD2(TXW)NS*5RS(,8>5I\HXCW3]S(2,N27K-
M8A8I5"*CD6PKNP2E+:]6D%HIBW.K&1+DS9NO(II.6?"8)VK.T7PTO:O,ES.M
MP-;D-T64B3HK'H@D/(Z(&NAJ*%(AE!A<H5@3);-J!( B2)!!$SJ 0)V8GP1
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M+=^&AES&<N8P<RP37L+'W2>4&'+2<)>8J%-R[AD:XV7-ESF1F #NIW'*V4$
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MT/'0::0!NX>/?(TXU0SO&M2?=848TL2KRH(*PX),^.V$HJAY*9%9@8%A( J
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MD1,(<B(ZCDDDLQ9FU)8DL3 !)))))CCKOWU@L% &XCJ&I$\>$;A!'@-<H4H
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MY^MIA/YB_P!?P!QGNN_ZL>Y!T^GMID7J^$_33VJ63^[G=ED0>/\ )IA3W_\
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MG^JDUW?ZPV=U3Z[ZC3[Y=C>NSYOB?J:T^G'='F'^&^1_%5EWYCZQ^#?EB/\
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..;.3\JB3.1MTQ&L2*_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>53
<FILENAME>g459793g71r05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g459793g71r05.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( /X!+P,!$0 "$0$#$0'_Q  >  $
M @(# 0$!            !P@&"0,$!0$""O_$ %,0  $$ @(  @(*# H'" ,!
M  4#! 8' 0( " D1$A,4%188&2%XF+?8(C$W.#E76%F7MM77%QHC,G9WF;6X
MUB0S-$%4DY0*0U%587%TLR4V0F/_Q  7 0$! 0$                  0(#
M_\0 ,Q$  @$!!08$!04! 0$       $1 B$Q05%A$G&1H;'1@9+!\"(R4G+A
M$T)BHM+Q@N+_V@ , P$  A$#$0 _ /[^. . . . . . . . . . <:JJ2"2B
MZZB:***>ZJRRN^J:222>N=U%%%-\XT333TQG;??;.-==<9VVSC&,YX!0)3M5
M:785^] ]%X1&)9$&3QP,+]NK?V,M.N;5XU54;O4JACD>=#9QV;?#G*.[=R_B
M)B!5#NKA=JTNQV:'OP*0L0K7;ECXY:7O0]%+H\XG>,/>S?9KLA?A!?[-U&0E
MC&^MM/-=MOCW'#JSZXOZZ<G8_C;SRD-MV8VT_P!O/&'II]ZM'*8-Y)+F^+GE
M!W4_#+\._;.RA3I'U=E;Q37;54M/J3@%BG5\;?%MLYD$[!R(VY4WQ_.57?J*
M;?\ ];YX+M5?4^+SGK:<6WAL=,!W\I7U/[42^3SZ;0IUHGUE]:2#%;'GZ*K9
M6B9A7Z6VN-OC5:.4' ]YKYH/V;IMNHCN)M-WN=]O6?Q;F>:XJCNA1.,DJ4O)
MMVDAK+&%%J5[6:!@,_V9)[>GNPKWLU6T6%KMGB:.%-636Z:PM)X:>;MT"=D1
MIIJJ1T%E.]1JIC&].=+HA8,F>A^T4#O-](X9@5*JNNN!-VB]ET%:8]F M*#H
M/EE6S UNR8$"\?F4%,.$%TH[9M=GY=7<A417:BY,L29D&#,1J-5@U<_>3M+)
M\$' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
M' -:I]J\\0.Q9?!%'CMKT8I^5DX186HUTHTV[?V_%7^64OKA8@UWT<;];:H-
MMW$6LEFS52Q<UF#SU>$UL5U"):*L86[>^6N]X9*V]IJ+NU5W6G4)_NO&:ME2
M$6BM*]-NK4[@8\:]AP9C4LEEUA]FXP:) @+N*D42#8M'JP@(Y( 654"#4!FN
MH9@Q4./E7(L2D[VW5-]L)-76XOW)E%I=TY,2T:1F)#UX:EK=C&)JRQH=:O#D
M?:TWX@_7_K%-XS8@<L$]2%0O:'V,\F-=/&[O9V4@F2[U%1+?0>7<@E?.5V^E
MN?"%.\BQAXDK_%FR:0(/8.XC5B51UUQ6=?R^T8S"P%8V#(7W?4K)0UN2LT-8
MI0.:G,T1":ZEPL@Y*8BTT<#@HUB9(#M6<L#9LW-VP\-GDIG<6(%]Y9<K(0^D
M@JV+"(8<O8I2")D!83^;2$&1!V3%:Y=%9?$6$,%F18PF]G,82:&HVUF8.-R-
M\.$6 ^BD7.(3X:)&KN6%EJF^3(KI[D&H',;"@<9A@QR3AIE[#5'1PXNR*MWK
M[K',^Q$?M-*.Z"UDRE2(NXBZK<F6P3:+[2D=+\H[:XB"C$R"7XBW&/?Y.JEU
MMT[#4!2]@$;%D4=['AHN&LZH^Q8=88;EU6R^91T.5,BQ:^PP2C,*@E3OS;SF
MII3A]%Y5'W:@//L#41$7T;"8;Q4W39CCT9,O5V^C=P@);$K.CXZ"=B*2D#>
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M'A%L7N8]R=L'V3J69-:&=P..F)R=OZ %KPKN.!Q,;8R%A! S&&8E4UD>\G-
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MWJ6JF_(6\KVXH)'Y_$G;AL_T&'6F5%A9AAOE47(HZ5;[MS$7E05QY/ $JCA
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MW=(937134U ]W@#@#@#@%(_$Q_!Q=_OD4]IOH-G7!JCYZ?NIZHNDQ_V)G_\
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M-Q^6[Y%HBD@<.I$@GW[YYG8']2*"#YCF0T/+A,16IA%'"= EBV:&2WJ^-,#
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MOZ@Q_@$Y\ < < < < < < < HUV&^_"\/C^E_9'_  ^23@N#WKI47EX(. .
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M]??T(BG]PL.4AF_ ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
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M5-))/771-/77337&N,8P(4A\37\'GW2^39;?ZGE.#5'ST_=3U1>7@R. . .
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MLTC\A9::DF)8$:!2(([58FHY)@IL$\60%F,#DSX"/EA8U5AK2B<[2Z/4U<9
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MC=LH=@QU1#&Z>^KQX)E[XZ^D%E^"%&HS^$KNWY#75OZ?.X/!<%O?2DO+P0<
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>54
<FILENAME>g459793g73a10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g459793g73a10.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[23^4&AO=&]S:&]P(#,N,  X0DE-! 0
M    ).*^E$(X0DE-! 0      "T< 5H  QLE1QP!6@ #&R5'' (   (  !P"
M!0 11FEG=7)E,C!?,#@R-#(P,C, .$))300E       06#+A%NC,2125AU0K
M[,)E/3A"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /
M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 [_^-0 "  $#O_XU  (  3A"24T$)@
M#@             _@   .$))30/R       *  #_______\  #A"24T$#0
M    !    %HX0DE-!!D       0    >.$))30/S       )           !
M #A"24TG$       "@ !          $X0DE- _4      $@ +V9F  $ ;&9F
M  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $
M-0    $ +0    8       $X0DE- _@      '   /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H     /__________________________
M__\#Z   .$))300(       0     0   D    )      #A"24T$'@
M!      X0DE-!!H      S4    &              80   '4          !
M                          $             !U    80
M          $                         $     $       !N=6QL
M @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M          !,969T;&]N9P          0G1O;6QO;F<   80     %)G:'1L
M;VYG   '4     9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4
M   2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &
M;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9
M  !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J
M8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO
M;F<          $)T;VUL;VYG   &$     !29VAT;&]N9P  !U     #=7)L
M5$585     $       !N=6QL5$585     $       !-<V=E5$585     $
M      9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $
M   (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L
M:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%
M4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T
M   115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N
M9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "
M/_         X0DE-!!$       $! #A"24T$%       !     8X0DE-! P
M    &CL    !    H    (4   '@  #Y8   &A\ &  !_]C_[0 ,061O8F5?
M0TT  O_N  Y!9&]B90!D@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/
M%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!
M#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,
M# P,# P,# P,# P,# P,# P,#/_  !$( (4 H ,!(@ "$0$#$0'_W0 $  K_
MQ $_   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
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MQF-.>RR>CX=-]5/5'M->3:7/<UEMCF2XN'^$V[F_V$3ZRVVT]%R+*;'56#8
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MS/\ @U.KH-65]7&8EE+,?,R<2JG(M?6TV L96W](YA:YSJO3_1_I/T:%U/!
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M]
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M-#94575VP=0B5E>6M-+5UN'Q,B-"4@B"%V9R"20E8C,U0T5&9'.#A)*R_]H
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , @AU!OR8TC]M7A=^L7 <ZRQ_E]:>Z]
MJ.HZ::6O?):)[8J7K.BD[\Y,W1 6OOG+^3_V0^)/Z3N5&=?3/,6HO>6T75]G
MC1N/..L?8]4_C*W)]9R!O!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MYC=$HMB2N3.[HR7!L7IA""$0DZQ$H(4$B$$.]EF!WL.M_)@';8 P!@# & ,
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M-J[ #'FC4U40Y(Y(8F9*?0D;?=QI*\*U[J4QZ<MJ0M>G)6:N$C"2-5X#A#+
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M\6MF&C%L#V^ , 8 P!@# *X.G[__ ']U*_\ ]1FP?U<^,6 6/X P!@# & ,
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M%]I2P/U0.3>8M_X?]S/0T#;JSP@8 P!@# & , 8 P!@# & , 8 P!@# & ,
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MK'-WF&]^:).:_P#C/O>F;T_6$Y3671U?4'Q-LOCLVRIFNBS.,\-@_)EDL)B
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MDIO_  ]NG%]I2P/U0.3>8M_X?]S/0T#;JSP@8 P!@# & , 8 P!@# & , 8
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M:])&;DU)T%H.0HP!@# (']4CYM?GS]CWD7^BB58!KPL']XF7_JEN_P!C)S]
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M]&7YMOCM_P!+NW]86V,\#5ZZUZ2,W)J3H+0<A1@# & 0/ZI'S:_/G['O(O\
M11*L UX6#^\3+_U2W?[&3GZ >DIO_#VZ<7VE+ _5 Y-YBW_A_P!S/0T#;JSP
M@8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , @AU!?R94C]M7A?^
M/[1<!_XU_CSK+'^7UI[KVHZCIII:]\EHGMBI>LZ*3OSDS=$!:^^<OY/_ &0^
M)/Z3N5&=?3/,6HO>6T75]GC1N/..L?8]4_C*W)]9R!O!@# & , 8 P!@# &
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M&9S2B$( 5+>YMR)2B6IQ# ,.CDQYA>Q!$'0NX=ZT!V_W'ZE^BZNO]"8U_NS
M'W'ZE^BZNO\ 0F-?[LP!]Q^I?HNKK_0F-?[LP!]Q^I?HNKK_ $)C7^[, ?<?
MJ7Z+JZ_T)C7^[, \U+HEQU@#"LE,[C-*PJ,-^R0KY'+F6#1MA0B4G 3I]+'=
MY3(F]-M0H,+()T<H!LTXP!1?B&((=@1NXN\8*GI5)8T6E *1F#[=O('D;R+K
M](A98T>N/K>Q;"^%S>@:4CBD]8ZHH:VRJ/MSNO9"E#"A.=&T)!X"%Z+9\1(<
MJKRK$$MON/U+]%U=?Z$QK_=F4#[C]2_1=77^A,:_W9@'<L<"@L86#<8U"XG'
MG Q.-(8N8XXSM*P:4TPHTQ,-2@1ISQ)S#2"3!DB'LL9A)0Q!V(L&] >LP!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# ((=07\F5(_;5X7_K%P'.LL?Y?6
MGNO:CJ.FFEKWR6B>V*EZSHI._.3-T0%K[YR_D_\ 9#XD_I.Y49U],\Q:ATVE
MM%U?9Y/@:-QYQUC['JG\96Y/K.0-X, 8 P!@# & , 8 P!@# & , 8 P!@#
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MSU1'OC[W>?Z7U_HO,]3Z+U/_ "?U7E>1Y_\ )>9YGX. <W /B(00!$,8@@
M.Q#&+>@A"$.M[$(0M[UH(0ZUO>][WK6M:WO>^V >>B,PB4_C;/,H'*8Y-HA(
M4FE[!*XB]MDDC;XA$,905K.^,RI:UN:01A9A>E*)4>3L98P:'X@BUH#SLON"
MI*^7'-D^M*N80Y)V1+)3V^7S>,QI<3'%LD:X:B?SDCTYHCRV17+WQEBB5U&6
M%"HDCPUL11XW1P2)3@,BX P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M+ZO89,1=K3'VATB))(RCFGKWT%-FW*!@# & , 8 P!@# & , 8 P!@# & ,
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MJ^^':G!N.IFDBY;+/'R?1;:A*T.KG#S+'A,/+EK<W*M-XBW/R&P^@MOP!@#
M& , 8 P!@# & , 8 P!@# & 00Z@OY,J1^VKPO\ UBX#G66/\OK3W7M1U'33
M2U[Y+1/;%2]9T4G?G)FZ("U]\Y?R?^R'Q)_2=RHSKZ9YBU%[RVBZOL\:-QYQ
MUC['JG\96Y/K.0-X, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MEH"Y"VJ6O:),JCPO3*A.,5([[PUW@XDNZ1UAQ>RWZ>\-^:TJXAI;7I&CZ)Y
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MDTU>2[/L0DJ!,D+7C<-#:%)QJ0M-LDXT#@V/;\&JE?5[;-'!6A5W%9S74$%
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M&C<><=8^QZI_&5N3ZSD#># & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M/A"CT [9A$Y]6^%RZ2F!VGK^=.A^>"F)FZ1-=JW(Q4J1^096E )=A4(A["J
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M_5Q1J4.QCI/W&(OC9(E.F$TID8%"'WE0&+512[^@)B2'P!@# & , 8 P!@#
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M=Q:T$8-"X1OQT:(8I#"7$JS)153.)2V1/4=(> M"4)6W!&UI"1I2$B U( Y
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M&",3+/*)3C)/%M$H,5["/^4\98\3%8JN*71T02,)+%;UXTAB1I*DC4HNEX7
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M(>YG['W:'3G=7W4&@< (;.0<XBZ-GKZ*(HBW+D+! :J2)'Y[1(=[+<Y6[$[
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MSD#># & , 8 P!@# & , 8 P!@# *R>LL#1G2_YF%[_$*IAZW\GBWV^$L?\
MET'>MZ%O7X]:WK>M[^3>"+O\>/-I/S%>#L,W/;F@328$P],B>G&5.!049YY.
MR8\BTY!--&62<5H)(4IPM%G:"#?X'?MY81Z;[ZN3/!"0P2$UE=F@J*BX2PYD
MF;E#)&9&NHM$\%J#/>E20X%E^4$DG1"8EM\0TV_$$LX@&R%)P=EZ\.]DJ#M;
MUXM["#'*918*JHJK!$:@BK%&6DR?^466F6OHY62RTRK2HC;,;%+D:15QDLH2
MG%$3D-,R\VHF!75R8;-F';0D.92-"(TP(C-&+UQ+JD*UO0=>>,("5R?1FPA[
MA#YN_,$#8LRT)!6H*N3=-E(JD52"+DHTTD81R8)-40D,55;]4E1=,$1):8W7
MEJW1MC$=J-KE'(Z62DB)*MN*",0IR<C4@"EBANTW.DJ+1IQF"=W0))A[0B.2
MH$9B4)0E1HS2E"0DU/MZGJ&N*_>JYJ>@4BGM,9"OFW+MI7+AEXJY"O7RIP3"
M-(RVK.6VSEJRJ,92HL/,[</7JQ=LHK",Q5ZVTRY81K*@K&4]5A&FFD^DRC-Z
M)<DHV^<S[NC?,2D;/C(+!BDI31J"NKTRH'-MV!U3%1UH'(E!S?N1)??1&:=M
M'M(4N;0F:;U8]'[&6(DP&_VUW9"T=G6&G];U6_HM%954[[16'SB"*J?2>.&G
MC+MI53Z+MXTP\:95&F66D4R>49\PPT\1A6G;,U>,JBLLLJJHC;<%5IVPVJ*C
M#3:,Y=S,S3P(95CM6E?-Y!0E2M9R#D[.E)UV'I0<Y-D.)+T646'0]B.4%:"'
M6@>/7;L O7B^3FH_2:9Q85$6:+);EE@LX:)XH?FBBXK"<5FF"3U\2).%\E_2
M6X<U)(XWQ"05@R(6YD(:8VF;B4*%$4VM"Y\:T!17JQ)S#1DF^K4H0J#S-F'G
M"3K"O-'H0MEE/XQXNC#1G,KD3?G^)J(*JH6T_P!>:@4:MJVV$RJ_X0]E[+0A
M1HE1CFY$&B4M_D:VG.(.\L!AZ@@6PG+!*S3=^8,?BJ]G3,)*4M"(D(<_85&T
MG$2I_P BZZA+4I(V=()V-B&>9V-)*1J9(TMI)HQ""82$?HRE&BA"";O0P!$$
M(M^6#"35$2$5542*HD51,I;]$_Y(BI"_!E-2M722$(K'-'.;]U0M48@G'@4<
MC36T-+6TKRT"U V."<E %Q0("5?D.A9 ]%:6')D2)><G6$;6[3^G/."+1Q ,
M\C3EZPCE6G;;*4C)X!597_61MO@V%=_\F6GGT66DBRJHJ(LEAFK*LPBRTD<B
M'T5_^TAD0@G^^*9*7JBQ21I)\Q&5'"N<O(%'Y!"5"[19VE9?A**3D[-<H>%X
M6&A)*+) +8%JA:6/6TQ'G*0&C\@/C["PR5G)4A&,4A#)9RFK\S,US13.AC"Z
M"1O64((RBM,K'4K+206>4BPA<6,>Y^&-Q8;$>[A1L1*PM.<[,A[D86H'M&XJ
M-IU: !)J<D[3:<,0BMIE!Q91:H@3FF+-$'0BQXQ25_TE1&9+-5152"P@J*B*
ML;I+.141;X+!41KB7&4887JEZZ"ZGK,-##9/%*>S6S8*S+;7@K.V*(G)MDE"
M5;"3(6<DXXAU5B]\%9A")0H$L3B4F%JDXA!$#9A)1FZD516H+DHRRTJP5((U
ME*RL\&D9:5-"1N4BHD$6*7PBD%5%O62*JI*:QXXFD&K**+JV5#\.R@[>B1D[
M%K00:#J7H.VM^'Y!>668,(Q:^70A"T'6O#O&M(*DE1<%2\BS5=4E2_#'"$XZ
M%N6"F\YTDH+ 5D XY.D.6$M-DZ@B*?PM,D2K6GX2/3A'RE\C:%+B S9)2=:9
MLT;Y[XDG!6H21^0=K:@M46+!(HNE;USYHZKDAB5U=:NDW2+\Q^+URN"5(%0[
MW-5[, E&?I8 *%LE+2-P+5K# BT8H2KU#@>(8S3!':'H[N;KN/(L$A%42*P2
M*WJL;M-]PQQFB_#D6>CHAKB6NT%/',6Z6P 0JAE6I*PMZ(!@O,5N3D^E)5:8
MD)8![$,LDI9O>Q=@EZ*'L8R?#H8=E5%7TBM:UJ^K:+1VZ52*92'3METPKK*1
MVTTRKUXQPL'3+3NCJ^>JV^:R&&6%RD^C \CAVC;]TPTBHCQM66U@JP=P::;:
M@RBK]%VRTU)%5<RJ;R_31N;C5(:2B5/-SW$ZFF[.G*"YP)Q=B&E/+W5P0!.=
MU#*G/2-J1T\DUC*,$A0JWS0&[T9*T9N@B+!VML>YU6UF:4]I%%HM)IU4Y3UA
MBG(Z=/7CMTTV[X)*2\=M*\857C2,1>NF&FFU>*[1&&D1G]M(H;#+3+%$;6DI
M/*989;RF599REBK3#*-,HS])59BB*C;,8LJ:B//:&2&!=2:\&AY$6!W='\V1
M$'"(V46H*=5C6\(EXRQC..V!8E/"L#LWNH$G$ 0P%C%L(/7$4@BQ2#5RX*JL
MHW!%SY*HU"]$5(FMC'*2/^*JD4C>EZ+A*Z_2D)&%.$L7@\YYDU#!;#3[41:6
M714$??-*5:M"@TTK'E"F7!<%2019Q1*@M<(&M@4I]A%O8_. '1@@U$58P2,$
M5>)(17G0JQ@TN###3;:W9+#,,MI5_P"*)?*23BD4CNN7]>5%\>*R?^-,,E:>
M)QI(6C.3196Z+9 ].R=$Y^G-='LTA,L7K'1<L..<S2GGR?4$)M>@),3MVD^=
M34EB;0VA<)3*MJYZ^H_"*RP^:989<MO7#++S(>-OE=)D-,/&D8;=O'B\,CM&
MF&((\3];NAO&F66FFG3MVTK3*H]7)>?1R8-(RB(J,M*U!EM$@TK+4(Y*PT=>
M0D.*K"W+;8D:MK>6Z11YX?6=U9"Q!:U@'1$X>-,@-$2468)L(=]$JR2?-*2G
MI5*71PM@UK>GK*J*TJ9ZPYK2KZ75SQ\BMNG=+=M.VFV.$;81655V[1I<IE4D
MPS-4@RB-,Q_,\=O'2,\,PKO*:5&57_!O)6>2TJ9+2).Y;TDL4+WO<]4!IU^B
M=E3EW+3@M:#FQPJ/N(C](-IDDA-=T*<D*\>PC\Y0O1$%DDHQ%G>N$D&#SC]E
M:U^!EAMM49995I52*(RD55$85M51$S,(K2YF455@1EA6FD1$55:CDI*"POAI
MG.,YRO,M]=&BY#(:R46J_O@U[\46FD):P_1R@U26VA-*+)3".T$6TYY0C"/$
M5YWC =YX!&;$4',5^BJHU]%68HTBR5%95IE472C3+3*I?%%2]"*RK+2HL45G
M_)F,,E(PBL+DBF,EFB7E/74V5*7%TX,EH]:"H=.GIPN( #8M:$ LMJEB[>Q?
M)O>M]D^]_)O?AT#?\F/>P["Y>-(8#LT1EV:H3+?^GLTN%7\9X]%&Y&2W2RV$
M@IG)BV8O>EX6/T1YS.]/"OMYFA*2T9Q:8&]Z)+"X$FD^(*M:3@)NBPQNSXQA
M/&!7EUKG"PY:[55)9JE:=)F/Q0UG?"4P27YT"8-8]@]^A>]R;9OC"1OTXM+#
MRP&$#-)()VI.\T1;X+%<4P2*+='DA&.&-_+>8BKD/6[)9Q(V=Y3HG^A%[FW/
M: AQ:W%*P<:Z_=%@34*D(RE*KTZ,\YN+$$W85111@B1!"+%ZHF*JB)I55@B:
MU541$Q541)E@D4Y$3C3L30;E-A*DY?'CWA4-R%6PMZHDXF.KC3A$;VH3*AHC
MC2#"1Z.+1#4!(+UX1 !K6@ZWL9?R1%BF4BQ18K'-!8+J@J*BQFBE:@E\)KDW
MHL\TL="GY^-SUFOICF5+88[HO>Q"\33:UC3B1EHDBQI/D)#FU*F\DL6R DJ4
M3@86 )'A 6J >5L !EC[906,,51&H9F5C!5A<DE6*]$"(BM+))Q6$;EA'#&"
M3UP@N:771HI*+6]S;DR"6+D[617\LEDH5'+346MJ#6QW(*:D20I44: :@;N
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M"RC@VRJ2FJ196Q5(R2<HJMT9<JZEP3%2A9BB4?*OCE!.T:<I4ZANBR6=*K4
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M0>^N_86];%K>]?BWV%OY?Y]_CSZ+1()#,>]=]]]1B]II"HF*7AG[17,2;YJ
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M7R;_ )M:_%G?)OO(^ASYX P!@# & , 8 P!@# & , @AU!?R94C]M7A?^L7
M<ZRQ_E]:>Z]J.HZ::6O?):)[8J7K.BD[\Y,W1 6OOG+^3_V0^)/Z3N5&=?3/
M,6HO>6T75]GC1N/..L?8]4_C*W)]9R!O!@# & , 8 P!@# & , 8 P!@# &
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M^3WV0^)7Z3N4^=?3/,:HKO.2T6,__J^S]Z8&C<><=8^QZI_&5N3ZSD#># &
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M1OC&HVV!D/C+7G!/B+QUNB$9CL3://\ >F+L31'6SU1NCU/O<R-Z=M1>H.T
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MOY/EP#[1\C:"+ 6:9[J2ODLLW6]E&#I9L 69K0 &;V 8H/H(M: 8 >_#O?8
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M'\(-Z$86'\+>OPC !_&,.MT'R3\CJ!5J"$J;W4G>QRA2H+2IR2Z8:A#.4&F
M*+)+U\"/PAB&8 /;7XO%K>^VN^\1W@N^&\4']G]UR,X_[!HS7NIJ[=A\(1=@
MU(P"'K0MZUKQ%ZAVS [[[UK81!T(.]]A:UOY, [ V^:,(. G/]U*782>9X?
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MKX/23D(QQ]J)@]=3) TK%*DT8G=V$ZC\@TUN*+,"4(EJ<'EN*5@- =Y@SC/
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ME V^%Q-W>8W-&7>H^].88LVL(XXYQUM4)2SA(S4QSJZK$:LM2:Y#VL#K>BM
M "RT11--V$,V$L52$[X27,L)%TA>"RL:9,W%&\B^<X2T)030IT6E<CI !:1.
M6<88;H*71NRRBSQG#"43X#!#%WWC'??#/\"SG>LTA='#BGC=H*[Z5?87&'==
M)YM!F>QD#0@G#.ACSLY/K2G+>Y<RK$$7?T"UD4(U CXD_:T^%HQFA1K#4XD:
ML/@4[&2))=.9;L(:(PBJQNG(N1O#A6YTEQBJ#DB6VM\E:5 XU+UT9F+06L:
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MW2J(EUR\7!%%X$QJ^**9<Q*%8-:&0/8(^H(2%I=>4'P)QG*PA+T$.@Z,%O\
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MA3E4S8Q;>G5B,F25HD#N:4U>M.+4B7:0%*34!1!:I,+3<Y"&0$H("#R-B,+
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MBZJ;=G*HD\>2. $38J6C+0I6Y"N=U*LA$R[7*0GI@ 4#4!,\)A2<96B])O$
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MQ-1"(1ZC9H02[IGHQT'AFWHK=+]G,(.;.)401G)E)"P@XJ86EYQ2I*8$U.>
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P""'4&_)C2/VU>%WZQ<!SK+'^7U
MI[KVHZCIII:]\EHGMBI>LZ*3OSDS=$!:^^<OY/\ V0^)/Z3N5&=?3/,6HO>6
MT75]GC1N/..L?8]4_C*W)]9R!O!@# & , 8 P!@# & , 8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MDA\8I4_T)<WO8<Y0?NSR^)E8>M;*2_\ -E0?/SXAX=HOH==;"KCY(?&*5/\
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& , 8!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>55
<FILENAME>g459793g73b20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g459793g73b20.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1K84&AO=&]S:&]P(#,N,  X0DE-! 0
M    &KR^:$0X0DE-! 0      "T< 5H  QLE1QP!6@ #&R5'' (   (  !P"
M!0 11FEG=7)E,C%?,#@R-#(P,C, .$))300E       0F2;._WP\RBW+Z^6B
MD6M:JCA"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /
M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
M    3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT
M<F)O;VP      $)C:V=/8FIC     0       %)'0D,    #     %)D("!D
M;W5B0&_@            1W)N(&1O=6) ;^            !";" @9&]U8D!O
MX            $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L
M=                %)S;'15;G1&(U!X;$!UX           "G9E8W1O<D1A
M=&%B;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N
M=$8C4FQT                5&]P(%5N=$8C4FQT                4V-L
M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 [_^-0 "  $#O_XU  (  3A"24T$)@
M#@             _@   .$))30/R       *  #_______\  #A"24T$#0
M    !    %HX0DE-!!D       0    >.$))30/S       )           !
M #A"24TG$       "@ !          $X0DE- _4      $@ +V9F  $ ;&9F
M  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $
M-0    $ +0    8       $X0DE- _@      '   /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H     /__________________________
M__\#Z   .$))300(       0     0   D    )      #A"24T$'@
M!      X0DE-!!H      S4    &              ."   (DP         !
M                          $             "),   ."
M          $                         $     $       !N=6QL
M @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M          !,969T;&]N9P          0G1O;6QO;F<   ."     %)G:'1L
M;VYG   (DP    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4
M   2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &
M;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9
M  !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J
M8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO
M;F<          $)T;VUL;VYG   #@@    !29VAT;&]N9P  "),    #=7)L
M5$585     $       !N=6QL5$585     $       !-<V=E5$585     $
M      9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $
M   (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L
M:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%
M4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T
M   115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N
M9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "
M/_         X0DE-!!$       $! #A"24T$%       !     8X0DE-! P
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MQ $_   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
M      $  @,$!08'" D*"Q   00! P($ @4'!@@% PPS 0 "$0,$(1(Q!4%1
M81,B<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"
MHW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W
M1U=G=X>7I[?'U^?W$0 " @$"! 0#! 4&!P<&!34!  (1 R$Q$@1!46%Q(A,%
M,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55
M-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=W
MAY>GM\?_V@ , P$  A$#$0 _ /55SG4\'.KRCD-:W9?; ?\ :,L!OTG5ON93
M8VC'J;'O_P 'O?Z:T_V#TJ7GT/YS=N&]\'>?4?[=^WW/]ZDZIF&_&IQ*6N>&
MO96ZQ[O:SVV/;O(N>_<YK$E,>G75T8Y;D9%1L+W.,7.M$$_OY!W_ -CZ"%7<
MQO5[;38P4FMI%A>_:=WM].O=9]E]6MU&^WTZ_4].VG^W%W6<MKG X3W;26AS
M/>UT?G,=I])HW_U%D?6#ZU?\V\YL].9=?G,]2Q[+BW2O]&S<U]+O=JG0A*<A
M&(LE1-"R[/6;Z[L1K<=[+;/49[&O>"=Q]+=NQ'LM;75ZGJW_ $V?9Z[5>;FX
MNT;[ZMT>Z'")[QJN#O\ \9[<BIU-W1]];Q#FG(T/_@"DW_&H6M#6](@ 0 ,@
M0 /_ $'4OW7/^Y^,5O''N]W]MP_]/7_G#^]+[;A_Z>O_ #A_>N%_\=5__E3_
M .S _P#>=./\:KR0!TG4Z#]8'_I!+[IG_<_&*N./=[C[;A_Z>O\ SA_>G^VX
M?^GK_P X?WKBS_C*RVF'=&@D$_TIG8!Q_P #_*0?_'5?_P"5/_LP/_>=+[KF
M_=_&*N./=[K[;A_Z>O\ SA_>F^VX?^GK_P X?WKAO_'5?_Y4_P#LP/\ WG2_
M\=5__E3_ .S _P#>=+[IF_<_&*N./=Z[JYKRL,TX^12VW<US2^U[![3,[\6R
MF[_IK*9C7.-C76@6MB+AEY==1:__ $-C[;FW7UN]3U?9_P!QU@XW^,NK%8:\
M?HWIL)+BT9&DGGFA%Q_\8&.[,^VCI+:\B^O8ZPY!)+6N<T5M:W'<W\S^0@>6
MRQU,:^L4B<3L7JKW['XM&)G6,J'L>0&WB&#U-^7D7^I:SU6L]#U-_P#.6(G4
MLH.J9]ES#0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M,P+QJ;7\&KB*XV$6'>BV IM(8V1+%[8"CB/=(KLN#,#/%S-;(JYY\17JD=,
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MY) @A5QZIW^S:YO<VNR&VP*LE+>X_KH]K&.%E2H8</2]Z[.,Q3;Q%# TB1:
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M<X\\9QG';+RSC./IQG'T9Q]..$7[\N=I_KEZ_P#X:-B_JRX1/ESM/]<O7_\
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MN\=5"_6N\/V)BMNPY,NQ2"MD+[/^(16TKLDY,FO%YD!VQSK*-(KXZ\IT77=
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MJ:-_2F_OR>]/X8#J?]ISMC_5Z(_)+CX>?")Z]IWV55]R>:FC?TIO[\GO3^&
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MKH4ASK=0:[N/2YXG<2RH _::*U-#Z2VIURVHGS><>W-6.PT+7A>C!8K8VH%
M;:/CB2<\#EU-Y='R^SYN6.T+/ID;=Z[!^XFHZW;N_H6S["\7'<#]KMX<SN>H
M5.J:J*U.]6?5NQ#%VUAUFV_LRS0=VDH*84]K2$8=,MME :^A7"W4JL/(8LY7
MH[3D_ECLZ.7T])5P_"5(]F=D]NNM>Y.RH;:<Z_2_!R):_P!A7G8U+/5PG(OM
M4[]WT9%KUKE$PPMM%[^4! HI/ASTMG2T-6++);E-D%3WR#IS[!^?R=O8%@*U
MN#O&(\7"\4J3:>SNUM=6K=FZJF IPI&X=85/4NM5:R+SJ6=NU NNH++ULM^G
M*\2CAX]%VUJ_<E#VI;[++B$SC9!V7+JL\G//S_E]_P V/Q5%MD[W[E]CNG4?
M41^'VYN!<7X0'92L]DJ]>=3[D$Q;#VY!;8UI @"B*[/41L:[;,%UF225%>K[
MA?VA)93<60ZYB<Q%*')'7_*<\NOE]_3R4U1=L]WZ[2-U!M$[*\0.R=20*.@(
MW>6S+_K>\,=E=*3SMM("^ZH?K,(L&LA%K].G:]C5Z2<%T:I6&OZXF2)TVB9'
MQ4MO.DY]6>KY>GGTCL]GR*ST'LWM?55DZA7&I7KQ(=C]42A'Q&]=.6W>.GKP
M=V%?K*NNZX>ZM9G *149.Q[#49ECBWH?I"^;CJ]?NQ)S!5\^@<+:A/H*CJZ?
MG!^_E^/3[5Y\TBP=I-=WNF]J=HS/$$L^]KSX&P3X6FA0+(BVVK=P?8VR8%RI
M$H_8M/;(K=2,4RGML[E4/M]?)F!END_- <*?-DP%<F%.?2<_RCH Z>>?G&>C
M[BIHT9L+OQ?XHK3K>\NXL2A&_$YZLU*'LR!)W<2NT?K)M'J_LDMM5 ;:>^=,
M:]V$8UU^T$*S&9N=IU\$$@;(Q",5B&*:DU^3)*\\_/\ =CWJ-=O;I\4&K:PU
MK2BFS>V@K65$V+XB%"#[?;?W.+VG<+IJW:?PCJ['V;;]2]>MT7J]HE41<\C1
M MAJ];U]N,FTZS:;@N(*AL9*<\CIZ7=7MY=1_(?G-&\-U>)K#O%G^<;]W!K?
M;D/K+H))Z/:HTEJNW1>JV^[I;:;2'NVLO=\*/KF55$H';&DW^+<Q&WCE!FZQ
MJD,6Z"8:0TR^LKSSSSU8P.7M[<<^WJZ.LJ:R79SN3!W\*T,^3[3MWT?XWMAF
MV%$#7&T9U&C=#;#K,O(H(3%_?KT?7,_5I6QN1Y(*L+M2,K>%RI,^-"C17)&"
M<_;TGJZN9'S='/MY+/\ @M;>[DGNS&S]>]B;9V4W($7I@G9S6SM@)W/4=>UO
M8 S9\47!J]QTQOG2U;D:DW:;#DC#^:KHG<%EU!&K5>EX:JTAU PV+(,]?T_)
M[,#I^=:'V/?\1!BN^*EO76FWNWB2NL>WM<TQJ360(E88E-K/6"R_V?3.W-J:
MKK S7%QM!VRA0DJUBPERK0J[8UX#<N]@I53?MS3SZRASSZ>D?1RSCESZ^WV*
M)JYN;NNYJ;0+?8+=_<^M]+2O:/MH&M6]NOX#?]A[%#=?U_5M1G]::X=O]DZ[
M4K?5JU\3VZ[L\:*V/)U7 ^;(\6J5NW$$1A^7GBOSD#Y.?W@\NGG@=2U7=55[
M<237<'M3J:[=^Z#M;7?AO="KKK(D<IHBA[6W%L<+>]CJ=#[SI5&K1VM6NS#:
M_+DNW74P22L2V[:GG[B"=)Q1V!K_ #W[/DZ_O4Y\R,_RC'+KY_?[%-UT[!]R
M#'BA#H==(]P*UKACMD>TEL76]R=V?8=4%-,3^OY98*ZA:2!T!6= T35]IO#4
M%[7=GG[;O^Z;"741(&I0L>RJ/'*\\]?3S^3!Z/GQ[>WHP*!:LKG>C2/7>I7+
MKQK7<=4VJ \&/0=)(F!5#M,*YU4:YX@UWF[<AU9#U0L$Z'L@!J4D8L3$(=63
M]P B7<6@+6YQ"*,0Z09P/D'Y95X]#G._&Y9_4?5Y_??; 1HS8O>#LG3I&S:4
M6W3"V(WU["]97;**#V3<>Y-#ZENUFJB-O0C RC;0M6OA9V.LDH$$L.+#7!A"
M&3GRZ>G[@#V^T=/M4%V?LIWK!:)T1*W_ +I[V4B!6^B/=.QT2W:<JMB?V/<N
MWFINQ^TZ;JI[M&D512TAFA(T)5ZG8(AW94*M4&P.XL=M+6),F+((-DR<<P<X
M/0.SW]0/R+EJ78OQ1[5NKJA/C[)W?'19-+>%W8='H4WNDSJ_=-6V)IK7QWM8
M?V-6J#U\V%KK8A,M;B&P8E_N6UMN:TL6K(C-?LM63(BLI>?)SR1T=&/DZ_GZ
MOR7]H?"J<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G
M")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB
M<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(JG
M=CNB_4KMP5K)WL9HZH[0-U 64! #!=PT-*1:\;>8D&*U*(5XJ'EEJP4?CM/3
MZT8=G@I3F%K>'K4Z]E9%9T($#UH*(KE=%#P5?KXN $!!!,-@>*#AQ41J ,%#
M($5MJ+!'CX3#$2%#C--L1HS+3++:&T)3@BRG")PB<(G")PB<(G")PB<(G")P
MB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"+^>F#W9[5+N;N
MHY-WD)/1?$X]];MN*O5LM3.B1#Q"U=/!^I9"L \P&+$N]?&:O"-MQTVI[7U6
M>)O&$V)_)ITG?O\ (HWZC]_.T!G7C>'[_:^QUVV)U>TU>(I&H(UAV3:TQL2T
MDD#MA7F^4[K?JG7EMU="KPHRR:"Z1O4&[EKN:!2*_!O%1AUZY'7"+<],]]NS
M16\]-W24S9NV2&WJ1UBD'=952#U["L$:'=NJI"Y[9V3<]=VJ=3.P4#83>X1)
MBWA[E4Q\3KV[K)FL@QT[%KGF0THG?OE6HU9XEM&']9NF=OM&X=.7^X[ U^ @
M=A;'*V-2QTK7^PD]7=C[=8:N(T!)9'U*Q76^:SGU2+72D(&IR9(*P@X]<\<F
M F<\#MZ_H^7M[]:*."/BMW_Y)^<8%<Z_#BLW-?@YU,?V@@5N.H,2E:?]ZV*=
M 6TG0Z-.I5F8V9))4<78=E:QF%PSFO7Z_8KI8KZNIUVHK"W;Q#H<+66@[G5C
MO7\)+VAJ(UM2X'=HWZU5[75:.@-=ZTV% TQ%FLU-J]Q[]L\1LJ-8-?(*T;YE
MD:[KI^\#];6U;<&OS"+J]F^_5YU';-D,ZPJ&M]B:]UM4^O63EJ^<H29$&\;[
MWUN#1L]HE,(G:E0@U?U(1TU84VUJRWJMRY]QF0:-.)TQQLB=@$6G8\2R\S=2
M:IN97550T;*OK]Y;E;7WUL*JL]:"?R#6[V?:CT786K[7?)9Z;L+Y,8R :6SA
M(<*1,F!.=CS*JV"LA%%XOQ&MVZTI)(GLV/J\RW>MF]I(6HK$7F'Q$P,(UCWU
M)]>Q57ND9\-3JU*?ATVT5YNF/'#FK!KV:DD;L"\#BYUT^T3OWZ%!HKQ6]ZR9
M.=SHKS1:IRZ4S)_8X/)TA58"G"3^@:))M4^_/O1(K%)I9N\6K95C(3;]&K\*
MJL%&YUS8#P&;'#G//LP/SS^2*R=4\3K=5AAYLO[#Z3*K-/CZ,;N8L#=H=HMU
MZE;U[:=@.JM<E:KDT0Y>:$UZ4O3P6[/AI-QMBTR["5H+9M^2'8M<ZIW[]^2B
MVQ>,3L0&,8R)I/7^^RI@.IVAVV4[<("#KFK23^JC^SYNIKE9MD6S7@87LJ&^
M,16<)0?652&%678&*!)E#WM<PR+WAJ1Q^S56LV24(F5^38*^&.2 )%V*^0"/
MEAL:>Z(G/077X3TP:Y(5#E.PWWHKC[*UQW7&LH6HBV#A$X1.$3A$X1.$3A$X
M1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A%0KQ)-J7C3O63-OU]?OV8G)6[>M
MM.FW3-AHU00)JU]WUKVG7##UOV34KW2:BQ-K!HK!>M!^IFX8!N0HI[FIR,A2
M2A[]'YJJ&A^QW8RZ4;I\=?W$)/@3/=[=&A=H$DB]?[#G[8IHD9NHSK-5<W7K
MV'4=9'ZZ""U0/'L]IHVJP)"T6F T+7*JLJKW ?;BJZW0CN1OG8(>X$]L0;EN
M*TF:9HJZDJ?JRPZAOD?1=BVC(V_&M]/M\>+3=&3]6%Z 4HC :V:ALIK=%KJ,
M!BMDL7VSE+!8V!Y%I6KMA=YV?"\V'VE/;JMHW:)7IY5=[U:V;'_8QM,(\ZC3
MI/9%D*T2D:\U3I?% +&Y+@Z.,8V"8VR, ,28^7@IQT5*06'H/5[>Q%L&^N[&
MYM,;RV5/!7@7;2=4VY>-?3^L-B+:OJ];J>C@G6FM;'JV_IY@Q$K5K%.D]LE1
M(-5PNNSZYJ0FW=XU (E*?/BL6\&13RSXAC!G06D+^+/Z)KESVEL$O1[@;O\
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M6(\5FRC69@QYN"?:C1(L=LS%2T10Q&CLIDX;9;2GDK:H_P!I#=!E)0G0]O,
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M<>6A&5I]KSP1>)GA5@'J5N/MQ\1U9=ZP5VWL2P;"5;2>@[MK" 0'N;(V98H
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M%)0VVVVG*EN.+5G"4(0G&5*4K.$I3C.<YQC'/. 20 "22  !DDGD  .9)/(
M=*JK5UWB[67%(E-SL4MJY$8I ['Q0L6- )BOW#8^Q3E;AR6[2E)1JQ1*:W3H
MEECY]N+%,19,8>XX.;B+S]%K[M+#HX]'==-2-T<+O'C7,[K%73M/@L/::O\
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M1SCDM<J][I&W-4VXU2[)5]@A;O<M@:^;)!)XJQ 9DR/;"NM945]2/?8)!@+
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M+AYI36"+3M?3;!*UT+-7P%!IMJL-EBF;)789M)R"",0RT5\Q!9,YB#,3V67
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M#KN/9P&>K[D47;CO8PU@IJ$37[-;S5BHIFPK@UYU(N*5#,.X%R!(^UNSH$6
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M;)"AR!&) *&X5;'SI,.(])1&F'B*5P0T16&E*EE)B<Q1\9+LN3[+#+BL4#)
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M>'+(HYK7AO\ 6&AE"]O= V*_S9U8OS%G#[0.-7FIW:U; M)J]W39=OJ14=D
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MPYO3RM3SYE>E.$3A%XED/!8I9N$7!'.Q&R)55L,S9<8K7XX6%ED?5KU$U^[
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M=?\ CHVC:UJL4[>AENKPTI/MUD/U)#$N#0B5:L<:(!&U.=)=1%(FH+XTP\S
M?5%A31Y!K"FW?OW_ ,N?+JZ>7;V*1*'0*OK6K!J=4X4B,&!08X^$HB2(G"KD
M>+A6&,D#AF5.+DWFDJRAMZ?-D.-,X0PUEMAMII!4#');GPB<(G")PB<(G")P
MB<(G")PB<(G")PB<(G")PB<(G"+7+@W97JE:6J8_"BW!VN&VZI))I]L='LJQ
MDE()\@CV'?;A-%,Q7):?3<]IA+F/87Y^SDBJQT/"]C /7P4.[0.V]>R$6:S.
MQV-A6"F6J^0ZRY,;R-8M5@U^0+5,E+<GX+31*AA2<J)6)8*!-5%GQ)(^&1;#
MOK6VRKUMCJZ4H]OV74JK4-F&#VW%TR\,URMEZ,+J10T+K]KKBW?5MN;+L,12
M:_EI,28S IQ*^-JS FDAY*(160L0\D6 &Q8<].JQ8D*(01EF&1!,\E7Y\J*Z
MQ$-0()Z 4!RYHQ]:)D6,8&$1;S[*&Y\&7%4ZPX1>8W4<%XC@S<&DW.RS8I[3
M0KH]4*G;WF]C"#=HD]F8@W2L^X6;8E?'5=IB;>"ED5M0)$)U:WGZ,BJAHQ*,
MZ+,FI,(L4]W?J[]BDWL.'[,'^U6CAVIY/8*I:J^1;\G86R:,5T 1U,$-DJO>
M ]7%']>[#-Q+P1LWS!.KEP5<X]6V&# N4^G5@54\0[OLDX))_P!N_1[.WV8Y
ME6)Z[0]KB.KNBQ^Z%G)N\A>@]8P]L..SJ^4LDO:\+7@1B]K<)1WW:J1./V]H
MJI<YF2Y7YD]>7VWUCG$N9*KRUZK5;Q+V]Y]?CNT(^_P.E83VP$;0J&ZK_P!?
M[26%#B8G;BQD,[8=87P\Y=7XAJ1IB:(,Q:HY/,E'++%!1]#42G2ZMM,IS[_/
MR^;\#[.=[NX8SLJ0)]>G^N#-Y=F"]SU,EL%5=LNO05-S0H]CKF;=&V9#N! <
M?+ 9M)S<(PU%-8L\UHNMB,JIH,D:U?\ 7I58_P .NK]FZ;UF 5WMM/M1G;HX
M^<:E'[V:#%KI80V4P<Q3%EC5J_[3K("9()?%VH0:N[!L0O(5@680U6))>33*
MX4'1S[_>>OLY=2I8R)\41S>[2]C@=ELTTOW5K5I!'^O^V-+V+55)ZSQ 6I$%
M:W>*5LR+J2]'P)!D/9JD02&>-'1Q2X[?V;%J=C/5?3D P55Z.^\'M\5Z^%Q7
M2EFN*VW.,CO?I9BXMT@W$J4*,0)3FJ,7G5:U _F@R9A@:^^D\P*B,54M9I@X
MX*L,8+,:(?9W^XK4NB=:[C5R3V13VO/ES@LCNTU,THNR.5!9I-)5A_WF9#;I
MEJMP^!39[BAORH,FRJZ5BXC%7)-&J;4B/$?(/?\ C^2] .$6&L5<KUP EZM;
M0(6T5BP#Y0D]7+$+@FP)L5.:4Q-&%Q!-B4/)#Y;"ULRH4V.]&D-*4VZVM"LX
MR14/$67>0/ON+U4$U?&"]9P.C<#0AH5J1T?6 PN#"#2!F!.VXD1@&/(HM++U
M-;TQ"EH=B5P/ N"*^U$RT523OW[_ (*[E^R431KDL&6+ 3+=7/."C8$!&M9P
M20;%REPR(:KS(\N+8RL-]+;X\'(BR&2LM#4%QAU+^4*(HJZI#-DB>M^EXFWW
M(N-D*H &=:1D*K@Z9%J\PK%P3CT=FMUH>)!CDT(?,B4O.1HH9'F* JGX'05R
ME162#OU*B/<S</?'6AOLY/T3HQ.Z5T_66ASW7 C6-7CR)6D$K;_:);WM*D3;
M7=1'[5+0AC6VN0J*O07(Y.NL[*HTZ?2+'"07=/E.>?9@=G3SS^7?*O;V;O5L
MH/7C8U\IC%\BVT)7(A$2/U_JF7N_8RICQ(:RZ'J^LP4E]%ALTQB0^,@R7'"5
M>KLU]-I.Q#-<"D8,PJH%Z<6_LJ;M5C$[I$UV)29'73J]LVK$*KI6\Z='/[AV
M?)W7+[&P2L6_LCS\NU*M@"O6LP$)5RFFZO!N(5NR56(=*32A@H/R'?J_ * .
M\V[>U%3W6U2]#5JY6L.*UE6KA[N]U-V'?*2$M<W8D$$L]5-T :5L$.YLFN52
M2=M),5\ )O4RI!TO@-;;HNMH'50>55]Z#<=I%^J=-O\ = Q2N;J)=?P-NM5?
M10I4\R$V?*UY%,&Q+>L&K%%G320^U+DQ&Z(BUQ)DF2TFOX/17W/?VR+SNZ>;
MJ[LVOL-1@^WM;V,-K"Z:KO1NY6!&D+5K%1K8-5V=LFFU+9FPR5MTW4F&9MPU
M!4M/B E75;J?LK"40K 7T56*B3:C4XG?L4\]Y=O=F*%<M(5G4FEK-<-/6!_8
M9#=VS06JQ6]UT]035.Q#NNHT?4L2[5RYFUB+^ K=OF_!A[DJR2AM>UY52;5N
MM\*,IW[]PBGKIS?MG;(ZV4&][=B6-N_F\W*5/&VG6ECU!=8PJ-=[-%J NX4&
MXA*G*#W>'4(P&!;)8\0.IAVS,DS]'=?I),%.?(O,?3O8SQ,+/V>UHG8'627K
M2FWG>6PZ3L<45U:YDD!TE6:F'M%)D&=R4QF]T,L*I$ZZ'8%6.S]D4_%UNK=V
M:K]:+L%6P0 IS_'V8_'/T^T+W;X53A$X1.$3A$X1.$3A%2OLW2]3Z=";J[P-
MZL@W#<FM]"7)MMV?8;-!"& E=#SRK;!@)'F3:M#>;9;7"*7UNJ3+D.J"9@J.
M3<$-)&**8[]^_P!"SO2ZP5;9O5_4%J&T.EU@0BOSJF#&51UP_4) #7E@,:^
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MHJA$.J.P1IU>PM8Z?8;7893*XNUMHF=E5@94K)!+443-KS(,_J*Z/62PI06
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M,?1C&/HQCZ,<(JC=E^X5*ZOG*B-MU!V1;81VD;(V=9[)18U(DBM8:LU0>U<
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,3A$X1.$3A$X1?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>56
<FILENAME>g459793g76a10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g459793g76a10.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1X64&AO=&]S:&]P(#,N,  X0DE-! 0
M    '?J^=G0X0DE-! 0      $D< 5H  QLE1QP"   "   < G@ #&9I9W5R
M92 R,BTP,AP"!0 ,9FEG=7)E(#(R+3 R' (W  @R,#(S,#<R.!P"/  &,3,P
M-S U #A"24T$)0      $.4%0OO[!..-<R3UMPHV;-,X0DE-!#H      .4
M   0     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $
M26YT965N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O
M;VP     "W!R:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T
M=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E
M='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#
M35E+ #A"24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I
M;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L
M      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.
M9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J
M8P    $       !21T)#     P    !29" @9&]U8D!OX            $=R
M;B!D;W5B0&_@            0FP@(&1O=6) ;^            !"<F1456YT
M1B-2;'0               !";&0@56YT1B-2;'0               !2<VQT
M56YT1B-0>&Q >0            IV96-T;W)$871A8F]O; $     4&=0<V5N
M=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M    $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO
M;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG
M:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0
M$ "4S,P  0 ! )3,S  !  $X0DE-!"8       X             /X   #A"
M24T$#0      !    !XX0DE-!!D       0    >.$))30/S       )
M       ! #A"24TG$       "@ !          $X0DE- _0      !( -0
M  $ +0    8       $X0DE- _<      !P  /______________________
M______\#Z   .$))300(       0     0   D    )      #A"24T$1
M    $     (   )    "0      X0DE-!!X       0     .$))300:
M  -!    !@             "2@  "=H    & &< -P V &$ ,0 P     0
M                       !              G:   "2@
M       !                         !     !        ;G5L;     (
M   &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M        3&5F=&QO;F<          $)T;VUL;VYG   "2@    !29VAT;&]N
M9P  "=H    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M$@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R
M:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
M5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,
M   !        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M          !"=&]M;&]N9P   DH     4F=H=&QO;F<   G:     W5R;%1%
M6%0    !        ;G5L;%1%6%0    !        37-G951%6%0    !
M   &86QT5&%G5$585     $       YC96QL5&5X=$ES2%1-3&)O;VP!
M"&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M    #T53;&EC
M94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N=6T    /15-L
M:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M
M$453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M       *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M        "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M        .$))3001       ! 0 X0DE-!!0       0    #.$))300,
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M/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M@-N]5EMUGO\ U?\ P?Z+V>H
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M4Y.D\ V+@,>M9*^BAS 0>LEN7IR#S"X'=_3BOH&E X<*+BY/;C^-1IZ?S.6
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M@MSICME%K9J&%7A'-6:\-6+%)[0HZT]14@=MG*QL#N,A3#4_,M=9':L0 2G
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M^"]1^<:]"&^U5N][OM?_ !&4YLM7O\E9C]ZVPW_7>%D]\M\^+7]/C-\>7?\
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MRP'[?J4:4S/8!IZ2=K[3D\M1.?4>/T=V"N>HHRO!XI&R-:F['E .(3"*X2$
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MWA]Y/QM[!<EWXXXXXXXXXXXY_.^^NNN^^^^NNNNN^^^^^_5UUUU^GOOOOO\
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M[=VN7UZBEA32NZCE%B#'O2:N36TYD)B[1ODW7RQ<N,\.D^">'\Y?!_661O\
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M;0'_ $.CO^SN:Q;E"=2:[UIMM[?P89 :JED1+UE)Y=!ZC?S.6@T+.8N(.B^
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M/^VRS=STS+"'[Q@Y[;KHK?,KY_-*IY_)SZTM >*WQ\Q6OSE9QK5Z! 8Q(I;
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MD4J3E"<HD@:Q(7!8?';'BQ\P2BUA#XZ+PF@8ZHVQ4[R\!U!UHBTM#SJ-TY$
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MJA^7X ^CI/*7]O7F,F[<OE/KU-TX2)_24UE,,L 3KQ3Z<2:#0^IH16D=H:G
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:BGAUU@FDDGCC@GACUUCAACUCCUUUUUUS_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>57
<FILENAME>g459793g76b20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g459793g76b20.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1X(4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '>R^=F X0DE-! 0      $D< 5H  QLE1QP"   "   < G@ #&9I9W5R
M92 R,RTP,AP"!0 ,9FEG=7)E(#(S+3 R' (W  @R,#(S,#<R.!P"/  &,3,P
M.#(T #A"24T$)0      $ ^Z0V@F57^>N[VI\NG>U\,X0DE-!#H      .4
M   0     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $
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M=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M    $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO
M;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG
M:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0
M$ "4S,P  0 ! )3,S  !  $X0DE-!"8       X             /X   #A"
M24T$#0      !    !XX0DE-!!D       0    >.$))30/S       )
M       ! #A"24TG$       "@ !          $X0DE- _4      $@ +V9F
M  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M      $ -0    $ +0    8       $X0DE- _@      '   /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H     /__________________
M__________\#Z   .$))300(       0     0   D    )      #A"24T$
M1       $     (   )    "0      X0DE-!!X       0     .$))300:
M      -!    !@             "3P  "=D    & &< -P V &( ,@ P
M 0                         !              G9   "3P
M           !                         !     !        ;G5L;
M  (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   "3P    !29VAT
M;&]N9P  "=D    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M!F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
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M;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
M C_P        .$))3001       ! 0 X0DE-!!0       0    #.$))300,
M      J*     0   *     F   !X   1T    IN !@  ?_8_^T #$%D;V)E
M7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,
M#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,
M# P,# P,# P,# P,# P,# P,# S_P  1"  F * # 2(  A$! Q$!_]T !  *
M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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MO#&QMW$P)<=C!P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! ?_  !$( (X"70,!$0 "$0$#$0'_Q  ?  $  @(" P$!
M        " D*"P8' P0% @'_Q !8$   !@,   $%"P@## 8)!0 " P0%!@<
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M8P,++>]CMC,R,J!*U-#2VHN->E$Z-N;&U"40B0(4A!8"$R1*24G()  LHL
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M)7$Y*'2C5U&X=!VWX9XWRNY&Q2 [HOI<QZF,>:7)UHUT<ZLHKNRC7,N&6&L
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M8H))&%:%T=,5QT=SG"9+$"I'%W%G[ZXWK:202Q&M/&)Y&9W NXN>BI5&79E
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M5LZ%H8YNADEH4&[E.,0*T[JG_:1O+$6F<R9.QQIS1JSBT^T!@M';*"P[ 8#
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M?* X%^L+:'\G72V!,' 8# 8&F+\?[]<KX@_[^G#^&X[@4]X&Q4\A[_09W_\
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M2MI!2$I*((BM)BPE;#L'YL"+SQK6N^*YUK6M:UR!<^M:U^;6M:N>A?-K6O\
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M?HV(ITY3Z\QB9(V%9.9A-F/K'HJ!/]L!VA6HO?J!5USF78K(Z.TWD45ER?\
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M$\0.N*J8]%1ZRC9HR>]@X>WJFUS;G@I.0W,!C$R-(6X8$-.ZOT/5Y]</@?\
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M/F,:#3&\2<8@Z)Z(^4!P+]86T/Y.NEL"8. P& P-,7X_WZY7Q!_W].'\-QW
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M@RVVGC<TFVVI.WP15/TFF!U:4*G N6P(@O'R^*Z^J#='XST+@2^P& P/R/\
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M-<RB5>Z"#/=&VA<8-8U[.]/:!4,:A)ZHX6Q["+*+Y?4C^J!"OQGG^!+_  &
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M.MX/:WA\2.(QB%3Z[ZOKFQU[,7,:*F\Z"!I@S]*)2)UD$Q>R&1>2:[+-[8D
MFTL)>5+U3R/6S,YM<K\3RJ+V6+W/WP32&VKXY ;WEF3>Y$Z;WF;2Z9BM0L8V
MSUI)B[TW5E<W7W4J4!]]/<>DZ1.$_$ZA.K3D*TAY*I*J)*4)E*<T!R=0G. $
MPD\@XL0BS23BQ!,*-+$(!@!!& 6P[UO8::;RA?\ 70^(%^^5%_ $,P*9L#+8
M\C&_6PV3]26W?Q:H' VD& P& P& P(HO_P N.I_JH]"?B]S)FA@_*DQ^X9-_
MFSURZ?QJJ_2Z]_;ER5V9YU# 8$07CY?%=?5!NC\9Z%P.;= ]&LO/XJI;U5>V
M;:<JNFPE]9U_"JI;HBND;I(6JMI_;+J<H,G$S@<=0-;=":TE3@>J5/X#C#TR
M5$E2J5"LL&@ZS_NN+"^@7VI_\OY@_P#RAP/AO_<RN%$LSI8O'W7->15VFM>P
M11,Y*S\_J8^PN]G3R-UO%5+T5%NAI)( MATKE;*D6J&MB=%"0A0-7M(,HDS8
M0G</_$%_JB_Y;P-"':/Z3+$_;J7?Q X8'!<#;J>2J_J0>4OVFZ(_F'L[ R),
M!@,!@=(=*V>52O/]QVV?,H77A5=5W*9<*<V(QR&3PB*^\C4H6A>Y+&(DX-4J
MDS:A$7HXV-QMS;WQ^&$#2U+$ZY80:$*RZ\Z-GW1#UX2<WF,3:'@<[M6VYRKN
M:JWRMG.C7-Q*Y6[2C+?"VU*R7)8\P;;$ P-Z)]F3*V[F];Q1[T_1-LN*5KV@
MHQ<%T> P& P-,GY01^N:\07]^1O\(Q; ISP-D/Y$3\DGM?ZQ<)_#1-@9N. P
M& P/$<00I!ZI024>7Z91GJSBP&@]828 XDST!Z$'TRC@ -*'YO2+,  8-Z$'
M6]!$5%\OJ1_5 A7XSS_ E_@,!@>,[_)&_P"S'_W=X&@:=?\ .CE_OZS_ ,09
M@>A@;>CR63]1IQK_ ,2Z1_FGNG R$,!@,!@<+L:'IK!@$T@RQ0ZI4LNB[Y'3
MU#'))##W<DMW;E"+8V^4Q)Q:9-'U.O7:]6ZL3FA=$>_\,C4E'!"+ JP@E"VC
M0Z_P9J_GMHK7,^GH/':)E];,R.,.5>J+-KG@>\F&264S3)?#VVT7)4O.:53.
MB3.;\DCJEF]0YG1-&^FFJ0A-3M:TK IZ@%LNJYR9&:<.5M<T5FTO,B81R=I9
MDUU]+5'33Z[FL '1E]]%37'IZZKVQ,8Z)"-N:=&-0(P@!A)@?,^";LGZ84'^
MZRT>US XW,H%V=&(A*I(1UW U1\>C;X^$ICN6VL!2@UI:U2\L@T8+<],!9PT
M^BQB!_?!"+>P_GUK D?0TT>+(HVF+$D0489!/:HKJ:/@6X@:9O"\2F(,[XYA
M0IC#E!B='I:N/TE(,4'C*(T L9QH@[&(-/%X_P!^N5\0?]_3A_#<=P*>\#8J
M>0]_H,[_ /WL4;_!\^P,Z3 8&,WY0!_6_F3]F[0_M2$Y<_0_[M/>_J'ZZTF]
MO?:RSNZU^4!DR9#%(,!@</L*>Q.JH#-[/GKP3'H-7,1DD[F;\H+4'$,D5B+.
ML?Y ['$I2CU1Q;<TMZM6,E*0<H-"3LL@DTT0 ""OB^N@:XZ"YA@]AP14]HFA
MH[CXGB<E:YK'G6$RB(R:+]Q<_DO;'*8](4Z)>SK4A9J5>#9X-IE;6O0.:-0>
MA6)SQA8G^640_P#6J-__ #QK_P#NL#K"Y8_7%TUM(ZR?YHPHV:3^\X7 XES8
M5@A$-+^UOVTPTJX\U(H3K1M842HH\L8!IE!VO1WOS8$%:Z\/RFZRE%JGL-^J
MEM=V]+*0D+_ WL^-+7!C9>=I^[V!5,"B,Q3N:)6W1%A.7-41-]]6E]D*F$QY
MO;@OQ+V:JD1@6<_EE$/_ %JC?_SQK_\ NL#$B\LW?V%U\+"H4[6]M#DH!W%5
M9PR$#DC6'!*#2O1(!&B*3G&#"6$9@ ['L.@Z$, =[\XM:V&L(P&!OD*@F$2!
M4U7@'*(Z 8*[A(1@$]M@1!$&--FA!$':K6PB#O6];UO6MZWK>MZ\^!J ?*#E
M29;XS/?JI&H(5ICKC1#)4ICBSR#@?D##=>D4<4(99@?/K>O2 +>O/K>O/Y]8
M%-N!EE^1J.+>U^*W9"ES7HFY/OBBW"M*%RHA(3LT5LT&()>C5!A9>S!! +80
M>EZ6]!%O6MZUOS!M$$TIC*P\I*DD;$J4GBT E.F=V\\\X>_/O0"B2E C#!;U
MK?F" .][\V_S8'W<!@,!@,"*+_\ +CJ?ZJ/0GXO<R9H8/RI,?N&3?YL]<NG\
M:JOTNO?VY<E=F>=0P&!$%X^7Q77U0;H_&>A<#B/5ORD_#'^MU;'_ -/GM; G
M9@0A\0[Y,V_K$<4?SI\_8$W!_P"(+_5%_P MX&A#M'])EB?MU+OX@<,#@N!M
MU/)5?U(/*7[3=$?S#V=@9$F P& P/X((1:V$6M"#O\V]"UK>MZ_ZMZW^;>!#
M'I4(0] >'<$(=!#KJ"SO,$.M:UK_ -!SKC^C6O-K6!WO=UQQ:@ZV>+0F**0N
M;*TNT-8 -43:P/,C=WZ?S:.U[$VAG;35:$E0L=97*F5N!M0M2)B J1*5*@D@
MDPP(=+?W6CW]$/L'_L\K_P!JV!\62=J[B,=?I9(^4NO6N/1AE=)"_.9U=04P
MEN9F5">Y.B\TM/:1R@PM&A3'J# $$FG""7L)18Q["'83!C;^W2J.L,H:!&C:
M9(RM;^V#/*V0>-N>$)#BB$<2+>Q$FB3*2MF%"WO98][!O>]ZP--;Y01^N:\0
M7]^1O\(Q; ISP-D/Y$3\DGM?ZQ<)_#1-@9N. P& P&!$!%\OJ1_5 A7XSS_
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M9Q@7:53.+"FZ)W4V#2DFI94@5)B&UODTOKJ7'/B<XDPP]:E/KN42=(C*2&!
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M[^H?KK2;V]]K+.[K7Y0&3)D,4@P& P& P*]KT>^/-7NIG,S[,@=%WI$:2GE
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M1.TXP[??_EQU/]5'H3\7N9,T,'Y4F/W#)O\ -GKET_C55^EU[^W+DKLSSJ&
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@AT=-+3%TT--'U/XHL7MT:/X]/K=OJ_\ NCL[?^]G_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>58
<FILENAME>g459793g77a10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g459793g77a10.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1MT4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &UB^<  X0DE-! 0      $<< 5H  QLE1QP!6@ #&R5'' (   (!@!P"
M4  (<G(S-3<V.3@< @4 'DUI8W)O<V]F="!7;W)D("T@4FED97(@1F]R8FEO
M;@ X0DE-!"4      !#-;. H()4F&5PPXEN"5F#D.$))300Z      #E
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M<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
M    0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T
M=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,
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M;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT
M;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #
MO_XU  (  @.__C4  @ ".$))300F       .             #^    X0DE-
M _(       H  /_______P  .$))300-       $    >#A"24T$&0
M!    !XX0DE- _,       D           $ .$))32<0       *  $
M     CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H
M!@       0 R     0!:    !@       0 U     0 M    !@       3A"
M24T#^       <   _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H   X0DE-! @      !
M   !   "0    D      .$))300>       $     #A"24T$&@     #-0
M  8              $D   "K          $
M 0              JP   $D                      0
M           0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   $D     4F=H=&QO;F<   "K    !G-L:6-E<U9L
M3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M        !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC
M94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC
M951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
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M=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M 0$ .$))3004       $    !3A"24T$#      0W     $   "@    1
M >   '^    0P  8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.
M#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M_\  $0@ 1 "@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
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MU.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\
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M_P#Q2]$_JY?_ )[J6TN?Z]EXV%U[HV3EVMHH8,H.M>8:"YE>W7^4GP
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                        _^$__FAT=' Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+ON[\B(&ED/2)7
M-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX*/'@Z>&UP;65T82!X;6QN<SIX
M/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0($-O<F4@-2XS
M+6,P,3$@-C8N,30U-C8Q+" R,#$R+S R+S V+3$T.C4V.C(W(" @(" @(" B
M/@H@(" \<F1F.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y
M.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@H@(" @(" \<F1F.D1E<V-R:7!T
M:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIP9&8](FAT=' Z
M+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B/@H@(" @(" @(" \<&1F.E!R;V1U
M8V5R/D%C<F]B870@1&ES=&EL;&5R(#$P+C$N,38@*%=I;F1O=W,I/"]P9&8Z
M4')O9'5C97(^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F
M.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX
M;7 ](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B/@H@(" @(" @(" \
M>&UP.D-R96%T;W)4;V]L/D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I
M/"]X;7 Z0W)E871O<E1O;VP^"B @(" @(" @(#QX;7 Z36]D:69Y1&%T93XR
M,#(S+3 V+3$Q5#$W.C P.C,X*S U.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @
M(" @(" @/'AM<#I#<F5A=&5$871E/C(P,C,M,#8M,3%4,38Z-#DZ-#<K,#4Z
M,S \+WAM<#I#<F5A=&5$871E/@H@(" @(" @(" \>&UP.DUE=&%D871A1&%T
M93XR,#(S+3 V+3$Q5#$W.C P.C,X*S U.C,P/"]X;7 Z365T861A=&%$871E
M/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP
M=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z
M+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(CX*(" @(" @(" @/&1C.G1I
M=&QE/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @(" @(" @(" @(" @/')D
M9CIL:2!X;6PZ;&%N9STB>"UD969A=6QT(CY-:6-R;W-O9G0@5V]R9" M(%)I
M9&5R($9O<F)I;VX\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@
M(" @(" @(" \+V1C.G1I=&QE/@H@(" @(" @(" \9&,Z8W)E871O<CX*(" @
M(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D^<G(S
M-3<V.3@\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @
M(" \+V1C.F-R96%T;W(^"B @(" @(" @(#QD8SIF;W)M870^:6UA9V4O97!S
M9CPO9&,Z9F]R;6%T/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @
M/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL
M;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B"B @
M(" @(" @(" @('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B"B @(" @(" @(" @('AM;&YS
M.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S
M;W5R8V52968C(CX*(" @(" @(" @/'AM<$U-.DEN<W1A;F-E240^>&UP+FEI
M9#I%,48U.$,V,S1",#A%13$Q.3-$,40S-T8V.35&-S=$,3PO>&UP34TZ26YS
M=&%N8V5)1#X*(" @(" @(" @/'AM<$U-.D1O8W5M96YT240^>&UP+F1I9#HQ
M149&14)$1C1!,#A%13$Q.3-$,40S-T8V.35&-S=$,3PO>&UP34TZ1&]C=6UE
M;G1)1#X*(" @(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YX;7 N
M9&ED.C%%1D9%0D1&-$$P.$5%,3$Y,T0Q1#,W1C8Y-48W-T0Q/"]X;7!-33I/
M<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I(:7-T;W)Y/@H@
M(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HQ149&14)$1C1!,#A%
M13$Q.3-$,40S-T8V.35&-S=$,3PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @
M(" @(" @(" @(" @/'-T179T.G=H96X^,C R,RTP-BTQ,50Q-CHU-CHU-RLP
M-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O
M9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+W-T
M179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC
M:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E
M9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS
M=&%N8V5)1#YX;7 N:6ED.C(W1D9%0D1&-$$P.$5%,3$Y,T0Q1#,W1C8Y-48W
M-T0Q/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z=VAE;CXR,#(S+3 V+3$Q5#$W.C P.C,X*S U.C,P/"]S=$5V=#IW:&5N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B
M92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N
M=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z
M8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F-O;G9E<G1E9#PO<W1%=G0Z86-T
M:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYF<F]M
M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O97!S
M9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F1E<FEV960\
M+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G!A<F%M
M971E<G,^8V]N=F5R=&5D(&9R;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H
M;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A;65T97)S/@H@(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#I%,48U.$,V,S1",#A%
M13$Q.3-$,40S-T8V.35&-S=$,3PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @
M(" @(" @(" @(" @/'-T179T.G=H96X^,C R,RTP-BTQ,50Q-SHP,#HS."LP
M-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O
M9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+W-T
M179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC
M:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP34TZ
M2&ES=&]R>3X*(" @(" @(" @/'AM<$U-.D1E<FEV961&<F]M(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T4F5F.FEN<W1A;F-E
M240^>&UP+FEI9#HR-T9&14)$1C1!,#A%13$Q.3-$,40S-T8V.35&-S=$,3PO
M<W12968Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @/'-T4F5F.F1O8W5M96YT
M240^>&UP+F1I9#HQ149&14)$1C1!,#A%13$Q.3-$,40S-T8V.35&-S=$,3PO
M<W12968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.F]R:6=I;F%L
M1&]C=6UE;G1)1#YX;7 N9&ED.C%%1D9%0D1&-$$P.$5%,3$Y,T0Q1#,W1C8Y
M-48W-T0Q/"]S=%)E9CIO<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#PO
M>&UP34TZ1&5R:79E9$9R;VT^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@
M(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @
M("!X;6QN<SIP:&]T;W-H;W ](FAT=' Z+R]N<RYA9&]B92YC;VTO<&AO=&]S
M:&]P+S$N,"\B/@H@(" @(" @(" \<&AO=&]S:&]P.D-O;&]R36]D93XT/"]P
M:&]T;W-H;W Z0V]L;W)-;V1E/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*
M(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,  0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( "H
M8P,!$0 "$0$#$0'_Q  >   !! ,  P             (  8)"@(%!P$#!/_$
M $ 0  $$ @$#  0'# L       4" P0& 0<(  D1$A,4(146,38W=[8*&"(F
M05%8@9:QN-8C,CA6<71U=I&T\/_$ !P!  (" P$!               &!0<#
M! @! O_$ $$1  (" 0,# 0(*!0H'      (# 00%  81!Q(3(105(C$U05%5
M=8&4U#1Q=+2V(R0R,S9A<Y&RLQ<EH;'!Q-'_V@ , P$  A$#$0 _ +WVT"I
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MX[!;ES5J\I#+#% Y,'"0,5DP8?ATK,18P(*!,IB"B9GXYG2RF_.I^!KJO9C
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MU*L;SI&C;06)6<S D"X]@MI^=7,JS$ BYI1L= $!L2''"DS'JY[ZHJ65?9V
MV+TYC(92ON6IF[[JWL\R%W&>:$"8NE%6NJQZ$]JU=[6OXX6$? 'ODI_=.=WA
MOHZ&/LX"SBJ:;4/@?8\GX_/*R7Y[#S1ZBD&,A8+5,_#+T.>(@<NY&NLM6?AY
MP2TV=(V^O\>-9"*I**/5RR!Y1K;VVC[)6Z$/BR0%1#Z,R<L@7XL9 YV5[,\B
M*Q[0XWE;C!L"+$IW1O/+H74L9_)G;%46$.%&(PZ"135[2EAIGL&+,$R#[.Z.
MZ8&)@1AMZG7AFWMJXMQV$X3'!7\I5W*EN3R3//:F*[5@Z.X?!,#V=W'P8[IB
M9)\ZGW/IGA'W9KWLEV3)QJ_354V(%K4=P03"D['-&:#DUNK@T#)XZ)/&E;2>
M3#'I7/@1FF),Y4J3EJ-A3O6GE<1EMY=,*6.& '*9BQC&V)ERVJK ><"Q:=+%
ML);EUJ\FR869R0A$!R7'.UC<GC-J]0+-_DSQ^,7D5UX%)J8\QPYUJR_&8":B
MLN[ CO 8 S[V<+B9A@:ZGD>25AY@]QODY++9=J].N135<!VK6>?5C^XCPF55
MM;AH1AD5, P0&JI4ZORX\0@4A^O*QZ]&?S(2[/0]OW@7M].T]@[<!7;8MU%9
M(_:*HVDX=!Q;R#S1+0<U^4%;1,UJ,84RP? ]H2.G586;=N3>.<-G<BK9;1&$
M62KNR;PFM02+H6:5HQTL20";1DFA7#UF3B>Q=IC;0GB[QF[A7)A3Q")L"+K$
M5K_5DY%;L!&!BRD$%)2LO&X(F2$&JB'B-+F.LEB4/UV6HN,)5A:?60_4[%.W
M+N'8>WI$#HLRC\CE@BQ76<H7(#/:EC8>SNKJM@)+6R(YF.?Z7$IT_P FK X7
M>&:DC7>'')H8XH0\QA[).9[FK62ES#3J',,8$SVQ,\Q(SIO]C*O:PL/,2T;J
MWE*)%5:LJ<VW5O.:M:KK(F;+M!MB#$L!!%?"'GDOC8#EAGL2YZ&7%&7H,N.^
MI^,OQFZS/R*=IIQ.%!2O>EL:=G^<UZ8KQU=1M977+GH&8<R$*( (HE,&$C$'
M'.+I6K'MW*S(Y4V,C'5CMUXBO8MD=]S1 &GX4N*)6!-;W%VSYH X+@"XD]YK
M=Z'E)IG8NSJ_7>(M9LG&Z!8,5*M;"V[K3;8L-=XLB$C#F9;I28!"2F"DMDED
M?"7!:7)@1\+4R[G#J^J[V?TAVSE<?C+-C=-I.?97]KL4<1DL2QM$Q,I@1A</
M>,I62Y8<'PLR[>Z>8B'?<_5#<..OY"O7V]5=A ?[-7MY3&Y186Q(.9DI8==)
M0PA.0"0B2"/Z,SHC^VGW!@O(75&W-A[*TOK#24U)%ZE5).CM.;#>^,;#0/V\
MODR7"B+-'=0Q,G"V8L'$QAQMW#SK["L+CJZ7NH>Q68/*8FCC<OD\N$J&[;]^
M9?'A%:9=()\*7.K3'<M;C)G:7I(<3Q/&IO8^\EYC'Y2YD,7C\6R"FI6G$8F]
M/G&$RQL-:E=H>!(EB(28>O/,<\3J;S3T>1#U)JV)+COQ)<77-(CRHLIEV/)C
M2&*R,:>CR([R4/,/LN)4V\RZA#K3B5(<2E:<XQ4&6(3RN3("$Q+(7"$A*"$A
MFRR8(2&9$AF)B8*)F)B8F)F-6Y4YBK6B8F)BNGF)B8F)\8\Q,3ZQ/TQ/K'Q3
MJLGWW=9\C.57*+CEHO5NJ-E6.@T\-'P0N8BGV&=38%PVK9!X\DZ0-,P<B/5U
MVO  <R9)<E>J@M$);;CK2L2DXZ)Z+9# [9VUG\UDLKC:]RV\YBFVW7"Z=/%5
M_(N%UY.'3-BQ8L "^V9;(!(Q,<<T'U9IYG/;@P^*H8^^ZI60$3975L%6"WD;
M'89$X5RJ(2BN@C.3B $BB9&>>-YWM>V85-ZCX_[2XWZ^,VBR:8JE<T=::S3@
MTHO8#- &Q6H],-H&#679D^17B?M\0B^RPZ\J(=9??4F*.])O7Z/=0P7D\[B\
M_D%5DY:U9S52S;<*5+OM+FXCRLGL"+"H%@"1B/<DXB>YD\Y^J.Q2G'XC(X6D
MU[<;6KXBS7JI)K6TU!VU'>,!(CE)R2V%Q,]K!Y^"$<&?Q;Y$\BL]J&\$+QJ+
M; SDAI+6%BU@'KQFA6EFTW,RP'2$UA90XJ2-P1-86R2#MFI$1+_JYP0K+F+C
MM*RI*CN7;N"_XH45U,IBF[?S.11E'/3>JS5IJ\I.RE5S@;*D2))?*8,H[EN4
M(Q,\QIEP.=S,=.KIV<?D0S>*HMQR4MIV!?:82Q3C;"EDN&.'M:H6$,3\)+)G
MB.-!-]SU<.MGZUOG(#?&[=:W*A6!04+KNFMWNO$P!,@V=G+LUR)0XIB+'DNH
M2L/7(JB"$90O,J9'2XI7KTI<.N^Z\?D*."PF(R-2Z@K%C(7)I6$V%C[.L:M-
M9DDC@9B66I$9GCB!*8B8C2ST;V[=IV\QELG1MU&@E-&K%VLU!G+SFQ9:$. 2
MG@5H&3'X_(43,^NK3#R6VFG75)RK#;:W,X2CTUYPA.59PE"4Y4I7C&<)3C&<
MYSGQC&<YZYKX_OY_7,#'WSZ1$?3,SQ]/IJ_9GB)F>>(B9](F9^Z(]9GZ(CU^
MCUU3:X@<;>07)+O$DN2NX-*[0I.O8.S+YNB$9O-)L-=$^RUUQZ+K0-&E&X$1
MI<J.^[6LQ8*59D8CCWWLM^A&>RGK3=FX,'MWI0.WL5E\==O,QE#"^.C;JO;W
MV! LF\P2PB@2$;<DSB8@FQ'I,^O,^VL+EL[U(+-Y#%WZE0<C<R_?<JV4K@4]
M\4%";E@,D)%6B!CUD5SZ<06N!<X. W*#D=W2=R!Z;I[84:G;*W(*AQ-GS*@<
M:H0T'*$ 6R5HDV-R&@6X,%L-3)#JFI2E2'(JHL;#LIQMI4YL[>^VL#TVP[[>
M5HS9QV',V8Y=M7M['J<UBZXUN^6^5YRM0\KB([N\B$(F8B-T[4SN9WYE$UL;
M=A-_+ *[QU6C26H@4)O*SV>*5J"#87!=Q\2 \E,1,Q/=.X[G](=L+7G#OBUJ
M^[W>%.MU+KQB'2:L6LA:8(K3DNZG+/8L!(4C+;YVWCQDV5*DI;0Y+?1&8_HF
MT-MU-TSSR<UU'R.[-R9"E3-=2XU$W+2JR5-M=E)=:M-@QF1KTV.$($NZ!#F9
MYGDK)W_AFX?8F.VS@*5RV#+5-+HJ5V6&&JMW77/L>$"[9=96LIDHCDCB!B8&
M(C=]O[@(=-]GNY<==AA"NNK[R(9V8=+0+*+E#"U9L#AS VB2C0V0RU.9;CXI
ME:,KCN-I?5 DX2E.,Y3UBWUOA-;JQ2S]!J+]';\8VNLZK1:FRGP>:^*6A)!,
ME-VTH2&>(,8YF9C6;9^T&OZ;7,-<6RE<S97WF-A1+8AH6/%2)JCB#B.VI6:0
ME$%V%Q$1S$:@%TF#[C7:(W\?M@_0-J((FP)=.LD61535LUML"OH(,S8KX^PU
M=+[/K&I,-F>+(1)C!"$EUV/*CH1*EQ%W=F6[ ZHX--9F;JB $%RL0VTU,C1?
M*R$ULKV)DX+M.0:!KE9]L$L^8$M5'B%;VZ?YEKDX:V32 ZKU33L6Z5Q,$)"2
MW5H[9B" 348'!CSP8Q$R.NW<TN67<![H=!INIA_"Z[5NL5VX-7%:*52]ADGC
M!ID20#C_ (2F%H;<*+#@L$R2VLJ2WC#DCTG'O*4>8C:6U-B].;EW*SNVI9?:
MIE3[KM[&J%29<II^(%'+)89)6,\=WP8*(B9F(U*;GW'O'?-:MC"VO;0NM:BS
MXZE/(F;&PMBAEAN 0$!AI\<Q$<E'PN(U: [6'',SQFX-Z4UI< ,BM7MP:5MU
M["R\,XG#K1;2\LM)@S_4K>;S,'0'1PUY.'G4MYAX:2K*6T^.<NI>=3N/>F9R
M-5XV*0M73HN"9E;*M18J!BXGX@88FP?B]#B>(F9U>O3[#-P6U,73LI)%PP9;
MMJ/M[UOM,)DK+M].0#L&8^.)B8F9F-2)8]V,8_-TB:=-+HT:71HTNC1I=&C2
<Z-&ET:-+HT:71HTNC1I=&C2Z-&ET:-+HT:__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>59
<FILENAME>g459793g79a79.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g459793g79a79.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[2(64&AO=&]S:&]P(#,N,  X0DE-! 0
M    (?J^AI@X0DE-! 0      $D< 5H  QLE1QP"   "   < G@ #&9I9W5R
M92 R-"TP,AP"!0 ,9FEG=7)E(#(T+3 R' (W  @R,#(S,#<R.!P"/  &,3,P
M.3(Y #A"24T$)0      $!7GJNZ4N$+[1+LI%O#L1<4X0DE-!#H      .4
M   0     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $
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M=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M    $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO
M;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG
M:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0
M$ "4S,P  0 ! )3,S  !  $X0DE-!"8       X             /X   #A"
M24T$#0      !    !XX0DE-!!D       0    >.$))30/S       )
M       ! #A"24TG$       "@ !          $X0DE- _4      $@ +V9F
M  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M      $ -0    $ +0    8       $X0DE- _@      '   /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H     /__________________
M__________\#Z   .$))300(       0     0   D    )      #A"24T$
M1       $     (   )    "0      X0DE-!!X       0     .$))300:
M      -!    !@             $7   "*X    & &< -P Y &$ -P Y
M 0                         !              BN   $7
M           !                         !     !        ;G5L;
M  (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   $7     !29VAT
M;&]N9P  "*X    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M!F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
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M;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
M       !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!
M46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%
MPJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V
M-T=79W>'EZ>WQ]?G]Q$  @(! @0$ P0%!@<'!@4U 0 "$0,A,1($05%A<2(3
M!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%
M539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G
M=X>7I[?'_]H # ,!  (1 Q$ /P#U,GW@>1_[ZJUN;=7<]@Q+;6M^B^O;!T!_
MPCJ_SG*R?YQO]4_E:I)*:(ZA>3M^Q7SR?HQ$_O%X:G^W9!:2,*T$[0UKMHG=
MN^E#G;&U[?>B9.#7DO:ZQ]C0SAK'EK3J'RX-_.]J'^RL?3])=H9CU7=M?%)2
MXSLCWSAV^R2(VD. =L]ON^E^>F_:%T/(PK_:);(;[C+6[?I?RDF=+H8\/%EQ
M(.[6QT$@[O=K[E=24C#GEM9<-CG?2;,P=I]LJ&5?=2&FJDW3.Z#&T#\[ASG?
MV&[T5WTF?'^#EFWY#\JMK+<+(#FP^6$"'$%GM?N9NV;TE.ACV/MJ:^RLU.,S
M6=2->'?^8>S]S>I5F6@G7G\JIXV38WTZ!BWM8('J6$&!^]8YS][E;K^@/G^5
M)2/)OOJV>E0Z\./OVD#:/'W?2_JH/[0N@.^Q7P8C1DZG\YN_^TBY.%1DN8^S
M<'USZ;FN+2V8]PV_U$+]E4Z1;>"(D^J_6!'NDI*6'4,@S^HWP# ^AKQKJ\(E
M&7;;8UCL:RJ1+G/X$?RA^=N0QTB@;HNO&[DBUW,;=W];;[42KI]-5HM8^V09
MVNL<X<.&NZ?WDE-I19/NGQ*DH,_._K%)37_:O3][F>L-S2YKA!T+)WCC^2D.
MJ].+@T7M+C  '<GAO]96MK>8&G'Y$P8P0 T #4:=TE-0]8Z:'N8;A+)G0P=O
MTMAC])M_D*U:88"#'N;_ -4$Y8PB"T$?!1M'L [;F_\ 5-24_P#_T-CZX]9^
MLG0LW=B]299CV@O;2ZNHVUR?H']'^DK=_@?\)_F>HLYWUE^N@>6CJ6(\>X->
MWT(<62'L'Z/=])KF>]7OK'B8F'U&VS/Z15D^NYUC,IUUQ#Q/>;/T;F>QCV?F
M?\7Z:RW?L,.V.Z!2':#:7W Z_1TWJS#$3$$0XO'T?]\P2R 2(,J\/5_WJ9OU
MC^O#G!OV[&&L$SC::.<=VF[Z+/\ 6Q1J^M'UVM8RP9V.RNR(<_T&\AKFDLV^
MIM_2,^BW_J+$+=]7_P#RCQ_^W+?_ ":6_P"K_P#Y1X__ &Y;_P"E$_V9?YO_
M *'_ 'R/=A^__P!+_O4H^L_UW)</MM <TB010T>YM=S(>]K6>]E]?MW)_P#G
M+]=Y(^WXTB-TG'@!T;#NV_ROHH._H'?H='_;MO\ Z42W?5__ ,H\?_MRW_TH
ME[,O\W_T/^^5[L/W_P#I?]ZS'UJ^NAH^T'.H;6*C=!%&_:&EP_1!OJ;W_0VH
MA^L?UWF/VABE^NYLXX@#22YS6L_S$#?T#_RCQ_'^<M_\FEN^K_\ Y1X__;EO
M_DTO9E_F_P#H?]\KW8_O_P#2_P"]2L^M'UV?75;]NQV5W!KF.?Z#3#OH.=7M
M]5K7?U$__.3Z\3 S<8GPG&!U.T:.&[\Y!W] Y/0\>?'U;?\ THEN^K__ )1X
M_P#VY;_Z42]F7^;_ .A_WRO=C^__ -+_ +U*/K1]=B7[<['(K=M<X_9VB1I[
M7.;[O=_KZ:7_ #G^NXYSJ![7.@"AQALAWL:S=]+_ -*(6_ZO_P#E'C_]N6_^
ME$M_0!QT/''_ %VW_P!*)>S+_-_]#_OE>[#]_P#Z7_>H!]??K61/VQNO_ U?
M^02_Y^_6O_N8W_MFK_R"L>KT+_RDH_[=N_\ 2B7J]"_\I*/^W;O_ $HE[,O\
MU_T/^^1[L?W_ /I-?_GY]:_^YC?^V:O_ ""7_/SZU_\ <QO_ &S5_P"05D6]
M #@7]$I+9&Z+;9C\Z/>NMP/JK]3.H8S<K&P6.K?I]*P$$?28]OJ>U[4R8$*X
ML=7_ '5T3Q?+.Z\WB?\ GY]:_P#N8W_MFK_R"N]&^OWUA'4:FY9.?CO.U]%=
M;&OU( ?5Z;6;K-WT:_\ "_078_\ ,;ZJ?^5[/\^S_P!**ST_ZK]!Z;D#)PL-
MM5P! ?+G1/AZCGMW?RE&9XZ/I7B,[^9U&G<T&")$P>0HV_1']9O_ %35-0M^
MB/ZS?^J:HF1__]'H.L8F-EYU_P!OR<L6!Q'IAE8:& GTFU_I?YK;[F?]N?SB
M%Z.-&F?F@>XP&4@2_=ZCH:_\]SW[UJ=4]?.R'DV8K6M+JP
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MM]-XAI*TML+&_\0 ' $! 0 " P$!              $" P0%!@<(_\0 51$
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M8VMKH360L%%UP8"94RL195@I&[T(F/U^?RLBL\5M+=!_O5.51,77K))"[U)
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M$&^WT)B$#:5CLX-4+C#%%6U>_+JN;VM0Q]L2M214[N%2R=VN2@A*6:M4T))
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MWY3+@NAPDB*HLJ99+U7-N6X!:[E!@YRAYL!8&_;.;"&)]82&A/>@RXZ19$'
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M+G)T_;CW4W4Y*XT_9#WU3VQ!:K5]J!A[]/9H<M7_ %+?6G?U8;B\N<G3[_\
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M+@R6)SPQY:?O$C79S<X'1D6PI*^8/I(I65%#F3U<;',8'.GT@!='(&E[+@8
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MB_Y+:ZM/'Q::?&.SC(I_GF],,I_^(PYN]-R^5N2C[:+WU3J1F;+M7W=T\?\
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MH1,(B=6E&>US&N.#79I;? D$M!TM?>C*1=\:7!G766B:A,N)JG4)Q7S?TNV
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M0!<FYY##LP 7=G)0)VAUI9#,31R:R&LH!#82W+J6^HJ1$MQ)99* M,:4!&4
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MN5((O&W]_4IB#2VEF<EU249VJHV&[)*:&2HFR9((XFE\A:^-Y#1K(:QQ<ZW
M!?@NML&RK(%1+'!%E")TDK@U@+9&@DFP&<Y@:,<+D@77H*Q/K)*&1HDL:=VU
M_CT@;$+TQ/K,N3.;0\M#FF*6MSHUN*,PY(O;UZ0XE4C6)3C4ZE.:6<28,L81
M5\PO0JW1)0%2TJ#0N"YSH&1S$BJEQ)J0H+$EE[XE$@ "IANE&U")JV-INRI0
M]N1I3Z%E4,VH!%)L$3!$P1,$3!$P1,$3!$P1,$3!$P1,$3!%K/F*?R&/@?MU
MP)O!=U<(-CP-:!NN^FT;R:=\M@X(=HW#MU-QZ=MVW=BK1L-KKLR+)UV;30J]
M4*<().V\Q6UJS4Z]O<$)]4+]&7] (1K/*8N[  ,]FD3*H%50WN!-!!K01R):
M0L;%BY"IV12R0R,FB>Z.6-P?&]A+7,<TW#@1J(*PDCCFC?%*QLD<C2Q['"[7
M-<+$$'>(^2\!+W62FUH)F="IB$M0['D+G*(2]N1;@C]TXV@$&JEV:TH*B3L\
MS9"34])Y"0#%O8:<5((_57%'$@3=^A=@NSF/*L;,FY2>R/*$;0&/=8-J6C^9
MM]3^.R_.,-7Q#9?L1DR9(ZNH6N?0O-W-!)= X_R/M_+R;]_[KA< G7H8SP"J
M 8AT$&M:5I6M=-*\5?T8^JC-(P U:[#IU;_F\]C@OGF(.MPU86/"<-=Q; 6.
M^==C=4VXW\H/RUPS0-X= ].H:S]!->%\;FV.%AJQYK;]L%3;3?QQ>7%L. =
M0FPP<3O:SK&OT:NG ZTVTW\<7EQ !O@=&'Y8X:TQPL7;]P38X#S] UC78BR;
M<;^4%Y:XN:. = 4\8\)X,3@=_P!-@<. IMQOXXO+B9HP%@/0,?9^5M_@5N;$
MW]!)X=['5SF^(LJ[<;^4'Y:X6;P-Z!OGO]JGC?\ %OVUZ]7HP/YXJFW&_E!>
M6N+FC@'0.Y+D6Q/3A:]K8'FOK _--N-_*"Y^.O'SX6;P#H"HN#XQ-KD:_-?
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M?.1T?J"BV1Q47ESGCNG'[J%G98X.WE2*2)']B<YI/4- &GVD>VLY,[M+3!G
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MQ)UBZ8'\DQOOZN;S^-P7UXGSWU)B?7IW\>X8<UPJ<;[^H VP Z!8:S>_ +D
MIA<\&]Z.G7[%CP8V_.QN<;D#5O##''$IAS_7-PX=][70\&%M>&O$ZL3:_#S"
MUTQ?KF2V!X;XG? PO<$X&^_PW%]5V"6..L7M;@O; 7N<+&VO5B<+I@J-=AZ1
MPBPUG58XV-M_G3#Z])]'#OVYTP]-@,;#4->L@ZM1U@C&V*8*BX)OY[# DVX!
M?'AWC>^("8AP'FX.#@&JQ.'Y<ZAQ/ ;;]K''$G7PG#5;&]L%RD$'*3BDZ<HP
M]0>8 DDDH C#333!4" LL :5$,8Q5H$(0TK6M:TI2FG!SFM!<YP:UH)<20
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M_P"\6=G)JMAJ8.CVKJ]Q&R+R%_68=>)URD;V/"N2B&H"#4P396%.<84:<G#
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MP708(I'6YJ$PDD&&2Y>HES:<$PT1S7%%:)(!J9Z@$8(-:;N-<]F,=!&_Q(D
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MHO*H>;[1O?8>FWZK5M"JY"7LW?1]";)#QT=F:NGEHZM_[13#]X46/\3"+?\
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MD ,8" C$127!$P1,$3!$P1,$3!$P1,$3!$P1,$3!$P1:TYB(RGD7 _;[5/\
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M[TK$->_R>0N1RAT?7QP--6N3@H-/.'HJ  /.$EQ))))-R3B23K)*[@
M"P U +(.(JF")@B8(F")@B8(F")@B8(F"*,Q(P)C2H$%0[J:4D4Q+VU[IL5H
M1%2Y\*&052IAG\E)1 JF8J[*FR8R6X6UE:=J 12;!$P1,$3!$P1,$3!$P1,$
M3!$P1,$3!$P1:T9B5Q"+@?M\@NXQ;;P@V/L6%5-W5L-Y-EO[H7(MCM&SIO7_
M #FG;G'[C1]F102_L[R$FS@F,9DC,NT@N%%F9*:0U70B\1F$FC3'(QC5I  "
M],SNM94#T-O$L*3T$E+7[E JH690LLRF36N=]UKG6UYH)MT!0EH^\0/.0/S6
MNLCD/0DS6N@$C'E"1';Z,(]O:[-6]5J]I+?FTQ214@,1+KN-6F":E<CMEH2M
MQRM4((PDB ++12G5')U'=RF>SC-ZP[U?>$O0BO<QDR\T=O/H=B:*37HWVX<Q
MW<IG,XS.D)PEZ$5[F,F7FCMW]#L712\G)U'=RN>SC-ZP[TX2]"*]S&3+S1V[
M^AV&BEY.3J.[DSV<9O6'>G"7H17N8R9>:.W?T.PT4O)R=1W<F<SC-Z1WIPEZ
M$5[F,F7FCMY]#L312:]&^W#F.[DSV<9O6'>G"7H17N8R9>:.WGT.Q=%+R<G4
M=W)G,XS>D;VK?WDX2]"*]S&3+S1V[^A^&BEY.3J.[DSV<9O6'>G"7H17N8R9
M>:.WGT.Q-%)R;^H[N3.9QF]([TX2]"*]S&3+S1V[^AV+HI>3DZCNY,]G&;UA
MWIPEZ$5[F,F7FCMW]#\312<F_'5XCL?8F>SC-ZP[TX2]"*]S&3+G^]';OZ'_
M !<>+HI>3DZCNY3.9QF=(WM70G"7H17N8R9>:.W?T.Q-%)R;^H[N5SV<9O6'
M>G"7H17N8R9>:.W?T/Q=%+R<G4=W*9S#K<SI"<)>A%>YC)EYH[=_0[#12\G)
MU'=RN<SC-Z1WIPEZ$5[F,F7FCMW]#L312<F_J.[DSF<9O2.].$O0BO<QDR\T
M=N_H=AHI.3?U'=R9[.,WK#O3A+T(KW,9,O-';OZ'8NBEY.3J.[DSF<9O!K&K
M@UIPEZ$5[F,F7FCMW]#L312<F_J.[DSV<9O6'>G"7H17N8R9>:.W?T.Q=%+R
M<G4=W)G,XS>D=Z<)>A%>YC)EYH[=_0[$T4G)OZCNY,]G&;UAWJPII!T).DF>
M#AL>4,:,;''"R$)MFK> :4R@I?)Q*E2%9P2J%0XK"SD93HFH6$2-,A:#1#'1
M:&A;12<F_J.[DSV<9O6'>K]PEZ$5[F,F7FCMW]#L712\G)U'=RF<SC,Z0G"7
MH17N8R9>:.WGT.PT4O)R=1V]KWMY7.9QF]([TX2]"*]S&3+S1V[^AV&BEY.3
MJ.[DSV<9O6'>G"7H17N8R9>:.W?T/PT4HUQR#_R.[DSF<9O2.].$O0BO<QDR
M\T=O/H=AHI>3DZCNY,]G&;UAWIPEZ$5[F,F7FCMW]#L-%+R<G4=W)G,XS>D=
MZ<)>A%>YC)EYH[>?0[$T4G)OX?N.U<.I,]G&;UAWJU'2+H3^_C<,I@R5!9*-
M+R%P2"L[;\2HYU$L8JM"@I12%5*)(3) /A:@@9Q9B@Q6E,**."F-&3=%+R<G
M4=W<Q3/9QF]8=ZNO"7H17N8R9>:.W?T.Q-%)R;^H[N3.9QF]([TX2]"*]S&3
M+S1V[^AV&BDY-_4=O:]Y,YG&;TCO3A+T(KW,9,O-';OZ'8NBEY.3J.[DSF<9
MO2.].$O0BO<QDR\T=N_H=B:*3DW]1W<F>SC-ZP[TX2]"*]S&3+S1V\^AV+HI
M>3DW_P"1V]KWM[?3.9QF]([TX2]"*]S&3+S1V[^AV&BEY.3J.[DSV<9O6'>G
M"7H17N8R9>:.WGT.PT4NK1R7X,QW<F<SC-Z1WK,$)S59![:,8(Q;FY-D(!&P
M*E*X$>A+:W15C M6"")8L"TL30@0!5JQ@")2HHGH<>((1&C'6E*XFCDY-_5=
MZ-Y,]G&;UAO^E2[IZ<H?;_M]\)'_ ++AHI.3?U'=R9[.,WK#O3IZLH?;_M]\
M)*/V3%T4O)R=1W<F>SC-ZP[TZ>G*'V_[??"1_P"RX:*7DY.H[N3/9QF]8=Z=
M/3E#[?\ ;[X2/_9>_P#717$T4G)OZCNY,]G&;UAWIT].4/M_V^^$C_V7%T4O
M)R<'W':^#4F>SC-ZP[TZ>G*'V_[?<_\ C(_]E^+CPT4O)R=1W<F>SC-ZP[TZ
M>G*'V_[?:O\ SD?^RZ_%AHI>3DX?N.U<.I,]G&;UAWIT].4/M_V^^$C_ -EP
MT4O)R=1W<F>SC-ZP[TZ>G*'V_P"WWPD?^RXFCDY-_4=W)GLXS>L.].GJRA]O
M^WWPBH_9,712\G)U'=R9[.,WK#O3IZ<H?;_M]\)'_LN&BEY.3J.\_!P8IGLX
MS>L.].GIRA]O^WWPD?\ LN)HI.3?U'=R9[.,WK#O5CCN>7*64WG 59B8<L-J
M]24P)SHI4I5(4YLC=34J8LH:<=1($249*-I4;*@5C60B5@ 6 \)8;HI>3DZC
MNY,]G&;UAWJ^=/3E#[?]OOA(_P#9<-%+R<G4=W<XZ4SV<9O6'>G3U90^W_;[
MX14?LF)HI.3?U'=R9[.,WK#O3IZ<H?;_ +??"1_[+BZ*7DY.H[N3/9QF]8=Z
M=/5E#[?]OOA%1^R8:*7DY.H[N3/9QF]8=Z=/5E#[?]OOA)1^R8:*7DY.H[N3
M/9QF]8=ZKT].4/M_V]^$C_V7#12\G)U'=W..E,]G&;UAWKYKGKR@AI40LP%O
M AI2M1"$YGA"&E-=:B$)+0(0TIKK6M:4I376M*8FBDY-_4=P7X.#'S)GLXS>
ML.];1-+LU/[4VOK$Y('ID>D"-U9WAJ6)W!K=6MP3EJT#DVKTAAR5<@7)3BE*
M16F--3J4YI9Q)@RQA%7!9*X8(F")@B8(F")@BUJS#OY#'P/V^XLQ@&ZN$&QX
M)LIKQOMM&\FRWPVM:DW/N#;J;EV6V;=NU3HV&U5V4-]ZWI%_U"*-9I<KC??1
MK)E$44H8O>:,MIJ*-R530\EHE#+MIJPRWMP*H2C5JF*K59IRIG>D9*A^@#\H
M,D,?*7(EDIBLNY5+52TDK98CJP<P_=>W?:X?D=8.(6F>!E1&8WCG:X:VNWB/
MU&^,%X'R\F=1=S>&MS#(HZ\QUT,9)5%7L^F_<3?"R250FMS$F..2JTZE&H3.
MC$_-IZIDE#"M;I"PKES2X)E OH>3ZRDKXFO8UH=J>P@9S';X(X-9:1@X<Z\?
M64\])+FN>_,-\UP)L1P@_F-8Q4&X7R3LPNU?[X-^/[/]&C':"FB.(:WJ_-<;
M.?RC^GY*G"^2]F%WYP9\[#:T7%;U?FF<_E']/R3A?).S"[\X-U__ #TPVM'Q
M6]7YIG/Y1_3\E7A?)>RZ[CY%!OQ?9UT_'AM:/BMZOS3.DY1_2G"^2:?\<+OS
M@W1X/N^?5\>&UH^*WJ_-,Y_*/Z?DG"Z2=F5VOG/-XN?[KD_335IPVM%Q6]7Y
MIG/Y1_3\DK+Y)V77<_\ 2#=6NM-7V?%R:].&UHN*WJ_-,Y_*/Z?DG"^2=F%W
M%UP;Y?NO[--<-K1<5O5^:9TG*/Z4X7R3LPMI_P X-U?_ #U\'%^O#:T7%;U?
MFF<_E']/R3A?).S"VO\ S@[Y_P"G7\6&UHN*WJ_-,Y_*/Z?DG"^2:_Y87?G!
MOD^[^6O-AM:+BMZOS3.?RC^GY)PODG9==XU!W+Q?Y_Z>.E/*VM%Q6]7YIG/Y
M1_3\DI+Y)7_OPNUUZX-[^K[O7WM?>U\C:T7%;U?FF=)RC^E.%\D[+KJ_\X-U
MTU_^/Q=_O>'#:T7%;U?FF=)RC^E.%\D[,+OS@WY_Z>?R-K1<5O5^:9S^4?T_
M).%TE[,+N3_;!O+_ .]Y?!AM:/BMZOS3.?RC^GY)PODFG_&ZWCXMT&U__OI^
MNK#:T7%;U?FF<_E']/R3A?).1W75T_[X-K^@5._I[W%SU;6CXK>K\TSI.4?T
MIPODG9E=[^9S:_\ /_UZ=5.3#:T7%;U?FF<_E']/R3A?).S"W7_O@[R4^RX_
M#IIW\-K1<5O5^:9S^4?T_).%\D[,+OS@WOZ_N^3Z\NEM:+BMZOS3.DY1_2G"
M^2=F%W%J_C!OS_[-/>PVM%Q6]7YIG/Y1_3\E3A?).S"[\X-^?AM:+BMZOS3.
M?RC^GY*O"^2=F%WB4&UU:O\ Q_DY=>K4VM%Q6]7YIG/Y1_3\DX723LPN]_-\
MOW7UU][2VM%Q6]7YIG2<H_I3A?)-?\L+?S@WXOLM'EY]6&UHN*WJ_-,Y_*/Z
M?DE)?).S"[\X-Y-?X]./BK\6FN&UHN*WJ_-,Z3E']*<+Y)H_QPN]_-\GW?AY
M/TZFUHN*WJ_-,Y_*/Z?DE9?)-/\ CA=XSS:<?_O^37AM:+BMZOS3.?RC^GY)
M6726FC^6%VNE*_T@WE\(O[,-K1<5O5^:9S^4?T_).%\E[,+OS@S7_P#/KIJX
MZ8;6BXK>K\TSG\H_I^2<+Y)V87:Z:OXP9S_\>FCBT<N&UHN*WJ_-,Y_*/Z?D
MG"^2=F%WYP;Y?N_T\^&UHN*WJ_-,Y_*/Z?DG"^2:_P"6%WYP;\_DY./3AM:+
MBMZOS3.?RC^GY)PODFG_ !PNU:>-0;KU::?Y_+R?KPVM%Q6]7YIG2<H_I3A?
M).S"[\X-^?J^NBFC#:T7%;U?FF<_E']/R3A=)*UK_+"[BK7^D&_%]GR?HIQ<
MF&UHN*WJ_-,Y_*/Z?DG"^2]EUW+H_C!NOO\ W7)WJ4PVM%Q6]7YIG2<H_GQ^
MOU3A?)./?=;Q]<&\W%]WR>7BY\-K1<5O5^:9S^4?T_).%\DU_P L+?S@WG_X
MWZ>3OX;6BXK>K\TSG\H_I^2<+Y)V87?G!O-_Q^2OUT:L-K1<5O5^:9S^4?T_
M).%\D[,+JZORYO'_ /K\7-WJ\K:T7%;U?FF<_E']/R3A?).S"WBZX-^?HT_%
MX\-K1<5O5^:9TG*/Z4X7R3LPN\&Z#?G^/57Y,-K1<5O5^:9S^4?T_).%\D[+
MKOS@WX_L^7FU<G)AM:+BMZOS3.?RC^GY)PODE=6_"[PU4&_']E7Q5\O>;6BX
MK>K\TSG\H_I^2<+Y)I_QPNKWMT&<W_'Y/#IKQ<>&UHN*WJ_-,Y_*/Z?DG"^2
M]F%VKEW0;S_\?1WO'AM:+BMZOS3.?RC^GY)PODG%ONNU<==T&_IV>CXN;CKA
MM:/BMZOS3.?RC^GY)PODG9A=IKHXU!NBFGOT'^FF&UHN*WJ_-,Y_*/Z?DG"^
M2:OY87=_^,&_/KQ_JXN=M:+BMZOS3.?RC^GY)PODFK^6%WYP;W__ !]'U\-,
M-K1<5O5^:9TG*/Z53A?).S"[\X-^=\G'AM:+BMZOS3.?RC^GY*O"^2=F%U/^
M<&_/T_7FPVM%Q6]7YIG/Y1_3\DX7R2G&\+M'%IHH-Y.;[+Y>/BPVM%Q6]7YI
MG/Y1_3\DX727LPNT:]=5!M-.BO?'\5,-K1<5O5^:9S^4?T_)?9<RDA9@#*.Z
MVM0"".G\8-U5#732FL?/2E>7CP--'8^*W5Q;?JF=)O2.OSG#TK>K*+FV4V/5
M[POFZE]DW)6>KD$?1D'+7"U+HM/,4N,YA+<F :I5PE>J--7S^#-Y1AK4H&IF
MT.1"5'29E?O$9:R*82ZIIF79<F6)H^[PO8!O;[VC5]X87MZ/)F4A*!!.ZSQX
MK7$Z[8!KB=_>:Z^.HXV)]Z&MT;'QL;GIE<4+NSNZ%(Z-+LV*R%[:YMJ].6K0
MN#>N2F&I5J%:E-*4I%:8TPA00:6<28,L815\LN\7>P1,$3!$P1,$6MN864TC
M7!#3===;#=N__P#0XF9*-_-S;R_SFUAKN'>S;_L-.C=.^ ]']'K@BV2P1>3G
M1%J6L='Z$,[$0!5F-!O!1P,:0$FI$=DU#\HJ[HKMEEZ#%;<Z#K(@V2:BQ@EX
MKCT='2+&)+?HKV+ =ID@5FW&&D-B"-*3?1YA.(>,+WQS=^^(-@5P,HNIVT[M
ML"X-PP"V=G?\/Z[UL-=EY:W/@K'!#DC?1[,4RI0(2EUCA28HPF-I# T&D2.3
MJ!36ACT8$03%#<2DT(BZT"I/ >*I /ID#GN%R!:WWKX./"T6&&JQWQPBQ/C;
M $V^Z3<#@]/YVPOP&X61K+P2"FV]E]T)NP F8FV:0NW<;C"^3G0N+DN\N XJ
MC9',Y,E.2J6UC;4K=M19E%S>DHI/$)<K+(#0PO@UU14"I@I()# '03U,LK8A
M/*60YK1%!$0X.D<YUSXKG6'B@E<ZFBBT4D\K=):2.%D9>8V!TF<<^1XL6M ;
MAB!>]S99V9[&QHQSFC2[6RCT:<C;G94VQE:!3)?.&-&RW+72$+M1OD[2O2N2
MAADZ4M I- 4Y&N:9-0!29UJ,!2C'7ORA*&02,JI96BDRL][]"V"1SZ419F=$
M]I8)8B7 $LS"[$LM@N0VF9>9KH6,.FH UND,C0V<OSLU[2'%KQ:_C9P&IVHK
M&G2KDNSA1#2<L\>F,R,NH\VY@!# ]+V]Q9+=.TB1GDKI0I<A581+ZQMX+8RE
M9+V8<F1D&.2\@]2&M>5^]RQN=M>22"#:<=34F1C7-DJ61N!;$UGVF;I6:0M+
M "XYC2 M6T0XYND#99-.Z&$,<X.;"YXQ>7>+?,=FW#L "XW*D4SR]PQU9([(
MXC(VI"_Q^Q-E+BRVW8&%V!OBV/R"-()%(AR<U11NWV6.3Q1>>TD)C*&)30F
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M.C"5$+KMCRP.,MN% WN0N,2=V,$=E5O84XSA82)MW<Y*W5E<6IN,JD=T8@*
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M8(PT3B>0GE4E)+62MBC%A<9[S@UC=\DZK\4:R>  D:*BH93QE[\3_*P?>>>
M#\SJ&_O+Q\!*'V.)GQX:6J7RZZ$F<5;L\7!E2,)RP3TO3ITR^5J1EI2 NDJ4
MI4B1M;PDMC/&X>RH&I@B34BC[.S-39]!H:2EHXFQ,<VU@9'7&=([?SC;4=\:
MB+"P%PO(54\]3(9'L?K\1H!#6C@&_P"GA!X;K7=3#)FL4'*E30\*5*DTP]0H
M.2JC3CCC1U&8::8,%1C&,8JB&(51"$*HA5K6M:X[05,(%@Y@ _XAO:][>WUQ
M<V3DG?7H61+>/]X;85>R(RV5.:),F3I))&Y%%D$GC#\2B-$>AHZ,+ZWK6]0<
M@/&,U&JH06J3",,"4< LTT ^-4LHZO1F4EKXB3%+%,^&6,N&:X-DC+7 .&!;
M>QPN%NBEJ(<\,C):\ /8]C7L< ;C.8]KFD@ZC:XQQ4N6W9S%KGUQD1@C27!R
M>[=R T*2',R5"0OM4(\4# B0$- $J-$PT4F@ A(*"F7%Z .):N@ XT"DR:V-
ML6;=K(ZF/QIY"XLK+;8SG%V<3(1?.)NVWBD8K8:JL+G/+3=SH7FS&@7@OH@
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MT.H<F%H99S6B.2$M942LSXY973O8\M<"YID<YX!-A>P\7!;!65K279MW%[)
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M:)*139E(RTQ0QECY @H1,)FEPD#8VOM42YLNA;FQNG;G6E>QIMG2!SC<%Q)
M(TF>J,9C,8+;O+?LV79I'9SQ&<R\;7$8M:0!O *]/=V<Q#XX.3N=03>ZO+A"
M'IV<62',[.L<7^W:YP<HL_JU"!I),,>4JYS5'*5^G;5]*)B%NW)D:4DG!E)D
MV-K6!N<R-L\;&R3R/:R.I:ULL0#G$",M8T-;J9B6V+B3FZJK'$NS2'.=&]SF
ML8PN?$7%CR6M%W N-W8%V -PT+[<[MYA7)U:G8M(E9SV8^6+TZ6/0-@8VL]X
MG+,JC\L?W)L;F8E&Y/KRU+#TA[FN(.4$!J$2*J40:5Q&T>3FL>PYT@D$+2Z2
MIED>&4SQ)#&QSG%S(XW@$,:0"?O H:NL<YKLS-S3(0&1L:W.E:6R.+6M <]S
M207.N1O$+[A\^N,PM;BD>HV[O*IKM#*K2VY$6VD(28LAFCB88]N"LPE"%4XG
MEMKG("40C3##PJG F@SPI2*%TL\%/(YI8]C ZMAK*D%[G&4P-LQHN;,&<R,N
ML+$,.%R2D<\S 0Z-[BVG?!#@!F"0DO)( )(#G@'$W=O 66 > LL[ NG'Q51*
M-?'_ .3^/DY*<W8[:BXS>L.Y<7-DY-WUZ$X"2VFC^07/GT[B4_J+UZZ:^;DY
M<3;47'9UAW)FR<FY4X"2WL"Z?F2C_P"W_9W^/1=M1<9O6'<F;)R;OKT*M8)+
M-&IA=/S)1Q^':]5/'7C\.&VHN,WK#NYQTIFR\D[Z]"IP$EO8%SIS_P 24_J+
MKIII_P!6&V8N,WK?),V3DW="KP$EG8%TU4ZQ4>#\GR:>]Q<>G7AMF+C-ZP[D
MS9>2=]>A. DLK_WA=*=_<2CQ<1?'J\>&V8N,WK?),V7DG?7H2D$EM==6)SIX
M42FO@U[5]>;#;47'9UAP7X.#'S)FR\D[Z]"<!99V!<]&JNBB%1R5KS@KKU^#
M1Y,-LQ<9O6^29LO).^O0G 66\>\+IJ_WDHY]%.(NFC1J[W)X6VHN,WK#N3-D
MY-R<!)9RL+IR_P"TE.NO-K+X^?53EU\6&V8N,WK?),V7DG?7H2L$EFO^07/Q
M(E/ZP?+R=^E&V8N,WK#N3-DY-WUZ$X"2WL"Z:-.C3N)3Q5TZ_P";\7/77JY,
M-LQ<9O6^29LG)N3@)+.P+IW_ .)*?_MUT=_CXZ:*8;:BXS>L.Y,V3DW)P$EN
MG6PNFK_>*C_[?-KKJY^/E;9BXS>M\DS9>2=]>A. LMT:V!TT\E=QJ.]J_F^+
ME[W-SMLQ<9O6^29LG)OZ$X"2WL$Z:>:B)3HY=/\ W*GZ*4U\VFM&VHN,WK#N
M3-DY-RIP$EO8%S_,E&GCT?D^;7H^M6V8N,WK?),V3DW*O .6]@73P[A4Z.3_
M ,GW]>K]6&V8N,WK?),V3DW?7H3@)+>P+I2E=&O<*CD_]SOTK7OZ.]AMF+C-
MZP[DS9>2=]>A. DLU?R"Z?F2BG-R[76OZ=%=.BG.VS%QF]8=R9LO).^O0G 2
M6=@73EU51J/%Q%TX]6KPZ^7#;47&;UAW<XZ4S9.3=]>A. DL[ NE:Z_]I**\
MG_J^37IKI^7#;,7&;UODF;+R3OKT)P%ENK^07/13DW&I[VGC+T<]:\FFO+3B
M;9BXS>L.Y,V3DW?7H3@)+>P+IS?T)17CT\X/#S=ZG,VS%QF];Y)FR\D[Z]"4
M@DM[ NGAW$H\O\WJT<NCDPVS%QF];Y)FR<F[Z]"<!)9Q[PNGB1**<G_J^.E=
M&G7\N&V8N,WK?),V7DG?7H3@)+>/>!TT4K3_ &DIT:-.O_N==>OR4YZX;9BX
MS>L.Y,V3DW?7H3@)+*\3"YZ=-=6XE/%[W3BY/CT4TX;9BXS>L.Y,V7DG?7H3
M@'+=>A@=*\W\24ZZ][^#KX:Z=>CBPVS%QF]8=R9LG)N4DA]OU2B2-)4N9I$3
M':J!"<ZM: T:XTLLDTPE*14P% %56*0DHQJ:T'5*4>-2$H^I5"AXOJ6!ILYE
M^$NP'/JOYAOFPN-8H;(3;1N'H/<O0VP&7]9FG7(9+)T 6#+''MDV,S*VF')2
MKM%HSQEJ(ZP*"1@-#:@H\L9,QEA)HE5UEM5D?:% 826\.DQ\+EC+!G+J:F<=
M'<B64'&0VL6M(-LS6#; ZF^+B[TV3LG"(-GG%Y" 6,.I@WB1QM_FUG'5[0)$
M:1O2)4"!*G0H42<A&B1)""DR1(D3%!)3)4J8D("4Z=.2 !1!!0 %%% "66$(
M0TI3S:[E=C!$P1,$3!$P1:Y9@'-2W<$MS2VW,7V[?[9\/V4+QN[:]Y=CO3LF
METW/N79BW?HVC;MT(M.V[5_!D4EF>6[+O<>0J9=<.PEEYY*UB5&A5R>9VM@T
MHD*I$W &6WHU+T^,2YR/2H2S#"T:<U2(I* P82  "(5*VY&HD>E0@'6 ?.L<
MR+*%E-0MQ1Z'+!E91'B>(XE$>]62MF2B$E7R)K0KDI8P1?95<ER%0H1,I?W)
MSRH0$CI4(Q4PN>$])2PX!T!7WI-LH/<J9;O,;;#Z+X7/">DI8< Z G2;90>Y
M4RW>8VV'T7PN>$])2PX!T!.DVR@]RIEN\QML/HOA<\)Z2EAP#H"=)ME![E3+
M=YC;8?1?"YX3TE+#@'0$Z3;*#W*F6[S&VP^B^%SPGI*6' .@)TFV4'N5,MWF
M-MA]%\+GA/24L. = 3I-LH/<J9;O,;;#Z+X7/">DI8< Z G2;90>Y4RW>8VV
M'T7PN>$])2PX!T!.DVR@]RIEN\QML/HOA<\)Z2EAP#H"=)ME![E3+=YC;8?1
M?"YX3TE+#@'0$Z3;*#W*F6[S&VP^B^%SPGI*6' .@)TFV4'N5,MWF-MA]%\+
MGA/24L. = 3I-LH/<J9;O,;;#Z+X7/">DI8< Z G2;90>Y4RW>8VV'T7PN>$
M])2PX!T!.DVR@]RIEN\QML/HOA<\)Z2EAP#H"=)ME![E3+=YC;8?1?"YX3TE
M+#@'0$Z3;*#W*F6[S&VP^B^%SPGI*6' .@)TFV4'N5,MWF-MA]%\+GA/24L.
M = 3I-LH/<J9;O,;;#Z+X7/">DI8< Z G2;90>Y4RW>8VV'T7PN>$])2PX!T
M!6)-E"RG#DSP@,RP96#&]*QQU8E0$V2MF)\2JURZ3DKE;D16+[ MJ6DM[>2S
M&AILCE:!]".M:$ T+GA/24L. = 5]Z3;*#W*F6[S&VP^B^&<[A/24L. = 3I
M-LH/<J9;O,;;#Z+X7/">DI8< Z G2;90>Y4RW>8VV'T7PN>$])2PX!T!.DVR
M@]RIEN\QML/HOA<\)Z2EAP#H"=)ME![E3+=YC;8?1?"YX3TE+#@'0$Z3;*#W
M*F6[S&VP^B^%SPGI*6' .@)TFV4'N5,MWF-MA]%\+GA/24L. = 5B/R;93>$
MK70&47+H8@WB?JJ'0-G[;%)TJO?"-[C0&- 8Y1.M.7D[N4$.1A!AS6!M4)2#
M20.Z@![.=PGI*6' .@*^])ME![E3+=YC;8?1?#.=PGI*6' .@)TFV4'N5,MW
MF-MA]%\+GA/24L. = 3I-LH/<J9;O,;;#Z+X7/">DI8< Z G2;90>Y4RW>8V
MV'T7PN>$])2PX!T!.DVR@]RIEN\QML/HOA<\)Z2EAP#H"=)ME![E3+=YC;8?
M1?#.=PGI*6' .@)TFV4'N5,MWF-MA]%\+GA/24L. = 3I-LH/<J9;O,;;#Z+
MX7/">DI8< Z G2;90>Y4RW>8VV'T7PN>$])2PX!T!.DVR@]RIEN\QML/HOA<
M\)Z2EAP#H"=)ME![E3+=YC;8?1?"YX3TE+#@'0$Z3;*#W*F6[S&VP^B^%SPG
MI*6' .@)TFV4'N5,MWF-MA]%\+GA/24L. = 3I-LH/<J9;O,;;#Z+X7/">DI
M8< Z G2;90>Y4RW>8VV'T7PN>$])2PX!T!.DVR@]RIEN\QML/HOA<\)Z2EAP
M#H"=)ME![E3+=YC;8?1?"YX3TE+#@'0$Z3;*#W*F6[S&VP^B^%SPGI*6' .@
M)TFV4'N5,MWF-MA]%\+GA/24L. = 3I-LH/<J9;O,;;#Z+X7/">DI8< Z K)
M'LH.4U:WG'+<K^5I:>!YD:4)S/9*V1R,*5!(G1"A2F#%%ZUHY(4*=.B>BZ?8
MDO*=>2"E  #3"YX3TE+#@'0%>^DVR@]RIEN\QML/HOAG.X3TE+#@'0$Z3;*#
MW*F6[S&VP^B^%SPGI*6' .@)TFV4'N5,MWF-MA]%\,YW">DI8< Z G2;90>Y
M4RW>8VV'T7PN>$])2PX!T!.DVR@]RIEN\QML/HOA<\)Z2EAP#H"=)ME![E3+
M=YC;8?1?"YX3TE+#@'0%0633* ((@BRIY;1!%2H1!%8RV%0B#6FBH14K%ZTK
M2M*UI6E::*TU5PN>$])2PX!T!;$(4*)L1(VUM1I6]N;TJ="@0(4Y21$A1)"@
M)TJ-&E3@+(3)4Q!99*=.26 HDH "RP! $(:15=K!$P1,$3!$P1,$6NE_C5)7
M!/<ZJR";9;_;/V92R#-GHWFV/!S;B3M&QTBWXV.QT[)KV6G1301;%X(H3/IM
M%X$Q >Y8,=&X3D@2$DDHAN*DU74VJRAY*,L(S!ELZ5&KD#@I"'0UM30O=C1
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H(F")@B8(F")@B8(F")@B8(F")@B8(F")@B8(F")@B8(F")@B8(O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>60
<FILENAME>g459793g81a10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g459793g81a10.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1_&4&AO=&]S:&]P(#,N,  X0DE-! 0
M    'ZJ^@08X0DE-! 0      $D< 5H  QLE1QP"   "   < G@ #&9I9W5R
M92 R-2TP,AP"!0 ,9FEG=7)E(#(U+3 R' (W  @R,#(S,#<R.!P"/  &,3,Q
M,3 Q #A"24T$)0      $.X5_28)^C%+L4=\ #EA3.XX0DE-!#H      .4
M   0     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $
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M=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M    $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO
M;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG
M:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0
M$ "4S,P  0 ! )3,S  !  $X0DE-!"8       X             /X   #A"
M24T$#0      !    !XX0DE-!!D       0    >.$))30/S       )
M       ! #A"24TG$       "@ !          $X0DE- _4      $@ +V9F
M  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M      $ -0    $ +0    8       $X0DE- _@      '   /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H     /__________________
M__________\#Z   .$))300(       0     0   D    )      #A"24T$
M1       $     (   )    "0      X0DE-!!X       0     .$))300:
M      -!    !@             # P  "=H    & &< .  Q &$ ,0 P
M 0                         !              G:   # P
M           !                         !     !        ;G5L;
M  (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   # P    !29VAT
M;&]N9P  "=H    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M!F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
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M;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
M       !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!
M46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%
MPJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V
M-T=79W>'EZ>WQ]?G]Q$  @(! @0$ P0%!@<'!@4U 0 "$0,A,1($05%A<2(3
M!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%
M539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G
M=X>7I[?'_]H # ,!  (1 Q$ /P#T[+PL?-K;7D!SFL<'@->]FHD<U.9N^E]%
M"Z0YS^FT.>XN=!]SB7'0N'TG2Y4L$Y743GM?DW8XHS75U&LLW;:VL,>^G^;L
M]3Z&W_KBM]%_Y,HU)T.IY^D[PA)3>22224I)),7 $ D NT'F>4E+IBYH(!(!
M/ \55RW,&7A!V*+W&Q^R\[)I/IO_ $C=_P"D_2-_0_H?S'H[Z*'V5VOK:ZVF
M34]P!<S<-K_3<?<S>WVNVI*2))))*4@9SKFX5[J"6VMK>:W!IL(<&G:14WW6
M_P#%_GHZR>H666]8Q>G.,XF51><BN1#FM#:_3<WT]_O];Z;+_P#!/_1I*:_1
M>H]2NM8R^Q^34]]K76/Q+,8L+&TOK!W/>S8[?9M>_P#G_P#!?S:WES71W='=
MG8S>E574U!V2][;6W-EY;CM<[]8^E[=G_?%TJ2E(=UME>S92^[>\,=L+!L:>
M;G^J^O\ 1L_.]/U+?^#1%E=>SZ\(8!?D?9O5S*F'0'<T[M['2YFRO]^S\Q)3
MJH-V;AT6LINOKJMM@55O>UKG$G8-C''<_P!SMJ,LKJ6-DW=2PWTUX+VL(=8<
MEA=D!K7L<YV&YOT=O_G[TDE-K]J],(<1ETD,D//J-@$$-.[W>WW.4F]2Z<XM
M:W*I)L=MK'J-]SM/:S7W_39]%9QPLTW/-C.G!I):PBL[A+0VO?N^F_<:_9N9
M[%;IQNGUBIN17BMRF!KW!C6B'CV^I6'>]ON^@Y)3_]#MNDXUKK^JY&!:VJV[
M-(M?=2UP/ICTWUM=CY&^QO[GJ/K]-_J_H%H]%G]ET3J8,D"!])W:7(&#7U>D
M=0LL8+KK,LNQFVV!C31%3&>ZEEOI[&>I]*KU7[/TO^D1^BS^RZ)T,&0#(^D[
MO#4E-Y))))2EB=:Z_P!(Z?GX=&7;4VUKS8=];K'5M++&>NRQO\QOG[-O_P"[
M*O9Y'VC!'HLN_3F'O(!J/I7GUZ]WTG^D+:/T?O\ TW^B]5<=]<V,=UB]SF@N
M9C,V$\B?4=I_:8Q.A'BE3'FR>W#BJ_[7INI==Z/BYN/5D93*WU$O>V'&&NKL
MV.<YC7-9N_EJ_D.L&7BM:]S6.+]S1$.ANX;I:7?YKEP7UG _:F027 ^C5 :7
M!O\ -;_TFSV?F_X7_BUH_63KW5\3K#JL6QK*L7:]H%0=,U[WMR+''^:LW[?T
M?I6?0_2IWMDB-:\0M;[X$IB6@@1&^]O:I*K;U'&JRZ\,[W7V1HQCG-:#NVNN
MM:WTJ=VW:SU7_I/S%D]0^L/3<;ZPX^-=NW4L>RVX5O(K==Z3ZZR6.V_IMK/T
MGHW>E_URS9&!>S,2!N:\WH%C]0IKL^L?2GN,OI9D/8S:PP"UC'O<ZRUEK?I,
M;7]GHM_PG^"WK865D85Y^LF)G,K#J1C74VV$,.P[JWU!CC^F;ZWOW;/9^B24
MBQSU<]2P_P!JMQVVQD;/LQ>6[8HVSZS6_G>I_P"!K:7-])=TP]2H'3\ZW.UR
M?5-UKK'-=&-N;MLCVL]G^>ND24CO?<Q@--8M<7L!:7;(8YS6W6;H=_-5%]NS
M_"_S:Y?Z_P#T.E:$_KC>#$?RCJ-[?^#6SU_-9A855KK13NRL9FYU@J]INJ^T
M>]WTFLQ6WVV,_P!#78L;Z_ %G2Y ,9;2V>Q'T7#^4G1W"V?REZQ5LKIV#F$'
M*H9>6@@;VAT
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! ?_  !$( +D"70,!$0 "$0$#$0'_Q  ?  $  @(# 0$! 0
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M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M!A]/[:.2 ?-%3XQ[J37!^;"F$_&-V[6;CX_L4O*&RI*V3O./&ES, NNVPAV
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MO+P]OV';GXPWIK^OB%/'U[D]>03^ON]_K[W86&T H!0"@% * 4 H!0"@% *
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MP=#4,)VN]_[D)6T,B@(C=Y?M1MW?P:'_ -I0= 2YH!0"@% * 4 H!0"@% *
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MRP!RB4PTJD5B#+.71YVTD4,,Q^1,<F)\(,>*),RJ"#]%!0<22=C';QFXPO\
MMZ_*#!OA7P6/0GP^.270/X\L^V)H'3NUIF2DDOE\U*G)[/M8Q$U+3JQ69G#Y
M%MB5)J*.["6#IJ$89J9X#!K)+/).^06!T H#\TS0WV&M;_P4&?U564TSZ/V?
MXOIOJT*'Z^Q^.NI_CJN3E_\ ,[MY+WK_ +H;H_@5_:J.3OWMVU^7O:=5TK?9
ME7\)G^M>7BM?M;;O@-)]GC+;*ZQWA0"@% * 4 H!0"@% * 4 H!0"@*F?&N)
M9"^#SZJCL2U&.MW<SBI#:6[=-Z-UH]C)??$"&R 7MW9,4>,)G'M7%!3IRPEC
MZ'N4SK%NNB4M;,:/)89 =/X/0S70O4VV4M<A>40H]78@]0@CR=V=LCM*++//
MDTQQP5E,PV5:Q&''[(6QQ0C0[_@3@=9 IG_AU\Z#Y,?-]RJ6*='M=C/M![A8
MZB,2"/;.>Z\E+.#'XG'X_*Y2$D;H2Y0&EXW&I5)X7&SAX:LI9X(&&Y2$'.R"
M+=)R]Q3ROAF!65H#/Q3UIT\2E:5Q;6VE#'R=5W6C$R6HEI%BGH5&"$Y&UUV6
M5VRRV86*-^BRTNC*,F*AXL()Q0$^.G<A@ J\ S'X7&,^QA'7&.TEH@OL/'OC
MI*TO6@#<RTA:AOW\1]5E&VTB=/3B(J]_9]/@4=+N[?KO>*9?16/'W5^Y G]?
M]_<]?'F6>5D"@% * 4 H!0"@% * 4 H"DSQ8.@];<)PK7NX=B=)=1P-/;O1^
MIX.W#Z_-J&@0Z)N)>(.[;2'A$X\XQ$-&FJ!,OL*MB[<E;F7(_ .V<N;9J-@+
M;=::_P#F\#/!MIWL2?XD'_Q/$ILF1XR4LTQ4:MF]F+%WB/'>G'6LAZC%KDCG
MEBY7<*7S_P )[.(&1J TS>X_MDO>/\/M$_>_ZI.A?Z*G'HP]IJ_L]LW=O=^:
M4W/P]SFG>F"F/X2?I;8_X=C_ )G<"/\ Y>=ON_5?Z_P^5OP^5_+^G]VI+RJ*
MO8F%[NY$7FG/&45>7;V_(A74D!PE]LPX9\_K^.]"?FT;0\K_ ,__ /GW*B_I
M03%LMWP]WT4\G+NYI[R*O;WED?P:O2/47Q)%]O@-M??WV"-U_P 4FR/['&:A
M,N.:'_-MO^;QHB_W?F=UI_8T-_3Y?3_LJTE@7] V5,)SM-NY\D_Z.%/<RJ)[
MO+.57P_-#7/IKJ_^)[]_-*HS3;[_ .'SOY^?U?\ C]%OH\OP6\O.O8QR]SN7
MEC//MY9QE>7;V\USG&K%T_@1?Y=W/_&KIS\CHRJ]](GI/4?!:+W/[AO<7RZ!
M/W<6[XPNWVQYE+QX?VLG/W\LW4_]@-OUYFCO2:S_  E?J938>EK]W.K/BYOV
MNF-9/?VVXSS_  0EMTY$RDCS'*BP2F,=8,U35VQ0A@FE@N0<9(V:"45[^]4R
M67LA9UFBG@GDX<)^<_7NZ4]DH9;I-32U'"6*%>KQM=,J2R)M17NVHV)'NR[<
MY45VU-NYR%&=&Z;K]9WBGTU27&GH4G;45:+732MI=]/"KG*R&-'++4N8FUJ,
M9OX:/<KD8QV,C(FD))!$Y$V:OF+<]$TS3=D3;79DV2!4-B^1:D6=\L\FKYLF
MOBD[;WRRN@NFHG?*]\+WKT6RI/2-G1CV)/2I,ULJ*R1J21(_9(SGL>B.P]O-
M6OW)E>2GAOI7T-V?1220ROH[BZE?+3R)+!(^GJ5A=)!*B(DL+U8KHI$1$>Q6
MNPF3;\\,;[6_P)_(RYD_(Q#*J6?J.3CH!0"@% >5FL@A$5C9"1;%-Q6-Q 59
M!<J=FI(0'C8VRSA)HV6($SBS<8SLJ[<(MD%'*Z?MN%TD4[W45PQR J-\,WI=
M?>NZ_$1C<VYFD6@4H+V,L-U^?G^ Q-MLW*VN(W%_3P[WP839P5'@-6A=DOFP
M!S(!J$;V;%GC R_:Y8E'P%SE * 4 H!0"@*+O%<SVH2WWRMKC5XWKTP-G&O^
MBYA-8UQ(YYW@NT3). $]"B8K))-LGHH,_B[N*1QE,CXE:#BGPLZ0>R(6>LL[
M8QS-G<"S[C\2>!<UZE$R<;NL.>91YRD2&]%FM=R+=C1:YHHIBGL$UJ;!/71
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M5_\ O.7'CW*G+"<\^_NC^!7]JHY._>W;7Y>]IU72M]F5?PF?ZUY>*U^UMN^
MTGV>,MLKK'>% * 4 H!0"@% * A;SGW-KCIK9VT=3PS6/1D0DFFU[CM@OML:
M3E6NHT"D.8V(GF426/&L;-/E65BLYC4Q$@<O8>OXF0Q/(89,K6SR FE0"@%
M* 4!T<BC$;F E<#+8\#E -UF@HZ#2(2P-B7*C9;!PVS7'$V[IFMFW<)IKH9*
M(Y9)+)X*IWQSQQRL!P8I!(1 VKIC!H;%88R?.,7;UG%(\(CK5XZQ3Q1Q<NFX
MAFS2<.,4L<4L5E<,U+)XXX6RMC:UJ ]50"@*\O#V_8=N_C#>FOZ^(4!8;0"@
M% * 4 H!0"@% * 4 H"&7<P>.FM7:L0D@H*600Z_XI78(FV+%^BB_4ZIU*QN
MLT3?I*X)O%![P@SNHC:RV3-T\;^=T%U\,P)FT H#3-[C^V2]X_P^T3]__JDZ
M%_O]_P"]]VIQZ+\^1J_'/])NY=_*EI<8\<>\J>*%,?PD_2VQ_P .Q_S.X& /
M/[O^Z]OJ_F_#_3Y5)/9C/_\ *^YV9QW85?E54["NI(#A/[9APS^_O0GYM&T/
MN_=J,>E'VKMO=^?NY=_L:3U[$3.<)@LC^#5Z1ZB^)(OM\!MK;^^P1NO^*39'
M]CC-0F7'-#KG2RU^<M'6;9)X.;Z8UQ9#-;#)1+!6\+#V3R5PPRPRS3QS]F^>
M&.>&6>-KVMEC?]=:TE@SY!LV,)^B+<B*N<96BBVJ["IE.>%1%3*+V]A^:6MM
MJ:WU;O1RL_&F^[T:J-<K?*M5N1JJCD1RIE$545$7FJ+V'"YY$;_"Q(RVZ*E,
M8EDN5E11P&?1=FW9M6T7S3:X,&B_I! 1#-3U>#Y=MCDSS=(,EVR+MXX7QR30
M^+'%>XJ25M]J:6JJEJI5A?3,:QB4RHS8UR)'"F6N1[FY8JHQS&O>Y45&\NM:
MG1M5<Z5^B+?<+=;&VZF9517"5\DDEP1TBS2LXE35O1JQK"Q^)4C=*R1T43&*
MBOV(O B_R[N?^-73GY'1E0MTA^DU1\%HOJ&EPN@3]W%N^,+M]L>92\>']K)S
M]_+-U/\ V V_7FZ.])K/\)7ZF7/T=O=XFP]+7[N=6?%S?M=,:SN_HIMB::U)
M@-+3ECKV=.7XQ9K(2"*F:&(]!WBJ18V<(,2;ABJ[1QM[+MNP<YWLEDUO9+!R
MHNE8&]4UTJZ"6"T5C:"L<^)63O15:C&O19&92.1T:O;V.2-SD3S<(URN;171
MUQTY:[[3UFJK1->[0R*H;+0P.1'K,^)6P2['34[)FQO[8WS,;SXGG.C:QWO4
MFQAE!$V<B)(F3[.)8-3AANVP9(%3#</9$D219)VLFS2?/L%W2;7#]8VP4Q2Q
M^C"U=Q&RLI&MFD269E,ULTR-V-DF2+\I(C<^8V1V7(Q.2;D;R/'?)2RW9\M%
M ^EHY;BZ2DI7R+,^GI7U*NIX'3.\Z5\42LC=(O-ZM5R\U-OOPQOM;_ G\C+F
M3\C$,JIA^HY)#;^YM4:/BR$HV[M?6^G0ADPQB("3[1E\?AD>>3$[@YQ @FQ"
M1DA;-\5?*-EUFPENXR>NF[1VJFG[INLHF!KY+<I^+H:T9L3P^.ANW-8;!F_6
M(O=>P8STD!3V "G.J8;KR5:/3=PT3\GP\027$2U>;9V<1_!+!J$CY"1Q,>85
M%.1F3 "\#C'4,MYYYATIH#86SUMP;"T[KV/PJ73]Z1?D24B>CD,\6A-W<NNX
M,MTEV%FZ8]N47<.4&""#?UCW%"SI4"4% :"77N^>C.XM$S;7O6/7+UEHISM
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M:NG/R.C*A?I#])JCX+1?4-+@= G[N+=\87;[8\REX\/[63G[S^K].;JCS_\
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MN?[\ES,JS509)@L$7+(7#0)!:'YY\>\#M[HDKMCN_DXAKP_*!KC4:)GFXUL
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MP\*WN?H4FOTUMOMWG9Q)](:.GX00%A?'<UC@HK'&[BVP'[5Y\2ZGD:^!1T0
MH-&Q'!7T[5LJI[8]SGY96]>RWRLL-1+5438'22P+ ]*ACWL1BO9(JHC)(U1V
MZ-O-55,9Y=Z:OJK25KUA14]!=7U;(*:J2KC6CFCAD65(98</=)#,BLV3.541
MJ+N1J[L91?$^'UX67;6OL=+]LZN[5Y]#R_9_-8^S:,2[D.92@,#C.\F.L-EE
M1:RH_I^-."182]B8%@T+X9,6ZJ&!%3,5;)XC9GS7S4=?J#JO7F4S>J<;A=7C
M?'GC\+?OWRRYQP6;<;<<\YY8ZNDM#6;1G7_)#ZY_E'JW6.N3Q38ZIUCA</A4
M\&W/69-^=V<-QMPN?;=F\N^)E$,A.XYQVCS;,'4SWCSCHD0S'<M['!X!6W1.
M\('HVSMHU7Z7*)"PL07V+F?S!-'3K*2HM'K-T0&NR:Q##PD<J(B)CQ[._/)<
MY_I@W(FAIKD_Q9M0@B$9']X<GOP6+VUP3$_QSM"4)BV*5E+6L.MGUD R"X.\
ME/>NA"&9%@BLG99LXLHLZR6PJYY_/RQ]Z_."BLOX)W1^DM[<K<DC>R]4%VNZ
M8%O8T+F#KF*1HJ19KH-AK9WDS>B<>@L_CJTFML/##!TD_$8";B<L\FY"SVV+
M7<Z+7=ZH*2FHH(Z!8:6%D$:R03.D5D;4:U7N;4-1783FJ-:F>Q$(KNW1!I2\
MW*NNM7->$J;A4RU4Z0UE.R)))G*YZ1M=1O<UF57#5>["=JJ6L1;PK^^H-Q8T
MX5&]B\@S31XX64%?!-A\130J^D+$O/W^QW@Z2D;]2/!#IBK("*^%\+1);'X<
MF@US154MFXST]\CI)7RN1-TCW2.1$\W<]RN7"*O9E5PBK\I)\$+:>"&!BN5D
M$4<+%<J*Y6Q,1C5<J(B*[#4RJ(B*O8B=A"W7/AQ=<[8Z%Z%T"4Z&Y#8$.6 >
MC6:$F<<72(^U+L=RP0](L! ,>YZ,'KQT9&F@]V$]W@[<I%FSY12S08EDHSSP
MKU7M1/F\.SO[NXY2:G77A4]]]L!=- MU=S\SYM=&RQY-(>M&N*YPP=O#SV'E
M(4HXD*I;K([@0LF.+.'Z&39(>ND92;/K+WQ2NAGW+;<)K7705].R&2:G5[HV
M3QK)#N?&Z/<YB.8JJQ'JZ-4<BM>C7=J'D7ZRTNH;55V>MEJH:6M;&V9]'*D%
M1LCFCFV-D<R1$;(L:1RM5CD?$Y[%Y.R5D\ ^#+T#L9WI/N>#=.<X0786G]W[
MY90\62X],R!HJ6U'M7;N@73L\]']"QIV3%R%:..IPV%HYL5PQAT.QL1?+#57
MK_OW?4%1>8XV5%';('1R+(DU)2<"==R/W,=(LCU=&YSU>YN.<B([.<Y\?3>C
M*+2\TTM#=+]5,GA2%U+<KEUND;M6/9+'#P8T9,QD:1,>B\HG.9A4V[;)>Y@_
MC0Z$TQN?I%CVKRR9B&CM.S'9Q.,QCF:>Z^7,8P<&4/O1+9!QOF;7]82;M+(H
MDGA-R@GGGC;T".*&-E?"141%Y97WL_3E,&WF9M$Z:\:[-BW/2KN+DE0+((T(
M,#43G*L]G6:;@LFD2LFG@AT-"7K3-L@XS256S)+-<\<TD4A^6*:2K/*JBHF.
M2^]CZ<JJ_,"A'L'@_P#1!6K^L&_00COB,O)1TEOH=H/7+S7FS]@:XCF0\B+/
MS.!"7VGWL:,0F%PED+AI1NL R+39TS+(++%2\J>'2<D)_(+I^0N8O'KCNC#T
M.Z*[VYI3F1 Y(FHHE(=#27><U%1IZ.9LF;AKLJ*[-YZ;-U\7N)$B*:D(C)"P
MNZR2ZTE4P40!A2<O=]\$>WG%WB+ONIV6@SO;^B'<GDO/L@W24GJG,>RBF:K(
M'/HQKO*).47G42! G@Z3/(O[$G)!))%!C8=<6KCG@Y2^]Z^"?(F/O!F+KCPF
M?$%[1Y:&\A;;\0?18_5+$Y%C;IS"N0)X(EIW&'*O'((,?+ENKS[(B":OW#,E
M9A\(2OB^!@UD5T;#[8*?*KE57Q!KDZ?_ $,!NC8.VM\1S6G5VJ79'E#J*(ZA
MD;K8>JI /$240IJ#4>[7$S'!A\@F*)!PUMLQK'+Z_,Y-1II,0Z>.IBP2(6'M
M\ WHN?(3VO&)*:=]-] Z"V[$UP7IH^$U)SC+M,&1DA]>S4L4)G9#OW;;4J,L
M-3?-/A* 48OZIPW>?$_=MLVC@"6U * 4 H!0"@% >6;P:%-)@_V$UA\6;3XJ
M%;1LI.&\?$HS E'6;BSMF!?R5-IB:>!6KNUG386X>J,4'%K+)(8*6ME0'J:
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MH=NE#3VPBFLWFI[ATIX8FHN)&'L8BP)X7#F5!ZTD.I#Q2C\#B*E+=-QEE')
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M<L;VRRM<#Z)IIHX8I))X))X6]G!-/#'###'[V.&-K8XV_!:UK4!_N@% * 4
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MVPUI?!D.9.\'#E-]E@B!EB@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0
M"@% * 4!X76O^98C_P#4+?\ SHC0'NJ 4 H!0"@% * 4 H!0"@% * 4 H!0"
M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
;4 H!0"@% * 4 H!0"@% * 4 H!0"@% * __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>61
<FILENAME>g459793g81b20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g459793g81b20.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1X$4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '>B^=E8X0DE-! 0      $D< 5H  QLE1QP"   "   < G@ #&9I9W5R
M92 R-BTP,AP"!0 ,9FEG=7)E(#(V+3 R' (W  @R,#(S,#<R.!P"/  &,3,Q
M,C,Y #A"24T$)0      $':3HW<;,6"]1>4;@*0UNP<X0DE-!#H      .4
M   0     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $
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M=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M    $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO
M;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG
M:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0
M$ "4S,P  0 ! )3,S  !  $X0DE-!"8       X             /X   #A"
M24T$#0      !    !XX0DE-!!D       0    >.$))30/S       )
M       ! #A"24TG$       "@ !          $X0DE- _4      $@ +V9F
M  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M      $ -0    $ +0    8       $X0DE- _@      '   /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H     /__________________
M__________\#Z   .$))300(       0     0   D    )      #A"24T$
M1       $     (   )    "0      X0DE-!!X       0     .$))300:
M      -!    !@             "1@  "=H    & &< .  Q &( ,@ P
M 0                         !              G:   "1@
M           !                         !     !        ;G5L;
M  (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   "1@    !29VAT
M;&]N9P  "=H    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M!F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
M    5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B
M:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE9G1L
M;VYG          !"=&]M;&]N9P   D8     4F=H=&QO;F<   G:     W5R
M;%1%6%0    !        ;G5L;%1%6%0    !        37-G951%6%0    !
M       &86QT5&%G5$585     $       YC96QL5&5X=$ES2%1-3&)O;VP!
M    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M    #T53
M;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N=6T    /
M15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M
M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N
M9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO
M;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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MC_K=;7;>UV/=9=26"NL.+:/M'HM?:VMMCFU[OT?Z1..,_AQ?1:,T#W^<X_\
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MNHY697GAOID
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*31"1U)696AU=K5$5V1F9W*"A(:F\=+_Q  = 0$  @(# 0$
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MMI;A0A PE9(5FL_$!LN=*.D\Q@;YA**.6[X&*&*#<0+/'.X'3Z 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@.(S]LE!&K#'+R5L/*+
M4B-AFW GM4LZ7B>S()0[C52J@=3D<,; (;+(Z<*)*D. %W'T09,:_.W<\K@1
M^A[B>\/[8"1FW$4,;7Q'(TEO 12";#,;2X.;6UL1'1U!P*F! OF3"Q%R(HJ2
MI*0]N^8]P5)CY]/<<K@24>DY1I'SG)-%UK"N06#A=LF\LRC+>ZVAI95Y.4PS
MVL9<;I0FXIM=J@+CE*F4@@,Y5A)#%, B97RQ!QN+8#R:/M-#3@;;>=:.??Q]
M*=Q<(\TRX,*37Y0NA*%2"Z[==;K1SCW%V+;<+)9P@8/N--1#*$FB*:43/J!8
MZJ)Y8R!]X^MAXFC@@W%1UKRR FNMI+S\2#Z*Q'^[2F#+; 3<'<#H63#2:ZX&
MV4-*!=K>%-J+DR22^ :AW>.>6)4[<L!_ASV;A.QM83"[O,J:VWU>[>5VXAM%
MZN!U$W#XZ<2&"@9-5#;B@XAEPX,TG,JIR073!E!2:2$IO@@7,,PJ(O6 ]09F
MB-")".E-2<ET<I*SMP83'NN(S@0S*B]!"#@4,&NID5=*)'FLN96:ZVFV3G86
M1#/E$6 :O>_*5134DX!S #<_649/3E@:54U+1%HD0/H*\X$-V-M <1<^DIBW
MW+;7%] 34EQ&DL@LI7E(11#A\ZU#Q\LDN8NDJV?@5@.FILYPHLR>L0DD2_%Z
MK,K>3KK"_$J<_FJ>DM#2<0D\?)35V*65170FI^("NE#9'#B6"7L$IIXEQ.X.
M%[B >D>S!9TC):8BO=!)N)+1W:RWVF$SUQ\0B;NCIUI#X92Z%<N,!GX8WG8@
MHZV2MGGD!<V0!L8"& N(%F!'57T+T[7;RMFJ:]QX8'FUP);KDPY@G&2J@X'*
MBNE0?28N%E$F< /-Q3+OA86'I<XUC"(,.[EE8<QG(9;55 \8 XYNRU6TQ8TT
MN9+,04IKM!G[OZ3MAJMI") )J*WFZ@R*DI:*B)"<5P#+$4Q*3BI8D1)EP\ 2
MQ4 ,$/#'#"UK 6.4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
M H!0"@% * 4 H",\BZ;:O2XDK:')<*,IZ)3DDHU+ZX272AHV&HR*H- G'ZJX
MQ\O"\1;9K;%(@,Y?3 Q,$5?;.9M$64X\G'SQ<R!ZIDZVP1&\H/R:6)%C2:TH
MR: &6?#R2$_P9470,<R(Q@/+"PF1-/LJ&4Q,/+UTHJ1R<2BF)JDO743Y H8!
M YAJ-U[/>U[-'XFS0$O: 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"
M@% * 4 H!0"@(8[R:6-3>B+6A&+JDB1XHNQI7:TP-MYQ:(TL'01=#22',CIH
M=K/9K/!"%3Q"[I/"& AD80;(8$M<,8/#$7 0BVU0$/H$X.C3A*?8@GY5V[VC
MF-5A9?<;G:C-DF\'A- 9;<D>O&-3!U2Q8\.M!?%S*(#X6LR88"V %8Y< 0<,
M8/"X>7*N5=Z@LR7H+BUUR27E9ULYONIX)C?;J WC[D0$!<R:>+87E]QIZNU#
M"DEF5% 7<U-P"BFE%//!9">+$?,,,$<C883@$=6;H3&S"8R0Q6P]'8EED%N&
MV8GJY1BZYESIAEJZ*A(3F:[E1P8+P9;X(NPLU&H97SSW:KA71SS:2QBBL3"R
M40#X'HUK1> EYML]MJ24OJ&$?,DVSV&LK:X([%UDG,_<P$2'PT#KQ+N$%L/)
MM'(B9ZBB&$(JGH-CH:H(J-]3"4S(-P/L\M0&*$M+[K3'I)*0]G0XK/9>=P*H
MV54\IOT-/<37*O0VBN5I+K0'5RD:.I7AX(H,VQ$$2+06TUS".-=C,8\W /\
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ME;4X/YORFW&(?E)<Q63;@4D"1'"**JD(8&+E4#"\S2V,3>9Y.-'[K.3>LHF
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M%UMI=P)#I!QM+SG3"))7%4"9\NH%RI7/(QF0N(:[W8(+.]@)1T H!0"@% *
M4 H!0%3>EBB6'VHV$2U1III RFN+8W.-G24?$\J*0JM4[LRLF).*,1CR9#C4
M92%W$A9)5I@4&9*C](#R(2)9-0FGL$\@@D0+9* 4 H"(6HW7L][7LT?B;- 2
M]H!0"@% * 4 H!0% @?'10H,D_91O<1#6F:]+8KC^359H:WRTOQ/-[P;^PS;
M;ZXJH*NND3J/%MD1.$QQ":;@(&BBN<1E!-?J43*'1Q4X104@+NXGE!DS=%\=
M3+&JODOQY*S(:\BL9<S(*"4(KM)Y(I)PMY2$2U8J254T0ZE*!4P(04B90^3S
M$R+G"P!@,0+$#H% * 4 H!0"@% * Y-.4Z1'K5%;NFV=7VBQK%;$)E3KJ>2_
MD:\7)8)]1)HZ<%8 B6.*!XZI*R@02TQ-329Q145$X6)$BHYD<,/("D5::6WD
MM[VZAN"!>*[+"CII.>LLX3WD(GLK70XKGD1CKD:)8&#2'#@8I'Y],5<YTCL9
M(4I"9+@=36(--W@#*8BFJE/! +B]9-D(&V:CB[MU^G-L["-EHK!B.G)(#<4D
MA0S-/1LDD^RQBN8H2:BI)98/@G"2[G9)1TQ#.DU<HI-\KBB'"%[@2(H#*-QS
MM]8]V&UVVET'C;668)8EIJR2T&<9<#B*MQN1 FN=FKS5>2HLIB^@S$BOA2.)
M2.9#LDDSK<)I1U1-6Q5 3!( 0N8]S#\MXYBM/UUA]!)4T^VZ/C6R0-3;997-
MM)*QUTVFWNB)9;HNAAN.<(&3LM5WY-QS'*?#Z[B8ZCK>6&LD=Q,JO2-^U!32
MQV<K'(B;>TEM42Z7I%T(VJ6M6N(EKH^GTS-QFW'+)A*3;+6LD?ERS^8Y-861
M)&;S,1FPH/R<@$<XQ&HSU]##+.-Q*83J3%9I)+7"+*("A@H ?IV6,?;6LP]<
M+J>NY(EG;'9BM6)-J\BS(]8$:BM5JJZ1.RLSX3FHOX9PC9(DPB7'6YDP]<+@
MJ6TDE0KI6O;4NV-F%*5T25;GJCVO38@<G%[4M^+8]S=[NH^TS"W,@Y!GN-4!
M\-=KKSB?S5Q0)&2T1'>"6MQL^7#'CF**I!NN)UHX?>G$V5/$H(27CV!@G8 ?
M*X68F0(?C3P2TT\U-.Q8YJ>62":-5159+$]8Y&*K55JJU[5:JM546VBJFIEE
M%64V(T=)B%%*D]'74T%923M1S6S4U3$V:"5K7M:]J21/:]$>UKD1;.:BW0ZQ
M*<HL&$XZ>4M2DY"C/CN/D$\YWBZ#P!XT30D%-#[Z>43!=,*GE 8(N']%D&3)
MF1\NH,+._175OW'T*J(BJJHB(EU5=$1$WJJ\B(47<03B9\-38/4R48K+RPVI
M04ET9D&DMGKL+2JL$SIQ%D!KJXIG HX8QR3,3!!/)GC88PM\!,, Q,0<N^9V
MPR^[\F8E_5]<G_TD_P#X?,>1^Z++_P#7F#_]IT7_ (Y,Y'XQ7#+N,A-U)V40
MB%CIY$;"$1O&4P(R=@<4SA1#04DN*:C@DFD QSIDDG$@Q!2Y8/,4$''+#'N;
M6_$E!70L=)-1U<4;+;4DE/,QC;JB)M.<Q&I=51$NJ7541-50[H,:P>JE9!2X
MMAM3/)=(X8*^EFE>K6J]R,CCE<]VRUKG+LM6S6JJZ(JEH-?(>D* 4 H!0"@%
M * 4!2AJB.@&^(A+8L<+L5GX[+(<IHUD)E,]52G(V7"W7(RB:H3<RPL1\45<
MS9@V>%S.XF'ADDGED-6R2LC!,JF$: NOH!0$ N(+]3FJ/M^Z>?*J0H"?M *
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M4G:E+Y/#ZMI8]74?0* 4 H!0"@% * YA-K?D!UPY*K8B=ZEHWD]PQV\D6/)
M.)("\49+T4V^H$VRZ3**9QS+J@*$L#%%(0D-@*&8Q+W#S"%QO</("!/!::\H
M-+A=Z9)LM/XI(CB.PPVG"B*Y-+#3 T:/7*!==C9E"=[ +74#+)8Y]#;)E4&
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MQTNO%M$%)NHJDZ$0)*7":<?;:&KJC= N;H!0"@(A:C=>SWM>S1^)LT!+V@%
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M:*$;S LMH!0%<VIK!V ;D_[$.&7T63"[<<#UE0XQEAW.8ZOM4\VCDMK1N/\
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MSMWIJU+ZZ)]2);=S \OLHS&M'FD,ZL9E(I)NM-JZ[R,B("&GXBV*)J619"N
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M1!CI@QU9*3!<D;(P9)W),$FHW&-W[_8TH&@K?20PJ_37;-]+WZ0>&C?2??\
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MZ6;-7"+J-O Q!Z JLE.5^(82UMA0:*4.<5Z2 9PD@V^5%5C!H($K.J"A'+L
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M CE2E9IEF_![N5%!R1B@JZ(@J3S(V);5"BCMQ.77,C(XI[/N00U0]<CC:YH
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M40;  BE?%M\S&)HN!Q;R%W:^R6UR^\_?_P"F/0'Q"1]NF-<.XVR&MHMP1+#
MW$T[?@EPA<;7MB*'?+<:]PQ,;97M;/'EE:U[VM?IO0'R^0N[7V2VN7WG[_\
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M9$30)/)+=:KLN_B2,*6/"%C(XHK35;F2@)@B'B5$-8GBP$C* 4 H!0"@% *
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M@KCJ?.N#PP6$XT:01<RJRV#90--;"X#;!;*)F8^:BHJJP8&5L^%Y.E?V*O[
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70* 4 H!0"@% * 4 H!0"@% * 4!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>62
<FILENAME>g459793g84a84.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g459793g84a84.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1[$4&AO=&]S:&]P(#,N,  X0DE-! 0
M    'JB^>$@X0DE-! 0      $D< 5H  QLE1QP"   "   < G@ #&9I9W5R
M92 R-RTP,QP"!0 ,9FEG=7)E(#(W+3 S' (W  @R,#(S,#<R.!P"/  &,3,R
M,#4Y #A"24T$)0      $!B _[28V$DJCNX<XNK-?50X0DE-!#H      .4
M   0     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $
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M=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M    $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO
M;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG
M:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0
M$ "4S,P  0 ! )3,S  !  $X0DE-!"8       X             /X   #A"
M24T$#0      !    !XX0DE-!!D       0    >.$))30/S       )
M       ! #A"24TG$       "@ !          $X0DE- _4      $@ +V9F
M  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M      $ -0    $ +0    8       $X0DE- _@      '   /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H     /__________________
M__________\#Z   .$))300(       0     0   D    )      #A"24T$
M1       $     (   )    "0      X0DE-!!X       0     .$))300:
M      -!    !@             #%P  "=H    & &< .  T &$ .  T
M 0                         !              G:   #%P
M           !                         !     !        ;G5L;
M  (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   #%P    !29VAT
M;&]N9P  "=H    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M!F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
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M;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M*22G)'U>8..H9\Q$_:7GO,Z^WW)W?5^IS@XYV= ;M#?M#P(%?H3_ %_\-O\
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M<K-:&66EUK7Y5VFZEG
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MM1<SI3ZC%3[HD)T 9I3;.G52M$ZD[*T1>RY6N9F=@:;W!.N@&OV<:W0+O<5
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MP?H%Z'Q-=BYNDCW=X=9A]8A[2&S;JQ;+0Z?N[M5!OXHPBSCZG%B%RDF<N,Y
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MAREFH,#XO,(C1X:R\N;#DJ3 R15_M_JP[Y8"=C*[1]9?B-S7G5?U--W ]YS
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M;,[-Z'MNR=M W*M;1W9;M3K9NIRXH",6J-<U5V V!K^J5.PKJQ<_6R%EK5>
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MAZ"%E4U HW7G9<K<6F:\TM9Q3RHM#V7-E6T:\ZZY,ESWE,%Y)&!A,1)%B/\
M8V>D&4;687U^K+\3=(2SUN]CY1NZ2Q> -UM\;8-N$T@7)LSH[54&R7V"/NYF
M/JN+3$$+>,%661APR+'S8Q%S@OIW=.JZ)K%?"Z>3!KU3V'^UF%76[]M!RO&M
MDX,5"QHN=\!/W5T3LTXU9Z%4;4Q*V-#M7P]K#-6=E+9Z1-(R2*2=*]3M!==Y
M=MDZ:H\FDQ[HI[YL CW.^EZ</8D$B)B1 IM&L-H+TW78E\F6(37@^OP59%.O
M2/+D-6&F,-$40P/31Z,B[-K"WCNO=9A'],C=5B]:RHQV[-1:VQI"S/V_4LO
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MTM>2Q&,Q1:Z.N='R#2\5C$5$7Z6'0W<3L!$IM6VPCN6%VN"]1NJW?9UV8L-
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M9G,$6T?TXZ/OJE=1-2N=HKIM2Y]A;A71%QV[^UHR&+&ZK<IX(0,GTT,Q7H,
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MS;.)'NDD14N4/F81\1#?=CN-K410)M+LH[J*]W(1;:!-:UW3.M^V.PCUZB6
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MCI#^JPYP?9<<'PP]_?OW)\O#W;\7XI^OM0_6K_PD"S_[Y^^,X_3Z?7[Y_/\
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M^'?;R0R[[_!.;A[YA\5\TGX.-F]I/+?.QWV\_P!OGW.YSG!YGNV=AL1MOY>
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M?5&ZC3;HG"%F72&V(OE&QJEN.+4):KF,ZC*5:J9JU>PQ_5,;[%NQ',R-@='
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M[6IW;$N'K(Z?.E-S>Z'$*9K!#)NF5.L4,K1;(,DD:I>*6$V"Y6-@UVOG^/\
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M<=-8Q[U;J,J5CK!HUG/L83%5AS&'9D9&<-KEJP\]&CJ::E3!@:W;C3A\T_\
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M-TR$RRR2\[(P7&+JM/*T; 'E+7EQ<, %V"3R[K-B&A^W>UQT!S8VRH-?82I
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M+9CRJ)PB<(G")PB<(J+]EX^"-[8';0T3M'<FHVZA7B^M9^F!>)5PI^WHL_8
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MM0]6$1DG/1CL30L;,QC[#(@YCI&Q.;@->S^QRN'.Q'8$S7B^X[8'E-#88X;
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M7*=4XG#$=6$./8]XXC&6F7W&XCJOI@]&>CPR36>-- GZ<,DW1TV_!JEAXCY
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M!DG.M>^5V&/5^X[@UO3@A)+M?-RJL)<D6-8;*5HE'1,M@- 6T4GMJS&9::*
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MMVX3[+:K+/KWRR?0KE65@F8!C9]<0<.2+.#$088PM8M0WD576_BE$K%\D)D
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MA-LQXM'77Z?\]/HS_DSC^&#I+./]6/I^[\N8=_>K)X_0&=_![1W[;]_,Y&V
MI%PI]?4?]3_"3KUH\CR[,G"+RE=OGEM^H!W.PF1[K";EII2DX4K/L^>KFE7,
M*5A+^<->6X[[V,N)@^TU$DR\.O,"Y=AHNXT[\T_/A(3W\F-(]W@<9]Y_1+F\
MWXS^L*W_ -FW!QX]>8>6_< XYL9#3@O$<\&*>D8@RL?$N^?B_&$^Z?PKSF9A
MK",-8@>VI2G%)92U\"YE3RT0L0'7W4UJ=G]LY\\Y&?L]_NQXC;W*(YW;^KY-
M&V,G<.'EG/-YNYACJ#L''GU2)>$27%>VRG"4H0\[AS+DMCV,-X1%G^_4[F;$
M2TAK!54G)$?AJ*:_$(QK<-QP3N3L//'<]_'&^.^<Y& [(ZE@R .P^P# '^[C
MZ)S^;QRDES.F[U3X^(>5(CJ3+4I*HGM86GWCB584I*TN)=0J8VXE2)+#B'L3
MY:7&YD5]!":V7AEMA/+O]$^)WWWWR=B#X'.#G.X+ZC #L@9YAX#;OX8;@@@@
MCE;@@CE'(YD$0[S=?7H7=2?B7'<JUKL?'LI;><RK&*L;6M/LXA3,Y_M;#KBO
M[2K"&XTB0I49H;*+TWS>/FI#X\CCXD?1.<;';\;#)&74(%ZGVQZS ,X [2L!
MSNWS /;)VQ[09+[2]?\ \@Z3_FC6_P#8T+D:7;5EW")PB<(G")PB<(G")PBU
M&=G.BG9#L;O?9NP"NT-++UXQ1Z('ZVUTU5M@/674EGI%_P!7;D+SB3PRS0JP
M59VULC5P$9L0]@))M,76X6N5JJ2Q.6+#FR$4>Z$]**XZOVC0;#<=M5FRZ^BM
M6/8>R@U:&W2H7(GNR[:FWIIVV0J/:A%GA2ZQK#->WV?*U^7'?BWP&8KH=V*1
M0]*S.%D4W=4=%Z[Z_=^.X-.UHU=6@1'JQT=L,I-ZVMM7;Y;).7L[O2/>S'LF
MWKI>K)#@?##(F&@T,M'#QW\29D> U,G3GY!%M'X1?#KB&6W'G,YPAI"W%Y2A
M;BL(0G*E92AM*EKSXQGPA"5+5GZ)3G.<8S0D $GL 2=B=AN=ADGX#=4)#02>
MP!)P"3@#)P!DGX $GP6O4*ZD_;;SL_8%KD6VA# U2VQ9:-:PE@EP*,Z/?+6;
M2,/5\YP71QP8S!$>P=MX8]4UWUXA9( RV$RL1 !@1SK7-7I:=#J^O:S89-HF
M@4(]<U&I-5E?)!- )+>E#3IR8(Q:#&-,E9\/K#WV88YN<2L;'!M/I3:_Q YD
MMAEZDTZ=J-C3[M.RYM*YU9+6@NTRWRTX(9*T+!:O035'71ZQ$+;WL?"V%J;3
M\_>6Q#N_-M5IMNI'/,BBTPP_,?RIA.(T4<1G#WLY8S 2,B-NH;4Y\&4GR79[
M<%N'B-[7 _1_Z.K?I2XQU7TL>D#18V\/:KF;A;AS4)+$A,0$%>G;LU)#TW5!
M1KMD <[H7[4[[;*S*XA#NLVK;:5>.C4ES+&<3S, &^Y+6N&_-S'WEH:&\Q.5
M:Z_[HT_I2 .C72V@:HQXB0!82.G+TUN*CX:.SB(!$,2)C V$P\PI;K<-$2)$
MPG/M)1A"<_1?$7'/ _ %6I7UO6--T6%K8*E+3H6\TT<#.E#$R#3:,<DT52O&
M^/+FP,@@A P0T +9\+\ \8\:R3#AS0KVIMB9)+-:PR"FTM;(_D=>M/AJF>4Q
MO9'%UC+))[+6DYQ5"5W(VM?(\G.@NN=MM,:-+2ZFT6=N3"KQ (HC.A19@QEO
M YR4LFS':D-922RY 5\:W(A2&X:I"^.3>G+C'B**4^CCT7ZSJ\44PD&K:LR6
M'3K5 V9X(9JD<?JKI76F1LE:1;)K'KLD@E;"9#V2'T(<'\/21#TB^D[1M(EE
MA+#I.E.BGU*M?%:O/-!;D<;386U'ROC?FKRV1T'QSQ.G;&."JF]W]QD,4C8=
MH#Z@J0*=\>7NFNW'8QFU*E-CB,$2'=CD$SL,!%/2(3LMMP3"?=9?:(8,NLLK
MSX'0_3_QQ8'#_$^K4>"=&T^QZQ=UWAATD5[6'3,K6:U.D^*T)^G0ZDD#Y6/I
MP/DCE;9-Y\<3CD#7/0'P17^7^&=(O<:ZSJ%?U>EH7$[62T='$+[-6Q=NLEJF
MN9+X9'.R%[;L\;'QOK>HLD>T9 SZ?&N2<V29V!?=A[!L$U15) R9)1L223,R
MMHKP=4_,A@B](FU5>'"0";\0CW3WP\.:Q,'Q41E;&/\ )IX8MSS7N).(^)N)
M=3LNN"U>NVHQ):CFTL:;1-@2LM/?8TAW-;T^<2MY9!%#/'-6B$1UK_RDN)ZD
M$5'AOAWAGAO3:XIFM1HU)3%5?!JCM2NBN(I*S&5]8;RU-1K])W-'U9H)(+,K
MI18*D=8]%T08(@C=:4\C.$Q!S&+"=K8,J?G2AS&&D%9<]\?X02D+]N3(>A-1
M&U2'%+;:;2EM*.E:!Z)O1[P[4I5JO"NB6IZ4-:/Y2U'3*%W4;$U:,,%R>Q+7
M.+4CN:622%D+3(XN:QH#0WF^O^E?T@<0V[MBUQ5K=6O=FM2?)NGZI?IZ=7AM
M2&1U.&O%9'-5C;RQ11SOF<(FAKGN)<3*4*DTT76UT^#5J]#J2XLZ&[6V1$!L
M"N$2?DRB,5T7ACX%<6;(F2WY;*V<M/N27UNI4IU><S"OH.AU=+.B5](TV'1W
M0V*[M+92KMT]T%J266S"ZIT^@Z*Q+/-)-&YA9(^61S@2]V8C/KVMV]4;K5C5
M]3GUELM>=FJ27;+M1;/5CBAK3,N&3UALL$4$,<,C9 ^-D4;6$!C0.W'B1(E*
MT"A@X:AU$9+B1\*-#2ZB'&:A0TK3&;;PM$6&PS$C85C.&(S+3#7LM-H1C,K4
MJ5(.;3J5:C7B)KVUJ\4 <V")D$#7")C X0P1QPQ Y$<3&1LY6-:T85F[<N.:
MZY;LVG,,KFFS/+.YKIY7SSEIE>XM,T\DDTI&#)*]\C\O<XG]WYT*+[OXF9%C
M^]]KW7OGVFO>^RE2U>[]M:?;]E"%*S[/GPE.<Y^F,\RP"<X!..^!G'Q7DR*6
M3FZ<4C^7Z7(QSN7)P.;E!QDD#?&YQW77YL07*V4-$(\E3Z&WF\15XDX^&<4A
M&):E,^VE$1*G$8<DJSAI'MI]I6/..5Y';Y!&-MQC??V=_'8[=U[BC;P]SH)(
MPPN:>HTQ_.-!/2 ?@NE(!Y8P"YQ! !75OWBNH]A,66LFZZWE3#8QAZ9AYU6<
MI8C8>:1EA$B0M*DMH<<1A.,9<>RVWE*\W=)_B.7S+B!@=R3XX ]V_ADK(9I%
MXY,D0KM8</=8>V+D: "^0M>0XL8""YS6G.>5O,[9=B$.-FD/J2RMA364.MHS
MAQQ+D*1[2H4CXE+6(:UR6T9>RS%D2LLM+9R\M"W<(Q1[>7&^>X^T=QC.1@[9
M(&3G;9>%RFZH6 N#PX.:XCE!$L9 F8(R[JAL;B&<\L<7.X.Y6D-R>]Y8L-.$
M3A$X1?A)C,3([T24TA^-(:6R^RZG"FW6G$Y2M"TY^^%)SG&?S_/&<9^O*@D$
M$;$'(/D0KXY'Q/9)&XLDC<'L>TX+7-.00?,$+\!PV )B-0!L5J'$9]KW;#.,
MX2G*U96M6<YSE2E*5G*E+6I2E9S]<YX<XN.7$DGQ*OGL369733R.EE?CF>[&
M3@            >2B>#UZTX.MZ;U$I$-NS,V(A;8$M9(X_!"V0S))3CYBN@I
M!1T!6YME)&"9>T+ #!N+.;F.FCZ2)7")B:+Q60%M2Z]-5#%$FUUM%8;-JLL>
M"-(EPLJ!8%V)^UK,C#(8A -BB2K!*E$%2QQ&*\K,J3&RK,.0]'61=8&T7J<
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M9SS1&20BC@PM@L,=ESHB!\ZLC2T)L:''K;%O-S94J1 B%)ZV9*&)9>U?TO\
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MV"I]I3#GPC:I;4=#:T+:4.:EL(>@J><4I]SW<Q2H3T=K(]UI,E_#=.NT>#G
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M* ;^*)6Q66Y(U^/Q^Q%MOX11CNS_  ,[<_\ PQOO_P"52W"+S@=?O\ ND/\
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1(G")PB<(G")PB<(G")PB_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>63
<FILENAME>g459793g93z51.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g459793g93z51.jpg
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ME9>8M]89(R0V.$%U,C,U47:6M+6XU=DT-[D*4E1AP?_$ !<! 0$! 0
M           ! @/_Q  Q$0$  0($!00! P0# 0$      1$A,4%180)QD:'1
M@;'!\!(R4I(BTN'Q0F)R@J+_V@ , P$  A$#$0 _ /\ ?Q@1++.V8VX2I^K3
MF>N9IUI9L:<3V25$5<<RM%05R^IO-TI:K1Z EBUMK6/O#<(6]/,(B:^?6PUZ
M#YQE;&A&#SBTSF:<\9Y1\S2-W5@@'E [-_I,XOZF.8FA1^%J(\ZUH9<T\;-#
M^/8#+QOXE+!W<10=Z  (.56D(3]"-&>J)$%.$O\ 3E$SO-NT><]K\@/#")V_
M#L'K+N:Q%(M?SZG?2D@IOT^]_P"7OU'F)JHEJ2;'OQWX-[>C"7X^!&B@ZUK1
M*Z1$>E?>K^_R>E$ _G"+![<3*_Q^O \I/Y0XY0(7X_.,+5]0*49^O'PWZ(]*
M:1\6@^B\S7FX7\ITX?X\/A^1<52%B_G:Q[8[8KM47^$G"YVA#+U;1"UX>!2Y
M'TQ6ES*E20>M>C/"G<D*[98A"2N*15YBH!*ZQ$]O:8^^KC&)/*(5+K:A(\\]
M]B1A-XB&SN;._<KW1I('_+]4DK>XV[3\Z?1:UYR5"JB5&,AXQ>A5/C> /K6Q
M_3.L=].5,YG':(;"J'L.L;/F0:DDC1-Z(OT*%4Y&4->C&DAT_<FYO"#;F\0%
MR;W1^KVXXVV>>#W3E%-3>?L#2(PLAY<&U8+:4(F*9Q,:Q/V8Y3$2J["& P&
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MT=C@J_2#<"8>Q,,6)6$")4$QYA8F<HP#>RMB=*/C!U,(I6J:P6B=H+#6J*+
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M" .@Z#\)8W'4)HCT3 RHSQ(S&X1R5J0IS1-YQVU!R 1A1 ![1FJ-[/,2[%Z
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MQ!L)*(++6)QZQCO6,Y]8WEVP.U)'!?Z+T?R5TU3QY&]@4RJ P%9U55RK>O\
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M6-9W5/[?]3_(WW)]7UVI]AN$I.W6/)[?]3_(WW)]7UVI]AN"D[=8\GM_U/\
M(WW)]7UVI]AN"D[=8\GM_P!3_(WW)]7UVI]AN"D[=8\GM_U/\C?<GU?7:GV&
MX*3MUCR>W_4_R-]R?5]=J?8;@I.W6/)[?]3_ "-]R?5]=J?8;@I.W6/)[?\
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M_P _'A# ZE__ -!/7^$N/_!G8$C>3@_)X<%_0PY<_<?!L+Q8SSGW6?A# 8#
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MU5V/@$Q890:R+="$ ;<_HVE<I6L#H28 92AK>4Z%P3' &2H3%&@$#1)BC;^
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ML:?=/OW5:1:^=\\HRBDTK7>.:W.67VS'[5YGV@=9.G J\9!N*-MAQ(B+@9H
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MW8R1'%JRF\+X\1A0XHMGDE$.[<@E$??(PZKV<U>D:9*T.,?<SDCND/1 (S_
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MPXN7S"Y<(8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M6%C'TXO:5R80P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P(:F?Y2OF[Z#7;7[_/)_87*><>W$N7"(#<[1M ,H\H<RAL9W
M;PU'%8,ZT\E*8X%M1##I#2>Y,!8U:6Q!2;) O4Z2N"=,&8:E)!JE(I:&\LOT
M!B<)=)Z\XGQ,,>B5]V1"^B7^(WW))&W0!Q6WL\57.8^FK>0T'.(771ISDNC3
MNXLD;06S5]UT\P,KNGFC)+53G"9NI;9:^Q20J#B4T)AA:6M&%*XUOAM,3E2*
M^\YQR9T-.K"DEVUS=J0V-3V&2*+6%#VYXB3S EPZ-O).I6URUK6Z1HFLYT?:
M^GK+9%&NSZWIQ(Y2MKMLE0/0*)<6WD$F*4O$UTFN'VK%NA>DK H_H=80B,/E
ML ;>;FV9#K U1'8\A7S1]Z'K^JDD@]]WO-?94D,0-$O4&":]+C&57M.'0D2=
M2/2XL1$33G-=HB*^>C)ZH[*76K*E,'0UNR-,IB#ZO:[01+K/2DI&9N1]/]!<
MJ@?:^6N<0:!V*GU.N>)"ZK&]>D@KJ0S2F&I$:-SD3P%E *4SY=*_,1UTO<9)
MQ2@HH\@TL\@\L!Q)Q(PF%'%&!T,LTHP&Q ,+, +0P# +81AWH0=[UO6\(A_R
MBW]F+?TC.(O^MGGK"QCZ<7M*Y,(8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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4$4XKS$Z3L]D,,& P& P& P&!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>64
<FILENAME>g459793snap1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g459793snap1.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M !0 4 % !0!6N]0LK (;R\@M@_W?-D"9^F: )8)X;F%9H)4EB895T8,I^A%
M$E !0 4 % !0 4 % '*^._'>G> ='AO[^&:<SR^5%%%C+'&2<GH !0!<\'^*
M['QGX=@UG3U=(Y"R-')C=&P/(./S^AH WJ "@ H * /BGPIXOO?!/C0:K:LQ
MC$I6XA!XEC)Y7Z^GO0!]B:#KEAXDT2UU;39?,M;A=RD\$>H([$'@T >"?'3X
ME)J,K^$M'F)MX7_TZ1>DC#&$!] >ON/:@#N?V??^29#_ *_)?_9: -OQ;\6O
M"W@V^-A?3S7%ZHRT-J@<IZ;B2 #[9S0!G:!\<O!VO:A%8^9<V$TK;4-W&%0G
ML-P) _'% '=:WK%MH&B7FK7@<VUI&9)!&,M@>@H Y"R^,7A>^\,ZEKZ?;$L]
M/=(Y \(#LS_="@$Y_2@"7P'\5-%\>W-S:6<,]K=P+O\ *G ^=,XR"#[C(]Z
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M_>,[7DM(U:,'V8L,_AQ0!TG@WX@Z'XZCG;2#<AK?'F+-"5VYZ<\J?IF@#JJ
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M&P,+T_'K0!Q/C+1K+P#\;M*&AH88/-@N%C)R$W/AE'MP?SH ^J* /!OVE_\
MCR\._P#72;^24 >C?";_ ))9X?\ ^O<_^A-0!U&JW366D7MV@RT$#R#ZA2?Z
M4 ?&?A7Q4FAZ_<:S>Z)#K=W(2P-R20CDY+8QR?K0 >+O$G_"3:['J]KH<>D7
M  WBV)VLP/#8P,'_  H ]N^,FB_\)%\*-,\1M%F_LXHIG8<'9(HWC\RI_ T
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M&EZ+,P0W&G1^6_\ <<#*G\P* /&]%\5>./@W/=:+=:8LMN[[DCN S1AO[T;
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M3(H 73-$TK18C'I>FVMDAZB")4S]<"@"_0 4 % !0 4 % !0 4 % !0 4 %
3!0 4 % !0 4 % !0 4 % '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>65
<FILENAME>g459793snap1a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g459793snap1a.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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K(S]:G^SZ5+)Y4<HX!25=RGGN* *OAN[^TV;@6\$"HW"PIM'Y4 ;5 '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>66
<FILENAME>g459793snap1b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g459793snap1b.jpg
M_]C_X  02D9)1@ !  $ 8 !@  #__@ ?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$  @&!@<&!0@'!P<*"0@*#18.#0P,#1L3%! 6(!PB(1\<
M'QXC*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3<!"0H*#0L-&@X.&C<D
M'R0W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W
M-S<W-S<W-__$ :(   $% 0$! 0$!           ! @,$!08'" D*"P$  P$!
M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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(I0 4 % '_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
